1	The	the	DT	_	3	det	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	intake	intake	NN	_	10	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	does	do	VBZ	_	10	aux	_	_
9	not	not	RB	_	10	neg	_	_
10	affect	affect	VB	_	0	root	_	_
11	the	the	DT	_	12	det	_	_
12	pharmacokinetics	pharmacokinetics	NNS	_	10	obj	_	_
13	of	of	IN	_	15	case	_	_
14	either	either	CC	_	15	cc	_	_
15	drug3	drug0	NN	_	12	ppmod	_	_
16	or	or	CC	_	15	cc	_	_
17	drug4	drug0	NN	_	15	conj	_	_
18	.	.	.	_	10	p	_	_

1	Pharmacokinetic	pharmacokinetic	JJ	_	2	attr	_	_
2	studies	study	NNS	_	3	dep	_	_
3	indicate	indicate	VBP	_	0	root	_	_
4	that	that	IN	_	12	mark	_	_
5	administration	administration	NN	_	12	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	or	or	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	does	do	VBZ	_	12	aux	_	_
11	not	not	RB	_	12	neg	_	_
12	affect	affect	VB	_	3	comp	_	_
13	the	the	DT	_	14	det	_	_
14	pharmacokinetics	pharmacokinetics	NNS	_	12	obj	_	_
15	of	of	IN	_	16	case	_	_
16	drug3	drug0	NN	_	14	ppmod	_	_
17	.	.	.	_	3	p	_	_

1	Co-administration	co-administration	NN	_	6	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	5	case	_	_
5	drug2	drug0	NN	_	1	ppmod	_	_
6	produced	produce	VBD	_	0	root	_	_
7	a	a	DT	_	10	det	_	_
8	25	0	CD	_	10	num	_	_
9	%	%	NN	_	8	meta	_	_
10	increase	increase	NN	_	6	obj	_	_
11	in	in	IN	_	12	case	_	_
12	AUC	auc	NN	_	10	ppmod	_	_
13	and	and	CC	_	10	cc	_	_
14	a	a	DT	_	17	det	_	_
15	33	0	CD	_	17	num	_	_
16	%	%	NN	_	15	meta	_	_
17	increase	increase	NN	_	10	conj	_	_
18	in	in	IN	_	20	case	_	_
19	the	the	DT	_	20	det	_	_
20	Cmax	cmax	NN	_	17	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	drug3	drug0	NN	_	20	ppmod	_	_
23	.	.	.	_	6	p	_	_

1	No	no	DT	_	2	det	_	_
2	adjustment	adjustment	NN	_	6	dep	_	_
3	of	of	IN	_	4	case	_	_
4	dosage	dosage	NN	_	2	ppmod	_	_
5	is	be	VBZ	_	6	aux	_	_
6	recommended	recommend	VBN	_	0	root	_	_
7	in	in	IN	_	9	case	_	_
8	such	such	JJ	_	9	attr	_	_
9	patients	patient	NNS	_	6	ppmod	_	_
10	.	.	.	_	6	p	_	_

1	The	the	DT	_	2	det	_	_
2	pharmacokinetics	pharmacokinetics	NNS	_	11	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	2	cc	_	_
6	its	its	PRP$	_	8	poss	_	_
7	major	major	JJ	_	8	attr	_	_
8	metabolite	metabolite	NN	_	2	conj	_	_
9	drug2	drug0	CD	_	8	num	_	_
10	were	be	VBD	_	11	aux	_	_
11	unaffected	unaffected	VBN	_	0	root	_	_
12	following	follow	VBG	_	13	adv	_	_
13	co-administration	co-administration	NN	_	11	ppmod	_	_
14	with	with	IN	_	15	case	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	11	p	_	_

1	Other	other	JJ	_	3	attr	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	therapies	therapy	NNS	_	0	root	_	_
4	:	:	:	_	3	p	_	_
5	In	in	IN	_	7	case	_	_
6	clinical	clinical	JJ	_	7	attr	_	_
7	trials	trial	NNS	_	31	ppmod	_	_
8	,	,	,	_	31	p	_	_
9	the	the	DT	_	11	det	_	_
10	safety	safety	NN	_	11	com	_	_
11	profile	profile	NN	_	31	dep	_	_
12	in	in	IN	_	13	case	_	_
13	subjects	subject	NNS	_	11	ppmod	_	_
14	treated	treat	VBN	_	13	acl	_	_
15	with	with	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	concomitantly	concomitantly	RB	_	14	adv	_	_
18	with	with	IN	_	19	case	_	_
19	drug2	drug0	NN	_	14	ppmod	_	_
20	,	,	,	_	19	p	_	_
21	drug3	drug0	NN	_	19	conj	_	_
22	and	and	CC	_	21	cc	_	_
23	drug4	drug0	NN	_	21	conj	_	_
24	(	-lrb-	-LRB-	_	25	p	_	_
25	including	include	VBG	_	21	prn	_	_
26	drug5	drug0	NN	_	25	obj	_	_
27	)	-rrb-	-RRB-	_	25	p	_	_
28	,	,	,	_	21	p	_	_
29	or	or	CC	_	21	cc	_	_
30	drug6	drug0	NN	_	19	conj	_	_
31	was	be	VBD	_	3	acl	_	_
32	similar	similar	JJ	_	31	dep	_	_
33	to	to	TO	_	34	aux	_	_
34	that	that	DT	_	32	ppmod	_	_
35	of	of	IN	_	36	case	_	_
36	subjects	subject	NNS	_	34	ppmod	_	_
37	taking	take	VBG	_	36	acl	_	_
38	placebo	placebo	NN	_	37	obj	_	_
39	with	with	IN	_	42	case	_	_
40	these	these	DT	_	42	det	_	_
41	concomitant	concomitant	JJ	_	42	attr	_	_
42	medications	medication	NNS	_	37	ppmod	_	_
43	.	.	.	_	3	p	_	_

1	Patients	patient	NNS	_	9	dep	_	_
2	taking	take	VBG	_	1	acl	_	_
3	drug1	drug0	NN	_	2	obj	_	_
4	concomitantly	concomitantly	RB	_	6	adv	_	_
5	with	with	IN	_	6	case	_	_
6	drug2	drug0	NN	_	3	ppmod	_	_
7	more	more	RBR	_	8	com	_	_
8	commonly	commonly	RB	_	9	adv	_	_
9	reported	report	VBD	_	0	root	_	_
10	both	both	CC	_	12	cc	_	_
11	weight	weight	NN	_	12	com	_	_
12	gain	gain	NN	_	9	obj	_	_
13	and	and	CC	_	12	cc	_	_
14	weight	weight	NN	_	15	com	_	_
15	loss	loss	NN	_	12	conj	_	_
16	,	,	,	_	9	p	_	_
17	compared	compare	VBN	_	9	comp	_	_
18	with	with	IN	_	19	case	_	_
19	patients	patient	NNS	_	17	ppmod	_	_
20	taking	take	VBG	_	22	lv	_	_
21	either	either	DT	_	22	det	_	_
22	medication	medication	NN	_	19	acl	_	_
23	alone	alone	RB	_	22	adv	_	_
24	.	.	.	_	9	p	_	_

1	Drug	drug	NN	_	2	com	_	_
2	interactions	interaction	NNS	_	12	dep	_	_
3	between	between	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	other	other	JJ	_	7	attr	_	_
7	drugs	drug	NNS	_	4	conj	_	_
8	have	have	VBP	_	12	aux	_	_
9	not	not	RB	_	12	neg	_	_
10	been	be	VBN	_	12	aux	_	_
11	fully	fully	RB	_	12	adv	_	_
12	evaluated	evaluate	VBN	_	0	root	_	_
13	.	.	.	_	12	p	_	_

1	Drugs	drug	NNS	_	16	dep	_	_
2	which	which	WDT	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	potentiate	potentiate	VB	_	1	relcl	_	_
5	the	the	DT	_	6	det	_	_
6	release	release	NN	_	4	obj	_	_
7	of	of	IN	_	8	case	_	_
8	neutrophils	neutrophil	NNS	_	6	ppmod	_	_
9	,	,	,	_	1	p	_	_
10	such	such	JJ	_	12	adv	_	_
11	as	as	IN	_	12	case	_	_
12	drug1	drug0	NN	_	1	ppmod	_	_
13	,	,	,	_	1	p	_	_
14	should	should	MD	_	16	modal	_	_
15	be	be	VB	_	16	aux	_	_
16	used	use	VBN	_	0	root	_	_
17	with	with	IN	_	18	case	_	_
18	caution	caution	NN	_	16	ppmod	_	_
19	.	.	.	_	16	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	augment	augment	VB	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	activity	activity	NN	_	3	obj	_	_
6	of	of	IN	_	8	case	_	_
7	other	other	JJ	_	8	attr	_	_
8	drug2	drug0	NNS	_	5	ppmod	_	_
9	.	.	.	_	3	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	use	use	NN	_	8	dep	_	_
3	with	with	IN	_	5	case	_	_
4	other	other	JJ	_	5	attr	_	_
5	drug1	drug0	NN	_	2	ppmod	_	_
6	is	be	VBZ	_	8	aux	_	_
7	not	not	RB	_	8	neg	_	_
8	recommended	recommend	VBN	_	0	root	_	_
9	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	highly	highly	RB	_	4	adv	_	_
4	bound	bind	VBN	_	0	root	_	_
5	to	to	TO	_	8	aux	_	_
6	human	human	JJ	_	8	attr	_	_
7	plasma	plasma	NN	_	8	com	_	_
8	protein	protein	NN	_	4	ppmod	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	mean	mean	NN	_	8	prn	_	_
11	99.2	0	CD	_	10	num	_	_
12	%	%	NN	_	10	meta	_	_
13	)	-rrb-	-RRB-	_	10	p	_	_
14	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	21	dep	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	,	,	,	_	3	p	_	_
5	drug3	drug0	NN	_	1	conj	_	_
6	,	,	,	_	5	p	_	_
7	and	and	CC	_	5	cc	_	_
8	drug4	drug0	NN	_	12	attr	_	_
9	The	the	DT	_	12	det	_	_
10	in	in	FW	_	11	adv	_	_
11	vitro	vitro	FW	_	12	attr	_	_
12	binding	binding	NN	_	1	conj	_	_
13	of	of	IN	_	14	case	_	_
14	drug5	drug0	NN	_	1	ppmod	_	_
15	to	to	TO	_	17	aux	_	_
16	plasma	plasma	NN	_	17	com	_	_
17	proteins	protein	NNS	_	1	ppmod	_	_
18	is	be	VBZ	_	21	aux	_	_
19	only	only	RB	_	20	com	_	_
20	slightly	slightly	RB	_	21	adv	_	_
21	reduced	reduce	VBN	_	0	root	_	_
22	by	by	IN	_	23	case	_	_
23	drug6	drug0	NN	_	21	ppmod	_	_
24	(	-lrb-	-LRB-	_	27	p	_	_
25	99.5	0	CD	_	27	num	_	_
26	%	%	NN	_	27	meta	_	_
27	control	control	NN	_	23	prn	_	_
28	vs	vs	CC	_	27	cc	_	_
29	99.3	0	CD	_	27	conj	_	_
30	%	%	NN	_	29	meta	_	_
31	)	-rrb-	-RRB-	_	27	p	_	_
32	when	when	WRB	_	36	adv	_	_
33	drug7	drug0	NN	_	35	com	_	_
34	plasma	plasma	NN	_	35	com	_	_
35	concentrations	concentration	NNS	_	36	dep	_	_
36	reach	reach	VBP	_	21	comp	_	_
37	5	0	CD	_	40	num	_	_
38	to10	to0	CD	_	39	num	_	_
39	m	m	NN	_	40	com	_	_
40	g/mL	g/ml	NN	_	36	obj	_	_
41	.	.	.	_	21	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	does	do	VBZ	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	alter	alter	VB	_	0	root	_	_
5	drug2	drug0	NN	_	7	com	_	_
6	protein	protein	NN	_	7	com	_	_
7	binding	binding	NN	_	4	obj	_	_
8	.	.	.	_	4	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	studies	study	NNS	_	4	dep	_	_
4	indicate	indicate	VBP	_	0	root	_	_
5	that	that	IN	_	23	mark	_	_
6	,	,	,	_	23	p	_	_
7	at	at	IN	_	9	case	_	_
8	therapeutic	therapeutic	JJ	_	9	attr	_	_
9	concentrations	concentration	NNS	_	23	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	(	-lrb-	-LRB-	_	15	p	_	_
13	300	0	CD	_	15	num	_	_
14	m	m	NN	_	15	com	_	_
15	g/mL	g/ml	NN	_	11	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	,	,	,	_	23	p	_	_
18	the	the	DT	_	19	det	_	_
19	binding	binding	NN	_	23	dep	_	_
20	of	of	IN	_	21	case	_	_
21	drug2	drug0	NN	_	19	ppmod	_	_
22	was	be	VBD	_	23	aux	_	_
23	reduced	reduce	VBN	_	4	comp	_	_
24	from	from	IN	_	26	case	_	_
25	approximately	approximately	RB	_	26	adv	_	_
26	99.2	0	CD	_	23	ppmod	_	_
27	%	%	NN	_	26	meta	_	_
28	to	to	TO	_	26	cc	_	_
29	97.5	0	CD	_	26	conj	_	_
30	%	%	NN	_	26	meta	_	_
31	,	,	,	_	23	p	_	_
32	representing	represent	VBG	_	23	comp	_	_
33	a	a	DT	_	36	det	_	_
34	potential	potential	JJ	_	36	attr	_	_
35	twofold	twofold	JJ	_	36	attr	_	_
36	increase	increase	NN	_	32	obj	_	_
37	in	in	IN	_	41	case	_	_
38	unbound	unbound	JJ	_	41	attr	_	_
39	drug3	drug0	NN	_	41	com	_	_
40	plasma	plasma	NN	_	41	com	_	_
41	levels	level	NNS	_	36	ppmod	_	_
42	.	.	.	_	4	p	_	_

1	Therapeutic	therapeutic	JJ	_	2	attr	_	_
2	concentrations	concentration	NNS	_	20	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	,	,	,	_	4	p	_	_
6	drug2	drug0	NN	_	4	appo	_	_
7	,	,	,	_	4	p	_	_
8	drug3	drug0	NN	_	4	appo	_	_
9	,	,	,	_	4	p	_	_
10	drug4	drug0	NN	_	4	appo	_	_
11	,	,	,	_	4	p	_	_
12	drug5	drug0	NN	_	4	appo	_	_
13	,	,	,	_	4	p	_	_
14	drug6	drug0	NN	_	4	appo	_	_
15	,	,	,	_	4	p	_	_
16	drug7	drug0	NN	_	17	com	_	_
17	andtolbutamide	andtolbutamide	NN	_	4	appo	_	_
18	did	do	VBD	_	20	aux	_	_
19	not	not	RB	_	20	neg	_	_
20	alter	alter	VB	_	0	root	_	_
21	drug8	drug0	NN	_	23	com	_	_
22	protein	protein	NN	_	23	com	_	_
23	binding	binding	NN	_	20	obj	_	_
24	.	.	.	_	20	p	_	_

1	In	in	IN	_	3	case	_	_
2	a	a	DT	_	3	det	_	_
3	study	study	NN	_	11	ppmod	_	_
4	involving	involve	VBG	_	3	acl	_	_
5	12	0	CD	_	7	num	_	_
6	adult	adult	JJ	_	7	attr	_	_
7	volunteers	volunteer	NNS	_	4	obj	_	_
8	,	,	,	_	11	p	_	_
9	TORADOLORAL	toradoloral	NN	_	11	dep	_	_
10	was	be	VBD	_	11	aux	_	_
11	coadministered	coadministered	VBN	_	0	root	_	_
12	with	with	IN	_	15	case	_	_
13	a	a	DT	_	15	det	_	_
14	single	single	JJ	_	15	attr	_	_
15	dose	dose	NN	_	11	ppmod	_	_
16	of	of	IN	_	19	case	_	_
17	25	0	CD	_	18	num	_	_
18	mg	mg	NN	_	19	com	_	_
19	drug1	drug0	NN	_	15	ppmod	_	_
20	,	,	,	_	11	p	_	_
21	causing	cause	VBG	_	11	comp	_	_
22	no	no	DT	_	24	det	_	_
23	significant	significant	JJ	_	24	attr	_	_
24	changes	change	NNS	_	21	obj	_	_
25	in	in	IN	_	26	case	_	_
26	pharmacokinetics	pharmacokinetics	NNS	_	24	ppmod	_	_
27	or	or	CC	_	26	cc	_	_
28	pharmacodynamics	pharmacodynamics	NNS	_	26	conj	_	_
29	of	of	IN	_	30	case	_	_
30	drug2	drug0	NN	_	26	ppmod	_	_
31	.	.	.	_	11	p	_	_

1	In	in	IN	_	3	case	_	_
2	another	another	DT	_	3	det	_	_
3	study	study	NN	_	7	ppmod	_	_
4	,	,	,	_	7	p	_	_
5	TORADOLIV/IM	toradoliv/im	NN	_	7	dep	_	_
6	was	be	VBD	_	7	aux	_	_
7	given	give	VBN	_	0	root	_	_
8	with	with	IN	_	10	case	_	_
9	two	#crd#	CD	_	10	num	_	_
10	doses	dose	NNS	_	7	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	5000	0	CD	_	13	num	_	_
13	U	u	NN	_	10	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	to	to	TO	_	19	aux	_	_
17	11	0	CD	_	19	num	_	_
18	healthy	healthy	JJ	_	19	attr	_	_
19	volunteers	volunteer	NNS	_	13	ppmod	_	_
20	,	,	,	_	7	p	_	_
21	resulting	result	VBG	_	7	comp	_	_
22	in	in	IN	_	27	case	_	_
23	a	a	DT	_	27	det	_	_
24	mean	mean	NN	_	27	attr	_	_
25	template	template	NN	_	27	attr	_	_
26	bleeding	bleeding	JJ	_	27	attr	_	_
27	time	time	NN	_	21	ppmod	_	_
28	of	of	IN	_	30	case	_	_
29	6.4	0	CD	_	30	num	_	_
30	minutes	minute	NNS	_	27	ppmod	_	_
31	(	-lrb-	-LRB-	_	35	p	_	_
32	3.2	0	CD	_	35	num	_	_
33	to	to	TO	_	32	cc	_	_
34	11.4	0	CD	_	32	conj	_	_
35	min	min	NN	_	30	prn	_	_
36	)	-rrb-	-RRB-	_	35	p	_	_
37	compared	compare	VBN	_	21	comp	_	_
38	to	to	TO	_	40	aux	_	_
39	a	a	DT	_	40	det	_	_
40	mean	mean	NN	_	37	ppmod	_	_
41	of	of	IN	_	43	case	_	_
42	6.0	0	CD	_	43	num	_	_
43	minutes	minute	NNS	_	37	ppmod	_	_
44	(	-lrb-	-LRB-	_	48	p	_	_
45	3.4	0	CD	_	48	num	_	_
46	to	to	TO	_	45	cc	_	_
47	7.5	0	CD	_	45	conj	_	_
48	min	min	NN	_	43	prn	_	_
49	)	-rrb-	-RRB-	_	48	p	_	_
50	for	for	IN	_	51	case	_	_
51	drug2	drug0	NN	_	43	ppmod	_	_
52	alone	alone	RB	_	43	adv	_	_
53	and	and	CC	_	43	cc	_	_
54	5.1	0	CD	_	55	num	_	_
55	minutes	minute	NNS	_	43	conj	_	_
56	(	-lrb-	-LRB-	_	60	p	_	_
57	3.5	0	CD	_	60	num	_	_
58	to	to	TO	_	57	cc	_	_
59	8.5	0	CD	_	57	conj	_	_
60	min	min	NN	_	55	prn	_	_
61	)	-rrb-	-RRB-	_	60	p	_	_
62	for	for	IN	_	63	case	_	_
63	placebo	placebo	NN	_	37	ppmod	_	_
64	.	.	.	_	7	p	_	_

1	Although	although	IN	_	6	mark	_	_
2	these	these	DT	_	3	det	_	_
3	results	result	NNS	_	6	dep	_	_
4	do	do	VBP	_	6	aux	_	_
5	not	not	RB	_	6	neg	_	_
6	indicate	indicate	VB	_	27	advcl	_	_
7	a	a	DT	_	9	det	_	_
8	significant	significant	JJ	_	9	attr	_	_
9	interaction	interaction	NN	_	6	obj	_	_
10	between	between	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	drug2	drug0	NN	_	11	conj	_	_
14	or	or	CC	_	13	cc	_	_
15	drug3	drug0	NN	_	11	conj	_	_
16	,	,	,	_	27	p	_	_
17	the	the	DT	_	18	det	_	_
18	administration	administration	NN	_	27	dep	_	_
19	of	of	IN	_	20	case	_	_
20	drug4	drug0	NN	_	18	ppmod	_	_
21	to	to	TO	_	22	aux	_	_
22	patients	patient	NNS	_	18	ppmod	_	_
23	taking	take	VBG	_	22	acl	_	_
24	drug5	drug0	NN	_	23	obj	_	_
25	should	should	MD	_	27	modal	_	_
26	be	be	VB	_	27	aux	_	_
27	done	do	VBN	_	0	root	_	_
28	extremely	extremely	RB	_	29	com	_	_
29	cautiously	cautiously	RB	_	27	adv	_	_
30	,	,	,	_	27	p	_	_
31	and	and	CC	_	27	cc	_	_
32	patients	patient	NNS	_	36	dep	_	_
33	should	should	MD	_	36	modal	_	_
34	be	be	VB	_	36	aux	_	_
35	closely	closely	RB	_	36	adv	_	_
36	monitored	monitor	VBN	_	27	conj	_	_
37	.	.	.	_	36	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	4	com	_	_
4	IV/IM	iv/im	NN	_	5	dep	_	_
5	reduced	reduce	VBD	_	1	acl	_	_
6	the	the	DT	_	8	det	_	_
7	drug3	drug0	NN	_	8	com	_	_
8	response	response	NN	_	5	obj	_	_
9	to	to	TO	_	10	aux	_	_
10	drug4	drug0	NN	_	8	ppmod	_	_
11	in	in	IN	_	14	case	_	_
12	normovolemic	normovolemic	JJ	_	14	attr	_	_
13	healthy	healthy	JJ	_	14	attr	_	_
14	subjects	subject	NNS	_	8	ppmod	_	_
15	by	by	IN	_	17	case	_	_
16	approximately	approximately	RB	_	17	adv	_	_
17	20	0	CD	_	5	ppmod	_	_
18	%	%	NN	_	17	meta	_	_
19	(	-lrb-	-LRB-	_	25	p	_	_
20	mean	mean	JJ	_	21	attr	_	_
21	sodium	sodium	NN	_	25	dep	_	_
22	and	and	CC	_	21	cc	_	_
23	urinary	urinary	JJ	_	24	attr	_	_
24	output	output	NN	_	21	conj	_	_
25	decreased	decrease	VBD	_	5	prn	_	_
26	17	0	CD	_	25	obj	_	_
27	%	%	NN	_	26	meta	_	_
28	)	-rrb-	-RRB-	_	25	p	_	_
29	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Concomitant	concomitant	JJ	_	4	attr	_	_
4	administration	administration	NN	_	10	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	ORAL	oral	JJ	_	6	attr	_	_
8	and	and	CC	_	6	cc	_	_
9	drug3	drug0	NN	_	6	conj	_	_
10	resulted	result	VBD	_	1	acl	_	_
11	in	in	IN	_	13	case	_	_
12	decreased	decrease	VBN	_	13	attr	_	_
13	clearance	clearance	NN	_	10	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug4	drug0	NN	_	13	ppmod	_	_
16	and	and	CC	_	13	cc	_	_
17	significant	significant	JJ	_	18	attr	_	_
18	increases	increase	NNS	_	13	conj	_	_
19	in	in	IN	_	22	case	_	_
20	drug5	drug0	NN	_	22	com	_	_
21	plasma	plasma	NN	_	22	com	_	_
22	levels	level	NNS	_	18	ppmod	_	_
23	(	-lrb-	-LRB-	_	25	p	_	_
24	total	total	JJ	_	25	attr	_	_
25	AUC	auc	NN	_	22	prn	_	_
26	increased	increase	VBD	_	25	acl	_	_
27	approximately	approximately	RB	_	28	com	_	_
28	threefold	threefold	RB	_	26	adv	_	_
29	from	from	IN	_	34	case	_	_
30	5.4	0	CD	_	33	num	_	_
31	to	to	TO	_	30	cc	_	_
32	17.8	0	CD	_	30	conj	_	_
33	m	m	NN	_	34	com	_	_
34	g/h/mL	g/h/ml	NN	_	26	ppmod	_	_
35	)	-rrb-	-RRB-	_	25	p	_	_
36	and	and	CC	_	10	cc	_	_
37	terminal	terminal	JJ	_	38	attr	_	_
38	half-life	half-life	NN	_	39	dep	_	_
39	increased	increase	VBD	_	10	conj	_	_
40	approximately	approximately	RB	_	41	com	_	_
41	twofold	twofold	RB	_	39	adv	_	_
42	from	from	IN	_	46	case	_	_
43	6.6	0	CD	_	46	num	_	_
44	to	to	TO	_	43	cc	_	_
45	15.1	0	CD	_	43	conj	_	_
46	hours	hour	NNS	_	39	ppmod	_	_
47	.	.	.	_	1	p	_	_

1	Therefore	therefore	RB	_	10	adv	_	_
2	,	,	,	_	10	p	_	_
3	concomitant	concomitant	JJ	_	4	attr	_	_
4	use	use	NN	_	10	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	is	be	VBZ	_	10	aux	_	_
10	contraindicated	contraindicate	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Inhibition	inhibition	NN	_	20	dep	_	_
4	of	of	IN	_	7	case	_	_
5	renal	renal	JJ	_	7	attr	_	_
6	drug2	drug0	NN	_	7	com	_	_
7	clearance	clearance	NN	_	3	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	leading	lead	VBG	_	7	acl	_	_
10	to	to	TO	_	12	aux	_	_
11	an	an	DT	_	12	det	_	_
12	increase	increase	NN	_	9	ppmod	_	_
13	in	in	IN	_	16	case	_	_
14	plasma	plasma	NN	_	16	com	_	_
15	drug3	drug0	NN	_	16	com	_	_
16	concentration	concentration	NN	_	12	ppmod	_	_
17	,	,	,	_	7	p	_	_
18	has	have	VBZ	_	20	aux	_	_
19	been	be	VBN	_	20	aux	_	_
20	reported	report	VBN	_	1	acl	_	_
21	with	with	IN	_	25	case	_	_
22	some	some	DT	_	25	det	_	_
23	prostaglandin	prostaglandin	NN	_	25	attr	_	_
24	synthesis-inhibiting	synthesis-inhibiting	JJ	_	25	attr	_	_
25	drugs	drug	NNS	_	20	ppmod	_	_
26	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	11	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	on	on	IN	_	7	case	_	_
6	plasma	plasma	NN	_	7	com	_	_
7	drug2	drug0	NNS	_	2	ppmod	_	_
8	has	have	VBZ	_	11	aux	_	_
9	not	not	RB	_	11	neg	_	_
10	been	be	VBN	_	11	aux	_	_
11	studied	study	VBN	_	0	root	_	_
12	,	,	,	_	11	p	_	_
13	but	but	CC	_	11	cc	_	_
14	cases	case	NNS	_	25	dep	_	_
15	of	of	IN	_	19	case	_	_
16	increased	increase	VBN	_	19	attr	_	_
17	drug3	drug0	NN	_	19	com	_	_
18	plasma	plasma	NN	_	19	com	_	_
19	levels	level	NNS	_	14	ppmod	_	_
20	during	during	IN	_	22	case	_	_
21	drug4	drug0	NN	_	22	com	_	_
22	therapy	therapy	NN	_	19	ppmod	_	_
23	have	have	VBP	_	25	aux	_	_
24	been	be	VBN	_	25	aux	_	_
25	reported	report	VBN	_	11	conj	_	_
26	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Concomitant	concomitant	JJ	_	4	attr	_	_
4	administration	administration	NN	_	12	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	some	some	DT	_	9	det	_	_
9	drug3	drug0	NN	_	6	conj	_	_
10	has	have	VBZ	_	12	aux	_	_
11	been	be	VBN	_	12	aux	_	_
12	reported	report	VBN	_	1	acl	_	_
13	to	to	TO	_	14	aux	_	_
14	reduce	reduce	VB	_	12	comp	_	_
15	the	the	DT	_	16	det	_	_
16	clearance	clearance	NN	_	14	obj	_	_
17	of	of	IN	_	18	case	_	_
18	drug4	drug0	NNS	_	16	ppmod	_	_
19	,	,	,	_	12	p	_	_
20	enhancing	enhance	VBG	_	12	comp	_	_
21	the	the	DT	_	22	det	_	_
22	toxicity	toxicity	NN	_	20	obj	_	_
23	of	of	IN	_	24	case	_	_
24	drug5	drug0	NN	_	22	ppmod	_	_
25	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	11	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	on	on	IN	_	7	case	_	_
6	drug2	drug0	NN	_	7	com	_	_
7	clearance	clearance	NN	_	2	ppmod	_	_
8	has	have	VBZ	_	11	aux	_	_
9	not	not	RB	_	11	neg	_	_
10	been	be	VBN	_	11	aux	_	_
11	studied	study	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	4	case	_	_
4	postmarketing	postmarketing	NN	_	5	ppmod	_	_
5	experience	experience	VBP	_	1	acl	_	_
6	there	there	EX	_	8	dep	_	_
7	have	have	VBP	_	8	aux	_	_
8	been	be	VBN	_	5	comp	_	_
9	reports	report	NNS	_	8	obj	_	_
10	of	of	IN	_	13	case	_	_
11	a	a	DT	_	13	det	_	_
12	possible	possible	JJ	_	13	attr	_	_
13	interaction	interaction	NN	_	9	ppmod	_	_
14	between	between	IN	_	15	case	_	_
15	TORADOLIV/IM	toradoliv/im	NN	_	13	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	drug2	drug0	NN	_	15	conj	_	_
18	that	that	WDT	_	19	dep	_	_
19	resulted	result	VBD	_	9	relcl	_	_
20	in	in	IN	_	21	case	_	_
21	apnea	apnea	NN	_	19	ppmod	_	_
22	.	.	.	_	1	p	_	_

1	The	the	DT	_	3	det	_	_
2	concurrent	concurrent	JJ	_	3	attr	_	_
3	use	use	NN	_	12	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drug2	drug0	NN	_	3	ppmod	_	_
8	has	have	VBZ	_	12	aux	_	_
9	not	not	RB	_	12	neg	_	_
10	been	be	VBN	_	12	aux	_	_
11	formally	formally	RB	_	12	adv	_	_
12	studied	study	VBN	_	0	root	_	_
13	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Concomitant	concomitant	JJ	_	4	attr	_	_
4	use	use	NN	_	8	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	may	may	MD	_	8	modal	_	_
8	increase	increase	VB	_	1	acl	_	_
9	the	the	DT	_	10	det	_	_
10	risk	risk	NN	_	8	obj	_	_
11	of	of	IN	_	13	case	_	_
12	renal	renal	JJ	_	13	attr	_	_
13	impairment	impairment	NN	_	10	ppmod	_	_
14	,	,	,	_	8	p	_	_
15	particularly	particularly	RB	_	18	adv	_	_
16	in	in	IN	_	18	case	_	_
17	volume-depleted	volume-depleted	JJ	_	18	attr	_	_
18	patients	patient	NNS	_	8	ppmod	_	_
19	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Sporadic	sporadic	JJ	_	4	attr	_	_
4	cases	case	NNS	_	9	dep	_	_
5	of	of	IN	_	6	case	_	_
6	seizures	seizure	NNS	_	4	ppmod	_	_
7	have	have	VBP	_	9	aux	_	_
8	been	be	VBN	_	9	aux	_	_
9	reported	report	VBN	_	1	acl	_	_
10	during	during	IN	_	12	case	_	_
11	concomitant	concomitant	JJ	_	12	attr	_	_
12	use	use	NN	_	9	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	drug3	drug0	NN	_	14	conj	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	drug4	drug0	NN	_	14	prn	_	_
19	,	,	,	_	18	p	_	_
20	drug5	drug0	NN	_	18	appo	_	_
21	)	-rrb-	-RRB-	_	18	p	_	_
22	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Hallucinations	hallucination	NNS	_	6	dep	_	_
4	have	have	VBP	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	reported	report	VBN	_	1	acl	_	_
7	when	when	WRB	_	10	adv	_	_
8	drug2	drug0	NN	_	10	dep	_	_
9	was	be	VBD	_	10	aux	_	_
10	used	use	VBN	_	6	comp	_	_
11	in	in	IN	_	12	case	_	_
12	patients	patient	NNS	_	10	ppmod	_	_
13	taking	take	VBG	_	12	acl	_	_
14	drug3	drug0	NN	_	13	obj	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	drug4	drug0	NN	_	14	prn	_	_
17	,	,	,	_	16	p	_	_
18	drug5	drug0	NN	_	16	appo	_	_
19	,	,	,	_	16	p	_	_
20	drug6	drug0	NN	_	16	appo	_	_
21	)	-rrb-	-RRB-	_	16	p	_	_
22	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	TORADOLIV/IM	toradoliv/im	NN	_	6	dep	_	_
4	has	have	VBZ	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	administered	administer	VBN	_	1	acl	_	_
7	concurrently	concurrently	RB	_	6	adv	_	_
8	with	with	IN	_	9	case	_	_
9	drug2	drug0	NN	_	6	ppmod	_	_
10	in	in	IN	_	13	case	_	_
11	several	several	JJ	_	13	attr	_	_
12	clinical	clinical	JJ	_	13	attr	_	_
13	trials	trial	NNS	_	6	ppmod	_	_
14	of	of	IN	_	16	case	_	_
15	postoperative	postoperative	JJ	_	16	attr	_	_
16	pain	pain	NN	_	13	ppmod	_	_
17	without	without	IN	_	18	case	_	_
18	evidence	evidence	NN	_	13	ppmod	_	_
19	of	of	IN	_	21	case	_	_
20	adverse	adverse	JJ	_	21	attr	_	_
21	interactions	interaction	NNS	_	18	ppmod	_	_
22	.	.	.	_	1	p	_	_

1	Do	do	VBP	_	0	root	_	_
2	not	not	RB	_	1	neg	_	_
3	mix	mix	NN	_	1	obj	_	_
4	drug1	drug0	NN	_	3	attr	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	in	in	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	same	same	JJ	_	10	attr	_	_
10	syringe	syringe	NN	_	1	ppmod	_	_
11	.	.	.	_	1	p	_	_

1	There	there	EX	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	no	no	DT	_	4	det	_	_
4	evidence	evidence	NN	_	2	obj	_	_
5	in	in	IN	_	9	case	_	_
6	animal	animal	JJ	_	9	attr	_	_
7	or	or	CC	_	6	cc	_	_
8	human	human	JJ	_	6	conj	_	_
9	studies	study	NNS	_	4	ppmod	_	_
10	that	that	IN	_	12	mark	_	_
11	drug1	drug0	NN	_	12	dep	_	_
12	induces	induce	VBZ	_	4	acl	_	_
13	or	or	CC	_	12	cc	_	_
14	inhibits	inhibit	VBZ	_	12	conj	_	_
15	hepatic	hepatic	JJ	_	16	attr	_	_
16	enzymes	enzyme	NNS	_	14	obj	_	_
17	capable	capable	JJ	_	16	attr	_	_
18	of	of	IN	_	19	case	_	_
19	metabolizing	metabolize	VBG	_	17	ppmod	_	_
20	itself	itself	PRP	_	19	obj	_	_
21	or	or	CC	_	20	cc	_	_
22	other	other	JJ	_	23	attr	_	_
23	drugs	drug	NNS	_	20	conj	_	_

1	.	.	.	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	Synergism	synergism	NN	_	17	dep	_	_
2	between	between	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	(	-lrb-	-LRB-	_	7	p	_	_
5	e.g.	e.g.	FW	_	7	ppmod	_	_
6	,	,	,	_	7	p	_	_
7	drug2	drug0	NN	_	3	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	,	,	,	_	3	p	_	_
10	drug3	drug0	NN	_	3	conj	_	_
11	,	,	,	_	10	p	_	_
12	and	and	CC	_	10	cc	_	_
13	other	other	JJ	_	14	attr	_	_
14	drug4	drug0	NNS	_	3	conj	_	_
15	has	have	VBZ	_	17	aux	_	_
16	been	be	VBN	_	17	aux	_	_
17	reported	report	VBN	_	0	root	_	_
18	.	.	.	_	17	p	_	_

1	This	this	DT	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	considered	consider	VBN	_	9	advcl	_	_
5	whenever	whenever	RB	_	4	adv	_	_
6	these	these	DT	_	7	det	_	_
7	agents	agent	NNS	_	9	dep	_	_
8	are	be	VBP	_	9	aux	_	_
9	prescribed	prescribe	VBN	_	0	root	_	_
10	concomitantly	concomitantly	RB	_	9	adv	_	_
11	.	.	.	_	9	p	_	_

1	Concurrent	concurrent	JJ	_	2	attr	_	_
2	administration	administration	NN	_	16	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	,	,	,	_	2	p	_	_
8	which	which	WDT	_	9	dep	_	_
9	competes	compete	VBZ	_	2	relcl	_	_
10	for	for	IN	_	12	case	_	_
11	tubular	tubular	JJ	_	12	attr	_	_
12	secretion	secretion	NN	_	9	ppmod	_	_
13	,	,	,	_	2	p	_	_
14	has	have	VBZ	_	16	aux	_	_
15	been	be	VBN	_	16	aux	_	_
16	shown	show	VBN	_	0	root	_	_
17	to	to	TO	_	18	aux	_	_
18	increase	increase	VB	_	16	comp	_	_
19	the	the	DT	_	21	det	_	_
20	plasma	plasma	NN	_	21	com	_	_
21	half-life	half-life	NN	_	18	obj	_	_
22	of	of	IN	_	23	case	_	_
23	drug3	drug0	NN	_	21	ppmod	_	_
24	.	.	.	_	16	p	_	_

1	Few	few	JJ	_	3	attr	_	_
2	systemic	systemic	JJ	_	3	attr	_	_
3	data	datum	NNS	_	6	dep	_	_
4	have	have	VBP	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	collected	collect	VBN	_	0	root	_	_
7	on	on	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	metabolism	metabolism	NN	_	6	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	following	follow	VBG	_	14	adv	_	_
13	concomitant	concomitant	JJ	_	14	attr	_	_
14	administration	administration	NN	_	6	ppmod	_	_
15	with	with	IN	_	17	case	_	_
16	other	other	JJ	_	17	attr	_	_
17	drugs	drug	NNS	_	14	ppmod	_	_
18	or	or	CC	_	17	cc	_	_
19	,	,	,	_	17	p	_	_
20	alternatively	alternatively	RB	_	17	adv	_	_
21	,	,	,	_	17	p	_	_
22	the	the	DT	_	23	det	_	_
23	effect	effect	NN	_	17	conj	_	_
24	of	of	IN	_	26	case	_	_
25	concomitant	concomitant	JJ	_	26	attr	_	_
26	administration	administration	NN	_	23	ppmod	_	_
27	of	of	IN	_	28	case	_	_
28	drug2	drug0	NN	_	26	ppmod	_	_
29	on	on	IN	_	31	case	_	_
30	the	the	DT	_	31	det	_	_
31	metabolism	metabolism	NN	_	23	ppmod	_	_
32	of	of	IN	_	34	case	_	_
33	other	other	JJ	_	34	attr	_	_
34	drugs	drug	NNS	_	31	ppmod	_	_
35	.	.	.	_	6	p	_	_

1	Because	because	IN	_	5	mark	_	_
2	drug1	drug0	NN	_	5	dep	_	_
3	is	be	VBZ	_	5	aux	_	_
4	extensively	extensively	RB	_	5	adv	_	_
5	metabolized	metabolize	VBN	_	13	advcl	_	_
6	,	,	,	_	13	p	_	_
7	the	the	DT	_	8	det	_	_
8	coadministration	coadministration	NN	_	13	dep	_	_
9	of	of	IN	_	11	case	_	_
10	other	other	JJ	_	11	attr	_	_
11	drugs	drug	NNS	_	8	ppmod	_	_
12	may	may	MD	_	13	modal	_	_
13	affect	affect	VB	_	0	root	_	_
14	its	its	PRP$	_	16	poss	_	_
15	clinical	clinical	JJ	_	16	attr	_	_
16	activity	activity	NN	_	13	obj	_	_
17	.	.	.	_	13	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	studies	study	NNS	_	4	dep	_	_
4	indicate	indicate	VBP	_	0	root	_	_
5	that	that	IN	_	9	mark	_	_
6	drug1	drug0	NN	_	9	dep	_	_
7	is	be	VBZ	_	9	aux	_	_
8	primarily	primarily	RB	_	9	adv	_	_
9	metabolized	metabolize	VBN	_	4	comp	_	_
10	to	to	TO	_	11	aux	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	by	by	IN	_	15	case	_	_
13	the	the	DT	_	15	det	_	_
14	CYP2B6	cyp0b0	NN	_	15	com	_	_
15	isoenzyme	isoenzyme	NN	_	9	ppmod	_	_
16	.	.	.	_	4	p	_	_

1	Therefore	therefore	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	the	the	DT	_	4	det	_	_
4	potential	potential	NN	_	5	dep	_	_
5	exists	exist	VBZ	_	0	root	_	_
6	for	for	IN	_	9	case	_	_
7	a	a	DT	_	9	det	_	_
8	drug	drug	NN	_	9	com	_	_
9	interaction	interaction	NN	_	5	ppmod	_	_
10	between	between	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	drugs	drug	NNS	_	11	conj	_	_
14	that	that	WDT	_	15	dep	_	_
15	affect	affect	VBP	_	13	relcl	_	_
16	the	the	DT	_	18	det	_	_
17	CYP2B6	cyp0b0	NN	_	18	com	_	_
18	isoenzyme	isoenzyme	NN	_	15	obj	_	_
19	(	-lrb-	-LRB-	_	22	p	_	_
20	e.g.	e.g.	FW	_	22	adv	_	_
21	,	,	,	_	22	p	_	_
22	drug2	drug0	NN	_	18	prn	_	_
23	and	and	CC	_	22	cc	_	_
24	drug3	drug0	NN	_	22	conj	_	_
25	)	-rrb-	-RRB-	_	22	p	_	_
26	.	.	.	_	5	p	_	_

1	The	the	DT	_	3	det	_	_
2	drug1	drug0	JJ	_	3	attr	_	_
3	metabolite	metabolite	NN	_	8	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	does	do	VBZ	_	8	aux	_	_
7	not	not	RB	_	8	neg	_	_
8	appear	appear	VB	_	0	root	_	_
9	to	to	TO	_	11	aux	_	_
10	be	be	VB	_	11	aux	_	_
11	produced	produce	VBN	_	8	comp	_	_
12	by	by	IN	_	16	case	_	_
13	the	the	DT	_	16	det	_	_
14	cytochrome	cytochrome	NN	_	16	com	_	_
15	P450	p0	NN	_	16	com	_	_
16	isoenzymes	isoenzymes	NNS	_	11	ppmod	_	_
17	.	.	.	_	8	p	_	_

1	The	the	DT	_	2	det	_	_
2	effects	effect	NNS	_	18	dep	_	_
3	of	of	IN	_	5	case	_	_
4	concomitant	concomitant	JJ	_	5	attr	_	_
5	administration	administration	NN	_	2	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	on	on	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	pharmacokinetics	pharmacokinetics	NNS	_	2	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	its	its	PRP$	_	16	poss	_	_
15	active	active	JJ	_	16	attr	_	_
16	metabolites	metabolite	NNS	_	12	conj	_	_
17	were	be	VBD	_	18	aux	_	_
18	studied	study	VBN	_	0	root	_	_
19	in	in	IN	_	24	case	_	_
20	24	0	CD	_	24	num	_	_
21	healthy	healthy	JJ	_	24	attr	_	_
22	young	young	JJ	_	24	attr	_	_
23	male	male	JJ	_	24	attr	_	_
24	volunteers	volunteer	NNS	_	18	ppmod	_	_
25	.	.	.	_	18	p	_	_

1	Following	follow	VBG	_	3	adv	_	_
2	oral	oral	JJ	_	3	attr	_	_
3	administration	administration	NN	_	24	ppmod	_	_
4	of	of	IN	_	8	case	_	_
5	two	#crd#	CD	_	8	num	_	_
6	150-mg	0-mg	NN	_	8	com	_	_
7	sustained-release	sustained-release	NN	_	8	com	_	_
8	tablets	tablet	NNS	_	3	ppmod	_	_
9	with	with	IN	_	8	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	without	without	IN	_	13	case	_	_
12	800	0	CD	_	13	num	_	_
13	mg	mg	NN	_	9	conj	_	_
14	of	of	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	,	,	,	_	24	p	_	_
17	the	the	DT	_	18	det	_	_
18	pharmacokinetics	pharmacokinetics	NNS	_	24	dep	_	_
19	of	of	IN	_	20	case	_	_
20	drug2	drug0	NN	_	18	ppmod	_	_
21	and	and	CC	_	20	cc	_	_
22	drug3	drug0	NN	_	20	conj	_	_
23	were	be	VBD	_	24	aux	_	_
24	unaffected	unaffected	VBN	_	0	root	_	_
25	.	.	.	_	24	p	_	_

1	However	however	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	there	there	EX	_	4	dep	_	_
4	were	be	VBD	_	0	root	_	_
5	16	0	CD	_	4	obj	_	_
6	%	%	NN	_	5	meta	_	_
7	and	and	CC	_	5	cc	_	_
8	32	0	CD	_	10	num	_	_
9	%	%	NN	_	8	meta	_	_
10	increases	increase	NNS	_	5	conj	_	_
11	in	in	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	AUC	auc	NN	_	10	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	Cmax	cmax	NN	_	13	conj	_	_
16	,	,	,	_	10	p	_	_
17	respectively	respectively	RB	_	10	adv	_	_
18	,	,	,	_	10	p	_	_
19	of	of	IN	_	22	case	_	_
20	the	the	DT	_	22	det	_	_
21	combined	combined	JJ	_	22	attr	_	_
22	moieties	moiety	NNS	_	5	conj	_	_
23	of	of	IN	_	24	case	_	_
24	drug1	drug0	NN	_	22	ppmod	_	_
25	and	and	CC	_	24	cc	_	_
26	drug2	drug0	NN	_	24	conj	_	_
27	.	.	.	_	4	p	_	_

1	While	while	IN	_	4	mark	_	_
2	not	not	RB	_	4	neg	_	_
3	systematically	systematically	RB	_	4	adv	_	_
4	studied	study	VBN	_	9	advcl	_	_
5	,	,	,	_	9	p	_	_
6	certain	certain	JJ	_	7	attr	_	_
7	drugs	drug	NNS	_	9	dep	_	_
8	may	may	MD	_	9	modal	_	_
9	induce	induce	VB	_	0	root	_	_
10	the	the	DT	_	11	det	_	_
11	metabolism	metabolism	NN	_	9	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	(	-lrb-	-LRB-	_	17	p	_	_
15	e.g.	e.g.	FW	_	17	ppmod	_	_
16	,	,	,	_	17	p	_	_
17	drug2	drug0	NN	_	13	prn	_	_
18	,	,	,	_	17	p	_	_
19	drug3	drug0	NN	_	17	appo	_	_
20	,	,	,	_	17	p	_	_
21	drug4	drug0	NN	_	17	appo	_	_
22	)	-rrb-	-RRB-	_	17	p	_	_
23	.	.	.	_	9	p	_	_

1	Animal	animal	NN	_	2	com	_	_
2	data	datum	NNS	_	3	dep	_	_
3	indicated	indicate	VBD	_	0	root	_	_
4	that	that	IN	_	7	mark	_	_
5	drug1	drug0	NN	_	7	dep	_	_
6	may	may	MD	_	7	modal	_	_
7	be	be	VB	_	3	comp	_	_
8	an	an	DT	_	9	det	_	_
9	inducer	inducer	NN	_	7	obj	_	_
10	of	of	IN	_	12	case	_	_
11	drug-metabolizing	drug-metabolizing	JJ	_	12	attr	_	_
12	enzymes	enzyme	NNS	_	9	ppmod	_	_
13	in	in	IN	_	14	case	_	_
14	humans	human	NNS	_	12	ppmod	_	_
15	.	.	.	_	3	p	_	_

1	In	in	IN	_	3	case	_	_
2	one	#crd#	CD	_	3	num	_	_
3	study	study	NN	_	26	ppmod	_	_
4	,	,	,	_	26	p	_	_
5	following	follow	VBG	_	7	adv	_	_
6	chronic	chronic	JJ	_	7	attr	_	_
7	administration	administration	NN	_	26	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	9	p	_	_
11	100	0	CD	_	12	num	_	_
12	mg	mg	NN	_	9	appo	_	_
13	3	0	CD	_	15	num	_	_
14	times	time	NNS	_	15	advnp	_	_
15	daily	daily	JJ	_	12	attr	_	_
16	to	to	TO	_	20	aux	_	_
17	8	0	CD	_	20	num	_	_
18	healthy	healthy	JJ	_	20	attr	_	_
19	male	male	JJ	_	20	attr	_	_
20	volunteers	volunteer	NNS	_	15	ppmod	_	_
21	for	for	IN	_	23	case	_	_
22	14	0	CD	_	23	num	_	_
23	days	day	NNS	_	15	ppmod	_	_
24	,	,	,	_	26	p	_	_
25	there	there	EX	_	26	dep	_	_
26	was	be	VBD	_	0	root	_	_
27	no	no	DT	_	28	det	_	_
28	evidence	evidence	NN	_	26	obj	_	_
29	of	of	IN	_	30	case	_	_
30	induction	induction	NN	_	28	ppmod	_	_
31	of	of	IN	_	34	case	_	_
32	its	its	PRP$	_	34	poss	_	_
33	own	own	JJ	_	34	attr	_	_
34	metabolism	metabolism	NN	_	30	ppmod	_	_
35	.	.	.	_	26	p	_	_

1	Nevertheless	nevertheless	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	there	there	EX	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	be	be	VB	_	0	root	_	_
6	the	the	DT	_	7	det	_	_
7	potential	potential	NN	_	5	obj	_	_
8	for	for	IN	_	11	case	_	_
9	clinically	clinically	RB	_	10	adv	_	_
10	important	important	JJ	_	11	attr	_	_
11	alterations	alteration	NNS	_	7	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	blood	blood	NN	_	14	com	_	_
14	levels	level	NNS	_	11	ppmod	_	_
15	of	of	IN	_	17	case	_	_
16	coadministered	coadministered	JJ	_	17	attr	_	_
17	drugs	drug	NNS	_	14	ppmod	_	_
18	.	.	.	_	5	p	_	_

1	Drugs	drug	NNS	_	30	dep	_	_
2	Metabolized	metabolize	VBN	_	1	acl	_	_
3	by	by	IN	_	11	case	_	_
4	Cytochrome	cytochrome	NN	_	5	com	_	_
5	P450IID6	p0iid0	NN	_	11	attr	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	CYP2D6	cyp0d0	NN	_	5	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	:	:	:	_	11	p	_	_
10	Many	many	JJ	_	11	attr	_	_
11	drugs	drug	NNS	_	2	ppmod	_	_
12	,	,	,	_	11	p	_	_
13	including	include	VBG	_	15	adv	_	_
14	most	most	JJ	_	15	attr	_	_
15	drug1	drug0	NN	_	11	ppmod	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	SSRIs	ssris	NN	_	15	prn	_	_
18	,	,	,	_	17	p	_	_
19	many	many	JJ	_	20	attr	_	_
20	drug2	drug0	NNS	_	17	appo	_	_
21	)	-rrb-	-RRB-	_	17	p	_	_
22	,	,	,	_	15	p	_	_
23	drug3	drug0	NN	_	15	conj	_	_
24	,	,	,	_	23	p	_	_
25	drug4	drug0	NN	_	15	conj	_	_
26	,	,	,	_	25	p	_	_
27	and	and	CC	_	25	cc	_	_
28	drug5	drug0	NN	_	15	conj	_	_
29	are	be	VBP	_	30	aux	_	_
30	metabolized	metabolize	VBN	_	0	root	_	_
31	by	by	IN	_	34	case	_	_
32	the	the	DT	_	34	det	_	_
33	CYP2D6	cyp0d0	NN	_	34	com	_	_
34	isoenzyme	isoenzyme	NN	_	30	ppmod	_	_
35	.	.	.	_	30	p	_	_

1	Although	although	IN	_	5	mark	_	_
2	drug1	drug0	NN	_	5	dep	_	_
3	is	be	VBZ	_	5	aux	_	_
4	not	not	RB	_	5	neg	_	_
5	metabolized	metabolize	VBN	_	13	advcl	_	_
6	by	by	IN	_	8	case	_	_
7	this	this	DT	_	8	det	_	_
8	isoenzyme	isoenzyme	NN	_	5	ppmod	_	_
9	,	,	,	_	13	p	_	_
10	drug2	drug0	NN	_	13	dep	_	_
11	and	and	CC	_	10	cc	_	_
12	drug3	drug0	NN	_	10	conj	_	_
13	are	be	VBP	_	0	root	_	_
14	inhibitors	inhibitor	NNS	_	13	obj	_	_
15	of	of	IN	_	18	case	_	_
16	the	the	DT	_	18	det	_	_
17	CYP2D6	cyp0d0	NN	_	18	com	_	_
18	isoenzyme	isoenzyme	NN	_	14	ppmod	_	_
19	in	in	FW	_	20	adv	_	_
20	vitro	vitro	FW	_	13	adv	_	_
21	.	.	.	_	13	p	_	_

1	In	in	IN	_	3	case	_	_
2	a	a	DT	_	3	det	_	_
3	study	study	NN	_	43	ppmod	_	_
4	of	of	IN	_	7	case	_	_
5	15	0	CD	_	7	num	_	_
6	male	male	JJ	_	7	attr	_	_
7	subjects	subject	NNS	_	3	ppmod	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	ages	age	NNS	_	7	prn	_	_
10	19	0	CD	_	13	num	_	_
11	to	to	TO	_	13	attr	_	_
12	35	0	CD	_	13	num	_	_
13	years	year	NNS	_	9	attr	_	_
14	)	-rrb-	-RRB-	_	9	p	_	_
15	who	who	WP	_	16	dep	_	_
16	were	be	VBD	_	7	relcl	_	_
17	extensive	extensive	JJ	_	18	attr	_	_
18	metabolizers	metabolizers	NNS	_	16	obj	_	_
19	of	of	IN	_	22	case	_	_
20	the	the	DT	_	22	det	_	_
21	CYP2D6	cyp0d0	NN	_	22	com	_	_
22	isoenzyme	isoenzyme	NN	_	18	ppmod	_	_
23	,	,	,	_	43	p	_	_
24	daily	daily	JJ	_	25	attr	_	_
25	doses	dose	NNS	_	43	dep	_	_
26	of	of	IN	_	27	case	_	_
27	drug1	drug0	NN	_	25	ppmod	_	_
28	given	give	VBN	_	27	acl	_	_
29	as	as	IN	_	31	case	_	_
30	150	0	CD	_	31	num	_	_
31	mg	mg	NN	_	28	ppmod	_	_
32	twice	twice	RB	_	33	com	_	_
33	daily	daily	RB	_	34	adv	_	_
34	followed	followed	VBN	_	31	acl	_	_
35	by	by	IN	_	38	case	_	_
36	a	a	DT	_	38	det	_	_
37	single	single	JJ	_	38	attr	_	_
38	dose	dose	NN	_	34	ppmod	_	_
39	of	of	IN	_	42	case	_	_
40	50	0	CD	_	41	num	_	_
41	mg	mg	NN	_	42	com	_	_
42	drug2	drug0	NN	_	38	ppmod	_	_
43	increased	increase	VBD	_	0	root	_	_
44	the	the	DT	_	45	det	_	_
45	Cmax	cmax	NN	_	43	obj	_	_
46	,	,	,	_	45	p	_	_
47	AUC	auc	NN	_	45	conj	_	_
48	,	,	,	_	47	p	_	_
49	and	and	CC	_	47	cc	_	_
50	t1/2	t0	NN	_	45	conj	_	_
51	of	of	IN	_	52	case	_	_
52	drug3	drug0	NN	_	45	ppmod	_	_
53	by	by	IN	_	55	case	_	_
54	an	an	DT	_	55	det	_	_
55	average	average	NN	_	43	ppmod	_	_
56	of	of	IN	_	58	case	_	_
57	approximately	approximately	RB	_	58	adv	_	_
58	2-	0-	CD	_	55	ppmod	_	_
59	,	,	,	_	58	p	_	_
60	5-	0-	CD	_	58	appo	_	_
61	and	and	CC	_	43	cc	_	_
62	2-fold	0-fold	RB	_	43	adv	_	_
63	,	,	,	_	43	p	_	_
64	respectively	respectively	RB	_	43	conj	_	_
65	.	.	.	_	43	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	3	dep	_	_
3	was	be	VBD	_	0	root	_	_
4	present	present	JJ	_	3	dep	_	_
5	for	for	IN	_	9	case	_	_
6	at	at	IN	_	8	case	_	_
7	least	least	JJS	_	8	attr	_	_
8	7	0	CD	_	9	num	_	_
9	days	day	NNS	_	3	ppmod	_	_
10	after	after	IN	_	13	case	_	_
11	the	the	DT	_	13	det	_	_
12	last	last	JJ	_	13	attr	_	_
13	dose	dose	NN	_	3	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	3	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	use	use	NN	_	15	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	with	with	IN	_	7	case	_	_
6	other	other	JJ	_	7	attr	_	_
7	drugs	drug	NNS	_	2	ppmod	_	_
8	metabolized	metabolize	VBN	_	7	acl	_	_
9	by	by	IN	_	10	case	_	_
10	CYP2D6	cyp0d0	NN	_	8	ppmod	_	_
11	has	have	VBZ	_	15	aux	_	_
12	not	not	RB	_	15	neg	_	_
13	been	be	VBN	_	15	aux	_	_
14	formally	formally	RB	_	15	adv	_	_
15	studied	study	VBN	_	0	root	_	_
16	.	.	.	_	15	p	_	_

1	Therefore	therefore	RB	_	63	adv	_	_
2	,	,	,	_	63	p	_	_
3	co-administration	co-administration	NN	_	63	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drugs	drug	NNS	_	3	ppmod	_	_
8	that	that	WDT	_	10	dep	_	_
9	are	be	VBP	_	10	aux	_	_
10	metabolized	metabolize	VBN	_	7	relcl	_	_
11	by	by	IN	_	13	case	_	_
12	CYP2D6	cyp0d0	NN	_	13	com	_	_
13	isoenzyme	isoenzyme	NN	_	10	ppmod	_	_
14	including	include	VBG	_	16	adv	_	_
15	certain	certain	JJ	_	16	attr	_	_
16	drug2	drug0	NNS	_	13	ppmod	_	_
17	(	-lrb-	-LRB-	_	20	p	_	_
18	e.g.	e.g.	FW	_	20	adv	_	_
19	,	,	,	_	20	p	_	_
20	drug3	drug0	NN	_	16	prn	_	_
21	,	,	,	_	20	p	_	_
22	drug4	drug0	NN	_	20	appo	_	_
23	,	,	,	_	20	p	_	_
24	drug5	drug0	NN	_	20	appo	_	_
25	,	,	,	_	20	p	_	_
26	drug6	drug0	NN	_	20	appo	_	_
27	,	,	,	_	20	p	_	_
28	drug7	drug0	NN	_	20	appo	_	_
29	,	,	,	_	20	p	_	_
30	drug8	drug0	NN	_	20	appo	_	_
31	)	-rrb-	-RRB-	_	20	p	_	_
32	,	,	,	_	16	p	_	_
33	drug9	drug0	CD	_	16	appo	_	_
34	(	-lrb-	-LRB-	_	41	p	_	_
35	e.g.	e.g.	FW	_	41	ppmod	_	_
36	,	,	,	_	41	p	_	_
37	drug10	drug0	CD	_	41	num	_	_
38	,	,	,	_	41	p	_	_
39	drug11	drug0	CD	_	41	num	_	_
40	,	,	,	_	41	p	_	_
41	drug12	drug0	CD	_	33	num	_	_
42	)	-rrb-	-RRB-	_	41	p	_	_
43	,	,	,	_	33	p	_	_
44	drug13	drug0	CD	_	33	conj	_	_
45	(	-lrb-	-LRB-	_	48	p	_	_
46	e.g.	e.g.	FW	_	48	ppmod	_	_
47	,	,	,	_	48	p	_	_
48	drug14	drug0	CD	_	44	num	_	_
49	)	-rrb-	-RRB-	_	48	p	_	_
50	,	,	,	_	44	p	_	_
51	and	and	CC	_	44	cc	_	_
52	drug15	drug0	CD	_	33	conj	_	_
53	(	-lrb-	-LRB-	_	58	p	_	_
54	e.g.	e.g.	FW	_	56	adv	_	_
55	,	,	,	_	56	p	_	_
56	drug16	drug0	NN	_	58	ppmod	_	_
57	,	,	,	_	58	p	_	_
58	drug17	drug0	CD	_	52	num	_	_
59	)	-rrb-	-RRB-	_	58	p	_	_
60	,	,	,	_	16	p	_	_
61	should	should	MD	_	63	modal	_	_
62	be	be	VB	_	63	aux	_	_
63	approached	approach	VBN	_	0	root	_	_
64	with	with	IN	_	65	case	_	_
65	caution	caution	NN	_	63	ppmod	_	_
66	and	and	CC	_	63	cc	_	_
67	should	should	MD	_	69	modal	_	_
68	be	be	VB	_	69	aux	_	_
69	initiated	initiate	VBN	_	63	conj	_	_
70	at	at	IN	_	73	case	_	_
71	the	the	DT	_	73	det	_	_
72	lower	low	JJR	_	73	attr	_	_
73	end	end	NN	_	69	ppmod	_	_
74	of	of	IN	_	77	case	_	_
75	the	the	DT	_	77	det	_	_
76	dose	dose	NN	_	77	com	_	_
77	range	range	NN	_	73	ppmod	_	_
78	of	of	IN	_	81	case	_	_
79	the	the	DT	_	81	det	_	_
80	concomitant	concomitant	JJ	_	81	attr	_	_
81	medication	medication	NN	_	77	ppmod	_	_
82	.	.	.	_	63	p	_	_

1	If	if	IN	_	4	mark	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	added	add	VBN	_	32	advcl	_	_
5	to	to	TO	_	8	aux	_	_
6	the	the	DT	_	8	det	_	_
7	treatment	treatment	NN	_	8	com	_	_
8	regimen	regimen	NN	_	4	ppmod	_	_
9	of	of	IN	_	11	case	_	_
10	a	a	DT	_	11	det	_	_
11	patient	patient	NN	_	8	ppmod	_	_
12	already	already	RB	_	13	adv	_	_
13	receiving	receive	VBG	_	11	acl	_	_
14	a	a	DT	_	15	det	_	_
15	drug	drug	NN	_	13	obj	_	_
16	metabolized	metabolize	VBN	_	15	acl	_	_
17	by	by	IN	_	18	case	_	_
18	CYP2D6	cyp0d0	NN	_	16	ppmod	_	_
19	,	,	,	_	32	p	_	_
20	the	the	DT	_	21	det	_	_
21	need	need	NN	_	32	dep	_	_
22	to	to	TO	_	23	aux	_	_
23	decrease	decrease	VB	_	21	acl	_	_
24	the	the	DT	_	25	det	_	_
25	dose	dose	NN	_	23	obj	_	_
26	of	of	IN	_	29	case	_	_
27	the	the	DT	_	29	det	_	_
28	original	original	JJ	_	29	attr	_	_
29	medication	medication	NN	_	25	ppmod	_	_
30	should	should	MD	_	32	modal	_	_
31	be	be	VB	_	32	aux	_	_
32	considered	consider	VBN	_	0	root	_	_
33	,	,	,	_	32	p	_	_
34	particularly	particularly	RB	_	32	adv	_	_
35	for	for	IN	_	38	case	_	_
36	those	those	DT	_	38	det	_	_
37	concomitant	concomitant	JJ	_	38	attr	_	_
38	medications	medication	NNS	_	32	ppmod	_	_
39	with	with	IN	_	43	case	_	_
40	a	a	DT	_	43	det	_	_
41	narrow	narrow	JJ	_	43	attr	_	_
42	therapeutic	therapeutic	JJ	_	43	attr	_	_
43	index	index	NN	_	38	ppmod	_	_
44	.	.	.	_	32	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Studies	study	NNS	_	6	dep	_	_
4	in	in	IN	_	5	case	_	_
5	animals	animal	NNS	_	3	ppmod	_	_
6	demonstrate	demonstrate	VBP	_	1	acl	_	_
7	that	that	IN	_	14	mark	_	_
8	the	the	DT	_	10	det	_	_
9	acute	acute	JJ	_	10	attr	_	_
10	toxicity	toxicity	NN	_	14	dep	_	_
11	of	of	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	is	be	VBZ	_	14	aux	_	_
14	enhanced	enhance	VBN	_	6	comp	_	_
15	by	by	IN	_	18	case	_	_
16	the	the	DT	_	18	det	_	_
17	drug3	drug0	NN	_	18	com	_	_
18	drug4	drug0	NN	_	14	ppmod	_	_
19	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	:	:	:	_	1	p	_	_
5	Limited	limited	JJ	_	7	attr	_	_
6	clinical	clinical	JJ	_	7	attr	_	_
7	data	datum	NNS	_	8	dep	_	_
8	suggest	suggest	VBP	_	1	acl	_	_
9	a	a	DT	_	11	det	_	_
10	higher	high	JJR	_	11	attr	_	_
11	incidence	incidence	NN	_	8	obj	_	_
12	of	of	IN	_	14	case	_	_
13	adverse	adverse	JJ	_	14	attr	_	_
14	experiences	experience	NNS	_	11	ppmod	_	_
15	in	in	IN	_	16	case	_	_
16	patients	patient	NNS	_	14	ppmod	_	_
17	receiving	receive	VBG	_	16	acl	_	_
18	drug3	drug0	NN	_	17	obj	_	_
19	concurrently	concurrently	RB	_	22	adv	_	_
20	with	with	IN	_	22	case	_	_
21	either	either	CC	_	22	cc	_	_
22	drug4	drug0	NN	_	14	ppmod	_	_
23	or	or	CC	_	22	cc	_	_
24	drug5	drug0	NN	_	22	conj	_	_
25	.	.	.	_	1	p	_	_

1	Administration	administration	NN	_	15	dep	_	_
2	of	of	IN	_	4	case	_	_
3	drug1	drug0	JJ	_	4	attr	_	_
4	Tablets	tablet	NNS	_	1	ppmod	_	_
5	to	to	TO	_	6	aux	_	_
6	patients	patient	NNS	_	1	ppmod	_	_
7	receiving	receive	VBG	_	6	acl	_	_
8	either	either	CC	_	9	cc	_	_
9	drug2	drug0	NN	_	7	obj	_	_
10	or	or	CC	_	9	cc	_	_
11	drug3	drug0	NN	_	9	conj	_	_
12	concurrently	concurrently	RB	_	15	adv	_	_
13	should	should	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	undertaken	undertake	VBN	_	0	root	_	_
16	with	with	IN	_	17	case	_	_
17	caution	caution	NN	_	15	ppmod	_	_
18	,	,	,	_	15	p	_	_
19	using	use	VBG	_	15	comp	_	_
20	small	small	JJ	_	22	attr	_	_
21	initial	initial	JJ	_	22	attr	_	_
22	doses	dose	NNS	_	19	obj	_	_
23	and	and	CC	_	22	cc	_	_
24	small	small	JJ	_	27	attr	_	_
25	gradual	gradual	JJ	_	27	attr	_	_
26	dose	dose	NN	_	27	com	_	_
27	increases	increase	NNS	_	22	conj	_	_
28	.	.	.	_	15	p	_	_

1	Drugs	drug	NNS	_	0	root	_	_
2	that	that	IN	_	5	case	_	_
3	Lower	low	JJR	_	5	attr	_	_
4	Seizure	seizure	NN	_	5	com	_	_
5	Threshold	threshold	NN	_	1	ppmod	_	_
6	:	:	:	_	1	p	_	_
7	Concurrent	concurrent	JJ	_	8	attr	_	_
8	administration	administration	NN	_	1	appo	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	8	cc	_	_
12	agents	agent	NNS	_	8	conj	_	_
13	(	-lrb-	-LRB-	_	16	p	_	_
14	e.g.	e.g.	FW	_	16	ppmod	_	_
15	,	,	,	_	16	p	_	_
16	drug2	drug0	NN	_	12	prn	_	_
17	,	,	,	_	16	p	_	_
18	other	other	JJ	_	19	attr	_	_
19	drug3	drug0	NN	_	16	conj	_	_
20	,	,	,	_	19	p	_	_
21	drug4	drug0	NN	_	16	conj	_	_
22	,	,	,	_	21	p	_	_
23	systemic	systemic	JJ	_	24	attr	_	_
24	drug5	drug0	NN	_	16	conj	_	_
25	,	,	,	_	24	p	_	_
26	etc.	etc.	NN	_	16	conj	_	_
27	)	-rrb-	-RRB-	_	16	p	_	_
28	that	that	WDT	_	34	dep	_	_
29	lower	low	JJR	_	31	attr	_	_
30	seizure	seizure	NN	_	31	com	_	_
31	threshold	threshold	NN	_	34	dep	_	_
32	should	should	MD	_	34	modal	_	_
33	be	be	VB	_	34	aux	_	_
34	undertaken	undertake	VBN	_	12	relcl	_	_
35	only	only	RB	_	34	adv	_	_
36	with	with	IN	_	38	case	_	_
37	extreme	extreme	JJ	_	38	attr	_	_
38	caution	caution	NN	_	34	ppmod	_	_
39	.	.	.	_	1	p	_	_

1	Low	low	JJ	_	3	attr	_	_
2	initial	initial	JJ	_	3	attr	_	_
3	dosing	dosing	NN	_	11	dep	_	_
4	and	and	CC	_	3	cc	_	_
5	small	small	JJ	_	8	attr	_	_
6	gradual	gradual	JJ	_	8	attr	_	_
7	dose	dose	NN	_	8	com	_	_
8	increases	increase	NNS	_	3	conj	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	employed	employ	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	3	attr	_	_
2	Transdermal	transdermal	JJ	_	3	attr	_	_
3	System	system	NN	_	0	root	_	_
4	:	:	:	_	3	p	_	_
5	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	5	case	_	_
4	post-marketing	post-marketing	JJ	_	5	attr	_	_
5	experience	experience	VBP	_	9	ppmod	_	_
6	,	,	,	_	9	p	_	_
7	there	there	EX	_	9	dep	_	_
8	have	have	VBP	_	9	aux	_	_
9	been	be	VBN	_	1	acl	_	_
10	rare	rare	JJ	_	11	attr	_	_
11	reports	report	NNS	_	9	obj	_	_
12	of	of	IN	_	15	case	_	_
13	adverse	adverse	JJ	_	15	attr	_	_
14	neuropsychiatric	neuropsychiatric	JJ	_	15	attr	_	_
15	events	event	NNS	_	11	ppmod	_	_
16	or	or	CC	_	15	cc	_	_
17	reduced	reduce	VBN	_	19	attr	_	_
18	drug2	drug0	NN	_	19	com	_	_
19	tolerance	tolerance	NN	_	15	conj	_	_
20	in	in	IN	_	21	case	_	_
21	patients	patient	NNS	_	11	ppmod	_	_
22	who	who	WP	_	24	dep	_	_
23	were	be	VBD	_	24	aux	_	_
24	drinking	drink	VBG	_	21	relcl	_	_
25	drug3	drug0	NN	_	24	obj	_	_
26	during	during	IN	_	27	case	_	_
27	treatment	treatment	NN	_	24	ppmod	_	_
28	with	with	IN	_	29	case	_	_
29	drug4	drug0	NN	_	27	ppmod	_	_
30	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	consumption	consumption	NN	_	11	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	during	during	IN	_	6	case	_	_
6	treatment	treatment	NN	_	2	ppmod	_	_
7	with	with	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	minimized	minimize	VBN	_	0	root	_	_
12	or	or	CC	_	11	cc	_	_
13	avoided	avoid	VBN	_	11	conj	_	_
14	(	-lrb-	-LRB-	_	16	p	_	_
15	also	also	RB	_	16	adv	_	_
16	see	see	VB	_	11	prn	_	_
17	a	a	DT	_	22	det	_	_
18	href=	href=	CD	_	22	num	_	_
19	bupropz_od.htm	#hlink#	NN	_	20	com	_	_
20	#	#	NN	_	22	attr	_	_
21	CI	ci	CD	_	20	num	_	_
22	CONTRAINDICATIONS	contraindication	NNS	_	16	obj	_	_
23	)	-rrb-	-RRB-	_	16	p	_	_

1	.	.	.	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	The	the	DT	_	2	det	_	_
2	action	action	NN	_	7	dep	_	_
3	of	of	IN	_	5	case	_	_
4	nondepolarizing	nondepolarizing	JJ	_	5	attr	_	_
5	relaxants	relaxant	NNS	_	2	ppmod	_	_
6	is	be	VBZ	_	7	aux	_	_
7	augmented	augment	VBN	_	0	root	_	_
8	by	by	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	.	.	.	_	7	p	_	_

1	Less	less	JJR	_	11	dep	_	_
2	than	than	IN	_	5	case	_	_
3	the	the	DT	_	5	det	_	_
4	usual	usual	JJ	_	5	attr	_	_
5	amounts	amount	NNS	_	1	ppmod	_	_
6	of	of	IN	_	8	case	_	_
7	these	these	DT	_	8	det	_	_
8	medicines	medicine	NNS	_	5	ppmod	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	used	use	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	If	if	IN	_	9	mark	_	_
2	the	the	DT	_	4	det	_	_
3	usual	usual	JJ	_	4	attr	_	_
4	amounts	amount	NNS	_	9	dep	_	_
5	of	of	IN	_	7	case	_	_
6	nondepolarizing	nondepolarizing	JJ	_	7	attr	_	_
7	relaxants	relaxant	NNS	_	4	ppmod	_	_
8	are	be	VBP	_	9	aux	_	_
9	given	give	VBN	_	19	advcl	_	_
10	,	,	,	_	19	p	_	_
11	the	the	DT	_	12	det	_	_
12	time	time	NN	_	19	dep	_	_
13	for	for	IN	_	14	case	_	_
14	recovery	recovery	NN	_	12	ppmod	_	_
15	from	from	IN	_	17	case	_	_
16	neuromuscular	neuromuscular	JJ	_	17	attr	_	_
17	blockade	blockade	NN	_	14	ppmod	_	_
18	will	will	MD	_	19	modal	_	_
19	be	be	VB	_	0	root	_	_
20	longer	long	JJR	_	19	dep	_	_
21	in	in	IN	_	23	case	_	_
22	the	the	DT	_	23	det	_	_
23	presence	presence	NN	_	20	ppmod	_	_
24	of	of	IN	_	25	case	_	_
25	drug1	drug0	NN	_	23	ppmod	_	_
26	than	than	IN	_	36	case	_	_
27	when	when	WRB	_	36	adv	_	_
28	drug2	drug0	NN	_	36	dep	_	_
29	or	or	CC	_	28	cc	_	_
30	drug3	drug0	NN	_	28	conj	_	_
31	with	with	IN	_	34	case	_	_
32	a	a	DT	_	34	det	_	_
33	balanced	balanced	JJ	_	34	attr	_	_
34	technique	technique	NN	_	28	ppmod	_	_
35	are	be	VBP	_	36	aux	_	_
36	used	use	VBN	_	20	ppmod	_	_
37	.	.	.	_	19	p	_	_

1	The	the	DT	_	2	det	_	_
2	rate	rate	NN	_	13	dep	_	_
3	of	of	IN	_	4	case	_	_
4	metabolism	metabolism	NN	_	2	ppmod	_	_
5	and	and	CC	_	2	cc	_	_
6	the	the	DT	_	8	det	_	_
7	leukopenic	leukopenic	JJ	_	8	attr	_	_
8	activity	activity	NN	_	2	conj	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	reportedly	reportedly	RB	_	13	adv	_	_
12	are	be	VBP	_	13	aux	_	_
13	increased	increase	VBN	_	0	root	_	_
14	by	by	IN	_	16	case	_	_
15	chronic	chronic	JJ	_	16	attr	_	_
16	administration	administration	NN	_	13	ppmod	_	_
17	of	of	IN	_	19	case	_	_
18	high	high	JJ	_	19	attr	_	_
19	doses	dose	NNS	_	16	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	drug2	drug0	NN	_	19	ppmod	_	_
22	.	.	.	_	13	p	_	_

1	The	the	DT	_	2	det	_	_
2	physician	physician	NN	_	4	dep	_	_
3	should	should	MD	_	4	modal	_	_
4	be	be	VB	_	0	root	_	_
5	alert	alert	JJ	_	4	dep	_	_
6	for	for	IN	_	10	case	_	_
7	possible	possible	JJ	_	10	attr	_	_
8	combined	combined	JJ	_	10	attr	_	_
9	drug	drug	NN	_	10	com	_	_
10	actions	action	NNS	_	5	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	desirable	desirable	JJ	_	10	attr	_	_
13	or	or	CC	_	12	cc	_	_
14	undesirable	undesirable	JJ	_	12	conj	_	_
15	,	,	,	_	10	p	_	_
16	involving	involve	VBG	_	10	acl	_	_
17	drug1	drug0	NN	_	16	obj	_	_
18	even	even	RB	_	23	adv	_	_
19	though	though	IN	_	23	mark	_	_
20	drug2	drug0	NN	_	23	dep	_	_
21	has	have	VBZ	_	23	aux	_	_
22	been	be	VBN	_	23	aux	_	_
23	used	use	VBN	_	4	comp	_	_
24	successfully	successfully	RB	_	23	adv	_	_
25	concurrently	concurrently	RB	_	28	adv	_	_
26	with	with	IN	_	28	case	_	_
27	other	other	JJ	_	28	attr	_	_
28	drugs	drug	NNS	_	23	ppmod	_	_
29	,	,	,	_	28	p	_	_
30	including	include	VBG	_	33	adv	_	_
31	other	other	JJ	_	33	attr	_	_
32	cytotoxic	cytotoxic	JJ	_	33	attr	_	_
33	drugs	drug	NNS	_	28	ppmod	_	_
34	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	treatment	treatment	NN	_	15	dep	_	_
3	,	,	,	_	2	p	_	_
4	which	which	WDT	_	5	dep	_	_
5	causes	cause	VBZ	_	2	relcl	_	_
6	a	a	DT	_	10	det	_	_
7	marked	marked	JJ	_	10	attr	_	_
8	and	and	CC	_	7	cc	_	_
9	persistent	persistent	JJ	_	7	conj	_	_
10	inhibition	inhibition	NN	_	5	obj	_	_
11	of	of	IN	_	13	case	_	_
12	cholinesterase	cholinesterase	NN	_	13	com	_	_
13	activity	activity	NN	_	10	ppmod	_	_
14	,	,	,	_	2	p	_	_
15	potentiates	potentiate	VBZ	_	0	root	_	_
16	the	the	DT	_	17	det	_	_
17	effect	effect	NN	_	15	obj	_	_
18	of	of	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	.	.	.	_	15	p	_	_

1	If	if	IN	_	6	mark	_	_
2	a	a	DT	_	3	det	_	_
3	patient	patient	NN	_	6	dep	_	_
4	has	have	VBZ	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	treated	treat	VBN	_	20	advcl	_	_
7	with	with	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	within	within	IN	_	11	case	_	_
10	10	0	CD	_	11	num	_	_
11	days	day	NNS	_	6	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	general	general	JJ	_	14	attr	_	_
14	anesthesia	anesthesia	NN	_	11	ppmod	_	_
15	,	,	,	_	20	p	_	_
16	the	the	DT	_	17	det	_	_
17	anesthesiologist	anesthesiologist	NN	_	20	dep	_	_
18	should	should	MD	_	20	modal	_	_
19	be	be	VB	_	20	aux	_	_
20	alerted	alert	VBN	_	0	root	_	_
21	.	.	.	_	20	p	_	_

1	Both	both	CC	_	3	cc	_	_
2	the	the	DT	_	3	det	_	_
3	magnitude	magnitude	NN	_	15	dep	_	_
4	and	and	CC	_	3	cc	_	_
5	duration	duration	NN	_	3	conj	_	_
6	of	of	IN	_	9	case	_	_
7	central	central	JJ	_	9	attr	_	_
8	nervous	nervous	JJ	_	9	attr	_	_
9	system	system	NN	_	3	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	cardiovascular	cardiovascular	JJ	_	12	attr	_	_
12	effects	effect	NNS	_	9	conj	_	_
13	may	may	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	enhanced	enhance	VBN	_	0	root	_	_
16	when	when	WRB	_	19	adv	_	_
17	drug1	drug0	NN	_	19	dep	_	_
18	is	be	VBZ	_	19	aux	_	_
19	administered	administer	VBN	_	15	comp	_	_
20	in	in	IN	_	21	case	_	_
21	combination	combination	NN	_	19	ppmod	_	_
22	with	with	IN	_	24	case	_	_
23	other	other	JJ	_	24	attr	_	_
24	drug2	drug0	NNS	_	21	ppmod	_	_
25	such	such	JJ	_	27	adv	_	_
26	as	as	IN	_	27	case	_	_
27	drug3	drug0	NN	_	24	ppmod	_	_
28	,	,	,	_	27	p	_	_
29	drug4	drug0	NN	_	27	conj	_	_
30	,	,	,	_	29	p	_	_
31	drug5	drug0	NN	_	27	conj	_	_
32	,	,	,	_	31	p	_	_
33	or	or	CC	_	31	cc	_	_
34	inhalation	inhalation	NN	_	36	attr	_	_
35	general	general	JJ	_	36	attr	_	_
36	drug6	drug0	NN	_	27	conj	_	_
37	.	.	.	_	15	p	_	_

1	Postoperative	postoperative	JJ	_	3	attr	_	_
2	respiratory	respiratory	JJ	_	3	attr	_	_
3	depression	depression	NN	_	6	dep	_	_
4	may	may	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	enhanced	enhance	VBN	_	0	root	_	_
7	or	or	CC	_	6	cc	_	_
8	prolonged	prolong	VBD	_	6	conj	_	_
9	by	by	IN	_	11	case	_	_
10	these	these	DT	_	11	det	_	_
11	agents	agent	NNS	_	8	ppmod	_	_
12	.	.	.	_	6	p	_	_

1	In	in	IN	_	3	case	_	_
2	such	such	JJ	_	3	attr	_	_
3	cases	case	NNS	_	17	ppmod	_	_
4	of	of	IN	_	6	case	_	_
5	combined	combined	JJ	_	6	attr	_	_
6	treatment	treatment	NN	_	3	ppmod	_	_
7	,	,	,	_	17	p	_	_
8	the	the	DT	_	9	det	_	_
9	dose	dose	NN	_	17	dep	_	_
10	of	of	IN	_	11	case	_	_
11	one	#crd#	CD	_	9	ppmod	_	_
12	or	or	CC	_	11	cc	_	_
13	both	both	DT	_	14	attr	_	_
14	agents	agent	NNS	_	11	conj	_	_
15	should	should	MD	_	17	modal	_	_
16	be	be	VB	_	17	aux	_	_
17	reduced	reduce	VBN	_	0	root	_	_
18	.	.	.	_	17	p	_	_

1	Limited	limited	JJ	_	3	attr	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	experience	experience	VBP	_	4	dep	_	_
4	indicates	indicate	VBZ	_	0	root	_	_
5	that	that	IN	_	10	mark	_	_
6	requirements	requirement	NNS	_	10	dep	_	_
7	for	for	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	are	be	VBP	_	10	aux	_	_
10	reduced	reduce	VBN	_	4	comp	_	_
11	by	by	IN	_	12	case	_	_
12	30	0	CD	_	10	ppmod	_	_
13	to	to	TO	_	12	cc	_	_
14	50	0	CD	_	12	conj	_	_
15	%	%	NN	_	12	meta	_	_
16	for	for	IN	_	23	case	_	_
17	the	the	DT	_	23	det	_	_
18	first	#ord#	JJ	_	23	attr	_	_
19	sixty	#crd#	NN	_	23	attr	_	_
20	(	-lrb-	-LRB-	_	23	p	_	_
21	60	0	CD	_	23	num	_	_
22	)	-rrb-	-RRB-	_	23	p	_	_
23	minutes	minute	NNS	_	12	ppmod	_	_
24	following	follow	VBG	_	26	adv	_	_
25	drug2	drug0	NN	_	26	com	_	_
26	induction	induction	NN	_	23	ppmod	_	_
27	The	the	DT	_	29	det	_	_
28	concomitant	concomitant	JJ	_	29	attr	_	_
29	use	use	NN	_	36	dep	_	_
30	of	of	IN	_	31	case	_	_
31	drug3	drug0	NN	_	29	ppmod	_	_
32	with	with	IN	_	33	case	_	_
33	drug4	drug0	NN	_	29	ppmod	_	_
34	can	can	MD	_	36	modal	_	_
35	significantly	significantly	RB	_	36	adv	_	_
36	inhibit	inhibit	VB	_	26	acl	_	_
37	drug5	drug0	NN	_	38	com	_	_
38	clearance	clearance	NN	_	36	obj	_	_
39	and	and	CC	_	36	cc	_	_
40	may	may	MD	_	41	modal	_	_
41	increase	increase	VB	_	36	conj	_	_
42	the	the	DT	_	43	det	_	_
43	risk	risk	NN	_	41	obj	_	_
44	of	of	IN	_	49	case	_	_
45	prolonged	prolonged	JJ	_	49	attr	_	_
46	or	or	CC	_	45	cc	_	_
47	delayed	delay	VBN	_	45	conj	_	_
48	respiratory	respiratory	JJ	_	49	attr	_	_
49	depression	depression	NN	_	43	ppmod	_	_
50	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	reduces	reduce	VBZ	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	clearance	clearance	NN	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	.	.	.	_	2	p	_	_

1	Therefore	therefore	RB	_	2	adv	_	_
2	smaller	small	JJR	_	4	attr	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	doses	dose	NNS	_	7	dep	_	_
5	will	will	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	required	require	VBN	_	0	root	_	_
8	with	with	IN	_	10	case	_	_
9	prolonged	prolonged	JJ	_	10	attr	_	_
10	administration	administration	NN	_	7	ppmod	_	_
11	and	and	CC	_	7	cc	_	_
12	the	the	DT	_	13	det	_	_
13	duration	duration	NN	_	20	dep	_	_
14	of	of	IN	_	15	case	_	_
15	action	action	NN	_	13	ppmod	_	_
16	of	of	IN	_	18	case	_	_
17	drug2	drug0	NN	_	18	com	_	_
18	my	my	NNS	_	15	ppmod	_	_
19	be	be	VB	_	20	aux	_	_
20	extended	extend	VBN	_	7	conj	_	_
21	.	.	.	_	20	p	_	_

1	Perioperative	perioperative	JJ	_	2	attr	_	_
2	administration	administration	NN	_	13	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drugs	drug	NNS	_	2	ppmod	_	_
5	affecting	affect	VBG	_	4	acl	_	_
6	hepatic	hepatic	JJ	_	8	attr	_	_
7	blood	blood	NN	_	8	com	_	_
8	flow	flow	NN	_	5	obj	_	_
9	or	or	CC	_	8	cc	_	_
10	enzyme	enzyme	NN	_	11	com	_	_
11	function	function	NN	_	8	conj	_	_
12	may	may	MD	_	13	modal	_	_
13	reduce	reduce	VB	_	0	root	_	_
14	plasma	plasma	NN	_	15	com	_	_
15	clearance	clearance	NN	_	13	obj	_	_
16	and	and	CC	_	13	cc	_	_
17	prolong	prolong	VB	_	13	conj	_	_
18	recovery	recovery	NN	_	17	obj	_	_
19	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	should	should	MD	_	5	modal	_	_
3	not	not	RB	_	5	neg	_	_
4	be	be	VB	_	5	aux	_	_
5	administered	administer	VBN	_	0	root	_	_
6	concomitantly	concomitantly	RB	_	5	adv	_	_
7	with	with	IN	_	8	case	_	_
8	drug2	drug0	NN	_	5	ppmod	_	_
9	,	,	,	_	8	p	_	_
10	drug3	drug0	NN	_	8	conj	_	_
11	,	,	,	_	10	p	_	_
12	drug4	drug0	NN	_	8	conj	_	_
13	,	,	,	_	12	p	_	_
14	drug5	drug0	NN	_	8	conj	_	_
15	,	,	,	_	14	p	_	_
16	or	or	CC	_	14	cc	_	_
17	drug6	drug0	NN	_	8	conj	_	_
18	.	.	.	_	5	p	_	_

1	Interactions	interaction	NNS	_	11	dep	_	_
2	between	between	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	other	other	JJ	_	6	attr	_	_
6	drugs	drug	NNS	_	3	conj	_	_
7	have	have	VBP	_	11	aux	_	_
8	not	not	RB	_	11	neg	_	_
9	been	be	VBN	_	11	aux	_	_
10	fully	fully	RB	_	11	adv	_	_
11	evaluated	evaluate	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	Although	although	IN	_	11	mark	_	_
2	studies	study	NNS	_	11	dep	_	_
3	designed	design	VBN	_	2	acl	_	_
4	to	to	TO	_	5	aux	_	_
5	examine	examine	VB	_	3	comp	_	_
6	drug	drug	NN	_	7	com	_	_
7	interactions	interaction	NNS	_	5	obj	_	_
8	have	have	VBP	_	11	aux	_	_
9	not	not	RB	_	11	neg	_	_
10	been	be	VBN	_	11	aux	_	_
11	done	do	VBN	_	15	advcl	_	_
12	,	,	,	_	15	p	_	_
13	it	it	PRP	_	15	dep	_	_
14	was	be	VBD	_	15	aux	_	_
15	noted	note	VBN	_	0	root	_	_
16	that	that	IN	_	32	mark	_	_
17	drug1	drug0	NN	_	32	dep	_	_
18	or	or	CC	_	17	cc	_	_
19	drug2	drug0	NN	_	20	com	_	_
20	treatment	treatment	NN	_	17	conj	_	_
21	of	of	IN	_	22	case	_	_
22	relapses	relapse	NNS	_	17	ppmod	_	_
23	for	for	IN	_	24	case	_	_
24	periods	period	NNS	_	17	ppmod	_	_
25	of	of	IN	_	29	case	_	_
26	up	up	RB	_	28	adv	_	_
27	to	to	TO	_	28	attr	_	_
28	28	0	CD	_	29	num	_	_
29	days	day	NNS	_	24	ppmod	_	_
30	has	have	VBZ	_	32	aux	_	_
31	been	be	VBN	_	32	aux	_	_
32	administered	administer	VBN	_	15	comp	_	_
33	to	to	TO	_	34	aux	_	_
34	patients	patient	NNS	_	32	ppmod	_	_
35	(	-lrb-	-LRB-	_	36	p	_	_
36	N=180	n=0	NN	_	34	prn	_	_
37	)	-rrb-	-RRB-	_	36	p	_	_
38	receiving	receive	VBG	_	34	acl	_	_
39	drug3	drug0	NN	_	38	obj	_	_
40	.	.	.	_	15	p	_	_

1	drug1	drug0	JJ	_	2	attr	_	_
2	administration	administration	NN	_	17	dep	_	_
3	to	to	TO	_	6	aux	_	_
4	three	#crd#	CD	_	6	num	_	_
5	cancer	cancer	NN	_	6	com	_	_
6	patients	patient	NNS	_	2	ppmod	_	_
7	over	over	IN	_	10	case	_	_
8	a	a	DT	_	10	det	_	_
9	dose	dose	NN	_	10	com	_	_
10	range	range	NN	_	6	ppmod	_	_
11	of	of	IN	_	16	case	_	_
12	0.025	0	CD	_	16	num	_	_
13	mg	mg	NN	_	12	attr	_	_
14	to	to	TO	_	12	cc	_	_
15	2.2	0	CD	_	12	conj	_	_
16	mg	mg	NN	_	10	ppmod	_	_
17	led	lead	VBD	_	0	root	_	_
18	to	to	TO	_	21	aux	_	_
19	a	a	DT	_	21	det	_	_
20	dose-dependent	dose-dependent	JJ	_	21	attr	_	_
21	inhibition	inhibition	NN	_	17	ppmod	_	_
22	of	of	IN	_	24	case	_	_
23	drug2	drug0	NN	_	24	com	_	_
24	elimination.14	elimination.0	NN	_	21	ppmod	_	_
25	The	the	DT	_	26	det	_	_
26	effect	effect	NN	_	41	dep	_	_
27	of	of	IN	_	29	case	_	_
28	alternate-day	alternate-day	JJ	_	29	attr	_	_
29	administration	administration	NN	_	26	ppmod	_	_
30	of	of	IN	_	32	case	_	_
31	0.25	0	CD	_	32	num	_	_
32	mg	mg	NN	_	29	ppmod	_	_
33	of	of	IN	_	34	case	_	_
34	drug3	drug0	NN	_	32	ppmod	_	_
35	on	on	IN	_	37	case	_	_
36	drug	drug	NN	_	37	com	_	_
37	metabolism	metabolism	NN	_	26	ppmod	_	_
38	in	in	IN	_	40	case	_	_
39	MS	ms	NN	_	40	com	_	_
40	patients	patient	NNS	_	37	ppmod	_	_
41	is	be	VBZ	_	24	acl	_	_
42	unknown	unknown	JJ	_	41	dep	_	_
43	.	.	.	_	17	p	_	_

1	Drug-Drug	drug-drug	JJ	_	2	attr	_	_
2	Interactions	interaction	NNS	_	8	dep	_	_
3	drug1	drug0	NN	_	2	appo	_	_
4	-	-	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	should	should	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	administered	administer	VBN	_	0	root	_	_
9	with	with	IN	_	10	case	_	_
10	caution	caution	NN	_	8	ppmod	_	_
11	to	to	TO	_	12	aux	_	_
12	patients	patient	NNS	_	8	ppmod	_	_
13	being	be	VBG	_	14	aux	_	_
14	treated	treat	VBN	_	12	acl	_	_
15	with	with	IN	_	22	case	_	_
16	systemically-administered	systemically-administered	JJ	_	22	attr	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	oral	oral	JJ	_	16	prn	_	_
19	or	or	CC	_	18	cc	_	_
20	intravenous	intravenous	JJ	_	18	conj	_	_
21	)	-rrb-	-RRB-	_	18	p	_	_
22	drug3	drug0	NN	_	14	ppmod	_	_
23	(	-lrb-	-LRB-	_	12	p	_	_
24	or	or	CC	_	12	cc	_	_
25	other	other	JJ	_	26	attr	_	_
26	drug4	drug0	NNS	_	12	conj	_	_
27	)	-rrb-	-RRB-	_	26	p	_	_
28	because	because	IN	_	39	mark	_	_
29	the	the	DT	_	30	det	_	_
30	action	action	NN	_	39	dep	_	_
31	of	of	IN	_	32	case	_	_
32	drug5	drug0	NN	_	30	ppmod	_	_
33	on	on	IN	_	36	case	_	_
34	the	the	DT	_	36	det	_	_
35	cardiovascular	cardiovascular	JJ	_	36	attr	_	_
36	system	system	NN	_	30	ppmod	_	_
37	can	can	MD	_	39	modal	_	_
38	be	be	VB	_	39	aux	_	_
39	potentiated	potentiate	VBN	_	8	comp	_	_
40	resulting	result	VBG	_	39	comp	_	_
41	in	in	IN	_	42	case	_	_
42	increases	increase	NNS	_	40	ppmod	_	_
43	in	in	IN	_	45	case	_	_
44	heart	heart	NN	_	45	com	_	_
45	rate	rate	NN	_	42	ppmod	_	_
46	and	and	CC	_	45	cc	_	_
47	blood	blood	NN	_	48	com	_	_
48	pressure	pressure	NN	_	45	conj	_	_
49	.	.	.	_	8	p	_	_

1	CYP2D6	cyp0d0	NN	_	2	com	_	_
2	inhibitors	inhibitor	NNS	_	7	dep	_	_
3	-	-	CC	_	2	cc	_	_
4	drug1	drug0	NN	_	2	conj	_	_
5	is	be	VBZ	_	7	aux	_	_
6	primarily	primarily	RB	_	7	adv	_	_
7	metabolized	metabolize	VBN	_	0	root	_	_
8	by	by	IN	_	11	case	_	_
9	the	the	DT	_	11	det	_	_
10	CYP2D6	cyp0d0	NN	_	11	com	_	_
11	pathway	pathway	NN	_	7	ppmod	_	_
12	to	to	TO	_	13	aux	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	.	.	.	_	7	p	_	_

1	In	in	IN	_	2	case	_	_
2	EMs	ems	NN	_	8	ppmod	_	_
3	,	,	,	_	8	p	_	_
4	selective	selective	JJ	_	5	attr	_	_
5	inhibitors	inhibitor	NNS	_	8	dep	_	_
6	of	of	IN	_	7	case	_	_
7	CYP2D6	cyp0d0	NN	_	5	ppmod	_	_
8	increase	increase	VBP	_	0	root	_	_
9	drug1	drug0	JJ	_	12	attr	_	_
10	steady-state	steady-state	JJ	_	12	attr	_	_
11	plasma	plasma	NN	_	12	com	_	_
12	concentrations	concentration	NNS	_	8	obj	_	_
13	to	to	TO	_	14	aux	_	_
14	exposures	exposure	NNS	_	8	ppmod	_	_
15	similar	similar	JJ	_	14	attr	_	_
16	to	to	TO	_	17	aux	_	_
17	those	those	DT	_	15	ppmod	_	_
18	observed	observe	VBN	_	17	acl	_	_
19	in	in	IN	_	20	case	_	_
20	PMs	pms	NN	_	18	ppmod	_	_
21	.	.	.	_	8	p	_	_

1	Dosage	dosage	NN	_	2	com	_	_
2	adjustment	adjustment	NN	_	6	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	may	may	MD	_	6	modal	_	_
6	be	be	VB	_	0	root	_	_
7	necessary	necessary	JJ	_	6	dep	_	_
8	when	when	WRB	_	9	adv	_	_
9	coadministered	coadministered	VBN	_	6	comp	_	_
10	with	with	IN	_	12	case	_	_
11	CYP2D6	cyp0d0	NN	_	12	com	_	_
12	inhibitors	inhibitor	NNS	_	9	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	e.g.	e.g.	FW	_	16	adv	_	_
15	,	,	,	_	16	p	_	_
16	drug2	drug0	NN	_	12	ppmod	_	_
17	,	,	,	_	16	p	_	_
18	drug3	drug0	NN	_	16	conj	_	_
19	,	,	,	_	18	p	_	_
20	and	and	CC	_	18	cc	_	_
21	drug4	drug0	NN	_	16	conj	_	_
22	.	.	.	_	6	p	_	_

1	In	in	IN	_	3	case	_	_
2	EM	em	JJ	_	3	attr	_	_
3	individuals	individual	NNS	_	14	ppmod	_	_
4	treated	treat	VBN	_	3	acl	_	_
5	with	with	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	or	or	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	,	,	,	_	14	p	_	_
10	the	the	DT	_	11	det	_	_
11	AUC	auc	NN	_	14	dep	_	_
12	of	of	IN	_	13	case	_	_
13	drug3	drug0	NN	_	11	ppmod	_	_
14	is	be	VBZ	_	0	root	_	_
15	approximately	approximately	RB	_	16	adv	_	_
16	6-	0-	CD	_	14	obj	_	_
17	to	to	TO	_	16	attr	_	_
18	8-fold	0-fold	JJ	_	16	attr	_	_
19	and	and	CC	_	14	cc	_	_
20	Css	css	NN	_	23	dep	_	_
21	,	,	,	_	20	p	_	_
22	max	max	NN	_	20	appo	_	_
23	is	be	VBZ	_	14	conj	_	_
24	about	about	RB	_	25	adv	_	_
25	3-	0-	CD	_	28	num	_	_
26	to	to	TO	_	25	attr	_	_
27	4-fold	0-fold	RB	_	25	adv	_	_
28	greater	great	JJR	_	23	dep	_	_
29	than	than	IN	_	30	case	_	_
30	drug4	drug0	NN	_	28	ppmod	_	_
31	alone	alone	RB	_	30	adv	_	_
32	.	.	.	_	14	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	studies	study	NNS	_	4	dep	_	_
4	suggest	suggest	VBP	_	0	root	_	_
5	that	that	IN	_	15	mark	_	_
6	coadministration	coadministration	NN	_	15	dep	_	_
7	of	of	IN	_	10	case	_	_
8	cytochrome	cytochrome	NN	_	10	com	_	_
9	P450	p0	NN	_	10	com	_	_
10	inhibitors	inhibitor	NNS	_	6	ppmod	_	_
11	to	to	TO	_	12	aux	_	_
12	PMs	pms	NN	_	6	ppmod	_	_
13	will	will	MD	_	15	modal	_	_
14	not	not	RB	_	15	neg	_	_
15	increase	increase	VB	_	4	comp	_	_
16	the	the	DT	_	18	det	_	_
17	plasma	plasma	NN	_	18	com	_	_
18	concentrations	concentration	NNS	_	15	obj	_	_
19	of	of	IN	_	20	case	_	_
20	drug1	drug0	NN	_	18	ppmod	_	_
21	.	.	.	_	4	p	_	_

1	Pressor	pressor	JJ	_	2	attr	_	_
2	agents	agent	NNS	_	15	dep	_	_
3	-	-	:	_	15	p	_	_
4	Because	because	IN	_	7	case	_	_
5	of	of	IN	_	7	case	_	_
6	possible	possible	JJ	_	7	attr	_	_
7	effects	effect	NNS	_	15	ppmod	_	_
8	on	on	IN	_	10	case	_	_
9	blood	blood	NN	_	10	com	_	_
10	pressure	pressure	NN	_	7	ppmod	_	_
11	,	,	,	_	15	p	_	_
12	drug1	drug0	NN	_	15	dep	_	_
13	should	should	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	used	use	VBN	_	0	root	_	_
16	cautiously	cautiously	RB	_	15	adv	_	_
17	with	with	IN	_	19	case	_	_
18	pressor	pressor	JJ	_	19	attr	_	_
19	agents	agent	NNS	_	15	ppmod	_	_
20	.	.	.	_	15	p	_	_

1	Caution	caution	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	exercised	exercise	VBN	_	0	root	_	_
5	when	when	WRB	_	8	adv	_	_
6	drug1	drug0	NN	_	8	dep	_	_
7	are	be	VBP	_	8	aux	_	_
8	given	give	VBN	_	4	comp	_	_
9	in	in	IN	_	10	case	_	_
10	conjunction	conjunction	NN	_	8	ppmod	_	_
11	with	with	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	4	p	_	_

1	Usually	usually	RB	_	10	adv	_	_
2	,	,	,	_	10	p	_	_
3	the	the	DT	_	4	det	_	_
4	dosage	dosage	NN	_	10	dep	_	_
5	of	of	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	drug1	drug0	NN	_	4	ppmod	_	_
8	should	should	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	reduced	reduce	VBN	_	0	root	_	_
11	by	by	IN	_	12	case	_	_
12	one-half	one-half	NN	_	10	ppmod	_	_
13	(	-lrb-	-LRB-	_	18	p	_	_
14	depending	depend	VBG	_	18	adv	_	_
15	on	on	IN	_	18	case	_	_
16	the	the	DT	_	18	det	_	_
17	individual	individual	JJ	_	18	attr	_	_
18	case	case	NN	_	10	prn	_	_
19	)	-rrb-	-RRB-	_	18	p	_	_
20	to	to	TO	_	21	aux	_	_
21	maintain	maintain	VB	_	10	comp	_	_
22	the	the	DT	_	24	det	_	_
23	prothrombin	prothrombin	NN	_	24	com	_	_
24	time	time	NN	_	21	obj	_	_
25	at	at	IN	_	28	case	_	_
26	the	the	DT	_	28	det	_	_
27	desired	desired	JJ	_	28	attr	_	_
28	level	level	NN	_	21	ppmod	_	_
29	to	to	TO	_	30	aux	_	_
30	prevent	prevent	VB	_	28	acl	_	_
31	bleeding	bleeding	JJ	_	32	attr	_	_
32	complications	complication	NNS	_	30	obj	_	_
33	.	.	.	_	10	p	_	_

1	Frequent	frequent	JJ	_	3	attr	_	_
2	prothrombin	prothrombin	NN	_	3	com	_	_
3	determinations	determination	NNS	_	4	dep	_	_
4	are	be	VBP	_	0	root	_	_
5	advisable	advisable	JJ	_	4	dep	_	_
6	until	until	IN	_	10	mark	_	_
7	it	it	PRP	_	10	dep	_	_
8	has	have	VBZ	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	determined	determine	VBN	_	5	comp	_	_
11	definitely	definitely	RB	_	10	adv	_	_
12	that	that	IN	_	18	mark	_	_
13	the	the	DT	_	15	det	_	_
14	prothrombin	prothrombin	NN	_	15	com	_	_
15	level	level	NN	_	18	dep	_	_
16	has	have	VBZ	_	18	aux	_	_
17	been	be	VBN	_	18	aux	_	_
18	stabilized	stabilize	VBN	_	10	comp	_	_
19	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	displace	displace	VB	_	0	root	_	_
4	acidic	acidic	JJ	_	5	attr	_	_
5	drugs	drug	NNS	_	3	obj	_	_
6	such	such	JJ	_	8	adv	_	_
7	as	as	IN	_	8	case	_	_
8	drug2	drug0	NN	_	5	ppmod	_	_
9	or	or	CC	_	8	cc	_	_
10	drug3	drug0	NN	_	8	conj	_	_
11	from	from	IN	_	14	case	_	_
12	their	their	PRP$	_	14	poss	_	_
13	binding	binding	NN	_	14	com	_	_
14	sites	site	NNS	_	8	ppmod	_	_
15	.	.	.	_	3	p	_	_

1	Caution	caution	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	exercised	exercise	VBN	_	0	root	_	_
5	when	when	WRB	_	6	adv	_	_
6	treating	treat	VBG	_	4	comp	_	_
7	patients	patient	NNS	_	6	obj	_	_
8	with	with	IN	_	9	case	_	_
9	either	either	DT	_	7	ppmod	_	_
10	of	of	IN	_	12	case	_	_
11	these	these	DT	_	12	det	_	_
12	drugs	drug	NNS	_	9	ppmod	_	_
13	or	or	CC	_	12	cc	_	_
14	other	other	JJ	_	17	attr	_	_
15	highly	highly	RB	_	16	adv	_	_
16	protein-bound	protein-bound	JJ	_	17	attr	_	_
17	drugs	drug	NNS	_	12	conj	_	_
18	and	and	CC	_	17	cc	_	_
19	drug1	drug0	NN	_	17	conj	_	_
20	.	.	.	_	4	p	_	_

1	The	the	DT	_	3	det	_	_
2	hypoglycemic	hypoglycemic	JJ	_	3	attr	_	_
3	effect	effect	NN	_	8	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	has	have	VBZ	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	reported	report	VBN	_	0	root	_	_
9	to	to	TO	_	10	aux	_	_
10	increase	increase	VB	_	8	comp	_	_
11	when	when	WRB	_	14	adv	_	_
12	drug2	drug0	NN	_	14	dep	_	_
13	is	be	VBZ	_	14	aux	_	_
14	given	give	VBN	_	10	comp	_	_
15	concurrently	concurrently	RB	_	14	adv	_	_
16	.	.	.	_	8	p	_	_

1	Fulminant	fulminant	JJ	_	2	attr	_	_
2	rhabdomyolysis	rhabdomyolysis	NN	_	5	dep	_	_
3	has	have	VBZ	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	seen	see	VBN	_	0	root	_	_
6	as	as	RB	_	7	com	_	_
7	early	early	RB	_	5	adv	_	_
8	as	as	IN	_	10	case	_	_
9	three	#crd#	CD	_	10	num	_	_
10	weeks	week	NNS	_	5	ppmod	_	_
11	after	after	IN	_	12	case	_	_
12	initiation	initiation	NN	_	10	ppmod	_	_
13	of	of	IN	_	15	case	_	_
14	combined	combined	JJ	_	15	attr	_	_
15	therapy	therapy	NN	_	12	ppmod	_	_
16	with	with	IN	_	18	case	_	_
17	another	another	DT	_	18	det	_	_
18	drug1	drug0	NN	_	15	ppmod	_	_
19	and	and	CC	_	18	cc	_	_
20	drug2	drug0	NN	_	18	conj	_	_
21	but	but	CC	_	5	cc	_	_
22	may	may	MD	_	24	modal	_	_
23	be	be	VB	_	24	aux	_	_
24	seen	see	VBN	_	5	conj	_	_
25	after	after	IN	_	27	case	_	_
26	several	several	JJ	_	27	attr	_	_
27	months	month	NNS	_	24	ppmod	_	_
28	.	.	.	_	5	p	_	_

1	For	for	IN	_	3	case	_	_
2	these	these	DT	_	3	det	_	_
3	reasons	reason	NNS	_	7	ppmod	_	_
4	,	,	,	_	7	p	_	_
5	it	it	PRP	_	7	dep	_	_
6	is	be	VBZ	_	7	aux	_	_
7	felt	feel	VBN	_	0	root	_	_
8	that	that	IN	_	38	mark	_	_
9	,	,	,	_	38	p	_	_
10	in	in	IN	_	12	case	_	_
11	most	most	JJS	_	12	attr	_	_
12	subjects	subject	NNS	_	38	ppmod	_	_
13	who	who	WP	_	14	dep	_	_
14	have	have	VBP	_	12	relcl	_	_
15	had	have	VBD	_	14	comp	_	_
16	an	an	DT	_	19	det	_	_
17	unsatisfactory	unsatisfactory	JJ	_	19	attr	_	_
18	lipid	lipid	NN	_	19	com	_	_
19	response	response	NN	_	15	obj	_	_
20	to	to	TO	_	22	aux	_	_
21	either	either	DT	_	22	det	_	_
22	drug	drug	NN	_	19	ppmod	_	_
23	alone	alone	RB	_	22	adv	_	_
24	,	,	,	_	38	p	_	_
25	the	the	DT	_	27	det	_	_
26	possible	possible	JJ	_	27	attr	_	_
27	benefits	benefit	NNS	_	38	dep	_	_
28	of	of	IN	_	30	case	_	_
29	combined	combined	JJ	_	30	attr	_	_
30	therapy	therapy	NN	_	27	ppmod	_	_
31	with	with	IN	_	32	case	_	_
32	drug1	drug0	NN	_	30	ppmod	_	_
33	and	and	CC	_	32	cc	_	_
34	a	a	DT	_	35	det	_	_
35	drug2	drug0	NN	_	32	conj	_	_
36	do	do	VBP	_	38	aux	_	_
37	not	not	RB	_	38	neg	_	_
38	outweigh	outweigh	VB	_	7	comp	_	_
39	the	the	DT	_	40	det	_	_
40	risks	risk	NNS	_	38	obj	_	_
41	of	of	IN	_	43	case	_	_
42	severe	severe	JJ	_	43	attr	_	_
43	myopathy	myopathy	NN	_	40	ppmod	_	_
44	,	,	,	_	43	p	_	_
45	rhabdomyolysis	rhabdomyolysis	NN	_	43	conj	_	_
46	,	,	,	_	45	p	_	_
47	and	and	CC	_	45	cc	_	_
48	acute	acute	JJ	_	50	attr	_	_
49	renal	renal	JJ	_	50	attr	_	_
50	failure	failure	NN	_	43	conj	_	_
51	.	.	.	_	7	p	_	_

1	While	while	IN	_	5	mark	_	_
2	it	it	PRP	_	5	dep	_	_
3	is	be	VBZ	_	5	aux	_	_
4	not	not	RB	_	5	neg	_	_
5	known	know	VBN	_	22	advcl	_	_
6	whether	whether	IN	_	9	mark	_	_
7	this	this	DT	_	8	det	_	_
8	interaction	interaction	NN	_	9	dep	_	_
9	occurs	occur	VBZ	_	5	comp	_	_
10	with	with	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	other	other	JJ	_	13	com	_	_
13	than	than	IN	_	11	cc	_	_
14	drug2	drug0	NN	_	11	conj	_	_
15	,	,	,	_	22	p	_	_
16	myopathy	myopathy	NN	_	22	dep	_	_
17	and	and	CC	_	16	cc	_	_
18	rhabdomyolysis	rhabdomyolysis	NN	_	16	conj	_	_
19	have	have	VBP	_	22	aux	_	_
20	occasionally	occasionally	RB	_	22	adv	_	_
21	been	be	VBN	_	22	aux	_	_
22	associated	associate	VBN	_	0	root	_	_
23	with	with	IN	_	25	case	_	_
24	the	the	DT	_	25	det	_	_
25	use	use	NN	_	22	ppmod	_	_
26	of	of	IN	_	27	case	_	_
27	drug3	drug0	NN	_	25	ppmod	_	_
28	alone	alone	RB	_	27	adv	_	_
29	,	,	,	_	27	p	_	_
30	including	include	VBG	_	31	adv	_	_
31	drug4	drug0	NN	_	27	ppmod	_	_
32	.	.	.	_	22	p	_	_

1	Therefore	therefore	RB	_	13	adv	_	_
2	,	,	,	_	13	p	_	_
3	the	the	DT	_	5	det	_	_
4	combined	combined	JJ	_	5	attr	_	_
5	use	use	NN	_	13	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	with	with	IN	_	9	case	_	_
9	drug2	drug0	NN	_	5	ppmod	_	_
10	should	should	MD	_	13	modal	_	_
11	generally	generally	RB	_	13	adv	_	_
12	be	be	VB	_	13	aux	_	_
13	avoided	avoid	VBN	_	0	root	_	_
14	.	.	.	_	13	p	_	_

1	Drug	drug	NN	_	2	com	_	_
2	Interactions	interaction	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	drug1	drug0	NN	_	6	dep	_	_
5	may	may	MD	_	6	modal	_	_
6	interact	interact	VB	_	41	advcl	_	_
7	with	with	IN	_	9	case	_	_
8	some	some	DT	_	9	det	_	_
9	drugs	drug	NNS	_	6	ppmod	_	_
10	,	,	,	_	9	p	_	_
11	like	like	IN	_	12	case	_	_
12	drug2	drug0	NN	_	9	ppmod	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	drug3	drug0	NN	_	12	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	:	:	:	_	41	p	_	_
17	drug4	drug0	NN	_	20	dep	_	_
18	could	could	MD	_	20	modal	_	_
19	theoretically	theoretically	RB	_	20	adv	_	_
20	affect	affect	VB	_	41	advcl	_	_
21	drug5	drug0	NN	_	22	com	_	_
22	pharmacodynamics	pharmacodynamics	NNS	_	20	obj	_	_
23	-	-	:	_	22	p	_	_
24	drug6	drug0	NN	_	22	appo	_	_
25	-	-	CC	_	24	cc	_	_
26	Eproxindine	eproxindine	NN	_	24	conj	_	_
27	-	-	CC	_	26	cc	_	_
28	drug7	drug0	NN	_	26	conj	_	_
29	:	:	:	_	41	p	_	_
30	drug8	drug0	NN	_	33	dep	_	_
31	and	and	CC	_	30	cc	_	_
32	drug9	drug0	NN	_	30	conj	_	_
33	cause	cause	VBP	_	41	advcl	_	_
34	additive	additive	JJ	_	36	attr	_	_
35	CNS	cns	NN	_	36	com	_	_
36	depression	depression	NN	_	33	obj	_	_
37	-	-	CC	_	36	cc	_	_
38	drug10	drug0	NN	_	36	conj	_	_
39	:	:	:	_	41	p	_	_
40	drug11	drug0	NN	_	41	dep	_	_
41	increases	increase	VBZ	_	2	acl	_	_
42	the	the	DT	_	43	det	_	_
43	effect	effect	NN	_	41	obj	_	_
44	of	of	IN	_	45	case	_	_
45	drug12	drug0	NN	_	43	ppmod	_	_

1	The	the	DT	_	3	det	_	_
2	vasodilating	vasodilating	JJ	_	3	attr	_	_
3	effects	effect	NNS	_	7	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	may	may	MD	_	7	modal	_	_
7	be	be	VB	_	0	root	_	_
8	additive	additive	JJ	_	7	dep	_	_
9	with	with	IN	_	10	case	_	_
10	those	those	DT	_	8	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	other	other	JJ	_	13	attr	_	_
13	drug2	drug0	NNS	_	10	ppmod	_	_
14	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	8	dep	_	_
2	,	,	,	_	1	p	_	_
3	in	in	IN	_	4	case	_	_
4	particular	particular	JJ	_	1	ppmod	_	_
5	,	,	,	_	1	p	_	_
6	has	have	VBZ	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	found	find	VBN	_	0	root	_	_
9	to	to	TO	_	10	aux	_	_
10	exhibit	exhibit	VBP	_	8	comp	_	_
11	additive	additive	JJ	_	12	attr	_	_
12	effects	effect	NNS	_	10	obj	_	_
13	of	of	IN	_	15	case	_	_
14	this	this	DT	_	15	det	_	_
15	variety	variety	NN	_	12	ppmod	_	_
16	.	.	.	_	8	p	_	_

1	Marked	marked	JJ	_	4	attr	_	_
2	symptomatic	symptomatic	JJ	_	4	attr	_	_
3	orthostatic	orthostatic	JJ	_	4	attr	_	_
4	hypotension	hypotension	NN	_	7	dep	_	_
5	has	have	VBZ	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	reported	report	VBN	_	0	root	_	_
8	when	when	WRB	_	14	adv	_	_
9	drug1	drug0	NN	_	14	dep	_	_
10	and	and	CC	_	9	cc	_	_
11	organic	organic	JJ	_	12	attr	_	_
12	drug2	drug0	NN	_	9	conj	_	_
13	were	be	VBD	_	14	aux	_	_
14	used	use	VBN	_	7	comp	_	_
15	in	in	IN	_	16	case	_	_
16	combination	combination	NN	_	14	ppmod	_	_
17	.	.	.	_	7	p	_	_

1	Dose	dose	NN	_	2	com	_	_
2	adjustments	adjustment	NNS	_	9	dep	_	_
3	of	of	IN	_	5	case	_	_
4	either	either	DT	_	5	det	_	_
5	class	class	NN	_	2	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	agents	agent	NNS	_	5	ppmod	_	_
8	may	may	MD	_	9	modal	_	_
9	be	be	VB	_	0	root	_	_
10	necessary	necessary	JJ	_	9	dep	_	_
11	.	.	.	_	9	p	_	_

1	In	in	IN	_	3	case	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	studies	study	NNS	_	33	ppmod	_	_
4	performed	performed	VBN	_	3	acl	_	_
5	with	with	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	,	,	,	_	33	p	_	_
8	the	the	DT	_	10	det	_	_
9	concomitant	concomitant	JJ	_	10	attr	_	_
10	use	use	NN	_	33	dep	_	_
11	of	of	IN	_	13	case	_	_
12	oral	oral	JJ	_	13	attr	_	_
13	drug2	drug0	NN	_	10	ppmod	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	drug3	drug0	NN	_	13	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	,	,	,	_	13	p	_	_
18	drug4	drug0	NN	_	13	conj	_	_
19	(	-lrb-	-LRB-	_	20	p	_	_
20	drug5	drug0	NN	_	18	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	,	,	,	_	18	p	_	_
23	drug6	drug0	NN	_	13	conj	_	_
24	(	-lrb-	-LRB-	_	25	p	_	_
25	drug7	drug0	NN	_	23	prn	_	_
26	)	-rrb-	-RRB-	_	25	p	_	_
27	,	,	,	_	23	p	_	_
28	and	and	CC	_	23	cc	_	_
29	drug8	drug0	NN	_	13	conj	_	_
30	did	do	VBD	_	33	aux	_	_
31	not	not	RB	_	33	neg	_	_
32	significantly	significantly	RB	_	33	adv	_	_
33	affect	affect	VB	_	0	root	_	_
34	the	the	DT	_	35	det	_	_
35	pharmacokinetics/pharmacodynamics	pharmacokinetics/pharmacodynamics	NNS	_	33	obj	_	_
36	of	of	IN	_	37	case	_	_
37	drug9	drug0	NN	_	35	ppmod	_	_
38	.	.	.	_	33	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	6	ppmod	_	_
3	,	,	,	_	6	p	_	_
4	drug1	drug0	NN	_	6	dep	_	_
5	neither	neither	RB	_	6	neg	_	_
6	influenced	influence	VBD	_	0	root	_	_
7	the	the	DT	_	8	det	_	_
8	pharmacodynamics	pharmacodynamics	NNS	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	drug3	drug0	NN	_	10	conj	_	_
13	,	,	,	_	12	p	_	_
14	drug4	drug0	NN	_	10	conj	_	_
15	,	,	,	_	14	p	_	_
16	and	and	CC	_	14	cc	_	_
17	drug5	drug0	NN	_	10	conj	_	_
18	,	,	,	_	8	p	_	_
19	nor	nor	CC	_	8	cc	_	_
20	the	the	DT	_	21	det	_	_
21	pharmacokinetics	pharmacokinetics	NNS	_	8	conj	_	_
22	of	of	IN	_	23	case	_	_
23	drug6	drug0	NN	_	21	ppmod	_	_
24	at	at	IN	_	26	case	_	_
25	steady	steady	JJ	_	26	attr	_	_
26	state	state	NN	_	6	ppmod	_	_
27	.	.	.	_	6	p	_	_

1	Agents	agent	NNS	_	11	dep	_	_
2	that	that	WDT	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	enhance	enhance	VB	_	1	relcl	_	_
5	the	the	DT	_	6	det	_	_
6	risk	risk	NN	_	4	obj	_	_
7	of	of	IN	_	8	case	_	_
8	hemorrhage	hemorrhage	NN	_	6	ppmod	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	discontinued	discontinue	VBN	_	0	root	_	_
12	prior	prior	JJ	_	14	adv	_	_
13	to	to	TO	_	14	aux	_	_
14	initiation	initiation	NN	_	11	ppmod	_	_
15	of	of	IN	_	17	case	_	_
16	drug1	drug0	NN	_	17	com	_	_
17	therapy	therapy	NN	_	14	ppmod	_	_
18	.	.	.	_	11	p	_	_

1	If	if	IN	_	3	mark	_	_
2	co-administration	co-administration	NN	_	3	dep	_	_
3	is	be	VBZ	_	9	advcl	_	_
4	essential	essential	JJ	_	3	dep	_	_
5	,	,	,	_	9	p	_	_
6	close	close	JJ	_	7	attr	_	_
7	monitoring	monitoring	NN	_	9	dep	_	_
8	may	may	MD	_	9	modal	_	_
9	be	be	VB	_	0	root	_	_
10	appropriate	appropriate	JJ	_	9	dep	_	_
11	.	.	.	_	9	p	_	_

1	In	in	IN	_	5	case	_	_
2	an	an	DT	_	5	det	_	_
3	in	in	FW	_	4	adv	_	_
4	vitro	vitro	FW	_	5	attr	_	_
5	study	study	NN	_	29	ppmod	_	_
6	in	in	IN	_	9	case	_	_
7	human	human	JJ	_	9	attr	_	_
8	liver	liver	NN	_	9	com	_	_
9	microsomes	microsome	NNS	_	5	ppmod	_	_
10	,	,	,	_	29	p	_	_
11	inhibition	inhibition	NN	_	29	dep	_	_
12	of	of	IN	_	14	case	_	_
13	CYP2A6	cyp0a0	NN	_	14	com	_	_
14	hydroxylation	hydroxylation	NN	_	11	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	by	by	IN	_	18	case	_	_
18	drug2	drug0	NN	_	11	ppmod	_	_
19	(	-lrb-	-LRB-	_	23	p	_	_
20	200	0	CD	_	23	num	_	_
21	m	m	NN	_	23	com	_	_
22	m	m	NN	_	23	com	_	_
23	M	m	NN	_	18	prn	_	_
24	i.e.	i.e.	FW	_	27	adv	_	_
25	,	,	,	_	27	p	_	_
26	350	0	CD	_	27	num	_	_
27	mg/L	mg/l	NN	_	23	ppmod	_	_
28	)	-rrb-	-RRB-	_	23	p	_	_
29	was	be	VBD	_	0	root	_	_
30	17-28	0	CD	_	29	obj	_	_
31	%	%	NN	_	30	meta	_	_
32	.	.	.	_	29	p	_	_

1	Inhibition	inhibition	NN	_	22	dep	_	_
2	of	of	IN	_	5	case	_	_
3	the	the	DT	_	5	det	_	_
4	other	other	JJ	_	5	attr	_	_
5	isozymes	isozymes	NNS	_	1	ppmod	_	_
6	evaluated	evaluate	VBN	_	5	acl	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	CYPs	cyps	NNS	_	6	prn	_	_
9	2A1	0a0	NN	_	8	attr	_	_
10	,	,	,	_	9	p	_	_
11	2C9	0c0	NN	_	9	conj	_	_
12	,	,	,	_	11	p	_	_
13	2C19	0c0	NN	_	9	conj	_	_
14	,	,	,	_	13	p	_	_
15	2D6	0d0	NN	_	9	conj	_	_
16	,	,	,	_	15	p	_	_
17	3A4	0a0	NN	_	9	conj	_	_
18	,	,	,	_	17	p	_	_
19	and	and	CC	_	17	cc	_	_
20	3E1	0e0	NN	_	9	conj	_	_
21	)	-rrb-	-RRB-	_	8	p	_	_
22	was	be	VBD	_	0	root	_	_
23	0-16	0	CD	_	22	obj	_	_
24	%	%	NN	_	23	meta	_	_
25	.	.	.	_	22	p	_	_

1	Since	since	IN	_	6	mark	_	_
2	drug1	drug0	NN	_	6	dep	_	_
3	does	do	VBZ	_	6	aux	_	_
4	not	not	RB	_	6	neg	_	_
5	markedly	markedly	RB	_	6	adv	_	_
6	inhibit	inhibit	VB	_	30	advcl	_	_
7	CYP450s	cyp0s	NNS	_	6	obj	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	CYP1A2	cyp0a0	NN	_	7	prn	_	_
10	,	,	,	_	9	p	_	_
11	CYP2A6	cyp0a0	NN	_	9	conj	_	_
12	,	,	,	_	11	p	_	_
13	CYP2C9	cyp0c0	NN	_	9	conj	_	_
14	,	,	,	_	13	p	_	_
15	CYP2C19	cyp0c0	NN	_	9	conj	_	_
16	,	,	,	_	15	p	_	_
17	CYP2D6	cyp0d0	NN	_	9	conj	_	_
18	,	,	,	_	17	p	_	_
19	CYP2E1	cyp0e0	NN	_	9	conj	_	_
20	,	,	,	_	19	p	_	_
21	or	or	CC	_	19	cc	_	_
22	CYP3A4	cyp0a0	NN	_	9	conj	_	_
23	)	-rrb-	-RRB-	_	9	p	_	_
24	in	in	FW	_	25	adv	_	_
25	vitro	vitro	FW	_	6	adv	_	_
26	,	,	,	_	30	p	_	_
27	drug2	drug0	NN	_	30	dep	_	_
28	is	be	VBZ	_	30	aux	_	_
29	not	not	RB	_	30	neg	_	_
30	expected	expect	VBN	_	0	root	_	_
31	to	to	TO	_	33	aux	_	_
32	significantly	significantly	RB	_	33	adv	_	_
33	interact	interact	VB	_	30	comp	_	_
34	with	with	IN	_	36	case	_	_
35	other	other	JJ	_	36	attr	_	_
36	drugs	drug	NNS	_	33	ppmod	_	_
37	in	in	FW	_	38	adv	_	_
38	vivo	vivo	FW	_	33	adv	_	_
39	by	by	IN	_	40	case	_	_
40	inhibition	inhibition	NN	_	33	ppmod	_	_
41	of	of	IN	_	42	case	_	_
42	metabolism	metabolism	NN	_	40	ppmod	_	_
43	mediated	mediate	VBN	_	42	acl	_	_
44	by	by	IN	_	46	case	_	_
45	these	these	DT	_	46	det	_	_
46	isozymes	isozymes	NNS	_	43	ppmod	_	_
47	.	.	.	_	30	p	_	_

1	Since	since	IN	_	5	mark	_	_
2	drug1	drug0	NN	_	5	dep	_	_
3	does	do	VBZ	_	5	aux	_	_
4	not	not	RB	_	5	neg	_	_
5	bind	bind	VB	_	21	advcl	_	_
6	significantly	significantly	RB	_	5	adv	_	_
7	to	to	TO	_	9	aux	_	_
8	plasma	plasma	NN	_	9	com	_	_
9	proteins	protein	NNS	_	5	ppmod	_	_
10	other	other	JJ	_	9	attr	_	_
11	than	than	IN	_	12	case	_	_
12	ATIII	atiii	NN	_	10	ppmod	_	_
13	,	,	,	_	21	p	_	_
14	no	no	DT	_	16	det	_	_
15	drug	drug	NN	_	16	com	_	_
16	interactions	interaction	NNS	_	21	dep	_	_
17	by	by	IN	_	19	case	_	_
18	protein-binding	protein-binding	JJ	_	19	attr	_	_
19	displacement	displacement	NN	_	16	ppmod	_	_
20	are	be	VBP	_	21	aux	_	_
21	expected	expect	VBN	_	0	root	_	_
22	.	.	.	_	21	p	_	_

1	Prospective	prospective	JJ	_	2	attr	_	_
2	studies	study	NNS	_	16	dep	_	_
3	on	on	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	potential	potential	NN	_	2	ppmod	_	_
6	for	for	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	to	to	TO	_	9	aux	_	_
9	interact	interact	VB	_	5	acl	_	_
10	with	with	IN	_	12	case	_	_
11	other	other	JJ	_	12	attr	_	_
12	drugs	drug	NNS	_	9	ppmod	_	_
13	have	have	VBP	_	16	aux	_	_
14	not	not	RB	_	16	neg	_	_
15	been	be	VBN	_	16	aux	_	_
16	performed	performed	VBN	_	0	root	_	_
17	.	.	.	_	16	p	_	_

1	Concurrent	concurrent	JJ	_	2	attr	_	_
2	use	use	NN	_	13	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	other	other	JJ	_	8	attr	_	_
7	myelosuppressive	myelosuppressive	JJ	_	8	attr	_	_
8	agents	agent	NNS	_	4	conj	_	_
9	or	or	CC	_	8	cc	_	_
10	radiation	radiation	NN	_	11	com	_	_
11	therapy	therapy	NN	_	8	conj	_	_
12	may	may	MD	_	13	modal	_	_
13	increase	increase	VB	_	0	root	_	_
14	the	the	DT	_	15	det	_	_
15	likelihood	likelihood	NN	_	13	obj	_	_
16	of	of	IN	_	19	case	_	_
17	bone	bone	NN	_	19	com	_	_
18	marrow	marrow	NN	_	19	com	_	_
19	depression	depression	NN	_	15	ppmod	_	_
20	or	or	CC	_	19	cc	_	_
21	other	other	JJ	_	23	attr	_	_
22	adverse	adverse	JJ	_	23	attr	_	_
23	events	event	NNS	_	19	conj	_	_
24	.	.	.	_	13	p	_	_

1	Since	since	IN	_	4	mark	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	raise	raise	VB	_	17	advcl	_	_
5	the	the	DT	_	9	det	_	_
6	serum	serum	NN	_	9	com	_	_
7	uric	uric	NN	_	9	com	_	_
8	acid	acid	NN	_	9	com	_	_
9	level	level	NN	_	4	obj	_	_
10	,	,	,	_	17	p	_	_
11	dosage	dosage	NN	_	12	com	_	_
12	adjustment	adjustment	NN	_	17	dep	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	may	may	MD	_	17	modal	_	_
16	be	be	VB	_	17	aux	_	_
17	necessary	necessary	JJ	_	0	root	_	_

1	.	.	.	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	,	,	,	_	1	p	_	_
3	oral	oral	JJ	_	1	appo	_	_

1	(	-lrb-	-LRB-	_	2	p	_	_
2	Effects	effect	NNS	_	5	dep	_	_
3	may	may	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	decreased	decrease	VBN	_	0	root	_	_
6	when	when	WRB	_	7	adv	_	_
7	used	use	VBN	_	5	comp	_	_
8	concurrently	concurrently	RB	_	7	adv	_	_
9	with	with	IN	_	10	case	_	_
10	drug1	drug0	NN	_	7	ppmod	_	_
11	;	;	:	_	5	p	_	_

1	dosage	dosage	NN	_	2	com	_	_
2	adjustments	adjustment	NNS	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	be	be	VB	_	0	root	_	_
5	necessary	necessary	JJ	_	4	dep	_	_
6	.	.	.	_	4	p	_	_
7	)	-rrb-	-RRB-	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	(	-lrb-	-LRB-	_	4	p	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	raise	raise	VB	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	level	level	NN	_	4	obj	_	_
7	of	of	IN	_	10	case	_	_
8	blood	blood	NN	_	10	attr	_	_
9	uric	uric	JJ	_	10	attr	_	_
10	acid	acid	NN	_	6	ppmod	_	_
11	;	;	:	_	4	p	_	_

1	dosage	dosage	JJ	_	2	attr	_	_
2	adjustment	adjustment	NN	_	6	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	may	may	MD	_	6	modal	_	_
6	be	be	VB	_	0	root	_	_
7	necessary	necessary	JJ	_	6	dep	_	_
8	to	to	TO	_	9	aux	_	_
9	control	control	VB	_	7	comp	_	_
10	hyperuricemia	hyperuricemia	NN	_	9	obj	_	_
11	and	and	CC	_	10	cc	_	_
12	gout	gout	NN	_	10	conj	_	_
13	.	.	.	_	6	p	_	_
14	)	-rrb-	-RRB-	_	6	p	_	_

1	drug1	drug0	NN	_	12	attr	_	_
2	,	,	,	_	1	p	_	_
3	other	other	JJ	_	1	conj	_	_
4	,	,	,	_	3	p	_	_
5	especially	especially	RB	_	6	adv	_	_
6	drug2	drug0	JJ	_	3	conj	_	_
7	,	,	,	_	6	p	_	_
8	or	or	CC	_	6	cc	_	_
9	preanesthetic	preanesthetic	JJ	_	3	conj	_	_
10	and	and	CC	_	3	cc	_	_
11	drug3	drug0	NN	_	1	conj	_	_
12	agents	agent	NNS	_	0	root	_	_
13	used	use	VBN	_	12	acl	_	_
14	in	in	IN	_	15	case	_	_
15	surgery	surgery	NN	_	13	ppmod	_	_
16	or	or	CC	_	15	cc	_	_
17	drug4	drug0	NN	_	15	conj	_	_
18	,	,	,	_	12	p	_	_
19	nondepolarizing	nondepolarizing	NN	_	12	appo	_	_
20	,	,	,	_	12	p	_	_
21	used	use	VBN	_	12	acl	_	_
22	in	in	IN	_	23	case	_	_
23	surgery	surgery	NN	_	21	ppmod	_	_

1	(	-lrb-	-LRB-	_	2	p	_	_
2	Effects	effect	NNS	_	5	dep	_	_
3	may	may	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	potentiated	potentiate	VBN	_	0	root	_	_
6	when	when	WRB	_	7	adv	_	_
7	used	use	VBN	_	5	comp	_	_
8	concurrently	concurrently	RB	_	7	adv	_	_
9	with	with	IN	_	10	case	_	_
10	drug1	drug0	NN	_	7	ppmod	_	_
11	;	;	:	_	5	p	_	_

1	dosage	dosage	NN	_	2	com	_	_
2	adjustments	adjustment	NNS	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	be	be	VB	_	0	root	_	_
5	necessary	necessary	JJ	_	4	dep	_	_
6	.	.	.	_	4	p	_	_
7	)	-rrb-	-RRB-	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	or	or	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	or	or	CC	_	1	cc	_	_
5	drug3	drug0	NN	_	1	conj	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	drug4	drug0	NN	_	5	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_

1	(	-lrb-	-LRB-	_	7	p	_	_
2	Concurrent	concurrent	JJ	_	3	attr	_	_
3	use	use	NN	_	7	dep	_	_
4	with	with	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	may	may	MD	_	7	modal	_	_
7	intensify	intensify	VB	_	0	root	_	_
8	electrolyte	electrolyte	NN	_	9	com	_	_
9	imbalance	imbalance	NN	_	7	obj	_	_
10	,	,	,	_	9	p	_	_
11	particularly	particularly	RB	_	12	adv	_	_
12	hypokalemia	hypokalemia	NN	_	9	appo	_	_
13	.	.	.	_	9	p	_	_
14	)	-rrb-	-RRB-	_	7	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	(	-lrb-	-LRB-	_	7	p	_	_
2	Concurrent	concurrent	JJ	_	3	attr	_	_
3	use	use	NN	_	7	dep	_	_
4	with	with	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	may	may	MD	_	7	modal	_	_
7	enhance	enhance	VB	_	0	root	_	_
8	the	the	DT	_	9	det	_	_
9	possibility	possibility	NN	_	7	obj	_	_
10	of	of	IN	_	12	case	_	_
11	drug2	drug0	NN	_	12	com	_	_
12	toxicity	toxicity	NN	_	9	ppmod	_	_
13	associated	associate	VBN	_	9	acl	_	_
14	with	with	IN	_	15	case	_	_
15	hypokalemia	hypokalemia	NN	_	13	ppmod	_	_
16	.	.	.	_	9	p	_	_
17	)	-rrb-	-RRB-	_	7	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	(	-lrb-	-LRB-	_	3	p	_	_
2	May	may	MD	_	3	modal	_	_
3	inhibit	inhibit	VB	_	0	root	_	_
4	gastrointestinal	gastrointestinal	JJ	_	5	attr	_	_
5	absorption	absorption	NN	_	3	obj	_	_
6	of	of	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	drug1	drug0	NN	_	5	ppmod	_	_
9	;	;	:	_	3	p	_	_

1	administration	administration	NN	_	3	attr	_	_
2	1	0	CD	_	3	num	_	_
3	hour	hour	NN	_	11	dep	_	_
4	before	before	IN	_	7	case	_	_
5	or	or	CC	_	7	cc	_	_
6	4	0	CD	_	7	num	_	_
7	hours	hour	NNS	_	3	ppmod	_	_
8	after	after	IN	_	9	case	_	_
9	drug1	drug0	NN	_	3	ppmod	_	_
10	is	be	VBZ	_	11	aux	_	_
11	recommended	recommend	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_
13	)	-rrb-	-RRB-	_	11	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	(	-lrb-	-LRB-	_	4	p	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	raise	raise	VB	_	0	root	_	_
5	blood	blood	NN	_	7	com	_	_
6	glucose	glucose	NN	_	7	com	_	_
7	levels	level	NNS	_	4	obj	_	_
8	;	;	:	_	4	p	_	_

1	for	for	IN	_	3	case	_	_
2	adult-onset	adult-onset	JJ	_	3	attr	_	_
3	diabetics	diabetic	NNS	_	10	ppmod	_	_
4	,	,	,	_	10	p	_	_
5	dosage	dosage	NN	_	6	com	_	_
6	adjustment	adjustment	NN	_	10	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	may	may	MD	_	10	modal	_	_
10	be	be	VB	_	0	root	_	_
11	necessary	necessary	JJ	_	10	dep	_	_
12	during	during	IN	_	11	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	after	after	IN	_	16	case	_	_
15	drug2	drug0	NN	_	16	com	_	_
16	therapy	therapy	NN	_	12	conj	_	_
17	;	;	:	_	10	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	requirements	requirement	NNS	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	be	be	VB	_	0	root	_	_
5	increased	increase	VBN	_	4	dep	_	_
6	,	,	,	_	5	p	_	_
7	decreased	decrease	VBN	_	5	conj	_	_
8	,	,	,	_	7	p	_	_
9	or	or	CC	_	7	cc	_	_
10	unchanged	unchanged	JJ	_	5	conj	_	_
11	.	.	.	_	4	p	_	_
12	)	-rrb-	-RRB-	_	4	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	salts	salt	NNS	_	0	root	_	_

1	(	-lrb-	-LRB-	_	8	p	_	_
2	Concurrent	concurrent	JJ	_	3	attr	_	_
3	use	use	NN	_	8	dep	_	_
4	with	with	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	is	be	VBZ	_	8	aux	_	_
7	not	not	RB	_	8	neg	_	_
8	recommended	recommend	VBN	_	0	root	_	_
9	,	,	,	_	8	p	_	_
10	as	as	IN	_	13	mark	_	_
11	they	they	PRP	_	13	dep	_	_
12	may	may	MD	_	13	modal	_	_
13	provoke	provoke	VB	_	8	comp	_	_
14	drug2	drug0	NN	_	15	com	_	_
15	toxicity	toxicity	NN	_	13	obj	_	_
16	because	because	IN	_	20	case	_	_
17	of	of	IN	_	20	case	_	_
18	reduced	reduce	VBN	_	20	attr	_	_
19	renal	renal	JJ	_	20	attr	_	_
20	clearance	clearance	NN	_	13	ppmod	_	_
21	.	.	.	_	8	p	_	_
22	)	-rrb-	-RRB-	_	8	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	(	-lrb-	-LRB-	_	5	p	_	_
2	Effectiveness	effectiveness	NN	_	5	dep	_	_
3	may	may	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	decreased	decrease	VBN	_	0	root	_	_
6	when	when	WRB	_	7	adv	_	_
7	used	use	VBN	_	5	comp	_	_
8	concurrently	concurrently	RB	_	7	adv	_	_
9	with	with	IN	_	10	case	_	_
10	drug1	drug0	NN	_	7	ppmod	_	_
11	because	because	IN	_	13	case	_	_
12	of	of	IN	_	13	case	_	_
13	alkalinization	alkalinization	NN	_	7	ppmod	_	_
14	of	of	IN	_	16	case	_	_
15	the	the	DT	_	16	det	_	_
16	urine	urine	NN	_	13	ppmod	_	_
17	.	.	.	_	7	p	_	_
18	)	-rrb-	-RRB-	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	(	-lrb-	-LRB-	_	9	p	_	_
2	In	in	IN	_	4	case	_	_
3	some	some	DT	_	4	det	_	_
4	patients	patient	NNS	_	9	ppmod	_	_
5	,	,	,	_	9	p	_	_
6	the	the	DT	_	7	det	_	_
7	drug1	drug0	NN	_	9	dep	_	_
8	can	can	MD	_	9	modal	_	_
9	reduce	reduce	VB	_	0	root	_	_
10	the	the	DT	_	17	det	_	_
11	diuretic	diuretic	JJ	_	17	attr	_	_
12	,	,	,	_	11	p	_	_
13	natriuretic	natriuretic	JJ	_	11	conj	_	_
14	,	,	,	_	13	p	_	_
15	and	and	CC	_	13	cc	_	_
16	antihypertensive	antihypertensive	JJ	_	11	conj	_	_
17	effects	effect	NNS	_	9	obj	_	_
18	of	of	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	,	,	,	_	19	p	_	_
21	drug3	drug0	NN	_	19	conj	_	_
22	,	,	,	_	21	p	_	_
23	and	and	CC	_	21	cc	_	_
24	drug4	drug0	NN	_	19	conj	_	_
25	.	.	.	_	9	p	_	_

1	Therefore	therefore	RB	_	15	adv	_	_
2	,	,	,	_	15	p	_	_
3	when	when	WRB	_	8	adv	_	_
4	drug1	drug0	NN	_	8	dep	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	are	be	VBP	_	8	aux	_	_
8	used	use	VBN	_	15	advcl	_	_
9	concomitantly	concomitantly	RB	_	8	adv	_	_
10	,	,	,	_	15	p	_	_
11	the	the	DT	_	12	det	_	_
12	patient	patient	NN	_	15	dep	_	_
13	should	should	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	observed	observe	VBN	_	0	root	_	_
16	closely	closely	RB	_	15	adv	_	_
17	to	to	TO	_	18	aux	_	_
18	determine	determine	VB	_	15	comp	_	_
19	if	if	IN	_	27	mark	_	_
20	the	the	DT	_	22	det	_	_
21	desired	desired	JJ	_	22	attr	_	_
22	effect	effect	NN	_	27	dep	_	_
23	of	of	IN	_	25	case	_	_
24	the	the	DT	_	25	det	_	_
25	drug3	drug0	NN	_	22	ppmod	_	_
26	is	be	VBZ	_	27	aux	_	_
27	obtained	obtain	VBN	_	18	comp	_	_
28	.	.	.	_	15	p	_	_
29	)	-rrb-	-RRB-	_	15	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	(	-lrb-	-LRB-	_	4	p	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	decrease	decrease	VB	_	0	root	_	_
5	arterial	arterial	JJ	_	6	attr	_	_
6	responsiveness	responsiveness	NN	_	4	obj	_	_
7	to	to	TO	_	8	aux	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	.	.	.	_	4	p	_	_

1	This	this	DT	_	2	det	_	_
2	diminution	diminution	NN	_	3	dep	_	_
3	is	be	VBZ	_	0	root	_	_
4	not	not	RB	_	3	neg	_	_
5	sufficient	sufficient	JJ	_	3	dep	_	_
6	to	to	TO	_	7	aux	_	_
7	preclude	preclude	VB	_	5	comp	_	_
8	effectiveness	effectiveness	NN	_	7	obj	_	_
9	of	of	IN	_	12	case	_	_
10	the	the	DT	_	12	det	_	_
11	pressor	pressor	JJ	_	12	attr	_	_
12	agent	agent	NN	_	8	ppmod	_	_
13	for	for	IN	_	15	case	_	_
14	therapeutic	therapeutic	JJ	_	15	attr	_	_
15	use	use	NN	_	8	ppmod	_	_
16	.	.	.	_	3	p	_	_
17	)	-rrb-	-RRB-	_	3	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	(	-lrb-	-LRB-	_	4	p	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	increase	increase	VB	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	responsiveness	responsiveness	NN	_	4	obj	_	_
7	to	to	TO	_	8	aux	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	.	.	.	_	6	p	_	_
10	)	-rrb-	-RRB-	_	4	p	_	_

1	DIAGNOSTIC	diagnostic	JJ	_	2	attr	_	_
2	INTERFERENCE	interference	NN	_	73	dep	_	_
3	With	with	IN	_	6	case	_	_
4	expected	expect	VBN	_	6	attr	_	_
5	physiologic	physiologic	JJ	_	6	attr	_	_
6	effects	effect	NNS	_	2	ppmod	_	_
7	:	:	:	_	49	p	_	_
8	Blood	blood	NN	_	49	dep	_	_
9	and	and	CC	_	8	cc	_	_
10	urine	urine	NN	_	12	com	_	_
11	glucose	glucose	NN	_	12	com	_	_
12	levels	level	NNS	_	8	conj	_	_
13	(	-lrb-	-LRB-	_	17	p	_	_
14	usually	usually	RB	_	15	com	_	_
15	only	only	RB	_	17	adv	_	_
16	in	in	IN	_	17	case	_	_
17	patients	patient	NNS	_	8	prn	_	_
18	with	with	IN	_	20	case	_	_
19	a	a	DT	_	20	det	_	_
20	predisposition	predisposition	NN	_	17	ppmod	_	_
21	for	for	IN	_	23	case	_	_
22	glucose	glucose	NN	_	23	com	_	_
23	intolerance	intolerance	NN	_	20	ppmod	_	_
24	)	-rrb-	-RRB-	_	17	p	_	_
25	and	and	CC	_	8	cc	_	_
26	Serum	serum	NN	_	28	com	_	_
27	bilirubin	bilirubin	NN	_	28	com	_	_
28	levels	level	NNS	_	8	conj	_	_
29	(	-lrb-	-LRB-	_	31	p	_	_
30	by	by	IN	_	31	case	_	_
31	displacement	displacement	NN	_	28	prn	_	_
32	from	from	IN	_	34	case	_	_
33	albumin	albumin	NN	_	34	com	_	_
34	binding	binding	NN	_	31	ppmod	_	_
35	)	-rrb-	-RRB-	_	31	p	_	_
36	and	and	CC	_	28	cc	_	_
37	Serum	serum	NN	_	39	com	_	_
38	calcium	calcium	NN	_	39	com	_	_
39	levels	level	NNS	_	28	conj	_	_
40	(	-lrb-	-LRB-	_	28	p	_	_
41	drug1	drug0	NN	_	28	appo	_	_
42	should	should	MD	_	44	modal	_	_
43	be	be	VB	_	44	aux	_	_
44	discontinued	discontinue	VBN	_	28	acl	_	_
45	before	before	IN	_	47	case	_	_
46	parathyroid-function	parathyroid-function	JJ	_	47	attr	_	_
47	tests	test	NNS	_	44	ppmod	_	_
48	are	be	VBP	_	49	aux	_	_
49	carried	carry	VBN	_	6	prn	_	_
50	out	out	RP	_	49	prt	_	_
51	)	-rrb-	-RRB-	_	49	p	_	_
52	and	and	CC	_	2	cc	_	_
53	Serum	serum	NN	_	55	attr	_	_
54	uric	uric	JJ	_	55	attr	_	_
55	acid	acid	NN	_	56	com	_	_
56	levels	level	NNS	_	63	attr	_	_
57	(	-lrb-	-LRB-	_	56	p	_	_
58	may	may	MD	_	60	modal	_	_
59	be	be	VB	_	60	aux	_	_
60	increased	increase	VBN	_	56	acl	_	_
61	)	-rrb-	-RRB-	_	56	p	_	_
62	Serum	serum	NN	_	63	com	_	_
63	magnesium	magnesium	NN	_	2	conj	_	_
64	,	,	,	_	63	p	_	_
65	potassium	potassium	NN	_	63	conj	_	_
66	,	,	,	_	65	p	_	_
67	and	and	CC	_	65	cc	_	_
68	sodium	sodium	NN	_	69	com	_	_
69	levels	level	NNS	_	63	conj	_	_
70	(	-lrb-	-LRB-	_	73	p	_	_
71	may	may	MD	_	73	modal	_	_
72	be	be	VB	_	73	aux	_	_
73	decreased	decrease	VBN	_	0	root	_	_
74	;	;	:	_	73	p	_	_

1	serum	serum	NN	_	3	com	_	_
2	magnesium	magnesium	NN	_	3	com	_	_
3	levels	level	NNS	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	increase	increase	VB	_	0	root	_	_
6	in	in	IN	_	8	case	_	_
7	uremic	uremic	JJ	_	8	attr	_	_
8	patients	patient	NNS	_	5	ppmod	_	_
9	)	-rrb-	-RRB-	_	5	p	_	_
10	Serum	serum	NN	_	16	attr	_	_
11	protein-bound	protein-bound	JJ	_	16	attr	_	_
12	iodine	iodine	NN	_	16	attr	_	_
13	(	-lrb-	-LRB-	_	16	p	_	_
14	PBI	pbi	NN	_	16	attr	_	_
15	)	-rrb-	-RRB-	_	16	p	_	_
16	levels	level	NNS	_	5	obj	_	_
17	(	-lrb-	-LRB-	_	16	p	_	_
18	may	may	MD	_	20	modal	_	_
19	be	be	VB	_	20	aux	_	_
20	decreased	decrease	VBN	_	16	acl	_	_
21	)	-rrb-	-RRB-	_	16	p	_	_
22	drug1	drug0	WDT	_	25	dep	_	_
23	should	should	MD	_	25	modal	_	_
24	be	be	VB	_	25	aux	_	_
25	discontinued	discontinue	VBN	_	16	relcl	_	_
26	before	before	IN	_	27	case	_	_
27	carrying	carry	VBG	_	25	ppmod	_	_
28	out	out	RP	_	27	prt	_	_
29	tests	test	NNS	_	27	obj	_	_
30	for	for	IN	_	32	case	_	_
31	parathyroid	parathyroid	JJ	_	32	attr	_	_
32	function	function	NN	_	29	ppmod	_	_
33	.	.	.	_	5	p	_	_

1	Tablets	tablet	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	drug1	drug0	NNS	_	9	dep	_	_
5	,	,	,	_	4	p	_	_
6	including	include	VBG	_	7	adv	_	_
7	drug2	drug0	NN	_	4	ppmod	_	_
8	,	,	,	_	4	p	_	_
9	produce	produce	VBP	_	1	acl	_	_
10	CNS-depressant	cns-depressant	JJ	_	11	attr	_	_
11	effects	effect	NNS	_	9	obj	_	_
12	when	when	WRB	_	13	adv	_	_
13	administered	administer	VBN	_	9	comp	_	_
14	with	with	IN	_	16	case	_	_
15	such	such	JJ	_	16	attr	_	_
16	medications	medication	NNS	_	13	ppmod	_	_
17	as	as	IN	_	18	case	_	_
18	drug3	drug0	NN	_	13	ppmod	_	_
19	or	or	CC	_	18	cc	_	_
20	drug4	drug0	NN	_	18	conj	_	_
21	.	.	.	_	1	p	_	_

1	Injection	injection	NN	_	35	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	injection	injection	NN	_	11	dep	_	_
5	,	,	,	_	11	p	_	_
6	like	like	IN	_	9	case	_	_
7	other	other	JJ	_	9	attr	_	_
8	injectable	injectable	JJ	_	9	attr	_	_
9	drug2	drug0	NN	_	11	ppmod	_	_
10	,	,	,	_	11	p	_	_
11	produces	produce	VBZ	_	1	acl	_	_
12	depression	depression	NN	_	11	obj	_	_
13	of	of	IN	_	17	case	_	_
14	the	the	DT	_	17	det	_	_
15	central	central	JJ	_	17	attr	_	_
16	nervous	nervous	JJ	_	17	attr	_	_
17	system	system	NN	_	12	ppmod	_	_
18	when	when	WRB	_	19	adv	_	_
19	administered	administer	VBN	_	11	comp	_	_
20	with	with	IN	_	21	case	_	_
21	drug3	drug0	NN	_	19	ppmod	_	_
22	,	,	,	_	21	p	_	_
23	drug4	drug0	NN	_	21	conj	_	_
24	,	,	,	_	23	p	_	_
25	drug5	drug0	NN	_	21	conj	_	_
26	,	,	,	_	25	p	_	_
27	drug6	drug0	NN	_	21	conj	_	_
28	,	,	,	_	27	p	_	_
29	and	and	CC	_	27	cc	_	_
30	other	other	JJ	_	33	attr	_	_
31	drug7	drug0	NN	_	33	attr	_	_
32	.When	.when	JJ	_	33	attr	_	_
33	drug8	drug0	NN	_	21	conj	_	_
34	is	be	VBZ	_	35	aux	_	_
35	used	use	VBN	_	0	root	_	_
36	concomitantly	concomitantly	RB	_	35	adv	_	_
37	with	with	IN	_	39	case	_	_
38	injectable	injectable	JJ	_	39	attr	_	_
39	drug9	drug0	NN	_	35	ppmod	_	_
40	,	,	,	_	39	p	_	_
41	an	an	DT	_	43	det	_	_
42	increased	increase	VBN	_	43	attr	_	_
43	incidence	incidence	NN	_	39	appo	_	_
44	of	of	IN	_	45	case	_	_
45	sedation	sedation	NN	_	43	ppmod	_	_
46	,	,	,	_	39	p	_	_
47	hallucinations	hallucination	NNS	_	39	appo	_	_
48	,	,	,	_	35	p	_	_
49	and	and	CC	_	35	cc	_	_
50	irrational	irrational	JJ	_	51	attr	_	_
51	behavior	behavior	NN	_	54	dep	_	_
52	has	have	VBZ	_	54	aux	_	_
53	been	be	VBN	_	54	aux	_	_
54	observed	observe	VBN	_	35	conj	_	_
55	.	.	.	_	35	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	appears	appear	VBZ	_	0	root	_	_
3	to	to	TO	_	4	aux	_	_
4	decrease	decrease	VB	_	2	comp	_	_
5	the	the	DT	_	6	det	_	_
6	rate	rate	NN	_	4	obj	_	_
7	at	at	IN	_	8	case	_	_
8	which	which	WDT	_	12	ppmod	_	_
9	certain	certain	JJ	_	10	attr	_	_
10	drugs	drug	NNS	_	12	dep	_	_
11	are	be	VBP	_	12	aux	_	_
12	metabolized	metabolize	VBN	_	6	relcl	_	_
13	and	and	CC	_	2	cc	_	_
14	therefore	therefore	RB	_	16	adv	_	_
15	may	may	MD	_	16	modal	_	_
16	increase	increase	VB	_	2	conj	_	_
17	the	the	DT	_	19	det	_	_
18	blood	blood	NN	_	19	com	_	_
19	levels	level	NNS	_	16	obj	_	_
20	and	and	CC	_	19	cc	_	_
21	the	the	DT	_	22	det	_	_
22	possibility	possibility	NN	_	19	conj	_	_
23	of	of	IN	_	25	case	_	_
24	clinical	clinical	JJ	_	25	attr	_	_
25	toxicity	toxicity	NN	_	22	ppmod	_	_
26	of	of	IN	_	27	case	_	_
27	drugs	drug	NNS	_	25	ppmod	_	_
28	given	give	VBN	_	27	acl	_	_
29	concomitantly	concomitantly	RB	_	28	adv	_	_
30	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	SHOULD	should	MD	_	4	modal	_	_
3	BE	be	VB	_	4	aux	_	_
4	USED	use	VBN	_	0	root	_	_
5	WITH	with	IN	_	6	case	_	_
6	CAUTION	caution	NN	_	4	ppmod	_	_
7	IN	in	IN	_	9	case	_	_
8	THOSE	those	DT	_	9	det	_	_
9	PATIENTS	patient	NNS	_	4	ppmod	_	_
10	REVEIVING	reveiving	VBG	_	9	acl	_	_
11	drug2	drug0	NN	_	10	obj	_	_
12	AND	and	CC	_	11	cc	_	_
13	ITS	its	PRP$	_	14	poss	_	_
14	CONGENERS	congener	NNS	_	11	conj	_	_
15	.	.	.	_	4	p	_	_

1	SINCE	since	IN	_	10	mark	_	_
2	THE	the	DT	_	4	det	_	_
3	CONCOMITANT	concomitant	JJ	_	4	attr	_	_
4	ADMINISTRATION	administration	NN	_	10	dep	_	_
5	OF	of	IN	_	8	case	_	_
6	THESE	these	DT	_	8	det	_	_
7	TWO	#crd#	CD	_	8	num	_	_
8	DRUGS	drug	NNS	_	4	ppmod	_	_
9	CAN	can	MD	_	10	modal	_	_
10	LEAD	lead	VB	_	33	advcl	_	_
11	TO	to	TO	_	13	aux	_	_
12	drug1	drug0	NN	_	13	com	_	_
13	INTOXICATION	intoxication	NN	_	10	ppmod	_	_
14	,	,	,	_	33	p	_	_
15	PRIOR	prior	JJ	_	17	adv	_	_
16	TO	to	TO	_	17	aux	_	_
17	ADMINISTERING	administer	VBG	_	33	ppmod	_	_
18	drug2	drug0	NN	_	17	obj	_	_
19	TO	to	TO	_	21	aux	_	_
20	A	a	DT	_	21	det	_	_
21	PATIENT	patient	NN	_	17	ppmod	_	_
22	ON	on	IN	_	24	case	_	_
23	drug3	drug0	NN	_	24	com	_	_
24	THERAPY	therapy	NN	_	21	ppmod	_	_
25	,	,	,	_	33	p	_	_
26	A	a	DT	_	30	det	_	_
27	BASELINE	baseline	NN	_	30	com	_	_
28	drug4	drug0	NN	_	30	com	_	_
29	SERUM	serum	NN	_	30	com	_	_
30	LEVEL	level	NN	_	33	dep	_	_
31	SHOULD	should	MD	_	33	modal	_	_
32	BE	be	VB	_	33	aux	_	_
33	OBTAINED	obtain	VBN	_	0	root	_	_
34	.	.	.	_	33	p	_	_

1	SUBSEQUENT	subsequent	JJ	_	0	root	_	_
2	TO	to	TO	_	3	aux	_	_
3	INITIATION	initiation	NN	_	1	ppmod	_	_
4	OF	of	IN	_	6	case	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	THERAPY	therapy	NN	_	3	ppmod	_	_
7	.	.	.	_	1	p	_	_

1	SERUM	serum	NN	_	2	com	_	_
2	LEVELS	level	NNS	_	7	dep	_	_
3	OF	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	SHOULD	should	MD	_	7	modal	_	_
6	BE	be	VB	_	7	aux	_	_
7	DETERMINED	determine	VBN	_	0	root	_	_
8	ON	on	IN	_	10	case	_	_
9	DIFFERENT	different	JJ	_	10	attr	_	_
10	DAYS	day	NNS	_	7	ppmod	_	_
11	FOR	for	IN	_	12	case	_	_
12	EVIDENCE	evidence	NN	_	10	ppmod	_	_
13	OF	of	IN	_	15	case	_	_
14	AN	an	DT	_	15	det	_	_
15	INCREASE	increase	NN	_	12	ppmod	_	_
16	OR	or	CC	_	12	cc	_	_
17	FOR	for	IN	_	20	case	_	_
18	A	a	DT	_	20	det	_	_
19	CONTINUING	continue	VBG	_	20	attr	_	_
20	RISE	rise	NN	_	12	conj	_	_
21	IN	in	IN	_	22	case	_	_
22	LEVELS	level	NNS	_	20	ppmod	_	_
23	.	.	.	_	7	p	_	_

1	INCREASED	increase	VBN	_	3	attr	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	LEVELS	level	NNS	_	6	dep	_	_
4	SHOULD	should	MD	_	6	modal	_	_
5	BE	be	VB	_	6	aux	_	_
6	TREATED	treat	VBN	_	0	root	_	_
7	WITH	with	IN	_	10	case	_	_
8	APPROPRIATE	appropriate	JJ	_	10	attr	_	_
9	DOSAGE	dosage	NN	_	10	com	_	_
10	ADJUSTMENT	adjustment	NN	_	6	ppmod	_	_
11	.	.	.	_	6	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	be	be	VB	_	0	root	_	_
4	necessary	necessary	JJ	_	3	dep	_	_
5	to	to	TO	_	6	aux	_	_
6	adjust	adjust	VB	_	4	comp	_	_
7	the	the	DT	_	8	det	_	_
8	dosage	dosage	NN	_	6	obj	_	_
9	of	of	IN	_	11	case	_	_
10	oral	oral	JJ	_	11	attr	_	_
11	drug1	drug0	NN	_	8	ppmod	_	_
12	upon	upon	IN	_	13	case	_	_
13	beginning	beginning	NN	_	6	ppmod	_	_
14	or	or	CC	_	13	cc	_	_
15	stopping	stopping	NN	_	16	com	_	_
16	drug2	drug0	NN	_	13	conj	_	_
17	.	.	.	_	6	p	_	_
18	since	since	IN	_	21	mark	_	_
19	drug3	drug0	NN	_	21	dep	_	_
20	may	may	MD	_	21	modal	_	_
21	prolong	prolong	VB	_	3	comp	_	_
22	prothrombin	prothrombin	NN	_	23	com	_	_
23	time	time	NN	_	21	obj	_	_
24	.	.	.	_	3	p	_	_

1	Patients	patient	NNS	_	10	dep	_	_
2	taking	take	VBG	_	1	acl	_	_
3	drug1	drug0	NN	_	2	obj	_	_
4	when	when	WRB	_	7	adv	_	_
5	drug2	drug0	NN	_	7	dep	_	_
6	is	be	VBZ	_	7	aux	_	_
7	given	give	VBN	_	3	relcl	_	_
8	should	should	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	observed	observe	VBN	_	0	root	_	_
11	for	for	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	appearance	appearance	NN	_	10	ppmod	_	_
14	of	of	IN	_	16	case	_	_
15	unsteady	unsteady	NN	_	16	com	_	_
16	gait	gait	NN	_	13	ppmod	_	_
17	or	or	CC	_	13	cc	_	_
18	marked	marked	JJ	_	19	attr	_	_
19	changes	change	NNS	_	13	conj	_	_
20	in	in	IN	_	22	case	_	_
21	mental	mental	JJ	_	22	attr	_	_
22	status	status	NN	_	19	ppmod	_	_
23	;	;	:	_	10	p	_	_

1	the	the	DT	_	2	det	_	_
2	drug1	drug0	NN	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	discontinued	discontinue	VBN	_	0	root	_	_
6	if	if	IN	_	9	mark	_	_
7	such	such	JJ	_	8	attr	_	_
8	signs	sign	NNS	_	9	dep	_	_
9	appear	appear	VBP	_	5	comp	_	_
10	.	.	.	_	5	p	_	_

1	In	in	IN	_	2	case	_	_
2	rats	rat	NNS	_	18	ppmod	_	_
3	,	,	,	_	18	p	_	_
4	simultaneous	simultaneous	JJ	_	5	attr	_	_
5	ingestion	ingestion	NN	_	18	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	in	in	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	diet	diet	NN	_	5	ppmod	_	_
13	for	for	IN	_	15	case	_	_
14	78	0	CD	_	15	num	_	_
15	weeks	week	NNS	_	12	ppmod	_	_
16	has	have	VBZ	_	18	aux	_	_
17	been	be	VBN	_	18	aux	_	_
18	reported	report	VBN	_	0	root	_	_
19	to	to	TO	_	20	aux	_	_
20	cause	cause	VB	_	18	comp	_	_
21	tumors	tumor	NNS	_	20	obj	_	_
22	,	,	,	_	18	p	_	_
23	and	and	CC	_	18	cc	_	_
24	it	it	PRP	_	27	dep	_	_
25	has	have	VBZ	_	27	aux	_	_
26	been	be	VBN	_	27	aux	_	_
27	suggested	suggest	VBN	_	18	conj	_	_
28	that	that	IN	_	31	mark	_	_
29	drug3	drug0	NN	_	31	dep	_	_
30	may	may	MD	_	31	modal	_	_
31	react	react	VB	_	27	comp	_	_
32	with	with	IN	_	33	case	_	_
33	drug4	drug0	NN	_	31	ppmod	_	_
34	in	in	IN	_	37	case	_	_
35	the	the	DT	_	37	det	_	_
36	rat	rat	NN	_	37	com	_	_
37	stomach	stomach	NN	_	33	ppmod	_	_
38	to	to	TO	_	39	aux	_	_
39	form	form	VB	_	31	comp	_	_
40	a	a	DT	_	41	det	_	_
41	nitrosamine	nitrosamine	NN	_	39	obj	_	_
42	,	,	,	_	41	p	_	_
43	which	which	WDT	_	44	dep	_	_
44	is	be	VBZ	_	41	relcl	_	_
45	tumorigenic	tumorigenic	JJ	_	44	dep	_	_
46	.	.	.	_	18	p	_	_

1	drug1	drug0	NN	_	10	dep	_	_
2	alone	alone	RB	_	1	adv	_	_
3	in	in	IN	_	7	case	_	_
4	the	the	DT	_	7	det	_	_
5	rat	rat	NN	_	7	com	_	_
6	s	s	NN	_	7	com	_	_
7	diet	diet	NN	_	1	ppmod	_	_
8	did	do	VBD	_	10	aux	_	_
9	not	not	RB	_	10	neg	_	_
10	lead	lead	VB	_	0	root	_	_
11	to	to	TO	_	13	aux	_	_
12	such	such	JJ	_	13	attr	_	_
13	tumors	tumor	NNS	_	10	ppmod	_	_
14	.	.	.	_	10	p	_	_

1	The	the	DT	_	2	det	_	_
2	relevance	relevance	NN	_	10	dep	_	_
3	of	of	IN	_	5	case	_	_
4	this	this	DT	_	5	det	_	_
5	finding	finding	NN	_	2	ppmod	_	_
6	to	to	TO	_	7	aux	_	_
7	humans	human	NNS	_	2	ppmod	_	_
8	is	be	VBZ	_	10	aux	_	_
9	not	not	RB	_	10	neg	_	_
10	known	know	VBN	_	0	root	_	_
11	at	at	IN	_	13	case	_	_
12	this	this	DT	_	13	det	_	_
13	time	time	NN	_	10	ppmod	_	_
14	.	.	.	_	10	p	_	_

1	Inhibitors	inhibitor	NNS	_	8	dep	_	_
2	of	of	IN	_	5	case	_	_
3	CYP3A4-	cyp0a0-	JJ	_	5	attr	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	metabolism	metabolism	NN	_	1	ppmod	_	_
6	is	be	VBZ	_	8	aux	_	_
7	predominantly	predominantly	RB	_	8	adv	_	_
8	mediated	mediate	VBN	_	0	root	_	_
9	via	via	IN	_	10	case	_	_
10	CYP3A4	cyp0a0	NN	_	8	ppmod	_	_
11	.	.	.	_	8	p	_	_

1	A	a	DT	_	3	det	_	_
2	pharmacokinetic	pharmacokinetic	JJ	_	3	attr	_	_
3	study	study	NN	_	29	dep	_	_
4	evaluating	evaluate	VBG	_	3	acl	_	_
5	the	the	DT	_	6	det	_	_
6	administration	administration	NN	_	4	obj	_	_
7	of	of	IN	_	10	case	_	_
8	a	a	DT	_	10	det	_	_
9	single	single	JJ	_	10	attr	_	_
10	dose	dose	NN	_	6	ppmod	_	_
11	of	of	IN	_	14	case	_	_
12	drug1	drug0	NN	_	14	attr	_	_
13	100	0	CD	_	14	num	_	_
14	mg	mg	NN	_	10	ppmod	_	_
15	with	with	IN	_	19	case	_	_
16	drug2	drug0	NN	_	19	attr	_	_
17	200	0	CD	_	19	num	_	_
18	mg	mg	NN	_	19	com	_	_
19	BID	bid	NN	_	14	ppmod	_	_
20	,	,	,	_	19	p	_	_
21	a	a	DT	_	23	det	_	_
22	potent	potent	JJ	_	23	attr	_	_
23	inhibitor	inhibitor	NN	_	19	appo	_	_
24	of	of	IN	_	27	case	_	_
25	the	the	DT	_	27	det	_	_
26	CYP3A4	cyp0a0	NN	_	27	com	_	_
27	pathway	pathway	NN	_	23	ppmod	_	_
28	,	,	,	_	19	p	_	_
29	showed	show	VBD	_	0	root	_	_
30	a	a	DT	_	32	det	_	_
31	1.7-fold	0-fold	JJ	_	32	attr	_	_
32	increase	increase	NN	_	29	obj	_	_
33	in	in	IN	_	34	case	_	_
34	Cmax	cmax	NN	_	32	ppmod	_	_
35	of	of	IN	_	36	case	_	_
36	drug3	drug0	NN	_	34	ppmod	_	_
37	and	and	CC	_	32	cc	_	_
38	a	a	DT	_	40	det	_	_
39	5.4-fold	0-fold	JJ	_	40	attr	_	_
40	increase	increase	NN	_	32	conj	_	_
41	in	in	IN	_	42	case	_	_
42	AUC	auc	NN	_	40	ppmod	_	_
43	of	of	IN	_	44	case	_	_
44	drug4	drug0	NN	_	42	ppmod	_	_
45	.	.	.	_	29	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	should	should	MD	_	5	modal	_	_
3	not	not	RB	_	5	neg	_	_
4	be	be	VB	_	5	aux	_	_
5	used	use	VBN	_	0	root	_	_
6	with	with	IN	_	7	case	_	_
7	drugs	drug	NNS	_	5	ppmod	_	_
8	described	describe	VBN	_	7	acl	_	_
9	as	as	IN	_	11	case	_	_
10	strong	strong	JJ	_	11	attr	_	_
11	inhibitors	inhibitor	NNS	_	8	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	CYP3A4	cyp0a0	NN	_	11	ppmod	_	_
14	in	in	IN	_	16	case	_	_
15	their	their	PRP$	_	16	poss	_	_
16	labeling	labeling	NN	_	8	ppmod	_	_
17	.	.	.	_	5	p	_	_

1	Administration	administration	NN	_	31	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	7	case	_	_
5	other	other	JJ	_	7	attr	_	_
6	CYP3A4	cyp0a0	JJ	_	7	attr	_	_
7	inhibitors	inhibitor	NNS	_	3	ppmod	_	_
8	(	-lrb-	-LRB-	_	29	p	_	_
9	e.g.	e.g.	FW	_	13	adv	_	_
10	,	,	,	_	13	p	_	_
11	drug2	drug0	NN	_	13	attr	_	_
12	500	0	CD	_	13	num	_	_
13	mg	mg	NN	_	29	ppmod	_	_
14	BID	bid	NN	_	13	appo	_	_
15	,	,	,	_	13	p	_	_
16	drug3	drug0	NN	_	19	attr	_	_
17	240	0	NN	_	19	num	_	_
18	mg	mg	NN	_	19	com	_	_
19	QD	qd	NN	_	13	appo	_	_
20	,	,	,	_	13	p	_	_
21	drug4	drug0	NN	_	23	attr	_	_
22	1200	0	CD	_	23	num	_	_
23	mg	mg	NN	_	13	appo	_	_
24	TID	tid	NN	_	23	appo	_	_
25	,	,	,	_	13	p	_	_
26	drug5	drug0	NN	_	28	attr	_	_
27	200	0	CD	_	28	num	_	_
28	mg	mg	NN	_	13	appo	_	_
29	QD	qd	NN	_	7	prn	_	_
30	)	-rrb-	-RRB-	_	29	p	_	_
31	resulted	result	VBD	_	0	root	_	_
32	in	in	IN	_	33	case	_	_
33	increases	increase	NNS	_	31	ppmod	_	_
34	in	in	IN	_	35	case	_	_
35	Cmax	cmax	NN	_	33	ppmod	_	_
36	of	of	IN	_	37	case	_	_
37	drug6	drug0	NN	_	35	ppmod	_	_
38	ranging	range	VBG	_	37	acl	_	_
39	from	from	IN	_	40	case	_	_
40	1.4-	0-	NN	_	38	ppmod	_	_
41	to	to	TO	_	43	aux	_	_
42	1.6-	0-	JJ	_	43	attr	_	_
43	fold	fold	NN	_	38	ppmod	_	_
44	and	and	CC	_	35	cc	_	_
45	AUC	auc	NN	_	35	conj	_	_
46	from	from	IN	_	47	case	_	_
47	2.0-	0-	NN	_	45	ppmod	_	_
48	to	to	TO	_	50	aux	_	_
49	2.9-	0-	NN	_	50	com	_	_
50	fold	fold	NN	_	47	ppmod	_	_
51	.	.	.	_	31	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	(	-lrb-	-LRB-	_	9	p	_	_
5	Congestive	congestive	JJ	_	7	attr	_	_
6	Heart	heart	NN	_	7	com	_	_
7	Failure	failure	NN	_	9	attr	_	_
8	Post-Myocardial	post-myocardial	JJ	_	9	attr	_	_
9	Infarction	infarction	NN	_	1	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	-	-	:	_	1	p	_	_
12	In	in	FW	_	13	adv	_	_
13	EPHESUS	ephesus	FW	_	28	adv	_	_
14	,	,	,	_	28	p	_	_
15	3020	0	CD	_	20	num	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	91	0	CD	_	20	num	_	_
18	%	%	NN	_	17	meta	_	_
19	)	-rrb-	-RRB-	_	17	p	_	_
20	patients	patient	NNS	_	28	dep	_	_
21	receiving	receive	VBG	_	20	acl	_	_
22	drug3	drug0	NN	_	26	attr	_	_
23	25	0	CD	_	26	num	_	_
24	to	to	TO	_	23	cc	_	_
25	50	0	CD	_	23	conj	_	_
26	mg	mg	NN	_	21	obj	_	_
27	also	also	RB	_	28	adv	_	_
28	received	receive	VBD	_	1	acl	_	_
29	drug4	drug0	NN	_	28	obj	_	_
30	or	or	CC	_	29	cc	_	_
31	drug5	drug0	NN	_	29	conj	_	_
32	(	-lrb-	-LRB-	_	33	p	_	_
33	drug6	drug0	NN	_	29	prn	_	_
34	/	/	:	_	33	p	_	_
35	drug7	drug0	NN	_	33	appo	_	_
36	)	-rrb-	-RRB-	_	33	p	_	_
37	.	.	.	_	1	p	_	_

1	Rates	rate	NNS	_	10	dep	_	_
2	of	of	IN	_	3	case	_	_
3	patients	patient	NNS	_	1	ppmod	_	_
4	with	with	IN	_	9	case	_	_
5	maximum	maximum	NN	_	9	attr	_	_
6	potassium	potassium	NN	_	9	attr	_	_
7	levels	level	NNS	_	9	attr	_	_
8	5.5	0	CD	_	9	num	_	_
9	mEq/L	meq/l	NN	_	3	ppmod	_	_
10	were	be	VBD	_	0	root	_	_
11	similar	similar	JJ	_	10	dep	_	_
12	regardless	regardless	RB	_	11	adv	_	_
13	of	of	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	use	use	NN	_	12	ppmod	_	_
16	of	of	IN	_	19	case	_	_
17	drug1	drug0	NN	_	19	attr	_	_
18	/	/	:	_	19	p	_	_
19	drug2	drug0	NN	_	15	ppmod	_	_
20	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	Hypertension	hypertension	NN	_	1	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	-	-	:	_	1	p	_	_
8	In	in	IN	_	10	case	_	_
9	clinical	clinical	JJ	_	10	attr	_	_
10	studies	study	NNS	_	28	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	patients	patient	NNS	_	10	ppmod	_	_
13	with	with	IN	_	14	case	_	_
14	hypertension	hypertension	NN	_	12	ppmod	_	_
15	,	,	,	_	28	p	_	_
16	the	the	DT	_	17	det	_	_
17	addition	addition	NN	_	28	dep	_	_
18	of	of	IN	_	19	case	_	_
19	drug3	drug0	NN	_	17	ppmod	_	_
20	50	0	CD	_	19	num	_	_
21	to	to	TO	_	23	aux	_	_
22	100	0	CD	_	23	num	_	_
23	mg	mg	NN	_	17	ppmod	_	_
24	to	to	TO	_	25	aux	_	_
25	drug4	drug0	NN	_	17	ppmod	_	_
26	and	and	CC	_	25	cc	_	_
27	drug5	drug0	NN	_	25	conj	_	_
28	increased	increase	VBD	_	1	acl	_	_
29	mean	mean	NN	_	31	com	_	_
30	serum	serum	NN	_	31	com	_	_
31	potassium	potassium	NN	_	28	obj	_	_
32	slightly	slightly	RB	_	28	adv	_	_
33	(	-lrb-	-LRB-	_	36	p	_	_
34	about	about	RB	_	35	adv	_	_
35	0.09-0.13	0	CD	_	36	num	_	_
36	mEq/L	meq/l	NN	_	32	prn	_	_
37	)	-rrb-	-RRB-	_	36	p	_	_
38	.	.	.	_	1	p	_	_

1	In	in	IN	_	3	case	_	_
2	a	a	DT	_	3	det	_	_
3	study	study	NN	_	18	ppmod	_	_
4	in	in	IN	_	5	case	_	_
5	diabetics	diabetic	NNS	_	3	ppmod	_	_
6	with	with	IN	_	8	case	_	_
7	microalbuminuria	microalbuminuria	NN	_	8	com	_	_
8	drug1	drug0	NN	_	5	ppmod	_	_
9	200	0	CD	_	10	num	_	_
10	mg	mg	NN	_	18	dep	_	_
11	combined	combine	VBN	_	10	acl	_	_
12	with	with	IN	_	17	case	_	_
13	the	the	DT	_	17	det	_	_
14	drug2	drug0	NN	_	17	attr	_	_
15	drug3	drug0	NN	_	17	attr	_	_
16	10	0	CD	_	17	num	_	_
17	mg	mg	NN	_	11	ppmod	_	_
18	increased	increase	VBD	_	0	root	_	_
19	the	the	DT	_	20	det	_	_
20	frequency	frequency	NN	_	18	obj	_	_
21	of	of	IN	_	22	case	_	_
22	hyperkalemia	hyperkalemia	NN	_	20	ppmod	_	_
23	(	-lrb-	-LRB-	_	27	p	_	_
24	serum	serum	NN	_	27	attr	_	_
25	potassium	potassium	NN	_	27	attr	_	_
26	5.5	0	CD	_	27	num	_	_
27	mEq/L	meq/l	NN	_	22	prn	_	_
28	)	-rrb-	-RRB-	_	27	p	_	_
29	from	from	IN	_	30	case	_	_
30	17	0	CD	_	18	ppmod	_	_
31	%	%	NN	_	30	meta	_	_
32	on	on	IN	_	33	case	_	_
33	drug4	drug0	NN	_	18	ppmod	_	_
34	alone	alone	RB	_	33	adv	_	_
35	to	to	TO	_	36	aux	_	_
36	38	0	CD	_	18	ppmod	_	_
37	%	%	NN	_	36	meta	_	_
38	.	.	.	_	18	p	_	_

1	drug1	drug0	NN	_	5	com	_	_
2	-A	-a	NN	_	5	com	_	_
3	drug	drug	NN	_	5	com	_	_
4	interaction	interaction	NN	_	5	com	_	_
5	study	study	NN	_	13	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	with	with	IN	_	9	case	_	_
9	drug3	drug0	NN	_	5	ppmod	_	_
10	has	have	VBZ	_	13	aux	_	_
11	not	not	RB	_	13	neg	_	_
12	been	be	VBN	_	13	aux	_	_
13	conducted	conduct	VBN	_	0	root	_	_
14	.	.	.	_	13	p	_	_

1	Serum	serum	NN	_	3	com	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	levels	level	NNS	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	monitored	monitor	VBN	_	0	root	_	_
7	frequently	frequently	RB	_	6	adv	_	_
8	if	if	IN	_	11	mark	_	_
9	drug2	drug0	NN	_	11	dep	_	_
10	is	be	VBZ	_	11	aux	_	_
11	administered	administer	VBN	_	6	comp	_	_
12	concomitantly	concomitantly	RB	_	11	adv	_	_
13	with	with	IN	_	14	case	_	_
14	drug3	drug0	NN	_	11	ppmod	_	_
15	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	5	advnp	_	_
2	(	-lrb-	-LRB-	_	5	p	_	_
3	drug2	drug0	NN	_	5	advnp	_	_
4	)	-rrb-	-RRB-	_	5	p	_	_
5	-A	-a	JJ	_	8	attr	_	_
6	drug	drug	NN	_	8	com	_	_
7	interaction	interaction	NN	_	8	com	_	_
8	study	study	NN	_	17	dep	_	_
9	of	of	IN	_	10	case	_	_
10	drug3	drug0	NN	_	8	ppmod	_	_
11	with	with	IN	_	13	case	_	_
12	an	an	DT	_	13	det	_	_
13	drug4	drug0	NN	_	8	ppmod	_	_
14	has	have	VBZ	_	17	aux	_	_
15	not	not	RB	_	17	neg	_	_
16	been	be	VBN	_	17	aux	_	_
17	conducted	conduct	VBN	_	0	root	_	_
18	.	.	.	_	17	p	_	_

1	The	the	DT	_	2	det	_	_
2	administration	administration	NN	_	10	dep	_	_
3	of	of	IN	_	5	case	_	_
4	other	other	JJ	_	5	attr	_	_
5	drug1	drug0	NN	_	2	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drug2	drug0	NN	_	2	ppmod	_	_
8	has	have	VBZ	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	shown	show	VBN	_	0	root	_	_
11	to	to	TO	_	12	aux	_	_
12	reduce	reduce	VB	_	10	comp	_	_
13	the	the	DT	_	15	det	_	_
14	antihypertensive	antihypertensive	JJ	_	15	attr	_	_
15	effect	effect	NN	_	12	obj	_	_
16	in	in	IN	_	18	case	_	_
17	some	some	DT	_	18	det	_	_
18	patients	patient	NNS	_	12	ppmod	_	_
19	and	and	CC	_	12	cc	_	_
20	result	result	VB	_	12	conj	_	_
21	in	in	IN	_	23	case	_	_
22	severe	severe	JJ	_	23	attr	_	_
23	hyperkalemia	hyperkalemia	NN	_	20	ppmod	_	_
24	in	in	IN	_	25	case	_	_
25	patients	patient	NNS	_	20	ppmod	_	_
26	with	with	IN	_	29	case	_	_
27	impaired	impaired	JJ	_	29	attr	_	_
28	renal	renal	JJ	_	29	attr	_	_
29	function	function	NN	_	25	ppmod	_	_
30	.	.	.	_	10	p	_	_

1	Therefore	therefore	RB	_	14	adv	_	_
2	,	,	,	_	14	p	_	_
3	when	when	WRB	_	8	adv	_	_
4	drug1	drug0	NN	_	8	dep	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	are	be	VBP	_	8	aux	_	_
8	used	use	VBN	_	14	advcl	_	_
9	concomitantly	concomitantly	RB	_	8	adv	_	_
10	,	,	,	_	14	p	_	_
11	patients	patient	NNS	_	14	dep	_	_
12	should	should	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	observed	observe	VBN	_	0	root	_	_
15	to	to	TO	_	16	aux	_	_
16	determine	determine	VB	_	14	comp	_	_
17	whether	whether	IN	_	25	mark	_	_
18	the	the	DT	_	20	det	_	_
19	desired	desired	JJ	_	20	attr	_	_
20	effect	effect	NN	_	25	dep	_	_
21	on	on	IN	_	23	case	_	_
22	blood	blood	NN	_	23	com	_	_
23	pressure	pressure	NN	_	20	ppmod	_	_
24	is	be	VBZ	_	25	aux	_	_
25	obtained	obtain	VBN	_	16	comp	_	_
26	.	.	.	_	14	p	_	_

1	Tissue	tissue	NN	_	2	com	_	_
2	culture	culture	NN	_	6	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	animal	animal	NN	_	5	com	_	_
5	studies	study	NNS	_	2	conj	_	_
6	indicate	indicate	VBP	_	0	root	_	_
7	that	that	IN	_	10	mark	_	_
8	drug1	drug0	NN	_	10	dep	_	_
9	can	can	MD	_	10	modal	_	_
10	diminish	diminish	VB	_	6	comp	_	_
11	or	or	CC	_	10	cc	_	_
12	abolish	abolish	VB	_	10	conj	_	_
13	the	the	DT	_	14	det	_	_
14	effect	effect	NN	_	12	obj	_	_
15	of	of	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	on	on	IN	_	19	case	_	_
18	malignant	malignant	JJ	_	19	attr	_	_
19	cells.14	cells.0	NN	_	14	ppmod	_	_
20	This	this	DT	_	21	det	_	_
21	effect	effect	NN	_	12	obj	10:obj	_
22	on	on	IN	_	25	mark	_	_
23	drug3	drug0	NN	_	24	com	_	_
24	activity	activity	NN	_	25	dep	_	_
25	persists	persist	VBZ	_	21	acl	_	_
26	as	as	RB	_	33	adv	_	_
27	long	long	RB	_	33	adv	_	_
28	as	as	IN	_	33	mark	_	_
29	plasma	plasma	NN	_	31	com	_	_
30	asparagine	asparagine	NN	_	31	com	_	_
31	levels	level	NNS	_	33	dep	_	_
32	are	be	VBP	_	33	aux	_	_
33	suppressed	suppress	VBN	_	25	comp	_	_
34	.	.	.	_	6	p	_	_

1	These	these	DT	_	2	det	_	_
2	results	result	NNS	_	4	dep	_	_
3	would	would	MD	_	4	modal	_	_
4	seem	seem	VB	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	dictate	dictate	VB	_	4	comp	_	_
7	against	against	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	clinical	clinical	JJ	_	10	attr	_	_
10	use	use	NN	_	6	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	with	with	IN	_	14	case	_	_
14	drug2	drug0	NN	_	6	ppmod	_	_
15	,	,	,	_	14	p	_	_
16	or	or	CC	_	14	cc	_	_
17	during	during	IN	_	19	case	_	_
18	the	the	DT	_	19	det	_	_
19	period	period	NN	_	14	conj	_	_
20	following	follow	VBG	_	22	adv	_	_
21	drug3	drug0	NN	_	22	com	_	_
22	therapy	therapy	NN	_	19	ppmod	_	_
23	when	when	WRB	_	27	adv	_	_
24	plasma	plasma	NN	_	26	com	_	_
25	asparagine	asparagine	NN	_	26	com	_	_
26	levels	level	NNS	_	27	dep	_	_
27	are	be	VBP	_	4	comp	_	_
28	below	below	IN	_	29	case	_	_
29	normal	normal	JJ	_	27	ppmod	_	_
30	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	decrease	decrease	VB	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	amount	amount	NN	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	drug3	drug0	NN	_	7	prn	_	_
10	,	,	,	_	9	p	_	_
11	drug4	drug0	NN	_	9	appo	_	_
12	)	-rrb-	-RRB-	_	9	p	_	_
13	that	that	WDT	_	15	dep	_	_
14	gets	get	VBZ	_	15	aux	_	_
15	absorbed	absorb	VBN	_	7	relcl	_	_
16	into	into	IN	_	18	case	_	_
17	your	your	JJ	_	18	attr	_	_
18	body	body	NN	_	15	ppmod	_	_
19	.	.	.	_	3	p	_	_

1	In	in	IN	_	3	case	_	_
2	the	the	DT	_	3	det	_	_
3	case	case	NN	_	19	ppmod	_	_
4	that	that	WDT	_	7	dep	_	_
5	you	you	RB	_	7	adv	_	_
6	are	be	VBP	_	7	aux	_	_
7	taking	take	VBG	_	3	relcl	_	_
8	drug1	drug0	NN	_	7	obj	_	_
9	while	while	IN	_	10	mark	_	_
10	taking	take	VBG	_	8	acl	_	_
11	drug2	drug0	NN	_	10	obj	_	_
12	,	,	,	_	19	p	_	_
13	higher	high	JJR	_	14	attr	_	_
14	doses	dose	NNS	_	19	dep	_	_
15	of	of	IN	_	16	case	_	_
16	drug3	drug0	NN	_	14	ppmod	_	_
17	may	may	MD	_	19	modal	_	_
18	be	be	VB	_	19	aux	_	_
19	needed	need	VBN	_	0	root	_	_
20	.	.	.	_	19	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	may	may	MD	_	4	modal	_	_
3	also	also	RB	_	4	adv	_	_
4	decrease	decrease	VB	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	absorption	absorption	NN	_	4	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	,	,	,	_	6	p	_	_
10	which	which	WDT	_	12	dep	_	_
11	can	can	MD	_	12	modal	_	_
12	lead	lead	VB	_	6	relcl	_	_
13	to	to	TO	_	15	aux	_	_
14	a	a	NN	_	15	com	_	_
15	deficiency	deficiency	NN	_	12	ppmod	_	_
16	.	.	.	_	4	p	_	_

1	Therefore	therefore	RB	_	4	adv	_	_
2	you	you	NN	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	need	need	VBP	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	take	take	VB	_	4	comp	_	_
7	a	a	DT	_	9	det	_	_
8	drug1	drug0	JJ	_	9	attr	_	_
9	supplement	supplement	NN	_	6	obj	_	_
10	while	while	IN	_	11	mark	_	_
11	taking	take	VBG	_	6	comp	_	_
12	drug2	drug0	NN	_	11	obj	_	_
13	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	augment	augment	VB	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	activity	activity	NN	_	3	obj	_	_
6	of	of	IN	_	8	case	_	_
7	other	other	JJ	_	8	attr	_	_
8	drug2	drug0	NNS	_	5	ppmod	_	_
9	.	.	.	_	3	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	use	use	NN	_	8	dep	_	_
3	with	with	IN	_	5	case	_	_
4	other	other	JJ	_	5	attr	_	_
5	drug1	drug0	NN	_	2	ppmod	_	_
6	is	be	VBZ	_	8	aux	_	_
7	not	not	RB	_	8	neg	_	_
8	recommended	recommend	VBN	_	0	root	_	_

1	.	.	.	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	No	no	DT	_	2	det	_	_
2	information	information	NN	_	3	dep	_	_
3	is	be	VBZ	_	0	root	_	_
4	available	available	JJ	_	3	dep	_	_
5	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	accentuate	accentuate	VB	_	0	root	_	_
4	the	the	DT	_	6	det	_	_
5	electrolyte	electrolyte	NN	_	6	com	_	_
6	loss	loss	NN	_	3	obj	_	_
7	associated	associate	VBN	_	6	acl	_	_
8	with	with	IN	_	10	case	_	_
9	drug2	drug0	NN	_	10	com	_	_
10	therapy	therapy	NN	_	7	ppmod	_	_
11	.	.	.	_	3	p	_	_

1	Patients	patient	NNS	_	28	dep	_	_
2	receiving	receive	VBG	_	1	acl	_	_
3	other	other	JJ	_	5	attr	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	s	s	NNS	_	2	obj	_	_
6	,	,	,	_	1	p	_	_
7	general	general	JJ	_	8	attr	_	_
8	drug2	drug0	NN	_	1	appo	_	_
9	,	,	,	_	8	p	_	_
10	drug3	drug0	NN	_	8	conj	_	_
11	,	,	,	_	10	p	_	_
12	drug4	drug0	NN	_	8	conj	_	_
13	,	,	,	_	12	p	_	_
14	drug5	drug0	NN	_	8	conj	_	_
15	,	,	,	_	14	p	_	_
16	drug6	drug0	NN	_	8	conj	_	_
17	or	or	CC	_	16	cc	_	_
18	other	other	JJ	_	19	attr	_	_
19	drug7	drug0	NN	_	8	conj	_	_
20	(	-lrb-	-LRB-	_	21	p	_	_
21	including	include	VBG	_	1	prn	_	_
22	drug8	drug0	NN	_	21	obj	_	_
23	)	-rrb-	-RRB-	_	21	p	_	_
24	concomitantly	concomitantly	RB	_	26	adv	_	_
25	with	with	IN	_	26	case	_	_
26	drug9	drug0	NN	_	1	ppmod	_	_
27	may	may	MD	_	28	modal	_	_
28	exhibit	exhibit	VBP	_	0	root	_	_
29	an	an	DT	_	32	det	_	_
30	additive	additive	JJ	_	32	attr	_	_
31	CNS	cns	NN	_	32	com	_	_
32	depression	depression	NN	_	28	obj	_	_
33	.	.	.	_	28	p	_	_

1	When	when	WRB	_	6	adv	_	_
2	such	such	JJ	_	4	attr	_	_
3	combined	combined	JJ	_	4	attr	_	_
4	therapy	therapy	NN	_	6	dep	_	_
5	is	be	VBZ	_	6	aux	_	_
6	contemplated	contemplate	VBN	_	17	advcl	_	_
7	,	,	,	_	17	p	_	_
8	the	the	DT	_	9	det	_	_
9	dose	dose	NN	_	17	dep	_	_
10	of	of	IN	_	11	case	_	_
11	one	#crd#	CD	_	9	ppmod	_	_
12	or	or	CC	_	11	cc	_	_
13	both	both	DT	_	14	attr	_	_
14	agents	agent	NNS	_	11	conj	_	_
15	should	should	MD	_	17	modal	_	_
16	be	be	VB	_	17	aux	_	_
17	reduced	reduce	VBN	_	0	root	_	_
18	.	.	.	_	17	p	_	_

1	No	no	DT	_	9	det	_	_
2	significant	significant	JJ	_	9	attr	_	_
3	drug-drug	drug-drug	JJ	_	9	attr	_	_
4	pharmacokinetic	pharmacokinetic	JJ	_	9	attr	_	_
5	(	-lrb-	-LRB-	_	4	p	_	_
6	or	or	CC	_	4	cc	_	_
7	pharmacodynamic	pharmacodynamic	JJ	_	4	conj	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	interactions	interaction	NNS	_	12	dep	_	_
10	have	have	VBP	_	12	aux	_	_
11	been	be	VBN	_	12	aux	_	_
12	found	find	VBN	_	0	root	_	_
13	in	in	IN	_	15	case	_	_
14	interaction	interaction	NN	_	15	com	_	_
15	studies	study	NNS	_	12	ppmod	_	_
16	with	with	IN	_	17	case	_	_
17	drug1	drug0	NN	_	15	ppmod	_	_
18	,	,	,	_	17	p	_	_
19	drug2	drug0	NN	_	17	conj	_	_
20	,	,	,	_	19	p	_	_
21	drug3	drug0	NN	_	17	conj	_	_
22	,	,	,	_	21	p	_	_
23	and	and	CC	_	21	cc	_	_
24	drug4	drug0	NN	_	17	conj	_	_
25	.	.	.	_	12	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	studies	study	NNS	_	4	dep	_	_
4	show	show	VBP	_	0	root	_	_
5	significant	significant	JJ	_	6	attr	_	_
6	inhibition	inhibition	NN	_	4	obj	_	_
7	of	of	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	formation	formation	NN	_	6	ppmod	_	_
10	of	of	IN	_	13	case	_	_
11	oxidized	oxidize	VBN	_	13	attr	_	_
12	irbesartan	irbesartan	NN	_	13	com	_	_
13	metabolites	metabolite	NNS	_	9	ppmod	_	_
14	with	with	IN	_	21	case	_	_
15	the	the	DT	_	21	det	_	_
16	known	known	JJ	_	21	attr	_	_
17	cytochrome	cytochrome	NN	_	21	com	_	_
18	CYP	cyp	NN	_	21	com	_	_
19	2C9	0c0	NN	_	21	com	_	_
20	substrates/inhibitors	substrates/inhibitors	NN	_	21	com	_	_
21	drug1	drug0	NN	_	13	ppmod	_	_
22	,	,	,	_	21	p	_	_
23	drug2	drug0	NN	_	21	appo	_	_
24	and	and	CC	_	23	cc	_	_
25	drug3	drug0	NN	_	23	conj	_	_
26	.	.	.	_	4	p	_	_

1	However	however	RB	_	16	adv	_	_
2	,	,	,	_	16	p	_	_
3	in	in	IN	_	5	case	_	_
4	clinical	clinical	JJ	_	5	attr	_	_
5	studies	study	NNS	_	16	ppmod	_	_
6	the	the	DT	_	7	det	_	_
7	consequences	consequence	NNS	_	16	dep	_	_
8	of	of	IN	_	10	case	_	_
9	concomitant	concomitant	JJ	_	10	attr	_	_
10	drug1	drug0	NN	_	7	ppmod	_	_
11	on	on	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	pharmacodynamics	pharmacodynamics	NNS	_	7	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	were	be	VBD	_	0	root	_	_
17	negligible	negligible	JJ	_	16	dep	_	_
18	.	.	.	_	16	p	_	_

1	Based	base	VBN	_	5	adv	_	_
2	on	on	IN	_	5	case	_	_
3	in	in	FW	_	4	adv	_	_
4	vitro	vitro	FW	_	5	attr	_	_
5	data	datum	NNS	_	11	ppmod	_	_
6	,	,	,	_	11	p	_	_
7	no	no	DT	_	8	det	_	_
8	interaction	interaction	NN	_	11	dep	_	_
9	would	would	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	expected	expect	VBN	_	0	root	_	_
12	with	with	IN	_	13	case	_	_
13	drugs	drug	NNS	_	11	ppmod	_	_
14	whose	whose	WP$	_	15	poss	_	_
15	metabolism	metabolism	NN	_	16	dep	_	_
16	is	be	VBZ	_	13	relcl	_	_
17	dependent	dependent	JJ	_	16	dep	_	_
18	upon	upon	IN	_	22	case	_	_
19	cytochrome	cytochrome	NN	_	22	com	_	_
20	P450	p0	NN	_	22	com	_	_
21	isozymes	isozymes	NNS	_	22	com	_	_
22	1A1	0a0	NN	_	17	ppmod	_	_
23	,	,	,	_	22	p	_	_
24	1A2,2A6,2B6,2D6,2E1	0a0a0b0d0e0	NN	_	22	conj	_	_
25	,	,	,	_	24	p	_	_
26	or	or	CC	_	24	cc	_	_
27	3A4	0a0	NN	_	22	conj	_	_
28	.	.	.	_	11	p	_	_

1	In	in	IN	_	3	case	_	_
2	separate	separate	JJ	_	3	attr	_	_
3	studies	study	NNS	_	22	ppmod	_	_
4	of	of	IN	_	5	case	_	_
5	patients	patient	NNS	_	3	ppmod	_	_
6	receiving	receive	VBG	_	5	acl	_	_
7	maintenance	maintenance	NN	_	8	com	_	_
8	doses	dose	NNS	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	drug2	drug0	NN	_	10	conj	_	_
13	,	,	,	_	12	p	_	_
14	or	or	CC	_	12	cc	_	_
15	drug3	drug0	NN	_	10	conj	_	_
16	,	,	,	_	22	p	_	_
17	drug4	drug0	NN	_	18	com	_	_
18	administration	administration	NN	_	22	dep	_	_
19	for	for	IN	_	21	case	_	_
20	7	0	CD	_	21	num	_	_
21	days	day	NNS	_	18	ppmod	_	_
22	had	have	VBD	_	0	root	_	_
23	no	no	DT	_	24	det	_	_
24	effect	effect	NN	_	22	obj	_	_
25	on	on	IN	_	27	case	_	_
26	the	the	DT	_	27	det	_	_
27	pharmacodynamics	pharmacodynamics	NNS	_	22	ppmod	_	_
28	of	of	IN	_	29	case	_	_
29	drug5	drug0	NN	_	27	ppmod	_	_
30	(	-lrb-	-LRB-	_	32	p	_	_
31	prothrombin	prothrombin	NN	_	32	com	_	_
32	time	time	NN	_	29	prn	_	_
33	)	-rrb-	-RRB-	_	32	p	_	_
34	or	or	CC	_	27	cc	_	_
35	pharmacokinetics	pharmacokinetics	NNS	_	27	conj	_	_
36	of	of	IN	_	37	case	_	_
37	drug6	drug0	NN	_	27	ppmod	_	_
38	.	.	.	_	22	p	_	_

1	The	the	DT	_	2	det	_	_
2	pharmacokinetics	pharmacokinetics	NNS	_	7	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	were	be	VBD	_	7	aux	_	_
6	not	not	RB	_	7	neg	_	_
7	affected	affect	VBN	_	0	root	_	_
8	by	by	IN	_	9	case	_	_
9	coadministration	coadministration	NN	_	7	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	or	or	CC	_	11	cc	_	_
13	drug3	drug0	NN	_	11	conj	_	_

1	.	.	.	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	Interactions	interaction	NNS	_	11	dep	_	_
2	between	between	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	other	other	JJ	_	6	attr	_	_
6	drugs	drug	NNS	_	3	conj	_	_
7	have	have	VBP	_	11	aux	_	_
8	not	not	RB	_	11	neg	_	_
9	been	be	VBN	_	11	aux	_	_
10	fully	fully	RB	_	11	adv	_	_
11	evaluated	evaluate	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	Results	result	NNS	_	6	dep	_	_
2	from	from	IN	_	5	case	_	_
3	existing	existing	JJ	_	5	attr	_	_
4	clinical	clinical	JJ	_	5	attr	_	_
5	trials	trial	NNS	_	1	ppmod	_	_
6	suggest	suggest	VBP	_	0	root	_	_
7	no	no	DT	_	9	det	_	_
8	significant	significant	JJ	_	9	attr	_	_
9	interactions	interaction	NNS	_	6	obj	_	_
10	between	between	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	other	other	JJ	_	14	attr	_	_
14	therapies	therapy	NNS	_	11	conj	_	_
15	commonly	commonly	RB	_	16	adv	_	_
16	used	use	VBN	_	14	acl	_	_
17	in	in	IN	_	19	case	_	_
18	MS	ms	NN	_	19	com	_	_
19	patients	patient	NNS	_	16	ppmod	_	_
20	,	,	,	_	9	p	_	_
21	including	include	VBG	_	24	adv	_	_
22	the	the	DT	_	24	det	_	_
23	concurrent	concurrent	JJ	_	24	attr	_	_
24	use	use	NN	_	9	ppmod	_	_
25	of	of	IN	_	26	case	_	_
26	drug2	drug0	NN	_	24	ppmod	_	_
27	for	for	IN	_	31	case	_	_
28	up	up	RB	_	30	adv	_	_
29	to	to	TO	_	30	attr	_	_
30	28	0	CD	_	31	num	_	_
31	days	day	NNS	_	24	ppmod	_	_
32	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	has	have	VBZ	_	6	aux	_	_
3	not	not	RB	_	6	neg	_	_
4	been	be	VBN	_	6	aux	_	_
5	formally	formally	RB	_	6	adv	_	_
6	evaluated	evaluate	VBN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	combination	combination	NN	_	6	ppmod	_	_
9	with	with	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	6	p	_	_

1	However	however	RB	_	15	adv	_	_
2	,	,	,	_	15	p	_	_
3	10	0	CD	_	4	num	_	_
4	patients	patient	NNS	_	15	dep	_	_
5	who	who	WP	_	6	dep	_	_
6	switched	switch	VBD	_	4	relcl	_	_
7	from	from	IN	_	8	case	_	_
8	therapy	therapy	NN	_	6	ppmod	_	_
9	with	with	IN	_	10	case	_	_
10	drug1	drug0	NN	_	6	ppmod	_	_
11	to	to	TO	_	12	aux	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	did	do	VBD	_	15	aux	_	_
14	not	not	RB	_	15	neg	_	_
15	report	report	VBP	_	0	root	_	_
16	any	any	DT	_	21	det	_	_
17	serious	serious	JJ	_	21	attr	_	_
18	and	and	CC	_	17	cc	_	_
19	unexpected	unexpected	JJ	_	17	conj	_	_
20	adverse	adverse	JJ	_	21	attr	_	_
21	reactions	reaction	NNS	_	15	obj	_	_
22	thought	think	VBN	_	21	acl	_	_
23	to	to	TO	_	24	aux	_	_
24	be	be	VB	_	22	comp	_	_
25	related	related	JJ	_	24	dep	_	_
26	to	to	TO	_	27	aux	_	_
27	treatment	treatment	NN	_	25	ppmod	_	_
28	.	.	.	_	15	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	extensively	extensively	RB	_	4	adv	_	_
4	metabolized	metabolize	VBN	_	0	root	_	_
5	in	in	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	liver	liver	NN	_	4	ppmod	_	_
8	by	by	IN	_	9	case	_	_
9	CYP2C19	cyp0c0	NN	_	4	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	CYP3A4	cyp0a0	NN	_	9	conj	_	_
12	.	.	.	_	4	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	6	attr	_	_
3	and	and	CC	_	2	cc	_	_
4	in	in	FW	_	5	adv	_	_
5	vivo	vivo	FW	_	2	conj	_	_
6	studies	study	NNS	_	8	dep	_	_
7	have	have	VBP	_	8	aux	_	_
8	shown	show	VBN	_	0	root	_	_
9	that	that	IN	_	11	mark	_	_
10	drug1	drug0	NN	_	11	dep	_	_
11	is	be	VBZ	_	8	comp	_	_
12	not	not	RB	_	11	neg	_	_
13	likely	likely	JJ	_	11	dep	_	_
14	to	to	TO	_	15	aux	_	_
15	inhibit	inhibit	VB	_	13	comp	_	_
16	CYPs	cyps	NNS	_	15	obj	_	_
17	1A2	0a0	NN	_	16	attr	_	_
18	,	,	,	_	17	p	_	_
19	2A6	0a0	NN	_	17	conj	_	_
20	,	,	,	_	19	p	_	_
21	2C9	0c0	NN	_	17	conj	_	_
22	,	,	,	_	21	p	_	_
23	2D6	0d0	NN	_	17	conj	_	_
24	,	,	,	_	23	p	_	_
25	2E1	0e0	NN	_	17	conj	_	_
26	and	and	CC	_	25	cc	_	_
27	3A4	0a0	NN	_	17	conj	_	_
28	.	.	.	_	8	p	_	_

1	No	no	DT	_	4	det	_	_
2	clinically	clinically	RB	_	3	adv	_	_
3	relevant	relevant	JJ	_	4	attr	_	_
4	interactions	interaction	NNS	_	14	dep	_	_
5	with	with	IN	_	6	case	_	_
6	drugs	drug	NNS	_	4	ppmod	_	_
7	metabolized	metabolize	VBN	_	6	acl	_	_
8	by	by	IN	_	11	case	_	_
9	these	these	DT	_	11	det	_	_
10	CYP	cyp	JJ	_	11	attr	_	_
11	enzymes	enzyme	NNS	_	7	ppmod	_	_
12	would	would	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	expected	expect	VBN	_	0	root	_	_
15	.	.	.	_	14	p	_	_

1	Drug	drug	NN	_	3	com	_	_
2	interaction	interaction	NN	_	3	com	_	_
3	studies	study	NNS	_	5	dep	_	_
4	have	have	VBP	_	5	aux	_	_
5	shown	show	VBN	_	0	root	_	_
6	that	that	IN	_	14	mark	_	_
7	drug1	drug0	NN	_	14	dep	_	_
8	does	do	VBZ	_	14	aux	_	_
9	not	not	RB	_	14	neg	_	_
10	have	have	VB	_	14	lv	_	_
11	any	any	DT	_	14	det	_	_
12	clinically	clinically	RB	_	13	adv	_	_
13	significant	significant	JJ	_	14	attr	_	_
14	interactions	interaction	NNS	_	5	comp	_	_
15	with	with	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	,	,	,	_	16	p	_	_
18	drug3	drug0	NN	_	16	conj	_	_
19	,	,	,	_	18	p	_	_
20	drug4	drug0	NN	_	16	conj	_	_
21	,	,	,	_	20	p	_	_
22	drug5	drug0	NN	_	16	conj	_	_
23	or	or	CC	_	22	cc	_	_
24	drug6	drug0	NN	_	16	conj	_	_
25	.	.	.	_	5	p	_	_

1	Post-marketing	post-marketing	JJ	_	2	attr	_	_
2	reports	report	NNS	_	10	dep	_	_
3	of	of	IN	_	4	case	_	_
4	changes	change	NNS	_	2	ppmod	_	_
5	in	in	IN	_	7	case	_	_
6	prothrombin	prothrombin	NN	_	7	com	_	_
7	measures	measure	NNS	_	4	ppmod	_	_
8	have	have	VBP	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	received	receive	VBN	_	0	root	_	_
11	among	among	IN	_	12	case	_	_
12	patients	patient	NNS	_	10	ppmod	_	_
13	on	on	IN	_	15	case	_	_
14	concomitant	concomitant	JJ	_	15	attr	_	_
15	drug1	drug0	NN	_	12	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	drug2	drug0	JJ	_	18	attr	_	_
18	therapy	therapy	NN	_	15	conj	_	_
19	.	.	.	_	10	p	_	_

1	Increases	increase	NNS	_	8	dep	_	_
2	in	in	IN	_	3	case	_	_
3	INR	inr	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	prothrombin	prothrombin	NN	_	6	com	_	_
6	time	time	NN	_	3	conj	_	_
7	may	may	MD	_	8	modal	_	_
8	lead	lead	VB	_	0	root	_	_
9	to	to	TO	_	11	aux	_	_
10	abnormal	abnormal	JJ	_	11	attr	_	_
11	bleeding	bleeding	JJ	_	8	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	even	even	JJ	_	14	attr	_	_
14	death	death	NN	_	11	conj	_	_
15	.	.	.	_	8	p	_	_

1	Patients	patient	NNS	_	9	dep	_	_
2	treated	treat	VBN	_	1	acl	_	_
3	with	with	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	concomitantly	concomitantly	RB	_	2	adv	_	_
8	may	may	MD	_	9	modal	_	_
9	need	need	VBP	_	0	root	_	_
10	to	to	TO	_	12	aux	_	_
11	be	be	VB	_	12	aux	_	_
12	monitored	monitor	VBN	_	9	comp	_	_
13	for	for	IN	_	14	case	_	_
14	increases	increase	NNS	_	12	ppmod	_	_
15	in	in	IN	_	16	case	_	_
16	INR	inr	NN	_	14	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	prothrombin	prothrombin	NN	_	19	com	_	_
19	time	time	NN	_	16	conj	_	_
20	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	may	may	MD	_	4	modal	_	_
3	potentially	potentially	RB	_	4	adv	_	_
4	interfere	interfere	VB	_	0	root	_	_
5	with	with	IN	_	6	case	_	_
6	CYP2C19	cyp0c0	NN	_	4	ppmod	_	_
7	,	,	,	_	6	p	_	_
8	the	the	DT	_	12	det	_	_
9	major	major	JJ	_	12	attr	_	_
10	drug2	drug0	NN	_	12	com	_	_
11	metabolizing	metabolizing	NN	_	12	com	_	_
12	enzyme	enzyme	NN	_	6	appo	_	_
13	.	.	.	_	4	p	_	_

1	Coadministration	coadministration	NN	_	13	dep	_	_
2	of	of	IN	_	5	case	_	_
3	drug1	drug0	NN	_	5	attr	_	_
4	30	0	CD	_	5	num	_	_
5	mg	mg	NN	_	1	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	,	,	,	_	7	p	_	_
9	a	a	DT	_	11	det	_	_
10	CYP2C19	cyp0c0	NN	_	11	com	_	_
11	substrate	substrate	NN	_	7	appo	_	_
12	,	,	,	_	7	p	_	_
13	resulted	result	VBD	_	0	root	_	_
14	in	in	IN	_	18	case	_	_
15	a	a	DT	_	18	det	_	_
16	45	0	CD	_	18	num	_	_
17	%	%	NN	_	16	meta	_	_
18	decrease	decrease	NN	_	13	ppmod	_	_
19	in	in	IN	_	20	case	_	_
20	clearance	clearance	NN	_	18	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	drug3	drug0	NN	_	20	ppmod	_	_
23	.	.	.	_	13	p	_	_

1	Increased	increase	VBN	_	3	attr	_	_
2	plasma	plasma	NN	_	3	com	_	_
3	levels	level	NNS	_	7	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	were	be	VBD	_	7	aux	_	_
7	observed	observe	VBN	_	0	root	_	_
8	12	0	CD	_	9	num	_	_
9	hours	hour	NNS	_	11	dat	_	_
10	after	after	IN	_	11	case	_	_
11	dosing	dosing	NN	_	7	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	onwards	onwards	NN	_	11	conj	_	_
14	.	.	.	_	7	p	_	_

1	However	however	RB	_	12	adv	_	_
2	,	,	,	_	12	p	_	_
3	at	at	IN	_	5	case	_	_
4	that	that	DT	_	5	det	_	_
5	time	time	NN	_	12	ppmod	_	_
6	,	,	,	_	12	p	_	_
7	the	the	DT	_	9	det	_	_
8	plasma	plasma	NN	_	9	com	_	_
9	levels	level	NNS	_	12	dep	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	were	be	VBD	_	0	root	_	_
13	below	below	IN	_	16	case	_	_
14	the	the	DT	_	16	det	_	_
15	therapeutic	therapeutic	JJ	_	16	attr	_	_
16	interval	interval	NN	_	12	ppmod	_	_
17	,	,	,	_	12	p	_	_
18	and	and	CC	_	12	cc	_	_
19	thus	thus	RB	_	22	adv	_	_
20	this	this	DT	_	21	det	_	_
21	interaction	interaction	NN	_	22	dep	_	_
22	is	be	VBZ	_	12	conj	_	_
23	unlikely	unlikely	JJ	_	22	dep	_	_
24	to	to	TO	_	25	aux	_	_
25	be	be	VB	_	23	comp	_	_
26	of	of	IN	_	28	case	_	_
27	clinical	clinical	JJ	_	28	attr	_	_
28	relevance	relevance	NN	_	25	ppmod	_	_
29	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	inhibits	inhibit	VBZ	_	0	root	_	_
3	gastric	gastric	JJ	_	5	attr	_	_
4	acid	acid	NN	_	5	com	_	_
5	secretion	secretion	NN	_	2	obj	_	_
6	.	.	.	_	2	p	_	_

1	Therefore	therefore	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	drug1	drug0	NN	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	interfere	interfere	VB	_	0	root	_	_
6	with	with	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	absorption	absorption	NN	_	5	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drugs	drug	NNS	_	8	ppmod	_	_
11	where	where	WRB	_	14	adv	_	_
12	gastric	gastric	JJ	_	13	attr	_	_
13	pH	ph	NN	_	14	dep	_	_
14	is	be	VBZ	_	10	relcl	_	_
15	an	an	DT	_	17	det	_	_
16	important	important	JJ	_	17	attr	_	_
17	determinant	determinant	NN	_	14	obj	_	_
18	of	of	IN	_	19	case	_	_
19	bioavailability	bioavailability	NN	_	17	ppmod	_	_
20	(	-lrb-	-LRB-	_	21	p	_	_
21	eg	eg	NN	_	19	prn	_	_
22	,	,	,	_	21	p	_	_
23	drug2	drug0	NN	_	21	conj	_	_
24	,	,	,	_	23	p	_	_
25	drug3	drug0	NN	_	26	com	_	_
26	salts	salt	NNS	_	21	conj	_	_
27	and	and	CC	_	26	cc	_	_
28	drug4	drug0	NN	_	21	conj	_	_
29	)	-rrb-	-RRB-	_	21	p	_	_
30	.	.	.	_	5	p	_	_

1	Coadministration	coadministration	NN	_	14	dep	_	_
2	of	of	IN	_	4	case	_	_
3	oral	oral	JJ	_	4	attr	_	_
4	drug1	drug0	NN	_	1	ppmod	_	_
5	,	,	,	_	4	p	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	,	,	,	_	6	p	_	_
8	drug3	drug0	NN	_	4	conj	_	_
9	,	,	,	_	8	p	_	_
10	or	or	CC	_	8	cc	_	_
11	drug4	drug0	NN	_	4	conj	_	_
12	did	do	VBD	_	14	aux	_	_
13	not	not	RB	_	14	neg	_	_
14	seem	seem	VB	_	0	root	_	_
15	to	to	TO	_	16	aux	_	_
16	change	change	VB	_	14	comp	_	_
17	the	the	DT	_	19	det	_	_
18	pharmacokinetic	pharmacokinetic	JJ	_	19	attr	_	_
19	profile	profile	NN	_	16	obj	_	_
20	of	of	IN	_	21	case	_	_
21	drug5	drug0	NN	_	19	ppmod	_	_
22	.	.	.	_	14	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	administration	administration	NN	_	8	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	with	with	IN	_	6	case	_	_
6	drug2	drug0	NN	_	2	ppmod	_	_
7	is	be	VBZ	_	8	aux	_	_
8	contraindicated	contraindicate	VBN	_	0	root	_	_
9	.	.	.	_	8	p	_	_

1	No	no	DT	_	5	det	_	_
2	significant	significant	JJ	_	5	attr	_	_
3	drug-drug	drug-drug	JJ	_	5	attr	_	_
4	pharmacokinetic	pharmacokinetic	JJ	_	5	attr	_	_
5	interactions	interaction	NNS	_	8	dep	_	_
6	have	have	VBP	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	found	find	VBN	_	0	root	_	_
9	in	in	IN	_	11	case	_	_
10	interaction	interaction	NN	_	11	com	_	_
11	studies	study	NNS	_	8	ppmod	_	_
12	with	with	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	,	,	,	_	13	p	_	_
15	drug2	drug0	NN	_	13	conj	_	_
16	,	,	,	_	15	p	_	_
17	drug3	drug0	NN	_	13	conj	_	_
18	,	,	,	_	17	p	_	_
19	drug4	drug0	NN	_	13	conj	_	_
20	and	and	CC	_	19	cc	_	_
21	drug5	drug0	NN	_	13	conj	_	_
22	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	9	dep	_	_
2	,	,	,	_	1	p	_	_
3	an	an	DT	_	4	det	_	_
4	inducer	inducer	NN	_	1	appo	_	_
5	of	of	IN	_	7	case	_	_
6	drug	drug	NN	_	7	com	_	_
7	metabolism	metabolism	NN	_	4	ppmod	_	_
8	,	,	,	_	1	p	_	_
9	decreased	decrease	VBD	_	0	root	_	_
10	the	the	DT	_	11	det	_	_
11	concentrations	concentration	NNS	_	9	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	its	its	PRP$	_	17	poss	_	_
16	active	active	JJ	_	17	attr	_	_
17	metabolite	metabolite	NN	_	13	conj	_	_
18	.	.	.	_	9	p	_	_

1	In	in	IN	_	2	case	_	_
2	humans	human	NNS	_	11	ppmod	_	_
3	,	,	,	_	11	p	_	_
4	two	#crd#	CD	_	5	num	_	_
5	inhibitors	inhibitor	NNS	_	11	dep	_	_
6	of	of	IN	_	8	case	_	_
7	P450	p0	NN	_	8	com	_	_
8	3A4	0a0	NN	_	5	ppmod	_	_
9	have	have	VBP	_	11	aux	_	_
10	been	be	VBN	_	11	aux	_	_
11	studied	study	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	did	do	VBD	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	affect	affect	VB	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	conversion	conversion	NN	_	4	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	to	to	TO	_	12	aux	_	_
10	the	the	DT	_	12	det	_	_
11	active	active	JJ	_	12	attr	_	_
12	metabolite	metabolite	NN	_	6	ppmod	_	_
13	after	after	IN	_	15	case	_	_
14	intravenous	intravenous	JJ	_	15	attr	_	_
15	administration	administration	NN	_	12	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	drug3	drug0	NN	_	15	ppmod	_	_
18	,	,	,	_	4	p	_	_
19	and	and	CC	_	4	cc	_	_
20	drug4	drug0	NN	_	21	dep	_	_
21	had	have	VBD	_	4	conj	_	_
22	no	no	DT	_	25	det	_	_
23	clinically	clinically	RB	_	24	adv	_	_
24	significant	significant	JJ	_	25	attr	_	_
25	effect	effect	NN	_	21	obj	_	_
26	after	after	IN	_	28	case	_	_
27	oral	oral	JJ	_	28	attr	_	_
28	administration	administration	NN	_	21	ppmod	_	_
29	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	9	dep	_	_
2	,	,	,	_	1	p	_	_
3	an	an	DT	_	4	det	_	_
4	inhibitor	inhibitor	NN	_	1	appo	_	_
5	of	of	IN	_	7	case	_	_
6	P450	p0	NN	_	7	com	_	_
7	2C9	0c0	NNS	_	4	ppmod	_	_
8	,	,	,	_	1	p	_	_
9	decreased	decrease	VBD	_	0	root	_	_
10	active	active	JJ	_	12	attr	_	_
11	metabolite	metabolite	NN	_	12	com	_	_
12	concentration	concentration	NN	_	9	obj	_	_
13	and	and	CC	_	9	cc	_	_
14	increased	increase	VBD	_	9	conj	_	_
15	drug2	drug0	NN	_	16	com	_	_
16	concentration	concentration	NN	_	14	obj	_	_
17	.	.	.	_	9	p	_	_

1	The	the	DT	_	3	det	_	_
2	pharmacodynamic	pharmacodynamic	JJ	_	3	attr	_	_
3	consequences	consequence	NNS	_	17	dep	_	_
4	of	of	IN	_	6	case	_	_
5	concomitant	concomitant	JJ	_	6	attr	_	_
6	use	use	NN	_	3	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	6	cc	_	_
10	inhibitors	inhibitor	NNS	_	6	conj	_	_
11	of	of	IN	_	13	case	_	_
12	P450	p0	NN	_	13	com	_	_
13	2C9	0c0	NNS	_	10	ppmod	_	_
14	have	have	VBP	_	17	aux	_	_
15	not	not	RB	_	17	neg	_	_
16	been	be	VBN	_	17	aux	_	_
17	examined	examine	VBN	_	0	root	_	_
18	.	.	.	_	17	p	_	_

1	Subjects	subject	NNS	_	12	dep	_	_
2	who	who	WP	_	5	dep	_	_
3	do	do	VBP	_	5	aux	_	_
4	not	not	RB	_	5	neg	_	_
5	metabolize	metabolize	VB	_	1	relcl	_	_
6	drug1	drug0	NN	_	5	obj	_	_
7	to	to	TO	_	9	aux	_	_
8	active	active	JJ	_	9	attr	_	_
9	metabolite	metabolite	NN	_	6	ppmod	_	_
10	have	have	VBP	_	12	aux	_	_
11	been	be	VBN	_	12	aux	_	_
12	shown	show	VBN	_	0	root	_	_
13	to	to	TO	_	14	aux	_	_
14	have	have	VB	_	12	comp	_	_
15	a	a	DT	_	19	det	_	_
16	specific	specific	JJ	_	18	adv	_	_
17	,	,	,	_	18	p	_	_
18	rare	rare	JJ	_	19	attr	_	_
19	defect	defect	NN	_	14	obj	_	_
20	in	in	IN	_	23	case	_	_
21	cytochrome	cytochrome	NN	_	23	com	_	_
22	P450	p0	NN	_	23	com	_	_
23	2C9	0c0	NN	_	14	ppmod	_	_
24	.	.	.	_	12	p	_	_

1	These	these	DT	_	2	det	_	_
2	data	datum	NNS	_	3	dep	_	_
3	suggest	suggest	VBP	_	0	root	_	_
4	that	that	IN	_	14	mark	_	_
5	the	the	DT	_	6	det	_	_
6	conversion	conversion	NN	_	14	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	to	to	TO	_	12	aux	_	_
10	its	its	PRP$	_	12	poss	_	_
11	active	active	JJ	_	12	attr	_	_
12	metabolite	metabolite	NN	_	6	ppmod	_	_
13	is	be	VBZ	_	14	aux	_	_
14	mediated	mediate	VBN	_	3	comp	_	_
15	primarily	primarily	RB	_	14	adv	_	_
16	by	by	IN	_	18	case	_	_
17	P450	p0	NN	_	18	com	_	_
18	2C9	0c0	NN	_	14	ppmod	_	_
19	and	and	CC	_	14	cc	_	_
20	not	not	RB	_	22	neg	_	_
21	P450	p0	NN	_	22	com	_	_
22	3A4	0a0	NN	_	14	conj	_	_
23	.	.	.	_	3	p	_	_

1	As	as	IN	_	4	case	_	_
2	with	with	IN	_	4	case	_	_
3	other	other	JJ	_	4	attr	_	_
4	drugs	drug	NNS	_	36	ppmod	_	_
5	that	that	WDT	_	6	dep	_	_
6	block	block	VBP	_	4	relcl	_	_
7	angiotensin	angiotensin	NN	_	6	obj	_	_
8	II	ii	CD	_	7	num	_	_
9	or	or	CC	_	7	cc	_	_
10	its	its	PRP$	_	11	poss	_	_
11	effects	effect	NNS	_	7	conj	_	_
12	,	,	,	_	36	p	_	_
13	concomitant	concomitant	JJ	_	14	attr	_	_
14	use	use	NN	_	36	dep	_	_
15	of	of	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	(	-lrb-	-LRB-	_	20	p	_	_
18	e.g.	e.g.	FW	_	20	ppmod	_	_
19	,	,	,	_	20	p	_	_
20	drug2	drug0	NN	_	16	prn	_	_
21	,	,	,	_	20	p	_	_
22	drug3	drug0	NN	_	20	appo	_	_
23	,	,	,	_	20	p	_	_
24	drug4	drug0	NN	_	20	appo	_	_
25	)	-rrb-	-RRB-	_	20	p	_	_
26	,	,	,	_	16	p	_	_
27	drug5	drug0	NN	_	28	com	_	_
28	supplements	supplement	NNS	_	16	conj	_	_
29	,	,	,	_	28	p	_	_
30	or	or	CC	_	28	cc	_	_
31	salt	salt	NN	_	16	conj	_	_
32	substitutes	substitute	VBZ	_	31	attr	_	_
33	containing	contain	VBG	_	31	acl	_	_
34	potassium	potassium	NN	_	33	obj	_	_
35	may	may	MD	_	36	modal	_	_
36	lead	lead	VB	_	0	root	_	_
37	to	to	TO	_	38	aux	_	_
38	increases	increase	NNS	_	36	ppmod	_	_
39	in	in	IN	_	41	case	_	_
40	serum	serum	NN	_	41	com	_	_
41	potassium	potassium	NN	_	38	ppmod	_	_
42	.	.	.	_	36	p	_	_

1	As	as	IN	_	4	case	_	_
2	with	with	IN	_	4	case	_	_
3	other	other	JJ	_	4	attr	_	_
4	drug1	drug0	NN	_	13	ppmod	_	_
5	,	,	,	_	13	p	_	_
6	the	the	DT	_	8	det	_	_
7	antihypertensive	antihypertensive	JJ	_	8	attr	_	_
8	effect	effect	NN	_	13	dep	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	may	may	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	blunted	blunt	VBN	_	0	root	_	_
14	by	by	IN	_	17	case	_	_
15	the	the	DT	_	17	det	_	_
16	drug3	drug0	NN	_	17	com	_	_
17	drug4	drug0	NN	_	13	ppmod	_	_

1	.	.	.	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	used	use	VBN	_	0	root	_	_
5	with	with	IN	_	6	case	_	_
6	caution	caution	NN	_	4	ppmod	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	4	ppmod	_	_
9	receiving	receive	VBG	_	8	acl	_	_
10	drug2	drug0	NN	_	9	obj	_	_
11	.	.	.	_	4	p	_	_

1	When	when	WRB	_	12	adv	_	_
2	other	other	JJ	_	5	attr	_	_
3	potent	potent	JJ	_	5	attr	_	_
4	parental	parental	JJ	_	5	attr	_	_
5	drug1	drug0	NNS	_	12	dep	_	_
6	,	,	,	_	5	p	_	_
7	such	such	JJ	_	9	adv	_	_
8	as	as	IN	_	9	case	_	_
9	drug2	drug0	NN	_	5	ppmod	_	_
10	,	,	,	_	5	p	_	_
11	are	be	VBP	_	12	aux	_	_
12	used	use	VBN	_	22	advcl	_	_
13	in	in	IN	_	14	case	_	_
14	combination	combination	NN	_	12	ppmod	_	_
15	with	with	IN	_	16	case	_	_
16	drug3	drug0	NN	_	14	ppmod	_	_
17	,	,	,	_	22	p	_	_
18	patients	patient	NNS	_	22	dep	_	_
19	should	should	MD	_	22	modal	_	_
20	be	be	VB	_	22	aux	_	_
21	continuously	continuously	RB	_	22	adv	_	_
22	observed	observe	VBN	_	0	root	_	_
23	for	for	IN	_	25	case	_	_
24	several	several	JJ	_	25	attr	_	_
25	hours	hour	NNS	_	22	ppmod	_	_
26	for	for	IN	_	28	case	_	_
27	any	any	DT	_	28	det	_	_
28	excessive	excessive	JJ	_	25	ppmod	_	_
29	fall	fall	VBP	_	28	acl	_	_
30	in	in	IN	_	32	case	_	_
31	blood	blood	NN	_	32	com	_	_
32	pressure	pressure	NN	_	29	ppmod	_	_
33	.	.	.	_	22	p	_	_

1	Profound	profound	JJ	_	3	attr	_	_
2	hypotensive	hypotensive	JJ	_	3	attr	_	_
3	episodes	episode	NNS	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	occur	occur	VB	_	0	root	_	_
6	when	when	WRB	_	12	adv	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	infection	infection	NN	_	12	dep	_	_
9	and	and	CC	_	8	cc	_	_
10	drug2	drug0	NN	_	8	conj	_	_
11	are	be	VBP	_	12	aux	_	_
12	used	use	VBN	_	5	comp	_	_
13	concomitantly	concomitantly	RB	_	12	adv	_	_
14	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	8	attr	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	drug2	drug0	NN	_	1	prn	_	_
4	,	,	,	_	3	p	_	_
5	drug3	drug0	NN	_	3	appo	_	_
6	)	-rrb-	-RRB-	_	3	p	_	_
7	serum	serum	NN	_	8	com	_	_
8	concentrations	concentration	NNS	_	14	dep	_	_
9	and	and	CC	_	8	cc	_	_
10	pharmacologic	pharmacologic	JJ	_	11	attr	_	_
11	effects	effect	NNS	_	8	conj	_	_
12	may	may	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	increased	increase	VBN	_	0	root	_	_
15	.	.	.	_	14	p	_	_

1	Monitor	monitor	VB	_	0	root	_	_
2	cardiovascular	cardiovascular	JJ	_	3	attr	_	_
3	status	status	NN	_	1	obj	_	_
4	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	increases	increase	VBZ	_	0	root	_	_
3	drug2	drug0	NN	_	6	com	_	_
4	s	s	NN	_	6	com	_	_
5	serum	serum	NN	_	6	com	_	_
6	concentrations	concentration	NNS	_	2	obj	_	_
7	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	16	dep	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	,	,	,	_	3	p	_	_
5	and	and	CC	_	3	cc	_	_
6	drug3	drug0	NN	_	1	conj	_	_
7	(	-lrb-	-LRB-	_	10	p	_	_
8	low	low	JJ	_	10	attr	_	_
9	hepatic	hepatic	JJ	_	10	attr	_	_
10	clearance	clearance	NN	_	1	prn	_	_
11	or	or	CC	_	10	cc	_	_
12	no	no	NN	_	14	com	_	_
13	first-pass	first-pass	NN	_	14	com	_	_
14	metabolism	metabolism	NN	_	10	conj	_	_
15	)	-rrb-	-RRB-	_	10	p	_	_
16	are	be	VBP	_	0	root	_	_
17	unlikely	unlikely	JJ	_	16	dep	_	_
18	to	to	TO	_	20	aux	_	_
19	be	be	VB	_	20	aux	_	_
20	affected	affect	VBN	_	17	comp	_	_
21	.	.	.	_	16	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	decrease	decrease	VB	_	0	root	_	_
4	the	the	DT	_	6	det	_	_
5	hemodynamic	hemodynamic	JJ	_	6	attr	_	_
6	effects	effect	NNS	_	3	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	;	;	:	_	3	p	_	_

1	avoid	avoid	VB	_	2	aux	_	_
2	use	use	VB	_	0	root	_	_
3	if	if	IN	_	4	mark	_	_
4	possible	possible	JJ	_	2	comp	_	_
5	or	or	CC	_	2	cc	_	_
6	closely	closely	RB	_	7	adv	_	_
7	monitor	monitor	VB	_	2	conj	_	_
8	cardiovascular	cardiovascular	JJ	_	9	attr	_	_
9	status	status	NN	_	7	obj	_	_
10	at	at	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	end	end	NN	_	7	ppmod	_	_
13	of	of	IN	_	15	case	_	_
14	drug	drug	NN	_	15	com	_	_
15	interactions	interaction	NNS	_	12	ppmod	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Twelve	#crd#	CD	_	6	num	_	_
4	healthy	healthy	JJ	_	6	attr	_	_
5	male	male	JJ	_	6	attr	_	_
6	volunteers	volunteer	NNS	_	8	dep	_	_
7	were	be	VBD	_	8	aux	_	_
8	administered	administer	VBN	_	1	acl	_	_
9	one	#crd#	CD	_	12	num	_	_
10	200-mg	0-mg	NN	_	12	com	_	_
11	drug2	drug0	NN	_	12	com	_	_
12	capsule	capsule	NN	_	8	obj	_	_
13	twice	twice	RB	_	14	com	_	_
14	daily	daily	RB	_	8	adv	_	_
15	for	for	IN	_	17	case	_	_
16	6	0	CD	_	17	num	_	_
17	days	day	NNS	_	8	ppmod	_	_
18	.	.	.	_	1	p	_	_

1	With	with	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	morning	morning	NN	_	4	com	_	_
4	dose	dose	NN	_	13	ppmod	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	on	on	IN	_	8	case	_	_
8	day	day	NN	_	4	ppmod	_	_
9	6	0	CD	_	8	num	_	_
10	,	,	,	_	13	p	_	_
11	each	each	DT	_	12	det	_	_
12	volunteer	volunteer	NN	_	13	dep	_	_
13	received	receive	VBD	_	0	root	_	_
14	a	a	DT	_	17	det	_	_
15	single	single	JJ	_	17	attr	_	_
16	intravenous	intravenous	JJ	_	17	attr	_	_
17	infusion	infusion	NN	_	13	obj	_	_
18	of	of	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	(	-lrb-	-LRB-	_	22	p	_	_
21	4	0	CD	_	22	num	_	_
22	mg/kg	mg/kg	NN	_	19	prn	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	.	.	.	_	13	p	_	_

1	The	the	DT	_	2	det	_	_
2	pharmacokinetics	pharmacokinetics	NNS	_	7	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	were	be	VBD	_	7	aux	_	_
6	not	not	RB	_	7	neg	_	_
7	altered	alter	VBN	_	0	root	_	_
8	.	.	.	_	7	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	15	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	on	on	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	pharmacokinetics	pharmacokinetics	NNS	_	2	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NNS	_	7	ppmod	_	_
10	administered	administer	VBN	_	9	acl	_	_
11	orally	orally	RB	_	10	adv	_	_
12	has	have	VBZ	_	15	aux	_	_
13	not	not	RB	_	15	neg	_	_
14	been	be	VBN	_	15	aux	_	_
15	investigated	investigate	VBN	_	0	root	_	_
16	.	.	.	_	15	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	or	or	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	:	:	:	_	1	p	_	_
5	The	the	DT	_	6	det	_	_
6	effect	effect	NN	_	17	dep	_	_
7	of	of	IN	_	10	case	_	_
8	increased	increase	VBN	_	10	attr	_	_
9	gastric	gastric	JJ	_	10	attr	_	_
10	pH	ph	NN	_	6	ppmod	_	_
11	on	on	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	bioavailability	bioavailability	NN	_	6	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	was	be	VBD	_	17	aux	_	_
17	evaluated	evaluate	VBN	_	1	acl	_	_
18	in	in	IN	_	22	case	_	_
19	18	0	CD	_	22	num	_	_
20	healthy	healthy	JJ	_	22	attr	_	_
21	adult	adult	JJ	_	22	attr	_	_
22	volunteers	volunteer	NNS	_	17	ppmod	_	_
23	.	.	.	_	1	p	_	_

1	Each	each	DT	_	2	det	_	_
2	volunteer	volunteer	NN	_	4	dep	_	_
3	was	be	VBD	_	4	aux	_	_
4	administered	administer	VBN	_	0	root	_	_
5	one	#crd#	CD	_	8	num	_	_
6	400-mg	0-mg	NN	_	8	com	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	capsule	capsule	NN	_	4	obj	_	_
9	.	.	.	_	4	p	_	_

1	A	a	DT	_	3	det	_	_
2	single	single	JJ	_	3	attr	_	_
3	dose	dose	NN	_	9	dep	_	_
4	of	of	IN	_	6	case	_	_
5	liquid	liquid	JJ	_	6	attr	_	_
6	drug1	drug0	NN	_	3	ppmod	_	_
7	did	do	VBD	_	9	aux	_	_
8	not	not	RB	_	9	neg	_	_
9	affect	affect	VB	_	0	root	_	_
10	the	the	DT	_	12	det	_	_
11	C	c	NN	_	12	com	_	_
12	max	max	NN	_	9	obj	_	_
13	or	or	CC	_	12	cc	_	_
14	AUC	auc	NN	_	12	conj	_	_
15	of	of	IN	_	16	case	_	_
16	drug2	drug0	NNS	_	14	ppmod	_	_
17	;	;	:	_	9	p	_	_

1	however	however	RB	_	11	adv	_	_
2	,	,	,	_	11	p	_	_
3	150	0	CD	_	4	num	_	_
4	mg	mg	NN	_	11	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	q12h	q0h	IN	_	10	case	_	_
8	for	for	IN	_	10	case	_	_
9	3	0	CD	_	10	num	_	_
10	days	day	NNS	_	4	ppmod	_	_
11	increased	increase	VBD	_	0	root	_	_
12	the	the	DT	_	15	det	_	_
13	drug2	drug0	NN	_	15	com	_	_
14	C	c	NN	_	15	com	_	_
15	max	max	NN	_	11	obj	_	_
16	by	by	IN	_	17	case	_	_
17	23	0	CD	_	11	ppmod	_	_
18	%	%	NN	_	17	meta	_	_
19	and	and	CC	_	17	cc	_	_
20	drug3	drug0	NN	_	21	com	_	_
21	AUC	auc	NN	_	17	conj	_	_
22	by	by	IN	_	23	case	_	_
23	16	0	CD	_	11	ppmod	_	_
24	%	%	NN	_	23	meta	_	_
25	.	.	.	_	11	p	_	_

1	The	the	DT	_	3	det	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	relevance	relevance	NN	_	9	dep	_	_
4	of	of	IN	_	6	case	_	_
5	these	these	DT	_	6	det	_	_
6	increases	increase	NNS	_	3	ppmod	_	_
7	is	be	VBZ	_	9	aux	_	_
8	not	not	RB	_	9	neg	_	_
9	known	know	VBN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	Drug/Laboratory	drug/laboratory	NN	_	3	com	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	0	root	_	_
4	:	:	:	_	3	p	_	_
5	There	there	EX	_	7	dep	_	_
6	have	have	VBP	_	7	aux	_	_
7	been	be	VBN	_	3	acl	_	_
8	no	no	DT	_	13	det	_	_
9	chemical	chemical	JJ	_	13	attr	_	_
10	or	or	CC	_	9	cc	_	_
11	laboratory	laboratory	JJ	_	9	conj	_	_
12	test	test	NN	_	13	com	_	_
13	interactions	interaction	NNS	_	7	obj	_	_
14	with	with	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	noted	note	VBN	_	15	acl	_	_
17	to	to	TO	_	18	aux	_	_
18	date	date	NN	_	16	ppmod	_	_
19	.	.	.	_	3	p	_	_

1	False-positive	false-positive	JJ	_	4	attr	_	_
2	direct	direct	JJ	_	4	attr	_	_
3	Coombs	coombs	NN	_	4	com	_	_
4	tests	test	NNS	_	7	dep	_	_
5	have	have	VBP	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	reported	report	VBN	_	0	root	_	_
8	during	during	IN	_	9	case	_	_
9	treatment	treatment	NN	_	7	ppmod	_	_
10	with	with	IN	_	12	case	_	_
11	other	other	JJ	_	12	attr	_	_
12	drug1	drug0	NN	_	9	ppmod	_	_
13	.	.	.	_	7	p	_	_

1	Therefore	therefore	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	it	it	PRP	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	recognized	recognize	VBN	_	0	root	_	_
7	that	that	IN	_	13	mark	_	_
8	a	a	DT	_	11	det	_	_
9	positive	positive	JJ	_	11	attr	_	_
10	Coombs	coombs	NN	_	11	com	_	_
11	test	test	NN	_	13	dep	_	_
12	could	could	MD	_	13	modal	_	_
13	be	be	VB	_	6	comp	_	_
14	due	due	JJ	_	13	dep	_	_
15	to	to	TO	_	17	aux	_	_
16	the	the	DT	_	17	det	_	_
17	drug	drug	NN	_	14	ppmod	_	_
18	.	.	.	_	6	p	_	_

1	The	the	DT	_	2	det	_	_
2	results	result	NNS	_	22	dep	_	_
3	of	of	IN	_	4	case	_	_
4	assays	assay	NNS	_	2	ppmod	_	_
5	using	use	VBG	_	4	acl	_	_
6	red	red	JJ	_	7	attr	_	_
7	cells	cell	NNS	_	5	obj	_	_
8	from	from	IN	_	10	case	_	_
9	healthy	healthy	JJ	_	10	attr	_	_
10	subjects	subject	NNS	_	7	ppmod	_	_
11	to	to	TO	_	12	aux	_	_
12	determine	determine	VB	_	5	comp	_	_
13	whether	whether	IN	_	16	mark	_	_
14	drug1	drug0	NN	_	16	dep	_	_
15	would	would	MD	_	16	modal	_	_
16	cause	cause	VB	_	12	comp	_	_
17	direct	direct	JJ	_	19	attr	_	_
18	Coombs	coombs	NN	_	19	com	_	_
19	reactions	reaction	NNS	_	16	obj	_	_
20	in	in	FW	_	21	adv	_	_
21	vitro	vitro	FW	_	16	adv	_	_
22	showed	show	VBD	_	0	root	_	_
23	no	no	DT	_	25	det	_	_
24	positive	positive	JJ	_	25	attr	_	_
25	reaction	reaction	NN	_	22	obj	_	_
26	at	at	IN	_	28	case	_	_
27	drug2	drug0	NN	_	28	com	_	_
28	concentrations	concentration	NNS	_	22	ppmod	_	_
29	as	as	RB	_	30	adv	_	_
30	high	high	JJ	_	28	attr	_	_
31	as	as	IN	_	33	case	_	_
32	40	0	CD	_	33	num	_	_
33	g/mL	g/ml	NN	_	30	ppmod	_	_
34	.	.	.	_	22	p	_	_

1	Although	although	IN	_	7	mark	_	_
2	the	the	DT	_	3	det	_	_
3	occurrence	occurrence	NN	_	7	dep	_	_
4	has	have	VBZ	_	7	aux	_	_
5	not	not	RB	_	7	neg	_	_
6	been	be	VBN	_	7	aux	_	_
7	reported	report	VBN	_	14	advcl	_	_
8	with	with	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	14	p	_	_
11	nephrotoxicity	nephrotoxicity	NN	_	14	dep	_	_
12	has	have	VBZ	_	14	aux	_	_
13	been	be	VBN	_	14	aux	_	_
14	reported	report	VBN	_	0	root	_	_
15	following	follow	VBG	_	17	adv	_	_
16	concomitant	concomitant	JJ	_	17	attr	_	_
17	administration	administration	NN	_	14	ppmod	_	_
18	of	of	IN	_	20	case	_	_
19	other	other	JJ	_	20	attr	_	_
20	drug2	drug0	NN	_	17	ppmod	_	_
21	and	and	CC	_	20	cc	_	_
22	drug3	drug0	NN	_	20	conj	_	_
23	.	.	.	_	14	p	_	_

1	Although	although	IN	_	8	mark	_	_
2	acid-base	acid-base	NN	_	5	attr	_	_
3	and	and	CC	_	2	cc	_	_
4	electrolyte	electrolyte	NN	_	2	conj	_	_
5	disturbances	disturbance	NNS	_	8	dep	_	_
6	were	be	VBD	_	8	aux	_	_
7	not	not	RB	_	8	neg	_	_
8	reported	report	VBN	_	20	advcl	_	_
9	in	in	IN	_	12	case	_	_
10	the	the	DT	_	12	det	_	_
11	clinical	clinical	JJ	_	12	attr	_	_
12	trials	trial	NNS	_	8	ppmod	_	_
13	with	with	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	,	,	,	_	20	p	_	_
16	these	these	DT	_	17	det	_	_
17	disturbances	disturbance	NNS	_	20	dep	_	_
18	have	have	VBP	_	20	aux	_	_
19	been	be	VBN	_	20	aux	_	_
20	reported	report	VBN	_	0	root	_	_
21	with	with	IN	_	23	case	_	_
22	oral	oral	JJ	_	23	attr	_	_
23	drug2	drug0	NN	_	20	ppmod	_	_
24	and	and	CC	_	20	cc	_	_
25	have	have	VBP	_	20	conj	_	_
26	,	,	,	_	25	p	_	_
27	in	in	IN	_	29	case	_	_
28	some	some	DT	_	29	det	_	_
29	instances	instance	NNS	_	25	ppmod	_	_
30	,	,	,	_	25	p	_	_
31	resulted	result	VBD	_	25	comp	_	_
32	in	in	IN	_	34	case	_	_
33	drug	drug	NN	_	34	com	_	_
34	interactions	interaction	NNS	_	31	ppmod	_	_
35	(	-lrb-	-LRB-	_	38	p	_	_
36	e.g.	e.g.	FW	_	38	adv	_	_
37	,	,	,	_	38	p	_	_
38	toxicity	toxicity	NN	_	34	prn	_	_
39	associated	associate	VBN	_	38	acl	_	_
40	with	with	IN	_	43	case	_	_
41	high-dose	high-dose	JJ	_	43	attr	_	_
42	drug3	drug0	NN	_	43	com	_	_
43	therapy	therapy	NN	_	39	ppmod	_	_
44	)	-rrb-	-RRB-	_	38	p	_	_
45	.	.	.	_	20	p	_	_

1	Therefore	therefore	RB	_	11	adv	_	_
2	,	,	,	_	11	p	_	_
3	the	the	DT	_	4	det	_	_
4	potential	potential	NN	_	11	dep	_	_
5	for	for	IN	_	8	case	_	_
6	such	such	JJ	_	8	attr	_	_
7	drug	drug	NN	_	8	com	_	_
8	interactions	interaction	NNS	_	4	ppmod	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	considered	consider	VBN	_	0	root	_	_
12	in	in	IN	_	13	case	_	_
13	patients	patient	NNS	_	11	ppmod	_	_
14	receiving	receive	VBG	_	13	acl	_	_
15	drug1	drug0	NN	_	14	obj	_	_
16	.	.	.	_	11	p	_	_

1	Interactions	interaction	NNS	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	occur	occur	VB	_	0	root	_	_
4	between	between	IN	_	6	case	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	supplements	supplement	NNS	_	3	ppmod	_	_
7	and	and	CC	_	8	cc	_	_
8	drug2	drug0	NN	_	6	attr	_	_
9	and	and	CC	_	8	cc	_	_
10	other	other	JJ	_	11	attr	_	_
11	drug3	drug0	NN	_	8	conj	_	_
12	and	and	CC	_	6	cc	_	_
13	herbs	herb	NNS	_	6	conj	_	_
14	such	such	JJ	_	16	adv	_	_
15	as	as	IN	_	16	case	_	_
16	garlic	garlic	NN	_	6	ppmod	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	Allium	allium	NNP	_	16	prn	_	_
19	sativum	sativum	FW	_	18	attr	_	_
20	)	-rrb-	-RRB-	_	18	p	_	_
21	and	and	CC	_	16	cc	_	_
22	drug4	drug0	NN	_	16	conj	_	_
23	(	-lrb-	-LRB-	_	24	p	_	_
24	drug5	drug0	NN	_	22	prn	_	_
25	)	-rrb-	-RRB-	_	24	p	_	_
26	.	.	.	_	3	p	_	_

1	Such	such	JJ	_	2	attr	_	_
2	interactions	interaction	NNS	_	5	dep	_	_
3	might	might	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	manifested	manifest	VBN	_	0	root	_	_
6	by	by	IN	_	8	case	_	_
7	increased	increase	VBN	_	8	attr	_	_
8	susceptibility	susceptibility	NN	_	5	ppmod	_	_
9	to	to	TO	_	10	aux	_	_
10	bruising	bruising	NN	_	8	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	nosebleeds	nosebleeds	NN	_	10	conj	_	_
13	,	,	,	_	12	p	_	_
14	hemoptysis	hemoptysis	NN	_	10	conj	_	_
15	,	,	,	_	14	p	_	_
16	hematemesis	hematemesis	NN	_	10	conj	_	_
17	,	,	,	_	16	p	_	_
18	hematuria	hematuria	NN	_	10	conj	_	_
19	and	and	CC	_	18	cc	_	_
20	blood	blood	NN	_	10	conj	_	_
21	in	in	IN	_	23	case	_	_
22	the	the	DT	_	23	det	_	_
23	stool	stool	NN	_	10	ppmod	_	_
24	.	.	.	_	5	p	_	_

1	Most	most	JJS	_	14	dep	_	_
2	who	who	WP	_	3	dep	_	_
3	take	take	VBP	_	1	relcl	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	supplements	supplement	NNS	_	3	obj	_	_
6	and	and	CC	_	1	cc	_	_
7	the	the	DT	_	9	det	_	_
8	above	above	JJ	_	9	attr	_	_
9	drugs	drug	NNS	_	1	conj	_	_
10	or	or	CC	_	9	cc	_	_
11	herbs	herb	NNS	_	9	conj	_	_
12	do	do	VBP	_	14	aux	_	_
13	not	not	RB	_	14	neg	_	_
14	suffer	suffer	VB	_	0	root	_	_
15	from	from	IN	_	17	case	_	_
16	these	these	DT	_	17	det	_	_
17	problems	problem	NNS	_	14	ppmod	_	_
18	and	and	CC	_	14	cc	_	_
19	if	if	IN	_	21	mark	_	_
20	they	they	PRP	_	21	dep	_	_
21	occur	occur	VBP	_	24	advcl	_	_
22	,	,	,	_	24	p	_	_
23	they	they	PRP	_	24	dep	_	_
24	are	be	VBP	_	14	conj	_	_
25	rare	rare	JJ	_	24	dep	_	_
26	.	.	.	_	14	p	_	_

1	If	if	IN	_	4	mark	_	_
2	they	they	PRP	_	4	dep	_	_
3	do	do	VBP	_	4	aux	_	_
4	occur	occur	VB	_	10	advcl	_	_
5	,	,	,	_	10	p	_	_
6	the	the	DT	_	8	det	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	dose	dose	NN	_	10	dep	_	_
9	should	should	MD	_	10	modal	_	_
10	be	be	VB	_	0	root	_	_
11	lowered	lowered	JJ	_	10	dep	_	_
12	or	or	CC	_	11	cc	_	_
13	discontinued	discontinued	JJ	_	11	conj	_	_
14	.	.	.	_	10	p	_	_

1	Conflicting	conflict	VBG	_	2	attr	_	_
2	results	result	NNS	_	5	dep	_	_
3	have	have	VBP	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	reported	report	VBN	_	0	root	_	_
6	regarding	regard	VBG	_	5	comp	_	_
7	the	the	DT	_	8	det	_	_
8	effects	effect	NNS	_	6	obj	_	_
9	of	of	IN	_	11	case	_	_
10	drug1	drug0	NN	_	11	com	_	_
11	supplements	supplement	NNS	_	8	ppmod	_	_
12	on	on	IN	_	14	case	_	_
13	glycemic	glycemic	JJ	_	14	attr	_	_
14	control	control	NN	_	8	ppmod	_	_
15	in	in	IN	_	16	case	_	_
16	non-diabetics	non-diabetics	NNS	_	14	ppmod	_	_
17	with	with	IN	_	19	case	_	_
18	glucose	glucose	NN	_	19	com	_	_
19	intolerance	intolerance	NN	_	16	ppmod	_	_
20	,	,	,	_	8	p	_	_
21	and	and	CC	_	8	cc	_	_
22	those	those	DT	_	8	conj	_	_
23	with	with	IN	_	26	case	_	_
24	type	type	NN	_	26	attr	_	_
25	2	0	CD	_	26	num	_	_
26	diabetes	diabetes	NNS	_	22	ppmod	_	_
27	.	.	.	_	5	p	_	_

1	Some	some	DT	_	3	det	_	_
2	early	early	JJ	_	3	attr	_	_
3	studies	study	NNS	_	4	dep	_	_
4	indicated	indicate	VBD	_	0	root	_	_
5	that	that	IN	_	9	mark	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	supplements	supplement	NNS	_	9	dep	_	_
8	might	might	MD	_	9	modal	_	_
9	have	have	VB	_	4	comp	_	_
10	detrimental	detrimental	JJ	_	11	attr	_	_
11	effects	effect	NNS	_	9	obj	_	_
12	in	in	IN	_	14	case	_	_
13	those	those	DT	_	14	det	_	_
14	groups	group	NNS	_	9	ppmod	_	_
15	.	.	.	_	4	p	_	_

1	Recent	recent	JJ	_	5	attr	_	_
2	,	,	,	_	5	p	_	_
3	better	well	RBR	_	4	adv	_	_
4	designed	design	VBN	_	5	attr	_	_
5	studies	study	NNS	_	8	dep	_	_
6	have	have	VBP	_	8	aux	_	_
7	not	not	RB	_	8	neg	_	_
8	reported	report	VBN	_	0	root	_	_
9	these	these	DT	_	11	det	_	_
10	adverse	adverse	JJ	_	11	attr	_	_
11	effects	effect	NNS	_	8	obj	_	_
12	.	.	.	_	8	p	_	_

1	There	there	EX	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	no	no	DT	_	4	det	_	_
4	evidence	evidence	NN	_	2	obj	_	_
5	that	that	IN	_	8	mark	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	supplements	supplement	NNS	_	8	dep	_	_
8	have	have	VBP	_	4	acl	_	_
9	detrimental	detrimental	JJ	_	10	attr	_	_
10	effects	effect	NNS	_	8	obj	_	_
11	on	on	IN	_	13	case	_	_
12	glucose	glucose	NN	_	13	com	_	_
13	tolerance	tolerance	NN	_	8	ppmod	_	_
14	,	,	,	_	13	p	_	_
15	insulin	insulin	NN	_	16	com	_	_
16	secretion	secretion	NN	_	13	conj	_	_
17	or	or	CC	_	16	cc	_	_
18	insulin	insulin	NN	_	19	com	_	_
19	resistance	resistance	NN	_	13	conj	_	_
20	in	in	IN	_	22	case	_	_
21	non-diabetic	non-diabetic	JJ	_	22	attr	_	_
22	subjects	subject	NNS	_	13	ppmod	_	_
23	.	.	.	_	2	p	_	_

1	Diabetics	diabetics	NN	_	3	dep	_	_
2	should	should	MD	_	3	modal	_	_
3	discuss	discuss	VBP	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	use	use	NN	_	3	obj	_	_
6	of	of	IN	_	8	case	_	_
7	these	these	DT	_	8	det	_	_
8	supplements	supplement	NNS	_	5	ppmod	_	_
9	with	with	IN	_	11	case	_	_
10	their	their	PRP$	_	11	poss	_	_
11	physicians	physician	NNS	_	5	ppmod	_	_
12	and	and	CC	_	3	cc	_	_
13	note	note	VB	_	3	conj	_	_
14	if	if	IN	_	17	mark	_	_
15	the	the	DT	_	16	det	_	_
16	supplements	supplement	NNS	_	17	dep	_	_
17	affect	affect	VBP	_	13	comp	_	_
18	their	their	PRP$	_	20	poss	_	_
19	glycemic	glycemic	JJ	_	20	attr	_	_
20	control	control	NN	_	17	obj	_	_
21	.	.	.	_	3	p	_	_

1	Diabetics	diabetic	NNS	_	8	dep	_	_
2	who	who	WP	_	3	dep	_	_
3	take	take	VBP	_	1	relcl	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	supplements	supplement	NNS	_	3	obj	_	_
6	should	should	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	monitored	monitor	VBN	_	0	root	_	_
9	by	by	IN	_	11	case	_	_
10	their	their	PRP$	_	11	poss	_	_
11	physicians	physician	NNS	_	8	ppmod	_	_
12	.	.	.	_	8	p	_	_

1	Caution	caution	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	advised	advise	VBN	_	0	root	_	_
4	in	in	IN	_	5	case	_	_
5	patients	patient	NNS	_	3	ppmod	_	_
6	receiving	receive	VBG	_	5	acl	_	_
7	concomitant	concomitant	JJ	_	9	attr	_	_
8	high-dose	high-dose	JJ	_	9	attr	_	_
9	drug1	drug0	NN	_	6	obj	_	_
10	and	and	CC	_	9	cc	_	_
11	drug2	drug0	NN	_	9	conj	_	_
12	,	,	,	_	3	p	_	_
13	as	as	IN	_	24	mark	_	_
14	anorexia	anorexia	NN	_	24	dep	_	_
15	,	,	,	_	14	p	_	_
16	tachypnea	tachypnea	NN	_	14	conj	_	_
17	,	,	,	_	16	p	_	_
18	lethargy	lethargy	NN	_	14	conj	_	_
19	and	and	CC	_	18	cc	_	_
20	coma	coma	NN	_	14	conj	_	_
21	have	have	VBP	_	24	aux	_	_
22	been	be	VBN	_	24	aux	_	_
23	rarely	rarely	RB	_	24	adv	_	_
24	reported	report	VBN	_	3	comp	_	_
25	due	due	JJ	_	30	adv	_	_
26	to	to	TO	_	30	aux	_	_
27	a	a	DT	_	30	det	_	_
28	possible	possible	JJ	_	30	attr	_	_
29	drug	drug	NN	_	30	com	_	_
30	interaction	interaction	NN	_	24	ppmod	_	_
31	.	.	.	_	3	p	_	_

1	No	no	DT	_	3	det	_	_
2	specific	specific	JJ	_	3	attr	_	_
3	information	information	NN	_	0	root	_	_
4	available	available	JJ	_	3	attr	_	_

1	.	.	.	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	does	do	VBZ	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	influence	influence	VB	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	pharmacokinetics	pharmacokinetics	NNS	_	4	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	.	.	.	_	4	p	_	_

1	Carcinogenesis	carcinogenesis	NN	_	11	attr	_	_
2	,	,	,	_	1	p	_	_
3	Mutagenesis	mutagenesis	NN	_	1	appo	_	_
4	,	,	,	_	1	p	_	_
5	Impairment	impairment	NN	_	1	appo	_	_
6	of	of	IN	_	8	case	_	_
7	Fertility	fertility	NN	_	8	com	_	_
8	No	no	NN	_	5	ppmod	_	_
9	long-term	long-term	JJ	_	11	attr	_	_
10	carcinogenicity	carcinogenicity	NN	_	11	com	_	_
11	studies	study	NNS	_	14	dep	_	_
12	have	have	VBP	_	14	aux	_	_
13	been	be	VBN	_	14	aux	_	_
14	carried	carry	VBN	_	0	root	_	_
15	out	out	RP	_	14	prt	_	_
16	with	with	IN	_	17	case	_	_
17	drug1	drug0	NN	_	14	ppmod	_	_
18	in	in	IN	_	19	case	_	_
19	animals	animal	NNS	_	17	ppmod	_	_
20	.	.	.	_	14	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	not	not	RB	_	2	neg	_	_
4	mutagenic	mutagenic	JJ	_	2	dep	_	_
5	in	in	IN	_	8	case	_	_
6	the	the	DT	_	8	det	_	_
7	Ames	ames	NN	_	8	com	_	_
8	test	test	NN	_	4	ppmod	_	_
9	but	but	CC	_	2	cc	_	_
10	was	be	VBD	_	11	aux	_	_
11	found	find	VBN	_	2	conj	_	_
12	to	to	TO	_	13	aux	_	_
13	be	be	VB	_	11	comp	_	_
14	clastogenic	clastogenic	JJ	_	13	dep	_	_
15	to	to	TO	_	17	aux	_	_
16	human	human	JJ	_	17	attr	_	_
17	lymphocytes	lymphocyte	NNS	_	14	ppmod	_	_
18	in	in	FW	_	19	adv	_	_
19	vitro	vitro	FW	_	17	adv	_	_
20	and	and	CC	_	17	cc	_	_
21	to	to	TO	_	25	aux	_	_
22	mouse	mouse	NN	_	24	com	_	_
23	bone	bone	NN	_	24	com	_	_
24	marrow	marrow	NN	_	25	com	_	_
25	erythrocytes	erythrocyte	NNS	_	17	conj	_	_
26	in	in	FW	_	27	adv	_	_
27	vivo	vivo	FW	_	14	adv	_	_
28	(	-lrb-	-LRB-	_	30	p	_	_
29	micronucleus	micronucleus	NN	_	30	com	_	_
30	test	test	NN	_	14	prn	_	_
31	)	-rrb-	-RRB-	_	30	p	_	_
32	.	.	.	_	2	p	_	_

1	The	the	DT	_	4	det	_	_
2	possible	possible	JJ	_	4	attr	_	_
3	adverse	adverse	JJ	_	4	attr	_	_
4	effects	effect	NNS	_	24	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	on	on	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	fertility	fertility	NN	_	4	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	humans	human	NNS	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	experimental	experimental	JJ	_	14	attr	_	_
14	animals	animal	NNS	_	11	conj	_	_
15	,	,	,	_	11	p	_	_
16	male	male	JJ	_	11	attr	_	_
17	or	or	CC	_	16	cc	_	_
18	female	female	JJ	_	16	conj	_	_
19	,	,	,	_	11	p	_	_
20	have	have	VBP	_	24	aux	_	_
21	not	not	RB	_	24	neg	_	_
22	been	be	VBN	_	24	aux	_	_
23	adequately	adequately	RB	_	24	adv	_	_
24	studied	study	VBN	_	0	root	_	_
25	.	.	.	_	24	p	_	_

1	Testicular	testicular	JJ	_	2	attr	_	_
2	atrophy	atrophy	NN	_	4	dep	_	_
3	was	be	VBD	_	4	aux	_	_
4	seen	see	VBN	_	0	root	_	_
5	with	with	IN	_	7	case	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	administration	administration	NN	_	4	ppmod	_	_
8	at	at	IN	_	9	case	_	_
9	doses	dose	NNS	_	4	ppmod	_	_
10	as	as	RB	_	11	adv	_	_
11	low	low	JJ	_	9	attr	_	_
12	as	as	IN	_	14	case	_	_
13	30	0	CD	_	14	num	_	_
14	mg/kg	mg/kg	NN	_	11	ppmod	_	_
15	weekly	weekly	RB	_	14	adv	_	_
16	for	for	IN	_	18	case	_	_
17	6	0	CD	_	18	num	_	_
18	weeks	week	NNS	_	14	ppmod	_	_
19	in	in	IN	_	20	case	_	_
20	rats	rat	NNS	_	18	ppmod	_	_
21	(	-lrb-	-LRB-	_	22	p	_	_
22	1/3	0	CD	_	20	num	_	_
23	the	the	DT	_	25	det	_	_
24	human	human	JJ	_	25	attr	_	_
25	dose	dose	NN	_	22	appo	_	_
26	on	on	IN	_	30	case	_	_
27	a	a	DT	_	30	det	_	_
28	mg/m	mg/m	NN	_	30	attr	_	_
29	2	0	CD	_	30	num	_	_
30	basis	basis	NN	_	25	ppmod	_	_
31	)	-rrb-	-RRB-	_	22	p	_	_
32	and	and	CC	_	14	cc	_	_
33	as	as	RB	_	36	adv	_	_
34	low	low	JJ	_	36	attr	_	_
35	as	as	IN	_	36	case	_	_
36	20	0	CD	_	37	num	_	_
37	mg/kg	mg/kg	NN	_	14	conj	_	_
38	weekly	weekly	RB	_	37	adv	_	_
39	for	for	IN	_	41	case	_	_
40	13	0	CD	_	41	num	_	_
41	weeks	week	NNS	_	14	ppmod	_	_
42	in	in	IN	_	43	case	_	_
43	dogs	dog	NNS	_	41	ppmod	_	_
44	(	-lrb-	-LRB-	_	46	p	_	_
45	approximately	approximately	RB	_	46	adv	_	_
46	equal	equal	JJ	_	43	prn	_	_
47	to	to	TO	_	50	aux	_	_
48	the	the	DT	_	50	det	_	_
49	human	human	JJ	_	50	attr	_	_
50	dose	dose	NN	_	46	ppmod	_	_
51	on	on	IN	_	55	case	_	_
52	a	a	DT	_	55	det	_	_
53	mg/m	mg/m	NN	_	55	attr	_	_
54	2	0	CD	_	55	num	_	_
55	basis	basis	NN	_	50	ppmod	_	_
56	)	-rrb-	-RRB-	_	46	p	_	_
57	.	.	.	_	4	p	_	_

1	Persons	person	NNS	_	9	dep	_	_
2	taking	take	VBG	_	1	acl	_	_
3	most	most	JJ	_	4	attr	_	_
4	drug1	drug0	NN	_	2	obj	_	_
5	,	,	,	_	4	p	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	and	and	CC	_	6	cc	_	_
8	drug3	drug0	NN	_	4	conj	_	_
9	invalidate	invalidate	VBP	_	0	root	_	_
10	drug4	drug0	NN	_	9	obj	_	_
11	and	and	CC	_	10	cc	_	_
12	drug5	drug0	NN	_	15	attr	_	_
13	diagnostic	diagnostic	JJ	_	15	attr	_	_
14	blood	blood	NN	_	15	com	_	_
15	assays	assay	NNS	_	10	conj	_	_
16	.	.	.	_	9	p	_	_

1	drug1	drug0	JJ	_	2	attr	_	_
2	drug2	drug0	NN	_	13	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	heavy	heavy	JJ	_	6	attr	_	_
5	drug3	drug0	NN	_	6	com	_	_
6	intake	intake	NN	_	2	conj	_	_
7	for	for	IN	_	11	case	_	_
8	longer	long	JJR	_	10	attr	_	_
9	than	than	IN	_	8	com	_	_
10	2	0	CD	_	11	num	_	_
11	weeks	week	NNS	_	2	ppmod	_	_
12	may	may	MD	_	13	modal	_	_
13	produce	produce	VB	_	0	root	_	_
14	malabsorption	malabsorption	NN	_	13	obj	_	_
15	of	of	IN	_	16	case	_	_
16	drug4	drug0	NN	_	14	ppmod	_	_
17	.	.	.	_	13	p	_	_

1	No	no	DT	_	2	det	_	_
2	drugs	drug	NNS	_	4	dep	_	_
3	are	be	VBP	_	4	aux	_	_
4	known	know	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	interfere	interfere	VB	_	4	comp	_	_
7	with	with	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	conversion	conversion	NN	_	6	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	to	to	TO	_	13	aux	_	_
13	drug2	drug0	NN	_	9	ppmod	_	_
14	.	.	.	_	4	p	_	_

1	Conversion	conversion	NN	_	4	dep	_	_
2	could	could	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	affected	affect	VBN	_	0	root	_	_
5	by	by	IN	_	6	case	_	_
6	alterations	alteration	NNS	_	4	ppmod	_	_
7	in	in	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	level	level	NN	_	6	ppmod	_	_
10	of	of	IN	_	12	case	_	_
11	phosphatase	phosphatase	NN	_	12	com	_	_
12	activity	activity	NN	_	9	ppmod	_	_
13	,	,	,	_	4	p	_	_
14	but	but	CC	_	4	cc	_	_
15	given	given	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	abundance	abundance	NN	_	27	ppmod	_	_
18	and	and	CC	_	17	cc	_	_
19	wide	wide	JJ	_	20	attr	_	_
20	distribution	distribution	NN	_	17	conj	_	_
21	of	of	IN	_	22	case	_	_
22	phosphatases	phosphatase	NNS	_	17	ppmod	_	_
23	in	in	IN	_	25	case	_	_
24	the	the	DT	_	25	det	_	_
25	body	body	NN	_	17	ppmod	_	_
26	it	it	PRP	_	27	dep	_	_
27	is	be	VBZ	_	4	conj	_	_
28	unlikely	unlikely	JJ	_	27	dep	_	_
29	that	that	IN	_	32	mark	_	_
30	drugs	drug	NNS	_	32	dep	_	_
31	would	would	MD	_	32	modal	_	_
32	affect	affect	VB	_	28	comp	_	_
33	this	this	DT	_	34	det	_	_
34	activity	activity	NN	_	32	obj	_	_
35	enough	enough	RB	_	37	adv	_	_
36	to	to	TO	_	37	aux	_	_
37	affect	affect	VB	_	34	advcl	_	_
38	conversion	conversion	NN	_	37	obj	_	_
39	of	of	IN	_	40	case	_	_
40	drug1	drug0	NN	_	38	ppmod	_	_
41	to	to	TO	_	42	aux	_	_
42	drug2	drug0	NN	_	38	ppmod	_	_
43	.	.	.	_	4	p	_	_

1	Drugs	drug	NNS	_	7	dep	_	_
2	highly	highly	RB	_	3	adv	_	_
3	bound	bind	VBN	_	1	acl	_	_
4	to	to	TO	_	5	aux	_	_
5	albumin	albumin	NN	_	3	ppmod	_	_
6	could	could	MD	_	7	modal	_	_
7	increase	increase	VB	_	0	root	_	_
8	the	the	DT	_	10	det	_	_
9	unbound	unbound	JJ	_	10	attr	_	_
10	fraction	fraction	NN	_	7	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	7	p	_	_

1	Although	although	IN	_	4	mark	_	_
2	,	,	,	_	4	p	_	_
3	it	it	PRP	_	4	dep	_	_
4	is	be	VBZ	_	17	advcl	_	_
5	unknown	unknown	JJ	_	4	dep	_	_
6	whether	whether	IN	_	9	mark	_	_
7	this	this	DT	_	9	dep	_	_
8	could	could	MD	_	9	modal	_	_
9	result	result	VB	_	4	comp	_	_
10	in	in	IN	_	13	case	_	_
11	clinically	clinically	RB	_	12	adv	_	_
12	significant	significant	JJ	_	13	attr	_	_
13	effects	effect	NNS	_	9	ppmod	_	_
14	,	,	,	_	17	p	_	_
15	caution	caution	NN	_	17	dep	_	_
16	is	be	VBZ	_	17	aux	_	_
17	advised	advise	VBN	_	0	root	_	_
18	when	when	WRB	_	19	adv	_	_
19	administering	administer	VBG	_	17	comp	_	_
20	drug1	drug0	NN	_	19	obj	_	_
21	with	with	IN	_	23	case	_	_
22	other	other	JJ	_	23	attr	_	_
23	drugs	drug	NNS	_	19	ppmod	_	_
24	that	that	WDT	_	26	dep	_	_
25	significantly	significantly	RB	_	26	adv	_	_
26	bind	bind	VBP	_	23	relcl	_	_
27	to	to	TO	_	29	aux	_	_
28	serum	serum	NN	_	29	com	_	_
29	albumin	albumin	NN	_	26	ppmod	_	_
30	.	.	.	_	17	p	_	_

1	The	the	DT	_	2	det	_	_
2	pharmacokinetics	pharmacokinetics	NNS	_	15	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	protein	protein	NN	_	5	com	_	_
5	binding	binding	NN	_	2	conj	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	2	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	,	,	,	_	9	p	_	_
11	and	and	CC	_	9	cc	_	_
12	drug3	drug0	NN	_	7	conj	_	_
13	were	be	VBD	_	15	aux	_	_
14	not	not	RB	_	15	neg	_	_
15	altered	alter	VBN	_	0	root	_	_
16	when	when	WRB	_	22	adv	_	_
17	drug4	drug0	NN	_	22	dep	_	_
18	and	and	CC	_	17	cc	_	_
19	drug5	drug0	NN	_	17	conj	_	_
20	were	be	VBD	_	22	aux	_	_
21	concurrently	concurrently	RB	_	22	adv	_	_
22	administered	administer	VBN	_	15	comp	_	_
23	in	in	IN	_	26	case	_	_
24	single	single	JJ	_	26	attr	_	_
25	submaximal	submaximal	JJ	_	26	attr	_	_
26	doses	dose	NNS	_	22	ppmod	_	_
27	.	.	.	_	15	p	_	_

1	The	the	DT	_	5	det	_	_
2	most	most	RBS	_	3	adv	_	_
3	significant	significant	JJ	_	5	attr	_	_
4	drug	drug	NN	_	5	com	_	_
5	interactions	interaction	NNS	_	11	dep	_	_
6	following	follow	VBG	_	5	acl	_	_
7	administration	administration	NN	_	6	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	are	be	VBP	_	11	aux	_	_
11	expected	expect	VBN	_	0	root	_	_
12	to	to	TO	_	13	aux	_	_
13	occur	occur	VB	_	11	comp	_	_
14	with	with	IN	_	15	case	_	_
15	drugs	drug	NNS	_	13	ppmod	_	_
16	that	that	WDT	_	17	dep	_	_
17	interact	interact	VBP	_	15	relcl	_	_
18	with	with	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	extensively	extensively	RB	_	4	adv	_	_
4	bound	bind	VBN	_	0	root	_	_
5	to	to	TO	_	8	aux	_	_
6	serum	serum	NN	_	8	com	_	_
7	plasma	plasma	NN	_	8	com	_	_
8	proteins	protein	NNS	_	4	ppmod	_	_
9	and	and	CC	_	4	cc	_	_
10	is	be	VBZ	_	4	conj	_	_
11	prone	prone	JJ	_	10	dep	_	_
12	to	to	TO	_	14	aux	_	_
13	competitive	competitive	JJ	_	14	attr	_	_
14	displacement	displacement	NN	_	11	ppmod	_	_
15	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	metabolized	metabolize	VBN	_	0	root	_	_
4	by	by	IN	_	8	case	_	_
5	hepatic	hepatic	JJ	_	8	attr	_	_
6	cytochrome	cytochrome	NN	_	8	com	_	_
7	P450	p0	NN	_	8	com	_	_
8	enzymes	enzyme	NNS	_	3	ppmod	_	_
9	and	and	CC	_	3	cc	_	_
10	is	be	VBZ	_	3	conj	_	_
11	particularly	particularly	RB	_	12	adv	_	_
12	susceptible	susceptible	JJ	_	10	dep	_	_
13	to	to	TO	_	16	aux	_	_
14	inhibitory	inhibitory	JJ	_	16	attr	_	_
15	drug	drug	NN	_	16	com	_	_
16	interactions	interaction	NNS	_	12	ppmod	_	_
17	because	because	IN	_	19	mark	_	_
18	it	it	PRP	_	19	dep	_	_
19	is	be	VBZ	_	10	comp	_	_
20	subject	subject	JJ	_	19	dep	_	_
21	to	to	TO	_	23	aux	_	_
22	saturable	saturable	JJ	_	23	attr	_	_
23	metabolism	metabolism	NN	_	20	ppmod	_	_
24	.	.	.	_	3	p	_	_

1	Inhibition	inhibition	NN	_	5	dep	_	_
2	of	of	IN	_	3	case	_	_
3	metabolism	metabolism	NN	_	1	ppmod	_	_
4	may	may	MD	_	5	modal	_	_
5	produce	produce	VB	_	0	root	_	_
6	significant	significant	JJ	_	7	attr	_	_
7	increases	increase	NNS	_	5	obj	_	_
8	in	in	IN	_	11	case	_	_
9	circulating	circulate	VBG	_	11	attr	_	_
10	drug1	drug0	NN	_	11	com	_	_
11	concentrations	concentration	NNS	_	7	ppmod	_	_
12	and	and	CC	_	5	cc	_	_
13	enhance	enhance	VB	_	5	conj	_	_
14	the	the	DT	_	15	det	_	_
15	risk	risk	NN	_	13	obj	_	_
16	of	of	IN	_	18	case	_	_
17	drug	drug	NN	_	18	com	_	_
18	toxicity	toxicity	NN	_	15	ppmod	_	_
19	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	a	a	DT	_	5	det	_	_
4	potent	potent	JJ	_	5	attr	_	_
5	inducer	inducer	NN	_	2	obj	_	_
6	of	of	IN	_	9	case	_	_
7	hepatic	hepatic	JJ	_	9	attr	_	_
8	drug-metabolizing	drug-metabolizing	JJ	_	9	attr	_	_
9	enzymes	enzyme	NNS	_	5	ppmod	_	_
10	.	.	.	_	2	p	_	_

1	The	the	DT	_	3	det	_	_
2	most	most	RBS	_	3	com	_	_
3	commonly	commonly	RB	_	4	adv	_	_
4	occurring	occur	VBG	_	0	root	_	_
5	drug	drug	NN	_	6	com	_	_
6	interactions	interaction	NNS	_	8	dep	_	_
7	are	be	VBP	_	8	aux	_	_
8	listed	list	VBN	_	4	comp	_	_
9	below	below	IN	_	65	case	_	_
10	:	:	:	_	12	p	_	_
11	-	-	:	_	12	p	_	_
12	Drugs	drug	NNS	_	65	attr	_	_
13	that	that	WDT	_	15	dep	_	_
14	may	may	MD	_	15	modal	_	_
15	increase	increase	VB	_	12	relcl	_	_
16	plasma	plasma	NN	_	18	com	_	_
17	drug1	drug0	NN	_	18	com	_	_
18	concentrations	concentration	NNS	_	19	dep	_	_
19	include	include	VBP	_	15	comp	_	_
20	:	:	:	_	19	p	_	_
21	acute	acute	JJ	_	23	attr	_	_
22	drug2	drug0	NN	_	23	com	_	_
23	intake	intake	NN	_	19	obj	_	_
24	,	,	,	_	23	p	_	_
25	drug3	drug0	NN	_	23	appo	_	_
26	,	,	,	_	23	p	_	_
27	chboramphenicol	chboramphenicol	NN	_	23	appo	_	_
28	,	,	,	_	23	p	_	_
29	drug4	drug0	NN	_	23	appo	_	_
30	,	,	,	_	23	p	_	_
31	drug5	drug0	NN	_	23	appo	_	_
32	,	,	,	_	23	p	_	_
33	drug6	drug0	NN	_	23	appo	_	_
34	,	,	,	_	23	p	_	_
35	drug7	drug0	NN	_	23	appo	_	_
36	,	,	,	_	23	p	_	_
37	drug8	drug0	NN	_	23	appo	_	_
38	,	,	,	_	23	p	_	_
39	drug9	drug0	NN	_	23	appo	_	_
40	,	,	,	_	23	p	_	_
41	drug10	drug0	CD	_	23	appo	_	_
42	,	,	,	_	23	p	_	_
43	drug11	drug0	NN	_	23	appo	_	_
44	,	,	,	_	23	p	_	_
45	drug12	drug0	CD	_	63	num	_	_
46	,	,	,	_	63	p	_	_
47	drug13	drug0	CD	_	63	num	_	_
48	,	,	,	_	63	p	_	_
49	drug14	drug0	CD	_	63	num	_	_
50	,	,	,	_	63	p	_	_
51	drug15	drug0	CD	_	63	num	_	_
52	,	,	,	_	63	p	_	_
53	drug16	drug0	CD	_	63	num	_	_
54	,	,	,	_	63	p	_	_
55	drug17	drug0	CD	_	63	num	_	_
56	,	,	,	_	63	p	_	_
57	drug18	drug0	CD	_	63	num	_	_
58	,	,	,	_	63	p	_	_
59	drug19	drug0	CD	_	63	num	_	_
60	,	,	,	_	63	p	_	_
61	drug20	drug0	CD	_	63	num	_	_
62	,	,	,	_	63	p	_	_
63	drug21	drug0	CD	_	23	num	_	_
64	,	,	,	_	12	p	_	_
65	drug22	drug0	NN	_	8	ppmod	_	_

1	.	.	.	_	0	root	_	_

1	-	-	CC	_	9	cc	_	_
2	Drugs	drug	NNS	_	9	dep	_	_
3	that	that	WDT	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	decrease	decrease	VB	_	2	relcl	_	_
6	plasma	plasma	NN	_	8	com	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	concentrations	concentration	NNS	_	5	obj	_	_
9	include	include	VBP	_	0	root	_	_
10	:	:	:	_	9	p	_	_
11	drug2	drug0	NN	_	9	obj	_	_
12	,	,	,	_	11	p	_	_
13	chronic	chronic	JJ	_	15	attr	_	_
14	drug3	drug0	NN	_	15	com	_	_
15	abuse	abuse	NN	_	11	appo	_	_
16	,	,	,	_	11	p	_	_
17	drug4	drug0	NN	_	11	appo	_	_

1	.	.	.	_	0	root	_	_

1	-	-	CC	_	2	cc	_	_
2	Drugs	drug	NNS	_	12	dep	_	_
3	that	that	WDT	_	6	dep	_	_
4	may	may	MD	_	6	modal	_	_
5	either	either	RB	_	6	adv	_	_
6	increase	increase	VB	_	2	relcl	_	_
7	or	or	CC	_	6	cc	_	_
8	decrease	decrease	VB	_	6	conj	_	_
9	plasma	plasma	NN	_	11	com	_	_
10	drug1	drug0	NN	_	11	com	_	_
11	concentrations	concentration	NNS	_	8	obj	_	_
12	include	include	VBP	_	0	root	_	_
13	:	:	:	_	12	p	_	_
14	drug2	drug0	NN	_	12	obj	_	_
15	,	,	,	_	14	p	_	_
16	vaiproic	vaiproic	JJ	_	17	attr	_	_
17	acid	acid	NN	_	14	conj	_	_
18	,	,	,	_	17	p	_	_
19	and	and	CC	_	17	cc	_	_
20	drug3	drug0	NN	_	14	conj	_	_
21	.	.	.	_	12	p	_	_

1	Similarly	similarly	RB	_	16	adv	_	_
2	,	,	,	_	16	p	_	_
3	the	the	DT	_	4	det	_	_
4	effects	effect	NNS	_	16	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	on	on	IN	_	8	case	_	_
8	drug2	drug0	NN	_	4	ppmod	_	_
9	,	,	,	_	8	p	_	_
10	drug3	drug0	NN	_	8	conj	_	_
11	and	and	CC	_	10	cc	_	_
12	sodium	sodium	NN	_	15	com	_	_
13	plasma	plasma	NN	_	15	com	_	_
14	drug4	drug0	NN	_	15	com	_	_
15	concentrations	concentration	NNS	_	8	conj	_	_
16	are	be	VBP	_	0	root	_	_
17	unpredictable	unpredictable	NN	_	16	obj	_	_

1	.	.	.	_	0	root	_	_

1	-	-	CC	_	11	cc	_	_
2	Although	although	IN	_	7	mark	_	_
3	not	not	RB	_	7	neg	_	_
4	a	a	DT	_	7	det	_	_
5	true	true	JJ	_	7	attr	_	_
6	drug	drug	NN	_	7	com	_	_
7	interaction	interaction	NN	_	11	advcl	_	_
8	,	,	,	_	11	p	_	_
9	drug1	drug0	NN	_	11	dep	_	_
10	may	may	MD	_	11	modal	_	_
11	precipitate	precipitate	VB	_	0	root	_	_
12	seizures	seizure	NNS	_	11	obj	_	_
13	in	in	IN	_	15	case	_	_
14	susceptible	susceptible	JJ	_	15	attr	_	_
15	patients	patient	NNS	_	12	ppmod	_	_
16	and	and	CC	_	11	cc	_	_
17	drug2	drug0	NN	_	18	com	_	_
18	dosage	dosage	NN	_	20	dep	_	_
19	may	may	MD	_	20	modal	_	_
20	need	need	VBP	_	11	conj	_	_
21	to	to	TO	_	23	aux	_	_
22	be	be	VB	_	23	aux	_	_
23	adjusted	adjust	VBN	_	20	comp	_	_

1	.	.	.	_	0	root	_	_

1	-	-	CC	_	2	cc	_	_
2	Drugs	drug	NNS	_	0	root	_	_
3	whose	whose	WP$	_	4	poss	_	_
4	efficacy	efficacy	NN	_	6	dep	_	_
5	is	be	VBZ	_	6	aux	_	_
6	impaired	impair	VBN	_	2	relcl	_	_
7	by	by	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	include	include	VBP	_	8	acl	_	_
10	:	:	:	_	8	p	_	_
11	drug2	drug0	NN	_	8	appo	_	_
12	,	,	,	_	11	p	_	_
13	drug3	drug0	NN	_	11	appo	_	_
14	,	,	,	_	11	p	_	_
15	drug4	drug0	NN	_	11	appo	_	_
16	,	,	,	_	11	p	_	_
17	drug5	drug0	NN	_	11	appo	_	_
18	,	,	,	_	11	p	_	_
19	drug6	drug0	NN	_	11	appo	_	_
20	,	,	,	_	11	p	_	_
21	drug7	drug0	NN	_	11	appo	_	_
22	,	,	,	_	11	p	_	_
23	drug8	drug0	NN	_	11	appo	_	_
24	,	,	,	_	11	p	_	_
25	oral	oral	JJ	_	26	attr	_	_
26	drug9	drug0	NN	_	11	appo	_	_
27	,	,	,	_	11	p	_	_
28	drug10	drug0	NN	_	11	appo	_	_
29	,	,	,	_	11	p	_	_
30	drug11	drug0	NN	_	11	appo	_	_
31	,	,	,	_	11	p	_	_
32	drug12	drug0	NN	_	11	appo	_	_
33	,	,	,	_	11	p	_	_
34	drug13	drug0	NN	_	11	appo	_	_
35	.	.	.	_	2	p	_	_

1	Monitoring	monitoring	NN	_	7	dep	_	_
2	of	of	IN	_	5	case	_	_
3	plasma	plasma	NN	_	5	com	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	concentrations	concentration	NNS	_	1	ppmod	_	_
6	may	may	MD	_	7	modal	_	_
7	be	be	VB	_	0	root	_	_
8	helpful	helpful	JJ	_	7	dep	_	_
9	when	when	WRB	_	14	adv	_	_
10	possible	possible	JJ	_	12	attr	_	_
11	drug	drug	NN	_	12	com	_	_
12	interactions	interaction	NNS	_	14	dep	_	_
13	are	be	VBP	_	14	aux	_	_
14	suspected	suspect	VBN	_	8	comp	_	_
15	.	.	.	_	7	p	_	_

1	Drug/Laboratory	drug/laboratory	JJ	_	3	attr	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	6	dep	_	_
4	drug1	drug0	NN	_	3	attr	_	_
5	may	may	MD	_	6	modal	_	_
6	decrease	decrease	VB	_	0	root	_	_
7	serum	serum	NN	_	8	com	_	_
8	concentrations	concentration	NNS	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	14	0	CD	_	8	ppmod	_	_
11	.	.	.	_	6	p	_	_

1	It	it	PRP	_	4	dep	_	_
2	may	may	MD	_	4	modal	_	_
3	also	also	RB	_	4	adv	_	_
4	produce	produce	VB	_	0	root	_	_
5	artifactually	artifactually	RB	_	6	adv	_	_
6	low	low	JJ	_	7	attr	_	_
7	results	result	NNS	_	4	obj	_	_
8	in	in	IN	_	9	case	_	_
9	dexamethasone	dexamethasone	NN	_	4	ppmod	_	_
10	or	or	CC	_	9	cc	_	_
11	metyrapone	metyrapone	NN	_	12	com	_	_
12	tests	test	NNS	_	9	conj	_	_
13	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	may	may	MD	_	4	modal	_	_
3	also	also	RB	_	4	adv	_	_
4	cause	cause	VB	_	0	root	_	_
5	increased	increase	VBN	_	7	attr	_	_
6	serum	serum	NN	_	7	com	_	_
7	concentrations	concentration	NNS	_	4	obj	_	_
8	of	of	IN	_	9	case	_	_
9	glucose	glucose	NN	_	7	ppmod	_	_
10	,	,	,	_	9	p	_	_
11	alkaline	alkaline	NN	_	12	com	_	_
12	phosphatase	phosphatase	NN	_	9	conj	_	_
13	,	,	,	_	12	p	_	_
14	and	and	CC	_	12	cc	_	_
15	gamma	gamma	NN	_	17	com	_	_
16	glutamyl	glutamyl	NN	_	17	com	_	_
17	transpeptidase	transpeptidase	NN	_	9	conj	_	_
18	(	-lrb-	-LRB-	_	19	p	_	_
19	GGT	ggt	NN	_	17	prn	_	_
20	)	-rrb-	-RRB-	_	19	p	_	_
21	.	.	.	_	4	p	_	_

1	Care	care	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	taken	take	VBN	_	0	root	_	_
5	when	when	WRB	_	6	adv	_	_
6	using	use	VBG	_	4	comp	_	_
7	immunoanalytical	immunoanalytical	JJ	_	8	attr	_	_
8	methods	method	NNS	_	6	obj	_	_
9	to	to	TO	_	10	aux	_	_
10	measure	measure	VB	_	6	comp	_	_
11	plasma	plasma	NN	_	13	com	_	_
12	drug1	drug0	NN	_	13	com	_	_
13	concentrations	concentration	NNS	_	10	obj	_	_
14	following	follow	VBG	_	16	adv	_	_
15	drug2	drug0	NN	_	16	com	_	_
16	administration	administration	NN	_	10	ppmod	_	_
17	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	4	attr	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	Administration	administration	NN	_	19	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug3	drug0	NN	_	4	ppmod	_	_
7	or	or	CC	_	6	cc	_	_
8	drug4	drug0	NN	_	6	conj	_	_
9	in	in	IN	_	10	case	_	_
10	patients	patient	NNS	_	4	ppmod	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	n=13	n=0	NN	_	10	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	and	and	CC	_	10	cc	_	_
15	volunteers	volunteer	NNS	_	10	conj	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	n=96	n=0	CD	_	15	num	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	resulted	result	VBD	_	0	root	_	_
20	in	in	IN	_	25	case	_	_
21	a	a	DT	_	25	det	_	_
22	rapid	rapid	JJ	_	25	attr	_	_
23	and	and	CC	_	22	cc	_	_
24	significant	significant	JJ	_	22	conj	_	_
25	decrease	decrease	NN	_	19	ppmod	_	_
26	in	in	IN	_	36	case	_	_
27	plasma	plasma	NN	_	36	attr	_	_
28	M1	m0	NN	_	36	attr	_	_
29	(	-lrb-	-LRB-	_	32	p	_	_
30	the	the	DT	_	32	det	_	_
31	active	active	JJ	_	32	attr	_	_
32	metabolite	metabolite	NN	_	28	prn	_	_
33	of	of	IN	_	34	case	_	_
34	drug5	drug0	NN	_	32	ppmod	_	_
35	)	-rrb-	-RRB-	_	32	p	_	_
36	concentration	concentration	NN	_	25	ppmod	_	_
37	.	.	.	_	19	p	_	_

1	Hepatotoxic	hepatotoxic	JJ	_	2	attr	_	_
2	Drugs	drug	NNS	_	5	attr	_	_
3	Increased	increase	VBN	_	5	attr	_	_
4	side	side	NN	_	5	com	_	_
5	effects	effect	NNS	_	7	dep	_	_
6	may	may	MD	_	7	modal	_	_
7	occur	occur	VB	_	0	root	_	_
8	when	when	WRB	_	11	adv	_	_
9	drug1	drug0	NN	_	11	dep	_	_
10	is	be	VBZ	_	11	aux	_	_
11	given	give	VBN	_	7	comp	_	_
12	concomitantly	concomitantly	RB	_	11	adv	_	_
13	with	with	IN	_	15	case	_	_
14	hepatotoxic	hepatotoxic	JJ	_	15	attr	_	_
15	substances	substance	NNS	_	11	ppmod	_	_
16	.	.	.	_	7	p	_	_

1	This	this	DT	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	also	also	RB	_	2	adv	_	_
4	to	to	TO	_	6	aux	_	_
5	be	be	VB	_	6	aux	_	_
6	considered	consider	VBN	_	2	comp	_	_
7	when	when	WRB	_	11	adv	_	_
8	drug1	drug0	NN	_	9	com	_	_
9	treatment	treatment	NN	_	11	dep	_	_
10	is	be	VBZ	_	11	aux	_	_
11	followed	followed	VBN	_	6	comp	_	_
12	by	by	IN	_	14	case	_	_
13	such	such	JJ	_	14	attr	_	_
14	drugs	drug	NNS	_	11	ppmod	_	_
15	without	without	IN	_	19	case	_	_
16	a	a	DT	_	19	det	_	_
17	drug	drug	NN	_	19	com	_	_
18	elimination	elimination	NN	_	19	com	_	_
19	procedure	procedure	NN	_	11	ppmod	_	_
20	.	.	.	_	2	p	_	_

1	In	in	IN	_	8	case	_	_
2	a	a	DT	_	8	det	_	_
3	small	small	JJ	_	8	attr	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	n=30	n=0	NN	_	3	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	combination	combination	NN	_	8	com	_	_
8	study	study	NN	_	23	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	with	with	IN	_	12	case	_	_
12	drug2	drug0	NN	_	8	ppmod	_	_
13	,	,	,	_	23	p	_	_
14	a	a	DT	_	18	det	_	_
15	2-	0-	CD	_	17	num	_	_
16	to	to	TO	_	17	adv	_	_
17	3-fold	0-fold	JJ	_	18	attr	_	_
18	elevation	elevation	NN	_	23	dep	_	_
19	in	in	IN	_	21	case	_	_
20	liver	liver	NN	_	21	com	_	_
21	enzymes	enzyme	NNS	_	18	ppmod	_	_
22	was	be	VBD	_	23	aux	_	_
23	seen	see	VBN	_	0	root	_	_
24	in	in	IN	_	25	case	_	_
25	5	0	CD	_	23	ppmod	_	_
26	of	of	IN	_	28	case	_	_
27	30	0	CD	_	28	num	_	_
28	patients	patient	NNS	_	25	ppmod	_	_
29	.	.	.	_	23	p	_	_

1	All	all	DT	_	2	det	_	_
2	elevations	elevation	NNS	_	3	dep	_	_
3	resolved	resolve	VBN	_	0	root	_	_
4	,	,	,	_	3	p	_	_
5	2	0	CD	_	3	obj	_	_
6	with	with	IN	_	7	case	_	_
7	continuation	continuation	NN	_	5	ppmod	_	_
8	of	of	IN	_	10	case	_	_
9	both	both	DT	_	10	det	_	_
10	drugs	drug	NNS	_	7	ppmod	_	_
11	and	and	CC	_	5	cc	_	_
12	3	0	CD	_	5	conj	_	_
13	after	after	IN	_	14	case	_	_
14	discontinuation	discontinuation	NN	_	12	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	.	.	.	_	3	p	_	_

1	A	a	DT	_	3	det	_	_
2	3-fold	0-fold	JJ	_	3	attr	_	_
3	increase	increase	NN	_	5	dep	_	_
4	was	be	VBD	_	5	aux	_	_
5	seen	see	VBN	_	0	root	_	_
6	in	in	IN	_	9	case	_	_
7	another	another	DT	_	9	det	_	_
8	5	0	CD	_	9	num	_	_
9	patients	patient	NNS	_	5	ppmod	_	_
10	.	.	.	_	5	p	_	_

1	All	all	DT	_	5	dep	_	_
2	of	of	IN	_	3	case	_	_
3	these	these	DT	_	1	ppmod	_	_
4	also	also	RB	_	5	adv	_	_
5	resolved	resolve	VBN	_	0	root	_	_
6	,	,	,	_	5	p	_	_
7	2	0	CD	_	5	obj	_	_
8	with	with	IN	_	9	case	_	_
9	continuation	continuation	NN	_	7	ppmod	_	_
10	of	of	IN	_	12	case	_	_
11	both	both	DT	_	12	det	_	_
12	drugs	drug	NNS	_	9	ppmod	_	_
13	and	and	CC	_	7	cc	_	_
14	3	0	CD	_	7	conj	_	_
15	after	after	IN	_	16	case	_	_
16	discontinuation	discontinuation	NN	_	14	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug1	drug0	NN	_	16	ppmod	_	_
19	.	.	.	_	5	p	_	_

1	Three	#crd#	CD	_	2	num	_	_
2	patients	patient	NNS	_	3	com	_	_
3	met	met	NN	_	0	root	_	_
4	ACR	acr	NN	_	5	com	_	_
5	criteria	criterion	NNS	_	3	obj	_	_
6	for	for	IN	_	8	case	_	_
7	liver	liver	NN	_	8	com	_	_
8	biopsy	biopsy	NN	_	5	ppmod	_	_
9	(	-lrb-	-LRB-	_	13	p	_	_
10	1	0	CD	_	13	num	_	_
11	:	:	:	_	13	p	_	_
12	Roegnik	roegnik	NN	_	13	com	_	_
13	Grade	grade	NN	_	8	prn	_	_
14	I	i	CD	_	13	num	_	_
15	,	,	,	_	13	p	_	_
16	2	0	CD	_	13	appo	_	_
17	:	:	:	_	13	p	_	_
18	Roegnik	roegnik	NNP	_	19	com	_	_
19	Grade	grade	NN	_	13	appo	_	_
20	IIIa	iiia	NN	_	19	appo	_	_
21	)	-rrb-	-RRB-	_	13	p	_	_
22	.	.	.	_	3	p	_	_

1	No	no	DT	_	3	det	_	_
2	pharmacokinetic	pharmacokinetic	JJ	_	3	attr	_	_
3	interaction	interaction	NN	_	5	dep	_	_
4	was	be	VBD	_	5	aux	_	_
5	identified	identify	VBN	_	0	root	_	_
6	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	6	case	_	_
4	in	in	FW	_	5	adv	_	_
5	vitro	vitro	FW	_	6	attr	_	_
6	studies	study	NNS	_	10	ppmod	_	_
7	,	,	,	_	10	p	_	_
8	M1	m0	NN	_	10	dep	_	_
9	was	be	VBD	_	10	aux	_	_
10	shown	show	VBN	_	1	acl	_	_
11	to	to	TO	_	12	aux	_	_
12	cause	cause	VB	_	10	comp	_	_
13	increases	increase	NNS	_	12	obj	_	_
14	ranging	range	VBG	_	13	acl	_	_
15	from	from	IN	_	16	case	_	_
16	13	0	CD	_	14	ppmod	_	_
17	-	-	TO	_	16	cc	_	_
18	50	0	CD	_	16	conj	_	_
19	%	%	NN	_	16	meta	_	_
20	in	in	IN	_	23	case	_	_
21	the	the	DT	_	23	det	_	_
22	free	free	JJ	_	23	attr	_	_
23	fraction	fraction	NN	_	14	ppmod	_	_
24	of	of	IN	_	25	case	_	_
25	drug2	drug0	NN	_	23	ppmod	_	_
26	and	and	CC	_	25	cc	_	_
27	drug3	drug0	NN	_	25	conj	_	_
28	at	at	IN	_	29	case	_	_
29	concentrations	concentration	NNS	_	14	ppmod	_	_
30	in	in	IN	_	33	case	_	_
31	the	the	DT	_	33	det	_	_
32	clinical	clinical	JJ	_	33	attr	_	_
33	range	range	NN	_	29	ppmod	_	_
34	.	.	.	_	1	p	_	_

1	The	the	DT	_	3	det	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	significance	significance	NN	_	7	dep	_	_
4	of	of	IN	_	6	case	_	_
5	this	this	DT	_	6	det	_	_
6	finding	finding	NN	_	3	ppmod	_	_
7	is	be	VBZ	_	0	root	_	_
8	unknown	unknown	JJ	_	7	dep	_	_
9	;	;	:	_	7	p	_	_

1	however	however	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	there	there	EX	_	4	dep	_	_
4	was	be	VBD	_	0	root	_	_
5	extensive	extensive	JJ	_	7	attr	_	_
6	concomitant	concomitant	JJ	_	7	attr	_	_
7	use	use	NN	_	4	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	in	in	IN	_	12	case	_	_
11	clinical	clinical	JJ	_	12	attr	_	_
12	studies	study	NNS	_	7	ppmod	_	_
13	and	and	CC	_	4	cc	_	_
14	no	no	DT	_	16	det	_	_
15	differential	differential	JJ	_	16	attr	_	_
16	effect	effect	NN	_	18	dep	_	_
17	was	be	VBD	_	18	aux	_	_
18	observed	observe	VBN	_	4	conj	_	_
19	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	6	case	_	_
4	in	in	FW	_	5	adv	_	_
5	vitro	vitro	FW	_	6	attr	_	_
6	studies	study	NNS	_	10	ppmod	_	_
7	,	,	,	_	10	p	_	_
8	M1	m0	NN	_	10	dep	_	_
9	was	be	VBD	_	10	aux	_	_
10	shown	show	VBN	_	1	acl	_	_
11	to	to	TO	_	12	aux	_	_
12	cause	cause	VB	_	10	comp	_	_
13	increases	increase	NNS	_	12	obj	_	_
14	ranging	range	VBG	_	13	acl	_	_
15	from	from	IN	_	16	case	_	_
16	13	0	CD	_	14	ppmod	_	_
17	-	-	TO	_	16	cc	_	_
18	50	0	CD	_	16	conj	_	_
19	%	%	NN	_	16	meta	_	_
20	in	in	IN	_	23	case	_	_
21	the	the	DT	_	23	det	_	_
22	free	free	JJ	_	23	attr	_	_
23	fraction	fraction	NN	_	14	ppmod	_	_
24	of	of	IN	_	25	case	_	_
25	drug2	drug0	NN	_	23	ppmod	_	_
26	at	at	IN	_	27	case	_	_
27	concentrations	concentration	NNS	_	14	ppmod	_	_
28	in	in	IN	_	31	case	_	_
29	the	the	DT	_	31	det	_	_
30	clinical	clinical	JJ	_	31	attr	_	_
31	range	range	NN	_	27	ppmod	_	_
32	.	.	.	_	1	p	_	_

1	The	the	DT	_	3	det	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	significance	significance	NN	_	7	dep	_	_
4	of	of	IN	_	6	case	_	_
5	this	this	DT	_	6	det	_	_
6	finding	finding	NN	_	3	ppmod	_	_
7	is	be	VBZ	_	0	root	_	_
8	unknown	unknown	JJ	_	7	dep	_	_
9	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Following	follow	VBG	_	5	adv	_	_
4	concomitant	concomitant	JJ	_	5	attr	_	_
5	administration	administration	NN	_	24	ppmod	_	_
6	of	of	IN	_	9	case	_	_
7	a	a	DT	_	9	det	_	_
8	single	single	JJ	_	9	attr	_	_
9	dose	dose	NN	_	5	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	to	to	TO	_	13	aux	_	_
13	subjects	subject	NNS	_	5	ppmod	_	_
14	receiving	receive	VBG	_	13	acl	_	_
15	multiple	multiple	JJ	_	16	attr	_	_
16	doses	dose	NNS	_	14	obj	_	_
17	of	of	IN	_	18	case	_	_
18	drug3	drug0	NN	_	16	ppmod	_	_
19	,	,	,	_	24	p	_	_
20	M1	m0	NN	_	22	com	_	_
21	peak	peak	NN	_	22	com	_	_
22	levels	level	NNS	_	24	dep	_	_
23	were	be	VBD	_	24	aux	_	_
24	increased	increase	VBN	_	1	acl	_	_
25	(	-lrb-	-LRB-	_	26	p	_	_
26	~40	~0	CD	_	24	num	_	_
27	%	%	NN	_	26	meta	_	_
28	)	-rrb-	-RRB-	_	26	p	_	_
29	over	over	IN	_	30	case	_	_
30	those	those	DT	_	24	ppmod	_	_
31	seen	see	VBN	_	30	acl	_	_
32	when	when	WRB	_	35	adv	_	_
33	drug4	drug0	NN	_	35	dep	_	_
34	was	be	VBD	_	35	aux	_	_
35	given	give	VBN	_	31	comp	_	_
36	alone	alone	RB	_	35	adv	_	_
37	.	.	.	_	1	p	_	_

1	Because	because	IN	_	4	case	_	_
2	of	of	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	potential	potential	NN	_	19	ppmod	_	_
5	for	for	IN	_	7	case	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	levels	level	NNS	_	4	ppmod	_	_
8	to	to	TO	_	9	aux	_	_
9	continue	continue	VBP	_	4	acl	_	_
10	to	to	TO	_	11	aux	_	_
11	increase	increase	VB	_	9	comp	_	_
12	with	with	IN	_	14	case	_	_
13	multiple	multiple	JJ	_	14	attr	_	_
14	dosing	dosing	NN	_	11	ppmod	_	_
15	,	,	,	_	19	p	_	_
16	caution	caution	NN	_	19	dep	_	_
17	should	should	MD	_	19	modal	_	_
18	be	be	VB	_	19	aux	_	_
19	used	use	VBN	_	0	root	_	_
20	if	if	IN	_	22	mark	_	_
21	patients	patient	NNS	_	22	dep	_	_
22	are	be	VBP	_	19	comp	_	_
23	to	to	TO	_	25	aux	_	_
24	be	be	VB	_	25	aux	_	_
25	receiving	receive	VBG	_	22	comp	_	_
26	both	both	CC	_	27	cc	_	_
27	drug2	drug0	NN	_	25	obj	_	_
28	and	and	CC	_	27	cc	_	_
29	drug3	drug0	NN	_	27	conj	_	_
30	.	.	.	_	19	p	_	_

1	drug1	drug0	NN	_	19	dep	_	_
2	:	:	:	_	1	p	_	_
3	Increased	increase	VBN	_	4	attr	_	_
4	INR	inr	NN	_	1	appo	_	_
5	(	-lrb-	-LRB-	_	8	p	_	_
6	International	international	NNP	_	8	attr	_	_
7	Normalized	normalize	VBN	_	8	attr	_	_
8	Ratio	ratio	NN	_	4	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	when	when	WRB	_	15	adv	_	_
11	drug2	drug0	NN	_	15	dep	_	_
12	and	and	CC	_	11	cc	_	_
13	drug3	drug0	NN	_	11	conj	_	_
14	were	be	VBD	_	15	aux	_	_
15	co-administered	co-administered	VBN	_	4	relcl	_	_
16	has	have	VBZ	_	19	aux	_	_
17	been	be	VBN	_	19	aux	_	_
18	rarely	rarely	RB	_	19	adv	_	_
19	reported	report	VBN	_	0	root	_	_
20	.	.	.	_	19	p	_	_

1	The	the	DT	_	2	det	_	_
2	potential	potential	NN	_	13	dep	_	_
3	for	for	IN	_	7	case	_	_
4	clinically	clinically	RB	_	5	adv	_	_
5	significant	significant	JJ	_	7	attr	_	_
6	drug-drug	drug-drug	JJ	_	7	attr	_	_
7	interactions	interaction	NNS	_	2	ppmod	_	_
8	posed	pose	VBN	_	7	acl	_	_
9	by	by	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug2	drug0	NN	_	10	conj	_	_
13	appears	appear	VBZ	_	0	root	_	_
14	to	to	TO	_	15	aux	_	_
15	be	be	VB	_	13	comp	_	_
16	low	low	JJ	_	15	dep	_	_
17	for	for	IN	_	18	case	_	_
18	drugs	drug	NNS	_	16	ppmod	_	_
19	commonly	commonly	RB	_	20	adv	_	_
20	used	use	VBN	_	18	acl	_	_
21	in	in	IN	_	22	case	_	_
22	chemotherapy	chemotherapy	NN	_	20	ppmod	_	_
23	or	or	CC	_	22	cc	_	_
24	surgery	surgery	NN	_	22	conj	_	_
25	,	,	,	_	13	p	_	_
26	because	because	IN	_	29	mark	_	_
27	drug3	drug0	NN	_	29	dep	_	_
28	is	be	VBZ	_	29	aux	_	_
29	eliminated	eliminate	VBN	_	13	comp	_	_
30	by	by	IN	_	32	case	_	_
31	multiple	multiple	JJ	_	32	attr	_	_
32	routes	route	NNS	_	29	ppmod	_	_
33	.	.	.	_	13	p	_	_

1	Blood	blood	NN	_	2	com	_	_
2	levels	level	NNS	_	5	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	increased	increase	VBD	_	0	root	_	_
6	24	0	CD	_	5	obj	_	_
7	%	%	NN	_	6	meta	_	_
8	when	when	WRB	_	11	adv	_	_
9	drug2	drug0	NN	_	11	dep	_	_
10	was	be	VBD	_	11	aux	_	_
11	coadministered	coadministered	VBN	_	5	comp	_	_
12	with	with	IN	_	13	case	_	_
13	drug3	drug0	NN	_	11	ppmod	_	_
14	(	-lrb-	-LRB-	_	16	p	_	_
15	nonselective	nonselective	JJ	_	16	attr	_	_
16	inhibitor	inhibitor	NN	_	13	prn	_	_
17	of	of	IN	_	19	case	_	_
18	cytochrome	cytochrome	NN	_	19	com	_	_
19	P-450	p-0	NN	_	16	ppmod	_	_
20	)	-rrb-	-RRB-	_	16	p	_	_
21	for	for	IN	_	23	case	_	_
22	7	0	CD	_	23	num	_	_
23	days	day	NNS	_	13	ppmod	_	_
24	,	,	,	_	5	p	_	_
25	and	and	CC	_	5	cc	_	_
26	decreased	decrease	VBD	_	5	conj	_	_
27	28	0	CD	_	26	obj	_	_
28	%	%	NN	_	27	meta	_	_
29	with	with	IN	_	30	case	_	_
30	coadministration	coadministration	NN	_	26	ppmod	_	_
31	of	of	IN	_	32	case	_	_
32	drug4	drug0	NN	_	30	ppmod	_	_
33	(	-lrb-	-LRB-	_	35	p	_	_
34	potent	potent	JJ	_	35	attr	_	_
35	inducer	inducer	NN	_	26	prn	_	_
36	of	of	IN	_	38	case	_	_
37	cytochrome	cytochrome	NN	_	38	com	_	_
38	P-450	p-0	NN	_	35	ppmod	_	_
39	)	-rrb-	-RRB-	_	35	p	_	_
40	for	for	IN	_	42	case	_	_
41	7	0	CD	_	42	num	_	_
42	days	day	NNS	_	26	ppmod	_	_
43	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	has	have	VBZ	_	5	aux	_	_
3	been	be	VBN	_	5	aux	_	_
4	safely	safely	RB	_	5	adv	_	_
5	coadministered	coadministered	VBN	_	0	root	_	_
6	with	with	IN	_	7	case	_	_
7	drugs	drug	NNS	_	5	ppmod	_	_
8	used	use	VBN	_	7	acl	_	_
9	in	in	IN	_	10	case	_	_
10	chemotherapy	chemotherapy	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	surgery	surgery	NN	_	10	conj	_	_
13	.	.	.	_	5	p	_	_

1	As	as	IN	_	4	case	_	_
2	with	with	IN	_	4	case	_	_
3	other	other	JJ	_	4	attr	_	_
4	agents	agent	NNS	_	13	ppmod	_	_
5	which	which	WDT	_	6	dep	_	_
6	prolong	prolong	VBP	_	4	relcl	_	_
7	ECG	ecg	NN	_	8	com	_	_
8	intervals	interval	NNS	_	6	obj	_	_
9	,	,	,	_	13	p	_	_
10	caution	caution	NN	_	13	dep	_	_
11	should	should	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	exercised	exercise	VBN	_	0	root	_	_
14	in	in	IN	_	15	case	_	_
15	patients	patient	NNS	_	13	ppmod	_	_
16	taking	take	VBG	_	15	acl	_	_
17	drugs	drug	NNS	_	16	obj	_	_
18	which	which	WDT	_	19	dep	_	_
19	prolong	prolong	VBP	_	17	relcl	_	_
20	ECG	ecg	NN	_	21	com	_	_
21	intervals	interval	NNS	_	19	obj	_	_
22	,	,	,	_	21	p	_	_
23	particularly	particularly	RB	_	21	adv	_	_
24	QTc	qtc	NN	_	21	appo	_	_
25	.	.	.	_	13	p	_	_

1	In	in	IN	_	2	case	_	_
2	patients	patient	NNS	_	26	ppmod	_	_
3	taking	take	VBG	_	4	adv	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	,	,	,	_	4	p	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	,	,	,	_	6	p	_	_
8	drug3	drug0	NN	_	4	conj	_	_
9	,	,	,	_	8	p	_	_
10	drug4	drug0	NN	_	4	conj	_	_
11	,	,	,	_	10	p	_	_
12	drug5	drug0	NN	_	4	conj	_	_
13	,	,	,	_	12	p	_	_
14	drug6	drug0	NN	_	4	conj	_	_
15	,	,	,	_	14	p	_	_
16	drug7	drug0	NN	_	4	conj	_	_
17	,	,	,	_	16	p	_	_
18	and	and	CC	_	16	cc	_	_
19	various	various	JJ	_	21	attr	_	_
20	chemotherapy	chemotherapy	NN	_	21	com	_	_
21	agents	agent	NNS	_	4	conj	_	_
22	,	,	,	_	26	p	_	_
23	no	no	DT	_	24	det	_	_
24	effect	effect	NN	_	26	dep	_	_
25	was	be	VBD	_	26	aux	_	_
26	shown	show	VBN	_	0	root	_	_
27	on	on	IN	_	29	case	_	_
28	the	the	DT	_	29	det	_	_
29	clearance	clearance	NN	_	26	ppmod	_	_
30	of	of	IN	_	31	case	_	_
31	drug8	drug0	NN	_	29	ppmod	_	_
32	.	.	.	_	26	p	_	_

1	Clearance	clearance	NN	_	4	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	decreased	decrease	VBD	_	0	root	_	_
5	by	by	IN	_	7	case	_	_
6	about	about	RB	_	7	adv	_	_
7	27	0	CD	_	4	ppmod	_	_
8	%	%	NN	_	7	meta	_	_
9	when	when	WRB	_	12	adv	_	_
10	drug2	drug0	NN	_	12	dep	_	_
11	was	be	VBD	_	12	aux	_	_
12	administered	administer	VBN	_	4	comp	_	_
13	intravenously	intravenously	RB	_	12	adv	_	_
14	concomitantly	concomitantly	RB	_	16	adv	_	_
15	with	with	IN	_	16	case	_	_
16	drug3	drug0	NN	_	12	ppmod	_	_
17	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	does	do	VBZ	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	influence	influence	VB	_	0	root	_	_
5	anesthesia	anesthesia	NN	_	7	com	_	_
6	recovery	recovery	NN	_	7	com	_	_
7	time	time	NN	_	4	obj	_	_
8	in	in	IN	_	9	case	_	_
9	patients	patient	NNS	_	7	ppmod	_	_
10	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	did	do	VBD	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	inhibit	inhibit	VB	_	0	root	_	_
5	the	the	DT	_	7	det	_	_
6	antitumor	antitumor	JJ	_	7	attr	_	_
7	activity	activity	NN	_	4	obj	_	_
8	of	of	IN	_	10	case	_	_
9	four	#crd#	CD	_	10	num	_	_
10	drug2	drug0	NNS	_	7	ppmod	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	drug3	drug0	NN	_	10	prn	_	_
13	,	,	,	_	12	p	_	_
14	drug4	drug0	NN	_	12	appo	_	_
15	,	,	,	_	12	p	_	_
16	drug5	drug0	NN	_	12	appo	_	_
17	,	,	,	_	12	p	_	_
18	drug6	drug0	NN	_	12	appo	_	_
19	)	-rrb-	-RRB-	_	12	p	_	_
20	in	in	IN	_	23	case	_	_
21	four	#crd#	CD	_	23	num	_	_
22	murine	murine	JJ	_	23	attr	_	_
23	models	model	NNS	_	7	ppmod	_	_
24	.	.	.	_	4	p	_	_

1	Coadministration	coadministration	NN	_	13	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	5	case	_	_
5	drugs	drug	NNS	_	1	ppmod	_	_
6	that	that	WDT	_	8	dep	_	_
7	are	be	VBP	_	8	aux	_	_
8	known	know	VBN	_	5	relcl	_	_
9	to	to	TO	_	10	aux	_	_
10	cause	cause	VB	_	8	comp	_	_
11	pancreatitis	pancreatitis	NN	_	10	obj	_	_
12	may	may	MD	_	13	modal	_	_
13	increase	increase	VB	_	0	root	_	_
14	the	the	DT	_	15	det	_	_
15	risk	risk	NN	_	13	obj	_	_
16	of	of	IN	_	18	case	_	_
17	this	this	DT	_	18	det	_	_
18	toxicity	toxicity	NN	_	15	ppmod	_	_
19	(	-lrb-	-LRB-	_	20	p	_	_
20	see	see	VB	_	13	prn	_	_
21	WARNINGS	warning	NNS	_	20	obj	_	_
22	)	-rrb-	-RRB-	_	20	p	_	_
23	and	and	CC	_	13	cc	_	_
24	should	should	MD	_	26	modal	_	_
25	be	be	VB	_	26	aux	_	_
26	done	do	VBN	_	13	conj	_	_
27	with	with	IN	_	29	case	_	_
28	extreme	extreme	JJ	_	29	attr	_	_
29	caution	caution	NN	_	26	ppmod	_	_
30	,	,	,	_	26	p	_	_
31	only	only	RB	_	35	adv	_	_
32	if	if	IN	_	35	mark	_	_
33	other	other	JJ	_	34	attr	_	_
34	alternatives	alternative	NNS	_	35	dep	_	_
35	are	be	VBP	_	26	advcl	_	_
36	not	not	RB	_	35	neg	_	_
37	available	available	JJ	_	35	dep	_	_
38	,	,	,	_	35	p	_	_
39	and	and	CC	_	35	cc	_	_
40	only	only	RB	_	43	adv	_	_
41	if	if	IN	_	43	mark	_	_
42	clearly	clearly	RB	_	43	adv	_	_
43	indicated	indicate	VBN	_	35	conj	_	_
44	.	.	.	_	13	p	_	_

1	Neuropathy	neuropathy	NN	_	3	dep	_	_
2	has	have	VBZ	_	3	aux	_	_
3	occurred	occur	VBN	_	0	root	_	_
4	more	more	RBR	_	5	com	_	_
5	frequently	frequently	RB	_	3	adv	_	_
6	in	in	IN	_	7	case	_	_
7	patients	patient	NNS	_	3	ppmod	_	_
8	with	with	IN	_	10	case	_	_
9	a	a	DT	_	10	det	_	_
10	history	history	NN	_	7	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	neuropathy	neuropathy	NN	_	10	ppmod	_	_
13	or	or	CC	_	10	cc	_	_
14	neurotoxic	neurotoxic	JJ	_	16	attr	_	_
15	drug	drug	NN	_	16	com	_	_
16	therapy	therapy	NN	_	10	conj	_	_
17	,	,	,	_	7	p	_	_
18	including	include	VBG	_	19	adv	_	_
19	drug1	drug0	NN	_	7	ppmod	_	_
20	,	,	,	_	3	p	_	_
21	and	and	CC	_	3	cc	_	_
22	these	these	DT	_	23	det	_	_
23	patients	patient	NNS	_	25	dep	_	_
24	may	may	MD	_	25	modal	_	_
25	be	be	VB	_	3	conj	_	_
26	at	at	IN	_	28	case	_	_
27	increased	increase	VBN	_	28	attr	_	_
28	risk	risk	NN	_	25	ppmod	_	_
29	of	of	IN	_	30	case	_	_
30	neuropathy	neuropathy	NN	_	28	ppmod	_	_
31	during	during	IN	_	33	case	_	_
32	drug2	drug0	NN	_	33	com	_	_
33	therapy	therapy	NN	_	25	ppmod	_	_
34	(	-lrb-	-LRB-	_	35	p	_	_
35	see	see	VB	_	33	prn	_	_
36	ADVERSE	adverse	JJ	_	37	attr	_	_
37	REACTIONS	reaction	NNS	_	35	obj	_	_
38	)	-rrb-	-RRB-	_	35	p	_	_
39	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	AUC	auc	NN	_	8	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	was	be	VBD	_	8	aux	_	_
8	increased	increase	VBN	_	1	acl	_	_
9	about	about	RB	_	10	com	_	_
10	4-fold	0-fold	RB	_	8	adv	_	_
11	when	when	WRB	_	17	adv	_	_
12	drug3	drug0	NN	_	17	dep	_	_
13	at	at	IN	_	15	case	_	_
14	300	0	CD	_	15	num	_	_
15	mg/day	mg/day	NN	_	12	ppmod	_	_
16	was	be	VBD	_	17	aux	_	_
17	coadministered	coadministered	VBN	_	8	comp	_	_
18	with	with	IN	_	22	case	_	_
19	a	a	DT	_	22	det	_	_
20	single	single	JJ	_	22	attr	_	_
21	200-mg	0-mg	NN	_	22	com	_	_
22	dose	dose	NN	_	17	ppmod	_	_
23	of	of	IN	_	24	case	_	_
24	drug4	drug0	NN	_	22	ppmod	_	_
25	to	to	TO	_	27	aux	_	_
26	two	#crd#	CD	_	27	num	_	_
27	patients	patient	NNS	_	22	ppmod	_	_
28	with	with	IN	_	30	case	_	_
29	renal	renal	JJ	_	30	attr	_	_
30	impairment	impairment	NN	_	27	ppmod	_	_
31	(	-lrb-	-LRB-	_	35	p	_	_
32	CLcr=15	clcr=0	CD	_	35	num	_	_
33	and	and	CC	_	32	cc	_	_
34	18	0	CD	_	32	conj	_	_
35	mL/min	ml/min	NN	_	30	prn	_	_
36	)	-rrb-	-RRB-	_	35	p	_	_
37	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	effects	effect	NNS	_	16	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	on	on	IN	_	7	case	_	_
6	drug2	drug0	NN	_	7	com	_	_
7	pharmacokinetics	pharmacokinetics	NNS	_	2	ppmod	_	_
8	in	in	IN	_	9	case	_	_
9	subjects	subject	NNS	_	7	ppmod	_	_
10	with	with	IN	_	13	case	_	_
11	normal	normal	JJ	_	13	attr	_	_
12	renal	renal	JJ	_	13	attr	_	_
13	function	function	NN	_	9	ppmod	_	_
14	are	be	VBP	_	16	aux	_	_
15	not	not	RB	_	16	neg	_	_
16	known	know	VBN	_	0	root	_	_
17	.	.	.	_	16	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Concomitant	concomitant	JJ	_	4	attr	_	_
4	administration	administration	NN	_	23	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NNS	_	4	ppmod	_	_
7	containing	contain	VBG	_	6	acl	_	_
8	drug3	drug0	NN	_	7	obj	_	_
9	or	or	CC	_	8	cc	_	_
10	drug4	drug0	NN	_	8	conj	_	_
11	with	with	IN	_	12	case	_	_
12	drug5	drug0	NN	_	8	ppmod	_	_
13	Chewable/Dispersible	chewable/dispersible	JJ	_	15	attr	_	_
14	Buffered	buffered	JJ	_	15	attr	_	_
15	Tablets	tablet	NNS	_	12	attr	_	_
16	or	or	CC	_	12	cc	_	_
17	Pediatric	pediatric	JJ	_	18	attr	_	_
18	Powder	powder	NN	_	12	conj	_	_
19	for	for	IN	_	21	case	_	_
20	Oral	oral	JJ	_	21	attr	_	_
21	Solution	solution	NN	_	8	ppmod	_	_
22	may	may	MD	_	23	modal	_	_
23	potentiate	potentiate	VB	_	1	acl	_	_
24	adverse	adverse	JJ	_	25	attr	_	_
25	events	event	NNS	_	23	obj	_	_
26	associated	associate	VBN	_	25	acl	_	_
27	with	with	IN	_	30	case	_	_
28	the	the	DT	_	30	det	_	_
29	drug6	drug0	NN	_	30	com	_	_
30	components	component	NNS	_	26	ppmod	_	_
31	.	.	.	_	1	p	_	_

1	Drugs	drug	NNS	_	0	root	_	_
2	Whose	whose	WP$	_	3	poss	_	_
3	Absorption	absorption	NN	_	6	dep	_	_
4	Can	can	MD	_	6	modal	_	_
5	Be	be	VB	_	6	aux	_	_
6	Affected	affect	VBN	_	1	relcl	_	_
7	by	by	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	Level	level	NN	_	6	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	Acidity	acidity	NN	_	9	ppmod	_	_
12	in	in	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	Stomach	stomach	NN	_	9	ppmod	_	_
15	:	:	:	_	1	p	_	_
16	Drugs	drug	NNS	_	24	dep	_	_
17	such	such	JJ	_	19	adv	_	_
18	as	as	IN	_	19	case	_	_
19	drug1	drug0	NN	_	16	ppmod	_	_
20	and	and	CC	_	19	cc	_	_
21	drug2	drug0	NN	_	19	conj	_	_
22	should	should	MD	_	24	modal	_	_
23	be	be	VB	_	24	aux	_	_
24	administered	administer	VBN	_	1	acl	_	_
25	at	at	IN	_	27	case	_	_
26	least	least	JJS	_	27	attr	_	_
27	2	0	CD	_	28	num	_	_
28	hours	hour	NNS	_	29	advnp	_	_
29	prior	prior	RB	_	24	adv	_	_
30	to	to	TO	_	31	aux	_	_
31	dosing	dosing	NN	_	29	ppmod	_	_
32	with	with	IN	_	33	case	_	_
33	drug3	drug0	NN	_	24	ppmod	_	_
34	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Administration	administration	NN	_	16	dep	_	_
4	of	of	IN	_	7	case	_	_
5	drug2	drug0	NN	_	7	attr	_	_
6	2	0	CD	_	7	num	_	_
7	hours	hour	NNS	_	3	ppmod	_	_
8	prior	prior	RB	_	7	adv	_	_
9	to	to	TO	_	8	adv	_	_
10	or	or	CC	_	8	cc	_	_
11	concurrent	concurrent	JJ	_	8	conj	_	_
12	with	with	IN	_	14	case	_	_
13	oral	oral	JJ	_	14	attr	_	_
14	drug3	drug0	NN	_	11	ppmod	_	_
15	was	be	VBD	_	16	aux	_	_
16	associated	associate	VBN	_	1	acl	_	_
17	with	with	IN	_	24	case	_	_
18	a	a	DT	_	24	det	_	_
19	111	0	NN	_	24	num	_	_
20	(	-lrb-	-LRB-	_	24	p	_	_
21	114	0	CD	_	24	num	_	_
22	)	-rrb-	-RRB-	_	24	p	_	_
23	%	%	NN	_	24	meta	_	_
24	increase	increase	NN	_	16	ppmod	_	_
25	in	in	IN	_	28	case	_	_
26	the	the	DT	_	28	det	_	_
27	steady-state	steady-state	JJ	_	28	attr	_	_
28	AUC	auc	NN	_	24	ppmod	_	_
29	of	of	IN	_	30	case	_	_
30	drug4	drug0	NN	_	28	ppmod	_	_
31	(	-lrb-	-LRB-	_	32	p	_	_
32	n	n	NN	_	30	prn	_	_
33	=	=	JJ	_	32	attr	_	_
34	12	0	CD	_	32	num	_	_
35	)	-rrb-	-RRB-	_	32	p	_	_
36	.	.	.	_	1	p	_	_

1	A	a	DT	_	7	det	_	_
2	21	0	CD	_	4	num	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	17	0	CD	_	7	num	_	_
5	)	-rrb-	-RRB-	_	4	p	_	_
6	%	%	NN	_	4	meta	_	_
7	decrease	decrease	NN	_	15	dep	_	_
8	in	in	IN	_	11	case	_	_
9	the	the	DT	_	11	det	_	_
10	steady-state	steady-state	JJ	_	11	attr	_	_
11	AUC	auc	NN	_	7	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	was	be	VBD	_	15	aux	_	_
15	observed	observe	VBN	_	0	root	_	_
16	when	when	WRB	_	19	adv	_	_
17	drug2	drug0	NN	_	19	dep	_	_
18	was	be	VBD	_	19	aux	_	_
19	administered	administer	VBN	_	15	comp	_	_
20	2	0	CD	_	21	num	_	_
21	hours	hour	NNS	_	22	advnp	_	_
22	prior	prior	RB	_	19	adv	_	_
23	to	to	TO	_	24	aux	_	_
24	drug3	drug0	NN	_	22	ppmod	_	_
25	,	,	,	_	15	p	_	_
26	but	but	CC	_	33	cc	_	_
27	not	not	RB	_	26	com	_	_
28	when	when	WRB	_	33	adv	_	_
29	the	the	DT	_	31	det	_	_
30	two	#crd#	CD	_	31	num	_	_
31	drugs	drug	NNS	_	33	dep	_	_
32	were	be	VBD	_	33	aux	_	_
33	administered	administer	VBN	_	15	advcl	_	_
34	simultaneously	simultaneously	RB	_	33	adv	_	_
35	(	-lrb-	-LRB-	_	36	p	_	_
36	n	n	NN	_	33	prn	_	_
37	=	=	JJ	_	36	attr	_	_
38	12	0	CD	_	36	num	_	_
39	)	-rrb-	-RRB-	_	36	p	_	_
40	.	.	.	_	15	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	s	s	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	drug2	drug0	NN	_	7	dep	_	_
5	should	should	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	administered	administer	VBN	_	2	acl	_	_
8	at	at	IN	_	10	case	_	_
9	least	least	JJS	_	10	attr	_	_
10	2	0	CD	_	11	num	_	_
11	hours	hour	NNS	_	7	obj	_	_
12	after	after	IN	_	11	case	_	_
13	or	or	CC	_	11	cc	_	_
14	6	0	CD	_	15	num	_	_
15	hours	hour	NNS	_	11	conj	_	_
16	before	before	IN	_	17	case	_	_
17	dosing	dosing	NN	_	15	ppmod	_	_
18	with	with	IN	_	19	case	_	_
19	drug3	drug0	NN	_	17	ppmod	_	_
20	because	because	IN	_	26	mark	_	_
21	plasma	plasma	NN	_	22	com	_	_
22	concentrations	concentration	NNS	_	26	dep	_	_
23	of	of	IN	_	24	case	_	_
24	drug4	drug0	NN	_	22	ppmod	_	_
25	are	be	VBP	_	26	aux	_	_
26	decreased	decrease	VBN	_	7	comp	_	_
27	when	when	WRB	_	28	adv	_	_
28	administered	administer	VBN	_	26	comp	_	_
29	with	with	IN	_	30	case	_	_
30	drug5	drug0	NN	_	28	ppmod	_	_
31	containing	contain	VBG	_	30	acl	_	_
32	drug6	drug0	NN	_	31	obj	_	_
33	,	,	,	_	32	p	_	_
34	drug7	drug0	NN	_	32	conj	_	_
35	,	,	,	_	34	p	_	_
36	or	or	CC	_	34	cc	_	_
37	drug8	drug0	NN	_	32	conj	_	_
38	.	.	.	_	2	p	_	_

1	In	in	IN	_	4	case	_	_
2	eight	#crd#	CD	_	4	num	_	_
3	HIV-infected	hiv-infected	JJ	_	4	attr	_	_
4	patients	patient	NNS	_	12	ppmod	_	_
5	,	,	,	_	12	p	_	_
6	the	the	DT	_	8	det	_	_
7	steady-state	steady-state	JJ	_	8	attr	_	_
8	AUC	auc	NN	_	12	dep	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	was	be	VBD	_	12	aux	_	_
12	decreased	decrease	VBN	_	0	root	_	_
13	an	an	DT	_	16	det	_	_
14	average	average	JJ	_	16	attr	_	_
15	of	of	IN	_	16	case	_	_
16	26	0	CD	_	12	obj	_	_
17	%	%	NN	_	16	meta	_	_
18	(	-lrb-	-LRB-	_	21	p	_	_
19	95	0	CD	_	21	num	_	_
20	%	%	NN	_	21	meta	_	_
21	CI	ci	NN	_	16	prn	_	_
22	=	=	JJ	_	21	attr	_	_
23	14	0	CD	_	21	num	_	_
24	%	%	NN	_	21	meta	_	_
25	,	,	,	_	21	p	_	_
26	37	0	CD	_	21	num	_	_
27	%	%	NN	_	21	meta	_	_
28	)	-rrb-	-RRB-	_	21	p	_	_
29	when	when	WRB	_	32	adv	_	_
30	drug2	drug0	NN	_	32	dep	_	_
31	was	be	VBD	_	32	aux	_	_
32	administered	administer	VBN	_	12	comp	_	_
33	2	0	CD	_	34	num	_	_
34	hours	hour	NNS	_	35	advnp	_	_
35	prior	prior	RB	_	32	adv	_	_
36	to	to	TO	_	41	aux	_	_
37	a	a	DT	_	41	det	_	_
38	marketed	market	VBN	_	41	attr	_	_
39	chewable/dispersible	chewable/dispersible	NN	_	41	com	_	_
40	tablet	tablet	NN	_	41	com	_	_
41	formulation	formulation	NN	_	35	ppmod	_	_
42	of	of	IN	_	43	case	_	_
43	drug3	drug0	NN	_	41	ppmod	_	_
44	.	.	.	_	12	p	_	_

1	The	the	DT	_	2	det	_	_
2	AUC	auc	NN	_	6	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	was	be	VBD	_	6	aux	_	_
6	decreased	decrease	VBN	_	0	root	_	_
7	an	an	DT	_	8	det	_	_
8	average	average	NN	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	15-fold	0-fold	JJ	_	8	ppmod	_	_
11	in	in	IN	_	14	case	_	_
12	12	0	CD	_	14	num	_	_
13	healthy	healthy	JJ	_	14	attr	_	_
14	subjects	subject	NNS	_	6	ppmod	_	_
15	given	given	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	drug3	drug0	NN	_	20	com	_	_
19	-placebo	-placebo	NN	_	20	com	_	_
20	tablets	tablet	NNS	_	16	conj	_	_
21	concurrently	concurrently	RB	_	20	adv	_	_
22	.	.	.	_	6	p	_	_

1	In	in	IN	_	4	case	_	_
2	a	a	DT	_	4	det	_	_
3	single	single	JJ	_	4	attr	_	_
4	subject	subject	NN	_	32	ppmod	_	_
5	given	give	VBN	_	4	acl	_	_
6	one	#crd#	CD	_	7	num	_	_
7	dose	dose	NN	_	5	obj	_	_
8	of	of	IN	_	11	case	_	_
9	drug1	drug0	NN	_	11	attr	_	_
10	2	0	CD	_	11	num	_	_
11	hours	hour	NNS	_	7	ppmod	_	_
12	after	after	IN	_	14	case	_	_
13	a	a	DT	_	14	det	_	_
14	dose	dose	NN	_	5	ppmod	_	_
15	of	of	IN	_	18	case	_	_
16	drug2	drug0	NN	_	18	com	_	_
17	-placebo	-placebo	NN	_	18	com	_	_
18	tablets	tablet	NNS	_	14	ppmod	_	_
19	,	,	,	_	32	p	_	_
20	a	a	DT	_	25	det	_	_
21	greater	great	JJR	_	23	attr	_	_
22	than	than	IN	_	21	com	_	_
23	50	0	CD	_	25	num	_	_
24	%	%	NN	_	23	meta	_	_
25	reduction	reduction	NN	_	32	dep	_	_
26	in	in	IN	_	28	case	_	_
27	the	the	DT	_	28	det	_	_
28	AUC	auc	NN	_	25	ppmod	_	_
29	of	of	IN	_	30	case	_	_
30	drug3	drug0	NN	_	28	ppmod	_	_
31	was	be	VBD	_	32	aux	_	_
32	observed	observe	VBN	_	0	root	_	_
33	.	.	.	_	32	p	_	_

1	Plasma	plasma	NN	_	2	com	_	_
2	concentrations	concentration	NNS	_	6	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	are	be	VBP	_	6	aux	_	_
6	decreased	decrease	VBN	_	0	root	_	_
7	when	when	WRB	_	8	adv	_	_
8	administered	administer	VBN	_	6	comp	_	_
9	with	with	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	containing	contain	VBG	_	10	acl	_	_
12	drug3	drug0	NN	_	11	obj	_	_
13	,	,	,	_	12	p	_	_
14	drug4	drug0	NN	_	12	conj	_	_
15	,	,	,	_	14	p	_	_
16	or	or	CC	_	14	cc	_	_
17	drug5	drug0	NN	_	12	conj	_	_
18	.	.	.	_	6	p	_	_

1	The	the	DT	_	4	det	_	_
2	optimal	optimal	JJ	_	4	attr	_	_
3	dosing	dosing	NN	_	4	com	_	_
4	interval	interval	NN	_	11	dep	_	_
5	for	for	IN	_	6	case	_	_
6	coadministration	coadministration	NN	_	4	ppmod	_	_
7	with	with	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	determined	determine	VBN	_	0	root	_	_
12	by	by	IN	_	13	case	_	_
13	consulting	consult	VBG	_	11	ppmod	_	_
14	the	the	DT	_	18	det	_	_
15	appropriate	appropriate	JJ	_	18	attr	_	_
16	drug2	drug0	NN	_	18	com	_	_
17	package	package	NN	_	18	com	_	_
18	insert	insert	NN	_	13	obj	_	_
19	.	.	.	_	11	p	_	_

1	Interactions	interaction	NNS	_	0	root	_	_
2	with	with	IN	_	4	case	_	_
3	Other	other	JJ	_	4	attr	_	_
4	drug1	drug0	NN	_	1	ppmod	_	_
5	:	:	:	_	1	p	_	_
6	Significant	significant	JJ	_	7	attr	_	_
7	decreases	decrease	NNS	_	23	dep	_	_
8	in	in	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	AUC	auc	NN	_	7	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	20	0	CD	_	12	num	_	_
15	%	%	NN	_	14	meta	_	_
16	)	-rrb-	-RRB-	_	14	p	_	_
17	and	and	CC	_	12	cc	_	_
18	drug3	drug0	NN	_	12	conj	_	_
19	(	-lrb-	-LRB-	_	20	p	_	_
20	84	0	CD	_	18	num	_	_
21	%	%	NN	_	20	meta	_	_
22	)	-rrb-	-RRB-	_	20	p	_	_
23	occurred	occur	VBD	_	1	acl	_	_
24	following	follow	VBG	_	26	adv	_	_
25	simultaneous	simultaneous	JJ	_	26	attr	_	_
26	administration	administration	NN	_	23	ppmod	_	_
27	of	of	IN	_	29	case	_	_
28	these	these	DT	_	29	det	_	_
29	agents	agent	NNS	_	26	ppmod	_	_
30	with	with	IN	_	31	case	_	_
31	drug4	drug0	NN	_	26	ppmod	_	_
32	.	.	.	_	1	p	_	_

1	To	to	TO	_	2	aux	_	_
2	avoid	avoid	VB	_	10	advcl	_	_
3	this	this	DT	_	4	det	_	_
4	interaction	interaction	NN	_	2	obj	_	_
5	,	,	,	_	10	p	_	_
6	drug1	drug0	NN	_	10	dep	_	_
7	or	or	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	should	should	MD	_	10	modal	_	_
10	be	be	VB	_	0	root	_	_
11	given	given	IN	_	13	case	_	_
12	1	0	CD	_	13	num	_	_
13	hour	hour	NN	_	10	ppmod	_	_
14	prior	prior	RB	_	10	adv	_	_
15	to	to	TO	_	16	aux	_	_
16	dosing	dosing	NN	_	14	ppmod	_	_
17	with	with	IN	_	18	case	_	_
18	drug3	drug0	NN	_	16	ppmod	_	_
19	.	.	.	_	10	p	_	_

1	The	the	DT	_	2	det	_	_
2	pharmacokinetics	pharmacokinetics	NNS	_	7	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	are	be	VBP	_	7	aux	_	_
6	not	not	RB	_	7	neg	_	_
7	altered	alter	VBN	_	0	root	_	_
8	to	to	TO	_	12	aux	_	_
9	a	a	DT	_	12	det	_	_
10	clinically	clinically	RB	_	11	adv	_	_
11	significant	significant	JJ	_	12	attr	_	_
12	degree	degree	NN	_	7	ppmod	_	_
13	when	when	WRB	_	16	adv	_	_
14	it	it	PRP	_	16	dep	_	_
15	is	be	VBZ	_	16	aux	_	_
16	administered	administer	VBN	_	12	relcl	_	_
17	with	with	IN	_	20	case	_	_
18	a	a	DT	_	20	det	_	_
19	light	light	JJ	_	20	attr	_	_
20	meal	meal	NN	_	16	ppmod	_	_
21	1	0	CD	_	22	num	_	_
22	hour	hour	NN	_	24	dat	_	_
23	after	after	IN	_	24	case	_	_
24	drug2	drug0	NN	_	16	ppmod	_	_
25	.	.	.	_	7	p	_	_

1	No	no	DT	_	5	det	_	_
2	formal	formal	JJ	_	5	attr	_	_
3	drug	drug	NN	_	5	com	_	_
4	interaction	interaction	NN	_	5	com	_	_
5	studies	study	NNS	_	8	dep	_	_
6	have	have	VBP	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	performed	performed	VBN	_	0	root	_	_
9	with	with	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	should	should	MD	_	5	modal	_	_
3	not	not	RB	_	5	neg	_	_
4	be	be	VB	_	5	aux	_	_
5	used	use	VBN	_	0	root	_	_
6	with	with	IN	_	8	case	_	_
7	other	other	JJ	_	8	attr	_	_
8	drug2	drug0	NN	_	5	ppmod	_	_
9	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	9	dep	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	and	and	CC	_	3	cc	_	_
5	drug3	drug0	NN	_	1	conj	_	_
6	should	should	MD	_	9	modal	_	_
7	not	not	RB	_	9	neg	_	_
8	be	be	VB	_	9	aux	_	_
9	administered	administer	VBN	_	0	root	_	_
10	during	during	IN	_	12	case	_	_
11	drug4	drug0	NN	_	12	com	_	_
12	treatment	treatment	NN	_	9	ppmod	_	_
13	.	.	.	_	9	p	_	_

1	Drug/Laboratory	drug/laboratory	JJ	_	4	attr	_	_
2	Test	test	NN	_	4	com	_	_
3	Interactions	interaction	NNS	_	4	com	_	_
4	Increases	increase	NNS	_	17	dep	_	_
5	in	in	IN	_	7	case	_	_
6	lymphocyte	lymphocyte	NN	_	7	com	_	_
7	counts	count	NNS	_	4	ppmod	_	_
8	related	related	JJ	_	7	attr	_	_
9	to	to	TO	_	12	aux	_	_
10	the	the	DT	_	12	det	_	_
11	pharmacologic	pharmacologic	JJ	_	12	attr	_	_
12	mechanism	mechanism	NN	_	8	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	action	action	NN	_	12	ppmod	_	_
15	are	be	VBP	_	17	aux	_	_
16	frequently	frequently	RB	_	17	adv	_	_
17	observed	observe	VBN	_	0	root	_	_
18	during	during	IN	_	20	case	_	_
19	drug1	drug0	NN	_	20	com	_	_
20	treatment	treatment	NN	_	17	ppmod	_	_
21	.	.	.	_	17	p	_	_

1	Concurrent	concurrent	JJ	_	2	attr	_	_
2	administration	administration	NN	_	19	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	(	-lrb-	-LRB-	_	9	p	_	_
6	another	another	DT	_	9	det	_	_
7	TNF	tnf	NN	_	9	com	_	_
8	-blocking	-blocking	NN	_	9	com	_	_
9	agent	agent	NN	_	4	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	and	and	CC	_	4	cc	_	_
12	drug2	drug0	NN	_	4	conj	_	_
13	(	-lrb-	-LRB-	_	15	p	_	_
14	an	an	DT	_	15	det	_	_
15	drug3	drug0	NN	_	12	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	has	have	VBZ	_	19	aux	_	_
18	been	be	VBN	_	19	aux	_	_
19	associated	associate	VBN	_	0	root	_	_
20	with	with	IN	_	23	case	_	_
21	an	an	DT	_	23	det	_	_
22	increased	increase	VBN	_	23	attr	_	_
23	risk	risk	NN	_	19	ppmod	_	_
24	of	of	IN	_	26	case	_	_
25	serious	serious	JJ	_	26	attr	_	_
26	infections	infection	NNS	_	23	ppmod	_	_
27	,	,	,	_	19	p	_	_
28	and	and	CC	_	19	cc	_	_
29	increased	increase	VBN	_	30	attr	_	_
30	risk	risk	NN	_	37	dep	_	_
31	of	of	IN	_	32	case	_	_
32	neutropenia	neutropenia	NN	_	30	ppmod	_	_
33	and	and	CC	_	32	cc	_	_
34	no	no	DT	_	36	det	_	_
35	additional	additional	JJ	_	36	attr	_	_
36	benefit	benefit	NN	_	32	conj	_	_
37	compared	compare	VBN	_	19	conj	_	_
38	to	to	TO	_	41	aux	_	_
39	these	these	DT	_	41	det	_	_
40	medicinal	medicinal	JJ	_	41	attr	_	_
41	products	product	NNS	_	37	ppmod	_	_
42	alone	alone	RB	_	37	adv	_	_
43	.	.	.	_	19	p	_	_

1	Other	other	JJ	_	2	attr	_	_
2	drug1	drug0	NNS	_	14	dep	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	including	include	VBG	_	2	prn	_	_
5	drug2	drug0	NN	_	4	obj	_	_
6	)	-rrb-	-RRB-	_	4	p	_	_
7	used	use	VBN	_	2	acl	_	_
8	in	in	IN	_	9	case	_	_
9	combination	combination	NN	_	7	ppmod	_	_
10	with	with	IN	_	11	case	_	_
11	drug3	drug0	NN	_	9	ppmod	_	_
12	may	may	MD	_	14	modal	_	_
13	also	also	RB	_	14	adv	_	_
14	result	result	VB	_	0	root	_	_
15	in	in	IN	_	17	case	_	_
16	similar	similar	JJ	_	17	attr	_	_
17	toxicities	toxicity	NNS	_	14	ppmod	_	_
18	.	.	.	_	14	p	_	_

1	Specific	specific	JJ	_	4	attr	_	_
2	drug	drug	NN	_	4	com	_	_
3	interaction	interaction	NN	_	4	com	_	_
4	studies	study	NNS	_	14	dep	_	_
5	,	,	,	_	4	p	_	_
6	including	include	VBG	_	7	adv	_	_
7	interactions	interaction	NNS	_	4	ppmod	_	_
8	with	with	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	4	p	_	_
11	have	have	VBP	_	14	aux	_	_
12	not	not	RB	_	14	neg	_	_
13	been	be	VBN	_	14	aux	_	_
14	conducted	conduct	VBN	_	0	root	_	_
15	.	.	.	_	14	p	_	_

1	The	the	DT	_	2	det	_	_
2	majority	majority	NN	_	14	dep	_	_
3	of	of	IN	_	4	case	_	_
4	patients	patient	NNS	_	2	ppmod	_	_
5	in	in	IN	_	7	case	_	_
6	rheumatoid	rheumatoid	JJ	_	7	attr	_	_
7	arthritis	arthritis	NN	_	4	ppmod	_	_
8	or	or	CC	_	7	cc	_	_
9	Crohn	crohn	NN	_	11	com	_	_
10	s	s	NN	_	11	com	_	_
11	disease	disease	NN	_	13	attr	_	_
12	clinical	clinical	JJ	_	13	attr	_	_
13	studies	study	NNS	_	7	conj	_	_
14	received	receive	VBD	_	0	root	_	_
15	one	#crd#	CD	_	19	num	_	_
16	or	or	CC	_	15	cc	_	_
17	more	more	JJR	_	15	conj	_	_
18	concomitant	concomitant	JJ	_	19	attr	_	_
19	medications	medication	NNS	_	14	obj	_	_
20	.	.	.	_	14	p	_	_

1	In	in	IN	_	3	case	_	_
2	rheumatoid	rheumatoid	JJ	_	3	attr	_	_
3	arthritis	arthritis	NN	_	9	ppmod	_	_
4	,	,	,	_	9	p	_	_
5	concomitant	concomitant	JJ	_	6	attr	_	_
6	medications	medication	NNS	_	9	dep	_	_
7	besides	besides	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	were	be	VBD	_	0	root	_	_
10	drug2	drug0	NN	_	9	obj	_	_
11	,	,	,	_	10	p	_	_
12	drug3	drug0	NN	_	10	conj	_	_
13	,	,	,	_	12	p	_	_
14	drug4	drug0	NN	_	10	conj	_	_
15	and/or	and/or	CC	_	14	cc	_	_
16	drug5	drug0	NN	_	10	conj	_	_
17	.	.	.	_	9	p	_	_

1	Concomitant	concomitant	JJ	_	4	attr	_	_
2	Crohn	crohn	NN	_	4	com	_	_
3	s	s	NN	_	4	com	_	_
4	disease	disease	NN	_	5	com	_	_
5	medications	medication	NNS	_	6	dep	_	_
6	were	be	VBD	_	0	root	_	_
7	drug1	drug0	NN	_	6	obj	_	_
8	,	,	,	_	7	p	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	,	,	,	_	9	p	_	_
11	drug3	drug0	NN	_	7	conj	_	_
12	,	,	,	_	11	p	_	_
13	drug4	drug0	NN	_	7	conj	_	_
14	/	/	:	_	13	p	_	_
15	drug5	drug0	NN	_	7	conj	_	_
16	and	and	CC	_	15	cc	_	_
17	aminosalicylates	aminosalicylates	NN	_	7	conj	_	_
18	.	.	.	_	6	p	_	_

1	In	in	IN	_	5	case	_	_
2	psoriatic	psoriatic	JJ	_	3	attr	_	_
3	arthritis	arthritis	NN	_	5	attr	_	_
4	clinical	clinical	JJ	_	5	attr	_	_
5	trials	trial	NNS	_	9	ppmod	_	_
6	,	,	,	_	9	p	_	_
7	concomitant	concomitant	JJ	_	8	attr	_	_
8	medications	medication	NNS	_	9	dep	_	_
9	included	include	VBD	_	0	root	_	_
10	drug1	drug0	NN	_	9	obj	_	_
11	in	in	IN	_	13	case	_	_
12	approximately	approximately	RB	_	13	adv	_	_
13	half	half	NN	_	10	ppmod	_	_
14	of	of	IN	_	16	case	_	_
15	the	the	DT	_	16	det	_	_
16	patients	patient	NNS	_	13	ppmod	_	_
17	as	as	RB	_	18	com	_	_
18	well	well	RB	_	13	cc	_	_
19	as	as	IN	_	18	com	_	_
20	drug2	drug0	NN	_	13	conj	_	_
21	,	,	,	_	20	p	_	_
22	drug3	drug0	NN	_	20	conj	_	_
23	and	and	CC	_	22	cc	_	_
24	drug4	drug0	NN	_	20	conj	_	_
25	.	.	.	_	9	p	_	_

1	Patients	patient	NNS	_	9	dep	_	_
2	with	with	IN	_	5	case	_	_
3	Crohn	crohn	NN	_	5	com	_	_
4	s	s	NN	_	5	com	_	_
5	disease	disease	NN	_	1	ppmod	_	_
6	who	who	WP	_	7	dep	_	_
7	received	receive	VBD	_	1	relcl	_	_
8	drug1	drug0	NN	_	7	obj	_	_
9	tended	tend	VBD	_	0	root	_	_
10	to	to	TO	_	11	aux	_	_
11	experience	experience	VBP	_	9	comp	_	_
12	fewer	few	JJR	_	14	attr	_	_
13	infusion	infusion	NN	_	14	com	_	_
14	reactions	reaction	NNS	_	11	obj	_	_
15	compared	compare	VBN	_	17	adv	_	_
16	to	to	TO	_	17	aux	_	_
17	patients	patient	NNS	_	11	ppmod	_	_
18	on	on	IN	_	20	case	_	_
19	no	no	NN	_	20	com	_	_
20	drug2	drug0	NN	_	17	ppmod	_	_
21	.	.	.	_	9	p	_	_

1	Serum	serum	NN	_	3	com	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	concentrations	concentration	NNS	_	4	dep	_	_
4	appeared	appear	VBD	_	0	root	_	_
5	to	to	TO	_	7	aux	_	_
6	be	be	VB	_	7	aux	_	_
7	unaffected	unaffected	VBN	_	4	comp	_	_
8	by	by	IN	_	10	case	_	_
9	baseline	baseline	NN	_	10	com	_	_
10	use	use	NN	_	7	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	medications	medication	NNS	_	10	ppmod	_	_
13	for	for	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	treatment	treatment	NN	_	10	ppmod	_	_
16	of	of	IN	_	19	case	_	_
17	Crohn	crohn	NN	_	19	com	_	_
18	s	s	NN	_	19	com	_	_
19	disease	disease	NN	_	15	ppmod	_	_
20	including	include	VBG	_	21	adv	_	_
21	drug2	drug0	NN	_	19	ppmod	_	_
22	,	,	,	_	21	p	_	_
23	drug3	drug0	NN	_	21	conj	_	_
24	(	-lrb-	-LRB-	_	25	p	_	_
25	drug4	drug0	NN	_	23	prn	_	_
26	or	or	CC	_	25	cc	_	_
27	drug5	drug0	NN	_	25	conj	_	_
28	)	-rrb-	-RRB-	_	25	p	_	_
29	and	and	CC	_	23	cc	_	_
30	aminosalicylates	aminosalicylates	NNS	_	21	conj	_	_
31	.	.	.	_	4	p	_	_

1	When	when	WRB	_	2	adv	_	_
2	given	give	VBN	_	8	advcl	_	_
3	concurrently	concurrently	RB	_	2	adv	_	_
4	the	the	DT	_	6	det	_	_
5	following	following	JJ	_	6	attr	_	_
6	drugs	drug	NNS	_	8	dep	_	_
7	may	may	MD	_	8	modal	_	_
8	interact	interact	VB	_	0	root	_	_
9	with	with	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	8	p	_	_

1	-	-	CC	_	2	cc	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	,	,	,	_	2	p	_	_
4	drug2	drug0	NN	_	2	conj	_	_
5	,	,	,	_	4	p	_	_
6	or	or	CC	_	4	cc	_	_
7	drug3	drug0	NN	_	2	conj	_	_
8	:	:	:	_	2	p	_	_
9	Potentiation	potentiation	NN	_	14	dep	_	_
10	of	of	IN	_	12	case	_	_
11	otthostatic	otthostatic	JJ	_	12	attr	_	_
12	hypotension	hypotension	NN	_	9	ppmod	_	_
13	may	may	MD	_	14	modal	_	_
14	occur	occur	VB	_	2	acl	_	_

1	.	.	.	_	0	root	_	_

1	-	-	CC	_	11	cc	_	_
2	drug1	drug0	NN	_	11	attr	_	_
3	:	:	:	_	2	p	_	_
4	(	-lrb-	-LRB-	_	6	p	_	_
5	Oral	oral	JJ	_	6	attr	_	_
6	agents	agent	NNS	_	2	prn	_	_
7	and	and	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	)	-rrb-	-RRB-	_	6	p	_	_
10	Dosage	dosage	NN	_	11	com	_	_
11	adjustment	adjustment	NN	_	17	dep	_	_
12	of	of	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	drug3	drug0	NN	_	11	ppmod	_	_
15	may	may	MD	_	17	modal	_	_
16	be	be	VB	_	17	aux	_	_
17	required	require	VBN	_	0	root	_	_

1	.	.	.	_	0	root	_	_

1	-	-	CC	_	3	cc	_	_
2	Other	other	JJ	_	3	attr	_	_
3	drug1	drug0	NN	_	0	root	_	_
4	:	:	:	_	3	p	_	_
5	Additive	additive	JJ	_	6	attr	_	_
6	effect	effect	NN	_	3	conj	_	_
7	or	or	CC	_	6	cc	_	_
8	potentiation	potentiation	NN	_	3	conj	_	_

1	.	.	.	_	0	root	_	_

1	-	-	CC	_	2	cc	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	and	and	CC	_	2	cc	_	_
4	drug2	drug0	NN	_	5	com	_	_
5	drug3	drug0	NN	_	2	conj	_	_
6	:	:	:	_	2	p	_	_
7	drug4	drug0	NN	_	11	dep	_	_
8	and	and	CC	_	7	cc	_	_
9	drug5	drug0	NN	_	10	com	_	_
10	drug6	drug0	NN	_	7	conj	_	_
11	have	have	VBP	_	2	acl	_	_
12	the	the	DT	_	13	det	_	_
13	potential	potential	NN	_	11	obj	_	_
14	of	of	IN	_	16	case	_	_
15	binding	binding	NN	_	16	com	_	_
16	drug7	drug0	NN	_	13	ppmod	_	_
17	and	and	CC	_	11	cc	_	_
18	reducing	reduce	VBG	_	11	conj	_	_
19	drug8	drug0	NN	_	20	com	_	_
20	absorption	absorption	NN	_	18	obj	_	_
21	from	from	IN	_	24	case	_	_
22	the	the	DT	_	24	det	_	_
23	gastrointestinal	gastrointestinal	JJ	_	24	attr	_	_
24	tract	tract	NN	_	20	ppmod	_	_

1	.	.	.	_	0	root	_	_

1	-	-	CC	_	2	cc	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	,	,	,	_	2	p	_	_
4	drug2	drug0	NN	_	2	appo	_	_
5	:	:	:	_	2	p	_	_
6	Intensified	intensified	JJ	_	8	attr	_	_
7	electrolyte	electrolyte	NN	_	8	com	_	_
8	depletion	depletion	NN	_	2	appo	_	_
9	,	,	,	_	2	p	_	_
10	particularly	particularly	RB	_	11	adv	_	_
11	hypokalemia	hypokalemia	NN	_	2	appo	_	_

1	.	.	.	_	0	root	_	_

1	-	-	CC	_	3	cc	_	_
2	Pressor	pressor	JJ	_	3	attr	_	_
3	amines	amine	NNS	_	0	root	_	_
4	(	-lrb-	-LRB-	_	7	p	_	_
5	e.g.	e.g.	FW	_	7	adv	_	_
6	,	,	,	_	7	p	_	_
7	drug1	drug0	NN	_	3	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	:	:	:	_	3	p	_	_
10	Possible	possible	JJ	_	12	attr	_	_
11	decreased	decrease	VBN	_	12	attr	_	_
12	response	response	NN	_	3	appo	_	_
13	to	to	TO	_	3	attr	_	_
14	pressor	pressor	JJ	_	15	attr	_	_
15	amines	amine	NNS	_	3	appo	_	_
16	but	but	CC	_	3	cc	_	_
17	not	not	RB	_	18	neg	_	_
18	sufficient	sufficient	JJ	_	3	conj	_	_
19	to	to	TO	_	20	aux	_	_
20	preclude	preclude	VB	_	18	comp	_	_
21	their	their	PRP$	_	22	poss	_	_
22	use	use	NN	_	20	obj	_	_

1	.	.	.	_	0	root	_	_

1	-	-	CC	_	2	cc	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	,	,	,	_	2	p	_	_
4	nondepolarizing	nondepolarizing	NN	_	2	appo	_	_
5	(	-lrb-	-LRB-	_	8	p	_	_
6	e.g.	e.g.	FW	_	8	ppmod	_	_
7	,	,	,	_	8	p	_	_
8	drug2	drug0	NN	_	2	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	:	:	:	_	2	p	_	_
11	Possible	possible	JJ	_	13	attr	_	_
12	increased	increase	VBN	_	13	attr	_	_
13	responsiveness	responsiveness	NN	_	2	appo	_	_
14	to	to	TO	_	16	aux	_	_
15	the	the	DT	_	16	det	_	_
16	drug3	drug0	NN	_	13	ppmod	_	_

1	.	.	.	_	0	root	_	_

1	-	-	:	_	2	p	_	_
2	drug1	drug0	NN	_	8	comp	_	_
3	:	:	:	_	8	p	_	_
4	Generally	generally	RB	_	8	adv	_	_
5	should	should	MD	_	8	modal	_	_
6	not	not	RB	_	8	neg	_	_
7	be	be	VB	_	8	aux	_	_
8	given	give	VBN	_	0	root	_	_
9	with	with	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	reduce	reduce	VBP	_	0	root	_	_
3	the	the	DT	_	5	det	_	_
4	renal	renal	JJ	_	5	attr	_	_
5	clearance	clearance	NN	_	2	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	2	cc	_	_
9	add	add	VBP	_	2	conj	_	_
10	a	a	DT	_	12	det	_	_
11	high	high	JJ	_	12	attr	_	_
12	risk	risk	NN	_	9	obj	_	_
13	of	of	IN	_	15	case	_	_
14	drug3	drug0	NN	_	15	com	_	_
15	toxicity	toxicity	NN	_	12	ppmod	_	_
16	.	.	.	_	2	p	_	_

1	Refer	refer	VBP	_	0	root	_	_
2	to	to	TO	_	5	aux	_	_
3	the	the	DT	_	5	det	_	_
4	package	package	JJ	_	5	attr	_	_
5	insert	insert	NN	_	1	ppmod	_	_
6	for	for	IN	_	8	case	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	preparations	preparation	NNS	_	5	ppmod	_	_
9	before	before	IN	_	10	case	_	_
10	use	use	NN	_	1	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	such	such	JJ	_	13	attr	_	_
13	preparations	preparation	NNS	_	10	ppmod	_	_
14	with	with	IN	_	15	case	_	_
15	drug2	drug0	NN	_	10	ppmod	_	_

1	.	.	.	_	0	root	_	_

1	-	-	CC	_	2	cc	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	In	in	IN	_	6	case	_	_
5	some	some	DT	_	6	det	_	_
6	patients	patient	NNS	_	14	ppmod	_	_
7	,	,	,	_	14	p	_	_
8	the	the	DT	_	9	det	_	_
9	administration	administration	NN	_	14	dep	_	_
10	of	of	IN	_	12	case	_	_
11	a	a	DT	_	12	det	_	_
12	drug2	drug0	NN	_	9	ppmod	_	_
13	can	can	MD	_	14	modal	_	_
14	reduce	reduce	VB	_	2	acl	_	_
15	the	the	DT	_	22	det	_	_
16	diuretic	diuretic	JJ	_	22	attr	_	_
17	,	,	,	_	16	p	_	_
18	natriuretic	natriuretic	JJ	_	16	conj	_	_
19	,	,	,	_	18	p	_	_
20	and	and	CC	_	18	cc	_	_
21	antihypertensive	antihypertensive	JJ	_	16	conj	_	_
22	effects	effect	NNS	_	14	obj	_	_
23	of	of	IN	_	24	case	_	_
24	drug3	drug0	NN	_	22	ppmod	_	_
25	,	,	,	_	24	p	_	_
26	drug4	drug0	NN	_	24	conj	_	_
27	and	and	CC	_	26	cc	_	_
28	drug5	drug0	NN	_	24	conj	_	_
29	.	.	.	_	2	p	_	_

1	Therefore	therefore	RB	_	15	adv	_	_
2	,	,	,	_	15	p	_	_
3	when	when	WRB	_	8	adv	_	_
4	drug1	drug0	NN	_	8	dep	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	are	be	VBP	_	8	aux	_	_
8	used	use	VBN	_	15	advcl	_	_
9	concomitantly	concomitantly	RB	_	8	adv	_	_
10	,	,	,	_	15	p	_	_
11	the	the	DT	_	12	det	_	_
12	patient	patient	NN	_	15	dep	_	_
13	should	should	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	observed	observe	VBN	_	0	root	_	_
16	closely	closely	RB	_	15	adv	_	_
17	to	to	TO	_	18	aux	_	_
18	determine	determine	VB	_	15	comp	_	_
19	if	if	IN	_	27	mark	_	_
20	the	the	DT	_	22	det	_	_
21	desired	desired	JJ	_	22	attr	_	_
22	effect	effect	NN	_	27	dep	_	_
23	of	of	IN	_	25	case	_	_
24	the	the	DT	_	25	det	_	_
25	drug3	drug0	NN	_	22	ppmod	_	_
26	is	be	VBZ	_	27	aux	_	_
27	obtained	obtain	VBN	_	18	comp	_	_

1	.	.	.	_	0	root	_	_

1	-	-	CC	_	4	cc	_	_
2	Drug/Laboratory	drug/laboratory	NN	_	4	com	_	_
3	Test	test	NN	_	4	com	_	_
4	Interactions	interaction	NNS	_	0	root	_	_
5	:	:	:	_	4	p	_	_
6	drug1	drug0	NN	_	9	dep	_	_
7	should	should	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	discontinued	discontinue	VBN	_	4	acl	_	_
10	before	before	IN	_	11	case	_	_
11	carrying	carry	VBG	_	9	ppmod	_	_
12	out	out	RP	_	11	prt	_	_
13	tests	test	NNS	_	11	obj	_	_
14	for	for	IN	_	16	case	_	_
15	parathyroid	parathyroid	JJ	_	16	attr	_	_
16	function	function	NN	_	13	ppmod	_	_
17	.	.	.	_	4	p	_	_

1	Caution	caution	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	exercised	exercise	VBN	_	0	root	_	_
5	when	when	WRB	_	10	adv	_	_
6	the	the	DT	_	8	det	_	_
7	following	follow	VBG	_	8	attr	_	_
8	drugs	drug	NNS	_	10	dep	_	_
9	are	be	VBP	_	10	aux	_	_
10	administered	administer	VBN	_	4	comp	_	_
11	concomitantly	concomitantly	RB	_	10	adv	_	_
12	with	with	IN	_	13	case	_	_
13	drug1	drug0	NN	_	10	ppmod	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	drug2	drug0	NN	_	13	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	given	give	VBN	_	13	acl	_	_
18	with	with	IN	_	19	case	_	_
19	drug3	drug0	NN	_	17	ppmod	_	_
20	or	or	CC	_	19	cc	_	_
21	drug4	drug0	NN	_	19	conj	_	_
22	-	-	CC	_	21	cc	_	_
23	drug5	drug0	NN	_	25	com	_	_
24	combination	combination	NN	_	25	com	_	_
25	products	product	NNS	_	21	conj	_	_
26	.	.	.	_	4	p	_	_

1	For	for	IN	_	2	case	_	_
2	patients	patient	NNS	_	6	ppmod	_	_
3	receiving	receive	VBG	_	2	acl	_	_
4	drug1	drug0	NN	_	3	obj	_	_
5	,	,	,	_	6	p	_	_
6	see	see	VB	_	0	root	_	_
7	CONTRAINDICATIONS	contraindication	NNS	_	6	obj	_	_
8	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	14	dep	_	_
2	(	-lrb-	-LRB-	_	5	p	_	_
3	e.g.	e.g.	FW	_	5	ppmod	_	_
4	,	,	,	_	5	p	_	_
5	drug2	drug0	NN	_	1	prn	_	_
6	,	,	,	_	5	p	_	_
7	drug3	drug0	NN	_	5	appo	_	_
8	,	,	,	_	5	p	_	_
9	drug4	drug0	NN	_	5	appo	_	_
10	)	-rrb-	-RRB-	_	5	p	_	_
11	and	and	CC	_	1	cc	_	_
12	drug5	drug0	NN	_	1	conj	_	_
13	may	may	MD	_	14	modal	_	_
14	reduce	reduce	VB	_	0	root	_	_
15	the	the	DT	_	17	det	_	_
16	therapeutic	therapeutic	JJ	_	17	attr	_	_
17	effects	effect	NNS	_	14	obj	_	_
18	of	of	IN	_	19	case	_	_
19	drug6	drug0	NN	_	17	ppmod	_	_
20	.	.	.	_	14	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	14	ppmod	_	_
3	,	,	,	_	14	p	_	_
4	the	the	DT	_	6	det	_	_
5	beneficial	beneficial	JJ	_	6	attr	_	_
6	effects	effect	NNS	_	14	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	in	in	IN	_	11	case	_	_
10	Parkinsons	parkinsons	NN	_	11	com	_	_
11	disease	disease	NN	_	6	ppmod	_	_
12	have	have	VBP	_	14	aux	_	_
13	been	be	VBN	_	14	aux	_	_
14	reported	report	VBN	_	0	root	_	_
15	to	to	TO	_	17	aux	_	_
16	be	be	VB	_	17	aux	_	_
17	reversed	reverse	VBN	_	14	comp	_	_
18	by	by	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	and	and	CC	_	19	cc	_	_
21	drug3	drug0	NN	_	19	conj	_	_
22	.	.	.	_	14	p	_	_

1	Patients	patient	NNS	_	18	dep	_	_
2	taking	take	VBG	_	1	acl	_	_
3	these	these	DT	_	4	det	_	_
4	drugs	drug	NNS	_	2	obj	_	_
5	with	with	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	or	or	CC	_	4	cc	_	_
10	drug3	drug0	NN	_	14	attr	_	_
11	-	-	CC	_	10	cc	_	_
12	drug4	drug0	NN	_	10	conj	_	_
13	combination	combination	NN	_	14	com	_	_
14	products	product	NNS	_	4	conj	_	_
15	should	should	MD	_	18	modal	_	_
16	be	be	VB	_	18	aux	_	_
17	carefully	carefully	RB	_	18	adv	_	_
18	observed	observe	VBN	_	0	root	_	_
19	for	for	IN	_	20	case	_	_
20	loss	loss	NN	_	18	ppmod	_	_
21	of	of	IN	_	23	case	_	_
22	therapeutic	therapeutic	JJ	_	23	attr	_	_
23	response	response	NN	_	20	ppmod	_	_
24	.	.	.	_	18	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	salts	salt	NNS	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	reduce	reduce	VB	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	bioavailability	bioavailability	NN	_	4	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	drug3	drug0	NN	_	8	conj	_	_
11	.	.	.	_	4	p	_	_

1	The	the	DT	_	3	det	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	relevance	relevance	NN	_	4	dep	_	_
4	is	be	VBZ	_	0	root	_	_
5	unclear	unclear	JJ	_	4	dep	_	_
6	.	.	.	_	4	p	_	_

1	Although	although	IN	_	4	mark	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	increase	increase	VB	_	18	advcl	_	_
5	the	the	DT	_	6	det	_	_
6	bioavailability	bioavailability	NN	_	4	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	by	by	IN	_	10	case	_	_
10	increasing	increase	VBG	_	4	ppmod	_	_
11	gastric	gastric	JJ	_	12	attr	_	_
12	emptying	emptying	NN	_	10	obj	_	_
13	,	,	,	_	18	p	_	_
14	drug3	drug0	NN	_	18	dep	_	_
15	may	may	MD	_	18	modal	_	_
16	also	also	RB	_	18	adv	_	_
17	adversely	adversely	RB	_	18	adv	_	_
18	affect	affect	VBP	_	0	root	_	_
19	disease	disease	NN	_	20	com	_	_
20	control	control	NN	_	18	obj	_	_
21	by	by	IN	_	24	case	_	_
22	its	its	PRP$	_	24	poss	_	_
23	dopamine	dopamine	NN	_	24	com	_	_
24	receptor	receptor	NN	_	18	ppmod	_	_
25	antagonistic	antagonistic	JJ	_	26	attr	_	_
26	properties	property	NNS	_	18	obj	_	_
27	.	.	.	_	18	p	_	_

1	Drugs	drug	NNS	_	0	root	_	_
2	that	that	WDT	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	increase	increase	VB	_	1	relcl	_	_
5	drug1	drug0	NN	_	7	com	_	_
6	plasma	plasma	NN	_	7	com	_	_
7	concentrations	concentration	NNS	_	4	obj	_	_
8	CYP3A4	cyp0a0	JJ	_	9	attr	_	_
9	Inhibitors	inhibitor	NNS	_	7	attr	_	_
10	:	:	:	_	1	p	_	_
11	drug2	drug0	NN	_	12	dep	_	_
12	is	be	VBZ	_	1	acl	_	_
13	a	a	DT	_	15	det	_	_
14	CYP3A4	cyp0a0	NN	_	15	com	_	_
15	substrate	substrate	NN	_	12	obj	_	_
16	.	.	.	_	1	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	use	use	NN	_	36	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drugs	drug	NNS	_	4	conj	_	_
7	that	that	WDT	_	8	dep	_	_
8	inhibit	inhibit	VBP	_	6	relcl	_	_
9	CYP3A4	cyp0a0	NN	_	8	obj	_	_
10	(	-lrb-	-LRB-	_	31	p	_	_
11	eg	eg	NN	_	31	dep	_	_
12	,	,	,	_	31	p	_	_
13	drug2	drug0	NN	_	31	attr	_	_
14	,	,	,	_	31	p	_	_
15	drug3	drug0	NN	_	31	attr	_	_
16	,	,	,	_	31	p	_	_
17	drug4	drug0	NN	_	31	attr	_	_
18	,	,	,	_	31	p	_	_
19	drug5	drug0	NN	_	31	attr	_	_
20	,	,	,	_	31	p	_	_
21	drug6	drug0	NN	_	31	attr	_	_
22	,	,	,	_	31	p	_	_
23	drug7	drug0	NN	_	31	attr	_	_
24	,	,	,	_	31	p	_	_
25	drug8	drug0	NN	_	31	attr	_	_
26	,	,	,	_	31	p	_	_
27	drug9	drug0	NN	_	31	attr	_	_
28	,	,	,	_	31	p	_	_
29	drug10	drug0	NN	_	31	attr	_	_
30	,	,	,	_	31	p	_	_
31	drug11	drug0	NN	_	9	prn	_	_
32	,	,	,	_	31	p	_	_
33	drug12	drug0	CD	_	31	num	_	_
34	)	-rrb-	-RRB-	_	31	p	_	_
35	may	may	MD	_	36	modal	_	_
36	increase	increase	VB	_	0	root	_	_
37	exposure	exposure	NN	_	36	obj	_	_
38	to	to	TO	_	39	aux	_	_
39	drug13	drug0	NN	_	37	ppmod	_	_
40	and	and	CC	_	36	cc	_	_
41	should	should	MD	_	43	modal	_	_
42	be	be	VB	_	43	aux	_	_
43	avoided	avoid	VBN	_	36	conj	_	_
44	.	.	.	_	36	p	_	_

1	In	in	IN	_	2	case	_	_
2	patients	patient	NNS	_	19	ppmod	_	_
3	receiving	receive	VBG	_	2	acl	_	_
4	treatment	treatment	NN	_	3	obj	_	_
5	with	with	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	,	,	,	_	19	p	_	_
8	close	close	JJ	_	9	attr	_	_
9	monitoring	monitoring	NN	_	19	dep	_	_
10	for	for	IN	_	11	case	_	_
11	toxicity	toxicity	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	a	a	DT	_	16	det	_	_
14	drug2	drug0	NN	_	16	com	_	_
15	dose	dose	NN	_	16	com	_	_
16	reduction	reduction	NN	_	11	conj	_	_
17	should	should	MD	_	19	modal	_	_
18	be	be	VB	_	19	aux	_	_
19	considered	consider	VBN	_	0	root	_	_
20	if	if	IN	_	30	mark	_	_
21	systemic	systemic	JJ	_	22	attr	_	_
22	administration	administration	NN	_	30	dep	_	_
23	of	of	IN	_	27	case	_	_
24	a	a	DT	_	27	det	_	_
25	potent	potent	JJ	_	27	attr	_	_
26	CYP3A4	cyp0a0	NN	_	27	com	_	_
27	inhibitor	inhibitor	NN	_	22	ppmod	_	_
28	cannot	cannot	MD	_	30	modal	_	_
29	be	be	VB	_	30	aux	_	_
30	avoided	avoid	VBN	_	19	comp	_	_
31	.	.	.	_	19	p	_	_

1	Drugs	drug	NNS	_	17	dep	_	_
2	that	that	WDT	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	decrease	decrease	VB	_	1	relcl	_	_
5	drug1	drug0	NN	_	7	com	_	_
6	plasma	plasma	NN	_	7	com	_	_
7	concentrations	concentration	NNS	_	4	obj	_	_
8	CYP3A4	cyp0a0	JJ	_	9	attr	_	_
9	Inducers	inducer	NNS	_	1	appo	_	_
10	:	:	:	_	1	p	_	_
11	Drugs	drug	NNS	_	1	appo	_	_
12	that	that	WDT	_	13	dep	_	_
13	induce	induce	VBP	_	11	relcl	_	_
14	CYP3A4	cyp0a0	NN	_	15	com	_	_
15	activity	activity	NN	_	13	obj	_	_
16	may	may	MD	_	17	modal	_	_
17	decrease	decrease	VB	_	0	root	_	_
18	drug2	drug0	NN	_	20	com	_	_
19	plasma	plasma	NN	_	20	com	_	_
20	concentrations	concentration	NNS	_	17	obj	_	_
21	.	.	.	_	17	p	_	_

1	In	in	IN	_	2	case	_	_
2	patients	patient	NNS	_	32	ppmod	_	_
3	in	in	IN	_	4	case	_	_
4	whom	whom	WP	_	21	ppmod	_	_
5	CYP3A4	cyp0a0	JJ	_	6	attr	_	_
6	inducers	inducer	NNS	_	21	dep	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	eg	eg	NN	_	6	prn	_	_
9	,	,	,	_	8	p	_	_
10	drug1	drug0	NN	_	8	appo	_	_
11	,	,	,	_	8	p	_	_
12	drug2	drug0	NN	_	8	appo	_	_
13	,	,	,	_	8	p	_	_
14	drug3	drug0	NN	_	8	appo	_	_
15	,	,	,	_	8	p	_	_
16	drug4	drug0	NN	_	8	appo	_	_
17	,	,	,	_	8	p	_	_
18	drug5	drug0	NN	_	8	appo	_	_
19	)	-rrb-	-RRB-	_	8	p	_	_
20	are	be	VBP	_	21	aux	_	_
21	indicated	indicate	VBN	_	2	relcl	_	_
22	,	,	,	_	32	p	_	_
23	alternative	alternative	JJ	_	24	attr	_	_
24	agents	agent	NNS	_	32	dep	_	_
25	with	with	IN	_	29	case	_	_
26	less	less	RBR	_	29	adv	_	_
27	enzyme	enzyme	NN	_	29	com	_	_
28	induction	induction	NN	_	29	com	_	_
29	potential	potential	NN	_	24	ppmod	_	_
30	should	should	MD	_	32	modal	_	_
31	be	be	VB	_	32	aux	_	_
32	used	use	VBN	_	0	root	_	_
33	.	.	.	_	32	p	_	_

1	If	if	IN	_	5	mark	_	_
2	drug1	drug0	NN	_	5	dep	_	_
3	must	must	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	administered	administer	VBN	_	18	advcl	_	_
6	with	with	IN	_	9	case	_	_
7	a	a	DT	_	9	det	_	_
8	CYP3A4	cyp0a0	NN	_	9	com	_	_
9	inducer	inducer	NN	_	5	ppmod	_	_
10	,	,	,	_	18	p	_	_
11	a	a	DT	_	13	det	_	_
12	dose	dose	NN	_	13	com	_	_
13	increase	increase	NN	_	18	dep	_	_
14	in	in	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	should	should	MD	_	18	modal	_	_
17	be	be	VB	_	18	aux	_	_
18	considered	consider	VBN	_	0	root	_	_
19	.	.	.	_	18	p	_	_

1	St.	st.	NN	_	3	com	_	_
2	Johns	johns	NNP	_	3	com	_	_
3	wort	wort	NN	_	9	dep	_	_
4	(	-lrb-	-LRB-	_	6	p	_	_
5	Hypericum	hypericum	NN	_	6	com	_	_
6	perforatum	perforatum	NN	_	3	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	may	may	MD	_	9	modal	_	_
9	decrease	decrease	VB	_	0	root	_	_
10	drug1	drug0	NN	_	12	com	_	_
11	plasma	plasma	NN	_	12	com	_	_
12	concentrations	concentration	NNS	_	9	obj	_	_
13	unpredictably	unpredictably	RB	_	9	adv	_	_
14	.	.	.	_	9	p	_	_

1	Patients	patient	NNS	_	6	dep	_	_
2	receiving	receive	VBG	_	1	acl	_	_
3	drug1	drug0	NN	_	2	obj	_	_
4	should	should	MD	_	6	modal	_	_
5	not	not	RB	_	6	neg	_	_
6	take	take	VB	_	0	root	_	_
7	St.	st.	NN	_	9	com	_	_
8	Johns	johns	NNP	_	9	com	_	_
9	wort	wort	NN	_	6	obj	_	_
10	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	4	attr	_	_
2	:	:	:	_	4	p	_	_
3	Nonclinical	nonclinical	NN	_	4	com	_	_
4	data	datum	NNS	_	5	dep	_	_
5	demonstrate	demonstrate	VBP	_	0	root	_	_
6	that	that	IN	_	11	mark	_	_
7	the	the	DT	_	8	det	_	_
8	solubility	solubility	NN	_	11	dep	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	is	be	VBZ	_	5	comp	_	_
12	pH	ph	NN	_	13	advnp	_	_
13	dependent	dependent	JJ	_	11	dep	_	_
14	.	.	.	_	5	p	_	_

1	Simultaneous	simultaneous	JJ	_	2	attr	_	_
2	administration	administration	NN	_	9	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	with	with	IN	_	6	case	_	_
6	drug2	drug0	NN	_	2	ppmod	_	_
7	should	should	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	avoided	avoid	VBN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	If	if	IN	_	5	mark	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	therapy	therapy	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	needed	need	VBN	_	12	advcl	_	_
6	,	,	,	_	12	p	_	_
7	the	the	DT	_	9	det	_	_
8	antacid	antacid	JJ	_	9	attr	_	_
9	dose	dose	NN	_	12	dep	_	_
10	should	should	MD	_	12	modal	_	_
11	be	be	VB	_	12	aux	_	_
12	administered	administer	VBN	_	0	root	_	_
13	at	at	IN	_	15	case	_	_
14	least	least	JJS	_	15	attr	_	_
15	2	0	CD	_	16	num	_	_
16	hours	hour	NNS	_	17	advnp	_	_
17	prior	prior	RB	_	12	adv	_	_
18	to	to	TO	_	21	aux	_	_
19	or	or	CC	_	21	cc	_	_
20	2	0	CD	_	21	num	_	_
21	hours	hour	NNS	_	17	ppmod	_	_
22	after	after	IN	_	24	case	_	_
23	the	the	DT	_	24	det	_	_
24	dose	dose	NN	_	12	ppmod	_	_
25	of	of	IN	_	26	case	_	_
26	drug2	drug0	NN	_	24	ppmod	_	_
27	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	22	dep	_	_
2	/	/	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	:	:	:	_	1	p	_	_
5	Long-term	long-term	JJ	_	6	attr	_	_
6	suppression	suppression	NN	_	1	appo	_	_
7	of	of	IN	_	10	case	_	_
8	gastric	gastric	JJ	_	10	attr	_	_
9	acid	acid	NN	_	10	com	_	_
10	secretion	secretion	NN	_	6	ppmod	_	_
11	by	by	IN	_	12	case	_	_
12	drug3	drug0	NN	_	6	ppmod	_	_
13	or	or	CC	_	12	cc	_	_
14	drug4	drug0	NN	_	12	conj	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	eg	eg	NN	_	14	prn	_	_
17	,	,	,	_	16	p	_	_
18	drug5	drug0	NN	_	16	conj	_	_
19	and	and	CC	_	18	cc	_	_
20	drug6	drug0	NN	_	16	conj	_	_
21	)	-rrb-	-RRB-	_	16	p	_	_
22	is	be	VBZ	_	0	root	_	_
23	likely	likely	JJ	_	22	dep	_	_
24	to	to	TO	_	25	aux	_	_
25	reduce	reduce	VB	_	23	comp	_	_
26	drug7	drug0	NN	_	27	com	_	_
27	exposure	exposure	NN	_	25	obj	_	_
28	.	.	.	_	22	p	_	_

1	The	the	DT	_	3	det	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	use	use	NN	_	12	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	or	or	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	with	with	IN	_	9	case	_	_
9	drug3	drug0	NN	_	3	ppmod	_	_
10	is	be	VBZ	_	12	aux	_	_
11	not	not	RB	_	12	neg	_	_
12	recommended	recommend	VBN	_	0	root	_	_
13	.	.	.	_	12	p	_	_

1	The	the	DT	_	2	det	_	_
2	use	use	NN	_	7	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	should	should	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	considered	consider	VBN	_	0	root	_	_
8	in	in	IN	_	9	case	_	_
9	place	place	NN	_	7	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	or	or	CC	_	11	cc	_	_
13	drug3	drug0	NN	_	11	conj	_	_
14	in	in	IN	_	15	case	_	_
15	patients	patient	NNS	_	9	ppmod	_	_
16	receiving	receive	VBG	_	15	acl	_	_
17	drug4	drug0	NN	_	18	com	_	_
18	therapy	therapy	NN	_	16	obj	_	_
19	.	.	.	_	7	p	_	_

1	Drugs	drug	NNS	_	8	dep	_	_
2	that	that	WDT	_	7	dep	_	_
3	may	may	MD	_	7	modal	_	_
4	have	have	VB	_	7	lv	_	_
5	their	their	PRP$	_	7	poss	_	_
6	plasma	plasma	NN	_	7	com	_	_
7	concentration	concentration	NN	_	1	relcl	_	_
8	altered	alter	VBN	_	15	advcl	_	_
9	by	by	IN	_	12	case	_	_
10	drug1	drug0	NN	_	12	com	_	_
11	CYP3A4	cyp0a0	NN	_	12	com	_	_
12	Substrates	substrate	NNS	_	8	ppmod	_	_
13	:	:	:	_	15	p	_	_
14	drug2	drug0	NN	_	15	dep	_	_
15	is	be	VBZ	_	0	root	_	_
16	a	a	DT	_	18	det	_	_
17	time-dependent	time-dependent	JJ	_	18	attr	_	_
18	inhibitor	inhibitor	NN	_	15	obj	_	_
19	of	of	IN	_	20	case	_	_
20	CYP3A4	cyp0a0	NN	_	18	ppmod	_	_
21	.	.	.	_	15	p	_	_

1	Therefore	therefore	RB	_	43	adv	_	_
2	,	,	,	_	43	p	_	_
3	CYP3A4	cyp0a0	NN	_	4	com	_	_
4	substrates	substrate	NNS	_	43	dep	_	_
5	known	know	VBN	_	4	acl	_	_
6	to	to	TO	_	7	aux	_	_
7	have	have	VB	_	5	comp	_	_
8	a	a	DT	_	11	det	_	_
9	narrow	narrow	JJ	_	11	attr	_	_
10	therapeutic	therapeutic	JJ	_	11	attr	_	_
11	index	index	NN	_	7	obj	_	_
12	such	such	JJ	_	14	adv	_	_
13	as	as	IN	_	14	case	_	_
14	drug1	drug0	NN	_	11	ppmod	_	_
15	,	,	,	_	14	p	_	_
16	drug2	drug0	NN	_	14	conj	_	_
17	,	,	,	_	16	p	_	_
18	drug3	drug0	NN	_	14	conj	_	_
19	,	,	,	_	18	p	_	_
20	drug4	drug0	NN	_	14	conj	_	_
21	,	,	,	_	20	p	_	_
22	drug5	drug0	NN	_	14	conj	_	_
23	,	,	,	_	22	p	_	_
24	drug6	drug0	NN	_	14	conj	_	_
25	,	,	,	_	24	p	_	_
26	drug7	drug0	NN	_	14	conj	_	_
27	,	,	,	_	26	p	_	_
28	drug8	drug0	NN	_	14	conj	_	_
29	,	,	,	_	28	p	_	_
30	drug9	drug0	NN	_	14	conj	_	_
31	,	,	,	_	30	p	_	_
32	drug10	drug0	NN	_	14	conj	_	_
33	,	,	,	_	32	p	_	_
34	or	or	CC	_	32	cc	_	_
35	drug11	drug0	NN	_	14	conj	_	_
36	(	-lrb-	-LRB-	_	39	p	_	_
37	drug12	drug0	CD	_	39	num	_	_
38	,	,	,	_	39	p	_	_
39	drug13	drug0	CD	_	7	num	_	_
40	)	-rrb-	-RRB-	_	39	p	_	_
41	should	should	MD	_	43	modal	_	_
42	be	be	VB	_	43	aux	_	_
43	administered	administer	VBN	_	0	root	_	_
44	with	with	IN	_	45	case	_	_
45	caution	caution	NN	_	43	ppmod	_	_
46	in	in	IN	_	47	case	_	_
47	patients	patient	NNS	_	43	ppmod	_	_
48	receiving	receive	VBG	_	47	acl	_	_
49	drug14	drug0	NN	_	48	obj	_	_
50	.	.	.	_	43	p	_	_

1	Hepatic	hepatic	JJ	_	2	attr	_	_
2	Impairment	impairment	NN	_	0	root	_	_
3	There	there	EX	_	4	dep	_	_
4	are	be	VBP	_	2	acl	_	_
5	currently	currently	RB	_	4	adv	_	_
6	no	no	DT	_	8	det	_	_
7	clinical	clinical	JJ	_	8	attr	_	_
8	studies	study	NNS	_	4	obj	_	_
9	with	with	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	in	in	IN	_	12	case	_	_
12	patients	patient	NNS	_	10	ppmod	_	_
13	with	with	IN	_	16	case	_	_
14	impaired	impaired	JJ	_	16	attr	_	_
15	liver	liver	NN	_	16	com	_	_
16	function	function	NN	_	12	ppmod	_	_
17	(	-lrb-	-LRB-	_	21	p	_	_
18	clinical	clinical	JJ	_	19	attr	_	_
19	studies	study	NNS	_	21	dep	_	_
20	have	have	VBP	_	21	aux	_	_
21	excluded	exclude	VBN	_	16	prn	_	_
22	patients	patient	NNS	_	21	obj	_	_
23	with	with	IN	_	24	case	_	_
24	ALT	alt	NN	_	22	ppmod	_	_
25	and/or	and/or	CC	_	24	cc	_	_
26	AST	ast	NN	_	28	attr	_	_
27	2.5	0	CD	_	28	num	_	_
28	times	time	NNS	_	24	conj	_	_
29	the	the	DT	_	31	det	_	_
30	upper	upper	JJ	_	31	attr	_	_
31	limit	limit	NN	_	28	appo	_	_
32	of	of	IN	_	35	case	_	_
33	the	the	DT	_	35	det	_	_
34	normal	normal	JJ	_	35	attr	_	_
35	range	range	NN	_	31	ppmod	_	_
36	and/or	and/or	CC	_	31	cc	_	_
37	total	total	JJ	_	38	attr	_	_
38	bilirubin	bilirubin	NN	_	31	conj	_	_
39	2	0	CD	_	40	num	_	_
40	times	time	NNS	_	38	appo	_	_
41	the	the	DT	_	43	det	_	_
42	upper	upper	JJ	_	43	attr	_	_
43	limit	limit	NN	_	40	attr	_	_
44	of	of	IN	_	47	case	_	_
45	the	the	DT	_	47	det	_	_
46	normal	normal	JJ	_	47	attr	_	_
47	range	range	NN	_	43	ppmod	_	_
48	)	-rrb-	-RRB-	_	21	p	_	_
49	.	.	.	_	2	p	_	_

1	Metabolism	metabolism	NN	_	4	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	is	be	VBZ	_	0	root	_	_
5	mainly	mainly	RB	_	4	adv	_	_
6	hepatic	hepatic	JJ	_	4	dep	_	_
7	.	.	.	_	4	p	_	_

1	Caution	caution	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	recommended	recommend	VBN	_	0	root	_	_
4	in	in	IN	_	5	case	_	_
5	patients	patient	NNS	_	3	ppmod	_	_
6	with	with	IN	_	8	case	_	_
7	hepatic	hepatic	JJ	_	8	attr	_	_
8	impairment	impairment	NN	_	5	ppmod	_	_
9	.	.	.	_	3	p	_	_

1	Renal	renal	JJ	_	2	attr	_	_
2	Impairment	impairment	NN	_	0	root	_	_
3	There	there	EX	_	4	dep	_	_
4	are	be	VBP	_	2	acl	_	_
5	currently	currently	RB	_	4	adv	_	_
6	no	no	DT	_	8	det	_	_
7	clinical	clinical	JJ	_	8	attr	_	_
8	studies	study	NNS	_	4	obj	_	_
9	with	with	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	in	in	IN	_	12	case	_	_
12	patients	patient	NNS	_	10	ppmod	_	_
13	with	with	IN	_	16	case	_	_
14	impaired	impaired	JJ	_	16	attr	_	_
15	renal	renal	JJ	_	16	attr	_	_
16	function	function	NN	_	12	ppmod	_	_
17	(	-lrb-	-LRB-	_	21	p	_	_
18	clinical	clinical	JJ	_	19	attr	_	_
19	studies	study	NNS	_	21	dep	_	_
20	have	have	VBP	_	21	aux	_	_
21	excluded	exclude	VBN	_	16	prn	_	_
22	patients	patient	NNS	_	21	obj	_	_
23	with	with	IN	_	26	case	_	_
24	serum	serum	NN	_	26	com	_	_
25	creatinine	creatinine	NN	_	26	com	_	_
26	concentration	concentration	NN	_	22	ppmod	_	_
27	1.5	0	CD	_	28	num	_	_
28	times	time	NNS	_	26	acl	_	_
29	the	the	DT	_	31	det	_	_
30	upper	upper	JJ	_	31	attr	_	_
31	limit	limit	NN	_	28	obj	_	_
32	of	of	IN	_	35	case	_	_
33	the	the	DT	_	35	det	_	_
34	normal	normal	JJ	_	35	attr	_	_
35	range	range	NN	_	31	ppmod	_	_
36	)	-rrb-	-RRB-	_	21	p	_	_
37	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	7	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	its	its	PRP$	_	4	poss	_	_
4	metabolites	metabolite	NNS	_	1	conj	_	_
5	are	be	VBP	_	7	aux	_	_
6	minimally	minimally	RB	_	7	adv	_	_
7	excreted	excrete	VBN	_	0	root	_	_
8	via	via	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	kidney	kidney	NN	_	7	ppmod	_	_
11	.	.	.	_	7	p	_	_

1	Since	since	IN	_	11	mark	_	_
2	the	the	DT	_	4	det	_	_
3	renal	renal	JJ	_	4	attr	_	_
4	excretion	excretion	NN	_	11	dep	_	_
5	of	of	IN	_	7	case	_	_
6	unchanged	unchanged	JJ	_	7	attr	_	_
7	drug1	drug0	NN	_	4	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	its	its	PRP$	_	10	poss	_	_
10	metabolites	metabolite	NNS	_	7	conj	_	_
11	is	be	VBZ	_	23	advcl	_	_
12	4	0	CD	_	11	obj	_	_
13	%	%	NN	_	12	meta	_	_
14	,	,	,	_	23	p	_	_
15	a	a	DT	_	16	det	_	_
16	decrease	decrease	NN	_	23	dep	_	_
17	in	in	IN	_	20	case	_	_
18	total	total	JJ	_	20	attr	_	_
19	body	body	NN	_	20	com	_	_
20	clearance	clearance	NN	_	16	ppmod	_	_
21	is	be	VBZ	_	23	aux	_	_
22	not	not	RB	_	23	neg	_	_
23	expected	expect	VBN	_	0	root	_	_
24	in	in	IN	_	25	case	_	_
25	patients	patient	NNS	_	23	ppmod	_	_
26	with	with	IN	_	28	case	_	_
27	renal	renal	JJ	_	28	attr	_	_
28	insufficiency	insufficiency	NN	_	25	ppmod	_	_
29	.	.	.	_	23	p	_	_

1	Drug	drug	NN	_	3	com	_	_
2	interaction	interaction	NN	_	3	com	_	_
3	studies	study	NNS	_	7	dep	_	_
4	have	have	VBP	_	7	aux	_	_
5	not	not	RB	_	7	neg	_	_
6	been	be	VBN	_	7	aux	_	_
7	performed	performed	VBN	_	0	root	_	_
8	with	with	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	.	.	.	_	7	p	_	_

1	No	no	DT	_	5	det	_	_
2	formal	formal	JJ	_	5	attr	_	_
3	drug-drug	drug-drug	JJ	_	5	attr	_	_
4	interaction	interaction	NN	_	5	com	_	_
5	studies	study	NNS	_	8	dep	_	_
6	have	have	VBP	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	performed	performed	VBN	_	0	root	_	_
9	.	.	.	_	8	p	_	_

1	No	no	DT	_	3	det	_	_
2	confirmed	confirm	VBN	_	3	attr	_	_
3	interactions	interaction	NNS	_	6	dep	_	_
4	have	have	VBP	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	reported	report	VBN	_	0	root	_	_
7	between	between	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	other	other	JJ	_	11	attr	_	_
11	drugs	drug	NNS	_	8	conj	_	_

1	drug1	drug0	NN	_	3	com	_	_
2	Inhalation	inhalation	NN	_	3	com	_	_
3	Aerosol	aerosol	NN	_	6	dep	_	_
4	has	have	VBZ	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	used	use	VBN	_	0	root	_	_
7	concomitantly	concomitantly	RB	_	6	adv	_	_
8	with	with	IN	_	10	case	_	_
9	other	other	JJ	_	10	attr	_	_
10	drugs	drug	NNS	_	6	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	including	include	VBG	_	13	adv	_	_
13	drug2	drug0	NN	_	10	ppmod	_	_
14	,	,	,	_	13	p	_	_
15	drug3	drug0	NN	_	13	conj	_	_
16	,	,	,	_	15	p	_	_
17	and	and	CC	_	15	cc	_	_
18	drug4	drug0	NN	_	13	conj	_	_
19	,	,	,	_	10	p	_	_
20	commonly	commonly	RB	_	21	adv	_	_
21	used	use	VBN	_	10	acl	_	_
22	in	in	IN	_	24	case	_	_
23	the	the	DT	_	24	det	_	_
24	treatment	treatment	NN	_	21	ppmod	_	_
25	of	of	IN	_	29	case	_	_
26	chronic	chronic	JJ	_	29	attr	_	_
27	obstructive	obstructive	JJ	_	29	attr	_	_
28	pulmonary	pulmonary	JJ	_	29	attr	_	_
29	disease	disease	NN	_	24	ppmod	_	_
30	.	.	.	_	6	p	_	_

1	With	with	IN	_	3	case	_	_
2	the	the	DT	_	3	det	_	_
3	exception	exception	NN	_	8	ppmod	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	,	,	,	_	8	p	_	_
7	there	there	EX	_	8	dep	_	_
8	are	be	VBP	_	0	root	_	_
9	no	no	DT	_	11	det	_	_
10	formal	formal	JJ	_	11	attr	_	_
11	studies	study	NNS	_	8	obj	_	_
12	fully	fully	RB	_	13	adv	_	_
13	evaluating	evaluate	VBG	_	11	acl	_	_
14	the	the	DT	_	16	det	_	_
15	interaction	interaction	NN	_	16	com	_	_
16	effects	effect	NNS	_	13	obj	_	_
17	of	of	IN	_	20	case	_	_
18	drug2	drug0	NN	_	20	com	_	_
19	Inhalation	inhalation	NN	_	20	com	_	_
20	Aerosol	aerosol	NN	_	16	ppmod	_	_
21	and	and	CC	_	20	cc	_	_
22	these	these	DT	_	23	det	_	_
23	drugs	drug	NNS	_	20	conj	_	_
24	with	with	IN	_	25	case	_	_
25	respect	respect	NN	_	23	ppmod	_	_
26	to	to	TO	_	27	aux	_	_
27	effectiveness	effectiveness	NN	_	25	ppmod	_	_
28	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Although	although	IN	_	7	mark	_	_
4	drug2	drug0	NN	_	7	dep	_	_
5	is	be	VBZ	_	7	aux	_	_
6	minimally	minimally	RB	_	7	adv	_	_
7	absorbed	absorb	VBN	_	14	advcl	_	_
8	into	into	IN	_	11	case	_	_
9	the	the	DT	_	11	det	_	_
10	systemic	systemic	JJ	_	11	attr	_	_
11	circulation	circulation	NN	_	7	ppmod	_	_
12	,	,	,	_	14	p	_	_
13	there	there	EX	_	14	dep	_	_
14	is	be	VBZ	_	1	acl	_	_
15	some	some	DT	_	16	det	_	_
16	potential	potential	NN	_	14	obj	_	_
17	for	for	IN	_	20	case	_	_
18	an	an	DT	_	20	det	_	_
19	additive	additive	JJ	_	20	attr	_	_
20	interaction	interaction	NN	_	16	ppmod	_	_
21	with	with	IN	_	24	case	_	_
22	concomitantly	concomitantly	RB	_	23	adv	_	_
23	used	use	VBN	_	24	attr	_	_
24	drug3	drug0	NN	_	20	ppmod	_	_
25	.	.	.	_	1	p	_	_

1	Caution	caution	NN	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	therefore	therefore	RB	_	4	adv	_	_
4	advised	advise	VBN	_	0	root	_	_
5	in	in	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	coadministration	coadministration	NN	_	4	ppmod	_	_
8	of	of	IN	_	11	case	_	_
9	drug1	drug0	NN	_	11	com	_	_
10	Inhalation	inhalation	NN	_	11	com	_	_
11	Aerosol	aerosol	NN	_	7	ppmod	_	_
12	with	with	IN	_	16	case	_	_
13	other	other	JJ	_	16	attr	_	_
14	drug2	drug0	NN	_	16	attr	_	_
15	-containing	-containing	JJ	_	16	attr	_	_
16	drugs	drug	NNS	_	7	ppmod	_	_
17	.	.	.	_	4	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	treatment	treatment	NN	_	12	dep	_	_
3	with	with	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	eg	eg	NN	_	4	prn	_	_
7	,	,	,	_	6	p	_	_
8	rt-PA	rt-pa	NN	_	6	conj	_	_
9	or	or	CC	_	8	cc	_	_
10	drug2	drug0	NN	_	6	conj	_	_
11	)	-rrb-	-RRB-	_	6	p	_	_
12	may	may	MD	_	15	advcl	_	_
13	:	:	:	_	12	p	_	_
14	-	-	TO	_	15	aux	_	_
15	increase	increase	VB	_	0	root	_	_
16	the	the	DT	_	17	det	_	_
17	risk	risk	NN	_	15	obj	_	_
18	of	of	IN	_	20	case	_	_
19	bleeding	bleeding	JJ	_	20	attr	_	_
20	complications	complication	NNS	_	17	ppmod	_	_
21	-	-	CC	_	15	cc	_	_
22	considerably	considerably	RB	_	23	adv	_	_
23	enhance	enhance	VB	_	15	conj	_	_
24	the	the	DT	_	25	det	_	_
25	effect	effect	NN	_	23	obj	_	_
26	of	of	IN	_	27	case	_	_
27	drug3	drug0	NN	_	25	ppmod	_	_
28	on	on	IN	_	30	case	_	_
29	aPTT	aptt	NN	_	30	com	_	_
30	prolongation	prolongation	NN	_	25	ppmod	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	treatment	treatment	NN	_	16	dep	_	_
3	with	with	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	drug2	drug0	NN	_	4	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	and	and	CC	_	4	cc	_	_
9	drugs	drug	NNS	_	4	conj	_	_
10	that	that	WDT	_	11	dep	_	_
11	affect	affect	VBP	_	9	relcl	_	_
12	platelet	platelet	NN	_	13	com	_	_
13	function	function	NN	_	11	obj	_	_
14	may	may	MD	_	16	modal	_	_
15	also	also	RB	_	16	adv	_	_
16	increase	increase	VB	_	0	root	_	_
17	the	the	DT	_	18	det	_	_
18	risk	risk	NN	_	16	obj	_	_
19	of	of	IN	_	20	case	_	_
20	bleeding	bleeding	JJ	_	18	ppmod	_	_
21	.	.	.	_	16	p	_	_

1	Co-administration	co-administration	NN	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	at	at	IN	_	5	case	_	_
5	steady-state	steady-state	NN	_	1	ppmod	_	_
6	with	with	IN	_	9	case	_	_
7	a	a	DT	_	9	det	_	_
8	single	single	JJ	_	9	attr	_	_
9	dose	dose	NN	_	1	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	1	p	_	_

1	Co-administration	co-administration	NN	_	19	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	at	at	IN	_	5	case	_	_
5	steady-state	steady-state	NN	_	1	ppmod	_	_
6	with	with	IN	_	9	case	_	_
7	a	a	DT	_	9	det	_	_
8	single	single	JJ	_	9	attr	_	_
9	dose	dose	NN	_	1	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	(	-lrb-	-LRB-	_	16	p	_	_
13	2	0	CD	_	16	num	_	_
14	x	x	CC	_	16	cc	_	_
15	600	0	CD	_	16	num	_	_
16	mg	mg	NN	_	9	prn	_	_
17	tablets	tablet	NNS	_	16	attr	_	_
18	)	-rrb-	-RRB-	_	16	p	_	_
19	results	result	VBZ	_	0	root	_	_
20	in	in	IN	_	24	case	_	_
21	increased	increase	VBN	_	24	attr	_	_
22	drug3	drug0	NN	_	24	com	_	_
23	serum	serum	NN	_	24	com	_	_
24	concentrations	concentration	NNS	_	19	ppmod	_	_
25	.	.	.	_	19	p	_	_

1	Although	although	IN	_	9	mark	_	_
2	a	a	DT	_	4	det	_	_
3	dose	dose	NN	_	4	com	_	_
4	adjustment	adjustment	NN	_	9	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	is	be	VBZ	_	9	aux	_	_
8	not	not	RB	_	9	neg	_	_
9	recommended	recommend	VBN	_	36	advcl	_	_
10	when	when	WRB	_	11	adv	_	_
11	administered	administer	VBN	_	9	comp	_	_
12	in	in	IN	_	13	case	_	_
13	combination	combination	NN	_	11	ppmod	_	_
14	with	with	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	,	,	,	_	36	p	_	_
17	close	close	JJ	_	18	attr	_	_
18	monitoring	monitoring	NN	_	36	dep	_	_
19	for	for	IN	_	22	case	_	_
20	known	known	JJ	_	22	attr	_	_
21	side	side	JJ	_	22	attr	_	_
22	effects	effect	NNS	_	18	ppmod	_	_
23	of	of	IN	_	24	case	_	_
24	drug3	drug0	NN	_	22	ppmod	_	_
25	,	,	,	_	22	p	_	_
26	such	such	JJ	_	30	adv	_	_
27	as	as	IN	_	30	case	_	_
28	liver	liver	NN	_	30	com	_	_
29	enzyme	enzyme	NN	_	30	com	_	_
30	abnormalities	abnormality	NNS	_	22	ppmod	_	_
31	and	and	CC	_	30	cc	_	_
32	hearing	hearing	NN	_	33	com	_	_
33	impairment	impairment	NN	_	30	conj	_	_
34	,	,	,	_	22	p	_	_
35	is	be	VBZ	_	36	aux	_	_
36	warranted	warrant	VBN	_	0	root	_	_
37	.	.	.	_	36	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	did	do	VBD	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	affect	affect	VB	_	0	root	_	_
5	the	the	DT	_	8	det	_	_
6	prothrombin	prothrombin	NN	_	8	com	_	_
7	time	time	NN	_	8	com	_	_
8	response	response	NN	_	4	obj	_	_
9	to	to	TO	_	12	aux	_	_
10	a	a	DT	_	12	det	_	_
11	single	single	JJ	_	12	attr	_	_
12	dose	dose	NN	_	8	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	4	p	_	_

1	However	however	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	prudent	prudent	JJ	_	5	attr	_	_
4	medical	medical	JJ	_	5	attr	_	_
5	practice	practice	NN	_	6	dep	_	_
6	dictates	dictate	VBZ	_	0	root	_	_
7	careful	careful	JJ	_	8	attr	_	_
8	monitoring	monitoring	NN	_	6	obj	_	_
9	of	of	IN	_	11	case	_	_
10	prothrombin	prothrombin	NN	_	11	com	_	_
11	time	time	NN	_	8	ppmod	_	_
12	in	in	IN	_	14	case	_	_
13	all	all	DT	_	14	det	_	_
14	patients	patient	NNS	_	8	ppmod	_	_
15	treated	treat	VBN	_	14	acl	_	_
16	with	with	IN	_	17	case	_	_
17	drug1	drug0	NN	_	15	ppmod	_	_
18	and	and	CC	_	17	cc	_	_
19	drug2	drug0	NN	_	17	conj	_	_
20	concomitantly	concomitantly	RB	_	15	adv	_	_
21	.	.	.	_	6	p	_	_

1	Concurrent	concurrent	JJ	_	2	attr	_	_
2	use	use	NN	_	12	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	in	in	IN	_	9	case	_	_
8	clinical	clinical	JJ	_	9	attr	_	_
9	practice	practice	NN	_	2	ppmod	_	_
10	has	have	VBZ	_	12	aux	_	_
11	been	be	VBN	_	12	aux	_	_
12	associated	associate	VBN	_	0	root	_	_
13	with	with	IN	_	16	case	_	_
14	increased	increase	VBN	_	16	attr	_	_
15	anticoagulant	anticoagulant	JJ	_	16	attr	_	_
16	effects	effect	NNS	_	12	ppmod	_	_
17	.	.	.	_	12	p	_	_

1	Drug	drug	NN	_	3	com	_	_
2	interaction	interaction	NN	_	3	com	_	_
3	studies	study	NNS	_	5	dep	_	_
4	were	be	VBD	_	5	aux	_	_
5	performed	performed	VBN	_	0	root	_	_
6	with	with	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	other	other	JJ	_	10	attr	_	_
10	drugs	drug	NNS	_	7	conj	_	_
11	likely	likely	RB	_	14	adv	_	_
12	to	to	TO	_	14	aux	_	_
13	be	be	VB	_	14	aux	_	_
14	co-administered	co-administered	VBN	_	5	comp	_	_
15	.	.	.	_	5	p	_	_

1	When	when	WRB	_	2	adv	_	_
2	used	use	VBN	_	8	advcl	_	_
3	in	in	IN	_	5	case	_	_
4	therapeutic	therapeutic	JJ	_	5	attr	_	_
5	doses	dose	NNS	_	2	ppmod	_	_
6	,	,	,	_	8	p	_	_
7	drug1	drug0	NN	_	8	dep	_	_
8	had	have	VBD	_	0	root	_	_
9	a	a	DT	_	11	det	_	_
10	modest	modest	JJ	_	11	attr	_	_
11	effect	effect	NN	_	8	obj	_	_
12	on	on	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	pharmacokinetics	pharmacokinetics	NNS	_	8	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	,	,	,	_	16	p	_	_
18	drug3	drug0	NN	_	16	conj	_	_
19	,	,	,	_	18	p	_	_
20	drug4	drug0	NN	_	16	conj	_	_
21	,	,	,	_	20	p	_	_
22	drug5	drug0	NN	_	16	conj	_	_
23	,	,	,	_	22	p	_	_
24	drug6	drug0	NN	_	16	conj	_	_
25	,	,	,	_	24	p	_	_
26	drug7	drug0	NN	_	16	conj	_	_
27	,	,	,	_	26	p	_	_
28	drug8	drug0	NN	_	16	conj	_	_
29	,	,	,	_	28	p	_	_
30	drug9	drug0	NN	_	16	conj	_	_
31	,	,	,	_	30	p	_	_
32	drug10	drug0	NN	_	16	conj	_	_
33	,	,	,	_	32	p	_	_
34	drug11	drug0	NN	_	16	conj	_	_
35	,	,	,	_	34	p	_	_
36	drug12	drug0	CD	_	16	conj	_	_
37	(	-lrb-	-LRB-	_	38	p	_	_
38	intravenous	intravenous	JJ	_	36	prn	_	_
39	and	and	CC	_	38	cc	_	_
40	oral	oral	JJ	_	38	conj	_	_
41	)	-rrb-	-RRB-	_	38	p	_	_
42	,	,	,	_	36	p	_	_
43	drug13	drug0	CD	_	36	appo	_	_
44	,	,	,	_	36	p	_	_
45	drug14	drug0	CD	_	36	appo	_	_
46	/	/	:	_	36	p	_	_
47	drug15	drug0	CD	_	36	appo	_	_
48	or	or	CC	_	36	cc	_	_
49	drug16	drug0	NN	_	16	conj	_	_
50	.	.	.	_	8	p	_	_

1	Co-administration	co-administration	NN	_	6	dep	_	_
2	with	with	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	or	or	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	had	have	VBD	_	0	root	_	_
7	a	a	DT	_	9	det	_	_
8	modest	modest	JJ	_	9	attr	_	_
9	effect	effect	NN	_	6	obj	_	_
10	on	on	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	pharmacokinetics	pharmacokinetics	NNS	_	6	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug3	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	6	p	_	_

1	No	no	DT	_	3	det	_	_
2	dosage	dosage	JJ	_	3	attr	_	_
3	adjustment	adjustment	NN	_	8	dep	_	_
4	of	of	IN	_	6	case	_	_
5	either	either	DT	_	6	det	_	_
6	drug	drug	NN	_	3	ppmod	_	_
7	is	be	VBZ	_	8	aux	_	_
8	recommended	recommend	VBN	_	0	root	_	_
9	when	when	WRB	_	13	adv	_	_
10	drug1	drug0	NN	_	13	dep	_	_
11	is	be	VBZ	_	13	aux	_	_
12	co	co	RB	_	13	adv	_	_
13	administered	administer	VBN	_	8	comp	_	_
14	with	with	IN	_	15	case	_	_
15	any	any	DT	_	13	ppmod	_	_
16	of	of	IN	_	19	case	_	_
17	the	the	DT	_	19	det	_	_
18	above	above	JJ	_	19	attr	_	_
19	agents	agent	NNS	_	15	ppmod	_	_
20	.	.	.	_	8	p	_	_

1	Interactions	interaction	NNS	_	10	dep	_	_
2	with	with	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	drugs	drug	NNS	_	1	ppmod	_	_
5	listed	list	VBN	_	4	acl	_	_
6	below	below	IN	_	5	case	_	_
7	have	have	VBP	_	10	aux	_	_
8	not	not	RB	_	10	neg	_	_
9	been	be	VBN	_	10	aux	_	_
10	reported	report	VBN	_	0	root	_	_
11	in	in	IN	_	13	case	_	_
12	clinical	clinical	JJ	_	13	attr	_	_
13	trials	trial	NNS	_	10	ppmod	_	_
14	with	with	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	;	;	:	_	10	p	_	_

1	however	however	RB	_	10	adv	_	_
2	,	,	,	_	10	p	_	_
3	no	no	DT	_	7	det	_	_
4	specific	specific	JJ	_	7	attr	_	_
5	drug	drug	NN	_	7	com	_	_
6	interaction	interaction	NN	_	7	com	_	_
7	studies	study	NNS	_	10	dep	_	_
8	have	have	VBP	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	performed	performed	VBN	_	0	root	_	_
11	to	to	TO	_	12	aux	_	_
12	evaluate	evaluate	VB	_	10	comp	_	_
13	potential	potential	JJ	_	15	attr	_	_
14	drug-drug	drug-drug	JJ	_	15	attr	_	_
15	interaction	interaction	NN	_	12	obj	_	_
16	.	.	.	_	10	p	_	_

1	Nonetheless	nonetheless	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	they	they	PRP	_	6	dep	_	_
4	have	have	VBP	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	observed	observe	VBN	_	0	root	_	_
7	with	with	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	.	.	.	_	6	p	_	_

1	Until	until	IN	_	5	mark	_	_
2	further	far	JJ	_	3	attr	_	_
3	data	datum	NNS	_	5	dep	_	_
4	are	be	VBP	_	5	aux	_	_
5	developed	develop	VBN	_	22	advcl	_	_
6	regarding	regard	VBG	_	5	comp	_	_
7	drug	drug	NN	_	8	com	_	_
8	interactions	interaction	NNS	_	6	obj	_	_
9	when	when	WRB	_	15	adv	_	_
10	drug1	drug0	NN	_	15	dep	_	_
11	and	and	CC	_	10	cc	_	_
12	these	these	DT	_	13	det	_	_
13	drugs	drug	NNS	_	10	conj	_	_
14	are	be	VBP	_	15	aux	_	_
15	used	use	VBN	_	5	comp	_	_
16	concomitantly	concomitantly	RB	_	15	adv	_	_
17	,	,	,	_	22	p	_	_
18	careful	careful	JJ	_	19	attr	_	_
19	monitoring	monitoring	NN	_	22	dep	_	_
20	of	of	IN	_	21	case	_	_
21	patients	patient	NNS	_	19	ppmod	_	_
22	is	be	VBZ	_	26	advcl	_	_
23	advised	advised	JJ	_	22	dep	_	_
24	:	:	:	_	26	p	_	_
25	drug2	drug0	NN	_	26	dep	_	_
26	elevated	elevate	VBD	_	0	root	_	_
27	drug3	drug0	NN	_	28	com	_	_
28	concentrations	concentration	NNS	_	26	obj	_	_
29	.	.	.	_	26	p	_	_

1	drug1	drug0	NN	_	7	dep	_	_
2	or	or	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	6	attr	_	_
4	acute	acute	JJ	_	6	attr	_	_
5	ergot	ergot	NN	_	6	com	_	_
6	toxicity	toxicity	NN	_	1	conj	_	_
7	characterized	characterize	VBN	_	0	root	_	_
8	by	by	IN	_	11	case	_	_
9	severe	severe	JJ	_	11	attr	_	_
10	peripheral	peripheral	JJ	_	11	attr	_	_
11	vasospasm	vasospasm	NN	_	7	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	dysesthesia	dysesthesia	NN	_	11	conj	_	_
14	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	and	and	CC	_	3	cc	_	_
5	drug3	drug0	NN	_	1	conj	_	_
6	concentrations	concentration	NNS	_	0	root	_	_
7	.	.	.	_	6	p	_	_

1	Laboratory	laboratory	NN	_	3	com	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	5	dep	_	_
4	There	there	RB	_	5	adv	_	_
5	are	be	VBP	_	0	root	_	_
6	no	no	DT	_	10	det	_	_
7	reported	report	VBN	_	10	attr	_	_
8	laboratory	laboratory	NN	_	10	com	_	_
9	test	test	NN	_	10	com	_	_
10	interactions	interaction	NNS	_	5	obj	_	_
11	.	.	.	_	5	p	_	_

1	Repeat	repeat	NN	_	3	com	_	_
2	Treatment	treatment	NN	_	3	com	_	_
3	Studies	study	NNS	_	15	dep	_	_
4	evaluating	evaluate	VBG	_	3	acl	_	_
5	the	the	DT	_	6	det	_	_
6	use	use	NN	_	4	obj	_	_
7	of	of	IN	_	9	case	_	_
8	repeated	repeated	JJ	_	9	attr	_	_
9	courses	course	NNS	_	6	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	have	have	VBP	_	15	aux	_	_
13	not	not	RB	_	15	neg	_	_
14	been	be	VBN	_	15	aux	_	_
15	conducted	conduct	VBN	_	0	root	_	_
16	.	.	.	_	15	p	_	_

1	Oral	oral	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	5	dep	_	_
3	:	:	:	_	2	p	_	_
4	drug2	drug0	NN	_	2	appo	_	_
5	appear	appear	VBP	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	increase	increase	VB	_	5	comp	_	_
8	catabolism	catabolism	NN	_	7	obj	_	_
9	of	of	IN	_	13	case	_	_
10	vitamin	vitamin	NN	_	13	com	_	_
11	K-dependent	k-dependent	NN	_	13	com	_	_
12	clotting	clotting	NN	_	13	com	_	_
13	factors	factor	NNS	_	8	ppmod	_	_
14	.	.	.	_	5	p	_	_

1	If	if	IN	_	7	mark	_	_
2	oral	oral	JJ	_	3	attr	_	_
3	drug1	drug0	NN	_	7	dep	_	_
4	are	be	VBP	_	7	aux	_	_
5	also	also	RB	_	7	adv	_	_
6	being	be	VBG	_	7	aux	_	_
7	given	give	VBN	_	16	advcl	_	_
8	,	,	,	_	16	p	_	_
9	compensatory	compensatory	JJ	_	10	attr	_	_
10	increases	increase	NNS	_	16	dep	_	_
11	in	in	IN	_	14	case	_	_
12	clotting	clotting	JJ	_	14	attr	_	_
13	factor	factor	NN	_	14	com	_	_
14	synthesis	synthesis	NN	_	10	ppmod	_	_
15	are	be	VBP	_	16	aux	_	_
16	impaired	impair	VBN	_	0	root	_	_
17	.	.	.	_	16	p	_	_

1	Patients	patient	NNS	_	16	dep	_	_
2	stabilized	stabilize	VBN	_	1	acl	_	_
3	on	on	IN	_	5	case	_	_
4	oral	oral	JJ	_	5	attr	_	_
5	drug1	drug0	NN	_	2	ppmod	_	_
6	who	who	WP	_	8	dep	_	_
7	are	be	VBP	_	8	aux	_	_
8	found	find	VBN	_	1	relcl	_	_
9	to	to	TO	_	10	aux	_	_
10	require	require	VB	_	8	comp	_	_
11	drug2	drug0	NN	_	13	com	_	_
12	replacement	replacement	NN	_	13	com	_	_
13	therapy	therapy	NN	_	10	obj	_	_
14	should	should	MD	_	16	modal	_	_
15	be	be	VB	_	16	aux	_	_
16	watched	watch	VBD	_	0	root	_	_
17	very	very	RB	_	18	com	_	_
18	closely	closely	RB	_	16	adv	_	_
19	when	when	WRB	_	22	adv	_	_
20	thyroid	thyroid	NN	_	22	dep	_	_
21	is	be	VBZ	_	22	aux	_	_
22	started	start	VBN	_	16	comp	_	_
23	.	.	.	_	16	p	_	_

1	If	if	IN	_	4	mark	_	_
2	a	a	DT	_	3	det	_	_
3	patient	patient	NN	_	4	dep	_	_
4	is	be	VBZ	_	9	advcl	_	_
5	truly	truly	RB	_	6	adv	_	_
6	hypothyroid	hypothyroid	JJ	_	4	dep	_	_
7	,	,	,	_	9	p	_	_
8	it	it	PRP	_	9	dep	_	_
9	is	be	VBZ	_	0	root	_	_
10	likely	likely	JJ	_	9	dep	_	_
11	that	that	IN	_	19	mark	_	_
12	a	a	DT	_	13	det	_	_
13	reduction	reduction	NN	_	19	dep	_	_
14	in	in	IN	_	16	case	_	_
15	drug1	drug0	NN	_	16	com	_	_
16	dosage	dosage	NN	_	13	ppmod	_	_
17	will	will	MD	_	19	modal	_	_
18	be	be	VB	_	19	aux	_	_
19	required	require	VBN	_	10	comp	_	_
20	.	.	.	_	9	p	_	_

1	No	no	DT	_	3	det	_	_
2	special	special	JJ	_	3	attr	_	_
3	precautions	precaution	NNS	_	4	dep	_	_
4	appear	appear	VBP	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	be	be	VB	_	4	comp	_	_
7	necessary	necessary	JJ	_	6	dep	_	_
8	when	when	WRB	_	13	adv	_	_
9	oral	oral	JJ	_	11	attr	_	_
10	anticoagulant	anticoagulant	NN	_	11	com	_	_
11	therapy	therapy	NN	_	13	dep	_	_
12	is	be	VBZ	_	13	aux	_	_
13	begun	begin	VBN	_	6	comp	_	_
14	in	in	IN	_	16	case	_	_
15	a	a	DT	_	16	det	_	_
16	patient	patient	NN	_	13	ppmod	_	_
17	already	already	RB	_	18	adv	_	_
18	stabilized	stabilize	VBN	_	16	acl	_	_
19	on	on	IN	_	23	case	_	_
20	maintenance	maintenance	NN	_	23	com	_	_
21	thyroid	thyroid	NN	_	23	com	_	_
22	replacement	replacement	NN	_	23	com	_	_
23	therapy	therapy	NN	_	18	ppmod	_	_
24	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	or	or	CC	_	1	cc	_	_
3	Oral	oral	JJ	_	4	attr	_	_
4	drug2	drug0	NN	_	1	conj	_	_
5	:	:	:	_	1	p	_	_
6	Initiating	initiate	VBG	_	9	attr	_	_
7	thyroid	thyroid	NN	_	9	com	_	_
8	replacement	replacement	NN	_	9	com	_	_
9	therapy	therapy	NN	_	11	dep	_	_
10	may	may	MD	_	11	modal	_	_
11	cause	cause	VB	_	1	acl	_	_
12	increases	increase	NNS	_	11	obj	_	_
13	in	in	IN	_	18	case	_	_
14	drug3	drug0	JJ	_	18	attr	_	_
15	or	or	CC	_	14	cc	_	_
16	oral	oral	JJ	_	14	conj	_	_
17	drug4	drug0	NN	_	18	com	_	_
18	requirements	requirement	NNS	_	12	ppmod	_	_
19	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	effects	effect	NNS	_	6	dep	_	_
3	seen	see	VBN	_	2	acl	_	_
4	are	be	VBP	_	6	aux	_	_
5	poorly	poorly	RB	_	6	adv	_	_
6	understood	understand	VBN	_	0	root	_	_
7	and	and	CC	_	6	cc	_	_
8	depend	depend	VB	_	6	conj	_	_
9	upon	upon	IN	_	11	case	_	_
10	a	a	DT	_	11	det	_	_
11	variety	variety	NN	_	8	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	factors	factor	NNS	_	11	ppmod	_	_
14	such	such	JJ	_	16	adv	_	_
15	as	as	IN	_	16	case	_	_
16	dose	dose	NN	_	13	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	type	type	NN	_	16	conj	_	_
19	of	of	IN	_	20	case	_	_
20	drug1	drug0	NN	_	16	ppmod	_	_
21	and	and	CC	_	16	cc	_	_
22	endocrine	endocrine	JJ	_	23	attr	_	_
23	status	status	NN	_	16	conj	_	_
24	of	of	IN	_	26	case	_	_
25	the	the	DT	_	26	det	_	_
26	patient	patient	NN	_	16	ppmod	_	_
27	.	.	.	_	6	p	_	_

1	Patients	patient	NNS	_	10	dep	_	_
2	receiving	receive	VBG	_	1	acl	_	_
3	drug1	drug0	NN	_	2	obj	_	_
4	or	or	CC	_	3	cc	_	_
5	oral	oral	JJ	_	6	attr	_	_
6	drug2	drug0	NN	_	3	conj	_	_
7	should	should	MD	_	10	modal	_	_
8	be	be	VB	_	10	aux	_	_
9	closely	closely	RB	_	10	adv	_	_
10	watched	watch	VBD	_	0	root	_	_
11	during	during	IN	_	12	case	_	_
12	initiation	initiation	NN	_	10	ppmod	_	_
13	of	of	IN	_	16	case	_	_
14	thyroid	thyroid	NN	_	16	com	_	_
15	replacement	replacement	NN	_	16	com	_	_
16	therapy	therapy	NN	_	12	ppmod	_	_
17	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	binds	bind	VBZ	_	0	root	_	_
5	both	both	CC	_	6	cc	_	_
6	drug3	drug0	NN	_	4	obj	_	_
7	and	and	CC	_	6	cc	_	_
8	drug4	drug0	NN	_	6	conj	_	_
9	in	in	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	intestine	intestine	NN	_	6	ppmod	_	_
12	,	,	,	_	4	p	_	_
13	thus	thus	RB	_	14	adv	_	_
14	impairing	impair	VBG	_	4	comp	_	_
15	absorption	absorption	NN	_	14	obj	_	_
16	of	of	IN	_	18	case	_	_
17	these	these	DT	_	18	det	_	_
18	drug5	drug0	NNS	_	15	ppmod	_	_
19	.	.	.	_	4	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	studies	study	NNS	_	4	dep	_	_
4	indicate	indicate	VBP	_	0	root	_	_
5	that	that	IN	_	11	mark	_	_
6	the	the	DT	_	7	det	_	_
7	binding	binding	NN	_	11	dep	_	_
8	is	be	VBZ	_	11	aux	_	_
9	not	not	RB	_	11	neg	_	_
10	easily	easily	RB	_	11	adv	_	_
11	removed	remove	VBN	_	4	comp	_	_
12	.	.	.	_	4	p	_	_

1	Therefore	therefore	RB	_	8	adv	_	_
2	,	,	,	_	8	p	_	_
3	4	0	CD	_	6	num	_	_
4	to	to	TO	_	3	cc	_	_
5	5	0	CD	_	3	conj	_	_
6	hours	hour	NNS	_	8	dep	_	_
7	should	should	MD	_	8	modal	_	_
8	elapse	elapse	VB	_	0	root	_	_
9	between	between	IN	_	10	case	_	_
10	administration	administration	NN	_	8	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	drug2	drug0	NN	_	12	conj	_	_
15	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	7	dep	_	_
2	,	,	,	_	1	p	_	_
3	Oral	oral	JJ	_	6	attr	_	_
4	drug2	drug0	NN	_	6	attr	_	_
5	:	:	:	_	6	p	_	_
6	drug3	drug0	NN	_	1	appo	_	_
7	tend	tend	VBP	_	0	root	_	_
8	to	to	TO	_	9	aux	_	_
9	increase	increase	VB	_	7	comp	_	_
10	serum	serum	NN	_	12	com	_	_
11	thyroxine-binding	thyroxine-binding	NN	_	12	com	_	_
12	globulin	globulin	NN	_	9	obj	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	TBg	tbg	NN	_	12	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	.	.	.	_	7	p	_	_

1	In	in	IN	_	3	case	_	_
2	a	a	DT	_	3	det	_	_
3	patient	patient	NN	_	20	ppmod	_	_
4	with	with	IN	_	8	case	_	_
5	a	a	DT	_	8	det	_	_
6	nonfunctioning	nonfunctioning	JJ	_	8	attr	_	_
7	thyroid	thyroid	NN	_	8	com	_	_
8	gland	gland	NN	_	3	ppmod	_	_
9	who	who	WP	_	11	dep	_	_
10	is	be	VBZ	_	11	aux	_	_
11	receiving	receive	VBG	_	3	relcl	_	_
12	thyroid	thyroid	NN	_	14	com	_	_
13	replacement	replacement	NN	_	14	com	_	_
14	therapy	therapy	NN	_	11	obj	_	_
15	,	,	,	_	20	p	_	_
16	free	free	JJ	_	17	attr	_	_
17	drug1	drug0	NN	_	20	dep	_	_
18	may	may	MD	_	20	modal	_	_
19	be	be	VB	_	20	aux	_	_
20	decreased	decrease	VBN	_	0	root	_	_
21	when	when	WRB	_	24	adv	_	_
22	drug2	drug0	NNS	_	24	dep	_	_
23	are	be	VBP	_	24	aux	_	_
24	started	start	VBN	_	20	comp	_	_
25	thus	thus	RB	_	26	adv	_	_
26	increasing	increase	VBG	_	24	comp	_	_
27	drug3	drug0	NN	_	28	com	_	_
28	requirements	requirement	NNS	_	26	obj	_	_
29	.	.	.	_	20	p	_	_

1	However	however	RB	_	18	adv	_	_
2	,	,	,	_	18	p	_	_
3	if	if	IN	_	10	mark	_	_
4	the	the	DT	_	7	det	_	_
5	patients	patient	NNS	_	7	com	_	_
6	thyroid	thyroid	NN	_	7	com	_	_
7	gland	gland	NN	_	10	dep	_	_
8	has	have	VBZ	_	10	lv	_	_
9	sufficient	sufficient	JJ	_	10	attr	_	_
10	function	function	NN	_	18	advcl	_	_
11	,	,	,	_	18	p	_	_
12	the	the	DT	_	16	det	_	_
13	decreased	decrease	VBN	_	16	attr	_	_
14	free	free	JJ	_	16	attr	_	_
15	drug1	drug0	NN	_	16	com	_	_
16	e	e	NN	_	18	dep	_	_
17	will	will	MD	_	18	modal	_	_
18	result	result	VB	_	0	root	_	_
19	in	in	IN	_	22	case	_	_
20	a	a	DT	_	22	det	_	_
21	compensatory	compensatory	JJ	_	22	attr	_	_
22	increase	increase	NN	_	18	ppmod	_	_
23	in	in	IN	_	25	case	_	_
24	thyroxine	thyroxine	JJ	_	25	attr	_	_
25	output	output	NN	_	22	ppmod	_	_
26	by	by	IN	_	28	case	_	_
27	the	the	DT	_	28	det	_	_
28	thyroid	thyroid	NN	_	25	ppmod	_	_
29	.	.	.	_	18	p	_	_

1	Therefore	therefore	RB	_	16	adv	_	_
2	,	,	,	_	16	p	_	_
3	patients	patient	NNS	_	16	dep	_	_
4	without	without	IN	_	8	case	_	_
5	a	a	DT	_	8	det	_	_
6	functioning	function	VBG	_	8	attr	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	gland	gland	NN	_	3	ppmod	_	_
9	who	who	WP	_	10	dep	_	_
10	are	be	VBP	_	3	relcl	_	_
11	on	on	IN	_	14	case	_	_
12	thyroid	thyroid	NN	_	14	com	_	_
13	replacement	replacement	NN	_	14	com	_	_
14	therapy	therapy	NN	_	10	ppmod	_	_
15	may	may	MD	_	16	modal	_	_
16	need	need	VBP	_	0	root	_	_
17	to	to	TO	_	18	aux	_	_
18	increase	increase	VB	_	16	comp	_	_
19	their	their	PRP$	_	21	poss	_	_
20	thyroid	thyroid	NN	_	21	com	_	_
21	dose	dose	NN	_	18	obj	_	_
22	if	if	IN	_	30	mark	_	_
23	drug2	drug0	NN	_	28	attr	_	_
24	or	or	CC	_	23	cc	_	_
25	drug3	drug0	NN	_	23	conj	_	_
26	-containing	-containing	JJ	_	28	attr	_	_
27	oral	oral	JJ	_	28	attr	_	_
28	drug4	drug0	NNS	_	30	dep	_	_
29	are	be	VBP	_	30	aux	_	_
30	given	give	VBN	_	18	comp	_	_
31	.	.	.	_	16	p	_	_

1	drug1	drug0	NN	_	24	dep	_	_
2	:	:	:	_	1	p	_	_
3	Use	use	NN	_	12	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drug3	drug0	NN	_	3	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	other	other	JJ	_	10	attr	_	_
10	drug4	drug0	NNS	_	7	conj	_	_
11	may	may	MD	_	12	modal	_	_
12	increase	increase	VB	_	1	acl	_	_
13	receptor	receptor	NN	_	14	com	_	_
14	sensitivity	sensitivity	NN	_	12	obj	_	_
15	and	and	CC	_	12	cc	_	_
16	enhance	enhance	VB	_	12	conj	_	_
17	antidepressant	antidepressant	JJ	_	18	attr	_	_
18	activity	activity	NN	_	16	obj	_	_
19	transient	transient	JJ	_	21	attr	_	_
20	cardiac	cardiac	JJ	_	21	attr	_	_
21	arrhythmias	arrhythmia	NNS	_	12	obj	_	_
22	have	have	VBP	_	24	aux	_	_
23	been	be	VBN	_	24	aux	_	_
24	observed	observe	VBN	_	0	root	_	_
25	.	.	.	_	24	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	activity	activity	NN	_	6	dep	_	_
3	may	may	MD	_	6	modal	_	_
4	also	also	RB	_	6	adv	_	_
5	be	be	VB	_	6	aux	_	_
6	enhanced	enhance	VBN	_	0	root	_	_
7	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	may	may	MD	_	5	modal	_	_
5	potentiate	potentiate	VB	_	0	root	_	_
6	the	the	DT	_	8	det	_	_
7	toxic	toxic	JJ	_	8	attr	_	_
8	effects	effect	NNS	_	5	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug3	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	5	p	_	_

1	Thyroid	thyroid	NN	_	3	attr	_	_
2	hormonal	hormonal	JJ	_	3	attr	_	_
3	replacement	replacement	NN	_	4	dep	_	_
4	increases	increase	VBZ	_	0	root	_	_
5	metabolic	metabolic	JJ	_	6	attr	_	_
6	rate	rate	NN	_	4	obj	_	_
7	,	,	,	_	6	p	_	_
8	which	which	WDT	_	9	dep	_	_
9	requires	require	VBZ	_	6	relcl	_	_
10	an	an	DT	_	11	det	_	_
11	increase	increase	NN	_	9	obj	_	_
12	in	in	IN	_	14	case	_	_
13	drug1	drug0	JJ	_	14	attr	_	_
14	dosage	dosage	NN	_	11	ppmod	_	_
15	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	When	when	WRB	_	4	adv	_	_
4	administered	administer	VBN	_	15	advcl	_	_
5	to	to	TO	_	6	aux	_	_
6	patients	patient	NNS	_	4	ppmod	_	_
7	on	on	IN	_	9	case	_	_
8	a	a	DT	_	9	det	_	_
9	drug2	drug0	NN	_	4	ppmod	_	_
10	,	,	,	_	15	p	_	_
11	this	this	DT	_	13	det	_	_
12	parenteral	parenteral	JJ	_	13	attr	_	_
13	drug3	drug0	NN	_	15	dep	_	_
14	may	may	MD	_	15	modal	_	_
15	cause	cause	VB	_	1	acl	_	_
16	hypertension	hypertension	NN	_	15	obj	_	_
17	and	and	CC	_	16	cc	_	_
18	tachycardia	tachycardia	NN	_	16	conj	_	_
19	.	.	.	_	1	p	_	_

1	Use	use	NN	_	6	dep	_	_
2	with	with	IN	_	3	case	_	_
3	caution	caution	NN	_	1	ppmod	_	_
4	and	and	CC	_	6	cc	_	_
5	be	be	VB	_	6	aux	_	_
6	prepared	prepare	VBN	_	0	root	_	_
7	to	to	TO	_	8	aux	_	_
8	treat	treat	VB	_	6	comp	_	_
9	hypertension	hypertension	NN	_	8	obj	_	_
10	,	,	,	_	6	p	_	_
11	if	if	IN	_	12	mark	_	_
12	necessary	necessary	JJ	_	6	comp	_	_
13	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	s	s	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	drug2	drug0	NN	_	5	dep	_	_
5	increases	increase	VBZ	_	2	acl	_	_
6	the	the	DT	_	8	det	_	_
7	adrenergic	adrenergic	JJ	_	8	attr	_	_
8	effect	effect	NN	_	5	obj	_	_
9	of	of	IN	_	10	case	_	_
10	catecholamines	catecholamine	NNS	_	8	ppmod	_	_
11	such	such	JJ	_	13	adv	_	_
12	as	as	IN	_	13	case	_	_
13	drug3	drug0	NN	_	10	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	drug4	drug0	NN	_	13	conj	_	_
16	.	.	.	_	2	p	_	_

1	Therefore	therefore	RB	_	11	adv	_	_
2	,	,	,	_	11	p	_	_
3	injection	injection	NN	_	11	dep	_	_
4	of	of	IN	_	6	case	_	_
5	these	these	DT	_	6	det	_	_
6	agents	agent	NNS	_	3	ppmod	_	_
7	into	into	IN	_	8	case	_	_
8	patients	patient	NNS	_	3	ppmod	_	_
9	receiving	receive	VBG	_	8	acl	_	_
10	drug1	drug0	NN	_	9	obj	_	_
11	increases	increase	VBZ	_	0	root	_	_
12	the	the	DT	_	13	det	_	_
13	risk	risk	NN	_	11	obj	_	_
14	of	of	IN	_	15	case	_	_
15	precipitating	precipitate	VBG	_	13	ppmod	_	_
16	coronary	coronary	JJ	_	17	attr	_	_
17	insufficiency	insufficiency	NN	_	15	obj	_	_
18	especially	especially	RB	_	20	adv	_	_
19	in	in	IN	_	20	case	_	_
20	patients	patient	NNS	_	15	ppmod	_	_
21	with	with	IN	_	24	case	_	_
22	coronary	coronary	JJ	_	24	attr	_	_
23	artery	artery	NN	_	24	com	_	_
24	disease	disease	NN	_	20	ppmod	_	_
25	.	.	.	_	11	p	_	_

1	Careful	careful	JJ	_	2	attr	_	_
2	observation	observation	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	required	require	VBN	_	0	root	_	_
5	.	.	.	_	4	p	_	_

1	Drug/Laboratory	drug/laboratory	JJ	_	3	attr	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	10	dep	_	_
4	The	the	DT	_	6	det	_	_
5	following	following	JJ	_	6	attr	_	_
6	drugs	drug	NNS	_	3	appo	_	_
7	or	or	CC	_	6	cc	_	_
8	moieties	moiety	NNS	_	6	conj	_	_
9	are	be	VBP	_	10	aux	_	_
10	known	know	VBN	_	0	root	_	_
11	to	to	TO	_	12	aux	_	_
12	interfere	interfere	VB	_	10	comp	_	_
13	with	with	IN	_	15	case	_	_
14	laboratory	laboratory	NN	_	15	com	_	_
15	tests	test	NNS	_	12	ppmod	_	_
16	performed	performed	VBN	_	15	acl	_	_
17	in	in	IN	_	18	case	_	_
18	patients	patient	NNS	_	16	ppmod	_	_
19	on	on	IN	_	21	case	_	_
20	drug1	drug0	NN	_	21	com	_	_
21	therapy	therapy	NN	_	18	ppmod	_	_
22	:	:	:	_	15	p	_	_
23	drug2	drug0	NN	_	15	appo	_	_
24	,	,	,	_	23	p	_	_
25	drug3	drug0	NN	_	23	conj	_	_
26	,	,	,	_	25	p	_	_
27	drug4	drug0	NN	_	23	conj	_	_
28	,	,	,	_	27	p	_	_
29	oral	oral	JJ	_	32	attr	_	_
30	drug5	drug0	NN	_	32	com	_	_
31	containing	containing	NN	_	32	com	_	_
32	drug6	drug0	NN	_	23	conj	_	_
33	,	,	,	_	32	p	_	_
34	drug7	drug0	NN	_	36	attr	_	_
35	-containing	-containing	JJ	_	36	attr	_	_
36	preparations	preparation	NNS	_	23	conj	_	_
37	and	and	CC	_	36	cc	_	_
38	the	the	DT	_	40	det	_	_
39	numerous	numerous	JJ	_	40	attr	_	_
40	preparations	preparation	NNS	_	23	conj	_	_
41	containing	contain	VBG	_	40	acl	_	_
42	drug8	drug0	NN	_	41	obj	_	_
43	.	.	.	_	10	p	_	_

1	-	-	CC	_	2	cc	_	_
2	Changes	change	NNS	_	8	dep	_	_
3	in	in	IN	_	5	case	_	_
4	TBg	tbg	NN	_	5	com	_	_
5	concentration	concentration	NN	_	2	ppmod	_	_
6	should	should	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	taken	take	VBN	_	0	root	_	_
9	into	into	IN	_	10	case	_	_
10	consideration	consideration	NN	_	8	ppmod	_	_
11	in	in	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	interpretation	interpretation	NN	_	8	ppmod	_	_
14	of	of	IN	_	18	case	_	_
15	T4	t0	NN	_	18	attr	_	_
16	and	and	CC	_	15	cc	_	_
17	T3	t0	NN	_	15	conj	_	_
18	values	value	NNS	_	13	ppmod	_	_
19	.	.	.	_	8	p	_	_

1	In	in	IN	_	3	case	_	_
2	such	such	JJ	_	3	attr	_	_
3	cases	case	NNS	_	13	ppmod	_	_
4	,	,	,	_	13	p	_	_
5	the	the	DT	_	10	det	_	_
6	unbound	unbound	JJ	_	10	attr	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	free	free	JJ	_	6	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	hormone	hormone	NN	_	13	dep	_	_
11	should	should	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	measured	measure	VBN	_	0	root	_	_
14	.	.	.	_	13	p	_	_

1	Pregnancy	pregnancy	NN	_	2	com	_	_
2	drug1	drug0	NN	_	8	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	drug2	drug0	NN	_	7	attr	_	_
5	-containing	-containing	JJ	_	7	attr	_	_
6	oral	oral	JJ	_	7	attr	_	_
7	drug3	drug0	NN	_	2	conj	_	_
8	increase	increase	VBP	_	0	root	_	_
9	TBg	tbg	NN	_	10	com	_	_
10	concentrations	concentration	NNS	_	8	obj	_	_
11	.	.	.	_	8	p	_	_

1	TBg	tbg	NN	_	5	dep	_	_
2	may	may	MD	_	5	modal	_	_
3	also	also	RB	_	5	adv	_	_
4	be	be	VB	_	5	aux	_	_
5	increased	increase	VBN	_	0	root	_	_
6	during	during	IN	_	8	case	_	_
7	infectious	infectious	JJ	_	8	attr	_	_
8	hepatitis	hepatitis	NN	_	5	ppmod	_	_
9	.	.	.	_	5	p	_	_

1	Decreases	decrease	NNS	_	6	dep	_	_
2	in	in	IN	_	4	case	_	_
3	TBg	tbg	NN	_	4	com	_	_
4	concentrations	concentration	NNS	_	1	ppmod	_	_
5	are	be	VBP	_	6	aux	_	_
6	observed	observe	VBN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	nephrosis	nephrosis	NN	_	6	ppmod	_	_
9	,	,	,	_	8	p	_	_
10	acromegaly	acromegaly	NN	_	8	appo	_	_
11	and	and	CC	_	8	cc	_	_
12	after	after	IN	_	13	case	_	_
13	drug1	drug0	NN	_	8	conj	_	_
14	or	or	CC	_	13	cc	_	_
15	drug2	drug0	NN	_	16	com	_	_
16	therapy	therapy	NN	_	13	conj	_	_
17	.	.	.	_	6	p	_	_

1	Familial	familial	JJ	_	2	attr	_	_
2	hyper-	hyper-	JJ	_	7	dep	_	_
3	or	or	CC	_	2	cc	_	_
4	hypo-thyroxine-binding-globulinemias	hypo-thyroxine-binding-globulinemias	JJ	_	2	conj	_	_
5	have	have	VBP	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	described	describe	VBN	_	0	root	_	_
8	.	.	.	_	7	p	_	_

1	The	the	DT	_	2	det	_	_
2	incidence	incidence	NN	_	6	dep	_	_
3	of	of	IN	_	5	case	_	_
4	TBg	tbg	NN	_	5	com	_	_
5	deficiency	deficiency	NN	_	2	ppmod	_	_
6	approximates	approximate	VBZ	_	0	root	_	_
7	1	0	CD	_	6	obj	_	_
8	in	in	IN	_	9	case	_	_
9	9000	0	CD	_	7	ppmod	_	_
10	.	.	.	_	6	p	_	_

1	The	the	DT	_	2	det	_	_
2	binding	binding	NN	_	12	dep	_	_
3	of	of	IN	_	4	case	_	_
4	thyroxine	thyroxine	NN	_	2	ppmod	_	_
5	by	by	IN	_	7	case	_	_
6	thyroxine-binding	thyroxine-binding	JJ	_	7	attr	_	_
7	prealbumin	prealbumin	NN	_	2	ppmod	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	TBPA	tbpa	NN	_	7	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	is	be	VBZ	_	12	aux	_	_
12	inhibited	inhibit	VBN	_	0	root	_	_
13	by	by	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_

1	.	.	.	_	0	root	_	_

1	-	-	CC	_	2	cc	_	_
2	Medicinal	medicinal	NN	_	0	root	_	_
3	or	or	CC	_	2	cc	_	_
4	dietary	dietary	NN	_	5	com	_	_
5	drug1	drug0	NN	_	2	conj	_	_
6	interferes	interfere	VBZ	_	2	acl	_	_
7	with	with	IN	_	11	case	_	_
8	all	all	DT	_	11	det	_	_
9	in	in	FW	_	10	adv	_	_
10	vivo	vivo	FW	_	11	attr	_	_
11	tests	test	NNS	_	6	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	radio-iodine	radio-iodine	NN	_	14	com	_	_
14	uptake	uptake	NN	_	11	ppmod	_	_
15	producing	produce	VBG	_	11	acl	_	_
16	low	low	JJ	_	17	attr	_	_
17	uptakes	uptake	NNS	_	15	obj	_	_
18	which	which	WDT	_	21	dep	_	_
19	may	may	MD	_	21	modal	_	_
20	not	not	RB	_	21	neg	_	_
21	be	be	VB	_	17	relcl	_	_
22	reflective	reflective	JJ	_	21	dep	_	_
23	of	of	IN	_	26	case	_	_
24	a	a	DT	_	26	det	_	_
25	true	true	JJ	_	26	attr	_	_
26	decrease	decrease	NN	_	22	ppmod	_	_
27	in	in	IN	_	29	case	_	_
28	hormone	hormone	NN	_	29	com	_	_
29	synthesis	synthesis	NN	_	26	ppmod	_	_

1	.	.	.	_	0	root	_	_

1	-	-	CC	_	3	cc	_	_
2	The	the	DT	_	3	det	_	_
3	persistence	persistence	NN	_	17	dep	_	_
4	of	of	IN	_	8	case	_	_
5	clinical	clinical	JJ	_	8	attr	_	_
6	and	and	CC	_	5	cc	_	_
7	laboratory	laboratory	JJ	_	5	conj	_	_
8	evidence	evidence	NN	_	3	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	hypothyroidism	hypothyroidism	NN	_	8	ppmod	_	_
11	in	in	IN	_	12	case	_	_
12	spite	spite	NN	_	3	ppmod	_	_
13	of	of	IN	_	16	case	_	_
14	adequate	adequate	JJ	_	16	attr	_	_
15	dosage	dosage	NN	_	16	com	_	_
16	replacement	replacement	NN	_	12	ppmod	_	_
17	indicates	indicate	VBZ	_	0	root	_	_
18	either	either	DT	_	21	det	_	_
19	poor	poor	JJ	_	21	attr	_	_
20	patient	patient	NN	_	21	com	_	_
21	compliance	compliance	NN	_	17	obj	_	_
22	,	,	,	_	21	p	_	_
23	poor	poor	JJ	_	24	attr	_	_
24	absorption	absorption	NN	_	21	conj	_	_
25	,	,	,	_	24	p	_	_
26	excessive	excessive	JJ	_	28	attr	_	_
27	fecal	fecal	NN	_	28	com	_	_
28	loss	loss	NN	_	21	conj	_	_
29	,	,	,	_	28	p	_	_
30	or	or	CC	_	28	cc	_	_
31	inactivity	inactivity	NN	_	21	conj	_	_
32	of	of	IN	_	34	case	_	_
33	the	the	DT	_	34	det	_	_
34	preparation	preparation	NN	_	31	ppmod	_	_
35	.	.	.	_	17	p	_	_

1	Intracellular	intracellular	JJ	_	2	attr	_	_
2	resistance	resistance	NN	_	5	dep	_	_
3	to	to	TO	_	4	aux	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	is	be	VBZ	_	0	root	_	_
6	quite	quite	RB	_	7	adv	_	_
7	rare	rare	JJ	_	5	dep	_	_
8	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	injection	injection	NN	_	8	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	drug2	drug0	NN	_	2	conj	_	_
5	should	should	MD	_	8	modal	_	_
6	not	not	RB	_	8	neg	_	_
7	be	be	VB	_	8	aux	_	_
8	administered	administer	VBN	_	0	root	_	_
9	simultaneously	simultaneously	RB	_	8	adv	_	_
10	because	because	IN	_	13	mark	_	_
11	both	both	DT	_	12	det	_	_
12	drugs	drug	NNS	_	13	dep	_	_
13	are	be	VBP	_	8	comp	_	_
14	direct	direct	JJ	_	16	attr	_	_
15	cardiac	cardiac	JJ	_	16	attr	_	_
16	stimulants	stimulant	NNS	_	13	obj	_	_
17	and	and	CC	_	13	cc	_	_
18	their	their	PRP$	_	20	poss	_	_
19	combined	combined	JJ	_	20	attr	_	_
20	effects	effect	NNS	_	22	dep	_	_
21	may	may	MD	_	22	modal	_	_
22	induce	induce	VB	_	13	conj	_	_
23	serious	serious	JJ	_	24	attr	_	_
24	arrhythmias	arrhythmia	NNS	_	22	obj	_	_
25	.	.	.	_	8	p	_	_

1	The	the	DT	_	2	det	_	_
2	drugs	drug	NNS	_	10	dep	_	_
3	may	may	MD	_	10	modal	_	_
4	,	,	,	_	10	p	_	_
5	however	however	RB	_	10	adv	_	_
6	,	,	,	_	10	p	_	_
7	be	be	VB	_	10	aux	_	_
8	administered	administer	VBN	_	10	aux	_	_
9	alternately	alternately	RB	_	10	adv	_	_
10	provided	provided	VBN	_	0	root	_	_
11	a	a	DT	_	13	det	_	_
12	proper	proper	JJ	_	13	attr	_	_
13	interval	interval	NN	_	15	dep	_	_
14	has	have	VBZ	_	15	aux	_	_
15	elapsed	elapse	VBN	_	10	comp	_	_
16	between	between	IN	_	17	case	_	_
17	doses	dose	NNS	_	15	ppmod	_	_
18	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	used	use	VBN	_	0	root	_	_
5	with	with	IN	_	6	case	_	_
6	caution	caution	NN	_	4	ppmod	_	_
7	,	,	,	_	4	p	_	_
8	if	if	IN	_	20	mark	_	_
9	at	at	IN	_	10	case	_	_
10	all	all	NN	_	20	ppmod	_	_
11	,	,	,	_	20	p	_	_
12	when	when	WRB	_	20	adv	_	_
13	potent	potent	JJ	_	15	attr	_	_
14	inhalational	inhalational	JJ	_	15	attr	_	_
15	drug2	drug0	NNS	_	20	dep	_	_
16	such	such	JJ	_	18	adv	_	_
17	as	as	IN	_	18	case	_	_
18	drug3	drug0	NN	_	15	ppmod	_	_
19	are	be	VBP	_	20	aux	_	_
20	employed	employ	VBN	_	4	comp	_	_
21	because	because	IN	_	23	case	_	_
22	of	of	IN	_	23	case	_	_
23	potential	potential	NN	_	20	ppmod	_	_
24	to	to	TO	_	25	aux	_	_
25	sensitize	sensitize	VB	_	20	comp	_	_
26	the	the	DT	_	27	det	_	_
27	myocardium	myocardium	NN	_	25	obj	_	_
28	to	to	TO	_	29	aux	_	_
29	effects	effect	NNS	_	25	ppmod	_	_
30	of	of	IN	_	31	case	_	_
31	drug4	drug0	NN	_	29	ppmod	_	_
32	.	.	.	_	4	p	_	_

1	Taking	take	VBG	_	7	advcl	_	_
2	drug1	drug0	NN	_	1	obj	_	_
3	after	after	IN	_	5	case	_	_
4	drinking	drinking	JJ	_	5	attr	_	_
5	drug2	drug0	NN	_	1	ppmod	_	_
6	may	may	MD	_	7	modal	_	_
7	worsen	worsen	VB	_	0	root	_	_
8	side	side	JJ	_	9	attr	_	_
9	effects	effect	NNS	_	7	obj	_	_
10	and	and	CC	_	7	cc	_	_
11	may	may	MD	_	12	modal	_	_
12	cause	cause	VB	_	7	conj	_	_
13	severe	severe	JJ	_	14	attr	_	_
14	hypotension	hypotension	NN	_	12	obj	_	_
15	and	and	CC	_	14	cc	_	_
16	cardiovascular	cardiovascular	JJ	_	17	attr	_	_
17	collapse	collapse	NN	_	14	conj	_	_
18	.	.	.	_	7	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	mixing	mixing	NN	_	16	dep	_	_
4	of	of	IN	_	6	case	_	_
5	an	an	DT	_	6	det	_	_
6	drug1	drug0	NN	_	3	ppmod	_	_
7	with	with	IN	_	9	case	_	_
8	beta-lactamtype	beta-lactamtype	JJ	_	9	attr	_	_
9	drug2	drug0	NNS	_	3	ppmod	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	drug3	drug0	NN	_	9	prn	_	_
12	or	or	CC	_	11	cc	_	_
13	drug4	drug0	NN	_	11	conj	_	_
14	)	-rrb-	-RRB-	_	11	p	_	_
15	may	may	MD	_	16	modal	_	_
16	result	result	VB	_	0	root	_	_
17	in	in	IN	_	21	case	_	_
18	a	a	DT	_	21	det	_	_
19	significant	significant	JJ	_	21	attr	_	_
20	mutual	mutual	JJ	_	21	attr	_	_
21	inactivation	inactivation	NN	_	16	ppmod	_	_
22	.	.	.	_	16	p	_	_

1	Even	even	RB	_	2	com	_	_
2	when	when	WRB	_	11	adv	_	_
3	an	an	DT	_	4	det	_	_
4	drug1	drug0	NN	_	11	dep	_	_
5	and	and	CC	_	4	cc	_	_
6	a	a	DT	_	9	det	_	_
7	drug2	drug0	NN	_	9	attr	_	_
8	-type	-type	JJ	_	9	attr	_	_
9	drug	drug	NN	_	4	conj	_	_
10	are	be	VBP	_	11	aux	_	_
11	administered	administer	VBN	_	28	advcl	_	_
12	separately	separately	RB	_	11	adv	_	_
13	by	by	IN	_	15	case	_	_
14	different	different	JJ	_	15	attr	_	_
15	routes	route	NNS	_	11	ppmod	_	_
16	,	,	,	_	28	p	_	_
17	a	a	DT	_	18	det	_	_
18	reduction	reduction	NN	_	28	dep	_	_
19	in	in	IN	_	22	case	_	_
20	drug3	drug0	NN	_	22	com	_	_
21	serum	serum	NN	_	22	com	_	_
22	half-life	half-life	NN	_	18	ppmod	_	_
23	or	or	CC	_	22	cc	_	_
24	serum	serum	NN	_	25	com	_	_
25	levels	level	NNS	_	22	conj	_	_
26	has	have	VBZ	_	28	aux	_	_
27	been	be	VBN	_	28	aux	_	_
28	reported	report	VBN	_	0	root	_	_
29	in	in	IN	_	30	case	_	_
30	patients	patient	NNS	_	28	ppmod	_	_
31	with	with	IN	_	34	case	_	_
32	impaired	impaired	JJ	_	34	attr	_	_
33	renal	renal	JJ	_	34	attr	_	_
34	function	function	NN	_	30	ppmod	_	_
35	and	and	CC	_	30	cc	_	_
36	in	in	IN	_	38	case	_	_
37	some	some	DT	_	38	det	_	_
38	patients	patient	NNS	_	30	conj	_	_
39	with	with	IN	_	42	case	_	_
40	normal	normal	JJ	_	42	attr	_	_
41	renal	renal	JJ	_	42	attr	_	_
42	function	function	NN	_	38	ppmod	_	_
43	.	.	.	_	28	p	_	_

1	Usually	usually	RB	_	8	adv	_	_
2	,	,	,	_	8	p	_	_
3	such	such	JJ	_	4	attr	_	_
4	inactivation	inactivation	NN	_	8	dep	_	_
5	of	of	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	drug1	drug0	NN	_	4	ppmod	_	_
8	is	be	VBZ	_	0	root	_	_
9	clinically	clinically	RB	_	10	adv	_	_
10	significant	significant	JJ	_	8	dep	_	_
11	only	only	RB	_	13	adv	_	_
12	in	in	IN	_	13	case	_	_
13	patients	patient	NNS	_	10	ppmod	_	_
14	with	with	IN	_	18	case	_	_
15	severely	severely	RB	_	16	adv	_	_
16	impaired	impaired	JJ	_	18	attr	_	_
17	renal	renal	JJ	_	18	attr	_	_
18	function	function	NN	_	13	ppmod	_	_
19	.	.	.	_	8	p	_	_
20	.	.	.	_	8	p	_	_

1	See	see	VB	_	0	root	_	_

1	No	no	DT	_	5	det	_	_
2	formal	formal	JJ	_	5	attr	_	_
3	drug	drug	NN	_	5	com	_	_
4	interaction	interaction	NN	_	5	com	_	_
5	studies	study	NNS	_	8	dep	_	_
6	have	have	VBP	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	conducted	conduct	VBN	_	0	root	_	_
9	.	.	.	_	8	p	_	_

1	The	the	DT	_	2	det	_	_
2	effects	effect	NNS	_	7	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	may	may	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	potentiated	potentiate	VBN	_	0	root	_	_
8	by	by	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	which	which	WDT	_	11	dep	_	_
11	inhibits	inhibit	VBZ	_	9	relcl	_	_
12	the	the	DT	_	13	det	_	_
13	metabolism	metabolism	NN	_	11	obj	_	_
14	of	of	IN	_	15	case	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	7	p	_	_

1	The	the	DT	_	3	det	_	_
2	pressor	pressor	JJ	_	3	attr	_	_
3	effects	effect	NNS	_	10	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	other	other	JJ	_	8	attr	_	_
8	drug2	drug0	NNS	_	5	conj	_	_
9	can	can	MD	_	10	modal	_	_
10	combine	combine	VB	_	0	root	_	_
11	to	to	TO	_	12	aux	_	_
12	cause	cause	VB	_	10	comp	_	_
13	dangerous	dangerous	JJ	_	14	attr	_	_
14	hypertension	hypertension	NN	_	12	obj	_	_
15	.	.	.	_	10	p	_	_

1	Administration	administration	NN	_	27	dep	_	_
2	of	of	IN	_	9	case	_	_
3	0.1-mg/kg	0-mg/kg	JJ	_	9	attr	_	_
4	(	-lrb-	-LRB-	_	7	p	_	_
5	2	0	CD	_	7	num	_	_
6	x	x	NN	_	7	com	_	_
7	ED95	ed0	NN	_	3	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	drug1	drug0	NN	_	1	ppmod	_	_
10	at	at	IN	_	11	case	_	_
11	10	0	CD	_	9	ppmod	_	_
12	%	%	NN	_	11	meta	_	_
13	or	or	CC	_	9	cc	_	_
14	95	0	CD	_	16	num	_	_
15	%	%	NN	_	14	meta	_	_
16	recovery	recovery	NN	_	9	conj	_	_
17	following	follow	VBG	_	20	adv	_	_
18	an	an	DT	_	20	det	_	_
19	intubating	intubating	JJ	_	20	attr	_	_
20	dose	dose	NN	_	16	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	drug2	drug0	NN	_	20	ppmod	_	_
23	(	-lrb-	-LRB-	_	25	p	_	_
24	1	0	CD	_	25	num	_	_
25	mg/kg	mg/kg	NN	_	20	prn	_	_
26	)	-rrb-	-RRB-	_	25	p	_	_
27	produced	produce	VBD	_	0	root	_	_
28	95	0	CD	_	31	num	_	_
29	%	%	NN	_	28	meta	_	_
30	neuromuscular	neuromuscular	NN	_	31	com	_	_
31	block	block	NN	_	27	obj	_	_
32	.	.	.	_	27	p	_	_

1	The	the	DT	_	2	det	_	_
2	time	time	NN	_	10	dep	_	_
3	to	to	TO	_	4	aux	_	_
4	onset	onset	NN	_	2	ppmod	_	_
5	of	of	IN	_	7	case	_	_
6	maximum	maximum	NN	_	7	com	_	_
7	block	block	NN	_	4	ppmod	_	_
8	following	follow	VBG	_	9	adv	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	is	be	VBZ	_	0	root	_	_
11	approximately	approximately	RB	_	12	adv	_	_
12	2	0	CD	_	13	num	_	_
13	minutes	minute	NNS	_	14	advnp	_	_
14	faster	fast	JJR	_	10	dep	_	_
15	with	with	IN	_	17	case	_	_
16	prior	prior	JJ	_	17	attr	_	_
17	administration	administration	NN	_	14	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	.	.	.	_	10	p	_	_

1	Prior	prior	JJ	_	2	attr	_	_
2	administration	administration	NN	_	5	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	had	have	VBD	_	0	root	_	_
6	no	no	DT	_	7	det	_	_
7	effect	effect	NN	_	5	obj	_	_
8	on	on	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	duration	duration	NN	_	5	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	neuromuscular	neuromuscular	JJ	_	13	attr	_	_
13	block	block	NN	_	10	ppmod	_	_
14	following	follow	VBG	_	19	adv	_	_
15	initial	initial	JJ	_	19	attr	_	_
16	or	or	CC	_	19	cc	_	_
17	maintenance	maintenance	NN	_	19	com	_	_
18	bolus	bolus	NN	_	19	com	_	_
19	doses	dose	NNS	_	13	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	drug2	drug0	NN	_	19	ppmod	_	_
22	.	.	.	_	5	p	_	_

1	Infusion	infusion	NN	_	2	com	_	_
2	requirements	requirement	NNS	_	14	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	in	in	IN	_	6	case	_	_
6	patients	patient	NNS	_	4	ppmod	_	_
7	administered	administer	VBN	_	6	acl	_	_
8	drug2	drug0	NN	_	9	advnp	_	_
9	prior	prior	RB	_	7	adv	_	_
10	to	to	TO	_	11	aux	_	_
11	infusions	infusion	NNS	_	7	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug3	drug0	NN	_	11	ppmod	_	_
14	were	be	VBD	_	0	root	_	_
15	comparable	comparable	JJ	_	14	dep	_	_
16	to	to	TO	_	15	ppmod	_	_
17	or	or	CC	_	15	cc	_	_
18	slightly	slightly	RB	_	19	adv	_	_
19	greater	great	JJR	_	15	conj	_	_
20	than	than	IN	_	25	case	_	_
21	when	when	WRB	_	25	adv	_	_
22	drug4	drug0	NN	_	25	dep	_	_
23	was	be	VBD	_	25	aux	_	_
24	not	not	RB	_	25	neg	_	_
25	administered	administer	VBN	_	19	ppmod	_	_
26	.	.	.	_	14	p	_	_

1	The	the	DT	_	2	det	_	_
2	use	use	NN	_	19	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	before	before	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	to	to	TO	_	8	aux	_	_
8	attenuate	attenuate	VB	_	2	acl	_	_
9	some	some	DT	_	8	obj	_	_
10	of	of	IN	_	13	case	_	_
11	the	the	DT	_	13	det	_	_
12	side	side	JJ	_	13	attr	_	_
13	effects	effect	NNS	_	9	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug3	drug0	NNS	_	13	ppmod	_	_
16	has	have	VBZ	_	19	aux	_	_
17	not	not	RB	_	19	neg	_	_
18	been	be	VBN	_	19	aux	_	_
19	studied	study	VBN	_	0	root	_	_
20	.	.	.	_	19	p	_	_

1	Although	although	IN	_	3	mark	_	_
2	not	not	RB	_	3	neg	_	_
3	studied	study	VBN	_	13	advcl	_	_
4	systematically	systematically	RB	_	3	adv	_	_
5	in	in	IN	_	7	case	_	_
6	clinical	clinical	JJ	_	7	attr	_	_
7	trials	trial	NNS	_	3	ppmod	_	_
8	,	,	,	_	13	p	_	_
9	no	no	DT	_	11	det	_	_
10	drug	drug	NN	_	11	com	_	_
11	interactions	interaction	NNS	_	13	dep	_	_
12	were	be	VBD	_	13	aux	_	_
13	observed	observe	VBN	_	0	root	_	_
14	when	when	WRB	_	22	adv	_	_
15	drug1	drug0	NN	_	22	dep	_	_
16	,	,	,	_	15	p	_	_
17	drug2	drug0	NN	_	15	conj	_	_
18	,	,	,	_	17	p	_	_
19	or	or	CC	_	17	cc	_	_
20	drug3	drug0	NN	_	15	conj	_	_
21	were	be	VBD	_	22	aux	_	_
22	administered	administer	VBN	_	13	comp	_	_
23	following	follow	VBG	_	25	adv	_	_
24	varying	vary	VBG	_	25	attr	_	_
25	degrees	degree	NNS	_	22	ppmod	_	_
26	of	of	IN	_	27	case	_	_
27	recovery	recovery	NN	_	25	ppmod	_	_
28	from	from	IN	_	30	case	_	_
29	single	single	JJ	_	30	attr	_	_
30	doses	dose	NNS	_	27	ppmod	_	_
31	or	or	CC	_	30	cc	_	_
32	infusions	infusion	NNS	_	30	conj	_	_
33	of	of	IN	_	34	case	_	_
34	drug4	drug0	NN	_	30	ppmod	_	_
35	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	18	dep	_	_
2	or	or	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	administered	administer	VBN	_	1	acl	_	_
5	with	with	IN	_	6	case	_	_
6	drug3	drug0	NN	_	4	ppmod	_	_
7	/	/	:	_	1	p	_	_
8	drug4	drug0	NN	_	1	appo	_	_
9	to	to	TO	_	10	aux	_	_
10	achieve	achieve	VB	_	1	acl	_	_
11	1.25	0	CD	_	12	num	_	_
12	MAC	mac	NN	_	15	com	_	_
13	-LSB-Minimum	-lsb-minimum	NN	_	15	com	_	_
14	Alveolar	alveolar	NN	_	15	com	_	_
15	Concentration	concentration	NN	_	10	obj	_	_
16	]	-rsb-	-RRB-	_	1	p	_	_
17	may	may	MD	_	18	modal	_	_
18	prolong	prolong	VB	_	0	root	_	_
19	the	the	DT	_	22	det	_	_
20	clinically	clinically	RB	_	21	adv	_	_
21	effective	effective	JJ	_	22	attr	_	_
22	duration	duration	NN	_	18	obj	_	_
23	of	of	IN	_	24	case	_	_
24	action	action	NN	_	22	ppmod	_	_
25	of	of	IN	_	29	case	_	_
26	initial	initial	JJ	_	29	attr	_	_
27	and	and	CC	_	29	cc	_	_
28	maintenance	maintenance	NN	_	29	com	_	_
29	doses	dose	NNS	_	24	ppmod	_	_
30	of	of	IN	_	31	case	_	_
31	drug5	drug0	NN	_	29	ppmod	_	_
32	and	and	CC	_	18	cc	_	_
33	decrease	decrease	VB	_	18	conj	_	_
34	the	the	DT	_	37	det	_	_
35	required	required	JJ	_	37	attr	_	_
36	infusion	infusion	NN	_	37	com	_	_
37	rate	rate	NN	_	33	obj	_	_
38	of	of	IN	_	39	case	_	_
39	drug6	drug0	NN	_	37	ppmod	_	_
40	.	.	.	_	18	p	_	_

1	The	the	DT	_	2	det	_	_
2	magnitude	magnitude	NN	_	7	dep	_	_
3	of	of	IN	_	5	case	_	_
4	these	these	DT	_	5	det	_	_
5	effects	effect	NNS	_	2	ppmod	_	_
6	may	may	MD	_	7	modal	_	_
7	depend	depend	VB	_	0	root	_	_
8	on	on	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	duration	duration	NN	_	7	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	administration	administration	NN	_	10	ppmod	_	_
13	of	of	IN	_	16	case	_	_
14	the	the	DT	_	16	det	_	_
15	volatile	volatile	JJ	_	16	attr	_	_
16	agents	agent	NNS	_	12	ppmod	_	_
17	.	.	.	_	7	p	_	_

1	Fifteen	#crd#	CD	_	4	num	_	_
2	to	to	TO	_	4	attr	_	_
3	30	0	CD	_	4	num	_	_
4	minutes	minute	NNS	_	13	dep	_	_
5	of	of	IN	_	6	case	_	_
6	exposure	exposure	NN	_	4	ppmod	_	_
7	to	to	TO	_	10	aux	_	_
8	1.25	0	CD	_	9	num	_	_
9	MAC	mac	NN	_	10	com	_	_
10	drug1	drug0	NN	_	6	ppmod	_	_
11	or	or	CC	_	10	cc	_	_
12	drug2	drug0	NN	_	10	conj	_	_
13	had	have	VBD	_	0	root	_	_
14	minimal	minimal	JJ	_	15	attr	_	_
15	effects	effect	NNS	_	13	obj	_	_
16	on	on	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	duration	duration	NN	_	13	ppmod	_	_
19	of	of	IN	_	20	case	_	_
20	action	action	NN	_	18	ppmod	_	_
21	of	of	IN	_	23	case	_	_
22	initial	initial	JJ	_	23	attr	_	_
23	doses	dose	NNS	_	20	ppmod	_	_
24	of	of	IN	_	25	case	_	_
25	drug3	drug0	NN	_	23	ppmod	_	_
26	and	and	CC	_	13	cc	_	_
27	therefore	therefore	RB	_	36	adv	_	_
28	,	,	,	_	36	p	_	_
29	no	no	DT	_	30	det	_	_
30	adjustment	adjustment	NN	_	36	dep	_	_
31	to	to	TO	_	34	aux	_	_
32	the	the	DT	_	34	det	_	_
33	initial	initial	JJ	_	34	attr	_	_
34	dose	dose	NN	_	30	ppmod	_	_
35	should	should	MD	_	36	modal	_	_
36	be	be	VB	_	13	conj	_	_
37	necessary	necessary	JJ	_	36	dep	_	_
38	when	when	WRB	_	41	adv	_	_
39	drug4	drug0	NN	_	41	dep	_	_
40	is	be	VBZ	_	41	aux	_	_
41	administered	administer	VBN	_	36	comp	_	_
42	shortly	shortly	RB	_	41	adv	_	_
43	after	after	IN	_	44	case	_	_
44	initiation	initiation	NN	_	41	ppmod	_	_
45	of	of	IN	_	47	case	_	_
46	volatile	volatile	JJ	_	47	attr	_	_
47	agents	agent	NNS	_	44	ppmod	_	_
48	.	.	.	_	36	p	_	_

1	In	in	IN	_	4	case	_	_
2	long	long	JJ	_	4	attr	_	_
3	surgical	surgical	JJ	_	4	attr	_	_
4	procedures	procedure	NNS	_	27	ppmod	_	_
5	during	during	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	or	or	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	9	com	_	_
9	anesthesia	anesthesia	NN	_	6	conj	_	_
10	,	,	,	_	27	p	_	_
11	less	less	RBR	_	12	adv	_	_
12	frequent	frequent	JJ	_	14	attr	_	_
13	maintenance	maintenance	NN	_	14	com	_	_
14	dosing	dosing	NN	_	27	dep	_	_
15	,	,	,	_	14	p	_	_
16	lower	low	JJR	_	18	attr	_	_
17	maintenance	maintenance	NN	_	18	com	_	_
18	doses	dose	NNS	_	14	conj	_	_
19	,	,	,	_	18	p	_	_
20	or	or	CC	_	18	cc	_	_
21	reduced	reduce	VBN	_	23	attr	_	_
22	infusion	infusion	NN	_	23	com	_	_
23	rates	rate	NNS	_	14	conj	_	_
24	of	of	IN	_	25	case	_	_
25	drug3	drug0	NN	_	23	ppmod	_	_
26	may	may	MD	_	27	modal	_	_
27	be	be	VB	_	0	root	_	_
28	necessary	necessary	JJ	_	27	dep	_	_
29	.	.	.	_	27	p	_	_

1	The	the	DT	_	4	det	_	_
2	average	average	JJ	_	4	attr	_	_
3	infusion	infusion	NN	_	4	com	_	_
4	rate	rate	NN	_	5	com	_	_
5	requirement	requirement	NN	_	8	dep	_	_
6	may	may	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	decreased	decrease	VBN	_	0	root	_	_
9	by	by	IN	_	13	case	_	_
10	as	as	RB	_	13	adv	_	_
11	much	much	JJ	_	13	attr	_	_
12	as	as	IN	_	13	case	_	_
13	30	0	CD	_	8	ppmod	_	_
14	%	%	NN	_	13	meta	_	_
15	to	to	TO	_	16	aux	_	_
16	40	0	CD	_	8	ppmod	_	_
17	%	%	NN	_	16	meta	_	_
18	.	.	.	_	8	p	_	_

1	In	in	IN	_	3	case	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	studies	study	NNS	_	5	ppmod	_	_
4	drug1	drug0	NN	_	5	dep	_	_
5	had	have	VBD	_	0	root	_	_
6	no	no	DT	_	7	det	_	_
7	effect	effect	NN	_	5	obj	_	_
8	on	on	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	duration	duration	NN	_	5	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	action	action	NN	_	10	ppmod	_	_
13	or	or	CC	_	10	cc	_	_
14	dosing	dosing	NN	_	15	com	_	_
15	requirements	requirement	NNS	_	10	conj	_	_
16	for	for	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	.	.	.	_	5	p	_	_

1	Other	other	JJ	_	2	attr	_	_
2	drugs	drug	NNS	_	15	dep	_	_
3	which	which	WDT	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	enhance	enhance	VB	_	2	relcl	_	_
6	the	the	DT	_	9	det	_	_
7	neuromuscular	neuromuscular	JJ	_	9	attr	_	_
8	blocking	blocking	NN	_	9	com	_	_
9	action	action	NN	_	5	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	such	such	JJ	_	14	adv	_	_
13	as	as	IN	_	14	case	_	_
14	drug2	drug0	NN	_	11	ppmod	_	_
15	include	include	VBP	_	0	root	_	_
16	certain	certain	JJ	_	17	attr	_	_
17	drug3	drug0	NN	_	15	obj	_	_
18	(	-lrb-	-LRB-	_	20	p	_	_
19	e.	e.	FW	_	20	attr	_	_
20	g.	g.	FW	_	17	prn	_	_
21	,	,	,	_	20	p	_	_
22	drug4	drug0	NN	_	20	attr	_	_
23	,	,	,	_	22	p	_	_
24	drug5	drug0	NN	_	22	conj	_	_
25	,	,	,	_	24	p	_	_
26	drug6	drug0	NN	_	22	conj	_	_
27	,	,	,	_	26	p	_	_
28	drug7	drug0	NN	_	22	conj	_	_
29	,	,	,	_	28	p	_	_
30	drug8	drug0	NN	_	22	conj	_	_
31	,	,	,	_	30	p	_	_
32	drug9	drug0	NN	_	22	conj	_	_
33	,	,	,	_	32	p	_	_
34	drug10	drug0	NN	_	22	conj	_	_
35	,	,	,	_	34	p	_	_
36	and	and	CC	_	34	cc	_	_
37	drug11	drug0	NN	_	22	conj	_	_
38	)	-rrb-	-RRB-	_	20	p	_	_
39	,	,	,	_	17	p	_	_
40	drug12	drug0	NN	_	41	com	_	_
41	salts	salt	NNS	_	17	conj	_	_
42	,	,	,	_	41	p	_	_
43	drug13	drug0	NN	_	17	conj	_	_
44	,	,	,	_	43	p	_	_
45	local	local	JJ	_	46	attr	_	_
46	drug14	drug0	NN	_	17	conj	_	_
47	,	,	,	_	46	p	_	_
48	drug15	drug0	NN	_	17	conj	_	_
49	,	,	,	_	48	p	_	_
50	and	and	CC	_	48	cc	_	_
51	drug16	drug0	NN	_	17	conj	_	_
52	.	.	.	_	15	p	_	_

1	Resistance	resistance	NN	_	11	dep	_	_
2	to	to	TO	_	6	aux	_	_
3	the	the	DT	_	6	det	_	_
4	neuromuscular	neuromuscular	JJ	_	6	attr	_	_
5	blocking	blocking	NN	_	6	com	_	_
6	action	action	NN	_	1	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	has	have	VBZ	_	11	aux	_	_
10	been	be	VBN	_	11	aux	_	_
11	demonstrated	demonstrate	VBN	_	0	root	_	_
12	in	in	IN	_	13	case	_	_
13	patients	patient	NNS	_	11	ppmod	_	_
14	chronically	chronically	RB	_	15	adv	_	_
15	administered	administer	VBN	_	13	acl	_	_
16	drug2	drug0	NN	_	15	comp	_	_
17	or	or	CC	_	16	cc	_	_
18	drug3	drug0	NN	_	16	conj	_	_
19	.	.	.	_	11	p	_	_

1	While	while	IN	_	15	mark	_	_
2	the	the	DT	_	3	det	_	_
3	effects	effect	NNS	_	15	dep	_	_
4	of	of	IN	_	6	case	_	_
5	chronic	chronic	JJ	_	6	attr	_	_
6	drug1	drug0	NN	_	3	ppmod	_	_
7	or	or	CC	_	6	cc	_	_
8	drug2	drug0	JJ	_	9	attr	_	_
9	therapy	therapy	NN	_	6	conj	_	_
10	on	on	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	action	action	NN	_	3	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug3	drug0	NN	_	12	ppmod	_	_
15	are	be	VBP	_	26	advcl	_	_
16	unknown	unknown	JJ	_	15	dep	_	_
17	,	,	,	_	26	p	_	_
18	slightly	slightly	RB	_	19	adv	_	_
19	shorter	short	JJR	_	20	attr	_	_
20	durations	duration	NNS	_	26	dep	_	_
21	of	of	IN	_	23	case	_	_
22	neuromuscular	neuromuscular	JJ	_	23	attr	_	_
23	block	block	NN	_	20	ppmod	_	_
24	may	may	MD	_	26	modal	_	_
25	be	be	VB	_	26	aux	_	_
26	anticipated	anticipate	VBN	_	0	root	_	_
27	and	and	CC	_	26	cc	_	_
28	infusion	infusion	NN	_	30	com	_	_
29	rate	rate	NN	_	30	com	_	_
30	requirements	requirement	NNS	_	32	dep	_	_
31	may	may	MD	_	32	modal	_	_
32	be	be	VB	_	26	conj	_	_
33	higher	high	JJR	_	32	dep	_	_
34	.	.	.	_	26	p	_	_

1	Drug/Laboratory	drug/laboratory	JJ	_	3	attr	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	5	dep	_	_
4	None	none	NN	_	5	dep	_	_
5	known	know	VBN	_	0	root	_	_
6	.	.	.	_	5	p	_	_

1	In	in	IN	_	3	case	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	studies	study	NNS	_	8	ppmod	_	_
4	,	,	,	_	8	p	_	_
5	drug1	drug0	NN	_	8	dep	_	_
6	has	have	VBZ	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	co-administered	co-administered	VBN	_	0	root	_	_
9	with	with	IN	_	12	case	_	_
10	other	other	JJ	_	12	attr	_	_
11	anti-asthma	anti-asthma	NN	_	12	com	_	_
12	medications	medication	NNS	_	8	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	including	include	VBG	_	18	adv	_	_
15	inhaled	inhaled	JJ	_	18	attr	_	_
16	and	and	CC	_	15	cc	_	_
17	oral	oral	JJ	_	15	conj	_	_
18	drug2	drug0	NN	_	12	ppmod	_	_
19	,	,	,	_	18	p	_	_
20	and	and	CC	_	18	cc	_	_
21	inhaled	inhaled	JJ	_	22	attr	_	_
22	drug3	drug0	NN	_	18	conj	_	_
23	,	,	,	_	12	p	_	_
24	with	with	IN	_	26	case	_	_
25	no	no	DT	_	26	det	_	_
26	evidence	evidence	NN	_	8	ppmod	_	_
27	of	of	IN	_	29	case	_	_
28	increased	increase	VBN	_	29	attr	_	_
29	frequency	frequency	NN	_	26	ppmod	_	_
30	of	of	IN	_	32	case	_	_
31	adverse	adverse	JJ	_	32	attr	_	_
32	events	event	NNS	_	29	ppmod	_	_
33	or	or	CC	_	32	cc	_	_
34	laboratory	laboratory	NN	_	35	com	_	_
35	abnormalities	abnormality	NNS	_	32	conj	_	_
36	.	.	.	_	8	p	_	_

1	No	no	DT	_	5	det	_	_
2	formal	formal	JJ	_	5	attr	_	_
3	drug-drug	drug-drug	JJ	_	5	attr	_	_
4	interaction	interaction	NN	_	5	com	_	_
5	studies	study	NNS	_	11	dep	_	_
6	,	,	,	_	11	p	_	_
7	however	however	RB	_	11	adv	_	_
8	,	,	,	_	11	p	_	_
9	have	have	VBP	_	11	aux	_	_
10	been	be	VBN	_	11	aux	_	_
11	conducted	conduct	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	can	can	MD	_	3	modal	_	_
3	interact	interact	VB	_	0	root	_	_
4	with	with	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	or	or	CC	_	5	cc	_	_
7	other	other	JJ	_	8	attr	_	_
8	drug3	drug0	NN	_	5	conj	_	_
9	(	-lrb-	-LRB-	_	11	p	_	_
10	may	may	MD	_	11	modal	_	_
11	potentiate	potentiate	VB	_	5	prn	_	_
12	the	the	DT	_	15	det	_	_
13	CNS	cns	NN	_	15	com	_	_
14	depressant	depressant	NN	_	15	com	_	_
15	effects	effect	NNS	_	11	obj	_	_
16	of	of	IN	_	19	case	_	_
17	either	either	CC	_	19	cc	_	_
18	these	these	DT	_	19	det	_	_
19	medications	medication	NNS	_	15	ppmod	_	_
20	or	or	CC	_	19	cc	_	_
21	drug4	drug0	NNS	_	19	conj	_	_
22	)	-rrb-	-RRB-	_	11	p	_	_
23	,	,	,	_	5	p	_	_
24	drug5	drug0	NN	_	5	conj	_	_
25	or	or	CC	_	24	cc	_	_
26	other	other	JJ	_	27	attr	_	_
27	medications	medication	NNS	_	24	conj	_	_
28	with	with	IN	_	30	case	_	_
29	anticholinergic	anticholinergic	JJ	_	30	attr	_	_
30	activity	activity	NN	_	27	ppmod	_	_
31	(	-lrb-	-LRB-	_	36	p	_	_
32	anticholinergic	anticholinergic	JJ	_	33	attr	_	_
33	effects	effect	NNS	_	36	dep	_	_
34	may	may	MD	_	36	modal	_	_
35	be	be	VB	_	36	aux	_	_
36	potentiated	potentiate	VBN	_	24	prn	_	_
37	when	when	WRB	_	41	adv	_	_
38	these	these	DT	_	39	det	_	_
39	medications	medication	NNS	_	41	dep	_	_
40	are	be	VBP	_	41	aux	_	_
41	used	use	VBN	_	36	comp	_	_
42	concurrently	concurrently	RB	_	41	adv	_	_
43	with	with	IN	_	44	case	_	_
44	drug6	drug0	NN	_	41	ppmod	_	_
45	)	-rrb-	-RRB-	_	36	p	_	_
46	,	,	,	_	24	p	_	_
47	and	and	CC	_	24	cc	_	_
48	drug7	drug0	NN	_	5	conj	_	_
49	(	-lrb-	-LRB-	_	55	p	_	_
50	concurrent	concurrent	JJ	_	51	attr	_	_
51	use	use	NN	_	55	dep	_	_
52	with	with	IN	_	53	case	_	_
53	drug8	drug0	NN	_	51	ppmod	_	_
54	may	may	MD	_	55	modal	_	_
55	prolong	prolong	VB	_	48	prn	_	_
56	and	and	CC	_	55	cc	_	_
57	intensify	intensify	VB	_	55	conj	_	_
58	the	the	DT	_	59	det	_	_
59	anticholinergic	anticholinergic	NN	_	57	obj	_	_
60	and	and	CC	_	59	cc	_	_
61	CNS	cns	NN	_	63	com	_	_
62	depressant	depressant	NN	_	63	com	_	_
63	effects	effect	NNS	_	59	conj	_	_
64	of	of	IN	_	65	case	_	_
65	drug9	drug0	NN	_	59	ppmod	_	_
66	)	-rrb-	-RRB-	_	55	p	_	_
67	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	such	such	JJ	_	4	adv	_	_
3	as	as	IN	_	4	case	_	_
4	drug2	drug0	NN	_	1	ppmod	_	_
5	(	-lrb-	-LRB-	_	8	p	_	_
6	e.g.	e.g.	FW	_	8	ppmod	_	_
7	,	,	,	_	8	p	_	_
8	drug3	drug0	NN	_	4	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	,	,	,	_	4	p	_	_
11	drug4	drug0	NN	_	4	conj	_	_
12	(	-lrb-	-LRB-	_	15	p	_	_
13	e.g.	e.g.	FW	_	15	ppmod	_	_
14	,	,	,	_	15	p	_	_
15	drug5	drug0	NN	_	11	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	,	,	,	_	11	p	_	_
18	drug6	drug0	NN	_	4	conj	_	_
19	(	-lrb-	-LRB-	_	22	p	_	_
20	e.g.	e.g.	FW	_	22	ppmod	_	_
21	,	,	,	_	22	p	_	_
22	drug7	drug0	NN	_	18	prn	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	,	,	,	_	18	p	_	_
25	drug8	drug0	NN	_	4	conj	_	_
26	(	-lrb-	-LRB-	_	29	p	_	_
27	e.g.	e.g.	FW	_	29	ppmod	_	_
28	,	,	,	_	29	p	_	_
29	drug9	drug0	NN	_	25	prn	_	_
30	)	-rrb-	-RRB-	_	29	p	_	_
31	,	,	,	_	25	p	_	_
32	and	and	CC	_	25	cc	_	_
33	drug10	drug0	NN	_	4	conj	_	_
34	(	-lrb-	-LRB-	_	37	p	_	_
35	e.g.	e.g.	FW	_	37	ppmod	_	_
36	,	,	,	_	37	p	_	_
37	drug11	drug0	NN	_	33	prn	_	_
38	)	-rrb-	-RRB-	_	37	p	_	_
39	:	:	:	_	1	p	_	_
40	Using	use	VBG	_	46	advcl	_	_
41	these	these	DT	_	42	det	_	_
42	medicines	medicine	NNS	_	40	obj	_	_
43	with	with	IN	_	44	case	_	_
44	drug12	drug0	NN	_	40	ppmod	_	_
45	may	may	MD	_	46	modal	_	_
46	increase	increase	VB	_	1	acl	_	_
47	the	the	DT	_	48	det	_	_
48	chance	chance	NN	_	46	obj	_	_
49	of	of	IN	_	51	case	_	_
50	side	side	JJ	_	51	attr	_	_
51	effects	effect	NNS	_	48	ppmod	_	_
52	.	.	.	_	1	p	_	_

1	Addition	addition	NN	_	17	dep	_	_
2	or	or	CC	_	1	cc	_	_
3	deletion	deletion	NN	_	1	conj	_	_
4	of	of	IN	_	6	case	_	_
5	any	any	DT	_	6	det	_	_
6	drug	drug	NN	_	3	ppmod	_	_
7	from	from	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	therapeutic	therapeutic	JJ	_	10	attr	_	_
10	regimen	regimen	NN	_	3	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	patients	patient	NNS	_	10	ppmod	_	_
13	receiving	receive	VBG	_	12	acl	_	_
14	oral	oral	JJ	_	15	attr	_	_
15	drug1	drug0	NN	_	13	obj	_	_
16	may	may	MD	_	17	modal	_	_
17	affect	affect	VB	_	0	root	_	_
18	patient	patient	NN	_	19	com	_	_
19	response	response	NN	_	17	obj	_	_
20	to	to	TO	_	22	aux	_	_
21	the	the	DT	_	22	det	_	_
22	drug2	drug0	NN	_	19	ppmod	_	_
23	.	.	.	_	17	p	_	_

1	Frequent	frequent	JJ	_	2	attr	_	_
2	determination	determination	NN	_	12	dep	_	_
3	of	of	IN	_	5	case	_	_
4	prothrombin	prothrombin	NN	_	5	com	_	_
5	time	time	NN	_	2	ppmod	_	_
6	and	and	CC	_	2	cc	_	_
7	close	close	JJ	_	8	attr	_	_
8	monitoring	monitoring	NN	_	2	conj	_	_
9	of	of	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	patient	patient	NN	_	2	ppmod	_	_
12	is	be	VBZ	_	0	root	_	_
13	essential	essential	JJ	_	12	dep	_	_
14	to	to	TO	_	15	aux	_	_
15	ascertain	ascertain	VB	_	13	comp	_	_
16	when	when	WRB	_	24	adv	_	_
17	adjustment	adjustment	NN	_	24	dep	_	_
18	of	of	IN	_	19	case	_	_
19	dosage	dosage	NN	_	17	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	drug1	drug0	NN	_	19	ppmod	_	_
22	may	may	MD	_	24	modal	_	_
23	be	be	VB	_	24	aux	_	_
24	needed	need	VBN	_	15	comp	_	_
25	.	.	.	_	12	p	_	_

1	Because	because	IN	_	4	case	_	_
2	of	of	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	variability	variability	NN	_	44	ppmod	_	_
5	of	of	IN	_	8	case	_	_
6	individual	individual	JJ	_	8	attr	_	_
7	patient	patient	NN	_	8	com	_	_
8	response	response	NN	_	4	ppmod	_	_
9	,	,	,	_	4	p	_	_
10	multiple	multiple	JJ	_	12	attr	_	_
11	interacting	interact	VBG	_	12	attr	_	_
12	mechanisms	mechanism	NNS	_	4	conj	_	_
13	with	with	IN	_	15	case	_	_
14	some	some	DT	_	15	det	_	_
15	drugs	drug	NNS	_	12	ppmod	_	_
16	,	,	,	_	12	p	_	_
17	the	the	DT	_	18	det	_	_
18	dependency	dependency	NN	_	4	conj	_	_
19	of	of	IN	_	21	case	_	_
20	the	the	DT	_	21	det	_	_
21	extent	extent	NN	_	18	ppmod	_	_
22	of	of	IN	_	24	case	_	_
23	the	the	DT	_	24	det	_	_
24	interaction	interaction	NN	_	21	ppmod	_	_
25	on	on	IN	_	27	case	_	_
26	the	the	DT	_	27	det	_	_
27	dosage	dosage	NN	_	24	ppmod	_	_
28	and	and	CC	_	27	cc	_	_
29	duration	duration	NN	_	27	conj	_	_
30	of	of	IN	_	31	case	_	_
31	therapy	therapy	NN	_	27	ppmod	_	_
32	,	,	,	_	18	p	_	_
33	and	and	CC	_	18	cc	_	_
34	the	the	DT	_	36	det	_	_
35	possible	possible	JJ	_	36	attr	_	_
36	administration	administration	NN	_	4	conj	_	_
37	of	of	IN	_	40	case	_	_
38	several	several	JJ	_	40	attr	_	_
39	interacting	interact	VBG	_	40	attr	_	_
40	drugs	drug	NNS	_	36	ppmod	_	_
41	simultaneously	simultaneously	RB	_	40	adv	_	_
42	,	,	,	_	44	p	_	_
43	it	it	PRP	_	44	dep	_	_
44	is	be	VBZ	_	0	root	_	_
45	difficult	difficult	JJ	_	44	dep	_	_
46	to	to	TO	_	47	aux	_	_
47	predict	predict	VB	_	45	comp	_	_
48	the	the	DT	_	49	det	_	_
49	direction	direction	NN	_	47	obj	_	_
50	and	and	CC	_	49	cc	_	_
51	degree	degree	NN	_	49	conj	_	_
52	of	of	IN	_	55	case	_	_
53	the	the	DT	_	55	det	_	_
54	ultimate	ultimate	JJ	_	55	attr	_	_
55	effect	effect	NN	_	49	ppmod	_	_
56	of	of	IN	_	58	case	_	_
57	concomitant	concomitant	JJ	_	58	attr	_	_
58	medications	medication	NNS	_	55	ppmod	_	_
59	on	on	IN	_	61	case	_	_
60	drug1	drug0	NN	_	61	com	_	_
61	response	response	NN	_	55	ppmod	_	_
62	.	.	.	_	44	p	_	_

1	For	for	IN	_	2	case	_	_
2	example	example	NN	_	22	ppmod	_	_
3	,	,	,	_	22	p	_	_
4	since	since	IN	_	7	mark	_	_
5	drug1	drug0	NN	_	7	dep	_	_
6	may	may	MD	_	7	modal	_	_
7	reduce	reduce	VB	_	22	advcl	_	_
8	the	the	DT	_	10	det	_	_
9	gastrointestinal	gastrointestinal	JJ	_	10	attr	_	_
10	absorption	absorption	NN	_	7	obj	_	_
11	of	of	IN	_	15	case	_	_
12	both	both	CC	_	15	cc	_	_
13	the	the	DT	_	15	det	_	_
14	oral	oral	JJ	_	15	attr	_	_
15	drug2	drug0	NN	_	10	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	drug3	drug0	NN	_	15	conj	_	_
18	,	,	,	_	22	p	_	_
19	the	the	DT	_	21	det	_	_
20	net	net	JJ	_	21	attr	_	_
21	effects	effect	NNS	_	22	dep	_	_
22	are	be	VBP	_	0	root	_	_
23	unpredictable	unpredictable	JJ	_	22	dep	_	_
24	.	.	.	_	22	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	cause	cause	VB	_	0	root	_	_
4	an	an	DT	_	7	det	_	_
5	increased	increase	VBN	_	7	attr	_	_
6	prothrombin	prothrombin	NN	_	7	com	_	_
7	response	response	NN	_	3	obj	_	_
8	by	by	IN	_	9	case	_	_
9	displacing	displace	VBG	_	3	ppmod	_	_
10	the	the	DT	_	11	det	_	_
11	drug2	drug0	NN	_	9	obj	_	_
12	from	from	IN	_	15	case	_	_
13	protein	protein	NN	_	15	com	_	_
14	binding	binding	NN	_	15	com	_	_
15	sites	site	NNS	_	11	ppmod	_	_
16	or	or	CC	_	11	cc	_	_
17	a	a	DT	_	20	det	_	_
18	diminished	diminish	VBN	_	20	attr	_	_
19	prothrombin	prothrombin	NN	_	20	com	_	_
20	response	response	NN	_	11	conj	_	_
21	through	through	IN	_	23	case	_	_
22	increased	increase	VBN	_	23	attr	_	_
23	metabolism	metabolism	NN	_	9	ppmod	_	_
24	of	of	IN	_	27	case	_	_
25	the	the	DT	_	27	det	_	_
26	unbound	unbound	JJ	_	27	attr	_	_
27	drug	drug	NN	_	23	ppmod	_	_
28	by	by	IN	_	31	case	_	_
29	hepatic	hepatic	JJ	_	31	attr	_	_
30	enzyme	enzyme	NN	_	31	com	_	_
31	induction	induction	NN	_	23	ppmod	_	_
32	,	,	,	_	9	p	_	_
33	thus	thus	RB	_	34	adv	_	_
34	leading	lead	VBG	_	9	comp	_	_
35	to	to	TO	_	37	aux	_	_
36	inter-patient	inter-patient	JJ	_	37	attr	_	_
37	variation	variation	NN	_	34	ppmod	_	_
38	in	in	IN	_	41	case	_	_
39	ultimate	ultimate	JJ	_	41	attr	_	_
40	prothrombin	prothrombin	NN	_	41	com	_	_
41	effect	effect	NN	_	37	ppmod	_	_
42	.	.	.	_	3	p	_	_

1	An	an	DT	_	3	det	_	_
2	interacting	interact	VBG	_	3	attr	_	_
3	drug	drug	NN	_	32	dep	_	_
4	which	which	WDT	_	5	dep	_	_
5	leads	lead	VBZ	_	3	relcl	_	_
6	to	to	TO	_	8	aux	_	_
7	a	a	DT	_	8	det	_	_
8	decrease	decrease	NN	_	5	ppmod	_	_
9	in	in	IN	_	11	case	_	_
10	prothrombin	prothrombin	NN	_	11	com	_	_
11	time	time	NN	_	8	ppmod	_	_
12	necessitating	necessitate	VBG	_	5	comp	_	_
13	an	an	DT	_	15	det	_	_
14	increased	increase	VBN	_	15	attr	_	_
15	dose	dose	NN	_	12	obj	_	_
16	of	of	IN	_	18	case	_	_
17	oral	oral	JJ	_	18	attr	_	_
18	drug1	drug0	NN	_	15	ppmod	_	_
19	to	to	TO	_	20	aux	_	_
20	maintain	maintain	VB	_	12	comp	_	_
21	an	an	DT	_	23	det	_	_
22	adequate	adequate	JJ	_	23	attr	_	_
23	degree	degree	NN	_	20	obj	_	_
24	of	of	IN	_	25	case	_	_
25	anticoagulation	anticoagulation	NN	_	23	ppmod	_	_
26	may	may	MD	_	32	modal	_	_
27	,	,	,	_	32	p	_	_
28	if	if	IN	_	30	mark	_	_
29	abruptly	abruptly	RB	_	30	adv	_	_
30	discontinued	discontinue	VBN	_	32	comp	_	_
31	,	,	,	_	32	p	_	_
32	increase	increase	VB	_	0	root	_	_
33	the	the	DT	_	34	det	_	_
34	risk	risk	NN	_	32	obj	_	_
35	of	of	IN	_	37	case	_	_
36	subsequent	subsequent	JJ	_	37	attr	_	_
37	bleeding	bleeding	JJ	_	34	ppmod	_	_
38	.	.	.	_	32	p	_	_

1	Drugs	drug	NNS	_	22	dep	_	_
2	that	that	WDT	_	5	dep	_	_
3	have	have	VBP	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	reported	report	VBN	_	1	relcl	_	_
6	to	to	TO	_	7	aux	_	_
7	diminish	diminish	VB	_	5	comp	_	_
8	oral	oral	JJ	_	10	attr	_	_
9	drug1	drug0	NN	_	10	com	_	_
10	response	response	NN	_	7	obj	_	_
11	,	,	,	_	10	p	_	_
12	ie	ie	NN	_	10	appo	_	_
13	,	,	,	_	10	p	_	_
14	decreased	decrease	VBN	_	17	attr	_	_
15	prothrom-bin	prothrom-bin	JJ	_	17	attr	_	_
16	time	time	NN	_	17	com	_	_
17	response	response	NN	_	10	appo	_	_
18	,	,	,	_	10	p	_	_
19	in	in	IN	_	20	case	_	_
20	man	man	NN	_	7	ppmod	_	_
21	significantly	significantly	RB	_	22	adv	_	_
22	include	include	VBP	_	0	root	_	_
23	:	:	:	_	22	p	_	_
24	drug2	drug0	NN	_	22	obj	_	_
25	;	;	:	_	22	p	_	_

1	drug1	drug0	NNP	_	2	com	_	_
2	*	*	NNP	_	0	root	_	_
3	;	;	:	_	2	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	2	com	_	_
2	*	*	NNP	_	0	root	_	_
3	;	;	:	_	2	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	diet	diet	NN	_	2	dep	_	_
2	high	high	JJ	_	0	root	_	_
3	in	in	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	;	;	:	_	2	p	_	_

1	drug1	drug0	NNP	_	2	com	_	_
2	*	*	NNP	_	0	root	_	_
3	;	;	:	_	2	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	oral	oral	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	;	;	:	_	2	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	2	com	_	_
2	*	*	NNP	_	0	root	_	_
3	;	;	:	_	2	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	unreliable	unreliable	JJ	_	4	attr	_	_
2	prothrombin	prothrombin	NN	_	4	com	_	_
3	time	time	NN	_	4	com	_	_
4	determinations	determination	NNS	_	0	root	_	_
5	;	;	:	_	4	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	Drugs	drug	NNS	_	0	root	_	_
2	that	that	WDT	_	5	dep	_	_
3	have	have	VBP	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	reported	report	VBN	_	1	relcl	_	_
6	to	to	TO	_	7	aux	_	_
7	diminish	diminish	VB	_	5	comp	_	_
8	oral	oral	JJ	_	10	attr	_	_
9	drug1	drug0	NN	_	10	com	_	_
10	response	response	NN	_	7	obj	_	_
11	,	,	,	_	7	p	_	_
12	ie	ie	NN	_	22	dep	_	_
13	,	,	,	_	12	p	_	_
14	decreased	decrease	VBD	_	12	acl	_	_
15	prothrom-bin	prothrom-bin	NN	_	17	com	_	_
16	time	time	NN	_	17	com	_	_
17	response	response	NN	_	14	obj	_	_
18	,	,	,	_	12	p	_	_
19	in	in	IN	_	20	case	_	_
20	man	man	NN	_	22	ppmod	_	_
21	significantly	significantly	RB	_	22	adv	_	_
22	include	include	VBP	_	7	comp	_	_
23	:	:	:	_	22	p	_	_
24	drug2	drug0	NN	_	22	obj	_	_
25	;	;	:	_	24	p	_	_
26	drug3	drug0	NN	_	27	com	_	_
27	*	*	NN	_	24	appo	_	_
28	;	;	:	_	24	p	_	_
29	drug4	drug0	NN	_	24	appo	_	_
30	;	;	:	_	24	p	_	_
31	drug5	drug0	NN	_	24	appo	_	_
32	;	;	:	_	24	p	_	_
33	drug6	drug0	NN	_	42	attr	_	_
34	;	;	:	_	42	p	_	_
35	drug7	drug0	NN	_	33	appo	_	_
36	;	;	:	_	42	p	_	_
37	drug8	drug0	NN	_	38	com	_	_
38	*	*	NN	_	33	appo	_	_
39	;	;	:	_	42	p	_	_
40	drug9	drug0	NN	_	33	appo	_	_
41	;	;	:	_	42	p	_	_
42	drug10	drug0	CD	_	24	appo	_	_
43	;	;	:	_	24	p	_	_
44	diet	diet	NN	_	82	attr	_	_
45	high	high	JJ	_	82	attr	_	_
46	in	in	IN	_	81	case	_	_
47	drug11	drug0	NN	_	60	attr	_	_
48	;	;	:	_	60	p	_	_
49	drug12	drug0	CD	_	50	num	_	_
50	*	*	NN	_	47	appo	_	_
51	;	;	:	_	60	p	_	_
52	drug13	drug0	CD	_	47	appo	_	_
53	;	;	:	_	60	p	_	_
54	drug14	drug0	CD	_	60	num	_	_
55	;	;	:	_	60	p	_	_
56	drug15	drug0	CD	_	60	num	_	_
57	;	;	:	_	60	p	_	_
58	drug16	drug0	CD	_	60	num	_	_
59	;	;	:	_	60	p	_	_
60	drug17	drug0	CD	_	81	num	_	_
61	;	;	:	_	81	p	_	_
62	oral	oral	JJ	_	63	attr	_	_
63	drug18	drug0	NN	_	60	appo	_	_
64	;	;	:	_	81	p	_	_
65	drug19	drug0	CD	_	60	appo	_	_
66	;	;	:	_	81	p	_	_
67	drug20	drug0	CD	_	70	num	_	_
68	;	;	:	_	70	p	_	_
69	drug21	drug0	CD	_	70	num	_	_
70	*	*	NN	_	60	appo	_	_
71	;	;	:	_	81	p	_	_
72	drug22	drug0	CD	_	60	appo	_	_
73	;	;	:	_	81	p	_	_
74	unreliable	unreliable	JJ	_	77	attr	_	_
75	prothrombin	prothrombin	NN	_	77	com	_	_
76	time	time	NN	_	77	com	_	_
77	determinations	determination	NNS	_	60	appo	_	_
78	;	;	:	_	81	p	_	_
79	drug23	drug0	CD	_	81	num	_	_
80	;	;	:	_	81	p	_	_
81	drug24	drug0	CD	_	45	ppmod	_	_
82	under-dosage	under-dosage	NN	_	24	appo	_	_
83	.	.	.	_	1	p	_	_

1	Drugs	drug	NNS	_	18	dep	_	_
2	that	that	WDT	_	5	dep	_	_
3	reportedly	reportedly	RB	_	5	adv	_	_
4	may	may	MD	_	5	modal	_	_
5	increase	increase	VB	_	1	relcl	_	_
6	oral	oral	JJ	_	8	attr	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	response	response	NN	_	5	obj	_	_
9	,	,	,	_	8	p	_	_
10	ie	ie	NN	_	8	appo	_	_
11	,	,	,	_	8	p	_	_
12	increased	increase	VBN	_	14	attr	_	_
13	prothrombin	prothrombin	NN	_	14	com	_	_
14	response	response	NN	_	8	appo	_	_
15	,	,	,	_	8	p	_	_
16	in	in	IN	_	17	case	_	_
17	man	man	NN	_	5	ppmod	_	_
18	include	include	VBP	_	0	root	_	_
19	:	:	:	_	18	p	_	_
20	drug2	drug0	NN	_	21	com	_	_
21	*	*	NNS	_	18	obj	_	_
22	;	;	:	_	18	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	2	com	_	_
2	*	*	NNP	_	0	root	_	_
3	;	;	:	_	2	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	dietary	dietary	JJ	_	2	attr	_	_
2	deficiencies	deficiency	NNS	_	0	root	_	_
3	;	;	:	_	2	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	2	com	_	_
2	*	*	NNP	_	0	root	_	_
3	;	;	:	_	2	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drugs	drug	NNS	_	0	root	_	_
2	affecting	affect	VBG	_	1	acl	_	_
3	blood	blood	NN	_	4	com	_	_
4	elements	element	NNS	_	2	obj	_	_
5	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	hepatotoxic	hepatotoxic	JJ	_	2	attr	_	_
2	drugs	drug	NNS	_	0	root	_	_
3	;	;	:	_	2	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	inhalation	inhalation	NN	_	2	com	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	;	;	:	_	2	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	prolonged	prolonged	JJ	_	3	attr	_	_
2	hot	hot	JJ	_	3	attr	_	_
3	weather	weather	NN	_	0	root	_	_
4	;	;	:	_	3	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	2	com	_	_
2	*	*	NNP	_	0	root	_	_
3	;	;	:	_	2	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	;	;	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	;	;	:	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	,	,	,	_	1	p	_	_
3	long	long	JJ	_	4	attr	_	_
4	acting	acting	NN	_	1	appo	_	_
5	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	/	/	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	;	;	:	_	1	p	_	_

1	unreliable	unreliable	JJ	_	4	attr	_	_
2	prothrombin	prothrombin	NN	_	4	com	_	_
3	time	time	NN	_	4	com	_	_
4	determinations	determination	NNS	_	0	root	_	_
5	;	;	:	_	4	p	_	_

1	Drugs	drug	NNS	_	134	dep	_	_
2	that	that	IN	_	134	case	_	_
3	reportedly	reportedly	RB	_	134	adv	_	_
4	may	may	MD	_	134	dep	_	_
5	increase	increase	NN	_	134	dep	_	_
6	oral	oral	JJ	_	134	dep	_	_
7	drug1	drug0	NN	_	134	dep	_	_
8	response	response	NN	_	134	dep	_	_
9	,	,	,	_	134	p	_	_
10	ie	ie	JJ	_	134	dep	_	_
11	,	,	,	_	134	p	_	_
12	increased	increase	VBN	_	134	dep	_	_
13	prothrombin	prothrombin	NN	_	134	dep	_	_
14	response	response	NN	_	134	dep	_	_
15	,	,	,	_	134	p	_	_
16	in	in	IN	_	134	case	_	_
17	man	man	NN	_	134	dep	_	_
18	include	include	VBP	_	134	dep	_	_
19	:	:	:	_	134	p	_	_
20	drug2	drug0	NN	_	134	dep	_	_
21	*	*	NN	_	134	dep	_	_
22	;	;	:	_	134	p	_	_
23	drug3	drug0	NN	_	134	dep	_	_
24	;	;	:	_	134	p	_	_
25	drug4	drug0	NN	_	134	dep	_	_
26	;	;	:	_	134	p	_	_
27	drug5	drug0	NN	_	134	dep	_	_
28	;	;	:	_	134	p	_	_
29	drug6	drug0	NN	_	134	dep	_	_
30	;	;	:	_	134	p	_	_
31	drug7	drug0	NN	_	134	dep	_	_
32	;	;	:	_	134	p	_	_
33	drug8	drug0	NN	_	134	dep	_	_
34	;	;	:	_	134	p	_	_
35	drug9	drug0	NN	_	134	dep	_	_
36	*	*	NN	_	134	dep	_	_
37	;	;	:	_	134	p	_	_
38	drug10	drug0	NN	_	134	dep	_	_
39	;	;	:	_	134	p	_	_
40	drug11	drug0	NN	_	134	dep	_	_
41	;	;	:	_	134	p	_	_
42	drug12	drug0	NN	_	134	dep	_	_
43	;	;	:	_	134	p	_	_
44	drug13	drug0	NN	_	134	dep	_	_
45	;	;	:	_	134	p	_	_
46	drug14	drug0	NN	_	134	dep	_	_
47	;	;	:	_	134	p	_	_
48	drug15	drug0	NN	_	134	dep	_	_
49	;	;	:	_	134	p	_	_
50	drug16	drug0	NN	_	134	dep	_	_
51	;	;	:	_	134	p	_	_
52	drug17	drug0	NN	_	134	dep	_	_
53	;	;	:	_	134	p	_	_
54	dietary	dietary	JJ	_	134	dep	_	_
55	deficiencies	deficiency	NNS	_	134	dep	_	_
56	;	;	:	_	134	p	_	_
57	drug18	drug0	NN	_	134	dep	_	_
58	;	;	:	_	134	p	_	_
59	drug19	drug0	NN	_	134	dep	_	_
60	;	;	:	_	134	p	_	_
61	drugs	drug	NNS	_	134	dep	_	_
62	affecting	affect	VBG	_	134	dep	_	_
63	blood	blood	NN	_	134	dep	_	_
64	elements	element	NNS	_	134	dep	_	_
65	;	;	:	_	134	p	_	_
66	drug20	drug0	CD	_	134	num	_	_
67	;	;	:	_	134	p	_	_
68	drug21	drug0	NN	_	134	dep	_	_
69	;	;	:	_	134	p	_	_
70	drug22	drug0	NN	_	134	dep	_	_
71	;	;	:	_	134	p	_	_
72	hepatotoxic	hepatotoxic	JJ	_	134	dep	_	_
73	drugs	drug	NNS	_	134	dep	_	_
74	;	;	:	_	134	p	_	_
75	drug23	drug0	NN	_	134	dep	_	_
76	;	;	:	_	134	p	_	_
77	drug24	drug0	CD	_	134	num	_	_
78	;	;	:	_	134	p	_	_
79	drug25	drug0	CD	_	134	num	_	_
80	;	;	:	_	134	p	_	_
81	inhalation	inhalation	NN	_	134	dep	_	_
82	drug26	drug0	CD	_	134	num	_	_
83	;	;	:	_	134	p	_	_
84	drug27	drug0	NN	_	134	dep	_	_
85	;	;	:	_	134	p	_	_
86	drug28	drug0	NN	_	134	dep	_	_
87	;	;	:	_	134	p	_	_
88	drug29	drug0	CD	_	134	num	_	_
89	;	;	:	_	134	p	_	_
90	drug30	drug0	CD	_	134	num	_	_
91	;	;	:	_	134	p	_	_
92	drug31	drug0	CD	_	134	num	_	_
93	;	;	:	_	134	p	_	_
94	drug32	drug0	NN	_	134	dep	_	_
95	;	;	:	_	134	p	_	_
96	drug33	drug0	CD	_	134	num	_	_
97	;	;	:	_	134	p	_	_
98	drug34	drug0	NN	_	134	dep	_	_
99	;	;	:	_	134	p	_	_
100	drug35	drug0	CD	_	134	num	_	_
101	;	;	:	_	134	p	_	_
102	drug36	drug0	CD	_	134	num	_	_
103	;	;	:	_	134	p	_	_
104	drug37	drug0	CD	_	134	num	_	_
105	;	;	:	_	134	p	_	_
106	drug38	drug0	CD	_	134	num	_	_
107	;	;	:	_	134	p	_	_
108	drug39	drug0	CD	_	134	num	_	_
109	;	;	:	_	134	p	_	_
110	drug40	drug0	NN	_	134	dep	_	_
111	;	;	:	_	134	p	_	_
112	prolonged	prolonged	JJ	_	134	dep	_	_
113	hot	hot	JJ	_	134	dep	_	_
114	weather	weather	NN	_	134	dep	_	_
115	;	;	:	_	134	p	_	_
116	drug41	drug0	CD	_	134	num	_	_
117	;	;	:	_	134	p	_	_
118	drug42	drug0	CD	_	134	num	_	_
119	;	;	:	_	134	p	_	_
120	drug43	drug0	NN	_	134	dep	_	_
121	;	;	:	_	134	p	_	_
122	drug44	drug0	CD	_	134	num	_	_
123	;	;	:	_	134	p	_	_
124	drug45	drug0	CD	_	134	num	_	_
125	*	*	NN	_	134	dep	_	_
126	;	;	:	_	134	p	_	_
127	drug46	drug0	CD	_	134	num	_	_
128	;	;	:	_	134	p	_	_
129	drug47	drug0	CD	_	134	num	_	_
130	;	;	:	_	134	p	_	_
131	drug48	drug0	CD	_	134	num	_	_
132	,	,	,	_	134	p	_	_
133	long	long	JJ	_	134	dep	_	_
134	acting	act	VBG	_	0	root	_	_
135	;	;	:	_	134	p	_	_
136	drug49	drug0	CD	_	134	num	_	_
137	;	;	:	_	134	p	_	_
138	drug50	drug0	CD	_	134	num	_	_
139	;	;	:	_	134	p	_	_
140	drug51	drug0	CD	_	134	num	_	_
141	;	;	:	_	134	p	_	_
142	drug52	drug0	CD	_	134	num	_	_
143	;	;	:	_	134	p	_	_
144	drug53	drug0	CD	_	134	num	_	_
145	/	/	:	_	134	p	_	_
146	drug54	drug0	CD	_	134	num	_	_
147	;	;	:	_	134	p	_	_
148	unreliable	unreliable	JJ	_	134	dep	_	_
149	prothrombin	prothrombin	NN	_	134	dep	_	_
150	time	time	NN	_	134	dep	_	_
151	determinations	determination	NNS	_	134	dep	_	_
152	;	;	:	_	134	p	_	_
153	drug55	drug0	CD	_	134	num	_	_
154	overdosage	overdosage	NN	_	134	dep	_	_
155	.	.	.	_	134	p	_	_

1	Oral	oral	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	potentiate	potentiate	VB	_	0	root	_	_
5	the	the	DT	_	7	det	_	_
6	hypoglycemic	hypoglycemic	JJ	_	7	attr	_	_
7	action	action	NN	_	4	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	9	p	_	_
11	eg	eg	NN	_	9	conj	_	_
12	,	,	,	_	11	p	_	_
13	drug3	drug0	NN	_	9	conj	_	_
14	and	and	CC	_	13	cc	_	_
15	drug4	drug0	NN	_	9	conj	_	_
16	,	,	,	_	4	p	_	_
17	by	by	IN	_	18	case	_	_
18	inhibiting	inhibit	VBG	_	4	ppmod	_	_
19	their	their	PRP$	_	20	poss	_	_
20	metabolism	metabolism	NN	_	18	obj	_	_
21	in	in	IN	_	23	case	_	_
22	the	the	DT	_	23	det	_	_
23	liver	liver	NN	_	20	ppmod	_	_
24	.	.	.	_	4	p	_	_

1	Because	because	IN	_	5	mark	_	_
2	oral	oral	JJ	_	3	attr	_	_
3	drug1	drug0	NN	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	interfere	interfere	VB	_	19	advcl	_	_
6	with	with	IN	_	9	case	_	_
7	the	the	DT	_	9	det	_	_
8	hepatic	hepatic	JJ	_	9	attr	_	_
9	metabolism	metabolism	NN	_	5	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	,	,	,	_	19	p	_	_
13	toxic	toxic	JJ	_	14	attr	_	_
14	levels	level	NNS	_	19	dep	_	_
15	of	of	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	drug3	drug0	NN	_	14	ppmod	_	_
18	may	may	MD	_	19	modal	_	_
19	occur	occur	VB	_	0	root	_	_
20	when	when	WRB	_	27	adv	_	_
21	an	an	DT	_	23	det	_	_
22	oral	oral	JJ	_	23	attr	_	_
23	drug4	drug0	NN	_	27	dep	_	_
24	and	and	CC	_	23	cc	_	_
25	drug5	drug0	NN	_	23	conj	_	_
26	are	be	VBP	_	27	aux	_	_
27	administered	administer	VBN	_	19	comp	_	_
28	concurrently	concurrently	RB	_	27	adv	_	_
29	.	.	.	_	19	p	_	_

1	Drugs	drug	NNS	_	42	dep	_	_
2	that	that	WDT	_	3	dep	_	_
3	reduce	reduce	VBP	_	1	relcl	_	_
4	the	the	DT	_	5	det	_	_
5	number	number	NN	_	3	obj	_	_
6	of	of	IN	_	8	case	_	_
7	blood	blood	NN	_	8	com	_	_
8	platelets	platelet	NNS	_	5	ppmod	_	_
9	by	by	IN	_	10	case	_	_
10	causing	cause	VBG	_	3	ppmod	_	_
11	bone	bone	NN	_	13	com	_	_
12	marrow	marrow	NN	_	13	com	_	_
13	depression	depression	NN	_	10	obj	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	such	such	JJ	_	13	prn	_	_
16	as	as	IN	_	17	case	_	_
17	drug1	drug0	NN	_	15	ppmod	_	_
18	)	-rrb-	-RRB-	_	15	p	_	_
19	or	or	CC	_	1	cc	_	_
20	drugs	drug	NNS	_	1	conj	_	_
21	which	which	WDT	_	22	dep	_	_
22	inhibit	inhibit	VBP	_	1	relcl	_	_
23	platelet	platelet	NN	_	24	com	_	_
24	function	function	NN	_	22	obj	_	_
25	(	-lrb-	-LRB-	_	33	p	_	_
26	eg	eg	NN	_	33	dep	_	_
27	,	,	,	_	26	p	_	_
28	drug2	drug0	NN	_	26	conj	_	_
29	and	and	CC	_	28	cc	_	_
30	other	other	JJ	_	31	attr	_	_
31	drug3	drug0	NN	_	26	conj	_	_
32	,	,	,	_	33	p	_	_
33	drug4	drug0	NN	_	22	prn	_	_
34	,	,	,	_	33	p	_	_
35	drug5	drug0	NN	_	33	appo	_	_
36	,	,	,	_	33	p	_	_
37	drug6	drug0	NN	_	33	appo	_	_
38	,	,	,	_	33	p	_	_
39	drug7	drug0	NN	_	33	appo	_	_
40	)	-rrb-	-RRB-	_	33	p	_	_
41	may	may	MD	_	42	modal	_	_
42	increase	increase	VB	_	0	root	_	_
43	the	the	DT	_	45	det	_	_
44	bleeding	bleeding	JJ	_	45	attr	_	_
45	tendency	tendency	NN	_	42	obj	_	_
46	produced	produce	VBN	_	45	acl	_	_
47	by	by	IN	_	48	case	_	_
48	drug8	drug0	NN	_	46	ppmod	_	_
49	without	without	IN	_	50	case	_	_
50	altering	alter	VBG	_	46	ppmod	_	_
51	prothrombin	prothrombin	NN	_	53	com	_	_
52	time	time	NN	_	53	com	_	_
53	determinations	determination	NNS	_	50	obj	_	_
54	.	.	.	_	42	p	_	_

1	The	the	DT	_	3	det	_	_
2	beneficial	beneficial	JJ	_	3	attr	_	_
3	effects	effect	NNS	_	17	dep	_	_
4	on	on	IN	_	7	case	_	_
5	arterial	arterial	JJ	_	7	attr	_	_
6	thrombus	thrombus	NN	_	7	com	_	_
7	formation	formation	NN	_	3	ppmod	_	_
8	from	from	IN	_	10	case	_	_
9	combined	combined	JJ	_	10	attr	_	_
10	therapy	therapy	NN	_	3	ppmod	_	_
11	with	with	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	drug2	drug0	NN	_	12	conj	_	_
15	must	must	MD	_	17	modal	_	_
16	be	be	VB	_	17	aux	_	_
17	weighed	weigh	VBN	_	0	root	_	_
18	against	against	IN	_	21	case	_	_
19	an	an	DT	_	21	det	_	_
20	increased	increase	VBN	_	21	attr	_	_
21	risk	risk	NN	_	17	ppmod	_	_
22	of	of	IN	_	24	case	_	_
23	inducing	inducing	NN	_	24	com	_	_
24	hemorrhage	hemorrhage	NN	_	21	ppmod	_	_
25	.	.	.	_	17	p	_	_

1	*	*	JJ	_	2	adv	_	_
2	Increased	increase	VBN	_	10	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	decreased	decrease	VBN	_	6	attr	_	_
5	prothrombin	prothrombin	NN	_	6	com	_	_
6	time	time	NN	_	7	com	_	_
7	responses	response	NNS	_	2	conj	_	_
8	have	have	VBP	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	reported	report	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	Drug/Laboratory	drug/laboratory	JJ	_	3	attr	_	_
2	Test	test	NN	_	3	com	_	_
3	Interferences	interference	NNS	_	16	dep	_	_
4	:	:	:	_	3	p	_	_
5	drug1	drug0	NN	_	3	appo	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	,	,	,	_	3	p	_	_
9	including	include	VBG	_	10	adv	_	_
10	drug3	drug0	NN	_	3	ppmod	_	_
11	,	,	,	_	3	p	_	_
12	or	or	CC	_	3	cc	_	_
13	their	their	PRP$	_	14	poss	_	_
14	metabolites	metabolite	NNS	_	3	conj	_	_
15	may	may	MD	_	16	modal	_	_
16	color	color	NN	_	0	root	_	_
17	alkaline	alkaline	NN	_	18	com	_	_
18	urine	urine	NN	_	16	obj	_	_
19	red-orange	red-orange	JJ	_	18	attr	_	_
20	,	,	,	_	18	p	_	_
21	which	which	WDT	_	23	dep	_	_
22	may	may	MD	_	23	modal	_	_
23	interfere	interfere	VB	_	18	relcl	_	_
24	with	with	IN	_	29	case	_	_
25	spectrophotometrically	spectrophotometrically	RB	_	26	adv	_	_
26	determined	determine	VBN	_	29	attr	_	_
27	urinary	urinary	JJ	_	29	attr	_	_
28	laboratory	laboratory	NN	_	29	com	_	_
29	tests	test	NNS	_	23	ppmod	_	_
30	.	.	.	_	16	p	_	_

1	The	the	DT	_	2	det	_	_
2	color	color	NN	_	3	dep	_	_
3	reverses	reverse	VBZ	_	0	root	_	_
4	when	when	WRB	_	9	adv	_	_
5	the	the	DT	_	7	det	_	_
6	test	test	NN	_	7	com	_	_
7	sample	sample	NN	_	9	dep	_	_
8	is	be	VBZ	_	9	aux	_	_
9	acidified	acidify	VBN	_	3	comp	_	_
10	in	in	FW	_	11	adv	_	_
11	vitro	vitro	FW	_	9	adv	_	_
12	to	to	TO	_	14	aux	_	_
13	a	a	DT	_	14	det	_	_
14	pH	ph	NN	_	9	ppmod	_	_
15	below	below	IN	_	16	case	_	_
16	4	0	CD	_	14	ppmod	_	_
17	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	preparations	preparation	NNS	_	3	dep	_	_
3	are	be	VBP	_	0	root	_	_
4	incompatible	incompatible	JJ	_	3	dep	_	_
5	with	with	IN	_	7	case	_	_
6	drug2	drug0	NN	_	7	com	_	_
7	preparations	preparation	NNS	_	4	ppmod	_	_
8	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	10	dep	_	_
2	-	-	CC	_	1	cc	_	_
3	Concomitant	concomitant	JJ	_	4	attr	_	_
4	use	use	NN	_	1	conj	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	1	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	may	may	MD	_	10	modal	_	_
10	enhance	enhance	VB	_	0	root	_	_
11	nutrient	nutrient	JJ	_	12	attr	_	_
12	absorption	absorption	NN	_	10	obj	_	_
13	in	in	IN	_	14	case	_	_
14	those	those	DT	_	10	ppmod	_	_
15	with	with	IN	_	19	case	_	_
16	severe	severe	JJ	_	19	attr	_	_
17	short	short	JJ	_	19	attr	_	_
18	bowel	bowel	NN	_	19	com	_	_
19	syndrome	syndrome	NN	_	14	ppmod	_	_
20	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	has	have	VBZ	_	0	root	_	_
3	orphan	orphan	NN	_	5	com	_	_
4	drug	drug	NN	_	5	com	_	_
5	status	status	NN	_	2	obj	_	_
6	for	for	IN	_	8	case	_	_
7	this	this	DT	_	8	det	_	_
8	indication	indication	NN	_	2	ppmod	_	_
9	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	10	dep	_	_
2	-	-	CC	_	1	cc	_	_
3	Concomitant	concomitant	JJ	_	4	attr	_	_
4	use	use	NN	_	1	conj	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	1	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	may	may	MD	_	10	modal	_	_
10	ameliorate	ameliorate	VB	_	0	root	_	_
11	increased	increase	VBN	_	13	attr	_	_
12	intestinal	intestinal	JJ	_	13	attr	_	_
13	permeability	permeability	NN	_	10	obj	_	_
14	caused	cause	VBN	_	13	acl	_	_
15	by	by	IN	_	16	case	_	_
16	drug4	drug0	NN	_	14	ppmod	_	_
17	.	.	.	_	10	p	_	_

1	The	the	DT	_	3	det	_	_
2	reported	report	VBN	_	3	attr	_	_
3	dose	dose	NN	_	7	dep	_	_
4	used	use	VBN	_	3	acl	_	_
5	for	for	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	was	be	VBD	_	0	root	_	_
8	21	0	CD	_	9	num	_	_
9	grams	gram	NNS	_	7	dat	_	_
10	daily	daily	RB	_	11	adv	_	_
11	taken	take	VBN	_	9	acl	_	_
12	in	in	IN	_	14	case	_	_
13	divided	divided	JJ	_	14	attr	_	_
14	doses	dose	NNS	_	11	ppmod	_	_
15	three	#crd#	CD	_	16	num	_	_
16	times	time	NNS	_	7	obj	_	_
17	a	a	DT	_	18	det	_	_
18	day	day	NN	_	16	appo	_	_
19	.	.	.	_	7	p	_	_

1	Further	far	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	drug1	drug0	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	reported	report	VBN	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	have	have	VB	_	5	comp	_	_
8	a	a	DT	_	10	det	_	_
9	synergistic	synergistic	JJ	_	10	attr	_	_
10	effect	effect	NN	_	7	obj	_	_
11	with	with	IN	_	13	case	_	_
12	this	this	DT	_	13	det	_	_
13	combination	combination	NN	_	7	ppmod	_	_
14	in	in	IN	_	15	case	_	_
15	ameliorating	ameliorate	VBG	_	7	ppmod	_	_
16	intestinal	intestinal	JJ	_	17	attr	_	_
17	permeability	permeability	NN	_	15	obj	_	_
18	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	-	-	:	_	1	p	_	_
3	There	there	EX	_	4	dep	_	_
4	is	be	VBZ	_	1	acl	_	_
5	one	#crd#	CD	_	6	num	_	_
6	report	report	NN	_	4	obj	_	_
7	that	that	IN	_	10	mark	_	_
8	drug2	drug0	NN	_	10	dep	_	_
9	may	may	MD	_	10	modal	_	_
10	decrease	decrease	VB	_	6	acl	_	_
11	the	the	DT	_	13	det	_	_
12	possible	possible	JJ	_	13	attr	_	_
13	effectiveness	effectiveness	NN	_	10	obj	_	_
14	of	of	IN	_	16	case	_	_
15	supplemental	supplemental	JJ	_	16	attr	_	_
16	drug3	drug0	NN	_	13	ppmod	_	_
17	for	for	IN	_	19	case	_	_
18	chemotherapy-induced	chemotherapy-induced	JJ	_	19	attr	_	_
19	mucositis	mucositis	NN	_	13	ppmod	_	_
20	.	.	.	_	1	p	_	_

1	In	in	IN	_	3	case	_	_
2	another	another	DT	_	3	det	_	_
3	report	report	NN	_	11	ppmod	_	_
4	,	,	,	_	11	p	_	_
5	nine	#crd#	CD	_	6	num	_	_
6	patients	patient	NNS	_	11	dep	_	_
7	with	with	IN	_	9	case	_	_
8	breast	breast	NN	_	9	com	_	_
9	cancer	cancer	NN	_	6	ppmod	_	_
10	were	be	VBD	_	11	aux	_	_
11	reported	report	VBN	_	0	root	_	_
12	to	to	TO	_	13	aux	_	_
13	have	have	VB	_	11	comp	_	_
14	decreased	decrease	VBN	_	15	attr	_	_
15	symptoms	symptom	NNS	_	13	obj	_	_
16	of	of	IN	_	19	case	_	_
17	drug1	drug0	NN	_	19	attr	_	_
18	-related	-related	JJ	_	19	attr	_	_
19	toxicity	toxicity	NN	_	15	ppmod	_	_
20	when	when	WRB	_	21	adv	_	_
21	given	give	VBN	_	13	comp	_	_
22	supplemental	supplemental	JJ	_	23	attr	_	_
23	drug2	drug0	NN	_	21	obj	_	_
24	at	at	IN	_	26	case	_	_
25	a	a	DT	_	26	det	_	_
26	dose	dose	NN	_	21	ppmod	_	_
27	of	of	IN	_	29	case	_	_
28	0.5	0	CD	_	29	num	_	_
29	gram/kilogram/day	gram/kilogram/day	NN	_	26	ppmod	_	_
30	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	-	-	:	_	1	p	_	_
3	In	in	IN	_	5	case	_	_
4	one	#crd#	CD	_	5	num	_	_
5	report	report	NN	_	25	ppmod	_	_
6	,	,	,	_	25	p	_	_
7	drug2	drug0	NN	_	25	dep	_	_
8	at	at	IN	_	10	case	_	_
9	a	a	DT	_	10	det	_	_
10	dose	dose	NN	_	7	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	10	0	CD	_	13	num	_	_
13	grams	gram	NNS	_	10	ppmod	_	_
14	three	#crd#	CD	_	15	num	_	_
15	times	time	NNS	_	16	advnp	_	_
16	daily	daily	RB	_	10	adv	_	_
17	,	,	,	_	10	p	_	_
18	given	give	VBN	_	10	acl	_	_
19	24	0	CD	_	20	num	_	_
20	hours	hour	NNS	_	18	ppmod	_	_
21	after	after	IN	_	20	case	_	_
22	receiving	receive	VBG	_	20	comp	_	_
23	drug3	drug0	NN	_	22	obj	_	_
24	,	,	,	_	10	p	_	_
25	appeared	appear	VBD	_	1	acl	_	_
26	to	to	TO	_	27	aux	_	_
27	prevent	prevent	VB	_	25	comp	_	_
28	the	the	DT	_	29	det	_	_
29	development	development	NN	_	27	obj	_	_
30	of	of	IN	_	31	case	_	_
31	myalgia	myalgia	NN	_	29	ppmod	_	_
32	and	and	CC	_	31	cc	_	_
33	arthralgia	arthralgia	NN	_	31	conj	_	_
34	,	,	,	_	31	p	_	_
35	adverse	adverse	JJ	_	36	attr	_	_
36	reactions	reaction	NNS	_	31	appo	_	_
37	of	of	IN	_	38	case	_	_
38	drug4	drug0	NN	_	36	ppmod	_	_
39	.	.	.	_	1	p	_	_

1	In	in	IN	_	7	case	_	_
2	two	#crd#	CD	_	7	num	_	_
3	controlled	controlled	JJ	_	7	attr	_	_
4	crossover	crossover	NN	_	7	attr	_	_
5	clinical	clinical	JJ	_	7	attr	_	_
6	pharmacology	pharmacology	NN	_	7	com	_	_
7	studies	study	NNS	_	41	ppmod	_	_
8	in	in	IN	_	26	case	_	_
9	healthy	healthy	JJ	_	10	adv	_	_
10	male	male	JJ	_	26	attr	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	n=12	n=0	NN	_	10	prn	_	_
13	in	in	IN	_	15	case	_	_
14	each	each	DT	_	15	det	_	_
15	study	study	NN	_	12	ppmod	_	_
16	)	-rrb-	-RRB-	_	12	p	_	_
17	a	a	DT	_	19	det	_	_
18	nd	nd	JJ	_	19	attr	_	_
19	female	female	NN	_	26	attr	_	_
20	(	-lrb-	-LRB-	_	21	p	_	_
21	n=12	n=0	NN	_	19	prn	_	_
22	in	in	IN	_	24	case	_	_
23	each	each	DT	_	24	det	_	_
24	study	study	NN	_	21	ppmod	_	_
25	)	-rrb-	-RRB-	_	21	p	_	_
26	volunteers	volunteer	NNS	_	7	ppmod	_	_
27	,	,	,	_	41	p	_	_
28	drug1	drug0	NN	_	30	attr	_	_
29	7.5	0	CD	_	30	num	_	_
30	mg	mg	NN	_	41	dep	_	_
31	(	-lrb-	-LRB-	_	33	p	_	_
32	1.5	0	CD	_	33	num	_	_
33	times	time	NNS	_	30	prn	_	_
34	the	the	DT	_	36	det	_	_
35	daily	daily	JJ	_	36	attr	_	_
36	dose	dose	NN	_	33	appo	_	_
37	)	-rrb-	-RRB-	_	33	p	_	_
38	once	once	RB	_	39	com	_	_
39	daily	daily	RB	_	30	adv	_	_
40	was	be	VBD	_	41	aux	_	_
41	coadministered	coadministered	VBN	_	0	root	_	_
42	with	with	IN	_	45	case	_	_
43	drug2	drug0	NN	_	45	attr	_	_
44	500	0	CD	_	45	num	_	_
45	mg	mg	NN	_	41	ppmod	_	_
46	every	every	DT	_	48	det	_	_
47	8	0	CD	_	48	num	_	_
48	hours	hour	NNS	_	45	appo	_	_
49	or	or	CC	_	45	cc	_	_
50	drug3	drug0	NN	_	52	attr	_	_
51	200	0	CD	_	52	num	_	_
52	mg	mg	NN	_	45	conj	_	_
53	every	every	DT	_	55	det	_	_
54	12	0	CD	_	55	num	_	_
55	hours	hour	NNS	_	52	appo	_	_
56	for	for	IN	_	58	case	_	_
57	10	0	CD	_	58	num	_	_
58	days	day	NNS	_	52	ppmod	_	_
59	.	.	.	_	41	p	_	_

1	In	in	IN	_	10	case	_	_
2	three	#crd#	CD	_	10	num	_	_
3	separate	separate	JJ	_	10	attr	_	_
4	controlled	controlled	JJ	_	10	attr	_	_
5	,	,	,	_	10	p	_	_
6	parallel	parallel	JJ	_	10	attr	_	_
7	group	group	NN	_	10	attr	_	_
8	clinical	clinical	JJ	_	10	attr	_	_
9	pharmacology	pharmacology	NN	_	10	com	_	_
10	studies	study	NNS	_	22	ppmod	_	_
11	,	,	,	_	22	p	_	_
12	drug1	drug0	NN	_	22	dep	_	_
13	at	at	IN	_	16	case	_	_
14	the	the	DT	_	16	det	_	_
15	clinical	clinical	JJ	_	16	attr	_	_
16	dose	dose	NN	_	12	ppmod	_	_
17	of	of	IN	_	19	case	_	_
18	5	0	CD	_	19	num	_	_
19	mg	mg	NN	_	16	ppmod	_	_
20	has	have	VBZ	_	22	aux	_	_
21	been	be	VBN	_	22	aux	_	_
22	coadministered	coadministered	VBN	_	0	root	_	_
23	with	with	IN	_	26	case	_	_
24	drug2	drug0	NN	_	26	attr	_	_
25	500	0	CD	_	26	num	_	_
26	mg	mg	NN	_	22	ppmod	_	_
27	followed	followed	VBN	_	26	acl	_	_
28	by	by	IN	_	30	case	_	_
29	250	0	CD	_	30	num	_	_
30	mg	mg	NN	_	27	ppmod	_	_
31	once	once	IN	_	32	case	_	_
32	daily	daily	JJ	_	30	ppmod	_	_
33	for	for	IN	_	35	case	_	_
34	4	0	CD	_	35	num	_	_
35	days	day	NNS	_	32	ppmod	_	_
36	(	-lrb-	-LRB-	_	37	p	_	_
37	n=18	n=0	NN	_	35	prn	_	_
38	)	-rrb-	-RRB-	_	37	p	_	_
39	or	or	CC	_	26	cc	_	_
40	with	with	IN	_	43	case	_	_
41	drug3	drug0	NN	_	43	attr	_	_
42	20	0	CD	_	43	num	_	_
43	mg	mg	NN	_	26	conj	_	_
44	once	once	RB	_	45	adv	_	_
45	daily	daily	JJ	_	43	attr	_	_
46	for	for	IN	_	48	case	_	_
47	7	0	CD	_	48	num	_	_
48	days	day	NNS	_	45	ppmod	_	_
49	after	after	IN	_	54	case	_	_
50	a	a	DT	_	54	det	_	_
51	23	0	CD	_	52	num	_	_
52	day	day	NN	_	54	com	_	_
53	pretreatment	pretreatment	NN	_	54	com	_	_
54	period	period	NN	_	48	ppmod	_	_
55	with	with	IN	_	56	case	_	_
56	drug4	drug0	NN	_	54	ppmod	_	_
57	(	-lrb-	-LRB-	_	56	p	_	_
58	n=18	n=0	CD	_	56	num	_	_
59	)	-rrb-	-RRB-	_	56	p	_	_
60	or	or	CC	_	54	cc	_	_
61	with	with	IN	_	64	case	_	_
62	drug5	drug0	NN	_	64	attr	_	_
63	600	0	CD	_	64	num	_	_
64	mg	mg	NN	_	77	ppmod	_	_
65	every	every	DT	_	67	det	_	_
66	12	0	CD	_	67	num	_	_
67	hours	hour	NNS	_	64	appo	_	_
68	for	for	IN	_	70	case	_	_
69	14	0	CD	_	70	num	_	_
70	days	day	NNS	_	64	ppmod	_	_
71	(	-lrb-	-LRB-	_	72	p	_	_
72	n=18	n=0	CD	_	70	num	_	_
73	)	-rrb-	-RRB-	_	72	p	_	_
74	under	under	IN	_	77	case	_	_
75	steady	steady	JJ	_	77	attr	_	_
76	state	state	NN	_	77	com	_	_
77	conditions	condition	NNS	_	54	conj	_	_
78	to	to	TO	_	84	aux	_	_
79	normal	normal	JJ	_	84	attr	_	_
80	healthy	healthy	JJ	_	84	attr	_	_
81	male	male	JJ	_	84	attr	_	_
82	and	and	CC	_	81	cc	_	_
83	female	female	JJ	_	81	conj	_	_
84	volunteers	volunteer	NNS	_	77	ppmod	_	_
85	.	.	.	_	22	p	_	_

1	Although	although	IN	_	18	mark	_	_
2	increased	increase	VBN	_	4	attr	_	_
3	plasma	plasma	NN	_	4	com	_	_
4	concentrations	concentration	NNS	_	18	dep	_	_
5	(	-lrb-	-LRB-	_	7	p	_	_
6	C	c	NN	_	7	com	_	_
7	max	max	NN	_	4	prn	_	_
8	and	and	CC	_	7	cc	_	_
9	AUC	auc	NN	_	11	attr	_	_
10	0-24	0	CD	_	11	num	_	_
11	hrs	hr	NNS	_	7	conj	_	_
12	)	-rrb-	-RRB-	_	7	p	_	_
13	of	of	IN	_	14	case	_	_
14	drug1	drug0	NN	_	4	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	drug2	drug0	NN	_	14	conj	_	_
17	were	be	VBD	_	18	aux	_	_
18	observed	observe	VBN	_	21	advcl	_	_
19	,	,	,	_	21	p	_	_
20	there	there	EX	_	21	dep	_	_
21	were	be	VBD	_	0	root	_	_
22	no	no	DT	_	25	det	_	_
23	clinically	clinically	RB	_	24	adv	_	_
24	relevant	relevant	JJ	_	25	attr	_	_
25	changes	change	NNS	_	21	obj	_	_
26	in	in	IN	_	29	case	_	_
27	the	the	DT	_	29	det	_	_
28	safety	safety	NN	_	29	com	_	_
29	profile	profile	NN	_	21	ppmod	_	_
30	of	of	IN	_	31	case	_	_
31	drug3	drug0	NN	_	29	ppmod	_	_
32	,	,	,	_	21	p	_	_
33	as	as	IN	_	34	mark	_	_
34	assessed	assess	VBN	_	21	comp	_	_
35	by	by	IN	_	37	case	_	_
36	electrocardiographic	electrocardiographic	JJ	_	37	attr	_	_
37	parameters	parameter	NNS	_	34	ppmod	_	_
38	(	-lrb-	-LRB-	_	39	p	_	_
39	including	include	VBG	_	37	prn	_	_
40	the	the	DT	_	43	det	_	_
41	corrected	corrected	JJ	_	43	attr	_	_
42	QT	qt	JJ	_	43	attr	_	_
43	interval	interval	NN	_	39	obj	_	_
44	)	-rrb-	-RRB-	_	39	p	_	_
45	,	,	,	_	37	p	_	_
46	clinical	clinical	JJ	_	48	attr	_	_
47	laboratory	laboratory	NN	_	48	com	_	_
48	tests	test	NNS	_	37	conj	_	_
49	,	,	,	_	48	p	_	_
50	vital	vital	JJ	_	51	attr	_	_
51	signs	sign	NNS	_	37	conj	_	_
52	,	,	,	_	51	p	_	_
53	and	and	CC	_	51	cc	_	_
54	adverse	adverse	JJ	_	55	attr	_	_
55	events	event	NNS	_	37	conj	_	_
56	.	.	.	_	21	p	_	_

1	Table	table	NN	_	3	attr	_	_
2	1	0	CD	_	3	num	_	_
3	Changes	change	NNS	_	0	root	_	_
4	in	in	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	8	com	_	_
8	Pharmacokinetics	pharmacokinetics	NNS	_	5	conj	_	_
9	in	in	IN	_	14	case	_	_
10	Healthy	healthy	JJ	_	14	attr	_	_
11	Male	male	JJ	_	14	attr	_	_
12	and	and	CC	_	11	cc	_	_
13	Female	female	JJ	_	11	conj	_	_
14	Volunteers	volunteer	NNS	_	3	ppmod	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	drug2	drug0	NN	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	C	c	NN	_	10	attr	_	_
2	max	max	NN	_	10	attr	_	_
3	AUC	auc	NN	_	10	attr	_	_
4	0-24	0	CD	_	10	num	_	_
5	hrs	hr	NNS	_	10	attr	_	_
6	C	c	NN	_	10	attr	_	_
7	max	max	NN	_	10	attr	_	_
8	AUC	auc	NN	_	10	attr	_	_
9	0-24	0	NN	_	10	num	_	_
10	hrs	hr	NNS	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	(	-lrb-	-LRB-	_	4	p	_	_
2	500	0	CD	_	3	num	_	_
3	mg	mg	NN	_	4	com	_	_
4	Q8h	q0h	NN	_	0	root	_	_
5	)	-rrb-	-RRB-	_	4	p	_	_

1	+24	0	CD	_	5	num	_	_
2	%	%	NN	_	5	meta	_	_
3	+14	0	CD	_	5	num	_	_
4	%	%	NN	_	5	meta	_	_
5	+43	0	CD	_	0	root	_	_
6	%	%	NN	_	5	meta	_	_
7	+40	0	CD	_	5	appo	_	_
8	%	%	NN	_	7	meta	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	(	-lrb-	-LRB-	_	3	p	_	_
2	200	0	CD	_	3	num	_	_
3	mg	mg	NN	_	0	root	_	_
4	Q12h	q0h	IN	_	3	case	_	_
5	)	-rrb-	-RRB-	_	3	p	_	_

1	+45	0	NN	_	0	root	_	_
2	%	%	NN	_	1	meta	_	_
3	+39	0	CD	_	1	num	_	_
4	%	%	NN	_	1	meta	_	_
5	+43	0	CD	_	1	num	_	_
6	%	%	NN	_	1	meta	_	_
7	+72	0	CD	_	1	appo	_	_
8	%	%	NN	_	7	meta	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	(	-lrb-	-LRB-	_	11	p	_	_
2	500	0	CD	_	4	num	_	_
3	mg	mg	NN	_	4	com	_	_
4	day	day	NN	_	11	dep	_	_
5	1	0	CD	_	4	num	_	_
6	,	,	,	_	11	p	_	_
7	250	0	CD	_	11	num	_	_
8	mg	mg	NN	_	11	attr	_	_
9	QD	qd	NN	_	11	attr	_	_
10	4	0	CD	_	11	num	_	_
11	days	day	NNS	_	0	root	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_

1	+15	0	CD	_	3	num	_	_
2	%	%	NN	_	3	meta	_	_
3	+5	0	NN	_	0	root	_	_
4	%	%	NN	_	3	meta	_	_
5	+15	0	CD	_	3	num	_	_
6	%	%	NN	_	3	meta	_	_
7	+4	0	CD	_	3	appo	_	_
8	%	%	NN	_	7	meta	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	(	-lrb-	-LRB-	_	4	p	_	_
2	20	0	CD	_	3	num	_	_
3	mg	mg	NN	_	4	com	_	_
4	QD	qd	NN	_	0	root	_	_
5	)	-rrb-	-RRB-	_	4	p	_	_

1	+15	0	CD	_	3	num	_	_
2	%	%	NN	_	3	meta	_	_
3	+0	0	NN	_	0	root	_	_
4	%	%	NN	_	3	meta	_	_
5	+17	0	CD	_	3	num	_	_
6	%	%	NN	_	3	meta	_	_
7	+13	0	CD	_	3	num	_	_
8	%	%	NN	_	3	meta	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	(	-lrb-	-LRB-	_	3	p	_	_
2	600	0	CD	_	3	num	_	_
3	mg	mg	NN	_	0	root	_	_
4	Q12h	q0h	IN	_	3	case	_	_
5	)	-rrb-	-RRB-	_	3	p	_	_

1	+12	0	CD	_	0	root	_	_
2	%	%	NN	_	1	meta	_	_
3	+19	0	CD	_	5	num	_	_
4	%	%	NN	_	5	meta	_	_
5	-11	0	NN	_	1	appo	_	_
6	%	%	NN	_	5	meta	_	_
7	-3	0	CD	_	5	num	_	_
8	%	%	NN	_	5	meta	_	_

1	No	no	DT	_	9	det	_	_
2	specific	specific	JJ	_	9	attr	_	_
3	pharmacokinetic	pharmacokinetic	JJ	_	9	attr	_	_
4	or	or	CC	_	3	cc	_	_
5	other	other	JJ	_	3	conj	_	_
6	formal	formal	JJ	_	9	attr	_	_
7	drug	drug	NN	_	9	com	_	_
8	interaction	interaction	NN	_	9	com	_	_
9	studies	study	NNS	_	11	dep	_	_
10	were	be	VBD	_	11	aux	_	_
11	conducted	conduct	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	4	attr	_	_
2	:	:	:	_	4	p	_	_
3	Supraventricular	supraventricular	JJ	_	4	attr	_	_
4	arrhythmias	arrhythmia	NNS	_	6	dep	_	_
5	may	may	MD	_	6	modal	_	_
6	mask	mask	VB	_	0	root	_	_
7	the	the	DT	_	8	det	_	_
8	cardiotoxicity	cardiotoxicity	NN	_	6	obj	_	_
9	associated	associate	VBN	_	8	acl	_	_
10	with	with	IN	_	13	case	_	_
11	excessive	excessive	JJ	_	13	attr	_	_
12	drug2	drug0	NN	_	13	com	_	_
13	levels	level	NNS	_	9	ppmod	_	_
14	.	.	.	_	6	p	_	_

1	Therefore	therefore	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	it	it	PRP	_	4	dep	_	_
4	is	be	VBZ	_	0	root	_	_
5	advisable	advisable	JJ	_	4	dep	_	_
6	to	to	TO	_	7	aux	_	_
7	be	be	VB	_	5	comp	_	_
8	particularly	particularly	RB	_	9	adv	_	_
9	cautious	cautious	JJ	_	7	dep	_	_
10	in	in	IN	_	11	case	_	_
11	patients	patient	NNS	_	9	ppmod	_	_
12	whose	whose	WP$	_	15	poss	_	_
13	plasma	plasma	NN	_	15	com	_	_
14	drug1	drug0	NN	_	15	com	_	_
15	levels	level	NNS	_	19	dep	_	_
16	are	be	VBP	_	19	aux	_	_
17	above	above	JJ	_	19	dep	_	_
18	or	or	CC	_	19	cc	_	_
19	suspected	suspect	VBN	_	11	relcl	_	_
20	to	to	TO	_	21	aux	_	_
21	be	be	VB	_	19	comp	_	_
22	above	above	IN	_	26	case	_	_
23	the	the	DT	_	26	det	_	_
24	usual	usual	JJ	_	26	attr	_	_
25	therapeutic	therapeutic	JJ	_	26	attr	_	_
26	range	range	NN	_	21	ppmod	_	_
27	.	.	.	_	4	p	_	_

1	Coadministration	coadministration	NN	_	6	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	did	do	VBD	_	6	aux	_	_
5	not	not	RB	_	6	neg	_	_
6	have	have	VB	_	0	root	_	_
7	effects	effect	NNS	_	6	obj	_	_
8	on	on	IN	_	11	case	_	_
9	either	either	CC	_	11	cc	_	_
10	the	the	DT	_	11	det	_	_
11	safety	safety	NN	_	7	ppmod	_	_
12	or	or	CC	_	11	cc	_	_
13	efficacy	efficacy	NN	_	11	conj	_	_
14	of	of	IN	_	15	case	_	_
15	drug2	drug0	NN	_	11	ppmod	_	_
16	in	in	IN	_	19	case	_	_
17	the	the	DT	_	19	det	_	_
18	clinical	clinical	JJ	_	19	attr	_	_
19	trials	trial	NNS	_	6	ppmod	_	_
20	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Coadministration	coadministration	NN	_	8	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	did	do	VBD	_	8	aux	_	_
7	not	not	RB	_	8	neg	_	_
8	have	have	VB	_	1	acl	_	_
9	any	any	DT	_	10	det	_	_
10	effect	effect	NN	_	8	obj	_	_
11	on	on	IN	_	14	case	_	_
12	either	either	CC	_	14	cc	_	_
13	the	the	DT	_	14	det	_	_
14	safety	safety	NN	_	8	ppmod	_	_
15	or	or	CC	_	14	cc	_	_
16	efficacy	efficacy	NN	_	14	conj	_	_
17	of	of	IN	_	18	case	_	_
18	drug3	drug0	NN	_	14	ppmod	_	_
19	in	in	IN	_	22	case	_	_
20	the	the	DT	_	22	det	_	_
21	clinical	clinical	JJ	_	22	attr	_	_
22	trials	trial	NNS	_	14	ppmod	_	_
23	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Coadministration	coadministration	NN	_	8	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	did	do	VBD	_	8	aux	_	_
7	not	not	RB	_	8	neg	_	_
8	have	have	VB	_	1	acl	_	_
9	any	any	DT	_	10	det	_	_
10	effect	effect	NN	_	8	obj	_	_
11	on	on	IN	_	14	case	_	_
12	either	either	CC	_	14	cc	_	_
13	the	the	DT	_	14	det	_	_
14	safety	safety	NN	_	8	ppmod	_	_
15	or	or	CC	_	14	cc	_	_
16	efficacy	efficacy	NN	_	14	conj	_	_
17	of	of	IN	_	18	case	_	_
18	drug3	drug0	NN	_	14	ppmod	_	_
19	in	in	IN	_	22	case	_	_
20	the	the	DT	_	22	det	_	_
21	clinical	clinical	JJ	_	22	attr	_	_
22	trials	trial	NNS	_	14	ppmod	_	_
23	.	.	.	_	1	p	_	_

1	Use	use	NN	_	12	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	in	in	IN	_	6	case	_	_
5	a	a	DT	_	6	det	_	_
6	patient	patient	NN	_	1	ppmod	_	_
7	who	who	WP	_	10	dep	_	_
8	has	have	VBZ	_	10	aux	_	_
9	previously	previously	RB	_	10	adv	_	_
10	received	receive	VBN	_	6	relcl	_	_
11	drug2	drug0	NN	_	10	obj	_	_
12	increases	increase	VBZ	_	0	root	_	_
13	the	the	DT	_	14	det	_	_
14	risk	risk	NN	_	12	obj	_	_
15	of	of	IN	_	16	case	_	_
16	cardiotoxicity	cardiotoxicity	NN	_	14	ppmod	_	_
17	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	should	should	MD	_	5	modal	_	_
3	not	not	RB	_	5	neg	_	_
4	be	be	VB	_	5	aux	_	_
5	used	use	VBN	_	0	root	_	_
6	in	in	IN	_	7	case	_	_
7	patients	patient	NNS	_	5	ppmod	_	_
8	who	who	WP	_	11	dep	_	_
9	have	have	VBP	_	11	aux	_	_
10	previously	previously	RB	_	11	adv	_	_
11	received	receive	VBN	_	7	relcl	_	_
12	the	the	DT	_	16	det	_	_
13	recommended	recommend	VBN	_	16	attr	_	_
14	maximum	maximum	JJ	_	16	attr	_	_
15	cumulative	cumulative	JJ	_	16	attr	_	_
16	doses	dose	NNS	_	11	obj	_	_
17	of	of	IN	_	18	case	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	or	or	CC	_	18	cc	_	_
20	drug3	drug0	NN	_	18	conj	_	_
21	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	8	dep	_	_
2	used	use	VBN	_	1	acl	_	_
3	concurrently	concurrently	RB	_	2	adv	_	_
4	with	with	IN	_	5	case	_	_
5	drug2	drug0	NN	_	2	ppmod	_	_
6	may	may	MD	_	8	modal	_	_
7	also	also	RB	_	8	adv	_	_
8	result	result	VB	_	0	root	_	_
9	in	in	IN	_	11	case	_	_
10	increased	increase	VBN	_	11	attr	_	_
11	cardiotoxicity	cardiotoxicity	NN	_	8	ppmod	_	_
12	.	.	.	_	8	p	_	_

1	Dosage	dosage	JJ	_	2	attr	_	_
2	reduction	reduction	NN	_	7	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	may	may	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	required	require	VBN	_	0	root	_	_
8	when	when	WRB	_	9	adv	_	_
9	used	use	VBN	_	7	comp	_	_
10	concurrently	concurrently	RB	_	9	adv	_	_
11	with	with	IN	_	14	case	_	_
12	other	other	JJ	_	14	attr	_	_
13	myelosuppressive	myelosuppressive	JJ	_	14	attr	_	_
14	agents	agent	NNS	_	9	ppmod	_	_
15	.	.	.	_	7	p	_	_

1	Hepatotoxic	hepatotoxic	JJ	_	2	attr	_	_
2	medications	medication	NNS	_	10	dep	_	_
3	,	,	,	_	2	p	_	_
4	such	such	JJ	_	7	adv	_	_
5	as	as	IN	_	7	case	_	_
6	high-dose	high-dose	JJ	_	7	attr	_	_
7	drug1	drug0	NN	_	2	ppmod	_	_
8	,	,	,	_	2	p	_	_
9	may	may	MD	_	10	modal	_	_
10	impair	impair	VB	_	0	root	_	_
11	liver	liver	NN	_	12	com	_	_
12	function	function	NN	_	10	obj	_	_
13	and	and	CC	_	10	cc	_	_
14	increase	increase	VB	_	10	conj	_	_
15	the	the	DT	_	16	det	_	_
16	risk	risk	NN	_	14	obj	_	_
17	of	of	IN	_	18	case	_	_
18	toxicity	toxicity	NN	_	16	ppmod	_	_
19	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	metabolized	metabolize	VBN	_	0	root	_	_
4	by	by	IN	_	6	case	_	_
5	CYP	cyp	NN	_	6	com	_	_
6	3A4	0a0	NN	_	3	ppmod	_	_
7	in	in	FW	_	8	adv	_	_
8	vitro	vitro	FW	_	3	adv	_	_
9	.	.	.	_	3	p	_	_

1	Clinical	clinical	JJ	_	2	attr	_	_
2	studies	study	NNS	_	19	dep	_	_
3	of	of	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	effect	effect	NN	_	2	ppmod	_	_
6	of	of	IN	_	10	case	_	_
7	strong	strong	JJ	_	10	attr	_	_
8	CYP	cyp	NN	_	10	com	_	_
9	3A4	0a0	NN	_	10	com	_	_
10	inhibitors	inhibitor	NNS	_	5	ppmod	_	_
11	on	on	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	pharmacokinetics	pharmacokinetics	NNS	_	5	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	have	have	VBP	_	19	aux	_	_
17	not	not	RB	_	19	neg	_	_
18	been	be	VBN	_	19	aux	_	_
19	performed	performed	VBN	_	0	root	_	_
20	.	.	.	_	19	p	_	_

1	Carcinogenesis	carcinogenesis	NN	_	0	root	_	_
2	,	,	,	_	1	p	_	_
3	Mutagenesis	mutagenesis	NN	_	1	conj	_	_
4	and	and	CC	_	3	cc	_	_
5	Impairment	impairment	NN	_	1	conj	_	_
6	of	of	IN	_	7	case	_	_
7	Fertility	fertility	NN	_	5	ppmod	_	_
8	A	a	DT	_	11	det	_	_
9	two-year	two-year	JJ	_	11	attr	_	_
10	carcinogenesis	carcinogenesis	NN	_	11	com	_	_
11	study	study	NN	_	13	dep	_	_
12	was	be	VBD	_	13	aux	_	_
13	conducted	conduct	VBN	_	1	acl	_	_
14	in	in	IN	_	18	case	_	_
15	female	female	JJ	_	18	attr	_	_
16	and	and	CC	_	15	cc	_	_
17	male	male	JJ	_	15	conj	_	_
18	rats	rat	NNS	_	13	ppmod	_	_
19	,	,	,	_	13	p	_	_
20	at	at	IN	_	22	case	_	_
21	intramuscular	intramuscular	JJ	_	22	attr	_	_
22	doses	dose	NNS	_	13	ppmod	_	_
23	of	of	IN	_	26	case	_	_
24	15	0	CD	_	26	num	_	_
25	mg/kg/30	mg/kg/0	NN	_	26	com	_	_
26	days	day	NNS	_	22	ppmod	_	_
27	,	,	,	_	26	p	_	_
28	10	0	CD	_	30	num	_	_
29	mg/rat/30	mg/rat/0	NN	_	30	com	_	_
30	days	day	NNS	_	26	appo	_	_
31	and	and	CC	_	30	cc	_	_
32	10	0	CD	_	34	num	_	_
33	mg/rat/15	mg/rat/0	NN	_	34	com	_	_
34	days	day	NNS	_	30	conj	_	_
35	.	.	.	_	1	p	_	_

1	These	these	DT	_	2	det	_	_
2	doses	dose	NNS	_	3	dep	_	_
3	correspond	correspond	VBP	_	0	root	_	_
4	to	to	TO	_	6	aux	_	_
5	approximately	approximately	RB	_	6	adv	_	_
6	1-	0-	CD	_	3	ppmod	_	_
7	,	,	,	_	6	p	_	_
8	3-	0-	CD	_	6	conj	_	_
9	,	,	,	_	8	p	_	_
10	and	and	CC	_	8	cc	_	_
11	5-fold	0-fold	JJ	_	6	conj	_	_
12	(	-lrb-	-LRB-	_	14	p	_	_
13	in	in	IN	_	14	case	_	_
14	females	female	NNS	_	11	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	and	and	CC	_	11	cc	_	_
17	1.3-	0-	NN	_	11	conj	_	_
18	,	,	,	_	17	p	_	_
19	1.3-	0-	NN	_	17	conj	_	_
20	,	,	,	_	19	p	_	_
21	and	and	CC	_	19	cc	_	_
22	1.6-fold	0-fold	NN	_	17	conj	_	_
23	(	-lrb-	-LRB-	_	29	p	_	_
24	in	in	IN	_	25	case	_	_
25	males	male	NNS	_	29	ppmod	_	_
26	)	-rrb-	-RRB-	_	29	p	_	_
27	the	the	DT	_	29	det	_	_
28	systemic	systemic	JJ	_	29	attr	_	_
29	exposure	exposure	NN	_	17	prn	_	_
30	-LSB-AUC0-30	-lsb-auc0	CD	_	31	num	_	_
31	days	day	NNS	_	29	appo	_	_
32	]	-rsb-	-RRB-	_	29	p	_	_
33	]	-rsb-	-RRB-	_	29	p	_	_
34	achieved	achieve	VBN	_	11	acl	_	_
35	in	in	IN	_	36	case	_	_
36	women	woman	NNS	_	34	ppmod	_	_
37	receiving	receive	VBG	_	36	acl	_	_
38	the	the	DT	_	40	det	_	_
39	recommended	recommend	VBN	_	40	attr	_	_
40	dose	dose	NN	_	37	obj	_	_
41	of	of	IN	_	43	case	_	_
42	250	0	CD	_	43	num	_	_
43	mg/month	mg/month	NN	_	40	ppmod	_	_
44	.	.	.	_	3	p	_	_

1	An	an	DT	_	3	det	_	_
2	increased	increase	VBN	_	3	attr	_	_
3	incidence	incidence	NN	_	15	dep	_	_
4	of	of	IN	_	9	case	_	_
5	benign	benign	JJ	_	9	attr	_	_
6	ovarian	ovarian	JJ	_	9	attr	_	_
7	granulosa	granulosa	NN	_	9	com	_	_
8	cell	cell	NN	_	9	com	_	_
9	tumors	tumor	NNS	_	3	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	testicular	testicular	JJ	_	14	attr	_	_
12	Leydig	leydig	NN	_	14	com	_	_
13	cell	cell	NN	_	14	com	_	_
14	tumors	tumor	NNS	_	9	conj	_	_
15	was	be	VBD	_	0	root	_	_
16	evident	evident	JJ	_	15	dep	_	_
17	,	,	,	_	15	p	_	_
18	in	in	IN	_	19	case	_	_
19	females	female	NNS	_	15	ppmod	_	_
20	dosed	dose	VBN	_	19	acl	_	_
21	at	at	IN	_	24	case	_	_
22	10	0	CD	_	24	num	_	_
23	mg/rat/15	mg/rat/0	NN	_	24	com	_	_
24	days	day	NNS	_	20	ppmod	_	_
25	and	and	CC	_	19	cc	_	_
26	males	male	NNS	_	19	conj	_	_
27	dosed	dose	VBN	_	26	acl	_	_
28	at	at	IN	_	31	case	_	_
29	15	0	CD	_	31	num	_	_
30	mg/rat/30	mg/rat/0	NN	_	31	com	_	_
31	days	day	NNS	_	27	ppmod	_	_
32	,	,	,	_	15	p	_	_
33	respectively	respectively	RB	_	15	adv	_	_
34	.	.	.	_	15	p	_	_

1	Induction	induction	NN	_	5	dep	_	_
2	of	of	IN	_	4	case	_	_
3	such	such	JJ	_	4	attr	_	_
4	tumors	tumor	NNS	_	1	ppmod	_	_
5	is	be	VBZ	_	0	root	_	_
6	consistent	consistent	JJ	_	5	dep	_	_
7	with	with	IN	_	12	case	_	_
8	the	the	DT	_	12	det	_	_
9	pharmacology-related	pharmacology-related	JJ	_	12	attr	_	_
10	endocrine	endocrine	JJ	_	12	attr	_	_
11	feedback	feedback	NN	_	12	com	_	_
12	alterations	alteration	NNS	_	6	ppmod	_	_
13	in	in	IN	_	15	case	_	_
14	gonadotropin	gonadotropin	NN	_	15	com	_	_
15	levels	level	NNS	_	12	ppmod	_	_
16	caused	cause	VBN	_	12	acl	_	_
17	by	by	IN	_	19	case	_	_
18	an	an	DT	_	19	det	_	_
19	drug1	drug0	NN	_	16	ppmod	_	_
20	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	not	not	RB	_	2	neg	_	_
4	mutagenic	mutagenic	JJ	_	2	dep	_	_
5	or	or	CC	_	4	cc	_	_
6	clastogenic	clastogenic	JJ	_	4	conj	_	_
7	in	in	IN	_	11	case	_	_
8	multiple	multiple	JJ	_	11	attr	_	_
9	in	in	FW	_	10	adv	_	_
10	vitro	vitro	FW	_	11	attr	_	_
11	tests	test	NNS	_	2	ppmod	_	_
12	with	with	IN	_	2	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	without	without	IN	_	16	case	_	_
15	the	the	DT	_	16	det	_	_
16	addition	addition	NN	_	12	conj	_	_
17	of	of	IN	_	23	case	_	_
18	a	a	DT	_	23	det	_	_
19	mammalian	mammalian	JJ	_	23	attr	_	_
20	liver	liver	NN	_	23	attr	_	_
21	metabolic	metabolic	JJ	_	23	attr	_	_
22	activation	activation	NN	_	23	com	_	_
23	factor	factor	NN	_	16	ppmod	_	_
24	(	-lrb-	-LRB-	_	2	p	_	_
25	bacterial	bacterial	JJ	_	27	attr	_	_
26	mutation	mutation	NN	_	27	com	_	_
27	assay	assay	NN	_	2	obj	_	_
28	in	in	IN	_	29	case	_	_
29	strains	strain	NNS	_	27	ppmod	_	_
30	of	of	IN	_	32	case	_	_
31	Salmonella	salmonella	FW	_	32	attr	_	_
32	typhimurium	typhimurium	FW	_	29	ppmod	_	_
33	and	and	CC	_	32	cc	_	_
34	Escherichia	escherichia	FW	_	35	attr	_	_
35	coli	coli	FW	_	32	conj	_	_
36	,	,	,	_	27	p	_	_
37	in	in	FW	_	38	adv	_	_
38	vitro	vitro	FW	_	40	attr	_	_
39	cytogenetics	cytogenetics	NNS	_	40	com	_	_
40	study	study	NN	_	27	conj	_	_
41	in	in	IN	_	43	case	_	_
42	human	human	JJ	_	43	attr	_	_
43	lymphocytes	lymphocyte	NNS	_	40	ppmod	_	_
44	,	,	,	_	40	p	_	_
45	mammalian	mammalian	JJ	_	48	attr	_	_
46	cell	cell	NN	_	48	com	_	_
47	mutation	mutation	NN	_	48	com	_	_
48	assay	assay	NN	_	27	conj	_	_
49	in	in	IN	_	52	case	_	_
50	mouse	mouse	NN	_	52	com	_	_
51	lymphoma	lymphoma	NN	_	52	com	_	_
52	cells	cell	NNS	_	48	ppmod	_	_
53	and	and	CC	_	48	cc	_	_
54	in	in	FW	_	55	adv	_	_
55	vivo	vivo	FW	_	57	attr	_	_
56	micronucleus	micronucleus	NN	_	57	com	_	_
57	test	test	NN	_	27	conj	_	_
58	in	in	IN	_	59	case	_	_
59	rat	rat	NN	_	57	ppmod	_	_
60	.	.	.	_	2	p	_	_

1	In	in	IN	_	3	case	_	_
2	female	female	JJ	_	3	attr	_	_
3	rats	rat	NNS	_	39	ppmod	_	_
4	,	,	,	_	39	p	_	_
5	drug1	drug0	NN	_	39	dep	_	_
6	administered	administer	VBN	_	5	acl	_	_
7	at	at	IN	_	8	case	_	_
8	doses	dose	NNS	_	6	ppmod	_	_
9	0.01	0	CD	_	10	num	_	_
10	mg/kg/day	mg/kg/day	NN	_	8	appo	_	_
11	(	-lrb-	-LRB-	_	13	p	_	_
12	approximately	approximately	RB	_	13	adv	_	_
13	one-hundredth	one-hundredth	CD	_	10	num	_	_
14	of	of	IN	_	18	case	_	_
15	the	the	DT	_	18	det	_	_
16	human	human	JJ	_	18	attr	_	_
17	recommended	recommend	VBN	_	18	attr	_	_
18	dose	dose	NN	_	13	ppmod	_	_
19	based	base	VBN	_	18	acl	_	_
20	on	on	IN	_	24	case	_	_
21	body	body	NN	_	24	com	_	_
22	surface	surface	NN	_	24	com	_	_
23	area	area	NN	_	24	com	_	_
24	-LSB-BSA	-lsb-bsa	NN	_	19	ppmod	_	_
25	]	-rsb-	-RRB-	_	13	p	_	_
26	,	,	,	_	8	p	_	_
27	for	for	IN	_	29	case	_	_
28	2	0	CD	_	29	num	_	_
29	weeks	week	NNS	_	8	conj	_	_
30	prior	prior	JJ	_	29	attr	_	_
31	to	to	TO	_	30	ppmod	_	_
32	and	and	CC	_	29	cc	_	_
33	for	for	IN	_	35	case	_	_
34	1	0	CD	_	35	num	_	_
35	week	week	NN	_	8	conj	_	_
36	following	follow	VBG	_	37	adv	_	_
37	mating	mating	NN	_	35	ppmod	_	_
38	,	,	,	_	5	p	_	_
39	caused	cause	VBD	_	0	root	_	_
40	a	a	DT	_	41	det	_	_
41	reduction	reduction	NN	_	39	obj	_	_
42	in	in	IN	_	43	case	_	_
43	fertility	fertility	NN	_	41	ppmod	_	_
44	and	and	CC	_	43	cc	_	_
45	embryonic	embryonic	JJ	_	46	attr	_	_
46	survival	survival	NN	_	43	conj	_	_
47	.	.	.	_	39	p	_	_

1	No	no	DT	_	3	det	_	_
2	adverse	adverse	JJ	_	3	attr	_	_
3	effects	effect	NNS	_	10	dep	_	_
4	on	on	IN	_	6	case	_	_
5	female	female	NN	_	6	com	_	_
6	fertility	fertility	NN	_	3	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	embryonic	embryonic	JJ	_	9	attr	_	_
9	survival	survival	NN	_	6	conj	_	_
10	were	be	VBD	_	0	root	_	_
11	evident	evident	JJ	_	10	dep	_	_
12	in	in	IN	_	14	case	_	_
13	female	female	JJ	_	14	attr	_	_
14	animals	animal	NNS	_	11	ppmod	_	_
15	dosed	dose	VBN	_	14	acl	_	_
16	at	at	IN	_	18	case	_	_
17	0.001	0	CD	_	18	num	_	_
18	mg/kg/day	mg/kg/day	NN	_	15	ppmod	_	_
19	(	-lrb-	-LRB-	_	21	p	_	_
20	approximately	approximately	RB	_	21	adv	_	_
21	one-thousandth	one-thousandth	CD	_	18	num	_	_
22	of	of	IN	_	25	case	_	_
23	the	the	DT	_	25	det	_	_
24	human	human	JJ	_	25	attr	_	_
25	dose	dose	NN	_	21	ppmod	_	_
26	based	base	VBN	_	25	acl	_	_
27	on	on	IN	_	28	case	_	_
28	BSA	bsa	NN	_	26	ppmod	_	_
29	)	-rrb-	-RRB-	_	21	p	_	_
30	.	.	.	_	10	p	_	_

1	Restoration	restoration	NN	_	10	dep	_	_
2	of	of	IN	_	4	case	_	_
3	female	female	NN	_	4	com	_	_
4	fertility	fertility	NN	_	1	ppmod	_	_
5	to	to	TO	_	6	aux	_	_
6	values	value	NNS	_	1	ppmod	_	_
7	similar	similar	JJ	_	6	attr	_	_
8	to	to	TO	_	9	aux	_	_
9	controls	control	NNS	_	7	ppmod	_	_
10	was	be	VBD	_	0	root	_	_
11	evident	evident	JJ	_	10	dep	_	_
12	following	follow	VBG	_	16	adv	_	_
13	a	a	DT	_	16	det	_	_
14	29-day	0-day	JJ	_	16	attr	_	_
15	withdrawal	withdrawal	NN	_	16	com	_	_
16	period	period	NN	_	10	ppmod	_	_
17	after	after	IN	_	18	case	_	_
18	dosing	dosing	NN	_	10	ppmod	_	_
19	at	at	IN	_	21	case	_	_
20	2	0	CD	_	21	num	_	_
21	mg/kg/day	mg/kg/day	NN	_	18	ppmod	_	_
22	(	-lrb-	-LRB-	_	26	p	_	_
23	twice	twice	RB	_	26	adv	_	_
24	the	the	DT	_	26	det	_	_
25	human	human	JJ	_	26	attr	_	_
26	dose	dose	NN	_	10	prn	_	_
27	based	base	VBN	_	26	acl	_	_
28	on	on	IN	_	29	case	_	_
29	BSA	bsa	NN	_	27	ppmod	_	_
30	)	-rrb-	-RRB-	_	26	p	_	_
31	.	.	.	_	10	p	_	_

1	The	the	DT	_	2	det	_	_
2	effects	effect	NNS	_	11	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	on	on	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	fertility	fertility	NN	_	2	ppmod	_	_
8	of	of	IN	_	10	case	_	_
9	female	female	JJ	_	10	attr	_	_
10	rats	rat	NNS	_	7	ppmod	_	_
11	appear	appear	VBP	_	0	root	_	_
12	to	to	TO	_	13	aux	_	_
13	be	be	VB	_	11	comp	_	_
14	consistent	consistent	JJ	_	13	dep	_	_
15	with	with	IN	_	18	case	_	_
16	its	its	PRP$	_	18	poss	_	_
17	anti-estrogenic	anti-estrogenic	JJ	_	18	attr	_	_
18	activity	activity	NN	_	14	ppmod	_	_
19	.	.	.	_	11	p	_	_

1	The	the	DT	_	3	det	_	_
2	potential	potential	JJ	_	3	attr	_	_
3	effects	effect	NNS	_	14	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	on	on	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	fertility	fertility	NN	_	3	ppmod	_	_
9	of	of	IN	_	11	case	_	_
10	male	male	JJ	_	11	attr	_	_
11	animals	animal	NNS	_	8	ppmod	_	_
12	were	be	VBD	_	14	aux	_	_
13	not	not	RB	_	14	neg	_	_
14	studied	study	VBN	_	0	root	_	_
15	but	but	CC	_	14	cc	_	_
16	in	in	IN	_	20	case	_	_
17	a	a	DT	_	20	det	_	_
18	6-month	0-month	JJ	_	20	attr	_	_
19	toxicology	toxicology	NN	_	20	com	_	_
20	study	study	NN	_	42	ppmod	_	_
21	,	,	,	_	42	p	_	_
22	male	male	JJ	_	23	attr	_	_
23	rats	rat	NNS	_	42	dep	_	_
24	treated	treat	VBN	_	23	acl	_	_
25	with	with	IN	_	27	case	_	_
26	intramuscular	intramuscular	JJ	_	27	attr	_	_
27	doses	dose	NNS	_	24	ppmod	_	_
28	of	of	IN	_	41	case	_	_
29	15	0	CD	_	31	num	_	_
30	mg/kg/30	mg/kg/0	NN	_	31	com	_	_
31	days	day	NNS	_	41	attr	_	_
32	,	,	,	_	31	p	_	_
33	10	0	CD	_	35	num	_	_
34	mg/rat/30	mg/rat/0	NN	_	35	com	_	_
35	days	day	NNS	_	31	conj	_	_
36	,	,	,	_	35	p	_	_
37	or	or	CC	_	35	cc	_	_
38	10	0	CD	_	40	num	_	_
39	mg/rat/15	mg/rat/0	NN	_	40	com	_	_
40	days	day	NNS	_	31	conj	_	_
41	drug2	drug0	NN	_	27	ppmod	_	_
42	showed	show	VBD	_	14	conj	_	_
43	a	a	DT	_	44	det	_	_
44	loss	loss	NN	_	42	obj	_	_
45	of	of	IN	_	46	case	_	_
46	spermatozoa	spermatozoon	NN	_	44	ppmod	_	_
47	from	from	IN	_	50	case	_	_
48	the	the	DT	_	50	det	_	_
49	seminiferous	seminiferous	JJ	_	50	attr	_	_
50	tubules	tubule	NNS	_	46	ppmod	_	_
51	,	,	,	_	44	p	_	_
52	seminiferous	seminiferous	JJ	_	54	attr	_	_
53	tubular	tubular	JJ	_	54	attr	_	_
54	atrophy	atrophy	NN	_	44	conj	_	_
55	,	,	,	_	54	p	_	_
56	and	and	CC	_	54	cc	_	_
57	degenerative	degenerative	JJ	_	58	attr	_	_
58	changes	change	NNS	_	44	conj	_	_
59	in	in	IN	_	61	case	_	_
60	the	the	DT	_	61	det	_	_
61	epididymides	epididymis	NNS	_	58	ppmod	_	_
62	.	.	.	_	14	p	_	_

1	Changes	change	NNS	_	9	dep	_	_
2	in	in	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	testes	testis	NNS	_	1	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	epididymides	epididymis	NNS	_	4	conj	_	_
7	had	have	VBD	_	9	aux	_	_
8	not	not	RB	_	9	neg	_	_
9	recovered	recover	VBN	_	0	root	_	_
10	20	0	CD	_	11	num	_	_
11	weeks	week	NNS	_	13	dat	_	_
12	after	after	IN	_	13	case	_	_
13	cessation	cessation	NN	_	9	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	dosing	dosing	NN	_	13	ppmod	_	_
16	.	.	.	_	9	p	_	_

1	These	these	DT	_	3	det	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	doses	dose	NNS	_	4	dep	_	_
4	correspond	correspond	VBP	_	0	root	_	_
5	to	to	TO	_	7	aux	_	_
6	approximately	approximately	RB	_	7	adv	_	_
7	2-	0-	CD	_	4	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	3-	0-	CD	_	7	conj	_	_
10	,	,	,	_	9	p	_	_
11	and	and	CC	_	9	cc	_	_
12	3-fold	0-fold	RB	_	17	adv	_	_
13	the	the	DT	_	17	det	_	_
14	systemic	systemic	JJ	_	17	attr	_	_
15	exposure	exposure	NN	_	17	attr	_	_
16	-LSB-AUC0-30	-lsb-auc0	CD	_	17	num	_	_
17	days	day	NNS	_	7	conj	_	_
18	]	-rsb-	-RRB-	_	17	p	_	_
19	achieved	achieve	VBN	_	17	acl	_	_
20	in	in	IN	_	21	case	_	_
21	women	woman	NNS	_	19	ppmod	_	_
22	.	.	.	_	4	p	_	_

1	Pregnancy	pregnancy	NN	_	4	com	_	_
2	Pregnancy	pregnancy	NN	_	4	com	_	_
3	Category	category	NN	_	4	com	_	_
4	D	d	NN	_	0	root	_	_
5	:	:	:	_	4	p	_	_
6	.	.	.	_	4	p	_	_

1	In	in	IN	_	2	case	_	_
2	studies	study	NNS	_	0	root	_	_
3	in	in	IN	_	5	case	_	_
4	female	female	JJ	_	5	attr	_	_
5	rats	rat	NNS	_	2	ppmod	_	_
6	at	at	IN	_	9	case	_	_
7	doses	dose	NNS	_	9	attr	_	_
8	0.01	0	CD	_	9	num	_	_
9	mg/kg/day	mg/kg/day	NN	_	5	ppmod	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	IM	im	NN	_	2	prn	_	_
12	;	;	:	_	2	p	_	_

1	approximately	approximately	RB	_	2	adv	_	_
2	one-hundredth	one-hundredth	CD	_	18	num	_	_
3	of	of	IN	_	7	case	_	_
4	the	the	DT	_	7	det	_	_
5	human	human	JJ	_	7	attr	_	_
6	recommended	recommend	VBN	_	7	attr	_	_
7	dose	dose	NN	_	2	ppmod	_	_
8	based	base	VBN	_	7	acl	_	_
9	on	on	IN	_	12	case	_	_
10	body	body	NN	_	12	com	_	_
11	surface	surface	NN	_	12	com	_	_
12	area	area	NN	_	8	ppmod	_	_
13	-LSB-BSA	-lsb-bsa	NN	_	12	prn	_	_
14	]	-rsb-	-RRB-	_	13	p	_	_
15	)	-rrb-	-RRB-	_	13	p	_	_
16	,	,	,	_	2	p	_	_
17	drug1	drug0	NN	_	2	appo	_	_
18	caused	cause	VBD	_	0	root	_	_
19	a	a	DT	_	21	det	_	_
20	reversible	reversible	JJ	_	21	attr	_	_
21	reduction	reduction	NN	_	18	obj	_	_
22	in	in	IN	_	24	case	_	_
23	female	female	NN	_	24	com	_	_
24	fertility	fertility	NN	_	21	ppmod	_	_
25	,	,	,	_	21	p	_	_
26	as	as	RB	_	27	com	_	_
27	well	well	RB	_	21	cc	_	_
28	as	as	IN	_	27	com	_	_
29	effects	effect	NNS	_	21	conj	_	_
30	on	on	IN	_	32	case	_	_
31	embryo/fetal	embryo/fetal	JJ	_	32	attr	_	_
32	development	development	NN	_	29	ppmod	_	_
33	consistent	consistent	JJ	_	18	comp	_	_
34	with	with	IN	_	37	case	_	_
35	its	its	PRP$	_	37	poss	_	_
36	anti-estrogenic	anti-estrogenic	JJ	_	37	attr	_	_
37	activity	activity	NN	_	33	ppmod	_	_
38	.	.	.	_	18	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	caused	cause	VBD	_	0	root	_	_
3	an	an	DT	_	5	det	_	_
4	increased	increase	VBN	_	5	attr	_	_
5	incidence	incidence	NN	_	2	dat	_	_
6	of	of	IN	_	8	case	_	_
7	fetal	fetal	JJ	_	8	attr	_	_
8	abnormalities	abnormality	NNS	_	5	ppmod	_	_
9	in	in	IN	_	10	case	_	_
10	rats	rat	NNS	_	5	ppmod	_	_
11	(	-lrb-	-LRB-	_	2	p	_	_
12	tarsal	tarsal	JJ	_	13	attr	_	_
13	flexure	flexure	NN	_	2	obj	_	_
14	of	of	IN	_	17	case	_	_
15	the	the	DT	_	17	det	_	_
16	hind	hind	JJ	_	17	attr	_	_
17	paw	paw	NN	_	13	ppmod	_	_
18	at	at	IN	_	20	case	_	_
19	2	0	CD	_	20	num	_	_
20	mg/kg/day	mg/kg/day	NN	_	2	ppmod	_	_
21	IM	im	CD	_	20	num	_	_
22	;	;	:	_	2	p	_	_

1	twice	twice	RB	_	4	adv	_	_
2	the	the	DT	_	4	det	_	_
3	human	human	JJ	_	4	attr	_	_
4	dose	dose	NN	_	6	dep	_	_
5	on	on	IN	_	6	case	_	_
6	BSA	bsa	NN	_	0	root	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	and	and	CC	_	6	cc	_	_
9	non-ossification	non-ossification	NN	_	6	conj	_	_
10	of	of	IN	_	15	case	_	_
11	the	the	DT	_	15	det	_	_
12	odontoid	odontoid	JJ	_	15	attr	_	_
13	and	and	CC	_	12	cc	_	_
14	ventral	ventral	JJ	_	12	conj	_	_
15	tubercle	tubercle	NN	_	9	ppmod	_	_
16	of	of	IN	_	20	case	_	_
17	the	the	DT	_	20	det	_	_
18	first	#ord#	JJ	_	20	attr	_	_
19	cervical	cervical	JJ	_	20	attr	_	_
20	vertebra	vertebra	NN	_	15	ppmod	_	_
21	at	at	IN	_	22	case	_	_
22	doses	dose	NNS	_	9	ppmod	_	_
23	0.1	0	CD	_	24	num	_	_
24	mg/kg/day	mg/kg/day	NN	_	25	com	_	_
25	IM	im	NN	_	22	attr	_	_
26	(	-lrb-	-LRB-	_	28	p	_	_
27	approximately	approximately	RB	_	28	adv	_	_
28	one-tenth	one-tenth	CD	_	25	num	_	_
29	of	of	IN	_	32	case	_	_
30	the	the	DT	_	32	det	_	_
31	human	human	JJ	_	32	attr	_	_
32	dose	dose	NN	_	28	ppmod	_	_
33	on	on	IN	_	34	case	_	_
34	BSA	bsa	NN	_	32	ppmod	_	_
35	)	-rrb-	-RRB-	_	28	p	_	_
36	when	when	WRB	_	37	adv	_	_
37	administered	administer	VBN	_	6	comp	_	_
38	during	during	IN	_	40	case	_	_
39	the	the	DT	_	40	det	_	_
40	period	period	NN	_	37	ppmod	_	_
41	of	of	IN	_	42	case	_	_
42	organogenesis	organogenesis	NN	_	40	ppmod	_	_
43	.	.	.	_	6	p	_	_

1	Rabbits	rabbit	NNS	_	2	dep	_	_
2	failed	fail	VBD	_	0	root	_	_
3	to	to	TO	_	4	aux	_	_
4	maintain	maintain	VB	_	2	comp	_	_
5	pregnancy	pregnancy	NN	_	4	obj	_	_
6	when	when	WRB	_	7	adv	_	_
7	dosed	dose	VBN	_	5	relcl	_	_
8	with	with	IN	_	12	case	_	_
9	1	0	CD	_	10	num	_	_
10	mg/kg/day	mg/kg/day	NN	_	12	com	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	IM	im	NN	_	7	ppmod	_	_
13	(	-lrb-	-LRB-	_	17	p	_	_
14	twice	twice	RB	_	17	adv	_	_
15	the	the	DT	_	17	det	_	_
16	human	human	JJ	_	17	attr	_	_
17	dose	dose	NN	_	12	prn	_	_
18	on	on	IN	_	19	case	_	_
19	BSA	bsa	NN	_	17	ppmod	_	_
20	)	-rrb-	-RRB-	_	17	p	_	_
21	during	during	IN	_	23	case	_	_
22	the	the	DT	_	23	det	_	_
23	period	period	NN	_	4	ppmod	_	_
24	of	of	IN	_	25	case	_	_
25	organogenesis	organogenesis	NN	_	23	ppmod	_	_
26	.	.	.	_	2	p	_	_

1	Further	far	RB	_	27	adv	_	_
2	,	,	,	_	27	p	_	_
3	in	in	IN	_	4	case	_	_
4	rabbits	rabbit	NNS	_	27	ppmod	_	_
5	dosed	dose	VBN	_	4	acl	_	_
6	at	at	IN	_	8	case	_	_
7	0.25	0	CD	_	8	num	_	_
8	mg/kg/day	mg/kg/day	NN	_	5	ppmod	_	_
9	(	-lrb-	-LRB-	_	14	p	_	_
10	about	about	IN	_	11	case	_	_
11	one-half	one-half	NN	_	14	ppmod	_	_
12	the	the	DT	_	14	det	_	_
13	human	human	JJ	_	14	attr	_	_
14	dose	dose	NN	_	8	prn	_	_
15	on	on	IN	_	16	case	_	_
16	BSA	bsa	NN	_	14	ppmod	_	_
17	)	-rrb-	-RRB-	_	14	p	_	_
18	,	,	,	_	27	p	_	_
19	increases	increase	NNS	_	27	dep	_	_
20	in	in	IN	_	22	case	_	_
21	placental	placental	JJ	_	22	attr	_	_
22	weight	weight	NN	_	19	ppmod	_	_
23	and	and	CC	_	22	cc	_	_
24	post-implantation	post-implantation	NN	_	25	com	_	_
25	loss	loss	NN	_	22	conj	_	_
26	were	be	VBD	_	27	aux	_	_
27	observed	observe	VBN	_	0	root	_	_
28	but	but	CC	_	27	cc	_	_
29	,	,	,	_	27	p	_	_
30	there	there	EX	_	31	dep	_	_
31	were	be	VBD	_	27	conj	_	_
32	no	no	DT	_	34	det	_	_
33	observed	observe	VBN	_	34	attr	_	_
34	effects	effect	NNS	_	31	obj	_	_
35	on	on	IN	_	37	case	_	_
36	fetal	fetal	JJ	_	37	attr	_	_
37	development	development	NN	_	34	ppmod	_	_
38	.	.	.	_	27	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	was	be	VBD	_	3	aux	_	_
3	associated	associate	VBN	_	0	root	_	_
4	with	with	IN	_	7	case	_	_
5	an	an	DT	_	7	det	_	_
6	increased	increase	VBN	_	7	attr	_	_
7	incidence	incidence	NN	_	3	ppmod	_	_
8	of	of	IN	_	10	case	_	_
9	fetal	fetal	JJ	_	10	attr	_	_
10	variations	variation	NNS	_	7	ppmod	_	_
11	in	in	IN	_	12	case	_	_
12	rabbits	rabbit	NNS	_	10	ppmod	_	_
13	(	-lrb-	-LRB-	_	15	p	_	_
14	backwards	backwards	NNS	_	15	com	_	_
15	displacement	displacement	NN	_	3	prn	_	_
16	of	of	IN	_	19	case	_	_
17	the	the	DT	_	19	det	_	_
18	pelvic	pelvic	JJ	_	19	attr	_	_
19	girdle	girdle	NN	_	15	ppmod	_	_
20	,	,	,	_	15	p	_	_
21	and	and	CC	_	15	cc	_	_
22	27	0	CD	_	24	num	_	_
23	pre-sacral	pre-sacral	JJ	_	24	attr	_	_
24	vertebrae	vertebra	NNS	_	15	conj	_	_
25	at	at	IN	_	27	case	_	_
26	0.25	0	CD	_	27	num	_	_
27	mg/kg/day	mg/kg/day	NN	_	24	ppmod	_	_
28	IM	im	CD	_	27	num	_	_
29	;	;	:	_	3	p	_	_

1	one-half	one-half	NN	_	6	dep	_	_
2	the	the	DT	_	4	det	_	_
3	human	human	JJ	_	4	attr	_	_
4	dose	dose	NN	_	1	attr	_	_
5	on	on	IN	_	6	case	_	_
6	BSA	bsa	NN	_	0	root	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	when	when	WRB	_	9	adv	_	_
9	administered	administer	VBN	_	6	comp	_	_
10	during	during	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	period	period	NN	_	9	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	organogenesis	organogenesis	NN	_	12	ppmod	_	_
15	.	.	.	_	6	p	_	_

1	Because	because	IN	_	6	mark	_	_
2	pregnancy	pregnancy	NN	_	6	dep	_	_
3	could	could	MD	_	6	modal	_	_
4	not	not	RB	_	6	neg	_	_
5	be	be	VB	_	6	aux	_	_
6	maintained	maintain	VBN	_	22	advcl	_	_
7	in	in	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	rabbit	rabbit	NN	_	6	ppmod	_	_
10	following	follow	VBG	_	11	adv	_	_
11	doses	dose	NNS	_	6	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	of	of	IN	_	16	case	_	_
15	1	0	CD	_	16	num	_	_
16	mg/kg/day	mg/kg/day	NN	_	13	ppmod	_	_
17	and	and	CC	_	11	cc	_	_
18	above	above	JJ	_	11	conj	_	_
19	,	,	,	_	22	p	_	_
20	this	this	DT	_	21	det	_	_
21	study	study	NN	_	22	dep	_	_
22	was	be	VBD	_	0	root	_	_
23	inadequate	inadequate	JJ	_	22	dep	_	_
24	to	to	TO	_	26	aux	_	_
25	fully	fully	RB	_	26	adv	_	_
26	define	define	VB	_	23	comp	_	_
27	the	the	DT	_	30	det	_	_
28	possible	possible	JJ	_	30	attr	_	_
29	adverse	adverse	JJ	_	30	attr	_	_
30	effects	effect	NNS	_	26	obj	_	_
31	on	on	IN	_	33	case	_	_
32	fetal	fetal	JJ	_	33	attr	_	_
33	development	development	NN	_	30	ppmod	_	_
34	at	at	IN	_	37	case	_	_
35	clinically	clinically	RB	_	36	adv	_	_
36	relevant	relevant	JJ	_	37	attr	_	_
37	exposures	exposure	NNS	_	30	ppmod	_	_
38	.	.	.	_	22	p	_	_

1	Nursing	nursing	JJ	_	3	attr	_	_
2	Mothers	mother	NNS	_	3	com	_	_
3	drug1	drug0	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	found	find	VBN	_	0	root	_	_
6	in	in	IN	_	8	case	_	_
7	rat	rat	NN	_	8	com	_	_
8	milk	milk	NN	_	5	ppmod	_	_
9	at	at	IN	_	10	case	_	_
10	levels	level	NNS	_	5	ppmod	_	_
11	significantly	significantly	RB	_	12	adv	_	_
12	higher	high	JJR	_	10	attr	_	_
13	(	-lrb-	-LRB-	_	15	p	_	_
14	approximately	approximately	RB	_	15	adv	_	_
15	12-fold	0-fold	JJ	_	12	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	than	than	IN	_	18	case	_	_
18	plasma	plasma	NN	_	12	ppmod	_	_
19	after	after	IN	_	20	case	_	_
20	administration	administration	NN	_	18	ppmod	_	_
21	of	of	IN	_	23	case	_	_
22	2	0	CD	_	23	num	_	_
23	mg/kg	mg/kg	NN	_	20	ppmod	_	_
24	.	.	.	_	5	p	_	_

1	Drug	drug	NN	_	2	com	_	_
2	exposure	exposure	NN	_	12	dep	_	_
3	in	in	IN	_	5	case	_	_
4	rodent	rodent	JJ	_	5	attr	_	_
5	pups	pup	NNS	_	2	ppmod	_	_
6	from	from	IN	_	10	case	_	_
7	drug1	drug0	NN	_	10	attr	_	_
8	-treated	-treated	JJ	_	10	attr	_	_
9	lactating	lactating	JJ	_	10	attr	_	_
10	dams	dam	NNS	_	5	ppmod	_	_
11	was	be	VBD	_	12	aux	_	_
12	estimated	estimate	VBN	_	0	root	_	_
13	as	as	IN	_	14	case	_	_
14	10	0	CD	_	12	ppmod	_	_
15	%	%	NN	_	14	meta	_	_
16	of	of	IN	_	19	case	_	_
17	the	the	DT	_	19	det	_	_
18	administered	administer	VBN	_	19	attr	_	_
19	dose	dose	NN	_	14	ppmod	_	_
20	.	.	.	_	12	p	_	_

1	It	it	PRP	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	known	know	VBN	_	0	root	_	_
5	if	if	IN	_	8	mark	_	_
6	drug1	drug0	NN	_	8	dep	_	_
7	is	be	VBZ	_	8	aux	_	_
8	excreted	excrete	VBN	_	4	comp	_	_
9	in	in	IN	_	11	case	_	_
10	human	human	JJ	_	11	attr	_	_
11	milk	milk	NN	_	8	ppmod	_	_
12	.	.	.	_	4	p	_	_

1	Because	because	IN	_	5	mark	_	_
2	many	many	JJ	_	3	attr	_	_
3	drugs	drug	NNS	_	5	dep	_	_
4	are	be	VBP	_	5	aux	_	_
5	excreted	excrete	VBN	_	29	advcl	_	_
6	in	in	IN	_	8	case	_	_
7	human	human	JJ	_	8	attr	_	_
8	milk	milk	NN	_	5	ppmod	_	_
9	,	,	,	_	5	p	_	_
10	and	and	CC	_	5	cc	_	_
11	because	because	IN	_	14	case	_	_
12	of	of	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	potential	potential	NN	_	5	conj	_	_
15	for	for	IN	_	18	case	_	_
16	serious	serious	JJ	_	18	attr	_	_
17	adverse	adverse	JJ	_	18	attr	_	_
18	reactions	reaction	NNS	_	14	ppmod	_	_
19	from	from	IN	_	20	case	_	_
20	drug1	drug0	NN	_	18	ppmod	_	_
21	in	in	IN	_	23	case	_	_
22	nursing	nursing	JJ	_	23	attr	_	_
23	infants	infant	NNS	_	20	ppmod	_	_
24	,	,	,	_	29	p	_	_
25	a	a	DT	_	26	det	_	_
26	decision	decision	NN	_	29	dep	_	_
27	should	should	MD	_	29	modal	_	_
28	be	be	VB	_	29	aux	_	_
29	made	make	VBN	_	0	root	_	_
30	whether	whether	IN	_	32	mark	_	_
31	to	to	TO	_	32	aux	_	_
32	discontinue	discontinue	VBP	_	29	comp	_	_
33	nursing	nursing	NN	_	32	obj	_	_
34	or	or	CC	_	32	cc	_	_
35	to	to	TO	_	36	aux	_	_
36	discontinue	discontinue	VBP	_	32	conj	_	_
37	the	the	DT	_	38	det	_	_
38	drug	drug	NN	_	36	obj	_	_
39	taking	take	VBG	_	38	acl	_	_
40	into	into	IN	_	41	mark	_	_
41	account	account	VBP	_	39	comp	_	_
42	the	the	DT	_	43	det	_	_
43	importance	importance	NN	_	41	obj	_	_
44	of	of	IN	_	46	case	_	_
45	the	the	DT	_	46	det	_	_
46	drug	drug	NN	_	43	ppmod	_	_
47	to	to	TO	_	49	aux	_	_
48	the	the	DT	_	49	det	_	_
49	mother	mother	NN	_	43	ppmod	_	_
50	.	.	.	_	29	p	_	_

1	Pediatric	pediatric	JJ	_	2	attr	_	_
2	Use	use	NN	_	15	dep	_	_
3	The	the	DT	_	4	det	_	_
4	safety	safety	NN	_	2	attr	_	_
5	and	and	CC	_	4	cc	_	_
6	efficacy	efficacy	NN	_	4	conj	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	2	ppmod	_	_
9	in	in	IN	_	11	case	_	_
10	pediatric	pediatric	JJ	_	11	attr	_	_
11	patients	patient	NNS	_	2	ppmod	_	_
12	have	have	VBP	_	15	aux	_	_
13	not	not	RB	_	15	neg	_	_
14	been	be	VBN	_	15	aux	_	_
15	established	establish	VBN	_	0	root	_	_
16	.	.	.	_	15	p	_	_

1	Geriatric	geriatric	JJ	_	2	attr	_	_
2	Use	use	NN	_	14	dep	_	_
3	When	when	WRB	_	7	adv	_	_
4	tumor	tumor	NN	_	5	com	_	_
5	response	response	NN	_	7	dep	_	_
6	was	be	VBD	_	7	aux	_	_
7	considered	consider	VBN	_	14	advcl	_	_
8	by	by	IN	_	9	case	_	_
9	age	age	NN	_	7	ppmod	_	_
10	,	,	,	_	14	p	_	_
11	objective	objective	NN	_	12	com	_	_
12	responses	response	NNS	_	14	dep	_	_
13	were	be	VBD	_	14	aux	_	_
14	seen	see	VBN	_	0	root	_	_
15	in	in	IN	_	16	case	_	_
16	24	0	CD	_	14	ppmod	_	_
17	%	%	NN	_	16	meta	_	_
18	and	and	CC	_	16	cc	_	_
19	22	0	CD	_	16	conj	_	_
20	%	%	NN	_	19	meta	_	_
21	of	of	IN	_	22	case	_	_
22	patients	patient	NNS	_	16	ppmod	_	_
23	under	under	IN	_	25	case	_	_
24	65	0	CD	_	25	num	_	_
25	years	year	NNS	_	22	ppmod	_	_
26	of	of	IN	_	27	case	_	_
27	age	age	NN	_	25	ppmod	_	_
28	and	and	CC	_	16	cc	_	_
29	in	in	IN	_	30	case	_	_
30	16	0	CD	_	16	conj	_	_
31	%	%	NN	_	30	meta	_	_
32	and	and	CC	_	30	cc	_	_
33	11	0	CD	_	30	conj	_	_
34	%	%	NN	_	33	meta	_	_
35	of	of	IN	_	38	case	_	_
36	patients	patient	NNS	_	38	attr	_	_
37	65	0	CD	_	38	num	_	_
38	years	year	NNS	_	33	ppmod	_	_
39	of	of	IN	_	40	case	_	_
40	age	age	NN	_	38	ppmod	_	_
41	and	and	CC	_	40	cc	_	_
42	older	old	JJR	_	40	conj	_	_
43	,	,	,	_	38	p	_	_
44	who	who	WP	_	46	dep	_	_
45	were	be	VBD	_	46	aux	_	_
46	treated	treat	VBN	_	38	relcl	_	_
47	with	with	IN	_	48	case	_	_
48	drug1	drug0	NN	_	46	ppmod	_	_
49	in	in	IN	_	51	case	_	_
50	the	the	DT	_	51	det	_	_
51	European	european	NNP	_	46	ppmod	_	_
52	and	and	CC	_	51	cc	_	_
53	North	north	NNP	_	54	com	_	_
54	American	american	NNP	_	55	com	_	_
55	trials	trial	NNS	_	51	conj	_	_
56	,	,	,	_	33	p	_	_
57	respectively	respectively	RB	_	30	conj	_	_
58	.	.	.	_	14	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	predominantly	predominantly	RB	_	4	adv	_	_
4	eliminated	eliminate	VBN	_	0	root	_	_
5	in	in	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	urine	urine	NN	_	4	ppmod	_	_
8	by	by	IN	_	12	case	_	_
9	active	active	JJ	_	12	attr	_	_
10	organic	organic	JJ	_	12	attr	_	_
11	cationic	cationic	NN	_	12	com	_	_
12	secretion	secretion	NN	_	4	ppmod	_	_
13	.	.	.	_	4	p	_	_

1	The	the	DT	_	2	det	_	_
2	possibility	possibility	NN	_	12	dep	_	_
3	of	of	IN	_	4	case	_	_
4	interactions	interaction	NNS	_	2	ppmod	_	_
5	with	with	IN	_	7	case	_	_
6	other	other	JJ	_	7	attr	_	_
7	drugs	drug	NNS	_	4	ppmod	_	_
8	administered	administer	VBN	_	7	acl	_	_
9	concurrently	concurrently	RB	_	8	adv	_	_
10	should	should	MD	_	12	modal	_	_
11	be	be	VB	_	12	aux	_	_
12	considered	consider	VBN	_	0	root	_	_
13	,	,	,	_	12	p	_	_
14	particularly	particularly	RB	_	15	com	_	_
15	when	when	WRB	_	21	adv	_	_
16	their	their	PRP$	_	18	poss	_	_
17	main	main	JJ	_	18	attr	_	_
18	route	route	NN	_	21	dep	_	_
19	of	of	IN	_	20	case	_	_
20	elimination	elimination	NN	_	18	ppmod	_	_
21	is	be	VBZ	_	12	comp	_	_
22	active	active	JJ	_	24	attr	_	_
23	renal	renal	JJ	_	24	attr	_	_
24	secretion	secretion	NN	_	21	obj	_	_
25	via	via	IN	_	30	case	_	_
26	the	the	DT	_	30	det	_	_
27	organic	organic	JJ	_	30	attr	_	_
28	cationic	cationic	NN	_	30	com	_	_
29	transport	transport	NN	_	30	com	_	_
30	system	system	NN	_	21	ppmod	_	_
31	(	-lrb-	-LRB-	_	34	p	_	_
32	e.g.	e.g.	FW	_	34	ppmod	_	_
33	,	,	,	_	34	p	_	_
34	drug1	drug0	NN	_	30	prn	_	_
35	)	-rrb-	-RRB-	_	34	p	_	_
36	.	.	.	_	12	p	_	_

1	No	no	DT	_	2	det	_	_
2	change	change	NN	_	9	dep	_	_
3	in	in	IN	_	4	case	_	_
4	dose	dose	NN	_	2	ppmod	_	_
5	of	of	IN	_	7	case	_	_
6	either	either	DT	_	7	det	_	_
7	drug	drug	NN	_	4	ppmod	_	_
8	is	be	VBZ	_	9	aux	_	_
9	recommended	recommend	VBN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	There	there	EX	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	no	no	DT	_	4	det	_	_
4	information	information	NN	_	2	obj	_	_
5	regarding	regard	VBG	_	7	adv	_	_
6	the	the	DT	_	7	det	_	_
7	effect	effect	NN	_	4	ppmod	_	_
8	on	on	IN	_	10	case	_	_
9	drug1	drug0	NN	_	10	com	_	_
10	pharmacokinetics	pharmacokinetics	NNS	_	7	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	higher	high	JJR	_	13	attr	_	_
13	doses	dose	NNS	_	10	ppmod	_	_
14	of	of	IN	_	17	case	_	_
15	drug2	drug0	NN	_	17	attr	_	_
16	/	/	:	_	17	p	_	_
17	drug3	drug0	NN	_	13	ppmod	_	_
18	such	such	JJ	_	20	adv	_	_
19	as	as	IN	_	20	case	_	_
20	those	those	DT	_	10	ppmod	_	_
21	used	use	VBN	_	20	acl	_	_
22	to	to	TO	_	23	aux	_	_
23	treat	treat	VB	_	21	comp	_	_
24	Pneumocystis	pneumocystis	NN	_	26	com	_	_
25	carinii	carinii	NN	_	26	com	_	_
26	pneumonia	pneumonia	NN	_	23	obj	_	_
27	.	.	.	_	2	p	_	_

1	No	no	DT	_	2	det	_	_
2	data	datum	NNS	_	3	dep	_	_
3	are	be	VBP	_	0	root	_	_
4	available	available	JJ	_	3	dep	_	_
5	regarding	regard	VBG	_	6	adv	_	_
6	interactions	interaction	NNS	_	4	ppmod	_	_
7	with	with	IN	_	9	case	_	_
8	other	other	JJ	_	9	attr	_	_
9	drugs	drug	NNS	_	6	ppmod	_	_
10	that	that	WDT	_	11	dep	_	_
11	have	have	VBP	_	9	relcl	_	_
12	renal	renal	JJ	_	14	attr	_	_
13	clearance	clearance	NN	_	14	com	_	_
14	mechanisms	mechanism	NNS	_	11	obj	_	_
15	similar	similar	JJ	_	14	attr	_	_
16	to	to	TO	_	17	aux	_	_
17	that	that	DT	_	15	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug1	drug0	NN	_	17	ppmod	_	_
20	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	may	may	MD	_	5	modal	_	_
5	inhibit	inhibit	VB	_	0	root	_	_
6	the	the	DT	_	8	det	_	_
7	intracellular	intracellular	JJ	_	8	attr	_	_
8	phosphorylation	phosphorylation	NN	_	5	obj	_	_
9	of	of	IN	_	10	case	_	_
10	one	#crd#	CD	_	8	ppmod	_	_
11	another	another	DT	_	10	det	_	_
12	.	.	.	_	5	p	_	_

1	Therefore	therefore	RB	_	12	adv	_	_
2	,	,	,	_	12	p	_	_
3	use	use	NN	_	12	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	in	in	IN	_	7	case	_	_
7	combination	combination	NN	_	3	ppmod	_	_
8	with	with	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	is	be	VBZ	_	12	aux	_	_
11	not	not	RB	_	12	neg	_	_
12	recommended	recommend	VBN	_	0	root	_	_

1	.	.	.	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	decreases	decrease	VBZ	_	0	root	_	_
3	drug2	drug0	NN	_	4	com	_	_
4	clearance	clearance	NN	_	2	obj	_	_
5	by	by	IN	_	8	case	_	_
6	up	up	RB	_	8	adv	_	_
7	to	to	TO	_	8	attr	_	_
8	25	0	CD	_	2	ppmod	_	_
9	%	%	NN	_	8	meta	_	_
10	,	,	,	_	2	p	_	_
11	and	and	CC	_	2	cc	_	_
12	may	may	MD	_	13	modal	_	_
13	produce	produce	VB	_	2	conj	_	_
14	AUCs	auc	NNS	_	13	obj	_	_
15	1500	0	NN	_	17	num	_	_
16	M	m	NN	_	17	com	_	_
17	min	min	NN	_	14	attr	_	_
18	in	in	IN	_	20	case	_	_
19	some	some	DT	_	20	det	_	_
20	patients	patient	NNS	_	13	ppmod	_	_
21	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	18	dep	_	_
2	,	,	,	_	1	p	_	_
3	and	and	CC	_	1	cc	_	_
4	the	the	DT	_	6	det	_	_
5	drug2	drug0	NN	_	6	com	_	_
6	drug3	drug0	NN	_	1	conj	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	drug4	drug0	NN	_	1	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	and	and	CC	_	1	cc	_	_
11	drug5	drug0	NN	_	1	conj	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	drug6	drug0	NN	_	11	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	have	have	VBP	_	18	aux	_	_
16	all	all	RB	_	18	adv	_	_
17	been	be	VBN	_	18	aux	_	_
18	used	use	VBN	_	0	root	_	_
19	with	with	IN	_	20	case	_	_
20	drug7	drug0	NN	_	18	ppmod	_	_
21	.	.	.	_	18	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	increases	increase	VBZ	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	clearance	clearance	NN	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	by	by	IN	_	8	case	_	_
8	15	0	CD	_	2	ppmod	_	_
9	%	%	NN	_	8	meta	_	_
10	or	or	CC	_	8	cc	_	_
11	more	more	JJR	_	8	conj	_	_
12	,	,	,	_	2	p	_	_
13	possibly	possibly	RB	_	17	adv	_	_
14	due	due	JJ	_	17	adv	_	_
15	to	to	TO	_	17	aux	_	_
16	the	the	DT	_	17	det	_	_
17	induction	induction	NN	_	2	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	glutathione-S-transferase	glutathione-s-transferase	NN	_	17	ppmod	_	_
20	.	.	.	_	2	p	_	_

1	Since	since	IN	_	7	mark	_	_
2	the	the	DT	_	3	det	_	_
3	pharmacokinetics	pharmacokinetics	NNS	_	7	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	were	be	VBD	_	7	aux	_	_
7	studied	study	VBN	_	23	advcl	_	_
8	in	in	IN	_	9	case	_	_
9	patients	patient	NNS	_	7	ppmod	_	_
10	treated	treat	VBN	_	9	acl	_	_
11	with	with	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	,	,	,	_	23	p	_	_
14	the	the	DT	_	15	det	_	_
15	clearance	clearance	NN	_	23	dep	_	_
16	of	of	IN	_	17	case	_	_
17	drug3	drug0	NN	_	15	ppmod	_	_
18	at	at	IN	_	21	case	_	_
19	the	the	DT	_	21	det	_	_
20	recommended	recommend	VBN	_	21	attr	_	_
21	dose	dose	NN	_	15	ppmod	_	_
22	may	may	MD	_	23	modal	_	_
23	be	be	VB	_	0	root	_	_
24	lower	low	JJR	_	23	dep	_	_
25	and	and	CC	_	24	cc	_	_
26	exposure	exposure	NN	_	30	advnp	_	_
27	(	-lrb-	-LRB-	_	28	p	_	_
28	AUC	auc	NN	_	26	prn	_	_
29	)	-rrb-	-RRB-	_	28	p	_	_
30	higher	high	JJR	_	24	conj	_	_
31	in	in	IN	_	32	case	_	_
32	patients	patient	NNS	_	30	ppmod	_	_
33	not	not	RB	_	34	neg	_	_
34	treated	treat	VBN	_	32	acl	_	_
35	with	with	IN	_	36	case	_	_
36	drug4	drug0	NN	_	34	ppmod	_	_
37	.	.	.	_	23	p	_	_

1	Because	because	IN	_	4	mark	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	eliminated	eliminate	VBN	_	27	advcl	_	_
5	from	from	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	body	body	NN	_	4	ppmod	_	_
8	via	via	IN	_	9	case	_	_
9	conjugation	conjugation	NN	_	4	ppmod	_	_
10	with	with	IN	_	11	case	_	_
11	glutathione	glutathione	NN	_	9	ppmod	_	_
12	,	,	,	_	27	p	_	_
13	use	use	NN	_	27	dep	_	_
14	of	of	IN	_	15	case	_	_
15	drug2	drug0	JJ	_	13	ppmod	_	_
16	prior	prior	JJ	_	15	attr	_	_
17	to	to	TO	_	16	ppmod	_	_
18	(	-lrb-	-LRB-	_	20	p	_	_
19	72	0	CD	_	20	num	_	_
20	hours	hour	NNS	_	15	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	or	or	CC	_	15	cc	_	_
23	concurrent	concurrent	JJ	_	15	conj	_	_
24	with	with	IN	_	25	case	_	_
25	drug3	drug0	NN	_	23	ppmod	_	_
26	may	may	MD	_	27	modal	_	_
27	result	result	VB	_	0	root	_	_
28	in	in	IN	_	31	case	_	_
29	reduced	reduce	VBN	_	31	attr	_	_
30	drug4	drug0	NN	_	31	com	_	_
31	clearance	clearance	NN	_	27	ppmod	_	_
32	based	base	VBN	_	31	acl	_	_
33	upon	upon	IN	_	36	case	_	_
34	the	the	DT	_	36	det	_	_
35	known	known	JJ	_	36	attr	_	_
36	property	property	NN	_	32	ppmod	_	_
37	of	of	IN	_	38	case	_	_
38	drug5	drug0	NN	_	36	ppmod	_	_
39	to	to	TO	_	40	aux	_	_
40	decrease	decrease	VB	_	36	acl	_	_
41	glutathione	glutathione	NN	_	42	com	_	_
42	levels	level	NNS	_	40	obj	_	_
43	in	in	IN	_	45	case	_	_
44	the	the	DT	_	45	det	_	_
45	blood	blood	NN	_	42	ppmod	_	_
46	and	and	CC	_	45	cc	_	_
47	tissues	tissue	NNS	_	45	conj	_	_
48	.	.	.	_	27	p	_	_

1	Catecholamine-depleting	catecholamine-depleting	JJ	_	2	attr	_	_
2	drugs	drug	NNS	_	9	dep	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	eg	eg	NN	_	2	prn	_	_
5	,	,	,	_	4	p	_	_
6	drug1	drug0	NN	_	4	appo	_	_
7	)	-rrb-	-RRB-	_	4	p	_	_
8	may	may	MD	_	9	modal	_	_
9	have	have	VB	_	0	root	_	_
10	an	an	DT	_	12	det	_	_
11	additive	additive	JJ	_	12	attr	_	_
12	effect	effect	NN	_	9	obj	_	_
13	when	when	WRB	_	14	adv	_	_
14	given	give	VBN	_	9	comp	_	_
15	with	with	IN	_	17	case	_	_
16	drug2	drug0	CD	_	17	num	_	_
17	s	s	NN	_	14	ppmod	_	_
18	.	.	.	_	9	p	_	_

1	Patients	patient	NNS	_	13	dep	_	_
2	treated	treat	VBN	_	1	acl	_	_
3	with	with	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	plus	plus	CC	_	4	cc	_	_
6	a	a	DT	_	8	det	_	_
7	catecholamine	catecholamine	NN	_	8	com	_	_
8	depletor	depletor	NN	_	4	conj	_	_
9	should	should	MD	_	13	modal	_	_
10	therefore	therefore	RB	_	13	adv	_	_
11	be	be	VB	_	13	aux	_	_
12	closely	closely	RB	_	13	adv	_	_
13	observed	observe	VBN	_	0	root	_	_
14	for	for	IN	_	15	case	_	_
15	evidence	evidence	NN	_	13	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	hypotension	hypotension	NN	_	15	ppmod	_	_
18	and/or	and/or	CC	_	17	cc	_	_
19	marked	marked	JJ	_	20	attr	_	_
20	bradycardia	bradycardia	NN	_	17	conj	_	_
21	which	which	WDT	_	23	dep	_	_
22	may	may	MD	_	23	modal	_	_
23	produce	produce	VB	_	17	relcl	_	_
24	vertigo	vertigo	NN	_	23	obj	_	_
25	,	,	,	_	24	p	_	_
26	syncope	syncope	NN	_	24	conj	_	_
27	,	,	,	_	26	p	_	_
28	or	or	CC	_	26	cc	_	_
29	postural	postural	JJ	_	30	attr	_	_
30	hypotension	hypotension	NN	_	24	conj	_	_
31	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	may	may	MD	_	4	modal	_	_
3	also	also	RB	_	4	adv	_	_
4	have	have	VB	_	0	root	_	_
5	an	an	DT	_	7	det	_	_
6	additive	additive	JJ	_	7	attr	_	_
7	effect	effect	NN	_	4	obj	_	_
8	when	when	WRB	_	9	adv	_	_
9	given	give	VBN	_	4	comp	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	exacerbate	exacerbate	VB	_	0	root	_	_
4	the	the	DT	_	6	det	_	_
5	rebound	rebound	JJ	_	6	attr	_	_
6	hypertension	hypertension	NN	_	3	obj	_	_
7	which	which	WDT	_	9	dep	_	_
8	can	can	MD	_	9	modal	_	_
9	follow	follow	VBP	_	6	relcl	_	_
10	the	the	DT	_	11	det	_	_
11	withdrawal	withdrawal	NN	_	9	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	.	.	.	_	3	p	_	_

1	If	if	IN	_	6	mark	_	_
2	the	the	DT	_	4	det	_	_
3	two	#crd#	CD	_	4	num	_	_
4	drugs	drug	NNS	_	6	dep	_	_
5	are	be	VBP	_	6	aux	_	_
6	coadministered	coadministered	VBN	_	12	advcl	_	_
7	,	,	,	_	12	p	_	_
8	the	the	DT	_	9	det	_	_
9	drug1	drug0	NN	_	12	dep	_	_
10	should	should	MD	_	12	modal	_	_
11	be	be	VB	_	12	aux	_	_
12	withdrawn	withdraw	VBN	_	0	root	_	_
13	several	several	JJ	_	14	attr	_	_
14	days	day	NNS	_	12	obj	_	_
15	before	before	IN	_	18	case	_	_
16	the	the	DT	_	18	det	_	_
17	gradual	gradual	JJ	_	18	attr	_	_
18	withdrawal	withdrawal	NN	_	12	ppmod	_	_
19	of	of	IN	_	20	case	_	_
20	drug2	drug0	NN	_	18	ppmod	_	_
21	.	.	.	_	12	p	_	_

1	If	if	IN	_	2	case	_	_
2	replacing	replace	VBG	_	14	ppmod	_	_
3	drug1	drug0	NN	_	2	obj	_	_
4	by	by	IN	_	6	case	_	_
5	drug2	drug0	NN	_	6	com	_	_
6	therapy	therapy	NN	_	2	ppmod	_	_
7	,	,	,	_	14	p	_	_
8	the	the	DT	_	9	det	_	_
9	introduction	introduction	NN	_	14	dep	_	_
10	of	of	IN	_	11	case	_	_
11	drug3	drug0	NN	_	9	ppmod	_	_
12	should	should	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	delayed	delay	VBN	_	0	root	_	_
15	for	for	IN	_	17	case	_	_
16	several	several	JJ	_	17	attr	_	_
17	days	day	NNS	_	14	ppmod	_	_
18	after	after	IN	_	20	case	_	_
19	drug4	drug0	NN	_	20	com	_	_
20	administration	administration	NN	_	17	ppmod	_	_
21	has	have	VBZ	_	22	aux	_	_
22	stopped	stop	VBN	_	20	acl	_	_
23	.	.	.	_	14	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	use	use	NN	_	14	dep	_	_
3	of	of	IN	_	7	case	_	_
4	prostaglandin	prostaglandin	NN	_	5	com	_	_
5	synthase	synthase	NN	_	7	attr	_	_
6	inhibiting	inhibiting	JJ	_	7	attr	_	_
7	drugs	drug	NNS	_	2	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	eg	eg	FW	_	11	adv	_	_
10	,	,	,	_	11	p	_	_
11	drug1	drug0	NN	_	7	ppmod	_	_
12	,	,	,	_	7	p	_	_
13	may	may	MD	_	14	modal	_	_
14	decrease	decrease	VB	_	0	root	_	_
15	the	the	DT	_	17	det	_	_
16	hypotensive	hypotensive	JJ	_	17	attr	_	_
17	effects	effect	NNS	_	14	obj	_	_
18	of	of	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	.	.	.	_	14	p	_	_

1	Information	information	NN	_	10	dep	_	_
2	on	on	IN	_	4	case	_	_
3	concurrent	concurrent	JJ	_	4	attr	_	_
4	usage	usage	NN	_	1	ppmod	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	is	be	VBZ	_	10	aux	_	_
10	limited	limit	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	Data	datum	NNS	_	15	dep	_	_
2	from	from	IN	_	4	case	_	_
3	several	several	JJ	_	4	attr	_	_
4	studies	study	NNS	_	1	ppmod	_	_
5	,	,	,	_	1	p	_	_
6	ie	ie	NN	_	1	appo	_	_
7	,	,	,	_	6	p	_	_
8	TIMI-II	timi-ii	NN	_	6	appo	_	_
9	,	,	,	_	6	p	_	_
10	ISIS-2	isis-0	NN	_	6	appo	_	_
11	,	,	,	_	1	p	_	_
12	currently	currently	RB	_	15	adv	_	_
13	do	do	VBP	_	15	aux	_	_
14	not	not	RB	_	15	neg	_	_
15	suggest	suggest	VBP	_	0	root	_	_
16	any	any	DT	_	18	det	_	_
17	clinical	clinical	JJ	_	18	attr	_	_
18	interaction	interaction	NN	_	15	obj	_	_
19	between	between	IN	_	20	case	_	_
20	drug1	drug0	NN	_	18	ppmod	_	_
21	and	and	CC	_	20	cc	_	_
22	drug2	drug0	NN	_	20	conj	_	_
23	in	in	IN	_	28	case	_	_
24	the	the	DT	_	28	det	_	_
25	acute	acute	JJ	_	27	attr	_	_
26	myocardial	myocardial	JJ	_	27	attr	_	_
27	infarction	infarction	NN	_	28	com	_	_
28	setting	setting	NN	_	20	ppmod	_	_
29	.	.	.	_	15	p	_	_

1	While	while	IN	_	2	mark	_	_
2	taking	take	VBG	_	22	advcl	_	_
3	drug1	drug0	NN	_	2	obj	_	_
4	,	,	,	_	22	p	_	_
5	patients	patient	NNS	_	22	dep	_	_
6	with	with	IN	_	8	case	_	_
7	a	a	DT	_	8	det	_	_
8	history	history	NN	_	5	ppmod	_	_
9	of	of	IN	_	11	case	_	_
10	anaphylactic	anaphylactic	JJ	_	11	attr	_	_
11	reaction	reaction	NN	_	8	ppmod	_	_
12	to	to	TO	_	14	aux	_	_
13	a	a	DT	_	14	det	_	_
14	variety	variety	NN	_	11	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	allergens	allergen	NNS	_	14	ppmod	_	_
17	may	may	MD	_	22	modal	_	_
18	have	have	VB	_	22	lv	_	_
19	a	a	DT	_	22	det	_	_
20	more	more	RBR	_	21	adv	_	_
21	severe	severe	JJ	_	22	attr	_	_
22	reaction	reaction	NN	_	0	root	_	_
23	on	on	IN	_	25	case	_	_
24	repeated	repeated	JJ	_	25	attr	_	_
25	challenge	challenge	NN	_	22	ppmod	_	_
26	,	,	,	_	25	p	_	_
27	either	either	CC	_	28	cc	_	_
28	accidental	accidental	JJ	_	25	dep	_	_
29	,	,	,	_	28	p	_	_
30	diagnostic	diagnostic	JJ	_	28	conj	_	_
31	or	or	CC	_	30	cc	_	_
32	therapeutic	therapeutic	JJ	_	30	conj	_	_
33	.	.	.	_	22	p	_	_

1	Such	such	JJ	_	2	attr	_	_
2	patients	patient	NNS	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	be	be	VB	_	0	root	_	_
5	unresponsive	unresponsive	JJ	_	4	dep	_	_
6	to	to	TO	_	9	aux	_	_
7	the	the	DT	_	9	det	_	_
8	usual	usual	JJ	_	9	attr	_	_
9	doses	dose	NNS	_	5	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	used	use	VBN	_	9	acl	_	_
13	to	to	TO	_	14	aux	_	_
14	treat	treat	VB	_	12	comp	_	_
15	the	the	DT	_	17	det	_	_
16	allergic	allergic	JJ	_	17	attr	_	_
17	reaction	reaction	NN	_	14	obj	_	_
18	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	augments	augment	VBZ	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	action	action	NN	_	2	obj	_	_
5	of	of	IN	_	7	case	_	_
6	drug2	drug0	NN	_	7	com	_	_
7	s	s	NNS	_	4	ppmod	_	_
8	and	and	CC	_	4	cc	_	_
9	the	the	DT	_	12	det	_	_
10	muscle	muscle	NN	_	12	attr	_	_
11	relaxant	relaxant	JJ	_	12	attr	_	_
12	effects	effect	NNS	_	4	conj	_	_
13	of	of	IN	_	14	case	_	_
14	drug3	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	augment	augment	VB	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	hypotension	hypotension	NN	_	3	obj	_	_
6	caused	cause	VBN	_	5	acl	_	_
7	by	by	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	ganglionic-blocking	ganglionic-blocking	JJ	_	10	attr	_	_
10	effect	effect	NN	_	6	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	3	p	_	_

1	Caution	caution	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	exercised	exercise	VBN	_	0	root	_	_
5	during	during	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	administration	administration	NN	_	4	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	to	to	TO	_	11	aux	_	_
11	patients	patient	NNS	_	7	ppmod	_	_
12	anaesthetised	anaesthetised	JJ	_	11	acl	_	_
13	with	with	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	as	as	IN	_	18	mark	_	_
16	arrhythmias	arrhythmia	NNS	_	18	dep	_	_
17	may	may	MD	_	18	modal	_	_
18	be	be	VB	_	12	comp	_	_
19	precipitated	precipitated	JJ	_	18	dep	_	_
20	.	.	.	_	4	p	_	_

1	For	for	IN	_	3	case	_	_
2	this	this	DT	_	3	det	_	_
3	reason	reason	NN	_	10	ppmod	_	_
4	the	the	DT	_	5	det	_	_
5	dose	dose	NN	_	10	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	should	should	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	restricted	restrict	VBN	_	0	root	_	_
11	and	and	CC	_	10	cc	_	_
12	an	an	DT	_	13	det	_	_
13	drug2	drug0	NN	_	10	conj	_	_
14	administered	administer	VBN	_	13	acl	_	_
15	as	as	IN	_	16	case	_	_
16	appropriate	appropriate	JJ	_	14	ppmod	_	_
17	.	.	.	_	10	p	_	_

1	Caution	caution	NN	_	5	dep	_	_
2	should	should	MD	_	5	modal	_	_
3	also	also	RB	_	5	adv	_	_
4	be	be	VB	_	5	aux	_	_
5	applied	apply	VBN	_	0	root	_	_
6	for	for	IN	_	8	case	_	_
7	other	other	JJ	_	8	attr	_	_
8	drug1	drug0	NN	_	5	ppmod	_	_
9	,	,	,	_	8	p	_	_
10	and	and	CC	_	8	cc	_	_
11	for	for	IN	_	12	case	_	_
12	drug2	drug0	NN	_	8	conj	_	_
13	and	and	CC	_	12	cc	_	_
14	drug3	drug0	NN	_	12	conj	_	_
15	and	and	CC	_	14	cc	_	_
16	drug4	drug0	NN	_	14	conj	_	_
17	,	,	,	_	5	p	_	_
18	which	which	WDT	_	21	dep	_	_
19	may	may	MD	_	21	modal	_	_
20	also	also	RB	_	21	adv	_	_
21	precipitate	precipitate	VB	_	5	comp	_	_
22	arrhythmias	arrhythmias	NN	_	21	obj	_	_
23	.	.	.	_	5	p	_	_

1	Limited	limited	JJ	_	5	attr	_	_
2	PK	pk	NN	_	5	attr	_	_
3	and/or	and/or	CC	_	2	cc	_	_
4	PD	pd	NN	_	2	conj	_	_
5	studies	study	NNS	_	17	dep	_	_
6	investigating	investigate	VBG	_	5	acl	_	_
7	possible	possible	JJ	_	8	attr	_	_
8	interactions	interaction	NNS	_	6	obj	_	_
9	between	between	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	other	other	JJ	_	14	attr	_	_
13	medicinal	medicinal	JJ	_	14	attr	_	_
14	products	product	NNS	_	10	conj	_	_
15	have	have	VBP	_	17	aux	_	_
16	been	be	VBN	_	17	aux	_	_
17	conducted	conduct	VBN	_	0	root	_	_
18	.	.	.	_	17	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vivo	vivo	FW	_	4	attr	_	_
3	interaction	interaction	NN	_	4	com	_	_
4	studies	study	NNS	_	8	dep	_	_
5	in	in	IN	_	6	case	_	_
6	humans	human	NNS	_	4	ppmod	_	_
7	have	have	VBP	_	8	aux	_	_
8	demonstrated	demonstrate	VBN	_	0	root	_	_
9	that	that	IN	_	15	mark	_	_
10	drug1	drug0	NN	_	15	dep	_	_
11	and	and	CC	_	10	cc	_	_
12	drug2	drug0	NN	_	10	conj	_	_
13	do	do	VBP	_	15	aux	_	_
14	not	not	RB	_	15	neg	_	_
15	affect	affect	VB	_	8	comp	_	_
16	the	the	DT	_	18	det	_	_
17	PK	pk	NN	_	18	com	_	_
18	properties	property	NNS	_	15	obj	_	_
19	of	of	IN	_	20	case	_	_
20	drug3	drug0	NN	_	18	ppmod	_	_
21	,	,	,	_	15	p	_	_
22	nor	nor	CC	_	15	cc	_	_
23	does	do	VBZ	_	25	aux	_	_
24	drug4	drug0	RB	_	25	adv	_	_
25	affect	affect	VB	_	15	conj	_	_
26	the	the	DT	_	28	det	_	_
27	PK	pk	NN	_	28	com	_	_
28	properties	property	NNS	_	25	obj	_	_
29	of	of	IN	_	30	case	_	_
30	drug5	drug0	NN	_	28	ppmod	_	_
31	or	or	CC	_	30	cc	_	_
32	drug6	drug0	NN	_	30	conj	_	_
33	.	.	.	_	8	p	_	_

1	Although	although	IN	_	9	mark	_	_
2	additional	additional	JJ	_	5	attr	_	_
3	drug	drug	NN	_	5	com	_	_
4	interaction	interaction	NN	_	5	com	_	_
5	studies	study	NNS	_	9	dep	_	_
6	have	have	VBP	_	9	aux	_	_
7	not	not	RB	_	9	neg	_	_
8	been	be	VBN	_	9	aux	_	_
9	conducted	conduct	VBN	_	22	advcl	_	_
10	,	,	,	_	22	p	_	_
11	the	the	DT	_	14	det	_	_
12	most	most	RBS	_	13	adv	_	_
13	common	common	JJ	_	14	attr	_	_
14	medications	medication	NNS	_	22	dep	_	_
15	used	use	VBN	_	14	acl	_	_
16	concomitantly	concomitantly	RB	_	18	adv	_	_
17	with	with	IN	_	18	case	_	_
18	drug1	drug0	NN	_	15	ppmod	_	_
19	in	in	IN	_	21	case	_	_
20	clinical	clinical	JJ	_	21	attr	_	_
21	trials	trial	NNS	_	18	ppmod	_	_
22	were	be	VBD	_	0	root	_	_
23	drug2	drug0	NN	_	22	obj	_	_
24	,	,	,	_	23	p	_	_
25	drug3	drug0	NN	_	23	conj	_	_
26	,	,	,	_	25	p	_	_
27	drug4	drug0	NN	_	23	conj	_	_
28	,	,	,	_	27	p	_	_
29	drug5	drug0	NN	_	23	conj	_	_
30	,	,	,	_	29	p	_	_
31	drug6	drug0	NN	_	23	conj	_	_
32	,	,	,	_	31	p	_	_
33	drug7	drug0	NN	_	23	conj	_	_
34	,	,	,	_	33	p	_	_
35	and	and	CC	_	33	cc	_	_
36	drug8	drug0	NN	_	23	conj	_	_
37	.	.	.	_	22	p	_	_

1	There	there	EX	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	no	no	DT	_	5	det	_	_
4	clinical	clinical	JJ	_	5	attr	_	_
5	evidence	evidence	NN	_	2	obj	_	_
6	to	to	TO	_	7	aux	_	_
7	suggest	suggest	VB	_	5	acl	_	_
8	that	that	IN	_	10	mark	_	_
9	drug1	drug0	NN	_	10	dep	_	_
10	interacts	interact	VBZ	_	7	comp	_	_
11	with	with	IN	_	12	case	_	_
12	any	any	DT	_	10	ppmod	_	_
13	of	of	IN	_	15	case	_	_
14	these	these	DT	_	15	det	_	_
15	compounds	compound	NNS	_	12	ppmod	_	_
16	.	.	.	_	2	p	_	_

1	An	an	DT	_	5	det	_	_
2	in	in	FW	_	3	adv	_	_
3	vivo	vivo	FW	_	5	attr	_	_
4	interaction	interaction	NN	_	5	com	_	_
5	study	study	NN	_	8	dep	_	_
6	in	in	IN	_	7	case	_	_
7	humans	human	NNS	_	5	ppmod	_	_
8	demonstrated	demonstrate	VBD	_	0	root	_	_
9	that	that	IN	_	29	mark	_	_
10	a	a	DT	_	13	det	_	_
11	single	single	JJ	_	13	attr	_	_
12	1mg	0mg	NN	_	13	com	_	_
13	dose	dose	NN	_	29	dep	_	_
14	of	of	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	administered	administer	VBN	_	13	acl	_	_
17	concomitantly	concomitantly	RB	_	16	adv	_	_
18	with	with	IN	_	23	case	_	_
19	a	a	DT	_	23	det	_	_
20	single	single	JJ	_	23	attr	_	_
21	900	0	CD	_	22	num	_	_
22	mg	mg	NN	_	23	com	_	_
23	dose	dose	NN	_	16	ppmod	_	_
24	of	of	IN	_	25	case	_	_
25	drug2	drug0	NN	_	23	ppmod	_	_
26	was	be	VBD	_	29	aux	_	_
27	generally	generally	RB	_	29	adv	_	_
28	well	well	RB	_	29	adv	_	_
29	tolerated	tolerate	VBN	_	8	comp	_	_
30	.	.	.	_	8	p	_	_

1	There	there	EX	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	no	no	DT	_	4	det	_	_
4	effect	effect	NN	_	2	obj	_	_
5	on	on	IN	_	7	case	_	_
6	bleeding	bleeding	JJ	_	7	attr	_	_
7	time	time	NN	_	2	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	PT	pt	NN	_	7	appo	_	_
10	or	or	CC	_	9	cc	_	_
11	aPTT	aptt	NN	_	9	conj	_	_
12	.	.	.	_	2	p	_	_

1	No	no	DT	_	5	det	_	_
2	clinically	clinically	RB	_	3	adv	_	_
3	relevant	relevant	JJ	_	5	attr	_	_
4	pharmacokinetic	pharmacokinetic	JJ	_	5	attr	_	_
5	interactions	interaction	NNS	_	11	dep	_	_
6	between	between	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	were	be	VBD	_	11	aux	_	_
11	observed	observe	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	In	in	IN	_	4	case	_	_
2	that	that	DT	_	4	det	_	_
3	same	same	JJ	_	4	attr	_	_
4	study	study	NN	_	8	ppmod	_	_
5	,	,	,	_	8	p	_	_
6	drug1	drug0	NN	_	8	dep	_	_
7	alone	alone	RB	_	8	adv	_	_
8	produced	produce	VBD	_	0	root	_	_
9	a	a	DT	_	11	det	_	_
10	marked	marked	JJ	_	11	attr	_	_
11	inhibition	inhibition	NN	_	8	obj	_	_
12	in	in	IN	_	14	case	_	_
13	platelet	platelet	NN	_	14	com	_	_
14	aggregation	aggregation	NN	_	8	ppmod	_	_
15	ex	ex	FW	_	16	adv	_	_
16	vivo	vivo	FW	_	8	adv	_	_
17	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	alone	alone	RB	_	3	adv	_	_
3	had	have	VBD	_	0	root	_	_
4	no	no	DT	_	5	det	_	_
5	effect	effect	NN	_	3	obj	_	_
6	on	on	IN	_	8	case	_	_
7	platelet	platelet	NN	_	8	com	_	_
8	aggregation	aggregation	NN	_	3	ppmod	_	_
9	,	,	,	_	3	p	_	_
10	but	but	CC	_	3	cc	_	_
11	did	do	VBD	_	13	aux	_	_
12	slightly	slightly	RB	_	13	adv	_	_
13	enhance	enhance	VB	_	3	conj	_	_
14	the	the	DT	_	15	det	_	_
15	inhibition	inhibition	NN	_	13	obj	_	_
16	of	of	IN	_	18	case	_	_
17	platelet	platelet	NN	_	18	com	_	_
18	aggregation	aggregation	NN	_	15	ppmod	_	_
19	by	by	IN	_	20	case	_	_
20	drug2	drug0	NN	_	15	ppmod	_	_
21	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	metabolized	metabolize	VBN	_	0	root	_	_
4	at	at	IN	_	5	case	_	_
5	least	least	JJS	_	7	adv	_	_
6	in	in	IN	_	7	case	_	_
7	part	part	NN	_	3	ppmod	_	_
8	by	by	IN	_	9	case	_	_
9	CYP1A2	cyp0a0	NN	_	3	ppmod	_	_
10	.	.	.	_	3	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	known	know	VBN	_	0	root	_	_
4	that	that	IN	_	7	mark	_	_
5	CYP1A2	cyp0a0	NN	_	7	dep	_	_
6	is	be	VBZ	_	7	aux	_	_
7	inhibited	inhibit	VBN	_	3	advcl	_	_
8	by	by	IN	_	11	case	_	_
9	several	several	JJ	_	11	attr	_	_
10	medicinal	medicinal	NN	_	11	com	_	_
11	products	product	NNS	_	7	ppmod	_	_
12	,	,	,	_	11	p	_	_
13	including	include	VBG	_	14	adv	_	_
14	drug1	drug0	NN	_	11	ppmod	_	_
15	,	,	,	_	7	p	_	_
16	and	and	CC	_	7	cc	_	_
17	such	such	IN	_	23	mark	_	_
18	medicinal	medicinal	NN	_	19	com	_	_
19	products	product	NNS	_	23	dep	_	_
20	could	could	MD	_	23	modal	_	_
21	theoretically	theoretically	RB	_	23	adv	_	_
22	adversely	adversely	RB	_	23	adv	_	_
23	influence	influence	VB	_	7	conj	_	_
24	the	the	DT	_	25	det	_	_
25	clearance	clearance	NN	_	23	obj	_	_
26	of	of	IN	_	27	case	_	_
27	drug2	drug0	NN	_	25	ppmod	_	_
28	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	demonstrates	demonstrate	VBZ	_	0	root	_	_
3	some	some	DT	_	6	det	_	_
4	limited	limited	JJ	_	6	attr	_	_
5	inhibitory	inhibitory	JJ	_	6	attr	_	_
6	activity	activity	NN	_	2	obj	_	_
7	towards	towards	IN	_	8	case	_	_
8	CYP1A2	cyp0a0	NN	_	6	ppmod	_	_
9	which	which	WDT	_	11	dep	_	_
10	may	may	MD	_	11	modal	_	_
11	present	present	VB	_	6	relcl	_	_
12	a	a	DT	_	14	det	_	_
13	theoretical	theoretical	JJ	_	14	attr	_	_
14	potential	potential	NN	_	11	obj	_	_
15	for	for	IN	_	16	case	_	_
16	interaction	interaction	NN	_	14	ppmod	_	_
17	with	with	IN	_	21	case	_	_
18	other	other	JJ	_	21	attr	_	_
19	coadministered	coadministered	JJ	_	21	attr	_	_
20	medicinal	medicinal	NN	_	21	com	_	_
21	products	product	NNS	_	16	ppmod	_	_
22	sharing	share	VBG	_	2	comp	_	_
23	that	that	DT	_	25	det	_	_
24	clearance	clearance	NN	_	25	com	_	_
25	mechanism	mechanism	NN	_	22	obj	_	_
26	e.g.	e.g.	FW	_	2	dep	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	demonstrates	demonstrate	VBZ	_	0	root	_	_
3	some	some	DT	_	6	det	_	_
4	limited	limited	JJ	_	6	attr	_	_
5	inhibitory	inhibitory	JJ	_	6	attr	_	_
6	activity	activity	NN	_	2	obj	_	_
7	towards	towards	IN	_	8	case	_	_
8	CYP1A2	cyp0a0	NN	_	6	ppmod	_	_
9	which	which	WDT	_	11	dep	_	_
10	may	may	MD	_	11	modal	_	_
11	present	present	VBP	_	6	relcl	_	_
12	a	a	DT	_	14	det	_	_
13	theoretical	theoretical	JJ	_	14	attr	_	_
14	potential	potential	NN	_	11	obj	_	_
15	for	for	IN	_	16	case	_	_
16	interaction	interaction	NN	_	14	ppmod	_	_
17	with	with	IN	_	21	case	_	_
18	other	other	JJ	_	21	attr	_	_
19	coadministered	coadministered	JJ	_	21	attr	_	_
20	medicinal	medicinal	NN	_	21	com	_	_
21	products	product	NNS	_	16	ppmod	_	_
22	sharing	share	VBG	_	21	acl	_	_
23	that	that	DT	_	25	det	_	_
24	clearance	clearance	NN	_	25	com	_	_
25	mechanism	mechanism	NN	_	22	obj	_	_
26	e.g.	e.g.	FW	_	27	adv	_	_
27	drug2	drug0	NN	_	25	ppmod	_	_
28	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	an	an	DT	_	4	det	_	_
4	inhibitor	inhibitor	NN	_	2	obj	_	_
5	of	of	IN	_	8	case	_	_
6	cyclic	cyclic	JJ	_	8	attr	_	_
7	AMP	amp	NN	_	8	com	_	_
8	PDE	pde	NN	_	4	ppmod	_	_
9	III	iii	CD	_	8	num	_	_
10	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	effects	effect	NNS	_	22	dep	_	_
3	of	of	IN	_	5	case	_	_
4	medicinal	medicinal	NN	_	5	com	_	_
5	products	product	NNS	_	2	ppmod	_	_
6	with	with	IN	_	8	case	_	_
7	similar	similar	JJ	_	8	attr	_	_
8	properties	property	NNS	_	2	ppmod	_	_
9	such	such	JJ	_	11	adv	_	_
10	as	as	IN	_	11	case	_	_
11	inotropes	inotropes	NNS	_	8	ppmod	_	_
12	drug1	drug0	NN	_	11	attr	_	_
13	,	,	,	_	12	p	_	_
14	drug2	drug0	NN	_	12	conj	_	_
15	,	,	,	_	14	p	_	_
16	drug3	drug0	NN	_	12	conj	_	_
17	,	,	,	_	16	p	_	_
18	drug4	drug0	NN	_	12	conj	_	_
19	and	and	CC	_	18	cc	_	_
20	drug5	drug0	NN	_	12	conj	_	_
21	may	may	MD	_	22	modal	_	_
22	be	be	VB	_	0	root	_	_
23	exacerbated	exacerbated	JJ	_	22	dep	_	_
24	by	by	IN	_	25	case	_	_
25	drug6	drug0	NN	_	23	ppmod	_	_
26	.	.	.	_	22	p	_	_

1	There	there	EX	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	a	a	DT	_	6	det	_	_
4	single	single	JJ	_	6	attr	_	_
5	case	case	NN	_	6	com	_	_
6	report	report	NN	_	2	obj	_	_
7	,	,	,	_	6	p	_	_
8	which	which	WDT	_	9	dep	_	_
9	suggests	suggest	VBZ	_	6	relcl	_	_
10	that	that	IN	_	13	mark	_	_
11	drug1	drug0	NN	_	13	dep	_	_
12	may	may	MD	_	13	modal	_	_
13	interfere	interfere	VB	_	9	comp	_	_
14	with	with	IN	_	16	case	_	_
15	drug2	drug0	NN	_	16	com	_	_
16	absorption	absorption	NN	_	13	ppmod	_	_
17	.	.	.	_	2	p	_	_

1	Food	food	NN	_	2	dep	_	_
2	has	have	VBZ	_	0	root	_	_
3	no	no	DT	_	6	det	_	_
4	clinically	clinically	RB	_	5	adv	_	_
5	significant	significant	JJ	_	6	attr	_	_
6	effect	effect	NN	_	2	obj	_	_
7	on	on	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	bioavailability	bioavailability	NN	_	2	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	2	p	_	_

1	Potential	potential	NN	_	0	root	_	_
2	for	for	IN	_	3	case	_	_
3	Interaction	interaction	NN	_	1	ppmod	_	_
4	with	with	IN	_	5	case	_	_
5	drug1	drug0	NN	_	1	ppmod	_	_

1	In	in	IN	_	2	case	_	_
2	patients	patient	NNS	_	16	ppmod	_	_
3	receiving	receive	VBG	_	2	acl	_	_
4	another	another	DT	_	5	det	_	_
5	drug1	drug0	NN	_	3	obj	_	_
6	in	in	IN	_	7	case	_	_
7	combination	combination	NN	_	5	ppmod	_	_
8	with	with	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	drug3	drug0	NN	_	9	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	,	,	,	_	16	p	_	_
14	there	there	EX	_	16	dep	_	_
15	have	have	VBP	_	16	aux	_	_
16	been	be	VBN	_	0	root	_	_
17	reports	report	NNS	_	16	obj	_	_
18	of	of	IN	_	24	case	_	_
19	serious	serious	JJ	_	24	attr	_	_
20	,	,	,	_	24	p	_	_
21	sometimes	sometimes	RB	_	22	adv	_	_
22	fatal	fatal	JJ	_	24	attr	_	_
23	,	,	,	_	24	p	_	_
24	reactions	reaction	NNS	_	17	ppmod	_	_
25	including	include	VBG	_	26	adv	_	_
26	hyperthermia	hyperthermia	NN	_	17	ppmod	_	_
27	,	,	,	_	26	p	_	_
28	rigidity	rigidity	NN	_	26	conj	_	_
29	,	,	,	_	28	p	_	_
30	myoclonus	myoclonus	NN	_	26	conj	_	_
31	,	,	,	_	30	p	_	_
32	autonomic	autonomic	JJ	_	33	attr	_	_
33	instability	instability	NN	_	26	conj	_	_
34	with	with	IN	_	37	case	_	_
35	possible	possible	JJ	_	37	attr	_	_
36	rapid	rapid	JJ	_	37	attr	_	_
37	fluctuations	fluctuation	NNS	_	33	ppmod	_	_
38	of	of	IN	_	40	case	_	_
39	vital	vital	JJ	_	40	attr	_	_
40	signs	sign	NNS	_	37	ppmod	_	_
41	,	,	,	_	33	p	_	_
42	and	and	CC	_	33	cc	_	_
43	mental	mental	JJ	_	45	attr	_	_
44	status	status	NN	_	45	com	_	_
45	changes	change	NNS	_	26	conj	_	_
46	that	that	WDT	_	47	dep	_	_
47	include	include	VBP	_	45	relcl	_	_
48	extreme	extreme	JJ	_	49	attr	_	_
49	agitation	agitation	NN	_	47	obj	_	_
50	progressing	progress	VBG	_	49	acl	_	_
51	to	to	TO	_	52	aux	_	_
52	delirium	delirium	NN	_	50	ppmod	_	_
53	and	and	CC	_	52	cc	_	_
54	coma	coma	NN	_	52	conj	_	_
55	.	.	.	_	16	p	_	_

1	These	these	DT	_	2	det	_	_
2	reactions	reaction	NNS	_	6	dep	_	_
3	have	have	VBP	_	6	aux	_	_
4	also	also	RB	_	6	adv	_	_
5	been	be	VBN	_	6	aux	_	_
6	reported	report	VBN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	6	ppmod	_	_
9	who	who	WP	_	11	dep	_	_
10	have	have	VBP	_	11	aux	_	_
11	discontinued	discontinue	VBN	_	8	relcl	_	_
12	that	that	DT	_	13	det	_	_
13	drug	drug	NN	_	11	obj	_	_
14	and	and	CC	_	11	cc	_	_
15	have	have	VBP	_	17	aux	_	_
16	been	be	VBN	_	17	aux	_	_
17	started	start	VBN	_	11	conj	_	_
18	on	on	IN	_	20	case	_	_
19	a	a	DT	_	20	det	_	_
20	drug1	drug0	NN	_	17	ppmod	_	_
21	.	.	.	_	6	p	_	_

1	Some	some	DT	_	2	det	_	_
2	cases	case	NNS	_	3	dep	_	_
3	presented	present	VBD	_	0	root	_	_
4	with	with	IN	_	5	case	_	_
5	features	feature	NNS	_	3	ppmod	_	_
6	resembling	resemble	VBG	_	5	acl	_	_
7	neuroleptic	neuroleptic	JJ	_	9	attr	_	_
8	malignant	malignant	JJ	_	9	attr	_	_
9	syndrome	syndrome	NN	_	6	obj	_	_
10	.	.	.	_	3	p	_	_

1	Therefore	therefore	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	it	it	PRP	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	recommended	recommend	VBN	_	0	root	_	_
6	that	that	IN	_	11	mark	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	Tablets	tablet	NNS	_	11	dep	_	_
9	not	not	RB	_	11	neg	_	_
10	be	be	VB	_	11	aux	_	_
11	used	use	VBN	_	5	comp	_	_
12	in	in	IN	_	13	case	_	_
13	combination	combination	NN	_	11	ppmod	_	_
14	with	with	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	,	,	,	_	13	p	_	_
17	or	or	CC	_	13	cc	_	_
18	within	within	IN	_	20	case	_	_
19	14	0	CD	_	20	num	_	_
20	days	day	NNS	_	13	conj	_	_
21	of	of	IN	_	23	case	_	_
22	discontinuing	discontinuing	NN	_	23	com	_	_
23	treatment	treatment	NN	_	20	ppmod	_	_
24	with	with	IN	_	26	case	_	_
25	a	a	DT	_	26	det	_	_
26	drug3	drug0	NN	_	23	ppmod	_	_
27	.	.	.	_	5	p	_	_

1	After	after	IN	_	2	case	_	_
2	stopping	stop	VBG	_	12	ppmod	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	Tablets	tablet	NNS	_	2	obj	_	_
5	,	,	,	_	12	p	_	_
6	at	at	IN	_	8	case	_	_
7	least	least	JJS	_	8	attr	_	_
8	2	0	CD	_	9	num	_	_
9	weeks	week	NNS	_	12	dep	_	_
10	should	should	MD	_	12	modal	_	_
11	be	be	VB	_	12	aux	_	_
12	allowed	allow	VBN	_	0	root	_	_
13	before	before	IN	_	14	case	_	_
14	starting	start	VBG	_	12	ppmod	_	_
15	a	a	DT	_	16	det	_	_
16	drug2	drug0	NN	_	14	obj	_	_
17	.	.	.	_	12	p	_	_

1	Potential	potential	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	,	,	,	_	2	p	_	_
4	drug2	drug0	NN	_	2	conj	_	_
5	,	,	,	_	4	p	_	_
6	and	and	CC	_	4	cc	_	_
7	drug3	drug0	NN	_	8	com	_	_
8	Interactions	interaction	NNS	_	2	conj	_	_

1	drug1	drug0	NN	_	8	dep	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	and	and	CC	_	3	cc	_	_
5	drug3	drug0	NN	_	1	conj	_	_
6	are	be	VBP	_	8	aux	_	_
7	all	all	RB	_	8	adv	_	_
8	metabolized	metabolize	VBN	_	0	root	_	_
9	by	by	IN	_	13	case	_	_
10	the	the	DT	_	13	det	_	_
11	cytochrome	cytochrome	NN	_	13	com	_	_
12	P450IIIA4	p0iiia0	NN	_	13	com	_	_
13	isozyme	isozyme	NN	_	8	ppmod	_	_
14	,	,	,	_	8	p	_	_
15	and	and	CC	_	8	cc	_	_
16	it	it	PRP	_	19	dep	_	_
17	has	have	VBZ	_	19	aux	_	_
18	been	be	VBN	_	19	aux	_	_
19	demonstrated	demonstrate	VBN	_	8	conj	_	_
20	that	that	IN	_	29	mark	_	_
21	drug4	drug0	NN	_	29	dep	_	_
22	,	,	,	_	21	p	_	_
23	a	a	DT	_	25	det	_	_
24	potent	potent	JJ	_	25	attr	_	_
25	inhibitor	inhibitor	NN	_	21	appo	_	_
26	of	of	IN	_	27	case	_	_
27	IIIA4	iiia0	NN	_	25	ppmod	_	_
28	,	,	,	_	21	p	_	_
29	blocks	block	VBZ	_	19	comp	_	_
30	the	the	DT	_	31	det	_	_
31	metabolism	metabolism	NN	_	29	obj	_	_
32	of	of	IN	_	34	case	_	_
33	these	these	DT	_	34	det	_	_
34	drugs	drug	NNS	_	31	ppmod	_	_
35	,	,	,	_	29	p	_	_
36	resulting	result	VBG	_	29	comp	_	_
37	in	in	IN	_	40	case	_	_
38	increased	increase	VBN	_	40	attr	_	_
39	plasma	plasma	NN	_	40	com	_	_
40	concentrations	concentration	NNS	_	36	ppmod	_	_
41	of	of	IN	_	43	case	_	_
42	parent	parent	JJ	_	43	attr	_	_
43	drug	drug	NN	_	40	ppmod	_	_
44	.	.	.	_	8	p	_	_

1	Increased	increase	VBN	_	3	attr	_	_
2	plasma	plasma	NN	_	3	com	_	_
3	concentrations	concentration	NNS	_	11	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	,	,	,	_	5	p	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	,	,	,	_	7	p	_	_
9	and	and	CC	_	7	cc	_	_
10	drug3	drug0	NN	_	5	conj	_	_
11	cause	cause	VBP	_	0	root	_	_
12	QT	qt	NN	_	13	com	_	_
13	prolongation	prolongation	NN	_	11	obj	_	_
14	and	and	CC	_	11	cc	_	_
15	have	have	VBP	_	17	aux	_	_
16	been	be	VBN	_	17	aux	_	_
17	associated	associate	VBN	_	11	conj	_	_
18	with	with	IN	_	19	case	_	_
19	torsades	torsades	NNS	_	17	ppmod	_	_
20	de	de	FW	_	23	adv	_	_
21	pointes-type	pointes-type	JJ	_	23	attr	_	_
22	ventricular	ventricular	JJ	_	23	attr	_	_
23	tachycardia	tachycardia	NN	_	19	ppmod	_	_
24	,	,	,	_	17	p	_	_
25	sometimes	sometimes	RB	_	17	adv	_	_
26	fatal	fatal	JJ	_	17	dep	_	_
27	.	.	.	_	11	p	_	_

1	As	as	IN	_	2	mark	_	_
2	noted	note	VBN	_	0	root	_	_
3	below	below	IN	_	2	case	_	_
4	,	,	,	_	2	p	_	_
5	a	a	DT	_	6	det	_	_
6	sub-	sub-	NN	_	2	dep	_	_
7	for	for	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	in	in	IN	_	10	case	_	_
10	combination	combination	NN	_	6	ppmod	_	_
11	with	with	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	,	,	,	_	6	p	_	_
14	a	a	DT	_	15	det	_	_
15	drug	drug	NN	_	6	appo	_	_
16	that	that	WDT	_	18	dep	_	_
17	is	be	VBZ	_	18	aux	_	_
18	known	know	VBN	_	15	relcl	_	_
19	to	to	TO	_	21	aux	_	_
20	be	be	VB	_	21	aux	_	_
21	metabolized	metabolize	VBN	_	18	comp	_	_
22	by	by	IN	_	25	case	_	_
23	the	the	DT	_	25	det	_	_
24	IIIA4	iiia0	JJ	_	25	attr	_	_
25	isozyme	isozyme	NN	_	21	ppmod	_	_
26	.	.	.	_	2	p	_	_

1	Although	although	IN	_	7	mark	_	_
2	it	it	PRP	_	7	dep	_	_
3	has	have	VBZ	_	7	aux	_	_
4	not	not	RB	_	7	neg	_	_
5	been	be	VBN	_	7	aux	_	_
6	definitively	definitively	RB	_	7	adv	_	_
7	demonstrated	demonstrate	VBN	_	17	advcl	_	_
8	that	that	IN	_	10	mark	_	_
9	drug1	drug0	NN	_	10	dep	_	_
10	is	be	VBZ	_	7	comp	_	_
11	a	a	DT	_	14	det	_	_
12	potent	potent	JJ	_	14	attr	_	_
13	IIIA4	iiia0	NN	_	14	com	_	_
14	inhibitor	inhibitor	NN	_	10	obj	_	_
15	,	,	,	_	17	p	_	_
16	it	it	PRP	_	17	dep	_	_
17	is	be	VBZ	_	0	root	_	_
18	likely	likely	JJ	_	17	dep	_	_
19	to	to	TO	_	20	aux	_	_
20	be	be	VB	_	18	comp	_	_
21	,	,	,	_	20	p	_	_
22	given	given	IN	_	25	case	_	_
23	the	the	DT	_	25	det	_	_
24	substantial	substantial	JJ	_	25	attr	_	_
25	interaction	interaction	NN	_	20	ppmod	_	_
26	of	of	IN	_	27	case	_	_
27	drug2	drug0	NN	_	25	ppmod	_	_
28	with	with	IN	_	29	case	_	_
29	drug3	drug0	NN	_	25	ppmod	_	_
30	.	.	.	_	17	p	_	_

1	Consequently	consequently	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	it	it	PRP	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	recommended	recommend	VBN	_	0	root	_	_
6	that	that	IN	_	10	mark	_	_
7	drug1	drug0	NN	_	10	dep	_	_
8	not	not	RB	_	10	neg	_	_
9	be	be	VB	_	10	aux	_	_
10	used	use	VBN	_	5	comp	_	_
11	in	in	IN	_	12	case	_	_
12	combination	combination	NN	_	10	ppmod	_	_
13	with	with	IN	_	15	case	_	_
14	either	either	CC	_	15	cc	_	_
15	drug2	drug0	NN	_	12	ppmod	_	_
16	,	,	,	_	15	p	_	_
17	drug3	drug0	NN	_	15	conj	_	_
18	,	,	,	_	17	p	_	_
19	or	or	CC	_	17	cc	_	_
20	drug4	drug0	NN	_	15	conj	_	_
21	.	.	.	_	5	p	_	_

1	Other	other	JJ	_	5	attr	_	_
2	Potentially	potentially	RB	_	3	adv	_	_
3	Important	important	JJ	_	5	attr	_	_
4	Drug	drug	NN	_	5	com	_	_
5	Interactions	interaction	NNS	_	0	root	_	_
6	:	:	:	_	5	p	_	_
7	drug1	drug0	NN	_	26	dep	_	_
8	:	:	:	_	7	p	_	_
9	drug2	drug0	NN	_	7	appo	_	_
10	metabolized	metabolize	VBN	_	9	acl	_	_
11	by	by	IN	_	13	case	_	_
12	hepatic	hepatic	JJ	_	13	attr	_	_
13	oxidation	oxidation	NN	_	10	ppmod	_	_
14	(	-lrb-	-LRB-	_	17	p	_	_
15	e.g.	e.g.	FW	_	17	adv	_	_
16	,	,	,	_	17	p	_	_
17	drug3	drug0	NN	_	13	prn	_	_
18	,	,	,	_	17	p	_	_
19	drug4	drug0	NN	_	17	conj	_	_
20	,	,	,	_	19	p	_	_
21	drug5	drug0	CC	_	19	cc	_	_
22	elc.	elc.	NN	_	17	conj	_	_
23	)	-rrb-	-RRB-	_	17	p	_	_
24	should	should	MD	_	26	modal	_	_
25	be	be	VB	_	26	aux	_	_
26	used	use	VBN	_	5	acl	_	_
27	with	with	IN	_	28	case	_	_
28	caution	caution	NN	_	26	ppmod	_	_
29	because	because	IN	_	35	mark	_	_
30	the	the	DT	_	31	det	_	_
31	clearance	clearance	NN	_	35	dep	_	_
32	of	of	IN	_	34	case	_	_
33	these	these	DT	_	34	det	_	_
34	drugs	drug	NNS	_	31	ppmod	_	_
35	is	be	VBZ	_	26	comp	_	_
36	likely	likely	JJ	_	35	dep	_	_
37	to	to	TO	_	39	aux	_	_
38	be	be	VB	_	39	aux	_	_
39	reduced	reduce	VBN	_	36	comp	_	_
40	by	by	IN	_	41	case	_	_
41	drug6	drug0	NN	_	39	ppmod	_	_
42	.	.	.	_	5	p	_	_

1	The	the	DT	_	2	det	_	_
2	clearance	clearance	NN	_	18	dep	_	_
3	of	of	IN	_	5	case	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	metabolized	metabolized	NN	_	2	ppmod	_	_
6	by	by	IN	_	7	case	_	_
7	glucuronidation	glucuronidation	NN	_	2	ppmod	_	_
8	(	-lrb-	-LRB-	_	10	p	_	_
9	e.	e.	FW	_	10	attr	_	_
10	g.	g.	FW	_	7	prn	_	_
11	,	,	,	_	10	p	_	_
12	drug2	drug0	NN	_	10	attr	_	_
13	,	,	,	_	10	p	_	_
14	drug3	drug0	NN	_	12	appo	_	_
15	,	,	,	_	10	p	_	_
16	drug4	drug0	NN	_	12	appo	_	_
17	)	-rrb-	-RRB-	_	10	p	_	_
18	is	be	VBZ	_	0	root	_	_
19	unlikely	unlikely	JJ	_	18	dep	_	_
20	to	to	TO	_	22	aux	_	_
21	be	be	VB	_	22	aux	_	_
22	affected	affect	VBN	_	19	comp	_	_
23	by	by	IN	_	24	case	_	_
24	drug5	drug0	NN	_	22	ppmod	_	_
25	.	.	.	_	18	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	38	p	_	_
3	When	when	WRB	_	38	adv	_	_
4	drug2	drug0	NN	_	38	dep	_	_
5	(	-lrb-	-LRB-	_	8	p	_	_
6	100	0	CD	_	7	num	_	_
7	mg	mg	NN	_	8	com	_	_
8	qd	qd	NN	_	4	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	and	and	CC	_	4	cc	_	_
11	drug3	drug0	NN	_	4	conj	_	_
12	(	-lrb-	-LRB-	_	15	p	_	_
13	1	0	CD	_	14	num	_	_
14	mg	mg	NN	_	15	com	_	_
15	q.d.	q.d.	NN	_	11	prn	_	_
16	were	be	VBD	_	15	acl	_	_
17	co-administered	co-administered	VBN	_	16	dep	_	_
18	to	to	TO	_	20	aux	_	_
19	steady	steady	JJ	_	20	attr	_	_
20	state	state	NN	_	16	ppmod	_	_
21	,	,	,	_	20	p	_	_
22	plasma	plasma	NN	_	23	com	_	_
23	concentration	concentration	NN	_	20	appo	_	_
24	and	and	CC	_	23	cc	_	_
25	other	other	JJ	_	27	attr	_	_
26	pharmacokinetics	pharmacokinetics	NNS	_	27	com	_	_
27	parameters	parameter	NNS	_	23	conj	_	_
28	(	-lrb-	-LRB-	_	29	p	_	_
29	AUC	auc	NN	_	27	prn	_	_
30	,	,	,	_	29	p	_	_
31	Cmax	cmax	NN	_	29	appo	_	_
32	,	,	,	_	29	p	_	_
33	T1/2	t0	NN	_	29	appo	_	_
34	,	,	,	_	20	p	_	_
35	)	-rrb-	-RRB-	_	15	p	_	_
36	of	of	IN	_	37	case	_	_
37	drug4	drug0	NN	_	4	ppmod	_	_
38	were	be	VBD	_	1	prn	_	_
39	approximately	approximately	RB	_	40	com	_	_
40	twice	twice	RB	_	38	adv	_	_
41	those	those	DT	_	38	obj	_	_
42	observed	observe	VBN	_	41	acl	_	_
43	when	when	WRB	_	46	adv	_	_
44	drug5	drug0	NN	_	46	dep	_	_
45	was	be	VBD	_	46	aux	_	_
46	administered	administer	VBN	_	42	comp	_	_
47	alone	alone	RB	_	46	adv	_	_
48	;	;	:	_	38	p	_	_

1	oral	oral	JJ	_	2	attr	_	_
2	clearance	clearance	NN	_	4	dep	_	_
3	was	be	VBD	_	4	aux	_	_
4	reduced	reduce	VBN	_	0	root	_	_
5	by	by	IN	_	7	case	_	_
6	about	about	RB	_	7	adv	_	_
7	50	0	CD	_	4	ppmod	_	_
8	%	%	NN	_	7	meta	_	_
9	.	.	.	_	4	p	_	_

1	The	the	DT	_	5	det	_	_
2	elevated	elevated	JJ	_	5	attr	_	_
3	plasma	plasma	NN	_	5	com	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	concentrations	concentration	NNS	_	6	dep	_	_
6	resulted	result	VBD	_	0	root	_	_
7	in	in	IN	_	10	case	_	_
8	decreased	decrease	VBN	_	10	attr	_	_
9	psychomotor	psychomotor	NN	_	10	com	_	_
10	performance	performance	NN	_	6	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	memory	memory	NN	_	10	conj	_	_
13	.	.	.	_	6	p	_	_

1	This	this	DT	_	2	det	_	_
2	interaction	interaction	NN	_	16	dep	_	_
3	,	,	,	_	2	p	_	_
4	which	which	WDT	_	8	dep	_	_
5	has	have	VBZ	_	8	aux	_	_
6	not	not	RB	_	8	neg	_	_
7	been	be	VBN	_	8	aux	_	_
8	investigated	investigate	VBN	_	2	relcl	_	_
9	using	use	VBG	_	8	comp	_	_
10	higher	high	JJR	_	11	attr	_	_
11	doses	dose	NNS	_	9	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	,	,	,	_	2	p	_	_
15	may	may	MD	_	16	modal	_	_
16	be	be	VB	_	0	root	_	_
17	more	more	RBR	_	18	adv	_	_
18	pronounced	pronounced	JJ	_	16	dep	_	_
19	if	if	IN	_	26	mark	_	_
20	a	a	DT	_	24	det	_	_
21	300	0	CD	_	22	num	_	_
22	mg	mg	NN	_	24	attr	_	_
23	daily	daily	JJ	_	24	attr	_	_
24	dose	dose	NN	_	26	dep	_	_
25	is	be	VBZ	_	26	aux	_	_
26	co-administered	co-administered	VBN	_	16	comp	_	_
27	,	,	,	_	26	p	_	_
28	particularly	particularly	RB	_	56	adv	_	_
29	since	since	IN	_	31	mark	_	_
30	drug2	drug0	NN	_	31	dep	_	_
31	exhibits	exhibit	VBZ	_	56	advcl	_	_
32	non-linear	non-linear	JJ	_	33	attr	_	_
33	pharmacokinetics	pharmacokinetics	NNS	_	31	obj	_	_
34	over	over	IN	_	37	case	_	_
35	the	the	DT	_	37	det	_	_
36	dosage	dosage	NN	_	37	com	_	_
37	range	range	NN	_	31	ppmod	_	_
38	100-300	0	CD	_	37	num	_	_
39	mg.	mg.	CC	_	31	cc	_	_
40	If	if	IN	_	43	mark	_	_
41	drug3	drug0	NN	_	43	dep	_	_
42	is	be	VBZ	_	43	aux	_	_
43	co-administered	co-administered	VBN	_	31	conj	_	_
44	with	with	IN	_	46	case	_	_
45	drug4	drug0	NN	_	46	com	_	_
46	Tablets	tablet	NNS	_	43	ppmod	_	_
47	,	,	,	_	56	p	_	_
48	the	the	DT	_	51	det	_	_
49	initial	initial	JJ	_	51	attr	_	_
50	drug5	drug0	NN	_	51	com	_	_
51	dosage	dosage	NN	_	56	dep	_	_
52	should	should	MD	_	56	modal	_	_
53	be	be	VB	_	56	aux	_	_
54	at	at	IN	_	55	case	_	_
55	least	least	JJS	_	56	adv	_	_
56	halved	halve	VBN	_	26	advcl	_	_
57	and	and	CC	_	26	cc	_	_
58	titration	titration	NN	_	65	dep	_	_
59	to	to	TO	_	63	aux	_	_
60	the	the	DT	_	63	det	_	_
61	lowest	low	JJS	_	62	adv	_	_
62	effective	effective	JJ	_	63	attr	_	_
63	dose	dose	NN	_	58	ppmod	_	_
64	is	be	VBZ	_	65	aux	_	_
65	recommended	recommend	VBN	_	26	conj	_	_
66	.	.	.	_	16	p	_	_

1	No	no	DT	_	3	det	_	_
2	dosage	dosage	JJ	_	3	attr	_	_
3	adjustment	adjustment	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	required	require	VBN	_	0	root	_	_
6	for	for	IN	_	8	case	_	_
7	drug1	drug0	JJ	_	8	attr	_	_
8	Tablets	tablet	NNS	_	5	ppmod	_	_
9	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	co-administration	co-administration	NN	_	10	dep	_	_
5	of	of	IN	_	7	case	_	_
6	drug2	drug0	NN	_	7	com	_	_
7	Tablets	tablet	NNS	_	4	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug3	drug0	NNS	_	7	conj	_	_
10	is	be	VBZ	_	1	acl	_	_
11	generally	generally	RB	_	10	adv	_	_
12	not	not	RB	_	10	neg	_	_
13	advisable	advisable	JJ	_	10	dep	_	_
14	.	.	.	_	1	p	_	_

1	Because	because	IN	_	3	mark	_	_
2	drug1	drug0	NN	_	3	dep	_	_
3	reduces	reduce	VBZ	_	17	advcl	_	_
4	the	the	DT	_	5	det	_	_
5	clearance	clearance	NN	_	3	obj	_	_
6	of	of	IN	_	8	case	_	_
7	both	both	CC	_	8	cc	_	_
8	drug2	drug0	NN	_	5	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	its	its	PRP$	_	12	poss	_	_
11	active	active	JJ	_	12	attr	_	_
12	metabolite	metabolite	NN	_	8	conj	_	_
13	,	,	,	_	12	p	_	_
14	drug3	drug0	NN	_	12	appo	_	_
15	,	,	,	_	17	p	_	_
16	there	there	EX	_	17	dep	_	_
17	is	be	VBZ	_	0	root	_	_
18	a	a	DT	_	20	det	_	_
19	strong	strong	JJ	_	20	attr	_	_
20	likelihood	likelihood	NN	_	17	obj	_	_
21	of	of	IN	_	23	case	_	_
22	substantial	substantial	JJ	_	23	attr	_	_
23	accumulation	accumulation	NN	_	20	ppmod	_	_
24	of	of	IN	_	26	case	_	_
25	both	both	DT	_	26	det	_	_
26	species	species	NNS	_	23	ppmod	_	_
27	during	during	IN	_	29	case	_	_
28	chronic	chronic	JJ	_	29	attr	_	_
29	co-administration	co-administration	NN	_	23	ppmod	_	_
30	.	.	.	_	17	p	_	_

1	Evidence	evidence	NN	_	15	dep	_	_
2	supporting	support	VBG	_	1	acl	_	_
3	the	the	DT	_	4	det	_	_
4	conclusion	conclusion	NN	_	2	obj	_	_
5	that	that	IN	_	7	mark	_	_
6	it	it	PRP	_	7	dep	_	_
7	is	be	VBZ	_	4	acl	_	_
8	inadvisable	inadvisable	JJ	_	7	dep	_	_
9	to	to	TO	_	11	aux	_	_
10	co-administer	co-administer	NN	_	11	com	_	_
11	drug1	drug0	NN	_	8	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	drug2	drug0	NN	_	11	conj	_	_
14	is	be	VBZ	_	15	aux	_	_
15	derived	derive	VBN	_	0	root	_	_
16	from	from	IN	_	18	case	_	_
17	a	a	DT	_	18	det	_	_
18	study	study	NN	_	15	ppmod	_	_
19	in	in	IN	_	20	case	_	_
20	which	which	WDT	_	29	ppmod	_	_
21	healthy	healthy	JJ	_	22	attr	_	_
22	volunteers	volunteer	NNS	_	29	dep	_	_
23	taking	take	VBG	_	22	acl	_	_
24	150	0	CD	_	25	num	_	_
25	mg/day	mg/day	NN	_	23	obj	_	_
26	of	of	IN	_	27	case	_	_
27	drug3	drug0	NN	_	25	ppmod	_	_
28	were	be	VBD	_	29	aux	_	_
29	administered	administer	VBN	_	18	relcl	_	_
30	a	a	DT	_	33	det	_	_
31	single	single	JJ	_	33	attr	_	_
32	oral	oral	JJ	_	33	attr	_	_
33	dose	dose	NN	_	29	obj	_	_
34	of	of	IN	_	36	case	_	_
35	10	0	CD	_	36	num	_	_
36	mg	mg	NN	_	33	ppmod	_	_
37	of	of	IN	_	38	case	_	_
38	drug4	drug0	NN	_	36	ppmod	_	_
39	.	.	.	_	15	p	_	_

1	In	in	IN	_	3	case	_	_
2	these	these	DT	_	3	det	_	_
3	subjects	subject	NNS	_	14	ppmod	_	_
4	(	-lrb-	-LRB-	_	6	p	_	_
5	R=	r=	NN	_	6	com	_	_
6	B	b	NN	_	3	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	,	,	,	_	14	p	_	_
9	the	the	DT	_	10	det	_	_
10	clearance	clearance	NN	_	14	dep	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	was	be	VBD	_	14	aux	_	_
14	reduced	reduce	VBN	_	0	root	_	_
15	by	by	IN	_	16	case	_	_
16	65	0	CD	_	14	ppmod	_	_
17	%	%	NN	_	16	meta	_	_
18	and	and	CC	_	16	cc	_	_
19	that	that	DT	_	16	conj	_	_
20	of	of	IN	_	21	case	_	_
21	drug2	drug0	NN	_	19	ppmod	_	_
22	to	to	TO	_	24	aux	_	_
23	a	a	DT	_	24	det	_	_
24	level	level	NN	_	14	ppmod	_	_
25	that	that	WDT	_	26	dep	_	_
26	was	be	VBD	_	24	relcl	_	_
27	too	too	RB	_	28	adv	_	_
28	low	low	JJ	_	26	dep	_	_
29	to	to	TO	_	30	aux	_	_
30	measure	measure	VB	_	28	comp	_	_
31	over	over	IN	_	33	case	_	_
32	the	the	DT	_	33	det	_	_
33	course	course	NN	_	30	ppmod	_	_
34	of	of	IN	_	39	case	_	_
35	the	the	DT	_	39	det	_	_
36	2	0	CD	_	37	num	_	_
37	week	week	NN	_	39	attr	_	_
38	long	long	JJ	_	39	attr	_	_
39	study	study	NN	_	33	ppmod	_	_
40	.	.	.	_	14	p	_	_

1	It	it	PRP	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	likely	likely	JJ	_	2	dep	_	_
4	that	that	IN	_	5	mark	_	_
5	experience	experience	VBP	_	3	comp	_	_
6	significantly	significantly	RB	_	7	adv	_	_
7	underestimates	underestimate	VBZ	_	5	comp	_	_
8	the	the	DT	_	9	det	_	_
9	degree	degree	NN	_	7	obj	_	_
10	of	of	IN	_	11	case	_	_
11	accumulation	accumulation	NN	_	9	ppmod	_	_
12	that	that	WDT	_	14	dep	_	_
13	might	might	MD	_	14	modal	_	_
14	occur	occur	VB	_	11	relcl	_	_
15	with	with	IN	_	18	case	_	_
16	repealed	repealed	JJ	_	18	attr	_	_
17	drug1	drug0	NN	_	18	com	_	_
18	administration	administration	NN	_	14	ppmod	_	_
19	.	.	.	_	2	p	_	_

1	Moreover	moreover	RB	_	14	adv	_	_
2	,	,	,	_	14	p	_	_
3	as	as	IN	_	4	mark	_	_
4	noted	note	VBN	_	14	advcl	_	_
5	with	with	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	,	,	,	_	14	p	_	_
8	the	the	DT	_	9	det	_	_
9	effect	effect	NN	_	14	dep	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	may	may	MD	_	14	modal	_	_
13	even	even	RB	_	14	adv	_	_
14	be	be	VB	_	0	root	_	_
15	more	more	RBR	_	16	adv	_	_
16	pronounced	pronounced	JJ	_	14	dep	_	_
17	when	when	WRB	_	20	adv	_	_
18	it	it	PRP	_	20	dep	_	_
19	is	be	VBZ	_	20	aux	_	_
20	administered	administer	VBN	_	14	comp	_	_
21	at	at	IN	_	23	case	_	_
22	higher	high	JJR	_	23	attr	_	_
23	doses	dose	NNS	_	20	ppmod	_	_
24	.	.	.	_	14	p	_	_

1	Accordingly	accordingly	RB	_	10	adv	_	_
2	,	,	,	_	10	p	_	_
3	drug1	drug0	NN	_	10	dep	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	should	should	MD	_	10	modal	_	_
7	not	not	RB	_	10	neg	_	_
8	ordinarily	ordinarily	RB	_	10	adv	_	_
9	be	be	VB	_	10	aux	_	_
10	co-administered	co-administered	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	effect	effect	NN	_	29	dep	_	_
5	of	of	IN	_	10	case	_	_
6	steady-state	steady-state	JJ	_	10	attr	_	_
7	drug2	drug0	NN	_	10	com	_	_
8	l50	l0	NN	_	10	com	_	_
9	mg	mg	NN	_	10	com	_	_
10	bid	bid	NN	_	4	ppmod	_	_
11	on	on	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	pharmacokinetics	pharmacokinetics	NNS	_	4	ppmod	_	_
14	of	of	IN	_	17	case	_	_
15	a	a	DT	_	17	det	_	_
16	single	single	JJ	_	17	attr	_	_
17	dose	dose	NN	_	13	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug3	drug0	NN	_	17	ppmod	_	_
20	(	-lrb-	-LRB-	_	22	p	_	_
21	375	0	CD	_	22	num	_	_
22	mg	mg	NN	_	17	prn	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	as	as	IN	_	27	case	_	_
25	442	0	CD	_	26	num	_	_
26	mg	mg	NN	_	27	com	_	_
27	drug4	drug0	NN	_	13	ppmod	_	_
28	was	be	VBD	_	29	aux	_	_
29	evaluated	evaluate	VBN	_	1	acl	_	_
30	in	in	IN	_	36	case	_	_
31	12	0	CD	_	36	num	_	_
32	healthy	healthy	JJ	_	33	adv	_	_
33	non-smoking	non-smoking	JJ	_	35	adv	_	_
34	,	,	,	_	35	p	_	_
35	male	male	JJ	_	36	attr	_	_
36	volunteers	volunteer	NNS	_	29	ppmod	_	_
37	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	clearance	clearance	NN	_	6	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	was	be	VBD	_	6	aux	_	_
6	decreased	decrease	VBN	_	0	root	_	_
7	approximately	approximately	RB	_	8	com	_	_
8	3-fold	0-fold	RB	_	6	adv	_	_
9	.	.	.	_	6	p	_	_

1	Therefore	therefore	RB	_	14	adv	_	_
2	,	,	,	_	14	p	_	_
3	if	if	IN	_	6	mark	_	_
4	drug1	drug0	NN	_	6	dep	_	_
5	is	be	VBZ	_	6	aux	_	_
6	co-administered	co-administered	VBN	_	14	advcl	_	_
7	with	with	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	,	,	,	_	14	p	_	_
10	its	its	PRP$	_	11	poss	_	_
11	dose	dose	NN	_	14	dep	_	_
12	should	should	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	reduced	reduce	VBN	_	0	root	_	_
15	to	to	TO	_	16	aux	_	_
16	one	#crd#	CD	_	14	ppmod	_	_
17	third	#ord#	JJ	_	16	attr	_	_
18	of	of	IN	_	23	case	_	_
19	the	the	DT	_	23	det	_	_
20	usual	usual	JJ	_	23	attr	_	_
21	daily	daily	JJ	_	23	attr	_	_
22	maintenance	maintenance	NN	_	23	com	_	_
23	dose	dose	NN	_	16	ppmod	_	_
24	and	and	CC	_	23	cc	_	_
25	plasma	plasma	NN	_	26	com	_	_
26	concentrations	concentration	NNS	_	23	conj	_	_
27	of	of	IN	_	28	case	_	_
28	drug3	drug0	NN	_	23	ppmod	_	_
29	should	should	MD	_	31	dep	_	_
30	to	to	TO	_	31	aux	_	_
31	monitored	monitor	VBN	_	23	acl	_	_
32	.	.	.	_	14	p	_	_

1	No	no	DT	_	3	det	_	_
2	dosage	dosage	JJ	_	3	attr	_	_
3	adjustment	adjustment	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	required	require	VBN	_	0	root	_	_
6	for	for	IN	_	8	case	_	_
7	drug1	drug0	JJ	_	8	attr	_	_
8	Tablets	tablet	NNS	_	5	ppmod	_	_
9	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	When	when	WRB	_	11	adv	_	_
4	drug2	drug0	NN	_	11	dep	_	_
5	(	-lrb-	-LRB-	_	8	p	_	_
6	50	0	CD	_	7	num	_	_
7	mg	mg	NN	_	8	com	_	_
8	tid	tid	NN	_	4	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	was	be	VBD	_	11	aux	_	_
11	administered	administer	VBN	_	22	advcl	_	_
12	concomitantly	concomitantly	RB	_	11	adv	_	_
13	with	with	IN	_	14	case	_	_
14	drug3	drug0	NN	_	11	ppmod	_	_
15	for	for	IN	_	17	case	_	_
16	two	#crd#	CD	_	17	num	_	_
17	weeks	week	NNS	_	11	ppmod	_	_
18	,	,	,	_	22	p	_	_
19	drug4	drug0	NN	_	21	com	_	_
20	plasma	plasma	NN	_	21	com	_	_
21	concentrations	concentration	NNS	_	22	dep	_	_
22	increased	increase	VBD	_	1	acl	_	_
23	by	by	IN	_	24	case	_	_
24	98	0	CD	_	22	ppmod	_	_
25	%	%	NN	_	24	meta	_	_
26	and	and	CC	_	22	cc	_	_
27	prothrombin	prothrombin	NN	_	28	com	_	_
28	times	time	NNS	_	29	dep	_	_
29	were	be	VBD	_	22	conj	_	_
30	prolonged	prolonged	JJ	_	29	dep	_	_
31	.	.	.	_	1	p	_	_

1	Thus	thus	RB	_	10	adv	_	_
2	patients	patient	NNS	_	10	dep	_	_
3	receiving	receive	VBG	_	2	acl	_	_
4	oral	oral	JJ	_	5	attr	_	_
5	drug1	drug0	NN	_	3	obj	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	8	com	_	_
8	Tablets	tablet	NNS	_	5	conj	_	_
9	should	should	MD	_	10	modal	_	_
10	have	have	VBP	_	0	root	_	_
11	their	their	PRP$	_	13	poss	_	_
12	prothrombin	prothrombin	NN	_	13	com	_	_
13	time	time	NN	_	10	obj	_	_
14	monitored	monitor	VBN	_	13	acl	_	_
15	and	and	CC	_	13	cc	_	_
16	their	their	PRP$	_	18	poss	_	_
17	drug3	drug0	NN	_	18	com	_	_
18	dose	dose	NN	_	13	conj	_	_
19	adjusted	adjust	VBN	_	18	acl	_	_
20	accordingly	accordingly	RB	_	19	adv	_	_
21	.	.	.	_	10	p	_	_

1	No	no	DT	_	3	det	_	_
2	dosage	dosage	JJ	_	3	attr	_	_
3	adjustment	adjustment	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	required	require	VBN	_	0	root	_	_
6	for	for	IN	_	8	case	_	_
7	drug1	drug0	JJ	_	8	attr	_	_
8	Tablets	tablet	NNS	_	5	ppmod	_	_
9	.	.	.	_	5	p	_	_

1	In	in	IN	_	4	case	_	_
2	occasional	occasional	JJ	_	4	attr	_	_
3	susceptible	susceptible	JJ	_	4	attr	_	_
4	patients	patient	NNS	_	22	ppmod	_	_
5	or	or	CC	_	4	cc	_	_
6	in	in	IN	_	7	case	_	_
7	those	those	DT	_	4	conj	_	_
8	receiving	receive	VBG	_	7	acl	_	_
9	drug1	drug0	NN	_	8	obj	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	including	include	VBG	_	9	prn	_	_
12	antiparkinsonism	antiparkinsonism	NN	_	13	com	_	_
13	agents	agent	NNS	_	11	obj	_	_
14	)	-rrb-	-RRB-	_	11	p	_	_
15	in	in	IN	_	16	case	_	_
16	addition	addition	NN	_	8	ppmod	_	_
17	,	,	,	_	22	p	_	_
18	the	the	DT	_	20	det	_	_
19	atropine-like	atropine-like	JJ	_	20	attr	_	_
20	effects	effect	NNS	_	22	dep	_	_
21	may	may	MD	_	22	modal	_	_
22	become	become	VB	_	0	root	_	_
23	more	more	RBR	_	24	adv	_	_
24	pronounced	pronounced	JJ	_	22	dep	_	_
25	(	-lrb-	-LRB-	_	29	p	_	_
26	e.g.	e.g.	FW	_	29	adv	_	_
27	,	,	,	_	29	p	_	_
28	paralytic	paralytic	JJ	_	29	attr	_	_
29	ileus	ileus	NNS	_	24	prn	_	_
30	)	-rrb-	-RRB-	_	29	p	_	_
31	.	.	.	_	22	p	_	_

1	Close	close	JJ	_	2	attr	_	_
2	supervision	supervision	NN	_	9	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	careful	careful	JJ	_	5	attr	_	_
5	adjustment	adjustment	NN	_	2	conj	_	_
6	of	of	IN	_	7	case	_	_
7	dosage	dosage	NN	_	2	ppmod	_	_
8	is	be	VBZ	_	9	aux	_	_
9	required	require	VBN	_	0	root	_	_
10	when	when	WRB	_	14	adv	_	_
11	this	this	DT	_	12	det	_	_
12	drug	drug	NN	_	14	dep	_	_
13	is	be	VBZ	_	14	aux	_	_
14	administered	administer	VBN	_	9	comp	_	_
15	concomitantly	concomitantly	RB	_	14	adv	_	_
16	with	with	IN	_	17	case	_	_
17	drug1	drug0	NN	_	14	ppmod	_	_
18	.	.	.	_	9	p	_	_

1	Avoid	avoid	VB	_	0	root	_	_
2	the	the	DT	_	3	det	_	_
3	use	use	NN	_	1	obj	_	_
4	of	of	IN	_	5	case	_	_
5	preparations	preparation	NNS	_	3	ppmod	_	_
6	such	such	JJ	_	8	adv	_	_
7	as	as	IN	_	8	case	_	_
8	drug1	drug0	NN	_	5	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	local	local	JJ	_	11	attr	_	_
11	drug2	drug0	NN	_	8	conj	_	_
12	which	which	WDT	_	13	dep	_	_
13	contain	contain	VBP	_	8	relcl	_	_
14	any	any	DT	_	15	det	_	_
15	drug3	drug0	NN	_	13	obj	_	_
16	(	-lrb-	-LRB-	_	21	p	_	_
17	e.g.	e.g.	FW	_	19	adv	_	_
18	,	,	,	_	19	p	_	_
19	drug4	drug0	NN	_	21	ppmod	_	_
20	,	,	,	_	21	p	_	_
21	drug5	drug0	NNS	_	15	prn	_	_
22	)	-rrb-	-RRB-	_	21	p	_	_
23	,	,	,	_	1	p	_	_
24	since	since	IN	_	28	mark	_	_
25	it	it	PRP	_	28	dep	_	_
26	has	have	VBZ	_	28	aux	_	_
27	been	be	VBN	_	28	aux	_	_
28	reported	report	VBN	_	1	comp	_	_
29	that	that	IN	_	32	mark	_	_
30	drug6	drug0	NN	_	32	dep	_	_
31	can	can	MD	_	32	modal	_	_
32	potentiate	potentiate	VB	_	28	comp	_	_
33	the	the	DT	_	34	det	_	_
34	effects	effect	NNS	_	32	obj	_	_
35	of	of	IN	_	36	case	_	_
36	catecholamines	catecholamine	NNS	_	34	ppmod	_	_
37	.	.	.	_	1	p	_	_

1	Caution	caution	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	exercised	exercise	VBN	_	0	root	_	_
5	when	when	WRB	_	8	adv	_	_
6	drug1	drug0	NN	_	8	dep	_	_
7	is	be	VBZ	_	8	aux	_	_
8	used	use	VBN	_	4	comp	_	_
9	with	with	IN	_	10	case	_	_
10	agents	agent	NNS	_	8	ppmod	_	_
11	that	that	IN	_	14	case	_	_
12	lower	low	JJR	_	14	attr	_	_
13	blood	blood	NN	_	14	com	_	_
14	pressure	pressure	NN	_	10	ppmod	_	_
15	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	potentiate	potentiate	VB	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	effects	effect	NNS	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	.	.	.	_	3	p	_	_

1	The	the	DT	_	3	det	_	_
2	plasma	plasma	NN	_	3	com	_	_
3	concentration	concentration	NN	_	7	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	may	may	MD	_	7	modal	_	_
7	increase	increase	VB	_	0	root	_	_
8	when	when	WRB	_	12	adv	_	_
9	the	the	DT	_	10	det	_	_
10	drug	drug	NN	_	12	dep	_	_
11	is	be	VBZ	_	12	aux	_	_
12	given	give	VBN	_	7	comp	_	_
13	concomitantly	concomitantly	RB	_	12	adv	_	_
14	with	with	IN	_	17	case	_	_
15	hepatic	hepatic	JJ	_	17	attr	_	_
16	enzyme	enzyme	NN	_	17	com	_	_
17	inhibitors	inhibitor	NNS	_	12	ppmod	_	_
18	(	-lrb-	-LRB-	_	23	p	_	_
19	e.g.	e.g.	FW	_	21	adv	_	_
20	,	,	,	_	21	p	_	_
21	drug2	drug0	NN	_	23	ppmod	_	_
22	,	,	,	_	23	p	_	_
23	drug3	drug0	NN	_	17	prn	_	_
24	)	-rrb-	-RRB-	_	23	p	_	_
25	and	and	CC	_	7	cc	_	_
26	decrease	decrease	VB	_	7	conj	_	_
27	by	by	IN	_	29	case	_	_
28	concomitant	concomitant	JJ	_	29	attr	_	_
29	administration	administration	NN	_	26	ppmod	_	_
30	of	of	IN	_	33	case	_	_
31	hepatic	hepatic	JJ	_	33	attr	_	_
32	enzyme	enzyme	NN	_	33	com	_	_
33	inducers	inducer	NNS	_	29	ppmod	_	_
34	(	-lrb-	-LRB-	_	39	p	_	_
35	e.g.	e.g.	FW	_	37	adv	_	_
36	,	,	,	_	37	p	_	_
37	drug4	drug0	NN	_	39	ppmod	_	_
38	,	,	,	_	39	p	_	_
39	drug5	drug0	NN	_	33	prn	_	_
40	)	-rrb-	-RRB-	_	39	p	_	_
41	,	,	,	_	7	p	_	_
42	and	and	CC	_	7	cc	_	_
43	adjustment	adjustment	NN	_	51	dep	_	_
44	of	of	IN	_	46	case	_	_
45	the	the	DT	_	46	det	_	_
46	dosage	dosage	NN	_	43	ppmod	_	_
47	of	of	IN	_	48	case	_	_
48	drug6	drug0	NN	_	46	ppmod	_	_
49	may	may	MD	_	51	modal	_	_
50	therefore	therefore	RB	_	51	adv	_	_
51	be	be	VB	_	7	conj	_	_
52	necessary	necessary	JJ	_	51	dep	_	_
53	.	.	.	_	51	p	_	_

1	Drugs	drug	NNS	_	2	dep	_	_
2	Metabolized	metabolize	VBN	_	22	advcl	_	_
3	by	by	IN	_	5	case	_	_
4	P450	p0	NN	_	5	com	_	_
5	2D6	0d0	NN	_	2	ppmod	_	_
6	The	the	DT	_	8	det	_	_
7	biochemical	biochemical	JJ	_	8	attr	_	_
8	activity	activity	NN	_	22	dep	_	_
9	of	of	IN	_	16	case	_	_
10	the	the	DT	_	16	det	_	_
11	drug	drug	NN	_	16	com	_	_
12	metabolizing	metabolizing	NN	_	16	com	_	_
13	isozyme	isozyme	NN	_	16	com	_	_
14	cytochrome	cytochrome	NN	_	16	com	_	_
15	P450	p0	NN	_	16	com	_	_
16	2D6	0d0	NN	_	8	ppmod	_	_
17	(	-lrb-	-LRB-	_	19	p	_	_
18	debrisoquin	debrisoquin	NN	_	19	com	_	_
19	hydroxylase	hydroxylase	NN	_	16	prn	_	_
20	)	-rrb-	-RRB-	_	19	p	_	_
21	is	be	VBZ	_	22	aux	_	_
22	reduced	reduce	VBN	_	0	root	_	_
23	in	in	IN	_	25	case	_	_
24	a	a	DT	_	25	det	_	_
25	subset	subset	NN	_	22	ppmod	_	_
26	of	of	IN	_	29	case	_	_
27	the	the	DT	_	29	det	_	_
28	caucasian	caucasian	NN	_	29	com	_	_
29	population	population	NN	_	25	ppmod	_	_
30	(	-lrb-	-LRB-	_	40	p	_	_
31	about	about	RB	_	32	adv	_	_
32	7	0	CD	_	40	num	_	_
33	to	to	TO	_	32	cc	_	_
34	10	0	CD	_	32	conj	_	_
35	%	%	NN	_	32	meta	_	_
36	of	of	IN	_	37	case	_	_
37	caucasians	caucasian	NNS	_	32	ppmod	_	_
38	are	be	VBP	_	40	aux	_	_
39	so	so	RB	_	40	adv	_	_
40	called	call	VBN	_	22	prn	_	_
41	poor	poor	JJ	_	42	attr	_	_
42	metabolizers	metabolizers	NNS	_	40	obj	_	_
43	)	-rrb-	-RRB-	_	40	p	_	_
44	;	;	:	_	22	p	_	_

1	reliable	reliable	JJ	_	2	attr	_	_
2	estimates	estimate	NNS	_	19	dep	_	_
3	of	of	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	prevalence	prevalence	NN	_	2	ppmod	_	_
6	of	of	IN	_	11	case	_	_
7	reduced	reduce	VBN	_	11	attr	_	_
8	P450	p0	NN	_	11	com	_	_
9	2D6	0d0	NN	_	11	com	_	_
10	isozyme	isozyme	NN	_	11	com	_	_
11	activity	activity	NN	_	5	ppmod	_	_
12	among	among	IN	_	18	case	_	_
13	Asian	asian	JJ	_	18	attr	_	_
14	,	,	,	_	13	p	_	_
15	African	african	JJ	_	13	conj	_	_
16	and	and	CC	_	15	cc	_	_
17	other	other	JJ	_	13	conj	_	_
18	populations	population	NNS	_	5	ppmod	_	_
19	are	be	VBP	_	0	root	_	_
20	not	not	RB	_	19	neg	_	_
21	yet	yet	RB	_	19	adv	_	_
22	available	available	JJ	_	19	dep	_	_
23	.	.	.	_	19	p	_	_

1	Poor	poor	JJ	_	2	attr	_	_
2	metabolizers	metabolizers	NNS	_	8	dep	_	_
3	have	have	VBP	_	8	lv	_	_
4	higher	high	JJR	_	8	attr	_	_
5	than	than	IN	_	8	case	_	_
6	expected	expect	VBN	_	8	attr	_	_
7	plasma	plasma	NN	_	8	com	_	_
8	concentrations	concentration	NNS	_	0	root	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	drug2	drug0	NN	_	10	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	when	when	WRB	_	15	adv	_	_
15	given	give	VBN	_	8	comp	_	_
16	usual	usual	JJ	_	17	attr	_	_
17	doses	dose	NNS	_	15	obj	_	_
18	.	.	.	_	8	p	_	_

1	Depending	depend	VBG	_	4	adv	_	_
2	on	on	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	fraction	fraction	NN	_	18	ppmod	_	_
5	of	of	IN	_	6	case	_	_
6	drug	drug	NN	_	4	ppmod	_	_
7	metabolized	metabolize	VBN	_	6	acl	_	_
8	by	by	IN	_	10	case	_	_
9	P450	p0	NN	_	10	com	_	_
10	2D6	0d0	NN	_	7	ppmod	_	_
11	,	,	,	_	18	p	_	_
12	the	the	DT	_	13	det	_	_
13	increase	increase	NN	_	18	dep	_	_
14	in	in	IN	_	16	case	_	_
15	plasma	plasma	NN	_	16	com	_	_
16	concentration	concentration	NN	_	13	ppmod	_	_
17	may	may	MD	_	18	modal	_	_
18	be	be	VB	_	0	root	_	_
19	small	small	JJ	_	18	dep	_	_
20	,	,	,	_	19	p	_	_
21	or	or	CC	_	19	cc	_	_
22	quite	quite	RB	_	23	adv	_	_
23	large	large	JJ	_	19	conj	_	_
24	(	-lrb-	-LRB-	_	26	p	_	_
25	8-fold	0-fold	JJ	_	26	attr	_	_
26	increase	increase	NN	_	23	prn	_	_
27	in	in	IN	_	29	case	_	_
28	plasma	plasma	NN	_	29	com	_	_
29	AUC	auc	NN	_	26	ppmod	_	_
30	of	of	IN	_	32	case	_	_
31	the	the	DT	_	32	det	_	_
32	drug1	drug0	NN	_	29	ppmod	_	_
33	)	-rrb-	-RRB-	_	26	p	_	_
34	.	.	.	_	18	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	16	ppmod	_	_
3	,	,	,	_	16	p	_	_
4	certain	certain	JJ	_	5	attr	_	_
5	drugs	drug	NNS	_	16	dep	_	_
6	inhibit	inhibit	VB	_	16	dep	_	_
7	the	the	DT	_	8	det	_	_
8	activity	activity	NN	_	6	obj	_	_
9	of	of	IN	_	11	case	_	_
10	this	this	DT	_	11	det	_	_
11	isozyme	isozyme	NN	_	8	ppmod	_	_
12	and	and	CC	_	6	cc	_	_
13	make	make	VB	_	6	conj	_	_
14	normal	normal	JJ	_	15	attr	_	_
15	metabolizers	metabolizers	NNS	_	13	obj	_	_
16	resemble	resemble	VBP	_	0	root	_	_
17	p.o.	p.o.	NN	_	16	obj	_	_

1	metabolizers	metabolizers	NN	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	An	an	DT	_	2	det	_	_
2	individual	individual	JJ	_	13	dep	_	_
3	who	who	WP	_	4	dep	_	_
4	is	be	VBZ	_	2	relcl	_	_
5	stable	stable	JJ	_	4	dep	_	_
6	on	on	IN	_	9	case	_	_
7	a	a	DT	_	9	det	_	_
8	given	given	JJ	_	9	attr	_	_
9	dose	dose	NN	_	5	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	may	may	MD	_	13	modal	_	_
13	become	become	VB	_	0	root	_	_
14	abruptly	abruptly	RB	_	15	adv	_	_
15	toxic	toxic	JJ	_	13	dep	_	_
16	when	when	WRB	_	17	adv	_	_
17	given	give	VBN	_	13	comp	_	_
18	one	#crd#	CD	_	17	obj	_	_
19	of	of	IN	_	22	case	_	_
20	these	these	DT	_	22	det	_	_
21	inhibiting	inhibiting	JJ	_	22	attr	_	_
22	drugs	drug	NNS	_	18	ppmod	_	_
23	as	as	IN	_	25	case	_	_
24	concomitant	concomitant	JJ	_	25	attr	_	_
25	therapy	therapy	NN	_	22	ppmod	_	_
26	.	.	.	_	13	p	_	_

1	The	the	DT	_	2	det	_	_
2	drugs	drug	NNS	_	8	dep	_	_
3	that	that	WDT	_	4	dep	_	_
4	inhibit	inhibit	VBP	_	2	relcl	_	_
5	cytochrome	cytochrome	NN	_	7	com	_	_
6	P450	p0	NN	_	7	com	_	_
7	2D6	0d0	NN	_	4	obj	_	_
8	include	include	VBP	_	0	root	_	_
9	some	some	DT	_	8	obj	_	_
10	that	that	WDT	_	13	dep	_	_
11	are	be	VBP	_	13	aux	_	_
12	not	not	RB	_	13	neg	_	_
13	metabolized	metabolize	VBN	_	9	relcl	_	_
14	by	by	IN	_	18	case	_	_
15	the	the	DT	_	18	det	_	_
16	enzyme	enzyme	NN	_	18	attr	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	drug1	drug0	NN	_	13	ppmod	_	_
19	;	;	:	_	8	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	)	-rrb-	-RRB-	_	1	p	_	_
3	and	and	CC	_	1	cc	_	_
4	many	many	JJ	_	1	conj	_	_
5	that	that	WDT	_	6	dep	_	_
6	are	be	VBP	_	4	relcl	_	_
7	substrates	substrate	NNS	_	6	obj	_	_
8	for	for	IN	_	10	case	_	_
9	P450	p0	NN	_	10	com	_	_
10	2D6	0d0	NN	_	7	ppmod	_	_
11	(	-lrb-	-LRB-	_	14	p	_	_
12	many	many	JJ	_	14	attr	_	_
13	other	other	JJ	_	14	attr	_	_
14	drug2	drug0	NN	_	10	prn	_	_
15	,	,	,	_	14	p	_	_
16	drug3	drug0	NN	_	14	conj	_	_
17	,	,	,	_	16	p	_	_
18	and	and	CC	_	16	cc	_	_
19	the	the	DT	_	21	det	_	_
20	drug4	drug0	NN	_	21	com	_	_
21	drug5	drug0	NN	_	14	conj	_	_
22	and	and	CC	_	21	cc	_	_
23	drug6	drug0	NN	_	21	conj	_	_
24	)	-rrb-	-RRB-	_	14	p	_	_
25	.	.	.	_	1	p	_	_

1	While	while	IN	_	19	mark	_	_
2	all	all	PDT	_	4	det	_	_
3	the	the	DT	_	4	det	_	_
4	drug1	drug0	NNS	_	19	dep	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	drug2	drug0	NN	_	4	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	,	,	,	_	4	p	_	_
9	e.	e.	FW	_	10	attr	_	_
10	g.	g.	FW	_	4	appo	_	_
11	,	,	,	_	10	p	_	_
12	drug3	drug0	NN	_	10	attr	_	_
13	,	,	,	_	10	p	_	_
14	drug4	drug0	NN	_	10	conj	_	_
15	,	,	,	_	14	p	_	_
16	and	and	CC	_	14	cc	_	_
17	drug5	drug0	NN	_	10	conj	_	_
18	,	,	,	_	4	p	_	_
19	inhibit	inhibit	VBP	_	25	advcl	_	_
20	P450	p0	NN	_	21	com	_	_
21	2D6	0d0	NN	_	19	obj	_	_
22	,	,	,	_	25	p	_	_
23	they	they	PRP	_	25	dep	_	_
24	may	may	MD	_	25	modal	_	_
25	vary	vary	VB	_	0	root	_	_
26	in	in	IN	_	28	case	_	_
27	the	the	DT	_	28	det	_	_
28	extent	extent	NN	_	25	ppmod	_	_
29	of	of	IN	_	30	case	_	_
30	inhibition	inhibition	NN	_	28	ppmod	_	_
31	.	.	.	_	25	p	_	_

1	The	the	DT	_	2	det	_	_
2	extent	extent	NN	_	14	dep	_	_
3	to	to	TO	_	4	aux	_	_
4	which	which	WDT	_	10	ppmod	_	_
5	drug1	drug0	NN	_	8	attr	_	_
6	-	-	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	interactions	interaction	NNS	_	10	dep	_	_
9	may	may	MD	_	10	modal	_	_
10	pose	pose	VBP	_	2	relcl	_	_
11	clinical	clinical	JJ	_	12	attr	_	_
12	problems	problem	NNS	_	10	obj	_	_
13	will	will	MD	_	14	modal	_	_
14	depend	depend	VB	_	0	root	_	_
15	on	on	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	degree	degree	NN	_	14	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	inhibition	inhibition	NN	_	17	ppmod	_	_
20	,	,	,	_	17	p	_	_
21	and	and	CC	_	17	cc	_	_
22	the	the	DT	_	23	det	_	_
23	pharmacokinetics	pharmacokinetics	NNS	_	17	conj	_	_
24	of	of	IN	_	26	case	_	_
25	the	the	DT	_	26	det	_	_
26	drug3	drug0	NN	_	23	ppmod	_	_
27	involved	involve	VBN	_	26	acl	_	_
28	.	.	.	_	14	p	_	_

1	Nevertheless	nevertheless	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	caution	caution	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	indicated	indicate	VBN	_	0	root	_	_
6	in	in	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	co-administration	co-administration	NN	_	5	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	TCA5	tca0	NN	_	8	ppmod	_	_
11	with	with	IN	_	12	case	_	_
12	any	any	DT	_	8	ppmod	_	_
13	of	of	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	drug1	drug0	NN	_	12	ppmod	_	_
16	and	and	CC	_	8	cc	_	_
17	also	also	RB	_	19	adv	_	_
18	in	in	IN	_	19	case	_	_
19	switching	switching	NN	_	8	conj	_	_
20	from	from	IN	_	22	case	_	_
21	one	#crd#	CD	_	22	num	_	_
22	class	class	NN	_	19	ppmod	_	_
23	to	to	TO	_	25	aux	_	_
24	the	the	DT	_	25	det	_	_
25	other	other	JJ	_	19	ppmod	_	_
26	.	.	.	_	5	p	_	_

1	Of	of	IN	_	3	case	_	_
2	particular	particular	JJ	_	3	attr	_	_
3	importance	importance	NN	_	8	ppmod	_	_
4	,	,	,	_	8	p	_	_
5	sufficient	sufficient	JJ	_	6	attr	_	_
6	time	time	NN	_	8	dep	_	_
7	must	must	MD	_	8	modal	_	_
8	elapse	elapse	VB	_	0	root	_	_
9	before	before	IN	_	10	case	_	_
10	initiating	initiate	VBG	_	8	ppmod	_	_
11	TCA	tca	NN	_	12	com	_	_
12	treatment	treatment	NN	_	10	obj	_	_
13	in	in	IN	_	15	case	_	_
14	a	a	DT	_	15	det	_	_
15	patient	patient	NN	_	10	ppmod	_	_
16	being	be	VBG	_	17	aux	_	_
17	withdrawn	withdraw	VBN	_	15	acl	_	_
18	from	from	IN	_	19	case	_	_
19	drug1	drug0	NN	_	17	ppmod	_	_
20	,	,	,	_	19	p	_	_
21	given	give	VBN	_	19	acl	_	_
22	the	the	DT	_	24	det	_	_
23	long	long	JJ	_	24	attr	_	_
24	half-life	half-life	NN	_	21	obj	_	_
25	of	of	IN	_	27	case	_	_
26	the	the	DT	_	27	det	_	_
27	parent	parent	NN	_	24	ppmod	_	_
28	and	and	CC	_	19	cc	_	_
29	active	active	JJ	_	30	attr	_	_
30	metabolite	metabolite	NN	_	19	conj	_	_
31	(	-lrb-	-LRB-	_	35	p	_	_
32	at	at	IN	_	34	case	_	_
33	least	least	JJS	_	34	attr	_	_
34	5	0	CD	_	35	num	_	_
35	weeks	week	NNS	_	30	prn	_	_
36	may	may	MD	_	37	modal	_	_
37	be	be	VB	_	35	acl	_	_
38	necessary	necessary	JJ	_	37	dep	_	_
39	)	-rrb-	-RRB-	_	35	p	_	_
40	.	.	.	_	8	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	use	use	NN	_	14	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	with	with	IN	_	6	case	_	_
6	drugs	drug	NNS	_	2	ppmod	_	_
7	that	that	WDT	_	9	dep	_	_
8	can	can	MD	_	9	modal	_	_
9	inhibit	inhibit	VB	_	6	relcl	_	_
10	cytochrome	cytochrome	NN	_	12	com	_	_
11	P450	p0	NN	_	12	com	_	_
12	2D6	0d0	NN	_	9	obj	_	_
13	may	may	MD	_	14	modal	_	_
14	require	require	VB	_	0	root	_	_
15	lower	low	JJR	_	16	attr	_	_
16	doses	dose	NNS	_	14	obj	_	_
17	than	than	IN	_	18	case	_	_
18	usually	usually	RB	_	19	adv	_	_
19	prescribed	prescribe	VBN	_	16	acl	_	_
20	for	for	IN	_	23	case	_	_
21	either	either	CC	_	23	cc	_	_
22	the	the	DT	_	23	det	_	_
23	drug2	drug0	NN	_	19	ppmod	_	_
24	or	or	CC	_	23	cc	_	_
25	the	the	DT	_	27	det	_	_
26	other	other	JJ	_	27	attr	_	_
27	drug	drug	NN	_	23	conj	_	_
28	.	.	.	_	14	p	_	_

1	Furthermore	furthermore	RB	_	21	adv	_	_
2	,	,	,	_	21	p	_	_
3	whenever	whenever	RB	_	10	adv	_	_
4	one	#crd#	CD	_	10	num	_	_
5	of	of	IN	_	8	case	_	_
6	these	these	DT	_	8	det	_	_
7	other	other	JJ	_	8	attr	_	_
8	drugs	drug	NNS	_	4	ppmod	_	_
9	is	be	VBZ	_	10	aux	_	_
10	withdrawn	withdraw	VBN	_	21	advcl	_	_
11	from	from	IN	_	12	case	_	_
12	cotherapy	cotherapy	NN	_	10	ppmod	_	_
13	,	,	,	_	21	p	_	_
14	an	an	DT	_	16	det	_	_
15	increased	increase	VBN	_	16	attr	_	_
16	dose	dose	NN	_	21	dep	_	_
17	of	of	IN	_	18	case	_	_
18	drug1	drug0	NN	_	16	ppmod	_	_
19	may	may	MD	_	21	modal	_	_
20	be	be	VB	_	21	aux	_	_
21	required	require	VBN	_	0	root	_	_
22	.	.	.	_	21	p	_	_

1	It	it	PRP	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	desirable	desirable	JJ	_	2	dep	_	_
4	to	to	TO	_	5	aux	_	_
5	monitor	monitor	VB	_	2	comp	_	_
6	drug1	drug0	NN	_	8	com	_	_
7	plasma	plasma	NN	_	8	com	_	_
8	levels	level	NNS	_	5	obj	_	_
9	whenever	whenever	RB	_	12	adv	_	_
10	a	a	DT	_	11	det	_	_
11	drug2	drug0	NN	_	12	dep	_	_
12	is	be	VBZ	_	5	comp	_	_
13	going	going	JJ	_	12	dep	_	_
14	to	to	TO	_	16	aux	_	_
15	be	be	VB	_	16	aux	_	_
16	co-administered	co-administered	VBN	_	13	comp	_	_
17	with	with	IN	_	19	case	_	_
18	another	another	DT	_	19	det	_	_
19	drug	drug	NN	_	16	ppmod	_	_
20	known	know	VBN	_	19	acl	_	_
21	to	to	TO	_	22	aux	_	_
22	be	be	VB	_	20	comp	_	_
23	an	an	DT	_	24	det	_	_
24	inhibitor	inhibitor	NN	_	22	obj	_	_
25	of	of	IN	_	27	case	_	_
26	P450	p0	NN	_	27	com	_	_
27	2D6	0d0	NN	_	24	ppmod	_	_
28	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	10	dep	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	,	,	,	_	3	p	_	_
5	Metal	metal	JJ	_	6	attr	_	_
6	Cations	cation	NNS	_	1	conj	_	_
7	,	,	,	_	6	p	_	_
8	drug3	drug0	CC	_	6	cc	_	_
9	drug4	drug0	NN	_	1	conj	_	_
10	form	form	VBP	_	0	root	_	_
11	chelates	chelate	NNS	_	10	obj	_	_
12	with	with	IN	_	14	case	_	_
13	alkaline	alkaline	NN	_	14	com	_	_
14	earth	earth	NN	_	10	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	transition	transition	NN	_	18	attr	_	_
17	metal	metal	JJ	_	18	attr	_	_
18	cations	cation	NNS	_	14	conj	_	_
19	.	.	.	_	10	p	_	_

1	Administration	administration	NN	_	58	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	5	case	_	_
5	drug2	drug0	NNS	_	3	ppmod	_	_
6	containing	contain	VBG	_	5	acl	_	_
7	drug3	drug0	NN	_	6	obj	_	_
8	,	,	,	_	7	p	_	_
9	drug4	drug0	NN	_	7	conj	_	_
10	,	,	,	_	9	p	_	_
11	or	or	CC	_	9	cc	_	_
12	drug5	drug0	NN	_	7	conj	_	_
13	,	,	,	_	5	p	_	_
14	with	with	IN	_	15	case	_	_
15	drug6	drug0	NN	_	5	conj	_	_
16	,	,	,	_	15	p	_	_
17	with	with	IN	_	19	case	_	_
18	metal	metal	JJ	_	19	attr	_	_
19	cations	cation	NNS	_	5	conj	_	_
20	such	such	JJ	_	22	adv	_	_
21	as	as	IN	_	22	case	_	_
22	drug7	drug0	NN	_	19	ppmod	_	_
23	,	,	,	_	19	p	_	_
24	or	or	CC	_	19	cc	_	_
25	with	with	IN	_	26	case	_	_
26	drug8	drug0	NN	_	5	conj	_	_
27	containing	contain	VBG	_	3	acl	_	_
28	drug9	drug0	NN	_	27	obj	_	_
29	or	or	CC	_	28	cc	_	_
30	drug10	drug0	NN	_	28	conj	_	_
31	,	,	,	_	58	p	_	_
32	or	or	CC	_	34	cc	_	_
33	with	with	IN	_	34	case	_	_
34	formulations	formulation	NNS	_	58	ppmod	_	_
35	containing	contain	VBG	_	34	acl	_	_
36	divalent	divalent	JJ	_	39	attr	_	_
37	and	and	CC	_	39	cc	_	_
38	trivalent	trivalent	JJ	_	39	attr	_	_
39	cations	cation	NNS	_	35	obj	_	_
40	such	such	JJ	_	47	adv	_	_
41	as	as	IN	_	47	case	_	_
42	drug11	drug0	NN	_	47	attr	_	_
43	(	-lrb-	-LRB-	_	47	p	_	_
44	drug12	drug0	CD	_	47	num	_	_
45	)	-rrb-	-RRB-	_	47	p	_	_
46	chewable/buffered	chewable/buffered	JJ	_	47	attr	_	_
47	tablets	tablet	NNS	_	39	ppmod	_	_
48	or	or	CC	_	47	cc	_	_
49	the	the	DT	_	51	det	_	_
50	pediatric	pediatric	JJ	_	51	attr	_	_
51	powder	powder	NN	_	47	conj	_	_
52	for	for	IN	_	54	case	_	_
53	oral	oral	JJ	_	54	attr	_	_
54	solution	solution	NN	_	51	ppmod	_	_
55	,	,	,	_	58	p	_	_
56	may	may	MD	_	58	modal	_	_
57	substantially	substantially	RB	_	58	adv	_	_
58	interfere	interfere	VB	_	0	root	_	_
59	with	with	IN	_	61	case	_	_
60	the	the	DT	_	61	det	_	_
61	absorption	absorption	NN	_	58	ppmod	_	_
62	of	of	IN	_	63	case	_	_
63	drug13	drug0	NN	_	61	ppmod	_	_
64	,	,	,	_	58	p	_	_
65	resulting	result	VBG	_	58	comp	_	_
66	in	in	IN	_	68	case	_	_
67	systemic	systemic	JJ	_	68	attr	_	_
68	concentrations	concentration	NNS	_	65	ppmod	_	_
69	considerably	considerably	RB	_	70	adv	_	_
70	lower	low	JJR	_	68	attr	_	_
71	than	than	IN	_	72	case	_	_
72	desired	desired	JJ	_	70	ppmod	_	_
73	.	.	.	_	58	p	_	_

1	These	these	DT	_	2	det	_	_
2	agents	agent	NNS	_	6	dep	_	_
3	should	should	MD	_	6	modal	_	_
4	not	not	RB	_	6	neg	_	_
5	be	be	VB	_	6	aux	_	_
6	taken	take	VBN	_	0	root	_	_
7	within	within	IN	_	9	case	_	_
8	4	0	CD	_	9	num	_	_
9	hours	hour	NNS	_	6	ppmod	_	_
10	before	before	IN	_	9	case	_	_
11	or	or	CC	_	9	cc	_	_
12	4	0	CD	_	13	num	_	_
13	hours	hour	NNS	_	9	conj	_	_
14	after	after	IN	_	16	case	_	_
15	drug1	drug0	NN	_	16	com	_	_
16	administration	administration	NN	_	13	ppmod	_	_
17	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	3	com	_	_
2	drug2	drug0	NN	_	3	com	_	_
3	drug3	drug0	NNS	_	10	dep	_	_
4	,	,	,	_	3	p	_	_
5	like	like	IN	_	7	case	_	_
6	other	other	JJ	_	7	attr	_	_
7	drug4	drug0	NNS	_	3	ppmod	_	_
8	,	,	,	_	3	p	_	_
9	may	may	MD	_	10	modal	_	_
10	inhibit	inhibit	VB	_	0	root	_	_
11	the	the	DT	_	12	det	_	_
12	metabolism	metabolism	NN	_	10	obj	_	_
13	of	of	IN	_	14	case	_	_
14	drug5	drug0	NN	_	12	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	drug6	drug0	NN	_	14	conj	_	_
17	.	.	.	_	10	p	_	_

1	These	these	DT	_	2	det	_	_
2	stimulants	stimulant	NNS	_	5	dep	_	_
3	are	be	VBP	_	5	aux	_	_
4	commonly	commonly	RB	_	5	adv	_	_
5	found	find	VBN	_	0	root	_	_
6	in	in	IN	_	7	case	_	_
7	coffee	coffee	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	tea	tea	NN	_	7	conj	_	_
10	,	,	,	_	5	p	_	_
11	respectively	respectively	RB	_	5	adv	_	_
12	.	.	.	_	5	p	_	_

1	In	in	IN	_	3	case	_	_
2	some	some	DT	_	3	det	_	_
3	patients	patient	NNS	_	7	ppmod	_	_
4	,	,	,	_	7	p	_	_
5	this	this	DT	_	7	dep	_	_
6	may	may	MD	_	7	modal	_	_
7	lead	lead	VB	_	0	root	_	_
8	to	to	TO	_	10	aux	_	_
9	reduced	reduce	VBN	_	10	attr	_	_
10	clearance	clearance	NN	_	7	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	prolongation	prolongation	NN	_	10	conj	_	_
13	of	of	IN	_	15	case	_	_
14	plasma	plasma	NN	_	15	com	_	_
15	half-life	half-life	NN	_	12	ppmod	_	_
16	,	,	,	_	12	p	_	_
17	and	and	CC	_	12	cc	_	_
18	enhanced	enhance	VBN	_	19	attr	_	_
19	effects	effect	NNS	_	10	conj	_	_
20	of	of	IN	_	21	case	_	_
21	drug1	drug0	NN	_	19	ppmod	_	_
22	and	and	CC	_	21	cc	_	_
23	drug2	drug0	NN	_	21	conj	_	_
24	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	is	be	VBZ	_	0	root	_	_
5	a	a	DT	_	7	det	_	_
6	competitive	competitive	JJ	_	7	attr	_	_
7	inhibitor	inhibitor	NN	_	4	obj	_	_
8	of	of	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	metabolism	metabolism	NN	_	7	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	4	p	_	_

1	Serum	serum	NN	_	3	com	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	concentrations	concentration	NNS	_	4	dep	_	_
4	increase	increase	VBP	_	0	root	_	_
5	when	when	WRB	_	8	adv	_	_
6	drug2	drug0	NN	_	8	dep	_	_
7	is	be	VBZ	_	8	aux	_	_
8	initiated	initiate	VBN	_	4	comp	_	_
9	in	in	IN	_	11	case	_	_
10	a	a	DT	_	11	det	_	_
11	patient	patient	NN	_	8	ppmod	_	_
12	maintained	maintain	VBN	_	11	acl	_	_
13	on	on	IN	_	14	case	_	_
14	drug3	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	4	p	_	_

1	When	when	WRB	_	2	adv	_	_
2	initiating	initiate	VBG	_	21	advcl	_	_
3	a	a	DT	_	5	det	_	_
4	multi-day	multi-day	JJ	_	5	attr	_	_
5	course	course	NN	_	2	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	in	in	IN	_	10	case	_	_
9	a	a	DT	_	10	det	_	_
10	patient	patient	NN	_	2	ppmod	_	_
11	maintained	maintain	VBN	_	10	acl	_	_
12	on	on	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	,	,	,	_	21	p	_	_
15	the	the	DT	_	18	det	_	_
16	drug3	drug0	NN	_	18	com	_	_
17	maintenance	maintenance	NN	_	18	com	_	_
18	dose	dose	NN	_	21	dep	_	_
19	should	should	MD	_	21	modal	_	_
20	be	be	VB	_	21	aux	_	_
21	halved	halve	VBN	_	0	root	_	_
22	for	for	IN	_	24	case	_	_
23	the	the	DT	_	24	det	_	_
24	period	period	NN	_	21	ppmod	_	_
25	of	of	IN	_	27	case	_	_
26	concurrent	concurrent	JJ	_	27	attr	_	_
27	use	use	NN	_	24	ppmod	_	_
28	of	of	IN	_	29	case	_	_
29	drug4	drug0	NN	_	27	ppmod	_	_
30	and	and	CC	_	21	cc	_	_
31	monitoring	monitoring	NN	_	38	dep	_	_
32	of	of	IN	_	35	case	_	_
33	serum	serum	NN	_	35	com	_	_
34	drug5	drug0	NN	_	35	com	_	_
35	concentrations	concentration	NNS	_	31	ppmod	_	_
36	should	should	MD	_	38	modal	_	_
37	be	be	VB	_	38	aux	_	_
38	initiated	initiate	VBN	_	21	conj	_	_
39	as	as	IN	_	41	case	_	_
40	a	a	DT	_	41	det	_	_
41	guide	guide	NN	_	38	ppmod	_	_
42	to	to	TO	_	45	aux	_	_
43	further	far	JJ	_	45	attr	_	_
44	dosage	dosage	JJ	_	45	attr	_	_
45	adjustments	adjustment	NNS	_	41	ppmod	_	_
46	.	.	.	_	21	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	4	case	_	_
4	subjects	subject	NNS	_	15	ppmod	_	_
5	receiving	receive	VBG	_	4	acl	_	_
6	drug2	drug0	NN	_	5	obj	_	_
7	,	,	,	_	15	p	_	_
8	no	no	DT	_	10	det	_	_
9	significant	significant	JJ	_	10	attr	_	_
10	change	change	NN	_	15	dep	_	_
11	in	in	IN	_	13	case	_	_
12	clotting	clotting	NN	_	13	com	_	_
13	time	time	NN	_	10	ppmod	_	_
14	was	be	VBD	_	15	aux	_	_
15	observed	observe	VBN	_	1	acl	_	_
16	when	when	WRB	_	19	adv	_	_
17	drug3	drug0	NN	_	19	dep	_	_
18	was	be	VBD	_	19	aux	_	_
19	coadministered	coadministered	VBN	_	15	comp	_	_
20	.	.	.	_	1	p	_	_

1	However	however	RB	_	28	adv	_	_
2	,	,	,	_	28	p	_	_
3	because	because	IN	_	8	mark	_	_
4	some	some	DT	_	5	det	_	_
5	drug1	drug0	NNS	_	8	dep	_	_
6	have	have	VBP	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	reported	report	VBN	_	28	advcl	_	_
9	to	to	TO	_	10	aux	_	_
10	enhance	enhance	VB	_	8	comp	_	_
11	the	the	DT	_	12	det	_	_
12	effects	effect	NNS	_	10	obj	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	or	or	CC	_	14	cc	_	_
16	its	its	PRP$	_	17	poss	_	_
17	derivatives	derivative	NNS	_	14	conj	_	_
18	,	,	,	_	28	p	_	_
19	prothrombin	prothrombin	NN	_	20	com	_	_
20	time	time	NN	_	28	dep	_	_
21	or	or	CC	_	20	cc	_	_
22	other	other	JJ	_	25	attr	_	_
23	suitable	suitable	JJ	_	25	attr	_	_
24	anticoagulation	anticoagulation	NN	_	25	com	_	_
25	test	test	NN	_	20	conj	_	_
26	should	should	MD	_	28	modal	_	_
27	be	be	VB	_	28	aux	_	_
28	monitored	monitor	VBN	_	0	root	_	_
29	closely	closely	RB	_	28	adv	_	_
30	if	if	IN	_	34	mark	_	_
31	a	a	DT	_	32	det	_	_
32	drug3	drug0	NN	_	34	dep	_	_
33	is	be	VBZ	_	34	aux	_	_
34	administered	administer	VBN	_	28	comp	_	_
35	with	with	IN	_	36	case	_	_
36	drug4	drug0	NN	_	34	ppmod	_	_
37	or	or	CC	_	36	cc	_	_
38	its	its	PRP$	_	39	poss	_	_
39	derivatives	derivative	NNS	_	36	conj	_	_
40	.	.	.	_	28	p	_	_

1	Drugs	drug	NNS	_	2	dep	_	_
2	Metabolized	metabolize	VBN	_	0	root	_	_
3	by	by	IN	_	6	case	_	_
4	Cytochrome	cytochrome	NN	_	6	com	_	_
5	P450	p0	NN	_	6	com	_	_
6	Enzymes	enzyme	NNS	_	2	ppmod	_	_
7	The	the	DT	_	10	det	_	_
8	drug	drug	NN	_	10	com	_	_
9	interaction	interaction	NN	_	10	com	_	_
10	study	study	NN	_	18	dep	_	_
11	evaluating	evaluate	VBG	_	10	acl	_	_
12	the	the	DT	_	13	det	_	_
13	effect	effect	NN	_	11	obj	_	_
14	of	of	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	on	on	IN	_	17	case	_	_
17	drug2	drug0	NN	_	13	ppmod	_	_
18	indicates	indicate	VBZ	_	6	acl	_	_
19	that	that	IN	_	21	mark	_	_
20	drug3	drug0	NN	_	21	dep	_	_
21	inhibits	inhibit	VBZ	_	18	comp	_	_
22	drug4	drug0	NN	_	23	com	_	_
23	metabolism	metabolism	NN	_	21	obj	_	_
24	,	,	,	_	23	p	_	_
25	which	which	WDT	_	27	dep	_	_
26	is	be	VBZ	_	27	aux	_	_
27	mediated	mediate	VBN	_	23	relcl	_	_
28	by	by	IN	_	29	case	_	_
29	CYP1A2	cyp0a0	NN	_	27	ppmod	_	_
30	.	.	.	_	2	p	_	_

1	While	while	IN	_	7	case	_	_
2	no	no	DT	_	4	det	_	_
3	clinical	clinical	JJ	_	4	attr	_	_
4	studies	study	NNS	_	7	dep	_	_
5	have	have	VBP	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	conducted	conduct	VBN	_	0	root	_	_
8	to	to	TO	_	9	aux	_	_
9	evaluate	evaluate	VB	_	7	comp	_	_
10	the	the	DT	_	11	det	_	_
11	effect	effect	NN	_	9	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	on	on	IN	_	16	case	_	_
15	the	the	DT	_	16	det	_	_
16	metabolism	metabolism	NN	_	11	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	C.P.A.	c.p.a.	NN	_	16	ppmod	_	_

1	substrates	substrate	NNS	_	6	dep	_	_
2	,	,	,	_	6	p	_	_
3	in	in	FW	_	4	adv	_	_
4	vitro	vitro	FW	_	5	attr	_	_
5	data	datum	NNS	_	6	dep	_	_
6	suggest	suggest	VBP	_	0	root	_	_
7	similar	similar	JJ	_	8	attr	_	_
8	effects	effect	NNS	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	in	in	IN	_	14	case	_	_
12	CYP3A4	cyp0a0	JJ	_	14	attr	_	_
13	mediated	mediated	JJ	_	14	attr	_	_
14	metabolism	metabolism	NN	_	8	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	drug2	drug0	NN	_	17	com	_	_
17	metabolism	metabolism	NN	_	14	conj	_	_
18	.	.	.	_	6	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	8	ppmod	_	_
3	,	,	,	_	8	p	_	_
4	other	other	JJ	_	5	attr	_	_
5	drug1	drug0	NNS	_	8	dep	_	_
6	have	have	VBP	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	reported	report	VBN	_	0	root	_	_
9	to	to	TO	_	10	aux	_	_
10	decrease	decrease	VB	_	8	comp	_	_
11	the	the	DT	_	13	det	_	_
12	CYP3A4-mediated	cyp0a0-mediated	JJ	_	13	attr	_	_
13	metabolism	metabolism	NN	_	10	obj	_	_
14	of	of	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	8	p	_	_

1	Other	other	JJ	_	2	attr	_	_
2	drugs	drug	NNS	_	0	root	_	_
3	metabolized	metabolize	VBN	_	2	acl	_	_
4	by	by	IN	_	5	case	_	_
5	C.P.A.	c.p.a.	NNP	_	3	ppmod	_	_

1	include	include	VBP	_	0	root	_	_
2	drug1	drug0	NN	_	1	obj	_	_
3	,	,	,	_	2	p	_	_
4	drug2	drug0	NN	_	2	conj	_	_
5	,	,	,	_	4	p	_	_
6	drug3	drug0	NN	_	2	conj	_	_
7	,	,	,	_	6	p	_	_
8	drug4	drug0	NN	_	2	conj	_	_
9	,	,	,	_	8	p	_	_
10	and	and	CC	_	8	cc	_	_
11	drug5	drug0	NN	_	2	conj	_	_
12	.	.	.	_	1	p	_	_

1	The	the	DT	_	3	det	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	relevance	relevance	NN	_	18	dep	_	_
4	of	of	IN	_	7	case	_	_
5	the	the	DT	_	7	det	_	_
6	potential	potential	JJ	_	7	attr	_	_
7	effect	effect	NN	_	3	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	on	on	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	metabolism	metabolism	NN	_	7	ppmod	_	_
13	of	of	IN	_	15	case	_	_
14	C.P.A.	c.p.a.	NN	_	15	com	_	_
15	substrates	substrate	NNS	_	12	ppmod	_	_
16	is	be	VBZ	_	18	aux	_	_
17	not	not	RB	_	18	neg	_	_
18	known	know	VBN	_	0	root	_	_
19	.	.	.	_	18	p	_	_

1	Patients	patient	NNS	_	11	dep	_	_
2	receiving	receive	VBG	_	1	acl	_	_
3	concurrent	concurrent	JJ	_	4	attr	_	_
4	administration	administration	NN	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	substrates	substrate	NNS	_	4	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	C.P.A.	c.p.a.	NNP	_	6	ppmod	_	_
9	were	be	VBD	_	11	aux	_	_
10	not	not	RB	_	11	neg	_	_
11	excluded	exclude	VBN	_	0	root	_	_
12	from	from	IN	_	14	case	_	_
13	clinical	clinical	JJ	_	14	attr	_	_
14	trials	trial	NNS	_	11	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	drug2	drug0	NN	_	1	prn	_	_
4	)	-rrb-	-RRB-	_	3	p	_	_
5	:	:	:	_	1	p	_	_
6	The	the	DT	_	8	det	_	_
7	concomitant	concomitant	JJ	_	8	attr	_	_
8	administration	administration	NN	_	16	dep	_	_
9	of	of	IN	_	11	case	_	_
10	a	a	DT	_	11	det	_	_
11	drug3	drug0	NN	_	8	ppmod	_	_
12	with	with	IN	_	14	case	_	_
13	a	a	DT	_	14	det	_	_
14	drug4	drug0	NN	_	11	ppmod	_	_
15	may	may	MD	_	16	modal	_	_
16	increase	increase	VBP	_	1	acl	_	_
17	the	the	DT	_	18	det	_	_
18	risks	risk	NNS	_	16	obj	_	_
19	of	of	IN	_	21	case	_	_
20	CNS	cns	NN	_	21	com	_	_
21	stimulation	stimulation	NN	_	18	ppmod	_	_
22	and	and	CC	_	21	cc	_	_
23	convulsions	convulsions	NN	_	21	conj	_	_
24	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Disturbances	disturbance	NNS	_	15	dep	_	_
4	of	of	IN	_	6	case	_	_
5	blood	blood	NN	_	6	com	_	_
6	glucose	glucose	NN	_	3	ppmod	_	_
7	,	,	,	_	3	p	_	_
8	including	include	VBG	_	9	adv	_	_
9	hyperglycemia	hyperglycemia	NN	_	3	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	hypoglycemia	hypoglycemia	NN	_	9	conj	_	_
12	,	,	,	_	3	p	_	_
13	have	have	VBP	_	15	aux	_	_
14	been	be	VBN	_	15	aux	_	_
15	reported	report	VBN	_	1	acl	_	_
16	in	in	IN	_	17	case	_	_
17	patients	patient	NNS	_	15	ppmod	_	_
18	treated	treat	VBN	_	17	acl	_	_
19	concomitantly	concomitantly	RB	_	18	adv	_	_
20	with	with	IN	_	21	case	_	_
21	drug2	drug0	NN	_	18	ppmod	_	_
22	and	and	CC	_	21	cc	_	_
23	an	an	DT	_	24	det	_	_
24	drug3	drug0	NN	_	21	conj	_	_
25	.	.	.	_	1	p	_	_

1	Therefore	therefore	RB	_	9	adv	_	_
2	,	,	,	_	9	p	_	_
3	careful	careful	JJ	_	4	attr	_	_
4	monitoring	monitoring	NN	_	9	dep	_	_
5	of	of	IN	_	7	case	_	_
6	blood	blood	NN	_	7	com	_	_
7	glucose	glucose	NN	_	4	ppmod	_	_
8	is	be	VBZ	_	9	aux	_	_
9	recommended	recommend	VBN	_	0	root	_	_
10	when	when	WRB	_	14	adv	_	_
11	these	these	DT	_	12	det	_	_
12	agents	agent	NNS	_	14	dep	_	_
13	are	be	VBP	_	14	aux	_	_
14	coadministered	coadministered	VBN	_	9	comp	_	_
15	.	.	.	_	9	p	_	_

1	The	the	DT	_	2	det	_	_
2	absorption	absorption	NN	_	7	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	may	may	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	affected	affect	VBN	_	0	root	_	_
8	by	by	IN	_	11	case	_	_
9	the	the	DT	_	11	det	_	_
10	simultaneous	simultaneous	JJ	_	11	attr	_	_
11	administration	administration	NN	_	7	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	indigestion	indigestion	NN	_	14	com	_	_
14	remedies	remedy	NNS	_	11	ppmod	_	_
15	,	,	,	_	11	p	_	_
16	drug2	drug0	NN	_	11	conj	_	_
17	or	or	CC	_	16	cc	_	_
18	drug3	drug0	NN	_	19	com	_	_
19	supplements	supplement	NNS	_	11	conj	_	_
20	.	.	.	_	7	p	_	_

1	Oral	oral	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	be	be	VB	_	0	root	_	_
5	less	less	RBR	_	6	adv	_	_
6	effective	effective	JJ	_	4	dep	_	_
7	while	while	IN	_	10	mark	_	_
8	you	you	NN	_	10	dep	_	_
9	are	be	VBP	_	10	aux	_	_
10	taking	take	VBG	_	4	comp	_	_
11	drug2	drug0	NN	_	10	obj	_	_
12	.	.	.	_	4	p	_	_

1	Potential	potential	JJ	_	3	attr	_	_
2	drug	drug	NN	_	3	com	_	_
3	interactions	interaction	NNS	_	22	dep	_	_
4	between	between	IN	_	10	case	_	_
5	drug1	drug0	NN	_	10	attr	_	_
6	(	-lrb-	-LRB-	_	10	p	_	_
7	drug2	drug0	NN	_	10	attr	_	_
8	cream	cream	NN	_	10	attr	_	_
9	)	-rrb-	-RRB-	_	10	p	_	_
10	Cream	cream	NN	_	3	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	1	0	CD	_	10	conj	_	_
13	%	%	NN	_	12	meta	_	_
14	,	,	,	_	12	p	_	_
15	and	and	CC	_	12	cc	_	_
16	other	other	JJ	_	17	attr	_	_
17	drugs	drug	NNS	_	10	conj	_	_
18	have	have	VBP	_	22	aux	_	_
19	not	not	RB	_	22	neg	_	_
20	been	be	VBN	_	22	aux	_	_
21	systematically	systematically	RB	_	22	adv	_	_
22	evaluated	evaluate	VBN	_	0	root	_	_
23	.	.	.	_	22	p	_	_

1	drug1	drug0	NN	_	10	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	drug3	drug0	NN	_	3	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	has	have	VBZ	_	10	aux	_	_
8	been	be	VBN	_	10	aux	_	_
9	safely	safely	RB	_	10	adv	_	_
10	coadministered	coadministered	VBN	_	0	root	_	_
11	with	with	IN	_	12	case	_	_
12	drug4	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	10	dep	_	_
2	:	:	:	_	1	p	_	_
3	A	a	DT	_	4	det	_	_
4	study	study	NN	_	1	appo	_	_
5	in	in	IN	_	8	case	_	_
6	normal	normal	JJ	_	8	attr	_	_
7	healthy	healthy	JJ	_	8	attr	_	_
8	volunteers	volunteer	NNS	_	4	ppmod	_	_
9	has	have	VBZ	_	10	aux	_	_
10	shown	show	VBN	_	0	root	_	_
11	that	that	IN	_	23	mark	_	_
12	concomitant	concomitant	JJ	_	13	attr	_	_
13	administration	administration	NN	_	23	dep	_	_
14	of	of	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	drug3	drug0	NN	_	15	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	and	and	CC	_	15	cc	_	_
20	drug4	drug0	NN	_	15	conj	_	_
21	does	do	VBZ	_	23	aux	_	_
22	not	not	RB	_	23	neg	_	_
23	result	result	VB	_	10	comp	_	_
24	in	in	IN	_	26	case	_	_
25	altered	altered	JJ	_	26	attr	_	_
26	pharmacoktnetics	pharmacoktnetics	NNS	_	23	ppmod	_	_
27	of	of	IN	_	29	case	_	_
28	either	either	DT	_	29	det	_	_
29	drug	drug	NN	_	26	ppmod	_	_
30	.	.	.	_	10	p	_	_

1	In	in	IN	_	3	case	_	_
2	a	a	DT	_	3	det	_	_
3	study	study	NN	_	17	ppmod	_	_
4	in	in	IN	_	6	case	_	_
5	hypertensive	hypertensive	JJ	_	6	attr	_	_
6	patients	patient	NNS	_	3	ppmod	_	_
7	,	,	,	_	17	p	_	_
8	addition	addition	NN	_	17	dep	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	to	to	TO	_	14	aux	_	_
12	existing	existing	NN	_	14	com	_	_
13	drug2	drug0	NN	_	14	com	_	_
14	therapy	therapy	NN	_	8	ppmod	_	_
15	did	do	VBD	_	17	aux	_	_
16	not	not	RB	_	17	neg	_	_
17	result	result	VB	_	0	root	_	_
18	in	in	IN	_	22	case	_	_
19	any	any	DT	_	22	det	_	_
20	unexpected	unexpected	JJ	_	22	attr	_	_
21	adverse	adverse	JJ	_	22	attr	_	_
22	effects	effect	NNS	_	17	ppmod	_	_
23	,	,	,	_	17	p	_	_
24	and	and	CC	_	17	cc	_	_
25	drug3	drug0	NN	_	26	dep	_	_
26	had	have	VBD	_	17	conj	_	_
27	an	an	DT	_	30	det	_	_
28	additional	additional	JJ	_	30	attr	_	_
29	antihypertensive	antihypertensive	JJ	_	30	attr	_	_
30	effect	effect	NN	_	26	obj	_	_
31	.	.	.	_	17	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	7	case	_	_
4	a	a	DT	_	7	det	_	_
5	single	single	JJ	_	7	attr	_	_
6	dose	dose	NN	_	7	com	_	_
7	study	study	NN	_	15	ppmod	_	_
8	in	in	IN	_	10	case	_	_
9	normal	normal	JJ	_	10	attr	_	_
10	volunteers	volunteer	NNS	_	7	ppmod	_	_
11	,	,	,	_	15	p	_	_
12	coadministration	coadministration	NN	_	15	dep	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	had	have	VBD	_	1	acl	_	_
16	a	a	DT	_	18	det	_	_
17	small	small	JJ	_	18	attr	_	_
18	effect	effect	NN	_	15	obj	_	_
19	on	on	IN	_	21	case	_	_
20	the	the	DT	_	21	det	_	_
21	rate	rate	NN	_	18	ppmod	_	_
22	but	but	CC	_	18	cc	_	_
23	no	no	DT	_	24	det	_	_
24	effect	effect	NN	_	18	conj	_	_
25	on	on	IN	_	27	case	_	_
26	the	the	DT	_	27	det	_	_
27	extent	extent	NN	_	24	ppmod	_	_
28	of	of	IN	_	30	case	_	_
29	drug3	drug0	NN	_	30	com	_	_
30	bioavailability	bioavailability	NN	_	27	ppmod	_	_
31	.	.	.	_	1	p	_	_

1	Significant	significant	JJ	_	2	attr	_	_
2	increases	increase	NNS	_	26	dep	_	_
3	In	in	IN	_	4	case	_	_
4	AUC	auc	NN	_	2	ppmod	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	27	0	CD	_	4	num	_	_
7	%	%	NN	_	6	meta	_	_
8	)	-rrb-	-RRB-	_	6	p	_	_
9	and	and	CC	_	4	cc	_	_
10	Cmax	cmax	NN	_	4	conj	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	58	0	CD	_	10	num	_	_
13	%	%	NN	_	12	meta	_	_
14	)	-rrb-	-RRB-	_	12	p	_	_
15	and	and	CC	_	2	cc	_	_
16	decreases	decrease	NNS	_	2	conj	_	_
17	in	in	IN	_	18	case	_	_
18	tmax	tmax	NN	_	16	ppmod	_	_
19	(	-lrb-	-LRB-	_	20	p	_	_
20	23	0	CD	_	18	num	_	_
21	%	%	NN	_	20	meta	_	_
22	)	-rrb-	-RRB-	_	20	p	_	_
23	of	of	IN	_	24	case	_	_
24	drug1	drug0	NN	_	18	ppmod	_	_
25	were	be	VBD	_	26	aux	_	_
26	noted	note	VBN	_	0	root	_	_
27	in	in	IN	_	29	case	_	_
28	this	this	DT	_	29	det	_	_
29	study	study	NN	_	26	ppmod	_	_
30	.	.	.	_	26	p	_	_

1	However	however	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	concomitant	concomitant	JJ	_	4	attr	_	_
4	administration	administration	NN	_	0	root	_	_
5	of	of	IN	_	9	case	_	_
6	5	0	CD	_	7	num	_	_
7	mg	mg	NN	_	9	com	_	_
8	b.i.d.	b.i.d.	NN	_	9	com	_	_
9	drug1	drug0	NN	_	4	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	40	0	CD	_	12	num	_	_
12	mg	mg	NN	_	13	com	_	_
13	b.i.d.	b.i.d.	NN	_	9	conj	_	_

1	drug1	drug0	NN	_	8	dep	_	_
2	to	to	TO	_	4	aux	_	_
3	healthy	healthy	JJ	_	4	attr	_	_
4	volunteers	volunteer	NNS	_	1	ppmod	_	_
5	under	under	IN	_	7	case	_	_
6	steady-state	steady-state	JJ	_	7	attr	_	_
7	conditions	condition	NNS	_	1	ppmod	_	_
8	had	have	VBD	_	0	root	_	_
9	no	no	DT	_	11	det	_	_
10	relevant	relevant	JJ	_	11	attr	_	_
11	effect	effect	NN	_	8	obj	_	_
12	on	on	IN	_	16	case	_	_
13	either	either	DT	_	16	det	_	_
14	drug	drug	NN	_	16	com	_	_
15	s	s	NN	_	16	com	_	_
16	bioavailability	bioavailability	NN	_	11	ppmod	_	_
17	,	,	,	_	11	p	_	_
18	AUC	auc	NN	_	11	appo	_	_
19	and	and	CC	_	18	cc	_	_
20	Cmax	cmax	NN	_	18	conj	_	_
21	,	,	,	_	11	p	_	_
22	differences	difference	NNS	_	11	appo	_	_
23	were	be	VBD	_	22	acl	_	_
24	20	0	CD	_	23	obj	_	_
25	%	%	NN	_	24	meta	_	_
26	between	between	IN	_	27	case	_	_
27	drug2	drug0	NN	_	23	ppmod	_	_
28	given	give	VBN	_	27	acl	_	_
29	singly	singly	RB	_	28	adv	_	_
30	and	and	CC	_	29	cc	_	_
31	in	in	IN	_	32	case	_	_
32	combination	combination	NN	_	29	conj	_	_
33	with	with	IN	_	34	case	_	_
34	drug3	drug0	NN	_	32	ppmod	_	_
35	,	,	,	_	27	p	_	_
36	and	and	CC	_	27	cc	_	_
37	between	between	IN	_	38	case	_	_
38	drug4	drug0	NNS	_	27	conj	_	_
39	given	give	VBN	_	38	acl	_	_
40	singly	singly	RB	_	39	adv	_	_
41	and	and	CC	_	40	cc	_	_
42	in	in	IN	_	43	case	_	_
43	combination	combination	NN	_	40	conj	_	_
44	with	with	IN	_	45	case	_	_
45	drug5	drug0	NN	_	43	ppmod	_	_
46	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	5	case	_	_
4	a	a	DT	_	5	det	_	_
5	study	study	NN	_	31	ppmod	_	_
6	in	in	IN	_	8	case	_	_
7	healthy	healthy	JJ	_	8	attr	_	_
8	volunteers	volunteer	NNS	_	5	ppmod	_	_
9	,	,	,	_	31	p	_	_
10	a	a	DT	_	12	det	_	_
11	one-week	one-week	JJ	_	12	attr	_	_
12	course	course	NN	_	31	dep	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	at	at	IN	_	18	case	_	_
16	400	0	CD	_	17	num	_	_
17	mg	mg	NN	_	18	com	_	_
18	b.i.d.	b.i.d.	NN	_	14	ppmod	_	_
19	with	with	IN	_	24	case	_	_
20	a	a	DT	_	24	det	_	_
21	single	single	JJ	_	24	attr	_	_
22	5	0	CD	_	23	num	_	_
23	mg	mg	NN	_	24	com	_	_
24	dose	dose	NN	_	14	ppmod	_	_
25	of	of	IN	_	26	case	_	_
26	drug3	drug0	NN	_	24	ppmod	_	_
27	on	on	IN	_	30	case	_	_
28	the	the	DT	_	30	det	_	_
29	sixth	#ord#	JJ	_	30	attr	_	_
30	day	day	NN	_	26	ppmod	_	_
31	showed	show	VBD	_	1	acl	_	_
32	an	an	DT	_	33	det	_	_
33	increase	increase	NN	_	31	obj	_	_
34	in	in	IN	_	39	case	_	_
35	drug4	drug0	JJ	_	39	attr	_	_
36	mean	mean	JJ	_	39	attr	_	_
37	peak	peak	NN	_	39	com	_	_
38	plasma	plasma	NN	_	39	com	_	_
39	concentrations	concentration	NNS	_	33	ppmod	_	_
40	(	-lrb-	-LRB-	_	41	p	_	_
41	36	0	CD	_	39	num	_	_
42	%	%	NN	_	41	meta	_	_
43	)	-rrb-	-RRB-	_	41	p	_	_
44	and	and	CC	_	33	cc	_	_
45	significant	significant	JJ	_	46	attr	_	_
46	increase	increase	NN	_	33	conj	_	_
47	in	in	IN	_	48	case	_	_
48	area	area	NN	_	46	ppmod	_	_
49	under	under	IN	_	51	case	_	_
50	the	the	DT	_	51	det	_	_
51	curve	curve	NN	_	48	ppmod	_	_
52	(	-lrb-	-LRB-	_	53	p	_	_
53	50	0	CD	_	51	num	_	_
54	%	%	NN	_	53	meta	_	_
55	)	-rrb-	-RRB-	_	53	p	_	_
56	.	.	.	_	1	p	_	_

1	If	if	IN	_	5	mark	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	therapy	therapy	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	initiated	initiate	VBN	_	17	advcl	_	_
6	in	in	IN	_	8	case	_	_
7	a	a	DT	_	8	det	_	_
8	patient	patient	NN	_	5	ppmod	_	_
9	currently	currently	RB	_	10	adv	_	_
10	receiving	receive	VBG	_	8	acl	_	_
11	drug2	drug0	NN	_	13	attr	_	_
12	careful	careful	JJ	_	13	attr	_	_
13	monitoring	monitoring	NN	_	10	obj	_	_
14	for	for	IN	_	16	case	_	_
15	adverse	adverse	JJ	_	16	attr	_	_
16	reactions	reaction	NNS	_	13	ppmod	_	_
17	is	be	VBZ	_	0	root	_	_
18	advised	advised	JJ	_	17	dep	_	_
19	and	and	CC	_	17	cc	_	_
20	downward	downward	JJ	_	22	attr	_	_
21	dose	dose	NN	_	22	com	_	_
22	adjustment	adjustment	NN	_	25	dep	_	_
23	may	may	MD	_	25	modal	_	_
24	be	be	VB	_	25	aux	_	_
25	required	require	VBN	_	17	conj	_	_
26	.	.	.	_	17	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	5	case	_	_
4	a	a	DT	_	5	det	_	_
5	study	study	NN	_	27	ppmod	_	_
6	in	in	IN	_	8	case	_	_
7	healthy	healthy	JJ	_	8	attr	_	_
8	volunteers	volunteer	NNS	_	5	ppmod	_	_
9	,	,	,	_	27	p	_	_
10	a	a	DT	_	12	det	_	_
11	six-day	six-day	JJ	_	12	attr	_	_
12	course	course	NN	_	27	dep	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	at	at	IN	_	17	case	_	_
16	600	0	CD	_	17	num	_	_
17	mg/day	mg/day	NN	_	12	ppmod	_	_
18	followed	followed	VBN	_	17	acl	_	_
19	by	by	IN	_	24	case	_	_
20	a	a	DT	_	24	det	_	_
21	single	single	JJ	_	24	attr	_	_
22	5	0	CD	_	23	num	_	_
23	mg	mg	NN	_	24	com	_	_
24	dose	dose	NN	_	18	ppmod	_	_
25	of	of	IN	_	26	case	_	_
26	drug3	drug0	NN	_	24	ppmod	_	_
27	resulted	result	VBD	_	1	acl	_	_
28	in	in	IN	_	30	case	_	_
29	a	a	DT	_	30	det	_	_
30	reduction	reduction	NN	_	27	ppmod	_	_
31	in	in	IN	_	33	case	_	_
32	drug4	drug0	NN	_	33	com	_	_
33	levels	level	NNS	_	30	ppmod	_	_
34	to	to	TO	_	30	ppmod	_	_
35	below	below	IN	_	37	case	_	_
36	detectable	detectable	JJ	_	37	attr	_	_
37	limits	limit	NNS	_	30	ppmod	_	_
38	.	.	.	_	1	p	_	_

1	If	if	IN	_	5	mark	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	therapy	therapy	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	required	require	VBN	_	12	advcl	_	_
6	,	,	,	_	12	p	_	_
7	drug2	drug0	NN	_	8	com	_	_
8	concentrations	concentration	NNS	_	12	dep	_	_
9	and	and	CC	_	8	cc	_	_
10	therapeutic	therapeutic	JJ	_	11	attr	_	_
11	effects	effect	NNS	_	8	conj	_	_
12	are	be	VBP	_	0	root	_	_
13	likely	likely	JJ	_	12	dep	_	_
14	to	to	TO	_	17	aux	_	_
15	be	be	VB	_	17	aux	_	_
16	markedly	markedly	RB	_	17	adv	_	_
17	reduced	reduce	VBN	_	13	comp	_	_
18	or	or	CC	_	17	cc	_	_
19	abolished	abolish	VBN	_	17	conj	_	_
20	as	as	IN	_	22	case	_	_
21	a	a	DT	_	22	det	_	_
22	consequence	consequence	NN	_	19	ppmod	_	_
23	of	of	IN	_	25	case	_	_
24	increased	increase	VBN	_	25	attr	_	_
25	metabolism	metabolism	NN	_	22	ppmod	_	_
26	and	and	CC	_	25	cc	_	_
27	higher	high	JJR	_	28	attr	_	_
28	clearance	clearance	NN	_	25	conj	_	_
29	of	of	IN	_	30	case	_	_
30	drug3	drug0	NN	_	28	ppmod	_	_
31	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	5	case	_	_
4	a	a	DT	_	5	det	_	_
5	study	study	NN	_	23	ppmod	_	_
6	in	in	IN	_	8	case	_	_
7	healthy	healthy	JJ	_	8	attr	_	_
8	volunteers	volunteer	NNS	_	5	ppmod	_	_
9	,	,	,	_	23	p	_	_
10	no	no	DT	_	16	det	_	_
11	clinically	clinically	RB	_	12	adv	_	_
12	relevant	relevant	JJ	_	16	attr	_	_
13	pharmacokinetic	pharmacokinetic	JJ	_	16	attr	_	_
14	or	or	CC	_	13	cc	_	_
15	pharmacodynamic	pharmacodynamic	JJ	_	13	conj	_	_
16	interaction	interaction	NN	_	23	dep	_	_
17	between	between	IN	_	18	case	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	and	and	CC	_	18	cc	_	_
20	racemic	racemic	JJ	_	21	attr	_	_
21	drug3	drug0	NN	_	18	conj	_	_
22	was	be	VBD	_	23	aux	_	_
23	seen	see	VBN	_	1	acl	_	_
24	when	when	WRB	_	38	adv	_	_
25	two	#crd#	CD	_	28	num	_	_
26	single	single	JJ	_	28	attr	_	_
27	oral	oral	JJ	_	28	attr	_	_
28	doses	dose	NNS	_	38	dep	_	_
29	of	of	IN	_	30	case	_	_
30	drug4	drug0	NN	_	28	ppmod	_	_
31	(	-lrb-	-LRB-	_	35	p	_	_
32	0.7	0	CD	_	35	num	_	_
33	mg/kg	mg/kg	NN	_	35	com	_	_
34	body	body	NN	_	35	com	_	_
35	weight	weight	NN	_	30	prn	_	_
36	)	-rrb-	-RRB-	_	35	p	_	_
37	were	be	VBD	_	38	aux	_	_
38	administered	administer	VBN	_	23	comp	_	_
39	during	during	IN	_	41	case	_	_
40	11	0	CD	_	41	num	_	_
41	days	day	NNS	_	38	ppmod	_	_
42	of	of	IN	_	44	case	_	_
43	multipledose	multipledose	NN	_	44	com	_	_
44	treatment	treatment	NN	_	41	ppmod	_	_
45	with	with	IN	_	49	case	_	_
46	5	0	CD	_	47	num	_	_
47	mg	mg	NN	_	49	com	_	_
48	b.i.d.	b.i.d.	NN	_	49	com	_	_
49	drug5	drug0	NN	_	44	ppmod	_	_
50	.	.	.	_	1	p	_	_

1	Neither	neither	CC	_	3	cc	_	_
2	racemic	racemic	JJ	_	3	attr	_	_
3	drug1	drug0	NN	_	13	dep	_	_
4	nor	nor	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	6	com	_	_
6	binding	binding	NN	_	3	conj	_	_
7	to	to	TO	_	9	aux	_	_
8	plasma	plasma	NN	_	9	com	_	_
9	proteins	protein	NNS	_	6	ppmod	_	_
10	in	in	FW	_	11	adv	_	_
11	vitro	vitro	FW	_	6	adv	_	_
12	was	be	VBD	_	13	aux	_	_
13	altered	alter	VBN	_	0	root	_	_
14	by	by	IN	_	16	case	_	_
15	the	the	DT	_	16	det	_	_
16	addition	addition	NN	_	13	ppmod	_	_
17	of	of	IN	_	20	case	_	_
18	the	the	DT	_	20	det	_	_
19	other	other	JJ	_	20	attr	_	_
20	drug	drug	NN	_	16	ppmod	_	_
21	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	5	det	_	_
4	concomitant	concomitant	JJ	_	5	attr	_	_
5	administration	administration	NN	_	20	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	drug3	drug0	NN	_	7	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	and	and	CC	_	7	cc	_	_
12	drug4	drug0	NN	_	7	conj	_	_
13	in	in	IN	_	17	case	_	_
14	a	a	DT	_	17	det	_	_
15	single-dose	single-dose	JJ	_	17	attr	_	_
16	pharmacokinetic	pharmacokinetic	JJ	_	17	attr	_	_
17	study	study	NN	_	5	ppmod	_	_
18	did	do	VBD	_	20	aux	_	_
19	not	not	RB	_	20	neg	_	_
20	affect	affect	VB	_	1	acl	_	_
21	renal	renal	JJ	_	27	attr	_	_
22	,	,	,	_	21	p	_	_
23	nonrenal	nonrenal	JJ	_	21	conj	_	_
24	and	and	CC	_	23	cc	_	_
25	total	total	JJ	_	21	conj	_	_
26	body	body	NN	_	27	com	_	_
27	clearance	clearance	NN	_	20	obj	_	_
28	of	of	IN	_	29	case	_	_
29	drug5	drug0	NN	_	27	ppmod	_	_
30	.	.	.	_	1	p	_	_

1	drug1	drug0	JJ	_	2	attr	_	_
2	Anesthesia	anesthesia	NN	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	Severe	severe	JJ	_	5	attr	_	_
5	hypotension	hypotension	NN	_	8	dep	_	_
6	has	have	VBZ	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	reported	report	VBN	_	2	acl	_	_
9	during	during	IN	_	11	case	_	_
10	drug2	drug0	NN	_	11	com	_	_
11	anesthesia	anesthesia	NN	_	8	ppmod	_	_
12	with	with	IN	_	14	case	_	_
13	concomitant	concomitant	JJ	_	14	attr	_	_
14	use	use	NN	_	11	ppmod	_	_
15	of	of	IN	_	17	case	_	_
16	a	a	DT	_	17	det	_	_
17	drug3	drug0	NN	_	14	ppmod	_	_
18	and	and	CC	_	17	cc	_	_
19	a	a	DT	_	20	det	_	_
20	drug4	drug0	NN	_	17	conj	_	_
21	.	.	.	_	2	p	_	_

1	Even	even	RB	_	8	adv	_	_
2	though	though	IN	_	8	mark	_	_
3	such	such	JJ	_	4	attr	_	_
4	interactions	interaction	NNS	_	8	dep	_	_
5	have	have	VBP	_	8	aux	_	_
6	not	not	RB	_	8	neg	_	_
7	been	be	VBN	_	8	aux	_	_
8	seen	see	VBN	_	26	advcl	_	_
9	in	in	IN	_	11	case	_	_
10	clinical	clinical	JJ	_	11	attr	_	_
11	studies	study	NNS	_	8	ppmod	_	_
12	with	with	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	drug2	drug0	NN	_	13	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	,	,	,	_	26	p	_	_
18	an	an	DT	_	20	det	_	_
19	increased	increase	VBN	_	20	attr	_	_
20	volume	volume	NN	_	26	dep	_	_
21	of	of	IN	_	23	case	_	_
22	circulating	circulate	VBG	_	23	attr	_	_
23	fluids	fluid	NNS	_	20	ppmod	_	_
24	might	might	MD	_	26	modal	_	_
25	be	be	VB	_	26	aux	_	_
26	required	require	VBN	_	0	root	_	_
27	if	if	IN	_	31	mark	_	_
28	such	such	PDT	_	30	det	_	_
29	an	an	DT	_	30	det	_	_
30	interaction	interaction	NN	_	31	dep	_	_
31	were	be	VBD	_	26	comp	_	_
32	to	to	TO	_	33	aux	_	_
33	occur	occur	VB	_	31	comp	_	_
34	.	.	.	_	26	p	_	_

1	In	in	IN	_	3	case	_	_
2	normal	normal	JJ	_	3	attr	_	_
3	volunteers	volunteer	NNS	_	11	ppmod	_	_
4	receiving	receive	VBG	_	3	acl	_	_
5	drug1	drug0	NN	_	4	obj	_	_
6	,	,	,	_	11	p	_	_
7	the	the	DT	_	8	det	_	_
8	administration	administration	NN	_	11	dep	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	decreased	decrease	VBD	_	0	root	_	_
12	the	the	DT	_	14	det	_	_
13	renal	renal	JJ	_	14	attr	_	_
14	clearance	clearance	NN	_	11	obj	_	_
15	and	and	CC	_	11	cc	_	_
16	significantly	significantly	RB	_	17	adv	_	_
17	increased	increase	VBD	_	11	conj	_	_
18	the	the	DT	_	20	det	_	_
19	plasma	plasma	NN	_	20	com	_	_
20	levels	level	NNS	_	17	obj	_	_
21	of	of	IN	_	22	case	_	_
22	drug3	drug0	NN	_	20	ppmod	_	_
23	.	.	.	_	11	p	_	_

1	In	in	IN	_	3	case	_	_
2	some	some	DT	_	3	det	_	_
3	patients	patient	NNS	_	13	ppmod	_	_
4	,	,	,	_	13	p	_	_
5	combined	combined	JJ	_	6	attr	_	_
6	use	use	NN	_	13	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	drug2	drug0	NN	_	8	conj	_	_
11	has	have	VBZ	_	13	aux	_	_
12	been	be	VBN	_	13	aux	_	_
13	associated	associate	VBN	_	0	root	_	_
14	with	with	IN	_	17	case	_	_
15	fatal	fatal	JJ	_	17	attr	_	_
16	gastrointestinal	gastrointestinal	JJ	_	17	attr	_	_
17	hemorrhage	hemorrhage	NN	_	13	ppmod	_	_
18	.	.	.	_	13	p	_	_

1	Therefore	therefore	RB	_	9	adv	_	_
2	,	,	,	_	9	p	_	_
3	drug1	drug0	NN	_	9	dep	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	should	should	MD	_	9	modal	_	_
7	not	not	RB	_	9	neg	_	_
8	be	be	VB	_	9	aux	_	_
9	used	use	VBN	_	0	root	_	_
10	concomitantly	concomitantly	RB	_	9	adv	_	_
11	.	.	.	_	9	p	_	_

1	In	in	IN	_	3	case	_	_
2	a	a	DT	_	3	det	_	_
3	study	study	NN	_	10	ppmod	_	_
4	in	in	IN	_	6	case	_	_
5	normal	normal	JJ	_	6	attr	_	_
6	volunteers	volunteer	NNS	_	3	ppmod	_	_
7	,	,	,	_	10	p	_	_
8	it	it	PRP	_	10	dep	_	_
9	was	be	VBD	_	10	aux	_	_
10	found	find	VBN	_	0	root	_	_
11	that	that	IN	_	22	mark	_	_
12	chronic	chronic	JJ	_	14	attr	_	_
13	concurrent	concurrent	JJ	_	14	attr	_	_
14	administration	administration	NN	_	22	dep	_	_
15	of	of	IN	_	17	case	_	_
16	3.6	0	CD	_	17	num	_	_
17	g	g	NN	_	14	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug1	drug0	NN	_	17	ppmod	_	_
20	per	per	IN	_	21	case	_	_
21	day	day	NN	_	17	ppmod	_	_
22	decreases	decrease	VBZ	_	10	comp	_	_
23	drug2	drug0	NN	_	25	com	_	_
24	blood	blood	NN	_	25	com	_	_
25	levels	level	NNS	_	22	obj	_	_
26	approximately	approximately	RB	_	27	adv	_	_
27	20	0	CD	_	25	num	_	_
28	%	%	NN	_	27	meta	_	_
29	.	.	.	_	10	p	_	_

1	The	the	DT	_	3	det	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	use	use	NN	_	11	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	with	with	IN	_	8	case	_	_
7	other	other	JJ	_	8	attr	_	_
8	drug2	drug0	NNS	_	3	ppmod	_	_
9	is	be	VBZ	_	11	aux	_	_
10	not	not	RB	_	11	neg	_	_
11	recommended	recommend	VBN	_	0	root	_	_
12	due	due	JJ	_	16	adv	_	_
13	to	to	TO	_	16	aux	_	_
14	the	the	DT	_	16	det	_	_
15	increased	increase	VBN	_	16	attr	_	_
16	possibility	possibility	NN	_	11	ppmod	_	_
17	of	of	IN	_	19	case	_	_
18	gastrointestinal	gastrointestinal	JJ	_	19	attr	_	_
19	toxicity	toxicity	NN	_	16	ppmod	_	_
20	,	,	,	_	11	p	_	_
21	with	with	IN	_	22	case	_	_
22	little	little	JJ	_	11	ppmod	_	_
23	or	or	CC	_	22	cc	_	_
24	no	no	DT	_	25	attr	_	_
25	increase	increase	NN	_	22	conj	_	_
26	in	in	IN	_	27	case	_	_
27	efficacy	efficacy	NN	_	25	ppmod	_	_
28	.	.	.	_	11	p	_	_

1	Clinical	clinical	JJ	_	2	attr	_	_
2	studies	study	NNS	_	4	dep	_	_
3	have	have	VBP	_	4	aux	_	_
4	shown	show	VBN	_	0	root	_	_
5	that	that	IN	_	9	mark	_	_
6	drug1	drug0	NN	_	9	dep	_	_
7	does	do	VBZ	_	9	aux	_	_
8	not	not	RB	_	9	neg	_	_
9	influence	influence	VB	_	4	comp	_	_
10	the	the	DT	_	11	det	_	_
11	hypoprothrombinemia	hypoprothrombinemia	NN	_	9	obj	_	_
12	produced	produce	VBN	_	11	acl	_	_
13	by	by	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	4	p	_	_

1	However	however	RB	_	26	adv	_	_
2	,	,	,	_	26	p	_	_
3	when	when	WRB	_	12	adv	_	_
4	any	any	DT	_	6	det	_	_
5	additional	additional	JJ	_	6	attr	_	_
6	drug	drug	NN	_	12	dep	_	_
7	,	,	,	_	6	p	_	_
8	including	include	VBG	_	9	adv	_	_
9	drug1	drug0	NN	_	6	ppmod	_	_
10	,	,	,	_	6	p	_	_
11	is	be	VBZ	_	12	aux	_	_
12	added	add	VBN	_	26	advcl	_	_
13	to	to	TO	_	15	aux	_	_
14	the	the	DT	_	15	det	_	_
15	treatment	treatment	NN	_	12	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	patients	patient	NNS	_	15	ppmod	_	_
18	on	on	IN	_	20	case	_	_
19	drug2	drug0	NN	_	20	com	_	_
20	therapy	therapy	NN	_	17	ppmod	_	_
21	,	,	,	_	26	p	_	_
22	the	the	DT	_	23	det	_	_
23	patients	patient	NNS	_	26	dep	_	_
24	should	should	MD	_	26	modal	_	_
25	be	be	VB	_	26	aux	_	_
26	observed	observe	VBN	_	0	root	_	_
27	for	for	IN	_	28	case	_	_
28	alterations	alteration	NNS	_	26	ppmod	_	_
29	of	of	IN	_	32	case	_	_
30	the	the	DT	_	32	det	_	_
31	prothrombin	prothrombin	NN	_	32	com	_	_
32	time	time	NN	_	28	ppmod	_	_
33	.	.	.	_	26	p	_	_

1	In	in	IN	_	3	case	_	_
2	post-marketing	post-marketing	JJ	_	3	attr	_	_
3	experience	experience	VBP	_	8	ppmod	_	_
4	,	,	,	_	8	p	_	_
5	bleeding	bleeding	JJ	_	8	dep	_	_
6	has	have	VBZ	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	reported	report	VBN	_	0	root	_	_
9	in	in	IN	_	10	case	_	_
10	patients	patient	NNS	_	8	ppmod	_	_
11	on	on	IN	_	13	case	_	_
12	concomitant	concomitant	JJ	_	13	attr	_	_
13	treatment	treatment	NN	_	10	ppmod	_	_
14	with	with	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	drug2	drug0	NN	_	15	conj	_	_
18	.	.	.	_	8	p	_	_

1	Caution	caution	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	exercised	exercise	VBN	_	0	root	_	_
5	when	when	WRB	_	10	adv	_	_
6	drug1	drug0	NN	_	10	dep	_	_
7	and	and	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	are	be	VBP	_	10	aux	_	_
10	administered	administer	VBN	_	4	comp	_	_
11	concomitantly	concomitantly	RB	_	10	adv	_	_
12	.	.	.	_	4	p	_	_

1	When	when	WRB	_	4	adv	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	given	give	VBN	_	15	advcl	_	_
5	to	to	TO	_	6	aux	_	_
6	patients	patient	NNS	_	4	ppmod	_	_
7	receiving	receive	VBG	_	6	acl	_	_
8	drug2	drug0	NN	_	7	obj	_	_
9	,	,	,	_	15	p	_	_
10	the	the	DT	_	12	det	_	_
11	plasma	plasma	NN	_	12	com	_	_
12	levels	level	NNS	_	15	dep	_	_
13	of	of	IN	_	14	case	_	_
14	drug3	drug0	NN	_	12	ppmod	_	_
15	are	be	VBP	_	0	root	_	_
16	likely	likely	JJ	_	15	dep	_	_
17	to	to	TO	_	19	aux	_	_
18	be	be	VB	_	19	aux	_	_
19	increased	increase	VBN	_	16	comp	_	_
20	.	.	.	_	15	p	_	_

1	Therefore	therefore	RB	_	11	adv	_	_
2	,	,	,	_	11	p	_	_
3	a	a	DT	_	7	det	_	_
4	lower	low	RBR	_	5	adv	_	_
5	total	total	JJ	_	7	attr	_	_
6	daily	daily	JJ	_	7	attr	_	_
7	dosage	dosage	NN	_	11	dep	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	may	may	MD	_	11	modal	_	_
11	produce	produce	VB	_	0	root	_	_
12	a	a	DT	_	15	det	_	_
13	satisfactory	satisfactory	JJ	_	15	attr	_	_
14	therapeutic	therapeutic	JJ	_	15	attr	_	_
15	effect	effect	NN	_	11	obj	_	_
16	.	.	.	_	11	p	_	_

1	When	when	WRB	_	9	adv	_	_
2	increases	increase	NNS	_	9	dep	_	_
3	in	in	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	dose	dose	NN	_	2	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	are	be	VBP	_	9	aux	_	_
9	made	make	VBN	_	14	advcl	_	_
10	,	,	,	_	14	p	_	_
11	they	they	PRP	_	14	dep	_	_
12	should	should	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	made	make	VBN	_	0	root	_	_
15	carefully	carefully	RB	_	14	adv	_	_
16	and	and	CC	_	15	cc	_	_
17	in	in	IN	_	19	case	_	_
18	small	small	JJ	_	19	attr	_	_
19	increments	increment	NNS	_	15	conj	_	_
20	.	.	.	_	14	p	_	_

1	Caution	caution	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	used	use	VBN	_	0	root	_	_
5	if	if	IN	_	8	mark	_	_
6	drug1	drug0	NN	_	8	dep	_	_
7	is	be	VBZ	_	8	aux	_	_
8	administered	administer	VBN	_	4	comp	_	_
9	simultaneously	simultaneously	RB	_	8	adv	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NN	_	8	ppmod	_	_
12	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	reported	report	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	decrease	decrease	VB	_	4	comp	_	_
7	the	the	DT	_	9	det	_	_
8	tubular	tubular	JJ	_	9	attr	_	_
9	secretion	secretion	NN	_	6	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	6	cc	_	_
13	to	to	TO	_	14	aux	_	_
14	potentiate	potentiate	VB	_	6	conj	_	_
15	its	its	PRP$	_	16	poss	_	_
16	toxicity	toxicity	NN	_	14	obj	_	_
17	.	.	.	_	4	p	_	_

1	Administration	administration	NN	_	9	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	concomitantly	concomitantly	RB	_	6	adv	_	_
5	with	with	IN	_	6	case	_	_
6	drug2	drug0	NN	_	1	ppmod	_	_
7	has	have	VBZ	_	9	aux	_	_
8	been	be	VBN	_	9	aux	_	_
9	associated	associate	VBN	_	0	root	_	_
10	with	with	IN	_	12	case	_	_
11	an	an	DT	_	12	det	_	_
12	increase	increase	NN	_	9	ppmod	_	_
13	in	in	IN	_	16	case	_	_
14	drug3	drug0	NN	_	16	attr	_	_
15	-induced	-induced	JJ	_	16	attr	_	_
16	toxicity	toxicity	NN	_	12	ppmod	_	_
17	,	,	,	_	9	p	_	_
18	possibly	possibly	RB	_	22	adv	_	_
19	due	due	JJ	_	22	adv	_	_
20	to	to	TO	_	22	aux	_	_
21	decreased	decrease	VBN	_	22	attr	_	_
22	synthesis	synthesis	NN	_	9	ppmod	_	_
23	of	of	IN	_	25	case	_	_
24	renal	renal	JJ	_	25	attr	_	_
25	prostacyclin	prostacyclin	NN	_	22	ppmod	_	_
26	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	used	use	VBN	_	0	root	_	_
5	with	with	IN	_	6	case	_	_
6	caution	caution	NN	_	4	ppmod	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	4	ppmod	_	_
9	taking	take	VBG	_	8	acl	_	_
10	drug2	drug0	NN	_	9	obj	_	_
11	,	,	,	_	4	p	_	_
12	and	and	CC	_	4	cc	_	_
13	renal	renal	JJ	_	14	attr	_	_
14	function	function	NN	_	18	dep	_	_
15	should	should	MD	_	18	modal	_	_
16	be	be	VB	_	18	aux	_	_
17	carefully	carefully	RB	_	18	adv	_	_
18	monitored	monitor	VBN	_	4	conj	_	_
19	.	.	.	_	4	p	_	_

1	Capsules	capsule	NNS	_	6	dep	_	_
2	drug1	drug0	IN	_	5	case	_	_
3	50	0	CD	_	4	num	_	_
4	mg	mg	NN	_	5	com	_	_
5	t.i.d.	t.i.d.	NN	_	1	ppmod	_	_
6	produced	produce	VBD	_	0	root	_	_
7	a	a	DT	_	10	det	_	_
8	clinically	clinically	RB	_	9	adv	_	_
9	relevant	relevant	JJ	_	10	attr	_	_
10	elevation	elevation	NN	_	6	obj	_	_
11	of	of	IN	_	13	case	_	_
12	plasma	plasma	NN	_	13	com	_	_
13	drug2	drug0	NN	_	10	ppmod	_	_
14	and	and	CC	_	10	cc	_	_
15	reduction	reduction	NN	_	10	conj	_	_
16	in	in	IN	_	19	case	_	_
17	renal	renal	JJ	_	19	attr	_	_
18	drug3	drug0	NN	_	19	com	_	_
19	clearance	clearance	NN	_	15	ppmod	_	_
20	in	in	IN	_	22	case	_	_
21	psychiatric	psychiatric	JJ	_	22	attr	_	_
22	patients	patient	NNS	_	19	ppmod	_	_
23	and	and	CC	_	22	cc	_	_
24	normal	normal	JJ	_	25	attr	_	_
25	subjects	subject	NNS	_	22	conj	_	_
26	with	with	IN	_	31	case	_	_
27	steady	steady	JJ	_	31	attr	_	_
28	state	state	NN	_	31	com	_	_
29	plasma	plasma	NN	_	31	com	_	_
30	drug4	drug0	NN	_	31	com	_	_
31	concentrations	concentration	NNS	_	22	ppmod	_	_
32	.	.	.	_	6	p	_	_

1	This	this	DT	_	2	det	_	_
2	effect	effect	NN	_	5	dep	_	_
3	has	have	VBZ	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	attributed	attribute	VBN	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	inhibition	inhibition	NN	_	5	ppmod	_	_
8	of	of	IN	_	10	case	_	_
9	prostaglandin	prostaglandin	NN	_	10	com	_	_
10	synthesis	synthesis	NN	_	7	ppmod	_	_
11	.	.	.	_	5	p	_	_

1	As	as	IN	_	3	case	_	_
2	a	a	DT	_	3	det	_	_
3	consequence	consequence	NN	_	18	ppmod	_	_
4	,	,	,	_	18	p	_	_
5	when	when	WRB	_	10	adv	_	_
6	drug1	drug0	NN	_	10	dep	_	_
7	and	and	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	are	be	VBP	_	10	aux	_	_
10	given	give	VBN	_	18	advcl	_	_
11	concomitantly	concomitantly	RB	_	10	adv	_	_
12	,	,	,	_	18	p	_	_
13	the	the	DT	_	14	det	_	_
14	patient	patient	NN	_	18	dep	_	_
15	should	should	MD	_	18	modal	_	_
16	be	be	VB	_	18	aux	_	_
17	carefully	carefully	RB	_	18	adv	_	_
18	observed	observe	VBN	_	0	root	_	_
19	for	for	IN	_	20	case	_	_
20	signs	sign	NNS	_	18	ppmod	_	_
21	of	of	IN	_	23	case	_	_
22	drug3	drug0	NN	_	23	com	_	_
23	toxicity	toxicity	NN	_	20	ppmod	_	_
24	.	.	.	_	18	p	_	_

1	(	-lrb-	-LRB-	_	3	p	_	_
2	Read	read	VBN	_	3	attr	_	_
3	circulars	circular	NNS	_	0	root	_	_
4	for	for	IN	_	6	case	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	preparations	preparation	NNS	_	3	ppmod	_	_
7	before	before	IN	_	8	case	_	_
8	use	use	NN	_	3	ppmod	_	_
9	of	of	IN	_	12	case	_	_
10	such	such	JJ	_	12	attr	_	_
11	concomitant	concomitant	JJ	_	12	attr	_	_
12	therapy	therapy	NN	_	8	ppmod	_	_
13	.	.	.	_	3	p	_	_
14	)	-rrb-	-RRB-	_	3	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	13	ppmod	_	_
3	,	,	,	_	13	p	_	_
4	the	the	DT	_	5	det	_	_
5	frequency	frequency	NN	_	13	dep	_	_
6	of	of	IN	_	7	case	_	_
7	monitoring	monitor	VBG	_	5	ppmod	_	_
8	serum	serum	NN	_	10	com	_	_
9	drug1	drug0	NN	_	10	com	_	_
10	concentration	concentration	NN	_	7	obj	_	_
11	should	should	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	increased	increase	VBN	_	0	root	_	_
14	at	at	IN	_	16	case	_	_
15	the	the	DT	_	16	det	_	_
16	outset	outset	NN	_	13	ppmod	_	_
17	of	of	IN	_	21	case	_	_
18	such	such	JJ	_	21	attr	_	_
19	combination	combination	NN	_	21	com	_	_
20	drug	drug	NN	_	21	com	_	_
21	treatment	treatment	NN	_	16	ppmod	_	_
22	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	8	dep	_	_
2	given	give	VBN	_	1	acl	_	_
3	concomitantly	concomitantly	RB	_	2	adv	_	_
4	with	with	IN	_	5	case	_	_
5	drug2	drug0	NN	_	2	ppmod	_	_
6	has	have	VBZ	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	reported	report	VBN	_	0	root	_	_
9	to	to	TO	_	10	aux	_	_
10	increase	increase	VB	_	8	comp	_	_
11	the	the	DT	_	13	det	_	_
12	serum	serum	NN	_	13	com	_	_
13	concentration	concentration	NN	_	10	obj	_	_
14	and	and	CC	_	10	cc	_	_
15	prolong	prolong	VB	_	10	conj	_	_
16	the	the	DT	_	17	det	_	_
17	half-life	half-life	NN	_	15	obj	_	_
18	of	of	IN	_	19	case	_	_
19	drug3	drug0	NN	_	17	ppmod	_	_
20	.	.	.	_	8	p	_	_

1	Therefore	therefore	RB	_	17	adv	_	_
2	,	,	,	_	17	p	_	_
3	when	when	WRB	_	8	adv	_	_
4	drug1	drug0	NN	_	8	dep	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	are	be	VBP	_	8	aux	_	_
8	used	use	VBN	_	17	advcl	_	_
9	concomitantly	concomitantly	RB	_	8	adv	_	_
10	,	,	,	_	17	p	_	_
11	serum	serum	NN	_	13	com	_	_
12	drug3	drug0	NN	_	13	com	_	_
13	levels	level	NNS	_	17	dep	_	_
14	should	should	MD	_	17	modal	_	_
15	be	be	VB	_	17	aux	_	_
16	closely	closely	RB	_	17	adv	_	_
17	monitored	monitor	VBN	_	0	root	_	_
18	.	.	.	_	17	p	_	_

1	In	in	IN	_	3	case	_	_
2	some	some	DT	_	3	det	_	_
3	patients	patient	NNS	_	10	ppmod	_	_
4	,	,	,	_	10	p	_	_
5	the	the	DT	_	6	det	_	_
6	administration	administration	NN	_	10	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	can	can	MD	_	10	modal	_	_
10	reduce	reduce	VB	_	0	root	_	_
11	the	the	DT	_	18	det	_	_
12	diuretic	diuretic	JJ	_	18	attr	_	_
13	,	,	,	_	12	p	_	_
14	natriuretic	natriuretic	JJ	_	12	conj	_	_
15	,	,	,	_	14	p	_	_
16	and	and	CC	_	14	cc	_	_
17	antihypertensive	antihypertensive	JJ	_	12	conj	_	_
18	effects	effect	NNS	_	10	obj	_	_
19	of	of	IN	_	20	case	_	_
20	drug2	drug0	NN	_	18	ppmod	_	_
21	,	,	,	_	20	p	_	_
22	drug3	drug0	NN	_	20	conj	_	_
23	,	,	,	_	22	p	_	_
24	and	and	CC	_	22	cc	_	_
25	drug4	drug0	NN	_	20	conj	_	_
26	.	.	.	_	10	p	_	_

1	Therefore	therefore	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	when	when	IN	_	4	case	_	_
4	drug1	drug0	NN	_	0	root	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	.	.	.	_	4	p	_	_

1	(	-lrb-	-LRB-	_	4	p	_	_
2	drug1	drug0	NN	_	4	attr	_	_
3	)	-rrb-	-RRB-	_	4	p	_	_
4	drug2	drug0	NNS	_	6	dep	_	_
5	are	be	VBP	_	6	aux	_	_
6	used	use	VBN	_	13	advcl	_	_
7	concomitantly	concomitantly	RB	_	6	adv	_	_
8	,	,	,	_	13	p	_	_
9	the	the	DT	_	10	det	_	_
10	patient	patient	NN	_	13	dep	_	_
11	should	should	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	observed	observe	VBN	_	0	root	_	_
14	closely	closely	RB	_	13	adv	_	_
15	to	to	TO	_	16	aux	_	_
16	determine	determine	VB	_	13	comp	_	_
17	if	if	IN	_	25	mark	_	_
18	the	the	DT	_	20	det	_	_
19	desired	desired	JJ	_	20	attr	_	_
20	effect	effect	NN	_	25	dep	_	_
21	of	of	IN	_	23	case	_	_
22	the	the	DT	_	23	det	_	_
23	drug3	drug0	NN	_	20	ppmod	_	_
24	is	be	VBZ	_	25	aux	_	_
25	obtained	obtain	VBN	_	16	comp	_	_
26	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	reduces	reduce	VBZ	_	0	root	_	_
3	basal	basal	JJ	_	6	attr	_	_
4	plasma	plasma	NN	_	6	com	_	_
5	renin	renin	NN	_	6	com	_	_
6	activity	activity	NN	_	2	obj	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	PRA	pra	NN	_	6	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	,	,	,	_	6	p	_	_
11	as	as	RB	_	12	com	_	_
12	well	well	RB	_	6	cc	_	_
13	as	as	IN	_	12	com	_	_
14	those	those	DT	_	15	det	_	_
15	elevations	elevation	NNS	_	6	conj	_	_
16	of	of	IN	_	17	case	_	_
17	PRA	pra	NN	_	15	ppmod	_	_
18	induced	induce	VBN	_	17	acl	_	_
19	by	by	IN	_	21	case	_	_
20	drug2	drug0	NN	_	21	com	_	_
21	administration	administration	NN	_	18	ppmod	_	_
22	,	,	,	_	21	p	_	_
23	or	or	CC	_	21	cc	_	_
24	salt	salt	NN	_	21	conj	_	_
25	or	or	CC	_	24	cc	_	_
26	volume	volume	NN	_	27	com	_	_
27	depletion	depletion	NN	_	21	conj	_	_
28	.	.	.	_	2	p	_	_

1	These	these	DT	_	2	det	_	_
2	facts	fact	NNS	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	considered	consider	VBN	_	0	root	_	_
6	when	when	WRB	_	7	adv	_	_
7	evaluating	evaluate	VBG	_	5	comp	_	_
8	plasma	plasma	NN	_	9	com	_	_
9	renin	renin	NN	_	10	com	_	_
10	activity	activity	NN	_	7	obj	_	_
11	in	in	IN	_	13	case	_	_
12	hypertensive	hypertensive	JJ	_	13	attr	_	_
13	patients	patient	NNS	_	10	ppmod	_	_
14	.	.	.	_	5	p	_	_

1	It	it	PRP	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	reported	report	VBN	_	0	root	_	_
5	that	that	IN	_	16	mark	_	_
6	the	the	DT	_	7	det	_	_
7	addition	addition	NN	_	16	dep	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	to	to	TO	_	13	aux	_	_
11	a	a	DT	_	13	det	_	_
12	maintenance	maintenance	NN	_	13	com	_	_
13	schedule	schedule	NN	_	7	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	resulted	result	VBD	_	4	comp	_	_
17	in	in	IN	_	21	case	_	_
18	reversible	reversible	JJ	_	21	attr	_	_
19	acute	acute	JJ	_	21	attr	_	_
20	renal	renal	JJ	_	21	attr	_	_
21	failure	failure	NN	_	16	ppmod	_	_
22	in	in	IN	_	23	case	_	_
23	two	#crd#	CD	_	21	ppmod	_	_
24	of	of	IN	_	27	case	_	_
25	four	#crd#	CD	_	27	num	_	_
26	healthy	healthy	JJ	_	27	attr	_	_
27	volunteers	volunteer	NNS	_	23	ppmod	_	_
28	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	7	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	should	should	MD	_	7	modal	_	_
5	not	not	RB	_	7	neg	_	_
6	be	be	VB	_	7	aux	_	_
7	administered	administer	VBN	_	0	root	_	_
8	together	together	RB	_	7	adv	_	_
9	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	7	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	each	each	DT	_	1	appo	_	_
5	may	may	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	associated	associate	VBN	_	0	root	_	_
8	with	with	IN	_	12	case	_	_
9	increased	increase	VBN	_	12	attr	_	_
10	serum	serum	NN	_	12	com	_	_
11	potassium	potassium	NN	_	12	com	_	_
12	levels	level	NNS	_	7	ppmod	_	_
13	.	.	.	_	7	p	_	_

1	The	the	DT	_	3	det	_	_
2	potential	potential	JJ	_	3	attr	_	_
3	effects	effect	NNS	_	16	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	on	on	IN	_	10	case	_	_
9	potassium	potassium	NN	_	10	com	_	_
10	kinetics	kinetics	NNS	_	3	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	renal	renal	JJ	_	13	attr	_	_
13	function	function	NN	_	10	conj	_	_
14	should	should	MD	_	16	modal	_	_
15	be	be	VB	_	16	aux	_	_
16	considered	consider	VBN	_	0	root	_	_
17	when	when	WRB	_	21	adv	_	_
18	these	these	DT	_	19	det	_	_
19	agents	agent	NNS	_	21	dep	_	_
20	are	be	VBP	_	21	aux	_	_
21	administered	administer	VBN	_	16	comp	_	_
22	concurrently	concurrently	RB	_	21	adv	_	_
23	.	.	.	_	16	p	_	_

1	Most	most	JJS	_	10	dep	_	_
2	of	of	IN	_	5	case	_	_
3	the	the	DT	_	5	det	_	_
4	above	above	JJ	_	5	attr	_	_
5	effects	effect	NNS	_	1	ppmod	_	_
6	concerning	concern	VBG	_	5	acl	_	_
7	drug1	drug0	NN	_	6	obj	_	_
8	have	have	VBP	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	attributed	attribute	VBN	_	0	root	_	_
11	,	,	,	_	10	p	_	_
12	at	at	IN	_	13	case	_	_
13	least	least	JJS	_	15	adv	_	_
14	in	in	IN	_	15	case	_	_
15	part	part	NN	_	10	ppmod	_	_
16	,	,	,	_	10	p	_	_
17	to	to	TO	_	18	aux	_	_
18	mechanisms	mechanism	NNS	_	10	ppmod	_	_
19	involving	involve	VBG	_	18	acl	_	_
20	inhibition	inhibition	NN	_	19	obj	_	_
21	of	of	IN	_	23	case	_	_
22	prostaglandin	prostaglandin	NN	_	23	com	_	_
23	synthesis	synthesis	NN	_	20	ppmod	_	_
24	by	by	IN	_	25	case	_	_
25	drug2	drug0	NN	_	20	ppmod	_	_
26	.	.	.	_	10	p	_	_

1	Blunting	blunting	NN	_	14	dep	_	_
2	of	of	IN	_	5	case	_	_
3	the	the	DT	_	5	det	_	_
4	antihypertensive	antihypertensive	JJ	_	5	attr	_	_
5	effect	effect	NN	_	1	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	by	by	IN	_	9	case	_	_
9	drug2	drug0	NNS	_	1	ppmod	_	_
10	including	include	VBG	_	11	adv	_	_
11	drug3	drug0	NN	_	9	ppmod	_	_
12	has	have	VBZ	_	14	aux	_	_
13	been	be	VBN	_	14	aux	_	_
14	reported	report	VBN	_	0	root	_	_
15	.	.	.	_	14	p	_	_

1	Therefore	therefore	RB	_	15	adv	_	_
2	,	,	,	_	15	p	_	_
3	when	when	WRB	_	4	adv	_	_
4	using	use	VBG	_	15	advcl	_	_
5	these	these	DT	_	7	det	_	_
6	blocking	block	VBG	_	7	attr	_	_
7	agents	agent	NNS	_	4	obj	_	_
8	to	to	TO	_	9	aux	_	_
9	treat	treat	VB	_	4	comp	_	_
10	hypertension	hypertension	NN	_	9	obj	_	_
11	,	,	,	_	15	p	_	_
12	patients	patient	NNS	_	15	dep	_	_
13	should	should	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	observed	observe	VBN	_	0	root	_	_
16	carefully	carefully	RB	_	15	adv	_	_
17	in	in	IN	_	20	mark	_	_
18	order	order	NN	_	20	dep	_	_
19	to	to	TO	_	20	aux	_	_
20	confirm	confirm	VB	_	15	comp	_	_
21	that	that	IN	_	28	mark	_	_
22	the	the	DT	_	25	det	_	_
23	desired	desired	JJ	_	25	attr	_	_
24	therapeutic	therapeutic	JJ	_	25	attr	_	_
25	effect	effect	NN	_	28	dep	_	_
26	has	have	VBZ	_	28	aux	_	_
27	been	be	VBN	_	28	aux	_	_
28	obtained	obtain	VBN	_	20	comp	_	_
29	.	.	.	_	15	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	can	can	MD	_	3	modal	_	_
3	reduce	reduce	VB	_	0	root	_	_
4	the	the	DT	_	6	det	_	_
5	antihypertensive	antihypertensive	JJ	_	6	attr	_	_
6	effects	effect	NNS	_	3	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	drug3	drug0	NN	_	8	conj	_	_
11	.	.	.	_	3	p	_	_

1	False-negative	false-negative	JJ	_	2	attr	_	_
2	results	result	NNS	_	19	dep	_	_
3	in	in	IN	_	7	case	_	_
4	the	the	DT	_	7	det	_	_
5	dexamethasone	dexamethasone	NN	_	7	com	_	_
6	suppression	suppression	NN	_	7	com	_	_
7	test	test	NN	_	2	ppmod	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	DST	dst	NN	_	7	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	in	in	IN	_	12	case	_	_
12	patients	patient	NNS	_	7	ppmod	_	_
13	being	be	VBG	_	14	aux	_	_
14	treated	treat	VBN	_	12	acl	_	_
15	with	with	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	have	have	VBP	_	19	aux	_	_
18	been	be	VBN	_	19	aux	_	_
19	reported	report	VBN	_	0	root	_	_
20	.	.	.	_	19	p	_	_

1	Thus	thus	RB	_	9	adv	_	_
2	,	,	,	_	9	p	_	_
3	results	result	NNS	_	9	dep	_	_
4	of	of	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	DST	dst	NN	_	3	ppmod	_	_
7	should	should	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	interpreted	interpret	VBN	_	0	root	_	_
10	with	with	IN	_	11	case	_	_
11	caution	caution	NN	_	9	ppmod	_	_
12	in	in	IN	_	14	case	_	_
13	these	these	DT	_	14	det	_	_
14	patients	patient	NNS	_	9	ppmod	_	_
15	.	.	.	_	9	p	_	_

1	Patients	patient	NNS	_	6	dep	_	_
2	on	on	IN	_	4	case	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	therapy	therapy	NN	_	1	ppmod	_	_
5	may	may	MD	_	6	modal	_	_
6	require	require	VB	_	0	root	_	_
7	dosage	dosage	NN	_	8	com	_	_
8	adjustment	adjustment	NN	_	6	obj	_	_
9	of	of	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	anticoagulant	anticoagulant	NN	_	8	ppmod	_	_
12	during	during	IN	_	6	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	after	after	IN	_	16	case	_	_
15	drug2	drug0	NN	_	16	com	_	_
16	therapy	therapy	NN	_	12	conj	_	_
17	.	.	.	_	6	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	use	use	NN	_	6	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	usually	usually	RB	_	6	adv	_	_
6	depresses	depress	VBZ	_	0	root	_	_
7	drug2	drug0	NN	_	8	com	_	_
8	activity	activity	NN	_	6	obj	_	_
9	and	and	CC	_	6	cc	_	_
10	may	may	MD	_	11	modal	_	_
11	necessitate	necessitate	VBP	_	6	conj	_	_
12	raising	raise	VBG	_	11	comp	_	_
13	the	the	DT	_	14	det	_	_
14	dosage	dosage	NN	_	12	obj	_	_
15	.	.	.	_	6	p	_	_

1	The	the	DT	_	3	det	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	administration	administration	NN	_	8	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	has	have	VBZ	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	reported	report	VBN	_	0	root	_	_
9	to	to	TO	_	10	aux	_	_
10	reduce	reduce	VB	_	8	comp	_	_
11	the	the	DT	_	12	det	_	_
12	efficacy	efficacy	NN	_	10	obj	_	_
13	of	of	IN	_	15	case	_	_
14	oral	oral	JJ	_	15	attr	_	_
15	drug2	drug0	NN	_	12	ppmod	_	_
16	and	and	CC	_	10	cc	_	_
17	to	to	TO	_	18	aux	_	_
18	increase	increase	VB	_	10	conj	_	_
19	the	the	DT	_	20	det	_	_
20	incidence	incidence	NN	_	18	obj	_	_
21	of	of	IN	_	23	case	_	_
22	breakthrough	breakthrough	JJ	_	23	attr	_	_
23	bleeding	bleeding	JJ	_	20	ppmod	_	_
24	.	.	.	_	8	p	_	_

1	The	the	DT	_	3	det	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	administration	administration	NN	_	14	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	9	attr	_	_
8	-containing	-containing	JJ	_	9	attr	_	_
9	drug3	drug0	NN	_	5	conj	_	_
10	has	have	VBZ	_	14	aux	_	_
11	not	not	RB	_	14	neg	_	_
12	been	be	VBN	_	14	aux	_	_
13	formally	formally	RB	_	14	adv	_	_
14	studied	study	VBN	_	0	root	_	_
15	.	.	.	_	14	p	_	_

1	Although	although	IN	_	3	mark	_	_
2	drug1	drug0	NN	_	3	dep	_	_
3	has	have	VBZ	_	17	advcl	_	_
4	a	a	DT	_	6	det	_	_
5	lower	low	JJR	_	6	attr	_	_
6	affinity	affinity	NN	_	3	obj	_	_
7	for	for	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	than	than	IN	_	11	case	_	_
10	for	for	IN	_	11	case	_	_
11	drug3	drug0	NN	_	6	ppmod	_	_
12	,	,	,	_	17	p	_	_
13	drug4	drug0	NN	_	17	dep	_	_
14	should	should	MD	_	17	modal	_	_
15	not	not	RB	_	17	neg	_	_
16	be	be	VB	_	17	aux	_	_
17	taken	take	VBN	_	0	root	_	_
18	with	with	IN	_	21	case	_	_
19	drug5	drug0	NN	_	20	advnp	_	_
20	-containing	-containing	JJ	_	21	attr	_	_
21	drug6	drug0	NN	_	17	ppmod	_	_
22	.	.	.	_	17	p	_	_

1	In	in	IN	_	3	case	_	_
2	healthy	healthy	JJ	_	3	attr	_	_
3	volunteers	volunteer	NNS	_	6	ppmod	_	_
4	,	,	,	_	6	p	_	_
5	drug1	drug0	NN	_	6	dep	_	_
6	had	have	VBD	_	0	root	_	_
7	no	no	DT	_	8	det	_	_
8	effect	effect	NN	_	6	obj	_	_
9	on	on	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	pharmacokinetics	pharmacokinetics	NNS	_	6	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	.	.	.	_	6	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	11	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	on	on	IN	_	7	case	_	_
6	drug2	drug0	NN	_	7	com	_	_
7	pharmacokinetics	pharmacokinetics	NNS	_	2	ppmod	_	_
8	has	have	VBZ	_	11	aux	_	_
9	not	not	RB	_	11	neg	_	_
10	been	be	VBN	_	11	aux	_	_
11	studied	study	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	The	the	DT	_	3	det	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	administration	administration	NN	_	12	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	has	have	VBZ	_	12	aux	_	_
9	not	not	RB	_	12	neg	_	_
10	been	be	VBN	_	12	aux	_	_
11	formally	formally	RB	_	12	adv	_	_
12	studied	study	VBN	_	0	root	_	_
13	.	.	.	_	12	p	_	_

1	Doses	dose	NNS	_	9	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	up	up	RB	_	6	adv	_	_
5	to	to	TO	_	6	attr	_	_
6	200	0	CD	_	7	num	_	_
7	mg	mg	NN	_	1	appo	_	_
8	were	be	VBD	_	9	aux	_	_
9	allowed	allow	VBN	_	0	root	_	_
10	in	in	IN	_	12	case	_	_
11	clinical	clinical	JJ	_	12	attr	_	_
12	studies	study	NNS	_	9	ppmod	_	_
13	without	without	IN	_	15	case	_	_
14	negative	negative	JJ	_	15	attr	_	_
15	consequences	consequence	NNS	_	12	ppmod	_	_
16	.	.	.	_	9	p	_	_

1	The	the	DT	_	2	det	_	_
2	interaction	interaction	NN	_	11	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	with	with	IN	_	6	case	_	_
6	drug2	drug0	NN	_	2	ppmod	_	_
7	has	have	VBZ	_	11	aux	_	_
8	not	not	RB	_	11	neg	_	_
9	been	be	VBN	_	11	aux	_	_
10	formally	formally	RB	_	11	adv	_	_
11	studied	study	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	No	no	DT	_	2	det	_	_
2	inhibition	inhibition	NN	_	9	dep	_	_
3	of	of	IN	_	5	case	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	metabolism	metabolism	NN	_	2	ppmod	_	_
6	by	by	IN	_	7	case	_	_
7	drug2	drug0	NN	_	2	ppmod	_	_
8	is	be	VBZ	_	9	aux	_	_
9	expected	expect	VBN	_	0	root	_	_
10	based	base	VBN	_	13	adv	_	_
11	on	on	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	results	result	NNS	_	9	ppmod	_	_
14	of	of	IN	_	18	case	_	_
15	an	an	DT	_	18	det	_	_
16	in	in	FW	_	17	adv	_	_
17	vitro	vitro	FW	_	18	attr	_	_
18	study	study	NN	_	13	ppmod	_	_
19	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	should	should	MD	_	5	modal	_	_
3	not	not	RB	_	5	neg	_	_
4	be	be	VB	_	5	aux	_	_
5	combined	combine	VBN	_	0	root	_	_
6	with	with	IN	_	10	case	_	_
7	other	other	JJ	_	10	attr	_	_
8	iron	iron	NN	_	10	com	_	_
9	chelator	chelator	NN	_	10	com	_	_
10	therapies	therapy	NNS	_	5	ppmod	_	_
11	,	,	,	_	5	p	_	_
12	as	as	IN	_	20	mark	_	_
13	safety	safety	NN	_	20	dep	_	_
14	of	of	IN	_	16	case	_	_
15	such	such	JJ	_	16	attr	_	_
16	combinations	combination	NNS	_	13	ppmod	_	_
17	has	have	VBZ	_	20	aux	_	_
18	not	not	RB	_	20	neg	_	_
19	been	be	VBN	_	20	aux	_	_
20	established	establish	VBN	_	5	comp	_	_
21	.	.	.	_	5	p	_	_

1	Drug/Food	drug/food	NN	_	2	com	_	_
2	Interactions	interaction	NNS	_	12	dep	_	_
3	The	the	DT	_	4	det	_	_
4	bioavailability	bioavailability	NN	_	2	attr	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	AUC	auc	NN	_	4	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	2	ppmod	_	_
10	was	be	VBD	_	12	aux	_	_
11	variably	variably	RB	_	12	adv	_	_
12	increased	increase	VBN	_	0	root	_	_
13	when	when	WRB	_	14	adv	_	_
14	taken	take	VBN	_	12	comp	_	_
15	with	with	IN	_	17	case	_	_
16	a	a	DT	_	17	det	_	_
17	meal	meal	NN	_	14	ppmod	_	_
18	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	taken	take	VBN	_	0	root	_	_
5	on	on	IN	_	8	case	_	_
6	an	an	DT	_	8	det	_	_
7	empty	empty	JJ	_	8	attr	_	_
8	stomach	stomach	NN	_	4	ppmod	_	_
9	30	0	CD	_	10	num	_	_
10	minutes	minute	NNS	_	12	dat	_	_
11	before	before	IN	_	12	case	_	_
12	eating	eating	NN	_	4	ppmod	_	_
13	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	tablets	tablet	NNS	_	8	dep	_	_
3	for	for	IN	_	5	case	_	_
4	oral	oral	JJ	_	5	attr	_	_
5	suspension	suspension	NN	_	2	ppmod	_	_
6	can	can	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	dispersed	disperse	VBN	_	0	root	_	_
9	in	in	IN	_	10	case	_	_
10	water	water	NN	_	8	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	orange	orange	NN	_	13	com	_	_
13	juice	juice	NN	_	10	conj	_	_
14	,	,	,	_	13	p	_	_
15	or	or	CC	_	13	cc	_	_
16	apple	apple	NN	_	17	com	_	_
17	juice	juice	NN	_	10	conj	_	_
18	.	.	.	_	8	p	_	_

1	The	the	DT	_	2	det	_	_
2	use	use	NN	_	12	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	in	in	IN	_	6	case	_	_
6	patients	patient	NNS	_	2	ppmod	_	_
7	who	who	WP	_	9	dep	_	_
8	are	be	VBP	_	9	aux	_	_
9	receiving	receive	VBG	_	6	relcl	_	_
10	drug2	drug0	NN	_	9	obj	_	_
11	may	may	MD	_	12	modal	_	_
12	potentiate	potentiate	VB	_	0	root	_	_
13	renal	renal	JJ	_	15	attr	_	_
14	disease	disease	NN	_	15	com	_	_
15	states	state	NNS	_	12	obj	_	_
16	.	.	.	_	12	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	studies	study	NNS	_	5	dep	_	_
4	have	have	VBP	_	5	aux	_	_
5	shown	show	VBN	_	0	root	_	_
6	that	that	IN	_	18	mark	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	anion	anion	NN	_	18	dep	_	_
9	,	,	,	_	18	p	_	_
10	because	because	IN	_	13	case	_	_
11	of	of	IN	_	13	case	_	_
12	its	its	PRP$	_	13	poss	_	_
13	affinity	affinity	NN	_	18	ppmod	_	_
14	for	for	IN	_	15	case	_	_
15	protein	protein	NN	_	13	ppmod	_	_
16	,	,	,	_	18	p	_	_
17	may	may	MD	_	18	modal	_	_
18	displace	displace	VB	_	5	comp	_	_
19	from	from	IN	_	22	case	_	_
20	their	their	PRP$	_	22	poss	_	_
21	binding	binding	NN	_	22	com	_	_
22	sites	site	NNS	_	18	ppmod	_	_
23	other	other	JJ	_	24	attr	_	_
24	drugs	drug	NNS	_	18	obj	_	_
25	which	which	WDT	_	26	dep	_	_
26	are	be	VBP	_	24	relcl	_	_
27	also	also	RB	_	26	adv	_	_
28	albumin-bound	albumin-bound	JJ	_	26	dep	_	_
29	.	.	.	_	5	p	_	_

1	Theoretically	theoretically	RB	_	10	adv	_	_
2	,	,	,	_	10	p	_	_
3	the	the	DT	_	5	det	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	anion	anion	NN	_	10	dep	_	_
6	itself	itself	PRP	_	5	attr	_	_
7	could	could	MD	_	10	modal	_	_
8	likewise	likewise	RB	_	10	adv	_	_
9	be	be	VB	_	10	aux	_	_
10	displaced	displace	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	Short-term	short-term	JJ	_	3	attr	_	_
2	controlled	controlled	JJ	_	3	attr	_	_
3	studies	study	NNS	_	4	dep	_	_
4	failed	fail	VBD	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	show	show	VB	_	4	comp	_	_
7	that	that	IN	_	12	mark	_	_
8	taking	take	VBG	_	12	advcl	_	_
9	the	the	DT	_	10	det	_	_
10	drug	drug	NN	_	8	obj	_	_
11	significantly	significantly	RB	_	12	adv	_	_
12	affects	affect	VBZ	_	6	comp	_	_
13	prothrombin	prothrombin	NN	_	14	com	_	_
14	times	time	NNS	_	12	obj	_	_
15	when	when	WRB	_	16	adv	_	_
16	administered	administer	VBN	_	12	comp	_	_
17	to	to	TO	_	18	aux	_	_
18	individuals	individual	NNS	_	16	ppmod	_	_
19	on	on	IN	_	20	case	_	_
20	drug1	drug0	NN	_	18	ppmod	_	_
21	.	.	.	_	4	p	_	_

1	Caution	caution	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	advised	advise	VBN	_	0	root	_	_
4	nonetheless	nonetheless	RB	_	3	adv	_	_
5	,	,	,	_	3	p	_	_
6	since	since	IN	_	10	mark	_	_
7	interactions	interaction	NNS	_	10	dep	_	_
8	have	have	VBP	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	seen	see	VBN	_	3	comp	_	_
11	with	with	IN	_	14	case	_	_
12	other	other	JJ	_	14	attr	_	_
13	nonsteroidal	nonsteroidal	JJ	_	14	attr	_	_
14	agents	agent	NNS	_	10	ppmod	_	_
15	of	of	IN	_	17	case	_	_
16	this	this	DT	_	17	det	_	_
17	class	class	NN	_	14	ppmod	_	_
18	.	.	.	_	3	p	_	_

1	Similarly	similarly	RB	_	16	adv	_	_
2	,	,	,	_	16	p	_	_
3	patients	patient	NNS	_	16	dep	_	_
4	receiving	receive	VBG	_	3	acl	_	_
5	the	the	DT	_	6	det	_	_
6	drug	drug	NN	_	4	obj	_	_
7	and	and	CC	_	6	cc	_	_
8	a	a	DT	_	9	det	_	_
9	drug1	drug0	NN	_	6	conj	_	_
10	,	,	,	_	9	p	_	_
11	drug2	drug0	NN	_	9	conj	_	_
12	or	or	CC	_	11	cc	_	_
13	drug3	drug0	NN	_	9	conj	_	_
14	should	should	MD	_	16	modal	_	_
15	be	be	VB	_	16	aux	_	_
16	observed	observe	VBN	_	0	root	_	_
17	for	for	IN	_	18	case	_	_
18	signs	sign	NNS	_	16	ppmod	_	_
19	of	of	IN	_	20	case	_	_
20	toxicity	toxicity	NN	_	18	ppmod	_	_
21	to	to	TO	_	23	aux	_	_
22	these	these	DT	_	23	det	_	_
23	drugs	drug	NNS	_	20	ppmod	_	_
24	.	.	.	_	16	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	administration	administration	NN	_	9	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	is	be	VBZ	_	9	aux	_	_
8	not	not	RB	_	9	neg	_	_
9	recommended	recommend	VBN	_	0	root	_	_
10	because	because	IN	_	13	mark	_	_
11	drug3	drug0	NN	_	13	dep	_	_
12	is	be	VBZ	_	13	aux	_	_
13	displaced	displace	VBN	_	9	comp	_	_
14	from	from	IN	_	17	case	_	_
15	its	its	PRP$	_	17	poss	_	_
16	binding	binding	NN	_	17	com	_	_
17	sites	site	NNS	_	13	ppmod	_	_
18	during	during	IN	_	21	case	_	_
19	the	the	DT	_	21	det	_	_
20	concomitant	concomitant	JJ	_	21	attr	_	_
21	administration	administration	NN	_	13	ppmod	_	_
22	of	of	IN	_	23	case	_	_
23	drug4	drug0	NN	_	21	ppmod	_	_
24	,	,	,	_	13	p	_	_
25	resulting	result	VBG	_	13	comp	_	_
26	in	in	IN	_	29	case	_	_
27	lower	low	JJR	_	29	attr	_	_
28	plasma	plasma	NN	_	29	com	_	_
29	concentrations	concentration	NNS	_	25	ppmod	_	_
30	and	and	CC	_	29	cc	_	_
31	peak	peak	NN	_	33	com	_	_
32	plasma	plasma	NN	_	33	com	_	_
33	levels	level	NNS	_	29	conj	_	_
34	.	.	.	_	9	p	_	_

1	The	the	DT	_	3	det	_	_
2	natriuretic	natriuretic	JJ	_	3	attr	_	_
3	effect	effect	NN	_	8	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	has	have	VBZ	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	reported	report	VBN	_	0	root	_	_
9	to	to	TO	_	11	aux	_	_
10	be	be	VB	_	11	aux	_	_
11	inhibited	inhibit	VBN	_	8	comp	_	_
12	by	by	IN	_	14	case	_	_
13	some	some	DT	_	14	det	_	_
14	drugs	drug	NNS	_	11	ppmod	_	_
15	of	of	IN	_	17	case	_	_
16	this	this	DT	_	17	det	_	_
17	class	class	NN	_	14	ppmod	_	_
18	.	.	.	_	8	p	_	_

1	Inhibition	inhibition	NN	_	16	dep	_	_
2	of	of	IN	_	5	case	_	_
3	renal	renal	JJ	_	5	attr	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	clearance	clearance	NN	_	1	ppmod	_	_
6	leading	lead	VBG	_	5	acl	_	_
7	to	to	TO	_	8	aux	_	_
8	increases	increase	NNS	_	6	ppmod	_	_
9	in	in	IN	_	12	case	_	_
10	plasma	plasma	NN	_	12	com	_	_
11	drug2	drug0	NN	_	12	com	_	_
12	concentrations	concentration	NNS	_	8	ppmod	_	_
13	has	have	VBZ	_	16	aux	_	_
14	also	also	RB	_	16	adv	_	_
15	been	be	VBN	_	16	aux	_	_
16	reported	report	VBN	_	0	root	_	_
17	.	.	.	_	16	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	other	other	JJ	_	4	attr	_	_
4	drug2	drug0	NN	_	1	conj	_	_
5	can	can	MD	_	6	modal	_	_
6	reduce	reduce	VB	_	0	root	_	_
7	the	the	DT	_	9	det	_	_
8	antihypertensive	antihypertensive	JJ	_	9	attr	_	_
9	effect	effect	NN	_	6	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug3	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	other	other	JJ	_	14	attr	_	_
14	drug4	drug0	NN	_	11	conj	_	_
15	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	given	give	VBN	_	1	acl	_	_
3	concurrently	concurrently	RB	_	2	adv	_	_
4	increases	increase	VBZ	_	0	root	_	_
5	drug2	drug0	NN	_	8	com	_	_
6	anion	anion	NN	_	8	com	_	_
7	plasma	plasma	NN	_	8	com	_	_
8	levels	level	NNS	_	4	obj	_	_
9	and	and	CC	_	4	cc	_	_
10	extends	extend	VBZ	_	4	conj	_	_
11	its	its	PRP$	_	13	poss	_	_
12	plasma	plasma	NN	_	13	com	_	_
13	half-life	half-life	NN	_	10	obj	_	_
14	significantly	significantly	RB	_	10	adv	_	_
15	.	.	.	_	4	p	_	_

1	Caution	caution	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	used	use	VBN	_	0	root	_	_
5	if	if	IN	_	8	mark	_	_
6	drug1	drug0	NN	_	8	dep	_	_
7	is	be	VBZ	_	8	aux	_	_
8	administered	administer	VBN	_	4	comp	_	_
9	concomitantly	concomitantly	RB	_	8	adv	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NN	_	8	ppmod	_	_
12	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	9	dep	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	and	and	CC	_	3	cc	_	_
5	other	other	JJ	_	6	attr	_	_
6	drug3	drug0	NN	_	1	conj	_	_
7	have	have	VBP	_	9	aux	_	_
8	been	be	VBN	_	9	aux	_	_
9	reported	report	VBN	_	0	root	_	_
10	to	to	TO	_	11	aux	_	_
11	reduce	reduce	VB	_	9	comp	_	_
12	the	the	DT	_	14	det	_	_
13	tubular	tubular	JJ	_	14	attr	_	_
14	secretion	secretion	NN	_	11	obj	_	_
15	of	of	IN	_	16	case	_	_
16	drug4	drug0	NN	_	14	ppmod	_	_
17	in	in	IN	_	20	case	_	_
18	an	an	DT	_	20	det	_	_
19	animal	animal	JJ	_	20	attr	_	_
20	model	model	NN	_	14	ppmod	_	_
21	,	,	,	_	11	p	_	_
22	possibly	possibly	RB	_	23	adv	_	_
23	increasing	increase	VBG	_	11	comp	_	_
24	the	the	DT	_	25	det	_	_
25	toxicity	toxicity	NN	_	23	obj	_	_
26	of	of	IN	_	27	case	_	_
27	drug5	drug0	NN	_	25	ppmod	_	_
28	.	.	.	_	9	p	_	_

1	Drug/Laboratory	drug/laboratory	JJ	_	3	attr	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	6	dep	_	_
4	drug1	drug0	NN	_	3	attr	_	_
5	may	may	MD	_	6	modal	_	_
6	decrease	decrease	VB	_	0	root	_	_
7	platelet	platelet	NN	_	8	com	_	_
8	aggregation	aggregation	NN	_	6	obj	_	_
9	and	and	CC	_	6	cc	_	_
10	prolong	prolong	VB	_	6	conj	_	_
11	bleeding	bleeding	JJ	_	12	attr	_	_
12	time	time	NN	_	10	obj	_	_
13	.	.	.	_	6	p	_	_

1	This	this	DT	_	2	det	_	_
2	effect	effect	NN	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	kept	keep	VBN	_	0	root	_	_
6	in	in	IN	_	7	case	_	_
7	mind	mind	NN	_	5	ppmod	_	_
8	when	when	WRB	_	12	adv	_	_
9	bleeding	bleeding	JJ	_	10	attr	_	_
10	times	time	NNS	_	12	dep	_	_
11	are	be	VBP	_	12	aux	_	_
12	determined	determine	VBN	_	5	comp	_	_
13	.	.	.	_	5	p	_	_

1	The	the	DT	_	2	det	_	_
2	administration	administration	NN	_	6	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	may	may	MD	_	6	modal	_	_
6	result	result	VB	_	0	root	_	_
7	in	in	IN	_	10	case	_	_
8	increased	increase	VBN	_	10	attr	_	_
9	urinary	urinary	JJ	_	10	attr	_	_
10	values	value	NNS	_	6	ppmod	_	_
11	for	for	IN	_	13	case	_	_
12	17-ketogenic	0-ketogenic	JJ	_	13	attr	_	_
13	steroids	steroid	NNS	_	10	ppmod	_	_
14	because	because	IN	_	17	case	_	_
15	of	of	IN	_	17	case	_	_
16	an	an	DT	_	17	det	_	_
17	interaction	interaction	NN	_	6	ppmod	_	_
18	between	between	IN	_	20	case	_	_
19	the	the	DT	_	20	det	_	_
20	drug	drug	NN	_	17	ppmod	_	_
21	and/or	and/or	CC	_	20	cc	_	_
22	its	its	PRP$	_	23	poss	_	_
23	metabolites	metabolite	NNS	_	20	conj	_	_
24	with	with	IN	_	25	case	_	_
25	m-dinitrobenzene	m-dinitrobenzene	NN	_	17	ppmod	_	_
26	used	use	VBN	_	25	acl	_	_
27	in	in	IN	_	29	case	_	_
28	this	this	DT	_	29	det	_	_
29	assay	assay	NN	_	26	ppmod	_	_
30	.	.	.	_	6	p	_	_

1	Although	although	IN	_	10	mark	_	_
2	17-hydroxy-corticosteroid	0-hydroxy-corticosteroid	JJ	_	3	attr	_	_
3	measurements	measurement	NNS	_	10	dep	_	_
4	(	-lrb-	-LRB-	_	6	p	_	_
5	Porter-Silber	porter-silber	NN	_	6	com	_	_
6	test	test	NN	_	3	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	do	do	VBP	_	10	aux	_	_
9	not	not	RB	_	10	neg	_	_
10	appear	appear	VB	_	18	advcl	_	_
11	to	to	TO	_	14	aux	_	_
12	be	be	VB	_	14	aux	_	_
13	artifactually	artifactually	RB	_	14	adv	_	_
14	altered	alter	VBN	_	10	comp	_	_
15	,	,	,	_	18	p	_	_
16	it	it	PRP	_	18	dep	_	_
17	is	be	VBZ	_	18	aux	_	_
18	suggested	suggest	VBN	_	0	root	_	_
19	that	that	IN	_	25	mark	_	_
20	therapy	therapy	NN	_	25	dep	_	_
21	with	with	IN	_	22	case	_	_
22	drug1	drug0	NN	_	20	ppmod	_	_
23	be	be	VB	_	25	aux	_	_
24	temporarily	temporarily	RB	_	25	adv	_	_
25	discontinued	discontinue	VBN	_	18	comp	_	_
26	72	0	CD	_	27	num	_	_
27	hours	hour	NNS	_	31	dat	_	_
28	before	before	IN	_	31	case	_	_
29	adrenal	adrenal	JJ	_	31	attr	_	_
30	function	function	NN	_	31	com	_	_
31	tests	test	NNS	_	25	ppmod	_	_
32	are	be	VBP	_	33	aux	_	_
33	performed	performed	VBN	_	31	acl	_	_
34	if	if	IN	_	38	mark	_	_
35	the	the	DT	_	37	det	_	_
36	Porter-Silber	porter-silber	NN	_	37	com	_	_
37	test	test	NN	_	38	dep	_	_
38	is	be	VBZ	_	33	comp	_	_
39	to	to	TO	_	41	aux	_	_
40	be	be	VB	_	41	aux	_	_
41	used	use	VBN	_	38	comp	_	_
42	.	.	.	_	18	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	interfere	interfere	VB	_	0	root	_	_
4	with	with	IN	_	7	case	_	_
5	some	some	DT	_	7	det	_	_
6	urinary	urinary	JJ	_	7	attr	_	_
7	assays	assay	NNS	_	3	ppmod	_	_
8	of	of	IN	_	11	case	_	_
9	5-hydroxy	0-hydroxy	JJ	_	11	attr	_	_
10	indoleacetic	indoleacetic	JJ	_	11	attr	_	_
11	acid	acid	NN	_	7	ppmod	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	5HIAA	0hiaa	NN	_	11	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	.	.	.	_	3	p	_	_

1	The	the	DT	_	3	det	_	_
2	concurrent	concurrent	JJ	_	3	attr	_	_
3	use	use	NN	_	38	dep	_	_
4	of	of	IN	_	8	case	_	_
5	two	#crd#	CD	_	8	num	_	_
6	or	or	CC	_	5	cc	_	_
7	more	more	JJR	_	5	conj	_	_
8	drugs	drug	NNS	_	3	ppmod	_	_
9	with	with	IN	_	11	case	_	_
10	anticholinergic	anticholinergic	JJ	_	11	attr	_	_
11	activity--such	activity--such	NN	_	8	ppmod	_	_
12	as	as	IN	_	14	case	_	_
13	an	an	DT	_	14	det	_	_
14	drug1	drug0	NN	_	8	ppmod	_	_
15	(	-lrb-	-LRB-	_	18	p	_	_
16	eg	eg	NN	_	18	dep	_	_
17	,	,	,	_	18	p	_	_
18	drug2	drug0	NN	_	14	prn	_	_
19	)	-rrb-	-RRB-	_	18	p	_	_
20	,	,	,	_	14	p	_	_
21	an	an	DT	_	22	det	_	_
22	drug3	drug0	NN	_	14	conj	_	_
23	(	-lrb-	-LRB-	_	26	p	_	_
24	eg	eg	NN	_	26	dep	_	_
25	,	,	,	_	26	p	_	_
26	drug4	drug0	NN	_	22	prn	_	_
27	)	-rrb-	-RRB-	_	26	p	_	_
28	,	,	,	_	22	p	_	_
29	and/or	and/or	CC	_	22	cc	_	_
30	a	a	DT	_	31	det	_	_
31	drug5	drug0	NN	_	14	conj	_	_
32	(	-lrb-	-LRB-	_	35	p	_	_
33	eg	eg	NN	_	35	dep	_	_
34	,	,	,	_	35	p	_	_
35	drug6	drug0	NN	_	31	prn	_	_
36	)	-rrb-	-RRB-	_	35	p	_	_
37	--commonly	--commonly	RB	_	38	adv	_	_
38	results	result	VBZ	_	0	root	_	_
39	in	in	IN	_	42	case	_	_
40	excessive	excessive	JJ	_	42	attr	_	_
41	anticholinergic	anticholinergic	JJ	_	42	attr	_	_
42	effects	effect	NNS	_	38	ppmod	_	_
43	,	,	,	_	42	p	_	_
44	including	include	VBG	_	46	adv	_	_
45	dry	dry	JJ	_	46	attr	_	_
46	mouth	mouth	NN	_	42	ppmod	_	_
47	and	and	CC	_	46	cc	_	_
48	associated	associate	VBN	_	50	attr	_	_
49	dental	dental	JJ	_	50	attr	_	_
50	complications	complication	NNS	_	46	conj	_	_
51	,	,	,	_	50	p	_	_
52	blurred	blurred	JJ	_	53	attr	_	_
53	vision	vision	NN	_	46	conj	_	_
54	,	,	,	_	53	p	_	_
55	and	and	CC	_	53	cc	_	_
56	,	,	,	_	53	p	_	_
57	in	in	IN	_	58	case	_	_
58	patients	patient	NNS	_	53	ppmod	_	_
59	exposed	expose	VBN	_	58	acl	_	_
60	to	to	TO	_	62	aux	_	_
61	high	high	JJ	_	62	attr	_	_
62	temperature	temperature	NN	_	59	ppmod	_	_
63	and	and	CC	_	62	cc	_	_
64	humidity	humidity	NN	_	62	conj	_	_
65	,	,	,	_	53	p	_	_
66	hyperpyrexia	hyperpyrexia	NN	_	46	conj	_	_
67	.	.	.	_	38	p	_	_

1	Interactions	interaction	NNS	_	4	dep	_	_
2	may	may	MD	_	4	modal	_	_
3	also	also	RB	_	4	adv	_	_
4	occur	occur	VB	_	0	root	_	_
5	with	with	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	following	following	NN	_	4	ppmod	_	_
8	:	:	:	_	7	p	_	_
9	drug1	drug0	NN	_	7	appo	_	_
10	/	/	:	_	7	p	_	_
11	drug2	drug0	NN	_	7	appo	_	_
12	,	,	,	_	7	p	_	_
13	drugs	drug	NNS	_	7	appo	_	_
14	used	use	VBN	_	13	acl	_	_
15	to	to	TO	_	16	aux	_	_
16	treat	treat	VB	_	14	comp	_	_
17	an	an	DT	_	19	det	_	_
18	overactive	overactive	JJ	_	19	attr	_	_
19	thyroid	thyroid	NN	_	16	obj	_	_
20	,	,	,	_	7	p	_	_
21	drug3	drug0	NN	_	7	appo	_	_
22	(	-lrb-	-LRB-	_	25	p	_	_
23	e.g.	e.g.	FW	_	25	ppmod	_	_
24	,	,	,	_	25	p	_	_
25	drug4	drug0	NN	_	21	prn	_	_
26	)	-rrb-	-RRB-	_	25	p	_	_
27	,	,	,	_	7	p	_	_
28	drug5	drug0	NN	_	7	appo	_	_
29	,	,	,	_	7	p	_	_
30	drug6	drug0	NN	_	7	appo	_	_
31	,	,	,	_	7	p	_	_
32	drug7	drug0	NN	_	7	appo	_	_
33	,	,	,	_	7	p	_	_
34	drug8	drug0	NN	_	7	appo	_	_
35	,	,	,	_	7	p	_	_
36	drug9	drug0	NN	_	7	appo	_	_
37	,	,	,	_	7	p	_	_
38	drug10	drug0	NN	_	7	appo	_	_
39	,	,	,	_	7	p	_	_
40	drug11	drug0	NN	_	7	appo	_	_
41	,	,	,	_	7	p	_	_
42	drug12	drug0	NN	_	44	com	_	_
43	pain	pain	NN	_	44	com	_	_
44	medication	medication	NN	_	7	appo	_	_
45	(	-lrb-	-LRB-	_	48	p	_	_
46	e.g.	e.g.	FW	_	48	ppmod	_	_
47	,	,	,	_	48	p	_	_
48	drug13	drug0	NN	_	44	prn	_	_
49	)	-rrb-	-RRB-	_	48	p	_	_
50	,	,	,	_	7	p	_	_
51	drugs	drug	NNS	_	7	appo	_	_
52	used	use	VBN	_	51	acl	_	_
53	to	to	TO	_	54	aux	_	_
54	aid	aid	VB	_	52	comp	_	_
55	sleep	sleep	NN	_	54	obj	_	_
56	,	,	,	_	7	p	_	_
57	drowsiness-causing	drowsiness-causing	JJ	_	58	attr	_	_
58	drug14	drug0	NN	_	7	appo	_	_
59	(	-lrb-	-LRB-	_	62	p	_	_
60	e.g.	e.g.	FW	_	62	ppmod	_	_
61	,	,	,	_	62	p	_	_
62	drug15	drug0	NN	_	58	prn	_	_
63	)	-rrb-	-RRB-	_	62	p	_	_
64	,	,	,	_	7	p	_	_
65	any	any	DT	_	67	det	_	_
66	other	other	JJ	_	67	attr	_	_
67	drugs	drug	NNS	_	7	appo	_	_
68	that	that	WDT	_	70	dep	_	_
69	may	may	MD	_	70	modal	_	_
70	make	make	VB	_	67	relcl	_	_
71	you	you	RB	_	72	adv	_	_
72	drowsy	drowsy	JJ	_	70	dep	_	_
73	.	.	.	_	4	p	_	_

1	Drug	drug	NN	_	2	com	_	_
2	Interactions	interaction	NNS	_	0	root	_	_
3	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	administered	administer	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	patients	patient	NNS	_	4	ppmod	_	_
7	receiving	receive	VBG	_	6	acl	_	_
8	drug2	drug0	NN	_	7	obj	_	_
9	or	or	CC	_	8	cc	_	_
10	drug3	drug0	NN	_	8	conj	_	_
11	without	without	IN	_	13	case	_	_
12	adverse	adverse	JJ	_	13	attr	_	_
13	effects	effect	NNS	_	7	ppmod	_	_
14	.	.	.	_	4	p	_	_

1	During	during	IN	_	2	case	_	_
2	administration	administration	NN	_	30	ppmod	_	_
3	of	of	IN	_	6	case	_	_
4	multiple	multiple	JJ	_	6	attr	_	_
5	oral	oral	JJ	_	6	attr	_	_
6	doses	dose	NNS	_	2	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	to	to	TO	_	11	aux	_	_
10	healthy	healthy	JJ	_	11	attr	_	_
11	subjects	subject	NNS	_	2	ppmod	_	_
12	stabilized	stabilize	VBN	_	11	acl	_	_
13	on	on	IN	_	16	case	_	_
14	a	a	DT	_	16	det	_	_
15	maintenance	maintenance	NN	_	16	com	_	_
16	dose	dose	NN	_	12	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	,	,	,	_	30	p	_	_
20	a	a	DT	_	25	det	_	_
21	13	0	CD	_	25	num	_	_
22	%	%	NN	_	21	meta	_	_
23	-19	0	CD	_	25	num	_	_
24	%	%	NN	_	23	meta	_	_
25	increase	increase	NN	_	30	dep	_	_
26	in	in	IN	_	29	case	_	_
27	plasma	plasma	NN	_	29	com	_	_
28	drug3	drug0	NN	_	29	com	_	_
29	levels	level	NNS	_	25	ppmod	_	_
30	occurred	occur	VBD	_	0	root	_	_
31	at	at	IN	_	33	case	_	_
32	six	#crd#	CD	_	33	num	_	_
33	hours	hour	NNS	_	30	ppmod	_	_
34	postdose	postdose	NN	_	30	obj	_	_
35	.	.	.	_	30	p	_	_

1	In	in	IN	_	3	case	_	_
2	a	a	DT	_	3	det	_	_
3	study	study	NN	_	17	ppmod	_	_
4	involving	involve	VBG	_	3	acl	_	_
5	healthy	healthy	JJ	_	6	attr	_	_
6	subjects	subject	NNS	_	4	obj	_	_
7	receiving	receive	VBG	_	6	acl	_	_
8	drug1	drug0	NN	_	7	obj	_	_
9	and	and	CC	_	8	cc	_	_
10	drug2	drug0	NN	_	8	conj	_	_
11	concurrently	concurrently	RB	_	17	adv	_	_
12	,	,	,	_	17	p	_	_
13	plasma	plasma	NN	_	15	com	_	_
14	drug3	drug0	NN	_	15	com	_	_
15	levels	level	NNS	_	17	dep	_	_
16	were	be	VBD	_	17	aux	_	_
17	increased	increase	VBN	_	0	root	_	_
18	about	about	IN	_	19	case	_	_
19	20	0	CD	_	17	ppmod	_	_
20	%	%	NN	_	19	meta	_	_
21	and	and	CC	_	17	cc	_	_
22	drug4	drug0	NN	_	23	com	_	_
23	levels	level	NNS	_	25	dep	_	_
24	were	be	VBD	_	25	aux	_	_
25	increased	increase	VBN	_	17	conj	_	_
26	about	about	IN	_	27	case	_	_
27	30	0	CD	_	25	ppmod	_	_
28	%	%	NN	_	27	meta	_	_
29	compared	compare	VBN	_	25	comp	_	_
30	to	to	TO	_	32	aux	_	_
31	control	control	NN	_	32	com	_	_
32	values	value	NNS	_	29	ppmod	_	_
33	.	.	.	_	17	p	_	_

1	In	in	IN	_	5	case	_	_
2	this	this	DT	_	5	det	_	_
3	formal	formal	JJ	_	5	attr	_	_
4	interaction	interaction	NN	_	5	com	_	_
5	study	study	NN	_	12	ppmod	_	_
6	,	,	,	_	12	p	_	_
7	drug1	drug0	NN	_	12	dep	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	were	be	VBD	_	12	aux	_	_
11	each	each	DT	_	12	det	_	_
12	found	find	VBN	_	0	root	_	_
13	to	to	TO	_	14	aux	_	_
14	have	have	VB	_	12	comp	_	_
15	negative	negative	JJ	_	17	attr	_	_
16	inotropic	inotropic	JJ	_	17	attr	_	_
17	effects	effect	NNS	_	14	obj	_	_
18	;	;	:	_	12	p	_	_

1	when	when	WRB	_	5	adv	_	_
2	the	the	DT	_	3	det	_	_
3	drugs	drug	NNS	_	5	dep	_	_
4	were	be	VBD	_	5	aux	_	_
5	administered	administer	VBN	_	10	advcl	_	_
6	together	together	RB	_	5	adv	_	_
7	,	,	,	_	10	p	_	_
8	the	the	DT	_	9	det	_	_
9	effects	effect	NNS	_	10	dep	_	_
10	were	be	VBD	_	0	root	_	_
11	additive	additive	JJ	_	10	dep	_	_
12	.	.	.	_	10	p	_	_

1	The	the	DT	_	2	det	_	_
2	effects	effect	NNS	_	14	dep	_	_
3	of	of	IN	_	5	case	_	_
4	concomitant	concomitant	JJ	_	5	attr	_	_
5	administration	administration	NN	_	2	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	on	on	IN	_	13	case	_	_
11	the	the	DT	_	13	det	_	_
12	PR	pr	NN	_	13	com	_	_
13	interval	interval	NNS	_	2	ppmod	_	_
14	were	be	VBD	_	0	root	_	_
15	less	less	JJR	_	14	dep	_	_
16	than	than	IN	_	17	case	_	_
17	additive	additive	JJ	_	15	ppmod	_	_
18	.	.	.	_	14	p	_	_

1	In	in	IN	_	4	case	_	_
2	drug1	drug0	NN	_	4	attr	_	_
3	clinical	clinical	JJ	_	4	attr	_	_
4	trials	trial	NNS	_	14	ppmod	_	_
5	,	,	,	_	14	p	_	_
6	patients	patient	NNS	_	14	dep	_	_
7	who	who	WP	_	9	dep	_	_
8	were	be	VBD	_	9	aux	_	_
9	receiving	receive	VBG	_	6	relcl	_	_
10	drug2	drug0	NN	_	9	obj	_	_
11	concurrently	concurrently	RB	_	14	adv	_	_
12	did	do	VBD	_	14	aux	_	_
13	not	not	RB	_	14	neg	_	_
14	experience	experience	VBP	_	0	root	_	_
15	an	an	DT	_	17	det	_	_
16	increased	increase	VBN	_	17	attr	_	_
17	incidence	incidence	NN	_	14	obj	_	_
18	of	of	IN	_	20	case	_	_
19	side	side	JJ	_	20	attr	_	_
20	effects	effect	NNS	_	17	ppmod	_	_
21	.	.	.	_	14	p	_	_

1	Nevertheless	nevertheless	RB	_	16	adv	_	_
2	,	,	,	_	16	p	_	_
3	the	the	DT	_	4	det	_	_
4	possibility	possibility	NN	_	16	dep	_	_
5	of	of	IN	_	9	case	_	_
6	additive	additive	JJ	_	9	attr	_	_
7	negative	negative	JJ	_	9	attr	_	_
8	inotropic	inotropic	JJ	_	9	attr	_	_
9	effects	effect	NNS	_	4	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	drug2	drug0	NN	_	11	conj	_	_
14	should	should	MD	_	16	modal	_	_
15	be	be	VB	_	16	aux	_	_
16	recognized	recognize	VBN	_	0	root	_	_
17	.	.	.	_	16	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	is	be	VBZ	_	5	aux	_	_
3	not	not	RB	_	5	neg	_	_
4	extensively	extensively	RB	_	5	adv	_	_
5	bound	bind	VBN	_	0	root	_	_
6	to	to	TO	_	8	aux	_	_
7	plasma	plasma	NN	_	8	com	_	_
8	proteins	protein	NNS	_	5	ppmod	_	_
9	.	.	.	_	5	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	studies	study	NNS	_	12	dep	_	_
4	with	with	IN	_	6	case	_	_
5	several	several	JJ	_	6	attr	_	_
6	drugs	drug	NNS	_	3	ppmod	_	_
7	which	which	WDT	_	10	dep	_	_
8	may	may	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	administered	administer	VBN	_	6	relcl	_	_
11	concomitantly	concomitantly	RB	_	10	adv	_	_
12	showed	show	VBD	_	0	root	_	_
13	that	that	IN	_	23	mark	_	_
14	the	the	DT	_	15	det	_	_
15	extent	extent	NN	_	23	dep	_	_
16	of	of	IN	_	18	case	_	_
17	drug1	drug0	NN	_	18	com	_	_
18	binding	binding	NN	_	15	ppmod	_	_
19	to	to	TO	_	22	aux	_	_
20	human	human	JJ	_	22	attr	_	_
21	plasma	plasma	NN	_	22	com	_	_
22	proteins	protein	NNS	_	18	ppmod	_	_
23	is	be	VBZ	_	12	comp	_	_
24	either	either	CC	_	25	cc	_	_
25	unchanged	unchanged	JJ	_	23	dep	_	_
26	or	or	CC	_	25	cc	_	_
27	only	only	RB	_	28	com	_	_
28	slightly	slightly	RB	_	29	adv	_	_
29	less	less	JJR	_	25	conj	_	_
30	.	.	.	_	12	p	_	_

1	Consequently	consequently	RB	_	20	adv	_	_
2	,	,	,	_	20	p	_	_
3	interactions	interaction	NNS	_	20	dep	_	_
4	with	with	IN	_	6	case	_	_
5	other	other	JJ	_	6	attr	_	_
6	drugs	drug	NNS	_	3	ppmod	_	_
7	which	which	WDT	_	8	dep	_	_
8	are	be	VBP	_	6	relcl	_	_
9	highly	highly	RB	_	8	adv	_	_
10	protein	protein	NN	_	11	advnp	_	_
11	bound	bind	VBN	_	8	dep	_	_
12	(	-lrb-	-LRB-	_	15	p	_	_
13	e.g.	e.g.	FW	_	15	ppmod	_	_
14	,	,	,	_	15	p	_	_
15	drug1	drug0	NN	_	8	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	would	would	MD	_	20	modal	_	_
18	not	not	RB	_	20	neg	_	_
19	be	be	VB	_	20	aux	_	_
20	expected	expect	VBN	_	0	root	_	_
21	.	.	.	_	20	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	used	use	VBN	_	0	root	_	_
5	in	in	IN	_	8	case	_	_
6	a	a	DT	_	8	det	_	_
7	large	large	JJ	_	8	attr	_	_
8	number	number	NN	_	4	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	patients	patient	NNS	_	8	ppmod	_	_
11	receiving	receive	VBG	_	10	acl	_	_
12	drug2	drug0	NN	_	11	obj	_	_
13	without	without	IN	_	15	case	_	_
14	apparent	apparent	JJ	_	15	attr	_	_
15	interaction	interaction	NN	_	11	ppmod	_	_
16	.	.	.	_	4	p	_	_

1	Limited	limited	JJ	_	2	attr	_	_
2	data	datum	NNS	_	16	dep	_	_
3	in	in	IN	_	4	case	_	_
4	patients	patient	NNS	_	2	ppmod	_	_
5	receiving	receive	VBG	_	4	acl	_	_
6	known	known	JJ	_	8	attr	_	_
7	enzyme	enzyme	NN	_	8	com	_	_
8	inducers	inducer	NNS	_	5	obj	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	drug1	drug0	NN	_	8	prn	_	_
11	,	,	,	_	10	p	_	_
12	drug2	drug0	NN	_	10	appo	_	_
13	,	,	,	_	10	p	_	_
14	drug3	drug0	NN	_	10	appo	_	_
15	)	-rrb-	-RRB-	_	10	p	_	_
16	indicate	indicate	VBP	_	0	root	_	_
17	only	only	RB	_	21	adv	_	_
18	a	a	DT	_	21	det	_	_
19	30	0	CD	_	21	num	_	_
20	%	%	NN	_	21	meta	_	_
21	increase	increase	NN	_	16	obj	_	_
22	in	in	IN	_	24	case	_	_
23	the	the	DT	_	24	det	_	_
24	rate	rate	NN	_	21	ppmod	_	_
25	of	of	IN	_	27	case	_	_
26	drug4	drug0	NN	_	27	com	_	_
27	elimination	elimination	NN	_	24	ppmod	_	_
28	.	.	.	_	16	p	_	_

1	In	in	IN	_	3	case	_	_
2	healthy	healthy	JJ	_	3	attr	_	_
3	subjects	subject	NNS	_	18	ppmod	_	_
4	receiving	receive	VBG	_	3	acl	_	_
5	drug1	drug0	NN	_	4	obj	_	_
6	(	-lrb-	-LRB-	_	8	p	_	_
7	1	0	CD	_	8	num	_	_
8	gm	gm	NN	_	5	prn	_	_
9	daily	daily	JJ	_	8	attr	_	_
10	)	-rrb-	-RRB-	_	8	p	_	_
11	for	for	IN	_	13	case	_	_
12	one	#crd#	CD	_	13	num	_	_
13	week	week	NN	_	4	ppmod	_	_
14	,	,	,	_	18	p	_	_
15	plasma	plasma	NN	_	17	com	_	_
16	drug2	drug0	NN	_	17	com	_	_
17	levels	level	NNS	_	18	dep	_	_
18	increased	increase	VBD	_	0	root	_	_
19	by	by	IN	_	21	case	_	_
20	about	about	RB	_	21	adv	_	_
21	30	0	CD	_	18	ppmod	_	_
22	%	%	NN	_	21	meta	_	_
23	and	and	CC	_	18	cc	_	_
24	half-life	half-life	NN	_	25	dep	_	_
25	increased	increase	VBD	_	18	conj	_	_
26	by	by	IN	_	28	case	_	_
27	about	about	RB	_	28	adv	_	_
28	10	0	CD	_	25	ppmod	_	_
29	%	%	NN	_	28	meta	_	_
30	.	.	.	_	18	p	_	_

1	When	when	WRB	_	4	adv	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	added	add	VBN	_	13	advcl	_	_
5	to	to	TO	_	7	aux	_	_
6	drug2	drug0	NN	_	7	com	_	_
7	therapy	therapy	NN	_	4	ppmod	_	_
8	,	,	,	_	13	p	_	_
9	plasma	plasma	NN	_	11	com	_	_
10	drug3	drug0	NN	_	11	com	_	_
11	levels	level	NNS	_	13	dep	_	_
12	may	may	MD	_	13	modal	_	_
13	increase	increase	VB	_	0	root	_	_
14	two-fold	two-fold	RB	_	13	adv	_	_
15	or	or	CC	_	14	cc	_	_
16	more	more	RBR	_	14	conj	_	_
17	in	in	IN	_	19	case	_	_
18	some	some	DT	_	19	det	_	_
19	patients	patient	NNS	_	13	ppmod	_	_
20	,	,	,	_	13	p	_	_
21	if	if	IN	_	26	mark	_	_
22	drug4	drug0	NN	_	23	com	_	_
23	dosage	dosage	NN	_	26	dep	_	_
24	is	be	VBZ	_	26	aux	_	_
25	not	not	RB	_	26	neg	_	_
26	reduced	reduce	VBN	_	13	comp	_	_
27	.	.	.	_	13	p	_	_

1	Drugs	drug	NNS	_	12	dep	_	_
2	that	that	WDT	_	3	dep	_	_
3	inhibit	inhibit	VBP	_	1	relcl	_	_
4	cytochrome	cytochrome	NN	_	5	com	_	_
5	P450IID6	p0iid0	NN	_	3	obj	_	_
6	,	,	,	_	1	p	_	_
7	such	such	JJ	_	9	adv	_	_
8	as	as	IN	_	9	case	_	_
9	drug1	drug0	NN	_	1	ppmod	_	_
10	,	,	,	_	1	p	_	_
11	might	might	MD	_	12	modal	_	_
12	increase	increase	VB	_	0	root	_	_
13	the	the	DT	_	15	det	_	_
14	plasma	plasma	NN	_	15	com	_	_
15	concentrations	concentration	NNS	_	12	obj	_	_
16	of	of	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	in	in	IN	_	19	case	_	_
19	patients	patient	NNS	_	15	ppmod	_	_
20	that	that	WDT	_	21	dep	_	_
21	are	be	VBP	_	19	relcl	_	_
22	on	on	IN	_	25	case	_	_
23	chronic	chronic	JJ	_	25	attr	_	_
24	drug3	drug0	NN	_	25	com	_	_
25	therapy	therapy	NN	_	21	ppmod	_	_
26	;	;	:	_	12	p	_	_

1	especially	especially	RB	_	4	adv	_	_
2	if	if	IN	_	4	case	_	_
3	these	these	DT	_	4	det	_	_
4	patients	patient	NNS	_	5	ppmod	_	_
5	are	be	VBP	_	0	root	_	_
6	extensive	extensive	JJ	_	7	attr	_	_
7	metabolizers	metabolizers	NNS	_	5	obj	_	_
8	.	.	.	_	5	p	_	_

1	There	there	EX	_	3	dep	_	_
2	has	have	VBZ	_	3	aux	_	_
3	been	be	VBN	_	0	root	_	_
4	little	little	JJ	_	5	attr	_	_
5	experience	experience	VBP	_	3	obj	_	_
6	with	with	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	coadministration	coadministration	NN	_	3	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	either	either	CC	_	13	cc	_	_
13	drug2	drug0	NN	_	10	conj	_	_
14	or	or	CC	_	13	cc	_	_
15	drug3	drug0	NN	_	13	conj	_	_
16	.	.	.	_	3	p	_	_

1	Because	because	IN	_	17	mark	_	_
2	both	both	DT	_	17	dep	_	_
3	of	of	IN	_	6	mark	_	_
4	these	these	DT	_	5	det	_	_
5	drugs	drug	NNS	_	6	dep	_	_
6	have	have	VBP	_	2	acl	_	_
7	negative	negative	JJ	_	9	attr	_	_
8	inotropic	inotropic	JJ	_	9	attr	_	_
9	properties	property	NNS	_	6	obj	_	_
10	and	and	CC	_	9	cc	_	_
11	the	the	DT	_	12	det	_	_
12	effects	effect	NNS	_	9	conj	_	_
13	of	of	IN	_	14	case	_	_
14	coadministration	coadministration	NN	_	12	ppmod	_	_
15	with	with	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	are	be	VBP	_	26	advcl	_	_
18	unknown	unknown	JJ	_	17	dep	_	_
19	,	,	,	_	26	p	_	_
20	neither	neither	CC	_	21	cc	_	_
21	drug2	drug0	NN	_	26	dep	_	_
22	nor	nor	CC	_	21	cc	_	_
23	drug3	drug0	NN	_	21	conj	_	_
24	should	should	MD	_	26	modal	_	_
25	be	be	VB	_	26	aux	_	_
26	administered	administer	VBN	_	0	root	_	_
27	concurrently	concurrently	RB	_	26	adv	_	_
28	with	with	IN	_	29	case	_	_
29	drug4	drug0	NN	_	26	ppmod	_	_
30	unless	unless	IN	_	44	mark	_	_
31	,	,	,	_	44	p	_	_
32	in	in	IN	_	34	case	_	_
33	the	the	DT	_	34	det	_	_
34	judgment	judgment	NN	_	44	ppmod	_	_
35	of	of	IN	_	37	case	_	_
36	the	the	DT	_	37	det	_	_
37	physician	physician	NN	_	34	ppmod	_	_
38	,	,	,	_	44	p	_	_
39	the	the	DT	_	40	det	_	_
40	benefits	benefit	NNS	_	44	dep	_	_
41	of	of	IN	_	43	case	_	_
42	this	this	DT	_	43	det	_	_
43	combination	combination	NN	_	40	ppmod	_	_
44	outweigh	outweigh	VBP	_	26	comp	_	_
45	the	the	DT	_	46	det	_	_
46	risks	risk	NNS	_	44	obj	_	_
47	.	.	.	_	26	p	_	_

1	There	there	EX	_	3	dep	_	_
2	has	have	VBZ	_	3	aux	_	_
3	been	be	VBN	_	0	root	_	_
4	too	too	RB	_	5	adv	_	_
5	little	little	JJ	_	3	dep	_	_
6	experience	experience	VBP	_	5	comp	_	_
7	with	with	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	coadministration	coadministration	NN	_	6	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	with	with	IN	_	13	case	_	_
13	drug2	drug0	NN	_	9	ppmod	_	_
14	or	or	CC	_	13	cc	_	_
15	drug3	drug0	NN	_	13	conj	_	_
16	to	to	TO	_	17	aux	_	_
17	recommend	recommend	VB	_	6	comp	_	_
18	concomitant	concomitant	JJ	_	19	attr	_	_
19	use	use	NN	_	17	obj	_	_
20	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	23	dep	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	effect	effect	NN	_	1	conj	_	_
5	of	of	IN	_	7	case	_	_
6	an	an	DT	_	7	det	_	_
7	drug2	drug0	NN	_	4	ppmod	_	_
8	-	-	:	_	4	p	_	_
9	and	and	CC	_	4	cc	_	_
10	drug3	drug0	NN	_	16	attr	_	_
11	-containing	-containing	JJ	_	16	attr	_	_
12	drug4	drug0	NN	_	16	attr	_	_
13	(	-lrb-	-LRB-	_	16	p	_	_
14	drug5	drug0	NN	_	16	attr	_	_
15	)	-rrb-	-RRB-	_	16	p	_	_
16	*	*	NN	_	1	conj	_	_
17	on	on	IN	_	19	case	_	_
18	the	the	DT	_	19	det	_	_
19	pharmacokinetics	pharmacokinetics	NNS	_	16	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	drug6	drug0	NN	_	19	ppmod	_	_
22	was	be	VBD	_	23	aux	_	_
23	investigated	investigate	VBN	_	0	root	_	_
24	in	in	IN	_	27	case	_	_
25	12	0	CD	_	27	num	_	_
26	cancer	cancer	NN	_	27	com	_	_
27	patients	patient	NNS	_	23	ppmod	_	_
28	.	.	.	_	23	p	_	_

1	There	there	EX	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	a	a	DT	_	5	det	_	_
4	small	small	JJ	_	5	attr	_	_
5	increase	increase	NN	_	2	obj	_	_
6	in	in	IN	_	8	case	_	_
7	plasma	plasma	NN	_	8	com	_	_
8	concentrations	concentration	NNS	_	5	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	5	cc	_	_
12	one	#crd#	CD	_	13	num	_	_
13	metabolite	metabolite	NN	_	5	conj	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	drug2	drug0	NN	_	13	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	;	;	:	_	2	p	_	_

1	there	there	EX	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	no	no	DT	_	4	det	_	_
4	effect	effect	NN	_	2	obj	_	_
5	on	on	IN	_	9	case	_	_
6	the	the	DT	_	9	det	_	_
7	3	0	CD	_	9	num	_	_
8	major	major	JJ	_	9	attr	_	_
9	metabolites	metabolite	NNS	_	4	ppmod	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	drug1	drug0	NN	_	9	prn	_	_
12	,	,	,	_	11	p	_	_
13	drug2	drug0	NN	_	11	conj	_	_
14	and	and	CC	_	13	cc	_	_
15	drug3	drug0	NN	_	11	conj	_	_
16	)	-rrb-	-RRB-	_	11	p	_	_
17	.	.	.	_	2	p	_	_

1	drug1	drug0	JJ	_	4	attr	_	_
2	Altered	altered	JJ	_	4	attr	_	_
3	coagulation	coagulation	NN	_	4	com	_	_
4	parameters	parameter	NNS	_	9	dep	_	_
5	and/or	and/or	CC	_	4	cc	_	_
6	bleeding	bleeding	JJ	_	4	conj	_	_
7	have	have	VBP	_	9	aux	_	_
8	been	be	VBN	_	9	aux	_	_
9	reported	report	VBN	_	0	root	_	_
10	in	in	IN	_	11	case	_	_
11	patients	patient	NNS	_	9	ppmod	_	_
12	taking	take	VBG	_	11	acl	_	_
13	drug2	drug0	VBN	_	16	adv	_	_
14	concomitantly	concomitantly	RB	_	16	adv	_	_
15	with	with	IN	_	16	case	_	_
16	drug3	drug0	NNS	_	12	ppmod	_	_
17	such	such	JJ	_	19	adv	_	_
18	as	as	IN	_	19	case	_	_
19	drug4	drug0	NN	_	16	ppmod	_	_
20	and	and	CC	_	19	cc	_	_
21	drug5	drug0	NN	_	19	conj	_	_
22	.	.	.	_	9	p	_	_

1	Patients	patient	NNS	_	9	dep	_	_
2	taking	take	VBG	_	1	acl	_	_
3	drug1	drug0	NN	_	2	obj	_	_
4	concomitantly	concomitantly	RB	_	6	adv	_	_
5	with	with	IN	_	6	case	_	_
6	drug2	drug0	NN	_	1	ppmod	_	_
7	should	should	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	monitored	monitor	VBN	_	0	root	_	_
10	regularly	regularly	RB	_	9	adv	_	_
11	for	for	IN	_	12	case	_	_
12	alterations	alteration	NNS	_	9	ppmod	_	_
13	in	in	IN	_	16	case	_	_
14	their	their	PRP$	_	16	poss	_	_
15	coagulation	coagulation	NN	_	16	com	_	_
16	parameters	parameter	NNS	_	12	ppmod	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	PT	pt	NN	_	16	prn	_	_
19	or	or	CC	_	18	cc	_	_
20	INR	inr	NN	_	18	conj	_	_
21	)	-rrb-	-RRB-	_	18	p	_	_
22	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	concentration	concentration	NN	_	8	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	is	be	VBZ	_	8	aux	_	_
8	increased	increase	VBN	_	1	acl	_	_
9	and	and	CC	_	8	cc	_	_
10	its	its	PRP$	_	11	poss	_	_
11	toxicity	toxicity	NN	_	14	dep	_	_
12	may	may	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	enhanced	enhance	VBN	_	8	conj	_	_
15	by	by	IN	_	16	case	_	_
16	drug3	drug0	NN	_	14	ppmod	_	_
17	.	.	.	_	1	p	_	_

1	Deaths	death	NNS	_	12	dep	_	_
2	from	from	IN	_	4	case	_	_
3	severe	severe	JJ	_	4	attr	_	_
4	enterocolitis	enterocolitis	NN	_	1	ppmod	_	_
5	,	,	,	_	4	p	_	_
6	diarrhea	diarrhea	NN	_	4	conj	_	_
7	,	,	,	_	6	p	_	_
8	and	and	CC	_	6	cc	_	_
9	dehydration	dehydration	NN	_	4	conj	_	_
10	have	have	VBP	_	12	aux	_	_
11	been	be	VBN	_	12	aux	_	_
12	reported	report	VBN	_	0	root	_	_
13	in	in	IN	_	15	case	_	_
14	elderly	elderly	JJ	_	15	attr	_	_
15	patients	patient	NNS	_	12	ppmod	_	_
16	receiving	receive	VBG	_	15	acl	_	_
17	weekly	weekly	RB	_	18	adv	_	_
18	drug1	drug0	NN	_	16	obj	_	_
19	and	and	CC	_	18	cc	_	_
20	drug2	drug0	NN	_	18	conj	_	_
21	.	.	.	_	12	p	_	_

1	Cytochrome	cytochrome	NN	_	3	com	_	_
2	P450	p0	NN	_	3	com	_	_
3	1A2	0a0	NN	_	8	dep	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	CYP1A2	cyp0a0	NN	_	3	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	is	be	VBZ	_	8	aux	_	_
8	known	know	VBN	_	0	root	_	_
9	to	to	TO	_	10	aux	_	_
10	be	be	VB	_	8	comp	_	_
11	the	the	DT	_	13	det	_	_
12	major	major	JJ	_	13	attr	_	_
13	enzyme	enzyme	NN	_	10	obj	_	_
14	involved	involve	VBN	_	13	acl	_	_
15	in	in	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	metabolism	metabolism	NN	_	14	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug1	drug0	NN	_	17	ppmod	_	_
20	.	.	.	_	8	p	_	_

1	Therefore	therefore	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	drug1	drug0	NN	_	4	dep	_	_
4	has	have	VBZ	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	potential	potential	NN	_	4	obj	_	_
7	to	to	TO	_	8	aux	_	_
8	interact	interact	VB	_	6	acl	_	_
9	with	with	IN	_	10	case	_	_
10	drugs	drug	NNS	_	8	ppmod	_	_
11	that	that	WDT	_	12	dep	_	_
12	are	be	VBP	_	10	relcl	_	_
13	substrates	substrate	NNS	_	12	obj	_	_
14	for	for	IN	_	15	case	_	_
15	CYP1A2	cyp0a0	NN	_	13	ppmod	_	_
16	,	,	,	_	8	p	_	_
17	inhibit	inhibit	VB	_	8	conj	_	_
18	CYP1A2	cyp0a0	NN	_	17	obj	_	_
19	,	,	,	_	17	p	_	_
20	or	or	CC	_	17	cc	_	_
21	induce	induce	VB	_	8	conj	_	_
22	CYP1A2	cyp0a0	NN	_	21	obj	_	_
23	.	.	.	_	4	p	_	_

1	Few	few	JJ	_	2	attr	_	_
2	data	datum	NNS	_	3	dep	_	_
3	exist	exist	VBP	_	0	root	_	_
4	on	on	IN	_	6	case	_	_
5	drug	drug	NN	_	6	com	_	_
6	interactions	interaction	NNS	_	3	ppmod	_	_
7	with	with	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	in	in	IN	_	11	case	_	_
10	preterm	preterm	NN	_	11	com	_	_
11	neonates	neonate	NNS	_	8	ppmod	_	_
12	.	.	.	_	3	p	_	_

1	Based	base	VBN	_	4	adv	_	_
2	on	on	IN	_	4	case	_	_
3	adult	adult	JJ	_	4	attr	_	_
4	data	datum	NNS	_	12	ppmod	_	_
5	,	,	,	_	12	p	_	_
6	lower	low	JJR	_	7	attr	_	_
7	doses	dose	NNS	_	12	dep	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	may	may	MD	_	12	modal	_	_
11	be	be	VB	_	12	aux	_	_
12	needed	need	VBN	_	0	root	_	_
13	following	follow	VBG	_	14	adv	_	_
14	coadministration	coadministration	NN	_	12	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drugs	drug	NNS	_	14	ppmod	_	_
17	which	which	WDT	_	19	dep	_	_
18	are	be	VBP	_	19	aux	_	_
19	reported	report	VBN	_	16	relcl	_	_
20	to	to	TO	_	21	aux	_	_
21	decrease	decrease	VB	_	19	comp	_	_
22	drug2	drug0	NN	_	23	com	_	_
23	elimination	elimination	NN	_	21	obj	_	_
24	(	-lrb-	-LRB-	_	27	p	_	_
25	e.g.	e.g.	FW	_	27	ppmod	_	_
26	,	,	,	_	27	p	_	_
27	drug3	drug0	NN	_	21	prn	_	_
28	and	and	CC	_	27	cc	_	_
29	drug4	drug0	NN	_	27	conj	_	_
30	)	-rrb-	-RRB-	_	27	p	_	_
31	and	and	CC	_	12	cc	_	_
32	higher	high	JJR	_	34	attr	_	_
33	drug5	drug0	NN	_	34	com	_	_
34	doses	dose	NNS	_	37	dep	_	_
35	may	may	MD	_	37	modal	_	_
36	be	be	VB	_	37	aux	_	_
37	needed	need	VBN	_	12	conj	_	_
38	following	follow	VBG	_	39	adv	_	_
39	coadministration	coadministration	NN	_	37	ppmod	_	_
40	of	of	IN	_	41	case	_	_
41	drugs	drug	NNS	_	39	ppmod	_	_
42	that	that	WDT	_	43	dep	_	_
43	increase	increase	VBP	_	41	relcl	_	_
44	drug6	drug0	NN	_	45	com	_	_
45	elimination	elimination	NN	_	43	obj	_	_
46	(	-lrb-	-LRB-	_	49	p	_	_
47	e.g.	e.g.	FW	_	49	adv	_	_
48	,	,	,	_	49	p	_	_
49	drug7	drug0	NN	_	45	prn	_	_
50	and	and	CC	_	49	cc	_	_
51	drug8	drug0	NN	_	49	conj	_	_
52	)	-rrb-	-RRB-	_	49	p	_	_
53	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	administered	administer	VBN	_	1	acl	_	_
3	concurrently	concurrently	RB	_	2	adv	_	_
4	with	with	IN	_	5	case	_	_
5	drug2	drug0	NN	_	2	ppmod	_	_
6	reduced	reduce	VBD	_	0	root	_	_
7	the	the	DT	_	9	det	_	_
8	urine	urine	NN	_	9	com	_	_
9	volume	volume	NN	_	6	obj	_	_
10	in	in	IN	_	13	case	_	_
11	4	0	CD	_	13	num	_	_
12	healthy	healthy	JJ	_	13	attr	_	_
13	volunteers	volunteer	NNS	_	6	ppmod	_	_
14	.	.	.	_	6	p	_	_

1	The	the	DT	_	3	det	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	significance	significance	NN	_	12	dep	_	_
4	of	of	IN	_	6	case	_	_
5	this	this	DT	_	6	det	_	_
6	interaction	interaction	NN	_	3	ppmod	_	_
7	in	in	IN	_	9	case	_	_
8	preterm	preterm	NN	_	9	com	_	_
9	neonates	neonate	NNS	_	3	ppmod	_	_
10	is	be	VBZ	_	12	aux	_	_
11	not	not	RB	_	12	neg	_	_
12	known	know	VBN	_	0	root	_	_
13	.	.	.	_	12	p	_	_

1	Interconversion	interconversion	NN	_	8	dep	_	_
2	between	between	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	has	have	VBZ	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	reported	report	VBN	_	0	root	_	_
9	in	in	IN	_	11	case	_	_
10	preterm	preterm	NN	_	11	com	_	_
11	neonates	neonate	NNS	_	8	ppmod	_	_
12	.	.	.	_	8	p	_	_

1	The	the	DT	_	3	det	_	_
2	concurrent	concurrent	JJ	_	3	attr	_	_
3	use	use	NN	_	9	dep	_	_
4	of	of	IN	_	6	case	_	_
5	these	these	DT	_	6	det	_	_
6	drugs	drug	NNS	_	3	ppmod	_	_
7	is	be	VBZ	_	9	aux	_	_
8	not	not	RB	_	9	neg	_	_
9	recommended	recommend	VBN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	No	no	DT	_	4	det	_	_
2	drug	drug	NN	_	4	com	_	_
3	interaction	interaction	NN	_	4	com	_	_
4	studies	study	NNS	_	7	dep	_	_
5	have	have	VBP	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	performed	performed	VBN	_	0	root	_	_
8	.	.	.	_	7	p	_	_

1	Other	other	JJ	_	2	attr	_	_
2	medicines	medicine	NNS	_	0	root	_	_
3	-	-	:	_	2	p	_	_
4	Although	although	IN	_	10	mark	_	_
5	certain	certain	JJ	_	6	attr	_	_
6	medicines	medicine	NNS	_	10	dep	_	_
7	should	should	MD	_	10	modal	_	_
8	not	not	RB	_	10	neg	_	_
9	be	be	VB	_	10	aux	_	_
10	used	use	VBN	_	23	advcl	_	_
11	together	together	RB	_	10	adv	_	_
12	at	at	IN	_	13	case	_	_
13	all	all	NN	_	10	ppmod	_	_
14	,	,	,	_	23	p	_	_
15	in	in	IN	_	17	case	_	_
16	other	other	JJ	_	17	attr	_	_
17	cases	case	NNS	_	23	ppmod	_	_
18	two	#crd#	CD	_	20	num	_	_
19	different	different	JJ	_	20	attr	_	_
20	medicines	medicine	NNS	_	23	dep	_	_
21	may	may	MD	_	23	modal	_	_
22	be	be	VB	_	23	aux	_	_
23	used	use	VBN	_	2	acl	_	_
24	together	together	RB	_	23	adv	_	_
25	even	even	RB	_	30	adv	_	_
26	if	if	IN	_	30	mark	_	_
27	an	an	DT	_	28	det	_	_
28	interaction	interaction	NN	_	30	dep	_	_
29	might	might	MD	_	30	modal	_	_
30	occur	occur	VB	_	23	comp	_	_
31	.	.	.	_	2	p	_	_

1	In	in	IN	_	3	case	_	_
2	these	these	DT	_	3	det	_	_
3	cases	case	NNS	_	8	ppmod	_	_
4	,	,	,	_	8	p	_	_
5	your	your	NN	_	6	com	_	_
6	doctor	doctor	NN	_	8	dep	_	_
7	may	may	MD	_	8	modal	_	_
8	want	want	VBP	_	0	root	_	_
9	to	to	TO	_	10	aux	_	_
10	change	change	VB	_	8	comp	_	_
11	the	the	DT	_	12	det	_	_
12	dose	dose	NN	_	10	obj	_	_
13	,	,	,	_	8	p	_	_
14	or	or	CC	_	8	cc	_	_
15	other	other	JJ	_	16	attr	_	_
16	precautions	precaution	NNS	_	18	dep	_	_
17	may	may	MD	_	18	modal	_	_
18	be	be	VB	_	8	conj	_	_
19	necessary	necessary	JJ	_	18	dep	_	_
20	.	.	.	_	8	p	_	_

1	When	when	WRB	_	4	adv	_	_
2	you	you	RB	_	4	adv	_	_
3	are	be	VBP	_	4	aux	_	_
4	using	use	VBG	_	8	advcl	_	_
5	drug1	drug0	NN	_	4	obj	_	_
6	,	,	,	_	8	p	_	_
7	it	it	PRP	_	8	dep	_	_
8	is	be	VBZ	_	0	root	_	_
9	especially	especially	RB	_	10	adv	_	_
10	important	important	JJ	_	8	dep	_	_
11	that	that	IN	_	16	mark	_	_
12	your	your	NN	_	15	com	_	_
13	health	health	NN	_	15	com	_	_
14	care	care	NN	_	15	com	_	_
15	professional	professional	NN	_	16	dep	_	_
16	know	know	VB	_	8	comp	_	_
17	if	if	IN	_	20	mark	_	_
18	you	you	NN	_	20	dep	_	_
19	are	be	VBP	_	20	aux	_	_
20	using	use	VBG	_	16	comp	_	_
21	the	the	DT	_	22	det	_	_
22	following	following	NN	_	20	obj	_	_
23	:	:	:	_	8	p	_	_
24	Eye	eye	NN	_	25	com	_	_
25	product	product	NN	_	8	dep	_	_
26	containing	contain	VBG	_	25	acl	_	_
27	drug2	drug0	NN	_	26	obj	_	_
28	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	interact	interact	VB	_	0	root	_	_
4	with	with	IN	_	7	case	_	_
5	the	the	DT	_	7	det	_	_
6	drug2	drug0	NN	_	7	com	_	_
7	preparation	preparation	NN	_	3	ppmod	_	_
8	causing	cause	VBG	_	7	acl	_	_
9	a	a	DT	_	11	det	_	_
10	gritty	gritty	NN	_	11	com	_	_
11	substance	substance	NN	_	8	obj	_	_
12	to	to	TO	_	13	aux	_	_
13	form	form	VB	_	3	comp	_	_
14	or	or	CC	_	3	cc	_	_
15	may	may	MD	_	16	modal	_	_
16	interact	interact	VB	_	3	conj	_	_
17	with	with	IN	_	19	case	_	_
18	the	the	DT	_	19	det	_	_
19	preservative	preservative	NN	_	16	ppmod	_	_
20	in	in	IN	_	23	case	_	_
21	the	the	DT	_	23	det	_	_
22	drug3	drug0	NN	_	23	com	_	_
23	preparation	preparation	NN	_	19	ppmod	_	_
24	causing	cause	VBG	_	23	acl	_	_
25	a	a	DT	_	27	det	_	_
26	toxic	toxic	JJ	_	27	attr	_	_
27	effect	effect	NN	_	24	obj	_	_
28	in	in	IN	_	30	case	_	_
29	the	the	DT	_	30	det	_	_
30	eye	eye	NN	_	24	ppmod	_	_
31	.	.	.	_	3	p	_	_

1	No	no	DT	_	4	det	_	_
2	well-known	well-known	JJ	_	4	attr	_	_
3	drug	drug	NN	_	4	com	_	_
4	interactions	interaction	NNS	_	0	root	_	_
5	with	with	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_

1	Clinical	clinical	JJ	_	2	attr	_	_
2	trials	trial	NNS	_	4	dep	_	_
3	have	have	VBP	_	4	aux	_	_
4	indicated	indicate	VBN	_	0	root	_	_
5	that	that	IN	_	12	mark	_	_
6	drug1	drug0	NN	_	12	dep	_	_
7	can	can	MD	_	12	modal	_	_
8	be	be	VB	_	12	aux	_	_
9	effectively	effectively	RB	_	12	adv	_	_
10	and	and	CC	_	9	cc	_	_
11	safely	safely	RB	_	9	conj	_	_
12	used	use	VBN	_	4	comp	_	_
13	in	in	IN	_	14	case	_	_
14	conjunction	conjunction	NN	_	12	ppmod	_	_
15	with	with	IN	_	19	case	_	_
16	standard	standard	JJ	_	18	attr	_	_
17	cystic	cystic	JJ	_	18	attr	_	_
18	fibrosis	fibrosis	NN	_	19	com	_	_
19	therapies	therapy	NNS	_	14	ppmod	_	_
20	including	include	VBG	_	26	adv	_	_
21	oral	oral	JJ	_	26	attr	_	_
22	,	,	,	_	21	p	_	_
23	inhaled	inhaled	JJ	_	21	conj	_	_
24	and/or	and/or	CC	_	23	cc	_	_
25	parenteral	parenteral	JJ	_	21	conj	_	_
26	drug2	drug0	NN	_	19	ppmod	_	_
27	,	,	,	_	26	p	_	_
28	drug3	drug0	NN	_	26	conj	_	_
29	,	,	,	_	28	p	_	_
30	enzyme	enzyme	NN	_	31	com	_	_
31	supplements	supplement	NNS	_	26	conj	_	_
32	,	,	,	_	31	p	_	_
33	drug4	drug0	NN	_	26	conj	_	_
34	,	,	,	_	33	p	_	_
35	oral	oral	JJ	_	38	attr	_	_
36	or	or	CC	_	35	cc	_	_
37	inhaled	inhaled	JJ	_	35	conj	_	_
38	drug5	drug0	NN	_	26	conj	_	_
39	,	,	,	_	38	p	_	_
40	and	and	CC	_	38	cc	_	_
41	drug6	drug0	NN	_	26	conj	_	_
42	.	.	.	_	4	p	_	_

1	No	no	DT	_	5	det	_	_
2	formal	formal	JJ	_	5	attr	_	_
3	drug	drug	NN	_	5	com	_	_
4	interaction	interaction	NN	_	5	com	_	_
5	studies	study	NNS	_	8	dep	_	_
6	have	have	VBP	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	performed	performed	VBN	_	0	root	_	_
9	.	.	.	_	8	p	_	_

1	Clinically	clinically	RB	_	2	adv	_	_
2	meaningful	meaningful	JJ	_	4	attr	_	_
3	drug	drug	NN	_	4	com	_	_
4	interactions	interaction	NNS	_	6	dep	_	_
5	have	have	VBP	_	6	aux	_	_
6	occurred	occur	VBN	_	31	advcl	_	_
7	with	with	IN	_	9	case	_	_
8	concomitant	concomitant	JJ	_	9	attr	_	_
9	medications	medication	NNS	_	6	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	include	include	VBP	_	9	conj	_	_
12	,	,	,	_	6	p	_	_
13	but	but	CC	_	6	cc	_	_
14	are	be	VBP	_	6	conj	_	_
15	not	not	RB	_	14	neg	_	_
16	limited	limited	JJ	_	14	dep	_	_
17	to	to	TO	_	19	aux	_	_
18	the	the	DT	_	19	det	_	_
19	following	following	NN	_	16	ppmod	_	_
20	:	:	:	_	31	p	_	_
21	Agents	agent	NNS	_	31	dep	_	_
22	Highly	highly	RB	_	23	adv	_	_
23	Bound	bind	VBN	_	21	acl	_	_
24	to	to	TO	_	27	aux	_	_
25	Plasma	plasma	NN	_	27	com	_	_
26	Protein	protein	NN	_	27	com	_	_
27	drug1	drug0	NN	_	23	ppmod	_	_
28	is	be	VBZ	_	31	aux	_	_
29	not	not	RB	_	31	neg	_	_
30	highly	highly	RB	_	31	adv	_	_
31	bound	bind	VBN	_	0	root	_	_
32	to	to	TO	_	34	aux	_	_
33	plasma	plasma	NN	_	34	com	_	_
34	proteins	protein	NNS	_	31	ppmod	_	_
35	;	;	:	_	31	p	_	_

1	therefore	therefore	RB	_	19	adv	_	_
2	,	,	,	_	19	p	_	_
3	administration	administration	NN	_	19	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	to	to	TO	_	8	aux	_	_
7	a	a	DT	_	8	det	_	_
8	patient	patient	NN	_	3	ppmod	_	_
9	taking	take	VBG	_	8	acl	_	_
10	another	another	DT	_	11	det	_	_
11	drug	drug	NN	_	9	obj	_	_
12	that	that	WDT	_	16	dep	_	_
13	is	be	VBZ	_	16	aux	_	_
14	highly	highly	RB	_	16	adv	_	_
15	protein	protein	NN	_	16	dep	_	_
16	bound	bind	VBN	_	11	relcl	_	_
17	should	should	MD	_	19	modal	_	_
18	not	not	RB	_	19	neg	_	_
19	cause	cause	VB	_	0	root	_	_
20	increased	increase	VBN	_	22	attr	_	_
21	free	free	JJ	_	22	attr	_	_
22	concentrations	concentration	NNS	_	19	obj	_	_
23	of	of	IN	_	26	case	_	_
24	the	the	DT	_	26	det	_	_
25	other	other	JJ	_	26	attr	_	_
26	drug	drug	NN	_	22	ppmod	_	_
27	.	.	.	_	19	p	_	_

1	Agents	agent	NNS	_	10	attr	_	_
2	that	that	WDT	_	3	dep	_	_
3	Inhibit	inhibit	VBP	_	1	relcl	_	_
4	Cytochrome	cytochrome	NN	_	6	com	_	_
5	P450	p0	NN	_	6	com	_	_
6	Isoenzymes	isoenzymes	NNS	_	3	obj	_	_
7	and/or	and/or	CC	_	1	cc	_	_
8	Epoxide	epoxide	NN	_	9	com	_	_
9	Hydrolase	hydrolase	NN	_	1	conj	_	_
10	drug1	drug0	NN	_	12	dep	_	_
11	is	be	VBZ	_	12	aux	_	_
12	metabolized	metabolize	VBN	_	0	root	_	_
13	mainly	mainly	RB	_	12	adv	_	_
14	by	by	IN	_	20	case	_	_
15	cytochrome	cytochrome	NN	_	20	attr	_	_
16	P450	p0	NN	_	20	attr	_	_
17	(	-lrb-	-LRB-	_	20	p	_	_
18	CYP	cyp	NN	_	20	attr	_	_
19	)	-rrb-	-RRB-	_	20	p	_	_
20	3A4	0a0	NN	_	12	ppmod	_	_
21	to	to	TO	_	20	attr	_	_
22	the	the	DT	_	24	det	_	_
23	active	active	JJ	_	24	attr	_	_
24	drug2	drug0	NN	_	20	appo	_	_
25	,	,	,	_	20	p	_	_
26	which	which	WDT	_	29	dep	_	_
27	is	be	VBZ	_	29	aux	_	_
28	further	far	RB	_	29	adv	_	_
29	metabolized	metabolize	VBN	_	20	relcl	_	_
30	to	to	TO	_	32	aux	_	_
31	the	the	DT	_	32	det	_	_
32	trans-diol	trans-diol	NN	_	29	ppmod	_	_
33	by	by	IN	_	35	case	_	_
34	epoxide	epoxide	NN	_	35	com	_	_
35	hydrolase	hydrolase	NN	_	29	ppmod	_	_
36	.	.	.	_	12	p	_	_

1	Therefore	therefore	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	the	the	DT	_	4	det	_	_
4	potential	potential	NN	_	5	dep	_	_
5	exists	exist	VBZ	_	0	root	_	_
6	for	for	IN	_	7	case	_	_
7	interaction	interaction	NN	_	5	ppmod	_	_
8	between	between	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	any	any	DT	_	12	det	_	_
12	agent	agent	NN	_	9	conj	_	_
13	that	that	WDT	_	14	dep	_	_
14	inhibits	inhibit	VBZ	_	12	relcl	_	_
15	CYP3A4	cyp0a0	NN	_	14	obj	_	_
16	and/or	and/or	CC	_	15	cc	_	_
17	epoxide	epoxide	NN	_	18	com	_	_
18	hydrolase	hydrolase	NN	_	15	conj	_	_
19	.	.	.	_	5	p	_	_

1	Agents	agent	NNS	_	0	root	_	_
2	that	that	WDT	_	3	dep	_	_
3	are	be	VBP	_	1	relcl	_	_
4	CYP3A4	cyp0a0	JJ	_	5	attr	_	_
5	inhibitors	inhibitor	NNS	_	3	obj	_	_
6	that	that	WDT	_	9	dep	_	_
7	have	have	VBP	_	9	aux	_	_
8	been	be	VBN	_	9	aux	_	_
9	found	find	VBN	_	5	relcl	_	_
10	,	,	,	_	9	p	_	_
11	or	or	CC	_	9	cc	_	_
12	are	be	VBP	_	13	aux	_	_
13	expected	expect	VBN	_	9	conj	_	_
14	,	,	,	_	13	p	_	_
15	to	to	TO	_	16	aux	_	_
16	increase	increase	VB	_	13	comp	_	_
17	plasma	plasma	NN	_	18	com	_	_
18	levels	level	NNS	_	16	obj	_	_
19	of	of	IN	_	20	case	_	_
20	drug1	drug0	NN	_	18	ppmod	_	_
21	are	be	VBP	_	20	acl	_	_
22	the	the	DT	_	23	det	_	_
23	following	following	NN	_	21	obj	_	_
24	:	:	:	_	1	p	_	_
25	drug2	drug0	NN	_	44	attr	_	_
26	,	,	,	_	25	p	_	_
27	drug3	drug0	NN	_	25	appo	_	_
28	,	,	,	_	25	p	_	_
29	drug4	drug0	NN	_	25	appo	_	_
30	,	,	,	_	25	p	_	_
31	drug5	drug0	NN	_	25	appo	_	_
32	(	-lrb-	-LRB-	_	31	p	_	_
33	1	0	CD	_	31	num	_	_
34	)	-rrb-	-RRB-	_	31	p	_	_
35	,	,	,	_	25	p	_	_
36	drug6	drug0	NN	_	25	appo	_	_
37	,	,	,	_	25	p	_	_
38	drug7	drug0	NN	_	25	appo	_	_
39	,	,	,	_	25	p	_	_
40	drug8	drug0	NN	_	25	appo	_	_
41	,	,	,	_	25	p	_	_
42	drug9	drug0	NN	_	25	appo	_	_
43	,	,	,	_	25	p	_	_
44	drug10	drug0	NN	_	46	attr	_	_
45	(	-lrb-	-LRB-	_	46	p	_	_
46	1	0	CD	_	1	appo	_	_
47	)	-rrb-	-RRB-	_	46	p	_	_
48	,	,	,	_	46	p	_	_
49	drug11	drug0	NN	_	46	appo	_	_
50	,	,	,	_	46	p	_	_
51	drug12	drug0	NN	_	46	appo	_	_
52	,	,	,	_	46	p	_	_
53	grapefruit	grapefruit	NN	_	54	com	_	_
54	juice	juice	NN	_	46	appo	_	_
55	,	,	,	_	46	p	_	_
56	drug13	drug0	NN	_	46	appo	_	_
57	,	,	,	_	46	p	_	_
58	drug14	drug0	NN	_	46	appo	_	_
59	,	,	,	_	46	p	_	_
60	drug15	drug0	NN	_	46	appo	_	_
61	,	,	,	_	46	p	_	_
62	drug16	drug0	NN	_	46	appo	_	_
63	,	,	,	_	46	p	_	_
64	drug17	drug0	CD	_	46	appo	_	_
65	,	,	,	_	46	p	_	_
66	drug18	drug0	NN	_	46	appo	_	_
67	,	,	,	_	46	p	_	_
68	drug19	drug0	NN	_	46	appo	_	_
69	,	,	,	_	46	p	_	_
70	drug20	drug0	NN	_	46	appo	_	_
71	,	,	,	_	46	p	_	_
72	drug21	drug0	NN	_	46	appo	_	_
73	,	,	,	_	46	p	_	_
74	drug22	drug0	NN	_	46	appo	_	_
75	,	,	,	_	46	p	_	_
76	drug23	drug0	NN	_	46	appo	_	_
77	,	,	,	_	46	p	_	_
78	drug24	drug0	NN	_	46	appo	_	_
79	,	,	,	_	46	p	_	_
80	drug25	drug0	NN	_	46	appo	_	_
81	(	-lrb-	-LRB-	_	80	p	_	_
82	1	0	CD	_	80	num	_	_
83	)	-rrb-	-RRB-	_	80	p	_	_
84	,	,	,	_	46	p	_	_
85	drug26	drug0	NN	_	46	appo	_	_
86	,	,	,	_	46	p	_	_
87	drug27	drug0	NN	_	46	appo	_	_
88	.	.	.	_	1	p	_	_

1	Thus	thus	RB	_	34	adv	_	_
2	,	,	,	_	34	p	_	_
3	if	if	IN	_	8	mark	_	_
4	a	a	DT	_	5	det	_	_
5	patient	patient	NN	_	8	dep	_	_
6	has	have	VBZ	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	titrated	titrate	VBN	_	34	advcl	_	_
9	to	to	TO	_	12	aux	_	_
10	a	a	DT	_	12	det	_	_
11	stable	stable	JJ	_	12	attr	_	_
12	dosage	dosage	NN	_	8	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	,	,	,	_	8	p	_	_
16	and	and	CC	_	8	cc	_	_
17	then	then	RB	_	18	adv	_	_
18	begins	begin	VBZ	_	8	conj	_	_
19	a	a	DT	_	20	det	_	_
20	course	course	NN	_	18	obj	_	_
21	of	of	IN	_	22	case	_	_
22	treatment	treatment	NN	_	20	ppmod	_	_
23	with	with	IN	_	24	case	_	_
24	one	#crd#	CD	_	18	ppmod	_	_
25	of	of	IN	_	31	case	_	_
26	these	these	DT	_	31	det	_	_
27	CYP3A4	cyp0a0	JJ	_	31	attr	_	_
28	or	or	CC	_	31	cc	_	_
29	epoxide	epoxide	NN	_	31	com	_	_
30	hydrolase	hydrolase	NN	_	31	com	_	_
31	inhibitors	inhibitor	NNS	_	24	ppmod	_	_
32	,	,	,	_	34	p	_	_
33	it	it	PRP	_	34	dep	_	_
34	is	be	VBZ	_	0	root	_	_
35	reasonable	reasonable	JJ	_	34	dep	_	_
36	to	to	TO	_	37	aux	_	_
37	expect	expect	VB	_	35	comp	_	_
38	that	that	IN	_	45	mark	_	_
39	a	a	DT	_	41	det	_	_
40	dose	dose	NN	_	41	com	_	_
41	reduction	reduction	NN	_	45	dep	_	_
42	for	for	IN	_	43	case	_	_
43	drug2	drug0	NN	_	41	ppmod	_	_
44	may	may	MD	_	45	modal	_	_
45	be	be	VB	_	37	comp	_	_
46	necessary	necessary	JJ	_	45	dep	_	_
47	.	.	.	_	34	p	_	_

1	Agents	agent	NNS	_	7	attr	_	_
2	that	that	WDT	_	3	dep	_	_
3	Induce	induce	VBP	_	1	relcl	_	_
4	Cytochrome	cytochrome	NN	_	6	com	_	_
5	P450	p0	NN	_	6	com	_	_
6	Isoenzymes	isoenzymes	NNS	_	3	obj	_	_
7	drug1	drug0	NN	_	9	dep	_	_
8	is	be	VBZ	_	9	aux	_	_
9	metabolized	metabolize	VBN	_	0	root	_	_
10	by	by	IN	_	11	case	_	_
11	CYP3A4	cyp0a0	NN	_	9	ppmod	_	_
12	.	.	.	_	9	p	_	_

1	Therefore	therefore	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	the	the	DT	_	4	det	_	_
4	potential	potential	NN	_	5	dep	_	_
5	exists	exist	VBZ	_	0	root	_	_
6	for	for	IN	_	7	case	_	_
7	interaction	interaction	NN	_	5	ppmod	_	_
8	between	between	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	any	any	DT	_	12	det	_	_
12	agent	agent	NN	_	9	conj	_	_
13	that	that	WDT	_	14	dep	_	_
14	induces	induce	VBZ	_	12	relcl	_	_
15	CYP3A4	cyp0a0	NN	_	14	obj	_	_
16	.	.	.	_	5	p	_	_

1	Agents	agent	NNS	_	0	root	_	_
2	that	that	WDT	_	3	dep	_	_
3	are	be	VBP	_	1	relcl	_	_
4	CYP	cyp	JJ	_	5	attr	_	_
5	inducers	inducer	NNS	_	3	obj	_	_
6	that	that	WDT	_	9	dep	_	_
7	have	have	VBP	_	9	aux	_	_
8	been	be	VBN	_	9	aux	_	_
9	found	find	VBN	_	5	relcl	_	_
10	,	,	,	_	9	p	_	_
11	or	or	CC	_	9	cc	_	_
12	are	be	VBP	_	13	aux	_	_
13	expected	expect	VBN	_	9	conj	_	_
14	,	,	,	_	13	p	_	_
15	to	to	TO	_	16	aux	_	_
16	decrease	decrease	VB	_	13	comp	_	_
17	plasma	plasma	NN	_	18	com	_	_
18	levels	level	NNS	_	16	obj	_	_
19	of	of	IN	_	20	case	_	_
20	drug1	drug0	NN	_	18	ppmod	_	_
21	are	be	VBP	_	16	comp	_	_
22	the	the	DT	_	23	det	_	_
23	following	following	NN	_	21	obj	_	_
24	:	:	:	_	1	p	_	_
25	drug2	drug0	NN	_	1	appo	_	_
26	,	,	,	_	25	p	_	_
27	drug3	drug0	NN	_	25	conj	_	_
28	,	,	,	_	27	p	_	_
29	drug4	drug0	NN	_	25	conj	_	_
30	,	,	,	_	29	p	_	_
31	drug5	drug0	NN	_	25	conj	_	_
32	,	,	,	_	31	p	_	_
33	drug6	drug0	NN	_	25	conj	_	_
34	,	,	,	_	33	p	_	_
35	drug7	drug0	NN	_	25	conj	_	_
36	(	-lrb-	-LRB-	_	35	p	_	_
37	2	0	CD	_	35	num	_	_
38	)	-rrb-	-RRB-	_	35	p	_	_
39	,	,	,	_	35	p	_	_
40	drug8	drug0	NN	_	25	conj	_	_
41	,	,	,	_	40	p	_	_
42	drug9	drug0	NN	_	25	conj	_	_
43	,	,	,	_	42	p	_	_
44	and	and	CC	_	42	cc	_	_
45	drug10	drug0	NN	_	25	conj	_	_
46	Thus	thus	RB	_	76	adv	_	_
47	,	,	,	_	76	p	_	_
48	if	if	IN	_	53	mark	_	_
49	a	a	DT	_	50	det	_	_
50	patient	patient	NN	_	53	dep	_	_
51	has	have	VBZ	_	53	aux	_	_
52	been	be	VBN	_	53	aux	_	_
53	titrated	titrate	VBN	_	76	advcl	_	_
54	to	to	TO	_	57	aux	_	_
55	a	a	DT	_	57	det	_	_
56	stable	stable	JJ	_	57	attr	_	_
57	dosage	dosage	NN	_	53	ppmod	_	_
58	on	on	IN	_	59	case	_	_
59	drug11	drug0	NN	_	53	ppmod	_	_
60	,	,	,	_	53	p	_	_
61	and	and	CC	_	53	cc	_	_
62	then	then	RB	_	63	adv	_	_
63	begins	begin	VBZ	_	53	conj	_	_
64	a	a	DT	_	65	det	_	_
65	course	course	NN	_	63	obj	_	_
66	of	of	IN	_	67	case	_	_
67	treatment	treatment	NN	_	65	ppmod	_	_
68	with	with	IN	_	69	case	_	_
69	one	#crd#	CD	_	67	ppmod	_	_
70	of	of	IN	_	73	case	_	_
71	these	these	DT	_	73	det	_	_
72	CYP3A4	cyp0a0	JJ	_	73	attr	_	_
73	inducers	inducer	NNS	_	69	ppmod	_	_
74	,	,	,	_	76	p	_	_
75	it	it	PRP	_	76	dep	_	_
76	is	be	VBZ	_	1	acl	_	_
77	reasonable	reasonable	JJ	_	76	dep	_	_
78	to	to	TO	_	79	aux	_	_
79	expect	expect	VB	_	77	comp	_	_
80	that	that	IN	_	87	mark	_	_
81	a	a	DT	_	83	det	_	_
82	dose	dose	NN	_	83	com	_	_
83	increase	increase	NN	_	87	dep	_	_
84	for	for	IN	_	85	case	_	_
85	drug12	drug0	NN	_	83	ppmod	_	_
86	may	may	MD	_	87	modal	_	_
87	be	be	VB	_	79	comp	_	_
88	necessary	necessary	JJ	_	87	dep	_	_
89	.	.	.	_	1	p	_	_

1	Agents	agent	NNS	_	17	dep	_	_
2	with	with	IN	_	4	case	_	_
3	Decreased	decrease	VBN	_	4	attr	_	_
4	Levels	level	NNS	_	1	ppmod	_	_
5	in	in	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	Presence	presence	NN	_	4	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	due	due	JJ	_	9	attr	_	_
11	to	to	TO	_	12	aux	_	_
12	Induction	induction	NN	_	10	ppmod	_	_
13	of	of	IN	_	16	case	_	_
14	Cytochrome	cytochrome	NN	_	16	com	_	_
15	P450	p0	NN	_	16	com	_	_
16	Enzymes	enzyme	NNS	_	12	ppmod	_	_
17	drug2	drug0	VBP	_	0	root	_	_
18	is	be	VBZ	_	19	aux	_	_
19	known	know	VBN	_	17	comp	_	_
20	to	to	TO	_	21	aux	_	_
21	induce	induce	VB	_	19	comp	_	_
22	CYP1A2	cyp0a0	NN	_	21	obj	_	_
23	and	and	CC	_	22	cc	_	_
24	CYP3A4	cyp0a0	NN	_	22	conj	_	_
25	.	.	.	_	17	p	_	_

1	Therefore	therefore	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	the	the	DT	_	4	det	_	_
4	potential	potential	NN	_	5	dep	_	_
5	exists	exist	VBZ	_	0	root	_	_
6	for	for	IN	_	7	case	_	_
7	interaction	interaction	NN	_	5	ppmod	_	_
8	between	between	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	any	any	DT	_	12	det	_	_
12	agent	agent	NN	_	9	conj	_	_
13	metabolized	metabolize	VBN	_	12	acl	_	_
14	by	by	IN	_	15	case	_	_
15	one	#crd#	CD	_	13	ppmod	_	_
16	(	-lrb-	-LRB-	_	15	p	_	_
17	or	or	CC	_	15	cc	_	_
18	more	more	JJR	_	15	conj	_	_
19	)	-rrb-	-RRB-	_	18	p	_	_
20	of	of	IN	_	22	case	_	_
21	these	these	DT	_	22	det	_	_
22	enzymes	enzyme	NNS	_	15	ppmod	_	_
23	.	.	.	_	5	p	_	_

1	Agents	agent	NNS	_	0	root	_	_
2	that	that	WDT	_	5	dep	_	_
3	have	have	VBP	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	found	find	VBN	_	1	relcl	_	_
6	,	,	,	_	5	p	_	_
7	or	or	CC	_	5	cc	_	_
8	are	be	VBP	_	9	aux	_	_
9	expected	expect	VBN	_	5	conj	_	_
10	to	to	TO	_	11	aux	_	_
11	have	have	VB	_	9	comp	_	_
12	decreased	decrease	VBN	_	14	attr	_	_
13	plasma	plasma	NN	_	14	com	_	_
14	levels	level	NNS	_	11	obj	_	_
15	in	in	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	presence	presence	NN	_	11	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug1	drug0	NN	_	17	ppmod	_	_
20	due	due	JJ	_	22	adv	_	_
21	to	to	TO	_	22	aux	_	_
22	induction	induction	NN	_	19	ppmod	_	_
23	of	of	IN	_	25	case	_	_
24	CYP	cyp	JJ	_	25	attr	_	_
25	enzymes	enzyme	NNS	_	22	ppmod	_	_
26	are	be	VBP	_	22	acl	_	_
27	the	the	DT	_	28	det	_	_
28	following	following	NN	_	26	obj	_	_
29	:	:	:	_	28	p	_	_
30	drug2	drug0	NN	_	76	attr	_	_
31	,	,	,	_	30	p	_	_
32	drug3	drug0	NN	_	30	appo	_	_
33	,	,	,	_	30	p	_	_
34	drug4	drug0	NN	_	30	appo	_	_
35	,	,	,	_	30	p	_	_
36	drug5	drug0	NN	_	30	appo	_	_
37	,	,	,	_	30	p	_	_
38	drug6	drug0	NN	_	30	appo	_	_
39	,	,	,	_	30	p	_	_
40	drug7	drug0	NN	_	30	appo	_	_
41	,	,	,	_	30	p	_	_
42	drug8	drug0	NN	_	30	appo	_	_
43	,	,	,	_	30	p	_	_
44	drug9	drug0	NN	_	30	appo	_	_
45	,	,	,	_	30	p	_	_
46	drug10	drug0	CD	_	30	appo	_	_
47	,	,	,	_	30	p	_	_
48	drug11	drug0	NN	_	30	appo	_	_
49	,	,	,	_	30	p	_	_
50	drug12	drug0	CD	_	30	appo	_	_
51	,	,	,	_	30	p	_	_
52	drug13	drug0	CD	_	76	num	_	_
53	,	,	,	_	76	p	_	_
54	drug14	drug0	CD	_	76	num	_	_
55	,	,	,	_	76	p	_	_
56	drug15	drug0	CD	_	76	num	_	_
57	,	,	,	_	76	p	_	_
58	drug16	drug0	CD	_	76	num	_	_
59	,	,	,	_	76	p	_	_
60	drug17	drug0	CD	_	76	num	_	_
61	,	,	,	_	76	p	_	_
62	drug18	drug0	CD	_	76	num	_	_
63	,	,	,	_	76	p	_	_
64	drug19	drug0	CD	_	76	num	_	_
65	,	,	,	_	76	p	_	_
66	drug20	drug0	CD	_	76	num	_	_
67	,	,	,	_	76	p	_	_
68	drug21	drug0	CD	_	76	num	_	_
69	,	,	,	_	76	p	_	_
70	drug22	drug0	CD	_	76	num	_	_
71	,	,	,	_	76	p	_	_
72	drug23	drug0	CD	_	76	num	_	_
73	,	,	,	_	76	p	_	_
74	drug24	drug0	CD	_	76	num	_	_
75	,	,	,	_	76	p	_	_
76	drug25	drug0	CD	_	89	num	_	_
77	,	,	,	_	76	p	_	_
78	drug26	drug0	CD	_	30	appo	_	_
79	,	,	,	_	76	p	_	_
80	drug27	drug0	NN	_	30	appo	_	_
81	,	,	,	_	76	p	_	_
82	drug28	drug0	CD	_	30	appo	_	_
83	,	,	,	_	76	p	_	_
84	drug29	drug0	CD	_	30	appo	_	_
85	,	,	,	_	76	p	_	_
86	drug30	drug0	NN	_	30	appo	_	_
87	,	,	,	_	76	p	_	_
88	oral	oral	JJ	_	89	attr	_	_
89	drug31	drug0	NN	_	113	dep	_	_
90	(	-lrb-	-LRB-	_	89	p	_	_
91	3	0	CD	_	89	num	_	_
92	)	-rrb-	-RRB-	_	89	p	_	_
93	,	,	,	_	89	p	_	_
94	drug32	drug0	NN	_	89	appo	_	_
95	,	,	,	_	89	p	_	_
96	drug33	drug0	NN	_	89	appo	_	_
97	(	-lrb-	-LRB-	_	96	p	_	_
98	4	0	CD	_	96	num	_	_
99	)	-rrb-	-RRB-	_	96	p	_	_
100	,	,	,	_	113	p	_	_
101	drug34	drug0	CD	_	113	num	_	_
102	,	,	,	_	113	p	_	_
103	drug35	drug0	CD	_	113	num	_	_
104	,	,	,	_	113	p	_	_
105	drug36	drug0	CD	_	113	num	_	_
106	,	,	,	_	113	p	_	_
107	drug37	drug0	CD	_	113	num	_	_
108	,	,	,	_	113	p	_	_
109	drug38	drug0	CD	_	113	num	_	_
110	,	,	,	_	113	p	_	_
111	drug39	drug0	CD	_	113	num	_	_
112	,	,	,	_	113	p	_	_
113	drug40	drug0	NN	_	28	acl	_	_
114	,	,	,	_	113	p	_	_
115	drug41	drug0	NN	_	113	appo	_	_
116	,	,	,	_	113	p	_	_
117	drug42	drug0	NN	_	113	appo	_	_
118	,	,	,	_	113	p	_	_
119	drug43	drug0	CD	_	113	appo	_	_
120	,	,	,	_	119	p	_	_
121	drug44	drug0	CD	_	123	num	_	_
122	(	-lrb-	-LRB-	_	123	p	_	_
123	5	0	CD	_	119	conj	_	_
124	)	-rrb-	-RRB-	_	123	p	_	_
125	,	,	,	_	123	p	_	_
126	drug45	drug0	CD	_	119	conj	_	_
127	,	,	,	_	126	p	_	_
128	and	and	CC	_	126	cc	_	_
129	drug46	drug0	CD	_	119	conj	_	_
130	.	.	.	_	1	p	_	_

1	Thus	thus	RB	_	33	adv	_	_
2	,	,	,	_	33	p	_	_
3	if	if	IN	_	8	mark	_	_
4	a	a	DT	_	5	det	_	_
5	patient	patient	NN	_	8	dep	_	_
6	has	have	VBZ	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	titrated	titrate	VBN	_	33	advcl	_	_
9	to	to	TO	_	12	aux	_	_
10	a	a	DT	_	12	det	_	_
11	stable	stable	JJ	_	12	attr	_	_
12	dosage	dosage	NN	_	8	ppmod	_	_
13	on	on	IN	_	14	case	_	_
14	one	#crd#	CD	_	8	ppmod	_	_
15	of	of	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	agents	agent	NNS	_	14	ppmod	_	_
18	in	in	IN	_	20	case	_	_
19	this	this	DT	_	20	det	_	_
20	category	category	NN	_	17	ppmod	_	_
21	,	,	,	_	8	p	_	_
22	and	and	CC	_	8	cc	_	_
23	then	then	RB	_	24	adv	_	_
24	begins	begin	VBZ	_	8	conj	_	_
25	a	a	DT	_	26	det	_	_
26	course	course	NN	_	24	obj	_	_
27	of	of	IN	_	28	case	_	_
28	treatment	treatment	NN	_	26	ppmod	_	_
29	with	with	IN	_	30	case	_	_
30	drug1	drug0	NN	_	24	ppmod	_	_
31	,	,	,	_	33	p	_	_
32	it	it	PRP	_	33	dep	_	_
33	is	be	VBZ	_	0	root	_	_
34	reasonable	reasonable	JJ	_	33	dep	_	_
35	to	to	TO	_	36	aux	_	_
36	expect	expect	VB	_	34	comp	_	_
37	that	that	IN	_	46	mark	_	_
38	a	a	DT	_	40	det	_	_
39	dose	dose	NN	_	40	com	_	_
40	increase	increase	NN	_	46	dep	_	_
41	for	for	IN	_	44	case	_	_
42	the	the	DT	_	44	det	_	_
43	concomitant	concomitant	JJ	_	44	attr	_	_
44	agent	agent	NN	_	40	ppmod	_	_
45	may	may	MD	_	46	modal	_	_
46	be	be	VB	_	36	comp	_	_
47	necessary	necessary	JJ	_	46	dep	_	_
48	.	.	.	_	33	p	_	_

1	Agents	agent	NNS	_	63	comp	_	_
2	with	with	IN	_	4	case	_	_
3	Increased	increase	VBN	_	4	attr	_	_
4	Levels	level	NNS	_	1	ppmod	_	_
5	in	in	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	Presence	presence	NN	_	4	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	:	:	:	_	1	p	_	_
11	drug2	drug0	NN	_	12	dep	_	_
12	increases	increase	VBZ	_	1	acl	_	_
13	the	the	DT	_	15	det	_	_
14	plasma	plasma	NN	_	15	com	_	_
15	levels	level	NNS	_	12	obj	_	_
16	of	of	IN	_	19	case	_	_
17	the	the	DT	_	19	det	_	_
18	following	following	JJ	_	19	attr	_	_
19	agents	agent	NNS	_	15	ppmod	_	_
20	:	:	:	_	1	p	_	_
21	drug3	drug0	NN	_	1	appo	_	_
22	,	,	,	_	21	p	_	_
23	drug4	drug0	NN	_	21	conj	_	_
24	(	-lrb-	-LRB-	_	23	p	_	_
25	6	0	CD	_	23	num	_	_
26	)	-rrb-	-RRB-	_	23	p	_	_
27	,	,	,	_	23	p	_	_
28	and	and	CC	_	23	cc	_	_
29	drug5	drug0	NN	_	21	conj	_	_
30	Thus	thus	RB	_	63	adv	_	_
31	,	,	,	_	63	p	_	_
32	if	if	IN	_	37	mark	_	_
33	a	a	DT	_	34	det	_	_
34	patient	patient	NN	_	37	dep	_	_
35	has	have	VBZ	_	37	aux	_	_
36	been	be	VBN	_	37	aux	_	_
37	titrated	titrate	VBN	_	63	advcl	_	_
38	to	to	TO	_	41	aux	_	_
39	a	a	DT	_	41	det	_	_
40	stable	stable	JJ	_	41	attr	_	_
41	dosage	dosage	NN	_	37	ppmod	_	_
42	on	on	IN	_	43	case	_	_
43	one	#crd#	CD	_	41	ppmod	_	_
44	of	of	IN	_	46	case	_	_
45	the	the	DT	_	46	det	_	_
46	agents	agent	NNS	_	43	ppmod	_	_
47	in	in	IN	_	49	case	_	_
48	this	this	DT	_	49	det	_	_
49	category	category	NN	_	46	ppmod	_	_
50	,	,	,	_	37	p	_	_
51	and	and	CC	_	37	cc	_	_
52	then	then	RB	_	53	adv	_	_
53	begins	begin	VBZ	_	37	conj	_	_
54	a	a	DT	_	55	det	_	_
55	course	course	NN	_	53	obj	_	_
56	of	of	IN	_	58	case	_	_
57	the	the	DT	_	58	det	_	_
58	treatment	treatment	NN	_	55	ppmod	_	_
59	with	with	IN	_	60	case	_	_
60	drug6	drug0	NN	_	58	ppmod	_	_
61	,	,	,	_	63	p	_	_
62	it	it	PRP	_	63	dep	_	_
63	is	be	VBZ	_	0	root	_	_
64	reasonable	reasonable	JJ	_	63	dep	_	_
65	to	to	TO	_	66	aux	_	_
66	expect	expect	VB	_	64	comp	_	_
67	that	that	IN	_	76	mark	_	_
68	a	a	DT	_	70	det	_	_
69	dose	dose	NN	_	70	com	_	_
70	decrease	decrease	NN	_	76	dep	_	_
71	for	for	IN	_	74	case	_	_
72	the	the	DT	_	74	det	_	_
73	concomitant	concomitant	JJ	_	74	attr	_	_
74	agent	agent	NN	_	70	ppmod	_	_
75	may	may	MD	_	76	modal	_	_
76	be	be	VB	_	66	comp	_	_
77	necessary	necessary	JJ	_	76	dep	_	_
78	.	.	.	_	63	p	_	_

1	Pharmacological/Pharmacodynamic	pharmacological/pharmacodynamic	JJ	_	2	attr	_	_
2	Interactions	interaction	NNS	_	12	dep	_	_
3	with	with	IN	_	6	case	_	_
4	drug1	drug0	JJ	_	6	attr	_	_
5	Concomitant	concomitant	JJ	_	6	attr	_	_
6	administration	administration	NN	_	2	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	drug3	drug0	NN	_	8	conj	_	_
11	may	may	MD	_	12	modal	_	_
12	increase	increase	VB	_	0	root	_	_
13	the	the	DT	_	14	det	_	_
14	risk	risk	NN	_	12	obj	_	_
15	of	of	IN	_	18	case	_	_
16	neurotoxic	neurotoxic	JJ	_	18	attr	_	_
17	side	side	JJ	_	18	attr	_	_
18	effects	effect	NNS	_	14	ppmod	_	_
19	.	.	.	_	12	p	_	_

1	Given	given	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	anticonvulsant	anticonvulsant	JJ	_	4	attr	_	_
4	properties	property	NNS	_	10	ppmod	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	,	,	,	_	10	p	_	_
8	drug2	drug0	NN	_	10	dep	_	_
9	may	may	MD	_	10	modal	_	_
10	reduce	reduce	VB	_	0	root	_	_
11	the	the	DT	_	13	det	_	_
12	thyroid	thyroid	NN	_	13	com	_	_
13	function	function	NN	_	10	obj	_	_
14	as	as	IN	_	17	mark	_	_
15	has	have	VBZ	_	17	aux	_	_
16	been	be	VBN	_	17	aux	_	_
17	reported	report	VBN	_	10	comp	_	_
18	with	with	IN	_	20	case	_	_
19	other	other	JJ	_	20	attr	_	_
20	drug3	drug0	NN	_	17	ppmod	_	_
21	.	.	.	_	10	p	_	_

1	Additionally	additionally	RB	_	12	adv	_	_
2	,	,	,	_	12	p	_	_
3	drug1	drug0	NN	_	12	dep	_	_
4	,	,	,	_	3	p	_	_
5	such	such	JJ	_	7	adv	_	_
6	as	as	IN	_	7	case	_	_
7	drug2	drug0	NN	_	3	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug3	drug0	NN	_	7	conj	_	_
10	,	,	,	_	3	p	_	_
11	may	may	MD	_	12	modal	_	_
12	antagonize	antagonize	VB	_	0	root	_	_
13	the	the	DT	_	14	det	_	_
14	activity	activity	NN	_	12	obj	_	_
15	of	of	IN	_	16	case	_	_
16	drug4	drug0	NN	_	14	ppmod	_	_
17	.	.	.	_	12	p	_	_

1	Thus	thus	RB	_	32	adv	_	_
2	if	if	IN	_	7	mark	_	_
3	a	a	DT	_	4	det	_	_
4	patient	patient	NN	_	7	dep	_	_
5	has	have	VBZ	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	titrated	titrate	VBN	_	1	comp	_	_
8	to	to	TO	_	11	aux	_	_
9	a	a	DT	_	11	det	_	_
10	stable	stable	JJ	_	11	attr	_	_
11	dosage	dosage	NN	_	7	ppmod	_	_
12	on	on	IN	_	13	case	_	_
13	one	#crd#	CD	_	11	ppmod	_	_
14	of	of	IN	_	16	case	_	_
15	the	the	DT	_	16	det	_	_
16	agents	agent	NNS	_	13	ppmod	_	_
17	in	in	IN	_	19	case	_	_
18	this	this	DT	_	19	det	_	_
19	category	category	NN	_	16	ppmod	_	_
20	,	,	,	_	7	p	_	_
21	and	and	CC	_	7	cc	_	_
22	then	then	RB	_	23	adv	_	_
23	begins	begin	VBZ	_	7	conj	_	_
24	a	a	DT	_	25	det	_	_
25	course	course	NN	_	23	obj	_	_
26	of	of	IN	_	27	case	_	_
27	treatment	treatment	NN	_	25	ppmod	_	_
28	with	with	IN	_	29	case	_	_
29	drug1	drug0	NN	_	27	ppmod	_	_
30	,	,	,	_	32	p	_	_
31	it	it	PRP	_	32	dep	_	_
32	is	be	VBZ	_	0	root	_	_
33	reasonable	reasonable	JJ	_	32	dep	_	_
34	to	to	TO	_	35	aux	_	_
35	expect	expect	VB	_	33	comp	_	_
36	that	that	IN	_	41	mark	_	_
37	a	a	DT	_	39	det	_	_
38	dose	dose	NN	_	39	com	_	_
39	adjustment	adjustment	NN	_	41	dep	_	_
40	may	may	MD	_	41	modal	_	_
41	be	be	VB	_	35	comp	_	_
42	necessary	necessary	JJ	_	41	dep	_	_
43	.	.	.	_	32	p	_	_

1	Because	because	IN	_	6	case	_	_
2	of	of	IN	_	6	case	_	_
3	its	its	PRP$	_	6	poss	_	_
4	primary	primary	JJ	_	6	attr	_	_
5	CNS	cns	NN	_	6	com	_	_
6	effect	effect	NN	_	11	ppmod	_	_
7	,	,	,	_	11	p	_	_
8	caution	caution	NN	_	11	dep	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	used	use	VBN	_	0	root	_	_
12	when	when	WRB	_	15	adv	_	_
13	drug1	drug0	NN	_	15	dep	_	_
14	is	be	VBZ	_	15	aux	_	_
15	taken	take	VBN	_	11	comp	_	_
16	with	with	IN	_	18	case	_	_
17	other	other	JJ	_	18	attr	_	_
18	drug2	drug0	NN	_	15	ppmod	_	_
19	and	and	CC	_	18	cc	_	_
20	drug3	drug0	NN	_	18	conj	_	_
21	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	-	-	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	may	may	MD	_	5	modal	_	_
5	counteract	counteract	VB	_	0	root	_	_
6	the	the	DT	_	8	det	_	_
7	antinaturetic	antinaturetic	JJ	_	8	attr	_	_
8	effect	effect	NN	_	5	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug3	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	-	-	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	may	may	MD	_	5	modal	_	_
5	increase	increase	VB	_	0	root	_	_
6	the	the	DT	_	7	det	_	_
7	absorption	absorption	NN	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_
10	if	if	IN	_	11	mark	_	_
11	taken	take	VBN	_	5	comp	_	_
12	concomitantly	concomitantly	RB	_	11	adv	_	_
13	.	.	.	_	5	p	_	_

1	Organic	organic	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	5	attr	_	_
3	-	-	CC	_	2	cc	_	_
4	drug2	drug0	NN	_	2	conj	_	_
5	supplements	supplement	NNS	_	8	dep	_	_
6	theoretically	theoretically	RB	_	8	adv	_	_
7	may	may	MD	_	8	modal	_	_
8	potentiate	potentiate	VB	_	0	root	_	_
9	the	the	DT	_	10	det	_	_
10	effects	effect	NNS	_	8	obj	_	_
11	of	of	IN	_	13	case	_	_
12	organic	organic	JJ	_	13	attr	_	_
13	drug3	drug0	NN	_	10	ppmod	_	_
14	if	if	IN	_	15	mark	_	_
15	taken	take	VBN	_	8	comp	_	_
16	concomitantly	concomitantly	RB	_	15	adv	_	_
17	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	-	-	:	_	1	p	_	_
3	Theoretically	theoretically	RB	_	13	adv	_	_
4	,	,	,	_	13	p	_	_
5	drug2	drug0	NN	_	6	com	_	_
6	supplements	supplement	NNS	_	13	dep	_	_
7	taken	take	VBN	_	6	acl	_	_
8	concomitantly	concomitantly	RB	_	7	adv	_	_
9	with	with	IN	_	10	case	_	_
10	drug3	drug0	NN	_	7	ppmod	_	_
11	,	,	,	_	6	p	_	_
12	may	may	MD	_	13	modal	_	_
13	potentiate	potentiate	VB	_	1	acl	_	_
14	the	the	DT	_	15	det	_	_
15	effects	effect	NNS	_	13	obj	_	_
16	of	of	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	drug	drug	NN	_	15	ppmod	_	_
19	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	decrease	decrease	VB	_	0	root	_	_
4	drug2	drug0	NN	_	5	com	_	_
5	response	response	NN	_	3	obj	_	_
6	to	to	TO	_	7	aux	_	_
7	drug3	drug0	NN	_	5	ppmod	_	_
8	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	an	an	DT	_	4	det	_	_
4	inhibitor	inhibitor	NN	_	2	obj	_	_
5	of	of	IN	_	10	case	_	_
6	the	the	DT	_	10	det	_	_
7	cytochrome	cytochrome	NN	_	10	com	_	_
8	P450	p0	NN	_	10	com	_	_
9	isoform	isoform	NN	_	10	com	_	_
10	CYP3A4	cyp0a0	NN	_	4	ppmod	_	_
11	.	.	.	_	2	p	_	_

1	Coadministration	coadministration	NN	_	11	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	drugs	drug	NNS	_	3	conj	_	_
6	primarily	primarily	RB	_	7	adv	_	_
7	metabolized	metabolize	VBN	_	3	acl	_	_
8	by	by	IN	_	9	case	_	_
9	CYP3A4	cyp0a0	NN	_	7	ppmod	_	_
10	may	may	MD	_	11	modal	_	_
11	result	result	VB	_	0	root	_	_
12	in	in	IN	_	15	case	_	_
13	increased	increase	VBN	_	15	attr	_	_
14	plasma	plasma	NN	_	15	com	_	_
15	concentrations	concentration	NNS	_	11	ppmod	_	_
16	of	of	IN	_	19	case	_	_
17	the	the	DT	_	19	det	_	_
18	other	other	JJ	_	19	attr	_	_
19	drug	drug	NN	_	15	ppmod	_	_
20	,	,	,	_	19	p	_	_
21	which	which	WDT	_	23	dep	_	_
22	could	could	MD	_	23	modal	_	_
23	increase	increase	VB	_	19	relcl	_	_
24	or	or	CC	_	23	cc	_	_
25	prolong	prolong	VB	_	23	conj	_	_
26	its	its	PRP$	_	30	poss	_	_
27	therapeutic	therapeutic	JJ	_	30	attr	_	_
28	and	and	CC	_	27	cc	_	_
29	adverse	adverse	JJ	_	27	conj	_	_
30	effects	effect	NNS	_	25	obj	_	_
31	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	metabolized	metabolize	VBN	_	0	root	_	_
4	by	by	IN	_	5	case	_	_
5	CYP3A4	cyp0a0	NN	_	3	ppmod	_	_
6	.	.	.	_	3	p	_	_

1	Drugs	drug	NNS	_	8	dep	_	_
2	that	that	WDT	_	3	dep	_	_
3	induce	induce	VBP	_	1	relcl	_	_
4	CYP3A4	cyp0a0	NN	_	5	com	_	_
5	activity	activity	NN	_	3	obj	_	_
6	would	would	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	expected	expect	VBN	_	0	root	_	_
9	to	to	TO	_	10	aux	_	_
10	increase	increase	VB	_	8	comp	_	_
11	the	the	DT	_	12	det	_	_
12	clearance	clearance	NN	_	10	obj	_	_
13	of	of	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	,	,	,	_	10	p	_	_
16	resulting	result	VBG	_	10	comp	_	_
17	in	in	IN	_	20	case	_	_
18	lowered	lowered	JJ	_	20	attr	_	_
19	plasma	plasma	NN	_	20	com	_	_
20	concentrations	concentration	NNS	_	16	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	drug2	drug0	NN	_	20	ppmod	_	_
23	.	.	.	_	8	p	_	_

1	Coadministration	coadministration	NN	_	11	dep	_	_
2	of	of	IN	_	6	case	_	_
3	drug1	drug0	JJ	_	6	attr	_	_
4	and	and	CC	_	3	cc	_	_
5	other	other	JJ	_	3	conj	_	_
6	drugs	drug	NNS	_	1	ppmod	_	_
7	that	that	WDT	_	8	dep	_	_
8	inhibit	inhibit	VBP	_	6	relcl	_	_
9	CYP3A4	cyp0a0	NN	_	8	obj	_	_
10	may	may	MD	_	11	modal	_	_
11	decrease	decrease	VB	_	0	root	_	_
12	the	the	DT	_	13	det	_	_
13	clearance	clearance	NN	_	11	obj	_	_
14	of	of	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	and	and	CC	_	11	cc	_	_
17	may	may	MD	_	18	modal	_	_
18	result	result	VB	_	11	conj	_	_
19	in	in	IN	_	22	case	_	_
20	increased	increase	VBN	_	22	attr	_	_
21	plasma	plasma	NN	_	22	com	_	_
22	concentrations	concentration	NNS	_	18	ppmod	_	_
23	of	of	IN	_	24	case	_	_
24	drug3	drug0	NN	_	22	ppmod	_	_
25	.	.	.	_	11	p	_	_

1	Table	table	NN	_	0	root	_	_
2	8	0	CD	_	1	num	_	_

1	Drugs	drug	NNS	_	0	root	_	_
2	That	that	WDT	_	6	dep	_	_
3	Should	should	MD	_	6	modal	_	_
4	Not	not	RB	_	6	neg	_	_
5	Be	be	VB	_	6	aux	_	_
6	Coadministered	coadministered	VBN	_	1	relcl	_	_
7	with	with	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_

1	Drug	drug	NN	_	2	com	_	_
2	Class	class	NN	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	Drug	drug	NN	_	7	attr	_	_
5	Name	name	NN	_	7	attr	_	_
6	Clinical	clinical	JJ	_	7	attr	_	_
7	Comment	comment	NN	_	2	appo	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_

1	CONTRAINDICATED	contraindicate	VBN	_	0	root	_	_
2	due	due	JJ	_	4	adv	_	_
3	to	to	TO	_	4	aux	_	_
4	potential	potential	NN	_	1	ppmod	_	_
5	for	for	IN	_	9	case	_	_
6	serious	serious	JJ	_	9	attr	_	_
7	and/or	and/or	CC	_	6	cc	_	_
8	life-threatening	life-threatening	JJ	_	6	conj	_	_
9	reactions	reaction	NNS	_	4	ppmod	_	_
10	such	such	JJ	_	13	adv	_	_
11	as	as	IN	_	13	case	_	_
12	cardiac	cardiac	JJ	_	13	attr	_	_
13	arrhythmias	arrhythmia	NNS	_	9	ppmod	_	_
14	.	.	.	_	1	p	_	_

1	Ergot	ergot	NN	_	2	com	_	_
2	derivatives	derivative	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	drug1	drug0	NN	_	2	appo	_	_
5	,	,	,	_	4	p	_	_
6	drug2	drug0	NN	_	4	appo	_	_
7	,	,	,	_	4	p	_	_
8	drug3	drug0	NN	_	4	appo	_	_
9	,	,	,	_	4	p	_	_
10	drug4	drug0	NN	_	4	appo	_	_

1	CONTRAINDICATED	contraindicate	VBN	_	0	root	_	_
2	due	due	JJ	_	4	adv	_	_
3	to	to	TO	_	4	aux	_	_
4	potential	potential	NN	_	1	ppmod	_	_
5	for	for	IN	_	9	case	_	_
6	serious	serious	JJ	_	9	attr	_	_
7	and/or	and/or	CC	_	6	cc	_	_
8	life-threatening	life-threatening	JJ	_	6	conj	_	_
9	reactions	reaction	NNS	_	4	ppmod	_	_
10	such	such	JJ	_	14	adv	_	_
11	as	as	IN	_	14	case	_	_
12	acute	acute	JJ	_	14	attr	_	_
13	ergot	ergot	NN	_	14	com	_	_
14	toxicity	toxicity	NN	_	9	ppmod	_	_
15	characterized	characterize	VBN	_	14	acl	_	_
16	by	by	IN	_	18	case	_	_
17	peripheral	peripheral	JJ	_	18	attr	_	_
18	vasospasm	vasospasm	NN	_	15	ppmod	_	_
19	and	and	CC	_	18	cc	_	_
20	ischemia	ischemia	NN	_	18	conj	_	_
21	of	of	IN	_	23	case	_	_
22	the	the	DT	_	23	det	_	_
23	extremities	extremities	NN	_	18	ppmod	_	_
24	and	and	CC	_	23	cc	_	_
25	other	other	JJ	_	26	attr	_	_
26	tissues	tissue	NNS	_	23	conj	_	_
27	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	/	/	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	:	:	:	_	1	p	_	_
5	drug3	drug0	NN	_	1	appo	_	_
6	,	,	,	_	5	p	_	_
7	drug4	drug0	NN	_	5	appo	_	_

1	CONTRAINDICATED	contraindicate	VBN	_	0	root	_	_
2	due	due	JJ	_	4	adv	_	_
3	to	to	TO	_	4	aux	_	_
4	potential	potential	NN	_	1	ppmod	_	_
5	for	for	IN	_	9	case	_	_
6	serious	serious	JJ	_	9	attr	_	_
7	and/or	and/or	CC	_	6	cc	_	_
8	life-threatening	life-threatening	JJ	_	6	conj	_	_
9	reactions	reaction	NNS	_	4	ppmod	_	_
10	such	such	JJ	_	15	adv	_	_
11	as	as	IN	_	15	case	_	_
12	prolonged	prolonged	JJ	_	15	attr	_	_
13	or	or	CC	_	12	cc	_	_
14	increased	increase	VBN	_	12	conj	_	_
15	sedation	sedation	NN	_	9	ppmod	_	_
16	or	or	CC	_	15	cc	_	_
17	respiratory	respiratory	JJ	_	18	attr	_	_
18	depression	depression	NN	_	15	conj	_	_
19	.	.	.	_	1	p	_	_

1	GI	gi	NN	_	3	com	_	_
2	motility	motility	NN	_	3	com	_	_
3	agents	agent	NNS	_	0	root	_	_
4	:	:	:	_	3	p	_	_
5	drug1	drug0	NN	_	3	appo	_	_

1	CONTRAINDICATED	contraindicate	VBN	_	0	root	_	_
2	due	due	JJ	_	4	adv	_	_
3	to	to	TO	_	4	aux	_	_
4	potential	potential	NN	_	1	ppmod	_	_
5	for	for	IN	_	9	case	_	_
6	serious	serious	JJ	_	9	attr	_	_
7	and/or	and/or	CC	_	6	cc	_	_
8	life-threatening	life-threatening	JJ	_	6	conj	_	_
9	reactions	reaction	NNS	_	4	ppmod	_	_
10	such	such	JJ	_	13	adv	_	_
11	as	as	IN	_	13	case	_	_
12	cardiac	cardiac	JJ	_	13	attr	_	_
13	arrhythmias	arrhythmia	NNS	_	9	ppmod	_	_
14	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_

1	CONTRAINDICATED	contraindicate	VBN	_	0	root	_	_
2	due	due	JJ	_	4	adv	_	_
3	to	to	TO	_	4	aux	_	_
4	potential	potential	NN	_	1	ppmod	_	_
5	for	for	IN	_	9	case	_	_
6	serious	serious	JJ	_	9	attr	_	_
7	and/or	and/or	CC	_	6	cc	_	_
8	life-threatening	life-threatening	JJ	_	6	conj	_	_
9	reactions	reaction	NNS	_	4	ppmod	_	_
10	such	such	JJ	_	13	adv	_	_
11	as	as	IN	_	13	case	_	_
12	cardiac	cardiac	JJ	_	13	attr	_	_
13	arrhythmias	arrhythmia	NNS	_	9	ppmod	_	_
14	.	.	.	_	1	p	_	_

1	Herbal	herbal	JJ	_	2	attr	_	_
2	products	product	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	St.	st.	NN	_	7	com	_	_
5	John	john	NN	_	7	com	_	_
6	s	s	NN	_	7	com	_	_
7	wort	wort	NN	_	2	appo	_	_
8	(	-lrb-	-LRB-	_	10	p	_	_
9	Hypericum	hypericum	NN	_	10	com	_	_
10	perforatum	perforatum	NN	_	7	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_

1	May	may	MD	_	2	modal	_	_
2	lead	lead	VB	_	0	root	_	_
3	to	to	TO	_	4	aux	_	_
4	loss	loss	NN	_	2	ppmod	_	_
5	of	of	IN	_	7	case	_	_
6	virologic	virologic	JJ	_	7	attr	_	_
7	response	response	NN	_	4	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	possible	possible	JJ	_	10	attr	_	_
10	resistance	resistance	NN	_	7	conj	_	_
11	to	to	TO	_	12	aux	_	_
12	drug1	drug0	NN	_	4	ppmod	_	_
13	or	or	CC	_	12	cc	_	_
14	to	to	TO	_	16	aux	_	_
15	the	the	DT	_	16	det	_	_
16	class	class	NN	_	12	conj	_	_
17	of	of	IN	_	18	case	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_

1	May	may	MD	_	2	modal	_	_
2	lead	lead	VB	_	0	root	_	_
3	to	to	TO	_	4	aux	_	_
4	loss	loss	NN	_	2	ppmod	_	_
5	of	of	IN	_	7	case	_	_
6	virologic	virologic	JJ	_	7	attr	_	_
7	response	response	NN	_	4	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	possible	possible	JJ	_	10	attr	_	_
10	resistance	resistance	NN	_	7	conj	_	_
11	to	to	TO	_	12	aux	_	_
12	drug1	drug0	NN	_	4	ppmod	_	_
13	or	or	CC	_	12	cc	_	_
14	to	to	TO	_	16	aux	_	_
15	the	the	DT	_	16	det	_	_
16	class	class	NN	_	12	conj	_	_
17	of	of	IN	_	18	case	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	or	or	CC	_	18	cc	_	_
20	other	other	JJ	_	22	attr	_	_
21	coadministered	coadministered	JJ	_	22	attr	_	_
22	drug3	drug0	NN	_	18	conj	_	_
23	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	,	,	,	_	1	p	_	_
5	drug3	drug0	NN	_	1	appo	_	_

1	Potential	potential	JJ	_	0	root	_	_
2	for	for	IN	_	4	case	_	_
3	serious	serious	JJ	_	4	attr	_	_
4	reactions	reaction	NNS	_	1	ppmod	_	_
5	such	such	JJ	_	7	adv	_	_
6	as	as	IN	_	7	case	_	_
7	risk	risk	NN	_	4	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	myopathy	myopathy	NN	_	7	ppmod	_	_
10	including	include	VBG	_	11	adv	_	_
11	rhabdomyolysis	rhabdomyolysis	NN	_	4	ppmod	_	_
12	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_

1	Both	both	CC	_	2	cc	_	_
2	drug1	drug0	NN	_	6	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	drug2	drug0	NN	_	2	conj	_	_
5	are	be	VBP	_	6	aux	_	_
6	associated	associate	VBN	_	0	root	_	_
7	with	with	IN	_	12	case	_	_
8	indirect	indirect	JJ	_	12	attr	_	_
9	(	-lrb-	-LRB-	_	12	p	_	_
10	unconjugated	unconjugated	JJ	_	12	attr	_	_
11	)	-rrb-	-RRB-	_	12	p	_	_
12	hyperbilirubinemia	hyperbilirubinemia	NN	_	6	ppmod	_	_
13	.	.	.	_	6	p	_	_

1	Combinations	combination	NNS	_	8	dep	_	_
2	of	of	IN	_	4	case	_	_
3	these	these	DT	_	4	det	_	_
4	drugs	drug	NNS	_	1	ppmod	_	_
5	have	have	VBP	_	8	aux	_	_
6	not	not	RB	_	8	neg	_	_
7	been	be	VBN	_	8	aux	_	_
8	studied	study	VBN	_	0	root	_	_
9	and	and	CC	_	8	cc	_	_
10	coadministration	coadministration	NN	_	17	dep	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	drug2	drug0	NN	_	12	conj	_	_
15	is	be	VBZ	_	17	aux	_	_
16	not	not	RB	_	17	neg	_	_
17	recommended	recommend	VBN	_	8	conj	_	_
18	.	.	.	_	8	p	_	_

1	Table	table	NN	_	0	root	_	_
2	9	0	CD	_	1	num	_	_

1	Established	established	JJ	_	7	attr	_	_
2	and	and	CC	_	1	cc	_	_
3	Other	other	JJ	_	1	conj	_	_
4	Potentially	potentially	RB	_	5	adv	_	_
5	Significant	significant	JJ	_	7	attr	_	_
6	Drug	drug	NN	_	7	com	_	_
7	Interactions	interaction	NNS	_	0	root	_	_
8	:	:	:	_	7	p	_	_
9	Alteration	alteration	NN	_	16	dep	_	_
10	in	in	IN	_	11	case	_	_
11	Dose	dose	NN	_	9	ppmod	_	_
12	or	or	CC	_	11	cc	_	_
13	Regimen	regimen	NN	_	11	conj	_	_
14	May	may	MD	_	16	modal	_	_
15	Be	be	VB	_	16	aux	_	_
16	Recommended	recommend	VBN	_	7	acl	_	_
17	Based	base	VBN	_	21	adv	_	_
18	on	on	IN	_	21	case	_	_
19	Drug	drug	NN	_	21	com	_	_
20	Interaction	interaction	NN	_	21	com	_	_
21	Studies	study	NNS	_	16	ppmod	_	_
22	or	or	CC	_	21	cc	_	_
23	Predicted	predict	VBN	_	24	attr	_	_
24	Interaction	interaction	NN	_	21	conj	_	_

1	Drug	drug	NN	_	2	com	_	_
2	Name	name	NN	_	0	root	_	_

1	Effect	effect	NN	_	0	root	_	_

1	Clinical	clinical	JJ	_	2	attr	_	_
2	Comment	comment	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	concentration	concentration	NN	_	0	root	_	_

1	Dose	dose	NN	_	2	com	_	_
2	reduction	reduction	NN	_	13	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	to	to	TO	_	7	aux	_	_
6	600	0	CD	_	7	num	_	_
7	mg	mg	NN	_	2	ppmod	_	_
8	every	every	DT	_	10	det	_	_
9	8	0	CD	_	10	num	_	_
10	hours	hour	NNS	_	7	appo	_	_
11	should	should	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	considered	consider	VBN	_	0	root	_	_
14	when	when	WRB	_	15	adv	_	_
15	taking	take	VBG	_	13	comp	_	_
16	drug2	drug0	NN	_	20	attr	_	_
17	400	0	CD	_	20	num	_	_
18	mg	mg	NN	_	20	attr	_	_
19	three	#crd#	CD	_	20	num	_	_
20	times	time	NNS	_	15	obj	_	_
21	a	a	DT	_	22	det	_	_
22	day	day	NN	_	20	appo	_	_
23	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	4	attr	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	formulations	formulation	NNS	_	9	dep	_	_
5	containing	contain	VBG	_	4	acl	_	_
6	buffer	buffer	NN	_	5	obj	_	_
7	should	should	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	administered	administer	VBN	_	0	root	_	_
10	at	at	IN	_	12	case	_	_
11	least	least	JJS	_	12	attr	_	_
12	one	#crd#	CD	_	13	num	_	_
13	hour	hour	NN	_	14	advnp	_	_
14	apart	apart	RB	_	9	adv	_	_
15	on	on	IN	_	18	case	_	_
16	an	an	DT	_	18	det	_	_
17	empty	empty	JJ	_	18	attr	_	_
18	stomach	stomach	NN	_	9	ppmod	_	_
19	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	concentration	concentration	NN	_	0	root	_	_

1	The	the	DT	_	3	det	_	_
2	optimal	optimal	JJ	_	3	attr	_	_
3	dose	dose	NN	_	16	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	,	,	,	_	3	p	_	_
7	when	when	WRB	_	8	adv	_	_
8	given	give	VBN	_	3	relcl	_	_
9	in	in	IN	_	10	case	_	_
10	combination	combination	NN	_	8	ppmod	_	_
11	with	with	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	,	,	,	_	3	p	_	_
14	is	be	VBZ	_	16	aux	_	_
15	not	not	RB	_	16	neg	_	_
16	known	know	VBN	_	0	root	_	_
17	.	.	.	_	16	p	_	_

1	Increasing	increase	VBG	_	13	advcl	_	_
2	the	the	DT	_	4	det	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	dose	dose	NN	_	1	obj	_	_
5	to	to	TO	_	7	aux	_	_
6	1000	0	CD	_	7	num	_	_
7	mg	mg	NN	_	1	ppmod	_	_
8	every	every	DT	_	10	det	_	_
9	8	0	CD	_	10	num	_	_
10	hours	hour	NNS	_	7	appo	_	_
11	does	do	VBZ	_	13	aux	_	_
12	not	not	RB	_	13	neg	_	_
13	compensate	compensate	VB	_	0	root	_	_
14	for	for	IN	_	18	case	_	_
15	the	the	DT	_	18	det	_	_
16	increased	increase	VBN	_	18	attr	_	_
17	drug2	drug0	NN	_	18	com	_	_
18	metabolism	metabolism	NN	_	13	ppmod	_	_
19	due	due	JJ	_	18	attr	_	_
20	to	to	TO	_	21	aux	_	_
21	drug3	drug0	NN	_	19	ppmod	_	_
22	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	concentration	concentration	NN	_	0	root	_	_

1	The	the	DT	_	3	det	_	_
2	appropriate	appropriate	JJ	_	3	attr	_	_
3	doses	dose	NNS	_	18	dep	_	_
4	for	for	IN	_	6	case	_	_
5	this	this	DT	_	6	det	_	_
6	combination	combination	NN	_	3	ppmod	_	_
7	,	,	,	_	3	p	_	_
8	with	with	IN	_	9	case	_	_
9	respect	respect	NN	_	3	ppmod	_	_
10	to	to	TO	_	11	aux	_	_
11	efficacy	efficacy	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	safety	safety	NN	_	11	conj	_	_
14	,	,	,	_	3	p	_	_
15	have	have	VBP	_	18	aux	_	_
16	not	not	RB	_	18	neg	_	_
17	been	be	VBN	_	18	aux	_	_
18	established	establish	VBN	_	0	root	_	_
19	.	.	.	_	18	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	concentration	concentration	NN	_	0	root	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	concentrations	concentration	NNS	_	5	dep	_	_
3	may	may	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	decreased	decrease	VBN	_	0	root	_	_
6	in	in	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	presence	presence	NN	_	5	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	5	p	_	_

1	The	the	DT	_	3	det	_	_
2	appropriate	appropriate	JJ	_	3	attr	_	_
3	doses	dose	NNS	_	18	dep	_	_
4	for	for	IN	_	6	case	_	_
5	this	this	DT	_	6	det	_	_
6	combination	combination	NN	_	3	ppmod	_	_
7	,	,	,	_	3	p	_	_
8	with	with	IN	_	9	case	_	_
9	respect	respect	NN	_	3	ppmod	_	_
10	to	to	TO	_	11	aux	_	_
11	efficacy	efficacy	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	safety	safety	NN	_	11	conj	_	_
14	,	,	,	_	3	p	_	_
15	have	have	VBP	_	18	aux	_	_
16	not	not	RB	_	18	neg	_	_
17	been	be	VBN	_	18	aux	_	_
18	established	establish	VBN	_	0	root	_	_
19	.	.	.	_	18	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	4	com	_	_
2	concentration	concentration	NN	_	4	com	_	_
3	drug2	drug0	NN	_	4	com	_	_
4	concentration	concentration	NN	_	0	root	_	_

1	The	the	DT	_	3	det	_	_
2	appropriate	appropriate	JJ	_	3	attr	_	_
3	doses	dose	NNS	_	18	dep	_	_
4	for	for	IN	_	6	case	_	_
5	this	this	DT	_	6	det	_	_
6	combination	combination	NN	_	3	ppmod	_	_
7	,	,	,	_	3	p	_	_
8	with	with	IN	_	9	case	_	_
9	respect	respect	NN	_	3	ppmod	_	_
10	to	to	TO	_	11	aux	_	_
11	efficacy	efficacy	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	safety	safety	NN	_	11	conj	_	_
14	,	,	,	_	3	p	_	_
15	have	have	VBP	_	18	aux	_	_
16	not	not	RB	_	18	neg	_	_
17	been	be	VBN	_	18	aux	_	_
18	established	establish	VBN	_	0	root	_	_
19	.	.	.	_	18	p	_	_

1	Preliminary	preliminary	JJ	_	3	attr	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	data	datum	NNS	_	4	dep	_	_
4	suggest	suggest	VBP	_	0	root	_	_
5	that	that	IN	_	10	mark	_	_
6	the	the	DT	_	7	det	_	_
7	incidence	incidence	NN	_	10	dep	_	_
8	of	of	IN	_	9	case	_	_
9	nephrolithiasis	nephrolithiasis	NN	_	7	ppmod	_	_
10	is	be	VBZ	_	4	comp	_	_
11	higher	high	JJR	_	10	dep	_	_
12	in	in	IN	_	13	case	_	_
13	patients	patient	NNS	_	11	ppmod	_	_
14	receiving	receive	VBG	_	13	acl	_	_
15	drug1	drug0	NN	_	14	obj	_	_
16	in	in	IN	_	17	case	_	_
17	combination	combination	NN	_	14	ppmod	_	_
18	with	with	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	than	than	IN	_	21	case	_	_
21	those	those	DT	_	11	ppmod	_	_
22	receiving	receive	VBG	_	21	acl	_	_
23	drug3	drug0	NN	_	25	attr	_	_
24	800	0	CD	_	25	num	_	_
25	mg	mg	NN	_	26	com	_	_
26	q8h	q0h	NN	_	22	obj	_	_
27	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	concentration	concentration	NN	_	0	root	_	_

1	The	the	DT	_	3	det	_	_
2	appropriate	appropriate	JJ	_	3	attr	_	_
3	doses	dose	NNS	_	18	dep	_	_
4	for	for	IN	_	6	case	_	_
5	this	this	DT	_	6	det	_	_
6	combination	combination	NN	_	3	ppmod	_	_
7	,	,	,	_	3	p	_	_
8	with	with	IN	_	9	case	_	_
9	respect	respect	NN	_	3	ppmod	_	_
10	to	to	TO	_	11	aux	_	_
11	efficacy	efficacy	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	safety	safety	NN	_	11	conj	_	_
14	,	,	,	_	3	p	_	_
15	have	have	VBP	_	18	aux	_	_
16	not	not	RB	_	18	neg	_	_
17	been	be	VBN	_	18	aux	_	_
18	established	establish	VBN	_	0	root	_	_
19	.	.	.	_	18	p	_	_

1	Other	other	JJ	_	2	attr	_	_
2	Agents	agent	NNS	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	,	,	,	_	3	p	_	_
5	drug3	drug0	NN	_	1	conj	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	systemic	systemic	JJ	_	5	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	and	and	CC	_	5	cc	_	_
10	drug4	drug0	NN	_	1	conj	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	concentration	concentration	NN	_	0	root	_	_

1	Caution	caution	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	warranted	warrant	VBN	_	0	root	_	_
4	and	and	CC	_	3	cc	_	_
5	therapeutic	therapeutic	JJ	_	7	attr	_	_
6	concentration	concentration	NN	_	7	com	_	_
7	monitoring	monitoring	NN	_	9	dep	_	_
8	is	be	VBZ	_	9	aux	_	_
9	recommended	recommend	VBN	_	3	conj	_	_
10	for	for	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	when	when	WRB	_	13	adv	_	_
13	coadministered	coadministered	VBN	_	9	comp	_	_
14	with	with	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	,	,	,	_	1	p	_	_
5	drug3	drug0	NN	_	1	appo	_	_
6	,	,	,	_	1	p	_	_
7	drug4	drug0	NN	_	1	appo	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	concentration	concentration	NN	_	0	root	_	_

1	Use	use	NN	_	0	root	_	_
2	with	with	IN	_	3	case	_	_
3	caution	caution	NN	_	1	ppmod	_	_
4	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	may	may	MD	_	5	modal	_	_
3	not	not	RB	_	5	neg	_	_
4	be	be	VB	_	5	aux	_	_
5	effective	effective	JJ	_	0	root	_	_
6	due	due	JJ	_	10	adv	_	_
7	to	to	TO	_	10	aux	_	_
8	decreased	decrease	VBN	_	10	attr	_	_
9	drug2	drug0	NN	_	10	com	_	_
10	concentrations	concentration	NNS	_	5	ppmod	_	_
11	in	in	IN	_	12	case	_	_
12	patients	patient	NNS	_	10	ppmod	_	_
13	taking	take	VBG	_	12	acl	_	_
14	these	these	DT	_	15	det	_	_
15	agents	agent	NNS	_	13	obj	_	_
16	concomitantly	concomitantly	RB	_	5	adv	_	_
17	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NNP	_	1	appo	_	_
4	:	:	:	_	3	p	_	_
5	e.g.	e.g.	FW	_	3	appo	_	_
6	,	,	,	_	1	p	_	_
7	drug3	drug0	NN	_	1	appo	_	_
8	,	,	,	_	1	p	_	_
9	drug4	drug0	NN	_	1	appo	_	_
10	,	,	,	_	1	p	_	_
11	drug5	drug0	NN	_	1	appo	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	concentration	concentration	NN	_	0	root	_	_

1	Caution	caution	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	warranted	warrant	VBN	_	0	root	_	_
4	and	and	CC	_	3	cc	_	_
5	clinical	clinical	JJ	_	6	attr	_	_
6	monitoring	monitoring	NN	_	10	dep	_	_
7	of	of	IN	_	8	case	_	_
8	patients	patient	NNS	_	6	ppmod	_	_
9	is	be	VBZ	_	10	aux	_	_
10	recommended	recommend	VBN	_	3	conj	_	_
11	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	4	com	_	_
2	concentration	concentration	NN	_	4	com	_	_
3	drug2	drug0	NN	_	4	com	_	_
4	concentration	concentration	NN	_	0	root	_	_

1	The	the	DT	_	3	det	_	_
2	appropriate	appropriate	JJ	_	3	attr	_	_
3	doses	dose	NNS	_	18	dep	_	_
4	for	for	IN	_	6	case	_	_
5	this	this	DT	_	6	det	_	_
6	combination	combination	NN	_	3	ppmod	_	_
7	,	,	,	_	3	p	_	_
8	with	with	IN	_	9	case	_	_
9	respect	respect	NN	_	3	ppmod	_	_
10	to	to	TO	_	11	aux	_	_
11	efficacy	efficacy	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	safety	safety	NN	_	11	conj	_	_
14	,	,	,	_	3	p	_	_
15	have	have	VBP	_	18	aux	_	_
16	not	not	RB	_	18	neg	_	_
17	been	be	VBN	_	18	aux	_	_
18	established	establish	VBN	_	0	root	_	_
19	.	.	.	_	18	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	concentration	concentration	NN	_	0	root	_	_

1	Use	use	VB	_	0	root	_	_
2	lowest	low	JJS	_	4	attr	_	_
3	possible	possible	JJ	_	4	attr	_	_
4	dose	dose	NN	_	1	obj	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	with	with	IN	_	9	case	_	_
8	careful	careful	JJ	_	9	attr	_	_
9	monitoring	monitoring	NN	_	6	ppmod	_	_
10	,	,	,	_	1	p	_	_
11	or	or	CC	_	1	cc	_	_
12	consider	consider	VB	_	1	conj	_	_
13	drug2	drug0	NNS	_	12	obj	_	_
14	that	that	WDT	_	18	dep	_	_
15	are	be	VBP	_	18	aux	_	_
16	not	not	RB	_	18	neg	_	_
17	primarily	primarily	RB	_	18	adv	_	_
18	metabolized	metabolize	VBN	_	13	relcl	_	_
19	by	by	IN	_	20	case	_	_
20	CYP3A4	cyp0a0	NN	_	18	ppmod	_	_
21	,	,	,	_	20	p	_	_
22	such	such	JJ	_	23	com	_	_
23	as	as	IN	_	20	cc	_	_
24	drug3	drug0	NN	_	20	conj	_	_
25	,	,	,	_	24	p	_	_
26	drug4	drug0	NN	_	20	conj	_	_
27	,	,	,	_	26	p	_	_
28	or	or	CC	_	26	cc	_	_
29	drug5	drug0	NN	_	20	conj	_	_
30	in	in	IN	_	31	case	_	_
31	combination	combination	NN	_	18	ppmod	_	_
32	with	with	IN	_	33	case	_	_
33	drug6	drug0	NN	_	31	ppmod	_	_
34	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	,	,	,	_	1	p	_	_
5	drug3	drug0	NN	_	1	appo	_	_
6	,	,	,	_	1	p	_	_
7	drug4	drug0	NN	_	1	appo	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	concentration	concentration	NN	_	0	root	_	_

1	Plasma	plasma	NN	_	2	com	_	_
2	concentrations	concentration	NNS	_	5	dep	_	_
3	may	may	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	increased	increase	VBN	_	0	root	_	_
6	by	by	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	concentration	concentration	NN	_	0	root	_	_

1	Dose	dose	NN	_	2	com	_	_
2	reduction	reduction	NN	_	12	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	to	to	TO	_	7	aux	_	_
6	600	0	CD	_	7	num	_	_
7	mg	mg	NN	_	2	ppmod	_	_
8	every	every	DT	_	10	det	_	_
9	8	0	CD	_	10	num	_	_
10	hours	hour	NNS	_	7	appo	_	_
11	is	be	VBZ	_	12	aux	_	_
12	recommended	recommend	VBN	_	0	root	_	_
13	when	when	WRB	_	14	adv	_	_
14	administering	administer	VBG	_	12	comp	_	_
15	drug2	drug0	NN	_	14	obj	_	_
16	concurrently	concurrently	RB	_	15	adv	_	_
17	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	concentration	concentration	NN	_	0	root	_	_

1	Dose	dose	NN	_	2	com	_	_
2	reduction	reduction	NN	_	13	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	to	to	TO	_	7	aux	_	_
6	600	0	CD	_	7	num	_	_
7	mg	mg	NN	_	2	ppmod	_	_
8	every	every	DT	_	10	det	_	_
9	8	0	CD	_	10	num	_	_
10	hours	hour	NNS	_	7	appo	_	_
11	should	should	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	considered	consider	VBN	_	0	root	_	_
14	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	4	com	_	_
2	concentration	concentration	NN	_	4	com	_	_
3	drug2	drug0	NN	_	4	com	_	_
4	concentration	concentration	NN	_	0	root	_	_

1	Dose	dose	NN	_	2	com	_	_
2	reduction	reduction	NN	_	28	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	to	to	TO	_	6	aux	_	_
6	half	half	NN	_	4	ppmod	_	_
7	the	the	DT	_	9	det	_	_
8	standard	standard	JJ	_	9	attr	_	_
9	dose	dose	NN	_	6	attr	_	_
10	and	and	CC	_	2	cc	_	_
11	a	a	DT	_	13	det	_	_
12	dose	dose	NN	_	13	com	_	_
13	increase	increase	NN	_	26	attr	_	_
14	of	of	IN	_	18	case	_	_
15	drug2	drug0	NN	_	18	attr	_	_
16	to	to	TO	_	18	attr	_	_
17	1000	0	CD	_	18	num	_	_
18	mg	mg	NN	_	13	ppmod	_	_
19	(	-lrb-	-LRB-	_	22	p	_	_
20	three	#crd#	CD	_	22	num	_	_
21	333-mg	0-mg	NN	_	22	com	_	_
22	capsules	capsule	NNS	_	18	prn	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	every	every	DT	_	26	det	_	_
25	8	0	CD	_	26	num	_	_
26	hours	hour	NNS	_	2	conj	_	_
27	are	be	VBP	_	28	aux	_	_
28	recommended	recommend	VBN	_	0	root	_	_
29	when	when	WRB	_	34	adv	_	_
30	drug3	drug0	NN	_	34	dep	_	_
31	and	and	CC	_	30	cc	_	_
32	drug4	drug0	NN	_	30	conj	_	_
33	are	be	VBP	_	34	aux	_	_
34	coadministered	coadministered	VBN	_	28	comp	_	_
35	.	.	.	_	28	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	concentration	concentration	NN	_	0	root	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	dose	dose	NN	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	not	not	RB	_	5	neg	_	_
5	exceed	exceed	VB	_	0	root	_	_
6	a	a	DT	_	7	det	_	_
7	maximum	maximum	NN	_	5	obj	_	_
8	of	of	IN	_	10	case	_	_
9	25	0	CD	_	10	num	_	_
10	mg	mg	NN	_	7	ppmod	_	_
11	in	in	IN	_	15	case	_	_
12	a	a	DT	_	15	det	_	_
13	48-	0-	CD	_	14	num	_	_
14	hour	hour	NN	_	15	com	_	_
15	period	period	NN	_	5	ppmod	_	_
16	in	in	IN	_	17	case	_	_
17	patients	patient	NNS	_	15	ppmod	_	_
18	receiving	receive	VBG	_	17	acl	_	_
19	concomitant	concomitant	JJ	_	21	attr	_	_
20	drug2	drug0	NN	_	21	com	_	_
21	therapy	therapy	NN	_	18	obj	_	_
22	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	concentration	concentration	NN	_	0	root	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	dose	dose	NN	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	not	not	RB	_	5	neg	_	_
5	exceed	exceed	VB	_	0	root	_	_
6	a	a	DT	_	7	det	_	_
7	maximum	maximum	NN	_	5	obj	_	_
8	of	of	IN	_	10	case	_	_
9	10	0	CD	_	10	num	_	_
10	mg	mg	NN	_	7	ppmod	_	_
11	in	in	IN	_	15	case	_	_
12	a	a	DT	_	15	det	_	_
13	72-	0-	NN	_	15	com	_	_
14	hour	hour	NN	_	15	com	_	_
15	period	period	NN	_	5	ppmod	_	_
16	in	in	IN	_	17	case	_	_
17	patients	patient	NNS	_	15	ppmod	_	_
18	receiving	receive	VBG	_	17	acl	_	_
19	concomitant	concomitant	JJ	_	21	attr	_	_
20	drug2	drug0	NN	_	21	com	_	_
21	therapy	therapy	NN	_	18	obj	_	_
22	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	concentration	concentration	NN	_	0	root	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	dose	dose	NN	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	not	not	RB	_	5	neg	_	_
5	exceed	exceed	VB	_	0	root	_	_
6	a	a	DT	_	7	det	_	_
7	maximum	maximum	NN	_	5	obj	_	_
8	of	of	IN	_	10	case	_	_
9	2.5	0	CD	_	10	num	_	_
10	mg	mg	NN	_	7	ppmod	_	_
11	in	in	IN	_	14	case	_	_
12	a	a	DT	_	14	det	_	_
13	24-hour	0-hour	JJ	_	14	attr	_	_
14	period	period	NN	_	5	ppmod	_	_
15	in	in	IN	_	16	case	_	_
16	patients	patient	NNS	_	14	ppmod	_	_
17	receiving	receive	VBG	_	16	acl	_	_
18	concomitant	concomitant	JJ	_	20	attr	_	_
19	drug2	drug0	NN	_	20	com	_	_
20	therapy	therapy	NN	_	17	obj	_	_
21	.	.	.	_	5	p	_	_

1	Note	note	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_

1	=	=	VBG	_	0	root	_	_
2	increase	increase	NN	_	1	obj	_	_
3	;	;	:	_	1	p	_	_

1	=	=	VBD	_	0	root	_	_
2	decrease	decrease	NN	_	1	obj	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	Interactions	interaction	NNS	_	0	root	_	_
2	for	for	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	drug2	drug0	NN	_	1	prn	_	_
6	,	,	,	_	5	p	_	_
7	drug3	drug0	NN	_	5	conj	_	_
8	,	,	,	_	7	p	_	_
9	drug4	drug0	NN	_	5	conj	_	_
10	,	,	,	_	9	p	_	_
11	and	and	CC	_	9	cc	_	_
12	drug5	drug0	NN	_	5	conj	_	_
13	)	-rrb-	-RRB-	_	5	p	_	_
14	:	:	:	_	1	p	_	_
15	drug6	drug0	NN	_	1	appo	_	_
16	:	:	:	_	15	p	_	_
17	drug7	drug0	NN	_	20	dep	_	_
18	has	have	VBZ	_	20	aux	_	_
19	been	be	VBN	_	20	aux	_	_
20	reported	report	VBN	_	15	acl	_	_
21	to	to	TO	_	22	aux	_	_
22	reduce	reduce	VB	_	20	comp	_	_
23	intestinal	intestinal	JJ	_	24	attr	_	_
24	absorption	absorption	NN	_	22	obj	_	_
25	of	of	IN	_	26	case	_	_
26	drug8	drug0	NN	_	24	ppmod	_	_
27	;	;	:	_	1	p	_	_

1	as	as	IN	_	2	case	_	_
2	such	such	JJ	_	5	ppmod	_	_
3	it	it	PRP	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	impair	impair	VB	_	0	root	_	_
6	intestinal	intestinal	JJ	_	7	attr	_	_
7	absorption	absorption	NN	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	any	any	DT	_	7	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	13	dep	_	_
2	/	/	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	:	:	:	_	1	p	_	_
5	The	the	DT	_	6	det	_	_
6	coadministration	coadministration	NN	_	1	appo	_	_
7	of	of	IN	_	8	case	_	_
8	drug3	drug0	NN	_	6	ppmod	_	_
9	or	or	CC	_	8	cc	_	_
10	drug4	drug0	NN	_	8	conj	_	_
11	will	will	MD	_	13	modal	_	_
12	not	not	RB	_	13	neg	_	_
13	affect	affect	VB	_	0	root	_	_
14	plasma	plasma	NN	_	15	com	_	_
15	concentrations	concentration	NNS	_	13	obj	_	_
16	of	of	IN	_	17	case	_	_
17	drug5	drug0	NN	_	15	ppmod	_	_
18	,	,	,	_	13	p	_	_
19	but	but	CC	_	13	cc	_	_
20	may	may	MD	_	21	modal	_	_
21	reduce	reduce	VB	_	13	conj	_	_
22	endogenous	endogenous	JJ	_	24	attr	_	_
23	plasma	plasma	NN	_	24	com	_	_
24	levels	level	NNS	_	21	obj	_	_
25	of	of	IN	_	27	case	_	_
26	drug6	drug0	NN	_	27	com	_	_
27	/ergocalcitriol	/ergocalcitriol	NN	_	24	ppmod	_	_
28	by	by	IN	_	29	case	_	_
29	accelerating	accelerate	VBG	_	21	ppmod	_	_
30	metabolism	metabolism	NN	_	29	obj	_	_
31	.	.	.	_	13	p	_	_

1	Since	since	IN	_	9	mark	_	_
2	blood	blood	NN	_	3	com	_	_
3	level	level	NN	_	9	dep	_	_
4	of	of	IN	_	6	case	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	/ergocalcitriol	/ergocalcitriol	NN	_	3	ppmod	_	_
7	will	will	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	reduced	reduce	VBN	_	16	advcl	_	_
10	,	,	,	_	16	p	_	_
11	higher	high	JJR	_	12	attr	_	_
12	doses	dose	NNS	_	16	dep	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	may	may	MD	_	16	modal	_	_
16	be	be	VB	_	0	root	_	_
17	necessary	necessary	JJ	_	16	dep	_	_
18	if	if	IN	_	22	mark	_	_
19	these	these	DT	_	20	det	_	_
20	drugs	drug	NNS	_	22	dep	_	_
21	are	be	VBP	_	22	aux	_	_
22	administered	administer	VBN	_	16	comp	_	_
23	simultaneously	simultaneously	RB	_	22	adv	_	_
24	.	.	.	_	16	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	are	be	VBP	_	5	aux	_	_
5	known	know	VBN	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	induce	induce	VB	_	5	comp	_	_
8	hypercalcemia	hypercalcemia	NN	_	7	obj	_	_
9	by	by	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	reduction	reduction	NN	_	7	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	calcium	calcium	NN	_	14	com	_	_
14	excretion	excretion	NN	_	11	ppmod	_	_
15	in	in	IN	_	16	case	_	_
16	urine	urine	NN	_	11	ppmod	_	_
17	.	.	.	_	5	p	_	_

1	Some	some	DT	_	2	det	_	_
2	reports	report	NNS	_	4	dep	_	_
3	have	have	VBP	_	4	aux	_	_
4	shown	show	VBN	_	0	root	_	_
5	that	that	IN	_	13	mark	_	_
6	the	the	DT	_	8	det	_	_
7	concomitant	concomitant	JJ	_	8	attr	_	_
8	administration	administration	NN	_	13	dep	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	with	with	IN	_	12	case	_	_
12	drug2	drug0	NN	_	8	ppmod	_	_
13	causes	cause	VBZ	_	4	comp	_	_
14	hypercalcemia	hypercalcemia	NN	_	13	obj	_	_
15	.	.	.	_	4	p	_	_

1	Therefore	therefore	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	precaution	precaution	NN	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	taken	take	VBN	_	0	root	_	_
7	when	when	WRB	_	9	adv	_	_
8	coadministration	coadministration	NN	_	9	dep	_	_
9	is	be	VBZ	_	6	comp	_	_
10	necessary	necessary	JJ	_	9	dep	_	_
11	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	4	com	_	_
4	dosage	dosage	NN	_	7	dep	_	_
5	must	must	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	determined	determine	VBN	_	1	acl	_	_
8	with	with	IN	_	9	case	_	_
9	care	care	NN	_	7	ppmod	_	_
10	in	in	IN	_	11	case	_	_
11	patients	patient	NNS	_	7	ppmod	_	_
12	undergoing	undergo	VBG	_	11	acl	_	_
13	treatment	treatment	NN	_	12	obj	_	_
14	with	with	IN	_	15	case	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	,	,	,	_	7	p	_	_
17	as	as	IN	_	23	mark	_	_
18	hypercalcemia	hypercalcemia	NN	_	23	dep	_	_
19	in	in	IN	_	21	case	_	_
20	such	such	JJ	_	21	attr	_	_
21	patients	patient	NNS	_	18	ppmod	_	_
22	may	may	MD	_	23	modal	_	_
23	precipitate	precipitate	VB	_	7	comp	_	_
24	cardiac	cardiac	JJ	_	25	attr	_	_
25	arrhythmias	arrhythmias	NN	_	23	obj	_	_
26	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	inhibit	inhibit	VB	_	1	acl	_	_
6	both	both	CC	_	7	cc	_	_
7	synthetic	synthetic	JJ	_	10	attr	_	_
8	and	and	CC	_	7	cc	_	_
9	catabolic	catabolic	JJ	_	7	conj	_	_
10	enzymes	enzyme	NNS	_	5	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	1	p	_	_

1	Reductions	reduction	NNS	_	10	dep	_	_
2	in	in	IN	_	7	case	_	_
3	serum	serum	NN	_	7	attr	_	_
4	endogenous	endogenous	JJ	_	6	attr	_	_
5	vitamin	vitamin	NN	_	6	com	_	_
6	D	d	NN	_	7	com	_	_
7	concentrations	concentration	NNS	_	1	ppmod	_	_
8	have	have	VBP	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	observed	observe	VBN	_	0	root	_	_
11	following	follow	VBG	_	13	adv	_	_
12	the	the	DT	_	13	det	_	_
13	administration	administration	NN	_	10	ppmod	_	_
14	of	of	IN	_	16	case	_	_
15	300	0	CD	_	16	num	_	_
16	mg/day	mg/day	NN	_	13	ppmod	_	_
17	to	to	TO	_	20	aux	_	_
18	1200	0	CD	_	19	num	_	_
19	mg/day	mg/day	NN	_	20	com	_	_
20	drug1	drug0	NN	_	13	ppmod	_	_
21	for	for	IN	_	23	case	_	_
22	a	a	DT	_	23	det	_	_
23	week	week	NN	_	20	ppmod	_	_
24	to	to	TO	_	26	aux	_	_
25	healthy	healthy	JJ	_	26	attr	_	_
26	men	man	NNS	_	23	ppmod	_	_
27	.	.	.	_	10	p	_	_

1	However	however	RB	_	15	adv	_	_
2	,	,	,	_	15	p	_	_
3	in	in	FW	_	4	adv	_	_
4	vivo	vivo	FW	_	7	attr	_	_
5	drug	drug	NN	_	7	com	_	_
6	interaction	interaction	NN	_	7	com	_	_
7	studies	study	NNS	_	15	dep	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NN	_	7	ppmod	_	_
12	have	have	VBP	_	15	aux	_	_
13	not	not	RB	_	15	neg	_	_
14	been	be	VBN	_	15	aux	_	_
15	investigated	investigate	VBN	_	0	root	_	_
16	.	.	.	_	15	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	A	a	DT	_	4	det	_	_
4	relationship	relationship	NN	_	8	dep	_	_
5	of	of	IN	_	7	case	_	_
6	functional	functional	JJ	_	7	attr	_	_
7	antagonism	antagonism	NN	_	4	ppmod	_	_
8	exists	exist	VBZ	_	1	acl	_	_
9	between	between	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	which	which	WDT	_	13	dep	_	_
13	promote	promote	VBP	_	10	relcl	_	_
14	calcium	calcium	NN	_	15	com	_	_
15	absorption	absorption	NN	_	13	obj	_	_
16	,	,	,	_	10	p	_	_
17	and	and	CC	_	10	cc	_	_
18	drug3	drug0	NN	_	10	conj	_	_
19	,	,	,	_	10	p	_	_
20	which	which	WDT	_	21	dep	_	_
21	inhibit	inhibit	VBP	_	10	relcl	_	_
22	calcium	calcium	NN	_	23	com	_	_
23	absorption	absorption	NN	_	21	obj	_	_
24	.	.	.	_	1	p	_	_

1	Phosphate-Binding	phosphate-binding	JJ	_	2	attr	_	_
2	Agents	agent	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	Since	since	IN	_	7	mark	_	_
5	drug1	drug0	NN	_	7	dep	_	_
6	also	also	RB	_	7	adv	_	_
7	has	have	VBZ	_	28	advcl	_	_
8	an	an	DT	_	9	det	_	_
9	effect	effect	NN	_	7	obj	_	_
10	on	on	IN	_	12	case	_	_
11	phosphate	phosphate	NN	_	12	com	_	_
12	transport	transport	NN	_	9	ppmod	_	_
13	in	in	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	intestine	intestine	NN	_	7	ppmod	_	_
16	,	,	,	_	15	p	_	_
17	kidneys	kidneys	NN	_	15	conj	_	_
18	and	and	CC	_	17	cc	_	_
19	bones	bones	NN	_	15	conj	_	_
20	,	,	,	_	28	p	_	_
21	the	the	DT	_	22	det	_	_
22	dosage	dosage	NN	_	28	dep	_	_
23	of	of	IN	_	25	case	_	_
24	phosphate-binding	phosphate-binding	JJ	_	25	attr	_	_
25	agents	agent	NNS	_	22	ppmod	_	_
26	must	must	MD	_	28	modal	_	_
27	be	be	VB	_	28	aux	_	_
28	adjusted	adjust	VBN	_	2	acl	_	_
29	in	in	IN	_	30	case	_	_
30	accordance	accordance	NN	_	28	ppmod	_	_
31	with	with	IN	_	35	case	_	_
32	the	the	DT	_	35	det	_	_
33	serum	serum	NN	_	35	com	_	_
34	phosphate	phosphate	NN	_	35	com	_	_
35	concentration	concentration	NN	_	30	ppmod	_	_
36	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	coadministration	coadministration	NN	_	12	dep	_	_
5	of	of	IN	_	6	case	_	_
6	any	any	DT	_	4	ppmod	_	_
7	of	of	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	drug2	drug0	NNS	_	6	ppmod	_	_
10	should	should	MD	_	12	modal	_	_
11	be	be	VB	_	12	aux	_	_
12	avoided	avoid	VBN	_	1	acl	_	_
13	as	as	IN	_	16	mark	_	_
14	this	this	DT	_	16	dep	_	_
15	could	could	MD	_	16	modal	_	_
16	create	create	VB	_	12	comp	_	_
17	possible	possible	JJ	_	19	attr	_	_
18	additive	additive	JJ	_	19	attr	_	_
19	effects	effect	NNS	_	16	obj	_	_
20	and	and	CC	_	19	cc	_	_
21	hypercalcemia	hypercalcemia	NN	_	19	conj	_	_
22	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	Supplements	supplement	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	Uncontrolled	uncontrolled	JJ	_	5	attr	_	_
5	intake	intake	NN	_	13	dep	_	_
6	of	of	IN	_	10	case	_	_
7	additional	additional	JJ	_	10	attr	_	_
8	drug2	drug0	NN	_	10	attr	_	_
9	-containing	-containing	JJ	_	10	attr	_	_
10	preparations	preparation	NNS	_	5	ppmod	_	_
11	should	should	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	avoided	avoid	VBN	_	2	acl	_	_
14	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	5	attr	_	_
4	-containing	-containing	JJ	_	5	attr	_	_
5	preparations	preparation	NNS	_	12	dep	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	eg	eg	NN	_	5	prn	_	_
8	,	,	,	_	7	p	_	_
9	drug3	drug0	NN	_	7	appo	_	_
10	)	-rrb-	-RRB-	_	7	p	_	_
11	may	may	MD	_	12	modal	_	_
12	cause	cause	VB	_	1	acl	_	_
13	hypermagnesemia	hypermagnesemia	NN	_	12	obj	_	_
14	and	and	CC	_	12	cc	_	_
15	should	should	MD	_	19	modal	_	_
16	therefore	therefore	RB	_	19	adv	_	_
17	not	not	RB	_	19	neg	_	_
18	be	be	VB	_	19	aux	_	_
19	taken	take	VBN	_	12	conj	_	_
20	during	during	IN	_	21	case	_	_
21	therapy	therapy	NN	_	19	ppmod	_	_
22	with	with	IN	_	23	case	_	_
23	drug4	drug0	NN	_	19	ppmod	_	_
24	by	by	IN	_	25	case	_	_
25	patients	patient	NNS	_	19	ppmod	_	_
26	on	on	IN	_	29	case	_	_
27	chronic	chronic	JJ	_	29	attr	_	_
28	renal	renal	JJ	_	29	attr	_	_
29	dialysis	dialysis	NN	_	25	ppmod	_	_
30	.	.	.	_	1	p	_	_

1	Drugs	drug	NNS	_	2	dep	_	_
2	Metabolized	metabolize	VBN	_	23	advcl	_	_
3	by	by	IN	_	5	case	_	_
4	P450	p0	NN	_	5	com	_	_
5	2D6	0d0	NN	_	2	ppmod	_	_
6	-	-	:	_	23	p	_	_
7	The	the	DT	_	9	det	_	_
8	biochemical	biochemical	JJ	_	9	attr	_	_
9	activity	activity	NN	_	23	dep	_	_
10	of	of	IN	_	17	case	_	_
11	the	the	DT	_	17	det	_	_
12	drug	drug	NN	_	17	com	_	_
13	metabolizing	metabolizing	NN	_	17	com	_	_
14	isozyme	isozyme	NN	_	17	com	_	_
15	cytochrome	cytochrome	NN	_	17	com	_	_
16	P450	p0	NN	_	17	com	_	_
17	2D6	0d0	NN	_	9	ppmod	_	_
18	(	-lrb-	-LRB-	_	20	p	_	_
19	debrisoquin	debrisoquin	NN	_	20	com	_	_
20	hydroxylase	hydroxylase	NN	_	17	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	is	be	VBZ	_	23	aux	_	_
23	reduced	reduce	VBN	_	0	root	_	_
24	in	in	IN	_	26	case	_	_
25	a	a	DT	_	26	det	_	_
26	subset	subset	NN	_	23	ppmod	_	_
27	of	of	IN	_	30	case	_	_
28	the	the	DT	_	30	det	_	_
29	caucasian	caucasian	NN	_	30	com	_	_
30	population	population	NN	_	26	ppmod	_	_
31	(	-lrb-	-LRB-	_	39	p	_	_
32	about	about	RB	_	33	adv	_	_
33	7-10	0	CD	_	39	num	_	_
34	%	%	NN	_	33	meta	_	_
35	of	of	IN	_	36	case	_	_
36	caucasians	caucasian	NNS	_	33	ppmod	_	_
37	are	be	VBP	_	39	aux	_	_
38	so	so	RB	_	39	adv	_	_
39	called	call	VBN	_	23	prn	_	_
40	poor	poor	JJ	_	41	attr	_	_
41	metabolizers	metabolizers	NNS	_	39	obj	_	_
42	)	-rrb-	-RRB-	_	39	p	_	_
43	;	;	:	_	23	p	_	_

1	reliable	reliable	JJ	_	2	attr	_	_
2	estimates	estimate	NNS	_	19	dep	_	_
3	of	of	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	prevalence	prevalence	NN	_	2	ppmod	_	_
6	of	of	IN	_	11	case	_	_
7	reduced	reduce	VBN	_	11	attr	_	_
8	P450	p0	NN	_	11	com	_	_
9	2D6	0d0	NN	_	11	com	_	_
10	isozyme	isozyme	NN	_	11	com	_	_
11	activity	activity	NN	_	5	ppmod	_	_
12	among	among	IN	_	18	case	_	_
13	Asian	asian	JJ	_	18	attr	_	_
14	,	,	,	_	13	p	_	_
15	African	african	JJ	_	13	conj	_	_
16	and	and	CC	_	15	cc	_	_
17	other	other	JJ	_	13	conj	_	_
18	populations	population	NNS	_	5	ppmod	_	_
19	are	be	VBP	_	0	root	_	_
20	not	not	RB	_	19	neg	_	_
21	yet	yet	RB	_	19	adv	_	_
22	available	available	JJ	_	19	dep	_	_
23	.	.	.	_	19	p	_	_

1	Poor	poor	JJ	_	2	attr	_	_
2	metabolizers	metabolizers	NNS	_	8	dep	_	_
3	have	have	VBP	_	8	lv	_	_
4	higher	high	JJR	_	8	attr	_	_
5	than	than	IN	_	8	case	_	_
6	expected	expect	VBN	_	8	attr	_	_
7	plasma	plasma	NN	_	8	com	_	_
8	concentrations	concentration	NNS	_	0	root	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	drug2	drug0	NN	_	10	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	when	when	WRB	_	15	adv	_	_
15	given	give	VBN	_	8	comp	_	_
16	usual	usual	JJ	_	17	attr	_	_
17	doses	dose	NNS	_	15	obj	_	_
18	.	.	.	_	8	p	_	_

1	Depending	depend	VBG	_	4	adv	_	_
2	on	on	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	fraction	fraction	NN	_	18	ppmod	_	_
5	of	of	IN	_	6	case	_	_
6	drug	drug	NN	_	4	ppmod	_	_
7	metabolized	metabolize	VBN	_	6	acl	_	_
8	by	by	IN	_	10	case	_	_
9	P450	p0	NN	_	10	com	_	_
10	2D6	0d0	NN	_	7	ppmod	_	_
11	,	,	,	_	18	p	_	_
12	the	the	DT	_	13	det	_	_
13	increase	increase	NN	_	18	dep	_	_
14	in	in	IN	_	16	case	_	_
15	plasma	plasma	NN	_	16	com	_	_
16	concentration	concentration	NN	_	13	ppmod	_	_
17	may	may	MD	_	18	modal	_	_
18	be	be	VB	_	0	root	_	_
19	small	small	JJ	_	18	dep	_	_
20	,	,	,	_	19	p	_	_
21	or	or	CC	_	19	cc	_	_
22	quite	quite	RB	_	23	adv	_	_
23	large	large	JJ	_	19	conj	_	_
24	(	-lrb-	-LRB-	_	26	p	_	_
25	8-fold	0-fold	JJ	_	26	attr	_	_
26	increase	increase	NN	_	23	prn	_	_
27	in	in	IN	_	29	case	_	_
28	plasma	plasma	NN	_	29	com	_	_
29	AUC	auc	NN	_	26	ppmod	_	_
30	of	of	IN	_	32	case	_	_
31	the	the	DT	_	32	det	_	_
32	drug1	drug0	NN	_	29	ppmod	_	_
33	)	-rrb-	-RRB-	_	26	p	_	_
34	.	.	.	_	18	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	16	ppmod	_	_
3	,	,	,	_	16	p	_	_
4	certain	certain	JJ	_	5	attr	_	_
5	drugs	drug	NNS	_	16	dep	_	_
6	inhibit	inhibit	VB	_	16	dep	_	_
7	the	the	DT	_	8	det	_	_
8	activity	activity	NN	_	6	obj	_	_
9	of	of	IN	_	11	case	_	_
10	this	this	DT	_	11	det	_	_
11	isozyme	isozyme	NN	_	8	ppmod	_	_
12	and	and	CC	_	6	cc	_	_
13	make	make	VB	_	6	conj	_	_
14	normal	normal	JJ	_	15	attr	_	_
15	metabolizers	metabolizers	NNS	_	13	obj	_	_
16	resemble	resemble	VBP	_	0	root	_	_
17	poor	poor	JJ	_	18	attr	_	_
18	metabolizers	metabolizers	NNS	_	16	obj	_	_
19	.	.	.	_	16	p	_	_

1	An	an	DT	_	2	det	_	_
2	individual	individual	JJ	_	13	dep	_	_
3	who	who	WP	_	4	dep	_	_
4	is	be	VBZ	_	2	relcl	_	_
5	stable	stable	JJ	_	4	dep	_	_
6	on	on	IN	_	9	case	_	_
7	a	a	DT	_	9	det	_	_
8	given	given	JJ	_	9	attr	_	_
9	dose	dose	NN	_	5	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	may	may	MD	_	13	modal	_	_
13	become	become	VB	_	0	root	_	_
14	abruptly	abruptly	RB	_	15	adv	_	_
15	toxic	toxic	JJ	_	13	dep	_	_
16	when	when	WRB	_	17	adv	_	_
17	given	give	VBN	_	13	comp	_	_
18	one	#crd#	CD	_	17	obj	_	_
19	of	of	IN	_	22	case	_	_
20	these	these	DT	_	22	det	_	_
21	inhibiting	inhibiting	JJ	_	22	attr	_	_
22	drugs	drug	NNS	_	18	ppmod	_	_
23	as	as	IN	_	25	case	_	_
24	concomitant	concomitant	JJ	_	25	attr	_	_
25	therapy	therapy	NN	_	22	ppmod	_	_
26	.	.	.	_	13	p	_	_

1	The	the	DT	_	2	det	_	_
2	drugs	drug	NNS	_	8	dep	_	_
3	that	that	WDT	_	4	dep	_	_
4	inhibit	inhibit	VBP	_	2	relcl	_	_
5	cytochrome	cytochrome	NN	_	7	com	_	_
6	P450	p0	NN	_	7	com	_	_
7	2D6	0d0	NN	_	4	obj	_	_
8	include	include	VBP	_	0	root	_	_
9	some	some	DT	_	8	obj	_	_
10	that	that	WDT	_	13	dep	_	_
11	are	be	VBP	_	13	aux	_	_
12	not	not	RB	_	13	neg	_	_
13	metabolized	metabolize	VBN	_	9	relcl	_	_
14	by	by	IN	_	18	case	_	_
15	the	the	DT	_	18	det	_	_
16	enzyme	enzyme	NN	_	18	attr	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	drug1	drug0	NN	_	13	ppmod	_	_
19	;	;	:	_	8	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	)	-rrb-	-RRB-	_	1	p	_	_
3	and	and	CC	_	1	cc	_	_
4	many	many	JJ	_	1	conj	_	_
5	that	that	WDT	_	6	dep	_	_
6	are	be	VBP	_	4	relcl	_	_
7	substrates	substrate	NNS	_	6	obj	_	_
8	for	for	IN	_	10	case	_	_
9	P450	p0	NN	_	10	com	_	_
10	2D6	0d0	NN	_	7	ppmod	_	_
11	(	-lrb-	-LRB-	_	14	p	_	_
12	many	many	JJ	_	14	attr	_	_
13	other	other	JJ	_	14	attr	_	_
14	drug2	drug0	NN	_	10	prn	_	_
15	,	,	,	_	14	p	_	_
16	drug3	drug0	NN	_	14	conj	_	_
17	,	,	,	_	16	p	_	_
18	and	and	CC	_	16	cc	_	_
19	the	the	DT	_	21	det	_	_
20	drug4	drug0	NN	_	21	com	_	_
21	drug5	drug0	NN	_	14	conj	_	_
22	and	and	CC	_	21	cc	_	_
23	drug6	drug0	NN	_	21	conj	_	_
24	)	-rrb-	-RRB-	_	14	p	_	_
25	.	.	.	_	1	p	_	_

1	While	while	IN	_	19	mark	_	_
2	all	all	PDT	_	5	det	_	_
3	the	the	DT	_	5	det	_	_
4	selective	selective	JJ	_	5	attr	_	_
5	drug1	drug0	NN	_	19	dep	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	drug2	drug0	NN	_	5	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	,	,	,	_	5	p	_	_
10	e.g.	e.g.	FW	_	12	adv	_	_
11	,	,	,	_	12	p	_	_
12	drug3	drug0	NN	_	5	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	drug4	drug0	NN	_	12	conj	_	_
15	,	,	,	_	14	p	_	_
16	and	and	CC	_	14	cc	_	_
17	drug5	drug0	NN	_	12	conj	_	_
18	,	,	,	_	5	p	_	_
19	inhibit	inhibit	VBP	_	25	advcl	_	_
20	P450	p0	NN	_	21	com	_	_
21	2D6	0d0	NN	_	19	obj	_	_
22	,	,	,	_	25	p	_	_
23	they	they	PRP	_	25	dep	_	_
24	may	may	MD	_	25	modal	_	_
25	vary	vary	VB	_	0	root	_	_
26	in	in	IN	_	28	case	_	_
27	the	the	DT	_	28	det	_	_
28	extent	extent	NN	_	25	ppmod	_	_
29	of	of	IN	_	30	case	_	_
30	inhibition	inhibition	NN	_	28	ppmod	_	_
31	.	.	.	_	25	p	_	_

1	The	the	DT	_	2	det	_	_
2	extent	extent	NN	_	14	dep	_	_
3	to	to	TO	_	4	aux	_	_
4	which	which	WDT	_	10	ppmod	_	_
5	drug1	drug0	NN	_	8	attr	_	_
6	-	-	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	interactions	interaction	NNS	_	10	dep	_	_
9	may	may	MD	_	10	modal	_	_
10	pose	pose	VBP	_	2	relcl	_	_
11	clinical	clinical	JJ	_	12	attr	_	_
12	problems	problem	NNS	_	10	obj	_	_
13	will	will	MD	_	14	modal	_	_
14	depend	depend	VB	_	0	root	_	_
15	on	on	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	degree	degree	NN	_	14	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	inhibition	inhibition	NN	_	17	ppmod	_	_
20	and	and	CC	_	17	cc	_	_
21	the	the	DT	_	22	det	_	_
22	pharmacokinetics	pharmacokinetics	NNS	_	17	conj	_	_
23	of	of	IN	_	25	case	_	_
24	the	the	DT	_	25	det	_	_
25	drug3	drug0	NN	_	22	ppmod	_	_
26	involved	involve	VBN	_	25	acl	_	_
27	.	.	.	_	14	p	_	_

1	Nevertheless	nevertheless	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	caution	caution	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	indicated	indicate	VBN	_	0	root	_	_
6	in	in	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	coadministration	coadministration	NN	_	5	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	with	with	IN	_	12	case	_	_
12	any	any	DT	_	8	ppmod	_	_
13	of	of	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	drug2	drug0	NN	_	12	ppmod	_	_
16	and	and	CC	_	8	cc	_	_
17	also	also	RB	_	19	adv	_	_
18	in	in	IN	_	19	case	_	_
19	switching	switching	NN	_	8	conj	_	_
20	from	from	IN	_	22	case	_	_
21	one	#crd#	CD	_	22	num	_	_
22	class	class	NN	_	19	ppmod	_	_
23	to	to	TO	_	25	aux	_	_
24	the	the	DT	_	25	det	_	_
25	other	other	JJ	_	19	ppmod	_	_
26	.	.	.	_	5	p	_	_

1	Of	of	IN	_	3	case	_	_
2	particular	particular	JJ	_	3	attr	_	_
3	importance	importance	NN	_	8	ppmod	_	_
4	,	,	,	_	8	p	_	_
5	sufficient	sufficient	JJ	_	6	attr	_	_
6	time	time	NN	_	8	dep	_	_
7	must	must	MD	_	8	modal	_	_
8	elapse	elapse	VB	_	0	root	_	_
9	before	before	IN	_	10	case	_	_
10	initiating	initiate	VBG	_	8	ppmod	_	_
11	TCA	tca	NN	_	12	com	_	_
12	treatment	treatment	NN	_	10	obj	_	_
13	in	in	IN	_	15	case	_	_
14	a	a	DT	_	15	det	_	_
15	patient	patient	NN	_	10	ppmod	_	_
16	being	be	VBG	_	17	aux	_	_
17	withdrawn	withdraw	VBN	_	15	acl	_	_
18	from	from	IN	_	19	case	_	_
19	drug1	drug0	NN	_	17	ppmod	_	_
20	,	,	,	_	19	p	_	_
21	given	give	VBN	_	19	acl	_	_
22	the	the	DT	_	24	det	_	_
23	long	long	JJ	_	24	attr	_	_
24	half-life	half-life	NN	_	21	obj	_	_
25	of	of	IN	_	27	case	_	_
26	the	the	DT	_	27	det	_	_
27	parent	parent	NN	_	24	ppmod	_	_
28	and	and	CC	_	19	cc	_	_
29	active	active	JJ	_	30	attr	_	_
30	metabolite	metabolite	NN	_	19	conj	_	_
31	(	-lrb-	-LRB-	_	35	p	_	_
32	at	at	IN	_	34	case	_	_
33	least	least	JJS	_	34	attr	_	_
34	5	0	CD	_	35	num	_	_
35	weeks	week	NNS	_	30	prn	_	_
36	may	may	MD	_	37	modal	_	_
37	be	be	VB	_	35	acl	_	_
38	necessary	necessary	JJ	_	37	dep	_	_
39	)	-rrb-	-RRB-	_	35	p	_	_
40	.	.	.	_	8	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	use	use	NN	_	14	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	with	with	IN	_	6	case	_	_
6	drugs	drug	NNS	_	2	ppmod	_	_
7	that	that	WDT	_	9	dep	_	_
8	can	can	MD	_	9	modal	_	_
9	inhibit	inhibit	VB	_	6	relcl	_	_
10	cytochrome	cytochrome	NN	_	12	com	_	_
11	P450	p0	NN	_	12	com	_	_
12	2D6	0d0	NN	_	9	obj	_	_
13	may	may	MD	_	14	modal	_	_
14	require	require	VB	_	0	root	_	_
15	lower	low	JJR	_	16	attr	_	_
16	doses	dose	NNS	_	14	obj	_	_
17	than	than	IN	_	18	case	_	_
18	usually	usually	RB	_	19	adv	_	_
19	prescribed	prescribe	VBN	_	16	acl	_	_
20	for	for	IN	_	23	case	_	_
21	either	either	CC	_	23	cc	_	_
22	the	the	DT	_	23	det	_	_
23	drug2	drug0	NN	_	19	ppmod	_	_
24	or	or	CC	_	23	cc	_	_
25	the	the	DT	_	27	det	_	_
26	other	other	JJ	_	27	attr	_	_
27	drug	drug	NN	_	23	conj	_	_
28	.	.	.	_	14	p	_	_

1	Furthermore	furthermore	RB	_	21	adv	_	_
2	,	,	,	_	21	p	_	_
3	whenever	whenever	RB	_	10	adv	_	_
4	one	#crd#	CD	_	10	num	_	_
5	of	of	IN	_	8	case	_	_
6	these	these	DT	_	8	det	_	_
7	other	other	JJ	_	8	attr	_	_
8	drugs	drug	NNS	_	4	ppmod	_	_
9	is	be	VBZ	_	10	aux	_	_
10	withdrawn	withdraw	VBN	_	21	advcl	_	_
11	from	from	IN	_	12	case	_	_
12	co-therapy	co-therapy	NN	_	10	ppmod	_	_
13	,	,	,	_	21	p	_	_
14	an	an	DT	_	16	det	_	_
15	increased	increase	VBN	_	16	attr	_	_
16	dose	dose	NN	_	21	dep	_	_
17	of	of	IN	_	18	case	_	_
18	drug1	drug0	NN	_	16	ppmod	_	_
19	may	may	MD	_	21	modal	_	_
20	be	be	VB	_	21	aux	_	_
21	required	require	VBN	_	0	root	_	_
22	.	.	.	_	21	p	_	_

1	It	it	PRP	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	desirable	desirable	JJ	_	2	dep	_	_
4	to	to	TO	_	5	aux	_	_
5	monitor	monitor	VB	_	2	comp	_	_
6	drug1	drug0	NN	_	8	com	_	_
7	plasma	plasma	NN	_	8	com	_	_
8	levels	level	NNS	_	5	obj	_	_
9	whenever	whenever	RB	_	12	adv	_	_
10	a	a	DT	_	11	det	_	_
11	drug2	drug0	NN	_	12	dep	_	_
12	is	be	VBZ	_	5	comp	_	_
13	going	going	JJ	_	12	dep	_	_
14	to	to	TO	_	16	aux	_	_
15	be	be	VB	_	16	aux	_	_
16	coadministered	coadministered	VBN	_	13	comp	_	_
17	with	with	IN	_	19	case	_	_
18	another	another	DT	_	19	det	_	_
19	drug	drug	NN	_	16	ppmod	_	_
20	known	know	VBN	_	19	acl	_	_
21	to	to	TO	_	22	aux	_	_
22	be	be	VB	_	20	comp	_	_
23	an	an	DT	_	24	det	_	_
24	inhibitor	inhibitor	NN	_	22	obj	_	_
25	of	of	IN	_	27	case	_	_
26	P450	p0	NN	_	27	com	_	_
27	2D6	0d0	NN	_	24	ppmod	_	_
28	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	JJ	_	7	attr	_	_
4	or	or	CC	_	3	cc	_	_
5	similarly	similarly	RB	_	6	adv	_	_
6	acting	act	VBG	_	3	conj	_	_
7	compounds	compound	NNS	_	1	appo	_	_
8	;	;	:	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	medication	medication	NN	_	1	appo	_	_
3	;	;	:	_	2	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	and	and	CC	_	3	cc	_	_
5	other	other	JJ	_	6	attr	_	_
6	drug3	drug0	NN	_	1	conj	_	_
7	;	;	:	_	6	p	_	_

1	and	and	CC	_	2	cc	_	_
2	drug1	drug0	NN	_	29	dep	_	_
3	When	when	WRB	_	6	adv	_	_
4	drug2	drug0	NN	_	6	dep	_	_
5	is	be	VBZ	_	6	aux	_	_
6	given	give	VBN	_	2	relcl	_	_
7	with	with	IN	_	9	case	_	_
8	drug3	drug0	NN	_	9	com	_	_
9	agents	agent	NNS	_	6	ppmod	_	_
10	or	or	CC	_	9	cc	_	_
11	drug4	drug0	NN	_	12	com	_	_
12	drugs	drug	NNS	_	9	conj	_	_
13	,	,	,	_	9	p	_	_
14	including	include	VBG	_	15	adv	_	_
15	drug5	drug0	NN	_	9	ppmod	_	_
16	combined	combine	VBN	_	15	acl	_	_
17	with	with	IN	_	19	case	_	_
18	local	local	JJ	_	19	attr	_	_
19	drug6	drug0	NN	_	16	ppmod	_	_
20	,	,	,	_	19	p	_	_
21	close	close	JJ	_	22	attr	_	_
22	supervision	supervision	NN	_	19	conj	_	_
23	and	and	CC	_	22	cc	_	_
24	careful	careful	JJ	_	25	attr	_	_
25	adjustment	adjustment	NN	_	19	conj	_	_
26	of	of	IN	_	27	case	_	_
27	dosages	dosage	NNS	_	25	ppmod	_	_
28	are	be	VBP	_	29	aux	_	_
29	required	require	VBN	_	0	root	_	_
30	.	.	.	_	29	p	_	_

1	Hyperpyrexia	hyperpyrexia	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	reported	report	VBN	_	0	root	_	_
5	when	when	WRB	_	8	adv	_	_
6	drug1	drug0	NN	_	8	dep	_	_
7	is	be	VBZ	_	8	aux	_	_
8	administered	administer	VBN	_	4	comp	_	_
9	with	with	IN	_	11	case	_	_
10	drug2	drug0	JJ	_	11	attr	_	_
11	agents	agent	NNS	_	8	ppmod	_	_
12	or	or	CC	_	11	cc	_	_
13	with	with	IN	_	15	case	_	_
14	drug3	drug0	NN	_	15	com	_	_
15	drugs	drug	NNS	_	11	conj	_	_
16	,	,	,	_	8	p	_	_
17	particularly	particularly	RB	_	20	adv	_	_
18	during	during	IN	_	20	case	_	_
19	hot	hot	JJ	_	20	attr	_	_
20	weather	weather	NN	_	8	ppmod	_	_
21	.	.	.	_	4	p	_	_

1	Paralytic	paralytic	JJ	_	2	attr	_	_
2	ileus	ileus	NN	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	occur	occur	VB	_	0	root	_	_
5	in	in	IN	_	6	case	_	_
6	patients	patient	NNS	_	4	ppmod	_	_
7	taking	take	VBG	_	6	acl	_	_
8	drug1	drug0	NN	_	7	obj	_	_
9	in	in	IN	_	10	case	_	_
10	combination	combination	NN	_	7	ppmod	_	_
11	with	with	IN	_	14	case	_	_
12	drug2	drug0	JJ	_	14	attr	_	_
13	-type	-type	JJ	_	14	attr	_	_
14	drugs	drug	NNS	_	10	ppmod	_	_
15	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	reported	report	VBN	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	reduce	reduce	VB	_	3	comp	_	_
6	hepatic	hepatic	JJ	_	7	attr	_	_
7	metabolism	metabolism	NN	_	5	obj	_	_
8	of	of	IN	_	10	case	_	_
9	certain	certain	JJ	_	10	attr	_	_
10	drug2	drug0	NNS	_	7	ppmod	_	_
11	,	,	,	_	3	p	_	_
12	thereby	thereby	RB	_	13	adv	_	_
13	delaying	delay	VBG	_	3	comp	_	_
14	elimination	elimination	NN	_	13	obj	_	_
15	and	and	CC	_	13	cc	_	_
16	increasing	increase	VBG	_	13	conj	_	_
17	steady-state	steady-state	JJ	_	18	attr	_	_
18	concentrations	concentration	NNS	_	16	obj	_	_
19	of	of	IN	_	21	case	_	_
20	these	these	DT	_	21	det	_	_
21	drug3	drug0	NNS	_	18	ppmod	_	_
22	.	.	.	_	3	p	_	_

1	Clinically	clinically	RB	_	2	adv	_	_
2	significant	significant	JJ	_	3	attr	_	_
3	effects	effect	NNS	_	6	dep	_	_
4	have	have	VBP	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	reported	report	VBN	_	0	root	_	_
7	with	with	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	drug1	drug0	NN	_	6	ppmod	_	_
10	when	when	WRB	_	11	adv	_	_
11	used	use	VBN	_	9	relcl	_	_
12	concomitantly	concomitantly	RB	_	11	adv	_	_
13	with	with	IN	_	14	case	_	_
14	drug2	drug0	NN	_	11	ppmod	_	_
15	.	.	.	_	6	p	_	_

1	Increases	increase	NNS	_	23	dep	_	_
2	in	in	IN	_	4	case	_	_
3	plasma	plasma	NN	_	4	com	_	_
4	levels	level	NNS	_	1	ppmod	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	,	,	,	_	4	p	_	_
8	and	and	CC	_	4	cc	_	_
9	in	in	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	frequency	frequency	NN	_	4	conj	_	_
12	and	and	CC	_	11	cc	_	_
13	severity	severity	NN	_	11	conj	_	_
14	of	of	IN	_	16	case	_	_
15	side	side	JJ	_	16	attr	_	_
16	effects	effect	NNS	_	11	ppmod	_	_
17	,	,	,	_	16	p	_	_
18	particularly	particularly	RB	_	16	adv	_	_
19	drug2	drug0	NN	_	16	appo	_	_
20	,	,	,	_	16	p	_	_
21	have	have	VBP	_	23	aux	_	_
22	been	be	VBN	_	23	aux	_	_
23	reported	report	VBN	_	0	root	_	_
24	when	when	WRB	_	27	adv	_	_
25	drug3	drug0	NN	_	27	dep	_	_
26	was	be	VBD	_	27	aux	_	_
27	added	add	VBN	_	23	comp	_	_
28	to	to	TO	_	31	aux	_	_
29	the	the	DT	_	31	det	_	_
30	drug4	drug0	NN	_	31	com	_	_
31	regimen	regimen	NN	_	27	ppmod	_	_
32	.	.	.	_	23	p	_	_

1	Discontinuation	discontinuation	NN	_	12	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	in	in	IN	_	6	case	_	_
5	well-controlled	well-controlled	JJ	_	6	attr	_	_
6	patients	patient	NNS	_	1	ppmod	_	_
7	receiving	receive	VBG	_	6	acl	_	_
8	drug2	drug0	NN	_	7	obj	_	_
9	and	and	CC	_	8	cc	_	_
10	drug3	drug0	NN	_	8	conj	_	_
11	may	may	MD	_	12	modal	_	_
12	decrease	decrease	VB	_	0	root	_	_
13	the	the	DT	_	15	det	_	_
14	plasma	plasma	NN	_	15	com	_	_
15	levels	level	NNS	_	12	obj	_	_
16	and	and	CC	_	15	cc	_	_
17	efficacy	efficacy	NN	_	15	conj	_	_
18	of	of	IN	_	20	case	_	_
19	the	the	DT	_	20	det	_	_
20	drug4	drug0	NN	_	17	ppmod	_	_
21	.	.	.	_	12	p	_	_

1	Caution	caution	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	advised	advise	VBN	_	0	root	_	_
4	if	if	IN	_	6	mark	_	_
5	patients	patient	NNS	_	6	dep	_	_
6	receive	receive	VBP	_	3	comp	_	_
7	large	large	JJ	_	8	attr	_	_
8	doses	dose	NNS	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	concurrently	concurrently	RB	_	6	adv	_	_
12	.	.	.	_	3	p	_	_

1	Transient	transient	JJ	_	2	attr	_	_
2	delirium	delirium	NN	_	5	dep	_	_
3	has	have	VBZ	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	reported	report	VBN	_	0	root	_	_
6	in	in	IN	_	7	case	_	_
7	patients	patient	NNS	_	5	ppmod	_	_
8	who	who	WP	_	10	dep	_	_
9	were	be	VBD	_	10	aux	_	_
10	treated	treat	VBN	_	7	relcl	_	_
11	with	with	IN	_	13	case	_	_
12	one	#crd#	CD	_	13	num	_	_
13	gram	gram	NN	_	10	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	and	and	CC	_	13	cc	_	_
17	75	0	CD	_	20	num	_	_
18	-	-	:	_	20	p	_	_
19	150	0	CD	_	20	num	_	_
20	mg	mg	NN	_	13	conj	_	_
21	of	of	IN	_	22	case	_	_
22	drug2	drug0	NN	_	20	ppmod	_	_
23	.	.	.	_	5	p	_	_

1	Increased	increase	VBN	_	2	attr	_	_
2	nephrotoxicity	nephrotoxicity	NN	_	5	dep	_	_
3	has	have	VBZ	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	reported	report	VBN	_	0	root	_	_
6	following	follow	VBG	_	8	adv	_	_
7	concomitant	concomitant	JJ	_	8	attr	_	_
8	administration	administration	NN	_	5	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug2	drug0	NN	_	10	conj	_	_
13	.	.	.	_	5	p	_	_

1	Drug/Laboratory	drug/laboratory	NN	_	3	com	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	10	dep	_	_
4	drug1	drug0	CD	_	3	num	_	_
5	,	,	,	_	3	p	_	_
6	including	include	VBG	_	7	adv	_	_
7	drug2	drug0	NN	_	3	ppmod	_	_
8	,	,	,	_	3	p	_	_
9	are	be	VBP	_	10	aux	_	_
10	known	know	VBN	_	0	root	_	_
11	to	to	TO	_	13	aux	_	_
12	occasionally	occasionally	RB	_	13	adv	_	_
13	induce	induce	VB	_	10	comp	_	_
14	a	a	DT	_	18	det	_	_
15	positive	positive	JJ	_	18	attr	_	_
16	direct	direct	JJ	_	18	attr	_	_
17	Coombs	coombs	NN	_	18	com	_	_
18	test	test	NN	_	13	obj	_	_
19	.	.	.	_	10	p	_	_

1	Steady	steady	JJ	_	5	attr	_	_
2	state	state	NN	_	5	com	_	_
3	plasma	plasma	NN	_	5	com	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	concentrations	concentration	NNS	_	8	dep	_	_
6	did	do	VBD	_	8	aux	_	_
7	not	not	RB	_	8	neg	_	_
8	appear	appear	VB	_	0	root	_	_
9	to	to	TO	_	10	aux	_	_
10	change	change	VB	_	8	comp	_	_
11	.	.	.	_	8	p	_	_

1	Therefore	therefore	RB	_	10	adv	_	_
2	,	,	,	_	10	p	_	_
3	monitoring	monitoring	NN	_	10	dep	_	_
4	of	of	IN	_	7	case	_	_
5	plasma	plasma	NN	_	7	com	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	levels	level	NNS	_	3	ppmod	_	_
8	may	may	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	indicated	indicate	VBN	_	0	root	_	_
11	in	in	IN	_	12	case	_	_
12	patients	patient	NNS	_	10	ppmod	_	_
13	receiving	receive	VBG	_	12	acl	_	_
14	similar	similar	JJ	_	17	attr	_	_
15	combination	combination	NN	_	17	com	_	_
16	chemotherapy	chemotherapy	NN	_	17	com	_	_
17	regimens	regimen	NNS	_	13	obj	_	_
18	.	.	.	_	10	p	_	_

1	The	the	DT	_	2	det	_	_
2	utilization	utilization	NN	_	10	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	for	for	IN	_	7	case	_	_
6	such	such	JJ	_	7	attr	_	_
7	patients	patient	NNS	_	2	ppmod	_	_
8	may	may	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	considered	consider	VBN	_	0	root	_	_
11	as	as	IN	_	13	case	_	_
12	an	an	DT	_	13	det	_	_
13	alternative	alternative	NN	_	10	ppmod	_	_
14	.	.	.	_	10	p	_	_

1	Also	also	RB	_	2	adv	_	_
2	drug1	drug0	VBN	_	0	root	_	_
3	.	.	.	_	2	p	_	_

1	No	no	DT	_	2	det	_	_
2	information	information	NN	_	0	root	_	_
3	provided	provided	VBN	_	2	acl	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Aerosol	aerosol	NN	_	4	com	_	_
4	drug2	drug0	NN	_	13	dep	_	_
5	of	of	IN	_	10	case	_	_
6	the	the	DT	_	10	det	_	_
7	short-acting	short-acting	JJ	_	10	attr	_	_
8	adrenergic	adrenergic	JJ	_	10	attr	_	_
9	stimulant	stimulant	NN	_	10	com	_	_
10	type	type	NN	_	4	ppmod	_	_
11	may	may	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	used	use	VBN	_	1	acl	_	_
14	for	for	IN	_	15	case	_	_
15	relief	relief	NN	_	13	ppmod	_	_
16	of	of	IN	_	18	case	_	_
17	breakthrough	breakthrough	NN	_	18	com	_	_
18	symptoms	symptom	NNS	_	15	ppmod	_	_
19	while	while	IN	_	20	mark	_	_
20	using	use	VBG	_	13	comp	_	_
21	drug3	drug0	NN	_	20	obj	_	_
22	.	.	.	_	1	p	_	_

1	However	however	RB	_	11	adv	_	_
2	,	,	,	_	11	p	_	_
3	increasing	increase	VBG	_	4	attr	_	_
4	use	use	NN	_	11	dep	_	_
5	of	of	IN	_	7	case	_	_
6	such	such	JJ	_	7	attr	_	_
7	preparations	preparation	NNS	_	4	ppmod	_	_
8	to	to	TO	_	10	aux	_	_
9	control	control	JJ	_	10	attr	_	_
10	symptoms	symptom	NNS	_	4	ppmod	_	_
11	indicates	indicate	VBZ	_	0	root	_	_
12	deterioration	deterioration	NN	_	11	obj	_	_
13	of	of	IN	_	15	case	_	_
14	asthma	asthma	NN	_	15	com	_	_
15	control	control	NN	_	12	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	the	the	DT	_	18	det	_	_
18	need	need	NN	_	15	conj	_	_
19	to	to	TO	_	20	aux	_	_
20	reassess	reassess	VB	_	18	acl	_	_
21	the	the	DT	_	24	det	_	_
22	patient	patient	NN	_	24	com	_	_
23	s	s	NN	_	24	com	_	_
24	therapy	therapy	NN	_	20	obj	_	_
25	.	.	.	_	11	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	administration	administration	NN	_	7	dep	_	_
3	of	of	IN	_	5	case	_	_
4	other	other	JJ	_	5	attr	_	_
5	drug1	drug0	NN	_	2	ppmod	_	_
6	may	may	MD	_	7	modal	_	_
7	potentiate	potentiate	VB	_	0	root	_	_
8	the	the	DT	_	10	det	_	_
9	undesirable	undesirable	JJ	_	10	attr	_	_
10	effects	effect	NNS	_	7	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	:	:	:	_	1	p	_	_
5	drug3	drug0	NN	_	8	dep	_	_
6	should	should	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	administered	administer	VBN	_	1	acl	_	_
9	with	with	IN	_	11	case	_	_
10	extreme	extreme	JJ	_	11	attr	_	_
11	caution	caution	NN	_	8	ppmod	_	_
12	in	in	IN	_	13	case	_	_
13	patients	patient	NNS	_	11	ppmod	_	_
14	being	be	VBG	_	15	aux	_	_
15	treated	treat	VBN	_	13	acl	_	_
16	with	with	IN	_	17	case	_	_
17	drug4	drug0	NN	_	15	ppmod	_	_
18	or	or	CC	_	17	cc	_	_
19	drug5	drug0	NN	_	17	conj	_	_
20	because	because	IN	_	31	mark	_	_
21	the	the	DT	_	22	det	_	_
22	action	action	NN	_	31	dep	_	_
23	of	of	IN	_	24	case	_	_
24	drug6	drug0	NN	_	22	ppmod	_	_
25	on	on	IN	_	28	case	_	_
26	the	the	DT	_	28	det	_	_
27	cardiovascular	cardiovascular	JJ	_	28	attr	_	_
28	system	system	NN	_	22	ppmod	_	_
29	may	may	MD	_	31	modal	_	_
30	be	be	VB	_	31	aux	_	_
31	potentiated	potentiate	VBN	_	15	comp	_	_
32	by	by	IN	_	34	case	_	_
33	these	these	DT	_	34	det	_	_
34	agents	agent	NNS	_	31	ppmod	_	_
35	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	and	and	CC	_	3	cc	_	_
5	drug3	drug0	NN	_	1	conj	_	_
6	:	:	:	_	1	p	_	_
7	Concomitant	concomitant	JJ	_	8	attr	_	_
8	treatment	treatment	NN	_	17	dep	_	_
9	with	with	IN	_	10	case	_	_
10	drug4	drug0	NN	_	8	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	drug5	drug0	NN	_	10	conj	_	_
13	,	,	,	_	12	p	_	_
14	or	or	CC	_	12	cc	_	_
15	drug6	drug0	NN	_	10	conj	_	_
16	may	may	MD	_	17	modal	_	_
17	potentiate	potentiate	VB	_	1	acl	_	_
18	a	a	DT	_	21	det	_	_
19	possible	possible	JJ	_	21	attr	_	_
20	hypokalemic	hypokalemic	JJ	_	21	attr	_	_
21	effect	effect	NN	_	17	obj	_	_
22	of	of	IN	_	23	case	_	_
23	drug7	drug0	NN	_	21	ppmod	_	_

1	Hypokalemia	hypokalemia	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	increase	increase	VB	_	0	root	_	_
4	susceptibility	susceptibility	NN	_	3	obj	_	_
5	to	to	TO	_	7	aux	_	_
6	cardiac	cardiac	JJ	_	7	attr	_	_
7	arrhythmias	arrhythmia	NNS	_	4	ppmod	_	_
8	in	in	IN	_	9	case	_	_
9	patients	patient	NNS	_	3	ppmod	_	_
10	treated	treat	VBN	_	9	acl	_	_
11	with	with	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	3	p	_	_

1	-adrenergic	-adrenergic	JJ	_	5	attr	_	_
2	Blockers	blockers	NN	_	5	attr	_	_
3	:	:	:	_	5	p	_	_
4	-adrenergic	-adrenergic	JJ	_	5	attr	_	_
5	blockers	blocker	NNS	_	7	dep	_	_
6	may	may	MD	_	7	modal	_	_
7	weaken	weaken	VB	_	0	root	_	_
8	or	or	CC	_	7	cc	_	_
9	antagonise	antagonise	VB	_	7	conj	_	_
10	the	the	DT	_	11	det	_	_
11	effect	effect	NN	_	9	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	.	.	.	_	7	p	_	_

1	Therefore	therefore	RB	_	6	adv	_	_
2	drug1	drug0	NN	_	6	dep	_	_
3	should	should	MD	_	6	modal	_	_
4	not	not	RB	_	6	neg	_	_
5	be	be	VB	_	6	aux	_	_
6	given	give	VBN	_	0	root	_	_
7	together	together	RB	_	6	adv	_	_
8	with	with	IN	_	10	case	_	_
9	-adrenergic	-adrenergic	JJ	_	10	attr	_	_
10	blockers	blocker	NNS	_	6	ppmod	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	including	include	VBG	_	10	prn	_	_
13	eye	eye	NN	_	14	com	_	_
14	drops	drops	NN	_	12	obj	_	_
15	)	-rrb-	-RRB-	_	12	p	_	_
16	unless	unless	IN	_	18	mark	_	_
17	there	there	EX	_	18	dep	_	_
18	are	be	VBP	_	6	comp	_	_
19	compelling	compelling	JJ	_	20	attr	_	_
20	reasons	reason	NNS	_	18	obj	_	_
21	for	for	IN	_	23	case	_	_
22	their	their	PRP$	_	23	poss	_	_
23	use	use	NN	_	20	ppmod	_	_
24	.	.	.	_	6	p	_	_

1	Other	other	JJ	_	2	attr	_	_
2	Drugs	drug	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	Drugs	drug	NNS	_	21	dep	_	_
5	such	such	JJ	_	7	adv	_	_
6	as	as	IN	_	7	case	_	_
7	drug1	drug0	NN	_	4	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	,	,	,	_	9	p	_	_
11	drug3	drug0	NN	_	7	conj	_	_
12	,	,	,	_	11	p	_	_
13	drug4	drug0	NN	_	7	conj	_	_
14	,	,	,	_	13	p	_	_
15	drug5	drug0	NN	_	7	conj	_	_
16	,	,	,	_	15	p	_	_
17	and	and	CC	_	15	cc	_	_
18	drug6	drug0	NN	_	7	conj	_	_
19	may	may	MD	_	21	modal	_	_
20	be	be	VB	_	21	aux	_	_
21	associated	associate	VBN	_	2	acl	_	_
22	with	with	IN	_	24	case	_	_
23	QT-interval	qt-interval	JJ	_	24	attr	_	_
24	prolongation	prolongation	NN	_	21	ppmod	_	_
25	and	and	CC	_	24	cc	_	_
26	an	an	DT	_	28	det	_	_
27	increased	increase	VBN	_	28	attr	_	_
28	risk	risk	NN	_	24	conj	_	_
29	of	of	IN	_	31	case	_	_
30	ventricular	ventricular	JJ	_	31	attr	_	_
31	arrhythmia	arrhythmia	NN	_	28	ppmod	_	_
32	.	.	.	_	2	p	_	_

1	INFORMATION	information	NN	_	4	dep	_	_
2	TO	to	TO	_	4	aux	_	_
3	BE	be	VB	_	4	aux	_	_
4	PROVIDED	provided	VBN	_	0	root	_	_
5	TO	to	TO	_	7	aux	_	_
6	THE	the	DT	_	7	det	_	_
7	PATIENT	patient	NN	_	4	ppmod	_	_
8	OR	or	CC	_	4	cc	_	_
9	GUARDIAN	guardian	NNP	_	11	dep	_	_
10	See	see	VB	_	11	aux	_	_
11	illustrated	illustrate	VBN	_	4	conj	_	_
12	Information	information	NN	_	11	obj	_	_
13	For	for	IN	_	15	case	_	_
14	The	the	DT	_	15	det	_	_
15	Patient	patient	NN	_	12	ppmod	_	_
16	or	or	CC	_	15	cc	_	_
17	Guardian	guardian	NN	_	18	com	_	_
18	section	section	NN	_	15	conj	_	_
19	.	.	.	_	4	p	_	_

1	It	it	PRP	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	important	important	JJ	_	2	dep	_	_
4	that	that	IN	_	6	mark	_	_
5	patients	patient	NNS	_	6	dep	_	_
6	understand	understand	VB	_	2	comp	_	_
7	how	how	WRB	_	9	adv	_	_
8	to	to	TO	_	9	aux	_	_
9	use	use	VB	_	6	advcl	_	_
10	drug1	drug0	NN	_	14	attr	_	_
11	(	-lrb-	-LRB-	_	14	p	_	_
12	drug2	drug0	NN	_	14	attr	_	_
13	)	-rrb-	-RRB-	_	14	p	_	_
14	capsules	capsule	NNS	_	9	obj	_	_
15	with	with	IN	_	20	case	_	_
16	the	the	DT	_	20	det	_	_
17	supplied	supply	VBN	_	20	attr	_	_
18	AerolizerTM	aerolizertm	NN	_	20	com	_	_
19	inhalation	inhalation	NN	_	20	com	_	_
20	device	device	NN	_	14	ppmod	_	_
21	and	and	CC	_	9	cc	_	_
22	how	how	WRB	_	26	adv	_	_
23	it	it	PRP	_	26	dep	_	_
24	should	should	MD	_	26	modal	_	_
25	be	be	VB	_	26	aux	_	_
26	used	use	VBN	_	9	conj	_	_
27	in	in	IN	_	28	case	_	_
28	relation	relation	NN	_	26	ppmod	_	_
29	to	to	TO	_	31	aux	_	_
30	other	other	JJ	_	31	attr	_	_
31	asthma	asthma	NN	_	28	ppmod	_	_
32	or	or	CC	_	31	cc	_	_
33	COPD	copd	NN	_	34	com	_	_
34	medications	medication	NNS	_	31	conj	_	_
35	they	they	PRP	_	37	dep	_	_
36	are	be	VBP	_	37	aux	_	_
37	taking	take	VBG	_	26	comp	_	_
38	.	.	.	_	2	p	_	_

1	Patients/Guardians	patients/guardians	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	given	give	VBN	_	0	root	_	_
5	the	the	DT	_	7	det	_	_
6	following	follow	VBG	_	7	attr	_	_
7	information	information	NN	_	9	dep	_	_
8	:	:	:	_	9	p	_	_
9	i	i	NN	_	4	comp	_	_
10	.	.	.	_	4	p	_	_

1	The	the	DT	_	3	det	_	_
2	recommended	recommend	VBN	_	3	attr	_	_
3	dosage	dosage	NN	_	19	dep	_	_
4	(	-lrb-	-LRB-	_	8	p	_	_
5	one	#crd#	CD	_	8	num	_	_
6	or	or	CC	_	5	cc	_	_
7	two	#crd#	CD	_	5	conj	_	_
8	capsules	capsule	NNS	_	3	prn	_	_
9	twice	twice	RB	_	10	com	_	_
10	daily	daily	RB	_	8	adv	_	_
11	,	,	,	_	8	p	_	_
12	morning	morning	NN	_	8	appo	_	_
13	and	and	CC	_	12	cc	_	_
14	evening	evening	NN	_	12	conj	_	_
15	)	-rrb-	-RRB-	_	8	p	_	_
16	should	should	MD	_	19	modal	_	_
17	not	not	RB	_	19	neg	_	_
18	be	be	VB	_	19	aux	_	_
19	exceeded	exceed	VBD	_	0	root	_	_
20	.	.	.	_	19	p	_	_

1	ii	ii	NN	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	not	not	RB	_	2	neg	_	_
4	meant	meant	JJ	_	2	dep	_	_
5	to	to	TO	_	6	aux	_	_
6	relieve	relieve	VBP	_	2	comp	_	_
7	acute	acute	JJ	_	8	attr	_	_
8	asthma	asthma	NN	_	6	obj	_	_
9	or	or	CC	_	8	cc	_	_
10	COPD	copd	NN	_	11	com	_	_
11	symptoms	symptom	NNS	_	8	conj	_	_
12	and	and	CC	_	2	cc	_	_
13	extra	extra	JJ	_	14	attr	_	_
14	doses	dose	NNS	_	18	dep	_	_
15	should	should	MD	_	18	modal	_	_
16	not	not	RB	_	18	neg	_	_
17	be	be	VB	_	18	aux	_	_
18	used	use	VBN	_	2	conj	_	_
19	for	for	IN	_	21	case	_	_
20	that	that	DT	_	21	det	_	_
21	purpose	purpose	NN	_	18	ppmod	_	_
22	.	.	.	_	2	p	_	_

1	Acute	acute	JJ	_	2	attr	_	_
2	symptoms	symptom	NNS	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	treated	treat	VBN	_	0	root	_	_
6	with	with	IN	_	11	case	_	_
7	a	a	DT	_	11	det	_	_
8	short-acting	short-acting	JJ	_	11	attr	_	_
9	,	,	,	_	11	p	_	_
10	inhaled	inhaled	JJ	_	11	attr	_	_
11	drug1	drug0	NN	_	5	ppmod	_	_
12	such	such	JJ	_	14	adv	_	_
13	as	as	IN	_	14	case	_	_
14	drug2	drug0	NN	_	11	ppmod	_	_
15	(	-lrb-	-LRB-	_	19	p	_	_
16	the	the	DT	_	17	det	_	_
17	physician	physician	NN	_	19	dep	_	_
18	should	should	MD	_	19	modal	_	_
19	provide	provide	VB	_	14	prn	_	_
20	the	the	DT	_	21	det	_	_
21	patient	patient	NN	_	19	obj	_	_
22	with	with	IN	_	24	case	_	_
23	such	such	JJ	_	24	attr	_	_
24	medication	medication	NN	_	21	ppmod	_	_
25	and	and	CC	_	19	cc	_	_
26	instruct	instruct	VBP	_	19	conj	_	_
27	the	the	DT	_	28	det	_	_
28	patient	patient	NN	_	26	obj	_	_
29	in	in	IN	_	34	case	_	_
30	how	how	WRB	_	34	adv	_	_
31	it	it	PRP	_	34	dep	_	_
32	should	should	MD	_	34	modal	_	_
33	be	be	VB	_	34	aux	_	_
34	used	use	VBN	_	26	ppmod	_	_
35	)	-rrb-	-RRB-	_	19	p	_	_
36	.	.	.	_	5	p	_	_

1	iii	iii	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	physician	physician	NN	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	notified	notify	VBN	_	0	root	_	_
6	immediately	immediately	RB	_	5	adv	_	_
7	if	if	IN	_	13	mark	_	_
8	any	any	DT	_	13	dep	_	_
9	of	of	IN	_	12	case	_	_
10	the	the	DT	_	12	det	_	_
11	following	following	JJ	_	12	attr	_	_
12	situations	situation	NNS	_	8	ppmod	_	_
13	occur	occur	VBP	_	5	comp	_	_
14	,	,	,	_	13	p	_	_
15	which	which	WDT	_	17	dep	_	_
16	may	may	MD	_	17	modal	_	_
17	be	be	VB	_	13	comp	_	_
18	a	a	DT	_	19	det	_	_
19	sign	sign	NN	_	17	obj	_	_
20	of	of	IN	_	23	case	_	_
21	seriously	seriously	RB	_	22	adv	_	_
22	worsening	worsening	JJ	_	23	attr	_	_
23	asthma	asthma	NN	_	19	ppmod	_	_
24	:	:	:	_	5	p	_	_
25	Decreased	decrease	VBN	_	26	attr	_	_
26	effectiveness	effectiveness	NN	_	5	dep	_	_
27	of	of	IN	_	28	case	_	_
28	drug1	drug0	NN	_	26	ppmod	_	_
29	;	;	:	_	5	p	_	_

1	Need	need	VBP	_	0	root	_	_
2	for	for	IN	_	4	case	_	_
3	more	more	JJR	_	4	attr	_	_
4	inhalations	inhalation	NNS	_	1	ppmod	_	_
5	than	than	IN	_	6	case	_	_
6	usual	usual	JJ	_	4	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	.	.	.	_	1	p	_	_

1	iv	iv	NN	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	should	should	MD	_	5	modal	_	_
3	not	not	RB	_	5	neg	_	_
4	be	be	VB	_	5	aux	_	_
5	used	use	VBN	_	0	root	_	_
6	as	as	IN	_	7	case	_	_
7	a	a	DT	_	5	ppmod	_	_
8	substitute	substitute	VB	_	7	acl	_	_
9	for	for	IN	_	13	case	_	_
10	oral	oral	JJ	_	13	attr	_	_
11	or	or	CC	_	10	cc	_	_
12	inhaled	inhaled	JJ	_	10	conj	_	_
13	drug2	drug0	NN	_	8	ppmod	_	_
14	.	.	.	_	5	p	_	_

1	The	the	DT	_	2	det	_	_
2	dosage	dosage	NN	_	9	dep	_	_
3	of	of	IN	_	5	case	_	_
4	these	these	DT	_	5	det	_	_
5	medications	medication	NNS	_	2	ppmod	_	_
6	should	should	MD	_	9	modal	_	_
7	not	not	RB	_	9	neg	_	_
8	be	be	VB	_	9	aux	_	_
9	changed	change	VBN	_	0	root	_	_
10	and	and	CC	_	9	cc	_	_
11	they	they	PRP	_	15	dep	_	_
12	should	should	MD	_	15	modal	_	_
13	not	not	RB	_	15	neg	_	_
14	be	be	VB	_	15	aux	_	_
15	stopped	stop	VBN	_	9	conj	_	_
16	without	without	IN	_	17	case	_	_
17	consulting	consult	VBG	_	15	ppmod	_	_
18	the	the	DT	_	19	det	_	_
19	physician	physician	NN	_	17	obj	_	_
20	,	,	,	_	15	p	_	_
21	even	even	RB	_	25	adv	_	_
22	if	if	IN	_	25	mark	_	_
23	the	the	DT	_	24	det	_	_
24	patient	patient	NN	_	25	dep	_	_
25	feels	feel	VBZ	_	15	comp	_	_
26	better	well	RB	_	25	adv	_	_
27	after	after	IN	_	28	case	_	_
28	initiating	initiate	VBG	_	25	ppmod	_	_
29	treatment	treatment	NN	_	28	obj	_	_
30	with	with	IN	_	31	case	_	_
31	drug1	drug0	NN	_	29	ppmod	_	_
32	.	.	.	_	9	p	_	_

1	v.	v.	NN	_	2	com	_	_
2	Patients	patient	NNS	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	cautioned	caution	VBN	_	0	root	_	_
6	regarding	regard	VBG	_	10	adv	_	_
7	potential	potential	JJ	_	10	attr	_	_
8	adverse	adverse	JJ	_	10	attr	_	_
9	cardiovascular	cardiovascular	JJ	_	10	attr	_	_
10	effects	effect	NNS	_	5	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	such	such	JJ	_	14	adv	_	_
13	as	as	IN	_	14	case	_	_
14	palpitations	palpitation	NNS	_	10	ppmod	_	_
15	or	or	CC	_	14	cc	_	_
16	chest	chest	NN	_	17	com	_	_
17	pain	pain	NN	_	14	conj	_	_
18	.	.	.	_	5	p	_	_

1	vi	vi	LS	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	In	in	IN	_	2	case	_	_
2	patients	patient	NNS	_	11	ppmod	_	_
3	receiving	receive	VBG	_	2	acl	_	_
4	drug1	drug0	NN	_	3	obj	_	_
5	,	,	,	_	11	p	_	_
6	other	other	JJ	_	8	attr	_	_
7	inhaled	inhaled	JJ	_	8	attr	_	_
8	medications	medication	NNS	_	11	dep	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	used	use	VBN	_	0	root	_	_
12	only	only	RB	_	11	adv	_	_
13	as	as	IN	_	14	mark	_	_
14	directed	direct	VBN	_	11	comp	_	_
15	by	by	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	physician	physician	NN	_	14	ppmod	_	_
18	.	.	.	_	11	p	_	_

1	vii	vii	NN	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	Guardians	guardian	NNS	_	11	dep	_	_
2	of	of	IN	_	3	case	_	_
3	children	child	NNS	_	1	ppmod	_	_
4	who	who	WP	_	7	dep	_	_
5	have	have	VBP	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	prescribed	prescribe	VBN	_	3	relcl	_	_
8	drug1	drug0	NN	_	7	obj	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	alerted	alert	VBN	_	0	root	_	_
12	to	to	TO	_	15	aux	_	_
13	the	the	DT	_	15	det	_	_
14	general	general	JJ	_	15	attr	_	_
15	concern	concern	NN	_	11	ppmod	_	_
16	regarding	regard	VBG	_	15	acl	_	_
17	asthma	asthma	NN	_	18	com	_	_
18	therapy	therapy	NN	_	16	obj	_	_
19	compliance	compliance	NN	_	18	attr	_	_
20	,	,	,	_	18	p	_	_
21	especially	especially	RB	_	22	adv	_	_
22	neglect	neglect	NN	_	18	conj	_	_
23	of	of	IN	_	25	case	_	_
24	anti-inflammatory	anti-inflammatory	JJ	_	25	attr	_	_
25	therapy	therapy	NN	_	22	ppmod	_	_
26	and	and	CC	_	22	cc	_	_
27	overuse	overuse	NN	_	18	conj	_	_
28	of	of	IN	_	29	case	_	_
29	drug2	drug0	NN	_	27	ppmod	_	_
30	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	increase	increase	VB	_	0	root	_	_
4	slightly	slightly	RB	_	3	adv	_	_
5	the	the	DT	_	6	det	_	_
6	effect	effect	NN	_	3	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	,	,	,	_	3	p	_	_
10	e.g.	e.g.	FW	_	12	adv	_	_
11	,	,	,	_	12	p	_	_
12	drug3	drug0	NN	_	3	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	drug4	drug0	NN	_	12	appo	_	_
15	,	,	,	_	12	p	_	_
16	drug5	drug0	NN	_	12	appo	_	_
17	.	.	.	_	3	p	_	_

1	Other	other	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	used	use	VBN	_	0	root	_	_
6	with	with	IN	_	7	case	_	_
7	caution	caution	NN	_	5	ppmod	_	_
8	in	in	IN	_	9	case	_	_
9	patients	patient	NNS	_	5	ppmod	_	_
10	taking	take	VBG	_	9	acl	_	_
11	drug2	drug0	NN	_	10	obj	_	_
12	,	,	,	_	5	p	_	_
13	since	since	IN	_	17	mark	_	_
14	the	the	DT	_	15	det	_	_
15	effects	effect	NNS	_	17	dep	_	_
16	may	may	MD	_	17	modal	_	_
17	be	be	VB	_	5	comp	_	_
18	additive	additive	JJ	_	17	dep	_	_
19	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	21	dep	_	_
2	including	include	VBG	_	4	adv	_	_
3	coumarin	coumarin	NN	_	4	com	_	_
4	derivatives	derivative	NNS	_	1	ppmod	_	_
5	,	,	,	_	4	p	_	_
6	indandione	indandione	NN	_	7	com	_	_
7	derivatives	derivative	NNS	_	4	conj	_	_
8	,	,	,	_	7	p	_	_
9	and	and	CC	_	7	cc	_	_
10	drug2	drug0	NNS	_	4	conj	_	_
11	such	such	JJ	_	13	adv	_	_
12	as	as	IN	_	13	case	_	_
13	drug3	drug0	NN	_	10	ppmod	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	drug4	drug0	NN	_	13	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	,	,	,	_	13	p	_	_
18	and	and	CC	_	13	cc	_	_
19	drug5	drug0	NN	_	13	conj	_	_
20	may	may	MD	_	21	modal	_	_
21	increase	increase	VB	_	0	root	_	_
22	the	the	DT	_	23	det	_	_
23	risk	risk	NN	_	21	obj	_	_
24	of	of	IN	_	25	case	_	_
25	bleeding	bleeding	JJ	_	23	ppmod	_	_
26	when	when	WRB	_	27	adv	_	_
27	administered	administer	VBN	_	21	comp	_	_
28	concomitantly	concomitantly	RB	_	27	adv	_	_
29	with	with	IN	_	30	case	_	_
30	drug6	drug0	NN	_	27	ppmod	_	_
31	.	.	.	_	21	p	_	_

1	A	a	DT	_	6	det	_	_
2	30	0	CD	_	6	num	_	_
3	to	to	TO	_	2	cc	_	_
4	45	0	CD	_	2	conj	_	_
5	%	%	NN	_	2	meta	_	_
6	increase	increase	NN	_	14	dep	_	_
7	in	in	IN	_	8	case	_	_
8	AUC	auc	NN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	Cmax	cmax	NN	_	8	conj	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	8	ppmod	_	_
13	was	be	VBD	_	14	aux	_	_
14	observed	observe	VBN	_	0	root	_	_
15	with	with	IN	_	17	case	_	_
16	concomitant	concomitant	JJ	_	17	attr	_	_
17	administration	administration	NN	_	14	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	twice	twice	RB	_	21	com	_	_
21	daily	daily	RB	_	17	adv	_	_
22	.	.	.	_	14	p	_	_

1	drug1	drug0	NN	_	3	attr	_	_
2	150	0	CD	_	3	num	_	_
3	mg	mg	NN	_	8	dep	_	_
4	twice	twice	RB	_	5	com	_	_
5	daily	daily	RB	_	3	adv	_	_
6	did	do	VBD	_	8	aux	_	_
7	not	not	RB	_	8	neg	_	_
8	interact	interact	VB	_	0	root	_	_
9	significantly	significantly	RB	_	8	adv	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NN	_	8	ppmod	_	_
12	(	-lrb-	-LRB-	_	15	p	_	_
13	AUC	auc	NN	_	15	dep	_	_
14	was	be	VBD	_	15	aux	_	_
15	decreased	decrease	VBN	_	8	prn	_	_
16	by	by	IN	_	17	case	_	_
17	15-20	0	CD	_	15	ppmod	_	_
18	%	%	NN	_	17	meta	_	_
19	)	-rrb-	-RRB-	_	15	p	_	_
20	.	.	.	_	8	p	_	_

1	No	no	DT	_	3	det	_	_
2	pharmacodynamic	pharmacodynamic	JJ	_	3	attr	_	_
3	effects	effect	NNS	_	8	dep	_	_
4	of	of	IN	_	6	case	_	_
5	either	either	DT	_	6	det	_	_
6	drug1	drug0	NN	_	3	ppmod	_	_
7	were	be	VBD	_	8	aux	_	_
8	observed	observe	VBN	_	0	root	_	_
9	.	.	.	_	8	p	_	_

1	Coadministration	coadministration	NN	_	12	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	8	case	_	_
5	40	0	CD	_	8	num	_	_
6	mg	mg	NN	_	8	com	_	_
7	drug2	drug0	NN	_	8	com	_	_
8	tablets	tablet	NNS	_	1	ppmod	_	_
9	in	in	IN	_	11	case	_	_
10	epileptic	epileptic	JJ	_	11	attr	_	_
11	patients	patient	NNS	_	8	ppmod	_	_
12	lowered	lower	VBD	_	0	root	_	_
13	the	the	DT	_	16	det	_	_
14	drug3	drug0	NN	_	16	com	_	_
15	plasma	plasma	NN	_	16	com	_	_
16	concentrations	concentration	NNS	_	12	obj	_	_
17	to	to	TO	_	19	aux	_	_
18	undetectable	undetectable	JJ	_	19	attr	_	_
19	levels	level	NNS	_	12	ppmod	_	_
20	.	.	.	_	12	p	_	_

1	Coadministration	coadministration	NN	_	13	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	5	case	_	_
5	drug2	drug0	NN	_	1	ppmod	_	_
6	or	or	CC	_	5	cc	_	_
7	any	any	DT	_	10	det	_	_
8	known	known	JJ	_	10	attr	_	_
9	CYP3A4	cyp0a0	NN	_	10	com	_	_
10	inducer	inducer	NN	_	5	conj	_	_
11	should	should	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	avoided	avoid	VBN	_	0	root	_	_
14	and	and	CC	_	13	cc	_	_
15	alternative	alternative	JJ	_	17	attr	_	_
16	drug3	drug0	NN	_	17	com	_	_
17	therapy	therapy	NN	_	20	dep	_	_
18	should	should	MD	_	20	modal	_	_
19	be	be	VB	_	20	aux	_	_
20	considered	consider	VBN	_	13	conj	_	_
21	.	.	.	_	13	p	_	_

1	Pharmacokinetic	pharmacokinetic	JJ	_	2	attr	_	_
2	interactions	interaction	NNS	_	12	dep	_	_
3	between	between	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	drug3	drug0	NN	_	4	prn	_	_
9	,	,	,	_	8	p	_	_
10	drug4	drug0	NN	_	8	appo	_	_
11	)	-rrb-	-RRB-	_	8	p	_	_
12	were	be	VBD	_	0	root	_	_
13	variable	variable	JJ	_	12	dep	_	_
14	and	and	CC	_	13	cc	_	_
15	not	not	RB	_	16	neg	_	_
16	significant	significant	JJ	_	13	conj	_	_
17	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	attenuated	attenuate	VBD	_	0	root	_	_
3	the	the	DT	_	6	det	_	_
4	heart	heart	NN	_	6	com	_	_
5	rate	rate	NN	_	6	com	_	_
6	increase	increase	NN	_	2	obj	_	_
7	following	follow	VBG	_	8	adv	_	_
8	administration	administration	NN	_	2	ppmod	_	_
9	of	of	IN	_	12	case	_	_
10	immediate	immediate	JJ	_	12	attr	_	_
11	release	release	NN	_	12	com	_	_
12	drug2	drug0	NN	_	8	ppmod	_	_
13	.	.	.	_	2	p	_	_

1	The	the	DT	_	4	det	_	_
2	blood	blood	NN	_	4	com	_	_
3	pressure	pressure	NN	_	4	com	_	_
4	effect	effect	NN	_	7	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	tended	tend	VBD	_	0	root	_	_
8	to	to	TO	_	9	aux	_	_
9	be	be	VB	_	7	comp	_	_
10	greater	great	JJR	_	9	dep	_	_
11	in	in	IN	_	12	case	_	_
12	patients	patient	NNS	_	10	ppmod	_	_
13	on	on	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	than	than	IN	_	17	case	_	_
16	in	in	IN	_	17	case	_	_
17	patients	patient	NNS	_	10	ppmod	_	_
18	on	on	IN	_	22	case	_	_
19	no	no	DT	_	22	det	_	_
20	other	other	JJ	_	22	attr	_	_
21	drug3	drug0	NN	_	22	com	_	_
22	therapy	therapy	NN	_	17	ppmod	_	_
23	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	at	at	IN	_	5	case	_	_
3	648	0	CD	_	4	num	_	_
4	mg	mg	NN	_	5	com	_	_
5	bid	bid	NN	_	1	ppmod	_	_
6	decreased	decrease	VBD	_	0	root	_	_
7	the	the	DT	_	8	det	_	_
8	bioavailability	bioavailability	NN	_	6	dat	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	AUC	auc	NN	_	8	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	8	ppmod	_	_
14	by	by	IN	_	15	case	_	_
15	26	0	CD	_	6	ppmod	_	_
16	%	%	NN	_	15	meta	_	_
17	,	,	,	_	6	p	_	_
18	but	but	CC	_	6	cc	_	_
19	not	not	RB	_	18	com	_	_
20	the	the	DT	_	22	det	_	_
21	peak	peak	JJ	_	22	attr	_	_
22	concentration	concentration	NN	_	6	conj	_	_
23	.	.	.	_	6	p	_	_

1	The	the	DT	_	3	det	_	_
2	immediate	immediate	JJ	_	3	attr	_	_
3	release	release	NN	_	12	dep	_	_
4	,	,	,	_	3	p	_	_
5	but	but	CC	_	3	cc	_	_
6	not	not	RB	_	5	com	_	_
7	the	the	DT	_	9	det	_	_
8	coat-core	coat-core	JJ	_	9	attr	_	_
9	formulation	formulation	NN	_	3	conj	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	increased	increase	VBD	_	0	root	_	_
13	plasma	plasma	NN	_	15	com	_	_
14	drug2	drug0	NN	_	15	com	_	_
15	concentrations	concentration	NNS	_	12	obj	_	_
16	by	by	IN	_	18	case	_	_
17	about	about	RB	_	18	adv	_	_
18	20	0	CD	_	12	ppmod	_	_
19	%	%	NN	_	18	meta	_	_
20	.	.	.	_	12	p	_	_

1	This	this	DT	_	2	det	_	_
2	interaction	interaction	NN	_	5	dep	_	_
3	was	be	VBD	_	5	aux	_	_
4	not	not	RB	_	5	neg	_	_
5	accompanied	accompany	VBN	_	0	root	_	_
6	by	by	IN	_	8	case	_	_
7	ECG	ecg	NN	_	8	com	_	_
8	changes	change	NNS	_	5	ppmod	_	_
9	and	and	CC	_	5	cc	_	_
10	its	its	PRP$	_	12	poss	_	_
11	clinical	clinical	JJ	_	12	attr	_	_
12	significance	significance	NN	_	15	dep	_	_
13	is	be	VBZ	_	15	aux	_	_
14	not	not	RB	_	15	neg	_	_
15	known	know	VBN	_	5	conj	_	_
16	.	.	.	_	5	p	_	_

1	No	no	DT	_	3	det	_	_
2	significant	significant	JJ	_	3	attr	_	_
3	interactions	interaction	NNS	_	5	dep	_	_
4	were	be	VBD	_	5	aux	_	_
5	found	find	VBN	_	0	root	_	_
6	between	between	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	or	or	CC	_	9	cc	_	_
11	drug3	drug0	NN	_	7	conj	_	_
12	.	.	.	_	5	p	_	_

1	Hypotension	hypotension	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Patients	patient	NNS	_	24	dep	_	_
4	on	on	IN	_	6	case	_	_
5	Diuretic	diuretic	JJ	_	6	attr	_	_
6	Therapy	therapy	NN	_	3	ppmod	_	_
7	:	:	:	_	3	p	_	_
8	Patients	patient	NNS	_	3	appo	_	_
9	on	on	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	3	cc	_	_
12	especially	especially	RB	_	13	adv	_	_
13	those	those	DT	_	3	conj	_	_
14	in	in	IN	_	15	case	_	_
15	whom	whom	WP	_	20	ppmod	_	_
16	diuretic	diuretic	JJ	_	17	attr	_	_
17	therapy	therapy	NN	_	20	dep	_	_
18	was	be	VBD	_	20	aux	_	_
19	recently	recently	RB	_	20	adv	_	_
20	instituted	institute	VBN	_	13	relcl	_	_
21	,	,	,	_	13	p	_	_
22	may	may	MD	_	24	modal	_	_
23	occasionally	occasionally	RB	_	24	adv	_	_
24	experience	experience	VBP	_	1	acl	_	_
25	an	an	DT	_	27	det	_	_
26	excessive	excessive	JJ	_	27	attr	_	_
27	reduction	reduction	NN	_	24	obj	_	_
28	of	of	IN	_	30	case	_	_
29	blood	blood	NN	_	30	com	_	_
30	pressure	pressure	NN	_	27	ppmod	_	_
31	after	after	IN	_	32	case	_	_
32	initiation	initiation	NN	_	27	ppmod	_	_
33	of	of	IN	_	34	case	_	_
34	therapy	therapy	NN	_	32	ppmod	_	_
35	with	with	IN	_	36	case	_	_
36	drug2	drug0	NN	_	34	ppmod	_	_
37	or	or	CC	_	36	cc	_	_
38	drug3	drug0	NN	_	36	conj	_	_
39	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	possibility	possibility	NN	_	12	dep	_	_
3	of	of	IN	_	5	case	_	_
4	hypotensive	hypotensive	JJ	_	5	attr	_	_
5	effects	effect	NNS	_	2	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	or	or	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	can	can	MD	_	12	modal	_	_
11	be	be	VB	_	12	aux	_	_
12	minimized	minimize	VBN	_	0	root	_	_
13	by	by	IN	_	15	case	_	_
14	either	either	CC	_	15	cc	_	_
15	discontinuing	discontinue	VBG	_	12	ppmod	_	_
16	the	the	DT	_	17	det	_	_
17	drug3	drug0	NN	_	15	obj	_	_
18	or	or	CC	_	15	cc	_	_
19	increasing	increase	VBG	_	15	conj	_	_
20	the	the	DT	_	22	det	_	_
21	salt	salt	NN	_	22	com	_	_
22	intake	intake	NN	_	19	obj	_	_
23	prior	prior	RB	_	22	adv	_	_
24	to	to	TO	_	25	aux	_	_
25	initiation	initiation	NN	_	23	ppmod	_	_
26	of	of	IN	_	27	case	_	_
27	treatment	treatment	NN	_	25	ppmod	_	_
28	with	with	IN	_	29	case	_	_
29	drug4	drug0	NN	_	27	ppmod	_	_
30	or	or	CC	_	29	cc	_	_
31	drug5	drug0	NN	_	29	conj	_	_
32	.	.	.	_	12	p	_	_

1	If	if	IN	_	3	mark	_	_
2	it	it	PRP	_	3	dep	_	_
3	is	be	VBZ	_	28	advcl	_	_
4	necessary	necessary	JJ	_	3	dep	_	_
5	to	to	TO	_	6	aux	_	_
6	continue	continue	VBP	_	4	comp	_	_
7	the	the	DT	_	8	det	_	_
8	drug1	drug0	NN	_	6	obj	_	_
9	,	,	,	_	28	p	_	_
10	provide	provide	VBP	_	28	aux	_	_
11	close	close	JJ	_	13	attr	_	_
12	medical	medical	JJ	_	13	attr	_	_
13	supervision	supervision	NN	_	28	obj	_	_
14	after	after	IN	_	17	case	_	_
15	the	the	DT	_	17	det	_	_
16	initial	initial	JJ	_	17	attr	_	_
17	dose	dose	NN	_	13	ppmod	_	_
18	for	for	IN	_	22	case	_	_
19	at	at	IN	_	21	case	_	_
20	least	least	JJS	_	21	attr	_	_
21	two	#crd#	CD	_	22	num	_	_
22	hours	hour	NNS	_	13	ppmod	_	_
23	and	and	CC	_	22	cc	_	_
24	until	until	IN	_	26	case	_	_
25	blood	blood	NN	_	26	com	_	_
26	pressure	pressure	NN	_	22	conj	_	_
27	has	have	VBZ	_	28	aux	_	_
28	stabilized	stabilize	VBN	_	0	root	_	_
29	for	for	IN	_	34	case	_	_
30	at	at	IN	_	31	case	_	_
31	least	least	JJS	_	34	adv	_	_
32	an	an	DT	_	34	det	_	_
33	additional	additional	JJ	_	34	attr	_	_
34	hour	hour	NN	_	28	ppmod	_	_
35	.	.	.	_	28	p	_	_
36	.	.	.	_	28	p	_	_

1	Agents	agent	NNS	_	0	root	_	_
2	Causing	cause	VBG	_	1	acl	_	_
3	Renin	renin	NN	_	4	com	_	_
4	Release	release	NN	_	2	obj	_	_
5	:	:	:	_	1	p	_	_
6	The	the	DT	_	8	det	_	_
7	antihypertensive	antihypertensive	JJ	_	8	attr	_	_
8	effect	effect	NN	_	15	dep	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug2	drug0	NN	_	10	conj	_	_
13	IV	iv	CD	_	12	num	_	_
14	is	be	VBZ	_	15	aux	_	_
15	augmented	augment	VBN	_	1	acl	_	_
16	by	by	IN	_	17	case	_	_
17	drug3	drug0	NN	_	15	ppmod	_	_
18	that	that	WDT	_	19	dep	_	_
19	cause	cause	VBP	_	17	relcl	_	_
20	renin	renin	NN	_	21	com	_	_
21	release	release	NN	_	19	obj	_	_
22	(	-lrb-	-LRB-	_	25	p	_	_
23	e.g.	e.g.	FW	_	25	ppmod	_	_
24	,	,	,	_	25	p	_	_
25	drug4	drug0	NNS	_	21	prn	_	_
26	)	-rrb-	-RRB-	_	25	p	_	_
27	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	5	case	_	_
4	some	some	DT	_	5	det	_	_
5	patients	patient	NNS	_	22	ppmod	_	_
6	with	with	IN	_	9	case	_	_
7	compromised	compromise	VBN	_	9	attr	_	_
8	renal	renal	JJ	_	9	attr	_	_
9	function	function	NN	_	5	ppmod	_	_
10	who	who	WP	_	13	dep	_	_
11	are	be	VBP	_	13	aux	_	_
12	being	be	VBG	_	13	aux	_	_
13	treated	treat	VBN	_	5	relcl	_	_
14	with	with	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	,	,	,	_	22	p	_	_
17	the	the	DT	_	18	det	_	_
18	co-administration	co-administration	NN	_	22	dep	_	_
19	of	of	IN	_	20	case	_	_
20	drug3	drug0	NN	_	18	ppmod	_	_
21	may	may	MD	_	22	modal	_	_
22	result	result	VB	_	1	acl	_	_
23	in	in	IN	_	26	case	_	_
24	a	a	DT	_	26	det	_	_
25	further	far	JJ	_	26	attr	_	_
26	deterioration	deterioration	NN	_	22	ppmod	_	_
27	of	of	IN	_	29	case	_	_
28	renal	renal	JJ	_	29	attr	_	_
29	function	function	NN	_	26	ppmod	_	_
30	.	.	.	_	1	p	_	_

1	These	these	DT	_	2	det	_	_
2	effects	effect	NNS	_	3	dep	_	_
3	are	be	VBP	_	0	root	_	_
4	usually	usually	RB	_	3	adv	_	_
5	reversible	reversible	JJ	_	3	dep	_	_
6	.	.	.	_	3	p	_	_

1	In	in	IN	_	5	case	_	_
2	a	a	DT	_	5	det	_	_
3	clinical	clinical	JJ	_	5	attr	_	_
4	pharmacology	pharmacology	NN	_	5	com	_	_
5	study	study	NN	_	11	ppmod	_	_
6	,	,	,	_	11	p	_	_
7	drug1	drug0	NN	_	11	dep	_	_
8	or	or	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	was	be	VBD	_	11	aux	_	_
11	administered	administer	VBN	_	0	root	_	_
12	to	to	TO	_	14	aux	_	_
13	hypertensive	hypertensive	JJ	_	14	attr	_	_
14	patients	patient	NNS	_	11	ppmod	_	_
15	receiving	receive	VBG	_	14	acl	_	_
16	drug3	drug0	NN	_	15	obj	_	_
17	.	.	.	_	11	p	_	_

1	In	in	IN	_	3	case	_	_
2	this	this	DT	_	3	det	_	_
3	study	study	NN	_	5	ppmod	_	_
4	there	there	EX	_	5	dep	_	_
5	was	be	VBD	_	0	root	_	_
6	no	no	DT	_	7	det	_	_
7	evidence	evidence	NN	_	5	obj	_	_
8	of	of	IN	_	10	case	_	_
9	a	a	DT	_	10	det	_	_
10	blunting	blunting	NN	_	7	ppmod	_	_
11	of	of	IN	_	14	case	_	_
12	the	the	DT	_	14	det	_	_
13	antihypertensive	antihypertensive	JJ	_	14	attr	_	_
14	action	action	NN	_	10	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	.	.	.	_	5	p	_	_

1	However	however	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	reports	report	NNS	_	4	dep	_	_
4	suggest	suggest	VBP	_	0	root	_	_
5	that	that	IN	_	8	mark	_	_
6	drug1	drug0	NN	_	8	dep	_	_
7	may	may	MD	_	8	modal	_	_
8	diminish	diminish	VB	_	4	comp	_	_
9	the	the	DT	_	11	det	_	_
10	antihypertensive	antihypertensive	JJ	_	11	attr	_	_
11	effect	effect	NN	_	8	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	.	.	.	_	4	p	_	_

1	This	this	DT	_	2	det	_	_
2	interaction	interaction	NN	_	6	dep	_	_
3	should	should	MD	_	6	modal	_	_
4	be	be	VB	_	6	aux	_	_
5	given	give	VBN	_	6	lv	_	_
6	consideration	consideration	NN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	6	ppmod	_	_
9	taking	take	VBG	_	8	acl	_	_
10	drug1	drug0	NN	_	9	obj	_	_
11	concomitantly	concomitantly	RB	_	6	adv	_	_
12	with	with	IN	_	13	case	_	_
13	drug2	drug0	NN	_	6	ppmod	_	_
14	.	.	.	_	6	p	_	_

1	Other	other	JJ	_	3	attr	_	_
2	Cardiovascular	cardiovascular	NN	_	3	com	_	_
3	Agents	agent	NNS	_	11	dep	_	_
4	:	:	:	_	3	p	_	_
5	drug1	drug0	NN	_	3	appo	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	IV	iv	CD	_	7	num	_	_
9	have	have	VBP	_	11	aux	_	_
10	been	be	VBN	_	11	aux	_	_
11	used	use	VBN	_	0	root	_	_
12	concomitantly	concomitantly	RB	_	11	adv	_	_
13	with	with	IN	_	14	case	_	_
14	drug3	drug0	NN	_	11	ppmod	_	_
15	,	,	,	_	14	p	_	_
16	drug4	drug0	NN	_	14	conj	_	_
17	,	,	,	_	16	p	_	_
18	drug5	drug0	NN	_	14	conj	_	_
19	,	,	,	_	18	p	_	_
20	drug6	drug0	NN	_	14	conj	_	_
21	,	,	,	_	20	p	_	_
22	drug7	drug0	NN	_	14	conj	_	_
23	,	,	,	_	22	p	_	_
24	drug8	drug0	NN	_	14	conj	_	_
25	and	and	CC	_	24	cc	_	_
26	drug9	drug0	NN	_	14	conj	_	_
27	without	without	IN	_	28	case	_	_
28	evidence	evidence	NN	_	11	ppmod	_	_
29	of	of	IN	_	33	case	_	_
30	clinically	clinically	RB	_	31	adv	_	_
31	significant	significant	JJ	_	33	attr	_	_
32	adverse	adverse	JJ	_	33	attr	_	_
33	interactions	interaction	NNS	_	28	ppmod	_	_
34	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	IV	iv	CD	_	1	num	_	_
3	has	have	VBZ	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	used	use	VBN	_	0	root	_	_
6	concomitantly	concomitantly	RB	_	5	adv	_	_
7	with	with	IN	_	8	case	_	_
8	drug2	drug0	NN	_	5	ppmod	_	_
9	without	without	IN	_	10	case	_	_
10	evidence	evidence	NN	_	5	ppmod	_	_
11	of	of	IN	_	15	case	_	_
12	clinically	clinically	RB	_	13	adv	_	_
13	significant	significant	JJ	_	15	attr	_	_
14	adverse	adverse	JJ	_	15	attr	_	_
15	reactions	reaction	NNS	_	10	ppmod	_	_
16	.	.	.	_	5	p	_	_

1	Agents	agent	NNS	_	2	dep	_	_
2	Increasing	increase	VBG	_	10	advcl	_	_
3	Serum	serum	NN	_	4	com	_	_
4	Potassium	potassium	NN	_	2	obj	_	_
5	:	:	:	_	10	p	_	_
6	drug1	drug0	NN	_	10	dep	_	_
7	and	and	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	IV	iv	CD	_	8	num	_	_
10	attenuate	attenuate	VBP	_	0	root	_	_
11	potassium	potassium	NN	_	12	com	_	_
12	loss	loss	NN	_	10	obj	_	_
13	caused	cause	VBN	_	12	acl	_	_
14	by	by	IN	_	15	case	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	22	dep	_	_
2	(	-lrb-	-LRB-	_	5	p	_	_
3	e.g.	e.g.	FW	_	5	adv	_	_
4	,	,	,	_	5	p	_	_
5	drug2	drug0	NN	_	1	prn	_	_
6	,	,	,	_	5	p	_	_
7	drug3	drug0	NN	_	5	conj	_	_
8	,	,	,	_	7	p	_	_
9	or	or	CC	_	7	cc	_	_
10	drug4	drug0	NN	_	5	conj	_	_
11	)	-rrb-	-RRB-	_	5	p	_	_
12	,	,	,	_	1	p	_	_
13	drug5	drug0	NN	_	14	com	_	_
14	supplements	supplement	NNS	_	1	conj	_	_
15	,	,	,	_	14	p	_	_
16	or	or	CC	_	14	cc	_	_
17	drug6	drug0	NN	_	19	attr	_	_
18	-containing	-containing	JJ	_	19	attr	_	_
19	salt	salt	NN	_	1	conj	_	_
20	substitutes	substitute	VBZ	_	19	attr	_	_
21	may	may	MD	_	22	modal	_	_
22	lead	lead	VB	_	0	root	_	_
23	to	to	TO	_	25	aux	_	_
24	significant	significant	JJ	_	25	attr	_	_
25	increases	increase	NNS	_	22	ppmod	_	_
26	in	in	IN	_	28	case	_	_
27	serum	serum	NN	_	28	com	_	_
28	potassium	potassium	NN	_	25	ppmod	_	_
29	.	.	.	_	22	p	_	_

1	Therefore	therefore	RB	_	19	adv	_	_
2	,	,	,	_	19	p	_	_
3	if	if	IN	_	10	mark	_	_
4	concomitant	concomitant	JJ	_	5	attr	_	_
5	use	use	NN	_	10	dep	_	_
6	of	of	IN	_	8	case	_	_
7	these	these	DT	_	8	det	_	_
8	agents	agent	NNS	_	5	ppmod	_	_
9	is	be	VBZ	_	10	aux	_	_
10	indicated	indicate	VBN	_	19	advcl	_	_
11	because	because	IN	_	14	case	_	_
12	of	of	IN	_	14	case	_	_
13	demonstrated	demonstrate	VBN	_	14	attr	_	_
14	hypokalemia	hypokalemia	NN	_	10	ppmod	_	_
15	,	,	,	_	19	p	_	_
16	they	they	PRP	_	19	dep	_	_
17	should	should	MD	_	19	modal	_	_
18	be	be	VB	_	19	aux	_	_
19	used	use	VBN	_	0	root	_	_
20	with	with	IN	_	21	case	_	_
21	caution	caution	NN	_	19	ppmod	_	_
22	and	and	CC	_	21	cc	_	_
23	with	with	IN	_	25	case	_	_
24	frequent	frequent	JJ	_	25	attr	_	_
25	monitoring	monitoring	NN	_	21	conj	_	_
26	of	of	IN	_	28	case	_	_
27	serum	serum	NN	_	28	com	_	_
28	potassium	potassium	NN	_	25	ppmod	_	_
29	.	.	.	_	19	p	_	_

1	Potassium	potassium	NN	_	3	com	_	_
2	sparing	sparing	NN	_	3	com	_	_
3	agents	agent	NNS	_	8	dep	_	_
4	should	should	MD	_	8	modal	_	_
5	generally	generally	RB	_	8	adv	_	_
6	not	not	RB	_	8	neg	_	_
7	be	be	VB	_	8	aux	_	_
8	used	use	VBN	_	0	root	_	_
9	in	in	IN	_	10	case	_	_
10	patients	patient	NNS	_	8	ppmod	_	_
11	with	with	IN	_	13	case	_	_
12	heart	heart	NN	_	13	com	_	_
13	failure	failure	NN	_	10	ppmod	_	_
14	receiving	receive	VBG	_	10	acl	_	_
15	drug1	drug0	NN	_	14	obj	_	_
16	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	JJ	_	4	attr	_	_
4	toxicity	toxicity	NN	_	7	dep	_	_
5	has	have	VBZ	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	reported	report	VBN	_	1	acl	_	_
8	in	in	IN	_	9	case	_	_
9	patients	patient	NNS	_	7	ppmod	_	_
10	receiving	receive	VBG	_	9	acl	_	_
11	drug3	drug0	NN	_	10	obj	_	_
12	concomitantly	concomitantly	RB	_	14	adv	_	_
13	with	with	IN	_	14	case	_	_
14	drugs	drug	NNS	_	9	ppmod	_	_
15	which	which	WDT	_	16	dep	_	_
16	cause	cause	VBP	_	14	relcl	_	_
17	elimination	elimination	NN	_	16	obj	_	_
18	of	of	IN	_	19	case	_	_
19	sodium	sodium	NN	_	17	ppmod	_	_
20	,	,	,	_	14	p	_	_
21	including	include	VBG	_	22	adv	_	_
22	drug4	drug0	NN	_	14	ppmod	_	_
23	.	.	.	_	1	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	recommended	recommend	VBN	_	0	root	_	_
4	that	that	IN	_	9	mark	_	_
5	serum	serum	NN	_	7	com	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	levels	level	NNS	_	9	dep	_	_
8	be	be	VB	_	9	aux	_	_
9	monitored	monitor	VBN	_	3	comp	_	_
10	frequently	frequently	RB	_	9	adv	_	_
11	if	if	IN	_	14	mark	_	_
12	drug2	drug0	NN	_	14	dep	_	_
13	is	be	VBZ	_	14	aux	_	_
14	administered	administer	VBN	_	9	comp	_	_
15	concomitantly	concomitantly	RB	_	14	adv	_	_
16	with	with	IN	_	17	case	_	_
17	drug3	drug0	NN	_	14	ppmod	_	_
18	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	administered	administer	VBN	_	0	root	_	_
5	with	with	IN	_	6	case	_	_
6	caution	caution	NN	_	4	ppmod	_	_
7	to	to	TO	_	8	aux	_	_
8	patients	patient	NNS	_	4	ppmod	_	_
9	receiving	receive	VBG	_	8	acl	_	_
10	drug2	drug0	NN	_	9	obj	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	drug3	drug0	NN	_	10	prn	_	_
13	,	,	,	_	12	p	_	_
14	Wyeth-Ayerst	wyeth-ayerst	NN	_	15	com	_	_
15	Laboratories	laboratory	NNS	_	12	appo	_	_
16	)	-rrb-	-RRB-	_	12	p	_	_
17	.	.	.	_	4	p	_	_

1	In	in	IN	_	4	case	_	_
2	a	a	DT	_	4	det	_	_
3	single	single	JJ	_	4	attr	_	_
4	study	study	NN	_	16	ppmod	_	_
5	,	,	,	_	16	p	_	_
6	rats	rat	NNS	_	16	dep	_	_
7	given	give	VBN	_	6	acl	_	_
8	high	high	JJ	_	10	attr	_	_
9	intraperitoneal	intraperitoneal	JJ	_	10	attr	_	_
10	doses	dose	NNS	_	7	obj	_	_
11	of	of	IN	_	13	case	_	_
12	an	an	DT	_	13	det	_	_
13	drug1	drug0	NN	_	10	ppmod	_	_
14	plus	plus	CC	_	13	cc	_	_
15	drug2	drug0	NN	_	13	conj	_	_
16	experienced	experience	VBN	_	0	root	_	_
17	severe	severe	JJ	_	18	attr	_	_
18	toxicity	toxicity	NN	_	16	obj	_	_
19	,	,	,	_	16	p	_	_
20	including	include	VBG	_	21	adv	_	_
21	convulsions	convulsions	NN	_	16	ppmod	_	_
22	and	and	CC	_	21	cc	_	_
23	death	death	NN	_	21	conj	_	_
24	.	.	.	_	16	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	use	use	NN	_	11	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	other	other	JJ	_	7	attr	_	_
7	drug2	drug0	NNS	_	4	conj	_	_
8	is	be	VBZ	_	11	aux	_	_
9	generally	generally	RB	_	11	adv	_	_
10	not	not	RB	_	11	neg	_	_
11	recommended	recommend	VBN	_	0	root	_	_
12	because	because	IN	_	16	case	_	_
13	of	of	IN	_	16	case	_	_
14	possible	possible	JJ	_	16	attr	_	_
15	potentiating	potentiating	NN	_	16	com	_	_
16	effects	effect	NNS	_	11	ppmod	_	_
17	.	.	.	_	11	p	_	_

1	This	this	DT	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	especially	especially	RB	_	4	adv	_	_
4	true	true	JJ	_	2	dep	_	_
5	in	in	IN	_	6	case	_	_
6	patients	patient	NNS	_	4	ppmod	_	_
7	who	who	WP	_	9	dep	_	_
8	may	may	MD	_	9	modal	_	_
9	subject	subject	NN	_	6	relcl	_	_
10	themselves	themselves	PRP	_	9	obj	_	_
11	to	to	TO	_	13	aux	_	_
12	an	an	DT	_	13	det	_	_
13	overdosage	overdosage	NN	_	9	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drugs	drug	NNS	_	13	ppmod	_	_
16	.	.	.	_	2	p	_	_

1	If	if	IN	_	5	mark	_	_
2	combination	combination	NN	_	3	com	_	_
3	therapy	therapy	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	needed	need	VBN	_	11	advcl	_	_
6	,	,	,	_	11	p	_	_
7	careful	careful	JJ	_	8	attr	_	_
8	consideration	consideration	NN	_	11	dep	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	given	give	VBN	_	0	root	_	_
12	to	to	TO	_	14	aux	_	_
13	the	the	DT	_	14	det	_	_
14	pharmacology	pharmacology	NN	_	11	ppmod	_	_
15	of	of	IN	_	17	case	_	_
16	all	all	DT	_	17	det	_	_
17	agents	agent	NNS	_	14	ppmod	_	_
18	to	to	TO	_	20	aux	_	_
19	be	be	VB	_	20	aux	_	_
20	used	use	VBN	_	14	acl	_	_
21	.	.	.	_	11	p	_	_

1	The	the	DT	_	5	det	_	_
2	monoamine	monoamine	NN	_	3	com	_	_
3	oxidase	oxidase	NN	_	5	attr	_	_
4	inhibitory	inhibitory	JJ	_	5	attr	_	_
5	effects	effect	NNS	_	9	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	may	may	MD	_	9	modal	_	_
9	persist	persist	VB	_	0	root	_	_
10	for	for	IN	_	13	case	_	_
11	a	a	DT	_	13	det	_	_
12	substantial	substantial	JJ	_	13	attr	_	_
13	period	period	NN	_	9	ppmod	_	_
14	after	after	IN	_	15	case	_	_
15	discontinuation	discontinuation	NN	_	13	ppmod	_	_
16	of	of	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	drug	drug	NN	_	15	ppmod	_	_
19	,	,	,	_	9	p	_	_
20	and	and	CC	_	9	cc	_	_
21	this	this	DT	_	24	dep	_	_
22	should	should	MD	_	24	modal	_	_
23	be	be	VB	_	24	aux	_	_
24	borne	bear	VBN	_	9	conj	_	_
25	in	in	IN	_	26	case	_	_
26	mind	mind	NN	_	24	ppmod	_	_
27	when	when	WRB	_	31	adv	_	_
28	another	another	DT	_	29	det	_	_
29	drug	drug	NN	_	31	dep	_	_
30	is	be	VBZ	_	31	aux	_	_
31	prescribed	prescribe	VBN	_	24	comp	_	_
32	following	follow	VBG	_	33	adv	_	_
33	drug2	drug0	NN	_	31	ppmod	_	_
34	.	.	.	_	9	p	_	_

1	To	to	TO	_	2	aux	_	_
2	avoid	avoid	VB	_	7	advcl	_	_
3	potentiation	potentiation	NN	_	2	obj	_	_
4	,	,	,	_	7	p	_	_
5	the	the	DT	_	6	det	_	_
6	physician	physician	NN	_	7	dep	_	_
7	wishing	wish	VBG	_	0	root	_	_
8	to	to	TO	_	9	aux	_	_
9	terminate	terminate	VB	_	7	comp	_	_
10	treatment	treatment	NN	_	9	obj	_	_
11	with	with	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	and	and	CC	_	9	cc	_	_
14	begin	begin	VBP	_	9	conj	_	_
15	therapy	therapy	NN	_	20	dep	_	_
16	with	with	IN	_	18	case	_	_
17	another	another	DT	_	18	det	_	_
18	agent	agent	NN	_	15	ppmod	_	_
19	should	should	MD	_	20	modal	_	_
20	allow	allow	VB	_	14	comp	_	_
21	for	for	IN	_	23	case	_	_
22	an	an	DT	_	23	det	_	_
23	interval	interval	NN	_	20	ppmod	_	_
24	of	of	IN	_	26	case	_	_
25	10	0	CD	_	26	num	_	_
26	days	day	NNS	_	23	ppmod	_	_
27	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	/	/	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	,	,	,	_	3	p	_	_
5	drug3	drug0	NN	_	3	appo	_	_
6	,	,	,	_	3	p	_	_
7	Including	include	VBG	_	8	adv	_	_
8	drug4	drug0	NN	_	3	ppmod	_	_

1	The	the	DT	_	2	det	_	_
2	administration	administration	NN	_	19	dep	_	_
3	of	of	IN	_	5	case	_	_
4	local	local	JJ	_	5	attr	_	_
5	drug1	drug0	NN	_	2	ppmod	_	_
6	containing	contain	VBG	_	5	acl	_	_
7	drug2	drug0	NN	_	6	obj	_	_
8	or	or	CC	_	7	cc	_	_
9	drug3	drug0	NN	_	7	conj	_	_
10	to	to	TO	_	11	aux	_	_
11	patients	patient	NNS	_	6	ppmod	_	_
12	receiving	receive	VBG	_	11	acl	_	_
13	drug4	drug0	NN	_	12	obj	_	_
14	,	,	,	_	13	p	_	_
15	drug5	drug0	NN	_	13	conj	_	_
16	or	or	CC	_	15	cc	_	_
17	drug6	drug0	NN	_	13	conj	_	_
18	may	may	MD	_	19	modal	_	_
19	produce	produce	VB	_	0	root	_	_
20	severe	severe	JJ	_	22	adv	_	_
21	,	,	,	_	22	p	_	_
22	prolonged	prolonged	JJ	_	23	attr	_	_
23	hypotension	hypotension	NN	_	19	obj	_	_
24	or	or	CC	_	23	cc	_	_
25	hypertension	hypertension	NN	_	23	conj	_	_
26	.	.	.	_	19	p	_	_

1	Concurrent	concurrent	JJ	_	2	attr	_	_
2	use	use	NN	_	9	dep	_	_
3	of	of	IN	_	5	case	_	_
4	these	these	DT	_	5	det	_	_
5	agents	agent	NNS	_	2	ppmod	_	_
6	should	should	MD	_	9	modal	_	_
7	generally	generally	RB	_	9	adv	_	_
8	be	be	VB	_	9	aux	_	_
9	avoided	avoid	VBN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	In	in	IN	_	2	case	_	_
2	situations	situation	NNS	_	12	ppmod	_	_
3	when	when	WRB	_	6	adv	_	_
4	concurrent	concurrent	JJ	_	5	attr	_	_
5	therapy	therapy	NN	_	6	dep	_	_
6	is	be	VBZ	_	2	relcl	_	_
7	necessary	necessary	JJ	_	6	dep	_	_
8	,	,	,	_	12	p	_	_
9	careful	careful	JJ	_	11	attr	_	_
10	patient	patient	NN	_	11	com	_	_
11	monitoring	monitoring	NN	_	12	dep	_	_
12	is	be	VBZ	_	0	root	_	_
13	essential	essential	JJ	_	12	dep	_	_
14	.	.	.	_	12	p	_	_

1	Concurrent	concurrent	JJ	_	2	attr	_	_
2	administration	administration	NN	_	19	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	(	-lrb-	-LRB-	_	8	p	_	_
6	for	for	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	treatment	treatment	NN	_	4	prn	_	_
9	of	of	IN	_	10	case	_	_
10	hypotension	hypotension	NN	_	8	ppmod	_	_
11	related	related	JJ	_	8	attr	_	_
12	to	to	TO	_	14	aux	_	_
13	obstetric	obstetric	JJ	_	14	attr	_	_
14	blocks	block	NNS	_	11	ppmod	_	_
15	)	-rrb-	-RRB-	_	8	p	_	_
16	and	and	CC	_	4	cc	_	_
17	drug2	drug0	NN	_	4	conj	_	_
18	may	may	MD	_	19	modal	_	_
19	cause	cause	VB	_	0	root	_	_
20	severe	severe	JJ	_	23	attr	_	_
21	,	,	,	_	23	p	_	_
22	persistent	persistent	JJ	_	23	attr	_	_
23	hypertension	hypertension	NN	_	19	obj	_	_
24	or	or	CC	_	23	cc	_	_
25	cerebrovascular	cerebrovascular	JJ	_	26	attr	_	_
26	accidents	accidents	NN	_	23	conj	_	_
27	.	.	.	_	19	p	_	_

1	The	the	DT	_	4	det	_	_
2	para-aminobenzoic	para-aminobenzoic	JJ	_	4	attr	_	_
3	acid	acid	NN	_	4	com	_	_
4	metabolite	metabolite	NN	_	7	dep	_	_
5	of	of	IN	_	6	case	_	_
6	chloroprocaine	chloroprocaine	NN	_	4	ppmod	_	_
7	inhibits	inhibit	VBZ	_	0	root	_	_
8	the	the	DT	_	9	det	_	_
9	action	action	NN	_	7	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	7	p	_	_

1	Therefore	therefore	RB	_	7	adv	_	_
2	,	,	,	_	7	p	_	_
3	drug1	drug0	NN	_	7	dep	_	_
4	should	should	MD	_	7	modal	_	_
5	not	not	RB	_	7	neg	_	_
6	be	be	VB	_	7	aux	_	_
7	used	use	VBN	_	0	root	_	_
8	in	in	IN	_	10	case	_	_
9	any	any	DT	_	10	det	_	_
10	condition	condition	NN	_	7	ppmod	_	_
11	in	in	IN	_	12	case	_	_
12	which	which	WDT	_	17	ppmod	_	_
13	a	a	DT	_	14	det	_	_
14	drug2	drug0	NN	_	17	dep	_	_
15	is	be	VBZ	_	17	aux	_	_
16	being	be	VBG	_	17	aux	_	_
17	employed	employ	VBN	_	10	relcl	_	_
18	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	19	dep	_	_
2	including	include	VBG	_	3	adv	_	_
3	drug2	drug0	NN	_	1	ppmod	_	_
4	,	,	,	_	3	p	_	_
5	drug3	drug0	NN	_	3	conj	_	_
6	,	,	,	_	5	p	_	_
7	and	and	CC	_	5	cc	_	_
8	drug4	drug0	NN	_	9	com	_	_
9	HC1	hc0	NN	_	3	conj	_	_
10	:	:	:	_	1	p	_	_
11	Concomitant	concomitant	JJ	_	12	attr	_	_
12	use	use	NN	_	1	conj	_	_
13	of	of	IN	_	14	case	_	_
14	drug5	drug0	NN	_	12	ppmod	_	_
15	and	and	CC	_	12	cc	_	_
16	non-selective	non-selective	JJ	_	17	attr	_	_
17	drug6	drug0	NN	_	1	conj	_	_
18	may	may	MD	_	19	modal	_	_
19	cause	cause	VB	_	0	root	_	_
20	hypertension	hypertension	NN	_	19	obj	_	_
21	.	.	.	_	19	p	_	_

1	Concurrent	concurrent	JJ	_	2	attr	_	_
2	use	use	NN	_	16	dep	_	_
3	with	with	IN	_	7	case	_	_
4	drug1	drug0	JJ	_	7	attr	_	_
5	or	or	CC	_	4	cc	_	_
6	other	other	JJ	_	4	conj	_	_
7	drugs	drug	NNS	_	2	ppmod	_	_
8	significantly	significantly	RB	_	9	adv	_	_
9	eliminated	eliminate	VBN	_	7	acl	_	_
10	by	by	IN	_	14	case	_	_
11	active	active	JJ	_	14	attr	_	_
12	renal	renal	JJ	_	14	attr	_	_
13	tubular	tubular	JJ	_	14	attr	_	_
14	secretion	secretion	NN	_	9	ppmod	_	_
15	may	may	MD	_	16	modal	_	_
16	result	result	VB	_	0	root	_	_
17	in	in	IN	_	20	case	_	_
18	increased	increase	VBN	_	20	attr	_	_
19	plasma	plasma	NN	_	20	com	_	_
20	concentrations	concentration	NNS	_	16	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	drug2	drug0	NN	_	20	ppmod	_	_
23	.	.	.	_	16	p	_	_

1	The	the	DT	_	2	det	_	_
2	conversion	conversion	NN	_	8	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	to	to	TO	_	6	aux	_	_
6	drug2	drug0	NN	_	2	ppmod	_	_
7	is	be	VBZ	_	8	aux	_	_
8	catalyzed	catalyze	VBN	_	0	root	_	_
9	by	by	IN	_	11	case	_	_
10	aldehyde	aldehyde	NN	_	11	com	_	_
11	oxidase	oxidase	NN	_	8	ppmod	_	_
12	.	.	.	_	8	p	_	_

1	Interactions	interaction	NNS	_	11	dep	_	_
2	with	with	IN	_	4	case	_	_
3	other	other	JJ	_	4	attr	_	_
4	drugs	drug	NNS	_	1	ppmod	_	_
5	metabolized	metabolize	VBN	_	4	acl	_	_
6	by	by	IN	_	8	case	_	_
7	this	this	DT	_	8	det	_	_
8	enzyme	enzyme	NN	_	5	ppmod	_	_
9	could	could	MD	_	11	modal	_	_
10	potentially	potentially	RB	_	11	adv	_	_
11	occur	occur	VB	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	enhances	enhance	VBZ	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	effect	effect	NN	_	4	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug3	drug0	NN	_	6	ppmod	_	_
9	.	.	.	_	4	p	_	_

1	Therefore	therefore	RB	_	19	adv	_	_
2	,	,	,	_	19	p	_	_
3	when	when	WRB	_	6	adv	_	_
4	drug1	drug0	NN	_	6	dep	_	_
5	is	be	VBZ	_	6	aux	_	_
6	given	give	VBN	_	19	advcl	_	_
7	to	to	TO	_	9	aux	_	_
8	a	a	DT	_	9	det	_	_
9	patient	patient	NN	_	6	ppmod	_	_
10	receiving	receive	VBG	_	9	acl	_	_
11	drug2	drug0	NN	_	10	obj	_	_
12	,	,	,	_	19	p	_	_
13	the	the	DT	_	14	det	_	_
14	dosage	dosage	NN	_	19	dep	_	_
15	of	of	IN	_	16	case	_	_
16	drug3	drug0	NN	_	14	ppmod	_	_
17	should	should	MD	_	19	modal	_	_
18	be	be	VB	_	19	aux	_	_
19	reduced	reduce	VBN	_	0	root	_	_
20	to	to	TO	_	21	aux	_	_
21	prevent	prevent	VB	_	19	comp	_	_
22	excessive	excessive	JJ	_	23	attr	_	_
23	prolongation	prolongation	NN	_	21	obj	_	_
24	of	of	IN	_	27	case	_	_
25	the	the	DT	_	27	det	_	_
26	prothrombin	prothrombin	NN	_	27	com	_	_
27	time	time	NN	_	23	ppmod	_	_
28	.	.	.	_	19	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Concurrent	concurrent	JJ	_	4	attr	_	_
4	administration	administration	NN	_	8	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	may	may	MD	_	8	modal	_	_
8	lower	low	JJR	_	1	acl	_	_
9	drug3	drug0	NN	_	11	com	_	_
10	plasma	plasma	NN	_	11	com	_	_
11	levels	level	NNS	_	8	obj	_	_
12	,	,	,	_	8	p	_	_
13	possibly	possibly	RB	_	15	adv	_	_
14	by	by	IN	_	15	case	_	_
15	competing	compete	VBG	_	8	ppmod	_	_
16	for	for	IN	_	18	case	_	_
17	protein-binding	protein-binding	JJ	_	18	attr	_	_
18	sites	site	NNS	_	15	ppmod	_	_
19	.	.	.	_	1	p	_	_

1	The	the	DT	_	3	det	_	_
2	urinary	urinary	JJ	_	3	attr	_	_
3	excretion	excretion	NN	_	7	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	is	be	VBZ	_	7	aux	_	_
7	unaffected	unaffected	VBN	_	0	root	_	_
8	by	by	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	7	p	_	_
11	indicating	indicate	VBG	_	7	comp	_	_
12	no	no	DT	_	13	det	_	_
13	change	change	NN	_	11	obj	_	_
14	in	in	IN	_	16	case	_	_
15	drug3	drug0	NN	_	16	com	_	_
16	absorption	absorption	NN	_	13	ppmod	_	_
17	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	does	do	VBZ	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	affect	affect	VB	_	0	root	_	_
5	serum	serum	NN	_	7	com	_	_
6	drug2	drug0	NN	_	7	com	_	_
7	levels	level	NNS	_	4	obj	_	_
8	.	.	.	_	4	p	_	_

1	Greater	great	JJR	_	4	attr	_	_
2	fecal	fecal	NN	_	4	com	_	_
3	blood	blood	NN	_	4	com	_	_
4	loss	loss	NN	_	5	dep	_	_
5	results	result	VBZ	_	0	root	_	_
6	from	from	IN	_	8	case	_	_
7	concomitant	concomitant	JJ	_	8	attr	_	_
8	administration	administration	NN	_	5	ppmod	_	_
9	of	of	IN	_	11	case	_	_
10	both	both	DT	_	11	det	_	_
11	drugs	drug	NNS	_	8	ppmod	_	_
12	than	than	IN	_	15	case	_	_
13	from	from	IN	_	15	case	_	_
14	either	either	DT	_	15	det	_	_
15	drug	drug	NN	_	8	ppmod	_	_
16	alone	alone	RB	_	15	adv	_	_
17	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	10	dep	_	_
2	:	:	:	_	10	p	_	_
3	The	the	DT	_	5	det	_	_
4	concurrent	concurrent	JJ	_	5	attr	_	_
5	administration	administration	NN	_	10	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	does	do	VBZ	_	10	aux	_	_
9	not	not	RB	_	10	neg	_	_
10	affect	affect	VB	_	0	root	_	_
11	the	the	DT	_	12	det	_	_
12	bioavailability	bioavailability	NN	_	10	obj	_	_
13	of	of	IN	_	14	case	_	_
14	drug3	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Concomitant	concomitant	JJ	_	4	attr	_	_
4	administration	administration	NN	_	12	dep	_	_
5	of	of	IN	_	9	case	_	_
6	drug2	drug0	NN	_	9	attr	_	_
7	and	and	CC	_	6	cc	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	s	s	NNS	_	4	ppmod	_	_
10	does	do	VBZ	_	12	aux	_	_
11	not	not	RB	_	12	neg	_	_
12	interfere	interfere	VB	_	1	acl	_	_
13	with	with	IN	_	14	case	_	_
14	absorption	absorption	NN	_	12	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug4	drug0	NN	_	14	ppmod	_	_
17	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	affect	affect	VB	_	0	root	_	_
4	central	central	JJ	_	6	attr	_	_
5	nervous	nervous	JJ	_	6	attr	_	_
6	function	function	NN	_	3	obj	_	_
7	.	.	.	_	3	p	_	_

1	Therefore	therefore	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	interactions	interaction	NNS	_	5	dep	_	_
4	could	could	MD	_	5	modal	_	_
5	occur	occur	VB	_	0	root	_	_
6	following	follow	VBG	_	8	adv	_	_
7	concomitant	concomitant	JJ	_	8	attr	_	_
8	administration	administration	NN	_	5	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	(	-lrb-	-LRB-	_	14	p	_	_
12	e.g.	e.g.	FW	_	14	ppmod	_	_
13	,	,	,	_	14	p	_	_
14	drug2	drug0	NN	_	10	prn	_	_
15	,	,	,	_	14	p	_	_
16	drug3	drug0	NN	_	14	appo	_	_
17	,	,	,	_	14	p	_	_
18	drug4	drug0	NN	_	14	appo	_	_
19	,	,	,	_	14	p	_	_
20	drug5	drug0	NN	_	14	appo	_	_
21	,	,	,	_	14	p	_	_
22	drug6	drug0	NN	_	14	appo	_	_
23	)	-rrb-	-RRB-	_	14	p	_	_
24	.	.	.	_	5	p	_	_

1	Concurrent	concurrent	JJ	_	2	attr	_	_
2	administration	administration	NN	_	42	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drugs	drug	NNS	_	2	ppmod	_	_
5	possessing	possess	VBG	_	4	acl	_	_
6	nephrotoxic	nephrotoxic	JJ	_	38	attr	_	_
7	(	-lrb-	-LRB-	_	12	p	_	_
8	e.g.	e.g.	FW	_	10	adv	_	_
9	,	,	,	_	10	p	_	_
10	drug1	drug0	NN	_	12	ppmod	_	_
11	,	,	,	_	12	p	_	_
12	drug2	drug0	NN	_	6	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	,	,	,	_	6	p	_	_
15	myelotoxic	myelotoxic	JJ	_	6	conj	_	_
16	(	-lrb-	-LRB-	_	20	p	_	_
17	e.g.	e.g.	FW	_	20	adv	_	_
18	,	,	,	_	20	p	_	_
19	drug3	drug0	NN	_	20	com	_	_
20	chemotherapy	chemotherapy	NN	_	15	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	,	,	,	_	15	p	_	_
23	cardiotoxic	cardiotoxic	JJ	_	6	conj	_	_
24	(	-lrb-	-LRB-	_	27	p	_	_
25	e.g.	e.g.	FW	_	27	ppmod	_	_
26	,	,	,	_	27	p	_	_
27	drug4	drug0	NN	_	23	prn	_	_
28	)	-rrb-	-RRB-	_	27	p	_	_
29	or	or	CC	_	23	cc	_	_
30	hepatotoxic	hepatotoxic	JJ	_	6	conj	_	_
31	(	-lrb-	-LRB-	_	36	p	_	_
32	e.g.	e.g.	FW	_	34	adv	_	_
33	,	,	,	_	34	p	_	_
34	drug5	drug0	NN	_	36	ppmod	_	_
35	,	,	,	_	36	p	_	_
36	drug6	drug0	NN	_	30	prn	_	_
37	)	-rrb-	-RRB-	_	36	p	_	_
38	effects	effect	NNS	_	5	obj	_	_
39	with	with	IN	_	40	case	_	_
40	drug7	drug0	NN	_	5	ppmod	_	_
41	may	may	MD	_	42	modal	_	_
42	increase	increase	VB	_	0	root	_	_
43	toxicity	toxicity	NN	_	42	obj	_	_
44	in	in	IN	_	47	case	_	_
45	these	these	DT	_	47	det	_	_
46	organ	organ	NN	_	47	com	_	_
47	systems	system	NNS	_	42	ppmod	_	_
48	.	.	.	_	42	p	_	_

1	The	the	DT	_	2	det	_	_
2	safety	safety	NN	_	15	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	efficacy	efficacy	NN	_	2	conj	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	2	ppmod	_	_
7	in	in	IN	_	8	case	_	_
8	combination	combination	NN	_	2	ppmod	_	_
9	with	with	IN	_	11	case	_	_
10	any	any	DT	_	11	det	_	_
11	drug2	drug0	NN	_	8	ppmod	_	_
12	have	have	VBP	_	15	aux	_	_
13	not	not	RB	_	15	neg	_	_
14	been	be	VBN	_	15	aux	_	_
15	established	establish	VBN	_	0	root	_	_
16	.	.	.	_	15	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	14	ppmod	_	_
3	,	,	,	_	14	p	_	_
4	reduced	reduce	VBN	_	8	attr	_	_
5	kidney	kidney	NN	_	8	attr	_	_
6	and	and	CC	_	5	cc	_	_
7	liver	liver	NN	_	5	conj	_	_
8	function	function	NN	_	14	dep	_	_
9	secondary	secondary	JJ	_	8	attr	_	_
10	to	to	TO	_	12	aux	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	treatment	treatment	NN	_	9	ppmod	_	_
13	may	may	MD	_	14	modal	_	_
14	delay	delay	VB	_	0	root	_	_
15	elimination	elimination	NN	_	14	obj	_	_
16	of	of	IN	_	18	case	_	_
17	concomitant	concomitant	JJ	_	18	attr	_	_
18	medications	medication	NNS	_	15	ppmod	_	_
19	and	and	CC	_	14	cc	_	_
20	increase	increase	VB	_	14	conj	_	_
21	the	the	DT	_	22	det	_	_
22	risk	risk	NN	_	20	obj	_	_
23	of	of	IN	_	25	case	_	_
24	adverse	adverse	JJ	_	25	attr	_	_
25	events	event	NNS	_	22	ppmod	_	_
26	from	from	IN	_	28	case	_	_
27	those	those	DT	_	28	det	_	_
28	drugs	drug	NNS	_	22	ppmod	_	_
29	.	.	.	_	14	p	_	_

1	Hypersensitivity	hypersensitivity	NN	_	2	com	_	_
2	reactions	reaction	NNS	_	5	dep	_	_
3	have	have	VBP	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	reported	report	VBN	_	0	root	_	_
6	in	in	IN	_	7	case	_	_
7	patients	patient	NNS	_	5	ppmod	_	_
8	receiving	receive	VBG	_	7	acl	_	_
9	combination	combination	NN	_	10	com	_	_
10	regimens	regimen	NNS	_	8	obj	_	_
11	containing	contain	VBG	_	10	acl	_	_
12	sequential	sequential	JJ	_	15	attr	_	_
13	high	high	JJ	_	15	attr	_	_
14	dose	dose	NN	_	15	com	_	_
15	drug1	drug0	NN	_	11	obj	_	_
16	and	and	CC	_	15	cc	_	_
17	drug2	drug0	NN	_	15	conj	_	_
18	,	,	,	_	15	p	_	_
19	specifically	specifically	RB	_	15	adv	_	_
20	,	,	,	_	15	p	_	_
21	drug3	drug0	NN	_	15	appo	_	_
22	,	,	,	_	21	p	_	_
23	drug4	drug0	NN	_	21	conj	_	_
24	,	,	,	_	23	p	_	_
25	drug5	drug0	NN	_	21	conj	_	_
26	and	and	CC	_	25	cc	_	_
27	drug6	drug0	NN	_	21	conj	_	_
28	.	.	.	_	5	p	_	_

1	These	these	DT	_	2	det	_	_
2	reactions	reaction	NNS	_	3	dep	_	_
3	consisted	consist	VBD	_	0	root	_	_
4	of	of	IN	_	5	case	_	_
5	erythema	erythema	NN	_	3	ppmod	_	_
6	,	,	,	_	5	p	_	_
7	pruritus	pruritus	NN	_	5	conj	_	_
8	,	,	,	_	7	p	_	_
9	and	and	CC	_	7	cc	_	_
10	hypotension	hypotension	NN	_	5	conj	_	_
11	and	and	CC	_	3	cc	_	_
12	occurred	occur	VBD	_	3	conj	_	_
13	within	within	IN	_	14	case	_	_
14	hours	hour	NNS	_	12	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	administration	administration	NN	_	14	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	chemotherapy	chemotherapy	NN	_	16	ppmod	_	_
19	.	.	.	_	3	p	_	_

1	These	these	DT	_	2	det	_	_
2	events	event	NNS	_	3	dep	_	_
3	required	require	VBD	_	0	root	_	_
4	medical	medical	JJ	_	5	attr	_	_
5	intervention	intervention	NN	_	3	obj	_	_
6	in	in	IN	_	8	case	_	_
7	some	some	DT	_	8	det	_	_
8	patients	patient	NNS	_	5	ppmod	_	_
9	.	.	.	_	3	p	_	_

1	Myocardial	myocardial	JJ	_	2	attr	_	_
2	injury	injury	NN	_	16	dep	_	_
3	,	,	,	_	2	p	_	_
4	including	include	VBG	_	6	adv	_	_
5	myocardial	myocardial	JJ	_	6	attr	_	_
6	infarction	infarction	NN	_	2	ppmod	_	_
7	,	,	,	_	6	p	_	_
8	myocarditis	myocarditis	NN	_	6	conj	_	_
9	,	,	,	_	8	p	_	_
10	ventricular	ventricular	JJ	_	11	attr	_	_
11	hypokinesia	hypokinesia	NN	_	6	conj	_	_
12	,	,	,	_	11	p	_	_
13	and	and	CC	_	11	cc	_	_
14	severe	severe	JJ	_	15	attr	_	_
15	rhabdomyolysis	rhabdomyolysis	NN	_	6	conj	_	_
16	appear	appear	VBP	_	0	root	_	_
17	to	to	TO	_	19	aux	_	_
18	be	be	VB	_	19	aux	_	_
19	increased	increase	VBN	_	16	comp	_	_
20	in	in	IN	_	21	case	_	_
21	patients	patient	NNS	_	19	ppmod	_	_
22	receiving	receive	VBG	_	21	acl	_	_
23	drug1	drug0	NN	_	22	obj	_	_
24	and	and	CC	_	23	cc	_	_
25	drug2	drug0	NN	_	23	conj	_	_
26	concurrently	concurrently	RB	_	19	adv	_	_
27	.	.	.	_	16	p	_	_

1	Exacerbation	exacerbation	NN	_	16	dep	_	_
2	or	or	CC	_	1	cc	_	_
3	the	the	DT	_	5	det	_	_
4	initial	initial	JJ	_	5	attr	_	_
5	presentation	presentation	NN	_	1	conj	_	_
6	of	of	IN	_	8	case	_	_
7	a	a	DT	_	8	det	_	_
8	number	number	NN	_	1	ppmod	_	_
9	of	of	IN	_	13	case	_	_
10	autoimmune	autoimmune	JJ	_	13	attr	_	_
11	and	and	CC	_	10	cc	_	_
12	inflammatory	inflammatory	JJ	_	10	conj	_	_
13	disorders	disorder	NNS	_	8	ppmod	_	_
14	has	have	VBZ	_	16	aux	_	_
15	been	be	VBN	_	16	aux	_	_
16	observed	observe	VBN	_	0	root	_	_
17	following	follow	VBG	_	19	adv	_	_
18	concurrent	concurrent	JJ	_	19	attr	_	_
19	use	use	NN	_	16	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	drug1	drug0	NN	_	19	ppmod	_	_
22	and	and	CC	_	21	cc	_	_
23	drug2	drug0	NN	_	21	conj	_	_
24	,	,	,	_	21	p	_	_
25	including	include	VBG	_	28	adv	_	_
26	crescentic	crescentic	JJ	_	28	attr	_	_
27	IgA	iga	NN	_	28	com	_	_
28	glomerulonephritis	glomerulonephritis	NN	_	21	ppmod	_	_
29	,	,	,	_	28	p	_	_
30	oculo-bulbar	oculo-bulbar	JJ	_	32	attr	_	_
31	myasthenia	myasthenia	NN	_	32	com	_	_
32	gravis	gravis	NN	_	28	conj	_	_
33	,	,	,	_	32	p	_	_
34	inflammatory	inflammatory	JJ	_	35	attr	_	_
35	arthritis	arthritis	NN	_	28	conj	_	_
36	,	,	,	_	35	p	_	_
37	thyroiditis	thyroiditis	NN	_	28	conj	_	_
38	,	,	,	_	37	p	_	_
39	bullous	bullous	NN	_	40	com	_	_
40	pemphigoid	pemphigoid	NN	_	28	conj	_	_
41	,	,	,	_	40	p	_	_
42	and	and	CC	_	40	cc	_	_
43	Stevens-Johnson	stevens-johnson	NN	_	44	com	_	_
44	syndrome	syndrome	NN	_	28	conj	_	_
45	.	.	.	_	16	p	_	_

1	Although	although	IN	_	5	mark	_	_
2	drug1	drug0	NN	_	5	dep	_	_
3	have	have	VBP	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	shown	show	VBN	_	33	advcl	_	_
6	to	to	TO	_	7	aux	_	_
7	reduce	reduce	VB	_	5	comp	_	_
8	drug2	drug0	NN	_	11	attr	_	_
9	-induced	-induced	JJ	_	11	attr	_	_
10	side	side	JJ	_	11	attr	_	_
11	effects	effect	NNS	_	7	obj	_	_
12	including	include	VBG	_	13	adv	_	_
13	fever	fever	NN	_	11	ppmod	_	_
14	,	,	,	_	13	p	_	_
15	renal	renal	JJ	_	16	attr	_	_
16	insufficiency	insufficiency	NN	_	13	conj	_	_
17	,	,	,	_	16	p	_	_
18	hyperbilirubinemia	hyperbilirubinemia	NN	_	13	conj	_	_
19	,	,	,	_	18	p	_	_
20	confusion	confusion	NN	_	13	conj	_	_
21	,	,	,	_	20	p	_	_
22	and	and	CC	_	20	cc	_	_
23	dyspnea	dyspnea	NN	_	13	conj	_	_
24	,	,	,	_	33	p	_	_
25	concomitant	concomitant	JJ	_	26	attr	_	_
26	administration	administration	NN	_	33	dep	_	_
27	of	of	IN	_	29	case	_	_
28	these	these	DT	_	29	det	_	_
29	agents	agent	NNS	_	26	ppmod	_	_
30	with	with	IN	_	31	case	_	_
31	drug3	drug0	NN	_	26	ppmod	_	_
32	may	may	MD	_	33	modal	_	_
33	reduce	reduce	VB	_	0	root	_	_
34	the	the	DT	_	36	det	_	_
35	antitumor	antitumor	JJ	_	36	attr	_	_
36	effectiveness	effectiveness	NN	_	33	obj	_	_
37	of	of	IN	_	38	case	_	_
38	drug4	drug0	NN	_	36	ppmod	_	_
39	and	and	CC	_	33	cc	_	_
40	thus	thus	RB	_	43	adv	_	_
41	should	should	MD	_	43	modal	_	_
42	be	be	VB	_	43	aux	_	_
43	avoided.	avoided.	VBN	_	33	conj	_	_
44	12	0	CD	_	45	num	_	_
45	drug5	drug0	NN	_	43	obj	_	_
46	and	and	CC	_	33	cc	_	_
47	other	other	JJ	_	48	attr	_	_
48	drug6	drug0	NN	_	50	dep	_	_
49	may	may	MD	_	50	modal	_	_
50	potentiate	potentiate	VB	_	33	conj	_	_
51	the	the	DT	_	52	det	_	_
52	hypotension	hypotension	NN	_	50	obj	_	_
53	seen	see	VBN	_	52	acl	_	_
54	with	with	IN	_	55	case	_	_
55	drug7	drug0	NN	_	53	ppmod	_	_
56	.	.	.	_	33	p	_	_

1	Delayed	delay	VBN	_	3	attr	_	_
2	Adverse	adverse	JJ	_	3	attr	_	_
3	Reactions	reaction	NNS	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	:	:	:	_	3	p	_	_
7	A	a	DT	_	8	det	_	_
8	review	review	NN	_	3	appo	_	_
9	of	of	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	literature	literature	NN	_	8	ppmod	_	_
12	revealed	reveal	VBN	_	11	acl	_	_
13	that	that	IN	_	14	case	_	_
14	12.6	0	CD	_	12	ppmod	_	_
15	%	%	NN	_	14	meta	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	range	range	NN	_	14	prn	_	_
18	11-28	0	CD	_	17	num	_	_
19	%	%	NN	_	17	meta	_	_
20	)	-rrb-	-RRB-	_	17	p	_	_
21	of	of	IN	_	23	case	_	_
22	501	0	CD	_	23	num	_	_
23	patients	patient	NNS	_	14	ppmod	_	_
24	treated	treat	VBN	_	23	acl	_	_
25	with	with	IN	_	29	case	_	_
26	various	various	JJ	_	29	attr	_	_
27	drug2	drug0	NN	_	29	com	_	_
28	containing	containing	NN	_	29	com	_	_
29	regimens	regimen	NNS	_	24	ppmod	_	_
30	who	who	WP	_	33	dep	_	_
31	were	be	VBD	_	33	aux	_	_
32	subsequently	subsequently	RB	_	33	adv	_	_
33	administered	administer	VBN	_	29	relcl	_	_
34	drug3	drug0	NN	_	33	obj	_	_
35	experienced	experience	VBN	_	34	acl	_	_
36	acute	acute	JJ	_	38	adv	_	_
37	,	,	,	_	38	p	_	_
38	atypical	atypical	JJ	_	40	attr	_	_
39	adverse	adverse	JJ	_	40	attr	_	_
40	reactions	reaction	NNS	_	35	obj	_	_
41	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	onset	onset	NN	_	6	dep	_	_
3	of	of	IN	_	4	case	_	_
4	symptoms	symptom	NNS	_	2	ppmod	_	_
5	usually	usually	RB	_	6	adv	_	_
6	occurred	occur	VBD	_	0	root	_	_
7	within	within	IN	_	8	case	_	_
8	hours	hour	NNS	_	6	ppmod	_	_
9	(	-lrb-	-LRB-	_	15	p	_	_
10	most	most	RBS	_	11	com	_	_
11	commonly	commonly	RB	_	15	adv	_	_
12	1	0	CD	_	15	num	_	_
13	to	to	TO	_	12	cc	_	_
14	4	0	CD	_	12	conj	_	_
15	hours	hour	NNS	_	8	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	following	follow	VBG	_	19	adv	_	_
18	the	the	DT	_	19	det	_	_
19	administration	administration	NN	_	8	ppmod	_	_
20	of	of	IN	_	22	case	_	_
21	contrast	contrast	NN	_	22	com	_	_
22	media	medium	NNS	_	19	ppmod	_	_
23	.	.	.	_	6	p	_	_

1	These	these	DT	_	2	det	_	_
2	reactions	reaction	NNS	_	3	dep	_	_
3	include	include	VBP	_	0	root	_	_
4	fever	fever	NN	_	3	obj	_	_
5	,	,	,	_	4	p	_	_
6	chills	chills	NN	_	4	appo	_	_
7	,	,	,	_	4	p	_	_
8	nausea	nausea	NN	_	4	appo	_	_
9	,	,	,	_	8	p	_	_
10	vomiting	vomiting	NN	_	8	conj	_	_
11	,	,	,	_	10	p	_	_
12	pruritus	pruritus	NN	_	8	conj	_	_
13	,	,	,	_	12	p	_	_
14	rash	rash	NN	_	8	conj	_	_
15	,	,	,	_	14	p	_	_
16	diarrhea	diarrhea	NN	_	8	conj	_	_
17	,	,	,	_	16	p	_	_
18	hypotension	hypotension	NN	_	8	conj	_	_
19	,	,	,	_	18	p	_	_
20	edema	edema	NN	_	8	conj	_	_
21	,	,	,	_	20	p	_	_
22	and	and	CC	_	20	cc	_	_
23	oliguria	oliguria	NN	_	8	conj	_	_
24	.	.	.	_	3	p	_	_

1	Some	some	DT	_	2	det	_	_
2	clinicians	clinician	NNS	_	4	dep	_	_
3	have	have	VBP	_	4	aux	_	_
4	noted	note	VBN	_	0	root	_	_
5	that	that	IN	_	27	mark	_	_
6	these	these	DT	_	7	det	_	_
7	reactions	reaction	NNS	_	8	dep	_	_
8	resemble	resemble	VBP	_	27	advcl	_	_
9	the	the	DT	_	12	det	_	_
10	immediate	immediate	JJ	_	12	attr	_	_
11	side	side	JJ	_	12	attr	_	_
12	effects	effect	NNS	_	8	obj	_	_
13	caused	cause	VBN	_	12	acl	_	_
14	by	by	IN	_	16	case	_	_
15	drug1	drug0	NN	_	16	com	_	_
16	administration	administration	NN	_	13	ppmod	_	_
17	,	,	,	_	27	p	_	_
18	however	however	RB	_	27	adv	_	_
19	the	the	DT	_	20	det	_	_
20	cause	cause	NN	_	27	dep	_	_
21	of	of	IN	_	23	case	_	_
22	contrast	contrast	NN	_	23	com	_	_
23	reactions	reaction	NNS	_	20	ppmod	_	_
24	after	after	IN	_	26	case	_	_
25	interleukin-2	interleukin-0	NN	_	26	com	_	_
26	therapy	therapy	NN	_	20	ppmod	_	_
27	is	be	VBZ	_	4	comp	_	_
28	unknown	unknown	JJ	_	27	dep	_	_
29	.	.	.	_	4	p	_	_

1	Most	most	JJ	_	2	attr	_	_
2	events	event	NNS	_	4	dep	_	_
3	were	be	VBD	_	4	aux	_	_
4	reported	report	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	occur	occur	VB	_	4	comp	_	_
7	when	when	WRB	_	11	adv	_	_
8	contrast	contrast	NN	_	9	com	_	_
9	media	medium	NNS	_	11	dep	_	_
10	was	be	VBD	_	11	aux	_	_
11	given	give	VBN	_	6	comp	_	_
12	within	within	IN	_	14	case	_	_
13	4	0	CD	_	14	num	_	_
14	weeks	week	NNS	_	11	ppmod	_	_
15	after	after	IN	_	18	case	_	_
16	the	the	DT	_	18	det	_	_
17	last	last	JJ	_	18	attr	_	_
18	dose	dose	NN	_	11	ppmod	_	_
19	of	of	IN	_	20	case	_	_
20	drug1	drug0	NN	_	18	ppmod	_	_
21	.	.	.	_	4	p	_	_

1	These	these	DT	_	2	det	_	_
2	events	event	NNS	_	5	dep	_	_
3	were	be	VBD	_	5	aux	_	_
4	also	also	RB	_	5	adv	_	_
5	reported	report	VBN	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	occur	occur	VB	_	5	comp	_	_
8	when	when	WRB	_	12	adv	_	_
9	contrast	contrast	NN	_	10	com	_	_
10	media	medium	NNS	_	12	dep	_	_
11	was	be	VBD	_	12	aux	_	_
12	given	give	VBN	_	7	comp	_	_
13	several	several	JJ	_	14	attr	_	_
14	months	month	NNS	_	12	obj	_	_
15	after	after	IN	_	17	case	_	_
16	drug1	drug0	NN	_	17	com	_	_
17	treatment	treatment	NN	_	12	ppmod	_	_
18	.	.	.	_	5	p	_	_

1	Drugs	drug	NNS	_	0	root	_	_
2	that	that	WDT	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	alter	alter	VB	_	1	relcl	_	_
5	drug1	drug0	NN	_	7	com	_	_
6	plasma	plasma	NN	_	7	com	_	_
7	concentrations	concentration	NNS	_	4	obj	_	_
8	Drugs	drug	NNS	_	1	appo	_	_
9	that	that	WDT	_	11	dep	_	_
10	may	may	MD	_	11	modal	_	_
11	increase	increase	VB	_	8	relcl	_	_
12	drug2	drug0	NN	_	14	com	_	_
13	plasma	plasma	NN	_	14	com	_	_
14	concentrations	concentration	NNS	_	11	obj	_	_
15	:	:	:	_	1	p	_	_
16	Caution	caution	NN	_	18	dep	_	_
17	is	be	VBZ	_	18	aux	_	_
18	recommended	recommend	VBN	_	1	acl	_	_
19	when	when	WRB	_	20	adv	_	_
20	administering	administer	VBG	_	18	comp	_	_
21	drug3	drug0	NN	_	20	obj	_	_
22	with	with	IN	_	23	case	_	_
23	inhibitors	inhibitor	NNS	_	20	ppmod	_	_
24	of	of	IN	_	27	case	_	_
25	the	the	DT	_	27	det	_	_
26	CYP3A4	cyp0a0	NN	_	27	com	_	_
27	family	family	NN	_	23	ppmod	_	_
28	(	-lrb-	-LRB-	_	31	p	_	_
29	e.g.	e.g.	FW	_	31	ppmod	_	_
30	,	,	,	_	31	p	_	_
31	drug4	drug0	NN	_	27	prn	_	_
32	,	,	,	_	31	p	_	_
33	drug5	drug0	NN	_	31	appo	_	_
34	,	,	,	_	31	p	_	_
35	drug6	drug0	NN	_	31	appo	_	_
36	,	,	,	_	31	p	_	_
37	drug7	drug0	NN	_	31	appo	_	_
38	)	-rrb-	-RRB-	_	31	p	_	_
39	.	.	.	_	1	p	_	_

1	Substances	substance	NNS	_	13	dep	_	_
2	that	that	WDT	_	3	dep	_	_
3	inhibit	inhibit	VBP	_	1	relcl	_	_
4	the	the	DT	_	11	det	_	_
5	cytochrome	cytochrome	NN	_	11	attr	_	_
6	P450	p0	NN	_	11	attr	_	_
7	isoenzyme	isoenzyme	NN	_	11	attr	_	_
8	(	-lrb-	-LRB-	_	11	p	_	_
9	CYP3A4	cyp0a0	NN	_	11	attr	_	_
10	)	-rrb-	-RRB-	_	11	p	_	_
11	activity	activity	NN	_	3	obj	_	_
12	may	may	MD	_	13	modal	_	_
13	decrease	decrease	VB	_	0	root	_	_
14	metabolism	metabolism	NN	_	13	obj	_	_
15	and	and	CC	_	13	cc	_	_
16	increase	increase	VB	_	13	conj	_	_
17	drug1	drug0	NN	_	18	com	_	_
18	concentrations	concentration	NNS	_	16	obj	_	_
19	.	.	.	_	13	p	_	_

1	There	there	EX	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	a	a	DT	_	5	det	_	_
4	significant	significant	JJ	_	5	attr	_	_
5	increase	increase	NN	_	2	obj	_	_
6	in	in	IN	_	7	case	_	_
7	exposure	exposure	NN	_	5	ppmod	_	_
8	to	to	TO	_	9	aux	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	when	when	WRB	_	13	adv	_	_
11	drug2	drug0	NN	_	13	dep	_	_
12	is	be	VBZ	_	13	aux	_	_
13	coadministered	coadministered	VBN	_	2	comp	_	_
14	with	with	IN	_	15	case	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	(	-lrb-	-LRB-	_	18	p	_	_
17	CYP3A4	cyp0a0	NN	_	18	com	_	_
18	inhibitor	inhibitor	NN	_	15	prn	_	_
19	)	-rrb-	-RRB-	_	18	p	_	_
20	.	.	.	_	2	p	_	_

1	Drugs	drug	NNS	_	17	dep	_	_
2	that	that	WDT	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	decrease	decrease	VB	_	1	relcl	_	_
5	drug1	drug0	NN	_	7	com	_	_
6	plasma	plasma	NN	_	7	com	_	_
7	concentrations	concentration	NNS	_	4	obj	_	_
8	:	:	:	_	1	p	_	_
9	Substances	substance	NNS	_	1	appo	_	_
10	that	that	WDT	_	11	dep	_	_
11	are	be	VBP	_	9	relcl	_	_
12	inducers	inducer	NNS	_	11	obj	_	_
13	of	of	IN	_	15	case	_	_
14	CYP3A4	cyp0a0	NN	_	15	com	_	_
15	activity	activity	NN	_	12	ppmod	_	_
16	may	may	MD	_	17	modal	_	_
17	increase	increase	VBP	_	0	root	_	_
18	metabolism	metabolism	NN	_	17	obj	_	_
19	and	and	CC	_	17	cc	_	_
20	decrease	decrease	VBP	_	17	conj	_	_
21	drug2	drug0	NN	_	23	com	_	_
22	plasma	plasma	NN	_	23	com	_	_
23	concentrations	concentration	NNS	_	20	obj	_	_
24	.	.	.	_	17	p	_	_

1	Co-medications	co-medications	NNS	_	0	root	_	_
2	that	that	WDT	_	3	dep	_	_
3	induce	induce	VBP	_	1	relcl	_	_
4	CYP3A4	cyp0a0	NN	_	3	obj	_	_
5	(	-lrb-	-LRB-	_	8	p	_	_
6	e.g.	e.g.	FW	_	8	adv	_	_
7	,	,	,	_	8	p	_	_
8	drug1	drug0	NN	_	1	prn	_	_
9	,	,	,	_	8	p	_	_
10	drug2	drug0	NN	_	8	conj	_	_
11	,	,	,	_	10	p	_	_
12	drug3	drug0	NN	_	8	conj	_	_
13	,	,	,	_	12	p	_	_
14	drug4	drug0	NN	_	8	conj	_	_
15	,	,	,	_	14	p	_	_
16	drug5	drug0	NN	_	8	conj	_	_
17	or	or	CC	_	16	cc	_	_
18	St.	st.	NN	_	8	conj	_	_

1	Johns	johns	NNP	_	2	com	_	_
2	Wort	wort	NNP	_	6	dep	_	_
3	)	-rrb-	-RRB-	_	2	p	_	_
4	may	may	MD	_	6	modal	_	_
5	significantly	significantly	RB	_	6	adv	_	_
6	reduce	reduce	VB	_	0	root	_	_
7	exposure	exposure	NN	_	6	obj	_	_
8	to	to	TO	_	9	aux	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	.	.	.	_	6	p	_	_

1	Pretreatment	pretreatment	NN	_	18	dep	_	_
2	of	of	IN	_	4	case	_	_
3	healthy	healthy	JJ	_	4	attr	_	_
4	volunteers	volunteer	NNS	_	1	ppmod	_	_
5	with	with	IN	_	7	case	_	_
6	multiple	multiple	JJ	_	7	attr	_	_
7	doses	dose	NNS	_	1	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	followed	followed	VBN	_	9	acl	_	_
11	by	by	IN	_	14	case	_	_
12	a	a	DT	_	14	det	_	_
13	single	single	JJ	_	14	attr	_	_
14	dose	dose	NN	_	10	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	,	,	,	_	1	p	_	_
18	increased	increase	VBD	_	0	root	_	_
19	drug3	drug0	NN	_	21	attr	_	_
20	oral-dose	oral-dose	JJ	_	21	attr	_	_
21	clearance	clearance	NN	_	18	obj	_	_
22	by	by	IN	_	23	case	_	_
23	3.8-fold	0-fold	JJ	_	18	ppmod	_	_
24	,	,	,	_	18	p	_	_
25	which	which	WDT	_	31	dep	_	_
26	significantly	significantly	RB	_	31	adv	_	_
27	(	-lrb-	-LRB-	_	28	p	_	_
28	p	p	NN	_	26	prn	_	_
29	0.05	0	CD	_	28	num	_	_
30	)	-rrb-	-RRB-	_	28	p	_	_
31	decreased	decrease	VBD	_	18	comp	_	_
32	mean	mean	NN	_	33	com	_	_
33	cmax	cmax	NN	_	31	obj	_	_
34	and	and	CC	_	33	cc	_	_
35	AUC	auc	NN	_	33	conj	_	_
36	(	-lrb-	-LRB-	_	37	p	_	_
37	0-8	0	NN	_	35	num	_	_
38	)	-rrb-	-RRB-	_	37	p	_	_
39	.	.	.	_	18	p	_	_

1	In	in	IN	_	2	case	_	_
2	patients	patient	NNS	_	22	ppmod	_	_
3	where	where	WRB	_	10	adv	_	_
4	drug1	drug0	NN	_	10	dep	_	_
5	or	or	CC	_	4	cc	_	_
6	other	other	JJ	_	8	attr	_	_
7	CYP3A4	cyp0a0	NN	_	8	com	_	_
8	inducers	inducer	NNS	_	4	conj	_	_
9	are	be	VBP	_	10	aux	_	_
10	indicated	indicate	VBN	_	2	relcl	_	_
11	,	,	,	_	22	p	_	_
12	alternative	alternative	JJ	_	14	attr	_	_
13	therapeutic	therapeutic	JJ	_	14	attr	_	_
14	agents	agent	NNS	_	22	dep	_	_
15	with	with	IN	_	19	case	_	_
16	less	less	RBR	_	19	adv	_	_
17	enzyme	enzyme	NN	_	19	com	_	_
18	induction	induction	NN	_	19	com	_	_
19	potential	potential	NN	_	14	ppmod	_	_
20	should	should	MD	_	22	modal	_	_
21	be	be	VB	_	22	aux	_	_
22	considered	consider	VBN	_	0	root	_	_
23	.	.	.	_	22	p	_	_

1	Drugs	drug	NNS	_	8	dep	_	_
2	that	that	WDT	_	7	dep	_	_
3	may	may	MD	_	7	modal	_	_
4	have	have	VB	_	7	lv	_	_
5	their	their	PRP$	_	7	poss	_	_
6	plasma	plasma	NN	_	7	com	_	_
7	concentration	concentration	NN	_	1	relcl	_	_
8	altered	alter	VBN	_	0	root	_	_
9	by	by	IN	_	12	mark	_	_
10	drug1	drug0	NN	_	11	com	_	_
11	drug2	drug0	NN	_	12	dep	_	_
12	increases	increase	VBZ	_	8	comp	_	_
13	the	the	DT	_	15	det	_	_
14	mean	mean	JJ	_	15	attr	_	_
15	cmax	cmax	NN	_	12	obj	_	_
16	and	and	CC	_	15	cc	_	_
17	AUC	auc	NN	_	15	conj	_	_
18	of	of	IN	_	19	case	_	_
19	drug3	drug0	NN	_	15	ppmod	_	_
20	(	-lrb-	-LRB-	_	22	p	_	_
21	CYP3A4	cyp0a0	NN	_	22	com	_	_
22	substrate	substrate	NN	_	19	prn	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	2-	0-	CD	_	19	num	_	_
25	and	and	CC	_	19	cc	_	_
26	3.5-fold	0-fold	NN	_	19	conj	_	_
27	,	,	,	_	26	p	_	_
28	respectively	respectively	RB	_	19	conj	_	_
29	,	,	,	_	12	p	_	_
30	suggesting	suggest	VBG	_	12	comp	_	_
31	an	an	DT	_	32	det	_	_
32	inhibition	inhibition	NN	_	30	obj	_	_
33	of	of	IN	_	35	case	_	_
34	the	the	DT	_	35	det	_	_
35	CYP3A4	cyp0a0	NN	_	32	ppmod	_	_
36	by	by	IN	_	37	case	_	_
37	drug4	drug0	NN	_	32	ppmod	_	_
38	.	.	.	_	8	p	_	_

1	Particular	particular	JJ	_	2	attr	_	_
2	caution	caution	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	recommended	recommend	VBN	_	0	root	_	_
5	when	when	WRB	_	6	adv	_	_
6	administering	administer	VBG	_	4	comp	_	_
7	drug1	drug0	NN	_	6	obj	_	_
8	with	with	IN	_	10	case	_	_
9	CYP3A4	cyp0a0	JJ	_	10	attr	_	_
10	substrates	substrate	NNS	_	6	ppmod	_	_
11	that	that	WDT	_	12	dep	_	_
12	have	have	VBP	_	10	relcl	_	_
13	a	a	DT	_	16	det	_	_
14	narrow	narrow	JJ	_	16	attr	_	_
15	therapeutic	therapeutic	JJ	_	16	attr	_	_
16	window	window	NN	_	12	obj	_	_
17	(	-lrb-	-LRB-	_	20	p	_	_
18	e.g.	e.g.	FW	_	20	adv	_	_
19	,	,	,	_	20	p	_	_
20	drug2	drug0	NN	_	16	prn	_	_
21	or	or	CC	_	20	cc	_	_
22	drug3	drug0	NN	_	20	conj	_	_
23	)	-rrb-	-RRB-	_	20	p	_	_
24	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	will	will	MD	_	3	modal	_	_
3	increase	increase	VB	_	0	root	_	_
4	plasmaconcentration	plasmaconcentration	NN	_	3	obj	_	_
5	of	of	IN	_	9	case	_	_
6	other	other	JJ	_	9	attr	_	_
7	CYP3A4	cyp0a0	JJ	_	9	attr	_	_
8	metabolized	metabolized	JJ	_	9	attr	_	_
9	drugs	drug	NNS	_	4	ppmod	_	_
10	(	-lrb-	-LRB-	_	14	p	_	_
11	e.g.	e.g.	FW	_	14	ppmod	_	_
12	,	,	,	_	14	p	_	_
13	triazolo-	triazolo-	JJ	_	14	attr	_	_
14	drug2	drug0	NNS	_	9	prn	_	_
15	,	,	,	_	14	p	_	_
16	drug3	drug0	NN	_	14	appo	_	_
17	,	,	,	_	14	p	_	_
18	certain	certain	JJ	_	19	attr	_	_
19	drug4	drug0	NNS	_	14	appo	_	_
20	,	,	,	_	14	p	_	_
21	etc	etc	NN	_	14	appo	_	_
22	.	.	.	_	14	p	_	_
23	)	-rrb-	-RRB-	_	14	p	_	_
24	.	.	.	_	3	p	_	_

1	Because	because	IN	_	4	mark	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	metabolized	metabolize	VBN	_	15	advcl	_	_
5	by	by	IN	_	6	case	_	_
6	CYP2C9	cyp0c0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	CYP3A4	cyp0a0	NN	_	6	conj	_	_
9	,	,	,	_	15	p	_	_
10	patients	patient	NNS	_	15	dep	_	_
11	who	who	WP	_	12	dep	_	_
12	require	require	VBP	_	10	relcl	_	_
13	anticoagulation	anticoagulation	NN	_	12	obj	_	_
14	should	should	MD	_	15	modal	_	_
15	receive	receive	VBP	_	0	root	_	_
16	low-molecular	low-molecular	JJ	_	17	attr	_	_
17	weight	weight	NN	_	15	obj	_	_
18	or	or	CC	_	17	cc	_	_
19	standard	standard	JJ	_	20	attr	_	_
20	drug2	drug0	NN	_	17	conj	_	_
21	.	.	.	_	15	p	_	_

1	in	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	5	adv	_	_
3	,	,	,	_	5	p	_	_
4	drug1	drug0	NN	_	5	dep	_	_
5	inhibits	inhibit	VBZ	_	0	root	_	_
6	the	the	DT	_	11	det	_	_
7	cytochrome	cytochrome	NN	_	8	com	_	_
8	P450	p0	NN	_	11	com	_	_
9	isoenzyme	isoenzyme	NN	_	11	com	_	_
10	CYP2D6	cyp0d0	NN	_	11	com	_	_
11	activity	activity	NN	_	5	obj	_	_
12	at	at	IN	_	14	case	_	_
13	similar	similar	JJ	_	14	attr	_	_
14	concentrations	concentration	NNS	_	5	ppmod	_	_
15	that	that	WDT	_	16	dep	_	_
16	affect	affect	VBP	_	14	relcl	_	_
17	CYP3A4	cyp0a0	NN	_	18	com	_	_
18	activity	activity	NN	_	16	obj	_	_
19	.	.	.	_	5	p	_	_

1	Systemic	systemic	JJ	_	2	attr	_	_
2	exposure	exposure	NN	_	8	dep	_	_
3	to	to	TO	_	4	aux	_	_
4	substrates	substrate	NNS	_	2	ppmod	_	_
5	of	of	IN	_	6	case	_	_
6	CYP2D6	cyp0d0	NN	_	4	ppmod	_	_
7	is	be	VBZ	_	8	aux	_	_
8	expected	expect	VBN	_	0	root	_	_
9	to	to	TO	_	11	aux	_	_
10	be	be	VB	_	11	aux	_	_
11	increased	increase	VBN	_	8	comp	_	_
12	when	when	WRB	_	13	adv	_	_
13	coadministered	coadministered	VBN	_	11	comp	_	_
14	with	with	IN	_	15	case	_	_
15	Gleevec	gleevec	NNP	_	13	ppmod	_	_
16	.	.	.	_	8	p	_	_

1	No	no	DT	_	3	det	_	_
2	specific	specific	JJ	_	3	attr	_	_
3	studies	study	NNS	_	6	dep	_	_
4	have	have	VBP	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	performed	performed	VBN	_	0	root	_	_
7	and	and	CC	_	6	cc	_	_
8	caution	caution	NN	_	10	dep	_	_
9	is	be	VBZ	_	10	aux	_	_
10	recommended	recommend	VBN	_	6	conj	_	_
11	.	.	.	_	6	p	_	_

1	in	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	5	adv	_	_
3	,	,	,	_	5	p	_	_
4	drug1	drug0	NN	_	5	dep	_	_
5	inhibits	inhibit	VBZ	_	0	root	_	_
6	acetaminophen	acetaminophen	NN	_	7	com	_	_
7	O-glucuronidation	o-glucuronidation	NN	_	5	obj	_	_
8	(	-lrb-	-LRB-	_	10	p	_	_
9	Ki	ki	NN	_	10	com	_	_
10	value	value	NN	_	7	prn	_	_
11	of	of	IN	_	13	case	_	_
12	58.5	0	CD	_	13	num	_	_
13	M	m	NN	_	10	ppmod	_	_
14	)	-rrb-	-RRB-	_	10	p	_	_
15	at	at	IN	_	17	case	_	_
16	therapeutic	therapeutic	JJ	_	17	attr	_	_
17	levels	level	NNS	_	5	ppmod	_	_
18	.	.	.	_	5	p	_	_

1	Systemic	systemic	JJ	_	2	attr	_	_
2	exposure	exposure	NN	_	6	dep	_	_
3	to	to	TO	_	4	aux	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	is	be	VBZ	_	6	aux	_	_
6	expected	expect	VBN	_	0	root	_	_
7	to	to	TO	_	9	aux	_	_
8	be	be	VB	_	9	aux	_	_
9	increased	increase	VBN	_	6	comp	_	_
10	when	when	WRB	_	11	adv	_	_
11	coadministered	coadministered	VBN	_	9	comp	_	_
12	with	with	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	.	.	.	_	6	p	_	_

1	No	no	DT	_	3	det	_	_
2	specific	specific	JJ	_	3	attr	_	_
3	studies	study	NNS	_	8	dep	_	_
4	in	in	IN	_	5	case	_	_
5	humans	human	NNS	_	3	ppmod	_	_
6	have	have	VBP	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	performed	performed	VBN	_	0	root	_	_
9	and	and	CC	_	8	cc	_	_
10	caution	caution	NN	_	12	dep	_	_
11	is	be	VBZ	_	12	aux	_	_
12	recommended	recommend	VBN	_	8	conj	_	_
13	.	.	.	_	8	p	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	Careful	careful	JJ	_	2	attr	_	_
2	observation	observation	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	required	require	VBN	_	0	root	_	_
5	when	when	WRB	_	8	adv	_	_
6	drug1	drug0	NN	_	8	dep	_	_
7	is	be	VBZ	_	8	aux	_	_
8	administered	administer	VBN	_	4	comp	_	_
9	concurrently	concurrently	RB	_	8	adv	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NN	_	8	ppmod	_	_
12	.	.	.	_	4	p	_	_

1	Coadministration	coadministration	NN	_	6	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	has	have	VBZ	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	reported	report	VBN	_	0	root	_	_
7	to	to	TO	_	8	aux	_	_
8	worsen	worsen	VB	_	6	comp	_	_
9	the	the	DT	_	10	det	_	_
10	tremor	tremor	NN	_	8	obj	_	_
11	in	in	IN	_	13	case	_	_
12	elderly	elderly	JJ	_	13	attr	_	_
13	patients	patient	NNS	_	10	ppmod	_	_
14	with	with	IN	_	16	case	_	_
15	Parkinsons	parkinsons	JJ	_	16	attr	_	_
16	disease	disease	NN	_	13	ppmod	_	_
17	;	;	:	_	6	p	_	_

1	however	however	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	it	it	PRP	_	6	dep	_	_
4	is	be	VBZ	_	6	aux	_	_
5	not	not	RB	_	6	neg	_	_
6	known	know	VBN	_	0	root	_	_
7	if	if	IN	_	10	mark	_	_
8	other	other	JJ	_	9	attr	_	_
9	drug1	drug0	NNS	_	10	dep	_	_
10	produce	produce	VBP	_	6	comp	_	_
11	a	a	DT	_	13	det	_	_
12	similar	similar	JJ	_	13	attr	_	_
13	response	response	NN	_	10	obj	_	_
14	.	.	.	_	6	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	use	use	NN	_	7	dep	_	_
3	with	with	IN	_	5	case	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	s	s	NNS	_	2	ppmod	_	_
6	may	may	MD	_	7	modal	_	_
7	result	result	VB	_	0	root	_	_
8	in	in	IN	_	11	case	_	_
9	the	the	DT	_	11	det	_	_
10	reduced	reduce	VBN	_	11	attr	_	_
11	absorption	absorption	NN	_	7	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	.	.	.	_	7	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	studies	study	NNS	_	5	dep	_	_
4	have	have	VBP	_	5	aux	_	_
5	shown	show	VBN	_	0	root	_	_
6	that	that	IN	_	8	mark	_	_
7	precipitation	precipitation	NN	_	8	dep	_	_
8	occurs	occur	VBZ	_	5	comp	_	_
9	when	when	WRB	_	15	adv	_	_
10	eye	eye	NN	_	13	com	_	_
11	drops	drops	NN	_	13	com	_	_
12	containing	containing	NN	_	13	com	_	_
13	drug1	drug0	NN	_	15	dep	_	_
14	are	be	VBP	_	15	aux	_	_
15	mixed	mix	VBN	_	8	comp	_	_
16	with	with	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	.	.	.	_	5	p	_	_

1	If	if	IN	_	5	mark	_	_
2	such	such	JJ	_	3	attr	_	_
3	drugs	drug	NNS	_	5	dep	_	_
4	are	be	VBP	_	5	aux	_	_
5	used	use	VBN	_	9	advcl	_	_
6	they	they	PRP	_	9	dep	_	_
7	should	should	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	administered	administer	VBN	_	0	root	_	_
10	with	with	IN	_	12	case	_	_
11	an	an	DT	_	12	det	_	_
12	interval	interval	NN	_	9	ppmod	_	_
13	of	of	IN	_	17	case	_	_
14	at	at	IN	_	16	case	_	_
15	least	least	JJS	_	16	attr	_	_
16	5	0	CD	_	17	num	_	_
17	minutes	minute	NNS	_	12	ppmod	_	_
18	between	between	IN	_	19	case	_	_
19	applications	application	NNS	_	12	ppmod	_	_
20	.	.	.	_	9	p	_	_

1	The	the	DT	_	4	det	_	_
2	following	following	JJ	_	4	attr	_	_
3	drug	drug	NN	_	4	com	_	_
4	interactions	interaction	NNS	_	7	dep	_	_
5	have	have	VBP	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	reported	report	VBN	_	0	root	_	_
8	with	with	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	.	.	.	_	7	p	_	_

1	Drug	drug	NN	_	2	com	_	_
2	Effect	effect	NN	_	0	root	_	_

1	drug1	drug0	NN	_	3	attr	_	_
2	Prolonged	prolonged	JJ	_	3	attr	_	_
3	action	action	NN	_	0	root	_	_
4	of	of	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	Hypotension	hypotension	NN	_	0	root	_	_

1	drug1	drug0	NN	_	3	com	_	_
2	drug2	drug0	NN	_	3	com	_	_
3	antagonism	antagonism	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	Decreased	decrease	VBN	_	4	attr	_	_
3	antinociceptive	antinociceptive	JJ	_	4	attr	_	_
4	action	action	NN	_	1	appo	_	_

1	drug1	drug0	NN	_	3	com	_	_
2	drug2	drug0	NN	_	3	com	_	_
3	antagonism	antagonism	NN	_	0	root	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	Synergism	synergism	NN	_	0	root	_	_

1	CNS	cns	NN	_	2	com	_	_
2	depression	depression	NN	_	9	dep	_	_
3	producing	produce	VBG	_	2	acl	_	_
4	medications	medication	NNS	_	3	obj	_	_
5	-	-	CC	_	4	cc	_	_
6	concurrent	concurrent	JJ	_	7	attr	_	_
7	use	use	NN	_	4	conj	_	_
8	may	may	MD	_	9	modal	_	_
9	potentiate	potentiate	VB	_	0	root	_	_
10	the	the	DT	_	11	det	_	_
11	effects	effect	NNS	_	9	obj	_	_
12	of	of	IN	_	15	case	_	_
13	either	either	CC	_	15	cc	_	_
14	these	these	DT	_	15	det	_	_
15	medications	medication	NNS	_	11	ppmod	_	_
16	or	or	CC	_	15	cc	_	_
17	drug1	drug0	NN	_	15	conj	_	_
18	;	;	:	_	9	p	_	_

1	drug1	drug0	NN	_	13	dep	_	_
2	or	or	CC	_	1	cc	_	_
3	other	other	JJ	_	4	attr	_	_
4	medications	medication	NNS	_	1	conj	_	_
5	with	with	IN	_	7	case	_	_
6	anticholinergic	anticholinergic	JJ	_	7	attr	_	_
7	activity	activity	NN	_	1	ppmod	_	_
8	-	-	CC	_	7	cc	_	_
9	anticholinergic	anticholinergic	JJ	_	10	attr	_	_
10	effects	effect	NNS	_	7	conj	_	_
11	may	may	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	potentiated	potentiate	VBN	_	0	root	_	_
14	when	when	WRB	_	18	adv	_	_
15	these	these	DT	_	16	det	_	_
16	medications	medication	NNS	_	18	dep	_	_
17	are	be	VBP	_	18	aux	_	_
18	used	use	VBN	_	13	comp	_	_
19	concurrently	concurrently	RB	_	18	adv	_	_
20	with	with	IN	_	21	case	_	_
21	drug2	drug0	NN	_	18	ppmod	_	_
22	;	;	:	_	13	p	_	_

1	drug1	drug0	NN	_	8	dep	_	_
2	-	-	CC	_	1	cc	_	_
3	prior	prior	JJ	_	4	attr	_	_
4	ingestion	ingestion	NN	_	1	conj	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	1	ppmod	_	_
7	may	may	MD	_	8	modal	_	_
8	decrease	decrease	VB	_	0	root	_	_
9	the	the	DT	_	11	det	_	_
10	drug3	drug0	NN	_	11	com	_	_
11	response	response	NN	_	8	obj	_	_
12	to	to	TO	_	13	aux	_	_
13	drug4	drug0	NN	_	11	ppmod	_	_
14	in	in	IN	_	16	case	_	_
15	the	the	DT	_	16	det	_	_
16	treatment	treatment	NN	_	11	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	poisoning	poisoning	NN	_	16	ppmod	_	_
19	.	.	.	_	8	p	_	_

1	Nephrotoxicity	nephrotoxicity	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	reported	report	VBN	_	0	root	_	_
5	following	follow	VBG	_	7	adv	_	_
6	concomitant	concomitant	JJ	_	7	attr	_	_
7	administration	administration	NN	_	4	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	drug2	drug0	NN	_	9	conj	_	_
12	.	.	.	_	4	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	administration	administration	NN	_	5	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	doubled	double	VBD	_	0	root	_	_
6	the	the	DT	_	7	det	_	_
7	AUC	auc	NN	_	5	obj	_	_
8	for	for	IN	_	9	case	_	_
9	drug2	drug0	NN	_	5	ppmod	_	_
10	.	.	.	_	5	p	_	_

1	The	the	DT	_	2	det	_	_
2	bioavailability	bioavailability	NN	_	11	dep	_	_
3	of	of	IN	_	6	case	_	_
4	the	the	DT	_	6	det	_	_
5	capsule	capsule	JJ	_	6	attr	_	_
6	formulation	formulation	NN	_	2	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	was	be	VBD	_	11	aux	_	_
10	not	not	RB	_	11	neg	_	_
11	affected	affect	VBN	_	0	root	_	_
12	when	when	WRB	_	13	adv	_	_
13	administered	administer	VBN	_	11	comp	_	_
14	5	0	CD	_	15	num	_	_
15	minutes	minute	NNS	_	13	obj	_	_
16	following	follow	VBG	_	18	adv	_	_
17	an	an	DT	_	18	det	_	_
18	drug2	drug0	NN	_	13	ppmod	_	_
19	.	.	.	_	11	p	_	_

1	Nephrotoxicity	nephrotoxicity	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	reported	report	VBN	_	0	root	_	_
5	following	follow	VBG	_	7	adv	_	_
6	concomitant	concomitant	JJ	_	7	attr	_	_
7	administration	administration	NN	_	4	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NN	_	7	ppmod	_	_
12	or	or	CC	_	11	cc	_	_
13	potent	potent	JJ	_	14	attr	_	_
14	drug3	drug0	NNS	_	11	conj	_	_
15	such	such	JJ	_	17	adv	_	_
16	as	as	IN	_	17	case	_	_
17	drug4	drug0	NN	_	14	ppmod	_	_
18	.	.	.	_	4	p	_	_

1	Renal	renal	JJ	_	2	attr	_	_
2	function	function	NN	_	6	dep	_	_
3	should	should	MD	_	6	modal	_	_
4	be	be	VB	_	6	aux	_	_
5	carefully	carefully	RB	_	6	adv	_	_
6	monitored	monitor	VBN	_	0	root	_	_
7	,	,	,	_	6	p	_	_
8	especially	especially	RB	_	15	adv	_	_
9	if	if	IN	_	15	mark	_	_
10	higher	high	JJR	_	11	attr	_	_
11	dosages	dosage	NNS	_	15	dep	_	_
12	of	of	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	drug1	drug0	NN	_	11	ppmod	_	_
15	are	be	VBP	_	6	advcl	_	_
16	to	to	TO	_	18	aux	_	_
17	be	be	VB	_	18	aux	_	_
18	administered	administer	VBN	_	15	comp	_	_
19	or	or	CC	_	15	cc	_	_
20	if	if	IN	_	22	mark	_	_
21	therapy	therapy	NN	_	22	dep	_	_
22	is	be	VBZ	_	15	conj	_	_
23	prolonged	prolonged	JJ	_	22	dep	_	_
24	,	,	,	_	22	p	_	_
25	because	because	IN	_	29	case	_	_
26	of	of	IN	_	29	case	_	_
27	the	the	DT	_	29	det	_	_
28	potential	potential	JJ	_	29	attr	_	_
29	nephrotoxicity	nephrotoxicity	NN	_	22	ppmod	_	_
30	and	and	CC	_	29	cc	_	_
31	ototoxicity	ototoxicity	NN	_	29	conj	_	_
32	of	of	IN	_	33	case	_	_
33	drug2	drug0	NN	_	29	ppmod	_	_
34	.	.	.	_	6	p	_	_

1	Nephrotoxicity	nephrotoxicity	NN	_	6	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	ototoxicity	ototoxicity	NN	_	1	conj	_	_
4	were	be	VBD	_	6	aux	_	_
5	not	not	RB	_	6	neg	_	_
6	noted	note	VBN	_	0	root	_	_
7	when	when	WRB	_	10	adv	_	_
8	drug1	drug0	NN	_	10	dep	_	_
9	was	be	VBD	_	10	aux	_	_
10	given	give	VBN	_	6	comp	_	_
11	alone	alone	RB	_	10	adv	_	_
12	in	in	IN	_	14	case	_	_
13	clinical	clinical	JJ	_	14	attr	_	_
14	trials	trial	NNS	_	10	ppmod	_	_
15	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	shown	show	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	be	be	VB	_	4	comp	_	_
7	antagonistic	antagonistic	JJ	_	6	dep	_	_
8	to	to	TO	_	9	aux	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	9	p	_	_
11	including	include	VBG	_	12	adv	_	_
12	drug3	drug0	NN	_	9	ppmod	_	_
13	,	,	,	_	9	p	_	_
14	based	base	VBN	_	9	acl	_	_
15	on	on	IN	_	18	case	_	_
16	in	in	FW	_	17	adv	_	_
17	vitro	vitro	FW	_	18	attr	_	_
18	studies	study	NNS	_	14	ppmod	_	_
19	and	and	CC	_	18	cc	_	_
20	time	time	NN	_	22	attr	_	_
21	kill	kill	VB	_	22	attr	_	_
22	curves	curve	NNS	_	18	conj	_	_
23	with	with	IN	_	26	case	_	_
24	enteric	enteric	JJ	_	26	attr	_	_
25	gram-negative	gram-negative	JJ	_	26	attr	_	_
26	bacilli	bacillus	NNS	_	18	ppmod	_	_
27	.	.	.	_	4	p	_	_

1	Due	due	IN	_	4	case	_	_
2	to	to	TO	_	4	aux	_	_
3	the	the	DT	_	4	det	_	_
4	possibility	possibility	NN	_	22	ppmod	_	_
5	of	of	IN	_	6	case	_	_
6	antagonism	antagonism	NN	_	4	ppmod	_	_
7	in	in	FW	_	8	adv	_	_
8	vivo	vivo	FW	_	6	adv	_	_
9	,	,	,	_	22	p	_	_
10	particularly	particularly	RB	_	11	com	_	_
11	when	when	WRB	_	15	adv	_	_
12	bactericidal	bactericidal	JJ	_	13	attr	_	_
13	activity	activity	NN	_	15	dep	_	_
14	is	be	VBZ	_	15	aux	_	_
15	desired	desire	VBN	_	22	advcl	_	_
16	,	,	,	_	22	p	_	_
17	this	this	DT	_	19	det	_	_
18	drug	drug	NN	_	19	com	_	_
19	combination	combination	NN	_	22	dep	_	_
20	should	should	MD	_	22	modal	_	_
21	be	be	VB	_	22	aux	_	_
22	avoided	avoid	VBN	_	0	root	_	_
23	.	.	.	_	22	p	_	_

1	Drug/Laboratory	drug/laboratory	JJ	_	3	attr	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	0	root	_	_
4	The	the	DT	_	5	det	_	_
5	administration	administration	NN	_	9	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	may	may	MD	_	9	modal	_	_
9	result	result	VB	_	3	acl	_	_
10	in	in	IN	_	13	case	_	_
11	a	a	DT	_	13	det	_	_
12	false-positive	false-positive	JJ	_	13	attr	_	_
13	reaction	reaction	NN	_	9	ppmod	_	_
14	for	for	IN	_	15	case	_	_
15	glucose	glucose	NN	_	13	ppmod	_	_
16	in	in	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	urine	urine	NN	_	13	ppmod	_	_
19	when	when	WRB	_	20	adv	_	_
20	using	use	VBG	_	9	comp	_	_
21	CLINITEST	clinitest	NN	_	22	com	_	_
22	tablets	tablet	NNS	_	20	obj	_	_
23	,	,	,	_	22	p	_	_
24	Benedicts	benedicts	NN	_	25	com	_	_
25	solution	solution	NN	_	22	conj	_	_
26	,	,	,	_	25	p	_	_
27	or	or	CC	_	25	cc	_	_
28	Fehlings	fehlings	NN	_	29	com	_	_
29	solution	solution	NN	_	22	conj	_	_
30	.	.	.	_	3	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	recommended	recommend	VBN	_	0	root	_	_
4	that	that	IN	_	21	mark	_	_
5	glucose	glucose	NN	_	6	com	_	_
6	tests	test	NNS	_	21	dep	_	_
7	based	base	VBN	_	6	acl	_	_
8	on	on	IN	_	12	case	_	_
9	enzymatic	enzymatic	JJ	_	12	attr	_	_
10	glucose	glucose	NN	_	12	com	_	_
11	oxidase	oxidase	NN	_	12	com	_	_
12	reactions	reaction	NNS	_	7	ppmod	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	such	such	JJ	_	12	prn	_	_
15	as	as	IN	_	16	case	_	_
16	CLINISTIX	clinistix	NN	_	14	ppmod	_	_
17	or	or	CC	_	16	cc	_	_
18	TES-TAPE	tes-tape	NN	_	16	conj	_	_
19	)	-rrb-	-RRB-	_	14	p	_	_
20	be	be	VB	_	21	aux	_	_
21	used	use	VBN	_	3	comp	_	_
22	.	.	.	_	3	p	_	_

1	Some	some	DT	_	2	det	_	_
2	drug1	drug0	NNS	_	10	dep	_	_
3	,	,	,	_	2	p	_	_
4	including	include	VBG	_	5	adv	_	_
5	drug2	drug0	NN	_	2	ppmod	_	_
6	,	,	,	_	2	p	_	_
7	have	have	VBP	_	10	aux	_	_
8	also	also	RB	_	10	adv	_	_
9	been	be	VBN	_	10	aux	_	_
10	shown	show	VBN	_	0	root	_	_
11	to	to	TO	_	12	aux	_	_
12	interfere	interfere	VB	_	10	comp	_	_
13	with	with	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	metabolism	metabolism	NN	_	12	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	drug3	drug0	NN	_	15	ppmod	_	_
18	.	.	.	_	10	p	_	_

1	This	this	DT	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	lead	lead	VB	_	0	root	_	_
4	to	to	TO	_	6	aux	_	_
5	reduced	reduce	VBN	_	6	attr	_	_
6	clearance	clearance	NN	_	3	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	6	cc	_	_
10	a	a	DT	_	11	det	_	_
11	prolongation	prolongation	NN	_	6	conj	_	_
12	of	of	IN	_	15	case	_	_
13	its	its	PRP$	_	15	poss	_	_
14	serum	serum	NN	_	15	com	_	_
15	half-life	half-life	NN	_	11	ppmod	_	_
16	.	.	.	_	3	p	_	_

1	Some	some	DT	_	2	det	_	_
2	drug1	drug0	NNS	_	9	dep	_	_
3	,	,	,	_	2	p	_	_
4	including	include	VBG	_	5	adv	_	_
5	drug2	drug0	NN	_	2	ppmod	_	_
6	,	,	,	_	2	p	_	_
7	have	have	VBP	_	9	aux	_	_
8	been	be	VBN	_	9	aux	_	_
9	associated	associate	VBN	_	0	root	_	_
10	with	with	IN	_	12	case	_	_
11	transient	transient	JJ	_	12	attr	_	_
12	elevations	elevation	NNS	_	9	ppmod	_	_
13	in	in	IN	_	15	case	_	_
14	serum	serum	NN	_	15	com	_	_
15	creatinine	creatinine	NN	_	12	ppmod	_	_
16	in	in	IN	_	17	case	_	_
17	patients	patient	NNS	_	15	ppmod	_	_
18	receiving	receive	VBG	_	17	acl	_	_
19	drug3	drug0	NN	_	18	obj	_	_
20	concomitantly	concomitantly	RB	_	9	adv	_	_
21	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	5	det	_	_
4	concomitant	concomitant	JJ	_	5	attr	_	_
5	administration	administration	NN	_	18	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	with	with	IN	_	11	case	_	_
9	the	the	DT	_	11	det	_	_
10	drug3	drug0	NN	_	11	com	_	_
11	drug4	drug0	NN	_	5	ppmod	_	_
12	has	have	VBZ	_	18	aux	_	_
13	,	,	,	_	18	p	_	_
14	on	on	IN	_	16	case	_	_
15	rare	rare	JJ	_	16	attr	_	_
16	occasions	occasion	NNS	_	18	ppmod	_	_
17	,	,	,	_	18	p	_	_
18	resulted	result	VBD	_	1	acl	_	_
19	in	in	IN	_	21	case	_	_
20	severe	severe	JJ	_	21	attr	_	_
21	hypoglycemia	hypoglycemia	NN	_	18	ppmod	_	_
22	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	appear	appear	VBP	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	have	have	VB	_	4	comp	_	_
7	no	no	DT	_	9	det	_	_
8	significant	significant	JJ	_	9	attr	_	_
9	effect	effect	NN	_	6	obj	_	_
10	on	on	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	bioavailability	bioavailability	NN	_	6	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug3	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	4	attr	_	_
2	Renal	renal	JJ	_	4	attr	_	_
3	tubular	tubular	JJ	_	4	attr	_	_
4	transport	transport	NN	_	9	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	may	may	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	inhibited	inhibit	VBN	_	0	root	_	_
10	by	by	IN	_	12	case	_	_
11	concomitant	concomitant	JJ	_	12	attr	_	_
12	administration	administration	NN	_	9	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug3	drug0	NN	_	12	ppmod	_	_
15	,	,	,	_	9	p	_	_
16	potentially	potentially	RB	_	17	adv	_	_
17	leading	lead	VBG	_	9	comp	_	_
18	to	to	TO	_	21	aux	_	_
19	increased	increase	VBN	_	21	attr	_	_
20	plasma	plasma	NN	_	21	com	_	_
21	levels	level	NNS	_	17	ppmod	_	_
22	of	of	IN	_	23	case	_	_
23	drug4	drug0	NN	_	21	ppmod	_	_
24	.	.	.	_	9	p	_	_

1	This	this	DT	_	3	dep	_	_
2	might	might	MD	_	3	modal	_	_
3	increase	increase	VB	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	risk	risk	NN	_	3	obj	_	_
6	of	of	IN	_	9	case	_	_
7	drug1	drug0	JJ	_	9	attr	_	_
8	toxic	toxic	JJ	_	9	attr	_	_
9	reactions	reaction	NNS	_	5	ppmod	_	_
10	.	.	.	_	3	p	_	_

1	Therefore	therefore	RB	_	10	adv	_	_
2	,	,	,	_	10	p	_	_
3	patients	patient	NNS	_	10	dep	_	_
4	under	under	IN	_	6	case	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	therapy	therapy	NN	_	3	ppmod	_	_
7	should	should	MD	_	10	modal	_	_
8	be	be	VB	_	10	aux	_	_
9	carefully	carefully	RB	_	10	adv	_	_
10	monitored	monitor	VBN	_	0	root	_	_
11	when	when	WRB	_	16	adv	_	_
12	concomitant	concomitant	JJ	_	14	attr	_	_
13	drug2	drug0	NN	_	14	com	_	_
14	therapy	therapy	NN	_	16	dep	_	_
15	is	be	VBZ	_	16	aux	_	_
16	indicated	indicate	VBN	_	10	comp	_	_
17	.	.	.	_	10	p	_	_

1	Multivalent	multivalent	JJ	_	3	attr	_	_
2	Cation-Containing	cation-containing	JJ	_	3	attr	_	_
3	Products	product	NNS	_	0	root	_	_
4	:	:	:	_	3	p	_	_
5	Concurrent	concurrent	JJ	_	6	attr	_	_
6	administration	administration	NN	_	45	dep	_	_
7	of	of	IN	_	9	case	_	_
8	a	a	DT	_	9	det	_	_
9	drug1	drug0	NN	_	6	ppmod	_	_
10	,	,	,	_	9	p	_	_
11	including	include	VBG	_	9	acl	_	_
12	drug2	drug0	NN	_	11	obj	_	_
13	,	,	,	_	9	p	_	_
14	with	with	IN	_	17	case	_	_
15	multivalent	multivalent	JJ	_	17	attr	_	_
16	cation-containing	cation-containing	JJ	_	17	attr	_	_
17	products	product	NNS	_	6	ppmod	_	_
18	such	such	JJ	_	20	adv	_	_
19	as	as	IN	_	20	case	_	_
20	drug3	drug0	NN	_	17	ppmod	_	_
21	or	or	CC	_	20	cc	_	_
22	drug4	drug0	NN	_	23	com	_	_
23	drug5	drug0	NN	_	20	conj	_	_
24	,	,	,	_	17	p	_	_
25	drug6	drug0	NN	_	17	appo	_	_
26	,	,	,	_	25	p	_	_
27	drug7	drug0	NN	_	29	attr	_	_
28	chewable/buffered	chewable/buffered	JJ	_	29	attr	_	_
29	tablets	tablet	NNS	_	25	conj	_	_
30	or	or	CC	_	29	cc	_	_
31	pediatric	pediatric	JJ	_	32	attr	_	_
32	powder	powder	NN	_	25	conj	_	_
33	,	,	,	_	17	p	_	_
34	or	or	CC	_	17	cc	_	_
35	products	product	NNS	_	17	conj	_	_
36	containing	contain	VBG	_	17	acl	_	_
37	drug8	drug0	NN	_	36	obj	_	_
38	,	,	,	_	37	p	_	_
39	drug9	drug0	NN	_	37	conj	_	_
40	,	,	,	_	39	p	_	_
41	or	or	CC	_	39	cc	_	_
42	drug10	drug0	NN	_	37	conj	_	_
43	may	may	MD	_	45	modal	_	_
44	substantially	substantially	RB	_	45	adv	_	_
45	decrease	decrease	VB	_	3	acl	_	_
46	the	the	DT	_	47	det	_	_
47	absorption	absorption	NN	_	45	obj	_	_
48	of	of	IN	_	49	case	_	_
49	drug11	drug0	NN	_	47	ppmod	_	_
50	,	,	,	_	45	p	_	_
51	resulting	result	VBG	_	45	comp	_	_
52	in	in	IN	_	56	case	_	_
53	serum	serum	NN	_	56	attr	_	_
54	and	and	CC	_	53	cc	_	_
55	urine	urine	NN	_	53	conj	_	_
56	levels	level	NNS	_	51	ppmod	_	_
57	considerably	considerably	RB	_	58	adv	_	_
58	lower	low	JJR	_	56	attr	_	_
59	than	than	IN	_	60	case	_	_
60	desired	desired	JJ	_	58	ppmod	_	_
61	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	administered	administer	VBN	_	0	root	_	_
5	at	at	IN	_	7	case	_	_
6	least	least	JJS	_	7	attr	_	_
7	4	0	CD	_	8	num	_	_
8	hours	hour	NNS	_	4	obj	_	_
9	before	before	IN	_	8	case	_	_
10	or	or	CC	_	8	cc	_	_
11	2	0	CD	_	12	num	_	_
12	hours	hour	NNS	_	8	conj	_	_
13	after	after	IN	_	15	case	_	_
14	these	these	DT	_	15	det	_	_
15	products	product	NNS	_	12	ppmod	_	_
16	.	.	.	_	4	p	_	_

1	This	this	DT	_	3	det	_	_
2	time	time	NN	_	3	com	_	_
3	window	window	NN	_	4	dep	_	_
4	is	be	VBZ	_	0	root	_	_
5	different	different	JJ	_	4	dep	_	_
6	than	than	IN	_	10	case	_	_
7	for	for	IN	_	10	case	_	_
8	other	other	JJ	_	10	attr	_	_
9	oral	oral	JJ	_	10	attr	_	_
10	formulations	formulation	NNS	_	5	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	,	,	,	_	10	p	_	_
14	which	which	WDT	_	17	dep	_	_
15	are	be	VBP	_	17	aux	_	_
16	usually	usually	RB	_	17	adv	_	_
17	administered	administer	VBN	_	10	relcl	_	_
18	2	0	CD	_	19	num	_	_
19	hours	hour	NNS	_	17	obj	_	_
20	before	before	IN	_	19	case	_	_
21	or	or	CC	_	19	cc	_	_
22	6	0	CD	_	23	num	_	_
23	hours	hour	NNS	_	19	conj	_	_
24	after	after	IN	_	25	case	_	_
25	drug2	drug0	NN	_	23	ppmod	_	_
26	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	(	-lrb-	-LRB-	_	5	p	_	_
3	but	but	CC	_	5	cc	_	_
4	not	not	RB	_	3	com	_	_
5	drug2	drug0	NN	_	1	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	:	:	:	_	1	p	_	_
8	These	these	DT	_	9	det	_	_
9	drugs	drug	NNS	_	20	dep	_	_
10	in	in	IN	_	11	case	_	_
11	combination	combination	NN	_	9	ppmod	_	_
12	with	with	IN	_	15	case	_	_
13	very	very	RB	_	14	adv	_	_
14	high	high	JJ	_	15	attr	_	_
15	doses	dose	NNS	_	11	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	drug3	drug0	NN	_	15	ppmod	_	_
18	have	have	VBP	_	20	aux	_	_
19	been	be	VBN	_	20	aux	_	_
20	shown	show	VBN	_	1	acl	_	_
21	to	to	TO	_	22	aux	_	_
22	provoke	provoke	VB	_	20	comp	_	_
23	convulsions	convulsions	NN	_	22	obj	_	_
24	in	in	IN	_	26	case	_	_
25	pre-clinical	pre-clinical	JJ	_	26	attr	_	_
26	studies	study	NNS	_	22	ppmod	_	_
27	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	rate	rate	NN	_	11	dep	_	_
5	and	and	CC	_	4	cc	_	_
6	extent	extent	NN	_	4	conj	_	_
7	of	of	IN	_	8	case	_	_
8	absorption	absorption	NN	_	4	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	was	be	VBD	_	1	acl	_	_
12	bioequivalent	bioequivalent	JJ	_	11	dep	_	_
13	when	when	WRB	_	16	adv	_	_
14	drug3	drug0	NN	_	16	dep	_	_
15	was	be	VBD	_	16	aux	_	_
16	given	give	VBN	_	11	advcl	_	_
17	alone	alone	RB	_	16	adv	_	_
18	or	or	CC	_	16	cc	_	_
19	when	when	WRB	_	22	adv	_	_
20	drug4	drug0	NN	_	22	dep	_	_
21	was	be	VBD	_	22	aux	_	_
22	given	give	VBN	_	16	conj	_	_
23	2	0	CD	_	24	num	_	_
24	hours	hour	NNS	_	26	dat	_	_
25	after	after	IN	_	26	case	_	_
26	drug5	drug0	NN	_	22	ppmod	_	_
27	at	at	IN	_	29	case	_	_
28	the	the	DT	_	29	det	_	_
29	dose	dose	NN	_	22	ppmod	_	_
30	that	that	WDT	_	32	dep	_	_
31	maximally	maximally	RB	_	32	adv	_	_
32	suppresses	suppress	VBZ	_	29	relcl	_	_
33	gastric	gastric	JJ	_	35	attr	_	_
34	acid	acid	NN	_	35	com	_	_
35	secretion	secretion	NN	_	32	obj	_	_
36	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	taken	take	VBN	_	0	root	_	_
5	as	as	IN	_	6	mark	_	_
6	directed	direct	VBN	_	4	comp	_	_
7	and	and	CC	_	4	cc	_	_
8	drug2	drug0	NN	_	11	dep	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	taken	take	VBN	_	4	conj	_	_
12	with	with	IN	_	15	case	_	_
13	a	a	DT	_	15	det	_	_
14	main	main	JJ	_	15	attr	_	_
15	meal	meal	NN	_	11	ppmod	_	_
16	of	of	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	day	day	NN	_	15	ppmod	_	_
19	,	,	,	_	15	p	_	_
20	preferably	preferably	RB	_	23	adv	_	_
21	the	the	DT	_	23	det	_	_
22	evening	evening	NN	_	23	com	_	_
23	meal	meal	NN	_	15	appo	_	_
24	.	.	.	_	11	p	_	_
25	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Altered	altered	JJ	_	5	attr	_	_
4	serum	serum	NN	_	5	com	_	_
5	levels	level	NNS	_	15	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	increased	increase	VBN	_	7	prn	_	_
10	and	and	CC	_	9	cc	_	_
11	decreased	decrease	VBN	_	9	conj	_	_
12	)	-rrb-	-RRB-	_	9	p	_	_
13	have	have	VBP	_	15	aux	_	_
14	been	be	VBN	_	15	aux	_	_
15	reported	report	VBN	_	1	acl	_	_
16	in	in	IN	_	17	case	_	_
17	patients	patient	NNS	_	15	ppmod	_	_
18	receiving	receive	VBG	_	17	acl	_	_
19	concomitant	concomitant	JJ	_	20	attr	_	_
20	drug3	drug0	NN	_	18	obj	_	_
21	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	4	dep	_	_
4	interferes	interfere	VBZ	_	1	acl	_	_
5	with	with	IN	_	8	case	_	_
6	renal	renal	JJ	_	8	attr	_	_
7	tubular	tubular	JJ	_	8	attr	_	_
8	secretion	secretion	NN	_	4	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug3	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	4	cc	_	_
12	produces	produce	VBZ	_	4	conj	_	_
13	an	an	DT	_	14	det	_	_
14	increase	increase	NN	_	12	obj	_	_
15	in	in	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	level	level	NN	_	14	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug4	drug0	NN	_	17	ppmod	_	_
20	in	in	IN	_	21	case	_	_
21	serum	serum	NN	_	17	ppmod	_	_
22	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	As	as	IN	_	7	case	_	_
4	with	with	IN	_	7	case	_	_
5	some	some	DT	_	7	det	_	_
6	other	other	JJ	_	7	attr	_	_
7	drug2	drug0	NNS	_	16	ppmod	_	_
8	,	,	,	_	16	p	_	_
9	concurrent	concurrent	JJ	_	10	attr	_	_
10	administration	administration	NN	_	16	dep	_	_
11	of	of	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	with	with	IN	_	14	case	_	_
14	drug4	drug0	NN	_	10	ppmod	_	_
15	may	may	MD	_	16	modal	_	_
16	lead	lead	VB	_	1	acl	_	_
17	to	to	TO	_	20	aux	_	_
18	elevated	elevated	JJ	_	20	attr	_	_
19	serum	serum	NN	_	20	com	_	_
20	concentrations	concentration	NNS	_	16	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	drug5	drug0	NN	_	20	ppmod	_	_
23	and	and	CC	_	22	cc	_	_
24	prolongation	prolongation	NN	_	22	conj	_	_
25	of	of	IN	_	28	case	_	_
26	its	its	PRP$	_	28	poss	_	_
27	elimination	elimination	NN	_	28	com	_	_
28	half-life	half-life	NN	_	22	ppmod	_	_
29	.	.	.	_	1	p	_	_

1	This	this	DT	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	result	result	VB	_	0	root	_	_
4	in	in	IN	_	6	case	_	_
5	increased	increase	VBN	_	6	attr	_	_
6	risk	risk	NN	_	3	ppmod	_	_
7	of	of	IN	_	11	case	_	_
8	drug1	drug0	JJ	_	11	attr	_	_
9	-related	-related	JJ	_	11	attr	_	_
10	adverse	adverse	JJ	_	11	attr	_	_
11	reactions	reaction	NNS	_	6	ppmod	_	_
12	.	.	.	_	3	p	_	_

1	If	if	IN	_	6	mark	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	use	use	NN	_	6	dep	_	_
4	cannot	cannot	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	avoided	avoid	VBN	_	14	advcl	_	_
7	,	,	,	_	14	p	_	_
8	serum	serum	NN	_	9	com	_	_
9	levels	level	NNS	_	14	dep	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	should	should	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	monitored	monitor	VBN	_	0	root	_	_
15	and	and	CC	_	14	cc	_	_
16	dosage	dosage	NN	_	17	com	_	_
17	adjustments	adjustment	NNS	_	18	dep	_	_
18	made	make	VBD	_	14	conj	_	_
19	as	as	IN	_	20	case	_	_
20	appropriate	appropriate	JJ	_	18	ppmod	_	_
21	.	.	.	_	14	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	have	have	VBP	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	reported	report	VBN	_	0	root	_	_
7	to	to	TO	_	8	aux	_	_
8	enhance	enhance	VB	_	6	comp	_	_
9	the	the	DT	_	10	det	_	_
10	effects	effect	NNS	_	8	obj	_	_
11	of	of	IN	_	15	case	_	_
12	the	the	DT	_	15	det	_	_
13	oral	oral	JJ	_	15	attr	_	_
14	drug3	drug0	NN	_	15	com	_	_
15	drug4	drug0	NN	_	10	ppmod	_	_
16	or	or	CC	_	15	cc	_	_
17	its	its	PRP$	_	18	poss	_	_
18	derivatives	derivative	NNS	_	15	conj	_	_
19	.	.	.	_	6	p	_	_

1	When	when	WRB	_	5	adv	_	_
2	these	these	DT	_	3	det	_	_
3	products	product	NNS	_	5	dep	_	_
4	are	be	VBP	_	5	aux	_	_
5	administered	administer	VBN	_	17	advcl	_	_
6	concomitantly	concomitantly	RB	_	5	adv	_	_
7	,	,	,	_	17	p	_	_
8	prothrombin	prothrombin	NN	_	9	com	_	_
9	time	time	NN	_	17	dep	_	_
10	or	or	CC	_	9	cc	_	_
11	other	other	JJ	_	14	attr	_	_
12	suitable	suitable	JJ	_	14	attr	_	_
13	coagulation	coagulation	NN	_	14	com	_	_
14	tests	test	NNS	_	9	conj	_	_
15	should	should	MD	_	17	modal	_	_
16	be	be	VB	_	17	aux	_	_
17	monitored	monitor	VBN	_	0	root	_	_
18	.	.	.	_	17	p	_	_

1	DRUG	drug	NN	_	2	com	_	_
2	INTERACTIONS	interaction	NNS	_	0	root	_	_

1	Several	several	JJ	_	4	attr	_	_
2	drug	drug	NN	_	4	com	_	_
3	interaction	interaction	NN	_	4	com	_	_
4	studies	study	NNS	_	7	dep	_	_
5	have	have	VBP	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	completed	complete	VBN	_	0	root	_	_
8	with	with	IN	_	10	case	_	_
9	both	both	CC	_	10	cc	_	_
10	drug1	drug0	NN	_	7	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug2	drug0	NN	_	10	conj	_	_
13	.	.	.	_	7	p	_	_

1	Observations	observation	NNS	_	10	dep	_	_
2	from	from	IN	_	5	case	_	_
3	drug	drug	NN	_	5	com	_	_
4	interaction	interaction	NN	_	5	com	_	_
5	studies	study	NNS	_	1	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	may	may	MD	_	10	modal	_	_
9	not	not	RB	_	10	neg	_	_
10	be	be	VB	_	0	root	_	_
11	predictive	predictive	JJ	_	10	dep	_	_
12	for	for	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	.	.	.	_	10	p	_	_

1	Because	because	IN	_	4	mark	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	coadministered	coadministered	VBN	_	9	advcl	_	_
5	,	,	,	_	9	p	_	_
6	prescribers	prescriber	NNS	_	9	dep	_	_
7	should	should	MD	_	9	modal	_	_
8	also	also	RB	_	9	adv	_	_
9	refer	refer	VBP	_	0	root	_	_
10	to	to	TO	_	13	aux	_	_
11	the	the	DT	_	13	det	_	_
12	prescribing	prescribing	JJ	_	13	attr	_	_
13	information	information	NN	_	9	ppmod	_	_
14	for	for	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	regarding	regard	VBG	_	18	adv	_	_
17	drug	drug	NN	_	18	com	_	_
18	interactions	interaction	NNS	_	13	ppmod	_	_
19	associated	associate	VBN	_	18	acl	_	_
20	with	with	IN	_	22	case	_	_
21	this	this	DT	_	22	det	_	_
22	agent	agent	NN	_	19	ppmod	_	_
23	.	.	.	_	9	p	_	_

1	The	the	DT	_	2	det	_	_
2	metabolism	metabolism	NN	_	6	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	is	be	VBZ	_	6	aux	_	_
6	mediated	mediate	VBN	_	0	root	_	_
7	by	by	IN	_	9	case	_	_
8	cytochrome	cytochrome	NN	_	9	com	_	_
9	P450	p0	NN	_	6	ppmod	_	_
10	,	,	,	_	6	p	_	_
11	with	with	IN	_	15	case	_	_
12	the	the	DT	_	15	det	_	_
13	specific	specific	JJ	_	15	attr	_	_
14	isoenzyme	isoenzyme	NN	_	15	com	_	_
15	CYP3A4	cyp0a0	NN	_	6	ppmod	_	_
16	responsible	responsible	JJ	_	15	attr	_	_
17	for	for	IN	_	18	case	_	_
18	90	0	CD	_	16	ppmod	_	_
19	%	%	NN	_	18	meta	_	_
20	of	of	IN	_	23	case	_	_
21	the	the	DT	_	23	det	_	_
22	hepatic	hepatic	JJ	_	23	attr	_	_
23	metabolism	metabolism	NN	_	18	ppmod	_	_
24	.	.	.	_	6	p	_	_

1	Additionally	additionally	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	drug1	drug0	NN	_	4	dep	_	_
4	is	be	VBZ	_	0	root	_	_
5	a	a	DT	_	6	det	_	_
6	substrate	substrate	NN	_	4	obj	_	_
7	for	for	IN	_	8	case	_	_
8	P-Glycoprotein	p-glycoprotein	NN	_	6	ppmod	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	Pgp	pgp	NN	_	8	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	.	.	.	_	4	p	_	_

1	Therefore	therefore	RB	_	11	adv	_	_
2	,	,	,	_	11	p	_	_
3	drugs	drug	NNS	_	11	dep	_	_
4	that	that	WDT	_	5	dep	_	_
5	affect	affect	VBP	_	3	relcl	_	_
6	CYP3A4	cyp0a0	NN	_	5	obj	_	_
7	and/or	and/or	CC	_	6	cc	_	_
8	Pgp	pgp	NN	_	6	conj	_	_
9	,	,	,	_	11	p	_	_
10	may	may	MD	_	11	modal	_	_
11	modify	modify	VB	_	0	root	_	_
12	the	the	DT	_	13	det	_	_
13	pharmacokinetics	pharmacokinetics	NNS	_	11	obj	_	_
14	of	of	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	11	p	_	_

1	Similarly	similarly	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	drug1	drug0	NN	_	6	dep	_	_
4	might	might	MD	_	6	modal	_	_
5	also	also	RB	_	6	adv	_	_
6	modify	modify	VB	_	0	root	_	_
7	the	the	DT	_	8	det	_	_
8	pharmacokinetics	pharmacokinetics	NNS	_	6	obj	_	_
9	of	of	IN	_	11	case	_	_
10	other	other	JJ	_	11	attr	_	_
11	drugs	drug	NNS	_	8	ppmod	_	_
12	that	that	WDT	_	13	dep	_	_
13	are	be	VBP	_	11	relcl	_	_
14	substrates	substrate	NNS	_	13	obj	_	_
15	for	for	IN	_	16	case	_	_
16	CYP3A4	cyp0a0	NN	_	14	ppmod	_	_
17	or	or	CC	_	16	cc	_	_
18	Pgp	pgp	NN	_	16	conj	_	_
19	.	.	.	_	6	p	_	_

1	Drugs	drug	NNS	_	19	dep	_	_
2	that	that	WDT	_	4	dep	_	_
3	are	be	VBP	_	4	aux	_	_
4	contraindicated	contraindicate	VBN	_	1	relcl	_	_
5	specifically	specifically	RB	_	10	adv	_	_
6	due	due	JJ	_	10	adv	_	_
7	to	to	TO	_	10	aux	_	_
8	the	the	DT	_	10	det	_	_
9	expected	expect	VBN	_	10	attr	_	_
10	magnitude	magnitude	NN	_	4	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	interaction	interaction	NN	_	10	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	potential	potential	NN	_	12	conj	_	_
15	for	for	IN	_	18	case	_	_
16	serious	serious	JJ	_	18	attr	_	_
17	adverse	adverse	JJ	_	18	attr	_	_
18	events	event	NNS	_	10	ppmod	_	_
19	are	be	VBP	_	0	root	_	_
20	listed	listed	JJ	_	21	attr	_	_
21	CONTRAINDICATIONS	contraindication	NNS	_	19	obj	_	_
22	.	.	.	_	19	p	_	_

1	Additional	additional	JJ	_	2	attr	_	_
2	drugs	drug	NNS	_	14	dep	_	_
3	that	that	WDT	_	6	dep	_	_
4	are	be	VBP	_	6	aux	_	_
5	not	not	RB	_	6	neg	_	_
6	recommended	recommend	VBN	_	2	relcl	_	_
7	for	for	IN	_	8	case	_	_
8	coadministration	coadministration	NN	_	6	ppmod	_	_
9	with	with	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug2	drug0	NN	_	10	conj	_	_
13	are	be	VBP	_	14	aux	_	_
14	included	include	VBN	_	0	root	_	_
15	below	below	IN	_	14	case	_	_
16	.	.	.	_	14	p	_	_

1	These	these	DT	_	2	det	_	_
2	recommendations	recommendation	NNS	_	4	dep	_	_
3	are	be	VBP	_	4	aux	_	_
4	based	base	VBN	_	0	root	_	_
5	on	on	IN	_	9	case	_	_
6	either	either	CC	_	9	cc	_	_
7	drug	drug	NN	_	9	com	_	_
8	interaction	interaction	NN	_	9	com	_	_
9	studies	study	NNS	_	4	ppmod	_	_
10	or	or	CC	_	9	cc	_	_
11	predicted	predict	VBN	_	12	attr	_	_
12	interactions	interaction	NNS	_	9	conj	_	_
13	due	due	JJ	_	12	attr	_	_
14	to	to	TO	_	17	aux	_	_
15	the	the	DT	_	17	det	_	_
16	expected	expect	VBN	_	17	attr	_	_
17	magnitude	magnitude	NN	_	13	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	interaction	interaction	NN	_	17	ppmod	_	_
20	and	and	CC	_	19	cc	_	_
21	potential	potential	NN	_	19	conj	_	_
22	for	for	IN	_	24	case	_	_
23	serious	serious	JJ	_	24	attr	_	_
24	events	event	NNS	_	17	ppmod	_	_
25	or	or	CC	_	24	cc	_	_
26	loss	loss	NN	_	24	conj	_	_
27	of	of	IN	_	28	case	_	_
28	efficacy	efficacy	NN	_	26	ppmod	_	_
29	.	.	.	_	4	p	_	_

1	With	with	IN	_	3	case	_	_
2	some	some	DT	_	3	det	_	_
3	agents	agent	NNS	_	9	ppmod	_	_
4	,	,	,	_	9	p	_	_
5	the	the	DT	_	6	det	_	_
6	metabolism	metabolism	NN	_	9	dep	_	_
7	may	may	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	induced	induce	VBN	_	0	root	_	_
10	,	,	,	_	9	p	_	_
11	resulting	result	VBG	_	9	comp	_	_
12	in	in	IN	_	14	case	_	_
13	decreased	decrease	VBN	_	14	attr	_	_
14	concentrations	concentration	NNS	_	11	ppmod	_	_
15	.	.	.	_	9	p	_	_

1	Drugs	drug	NNS	_	0	root	_	_
2	That	that	WDT	_	6	dep	_	_
3	Should	should	MD	_	6	modal	_	_
4	Not	not	RB	_	6	neg	_	_
5	Be	be	VB	_	6	aux	_	_
6	Coadministered	coadministered	VBN	_	1	relcl	_	_
7	With	with	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	/	/	:	_	1	p	_	_
10	drug2	drug0	NN	_	1	appo	_	_

1	Drug	drug	NN	_	2	com	_	_
2	Class	class	NN	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	Drug	drug	NN	_	7	attr	_	_
5	Name	name	NN	_	7	attr	_	_
6	Clinical	clinical	JJ	_	7	attr	_	_
7	Comment	comment	NN	_	2	appo	_	_

1	drug1	drug0	NN	_	12	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	,	,	,	_	3	p	_	_
5	drug3	drug0	NN	_	3	appo	_	_
6	,	,	,	_	3	p	_	_
7	drug4	drug0	NN	_	3	appo	_	_
8	,	,	,	_	3	p	_	_
9	drug5	drug0	NN	_	3	appo	_	_
10	,	,	,	_	3	p	_	_
11	drug6	drug0	NN	_	3	appo	_	_
12	CONTRAINDICATED	contraindicate	VBN	_	0	root	_	_
13	due	due	JJ	_	15	adv	_	_
14	to	to	TO	_	15	aux	_	_
15	potential	potential	NN	_	12	ppmod	_	_
16	for	for	IN	_	20	case	_	_
17	serious	serious	JJ	_	20	attr	_	_
18	and/or	and/or	CC	_	17	cc	_	_
19	life-threatening	life-threatening	JJ	_	17	conj	_	_
20	reactions	reaction	NNS	_	15	ppmod	_	_
21	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	8	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	7	attr	_	_
4	*	*	NN	_	7	attr	_	_
5	,	,	,	_	7	p	_	_
6	drug3	drug0	NN	_	7	com	_	_
7	*	*	NN	_	1	appo	_	_
8	CONTRAINDICATED	contraindicate	VBN	_	0	root	_	_
9	due	due	JJ	_	11	adv	_	_
10	to	to	TO	_	11	aux	_	_
11	potential	potential	NN	_	8	ppmod	_	_
12	for	for	IN	_	17	case	_	_
13	serious	serious	JJ	_	17	attr	_	_
14	and/or	and/or	CC	_	13	cc	_	_
15	life-threatening	life-threatening	JJ	_	13	conj	_	_
16	cardiac	cardiac	JJ	_	17	attr	_	_
17	arrhythmias	arrhythmia	NNS	_	11	ppmod	_	_
18	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	10	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	,	,	,	_	3	p	_	_
5	drug3	drug0	NN	_	3	appo	_	_
6	,	,	,	_	3	p	_	_
7	drug4	drug0	NN	_	3	appo	_	_
8	,	,	,	_	3	p	_	_
9	drug5	drug0	NN	_	3	appo	_	_
10	CONTRAINDICATED	contraindicate	VBN	_	0	root	_	_
11	due	due	JJ	_	13	adv	_	_
12	to	to	TO	_	13	aux	_	_
13	potential	potential	NN	_	10	ppmod	_	_
14	for	for	IN	_	18	case	_	_
15	serious	serious	JJ	_	18	attr	_	_
16	and	and	CC	_	15	cc	_	_
17	life-threatening	life-threatening	JJ	_	15	conj	_	_
18	reactions	reaction	NNS	_	13	ppmod	_	_
19	such	such	JJ	_	23	adv	_	_
20	as	as	IN	_	23	case	_	_
21	acute	acute	JJ	_	23	attr	_	_
22	drug6	drug0	NN	_	23	com	_	_
23	toxicity	toxicity	NN	_	18	ppmod	_	_
24	characterized	characterize	VBN	_	23	acl	_	_
25	by	by	IN	_	27	case	_	_
26	peripheral	peripheral	JJ	_	27	attr	_	_
27	vasospasm	vasospasm	NN	_	24	ppmod	_	_
28	and	and	CC	_	27	cc	_	_
29	ischemia	ischemia	NN	_	27	conj	_	_
30	of	of	IN	_	32	case	_	_
31	the	the	DT	_	32	det	_	_
32	extremities	extremity	NNS	_	27	ppmod	_	_
33	and	and	CC	_	32	cc	_	_
34	other	other	JJ	_	35	attr	_	_
35	tissues	tissue	NNS	_	32	conj	_	_
36	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	VBP	_	4	aux	_	_
4	CONTRAINDICATED	contraindicate	VBN	_	1	acl	_	_
5	since	since	IN	_	17	mark	_	_
6	the	the	DT	_	7	det	_	_
7	coadministration	coadministration	NN	_	17	dep	_	_
8	of	of	IN	_	10	case	_	_
9	this	this	DT	_	10	det	_	_
10	product	product	NN	_	7	ppmod	_	_
11	with	with	IN	_	12	case	_	_
12	drug3	drug0	NN	_	7	ppmod	_	_
13	in	in	IN	_	16	case	_	_
14	an	an	DT	_	16	det	_	_
15	drug4	drug0	NN	_	16	com	_	_
16	regimen	regimen	NN	_	7	ppmod	_	_
17	reduces	reduce	VBZ	_	4	comp	_	_
18	the	the	DT	_	20	det	_	_
19	plasma	plasma	NN	_	20	com	_	_
20	concentrations	concentration	NNS	_	17	obj	_	_
21	of	of	IN	_	22	case	_	_
22	drug5	drug0	NN	_	20	ppmod	_	_
23	.	.	.	_	1	p	_	_

1	Garlic	garlic	JJ	_	2	attr	_	_
2	Capsules	capsule	NNS	_	4	attr	_	_
3	Garlic	garlic	JJ	_	4	attr	_	_
4	capsules	capsule	NNS	_	8	dep	_	_
5	should	should	MD	_	8	modal	_	_
6	not	not	RB	_	8	neg	_	_
7	be	be	VB	_	8	aux	_	_
8	used	use	VBN	_	0	root	_	_
9	while	while	IN	_	10	mark	_	_
10	taking	take	VBG	_	8	comp	_	_
11	drug1	drug0	NN	_	10	obj	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	drug2	drug0	NN	_	11	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	as	as	IN	_	18	case	_	_
16	the	the	DT	_	18	det	_	_
17	sole	sole	JJ	_	18	attr	_	_
18	drug3	drug0	NN	_	10	ppmod	_	_
19	due	due	JJ	_	18	attr	_	_
20	to	to	TO	_	22	aux	_	_
21	the	the	DT	_	22	det	_	_
22	risk	risk	NN	_	19	ppmod	_	_
23	of	of	IN	_	27	case	_	_
24	decreased	decrease	VBN	_	27	attr	_	_
25	drug4	drug0	NN	_	27	com	_	_
26	plasma	plasma	NN	_	27	com	_	_
27	concentrations	concentration	NNS	_	22	ppmod	_	_
28	.	.	.	_	8	p	_	_

1	No	no	DT	_	2	det	_	_
2	data	datum	NNS	_	3	dep	_	_
3	are	be	VBP	_	0	root	_	_
4	available	available	JJ	_	3	dep	_	_
5	for	for	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	coadministration	coadministration	NN	_	4	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	/	/	:	_	9	p	_	_
11	drug2	drug0	NN	_	9	appo	_	_
12	or	or	CC	_	11	cc	_	_
13	drug3	drug0	NN	_	11	conj	_	_
14	/	/	:	_	9	p	_	_
15	drug4	drug0	NN	_	9	appo	_	_
16	and	and	CC	_	15	cc	_	_
17	garlic	garlic	JJ	_	18	attr	_	_
18	capsules	capsule	NNS	_	15	conj	_	_
19	.	.	.	_	3	p	_	_

1	GI	gi	NN	_	3	com	_	_
2	Motility	motility	NN	_	3	com	_	_
3	Agent	agent	NN	_	0	root	_	_
4	:	:	:	_	3	p	_	_
5	drug1	drug0	NN	_	7	dep	_	_
6	*	*	VBD	_	7	aux	_	_
7	CONTRAINDICATED	contraindicate	VBN	_	3	acl	_	_
8	due	due	JJ	_	10	adv	_	_
9	to	to	TO	_	10	aux	_	_
10	potential	potential	NN	_	7	ppmod	_	_
11	for	for	IN	_	15	case	_	_
12	serious	serious	JJ	_	15	attr	_	_
13	and/or	and/or	CC	_	12	cc	_	_
14	life-threatening	life-threatening	JJ	_	12	conj	_	_
15	reactions	reaction	NNS	_	10	ppmod	_	_
16	such	such	JJ	_	19	adv	_	_
17	as	as	IN	_	19	case	_	_
18	cardiac	cardiac	JJ	_	19	attr	_	_
19	arrhythmias	arrhythmia	NNS	_	15	ppmod	_	_
20	.	.	.	_	3	p	_	_

1	Herbal	herbal	JJ	_	2	attr	_	_
2	Products	product	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	St.	st.	NN	_	13	attr	_	_
5	John	john	NN	_	13	attr	_	_
6	s	s	NN	_	13	attr	_	_
7	wort	wort	NN	_	13	attr	_	_
8	(	-lrb-	-LRB-	_	13	p	_	_
9	hypericum	hypericum	NN	_	13	attr	_	_
10	perforatum	perforatum	NN	_	13	attr	_	_
11	)	-rrb-	-RRB-	_	13	p	_	_
12	WARNING	warning	NN	_	13	com	_	_
13	coadministration	coadministration	NN	_	15	dep	_	_
14	may	may	MD	_	15	modal	_	_
15	lead	lead	VB	_	2	acl	_	_
16	to	to	TO	_	17	aux	_	_
17	loss	loss	NN	_	15	ppmod	_	_
18	of	of	IN	_	20	case	_	_
19	virologic	virologic	JJ	_	20	attr	_	_
20	response	response	NN	_	17	ppmod	_	_
21	and	and	CC	_	20	cc	_	_
22	possible	possible	JJ	_	23	attr	_	_
23	resistance	resistance	NN	_	20	conj	_	_
24	to	to	TO	_	25	aux	_	_
25	drug1	drug0	NN	_	15	ppmod	_	_
26	or	or	CC	_	25	cc	_	_
27	to	to	TO	_	29	aux	_	_
28	the	the	DT	_	29	det	_	_
29	class	class	NN	_	25	conj	_	_
30	of	of	IN	_	32	case	_	_
31	protease	protease	NN	_	32	com	_	_
32	inhibitors	inhibitor	NNS	_	29	ppmod	_	_
33	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	,	,	,	_	3	p	_	_
5	drug3	drug0	NN	_	7	com	_	_
6	WARNING	warning	NN	_	7	com	_	_
7	potential	potential	NN	_	3	appo	_	_
8	for	for	IN	_	10	case	_	_
9	serious	serious	JJ	_	10	attr	_	_
10	reactions	reaction	NNS	_	7	ppmod	_	_
11	such	such	JJ	_	13	adv	_	_
12	as	as	IN	_	13	case	_	_
13	risk	risk	NN	_	10	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	myopathy	myopathy	NN	_	13	ppmod	_	_
16	including	include	VBG	_	17	adv	_	_
17	rhabdomyolysis	rhabdomyolysis	NN	_	13	ppmod	_	_
18	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	8	dep	_	_
2	/	/	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	:	:	:	_	1	p	_	_
5	drug3	drug0	NN	_	1	appo	_	_
6	,	,	,	_	5	p	_	_
7	drug4	drug0	NN	_	5	appo	_	_
8	CONTRAINDICATED	contraindicate	VBN	_	0	root	_	_
9	due	due	JJ	_	11	adv	_	_
10	to	to	TO	_	11	aux	_	_
11	potential	potential	NN	_	8	ppmod	_	_
12	for	for	IN	_	16	case	_	_
13	serious	serious	JJ	_	16	attr	_	_
14	and/or	and/or	CC	_	13	cc	_	_
15	life-threatening	life-threatening	JJ	_	13	conj	_	_
16	reactions	reaction	NNS	_	11	ppmod	_	_
17	such	such	JJ	_	22	adv	_	_
18	as	as	IN	_	22	case	_	_
19	prolonged	prolonged	JJ	_	22	attr	_	_
20	or	or	CC	_	19	cc	_	_
21	increased	increase	VBN	_	19	conj	_	_
22	sedation	sedation	NN	_	16	ppmod	_	_
23	or	or	CC	_	22	cc	_	_
24	respiratory	respiratory	JJ	_	25	attr	_	_
25	depression	depression	NN	_	22	conj	_	_
26	.	.	.	_	8	p	_	_

1	*	*	NN	_	2	com	_	_
2	No	no	NN	_	4	dep	_	_
3	longer	longer	RB	_	4	adv	_	_
4	marketed	market	VBN	_	0	root	_	_
5	in	in	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	US	us	PRP	_	4	ppmod	_	_
8	.	.	.	_	4	p	_	_

1	Drugs	drug	NNS	_	0	root	_	_
2	That	that	WDT	_	5	dep	_	_
3	Are	be	VBP	_	5	aux	_	_
4	Mainly	mainly	RB	_	5	adv	_	_
5	Metabolized	metabolize	VBN	_	1	relcl	_	_
6	by	by	IN	_	7	case	_	_
7	CYP3A4	cyp0a0	NN	_	5	ppmod	_	_

1	Although	although	IN	_	7	mark	_	_
2	specific	specific	JJ	_	3	attr	_	_
3	studies	study	NNS	_	7	dep	_	_
4	have	have	VBP	_	7	aux	_	_
5	not	not	RB	_	7	neg	_	_
6	been	be	VBN	_	7	aux	_	_
7	performed	performed	VBN	_	58	advcl	_	_
8	,	,	,	_	58	p	_	_
9	coadministration	coadministration	NN	_	58	dep	_	_
10	with	with	IN	_	11	case	_	_
11	drugs	drug	NNS	_	9	ppmod	_	_
12	that	that	WDT	_	15	dep	_	_
13	are	be	VBP	_	15	aux	_	_
14	mainly	mainly	RB	_	15	adv	_	_
15	metabolized	metabolize	VBN	_	11	relcl	_	_
16	by	by	IN	_	17	case	_	_
17	CYP3A4	cyp0a0	NN	_	15	ppmod	_	_
18	(	-lrb-	-LRB-	_	21	p	_	_
19	eg	eg	NN	_	21	dep	_	_
20	,	,	,	_	21	p	_	_
21	drug1	drug0	NN	_	17	prn	_	_
22	,	,	,	_	21	p	_	_
23	drug2	drug0	NN	_	21	appo	_	_
24	,	,	,	_	21	p	_	_
25	drug3	drug0	NN	_	21	appo	_	_
26	,	,	,	_	21	p	_	_
27	drug4	drug0	NN	_	21	appo	_	_
28	,	,	,	_	21	p	_	_
29	drug5	drug0	NN	_	21	appo	_	_
30	,	,	,	_	21	p	_	_
31	drug6	drug0	NN	_	21	appo	_	_
32	,	,	,	_	21	p	_	_
33	drug7	drug0	NN	_	21	appo	_	_
34	,	,	,	_	21	p	_	_
35	drug8	drug0	NN	_	21	appo	_	_
36	,	,	,	_	21	p	_	_
37	drug9	drug0	NN	_	21	appo	_	_
38	,	,	,	_	21	p	_	_
39	drug10	drug0	CD	_	21	num	_	_
40	,	,	,	_	39	p	_	_
41	drug11	drug0	CD	_	39	conj	_	_
42	,	,	,	_	41	p	_	_
43	drug12	drug0	CD	_	39	conj	_	_
44	,	,	,	_	43	p	_	_
45	drug13	drug0	CD	_	39	conj	_	_
46	,	,	,	_	45	p	_	_
47	drug14	drug0	CD	_	39	conj	_	_
48	,	,	,	_	47	p	_	_
49	drug15	drug0	CD	_	39	conj	_	_
50	,	,	,	_	49	p	_	_
51	and	and	CC	_	49	cc	_	_
52	drug16	drug0	CD	_	39	conj	_	_
53	)	-rrb-	-RRB-	_	21	p	_	_
54	may	may	MD	_	58	modal	_	_
55	have	have	VBP	_	58	lv	_	_
56	elevated	elevated	JJ	_	58	attr	_	_
57	plasma	plasma	NN	_	58	com	_	_
58	concentrations	concentration	NNS	_	0	root	_	_
59	when	when	WRB	_	60	adv	_	_
60	coadministered	coadministered	VBN	_	58	comp	_	_
61	with	with	IN	_	62	case	_	_
62	drug17	drug0	NN	_	60	ppmod	_	_
63	;	;	:	_	58	p	_	_

1	therefore	therefore	RB	_	7	adv	_	_
2	,	,	,	_	7	p	_	_
3	these	these	DT	_	4	det	_	_
4	combinations	combination	NNS	_	7	dep	_	_
5	should	should	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	used	use	VBN	_	0	root	_	_
8	with	with	IN	_	9	case	_	_
9	caution	caution	NN	_	7	ppmod	_	_
10	.	.	.	_	7	p	_	_

1	Since	since	IN	_	4	mark	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	coadministered	coadministered	VBN	_	13	advcl	_	_
5	with	with	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	,	,	,	_	13	p	_	_
8	the	the	DT	_	9	det	_	_
9	drug3	drug0	NN	_	13	dep	_	_
10	label	label	VB	_	9	acl	_	_
11	should	should	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	reviewed	review	VBN	_	0	root	_	_
14	for	for	IN	_	16	case	_	_
15	additional	additional	JJ	_	16	attr	_	_
16	drugs	drug	NNS	_	13	ppmod	_	_
17	that	that	WDT	_	21	dep	_	_
18	should	should	MD	_	21	modal	_	_
19	not	not	RB	_	21	neg	_	_
20	be	be	VB	_	21	aux	_	_
21	coadministered	coadministered	VBN	_	16	relcl	_	_
22	.	.	.	_	13	p	_	_

1	Inducers	inducer	NNS	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	CYP3A4	cyp0a0	NN	_	1	ppmod	_	_

1	Coadministration	coadministration	NN	_	22	dep	_	_
2	with	with	IN	_	3	case	_	_
3	compounds	compound	NNS	_	1	ppmod	_	_
4	that	that	WDT	_	5	dep	_	_
5	are	be	VBP	_	3	relcl	_	_
6	potent	potent	JJ	_	7	attr	_	_
7	inducers	inducer	NNS	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	CYP3A4	cyp0a0	NN	_	7	ppmod	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	eg	eg	NN	_	9	prn	_	_
12	,	,	,	_	11	p	_	_
13	drug1	drug0	NN	_	11	appo	_	_
14	,	,	,	_	11	p	_	_
15	drug2	drug0	NN	_	11	appo	_	_
16	,	,	,	_	11	p	_	_
17	drug3	drug0	NN	_	11	appo	_	_
18	,	,	,	_	11	p	_	_
19	drug4	drug0	NN	_	11	appo	_	_
20	)	-rrb-	-RRB-	_	11	p	_	_
21	may	may	MD	_	22	modal	_	_
22	result	result	VB	_	0	root	_	_
23	in	in	IN	_	26	case	_	_
24	decreased	decrease	VBN	_	26	attr	_	_
25	plasma	plasma	NN	_	26	com	_	_
26	levels	level	NNS	_	22	ppmod	_	_
27	of	of	IN	_	28	case	_	_
28	drug5	drug0	NN	_	26	ppmod	_	_
29	.	.	.	_	22	p	_	_

1	There	there	EX	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	no	no	DT	_	4	det	_	_
4	evidence	evidence	NN	_	2	obj	_	_
5	in	in	IN	_	7	case	_	_
6	clinical	clinical	JJ	_	7	attr	_	_
7	trials	trial	NNS	_	2	ppmod	_	_
8	of	of	IN	_	10	case	_	_
9	drug	drug	NN	_	10	com	_	_
10	interactions	interaction	NNS	_	7	ppmod	_	_
11	with	with	IN	_	13	case	_	_
12	concurrent	concurrent	JJ	_	13	attr	_	_
13	medications	medication	NNS	_	10	ppmod	_	_
14	.	.	.	_	2	p	_	_

1	Drug	drug	NN	_	3	com	_	_
2	interaction	interaction	NN	_	3	com	_	_
3	studies	study	NNS	_	9	dep	_	_
4	with	with	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	have	have	VBP	_	9	aux	_	_
7	not	not	RB	_	9	neg	_	_
8	been	be	VBN	_	9	aux	_	_
9	conducted	conduct	VBN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	studies	study	NNS	_	8	dep	_	_
4	in	in	IN	_	7	case	_	_
5	human	human	JJ	_	7	attr	_	_
6	liver	liver	NN	_	7	com	_	_
7	microsomes	microsome	NNS	_	3	ppmod	_	_
8	suggest	suggest	VBP	_	0	root	_	_
9	that	that	IN	_	11	mark	_	_
10	drug1	drug0	NN	_	11	dep	_	_
11	is	be	VBZ	_	8	comp	_	_
12	unlikely	unlikely	JJ	_	11	dep	_	_
13	to	to	TO	_	14	aux	_	_
14	inhibit	inhibit	VB	_	12	comp	_	_
15	or	or	CC	_	14	cc	_	_
16	induce	induce	VB	_	14	conj	_	_
17	cytochrome	cytochrome	NN	_	19	com	_	_
18	P450	p0	NN	_	19	com	_	_
19	enzymes	enzyme	NNS	_	16	obj	_	_
20	.	.	.	_	8	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	4	attr	_	_
3	metabolism	metabolism	NN	_	4	com	_	_
4	studies	study	NNS	_	6	dep	_	_
5	have	have	VBP	_	6	aux	_	_
6	suggested	suggest	VBN	_	0	root	_	_
7	that	that	IN	_	9	mark	_	_
8	drug1	drug0	NN	_	9	dep	_	_
9	is	be	VBZ	_	6	comp	_	_
10	not	not	RB	_	9	neg	_	_
11	a	a	DT	_	12	det	_	_
12	substrate	substrate	NN	_	9	obj	_	_
13	for	for	IN	_	19	case	_	_
14	the	the	DT	_	19	det	_	_
15	human	human	JJ	_	19	attr	_	_
16	liver	liver	NN	_	19	com	_	_
17	cytochrome	cytochrome	NN	_	19	com	_	_
18	P450	p0	NN	_	19	com	_	_
19	enzymes	enzyme	NNS	_	12	ppmod	_	_
20	.	.	.	_	6	p	_	_

1	As	as	IN	_	7	mark	_	_
2	plasma	plasma	NN	_	4	com	_	_
3	protein	protein	NN	_	4	com	_	_
4	binding	binding	NN	_	7	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	is	be	VBZ	_	29	advcl	_	_
8	negligible	negligible	JJ	_	7	dep	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	1	0	CD	_	8	num	_	_
11	%	%	NN	_	10	meta	_	_
12	)	-rrb-	-RRB-	_	10	p	_	_
13	,	,	,	_	29	p	_	_
14	interactions	interaction	NNS	_	29	dep	_	_
15	due	due	JJ	_	14	attr	_	_
16	to	to	TO	_	17	aux	_	_
17	displacement	displacement	NN	_	15	ppmod	_	_
18	of	of	IN	_	23	case	_	_
19	more	more	RBR	_	22	adv	_	_
20	highly	highly	RB	_	22	adv	_	_
21	protein	protein	NN	_	22	advnp	_	_
22	bound	bound	JJ	_	23	attr	_	_
23	drugs	drug	NNS	_	17	ppmod	_	_
24	from	from	IN	_	26	case	_	_
25	plasma	plasma	NN	_	26	com	_	_
26	proteins	protein	NNS	_	17	ppmod	_	_
27	are	be	VBP	_	29	aux	_	_
28	not	not	RB	_	29	neg	_	_
29	expected	expect	VBN	_	0	root	_	_
30	.	.	.	_	29	p	_	_

1	No	no	DT	_	5	det	_	_
2	formal	formal	JJ	_	5	attr	_	_
3	drug	drug	NN	_	5	com	_	_
4	interaction	interaction	NN	_	5	com	_	_
5	studies	study	NNS	_	8	dep	_	_
6	have	have	VBP	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	conducted	conduct	VBN	_	0	root	_	_
9	with	with	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	8	p	_	_

1	Until	until	IN	_	5	mark	_	_
2	specific	specific	JJ	_	4	attr	_	_
3	compatibility	compatibility	NN	_	4	com	_	_
4	data	datum	NNS	_	5	dep	_	_
5	are	be	VBP	_	11	advcl	_	_
6	available	available	JJ	_	5	dep	_	_
7	,	,	,	_	11	p	_	_
8	it	it	PRP	_	11	dep	_	_
9	is	be	VBZ	_	11	aux	_	_
10	not	not	RB	_	11	neg	_	_
11	recommended	recommend	VBN	_	0	root	_	_
12	that	that	IN	_	15	mark	_	_
13	drug1	drug0	NN	_	15	dep	_	_
14	be	be	VB	_	15	aux	_	_
15	mixed	mix	VBN	_	11	comp	_	_
16	with	with	IN	_	18	case	_	_
17	other	other	JJ	_	18	attr	_	_
18	drugs	drug	NNS	_	15	ppmod	_	_
19	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	interact	interact	VB	_	0	root	_	_
4	with	with	IN	_	5	case	_	_
5	drugs	drug	NNS	_	3	ppmod	_	_
6	known	know	VBN	_	5	acl	_	_
7	to	to	TO	_	8	aux	_	_
8	interact	interact	VB	_	6	comp	_	_
9	with	with	IN	_	12	case	_	_
10	the	the	DT	_	12	det	_	_
11	conventional	conventional	JJ	_	12	attr	_	_
12	formulation	formulation	NN	_	8	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	3	p	_	_

1	May	may	MD	_	2	modal	_	_
2	interact	interact	VB	_	0	root	_	_
3	with	with	IN	_	4	case	_	_
4	wthionamide	wthionamide	NN	_	2	ppmod	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	drug1	drug0	NN	_	4	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	and	and	CC	_	4	cc	_	_
9	drug2	drug0	NN	_	4	conj	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	drug3	drug0	NN	_	9	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	increase	increase	VB	_	0	root	_	_
4	sensitivity	sensitivity	NN	_	3	obj	_	_
5	to	to	TO	_	7	aux	_	_
6	oral	oral	JJ	_	7	attr	_	_
7	anticoagulahts	anticoagulahts	NNS	_	4	ppmod	_	_
8	.	.	.	_	3	p	_	_

1	Dosage	dosage	NN	_	6	dep	_	_
2	of	of	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	drug1	drug0	NN	_	1	ppmod	_	_
5	may	may	MD	_	6	modal	_	_
6	require	require	VB	_	0	root	_	_
7	reduction	reduction	NN	_	6	obj	_	_
8	in	in	IN	_	11	mark	_	_
9	order	order	NN	_	11	dep	_	_
10	to	to	TO	_	11	aux	_	_
11	maintain	maintain	VB	_	6	comp	_	_
12	satisfactory	satisfactory	JJ	_	14	attr	_	_
13	therapeutic	therapeutic	JJ	_	14	attr	_	_
14	hypoprothrombinemia	hypoprothrombinemia	NN	_	11	obj	_	_
15	.	.	.	_	6	p	_	_

1	Concurrent	concurrent	JJ	_	2	attr	_	_
2	administration	administration	NN	_	8	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	may	may	MD	_	8	modal	_	_
8	result	result	VB	_	0	root	_	_
9	in	in	IN	_	12	case	_	_
10	elevated	elevated	JJ	_	12	attr	_	_
11	serum	serum	NN	_	12	com	_	_
12	levels	level	NNS	_	8	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug3	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	8	p	_	_

1	In	in	IN	_	3	case	_	_
2	diabetic	diabetic	JJ	_	3	attr	_	_
3	patients	patient	NNS	_	11	ppmod	_	_
4	,	,	,	_	11	p	_	_
5	the	the	DT	_	7	det	_	_
6	metabolic	metabolic	JJ	_	7	attr	_	_
7	effects	effect	NNS	_	11	dep	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	may	may	MD	_	11	modal	_	_
11	decrease	decrease	VB	_	0	root	_	_
12	blood	blood	NN	_	13	com	_	_
13	glucose	glucose	NN	_	11	obj	_	_
14	and	and	CC	_	11	cc	_	_
15	therefore	therefore	RB	_	11	adv	_	_
16	,	,	,	_	11	p	_	_
17	drug2	drug0	NN	_	18	com	_	_
18	requirements	requirement	NNS	_	11	conj	_	_
19	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	shown	show	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	have	have	VBP	_	4	comp	_	_
7	neuromuscular	neuromuscular	JJ	_	9	attr	_	_
8	blocking	blocking	NN	_	9	com	_	_
9	properties	property	NNS	_	6	obj	_	_
10	that	that	WDT	_	12	dep	_	_
11	may	may	MD	_	12	modal	_	_
12	enhance	enhance	VB	_	9	relcl	_	_
13	the	the	DT	_	14	det	_	_
14	action	action	NN	_	12	obj	_	_
15	of	of	IN	_	17	case	_	_
16	other	other	JJ	_	17	attr	_	_
17	drug2	drug0	NN	_	14	ppmod	_	_
18	.	.	.	_	4	p	_	_

1	Therefore	therefore	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	it	it	PRP	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	used	use	VBN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	caution	caution	NN	_	6	ppmod	_	_
9	in	in	IN	_	10	case	_	_
10	patients	patient	NNS	_	6	ppmod	_	_
11	receiving	receive	VBG	_	10	acl	_	_
12	such	such	JJ	_	13	attr	_	_
13	agents	agent	NNS	_	11	obj	_	_
14	.	.	.	_	6	p	_	_

1	Antagonism	antagonism	NN	_	10	dep	_	_
2	between	between	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	in	in	FW	_	7	adv	_	_
7	vitro	vitro	FW	_	1	adv	_	_
8	has	have	VBZ	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	demonstrated	demonstrate	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	Because	because	IN	_	5	case	_	_
2	of	of	IN	_	5	case	_	_
3	possible	possible	JJ	_	5	attr	_	_
4	clinical	clinical	JJ	_	5	attr	_	_
5	significance	significance	NN	_	13	ppmod	_	_
6	,	,	,	_	13	p	_	_
7	the	the	DT	_	9	det	_	_
8	two	#crd#	CD	_	9	num	_	_
9	drugs	drug	NNS	_	13	dep	_	_
10	should	should	MD	_	13	modal	_	_
11	not	not	RB	_	13	neg	_	_
12	be	be	VB	_	13	aux	_	_
13	administered	administer	VBN	_	0	root	_	_
14	concurrently	concurrently	RB	_	13	adv	_	_
15	.	.	.	_	13	p	_	_

1	The	the	DT	_	2	det	_	_
2	drug1	drug0	NN	_	7	dep	_	_
3	,	,	,	_	2	p	_	_
4	including	include	VBG	_	5	adv	_	_
5	drug2	drug0	NN	_	2	ppmod	_	_
6	,	,	,	_	2	p	_	_
7	produce	produce	VBP	_	0	root	_	_
8	additive	additive	JJ	_	11	attr	_	_
9	CNS	cns	NN	_	11	com	_	_
10	depressant	depressant	NN	_	11	com	_	_
11	effects	effect	NNS	_	7	obj	_	_
12	when	when	WRB	_	13	adv	_	_
13	co-administered	co-administered	VBN	_	7	comp	_	_
14	with	with	IN	_	16	case	_	_
15	other	other	JJ	_	16	attr	_	_
16	drug3	drug0	NN	_	13	ppmod	_	_
17	,	,	,	_	16	p	_	_
18	drug4	drug0	NN	_	16	conj	_	_
19	,	,	,	_	18	p	_	_
20	drug5	drug0	NN	_	16	conj	_	_
21	,	,	,	_	20	p	_	_
22	drug6	drug0	NN	_	16	conj	_	_
23	,	,	,	_	22	p	_	_
24	and	and	CC	_	22	cc	_	_
25	other	other	JJ	_	26	attr	_	_
26	drugs	drug	NNS	_	16	conj	_	_
27	which	which	WDT	_	29	dep	_	_
28	themselves	themselves	PRP	_	29	dep	_	_
29	produce	produce	VBP	_	16	relcl	_	_
30	CNS	cns	NN	_	31	com	_	_
31	depression	depression	NN	_	29	obj	_	_
32	.	.	.	_	7	p	_	_

1	The	the	DT	_	5	det	_	_
2	steady	steady	JJ	_	5	attr	_	_
3	state	state	NN	_	5	com	_	_
4	plasma	plasma	NN	_	5	com	_	_
5	concentrations	concentration	NNS	_	12	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	have	have	VBP	_	12	aux	_	_
11	been	be	VBN	_	12	aux	_	_
12	reported	report	VBN	_	0	root	_	_
13	to	to	TO	_	15	aux	_	_
14	be	be	VB	_	15	aux	_	_
15	increased	increase	VBN	_	12	comp	_	_
16	an	an	DT	_	17	det	_	_
17	average	average	NN	_	15	obj	_	_
18	of	of	IN	_	19	case	_	_
19	31	0	CD	_	17	ppmod	_	_
20	%	%	NN	_	19	meta	_	_
21	and	and	CC	_	19	cc	_	_
22	20	0	CD	_	19	conj	_	_
23	%	%	NN	_	22	meta	_	_
24	,	,	,	_	22	p	_	_
25	respectively	respectively	RB	_	19	conj	_	_
26	,	,	,	_	15	p	_	_
27	by	by	IN	_	30	case	_	_
28	the	the	DT	_	30	det	_	_
29	concomitant	concomitant	JJ	_	30	attr	_	_
30	administration	administration	NN	_	15	ppmod	_	_
31	of	of	IN	_	33	case	_	_
32	drug3	drug0	NN	_	33	com	_	_
33	tablets	tablet	NNS	_	30	ppmod	_	_
34	in	in	IN	_	35	case	_	_
35	doses	dose	NNS	_	33	ppmod	_	_
36	up	up	RB	_	38	adv	_	_
37	to	to	TO	_	38	attr	_	_
38	4	0	CD	_	39	num	_	_
39	mg/day	mg/day	NN	_	35	attr	_	_
40	.	.	.	_	12	p	_	_

1	The	the	DT	_	3	det	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	significance	significance	NN	_	7	dep	_	_
4	of	of	IN	_	6	case	_	_
5	these	these	DT	_	6	det	_	_
6	changes	change	NNS	_	3	ppmod	_	_
7	is	be	VBZ	_	0	root	_	_
8	unknown	unknown	JJ	_	7	dep	_	_
9	.	.	.	_	7	p	_	_

1	Drugs	drug	NNS	_	0	root	_	_
2	That	that	WDT	_	3	dep	_	_
3	Inhibit	inhibit	VBP	_	1	relcl	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	Metabolism	metabolism	NN	_	3	obj	_	_
6	Via	via	IN	_	9	case	_	_
7	Cytochrome	cytochrome	NN	_	9	com	_	_
8	P450	p0	NN	_	9	com	_	_
9	3A	0a	NN	_	3	ppmod	_	_
10	:	:	:	_	1	p	_	_
11	The	the	DT	_	13	det	_	_
12	initial	initial	JJ	_	13	attr	_	_
13	step	step	NN	_	17	dep	_	_
14	in	in	IN	_	16	case	_	_
15	drug2	drug0	NN	_	16	com	_	_
16	metabolism	metabolism	NN	_	13	ppmod	_	_
17	is	be	VBZ	_	1	acl	_	_
18	hydroxylation	hydroxylation	NN	_	17	obj	_	_
19	catalyzed	catalyze	VBN	_	18	acl	_	_
20	by	by	IN	_	22	case	_	_
21	cytochrome	cytochrome	NN	_	22	com	_	_
22	P450	p0	NN	_	19	ppmod	_	_
23	3A	0a	NN	_	22	attr	_	_
24	(	-lrb-	-LRB-	_	26	p	_	_
25	CYP	cyp	NN	_	26	com	_	_
26	3A	0a	NN	_	23	prn	_	_
27	)	-rrb-	-RRB-	_	26	p	_	_
28	.	.	.	_	1	p	_	_

1	Drugs	drug	NNS	_	8	dep	_	_
2	which	which	WDT	_	3	dep	_	_
3	inhibit	inhibit	VBP	_	1	relcl	_	_
4	this	this	DT	_	6	det	_	_
5	metabolic	metabolic	JJ	_	6	attr	_	_
6	pathway	pathway	NN	_	3	obj	_	_
7	may	may	MD	_	8	modal	_	_
8	have	have	VB	_	0	root	_	_
9	a	a	DT	_	11	det	_	_
10	profound	profound	JJ	_	11	attr	_	_
11	effect	effect	NN	_	8	obj	_	_
12	on	on	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	clearance	clearance	NN	_	8	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	.	.	.	_	8	p	_	_

1	Drugs	drug	NNS	_	2	dep	_	_
2	Demonstrated	demonstrate	VBD	_	35	advcl	_	_
3	to	to	TO	_	4	aux	_	_
4	be	be	VB	_	2	comp	_	_
5	CYP	cyp	NN	_	7	com	_	_
6	3A	0a	NN	_	7	com	_	_
7	Inhibitors	inhibitor	NNS	_	4	obj	_	_
8	of	of	IN	_	11	case	_	_
9	Possible	possible	JJ	_	11	attr	_	_
10	Clinical	clinical	JJ	_	11	attr	_	_
11	Significance	significance	NN	_	7	ppmod	_	_
12	on	on	IN	_	17	case	_	_
13	the	the	DT	_	17	det	_	_
14	Basis	basis	NN	_	17	advnp	_	_
15	of	of	IN	_	17	case	_	_
16	Clinical	clinical	JJ	_	17	attr	_	_
17	Studies	study	NNS	_	4	ppmod	_	_
18	Involving	involve	VBG	_	17	acl	_	_
19	drug1	drug0	NN	_	18	obj	_	_
20	(	-lrb-	-LRB-	_	21	p	_	_
21	caution	caution	NN	_	19	prn	_	_
22	is	be	VBZ	_	23	aux	_	_
23	recommended	recommend	VBN	_	21	acl	_	_
24	during	during	IN	_	25	case	_	_
25	coadministration	coadministration	NN	_	23	ppmod	_	_
26	with	with	IN	_	27	case	_	_
27	drug2	drug0	NNS	_	25	ppmod	_	_
28	)	-rrb-	-RRB-	_	21	p	_	_
29	:	:	:	_	35	p	_	_
30	Coadministration	coadministration	NN	_	35	dep	_	_
31	of	of	IN	_	32	case	_	_
32	drug3	drug0	NN	_	30	ppmod	_	_
33	with	with	IN	_	34	case	_	_
34	drug4	drug0	NN	_	30	ppmod	_	_
35	increased	increase	VBD	_	0	root	_	_
36	the	the	DT	_	39	det	_	_
37	maximum	maximum	JJ	_	39	attr	_	_
38	plasma	plasma	NN	_	39	com	_	_
39	concentration	concentration	NN	_	35	obj	_	_
40	of	of	IN	_	41	case	_	_
41	drug5	drug0	NN	_	39	ppmod	_	_
42	by	by	IN	_	43	case	_	_
43	46	0	CD	_	35	ppmod	_	_
44	%	%	NN	_	43	meta	_	_
45	,	,	,	_	35	p	_	_
46	decreased	decrease	VBD	_	35	conj	_	_
47	clearance	clearance	NN	_	46	obj	_	_
48	by	by	IN	_	49	case	_	_
49	21	0	CD	_	46	ppmod	_	_
50	%	%	NN	_	49	meta	_	_
51	,	,	,	_	46	p	_	_
52	increased	increase	VBD	_	35	conj	_	_
53	half-life	half-life	NN	_	52	obj	_	_
54	by	by	IN	_	55	case	_	_
55	17	0	CD	_	52	ppmod	_	_
56	%	%	NN	_	55	meta	_	_
57	,	,	,	_	52	p	_	_
58	and	and	CC	_	52	cc	_	_
59	decreased	decrease	VBD	_	35	conj	_	_
60	measured	measure	VBN	_	62	attr	_	_
61	psychomotor	psychomotor	NN	_	62	com	_	_
62	performance	performance	NN	_	59	obj	_	_
63	.	.	.	_	35	p	_	_

1	Coadministration	coadministration	NN	_	4	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	decreased	decrease	VBD	_	0	root	_	_
5	the	the	DT	_	8	det	_	_
6	maximum	maximum	JJ	_	8	attr	_	_
7	plasma	plasma	NN	_	8	com	_	_
8	concentration	concentration	NN	_	4	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	by	by	IN	_	12	case	_	_
12	6	0	CD	_	4	ppmod	_	_
13	%	%	NN	_	12	meta	_	_
14	,	,	,	_	4	p	_	_
15	decreased	decrease	VBD	_	4	conj	_	_
16	clearance	clearance	NN	_	15	obj	_	_
17	by	by	IN	_	18	case	_	_
18	38	0	CD	_	15	ppmod	_	_
19	%	%	NN	_	18	meta	_	_
20	,	,	,	_	15	p	_	_
21	and	and	CC	_	15	cc	_	_
22	increased	increase	VBD	_	4	conj	_	_
23	half-life	half-life	NN	_	22	obj	_	_
24	by	by	IN	_	25	case	_	_
25	58	0	CD	_	22	ppmod	_	_
26	%	%	NN	_	25	meta	_	_
27	.	.	.	_	4	p	_	_

1	Coadministration	coadministration	NN	_	5	dep	_	_
2	of	of	IN	_	4	case	_	_
3	oral	oral	JJ	_	4	attr	_	_
4	drug1	drug0	NN	_	1	ppmod	_	_
5	increased	increase	VBD	_	0	root	_	_
6	the	the	DT	_	9	det	_	_
7	maximum	maximum	JJ	_	9	attr	_	_
8	plasma	plasma	NN	_	9	com	_	_
9	concentration	concentration	NN	_	5	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	by	by	IN	_	13	case	_	_
13	18	0	CD	_	5	ppmod	_	_
14	%	%	NN	_	13	meta	_	_
15	,	,	,	_	5	p	_	_
16	decreased	decrease	VBD	_	5	conj	_	_
17	clearance	clearance	NN	_	16	obj	_	_
18	by	by	IN	_	19	case	_	_
19	22	0	CD	_	16	ppmod	_	_
20	%	%	NN	_	19	meta	_	_
21	,	,	,	_	16	p	_	_
22	and	and	CC	_	16	cc	_	_
23	increased	increase	VBD	_	5	conj	_	_
24	half-life	half-life	NN	_	23	obj	_	_
25	by	by	IN	_	26	case	_	_
26	29	0	CD	_	23	ppmod	_	_
27	%	%	NN	_	26	meta	_	_
28	.	.	.	_	5	p	_	_

1	Drugs	drug	NNS	_	5	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	other	other	JJ	_	4	attr	_	_
4	substances	substance	NNS	_	1	conj	_	_
5	demonstrated	demonstrate	VBD	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	be	be	VB	_	5	comp	_	_
8	CYP	cyp	NN	_	10	com	_	_
9	3A	0a	NN	_	10	com	_	_
10	inhibitors	inhibitor	NNS	_	7	obj	_	_
11	on	on	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	basis	basis	NN	_	10	ppmod	_	_
14	of	of	IN	_	16	case	_	_
15	clinical	clinical	JJ	_	16	attr	_	_
16	studies	study	NNS	_	13	ppmod	_	_
17	involving	involve	VBG	_	16	acl	_	_
18	drug1	drug0	NN	_	17	obj	_	_
19	metabolized	metabolize	VBN	_	18	acl	_	_
20	similarly	similarly	RB	_	22	adv	_	_
21	to	to	TO	_	22	aux	_	_
22	drug2	drug0	NN	_	19	ppmod	_	_
23	or	or	CC	_	13	cc	_	_
24	on	on	IN	_	26	case	_	_
25	the	the	DT	_	26	det	_	_
26	basis	basis	NN	_	13	conj	_	_
27	of	of	IN	_	30	case	_	_
28	in	in	FW	_	29	adv	_	_
29	vitro	vitro	FW	_	30	attr	_	_
30	studies	study	NNS	_	26	ppmod	_	_
31	with	with	IN	_	32	case	_	_
32	drug3	drug0	NN	_	30	ppmod	_	_
33	or	or	CC	_	32	cc	_	_
34	other	other	JJ	_	35	attr	_	_
35	drug4	drug0	NN	_	32	conj	_	_
36	(	-lrb-	-LRB-	_	39	p	_	_
37	caution	caution	NN	_	39	dep	_	_
38	is	be	VBZ	_	39	aux	_	_
39	recommended	recommend	VBN	_	35	prn	_	_
40	during	during	IN	_	41	case	_	_
41	coadministration	coadministration	NN	_	39	ppmod	_	_
42	with	with	IN	_	43	case	_	_
43	drug5	drug0	NN	_	41	ppmod	_	_
44	)	-rrb-	-RRB-	_	43	p	_	_
45	:	:	:	_	43	p	_	_
46	Available	available	JJ	_	47	attr	_	_
47	data	datum	NNS	_	56	dep	_	_
48	from	from	IN	_	50	case	_	_
49	clinical	clinical	JJ	_	50	attr	_	_
50	studies	study	NNS	_	47	ppmod	_	_
51	of	of	IN	_	52	case	_	_
52	drug6	drug0	NN	_	50	ppmod	_	_
53	other	other	JJ	_	54	com	_	_
54	than	than	IN	_	52	cc	_	_
55	drug7	drug0	NN	_	52	conj	_	_
56	suggest	suggest	VBP	_	43	acl	_	_
57	a	a	DT	_	60	det	_	_
58	possible	possible	JJ	_	60	attr	_	_
59	drug	drug	NN	_	60	com	_	_
60	interaction	interaction	NN	_	56	obj	_	_
61	with	with	IN	_	62	case	_	_
62	drug8	drug0	NN	_	60	ppmod	_	_
63	for	for	IN	_	65	case	_	_
64	the	the	DT	_	65	det	_	_
65	following	following	NN	_	60	ppmod	_	_
66	:	:	:	_	65	p	_	_
67	drug9	drug0	NN	_	65	conj	_	_
68	,	,	,	_	67	p	_	_
69	drug10	drug0	NN	_	65	conj	_	_
70	,	,	,	_	69	p	_	_
71	drug11	drug0	NN	_	65	conj	_	_
72	such	such	JJ	_	74	adv	_	_
73	as	as	IN	_	74	case	_	_
74	drug12	drug0	NN	_	71	ppmod	_	_
75	and	and	CC	_	74	cc	_	_
76	drug13	drug0	NN	_	74	conj	_	_
77	,	,	,	_	71	p	_	_
78	and	and	CC	_	71	cc	_	_
79	grapefruit	grapefruit	NN	_	80	com	_	_
80	juice	juice	NN	_	65	conj	_	_
81	.	.	.	_	5	p	_	_

1	Data	datum	NNS	_	8	dep	_	_
2	from	from	IN	_	5	case	_	_
3	in	in	FW	_	4	adv	_	_
4	vitro	vitro	FW	_	5	attr	_	_
5	studies	study	NNS	_	1	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	suggest	suggest	VBP	_	0	root	_	_
9	a	a	DT	_	12	det	_	_
10	possible	possible	JJ	_	12	attr	_	_
11	drug	drug	NN	_	12	com	_	_
12	interaction	interaction	NN	_	8	obj	_	_
13	with	with	IN	_	14	case	_	_
14	drug2	drug0	NNS	_	12	ppmod	_	_
15	for	for	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	following	following	NN	_	14	ppmod	_	_
18	:	:	:	_	14	p	_	_
19	drug3	drug0	NN	_	14	appo	_	_
20	and	and	CC	_	19	cc	_	_
21	drug4	drug0	NN	_	19	conj	_	_
22	.	.	.	_	8	p	_	_

1	Data	datum	NNS	_	11	dep	_	_
2	from	from	IN	_	5	case	_	_
3	in	in	FW	_	4	adv	_	_
4	vitro	vitro	FW	_	5	attr	_	_
5	studies	study	NNS	_	1	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	other	other	JJ	_	9	com	_	_
9	than	than	IN	_	7	cc	_	_
10	drug2	drug0	NN	_	7	conj	_	_
11	suggest	suggest	VBP	_	0	root	_	_
12	a	a	DT	_	15	det	_	_
13	possible	possible	JJ	_	15	attr	_	_
14	drug	drug	NN	_	15	com	_	_
15	interaction	interaction	NN	_	11	obj	_	_
16	for	for	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	following	following	NN	_	15	ppmod	_	_
19	:	:	:	_	18	p	_	_
20	drug3	drug0	NN	_	18	conj	_	_
21	,	,	,	_	20	p	_	_
22	drug4	drug0	NN	_	18	conj	_	_
23	,	,	,	_	22	p	_	_
24	drug5	drug0	NN	_	18	conj	_	_
25	,	,	,	_	24	p	_	_
26	drug6	drug0	NN	_	18	conj	_	_
27	,	,	,	_	26	p	_	_
28	and	and	CC	_	26	cc	_	_
29	drug7	drug0	NN	_	18	conj	_	_
30	.	.	.	_	11	p	_	_

1	Caution	caution	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	recommended	recommend	VBN	_	0	root	_	_
4	during	during	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	coadministration	coadministration	NN	_	3	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	any	any	DT	_	6	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	these	these	DT	_	8	ppmod	_	_
11	with	with	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	3	p	_	_

1	Oral	oral	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	In	in	IN	_	7	case	_	_
5	some	some	DT	_	7	det	_	_
6	normal	normal	JJ	_	7	attr	_	_
7	volunteers	volunteer	NNS	_	21	ppmod	_	_
8	,	,	,	_	21	p	_	_
9	the	the	DT	_	11	det	_	_
10	concomitant	concomitant	JJ	_	11	attr	_	_
11	administration	administration	NN	_	21	dep	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	drug3	drug0	NN	_	13	conj	_	_
16	,	,	,	_	15	p	_	_
17	drug4	drug0	NN	_	13	conj	_	_
18	,	,	,	_	17	p	_	_
19	or	or	CC	_	17	cc	_	_
20	drug5	drug0	NN	_	13	conj	_	_
21	resulted	result	VBD	_	2	acl	_	_
22	in	in	IN	_	23	case	_	_
23	prolongation	prolongation	NN	_	21	ppmod	_	_
24	of	of	IN	_	26	case	_	_
25	prothrombin	prothrombin	NN	_	26	com	_	_
26	time	time	NN	_	23	ppmod	_	_
27	.	.	.	_	2	p	_	_

1	This	this	DT	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	occur	occur	VB	_	0	root	_	_
4	because	because	IN	_	7	mark	_	_
5	drug1	drug0	NN	_	7	dep	_	_
6	competitively	competitively	RB	_	7	adv	_	_
7	displaces	displace	VBZ	_	3	comp	_	_
8	drug2	drug0	NN	_	7	obj	_	_
9	from	from	IN	_	12	case	_	_
10	protein	protein	NN	_	12	com	_	_
11	binding	binding	NN	_	12	com	_	_
12	sites	site	NNS	_	7	ppmod	_	_
13	.	.	.	_	3	p	_	_

1	Accordingly	accordingly	RB	_	17	adv	_	_
2	,	,	,	_	17	p	_	_
3	when	when	WRB	_	6	adv	_	_
4	drug1	drug0	NN	_	6	dep	_	_
5	is	be	VBZ	_	6	aux	_	_
6	administered	administer	VBN	_	17	advcl	_	_
7	with	with	IN	_	9	case	_	_
8	oral	oral	JJ	_	9	attr	_	_
9	drug2	drug0	NN	_	6	ppmod	_	_
10	,	,	,	_	17	p	_	_
11	the	the	DT	_	13	det	_	_
12	prothrombin	prothrombin	NN	_	13	com	_	_
13	time	time	NN	_	17	dep	_	_
14	should	should	MD	_	17	modal	_	_
15	be	be	VB	_	17	aux	_	_
16	closely	closely	RB	_	17	adv	_	_
17	monitored	monitor	VBN	_	0	root	_	_
18	during	during	IN	_	17	ppmod	_	_
19	and	and	CC	_	18	cc	_	_
20	for	for	IN	_	22	case	_	_
21	several	several	JJ	_	22	attr	_	_
22	days	day	NNS	_	18	conj	_	_
23	after	after	IN	_	26	case	_	_
24	concomitant	concomitant	JJ	_	26	attr	_	_
25	drug	drug	NN	_	26	com	_	_
26	administration	administration	NN	_	22	ppmod	_	_
27	.	.	.	_	17	p	_	_

1	Adjustment	adjustment	NN	_	9	dep	_	_
2	of	of	IN	_	3	case	_	_
3	dosage	dosage	NN	_	1	ppmod	_	_
4	of	of	IN	_	6	case	_	_
5	oral	oral	JJ	_	6	attr	_	_
6	drug1	drug0	NN	_	3	ppmod	_	_
7	may	may	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	required	require	VBN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	5	case	_	_
4	diabetic	diabetic	JJ	_	5	attr	_	_
5	patients	patient	NNS	_	15	ppmod	_	_
6	receiving	receive	VBG	_	5	acl	_	_
7	drug2	drug0	NN	_	6	obj	_	_
8	and	and	CC	_	7	cc	_	_
9	drug3	drug0	NN	_	7	conj	_	_
10	,	,	,	_	15	p	_	_
11	no	no	DT	_	13	det	_	_
12	significant	significant	JJ	_	13	attr	_	_
13	effects	effect	NNS	_	15	dep	_	_
14	were	be	VBD	_	15	aux	_	_
15	seen	see	VBN	_	1	acl	_	_
16	on	on	IN	_	19	case	_	_
17	drug4	drug0	NN	_	19	com	_	_
18	plasma	plasma	NN	_	19	com	_	_
19	levels	level	NNS	_	15	ppmod	_	_
20	or	or	CC	_	19	cc	_	_
21	fasting	fasting	JJ	_	23	attr	_	_
22	blood	blood	NN	_	23	com	_	_
23	glucose	glucose	NN	_	19	conj	_	_
24	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	13	dep	_	_
2	:	:	:	_	13	p	_	_
3	In	in	IN	_	5	case	_	_
4	normal	normal	JJ	_	5	attr	_	_
5	volunteers	volunteer	NNS	_	13	ppmod	_	_
6	,	,	,	_	13	p	_	_
7	concomitant	concomitant	JJ	_	8	attr	_	_
8	administration	administration	NN	_	13	dep	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug3	drug0	NN	_	10	conj	_	_
13	resulted	result	VBD	_	0	root	_	_
14	in	in	IN	_	18	case	_	_
15	significantly	significantly	RB	_	16	adv	_	_
16	increased	increase	VBN	_	18	attr	_	_
17	plasma	plasma	NN	_	18	com	_	_
18	levels	level	NNS	_	13	ppmod	_	_
19	of	of	IN	_	20	case	_	_
20	drug4	drug0	NN	_	18	ppmod	_	_
21	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	decreased	decrease	VBD	_	0	root	_	_
3	the	the	DT	_	5	det	_	_
4	hyperuricemic	hyperuricemic	JJ	_	5	attr	_	_
5	effect	effect	NN	_	2	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	14	dep	_	_
2	:	:	:	_	14	p	_	_
3	In	in	IN	_	5	case	_	_
4	normal	normal	JJ	_	5	attr	_	_
5	volunteers	volunteer	NNS	_	14	ppmod	_	_
6	,	,	,	_	14	p	_	_
7	the	the	DT	_	9	det	_	_
8	concomitant	concomitant	JJ	_	9	attr	_	_
9	administration	administration	NN	_	14	dep	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	drug3	drug0	NN	_	11	conj	_	_
14	had	have	VBD	_	0	root	_	_
15	no	no	DT	_	16	det	_	_
16	effect	effect	NN	_	14	obj	_	_
17	on	on	IN	_	20	case	_	_
18	the	the	DT	_	20	det	_	_
19	diuretic	diuretic	JJ	_	20	attr	_	_
20	activity	activity	NN	_	14	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	drug4	drug0	NN	_	20	ppmod	_	_
23	.	.	.	_	14	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	decreased	decrease	VBD	_	0	root	_	_
3	the	the	DT	_	5	det	_	_
4	hyperuricemic	hyperuricemic	JJ	_	5	attr	_	_
5	effect	effect	NN	_	2	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	8	dep	_	_
2	:	:	:	_	1	p	_	_
3	Concomitant	concomitant	JJ	_	4	attr	_	_
4	administration	administration	NN	_	1	appo	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	may	may	MD	_	8	modal	_	_
8	reduce	reduce	VB	_	0	root	_	_
9	plasma	plasma	NN	_	10	com	_	_
10	levels	level	NNS	_	8	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	8	p	_	_

1	This	this	DT	_	2	det	_	_
2	effect	effect	NN	_	3	dep	_	_
3	is	be	VBZ	_	0	root	_	_
4	small	small	JJ	_	3	dep	_	_
5	with	with	IN	_	7	case	_	_
6	occasional	occasional	JJ	_	7	attr	_	_
7	doses	dose	NNS	_	4	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	3	p	_	_
11	but	but	CC	_	3	cc	_	_
12	may	may	MD	_	13	modal	_	_
13	be	be	VB	_	3	conj	_	_
14	clinically	clinically	RB	_	15	adv	_	_
15	significant	significant	JJ	_	13	dep	_	_
16	when	when	WRB	_	19	adv	_	_
17	drug2	drug0	NN	_	19	dep	_	_
18	are	be	VBP	_	19	aux	_	_
19	used	use	VBN	_	15	comp	_	_
20	on	on	IN	_	23	case	_	_
21	a	a	DT	_	23	det	_	_
22	continuous	continuous	JJ	_	23	attr	_	_
23	schedule	schedule	NN	_	19	ppmod	_	_
24	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	13	dep	_	_
2	:	:	:	_	13	p	_	_
3	In	in	IN	_	5	case	_	_
4	normal	normal	JJ	_	5	attr	_	_
5	volunteers	volunteer	NNS	_	13	ppmod	_	_
6	,	,	,	_	13	p	_	_
7	concomitant	concomitant	JJ	_	8	attr	_	_
8	administration	administration	NN	_	13	dep	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug3	drug0	NN	_	10	conj	_	_
13	resulted	result	VBD	_	0	root	_	_
14	in	in	IN	_	19	case	_	_
15	an	an	DT	_	19	det	_	_
16	approximate	approximate	JJ	_	19	attr	_	_
17	50	0	CD	_	19	num	_	_
18	%	%	NN	_	17	meta	_	_
19	increase	increase	NN	_	13	ppmod	_	_
20	in	in	IN	_	22	case	_	_
21	plasma	plasma	NN	_	22	com	_	_
22	levels	level	NNS	_	19	ppmod	_	_
23	of	of	IN	_	24	case	_	_
24	drug4	drug0	NN	_	22	ppmod	_	_
25	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	had	have	VBD	_	0	root	_	_
3	no	no	DT	_	4	det	_	_
4	effect	effect	NN	_	2	obj	_	_
5	on	on	IN	_	7	case	_	_
6	plasma	plasma	NN	_	7	com	_	_
7	levels	level	NNS	_	2	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	.	.	.	_	2	p	_	_

1	Since	since	IN	_	8	mark	_	_
2	drug1	drug0	NN	_	8	dep	_	_
3	in	in	IN	_	5	case	_	_
4	high	high	JJ	_	5	attr	_	_
5	doses	dose	NNS	_	2	ppmod	_	_
6	has	have	VBZ	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	associated	associate	VBN	_	20	advcl	_	_
9	with	with	IN	_	10	case	_	_
10	hepatotoxicity	hepatotoxicity	NN	_	8	ppmod	_	_
11	,	,	,	_	20	p	_	_
12	concomitant	concomitant	JJ	_	13	attr	_	_
13	administration	administration	NN	_	20	dep	_	_
14	of	of	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	drug3	drug0	NN	_	15	conj	_	_
18	should	should	MD	_	20	modal	_	_
19	be	be	VB	_	20	aux	_	_
20	used	use	VBN	_	0	root	_	_
21	cautiously	cautiously	RB	_	20	adv	_	_
22	,	,	,	_	20	p	_	_
23	with	with	IN	_	25	case	_	_
24	careful	careful	JJ	_	25	attr	_	_
25	monitoring	monitoring	NN	_	20	ppmod	_	_
26	of	of	IN	_	27	case	_	_
27	patients	patient	NNS	_	25	ppmod	_	_
28	.	.	.	_	20	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	administration	administration	NN	_	37	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	in	in	IN	_	8	case	_	_
8	dogs	dog	NNS	_	2	ppmod	_	_
9	,	,	,	_	8	p	_	_
10	but	but	CC	_	8	cc	_	_
11	not	not	RB	_	13	neg	_	_
12	in	in	IN	_	13	case	_	_
13	rats	rat	NNS	_	8	conj	_	_
14	,	,	,	_	13	p	_	_
15	at	at	IN	_	24	case	_	_
16	approximately	approximately	RB	_	17	adv	_	_
17	2	0	CD	_	24	num	_	_
18	times	time	NNS	_	17	attr	_	_
19	the	the	DT	_	24	det	_	_
20	recommended	recommend	VBN	_	24	attr	_	_
21	maximum	maximum	JJ	_	24	attr	_	_
22	human	human	JJ	_	24	attr	_	_
23	therapeutic	therapeutic	JJ	_	24	attr	_	_
24	dose	dose	NN	_	2	ppmod	_	_
25	of	of	IN	_	26	case	_	_
26	each	each	DT	_	24	ppmod	_	_
27	(	-lrb-	-LRB-	_	31	p	_	_
28	40	0	CD	_	31	num	_	_
29	to	to	TO	_	28	cc	_	_
30	52	0	CD	_	28	conj	_	_
31	mg/kg/day	mg/kg/day	NN	_	24	prn	_	_
32	of	of	IN	_	33	case	_	_
33	drug3	drug0	NN	_	31	ppmod	_	_
34	/	/	:	_	31	p	_	_
35	drug4	drug0	NN	_	31	appo	_	_
36	)	-rrb-	-RRB-	_	31	p	_	_
37	resulted	result	VBD	_	0	root	_	_
38	in	in	IN	_	41	case	_	_
39	greater	great	JJR	_	41	attr	_	_
40	gastrointestinal	gastrointestinal	JJ	_	41	attr	_	_
41	toxicity	toxicity	NN	_	37	ppmod	_	_
42	than	than	IN	_	47	case	_	_
43	when	when	WRB	_	47	adv	_	_
44	either	either	DT	_	45	det	_	_
45	drug	drug	NN	_	47	dep	_	_
46	was	be	VBD	_	47	aux	_	_
47	administered	administer	VBN	_	37	ppmod	_	_
48	alone	alone	RB	_	47	adv	_	_
49	.	.	.	_	37	p	_	_

1	The	the	DT	_	3	det	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	significance	significance	NN	_	10	dep	_	_
4	of	of	IN	_	6	case	_	_
5	these	these	DT	_	6	det	_	_
6	findings	finding	NNS	_	3	ppmod	_	_
7	has	have	VBZ	_	10	aux	_	_
8	not	not	RB	_	10	neg	_	_
9	been	be	VBN	_	10	aux	_	_
10	established	establish	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Caution	caution	NN	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	used	use	VBN	_	1	acl	_	_
7	if	if	IN	_	10	mark	_	_
8	drug2	drug0	NN	_	10	dep	_	_
9	is	be	VBZ	_	10	aux	_	_
10	administered	administer	VBN	_	6	comp	_	_
11	concomitantly	concomitantly	RB	_	10	adv	_	_
12	with	with	IN	_	13	case	_	_
13	drug3	drug0	NN	_	10	ppmod	_	_
14	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	have	have	VBP	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	reported	report	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	decrease	decrease	VB	_	4	comp	_	_
7	the	the	DT	_	9	det	_	_
8	tubular	tubular	JJ	_	9	attr	_	_
9	secretion	secretion	NN	_	6	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	6	cc	_	_
13	to	to	TO	_	14	aux	_	_
14	potentiate	potentiate	VB	_	6	conj	_	_
15	its	its	PRP$	_	16	poss	_	_
16	toxicity	toxicity	NN	_	14	obj	_	_
17	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Administration	administration	NN	_	11	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	concomitantly	concomitantly	RB	_	8	adv	_	_
7	with	with	IN	_	8	case	_	_
8	drug3	drug0	NN	_	3	ppmod	_	_
9	has	have	VBZ	_	11	aux	_	_
10	been	be	VBN	_	11	aux	_	_
11	associated	associate	VBN	_	1	acl	_	_
12	with	with	IN	_	14	case	_	_
13	an	an	DT	_	14	det	_	_
14	increase	increase	NN	_	11	ppmod	_	_
15	in	in	IN	_	18	case	_	_
16	drug4	drug0	NN	_	18	attr	_	_
17	-induced	-induced	JJ	_	18	attr	_	_
18	toxicity	toxicity	NN	_	14	ppmod	_	_
19	,	,	,	_	11	p	_	_
20	possibly	possibly	RB	_	24	adv	_	_
21	due	due	JJ	_	24	adv	_	_
22	to	to	TO	_	24	aux	_	_
23	decreased	decrease	VBN	_	24	attr	_	_
24	synthesis	synthesis	NN	_	11	ppmod	_	_
25	of	of	IN	_	27	case	_	_
26	renal	renal	JJ	_	27	attr	_	_
27	prostacyclin	prostacyclin	NN	_	24	ppmod	_	_
28	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	used	use	VBN	_	0	root	_	_
5	with	with	IN	_	6	case	_	_
6	caution	caution	NN	_	4	ppmod	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	4	ppmod	_	_
9	taking	take	VBG	_	8	acl	_	_
10	drug2	drug0	NN	_	9	obj	_	_
11	,	,	,	_	4	p	_	_
12	and	and	CC	_	4	cc	_	_
13	renal	renal	JJ	_	14	attr	_	_
14	function	function	NN	_	18	dep	_	_
15	should	should	MD	_	18	modal	_	_
16	be	be	VB	_	18	aux	_	_
17	carefully	carefully	RB	_	18	adv	_	_
18	monitored	monitor	VBN	_	4	conj	_	_
19	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	administration	administration	NN	_	12	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	to	to	TO	_	9	aux	_	_
8	normal	normal	JJ	_	9	attr	_	_
9	volunteers	volunteer	NNS	_	4	ppmod	_	_
10	receiving	receive	VBG	_	9	acl	_	_
11	drug3	drug0	NN	_	10	obj	_	_
12	decreased	decrease	VBD	_	1	acl	_	_
13	the	the	DT	_	15	det	_	_
14	renal	renal	JJ	_	15	attr	_	_
15	clearance	clearance	NN	_	12	obj	_	_
16	and	and	CC	_	12	cc	_	_
17	significantly	significantly	RB	_	18	adv	_	_
18	increased	increase	VBD	_	12	conj	_	_
19	the	the	DT	_	21	det	_	_
20	plasma	plasma	NN	_	21	com	_	_
21	levels	level	NNS	_	18	obj	_	_
22	of	of	IN	_	23	case	_	_
23	drug4	drug0	NN	_	21	ppmod	_	_
24	.	.	.	_	1	p	_	_

1	In	in	IN	_	3	case	_	_
2	some	some	DT	_	3	det	_	_
3	patients	patient	NNS	_	13	ppmod	_	_
4	the	the	DT	_	6	det	_	_
5	combined	combined	JJ	_	6	attr	_	_
6	use	use	NN	_	13	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	drug2	drug0	NN	_	8	conj	_	_
11	has	have	VBZ	_	13	aux	_	_
12	been	be	VBN	_	13	aux	_	_
13	associated	associate	VBN	_	0	root	_	_
14	with	with	IN	_	17	case	_	_
15	fatal	fatal	JJ	_	17	attr	_	_
16	gastrointestinal	gastrointestinal	JJ	_	17	attr	_	_
17	hemorrhage	hemorrhage	NN	_	13	ppmod	_	_
18	.	.	.	_	13	p	_	_

1	Therefore	therefore	RB	_	9	adv	_	_
2	,	,	,	_	9	p	_	_
3	drug1	drug0	NN	_	9	dep	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	should	should	MD	_	9	modal	_	_
7	not	not	RB	_	9	neg	_	_
8	be	be	VB	_	9	aux	_	_
9	used	use	VBN	_	0	root	_	_
10	concomitantly	concomitantly	RB	_	9	adv	_	_
11	.	.	.	_	9	p	_	_

1	The	the	DT	_	3	det	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	use	use	NN	_	12	dep	_	_
4	of	of	IN	_	6	case	_	_
5	drug1	drug0	JJ	_	6	attr	_	_
6	tablets	tablet	NNS	_	3	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	other	other	JJ	_	9	attr	_	_
9	drug2	drug0	NNS	_	6	conj	_	_
10	is	be	VBZ	_	12	aux	_	_
11	not	not	RB	_	12	neg	_	_
12	recommended	recommend	VBN	_	0	root	_	_
13	due	due	JJ	_	17	adv	_	_
14	to	to	TO	_	17	aux	_	_
15	the	the	DT	_	17	det	_	_
16	increased	increase	VBN	_	17	attr	_	_
17	possibility	possibility	NN	_	12	ppmod	_	_
18	of	of	IN	_	20	case	_	_
19	gastrointestinal	gastrointestinal	JJ	_	20	attr	_	_
20	toxicity	toxicity	NN	_	17	ppmod	_	_
21	,	,	,	_	12	p	_	_
22	with	with	IN	_	23	case	_	_
23	little	little	JJ	_	12	ppmod	_	_
24	or	or	CC	_	23	cc	_	_
25	no	no	DT	_	26	attr	_	_
26	increase	increase	NN	_	23	conj	_	_
27	in	in	IN	_	28	case	_	_
28	efficacy	efficacy	NN	_	26	ppmod	_	_
29	.	.	.	_	12	p	_	_

1	The	the	DT	_	3	det	_	_
2	following	follow	VBG	_	3	attr	_	_
3	information	information	NN	_	5	dep	_	_
4	was	be	VBD	_	5	aux	_	_
5	obtained	obtain	VBN	_	0	root	_	_
6	from	from	IN	_	7	case	_	_
7	studies	study	NNS	_	5	ppmod	_	_
8	in	in	IN	_	10	case	_	_
9	normal	normal	JJ	_	10	attr	_	_
10	volunteers	volunteer	NNS	_	7	ppmod	_	_
11	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	5	case	_	_
4	normal	normal	JJ	_	5	attr	_	_
5	volunteers	volunteer	NNS	_	14	ppmod	_	_
6	,	,	,	_	14	p	_	_
7	a	a	DT	_	9	det	_	_
8	small	small	JJ	_	9	attr	_	_
9	decrease	decrease	NN	_	14	dep	_	_
10	in	in	IN	_	12	case	_	_
11	drug2	drug0	NN	_	12	com	_	_
12	levels	level	NNS	_	9	ppmod	_	_
13	was	be	VBD	_	14	aux	_	_
14	observed	observe	VBN	_	1	acl	_	_
15	when	when	WRB	_	23	adv	_	_
16	multiple	multiple	JJ	_	17	attr	_	_
17	doses	dose	NNS	_	23	dep	_	_
18	of	of	IN	_	19	case	_	_
19	drug3	drug0	NN	_	17	ppmod	_	_
20	and	and	CC	_	19	cc	_	_
21	drug4	drug0	NN	_	19	conj	_	_
22	were	be	VBD	_	23	aux	_	_
23	administered	administer	VBN	_	14	comp	_	_
24	concomitantly	concomitantly	RB	_	23	adv	_	_
25	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	5	det	_	_
4	concomitant	concomitant	JJ	_	5	attr	_	_
5	administration	administration	NN	_	13	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug3	drug0	NN	_	7	conj	_	_
10	in	in	IN	_	12	case	_	_
11	normal	normal	JJ	_	12	attr	_	_
12	volunteers	volunteer	NNS	_	5	ppmod	_	_
13	resulted	result	VBD	_	1	acl	_	_
14	in	in	IN	_	15	case	_	_
15	lowering	lowering	NN	_	13	ppmod	_	_
16	of	of	IN	_	19	case	_	_
17	the	the	DT	_	19	det	_	_
18	plasma	plasma	NN	_	19	com	_	_
19	levels	level	NNS	_	15	ppmod	_	_
20	of	of	IN	_	25	case	_	_
21	the	the	DT	_	25	det	_	_
22	active	active	JJ	_	25	attr	_	_
23	sulindac	sulindac	NN	_	25	com	_	_
24	sulfide	sulfide	NN	_	25	com	_	_
25	metabolite	metabolite	NN	_	19	ppmod	_	_
26	by	by	IN	_	28	case	_	_
27	approximately	approximately	RB	_	28	adv	_	_
28	one-third	one-third	CD	_	15	ppmod	_	_
29	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	5	det	_	_
4	concomitant	concomitant	JJ	_	5	attr	_	_
5	administration	administration	NN	_	13	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug3	drug0	NN	_	7	conj	_	_
10	in	in	IN	_	12	case	_	_
11	normal	normal	JJ	_	12	attr	_	_
12	volunteers	volunteer	NNS	_	5	ppmod	_	_
13	had	have	VBD	_	1	acl	_	_
14	no	no	DT	_	15	det	_	_
15	effect	effect	NN	_	13	obj	_	_
16	on	on	IN	_	19	case	_	_
17	the	the	DT	_	19	det	_	_
18	plasma	plasma	NN	_	19	com	_	_
19	levels	level	NNS	_	13	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	drug4	drug0	NN	_	19	ppmod	_	_
22	,	,	,	_	13	p	_	_
23	but	but	CC	_	13	cc	_	_
24	significantly	significantly	RB	_	25	adv	_	_
25	decreased	decrease	VBD	_	13	conj	_	_
26	the	the	DT	_	28	det	_	_
27	urinary	urinary	JJ	_	28	attr	_	_
28	excretion	excretion	NN	_	25	obj	_	_
29	of	of	IN	_	30	case	_	_
30	drug5	drug0	NN	_	28	ppmod	_	_
31	and	and	CC	_	30	cc	_	_
32	its	its	PRP$	_	34	poss	_	_
33	glucuronide	glucuronide	JJ	_	34	attr	_	_
34	metabolite	metabolite	NN	_	30	conj	_	_
35	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	had	have	VBD	_	0	root	_	_
3	no	no	DT	_	4	det	_	_
4	effect	effect	NN	_	2	obj	_	_
5	on	on	IN	_	7	case	_	_
6	plasma	plasma	NN	_	7	com	_	_
7	levels	level	NNS	_	2	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	.	.	.	_	2	p	_	_

1	Drug	drug	NN	_	7	com	_	_
2	laboratory	laboratory	NN	_	7	com	_	_
3	Test	test	NN	_	7	com	_	_
4	Interactions	interaction	NNS	_	7	com	_	_
5	Serum	serum	NN	_	7	com	_	_
6	Salicylate	salicylate	NN	_	7	com	_	_
7	Assays	assay	NNS	_	0	root	_	_
8	:	:	:	_	7	p	_	_
9	Caution	caution	NN	_	12	dep	_	_
10	should	should	MD	_	12	modal	_	_
11	be	be	VB	_	12	aux	_	_
12	used	use	VBN	_	7	acl	_	_
13	in	in	IN	_	14	case	_	_
14	interpreting	interpret	VBG	_	12	ppmod	_	_
15	the	the	DT	_	16	det	_	_
16	results	result	NNS	_	14	obj	_	_
17	of	of	IN	_	20	case	_	_
18	serum	serum	NN	_	20	com	_	_
19	salicylate	salicylate	NN	_	20	com	_	_
20	assays	assay	NNS	_	16	ppmod	_	_
21	when	when	WRB	_	23	adv	_	_
22	drug1	drug0	NN	_	23	dep	_	_
23	is	be	VBZ	_	12	comp	_	_
24	present	present	JJ	_	23	dep	_	_
25	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	levels	level	NNS	_	5	dep	_	_
3	have	have	VBP	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	found	find	VBN	_	0	root	_	_
6	to	to	TO	_	9	aux	_	_
7	be	be	VB	_	9	aux	_	_
8	falsely	falsely	RB	_	9	adv	_	_
9	elevated	elevate	VBN	_	5	comp	_	_
10	with	with	IN	_	13	case	_	_
11	some	some	DT	_	13	det	_	_
12	assay	assay	NN	_	13	com	_	_
13	methods	method	NNS	_	9	ppmod	_	_
14	.	.	.	_	5	p	_	_

1	Co-administration	co-administration	NN	_	21	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	or	or	CC	_	3	cc	_	_
7	other	other	JJ	_	8	attr	_	_
8	agents	agent	NNS	_	3	conj	_	_
9	interfering	interfere	VBG	_	8	acl	_	_
10	with	with	IN	_	12	case	_	_
11	neuromuscular	neuromuscular	JJ	_	12	attr	_	_
12	transmission	transmission	NN	_	9	ppmod	_	_
13	(	-lrb-	-LRB-	_	16	p	_	_
14	e.g.	e.g.	FW	_	16	ppmod	_	_
15	,	,	,	_	16	p	_	_
16	drug3	drug0	NNS	_	8	prn	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	should	should	MD	_	21	modal	_	_
19	only	only	RB	_	21	adv	_	_
20	be	be	VB	_	21	aux	_	_
21	performed	performed	VBN	_	0	root	_	_
22	with	with	IN	_	23	case	_	_
23	caution	caution	NN	_	21	ppmod	_	_
24	as	as	IN	_	32	mark	_	_
25	the	the	DT	_	26	det	_	_
26	effect	effect	NN	_	32	dep	_	_
27	of	of	IN	_	29	case	_	_
28	the	the	DT	_	29	det	_	_
29	drug4	drug0	NNS	_	26	ppmod	_	_
30	may	may	MD	_	32	modal	_	_
31	be	be	VB	_	32	aux	_	_
32	potentiated	potentiate	VBN	_	21	comp	_	_
33	.	.	.	_	21	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	19	dep	_	_
3	of	of	IN	_	4	case	_	_
4	administering	administer	VBG	_	2	ppmod	_	_
5	different	different	JJ	_	7	attr	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	serotypes	serotype	NNS	_	4	obj	_	_
8	at	at	IN	_	11	case	_	_
9	the	the	DT	_	11	det	_	_
10	same	same	JJ	_	11	attr	_	_
11	time	time	NN	_	4	ppmod	_	_
12	or	or	CC	_	11	cc	_	_
13	within	within	IN	_	15	case	_	_
14	several	several	JJ	_	15	attr	_	_
15	months	month	NNS	_	11	conj	_	_
16	of	of	IN	_	18	case	_	_
17	each	each	DT	_	18	det	_	_
18	other	other	JJ	_	15	ppmod	_	_
19	is	be	VBZ	_	0	root	_	_
20	unknown	unknown	JJ	_	19	dep	_	_
21	.	.	.	_	19	p	_	_

1	Excessive	excessive	JJ	_	3	attr	_	_
2	neuromuscular	neuromuscular	NN	_	3	com	_	_
3	weakness	weakness	NN	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	be	be	VB	_	0	root	_	_
6	exacerbated	exacerbated	JJ	_	5	dep	_	_
7	by	by	IN	_	8	case	_	_
8	administration	administration	NN	_	6	ppmod	_	_
9	of	of	IN	_	11	case	_	_
10	another	another	DT	_	11	det	_	_
11	drug1	drug0	NN	_	8	ppmod	_	_
12	prior	prior	JJ	_	11	attr	_	_
13	to	to	TO	_	15	aux	_	_
14	the	the	DT	_	15	det	_	_
15	resolution	resolution	NN	_	12	ppmod	_	_
16	of	of	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	effects	effect	NNS	_	15	ppmod	_	_
19	of	of	IN	_	23	case	_	_
20	a	a	DT	_	23	det	_	_
21	previously	previously	RB	_	22	adv	_	_
22	administered	administer	VBN	_	23	attr	_	_
23	drug2	drug0	NN	_	18	ppmod	_	_
24	.	.	.	_	5	p	_	_

1	There	there	EX	_	2	dep	_	_
2	are	be	VBP	_	0	root	_	_
3	no	no	DT	_	6	det	_	_
4	known	known	JJ	_	6	attr	_	_
5	drug	drug	NN	_	6	com	_	_
6	interactions	interaction	NNS	_	2	obj	_	_
7	with	with	IN	_	9	case	_	_
8	drug1	drug0	NN	_	9	com	_	_
9	Injection	injection	NN	_	6	ppmod	_	_
10	.	.	.	_	2	p	_	_

1	Caution	caution	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	exercised	exercise	VBN	_	0	root	_	_
5	if	if	IN	_	9	mark	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	Injection	injection	NN	_	9	dep	_	_
8	is	be	VBZ	_	9	aux	_	_
9	administered	administer	VBN	_	4	comp	_	_
10	before	before	IN	_	9	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	after	after	IN	_	10	conj	_	_
13	,	,	,	_	12	p	_	_
14	or	or	CC	_	12	cc	_	_
15	in	in	IN	_	16	case	_	_
16	conjunction	conjunction	NN	_	10	conj	_	_
17	with	with	IN	_	19	case	_	_
18	other	other	JJ	_	19	attr	_	_
19	drugs	drug	NNS	_	16	ppmod	_	_
20	known	know	VBN	_	19	acl	_	_
21	to	to	TO	_	22	aux	_	_
22	cause	cause	VB	_	20	comp	_	_
23	immunosuppression	immunosuppression	NN	_	22	obj	_	_
24	or	or	CC	_	23	cc	_	_
25	myelosuppression	myelosuppression	NN	_	23	conj	_	_
26	.	.	.	_	4	p	_	_

1	Effects	effect	NNS	_	12	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	on	on	IN	_	7	case	_	_
5	Drug	drug	NN	_	7	com	_	_
6	Metabolizing	metabolizing	NN	_	7	com	_	_
7	Enzymes	enzyme	NNS	_	1	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	Drug	drug	NN	_	11	com	_	_
10	Transport	transport	NN	_	11	com	_	_
11	Systems	system	NNS	_	7	conj	_	_
12	drug2	drug0	VBP	_	0	root	_	_
13	inhibits	inhibit	VBZ	_	12	comp	_	_
14	CYP3A4	cyp0a0	NN	_	13	obj	_	_
15	and	and	CC	_	14	cc	_	_
16	CYP2C8	cyp0c0	NN	_	14	conj	_	_
17	in	in	FW	_	18	adv	_	_
18	vitro	vitro	FW	_	13	adv	_	_
19	at	at	IN	_	22	case	_	_
20	clinically	clinically	RB	_	21	adv	_	_
21	relevant	relevant	JJ	_	22	attr	_	_
22	concentrations	concentration	NNS	_	13	ppmod	_	_
23	.	.	.	_	12	p	_	_

1	Caution	caution	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	exercised	exercise	VBN	_	0	root	_	_
5	and	and	CC	_	4	cc	_	_
6	dose	dose	NN	_	7	com	_	_
7	reduction	reduction	NN	_	15	dep	_	_
8	of	of	IN	_	12	case	_	_
9	the	the	DT	_	12	det	_	_
10	concomitant	concomitant	JJ	_	12	attr	_	_
11	substrate	substrate	NN	_	12	com	_	_
12	drug	drug	NN	_	7	ppmod	_	_
13	should	should	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	considered	consider	VBN	_	4	conj	_	_
16	when	when	IN	_	18	case	_	_
17	dosing	dosing	NN	_	18	com	_	_
18	drug1	drug0	NN	_	15	ppmod	_	_
19	concurrently	concurrently	RB	_	21	adv	_	_
20	with	with	IN	_	21	case	_	_
21	medications	medication	NNS	_	18	ppmod	_	_
22	with	with	IN	_	25	case	_	_
23	narrow	narrow	JJ	_	24	adv	_	_
24	therapeutic	therapeutic	JJ	_	25	attr	_	_
25	windows	window	NNS	_	21	ppmod	_	_
26	that	that	WDT	_	27	dep	_	_
27	are	be	VBP	_	25	relcl	_	_
28	substrates	substrate	NNS	_	27	obj	_	_
29	of	of	IN	_	30	case	_	_
30	CYP3A4	cyp0a0	NN	_	28	ppmod	_	_
31	or	or	CC	_	30	cc	_	_
32	CYP2C8	cyp0c0	NN	_	30	conj	_	_
33	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	did	do	VBD	_	5	aux	_	_
3	not	not	RB	_	5	neg	_	_
4	significantly	significantly	RB	_	5	adv	_	_
5	inhibit	inhibit	VB	_	33	advcl	_	_
6	the	the	DT	_	8	det	_	_
7	following	following	JJ	_	8	attr	_	_
8	enzymes	enzyme	NNS	_	5	obj	_	_
9	in	in	IN	_	12	case	_	_
10	human	human	JJ	_	12	attr	_	_
11	liver	liver	NN	_	12	com	_	_
12	microsomes	microsome	NNS	_	8	ppmod	_	_
13	:	:	:	_	8	p	_	_
14	CYP1A2	cyp0a0	NN	_	8	appo	_	_
15	,	,	,	_	14	p	_	_
16	CYP2C9	cyp0c0	NN	_	14	conj	_	_
17	,	,	,	_	16	p	_	_
18	CYP2C19	cyp0c0	NN	_	14	conj	_	_
19	,	,	,	_	18	p	_	_
20	and	and	CC	_	18	cc	_	_
21	CYP2D6	cyp0d0	NN	_	14	conj	_	_
22	or	or	CC	_	8	cc	_	_
23	UGT	ugt	NN	_	24	com	_	_
24	enzymes	enzyme	NNS	_	8	conj	_	_
25	in	in	FW	_	26	adv	_	_
26	vitro	vitro	FW	_	5	adv	_	_
27	,	,	,	_	33	p	_	_
28	however	however	RB	_	33	adv	_	_
29	,	,	,	_	33	p	_	_
30	the	the	DT	_	32	det	_	_
31	clinical	clinical	JJ	_	32	attr	_	_
32	significance	significance	NN	_	33	dep	_	_
33	is	be	VBZ	_	0	root	_	_
34	unknown	unknown	JJ	_	33	dep	_	_
35	.	.	.	_	33	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	inhibits	inhibit	VBZ	_	0	root	_	_
3	human	human	JJ	_	4	attr	_	_
4	P-glycoprotein	p-glycoprotein	NN	_	2	obj	_	_
5	.	.	.	_	2	p	_	_

1	If	if	IN	_	4	mark	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	administered	administer	VBN	_	19	advcl	_	_
5	with	with	IN	_	6	case	_	_
6	drugs	drug	NNS	_	4	ppmod	_	_
7	that	that	WDT	_	8	dep	_	_
8	are	be	VBP	_	6	relcl	_	_
9	substrates	substrate	NNS	_	8	obj	_	_
10	of	of	IN	_	11	case	_	_
11	Pgp	pgp	NN	_	9	ppmod	_	_
12	,	,	,	_	19	p	_	_
13	increased	increase	VBN	_	14	attr	_	_
14	concentrations	concentration	NNS	_	19	dep	_	_
15	of	of	IN	_	18	case	_	_
16	the	the	DT	_	18	det	_	_
17	substrate	substrate	JJ	_	18	attr	_	_
18	drug	drug	NN	_	14	ppmod	_	_
19	are	be	VBP	_	0	root	_	_
20	likely	likely	JJ	_	19	dep	_	_
21	,	,	,	_	19	p	_	_
22	and	and	CC	_	19	cc	_	_
23	caution	caution	NN	_	26	dep	_	_
24	should	should	MD	_	26	modal	_	_
25	be	be	VB	_	26	aux	_	_
26	exercised	exercise	VBN	_	19	conj	_	_
27	.	.	.	_	19	p	_	_

1	Drugs	drug	NNS	_	0	root	_	_
2	that	that	WDT	_	3	dep	_	_
3	Inhibit	inhibit	VBP	_	1	relcl	_	_
4	or	or	CC	_	3	cc	_	_
5	Induce	induce	VBP	_	3	conj	_	_
6	Cytochrome	cytochrome	NN	_	8	com	_	_
7	P450	p0	NN	_	8	com	_	_
8	3A4	0a0	NN	_	9	com	_	_
9	Enzymes	enzyme	NNS	_	5	obj	_	_
10	drug1	drug0	NN	_	11	dep	_	_
11	undergoes	undergo	VBZ	_	9	acl	_	_
12	extensive	extensive	JJ	_	13	attr	_	_
13	metabolism	metabolism	NN	_	11	obj	_	_
14	by	by	IN	_	15	case	_	_
15	CYP3A4	cyp0a0	NN	_	11	ppmod	_	_
16	,	,	,	_	11	p	_	_
17	and	and	CC	_	11	cc	_	_
18	concomitant	concomitant	JJ	_	19	attr	_	_
19	administration	administration	NN	_	27	dep	_	_
20	of	of	IN	_	22	case	_	_
21	strong	strong	JJ	_	22	attr	_	_
22	inhibitors	inhibitor	NNS	_	19	ppmod	_	_
23	or	or	CC	_	22	cc	_	_
24	inducers	inducer	NNS	_	22	conj	_	_
25	of	of	IN	_	26	case	_	_
26	CYP3A4	cyp0a0	NN	_	24	ppmod	_	_
27	alter	alter	VB	_	11	conj	_	_
28	drug2	drug0	NN	_	29	com	_	_
29	concentrations	concentration	NNS	_	27	obj	_	_
30	significantly	significantly	RB	_	27	adv	_	_
31	.	.	.	_	1	p	_	_

1	Dose	dose	NN	_	2	com	_	_
2	adjustment	adjustment	NN	_	7	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	should	should	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	considered	consider	VBN	_	0	root	_	_
8	for	for	IN	_	9	case	_	_
9	patients	patient	NNS	_	7	ppmod	_	_
10	who	who	WP	_	12	dep	_	_
11	must	must	MD	_	12	modal	_	_
12	receive	receive	VBP	_	9	relcl	_	_
13	concomitant	concomitant	JJ	_	15	attr	_	_
14	strong	strong	JJ	_	15	attr	_	_
15	inhibitors	inhibitor	NNS	_	12	obj	_	_
16	or	or	CC	_	15	cc	_	_
17	concomitant	concomitant	JJ	_	19	attr	_	_
18	strong	strong	JJ	_	19	attr	_	_
19	inducers	inducer	NNS	_	15	conj	_	_
20	of	of	IN	_	22	case	_	_
21	CYP3A4	cyp0a0	JJ	_	22	attr	_	_
22	enzymes	enzyme	NNS	_	15	ppmod	_	_
23	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	5	case	_	_
4	healthy	healthy	JJ	_	5	attr	_	_
5	subjects	subject	NNS	_	30	ppmod	_	_
6	receiving	receive	VBG	_	5	acl	_	_
7	drug2	drug0	NN	_	6	obj	_	_
8	,	,	,	_	7	p	_	_
9	a	a	DT	_	11	det	_	_
10	CYP3A4	cyp0a0	NN	_	11	com	_	_
11	inhibitor	inhibitor	NN	_	7	appo	_	_
12	,	,	,	_	7	p	_	_
13	at	at	IN	_	15	case	_	_
14	200	0	CD	_	15	num	_	_
15	mg	mg	NN	_	6	ppmod	_	_
16	twice	twice	RB	_	17	com	_	_
17	daily	daily	RB	_	15	adv	_	_
18	for	for	IN	_	20	case	_	_
19	7	0	CD	_	20	num	_	_
20	days	day	NNS	_	17	ppmod	_	_
21	,	,	,	_	30	p	_	_
22	systemic	systemic	JJ	_	23	attr	_	_
23	exposure	exposure	NN	_	30	dep	_	_
24	(	-lrb-	-LRB-	_	25	p	_	_
25	AUC	auc	NN	_	23	prn	_	_
26	)	-rrb-	-RRB-	_	25	p	_	_
27	to	to	TO	_	28	aux	_	_
28	drug3	drug0	NN	_	23	ppmod	_	_
29	was	be	VBD	_	30	aux	_	_
30	increased	increase	VBN	_	1	acl	_	_
31	to	to	TO	_	33	aux	_	_
32	approximately	approximately	RB	_	33	adv	_	_
33	3.6-fold	0-fold	NN	_	30	ppmod	_	_
34	of	of	IN	_	35	case	_	_
35	control	control	NN	_	33	ppmod	_	_
36	and	and	CC	_	35	cc	_	_
37	half-life	half-life	NN	_	35	conj	_	_
38	increased	increase	VBD	_	33	acl	_	_
39	to	to	TO	_	40	aux	_	_
40	1.7-fold	0-fold	NN	_	38	ppmod	_	_
41	of	of	IN	_	42	case	_	_
42	control	control	NN	_	40	ppmod	_	_
43	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	5	case	_	_
4	healthy	healthy	JJ	_	5	attr	_	_
5	subjects	subject	NNS	_	38	ppmod	_	_
6	receiving	receive	VBG	_	5	acl	_	_
7	the	the	DT	_	9	det	_	_
8	CYP3A4	cyp0a0	NN	_	9	com	_	_
9	inducer	inducer	NN	_	6	obj	_	_
10	,	,	,	_	9	p	_	_
11	drug2	drug0	NN	_	9	appo	_	_
12	,	,	,	_	9	p	_	_
13	at	at	IN	_	15	case	_	_
14	100	0	CD	_	15	num	_	_
15	mg	mg	NN	_	6	ppmod	_	_
16	twice	twice	RB	_	17	adv	_	_
17	daily	daily	JJ	_	15	attr	_	_
18	for	for	IN	_	20	case	_	_
19	3	0	CD	_	20	num	_	_
20	days	day	NNS	_	17	ppmod	_	_
21	and	and	CC	_	15	cc	_	_
22	200	0	CD	_	23	num	_	_
23	mg	mg	NN	_	15	conj	_	_
24	twice	twice	RB	_	25	adv	_	_
25	daily	daily	JJ	_	23	attr	_	_
26	for	for	IN	_	28	case	_	_
27	17	0	CD	_	28	num	_	_
28	days	day	NNS	_	25	ppmod	_	_
29	,	,	,	_	38	p	_	_
30	systemic	systemic	JJ	_	31	attr	_	_
31	exposure	exposure	NN	_	38	dep	_	_
32	(	-lrb-	-LRB-	_	33	p	_	_
33	AUC	auc	NN	_	31	prn	_	_
34	)	-rrb-	-RRB-	_	33	p	_	_
35	to	to	TO	_	36	aux	_	_
36	drug3	drug0	NN	_	31	ppmod	_	_
37	was	be	VBD	_	38	aux	_	_
38	decreased	decrease	VBN	_	1	acl	_	_
39	approximately	approximately	RB	_	40	adv	_	_
40	72	0	CD	_	38	obj	_	_
41	%	%	NN	_	40	meta	_	_
42	.	.	.	_	1	p	_	_

1	Drugs	drug	NNS	_	8	dep	_	_
2	that	that	WDT	_	3	dep	_	_
3	Inhibit	inhibit	VBP	_	1	relcl	_	_
4	Drug	drug	NN	_	6	com	_	_
5	Transport	transport	NN	_	6	com	_	_
6	Systems	system	NNS	_	7	com	_	_
7	drug1	drug0	NN	_	3	obj	_	_
8	is	be	VBZ	_	0	root	_	_
9	a	a	DT	_	10	det	_	_
10	substrate	substrate	NN	_	8	obj	_	_
11	of	of	IN	_	15	case	_	_
12	the	the	DT	_	15	det	_	_
13	efflux	efflux	NN	_	15	com	_	_
14	transporter	transporter	NN	_	15	com	_	_
15	P-glycoprotein	p-glycoprotein	NN	_	10	ppmod	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	Pgp	pgp	NN	_	15	prn	_	_
18	,	,	,	_	17	p	_	_
19	ABCB1	abcb0	NN	_	17	appo	_	_
20	)	-rrb-	-RRB-	_	17	p	_	_
21	.	.	.	_	8	p	_	_

1	If	if	IN	_	4	mark	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	administered	administer	VBN	_	15	advcl	_	_
5	with	with	IN	_	6	case	_	_
6	drugs	drug	NNS	_	4	ppmod	_	_
7	that	that	WDT	_	8	dep	_	_
8	inhibit	inhibit	VBP	_	6	relcl	_	_
9	Pgp	pgp	NN	_	8	obj	_	_
10	,	,	,	_	15	p	_	_
11	increased	increase	VBN	_	12	attr	_	_
12	concentrations	concentration	NNS	_	15	dep	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	are	be	VBP	_	0	root	_	_
16	likely	likely	JJ	_	15	dep	_	_
17	,	,	,	_	15	p	_	_
18	and	and	CC	_	15	cc	_	_
19	caution	caution	NN	_	22	dep	_	_
20	should	should	MD	_	22	modal	_	_
21	be	be	VB	_	22	aux	_	_
22	exercised	exercise	VBN	_	15	conj	_	_
23	.	.	.	_	15	p	_	_

1	Other	other	JJ	_	3	attr	_	_
2	Chemotherapy	chemotherapy	NN	_	3	com	_	_
3	Agents	agent	NNS	_	7	dat	_	_
4	In	in	IN	_	7	case	_	_
5	a	a	DT	_	7	det	_	_
6	separate	separate	JJ	_	7	attr	_	_
7	study	study	NN	_	18	ppmod	_	_
8	,	,	,	_	18	p	_	_
9	concomitant	concomitant	JJ	_	10	attr	_	_
10	administration	administration	NN	_	18	dep	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	with	with	IN	_	14	case	_	_
14	drug2	drug0	NN	_	10	ppmod	_	_
15	did	do	VBD	_	18	aux	_	_
16	not	not	RB	_	18	neg	_	_
17	meaningfully	meaningfully	RB	_	18	adv	_	_
18	alter	alter	VB	_	0	root	_	_
19	the	the	DT	_	20	det	_	_
20	pharmacokinetics	pharmacokinetics	NNS	_	18	obj	_	_
21	of	of	IN	_	23	case	_	_
22	either	either	DT	_	23	det	_	_
23	agent	agent	NN	_	20	ppmod	_	_
24	(	-lrb-	-LRB-	_	27	p	_	_
25	or	or	CC	_	27	cc	_	_
26	the	the	DT	_	27	det	_	_
27	metabolites	metabolite	NNS	_	23	prn	_	_
28	of	of	IN	_	29	case	_	_
29	drug3	drug0	NN	_	27	ppmod	_	_
30	)	-rrb-	-RRB-	_	27	p	_	_
31	.	.	.	_	18	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	increases	increase	VBZ	_	1	prn	_	_
4	bioavailability	bioavailability	NN	_	3	obj	_	_
5	by	by	IN	_	6	case	_	_
6	50	0	CD	_	3	ppmod	_	_
7	%	%	NN	_	6	meta	_	_
8	)	-rrb-	-RRB-	_	3	p	_	_
9	,	,	,	_	1	p	_	_
10	drug2	drug0	NN	_	1	conj	_	_
11	,	,	,	_	10	p	_	_
12	and	and	CC	_	10	cc	_	_
13	valproates	valproates	NN	_	1	conj	_	_
14	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	5	det	_	_
4	concomitant	concomitant	JJ	_	5	attr	_	_
5	use	use	NN	_	16	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	with	with	IN	_	9	case	_	_
9	long-	long-	NN	_	5	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	short-acting	short-acting	JJ	_	12	attr	_	_
12	drug3	drug0	NN	_	9	conj	_	_
13	has	have	VBZ	_	16	aux	_	_
14	been	be	VBN	_	16	aux	_	_
15	safely	safely	RB	_	16	adv	_	_
16	tolerated	tolerate	VBN	_	1	acl	_	_
17	in	in	IN	_	18	case	_	_
18	patients	patient	NNS	_	16	ppmod	_	_
19	with	with	IN	_	22	case	_	_
20	stable	stable	JJ	_	22	attr	_	_
21	angina	angina	NN	_	22	com	_	_
22	pectoris	pectoris	NN	_	18	ppmod	_	_
23	.	.	.	_	1	p	_	_

1	Sublingual	sublingual	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	5	dep	_	_
3	may	may	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	taken	take	VBN	_	0	root	_	_
6	if	if	IN	_	7	mark	_	_
7	necessary	necessary	JJ	_	5	comp	_	_
8	for	for	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	control	control	NN	_	7	ppmod	_	_
11	of	of	IN	_	14	case	_	_
12	acute	acute	JJ	_	14	attr	_	_
13	angina	angina	NN	_	14	com	_	_
14	attacks	attack	NNS	_	10	ppmod	_	_
15	during	during	IN	_	17	case	_	_
16	drug2	drug0	NN	_	17	com	_	_
17	therapy	therapy	NN	_	14	ppmod	_	_
18	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	5	det	_	_
4	concomitant	concomitant	JJ	_	5	attr	_	_
5	use	use	NN	_	13	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug3	drug0	NN	_	7	conj	_	_
10	has	have	VBZ	_	13	aux	_	_
11	been	be	VBN	_	13	aux	_	_
12	well	well	RB	_	13	adv	_	_
13	tolerated	tolerate	VBN	_	1	acl	_	_
14	in	in	IN	_	15	case	_	_
15	patients	patient	NNS	_	13	ppmod	_	_
16	with	with	IN	_	18	case	_	_
17	stable	stable	JJ	_	18	attr	_	_
18	angina	angina	NNS	_	15	ppmod	_	_
19	.	.	.	_	1	p	_	_

1	Available	available	JJ	_	2	attr	_	_
2	data	datum	NNS	_	3	dep	_	_
3	are	be	VBP	_	0	root	_	_
4	not	not	RB	_	3	neg	_	_
5	sufficient	sufficient	JJ	_	3	dep	_	_
6	,	,	,	_	10	p	_	_
7	however	however	RB	_	10	adv	_	_
8	,	,	,	_	10	p	_	_
9	to	to	TO	_	10	aux	_	_
10	predict	predict	VB	_	5	comp	_	_
11	the	the	DT	_	12	det	_	_
12	effects	effect	NNS	_	10	obj	_	_
13	of	of	IN	_	15	case	_	_
14	concomitant	concomitant	JJ	_	15	attr	_	_
15	medication	medication	NN	_	12	ppmod	_	_
16	on	on	IN	_	17	case	_	_
17	patients	patient	NNS	_	12	ppmod	_	_
18	with	with	IN	_	21	case	_	_
19	impaired	impaired	JJ	_	21	attr	_	_
20	ventricular	ventricular	JJ	_	21	attr	_	_
21	function	function	NN	_	17	ppmod	_	_
22	or	or	CC	_	21	cc	_	_
23	cardiac	cardiac	JJ	_	25	attr	_	_
24	conduction	conduction	JJ	_	25	attr	_	_
25	abnormalities	abnormality	NNS	_	21	conj	_	_
26	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	5	case	_	_
4	controlled	controlled	JJ	_	5	attr	_	_
5	studies	study	NNS	_	12	ppmod	_	_
6	in	in	IN	_	8	case	_	_
7	healthy	healthy	JJ	_	8	attr	_	_
8	volunteers	volunteer	NNS	_	5	ppmod	_	_
9	,	,	,	_	12	p	_	_
10	drug2	drug0	NN	_	12	dep	_	_
11	either	either	CC	_	12	cc	_	_
12	had	have	VBD	_	1	acl	_	_
13	no	no	DT	_	14	det	_	_
14	effect	effect	NN	_	12	obj	_	_
15	(	-lrb-	-LRB-	_	17	p	_	_
16	one	#crd#	CD	_	17	num	_	_
17	study	study	NN	_	12	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	or	or	CC	_	12	cc	_	_
20	was	be	VBD	_	21	aux	_	_
21	associated	associate	VBN	_	12	conj	_	_
22	with	with	IN	_	24	case	_	_
23	modest	modest	JJ	_	24	attr	_	_
24	increases	increase	NNS	_	21	ppmod	_	_
25	,	,	,	_	24	p	_	_
26	about	about	RB	_	27	adv	_	_
27	30	0	CD	_	24	appo	_	_
28	%	%	NN	_	27	meta	_	_
29	(	-lrb-	-LRB-	_	31	p	_	_
30	two	#crd#	CD	_	31	num	_	_
31	studies	study	NNS	_	24	prn	_	_
32	)	-rrb-	-RRB-	_	31	p	_	_
33	in	in	IN	_	37	case	_	_
34	steady-state	steady-state	JJ	_	37	attr	_	_
35	serum	serum	NN	_	37	com	_	_
36	drug3	drug0	NN	_	37	com	_	_
37	concentrations	concentration	NNS	_	24	ppmod	_	_
38	.	.	.	_	1	p	_	_

1	Limited	limited	JJ	_	3	attr	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	data	datum	NNS	_	13	dep	_	_
4	in	in	IN	_	6	case	_	_
5	angina	angina	JJ	_	6	attr	_	_
6	patients	patient	NNS	_	3	ppmod	_	_
7	receiving	receive	VBG	_	6	acl	_	_
8	concomitant	concomitant	JJ	_	9	attr	_	_
9	drug1	drug0	NN	_	7	obj	_	_
10	and	and	CC	_	9	cc	_	_
11	drug2	drug0	NN	_	12	com	_	_
12	therapy	therapy	NN	_	9	conj	_	_
13	indicate	indicate	VBP	_	0	root	_	_
14	no	no	DT	_	16	det	_	_
15	discernible	discernible	JJ	_	16	attr	_	_
16	changes	change	NNS	_	13	obj	_	_
17	in	in	IN	_	20	case	_	_
18	serum	serum	NN	_	20	com	_	_
19	digoxin	digoxin	NN	_	20	com	_	_
20	levels	level	NNS	_	16	ppmod	_	_
21	.	.	.	_	13	p	_	_

1	Available	available	JJ	_	2	attr	_	_
2	data	datum	NNS	_	3	dep	_	_
3	are	be	VBP	_	0	root	_	_
4	neither	neither	CC	_	5	cc	_	_
5	sufficient	sufficient	JJ	_	3	dep	_	_
6	to	to	TO	_	7	aux	_	_
7	rule	rule	NN	_	3	ppmod	_	_
8	out	out	IN	_	10	case	_	_
9	possible	possible	JJ	_	10	attr	_	_
10	increases	increase	NNS	_	7	ppmod	_	_
11	in	in	IN	_	13	case	_	_
12	serum	serum	NN	_	13	com	_	_
13	drug1	drug0	NN	_	10	ppmod	_	_
14	with	with	IN	_	16	case	_	_
15	concomitant	concomitant	JJ	_	16	attr	_	_
16	treatment	treatment	NN	_	13	ppmod	_	_
17	in	in	IN	_	19	case	_	_
18	some	some	DT	_	19	det	_	_
19	patients	patient	NNS	_	16	ppmod	_	_
20	,	,	,	_	7	p	_	_
21	nor	nor	CC	_	7	cc	_	_
22	other	other	JJ	_	24	attr	_	_
23	possible	possible	JJ	_	24	attr	_	_
24	interactions	interaction	NNS	_	7	conj	_	_
25	,	,	,	_	24	p	_	_
26	particularly	particularly	RB	_	7	conj	_	_
27	in	in	IN	_	28	case	_	_
28	patients	patient	NNS	_	3	ppmod	_	_
29	with	with	IN	_	32	case	_	_
30	cardiac	cardiac	JJ	_	32	attr	_	_
31	conduction	conduction	NN	_	32	com	_	_
32	abnormalities	abnormality	NNS	_	28	ppmod	_	_
33	(	-lrb-	-LRB-	_	35	p	_	_
34	Also	also	RB	_	35	adv	_	_
35	see	see	VB	_	3	prn	_	_
36	WARNINGS	warning	NNS	_	35	obj	_	_
37	Congestive	congestive	JJ	_	39	attr	_	_
38	Heart	heart	NN	_	39	com	_	_
39	Failure	failure	NN	_	36	attr	_	_
40	)	-rrb-	-RRB-	_	35	p	_	_
41	.	.	.	_	3	p	_	_

1	Oral	oral	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	drug2	drug0	NN	_	8	dep	_	_
5	has	have	VBZ	_	8	aux	_	_
6	been	be	VBN	_	8	aux	_	_
7	safely	safely	RB	_	8	adv	_	_
8	used	use	VBN	_	2	acl	_	_
9	in	in	IN	_	11	case	_	_
10	diabetic	diabetic	JJ	_	11	attr	_	_
11	patients	patient	NNS	_	8	ppmod	_	_
12	without	without	IN	_	14	case	_	_
13	significantly	significantly	RB	_	14	adv	_	_
14	lowering	lower	VBG	_	8	ppmod	_	_
15	their	their	PRP$	_	18	poss	_	_
16	blood	blood	NN	_	18	com	_	_
17	glucose	glucose	NN	_	18	com	_	_
18	levels	level	NNS	_	14	obj	_	_
19	or	or	CC	_	14	cc	_	_
20	altering	alter	VBG	_	14	conj	_	_
21	their	their	PRP$	_	22	poss	_	_
22	need	need	NN	_	20	obj	_	_
23	for	for	IN	_	24	case	_	_
24	drug3	drug0	NN	_	22	ppmod	_	_
25	or	or	CC	_	24	cc	_	_
26	oral	oral	JJ	_	27	attr	_	_
27	drug4	drug0	NN	_	24	conj	_	_
28	.	.	.	_	2	p	_	_

1	General	general	JJ	_	2	attr	_	_
2	Interactions	interaction	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	Certain	certain	JJ	_	5	attr	_	_
5	drugs	drug	NNS	_	7	dep	_	_
6	could	could	MD	_	7	modal	_	_
7	increase	increase	VB	_	2	acl	_	_
8	the	the	DT	_	9	det	_	_
9	likelihood	likelihood	NN	_	7	obj	_	_
10	of	of	IN	_	14	case	_	_
11	potentially	potentially	RB	_	12	adv	_	_
12	serious	serious	JJ	_	14	attr	_	_
13	adverse	adverse	JJ	_	14	attr	_	_
14	effects	effect	NNS	_	9	ppmod	_	_
15	with	with	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	.	.	.	_	2	p	_	_

1	In	in	IN	_	2	case	_	_
2	general	general	JJ	_	5	ppmod	_	_
3	,	,	,	_	5	p	_	_
4	these	these	DT	_	5	dep	_	_
5	are	be	VBP	_	0	root	_	_
6	drugs	drug	NNS	_	5	obj	_	_
7	that	that	WDT	_	13	dep	_	_
8	have	have	VBP	_	13	lv	_	_
9	one	#crd#	CD	_	13	num	_	_
10	or	or	CC	_	9	cc	_	_
11	more	more	JJR	_	9	conj	_	_
12	pharmacologic	pharmacologic	JJ	_	13	attr	_	_
13	activities	activity	NNS	_	6	relcl	_	_
14	similar	similar	JJ	_	13	attr	_	_
15	to	to	TO	_	16	aux	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	,	,	,	_	6	p	_	_
18	including	include	VBG	_	19	adv	_	_
19	drug2	drug0	NNS	_	6	ppmod	_	_
20	such	such	JJ	_	22	adv	_	_
21	as	as	IN	_	22	case	_	_
22	drug3	drug0	NN	_	19	ppmod	_	_
23	and	and	CC	_	22	cc	_	_
24	drug4	drug0	NN	_	22	conj	_	_
25	,	,	,	_	6	p	_	_
26	drug5	drug0	NN	_	6	appo	_	_
27	and	and	CC	_	26	cc	_	_
28	drug6	drug0	NN	_	26	conj	_	_
29	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	could	could	MD	_	5	modal	_	_
5	exaggerate	exaggerate	VB	_	0	root	_	_
6	the	the	DT	_	7	det	_	_
7	prolongation	prolongation	NN	_	5	obj	_	_
8	of	of	IN	_	11	case	_	_
9	the	the	DT	_	11	det	_	_
10	QT	qt	JJ	_	11	attr	_	_
11	interval	interval	NN	_	7	ppmod	_	_
12	observed	observe	VBN	_	11	acl	_	_
13	with	with	IN	_	14	case	_	_
14	drug3	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	could	could	MD	_	3	modal	_	_
3	exaggerate	exaggerate	VB	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	depression	depression	NN	_	3	obj	_	_
6	of	of	IN	_	9	case	_	_
7	AV	av	NN	_	9	attr	_	_
8	nodal	nodal	JJ	_	9	attr	_	_
9	conduction	conduction	NN	_	5	ppmod	_	_
10	observed	observe	VBN	_	9	acl	_	_
11	with	with	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	3	p	_	_

1	Although	although	IN	_	9	mark	_	_
2	specific	specific	JJ	_	5	attr	_	_
3	drug	drug	NN	_	5	com	_	_
4	interaction	interaction	NN	_	5	com	_	_
5	studies	study	NNS	_	9	dep	_	_
6	have	have	VBP	_	9	aux	_	_
7	not	not	RB	_	9	neg	_	_
8	been	be	VBN	_	9	aux	_	_
9	conducted	conduct	VBN	_	37	advcl	_	_
10	with	with	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	,	,	,	_	37	p	_	_
13	the	the	DT	_	14	det	_	_
14	possibility	possibility	NN	_	37	dep	_	_
15	of	of	IN	_	20	case	_	_
16	an	an	DT	_	20	det	_	_
17	additive	additive	JJ	_	20	attr	_	_
18	or	or	NN	_	20	com	_	_
19	potentiating	potentiating	NN	_	20	com	_	_
20	effect	effect	NN	_	14	ppmod	_	_
21	with	with	IN	_	22	case	_	_
22	drug2	drug0	NN	_	14	ppmod	_	_
23	(	-lrb-	-LRB-	_	24	p	_	_
24	drug3	drug0	NN	_	22	prn	_	_
25	,	,	,	_	24	p	_	_
26	drug4	drug0	NN	_	24	conj	_	_
27	,	,	,	_	26	p	_	_
28	drug5	drug0	NN	_	24	conj	_	_
29	,	,	,	_	28	p	_	_
30	drug6	drug0	NN	_	24	conj	_	_
31	,	,	,	_	30	p	_	_
32	or	or	CC	_	30	cc	_	_
33	drug7	drug0	NN	_	24	conj	_	_
34	)	-rrb-	-RRB-	_	24	p	_	_
35	should	should	MD	_	37	modal	_	_
36	be	be	VB	_	37	aux	_	_
37	considered	consider	VBN	_	0	root	_	_
38	.	.	.	_	37	p	_	_

1	drug1	drug0	NN	_	8	dep	_	_
2	,	,	,	_	8	p	_	_
3	as	as	IN	_	5	case	_	_
4	a	a	DT	_	5	det	_	_
5	class	class	NN	_	8	ppmod	_	_
6	,	,	,	_	8	p	_	_
7	may	may	MD	_	8	modal	_	_
8	reduce	reduce	VB	_	0	root	_	_
9	pulse	pulse	NN	_	8	obj	_	_
10	and	and	CC	_	9	cc	_	_
11	blood	blood	NN	_	12	com	_	_
12	pressure	pressure	NN	_	9	conj	_	_
13	.	.	.	_	8	p	_	_

1	Caution	caution	NN	_	19	dep	_	_
2	in	in	IN	_	3	case	_	_
3	using	use	VBG	_	1	ppmod	_	_
4	concomitant	concomitant	JJ	_	5	attr	_	_
5	drugs	drug	NNS	_	3	obj	_	_
6	such	such	JJ	_	8	adv	_	_
7	as	as	IN	_	8	case	_	_
8	drug1	drug0	NN	_	5	ppmod	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	ophthalmic	ophthalmic	JJ	_	8	prn	_	_
11	and	and	CC	_	10	cc	_	_
12	systemic	systemic	JJ	_	10	conj	_	_
13	)	-rrb-	-RRB-	_	10	p	_	_
14	,	,	,	_	8	p	_	_
15	drug2	drug0	NN	_	8	conj	_	_
16	and/or	and/or	CC	_	15	cc	_	_
17	drug3	drug0	NN	_	8	conj	_	_
18	is	be	VBZ	_	19	aux	_	_
19	advised	advise	VBN	_	0	root	_	_
20	.	.	.	_	19	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	have	have	VBP	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	reported	report	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	blunt	blunt	VB	_	4	comp	_	_
7	the	the	DT	_	9	det	_	_
8	hypotensive	hypotensive	JJ	_	9	attr	_	_
9	effect	effect	NN	_	16	dep	_	_
10	of	of	IN	_	13	case	_	_
11	systemic	systemic	JJ	_	13	attr	_	_
12	drug2	drug0	NN	_	13	com	_	_
13	.It	.it	NN	_	9	ppmod	_	_
14	is	be	VBZ	_	16	aux	_	_
15	not	not	RB	_	16	neg	_	_
16	known	know	VBN	_	6	comp	_	_
17	whether	whether	IN	_	29	mark	_	_
18	the	the	DT	_	20	det	_	_
19	concurrent	concurrent	JJ	_	20	attr	_	_
20	use	use	NN	_	29	dep	_	_
21	of	of	IN	_	23	case	_	_
22	these	these	DT	_	23	det	_	_
23	agents	agent	NNS	_	20	ppmod	_	_
24	with	with	IN	_	25	case	_	_
25	drug3	drug0	NN	_	20	ppmod	_	_
26	in	in	IN	_	27	case	_	_
27	humans	human	NNS	_	25	ppmod	_	_
28	can	can	MD	_	29	modal	_	_
29	lead	lead	VB	_	16	comp	_	_
30	to	to	TO	_	32	aux	_	_
31	resulting	result	VBG	_	32	attr	_	_
32	interference	interference	NN	_	29	ppmod	_	_
33	with	with	IN	_	37	case	_	_
34	the	the	DT	_	37	det	_	_
35	IOP	iop	NN	_	37	attr	_	_
36	lowering	lowering	JJ	_	37	attr	_	_
37	effect	effect	NN	_	32	ppmod	_	_
38	.	.	.	_	4	p	_	_

1	No	no	DT	_	2	det	_	_
2	data	datum	NNS	_	12	dep	_	_
3	on	on	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	level	level	NN	_	2	ppmod	_	_
6	of	of	IN	_	8	case	_	_
7	circulating	circulating	JJ	_	8	attr	_	_
8	catecholamines	catecholamine	NNS	_	5	ppmod	_	_
9	after	after	IN	_	11	case	_	_
10	drug1	drug0	NN	_	11	com	_	_
11	administration	administration	NN	_	5	ppmod	_	_
12	are	be	VBP	_	0	root	_	_
13	available	available	JJ	_	12	dep	_	_
14	.	.	.	_	12	p	_	_

1	Caution	caution	NN	_	6	dep	_	_
2	,	,	,	_	6	p	_	_
3	however	however	RB	_	6	adv	_	_
4	,	,	,	_	6	p	_	_
5	is	be	VBZ	_	6	aux	_	_
6	advised	advise	VBN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	6	ppmod	_	_
9	taking	take	VBG	_	8	acl	_	_
10	drug1	drug0	NN	_	9	obj	_	_
11	which	which	WDT	_	13	dep	_	_
12	can	can	MD	_	13	modal	_	_
13	affect	affect	VB	_	10	relcl	_	_
14	the	the	DT	_	15	det	_	_
15	metabolism	metabolism	NN	_	13	obj	_	_
16	and	and	CC	_	15	cc	_	_
17	uptake	uptake	NN	_	15	conj	_	_
18	of	of	IN	_	20	case	_	_
19	circulating	circulate	VBG	_	20	attr	_	_
20	amines	amine	NNS	_	15	ppmod	_	_
21	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	-	-	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	may	may	MD	_	5	modal	_	_
5	sterilize	sterilize	VB	_	0	root	_	_
6	the	the	DT	_	7	det	_	_
7	bowel	bowel	NN	_	5	obj	_	_
8	and	and	CC	_	5	cc	_	_
9	decrease	decrease	VB	_	5	conj	_	_
10	the	the	DT	_	12	det	_	_
11	drug3	drug0	NN	_	12	com	_	_
12	contribution	contribution	NN	_	9	obj	_	_
13	to	to	TO	_	15	aux	_	_
14	the	the	DT	_	15	det	_	_
15	body	body	NN	_	12	ppmod	_	_
16	by	by	IN	_	19	case	_	_
17	the	the	DT	_	19	det	_	_
18	intestinal	intestinal	JJ	_	19	attr	_	_
19	microflora	microflora	NNS	_	12	ppmod	_	_
20	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	26	dep	_	_
2	-	-	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	containing	contain	VBG	_	1	acl	_	_
5	side	side	JJ	_	6	attr	_	_
6	chains	chain	NNS	_	4	obj	_	_
7	of	of	IN	_	8	case	_	_
8	N-methylthiotetrazole	n-methylthiotetrazole	NN	_	6	ppmod	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	drug3	drug0	NN	_	8	prn	_	_
11	,	,	,	_	10	p	_	_
12	drug4	drug0	NN	_	10	appo	_	_
13	,	,	,	_	10	p	_	_
14	drug5	drug0	NN	_	10	appo	_	_
15	,	,	,	_	10	p	_	_
16	drug6	drug0	NN	_	10	appo	_	_
17	,	,	,	_	10	p	_	_
18	drug7	drug0	NN	_	10	appo	_	_
19	)	-rrb-	-RRB-	_	10	p	_	_
20	or	or	CC	_	8	cc	_	_
21	methylthiadiazole	methylthiadiazole	NN	_	8	conj	_	_
22	(	-lrb-	-LRB-	_	23	p	_	_
23	drug8	drug0	NN	_	21	prn	_	_
24	)	-rrb-	-RRB-	_	23	p	_	_
25	can	can	MD	_	26	modal	_	_
26	cause	cause	VB	_	0	root	_	_
27	vitamin	vitamin	NN	_	29	com	_	_
28	K	k	NN	_	29	com	_	_
29	deficiency	deficiency	NN	_	26	obj	_	_
30	and	and	CC	_	29	cc	_	_
31	hypoprothrombinemia	hypoprothrombinemia	NN	_	29	conj	_	_
32	.	.	.	_	26	p	_	_

1	These	these	DT	_	2	det	_	_
2	drug1	drug0	NNS	_	3	dep	_	_
3	are	be	VBP	_	0	root	_	_
4	inhibitors	inhibitor	NNS	_	3	obj	_	_
5	of	of	IN	_	10	case	_	_
6	hepatic	hepatic	JJ	_	10	attr	_	_
7	vitamin	vitamin	NN	_	10	com	_	_
8	K	k	NN	_	10	com	_	_
9	epoxide	epoxide	NN	_	10	com	_	_
10	reductase	reductase	NN	_	4	ppmod	_	_
11	.	.	.	_	3	p	_	_

1	drug1	drug0	JJ	_	3	attr	_	_
2	-Concomitant	-concomitant	JJ	_	3	attr	_	_
3	intake	intake	NN	_	9	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug3	drug0	NN	_	5	conj	_	_
8	may	may	MD	_	9	modal	_	_
9	reduce	reduce	VB	_	0	root	_	_
10	the	the	DT	_	11	det	_	_
11	absorption	absorption	NN	_	9	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug4	drug0	NN	_	11	ppmod	_	_
14	.	.	.	_	9	p	_	_

1	drug1	drug0	JJ	_	3	attr	_	_
2	-Concomitant	-concomitant	JJ	_	3	attr	_	_
3	intake	intake	NN	_	9	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug3	drug0	NN	_	5	conj	_	_
8	may	may	MD	_	9	modal	_	_
9	reduce	reduce	VB	_	0	root	_	_
10	the	the	DT	_	11	det	_	_
11	absorption	absorption	NN	_	9	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug4	drug0	NN	_	11	ppmod	_	_
14	.	.	.	_	9	p	_	_

1	drug1	drug0	JJ	_	3	attr	_	_
2	-Concomitant	-concomitant	JJ	_	3	attr	_	_
3	intake	intake	NN	_	9	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug3	drug0	NN	_	5	conj	_	_
8	may	may	MD	_	9	modal	_	_
9	reduce	reduce	VB	_	0	root	_	_
10	the	the	DT	_	11	det	_	_
11	absorption	absorption	NN	_	9	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug4	drug0	NN	_	11	ppmod	_	_
14	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	-	-	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	may	may	MD	_	5	modal	_	_
5	decrease	decrease	VB	_	0	root	_	_
6	the	the	DT	_	7	det	_	_
7	absorption	absorption	NN	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_
10	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	8	dep	_	_
2	-	-	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	in	in	IN	_	6	case	_	_
5	large	large	JJ	_	6	attr	_	_
6	doses	dose	NNS	_	1	ppmod	_	_
7	may	may	MD	_	8	modal	_	_
8	inhibit	inhibit	VB	_	0	root	_	_
9	vitamin	vitamin	NN	_	12	com	_	_
10	K	k	NN	_	12	com	_	_
11	epoxide	epoxide	NN	_	12	com	_	_
12	reductase	reductase	NN	_	8	obj	_	_
13	resulting	result	VBG	_	12	acl	_	_
14	in	in	IN	_	17	case	_	_
15	vitamin	vitamin	NN	_	17	com	_	_
16	K	k	NN	_	17	com	_	_
17	deficiency	deficiency	NN	_	13	ppmod	_	_
18	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	-	-	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	can	can	MD	_	5	modal	_	_
5	antagonize	antagonize	VB	_	0	root	_	_
6	the	the	DT	_	7	det	_	_
7	effect	effect	NN	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_

1	The	the	DT	_	2	det	_	_
2	risk	risk	NN	_	13	dep	_	_
3	of	of	IN	_	4	case	_	_
4	myopathy	myopathy	NN	_	2	ppmod	_	_
5	during	during	IN	_	6	case	_	_
6	treatment	treatment	NN	_	2	ppmod	_	_
7	with	with	IN	_	8	case	_	_
8	drugs	drug	NNS	_	6	ppmod	_	_
9	of	of	IN	_	11	case	_	_
10	this	this	DT	_	11	det	_	_
11	class	class	NN	_	8	ppmod	_	_
12	is	be	VBZ	_	13	aux	_	_
13	increased	increase	VBN	_	0	root	_	_
14	with	with	IN	_	16	case	_	_
15	concurrent	concurrent	JJ	_	16	attr	_	_
16	administration	administration	NN	_	13	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug1	drug0	NN	_	16	ppmod	_	_
19	,	,	,	_	18	p	_	_
20	drug2	drug0	NN	_	18	appo	_	_
21	,	,	,	_	18	p	_	_
22	drug3	drug0	NN	_	18	appo	_	_
23	(	-lrb-	-LRB-	_	24	p	_	_
24	drug4	drug0	NN	_	22	prn	_	_
25	)	-rrb-	-RRB-	_	24	p	_	_
26	,	,	,	_	18	p	_	_
27	drug5	drug0	NN	_	18	appo	_	_
28	,	,	,	_	18	p	_	_
29	drug6	drug0	NN	_	18	appo	_	_
30	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	When	when	WRB	_	9	adv	_	_
4	drug2	drug0	NN	_	9	dep	_	_
5	and	and	CC	_	4	cc	_	_
6	drug3	drug0	NN	_	7	com	_	_
7	suspension	suspension	NN	_	4	conj	_	_
8	were	be	VBD	_	9	aux	_	_
9	coadministered	coadministered	VBN	_	15	advcl	_	_
10	,	,	,	_	15	p	_	_
11	plasma	plasma	NN	_	12	com	_	_
12	concentrations	concentration	NNS	_	15	dep	_	_
13	of	of	IN	_	14	case	_	_
14	drug4	drug0	NNS	_	12	ppmod	_	_
15	decreased	decrease	VBD	_	1	acl	_	_
16	approximately	approximately	RB	_	17	adv	_	_
17	35	0	CD	_	15	obj	_	_
18	%	%	NN	_	17	meta	_	_
19	.	.	.	_	1	p	_	_

1	However	however	RB	_	7	adv	_	_
2	,	,	,	_	7	p	_	_
3	LDL-C	ldl-c	NN	_	4	com	_	_
4	reduction	reduction	NN	_	7	dep	_	_
5	was	be	VBD	_	7	aux	_	_
6	not	not	RB	_	7	neg	_	_
7	altered	alter	VBN	_	0	root	_	_
8	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Because	because	IN	_	7	mark	_	_
4	drug2	drug0	NN	_	7	dep	_	_
5	does	do	VBZ	_	7	aux	_	_
6	not	not	RB	_	7	neg	_	_
7	affect	affect	VB	_	25	advcl	_	_
8	the	the	DT	_	9	det	_	_
9	pharmacokinetics	pharmacokinetics	NNS	_	7	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug3	drug0	NN	_	9	ppmod	_	_
12	,	,	,	_	25	p	_	_
13	interactions	interaction	NNS	_	25	dep	_	_
14	with	with	IN	_	16	case	_	_
15	other	other	JJ	_	16	attr	_	_
16	drug4	drug0	NNS	_	13	ppmod	_	_
17	metabolized	metabolize	VBN	_	16	acl	_	_
18	via	via	IN	_	22	case	_	_
19	the	the	DT	_	22	det	_	_
20	same	same	JJ	_	22	attr	_	_
21	cytochrome	cytochrome	NN	_	22	com	_	_
22	isozymes	isozymes	NNS	_	17	ppmod	_	_
23	are	be	VBP	_	25	aux	_	_
24	not	not	RB	_	25	neg	_	_
25	expected	expect	VBN	_	1	acl	_	_
26	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	4	attr	_	_
2	:	:	:	_	4	p	_	_
3	Plasma	plasma	NN	_	4	com	_	_
4	concentrations	concentration	NNS	_	7	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	decreased	decrease	VBD	_	0	root	_	_
8	approximately	approximately	RB	_	9	adv	_	_
9	25	0	CD	_	7	obj	_	_
10	%	%	NN	_	9	meta	_	_
11	when	when	WRB	_	16	adv	_	_
12	drug3	drug0	NN	_	16	dep	_	_
13	and	and	CC	_	12	cc	_	_
14	drug4	drug0	NN	_	12	conj	_	_
15	were	be	VBD	_	16	aux	_	_
16	coadministered	coadministered	VBN	_	7	comp	_	_
17	.	.	.	_	7	p	_	_

1	However	however	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	LDL-C	ldl-c	NN	_	4	com	_	_
4	reduction	reduction	NN	_	5	dep	_	_
5	was	be	VBD	_	0	root	_	_
6	greater	great	JJR	_	5	dep	_	_
7	when	when	WRB	_	12	adv	_	_
8	drug1	drug0	NN	_	12	dep	_	_
9	and	and	CC	_	8	cc	_	_
10	drug2	drug0	NN	_	8	conj	_	_
11	were	be	VBD	_	12	aux	_	_
12	coadministered	coadministered	VBN	_	5	comp	_	_
13	than	than	IN	_	18	case	_	_
14	when	when	WRB	_	18	adv	_	_
15	either	either	DT	_	16	det	_	_
16	drug	drug	NN	_	18	dep	_	_
17	was	be	VBD	_	18	aux	_	_
18	given	give	VBN	_	12	ppmod	_	_
19	alone	alone	RB	_	18	adv	_	_
20	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	11	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	5	com	_	_
4	plasma	plasma	NN	_	5	com	_	_
5	concentrations	concentration	NNS	_	1	conj	_	_
6	and	and	CC	_	5	cc	_	_
7	LDL-C	ldl-c	JJ	_	8	attr	_	_
8	reduction	reduction	NN	_	1	conj	_	_
9	were	be	VBD	_	11	aux	_	_
10	not	not	RB	_	11	neg	_	_
11	altered	alter	VBN	_	0	root	_	_
12	by	by	IN	_	13	case	_	_
13	coadministration	coadministration	NN	_	11	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	When	when	WRB	_	11	adv	_	_
4	multiple	multiple	JJ	_	5	attr	_	_
5	doses	dose	NNS	_	11	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug3	drug0	NN	_	7	conj	_	_
10	were	be	VBD	_	11	aux	_	_
11	coadministered	coadministered	VBN	_	17	advcl	_	_
12	,	,	,	_	17	p	_	_
13	steady-state	steady-state	JJ	_	16	attr	_	_
14	plasma	plasma	NN	_	16	com	_	_
15	drug4	drug0	NN	_	16	com	_	_
16	concentrations	concentration	NNS	_	17	dep	_	_
17	increased	increase	VBD	_	1	acl	_	_
18	by	by	IN	_	20	case	_	_
19	approximately	approximately	RB	_	20	adv	_	_
20	20	0	CD	_	17	ppmod	_	_
21	%	%	NN	_	20	meta	_	_
22	.	.	.	_	1	p	_	_

1	Patients	patient	NNS	_	6	dep	_	_
2	taking	take	VBG	_	1	acl	_	_
3	drug1	drug0	NN	_	2	obj	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	monitored	monitor	VBN	_	0	root	_	_
7	appropriately	appropriately	RB	_	6	adv	_	_
8	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	5	case	_	_
4	healthy	healthy	JJ	_	5	attr	_	_
5	individuals	individual	NNS	_	11	ppmod	_	_
6	,	,	,	_	11	p	_	_
7	plasma	plasma	NN	_	8	com	_	_
8	concentrations	concentration	NNS	_	11	dep	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	increased	increase	VBD	_	1	acl	_	_
12	approximately	approximately	RB	_	13	adv	_	_
13	40	0	CD	_	11	obj	_	_
14	%	%	NN	_	13	meta	_	_
15	with	with	IN	_	16	case	_	_
16	coadministration	coadministration	NN	_	11	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug3	drug0	NN	_	16	ppmod	_	_
19	and	and	CC	_	18	cc	_	_
20	drug4	drug0	NN	_	18	conj	_	_
21	,	,	,	_	18	p	_	_
22	a	a	DT	_	24	det	_	_
23	known	known	JJ	_	24	attr	_	_
24	inhibitor	inhibitor	NN	_	18	appo	_	_
25	of	of	IN	_	28	case	_	_
26	cytochrome	cytochrome	NN	_	28	com	_	_
27	P450	p0	NN	_	28	com	_	_
28	3A4	0a0	NN	_	24	ppmod	_	_
29	.	.	.	_	1	p	_	_

1	Oral	oral	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	Coadministration	coadministration	NN	_	11	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	4	cc	_	_
8	an	an	DT	_	10	det	_	_
9	oral	oral	JJ	_	10	attr	_	_
10	drug3	drug0	NN	_	4	conj	_	_
11	increased	increase	VBD	_	2	acl	_	_
12	AUC	auc	NN	_	13	com	_	_
13	values	value	NNS	_	11	obj	_	_
14	for	for	IN	_	15	case	_	_
15	drug4	drug0	NN	_	13	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	drug5	drug0	NN	_	15	conj	_	_
18	by	by	IN	_	20	case	_	_
19	approximately	approximately	RB	_	20	adv	_	_
20	30	0	CD	_	11	ppmod	_	_
21	%	%	NN	_	20	meta	_	_
22	and	and	CC	_	20	cc	_	_
23	20	0	CD	_	20	conj	_	_
24	%	%	NN	_	23	meta	_	_
25	.	.	.	_	2	p	_	_

1	These	these	DT	_	2	det	_	_
2	increases	increase	NNS	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	considered	consider	VBN	_	0	root	_	_
6	when	when	WRB	_	7	adv	_	_
7	selecting	select	VBG	_	5	comp	_	_
8	an	an	DT	_	10	det	_	_
9	oral	oral	JJ	_	10	attr	_	_
10	drug1	drug0	NN	_	7	obj	_	_
11	for	for	IN	_	13	case	_	_
12	a	a	DT	_	13	det	_	_
13	woman	woman	NN	_	10	ppmod	_	_
14	taking	take	VBG	_	13	acl	_	_
15	drug2	drug0	NN	_	14	obj	_	_
16	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	had	have	VBD	_	0	root	_	_
5	no	no	DT	_	8	det	_	_
6	clinically	clinically	RB	_	7	adv	_	_
7	significant	significant	JJ	_	8	attr	_	_
8	effect	effect	NN	_	4	obj	_	_
9	on	on	IN	_	11	case	_	_
10	prothrombin	prothrombin	NN	_	11	com	_	_
11	time	time	NN	_	4	ppmod	_	_
12	when	when	WRB	_	13	adv	_	_
13	administered	administer	VBN	_	4	comp	_	_
14	to	to	TO	_	15	aux	_	_
15	patients	patient	NNS	_	13	ppmod	_	_
16	receiving	receive	VBG	_	15	acl	_	_
17	chronic	chronic	JJ	_	19	attr	_	_
18	drug3	drug0	NN	_	19	com	_	_
19	treatment	treatment	NN	_	16	obj	_	_
20	.	.	.	_	4	p	_	_

1	Endocrine	endocrine	JJ	_	3	attr	_	_
2	Function	function	NN	_	3	com	_	_
3	drug1	drug0	NNS	_	4	dep	_	_
4	interfere	interfere	VBP	_	0	root	_	_
5	with	with	IN	_	7	case	_	_
6	cholesterol	cholesterol	NN	_	7	com	_	_
7	synthesis	synthesis	NN	_	4	ppmod	_	_
8	and	and	CC	_	4	cc	_	_
9	theoretically	theoretically	RB	_	11	adv	_	_
10	might	might	MD	_	11	modal	_	_
11	blunt	blunt	VB	_	4	conj	_	_
12	adrenal	adrenal	JJ	_	16	attr	_	_
13	and/or	and/or	CC	_	12	cc	_	_
14	gonadal	gonadal	JJ	_	12	conj	_	_
15	steroid	steroid	NN	_	16	com	_	_
16	production	production	NN	_	11	obj	_	_
17	.	.	.	_	4	p	_	_

1	Clinical	clinical	JJ	_	2	attr	_	_
2	studies	study	NNS	_	4	dep	_	_
3	have	have	VBP	_	4	aux	_	_
4	shown	show	VBN	_	0	root	_	_
5	that	that	IN	_	9	mark	_	_
6	drug1	drug0	NN	_	9	dep	_	_
7	does	do	VBZ	_	9	aux	_	_
8	not	not	RB	_	9	neg	15:neg	_
9	reduce	reduce	VB	_	4	comp	_	_
10	basal	basal	JJ	_	13	attr	_	_
11	plasma	plasma	NN	_	13	com	_	_
12	cortisol	cortisol	NN	_	13	com	_	_
13	concentration	concentration	NN	_	9	obj	_	_
14	or	or	CC	_	9	cc	_	_
15	impair	impair	VB	_	9	conj	_	_
16	adrenal	adrenal	JJ	_	17	attr	_	_
17	reserve	reserve	NN	_	15	obj	_	_
18	.	.	.	_	4	p	_	_

1	The	the	DT	_	2	det	_	_
2	effects	effect	NNS	_	11	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	on	on	IN	_	7	case	_	_
6	male	male	JJ	_	7	attr	_	_
7	fertility	fertility	NN	_	2	ppmod	_	_
8	have	have	VBP	_	11	aux	_	_
9	not	not	RB	_	11	neg	_	_
10	been	be	VBN	_	11	aux	_	_
11	studied	study	VBN	_	0	root	_	_
12	in	in	IN	_	14	case	_	_
13	adequate	adequate	JJ	_	14	attr	_	_
14	numbers	number	NNS	_	11	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	patients	patient	NNS	_	14	ppmod	_	_
17	.	.	.	_	11	p	_	_

1	The	the	DT	_	2	det	_	_
2	effects	effect	NNS	_	14	dep	_	_
3	,	,	,	_	5	p	_	_
4	if	if	IN	_	5	mark	_	_
5	any	any	DT	_	2	prn	_	_
6	,	,	,	_	5	p	_	_
7	on	on	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	pituitary-gonadal	pituitary-gonadal	JJ	_	10	attr	_	_
10	axis	axis	NN	_	2	ppmod	_	_
11	in	in	IN	_	13	case	_	_
12	premenopausal	premenopausal	JJ	_	13	attr	_	_
13	women	woman	NNS	_	2	ppmod	_	_
14	are	be	VBP	_	0	root	_	_
15	unknown	unknown	JJ	_	14	dep	_	_
16	.	.	.	_	14	p	_	_

1	Caution	caution	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	exercised	exercise	VBN	_	0	root	_	_
5	if	if	IN	_	9	mark	_	_
6	an	an	DT	_	7	det	_	_
7	drug1	drug0	NN	_	9	dep	_	_
8	is	be	VBZ	_	9	aux	_	_
9	administered	administer	VBN	_	4	comp	_	_
10	concomitantly	concomitantly	RB	_	9	adv	_	_
11	with	with	IN	_	12	case	_	_
12	drugs	drug	NNS	_	9	ppmod	_	_
13	that	that	WDT	_	15	dep	_	_
14	may	may	MD	_	15	modal	_	_
15	decrease	decrease	VB	_	12	relcl	_	_
16	the	the	DT	_	17	det	_	_
17	levels	level	NNS	_	15	obj	_	_
18	or	or	CC	_	17	cc	_	_
19	activity	activity	NN	_	17	conj	_	_
20	of	of	IN	_	23	case	_	_
21	endogenous	endogenous	JJ	_	23	attr	_	_
22	steroid	steroid	NN	_	23	com	_	_
23	hormones	hormone	NNS	_	17	ppmod	_	_
24	,	,	,	_	12	p	_	_
25	such	such	JJ	_	27	adv	_	_
26	as	as	IN	_	27	case	_	_
27	drug2	drug0	NN	_	12	ppmod	_	_
28	,	,	,	_	27	p	_	_
29	drug3	drug0	NN	_	27	conj	_	_
30	,	,	,	_	29	p	_	_
31	and	and	CC	_	29	cc	_	_
32	drug4	drug0	NN	_	27	conj	_	_
33	.	.	.	_	4	p	_	_

1	CNS	cns	NN	_	4	com	_	_
2	Toxicity	toxicity	NN	_	4	com	_	_
3	Brain	brain	NN	_	4	com	_	_
4	hemorrhage	hemorrhage	NN	_	6	dep	_	_
5	was	be	VBD	_	6	aux	_	_
6	seen	see	VBN	_	0	root	_	_
7	in	in	IN	_	10	case	_	_
8	a	a	DT	_	10	det	_	_
9	female	female	JJ	_	10	attr	_	_
10	dog	dog	NNS	_	6	ppmod	_	_
11	treated	treat	VBN	_	10	acl	_	_
12	for	for	IN	_	14	case	_	_
13	3	0	CD	_	14	num	_	_
14	months	month	NNS	_	11	ppmod	_	_
15	at	at	IN	_	17	case	_	_
16	120	0	CD	_	17	num	_	_
17	mg/kg/day	mg/kg/day	NN	_	11	ppmod	_	_
18	.	.	.	_	6	p	_	_

1	Brain	brain	NN	_	2	com	_	_
2	hemorrhage	hemorrhage	NN	_	8	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	optic	optic	JJ	_	6	attr	_	_
5	nerve	nerve	NN	_	6	com	_	_
6	vacuolation	vacuolation	NN	_	2	conj	_	_
7	were	be	VBD	_	8	aux	_	_
8	seen	see	VBN	_	0	root	_	_
9	in	in	IN	_	12	case	_	_
10	another	another	DT	_	12	det	_	_
11	female	female	JJ	_	12	attr	_	_
12	dog	dog	NN	_	8	ppmod	_	_
13	that	that	WDT	_	15	dep	_	_
14	was	be	VBD	_	15	aux	_	_
15	sacrificed	sacrifice	VBN	_	12	relcl	_	_
16	in	in	IN	_	18	case	_	_
17	moribund	moribund	NN	_	18	com	_	_
18	condition	condition	NN	_	15	ppmod	_	_
19	after	after	IN	_	21	case	_	_
20	11	0	CD	_	21	num	_	_
21	weeks	week	NNS	_	15	ppmod	_	_
22	of	of	IN	_	24	case	_	_
23	escalating	escalating	JJ	_	24	attr	_	_
24	doses	dose	NNS	_	21	ppmod	_	_
25	up	up	RP	_	28	prt	_	_
26	to	to	TO	_	28	aux	_	_
27	280	0	CD	_	28	num	_	_
28	mg/kg/day	mg/kg/day	NN	_	24	ppmod	_	_
29	.	.	.	_	8	p	_	_

1	The	the	DT	_	4	det	_	_
2	120	0	CD	_	4	num	_	_
3	mg/kg	mg/kg	NN	_	4	com	_	_
4	dose	dose	NN	_	5	dep	_	_
5	resulted	result	VBD	_	0	root	_	_
6	in	in	IN	_	9	case	_	_
7	a	a	DT	_	9	det	_	_
8	systemic	systemic	JJ	_	9	attr	_	_
9	exposure	exposure	NN	_	5	ppmod	_	_
10	approximately	approximately	RB	_	11	adv	_	_
11	16	0	CD	_	12	num	_	_
12	times	time	NNS	_	9	appo	_	_
13	the	the	DT	_	16	det	_	_
14	human	human	JJ	_	16	attr	_	_
15	plasma	plasma	NN	_	16	com	_	_
16	area-under-the-curve	area-under-the-curve	NN	_	12	appo	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	AUC	auc	NN	_	16	prn	_	_
19	,	,	,	_	18	p	_	_
20	0-24	0	CD	_	21	num	_	_
21	hours	hour	NNS	_	18	appo	_	_
22	)	-rrb-	-RRB-	_	18	p	_	_
23	based	base	VBN	_	16	acl	_	_
24	on	on	IN	_	28	case	_	_
25	the	the	DT	_	28	det	_	_
26	maximum	maximum	JJ	_	28	attr	_	_
27	human	human	JJ	_	28	attr	_	_
28	dose	dose	NN	_	23	ppmod	_	_
29	of	of	IN	_	31	case	_	_
30	80	0	CD	_	31	num	_	_
31	mg/day	mg/day	NN	_	28	ppmod	_	_
32	.	.	.	_	5	p	_	_

1	A	a	DT	_	4	det	_	_
2	single	single	JJ	_	4	attr	_	_
3	tonic	tonic	JJ	_	4	attr	_	_
4	convulsion	convulsion	NN	_	6	dep	_	_
5	was	be	VBD	_	6	aux	_	_
6	seen	see	VBN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	each	each	DT	_	6	ppmod	_	_
9	of	of	IN	_	12	case	_	_
10	2	0	CD	_	12	num	_	_
11	male	male	JJ	_	12	attr	_	_
12	dogs	dog	NNS	_	8	ppmod	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	one	#crd#	CD	_	6	num	_	_
15	treated	treat	VBN	_	14	acl	_	_
16	at	at	IN	_	18	case	_	_
17	10	0	CD	_	18	num	_	_
18	mg/kg/day	mg/kg/day	NN	_	15	ppmod	_	_
19	and	and	CC	_	14	cc	_	_
20	one	#crd#	CD	_	14	conj	_	_
21	at	at	IN	_	23	case	_	_
22	120	0	CD	_	23	num	_	_
23	mg/kg/day	mg/kg/day	NN	_	20	ppmod	_	_
24	)	-rrb-	-RRB-	_	14	p	_	_
25	in	in	IN	_	28	case	_	_
26	a	a	DT	_	28	det	_	_
27	2-year	0-year	JJ	_	28	attr	_	_
28	study	study	NN	_	6	ppmod	_	_
29	.	.	.	_	6	p	_	_

1	No	no	DT	_	3	det	_	_
2	CNS	cns	NN	_	3	com	_	_
3	lesions	lesion	NNS	_	6	dep	_	_
4	have	have	VBP	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	observed	observe	VBN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	mice	mouse	NNS	_	6	ppmod	_	_
9	after	after	IN	_	11	case	_	_
10	chronic	chronic	JJ	_	11	attr	_	_
11	treatment	treatment	NN	_	6	ppmod	_	_
12	for	for	IN	_	16	case	_	_
13	up	up	RB	_	15	adv	_	_
14	to	to	TO	_	15	attr	_	_
15	2	0	CD	_	16	num	_	_
16	years	year	NNS	_	11	ppmod	_	_
17	at	at	IN	_	18	case	_	_
18	doses	dose	NNS	_	6	ppmod	_	_
19	up	up	RB	_	21	adv	_	_
20	to	to	TO	_	21	attr	_	_
21	400	0	CD	_	22	num	_	_
22	mg/kg/day	mg/kg/day	NN	_	18	appo	_	_
23	or	or	CC	_	18	cc	_	_
24	in	in	IN	_	25	case	_	_
25	rats	rat	NNS	_	27	ppmod	_	_
26	at	at	IN	_	27	case	_	_
27	doses	dose	NNS	_	18	conj	_	_
28	up	up	RP	_	31	prt	_	_
29	to	to	TO	_	31	aux	_	_
30	100	0	CD	_	31	num	_	_
31	mg/kg/day	mg/kg/day	NN	_	27	ppmod	_	_
32	.	.	.	_	6	p	_	_

1	These	these	DT	_	2	det	_	_
2	doses	dose	NNS	_	3	dep	_	_
3	were	be	VBD	_	0	root	_	_
4	6	0	CD	_	7	num	_	_
5	to	to	TO	_	4	cc	_	_
6	11	0	CD	_	4	conj	_	_
7	times	time	NNS	_	3	obj	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	mouse	mouse	NN	_	7	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	and	and	CC	_	7	cc	_	_
12	8	0	CD	_	15	num	_	_
13	to	to	TO	_	12	cc	_	_
14	16	0	CD	_	12	conj	_	_
15	times	time	NNS	_	21	attr	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	rat	rat	NN	_	15	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	the	the	DT	_	21	det	_	_
20	human	human	JJ	_	21	attr	_	_
21	AUC	auc	NN	_	7	conj	_	_
22	(	-lrb-	-LRB-	_	23	p	_	_
23	0-24	0	NN	_	21	num	_	_
24	)	-rrb-	-RRB-	_	23	p	_	_
25	based	base	VBN	_	31	adv	_	_
26	on	on	IN	_	31	case	_	_
27	the	the	DT	_	31	det	_	_
28	maximum	maximum	JJ	_	31	attr	_	_
29	recommended	recommend	VBN	_	31	attr	_	_
30	human	human	JJ	_	31	attr	_	_
31	dose	dose	NN	_	3	ppmod	_	_
32	of	of	IN	_	34	case	_	_
33	80	0	CD	_	34	num	_	_
34	mg/day	mg/day	NN	_	31	ppmod	_	_
35	.	.	.	_	3	p	_	_

1	CNS	cns	NN	_	3	attr	_	_
2	vascular	vascular	JJ	_	3	attr	_	_
3	lesions	lesion	NNS	_	22	dep	_	_
4	,	,	,	_	3	p	_	_
5	characterized	characterize	VBN	_	3	acl	_	_
6	by	by	IN	_	8	case	_	_
7	perivascular	perivascular	JJ	_	8	attr	_	_
8	hemorrhages	hemorrhage	NNS	_	5	ppmod	_	_
9	,	,	,	_	8	p	_	_
10	edema	edema	NN	_	8	conj	_	_
11	,	,	,	_	10	p	_	_
12	and	and	CC	_	10	cc	_	_
13	mononuclear	mononuclear	JJ	_	15	attr	_	_
14	cell	cell	NN	_	15	com	_	_
15	infiltration	infiltration	NN	_	8	conj	_	_
16	of	of	IN	_	18	case	_	_
17	perivascular	perivascular	JJ	_	18	attr	_	_
18	spaces	space	NNS	_	15	ppmod	_	_
19	,	,	,	_	3	p	_	_
20	have	have	VBP	_	22	aux	_	_
21	been	be	VBN	_	22	aux	_	_
22	observed	observe	VBN	_	0	root	_	_
23	in	in	IN	_	24	case	_	_
24	dogs	dog	NNS	_	22	ppmod	_	_
25	treated	treat	VBN	_	24	acl	_	_
26	with	with	IN	_	28	case	_	_
27	other	other	JJ	_	28	attr	_	_
28	members	member	NNS	_	25	ppmod	_	_
29	of	of	IN	_	31	case	_	_
30	this	this	DT	_	31	det	_	_
31	class	class	NN	_	28	ppmod	_	_
32	.	.	.	_	22	p	_	_

1	A	a	DT	_	4	det	_	_
2	chemically	chemically	RB	_	3	adv	_	_
3	similar	similar	JJ	_	4	attr	_	_
4	drug	drug	NN	_	8	dep	_	_
5	in	in	IN	_	7	case	_	_
6	this	this	DT	_	7	det	_	_
7	class	class	NN	_	4	ppmod	_	_
8	produced	produce	VBD	_	0	root	_	_
9	optic	optic	JJ	_	11	attr	_	_
10	nerve	nerve	NN	_	11	com	_	_
11	degeneration	degeneration	NN	_	8	obj	_	_
12	(	-lrb-	-LRB-	_	14	p	_	_
13	Wallerian	wallerian	NNP	_	14	com	_	_
14	degeneration	degeneration	NN	_	11	prn	_	_
15	of	of	IN	_	17	case	_	_
16	retinogeniculate	retinogeniculate	NN	_	17	com	_	_
17	fibers	fiber	NNS	_	14	ppmod	_	_
18	)	-rrb-	-RRB-	_	14	p	_	_
19	in	in	IN	_	22	case	_	_
20	clinically	clinically	RB	_	21	adv	_	_
21	normal	normal	JJ	_	22	attr	_	_
22	dogs	dog	NNS	_	8	ppmod	_	_
23	in	in	IN	_	26	case	_	_
24	a	a	DT	_	26	det	_	_
25	dose-dependent	dose-dependent	JJ	_	26	attr	_	_
26	fashion	fashion	NN	_	8	ppmod	_	_
27	at	at	IN	_	29	case	_	_
28	a	a	DT	_	29	det	_	_
29	dose	dose	NN	_	8	ppmod	_	_
30	that	that	WDT	_	31	dep	_	_
31	produced	produce	VBD	_	29	relcl	_	_
32	plasma	plasma	NN	_	34	com	_	_
33	drug	drug	NN	_	34	com	_	_
34	levels	level	NNS	_	31	obj	_	_
35	about	about	RB	_	36	adv	_	_
36	30	0	CD	_	37	num	_	_
37	times	time	NNS	_	38	advnp	_	_
38	higher	high	JJR	_	34	attr	_	_
39	than	than	IN	_	43	case	_	_
40	the	the	DT	_	43	det	_	_
41	mean	mean	JJ	_	43	attr	_	_
42	drug	drug	NN	_	43	com	_	_
43	level	level	NN	_	38	ppmod	_	_
44	in	in	IN	_	45	case	_	_
45	humans	human	NNS	_	43	ppmod	_	_
46	taking	take	VBG	_	45	acl	_	_
47	the	the	DT	_	50	det	_	_
48	highest	high	JJS	_	50	attr	_	_
49	recommended	recommend	VBN	_	50	attr	_	_
50	dose	dose	NN	_	46	obj	_	_
51	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	,	,	,	_	1	p	_	_
5	drug3	drug0	NN	_	1	appo	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	drug4	drug0	NN	_	5	prn	_	_
8	,	,	,	_	1	p	_	_
9	drug5	drug0	NN	_	1	appo	_	_
10	,	,	,	_	1	p	_	_
11	drug6	drug0	NN	_	1	appo	_	_
12	:	:	:	_	1	p	_	_
13	Skeletal	skeletal	JJ	_	14	attr	_	_
14	Muscle	muscle	NN	_	1	appo	_	_
15	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	drug2	drug0	NN	_	1	prn	_	_
4	)	-rrb-	-RRB-	_	3	p	_	_
5	:	:	:	_	1	p	_	_
6	drug3	drug0	NN	_	8	com	_	_
7	plasma	plasma	NN	_	8	com	_	_
8	concentrations	concentration	NNS	_	11	dep	_	_
9	were	be	VBD	_	11	aux	_	_
10	not	not	RB	_	11	neg	_	_
11	affected	affect	VBN	_	1	acl	_	_
12	by	by	IN	_	13	case	_	_
13	co-administration	co-administration	NN	_	11	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug4	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	5	attr	_	_
2	:	:	:	_	5	p	_	_
3	drug2	drug0	NN	_	5	com	_	_
4	plasma	plasma	NN	_	5	com	_	_
5	concentrations	concentration	NNS	_	8	dep	_	_
6	were	be	VBD	_	8	aux	_	_
7	not	not	RB	_	8	neg	_	_
8	affected	affect	VBN	_	0	root	_	_
9	by	by	IN	_	10	case	_	_
10	co-administration	co-administration	NN	_	8	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	influence	influence	NN	_	16	dep	_	_
5	of	of	IN	_	9	case	_	_
6	the	the	DT	_	9	det	_	_
7	bile-acidsequestering	bile-acidsequestering	JJ	_	9	attr	_	_
8	agent	agent	NN	_	9	com	_	_
9	drug2	drug0	NN	_	4	ppmod	_	_
10	on	on	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	pharmacokinetits	pharmacokinetits	NNS	_	4	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug3	drug0	NN	_	12	ppmod	_	_
15	was	be	VBD	_	16	aux	_	_
16	evaluated	evaluate	VBN	_	1	acl	_	_
17	in	in	IN	_	20	case	_	_
18	12	0	CD	_	20	num	_	_
19	healthy	healthy	JJ	_	20	attr	_	_
20	males	male	NNS	_	16	ppmod	_	_
21	in	in	IN	_	26	case	_	_
22	2	0	CD	_	26	num	_	_
23	separate	separate	JJ	_	26	attr	_	_
24	randomized	randomized	JJ	_	26	attr	_	_
25	crossover	crossover	NN	_	26	com	_	_
26	studies	study	NNS	_	20	ppmod	_	_
27	.	.	.	_	1	p	_	_

1	In	in	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	first	#ord#	JJ	_	4	attr	_	_
4	study	study	NN	_	16	ppmod	_	_
5	,	,	,	_	16	p	_	_
6	concomitant	concomitant	JJ	_	7	attr	_	_
7	administration	administration	NN	_	16	dep	_	_
8	of	of	IN	_	11	case	_	_
9	0.2	0	CD	_	10	num	_	_
10	mg	mg	NN	_	11	com	_	_
11	drug1	drug0	NN	_	7	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	12	0	CD	_	14	num	_	_
14	g	g	NN	_	15	com	_	_
15	drug2	drug0	NN	_	11	conj	_	_
16	resulted	result	VBD	_	0	root	_	_
17	in	in	IN	_	18	case	_	_
18	decreases	decrease	NNS	_	16	ppmod	_	_
19	of	of	IN	_	22	case	_	_
20	more	more	JJR	_	22	attr	_	_
21	than	than	IN	_	20	com	_	_
22	22	0	CD	_	18	ppmod	_	_
23	%	%	NN	_	22	meta	_	_
24	for	for	IN	_	25	case	_	_
25	AUC	auc	NN	_	22	ppmod	_	_
26	and	and	CC	_	22	cc	_	_
27	40	0	CD	_	22	conj	_	_
28	%	%	NN	_	27	meta	_	_
29	for	for	IN	_	30	case	_	_
30	Cmax	cmax	NN	_	27	ppmod	_	_
31	when	when	WRB	_	32	adv	_	_
32	compared	compare	VBN	_	16	comp	_	_
33	to	to	TO	_	35	aux	_	_
34	dosing	dosing	NN	_	35	com	_	_
35	drug3	drug0	NN	_	32	ppmod	_	_
36	alone	alone	RB	_	32	adv	_	_
37	.	.	.	_	16	p	_	_

1	However	however	RB	_	31	adv	_	_
2	,	,	,	_	31	p	_	_
3	in	in	IN	_	6	case	_	_
4	the	the	DT	_	6	det	_	_
5	second	#ord#	JJ	_	6	attr	_	_
6	study	study	NN	_	31	ppmod	_	_
7	,	,	,	_	31	p	_	_
8	administration	administration	NN	_	31	dep	_	_
9	of	of	IN	_	14	case	_	_
10	12	0	CD	_	14	num	_	_
11	g	g	NN	_	14	attr	_	_
12	drug1	drug0	NN	_	14	attr	_	_
13	1	0	CD	_	14	num	_	_
14	hour	hour	NN	_	8	ppmod	_	_
15	before	before	IN	_	18	case	_	_
16	the	the	DT	_	18	det	_	_
17	evening	evening	NN	_	18	com	_	_
18	meal	meal	NN	_	8	ppmod	_	_
19	and	and	CC	_	18	cc	_	_
20	0.3	0	CD	_	21	num	_	_
21	mg	mg	NN	_	22	com	_	_
22	drug2	drug0	NN	_	25	attr	_	_
23	approximately	approximately	RB	_	24	adv	_	_
24	4	0	CD	_	25	num	_	_
25	hours	hour	NNS	_	18	conj	_	_
26	after	after	IN	_	30	case	_	_
27	the	the	DT	_	30	det	_	_
28	same	same	JJ	_	30	attr	_	_
29	evening	evening	NN	_	30	com	_	_
30	meal	meal	NN	_	18	ppmod	_	_
31	resulted	result	VBD	_	0	root	_	_
32	in	in	IN	_	34	case	_	_
33	a	a	DT	_	34	det	_	_
34	decrease	decrease	NN	_	31	ppmod	_	_
35	in	in	IN	_	38	case	_	_
36	the	the	DT	_	38	det	_	_
37	drug3	drug0	NN	_	38	com	_	_
38	AUC	auc	NN	_	34	ppmod	_	_
39	of	of	IN	_	42	case	_	_
40	less	less	JJR	_	42	attr	_	_
41	than	than	IN	_	40	com	_	_
42	8	0	CD	_	38	ppmod	_	_
43	%	%	NN	_	42	meta	_	_
44	,	,	,	_	34	p	_	_
45	and	and	CC	_	34	cc	_	_
46	a	a	DT	_	47	det	_	_
47	decrease	decrease	NN	_	34	conj	_	_
48	in	in	IN	_	49	case	_	_
49	Cmax	cmax	NN	_	47	ppmod	_	_
50	of	of	IN	_	52	case	_	_
51	about	about	RB	_	52	adv	_	_
52	30	0	CD	_	49	ppmod	_	_
53	%	%	NN	_	52	meta	_	_
54	when	when	WRB	_	55	adv	_	_
55	compared	compare	VBN	_	31	comp	_	_
56	to	to	TO	_	58	aux	_	_
57	dosing	dosing	NN	_	58	com	_	_
58	drug4	drug0	NN	_	55	ppmod	_	_
59	alone	alone	RB	_	58	adv	_	_
60	.	.	.	_	31	p	_	_

1	Therefore	therefore	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	it	it	PRP	_	6	dep	_	_
4	would	would	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	expected	expect	VBN	_	0	root	_	_
7	that	that	IN	_	25	mark	_	_
8	a	a	DT	_	10	det	_	_
9	dosing	dosing	NN	_	10	com	_	_
10	schedule	schedule	NN	_	25	dep	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	given	give	VBN	_	10	acl	_	_
14	at	at	IN	_	15	case	_	_
15	bedtime	bedtime	NN	_	13	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	drug2	drug0	NN	_	15	conj	_	_
18	given	give	VBN	_	15	acl	_	_
19	before	before	IN	_	22	case	_	_
20	the	the	DT	_	22	det	_	_
21	evening	evening	NN	_	22	com	_	_
22	meal	meal	NN	_	18	ppmod	_	_
23	would	would	MD	_	25	modal	_	_
24	not	not	RB	_	25	neg	_	_
25	result	result	VB	_	6	comp	_	_
26	in	in	IN	_	29	case	_	_
27	a	a	DT	_	29	det	_	_
28	significant	significant	JJ	_	29	attr	_	_
29	decrease	decrease	NN	_	25	ppmod	_	_
30	in	in	IN	_	33	case	_	_
31	the	the	DT	_	33	det	_	_
32	clinical	clinical	JJ	_	33	attr	_	_
33	effect	effect	NN	_	29	ppmod	_	_
34	of	of	IN	_	35	case	_	_
35	drug3	drug0	NN	_	33	ppmod	_	_
36	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	5	attr	_	_
2	:	:	:	_	5	p	_	_
3	Plasma	plasma	NN	_	5	com	_	_
4	drug2	drug0	NN	_	5	com	_	_
5	levels	level	NNS	_	13	dep	_	_
6	and	and	CC	_	5	cc	_	_
7	drug3	drug0	NN	_	8	com	_	_
8	clearance	clearance	NN	_	5	conj	_	_
9	at	at	IN	_	10	case	_	_
10	steady-state	steady-state	NN	_	8	ppmod	_	_
11	were	be	VBD	_	13	aux	_	_
12	not	not	RB	_	13	neg	_	_
13	affected	affect	VBN	_	0	root	_	_
14	by	by	IN	_	15	case	_	_
15	co-administration	co-administration	NN	_	13	ppmod	_	_
16	of	of	IN	_	19	case	_	_
17	0.2	0	CD	_	18	num	_	_
18	mg	mg	NN	_	19	com	_	_
19	drug4	drug0	NN	_	15	ppmod	_	_
20	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	3	com	_	_
2	plasma	plasma	NN	_	3	com	_	_
3	concentrations	concentration	NNS	_	7	dep	_	_
4	were	be	VBD	_	7	aux	_	_
5	also	also	RB	_	7	adv	_	_
6	not	not	RB	_	7	neg	_	_
7	affected	affect	VBN	_	0	root	_	_
8	by	by	IN	_	9	case	_	_
9	co-administration	co-administration	NN	_	7	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Co-	co-	NN	_	4	com	_	_
4	administration	administration	NN	_	14	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	to	to	TO	_	11	aux	_	_
10	healthy	healthy	JJ	_	11	attr	_	_
11	volunteers	volunteer	NNS	_	4	ppmod	_	_
12	did	do	VBD	_	14	aux	_	_
13	not	not	RB	_	14	neg	_	_
14	result	result	VB	_	1	acl	_	_
15	in	in	IN	_	17	case	_	_
16	any	any	DT	_	17	det	_	_
17	changes	change	NNS	_	14	ppmod	_	_
18	in	in	IN	_	20	case	_	_
19	prothrombin	prothrombin	NN	_	20	com	_	_
20	time	time	NN	_	17	ppmod	_	_
21	or	or	CC	_	20	cc	_	_
22	clotting	clotting	NN	_	24	com	_	_
23	factor	factor	NN	_	24	com	_	_
24	VII	vii	NN	_	20	conj	_	_
25	when	when	WRB	_	26	adv	_	_
26	compared	compare	VBN	_	14	comp	_	_
27	to	to	TO	_	28	aux	_	_
28	co-administration	co-administration	NN	_	26	ppmod	_	_
29	of	of	IN	_	30	case	_	_
30	drug4	drug0	NN	_	28	ppmod	_	_
31	and	and	CC	_	30	cc	_	_
32	placebo	placebo	NN	_	30	conj	_	_
33	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	AUC	auc	NN	_	19	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	Cmax	cmax	NN	_	2	conj	_	_
5	of	of	IN	_	15	case	_	_
6	both	both	DT	_	15	det	_	_
7	the	the	DT	_	15	attr	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	R	r	NN	_	7	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	and	and	CC	_	7	cc	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	S	s	NN	_	7	conj	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	isomers	isomer	NNS	_	2	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	drug1	drug0	NN	_	15	ppmod	_	_
18	were	be	VBD	_	19	aux	_	_
19	unaffected	unaffected	VBN	_	0	root	_	_
20	by	by	IN	_	22	case	_	_
21	concurrent	concurrent	JJ	_	22	attr	_	_
22	dosing	dosing	NN	_	19	ppmod	_	_
23	of	of	IN	_	26	case	_	_
24	0.3	0	CD	_	25	num	_	_
25	mg	mg	NN	_	26	com	_	_
26	drug2	drug0	NN	_	22	ppmod	_	_
27	.	.	.	_	19	p	_	_

1	Co-administration	co-administration	NN	_	8	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	did	do	VBD	_	8	aux	_	_
7	not	not	RB	_	8	neg	_	_
8	alter	alter	VB	_	0	root	_	_
9	the	the	DT	_	10	det	_	_
10	pharmacokinetics	pharmacokinetics	NNS	_	8	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	5	case	_	_
4	hypercholesterolemic	hypercholesterolemic	JJ	_	5	attr	_	_
5	patients	patient	NNS	_	12	ppmod	_	_
6	,	,	,	_	12	p	_	_
7	steady-state	steady-state	JJ	_	9	attr	_	_
8	drug2	drug0	NN	_	9	com	_	_
9	AUC	auc	NN	_	12	dep	_	_
10	and	and	CC	_	9	cc	_	_
11	Cmax	cmax	NN	_	9	conj	_	_
12	increased	increase	VBD	_	1	acl	_	_
13	approximately	approximately	RB	_	14	adv	_	_
14	50	0	CD	_	12	obj	_	_
15	%	%	NN	_	14	meta	_	_
16	and	and	CC	_	14	cc	_	_
17	24	0	CD	_	14	conj	_	_
18	%	%	NN	_	17	meta	_	_
19	respectively	respectively	RB	_	12	adv	_	_
20	after	after	IN	_	22	case	_	_
21	10	0	CD	_	22	num	_	_
22	days	day	NNS	_	12	ppmod	_	_
23	with	with	IN	_	24	case	_	_
24	co-administration	co-administration	NN	_	22	ppmod	_	_
25	of	of	IN	_	26	case	_	_
26	drug3	drug0	NN	_	24	ppmod	_	_
27	,	,	,	_	26	p	_	_
28	a	a	DT	_	30	det	_	_
29	known	known	JJ	_	30	attr	_	_
30	inhibitor	inhibitor	NN	_	26	appo	_	_
31	of	of	IN	_	34	case	_	_
32	cytochrome	cytochrome	NN	_	34	com	_	_
33	P450	p0	NN	_	34	com	_	_
34	3A4	0a0	NN	_	30	ppmod	_	_
35	.	.	.	_	1	p	_	_

1	OTHER	other	JJ	_	3	attr	_	_
2	CONCOMITANT	concomitant	JJ	_	3	attr	_	_
3	THERAPY	therapy	NN	_	0	root	_	_
4	:	:	:	_	3	p	_	_
5	Although	although	IN	_	11	mark	_	_
6	specific	specific	JJ	_	8	attr	_	_
7	interaction	interaction	NN	_	8	com	_	_
8	studies	study	NNS	_	11	dep	_	_
9	were	be	VBD	_	11	aux	_	_
10	not	not	RB	_	11	neg	_	_
11	performed	performed	VBN	_	19	advcl	_	_
12	,	,	,	_	11	p	_	_
13	in	in	IN	_	15	case	_	_
14	clinical	clinical	JJ	_	15	attr	_	_
15	studies	study	NNS	_	11	ppmod	_	_
16	,	,	,	_	19	p	_	_
17	drug1	drug0	NN	_	19	dep	_	_
18	was	be	VBD	_	19	aux	_	_
19	used	use	VBN	_	3	acl	_	_
20	concomitantly	concomitantly	RB	_	19	adv	_	_
21	with	with	IN	_	22	case	_	_
22	drug2	drug0	NN	_	19	ppmod	_	_
23	,	,	,	_	22	p	_	_
24	drug3	drug0	NN	_	22	conj	_	_
25	,	,	,	_	24	p	_	_
26	drug4	drug0	NN	_	22	conj	_	_
27	,	,	,	_	26	p	_	_
28	drug5	drug0	NN	_	22	conj	_	_
29	,	,	,	_	28	p	_	_
30	and	and	CC	_	28	cc	_	_
31	drug6	drug0	NN	_	22	conj	_	_
32	(	-lrb-	-LRB-	_	33	p	_	_
33	drug7	drug0	NN	_	31	prn	_	_
34	)	-rrb-	-RRB-	_	33	p	_	_
35	without	without	IN	_	36	case	_	_
36	evidence	evidence	NN	_	19	ppmod	_	_
37	of	of	IN	_	41	case	_	_
38	clinically	clinically	RB	_	39	adv	_	_
39	significant	significant	JJ	_	41	attr	_	_
40	adverse	adverse	JJ	_	41	attr	_	_
41	interactions	interaction	NNS	_	36	ppmod	_	_
42	.	.	.	_	3	p	_	_

1	Additive	additive	JJ	_	3	attr	_	_
2	adverse	adverse	JJ	_	3	attr	_	_
3	effects	effect	NNS	_	9	dep	_	_
4	resulting	result	VBG	_	3	acl	_	_
5	from	from	IN	_	7	case	_	_
6	cholinergic	cholinergic	JJ	_	7	attr	_	_
7	blockade	blockade	NN	_	4	ppmod	_	_
8	may	may	MD	_	9	modal	_	_
9	occur	occur	VB	_	0	root	_	_
10	when	when	WRB	_	13	adv	_	_
11	drug1	drug0	NN	_	13	dep	_	_
12	is	be	VBZ	_	13	aux	_	_
13	administered	administer	VBN	_	9	comp	_	_
14	concomitantly	concomitantly	RB	_	13	adv	_	_
15	with	with	IN	_	17	case	_	_
16	other	other	JJ	_	17	attr	_	_
17	drug2	drug0	NN	_	13	ppmod	_	_
18	,	,	,	_	17	p	_	_
19	drug3	drug0	NN	_	17	conj	_	_
20	,	,	,	_	19	p	_	_
21	drug4	drug0	NN	_	17	conj	_	_
22	,	,	,	_	21	p	_	_
23	drug5	drug0	NN	_	17	conj	_	_
24	,	,	,	_	23	p	_	_
25	drug6	drug0	NN	_	17	conj	_	_
26	,	,	,	_	25	p	_	_
27	drug7	drug0	NN	_	17	conj	_	_
28	or	or	CC	_	27	cc	_	_
29	some	some	DT	_	30	det	_	_
30	drug8	drug0	NN	_	17	conj	_	_
31	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	interfere	interfere	VB	_	0	root	_	_
4	with	with	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	absorption	absorption	NN	_	3	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	.	.	.	_	3	p	_	_

1	Administer	administer	NN	_	2	com	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	before	before	IN	_	4	case	_	_
4	meals	meals	NN	_	2	ppmod	_	_
5	;	;	:	_	2	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	after	after	IN	_	3	case	_	_
3	meals	meals	NN	_	1	ppmod	_	_
4	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	metabolized	metabolize	VBN	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	by	by	IN	_	14	case	_	_
7	the	the	DT	_	14	det	_	_
8	cytochrome	cytochrome	NN	_	9	com	_	_
9	P450	p0	NN	_	14	attr	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	CYP450	cyp0	NN	_	9	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	enzyme	enzyme	NN	_	14	com	_	_
14	group	group	NN	_	3	ppmod	_	_
15	,	,	,	_	14	p	_	_
16	specifically	specifically	RB	_	19	adv	_	_
17	cytochromes	cytochromes	NN	_	19	com	_	_
18	P450	p0	NN	_	19	com	_	_
19	3A4	0a0	NN	_	14	appo	_	_
20	(	-lrb-	-LRB-	_	21	p	_	_
21	CYP3A4	cyp0a0	NN	_	19	prn	_	_
22	)	-rrb-	-RRB-	_	21	p	_	_
23	and	and	CC	_	14	cc	_	_
24	CYP2C8	cyp0c0	NN	_	14	conj	_	_
25	.	.	.	_	3	p	_	_

1	The	the	DT	_	3	det	_	_
2	CYP3A4	cyp0a0	NN	_	3	com	_	_
3	isoenzyme	isoenzyme	NN	_	4	dep	_	_
4	is	be	VBZ	_	0	root	_	_
5	present	present	JJ	_	4	dep	_	_
6	in	in	IN	_	9	case	_	_
7	both	both	CC	_	9	cc	_	_
8	the	the	DT	_	9	det	_	_
9	liver	liver	NN	_	5	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	intestines	intestine	NNS	_	9	conj	_	_
12	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	also	also	RB	_	4	adv	_	_
4	known	know	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	be	be	VB	_	4	comp	_	_
7	an	an	DT	_	8	det	_	_
8	inhibitor	inhibitor	NN	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	CYP3A4	cyp0a0	NN	_	8	ppmod	_	_
11	.	.	.	_	4	p	_	_

1	Therefore	therefore	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	drug1	drug0	NN	_	4	dep	_	_
4	has	have	VBZ	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	potential	potential	NN	_	4	obj	_	_
7	for	for	IN	_	8	case	_	_
8	interactions	interaction	NNS	_	6	ppmod	_	_
9	with	with	IN	_	10	case	_	_
10	drugs	drug	NNS	_	8	ppmod	_	_
11	or	or	CC	_	10	cc	_	_
12	substances	substance	NNS	_	10	conj	_	_
13	that	that	WDT	_	15	dep	_	_
14	may	may	MD	_	15	modal	_	_
15	be	be	VB	_	10	relcl	_	_
16	substrates	substrate	NNS	_	15	obj	_	_
17	,	,	,	_	16	p	_	_
18	inhibitors	inhibitor	NNS	_	16	conj	_	_
19	or	or	CC	_	18	cc	_	_
20	inducers	inducer	NNS	_	16	conj	_	_
21	of	of	IN	_	22	case	_	_
22	CYP3A4	cyp0a0	NN	_	16	ppmod	_	_
23	.	.	.	_	4	p	_	_

1	While	while	IN	_	15	mark	_	_
2	only	only	RB	_	5	adv	_	_
3	a	a	DT	_	5	det	_	_
4	limited	limited	JJ	_	5	attr	_	_
5	number	number	NN	_	15	dep	_	_
6	of	of	IN	_	10	case	_	_
7	in	in	FW	_	8	adv	_	_
8	vivo	vivo	FW	_	10	attr	_	_
9	drug-drug	drug-drug	JJ	_	10	attr	_	_
10	interactions	interaction	NNS	_	5	ppmod	_	_
11	with	with	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	have	have	VBP	_	15	aux	_	_
14	been	be	VBN	_	15	aux	_	_
15	reported	report	VBN	_	30	advcl	_	_
16	,	,	,	_	15	p	_	_
17	chiefly	chiefly	RB	_	15	adv	_	_
18	with	with	IN	_	21	case	_	_
19	the	the	DT	_	21	det	_	_
20	oral	oral	JJ	_	21	attr	_	_
21	formulation	formulation	NN	_	15	ppmod	_	_
22	,	,	,	_	30	p	_	_
23	the	the	DT	_	24	det	_	_
24	potential	potential	NN	_	30	dep	_	_
25	for	for	IN	_	27	case	_	_
26	other	other	JJ	_	27	attr	_	_
27	interactions	interaction	NNS	_	24	ppmod	_	_
28	should	should	MD	_	30	modal	_	_
29	be	be	VB	_	30	aux	_	_
30	anticipated	anticipate	VBN	_	0	root	_	_
31	.	.	.	_	30	p	_	_

1	This	this	DT	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	especially	especially	RB	_	4	adv	_	_
4	important	important	JJ	_	2	dep	_	_
5	for	for	IN	_	6	case	_	_
6	drugs	drug	NNS	_	4	ppmod	_	_
7	associated	associate	VBN	_	6	acl	_	_
8	with	with	IN	_	10	case	_	_
9	serious	serious	JJ	_	10	attr	_	_
10	toxicity	toxicity	NN	_	7	ppmod	_	_
11	,	,	,	_	6	p	_	_
12	such	such	JJ	_	15	adv	_	_
13	as	as	IN	_	15	case	_	_
14	other	other	JJ	_	15	attr	_	_
15	drug1	drug0	NN	_	6	ppmod	_	_
16	.	.	.	_	2	p	_	_

1	If	if	IN	_	5	mark	_	_
2	such	such	JJ	_	3	attr	_	_
3	drugs	drug	NNS	_	5	dep	_	_
4	are	be	VBP	_	5	aux	_	_
5	needed	need	VBN	_	11	advcl	_	_
6	,	,	,	_	11	p	_	_
7	their	their	PRP$	_	8	poss	_	_
8	dose	dose	NN	_	11	dep	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	reassessed	reassess	VBN	_	0	root	_	_
12	and	and	CC	_	11	cc	_	_
13	,	,	,	_	11	p	_	_
14	where	where	WRB	_	15	adv	_	_
15	appropriate	appropriate	JJ	_	11	comp	_	_
16	,	,	,	_	11	p	_	_
17	plasma	plasma	NN	_	18	com	_	_
18	concentration	concentration	NN	_	11	conj	_	_
19	measured	measure	VBN	_	18	acl	_	_
20	.	.	.	_	11	p	_	_

1	In	in	IN	_	2	case	_	_
2	view	view	NN	_	16	ppmod	_	_
3	of	of	IN	_	8	case	_	_
4	the	the	DT	_	8	det	_	_
5	long	long	JJ	_	8	attr	_	_
6	and	and	CC	_	5	cc	_	_
7	variable	variable	JJ	_	5	conj	_	_
8	half-life	half-life	NN	_	2	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	,	,	,	_	16	p	_	_
12	potential	potential	NN	_	16	dep	_	_
13	for	for	IN	_	15	case	_	_
14	drug	drug	NN	_	15	com	_	_
15	interactions	interaction	NNS	_	12	ppmod	_	_
16	exists	exist	VBZ	_	0	root	_	_
17	not	not	RB	_	18	com	_	_
18	only	only	RB	_	21	cc	_	_
19	with	with	IN	_	21	case	_	_
20	concomitant	concomitant	JJ	_	21	attr	_	_
21	medication	medication	NN	_	16	ppmod	_	_
22	but	but	CC	_	21	cc	_	_
23	also	also	RB	_	22	com	_	_
24	with	with	IN	_	25	case	_	_
25	drugs	drug	NNS	_	21	conj	_	_
26	administered	administer	VBN	_	25	acl	_	_
27	after	after	IN	_	28	case	_	_
28	discontinuation	discontinuation	NN	_	26	ppmod	_	_
29	of	of	IN	_	30	case	_	_
30	drug2	drug0	NN	_	28	ppmod	_	_
31	.	.	.	_	16	p	_	_

1	Since	since	IN	_	3	mark	_	_
2	drug1	drug0	NN	_	3	dep	_	_
3	is	be	VBZ	_	17	advcl	_	_
4	a	a	DT	_	5	det	_	_
5	substrate	substrate	NN	_	3	obj	_	_
6	for	for	IN	_	7	case	_	_
7	CYP3A4	cyp0a0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	CYP2C8	cyp0c0	NN	_	7	conj	_	_
10	,	,	,	_	17	p	_	_
11	drugs/substances	drugs/substances	NNS	_	17	dep	_	_
12	that	that	WDT	_	13	dep	_	_
13	inhibit	inhibit	VBP	_	11	relcl	_	_
14	these	these	DT	_	15	det	_	_
15	isoenzymes	isoenzymes	NNS	_	13	obj	_	_
16	may	may	MD	_	17	modal	_	_
17	decrease	decrease	VB	_	0	root	_	_
18	the	the	DT	_	19	det	_	_
19	metabolism	metabolism	NN	_	17	obj	_	_
20	and	and	CC	_	17	cc	_	_
21	increase	increase	VB	_	17	conj	_	_
22	serum	serum	NN	_	23	com	_	_
23	concentration	concentration	NN	_	21	obj	_	_
24	of	of	IN	_	25	case	_	_
25	drug2	drug0	NN	_	23	ppmod	_	_
26	.	.	.	_	17	p	_	_

1	Reported	report	VBN	_	2	attr	_	_
2	examples	example	NNS	_	3	dep	_	_
3	include	include	VBP	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	following	following	NN	_	3	obj	_	_
6	:	:	:	_	5	p	_	_
7	drug1	drug0	NN	_	11	dep	_	_
8	:	:	:	_	7	p	_	_
9	drug2	drug0	NN	_	7	appo	_	_
10	are	be	VBP	_	11	aux	_	_
11	known	know	VBN	_	5	acl	_	_
12	to	to	TO	_	13	aux	_	_
13	inhibit	inhibit	VB	_	11	comp	_	_
14	CYP3A4	cyp0a0	NN	_	13	obj	_	_
15	to	to	TO	_	17	aux	_	_
16	varying	vary	VBG	_	17	attr	_	_
17	degrees	degree	NNS	_	14	ppmod	_	_
18	.	.	.	_	3	p	_	_

1	A	a	DT	_	3	det	_	_
2	case	case	NN	_	3	com	_	_
3	report	report	NN	_	19	dep	_	_
4	of	of	IN	_	6	case	_	_
5	one	#crd#	CD	_	6	num	_	_
6	patient	patient	NN	_	3	ppmod	_	_
7	taking	take	VBG	_	6	acl	_	_
8	drug1	drug0	NN	_	10	attr	_	_
9	200	0	CD	_	10	num	_	_
10	mg	mg	NN	_	7	obj	_	_
11	and	and	CC	_	10	cc	_	_
12	drug2	drug0	NN	_	14	attr	_	_
13	800	0	CD	_	14	num	_	_
14	mg	mg	NN	_	16	attr	_	_
15	three	#crd#	CD	_	16	num	_	_
16	times	time	NNS	_	10	conj	_	_
17	a	a	DT	_	18	det	_	_
18	day	day	NN	_	16	appo	_	_
19	resulted	result	VBD	_	0	root	_	_
20	in	in	IN	_	21	case	_	_
21	increases	increase	NNS	_	19	ppmod	_	_
22	in	in	IN	_	24	case	_	_
23	drug3	drug0	NN	_	24	com	_	_
24	concentrations	concentration	NNS	_	21	ppmod	_	_
25	from	from	IN	_	30	case	_	_
26	0.9	0	CD	_	30	num	_	_
27	mg/L	mg/l	NN	_	26	attr	_	_
28	to	to	TO	_	26	cc	_	_
29	1.3	0	CD	_	26	conj	_	_
30	mg/L	mg/l	NN	_	24	ppmod	_	_
31	.	.	.	_	19	p	_	_

1	DEA	dea	NN	_	2	com	_	_
2	concentrations	concentration	NNS	_	5	dep	_	_
3	were	be	VBD	_	5	aux	_	_
4	not	not	RB	_	5	neg	_	_
5	affected	affect	VBN	_	0	root	_	_
6	.	.	.	_	5	p	_	_

1	There	there	EX	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	no	no	DT	_	4	det	_	_
4	evidence	evidence	NN	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	toxicity	toxicity	NN	_	4	ppmod	_	_
7	.	.	.	_	2	p	_	_

1	Monitoring	monitoring	NN	_	18	dep	_	_
2	for	for	IN	_	4	case	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	toxicity	toxicity	NN	_	1	ppmod	_	_
5	and	and	CC	_	1	cc	_	_
6	serial	serial	JJ	_	7	attr	_	_
7	measurement	measurement	NN	_	1	conj	_	_
8	of	of	IN	_	11	case	_	_
9	drug2	drug0	NN	_	11	com	_	_
10	serum	serum	NN	_	11	com	_	_
11	concentration	concentration	NN	_	7	ppmod	_	_
12	during	during	IN	_	15	case	_	_
13	concomitant	concomitant	JJ	_	15	attr	_	_
14	drug3	drug0	NN	_	15	com	_	_
15	therapy	therapy	NN	_	1	ppmod	_	_
16	should	should	MD	_	18	modal	_	_
17	be	be	VB	_	18	aux	_	_
18	considered	consider	VBN	_	0	root	_	_
19	.	.	.	_	18	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	inhibits	inhibit	VBZ	_	0	root	_	_
5	CYP3A4	cyp0a0	NN	_	4	obj	_	_
6	and	and	CC	_	4	cc	_	_
7	can	can	MD	_	8	modal	_	_
8	increase	increase	VB	_	4	conj	_	_
9	serum	serum	NN	_	11	com	_	_
10	drug3	drug0	NN	_	11	com	_	_
11	levels	level	NNS	_	8	obj	_	_
12	.	.	.	_	4	p	_	_

1	Other	other	JJ	_	2	attr	_	_
2	substances	substance	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	Grapefruit	grapefruit	NN	_	5	com	_	_
5	juice	juice	NN	_	10	dep	_	_
6	given	give	VBN	_	5	acl	_	_
7	to	to	TO	_	9	aux	_	_
8	healthy	healthy	JJ	_	9	attr	_	_
9	volunteers	volunteer	NNS	_	6	ppmod	_	_
10	increased	increase	VBD	_	2	acl	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	AUC	auc	NN	_	10	obj	_	_
13	by	by	IN	_	14	case	_	_
14	50	0	CD	_	10	ppmod	_	_
15	%	%	NN	_	14	meta	_	_
16	and	and	CC	_	14	cc	_	_
17	Cmax	cmax	NN	_	14	conj	_	_
18	by	by	IN	_	19	case	_	_
19	84	0	CD	_	10	ppmod	_	_
20	%	%	NN	_	19	meta	_	_
21	,	,	,	_	10	p	_	_
22	resulting	result	VBG	_	10	comp	_	_
23	in	in	IN	_	26	case	_	_
24	increased	increase	VBN	_	26	attr	_	_
25	plasma	plasma	NN	_	26	com	_	_
26	levels	level	NNS	_	22	ppmod	_	_
27	of	of	IN	_	28	case	_	_
28	drug2	drug0	NN	_	26	ppmod	_	_
29	.	.	.	_	2	p	_	_

1	Grapefruit	grapefruit	NN	_	2	com	_	_
2	juice	juice	NN	_	6	dep	_	_
3	should	should	MD	_	6	modal	_	_
4	not	not	RB	_	6	neg	_	_
5	be	be	VB	_	6	aux	_	_
6	taken	take	VBN	_	0	root	_	_
7	during	during	IN	_	8	case	_	_
8	treatment	treatment	NN	_	6	ppmod	_	_
9	with	with	IN	_	11	case	_	_
10	oral	oral	JJ	_	11	attr	_	_
11	amiodarone	amiodarone	NN	_	8	ppmod	_	_
12	.	.	.	_	6	p	_	_

1	This	this	DT	_	2	det	_	_
2	information	information	NN	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	considered	consider	VBN	_	0	root	_	_
6	when	when	WRB	_	7	adv	_	_
7	changing	change	VBG	_	5	comp	_	_
8	from	from	IN	_	10	case	_	_
9	intravenous	intravenous	JJ	_	10	attr	_	_
10	drug1	drug0	NN	_	7	ppmod	_	_
11	to	to	TO	_	13	aux	_	_
12	oral	oral	JJ	_	13	attr	_	_
13	drug2	drug0	NN	_	10	ppmod	_	_
14	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	suppress	suppress	VBP	_	0	root	_	_
4	certain	certain	JJ	_	6	attr	_	_
5	CYP450	cyp0	NN	_	6	com	_	_
6	enzymes	enzyme	NNS	_	3	obj	_	_
7	,	,	,	_	6	p	_	_
8	including	include	VBG	_	9	adv	_	_
9	drug2	drug0	NN	_	6	ppmod	_	_
10	,	,	,	_	9	p	_	_
11	drug3	drug0	NN	_	9	conj	_	_
12	,	,	,	_	11	p	_	_
13	drug4	drug0	NN	_	9	conj	_	_
14	,	,	,	_	13	p	_	_
15	and	and	CC	_	13	cc	_	_
16	drug5	drug0	NN	_	9	conj	_	_
17	.	.	.	_	3	p	_	_

1	This	this	DT	_	2	det	_	_
2	inhibition	inhibition	NN	_	4	dep	_	_
3	can	can	MD	_	4	modal	_	_
4	result	result	VB	_	0	root	_	_
5	in	in	IN	_	9	case	_	_
6	unexpectedly	unexpectedly	RB	_	7	adv	_	_
7	high	high	JJ	_	9	attr	_	_
8	plasma	plasma	NN	_	9	com	_	_
9	levels	level	NNS	_	4	ppmod	_	_
10	of	of	IN	_	12	case	_	_
11	other	other	JJ	_	12	attr	_	_
12	drug1	drug0	NNS	_	9	ppmod	_	_
13	which	which	WDT	_	15	dep	_	_
14	are	be	VBP	_	15	aux	_	_
15	metabolized	metabolize	VBN	_	12	relcl	_	_
16	by	by	IN	_	19	case	_	_
17	those	those	DT	_	19	det	_	_
18	CYP450	cyp0	CD	_	19	num	_	_
19	enzymes	enzyme	NNS	_	15	ppmod	_	_
20	.	.	.	_	4	p	_	_

1	Reported	report	VBN	_	2	attr	_	_
2	examples	example	NNS	_	6	dep	_	_
3	of	of	IN	_	5	case	_	_
4	this	this	DT	_	5	det	_	_
5	interaction	interaction	NN	_	2	ppmod	_	_
6	include	include	VBP	_	26	advcl	_	_
7	the	the	DT	_	8	det	_	_
8	following	following	NN	_	6	obj	_	_
9	:	:	:	_	26	p	_	_
10	drug1	drug0	NN	_	13	attr	_	_
11	s	s	NN	_	13	attr	_	_
12	:	:	:	_	13	p	_	_
13	drug2	drug0	NN	_	26	dep	_	_
14	(	-lrb-	-LRB-	_	16	p	_	_
15	drug3	drug0	NN	_	16	com	_	_
16	substrate	substrate	NN	_	13	prn	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	administered	administer	VBN	_	13	acl	_	_
19	in	in	IN	_	20	case	_	_
20	combination	combination	NN	_	18	ppmod	_	_
21	with	with	IN	_	23	case	_	_
22	oral	oral	JJ	_	23	attr	_	_
23	drug4	drug0	NNS	_	20	ppmod	_	_
24	has	have	VBZ	_	26	aux	_	_
25	been	be	VBN	_	26	aux	_	_
26	reported	report	VBN	_	0	root	_	_
27	to	to	TO	_	28	aux	_	_
28	produce	produce	VB	_	26	comp	_	_
29	persistently	persistently	RB	_	30	adv	_	_
30	elevated	elevated	JJ	_	32	attr	_	_
31	plasma	plasma	NN	_	32	com	_	_
32	concentrations	concentration	NNS	_	28	obj	_	_
33	of	of	IN	_	34	case	_	_
34	drug5	drug0	NN	_	32	ppmod	_	_
35	resulting	result	VBG	_	34	acl	_	_
36	in	in	IN	_	38	case	_	_
37	elevated	elevated	JJ	_	38	attr	_	_
38	creatinine	creatinine	NN	_	35	ppmod	_	_
39	,	,	,	_	28	p	_	_
40	despite	despite	IN	_	41	case	_	_
41	reduction	reduction	NN	_	28	ppmod	_	_
42	in	in	IN	_	43	case	_	_
43	dose	dose	NN	_	41	ppmod	_	_
44	of	of	IN	_	45	case	_	_
45	drug6	drug0	NN	_	43	ppmod	_	_
46	.	.	.	_	26	p	_	_

1	drug1	drug0	NN	_	14	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	(	-lrb-	-LRB-	_	6	p	_	_
5	drug3	drug0	NN	_	6	com	_	_
6	substrate	substrate	NN	_	3	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	in	in	IN	_	9	case	_	_
9	combination	combination	NN	_	3	ppmod	_	_
10	with	with	IN	_	11	case	_	_
11	drug4	drug0	NN	_	9	ppmod	_	_
12	has	have	VBZ	_	14	aux	_	_
13	been	be	VBN	_	14	aux	_	_
14	associated	associate	VBN	_	0	root	_	_
15	with	with	IN	_	16	case	_	_
16	reports	report	NNS	_	14	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	myopathy/rhabdomyolysis	myopathy/rhabdomyolysis	NN	_	16	ppmod	_	_
19	.	.	.	_	14	p	_	_

1	Cardiovasculars	cardiovasculars	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug1	drug0	NN	_	1	appo	_	_
4	:	:	:	_	1	p	_	_
5	In	in	IN	_	6	case	_	_
6	patients	patient	NNS	_	16	ppmod	_	_
7	receiving	receive	VBG	_	6	acl	_	_
8	drug2	drug0	NN	_	9	com	_	_
9	therapy	therapy	NN	_	7	obj	_	_
10	,	,	,	_	16	p	_	_
11	administration	administration	NN	_	16	dep	_	_
12	of	of	IN	_	14	case	_	_
13	oral	oral	JJ	_	14	attr	_	_
14	drug3	drug0	NN	_	11	ppmod	_	_
15	regularly	regularly	RB	_	16	adv	_	_
16	results	result	VBZ	_	1	acl	_	_
17	in	in	IN	_	19	case	_	_
18	an	an	DT	_	19	det	_	_
19	increase	increase	NN	_	16	ppmod	_	_
20	in	in	IN	_	23	case	_	_
21	serum	serum	NN	_	23	com	_	_
22	drug4	drug0	NN	_	23	com	_	_
23	concentration	concentration	NN	_	19	ppmod	_	_
24	that	that	WDT	_	26	dep	_	_
25	may	may	MD	_	26	modal	_	_
26	reach	reach	VB	_	23	relcl	_	_
27	toxic	toxic	JJ	_	28	attr	_	_
28	levels	level	NNS	_	26	obj	_	_
29	with	with	IN	_	32	case	_	_
30	resultant	resultant	JJ	_	32	attr	_	_
31	clinical	clinical	JJ	_	32	attr	_	_
32	toxicity	toxicity	NN	_	26	ppmod	_	_
33	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	taken	take	VBN	_	1	acl	_	_
3	concomitantly	concomitantly	RB	_	2	adv	_	_
4	with	with	IN	_	5	case	_	_
5	drug2	drug0	NN	_	2	ppmod	_	_
6	increases	increase	VBZ	_	0	root	_	_
7	the	the	DT	_	10	det	_	_
8	serum	serum	NN	_	10	com	_	_
9	drug3	drug0	NN	_	10	com	_	_
10	concentration	concentration	NN	_	6	obj	_	_
11	by	by	IN	_	12	case	_	_
12	70	0	CD	_	6	ppmod	_	_
13	%	%	NN	_	12	meta	_	_
14	after	after	IN	_	16	case	_	_
15	one	#crd#	CD	_	16	num	_	_
16	day	day	NN	_	6	ppmod	_	_
17	.	.	.	_	6	p	_	_

1	On	on	IN	_	2	case	_	_
2	administration	administration	NN	_	14	ppmod	_	_
3	of	of	IN	_	5	case	_	_
4	oral	oral	JJ	_	5	attr	_	_
5	drug1	drug0	NN	_	2	ppmod	_	_
6	,	,	,	_	14	p	_	_
7	the	the	DT	_	8	det	_	_
8	need	need	NN	_	14	dep	_	_
9	for	for	IN	_	11	case	_	_
10	drug2	drug0	NN	_	11	com	_	_
11	therapy	therapy	NN	_	8	ppmod	_	_
12	should	should	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	reviewed	review	VBN	_	0	root	_	_
15	and	and	CC	_	14	cc	_	_
16	the	the	DT	_	17	det	_	_
17	dose	dose	NN	_	18	dep	_	_
18	reduced	reduce	VBN	_	14	conj	_	_
19	by	by	IN	_	21	case	_	_
20	approximately	approximately	RB	_	21	adv	_	_
21	50	0	CD	_	18	ppmod	_	_
22	%	%	NN	_	21	meta	_	_
23	or	or	CC	_	18	cc	_	_
24	discontinued	discontinue	VBN	_	18	conj	_	_
25	.	.	.	_	14	p	_	_

1	If	if	IN	_	5	mark	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	treatment	treatment	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	continued	continue	VBN	_	12	advcl	_	_
6	,	,	,	_	12	p	_	_
7	serum	serum	NN	_	8	com	_	_
8	levels	level	NNS	_	12	dep	_	_
9	should	should	MD	_	12	modal	_	_
10	be	be	VB	_	12	aux	_	_
11	closely	closely	RB	_	12	adv	_	_
12	monitored	monitor	VBN	_	0	root	_	_
13	and	and	CC	_	12	cc	_	_
14	patients	patient	NNS	_	15	dep	_	_
15	observed	observe	VBN	_	12	conj	_	_
16	for	for	IN	_	18	case	_	_
17	clinical	clinical	JJ	_	18	attr	_	_
18	evidence	evidence	NN	_	15	ppmod	_	_
19	of	of	IN	_	20	case	_	_
20	toxicity	toxicity	NN	_	18	ppmod	_	_
21	.	.	.	_	12	p	_	_

1	These	these	DT	_	2	det	_	_
2	precautions	precaution	NNS	_	5	dep	_	_
3	probably	probably	RB	_	5	adv	_	_
4	should	should	MD	_	5	modal	_	_
5	apply	apply	VB	_	0	root	_	_
6	to	to	TO	_	8	aux	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	administration	administration	NN	_	5	ppmod	_	_
9	as	as	IN	_	10	case	_	_
10	well	well	NN	_	5	ppmod	_	_
11	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Other	other	JJ	_	5	attr	_	_
4	drug2	drug0	NN	_	5	com	_	_
5	drugs	drug	NNS	_	20	dep	_	_
6	,	,	,	_	5	p	_	_
7	such	such	JJ	_	9	adv	_	_
8	as	as	IN	_	9	case	_	_
9	drug3	drug0	NN	_	5	ppmod	_	_
10	,	,	,	_	9	p	_	_
11	drug4	drug0	NN	_	9	conj	_	_
12	,	,	,	_	11	p	_	_
13	drug5	drug0	NN	_	9	conj	_	_
14	,	,	,	_	13	p	_	_
15	and	and	CC	_	13	cc	_	_
16	drug6	drug0	NN	_	9	conj	_	_
17	,	,	,	_	5	p	_	_
18	have	have	VBP	_	20	aux	_	_
19	been	be	VBN	_	20	aux	_	_
20	used	use	VBN	_	1	acl	_	_
21	concurrently	concurrently	RB	_	20	adv	_	_
22	with	with	IN	_	23	case	_	_
23	drug7	drug0	NN	_	20	ppmod	_	_
24	.	.	.	_	1	p	_	_

1	There	there	EX	_	3	dep	_	_
2	have	have	VBP	_	3	aux	_	_
3	been	be	VBN	_	0	root	_	_
4	case	case	NN	_	5	com	_	_
5	reports	report	NNS	_	3	obj	_	_
6	of	of	IN	_	9	case	_	_
7	increased	increase	VBN	_	9	attr	_	_
8	steady-state	steady-state	JJ	_	9	attr	_	_
9	levels	level	NNS	_	5	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	,	,	,	_	11	p	_	_
13	drug2	drug0	NN	_	11	conj	_	_
14	,	,	,	_	13	p	_	_
15	and	and	CC	_	13	cc	_	_
16	drug3	drug0	NN	_	11	conj	_	_
17	during	during	IN	_	19	case	_	_
18	concomitant	concomitant	JJ	_	19	attr	_	_
19	therapy	therapy	NN	_	3	ppmod	_	_
20	with	with	IN	_	21	case	_	_
21	drug4	drug0	NN	_	19	ppmod	_	_
22	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	decreases	decrease	VBZ	_	0	root	_	_
3	serum	serum	NN	_	5	com	_	_
4	amiodarone	amiodarone	NN	_	5	com	_	_
5	levels	level	NNS	_	2	obj	_	_
6	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	taken	take	VBN	_	1	acl	_	_
3	concomitantly	concomitantly	RB	_	2	adv	_	_
4	with	with	IN	_	5	case	_	_
5	drug2	drug0	NN	_	2	ppmod	_	_
6	increases	increase	VBZ	_	0	root	_	_
7	drug3	drug0	NN	_	9	com	_	_
8	serum	serum	NN	_	9	com	_	_
9	concentration	concentration	NN	_	6	obj	_	_
10	by	by	IN	_	11	case	_	_
11	33	0	CD	_	6	ppmod	_	_
12	%	%	NN	_	11	meta	_	_
13	after	after	IN	_	15	case	_	_
14	two	#crd#	CD	_	15	num	_	_
15	days	day	NNS	_	6	ppmod	_	_
16	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	11	dep	_	_
2	taken	take	VBN	_	1	acl	_	_
3	concomitantly	concomitantly	RB	_	2	adv	_	_
4	with	with	IN	_	5	case	_	_
5	drug2	drug0	NN	_	2	ppmod	_	_
6	for	for	IN	_	10	case	_	_
7	less	less	JJR	_	9	attr	_	_
8	than	than	IN	_	7	com	_	_
9	seven	#crd#	CD	_	10	num	_	_
10	days	day	NNS	_	2	ppmod	_	_
11	increases	increase	VBZ	_	0	root	_	_
12	plasma	plasma	NN	_	13	com	_	_
13	concentrations	concentration	NNS	_	11	obj	_	_
14	of	of	IN	_	15	case	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	n-acetyl	n-acetyl	JJ	_	18	attr	_	_
18	drug4	drug0	NN	_	15	conj	_	_
19	by	by	IN	_	20	case	_	_
20	55	0	CD	_	11	ppmod	_	_
21	%	%	NN	_	20	meta	_	_
22	and	and	CC	_	20	cc	_	_
23	33	0	CD	_	20	conj	_	_
24	%	%	NN	_	23	meta	_	_
25	,	,	,	_	23	p	_	_
26	respectively	respectively	RB	_	20	conj	_	_
27	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	4	attr	_	_
2	and	and	CC	_	1	cc	_	_
3	procainamide	procainamide	NN	_	1	conj	_	_
4	doses	dose	NNS	_	7	dep	_	_
5	should	should	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	reduced	reduce	VBN	_	0	root	_	_
8	by	by	IN	_	9	case	_	_
9	one-third	one-third	CD	_	7	ppmod	_	_
10	when	when	WRB	_	13	adv	_	_
11	either	either	DT	_	13	dep	_	_
12	is	be	VBZ	_	13	aux	_	_
13	administered	administer	VBN	_	7	comp	_	_
14	with	with	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	7	p	_	_

1	Plasma	plasma	NN	_	2	com	_	_
2	levels	level	NNS	_	7	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	have	have	VBP	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	reported	report	VBN	_	0	root	_	_
8	to	to	TO	_	9	aux	_	_
9	increase	increase	VB	_	7	comp	_	_
10	in	in	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	presence	presence	NN	_	9	ppmod	_	_
13	of	of	IN	_	15	case	_	_
14	oral	oral	JJ	_	15	attr	_	_
15	drug2	drug0	NN	_	12	ppmod	_	_
16	;	;	:	_	7	p	_	_

1	because	because	IN	_	3	case	_	_
2	of	of	IN	_	3	case	_	_
3	this	this	DT	_	11	ppmod	_	_
4	,	,	,	_	11	p	_	_
5	the	the	DT	_	6	det	_	_
6	dosage	dosage	NN	_	11	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	adjusted	adjust	VBN	_	0	root	_	_
12	when	when	WRB	_	16	adv	_	_
13	these	these	DT	_	14	det	_	_
14	drug2	drug0	NNS	_	16	dep	_	_
15	are	be	VBP	_	16	aux	_	_
16	administered	administer	VBN	_	11	comp	_	_
17	concomitantly	concomitantly	RB	_	16	adv	_	_
18	.	.	.	_	11	p	_	_

1	In	in	IN	_	2	case	_	_
2	general	general	JJ	_	9	ppmod	_	_
3	,	,	,	_	9	p	_	_
4	any	any	DT	_	6	det	_	_
5	added	add	VBN	_	6	attr	_	_
6	drug1	drug0	NN	_	9	dep	_	_
7	should	should	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	initiated	initiate	VBN	_	0	root	_	_
10	at	at	IN	_	15	case	_	_
11	a	a	DT	_	15	det	_	_
12	lower	low	JJR	_	15	attr	_	_
13	than	than	IN	_	15	case	_	_
14	usual	usual	JJ	_	15	attr	_	_
15	dose	dose	NN	_	9	ppmod	_	_
16	with	with	IN	_	18	case	_	_
17	careful	careful	JJ	_	18	attr	_	_
18	monitoring	monitoring	NN	_	15	ppmod	_	_
19	.	.	.	_	9	p	_	_

1	Combination	combination	NN	_	10	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	7	case	_	_
5	other	other	JJ	_	7	attr	_	_
6	drug2	drug0	NN	_	7	com	_	_
7	therapy	therapy	NN	_	1	ppmod	_	_
8	should	should	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	reserved	reserve	VBN	_	0	root	_	_
11	for	for	IN	_	12	case	_	_
12	patients	patient	NNS	_	10	ppmod	_	_
13	with	with	IN	_	16	case	_	_
14	life-threatening	life-threatening	JJ	_	16	attr	_	_
15	ventricular	ventricular	JJ	_	16	attr	_	_
16	arrhythmias	arrhythmia	NNS	_	12	ppmod	_	_
17	who	who	WP	_	18	dep	_	_
18	are	be	VBP	_	12	relcl	_	_
19	incompletely	incompletely	RB	_	20	adv	_	_
20	responsive	responsive	JJ	_	18	dep	_	_
21	to	to	TO	_	24	aux	_	_
22	a	a	DT	_	24	det	_	_
23	single	single	JJ	_	24	attr	_	_
24	agent	agent	NN	_	20	ppmod	_	_
25	or	or	CC	_	20	cc	_	_
26	incompletely	incompletely	RB	_	27	adv	_	_
27	responsive	responsive	JJ	_	20	conj	_	_
28	to	to	TO	_	29	aux	_	_
29	drug3	drug0	NN	_	27	ppmod	_	_
30	.	.	.	_	10	p	_	_

1	During	during	IN	_	2	case	_	_
2	transfer	transfer	NN	_	16	ppmod	_	_
3	to	to	TO	_	5	aux	_	_
4	oral	oral	JJ	_	5	attr	_	_
5	drug1	drug0	NN	_	2	ppmod	_	_
6	,	,	,	_	16	p	_	_
7	the	the	DT	_	9	det	_	_
8	dose	dose	NN	_	9	com	_	_
9	levels	level	NNS	_	16	dep	_	_
10	of	of	IN	_	13	case	_	_
11	previously	previously	RB	_	12	adv	_	_
12	administered	administer	VBN	_	13	attr	_	_
13	agents	agent	NNS	_	9	ppmod	_	_
14	should	should	MD	_	16	modal	_	_
15	be	be	VB	_	16	aux	_	_
16	reduced	reduce	VBN	_	0	root	_	_
17	by	by	IN	_	18	case	_	_
18	30	0	CD	_	16	ppmod	_	_
19	to	to	TO	_	18	cc	_	_
20	50	0	CD	_	18	conj	_	_
21	%	%	NN	_	18	meta	_	_
22	several	several	JJ	_	23	attr	_	_
23	days	day	NNS	_	26	dat	_	_
24	after	after	IN	_	26	case	_	_
25	the	the	DT	_	26	det	_	_
26	addition	addition	NN	_	16	ppmod	_	_
27	of	of	IN	_	29	case	_	_
28	oral	oral	JJ	_	29	attr	_	_
29	drug2	drug0	NN	_	26	ppmod	_	_
30	.	.	.	_	16	p	_	_

1	The	the	DT	_	3	det	_	_
2	continued	continued	JJ	_	3	attr	_	_
3	need	need	NN	_	11	dep	_	_
4	for	for	IN	_	8	case	_	_
5	the	the	DT	_	8	det	_	_
6	other	other	JJ	_	8	attr	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	agent	agent	NN	_	3	ppmod	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	reviewed	review	VBN	_	0	root	_	_
12	after	after	IN	_	19	mark	_	_
13	the	the	DT	_	14	det	_	_
14	effects	effect	NNS	_	19	dep	_	_
15	of	of	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	have	have	VBP	_	19	aux	_	_
18	been	be	VBN	_	19	aux	_	_
19	established	establish	VBN	_	11	comp	_	_
20	,	,	,	_	11	p	_	_
21	and	and	CC	_	11	cc	_	_
22	discontinuation	discontinuation	NN	_	26	dep	_	_
23	ordinarily	ordinarily	RB	_	26	adv	_	_
24	should	should	MD	_	26	modal	_	_
25	be	be	VB	_	26	aux	_	_
26	attempted	attempt	VBN	_	11	conj	_	_
27	.	.	.	_	11	p	_	_

1	If	if	IN	_	5	mark	_	_
2	the	the	DT	_	3	det	_	_
3	treatment	treatment	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	continued	continue	VBN	_	13	advcl	_	_
6	,	,	,	_	13	p	_	_
7	these	these	DT	_	8	det	_	_
8	patients	patient	NNS	_	13	dep	_	_
9	should	should	MD	_	13	modal	_	_
10	be	be	VB	_	13	aux	_	_
11	particularly	particularly	RB	_	13	adv	_	_
12	carefully	carefully	RB	_	13	adv	_	_
13	monitored	monitor	VBN	_	0	root	_	_
14	for	for	IN	_	16	case	_	_
15	adverse	adverse	JJ	_	16	attr	_	_
16	effects	effect	NNS	_	13	ppmod	_	_
17	,	,	,	_	16	p	_	_
18	especially	especially	RB	_	20	adv	_	_
19	conduction	conduction	NN	_	20	com	_	_
20	disturbances	disturbance	NNS	_	16	conj	_	_
21	and	and	CC	_	20	cc	_	_
22	exacerbation	exacerbation	NN	_	16	conj	_	_
23	of	of	IN	_	24	case	_	_
24	tachyarrhythmias	tachyarrhythmias	NN	_	22	ppmod	_	_
25	,	,	,	_	13	p	_	_
26	as	as	IN	_	29	mark	_	_
27	drug1	drug0	NN	_	29	dep	_	_
28	is	be	VBZ	_	29	aux	_	_
29	continued	continue	VBN	_	13	comp	_	_
30	.	.	.	_	13	p	_	_

1	In	in	IN	_	4	case	_	_
2	drug1	drug0	JJ	_	4	attr	_	_
3	-treated	-treated	JJ	_	4	attr	_	_
4	patients	patient	NNS	_	18	ppmod	_	_
5	who	who	WP	_	6	dep	_	_
6	require	require	VBP	_	4	relcl	_	_
7	additional	additional	JJ	_	9	attr	_	_
8	drug2	drug0	NN	_	9	com	_	_
9	therapy	therapy	NN	_	6	obj	_	_
10	,	,	,	_	18	p	_	_
11	the	the	DT	_	13	det	_	_
12	initial	initial	JJ	_	13	attr	_	_
13	dose	dose	NN	_	18	dep	_	_
14	of	of	IN	_	16	case	_	_
15	such	such	JJ	_	16	attr	_	_
16	agents	agent	NNS	_	13	ppmod	_	_
17	should	should	MD	_	18	modal	_	_
18	be	be	VB	_	0	root	_	_
19	approximately	approximately	RB	_	20	adv	_	_
20	half	half	NN	_	18	obj	_	_
21	of	of	IN	_	25	case	_	_
22	the	the	DT	_	25	det	_	_
23	usual	usual	JJ	_	25	attr	_	_
24	recommended	recommend	VBN	_	25	attr	_	_
25	dose	dose	NN	_	20	ppmod	_	_
26	.	.	.	_	18	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	used	use	VBN	_	1	acl	_	_
7	with	with	IN	_	8	case	_	_
8	caution	caution	NN	_	6	ppmod	_	_
9	in	in	IN	_	10	case	_	_
10	patients	patient	NNS	_	6	ppmod	_	_
11	receiving	receive	VBG	_	10	acl	_	_
12	-	-	CC	_	15	cc	_	_
13	drug3	drug0	NN	_	15	com	_	_
14	blocking	blocking	NN	_	15	com	_	_
15	agents	agent	NNS	_	11	obj	_	_
16	(	-lrb-	-LRB-	_	19	p	_	_
17	e.g.	e.g.	FW	_	19	adv	_	_
18	,	,	,	_	19	p	_	_
19	drug4	drug0	NN	_	15	prn	_	_
20	,	,	,	_	19	p	_	_
21	a	a	DT	_	23	det	_	_
22	drug5	drug0	NN	_	23	com	_	_
23	inhibitor	inhibitor	NN	_	19	appo	_	_
24	)	-rrb-	-RRB-	_	19	p	_	_
25	or	or	CC	_	15	cc	_	_
26	drug6	drug0	NN	_	27	com	_	_
27	antagonists	antagonist	NNS	_	15	conj	_	_
28	(	-lrb-	-LRB-	_	31	p	_	_
29	e.g.	e.g.	FW	_	31	adv	_	_
30	,	,	,	_	31	p	_	_
31	drug7	drug0	NN	_	27	prn	_	_
32	,	,	,	_	31	p	_	_
33	a	a	DT	_	35	det	_	_
34	drug8	drug0	NN	_	35	com	_	_
35	substrate	substrate	NN	_	31	conj	_	_
36	,	,	,	_	35	p	_	_
37	and	and	CC	_	35	cc	_	_
38	drug9	drug0	NN	_	31	conj	_	_
39	,	,	,	_	38	p	_	_
40	a	a	DT	_	42	det	_	_
41	drug10	drug0	NN	_	42	com	_	_
42	inhibitor	inhibitor	NN	_	38	appo	_	_
43	)	-rrb-	-RRB-	_	31	p	_	_
44	because	because	IN	_	48	case	_	_
45	of	of	IN	_	48	case	_	_
46	the	the	DT	_	48	det	_	_
47	possible	possible	JJ	_	48	attr	_	_
48	potentiation	potentiation	NN	_	11	ppmod	_	_
49	of	of	IN	_	50	case	_	_
50	bradycardia	bradycardia	NN	_	48	ppmod	_	_
51	,	,	,	_	50	p	_	_
52	sinus	sinus	NN	_	53	com	_	_
53	arrest	arrest	NN	_	50	conj	_	_
54	,	,	,	_	53	p	_	_
55	and	and	CC	_	53	cc	_	_
56	AV	av	NN	_	57	com	_	_
57	block	block	NN	_	50	conj	_	_
58	;	;	:	_	1	p	_	_

1	if	if	IN	_	2	mark	_	_
2	necessary	necessary	JJ	_	6	advcl	_	_
3	,	,	,	_	6	p	_	_
4	drug1	drug0	NN	_	6	dep	_	_
5	can	can	MD	_	6	modal	_	_
6	continue	continue	VBP	_	0	root	_	_
7	to	to	TO	_	9	aux	_	_
8	be	be	VB	_	9	aux	_	_
9	used	use	VBN	_	6	comp	_	_
10	after	after	IN	_	11	case	_	_
11	insertion	insertion	NN	_	9	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	a	a	DT	_	14	det	_	_
14	pacemaker	pacemaker	NN	_	11	ppmod	_	_
15	in	in	IN	_	16	case	_	_
16	patients	patient	NNS	_	11	ppmod	_	_
17	with	with	IN	_	19	case	_	_
18	severe	severe	JJ	_	19	attr	_	_
19	bradycardia	bradycardia	NN	_	16	ppmod	_	_
20	or	or	CC	_	19	cc	_	_
21	sinus	sinus	NN	_	22	com	_	_
22	arrest	arrest	NN	_	19	conj	_	_
23	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Potentiation	potentiation	NN	_	18	dep	_	_
4	of	of	IN	_	14	case	_	_
5	drug2	drug0	NN	_	6	advnp	_	_
6	-type	-type	JJ	_	14	attr	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	drug3	drug0	NN	_	6	prn	_	_
9	and	and	CC	_	8	cc	_	_
10	drug4	drug0	NN	_	11	com	_	_
11	substrate	substrate	NN	_	8	conj	_	_
12	)	-rrb-	-RRB-	_	8	p	_	_
13	drug5	drug0	NN	_	14	com	_	_
14	response	response	NN	_	3	ppmod	_	_
15	is	be	VBZ	_	18	aux	_	_
16	almost	almost	RB	_	17	com	_	_
17	always	always	RB	_	18	adv	_	_
18	seen	see	VBN	_	1	acl	_	_
19	in	in	IN	_	20	case	_	_
20	patients	patient	NNS	_	18	ppmod	_	_
21	receiving	receive	VBG	_	20	acl	_	_
22	drug6	drug0	NN	_	21	obj	_	_
23	and	and	CC	_	18	cc	_	_
24	can	can	MD	_	25	modal	_	_
25	result	result	VB	_	18	conj	_	_
26	in	in	IN	_	27	case	_	_
27	serious	serious	JJ	_	25	ppmod	_	_
28	or	or	CC	_	27	cc	_	_
29	fatal	fatal	JJ	_	30	attr	_	_
30	bleeding	bleeding	JJ	_	27	conj	_	_
31	.	.	.	_	1	p	_	_

1	Since	since	IN	_	9	mark	_	_
2	the	the	DT	_	4	det	_	_
3	concomitant	concomitant	JJ	_	4	attr	_	_
4	administration	administration	NN	_	9	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	with	with	IN	_	8	case	_	_
8	drug2	drug0	NN	_	4	ppmod	_	_
9	increases	increase	VBZ	_	29	advcl	_	_
10	the	the	DT	_	12	det	_	_
11	prothrombin	prothrombin	NN	_	12	com	_	_
12	time	time	NN	_	9	obj	_	_
13	by	by	IN	_	14	case	_	_
14	100	0	CD	_	9	ppmod	_	_
15	%	%	NN	_	14	meta	_	_
16	after	after	IN	_	20	case	_	_
17	3	0	CD	_	20	num	_	_
18	to	to	TO	_	17	cc	_	_
19	4	0	CD	_	17	conj	_	_
20	days	day	NNS	_	9	ppmod	_	_
21	,	,	,	_	29	p	_	_
22	the	the	DT	_	23	det	_	_
23	dose	dose	NN	_	29	dep	_	_
24	of	of	IN	_	26	case	_	_
25	the	the	DT	_	26	det	_	_
26	drug3	drug0	NN	_	23	ppmod	_	_
27	should	should	MD	_	29	modal	_	_
28	be	be	VB	_	29	aux	_	_
29	reduced	reduce	VBN	_	0	root	_	_
30	by	by	IN	_	31	case	_	_
31	one-third	one-third	CD	_	29	ppmod	_	_
32	to	to	TO	_	33	aux	_	_
33	one-half	one-half	NN	_	31	ppmod	_	_
34	,	,	,	_	29	p	_	_
35	and	and	CC	_	29	cc	_	_
36	prothrombin	prothrombin	NN	_	37	com	_	_
37	times	time	NNS	_	40	dep	_	_
38	should	should	MD	_	40	modal	_	_
39	be	be	VB	_	40	aux	_	_
40	monitored	monitor	VBN	_	29	conj	_	_
41	closely	closely	RB	_	40	adv	_	_
42	.	.	.	_	29	p	_	_

1	Some	some	DT	_	3	det	_	_
2	drug1	drug0	JJ	_	3	attr	_	_
3	/substances	/substances	NNS	_	5	dep	_	_
4	are	be	VBP	_	5	aux	_	_
5	known	know	VBN	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	accelerate	accelerate	VB	_	5	comp	_	_
8	the	the	DT	_	9	det	_	_
9	metabolism	metabolism	NN	_	7	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	by	by	IN	_	13	case	_	_
13	stimulating	stimulate	VBG	_	7	ppmod	_	_
14	the	the	DT	_	15	det	_	_
15	synthesis	synthesis	NN	_	13	obj	_	_
16	of	of	IN	_	17	case	_	_
17	drug3	drug0	NN	_	15	ppmod	_	_
18	(	-lrb-	-LRB-	_	20	p	_	_
19	enzyme	enzyme	NN	_	20	com	_	_
20	induction	induction	NN	_	17	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	.	.	.	_	5	p	_	_

1	This	this	DT	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	lead	lead	VB	_	0	root	_	_
4	to	to	TO	_	8	aux	_	_
5	low	low	JJ	_	8	attr	_	_
6	drug1	drug0	NN	_	8	com	_	_
7	serum	serum	NN	_	8	com	_	_
8	levels	level	NNS	_	3	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	potential	potential	JJ	_	11	attr	_	_
11	decrease	decrease	NN	_	8	conj	_	_
12	in	in	IN	_	13	case	_	_
13	efficacy	efficacy	NN	_	11	ppmod	_	_
14	.	.	.	_	3	p	_	_

1	Reported	report	VBN	_	2	attr	_	_
2	examples	example	NNS	_	6	dep	_	_
3	of	of	IN	_	5	case	_	_
4	this	this	DT	_	5	det	_	_
5	interaction	interaction	NN	_	2	ppmod	_	_
6	include	include	VBP	_	0	root	_	_
7	the	the	DT	_	8	det	_	_
8	following	following	NN	_	6	obj	_	_
9	:	:	:	_	8	p	_	_
10	drug1	drug0	NN	_	8	appo	_	_
11	:	:	:	_	8	p	_	_
12	drug2	drug0	NN	_	8	appo	_	_
13	is	be	VBZ	_	12	acl	_	_
14	a	a	DT	_	16	det	_	_
15	potent	potent	JJ	_	16	attr	_	_
16	inducer	inducer	NN	_	13	obj	_	_
17	of	of	IN	_	18	case	_	_
18	drug3	drug0	NN	_	16	ppmod	_	_
19	.	.	.	_	6	p	_	_

1	Administration	administration	NN	_	10	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	concomitantly	concomitantly	RB	_	7	adv	_	_
5	with	with	IN	_	7	case	_	_
6	oral	oral	JJ	_	7	attr	_	_
7	drug2	drug0	NN	_	1	ppmod	_	_
8	has	have	VBZ	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	shown	show	VBN	_	0	root	_	_
11	to	to	TO	_	12	aux	_	_
12	result	result	VB	_	10	comp	_	_
13	in	in	IN	_	14	case	_	_
14	decreases	decrease	NNS	_	12	ppmod	_	_
15	in	in	IN	_	17	case	_	_
16	serum	serum	NN	_	17	com	_	_
17	concentrations	concentration	NNS	_	14	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug3	drug0	NN	_	17	ppmod	_	_
20	and	and	CC	_	19	cc	_	_
21	drug4	drug0	NN	_	19	conj	_	_
22	.	.	.	_	10	p	_	_

1	Other	other	JJ	_	2	attr	_	_
2	substances	substance	NNS	_	0	root	_	_
3	,	,	,	_	2	p	_	_
4	including	include	VBG	_	6	adv	_	_
5	herbal	herbal	NN	_	6	com	_	_
6	preparations	preparation	NNS	_	2	ppmod	_	_
7	:	:	:	_	2	p	_	_
8	St.	st.	NN	_	11	com	_	_
9	John	john	NN	_	11	com	_	_
10	s	s	NN	_	11	com	_	_
11	Wort	wort	NN	_	16	dep	_	_
12	(	-lrb-	-LRB-	_	14	p	_	_
13	Hypericum	hypericum	NN	_	14	com	_	_
14	perforatum	perforatum	NN	_	11	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	induces	induce	VBZ	_	2	acl	_	_
17	CYP3A4	cyp0a0	NN	_	16	obj	_	_
18	.	.	.	_	2	p	_	_

1	Since	since	IN	_	3	mark	_	_
2	drug1	drug0	NN	_	3	dep	_	_
3	is	be	VBZ	_	10	advcl	_	_
4	a	a	DT	_	5	det	_	_
5	substrate	substrate	NN	_	3	obj	_	_
6	for	for	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	,	,	,	_	10	p	_	_
9	there	there	EX	_	10	dep	_	_
10	is	be	VBZ	_	0	root	_	_
11	the	the	DT	_	12	det	_	_
12	potential	potential	NN	_	10	obj	_	_
13	that	that	IN	_	26	mark	_	_
14	the	the	DT	_	15	det	_	_
15	use	use	NN	_	26	dep	_	_
16	of	of	IN	_	17	case	_	_
17	St.	st.	NN	_	15	ppmod	_	_
18	John	john	NNP	_	20	com	_	_
19	s	s	NNP	_	20	com	_	_
20	Wort	wort	NNP	_	17	attr	_	_
21	in	in	IN	_	22	case	_	_
22	patients	patient	NNS	_	15	ppmod	_	_
23	receiving	receive	VBG	_	22	acl	_	_
24	drug3	drug0	NN	_	23	obj	_	_
25	could	could	MD	_	26	modal	_	_
26	result	result	VB	_	12	acl	_	_
27	in	in	IN	_	30	case	_	_
28	reduced	reduce	VBN	_	30	attr	_	_
29	drug4	drug0	NN	_	30	com	_	_
30	levels	level	NNS	_	26	ppmod	_	_
31	.	.	.	_	10	p	_	_

1	Other	other	JJ	_	3	attr	_	_
2	reported	report	VBN	_	3	attr	_	_
3	interactions	interaction	NNS	_	17	dep	_	_
4	with	with	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	:	:	:	_	3	p	_	_
7	drug2	drug0	NN	_	3	appo	_	_
8	(	-lrb-	-LRB-	_	10	p	_	_
9	drug3	drug0	NN	_	10	com	_	_
10	substrate	substrate	NN	_	7	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	in	in	IN	_	13	case	_	_
13	combination	combination	NN	_	7	ppmod	_	_
14	with	with	IN	_	15	case	_	_
15	drug4	drug0	NN	_	13	ppmod	_	_
16	may	may	MD	_	17	modal	_	_
17	cause	cause	VB	_	0	root	_	_
18	hypotension	hypotension	NN	_	17	obj	_	_
19	,	,	,	_	18	p	_	_
20	bradycardia	bradycardia	NN	_	18	conj	_	_
21	,	,	,	_	20	p	_	_
22	and	and	CC	_	20	cc	_	_
23	decreased	decrease	VBN	_	25	attr	_	_
24	cardiac	cardiac	JJ	_	25	attr	_	_
25	output	output	NN	_	18	conj	_	_
26	.	.	.	_	17	p	_	_

1	Sinus	sinus	NN	_	2	com	_	_
2	bradycardia	bradycardia	NN	_	5	dep	_	_
3	has	have	VBZ	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	reported	report	VBN	_	0	root	_	_
6	with	with	IN	_	8	case	_	_
7	oral	oral	JJ	_	8	attr	_	_
8	drug1	drug0	NN	_	5	ppmod	_	_
9	in	in	IN	_	10	case	_	_
10	combination	combination	NN	_	8	ppmod	_	_
11	with	with	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	(	-lrb-	-LRB-	_	15	p	_	_
14	drug3	drug0	NN	_	15	com	_	_
15	substrate	substrate	NN	_	12	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	given	give	VBN	_	12	acl	_	_
18	for	for	IN	_	20	case	_	_
19	local	local	JJ	_	20	attr	_	_
20	drug4	drug0	NN	_	17	ppmod	_	_
21	.	.	.	_	5	p	_	_

1	Seizure	seizure	NN	_	11	dep	_	_
2	,	,	,	_	1	p	_	_
3	associated	associate	VBN	_	1	acl	_	_
4	with	with	IN	_	7	case	_	_
5	increased	increase	VBN	_	7	attr	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	concentrations	concentration	NNS	_	3	ppmod	_	_
8	,	,	,	_	1	p	_	_
9	has	have	VBZ	_	11	aux	_	_
10	been	be	VBN	_	11	aux	_	_
11	reported	report	VBN	_	0	root	_	_
12	with	with	IN	_	14	case	_	_
13	concomitant	concomitant	JJ	_	14	attr	_	_
14	administration	administration	NN	_	11	ppmod	_	_
15	of	of	IN	_	17	case	_	_
16	intravenous	intravenous	JJ	_	17	attr	_	_
17	drug2	drug0	NN	_	14	ppmod	_	_
18	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	a	a	DT	_	4	det	_	_
4	substrate	substrate	NN	_	2	obj	_	_
5	for	for	IN	_	7	case	_	_
6	both	both	CC	_	7	cc	_	_
7	drug2	drug0	NN	_	4	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug3	drug0	NN	_	7	conj	_	_
10	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	inhibits	inhibit	VBZ	_	0	root	_	_
3	drug2	drug0	NN	_	2	obj	_	_
4	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	increases	increase	VBZ	_	0	root	_	_
3	enterohepatic	enterohepatic	JJ	_	4	attr	_	_
4	elimination	elimination	NN	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	2	cc	_	_
8	may	may	MD	_	9	modal	_	_
9	reduce	reduce	VB	_	2	conj	_	_
10	its	its	PRP$	_	12	poss	_	_
11	serum	serum	NN	_	12	com	_	_
12	levels	level	NNS	_	9	obj	_	_
13	and	and	CC	_	12	cc	_	_
14	drug3	drug0	NN	_	12	conj	_	_
15	/2	0	CD	_	14	num	_	_
16	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	increases	increase	VBZ	_	0	root	_	_
3	QT	qt	NN	_	4	com	_	_
4	prolongation	prolongation	NN	_	2	obj	_	_
5	which	which	WDT	_	7	dep	_	_
6	could	could	MD	_	7	modal	_	_
7	cause	cause	VB	_	4	relcl	_	_
8	arrhythmia	arrhythmia	NN	_	7	obj	_	_
9	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	8	dep	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	,	,	,	_	3	p	_	_
5	and	and	CC	_	3	cc	_	_
6	azoles	azoles	NN	_	1	conj	_	_
7	are	be	VBP	_	8	aux	_	_
8	known	know	VBN	_	0	root	_	_
9	to	to	TO	_	10	aux	_	_
10	cause	cause	VB	_	8	comp	_	_
11	QTc	qtc	NN	_	12	com	_	_
12	prolongation	prolongation	NN	_	10	obj	_	_
13	.	.	.	_	8	p	_	_

1	There	there	EX	_	3	dep	_	_
2	have	have	VBP	_	3	aux	_	_
3	been	be	VBN	_	0	root	_	_
4	reports	report	NNS	_	3	obj	_	_
5	of	of	IN	_	7	case	_	_
6	QTc	qtc	NN	_	7	com	_	_
7	prolongation	prolongation	NN	_	4	ppmod	_	_
8	,	,	,	_	3	p	_	_
9	with	with	IN	_	3	ppmod	_	_
10	or	or	CC	_	9	cc	_	_
11	without	without	IN	_	12	case	_	_
12	TdP	tdp	NN	_	9	conj	_	_
13	,	,	,	_	3	p	_	_
14	in	in	IN	_	15	case	_	_
15	patients	patient	NNS	_	3	ppmod	_	_
16	taking	take	VBG	_	15	acl	_	_
17	drug1	drug0	NN	_	16	obj	_	_
18	when	when	WRB	_	26	adv	_	_
19	drug2	drug0	NN	_	26	dep	_	_
20	,	,	,	_	19	p	_	_
21	drug3	drug0	NN	_	19	conj	_	_
22	,	,	,	_	21	p	_	_
23	or	or	CC	_	21	cc	_	_
24	azoles	azoles	NN	_	19	conj	_	_
25	were	be	VBD	_	26	aux	_	_
26	administered	administer	VBN	_	3	comp	_	_
27	concomitantly	concomitantly	RB	_	26	adv	_	_
28	.	.	.	_	3	p	_	_

1	Hemodynamic	hemodynamic	JJ	_	4	attr	_	_
2	and	and	CC	_	1	cc	_	_
3	electrophysiologic	electrophysiologic	JJ	_	1	conj	_	_
4	interactions	interaction	NNS	_	8	dep	_	_
5	have	have	VBP	_	8	aux	_	_
6	also	also	RB	_	8	adv	_	_
7	been	be	VBN	_	8	aux	_	_
8	observed	observe	VBN	_	0	root	_	_
9	after	after	IN	_	11	case	_	_
10	concomitant	concomitant	JJ	_	11	attr	_	_
11	administration	administration	NN	_	8	ppmod	_	_
12	with	with	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	,	,	,	_	13	p	_	_
15	drug2	drug0	NN	_	13	conj	_	_
16	,	,	,	_	15	p	_	_
17	and	and	CC	_	15	cc	_	_
18	drug3	drug0	NN	_	13	conj	_	_
19	.	.	.	_	8	p	_	_

1	Volatile	volatile	JJ	_	3	attr	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	Agents	agent	NNS	_	0	root	_	_
4	:	:	:	_	3	p	_	_
5	.	.	.	_	3	p	_	_

1	In	in	IN	_	5	case	_	_
2	addition	addition	NN	_	5	advnp	_	_
3	to	to	TO	_	5	aux	_	_
4	the	the	DT	_	5	det	_	_
5	interactions	interaction	NNS	_	17	ppmod	_	_
6	noted	note	VBN	_	5	acl	_	_
7	above	above	RB	_	6	adv	_	_
8	,	,	,	_	17	p	_	_
9	chronic	chronic	JJ	_	16	attr	_	_
10	(	-lrb-	-LRB-	_	12	p	_	_
11	2	0	CD	_	12	num	_	_
12	weeks	week	NNS	_	16	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	oral	oral	JJ	_	16	attr	_	_
15	drug1	drug0	NN	_	16	com	_	_
16	administration	administration	NN	_	17	dep	_	_
17	impairs	impair	VBZ	_	0	root	_	_
18	metabolism	metabolism	NN	_	17	obj	_	_
19	of	of	IN	_	20	case	_	_
20	drug2	drug0	NN	_	18	ppmod	_	_
21	,	,	,	_	20	p	_	_
22	drug3	drug0	NN	_	20	conj	_	_
23	,	,	,	_	22	p	_	_
24	and	and	CC	_	22	cc	_	_
25	drug4	drug0	NN	_	20	conj	_	_
26	.	.	.	_	17	p	_	_

1	Electrolyte	electrolyte	NN	_	2	com	_	_
2	Disturbances	disturbance	NNS	_	9	dep	_	_
3	Patients	patient	NNS	_	2	appo	_	_
4	with	with	IN	_	5	case	_	_
5	hypokalemia	hypokalemia	NN	_	3	ppmod	_	_
6	or	or	CC	_	5	cc	_	_
7	hypomagnesemia	hypomagnesemia	NN	_	5	conj	_	_
8	should	should	MD	_	9	modal	_	_
9	have	have	VB	_	0	root	_	_
10	the	the	DT	_	11	det	_	_
11	condition	condition	NN	_	9	obj	_	_
12	corrected	correct	VBN	_	11	acl	_	_
13	whenever	whenever	NN	_	14	advnp	_	_
14	possible	possible	JJ	_	12	comp	_	_
15	before	before	IN	_	17	case	_	_
16	being	be	VBG	_	17	aux	_	_
17	treated	treat	VBN	_	9	ppmod	_	_
18	with	with	IN	_	19	case	_	_
19	drug1	drug0	NN	_	17	ppmod	_	_
20	,	,	,	_	9	p	_	_
21	as	as	IN	_	25	mark	_	_
22	these	these	DT	_	23	det	_	_
23	disorders	disorder	NNS	_	25	dep	_	_
24	can	can	MD	_	25	modal	_	_
25	exaggerate	exaggerate	VB	_	9	comp	_	_
26	the	the	DT	_	27	det	_	_
27	degree	degree	NN	_	25	obj	_	_
28	of	of	IN	_	30	case	_	_
29	QTc	qtc	NN	_	30	com	_	_
30	prolongation	prolongation	NN	_	27	ppmod	_	_
31	and	and	CC	_	25	cc	_	_
32	increase	increase	VB	_	25	conj	_	_
33	the	the	DT	_	34	det	_	_
34	potential	potential	NN	_	32	obj	_	_
35	for	for	IN	_	36	case	_	_
36	TdP	tdp	NN	_	34	ppmod	_	_
37	.	.	.	_	9	p	_	_

1	Special	special	JJ	_	2	attr	_	_
2	attention	attention	NN	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	given	give	VBN	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	electrolyte	electrolyte	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	acid-base	acid-base	NN	_	10	com	_	_
10	balance	balance	NN	_	7	conj	_	_
11	in	in	IN	_	12	case	_	_
12	patients	patient	NNS	_	7	ppmod	_	_
13	experiencing	experience	VBG	_	12	acl	_	_
14	severe	severe	JJ	_	17	attr	_	_
15	or	or	CC	_	14	cc	_	_
16	prolonged	prolonged	JJ	_	14	conj	_	_
17	diarrhea	diarrhea	NN	_	13	obj	_	_
18	or	or	CC	_	12	cc	_	_
19	in	in	IN	_	20	case	_	_
20	patients	patient	NNS	_	12	conj	_	_
21	receiving	receive	VBG	_	20	acl	_	_
22	concomitant	concomitant	JJ	_	23	attr	_	_
23	drug1	drug0	NN	_	21	obj	_	_
24	.	.	.	_	5	p	_	_

1	Concomitant	concomitant	JJ	_	3	attr	_	_
2	oral	oral	JJ	_	3	attr	_	_
3	administration	administration	NN	_	22	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	(	-lrb-	-LRB-	_	9	p	_	_
7	a	a	DT	_	9	det	_	_
8	known	known	JJ	_	9	attr	_	_
9	inhibitor	inhibitor	NN	_	5	prn	_	_
10	of	of	IN	_	12	case	_	_
11	CYP3A4	cyp0a0	NN	_	12	com	_	_
12	activity	activity	NN	_	9	ppmod	_	_
13	in	in	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	liver	liver	NN	_	12	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	in	in	IN	_	20	case	_	_
18	the	the	DT	_	20	det	_	_
19	intestinal	intestinal	JJ	_	20	attr	_	_
20	mucosa	mucosa	NN	_	15	conj	_	_
21	)	-rrb-	-RRB-	_	9	p	_	_
22	caused	cause	VBD	_	0	root	_	_
23	an	an	DT	_	25	det	_	_
24	eight-fold	eight-fold	JJ	_	25	attr	_	_
25	increase	increase	NN	_	22	obj	_	_
26	of	of	IN	_	29	case	_	_
27	the	the	DT	_	29	det	_	_
28	systemic	systemic	JJ	_	29	attr	_	_
29	exposure	exposure	NN	_	25	ppmod	_	_
30	to	to	TO	_	32	aux	_	_
31	oral	oral	JJ	_	32	attr	_	_
32	drug2	drug0	NN	_	29	ppmod	_	_
33	.	.	.	_	22	p	_	_

1	If	if	IN	_	26	mark	_	_
2	treatment	treatment	NN	_	26	dep	_	_
3	with	with	IN	_	4	case	_	_
4	inhibitors	inhibitor	NNS	_	2	ppmod	_	_
5	of	of	IN	_	7	case	_	_
6	CYP3A4	cyp0a0	NN	_	7	com	_	_
7	activity	activity	NN	_	4	ppmod	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	such	such	JJ	_	7	prn	_	_
10	as	as	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	,	,	,	_	9	p	_	_
13	drug2	drug0	NN	_	9	conj	_	_
14	,	,	,	_	13	p	_	_
15	drug3	drug0	NN	_	9	conj	_	_
16	,	,	,	_	15	p	_	_
17	drug4	drug0	NN	_	9	conj	_	_
18	,	,	,	_	17	p	_	_
19	drug5	drug0	NN	_	9	conj	_	_
20	,	,	,	_	19	p	_	_
21	drug6	drug0	NN	_	9	conj	_	_
22	,	,	,	_	21	p	_	_
23	etc.	etc.	NN	_	9	conj	_	_
24	)	-rrb-	-RRB-	_	9	p	_	_
25	is	be	VBZ	_	26	aux	_	_
26	indicated	indicate	VBN	_	35	advcl	_	_
27	,	,	,	_	35	p	_	_
28	reduction	reduction	NN	_	35	dep	_	_
29	of	of	IN	_	32	case	_	_
30	the	the	DT	_	32	det	_	_
31	drug7	drug0	NN	_	32	com	_	_
32	dose	dose	NN	_	28	ppmod	_	_
33	should	should	MD	_	35	modal	_	_
34	be	be	VB	_	35	aux	_	_
35	considered	consider	VBN	_	0	root	_	_
36	.	.	.	_	35	p	_	_

1	After	after	IN	_	3	case	_	_
2	extensive	extensive	JJ	_	3	attr	_	_
3	intake	intake	NN	_	25	ppmod	_	_
4	of	of	IN	_	6	case	_	_
5	grapefruit	grapefruit	NN	_	6	com	_	_
6	juice	juice	NN	_	3	ppmod	_	_
7	(	-lrb-	-LRB-	_	6	p	_	_
8	which	which	WDT	_	9	dep	_	_
9	inhibits	inhibit	VBZ	_	6	relcl	_	_
10	CYP3A4	cyp0a0	NN	_	11	com	_	_
11	activity	activity	NN	_	9	obj	_	_
12	predominantly	predominantly	RB	_	9	adv	_	_
13	in	in	IN	_	16	case	_	_
14	the	the	DT	_	16	det	_	_
15	intestinal	intestinal	JJ	_	16	attr	_	_
16	mucosa	mucosa	NN	_	9	ppmod	_	_
17	)	-rrb-	-RRB-	_	6	p	_	_
18	,	,	,	_	25	p	_	_
19	the	the	DT	_	21	det	_	_
20	systemic	systemic	JJ	_	21	attr	_	_
21	exposure	exposure	NN	_	25	dep	_	_
22	for	for	IN	_	24	case	_	_
23	oral	oral	JJ	_	24	attr	_	_
24	drug1	drug0	NN	_	21	ppmod	_	_
25	increased	increase	VBD	_	0	root	_	_
26	about	about	RB	_	27	adv	_	_
27	two	#crd#	CD	_	28	num	_	_
28	times	time	NNS	_	25	obj	_	_
29	.	.	.	_	25	p	_	_

1	As	as	IN	_	4	case	_	_
2	with	with	IN	_	4	case	_	_
3	other	other	JJ	_	4	attr	_	_
4	drugs	drug	NNS	_	19	ppmod	_	_
5	primarily	primarily	RB	_	7	adv	_	_
6	being	be	VBG	_	7	aux	_	_
7	metabolized	metabolize	VBN	_	4	acl	_	_
8	through	through	IN	_	9	case	_	_
9	CYP3A4	cyp0a0	NN	_	7	ppmod	_	_
10	,	,	,	_	19	p	_	_
11	ingestion	ingestion	NN	_	19	dep	_	_
12	of	of	IN	_	13	case	_	_
13	grapefruit	grapefruit	NN	_	11	ppmod	_	_
14	or	or	CC	_	13	cc	_	_
15	grapefruit	grapefruit	NN	_	16	com	_	_
16	juice	juice	NN	_	13	conj	_	_
17	should	should	MD	_	19	modal	_	_
18	be	be	VB	_	19	aux	_	_
19	avoided	avoid	VBN	_	0	root	_	_
20	in	in	IN	_	21	case	_	_
21	connection	connection	NN	_	19	ppmod	_	_
22	with	with	IN	_	24	case	_	_
23	drug1	drug0	NN	_	24	com	_	_
24	administration	administration	NN	_	21	ppmod	_	_
25	.	.	.	_	19	p	_	_

1	Plasma	plasma	NN	_	2	com	_	_
2	levels	level	NNS	_	6	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	may	may	MD	_	6	modal	_	_
6	become	become	VB	_	0	root	_	_
7	subtherapeutic	subtherapeutic	JJ	_	6	dep	_	_
8	during	during	IN	_	10	case	_	_
9	drug2	drug0	NN	_	10	com	_	_
10	therapy	therapy	NN	_	6	ppmod	_	_
11	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	inhibited	inhibit	VBN	_	0	root	_	_
4	by	by	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	action	action	NN	_	6	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	is	be	VBZ	_	6	aux	_	_
6	potentiated	potentiate	VBN	_	0	root	_	_
7	by	by	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	increase	increase	VB	_	0	root	_	_
4	sensitivity	sensitivity	NN	_	3	obj	_	_
5	to	to	TO	_	7	aux	_	_
6	the	the	DT	_	7	det	_	_
7	drug2	drug0	NN	_	4	ppmod	_	_
8	.	.	.	_	3	p	_	_

1	Response	response	NN	_	6	dep	_	_
2	to	to	TO	_	3	aux	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	may	may	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	enhanced	enhance	VBN	_	0	root	_	_
7	by	by	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	.	.	.	_	6	p	_	_

1	No	no	DT	_	3	det	_	_
2	formal	formal	JJ	_	3	attr	_	_
3	assessments	assessment	NNS	_	14	dep	_	_
4	of	of	IN	_	6	case	_	_
5	drug-drug	drug-drug	JJ	_	6	attr	_	_
6	interactions	interaction	NNS	_	3	ppmod	_	_
7	between	between	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	other	other	JJ	_	11	attr	_	_
11	agents	agent	NNS	_	8	conj	_	_
12	have	have	VBP	_	14	aux	_	_
13	been	be	VBN	_	14	aux	_	_
14	conducted	conduct	VBN	_	0	root	_	_

1	.	.	.	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Since	since	IN	_	6	mark	_	_
4	drug2	drug0	NN	_	6	dep	_	_
5	is	be	VBZ	_	6	aux	_	_
6	contraindicated	contraindicate	VBN	_	20	advcl	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	6	ppmod	_	_
9	with	with	IN	_	12	case	_	_
10	drug3	drug0	NN	_	11	advnp	_	_
11	-induced	-induced	JJ	_	12	attr	_	_
12	thrombocytopenia	thrombocytopenia	NN	_	8	ppmod	_	_
13	,	,	,	_	20	p	_	_
14	the	the	DT	_	15	det	_	_
15	co-administration	co-administration	NN	_	20	dep	_	_
16	of	of	IN	_	17	case	_	_
17	drug4	drug0	NN	_	15	ppmod	_	_
18	and	and	CC	_	17	cc	_	_
19	drug5	drug0	NN	_	17	conj	_	_
20	is	be	VBZ	_	1	acl	_	_
21	unlikely	unlikely	JJ	_	20	dep	_	_
22	for	for	IN	_	24	case	_	_
23	this	this	DT	_	24	det	_	_
24	indication	indication	NN	_	21	ppmod	_	_
25	.	.	.	_	1	p	_	_

1	However	however	RB	_	15	adv	_	_
2	,	,	,	_	15	p	_	_
3	if	if	IN	_	5	mark	_	_
4	drug1	drug0	NN	_	5	dep	_	_
5	is	be	VBZ	_	15	advcl	_	_
6	to	to	TO	_	8	aux	_	_
7	be	be	VB	_	8	aux	_	_
8	initiated	initiate	VBN	_	5	comp	_	_
9	after	after	IN	_	10	case	_	_
10	cessation	cessation	NN	_	8	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	drug2	drug0	NN	_	13	com	_	_
13	therapy	therapy	NN	_	10	ppmod	_	_
14	,	,	,	_	15	p	_	_
15	allow	allow	VBP	_	0	root	_	_
16	sufficient	sufficient	JJ	_	17	attr	_	_
17	time	time	NN	_	15	obj	_	_
18	for	for	IN	_	20	case	_	_
19	heparins	heparins	NN	_	20	com	_	_
20	effect	effect	NN	_	15	ppmod	_	_
21	on	on	IN	_	23	case	_	_
22	the	the	DT	_	23	det	_	_
23	aPTT	aptt	NN	_	20	ppmod	_	_
24	to	to	TO	_	25	aux	_	_
25	decrease	decrease	VB	_	23	acl	_	_
26	prior	prior	RB	_	25	adv	_	_
27	to	to	TO	_	28	aux	_	_
28	initiation	initiation	NN	_	25	ppmod	_	_
29	of	of	IN	_	31	case	_	_
30	drug3	drug0	NN	_	31	com	_	_
31	therapy	therapy	NN	_	28	ppmod	_	_
32	.	.	.	_	15	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	/	/	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	:	:	:	_	1	p	_	_
5	Pharmacokinetic	pharmacokinetic	JJ	_	9	attr	_	_
6	or	or	CC	_	5	cc	_	_
7	pharmacodynamic	pharmacodynamic	JJ	_	5	conj	_	_
8	drug-drug	drug-drug	JJ	_	9	attr	_	_
9	interactions	interaction	NNS	_	13	dep	_	_
10	have	have	VBP	_	13	aux	_	_
11	not	not	RB	_	13	neg	_	_
12	been	be	VBN	_	13	aux	_	_
13	demonstrated	demonstrate	VBN	_	1	acl	_	_
14	between	between	IN	_	15	case	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	concomitantly	concomitantly	RB	_	18	adv	_	_
18	administered	administer	VBN	_	19	attr	_	_
19	drug4	drug0	NN	_	15	conj	_	_
20	(	-lrb-	-LRB-	_	22	p	_	_
21	162.5	0	CD	_	22	num	_	_
22	mg	mg	NN	_	15	prn	_	_
23	orally	orally	RB	_	22	adv	_	_
24	given	given	IN	_	28	case	_	_
25	26	0	CD	_	28	num	_	_
26	and	and	CC	_	25	cc	_	_
27	2	0	CD	_	25	conj	_	_
28	hours	hour	NNS	_	23	ppmod	_	_
29	prior	prior	JJ	_	28	attr	_	_
30	to	to	TO	_	31	aux	_	_
31	initiation	initiation	NN	_	29	ppmod	_	_
32	of	of	IN	_	35	case	_	_
33	drug5	drug0	NN	_	35	attr	_	_
34	1	0	CD	_	35	num	_	_
35	g/kg/min.	g/kg/min.	NN	_	31	ppmod	_	_
36	over	over	IN	_	38	case	_	_
37	4	0	CD	_	38	num	_	_
38	hours	hour	NNS	_	35	ppmod	_	_
39	)	-rrb-	-RRB-	_	22	p	_	_
40	or	or	CC	_	15	cc	_	_
41	drug6	drug0	NN	_	15	conj	_	_
42	(	-lrb-	-LRB-	_	44	p	_	_
43	1000	0	CD	_	44	num	_	_
44	mg	mg	NN	_	41	prn	_	_
45	orally	orally	RB	_	46	adv	_	_
46	given	give	VBN	_	44	acl	_	_
47	12	0	CD	_	52	num	_	_
48	,	,	,	_	52	p	_	_
49	6	0	CD	_	52	num	_	_
50	and	and	CC	_	52	cc	_	_
51	0	0	CD	_	52	num	_	_
52	hours	hour	NNS	_	71	dat	_	_
53	prior	prior	JJ	_	52	attr	_	_
54	to	to	TO	_	53	ppmod	_	_
55	,	,	,	_	52	p	_	_
56	and	and	CC	_	52	cc	_	_
57	6	0	CD	_	60	num	_	_
58	and	and	CC	_	57	cc	_	_
59	12	0	CD	_	57	conj	_	_
60	hours	hour	NNS	_	52	conj	_	_
61	subsequent	subsequent	JJ	_	60	attr	_	_
62	to	to	TO	_	61	ppmod	_	_
63	,	,	,	_	60	p	_	_
64	initiation	initiation	NN	_	52	conj	_	_
65	of	of	IN	_	68	case	_	_
66	drug7	drug0	NN	_	68	attr	_	_
67	1.5	0	CD	_	68	num	_	_
68	g/kg/min.	g/kg/min.	NN	_	64	ppmod	_	_
69	over	over	IN	_	71	case	_	_
70	18	0	CD	_	71	num	_	_
71	hours	hour	NNS	_	46	ppmod	_	_
72	)	-rrb-	-RRB-	_	44	p	_	_
73	.	.	.	_	1	p	_	_

1	Oral	oral	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	Pharmacokinetic	pharmacokinetic	JJ	_	6	attr	_	_
5	drug-drug	drug-drug	JJ	_	6	attr	_	_
6	interactions	interaction	NNS	_	21	dep	_	_
7	between	between	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	drug3	drug0	NN	_	8	conj	_	_
11	(	-lrb-	-LRB-	_	16	p	_	_
12	7.5	0	CD	_	16	num	_	_
13	mg	mg	NN	_	16	attr	_	_
14	single	single	JJ	_	16	attr	_	_
15	oral	oral	JJ	_	16	attr	_	_
16	dose	dose	NN	_	8	prn	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	have	have	VBP	_	21	aux	_	_
19	not	not	RB	_	21	neg	_	_
20	been	be	VBN	_	21	aux	_	_
21	demonstrated	demonstrate	VBN	_	2	acl	_	_
22	.	.	.	_	2	p	_	_

1	However	however	RB	_	25	adv	_	_
2	,	,	,	_	25	p	_	_
3	the	the	DT	_	5	det	_	_
4	concomitant	concomitant	JJ	_	5	attr	_	_
5	use	use	NN	_	25	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	(	-lrb-	-LRB-	_	15	p	_	_
11	5-7.5	0	CD	_	12	num	_	_
12	mg	mg	NN	_	15	attr	_	_
13	initial	initial	JJ	_	15	attr	_	_
14	oral	oral	JJ	_	15	attr	_	_
15	dose	dose	NN	_	9	prn	_	_
16	followed	followed	VBN	_	15	acl	_	_
17	by	by	IN	_	19	case	_	_
18	2.5-6	0	CD	_	19	num	_	_
19	mg/day	mg/day	NN	_	16	ppmod	_	_
20	orally	orally	RB	_	19	adv	_	_
21	for	for	IN	_	23	case	_	_
22	6-10	0	CD	_	23	num	_	_
23	days	day	NNS	_	20	ppmod	_	_
24	)	-rrb-	-RRB-	_	15	p	_	_
25	results	result	VBZ	_	0	root	_	_
26	in	in	IN	_	27	case	_	_
27	prolongation	prolongation	NN	_	25	ppmod	_	_
28	of	of	IN	_	31	case	_	_
29	the	the	DT	_	31	det	_	_
30	prothrombin	prothrombin	NN	_	31	com	_	_
31	time	time	NN	_	27	ppmod	_	_
32	(	-lrb-	-LRB-	_	33	p	_	_
33	PT	pt	NN	_	31	prn	_	_
34	)	-rrb-	-RRB-	_	33	p	_	_
35	and	and	CC	_	31	cc	_	_
36	International	international	NNP	_	38	attr	_	_
37	Normalized	normalize	VBN	_	38	attr	_	_
38	Ratio	ratio	NN	_	31	conj	_	_
39	(	-lrb-	-LRB-	_	40	p	_	_
40	INR	inr	NN	_	38	prn	_	_
41	)	-rrb-	-RRB-	_	40	p	_	_
42	.	.	.	_	25	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	safety	safety	NN	_	14	dep	_	_
5	and	and	CC	_	4	cc	_	_
6	effectiveness	effectiveness	NN	_	4	conj	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	4	ppmod	_	_
9	with	with	IN	_	10	case	_	_
10	drug3	drug0	NN	_	4	ppmod	_	_
11	have	have	VBP	_	14	aux	_	_
12	not	not	RB	_	14	neg	_	_
13	been	be	VBN	_	14	aux	_	_
14	established	establish	VBN	_	1	acl	_	_
15	.	.	.	_	1	p	_	_

1	Co-administration	co-administration	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Concomitant	concomitant	JJ	_	4	attr	_	_
4	use	use	NN	_	16	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	with	with	IN	_	8	case	_	_
8	drug2	drug0	NN	_	4	ppmod	_	_
9	,	,	,	_	8	p	_	_
10	drug3	drug0	NN	_	8	conj	_	_
11	,	,	,	_	10	p	_	_
12	and	and	CC	_	10	cc	_	_
13	other	other	JJ	_	14	attr	_	_
14	drug4	drug0	NNS	_	8	conj	_	_
15	may	may	MD	_	16	modal	_	_
16	increase	increase	VB	_	1	acl	_	_
17	the	the	DT	_	18	det	_	_
18	risk	risk	NN	_	16	obj	_	_
19	of	of	IN	_	20	case	_	_
20	bleeding	bleeding	JJ	_	18	ppmod	_	_
21	.	.	.	_	1	p	_	_

1	Drug-drug	drug-drug	JJ	_	2	attr	_	_
2	interactions	interaction	NNS	_	6	dep	_	_
3	have	have	VBP	_	6	aux	_	_
4	not	not	RB	_	6	neg	_	_
5	been	be	VBN	_	6	aux	_	_
6	observed	observe	VBN	_	0	root	_	_
7	between	between	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	drug2	drug0	NN	_	8	conj	_	_
11	or	or	CC	_	10	cc	_	_
12	drug3	drug0	NN	_	8	conj	_	_
13	.	.	.	_	6	p	_	_

1	Possible	possible	JJ	_	3	attr	_	_
2	drug	drug	NN	_	3	com	_	_
3	interactions	interaction	NNS	_	0	root	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drug2	drug0	NN	_	3	ppmod	_	_
8	or	or	CC	_	7	cc	_	_
9	with	with	IN	_	11	case	_	_
10	other	other	JJ	_	11	attr	_	_
11	drug3	drug0	NN	_	7	conj	_	_
12	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	may	may	MD	_	5	modal	_	_
3	have	have	VBP	_	5	lv	_	_
4	life-threatening	life-threatening	JJ	_	5	attr	_	_
5	interactions	interaction	NNS	_	0	root	_	_
6	with	with	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	enhance	enhance	VB	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	effects	effect	NNS	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	drug3	drug0	NN	_	7	conj	_	_
10	,	,	,	_	9	p	_	_
11	and	and	CC	_	9	cc	_	_
12	other	other	JJ	_	13	attr	_	_
13	drug4	drug0	NN	_	7	conj	_	_
14	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	block	block	VB	_	0	root	_	_
4	the	the	DT	_	6	det	_	_
5	antihypertensive	antihypertensive	JJ	_	6	attr	_	_
6	action	action	NN	_	3	obj	_	_
7	of	of	IN	_	12	case	_	_
8	drug2	drug0	JJ	_	12	attr	_	_
9	and	and	CC	_	8	cc	_	_
10	similarly	similarly	RB	_	11	adv	_	_
11	acting	act	VBG	_	8	conj	_	_
12	compounds	compound	NNS	_	6	ppmod	_	_
13	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	enhance	enhance	VB	_	9	advcl	_	_
4	the	the	DT	_	6	det	_	_
5	seizure	seizure	JJ	_	6	attr	_	_
6	risk	risk	NN	_	3	obj	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	6	ppmod	_	_
9	taking	take	VBG	_	0	root	_	_
10	drug2	drug0	NN	_	9	obj	_	_

1	.	.	.	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	in	in	IN	_	4	case	_	_
3	large	large	JJ	_	4	attr	_	_
4	amounts	amount	NNS	_	1	ppmod	_	_
5	may	may	MD	_	6	modal	_	_
6	counteract	counteract	VB	_	0	root	_	_
7	the	the	DT	_	9	det	_	_
8	antiepileptic	antiepileptic	JJ	_	9	attr	_	_
9	effect	effect	NN	_	6	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	,	,	,	_	11	p	_	_
13	drug3	drug0	NN	_	11	conj	_	_
14	and	and	CC	_	13	cc	_	_
15	drug4	drug0	NN	_	11	conj	_	_
16	,	,	,	_	6	p	_	_
17	and	and	CC	_	6	cc	_	_
18	increase	increase	VB	_	6	conj	_	_
19	the	the	DT	_	20	det	_	_
20	frequency	frequency	NN	_	18	obj	_	_
21	of	of	IN	_	22	case	_	_
22	seizures	seizure	NNS	_	20	ppmod	_	_
23	in	in	IN	_	26	case	_	_
24	susceptible	susceptible	JJ	_	26	attr	_	_
25	pediatric	pediatric	JJ	_	26	attr	_	_
26	patients	patient	NNS	_	20	ppmod	_	_
27	.	.	.	_	6	p	_	_

1	Preliminary	preliminary	JJ	_	5	attr	_	_
2	animal	animal	JJ	_	5	attr	_	_
3	and	and	CC	_	2	cc	_	_
4	human	human	JJ	_	2	conj	_	_
5	studies	study	NNS	_	7	dep	_	_
6	have	have	VBP	_	7	aux	_	_
7	shown	show	VBN	_	0	root	_	_
8	that	that	IN	_	15	case	_	_
9	small	small	JJ	_	10	attr	_	_
10	quantities	quantity	NNS	_	15	dep	_	_
11	of	of	IN	_	14	case	_	_
12	systemically	systemically	RB	_	13	adv	_	_
13	administered	administer	VBN	_	14	attr	_	_
14	drug1	drug0	NN	_	10	ppmod	_	_
15	enter	enter	VBP	_	7	ppmod	_	_
16	the	the	DT	_	17	det	_	_
17	CSF	csf	NN	_	15	obj	_	_
18	primarily	primarily	RB	_	20	adv	_	_
19	as	as	IN	_	20	case	_	_
20	5-methyltetrahydro-folate	0-methyltetrahydro-folate	NN	_	15	ppmod	_	_
21	and	and	CC	_	15	cc	_	_
22	,	,	,	_	15	p	_	_
23	in	in	IN	_	24	case	_	_
24	humans	human	NNS	_	15	ppmod	_	_
25	,	,	,	_	15	p	_	_
26	remain	remain	VBP	_	15	conj	_	_
27	1	0	CD	_	30	num	_	_
28	to	to	TO	_	27	cc	_	_
29	3	0	CD	_	27	conj	_	_
30	orders	order	NNS	_	26	obj	_	_
31	of	of	IN	_	32	case	_	_
32	magnitude	magnitude	NN	_	30	ppmod	_	_
33	lower	low	JJR	_	30	attr	_	_
34	than	than	IN	_	38	case	_	_
35	the	the	DT	_	38	det	_	_
36	usual	usual	JJ	_	38	attr	_	_
37	drug2	drug0	NN	_	38	com	_	_
38	concentrations	concentration	NNS	_	33	ppmod	_	_
39	following	follow	VBG	_	38	acl	_	_
40	intrathecal	intrathecal	JJ	_	41	attr	_	_
41	administration	administration	NN	_	39	obj	_	_
42	.	.	.	_	7	p	_	_

1	However	however	RB	_	8	adv	_	_
2	,	,	,	_	8	p	_	_
3	high	high	JJ	_	4	attr	_	_
4	doses	dose	NNS	_	8	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	may	may	MD	_	8	modal	_	_
8	reduce	reduce	VB	_	0	root	_	_
9	the	the	DT	_	10	det	_	_
10	efficacy	efficacy	NN	_	8	obj	_	_
11	of	of	IN	_	14	case	_	_
12	intrathecally	intrathecally	RB	_	13	adv	_	_
13	administered	administer	VBN	_	14	attr	_	_
14	drug2	drug0	NN	_	10	ppmod	_	_
15	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	enhance	enhance	VB	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	toxicity	toxicity	NN	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	.	.	.	_	3	p	_	_

1	Certain	certain	JJ	_	2	attr	_	_
2	endocrine	endocrine	NN	_	9	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	liver	liver	NN	_	6	com	_	_
5	function	function	NN	_	6	com	_	_
6	tests	test	NNS	_	2	conj	_	_
7	may	may	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	affected	affect	VBN	_	0	root	_	_
10	by	by	IN	_	14	case	_	_
11	drug1	drug0	NN	_	14	attr	_	_
12	-containing	-containing	JJ	_	14	attr	_	_
13	oral	oral	JJ	_	14	attr	_	_
14	drug2	drug0	NNS	_	9	ppmod	_	_
15	.	.	.	_	9	p	_	_

1	The	the	DT	_	4	det	_	_
2	following	following	JJ	_	4	attr	_	_
3	similar	similar	JJ	_	4	attr	_	_
4	changes	change	NNS	_	7	dep	_	_
5	may	may	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	expected	expect	VBN	_	0	root	_	_
8	with	with	IN	_	10	case	_	_
9	larger	large	JJR	_	10	attr	_	_
10	doses	dose	NNS	_	7	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	:	:	:	_	7	p	_	_
14	Increased	increase	VBN	_	16	attr	_	_
15	sulfobromophthalein	sulfobromophthalein	NN	_	16	com	_	_
16	retention	retention	NN	_	7	dep	_	_
17	;	;	:	_	7	p	_	_

1	increased	increase	VBN	_	2	attr	_	_
2	prothrombin	prothrombin	NN	_	0	root	_	_
3	and	and	CC	_	2	cc	_	_
4	factors	factor	NNS	_	5	com	_	_
5	VII	vii	NN	_	2	conj	_	_
6	,	,	,	_	5	p	_	_
7	VIII	viii	NN	_	5	conj	_	_
8	,	,	,	_	7	p	_	_
9	IX	ix	NN	_	5	conj	_	_
10	,	,	,	_	9	p	_	_
11	and	and	CC	_	9	cc	_	_
12	X	x	NN	_	5	conj	_	_
13	;	;	:	_	5	p	_	_

1	decreased	decrease	VBD	_	0	root	_	_
2	antithrombin	antithrombin	NN	_	1	obj	_	_
3	3	0	CD	_	2	num	_	_
4	;	;	:	_	1	p	_	_

1	increased	increase	VBN	_	5	attr	_	_
2	norepinephrine-induced	norepinephrine-induced	JJ	_	5	attr	_	_
3	platel	platel	NN	_	5	attr	_	_
4	et	et	FW	_	5	attr	_	_
5	aggregation	aggregation	NN	_	0	root	_	_
6	;	;	:	_	5	p	_	_

1	increased	increase	VBN	_	4	attr	_	_
2	thyroid	thyroid	NN	_	4	com	_	_
3	binding	binding	NN	_	4	com	_	_
4	globulin	globulin	NN	_	8	dep	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	TBG	tbg	NN	_	4	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	leading	lead	VBG	_	0	root	_	_
9	to	to	TO	_	14	aux	_	_
10	increased	increase	VBN	_	14	attr	_	_
11	circulating	circulate	VBG	_	14	attr	_	_
12	total	total	JJ	_	14	attr	_	_
13	thyroid	thyroid	NN	_	14	com	_	_
14	hormone	hormone	NN	_	8	ppmod	_	_
15	,	,	,	_	8	p	_	_
16	as	as	IN	_	17	mark	_	_
17	measured	measure	VBN	_	8	comp	_	_
18	by	by	IN	_	19	case	_	_
19	PBI	pbi	NN	_	17	ppmod	_	_
20	,	,	,	_	19	p	_	_
21	T4	t0	NN	_	19	conj	_	_
22	by	by	IN	_	23	case	_	_
23	column	column	NN	_	21	ppmod	_	_
24	,	,	,	_	21	p	_	_
25	or	or	CC	_	21	cc	_	_
26	T4	t0	NN	_	19	conj	_	_
27	by	by	IN	_	28	case	_	_
28	radioimmunoassay	radioimmunoassay	NN	_	17	ppmod	_	_
29	.	.	.	_	8	p	_	_

1	Free	free	JJ	_	4	attr	_	_
2	T3	t0	NN	_	4	com	_	_
3	resin	resin	NN	_	4	com	_	_
4	uptake	uptake	NN	_	6	dep	_	_
5	is	be	VBZ	_	6	aux	_	_
6	decreased	decrease	VBN	_	0	root	_	_
7	,	,	,	_	6	p	_	_
8	reflecting	reflect	VBG	_	6	comp	_	_
9	the	the	DT	_	11	det	_	_
10	elevated	elevated	JJ	_	11	attr	_	_
11	TBG	tbg	NN	_	8	obj	_	_
12	;	;	:	_	6	p	_	_

1	free	free	JJ	_	3	attr	_	_
2	T4	t0	NN	_	3	com	_	_
3	concentration	concentration	NN	_	4	dep	_	_
4	is	be	VBZ	_	0	root	_	_
5	unaltered	unaltered	JJ	_	4	dep	_	_
6	:	:	:	_	4	p	_	_
7	impaired	impaired	JJ	_	9	attr	_	_
8	glucose	glucose	NN	_	9	com	_	_
9	tolerance	tolerance	NN	_	4	dep	_	_
10	;	;	:	_	4	p	_	_

1	decreased	decrease	VBN	_	3	attr	_	_
2	pregnanediol	pregnanediol	NN	_	3	com	_	_
3	excretion	excretion	NN	_	0	root	_	_
4	;	;	:	_	3	p	_	_

1	reduced	reduce	VBN	_	2	attr	_	_
2	response	response	NN	_	0	root	_	_
3	to	to	TO	_	5	aux	_	_
4	metyrapone	metyrapone	NN	_	5	com	_	_
5	test	test	NN	_	2	ppmod	_	_
6	;	;	:	_	2	p	_	_

1	reduced	reduce	VBN	_	4	attr	_	_
2	serum	serum	NN	_	4	com	_	_
3	folate	folate	NN	_	4	com	_	_
4	concentration	concentration	NN	_	0	root	_	_
5	;	;	:	_	4	p	_	_

1	increased	increase	VBN	_	0	root	_	_
2	serum	serum	NN	_	3	com	_	_
3	triglyceride	triglyceride	NN	_	1	obj	_	_
4	and	and	CC	_	3	cc	_	_
5	phospholipid	phospholipid	NN	_	6	com	_	_
6	concentration	concentration	NN	_	3	conj	_	_
7	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	administration	administration	NN	_	17	dep	_	_
3	of	of	IN	_	5	case	_	_
4	local	local	JJ	_	5	attr	_	_
5	drug1	drug0	NN	_	2	ppmod	_	_
6	containing	contain	VBG	_	5	acl	_	_
7	drug2	drug0	NN	_	6	obj	_	_
8	or	or	CC	_	7	cc	_	_
9	drug3	drug0	NN	_	7	conj	_	_
10	to	to	TO	_	11	aux	_	_
11	patients	patient	NNS	_	6	ppmod	_	_
12	receiving	receive	VBG	_	11	acl	_	_
13	drug4	drug0	NN	_	12	obj	_	_
14	or	or	CC	_	13	cc	_	_
15	drug5	drug0	NN	_	13	conj	_	_
16	may	may	MD	_	17	modal	_	_
17	produce	produce	VB	_	0	root	_	_
18	severe	severe	JJ	_	20	adv	_	_
19	,	,	,	_	20	p	_	_
20	prolonged	prolonged	JJ	_	21	attr	_	_
21	hypertension	hypertension	NN	_	17	obj	_	_
22	.	.	.	_	17	p	_	_

1	Concurrent	concurrent	JJ	_	2	attr	_	_
2	use	use	NN	_	9	dep	_	_
3	of	of	IN	_	5	case	_	_
4	these	these	DT	_	5	det	_	_
5	agents	agent	NNS	_	2	ppmod	_	_
6	should	should	MD	_	9	modal	_	_
7	generally	generally	RB	_	9	adv	_	_
8	be	be	VB	_	9	aux	_	_
9	avoided	avoid	VBN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	In	in	IN	_	2	case	_	_
2	situations	situation	NNS	_	13	ppmod	_	_
3	in	in	IN	_	4	case	_	_
4	which	which	WDT	_	7	ppmod	_	_
5	concurrent	concurrent	JJ	_	6	attr	_	_
6	therapy	therapy	NN	_	7	dep	_	_
7	is	be	VBZ	_	2	relcl	_	_
8	necessary	necessary	JJ	_	7	dep	_	_
9	,	,	,	_	13	p	_	_
10	careful	careful	JJ	_	12	attr	_	_
11	patient	patient	NN	_	12	com	_	_
12	monitoring	monitoring	NN	_	13	dep	_	_
13	is	be	VBZ	_	0	root	_	_
14	essential	essential	JJ	_	13	dep	_	_
15	.	.	.	_	13	p	_	_

1	Concurrent	concurrent	JJ	_	2	attr	_	_
2	administration	administration	NN	_	9	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	4	conj	_	_
8	may	may	MD	_	9	modal	_	_
9	cause	cause	VB	_	0	root	_	_
10	severe	severe	JJ	_	13	attr	_	_
11	,	,	,	_	13	p	_	_
12	persistent	persistent	JJ	_	13	attr	_	_
13	hypertension	hypertension	NN	_	9	obj	_	_
14	or	or	CC	_	13	cc	_	_
15	cerebrovascular	cerebrovascular	JJ	_	16	attr	_	_
16	accidents	accidents	NN	_	13	conj	_	_
17	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	may	may	MD	_	5	modal	_	_
5	reduce	reduce	VB	_	0	root	_	_
6	or	or	CC	_	5	cc	_	_
7	reverse	reverse	VB	_	5	conj	_	_
8	the	the	DT	_	10	det	_	_
9	pressor	pressor	JJ	_	10	attr	_	_
10	effect	effect	NN	_	7	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	5	p	_	_

1	The	the	DT	_	2	det	_	_
2	coadministration	coadministration	NN	_	5	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	decreases	decrease	VBZ	_	0	root	_	_
6	the	the	DT	_	8	det	_	_
7	biologic	biologic	JJ	_	8	attr	_	_
8	half-life	half-life	NN	_	5	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	because	because	IN	_	14	case	_	_
12	of	of	IN	_	14	case	_	_
13	an	an	DT	_	14	det	_	_
14	increase	increase	NN	_	5	ppmod	_	_
15	in	in	IN	_	17	case	_	_
16	metabolic	metabolic	JJ	_	17	attr	_	_
17	clearance	clearance	NN	_	14	ppmod	_	_
18	that	that	WDT	_	19	dep	_	_
19	results	result	VBZ	_	17	relcl	_	_
20	in	in	IN	_	23	case	_	_
21	a	a	DT	_	23	det	_	_
22	greater	great	JJR	_	23	attr	_	_
23	amount	amount	NN	_	19	ppmod	_	_
24	of	of	IN	_	25	case	_	_
25	drug3	drug0	NN	_	23	ppmod	_	_
26	in	in	IN	_	28	case	_	_
27	the	the	DT	_	28	det	_	_
28	urine	urine	NN	_	23	ppmod	_	_
29	.	.	.	_	5	p	_	_

1	Although	although	IN	_	13	mark	_	_
2	the	the	DT	_	3	det	_	_
3	mechanism	mechanism	NN	_	13	dep	_	_
4	of	of	IN	_	5	case	_	_
5	interaction	interaction	NN	_	3	ppmod	_	_
6	between	between	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	is	be	VBZ	_	13	aux	_	_
11	not	not	RB	_	13	neg	_	_
12	totally	totally	RB	_	13	adv	_	_
13	known	know	VBN	_	26	advcl	_	_
14	,	,	,	_	26	p	_	_
15	enzyme	enzyme	NN	_	16	com	_	_
16	induction	induction	NN	_	25	attr	_	_
17	and	and	CC	_	16	cc	_	_
18	displacement	displacement	NN	_	16	conj	_	_
19	of	of	IN	_	20	case	_	_
20	drug3	drug0	NN	_	18	ppmod	_	_
21	from	from	IN	_	23	case	_	_
22	plasma	plasma	NN	_	23	com	_	_
23	albumin	albumin	NN	_	18	ppmod	_	_
24	binding	binding	NN	_	25	com	_	_
25	sites	site	NNS	_	26	dep	_	_
26	are	be	VBP	_	0	root	_	_
27	possibilities	possibility	NNS	_	26	obj	_	_
28	.	.	.	_	26	p	_	_

1	Because	because	IN	_	6	mark	_	_
2	drug1	drug0	NN	_	6	dep	_	_
3	has	have	VBZ	_	6	aux	_	_
4	not	not	RB	_	6	neg	_	_
5	been	be	VBN	_	6	aux	_	_
6	shown	show	VBN	_	38	advcl	_	_
7	to	to	TO	_	8	aux	_	_
8	produce	produce	VB	_	6	comp	_	_
9	any	any	DT	_	11	det	_	_
10	additional	additional	JJ	_	11	attr	_	_
11	effect	effect	NN	_	8	obj	_	_
12	beyond	beyond	IN	_	13	case	_	_
13	that	that	DT	_	8	ppmod	_	_
14	obtained	obtain	VBN	_	13	acl	_	_
15	with	with	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	alone	alone	RB	_	16	adv	_	_
18	and	and	CC	_	6	cc	_	_
19	because	because	IN	_	21	mark	_	_
20	drug3	drug0	NN	_	21	dep	_	_
21	increases	increase	VBZ	_	6	conj	_	_
22	the	the	DT	_	23	det	_	_
23	rate	rate	NN	_	21	obj	_	_
24	of	of	IN	_	25	case	_	_
25	excretion	excretion	NN	_	23	ppmod	_	_
26	of	of	IN	_	27	case	_	_
27	drug4	drug0	NN	_	25	ppmod	_	_
28	,	,	,	_	38	p	_	_
29	the	the	DT	_	31	det	_	_
30	concomitant	concomitant	JJ	_	31	attr	_	_
31	use	use	NN	_	38	dep	_	_
32	of	of	IN	_	33	case	_	_
33	drug5	drug0	NN	_	31	ppmod	_	_
34	and	and	CC	_	33	cc	_	_
35	drug6	drug0	NN	_	33	conj	_	_
36	is	be	VBZ	_	38	aux	_	_
37	not	not	RB	_	38	neg	_	_
38	recommended	recommend	VBN	_	0	root	_	_
39	.	.	.	_	38	p	_	_

1	Chronic	chronic	JJ	_	2	attr	_	_
2	administration	administration	NN	_	13	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	,	,	,	_	4	p	_	_
6	a	a	DT	_	9	det	_	_
7	known	known	JJ	_	9	attr	_	_
8	enzyme	enzyme	NN	_	9	com	_	_
9	inducer	inducer	NN	_	4	appo	_	_
10	,	,	,	_	4	p	_	_
11	may	may	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	associated	associate	VBN	_	0	root	_	_
14	with	with	IN	_	16	case	_	_
15	a	a	DT	_	16	det	_	_
16	decrease	decrease	NN	_	13	ppmod	_	_
17	in	in	IN	_	20	case	_	_
18	the	the	DT	_	20	det	_	_
19	plasma	plasma	NN	_	20	com	_	_
20	half-life	half-life	NN	_	16	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	drug2	drug0	NN	_	20	ppmod	_	_
23	.	.	.	_	13	p	_	_

1	When	when	WRB	_	4	adv	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	added	add	VBN	_	17	advcl	_	_
5	to	to	TO	_	4	ppmod	_	_
6	or	or	CC	_	4	cc	_	_
7	withdrawn	withdraw	VBN	_	4	conj	_	_
8	from	from	IN	_	9	case	_	_
9	treatment	treatment	NN	_	7	ppmod	_	_
10	,	,	,	_	17	p	_	_
11	dosage	dosage	NN	_	12	com	_	_
12	adjustment	adjustment	NN	_	17	dep	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	may	may	MD	_	17	modal	_	_
16	be	be	VB	_	17	aux	_	_
17	required	require	VBN	_	0	root	_	_
18	.	.	.	_	17	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	studies	study	NNS	_	5	dep	_	_
4	have	have	VBP	_	5	aux	_	_
5	shown	show	VBN	_	0	root	_	_
6	that	that	IN	_	17	mark	_	_
7	drug1	drug0	NN	_	17	dep	_	_
8	,	,	,	_	17	p	_	_
9	because	because	IN	_	12	case	_	_
10	of	of	IN	_	12	case	_	_
11	its	its	PRP$	_	12	poss	_	_
12	affinity	affinity	NN	_	17	ppmod	_	_
13	for	for	IN	_	14	case	_	_
14	albumin	albumin	NN	_	12	ppmod	_	_
15	,	,	,	_	17	p	_	_
16	may	may	MD	_	17	modal	_	_
17	displace	displace	VB	_	5	comp	_	_
18	from	from	IN	_	21	case	_	_
19	their	their	PRP$	_	21	poss	_	_
20	binding	binding	NN	_	21	com	_	_
21	sites	site	NNS	_	17	ppmod	_	_
22	other	other	JJ	_	23	attr	_	_
23	drugs	drug	NNS	_	17	obj	_	_
24	that	that	WDT	_	28	dep	_	_
25	are	be	VBP	_	28	aux	_	_
26	also	also	RB	_	28	adv	_	_
27	albumin	albumin	NN	_	28	dep	_	_
28	bound	bind	VBN	_	23	relcl	_	_
29	,	,	,	_	17	p	_	_
30	and	and	CC	_	17	cc	_	_
31	this	this	DT	_	33	dep	_	_
32	may	may	MD	_	33	modal	_	_
33	lead	lead	VB	_	17	conj	_	_
34	to	to	TO	_	36	aux	_	_
35	drug	drug	NN	_	36	com	_	_
36	interaction	interaction	NN	_	33	ppmod	_	_
37	.	.	.	_	5	p	_	_

1	Theoretically	theoretically	RB	_	7	adv	_	_
2	,	,	,	_	7	p	_	_
3	drug1	drug0	NN	_	7	dep	_	_
4	could	could	MD	_	7	modal	_	_
5	likewise	likewise	RB	_	7	adv	_	_
6	be	be	VB	_	7	aux	_	_
7	displaced	displace	VBN	_	0	root	_	_
8	.	.	.	_	7	p	_	_

1	Patients	patient	NNS	_	11	dep	_	_
2	receiving	receive	VBG	_	1	acl	_	_
3	drug1	drug0	NN	_	2	obj	_	_
4	,	,	,	_	3	p	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	,	,	,	_	5	p	_	_
7	or	or	CC	_	5	cc	_	_
8	drug3	drug0	NN	_	3	conj	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	observed	observe	VBN	_	0	root	_	_
12	for	for	IN	_	14	case	_	_
13	increased	increase	VBN	_	14	attr	_	_
14	activity	activity	NN	_	11	ppmod	_	_
15	of	of	IN	_	17	case	_	_
16	these	these	DT	_	17	det	_	_
17	drugs	drug	NNS	_	14	ppmod	_	_
18	and	and	CC	_	11	cc	_	_
19	,	,	,	_	11	p	_	_
20	therefore	therefore	RB	_	11	adv	_	_
21	,	,	,	_	11	p	_	_
22	signs	sign	NNS	_	11	conj	_	_
23	of	of	IN	_	24	case	_	_
24	toxicity	toxicity	NN	_	22	ppmod	_	_
25	from	from	IN	_	27	case	_	_
26	these	these	DT	_	27	det	_	_
27	drugs	drug	NNS	_	22	ppmod	_	_
28	.	.	.	_	11	p	_	_

1	In	in	IN	_	2	case	_	_
2	patients	patient	NNS	_	13	ppmod	_	_
3	receiving	receive	VBG	_	2	acl	_	_
4	drug1	drug0	NN	_	3	obj	_	_
5	,	,	,	_	13	p	_	_
6	the	the	DT	_	7	det	_	_
7	addition	addition	NN	_	13	dep	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	to	to	TO	_	11	aux	_	_
11	therapy	therapy	NN	_	7	ppmod	_	_
12	could	could	MD	_	13	modal	_	_
13	prolong	prolong	VB	_	0	root	_	_
14	the	the	DT	_	16	det	_	_
15	prothrombin	prothrombin	NN	_	16	com	_	_
16	time	time	NN	_	13	obj	_	_
17	.	.	.	_	13	p	_	_

1	Patients	patient	NNS	_	6	dep	_	_
2	receiving	receive	VBG	_	1	acl	_	_
3	both	both	DT	_	4	det	_	_
4	drugs	drug	NNS	_	2	obj	_	_
5	should	should	MD	_	6	modal	_	_
6	be	be	VB	_	0	root	_	_
7	under	under	IN	_	9	case	_	_
8	careful	careful	JJ	_	9	attr	_	_
9	observation	observation	NN	_	6	ppmod	_	_
10	.	.	.	_	6	p	_	_

1	Patients	patient	NNS	_	6	dep	_	_
2	treated	treat	VBN	_	1	acl	_	_
3	with	with	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	may	may	MD	_	6	modal	_	_
6	be	be	VB	_	0	root	_	_
7	resistant	resistant	JJ	_	6	dep	_	_
8	to	to	TO	_	10	aux	_	_
9	the	the	DT	_	10	det	_	_
10	effects	effect	NNS	_	7	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	6	p	_	_

1	In	in	IN	_	2	case	_	_
2	patients	patient	NNS	_	16	ppmod	_	_
3	receiving	receive	VBG	_	2	acl	_	_
4	drug1	drug0	NN	_	3	obj	_	_
5	and	and	CC	_	4	cc	_	_
6	a	a	DT	_	7	det	_	_
7	drug2	drug0	NN	_	4	conj	_	_
8	concomitantly	concomitantly	RB	_	7	adv	_	_
9	,	,	,	_	16	p	_	_
10	any	any	DT	_	11	det	_	_
11	reduction	reduction	NN	_	16	dep	_	_
12	in	in	IN	_	14	case	_	_
13	drug3	drug0	NN	_	14	com	_	_
14	dosage	dosage	NN	_	11	ppmod	_	_
15	should	should	MD	_	16	modal	_	_
16	be	be	VB	_	0	root	_	_
17	gradual	gradual	JJ	_	16	dep	_	_
18	in	in	IN	_	21	mark	_	_
19	order	order	NN	_	21	dep	_	_
20	to	to	TO	_	21	aux	_	_
21	avoid	avoid	VB	_	16	comp	_	_
22	the	the	DT	_	24	det	_	_
23	possible	possible	JJ	_	24	attr	_	_
24	complications	complication	NNS	_	21	obj	_	_
25	of	of	IN	_	28	case	_	_
26	sudden	sudden	CD	_	28	num	_	_
27	drug4	drug0	NN	_	28	com	_	_
28	withdrawal	withdrawal	NN	_	24	ppmod	_	_
29	.	.	.	_	16	p	_	_

1	No	no	DT	_	2	det	_	_
2	information	information	NN	_	3	dep	_	_
3	available	available	JJ	_	0	root	_	_
4	.	.	.	_	3	p	_	_

1	None	none	NN	_	0	root	_	_
2	Reported	report	VBN	_	1	acl	_	_

1	Clinical	clinical	JJ	_	3	attr	_	_
2	interaction	interaction	NN	_	3	com	_	_
3	studies	study	NNS	_	8	dep	_	_
4	with	with	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	indicated	indicate	VBD	_	0	root	_	_
9	that	that	IN	_	19	mark	_	_
10	the	the	DT	_	11	det	_	_
11	coadministration	coadministration	NN	_	19	dep	_	_
12	of	of	IN	_	13	case	_	_
13	drug3	drug0	NN	_	11	ppmod	_	_
14	with	with	IN	_	16	case	_	_
15	these	these	DT	_	16	det	_	_
16	drugs	drug	NNS	_	11	ppmod	_	_
17	does	do	VBZ	_	19	aux	_	_
18	not	not	RB	_	19	neg	_	_
19	result	result	VB	_	8	comp	_	_
20	in	in	IN	_	24	case	_	_
21	clinically-	clinically-	JJ	_	24	attr	_	_
22	significant	significant	JJ	_	24	attr	_	_
23	drug	drug	NN	_	24	com	_	_
24	interactions	interaction	NNS	_	19	ppmod	_	_
25	.	.	.	_	8	p	_	_

1	(	-lrb-	-LRB-	_	2	p	_	_
2	See	see	VB	_	6	acl	_	_
3	CLINICAL	clinical	JJ	_	4	attr	_	_
4	PHARMACOLOGY	pharmacology	NN	_	2	obj	_	_
5	)	-rrb-	-RRB-	_	2	p	_	_
6	Coadministration	coadministration	NN	_	14	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	drug2	drug0	NN	_	12	attr	_	_
11	20	0	CD	_	12	num	_	_
12	mg	mg	NN	_	8	conj	_	_
13	daily	daily	RB	_	12	adv	_	_
14	resulted	result	VBD	_	0	root	_	_
15	in	in	IN	_	17	case	_	_
16	a	a	DT	_	17	det	_	_
17	reduction	reduction	NN	_	14	ppmod	_	_
18	of	of	IN	_	21	case	_	_
19	drug3	drug0	NN	_	21	com	_	_
20	plasma	plasma	NN	_	21	com	_	_
21	levels	level	NNS	_	17	ppmod	_	_
22	by	by	IN	_	23	case	_	_
23	38	0	CD	_	17	ppmod	_	_
24	%	%	NN	_	23	meta	_	_
25	on	on	IN	_	26	case	_	_
26	average	average	NN	_	23	ppmod	_	_
27	.	.	.	_	14	p	_	_

1	There	there	EX	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	no	no	DT	_	5	det	_	_
4	clinical	clinical	JJ	_	5	attr	_	_
5	experience	experience	VBP	_	2	obj	_	_
6	to	to	TO	_	7	aux	_	_
7	date	date	NN	_	5	ppmod	_	_
8	on	on	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	use	use	NN	_	5	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	in	in	IN	_	14	case	_	_
14	combination	combination	NN	_	10	ppmod	_	_
15	with	with	IN	_	18	case	_	_
16	other	other	JJ	_	18	attr	_	_
17	anticancer	anticancer	JJ	_	18	attr	_	_
18	agents	agent	NNS	_	14	ppmod	_	_
19	.	.	.	_	2	p	_	_

1	Drug/Laboratory	drug/laboratory	JJ	_	3	attr	_	_
2	Test-Interactions	test-interactions	NN	_	3	com	_	_
3	None	none	NN	_	4	dep	_	_
4	observed	observe	VBN	_	0	root	_	_
5	.	.	.	_	4	p	_	_

1	Urinary	urinary	JJ	_	3	attr	_	_
2	acidifying	acidifying	JJ	_	3	attr	_	_
3	agents	agent	NNS	_	13	dep	_	_
4	These	these	DT	_	5	det	_	_
5	agents	agent	NNS	_	3	appo	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	drug1	drug0	NN	_	5	prn	_	_
8	,	,	,	_	7	p	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	,	,	,	_	9	p	_	_
11	etc.	etc.	NN	_	7	conj	_	_
12	)	-rrb-	-RRB-	_	7	p	_	_
13	increase	increase	VBP	_	0	root	_	_
14	the	the	DT	_	15	det	_	_
15	concentration	concentration	NN	_	13	obj	_	_
16	of	of	IN	_	19	case	_	_
17	the	the	DT	_	19	det	_	_
18	ionized	ionize	VBN	_	19	attr	_	_
19	species	species	NNS	_	15	ppmod	_	_
20	of	of	IN	_	23	case	_	_
21	the	the	DT	_	23	det	_	_
22	drug3	drug0	NN	_	23	com	_	_
23	molecule	molecule	NN	_	15	ppmod	_	_
24	,	,	,	_	13	p	_	_
25	thereby	thereby	RB	_	26	adv	_	_
26	increasing	increase	VBG	_	13	comp	_	_
27	urinary	urinary	JJ	_	28	attr	_	_
28	excretion	excretion	NN	_	26	obj	_	_
29	.	.	.	_	13	p	_	_

1	Both	both	CC	_	2	cc	_	_
2	groups	group	NNS	_	5	dep	_	_
3	of	of	IN	_	4	case	_	_
4	agents	agent	NNS	_	2	ppmod	_	_
5	lower	low	JJR	_	0	root	_	_
6	blood	blood	NN	_	7	com	_	_
7	levels	level	NNS	_	5	obj	_	_
8	and	and	CC	_	7	cc	_	_
9	efficacy	efficacy	NN	_	7	conj	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	drug2	drug0	NNS	_	4	dep	_	_
3	are	be	VBP	_	4	aux	_	_
4	inhibited	inhibit	VBN	_	0	root	_	_
5	by	by	IN	_	6	case	_	_
6	drug3	drug0	NN	_	4	ppmod	_	_
7	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	4	com	_	_
4	drug3	drug0	NN	_	1	appo	_	_
5	may	may	MD	_	6	modal	_	_
6	enhance	enhance	VB	_	0	root	_	_
7	the	the	DT	_	8	det	_	_
8	activity	activity	NN	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug4	drug0	NN	_	8	ppmod	_	_
11	or	or	CC	_	10	cc	_	_
12	drug5	drug0	NN	_	10	conj	_	_
13	;	;	:	_	6	p	_	_

1	drug1	drug0	NN	_	10	dep	_	_
2	with	with	IN	_	3	case	_	_
3	drug2	drug0	NN	_	1	ppmod	_	_
4	or	or	CC	_	3	cc	_	_
5	drug3	drug0	NN	_	3	conj	_	_
6	and	and	CC	_	1	cc	_	_
7	possibly	possibly	RB	_	9	adv	_	_
8	other	other	JJ	_	9	attr	_	_
9	drug4	drug0	NNS	_	1	conj	_	_
10	cause	cause	VBP	_	0	root	_	_
11	striking	striking	JJ	_	14	attr	_	_
12	and	and	CC	_	11	cc	_	_
13	sustained	sustained	JJ	_	11	conj	_	_
14	increases	increase	NNS	_	10	obj	_	_
15	in	in	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	concentration	concentration	NN	_	14	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug5	drug0	NN	_	17	ppmod	_	_
20	in	in	IN	_	22	case	_	_
21	the	the	DT	_	22	det	_	_
22	brain	brain	NN	_	17	ppmod	_	_
23	;	;	:	_	10	p	_	_

1	cardiovascular	cardiovascular	JJ	_	2	attr	_	_
2	effects	effect	NNS	_	5	dep	_	_
3	can	can	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	potentiated	potentiate	VBN	_	0	root	_	_
6	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	drug2	drug0	NN	_	14	dep	_	_
3	,	,	,	_	2	p	_	_
4	as	as	RB	_	5	com	_	_
5	well	well	RB	_	2	cc	_	_
6	as	as	IN	_	5	com	_	_
7	a	a	DT	_	8	det	_	_
8	metabolite	metabolite	NN	_	2	conj	_	_
9	of	of	IN	_	10	case	_	_
10	drug3	drug0	NN	_	8	ppmod	_	_
11	,	,	,	_	8	p	_	_
12	slow	slow	JJ	_	14	attr	_	_
13	drug4	drug0	NN	_	14	com	_	_
14	metabolism	metabolism	NN	_	0	root	_	_
15	.	.	.	_	14	p	_	_

1	This	this	DT	_	2	det	_	_
2	slowing	slowing	NN	_	3	dep	_	_
3	potentiates	potentiate	VBZ	_	0	root	_	_
4	drug1	drug0	NN	_	3	obj	_	_
5	,	,	,	_	3	p	_	_
6	increasing	increase	VBG	_	3	comp	_	_
7	their	their	PRP$	_	8	poss	_	_
8	effect	effect	NN	_	6	obj	_	_
9	on	on	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	release	release	NN	_	8	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	norepinephrine	norepinephrine	NN	_	11	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	other	other	JJ	_	16	attr	_	_
16	monoamines	monoamine	NNS	_	13	conj	_	_
17	from	from	IN	_	20	case	_	_
18	adrenergic	adrenergic	JJ	_	20	attr	_	_
19	nerve	nerve	NN	_	20	com	_	_
20	endings	ending	NNS	_	11	ppmod	_	_
21	;	;	:	_	3	p	_	_

1	this	this	DT	_	3	dep	_	_
2	can	can	MD	_	3	modal	_	_
3	cause	cause	VB	_	0	root	_	_
4	headaches	headache	NNS	_	3	obj	_	_
5	and	and	CC	_	4	cc	_	_
6	other	other	JJ	_	7	attr	_	_
7	signs	sign	NNS	_	4	conj	_	_
8	of	of	IN	_	10	case	_	_
9	hypertensive	hypertensive	JJ	_	10	attr	_	_
10	crisis	crisis	NN	_	4	ppmod	_	_
11	.	.	.	_	3	p	_	_

1	A	a	DT	_	2	det	_	_
2	variety	variety	NN	_	11	dep	_	_
3	of	of	IN	_	6	case	_	_
4	toxic	toxic	JJ	_	6	attr	_	_
5	neurological	neurological	JJ	_	6	attr	_	_
6	effects	effect	NNS	_	2	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	malignant	malignant	JJ	_	9	attr	_	_
9	hyperpyrexia	hyperpyrexia	NN	_	6	conj	_	_
10	can	can	MD	_	11	modal	_	_
11	occur	occur	VB	_	0	root	_	_
12	,	,	,	_	11	p	_	_
13	sometimes	sometimes	RB	_	16	adv	_	_
14	with	with	IN	_	16	case	_	_
15	fatal	fatal	JJ	_	16	attr	_	_
16	results	result	NNS	_	11	ppmod	_	_
17	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	may	may	MD	_	5	modal	_	_
5	counteract	counteract	VB	_	0	root	_	_
6	the	the	DT	_	8	det	_	_
7	sedative	sedative	JJ	_	8	attr	_	_
8	effect	effect	NN	_	5	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug3	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	may	may	MD	_	5	modal	_	_
5	antagonize	antagonize	VB	_	0	root	_	_
6	the	the	DT	_	8	det	_	_
7	hypotensive	hypotensive	JJ	_	8	attr	_	_
8	effects	effect	NNS	_	5	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug3	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	blocks	block	VBZ	_	0	root	_	_
5	dopamine	dopamine	NN	_	8	attr	_	_
6	and	and	CC	_	5	cc	_	_
7	norepinephrine	norepinephrine	NN	_	5	conj	_	_
8	receptors	receptor	NNS	_	4	obj	_	_
9	,	,	,	_	4	p	_	_
10	thus	thus	RB	_	11	adv	_	_
11	inhibiting	inhibit	VBG	_	4	comp	_	_
12	the	the	DT	_	15	det	_	_
13	central	central	JJ	_	15	attr	_	_
14	stimulant	stimulant	JJ	_	15	attr	_	_
15	effects	effect	NNS	_	11	obj	_	_
16	of	of	IN	_	17	case	_	_
17	drug3	drug0	NN	_	15	ppmod	_	_
18	and	and	CC	_	4	cc	_	_
19	can	can	MD	_	21	modal	_	_
20	be	be	VB	_	21	aux	_	_
21	used	use	VBN	_	4	conj	_	_
22	to	to	TO	_	23	aux	_	_
23	treat	treat	VB	_	21	comp	_	_
24	drug4	drug0	NN	_	25	com	_	_
25	poisoning	poisoning	NN	_	23	obj	_	_
26	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	may	may	MD	_	5	modal	_	_
5	delay	delay	VB	_	0	root	_	_
6	intestinal	intestinal	JJ	_	7	attr	_	_
7	absorption	absorption	NN	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_
10	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	blocks	block	VBZ	_	0	root	_	_
5	dopamine	dopamine	NN	_	6	com	_	_
6	receptors	receptor	NNS	_	4	obj	_	_
7	,	,	,	_	4	p	_	_
8	thus	thus	RB	_	9	adv	_	_
9	inhibiting	inhibit	VBG	_	4	comp	_	_
10	the	the	DT	_	13	det	_	_
11	central	central	JJ	_	13	attr	_	_
12	stimulant	stimulant	JJ	_	13	attr	_	_
13	effects	effect	NNS	_	9	obj	_	_
14	of	of	IN	_	15	case	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	12	dep	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	7	det	_	_
4	anorectic	anorectic	JJ	_	7	attr	_	_
5	and	and	CC	_	4	cc	_	_
6	stimulatory	stimulatory	JJ	_	4	conj	_	_
7	effects	effect	NNS	_	1	appo	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	may	may	MD	_	12	modal	_	_
11	be	be	VB	_	12	aux	_	_
12	inhibited	inhibit	VBN	_	0	root	_	_
13	by	by	IN	_	14	case	_	_
14	drug3	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	potentiate	potentiate	VB	_	0	root	_	_
5	the	the	DT	_	7	det	_	_
6	analgesic	analgesic	JJ	_	7	attr	_	_
7	effect	effect	NN	_	4	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_
10	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	4	attr	_	_
2	therapy	therapy	NN	_	4	attr	_	_
3	Urinary	urinary	JJ	_	4	attr	_	_
4	excretion	excretion	NN	_	8	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	is	be	VBZ	_	8	aux	_	_
8	increased	increase	VBN	_	0	root	_	_
9	,	,	,	_	8	p	_	_
10	and	and	CC	_	8	cc	_	_
11	efficacy	efficacy	NN	_	13	dep	_	_
12	is	be	VBZ	_	13	aux	_	_
13	reduced	reduce	VBN	_	8	conj	_	_
14	by	by	IN	_	15	case	_	_
15	acidifying	acidify	VBG	_	13	ppmod	_	_
16	agents	agent	NNS	_	15	obj	_	_
17	used	use	VBN	_	16	acl	_	_
18	in	in	IN	_	20	case	_	_
19	drug3	drug0	NN	_	20	com	_	_
20	therapy	therapy	NN	_	17	ppmod	_	_
21	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	enhance	enhance	VBP	_	0	root	_	_
5	the	the	DT	_	7	det	_	_
6	adrenergic	adrenergic	JJ	_	7	attr	_	_
7	effect	effect	NN	_	4	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_
10	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	delay	delay	VB	_	1	acl	_	_
6	intestinal	intestinal	JJ	_	7	attr	_	_
7	absorption	absorption	NN	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_
10	;	;	:	_	1	p	_	_

1	co-administration	co-administration	NN	_	5	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	may	may	MD	_	5	modal	_	_
5	produce	produce	VB	_	0	root	_	_
6	a	a	DT	_	9	det	_	_
7	synergistic	synergistic	JJ	_	9	attr	_	_
8	anticonvulsant	anticonvulsant	JJ	_	9	attr	_	_
9	action	action	NN	_	5	obj	_	_
10	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	delay	delay	VB	_	1	acl	_	_
6	intestinal	intestinal	JJ	_	7	attr	_	_
7	absorption	absorption	NN	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_
10	;	;	:	_	1	p	_	_

1	co-administration	co-administration	NN	_	5	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	may	may	MD	_	5	modal	_	_
5	produce	produce	VB	_	0	root	_	_
6	a	a	DT	_	9	det	_	_
7	synergistic	synergistic	JJ	_	9	attr	_	_
8	anticonvulsant	anticonvulsant	JJ	_	9	attr	_	_
9	action	action	NN	_	5	obj	_	_
10	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	4	case	_	_
4	cases	case	NNS	_	13	ppmod	_	_
5	of	of	IN	_	7	case	_	_
6	drug2	drug0	NN	_	7	com	_	_
7	overdosage	overdosage	NN	_	4	ppmod	_	_
8	,	,	,	_	13	p	_	_
9	drug3	drug0	NN	_	11	com	_	_
10	CNS	cns	NN	_	11	com	_	_
11	stimulation	stimulation	NN	_	13	dep	_	_
12	is	be	VBZ	_	13	aux	_	_
13	potentiated	potentiate	VBN	_	1	acl	_	_
14	and	and	CC	_	13	cc	_	_
15	fatal	fatal	JJ	_	16	attr	_	_
16	convulsions	convulsion	NNS	_	18	dep	_	_
17	can	can	MD	_	18	modal	_	_
18	occur	occur	VB	_	13	conj	_	_
19	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	inhibit	inhibit	VBP	_	0	root	_	_
5	the	the	DT	_	7	det	_	_
6	hypotensive	hypotensive	JJ	_	7	attr	_	_
7	effect	effect	NN	_	4	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_
10	.	.	.	_	4	p	_	_

1	Drug/Laboratory	drug/laboratory	JJ	_	3	attr	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	7	dep	_	_
4	:	:	:	_	3	p	_	_
5	drug1	drug0	NN	_	3	appo	_	_
6	can	can	MD	_	7	modal	_	_
7	cause	cause	VB	_	0	root	_	_
8	a	a	DT	_	10	det	_	_
9	significant	significant	JJ	_	10	attr	_	_
10	elevation	elevation	NN	_	7	obj	_	_
11	in	in	IN	_	14	case	_	_
12	plasma	plasma	NN	_	14	com	_	_
13	corticosteroid	corticosteroid	NN	_	14	com	_	_
14	levels	level	NNS	_	10	ppmod	_	_
15	.	.	.	_	7	p	_	_

1	This	this	DT	_	2	det	_	_
2	increase	increase	NN	_	3	dep	_	_
3	is	be	VBZ	_	0	root	_	_
4	greatest	great	JJS	_	3	dep	_	_
5	in	in	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	evening	evening	NN	_	4	ppmod	_	_
8	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	interfere	interfere	VB	_	0	root	_	_
4	with	with	IN	_	7	case	_	_
5	urinary	urinary	JJ	_	7	attr	_	_
6	steroid	steroid	NN	_	7	com	_	_
7	determinations	determination	NNS	_	3	ppmod	_	_
8	.	.	.	_	3	p	_	_

1	No	no	DT	_	3	det	_	_
2	drug	drug	NN	_	3	com	_	_
3	interactions	interaction	NNS	_	6	dep	_	_
4	have	have	VBP	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	observed	observe	VBN	_	0	root	_	_
7	with	with	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	drug1	drug0	JJ	_	10	attr	_	_
10	Implant	implant	NN	_	6	ppmod	_	_
11	.	.	.	_	6	p	_	_

1	There	there	EX	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	limited	limit	VBN	_	0	root	_	_
4	experience	experience	VBP	_	6	adv	_	_
5	with	with	IN	_	6	case	_	_
6	use	use	NN	_	3	ppmod	_	_
7	of	of	IN	_	9	case	_	_
8	retinal	retinal	JJ	_	9	attr	_	_
9	tamponades	tamponade	NNS	_	6	ppmod	_	_
10	in	in	IN	_	11	case	_	_
11	conjunction	conjunction	NN	_	6	ppmod	_	_
12	with	with	IN	_	15	case	_	_
13	the	the	DT	_	15	det	_	_
14	drug1	drug0	NN	_	15	com	_	_
15	Implant	implant	NN	_	11	ppmod	_	_
16	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	results	result	NNS	_	24	dep	_	_
3	of	of	IN	_	5	case	_	_
4	a	a	DT	_	5	det	_	_
5	study	study	NN	_	2	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	coadministration	coadministration	NN	_	5	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	(	-lrb-	-LRB-	_	12	p	_	_
11	50	0	CD	_	12	num	_	_
12	mg/kg	mg/kg	NN	_	9	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	with	with	IN	_	16	case	_	_
15	an	an	DT	_	16	det	_	_
16	drug2	drug0	NN	_	7	ppmod	_	_
17	containing	contain	VBG	_	16	acl	_	_
18	drug3	drug0	NN	_	17	obj	_	_
19	to	to	TO	_	21	aux	_	_
20	13	0	CD	_	21	num	_	_
21	patients	patient	NNS	_	17	ppmod	_	_
22	with	with	IN	_	23	case	_	_
23	tuberculosis	tuberculosis	NN	_	21	ppmod	_	_
24	showed	show	VBD	_	0	root	_	_
25	a	a	DT	_	26	det	_	_
26	reduction	reduction	NN	_	24	obj	_	_
27	of	of	IN	_	30	case	_	_
28	mean	mean	JJ	_	30	attr	_	_
29	serum	serum	NN	_	30	com	_	_
30	concentrations	concentration	NNS	_	26	ppmod	_	_
31	and	and	CC	_	30	cc	_	_
32	urinary	urinary	JJ	_	33	attr	_	_
33	excretion	excretion	NN	_	30	conj	_	_
34	of	of	IN	_	35	case	_	_
35	drug4	drug0	NNS	_	33	ppmod	_	_
36	of	of	IN	_	38	case	_	_
37	approximately	approximately	RB	_	38	adv	_	_
38	20	0	CD	_	35	ppmod	_	_
39	%	%	NN	_	38	meta	_	_
40	and	and	CC	_	38	cc	_	_
41	13	0	CD	_	38	conj	_	_
42	%	%	NN	_	41	meta	_	_
43	,	,	,	_	41	p	_	_
44	respectively	respectively	RB	_	38	conj	_	_
45	,	,	,	_	24	p	_	_
46	suggesting	suggest	VBG	_	24	comp	_	_
47	that	that	IN	_	55	mark	_	_
48	the	the	DT	_	50	det	_	_
49	oral	oral	JJ	_	50	attr	_	_
50	absorption	absorption	NN	_	55	dep	_	_
51	of	of	IN	_	52	case	_	_
52	drug5	drug0	NN	_	50	ppmod	_	_
53	may	may	MD	_	55	modal	_	_
54	be	be	VB	_	55	aux	_	_
55	reduced	reduce	VBN	_	46	comp	_	_
56	by	by	IN	_	58	case	_	_
57	these	these	DT	_	58	det	_	_
58	drug6	drug0	NN	_	55	ppmod	_	_
59	.	.	.	_	24	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	recommended	recommend	VBN	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	avoid	avoid	VB	_	3	comp	_	_
6	concurrent	concurrent	JJ	_	7	attr	_	_
7	administration	administration	NN	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NN	_	5	ppmod	_	_
12	containing	contain	VBG	_	11	acl	_	_
13	drug3	drug0	NN	_	12	obj	_	_
14	for	for	IN	_	18	case	_	_
15	at	at	IN	_	17	case	_	_
16	least	least	JJS	_	17	attr	_	_
17	4	0	CD	_	18	num	_	_
18	hours	hour	NNS	_	13	ppmod	_	_
19	following	follow	VBG	_	21	adv	_	_
20	drug4	drug0	NN	_	21	com	_	_
21	administration	administration	NN	_	13	ppmod	_	_
22	.	.	.	_	3	p	_	_

1	No	no	DT	_	5	det	_	_
2	specific	specific	JJ	_	5	attr	_	_
3	drug	drug	NN	_	5	com	_	_
4	interaction	interaction	NN	_	5	com	_	_
5	studies	study	NNS	_	8	dep	_	_
6	have	have	VBP	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	conducted	conduct	VBN	_	0	root	_	_
9	.	.	.	_	8	p	_	_

1	For	for	IN	_	2	case	_	_
2	information	information	NN	_	13	ppmod	_	_
3	on	on	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	pharmacokinetics	pharmacokinetics	NNS	_	2	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	in	in	IN	_	11	case	_	_
11	combination	combination	NN	_	5	ppmod	_	_
12	,	,	,	_	13	p	_	_
13	see	see	VB	_	0	root	_	_
14	Drug	drug	NN	_	15	com	_	_
15	Interactions	interaction	NNS	_	13	obj	_	_
16	under	under	IN	_	19	case	_	_
17	CLINICAL	clinical	JJ	_	19	attr	_	_
18	PHARMACOLOGY	pharmacology	NN	_	19	com	_	_
19	section	section	NN	_	13	ppmod	_	_
20	.	.	.	_	13	p	_	_

1	When	when	WRB	_	2	adv	_	_
2	given	give	VBN	_	8	advcl	_	_
3	concurrently	concurrently	RB	_	2	adv	_	_
4	the	the	DT	_	6	det	_	_
5	following	following	JJ	_	6	attr	_	_
6	drugs	drug	NNS	_	8	dep	_	_
7	may	may	MD	_	8	modal	_	_
8	interact	interact	VB	_	0	root	_	_
9	with	with	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	13	dep	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	,	,	,	_	3	p	_	_
5	or	or	CC	_	3	cc	_	_
6	drug3	drug0	NN	_	1	conj	_	_
7	:	:	:	_	1	p	_	_
8	potentiation	potentiation	NN	_	1	appo	_	_
9	of	of	IN	_	11	case	_	_
10	orthostatic	orthostatic	JJ	_	11	attr	_	_
11	hypotension	hypotension	NN	_	8	ppmod	_	_
12	may	may	MD	_	13	modal	_	_
13	occur	occur	VB	_	0	root	_	_
14	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	17	dep	_	_
2	:	:	:	_	1	p	_	_
3	(	-lrb-	-LRB-	_	5	p	_	_
4	oral	oral	JJ	_	5	attr	_	_
5	agents	agent	NNS	_	1	prn	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NNS	_	5	conj	_	_
8	)	-rrb-	-RRB-	_	5	p	_	_
9	-	-	CC	_	1	cc	_	_
10	dosage	dosage	NN	_	11	com	_	_
11	adjustment	adjustment	NN	_	1	conj	_	_
12	of	of	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	drug3	drug0	NN	_	1	ppmod	_	_
15	may	may	MD	_	17	modal	_	_
16	be	be	VB	_	17	aux	_	_
17	required	require	VBN	_	0	root	_	_
18	.	.	.	_	17	p	_	_

1	Other	other	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	additive	additive	JJ	_	5	attr	_	_
5	effect	effect	NN	_	2	conj	_	_
6	or	or	CC	_	5	cc	_	_
7	potentiation	potentiation	NN	_	2	conj	_	_
8	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	4	com	_	_
4	drug3	drug0	NN	_	1	conj	_	_
5	:	:	:	_	1	p	_	_
6	Absorption	absorption	NN	_	10	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug4	drug0	NN	_	6	ppmod	_	_
9	is	be	VBZ	_	10	aux	_	_
10	impaired	impair	VBN	_	1	acl	_	_
11	in	in	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	presence	presence	NN	_	10	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug5	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	1	p	_	_

1	Single	single	JJ	_	2	attr	_	_
2	doses	dose	NNS	_	9	dep	_	_
3	of	of	IN	_	5	case	_	_
4	either	either	CC	_	5	cc	_	_
5	drug1	drug0	NN	_	2	ppmod	_	_
6	or	or	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	8	com	_	_
8	drug3	drug0	NN	_	5	conj	_	_
9	bind	bind	VB	_	0	root	_	_
10	the	the	DT	_	11	det	_	_
11	drug4	drug0	NN	_	9	obj	_	_
12	and	and	CC	_	9	cc	_	_
13	reduce	reduce	VB	_	9	conj	_	_
14	its	its	PRP$	_	15	poss	_	_
15	absorption	absorption	NN	_	13	obj	_	_
16	from	from	IN	_	19	case	_	_
17	the	the	DT	_	19	det	_	_
18	gastrointestinal	gastrointestinal	JJ	_	19	attr	_	_
19	tract	tract	NN	_	15	ppmod	_	_
20	by	by	IN	_	26	case	_	_
21	up	up	RB	_	23	adv	_	_
22	to	to	TO	_	23	attr	_	_
23	85	0	CD	_	26	num	_	_
24	and	and	CC	_	23	cc	_	_
25	43	0	CD	_	23	conj	_	_
26	percent	percent	NN	_	13	ppmod	_	_
27	,	,	,	_	26	p	_	_
28	respectively	respectively	RB	_	26	adv	_	_
29	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	:	:	:	_	1	p	_	_
5	intensified	intensified	JJ	_	7	attr	_	_
6	electrolyte	electrolyte	NN	_	7	com	_	_
7	depletion	depletion	NN	_	1	appo	_	_
8	,	,	,	_	7	p	_	_
9	particularly	particularly	RB	_	7	adv	_	_
10	hypokalemia	hypokalemia	NN	_	7	appo	_	_
11	.	.	.	_	1	p	_	_

1	Pressor	pressor	JJ	_	2	attr	_	_
2	amines	amine	NNS	_	0	root	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	e.g.	e.g.	FW	_	6	adv	_	_
5	,	,	,	_	6	p	_	_
6	drug1	drug0	NN	_	2	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	:	:	:	_	2	p	_	_
9	possible	possible	JJ	_	10	dep	_	_
10	decreased	decrease	VBD	_	2	acl	_	_
11	response	response	NN	_	10	obj	_	_
12	to	to	TO	_	14	aux	_	_
13	pressor	pressor	JJ	_	14	attr	_	_
14	amines	amine	NNS	_	11	ppmod	_	_
15	but	but	CC	_	10	cc	_	_
16	not	not	RB	_	17	neg	10:neg	_
17	sufficient	sufficient	JJ	_	10	conj	_	_
18	to	to	TO	_	19	aux	_	_
19	preclude	preclude	VB	_	17	comp	_	_
20	their	their	PRP$	_	21	poss	_	_
21	use	use	NN	_	19	obj	_	_
22	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	,	,	,	_	1	p	_	_
3	nondepolarizing	nondepolarizing	NN	_	1	appo	_	_
4	(	-lrb-	-LRB-	_	7	p	_	_
5	e.g.	e.g.	FW	_	7	ppmod	_	_
6	,	,	,	_	7	p	_	_
7	drug2	drug0	NN	_	3	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	:	:	:	_	1	p	_	_
10	possible	possible	JJ	_	12	attr	_	_
11	increased	increase	VBN	_	12	attr	_	_
12	responsiveness	responsiveness	NN	_	1	appo	_	_
13	to	to	TO	_	15	aux	_	_
14	the	the	DT	_	15	det	_	_
15	drug3	drug0	NN	_	12	ppmod	_	_
16	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	7	comp	_	_
2	:	:	:	_	7	p	_	_
3	generally	generally	RB	_	7	adv	_	_
4	should	should	MD	_	7	modal	_	_
5	not	not	RB	_	7	neg	_	_
6	be	be	VB	_	7	aux	_	_
7	given	give	VBN	_	0	root	_	_
8	with	with	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	reduce	reduce	VBP	_	0	root	_	_
3	the	the	DT	_	5	det	_	_
4	renal	renal	JJ	_	5	attr	_	_
5	clearance	clearance	NN	_	2	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	2	cc	_	_
9	add	add	VBP	_	2	conj	_	_
10	a	a	DT	_	12	det	_	_
11	high	high	JJ	_	12	attr	_	_
12	risk	risk	NN	_	9	obj	_	_
13	of	of	IN	_	15	case	_	_
14	drug3	drug0	NN	_	15	com	_	_
15	toxicity	toxicity	NN	_	12	ppmod	_	_
16	.	.	.	_	2	p	_	_

1	Refer	refer	VBP	_	0	root	_	_
2	to	to	TO	_	5	aux	_	_
3	the	the	DT	_	5	det	_	_
4	package	package	JJ	_	5	attr	_	_
5	insert	insert	NN	_	1	ppmod	_	_
6	for	for	IN	_	8	case	_	_
7	drug1	drug0	JJ	_	8	attr	_	_
8	preparations	preparation	NNS	_	5	ppmod	_	_
9	before	before	IN	_	10	case	_	_
10	use	use	NN	_	8	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	such	such	JJ	_	13	attr	_	_
13	preparations	preparation	NNS	_	10	ppmod	_	_
14	with	with	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	5	case	_	_
4	some	some	DT	_	5	det	_	_
5	patients	patient	NNS	_	13	ppmod	_	_
6	,	,	,	_	13	p	_	_
7	the	the	DT	_	8	det	_	_
8	administration	administration	NN	_	13	dep	_	_
9	of	of	IN	_	11	case	_	_
10	a	a	DT	_	11	det	_	_
11	drug2	drug0	NN	_	8	ppmod	_	_
12	can	can	MD	_	13	modal	_	_
13	reduce	reduce	VB	_	1	acl	_	_
14	the	the	DT	_	21	det	_	_
15	diuretic	diuretic	JJ	_	21	attr	_	_
16	,	,	,	_	15	p	_	_
17	natriuretic	natriuretic	JJ	_	15	conj	_	_
18	,	,	,	_	17	p	_	_
19	and	and	CC	_	17	cc	_	_
20	antihypertensive	antihypertensive	JJ	_	15	conj	_	_
21	effects	effect	NNS	_	13	obj	_	_
22	of	of	IN	_	23	case	_	_
23	drug3	drug0	NN	_	21	ppmod	_	_
24	,	,	,	_	23	p	_	_
25	drug4	drug0	NN	_	23	conj	_	_
26	and	and	CC	_	25	cc	_	_
27	drug5	drug0	NN	_	23	conj	_	_
28	.	.	.	_	1	p	_	_

1	Therefore	therefore	RB	_	15	adv	_	_
2	,	,	,	_	15	p	_	_
3	when	when	WRB	_	8	adv	_	_
4	drug1	drug0	NN	_	8	dep	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	are	be	VBP	_	8	aux	_	_
8	used	use	VBN	_	15	advcl	_	_
9	concomitantly	concomitantly	RB	_	8	adv	_	_
10	,	,	,	_	15	p	_	_
11	the	the	DT	_	12	det	_	_
12	patient	patient	NN	_	15	dep	_	_
13	should	should	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	observed	observe	VBN	_	0	root	_	_
16	closely	closely	RB	_	15	adv	_	_
17	to	to	TO	_	18	aux	_	_
18	determine	determine	VB	_	15	comp	_	_
19	if	if	IN	_	27	mark	_	_
20	the	the	DT	_	22	det	_	_
21	desired	desired	JJ	_	22	attr	_	_
22	effect	effect	NN	_	27	dep	_	_
23	of	of	IN	_	25	case	_	_
24	the	the	DT	_	25	det	_	_
25	drug3	drug0	NN	_	22	ppmod	_	_
26	is	be	VBZ	_	27	aux	_	_
27	obtained	obtain	VBN	_	18	comp	_	_
28	.	.	.	_	15	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Because	because	IN	_	6	case	_	_
4	of	of	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	relationship	relationship	NN	_	15	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	to	to	TO	_	10	aux	_	_
10	drug3	drug0	NN	_	6	ppmod	_	_
11	,	,	,	_	15	p	_	_
12	patients	patient	NNS	_	15	dep	_	_
13	should	should	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	advised	advise	VBN	_	1	acl	_	_
16	against	against	IN	_	17	case	_	_
17	taking	take	VBG	_	15	ppmod	_	_
18	drug4	drug0	NN	_	20	com	_	_
19	containing	containing	NN	_	20	com	_	_
20	drug5	drug0	NN	_	17	obj	_	_
21	to	to	TO	_	22	aux	_	_
22	avoid	avoid	VB	_	17	comp	_	_
23	additive	additive	JJ	_	25	attr	_	_
24	toxic	toxic	JJ	_	25	attr	_	_
25	effects	effect	NNS	_	22	obj	_	_

1	.	.	.	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Concomitant	concomitant	JJ	_	4	attr	_	_
4	treatment	treatment	NN	_	11	dep	_	_
5	with	with	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	avoided	avoid	VBN	_	1	acl	_	_
12	because	because	IN	_	17	mark	_	_
13	drug4	drug0	NN	_	14	com	_	_
14	use	use	NN	_	17	dep	_	_
15	has	have	VBZ	_	17	aux	_	_
16	been	be	VBN	_	17	aux	_	_
17	associated	associate	VBN	_	11	comp	_	_
18	with	with	IN	_	20	case	_	_
19	a	a	DT	_	20	det	_	_
20	number	number	NN	_	17	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	cases	case	NNS	_	20	ppmod	_	_
23	of	of	IN	_	25	case	_	_
24	pseudotumor	pseudotumor	JJ	_	25	attr	_	_
25	cerebri	cerebri	NN	_	22	ppmod	_	_
26	(	-lrb-	-LRB-	_	29	p	_	_
27	benign	benign	JJ	_	29	attr	_	_
28	intracranial	intracranial	JJ	_	29	attr	_	_
29	hypertension	hypertension	NN	_	25	prn	_	_
30	)	-rrb-	-RRB-	_	29	p	_	_
31	,	,	,	_	20	p	_	_
32	some	some	DT	_	35	dep	_	_
33	of	of	IN	_	34	case	_	_
34	which	which	WDT	_	32	ppmod	_	_
35	involved	involve	VBD	_	20	relcl	_	_
36	concomitant	concomitant	JJ	_	37	attr	_	_
37	use	use	NN	_	35	obj	_	_
38	of	of	IN	_	39	case	_	_
39	drug5	drug0	NN	_	37	ppmod	_	_

1	.	.	.	_	0	root	_	_

1	Micro-dosed	micro-dosed	JJ	_	3	attr	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	Preparations	preparation	NNS	_	0	root	_	_
4	:	:	:	_	3	p	_	_
5	Micro-dosed	micro-dosed	JJ	_	7	attr	_	_
6	drug2	drug0	NN	_	7	com	_	_
7	preparations	preparation	NNS	_	18	dep	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	minipills	minipills	NNS	_	7	prn	_	_
10	that	that	WDT	_	13	dep	_	_
11	do	do	VBP	_	13	aux	_	_
12	not	not	RB	_	13	neg	_	_
13	contain	contain	VB	_	9	relcl	_	_
14	an	an	DT	_	15	det	_	_
15	drug3	drug0	NN	_	13	obj	_	_
16	)	-rrb-	-RRB-	_	9	p	_	_
17	may	may	MD	_	18	modal	_	_
18	be	be	VB	_	3	acl	_	_
19	an	an	DT	_	21	det	_	_
20	inadequate	inadequate	JJ	_	21	attr	_	_
21	method	method	NN	_	18	obj	_	_
22	of	of	IN	_	23	case	_	_
23	contraception	contraception	NN	_	21	ppmod	_	_
24	during	during	IN	_	26	case	_	_
25	drug4	drug0	NN	_	26	com	_	_
26	therapy	therapy	NN	_	21	ppmod	_	_
27	.	.	.	_	3	p	_	_

1	Although	although	IN	_	4	mark	_	_
2	other	other	JJ	_	3	attr	_	_
3	drug1	drug0	NNS	_	4	dep	_	_
4	are	be	VBP	_	10	advcl	_	_
5	highly	highly	RB	_	6	adv	_	_
6	effective	effective	JJ	_	4	dep	_	_
7	,	,	,	_	10	p	_	_
8	there	there	EX	_	10	dep	_	_
9	have	have	VBP	_	10	aux	_	_
10	been	be	VBN	_	0	root	_	_
11	reports	report	NNS	_	10	obj	_	_
12	of	of	IN	_	13	case	_	_
13	pregnancy	pregnancy	NN	_	11	ppmod	_	_
14	from	from	IN	_	15	case	_	_
15	women	woman	NNS	_	11	ppmod	_	_
16	who	who	WP	_	18	dep	_	_
17	have	have	VBP	_	18	aux	_	_
18	used	use	VBN	_	15	relcl	_	_
19	drug2	drug0	NN	_	18	obj	_	_
20	,	,	,	_	11	p	_	_
21	as	as	RB	_	22	com	_	_
22	well	well	RB	_	11	cc	_	_
23	as	as	IN	_	22	com	_	_
24	topical/injectable/implantable/insertable	topical/injectable/implantable/insertable	JJ	_	28	attr	_	_
25	hormonal	hormonal	JJ	_	28	attr	_	_
26	birth	birth	NN	_	28	com	_	_
27	control	control	NN	_	28	com	_	_
28	products	product	NNS	_	11	conj	_	_
29	.	.	.	_	10	p	_	_

1	These	these	DT	_	2	det	_	_
2	reports	report	NNS	_	3	dep	_	_
3	are	be	VBP	_	0	root	_	_
4	more	more	RBR	_	5	adv	_	_
5	frequent	frequent	JJ	_	3	dep	_	_
6	for	for	IN	_	7	case	_	_
7	women	woman	NNS	_	3	ppmod	_	_
8	who	who	WP	_	9	dep	_	_
9	use	use	VBP	_	7	relcl	_	_
10	only	only	RB	_	9	adv	_	_
11	a	a	DT	_	13	det	_	_
12	single	single	JJ	_	13	attr	_	_
13	method	method	NN	_	9	obj	_	_
14	of	of	IN	_	15	case	_	_
15	contraception	contraception	NN	_	13	ppmod	_	_
16	.	.	.	_	3	p	_	_

1	It	it	PRP	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	known	know	VBN	_	0	root	_	_
5	if	if	IN	_	7	mark	_	_
6	drug1	drug0	NN	_	7	dep	_	_
7	differ	differ	VBP	_	4	comp	_	_
8	in	in	IN	_	10	case	_	_
9	their	their	PRP$	_	10	poss	_	_
10	effectiveness	effectiveness	NN	_	7	ppmod	_	_
11	when	when	WRB	_	12	adv	_	_
12	used	use	VBN	_	7	comp	_	_
13	with	with	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	4	p	_	_

1	Therefore	therefore	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	it	it	PRP	_	4	dep	_	_
4	is	be	VBZ	_	0	root	_	_
5	critically	critically	RB	_	6	adv	_	_
6	important	important	JJ	_	4	dep	_	_
7	for	for	IN	_	8	case	_	_
8	women	woman	NNS	_	6	ppmod	_	_
9	of	of	IN	_	11	case	_	_
10	childbearing	childbearing	JJ	_	11	attr	_	_
11	potential	potential	NN	_	8	ppmod	_	_
12	to	to	TO	_	13	aux	_	_
13	select	select	VB	_	11	acl	_	_
14	and	and	CC	_	13	cc	_	_
15	commit	commit	VB	_	13	conj	_	_
16	to	to	TO	_	17	aux	_	_
17	use	use	VB	_	15	comp	_	_
18	2	0	CD	_	19	num	_	_
19	forms	form	NNS	_	17	obj	_	_
20	of	of	IN	_	22	case	_	_
21	effective	effective	JJ	_	22	attr	_	_
22	contraception	contraception	NN	_	19	ppmod	_	_
23	simultaneously	simultaneously	RB	_	17	adv	_	_
24	,	,	,	_	4	p	_	_
25	at	at	IN	_	26	case	_	_
26	least	least	JJS	_	27	adv	_	_
27	1	0	CD	_	31	num	_	_
28	of	of	IN	_	29	case	_	_
29	which	which	WDT	_	27	ppmod	_	_
30	must	must	MD	_	31	modal	_	_
31	be	be	VB	_	4	comp	_	_
32	a	a	DT	_	34	det	_	_
33	primary	primary	JJ	_	34	attr	_	_
34	form	form	NN	_	31	obj	_	_
35	,	,	,	_	31	p	_	_
36	unless	unless	IN	_	39	mark	_	_
37	absolute	absolute	JJ	_	38	attr	_	_
38	abstinence	abstinence	NN	_	39	dep	_	_
39	is	be	VBZ	_	31	comp	_	_
40	the	the	DT	_	42	det	_	_
41	chosen	choose	VBN	_	42	attr	_	_
42	method	method	NN	_	39	obj	_	_
43	,	,	,	_	39	p	_	_
44	or	or	CC	_	39	cc	_	_
45	the	the	DT	_	46	det	_	_
46	patient	patient	NN	_	48	dep	_	_
47	has	have	VBZ	_	48	aux	_	_
48	undergone	undergo	VBN	_	39	conj	_	_
49	a	a	DT	_	50	det	_	_
50	hysterectomy	hysterectomy	NN	_	48	obj	_	_

1	.	.	.	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	7	dep	_	_
4	has	have	VBZ	_	7	aux	_	_
5	not	not	RB	_	7	neg	_	_
6	been	be	VBN	_	7	aux	_	_
7	shown	show	VBN	_	1	acl	_	_
8	to	to	TO	_	9	aux	_	_
9	alter	alter	VB	_	7	comp	_	_
10	the	the	DT	_	11	det	_	_
11	pharmacokinetics	pharmacokinetics	NNS	_	9	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug3	drug0	NN	_	11	ppmod	_	_
14	in	in	IN	_	16	case	_	_
15	a	a	DT	_	16	det	_	_
16	study	study	NN	_	11	ppmod	_	_
17	in	in	IN	_	20	case	_	_
18	seven	#crd#	CD	_	20	num	_	_
19	healthy	healthy	JJ	_	20	attr	_	_
20	volunteers	volunteer	NNS	_	16	ppmod	_	_
21	.	.	.	_	1	p	_	_

1	These	these	DT	_	2	det	_	_
2	results	result	NNS	_	3	dep	_	_
3	are	be	VBP	_	0	root	_	_
4	consistent	consistent	JJ	_	3	dep	_	_
5	with	with	IN	_	9	case	_	_
6	the	the	DT	_	9	det	_	_
7	in	in	FW	_	8	adv	_	_
8	vitro	vitro	FW	_	9	attr	_	_
9	finding	finding	NN	_	4	ppmod	_	_
10	that	that	IN	_	16	mark	_	_
11	neither	neither	CC	_	12	cc	_	_
12	drug1	drug0	NN	_	16	dep	_	_
13	nor	nor	CC	_	12	cc	_	_
14	its	its	PRP$	_	15	poss	_	_
15	metabolites	metabolite	NNS	_	12	conj	_	_
16	induce	induce	VBP	_	9	acl	_	_
17	or	or	CC	_	16	cc	_	_
18	inhibit	inhibit	VBP	_	16	conj	_	_
19	the	the	DT	_	20	det	_	_
20	activity	activity	NN	_	18	obj	_	_
21	of	of	IN	_	28	case	_	_
22	the	the	DT	_	28	det	_	_
23	CYP	cyp	NN	_	28	attr	_	_
24	2C9	0c0	NN	_	28	attr	_	_
25	human	human	JJ	_	28	attr	_	_
26	hepatic	hepatic	JJ	_	28	attr	_	_
27	P450	p0	NN	_	28	com	_	_
28	enzyme	enzyme	NN	_	20	ppmod	_	_
29	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	known	know	VBN	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	cause	cause	VB	_	3	comp	_	_
6	osteomalacia	osteomalacia	NN	_	5	obj	_	_
7	.	.	.	_	3	p	_	_

1	No	no	DT	_	4	det	_	_
2	formal	formal	JJ	_	4	attr	_	_
3	clinical	clinical	JJ	_	4	attr	_	_
4	studies	study	NNS	_	7	dep	_	_
5	have	have	VBP	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	conducted	conduct	VBN	_	0	root	_	_
8	to	to	TO	_	9	aux	_	_
9	assess	assess	VB	_	7	comp	_	_
10	if	if	IN	_	12	mark	_	_
11	there	there	EX	_	12	dep	_	_
12	is	be	VBZ	_	9	comp	_	_
13	an	an	DT	_	15	det	_	_
14	interactive	interactive	JJ	_	15	attr	_	_
15	effect	effect	NN	_	12	obj	_	_
16	on	on	IN	_	18	case	_	_
17	bone	bone	NN	_	18	com	_	_
18	loss	loss	NN	_	15	ppmod	_	_
19	between	between	IN	_	20	case	_	_
20	drug1	drug0	NN	_	15	ppmod	_	_
21	and	and	CC	_	20	cc	_	_
22	drug2	drug0	NN	_	20	conj	_	_
23	.	.	.	_	7	p	_	_

1	Therefore	therefore	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	caution	caution	NN	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	exercised	exercise	VBN	_	0	root	_	_
7	when	when	WRB	_	8	adv	_	_
8	using	use	VBG	_	6	comp	_	_
9	these	these	DT	_	10	det	_	_
10	drugs	drug	NNS	_	8	obj	_	_
11	together	together	RB	_	8	adv	_	_

1	.	.	.	_	0	root	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	are	be	VBP	_	5	aux	_	_
5	known	know	VBN	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	cause	cause	VB	_	5	comp	_	_
8	osteoporosis	osteoporosis	NN	_	7	obj	_	_
9	.	.	.	_	5	p	_	_

1	No	no	DT	_	4	det	_	_
2	formal	formal	JJ	_	4	attr	_	_
3	clinical	clinical	JJ	_	4	attr	_	_
4	studies	study	NNS	_	7	dep	_	_
5	have	have	VBP	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	conducted	conduct	VBN	_	0	root	_	_
8	to	to	TO	_	9	aux	_	_
9	assess	assess	VB	_	7	comp	_	_
10	if	if	IN	_	12	mark	_	_
11	there	there	EX	_	12	dep	_	_
12	is	be	VBZ	_	9	comp	_	_
13	an	an	DT	_	15	det	_	_
14	interactive	interactive	JJ	_	15	attr	_	_
15	effect	effect	NN	_	12	obj	_	_
16	on	on	IN	_	18	case	_	_
17	bone	bone	NN	_	18	com	_	_
18	loss	loss	NN	_	15	ppmod	_	_
19	between	between	IN	_	20	case	_	_
20	drug1	drug0	NN	_	15	ppmod	_	_
21	and	and	CC	_	20	cc	_	_
22	drug2	drug0	NN	_	20	conj	_	_
23	.	.	.	_	7	p	_	_

1	Therefore	therefore	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	caution	caution	NN	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	exercised	exercise	VBN	_	0	root	_	_
7	when	when	WRB	_	8	adv	_	_
8	using	use	VBG	_	6	comp	_	_
9	these	these	DT	_	10	det	_	_
10	drugs	drug	NNS	_	8	obj	_	_
11	together	together	RB	_	8	adv	_	_
12	.	.	.	_	6	p	_	_

1	Prescribers	prescriber	NNS	_	3	dep	_	_
2	are	be	VBP	_	3	aux	_	_
3	advised	advise	VBN	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	consult	consult	VB	_	3	comp	_	_
6	the	the	DT	_	8	det	_	_
7	package	package	JJ	_	8	attr	_	_
8	insert	insert	NN	_	5	obj	_	_
9	of	of	IN	_	10	case	_	_
10	medication	medication	NN	_	8	ppmod	_	_
11	administered	administer	VBN	_	10	acl	_	_
12	concomitantly	concomitantly	RB	_	11	adv	_	_
13	with	with	IN	_	14	case	_	_
14	drug1	drug0	NN	_	11	ppmod	_	_
15	,	,	,	_	3	p	_	_
16	since	since	IN	_	20	mark	_	_
17	some	some	DT	_	18	det	_	_
18	medications	medication	NNS	_	20	dep	_	_
19	may	may	MD	_	20	modal	_	_
20	decrease	decrease	VB	_	3	comp	_	_
21	the	the	DT	_	22	det	_	_
22	effectiveness	effectiveness	NN	_	20	obj	_	_
23	of	of	IN	_	27	case	_	_
24	these	these	DT	_	27	det	_	_
25	birth	birth	NN	_	27	com	_	_
26	control	control	NN	_	27	com	_	_
27	products	product	NNS	_	22	ppmod	_	_
28	.	.	.	_	3	p	_	_

1	drug1	drug0	JJ	_	2	attr	_	_
2	use	use	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	associated	associate	VBN	_	0	root	_	_
5	with	with	IN	_	6	case	_	_
6	depression	depression	NN	_	4	ppmod	_	_
7	in	in	IN	_	9	case	_	_
8	some	some	DT	_	9	det	_	_
9	patients	patient	NNS	_	6	ppmod	_	_
10	.	.	.	_	4	p	_	_

1	Pregnancies	pregnancy	NNS	_	4	dep	_	_
2	have	have	VBP	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	reported	report	VBN	_	0	root	_	_
5	by	by	IN	_	6	case	_	_
6	users	user	NNS	_	4	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	who	who	WP	_	11	dep	_	_
10	also	also	RB	_	11	adv	_	_
11	used	use	VBD	_	6	relcl	_	_
12	some	some	DT	_	13	det	_	_
13	form	form	NN	_	11	obj	_	_
14	of	of	IN	_	17	case	_	_
15	St.	st.	NN	_	17	com	_	_
16	Johns	johns	NNP	_	17	com	_	_
17	Wort	wort	NNP	_	13	ppmod	_	_
18	.	.	.	_	4	p	_	_

1	Laboratory	laboratory	NN	_	2	com	_	_
2	Tests	test	NNS	_	4	com	_	_
3	Pregnancy	pregnancy	NN	_	4	com	_	_
4	Test	test	NN	_	11	dep	_	_
5	Female	female	JJ	_	6	attr	_	_
6	patients	patient	NNS	_	4	appo	_	_
7	of	of	IN	_	9	case	_	_
8	childbearing	childbearing	JJ	_	9	attr	_	_
9	potential	potential	NN	_	4	ppmod	_	_
10	must	must	MD	_	11	modal	_	_
11	have	have	VB	_	0	root	_	_
12	negative	negative	JJ	_	13	attr	_	_
13	results	result	NNS	_	11	obj	_	_
14	from	from	IN	_	16	case	_	_
15	2	0	CD	_	16	num	_	_
16	urine	urine	NN	_	13	ppmod	_	_
17	or	or	CC	_	16	cc	_	_
18	serum	serum	NN	_	20	com	_	_
19	pregnancy	pregnancy	NN	_	20	com	_	_
20	tests	test	NNS	_	16	conj	_	_
21	with	with	IN	_	23	case	_	_
22	a	a	DT	_	23	det	_	_
23	sensitivity	sensitivity	NN	_	13	ppmod	_	_
24	of	of	IN	_	28	case	_	_
25	at	at	IN	_	27	case	_	_
26	least	least	JJS	_	27	attr	_	_
27	25	0	CD	_	28	num	_	_
28	mIU/mL	miu/ml	NN	_	23	ppmod	_	_
29	before	before	IN	_	30	case	_	_
30	receiving	receive	VBG	_	11	ppmod	_	_
31	the	the	DT	_	34	det	_	_
32	initial	initial	JJ	_	34	attr	_	_
33	drug1	drug0	NN	_	34	com	_	_
34	prescription	prescription	NN	_	30	obj	_	_
35	.	.	.	_	11	p	_	_

1	The	the	DT	_	3	det	_	_
2	first	#ord#	JJ	_	3	attr	_	_
3	test	test	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	obtained	obtain	VBN	_	0	root	_	_
6	by	by	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	prescriber	prescriber	NN	_	5	ppmod	_	_
9	when	when	WRB	_	13	adv	_	_
10	the	the	DT	_	11	det	_	_
11	decision	decision	NN	_	13	dep	_	_
12	is	be	VBZ	_	13	aux	_	_
13	made	make	VBN	_	5	comp	_	_
14	to	to	TO	_	15	aux	_	_
15	pursue	pursue	VBP	_	13	comp	_	_
16	qualification	qualification	NN	_	15	obj	_	_
17	of	of	IN	_	19	case	_	_
18	the	the	DT	_	19	det	_	_
19	patient	patient	NN	_	16	ppmod	_	_
20	for	for	IN	_	21	case	_	_
21	drug1	drug0	NN	_	16	ppmod	_	_
22	(	-lrb-	-LRB-	_	25	p	_	_
23	a	a	DT	_	25	det	_	_
24	screening	screening	JJ	_	25	attr	_	_
25	test	test	NN	_	21	prn	_	_
26	)	-rrb-	-RRB-	_	25	p	_	_
27	.	.	.	_	5	p	_	_

1	The	the	DT	_	4	det	_	_
2	second	#ord#	JJ	_	4	attr	_	_
3	pregnancy	pregnancy	NN	_	4	com	_	_
4	test	test	NN	_	12	dep	_	_
5	(	-lrb-	-LRB-	_	8	p	_	_
6	a	a	DT	_	8	det	_	_
7	confirmation	confirmation	NN	_	8	com	_	_
8	test	test	NN	_	4	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	should	should	MD	_	12	modal	_	_
11	be	be	VB	_	12	aux	_	_
12	done	do	VBN	_	0	root	_	_
13	during	during	IN	_	17	case	_	_
14	the	the	DT	_	17	det	_	_
15	first	#ord#	JJ	_	17	attr	_	_
16	5	0	CD	_	17	num	_	_
17	days	day	NNS	_	12	ppmod	_	_
18	of	of	IN	_	21	case	_	_
19	the	the	DT	_	21	det	_	_
20	menstrual	menstrual	JJ	_	21	attr	_	_
21	period	period	NN	_	17	ppmod	_	_
22	immediately	immediately	RB	_	23	adv	_	_
23	preceding	precede	VBG	_	21	acl	_	_
24	the	the	DT	_	25	det	_	_
25	beginning	beginning	NN	_	23	obj	_	_
26	of	of	IN	_	28	case	_	_
27	drug1	drug0	NN	_	28	com	_	_
28	therapy	therapy	NN	_	25	ppmod	_	_
29	.	.	.	_	12	p	_	_

1	For	for	IN	_	2	case	_	_
2	patients	patient	NNS	_	11	ppmod	_	_
3	with	with	IN	_	4	case	_	_
4	amenorrhea	amenorrhea	NN	_	2	ppmod	_	_
5	,	,	,	_	11	p	_	_
6	the	the	DT	_	8	det	_	_
7	second	#ord#	JJ	_	8	attr	_	_
8	test	test	NN	_	11	dep	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	done	do	VBN	_	0	root	_	_
12	at	at	IN	_	14	case	_	_
13	least	least	JJS	_	14	attr	_	_
14	11	0	CD	_	15	num	_	_
15	days	day	NNS	_	19	dat	_	_
16	after	after	IN	_	19	case	_	_
17	the	the	DT	_	19	det	_	_
18	last	last	JJ	_	19	attr	_	_
19	act	act	VBP	_	11	ppmod	_	_
20	of	of	IN	_	23	case	_	_
21	unprotected	unprotected	JJ	_	23	attr	_	_
22	sexual	sexual	JJ	_	23	attr	_	_
23	intercourse	intercourse	NN	_	19	ppmod	_	_
24	(	-lrb-	-LRB-	_	26	p	_	_
25	without	without	IN	_	26	case	_	_
26	using	use	VBG	_	23	prn	_	_
27	2	0	CD	_	29	num	_	_
28	effective	effective	JJ	_	29	attr	_	_
29	forms	form	NNS	_	26	obj	_	_
30	of	of	IN	_	31	case	_	_
31	contraception	contraception	NN	_	29	ppmod	_	_
32	)	-rrb-	-RRB-	_	26	p	_	_
33	.	.	.	_	11	p	_	_

1	Each	each	DT	_	2	det	_	_
2	month	month	NN	_	9	dep	_	_
3	of	of	IN	_	4	case	_	_
4	therapy	therapy	NN	_	2	ppmod	_	_
5	,	,	,	_	9	p	_	_
6	the	the	DT	_	7	det	_	_
7	patient	patient	NN	_	9	dep	_	_
8	must	must	MD	_	9	modal	_	_
9	have	have	VB	_	0	root	_	_
10	a	a	DT	_	12	det	_	_
11	negative	negative	JJ	_	12	attr	_	_
12	result	result	NN	_	9	obj	_	_
13	from	from	IN	_	15	case	_	_
14	a	a	DT	_	15	det	_	_
15	urine	urine	NN	_	9	ppmod	_	_
16	or	or	CC	_	15	cc	_	_
17	serum	serum	NN	_	19	com	_	_
18	pregnancy	pregnancy	NN	_	19	com	_	_
19	test	test	NN	_	15	conj	_	_
20	.	.	.	_	9	p	_	_

1	A	a	DT	_	3	det	_	_
2	pregnancy	pregnancy	NN	_	3	com	_	_
3	test	test	NN	_	6	dep	_	_
4	must	must	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	repeated	repeat	VBN	_	0	root	_	_
7	each	each	DT	_	8	det	_	_
8	month	month	NN	_	9	advnp	_	_
9	prior	prior	RB	_	6	adv	_	_
10	to	to	TO	_	13	aux	_	_
11	the	the	DT	_	13	det	_	_
12	female	female	JJ	_	13	attr	_	_
13	patient	patient	NN	_	9	ppmod	_	_
14	receiving	receive	VBG	_	13	acl	_	_
15	each	each	DT	_	16	det	_	_
16	prescription	prescription	NN	_	14	obj	_	_

1	.	.	.	_	0	root	_	_

1	Lipids	lipid	NNS	_	10	dep	_	_
2	:	:	:	_	1	p	_	_
3	Pretreatment	pretreatment	NN	_	1	conj	_	_
4	and	and	CC	_	3	cc	_	_
5	follow-up	follow-up	JJ	_	7	attr	_	_
6	blood	blood	NN	_	7	com	_	_
7	lipids	lipid	NNS	_	1	conj	_	_
8	should	should	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	obtained	obtain	VBN	_	0	root	_	_
11	under	under	IN	_	13	case	_	_
12	fasting	fasting	JJ	_	13	attr	_	_
13	conditions	condition	NNS	_	10	ppmod	_	_
14	.	.	.	_	10	p	_	_

1	After	after	IN	_	2	case	_	_
2	consumption	consumption	NN	_	11	ppmod	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	,	,	,	_	11	p	_	_
6	at	at	IN	_	8	case	_	_
7	least	least	JJS	_	8	attr	_	_
8	36	0	CD	_	9	num	_	_
9	hours	hour	NNS	_	11	dep	_	_
10	should	should	MD	_	11	modal	_	_
11	elapse	elapse	VB	_	0	root	_	_
12	before	before	IN	_	16	mark	_	_
13	these	these	DT	_	14	det	_	_
14	determinations	determination	NNS	_	16	dep	_	_
15	are	be	VBP	_	16	aux	_	_
16	made	make	VBN	_	11	comp	_	_
17	.	.	.	_	11	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	recommended	recommend	VBN	_	0	root	_	_
4	that	that	IN	_	8	mark	_	_
5	these	these	DT	_	6	det	_	_
6	tests	test	NNS	_	8	dep	_	_
7	be	be	VB	_	8	aux	_	_
8	performed	performed	VBN	_	3	comp	_	_
9	at	at	IN	_	13	case	_	_
10	weekly	weekly	JJ	_	13	attr	_	_
11	or	or	CC	_	10	cc	_	_
12	biweekly	biweekly	JJ	_	10	conj	_	_
13	intervals	interval	NNS	_	8	ppmod	_	_
14	until	until	IN	_	21	mark	_	_
15	the	the	DT	_	17	det	_	_
16	lipid	lipid	NN	_	17	com	_	_
17	response	response	NN	_	21	dep	_	_
18	to	to	TO	_	19	aux	_	_
19	drug1	drug0	NN	_	17	ppmod	_	_
20	is	be	VBZ	_	21	aux	_	_
21	established	establish	VBN	_	8	comp	_	_
22	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	incidence	incidence	NN	_	5	dep	_	_
3	of	of	IN	_	4	case	_	_
4	hypertriglyceridemia	hypertriglyceridemia	NNS	_	2	ppmod	_	_
5	is	be	VBZ	_	0	root	_	_
6	1	0	CD	_	7	num	_	_
7	patient	patient	NN	_	5	obj	_	_
8	in	in	IN	_	9	case	_	_
9	4	0	CD	_	7	ppmod	_	_
10	on	on	IN	_	12	case	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	therapy	therapy	NN	_	7	ppmod	_	_

1	.	.	.	_	0	root	_	_

1	Liver	liver	NN	_	3	com	_	_
2	Function	function	NN	_	3	com	_	_
3	Tests	test	NNS	_	0	root	_	_
4	:	:	:	_	3	p	_	_
5	Since	since	IN	_	12	mark	_	_
6	elevations	elevation	NNS	_	12	dep	_	_
7	of	of	IN	_	9	case	_	_
8	liver	liver	NN	_	9	com	_	_
9	enzymes	enzyme	NNS	_	6	ppmod	_	_
10	have	have	VBP	_	12	aux	_	_
11	been	be	VBN	_	12	aux	_	_
12	observed	observe	VBN	_	31	advcl	_	_
13	during	during	IN	_	15	case	_	_
14	clinical	clinical	JJ	_	15	attr	_	_
15	trials	trial	NNS	_	12	ppmod	_	_
16	,	,	,	_	12	p	_	_
17	and	and	CC	_	12	cc	_	_
18	hepatitis	hepatitis	NN	_	21	dep	_	_
19	has	have	VBZ	_	21	aux	_	_
20	been	be	VBN	_	21	aux	_	_
21	reported	report	VBN	_	12	conj	_	_
22	,	,	,	_	31	p	_	_
23	pretreatment	pretreatment	NN	_	31	dep	_	_
24	and	and	CC	_	23	cc	_	_
25	follow-up	follow-up	JJ	_	28	attr	_	_
26	liver	liver	NN	_	28	com	_	_
27	function	function	NN	_	28	com	_	_
28	tests	test	NNS	_	23	conj	_	_
29	should	should	MD	_	31	modal	_	_
30	be	be	VB	_	31	aux	_	_
31	performed	performed	VBN	_	3	acl	_	_
32	at	at	IN	_	36	case	_	_
33	weekly	weekly	JJ	_	36	attr	_	_
34	or	or	CC	_	33	cc	_	_
35	biweekly	biweekly	JJ	_	33	conj	_	_
36	intervals	interval	NNS	_	31	ppmod	_	_
37	until	until	IN	_	44	mark	_	_
38	the	the	DT	_	39	det	_	_
39	response	response	NN	_	44	dep	_	_
40	to	to	TO	_	41	aux	_	_
41	drug1	drug0	NN	_	39	ppmod	_	_
42	has	have	VBZ	_	44	aux	_	_
43	been	be	VBN	_	44	aux	_	_
44	established	establish	VBN	_	31	comp	_	_

1	.	.	.	_	0	root	_	_

1	Glucose	glucose	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Some	some	DT	_	4	det	_	_
4	patients	patient	NNS	_	8	dep	_	_
5	receiving	receive	VBG	_	4	acl	_	_
6	drug1	drug0	NN	_	5	obj	_	_
7	have	have	VBP	_	8	aux	_	_
8	experienced	experience	VBN	_	1	acl	_	_
9	problems	problem	NNS	_	8	obj	_	_
10	in	in	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	control	control	NN	_	8	ppmod	_	_
13	of	of	IN	_	16	case	_	_
14	their	their	PRP$	_	16	poss	_	_
15	blood	blood	NN	_	16	com	_	_
16	sugar	sugar	NN	_	12	ppmod	_	_
17	.	.	.	_	1	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	10	ppmod	_	_
3	,	,	,	_	10	p	_	_
4	new	new	JJ	_	5	attr	_	_
5	cases	case	NNS	_	10	dep	_	_
6	of	of	IN	_	7	case	_	_
7	diabetes	diabetes	NNS	_	5	ppmod	_	_
8	have	have	VBP	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	diagnosed	diagnose	VBN	_	0	root	_	_
11	during	during	IN	_	13	case	_	_
12	drug1	drug0	NN	_	13	com	_	_
13	therapy	therapy	NN	_	10	ppmod	_	_
14	,	,	,	_	10	p	_	_
15	although	although	IN	_	21	mark	_	_
16	no	no	DT	_	18	det	_	_
17	causal	causal	JJ	_	18	attr	_	_
18	relationship	relationship	NN	_	21	dep	_	_
19	has	have	VBZ	_	21	aux	_	_
20	been	be	VBN	_	21	aux	_	_
21	established	establish	VBN	_	10	comp	_	_

1	.	.	.	_	0	root	_	_

1	CPK	cpk	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Some	some	DT	_	4	det	_	_
4	patients	patient	NNS	_	14	dep	_	_
5	undergoing	undergo	VBG	_	4	acl	_	_
6	vigorous	vigorous	JJ	_	8	attr	_	_
7	physical	physical	JJ	_	8	attr	_	_
8	activity	activity	NN	_	5	obj	_	_
9	while	while	IN	_	12	case	_	_
10	on	on	IN	_	12	case	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	therapy	therapy	NN	_	5	ppmod	_	_
13	have	have	VBP	_	14	aux	_	_
14	experienced	experience	VBN	_	1	acl	_	_
15	elevated	elevated	JJ	_	17	attr	_	_
16	CPK	cpk	NN	_	17	com	_	_
17	levels	level	NNS	_	14	obj	_	_
18	;	;	:	_	1	p	_	_

1	however	however	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	the	the	DT	_	5	det	_	_
4	clinical	clinical	JJ	_	5	attr	_	_
5	significance	significance	NN	_	6	dep	_	_
6	is	be	VBZ	_	0	root	_	_
7	unknown	unknown	JJ	_	6	dep	_	_
8	.	.	.	_	6	p	_	_

1	There	there	EX	_	3	dep	_	_
2	have	have	VBP	_	3	aux	_	_
3	been	be	VBN	_	0	root	_	_
4	rare	rare	JJ	_	6	attr	_	_
5	postmarketing	postmarketing	JJ	_	6	attr	_	_
6	reports	report	NNS	_	3	obj	_	_
7	of	of	IN	_	8	case	_	_
8	rhabdomyolysis	rhabdomyolysis	NN	_	6	ppmod	_	_
9	,	,	,	_	6	p	_	_
10	some	some	DT	_	6	appo	_	_
11	associated	associate	VBN	_	10	acl	_	_
12	with	with	IN	_	15	case	_	_
13	strenuous	strenuous	JJ	_	15	attr	_	_
14	physical	physical	JJ	_	15	attr	_	_
15	activity	activity	NN	_	11	ppmod	_	_
16	.	.	.	_	3	p	_	_

1	In	in	IN	_	4	case	_	_
2	a	a	DT	_	4	det	_	_
3	clinical	clinical	JJ	_	4	attr	_	_
4	trial	trial	NN	_	26	ppmod	_	_
5	of	of	IN	_	8	case	_	_
6	217	0	CD	_	8	num	_	_
7	pediatric	pediatric	JJ	_	8	attr	_	_
8	patients	patient	NNS	_	4	ppmod	_	_
9	(	-lrb-	-LRB-	_	13	p	_	_
10	12	0	CD	_	13	num	_	_
11	to	to	TO	_	10	cc	_	_
12	17	0	CD	_	10	conj	_	_
13	years	year	NNS	_	8	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	with	with	IN	_	19	case	_	_
16	severe	severe	JJ	_	19	attr	_	_
17	recalcitrant	recalcitrant	JJ	_	19	attr	_	_
18	nodular	nodular	JJ	_	19	attr	_	_
19	acne	acne	NN	_	8	ppmod	_	_
20	,	,	,	_	26	p	_	_
21	transient	transient	JJ	_	22	attr	_	_
22	elevations	elevation	NNS	_	26	dep	_	_
23	in	in	IN	_	24	case	_	_
24	CPK	cpk	NN	_	22	ppmod	_	_
25	were	be	VBD	_	26	aux	_	_
26	observed	observe	VBN	_	0	root	_	_
27	in	in	IN	_	28	case	_	_
28	12	0	CD	_	26	ppmod	_	_
29	%	%	NN	_	28	meta	_	_
30	of	of	IN	_	31	case	_	_
31	patients	patient	NNS	_	28	ppmod	_	_
32	,	,	,	_	31	p	_	_
33	including	include	VBG	_	38	adv	_	_
34	those	those	DT	_	38	det	_	_
35	undergoing	undergo	VBG	_	38	attr	_	_
36	strenuous	strenuous	JJ	_	38	attr	_	_
37	physical	physical	JJ	_	38	attr	_	_
38	activity	activity	NN	_	31	ppmod	_	_
39	in	in	IN	_	40	case	_	_
40	association	association	NN	_	38	ppmod	_	_
41	with	with	IN	_	45	case	_	_
42	reported	report	VBN	_	45	attr	_	_
43	musculoskeletal	musculoskeletal	JJ	_	45	attr	_	_
44	adverse	adverse	JJ	_	45	attr	_	_
45	events	event	NNS	_	40	ppmod	_	_
46	such	such	JJ	_	49	adv	_	_
47	as	as	IN	_	49	case	_	_
48	back	back	RB	_	49	adv	_	_
49	pain	pain	NN	_	45	ppmod	_	_
50	,	,	,	_	49	p	_	_
51	arthralgia	arthralgia	NN	_	49	conj	_	_
52	,	,	,	_	51	p	_	_
53	limb	limb	NN	_	54	com	_	_
54	injury	injury	NN	_	49	conj	_	_
55	,	,	,	_	54	p	_	_
56	or	or	CC	_	54	cc	_	_
57	muscle	muscle	NN	_	58	com	_	_
58	sprain	sprain	NN	_	49	conj	_	_
59	.	.	.	_	26	p	_	_

1	In	in	IN	_	3	case	_	_
2	these	these	DT	_	3	det	_	_
3	patients	patient	NNS	_	11	ppmod	_	_
4	,	,	,	_	11	p	_	_
5	approximately	approximately	RB	_	6	adv	_	_
6	half	half	NN	_	11	dep	_	_
7	of	of	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	CPK	cpk	NN	_	10	com	_	_
10	elevations	elevation	NNS	_	6	ppmod	_	_
11	returned	return	VBD	_	0	root	_	_
12	to	to	TO	_	13	aux	_	_
13	normal	normal	JJ	_	11	ppmod	_	_
14	within	within	IN	_	16	case	_	_
15	2	0	CD	_	16	num	_	_
16	weeks	week	NNS	_	11	ppmod	_	_
17	and	and	CC	_	11	cc	_	_
18	half	half	NN	_	19	dep	_	_
19	returned	return	VBD	_	11	conj	_	_
20	to	to	TO	_	21	aux	_	_
21	normal	normal	JJ	_	19	ppmod	_	_
22	within	within	IN	_	24	case	_	_
23	4	0	CD	_	24	num	_	_
24	weeks	week	NNS	_	19	ppmod	_	_
25	.	.	.	_	11	p	_	_

1	No	no	DT	_	2	det	_	_
2	cases	case	NNS	_	6	dep	_	_
3	of	of	IN	_	4	case	_	_
4	rhabdomyolysis	rhabdomyolysis	NN	_	2	ppmod	_	_
5	were	be	VBD	_	6	aux	_	_
6	reported	report	VBN	_	0	root	_	_
7	in	in	IN	_	9	case	_	_
8	this	this	DT	_	9	det	_	_
9	trial	trial	NN	_	6	ppmod	_	_
10	.	.	.	_	6	p	_	_

1	No	no	DT	_	4	det	_	_
2	drug	drug	NN	_	4	com	_	_
3	interaction	interaction	NN	_	4	com	_	_
4	studies	study	NNS	_	6	dep	_	_
5	were	be	VBD	_	6	aux	_	_
6	performed	performed	VBN	_	0	root	_	_
7	.	.	.	_	6	p	_	_

1	No	no	DT	_	5	det	_	_
2	in	in	FW	_	3	adv	_	_
3	vitro	vitro	FW	_	5	attr	_	_
4	metabolism	metabolism	NN	_	5	com	_	_
5	studies	study	NNS	_	7	dep	_	_
6	were	be	VBD	_	7	aux	_	_
7	performed	performed	VBN	_	0	root	_	_
8	.	.	.	_	7	p	_	_

1	Both	both	CC	_	2	cc	_	_
2	drug1	drug0	NN	_	10	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	its	its	PRP$	_	6	poss	_	_
5	major	major	JJ	_	6	attr	_	_
6	metabolite	metabolite	NN	_	2	conj	_	_
7	,	,	,	_	6	p	_	_
8	drug2	drug0	NN	_	6	appo	_	_
9	,	,	,	_	6	p	_	_
10	are	be	VBP	_	0	root	_	_
11	inhibitors	inhibitor	NNS	_	10	obj	_	_
12	of	of	IN	_	18	case	_	_
13	the	the	DT	_	18	det	_	_
14	cytochrome	cytochrome	NN	_	16	com	_	_
15	P450	p0	NN	_	16	com	_	_
16	3A4	0a0	NN	_	18	com	_	_
17	enzyme	enzyme	NN	_	18	com	_	_
18	system	system	NN	_	11	ppmod	_	_
19	.	.	.	_	10	p	_	_

1	Coadministration	coadministration	NN	_	16	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	drugs	drug	NNS	_	3	conj	_	_
6	primarily	primarily	RB	_	7	adv	_	_
7	metabolized	metabolize	VBN	_	3	acl	_	_
8	by	by	IN	_	14	case	_	_
9	the	the	DT	_	14	det	_	_
10	cytochrome	cytochrome	NN	_	12	com	_	_
11	P450	p0	NN	_	12	com	_	_
12	3A4	0a0	NN	_	14	com	_	_
13	enzyme	enzyme	NN	_	14	com	_	_
14	system	system	NN	_	7	ppmod	_	_
15	may	may	MD	_	16	modal	_	_
16	result	result	VB	_	0	root	_	_
17	in	in	IN	_	20	case	_	_
18	increased	increase	VBN	_	20	attr	_	_
19	plasma	plasma	NN	_	20	com	_	_
20	concentrations	concentration	NNS	_	16	ppmod	_	_
21	of	of	IN	_	23	case	_	_
22	the	the	DT	_	23	det	_	_
23	drugs	drug	NNS	_	20	ppmod	_	_
24	that	that	WDT	_	26	dep	_	_
25	could	could	MD	_	26	modal	_	_
26	increase	increase	VB	_	23	relcl	_	_
27	or	or	CC	_	26	cc	_	_
28	prolong	prolong	VB	_	26	conj	_	_
29	both	both	CC	_	30	cc	_	_
30	therapeutic	therapeutic	JJ	_	33	attr	_	_
31	and	and	CC	_	30	cc	_	_
32	adverse	adverse	JJ	_	30	conj	_	_
33	effects	effect	NNS	_	28	obj	_	_
34	.	.	.	_	16	p	_	_

1	Therefore	therefore	RB	_	11	adv	_	_
2	,	,	,	_	11	p	_	_
3	unless	unless	IN	_	5	mark	_	_
4	otherwise	otherwise	RB	_	5	adv	_	_
5	specified	specify	VBN	_	11	advcl	_	_
6	,	,	,	_	11	p	_	_
7	appropriate	appropriate	JJ	_	9	attr	_	_
8	dosage	dosage	NN	_	9	com	_	_
9	adjustments	adjustment	NNS	_	11	dep	_	_
10	may	may	MD	_	11	modal	_	_
11	be	be	VB	_	0	root	_	_
12	necessary	necessary	JJ	_	11	dep	_	_
13	.	.	.	_	11	p	_	_

1	Coadministration	coadministration	NN	_	7	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	5	case	_	_
5	drug2	drug0	NN	_	1	ppmod	_	_
6	has	have	VBZ	_	7	aux	_	_
7	led	lead	VBN	_	0	root	_	_
8	to	to	TO	_	11	aux	_	_
9	elevated	elevated	JJ	_	11	attr	_	_
10	plasma	plasma	NN	_	11	com	_	_
11	concentrations	concentration	NNS	_	7	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug3	drug0	NN	_	11	ppmod	_	_
14	,	,	,	_	7	p	_	_
15	resulting	result	VBG	_	7	comp	_	_
16	in	in	IN	_	18	case	_	_
17	rare	rare	JJ	_	18	attr	_	_
18	instances	instance	NNS	_	15	ppmod	_	_
19	of	of	IN	_	23	case	_	_
20	life-	life-	JJ	_	23	attr	_	_
21	threatening	threatening	NN	_	23	attr	_	_
22	cardiac	cardiac	JJ	_	23	attr	_	_
23	dysrhythmias	dysrhythmia	NNS	_	18	ppmod	_	_
24	and	and	CC	_	23	cc	_	_
25	one	#crd#	CD	_	26	num	_	_
26	death	death	NN	_	23	conj	_	_
27	.	.	.	_	7	p	_	_

1	Another	another	DT	_	3	det	_	_
2	oral	oral	JJ	_	3	attr	_	_
3	drug1	drug0	NN	_	7	dep	_	_
4	,	,	,	_	3	p	_	_
5	drug2	drug0	NN	_	3	appo	_	_
6	,	,	,	_	3	p	_	_
7	inhibits	inhibit	VBZ	_	0	root	_	_
8	the	the	DT	_	9	det	_	_
9	metabolism	metabolism	NN	_	7	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug3	drug0	NN	_	9	ppmod	_	_
12	,	,	,	_	7	p	_	_
13	resulting	result	VBG	_	7	comp	_	_
14	in	in	IN	_	17	case	_	_
15	elevated	elevated	JJ	_	17	attr	_	_
16	plasma	plasma	NN	_	17	com	_	_
17	concentrations	concentration	NNS	_	13	ppmod	_	_
18	of	of	IN	_	24	case	_	_
19	drug4	drug0	NN	_	24	attr	_	_
20	and	and	CC	_	19	cc	_	_
21	its	its	PRP$	_	23	poss	_	_
22	active	active	JJ	_	23	attr	_	_
23	metabolite	metabolite	NN	_	19	conj	_	_
24	drug5	drug0	NNS	_	17	ppmod	_	_
25	which	which	WDT	_	27	dep	_	_
26	may	may	MD	_	27	modal	_	_
27	prolong	prolong	VB	_	24	relcl	_	_
28	QT	qt	VBG	_	29	attr	_	_
29	intervals	interval	NNS	_	27	obj	_	_
30	.	.	.	_	7	p	_	_

1	In	in	FW	_	3	attr	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	data	datum	NNS	_	4	dep	_	_
4	suggest	suggest	VBP	_	0	root	_	_
5	that	that	IN	_	13	mark	_	_
6	drug1	drug0	NN	_	13	dep	_	_
7	,	,	,	_	13	p	_	_
8	when	when	WRB	_	9	adv	_	_
9	compared	compare	VBN	_	13	advcl	_	_
10	to	to	TO	_	11	aux	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	,	,	,	_	13	p	_	_
13	has	have	VBZ	_	4	comp	_	_
14	a	a	DT	_	17	det	_	_
15	less	less	RBR	_	16	adv	_	_
16	pronounced	pronounced	JJ	_	17	attr	_	_
17	effect	effect	NN	_	13	obj	_	_
18	on	on	IN	_	21	case	_	_
19	the	the	DT	_	21	det	_	_
20	biotransformation	biotransformation	NN	_	21	com	_	_
21	system	system	NN	_	17	ppmod	_	_
22	responsible	responsible	JJ	_	21	attr	_	_
23	for	for	IN	_	25	case	_	_
24	the	the	DT	_	25	det	_	_
25	metabolism	metabolism	NN	_	22	ppmod	_	_
26	of	of	IN	_	27	case	_	_
27	drug3	drug0	NN	_	25	ppmod	_	_
28	.	.	.	_	4	p	_	_

1	Based	base	VBN	_	5	adv	_	_
2	on	on	IN	_	5	case	_	_
3	the	the	DT	_	5	det	_	_
4	chemical	chemical	JJ	_	5	attr	_	_
5	resemblance	resemblance	NN	_	17	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	,	,	,	_	17	p	_	_
11	coadministration	coadministration	NN	_	17	dep	_	_
12	of	of	IN	_	13	case	_	_
13	drug3	drug0	NN	_	11	ppmod	_	_
14	with	with	IN	_	15	case	_	_
15	drug4	drug0	NN	_	11	ppmod	_	_
16	is	be	VBZ	_	17	aux	_	_
17	contraindicated	contraindicate	VBN	_	0	root	_	_
18	.	.	.	_	17	p	_	_

1	Human	human	JJ	_	3	attr	_	_
2	pharmacokinetics	pharmacokinetics	NNS	_	3	com	_	_
3	data	datum	NNS	_	4	dep	_	_
4	indicate	indicate	VBP	_	0	root	_	_
5	that	that	IN	_	9	mark	_	_
6	oral	oral	JJ	_	7	attr	_	_
7	drug1	drug0	NN	_	9	dep	_	_
8	potently	potently	RB	_	9	adv	_	_
9	inhibits	inhibit	VBZ	_	4	comp	_	_
10	the	the	DT	_	11	det	_	_
11	metabolism	metabolism	NN	_	9	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	resulting	result	VBG	_	13	acl	_	_
15	in	in	IN	_	18	case	_	_
16	an	an	DT	_	18	det	_	_
17	eight-fold	eight-fold	JJ	_	18	attr	_	_
18	increase	increase	NN	_	14	ppmod	_	_
19	in	in	IN	_	22	case	_	_
20	the	the	DT	_	22	det	_	_
21	mean	mean	JJ	_	22	attr	_	_
22	AUC	auc	NN	_	18	ppmod	_	_
23	of	of	IN	_	24	case	_	_
24	drug3	drug0	NN	_	22	ppmod	_	_
25	.	.	.	_	4	p	_	_

1	Data	datum	NNS	_	2	dep	_	_
2	suggest	suggest	VBP	_	0	root	_	_
3	that	that	IN	_	11	mark	_	_
4	coadministration	coadministration	NN	_	11	dep	_	_
5	of	of	IN	_	7	case	_	_
6	oral	oral	JJ	_	7	attr	_	_
7	drug1	drug0	NN	_	4	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	can	can	MD	_	11	modal	_	_
11	result	result	VB	_	2	comp	_	_
12	in	in	IN	_	13	case	_	_
13	prolongation	prolongation	NN	_	11	ppmod	_	_
14	of	of	IN	_	17	case	_	_
15	the	the	DT	_	17	det	_	_
16	QT	qt	JJ	_	17	attr	_	_
17	interval	interval	NN	_	13	ppmod	_	_
18	on	on	IN	_	20	case	_	_
19	the	the	DT	_	20	det	_	_
20	ECG	ecg	NN	_	17	ppmod	_	_
21	.	.	.	_	2	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	data	datum	NNS	_	4	dep	_	_
4	suggest	suggest	VBP	_	0	root	_	_
5	that	that	IN	_	9	mark	_	_
6	drug1	drug0	NN	_	9	dep	_	_
7	also	also	RB	_	9	adv	_	_
8	markedly	markedly	RB	_	9	adv	_	_
9	inhibits	inhibit	VBZ	_	4	comp	_	_
10	the	the	DT	_	12	det	_	_
11	biotransformation	biotransformation	NN	_	12	com	_	_
12	system	system	NN	_	9	obj	_	_
13	mainly	mainly	RB	_	14	adv	_	_
14	responsible	responsible	JJ	_	12	attr	_	_
15	for	for	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	metabolism	metabolism	NN	_	14	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	;	;	:	_	4	p	_	_

1	therefore	therefore	RB	_	9	adv	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	administration	administration	NN	_	9	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drug2	drug0	NN	_	3	ppmod	_	_
8	is	be	VBZ	_	9	aux	_	_
9	contraindicated	contraindicate	VBN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	Coadministration	coadministration	NN	_	10	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	6	case	_	_
5	oral	oral	JJ	_	6	attr	_	_
6	drug2	drug0	NN	_	1	ppmod	_	_
7	or	or	CC	_	6	cc	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	has	have	VBZ	_	10	aux	_	_
10	resulted	result	VBD	_	0	root	_	_
11	in	in	IN	_	14	case	_	_
12	elevated	elevated	JJ	_	14	attr	_	_
13	plasma	plasma	NN	_	14	com	_	_
14	concentrations	concentration	NNS	_	10	ppmod	_	_
15	of	of	IN	_	19	case	_	_
16	the	the	DT	_	19	det	_	_
17	latter	latter	JJ	_	19	attr	_	_
18	two	#crd#	CD	_	19	num	_	_
19	drugs	drug	NNS	_	14	ppmod	_	_
20	.	.	.	_	10	p	_	_

1	This	this	DT	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	potentiate	potentiate	VB	_	0	root	_	_
4	and	and	CC	_	3	cc	_	_
5	prolong	prolong	VB	_	3	conj	_	_
6	hypnotic	hypnotic	JJ	_	9	attr	_	_
7	and	and	CC	_	6	cc	_	_
8	sedative	sedative	JJ	_	6	conj	_	_
9	effects	effect	NNS	_	5	obj	_	_
10	.	.	.	_	3	p	_	_

1	These	these	DT	_	2	det	_	_
2	agents	agent	NNS	_	6	dep	_	_
3	should	should	MD	_	6	modal	_	_
4	not	not	RB	_	6	neg	_	_
5	be	be	VB	_	6	aux	_	_
6	used	use	VBN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	6	ppmod	_	_
9	treated	treat	VBN	_	8	acl	_	_
10	with	with	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	6	p	_	_

1	If	if	IN	_	4	mark	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	administered	administer	VBN	_	10	advcl	_	_
5	parenterally	parenterally	RB	_	4	adv	_	_
6	,	,	,	_	10	p	_	_
7	special	special	JJ	_	8	attr	_	_
8	precaution	precaution	NN	_	10	dep	_	_
9	is	be	VBZ	_	10	aux	_	_
10	required	require	VBN	_	0	root	_	_
11	since	since	IN	_	16	mark	_	_
12	the	the	DT	_	14	det	_	_
13	sedative	sedative	JJ	_	14	attr	_	_
14	effect	effect	NN	_	16	dep	_	_
15	may	may	MD	_	16	modal	_	_
16	be	be	VB	_	10	comp	_	_
17	prolonged	prolonged	JJ	_	16	dep	_	_
18	.	.	.	_	10	p	_	_

1	Coadministration	coadministration	NN	_	11	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	,	,	,	_	5	p	_	_
7	drug3	drug0	NN	_	3	conj	_	_
8	or	or	CC	_	7	cc	_	_
9	drug4	drug0	NN	_	3	conj	_	_
10	has	have	VBZ	_	11	aux	_	_
11	led	lead	VBN	_	0	root	_	_
12	to	to	TO	_	15	aux	_	_
13	increased	increase	VBN	_	15	attr	_	_
14	plasma	plasma	NN	_	15	com	_	_
15	concentrations	concentration	NNS	_	11	ppmod	_	_
16	of	of	IN	_	20	case	_	_
17	the	the	DT	_	20	det	_	_
18	latter	latter	JJ	_	20	attr	_	_
19	three	#crd#	CD	_	20	num	_	_
20	drugs	drug	NNS	_	15	ppmod	_	_
21	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	6	attr	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	and	and	CC	_	3	cc	_	_
5	drug3	drug0	NN	_	1	conj	_	_
6	concentrations	concentration	NNS	_	9	dep	_	_
7	should	should	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	monitored	monitor	VBN	_	0	root	_	_
10	at	at	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	initiation	initiation	NN	_	9	ppmod	_	_
13	of	of	IN	_	15	case	_	_
14	drug4	drug0	NN	_	15	com	_	_
15	therapy	therapy	NN	_	12	ppmod	_	_
16	and	and	CC	_	9	cc	_	_
17	frequently	frequently	RB	_	9	conj	_	_
18	thereafter	thereafter	RB	_	17	adv	_	_
19	,	,	,	_	9	p	_	_
20	and	and	CC	_	9	cc	_	_
21	the	the	DT	_	22	det	_	_
22	dose	dose	NN	_	28	dep	_	_
23	of	of	IN	_	27	case	_	_
24	these	these	DT	_	27	det	_	_
25	three	#crd#	CD	_	27	num	_	_
26	drug	drug	NN	_	27	com	_	_
27	products	product	NNS	_	22	ppmod	_	_
28	adjusted	adjust	VBN	_	9	conj	_	_
29	appropriately	appropriately	RB	_	28	adv	_	_
30	.	.	.	_	28	p	_	_

1	Rhabdomyolysis	rhabdomyolysis	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	observed	observe	VBN	_	0	root	_	_
5	in	in	IN	_	6	case	_	_
6	patients	patient	NNS	_	4	ppmod	_	_
7	receiving	receive	VBG	_	6	acl	_	_
8	drug1	drug0	NN	_	7	obj	_	_
9	administered	administer	VBN	_	8	acl	_	_
10	alone	alone	RB	_	9	adv	_	_
11	(	-lrb-	-LRB-	_	14	p	_	_
12	at	at	IN	_	14	case	_	_
13	recommended	recommend	VBN	_	14	attr	_	_
14	dosages	dosage	NNS	_	10	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	or	or	CC	_	10	cc	_	_
17	concomitantly	concomitantly	RB	_	10	conj	_	_
18	with	with	IN	_	19	case	_	_
19	drug2	drug0	NNS	_	9	ppmod	_	_
20	including	include	VBG	_	21	adv	_	_
21	drug3	drug0	NN	_	19	ppmod	_	_
22	.	.	.	_	4	p	_	_

1	When	when	WRB	_	4	adv	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	was	be	VBD	_	4	aux	_	_
4	coadministered	coadministered	VBN	_	19	advcl	_	_
5	with	with	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	,	,	,	_	6	p	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	,	,	,	_	8	p	_	_
10	or	or	CC	_	8	cc	_	_
11	H2antagonists	h0antagonists	NN	_	6	conj	_	_
12	,	,	,	_	19	p	_	_
13	reduced	reduce	VBN	_	15	attr	_	_
14	plasma	plasma	NN	_	15	com	_	_
15	concentrations	concentration	NNS	_	19	dep	_	_
16	of	of	IN	_	17	case	_	_
17	drug4	drug0	NN	_	15	ppmod	_	_
18	were	be	VBD	_	19	aux	_	_
19	reported	report	VBN	_	0	root	_	_
20	.	.	.	_	19	p	_	_

1	The	the	DT	_	2	det	_	_
2	physician	physician	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	advised	advise	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	monitor	monitor	VB	_	4	comp	_	_
7	the	the	DT	_	9	det	_	_
8	plasma	plasma	NN	_	9	com	_	_
9	concentrations	concentration	NNS	_	6	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	when	when	WRB	_	18	adv	_	_
13	any	any	DT	_	18	dep	_	_
14	of	of	IN	_	16	case	_	_
15	these	these	DT	_	16	det	_	_
16	drugs	drug	NNS	_	13	ppmod	_	_
17	is	be	VBZ	_	18	aux	_	_
18	taken	take	VBN	_	6	comp	_	_
19	concurrently	concurrently	RB	_	18	adv	_	_
20	,	,	,	_	6	p	_	_
21	and	and	CC	_	6	cc	_	_
22	to	to	TO	_	23	aux	_	_
23	increase	increase	VB	_	6	conj	_	_
24	the	the	DT	_	25	det	_	_
25	dose	dose	NN	_	23	obj	_	_
26	of	of	IN	_	27	case	_	_
27	drug2	drug0	NN	_	25	ppmod	_	_
28	if	if	IN	_	29	mark	_	_
29	necessary	necessary	JJ	_	23	comp	_	_
30	.	.	.	_	4	p	_	_

1	Although	although	IN	_	6	mark	_	_
2	no	no	DT	_	3	det	_	_
3	studies	study	NNS	_	6	dep	_	_
4	have	have	VBP	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	conducted	conduct	VBN	_	15	advcl	_	_
7	,	,	,	_	15	p	_	_
8	concomitant	concomitant	JJ	_	9	attr	_	_
9	administration	administration	NN	_	15	dep	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	drug2	drug0	NN	_	11	conj	_	_
14	may	may	MD	_	15	modal	_	_
15	alter	alter	VB	_	0	root	_	_
16	the	the	DT	_	17	det	_	_
17	metabolism	metabolism	NN	_	15	obj	_	_
18	of	of	IN	_	19	case	_	_
19	drug3	drug0	NN	_	17	ppmod	_	_
20	;	;	:	_	15	p	_	_

1	therefore	therefore	RB	_	10	adv	_	_
2	,	,	,	_	10	p	_	_
3	plasma	plasma	NN	_	4	com	_	_
4	concentrations	concentration	NNS	_	10	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	should	should	MD	_	10	modal	_	_
8	also	also	RB	_	10	adv	_	_
9	be	be	VB	_	10	aux	_	_
10	monitored	monitor	VBN	_	0	root	_	_
11	when	when	WRB	_	14	adv	_	_
12	it	it	PRP	_	14	dep	_	_
13	is	be	VBZ	_	14	aux	_	_
14	given	give	VBN	_	10	comp	_	_
15	concurrently	concurrently	RB	_	14	adv	_	_
16	with	with	IN	_	17	case	_	_
17	drug2	drug0	NN	_	14	ppmod	_	_
18	.	.	.	_	10	p	_	_

1	It	it	PRP	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	reported	report	VBN	_	0	root	_	_
5	that	that	IN	_	7	mark	_	_
6	drug1	drug0	NN	_	7	dep	_	_
7	enhances	enhance	VBZ	_	4	comp	_	_
8	the	the	DT	_	10	det	_	_
9	anticoagulant	anticoagulant	JJ	_	10	attr	_	_
10	effect	effect	NN	_	7	obj	_	_
11	of	of	IN	_	14	case	_	_
12	drug2	drug0	JJ	_	14	attr	_	_
13	-like	-like	JJ	_	14	attr	_	_
14	drugs	drug	NNS	_	10	ppmod	_	_
15	.	.	.	_	4	p	_	_

1	Therefore	therefore	RB	_	8	adv	_	_
2	,	,	,	_	8	p	_	_
3	prothrombin	prothrombin	NN	_	4	com	_	_
4	time	time	NN	_	8	dep	_	_
5	should	should	MD	_	8	modal	_	_
6	be	be	VB	_	8	aux	_	_
7	carefully	carefully	RB	_	8	adv	_	_
8	monitored	monitor	VBN	_	0	root	_	_
9	in	in	IN	_	10	case	_	_
10	patients	patient	NNS	_	8	ppmod	_	_
11	receiving	receive	VBG	_	10	acl	_	_
12	drug1	drug0	NN	_	16	attr	_	_
13	and	and	CC	_	12	cc	_	_
14	drug2	drug0	NN	_	12	conj	_	_
15	-like	-like	JJ	_	16	attr	_	_
16	drugs	drug	NNS	_	11	obj	_	_
17	simultaneously	simultaneously	RB	_	8	adv	_	_
18	.	.	.	_	8	p	_	_

1	Plasma	plasma	NN	_	2	com	_	_
2	concentrations	concentration	NNS	_	6	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	are	be	VBP	_	6	aux	_	_
6	reduced	reduce	VBN	_	0	root	_	_
7	when	when	WRB	_	8	adv	_	_
8	given	give	VBN	_	6	comp	_	_
9	concurrently	concurrently	RB	_	8	adv	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NN	_	8	ppmod	_	_
12	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	3	com	_	_
2	plasma	plasma	NN	_	3	com	_	_
3	concentrations	concentration	NNS	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	monitored	monitor	VBN	_	0	root	_	_
7	when	when	WRB	_	12	adv	_	_
8	drug2	drug0	NN	_	12	dep	_	_
9	and	and	CC	_	8	cc	_	_
10	drug3	drug0	NN	_	8	conj	_	_
11	are	be	VBP	_	12	aux	_	_
12	coadministered	coadministered	VBN	_	6	comp	_	_
13	.	.	.	_	6	p	_	_

1	Severe	severe	JJ	_	2	attr	_	_
2	hypoglycemia	hypoglycemia	NN	_	5	dep	_	_
3	has	have	VBZ	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	reported	report	VBN	_	0	root	_	_
6	in	in	IN	_	7	case	_	_
7	patients	patient	NNS	_	5	ppmod	_	_
8	concomitantly	concomitantly	RB	_	9	adv	_	_
9	receiving	receive	VBG	_	7	acl	_	_
10	drug1	drug0	NN	_	9	obj	_	_
11	and	and	CC	_	10	cc	_	_
12	oral	oral	JJ	_	13	attr	_	_
13	drug2	drug0	NN	_	10	conj	_	_
14	.	.	.	_	5	p	_	_

1	Blood	blood	NN	_	3	com	_	_
2	glucose	glucose	NN	_	3	com	_	_
3	concentrations	concentration	NNS	_	7	dep	_	_
4	should	should	MD	_	7	modal	_	_
5	be	be	VB	_	7	aux	_	_
6	carefully	carefully	RB	_	7	adv	_	_
7	monitored	monitor	VBN	_	0	root	_	_
8	when	when	WRB	_	14	adv	_	_
9	drug1	drug0	NN	_	14	dep	_	_
10	and	and	CC	_	9	cc	_	_
11	oral	oral	JJ	_	12	attr	_	_
12	drug2	drug0	NN	_	9	conj	_	_
13	are	be	VBP	_	14	aux	_	_
14	coadministered	coadministered	VBN	_	7	comp	_	_
15	.	.	.	_	7	p	_	_

1	Tinnitus	tinnitus	NN	_	7	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	decreased	decrease	VBN	_	4	attr	_	_
4	hearing	hearing	NN	_	1	conj	_	_
5	have	have	VBP	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	reported	report	VBN	_	0	root	_	_
8	in	in	IN	_	9	case	_	_
9	patients	patient	NNS	_	7	ppmod	_	_
10	concomitantly	concomitantly	RB	_	11	adv	_	_
11	receiving	receive	VBG	_	9	acl	_	_
12	drug1	drug0	NN	_	11	obj	_	_
13	and	and	CC	_	12	cc	_	_
14	drug2	drug0	NN	_	12	conj	_	_
15	.	.	.	_	7	p	_	_

1	Edema	edema	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	reported	report	VBN	_	0	root	_	_
5	in	in	IN	_	6	case	_	_
6	patients	patient	NNS	_	4	ppmod	_	_
7	concomitantly	concomitantly	RB	_	8	adv	_	_
8	receiving	receive	VBG	_	6	acl	_	_
9	drug1	drug0	NN	_	8	obj	_	_
10	and	and	CC	_	9	cc	_	_
11	drug2	drug0	NN	_	9	conj	_	_
12	.	.	.	_	4	p	_	_

1	Appropriate	appropriate	JJ	_	3	attr	_	_
2	dosage	dosage	NN	_	3	com	_	_
3	adjustments	adjustment	NNS	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	be	be	VB	_	0	root	_	_
6	necessary	necessary	JJ	_	5	dep	_	_
7	.	.	.	_	5	p	_	_

1	The	the	DT	_	2	det	_	_
2	results	result	NNS	_	21	dep	_	_
3	from	from	IN	_	5	case	_	_
4	a	a	DT	_	5	det	_	_
5	study	study	NN	_	2	ppmod	_	_
6	in	in	IN	_	7	case	_	_
7	which	which	WDT	_	12	ppmod	_	_
8	eight	#crd#	CD	_	10	num	_	_
9	HIV-infected	hiv-infected	JJ	_	10	attr	_	_
10	individuals	individual	NNS	_	12	dep	_	_
11	were	be	VBD	_	12	aux	_	_
12	treated	treat	VBN	_	5	relcl	_	_
13	with	with	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	,	,	,	_	5	p	_	_
16	8	0	CD	_	19	num	_	_
17	+/-	+/-	CC	_	16	cc	_	_
18	0.4	0	CD	_	16	conj	_	_
19	mg/kg/day	mg/kg/day	NN	_	5	appo	_	_
20	,	,	,	_	5	p	_	_
21	showed	show	VBD	_	0	root	_	_
22	that	that	IN	_	29	mark	_	_
23	the	the	DT	_	24	det	_	_
24	pharmacokinetics	pharmacokinetics	NNS	_	29	dep	_	_
25	of	of	IN	_	26	case	_	_
26	drug2	drug0	NN	_	24	ppmod	_	_
27	were	be	VBD	_	29	aux	_	_
28	not	not	RB	_	29	neg	_	_
29	affected	affect	VBN	_	21	comp	_	_
30	during	during	IN	_	32	case	_	_
31	concomitant	concomitant	JJ	_	32	attr	_	_
32	administration	administration	NN	_	29	ppmod	_	_
33	of	of	IN	_	34	case	_	_
34	drug3	drug0	NN	_	32	ppmod	_	_
35	,	,	,	_	32	p	_	_
36	100	0	CD	_	37	num	_	_
37	mg	mg	NN	_	38	com	_	_
38	b.i.d.	b.i.d.	NN	_	32	appo	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	found	find	VBN	_	0	root	_	_
5	to	to	TO	_	7	aux	_	_
6	temporarily	temporarily	RB	_	7	adv	_	_
7	raise	raise	VBP	_	4	comp	_	_
8	serum	serum	NN	_	9	com	_	_
9	concentrations	concentration	NNS	_	7	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	potentiate	potentiate	VB	_	0	root	_	_
4	the	the	DT	_	6	det	_	_
5	adverse	adverse	JJ	_	6	attr	_	_
6	effects	effect	NNS	_	3	obj	_	_
7	of	of	IN	_	9	case	_	_
8	other	other	JJ	_	9	attr	_	_
9	drug2	drug0	NNS	_	6	ppmod	_	_
10	administered	administer	VBN	_	9	acl	_	_
11	concomitantly	concomitantly	RB	_	10	adv	_	_
12	.	.	.	_	3	p	_	_

1	In	in	IN	_	2	case	_	_
2	particular	particular	JJ	_	7	ppmod	_	_
3	,	,	,	_	7	p	_	_
4	convulsions	convulsion	NNS	_	7	dep	_	_
5	have	have	VBP	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	reported	report	VBN	_	0	root	_	_
8	when	when	WRB	_	11	adv	_	_
9	drug1	drug0	NN	_	11	dep	_	_
10	is	be	VBZ	_	11	aux	_	_
11	administered	administer	VBN	_	7	comp	_	_
12	with	with	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	and	and	CC	_	11	cc	_	_
15	special	special	JJ	_	16	attr	_	_
16	care	care	NN	_	19	dep	_	_
17	should	should	MD	_	19	modal	_	_
18	be	be	VB	_	19	aux	_	_
19	taken	take	VBN	_	11	conj	_	_
20	when	when	WRB	_	24	adv	_	_
21	the	the	DT	_	23	det	_	_
22	treatment	treatment	NN	_	23	com	_	_
23	regimen	regimen	NN	_	24	dep	_	_
24	includes	include	VBZ	_	19	comp	_	_
25	both	both	DT	_	24	obj	_	_
26	of	of	IN	_	28	case	_	_
27	these	these	DT	_	28	det	_	_
28	drugs	drug	NNS	_	25	ppmod	_	_
29	.	.	.	_	7	p	_	_

1	Excessive	excessive	JJ	_	3	attr	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	ingestion	ingestion	NN	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	avoided	avoid	VBN	_	0	root	_	_
7	because	because	IN	_	13	mark	_	_
8	a	a	DT	_	10	det	_	_
9	psychotic	psychotic	JJ	_	10	attr	_	_
10	reaction	reaction	NN	_	13	dep	_	_
11	has	have	VBZ	_	13	aux	_	_
12	been	be	VBN	_	13	aux	_	_
13	reported	report	VBN	_	6	comp	_	_
14	.	.	.	_	6	p	_	_

1	Potentially	potentially	RB	_	2	adv	_	_
2	fatal	fatal	JJ	_	4	attr	_	_
3	drug	drug	NN	_	4	com	_	_
4	interactions	interaction	NNS	_	6	dep	_	_
5	may	may	MD	_	6	modal	_	_
6	occur	occur	VB	_	0	root	_	_
7	when	when	WRB	_	8	adv	_	_
8	coadministered	coadministered	VBN	_	6	comp	_	_
9	with	with	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	,	,	,	_	8	p	_	_
12	as	as	IN	_	15	mark	_	_
13	this	this	DT	_	15	dep	_	_
14	may	may	MD	_	15	modal	_	_
15	enhance	enhance	VB	_	8	comp	_	_
16	cardiovascular	cardiovascular	JJ	_	17	attr	_	_
17	depression	depression	NN	_	15	obj	_	_
18	and	and	CC	_	15	cc	_	_
19	bradyarrhythmias	bradyarrhythmias	NNS	_	21	dep	_	_
20	may	may	MD	_	21	modal	_	_
21	occur	occur	VB	_	15	conj	_	_
22	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	14	dep	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	neostgmine	neostgmine	NN	_	1	prn	_	_
4	,	,	,	_	3	p	_	_
5	drug2	drug0	NN	_	3	appo	_	_
6	)	-rrb-	-RRB-	_	3	p	_	_
7	,	,	,	_	1	p	_	_
8	drug3	drug0	NN	_	1	appo	_	_
9	,	,	,	_	1	p	_	_
10	drug4	drug0	NN	_	1	appo	_	_
11	,	,	,	_	1	p	_	_
12	drug5	drug0	NN	_	1	appo	_	_
13	can	can	MD	_	14	modal	_	_
14	enhance	enhance	VB	_	0	root	_	_
15	toxicity	toxicity	NN	_	14	obj	_	_
16	and	and	CC	_	14	cc	_	_
17	cause	cause	VB	_	14	conj	_	_
18	cardio	cardio	NN	_	20	attr	_	_
19	respiratory	respiratory	JJ	_	20	attr	_	_
20	depression	depression	NN	_	17	obj	_	_
21	.	.	.	_	14	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	8	ppmod	_	_
3	,	,	,	_	8	p	_	_
4	neuromuscular	neuromuscular	JJ	_	6	attr	_	_
5	blocking	blocking	NN	_	6	com	_	_
6	action	action	NN	_	8	dep	_	_
7	is	be	VBZ	_	8	aux	_	_
8	enhanced	enhance	VBN	_	0	root	_	_
9	by	by	IN	_	11	case	_	_
10	general	general	JJ	_	11	attr	_	_
11	drug1	drug0	NN	_	8	ppmod	_	_
12	,	,	,	_	11	p	_	_
13	local	local	JJ	_	14	attr	_	_
14	drug2	drug0	NN	_	11	conj	_	_
15	like	like	IN	_	16	case	_	_
16	drug3	drug0	NN	_	14	ppmod	_	_
17	,	,	,	_	14	p	_	_
18	drug4	drug0	NN	_	11	conj	_	_
19	,	,	,	_	18	p	_	_
20	drug5	drug0	NN	_	11	conj	_	_
21	,	,	,	_	20	p	_	_
22	drug6	drug0	NN	_	11	conj	_	_
23	,	,	,	_	22	p	_	_
24	drug7	drug0	NN	_	11	conj	_	_
25	,	,	,	_	24	p	_	_
26	and	and	CC	_	24	cc	_	_
27	drug8	drug0	NN	_	11	conj	_	_
28	.	.	.	_	8	p	_	_

1	This	this	DT	_	2	det	_	_
2	drug	drug	NN	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	interact	interact	VB	_	0	root	_	_
5	with	with	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	or	or	CC	_	6	cc	_	_
8	other	other	JJ	_	9	attr	_	_
9	drug2	drug0	NNS	_	6	conj	_	_
10	(	-lrb-	-LRB-	_	9	p	_	_
11	may	may	MD	_	12	modal	_	_
12	potentiate	potentiate	VB	_	9	acl	_	_
13	the	the	DT	_	16	det	_	_
14	CNS	cns	NN	_	16	com	_	_
15	depressant	depressant	NN	_	16	com	_	_
16	effects	effect	NNS	_	12	obj	_	_
17	of	of	IN	_	20	case	_	_
18	either	either	CC	_	20	cc	_	_
19	these	these	DT	_	20	det	_	_
20	medications	medication	NNS	_	16	ppmod	_	_
21	or	or	CC	_	20	cc	_	_
22	drug3	drug0	NN	_	20	conj	_	_
23	)	-rrb-	-RRB-	_	9	p	_	_
24	,	,	,	_	9	p	_	_
25	drug4	drug0	NN	_	9	conj	_	_
26	or	or	CC	_	25	cc	_	_
27	other	other	JJ	_	28	attr	_	_
28	medications	medication	NNS	_	9	conj	_	_
29	with	with	IN	_	31	case	_	_
30	anticholinergic	anticholinergic	JJ	_	31	attr	_	_
31	activity	activity	NN	_	4	ppmod	_	_
32	(	-lrb-	-LRB-	_	37	p	_	_
33	anticholinergic	anticholinergic	JJ	_	34	attr	_	_
34	effects	effect	NNS	_	37	dep	_	_
35	may	may	MD	_	37	modal	_	_
36	be	be	VB	_	37	aux	_	_
37	potentiated	potentiate	VBN	_	31	prn	_	_
38	when	when	WRB	_	42	adv	_	_
39	these	these	DT	_	40	det	_	_
40	medications	medication	NNS	_	42	dep	_	_
41	are	be	VBP	_	42	aux	_	_
42	used	use	VBN	_	37	comp	_	_
43	concurrently	concurrently	RB	_	42	adv	_	_
44	with	with	IN	_	45	case	_	_
45	drug5	drug0	NN	_	42	ppmod	_	_
46	)	-rrb-	-RRB-	_	37	p	_	_
47	,	,	,	_	31	p	_	_
48	and	and	CC	_	31	cc	_	_
49	drug6	drug0	NN	_	31	conj	_	_
50	(	-lrb-	-LRB-	_	56	p	_	_
51	concurrent	concurrent	JJ	_	52	attr	_	_
52	use	use	NN	_	56	dep	_	_
53	with	with	IN	_	54	case	_	_
54	drug7	drug0	NN	_	52	ppmod	_	_
55	may	may	MD	_	56	modal	_	_
56	prolong	prolong	VB	_	49	prn	_	_
57	and	and	CC	_	56	cc	_	_
58	intensify	intensify	VB	_	56	conj	_	_
59	the	the	DT	_	64	det	_	_
60	anticholinergic	anticholinergic	JJ	_	64	attr	_	_
61	and	and	CC	_	64	cc	_	_
62	CNS	cns	NN	_	64	com	_	_
63	depressant	depressant	NN	_	64	com	_	_
64	effects	effect	NNS	_	58	obj	_	_
65	of	of	IN	_	66	case	_	_
66	drug8	drug0	NN	_	64	ppmod	_	_
67	)	-rrb-	-RRB-	_	56	p	_	_
68	.	.	.	_	4	p	_	_

1	Results	result	NNS	_	11	dep	_	_
2	from	from	IN	_	7	case	_	_
3	human	human	JJ	_	7	attr	_	_
4	in	in	FW	_	5	adv	_	_
5	vitro	vitro	FW	_	7	attr	_	_
6	metabolism	metabolism	NN	_	7	com	_	_
7	studies	study	NNS	_	1	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	nonclinical	nonclinical	JJ	_	10	attr	_	_
10	studies	study	NNS	_	7	conj	_	_
11	show	show	VBP	_	0	root	_	_
12	that	that	IN	_	19	mark	_	_
13	drug1	drug0	NN	_	19	dep	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	drug2	drug0	NN	_	13	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	is	be	VBZ	_	19	aux	_	_
18	neither	neither	RB	_	19	neg	_	_
19	metabolized	metabolize	VBN	_	11	comp	_	_
20	by	by	IN	_	22	mark	_	_
21	nor	nor	CC	_	22	cc	_	_
22	inhibits	inhibit	VBZ	_	19	comp	_	_
23	or	or	CC	_	22	cc	_	_
24	induces	induce	VBZ	_	22	conj	_	_
25	the	the	DT	_	28	det	_	_
26	cytochrome	cytochrome	NN	_	28	com	_	_
27	P450	p0	NN	_	28	com	_	_
28	pathway	pathway	NN	_	24	obj	_	_
29	suggesting	suggest	VBG	_	28	acl	_	_
30	that	that	IN	_	32	mark	_	_
31	drug3	drug0	NN	_	32	dep	_	_
32	is	be	VBZ	_	29	comp	_	_
33	not	not	RB	_	32	neg	_	_
34	likely	likely	JJ	_	32	dep	_	_
35	to	to	TO	_	36	aux	_	_
36	cause	cause	VB	_	34	comp	_	_
37	or	or	CC	_	36	cc	_	_
38	be	be	VB	_	36	conj	_	_
39	subject	subject	JJ	_	38	dep	_	_
40	to	to	TO	_	44	aux	_	_
41	P450-based	p0-based	JJ	_	44	attr	_	_
42	metabolic	metabolic	JJ	_	44	attr	_	_
43	drug	drug	NN	_	44	com	_	_
44	interactions	interaction	NNS	_	39	ppmod	_	_
45	in	in	IN	_	46	case	_	_
46	man	man	NN	_	44	ppmod	_	_
47	.	.	.	_	11	p	_	_

1	Co-administration	co-administration	NN	_	10	dep	_	_
2	of	of	IN	_	4	case	_	_
3	multiple	multiple	JJ	_	4	attr	_	_
4	doses	dose	NNS	_	1	ppmod	_	_
5	of	of	IN	_	7	case	_	_
6	10	0	CD	_	7	num	_	_
7	mg	mg	NN	_	4	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	had	have	VBD	_	0	root	_	_
11	no	no	DT	_	12	det	_	_
12	effect	effect	NN	_	10	obj	_	_
13	on	on	IN	_	16	case	_	_
14	the	the	DT	_	16	det	_	_
15	single	single	JJ	_	16	attr	_	_
16	dose	dose	NN	_	10	ppmod	_	_
17	pharmacokinetics	pharmacokinetics	NNS	_	16	appo	_	_
18	of	of	IN	_	19	case	_	_
19	drug2	drug0	NN	_	16	ppmod	_	_
20	and	and	CC	_	19	cc	_	_
21	drug3	drug0	NN	_	19	conj	_	_
22	.	.	.	_	10	p	_	_

1	Co-administration	co-administration	NN	_	7	dep	_	_
2	of	of	IN	_	6	case	_	_
3	single	single	JJ	_	6	attr	_	_
4	25-mg	0-mg	NN	_	6	com	_	_
5	dose	dose	NN	_	6	com	_	_
6	drug1	drug0	NN	_	1	ppmod	_	_
7	had	have	VBD	_	0	root	_	_
8	no	no	DT	_	9	det	_	_
9	effect	effect	NN	_	7	obj	_	_
10	on	on	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	pharmacokinetics	pharmacokinetics	NNS	_	7	ppmod	_	_
13	of	of	IN	_	15	case	_	_
14	total	total	JJ	_	15	attr	_	_
15	drug2	drug0	NN	_	12	ppmod	_	_
16	.	.	.	_	7	p	_	_

1	Expected	expect	VBN	_	2	attr	_	_
2	changes	change	NNS	_	11	dep	_	_
3	in	in	IN	_	5	case	_	_
4	laboratory	laboratory	JJ	_	5	attr	_	_
5	assessments	assessment	NNS	_	2	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	PT	pt	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	INR	inr	NN	_	7	conj	_	_
10	were	be	VBD	_	11	aux	_	_
11	observed	observe	VBN	_	0	root	_	_
12	after	after	IN	_	14	case	_	_
13	drug1	drug0	NN	_	14	com	_	_
14	administration	administration	NN	_	11	ppmod	_	_
15	,	,	,	_	11	p	_	_
16	but	but	CC	_	11	cc	_	_
17	these	these	DT	_	18	det	_	_
18	changes	change	NNS	_	21	dep	_	_
19	were	be	VBD	_	21	aux	_	_
20	not	not	RB	_	21	neg	_	_
21	affected	affect	VBN	_	11	conj	_	_
22	by	by	IN	_	25	case	_	_
23	concomitant	concomitant	JJ	_	25	attr	_	_
24	drug2	drug0	NN	_	25	com	_	_
25	administration	administration	NN	_	21	ppmod	_	_
26	.	.	.	_	11	p	_	_

1	Agents	agent	NNS	_	28	dep	_	_
2	Affecting	affect	VBG	_	1	acl	_	_
3	Cytochrome	cytochrome	NN	_	5	com	_	_
4	P450	p0	NN	_	5	com	_	_
5	3A4	0a0	NN	_	2	obj	_	_
6	Isoenzyme	isoenzyme	NN	_	8	com	_	_
7	System	system	NN	_	8	com	_	_
8	drug1	drug0	NN	_	10	dep	_	_
9	is	be	VBZ	_	10	aux	_	_
10	metabolized	metabolize	VBN	_	5	acl	_	_
11	mainly	mainly	RB	_	10	adv	_	_
12	via	via	IN	_	19	case	_	_
13	the	the	DT	_	19	det	_	_
14	human	human	JJ	_	17	attr	_	_
15	cytochrome	cytochrome	NN	_	17	com	_	_
16	P450	p0	NN	_	17	com	_	_
17	3A4	0a0	NN	_	19	com	_	_
18	isoenzyme	isoenzyme	NN	_	19	com	_	_
19	system	system	NN	_	10	ppmod	_	_
20	(	-lrb-	-LRB-	_	21	p	_	_
21	CYP3A4	cyp0a0	NN	_	5	prn	_	_
22	)	-rrb-	-RRB-	_	21	p	_	_
23	,	,	,	_	28	p	_	_
24	therefore	therefore	RB	_	28	adv	_	_
25	potential	potential	JJ	_	26	attr	_	_
26	interactions	interaction	NNS	_	28	dep	_	_
27	may	may	MD	_	28	modal	_	_
28	occur	occur	VB	_	0	root	_	_
29	when	when	WRB	_	32	adv	_	_
30	drug2	drug0	NN	_	32	dep	_	_
31	is	be	VBZ	_	32	aux	_	_
32	given	give	VBN	_	28	comp	_	_
33	concurrently	concurrently	RB	_	32	adv	_	_
34	with	with	IN	_	35	case	_	_
35	agents	agent	NNS	_	32	ppmod	_	_
36	that	that	WDT	_	37	dep	_	_
37	affect	affect	VBP	_	35	relcl	_	_
38	CYP3A4	cyp0a0	NN	_	39	com	_	_
39	activity	activity	NN	_	37	obj	_	_
40	.	.	.	_	28	p	_	_

1	Coadminstration	coadminstration	NN	_	9	dep	_	_
2	with	with	IN	_	3	case	_	_
3	agents	agent	NNS	_	1	ppmod	_	_
4	that	that	WDT	_	5	dep	_	_
5	induce	induce	VBP	_	3	relcl	_	_
6	3A4	0a0	NN	_	7	com	_	_
7	activity	activity	NN	_	5	obj	_	_
8	may	may	MD	_	9	modal	_	_
9	reduce	reduce	VB	_	0	root	_	_
10	the	the	DT	_	11	det	_	_
11	efficacy	efficacy	NN	_	9	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	.	.	.	_	9	p	_	_

1	The	the	DT	_	3	det	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	use	use	NN	_	29	dep	_	_
4	of	of	IN	_	6	case	_	_
5	transdermal	transdermal	JJ	_	6	attr	_	_
6	drug1	drug0	NN	_	3	ppmod	_	_
7	with	with	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	or	or	CC	_	8	cc	_	_
10	other	other	JJ	_	13	attr	_	_
11	potent	potent	JJ	_	13	attr	_	_
12	3A4	0a0	NN	_	13	com	_	_
13	inhibitors	inhibitor	NNS	_	8	conj	_	_
14	such	such	JJ	_	16	adv	_	_
15	as	as	IN	_	16	case	_	_
16	drug3	drug0	NN	_	13	ppmod	_	_
17	,	,	,	_	16	p	_	_
18	drug4	drug0	NN	_	16	conj	_	_
19	,	,	,	_	18	p	_	_
20	drug5	drug0	NN	_	16	conj	_	_
21	,	,	,	_	20	p	_	_
22	drug6	drug0	NN	_	16	conj	_	_
23	,	,	,	_	22	p	_	_
24	drug7	drug0	NN	_	16	conj	_	_
25	,	,	,	_	24	p	_	_
26	and	and	CC	_	24	cc	_	_
27	nefazadone	nefazadone	NN	_	16	conj	_	_
28	may	may	MD	_	29	modal	_	_
29	result	result	VB	_	0	root	_	_
30	in	in	IN	_	32	case	_	_
31	an	an	DT	_	32	det	_	_
32	increase	increase	NN	_	29	ppmod	_	_
33	in	in	IN	_	36	case	_	_
34	drug8	drug0	NN	_	36	com	_	_
35	plasma	plasma	NN	_	36	com	_	_
36	concentrations	concentration	NNS	_	32	ppmod	_	_
37	.	.	.	_	29	p	_	_

1	The	the	DT	_	3	det	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	use	use	NN	_	18	dep	_	_
4	of	of	IN	_	7	case	_	_
5	other	other	JJ	_	7	attr	_	_
6	CYP3A4	cyp0a0	JJ	_	7	attr	_	_
7	inhibitors	inhibitor	NNS	_	3	ppmod	_	_
8	such	such	JJ	_	10	adv	_	_
9	as	as	IN	_	10	case	_	_
10	drug1	drug0	NN	_	7	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug2	drug0	NN	_	10	conj	_	_
13	with	with	IN	_	15	case	_	_
14	transdermal	transdermal	JJ	_	15	attr	_	_
15	drug3	drug0	NN	_	10	ppmod	_	_
16	may	may	MD	_	18	modal	_	_
17	also	also	RB	_	18	adv	_	_
18	result	result	VB	_	0	root	_	_
19	in	in	IN	_	21	case	_	_
20	an	an	DT	_	21	det	_	_
21	increase	increase	NN	_	18	ppmod	_	_
22	in	in	IN	_	25	case	_	_
23	drug4	drug0	NN	_	25	com	_	_
24	plasma	plasma	NN	_	25	com	_	_
25	concentrations	concentration	NNS	_	21	ppmod	_	_
26	,	,	,	_	21	p	_	_
27	which	which	WDT	_	29	dep	_	_
28	could	could	MD	_	29	modal	_	_
29	increase	increase	VB	_	21	relcl	_	_
30	or	or	CC	_	29	cc	_	_
31	prolong	prolong	VB	_	29	conj	_	_
32	adverse	adverse	JJ	_	34	attr	_	_
33	drug	drug	NN	_	34	com	_	_
34	effects	effect	NNS	_	31	obj	_	_
35	and	and	CC	_	18	cc	_	_
36	may	may	MD	_	37	modal	_	_
37	cause	cause	VB	_	18	conj	_	_
38	serious	serious	JJ	_	40	attr	_	_
39	respiratory	respiratory	JJ	_	40	attr	_	_
40	depression	depression	NN	_	37	obj	_	_
41	.	.	.	_	18	p	_	_

1	In	in	IN	_	3	case	_	_
2	this	this	DT	_	3	det	_	_
3	situation	situation	NN	_	10	ppmod	_	_
4	,	,	,	_	10	p	_	_
5	special	special	JJ	_	7	attr	_	_
6	patient	patient	NN	_	7	com	_	_
7	care	care	NN	_	10	dep	_	_
8	and	and	CC	_	7	cc	_	_
9	observation	observation	NN	_	7	conj	_	_
10	are	be	VBP	_	0	root	_	_
11	appropriate	appropriate	JJ	_	10	dep	_	_
12	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	5	det	_	_
4	concomitant	concomitant	JJ	_	5	attr	_	_
5	use	use	NN	_	47	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	(	-lrb-	-LRB-	_	11	p	_	_
9	drug3	drug0	NN	_	11	attr	_	_
10	transdermal	transdermal	JJ	_	11	attr	_	_
11	system	system	NN	_	7	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	with	with	IN	_	15	case	_	_
14	other	other	JJ	_	15	attr	_	_
15	drug4	drug0	NNS	_	7	ppmod	_	_
16	,	,	,	_	15	p	_	_
17	including	include	VBG	_	15	acl	_	_
18	but	but	CC	_	17	cc	_	_
19	not	not	RB	_	20	neg	_	_
20	limited	limit	VBN	_	17	conj	_	_
21	to	to	TO	_	23	aux	_	_
22	other	other	JJ	_	23	attr	_	_
23	drug5	drug0	NN	_	20	ppmod	_	_
24	,	,	,	_	23	p	_	_
25	drug6	drug0	NN	_	23	conj	_	_
26	,	,	,	_	25	p	_	_
27	drug7	drug0	NN	_	23	conj	_	_
28	,	,	,	_	27	p	_	_
29	drug8	drug0	NN	_	23	conj	_	_
30	(	-lrb-	-LRB-	_	33	p	_	_
31	e.g.	e.g.	FW	_	33	ppmod	_	_
32	,	,	,	_	33	p	_	_
33	drug9	drug0	NN	_	29	prn	_	_
34	)	-rrb-	-RRB-	_	33	p	_	_
35	,	,	,	_	29	p	_	_
36	general	general	JJ	_	37	attr	_	_
37	drug10	drug0	NN	_	23	conj	_	_
38	,	,	,	_	37	p	_	_
39	drug11	drug0	NN	_	23	conj	_	_
40	,	,	,	_	39	p	_	_
41	drug12	drug0	NN	_	23	conj	_	_
42	,	,	,	_	41	p	_	_
43	and	and	CC	_	41	cc	_	_
44	drug13	drug0	NN	_	23	conj	_	_
45	,	,	,	_	15	p	_	_
46	may	may	MD	_	47	modal	_	_
47	cause	cause	VB	_	1	acl	_	_
48	respiratory	respiratory	JJ	_	49	attr	_	_
49	depression	depression	NN	_	47	obj	_	_
50	,	,	,	_	49	p	_	_
51	hypotension	hypotension	NN	_	49	conj	_	_
52	,	,	,	_	51	p	_	_
53	and	and	CC	_	51	cc	_	_
54	profound	profound	JJ	_	55	attr	_	_
55	sedation	sedation	NN	_	49	conj	_	_
56	,	,	,	_	47	p	_	_
57	or	or	CC	_	47	cc	_	_
58	potentially	potentially	RB	_	59	adv	_	_
59	result	result	VB	_	47	conj	_	_
60	in	in	IN	_	61	case	_	_
61	coma	coma	NN	_	59	ppmod	_	_
62	or	or	CC	_	61	cc	_	_
63	death	death	NN	_	61	conj	_	_
64	.	.	.	_	1	p	_	_

1	When	when	WRB	_	6	adv	_	_
2	such	such	JJ	_	4	attr	_	_
3	combined	combined	JJ	_	4	attr	_	_
4	therapy	therapy	NN	_	6	dep	_	_
5	is	be	VBZ	_	6	aux	_	_
6	contemplated	contemplate	VBN	_	18	advcl	_	_
7	,	,	,	_	18	p	_	_
8	the	the	DT	_	9	det	_	_
9	dose	dose	NN	_	18	dep	_	_
10	of	of	IN	_	11	case	_	_
11	one	#crd#	CD	_	9	ppmod	_	_
12	or	or	CC	_	11	cc	_	_
13	both	both	DT	_	14	attr	_	_
14	agents	agent	NNS	_	11	conj	_	_
15	should	should	MD	_	18	modal	_	_
16	be	be	VB	_	18	aux	_	_
17	significantly	significantly	RB	_	18	adv	_	_
18	reduced	reduce	VBN	_	0	root	_	_
19	.	.	.	_	18	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	6	dep	_	_
4	is	be	VBZ	_	6	aux	_	_
5	not	not	RB	_	6	neg	_	_
6	recommended	recommend	VBN	_	1	acl	_	_
7	for	for	IN	_	8	case	_	_
8	use	use	NN	_	6	ppmod	_	_
9	in	in	IN	_	10	case	_	_
10	patients	patient	NNS	_	6	ppmod	_	_
11	who	who	WP	_	13	dep	_	_
12	have	have	VBP	_	13	aux	_	_
13	received	receive	VBN	_	10	relcl	_	_
14	drug3	drug0	NN	_	13	obj	_	_
15	within	within	IN	_	17	case	_	_
16	14	0	CD	_	17	num	_	_
17	days	day	NNS	_	14	ppmod	_	_
18	because	because	IN	_	27	mark	_	_
19	severe	severe	JJ	_	22	attr	_	_
20	and	and	CC	_	19	cc	_	_
21	unpredictable	unpredictable	JJ	_	19	conj	_	_
22	potentiation	potentiation	NN	_	27	dep	_	_
23	by	by	IN	_	24	case	_	_
24	drug4	drug0	NN	_	22	ppmod	_	_
25	has	have	VBZ	_	27	aux	_	_
26	been	be	VBN	_	27	aux	_	_
27	reported	report	VBN	_	13	comp	_	_
28	with	with	IN	_	29	case	_	_
29	drug5	drug0	NN	_	27	ppmod	_	_

1	.	.	.	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	drug1	drug0	NN	_	15	dep	_	_
2	,	,	,	_	1	p	_	_
3	apparently	apparently	RB	_	1	adv	_	_
4	through	through	IN	_	6	case	_	_
5	an	an	DT	_	6	det	_	_
6	effect	effect	NN	_	1	ppmod	_	_
7	on	on	IN	_	11	case	_	_
8	certain	certain	JJ	_	11	attr	_	_
9	microsomal	microsomal	JJ	_	11	attr	_	_
10	enzyme	enzyme	NN	_	11	com	_	_
11	systems	system	NNS	_	6	ppmod	_	_
12	,	,	,	_	1	p	_	_
13	has	have	VBZ	_	15	aux	_	_
14	been	be	VBN	_	15	aux	_	_
15	reported	report	VBN	_	0	root	_	_
16	to	to	TO	_	17	aux	_	_
17	reduce	reduce	VB	_	15	comp	_	_
18	the	the	DT	_	20	det	_	_
19	hepatic	hepatic	JJ	_	20	attr	_	_
20	metabolism	metabolism	NN	_	17	obj	_	_
21	of	of	IN	_	22	case	_	_
22	drug2	drug0	NN	_	20	ppmod	_	_
23	,	,	,	_	22	p	_	_
24	drug3	drug0	NN	_	22	conj	_	_
25	,	,	,	_	24	p	_	_
26	drug4	drug0	NN	_	22	conj	_	_
27	,	,	,	_	26	p	_	_
28	drug5	drug0	NN	_	22	conj	_	_
29	,	,	,	_	28	p	_	_
30	drug6	drug0	NN	_	22	conj	_	_
31	,	,	,	_	30	p	_	_
32	drug7	drug0	NN	_	22	conj	_	_
33	,	,	,	_	32	p	_	_
34	certain	certain	JJ	_	35	attr	_	_
35	drug8	drug0	NN	_	22	conj	_	_
36	,	,	,	_	35	p	_	_
37	drug9	drug0	NN	_	22	conj	_	_
38	,	,	,	_	37	p	_	_
39	drug10	drug0	NN	_	22	conj	_	_
40	and	and	CC	_	39	cc	_	_
41	drug11	drug0	NN	_	22	conj	_	_
42	,	,	,	_	15	p	_	_
43	thereby	thereby	RB	_	44	adv	_	_
44	delaying	delay	VBG	_	15	comp	_	_
45	elimination	elimination	NN	_	44	obj	_	_
46	and	and	CC	_	44	cc	_	_
47	increasing	increase	VBG	_	44	conj	_	_
48	blood	blood	NN	_	49	com	_	_
49	levels	level	NNS	_	47	obj	_	_
50	of	of	IN	_	52	case	_	_
51	these	these	DT	_	52	det	_	_
52	drugs	drug	NNS	_	49	ppmod	_	_
53	.	.	.	_	15	p	_	_

1	Clinically	clinically	RB	_	2	adv	_	_
2	significant	significant	JJ	_	3	attr	_	_
3	effects	effect	NNS	_	6	dep	_	_
4	have	have	VBP	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	reported	report	VBN	_	0	root	_	_
7	with	with	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	drug1	drug0	NN	_	6	ppmod	_	_
10	;	;	:	_	6	p	_	_

1	therefore	therefore	RB	_	9	adv	_	_
2	,	,	,	_	9	p	_	_
3	close	close	JJ	_	4	attr	_	_
4	monitoring	monitoring	NN	_	9	dep	_	_
5	of	of	IN	_	7	case	_	_
6	prothrombin	prothrombin	NN	_	7	com	_	_
7	time	time	NN	_	4	ppmod	_	_
8	is	be	VBZ	_	9	aux	_	_
9	recommended	recommend	VBN	_	0	root	_	_
10	,	,	,	_	9	p	_	_
11	and	and	CC	_	9	cc	_	_
12	adjustment	adjustment	NN	_	18	dep	_	_
13	of	of	IN	_	16	case	_	_
14	the	the	DT	_	16	det	_	_
15	drug1	drug0	NN	_	16	com	_	_
16	dose	dose	NN	_	12	ppmod	_	_
17	may	may	MD	_	18	modal	_	_
18	be	be	VB	_	9	conj	_	_
19	necessary	necessary	JJ	_	18	dep	_	_
20	when	when	WRB	_	23	adv	_	_
21	drug2	drug0	NN	_	23	dep	_	_
22	is	be	VBZ	_	23	aux	_	_
23	administered	administer	VBN	_	19	comp	_	_
24	concomitantly	concomitantly	RB	_	23	adv	_	_
25	.	.	.	_	9	p	_	_

1	Interaction	interaction	NN	_	11	dep	_	_
2	with	with	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	,	,	,	_	3	p	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	and	and	CC	_	5	cc	_	_
7	drug3	drug0	NN	_	3	conj	_	_
8	has	have	VBZ	_	11	aux	_	_
9	also	also	RB	_	11	adv	_	_
10	been	be	VBN	_	11	aux	_	_
11	reported	report	VBN	_	0	root	_	_
12	to	to	TO	_	13	aux	_	_
13	produce	produce	VB	_	11	comp	_	_
14	adverse	adverse	JJ	_	16	attr	_	_
15	clinical	clinical	JJ	_	16	attr	_	_
16	effects	effect	NNS	_	13	obj	_	_
17	.	.	.	_	11	p	_	_

1	However	however	RB	_	36	adv	_	_
2	,	,	,	_	36	p	_	_
3	a	a	DT	_	5	det	_	_
4	crossover	crossover	NN	_	5	com	_	_
5	study	study	NN	_	36	dep	_	_
6	in	in	IN	_	8	case	_	_
7	healthy	healthy	JJ	_	8	attr	_	_
8	subjects	subject	NNS	_	5	ppmod	_	_
9	receiving	receive	VBG	_	8	acl	_	_
10	either	either	CC	_	13	cc	_	_
11	drug1	drug0	NN	_	13	attr	_	_
12	300	0	CD	_	13	num	_	_
13	mg	mg	NN	_	9	obj	_	_
14	q.i.d.	q.i.d.	CD	_	13	num	_	_
15	or	or	CC	_	13	cc	_	_
16	800	0	CD	_	17	num	_	_
17	mg	mg	NN	_	13	conj	_	_
18	h.s.	h.s.	VBG	_	17	acl	_	_
19	concomitantly	concomitantly	RB	_	18	adv	_	_
20	with	with	IN	_	25	case	_	_
21	a	a	DT	_	25	det	_	_
22	300	0	CD	_	23	num	_	_
23	mg	mg	NN	_	25	com	_	_
24	b.i.d.	b.i.d.	NN	_	25	com	_	_
25	dosage	dosage	NN	_	18	ppmod	_	_
26	of	of	IN	_	27	case	_	_
27	drug2	drug0	NN	_	25	ppmod	_	_
28	(	-lrb-	-LRB-	_	34	p	_	_
29	drug3	drug0	NN	_	34	dep	_	_
30	,	,	,	_	34	p	_	_
31	Key	key	JJ	_	34	attr	_	_
32	Pharmaceuticals	pharmaceuticals	NNP	_	34	attr	_	_
33	,	,	,	_	34	p	_	_
34	Inc.	inc.	NNP	_	18	prn	_	_
35	)	-rrb-	-RRB-	_	34	p	_	_
36	demonstrated	demonstrate	VBD	_	0	root	_	_
37	less	less	RBR	_	38	adv	_	_
38	alteration	alteration	NN	_	36	obj	_	_
39	in	in	IN	_	44	case	_	_
40	steady-state	steady-state	JJ	_	44	attr	_	_
41	drug4	drug0	NN	_	44	com	_	_
42	peak	peak	NN	_	44	com	_	_
43	serum	serum	NN	_	44	com	_	_
44	levels	level	NNS	_	36	ppmod	_	_
45	with	with	IN	_	50	case	_	_
46	the	the	DT	_	50	det	_	_
47	800	0	CD	_	48	num	_	_
48	mg	mg	NN	_	50	com	_	_
49	h.s.	h.s.	NN	_	50	com	_	_
50	regimen	regimen	NN	_	44	ppmod	_	_
51	,	,	,	_	36	p	_	_
52	particularly	particularly	RB	_	54	adv	_	_
53	in	in	IN	_	54	case	_	_
54	subjects	subject	NNS	_	36	ppmod	_	_
55	aged	aged	JJ	_	54	attr	_	_
56	54	0	CD	_	57	num	_	_
57	years	year	NNS	_	55	advnp	_	_
58	and	and	CC	_	57	cc	_	_
59	older	old	JJR	_	57	conj	_	_
60	.	.	.	_	36	p	_	_

1	Data	datum	NNS	_	5	dep	_	_
2	beyond	beyond	IN	_	4	case	_	_
3	10	0	CD	_	4	num	_	_
4	days	day	NNS	_	1	ppmod	_	_
5	are	be	VBP	_	0	root	_	_
6	not	not	RB	_	5	neg	_	_
7	available	available	JJ	_	5	dep	_	_
8	.	.	.	_	5	p	_	_

1	(	-lrb-	-LRB-	_	2	p	_	_
2	Note	note	NN	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	All	all	DT	_	5	det	_	_
5	patients	patient	NNS	_	10	dep	_	_
6	receiving	receive	VBG	_	5	acl	_	_
7	drug1	drug0	NN	_	6	obj	_	_
8	should	should	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	monitored	monitor	VBN	_	2	acl	_	_
11	appropriately	appropriately	RB	_	10	adv	_	_
12	,	,	,	_	10	p	_	_
13	regardless	regardless	RB	_	10	adv	_	_
14	of	of	IN	_	17	case	_	_
15	concomitant	concomitant	JJ	_	17	attr	_	_
16	drug	drug	NN	_	17	com	_	_
17	therapy	therapy	NN	_	13	ppmod	_	_
18	.	.	.	_	2	p	_	_
19	)	-rrb-	-RRB-	_	2	p	_	_

1	Dosage	dosage	NN	_	29	dep	_	_
2	of	of	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	drugs	drug	NNS	_	1	ppmod	_	_
5	mentioned	mention	VBN	_	4	acl	_	_
6	above	above	RB	_	5	adv	_	_
7	and	and	CC	_	4	cc	_	_
8	other	other	JJ	_	11	attr	_	_
9	similarly	similarly	RB	_	10	adv	_	_
10	metabolized	metabolize	VBN	_	11	attr	_	_
11	drugs	drug	NNS	_	4	conj	_	_
12	,	,	,	_	11	p	_	_
13	particularly	particularly	RB	_	14	adv	_	_
14	those	those	DT	_	11	appo	_	_
15	of	of	IN	_	18	case	_	_
16	low	low	JJ	_	18	attr	_	_
17	therapeutic	therapeutic	JJ	_	18	attr	_	_
18	ratio	ratio	NN	_	14	ppmod	_	_
19	or	or	CC	_	18	cc	_	_
20	in	in	IN	_	21	case	_	_
21	patients	patient	NNS	_	18	conj	_	_
22	with	with	IN	_	26	case	_	_
23	renal	renal	JJ	_	26	attr	_	_
24	and/or	and/or	CC	_	23	cc	_	_
25	hepatic	hepatic	JJ	_	23	conj	_	_
26	impairment	impairment	NN	_	21	ppmod	_	_
27	,	,	,	_	11	p	_	_
28	may	may	MD	_	29	modal	_	_
29	require	require	VB	_	0	root	_	_
30	adjustment	adjustment	NN	_	29	obj	_	_
31	when	when	WRB	_	32	adv	_	_
32	starting	start	VBG	_	30	relcl	_	_
33	or	or	CC	_	32	cc	_	_
34	stopping	stop	VBG	_	32	conj	_	_
35	concomitantly	concomitantly	RB	_	36	adv	_	_
36	administered	administer	VBN	_	37	attr	_	_
37	drug1	drug0	NN	_	34	obj	_	_
38	to	to	TO	_	39	aux	_	_
39	maintain	maintain	VB	_	37	acl	_	_
40	optimum	optimum	JJ	_	43	attr	_	_
41	therapeutic	therapeutic	JJ	_	43	attr	_	_
42	blood	blood	NN	_	43	com	_	_
43	levels	level	NNS	_	39	obj	_	_
44	.	.	.	_	29	p	_	_

1	Alteration	alteration	NN	_	5	dep	_	_
2	of	of	IN	_	3	case	_	_
3	pH	ph	NN	_	1	ppmod	_	_
4	may	may	MD	_	5	modal	_	_
5	affect	affect	VB	_	0	root	_	_
6	absorption	absorption	NN	_	5	obj	_	_
7	of	of	IN	_	9	case	_	_
8	certain	certain	JJ	_	9	attr	_	_
9	drugs	drug	NNS	_	6	ppmod	_	_
10	(	-lrb-	-LRB-	_	13	p	_	_
11	e.g.	e.g.	FW	_	13	adv	_	_
12	,	,	,	_	13	p	_	_
13	drug1	drug0	NN	_	9	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	.	.	.	_	5	p	_	_

1	If	if	IN	_	5	mark	_	_
2	these	these	DT	_	3	det	_	_
3	products	product	NNS	_	5	dep	_	_
4	are	be	VBP	_	5	aux	_	_
5	needed	need	VBN	_	10	advcl	_	_
6	,	,	,	_	10	p	_	_
7	they	they	PRP	_	10	dep	_	_
8	should	should	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	given	give	VBN	_	0	root	_	_
11	at	at	IN	_	13	case	_	_
12	least	least	JJS	_	13	attr	_	_
13	2	0	CD	_	14	num	_	_
14	hours	hour	NNS	_	10	obj	_	_
15	before	before	IN	_	17	case	_	_
16	drug1	drug0	NN	_	17	com	_	_
17	administration	administration	NN	_	10	ppmod	_	_
18	.	.	.	_	10	p	_	_

1	Additional	additional	JJ	_	3	attr	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	experience	experience	VBP	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	reveal	reveal	VBP	_	0	root	_	_
6	other	other	JJ	_	7	attr	_	_
7	drugs	drug	NNS	_	5	obj	_	_
8	affected	affect	VBN	_	7	acl	_	_
9	by	by	IN	_	12	case	_	_
10	the	the	DT	_	12	det	_	_
11	concomitant	concomitant	JJ	_	12	attr	_	_
12	administration	administration	NN	_	8	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	5	p	_	_

1	General	general	JJ	_	3	adv	_	_
2	:	:	:	_	3	p	_	_
3	Significant	significant	JJ	_	4	attr	_	_
4	interactions	interaction	NNS	_	6	dep	_	_
5	may	may	MD	_	6	modal	_	_
6	occur	occur	VB	_	0	root	_	_
7	when	when	WRB	_	10	adv	_	_
8	drug1	drug0	NN	_	10	dep	_	_
9	is	be	VBZ	_	10	aux	_	_
10	administered	administer	VBN	_	6	comp	_	_
11	together	together	RB	_	10	adv	_	_
12	with	with	IN	_	13	case	_	_
13	drugs	drug	NNS	_	10	ppmod	_	_
14	that	that	WDT	_	15	dep	_	_
15	inhibit	inhibit	VBP	_	13	relcl	_	_
16	P450	p0	NN	_	17	com	_	_
17	2C9	0c0	NN	_	15	obj	_	_
18	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	metabolism	metabolism	NN	_	5	dep	_	_
3	is	be	VBZ	_	5	aux	_	_
4	predominantly	predominantly	RB	_	5	adv	_	_
5	mediated	mediate	VBN	_	0	root	_	_
6	via	via	IN	_	9	case	_	_
7	cytochrome	cytochrome	NN	_	9	com	_	_
8	P450	p0	NN	_	9	com	_	_
9	2C9	0c0	NN	_	5	ppmod	_	_
10	in	in	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	liver	liver	NN	_	9	ppmod	_	_
13	.	.	.	_	5	p	_	_

1	Co-administration	co-administration	NN	_	14	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	5	case	_	_
5	drugs	drug	NNS	_	1	ppmod	_	_
6	that	that	WDT	_	8	dep	_	_
7	are	be	VBP	_	8	aux	_	_
8	known	know	VBN	_	5	relcl	_	_
9	to	to	TO	_	10	aux	_	_
10	inhibit	inhibit	VB	_	8	comp	_	_
11	2C9	0c0	NNS	_	10	obj	_	_
12	should	should	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	done	do	VBN	_	0	root	_	_
15	with	with	IN	_	16	case	_	_
16	caution	caution	NN	_	14	ppmod	_	_
17	.	.	.	_	14	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	studies	study	NNS	_	4	dep	_	_
4	indicate	indicate	VBP	_	0	root	_	_
5	that	that	IN	_	7	mark	_	_
6	drug1	drug0	NN	_	7	dep	_	_
7	is	be	VBZ	_	4	comp	_	_
8	not	not	RB	_	7	neg	_	_
9	an	an	DT	_	10	det	_	_
10	inhibitor	inhibitor	NN	_	7	obj	_	_
11	of	of	IN	_	14	case	_	_
12	cytochrome	cytochrome	NN	_	14	com	_	_
13	P450	p0	NN	_	14	com	_	_
14	2C9	0c0	NN	_	10	ppmod	_	_
15	,	,	,	_	10	p	_	_
16	2C19	0c0	NN	_	10	appo	_	_
17	or	or	CC	_	16	cc	_	_
18	3A4	0a0	NN	_	16	conj	_	_
19	.	.	.	_	4	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	studies	study	NNS	_	5	dep	_	_
4	also	also	RB	_	5	adv	_	_
5	indicate	indicate	VBP	_	0	root	_	_
6	that	that	IN	_	14	mark	_	_
7	drug1	drug0	NN	_	14	dep	_	_
8	,	,	,	_	7	p	_	_
9	although	although	IN	_	10	com	_	_
10	not	not	RB	_	7	cc	_	_
11	a	a	DT	_	12	det	_	_
12	substrate	substrate	NN	_	7	conj	_	_
13	,	,	,	_	12	p	_	_
14	is	be	VBZ	_	5	comp	_	_
15	an	an	DT	_	16	det	_	_
16	inhibitor	inhibitor	NN	_	14	obj	_	_
17	of	of	IN	_	20	case	_	_
18	cytochrome	cytochrome	NN	_	20	com	_	_
19	P450	p0	NN	_	20	com	_	_
20	2D6	0d0	NN	_	16	ppmod	_	_
21	.	.	.	_	5	p	_	_

1	Therefore	therefore	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	there	there	EX	_	4	dep	_	_
4	is	be	VBZ	_	0	root	_	_
5	a	a	DT	_	6	det	_	_
6	potential	potential	NN	_	4	obj	_	_
7	for	for	IN	_	12	case	_	_
8	an	an	DT	_	12	det	_	_
9	in	in	FW	_	10	adv	_	_
10	vivo	vivo	FW	_	12	attr	_	_
11	drug	drug	NN	_	12	com	_	_
12	interaction	interaction	NN	_	6	ppmod	_	_
13	with	with	IN	_	14	case	_	_
14	drugs	drug	NNS	_	12	ppmod	_	_
15	that	that	WDT	_	17	dep	_	_
16	are	be	VBP	_	17	aux	_	_
17	metabolized	metabolize	VBN	_	14	relcl	_	_
18	by	by	IN	_	20	case	_	_
19	P450	p0	NN	_	20	com	_	_
20	2D6	0d0	NN	_	17	ppmod	_	_
21	.	.	.	_	4	p	_	_

1	Clinical	clinical	JJ	_	2	attr	_	_
2	studies	study	NNS	_	6	dep	_	_
3	with	with	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	have	have	VBP	_	6	aux	_	_
6	identified	identify	VBN	_	0	root	_	_
7	potentially	potentially	RB	_	8	adv	_	_
8	significant	significant	JJ	_	9	attr	_	_
9	interactions	interaction	NNS	_	6	obj	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	drug3	drug0	NN	_	11	conj	_	_
14	.	.	.	_	6	p	_	_

1	Experience	experience	VBP	_	7	dep	_	_
2	with	with	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	drug2	drug0	NN	_	3	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	suggests	suggest	VBZ	_	0	root	_	_
8	the	the	DT	_	9	det	_	_
9	potential	potential	NN	_	7	obj	_	_
10	for	for	IN	_	11	case	_	_
11	interactions	interaction	NNS	_	9	ppmod	_	_
12	with	with	IN	_	13	case	_	_
13	drug3	drug0	NN	_	11	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	drug4	drug0	NN	_	13	conj	_	_
16	.	.	.	_	7	p	_	_

1	The	the	DT	_	2	det	_	_
2	effects	effect	NNS	_	24	dep	_	_
3	drug1	drug0	JJ	_	6	adv	_	_
4	on	on	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	pharmacokinetics	pharmacokinetics	NNS	_	2	ppmod	_	_
7	and/or	and/or	CC	_	6	cc	_	_
8	pharmacodynamics	pharmacodynamics	NNS	_	6	conj	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	6	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	drug3	drug0	NN	_	10	conj	_	_
13	,	,	,	_	12	p	_	_
14	drug4	drug0	NN	_	10	conj	_	_
15	,	,	,	_	14	p	_	_
16	drug5	drug0	NN	_	10	conj	_	_
17	,	,	,	_	16	p	_	_
18	drug6	drug0	NN	_	10	conj	_	_
19	,	,	,	_	18	p	_	_
20	and	and	CC	_	18	cc	_	_
21	drug7	drug0	NN	_	10	conj	_	_
22	have	have	VBP	_	24	aux	_	_
23	been	be	VBN	_	24	aux	_	_
24	studied	study	VBN	_	0	root	_	_
25	in	in	FW	_	26	adv	_	_
26	vivo	vivo	FW	_	24	adv	_	_
27	and	and	CC	_	24	cc	_	_
28	clinically	clinically	RB	_	29	adv	_	_
29	important	important	JJ	_	30	attr	_	_
30	interactions	interaction	NNS	_	34	dep	_	_
31	have	have	VBP	_	34	aux	_	_
32	not	not	RB	_	34	neg	_	_
33	been	be	VBN	_	34	aux	_	_
34	found	find	VBN	_	24	conj	_	_
35	.	.	.	_	24	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Reports	report	NNS	_	4	dep	_	_
4	suggest	suggest	VBP	_	1	acl	_	_
5	that	that	IN	_	8	mark	_	_
6	drug2	drug0	NN	_	8	dep	_	_
7	may	may	MD	_	8	modal	_	_
8	diminish	diminish	VB	_	4	comp	_	_
9	the	the	DT	_	11	det	_	_
10	antihypertensive	antihypertensive	JJ	_	11	attr	_	_
11	effect	effect	NN	_	8	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug3	drug0	NN	_	11	ppmod	_	_
14	.	.	.	_	1	p	_	_

1	This	this	DT	_	2	det	_	_
2	interaction	interaction	NN	_	6	dep	_	_
3	should	should	MD	_	6	modal	_	_
4	be	be	VB	_	6	aux	_	_
5	given	give	VBN	_	6	lv	_	_
6	consideration	consideration	NN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	6	ppmod	_	_
9	taking	take	VBG	_	8	acl	_	_
10	drug1	drug0	NN	_	9	obj	_	_
11	concomitantly	concomitantly	RB	_	6	adv	_	_
12	with	with	IN	_	13	case	_	_
13	drug2	drug0	NN	_	6	ppmod	_	_
14	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Clinical	clinical	JJ	_	4	attr	_	_
4	studies	study	NNS	_	14	dep	_	_
5	,	,	,	_	4	p	_	_
6	as	as	RB	_	7	com	_	_
7	well	well	RB	_	4	cc	_	_
8	as	as	IN	_	7	com	_	_
9	post	post	JJ	_	11	attr	_	_
10	marketing	marketing	JJ	_	11	attr	_	_
11	observations	observation	NNS	_	4	conj	_	_
12	,	,	,	_	11	p	_	_
13	have	have	VBP	_	14	aux	_	_
14	shown	show	VBN	_	1	acl	_	_
15	that	that	IN	_	18	mark	_	_
16	drug2	drug0	NN	_	18	dep	_	_
17	can	can	MD	_	18	modal	_	_
18	reduce	reduce	VB	_	14	comp	_	_
19	the	the	DT	_	21	det	_	_
20	natriuretic	natriuretic	JJ	_	21	attr	_	_
21	effect	effect	NN	_	18	obj	_	_
22	of	of	IN	_	23	case	_	_
23	drug3	drug0	NN	_	21	ppmod	_	_
24	and	and	CC	_	23	cc	_	_
25	drug4	drug0	NN	_	23	conj	_	_
26	in	in	IN	_	28	case	_	_
27	some	some	DT	_	28	det	_	_
28	patients	patient	NNS	_	21	ppmod	_	_
29	.	.	.	_	1	p	_	_

1	This	this	DT	_	2	det	_	_
2	response	response	NN	_	5	dep	_	_
3	has	have	VBZ	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	attributed	attribute	VBN	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	inhibition	inhibition	NN	_	5	ppmod	_	_
8	of	of	IN	_	11	case	_	_
9	renal	renal	JJ	_	11	attr	_	_
10	prostaglandin	prostaglandin	NN	_	11	com	_	_
11	synthesis	synthesis	NN	_	7	ppmod	_	_
12	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	can	can	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	used	use	VBN	_	0	root	_	_
7	with	with	IN	_	10	case	_	_
8	low	low	JJ	_	10	attr	_	_
9	dose	dose	NN	_	10	com	_	_
10	drug3	drug0	NN	_	6	ppmod	_	_
11	.	.	.	_	6	p	_	_

1	However	however	RB	_	10	adv	_	_
2	,	,	,	_	10	p	_	_
3	concomitant	concomitant	JJ	_	4	attr	_	_
4	administration	administration	NN	_	10	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	with	with	IN	_	8	case	_	_
8	drug2	drug0	NN	_	4	ppmod	_	_
9	may	may	MD	_	10	modal	_	_
10	result	result	VB	_	0	root	_	_
11	in	in	IN	_	14	case	_	_
12	an	an	DT	_	14	det	_	_
13	increased	increase	VBN	_	14	attr	_	_
14	rate	rate	NN	_	10	ppmod	_	_
15	of	of	IN	_	17	case	_	_
16	GI	gi	NN	_	17	com	_	_
17	ulceration	ulceration	NN	_	14	ppmod	_	_
18	or	or	CC	_	17	cc	_	_
19	other	other	JJ	_	20	attr	_	_
20	complications	complication	NNS	_	17	conj	_	_
21	,	,	,	_	10	p	_	_
22	compared	compare	VBN	_	24	adv	_	_
23	to	to	TO	_	24	aux	_	_
24	use	use	NN	_	10	ppmod	_	_
25	of	of	IN	_	26	case	_	_
26	drug3	drug0	NN	_	24	ppmod	_	_
27	alone	alone	RB	_	26	adv	_	_
28	.	.	.	_	10	p	_	_

1	Because	because	IN	_	4	case	_	_
2	of	of	IN	_	4	case	_	_
3	its	its	PRP$	_	4	poss	_	_
4	lack	lack	NN	_	13	ppmod	_	_
5	of	of	IN	_	7	case	_	_
6	platelet	platelet	NN	_	7	com	_	_
7	effects	effect	NNS	_	4	ppmod	_	_
8	,	,	,	_	13	p	_	_
9	drug1	drug0	NN	_	13	dep	_	_
10	is	be	VBZ	_	13	aux	_	_
11	not	not	RB	_	13	neg	_	_
12	a	a	DT	_	13	det	_	_
13	substitute	substitute	VB	_	0	root	_	_
14	for	for	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	for	for	IN	_	18	case	_	_
17	cardiovascular	cardiovascular	JJ	_	18	attr	_	_
18	prophylaxis	prophylaxis	NNS	_	13	ppmod	_	_
19	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Concomitant	concomitant	JJ	_	4	attr	_	_
4	administration	administration	NN	_	11	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	at	at	IN	_	10	case	_	_
8	200	0	CD	_	9	num	_	_
9	mg	mg	NN	_	10	com	_	_
10	QD	qd	NN	_	4	ppmod	_	_
11	resulted	result	VBD	_	1	acl	_	_
12	in	in	IN	_	15	case	_	_
13	a	a	DT	_	15	det	_	_
14	two-fold	two-fold	JJ	_	15	attr	_	_
15	increase	increase	NN	_	11	ppmod	_	_
16	in	in	IN	_	19	case	_	_
17	drug3	drug0	NN	_	19	com	_	_
18	plasma	plasma	NN	_	19	com	_	_
19	concentration	concentration	NN	_	15	ppmod	_	_
20	.	.	.	_	1	p	_	_

1	This	this	DT	_	2	det	_	_
2	increase	increase	NN	_	3	dep	_	_
3	is	be	VBZ	_	0	root	_	_
4	due	due	JJ	_	3	dep	_	_
5	to	to	TO	_	7	aux	_	_
6	the	the	DT	_	7	det	_	_
7	inhibition	inhibition	NN	_	4	ppmod	_	_
8	of	of	IN	_	10	case	_	_
9	drug1	drug0	NN	_	10	com	_	_
10	metabolism	metabolism	NN	_	7	ppmod	_	_
11	via	via	IN	_	13	case	_	_
12	P450	p0	NN	_	13	com	_	_
13	2C9	0c0	NN	_	3	ppmod	_	_
14	by	by	IN	_	15	case	_	_
15	drug2	drug0	NN	_	3	ppmod	_	_
16	(	-lrb-	-LRB-	_	19	p	_	_
17	see	see	VB	_	19	attr	_	_
18	CLINICAL	clinical	JJ	_	19	attr	_	_
19	PHARMACOLOGY	pharmacology	NN	_	3	prn	_	_
20	-	-	:	_	19	p	_	_
21	Pharmacokinetics	pharmacokinetics	NNS	_	19	appo	_	_
22	:	:	:	_	19	p	_	_
23	Metabolism	metabolism	NN	_	19	appo	_	_
24	)	-rrb-	-RRB-	_	19	p	_	_
25	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	introduced	introduce	VBN	_	0	root	_	_
5	at	at	IN	_	9	case	_	_
6	the	the	DT	_	9	det	_	_
7	lowest	low	JJS	_	9	attr	_	_
8	recommended	recommend	VBN	_	9	attr	_	_
9	dose	dose	NN	_	4	ppmod	_	_
10	in	in	IN	_	11	case	_	_
11	patients	patient	NNS	_	9	ppmod	_	_
12	receiving	receive	VBG	_	11	acl	_	_
13	drug2	drug0	NN	_	12	obj	_	_
14	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	5	case	_	_
4	a	a	DT	_	5	det	_	_
5	study	study	NN	_	16	ppmod	_	_
6	conducted	conduct	VBN	_	5	acl	_	_
7	in	in	IN	_	9	case	_	_
8	healthy	healthy	JJ	_	9	attr	_	_
9	subjects	subject	NNS	_	6	ppmod	_	_
10	,	,	,	_	16	p	_	_
11	mean	mean	JJ	_	15	attr	_	_
12	steady-state	steady-state	JJ	_	15	attr	_	_
13	drug2	drug0	NN	_	15	com	_	_
14	plasma	plasma	NN	_	15	com	_	_
15	levels	level	NNS	_	16	dep	_	_
16	increased	increase	VBD	_	1	acl	_	_
17	approximately	approximately	RB	_	18	adv	_	_
18	17	0	CD	_	16	obj	_	_
19	%	%	NN	_	18	meta	_	_
20	in	in	IN	_	21	case	_	_
21	subjects	subject	NNS	_	16	ppmod	_	_
22	receiving	receive	VBG	_	21	acl	_	_
23	drug3	drug0	NN	_	25	attr	_	_
24	450	0	CD	_	25	num	_	_
25	mg	mg	NN	_	22	obj	_	_
26	BID	bid	JJ	_	25	attr	_	_
27	with	with	IN	_	31	case	_	_
28	drug4	drug0	NN	_	31	attr	_	_
29	200	0	CD	_	30	num	_	_
30	mg	mg	NN	_	31	com	_	_
31	BID	bid	NN	_	26	ppmod	_	_
32	as	as	IN	_	33	mark	_	_
33	compared	compare	VBN	_	31	acl	_	_
34	to	to	TO	_	35	aux	_	_
35	subjects	subject	NNS	_	33	ppmod	_	_
36	receiving	receive	VBG	_	35	acl	_	_
37	drug5	drug0	NN	_	36	obj	_	_
38	alone	alone	RB	_	37	adv	_	_
39	.	.	.	_	1	p	_	_

1	Patients	patient	NNS	_	8	dep	_	_
2	on	on	IN	_	4	case	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	treatment	treatment	NN	_	1	ppmod	_	_
5	should	should	MD	_	8	modal	_	_
6	be	be	VB	_	8	aux	_	_
7	closely	closely	RB	_	8	adv	_	_
8	monitored	monitor	VBN	_	0	root	_	_
9	when	when	WRB	_	12	adv	_	_
10	drug2	drug0	NN	_	12	dep	_	_
11	is	be	VBZ	_	12	aux	_	_
12	introduced	introduce	VBN	_	8	comp	_	_
13	or	or	CC	_	12	cc	_	_
14	withdrawn	withdraw	VBN	_	12	conj	_	_
15	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	6	case	_	_
4	an	an	DT	_	6	det	_	_
5	interaction	interaction	NN	_	6	com	_	_
6	study	study	NN	_	17	ppmod	_	_
7	of	of	IN	_	10	case	_	_
8	rheumatoid	rheumatoid	JJ	_	10	attr	_	_
9	arthritis	arthritis	NN	_	10	com	_	_
10	patients	patient	NNS	_	6	ppmod	_	_
11	taking	take	VBG	_	10	acl	_	_
12	drug2	drug0	NN	_	11	obj	_	_
13	,	,	,	_	17	p	_	_
14	drug3	drug0	NN	_	17	dep	_	_
15	did	do	VBD	_	17	aux	_	_
16	not	not	RB	_	17	neg	_	_
17	have	have	VB	_	1	acl	_	_
18	a	a	DT	_	20	det	_	_
19	significant	significant	JJ	_	20	attr	_	_
20	effect	effect	NN	_	17	obj	_	_
21	on	on	IN	_	23	case	_	_
22	the	the	DT	_	23	det	_	_
23	pharmacokinetics	pharmacokinetics	NNS	_	17	ppmod	_	_
24	of	of	IN	_	25	case	_	_
25	drug4	drug0	NN	_	23	ppmod	_	_
26	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	effect	effect	NN	_	14	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	on	on	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	anti-coagulant	anti-coagulant	JJ	_	10	attr	_	_
10	effect	effect	NN	_	4	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	was	be	VBD	_	14	aux	_	_
14	studied	study	VBN	_	1	acl	_	_
15	in	in	IN	_	17	case	_	_
16	a	a	DT	_	17	det	_	_
17	group	group	NN	_	14	ppmod	_	_
18	of	of	IN	_	20	case	_	_
19	healthy	healthy	JJ	_	20	attr	_	_
20	subjects	subject	NNS	_	17	ppmod	_	_
21	receiving	receive	VBG	_	20	acl	_	_
22	daily	daily	JJ	_	23	attr	_	_
23	doses	dose	NNS	_	21	obj	_	_
24	of	of	IN	_	26	case	_	_
25	2-5	0	CD	_	26	num	_	_
26	mg	mg	NN	_	23	ppmod	_	_
27	of	of	IN	_	28	case	_	_
28	drug4	drug0	NN	_	26	ppmod	_	_
29	.	.	.	_	1	p	_	_

1	In	in	IN	_	3	case	_	_
2	these	these	DT	_	3	det	_	_
3	subjects	subject	NNS	_	8	ppmod	_	_
4	,	,	,	_	8	p	_	_
5	drug1	drug0	NN	_	8	dep	_	_
6	did	do	VBD	_	8	aux	_	_
7	not	not	RB	_	8	neg	_	_
8	alter	alter	VB	_	0	root	_	_
9	the	the	DT	_	11	det	_	_
10	anticoagulant	anticoagulant	JJ	_	11	attr	_	_
11	effect	effect	NN	_	8	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	as	as	IN	_	15	mark	_	_
15	determined	determine	VBN	_	8	comp	_	_
16	by	by	IN	_	18	case	_	_
17	prothrombin	prothrombin	NN	_	18	com	_	_
18	time	time	NN	_	15	ppmod	_	_
19	.	.	.	_	8	p	_	_

1	However	however	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	caution	caution	NN	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	used	use	VBN	_	0	root	_	_
7	when	when	WRB	_	8	adv	_	_
8	administering	administer	VBG	_	6	comp	_	_
9	drug1	drug0	NN	_	8	obj	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NN	_	8	ppmod	_	_
12	since	since	IN	_	15	mark	_	_
13	these	these	DT	_	14	det	_	_
14	patients	patient	NNS	_	15	dep	_	_
15	are	be	VBP	_	8	comp	_	_
16	at	at	IN	_	18	case	_	_
17	increased	increase	VBN	_	18	attr	_	_
18	risk	risk	NN	_	15	ppmod	_	_
19	of	of	IN	_	21	case	_	_
20	bleeding	bleeding	JJ	_	21	attr	_	_
21	complications	complication	NNS	_	18	ppmod	_	_
22	.	.	.	_	6	p	_	_

1	May	may	MD	_	2	modal	_	_
2	interact	interact	VB	_	0	root	_	_
3	with	with	IN	_	5	case	_	_
4	other	other	JJ	_	5	attr	_	_
5	creams	cream	NNS	_	2	ppmod	_	_
6	,	,	,	_	5	p	_	_
7	lotions	lotion	NNS	_	5	conj	_	_
8	,	,	,	_	7	p	_	_
9	or	or	CC	_	7	cc	_	_
10	skin	skin	NN	_	11	com	_	_
11	medicines	medicine	NNS	_	5	conj	_	_
12	when	when	WRB	_	13	adv	_	_
13	placed	place	VBN	_	2	comp	_	_
14	on	on	IN	_	17	case	_	_
15	the	the	DT	_	17	det	_	_
16	same	same	JJ	_	17	attr	_	_
17	areas	area	NNS	_	13	ppmod	_	_
18	of	of	IN	_	20	case	_	_
19	your	your	NN	_	20	com	_	_
20	skin	skin	NN	_	17	ppmod	_	_
21	that	that	WDT	_	24	dep	_	_
22	you	you	RB	_	24	adv	_	_
23	are	be	VBP	_	24	aux	_	_
24	using	use	VBG	_	20	relcl	_	_
25	drug1	drug0	NN	_	24	obj	_	_
26	.	.	.	_	2	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	studies	study	NNS	_	5	dep	_	_
4	have	have	VBP	_	5	aux	_	_
5	shown	show	VBN	_	0	root	_	_
6	that	that	IN	_	17	mark	_	_
7	,	,	,	_	17	p	_	_
8	because	because	IN	_	11	case	_	_
9	of	of	IN	_	11	case	_	_
10	its	its	PRP$	_	11	poss	_	_
11	affinity	affinity	NN	_	17	ppmod	_	_
12	for	for	IN	_	13	case	_	_
13	protein	protein	NN	_	11	ppmod	_	_
14	,	,	,	_	17	p	_	_
15	drug1	drug0	NN	_	17	dep	_	_
16	may	may	MD	_	17	modal	_	_
17	displace	displace	VB	_	5	comp	_	_
18	other	other	JJ	_	20	attr	_	_
19	protein-bound	protein-bound	JJ	_	20	attr	_	_
20	drugs	drug	NNS	_	17	obj	_	_
21	from	from	IN	_	24	case	_	_
22	their	their	PRP$	_	24	poss	_	_
23	binding	bind	VBG	_	24	attr	_	_
24	site	site	NN	_	17	ppmod	_	_
25	.	.	.	_	5	p	_	_

1	Caution	caution	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	exercised	exercise	VBN	_	0	root	_	_
5	when	when	WRB	_	6	adv	_	_
6	administering	administer	VBG	_	4	comp	_	_
7	drug1	drug0	NN	_	6	obj	_	_
8	with	with	IN	_	9	case	_	_
9	drug2	drug0	NN	_	6	ppmod	_	_
10	since	since	IN	_	14	mark	_	_
11	interactions	interaction	NNS	_	14	dep	_	_
12	have	have	VBP	_	14	aux	_	_
13	been	be	VBN	_	14	aux	_	_
14	seen	see	VBN	_	6	comp	_	_
15	with	with	IN	_	17	case	_	_
16	other	other	JJ	_	17	attr	_	_
17	drug3	drug0	NN	_	14	ppmod	_	_
18	.	.	.	_	4	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	administration	administration	NN	_	8	dep	_	_
3	of	of	IN	_	7	case	_	_
4	an	an	DT	_	7	det	_	_
5	drug1	drug0	NN	_	6	advnp	_	_
6	-containing	-containing	JJ	_	7	attr	_	_
7	drug2	drug0	NN	_	2	ppmod	_	_
8	had	have	VBD	_	0	root	_	_
9	no	no	DT	_	11	det	_	_
10	significant	significant	JJ	_	11	attr	_	_
11	effect	effect	NN	_	8	obj	_	_
12	in	in	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	bioavailability	bioavailability	NN	_	8	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug3	drug0	NN	_	14	ppmod	_	_
17	.	.	.	_	8	p	_	_

1	When	when	WRB	_	2	adv	_	_
2	administered	administer	VBN	_	9	advcl	_	_
3	with	with	IN	_	4	case	_	_
4	food	food	NN	_	2	ppmod	_	_
5	or	or	CC	_	4	cc	_	_
6	milk	milk	NN	_	4	conj	_	_
7	,	,	,	_	9	p	_	_
8	there	there	EX	_	9	dep	_	_
9	is	be	VBZ	_	0	root	_	_
10	more	more	RBR	_	11	adv	_	_
11	rapid	rapid	JJ	_	12	attr	_	_
12	absorption	absorption	NN	_	9	obj	_	_
13	;	;	:	_	9	p	_	_

1	however	however	RB	_	11	adv	_	_
2	,	,	,	_	11	p	_	_
3	the	the	DT	_	5	det	_	_
4	total	total	JJ	_	5	attr	_	_
5	amount	amount	NN	_	11	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	in	in	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	plasma	plasma	NN	_	5	ppmod	_	_
11	is	be	VBZ	_	0	root	_	_
12	unchanged	unchanged	JJ	_	11	dep	_	_
13	.	.	.	_	11	p	_	_

1	Hypotension	hypotension	NN	_	2	com	_	_
2	Patients	patient	NNS	_	35	dep	_	_
3	on	on	IN	_	5	case	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	Therapy	therapy	NN	_	2	ppmod	_	_
6	:	:	:	_	2	p	_	_
7	Patients	patient	NNS	_	2	appo	_	_
8	on	on	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	and	and	CC	_	2	cc	_	_
11	especially	especially	RB	_	12	adv	_	_
12	those	those	DT	_	2	conj	_	_
13	in	in	IN	_	14	case	_	_
14	whom	whom	WP	_	19	ppmod	_	_
15	drug3	drug0	NN	_	16	com	_	_
16	therapy	therapy	NN	_	19	dep	_	_
17	was	be	VBD	_	19	aux	_	_
18	recently	recently	RB	_	19	adv	_	_
19	instituted	institute	VBN	_	12	relcl	_	_
20	,	,	,	_	12	p	_	_
21	as	as	RB	_	22	com	_	_
22	well	well	RB	_	12	cc	_	_
23	as	as	IN	_	22	com	_	_
24	those	those	DT	_	2	conj	_	_
25	on	on	IN	_	29	case	_	_
26	severe	severe	JJ	_	29	attr	_	_
27	dietary	dietary	JJ	_	29	attr	_	_
28	salt	salt	NN	_	29	com	_	_
29	restriction	restriction	NN	_	24	ppmod	_	_
30	or	or	CC	_	29	cc	_	_
31	dialysis	dialysis	NN	_	29	conj	_	_
32	,	,	,	_	24	p	_	_
33	may	may	MD	_	35	modal	_	_
34	occasionally	occasionally	RB	_	35	adv	_	_
35	experience	experience	VBP	_	0	root	_	_
36	a	a	DT	_	38	det	_	_
37	precipitous	precipitous	JJ	_	38	attr	_	_
38	reduction	reduction	NN	_	35	obj	_	_
39	of	of	IN	_	41	case	_	_
40	blood	blood	NN	_	41	com	_	_
41	pressure	pressure	NN	_	38	ppmod	_	_
42	usually	usually	RB	_	35	adv	_	_
43	within	within	IN	_	46	case	_	_
44	the	the	DT	_	46	det	_	_
45	first	#ord#	JJ	_	46	attr	_	_
46	hour	hour	NN	_	35	ppmod	_	_
47	after	after	IN	_	48	case	_	_
48	receiving	receive	VBG	_	46	ppmod	_	_
49	the	the	DT	_	51	det	_	_
50	initial	initial	JJ	_	51	attr	_	_
51	dose	dose	NN	_	48	obj	_	_
52	of	of	IN	_	53	case	_	_
53	drug4	drug0	NN	_	51	ppmod	_	_
54	.	.	.	_	35	p	_	_

1	The	the	DT	_	2	det	_	_
2	possibility	possibility	NN	_	10	dep	_	_
3	of	of	IN	_	5	case	_	_
4	hypotensive	hypotensive	JJ	_	5	attr	_	_
5	effects	effect	NNS	_	2	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	can	can	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	minimized	minimize	VBN	_	0	root	_	_
11	by	by	IN	_	13	case	_	_
12	either	either	CC	_	13	cc	_	_
13	discontinuing	discontinue	VBG	_	10	ppmod	_	_
14	the	the	DT	_	15	det	_	_
15	drug2	drug0	NN	_	13	obj	_	_
16	or	or	CC	_	13	cc	_	_
17	increasing	increase	VBG	_	13	conj	_	_
18	the	the	DT	_	20	det	_	_
19	salt	salt	NN	_	20	com	_	_
20	intake	intake	NN	_	17	obj	_	_
21	approximately	approximately	RB	_	22	adv	_	_
22	one	#crd#	CD	_	23	num	_	_
23	week	week	NN	_	17	obj	13:obj	_
24	prior	prior	JJ	_	23	attr	_	_
25	to	to	TO	_	26	aux	_	_
26	initiation	initiation	NN	_	24	ppmod	_	_
27	of	of	IN	_	28	case	_	_
28	treatment	treatment	NN	_	26	ppmod	_	_
29	with	with	IN	_	30	case	_	_
30	drug3	drug0	NN	_	28	ppmod	_	_
31	(	-lrb-	-LRB-	_	35	p	_	_
32	drug4	drug0	NN	_	33	com	_	_
33	tablets	tablet	NNS	_	35	dep	_	_
34	,	,	,	_	35	p	_	_
35	USP	usp	NN	_	30	prn	_	_
36	)	-rrb-	-RRB-	_	35	p	_	_
37	or	or	CC	_	13	cc	_	_
38	initiating	initiate	VBG	_	13	conj	_	_
39	therapy	therapy	NN	_	38	obj	_	_
40	with	with	IN	_	42	case	_	_
41	small	small	JJ	_	42	attr	_	_
42	doses	dose	NNS	_	39	ppmod	_	_
43	(	-lrb-	-LRB-	_	47	p	_	_
44	6.25	0	CD	_	47	num	_	_
45	or	or	CC	_	44	cc	_	_
46	12.5	0	CD	_	44	conj	_	_
47	mg	mg	NN	_	42	prn	_	_
48	)	-rrb-	-RRB-	_	47	p	_	_
49	.	.	.	_	10	p	_	_

1	Alternatively	alternatively	RB	_	3	adv	_	_
2	,	,	,	_	3	p	_	_
3	provide	provide	VBP	_	0	root	_	_
4	medical	medical	JJ	_	5	attr	_	_
5	supervision	supervision	NN	_	3	obj	_	_
6	for	for	IN	_	10	case	_	_
7	at	at	IN	_	9	case	_	_
8	least	least	JJS	_	9	attr	_	_
9	one	#crd#	CD	_	10	num	_	_
10	hour	hour	NN	_	5	ppmod	_	_
11	after	after	IN	_	14	case	_	_
12	the	the	DT	_	14	det	_	_
13	initial	initial	JJ	_	14	attr	_	_
14	dose	dose	NN	_	5	ppmod	_	_
15	.	.	.	_	3	p	_	_

1	If	if	IN	_	3	mark	_	_
2	hypotension	hypotension	NN	_	3	dep	_	_
3	occurs	occur	VBZ	_	9	advcl	_	_
4	,	,	,	_	9	p	_	_
5	the	the	DT	_	6	det	_	_
6	patient	patient	NN	_	9	dep	_	_
7	should	should	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	placed	place	VBN	_	0	root	_	_
10	in	in	IN	_	13	case	_	_
11	a	a	DT	_	13	det	_	_
12	supine	supine	JJ	_	13	attr	_	_
13	position	position	NN	_	9	ppmod	_	_
14	and	and	CC	_	9	cc	_	_
15	,	,	,	_	9	p	_	_
16	if	if	IN	_	17	mark	_	_
17	necessary	necessary	JJ	_	9	comp	_	_
18	,	,	,	_	9	p	_	_
19	receive	receive	VBP	_	9	conj	_	_
20	an	an	DT	_	22	det	_	_
21	intravenous	intravenous	JJ	_	22	attr	_	_
22	infusion	infusion	NN	_	19	obj	_	_
23	of	of	IN	_	25	case	_	_
24	normal	normal	JJ	_	25	attr	_	_
25	saline	saline	NN	_	22	ppmod	_	_
26	.	.	.	_	9	p	_	_

1	This	this	DT	_	4	det	_	_
2	transient	transient	JJ	_	4	attr	_	_
3	hypotensive	hypotensive	JJ	_	4	attr	_	_
4	response	response	NN	_	5	dep	_	_
5	is	be	VBZ	_	0	root	_	_
6	not	not	RB	_	5	neg	_	_
7	a	a	DT	_	8	det	_	_
8	contraindication	contraindication	NN	_	5	obj	_	_
9	to	to	TO	_	11	aux	_	_
10	further	far	JJ	_	11	attr	_	_
11	doses	dose	NNS	_	8	ppmod	_	_
12	which	which	WDT	_	15	dep	_	_
13	can	can	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	given	give	VBN	_	11	relcl	_	_
16	without	without	IN	_	17	case	_	_
17	difficulty	difficulty	NN	_	15	ppmod	_	_
18	once	once	IN	_	23	mark	_	_
19	the	the	DT	_	21	det	_	_
20	blood	blood	NN	_	21	com	_	_
21	pressure	pressure	NN	_	23	dep	_	_
22	has	have	VBZ	_	23	aux	_	_
23	increased	increase	VBN	_	15	comp	_	_
24	after	after	IN	_	26	case	_	_
25	volume	volume	NN	_	26	com	_	_
26	expansion	expansion	NN	_	23	ppmod	_	_
27	.	.	.	_	5	p	_	_

1	Agents	agent	NNS	_	0	root	_	_
2	Having	have	VBG	_	4	lv	_	_
3	Vasodilator	vasodilator	NN	_	4	com	_	_
4	Activity	activity	NN	_	1	acl	_	_
5	:	:	:	_	1	p	_	_
6	Data	datum	NNS	_	23	dep	_	_
7	on	on	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	effect	effect	NN	_	6	ppmod	_	_
10	of	of	IN	_	12	case	_	_
11	concomitant	concomitant	JJ	_	12	attr	_	_
12	use	use	NN	_	9	ppmod	_	_
13	of	of	IN	_	15	case	_	_
14	other	other	JJ	_	15	attr	_	_
15	drug1	drug0	NN	_	12	ppmod	_	_
16	in	in	IN	_	17	case	_	_
17	patients	patient	NNS	_	12	ppmod	_	_
18	receiving	receive	VBG	_	17	acl	_	_
19	drug2	drug0	NN	_	18	obj	_	_
20	for	for	IN	_	22	case	_	_
21	heart	heart	NN	_	22	com	_	_
22	failure	failure	NN	_	18	ppmod	_	_
23	are	be	VBP	_	1	acl	_	_
24	not	not	RB	_	23	neg	_	_
25	available	available	JJ	_	23	dep	_	_
26	;	;	:	_	1	p	_	_

1	therefore	therefore	RB	_	27	adv	_	_
2	,	,	,	_	27	p	_	_
3	drug1	drug0	JJ	_	6	attr	_	_
4	or	or	CC	_	3	cc	_	_
5	other	other	JJ	_	3	conj	_	_
6	drug2	drug0	NNS	_	27	dep	_	_
7	(	-lrb-	-LRB-	_	9	p	_	_
8	as	as	RB	_	9	adv	_	_
9	used	use	VBN	_	6	prn	_	_
10	for	for	IN	_	11	case	_	_
11	management	management	NN	_	9	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	angina	angina	NN	_	11	ppmod	_	_
14	)	-rrb-	-RRB-	_	9	p	_	_
15	or	or	CC	_	6	cc	_	_
16	other	other	JJ	_	17	attr	_	_
17	drugs	drug	NNS	_	6	conj	_	_
18	having	have	VBG	_	20	lv	_	_
19	vasodilator	vasodilator	NN	_	20	com	_	_
20	activity	activity	NN	_	17	acl	_	_
21	should	should	MD	_	27	modal	_	_
22	,	,	,	_	27	p	_	_
23	if	if	IN	_	24	case	_	_
24	possible	possible	JJ	_	27	ppmod	_	_
25	,	,	,	_	27	p	_	_
26	be	be	VB	_	27	aux	_	_
27	discontinued	discontinue	VBN	_	0	root	_	_
28	before	before	IN	_	29	case	_	_
29	starting	start	VBG	_	27	ppmod	_	_
30	drug3	drug0	NN	_	29	obj	_	_
31	.	.	.	_	27	p	_	_

1	If	if	IN	_	2	mark	_	_
2	resumed	resume	VBN	_	11	advcl	_	_
3	during	during	IN	_	5	case	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	therapy	therapy	NN	_	2	ppmod	_	_
6	,	,	,	_	11	p	_	_
7	such	such	JJ	_	8	attr	_	_
8	agents	agent	NNS	_	11	dep	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	administered	administer	VBN	_	0	root	_	_
12	cautiously	cautiously	RB	_	11	adv	_	_
13	,	,	,	_	12	p	_	_
14	and	and	CC	_	12	cc	_	_
15	perhaps	perhaps	RB	_	12	conj	_	_
16	at	at	IN	_	18	case	_	_
17	lower	low	JJR	_	18	attr	_	_
18	dosage	dosage	NN	_	11	ppmod	_	_
19	.	.	.	_	11	p	_	_

1	Agents	agent	NNS	_	10	dep	_	_
2	Causing	cause	VBG	_	1	acl	_	_
3	Renin	renin	NN	_	4	com	_	_
4	Release	release	NN	_	2	obj	_	_
5	drug1	drug0	NN	_	7	attr	_	_
6	's	's	POS	_	7	case	_	_
7	effect	effect	NN	_	4	appo	_	_
8	will	will	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	augmented	augment	VBN	_	0	root	_	_
11	by	by	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	that	that	WDT	_	14	dep	_	_
14	cause	cause	VBP	_	12	relcl	_	_
15	renin	renin	NN	_	16	com	_	_
16	release	release	NN	_	14	obj	_	_
17	.	.	.	_	10	p	_	_

1	For	for	IN	_	2	case	_	_
2	example	example	NN	_	11	ppmod	_	_
3	,	,	,	_	11	p	_	_
4	drug1	drug0	NN	_	11	dep	_	_
5	(	-lrb-	-LRB-	_	8	p	_	_
6	e.g.	e.g.	FW	_	8	adv	_	_
7	,	,	,	_	8	p	_	_
8	drug2	drug0	NN	_	4	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	may	may	MD	_	11	modal	_	_
11	activate	activate	VB	_	0	root	_	_
12	the	the	DT	_	14	det	_	_
13	renin-angiotensin-aldosterone	renin-angiotensin-aldosterone	JJ	_	14	attr	_	_
14	system	system	NN	_	11	obj	_	_
15	.	.	.	_	11	p	_	_

1	Agents	agent	NNS	_	10	dep	_	_
2	Affecting	affect	VBG	_	1	acl	_	_
3	Sympathetic	sympathetic	JJ	_	4	attr	_	_
4	Activity	activity	NN	_	2	obj	_	_
5	The	the	DT	_	8	det	_	_
6	sympathetic	sympathetic	JJ	_	8	attr	_	_
7	nervous	nervous	JJ	_	8	attr	_	_
8	system	system	NN	_	4	attr	_	_
9	may	may	MD	_	10	modal	_	_
10	be	be	VB	_	0	root	_	_
11	especially	especially	RB	_	12	adv	_	_
12	important	important	JJ	_	10	dep	_	_
13	in	in	IN	_	14	case	_	_
14	supporting	support	VBG	_	12	ppmod	_	_
15	blood	blood	NN	_	16	com	_	_
16	pressure	pressure	NN	_	14	obj	_	_
17	in	in	IN	_	18	case	_	_
18	patients	patient	NNS	_	16	ppmod	_	_
19	receiving	receive	VBG	_	18	acl	_	_
20	drug1	drug0	NN	_	19	obj	_	_
21	alone	alone	RB	_	16	adv	_	_
22	or	or	CC	_	21	cc	_	_
23	with	with	IN	_	24	case	_	_
24	drug2	drug0	NN	_	21	conj	_	_
25	.	.	.	_	10	p	_	_

1	Therefore	therefore	RB	_	16	adv	_	_
2	,	,	,	_	16	p	_	_
3	agents	agent	NNS	_	16	dep	_	_
4	affecting	affect	VBG	_	3	acl	_	_
5	sympathetic	sympathetic	JJ	_	6	attr	_	_
6	activity	activity	NN	_	4	obj	_	_
7	(	-lrb-	-LRB-	_	10	p	_	_
8	e.g.	e.g.	FW	_	10	adv	_	_
9	,	,	,	_	10	p	_	_
10	drug1	drug0	NN	_	6	prn	_	_
11	or	or	CC	_	10	cc	_	_
12	drug2	drug0	NN	_	10	conj	_	_
13	)	-rrb-	-RRB-	_	10	p	_	_
14	should	should	MD	_	16	modal	_	_
15	be	be	VB	_	16	aux	_	_
16	used	use	VBN	_	0	root	_	_
17	with	with	IN	_	18	case	_	_
18	caution	caution	NN	_	16	ppmod	_	_
19	.	.	.	_	16	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	add	add	VBP	_	0	root	_	_
3	some	some	DT	_	6	det	_	_
4	further	far	JJ	_	6	attr	_	_
5	antihypertensive	antihypertensive	JJ	_	6	attr	_	_
6	effect	effect	NN	_	2	obj	_	_
7	to	to	TO	_	8	aux	_	_
8	drug2	drug0	NN	_	2	ppmod	_	_
9	,	,	,	_	2	p	_	_
10	but	but	CC	_	2	cc	_	_
11	the	the	DT	_	13	det	_	_
12	overall	overall	JJ	_	13	attr	_	_
13	response	response	NN	_	14	dep	_	_
14	is	be	VBZ	_	2	conj	_	_
15	less	less	JJR	_	14	dep	_	_
16	than	than	IN	_	17	case	_	_
17	additive	additive	JJ	_	15	ppmod	_	_
18	.	.	.	_	2	p	_	_

1	Agents	agent	NNS	_	2	dep	_	_
2	Increasing	increase	VBG	_	7	advcl	_	_
3	Serum	serum	NN	_	4	com	_	_
4	Potassium	potassium	NN	_	2	obj	_	_
5	Since	since	IN	_	6	case	_	_
6	drug1	drug0	NN	_	2	ppmod	_	_
7	decreases	decrease	VBZ	_	0	root	_	_
8	aldosterone	aldosterone	NN	_	9	com	_	_
9	production	production	NN	_	7	obj	_	_
10	,	,	,	_	7	p	_	_
11	elevation	elevation	NN	_	16	dep	_	_
12	of	of	IN	_	14	case	_	_
13	serum	serum	NN	_	14	com	_	_
14	potassium	potassium	NN	_	11	ppmod	_	_
15	may	may	MD	_	16	modal	_	_
16	occur	occur	VB	_	7	comp	_	_
17	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	16	dep	_	_
2	such	such	JJ	_	4	adv	_	_
3	as	as	IN	_	4	case	_	_
4	drug2	drug0	NN	_	1	ppmod	_	_
5	,	,	,	_	4	p	_	_
6	drug3	drug0	NN	_	4	conj	_	_
7	,	,	,	_	6	p	_	_
8	or	or	CC	_	6	cc	_	_
9	drug4	drug0	NN	_	4	conj	_	_
10	,	,	,	_	9	p	_	_
11	or	or	CC	_	9	cc	_	_
12	drug5	drug0	NN	_	13	com	_	_
13	supplements	supplement	NNS	_	4	conj	_	_
14	should	should	MD	_	16	modal	_	_
15	be	be	VB	_	16	aux	_	_
16	given	give	VBN	_	0	root	_	_
17	only	only	RB	_	16	adv	_	_
18	for	for	IN	_	20	case	_	_
19	documented	documented	JJ	_	20	attr	_	_
20	hypokalemia	hypokalemia	NN	_	16	ppmod	_	_
21	,	,	,	_	20	p	_	_
22	and	and	CC	_	20	cc	_	_
23	then	then	RB	_	25	adv	_	_
24	with	with	IN	_	25	case	_	_
25	caution	caution	NN	_	20	conj	_	_
26	,	,	,	_	16	p	_	_
27	since	since	IN	_	30	mark	_	_
28	they	they	PRP	_	30	dep	_	_
29	may	may	MD	_	30	modal	_	_
30	lead	lead	VB	_	16	comp	_	_
31	to	to	TO	_	34	aux	_	_
32	a	a	DT	_	34	det	_	_
33	significant	significant	JJ	_	34	attr	_	_
34	increase	increase	NN	_	30	ppmod	_	_
35	of	of	IN	_	37	case	_	_
36	serum	serum	NN	_	37	com	_	_
37	potassium	potassium	NN	_	34	ppmod	_	_
38	.	.	.	_	16	p	_	_

1	Salt	salt	NN	_	8	dep	_	_
2	substitutes	substitute	VBZ	_	1	attr	_	_
3	containing	contain	VBG	_	1	acl	_	_
4	drug1	drug0	NN	_	3	obj	_	_
5	should	should	MD	_	8	modal	_	_
6	also	also	RB	_	8	adv	_	_
7	be	be	VB	_	8	aux	_	_
8	used	use	VBN	_	0	root	_	_
9	with	with	IN	_	10	case	_	_
10	caution	caution	NN	_	8	ppmod	_	_
11	.	.	.	_	8	p	_	_

1	Inhibitors	inhibitor	NNS	_	9	dep	_	_
2	Of	of	IN	_	5	case	_	_
3	Endogenous	endogenous	JJ	_	5	attr	_	_
4	Prostaglandin	prostaglandin	NN	_	5	com	_	_
5	Synthesis	synthesis	NN	_	1	ppmod	_	_
6	It	it	PRP	_	1	appo	_	_
7	has	have	VBZ	_	9	aux	_	_
8	been	be	VBN	_	9	aux	_	_
9	reported	report	VBN	_	0	root	_	_
10	that	that	IN	_	13	mark	_	_
11	drug1	drug0	NN	_	13	dep	_	_
12	may	may	MD	_	13	modal	_	_
13	reduce	reduce	VB	_	9	comp	_	_
14	the	the	DT	_	16	det	_	_
15	antihypertensive	antihypertensive	JJ	_	16	attr	_	_
16	effect	effect	NN	_	13	obj	_	_
17	of	of	IN	_	18	case	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	,	,	,	_	13	p	_	_
20	especially	especially	RB	_	22	adv	_	_
21	in	in	IN	_	22	case	_	_
22	cases	case	NNS	_	13	ppmod	_	_
23	of	of	IN	_	26	case	_	_
24	low	low	JJ	_	26	attr	_	_
25	renin	renin	NN	_	26	com	_	_
26	hypertension	hypertension	NN	_	22	ppmod	_	_
27	.	.	.	_	9	p	_	_

1	Other	other	JJ	_	2	attr	_	_
2	drug1	drug0	NNS	_	10	dep	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	e.g.	e.g.	FW	_	6	ppmod	_	_
5	,	,	,	_	6	p	_	_
6	drug2	drug0	NNS	_	2	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	may	may	MD	_	10	modal	_	_
9	also	also	RB	_	10	adv	_	_
10	have	have	VB	_	0	root	_	_
11	this	this	DT	_	12	det	_	_
12	effect	effect	NN	_	10	obj	_	_
13	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Increased	increase	VBN	_	6	attr	_	_
4	serum	serum	NN	_	6	com	_	_
5	drug2	drug0	NN	_	6	com	_	_
6	levels	level	NNS	_	14	dep	_	_
7	and	and	CC	_	6	cc	_	_
8	symptoms	symptom	NNS	_	6	conj	_	_
9	of	of	IN	_	11	case	_	_
10	drug3	drug0	NN	_	11	com	_	_
11	toxicity	toxicity	NN	_	6	ppmod	_	_
12	have	have	VBP	_	14	aux	_	_
13	been	be	VBN	_	14	aux	_	_
14	reported	report	VBN	_	1	acl	_	_
15	in	in	IN	_	16	case	_	_
16	patients	patient	NNS	_	14	ppmod	_	_
17	receiving	receive	VBG	_	16	acl	_	_
18	concomitant	concomitant	JJ	_	19	attr	_	_
19	drug4	drug0	NN	_	17	obj	_	_
20	and	and	CC	_	19	cc	_	_
21	drug5	drug0	NN	_	22	com	_	_
22	therapy	therapy	NN	_	19	conj	_	_
23	.	.	.	_	1	p	_	_

1	These	these	DT	_	2	det	_	_
2	drugs	drug	NNS	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	coad-ministered	coad-ministered	VBN	_	0	root	_	_
6	with	with	IN	_	7	case	_	_
7	caution	caution	NN	_	5	ppmod	_	_
8	and	and	CC	_	5	cc	_	_
9	frequent	frequent	JJ	_	10	attr	_	_
10	monitoring	monitoring	NN	_	16	dep	_	_
11	of	of	IN	_	14	case	_	_
12	serum	serum	NN	_	14	com	_	_
13	drug1	drug0	NN	_	14	com	_	_
14	levels	level	NNS	_	10	ppmod	_	_
15	is	be	VBZ	_	16	aux	_	_
16	recommended	recommend	VBN	_	5	conj	_	_
17	.	.	.	_	5	p	_	_

1	If	if	IN	_	6	mark	_	_
2	a	a	DT	_	3	det	_	_
3	drug1	drug0	NN	_	6	dep	_	_
4	is	be	VBZ	_	6	aux	_	_
5	also	also	RB	_	6	adv	_	_
6	used	use	VBN	_	10	advcl	_	_
7	,	,	,	_	10	p	_	_
8	it	it	PRP	_	10	dep	_	_
9	may	may	MD	_	10	modal	_	_
10	increase	increase	VB	_	0	root	_	_
11	the	the	DT	_	12	det	_	_
12	risk	risk	NN	_	10	obj	_	_
13	of	of	IN	_	15	case	_	_
14	drug2	drug0	NN	_	15	com	_	_
15	toxicity	toxicity	NN	_	12	ppmod	_	_
16	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	5	case	_	_
4	a	a	DT	_	5	det	_	_
5	study	study	NN	_	23	ppmod	_	_
6	of	of	IN	_	10	case	_	_
7	young	young	JJ	_	10	attr	_	_
8	healthy	healthy	JJ	_	10	attr	_	_
9	male	male	JJ	_	10	attr	_	_
10	subjects	subject	NNS	_	5	ppmod	_	_
11	no	no	DT	_	12	det	_	_
12	evidence	evidence	NN	_	23	dep	_	_
13	of	of	IN	_	20	case	_	_
14	a	a	DT	_	20	det	_	_
15	direct	direct	JJ	_	20	attr	_	_
16	pharmacokinetic	pharmacokinetic	JJ	_	20	attr	_	_
17	drug2	drug0	NN	_	20	attr	_	_
18	-	-	:	_	20	p	_	_
19	drug3	drug0	NN	_	20	com	_	_
20	interaction	interaction	NN	_	12	ppmod	_	_
21	could	could	MD	_	23	modal	_	_
22	be	be	VB	_	23	aux	_	_
23	found	find	VBN	_	1	acl	_	_
24	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	10	dep	_	_
4	administered	administer	VBN	_	3	acl	_	_
5	concurrently	concurrently	RB	_	4	adv	_	_
6	with	with	IN	_	7	case	_	_
7	drug3	drug0	NN	_	4	ppmod	_	_
8	does	do	VBZ	_	10	aux	_	_
9	not	not	RB	_	10	neg	_	_
10	alter	alter	VB	_	1	acl	_	_
11	the	the	DT	_	12	det	_	_
12	pharmacokinetics	pharmacokinetics	NNS	_	10	obj	_	_
13	of	of	IN	_	14	case	_	_
14	drug4	drug0	NN	_	12	ppmod	_	_
15	in	in	IN	_	19	case	_	_
16	renally	renally	RB	_	17	adv	_	_
17	impaired	impaired	JJ	_	19	attr	_	_
18	hypertensive	hypertensive	NN	_	19	com	_	_
19	patients	patient	NNS	_	12	ppmod	_	_
20	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	14	dep	_	_
2	:	:	:	_	14	p	_	_
3	In	in	IN	_	5	case	_	_
4	a	a	DT	_	5	det	_	_
5	study	study	NN	_	14	ppmod	_	_
6	of	of	IN	_	9	case	_	_
7	healthy	healthy	JJ	_	9	attr	_	_
8	male	male	JJ	_	9	attr	_	_
9	volunteers	volunteer	NNS	_	5	ppmod	_	_
10	no	no	DT	_	13	det	_	_
11	significant	significant	JJ	_	13	attr	_	_
12	pharmacokinetic	pharmacokinetic	JJ	_	13	attr	_	_
13	interaction	interaction	NN	_	14	dep	_	_
14	occurred	occur	VBD	_	0	root	_	_
15	when	when	WRB	_	20	adv	_	_
16	drug2	drug0	NN	_	20	dep	_	_
17	and	and	CC	_	16	cc	_	_
18	drug3	drug0	NN	_	16	conj	_	_
19	were	be	VBD	_	20	aux	_	_
20	administered	administer	VBN	_	14	comp	_	_
21	concomitantly	concomitantly	RB	_	20	adv	_	_
22	for	for	IN	_	24	case	_	_
23	6	0	CD	_	24	num	_	_
24	days	day	NNS	_	20	ppmod	_	_
25	.	.	.	_	14	p	_	_

1	Drug/Laboratory	drug/laboratory	JJ	_	4	attr	_	_
2	Test	test	NN	_	4	com	_	_
3	Interaction	interaction	NN	_	4	com	_	_
4	drug1	drug0	NN	_	6	dep	_	_
5	may	may	MD	_	6	modal	_	_
6	cause	cause	VB	_	0	root	_	_
7	a	a	DT	_	10	det	_	_
8	false-positive	false-positive	JJ	_	10	attr	_	_
9	urine	urine	NN	_	10	com	_	_
10	test	test	NN	_	6	obj	_	_
11	for	for	IN	_	12	case	_	_
12	acetone	acetone	NN	_	10	ppmod	_	_
13	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Patients	patient	NNS	_	16	dep	_	_
4	on	on	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	,	,	,	_	3	p	_	_
7	especially	especially	RB	_	3	adv	_	_
8	those	those	DT	_	3	appo	_	_
9	with	with	IN	_	12	case	_	_
10	intravascular	intravascular	JJ	_	12	attr	_	_
11	volume	volume	NN	_	12	com	_	_
12	depletion	depletion	NN	_	8	ppmod	_	_
13	,	,	,	_	3	p	_	_
14	may	may	MD	_	16	modal	_	_
15	occasionally	occasionally	RB	_	16	adv	_	_
16	experience	experience	VBP	_	1	acl	_	_
17	an	an	DT	_	19	det	_	_
18	excessive	excessive	JJ	_	19	attr	_	_
19	reduction	reduction	NN	_	16	obj	_	_
20	of	of	IN	_	22	case	_	_
21	blood	blood	NN	_	22	com	_	_
22	pressure	pressure	NN	_	19	ppmod	_	_
23	after	after	IN	_	24	case	_	_
24	initiation	initiation	NN	_	19	ppmod	_	_
25	of	of	IN	_	26	case	_	_
26	therapy	therapy	NN	_	24	ppmod	_	_
27	with	with	IN	_	28	case	_	_
28	drug3	drug0	NN	_	24	ppmod	_	_
29	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	possibility	possibility	NN	_	8	dep	_	_
3	of	of	IN	_	5	case	_	_
4	hypotensive	hypotensive	JJ	_	5	attr	_	_
5	effects	effect	NNS	_	2	ppmod	_	_
6	can	can	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	minimized	minimize	VBN	_	0	root	_	_
9	by	by	IN	_	11	case	_	_
10	either	either	CC	_	11	cc	_	_
11	discontinuing	discontinue	VBG	_	8	ppmod	_	_
12	the	the	DT	_	13	det	_	_
13	drug1	drug0	NN	_	11	obj	_	_
14	or	or	CC	_	11	cc	_	_
15	increasing	increase	VBG	_	11	conj	_	_
16	salt	salt	NN	_	17	com	_	_
17	intake	intake	NN	_	15	obj	_	_
18	prior	prior	RB	_	17	adv	_	_
19	to	to	TO	_	20	aux	_	_
20	initiation	initiation	NN	_	18	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	treatment	treatment	NN	_	20	ppmod	_	_
23	with	with	IN	_	24	case	_	_
24	drug2	drug0	NN	_	22	ppmod	_	_
25	.	.	.	_	8	p	_	_

1	If	if	IN	_	3	mark	_	_
2	this	this	DT	_	3	dep	_	_
3	is	be	VBZ	_	12	advcl	_	_
4	not	not	RB	_	3	neg	_	_
5	possible	possible	JJ	_	3	dep	_	_
6	,	,	,	_	12	p	_	_
7	the	the	DT	_	9	det	_	_
8	starting	start	VBG	_	9	attr	_	_
9	dose	dose	NN	_	12	dep	_	_
10	should	should	MD	_	12	modal	_	_
11	be	be	VB	_	12	aux	_	_
12	reduced	reduce	VBN	_	0	root	_	_
13	and	and	CC	_	12	cc	_	_
14	the	the	DT	_	15	det	_	_
15	patient	patient	NN	_	18	dep	_	_
16	should	should	MD	_	18	modal	_	_
17	be	be	VB	_	18	aux	_	_
18	observed	observe	VBN	_	12	conj	_	_
19	closely	closely	RB	_	18	adv	_	_
20	for	for	IN	_	22	case	_	_
21	several	several	JJ	_	22	attr	_	_
22	hours	hour	NNS	_	18	ppmod	_	_
23	following	follow	VBG	_	26	adv	_	_
24	an	an	DT	_	26	det	_	_
25	initial	initial	JJ	_	26	attr	_	_
26	dose	dose	NN	_	18	ppmod	_	_
27	and	and	CC	_	18	cc	_	_
28	until	until	IN	_	32	mark	_	_
29	blood	blood	NN	_	30	com	_	_
30	pressure	pressure	NN	_	32	dep	_	_
31	has	have	VBZ	_	32	aux	_	_
32	stabilized	stabilize	VBN	_	18	conj	_	_
33	(	-lrb-	-LRB-	_	35	p	_	_
34	see	see	VB	_	35	attr	_	_
35	DOSAGE	dosage	NN	_	32	prn	_	_
36	AND	and	CC	_	35	cc	_	_
37	ADMINISTRATION	administration	NN	_	35	conj	_	_
38	.	.	.	_	35	p	_	_
39	)	-rrb-	-RRB-	_	35	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	Supplements	supplement	NNS	_	0	root	_	_
3	and	and	CC	_	2	cc	_	_
4	drug2	drug0	NNS	_	2	conj	_	_
5	:	:	:	_	2	p	_	_
6	drug3	drug0	NN	_	8	dep	_	_
7	can	can	MD	_	8	modal	_	_
8	attenuate	attenuate	VB	_	2	acl	_	_
9	potassium	potassium	NN	_	10	com	_	_
10	loss	loss	NN	_	8	obj	_	_
11	caused	cause	VBN	_	10	acl	_	_
12	by	by	IN	_	13	case	_	_
13	drug4	drug0	NN	_	11	ppmod	_	_
14	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	16	dep	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	drug2	drug0	NN	_	1	prn	_	_
4	,	,	,	_	3	p	_	_
5	drug3	drug0	NN	_	3	conj	_	_
6	,	,	,	_	5	p	_	_
7	drug4	drug0	NN	_	3	conj	_	_
8	,	,	,	_	7	p	_	_
9	and	and	CC	_	7	cc	_	_
10	others	other	NNS	_	3	conj	_	_
11	)	-rrb-	-RRB-	_	3	p	_	_
12	or	or	CC	_	1	cc	_	_
13	drug5	drug0	NN	_	14	com	_	_
14	supplements	supplement	NNS	_	1	conj	_	_
15	can	can	MD	_	16	modal	_	_
16	increase	increase	VB	_	0	root	_	_
17	the	the	DT	_	18	det	_	_
18	risk	risk	NN	_	16	obj	_	_
19	of	of	IN	_	20	case	_	_
20	hyperkalemia	hyperkalemia	NN	_	18	ppmod	_	_
21	.	.	.	_	16	p	_	_

1	Therefore	therefore	RB	_	15	adv	_	_
2	,	,	,	_	15	p	_	_
3	if	if	IN	_	10	mark	_	_
4	concomitant	concomitant	JJ	_	5	attr	_	_
5	use	use	NN	_	10	dep	_	_
6	of	of	IN	_	8	case	_	_
7	such	such	JJ	_	8	attr	_	_
8	agents	agent	NNS	_	5	ppmod	_	_
9	is	be	VBZ	_	10	aux	_	_
10	indicated	indicate	VBN	_	15	advcl	_	_
11	,	,	,	_	15	p	_	_
12	they	they	PRP	_	15	dep	_	_
13	should	should	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	given	give	VBN	_	0	root	_	_
16	with	with	IN	_	17	case	_	_
17	caution	caution	NN	_	15	ppmod	_	_
18	,	,	,	_	15	p	_	_
19	and	and	CC	_	15	cc	_	_
20	the	the	DT	_	23	det	_	_
21	patients	patient	NNS	_	23	com	_	_
22	serum	serum	NN	_	23	com	_	_
23	potassium	potassium	NN	_	26	dep	_	_
24	should	should	MD	_	26	modal	_	_
25	be	be	VB	_	26	aux	_	_
26	monitored	monitor	VBN	_	15	conj	_	_
27	frequently	frequently	RB	_	26	adv	_	_
28	.	.	.	_	15	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Increased	increase	VBN	_	6	attr	_	_
4	serum	serum	NN	_	6	com	_	_
5	drug2	drug0	NN	_	6	com	_	_
6	levels	level	NNS	_	14	dep	_	_
7	and	and	CC	_	6	cc	_	_
8	symptoms	symptom	NNS	_	6	conj	_	_
9	of	of	IN	_	11	case	_	_
10	drug3	drug0	NN	_	11	com	_	_
11	toxicity	toxicity	NN	_	6	ppmod	_	_
12	have	have	VBP	_	14	aux	_	_
13	been	be	VBN	_	14	aux	_	_
14	reported	report	VBN	_	1	acl	_	_
15	in	in	IN	_	16	case	_	_
16	patients	patient	NNS	_	14	ppmod	_	_
17	receiving	receive	VBG	_	16	acl	_	_
18	drug4	drug0	NN	_	17	obj	_	_
19	during	during	IN	_	20	case	_	_
20	therapy	therapy	NN	_	17	ppmod	_	_
21	with	with	IN	_	22	case	_	_
22	drug5	drug0	NN	_	20	ppmod	_	_
23	.	.	.	_	1	p	_	_

1	These	these	DT	_	2	det	_	_
2	drugs	drug	NNS	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	coadministered	coadministered	VBN	_	0	root	_	_
6	with	with	IN	_	7	case	_	_
7	caution	caution	NN	_	5	ppmod	_	_
8	,	,	,	_	5	p	_	_
9	and	and	CC	_	5	cc	_	_
10	frequent	frequent	JJ	_	11	attr	_	_
11	monitoring	monitoring	NN	_	17	dep	_	_
12	of	of	IN	_	15	case	_	_
13	serum	serum	NN	_	15	com	_	_
14	drug1	drug0	NN	_	15	com	_	_
15	levels	level	NNS	_	11	ppmod	_	_
16	is	be	VBZ	_	17	aux	_	_
17	recommended	recommend	VBN	_	5	conj	_	_
18	.	.	.	_	5	p	_	_

1	If	if	IN	_	6	mark	_	_
2	a	a	DT	_	3	det	_	_
3	drug1	drug0	NN	_	6	dep	_	_
4	is	be	VBZ	_	6	aux	_	_
5	also	also	RB	_	6	adv	_	_
6	used	use	VBN	_	15	advcl	_	_
7	,	,	,	_	15	p	_	_
8	the	the	DT	_	9	det	_	_
9	risk	risk	NN	_	15	dep	_	_
10	of	of	IN	_	12	case	_	_
11	lithium	lithium	NN	_	12	com	_	_
12	toxicity	toxicity	NN	_	9	ppmod	_	_
13	may	may	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	increased	increase	VBN	_	0	root	_	_
16	.	.	.	_	15	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	7	case	_	_
4	a	a	DT	_	7	det	_	_
5	clinical	clinical	JJ	_	7	attr	_	_
6	pharmacology	pharmacology	NN	_	7	com	_	_
7	study	study	NN	_	23	ppmod	_	_
8	,	,	,	_	23	p	_	_
9	coadministration	coadministration	NN	_	23	dep	_	_
10	of	of	IN	_	12	case	_	_
11	an	an	DT	_	12	det	_	_
12	drug2	drug0	NN	_	9	ppmod	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	drug3	drug0	NN	_	12	prn	_	_
15	,	,	,	_	14	p	_	_
16	drug4	drug0	NN	_	14	conj	_	_
17	,	,	,	_	16	p	_	_
18	and	and	CC	_	16	cc	_	_
19	drug5	drug0	NN	_	14	conj	_	_
20	)	-rrb-	-RRB-	_	14	p	_	_
21	with	with	IN	_	22	case	_	_
22	drug6	drug0	NN	_	9	ppmod	_	_
23	reduced	reduce	VBD	_	1	acl	_	_
24	serum	serum	NN	_	25	com	_	_
25	levels	level	NNS	_	23	obj	_	_
26	and	and	CC	_	25	cc	_	_
27	urinary	urinary	JJ	_	28	attr	_	_
28	excretion	excretion	NN	_	25	conj	_	_
29	of	of	IN	_	30	case	_	_
30	drug7	drug0	NN	_	28	ppmod	_	_
31	as	as	IN	_	32	mark	_	_
32	compared	compare	VBN	_	23	comp	_	_
33	with	with	IN	_	34	case	_	_
34	drug8	drug0	NN	_	32	ppmod	_	_
35	administered	administer	VBN	_	34	acl	_	_
36	alone	alone	RB	_	35	adv	_	_
37	,	,	,	_	23	p	_	_
38	suggesting	suggest	VBG	_	23	comp	_	_
39	that	that	IN	_	42	mark	_	_
40	drug9	drug0	NN	_	42	dep	_	_
41	may	may	MD	_	42	modal	_	_
42	impair	impair	VB	_	38	comp	_	_
43	absorption	absorption	NN	_	42	obj	_	_
44	of	of	IN	_	45	case	_	_
45	drug10	drug0	NN	_	43	ppmod	_	_
46	.	.	.	_	1	p	_	_

1	Therefore	therefore	RB	_	15	adv	_	_
2	,	,	,	_	15	p	_	_
3	if	if	IN	_	10	mark	_	_
4	concomitant	concomitant	JJ	_	5	attr	_	_
5	administration	administration	NN	_	10	dep	_	_
6	of	of	IN	_	8	case	_	_
7	these	these	DT	_	8	det	_	_
8	agents	agent	NNS	_	5	ppmod	_	_
9	is	be	VBZ	_	10	aux	_	_
10	indicated	indicate	VBN	_	15	advcl	_	_
11	,	,	,	_	15	p	_	_
12	dosing	dosing	NN	_	15	dep	_	_
13	should	should	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	separated	separate	VBN	_	0	root	_	_
16	by	by	IN	_	18	case	_	_
17	2	0	CD	_	18	num	_	_
18	hours	hour	NNS	_	15	ppmod	_	_
19	.	.	.	_	15	p	_	_

1	Other	other	JJ	_	4	attr	_	_
2	:	:	:	_	4	p	_	_
3	Neither	neither	CC	_	4	cc	_	_
4	drug1	drug0	NN	_	10	dep	_	_
5	nor	nor	CC	_	4	cc	_	_
6	its	its	PRP$	_	7	poss	_	_
7	metabolites	metabolite	NNS	_	4	conj	_	_
8	have	have	VBP	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	found	find	VBN	_	0	root	_	_
11	to	to	TO	_	12	aux	_	_
12	interact	interact	VB	_	10	comp	_	_
13	with	with	IN	_	14	case	_	_
14	food	food	NN	_	12	ppmod	_	_
15	.	.	.	_	10	p	_	_

1	In	in	IN	_	9	case	_	_
2	separate	separate	JJ	_	9	attr	_	_
3	single	single	JJ	_	9	attr	_	_
4	or	or	CC	_	3	cc	_	_
5	multiple	multiple	JJ	_	3	conj	_	_
6	dose	dose	NN	_	9	attr	_	_
7	pharmacokinetic	pharmacokinetic	JJ	_	9	attr	_	_
8	interaction	interaction	NN	_	9	com	_	_
9	studies	study	NNS	_	36	ppmod	_	_
10	with	with	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	,	,	,	_	11	p	_	_
13	drug2	drug0	NN	_	11	conj	_	_
14	,	,	,	_	13	p	_	_
15	drug3	drug0	NN	_	11	conj	_	_
16	,	,	,	_	15	p	_	_
17	drug4	drug0	NN	_	11	conj	_	_
18	,	,	,	_	17	p	_	_
19	drug5	drug0	NN	_	11	conj	_	_
20	,	,	,	_	19	p	_	_
21	drug6	drug0	NN	_	11	conj	_	_
22	,	,	,	_	21	p	_	_
23	drug7	drug0	NN	_	11	conj	_	_
24	,	,	,	_	23	p	_	_
25	drug8	drug0	NN	_	11	conj	_	_
26	,	,	,	_	25	p	_	_
27	and	and	CC	_	25	cc	_	_
28	drug9	drug0	NN	_	11	conj	_	_
29	,	,	,	_	36	p	_	_
30	the	the	DT	_	31	det	_	_
31	bioavailability	bioavailability	NN	_	36	dep	_	_
32	of	of	IN	_	33	case	_	_
33	drug10	drug0	NN	_	31	ppmod	_	_
34	was	be	VBD	_	36	aux	_	_
35	not	not	RB	_	36	neg	_	_
36	altered	alter	VBN	_	0	root	_	_
37	by	by	IN	_	38	case	_	_
38	coadministration	coadministration	NN	_	36	ppmod	_	_
39	of	of	IN	_	40	case	_	_
40	drug11	drug0	NN	_	38	ppmod	_	_
41	with	with	IN	_	43	case	_	_
42	any	any	DT	_	43	det	_	_
43	one	#crd#	CD	_	38	ppmod	_	_
44	of	of	IN	_	46	case	_	_
45	these	these	DT	_	46	det	_	_
46	drugs	drug	NNS	_	43	ppmod	_	_
47	.	.	.	_	36	p	_	_

1	In	in	IN	_	3	case	_	_
2	a	a	DT	_	3	det	_	_
3	study	study	NN	_	19	ppmod	_	_
4	with	with	IN	_	6	case	_	_
5	concomitant	concomitant	JJ	_	6	attr	_	_
6	administration	administration	NN	_	3	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	drug2	drug0	NN	_	8	conj	_	_
11	,	,	,	_	19	p	_	_
12	the	the	DT	_	13	det	_	_
13	bioavailability	bioavailability	NN	_	19	dep	_	_
14	of	of	IN	_	16	case	_	_
15	unbound	unbound	JJ	_	16	attr	_	_
16	drug3	drug0	NN	_	13	ppmod	_	_
17	was	be	VBD	_	19	aux	_	_
18	not	not	RB	_	19	neg	_	_
19	altered	alter	VBN	_	0	root	_	_
20	.	.	.	_	19	p	_	_

1	In	in	IN	_	5	case	_	_
2	a	a	DT	_	5	det	_	_
3	pharmacokinetic	pharmacokinetic	JJ	_	5	attr	_	_
4	interaction	interaction	NN	_	5	com	_	_
5	study	study	NN	_	33	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	,	,	,	_	33	p	_	_
9	bioavailability	bioavailability	NN	_	10	com	_	_
10	parameters	parameter	NNS	_	33	dep	_	_
11	,	,	,	_	10	p	_	_
12	the	the	DT	_	13	det	_	_
13	degree	degree	NN	_	10	conj	_	_
14	of	of	IN	_	16	case	_	_
15	protein	protein	NN	_	16	com	_	_
16	binding	binding	NN	_	13	ppmod	_	_
17	,	,	,	_	13	p	_	_
18	and	and	CC	_	13	cc	_	_
19	the	the	DT	_	21	det	_	_
20	anticoagulant	anticoagulant	JJ	_	21	attr	_	_
21	effect	effect	NN	_	10	conj	_	_
22	(	-lrb-	-LRB-	_	23	p	_	_
23	measured	measure	VBN	_	21	prn	_	_
24	by	by	IN	_	26	case	_	_
25	prothrombin	prothrombin	NN	_	26	com	_	_
26	time	time	NN	_	23	ppmod	_	_
27	)	-rrb-	-RRB-	_	23	p	_	_
28	of	of	IN	_	29	case	_	_
29	drug2	drug0	NN	_	21	ppmod	_	_
30	were	be	VBD	_	33	aux	_	_
31	not	not	RB	_	33	neg	_	_
32	significantly	significantly	RB	_	33	adv	_	_
33	changed	change	VBN	_	0	root	_	_
34	.	.	.	_	33	p	_	_

1	Drug/Laboratory	drug/laboratory	JJ	_	4	attr	_	_
2	Test	test	NN	_	4	com	_	_
3	Interaction	interaction	NN	_	4	com	_	_
4	drug1	drug0	NN	_	6	dep	_	_
5	may	may	MD	_	6	modal	_	_
6	cause	cause	VB	_	0	root	_	_
7	a	a	DT	_	10	det	_	_
8	false	false	JJ	_	10	attr	_	_
9	low	low	JJ	_	10	attr	_	_
10	measurement	measurement	NN	_	6	obj	_	_
11	of	of	IN	_	14	case	_	_
12	serum	serum	NN	_	14	com	_	_
13	drug2	drug0	NN	_	14	com	_	_
14	levels	level	NNS	_	10	ppmod	_	_
15	with	with	IN	_	20	case	_	_
16	the	the	DT	_	20	det	_	_
17	Digi-	digi-	NN	_	20	com	_	_
18	Tab	tab	NN	_	20	com	_	_
19	RIA	ria	NN	_	20	com	_	_
20	Kit	kit	NN	_	10	ppmod	_	_
21	for	for	IN	_	22	case	_	_
22	drug3	drug0	NN	_	20	ppmod	_	_
23	.	.	.	_	6	p	_	_

1	Other	other	JJ	_	2	attr	_	_
2	kits	kit	NNS	_	13	dep	_	_
3	,	,	,	_	2	p	_	_
4	such	such	JJ	_	9	adv	_	_
5	as	as	IN	_	9	case	_	_
6	the	the	DT	_	9	det	_	_
7	Coat-A-Count	coat-a-count	JJ	_	9	attr	_	_
8	RIA	ria	NN	_	9	com	_	_
9	Kit	kit	NN	_	2	ppmod	_	_
10	,	,	,	_	2	p	_	_
11	may	may	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	used	use	VBN	_	0	root	_	_
14	.	.	.	_	13	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	7	adv	_	_
3	,	,	,	_	7	p	_	_
4	drug1	drug0	NN	_	7	dep	_	_
5	has	have	VBZ	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	shown	show	VBN	_	0	root	_	_
8	to	to	TO	_	9	aux	_	_
9	inhibit	inhibit	VB	_	7	comp	_	_
10	the	the	DT	_	11	det	_	_
11	activity	activity	NN	_	9	obj	_	_
12	of	of	IN	_	16	case	_	_
13	liver	liver	NN	_	16	com	_	_
14	cytochrome	cytochrome	NN	_	16	com	_	_
15	P-450	p-0	NN	_	16	com	_	_
16	isoenzymes	isoenzymes	NNS	_	11	ppmod	_	_
17	and	and	CC	_	7	cc	_	_
18	therefore	therefore	RB	_	21	adv	_	_
19	,	,	,	_	21	p	_	_
20	may	may	MD	_	21	modal	_	_
21	reduce	reduce	VB	_	7	conj	_	_
22	the	the	DT	_	23	det	_	_
23	metabolism	metabolism	NN	_	21	obj	_	_
24	of	of	IN	_	25	case	_	_
25	compounds	compound	NNS	_	23	ppmod	_	_
26	requiring	require	VBG	_	25	acl	_	_
27	these	these	DT	_	28	det	_	_
28	systems	system	NNS	_	26	obj	_	_
29	.	.	.	_	7	p	_	_

1	Consequently	consequently	RB	_	23	adv	_	_
2	,	,	,	_	23	p	_	_
3	drugs	drug	NNS	_	23	dep	_	_
4	with	with	IN	_	8	case	_	_
5	a	a	DT	_	8	det	_	_
6	low	low	JJ	_	8	attr	_	_
7	therapeutic	therapeutic	JJ	_	8	attr	_	_
8	margin	margin	NN	_	3	ppmod	_	_
9	,	,	,	_	3	p	_	_
10	such	such	JJ	_	12	adv	_	_
11	as	as	IN	_	12	case	_	_
12	drug1	drug0	NN	_	3	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	drug2	drug0	NN	_	12	conj	_	_
15	,	,	,	_	14	p	_	_
16	and	and	CC	_	14	cc	_	_
17	drug3	drug0	NN	_	12	conj	_	_
18	,	,	,	_	3	p	_	_
19	could	could	MD	_	23	modal	_	_
20	have	have	VB	_	23	lv	_	_
21	a	a	DT	_	23	det	_	_
22	delayed	delay	VBN	_	23	attr	_	_
23	elimination	elimination	NN	_	0	root	_	_
24	and	and	CC	_	23	cc	_	_
25	increases	increase	NNS	_	23	conj	_	_
26	in	in	IN	_	29	case	_	_
27	their	their	PRP$	_	29	poss	_	_
28	serum	serum	NN	_	29	com	_	_
29	half-life	half-life	NN	_	23	ppmod	_	_
30	leading	lead	VBG	_	29	acl	_	_
31	to	to	TO	_	34	aux	_	_
32	a	a	DT	_	34	det	_	_
33	toxic	toxic	JJ	_	34	attr	_	_
34	level	level	NN	_	30	ppmod	_	_
35	.	.	.	_	23	p	_	_

1	The	the	DT	_	2	det	_	_
2	dosage	dosage	NN	_	13	dep	_	_
3	of	of	IN	_	5	case	_	_
4	these	these	DT	_	5	det	_	_
5	drugs	drug	NNS	_	2	ppmod	_	_
6	or	or	CC	_	5	cc	_	_
7	others	other	NNS	_	5	conj	_	_
8	with	with	IN	_	11	case	_	_
9	a	a	DT	_	11	det	_	_
10	similar	similar	JJ	_	11	attr	_	_
11	metabolism	metabolism	NN	_	5	ppmod	_	_
12	may	may	MD	_	13	modal	_	_
13	need	need	VBP	_	0	root	_	_
14	to	to	TO	_	16	aux	_	_
15	be	be	VB	_	16	aux	_	_
16	modified	modify	VBN	_	13	comp	_	_
17	if	if	IN	_	20	mark	_	_
18	they	they	PRP	_	20	dep	_	_
19	are	be	VBP	_	20	aux	_	_
20	administered	administer	VBN	_	16	comp	_	_
21	concomitantly	concomitantly	RB	_	20	adv	_	_
22	with	with	IN	_	23	case	_	_
23	drug1	drug0	NN	_	20	ppmod	_	_
24	.	.	.	_	13	p	_	_

1	For	for	IN	_	2	case	_	_
2	example	example	NN	_	17	ppmod	_	_
3	,	,	,	_	17	p	_	_
4	when	when	WRB	_	7	adv	_	_
5	drug1	drug0	NN	_	7	dep	_	_
6	are	be	VBP	_	7	aux	_	_
7	administered	administer	VBN	_	17	advcl	_	_
8	concomitantly	concomitantly	RB	_	7	adv	_	_
9	with	with	IN	_	10	case	_	_
10	drug2	drug0	NN	_	7	ppmod	_	_
11	,	,	,	_	17	p	_	_
12	prothrombin	prothrombin	NN	_	13	com	_	_
13	time	time	NN	_	17	dep	_	_
14	should	should	MD	_	17	modal	_	_
15	be	be	VB	_	17	aux	_	_
16	carefully	carefully	RB	_	17	adv	_	_
17	monitored	monitor	VBN	_	0	root	_	_
18	and	and	CC	_	17	cc	_	_
19	if	if	IN	_	20	mark	_	_
20	necessary	necessary	JJ	_	28	advcl	_	_
21	,	,	,	_	28	p	_	_
22	the	the	DT	_	23	det	_	_
23	dosage	dosage	NN	_	28	dep	_	_
24	of	of	IN	_	25	case	_	_
25	drug3	drug0	NN	_	23	ppmod	_	_
26	should	should	MD	_	28	modal	_	_
27	be	be	VB	_	28	aux	_	_
28	reduced	reduce	VBN	_	17	conj	_	_
29	.	.	.	_	17	p	_	_

1	The	the	DT	_	3	det	_	_
2	hypoglycemic	hypoglycemic	JJ	_	3	attr	_	_
3	action	action	NN	_	8	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	may	may	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	potentiated	potentiate	VBN	_	0	root	_	_
9	by	by	IN	_	11	case	_	_
10	certain	certain	JJ	_	11	attr	_	_
11	drugs	drug	NNS	_	8	ppmod	_	_
12	including	include	VBG	_	13	adv	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	other	other	JJ	_	16	attr	_	_
16	drugs	drug	NNS	_	13	conj	_	_
17	that	that	WDT	_	21	dep	_	_
18	are	be	VBP	_	21	aux	_	_
19	highly	highly	RB	_	21	adv	_	_
20	protein	protein	NN	_	21	dep	_	_
21	bound	bind	VBN	_	13	relcl	_	_
22	,	,	,	_	13	p	_	_
23	drug3	drug0	NN	_	13	conj	_	_
24	,	,	,	_	23	p	_	_
25	drug4	drug0	NN	_	13	conj	_	_
26	,	,	,	_	25	p	_	_
27	drug5	drug0	NN	_	13	conj	_	_
28	,	,	,	_	27	p	_	_
29	drug6	drug0	NN	_	13	conj	_	_
30	,	,	,	_	29	p	_	_
31	drug7	drug0	NN	_	13	conj	_	_
32	,	,	,	_	31	p	_	_
33	drug8	drug0	NN	_	13	conj	_	_
34	,	,	,	_	33	p	_	_
35	and	and	CC	_	33	cc	_	_
36	drug9	drug0	NN	_	13	conj	_	_
37	.	.	.	_	8	p	_	_

1	When	when	WRB	_	5	adv	_	_
2	such	such	JJ	_	3	attr	_	_
3	drugs	drug	NNS	_	5	dep	_	_
4	are	be	VBP	_	5	aux	_	_
5	administered	administer	VBN	_	16	advcl	_	_
6	to	to	TO	_	8	aux	_	_
7	a	a	DT	_	8	det	_	_
8	patient	patient	NN	_	5	ppmod	_	_
9	receiving	receive	VBG	_	8	acl	_	_
10	drug1	drug0	NN	_	9	obj	_	_
11	,	,	,	_	16	p	_	_
12	the	the	DT	_	13	det	_	_
13	patient	patient	NN	_	16	dep	_	_
14	should	should	MD	_	16	modal	_	_
15	be	be	VB	_	16	aux	_	_
16	observed	observe	VBN	_	0	root	_	_
17	closely	closely	RB	_	16	adv	_	_
18	for	for	IN	_	19	case	_	_
19	hypoglycemia	hypoglycemia	NN	_	16	ppmod	_	_
20	.	.	.	_	16	p	_	_

1	When	when	WRB	_	5	adv	_	_
2	such	such	JJ	_	3	attr	_	_
3	drugs	drug	NNS	_	5	dep	_	_
4	are	be	VBP	_	5	aux	_	_
5	withdrawn	withdraw	VBN	_	16	advcl	_	_
6	from	from	IN	_	8	case	_	_
7	a	a	DT	_	8	det	_	_
8	patient	patient	NN	_	5	ppmod	_	_
9	receiving	receive	VBG	_	8	acl	_	_
10	drug1	drug0	NN	_	9	obj	_	_
11	,	,	,	_	16	p	_	_
12	the	the	DT	_	13	det	_	_
13	patient	patient	NN	_	16	dep	_	_
14	should	should	MD	_	16	modal	_	_
15	be	be	VB	_	16	aux	_	_
16	observed	observe	VBN	_	0	root	_	_
17	closely	closely	RB	_	16	adv	_	_
18	for	for	IN	_	19	case	_	_
19	loss	loss	NN	_	16	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	control	control	NN	_	19	ppmod	_	_
22	.	.	.	_	16	p	_	_

1	Certain	certain	JJ	_	2	attr	_	_
2	drugs	drug	NNS	_	3	dep	_	_
3	tend	tend	VBP	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	produce	produce	VB	_	3	comp	_	_
6	hyperglycemia	hyperglycemia	NN	_	5	obj	_	_
7	and	and	CC	_	5	cc	_	_
8	may	may	MD	_	9	modal	_	_
9	lead	lead	VB	_	5	conj	_	_
10	to	to	TO	_	11	aux	_	_
11	loss	loss	NN	_	9	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	control	control	NN	_	11	ppmod	_	_
14	.	.	.	_	3	p	_	_

1	These	these	DT	_	2	det	_	_
2	drugs	drug	NNS	_	3	dep	_	_
3	include	include	VBP	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	drug1	drug0	NN	_	3	obj	_	_
6	and	and	CC	_	5	cc	_	_
7	other	other	JJ	_	8	attr	_	_
8	drug2	drug0	NNS	_	5	conj	_	_
9	,	,	,	_	5	p	_	_
10	drug3	drug0	NN	_	5	appo	_	_
11	,	,	,	_	10	p	_	_
12	phe-nothiazines	phe-nothiazines	NN	_	10	conj	_	_
13	,	,	,	_	12	p	_	_
14	drug4	drug0	NN	_	10	conj	_	_
15	,	,	,	_	14	p	_	_
16	drug5	drug0	NN	_	10	conj	_	_
17	,	,	,	_	16	p	_	_
18	oral	oral	JJ	_	19	attr	_	_
19	drug6	drug0	NN	_	10	conj	_	_
20	,	,	,	_	19	p	_	_
21	drug7	drug0	NN	_	10	conj	_	_
22	,	,	,	_	21	p	_	_
23	drug8	drug0	NN	_	10	conj	_	_
24	,	,	,	_	23	p	_	_
25	sympathomimet-ics	sympathomimet-ics	NN	_	10	conj	_	_
26	,	,	,	_	25	p	_	_
27	drug9	drug0	NN	_	10	conj	_	_
28	,	,	,	_	27	p	_	_
29	and	and	CC	_	27	cc	_	_
30	drug10	drug0	NN	_	10	conj	_	_
31	.	.	.	_	3	p	_	_

1	When	when	WRB	_	5	adv	_	_
2	such	such	JJ	_	3	attr	_	_
3	drugs	drug	NNS	_	5	dep	_	_
4	are	be	VBP	_	5	aux	_	_
5	administered	administer	VBN	_	17	advcl	_	_
6	to	to	TO	_	8	aux	_	_
7	a	a	DT	_	8	det	_	_
8	patient	patient	NN	_	5	ppmod	_	_
9	receiving	receive	VBG	_	8	acl	_	_
10	drug1	drug0	NN	_	9	obj	_	_
11	,	,	,	_	17	p	_	_
12	the	the	DT	_	13	det	_	_
13	patient	patient	NN	_	17	dep	_	_
14	should	should	MD	_	17	modal	_	_
15	be	be	VB	_	17	aux	_	_
16	closely	closely	RB	_	17	adv	_	_
17	observed	observe	VBN	_	0	root	_	_
18	for	for	IN	_	19	case	_	_
19	loss	loss	NN	_	17	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	control	control	NN	_	19	ppmod	_	_
22	.	.	.	_	17	p	_	_

1	When	when	WRB	_	5	adv	_	_
2	such	such	JJ	_	3	attr	_	_
3	drugs	drug	NNS	_	5	dep	_	_
4	are	be	VBP	_	5	aux	_	_
5	withdrawn	withdraw	VBN	_	16	advcl	_	_
6	from	from	IN	_	8	case	_	_
7	a	a	DT	_	8	det	_	_
8	patient	patient	NN	_	5	ppmod	_	_
9	receiving	receive	VBG	_	8	acl	_	_
10	drug1	drug0	NN	_	9	obj	_	_
11	,	,	,	_	16	p	_	_
12	the	the	DT	_	13	det	_	_
13	patient	patient	NN	_	16	dep	_	_
14	should	should	MD	_	16	modal	_	_
15	be	be	VB	_	16	aux	_	_
16	observed	observe	VBN	_	0	root	_	_
17	closely	closely	RB	_	16	adv	_	_
18	for	for	IN	_	19	case	_	_
19	hypoglycemia	hypoglycemia	NN	_	16	ppmod	_	_
20	.	.	.	_	16	p	_	_

1	A	a	DT	_	3	det	_	_
2	possible	possible	JJ	_	3	attr	_	_
3	interaction	interaction	NN	_	14	dep	_	_
4	between	between	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	,	,	,	_	5	p	_	_
9	a	a	DT	_	10	det	_	_
10	drug3	drug0	NN	_	5	appo	_	_
11	,	,	,	_	5	p	_	_
12	has	have	VBZ	_	14	aux	_	_
13	been	be	VBN	_	14	aux	_	_
14	reported	report	VBN	_	0	root	_	_
15	,	,	,	_	14	p	_	_
16	resulting	result	VBG	_	14	comp	_	_
17	in	in	IN	_	19	case	_	_
18	a	a	DT	_	19	det	_	_
19	potentiation	potentiation	NN	_	16	ppmod	_	_
20	of	of	IN	_	23	case	_	_
21	the	the	DT	_	23	det	_	_
22	hypoglycemic	hypoglycemic	JJ	_	23	attr	_	_
23	action	action	NN	_	19	ppmod	_	_
24	of	of	IN	_	25	case	_	_
25	drug4	drug0	NN	_	23	ppmod	_	_
26	.	.	.	_	14	p	_	_

1	The	the	DT	_	2	det	_	_
2	mechanism	mechanism	NN	_	8	dep	_	_
3	for	for	IN	_	5	case	_	_
4	this	this	DT	_	5	det	_	_
5	interaction	interaction	NN	_	2	ppmod	_	_
6	is	be	VBZ	_	8	aux	_	_
7	not	not	RB	_	8	neg	_	_
8	known	know	VBN	_	0	root	_	_
9	.	.	.	_	8	p	_	_

1	A	a	DT	_	3	det	_	_
2	potential	potential	JJ	_	3	attr	_	_
3	interaction	interaction	NN	_	16	dep	_	_
4	between	between	IN	_	6	case	_	_
5	oral	oral	JJ	_	6	attr	_	_
6	drug1	drug0	NN	_	3	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	oral	oral	JJ	_	9	attr	_	_
9	drug2	drug0	NN	_	6	conj	_	_
10	leading	lead	VBG	_	6	acl	_	_
11	to	to	TO	_	13	aux	_	_
12	severe	severe	JJ	_	13	attr	_	_
13	hypoglycemia	hypoglycemia	NN	_	10	ppmod	_	_
14	has	have	VBZ	_	16	aux	_	_
15	been	be	VBN	_	16	aux	_	_
16	reported	report	VBN	_	0	root	_	_
17	.	.	.	_	16	p	_	_

1	Whether	whether	IN	_	5	mark	_	_
2	this	this	DT	_	3	det	_	_
3	interaction	interaction	NN	_	5	dep	_	_
4	also	also	RB	_	5	adv	_	_
5	occurs	occur	VBZ	_	18	advcl	_	_
6	with	with	IN	_	13	case	_	_
7	the	the	DT	_	13	det	_	_
8	intravenous	intravenous	JJ	_	13	attr	_	_
9	,	,	,	_	8	p	_	_
10	topical	topical	JJ	_	8	conj	_	_
11	or	or	CC	_	10	cc	_	_
12	vaginal	vaginal	JJ	_	8	conj	_	_
13	preparations	preparation	NNS	_	5	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	is	be	VBZ	_	18	aux	_	_
17	not	not	RB	_	18	neg	_	_
18	known	know	VBN	_	0	root	_	_
19	.	.	.	_	18	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	7	case	_	_
4	a	a	DT	_	7	det	_	_
5	single-dose	single-dose	JJ	_	7	attr	_	_
6	interaction	interaction	NN	_	7	com	_	_
7	study	study	NN	_	19	ppmod	_	_
8	in	in	IN	_	10	case	_	_
9	NIDDM	niddm	NN	_	10	com	_	_
10	subjects	subject	NNS	_	7	ppmod	_	_
11	,	,	,	_	19	p	_	_
12	decreases	decrease	NNS	_	19	dep	_	_
13	in	in	IN	_	14	case	_	_
14	drug2	drug0	NNS	_	12	ppmod	_	_
15	AUC	auc	NN	_	14	appo	_	_
16	and	and	CC	_	15	cc	_	_
17	Cmax	cmax	NN	_	15	conj	_	_
18	were	be	VBD	_	19	aux	_	_
19	observed	observe	VBN	_	1	acl	_	_
20	,	,	,	_	19	p	_	_
21	but	but	CC	_	19	cc	_	_
22	were	be	VBD	_	19	conj	_	_
23	highly	highly	RB	_	24	adv	_	_
24	variable	variable	JJ	_	22	dep	_	_
25	.	.	.	_	1	p	_	_

1	The	the	DT	_	3	det	_	_
2	single-dose	single-dose	JJ	_	3	attr	_	_
3	nature	nature	NN	_	20	dep	_	_
4	of	of	IN	_	6	case	_	_
5	this	this	DT	_	6	det	_	_
6	study	study	NN	_	3	ppmod	_	_
7	and	and	CC	_	3	cc	_	_
8	the	the	DT	_	9	det	_	_
9	lack	lack	NN	_	3	conj	_	_
10	of	of	IN	_	11	case	_	_
11	correlation	correlation	NN	_	9	ppmod	_	_
12	between	between	IN	_	15	case	_	_
13	drug1	drug0	NN	_	15	com	_	_
14	blood	blood	NN	_	15	com	_	_
15	levels	level	NNS	_	11	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	pharmaco-dynamic	pharmaco-dynamic	JJ	_	18	attr	_	_
18	effects	effect	NNS	_	15	conj	_	_
19	,	,	,	_	9	p	_	_
20	makes	make	VBZ	_	0	root	_	_
21	the	the	DT	_	23	det	_	_
22	clinical	clinical	JJ	_	23	attr	_	_
23	significance	significance	NN	_	20	obj	_	_
24	of	of	IN	_	26	case	_	_
25	this	this	DT	_	26	det	_	_
26	interaction	interaction	NN	_	23	ppmod	_	_
27	uncertain	uncertain	JJ	_	26	attr	_	_
28	.	.	.	_	20	p	_	_

1	Coadministration	coadministration	NN	_	8	dep	_	_
2	of	of	IN	_	3	case	_	_
3	gly-buride	gly-buride	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	drug1	drug0	NN	_	3	conj	_	_
6	did	do	VBD	_	8	aux	_	_
7	not	not	RB	_	8	neg	_	_
8	result	result	VB	_	0	root	_	_
9	in	in	IN	_	11	case	_	_
10	any	any	DT	_	11	det	_	_
11	changes	change	NNS	_	8	ppmod	_	_
12	in	in	IN	_	15	case	_	_
13	either	either	CC	_	15	cc	_	_
14	drug2	drug0	NN	_	15	com	_	_
15	pharmacokinetics	pharmacokinetics	NNS	_	11	ppmod	_	_
16	or	or	CC	_	15	cc	_	_
17	pharmaco-dynamics	pharmaco-dynamics	NNS	_	15	conj	_	_
18	.	.	.	_	8	p	_	_

1	Interations	interations	NN	_	0	root	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	interact	interact	VB	_	0	root	_	_
4	with	with	IN	_	5	case	_	_
5	any	any	DT	_	3	ppmod	_	_
6	of	of	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	following	following	NN	_	5	ppmod	_	_
9	:	:	:	_	5	p	_	_
10	-	-	:	_	3	p	_	_
11	drug2	drug0	CD	_	3	num	_	_
12	(	-lrb-	-LRB-	_	22	p	_	_
13	e.g.	e.g.	FW	_	15	adv	_	_
14	,	,	,	_	15	p	_	_
15	drug3	drug0	NN	_	22	ppmod	_	_
16	)	-rrb-	-RRB-	_	22	p	_	_
17	(	-lrb-	-LRB-	_	22	p	_	_
18	with	with	IN	_	22	case	_	_
19	long-term	long-term	JJ	_	21	adv	_	_
20	,	,	,	_	21	p	_	_
21	high-dose	high-dose	JJ	_	22	attr	_	_
22	use	use	NN	_	11	prn	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	or	or	CC	_	11	cc	_	_

1	-	-	CC	_	8	cc	_	_
2	drug1	drug0	NN	_	8	attr	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	e.g.	e.g.	FW	_	6	adv	_	_
5	,	,	,	_	6	p	_	_
6	drug2	drug0	NN	_	8	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	or	or	NN	_	0	root	_	_

1	-	-	:	_	2	p	_	_
2	drug1	drug0	NN	_	28	prn	_	_
3	(	-lrb-	-LRB-	_	5	p	_	_
4	drug2	drug0	NN	_	5	com	_	_
5	-LSB-e.g.	-lsb-e.g.	NN	_	2	prn	_	_
6	,	,	,	_	5	p	_	_
7	drug3	drug0	NN	_	5	appo	_	_
8	]	-rsb-	-RRB-	_	5	p	_	_
9	,	,	,	_	2	p	_	_
10	drug4	drug0	NN	_	11	com	_	_
11	-LSB-e.g.	-lsb-e.g.	NN	_	2	appo	_	_
12	,	,	,	_	2	p	_	_
13	drug5	drug0	NN	_	2	appo	_	_
14	]	-rsb-	-RRB-	_	13	p	_	_
15	,	,	,	_	2	p	_	_
16	drug6	drug0	NN	_	17	com	_	_
17	-LSB-e.g.	-lsb-e.g.	NN	_	2	appo	_	_
18	,	,	,	_	2	p	_	_
19	drug7	drug0	NN	_	2	appo	_	_
20	]	-rsb-	-RRB-	_	19	p	_	_
21	,	,	,	_	2	p	_	_
22	drug8	drug0	NN	_	23	com	_	_
23	-LSB-e.g.	-lsb-e.g.	NN	_	2	appo	_	_
24	,	,	,	_	2	p	_	_
25	drug9	drug0	NN	_	2	appo	_	_
26	]	-rsb-	-RRB-	_	2	p	_	_
27	)	-rrb-	-RRB-	_	2	p	_	_
28	or	or	CC	_	0	root	_	_

1	-	-	CC	_	2	cc	_	_
2	drug1	drug0	CD	_	0	root	_	_
3	(	-lrb-	-LRB-	_	5	p	_	_
4	male	male	JJ	_	5	attr	_	_
5	hormones	hormone	NNS	_	2	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	or	or	CC	_	2	cc	_	_

1	-	-	CC	_	2	cc	_	_
2	drug1	drug0	CD	_	0	root	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	medicine	medicine	NN	_	2	prn	_	_
5	for	for	IN	_	7	case	_	_
6	overactive	overactive	JJ	_	7	attr	_	_
7	thyroid	thyroid	NN	_	4	ppmod	_	_
8	)	-rrb-	-RRB-	_	4	p	_	_
9	or	or	CC	_	2	cc	_	_

1	-	-	CC	_	8	cc	_	_
2	drug1	drug0	NN	_	8	attr	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	e.g.	e.g.	FW	_	6	adv	_	_
5	,	,	,	_	6	p	_	_
6	drug2	drug0	NN	_	8	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	or	or	NN	_	0	root	_	_

1	-	-	CC	_	8	cc	_	_
2	drug1	drug0	NN	_	8	attr	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	e.g.	e.g.	FW	_	6	adv	_	_
5	,	,	,	_	6	p	_	_
6	drug2	drug0	NN	_	8	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	or	or	NN	_	0	root	_	_

1	-	-	CC	_	8	cc	_	_
2	drug1	drug0	NN	_	8	attr	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	e.g.	e.g.	FW	_	6	adv	_	_
5	,	,	,	_	6	p	_	_
6	drug2	drug0	NN	_	8	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	or	or	NN	_	0	root	_	_

1	-	-	CC	_	8	cc	_	_
2	drug1	drug0	NN	_	8	attr	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	e.g.	e.g.	FW	_	6	adv	_	_
5	,	,	,	_	6	p	_	_
6	drug2	drug0	NN	_	8	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	or	or	NN	_	0	root	_	_

1	-	-	CC	_	8	cc	_	_
2	drug1	drug0	NN	_	8	attr	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	e.g.	e.g.	FW	_	6	adv	_	_
5	,	,	,	_	6	p	_	_
6	drug2	drug0	NN	_	8	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	or	or	NN	_	0	root	_	_

1	-	-	CC	_	8	cc	_	_
2	drug1	drug0	NN	_	8	attr	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	e.g.	e.g.	FW	_	6	adv	_	_
5	,	,	,	_	6	p	_	_
6	drug2	drug0	NN	_	8	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	or	or	NN	_	0	root	_	_

1	-	-	CC	_	8	cc	_	_
2	drug1	drug0	NN	_	8	attr	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	e.g.	e.g.	FW	_	6	adv	_	_
5	,	,	,	_	6	p	_	_
6	drug2	drug0	NN	_	8	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	or	or	NN	_	0	root	_	_

1	-	-	CC	_	2	cc	_	_
2	drug1	drug0	CD	_	0	root	_	_
3	(	-lrb-	-LRB-	_	5	p	_	_
4	female	female	NN	_	5	com	_	_
5	hormones	hormone	NNS	_	2	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	or	or	CC	_	2	cc	_	_

1	-	-	CC	_	8	cc	_	_
2	drug1	drug0	NN	_	8	attr	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	e.g.	e.g.	FW	_	6	adv	_	_
5	,	,	,	_	6	p	_	_
6	drug2	drug0	NN	_	8	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	or	or	NN	_	0	root	_	_

1	-	-	CC	_	3	cc	_	_
2	drug1	drug0	JJ	_	3	attr	_	_
3	salts	salt	NNS	_	0	root	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	medicine	medicine	NN	_	3	prn	_	_
6	for	for	IN	_	7	case	_	_
7	arthritis	arthritis	NN	_	5	ppmod	_	_
8	)	-rrb-	-RRB-	_	5	p	_	_
9	or	or	CC	_	3	cc	_	_

1	-	-	CC	_	8	cc	_	_
2	drug1	drug0	NN	_	8	attr	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	e.g.	e.g.	FW	_	6	adv	_	_
5	,	,	,	_	6	p	_	_
6	drug2	drug0	NN	_	8	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	or	or	NN	_	0	root	_	_

1	-	-	CC	_	8	cc	_	_
2	drug1	drug0	NN	_	8	attr	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	e.g.	e.g.	FW	_	6	adv	_	_
5	,	,	,	_	6	p	_	_
6	drug2	drug0	NN	_	8	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	or	or	NN	_	0	root	_	_

1	-	-	CC	_	2	cc	_	_
2	drug1	drug0	CD	_	0	root	_	_
3	(	-lrb-	-LRB-	_	13	p	_	_
4	e.g.	e.g.	FW	_	6	adv	_	_
5	,	,	,	_	6	p	_	_
6	drug2	drug0	NN	_	13	ppmod	_	_
7	)	-rrb-	-RRB-	_	13	p	_	_
8	(	-lrb-	-LRB-	_	13	p	_	_
9	with	with	IN	_	13	case	_	_
10	long-term	long-term	JJ	_	12	adv	_	_
11	,	,	,	_	12	p	_	_
12	high-dose	high-dose	JJ	_	13	attr	_	_
13	use	use	NN	_	2	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	or	or	CC	_	2	cc	_	_

1	-	-	CC	_	3	cc	_	_
2	Oral	oral	JJ	_	3	attr	_	_
3	drug1	drug0	NN	_	0	root	_	_
4	(	-lrb-	-LRB-	_	7	p	_	_
5	birth	birth	NN	_	7	com	_	_
6	control	control	NN	_	7	com	_	_
7	pills	pill	NNS	_	3	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	containing	contain	VBG	_	3	acl	_	_
10	drug2	drug0	NN	_	11	com	_	_
11	or	or	NN	_	9	obj	_	_

1	-	-	CC	_	3	cc	_	_
2	Other	other	JJ	_	3	attr	_	_
3	drug1	drug0	NN	_	0	root	_	_
4	by	by	IN	_	5	case	_	_
5	mouth	mouth	NN	_	3	ppmod	_	_
6	or	or	CC	_	5	cc	_	_
7	by	by	IN	_	8	case	_	_
8	injection	injection	NN	_	5	conj	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	medicine	medicine	NN	_	3	prn	_	_
11	for	for	IN	_	12	case	_	_
12	infection	infection	NN	_	10	ppmod	_	_
13	)	-rrb-	-RRB-	_	10	p	_	_
14	or	or	CC	_	3	cc	_	_

1	-	-	CC	_	2	cc	_	_
2	drug1	drug0	NN	_	76	dep	_	_
3	(	-lrb-	-LRB-	_	7	p	_	_
4	drug2	drug0	NN	_	7	attr	_	_
5	-LSB-e.g.	-lsb-e.g.	NN	_	7	attr	_	_
6	,	,	,	_	7	p	_	_
7	drug3	drug0	NN	_	2	prn	_	_
8	]	-rsb-	-RRB-	_	7	p	_	_
9	,	,	,	_	7	p	_	_
10	drug4	drug0	NN	_	11	com	_	_
11	-LSB-e.g.	-lsb-e.g.	NN	_	7	appo	_	_
12	,	,	,	_	7	p	_	_
13	drug5	drug0	NN	_	7	appo	_	_
14	]	-rsb-	-RRB-	_	7	p	_	_
15	,	,	,	_	2	p	_	_
16	drug6	drug0	NN	_	17	com	_	_
17	-LSB-e.g.	-lsb-e.g.	NN	_	2	appo	_	_
18	,	,	,	_	2	p	_	_
19	drug7	drug0	NN	_	2	appo	_	_
20	]	-rsb-	-RRB-	_	19	p	_	_
21	,	,	,	_	2	p	_	_
22	drug8	drug0	NN	_	23	com	_	_
23	-LSB-e.g.	-lsb-e.g.	NN	_	2	appo	_	_
24	,	,	,	_	2	p	_	_
25	drug9	drug0	NN	_	2	appo	_	_
26	]	-rsb-	-RRB-	_	25	p	_	_
27	,	,	,	_	2	p	_	_
28	drug10	drug0	NN	_	2	appo	_	_
29	-LSB-e.g.	-lsb-e.g.	CD	_	28	num	_	_
30	,	,	,	_	28	p	_	_
31	drug11	drug0	CD	_	28	num	_	_
32	]	-rsb-	-RRB-	_	28	p	_	_
33	,	,	,	_	2	p	_	_
34	drug12	drug0	NN	_	35	com	_	_
35	-LSB-e.g.	-lsb-e.g.	NN	_	2	appo	_	_
36	,	,	,	_	2	p	_	_
37	drug13	drug0	NN	_	2	appo	_	_
38	]	-rsb-	-RRB-	_	2	p	_	_
39	,	,	,	_	73	p	_	_
40	drug14	drug0	NNP	_	73	dep	_	_
41	-LSB-e.g.	-lsb-e.g.	CD	_	40	num	_	_
42	,	,	,	_	40	p	_	_
43	drug15	drug0	CD	_	40	num	_	_
44	]	-rsb-	-RRB-	_	40	p	_	_
45	,	,	,	_	73	p	_	_
46	drug16	drug0	NNP	_	73	dep	_	_
47	-LSB-e.g.	-lsb-e.g.	CD	_	46	num	_	_
48	,	,	,	_	46	p	_	_
49	drug17	drug0	CD	_	46	num	_	_
50	]	-rsb-	-RRB-	_	46	p	_	_
51	,	,	,	_	73	p	_	_
52	drug18	drug0	CD	_	53	num	_	_
53	-LSB-e.g.	-lsb-e.g.	NN	_	73	dep	_	_
54	,	,	,	_	73	p	_	_
55	drug19	drug0	CD	_	73	num	_	_
56	]	-rsb-	-RRB-	_	55	p	_	_
57	,	,	,	_	73	p	_	_
58	drug20	drug0	CD	_	59	num	_	_
59	-LSB-e.g.	-lsb-e.g.	NN	_	73	dep	_	_
60	,	,	,	_	73	p	_	_
61	drug21	drug0	CD	_	73	num	_	_
62	]	-rsb-	-RRB-	_	61	p	_	_
63	,	,	,	_	73	p	_	_
64	drug22	drug0	CD	_	65	num	_	_
65	-LSB-e.g.	-lsb-e.g.	NN	_	73	dep	_	_
66	,	,	,	_	73	p	_	_
67	drug23	drug0	CD	_	73	num	_	_
68	]	-rsb-	-RRB-	_	67	p	_	_
69	,	,	,	_	73	p	_	_
70	drug24	drug0	CD	_	71	num	_	_
71	-LSB-e.g.	-lsb-e.g.	NN	_	73	dep	_	_
72	,	,	,	_	73	p	_	_
73	drug25	drug0	CD	_	2	num	_	_
74	]	-rsb-	-RRB-	_	73	p	_	_
75	)	-rrb-	-RRB-	_	73	p	_	_
76	or	or	CC	_	0	root	_	_

1	-	-	CC	_	8	cc	_	_
2	drug1	drug0	NN	_	8	attr	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	e.g.	e.g.	FW	_	6	adv	_	_
5	,	,	,	_	6	p	_	_
6	drug2	drug0	NN	_	8	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	or	or	NN	_	0	root	_	_

1	-	-	CC	_	8	cc	_	_
2	drug1	drug0	NN	_	8	attr	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	e.g.	e.g.	FW	_	6	ppmod	_	_
5	,	,	,	_	6	p	_	_
6	drug2	drug0	NNS	_	8	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	Use	use	NN	_	15	dep	_	_
9	of	of	IN	_	10	case	_	_
10	drug3	drug0	NN	_	8	ppmod	_	_
11	with	with	IN	_	13	case	_	_
12	these	these	DT	_	13	det	_	_
13	medicines	medicine	NNS	_	8	ppmod	_	_
14	may	may	MD	_	15	modal	_	_
15	increase	increase	VB	_	0	root	_	_
16	the	the	DT	_	17	det	_	_
17	chance	chance	NN	_	15	obj	_	_
18	of	of	IN	_	20	case	_	_
19	side	side	JJ	_	20	attr	_	_
20	effects	effect	NNS	_	17	ppmod	_	_
21	affecting	affect	VBG	_	20	acl	_	_
22	the	the	DT	_	23	det	_	_
23	liver	liver	NN	_	21	obj	_	_

1	-	-	CC	_	8	cc	_	_
2	drug1	drug0	NN	_	8	attr	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	e.g.	e.g.	FW	_	6	adv	_	_
5	,	,	,	_	6	p	_	_
6	drug2	drug0	NN	_	8	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	or	or	NN	_	0	root	_	_

1	-	-	CC	_	3	cc	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	or	or	NN	_	0	root	_	_

1	-	-	CC	_	8	cc	_	_
2	drug1	drug0	NN	_	8	attr	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	e.g.	e.g.	FW	_	6	adv	_	_
5	,	,	,	_	6	p	_	_
6	drug2	drug0	NN	_	8	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	or	or	NN	_	0	root	_	_

1	-	-	CC	_	8	cc	_	_
2	drug1	drug0	NN	_	8	attr	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	e.g.	e.g.	FW	_	6	adv	_	_
5	,	,	,	_	6	p	_	_
6	drug2	drug0	NN	_	8	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	or	or	NN	_	0	root	_	_

1	-	-	CC	_	3	cc	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	or	or	NN	_	0	root	_	_

1	-	-	CC	_	8	cc	_	_
2	drug1	drug0	NN	_	8	attr	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	e.g.	e.g.	FW	_	6	adv	_	_
5	,	,	,	_	6	p	_	_
6	drug2	drug0	NN	_	8	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	or	or	NN	_	0	root	_	_

1	-	-	CC	_	8	cc	_	_
2	drug1	drug0	NN	_	8	attr	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	e.g.	e.g.	FW	_	6	adv	_	_
5	,	,	,	_	6	p	_	_
6	drug2	drug0	NN	_	8	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	or	or	NN	_	0	root	_	_

1	-	-	CC	_	8	cc	_	_
2	drug1	drug0	NN	_	8	attr	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	e.g.	e.g.	FW	_	6	adv	_	_
5	,	,	,	_	6	p	_	_
6	drug2	drug0	NN	_	8	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	or	or	NN	_	0	root	_	_

1	-	-	CC	_	8	cc	_	_
2	drug1	drug0	NN	_	8	attr	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	e.g.	e.g.	FW	_	6	adv	_	_
5	,	,	,	_	6	p	_	_
6	drug2	drug0	NN	_	8	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	or	or	NN	_	0	root	_	_

1	-	-	CC	_	10	cc	_	_
2	drug1	drug0	NN	_	10	attr	_	_
3	(	-lrb-	-LRB-	_	8	p	_	_
4	e.g.	e.g.	FW	_	6	adv	_	_
5	,	,	,	_	6	p	_	_
6	drug2	drug0	NN	_	8	ppmod	_	_
7	,	,	,	_	8	p	_	_
8	drug3	drug0	NNS	_	10	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	Use	use	NN	_	17	dep	_	_
11	of	of	IN	_	12	case	_	_
12	drug4	drug0	NN	_	10	ppmod	_	_
13	with	with	IN	_	15	case	_	_
14	these	these	DT	_	15	det	_	_
15	medicines	medicine	NNS	_	10	ppmod	_	_
16	may	may	MD	_	17	modal	_	_
17	increase	increase	VB	_	0	root	_	_
18	the	the	DT	_	19	det	_	_
19	chance	chance	NN	_	17	obj	_	_
20	of	of	IN	_	22	case	_	_
21	side	side	JJ	_	22	attr	_	_
22	effects	effect	NNS	_	19	ppmod	_	_
23	affecting	affect	VBG	_	22	acl	_	_
24	the	the	DT	_	25	det	_	_
25	blood	blood	NN	_	23	obj	_	_

1	-	-	CC	_	7	cc	_	_
2	drug1	drug0	NN	_	7	attr	_	_
3	(	-lrb-	-LRB-	_	7	p	_	_
4	drug2	drug0	NN	_	7	attr	_	_
5	s	s	NN	_	7	attr	_	_
6	)	-rrb-	-RRB-	_	7	p	_	_
7	or	or	NN	_	0	root	_	_

1	-	-	CC	_	8	cc	_	_
2	drug1	drug0	NN	_	8	attr	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	e.g.	e.g.	FW	_	6	adv	_	_
5	,	,	,	_	6	p	_	_
6	drug2	drug0	NN	_	8	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	or	or	NN	_	0	root	_	_

1	-	-	CC	_	8	cc	_	_
2	drug1	drug0	NN	_	8	attr	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	e.g.	e.g.	FW	_	6	ppmod	_	_
5	,	,	,	_	6	p	_	_
6	drug2	drug0	NN	_	2	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	Use	use	NN	_	15	dep	_	_
9	of	of	IN	_	10	case	_	_
10	drug3	drug0	NN	_	8	ppmod	_	_
11	with	with	IN	_	13	case	_	_
12	these	these	DT	_	13	det	_	_
13	medicines	medicine	NNS	_	8	ppmod	_	_
14	may	may	MD	_	15	modal	_	_
15	increase	increase	VB	_	0	root	_	_
16	the	the	DT	_	17	det	_	_
17	chance	chance	NN	_	15	obj	_	_
18	of	of	IN	_	20	case	_	_
19	side	side	JJ	_	20	attr	_	_
20	effects	effect	NNS	_	17	ppmod	_	_
21	of	of	IN	_	23	case	_	_
22	these	these	DT	_	23	det	_	_
23	medicines	medicine	NNS	_	20	ppmod	_	_

1	-	-	TO	_	2	aux	_	_
2	drug1	drug0	NN	_	20	ppmod	_	_
3	,	,	,	_	20	p	_	_
4	oral	oral	JJ	_	13	attr	_	_
5	(	-lrb-	-LRB-	_	9	p	_	_
6	diabetes	diabetes	NN	_	7	com	_	_
7	medicine	medicine	NN	_	9	dep	_	_
8	you	you	VBN	_	9	aux	_	_
9	take	take	VB	_	4	prn	_	_
10	by	by	IN	_	11	case	_	_
11	mouth	mouth	NN	_	9	ppmod	_	_
12	)	-rrb-	-RRB-	_	9	p	_	_
13	Use	use	NN	_	20	dep	_	_
14	of	of	IN	_	16	case	_	_
15	oral	oral	JJ	_	16	attr	_	_
16	drug2	drug0	NN	_	13	ppmod	_	_
17	with	with	IN	_	18	case	_	_
18	drug3	drug0	NN	_	16	ppmod	_	_
19	may	may	MD	_	20	modal	_	_
20	increase	increase	VB	_	0	root	_	_
21	the	the	DT	_	22	det	_	_
22	chance	chance	NN	_	20	obj	_	_
23	of	of	IN	_	25	case	_	_
24	side	side	JJ	_	25	attr	_	_
25	effects	effect	NNS	_	22	ppmod	_	_
26	affecting	affect	VBG	_	25	acl	_	_
27	the	the	DT	_	28	det	_	_
28	blood	blood	NN	_	26	obj	_	_
29	and/or	and/or	CC	_	28	cc	_	_
30	the	the	DT	_	32	det	_	_
31	side	side	JJ	_	32	attr	_	_
32	effects	effect	NNS	_	28	conj	_	_
33	or	or	CC	_	32	cc	_	_
34	oral	oral	JJ	_	35	attr	_	_
35	drug4	drug0	NNS	_	32	conj	_	_

1	-	-	CC	_	8	cc	_	_
2	drug1	drug0	NN	_	8	attr	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	e.g.	e.g.	FW	_	6	ppmod	_	_
5	,	,	,	_	6	p	_	_
6	drug2	drug0	NNS	_	8	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	Use	use	NN	_	14	dep	_	_
9	of	of	IN	_	10	case	_	_
10	drug3	drug0	NN	_	8	ppmod	_	_
11	with	with	IN	_	12	case	_	_
12	drug4	drug0	NN	_	8	ppmod	_	_
13	may	may	MD	_	14	modal	_	_
14	increase	increase	VB	_	0	root	_	_
15	the	the	DT	_	16	det	_	_
16	chance	chance	NN	_	14	obj	_	_
17	of	of	IN	_	19	case	_	_
18	side	side	JJ	_	19	attr	_	_
19	effects	effect	NNS	_	16	ppmod	_	_
20	affecting	affect	VBG	_	19	acl	_	_
21	the	the	DT	_	22	det	_	_
22	liver	liver	NN	_	20	obj	_	_
23	and/or	and/or	CC	_	16	cc	_	_
24	the	the	DT	_	26	det	_	_
25	side	side	JJ	_	26	attr	_	_
26	effects	effect	NNS	_	16	conj	_	_
27	of	of	IN	_	28	case	_	_
28	drug5	drug0	NN	_	26	ppmod	_	_

1	-	-	CC	_	8	cc	_	_
2	drug1	drug0	NN	_	8	attr	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	e.g.	e.g.	FW	_	6	ppmod	_	_
5	,	,	,	_	6	p	_	_
6	drug2	drug0	NNS	_	8	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	Use	use	NN	_	14	dep	_	_
9	of	of	IN	_	10	case	_	_
10	drug3	drug0	NN	_	8	ppmod	_	_
11	with	with	IN	_	12	case	_	_
12	drug4	drug0	NN	_	8	ppmod	_	_
13	may	may	MD	_	14	modal	_	_
14	increase	increase	VB	_	0	root	_	_
15	the	the	DT	_	16	det	_	_
16	chance	chance	NN	_	14	obj	_	_
17	of	of	IN	_	19	case	_	_
18	side	side	JJ	_	19	attr	_	_
19	effects	effect	NNS	_	16	ppmod	_	_
20	affecting	affect	VBG	_	22	adv	_	_
21	the	the	DT	_	22	det	_	_
22	liver	liver	NN	_	14	ppmod	_	_
23	and/or	and/or	CC	_	22	cc	_	_
24	the	the	DT	_	25	det	_	_
25	blood	blood	NN	_	22	conj	_	_

1	-	-	CC	_	8	cc	_	_
2	drug1	drug0	NN	_	8	attr	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	e.g.	e.g.	FW	_	6	ppmod	_	_
5	,	,	,	_	6	p	_	_
6	drug2	drug0	NNS	_	8	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	Use	use	NN	_	14	dep	_	_
9	of	of	IN	_	10	case	_	_
10	drug3	drug0	NN	_	8	ppmod	_	_
11	with	with	IN	_	12	case	_	_
12	drug4	drug0	NN	_	8	ppmod	_	_
13	may	may	MD	_	14	modal	_	_
14	increase	increase	VB	_	0	root	_	_
15	the	the	DT	_	16	det	_	_
16	chance	chance	NN	_	14	obj	_	_
17	of	of	IN	_	19	case	_	_
18	side	side	JJ	_	19	attr	_	_
19	effects	effect	NNS	_	16	ppmod	_	_
20	affecting	affect	VBG	_	19	acl	_	_
21	the	the	DT	_	22	det	_	_
22	liver	liver	NN	_	20	obj	_	_
23	and/or	and/or	CC	_	16	cc	_	_
24	the	the	DT	_	26	det	_	_
25	side	side	JJ	_	26	attr	_	_
26	effects	effect	NNS	_	16	conj	_	_
27	of	of	IN	_	28	case	_	_
28	drug5	drug0	NN	_	26	ppmod	_	_

1	drug1	drug0	JJ	_	2	attr	_	_
2	toxicity	toxicity	NN	_	5	dep	_	_
3	may	may	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	aggravated	aggravate	VBN	_	0	root	_	_
6	by	by	IN	_	9	case	_	_
7	the	the	DT	_	9	det	_	_
8	initial	initial	JJ	_	9	attr	_	_
9	release	release	NN	_	5	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	norepinephrine	norepinephrine	NN	_	9	ppmod	_	_
12	caused	cause	VBN	_	11	acl	_	_
13	by	by	IN	_	15	case	_	_
14	drug2	drug0	NN	_	15	com	_	_
15	Injection	injection	NN	_	12	ppmod	_	_
16	.	.	.	_	5	p	_	_

1	The	the	DT	_	3	det	_	_
2	pressor	pressor	NN	_	3	com	_	_
3	effects	effect	NNS	_	12	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	such	such	JJ	_	8	adv	_	_
7	as	as	IN	_	8	case	_	_
8	drug2	drug0	NN	_	3	ppmod	_	_
9	or	or	CC	_	8	cc	_	_
10	drug3	drug0	NN	_	8	conj	_	_
11	are	be	VBP	_	12	aux	_	_
12	enhanced	enhance	VBN	_	0	root	_	_
13	by	by	IN	_	14	case	_	_
14	drug4	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	12	p	_	_

1	When	when	WRB	_	4	adv	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	are	be	VBP	_	4	aux	_	_
4	administered	administer	VBN	_	10	advcl	_	_
5	,	,	,	_	10	p	_	_
6	dilute	dilute	NN	_	7	com	_	_
7	solutions	solution	NNS	_	10	dep	_	_
8	should	should	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	used	use	VBN	_	0	root	_	_
11	and	and	CC	_	10	cc	_	_
12	blood	blood	NN	_	13	com	_	_
13	pressure	pressure	NN	_	16	dep	_	_
14	should	should	MD	_	16	modal	_	_
15	be	be	VB	_	16	aux	_	_
16	monitored	monitor	VBN	_	10	conj	_	_
17	closely	closely	RB	_	16	adv	_	_
18	.	.	.	_	10	p	_	_

1	Although	although	IN	_	3	mark	_	_
2	there	there	EX	_	3	dep	_	_
3	is	be	VBZ	_	19	advcl	_	_
4	little	little	JJ	_	6	attr	_	_
5	published	publish	VBN	_	6	attr	_	_
6	information	information	NN	_	3	obj	_	_
7	on	on	IN	_	9	case	_	_
8	concomitant	concomitant	JJ	_	9	attr	_	_
9	administration	administration	NN	_	6	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	drug2	drug0	NN	_	11	conj	_	_
14	,	,	,	_	19	p	_	_
15	these	these	DT	_	16	det	_	_
16	drugs	drug	NNS	_	19	dep	_	_
17	are	be	VBP	_	19	aux	_	_
18	often	often	RB	_	19	adv	_	_
19	administered	administer	VBN	_	0	root	_	_
20	concurrently	concurrently	RB	_	19	adv	_	_
21	without	without	IN	_	23	case	_	_
22	any	any	DT	_	23	det	_	_
23	evidence	evidence	NN	_	19	ppmod	_	_
24	of	of	IN	_	25	case	_	_
25	interactions	interaction	NNS	_	23	ppmod	_	_
26	resulting	result	VBG	_	25	acl	_	_
27	in	in	IN	_	29	case	_	_
28	adverse	adverse	JJ	_	29	attr	_	_
29	effects	effect	NNS	_	26	ppmod	_	_
30	or	or	CC	_	29	cc	_	_
31	diminished	diminish	VBN	_	32	attr	_	_
32	efficacy	efficacy	NN	_	29	conj	_	_
33	.	.	.	_	19	p	_	_

1	drug1	drug0	NN	_	11	dep	_	_
2	or	or	CC	_	1	cc	_	_
3	other	other	JJ	_	4	attr	_	_
4	drug2	drug0	NN	_	7	attr	_	_
5	(	-lrb-	-LRB-	_	7	p	_	_
6	concurrent	concurrent	JJ	_	7	attr	_	_
7	use	use	NN	_	1	conj	_	_
8	with	with	IN	_	9	case	_	_
9	drug3	drug0	NN	_	1	ppmod	_	_
10	may	may	MD	_	11	modal	_	_
11	result	result	VB	_	0	root	_	_
12	in	in	IN	_	14	case	_	_
13	uterine	uterine	NN	_	14	com	_	_
14	hypertonus	hypertonus	NN	_	11	ppmod	_	_
15	,	,	,	_	11	p	_	_
16	possibly	possibly	RB	_	17	adv	_	_
17	causing	cause	VBG	_	11	comp	_	_
18	uterine	uterine	NN	_	19	com	_	_
19	rupture	rupture	NN	_	17	obj	_	_
20	or	or	CC	_	19	cc	_	_
21	cervical	cervical	JJ	_	22	attr	_	_
22	laceration	laceration	NN	_	19	conj	_	_
23	,	,	,	_	17	p	_	_
24	especially	especially	RB	_	27	adv	_	_
25	in	in	IN	_	27	case	_	_
26	the	the	DT	_	27	det	_	_
27	absence	absence	NN	_	17	ppmod	_	_
28	of	of	IN	_	31	case	_	_
29	adequate	adequate	JJ	_	31	attr	_	_
30	cervical	cervical	JJ	_	31	attr	_	_
31	dilatation	dilatation	NN	_	27	ppmod	_	_
32	;	;	:	_	11	p	_	_

1	although	although	IN	_	5	mark	_	_
2	combinations	combination	NNS	_	5	dep	_	_
3	are	be	VBP	_	5	aux	_	_
4	sometimes	sometimes	RB	_	5	adv	_	_
5	used	use	VBN	_	18	advcl	_	_
6	for	for	IN	_	8	case	_	_
7	therapeutic	therapeutic	JJ	_	8	attr	_	_
8	advantage	advantage	NN	_	5	ppmod	_	_
9	,	,	,	_	18	p	_	_
10	when	when	WRB	_	11	adv	_	_
11	used	use	VBN	_	18	advcl	_	_
12	concurrently	concurrently	RB	_	11	adv	_	_
13	,	,	,	_	18	p	_	_
14	patient	patient	NN	_	18	dep	_	_
15	should	should	MD	_	18	modal	_	_
16	be	be	VB	_	18	aux	_	_
17	closely	closely	RB	_	18	adv	_	_
18	monitored	monitor	VBN	_	0	root	_	_
19	.	.	.	_	18	p	_	_

1	No	no	DT	_	5	det	_	_
2	clinical	clinical	JJ	_	5	attr	_	_
3	drug	drug	NN	_	5	com	_	_
4	interaction	interaction	NN	_	5	com	_	_
5	studies	study	NNS	_	8	dep	_	_
6	have	have	VBP	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	conducted	conduct	VBN	_	0	root	_	_
9	.	.	.	_	8	p	_	_

1	However	however	RB	_	11	adv	_	_
2	,	,	,	_	11	p	_	_
3	in	in	IN	_	9	case	_	_
4	a	a	DT	_	9	det	_	_
5	single	single	JJ	_	9	attr	_	_
6	in	in	FW	_	7	adv	_	_
7	vivo	vivo	FW	_	9	attr	_	_
8	rodent	rodent	JJ	_	9	attr	_	_
9	study	study	NN	_	11	ppmod	_	_
10	drug1	drug0	NN	_	11	dep	_	_
11	had	have	VBD	_	0	root	_	_
12	no	no	DT	_	13	det	_	_
13	effect	effect	NN	_	11	obj	_	_
14	on	on	IN	_	16	case	_	_
15	P450	p0	NN	_	16	com	_	_
16	levels	level	NNS	_	11	ppmod	_	_
17	.	.	.	_	11	p	_	_

1	No	no	DT	_	4	det	_	_
2	formal	formal	JJ	_	4	attr	_	_
3	drug-interaction	drug-interaction	NN	_	4	com	_	_
4	studies	study	NNS	_	7	dep	_	_
5	have	have	VBP	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	performed	performed	VBN	_	0	root	_	_
8	,	,	,	_	7	p	_	_
9	and	and	CC	_	7	cc	_	_
10	a	a	DT	_	13	det	_	_
11	clinically	clinically	RB	_	12	adv	_	_
12	significant	significant	JJ	_	13	attr	_	_
13	interaction	interaction	NN	_	27	dep	_	_
14	with	with	IN	_	16	case	_	_
15	other	other	JJ	_	16	attr	_	_
16	medications	medication	NNS	_	13	ppmod	_	_
17	used	use	VBN	_	16	acl	_	_
18	in	in	IN	_	20	case	_	_
19	the	the	DT	_	20	det	_	_
20	treatment	treatment	NN	_	17	ppmod	_	_
21	of	of	IN	_	24	case	_	_
22	hypoxic	hypoxic	JJ	_	24	attr	_	_
23	respiratory	respiratory	JJ	_	24	attr	_	_
24	failure	failure	NN	_	20	ppmod	_	_
25	cannot	cannot	MD	_	27	modal	_	_
26	be	be	VB	_	27	aux	_	_
27	excluded	exclude	VBN	_	7	conj	_	_
28	based	base	VBN	_	32	adv	_	_
29	on	on	IN	_	32	case	_	_
30	the	the	DT	_	32	det	_	_
31	available	available	JJ	_	32	attr	_	_
32	data	datum	NNS	_	27	ppmod	_	_
33	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	administered	administer	VBN	_	0	root	_	_
5	with	with	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	,	,	,	_	6	p	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	,	,	,	_	8	p	_	_
10	drug4	drug0	NN	_	6	conj	_	_
11	,	,	,	_	10	p	_	_
12	drug5	drug0	NN	_	6	conj	_	_
13	,	,	,	_	12	p	_	_
14	drug6	drug0	NN	_	6	conj	_	_
15	,	,	,	_	14	p	_	_
16	and	and	CC	_	14	cc	_	_
17	high-frequency	high-frequency	VBP	_	18	attr	_	_
18	ventilation	ventilation	NN	_	6	conj	_	_
19	.	.	.	_	4	p	_	_

1	Although	although	IN	_	3	mark	_	_
2	there	there	EX	_	3	dep	_	_
3	are	be	VBP	_	20	advcl	_	_
4	no	no	DT	_	6	det	_	_
5	study	study	NN	_	6	com	_	_
6	data	data	NN	_	3	obj	_	_
7	to	to	TO	_	8	aux	_	_
8	evaluate	evaluate	VB	_	3	comp	_	_
9	the	the	DT	_	10	det	_	_
10	possibility	possibility	NN	_	8	obj	_	_
11	,	,	,	_	20	p	_	_
12	drug1	drug0	NN	_	20	dep	_	_
13	,	,	,	_	12	p	_	_
14	including	include	VBG	_	15	adv	_	_
15	drug2	drug0	NN	_	12	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	drug3	drug0	NN	_	15	conj	_	_
18	,	,	,	_	12	p	_	_
19	may	may	MD	_	20	modal	_	_
20	have	have	VB	_	0	root	_	_
21	an	an	DT	_	23	det	_	_
22	additive	additive	JJ	_	23	attr	_	_
23	effect	effect	NN	_	20	obj	_	_
24	with	with	IN	_	25	case	_	_
25	drug4	drug0	NN	_	23	ppmod	_	_
26	on	on	IN	_	28	case	_	_
27	the	the	DT	_	28	det	_	_
28	risk	risk	NN	_	23	ppmod	_	_
29	of	of	IN	_	30	case	_	_
30	developing	develop	VBG	_	28	ppmod	_	_
31	methemoglobinemia	methemoglobinemia	NN	_	30	obj	_	_
32	.	.	.	_	20	p	_	_

1	An	an	DT	_	2	det	_	_
2	association	association	NN	_	19	dep	_	_
3	between	between	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	an	an	DT	_	8	det	_	_
7	increased	increase	VBN	_	8	attr	_	_
8	risk	risk	NN	_	4	conj	_	_
9	of	of	IN	_	10	case	_	_
10	methaemoglobinaemia	methaemoglobinaemia	NN	_	8	ppmod	_	_
11	,	,	,	_	2	p	_	_
12	particularly	particularly	RB	_	2	adv	_	_
13	in	in	IN	_	14	case	_	_
14	infants	infant	NNS	_	2	ppmod	_	_
15	,	,	,	_	2	p	_	_
16	has	have	VBZ	_	19	aux	_	_
17	specifically	specifically	RB	_	19	adv	_	_
18	been	be	VBN	_	19	aux	_	_
19	described	describe	VBN	_	0	root	_	_
20	in	in	IN	_	24	case	_	_
21	a	a	DT	_	24	det	_	_
22	literature	literature	NN	_	24	com	_	_
23	case	case	NN	_	24	com	_	_
24	report	report	NN	_	19	ppmod	_	_
25	.	.	.	_	19	p	_	_

1	This	this	DT	_	2	det	_	_
2	risk	risk	NN	_	3	dep	_	_
3	is	be	VBZ	_	0	root	_	_
4	present	present	JJ	_	3	dep	_	_
5	whether	whether	IN	_	9	mark	_	_
6	the	the	DT	_	7	det	_	_
7	drugs	drug	NNS	_	9	dep	_	_
8	are	be	VBP	_	9	aux	_	_
9	administered	administer	VBN	_	3	comp	_	_
10	as	as	IN	_	17	case	_	_
11	oral	oral	JJ	_	17	attr	_	_
12	,	,	,	_	11	p	_	_
13	parenteral	parenteral	JJ	_	11	conj	_	_
14	,	,	,	_	13	p	_	_
15	or	or	CC	_	13	cc	_	_
16	topical	topical	JJ	_	11	conj	_	_
17	formulations	formulation	NNS	_	9	ppmod	_	_
18	.	.	.	_	3	p	_	_

1	Interactions	interaction	NNS	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	occur	occur	VB	_	0	root	_	_
4	with	with	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	following	following	NN	_	3	ppmod	_	_
7	:	:	:	_	6	p	_	_
8	adrenocorticoids	adrenocorticoids	NN	_	6	conj	_	_
9	(	-lrb-	-LRB-	_	11	p	_	_
10	cortisone-like	cortisone-like	JJ	_	11	attr	_	_
11	medicine	medicine	NN	_	8	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	,	,	,	_	8	p	_	_
14	drug1	drug0	NN	_	6	conj	_	_
15	(	-lrb-	-LRB-	_	17	p	_	_
16	drug2	drug0	CD	_	17	num	_	_
17	s	s	NN	_	14	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	,	,	,	_	14	p	_	_
20	drug3	drug0	NN	_	6	conj	_	_
21	,	,	,	_	20	p	_	_
22	drug4	drug0	NN	_	6	conj	_	_
23	(	-lrb-	-LRB-	_	24	p	_	_
24	drug5	drug0	NN	_	22	prn	_	_
25	may	may	MD	_	26	modal	_	_
26	decrease	decrease	VB	_	24	acl	_	_
27	the	the	DT	_	28	det	_	_
28	effects	effect	NNS	_	26	obj	_	_
29	of	of	IN	_	31	case	_	_
30	these	these	DT	_	31	det	_	_
31	medicines	medicine	NNS	_	28	ppmod	_	_
32	)	-rrb-	-RRB-	_	24	p	_	_
33	,	,	,	_	22	p	_	_
34	drug6	drug0	NN	_	6	conj	_	_
35	(	-lrb-	-LRB-	_	34	p	_	_
36	using	use	VBG	_	34	acl	_	_
37	these	these	DT	_	38	det	_	_
38	medicines	medicine	NNS	_	36	obj	_	_
39	with	with	IN	_	42	mark	_	_
40	drug7	drug0	NN	_	42	dep	_	_
41	may	may	MD	_	42	modal	_	_
42	result	result	VB	_	38	acl	_	_
43	in	in	IN	_	47	case	_	_
44	increased	increase	VBN	_	47	attr	_	_
45	CNS	cns	NN	_	47	com	_	_
46	depressant	depressant	NN	_	47	com	_	_
47	effects	effect	NNS	_	42	ppmod	_	_
48	)	-rrb-	-RRB-	_	34	p	_	_
49	,	,	,	_	34	p	_	_
50	drug8	drug0	NN	_	6	conj	_	_
51	,	,	,	_	50	p	_	_
52	drug9	drug0	NN	_	6	conj	_	_
53	(	-lrb-	-LRB-	_	52	p	_	_
54	using	use	VBG	_	52	acl	_	_
55	these	these	DT	_	56	det	_	_
56	medicines	medicine	NNS	_	54	obj	_	_
57	with	with	IN	_	58	case	_	_
58	drug10	drug0	NN	_	56	ppmod	_	_
59	may	may	MD	_	60	modal	_	_
60	change	change	VB	_	56	acl	_	_
61	the	the	DT	_	62	det	_	_
62	amount	amount	NN	_	60	obj	_	_
63	of	of	IN	_	65	case	_	_
64	either	either	DT	_	65	det	_	_
65	medicine	medicine	NN	_	62	ppmod	_	_
66	that	that	WDT	_	67	dep	_	_
67	you	you	VBZ	_	65	relcl	_	_
68	need	need	NN	_	70	dep	_	_
69	to	to	TO	_	70	aux	_	_
70	take	take	VB	_	67	comp	_	_
71	)	-rrb-	-RRB-	_	52	p	_	_
72	,	,	,	_	52	p	_	_
73	and	and	CC	_	52	cc	_	_
74	oral	oral	JJ	_	77	attr	_	_
75	drug11	drug0	NN	_	77	com	_	_
76	containing	containing	NN	_	77	com	_	_
77	drug12	drug0	NN	_	6	conj	_	_
78	(	-lrb-	-LRB-	_	81	p	_	_
79	drug13	drug0	NN	_	81	dep	_	_
80	may	may	MD	_	81	modal	_	_
81	decrease	decrease	VB	_	77	prn	_	_
82	the	the	DT	_	83	det	_	_
83	effectiveness	effectiveness	NN	_	81	obj	_	_
84	of	of	IN	_	87	case	_	_
85	these	these	DT	_	87	det	_	_
86	oral	oral	JJ	_	87	attr	_	_
87	drug14	drug0	NN	_	83	ppmod	_	_
88	,	,	,	_	81	p	_	_
89	and	and	CC	_	81	cc	_	_
90	you	you	RB	_	92	adv	_	_
91	may	may	MD	_	92	modal	_	_
92	need	need	VBP	_	81	conj	_	_
93	to	to	TO	_	94	aux	_	_
94	change	change	NN	_	92	ppmod	_	_
95	to	to	TO	_	98	aux	_	_
96	a	a	DT	_	98	det	_	_
97	different	different	JJ	_	98	attr	_	_
98	type	type	NN	_	92	ppmod	_	_
99	of	of	IN	_	101	case	_	_
100	birth	birth	NN	_	101	com	_	_
101	control	control	NN	_	98	ppmod	_	_
102	)	-rrb-	-RRB-	_	81	p	_	_
103	.	.	.	_	3	p	_	_

1	A	a	DT	_	4	det	_	_
2	drug-drug	drug-drug	JJ	_	4	attr	_	_
3	interaction	interaction	NN	_	4	com	_	_
4	study	study	NN	_	5	dep	_	_
5	evaluated	evaluate	VBD	_	0	root	_	_
6	the	the	DT	_	7	det	_	_
7	effect	effect	NN	_	5	obj	_	_
8	of	of	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	use	use	NN	_	7	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	drug1	drug0	NN	_	13	com	_	_
13	Gel	gel	NN	_	10	ppmod	_	_
14	,	,	,	_	13	p	_	_
15	5	0	CD	_	13	appo	_	_
16	%	%	NN	_	15	meta	_	_
17	,	,	,	_	13	p	_	_
18	in	in	IN	_	19	case	_	_
19	combination	combination	NN	_	7	ppmod	_	_
20	with	with	IN	_	22	case	_	_
21	double	double	JJ	_	22	attr	_	_
22	strength	strength	NN	_	19	ppmod	_	_
23	(	-lrb-	-LRB-	_	26	p	_	_
24	160	0	CD	_	26	num	_	_
25	mg/800	mg/0	CD	_	26	num	_	_
26	mg	mg	NN	_	22	prn	_	_
27	)	-rrb-	-RRB-	_	26	p	_	_
28	drug2	drug0	NN	_	22	appo	_	_
29	/	/	:	_	22	p	_	_
30	drug3	drug0	NN	_	22	appo	_	_
31	(	-lrb-	-LRB-	_	32	p	_	_
32	drug4	drug0	NN	_	30	prn	_	_
33	/	/	:	_	32	p	_	_
34	drug5	drug0	NN	_	32	appo	_	_
35	)	-rrb-	-RRB-	_	32	p	_	_
36	.	.	.	_	5	p	_	_

1	During	during	IN	_	2	case	_	_
2	co-administration	co-administration	NN	_	10	ppmod	_	_
3	,	,	,	_	10	p	_	_
4	systemic	systemic	JJ	_	5	attr	_	_
5	levels	level	NNS	_	10	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	were	be	VBD	_	0	root	_	_
11	essentially	essentially	RB	_	12	adv	_	_
12	unchanged	unchanged	JJ	_	10	dep	_	_
13	.	.	.	_	10	p	_	_

1	Notably	notably	RB	_	16	adv	_	_
2	,	,	,	_	16	p	_	_
3	systemic	systemic	JJ	_	4	attr	_	_
4	exposure	exposure	NN	_	16	dep	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	AUC0-12	auc0	CD	_	4	num	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	4	ppmod	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	drug2	drug0	NN	_	9	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	was	be	VBD	_	16	aux	_	_
14	more	more	RBR	_	16	adv	_	_
15	than	than	IN	_	14	case	_	_
16	doubled	double	VBN	_	0	root	_	_
17	in	in	IN	_	19	case	_	_
18	the	the	DT	_	19	det	_	_
19	presence	presence	NN	_	16	ppmod	_	_
20	of	of	IN	_	23	case	_	_
21	drug3	drug0	NN	_	23	attr	_	_
22	/	/	:	_	23	p	_	_
23	drug4	drug0	NN	_	19	ppmod	_	_
24	.	.	.	_	16	p	_	_

1	Exposure	exposure	NN	_	7	dep	_	_
2	from	from	IN	_	6	case	_	_
3	the	the	DT	_	6	det	_	_
4	proposed	proposed	JJ	_	6	attr	_	_
5	topical	topical	JJ	_	6	attr	_	_
6	dose	dose	NN	_	1	ppmod	_	_
7	is	be	VBZ	_	0	root	_	_
8	about	about	IN	_	9	case	_	_
9	1	0	CD	_	7	ppmod	_	_
10	%	%	NN	_	9	meta	_	_
11	of	of	IN	_	12	case	_	_
12	that	that	DT	_	9	ppmod	_	_
13	from	from	IN	_	18	case	_	_
14	the	the	DT	_	18	det	_	_
15	100	0	CD	_	16	num	_	_
16	mg	mg	NN	_	18	attr	_	_
17	oral	oral	JJ	_	18	attr	_	_
18	dose	dose	NN	_	12	ppmod	_	_
19	,	,	,	_	7	p	_	_
20	even	even	RB	_	21	com	_	_
21	when	when	WRB	_	22	adv	_	_
22	co-administered	co-administered	VBN	_	7	comp	_	_
23	with	with	IN	_	26	case	_	_
24	drug1	drug0	NN	_	26	attr	_	_
25	/	/	:	_	26	p	_	_
26	drug2	drug0	NN	_	22	ppmod	_	_
27	.	.	.	_	7	p	_	_

1	Certain	certain	JJ	_	3	attr	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	medications	medication	NNS	_	0	root	_	_
4	(	-lrb-	-LRB-	_	3	p	_	_
5	such	such	JJ	_	7	adv	_	_
6	as	as	IN	_	7	case	_	_
7	drug1	drug0	NN	_	3	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	drug2	drug0	NN	_	7	appo	_	_
10	,	,	,	_	7	p	_	_
11	St.	st.	NN	_	7	appo	_	_

1	John	john	NN	_	3	com	_	_
2	s	s	NN	_	3	com	_	_
3	wort	wort	NN	_	6	dep	_	_
4	)	-rrb-	-RRB-	_	3	p	_	_
5	may	may	MD	_	6	modal	_	_
6	increase	increase	VB	_	0	root	_	_
7	the	the	DT	_	8	det	_	_
8	formation	formation	NN	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	a	a	DT	_	13	det	_	_
13	metabolite	metabolite	NN	_	10	appo	_	_
14	of	of	IN	_	15	case	_	_
15	drug2	drug0	NNS	_	13	ppmod	_	_
16	associated	associate	VBN	_	15	acl	_	_
17	with	with	IN	_	18	case	_	_
18	hemolysis	hemolysis	NN	_	16	ppmod	_	_
19	.	.	.	_	6	p	_	_

1	With	with	IN	_	4	case	_	_
2	oral	oral	JJ	_	4	attr	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	treatment	treatment	NN	_	12	ppmod	_	_
5	,	,	,	_	12	p	_	_
6	drug2	drug0	NNS	_	12	dep	_	_
7	such	such	JJ	_	9	adv	_	_
8	as	as	IN	_	9	case	_	_
9	drug3	drug0	NN	_	6	ppmod	_	_
10	have	have	VBP	_	12	aux	_	_
11	been	be	VBN	_	12	aux	_	_
12	noted	note	VBN	_	0	root	_	_
13	to	to	TO	_	15	aux	_	_
14	possibly	possibly	RB	_	15	adv	_	_
15	increase	increase	VB	_	12	comp	_	_
16	the	the	DT	_	17	det	_	_
17	likelihood	likelihood	NN	_	15	obj	_	_
18	of	of	IN	_	20	case	_	_
19	hematologic	hematologic	JJ	_	20	attr	_	_
20	reactions	reaction	NNS	_	17	ppmod	_	_

1	.	.	.	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	An	an	DT	_	3	det	_	_
2	encephalopathic	encephalopathic	JJ	_	3	attr	_	_
3	syndrome	syndrome	NN	_	37	dep	_	_
4	(	-lrb-	-LRB-	_	3	p	_	_
5	characterized	characterize	VBN	_	3	acl	_	_
6	by	by	IN	_	7	case	_	_
7	weakness	weakness	NN	_	5	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	lethargy	lethargy	NN	_	7	conj	_	_
10	,	,	,	_	9	p	_	_
11	fever	fever	NN	_	7	conj	_	_
12	,	,	,	_	11	p	_	_
13	tremulousness	tremulousness	NN	_	7	conj	_	_
14	and	and	CC	_	13	cc	_	_
15	confusion	confusion	NN	_	7	conj	_	_
16	,	,	,	_	15	p	_	_
17	extrapyramidal	extrapyramidal	JJ	_	18	attr	_	_
18	symptoms	symptom	NNS	_	7	conj	_	_
19	,	,	,	_	18	p	_	_
20	leukocytosis	leukocytosis	NN	_	7	conj	_	_
21	,	,	,	_	20	p	_	_
22	elevated	elevated	JJ	_	24	attr	_	_
23	serum	serum	NN	_	24	com	_	_
24	enzymes	enzyme	NNS	_	7	conj	_	_
25	,	,	,	_	24	p	_	_
26	BUN	bun	NN	_	7	conj	_	_
27	,	,	,	_	26	p	_	_
28	and	and	CC	_	26	cc	_	_
29	FBS	fbs	NN	_	7	conj	_	_
30	)	-rrb-	-RRB-	_	3	p	_	_
31	followed	followed	VBN	_	3	acl	_	_
32	by	by	IN	_	35	case	_	_
33	irreversible	irreversible	JJ	_	35	attr	_	_
34	brain	brain	NN	_	35	com	_	_
35	damage	damage	NN	_	31	ppmod	_	_
36	has	have	VBZ	_	37	aux	_	_
37	occurred	occur	VBN	_	0	root	_	_
38	in	in	IN	_	41	case	_	_
39	a	a	DT	_	41	det	_	_
40	few	few	JJ	_	41	attr	_	_
41	patients	patient	NNS	_	37	ppmod	_	_
42	treated	treat	VBN	_	41	acl	_	_
43	with	with	IN	_	44	case	_	_
44	drug1	drug0	NN	_	42	ppmod	_	_
45	plus	plus	CC	_	44	cc	_	_
46	drug2	drug0	NN	_	44	conj	_	_
47	.	.	.	_	37	p	_	_

1	A	a	DT	_	3	det	_	_
2	causal	causal	JJ	_	3	attr	_	_
3	relationship	relationship	NN	_	18	dep	_	_
4	between	between	IN	_	6	case	_	_
5	these	these	DT	_	6	det	_	_
6	events	event	NNS	_	3	ppmod	_	_
7	and	and	CC	_	3	cc	_	_
8	the	the	DT	_	10	det	_	_
9	concomitant	concomitant	JJ	_	10	attr	_	_
10	administration	administration	NN	_	3	conj	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	drug2	drug0	NN	_	12	conj	_	_
15	has	have	VBZ	_	18	aux	_	_
16	not	not	RB	_	18	neg	_	_
17	been	be	VBN	_	18	aux	_	_
18	established	establish	VBN	_	0	root	_	_
19	;	;	:	_	18	p	_	_

1	however	however	RB	_	20	adv	_	_
2	,	,	,	_	20	p	_	_
3	patients	patient	NNS	_	20	dep	_	_
4	receiving	receive	VBG	_	3	acl	_	_
5	such	such	JJ	_	7	attr	_	_
6	combined	combined	JJ	_	7	attr	_	_
7	therapy	therapy	NN	_	4	obj	_	_
8	should	should	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	monitored	monitor	VBN	_	7	acl	_	_
11	closely	closely	RB	_	10	adv	_	_
12	for	for	IN	_	14	case	_	_
13	early	early	JJ	_	14	attr	_	_
14	evidence	evidence	NN	_	10	ppmod	_	_
15	of	of	IN	_	17	case	_	_
16	neurological	neurological	JJ	_	17	attr	_	_
17	toxicity	toxicity	NN	_	14	ppmod	_	_
18	and	and	CC	_	17	cc	_	_
19	treatment	treatment	NN	_	17	conj	_	_
20	discontinued	discontinue	VBD	_	0	root	_	_
21	promptly	promptly	RB	_	20	adv	_	_
22	if	if	IN	_	25	mark	_	_
23	such	such	JJ	_	24	attr	_	_
24	signs	sign	NNS	_	25	dep	_	_
25	appear	appear	VBP	_	20	comp	_	_
26	.	.	.	_	20	p	_	_

1	As	as	IN	_	4	case	_	_
2	with	with	IN	_	4	case	_	_
3	other	other	JJ	_	4	attr	_	_
4	drug1	drug0	NN	_	9	ppmod	_	_
5	,	,	,	_	9	p	_	_
6	it	it	PRP	_	9	dep	_	_
7	should	should	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	noted	note	VBN	_	0	root	_	_
10	that	that	IN	_	13	mark	_	_
11	drug2	drug0	NN	_	13	dep	_	_
12	may	may	MD	_	13	modal	_	_
13	be	be	VB	_	9	comp	_	_
14	capable	capable	JJ	_	13	dep	_	_
15	of	of	IN	_	16	case	_	_
16	potentiating	potentiate	VBG	_	14	ppmod	_	_
17	drug3	drug0	NN	_	16	obj	_	_
18	such	such	JJ	_	20	adv	_	_
19	as	as	IN	_	20	case	_	_
20	drug4	drug0	NN	_	17	ppmod	_	_
21	,	,	,	_	20	p	_	_
22	drug5	drug0	NN	_	20	conj	_	_
23	,	,	,	_	22	p	_	_
24	and	and	CC	_	22	cc	_	_
25	drug6	drug0	NN	_	20	conj	_	_
26	.	.	.	_	9	p	_	_

1	In	in	IN	_	3	case	_	_
2	a	a	DT	_	3	det	_	_
3	study	study	NN	_	18	ppmod	_	_
4	of	of	IN	_	7	case	_	_
5	12	0	CD	_	7	num	_	_
6	schizophrenic	schizophrenic	JJ	_	7	attr	_	_
7	patients	patient	NNS	_	3	ppmod	_	_
8	coadministered	coadministered	JJ	_	10	attr	_	_
9	oral	oral	JJ	_	10	attr	_	_
10	drug1	drug0	NN	_	7	attr	_	_
11	and	and	CC	_	10	cc	_	_
12	drug2	drug0	NN	_	10	conj	_	_
13	,	,	,	_	18	p	_	_
14	plasma	plasma	NN	_	16	com	_	_
15	drug3	drug0	NN	_	16	com	_	_
16	levels	level	NNS	_	18	dep	_	_
17	were	be	VBD	_	18	aux	_	_
18	decreased	decrease	VBN	_	0	root	_	_
19	by	by	IN	_	23	case	_	_
20	a	a	DT	_	23	det	_	_
21	mean	mean	NN	_	23	advnp	_	_
22	of	of	IN	_	23	case	_	_
23	70	0	CD	_	18	ppmod	_	_
24	%	%	NN	_	23	meta	_	_
25	and	and	CC	_	18	cc	_	_
26	mean	mean	NN	_	27	com	_	_
27	scores	score	NNS	_	35	dep	_	_
28	on	on	IN	_	33	case	_	_
29	the	the	DT	_	33	det	_	_
30	Brief	brief	JJ	_	33	attr	_	_
31	Psychiatric	psychiatric	JJ	_	33	attr	_	_
32	Rating	rating	NN	_	33	com	_	_
33	Scale	scale	NN	_	27	ppmod	_	_
34	were	be	VBD	_	35	aux	_	_
35	increased	increase	VBN	_	18	conj	_	_
36	from	from	IN	_	37	case	_	_
37	baseline	baseline	NN	_	35	ppmod	_	_
38	.	.	.	_	18	p	_	_

1	In	in	IN	_	5	case	_	_
2	5	0	CD	_	5	num	_	_
3	other	other	JJ	_	5	attr	_	_
4	schizophrenic	schizophrenic	JJ	_	5	attr	_	_
5	patients	patient	NNS	_	16	ppmod	_	_
6	treated	treat	VBN	_	5	acl	_	_
7	with	with	IN	_	9	case	_	_
8	oral	oral	JJ	_	9	attr	_	_
9	drug1	drug0	NN	_	6	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	drug2	drug0	NN	_	9	conj	_	_
12	,	,	,	_	16	p	_	_
13	discontinuation	discontinuation	NN	_	16	dep	_	_
14	of	of	IN	_	15	case	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	produced	produce	VBD	_	0	root	_	_
17	a	a	DT	_	20	det	_	_
18	mean	mean	JJ	_	20	attr	_	_
19	3.3-fold	0-fold	RB	_	20	adv	_	_
20	increase	increase	NN	_	16	obj	_	_
21	in	in	IN	_	23	case	_	_
22	drug4	drug0	NN	_	23	com	_	_
23	concentrations	concentration	NNS	_	20	ppmod	_	_
24	.	.	.	_	16	p	_	_

1	Thus	thus	RB	_	9	adv	_	_
2	,	,	,	_	9	p	_	_
3	careful	careful	JJ	_	4	attr	_	_
4	monitoring	monitoring	NN	_	9	dep	_	_
5	of	of	IN	_	7	case	_	_
6	clinical	clinical	JJ	_	7	attr	_	_
7	status	status	NN	_	4	ppmod	_	_
8	is	be	VBZ	_	9	aux	_	_
9	warranted	warrant	VBN	_	0	root	_	_
10	when	when	WRB	_	13	adv	_	_
11	drug1	drug0	NN	_	13	dep	_	_
12	is	be	VBZ	_	13	aux	_	_
13	administered	administer	VBN	_	9	comp	_	_
14	or	or	CC	_	13	cc	_	_
15	discontinued	discontinue	VBN	_	13	conj	_	_
16	in	in	IN	_	19	case	_	_
17	drug2	drug0	JJ	_	19	attr	_	_
18	-treated	-treated	JJ	_	19	attr	_	_
19	patients	patient	NNS	_	15	ppmod	_	_
20	.	.	.	_	9	p	_	_

1	Food	food	NN	_	3	attr	_	_
2	:	:	:	_	3	p	_	_
3	drug1	drug0	NN	_	7	dep	_	_
4	should	should	MD	_	7	modal	_	_
5	not	not	RB	_	7	neg	_	_
6	be	be	VB	_	7	aux	_	_
7	administered	administer	VBN	_	0	root	_	_
8	with	with	IN	_	9	case	_	_
9	food	food	NN	_	7	ppmod	_	_
10	.	.	.	_	7	p	_	_

1	Studies	study	NNS	_	3	dep	_	_
2	have	have	VBP	_	3	aux	_	_
3	shown	show	VBN	_	0	root	_	_
4	that	that	IN	_	10	mark	_	_
5	the	the	DT	_	6	det	_	_
6	bioavailability	bioavailability	NN	_	10	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	is	be	VBZ	_	10	aux	_	_
10	reduced	reduce	VBN	_	3	comp	_	_
11	significantly	significantly	RB	_	10	adv	_	_
12	when	when	WRB	_	13	adv	_	_
13	administered	administer	VBN	_	10	comp	_	_
14	with	with	IN	_	15	case	_	_
15	food	food	NN	_	13	ppmod	_	_
16	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	10	dep	_	_
2	:	:	:	_	1	p	_	_
3	A	a	DT	_	4	det	_	_
4	report	report	NN	_	1	appo	_	_
5	of	of	IN	_	8	case	_	_
6	severe	severe	JJ	_	8	attr	_	_
7	drug2	drug0	NN	_	8	com	_	_
8	toxicity	toxicity	NN	_	4	ppmod	_	_
9	was	be	VBD	_	10	aux	_	_
10	reported	report	VBN	_	0	root	_	_
11	in	in	IN	_	13	case	_	_
12	a	a	DT	_	13	det	_	_
13	patient	patient	NN	_	10	ppmod	_	_
14	receiving	receive	VBG	_	13	acl	_	_
15	drug3	drug0	NN	_	14	obj	_	_
16	.	.	.	_	10	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	believed	believe	VBN	_	0	root	_	_
4	that	that	IN	_	9	mark	_	_
5	the	the	DT	_	6	det	_	_
6	toxicity	toxicity	NN	_	9	dep	_	_
7	may	may	MD	_	9	modal	_	_
8	have	have	VB	_	9	aux	_	_
9	resulted	result	VBD	_	3	comp	_	_
10	from	from	IN	_	14	case	_	_
11	a	a	DT	_	14	det	_	_
12	previously	previously	RB	_	13	adv	_	_
13	unrecognized	unrecognized	JJ	_	14	attr	_	_
14	interaction	interaction	NN	_	9	ppmod	_	_
15	between	between	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	drug2	drug0	NN	_	16	conj	_	_
19	and	and	CC	_	9	cc	_	_
20	a	a	DT	_	22	det	_	_
21	molecular	molecular	JJ	_	22	attr	_	_
22	basis	basis	NN	_	28	dep	_	_
23	for	for	IN	_	25	case	_	_
24	this	this	DT	_	25	det	_	_
25	interaction	interaction	NN	_	22	ppmod	_	_
26	has	have	VBZ	_	28	aux	_	_
27	been	be	VBN	_	28	aux	_	_
28	proposed	propose	VBN	_	9	conj	_	_
29	.	.	.	_	3	p	_	_

1	However	however	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	current	current	JJ	_	4	attr	_	_
4	evidence	evidence	NN	_	5	dep	_	_
5	suggests	suggest	VBZ	_	0	root	_	_
6	that	that	IN	_	9	mark	_	_
7	drug1	drug0	NN	_	9	dep	_	_
8	does	do	VBZ	_	9	aux	_	_
9	induce	induce	VB	_	5	comp	_	_
10	P-450IIE1	p-0iie0	NN	_	9	obj	_	_
11	,	,	,	_	10	p	_	_
12	a	a	DT	_	15	det	_	_
13	mixed-function	mixed-function	JJ	_	15	attr	_	_
14	oxidase	oxidase	NN	_	15	com	_	_
15	enzyme	enzyme	NN	_	10	appo	_	_
16	that	that	WDT	_	17	dep	_	_
17	appears	appear	VBZ	_	15	relcl	_	_
18	to	to	TO	_	19	aux	_	_
19	generate	generate	VB	_	17	comp	_	_
20	the	the	DT	_	22	det	_	_
21	toxic	toxic	JJ	_	22	attr	_	_
22	metabolites	metabolite	NNS	_	19	obj	_	_
23	,	,	,	_	9	p	_	_
24	in	in	IN	_	26	case	_	_
25	the	the	DT	_	26	det	_	_
26	liver	liver	NN	_	9	ppmod	_	_
27	.	.	.	_	5	p	_	_

1	Furthermore	furthermore	RB	_	5	adv	_	_
2	it	it	PRP	_	5	dep	_	_
3	has	have	VBZ	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	proposed	propose	VBN	_	0	root	_	_
6	that	that	IN	_	8	mark	_	_
7	drug1	drug0	NN	_	8	dep	_	_
8	resulted	result	VBD	_	5	comp	_	_
9	In	in	IN	_	10	case	_	_
10	induction	induction	NN	_	8	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	P-450IIE1	p-0iie0	NN	_	10	ppmod	_	_
13	in	in	IN	_	16	case	_	_
14	the	the	DT	_	16	det	_	_
15	patients	patient	NNS	_	16	com	_	_
16	liver	liver	NN	_	12	ppmod	_	_
17	which	which	WDT	_	22	dep	_	_
18	,	,	,	_	22	p	_	_
19	in	in	IN	_	20	case	_	_
20	turn	turn	NN	_	22	ppmod	_	_
21	,	,	,	_	22	p	_	_
22	resulted	result	VBD	_	16	relcl	_	_
23	in	in	IN	_	26	case	_	_
24	a	a	DT	_	26	det	_	_
25	greater	great	JJR	_	26	attr	_	_
26	proportion	proportion	NN	_	22	ppmod	_	_
27	of	of	IN	_	30	case	_	_
28	the	the	DT	_	30	det	_	_
29	ingested	ingest	VBN	_	30	attr	_	_
30	drug2	drug0	NN	_	26	ppmod	_	_
31	being	be	VBG	_	32	aux	_	_
32	converted	convert	VBN	_	30	acl	_	_
33	to	to	TO	_	36	aux	_	_
34	the	the	DT	_	36	det	_	_
35	toxic	toxic	JJ	_	36	attr	_	_
36	metabolites	metabolite	NNS	_	32	ppmod	_	_
37	.	.	.	_	5	p	_	_

1	Studies	study	NNS	_	3	dep	_	_
2	have	have	VBP	_	3	aux	_	_
3	demonstrated	demonstrate	VBN	_	0	root	_	_
4	that	that	IN	_	8	mark	_	_
5	pretreatment	pretreatment	NN	_	8	dep	_	_
6	with	with	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	potentiates	potentiate	VBZ	_	3	comp	_	_
9	a	a	DT	_	11	det	_	_
10	cetaminophen	cetaminophen	JJ	_	11	attr	_	_
11	hepatoxicity	hepatoxicity	NN	_	8	obj	_	_
12	in	in	IN	_	13	case	_	_
13	rats	rat	NNS	_	11	ppmod	_	_
14	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	known	know	VBN	_	1	acl	_	_
6	to	to	TO	_	7	aux	_	_
7	slow	slow	JJ	_	5	comp	_	_
8	the	the	DT	_	9	det	_	_
9	metabolism	metabolism	NN	_	7	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug3	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	increase	increase	NN	_	16	attr	_	_
14	its	its	PRP$	_	16	poss	_	_
15	serum	serum	NN	_	16	com	_	_
16	levels	level	NNS	_	11	conj	_	_
17	drug4	drug0	NN	_	18	com	_	_
18	levels	level	NNS	_	21	dep	_	_
19	should	should	MD	_	21	modal	_	_
20	be	be	VB	_	21	aux	_	_
21	determined	determine	VBN	_	9	acl	_	_
22	prior	prior	RB	_	21	adv	_	_
23	to	to	TO	_	25	aux	_	_
24	concurrent	concurrent	JJ	_	25	attr	_	_
25	administration	administration	NN	_	22	ppmod	_	_
26	with	with	IN	_	27	case	_	_
27	drug5	drug0	NN	_	21	ppmod	_	_
28	,	,	,	_	21	p	_	_
29	signs	sign	NNS	_	37	dep	_	_
30	and	and	CC	_	29	cc	_	_
31	symptoms	symptom	NNS	_	29	conj	_	_
32	of	of	IN	_	34	case	_	_
33	drug6	drug0	NN	_	34	com	_	_
34	toxicity	toxicity	NN	_	29	ppmod	_	_
35	should	should	MD	_	37	modal	_	_
36	be	be	VB	_	37	aux	_	_
37	monitored	monitor	VBN	_	21	conj	_	_
38	closely	closely	RB	_	37	adv	_	_
39	,	,	,	_	37	p	_	_
40	and	and	CC	_	37	cc	_	_
41	appropriate	appropriate	JJ	_	43	attr	_	_
42	dosage	dosage	NN	_	43	com	_	_
43	adjustment	adjustment	NN	_	49	dep	_	_
44	of	of	IN	_	46	case	_	_
45	the	the	DT	_	46	det	_	_
46	drug7	drug0	NN	_	43	ppmod	_	_
47	should	should	MD	_	49	modal	_	_
48	be	be	VB	_	49	aux	_	_
49	made	make	VBN	_	21	conj	_	_
50	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Potential	potential	JJ	_	4	attr	_	_
4	interaction	interaction	NN	_	10	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	may	may	MD	_	10	modal	_	_
10	exist	exist	VB	_	1	acl	_	_
11	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	may	may	MD	_	5	modal	_	_
5	increase	increase	VB	_	0	root	_	_
6	serum	serum	NN	_	7	com	_	_
7	levels	level	NNS	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_
10	.	.	.	_	5	p	_	_

1	To	to	TO	_	2	aux	_	_
2	avoid	avoid	VB	_	13	advcl	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	intoxication	intoxication	NN	_	2	obj	_	_
5	,	,	,	_	13	p	_	_
6	appropriate	appropriate	JJ	_	7	attr	_	_
7	adjustment	adjustment	NN	_	13	dep	_	_
8	of	of	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	drug2	drug0	NN	_	7	ppmod	_	_
11	should	should	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	made	make	VBN	_	0	root	_	_
14	.	.	.	_	13	p	_	_

1	Therophylline	therophylline	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	A	a	DT	_	5	det	_	_
4	recent	recent	JJ	_	5	attr	_	_
5	study	study	NN	_	7	dep	_	_
6	has	have	VBZ	_	7	aux	_	_
7	shown	show	VBN	_	1	acl	_	_
8	that	that	IN	_	16	mark	_	_
9	concomitan	concomitan	NN	_	10	com	_	_
10	administration	administration	NN	_	16	dep	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	drug2	drug0	NN	_	12	conj	_	_
15	may	may	MD	_	16	modal	_	_
16	cause	cause	VB	_	7	comp	_	_
17	elevated	elevated	JJ	_	19	attr	_	_
18	plasma	plasma	NN	_	19	com	_	_
19	levels	level	NNS	_	16	obj	_	_
20	of	of	IN	_	21	case	_	_
21	drug3	drug0	NN	_	19	ppmod	_	_
22	,	,	,	_	16	p	_	_
23	and	and	CC	_	26	cc	_	_
24	in	in	IN	_	26	case	_	_
25	some	some	DT	_	26	det	_	_
26	instances	instance	NNS	_	16	ppmod	_	_
27	a	a	DT	_	29	det	_	_
28	slight	slight	JJ	_	29	attr	_	_
29	decrease	decrease	NN	_	26	obj	_	_
30	in	in	IN	_	32	case	_	_
31	the	the	DT	_	32	det	_	_
32	elimination	elimination	NN	_	29	ppmod	_	_
33	of	of	IN	_	34	case	_	_
34	drug4	drug0	NN	_	32	ppmod	_	_
35	.	.	.	_	1	p	_	_

1	Since	since	IN	_	7	mark	_	_
2	the	the	DT	_	4	det	_	_
3	therapeutic	therapeutic	JJ	_	4	attr	_	_
4	range	range	NN	_	7	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	is	be	VBZ	_	14	advcl	_	_
8	narrow	narrow	JJ	_	7	dep	_	_
9	drug2	drug0	NN	_	11	com	_	_
10	serum	serum	NN	_	11	com	_	_
11	levels	level	NNS	_	14	dep	_	_
12	should	should	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	monitored	monitor	VBN	_	0	root	_	_
15	closely	closely	RB	_	14	adv	_	_
16	,	,	,	_	14	p	_	_
17	and	and	CC	_	14	cc	_	_
18	appropriate	appropriate	JJ	_	20	attr	_	_
19	dosage	dosage	NN	_	20	com	_	_
20	adjustments	adjustment	NNS	_	25	dep	_	_
21	of	of	IN	_	22	case	_	_
22	drug3	drug0	NN	_	20	ppmod	_	_
23	should	should	MD	_	25	modal	_	_
24	be	be	VB	_	25	aux	_	_
25	made	make	VBN	_	14	conj	_	_
26	.	.	.	_	14	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	A	a	DT	_	6	det	_	_
4	recent	recent	JJ	_	6	attr	_	_
5	case	case	NN	_	6	com	_	_
6	study	study	NN	_	8	dep	_	_
7	has	have	VBZ	_	8	aux	_	_
8	shown	show	VBN	_	1	acl	_	_
9	a	a	DT	_	11	det	_	_
10	possible	possible	JJ	_	11	attr	_	_
11	increase	increase	NN	_	8	obj	_	_
12	in	in	IN	_	15	case	_	_
13	the	the	DT	_	15	det	_	_
14	plasma	plasma	NN	_	15	com	_	_
15	level	level	NN	_	11	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	when	when	WRB	_	20	adv	_	_
19	co	co	RB	_	20	adv	_	_
20	administered	administer	VBN	_	11	relcl	_	_
21	with	with	IN	_	22	case	_	_
22	drug3	drug0	NN	_	20	ppmod	_	_
23	.	.	.	_	1	p	_	_

1	Plasma	plasma	NN	_	3	com	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	concentration	concentration	NN	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	monitored	monitor	VBN	_	0	root	_	_
7	when	when	WRB	_	13	adv	_	_
8	drug2	drug0	NN	_	13	dep	_	_
9	and	and	CC	_	8	cc	_	_
10	drug3	drug0	NN	_	8	conj	_	_
11	are	be	VBP	_	13	aux	_	_
12	co	co	RB	_	13	adv	_	_
13	administered	administer	VBN	_	6	comp	_	_
14	,	,	,	_	6	p	_	_
15	and	and	CC	_	6	cc	_	_
16	appropriate	appropriate	JJ	_	18	attr	_	_
17	dosage	dosage	NN	_	18	com	_	_
18	adjustments	adjustment	NNS	_	23	dep	_	_
19	of	of	IN	_	20	case	_	_
20	drug4	drug0	NN	_	18	ppmod	_	_
21	should	should	MD	_	23	modal	_	_
22	be	be	VB	_	23	aux	_	_
23	made	make	VBN	_	6	conj	_	_
24	.	.	.	_	6	p	_	_

1	Concurrent	concurrent	JJ	_	2	attr	_	_
2	administration	administration	NN	_	8	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	may	may	MD	_	8	modal	_	_
8	cause	cause	VB	_	0	root	_	_
9	severe	severe	JJ	_	12	attr	_	_
10	orthostatic	orthostatic	JJ	_	12	attr	_	_
11	hypotension.	hypotension.	NN	_	12	com	_	_
12	drug3	drug0	NN	_	8	obj	_	_
13	,	,	,	_	12	p	_	_
14	an	an	DT	_	15	det	_	_
15	inhibitor	inhibitor	NN	_	12	appo	_	_
16	of	of	IN	_	19	case	_	_
17	microsomal	microsomal	JJ	_	19	attr	_	_
18	drug	drug	NN	_	19	com	_	_
19	metabolism	metabolism	NN	_	15	ppmod	_	_
20	,	,	,	_	19	p	_	_
21	increased	increase	VBN	_	24	attr	_	_
22	drug4	drug0	NN	_	24	com	_	_
23	s	s	NN	_	24	com	_	_
24	half-life	half-life	NN	_	19	conj	_	_
25	and	and	CC	_	24	cc	_	_
26	toxicity	toxicity	NN	_	19	conj	_	_
27	in	in	IN	_	30	case	_	_
28	a	a	DT	_	30	det	_	_
29	rat	rat	NN	_	30	com	_	_
30	model	model	NN	_	8	ppmod	_	_
31	.	.	.	_	8	p	_	_

1	Data	datum	NNS	_	17	dep	_	_
2	from	from	IN	_	5	case	_	_
3	a	a	DT	_	5	det	_	_
4	randomized	randomized	JJ	_	5	attr	_	_
5	trial	trial	NN	_	1	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	13	attr	_	_
10	plus	plus	JJ	_	13	attr	_	_
11	or	or	CC	_	10	cc	_	_
12	minus	minus	JJ	_	10	conj	_	_
13	drug3	drug0	NN	_	7	conj	_	_
14	in	in	IN	_	16	case	_	_
15	ovarian	ovarian	JJ	_	16	attr	_	_
16	cancer	cancer	NN	_	5	ppmod	_	_
17	indicated	indicate	VBD	_	0	root	_	_
18	that	that	IN	_	21	mark	_	_
19	drug4	drug0	NN	_	21	dep	_	_
20	significantly	significantly	RB	_	21	adv	_	_
21	reduced	reduce	VBD	_	17	comp	_	_
22	neurotoxicity	neurotoxicity	NN	_	21	obj	_	_
23	;	;	:	_	17	p	_	_

1	however	however	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	it	it	PRP	_	5	dep	_	_
4	adversely	adversely	RB	_	5	adv	_	_
5	affected	affect	VBD	_	0	root	_	_
6	response	response	NN	_	7	com	_	_
7	duration	duration	NN	_	5	obj	_	_
8	suggesting	suggest	VBG	_	5	comp	_	_
9	that	that	IN	_	14	mark	_	_
10	drug1	drug0	NN	_	14	dep	_	_
11	should	should	MD	_	14	modal	_	_
12	not	not	RB	_	14	neg	_	_
13	be	be	VB	_	14	aux	_	_
14	administered	administer	VBN	_	8	comp	_	_
15	with	with	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	and/or	and/or	CC	_	16	cc	_	_
18	drug3	drug0	NN	_	19	com	_	_
19	.1	0	NN	_	16	conj	_	_

1	No	no	DT	_	3	det	_	_
2	Important	important	JJ	_	3	attr	_	_
3	Interactions	interaction	NNS	_	13	dep	_	_
4	To	to	TO	_	6	aux	_	_
5	Date	date	NN	_	6	com	_	_
6	drug1	drug0	NN	_	3	ppmod	_	_
7	does	do	VBZ	_	13	aux	_	_
8	not	not	RB	_	13	neg	_	_
9	have	have	VB	_	13	lv	_	_
10	clinically	clinically	RB	_	11	adv	_	_
11	important	important	JJ	_	13	attr	_	_
12	pharmacokinetic	pharmacokinetic	JJ	_	13	attr	_	_
13	interactions	interaction	NNS	_	0	root	_	_
14	with	with	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	,	,	,	_	15	p	_	_
17	drug3	drug0	NN	_	15	conj	_	_
18	,	,	,	_	17	p	_	_
19	drug4	drug0	NN	_	15	conj	_	_
20	,	,	,	_	19	p	_	_
21	drug5	drug0	NN	_	15	conj	_	_
22	,	,	,	_	21	p	_	_
23	drug6	drug0	NN	_	15	conj	_	_
24	,	,	,	_	23	p	_	_
25	drug7	drug0	NN	_	15	conj	_	_
26	,	,	,	_	25	p	_	_
27	drug8	drug0	NN	_	15	conj	_	_
28	,	,	,	_	27	p	_	_
29	drug9	drug0	NN	_	15	conj	_	_
30	or	or	CC	_	29	cc	_	_
31	drug10	drug0	NN	_	15	conj	_	_
32	.	.	.	_	13	p	_	_

1	Drug	drug	NN	_	3	com	_	_
2	interaction	interaction	NN	_	3	com	_	_
3	studies	study	NNS	_	9	dep	_	_
4	with	with	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	have	have	VBP	_	9	aux	_	_
7	not	not	RB	_	9	neg	_	_
8	been	be	VBN	_	9	aux	_	_
9	performed	performed	VBN	_	0	root	_	_
10	in	in	IN	_	11	case	_	_
11	patients	patient	NNS	_	9	ppmod	_	_
12	with	with	IN	_	14	case	_	_
13	severe	severe	JJ	_	14	attr	_	_
14	sepsis	sepsis	NN	_	11	ppmod	_	_
15	.	.	.	_	9	p	_	_

1	However	however	RB	_	17	adv	_	_
2	,	,	,	_	17	p	_	_
3	since	since	IN	_	5	mark	_	_
4	there	there	EX	_	5	dep	_	_
5	is	be	VBZ	_	17	advcl	_	_
6	an	an	DT	_	8	det	_	_
7	increased	increase	VBN	_	8	attr	_	_
8	risk	risk	NN	_	5	obj	_	_
9	of	of	IN	_	10	case	_	_
10	bleeding	bleeding	JJ	_	8	ppmod	_	_
11	with	with	IN	_	12	case	_	_
12	drug1	drug0	NN	_	8	ppmod	_	_
13	,	,	,	_	17	p	_	_
14	caution	caution	NN	_	17	dep	_	_
15	should	should	MD	_	17	modal	_	_
16	be	be	VB	_	17	aux	_	_
17	employed	employ	VBN	_	0	root	_	_
18	when	when	WRB	_	21	adv	_	_
19	drug2	drug0	NN	_	21	dep	_	_
20	is	be	VBZ	_	21	aux	_	_
21	used	use	VBN	_	17	comp	_	_
22	with	with	IN	_	24	case	_	_
23	other	other	JJ	_	24	attr	_	_
24	drugs	drug	NNS	_	21	ppmod	_	_
25	that	that	WDT	_	26	dep	_	_
26	affect	affect	VBP	_	24	relcl	_	_
27	hemostasis	hemostasis	NN	_	26	obj	_	_
28	.	.	.	_	17	p	_	_

1	Approximately	approximately	RB	_	2	adv	_	_
2	2/3	0	CD	_	11	num	_	_
3	of	of	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	patients	patient	NNS	_	2	ppmod	_	_
6	in	in	IN	_	10	case	_	_
7	the	the	DT	_	10	det	_	_
8	Phase	phase	NN	_	10	attr	_	_
9	3	0	CD	_	10	num	_	_
10	study	study	NN	_	5	ppmod	_	_
11	received	receive	VBD	_	0	root	_	_
12	either	either	CC	_	15	cc	_	_
13	prophylactic	prophylactic	JJ	_	15	attr	_	_
14	low	low	JJ	_	15	attr	_	_
15	dose	dose	NN	_	11	obj	_	_
16	drug1	drug0	CD	_	15	num	_	_
17	(	-lrb-	-LRB-	_	22	p	_	_
18	drug2	drug0	CD	_	22	num	_	_
19	up	up	RP	_	18	prt	_	_
20	to	to	TO	_	18	cc	_	_
21	15,000	0	CD	_	18	conj	_	_
22	units/day	units/day	NN	_	15	prn	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	or	or	CC	_	15	cc	_	_
25	prophylactic	prophylactic	JJ	_	26	attr	_	_
26	doses	dose	NNS	_	15	conj	_	_
27	of	of	IN	_	28	case	_	_
28	drug3	drug0	NN	_	26	ppmod	_	_
29	as	as	IN	_	30	mark	_	_
30	indicated	indicate	VBN	_	11	comp	_	_
31	in	in	IN	_	34	case	_	_
32	the	the	DT	_	34	det	_	_
33	prescribing	prescribing	JJ	_	34	attr	_	_
34	information	information	NN	_	30	ppmod	_	_
35	for	for	IN	_	38	case	_	_
36	the	the	DT	_	38	det	_	_
37	specific	specific	JJ	_	38	attr	_	_
38	products	product	NNS	_	34	ppmod	_	_
39	.	.	.	_	11	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	use	use	NN	_	10	dep	_	_
3	of	of	IN	_	7	case	_	_
4	prophylactic	prophylactic	JJ	_	7	attr	_	_
5	low	low	JJ	_	7	attr	_	_
6	dose	dose	NN	_	7	com	_	_
7	drug1	drug0	NN	_	2	ppmod	_	_
8	did	do	VBD	_	10	aux	_	_
9	not	not	RB	_	10	neg	_	_
10	appear	appear	VB	_	0	root	_	_
11	to	to	TO	_	12	aux	_	_
12	affect	affect	VB	_	10	comp	_	_
13	safety	safety	NN	_	12	obj	_	_
14	,	,	,	_	13	p	_	_
15	however	however	RB	_	27	adv	_	_
16	,	,	,	_	27	p	_	_
17	its	its	PRP$	_	18	poss	_	_
18	effects	effect	NNS	_	27	dep	_	_
19	on	on	IN	_	21	case	_	_
20	the	the	DT	_	21	det	_	_
21	efficacy	efficacy	NN	_	18	ppmod	_	_
22	of	of	IN	_	23	case	_	_
23	drug2	drug0	NN	_	21	ppmod	_	_
24	have	have	VBP	_	27	aux	_	_
25	not	not	RB	_	27	neg	_	_
26	been	be	VBN	_	27	aux	_	_
27	evaluated	evaluate	VBN	_	13	acl	_	_
28	in	in	IN	_	34	case	_	_
29	an	an	DT	_	34	det	_	_
30	adequate	adequate	JJ	_	34	attr	_	_
31	and	and	CC	_	30	cc	_	_
32	well-controlled	well-controlled	JJ	_	30	conj	_	_
33	clinical	clinical	JJ	_	34	attr	_	_
34	trial	trial	NN	_	27	ppmod	_	_
35	.	.	.	_	10	p	_	_

1	Drug/Laboratory	drug/laboratory	JJ	_	3	attr	_	_
2	Test	test	NN	_	3	com	_	_
3	Interaction	interaction	NN	_	18	dep	_	_
4	Because	because	IN	_	7	mark	_	_
5	drug1	drug0	NN	_	7	dep	_	_
6	may	may	MD	_	7	modal	_	_
7	affect	affect	VB	_	18	advcl	_	_
8	the	the	DT	_	10	det	_	_
9	APTT	aptt	NN	_	10	com	_	_
10	assay	assay	NN	_	7	obj	_	_
11	,	,	,	_	18	p	_	_
12	drug2	drug0	NN	_	13	com	_	_
13	present	present	NN	_	18	dep	_	_
14	in	in	IN	_	16	case	_	_
15	plasma	plasma	NN	_	16	com	_	_
16	samples	sample	NNS	_	13	ppmod	_	_
17	may	may	MD	_	18	modal	_	_
18	interfere	interfere	VB	_	0	root	_	_
19	with	with	IN	_	22	case	_	_
20	one-stage	one-stage	JJ	_	22	attr	_	_
21	coagulation	coagulation	NN	_	22	com	_	_
22	assays	assay	NNS	_	18	ppmod	_	_
23	based	base	VBN	_	22	acl	_	_
24	on	on	IN	_	26	case	_	_
25	the	the	DT	_	26	det	_	_
26	APTT	aptt	NN	_	23	ppmod	_	_
27	(	-lrb-	-LRB-	_	28	p	_	_
28	such	such	JJ	_	26	prn	_	_
29	as	as	IN	_	31	case	_	_
30	factor	factor	NN	_	31	com	_	_
31	VIII	viii	NN	_	28	ppmod	_	_
32	,	,	,	_	31	p	_	_
33	IX	ix	NN	_	31	conj	_	_
34	,	,	,	_	33	p	_	_
35	and	and	CC	_	33	cc	_	_
36	XI	xi	NN	_	37	com	_	_
37	assays	assay	NNS	_	31	conj	_	_
38	)	-rrb-	-RRB-	_	28	p	_	_
39	.	.	.	_	18	p	_	_

1	This	this	DT	_	2	det	_	_
2	interference	interference	NN	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	result	result	VB	_	0	root	_	_
5	in	in	IN	_	9	case	_	_
6	an	an	DT	_	9	det	_	_
7	apparent	apparent	JJ	_	9	attr	_	_
8	factor	factor	NN	_	9	com	_	_
9	concentration	concentration	NN	_	4	ppmod	_	_
10	that	that	WDT	_	11	dep	_	_
11	is	be	VBZ	_	9	relcl	_	_
12	lower	low	JJR	_	11	dep	_	_
13	than	than	IN	_	16	case	_	_
14	the	the	DT	_	16	det	_	_
15	true	true	JJ	_	16	attr	_	_
16	concentration	concentration	NN	_	12	ppmod	_	_
17	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	present	present	NN	_	8	dep	_	_
3	in	in	IN	_	5	case	_	_
4	plasma	plasma	NN	_	5	com	_	_
5	samples	sample	NNS	_	2	ppmod	_	_
6	does	do	VBZ	_	8	aux	_	_
7	not	not	RB	_	8	neg	_	_
8	interfere	interfere	VB	_	0	root	_	_
9	with	with	IN	_	12	case	_	_
10	one-stage	one-stage	JJ	_	12	attr	_	_
11	factor	factor	NN	_	12	com	_	_
12	assays	assay	NNS	_	8	ppmod	_	_
13	based	base	VBN	_	12	acl	_	_
14	on	on	IN	_	16	case	_	_
15	the	the	DT	_	16	det	_	_
16	PT	pt	NN	_	13	ppmod	_	_
17	(	-lrb-	-LRB-	_	21	p	_	_
18	such	such	JJ	_	19	com	_	_
19	as	as	IN	_	21	cc	_	_
20	factor	factor	NN	_	21	com	_	_
21	II	ii	NN	_	16	prn	_	_
22	,	,	,	_	21	p	_	_
23	V	v	NN	_	21	conj	_	_
24	,	,	,	_	23	p	_	_
25	VII	vii	NN	_	21	conj	_	_
26	,	,	,	_	25	p	_	_
27	and	and	CC	_	25	cc	_	_
28	X	x	NN	_	29	com	_	_
29	assays	assay	NNS	_	21	conj	_	_
30	)	-rrb-	-RRB-	_	21	p	_	_
31	.	.	.	_	8	p	_	_

1	There	there	EX	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	no	no	DT	_	6	det	_	_
4	known	known	JJ	_	6	attr	_	_
5	drug	drug	NN	_	6	com	_	_
6	interference	interference	NN	_	2	obj	_	_
7	with	with	IN	_	11	case	_	_
8	standard	standard	JJ	_	11	attr	_	_
9	clinical	clinical	JJ	_	11	attr	_	_
10	laboratory	laboratory	NN	_	11	com	_	_
11	tests	test	NNS	_	6	ppmod	_	_
12	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	12	dep	_	_
2	enhance	enhance	VB	_	1	acl	_	_
3	the	the	DT	_	5	det	_	_
4	renal	renal	JJ	_	5	attr	_	_
5	toxicity	toxicity	NN	_	2	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	in	in	IN	_	11	case	_	_
9	animals.	animals.	NN	_	11	attr	_	_
10	7	0	CD	_	11	num	_	_
11	drug3	drug0	NN	_	5	ppmod	_	_
12	interferes	interfere	VBZ	_	24	acl	_	_
13	with	with	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	action	action	NN	_	12	ppmod	_	_
16	of	of	IN	_	18	case	_	_
17	drug4	drug0	NN	_	18	com	_	_
18	preparations	preparation	NNS	_	15	ppmod	_	_
19	by	by	IN	_	20	case	_	_
20	chelating	chelating	NN	_	12	ppmod	_	_
21	the	the	DT	_	22	det	_	_
22	drug5	drug0	NN	_	24	attr	_	_
23	.	.	.	_	24	p	_	_
24	7	0	CD	_	0	root	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	can	can	MD	_	3	modal	_	_
3	interact	interact	VB	_	0	root	_	_
4	with	with	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	or	or	CC	_	5	cc	_	_
7	other	other	JJ	_	8	attr	_	_
8	drug3	drug0	NN	_	5	conj	_	_
9	(	-lrb-	-LRB-	_	11	p	_	_
10	may	may	MD	_	11	modal	_	_
11	potentiate	potentiate	VB	_	5	prn	_	_
12	the	the	DT	_	15	det	_	_
13	CNS	cns	NN	_	15	com	_	_
14	depressant	depressant	NN	_	15	com	_	_
15	effects	effect	NNS	_	11	obj	_	_
16	of	of	IN	_	19	case	_	_
17	either	either	CC	_	19	cc	_	_
18	these	these	DT	_	19	det	_	_
19	medications	medication	NNS	_	15	ppmod	_	_
20	or	or	CC	_	19	cc	_	_
21	drug4	drug0	NNS	_	19	conj	_	_
22	)	-rrb-	-RRB-	_	11	p	_	_
23	,	,	,	_	5	p	_	_
24	drug5	drug0	NN	_	5	conj	_	_
25	or	or	CC	_	24	cc	_	_
26	other	other	JJ	_	27	attr	_	_
27	medications	medication	NNS	_	24	conj	_	_
28	with	with	IN	_	30	case	_	_
29	anticholinergic	anticholinergic	JJ	_	30	attr	_	_
30	activity	activity	NN	_	27	ppmod	_	_
31	(	-lrb-	-LRB-	_	36	p	_	_
32	anticholinergic	anticholinergic	JJ	_	33	attr	_	_
33	effects	effect	NNS	_	36	dep	_	_
34	may	may	MD	_	36	modal	_	_
35	be	be	VB	_	36	aux	_	_
36	potentiated	potentiate	VBN	_	24	prn	_	_
37	when	when	WRB	_	41	adv	_	_
38	these	these	DT	_	39	det	_	_
39	medications	medication	NNS	_	41	dep	_	_
40	are	be	VBP	_	41	aux	_	_
41	used	use	VBN	_	36	comp	_	_
42	concurrently	concurrently	RB	_	41	adv	_	_
43	with	with	IN	_	44	case	_	_
44	drug6	drug0	NN	_	41	ppmod	_	_
45	)	-rrb-	-RRB-	_	36	p	_	_
46	,	,	,	_	24	p	_	_
47	and	and	CC	_	24	cc	_	_
48	drug7	drug0	NN	_	5	conj	_	_
49	(	-lrb-	-LRB-	_	55	p	_	_
50	concurrent	concurrent	JJ	_	51	attr	_	_
51	use	use	NN	_	55	dep	_	_
52	with	with	IN	_	53	case	_	_
53	drug8	drug0	NN	_	51	ppmod	_	_
54	may	may	MD	_	55	modal	_	_
55	prolong	prolong	VB	_	48	prn	_	_
56	and	and	CC	_	55	cc	_	_
57	intensify	intensify	VB	_	55	conj	_	_
58	the	the	DT	_	59	det	_	_
59	anticholinergic	anticholinergic	NN	_	57	obj	_	_
60	and	and	CC	_	59	cc	_	_
61	CNS	cns	NN	_	63	com	_	_
62	depressant	depressant	NN	_	63	com	_	_
63	effects	effect	NNS	_	59	conj	_	_
64	of	of	IN	_	65	case	_	_
65	drug9	drug0	NN	_	59	ppmod	_	_
66	)	-rrb-	-RRB-	_	55	p	_	_
67	.	.	.	_	3	p	_	_

1	A	a	DT	_	4	det	_	_
2	drug	drug	NN	_	4	com	_	_
3	interaction	interaction	NN	_	4	com	_	_
4	study	study	NN	_	6	dep	_	_
5	was	be	VBD	_	6	aux	_	_
6	performed	performed	VBN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	which	which	WDT	_	11	ppmod	_	_
9	drug1	drug0	NN	_	11	dep	_	_
10	was	be	VBD	_	11	aux	_	_
11	administered	administer	VBN	_	6	comp	_	_
12	in	in	IN	_	13	case	_	_
13	combination	combination	NN	_	11	ppmod	_	_
14	with	with	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	6	p	_	_

1	There	there	EX	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	no	no	DT	_	4	det	_	_
4	evidence	evidence	NN	_	2	obj	_	_
5	of	of	IN	_	8	case	_	_
6	any	any	DT	_	8	det	_	_
7	pharmacokinetic	pharmacokinetic	JJ	_	8	attr	_	_
8	interactions	interaction	NNS	_	4	ppmod	_	_
9	between	between	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug2	drug0	NN	_	10	conj	_	_
13	.	.	.	_	2	p	_	_

1	Caution	caution	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	exercised	exercise	VBN	_	0	root	_	_
5	when	when	WRB	_	6	adv	_	_
6	administering	administer	VBG	_	4	comp	_	_
7	drug1	drug0	NN	_	6	obj	_	_
8	with	with	IN	_	9	case	_	_
9	drugs	drug	NNS	_	6	ppmod	_	_
10	that	that	WDT	_	12	dep	_	_
11	are	be	VBP	_	12	aux	_	_
12	known	know	VBN	_	9	relcl	_	_
13	to	to	TO	_	14	aux	_	_
14	inhibit	inhibit	VB	_	12	comp	_	_
15	phosphatase	phosphatase	NN	_	16	com	_	_
16	activities	activity	NNS	_	14	obj	_	_
17	(	-lrb-	-LRB-	_	20	p	_	_
18	e.g.	e.g.	FW	_	20	ppmod	_	_
19	,	,	,	_	20	p	_	_
20	drug2	drug0	NNS	_	16	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	.	.	.	_	4	p	_	_

1	High-dose	high-dose	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	14	dep	_	_
3	resulting	result	VBG	_	2	acl	_	_
4	in	in	IN	_	5	case	_	_
5	concentrations	concentration	NNS	_	3	ppmod	_	_
6	above	above	IN	_	8	case	_	_
7	2000	0	CD	_	8	num	_	_
8	ng/mL	ng/ml	NN	_	5	ppmod	_	_
9	administered	administer	VBN	_	8	acl	_	_
10	with	with	IN	_	12	case	_	_
11	oral	oral	JJ	_	12	attr	_	_
12	drug2	drug0	NN	_	9	ppmod	_	_
13	has	have	VBZ	_	14	aux	_	_
14	led	lead	VBN	_	0	root	_	_
15	to	to	TO	_	19	aux	_	_
16	an	an	DT	_	19	det	_	_
17	80	0	CD	_	19	num	_	_
18	%	%	NN	_	17	meta	_	_
19	increase	increase	NN	_	14	ppmod	_	_
20	in	in	IN	_	22	case	_	_
21	drug3	drug0	NN	_	22	com	_	_
22	exposure	exposure	NN	_	19	ppmod	_	_
23	with	with	IN	_	27	case	_	_
24	a	a	DT	_	27	det	_	_
25	38	0	CD	_	27	num	_	_
26	%	%	NN	_	25	meta	_	_
27	decrease	decrease	NN	_	22	ppmod	_	_
28	in	in	IN	_	31	case	_	_
29	total	total	JJ	_	31	attr	_	_
30	body	body	NN	_	31	com	_	_
31	clearance	clearance	NN	_	27	ppmod	_	_
32	of	of	IN	_	33	case	_	_
33	drug4	drug0	NN	_	31	ppmod	_	_
34	compared	compare	VBN	_	27	acl	_	_
35	to	to	TO	_	36	aux	_	_
36	drug5	drug0	NN	_	34	ppmod	_	_
37	alone	alone	RB	_	36	adv	_	_
38	.	.	.	_	14	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	inhibited	inhibit	VBD	_	0	root	_	_
3	in	in	FW	_	4	adv	_	_
4	vitro	vitro	FW	_	6	attr	_	_
5	metabolic	metabolic	JJ	_	6	attr	_	_
6	reactions	reaction	NNS	_	2	obj	_	_
7	catalyzed	catalyze	VBN	_	6	acl	_	_
8	by	by	IN	_	10	case	_	_
9	cytochromes	cytochromes	NN	_	10	com	_	_
10	P450	p0	NN	_	7	ppmod	_	_
11	1A2	0a0	NN	_	10	attr	_	_
12	,	,	,	_	10	p	_	_
13	2C8/9	0c0	NN	_	10	conj	_	_
14	,	,	,	_	13	p	_	_
15	and	and	CC	_	13	cc	_	_
16	3A4	0a0	NN	_	10	conj	_	_
17	but	but	CC	_	2	cc	_	_
18	only	only	RB	_	2	conj	_	_
19	at	at	IN	_	22	case	_	_
20	relatively	relatively	RB	_	21	adv	_	_
21	high	high	JJ	_	22	attr	_	_
22	concentrations	concentration	NNS	_	18	ppmod	_	_
23	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	did	do	VBD	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	inhibit	inhibit	VB	_	0	root	_	_
5	P450	p0	NN	_	6	com	_	_
6	2A6	0a0	NN	_	4	obj	_	_
7	or	or	CC	_	6	cc	_	_
8	the	the	DT	_	11	det	_	_
9	polymorphic	polymorphic	JJ	_	11	attr	_	_
10	P450	p0	NN	_	11	com	_	_
11	2D6	0d0	NN	_	6	conj	_	_
12	in	in	IN	_	15	case	_	_
13	human	human	JJ	_	15	attr	_	_
14	liver	liver	NN	_	15	com	_	_
15	microsomes	microsome	NNS	_	6	ppmod	_	_
16	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	did	do	VBD	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	alter	alter	VB	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	pharmacokinetics	pharmacokinetics	NNS	_	4	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	.	.	.	_	4	p	_	_

1	Although	although	IN	_	4	mark	_	_
2	there	there	EX	_	4	dep	_	_
3	have	have	VBP	_	4	aux	_	_
4	been	be	VBN	_	25	advcl	_	_
5	no	no	DT	_	8	det	_	_
6	formal	formal	JJ	_	8	attr	_	_
7	interaction	interaction	NN	_	8	com	_	_
8	studies	study	NNS	_	4	obj	_	_
9	other	other	JJ	_	10	com	_	_
10	than	than	IN	_	8	cc	_	_
11	with	with	IN	_	12	case	_	_
12	drug1	drug0	NN	_	8	conj	_	_
13	,	,	,	_	25	p	_	_
14	based	base	VBN	_	22	adv	_	_
15	on	on	IN	_	22	case	_	_
16	these	these	DT	_	22	det	_	_
17	in	in	FW	_	18	adv	_	_
18	vivo	vivo	FW	_	22	attr	_	_
19	and	and	CC	_	18	cc	_	_
20	in	in	FW	_	21	adv	_	_
21	vitro	vitro	FW	_	18	conj	_	_
22	studies	study	NNS	_	25	ppmod	_	_
23	,	,	,	_	25	p	_	_
24	it	it	PRP	_	25	dep	_	_
25	is	be	VBZ	_	0	root	_	_
26	unlikely	unlikely	JJ	_	25	dep	_	_
27	that	that	IN	_	40	mark	_	_
28	co-administration	co-administration	NN	_	40	dep	_	_
29	of	of	IN	_	33	case	_	_
30	a	a	DT	_	33	det	_	_
31	1	0	CD	_	32	num	_	_
32	mg	mg	NN	_	33	com	_	_
33	dose	dose	NN	_	28	ppmod	_	_
34	of	of	IN	_	35	case	_	_
35	drug2	drug0	NN	_	33	ppmod	_	_
36	with	with	IN	_	38	case	_	_
37	other	other	JJ	_	38	attr	_	_
38	drugs	drug	NNS	_	28	ppmod	_	_
39	will	will	MD	_	40	modal	_	_
40	result	result	VB	_	26	comp	_	_
41	in	in	IN	_	45	case	_	_
42	clinically	clinically	RB	_	43	adv	_	_
43	significant	significant	JJ	_	45	attr	_	_
44	drug	drug	NN	_	45	com	_	_
45	inhibition	inhibition	NN	_	40	ppmod	_	_
46	of	of	IN	_	49	case	_	_
47	cytochrome	cytochrome	NN	_	49	attr	_	_
48	P450-mediated	p0-mediated	JJ	_	49	attr	_	_
49	metabolism	metabolism	NN	_	45	ppmod	_	_
50	of	of	IN	_	53	case	_	_
51	the	the	DT	_	53	det	_	_
52	other	other	JJ	_	53	attr	_	_
53	drugs	drug	NNS	_	49	ppmod	_	_
54	.	.	.	_	25	p	_	_

1	An	an	DT	_	3	det	_	_
2	interaction	interaction	NN	_	3	com	_	_
3	study	study	NN	_	6	dep	_	_
4	with	with	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	showed	show	VBD	_	0	root	_	_
7	no	no	DT	_	10	det	_	_
8	clinically	clinically	RB	_	9	adv	_	_
9	significant	significant	JJ	_	10	attr	_	_
10	effect	effect	NN	_	6	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	on	on	IN	_	15	case	_	_
14	drug3	drug0	NN	_	15	com	_	_
15	pharmacokinetics	pharmacokinetics	NNS	_	10	ppmod	_	_
16	or	or	CC	_	15	cc	_	_
17	anticoagulant	anticoagulant	JJ	_	18	attr	_	_
18	activity	activity	NN	_	15	conj	_	_
19	.	.	.	_	6	p	_	_

1	At	at	IN	_	4	case	_	_
2	a	a	DT	_	4	det	_	_
3	median	median	NN	_	4	com	_	_
4	follow-up	follow-up	NN	_	17	ppmod	_	_
5	of	of	IN	_	7	case	_	_
6	33	0	CD	_	7	num	_	_
7	months	month	NNS	_	4	ppmod	_	_
8	,	,	,	_	17	p	_	_
9	the	the	DT	_	10	det	_	_
10	combination	combination	NN	_	17	dep	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	drug2	drug0	NN	_	12	conj	_	_
15	did	do	VBD	_	17	aux	_	_
16	not	not	RB	_	17	neg	_	_
17	demonstrate	demonstrate	VB	_	0	root	_	_
18	any	any	DT	_	20	det	_	_
19	efficacy	efficacy	NN	_	20	com	_	_
20	benefit	benefit	NN	_	17	obj	_	_
21	when	when	WRB	_	22	adv	_	_
22	compared	compare	VBN	_	17	comp	_	_
23	with	with	IN	_	24	case	_	_
24	drug3	drug0	NN	_	22	ppmod	_	_
25	in	in	IN	_	27	case	_	_
26	all	all	DT	_	27	det	_	_
27	patients	patient	NNS	_	22	ppmod	_	_
28	as	as	RB	_	29	com	_	_
29	well	well	RB	_	27	cc	_	_
30	as	as	IN	_	29	com	_	_
31	in	in	IN	_	35	case	_	_
32	the	the	DT	_	35	det	_	_
33	hormone	hormone	NN	_	34	advnp	_	_
34	receptor-positive	receptor-positive	JJ	_	35	attr	_	_
35	subpopulation	subpopulation	NN	_	27	conj	_	_
36	.	.	.	_	17	p	_	_

1	This	this	DT	_	3	det	_	_
2	treatment	treatment	NN	_	3	com	_	_
3	arm	arm	NN	_	5	dep	_	_
4	was	be	VBD	_	5	aux	_	_
5	discontinued	discontinue	VBN	_	0	root	_	_
6	from	from	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	trial	trial	NN	_	5	ppmod	_	_
9	.	.	.	_	5	p	_	_

1	Based	base	VBN	_	6	adv	_	_
2	on	on	IN	_	6	case	_	_
3	clinical	clinical	JJ	_	6	attr	_	_
4	and	and	CC	_	3	cc	_	_
5	pharmacokinetic	pharmacokinetic	JJ	_	3	conj	_	_
6	results	result	NNS	_	16	ppmod	_	_
7	from	from	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	ATAC	atac	NN	_	10	com	_	_
10	trial	trial	NN	_	6	ppmod	_	_
11	,	,	,	_	16	p	_	_
12	drug1	drug0	NN	_	16	dep	_	_
13	should	should	MD	_	16	modal	_	_
14	not	not	RB	_	16	neg	_	_
15	be	be	VB	_	16	aux	_	_
16	administered	administer	VBN	_	0	root	_	_
17	with	with	IN	_	18	case	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	(	-lrb-	-LRB-	_	20	p	_	_
20	see	see	VB	_	18	prn	_	_
21	CLINICAL	clinical	JJ	_	22	attr	_	_
22	PHARMACOLOGY	pharmacology	NN	_	20	obj	_	_
23	Drug	drug	NN	_	24	com	_	_
24	Interactions	interaction	NNS	_	22	attr	_	_
25	and	and	CC	_	22	cc	_	_
26	CLINICAL	clinical	JJ	_	27	attr	_	_
27	PHARMACOLOGY	pharmacology	NN	_	40	attr	_	_
28	-	-	CC	_	27	cc	_	_
29	Clinical	clinical	JJ	_	30	attr	_	_
30	Studies	study	NNS	_	27	conj	_	_
31	-	-	CC	_	30	cc	_	_
32	Adjuvant	adjuvant	JJ	_	33	attr	_	_
33	Treatment	treatment	NN	_	27	conj	_	_
34	of	of	IN	_	36	case	_	_
35	Breast	breast	NN	_	36	com	_	_
36	Cancer	cancer	NN	_	27	ppmod	_	_
37	in	in	IN	_	39	case	_	_
38	Postmenopausal	postmenopausal	JJ	_	39	attr	_	_
39	Women	woman	NNS	_	27	ppmod	_	_
40	subsections	subsection	NNS	_	22	conj	_	_
41	)	-rrb-	-RRB-	_	20	p	_	_
42	.	.	.	_	16	p	_	_

1	Co-administration	co-administration	NN	_	6	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	resulted	result	VBD	_	0	root	_	_
7	in	in	IN	_	9	case	_	_
8	a	a	DT	_	9	det	_	_
9	reduction	reduction	NN	_	6	ppmod	_	_
10	of	of	IN	_	13	case	_	_
11	drug3	drug0	NN	_	13	com	_	_
12	plasma	plasma	NN	_	13	com	_	_
13	levels	level	NNS	_	9	ppmod	_	_
14	by	by	IN	_	15	case	_	_
15	27	0	CD	_	9	ppmod	_	_
16	%	%	NN	_	15	meta	_	_
17	compared	compare	VBN	_	15	acl	_	_
18	with	with	IN	_	19	case	_	_
19	those	those	DT	_	17	ppmod	_	_
20	achieved	achieve	VBN	_	19	acl	_	_
21	with	with	IN	_	22	case	_	_
22	drug4	drug0	NN	_	20	ppmod	_	_
23	alone	alone	RB	_	22	adv	_	_
24	.	.	.	_	6	p	_	_

1	drug1	drug0	JJ	_	3	attr	_	_
2	-containing	-containing	JJ	_	3	attr	_	_
3	therapies	therapy	NNS	_	7	dep	_	_
4	should	should	MD	_	7	modal	_	_
5	not	not	RB	_	7	neg	_	_
6	be	be	VB	_	7	aux	_	_
7	used	use	VBN	_	0	root	_	_
8	with	with	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	as	as	IN	_	13	mark	_	_
11	they	they	PRP	_	13	dep	_	_
12	may	may	MD	_	13	modal	_	_
13	diminish	diminish	VB	_	7	comp	_	_
14	its	its	PRP$	_	16	poss	_	_
15	pharmacologic	pharmacologic	JJ	_	16	attr	_	_
16	action	action	NN	_	13	obj	_	_
17	.	.	.	_	7	p	_	_

1	Drug/Laboratory	drug/laboratory	JJ	_	3	attr	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	0	root	_	_
4	No	no	DT	_	7	det	_	_
5	clinically	clinically	RB	_	6	adv	_	_
6	significant	significant	JJ	_	7	attr	_	_
7	changes	change	NNS	_	17	dep	_	_
8	in	in	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	results	result	NNS	_	7	ppmod	_	_
11	of	of	IN	_	14	case	_	_
12	clinical	clinical	JJ	_	14	attr	_	_
13	laboratory	laboratory	NN	_	14	com	_	_
14	tests	test	NNS	_	10	ppmod	_	_
15	have	have	VBP	_	17	aux	_	_
16	been	be	VBN	_	17	aux	_	_
17	observed	observe	VBN	_	3	acl	_	_

1	.	.	.	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	Treatment	treatment	NN	_	13	dep	_	_
2	with	with	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	once	once	RB	_	5	com	_	_
5	weekly	weekly	RB	_	8	adv	_	_
6	for	for	IN	_	8	case	_	_
7	4	0	CD	_	8	num	_	_
8	weeks	week	NNS	_	1	ppmod	_	_
9	in	in	IN	_	11	case	_	_
10	healthy	healthy	JJ	_	11	attr	_	_
11	subjects	subject	NNS	_	8	ppmod	_	_
12	was	be	VBD	_	13	aux	_	_
13	associated	associate	VBN	_	0	root	_	_
14	with	with	IN	_	16	case	_	_
15	an	an	DT	_	16	det	_	_
16	inhibition	inhibition	NN	_	13	ppmod	_	_
17	of	of	IN	_	19	case	_	_
18	P450	p0	NN	_	19	com	_	_
19	1A2	0a0	NN	_	16	ppmod	_	_
20	and	and	CC	_	16	cc	_	_
21	a	a	DT	_	24	det	_	_
22	25	0	CD	_	24	num	_	_
23	%	%	NN	_	22	meta	_	_
24	increase	increase	NN	_	16	conj	_	_
25	in	in	IN	_	27	case	_	_
26	drug2	drug0	NN	_	27	com	_	_
27	AUC	auc	NN	_	24	ppmod	_	_
28	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	3	com	_	_
2	serum	serum	NN	_	3	com	_	_
3	levels	level	NNS	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	monitored	monitor	VBN	_	0	root	_	_
7	and	and	CC	_	6	cc	_	_
8	appropriate	appropriate	JJ	_	10	attr	_	_
9	dose	dose	NN	_	10	com	_	_
10	adjustments	adjustment	NNS	_	11	dep	_	_
11	considered	consider	VBN	_	6	conj	_	_
12	for	for	IN	_	13	case	_	_
13	patients	patient	NNS	_	11	ppmod	_	_
14	given	given	IN	_	16	case	_	_
15	both	both	CC	_	16	cc	_	_
16	drug2	drug0	NN	_	13	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	drug3	drug0	NN	_	16	conj	_	_
19	.	.	.	_	6	p	_	_

1	There	there	EX	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	no	no	DT	_	4	det	_	_
4	effect	effect	NN	_	2	obj	_	_
5	on	on	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	pharmacokinetics	pharmacokinetics	NNS	_	4	ppmod	_	_
8	of	of	IN	_	10	case	_	_
9	representative	representative	JJ	_	10	attr	_	_
10	drugs	drug	NNS	_	7	ppmod	_	_
11	metabolized	metabolize	VBN	_	10	acl	_	_
12	by	by	IN	_	14	case	_	_
13	CYP	cyp	NN	_	14	com	_	_
14	2C9	0c0	NN	_	11	ppmod	_	_
15	,	,	,	_	14	p	_	_
16	CYP	cyp	NN	_	17	com	_	_
17	2C19	0c0	NN	_	14	conj	_	_
18	,	,	,	_	17	p	_	_
19	CYP	cyp	NN	_	20	com	_	_
20	2D6	0d0	NN	_	14	conj	_	_
21	or	or	CC	_	20	cc	_	_
22	CYP	cyp	NN	_	23	com	_	_
23	3A4	0a0	NN	_	14	conj	_	_
24	.	.	.	_	2	p	_	_

1	In	in	IN	_	2	case	_	_
2	patients	patient	NNS	_	19	ppmod	_	_
3	with	with	IN	_	6	case	_	_
4	chronic	chronic	JJ	_	6	attr	_	_
5	hepatitis	hepatitis	NN	_	6	com	_	_
6	C	c	NN	_	2	ppmod	_	_
7	treated	treat	VBN	_	2	acl	_	_
8	with	with	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	in	in	IN	_	11	case	_	_
11	combination	combination	NN	_	7	ppmod	_	_
12	with	with	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	,	,	,	_	19	p	_	_
15	drug3	drug0	NN	_	16	com	_	_
16	treatment	treatment	NN	_	19	dep	_	_
17	did	do	VBD	_	19	aux	_	_
18	not	not	RB	_	19	neg	_	_
19	affect	affect	VB	_	0	root	_	_
20	drug4	drug0	NN	_	21	com	_	_
21	distribution	distribution	NN	_	19	obj	_	_
22	or	or	CC	_	21	cc	_	_
23	clearance	clearance	NN	_	21	conj	_	_
24	.	.	.	_	19	p	_	_

1	Nucleoside	nucleoside	NN	_	2	com	_	_
2	Analogues	analogue	NNS	_	4	com	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	Co-administration	co-administration	NN	_	11	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	is	be	VBZ	_	11	aux	_	_
10	not	not	RB	_	11	neg	_	_
11	recommended	recommend	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	Reports	report	NNS	_	21	dep	_	_
2	of	of	IN	_	5	case	_	_
3	fatal	fatal	JJ	_	5	attr	_	_
4	hepatic	hepatic	JJ	_	5	attr	_	_
5	failure	failure	NN	_	1	ppmod	_	_
6	,	,	,	_	5	p	_	_
7	as	as	RB	_	8	com	_	_
8	well	well	RB	_	5	cc	_	_
9	as	as	IN	_	8	com	_	_
10	peripheral	peripheral	JJ	_	11	attr	_	_
11	neuropathy	neuropathy	NN	_	5	conj	_	_
12	,	,	,	_	11	p	_	_
13	pancreatitis	pancreatitis	NN	_	5	conj	_	_
14	,	,	,	_	13	p	_	_
15	and	and	CC	_	13	cc	_	_
16	symptomatic	symptomatic	JJ	_	18	attr	_	_
17	hyperlactatemia/lactic	hyperlactatemia/lactic	JJ	_	18	attr	_	_
18	acidosis	acidosis	NN	_	5	conj	_	_
19	have	have	VBP	_	21	aux	_	_
20	been	be	VBN	_	21	aux	_	_
21	reported	report	VBN	_	0	root	_	_
22	in	in	IN	_	24	case	_	_
23	clinical	clinical	JJ	_	24	attr	_	_
24	trials	trial	NNS	_	21	ppmod	_	_
25	.	.	.	_	21	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	4	com	_	_
4	drug3	drug0	NN	_	1	conj	_	_
5	can	can	MD	_	6	modal	_	_
6	antagonize	antagonize	VB	_	0	root	_	_
7	the	the	DT	_	11	det	_	_
8	in	in	FW	_	9	adv	_	_
9	vitro	vitro	FW	_	11	attr	_	_
10	antiviral	antiviral	JJ	_	11	attr	_	_
11	activity	activity	NN	_	6	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug4	drug0	NN	_	11	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	drug5	drug0	NN	_	13	conj	_	_
16	against	against	IN	_	17	case	_	_
17	HIV	hiv	NN	_	11	ppmod	_	_
18	.	.	.	_	6	p	_	_

1	Therefore	therefore	RB	_	14	adv	_	_
2	,	,	,	_	14	p	_	_
3	concomitant	concomitant	JJ	_	4	attr	_	_
4	use	use	NN	_	14	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	with	with	IN	_	8	case	_	_
8	either	either	DT	_	4	ppmod	_	_
9	of	of	IN	_	11	case	_	_
10	these	these	DT	_	11	det	_	_
11	drugs	drug	NNS	_	8	ppmod	_	_
12	should	should	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	avoided	avoid	VBN	_	0	root	_	_
15	.	.	.	_	14	p	_	_

1	Carcinogenesis	carcinogenesis	NN	_	13	dep	_	_
2	,	,	,	_	1	p	_	_
3	Mutagenesis	mutagenesis	NN	_	1	appo	_	_
4	,	,	,	_	1	p	_	_
5	Impairment	impairment	NN	_	1	appo	_	_
6	of	of	IN	_	9	case	_	_
7	Fertility	fertility	NN	_	9	com	_	_
8	Carcinogenesis	carcinogenesis	NN	_	9	com	_	_
9	drug1	drug0	NN	_	1	ppmod	_	_
10	has	have	VBZ	_	13	aux	_	_
11	not	not	RB	_	13	neg	_	_
12	been	be	VBN	_	13	aux	_	_
13	tested	test	VBN	_	0	root	_	_
14	for	for	IN	_	17	case	_	_
15	its	its	PRP$	_	17	poss	_	_
16	carcinogenic	carcinogenic	JJ	_	17	attr	_	_
17	potential	potential	NN	_	13	ppmod	_	_
18	.	.	.	_	13	p	_	_

1	Mutagenesis	mutagenesis	NN	_	2	com	_	_
2	drug1	drug0	NN	_	5	dep	_	_
3	did	do	VBD	_	5	aux	_	_
4	not	not	RB	_	5	neg	_	_
5	cause	cause	VB	_	0	root	_	_
6	DNA	dna	NN	_	7	com	_	_
7	damage	damage	NN	_	5	obj	_	_
8	when	when	WRB	_	9	adv	_	_
9	tested	test	VBN	_	5	comp	_	_
10	in	in	IN	_	15	case	_	_
11	the	the	DT	_	15	det	_	_
12	Ames	ames	NN	_	15	attr	_	_
13	bacterial	bacterial	JJ	_	15	attr	_	_
14	mutagenicity	mutagenicity	NN	_	15	com	_	_
15	assay	assay	NN	_	9	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	in	in	IN	_	23	case	_	_
18	the	the	DT	_	23	det	_	_
19	in	in	FW	_	20	adv	_	_
20	vitro	vitro	FW	_	23	attr	_	_
21	chromosomal	chromosomal	NN	_	23	com	_	_
22	aberration	aberration	NN	_	23	com	_	_
23	assay	assay	NN	_	15	conj	_	_
24	in	in	IN	_	26	case	_	_
25	human	human	JJ	_	26	attr	_	_
26	lymphocytes	lymphocyte	NNS	_	23	ppmod	_	_
27	,	,	,	_	23	p	_	_
28	either	either	CC	_	23	cc	_	_
29	in	in	IN	_	31	case	_	_
30	the	the	DT	_	31	det	_	_
31	presence	presence	NN	_	15	conj	_	_
32	or	or	CC	_	31	cc	_	_
33	absence	absence	NN	_	31	conj	_	_
34	of	of	IN	_	36	case	_	_
35	metabolic	metabolic	JJ	_	36	attr	_	_
36	activation	activation	NN	_	31	ppmod	_	_
37	.	.	.	_	5	p	_	_

1	Use	use	NN	_	5	dep	_	_
2	With	with	IN	_	4	case	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	drug2	drug0	NNS	_	1	ppmod	_	_
5	is	be	VBZ	_	0	root	_	_
6	genotoxic	genotoxic	JJ	_	5	dep	_	_
7	and	and	CC	_	6	cc	_	_
8	mutagenic	mutagenic	JJ	_	6	conj	_	_
9	.	.	.	_	5	p	_	_

1	The	the	DT	_	3	det	_	_
2	carcinogenic	carcinogenic	JJ	_	3	attr	_	_
3	potential	potential	NN	_	10	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	has	have	VBZ	_	10	aux	_	_
7	not	not	RB	_	10	neg	_	_
8	been	be	VBN	_	10	aux	_	_
9	fully	fully	RB	_	10	adv	_	_
10	determined	determine	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	In	in	IN	_	9	case	_	_
2	a	a	DT	_	3	det	_	_
3	p53	p0	NN	_	9	attr	_	_
4	(	-lrb-	-LRB-	_	3	p	_	_
5	+/-	+/-	CC	_	3	cc	_	_
6	)	-rrb-	-RRB-	_	3	p	_	_
7	mouse	mouse	NN	_	9	com	_	_
8	carcinogenicity	carcinogenicity	NN	_	9	com	_	_
9	study	study	NN	_	22	ppmod	_	_
10	at	at	IN	_	11	case	_	_
11	doses	dose	NNS	_	9	ppmod	_	_
12	up	up	RP	_	17	prt	_	_
13	to	to	TO	_	17	aux	_	_
14	the	the	DT	_	17	det	_	_
15	maximum	maximum	JJ	_	17	attr	_	_
16	tolerated	tolerate	VBN	_	17	attr	_	_
17	dose	dose	NN	_	11	ppmod	_	_
18	of	of	IN	_	21	case	_	_
19	100	0	CD	_	20	num	_	_
20	mg/kg/day	mg/kg/day	NN	_	21	com	_	_
21	drug1	drug0	NN	_	17	ppmod	_	_
22	was	be	VBD	_	0	root	_	_
23	not	not	RB	_	22	neg	_	_
24	oncogenic	oncogenic	JJ	_	22	dep	_	_
25	.	.	.	_	22	p	_	_

1	However	however	RB	_	12	adv	_	_
2	,	,	,	_	12	p	_	_
3	on	on	IN	_	8	case	_	_
4	a	a	DT	_	7	det	_	_
5	body	body	NN	_	7	com	_	_
6	surface	surface	NN	_	7	com	_	_
7	area	area	NN	_	8	com	_	_
8	basis	basis	NN	_	12	ppmod	_	_
9	,	,	,	_	12	p	_	_
10	this	this	DT	_	11	det	_	_
11	dose	dose	NN	_	12	dep	_	_
12	was	be	VBD	_	0	root	_	_
13	0.5	0	CD	_	19	num	_	_
14	times	time	NNS	_	19	attr	_	_
15	maximum	maximum	JJ	_	19	attr	_	_
16	recommended	recommend	VBN	_	19	attr	_	_
17	human	human	JJ	_	19	attr	_	_
18	24-hour	0-hour	JJ	_	19	attr	_	_
19	dose	dose	NN	_	12	obj	_	_
20	of	of	IN	_	21	case	_	_
21	drug1	drug0	NN	_	19	ppmod	_	_
22	.	.	.	_	12	p	_	_

1	A	a	DT	_	2	det	_	_
2	study	study	NN	_	12	dep	_	_
3	in	in	IN	_	4	case	_	_
4	rats	rat	NNS	_	2	ppmod	_	_
5	to	to	TO	_	6	aux	_	_
6	assess	assess	VB	_	2	acl	_	_
7	the	the	DT	_	9	det	_	_
8	carcinogenic	carcinogenic	JJ	_	9	attr	_	_
9	potential	potential	NN	_	6	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	is	be	VBZ	_	0	root	_	_
13	ongoing	ongoing	JJ	_	12	dep	_	_
14	.	.	.	_	12	p	_	_

1	Mutagenesis	mutagenesis	NN	_	2	com	_	_
2	Impairment	impairment	NN	_	7	dep	_	_
3	of	of	IN	_	5	case	_	_
4	Fertility	fertility	NN	_	5	com	_	_
5	drug1	drug0	NN	_	2	ppmod	_	_
6	may	may	MD	_	7	modal	_	_
7	impair	impair	VB	_	0	root	_	_
8	fertility	fertility	NN	_	7	obj	_	_
9	in	in	IN	_	10	case	_	_
10	women	woman	NNS	_	8	ppmod	_	_
11	.	.	.	_	7	p	_	_

1	Prolonged	prolonged	JJ	_	3	attr	_	_
2	menstrual	menstrual	JJ	_	3	attr	_	_
3	cycles	cycle	NNS	_	7	dep	_	_
4	and/or	and/or	CC	_	3	cc	_	_
5	amenorrhea	amenorrhea	NN	_	3	conj	_	_
6	were	be	VBD	_	7	aux	_	_
7	observed	observe	VBN	_	0	root	_	_
8	in	in	IN	_	11	case	_	_
9	female	female	JJ	_	11	attr	_	_
10	cynomolgus	cynomolgus	NN	_	11	com	_	_
11	monkeys	monkey	NNS	_	7	ppmod	_	_
12	given	give	VBN	_	14	lv	_	_
13	sc	sc	NN	_	14	com	_	_
14	injections	injection	NNS	_	11	acl	_	_
15	of	of	IN	_	18	case	_	_
16	600	0	CD	_	17	num	_	_
17	m	m	NN	_	18	com	_	_
18	g/kg/dose	g/kg/dose	NN	_	14	ppmod	_	_
19	(	-lrb-	-LRB-	_	22	p	_	_
20	7200	0	CD	_	22	num	_	_
21	m	m	NN	_	22	com	_	_
22	g/m2/dose	g/m0/dose	NN	_	18	prn	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	of	of	IN	_	25	case	_	_
25	drug1	drug0	NN	_	14	ppmod	_	_
26	every	every	DT	_	28	det	_	_
27	other	other	JJ	_	28	attr	_	_
28	day	day	NN	_	31	dat	_	_
29	for	for	IN	_	31	case	_	_
30	one	#crd#	CD	_	31	num	_	_
31	month	month	NN	_	14	ppmod	_	_
32	,	,	,	_	7	p	_	_
33	at	at	IN	_	36	case	_	_
34	approximately	approximately	RB	_	35	adv	_	_
35	180	0	CD	_	36	num	_	_
36	times	time	NNS	_	7	ppmod	_	_
37	the	the	DT	_	41	det	_	_
38	recommended	recommend	VBN	_	41	attr	_	_
39	weekly	weekly	JJ	_	41	attr	_	_
40	human	human	JJ	_	41	attr	_	_
41	dose	dose	NN	_	36	appo	_	_
42	for	for	IN	_	46	case	_	_
43	a	a	DT	_	46	det	_	_
44	60	0	CD	_	45	num	_	_
45	kg	kg	NN	_	46	com	_	_
46	person	person	NN	_	41	ppmod	_	_
47	(	-lrb-	-LRB-	_	46	p	_	_
48	based	base	VBN	_	46	acl	_	_
49	on	on	IN	_	52	case	_	_
50	body	body	NN	_	52	com	_	_
51	surface	surface	NN	_	52	com	_	_
52	area	area	NN	_	48	ppmod	_	_
53	)	-rrb-	-RRB-	_	46	p	_	_
54	.	.	.	_	7	p	_	_

1	Menstrual	menstrual	JJ	_	3	attr	_	_
2	cycle	cycle	NN	_	3	com	_	_
3	irregularities	irregularity	NNS	_	5	dep	_	_
4	were	be	VBD	_	5	aux	_	_
5	accompanied	accompany	VBN	_	0	root	_	_
6	by	by	IN	_	9	case	_	_
7	both	both	CC	_	9	cc	_	_
8	a	a	DT	_	9	det	_	_
9	decrease	decrease	NN	_	5	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	delay	delay	NN	_	9	conj	_	_
12	in	in	IN	_	16	case	_	_
13	the	the	DT	_	16	det	_	_
14	peak	peak	NN	_	16	com	_	_
15	17b	0b	NN	_	16	com	_	_
16	-estradiol	-estradiol	NN	_	9	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	progesterone	progesterone	NN	_	19	com	_	_
19	levels	level	NNS	_	16	conj	_	_
20	following	follow	VBG	_	16	acl	_	_
21	administration	administration	NN	_	20	obj	_	_
22	of	of	IN	_	23	case	_	_
23	drug1	drug0	NN	_	21	ppmod	_	_
24	to	to	TO	_	26	aux	_	_
25	female	female	JJ	_	26	attr	_	_
26	monkeys	monkey	NNS	_	21	ppmod	_	_
27	.	.	.	_	5	p	_	_

1	A	a	DT	_	2	det	_	_
2	return	return	NN	_	7	dep	_	_
3	to	to	TO	_	6	aux	_	_
4	normal	normal	JJ	_	6	attr	_	_
5	menstrual	menstrual	JJ	_	6	attr	_	_
6	rhythm	rhythm	NN	_	2	ppmod	_	_
7	followed	followed	VBD	_	0	root	_	_
8	cessation	cessation	NN	_	7	obj	_	_
9	of	of	IN	_	10	case	_	_
10	treatment	treatment	NN	_	8	ppmod	_	_
11	.	.	.	_	7	p	_	_

1	Every	every	DT	_	3	det	_	_
2	other	other	JJ	_	3	attr	_	_
3	day	day	NN	_	4	com	_	_
4	dosing	dosing	NN	_	24	dep	_	_
5	with	with	IN	_	12	case	_	_
6	100m	0m	NN	_	12	attr	_	_
7	g/kg	g/kg	NN	_	12	attr	_	_
8	(	-lrb-	-LRB-	_	12	p	_	_
9	1200m	0m	NN	_	12	attr	_	_
10	g/m2	g/m0	NN	_	12	attr	_	_
11	)	-rrb-	-RRB-	_	12	p	_	_
12	drug1	drug0	NN	_	4	ppmod	_	_
13	(	-lrb-	-LRB-	_	22	p	_	_
14	equivalent	equivalent	JJ	_	22	attr	_	_
15	to	to	TO	_	18	aux	_	_
16	approximately	approximately	RB	_	17	adv	_	_
17	30	0	CD	_	18	num	_	_
18	times	time	NNS	_	14	ppmod	_	_
19	the	the	DT	_	22	det	_	_
20	recommended	recommend	VBN	_	22	attr	_	_
21	human	human	JJ	_	22	attr	_	_
22	dose	dose	NN	_	12	prn	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	had	have	VBD	_	0	root	_	_
25	no	no	DT	_	26	det	_	_
26	effects	effect	NNS	_	24	obj	_	_
27	on	on	IN	_	29	case	_	_
28	cycle	cycle	NN	_	29	com	_	_
29	duration	duration	NN	_	26	ppmod	_	_
30	or	or	CC	_	29	cc	_	_
31	reproductive	reproductive	JJ	_	33	attr	_	_
32	hormone	hormone	NN	_	33	com	_	_
33	status	status	NN	_	29	conj	_	_
34	.	.	.	_	24	p	_	_

1	The	the	DT	_	2	det	_	_
2	effects	effect	NNS	_	11	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	on	on	IN	_	7	case	_	_
6	male	male	JJ	_	7	attr	_	_
7	fertility	fertility	NN	_	2	ppmod	_	_
8	have	have	VBP	_	11	aux	_	_
9	not	not	RB	_	11	neg	_	_
10	been	be	VBN	_	11	aux	_	_
11	studied	study	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	However	however	RB	_	9	adv	_	_
2	,	,	,	_	9	p	_	_
3	no	no	DT	_	5	det	_	_
4	adverse	adverse	JJ	_	5	attr	_	_
5	effects	effect	NNS	_	9	dep	_	_
6	on	on	IN	_	7	case	_	_
7	fertility	fertility	NN	_	5	ppmod	_	_
8	were	be	VBD	_	9	aux	_	_
9	observed	observe	VBN	_	0	root	_	_
10	in	in	IN	_	13	case	_	_
11	male	male	JJ	_	13	attr	_	_
12	Rhesus	rhesus	NN	_	13	com	_	_
13	monkeys	monkey	NNS	_	9	ppmod	_	_
14	treated	treat	VBN	_	13	acl	_	_
15	with	with	IN	_	17	case	_	_
16	non-	non-	NN	_	17	com	_	_
17	drug1	drug0	NN	_	14	ppmod	_	_
18	for	for	IN	_	20	case	_	_
19	5	0	CD	_	20	num	_	_
20	months	month	NNS	_	17	ppmod	_	_
21	at	at	IN	_	22	case	_	_
22	doses	dose	NNS	_	14	ppmod	_	_
23	up	up	RP	_	28	prt	_	_
24	to	to	TO	_	28	aux	_	_
25	25	0	CD	_	28	num	_	_
26	x	x	CC	_	25	cc	_	_
27	106	0	CD	_	25	conj	_	_
28	IU/kg/day	iu/kg/day	NN	_	22	ppmod	_	_
29	.	.	.	_	9	p	_	_

1	Pregnancy	pregnancy	NN	_	6	attr	_	_
2	Pregnancy	pregnancy	NN	_	6	attr	_	_
3	:	:	:	_	6	p	_	_
4	Category	category	NN	_	6	com	_	_
5	C	c	NN	_	6	com	_	_
6	drug1	drug0	NN	_	10	dep	_	_
7	has	have	VBZ	_	10	aux	_	_
8	not	not	RB	_	10	neg	_	_
9	been	be	VBN	_	10	aux	_	_
10	studied	study	VBN	_	0	root	_	_
11	for	for	IN	_	14	case	_	_
12	its	its	PRP$	_	14	poss	_	_
13	teratogenic	teratogenic	JJ	_	14	attr	_	_
14	effect	effect	NN	_	10	ppmod	_	_
15	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	treatment	treatment	NN	_	17	dep	_	_
3	of	of	IN	_	6	case	_	_
4	pregnant	pregnant	JJ	_	6	attr	_	_
5	Rhesus	rhesus	NN	_	6	com	_	_
6	monkeys	monkey	NNS	_	2	ppmod	_	_
7	at	at	IN	_	16	case	_	_
8	approximately	approximately	RB	_	9	adv	_	_
9	20	0	CD	_	16	num	_	_
10	to	to	TO	_	9	cc	_	_
11	500	0	CD	_	9	conj	_	_
12	times	time	NNS	_	11	attr	_	_
13	the	the	DT	_	16	det	_	_
14	human	human	JJ	_	16	attr	_	_
15	weekly	weekly	JJ	_	16	attr	_	_
16	dose	dose	NN	_	2	ppmod	_	_
17	resulted	result	VBD	_	0	root	_	_
18	in	in	IN	_	22	case	_	_
19	a	a	DT	_	22	det	_	_
20	statistically	statistically	RB	_	21	adv	_	_
21	significant	significant	JJ	_	22	attr	_	_
22	increase	increase	NN	_	17	ppmod	_	_
23	in	in	IN	_	24	case	_	_
24	abortions	abortion	NNS	_	22	ppmod	_	_
25	.	.	.	_	17	p	_	_

1	No	no	DT	_	3	det	_	_
2	teratogenic	teratogenic	JJ	_	3	attr	_	_
3	effects	effect	NNS	_	5	dep	_	_
4	were	be	VBD	_	5	aux	_	_
5	seen	see	VBN	_	0	root	_	_
6	in	in	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	offspring	offspring	NN	_	5	ppmod	_	_
9	delivered	deliver	VBN	_	8	acl	_	_
10	at	at	IN	_	11	case	_	_
11	term	term	NN	_	9	ppmod	_	_
12	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	assumed	assume	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	have	have	VB	_	4	comp	_	_
7	abortifacient	abortifacient	JJ	_	8	attr	_	_
8	potential	potential	NN	_	6	obj	_	_
9	.	.	.	_	4	p	_	_

1	There	there	EX	_	2	dep	_	_
2	are	be	VBP	_	0	root	_	_
3	no	no	DT	_	7	det	_	_
4	adequate	adequate	JJ	_	7	attr	_	_
5	and	and	CC	_	4	cc	_	_
6	well-controlled	well-controlled	JJ	_	4	conj	_	_
7	studies	study	NNS	_	2	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	in	in	IN	_	12	case	_	_
11	pregnant	pregnant	JJ	_	12	attr	_	_
12	women	woman	NNS	_	7	ppmod	_	_
13	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	to	to	TO	_	5	aux	_	_
4	be	be	VB	_	5	aux	_	_
5	used	use	VBN	_	2	comp	_	_
6	during	during	IN	_	7	case	_	_
7	pregnancy	pregnancy	NN	_	5	ppmod	_	_
8	only	only	RB	_	13	adv	_	_
9	if	if	IN	_	13	mark	_	_
10	the	the	DT	_	12	det	_	_
11	potential	potential	JJ	_	12	attr	_	_
12	benefit	benefit	NN	_	13	dep	_	_
13	justifies	justify	VBZ	_	5	comp	_	_
14	the	the	DT	_	16	det	_	_
15	potential	potential	JJ	_	16	attr	_	_
16	risk	risk	NN	_	13	obj	_	_
17	to	to	TO	_	19	aux	_	_
18	the	the	DT	_	19	det	_	_
19	fetus	fetus	NN	_	16	ppmod	_	_
20	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	recommended	recommend	VBN	_	0	root	_	_
4	for	for	IN	_	5	case	_	_
5	use	use	NN	_	3	ppmod	_	_
6	in	in	IN	_	7	case	_	_
7	women	woman	NNS	_	5	ppmod	_	_
8	of	of	IN	_	10	case	_	_
9	childbearing	childbearing	JJ	_	10	attr	_	_
10	potential	potential	NN	_	7	ppmod	_	_
11	only	only	RB	_	12	com	_	_
12	when	when	WRB	_	15	adv	_	_
13	they	they	PRP	_	15	dep	_	_
14	are	be	VBP	_	15	aux	_	_
15	using	use	VBG	_	3	comp	_	_
16	effective	effective	JJ	_	17	attr	_	_
17	contraception	contraception	NN	_	15	obj	_	_
18	during	during	IN	_	19	case	_	_
19	therapy	therapy	NN	_	15	ppmod	_	_
20	.	.	.	_	3	p	_	_

1	Pregnancy	pregnancy	NN	_	17	attr	_	_
2	:	:	:	_	1	p	_	_
3	Category	category	NN	_	4	com	_	_
4	X	x	NN	_	1	appo	_	_
5	:	:	:	_	1	p	_	_
6	Use	use	NN	_	1	appo	_	_
7	With	with	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	see	see	VB	_	1	prn	_	_
11	CONTRAINDICATIONS	contraindication	NNS	_	10	obj	_	_
12	)	-rrb-	-RRB-	_	10	p	_	_
13	Significant	significant	JJ	_	17	attr	_	_
14	teratogenic	teratogenic	JJ	_	17	attr	_	_
15	and/or	and/or	CC	_	14	cc	_	_
16	embryocidal	embryocidal	JJ	_	14	conj	_	_
17	effects	effect	NNS	_	20	dep	_	_
18	have	have	VBP	_	20	aux	_	_
19	been	be	VBN	_	20	aux	_	_
20	demonstrated	demonstrate	VBN	_	0	root	_	_
21	in	in	IN	_	24	case	_	_
22	all	all	DT	_	24	det	_	_
23	animal	animal	JJ	_	24	attr	_	_
24	species	species	NNS	_	20	ppmod	_	_
25	exposed	expose	VBN	_	24	acl	_	_
26	to	to	TO	_	27	aux	_	_
27	drug2	drug0	NN	_	25	ppmod	_	_
28	.	.	.	_	20	p	_	_

1	drug1	drug0	JJ	_	2	attr	_	_
2	therapy	therapy	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	contraindicated	contraindicate	VBN	_	0	root	_	_
5	in	in	IN	_	6	case	_	_
6	women	woman	NNS	_	4	ppmod	_	_
7	who	who	WP	_	8	dep	_	_
8	are	be	VBP	_	6	relcl	_	_
9	pregnant	pregnant	JJ	_	8	dep	_	_
10	and	and	CC	_	6	cc	_	_
11	in	in	IN	_	14	case	_	_
12	the	the	DT	_	14	det	_	_
13	male	male	JJ	_	14	attr	_	_
14	partners	partner	NNS	_	6	conj	_	_
15	of	of	IN	_	16	case	_	_
16	women	woman	NNS	_	14	ppmod	_	_
17	who	who	WP	_	18	dep	_	_
18	are	be	VBP	_	16	relcl	_	_
19	pregnant	pregnant	JJ	_	18	dep	_	_
20	.	.	.	_	4	p	_	_

1	If	if	IN	_	3	mark	_	_
2	pregnancy	pregnancy	NN	_	3	dep	_	_
3	occurs	occur	VBZ	_	27	advcl	_	_
4	in	in	IN	_	6	case	_	_
5	a	a	DT	_	6	det	_	_
6	patient	patient	NN	_	3	ppmod	_	_
7	or	or	CC	_	6	cc	_	_
8	partner	partner	NN	_	6	conj	_	_
9	of	of	IN	_	11	case	_	_
10	a	a	DT	_	11	det	_	_
11	patient	patient	NN	_	6	ppmod	_	_
12	during	during	IN	_	13	case	_	_
13	treatment	treatment	NN	_	3	ppmod	_	_
14	or	or	CC	_	13	cc	_	_
15	during	during	IN	_	18	case	_	_
16	the	the	DT	_	18	det	_	_
17	6	0	CD	_	18	num	_	_
18	months	month	NNS	_	13	conj	_	_
19	after	after	IN	_	21	case	_	_
20	treatment	treatment	NN	_	21	com	_	_
21	cessation	cessation	NN	_	18	ppmod	_	_
22	,	,	,	_	27	p	_	_
23	such	such	JJ	_	24	attr	_	_
24	cases	case	NNS	_	27	dep	_	_
25	should	should	MD	_	27	modal	_	_
26	be	be	VB	_	27	aux	_	_
27	reported	report	VBN	_	0	root	_	_
28	to	to	TO	_	32	aux	_	_
29	the	the	DT	_	32	det	_	_
30	drug1	drug0	NN	_	32	com	_	_
31	Pregnancy	pregnancy	NN	_	32	com	_	_
32	Registry	registry	NN	_	27	ppmod	_	_
33	at	at	IN	_	34	case	_	_
34	1-800-526-6367	0	NN	_	27	ppmod	_	_
35	.	.	.	_	27	p	_	_

1	Nursing	nurse	VBG	_	6	advcl	_	_
2	Mothers	mother	NNS	_	1	obj	_	_
3	It	it	PRP	_	6	dep	_	_
4	is	be	VBZ	_	6	aux	_	_
5	not	not	RB	_	6	neg	_	_
6	known	know	VBN	_	0	root	_	_
7	whether	whether	IN	_	15	mark	_	_
8	drug1	drug0	NN	_	15	dep	_	_
9	or	or	CC	_	8	cc	_	_
10	drug2	drug0	NN	_	8	conj	_	_
11	or	or	CC	_	8	cc	_	_
12	its	its	PRP$	_	13	poss	_	_
13	components	component	NNS	_	8	conj	_	_
14	are	be	VBP	_	15	aux	_	_
15	excreted	excrete	VBN	_	6	comp	_	_
16	in	in	IN	_	18	case	_	_
17	human	human	JJ	_	18	attr	_	_
18	milk	milk	NN	_	15	ppmod	_	_
19	.	.	.	_	6	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	19	dep	_	_
3	of	of	IN	_	6	case	_	_
4	orally	orally	RB	_	5	adv	_	_
5	ingested	ingest	VBN	_	6	attr	_	_
6	drug1	drug0	NN	_	2	ppmod	_	_
7	or	or	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	from	from	IN	_	11	case	_	_
10	breast	breast	NN	_	11	com	_	_
11	milk	milk	NN	_	6	ppmod	_	_
12	on	on	IN	_	15	case	_	_
13	the	the	DT	_	15	det	_	_
14	nursing	nursing	JJ	_	15	attr	_	_
15	infant	infant	NN	_	2	ppmod	_	_
16	has	have	VBZ	_	19	aux	_	_
17	not	not	RB	_	19	neg	_	_
18	been	be	VBN	_	19	aux	_	_
19	evaluated	evaluate	VBN	_	0	root	_	_
20	.	.	.	_	19	p	_	_

1	Because	because	IN	_	4	case	_	_
2	of	of	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	potential	potential	NN	_	19	ppmod	_	_
5	for	for	IN	_	7	case	_	_
6	adverse	adverse	JJ	_	7	attr	_	_
7	reactions	reaction	NNS	_	4	ppmod	_	_
8	from	from	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	drugs	drug	NNS	_	7	ppmod	_	_
11	in	in	IN	_	13	case	_	_
12	nursing	nursing	JJ	_	13	attr	_	_
13	infants	infant	NNS	_	10	ppmod	_	_
14	,	,	,	_	19	p	_	_
15	a	a	DT	_	16	det	_	_
16	decision	decision	NN	_	19	dep	_	_
17	must	must	MD	_	19	modal	_	_
18	be	be	VB	_	19	aux	_	_
19	made	make	VBN	_	0	root	_	_
20	whether	whether	IN	_	22	mark	_	_
21	to	to	TO	_	22	aux	_	_
22	discontinue	discontinue	VBP	_	19	comp	_	_
23	nursing	nurse	VBG	_	26	adv	_	_
24	or	or	CC	_	26	cc	_	_
25	discontinue	discontinue	NN	_	26	com	_	_
26	drug1	drug0	NN	_	22	ppmod	_	_
27	and	and	CC	_	26	cc	_	_
28	drug2	drug0	NN	_	29	com	_	_
29	treatment	treatment	NN	_	26	conj	_	_
30	.	.	.	_	19	p	_	_

1	Pediatric	pediatric	JJ	_	2	attr	_	_
2	Use	use	NN	_	27	dep	_	_
3	The	the	DT	_	4	det	_	_
4	safety	safety	NN	_	2	attr	_	_
5	and	and	CC	_	4	cc	_	_
6	effectiveness	effectiveness	NN	_	4	conj	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	2	ppmod	_	_
9	,	,	,	_	8	p	_	_
10	alone	alone	RB	_	8	adv	_	_
11	or	or	CC	_	10	cc	_	_
12	in	in	IN	_	13	case	_	_
13	combination	combination	NN	_	10	conj	_	_
14	with	with	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	in	in	IN	_	17	case	_	_
17	patients	patient	NNS	_	15	ppmod	_	_
18	below	below	IN	_	20	case	_	_
19	the	the	DT	_	20	det	_	_
20	age	age	NN	_	17	ppmod	_	_
21	of	of	IN	_	23	case	_	_
22	18	0	CD	_	23	num	_	_
23	years	year	NNS	_	20	ppmod	_	_
24	have	have	VBP	_	27	aux	_	_
25	not	not	RB	_	27	neg	_	_
26	been	be	VBN	_	27	aux	_	_
27	established	establish	VBN	_	0	root	_	_
28	.	.	.	_	27	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	contains	contain	VBZ	_	0	root	_	_
3	drug2	drug0	NN	_	2	obj	_	_
4	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	reported	report	VBN	_	0	root	_	_
5	to	to	TO	_	7	aux	_	_
6	be	be	VB	_	7	aux	_	_
7	associated	associate	VBN	_	4	comp	_	_
8	with	with	IN	_	11	case	_	_
9	an	an	DT	_	11	det	_	_
10	increased	increase	VBN	_	11	attr	_	_
11	incidence	incidence	NN	_	7	ppmod	_	_
12	of	of	IN	_	16	case	_	_
13	neurological	neurological	JJ	_	16	attr	_	_
14	and	and	CC	_	16	cc	_	_
15	other	other	JJ	_	16	attr	_	_
16	complications	complication	NNS	_	11	ppmod	_	_
17	in	in	IN	_	18	case	_	_
18	neonates	neonate	NNS	_	11	ppmod	_	_
19	and	and	CC	_	18	cc	_	_
20	infants	infant	NNS	_	18	conj	_	_
21	,	,	,	_	4	p	_	_
22	which	which	WDT	_	23	dep	_	_
23	are	be	VBP	_	4	comp	_	_
24	sometimes	sometimes	RB	_	23	adv	_	_
25	fatal	fatal	JJ	_	23	dep	_	_
26	.	.	.	_	4	p	_	_

1	Geriatric	geriatric	JJ	_	4	attr	_	_
2	Use	use	NN	_	3	advnp	_	_
3	Younger	young	JJR	_	4	attr	_	_
4	patients	patient	NNS	_	5	dep	_	_
5	have	have	VBP	_	0	root	_	_
6	higher	high	JJR	_	9	attr	_	_
7	virologic	virologic	JJ	_	9	attr	_	_
8	response	response	NN	_	9	com	_	_
9	rates	rate	NNS	_	5	obj	_	_
10	than	than	IN	_	12	case	_	_
11	older	old	JJR	_	12	attr	_	_
12	patients	patient	NNS	_	5	ppmod	_	_
13	.	.	.	_	5	p	_	_

1	Clinical	clinical	JJ	_	2	attr	_	_
2	studies	study	NNS	_	13	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	alone	alone	RB	_	4	adv	_	_
6	or	or	CC	_	5	cc	_	_
7	in	in	IN	_	8	case	_	_
8	combination	combination	NN	_	5	conj	_	_
9	with	with	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	did	do	VBD	_	13	aux	_	_
12	not	not	RB	_	13	neg	_	_
13	include	include	VB	_	0	root	_	_
14	sufficient	sufficient	JJ	_	15	attr	_	_
15	numbers	number	NNS	_	13	obj	_	_
16	of	of	IN	_	17	case	_	_
17	subjects	subject	NNS	_	15	ppmod	_	_
18	aged	aged	JJ	_	17	attr	_	_
19	65	0	CD	_	18	num	_	_
20	or	or	CC	_	17	cc	_	_
21	over	over	IN	_	23	case	_	_
22	to	to	TO	_	23	aux	_	_
23	determine	determine	VB	_	17	conj	_	_
24	whether	whether	IN	_	26	mark	_	_
25	they	they	PRP	_	26	dep	_	_
26	respond	respond	VBP	_	23	comp	_	_
27	differently	differently	RB	_	26	adv	_	_
28	from	from	IN	_	30	case	_	_
29	younger	young	JJR	_	30	attr	_	_
30	subjects	subject	NNS	_	26	ppmod	_	_
31	.	.	.	_	13	p	_	_

1	Adverse	adverse	JJ	_	2	attr	_	_
2	reactions	reaction	NNS	_	23	dep	_	_
3	related	related	JJ	_	2	attr	_	_
4	to	to	TO	_	6	aux	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	s	s	NNS	_	3	ppmod	_	_
7	,	,	,	_	6	p	_	_
8	such	such	JJ	_	6	appo	_	_
9	as	as	IN	_	10	case	_	_
10	CNS	cns	NN	_	8	ppmod	_	_
11	,	,	,	_	8	p	_	_
12	cardiac	cardiac	JJ	_	8	conj	_	_
13	,	,	,	_	12	p	_	_
14	and	and	CC	_	12	cc	_	_
15	systemic	systemic	JJ	_	21	attr	_	_
16	(	-lrb-	-LRB-	_	19	p	_	_
17	eg	eg	FW	_	19	ppmod	_	_
18	,	,	,	_	19	p	_	_
19	flu-like	flu-like	JJ	_	15	prn	_	_
20	)	-rrb-	-RRB-	_	19	p	_	_
21	effects	effect	NNS	_	8	conj	_	_
22	may	may	MD	_	23	modal	_	_
23	be	be	VB	_	0	root	_	_
24	more	more	RBR	_	25	adv	_	_
25	severe	severe	JJ	_	23	dep	_	_
26	in	in	IN	_	28	case	_	_
27	the	the	DT	_	28	det	_	_
28	elderly	elderly	JJ	_	23	ppmod	_	_
29	and	and	CC	_	23	cc	_	_
30	caution	caution	NN	_	33	dep	_	_
31	should	should	MD	_	33	modal	_	_
32	be	be	VB	_	33	aux	_	_
33	exercised	exercise	VBN	_	23	conj	_	_
34	in	in	IN	_	36	case	_	_
35	the	the	DT	_	36	det	_	_
36	use	use	NN	_	33	ppmod	_	_
37	of	of	IN	_	38	case	_	_
38	drug2	drug0	NN	_	36	ppmod	_	_
39	in	in	IN	_	41	case	_	_
40	this	this	DT	_	41	det	_	_
41	population	population	NN	_	36	ppmod	_	_
42	.	.	.	_	23	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	are	be	VBP	_	5	aux	_	_
5	excreted	excrete	VBN	_	0	root	_	_
6	by	by	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	kidney	kidney	NN	_	5	ppmod	_	_
9	,	,	,	_	5	p	_	_
10	and	and	CC	_	5	cc	_	_
11	the	the	DT	_	12	det	_	_
12	risk	risk	NN	_	20	dep	_	_
13	of	of	IN	_	15	case	_	_
14	toxic	toxic	JJ	_	15	attr	_	_
15	reactions	reaction	NNS	_	12	ppmod	_	_
16	to	to	TO	_	18	aux	_	_
17	this	this	DT	_	18	det	_	_
18	therapy	therapy	NN	_	15	ppmod	_	_
19	may	may	MD	_	20	modal	_	_
20	be	be	VB	_	5	conj	_	_
21	greater	great	JJR	_	20	dep	_	_
22	in	in	IN	_	23	case	_	_
23	patients	patient	NNS	_	21	ppmod	_	_
24	with	with	IN	_	27	case	_	_
25	impaired	impaired	JJ	_	27	attr	_	_
26	renal	renal	JJ	_	27	attr	_	_
27	function	function	NN	_	23	ppmod	_	_
28	.	.	.	_	5	p	_	_

1	Because	because	IN	_	4	mark	_	_
2	elderly	elderly	JJ	_	3	attr	_	_
3	patients	patient	NNS	_	4	dep	_	_
4	are	be	VBP	_	16	advcl	_	_
5	more	more	RBR	_	6	adv	_	_
6	likely	likely	JJ	_	4	dep	_	_
7	to	to	TO	_	11	aux	_	_
8	have	have	VB	_	11	lv	_	_
9	decreased	decrease	VBN	_	11	attr	_	_
10	renal	renal	JJ	_	11	attr	_	_
11	function	function	NN	_	4	comp	_	_
12	,	,	,	_	16	p	_	_
13	care	care	NN	_	16	dep	_	_
14	should	should	MD	_	16	modal	_	_
15	be	be	VB	_	16	aux	_	_
16	taken	take	VBN	_	0	root	_	_
17	in	in	IN	_	19	case	_	_
18	dose	dose	NN	_	19	com	_	_
19	selection	selection	NN	_	16	ppmod	_	_
20	and	and	CC	_	16	cc	_	_
21	it	it	PRP	_	23	dep	_	_
22	may	may	MD	_	23	modal	_	_
23	be	be	VB	_	16	conj	_	_
24	useful	useful	JJ	_	23	dep	_	_
25	to	to	TO	_	26	aux	_	_
26	monitor	monitor	VB	_	24	comp	_	_
27	renal	renal	JJ	_	28	attr	_	_
28	function	function	NN	_	26	obj	_	_
29	.	.	.	_	16	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	used	use	VBN	_	0	root	_	_
5	with	with	IN	_	6	case	_	_
6	caution	caution	NN	_	4	ppmod	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	4	ppmod	_	_
9	with	with	IN	_	13	case	_	_
10	creatinine	creatinine	NN	_	13	attr	_	_
11	clearance	clearance	NN	_	13	attr	_	_
12	50	0	CD	_	13	num	_	_
13	mL/min	ml/min	NN	_	8	ppmod	_	_
14	and	and	CC	_	4	cc	_	_
15	drug2	drug0	NN	_	19	dep	_	_
16	should	should	MD	_	19	modal	_	_
17	not	not	RB	_	19	neg	_	_
18	be	be	VB	_	19	aux	_	_
19	administered	administer	VBN	_	4	conj	_	_
20	to	to	TO	_	21	aux	_	_
21	patients	patient	NNS	_	19	ppmod	_	_
22	with	with	IN	_	26	case	_	_
23	creatinine	creatinine	NN	_	26	attr	_	_
24	clearance	clearance	NN	_	26	attr	_	_
25	50	0	CD	_	26	num	_	_
26	mL/min	ml/min	NN	_	21	ppmod	_	_

1	.	.	.	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	General	general	JJ	_	4	attr	_	_
2	In	in	FW	_	3	adv	_	_
3	vitro	vitro	FW	_	4	attr	_	_
4	studies	study	NNS	_	9	dep	_	_
5	in	in	IN	_	8	case	_	_
6	human	human	JJ	_	8	attr	_	_
7	liver	liver	NN	_	8	com	_	_
8	microsomes	microsome	NNS	_	4	ppmod	_	_
9	demonstrated	demonstrate	VBD	_	0	root	_	_
10	no	no	DT	_	11	det	_	_
11	evidence	evidence	NN	_	9	obj	_	_
12	of	of	IN	_	16	case	_	_
13	cytochrome	cytochrome	NN	_	16	attr	_	_
14	P450-mediated	p0-mediated	JJ	_	16	attr	_	_
15	drug	drug	NN	_	16	com	_	_
16	interactions	interaction	NNS	_	11	ppmod	_	_
17	that	that	WDT	_	18	dep	_	_
18	are	be	VBP	_	16	relcl	_	_
19	likely	likely	JJ	_	18	dep	_	_
20	to	to	TO	_	21	aux	_	_
21	be	be	VB	_	19	comp	_	_
22	of	of	IN	_	24	case	_	_
23	clinical	clinical	JJ	_	24	attr	_	_
24	relevance	relevance	NN	_	21	ppmod	_	_
25	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	/	/	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	/	/	:	_	1	p	_	_
5	drug3	drug0	NN	_	1	appo	_	_
6	/	/	:	_	1	p	_	_
7	drug4	drug0	NN	_	1	appo	_	_
8	:	:	:	_	1	p	_	_
9	Co-administration	co-administration	NN	_	21	dep	_	_
10	of	of	IN	_	11	case	_	_
11	drug5	drug0	NN	_	9	ppmod	_	_
12	with	with	IN	_	13	case	_	_
13	drug6	drug0	NN	_	9	ppmod	_	_
14	,	,	,	_	13	p	_	_
15	drug7	drug0	NN	_	13	conj	_	_
16	,	,	,	_	15	p	_	_
17	drug8	drug0	NN	_	13	conj	_	_
18	,	,	,	_	17	p	_	_
19	and	and	CC	_	17	cc	_	_
20	drug9	drug0	NN	_	13	conj	_	_
21	is	be	VBZ	_	1	acl	_	_
22	likely	likely	JJ	_	21	dep	_	_
23	to	to	TO	_	24	aux	_	_
24	lead	lead	VB	_	22	comp	_	_
25	to	to	TO	_	27	aux	_	_
26	an	an	DT	_	27	det	_	_
27	enhancement	enhancement	NN	_	24	ppmod	_	_
28	of	of	IN	_	29	case	_	_
29	effects	effect	NNS	_	27	ppmod	_	_
30	.	.	.	_	1	p	_	_

1	Specific	specific	JJ	_	2	attr	_	_
2	studies	study	NNS	_	4	dep	_	_
3	have	have	VBP	_	4	aux	_	_
4	confirmed	confirm	VBN	_	0	root	_	_
5	these	these	DT	_	6	det	_	_
6	effects	effect	NNS	_	4	obj	_	_
7	with	with	IN	_	8	case	_	_
8	drug1	drug0	NN	_	4	ppmod	_	_
9	,	,	,	_	8	p	_	_
10	drug2	drug0	NN	_	8	conj	_	_
11	,	,	,	_	10	p	_	_
12	drug3	drug0	NN	_	8	conj	_	_
13	,	,	,	_	12	p	_	_
14	drug4	drug0	NN	_	8	conj	_	_
15	,	,	,	_	14	p	_	_
16	and	and	CC	_	14	cc	_	_
17	drug5	drug0	NN	_	8	conj	_	_
18	.	.	.	_	4	p	_	_

1	No	no	DT	_	3	det	_	_
2	pharmacokinetic	pharmacokinetic	JJ	_	3	attr	_	_
3	interactions	interaction	NNS	_	17	dep	_	_
4	between	between	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	,	,	,	_	7	p	_	_
9	drug3	drug0	NN	_	5	conj	_	_
10	,	,	,	_	9	p	_	_
11	drug4	drug0	NN	_	5	conj	_	_
12	,	,	,	_	11	p	_	_
13	and	and	CC	_	11	cc	_	_
14	drug5	drug0	NN	_	5	conj	_	_
15	have	have	VBP	_	17	aux	_	_
16	been	be	VBN	_	17	aux	_	_
17	demonstrated	demonstrate	VBN	_	0	root	_	_
18	.	.	.	_	17	p	_	_

1	However	however	RB	_	32	adv	_	_
2	,	,	,	_	32	p	_	_
3	due	due	IN	_	7	case	_	_
4	to	to	TO	_	7	aux	_	_
5	possible	possible	JJ	_	7	attr	_	_
6	pharmacodynamic	pharmacodynamic	JJ	_	7	attr	_	_
7	interactions	interaction	NNS	_	32	ppmod	_	_
8	,	,	,	_	32	p	_	_
9	when	when	WRB	_	10	adv	_	_
10	co-administered	co-administered	VBN	_	32	advcl	_	_
11	with	with	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	,	,	,	_	32	p	_	_
14	a	a	DT	_	15	det	_	_
15	reduction	reduction	NN	_	32	dep	_	_
16	in	in	IN	_	17	case	_	_
17	dosage	dosage	NN	_	15	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	on	on	IN	_	23	case	_	_
21	the	the	DT	_	23	det	_	_
22	concomitant	concomitant	JJ	_	23	attr	_	_
23	drug3	drug0	NN	_	15	ppmod	_	_
24	,	,	,	_	23	p	_	_
25	drug4	drug0	NN	_	23	conj	_	_
26	,	,	,	_	25	p	_	_
27	drug5	drug0	NN	_	23	conj	_	_
28	or	or	CC	_	27	cc	_	_
29	drug6	drug0	NN	_	23	conj	_	_
30	may	may	MD	_	32	modal	_	_
31	be	be	VB	_	32	aux	_	_
32	required	require	VBN	_	0	root	_	_
33	.	.	.	_	32	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	5	case	_	_
4	one	#crd#	CD	_	5	num	_	_
5	study	study	NN	_	27	ppmod	_	_
6	of	of	IN	_	9	case	_	_
7	10	0	CD	_	9	num	_	_
8	healthy	healthy	JJ	_	9	attr	_	_
9	volunteers	volunteer	NNS	_	5	ppmod	_	_
10	,	,	,	_	27	p	_	_
11	administration	administration	NN	_	27	dep	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	for	for	IN	_	16	case	_	_
15	45	0	CD	_	16	num	_	_
16	minutes	minute	NNS	_	11	ppmod	_	_
17	at	at	IN	_	20	case	_	_
18	a	a	DT	_	20	det	_	_
19	plasma	plasma	NN	_	20	com	_	_
20	concentration	concentration	NN	_	11	ppmod	_	_
21	of	of	IN	_	26	case	_	_
22	1	0	CD	_	26	num	_	_
23	(	-lrb-	-LRB-	_	26	p	_	_
24	one	#crd#	CD	_	26	num	_	_
25	)	-rrb-	-RRB-	_	26	p	_	_
26	ng/mL	ng/ml	NN	_	20	ppmod	_	_
27	resulted	result	VBD	_	1	acl	_	_
28	in	in	IN	_	32	case	_	_
29	no	no	DT	_	32	det	_	_
30	clinically	clinically	RB	_	31	adv	_	_
31	meaningful	meaningful	JJ	_	32	attr	_	_
32	increases	increase	NNS	_	27	ppmod	_	_
33	in	in	IN	_	35	case	_	_
34	the	the	DT	_	35	det	_	_
35	magnitude	magnitude	NN	_	32	ppmod	_	_
36	or	or	CC	_	35	cc	_	_
37	neuromuscular	neuromuscular	JJ	_	38	attr	_	_
38	blockade	blockade	NN	_	35	conj	_	_
39	associated	associate	VBN	_	35	acl	_	_
40	with	with	IN	_	42	case	_	_
41	drug3	drug0	NN	_	42	com	_	_
42	administration	administration	NN	_	39	ppmod	_	_
43	.	.	.	_	1	p	_	_

1	Effect	effect	NN	_	0	root	_	_
2	of	of	IN	_	4	case	_	_
3	other	other	JJ	_	4	attr	_	_
4	drugs	drug	NNS	_	1	ppmod	_	_
5	on	on	IN	_	6	case	_	_
6	drug1	drug0	NN	_	1	ppmod	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	studies	study	NNS	_	0	root	_	_
4	:	:	:	_	3	p	_	_
5	Studies	study	NNS	_	10	dep	_	_
6	in	in	IN	_	9	case	_	_
7	human	human	JJ	_	9	attr	_	_
8	liver	liver	NN	_	9	com	_	_
9	microsomes	microsome	NNS	_	5	ppmod	_	_
10	showed	show	VBD	_	3	acl	_	_
11	that	that	IN	_	14	mark	_	_
12	drug1	drug0	NN	_	14	dep	_	_
13	is	be	VBZ	_	14	aux	_	_
14	metabolized	metabolize	VBN	_	10	comp	_	_
15	primarily	primarily	RB	_	14	adv	_	_
16	by	by	IN	_	23	case	_	_
17	cytochrome	cytochrome	NN	_	18	com	_	_
18	P450	p0	NN	_	23	attr	_	_
19	(	-lrb-	-LRB-	_	20	p	_	_
20	CYP	cyp	NN	_	18	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	isoforms	isoforms	NNS	_	23	com	_	_
23	3A4/5	0a0	NN	_	14	ppmod	_	_
24	,	,	,	_	14	p	_	_
25	and	and	CC	_	14	cc	_	_
26	to	to	TO	_	29	aux	_	_
27	a	a	DT	_	29	det	_	_
28	lesser	less	JJR	_	29	attr	_	_
29	degree	degree	NN	_	14	conj	_	_
30	by	by	IN	_	31	case	_	_
31	CYP2C9	cyp0c0	NN	_	29	ppmod	_	_
32	.	.	.	_	3	p	_	_

1	Therefore	therefore	RB	_	8	adv	_	_
2	,	,	,	_	8	p	_	_
3	inhibitors	inhibitor	NNS	_	8	dep	_	_
4	of	of	IN	_	6	case	_	_
5	these	these	DT	_	6	det	_	_
6	enzymes	enzyme	NNS	_	3	ppmod	_	_
7	are	be	VBP	_	8	aux	_	_
8	expected	expect	VBN	_	0	root	_	_
9	to	to	TO	_	10	aux	_	_
10	reduce	reduce	VB	_	8	comp	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	clearance	clearance	NN	_	10	obj	_	_
13	.	.	.	_	8	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vivo	vivo	FW	_	3	attr	_	_
3	studies	study	NNS	_	0	root	_	_
4	:	:	:	_	3	p	_	_
5	Cytochrome	cytochrome	NN	_	7	com	_	_
6	P450	p0	NN	_	7	com	_	_
7	Inhibitors	inhibitor	NNS	_	3	appo	_	_

1	drug1	drug0	NN	_	7	dep	_	_
2	(	-lrb-	-LRB-	_	5	p	_	_
3	400	0	CD	_	4	num	_	_
4	mg	mg	NN	_	5	com	_	_
5	b.i.d.	b.i.d.	NN	_	1	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	had	have	VBD	_	0	root	_	_
8	no	no	DT	_	9	det	_	_
9	effect	effect	NN	_	7	obj	_	_
10	on	on	IN	_	12	case	_	_
11	drug2	drug0	NN	_	12	com	_	_
12	bioavailability	bioavailability	NN	_	7	ppmod	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	AUC	auc	NN	_	12	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	and	and	CC	_	12	cc	_	_
17	maximum	maximum	JJ	_	18	attr	_	_
18	concentration	concentration	NN	_	12	conj	_	_
19	(	-lrb-	-LRB-	_	20	p	_	_
20	Cmax	cmax	NN	_	18	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	of	of	IN	_	23	case	_	_
23	drug3	drug0	NN	_	12	ppmod	_	_
24	when	when	WRB	_	25	adv	_	_
25	co-administered	co-administered	VBN	_	7	comp	_	_
26	with	with	IN	_	29	case	_	_
27	20	0	CD	_	28	num	_	_
28	mg	mg	NN	_	29	com	_	_
29	drug4	drug0	NN	_	25	ppmod	_	_
30	in	in	IN	_	32	case	_	_
31	healthy	healthy	JJ	_	32	attr	_	_
32	volunteers	volunteer	NNS	_	29	ppmod	_	_
33	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	7	dep	_	_
2	(	-lrb-	-LRB-	_	5	p	_	_
3	500	0	CD	_	4	num	_	_
4	mg	mg	NN	_	5	com	_	_
5	t.i.d	t.i.d	NN	_	1	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	produced	produce	VBD	_	0	root	_	_
8	a	a	DT	_	10	det	_	_
9	4-fold	0-fold	JJ	_	10	attr	_	_
10	increase	increase	NN	_	7	obj	_	_
11	in	in	IN	_	13	case	_	_
12	drug2	drug0	NN	_	13	com	_	_
13	AUC	auc	NN	_	10	ppmod	_	_
14	and	and	CC	_	10	cc	_	_
15	a	a	DT	_	17	det	_	_
16	3-fold	0-fold	JJ	_	17	attr	_	_
17	increase	increase	NN	_	10	conj	_	_
18	in	in	IN	_	19	case	_	_
19	Cmax	cmax	NN	_	17	ppmod	_	_
20	when	when	WRB	_	21	adv	_	_
21	co-administered	co-administered	VBN	_	7	comp	_	_
22	with	with	IN	_	25	case	_	_
23	drug3	drug0	NN	_	25	attr	_	_
24	5	0	CD	_	25	num	_	_
25	mg	mg	NN	_	21	ppmod	_	_
26	in	in	IN	_	28	case	_	_
27	healthy	healthy	JJ	_	28	attr	_	_
28	volunteers	volunteer	NNS	_	25	ppmod	_	_
29	.	.	.	_	7	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	recommended	recommend	VBN	_	0	root	_	_
4	not	not	RB	_	6	neg	_	_
5	to	to	TO	_	6	aux	_	_
6	exceed	exceed	VB	_	3	comp	_	_
7	a	a	DT	_	11	det	_	_
8	single	single	JJ	_	11	attr	_	_
9	5	0	CD	_	10	num	_	_
10	mg	mg	NN	_	11	com	_	_
11	dose	dose	NN	_	6	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	in	in	IN	_	17	case	_	_
15	a	a	DT	_	17	det	_	_
16	24-hour	0-hour	JJ	_	17	attr	_	_
17	period	period	NN	_	6	ppmod	_	_
18	when	when	WRB	_	19	adv	_	_
19	used	use	VBN	_	17	relcl	_	_
20	in	in	IN	_	21	case	_	_
21	combination	combination	NN	_	19	ppmod	_	_
22	with	with	IN	_	23	case	_	_
23	drug2	drug0	NN	_	21	ppmod	_	_
24	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	8	dep	_	_
2	(	-lrb-	-LRB-	_	4	p	_	_
3	200	0	CD	_	4	num	_	_
4	mg	mg	NN	_	1	prn	_	_
5	once	once	RB	_	6	adv	_	_
6	daily	daily	JJ	_	4	attr	_	_
7	)	-rrb-	-RRB-	_	4	p	_	_
8	produced	produce	VBD	_	0	root	_	_
9	a	a	DT	_	11	det	_	_
10	10-fold	0-fold	JJ	_	11	attr	_	_
11	increase	increase	NN	_	8	obj	_	_
12	in	in	IN	_	14	case	_	_
13	drug2	drug0	NN	_	14	com	_	_
14	AUC	auc	NN	_	11	ppmod	_	_
15	and	and	CC	_	11	cc	_	_
16	a	a	DT	_	18	det	_	_
17	4-fold	0-fold	JJ	_	18	attr	_	_
18	increase	increase	NN	_	11	conj	_	_
19	in	in	IN	_	20	case	_	_
20	Cmax	cmax	NN	_	18	ppmod	_	_
21	when	when	WRB	_	22	adv	_	_
22	co-administered	co-administered	VBN	_	8	comp	_	_
23	with	with	IN	_	24	case	_	_
24	drug3	drug0	NN	_	22	ppmod	_	_
25	(	-lrb-	-LRB-	_	27	p	_	_
26	5	0	CD	_	27	num	_	_
27	mg	mg	NN	_	24	prn	_	_
28	)	-rrb-	-RRB-	_	27	p	_	_
29	in	in	IN	_	31	case	_	_
30	healthy	healthy	JJ	_	31	attr	_	_
31	volunteers	volunteer	NNS	_	24	ppmod	_	_
32	.	.	.	_	8	p	_	_

1	A	a	DT	_	4	det	_	_
2	5-mg	0-mg	JJ	_	4	attr	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	dose	dose	NN	_	8	dep	_	_
5	should	should	MD	_	8	modal	_	_
6	not	not	RB	_	8	neg	_	_
7	be	be	VB	_	8	aux	_	_
8	exceeded	exceed	VBD	_	0	root	_	_
9	when	when	WRB	_	10	adv	_	_
10	used	use	VBN	_	8	comp	_	_
11	in	in	IN	_	12	case	_	_
12	combination	combination	NN	_	10	ppmod	_	_
13	with	with	IN	_	15	case	_	_
14	200	0	CD	_	15	num	_	_
15	mg	mg	NN	_	12	ppmod	_	_
16	once	once	IN	_	18	case	_	_
17	daily	daily	JJ	_	18	attr	_	_
18	drug2	drug0	NN	_	15	ppmod	_	_
19	.	.	.	_	8	p	_	_

1	Since	since	IN	_	12	mark	_	_
2	higher	high	JJR	_	3	attr	_	_
3	doses	dose	NNS	_	12	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	(	-lrb-	-LRB-	_	8	p	_	_
7	400	0	CD	_	8	num	_	_
8	mg	mg	NN	_	3	prn	_	_
9	daily	daily	RB	_	8	adv	_	_
10	)	-rrb-	-RRB-	_	8	p	_	_
11	may	may	MD	_	12	modal	_	_
12	result	result	VB	_	31	advcl	_	_
13	in	in	IN	_	15	case	_	_
14	higher	high	JJR	_	15	attr	_	_
15	increases	increase	NNS	_	12	ppmod	_	_
16	in	in	IN	_	17	case	_	_
17	Cmax	cmax	NN	_	15	ppmod	_	_
18	and	and	CC	_	17	cc	_	_
19	AUC	auc	NN	_	17	conj	_	_
20	,	,	,	_	31	p	_	_
21	a	a	DT	_	25	det	_	_
22	single	single	JJ	_	25	attr	_	_
23	2.5	0	CD	_	24	num	_	_
24	mg	mg	NN	_	25	com	_	_
25	dose	dose	NN	_	31	dep	_	_
26	of	of	IN	_	27	case	_	_
27	drug2	drug0	NN	_	25	ppmod	_	_
28	should	should	MD	_	31	modal	_	_
29	not	not	RB	_	31	neg	_	_
30	be	be	VB	_	31	aux	_	_
31	exceeded	exceed	VBD	_	0	root	_	_
32	in	in	IN	_	35	case	_	_
33	a	a	DT	_	35	det	_	_
34	24-hour	0-hour	JJ	_	35	attr	_	_
35	period	period	NN	_	31	ppmod	_	_
36	when	when	WRB	_	37	adv	_	_
37	used	use	VBN	_	31	comp	_	_
38	in	in	IN	_	39	case	_	_
39	combination	combination	NN	_	37	ppmod	_	_
40	with	with	IN	_	43	case	_	_
41	drug3	drug0	NN	_	43	attr	_	_
42	400	0	CD	_	43	num	_	_
43	mg	mg	NN	_	39	ppmod	_	_
44	daily	daily	RB	_	43	adv	_	_
45	.	.	.	_	31	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	14	dep	_	_
4	(	-lrb-	-LRB-	_	7	p	_	_
5	800	0	CD	_	6	num	_	_
6	mg	mg	NN	_	7	com	_	_
7	t.i.d.	t.i.d.	NN	_	3	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	co-administered	co-administered	VBN	_	3	acl	_	_
10	with	with	IN	_	13	case	_	_
11	drug3	drug0	NN	_	13	attr	_	_
12	10	0	CD	_	13	num	_	_
13	mg	mg	NN	_	9	ppmod	_	_
14	resulted	result	VBD	_	1	acl	_	_
15	in	in	IN	_	18	case	_	_
16	a	a	DT	_	18	det	_	_
17	16-fold	0-fold	JJ	_	18	attr	_	_
18	increase	increase	NN	_	14	ppmod	_	_
19	in	in	IN	_	21	case	_	_
20	drug4	drug0	NN	_	21	com	_	_
21	AUC	auc	NN	_	18	ppmod	_	_
22	,	,	,	_	18	p	_	_
23	a	a	DT	_	25	det	_	_
24	7-fold	0-fold	JJ	_	25	attr	_	_
25	increase	increase	NN	_	18	conj	_	_
26	in	in	IN	_	28	case	_	_
27	drug5	drug0	NN	_	28	com	_	_
28	Cmax	cmax	NN	_	25	ppmod	_	_
29	and	and	CC	_	25	cc	_	_
30	a	a	DT	_	32	det	_	_
31	2-fold	0-fold	JJ	_	32	attr	_	_
32	increase	increase	NN	_	18	conj	_	_
33	in	in	IN	_	35	case	_	_
34	drug6	drug0	NN	_	35	com	_	_
35	half-life	half-life	NN	_	32	ppmod	_	_
36	.	.	.	_	1	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	recommended	recommend	VBN	_	0	root	_	_
4	not	not	RB	_	6	neg	_	_
5	to	to	TO	_	6	aux	_	_
6	exceed	exceed	VB	_	3	comp	_	_
7	a	a	DT	_	12	det	_	_
8	single	single	JJ	_	12	attr	_	_
9	2.5	0	CD	_	10	num	_	_
10	mg	mg	NN	_	12	com	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	dose	dose	NN	_	6	obj	_	_
13	in	in	IN	_	16	case	_	_
14	a	a	DT	_	16	det	_	_
15	24-hour	0-hour	JJ	_	16	attr	_	_
16	period	period	NN	_	6	ppmod	_	_
17	when	when	WRB	_	18	adv	_	_
18	used	use	VBN	_	16	relcl	_	_
19	in	in	IN	_	20	case	_	_
20	combination	combination	NN	_	18	ppmod	_	_
21	with	with	IN	_	22	case	_	_
22	drug2	drug0	NN	_	20	ppmod	_	_
23	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	12	dep	_	_
2	(	-lrb-	-LRB-	_	5	p	_	_
3	600	0	CD	_	4	num	_	_
4	mg	mg	NN	_	5	com	_	_
5	b.i.d.	b.i.d.	NN	_	1	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	co-administered	co-administered	VBN	_	1	acl	_	_
8	with	with	IN	_	11	case	_	_
9	drug2	drug0	NN	_	11	attr	_	_
10	5	0	CD	_	11	num	_	_
11	mg	mg	NN	_	7	ppmod	_	_
12	resulted	result	VBD	_	0	root	_	_
13	in	in	IN	_	16	case	_	_
14	a	a	DT	_	16	det	_	_
15	49-fold	0-fold	JJ	_	16	attr	_	_
16	increase	increase	NN	_	12	ppmod	_	_
17	in	in	IN	_	19	case	_	_
18	drug3	drug0	NN	_	19	com	_	_
19	AUC	auc	NN	_	16	ppmod	_	_
20	and	and	CC	_	16	cc	_	_
21	a	a	DT	_	23	det	_	_
22	13-fold	0-fold	RB	_	23	adv	_	_
23	increase	increase	NN	_	16	conj	_	_
24	in	in	IN	_	26	case	_	_
25	drug4	drug0	NN	_	26	com	_	_
26	Cmax	cmax	NN	_	23	ppmod	_	_
27	.	.	.	_	12	p	_	_

1	The	the	DT	_	2	det	_	_
2	interaction	interaction	NN	_	3	dep	_	_
3	is	be	VBZ	_	0	root	_	_
4	a	a	DT	_	5	det	_	_
5	consequence	consequence	NN	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	blocking	block	VBG	_	5	ppmod	_	_
8	hepatic	hepatic	JJ	_	9	attr	_	_
9	metabolism	metabolism	NN	_	7	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	by	by	IN	_	13	case	_	_
13	drug2	drug0	NN	_	7	ppmod	_	_
14	,	,	,	_	13	p	_	_
15	a	a	DT	_	19	det	_	_
16	highly	highly	RB	_	17	adv	_	_
17	potent	potent	JJ	_	19	attr	_	_
18	CYP3A4	cyp0a0	NN	_	19	com	_	_
19	inhibitor	inhibitor	NN	_	13	appo	_	_
20	,	,	,	_	19	p	_	_
21	which	which	WDT	_	23	dep	_	_
22	also	also	RB	_	23	adv	_	_
23	inhibits	inhibit	VBZ	_	19	relcl	_	_
24	CYP2C9	cyp0c0	NN	_	23	obj	_	_
25	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	significantly	significantly	RB	_	3	adv	_	_
3	prolonged	prolong	VBD	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	half-life	half-life	NN	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	to	to	TO	_	10	aux	_	_
9	26	0	CD	_	10	num	_	_
10	hours	hour	NNS	_	5	ppmod	_	_
11	.	.	.	_	3	p	_	_

1	Consequently	consequently	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	it	it	PRP	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	recommended	recommend	VBN	_	0	root	_	_
6	not	not	RB	_	8	neg	_	_
7	to	to	TO	_	8	aux	_	_
8	exceed	exceed	VB	_	5	comp	_	_
9	a	a	DT	_	14	det	_	_
10	single	single	JJ	_	14	attr	_	_
11	2.5	0	CD	_	12	num	_	_
12	mg	mg	NN	_	14	com	_	_
13	drug1	drug0	NN	_	14	com	_	_
14	dose	dose	NN	_	8	obj	_	_
15	in	in	IN	_	18	case	_	_
16	a	a	DT	_	18	det	_	_
17	72-hour	0-hour	JJ	_	18	attr	_	_
18	period	period	NN	_	8	ppmod	_	_
19	when	when	WRB	_	20	adv	_	_
20	used	use	VBN	_	18	relcl	_	_
21	in	in	IN	_	22	case	_	_
22	combination	combination	NN	_	20	ppmod	_	_
23	with	with	IN	_	24	case	_	_
24	drug2	drug0	NN	_	22	ppmod	_	_
25	.	.	.	_	5	p	_	_

1	Other	other	JJ	_	3	attr	_	_
2	Drug	drug	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	0	root	_	_
4	:	:	:	_	3	p	_	_
5	No	no	DT	_	7	det	_	_
6	pharmacokinetic	pharmacokinetic	JJ	_	7	attr	_	_
7	interactions	interaction	NNS	_	9	dep	_	_
8	were	be	VBD	_	9	aux	_	_
9	observed	observe	VBN	_	3	acl	_	_
10	between	between	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	the	the	DT	_	15	det	_	_
14	following	following	JJ	_	15	attr	_	_
15	drugs	drug	NNS	_	11	conj	_	_
16	:	:	:	_	3	p	_	_
17	drug2	drug0	NN	_	3	appo	_	_
18	,	,	,	_	17	p	_	_
19	drug3	drug0	NN	_	17	conj	_	_
20	,	,	,	_	19	p	_	_
21	drug4	drug0	NN	_	17	conj	_	_
22	,	,	,	_	21	p	_	_
23	drug5	drug0	NN	_	17	conj	_	_
24	,	,	,	_	23	p	_	_
25	and	and	CC	_	23	cc	_	_
26	drug6	drug0	NN	_	17	conj	_	_
27	.	.	.	_	3	p	_	_

1	In	in	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	drug1	drug0	JJ	_	4	attr	_	_
4	study	study	NN	_	7	ppmod	_	_
5	,	,	,	_	7	p	_	_
6	drug2	drug0	NN	_	7	dep	_	_
7	had	have	VBD	_	0	root	_	_
8	no	no	DT	_	9	det	_	_
9	effect	effect	NN	_	7	obj	_	_
10	on	on	IN	_	13	case	_	_
11	the	the	DT	_	13	det	_	_
12	prothrombin	prothrombin	NN	_	13	com	_	_
13	time	time	NN	_	7	ppmod	_	_
14	or	or	CC	_	13	cc	_	_
15	other	other	JJ	_	17	attr	_	_
16	pharmacodynamic	pharmacodynamic	JJ	_	17	attr	_	_
17	parameters	parameter	NNS	_	13	conj	_	_
18	.	.	.	_	7	p	_	_

1	Effects	effect	NNS	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	on	on	IN	_	6	case	_	_
5	other	other	JJ	_	6	attr	_	_
6	drugs	drug	NNS	_	1	ppmod	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	studies	study	NNS	_	0	root	_	_
4	:	:	:	_	3	p	_	_
5	drug1	drug0	NN	_	9	dep	_	_
6	and	and	CC	_	5	cc	_	_
7	its	its	PRP$	_	8	poss	_	_
8	metabolites	metabolite	NNS	_	5	conj	_	_
9	had	have	VBD	_	3	acl	_	_
10	no	no	DT	_	11	det	_	_
11	effect	effect	NN	_	9	obj	_	_
12	on	on	IN	_	13	case	_	_
13	CYP1A2	cyp0a0	NN	_	9	ppmod	_	_
14	,	,	,	_	13	p	_	_
15	2A6	0a0	NN	_	13	conj	_	_
16	,	,	,	_	15	p	_	_
17	and	and	CC	_	15	cc	_	_
18	2E1	0e0	NN	_	13	conj	_	_
19	(	-lrb-	-LRB-	_	21	p	_	_
20	Ki	ki	NN	_	21	com	_	_
21	100uM	0um	NN	_	18	prn	_	_
22	)	-rrb-	-RRB-	_	21	p	_	_
23	.	.	.	_	3	p	_	_

1	Weak	weak	JJ	_	3	attr	_	_
2	inhibitory	inhibitory	JJ	_	3	attr	_	_
3	effects	effect	NNS	_	19	dep	_	_
4	toward	toward	IN	_	6	case	_	_
5	other	other	JJ	_	6	attr	_	_
6	isoforms	isoforms	NNS	_	3	ppmod	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	CYP2C8	cyp0c0	NN	_	6	prn	_	_
9	,	,	,	_	8	p	_	_
10	2C9	0c0	NN	_	8	appo	_	_
11	,	,	,	_	8	p	_	_
12	2C19	0c0	NN	_	8	appo	_	_
13	,	,	,	_	8	p	_	_
14	2D6	0d0	NN	_	8	appo	_	_
15	,	,	,	_	8	p	_	_
16	3A4	0a0	NN	_	8	appo	_	_
17	)	-rrb-	-RRB-	_	8	p	_	_
18	were	be	VBD	_	19	aux	_	_
19	found	find	VBN	_	0	root	_	_
20	,	,	,	_	19	p	_	_
21	but	but	CC	_	19	cc	_	_
22	Ki	ki	NN	_	23	com	_	_
23	values	value	NNS	_	24	dep	_	_
24	were	be	VBD	_	19	conj	_	_
25	in	in	IN	_	26	case	_	_
26	excess	excess	NN	_	24	ppmod	_	_
27	of	of	IN	_	29	case	_	_
28	plasma	plasma	NN	_	29	com	_	_
29	concentrations	concentration	NNS	_	26	ppmod	_	_
30	achieved	achieve	VBN	_	29	acl	_	_
31	following	follow	VBG	_	32	adv	_	_
32	dosing	dosing	NN	_	30	ppmod	_	_
33	.	.	.	_	19	p	_	_

1	The	the	DT	_	5	det	_	_
2	most	most	RBS	_	3	adv	_	_
3	potent	potent	JJ	_	5	attr	_	_
4	inhibitory	inhibitory	JJ	_	5	attr	_	_
5	activity	activity	NN	_	7	dep	_	_
6	was	be	VBD	_	7	aux	_	_
7	observed	observe	VBN	_	0	root	_	_
8	for	for	IN	_	11	case	_	_
9	vardenafil	vardenafil	NN	_	11	com	_	_
10	metabolite	metabolite	NN	_	11	com	_	_
11	M1	m0	NN	_	7	ppmod	_	_
12	,	,	,	_	11	p	_	_
13	which	which	WDT	_	14	dep	_	_
14	had	have	VBD	_	11	relcl	_	_
15	a	a	DT	_	16	det	_	_
16	Ki	ki	NN	_	14	obj	_	_
17	of	of	IN	_	19	case	_	_
18	1.4	0	CD	_	19	num	_	_
19	uM	um	NN	_	16	ppmod	_	_
20	toward	toward	IN	_	21	case	_	_
21	CYP3A4	cyp0a0	NN	_	19	ppmod	_	_
22	,	,	,	_	16	p	_	_
23	which	which	WDT	_	24	dep	_	_
24	is	be	VBZ	_	16	relcl	_	_
25	about	about	RB	_	26	adv	_	_
26	20	0	CD	_	28	num	_	_
27	times	time	NNS	_	26	attr	_	_
28	higher	high	JJR	_	24	dep	_	_
29	than	than	IN	_	33	case	_	_
30	the	the	DT	_	33	det	_	_
31	M1	m0	NN	_	33	com	_	_
32	Cmax	cmax	NN	_	33	com	_	_
33	values	value	NNS	_	28	ppmod	_	_
34	after	after	IN	_	39	case	_	_
35	an	an	DT	_	39	det	_	_
36	80	0	CD	_	37	num	_	_
37	mg	mg	NN	_	39	com	_	_
38	drug1	drug0	NN	_	39	com	_	_
39	dose	dose	NN	_	33	ppmod	_	_
40	.	.	.	_	7	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vivo	vivo	FW	_	3	attr	_	_
3	studies	study	NNS	_	5	dep	_	_
4	:	:	:	_	5	p	_	_
5	drug1	drug0	NN	_	0	root	_	_
6	:	:	:	_	5	p	_	_
7	The	the	DT	_	11	det	_	_
8	blood	blood	NN	_	11	attr	_	_
9	pressure	pressure	NN	_	11	attr	_	_
10	lowering	lowering	JJ	_	11	attr	_	_
11	effects	effect	NNS	_	41	dep	_	_
12	of	of	IN	_	14	case	_	_
13	sublingual	sublingual	JJ	_	14	attr	_	_
14	drug2	drug0	NNS	_	11	ppmod	_	_
15	(	-lrb-	-LRB-	_	17	p	_	_
16	0.4	0	CD	_	17	num	_	_
17	mg	mg	NN	_	14	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	taken	take	VBN	_	14	acl	_	_
20	1	0	CD	_	23	num	_	_
21	and	and	CC	_	20	cc	_	_
22	4	0	CD	_	20	conj	_	_
23	hours	hour	NNS	_	25	dat	_	_
24	after	after	IN	_	25	case	_	_
25	drug3	drug0	NN	_	19	ppmod	_	_
26	and	and	CC	_	11	cc	_	_
27	increases	increase	NNS	_	11	conj	_	_
28	in	in	IN	_	30	case	_	_
29	heart	heart	NN	_	30	com	_	_
30	rate	rate	NN	_	27	ppmod	_	_
31	when	when	WRB	_	32	adv	_	_
32	taken	take	VBN	_	30	relcl	_	_
33	at	at	IN	_	39	case	_	_
34	1	0	CD	_	39	num	_	_
35	,	,	,	_	34	p	_	_
36	4	0	CD	_	34	conj	_	_
37	and	and	CC	_	36	cc	_	_
38	8	0	CD	_	34	conj	_	_
39	hours	hour	NNS	_	32	ppmod	_	_
40	were	be	VBD	_	41	aux	_	_
41	potentiated	potentiate	VBN	_	5	acl	_	_
42	by	by	IN	_	46	case	_	_
43	a	a	DT	_	46	det	_	_
44	20	0	CD	_	45	num	_	_
45	mg	mg	NN	_	46	com	_	_
46	dose	dose	NN	_	41	ppmod	_	_
47	of	of	IN	_	48	case	_	_
48	drug4	drug0	NN	_	46	ppmod	_	_
49	in	in	IN	_	52	case	_	_
50	healthy	healthy	JJ	_	52	attr	_	_
51	middle-aged	middle-aged	JJ	_	52	attr	_	_
52	subjects	subject	NNS	_	48	ppmod	_	_
53	.	.	.	_	5	p	_	_

1	These	these	DT	_	2	det	_	_
2	effects	effect	NNS	_	5	dep	_	_
3	were	be	VBD	_	5	aux	_	_
4	not	not	RB	_	5	neg	_	_
5	observed	observe	VBN	_	0	root	_	_
6	when	when	WRB	_	11	adv	_	_
7	drug1	drug0	NN	_	9	attr	_	_
8	20	0	CD	_	9	num	_	_
9	mg	mg	NN	_	11	dep	_	_
10	was	be	VBD	_	11	aux	_	_
11	taken	take	VBN	_	5	comp	_	_
12	24	0	CD	_	13	num	_	_
13	hours	hour	NNS	_	16	dat	_	_
14	before	before	IN	_	16	case	_	_
15	the	the	DT	_	16	det	_	_
16	drug2	drug0	NN	_	11	ppmod	_	_
17	.	.	.	_	5	p	_	_

1	Potentiation	potentiation	NN	_	17	dep	_	_
2	of	of	IN	_	5	case	_	_
3	the	the	DT	_	5	det	_	_
4	hypotensive	hypotensive	JJ	_	5	attr	_	_
5	effects	effect	NNS	_	1	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	for	for	IN	_	9	case	_	_
9	patients	patient	NNS	_	5	ppmod	_	_
10	with	with	IN	_	13	case	_	_
11	ischemic	ischemic	JJ	_	13	attr	_	_
12	heart	heart	NN	_	13	com	_	_
13	disease	disease	NN	_	9	ppmod	_	_
14	has	have	VBZ	_	17	aux	_	_
15	not	not	RB	_	17	neg	_	_
16	been	be	VBN	_	17	aux	_	_
17	evaluated	evaluate	VBN	_	0	root	_	_
18	,	,	,	_	17	p	_	_
19	and	and	CC	_	17	cc	_	_
20	concomitant	concomitant	JJ	_	21	attr	_	_
21	use	use	NN	_	27	dep	_	_
22	of	of	IN	_	23	case	_	_
23	drug2	drug0	NN	_	21	ppmod	_	_
24	and	and	CC	_	23	cc	_	_
25	drug3	drug0	NN	_	23	conj	_	_
26	is	be	VBZ	_	27	aux	_	_
27	contraindicated	contraindicate	VBN	_	17	conj	_	_
28	.	.	.	_	17	p	_	_

1	drug1	drug0	NN	_	22	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	5	attr	_	_
4	20	0	CD	_	5	num	_	_
5	mg	mg	NN	_	1	appo	_	_
6	,	,	,	_	1	p	_	_
7	when	when	WRB	_	8	adv	_	_
8	co-administered	co-administered	VBN	_	1	relcl	_	_
9	with	with	IN	_	13	case	_	_
10	slow-release	slow-release	JJ	_	13	attr	_	_
11	drug3	drug0	NN	_	13	attr	_	_
12	30	0	CD	_	13	num	_	_
13	mg	mg	NN	_	8	ppmod	_	_
14	or	or	CC	_	13	cc	_	_
15	60	0	CD	_	16	num	_	_
16	mg	mg	NN	_	13	conj	_	_
17	once	once	RB	_	18	com	_	_
18	daily	daily	RB	_	16	adv	_	_
19	,	,	,	_	1	p	_	_
20	did	do	VBD	_	22	aux	_	_
21	not	not	RB	_	22	neg	_	_
22	affect	affect	VB	_	0	root	_	_
23	the	the	DT	_	25	det	_	_
24	relative	relative	JJ	_	25	attr	_	_
25	bioavailability	bioavailability	NN	_	22	obj	_	_
26	(	-lrb-	-LRB-	_	27	p	_	_
27	AUC	auc	NN	_	25	prn	_	_
28	)	-rrb-	-RRB-	_	27	p	_	_
29	or	or	CC	_	25	cc	_	_
30	maximum	maximum	JJ	_	31	attr	_	_
31	concentration	concentration	NN	_	25	conj	_	_
32	(	-lrb-	-LRB-	_	33	p	_	_
33	Cmax	cmax	NN	_	31	prn	_	_
34	)	-rrb-	-RRB-	_	33	p	_	_
35	of	of	IN	_	36	case	_	_
36	drug4	drug0	NN	_	25	ppmod	_	_
37	,	,	,	_	36	p	_	_
38	a	a	DT	_	39	det	_	_
39	drug	drug	NN	_	36	appo	_	_
40	that	that	WDT	_	42	dep	_	_
41	is	be	VBZ	_	42	aux	_	_
42	metabolized	metabolize	VBN	_	39	relcl	_	_
43	via	via	IN	_	44	case	_	_
44	CYP3A4	cyp0a0	NN	_	42	ppmod	_	_
45	.	.	.	_	22	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	did	do	VBD	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	alter	alter	VB	_	0	root	_	_
5	the	the	DT	_	7	det	_	_
6	plasma	plasma	NN	_	7	com	_	_
7	levels	level	NNS	_	4	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	when	when	WRB	_	11	adv	_	_
11	taken	take	VBN	_	4	comp	_	_
12	in	in	IN	_	13	case	_	_
13	combination	combination	NN	_	11	ppmod	_	_
14	.	.	.	_	4	p	_	_

1	In	in	IN	_	3	case	_	_
2	these	these	DT	_	3	det	_	_
3	patients	patient	NNS	_	14	ppmod	_	_
4	whose	whose	WP$	_	5	poss	_	_
5	hypertension	hypertension	NN	_	7	dep	_	_
6	was	be	VBD	_	7	aux	_	_
7	controlled	control	VBN	_	3	relcl	_	_
8	with	with	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	14	p	_	_
11	drug2	drug0	NN	_	13	attr	_	_
12	20	0	CD	_	13	num	_	_
13	mg	mg	NN	_	14	dep	_	_
14	produced	produce	VBD	_	0	root	_	_
15	mean	mean	JJ	_	20	attr	_	_
16	additional	additional	JJ	_	20	attr	_	_
17	supine	supine	NN	_	20	attr	_	_
18	systolic/diastolic	systolic/diastolic	JJ	_	20	attr	_	_
19	blood	blood	NN	_	20	com	_	_
20	pressure	pressure	NN	_	21	com	_	_
21	reductions	reduction	NNS	_	14	obj	_	_
22	of	of	IN	_	25	case	_	_
23	6/5	0	CD	_	24	num	_	_
24	mm	mm	NN	_	25	com	_	_
25	Hg	hg	NN	_	21	ppmod	_	_
26	compared	compare	VBN	_	28	adv	_	_
27	to	to	TO	_	28	aux	_	_
28	placebo	placebo	NN	_	14	ppmod	_	_
29	.	.	.	_	14	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	When	when	WRB	_	9	adv	_	_
4	drug2	drug0	NN	_	9	dep	_	_
5	10	0	CD	_	4	num	_	_
6	or	or	CC	_	4	cc	_	_
7	20	0	CD	_	8	num	_	_
8	mg	mg	NN	_	4	conj	_	_
9	was	be	VBD	_	29	advcl	_	_
10	given	give	VBN	_	9	dep	_	_
11	to	to	TO	_	13	aux	_	_
12	healthy	healthy	JJ	_	13	attr	_	_
13	volunteers	volunteer	NNS	_	10	ppmod	_	_
14	either	either	CC	_	10	cc	_	_
15	simultaneously	simultaneously	RB	_	10	conj	_	_
16	or	or	CC	_	15	cc	_	_
17	6	0	CD	_	18	num	_	_
18	hours	hour	NNS	_	23	dat	_	_
19	after	after	IN	_	23	case	_	_
20	a	a	DT	_	23	det	_	_
21	10	0	CD	_	22	num	_	_
22	mg	mg	NN	_	23	com	_	_
23	dose	dose	NN	_	10	conj	_	_
24	of	of	IN	_	25	case	_	_
25	drug3	drug0	NN	_	23	ppmod	_	_
26	,	,	,	_	29	p	_	_
27	significant	significant	JJ	_	28	attr	_	_
28	hypotension	hypotension	NN	_	29	dep	_	_
29	developed	develop	VBD	_	1	acl	_	_
30	in	in	IN	_	33	case	_	_
31	a	a	DT	_	33	det	_	_
32	substantial	substantial	JJ	_	33	attr	_	_
33	number	number	NN	_	29	ppmod	_	_
34	of	of	IN	_	35	case	_	_
35	subjects	subject	NNS	_	33	ppmod	_	_
36	.	.	.	_	1	p	_	_

1	With	with	IN	_	3	case	_	_
2	simultaneous	simultaneous	JJ	_	3	attr	_	_
3	dosing	dosing	NN	_	17	ppmod	_	_
4	of	of	IN	_	7	case	_	_
5	drug1	drug0	NN	_	7	attr	_	_
6	10	0	CD	_	7	num	_	_
7	mg	mg	NN	_	3	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	11	attr	_	_
10	10	0	CD	_	11	num	_	_
11	mg	mg	NN	_	7	conj	_	_
12	,	,	,	_	17	p	_	_
13	6	0	CD	_	15	num	_	_
14	of	of	IN	_	15	case	_	_
15	8	0	CD	_	16	num	_	_
16	subjects	subject	NNS	_	17	dep	_	_
17	experienced	experience	VBN	_	0	root	_	_
18	a	a	DT	_	22	det	_	_
19	standing	standing	JJ	_	22	attr	_	_
20	systolic	systolic	JJ	_	22	attr	_	_
21	blood	blood	NN	_	22	com	_	_
22	pressure	pressure	NN	_	17	obj	_	_
23	of	of	IN	_	28	case	_	_
24	less	less	JJR	_	26	attr	_	_
25	than	than	IN	_	24	com	_	_
26	85	0	CD	_	28	num	_	_
27	mm	mm	NN	_	28	com	_	_
28	Hg	hg	NN	_	22	ppmod	_	_
29	.	.	.	_	17	p	_	_

1	With	with	IN	_	3	case	_	_
2	simultaneous	simultaneous	JJ	_	3	attr	_	_
3	dosing	dosing	NN	_	17	ppmod	_	_
4	of	of	IN	_	7	case	_	_
5	drug1	drug0	NN	_	7	attr	_	_
6	20	0	CD	_	7	num	_	_
7	mg	mg	NN	_	3	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	11	attr	_	_
10	10	0	CD	_	11	num	_	_
11	mg	mg	NN	_	7	conj	_	_
12	,	,	,	_	17	p	_	_
13	2	0	CD	_	15	num	_	_
14	of	of	IN	_	15	case	_	_
15	9	0	CD	_	16	num	_	_
16	subjects	subject	NNS	_	17	dep	_	_
17	experienced	experience	VBN	_	0	root	_	_
18	a	a	DT	_	22	det	_	_
19	standing	standing	JJ	_	22	attr	_	_
20	systolic	systolic	JJ	_	22	attr	_	_
21	blood	blood	NN	_	22	com	_	_
22	pressure	pressure	NN	_	17	obj	_	_
23	of	of	IN	_	28	case	_	_
24	less	less	JJR	_	26	attr	_	_
25	than	than	IN	_	24	com	_	_
26	85	0	CD	_	28	num	_	_
27	mm	mm	NN	_	28	com	_	_
28	Hg	hg	NN	_	22	ppmod	_	_
29	.	.	.	_	17	p	_	_

1	When	when	WRB	_	5	adv	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	dosing	dosing	NN	_	5	dep	_	_
4	was	be	VBD	_	5	aux	_	_
5	separated	separate	VBN	_	24	advcl	_	_
6	from	from	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	10	0	CD	_	9	num	_	_
9	mg	mg	NN	_	7	attr	_	_
10	by	by	IN	_	12	case	_	_
11	6	0	CD	_	12	num	_	_
12	hours	hour	NNS	_	5	ppmod	_	_
13	,	,	,	_	24	p	_	_
14	7	0	CD	_	16	num	_	_
15	of	of	IN	_	16	case	_	_
16	28	0	CD	_	17	num	_	_
17	subjects	subject	NNS	_	24	dep	_	_
18	who	who	WP	_	19	dep	_	_
19	received	receive	VBD	_	17	relcl	_	_
20	20	0	CD	_	21	num	_	_
21	mg	mg	NN	_	19	obj	_	_
22	of	of	IN	_	23	case	_	_
23	drug3	drug0	NN	_	21	ppmod	_	_
24	experienced	experience	VBN	_	0	root	_	_
25	a	a	DT	_	26	det	_	_
26	decrease	decrease	NN	_	24	obj	_	_
27	in	in	IN	_	31	case	_	_
28	standing	standing	JJ	_	31	attr	_	_
29	systolic	systolic	JJ	_	31	attr	_	_
30	blood	blood	NN	_	31	com	_	_
31	pressure	pressure	NN	_	26	ppmod	_	_
32	below	below	IN	_	35	case	_	_
33	85	0	CD	_	34	num	_	_
34	mm	mm	NN	_	35	com	_	_
35	Hg	hg	NN	_	31	ppmod	_	_
36	.	.	.	_	24	p	_	_

1	In	in	IN	_	4	case	_	_
2	a	a	DT	_	4	det	_	_
3	similar	similar	JJ	_	4	attr	_	_
4	study	study	NN	_	28	ppmod	_	_
5	with	with	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	in	in	IN	_	9	case	_	_
8	healthy	healthy	JJ	_	9	attr	_	_
9	volunteers	volunteer	NNS	_	4	ppmod	_	_
10	,	,	,	_	28	p	_	_
11	1	0	CD	_	13	num	_	_
12	of	of	IN	_	13	case	_	_
13	24	0	CD	_	14	num	_	_
14	subjects	subject	NNS	_	28	dep	_	_
15	dosed	dose	VBN	_	14	acl	_	_
16	with	with	IN	_	19	case	_	_
17	drug2	drug0	NN	_	19	attr	_	_
18	20	0	CD	_	19	num	_	_
19	mg	mg	NN	_	15	ppmod	_	_
20	and	and	CC	_	19	cc	_	_
21	drug3	drug0	NN	_	23	attr	_	_
22	0.4	0	CD	_	23	num	_	_
23	mg	mg	NN	_	19	conj	_	_
24	separated	separate	VBN	_	19	acl	_	_
25	by	by	IN	_	27	case	_	_
26	6	0	CD	_	27	num	_	_
27	hours	hour	NNS	_	24	ppmod	_	_
28	experienced	experience	VBN	_	0	root	_	_
29	a	a	DT	_	33	det	_	_
30	standing	standing	JJ	_	33	attr	_	_
31	systolic	systolic	JJ	_	33	attr	_	_
32	blood	blood	NN	_	33	com	_	_
33	pressure	pressure	NN	_	28	obj	_	_
34	below	below	IN	_	37	case	_	_
35	85	0	CD	_	36	num	_	_
36	mm	mm	NN	_	37	com	_	_
37	Hg	hg	NN	_	33	ppmod	_	_
38	.	.	.	_	28	p	_	_

1	Two	#crd#	CD	_	15	num	_	_
2	of	of	IN	_	4	case	_	_
3	16	0	CD	_	4	num	_	_
4	subjects	subject	NNS	_	1	ppmod	_	_
5	dosed	dose	VBN	_	4	acl	_	_
6	simultaneously	simultaneously	RB	_	5	adv	_	_
7	with	with	IN	_	10	case	_	_
8	drug1	drug0	NN	_	10	attr	_	_
9	10	0	CD	_	10	num	_	_
10	mg	mg	NN	_	5	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug2	drug0	NN	_	14	attr	_	_
13	0.4	0	CD	_	14	num	_	_
14	mg	mg	NN	_	10	conj	_	_
15	experienced	experience	VBN	_	0	root	_	_
16	a	a	DT	_	20	det	_	_
17	standing	standing	JJ	_	20	attr	_	_
18	systolic	systolic	JJ	_	20	attr	_	_
19	blood	blood	NN	_	20	com	_	_
20	pressure	pressure	NN	_	15	obj	_	_
21	below	below	IN	_	24	case	_	_
22	85	0	CD	_	23	num	_	_
23	mm	mm	NN	_	24	com	_	_
24	Hg	hg	NN	_	20	ppmod	_	_
25	.	.	.	_	15	p	_	_

1	The	the	DT	_	2	det	_	_
2	administration	administration	NN	_	14	dep	_	_
3	of	of	IN	_	5	case	_	_
4	lower	low	JJR	_	5	attr	_	_
5	doses	dose	NNS	_	2	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	with	with	IN	_	9	case	_	_
9	drug2	drug0	NN	_	2	ppmod	_	_
10	has	have	VBZ	_	14	aux	_	_
11	not	not	RB	_	14	neg	_	_
12	been	be	VBN	_	14	aux	_	_
13	completely	completely	RB	_	14	adv	_	_
14	evaluated	evaluate	VBN	_	0	root	_	_
15	to	to	TO	_	16	aux	_	_
16	determine	determine	VB	_	14	comp	_	_
17	if	if	IN	_	22	mark	_	_
18	they	they	PRP	_	22	dep	_	_
19	can	can	MD	_	22	modal	_	_
20	be	be	VB	_	22	aux	_	_
21	safely	safely	RB	_	22	adv	_	_
22	administered	administer	VBN	_	16	comp	_	_
23	together	together	RB	_	22	adv	_	_
24	.	.	.	_	14	p	_	_

1	Based	base	VBN	_	4	adv	_	_
2	on	on	IN	_	4	case	_	_
3	these	these	DT	_	4	det	_	_
4	data	datum	NNS	_	10	ppmod	_	_
5	,	,	,	_	10	p	_	_
6	drug1	drug0	NN	_	10	dep	_	_
7	should	should	MD	_	10	modal	_	_
8	not	not	RB	_	10	neg	_	_
9	be	be	VB	_	10	aux	_	_
10	used	use	VBN	_	0	root	_	_
11	in	in	IN	_	12	case	_	_
12	patients	patient	NNS	_	10	ppmod	_	_
13	on	on	IN	_	15	case	_	_
14	drug2	drug0	NN	_	15	com	_	_
15	therapy	therapy	NN	_	12	ppmod	_	_
16	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	:	:	:	_	1	p	_	_
5	Upon	upon	IN	_	7	case	_	_
6	concomitant	concomitant	JJ	_	7	attr	_	_
7	administration	administration	NN	_	26	ppmod	_	_
8	of	of	IN	_	10	case	_	_
9	5	0	CD	_	10	num	_	_
10	mg	mg	NN	_	7	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	with	with	IN	_	17	case	_	_
14	600	0	CD	_	15	num	_	_
15	mg	mg	NN	_	17	com	_	_
16	BID	bid	NN	_	17	com	_	_
17	drug4	drug0	NN	_	10	ppmod	_	_
18	,	,	,	_	26	p	_	_
19	the	the	DT	_	20	det	_	_
20	Cmax	cmax	NN	_	26	dep	_	_
21	and	and	CC	_	20	cc	_	_
22	AUC	auc	NN	_	20	conj	_	_
23	of	of	IN	_	24	case	_	_
24	drug5	drug0	NN	_	20	ppmod	_	_
25	were	be	VBD	_	26	aux	_	_
26	reduced	reduce	VBN	_	1	acl	_	_
27	by	by	IN	_	29	case	_	_
28	approximately	approximately	RB	_	29	adv	_	_
29	20	0	CD	_	26	ppmod	_	_
30	%	%	NN	_	29	meta	_	_
31	.	.	.	_	1	p	_	_

1	Upon	upon	IN	_	2	case	_	_
2	administration	administration	NN	_	21	ppmod	_	_
3	of	of	IN	_	5	case	_	_
4	10	0	CD	_	5	num	_	_
5	mg	mg	NN	_	2	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	with	with	IN	_	12	case	_	_
9	800	0	CD	_	10	num	_	_
10	mg	mg	NN	_	12	com	_	_
11	TID	tid	NN	_	12	com	_	_
12	drug2	drug0	NN	_	5	ppmod	_	_
13	,	,	,	_	21	p	_	_
14	the	the	DT	_	15	det	_	_
15	Cmax	cmax	NN	_	21	dep	_	_
16	and	and	CC	_	15	cc	_	_
17	AUC	auc	NN	_	15	conj	_	_
18	of	of	IN	_	19	case	_	_
19	drug3	drug0	NN	_	15	ppmod	_	_
20	were	be	VBD	_	21	aux	_	_
21	reduced	reduce	VBN	_	0	root	_	_
22	by	by	IN	_	23	case	_	_
23	40	0	CD	_	21	ppmod	_	_
24	%	%	NN	_	23	meta	_	_
25	and	and	CC	_	23	cc	_	_
26	30	0	CD	_	23	conj	_	_
27	%	%	NN	_	26	meta	_	_
28	,	,	,	_	26	p	_	_
29	respectively	respectively	RB	_	23	conj	_	_
30	.	.	.	_	21	p	_	_

1	drug1	drug0	NN	_	28	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	(	-lrb-	-LRB-	_	12	p	_	_
5	0.5	0	CD	_	8	num	_	_
6	g/kg	g/kg	NN	_	8	com	_	_
7	body	body	NN	_	8	com	_	_
8	weight	weight	NN	_	12	dep	_	_
9	:	:	:	_	12	p	_	_
10	approximately	approximately	RB	_	11	adv	_	_
11	40	0	CD	_	12	num	_	_
12	mL	ml	NN	_	3	prn	_	_
13	of	of	IN	_	15	case	_	_
14	absolute	absolute	JJ	_	15	attr	_	_
15	alcohol	alcohol	NN	_	12	ppmod	_	_
16	in	in	IN	_	20	case	_	_
17	a	a	DT	_	20	det	_	_
18	70	0	CD	_	19	num	_	_
19	kg	kg	NN	_	20	com	_	_
20	person	person	NN	_	15	ppmod	_	_
21	)	-rrb-	-RRB-	_	12	p	_	_
22	and	and	CC	_	3	cc	_	_
23	drug3	drug0	NN	_	25	com	_	_
24	plasma	plasma	NN	_	25	com	_	_
25	levels	level	NNS	_	1	conj	_	_
26	were	be	VBD	_	28	aux	_	_
27	not	not	RB	_	28	neg	_	_
28	altered	alter	VBN	_	0	root	_	_
29	when	when	WRB	_	30	adv	_	_
30	dosed	dose	VBN	_	28	comp	_	_
31	simultaneously	simultaneously	RB	_	30	adv	_	_
32	.	.	.	_	28	p	_	_

1	drug1	drug0	NN	_	8	dep	_	_
2	(	-lrb-	-LRB-	_	4	p	_	_
3	20	0	CD	_	4	num	_	_
4	mg	mg	NN	_	1	prn	_	_
5	)	-rrb-	-RRB-	_	4	p	_	_
6	did	do	VBD	_	8	aux	_	_
7	not	not	RB	_	8	neg	_	_
8	potentiate	potentiate	VB	_	0	root	_	_
9	the	the	DT	_	11	det	_	_
10	hypotensive	hypotensive	JJ	_	11	attr	_	_
11	effects	effect	NNS	_	8	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	during	during	IN	_	18	case	_	_
15	the	the	DT	_	18	det	_	_
16	4-hour	0-hour	JJ	_	18	attr	_	_
17	observation	observation	NN	_	18	com	_	_
18	period	period	NN	_	11	ppmod	_	_
19	in	in	IN	_	21	case	_	_
20	healthy	healthy	JJ	_	21	attr	_	_
21	volunteers	volunteer	NNS	_	18	ppmod	_	_
22	when	when	WRB	_	23	adv	_	_
23	administered	administer	VBN	_	8	comp	_	_
24	with	with	IN	_	25	case	_	_
25	drug3	drug0	NN	_	23	ppmod	_	_
26	(	-lrb-	-LRB-	_	30	p	_	_
27	0.5	0	CD	_	30	num	_	_
28	g/kg	g/kg	NN	_	30	com	_	_
29	body	body	NN	_	30	com	_	_
30	weight	weight	NN	_	25	prn	_	_
31	)	-rrb-	-RRB-	_	30	p	_	_
32	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	13	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	(	-lrb-	-LRB-	_	6	p	_	_
5	10	0	CD	_	6	num	_	_
6	mg	mg	NN	_	3	prn	_	_
7	and	and	CC	_	6	cc	_	_
8	20	0	CD	_	9	num	_	_
9	mg	mg	NN	_	6	conj	_	_
10	)	-rrb-	-RRB-	_	6	p	_	_
11	did	do	VBD	_	13	aux	_	_
12	not	not	RB	_	13	neg	_	_
13	potentiate	potentiate	VB	_	0	root	_	_
14	the	the	DT	_	15	det	_	_
15	increase	increase	NN	_	13	obj	_	_
16	in	in	IN	_	18	case	_	_
17	bleeding	bleeding	JJ	_	18	attr	_	_
18	time	time	NN	_	15	ppmod	_	_
19	caused	cause	VBN	_	18	acl	_	_
20	by	by	IN	_	21	case	_	_
21	drug3	drug0	NN	_	19	ppmod	_	_
22	(	-lrb-	-LRB-	_	26	p	_	_
23	two	#crd#	CD	_	26	num	_	_
24	81	0	CD	_	26	num	_	_
25	mg	mg	NN	_	26	com	_	_
26	tablets	tablet	NNS	_	21	prn	_	_
27	)	-rrb-	-RRB-	_	26	p	_	_
28	.	.	.	_	13	p	_	_

1	Other	other	JJ	_	2	attr	_	_
2	interactions	interaction	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	drug1	drug0	NN	_	5	dep	_	_
5	had	have	VBD	_	2	acl	_	_
6	no	no	DT	_	7	det	_	_
7	effect	effect	NN	_	5	obj	_	_
8	on	on	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	pharmacodynamics	pharmacodynamics	NNS	_	5	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	(	-lrb-	-LRB-	_	17	p	_	_
14	glucose	glucose	NN	_	17	attr	_	_
15	and	and	CC	_	14	cc	_	_
16	insulin	insulin	NN	_	14	conj	_	_
17	concentrations	concentration	NNS	_	12	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	and	and	CC	_	12	cc	_	_
20	drug3	drug0	NN	_	12	conj	_	_
21	(	-lrb-	-LRB-	_	23	p	_	_
22	prothrombin	prothrombin	NN	_	23	com	_	_
23	time	time	NN	_	20	prn	_	_
24	or	or	CC	_	23	cc	_	_
25	other	other	JJ	_	27	attr	_	_
26	pharmacodynamic	pharmacodynamic	JJ	_	27	attr	_	_
27	parameters	parameter	NNS	_	23	conj	_	_
28	)	-rrb-	-RRB-	_	23	p	_	_
29	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	When	when	WRB	_	4	adv	_	_
4	coadministered	coadministered	VBN	_	17	advcl	_	_
5	with	with	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	,	,	,	_	17	p	_	_
8	drug3	drug0	NN	_	17	dep	_	_
9	,	,	,	_	8	p	_	_
10	a	a	DT	_	11	det	_	_
11	drug	drug	NN	_	8	appo	_	_
12	which	which	WDT	_	13	dep	_	_
13	increases	increase	VBZ	_	11	relcl	_	_
14	gastrointestinal	gastrointestinal	JJ	_	15	attr	_	_
15	motility	motility	NN	_	13	obj	_	_
16	,	,	,	_	8	p	_	_
17	lowers	lower	VBZ	_	1	acl	_	_
18	the	the	DT	_	20	det	_	_
19	serum	serum	NN	_	20	com	_	_
20	concentration	concentration	NN	_	17	obj	_	_
21	and	and	CC	_	20	cc	_	_
22	urinary	urinary	JJ	_	23	attr	_	_
23	excretion	excretion	NN	_	20	conj	_	_
24	of	of	IN	_	25	case	_	_
25	drug4	drug0	NN	_	20	ppmod	_	_
26	.	.	.	_	1	p	_	_

1	Other	other	JJ	_	2	attr	_	_
2	drugs	drug	NNS	_	8	dep	_	_
3	that	that	WDT	_	4	dep	_	_
4	increase	increase	VBP	_	2	relcl	_	_
5	gastrointestinal	gastrointestinal	JJ	_	6	attr	_	_
6	motility	motility	NN	_	4	obj	_	_
7	may	may	MD	_	8	modal	_	_
8	produce	produce	VB	_	0	root	_	_
9	similar	similar	JJ	_	10	attr	_	_
10	effects	effect	NNS	_	8	obj	_	_
11	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	does	do	VBZ	_	6	aux	_	_
5	not	not	RB	_	6	neg	_	_
6	affect	affect	VB	_	0	root	_	_
7	the	the	DT	_	8	det	_	_
8	pharmacokinetics	pharmacokinetics	NNS	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug3	drug0	NN	_	8	ppmod	_	_
11	when	when	WRB	_	12	adv	_	_
12	coadministered	coadministered	VBN	_	6	comp	_	_
13	with	with	IN	_	14	case	_	_
14	drug4	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	6	p	_	_

1	Co-administration	co-administration	NN	_	8	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	5	case	_	_
5	drug2	drug0	NN	_	1	ppmod	_	_
6	has	have	VBZ	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	shown	show	VBN	_	0	root	_	_
9	to	to	TO	_	10	aux	_	_
10	increase	increase	VB	_	8	comp	_	_
11	the	the	DT	_	13	det	_	_
12	mean	mean	JJ	_	13	attr	_	_
13	half-life	half-life	NN	_	10	obj	_	_
14	and	and	CC	_	13	cc	_	_
15	the	the	DT	_	16	det	_	_
16	area	area	NN	_	13	conj	_	_
17	under	under	IN	_	20	case	_	_
18	the	the	DT	_	20	det	_	_
19	concentration-time	concentration-time	JJ	_	20	attr	_	_
20	curve	curve	NN	_	16	ppmod	_	_
21	.	.	.	_	8	p	_	_

1	Urinary	urinary	JJ	_	2	attr	_	_
2	excretion	excretion	NN	_	8	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	renal	renal	JJ	_	5	attr	_	_
5	clearance	clearance	NN	_	2	conj	_	_
6	were	be	VBD	_	8	aux	_	_
7	correspondingly	correspondingly	RB	_	8	adv	_	_
8	reduced	reduce	VBN	_	0	root	_	_
9	.	.	.	_	8	p	_	_

1	The	the	DT	_	3	det	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	effects	effect	NNS	_	10	dep	_	_
4	of	of	IN	_	6	case	_	_
5	this	this	DT	_	6	det	_	_
6	combination	combination	NN	_	3	ppmod	_	_
7	have	have	VBP	_	10	aux	_	_
8	not	not	RB	_	10	neg	_	_
9	been	be	VBN	_	10	aux	_	_
10	studied	study	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	No	no	NN	_	2	dep	_	_
2	reported	report	VBD	_	0	root	_	_
3	interactions	interaction	NNS	_	2	obj	_	_
4	.	.	.	_	2	p	_	_

1	Steady-state	steady-state	JJ	_	3	attr	_	_
2	serum	serum	NN	_	3	com	_	_
3	concentrations	concentration	NNS	_	7	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	are	be	VBP	_	7	aux	_	_
7	reported	report	VBN	_	0	root	_	_
8	to	to	TO	_	9	aux	_	_
9	fluctuate	fluctuate	VB	_	7	comp	_	_
10	significantly	significantly	RB	_	9	adv	_	_
11	when	when	WRB	_	15	adv	_	_
12	drug2	drug0	NN	_	15	dep	_	_
13	is	be	VBZ	_	15	aux	_	_
14	either	either	CC	_	15	cc	_	_
15	added	add	VBN	_	9	comp	_	_
16	or	or	CC	_	15	cc	_	_
17	deleted	delete	VBN	_	15	conj	_	_
18	from	from	IN	_	21	case	_	_
19	the	the	DT	_	21	det	_	_
20	drug	drug	NN	_	21	com	_	_
21	regimen	regimen	NN	_	17	ppmod	_	_
22	.	.	.	_	7	p	_	_

1	Serious	serious	JJ	_	3	attr	_	_
2	anticholinergic	anticholinergic	JJ	_	3	attr	_	_
3	symptoms	symptom	NNS	_	17	dep	_	_
4	(	-lrb-	-LRB-	_	7	p	_	_
5	severe	severe	JJ	_	7	attr	_	_
6	dry	dry	JJ	_	7	attr	_	_
7	mouth	mouth	NN	_	3	prn	_	_
8	,	,	,	_	7	p	_	_
9	urinary	urinary	JJ	_	10	attr	_	_
10	retention	retention	NN	_	7	appo	_	_
11	,	,	,	_	7	p	_	_
12	blurred	blurred	JJ	_	13	attr	_	_
13	vision	vision	NN	_	7	appo	_	_
14	)	-rrb-	-RRB-	_	7	p	_	_
15	have	have	VBP	_	17	aux	_	_
16	been	be	VBN	_	17	aux	_	_
17	associated	associate	VBN	_	0	root	_	_
18	with	with	IN	_	19	case	_	_
19	elevations	elevation	NNS	_	17	ppmod	_	_
20	in	in	IN	_	23	case	_	_
21	the	the	DT	_	23	det	_	_
22	serum	serum	NN	_	23	com	_	_
23	levels	level	NNS	_	19	ppmod	_	_
24	of	of	IN	_	25	case	_	_
25	drug1	drug0	NN	_	23	ppmod	_	_
26	when	when	WRB	_	29	adv	_	_
27	drug2	drug0	NN	_	29	dep	_	_
28	is	be	VBZ	_	29	aux	_	_
29	added	add	VBN	_	17	comp	_	_
30	to	to	TO	_	33	aux	_	_
31	the	the	DT	_	33	det	_	_
32	drug	drug	NN	_	33	com	_	_
33	regimen	regimen	NN	_	29	ppmod	_	_
34	.	.	.	_	17	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	13	ppmod	_	_
3	,	,	,	_	13	p	_	_
4	higher-than	higher-than	JJ	_	8	attr	_	_
5	expected	expect	VBN	_	8	attr	_	_
6	steady-state	steady-state	NN	_	8	com	_	_
7	serum	serum	NN	_	8	com	_	_
8	concentrations	concentration	NNS	_	13	dep	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	have	have	VBP	_	13	aux	_	_
12	been	be	VBN	_	13	aux	_	_
13	observed	observe	VBN	_	0	root	_	_
14	when	when	WRB	_	17	adv	_	_
15	therapy	therapy	NN	_	17	dep	_	_
16	is	be	VBZ	_	17	aux	_	_
17	initiated	initiate	VBN	_	13	comp	_	_
18	in	in	IN	_	19	case	_	_
19	patients	patient	NNS	_	17	ppmod	_	_
20	already	already	RB	_	21	adv	_	_
21	taking	take	VBG	_	19	acl	_	_
22	drug2	drug0	NN	_	21	obj	_	_
23	.	.	.	_	13	p	_	_

1	In	in	IN	_	3	case	_	_
2	well-controlled	well-controlled	JJ	_	3	attr	_	_
3	patients	patient	NNS	_	20	ppmod	_	_
4	undergoing	undergo	VBG	_	3	acl	_	_
5	concurrent	concurrent	JJ	_	6	attr	_	_
6	therapy	therapy	NN	_	4	obj	_	_
7	with	with	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	,	,	,	_	20	p	_	_
10	a	a	DT	_	11	det	_	_
11	decrease	decrease	NN	_	20	dep	_	_
12	in	in	IN	_	16	case	_	_
13	the	the	DT	_	16	det	_	_
14	steady-state	steady-state	JJ	_	16	attr	_	_
15	serum	serum	NN	_	16	com	_	_
16	concentrations	concentration	NNS	_	11	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	may	may	MD	_	20	modal	_	_
20	occur	occur	VB	_	0	root	_	_
21	when	when	WRB	_	25	adv	_	_
22	cime-tidine	cime-tidine	JJ	_	23	attr	_	_
23	therapy	therapy	NN	_	25	dep	_	_
24	is	be	VBZ	_	25	aux	_	_
25	discontinued	discontinue	VBN	_	20	comp	_	_
26	.	.	.	_	20	p	_	_

1	The	the	DT	_	3	det	_	_
2	therapeutic	therapeutic	JJ	_	3	attr	_	_
3	efficacy	efficacy	NN	_	8	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	may	may	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	compromised	compromise	VBN	_	0	root	_	_
9	in	in	IN	_	11	case	_	_
10	these	these	DT	_	11	det	_	_
11	patients	patient	NNS	_	8	ppmod	_	_
12	when	when	WRB	_	15	adv	_	_
13	drug2	drug0	NN	_	15	dep	_	_
14	is	be	VBZ	_	15	aux	_	_
15	discontinued	discontinue	VBN	_	8	comp	_	_
16	.	.	.	_	8	p	_	_

1	Several	several	JJ	_	7	dep	_	_
2	of	of	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	drug1	drug0	NN	_	1	ppmod	_	_
5	have	have	VBP	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	cited	cite	VBN	_	0	root	_	_
8	in	in	IN	_	10	case	_	_
9	these	these	DT	_	10	det	_	_
10	reports	report	NNS	_	7	ppmod	_	_
11	.	.	.	_	7	p	_	_

1	There	there	EX	_	3	dep	_	_
2	have	have	VBP	_	3	aux	_	_
3	been	be	VBN	_	0	root	_	_
4	greater	great	JJR	_	3	dep	_	_
5	than	than	IN	_	7	case	_	_
6	2-fold	0-fold	JJ	_	7	attr	_	_
7	increases	increase	NNS	_	4	ppmod	_	_
8	in	in	IN	_	12	case	_	_
9	previously	previously	RB	_	10	adv	_	_
10	stable	stable	JJ	_	12	attr	_	_
11	plasma	plasma	NN	_	12	com	_	_
12	levels	level	NNS	_	7	ppmod	_	_
13	of	of	IN	_	15	case	_	_
14	other	other	JJ	_	15	attr	_	_
15	drug1	drug0	NN	_	12	ppmod	_	_
16	,	,	,	_	7	p	_	_
17	including	include	VBG	_	18	adv	_	_
18	drug2	drug0	NN	_	7	ppmod	_	_
19	,	,	,	_	4	p	_	_
20	when	when	WRB	_	24	adv	_	_
21	drug3	drug0	NN	_	24	dep	_	_
22	has	have	VBZ	_	24	aux	_	_
23	been	be	VBN	_	24	aux	_	_
24	administered	administer	VBN	_	4	comp	_	_
25	in	in	IN	_	26	case	_	_
26	combination	combination	NN	_	24	ppmod	_	_
27	with	with	IN	_	29	case	_	_
28	these	these	DT	_	29	det	_	_
29	agents	agent	NNS	_	26	ppmod	_	_
30	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	9	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	its	its	PRP$	_	5	poss	_	_
4	active	active	JJ	_	5	attr	_	_
5	metabolite	metabolite	NN	_	1	conj	_	_
6	,	,	,	_	5	p	_	_
7	norfluoxe-tine	norfluoxe-tine	NN	_	5	appo	_	_
8	,	,	,	_	5	p	_	_
9	have	have	VBP	_	0	root	_	_
10	long	long	JJ	_	11	attr	_	_
11	half-lives	half-life	NNS	_	9	obj	_	_
12	(	-lrb-	-LRB-	_	16	p	_	_
13	4	0	CD	_	16	num	_	_
14	to	to	TO	_	13	cc	_	_
15	16	0	CD	_	13	conj	_	_
16	days	day	NNS	_	11	prn	_	_
17	for	for	IN	_	18	case	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	)	-rrb-	-RRB-	_	16	p	_	_
20	,	,	,	_	11	p	_	_
21	that	that	WDT	_	23	dep	_	_
22	may	may	MD	_	23	modal	_	_
23	affect	affect	VB	_	11	relcl	_	_
24	strategies	strategy	NNS	_	23	obj	_	_
25	during	during	IN	_	26	case	_	_
26	conversion	conversion	NN	_	23	ppmod	_	_
27	from	from	IN	_	29	case	_	_
28	one	#crd#	CD	_	29	num	_	_
29	drug	drug	NN	_	26	ppmod	_	_
30	to	to	TO	_	32	aux	_	_
31	the	the	DT	_	32	det	_	_
32	other	other	JJ	_	26	ppmod	_	_
33	.	.	.	_	9	p	_	_

1	Administration	administration	NN	_	11	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	during	during	IN	_	5	case	_	_
5	therapy	therapy	NN	_	1	ppmod	_	_
6	with	with	IN	_	8	case	_	_
7	a	a	DT	_	8	det	_	_
8	drug2	drug0	NN	_	1	ppmod	_	_
9	has	have	VBZ	_	11	aux	_	_
10	been	be	VBN	_	11	aux	_	_
11	shown	show	VBN	_	0	root	_	_
12	to	to	TO	_	13	aux	_	_
13	produce	produce	VB	_	11	comp	_	_
14	a	a	DT	_	16	det	_	_
15	stimulating	stimulating	JJ	_	16	attr	_	_
16	effect	effect	NN	_	13	obj	_	_
17	in	in	IN	_	20	case	_	_
18	some	some	DT	_	20	det	_	_
19	depressed	depressed	JJ	_	20	attr	_	_
20	patients	patient	NNS	_	13	ppmod	_	_
21	.	.	.	_	11	p	_	_

1	Close	close	JJ	_	2	attr	_	_
2	supervision	supervision	NN	_	10	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	careful	careful	JJ	_	5	attr	_	_
5	adjustment	adjustment	NN	_	2	conj	_	_
6	of	of	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	dosage	dosage	NN	_	2	ppmod	_	_
9	are	be	VBP	_	10	aux	_	_
10	required	require	VBN	_	0	root	_	_
11	when	when	WRB	_	14	adv	_	_
12	drug1	drug0	NN	_	14	dep	_	_
13	is	be	VBZ	_	14	aux	_	_
14	used	use	VBN	_	10	comp	_	_
15	with	with	IN	_	17	case	_	_
16	other	other	JJ	_	17	attr	_	_
17	drug2	drug0	NN	_	14	ppmod	_	_
18	or	or	CC	_	17	cc	_	_
19	drug3	drug0	NN	_	17	conj	_	_
20	.	.	.	_	10	p	_	_

1	The	the	DT	_	2	det	_	_
2	patient	patient	NN	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	informed	inform	VBN	_	0	root	_	_
6	that	that	IN	_	13	mark	_	_
7	the	the	DT	_	8	det	_	_
8	response	response	NN	_	13	dep	_	_
9	to	to	TO	_	10	aux	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	may	may	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	exaggerated	exaggerate	VBN	_	5	comp	_	_
14	.	.	.	_	5	p	_	_

1	Drugs	drug	NNS	_	2	dep	_	_
2	Metabolized	metabolize	VBN	_	0	root	_	_
3	by	by	IN	_	4	case	_	_
4	P450IID6	p0iid0	NN	_	2	ppmod	_	_
5	A	a	DT	_	6	det	_	_
6	subset	subset	NN	_	19	dep	_	_
7	(	-lrb-	-LRB-	_	11	p	_	_
8	3	0	CD	_	11	num	_	_
9	%	%	NN	_	11	meta	_	_
10	to	to	TO	_	11	attr	_	_
11	10	0	CD	_	6	num	_	_
12	%	%	NN	_	11	meta	_	_
13	)	-rrb-	-RRB-	_	11	p	_	_
14	of	of	IN	_	16	case	_	_
15	the	the	DT	_	16	det	_	_
16	population	population	NN	_	6	ppmod	_	_
17	has	have	VBZ	_	19	lv	_	_
18	reduced	reduce	VBN	_	19	attr	_	_
19	activity	activity	NN	_	4	acl	_	_
20	of	of	IN	_	24	case	_	_
21	certain	certain	JJ	_	24	attr	_	_
22	drug	drug	NN	_	24	com	_	_
23	metabolizing	metabolizing	NN	_	24	com	_	_
24	enzymes	enzyme	NNS	_	19	ppmod	_	_
25	such	such	JJ	_	31	adv	_	_
26	as	as	IN	_	31	case	_	_
27	the	the	DT	_	31	det	_	_
28	cytochrome	cytochrome	NN	_	31	com	_	_
29	P450	p0	NN	_	31	com	_	_
30	isoenzyme	isoenzyme	NN	_	31	com	_	_
31	P450IID6	p0iid0	NN	_	24	ppmod	_	_
32	.	.	.	_	2	p	_	_

1	Such	such	JJ	_	2	attr	_	_
2	individuals	individual	NNS	_	4	dep	_	_
3	are	be	VBP	_	4	aux	_	_
4	referred	refer	VBN	_	0	root	_	_
5	to	to	TO	_	4	ppmod	_	_
6	as	as	IN	_	8	case	_	_
7	poor	poor	JJ	_	8	attr	_	_
8	metabolizers	metabolizers	NNS	_	4	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drugs	drug	NNS	_	8	ppmod	_	_
11	such	such	JJ	_	13	adv	_	_
12	as	as	IN	_	13	case	_	_
13	drug1	drug0	NN	_	10	ppmod	_	_
14	,	,	,	_	13	p	_	_
15	drug2	drug0	NN	_	13	conj	_	_
16	,	,	,	_	15	p	_	_
17	and	and	CC	_	15	cc	_	_
18	the	the	DT	_	19	det	_	_
19	drug3	drug0	NN	_	13	conj	_	_
20	.	.	.	_	4	p	_	_

1	These	these	DT	_	2	det	_	_
2	individuals	individual	NNS	_	9	dep	_	_
3	may	may	MD	_	9	modal	_	_
4	have	have	VBP	_	9	lv	_	_
5	higher	high	JJR	_	9	attr	_	_
6	than	than	IN	_	9	case	_	_
7	expected	expect	VBN	_	9	attr	_	_
8	plasma	plasma	NN	_	9	com	_	_
9	concentrations	concentration	NNS	_	0	root	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	when	when	WRB	_	13	adv	_	_
13	given	give	VBN	_	9	comp	_	_
14	usual	usual	JJ	_	15	attr	_	_
15	doses	dose	NNS	_	13	obj	_	_
16	.	.	.	_	9	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	26	ppmod	_	_
3	,	,	,	_	26	p	_	_
4	certain	certain	JJ	_	5	attr	_	_
5	drugs	drug	NNS	_	26	dep	_	_
6	that	that	WDT	_	8	dep	_	_
7	are	be	VBP	_	8	aux	_	_
8	metabolized	metabolize	VBN	_	5	relcl	_	_
9	by	by	IN	_	11	case	_	_
10	this	this	DT	_	11	det	_	_
11	isoenzyme	isoenzyme	NN	_	8	ppmod	_	_
12	,	,	,	_	5	p	_	_
13	including	include	VBG	_	15	adv	_	_
14	many	many	JJ	_	15	attr	_	_
15	drug1	drug0	NNS	_	5	ppmod	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	drug2	drug0	NN	_	15	prn	_	_
18	,	,	,	_	17	p	_	_
19	drug3	drug0	NN	_	17	conj	_	_
20	,	,	,	_	19	p	_	_
21	and	and	CC	_	19	cc	_	_
22	others	other	NNS	_	17	conj	_	_
23	)	-rrb-	-RRB-	_	17	p	_	_
24	,	,	,	_	5	p	_	_
25	may	may	MD	_	26	modal	_	_
26	inhibit	inhibit	VB	_	0	root	_	_
27	the	the	DT	_	28	det	_	_
28	activity	activity	NN	_	26	obj	_	_
29	of	of	IN	_	31	case	_	_
30	this	this	DT	_	31	det	_	_
31	isoenzyme	isoenzyme	NN	_	28	ppmod	_	_
32	,	,	,	_	26	p	_	_
33	and	and	CC	_	26	cc	_	_
34	thus	thus	RB	_	36	adv	_	_
35	may	may	MD	_	36	modal	_	_
36	make	make	VB	_	26	conj	_	_
37	normal	normal	JJ	_	38	attr	_	_
38	metab-olizers	metab-olizers	NNS	_	39	dep	_	_
39	resemble	resemble	VBP	_	36	comp	_	_
40	poor	poor	JJ	_	41	attr	_	_
41	metabolizers	metabolizers	NNS	_	39	obj	_	_
42	with	with	IN	_	43	case	_	_
43	regard	regard	NN	_	39	ppmod	_	_
44	to	to	TO	_	46	aux	_	_
45	concomitant	concomitant	JJ	_	46	attr	_	_
46	therapy	therapy	NN	_	43	ppmod	_	_
47	with	with	IN	_	49	case	_	_
48	other	other	JJ	_	49	attr	_	_
49	drugs	drug	NNS	_	46	ppmod	_	_
50	metabolized	metabolize	VBN	_	49	acl	_	_
51	by	by	IN	_	54	case	_	_
52	this	this	DT	_	54	det	_	_
53	enzyme	enzyme	NN	_	54	com	_	_
54	system	system	NN	_	50	ppmod	_	_
55	,	,	,	_	39	p	_	_
56	leading	lead	VBG	_	39	comp	_	_
57	to	to	TO	_	59	aux	_	_
58	drug	drug	NN	_	59	com	_	_
59	interactions	interaction	NNS	_	56	ppmod	_	_
60	.	.	.	_	26	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	use	use	NN	_	13	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	with	with	IN	_	7	case	_	_
6	other	other	JJ	_	7	attr	_	_
7	drugs	drug	NNS	_	2	ppmod	_	_
8	metabolized	metabolize	VBN	_	7	acl	_	_
9	by	by	IN	_	11	case	_	_
10	cytochrome	cytochrome	NN	_	11	com	_	_
11	P450IID6	p0iid0	NN	_	8	ppmod	_	_
12	may	may	MD	_	13	modal	_	_
13	require	require	VB	_	0	root	_	_
14	lower	low	JJR	_	15	attr	_	_
15	doses	dose	NNS	_	13	obj	_	_
16	than	than	IN	_	17	case	_	_
17	usually	usually	RB	_	18	adv	_	_
18	prescribed	prescribe	VBN	_	15	acl	_	_
19	for	for	IN	_	22	case	_	_
20	either	either	CC	_	22	cc	_	_
21	the	the	DT	_	22	det	_	_
22	drug2	drug0	NN	_	18	ppmod	_	_
23	or	or	CC	_	22	cc	_	_
24	the	the	DT	_	26	det	_	_
25	other	other	JJ	_	26	attr	_	_
26	drug	drug	NN	_	22	conj	_	_
27	.	.	.	_	13	p	_	_

1	Therefore	therefore	RB	_	50	adv	_	_
2	,	,	,	_	50	p	_	_
3	co-administration	co-administration	NN	_	50	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	with	with	IN	_	8	case	_	_
7	other	other	JJ	_	8	attr	_	_
8	drugs	drug	NNS	_	3	ppmod	_	_
9	that	that	WDT	_	11	dep	_	_
10	are	be	VBP	_	11	aux	_	_
11	metabolized	metabolize	VBN	_	8	advcl	_	_
12	by	by	IN	_	14	case	_	_
13	this	this	DT	_	14	det	_	_
14	isoenzyme	isoenzyme	NN	_	11	ppmod	_	_
15	,	,	,	_	11	p	_	_
16	including	include	VBG	_	18	adv	_	_
17	other	other	JJ	_	18	attr	_	_
18	drug2	drug0	NN	_	11	ppmod	_	_
19	,	,	,	_	18	p	_	_
20	drug3	drug0	NN	_	18	conj	_	_
21	,	,	,	_	20	p	_	_
22	drug4	drug0	NN	_	18	conj	_	_
23	,	,	,	_	22	p	_	_
24	and	and	CC	_	22	cc	_	_
25	drug5	drug0	NN	_	18	conj	_	_
26	(	-lrb-	-LRB-	_	27	p	_	_
27	eg	eg	NN	_	25	prn	_	_
28	,	,	,	_	27	p	_	_
29	drug6	drug0	NN	_	27	conj	_	_
30	,	,	,	_	29	p	_	_
31	drug7	drug0	NN	_	27	conj	_	_
32	,	,	,	_	31	p	_	_
33	and	and	CC	_	31	cc	_	_
34	drug8	drug0	NN	_	27	conj	_	_
35	)	-rrb-	-RRB-	_	27	p	_	_
36	,	,	,	_	11	p	_	_
37	or	or	CC	_	11	cc	_	_
38	that	that	WDT	_	39	dep	_	_
39	inhibit	inhibit	VBP	_	11	conj	_	_
40	this	this	DT	_	41	det	_	_
41	enzyme	enzyme	NN	_	39	obj	_	_
42	(	-lrb-	-LRB-	_	43	p	_	_
43	eg	eg	NN	_	41	prn	_	_
44	,	,	,	_	43	p	_	_
45	drug9	drug0	NN	_	43	appo	_	_
46	)	-rrb-	-RRB-	_	43	p	_	_
47	,	,	,	_	8	p	_	_
48	should	should	MD	_	50	modal	_	_
49	be	be	VB	_	50	aux	_	_
50	approached	approach	VBN	_	0	root	_	_
51	with	with	IN	_	52	case	_	_
52	caution	caution	NN	_	50	ppmod	_	_
53	.	.	.	_	50	p	_	_

1	No	no	DT	_	3	det	_	_
2	drug	drug	NN	_	3	com	_	_
3	interactions	interaction	NNS	_	6	dep	_	_
4	have	have	VBP	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	identified	identify	VBN	_	0	root	_	_
7	.	.	.	_	6	p	_	_

1	Studies	study	NNS	_	15	dep	_	_
2	with	with	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	in	in	IN	_	5	case	_	_
5	man	man	NN	_	1	ppmod	_	_
6	,	,	,	_	5	p	_	_
7	in	in	IN	_	9	case	_	_
8	animal	animal	NN	_	9	com	_	_
9	models	model	NNS	_	5	conj	_	_
10	,	,	,	_	9	p	_	_
11	and	and	CC	_	9	cc	_	_
12	in	in	IN	_	13	case	_	_
13	vitro	vitro	FW	_	5	conj	_	_
14	have	have	VBP	_	15	aux	_	_
15	shown	show	VBN	_	0	root	_	_
16	no	no	DT	_	18	det	_	_
17	significant	significant	JJ	_	18	attr	_	_
18	interference	interference	NN	_	15	obj	_	_
19	with	with	IN	_	21	case	_	_
20	the	the	DT	_	21	det	_	_
21	disposition	disposition	NN	_	18	ppmod	_	_
22	of	of	IN	_	23	case	_	_
23	compounds	compound	NNS	_	21	ppmod	_	_
24	metabolized	metabolize	VBN	_	23	acl	_	_
25	by	by	IN	_	29	case	_	_
26	the	the	DT	_	29	det	_	_
27	hepatic	hepatic	JJ	_	29	attr	_	_
28	microsomal	microsomal	JJ	_	29	attr	_	_
29	enzymes	enzyme	NNS	_	24	ppmod	_	_
30	,	,	,	_	23	p	_	_
31	e.g.	e.g.	FW	_	35	adv	_	_
32	,	,	,	_	35	p	_	_
33	cytochrome	cytochrome	NN	_	34	com	_	_
34	P450	p0	NN	_	35	com	_	_
35	system	system	NN	_	23	ppmod	_	_
36	.	.	.	_	15	p	_	_

1	Compounds	compound	NNS	_	5	dep	_	_
2	tested	test	VBN	_	1	acl	_	_
3	in	in	IN	_	4	case	_	_
4	man	man	NN	_	2	ppmod	_	_
5	include	include	VBP	_	0	root	_	_
6	drug1	drug0	NN	_	5	obj	_	_
7	,	,	,	_	6	p	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	,	,	,	_	8	p	_	_
10	drug3	drug0	NN	_	6	conj	_	_
11	,	,	,	_	10	p	_	_
12	drug4	drug0	NN	_	6	conj	_	_
13	,	,	,	_	12	p	_	_
14	drug5	drug0	NN	_	6	conj	_	_
15	and	and	CC	_	14	cc	_	_
16	drug6	drug0	NN	_	6	conj	_	_
17	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	11	dep	_	_
2	as	as	IN	_	4	case	_	_
3	an	an	DT	_	4	det	_	_
4	index	index	NN	_	1	ppmod	_	_
5	of	of	IN	_	8	case	_	_
6	hepatic	hepatic	JJ	_	8	attr	_	_
7	drug	drug	NN	_	8	com	_	_
8	extraction	extraction	NN	_	4	ppmod	_	_
9	has	have	VBZ	_	11	aux	_	_
10	been	be	VBN	_	11	aux	_	_
11	tested	test	VBN	_	0	root	_	_
12	and	and	CC	_	11	cc	_	_
13	no	no	DT	_	15	det	_	_
14	significant	significant	JJ	_	15	attr	_	_
15	effects	effect	NNS	_	18	dep	_	_
16	have	have	VBP	_	18	aux	_	_
17	been	be	VBN	_	18	aux	_	_
18	found	find	VBN	_	11	conj	_	_
19	.	.	.	_	11	p	_	_

1	When	when	WRB	_	2	adv	_	_
2	administered	administer	VBN	_	9	advcl	_	_
3	concurrently	concurrently	RB	_	2	adv	_	_
4	,	,	,	_	9	p	_	_
5	the	the	DT	_	7	det	_	_
6	following	follow	VBG	_	7	attr	_	_
7	drugs	drug	NNS	_	9	dep	_	_
8	may	may	MD	_	9	modal	_	_
9	interact	interact	VB	_	0	root	_	_
10	with	with	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	:	:	:	_	9	p	_	_
13	drug2	drug0	NN	_	9	dep	_	_
14	,	,	,	_	13	p	_	_
15	general	general	JJ	_	13	appo	_	_
16	:	:	:	_	13	p	_	_
17	exaggeration	exaggeration	NN	_	13	appo	_	_
18	of	of	IN	_	20	case	_	_
19	the	the	DT	_	20	det	_	_
20	hypotension	hypotension	NN	_	17	ppmod	_	_
21	induced	induce	VBN	_	20	acl	_	_
22	by	by	IN	_	24	case	_	_
23	general	general	JJ	_	24	attr	_	_
24	drug3	drug0	NN	_	21	ppmod	_	_
25	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	(	-lrb-	-LRB-	_	4	p	_	_
3	oral	oral	JJ	_	4	attr	_	_
4	agents	agent	NNS	_	1	prn	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NNS	_	4	conj	_	_
7	)	-rrb-	-RRB-	_	4	p	_	_
8	:	:	:	_	1	p	_	_
9	hypoglycemia	hypoglycemia	NN	_	1	appo	_	_
10	or	or	CC	_	9	cc	_	_
11	hyperglycemia	hyperglycemia	NN	_	9	conj	_	_
12	;	;	:	_	1	p	_	_

1	adjust	adjust	VB	_	0	root	_	_
2	dosage	dosage	NN	_	1	obj	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	accordingly	accordingly	RB	_	1	adv	_	_
6	.	.	.	_	1	p	_	_

1	Catecholamine-depleting	catecholamine-depleting	JJ	_	2	attr	_	_
2	drugs	drug	NNS	_	0	root	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	e.g.	e.g.	FW	_	6	adv	_	_
5	,	,	,	_	6	p	_	_
6	drug1	drug0	NN	_	2	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	:	:	:	_	2	p	_	_
9	additive	additive	JJ	_	10	attr	_	_
10	effect	effect	NN	_	2	appo	_	_
11	;	;	:	_	2	p	_	_

1	monitor	monitor	NN	_	0	root	_	_
2	closely	closely	RB	_	1	adv	_	_
3	for	for	IN	_	4	case	_	_
4	evidence	evidence	NN	_	1	ppmod	_	_
5	of	of	IN	_	6	case	_	_
6	hypotension	hypotension	NN	_	4	ppmod	_	_
7	and/or	and/or	CC	_	6	cc	_	_
8	excessive	excessive	JJ	_	9	attr	_	_
9	bradycardia	bradycardia	NN	_	6	conj	_	_
10	(	-lrb-	-LRB-	_	13	p	_	_
11	e.g.	e.g.	FW	_	13	ppmod	_	_
12	,	,	,	_	13	p	_	_
13	vertigo	vertigo	NN	_	9	prn	_	_
14	,	,	,	_	13	p	_	_
15	syncope	syncope	NN	_	13	appo	_	_
16	,	,	,	_	13	p	_	_
17	postural	postural	JJ	_	18	attr	_	_
18	hypotension	hypotension	NN	_	13	appo	_	_
19	)	-rrb-	-RRB-	_	13	p	_	_
20	.	.	.	_	1	p	_	_

1	Response	response	NN	_	0	root	_	_
2	to	to	TO	_	3	aux	_	_
3	Treatment	treatment	NN	_	1	ppmod	_	_
4	for	for	IN	_	6	case	_	_
5	Anaphylactic	anaphylactic	JJ	_	6	attr	_	_
6	Reaction	reaction	NN	_	1	ppmod	_	_
7	:	:	:	_	1	p	_	_
8	While	while	IN	_	9	mark	_	_
9	taking	take	VBG	_	26	advcl	_	_
10	drug1	drug0	NN	_	9	obj	_	_
11	,	,	,	_	26	p	_	_
12	patients	patient	NNS	_	26	dep	_	_
13	with	with	IN	_	15	case	_	_
14	a	a	DT	_	15	det	_	_
15	history	history	NN	_	12	ppmod	_	_
16	of	of	IN	_	19	case	_	_
17	severe	severe	JJ	_	19	attr	_	_
18	anaphylactic	anaphylactic	JJ	_	19	attr	_	_
19	reaction	reaction	NN	_	15	ppmod	_	_
20	to	to	TO	_	22	aux	_	_
21	a	a	DT	_	22	det	_	_
22	variety	variety	NN	_	19	ppmod	_	_
23	of	of	IN	_	24	case	_	_
24	allergens	allergen	NNS	_	22	ppmod	_	_
25	may	may	MD	_	26	modal	_	_
26	be	be	VB	_	1	acl	_	_
27	more	more	RBR	_	28	adv	_	_
28	reactive	reactive	JJ	_	26	dep	_	_
29	to	to	TO	_	31	aux	_	_
30	repeated	repeated	JJ	_	31	attr	_	_
31	challenge	challenge	NN	_	28	ppmod	_	_
32	,	,	,	_	28	p	_	_
33	either	either	CC	_	28	cc	_	_
34	accidental	accidental	JJ	_	28	conj	_	_
35	,	,	,	_	34	p	_	_
36	diagnostic	diagnostic	JJ	_	28	conj	_	_
37	,	,	,	_	36	p	_	_
38	or	or	CC	_	36	cc	_	_
39	therapeutic	therapeutic	JJ	_	28	conj	_	_
40	.	.	.	_	1	p	_	_

1	Such	such	JJ	_	2	attr	_	_
2	patients	patient	NNS	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	be	be	VB	_	0	root	_	_
5	unresponsive	unresponsive	JJ	_	4	dep	_	_
6	to	to	TO	_	9	aux	_	_
7	the	the	DT	_	9	det	_	_
8	usual	usual	JJ	_	9	attr	_	_
9	doses	dose	NNS	_	5	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	used	use	VBN	_	9	acl	_	_
13	to	to	TO	_	14	aux	_	_
14	treat	treat	VB	_	12	comp	_	_
15	allergic	allergic	JJ	_	16	attr	_	_
16	reaction	reaction	NN	_	14	obj	_	_
17	.	.	.	_	4	p	_	_

1	Since	since	IN	_	7	mark	_	_
2	drug1	drug0	NN	_	7	dep	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	drug2	drug0	NN	_	2	prn	_	_
5	)	-rrb-	-RRB-	_	4	p	_	_
6	may	may	MD	_	7	modal	_	_
7	interact	interact	VB	_	21	advcl	_	_
8	with	with	IN	_	11	case	_	_
9	concurrently	concurrently	RB	_	10	adv	_	_
10	administered	administer	VBN	_	11	attr	_	_
11	drug3	drug0	NN	_	7	ppmod	_	_
12	,	,	,	_	21	p	_	_
13	periodic	periodic	JJ	_	16	attr	_	_
14	serum	serum	NN	_	16	com	_	_
15	level	level	NN	_	16	com	_	_
16	determinations	determination	NNS	_	21	dep	_	_
17	of	of	IN	_	19	case	_	_
18	these	these	DT	_	19	det	_	_
19	drugs	drug	NNS	_	16	ppmod	_	_
20	may	may	MD	_	21	modal	_	_
21	be	be	VB	_	0	root	_	_
22	necessary	necessary	JJ	_	21	dep	_	_
23	(	-lrb-	-LRB-	_	24	p	_	_
24	eg	eg	NN	_	22	prn	_	_
25	,	,	,	_	24	p	_	_
26	drug4	drug0	NN	_	28	dep	_	_
27	may	may	MD	_	28	modal	_	_
28	elevate	elevate	VBP	_	24	acl	_	_
29	drug5	drug0	NN	_	31	com	_	_
30	serum	serum	NN	_	31	com	_	_
31	levels	level	NNS	_	28	obj	_	_
32	and	and	CC	_	28	cc	_	_
33	drug6	drug0	NN	_	36	dep	_	_
34	has	have	VBZ	_	36	aux	_	_
35	been	be	VBN	_	36	aux	_	_
36	reported	report	VBN	_	28	conj	_	_
37	to	to	TO	_	39	aux	_	_
38	both	both	CC	_	39	cc	_	_
39	increase	increase	NN	_	36	ppmod	_	_
40	and	and	CC	_	39	cc	_	_
41	decrease	decrease	NN	_	43	com	_	_
42	drug7	drug0	NN	_	43	com	_	_
43	levels	level	NNS	_	39	conj	_	_
44	)	-rrb-	-RRB-	_	24	p	_	_
45	.	.	.	_	21	p	_	_

1	Results	result	NNS	_	9	dep	_	_
2	of	of	IN	_	4	case	_	_
3	preliminary	preliminary	JJ	_	4	attr	_	_
4	studies	study	NNS	_	1	ppmod	_	_
5	in	in	IN	_	6	case	_	_
6	humans	human	NNS	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	rats	rat	NNS	_	6	conj	_	_
9	suggest	suggest	VBP	_	0	root	_	_
10	that	that	IN	_	18	mark	_	_
11	nonabsorbable	nonabsorbable	JJ	_	12	attr	_	_
12	drug1	drug0	NN	_	18	dep	_	_
13	given	give	VBN	_	12	acl	_	_
14	concurrently	concurrently	RB	_	13	adv	_	_
15	with	with	IN	_	16	case	_	_
16	drug2	drug0	NN	_	13	ppmod	_	_
17	may	may	MD	_	18	modal	_	_
18	inhibit	inhibit	VB	_	9	comp	_	_
19	the	the	DT	_	23	det	_	_
20	desired	desired	JJ	_	23	attr	_	_
21	drug3	drug0	NN	_	23	attr	_	_
22	-induced	-induced	JJ	_	23	attr	_	_
23	drop	drop	NN	_	18	obj	_	_
24	in	in	IN	_	26	case	_	_
25	colonic	colonic	JJ	_	26	attr	_	_
26	pH	ph	NN	_	23	ppmod	_	_
27	.	.	.	_	9	p	_	_

1	Therefore	therefore	RB	_	13	adv	_	_
2	,	,	,	_	13	p	_	_
3	a	a	DT	_	5	det	_	_
4	possible	possible	JJ	_	5	attr	_	_
5	lack	lack	NN	_	13	dep	_	_
6	of	of	IN	_	8	case	_	_
7	desired	desired	JJ	_	8	attr	_	_
8	effect	effect	NN	_	5	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	treatment	treatment	NN	_	8	ppmod	_	_
11	should	should	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	taken	take	VBN	_	0	root	_	_
14	into	into	IN	_	15	case	_	_
15	consideration	consideration	NN	_	13	ppmod	_	_
16	before	before	IN	_	20	mark	_	_
17	such	such	JJ	_	18	attr	_	_
18	drugs	drug	NNS	_	20	dep	_	_
19	are	be	VBP	_	20	aux	_	_
20	given	give	VBN	_	13	comp	_	_
21	concomitantly	concomitantly	RB	_	20	adv	_	_
22	with	with	IN	_	23	case	_	_
23	drug1	drug0	NN	_	20	ppmod	_	_
24	.	.	.	_	13	p	_	_

1	Substances	substance	NNS	_	8	dep	_	_
2	that	that	WDT	_	3	dep	_	_
3	are	be	VBP	_	1	relcl	_	_
4	inducers	inducer	NNS	_	3	obj	_	_
5	of	of	IN	_	7	case	_	_
6	CYP3A4	cyp0a0	NN	_	7	com	_	_
7	activity	activity	NN	_	4	ppmod	_	_
8	increase	increase	VBP	_	0	root	_	_
9	the	the	DT	_	10	det	_	_
10	metabolism	metabolism	NN	_	8	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	and	and	CC	_	8	cc	_	_
14	decrease	decrease	VBP	_	8	conj	_	_
15	its	its	PRP$	_	17	poss	_	_
16	plasma	plasma	NN	_	17	com	_	_
17	concentrations	concentration	NNS	_	14	obj	_	_
18	.	.	.	_	8	p	_	_

1	In	in	IN	_	2	case	_	_
2	patients	patient	NNS	_	23	ppmod	_	_
3	receiving	receive	VBG	_	2	acl	_	_
4	a	a	DT	_	7	det	_	_
5	potent	potent	JJ	_	7	attr	_	_
6	CYP3A4	cyp0a0	NN	_	7	com	_	_
7	inducer	inducer	NN	_	3	obj	_	_
8	such	such	JJ	_	10	adv	_	_
9	as	as	IN	_	10	case	_	_
10	drug1	drug0	NN	_	7	ppmod	_	_
11	or	or	CC	_	10	cc	_	_
12	drug2	drug0	NN	_	10	conj	_	_
13	,	,	,	_	23	p	_	_
14	a	a	DT	_	16	det	_	_
15	dose	dose	NN	_	16	com	_	_
16	increase	increase	NN	_	23	dep	_	_
17	to	to	TO	_	19	aux	_	_
18	500	0	CD	_	19	num	_	_
19	mg	mg	NN	_	16	ppmod	_	_
20	daily	daily	RB	_	19	adv	_	_
21	should	should	MD	_	23	modal	_	_
22	be	be	VB	_	23	aux	_	_
23	considered	consider	VBN	_	0	root	_	_
24	in	in	IN	_	26	case	_	_
25	the	the	DT	_	26	det	_	_
26	absence	absence	NN	_	23	ppmod	_	_
27	of	of	IN	_	31	case	_	_
28	severe	severe	JJ	_	31	attr	_	_
29	adverse	adverse	JJ	_	31	attr	_	_
30	drug	drug	NN	_	31	com	_	_
31	reaction	reaction	NN	_	26	ppmod	_	_
32	,	,	,	_	23	p	_	_
33	and	and	CC	_	23	cc	_	_
34	clinical	clinical	JJ	_	35	attr	_	_
35	response	response	NN	_	42	dep	_	_
36	and	and	CC	_	35	cc	_	_
37	adverse	adverse	JJ	_	38	attr	_	_
38	events	event	NNS	_	35	conj	_	_
39	should	should	MD	_	42	modal	_	_
40	be	be	VB	_	42	aux	_	_
41	carefully	carefully	RB	_	42	adv	_	_
42	monitored	monitor	VBN	_	23	conj	_	_
43	(	-lrb-	-LRB-	_	44	p	_	_
44	see	see	VB	_	42	prn	_	_
45	CLINICAL	clinical	JJ	_	47	attr	_	_
46	PHARMACOLOGY-Pharmacokinetics-Drug-Drug	pharmacology-pharmacokinetics-drug-drug	JJ	_	47	attr	_	_
47	Interactions	interaction	NNS	_	44	obj	_	_
48	and	and	CC	_	47	cc	_	_
49	DOSAGE	dosage	NN	_	53	attr	_	_
50	AND	and	CC	_	49	cc	_	_
51	ADMINISTRATION-Dosage	administration-dosage	JJ	_	52	attr	_	_
52	Adjustment	adjustment	NN	_	49	conj	_	_
53	sections	section	NNS	_	47	conj	_	_
54	)	-rrb-	-RRB-	_	44	p	_	_
55	.	.	.	_	42	p	_	_

1	International	international	NNP	_	7	attr	_	_
2	Normalized	normalize	VBN	_	7	attr	_	_
3	Ratio	ratio	NN	_	7	attr	_	_
4	(	-lrb-	-LRB-	_	7	p	_	_
5	INR	inr	NN	_	7	attr	_	_
6	)	-rrb-	-RRB-	_	7	p	_	_
7	elevations	elevation	NNS	_	13	dep	_	_
8	and/or	and/or	CC	_	7	cc	_	_
9	bleeding	bleeding	JJ	_	10	attr	_	_
10	events	event	NNS	_	7	conj	_	_
11	have	have	VBP	_	13	aux	_	_
12	been	be	VBN	_	13	aux	_	_
13	reported	report	VBN	_	0	root	_	_
14	in	in	IN	_	16	case	_	_
15	some	some	DT	_	16	det	_	_
16	patients	patient	NNS	_	13	ppmod	_	_
17	taking	take	VBG	_	16	acl	_	_
18	drug1	drug0	NN	_	17	obj	_	_
19	while	while	IN	_	22	case	_	_
20	on	on	IN	_	22	case	_	_
21	drug2	drug0	NN	_	22	com	_	_
22	therapy	therapy	NN	_	17	ppmod	_	_
23	.	.	.	_	13	p	_	_

1	Patients	patient	NNS	_	6	dep	_	_
2	taking	take	VBG	_	1	acl	_	_
3	drug1	drug0	NN	_	2	obj	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	monitored	monitor	VBN	_	0	root	_	_
7	regularly	regularly	RB	_	6	adv	_	_
8	for	for	IN	_	9	case	_	_
9	changes	change	NNS	_	6	ppmod	_	_
10	in	in	IN	_	12	case	_	_
11	prothrombin	prothrombin	NN	_	12	com	_	_
12	time	time	NN	_	9	ppmod	_	_
13	or	or	CC	_	12	cc	_	_
14	INR	inr	NN	_	12	conj	_	_
15	.	.	.	_	6	p	_	_

1	Substances	substance	NNS	_	16	dep	_	_
2	that	that	WDT	_	3	dep	_	_
3	are	be	VBP	_	1	relcl	_	_
4	potent	potent	JJ	_	5	attr	_	_
5	inhibitors	inhibitor	NNS	_	3	obj	_	_
6	of	of	IN	_	8	case	_	_
7	CYP3A4	cyp0a0	NN	_	8	com	_	_
8	activity	activity	NN	_	5	ppmod	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	eg	eg	NN	_	1	prn	_	_
11	,	,	,	_	10	p	_	_
12	drug1	drug0	NN	_	10	conj	_	_
13	and	and	CC	_	12	cc	_	_
14	drug2	drug0	NN	_	10	conj	_	_
15	)	-rrb-	-RRB-	_	10	p	_	_
16	decrease	decrease	VBP	_	0	root	_	_
17	drug3	drug0	NN	_	18	com	_	_
18	metabolism	metabolism	NN	_	16	obj	_	_
19	and	and	CC	_	16	cc	_	_
20	increase	increase	VBP	_	16	conj	_	_
21	drug4	drug0	NN	_	23	com	_	_
22	plasma	plasma	NN	_	23	com	_	_
23	concentrations	concentration	NNS	_	20	obj	_	_
24	.	.	.	_	16	p	_	_

1	This	this	DT	_	2	det	_	_
2	increase	increase	NN	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	be	be	VB	_	0	root	_	_
5	clinically	clinically	RB	_	6	adv	_	_
6	relevant	relevant	JJ	_	4	dep	_	_
7	as	as	IN	_	10	mark	_	_
8	adverse	adverse	JJ	_	9	attr	_	_
9	experiences	experience	NNS	_	10	dep	_	_
10	are	be	VBP	_	4	comp	_	_
11	related	related	JJ	_	10	dep	_	_
12	to	to	TO	_	13	aux	_	_
13	dose	dose	NN	_	11	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	exposure	exposure	NN	_	13	conj	_	_
16	;	;	:	_	4	p	_	_

1	therefore	therefore	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	caution	caution	NN	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	used	use	VBN	_	0	root	_	_
7	when	when	WRB	_	8	adv	_	_
8	administering	administer	VBG	_	6	comp	_	_
9	CYP3A4	cyp0a0	JJ	_	10	attr	_	_
10	inhibitors	inhibitor	NNS	_	8	obj	_	_
11	with	with	IN	_	12	case	_	_
12	drug1	drug0	NN	_	8	ppmod	_	_
13	.	.	.	_	6	p	_	_

1	Drugs	drug	NNS	_	19	dep	_	_
2	that	that	WDT	_	3	dep	_	_
3	cause	cause	VBP	_	1	relcl	_	_
4	significant	significant	JJ	_	6	attr	_	_
5	sustained	sustained	JJ	_	6	attr	_	_
6	elevation	elevation	NN	_	3	obj	_	_
7	in	in	IN	_	9	case	_	_
8	gastric	gastric	JJ	_	9	attr	_	_
9	pH	ph	NN	_	6	ppmod	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	drug1	drug0	NN	_	9	prn	_	_
12	such	such	JJ	_	14	adv	_	_
13	as	as	IN	_	14	case	_	_
14	drug2	drug0	NN	_	11	ppmod	_	_
15	or	or	CC	_	14	cc	_	_
16	drug3	drug0	NN	_	14	conj	_	_
17	)	-rrb-	-RRB-	_	11	p	_	_
18	may	may	MD	_	19	modal	_	_
19	reduce	reduce	VB	_	0	root	_	_
20	plasma	plasma	NN	_	21	com	_	_
21	concentrations	concentration	NNS	_	19	obj	_	_
22	of	of	IN	_	23	case	_	_
23	drug4	drug0	NN	_	21	ppmod	_	_
24	and	and	CC	_	19	cc	_	_
25	therefore	therefore	RB	_	28	adv	_	_
26	potentially	potentially	RB	_	28	adv	_	_
27	may	may	MD	_	28	modal	_	_
28	reduce	reduce	VB	_	19	conj	_	_
29	efficacy	efficacy	NN	_	28	obj	_	_
30	.	.	.	_	19	p	_	_

1	Phase	phase	NN	_	5	attr	_	_
2	II	ii	CD	_	5	num	_	_
3	clinical	clinical	JJ	_	5	attr	_	_
4	trial	trial	NN	_	5	com	_	_
5	data	datum	NNS	_	16	dep	_	_
6	,	,	,	_	5	p	_	_
7	where	where	WRB	_	13	adv	_	_
8	drug1	drug0	NN	_	13	dep	_	_
9	and	and	CC	_	8	cc	_	_
10	drug2	drug0	NN	_	8	conj	_	_
11	have	have	VBP	_	13	aux	_	_
12	been	be	VBN	_	13	aux	_	_
13	used	use	VBN	_	5	relcl	_	_
14	concomitantly	concomitantly	RB	_	13	adv	_	_
15	,	,	,	_	5	p	_	_
16	indicate	indicate	VBP	_	0	root	_	_
17	that	that	IN	_	20	mark	_	_
18	drug3	drug0	NN	_	20	dep	_	_
19	may	may	MD	_	20	modal	_	_
20	exacerbate	exacerbate	VB	_	16	comp	_	_
21	the	the	DT	_	23	det	_	_
22	neutropenic	neutropenic	JJ	_	23	attr	_	_
23	effect	effect	NN	_	20	obj	_	_
24	of	of	IN	_	25	case	_	_
25	drug4	drug0	NN	_	23	ppmod	_	_
26	.	.	.	_	16	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	interact	interact	VB	_	0	root	_	_
4	with	with	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	,	,	,	_	5	p	_	_
7	drug3	drug0	NN	_	8	com	_	_
8	s	s	NN	_	5	conj	_	_
9	,	,	,	_	8	p	_	_
10	drug4	drug0	NN	_	5	conj	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	allergy	allergy	NN	_	10	prn	_	_
13	,	,	,	_	12	p	_	_
14	cold	cold	NN	_	12	conj	_	_
15	,	,	,	_	14	p	_	_
16	and	and	CC	_	14	cc	_	_
17	sinus	sinus	NN	_	18	com	_	_
18	medicines	medicine	NNS	_	12	conj	_	_
19	)	-rrb-	-RRB-	_	12	p	_	_
20	,	,	,	_	10	p	_	_
21	diabetic	diabetic	JJ	_	22	attr	_	_
22	drugs	drug	NNS	_	5	conj	_	_
23	,	,	,	_	22	p	_	_
24	drug5	drug0	NN	_	5	conj	_	_
25	,	,	,	_	24	p	_	_
26	drug6	drug0	NN	_	5	conj	_	_
27	,	,	,	_	26	p	_	_
28	drug7	drug0	NN	_	5	conj	_	_
29	like	like	IN	_	30	case	_	_
30	drug8	drug0	NN	_	28	ppmod	_	_
31	or	or	CC	_	30	cc	_	_
32	drug9	drug0	NN	_	30	conj	_	_
33	,	,	,	_	28	p	_	_
34	and	and	CC	_	28	cc	_	_
35	high	high	JJ	_	37	attr	_	_
36	blood	blood	NN	_	37	com	_	_
37	pressure	pressure	NN	_	38	com	_	_
38	medications	medication	NNS	_	5	conj	_	_
39	.	.	.	_	3	p	_	_

1	No	no	DT	_	3	det	_	_
2	drug	drug	NN	_	3	com	_	_
3	interactions	interaction	NNS	_	9	dep	_	_
4	of	of	IN	_	6	case	_	_
5	clinical	clinical	JJ	_	6	attr	_	_
6	importance	importance	NN	_	3	ppmod	_	_
7	have	have	VBP	_	9	aux	_	_
8	been	be	VBN	_	9	aux	_	_
9	identified	identify	VBN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	does	do	VBZ	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	appear	appear	VB	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	affect	affect	VB	_	4	comp	_	_
7	the	the	DT	_	12	det	_	_
8	cytochrome	cytochrome	NN	_	12	attr	_	_
9	P450-linked	p0-linked	JJ	_	12	attr	_	_
10	drug-metabolizing	drug-metabolizing	NN	_	12	com	_	_
11	enzyme	enzyme	NN	_	12	com	_	_
12	system	system	NN	_	6	obj	_	_
13	.	.	.	_	4	p	_	_

1	Compounds	compound	NNS	_	8	dep	_	_
2	that	that	WDT	_	5	dep	_	_
3	have	have	VBP	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	tested	test	VBN	_	1	relcl	_	_
6	in	in	IN	_	7	case	_	_
7	man	man	NN	_	5	ppmod	_	_
8	include	include	VBP	_	0	root	_	_
9	drug1	drug0	NN	_	8	obj	_	_
10	,	,	,	_	9	p	_	_
11	drug2	drug0	NN	_	9	conj	_	_
12	,	,	,	_	11	p	_	_
13	drug3	drug0	NN	_	9	conj	_	_
14	,	,	,	_	13	p	_	_
15	drug4	drug0	NN	_	9	conj	_	_
16	,	,	,	_	15	p	_	_
17	and	and	CC	_	15	cc	_	_
18	drug5	drug0	NN	_	9	conj	_	_
19	and	and	CC	_	8	cc	_	_
20	no	no	DT	_	23	det	_	_
21	clinically	clinically	RB	_	22	adv	_	_
22	meaningful	meaningful	JJ	_	23	attr	_	_
23	interactions	interaction	NNS	_	25	dep	_	_
24	were	be	VBD	_	25	aux	_	_
25	found	find	VBN	_	8	conj	_	_
26	.	.	.	_	8	p	_	_

1	Other	other	JJ	_	3	attr	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	therapy	therapy	NN	_	10	dep	_	_
4	Although	although	IN	_	7	case	_	_
5	specific	specific	JJ	_	7	attr	_	_
6	interaction	interaction	NN	_	7	com	_	_
7	studies	study	NNS	_	3	ppmod	_	_
8	were	be	VBD	_	10	aux	_	_
9	not	not	RB	_	10	neg	_	_
10	performed	performed	VBN	_	21	advcl	_	_
11	,	,	,	_	21	p	_	_
12	drug1	drug0	NN	_	13	com	_	_
13	doses	dose	NNS	_	21	dep	_	_
14	of	of	IN	_	16	case	_	_
15	1	0	CD	_	16	num	_	_
16	mg	mg	NN	_	13	ppmod	_	_
17	or	or	CC	_	13	cc	_	_
18	more	more	JJR	_	13	conj	_	_
19	were	be	VBD	_	21	aux	_	_
20	concomitantly	concomitantly	RB	_	21	adv	_	_
21	used	use	VBN	_	0	root	_	_
22	in	in	IN	_	24	case	_	_
23	clinical	clinical	JJ	_	24	attr	_	_
24	studies	study	NNS	_	21	ppmod	_	_
25	with	with	IN	_	26	case	_	_
26	drug2	drug0	NN	_	24	ppmod	_	_
27	,	,	,	_	26	p	_	_
28	drug3	drug0	NN	_	26	conj	_	_
29	,	,	,	_	28	p	_	_
30	a-blockers	a-blockers	NN	_	26	conj	_	_
31	,	,	,	_	30	p	_	_
32	drug4	drug0	NN	_	26	conj	_	_
33	,	,	,	_	32	p	_	_
34	drug5	drug0	NN	_	26	conj	_	_
35	,	,	,	_	34	p	_	_
36	drug6	drug0	NN	_	26	conj	_	_
37	,	,	,	_	36	p	_	_
38	drug7	drug0	NN	_	26	conj	_	_
39	,	,	,	_	38	p	_	_
40	drug8	drug0	NN	_	26	conj	_	_
41	,	,	,	_	40	p	_	_
42	drug9	drug0	NN	_	26	conj	_	_
43	,	,	,	_	42	p	_	_
44	cardiac	cardiac	JJ	_	45	attr	_	_
45	drug10	drug0	NN	_	26	conj	_	_
46	,	,	,	_	45	p	_	_
47	drug11	drug0	NN	_	26	conj	_	_
48	,	,	,	_	47	p	_	_
49	drug12	drug0	NN	_	26	conj	_	_
50	,	,	,	_	49	p	_	_
51	drug13	drug0	NN	_	26	conj	_	_
52	,	,	,	_	51	p	_	_
53	drug14	drug0	NN	_	26	conj	_	_
54	(	-lrb-	-LRB-	_	56	p	_	_
55	also	also	RB	_	56	adv	_	_
56	referred	refer	VBN	_	53	prn	_	_
57	to	to	TO	_	59	aux	_	_
58	as	as	JJ	_	59	attr	_	_
59	drug15	drug0	NN	_	56	ppmod	_	_
60	)	-rrb-	-RRB-	_	56	p	_	_
61	,	,	,	_	53	p	_	_
62	and	and	CC	_	53	cc	_	_
63	drug16	drug0	NN	_	26	conj	_	_
64	without	without	IN	_	65	case	_	_
65	evidence	evidence	NN	_	26	ppmod	_	_
66	of	of	IN	_	70	case	_	_
67	clinically	clinically	RB	_	68	adv	_	_
68	significant	significant	JJ	_	70	attr	_	_
69	adverse	adverse	JJ	_	70	attr	_	_
70	interactions	interaction	NNS	_	26	ppmod	_	_
71	.	.	.	_	21	p	_	_

1	Drug/Laboratory	drug/laboratory	NN	_	3	com	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	4	com	_	_
4	drug1	drug0	NN	_	5	dep	_	_
5	had	have	VBD	_	0	root	_	_
6	no	no	DT	_	7	det	_	_
7	effect	effect	NN	_	5	obj	_	_
8	on	on	IN	_	10	case	_	_
9	circulating	circulating	JJ	_	10	attr	_	_
10	levels	level	NNS	_	5	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	cortisol	cortisol	NN	_	10	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	thyroid-stimulating	thyroid-stimulating	JJ	_	15	attr	_	_
15	hormone	hormone	NN	_	12	conj	_	_
16	,	,	,	_	15	p	_	_
17	or	or	CC	_	15	cc	_	_
18	thyroxine	thyroxine	NN	_	12	conj	_	_
19	,	,	,	_	5	p	_	_
20	nor	nor	CC	_	5	cc	_	_
21	did	do	VBD	_	23	aux	_	_
22	it	it	PRP	_	23	obj	_	_
23	affect	affect	VB	_	5	conj	_	_
24	the	the	DT	_	27	det	_	_
25	plasma	plasma	NN	_	27	com	_	_
26	lipid	lipid	NN	_	27	com	_	_
27	profile	profile	NN	_	23	obj	_	_
28	(	-lrb-	-LRB-	_	32	p	_	_
29	e.g.	e.g.	FW	_	32	adv	_	_
30	,	,	,	_	32	p	_	_
31	total	total	JJ	_	32	attr	_	_
32	cholesterol	cholesterol	NN	_	27	prn	_	_
33	,	,	,	_	32	p	_	_
34	low-density	low-density	JJ	_	35	attr	_	_
35	lipoproteins	lipoprotein	NNS	_	32	conj	_	_
36	,	,	,	_	35	p	_	_
37	high-density	high-density	JJ	_	38	attr	_	_
38	lipoproteins	lipoprotein	NNS	_	32	conj	_	_
39	and	and	CC	_	38	cc	_	_
40	triglycerides	triglyceride	NNS	_	32	conj	_	_
41	)	-rrb-	-RRB-	_	32	p	_	_
42	or	or	CC	_	27	cc	_	_
43	bone	bone	NN	_	45	attr	_	_
44	mineral	mineral	JJ	_	45	attr	_	_
45	density	density	NN	_	27	conj	_	_
46	.	.	.	_	5	p	_	_

1	In	in	IN	_	2	case	_	_
2	studies	study	NNS	_	25	ppmod	_	_
3	with	with	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	,	,	,	_	25	p	_	_
6	no	no	DT	_	9	det	_	_
7	clinically	clinically	RB	_	8	adv	_	_
8	meaningful	meaningful	JJ	_	9	attr	_	_
9	changes	change	NNS	_	25	dep	_	_
10	in	in	IN	_	12	case	_	_
11	luteinizing	luteinizing	JJ	_	12	attr	_	_
12	hormone	hormone	NN	_	9	ppmod	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	LH	lh	NN	_	12	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	,	,	,	_	12	p	_	_
17	follicle-stimulating	follicle-stimulating	JJ	_	18	attr	_	_
18	hormone	hormone	NN	_	12	conj	_	_
19	(	-lrb-	-LRB-	_	20	p	_	_
20	FSH	fsh	NN	_	18	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	or	or	CC	_	18	cc	_	_
23	prolactin	prolactin	NN	_	12	conj	_	_
24	were	be	VBD	_	25	aux	_	_
25	detected	detect	VBN	_	0	root	_	_
26	.	.	.	_	25	p	_	_

1	In	in	IN	_	3	case	_	_
2	healthy	healthy	JJ	_	3	attr	_	_
3	volunteers	volunteer	NNS	_	10	ppmod	_	_
4	,	,	,	_	10	p	_	_
5	treatment	treatment	NN	_	10	dep	_	_
6	with	with	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	did	do	VBD	_	10	aux	_	_
9	not	not	RB	_	10	neg	_	_
10	alter	alter	VB	_	0	root	_	_
11	the	the	DT	_	12	det	_	_
12	response	response	NN	_	10	obj	_	_
13	of	of	IN	_	14	case	_	_
14	LH	lh	NN	_	12	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	FSH	fsh	NN	_	14	conj	_	_
17	to	to	TO	_	19	aux	_	_
18	gonadotropin-releasing	gonadotropin-releasing	JJ	_	19	attr	_	_
19	hormone	hormone	NN	_	12	ppmod	_	_
20	indicating	indicate	VBG	_	10	comp	_	_
21	that	that	IN	_	27	mark	_	_
22	the	the	DT	_	24	det	_	_
23	hypothalamic-pituitary-testicular	hypothalamic-pituitary-testicular	JJ	_	24	attr	_	_
24	axis	axis	NN	_	27	dep	_	_
25	was	be	VBD	_	27	aux	_	_
26	not	not	RB	_	27	neg	_	_
27	affected	affect	VBN	_	20	comp	_	_
28	.	.	.	_	10	p	_	_

1	In	in	IN	_	3	case	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	studies	study	NNS	_	29	ppmod	_	_
4	with	with	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	drug2	drug0	NN	_	5	prn	_	_
8	,	,	,	_	7	p	_	_
9	1	0	CD	_	10	num	_	_
10	mg	mg	NN	_	7	appo	_	_
11	)	-rrb-	-RRB-	_	7	p	_	_
12	in	in	IN	_	15	case	_	_
13	men	man	NNS	_	15	attr	_	_
14	18-41	0	CD	_	15	num	_	_
15	years	year	NNS	_	5	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	age	age	NN	_	15	ppmod	_	_
18	,	,	,	_	29	p	_	_
19	the	the	DT	_	21	det	_	_
20	mean	mean	NN	_	21	com	_	_
21	value	value	NN	_	29	dep	_	_
22	of	of	IN	_	25	case	_	_
23	serum	serum	NN	_	25	attr	_	_
24	prostate-specific	prostate-specific	JJ	_	25	attr	_	_
25	antigen	antigen	NN	_	21	ppmod	_	_
26	(	-lrb-	-LRB-	_	27	p	_	_
27	PSA	psa	NN	_	25	prn	_	_
28	)	-rrb-	-RRB-	_	27	p	_	_
29	decreased	decrease	VBD	_	0	root	_	_
30	from	from	IN	_	32	case	_	_
31	0.7	0	CD	_	32	num	_	_
32	ng/mL	ng/ml	NN	_	29	ppmod	_	_
33	at	at	IN	_	34	case	_	_
34	baseline	baseline	NN	_	29	ppmod	_	_
35	to	to	TO	_	37	aux	_	_
36	0.5	0	CD	_	37	num	_	_
37	ng/mL	ng/ml	NN	_	29	ppmod	_	_
38	at	at	IN	_	39	case	_	_
39	Month	month	NN	_	37	ppmod	_	_
40	12	0	CD	_	39	num	_	_
41	.	.	.	_	29	p	_	_

1	Further	far	RB	_	31	adv	_	_
2	,	,	,	_	31	p	_	_
3	in	in	IN	_	5	case	_	_
4	clinical	clinical	JJ	_	5	attr	_	_
5	studies	study	NNS	_	31	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	drug2	drug0	NN	_	7	prn	_	_
10	,	,	,	_	9	p	_	_
11	5	0	CD	_	12	num	_	_
12	mg	mg	NN	_	9	appo	_	_
13	)	-rrb-	-RRB-	_	9	p	_	_
14	when	when	WRB	_	15	adv	_	_
15	used	use	VBN	_	7	relcl	_	_
16	in	in	IN	_	18	case	_	_
17	older	old	JJR	_	18	attr	_	_
18	men	man	NNS	_	15	ppmod	_	_
19	who	who	WP	_	20	dep	_	_
20	have	have	VBP	_	18	relcl	_	_
21	benign	benign	JJ	_	23	attr	_	_
22	prostatic	prostatic	JJ	_	23	attr	_	_
23	hyperplasia	hyperplasia	NN	_	20	obj	_	_
24	(	-lrb-	-LRB-	_	25	p	_	_
25	BPH	bph	NN	_	23	prn	_	_
26	)	-rrb-	-RRB-	_	25	p	_	_
27	,	,	,	_	31	p	_	_
28	PSA	psa	NN	_	29	com	_	_
29	levels	level	NNS	_	31	dep	_	_
30	are	be	VBP	_	31	aux	_	_
31	decreased	decrease	VBN	_	0	root	_	_
32	by	by	IN	_	34	case	_	_
33	approximately	approximately	RB	_	34	adv	_	_
34	50	0	CD	_	31	ppmod	_	_
35	%	%	NN	_	34	meta	_	_
36	.	.	.	_	31	p	_	_

1	These	these	DT	_	2	det	_	_
2	findings	finding	NNS	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	taken	take	VBN	_	0	root	_	_
6	into	into	IN	_	7	case	_	_
7	account	account	NN	_	5	ppmod	_	_
8	for	for	IN	_	10	case	_	_
9	proper	proper	JJ	_	10	attr	_	_
10	interpretation	interpretation	NN	_	5	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	serum	serum	NN	_	13	com	_	_
13	PSA	psa	NN	_	10	ppmod	_	_
14	when	when	WRB	_	15	adv	_	_
15	evaluating	evaluate	VBG	_	5	comp	_	_
16	men	man	NNS	_	15	obj	_	_
17	treated	treat	VBN	_	16	acl	_	_
18	with	with	IN	_	19	case	_	_
19	drug1	drug0	NN	_	17	ppmod	_	_
20	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Reports	report	NNS	_	4	dep	_	_
4	suggest	suggest	VBP	_	1	acl	_	_
5	that	that	IN	_	8	mark	_	_
6	drug2	drug0	NN	_	8	dep	_	_
7	may	may	MD	_	8	modal	_	_
8	diminish	diminish	VB	_	4	comp	_	_
9	the	the	DT	_	11	det	_	_
10	antihypertensive	antihypertensive	JJ	_	11	attr	_	_
11	effect	effect	NN	_	8	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug3	drug0	NN	_	11	ppmod	_	_
14	.	.	.	_	1	p	_	_

1	In	in	IN	_	2	case	_	_
2	patients	patient	NNS	_	30	ppmod	_	_
3	with	with	IN	_	7	case	_	_
4	mild	mild	JJ	_	7	attr	_	_
5	to	to	TO	_	7	attr	_	_
6	moderate	moderate	JJ	_	7	attr	_	_
7	hypertension	hypertension	NN	_	2	ppmod	_	_
8	,	,	,	_	30	p	_	_
9	administration	administration	NN	_	30	dep	_	_
10	of	of	IN	_	12	case	_	_
11	25	0	CD	_	12	num	_	_
12	mg	mg	NN	_	9	ppmod	_	_
13	daily	daily	RB	_	12	adv	_	_
14	of	of	IN	_	15	case	_	_
15	drug1	drug0	NN	_	12	ppmod	_	_
16	with	with	IN	_	19	case	_	_
17	the	the	DT	_	19	det	_	_
18	drug2	drug0	NN	_	19	com	_	_
19	drug3	drug0	NN	_	12	ppmod	_	_
20	,	,	,	_	12	p	_	_
21	10	0	CD	_	24	num	_	_
22	to	to	TO	_	21	cc	_	_
23	40	0	CD	_	21	conj	_	_
24	mg	mg	NN	_	12	appo	_	_
25	for	for	IN	_	27	case	_	_
26	4	0	CD	_	27	num	_	_
27	weeks	week	NNS	_	24	ppmod	_	_
28	,	,	,	_	12	p	_	_
29	was	be	VBD	_	30	aux	_	_
30	associated	associate	VBN	_	0	root	_	_
31	with	with	IN	_	34	case	_	_
32	an	an	DT	_	34	det	_	_
33	average	average	JJ	_	34	attr	_	_
34	increase	increase	NN	_	30	ppmod	_	_
35	in	in	IN	_	38	case	_	_
36	mean	mean	JJ	_	38	attr	_	_
37	arterial	arterial	JJ	_	38	attr	_	_
38	pressure	pressure	NN	_	34	ppmod	_	_
39	of	of	IN	_	43	case	_	_
40	about	about	RB	_	41	adv	_	_
41	3	0	CD	_	43	num	_	_
42	mm	mm	NN	_	43	com	_	_
43	Hg	hg	NN	_	38	ppmod	_	_
44	compared	compare	VBN	_	46	adv	_	_
45	to	to	TO	_	46	aux	_	_
46	drug4	drug0	NN	_	38	ppmod	_	_
47	alone	alone	RB	_	46	adv	_	_
48	.	.	.	_	30	p	_	_

1	This	this	DT	_	2	det	_	_
2	interaction	interaction	NN	_	6	dep	_	_
3	should	should	MD	_	6	modal	_	_
4	be	be	VB	_	6	aux	_	_
5	given	give	VBN	_	6	lv	_	_
6	consideration	consideration	NN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	6	ppmod	_	_
9	taking	take	VBG	_	8	acl	_	_
10	drug1	drug0	NN	_	9	obj	_	_
11	concomitantly	concomitantly	RB	_	6	adv	_	_
12	with	with	IN	_	13	case	_	_
13	drug2	drug0	NN	_	6	ppmod	_	_
14	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Concomitant	concomitant	JJ	_	4	attr	_	_
4	administration	administration	NN	_	11	dep	_	_
5	of	of	IN	_	7	case	_	_
6	low-dose	low-dose	JJ	_	7	attr	_	_
7	drug2	drug0	NN	_	4	ppmod	_	_
8	with	with	IN	_	9	case	_	_
9	drug3	drug0	NN	_	4	ppmod	_	_
10	may	may	MD	_	11	modal	_	_
11	result	result	VB	_	1	acl	_	_
12	in	in	IN	_	15	case	_	_
13	an	an	DT	_	15	det	_	_
14	increased	increase	VBN	_	15	attr	_	_
15	rate	rate	NN	_	11	ppmod	_	_
16	of	of	IN	_	18	case	_	_
17	GI	gi	NN	_	18	com	_	_
18	ulceration	ulceration	NN	_	15	ppmod	_	_
19	or	or	CC	_	18	cc	_	_
20	other	other	JJ	_	21	attr	_	_
21	complications	complication	NNS	_	18	conj	_	_
22	,	,	,	_	11	p	_	_
23	compared	compare	VBN	_	25	adv	_	_
24	to	to	TO	_	25	aux	_	_
25	use	use	NN	_	11	ppmod	_	_
26	of	of	IN	_	27	case	_	_
27	drug4	drug0	NN	_	25	ppmod	_	_
28	alone	alone	RB	_	27	adv	_	_
29	.	.	.	_	1	p	_	_

1	In	in	IN	_	5	case	_	_
2	a	a	DT	_	5	det	_	_
3	12-week	0-week	JJ	_	5	attr	_	_
4	endoscopy	endoscopy	NN	_	5	com	_	_
5	study	study	NN	_	11	ppmod	_	_
6	conducted	conduct	VBN	_	5	acl	_	_
7	in	in	IN	_	9	case	_	_
8	OA	oa	JJ	_	9	attr	_	_
9	patients	patient	NNS	_	6	ppmod	_	_
10	there	there	EX	_	11	dep	_	_
11	was	be	VBD	_	0	root	_	_
12	no	no	DT	_	13	det	_	_
13	difference	difference	NN	_	11	obj	_	_
14	in	in	IN	_	17	case	_	_
15	the	the	DT	_	17	det	_	_
16	cumulative	cumulative	JJ	_	17	attr	_	_
17	incidence	incidence	NN	_	13	ppmod	_	_
18	of	of	IN	_	21	case	_	_
19	endoscopic	endoscopic	JJ	_	21	attr	_	_
20	gastroduodenal	gastroduodenal	JJ	_	21	attr	_	_
21	ulcers	ulcer	NNS	_	17	ppmod	_	_
22	in	in	IN	_	23	case	_	_
23	patients	patient	NNS	_	13	ppmod	_	_
24	taking	take	VBG	_	23	acl	_	_
25	low-dose	low-dose	JJ	_	32	attr	_	_
26	(	-lrb-	-LRB-	_	28	p	_	_
27	81	0	CD	_	28	num	_	_
28	mg	mg	NN	_	25	prn	_	_
29	)	-rrb-	-RRB-	_	28	p	_	_
30	enteric	enteric	JJ	_	32	attr	_	_
31	coated	coated	JJ	_	32	attr	_	_
32	drug1	drug0	NN	_	24	obj	_	_
33	plus	plus	CC	_	32	cc	_	_
34	drug2	drug0	NN	_	36	attr	_	_
35	25	0	CD	_	36	num	_	_
36	mg	mg	NN	_	32	conj	_	_
37	daily	daily	RB	_	36	adv	_	_
38	,	,	,	_	11	p	_	_
39	as	as	IN	_	40	mark	_	_
40	compared	compare	VBN	_	11	comp	_	_
41	to	to	TO	_	42	aux	_	_
42	those	those	DT	_	40	ppmod	_	_
43	taking	take	VBG	_	42	acl	_	_
44	drug3	drug0	NN	_	46	attr	_	_
45	2400	0	CD	_	46	num	_	_
46	mg	mg	NN	_	43	obj	_	_
47	daily	daily	RB	_	46	adv	_	_
48	alone	alone	RB	_	46	adv	_	_
49	.	.	.	_	11	p	_	_

1	Patients	patient	NNS	_	9	dep	_	_
2	taking	take	VBG	_	1	acl	_	_
3	low-dose	low-dose	JJ	_	4	attr	_	_
4	drug1	drug0	NN	_	2	obj	_	_
5	plus	plus	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	were	be	VBD	_	9	aux	_	_
8	not	not	RB	_	9	neg	_	_
9	studied	study	VBN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	At	at	IN	_	3	case	_	_
2	steady	steady	JJ	_	3	attr	_	_
3	state	state	NN	_	10	ppmod	_	_
4	,	,	,	_	10	p	_	_
5	drug1	drug0	NN	_	7	attr	_	_
6	50	0	CD	_	7	num	_	_
7	mg	mg	NN	_	10	dep	_	_
8	once	once	RB	_	9	com	_	_
9	daily	daily	RB	_	7	adv	_	_
10	had	have	VBD	_	0	root	_	_
11	no	no	DT	_	12	det	_	_
12	effect	effect	NN	_	10	obj	_	_
13	on	on	IN	_	16	case	_	_
14	the	the	DT	_	16	det	_	_
15	anti-platelet	anti-platelet	JJ	_	16	attr	_	_
16	activity	activity	NN	_	10	ppmod	_	_
17	of	of	IN	_	25	case	_	_
18	low-dose	low-dose	JJ	_	25	attr	_	_
19	(	-lrb-	-LRB-	_	21	p	_	_
20	81	0	CD	_	21	num	_	_
21	mg	mg	NN	_	18	prn	_	_
22	once	once	RB	_	23	adv	_	_
23	daily	daily	JJ	_	21	attr	_	_
24	)	-rrb-	-RRB-	_	21	p	_	_
25	drug2	drug0	NN	_	16	ppmod	_	_
26	,	,	,	_	10	p	_	_
27	as	as	IN	_	28	mark	_	_
28	assessed	assess	VBN	_	10	comp	_	_
29	by	by	IN	_	33	case	_	_
30	ex	ex	FW	_	31	adv	_	_
31	vivo	vivo	FW	_	33	attr	_	_
32	platelet	platelet	NN	_	33	com	_	_
33	aggregation	aggregation	NN	_	28	ppmod	_	_
34	and	and	CC	_	33	cc	_	_
35	serum	serum	NN	_	37	com	_	_
36	TXB2	txb0	NN	_	37	com	_	_
37	generation	generation	NN	_	33	conj	_	_
38	in	in	IN	_	40	case	_	_
39	clotting	clotting	JJ	_	40	attr	_	_
40	blood	blood	NN	_	33	ppmod	_	_
41	.	.	.	_	10	p	_	_

1	Because	because	IN	_	4	case	_	_
2	of	of	IN	_	4	case	_	_
3	its	its	PRP$	_	4	poss	_	_
4	lack	lack	NN	_	13	ppmod	_	_
5	of	of	IN	_	7	case	_	_
6	platelet	platelet	NN	_	7	com	_	_
7	effects	effect	NNS	_	4	ppmod	_	_
8	,	,	,	_	13	p	_	_
9	drug1	drug0	NN	_	13	dep	_	_
10	is	be	VBZ	_	13	aux	_	_
11	not	not	RB	_	13	neg	_	_
12	a	a	DT	_	13	det	_	_
13	substitute	substitute	VB	_	0	root	_	_
14	for	for	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	for	for	IN	_	18	case	_	_
17	cardiovascular	cardiovascular	JJ	_	18	attr	_	_
18	prophylaxis	prophylaxis	NNS	_	13	ppmod	_	_
19	.	.	.	_	13	p	_	_

1	Therefore	therefore	RB	_	13	adv	_	_
2	,	,	,	_	13	p	_	_
3	in	in	IN	_	4	case	_	_
4	patients	patient	NNS	_	13	ppmod	_	_
5	taking	take	VBG	_	4	acl	_	_
6	drug1	drug0	NN	_	5	obj	_	_
7	,	,	,	_	13	p	_	_
8	antiplatelet	antiplatelet	NN	_	9	com	_	_
9	therapies	therapy	NNS	_	13	dep	_	_
10	should	should	MD	_	13	modal	_	_
11	not	not	RB	_	13	neg	_	_
12	be	be	VB	_	13	aux	_	_
13	discontinued	discontinue	VBN	_	0	root	_	_
14	and	and	CC	_	13	cc	_	_
15	should	should	MD	_	17	modal	_	_
16	be	be	VB	_	17	aux	_	_
17	considered	consider	VBN	_	13	conj	_	_
18	in	in	IN	_	19	case	_	_
19	patients	patient	NNS	_	17	ppmod	_	_
20	with	with	IN	_	22	case	_	_
21	an	an	DT	_	22	det	_	_
22	indication	indication	NN	_	19	ppmod	_	_
23	for	for	IN	_	25	case	_	_
24	cardiovascular	cardiovascular	JJ	_	25	attr	_	_
25	prophylaxis	prophylaxis	NNS	_	22	ppmod	_	_
26	.	.	.	_	13	p	_	_

1	Prospective	prospective	JJ	_	3	adv	_	_
2	,	,	,	_	3	p	_	_
3	long-term	long-term	JJ	_	4	attr	_	_
4	studies	study	NNS	_	15	dep	_	_
5	on	on	IN	_	7	case	_	_
6	concomitant	concomitant	JJ	_	7	attr	_	_
7	administration	administration	NN	_	4	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	drug2	drug0	NN	_	9	conj	_	_
12	have	have	VBP	_	15	aux	_	_
13	not	not	RB	_	15	neg	_	_
14	been	be	VBN	_	15	aux	_	_
15	conducted	conduct	VBN	_	0	root	_	_
16	.	.	.	_	15	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Co-administration	co-administration	NN	_	14	dep	_	_
4	with	with	IN	_	6	case	_	_
5	high	high	JJ	_	6	attr	_	_
6	doses	dose	NNS	_	3	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	10	ppmod	_	_
9	-LSB-800	-lsb-0	CD	_	10	num	_	_
10	mg	mg	NN	_	6	prn	_	_
11	twice	twice	RB	_	12	com	_	_
12	daily	daily	RB	_	10	adv	_	_
13	]	-rsb-	-RRB-	_	10	p	_	_
14	increased	increase	VBD	_	1	acl	_	_
15	the	the	DT	_	16	det	_	_
16	Cmax	cmax	NN	_	14	dat	_	_
17	of	of	IN	_	18	case	_	_
18	drug3	drug0	NN	_	16	ppmod	_	_
19	by	by	IN	_	20	case	_	_
20	21	0	CD	_	14	ppmod	_	_
21	%	%	NN	_	20	meta	_	_
22	,	,	,	_	14	p	_	_
23	the	the	DT	_	24	det	_	_
24	AUC0-120hr	auc0hr	NN	_	14	obj	_	_
25	by	by	IN	_	26	case	_	_
26	23	0	CD	_	24	ppmod	_	_
27	%	%	NN	_	26	meta	_	_
28	and	and	CC	_	24	cc	_	_
29	the	the	DT	_	30	det	_	_
30	t1/2	t0	NN	_	24	conj	_	_
31	by	by	IN	_	32	case	_	_
32	15	0	CD	_	30	ppmod	_	_
33	%	%	NN	_	32	meta	_	_
34	.	.	.	_	1	p	_	_

1	These	these	DT	_	3	det	_	_
2	small	small	JJ	_	3	attr	_	_
3	changes	change	NNS	_	4	dep	_	_
4	are	be	VBP	_	0	root	_	_
5	not	not	RB	_	4	neg	_	_
6	clinically	clinically	RB	_	7	adv	_	_
7	significant	significant	JJ	_	4	dep	_	_
8	and	and	CC	_	4	cc	_	_
9	no	no	DT	_	11	det	_	_
10	dose	dose	NN	_	11	com	_	_
11	adjustment	adjustment	NN	_	12	dep	_	_
12	is	be	VBZ	_	4	conj	_	_
13	necessary	necessary	JJ	_	12	dep	_	_
14	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	5	attr	_	_
4	75	0	CD	_	5	num	_	_
5	mg	mg	NN	_	13	dep	_	_
6	once	once	RB	_	7	adv	_	_
7	daily	daily	JJ	_	5	attr	_	_
8	for	for	IN	_	10	case	_	_
9	11	0	CD	_	10	num	_	_
10	days	day	NNS	_	7	ppmod	_	_
11	does	do	VBZ	_	13	aux	_	_
12	not	not	RB	_	13	neg	_	_
13	alter	alter	VB	_	1	acl	_	_
14	the	the	DT	_	17	det	_	_
15	plasma	plasma	NN	_	17	com	_	_
16	concentration	concentration	NN	_	17	com	_	_
17	profile	profile	NN	_	13	obj	_	_
18	or	or	CC	_	17	cc	_	_
19	renal	renal	JJ	_	20	attr	_	_
20	elimination	elimination	NN	_	17	conj	_	_
21	of	of	IN	_	22	case	_	_
22	drug3	drug0	NN	_	20	ppmod	_	_
23	after	after	IN	_	29	case	_	_
24	a	a	DT	_	29	det	_	_
25	single	single	JJ	_	29	attr	_	_
26	0.5	0	CD	_	27	num	_	_
27	mg	mg	NN	_	29	attr	_	_
28	oral	oral	JJ	_	29	attr	_	_
29	dose	dose	NN	_	13	ppmod	_	_
30	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Clinical	clinical	JJ	_	4	attr	_	_
4	studies	study	NNS	_	13	dep	_	_
5	,	,	,	_	4	p	_	_
6	as	as	RB	_	7	com	_	_
7	well	well	RB	_	4	cc	_	_
8	as	as	IN	_	7	com	_	_
9	post-marketing	post-marketing	JJ	_	10	attr	_	_
10	observations	observation	NNS	_	4	conj	_	_
11	,	,	,	_	10	p	_	_
12	have	have	VBP	_	13	aux	_	_
13	shown	show	VBN	_	1	acl	_	_
14	that	that	IN	_	17	mark	_	_
15	drug2	drug0	NN	_	17	dep	_	_
16	can	can	MD	_	17	modal	_	_
17	reduce	reduce	VB	_	13	comp	_	_
18	the	the	DT	_	20	det	_	_
19	natriuretic	natriuretic	JJ	_	20	attr	_	_
20	effect	effect	NN	_	17	obj	_	_
21	of	of	IN	_	22	case	_	_
22	drug3	drug0	NN	_	20	ppmod	_	_
23	and	and	CC	_	22	cc	_	_
24	drug4	drug0	NN	_	22	conj	_	_
25	in	in	IN	_	27	case	_	_
26	some	some	DT	_	27	det	_	_
27	patients	patient	NNS	_	20	ppmod	_	_
28	.	.	.	_	1	p	_	_

1	This	this	DT	_	2	det	_	_
2	response	response	NN	_	5	dep	_	_
3	has	have	VBZ	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	attributed	attribute	VBN	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	inhibition	inhibition	NN	_	5	ppmod	_	_
8	of	of	IN	_	11	case	_	_
9	renal	renal	JJ	_	11	attr	_	_
10	prostaglandin	prostaglandin	NN	_	11	com	_	_
11	synthesis	synthesis	NN	_	7	ppmod	_	_
12	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	9	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	5	attr	_	_
4	400	0	CD	_	5	num	_	_
5	mg	mg	NN	_	1	appo	_	_
6	daily	daily	RB	_	5	adv	_	_
7	did	do	VBD	_	9	aux	_	_
8	not	not	RB	_	9	neg	_	_
9	have	have	VB	_	0	root	_	_
10	any	any	DT	_	13	det	_	_
11	clinically	clinically	RB	_	12	adv	_	_
12	important	important	JJ	_	13	attr	_	_
13	effect	effect	NN	_	9	obj	_	_
14	on	on	IN	_	16	case	_	_
15	the	the	DT	_	16	det	_	_
16	pharmacokinetics	pharmacokinetics	NNS	_	9	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug3	drug0	NN	_	16	ppmod	_	_
19	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	have	have	VBP	_	5	aux	_	_
5	produced	produce	VBN	_	0	root	_	_
6	an	an	DT	_	7	det	_	_
7	elevation	elevation	NN	_	5	obj	_	_
8	of	of	IN	_	11	case	_	_
9	plasma	plasma	NN	_	11	com	_	_
10	drug3	drug0	NN	_	11	com	_	_
11	levels	level	NNS	_	7	ppmod	_	_
12	and	and	CC	_	7	cc	_	_
13	a	a	DT	_	14	det	_	_
14	reduction	reduction	NN	_	7	conj	_	_
15	in	in	IN	_	18	case	_	_
16	renal	renal	JJ	_	18	attr	_	_
17	drug4	drug0	NN	_	18	com	_	_
18	clearance	clearance	NN	_	14	ppmod	_	_
19	.	.	.	_	5	p	_	_

1	In	in	IN	_	3	case	_	_
2	post-marketing	post-marketing	JJ	_	3	attr	_	_
3	experience	experience	VBP	_	6	ppmod	_	_
4	there	there	EX	_	6	dep	_	_
5	have	have	VBP	_	6	aux	_	_
6	been	be	VBN	_	0	root	_	_
7	reports	report	NNS	_	6	obj	_	_
8	of	of	IN	_	9	case	_	_
9	increases	increase	NNS	_	7	ppmod	_	_
10	in	in	IN	_	13	case	_	_
11	plasma	plasma	NN	_	13	com	_	_
12	drug1	drug0	NN	_	13	com	_	_
13	levels	level	NNS	_	9	ppmod	_	_
14	.	.	.	_	6	p	_	_

1	Thus	thus	RB	_	14	adv	_	_
2	,	,	,	_	14	p	_	_
3	when	when	WRB	_	8	adv	_	_
4	drug1	drug0	NN	_	8	dep	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	are	be	VBP	_	8	aux	_	_
8	administered	administer	VBN	_	14	advcl	_	_
9	concurrently	concurrently	RB	_	8	adv	_	_
10	,	,	,	_	14	p	_	_
11	subjects	subject	NNS	_	14	dep	_	_
12	should	should	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	observed	observe	VBN	_	0	root	_	_
15	carefully	carefully	RB	_	14	adv	_	_
16	for	for	IN	_	17	case	_	_
17	signs	sign	NNS	_	14	ppmod	_	_
18	of	of	IN	_	20	case	_	_
19	drug3	drug0	NN	_	20	com	_	_
20	toxicity	toxicity	NN	_	17	ppmod	_	_
21	.	.	.	_	14	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	drug2	drug0	NN	_	20	dep	_	_
3	12.5	0	CD	_	9	num	_	_
4	,	,	,	_	3	p	_	_
5	25	0	CD	_	3	conj	_	_
6	,	,	,	_	5	p	_	_
7	and	and	CC	_	5	cc	_	_
8	50	0	CD	_	3	conj	_	_
9	mg	mg	NN	_	2	attr	_	_
10	,	,	,	_	2	p	_	_
11	each	each	DT	_	12	det	_	_
12	dose	dose	NN	_	2	appo	_	_
13	administered	administer	VBN	_	12	acl	_	_
14	once	once	RB	_	15	com	_	_
15	daily	daily	RB	_	13	adv	_	_
16	for	for	IN	_	18	case	_	_
17	7	0	CD	_	18	num	_	_
18	days	day	NNS	_	13	ppmod	_	_
19	,	,	,	_	2	p	_	_
20	had	have	VBD	_	0	root	_	_
21	no	no	DT	_	22	det	_	_
22	effect	effect	NN	_	20	obj	_	_
23	on	on	IN	_	26	case	_	_
24	the	the	DT	_	26	det	_	_
25	plasma	plasma	NN	_	26	com	_	_
26	concentration	concentration	NN	_	20	ppmod	_	_
27	of	of	IN	_	28	case	_	_
28	drug3	drug0	NN	_	26	ppmod	_	_
29	as	as	IN	_	30	mark	_	_
30	measured	measure	VBN	_	20	comp	_	_
31	by	by	IN	_	32	case	_	_
32	AUC0-24hr	auc0hr	NN	_	30	ppmod	_	_
33	in	in	IN	_	34	case	_	_
34	patients	patient	NNS	_	32	ppmod	_	_
35	receiving	receive	VBG	_	34	acl	_	_
36	single	single	JJ	_	39	attr	_	_
37	weekly	weekly	JJ	_	39	attr	_	_
38	drug4	drug0	NN	_	39	com	_	_
39	doses	dose	NNS	_	35	obj	_	_
40	of	of	IN	_	44	case	_	_
41	7.5	0	CD	_	44	num	_	_
42	to	to	TO	_	41	cc	_	_
43	20	0	CD	_	41	conj	_	_
44	mg	mg	NN	_	39	ppmod	_	_
45	for	for	IN	_	47	case	_	_
46	rheumatoid	rheumatoid	JJ	_	47	attr	_	_
47	arthritis	arthritis	NN	_	35	ppmod	_	_
48	.	.	.	_	20	p	_	_

1	At	at	IN	_	5	case	_	_
2	higher	high	JJR	_	5	attr	_	_
3	than	than	IN	_	5	case	_	_
4	recommended	recommend	VBN	_	5	attr	_	_
5	doses	dose	NNS	_	16	ppmod	_	_
6	,	,	,	_	16	p	_	_
7	drug1	drug0	NN	_	9	attr	_	_
8	75	0	CD	_	9	num	_	_
9	mg	mg	NN	_	16	dep	_	_
10	administered	administer	VBN	_	9	acl	_	_
11	once	once	RB	_	12	com	_	_
12	daily	daily	RB	_	10	adv	_	_
13	for	for	IN	_	15	case	_	_
14	10	0	CD	_	15	num	_	_
15	days	day	NNS	_	10	ppmod	_	_
16	increased	increase	VBD	_	0	root	_	_
17	plasma	plasma	NN	_	18	com	_	_
18	concentrations	concentration	NNS	_	16	obj	_	_
19	by	by	IN	_	20	case	_	_
20	23	0	CD	_	16	ppmod	_	_
21	%	%	NN	_	20	meta	_	_
22	as	as	IN	_	23	mark	_	_
23	measured	measure	VBN	_	16	comp	_	_
24	by	by	IN	_	25	case	_	_
25	AUC0-24hr	auc0hr	NN	_	23	ppmod	_	_
26	in	in	IN	_	27	case	_	_
27	patients	patient	NNS	_	25	ppmod	_	_
28	receiving	receive	VBG	_	27	acl	_	_
29	drug2	drug0	NN	_	33	attr	_	_
30	7.5	0	CD	_	33	num	_	_
31	to	to	TO	_	33	attr	_	_
32	15	0	CD	_	33	num	_	_
33	mg/week	mg/week	NN	_	28	obj	_	_
34	for	for	IN	_	36	case	_	_
35	rheumatoid	rheumatoid	JJ	_	36	attr	_	_
36	arthritis	arthritis	NN	_	33	ppmod	_	_
37	.	.	.	_	16	p	_	_

1	At	at	IN	_	4	case	_	_
2	24	0	CD	_	4	num	_	_
3	hours	hour	NNS	_	4	com	_	_
4	postdose	postdose	NN	_	37	ppmod	_	_
5	,	,	,	_	37	p	_	_
6	a	a	DT	_	8	det	_	_
7	similar	similar	JJ	_	8	attr	_	_
8	proportion	proportion	NN	_	37	dep	_	_
9	of	of	IN	_	10	case	_	_
10	patients	patient	NNS	_	8	ppmod	_	_
11	treated	treat	VBN	_	10	acl	_	_
12	with	with	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	alone	alone	RB	_	11	adv	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	94	0	CD	_	14	num	_	_
17	%	%	NN	_	16	meta	_	_
18	)	-rrb-	-RRB-	_	16	p	_	_
19	and	and	CC	_	11	cc	_	_
20	subsequently	subsequently	RB	_	21	adv	_	_
21	treated	treat	VBN	_	11	conj	_	_
22	with	with	IN	_	24	case	_	_
23	drug2	drug0	NN	_	24	com	_	_
24	co-administered	co-administered	NN	_	21	ppmod	_	_
25	with	with	IN	_	27	case	_	_
26	75	0	CD	_	27	num	_	_
27	mg	mg	NN	_	21	ppmod	_	_
28	of	of	IN	_	29	case	_	_
29	drug3	drug0	NN	_	27	ppmod	_	_
30	(	-lrb-	-LRB-	_	31	p	_	_
31	88	0	CD	_	27	num	_	_
32	%	%	NN	_	31	meta	_	_
33	)	-rrb-	-RRB-	_	31	p	_	_
34	had	have	VBD	_	37	lv	_	_
35	drug4	drug0	NN	_	37	com	_	_
36	plasma	plasma	NN	_	37	com	_	_
37	concentrations	concentration	NNS	_	0	root	_	_
38	below	below	IN	_	41	case	_	_
39	the	the	DT	_	41	det	_	_
40	measurable	measurable	JJ	_	41	attr	_	_
41	limit	limit	NN	_	37	ppmod	_	_
42	(	-lrb-	-LRB-	_	44	p	_	_
43	5	0	CD	_	44	num	_	_
44	ng/mL	ng/ml	NN	_	41	prn	_	_
45	)	-rrb-	-RRB-	_	44	p	_	_
46	.	.	.	_	37	p	_	_

1	Standard	standard	JJ	_	2	attr	_	_
2	monitoring	monitoring	NN	_	9	dep	_	_
3	of	of	IN	_	6	case	_	_
4	drug1	drug0	NN	_	6	attr	_	_
5	-related	-related	JJ	_	6	attr	_	_
6	toxicity	toxicity	NN	_	2	ppmod	_	_
7	should	should	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	continued	continue	VBN	_	0	root	_	_
10	if	if	IN	_	15	mark	_	_
11	drug2	drug0	NN	_	15	dep	_	_
12	and	and	CC	_	11	cc	_	_
13	drug3	drug0	NN	_	11	conj	_	_
14	are	be	VBP	_	15	aux	_	_
15	administered	administer	VBN	_	9	comp	_	_
16	concomitantly	concomitantly	RB	_	15	adv	_	_
17	.	.	.	_	9	p	_	_

1	Oral	oral	JJ	_	3	attr	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	drug2	drug0	NN	_	6	dep	_	_
4	did	do	VBD	_	6	aux	_	_
5	not	not	RB	_	6	neg	_	_
6	have	have	VB	_	0	root	_	_
7	any	any	DT	_	10	det	_	_
8	clinically	clinically	RB	_	9	adv	_	_
9	important	important	JJ	_	10	attr	_	_
10	effect	effect	NN	_	6	obj	_	_
11	on	on	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	pharmacokinetics	pharmacokinetics	NNS	_	6	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	drug4	drug0	NN	_	15	conj	_	_
18	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	8	dep	_	_
2	/	/	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	:	:	:	_	1	p	_	_
5	drug3	drug0	NN	_	1	appo	_	_
6	did	do	VBD	_	8	aux	_	_
7	not	not	RB	_	8	neg	_	_
8	have	have	VB	_	0	root	_	_
9	any	any	DT	_	12	det	_	_
10	clinically	clinically	RB	_	11	adv	_	_
11	important	important	JJ	_	12	attr	_	_
12	effect	effect	NN	_	8	obj	_	_
13	on	on	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	pharmacokinetics	pharmacokinetics	NNS	_	8	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	drug4	drug0	NN	_	15	ppmod	_	_
18	or	or	CC	_	17	cc	_	_
19	drug5	drug0	NN	_	17	conj	_	_
20	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Co-administration	co-administration	NN	_	19	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	with	with	IN	_	9	case	_	_
7	drug3	drug0	NN	_	9	attr	_	_
8	600	0	CD	_	9	num	_	_
9	mg	mg	NN	_	3	ppmod	_	_
10	daily	daily	RB	_	9	adv	_	_
11	,	,	,	_	9	p	_	_
12	a	a	DT	_	14	det	_	_
13	potent	potent	JJ	_	14	attr	_	_
14	inducer	inducer	NN	_	9	appo	_	_
15	of	of	IN	_	17	case	_	_
16	hepatic	hepatic	JJ	_	17	attr	_	_
17	metabolism	metabolism	NN	_	14	ppmod	_	_
18	,	,	,	_	9	p	_	_
19	produced	produce	VBD	_	1	acl	_	_
20	an	an	DT	_	24	det	_	_
21	approximate	approximate	JJ	_	24	attr	_	_
22	50	0	CD	_	24	num	_	_
23	%	%	NN	_	22	meta	_	_
24	decrease	decrease	NN	_	19	obj	_	_
25	in	in	IN	_	28	case	_	_
26	drug4	drug0	NN	_	28	com	_	_
27	plasma	plasma	NN	_	28	com	_	_
28	concentrations	concentration	NNS	_	24	ppmod	_	_
29	.	.	.	_	1	p	_	_

1	Therefore	therefore	RB	_	14	adv	_	_
2	,	,	,	_	14	p	_	_
3	a	a	DT	_	6	det	_	_
4	starting	start	VBG	_	6	attr	_	_
5	daily	daily	JJ	_	6	attr	_	_
6	dose	dose	NN	_	14	dep	_	_
7	of	of	IN	_	9	case	_	_
8	25	0	CD	_	9	num	_	_
9	mg	mg	NN	_	6	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	should	should	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	considered	consider	VBN	_	0	root	_	_
15	for	for	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	treatment	treatment	NN	_	14	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	osteoarthritis	osteoarthritis	NN	_	17	ppmod	_	_
20	when	when	WRB	_	23	adv	_	_
21	drug2	drug0	NN	_	23	dep	_	_
22	is	be	VBZ	_	23	aux	_	_
23	co-administered	co-administered	VBN	_	14	comp	_	_
24	with	with	IN	_	26	case	_	_
25	potent	potent	JJ	_	26	attr	_	_
26	inducers	inducer	NNS	_	23	ppmod	_	_
27	of	of	IN	_	29	case	_	_
28	hepatic	hepatic	JJ	_	29	attr	_	_
29	metabolism	metabolism	NN	_	26	ppmod	_	_
30	.	.	.	_	14	p	_	_

1	drug1	drug0	NN	_	9	attr	_	_
2	drug2	drug0	NN	_	9	attr	_	_
3	12.5	0	CD	_	9	num	_	_
4	,	,	,	_	3	p	_	_
5	25	0	CD	_	3	conj	_	_
6	,	,	,	_	5	p	_	_
7	and	and	CC	_	5	cc	_	_
8	50	0	CD	_	3	conj	_	_
9	mg	mg	NN	_	16	dep	_	_
10	administered	administer	VBN	_	9	acl	_	_
11	once	once	RB	_	12	com	_	_
12	daily	daily	RB	_	10	adv	_	_
13	for	for	IN	_	15	case	_	_
14	7	0	CD	_	15	num	_	_
15	days	day	NNS	_	10	ppmod	_	_
16	increased	increase	VBD	_	0	root	_	_
17	plasma	plasma	NN	_	19	com	_	_
18	drug3	drug0	NN	_	19	com	_	_
19	concentrations	concentration	NNS	_	16	obj	_	_
20	(	-lrb-	-LRB-	_	21	p	_	_
21	AUC	auc	NN	_	19	prn	_	_
22	(	-lrb-	-LRB-	_	21	p	_	_
23	0-	0-	CD	_	21	num	_	_
24	)	-rrb-	-RRB-	_	21	p	_	_
25	)	-rrb-	-RRB-	_	21	p	_	_
26	by	by	IN	_	27	case	_	_
27	38	0	CD	_	16	ppmod	_	_
28	to	to	TO	_	27	cc	_	_
29	60	0	CD	_	27	conj	_	_
30	%	%	NN	_	27	meta	_	_
31	in	in	IN	_	33	case	_	_
32	healthy	healthy	JJ	_	33	attr	_	_
33	subjects	subject	NNS	_	27	ppmod	_	_
34	administered	administer	VBN	_	33	acl	_	_
35	a	a	DT	_	38	det	_	_
36	single	single	JJ	_	38	attr	_	_
37	300-mg	0-mg	JJ	_	38	attr	_	_
38	dose	dose	NN	_	34	obj	_	_
39	of	of	IN	_	40	case	_	_
40	drug4	drug0	NN	_	38	ppmod	_	_
41	.	.	.	_	16	p	_	_

1	Adequate	adequate	JJ	_	2	attr	_	_
2	monitoring	monitoring	NN	_	9	dep	_	_
3	of	of	IN	_	6	case	_	_
4	drug1	drug0	NN	_	6	com	_	_
5	plasma	plasma	NN	_	6	com	_	_
6	concentrations	concentration	NNS	_	2	ppmod	_	_
7	should	should	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	considered	consider	VBN	_	0	root	_	_
10	when	when	WRB	_	15	adv	_	_
11	therapy	therapy	NN	_	15	dep	_	_
12	with	with	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	is	be	VBZ	_	15	aux	_	_
15	initiated	initiate	VBN	_	9	comp	_	_
16	or	or	CC	_	15	cc	_	_
17	changed	change	VBN	_	15	conj	_	_
18	in	in	IN	_	19	case	_	_
19	patients	patient	NNS	_	17	ppmod	_	_
20	receiving	receive	VBG	_	19	acl	_	_
21	drug3	drug0	NN	_	20	obj	_	_
22	.	.	.	_	9	p	_	_

1	These	these	DT	_	2	det	_	_
2	data	datum	NNS	_	3	dep	_	_
3	suggest	suggest	VBP	_	0	root	_	_
4	that	that	IN	_	7	mark	_	_
5	drug1	drug0	NN	_	7	dep	_	_
6	may	may	MD	_	7	modal	_	_
7	produce	produce	VB	_	3	comp	_	_
8	a	a	DT	_	10	det	_	_
9	modest	modest	JJ	_	10	attr	_	_
10	inhibition	inhibition	NN	_	7	obj	_	_
11	of	of	IN	_	17	case	_	_
12	cytochrome	cytochrome	NN	_	13	com	_	_
13	P450	p0	NN	_	17	attr	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	CYP	cyp	NN	_	13	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	1A2	0a0	NN	_	10	ppmod	_	_
18	.	.	.	_	3	p	_	_

1	Therefore	therefore	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	there	there	EX	_	4	dep	_	_
4	is	be	VBZ	_	0	root	_	_
5	a	a	DT	_	6	det	_	_
6	potential	potential	NN	_	4	obj	_	_
7	for	for	IN	_	9	case	_	_
8	an	an	DT	_	9	det	_	_
9	interaction	interaction	NN	_	6	ppmod	_	_
10	with	with	IN	_	12	case	_	_
11	other	other	JJ	_	12	attr	_	_
12	drugs	drug	NNS	_	9	ppmod	_	_
13	that	that	WDT	_	15	dep	_	_
14	are	be	VBP	_	15	aux	_	_
15	metabolized	metabolize	VBN	_	12	relcl	_	_
16	by	by	IN	_	17	case	_	_
17	CYP	cyp	VBG	_	15	ppmod	_	_
18	1A2	0a0	NN	_	17	obj	_	_
19	(	-lrb-	-LRB-	_	22	p	_	_
20	e.g.	e.g.	FW	_	22	adv	_	_
21	,	,	,	_	22	p	_	_
22	drug1	drug0	NN	_	18	prn	_	_
23	,	,	,	_	22	p	_	_
24	drug2	drug0	NN	_	22	conj	_	_
25	,	,	,	_	24	p	_	_
26	and	and	CC	_	24	cc	_	_
27	drug3	drug0	NN	_	22	conj	_	_
28	)	-rrb-	-RRB-	_	22	p	_	_
29	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Anticoagulant	anticoagulant	NN	_	4	com	_	_
4	activity	activity	NN	_	7	dep	_	_
5	should	should	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	monitored	monitor	VBN	_	1	acl	_	_
8	,	,	,	_	7	p	_	_
9	particularly	particularly	RB	_	14	adv	_	_
10	in	in	IN	_	14	case	_	_
11	the	the	DT	_	14	det	_	_
12	first	#ord#	JJ	_	14	attr	_	_
13	few	few	JJ	_	14	attr	_	_
14	days	day	NNS	_	7	ppmod	_	_
15	after	after	IN	_	16	case	_	_
16	initiating	initiate	VBG	_	14	ppmod	_	_
17	or	or	CC	_	16	cc	_	_
18	changing	change	VBG	_	16	conj	_	_
19	drug2	drug0	NN	_	20	com	_	_
20	therapy	therapy	NN	_	18	obj	_	_
21	in	in	IN	_	22	case	_	_
22	patients	patient	NNS	_	20	ppmod	_	_
23	receiving	receive	VBG	_	22	acl	_	_
24	drug3	drug0	JJ	_	27	attr	_	_
25	or	or	CC	_	24	cc	_	_
26	similar	similar	JJ	_	24	conj	_	_
27	agents	agent	NNS	_	23	obj	_	_
28	,	,	,	_	7	p	_	_
29	since	since	IN	_	32	mark	_	_
30	these	these	DT	_	31	det	_	_
31	patients	patient	NNS	_	32	dep	_	_
32	are	be	VBP	_	7	comp	_	_
33	at	at	IN	_	36	case	_	_
34	an	an	DT	_	36	det	_	_
35	increased	increase	VBN	_	36	attr	_	_
36	risk	risk	NN	_	32	ppmod	_	_
37	of	of	IN	_	39	case	_	_
38	bleeding	bleeding	JJ	_	39	attr	_	_
39	complications	complication	NNS	_	36	ppmod	_	_
40	.	.	.	_	1	p	_	_

1	In	in	IN	_	6	case	_	_
2	single	single	JJ	_	6	attr	_	_
3	and	and	CC	_	2	cc	_	_
4	multiple	multiple	JJ	_	2	conj	_	_
5	dose	dose	NN	_	6	com	_	_
6	studies	study	NNS	_	24	ppmod	_	_
7	in	in	IN	_	9	case	_	_
8	healthy	healthy	JJ	_	9	attr	_	_
9	subjects	subject	NNS	_	6	ppmod	_	_
10	receiving	receive	VBG	_	9	acl	_	_
11	both	both	CC	_	12	cc	_	_
12	drug1	drug0	NN	_	10	obj	_	_
13	and	and	CC	_	12	cc	_	_
14	drug2	drug0	NN	_	12	conj	_	_
15	,	,	,	_	24	p	_	_
16	prothrombin	prothrombin	NN	_	17	com	_	_
17	time	time	NN	_	24	dep	_	_
18	(	-lrb-	-LRB-	_	19	p	_	_
19	measured	measure	VBN	_	17	prn	_	_
20	as	as	IN	_	21	case	_	_
21	INR	inr	NN	_	19	ppmod	_	_
22	)	-rrb-	-RRB-	_	19	p	_	_
23	was	be	VBD	_	24	aux	_	_
24	increased	increase	VBN	_	0	root	_	_
25	by	by	IN	_	27	case	_	_
26	approximately	approximately	RB	_	27	adv	_	_
27	8	0	CD	_	24	ppmod	_	_
28	%	%	NN	_	27	meta	_	_
29	to	to	TO	_	27	cc	_	_
30	11	0	CD	_	27	conj	_	_
31	%	%	NN	_	27	meta	_	_
32	.	.	.	_	24	p	_	_

1	In	in	IN	_	3	case	_	_
2	post-marketing	post-marketing	JJ	_	3	attr	_	_
3	experience	experience	VBP	_	9	ppmod	_	_
4	,	,	,	_	9	p	_	_
5	bleeding	bleeding	JJ	_	6	attr	_	_
6	events	event	NNS	_	9	dep	_	_
7	have	have	VBP	_	9	aux	_	_
8	been	be	VBN	_	9	aux	_	_
9	reported	report	VBN	_	0	root	_	_
10	,	,	,	_	9	p	_	_
11	predominantly	predominantly	RB	_	14	adv	_	_
12	in	in	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	elderly	elderly	JJ	_	9	ppmod	_	_
15	,	,	,	_	9	p	_	_
16	in	in	IN	_	17	case	_	_
17	association	association	NN	_	9	ppmod	_	_
18	with	with	IN	_	19	case	_	_
19	increases	increase	NNS	_	17	ppmod	_	_
20	in	in	IN	_	22	case	_	_
21	prothrombin	prothrombin	NN	_	22	com	_	_
22	time	time	NN	_	19	ppmod	_	_
23	in	in	IN	_	24	case	_	_
24	patients	patient	NNS	_	19	ppmod	_	_
25	receiving	receive	VBG	_	24	acl	_	_
26	drug1	drug0	NN	_	25	obj	_	_
27	concurrently	concurrently	RB	_	29	adv	_	_
28	with	with	IN	_	29	case	_	_
29	drug2	drug0	NN	_	25	ppmod	_	_
30	.	.	.	_	9	p	_	_

1	When	when	WRB	_	2	adv	_	_
2	administered	administer	VBN	_	9	advcl	_	_
3	concurrently	concurrently	RB	_	2	adv	_	_
4	,	,	,	_	9	p	_	_
5	the	the	DT	_	7	det	_	_
6	following	following	JJ	_	7	attr	_	_
7	drugs	drug	NNS	_	9	dep	_	_
8	may	may	MD	_	9	modal	_	_
9	interact	interact	VB	_	0	root	_	_
10	with	with	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Increased	increase	VBN	_	4	attr	_	_
4	possibility	possibility	NN	_	14	dep	_	_
5	of	of	IN	_	7	case	_	_
6	skin	skin	NN	_	7	com	_	_
7	rash	rash	NN	_	4	ppmod	_	_
8	,	,	,	_	4	p	_	_
9	particularly	particularly	RB	_	4	adv	_	_
10	in	in	IN	_	12	case	_	_
11	hyperuricemic	hyperuricemic	JJ	_	12	attr	_	_
12	patients	patient	NNS	_	4	ppmod	_	_
13	may	may	MD	_	14	modal	_	_
14	occur	occur	VB	_	1	acl	_	_
15	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	12	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	,	,	,	_	3	p	_	_
5	drug3	drug0	NN	_	1	conj	_	_
6	,	,	,	_	5	p	_	_
7	drug4	drug0	NN	_	1	conj	_	_
8	,	,	,	_	7	p	_	_
9	or	or	CC	_	7	cc	_	_
10	drug5	drug0	NN	_	1	conj	_	_
11	may	may	MD	_	12	modal	_	_
12	interfere	interfere	VB	_	0	root	_	_
13	with	with	IN	_	16	case	_	_
14	the	the	DT	_	16	det	_	_
15	bactericidal	bactericidal	JJ	_	16	attr	_	_
16	effect	effect	NN	_	12	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug6	drug0	NN	_	16	ppmod	_	_
19	.	.	.	_	12	p	_	_

1	This	this	DT	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	demonstrated	demonstrate	VBN	_	19	advcl	_	_
5	in	in	IN	_	6	case	_	_
6	view	view	NN	_	4	ppmod	_	_
7	,	,	,	_	19	p	_	_
8	however	however	RB	_	19	adv	_	_
9	,	,	,	_	19	p	_	_
10	the	the	DT	_	12	det	_	_
11	clinical	clinical	JJ	_	12	attr	_	_
12	significance	significance	NN	_	19	dep	_	_
13	of	of	IN	_	15	case	_	_
14	this	this	DT	_	15	det	_	_
15	interaction	interaction	NN	_	12	ppmod	_	_
16	is	be	VBZ	_	19	aux	_	_
17	not	not	RB	_	19	neg	_	_
18	well	well	RB	_	19	adv	_	_
19	documented	document	VBN	_	0	root	_	_
20	.	.	.	_	19	p	_	_

1	Oral	oral	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	13	dep	_	_
3	:	:	:	_	2	p	_	_
4	May	may	MD	_	5	modal	_	_
5	be	be	VB	_	2	acl	_	_
6	less	less	RBR	_	7	adv	_	_
7	effective	effective	JJ	_	5	dep	_	_
8	and	and	CC	_	5	cc	_	_
9	increased	increase	VBD	_	5	conj	_	_
10	breakthrough	breakthrough	RB	_	11	adv	_	_
11	bleeding	bleeding	JJ	_	9	dep	_	_
12	may	may	MD	_	13	modal	_	_
13	occur	occur	VB	_	0	root	_	_
14	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	:	:	:	_	1	p	_	_
3	May	may	MD	_	4	modal	_	_
4	decrease	decrease	VB	_	0	root	_	_
5	renal	renal	JJ	_	7	attr	_	_
6	tubular	tubular	JJ	_	7	attr	_	_
7	secretion	secretion	NN	_	4	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	resulting	result	VBG	_	9	acl	_	_
11	in	in	IN	_	14	case	_	_
12	increased	increase	VBN	_	14	attr	_	_
13	blood	blood	NN	_	14	com	_	_
14	levels	level	NNS	_	10	ppmod	_	_
15	and/or	and/or	CC	_	14	cc	_	_
16	drug3	drug0	NN	_	17	com	_	_
17	toxicity	toxicity	NN	_	14	conj	_	_
18	.	.	.	_	4	p	_	_

1	Drug/Laboratory	drug/laboratory	JJ	_	3	attr	_	_
2	Test	test	NN	_	3	com	_	_
3	Interaction	interaction	NN	_	18	dep	_	_
4	After	after	IN	_	5	case	_	_
5	treatment	treatment	NN	_	3	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drug1	drug0	NN	_	3	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	a	a	DT	_	11	det	_	_
10	false-positive	false-positive	JJ	_	11	attr	_	_
11	reaction	reaction	NN	_	7	appo	_	_
12	for	for	IN	_	13	case	_	_
13	glucose	glucose	NN	_	11	ppmod	_	_
14	in	in	IN	_	16	case	_	_
15	the	the	DT	_	16	det	_	_
16	urine	urine	NN	_	13	ppmod	_	_
17	may	may	MD	_	18	modal	_	_
18	occur	occur	VB	_	0	root	_	_
19	with	with	IN	_	21	case	_	_
20	drug2	drug0	NN	_	21	com	_	_
21	tests	test	NNS	_	18	ppmod	_	_
22	(	-lrb-	-LRB-	_	23	p	_	_
23	Benedicts	benedict	NNS	_	21	prn	_	_
24	solution	solution	NN	_	23	attr	_	_
25	,	,	,	_	24	p	_	_
26	Fehlings	fehlings	NN	_	27	com	_	_
27	solution	solution	NN	_	24	conj	_	_
28	,	,	,	_	27	p	_	_
29	or	or	CC	_	27	cc	_	_
30	Clinitest	clinitest	NN	_	31	com	_	_
31	tablets	tablet	NNS	_	24	conj	_	_
32	)	-rrb-	-RRB-	_	23	p	_	_
33	but	but	CC	_	21	cc	_	_
34	not	not	RB	_	38	neg	_	_
35	with	with	IN	_	38	case	_	_
36	enzyme	enzyme	NN	_	38	com	_	_
37	based	based	NN	_	38	com	_	_
38	tests	test	NNS	_	21	conj	_	_
39	such	such	JJ	_	41	adv	_	_
40	as	as	IN	_	41	case	_	_
41	Clinistix	clinistix	NN	_	38	ppmod	_	_
42	and	and	CC	_	41	cc	_	_
43	Glucose	glucose	NN	_	47	attr	_	_
44	Enzymatic	enzymatic	JJ	_	47	attr	_	_
45	Test	test	NN	_	47	com	_	_
46	Strip	strip	NN	_	47	com	_	_
47	USP	usp	NN	_	41	conj	_	_
48	.	.	.	_	18	p	_	_

1	in	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	data	datum	NNS	_	7	dep	_	_
4	on	on	IN	_	6	case	_	_
5	metabolic	metabolic	JJ	_	6	attr	_	_
6	interactions	interaction	NNS	_	3	ppmod	_	_
7	indicate	indicate	VBP	_	0	root	_	_
8	that	that	IN	_	10	mark	_	_
9	drug1	drug0	NN	_	10	dep	_	_
10	is	be	VBZ	_	7	comp	_	_
11	unlikely	unlikely	JJ	_	10	dep	_	_
12	to	to	TO	_	13	aux	_	_
13	produce	produce	VB	_	11	comp	_	_
14	,	,	,	_	13	p	_	_
15	or	or	CC	_	13	cc	_	_
16	be	be	VB	_	13	conj	_	_
17	subject	subject	JJ	_	16	dep	_	_
18	to	to	TO	_	21	aux	_	_
19	,	,	,	_	21	p	_	_
20	pharmacokinetic	pharmacokinetic	JJ	_	21	attr	_	_
21	interactions	interaction	NNS	_	17	ppmod	_	_
22	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	20	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	its	its	PRP$	_	5	poss	_	_
4	major	major	JJ	_	5	attr	_	_
5	metabolite	metabolite	NN	_	1	conj	_	_
6	,	,	,	_	20	p	_	_
7	at	at	IN	_	8	case	_	_
8	concentrations	concentration	NNS	_	20	ppmod	_	_
9	well	well	RB	_	12	adv	_	_
10	above	above	IN	_	12	case	_	_
11	cmax	cmax	NN	_	12	com	_	_
12	levels	level	NNS	_	8	ppmod	_	_
13	achieved	achieve	VBN	_	8	acl	_	_
14	within	within	IN	_	18	case	_	_
15	the	the	DT	_	18	det	_	_
16	therapeutic	therapeutic	JJ	_	18	attr	_	_
17	dose	dose	NN	_	18	com	_	_
18	range	range	NN	_	13	ppmod	_	_
19	,	,	,	_	20	p	_	_
20	are	be	VBP	_	0	root	_	_
21	neither	neither	CC	_	22	cc	_	_
22	inhibitors	inhibitor	NNS	_	20	obj	_	_
23	of	of	IN	_	22	case	_	_
24	nor	nor	CC	_	22	cc	_	_
25	high	high	JJ	_	27	attr	_	_
26	affinity	affinity	NN	_	27	com	_	_
27	substrates	substrate	NNS	_	22	conj	_	_
28	for	for	IN	_	33	case	_	_
29	human	human	JJ	_	32	attr	_	_
30	liver	liver	NN	_	32	com	_	_
31	cytochrome	cytochrome	NN	_	32	com	_	_
32	P450	p0	NN	_	33	com	_	_
33	isoforms	isoforms	NNS	_	27	ppmod	_	_
34	,	,	,	_	33	p	_	_
35	epoxide	epoxide	NN	_	36	com	_	_
36	hydrolase	hydrolase	NN	_	33	appo	_	_
37	or	or	CC	_	36	cc	_	_
38	UDP-glucuronidation	udp-glucuronidation	JJ	_	39	attr	_	_
39	enzymes	enzyme	NNS	_	36	conj	_	_
40	.	.	.	_	20	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	7	ppmod	_	_
3	,	,	,	_	7	p	_	_
4	drug1	drug0	NN	_	7	dep	_	_
5	does	do	VBZ	_	7	aux	_	_
6	not	not	RB	_	7	neg	_	_
7	affect	affect	VB	_	0	root	_	_
8	the	the	DT	_	11	det	_	_
9	in	in	FW	_	10	adv	_	_
10	vitro	vitro	FW	_	11	attr	_	_
11	glucuronidation	glucuronidation	NN	_	7	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	circulates	circulate	VBZ	_	0	root	_	_
3	largely	largely	RB	_	4	adv	_	_
4	unbound	unbound	JJ	_	2	dep	_	_
5	(	-lrb-	-LRB-	_	8	p	_	_
6	10	0	CD	_	8	num	_	_
7	%	%	NN	_	6	meta	_	_
8	bound	bound	JJ	_	4	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	to	to	TO	_	12	aux	_	_
11	plasma	plasma	NN	_	12	com	_	_
12	proteins	protein	NNS	_	4	ppmod	_	_
13	;	;	:	_	2	p	_	_

1	clinically	clinically	RB	_	2	adv	_	_
2	significant	significant	JJ	_	3	attr	_	_
3	interactions	interaction	NNS	_	13	dep	_	_
4	with	with	IN	_	6	case	_	_
5	other	other	JJ	_	6	attr	_	_
6	drugs	drug	NNS	_	3	ppmod	_	_
7	through	through	IN	_	8	case	_	_
8	competition	competition	NN	_	3	ppmod	_	_
9	for	for	IN	_	12	case	_	_
10	protein	protein	NN	_	12	com	_	_
11	binding	binding	NN	_	12	com	_	_
12	sites	site	NNS	_	8	ppmod	_	_
13	are	be	VBP	_	0	root	_	_
14	therefore	therefore	RB	_	13	adv	_	_
15	unlikely	unlikely	JJ	_	13	dep	_	_
16	.	.	.	_	13	p	_	_

1	Potential	potential	JJ	_	3	attr	_	_
2	pharmacokinetic	pharmacokinetic	JJ	_	3	attr	_	_
3	interactions	interaction	NNS	_	5	dep	_	_
4	were	be	VBD	_	5	aux	_	_
5	assessed	assess	VBN	_	0	root	_	_
6	in	in	IN	_	9	case	_	_
7	clinical	clinical	JJ	_	9	attr	_	_
8	pharmacokinetic	pharmacokinetic	JJ	_	9	attr	_	_
9	studies	study	NNS	_	5	ppmod	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	drug1	drug0	NN	_	9	prn	_	_
12	,	,	,	_	11	p	_	_
13	drug2	drug0	NN	_	11	appo	_	_
14	,	,	,	_	11	p	_	_
15	oral	oral	JJ	_	16	attr	_	_
16	drug3	drug0	NN	_	11	appo	_	_
17	,	,	,	_	11	p	_	_
18	drug4	drug0	NN	_	11	appo	_	_
19	,	,	,	_	11	p	_	_
20	drug5	drug0	NN	_	11	appo	_	_
21	,	,	,	_	11	p	_	_
22	drug6	drug0	NN	_	11	appo	_	_
23	)	-rrb-	-RRB-	_	11	p	_	_
24	and	and	CC	_	9	cc	_	_
25	through	through	IN	_	27	case	_	_
26	pharmacokinetic	pharmacokinetic	JJ	_	27	attr	_	_
27	screening	screening	NN	_	9	conj	_	_
28	in	in	IN	_	32	case	_	_
29	the	the	DT	_	32	det	_	_
30	placebo-controlled	placebo-controlled	JJ	_	31	adv	_	_
31	clinical	clinical	JJ	_	32	attr	_	_
32	studies	study	NNS	_	27	ppmod	_	_
33	in	in	IN	_	35	case	_	_
34	epilepsy	epilepsy	JJ	_	35	attr	_	_
35	patients	patient	NNS	_	32	ppmod	_	_
36	.	.	.	_	5	p	_	_

1	Drug-Drug	drug-drug	JJ	_	2	attr	_	_
2	Interactions	interaction	NNS	_	18	dep	_	_
3	Between	between	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	And	and	CC	_	4	cc	_	_
6	Other	other	JJ	_	12	attr	_	_
7	drug2	drug0	NN	_	12	attr	_	_
8	(	-lrb-	-LRB-	_	12	p	_	_
9	drug3	drug0	NN	_	12	attr	_	_
10	)	-rrb-	-RRB-	_	12	p	_	_
11	drug4	drug0	NN	_	12	com	_	_
12	drug5	drug0	NN	_	4	conj	_	_
13	(	-lrb-	-LRB-	_	15	p	_	_
14	3000	0	CD	_	15	num	_	_
15	mg	mg	NN	_	12	prn	_	_
16	daily	daily	RB	_	15	adv	_	_
17	)	-rrb-	-RRB-	_	15	p	_	_
18	had	have	VBD	_	0	root	_	_
19	no	no	DT	_	20	det	_	_
20	effect	effect	NN	_	18	obj	_	_
21	on	on	IN	_	24	case	_	_
22	the	the	DT	_	24	det	_	_
23	pharmacokinetic	pharmacokinetic	JJ	_	24	attr	_	_
24	disposition	disposition	NN	_	18	ppmod	_	_
25	of	of	IN	_	26	case	_	_
26	drug6	drug0	NN	_	24	ppmod	_	_
27	in	in	IN	_	28	case	_	_
28	patients	patient	NNS	_	26	ppmod	_	_
29	with	with	IN	_	31	case	_	_
30	refractory	refractory	JJ	_	31	attr	_	_
31	epilepsy	epilepsy	NN	_	28	ppmod	_	_
32	.	.	.	_	18	p	_	_

1	Pharmacokinetics	pharmacokinetics	NNS	_	7	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	were	be	VBD	_	7	aux	_	_
5	also	also	RB	_	7	adv	_	_
6	not	not	RB	_	7	neg	_	_
7	affected	affect	VBN	_	0	root	_	_
8	by	by	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	.	.	.	_	7	p	_	_

1	drug1	drug0	JJ	_	2	attr	_	_
2	drug2	drug0	NN	_	11	dep	_	_
3	(	-lrb-	-LRB-	_	5	p	_	_
4	1500	0	CD	_	5	num	_	_
5	mg	mg	NN	_	2	prn	_	_
6	twice	twice	RB	_	7	com	_	_
7	daily	daily	RB	_	5	adv	_	_
8	)	-rrb-	-RRB-	_	5	p	_	_
9	did	do	VBD	_	11	aux	_	_
10	not	not	RB	_	11	neg	_	_
11	alter	alter	VB	_	0	root	_	_
12	the	the	DT	_	13	det	_	_
13	pharmacokinetics	pharmacokinetics	NNS	_	11	obj	_	_
14	of	of	IN	_	15	case	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	in	in	IN	_	18	case	_	_
17	healthy	healthy	JJ	_	18	attr	_	_
18	volunteers	volunteer	NNS	_	13	ppmod	_	_
19	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	3	attr	_	_
2	500	0	CD	_	3	num	_	_
3	mg	mg	NN	_	8	dep	_	_
4	twice	twice	RB	_	5	com	_	_
5	daily	daily	RB	_	3	adv	_	_
6	did	do	VBD	_	8	aux	_	_
7	not	not	RB	_	8	neg	_	_
8	modify	modify	VB	_	0	root	_	_
9	the	the	DT	_	10	det	_	_
10	rate	rate	NN	_	8	obj	_	_
11	or	or	CC	_	10	cc	_	_
12	extent	extent	NN	_	10	conj	_	_
13	of	of	IN	_	15	case	_	_
14	drug2	drug0	NN	_	15	com	_	_
15	absorption	absorption	NN	_	10	ppmod	_	_
16	or	or	CC	_	10	cc	_	_
17	its	its	PRP$	_	19	poss	_	_
18	plasma	plasma	NN	_	19	com	_	_
19	clearance	clearance	NN	_	10	conj	_	_
20	or	or	CC	_	19	cc	_	_
21	urinary	urinary	JJ	_	22	attr	_	_
22	excretion	excretion	NN	_	19	conj	_	_
23	.	.	.	_	8	p	_	_

1	There	there	EX	_	3	dep	_	_
2	also	also	RB	_	3	adv	_	_
3	was	be	VBD	_	0	root	_	_
4	no	no	DT	_	5	det	_	_
5	effect	effect	NN	_	3	obj	_	_
6	on	on	IN	_	7	case	_	_
7	exposure	exposure	NN	_	5	ppmod	_	_
8	to	to	TO	_	11	aux	_	_
9	and	and	CC	_	11	cc	_	_
10	the	the	DT	_	11	det	_	_
11	excretion	excretion	NN	_	7	ppmod	_	_
12	of	of	IN	_	15	case	_	_
13	the	the	DT	_	15	det	_	_
14	primary	primary	JJ	_	15	attr	_	_
15	metabolite	metabolite	NN	_	11	ppmod	_	_
16	,	,	,	_	15	p	_	_
17	ucb	ucb	NN	_	18	com	_	_
18	L057	l0	NN	_	15	appo	_	_
19	.	.	.	_	3	p	_	_

1	Potential	potential	JJ	_	3	attr	_	_
2	drug	drug	NN	_	3	com	_	_
3	interactions	interaction	NNS	_	26	dep	_	_
4	between	between	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	other	other	JJ	_	8	attr	_	_
8	drug2	drug0	NNS	_	5	conj	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	drug3	drug0	NN	_	8	prn	_	_
11	,	,	,	_	10	p	_	_
12	drug4	drug0	NN	_	10	conj	_	_
13	,	,	,	_	12	p	_	_
14	drug5	drug0	NN	_	10	conj	_	_
15	,	,	,	_	14	p	_	_
16	drug6	drug0	NN	_	10	conj	_	_
17	,	,	,	_	16	p	_	_
18	drug7	drug0	NN	_	10	conj	_	_
19	,	,	,	_	18	p	_	_
20	drug8	drug0	NN	_	10	conj	_	_
21	and	and	CC	_	20	cc	_	_
22	drug9	drug0	NN	_	10	conj	_	_
23	)	-rrb-	-RRB-	_	10	p	_	_
24	were	be	VBD	_	26	aux	_	_
25	also	also	RB	_	26	adv	_	_
26	assessed	assess	VBN	_	0	root	_	_
27	by	by	IN	_	28	case	_	_
28	evaluating	evaluate	VBG	_	26	ppmod	_	_
29	the	the	DT	_	31	det	_	_
30	serum	serum	NN	_	31	com	_	_
31	concentrations	concentration	NNS	_	28	obj	_	_
32	of	of	IN	_	33	case	_	_
33	drug10	drug0	NN	_	31	ppmod	_	_
34	and	and	CC	_	33	cc	_	_
35	these	these	DT	_	36	det	_	_
36	drug11	drug0	NN	_	33	conj	_	_
37	during	during	IN	_	40	case	_	_
38	placebo-controlled	placebo-controlled	JJ	_	39	adv	_	_
39	clinical	clinical	JJ	_	40	attr	_	_
40	studies	study	NNS	_	28	ppmod	_	_
41	.	.	.	_	26	p	_	_

1	These	these	DT	_	2	det	_	_
2	data	datum	NNS	_	3	dep	_	_
3	indicate	indicate	VBP	_	0	root	_	_
4	that	that	IN	_	8	mark	_	_
5	drug1	drug0	NN	_	8	dep	_	_
6	does	do	VBZ	_	8	aux	_	_
7	not	not	RB	_	8	neg	_	_
8	influence	influence	VB	_	3	advcl	_	_
9	the	the	DT	_	11	det	_	_
10	plasma	plasma	NN	_	11	com	_	_
11	concentration	concentration	NN	_	8	obj	_	_
12	of	of	IN	_	14	case	_	_
13	other	other	JJ	_	14	attr	_	_
14	drug2	drug0	NN	_	11	ppmod	_	_
15	and	and	CC	_	8	cc	_	_
16	that	that	IN	_	21	mark	_	_
17	these	these	DT	_	18	det	_	_
18	drug3	drug0	NNS	_	21	dep	_	_
19	do	do	VBP	_	21	aux	_	_
20	not	not	RB	_	21	neg	_	_
21	influence	influence	VB	_	8	conj	_	_
22	the	the	DT	_	23	det	_	_
23	pharmacokinetics	pharmacokinetics	NNS	_	21	obj	_	_
24	of	of	IN	_	25	case	_	_
25	drug4	drug0	NN	_	23	ppmod	_	_
26	.	.	.	_	3	p	_	_

1	Effect	effect	NN	_	8	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	in	in	IN	_	6	case	_	_
5	Pediatric	pediatric	JJ	_	6	attr	_	_
6	Patients	patient	NNS	_	1	ppmod	_	_
7	There	there	EX	_	8	dep	_	_
8	was	be	VBD	_	0	root	_	_
9	about	about	IN	_	13	case	_	_
10	a	a	DT	_	13	det	_	_
11	22	0	CD	_	13	num	_	_
12	%	%	NN	_	11	meta	_	_
13	increase	increase	NN	_	8	ppmod	_	_
14	of	of	IN	_	18	case	_	_
15	apparent	apparent	JJ	_	18	attr	_	_
16	total	total	JJ	_	18	attr	_	_
17	body	body	NN	_	18	com	_	_
18	clearance	clearance	NN	_	13	ppmod	_	_
19	of	of	IN	_	20	case	_	_
20	drug2	drug0	NN	_	18	ppmod	_	_
21	when	when	WRB	_	24	adv	_	_
22	it	it	PRP	_	24	dep	_	_
23	was	be	VBD	_	24	aux	_	_
24	co-administered	co-administered	VBN	_	8	comp	_	_
25	with	with	IN	_	27	case	_	_
26	enzyme-inducing	enzyme-inducing	JJ	_	27	attr	_	_
27	drug3	drug0	NN	_	24	ppmod	_	_
28	.	.	.	_	8	p	_	_

1	Dose	dose	NN	_	2	com	_	_
2	adjustment	adjustment	NN	_	3	dep	_	_
3	is	be	VBZ	_	0	root	_	_
4	not	not	RB	_	3	neg	_	_
5	recommended.	recommended.	NN	_	6	com	_	_
6	drug1	drug0	NN	_	3	obj	_	_
7	had	have	VBD	_	6	acl	_	_
8	no	no	DT	_	9	det	_	_
9	effect	effect	NN	_	7	obj	_	_
10	on	on	IN	_	12	case	_	_
11	plasma	plasma	NN	_	12	com	_	_
12	concentrations	concentration	NNS	_	7	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	,	,	,	_	14	p	_	_
16	drug3	drug0	NN	_	14	conj	_	_
17	,	,	,	_	16	p	_	_
18	drug4	drug0	NN	_	14	conj	_	_
19	,	,	,	_	18	p	_	_
20	or	or	CC	_	18	cc	_	_
21	drug5	drug0	NN	_	14	conj	_	_
22	.	.	.	_	3	p	_	_

1	Other	other	JJ	_	3	attr	_	_
2	Drug	drug	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	15	dep	_	_
4	Oral	oral	JJ	_	6	attr	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	drug2	drug0	NN	_	3	attr	_	_
7	(	-lrb-	-LRB-	_	9	p	_	_
8	500	0	CD	_	9	num	_	_
9	mg	mg	NN	_	6	prn	_	_
10	twice	twice	RB	_	11	com	_	_
11	daily	daily	RB	_	9	adv	_	_
12	)	-rrb-	-RRB-	_	9	p	_	_
13	did	do	VBD	_	15	aux	_	_
14	not	not	RB	_	15	neg	_	_
15	influence	influence	VB	_	0	root	_	_
16	the	the	DT	_	17	det	_	_
17	pharmacokinetics	pharmacokinetics	NNS	_	15	obj	_	_
18	of	of	IN	_	21	case	_	_
19	an	an	DT	_	21	det	_	_
20	oral	oral	JJ	_	21	attr	_	_
21	drug3	drug0	NN	_	17	ppmod	_	_
22	containing	contain	VBG	_	21	acl	_	_
23	0.03	0	CD	_	24	num	_	_
24	mg	mg	NN	_	25	com	_	_
25	drug4	drug0	NN	_	22	obj	_	_
26	and	and	CC	_	25	cc	_	_
27	0.15	0	CD	_	28	num	_	_
28	mg	mg	NN	_	29	com	_	_
29	drug5	drug0	NN	_	25	conj	_	_
30	,	,	,	_	21	p	_	_
31	or	or	CC	_	21	cc	_	_
32	of	of	IN	_	35	case	_	_
33	the	the	DT	_	35	det	_	_
34	luteinizing	luteinizing	JJ	_	35	attr	_	_
35	hormone	hormone	NN	_	21	conj	_	_
36	and	and	CC	_	35	cc	_	_
37	progesterone	progesterone	NN	_	38	com	_	_
38	levels	level	NNS	_	35	conj	_	_
39	,	,	,	_	15	p	_	_
40	indicating	indicate	VBG	_	15	comp	_	_
41	that	that	IN	_	46	mark	_	_
42	impairment	impairment	NN	_	46	dep	_	_
43	of	of	IN	_	45	case	_	_
44	contraceptive	contraceptive	JJ	_	45	attr	_	_
45	efficacy	efficacy	NN	_	42	ppmod	_	_
46	is	be	VBZ	_	40	comp	_	_
47	unlikely	unlikely	JJ	_	46	dep	_	_
48	.	.	.	_	15	p	_	_

1	Coadministration	coadministration	NN	_	8	dep	_	_
2	of	of	IN	_	5	case	_	_
3	this	this	DT	_	5	det	_	_
4	oral	oral	JJ	_	5	attr	_	_
5	drug1	drug0	NN	_	1	ppmod	_	_
6	did	do	VBD	_	8	aux	_	_
7	not	not	RB	_	8	neg	_	_
8	influence	influence	VB	_	0	root	_	_
9	the	the	DT	_	10	det	_	_
10	pharmacokinetics	pharmacokinetics	NNS	_	8	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	drug2	drug0	NN	_	11	dep	_	_
3	(	-lrb-	-LRB-	_	5	p	_	_
4	1000	0	CD	_	5	num	_	_
5	mg	mg	NN	_	2	prn	_	_
6	twice	twice	RB	_	7	com	_	_
7	daily	daily	RB	_	5	adv	_	_
8	)	-rrb-	-RRB-	_	5	p	_	_
9	did	do	VBD	_	11	aux	_	_
10	not	not	RB	_	11	neg	_	_
11	influence	influence	VB	_	0	root	_	_
12	the	the	DT	_	13	det	_	_
13	pharmacokinetics	pharmacokinetics	NNS	_	11	obj	_	_
14	and	and	CC	_	13	cc	_	_
15	pharmacodynamics	pharmacodynamics	NNS	_	13	conj	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	ECG	ecg	NN	_	13	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	of	of	IN	_	20	case	_	_
20	drug3	drug0	NN	_	13	ppmod	_	_
21	given	give	VBN	_	20	acl	_	_
22	as	as	IN	_	26	case	_	_
23	a	a	DT	_	26	det	_	_
24	0.25	0	CD	_	25	num	_	_
25	mg	mg	NN	_	26	com	_	_
26	dose	dose	NN	_	21	ppmod	_	_
27	every	every	DT	_	28	det	_	_
28	day	day	NN	_	26	acl	_	_
29	.	.	.	_	11	p	_	_

1	Coadministration	coadministration	NN	_	6	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	did	do	VBD	_	6	aux	_	_
5	not	not	RB	_	6	neg	_	_
6	influence	influence	VB	_	0	root	_	_
7	the	the	DT	_	8	det	_	_
8	pharmacokinetics	pharmacokinetics	NNS	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	drug2	drug0	NN	_	11	dep	_	_
3	(	-lrb-	-LRB-	_	5	p	_	_
4	1000	0	CD	_	5	num	_	_
5	mg	mg	NN	_	2	prn	_	_
6	twice	twice	RB	_	7	com	_	_
7	daily	daily	RB	_	5	adv	_	_
8	)	-rrb-	-RRB-	_	5	p	_	_
9	did	do	VBD	_	11	aux	_	_
10	not	not	RB	_	11	neg	_	_
11	influence	influence	VB	_	0	root	_	_
12	the	the	DT	_	13	det	_	_
13	pharmacokinetics	pharmacokinetics	NNS	_	11	obj	_	_
14	of	of	IN	_	15	case	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	drug4	drug0	NN	_	15	conj	_	_
18	.	.	.	_	11	p	_	_

1	Prothrombin	prothrombin	NN	_	2	com	_	_
2	time	time	NN	_	5	dep	_	_
3	was	be	VBD	_	5	aux	_	_
4	not	not	RB	_	5	neg	_	_
5	affected	affect	VBN	_	0	root	_	_
6	by	by	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	.	.	.	_	5	p	_	_

1	Coadministration	coadministration	NN	_	6	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	did	do	VBD	_	6	aux	_	_
5	not	not	RB	_	6	neg	_	_
6	affect	affect	VB	_	0	root	_	_
7	the	the	DT	_	8	det	_	_
8	pharmacokinetics	pharmacokinetics	NNS	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	26	dep	_	_
4	,	,	,	_	3	p	_	_
5	a	a	DT	_	10	det	_	_
6	renal	renal	JJ	_	10	attr	_	_
7	tubular	tubular	JJ	_	10	attr	_	_
8	secretion	secretion	NN	_	10	com	_	_
9	blocking	blocking	NN	_	10	com	_	_
10	agent	agent	NN	_	3	appo	_	_
11	,	,	,	_	10	p	_	_
12	administered	administer	VBN	_	10	acl	_	_
13	at	at	IN	_	15	case	_	_
14	a	a	DT	_	15	det	_	_
15	dose	dose	NN	_	12	ppmod	_	_
16	of	of	IN	_	20	case	_	_
17	500	0	CD	_	20	num	_	_
18	mg	mg	NN	_	20	attr	_	_
19	four	#crd#	CD	_	20	num	_	_
20	times	time	NNS	_	15	ppmod	_	_
21	a	a	DT	_	22	det	_	_
22	day	day	NN	_	20	appo	_	_
23	,	,	,	_	3	p	_	_
24	did	do	VBD	_	26	aux	_	_
25	not	not	RB	_	26	neg	_	_
26	change	change	VB	_	1	acl	_	_
27	the	the	DT	_	28	det	_	_
28	pharmacokinetics	pharmacokinetics	NNS	_	26	obj	_	_
29	of	of	IN	_	32	case	_	_
30	drug3	drug0	NN	_	32	attr	_	_
31	1000	0	CD	_	32	num	_	_
32	mg	mg	NN	_	28	ppmod	_	_
33	twice	twice	RB	_	34	com	_	_
34	daily	daily	RB	_	32	adv	_	_
35	.	.	.	_	1	p	_	_

1	Cssmax	cssmax	NN	_	11	dep	_	_
2	of	of	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	metabolite	metabolite	NN	_	1	ppmod	_	_
5	,	,	,	_	4	p	_	_
6	ucb	ucb	NN	_	7	com	_	_
7	L057	l0	NN	_	4	appo	_	_
8	,	,	,	_	4	p	_	_
9	was	be	VBD	_	11	aux	_	_
10	approximately	approximately	RB	_	11	adv	_	_
11	doubled	double	VBN	_	0	root	_	_
12	in	in	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	presence	presence	NN	_	11	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	while	while	IN	_	22	mark	_	_
18	the	the	DT	_	19	det	_	_
19	fraction	fraction	NN	_	22	dep	_	_
20	of	of	IN	_	21	case	_	_
21	drug	drug	NN	_	19	ppmod	_	_
22	excreted	excrete	VBD	_	11	comp	_	_
23	unchanged	unchanged	JJ	_	22	dep	_	_
24	in	in	IN	_	26	case	_	_
25	the	the	DT	_	26	det	_	_
26	urine	urine	NN	_	22	ppmod	_	_
27	remained	remain	VBD	_	26	acl	_	_
28	the	the	DT	_	29	det	_	_
29	same	same	JJ	_	27	obj	_	_
30	.	.	.	_	11	p	_	_

1	Renal	renal	JJ	_	2	attr	_	_
2	clearance	clearance	NN	_	11	dep	_	_
3	of	of	IN	_	5	case	_	_
4	ucb	ucb	NN	_	5	com	_	_
5	L057	l0	NN	_	2	ppmod	_	_
6	in	in	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	presence	presence	NN	_	2	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	decreased	decrease	VBD	_	0	root	_	_
12	60	0	CD	_	11	obj	_	_
13	%	%	NN	_	12	meta	_	_
14	,	,	,	_	12	p	_	_
15	probably	probably	RB	_	16	adv	_	_
16	related	related	JJ	_	12	attr	_	_
17	to	to	TO	_	19	aux	_	_
18	competitive	competitive	JJ	_	19	attr	_	_
19	inhibition	inhibition	NN	_	16	ppmod	_	_
20	of	of	IN	_	22	case	_	_
21	tubular	tubular	JJ	_	22	attr	_	_
22	secretion	secretion	NN	_	19	ppmod	_	_
23	of	of	IN	_	25	case	_	_
24	ucb	ucb	JJ	_	25	attr	_	_
25	L057	l0	NN	_	22	ppmod	_	_
26	.	.	.	_	11	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	9	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	on	on	IN	_	6	case	_	_
6	drug2	drug0	NN	_	2	ppmod	_	_
7	was	be	VBD	_	9	aux	_	_
8	not	not	RB	_	9	neg	_	_
9	studied	study	VBN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	or	or	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	4	com	_	_
4	excess	excess	NN	_	1	conj	_	_
5	may	may	MD	_	6	modal	_	_
6	decrease	decrease	VB	_	0	root	_	_
7	the	the	DT	_	8	det	_	_
8	effect	effect	NN	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug3	drug0	NN	_	8	ppmod	_	_
11	,	,	,	_	6	p	_	_
12	and	and	CC	_	6	cc	_	_
13	an	an	DT	_	15	det	_	_
14	drug4	drug0	NN	_	15	com	_	_
15	deficiency	deficiency	NN	_	17	dep	_	_
16	can	can	MD	_	17	modal	_	_
17	increase	increase	VB	_	6	conj	_	_
18	the	the	DT	_	19	det	_	_
19	effect	effect	NN	_	17	obj	_	_
20	of	of	IN	_	21	case	_	_
21	drug5	drug0	NN	_	19	ppmod	_	_
22	.	.	.	_	6	p	_	_

1	Serum	serum	NN	_	2	com	_	_
2	concentration	concentration	NN	_	8	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	may	may	MD	_	8	modal	_	_
8	increase	increase	VB	_	0	root	_	_
9	when	when	WRB	_	11	adv	_	_
10	patients	patient	NNS	_	11	dep	_	_
11	take	take	VBP	_	8	comp	_	_
12	drug3	drug0	NN	_	11	obj	_	_
13	.	.	.	_	8	p	_	_

1	A	a	DT	_	2	det	_	_
2	decrease	decrease	NN	_	7	dep	_	_
3	of	of	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	dosage	dosage	NN	_	2	ppmod	_	_
6	may	may	MD	_	7	modal	_	_
7	be	be	VB	_	0	root	_	_
8	necessary	necessary	JJ	_	7	dep	_	_
9	when	when	WRB	_	11	adv	_	_
10	patient	patient	NN	_	11	dep	_	_
11	becomes	become	VBZ	_	8	comp	_	_
12	euthyroid	euthyroid	JJ	_	11	dep	_	_
13	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	decrease	decrease	VB	_	14	advcl	_	_
4	thyroidal	thyroidal	JJ	_	5	attr	_	_
5	uptake	uptake	NN	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	,	,	,	_	14	p	_	_
9	a	a	DT	_	10	det	_	_
10	rebound	rebound	NN	_	14	dep	_	_
11	in	in	IN	_	12	case	_	_
12	uptake	uptake	NN	_	10	ppmod	_	_
13	may	may	MD	_	14	modal	_	_
14	occur	occur	VB	_	0	root	_	_
15	up	up	RP	_	18	prt	_	_
16	to	to	TO	_	18	aux	_	_
17	5	0	CD	_	18	num	_	_
18	days	day	NNS	_	14	ppmod	_	_
19	after	after	IN	_	21	case	_	_
20	sudden	sudden	CD	_	21	num	_	_
21	withdrawal	withdrawal	NN	_	18	ppmod	_	_
22	of	of	IN	_	23	case	_	_
23	drug3	drug0	NN	_	21	ppmod	_	_
24	.	.	.	_	14	p	_	_

1	Patients	patient	NNS	_	2	com	_	_
2	response	response	NN	_	8	dep	_	_
3	to	to	TO	_	5	aux	_	_
4	oral	oral	JJ	_	5	attr	_	_
5	drug1	drug0	NN	_	2	ppmod	_	_
6	may	may	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	affected	affect	VBN	_	0	root	_	_
9	by	by	IN	_	11	case	_	_
10	his/her	his/her	JJ	_	11	attr	_	_
11	thyroid	thyroid	NN	_	8	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	metabolic	metabolic	JJ	_	14	attr	_	_
14	status	status	NN	_	11	conj	_	_
15	.	.	.	_	8	p	_	_

1	An	an	DT	_	2	det	_	_
2	evaluation	evaluation	NN	_	13	dep	_	_
3	of	of	IN	_	5	case	_	_
4	prothrombin	prothrombin	NN	_	5	com	_	_
5	time	time	NN	_	2	ppmod	_	_
6	and	and	CC	_	2	cc	_	_
7	an	an	DT	_	8	det	_	_
8	adjustment	adjustment	NN	_	2	conj	_	_
9	of	of	IN	_	11	case	_	_
10	drug1	drug0	NN	_	11	com	_	_
11	dosage	dosage	NN	_	8	ppmod	_	_
12	are	be	VBP	_	13	aux	_	_
13	recommended	recommend	VBN	_	0	root	_	_

1	No	no	DT	_	2	det	_	_
2	information	information	NN	_	3	dep	_	_
3	available	available	JJ	_	0	root	_	_
4	.	.	.	_	3	p	_	_

1	Caution	caution	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	observed	observe	VBN	_	0	root	_	_
5	when	when	WRB	_	8	adv	_	_
6	drug1	drug0	NN	_	8	dep	_	_
7	is	be	VBZ	_	8	aux	_	_
8	coadministered	coadministered	VBN	_	4	comp	_	_
9	with	with	IN	_	11	case	_	_
10	other	other	JJ	_	11	attr	_	_
11	drug2	drug0	NN	_	8	ppmod	_	_
12	,	,	,	_	11	p	_	_
13	drug3	drug0	NN	_	11	conj	_	_
14	,	,	,	_	13	p	_	_
15	drug4	drug0	NN	_	11	conj	_	_
16	,	,	,	_	15	p	_	_
17	or	or	CC	_	15	cc	_	_
18	drug5	drug0	NN	_	11	conj	_	_
19	,	,	,	_	8	p	_	_
20	as	as	IN	_	24	mark	_	_
21	these	these	DT	_	22	det	_	_
22	agents	agent	NNS	_	24	dep	_	_
23	may	may	MD	_	24	modal	_	_
24	increase	increase	VB	_	8	comp	_	_
25	respiratory	respiratory	JJ	_	28	attr	_	_
26	and	and	CC	_	25	cc	_	_
27	circulatory	circulatory	JJ	_	25	conj	_	_
28	depression	depression	NN	_	24	obj	_	_
29	.	.	.	_	4	p	_	_

1	CNS-Active	cns-active	JJ	_	2	attr	_	_
2	Drugs	drug	NNS	_	0	root	_	_
3	drug1	drug0	:	_	2	p	_	_
4	An	an	DT	_	6	det	_	_
5	additive	additive	JJ	_	6	attr	_	_
6	effect	effect	NN	_	11	dep	_	_
7	on	on	IN	_	9	case	_	_
8	psychomotor	psychomotor	NN	_	9	com	_	_
9	performance	performance	NN	_	6	ppmod	_	_
10	was	be	VBD	_	11	aux	_	_
11	seen	see	VBN	_	2	acl	_	_
12	with	with	IN	_	13	case	_	_
13	coadministration	coadministration	NN	_	11	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	and	and	CC	_	13	cc	_	_
17	drug3	drug0	NN	_	19	attr	_	_
18	0.70	0	CD	_	19	num	_	_
19	g/kg	g/kg	NN	_	13	conj	_	_
20	for	for	IN	_	24	case	_	_
21	up	up	RB	_	23	adv	_	_
22	to	to	TO	_	23	attr	_	_
23	4	0	CD	_	24	num	_	_
24	hours	hour	NNS	_	19	ppmod	_	_
25	after	after	IN	_	27	case	_	_
26	drug4	drug0	NN	_	27	com	_	_
27	administration	administration	NN	_	24	ppmod	_	_
28	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Coadministration	coadministration	NN	_	19	dep	_	_
4	of	of	IN	_	6	case	_	_
5	single	single	JJ	_	6	attr	_	_
6	doses	dose	NNS	_	3	ppmod	_	_
7	of	of	IN	_	10	case	_	_
8	drug2	drug0	NN	_	10	attr	_	_
9	3	0	CD	_	10	num	_	_
10	mg	mg	NN	_	6	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug3	drug0	NN	_	14	attr	_	_
13	20	0	CD	_	14	num	_	_
14	mg	mg	NN	_	10	conj	_	_
15	daily	daily	JJ	_	10	attr	_	_
16	for	for	IN	_	18	case	_	_
17	7	0	CD	_	18	num	_	_
18	days	day	NNS	_	15	ppmod	_	_
19	produced	produce	VBD	_	1	acl	_	_
20	no	no	DT	_	24	det	_	_
21	pharmacokinetic	pharmacokinetic	JJ	_	24	attr	_	_
22	or	or	CC	_	21	cc	_	_
23	pharmacodynamic	pharmacodynamic	JJ	_	21	conj	_	_
24	interaction	interaction	NN	_	19	obj	_	_
25	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Coadministration	coadministration	NN	_	17	dep	_	_
4	of	of	IN	_	6	case	_	_
5	single	single	JJ	_	6	attr	_	_
6	doses	dose	NNS	_	3	ppmod	_	_
7	of	of	IN	_	10	case	_	_
8	drug2	drug0	NN	_	10	attr	_	_
9	3	0	CD	_	10	num	_	_
10	mg	mg	NN	_	6	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug3	drug0	NN	_	14	attr	_	_
13	2	0	CD	_	14	num	_	_
14	mg	mg	NN	_	10	conj	_	_
15	did	do	VBD	_	17	aux	_	_
16	not	not	RB	_	17	neg	_	_
17	have	have	VB	_	1	acl	_	_
18	clinically	clinically	RB	_	19	adv	_	_
19	relevant	relevant	JJ	_	20	attr	_	_
20	effects	effect	NNS	_	17	obj	_	_
21	on	on	IN	_	23	case	_	_
22	the	the	DT	_	23	det	_	_
23	pharmacodynamics	pharmacodynamics	NNS	_	17	ppmod	_	_
24	or	or	CC	_	23	cc	_	_
25	pharmacokinetics	pharmacokinetics	NNS	_	23	conj	_	_
26	of	of	IN	_	28	case	_	_
27	either	either	DT	_	28	det	_	_
28	drug	drug	NN	_	23	ppmod	_	_
29	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Coadministration	coadministration	NN	_	12	dep	_	_
4	of	of	IN	_	7	case	_	_
5	drug2	drug0	NN	_	7	attr	_	_
6	3	0	CD	_	7	num	_	_
7	mg	mg	NN	_	3	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug3	drug0	NN	_	11	attr	_	_
10	10	0	CD	_	11	num	_	_
11	mg	mg	NN	_	7	conj	_	_
12	produced	produce	VBD	_	1	acl	_	_
13	a	a	DT	_	14	det	_	_
14	decrease	decrease	NN	_	12	obj	_	_
15	in	in	IN	_	17	case	_	_
16	DSST	dsst	NN	_	17	com	_	_
17	scores	score	NNS	_	14	ppmod	_	_
18	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	interaction	interaction	NN	_	3	dep	_	_
3	was	be	VBD	_	0	root	_	_
4	pharmacodynamic	pharmacodynamic	JJ	_	3	dep	_	_
5	;	;	:	_	3	p	_	_

1	there	there	EX	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	no	no	DT	_	4	det	_	_
4	alteration	alteration	NN	_	2	obj	_	_
5	in	in	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	pharmacokinetics	pharmacokinetics	NNS	_	4	ppmod	_	_
8	of	of	IN	_	10	case	_	_
9	either	either	DT	_	10	det	_	_
10	drug	drug	NN	_	7	ppmod	_	_
11	.	.	.	_	2	p	_	_

1	Drugs	drug	NNS	_	9	dep	_	_
2	That	that	WDT	_	3	dep	_	_
3	Inhibit	inhibit	VBP	_	1	relcl	_	_
4	CYP3A4	cyp0a0	NN	_	8	attr	_	_
5	(	-lrb-	-LRB-	_	8	p	_	_
6	drug1	drug0	NN	_	8	attr	_	_
7	)	-rrb-	-RRB-	_	8	p	_	_
8	CYP3A4	cyp0a0	NN	_	3	obj	_	_
9	is	be	VBZ	_	0	root	_	_
10	a	a	DT	_	13	det	_	_
11	major	major	JJ	_	13	attr	_	_
12	metabolic	metabolic	JJ	_	13	attr	_	_
13	pathway	pathway	NN	_	9	obj	_	_
14	for	for	IN	_	15	case	_	_
15	elimination	elimination	NN	_	13	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	.	.	.	_	9	p	_	_

1	The	the	DT	_	2	det	_	_
2	AUC	auc	NN	_	6	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	was	be	VBD	_	6	aux	_	_
6	increased	increase	VBN	_	0	root	_	_
7	2.2-fold	0-fold	RB	_	6	adv	_	_
8	by	by	IN	_	9	case	_	_
9	coadministration	coadministration	NN	_	6	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	,	,	,	_	11	p	_	_
13	a	a	DT	_	15	det	_	_
14	potent	potent	JJ	_	15	attr	_	_
15	inhibitor	inhibitor	NN	_	11	appo	_	_
16	of	of	IN	_	17	case	_	_
17	CYP3A4	cyp0a0	NN	_	15	ppmod	_	_
18	,	,	,	_	15	p	_	_
19	400	0	CD	_	20	num	_	_
20	mg	mg	NN	_	15	appo	_	_
21	daily	daily	JJ	_	20	attr	_	_
22	for	for	IN	_	24	case	_	_
23	5	0	CD	_	24	num	_	_
24	days	day	NNS	_	21	ppmod	_	_
25	.	.	.	_	6	p	_	_

1	Cmax	cmax	NN	_	5	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	t1/2	t0	NN	_	1	conj	_	_
4	were	be	VBD	_	5	aux	_	_
5	increased	increase	VBN	_	0	root	_	_
6	1.4-fold	0-fold	RB	_	5	adv	_	_
7	and	and	CC	_	6	cc	_	_
8	1.3-fold	0-fold	RB	_	6	conj	_	_
9	,	,	,	_	5	p	_	_
10	respectively	respectively	RB	_	5	adv	_	_
11	.	.	.	_	5	p	_	_

1	Other	other	JJ	_	3	attr	_	_
2	strong	strong	JJ	_	3	attr	_	_
3	inhibitors	inhibitor	NNS	_	23	dep	_	_
4	of	of	IN	_	5	case	_	_
5	CYP3A4	cyp0a0	NN	_	3	ppmod	_	_
6	(	-lrb-	-LRB-	_	9	p	_	_
7	e.g.	e.g.	FW	_	9	ppmod	_	_
8	,	,	,	_	9	p	_	_
9	drug1	drug0	NN	_	3	prn	_	_
10	,	,	,	_	9	p	_	_
11	drug2	drug0	NN	_	9	appo	_	_
12	,	,	,	_	9	p	_	_
13	drug3	drug0	NN	_	9	appo	_	_
14	,	,	,	_	9	p	_	_
15	drug4	drug0	NN	_	9	appo	_	_
16	,	,	,	_	9	p	_	_
17	drug5	drug0	NN	_	9	appo	_	_
18	,	,	,	_	9	p	_	_
19	drug6	drug0	NN	_	9	appo	_	_
20	)	-rrb-	-RRB-	_	9	p	_	_
21	would	would	MD	_	23	modal	_	_
22	be	be	VB	_	23	aux	_	_
23	expected	expect	VBN	_	0	root	_	_
24	to	to	TO	_	25	aux	_	_
25	behave	behave	VBP	_	23	comp	_	_
26	similarly	similarly	RB	_	25	adv	_	_
27	.	.	.	_	23	p	_	_

1	Drugs	drug	NNS	_	12	dep	_	_
2	That	that	WDT	_	3	dep	_	_
3	Induce	induce	VBP	_	1	relcl	_	_
4	CYP3A4	cyp0a0	NN	_	8	advnp	_	_
5	(	-lrb-	-LRB-	_	8	p	_	_
6	drug1	drug0	NN	_	8	advnp	_	_
7	)	-rrb-	-RRB-	_	8	p	_	_
8	Racemic	racemic	JJ	_	10	attr	_	_
9	drug2	drug0	NN	_	10	com	_	_
10	exposure	exposure	NN	_	3	obj	_	_
11	was	be	VBD	_	12	aux	_	_
12	decreased	decrease	VBN	_	0	root	_	_
13	80	0	CD	_	12	obj	_	_
14	%	%	NN	_	13	meta	_	_
15	by	by	IN	_	18	case	_	_
16	concomitant	concomitant	JJ	_	18	attr	_	_
17	useof	useof	NN	_	18	com	_	_
18	drug3	drug0	NN	_	12	ppmod	_	_
19	,	,	,	_	18	p	_	_
20	a	a	DT	_	22	det	_	_
21	potent	potent	JJ	_	22	attr	_	_
22	inducer	inducer	NN	_	18	appo	_	_
23	of	of	IN	_	24	case	_	_
24	CYP3A4	cyp0a0	NN	_	22	ppmod	_	_
25	.	.	.	_	12	p	_	_

1	A	a	DT	_	3	det	_	_
2	similar	similar	JJ	_	3	attr	_	_
3	effect	effect	NN	_	6	dep	_	_
4	would	would	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	expected	expect	VBN	_	0	root	_	_
7	with	with	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	.	.	.	_	6	p	_	_

1	Drugs	drug	NNS	_	11	dep	_	_
2	Highly	highly	RB	_	3	adv	_	_
3	Bound	bind	VBN	_	1	acl	_	_
4	To	to	TO	_	7	aux	_	_
5	Plasma	plasma	NN	_	7	com	_	_
6	Protein	protein	NN	_	7	com	_	_
7	drug1	drug0	NN	_	3	ppmod	_	_
8	is	be	VBZ	_	11	aux	_	_
9	not	not	RB	_	11	neg	_	_
10	highly	highly	RB	_	11	adv	_	_
11	bound	bind	VBN	_	0	root	_	_
12	to	to	TO	_	14	aux	_	_
13	plasma	plasma	NN	_	14	com	_	_
14	proteins	protein	NNS	_	11	ppmod	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	52-59	0	CD	_	11	num	_	_
17	%	%	NN	_	16	meta	_	_
18	bound	bind	VBD	_	16	acl	_	_
19	)	-rrb-	-RRB-	_	16	p	_	_
20	;	;	:	_	11	p	_	_

1	therefore	therefore	RB	_	9	adv	_	_
2	,	,	,	_	9	p	_	_
3	the	the	DT	_	4	det	_	_
4	disposition	disposition	NN	_	9	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	is	be	VBZ	_	9	aux	_	_
8	not	not	RB	_	9	neg	_	_
9	expected	expect	VBN	_	0	root	_	_
10	to	to	TO	_	11	aux	_	_
11	be	be	VB	_	9	comp	_	_
12	sensitive	sensitive	JJ	_	11	dep	_	_
13	to	to	TO	_	14	aux	_	_
14	alterations	alteration	NNS	_	12	ppmod	_	_
15	in	in	IN	_	17	case	_	_
16	protein	protein	NN	_	17	com	_	_
17	binding	binding	NN	_	14	ppmod	_	_
18	.	.	.	_	9	p	_	_

1	Administration	administration	NN	_	19	dep	_	_
2	of	of	IN	_	5	case	_	_
3	drug1	drug0	NN	_	5	attr	_	_
4	3	0	CD	_	5	num	_	_
5	mg	mg	NN	_	1	ppmod	_	_
6	to	to	TO	_	8	aux	_	_
7	a	a	DT	_	8	det	_	_
8	patient	patient	NN	_	1	ppmod	_	_
9	taking	take	VBG	_	8	acl	_	_
10	another	another	DT	_	11	det	_	_
11	drug	drug	NN	_	9	obj	_	_
12	that	that	WDT	_	13	dep	_	_
13	is	be	VBZ	_	11	relcl	_	_
14	highly	highly	RB	_	15	adv	_	_
15	protein-bound	protein-bound	JJ	_	13	dep	_	_
16	would	would	MD	_	19	modal	_	_
17	not	not	RB	_	19	neg	_	_
18	be	be	VB	_	19	aux	_	_
19	expected	expect	VBN	_	0	root	_	_
20	to	to	TO	_	21	aux	_	_
21	cause	cause	VB	_	19	comp	_	_
22	an	an	DT	_	23	det	_	_
23	alteration	alteration	NN	_	21	obj	_	_
24	in	in	IN	_	27	case	_	_
25	the	the	DT	_	27	det	_	_
26	free	free	JJ	_	27	attr	_	_
27	concentration	concentration	NN	_	23	ppmod	_	_
28	of	of	IN	_	30	case	_	_
29	either	either	DT	_	30	det	_	_
30	drug	drug	NN	_	27	ppmod	_	_
31	.	.	.	_	19	p	_	_

1	Drugs	drug	NNS	_	17	dep	_	_
2	With	with	IN	_	7	case	_	_
3	A	a	DT	_	7	det	_	_
4	Narrow	narrow	JJ	_	7	attr	_	_
5	Therapeutic	therapeutic	JJ	_	7	attr	_	_
6	Index	index	NN	_	7	com	_	_
7	drug1	drug0	NN	_	1	ppmod	_	_
8	A	a	DT	_	10	det	_	_
9	single	single	JJ	_	10	attr	_	_
10	dose	dose	NN	_	1	appo	_	_
11	of	of	IN	_	14	case	_	_
12	drug2	drug0	NN	_	14	attr	_	_
13	3	0	CD	_	14	num	_	_
14	mg	mg	NN	_	10	ppmod	_	_
15	did	do	VBD	_	17	aux	_	_
16	not	not	RB	_	17	neg	_	_
17	affect	affect	VB	_	0	root	_	_
18	the	the	DT	_	19	det	_	_
19	pharmacokinetics	pharmacokinetics	NNS	_	17	obj	_	_
20	of	of	IN	_	21	case	_	_
21	drug3	drug0	NN	_	19	ppmod	_	_
22	measured	measure	VBN	_	21	acl	_	_
23	at	at	IN	_	25	case	_	_
24	steady	steady	JJ	_	25	attr	_	_
25	state	state	NN	_	22	ppmod	_	_
26	following	follow	VBG	_	27	adv	_	_
27	dosing	dosing	NN	_	22	ppmod	_	_
28	of	of	IN	_	30	case	_	_
29	0.5	0	CD	_	30	num	_	_
30	mg	mg	NN	_	27	ppmod	_	_
31	twice	twice	RB	_	32	adv	_	_
32	daily	daily	JJ	_	30	attr	_	_
33	for	for	IN	_	35	case	_	_
34	one	#crd#	CD	_	35	num	_	_
35	day	day	NN	_	32	ppmod	_	_
36	and	and	CC	_	30	cc	_	_
37	0.25	0	CD	_	38	num	_	_
38	mg	mg	NN	_	30	conj	_	_
39	daily	daily	JJ	_	38	attr	_	_
40	for	for	IN	_	44	case	_	_
41	the	the	DT	_	44	det	_	_
42	next	next	JJ	_	44	attr	_	_
43	6	0	CD	_	44	num	_	_
44	days	day	NNS	_	39	ppmod	_	_
45	.	.	.	_	17	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	5	attr	_	_
4	3	0	CD	_	5	num	_	_
5	mg	mg	NN	_	13	dep	_	_
6	administered	administer	VBN	_	5	acl	_	_
7	daily	daily	RB	_	6	adv	_	_
8	for	for	IN	_	10	case	_	_
9	5	0	CD	_	10	num	_	_
10	days	day	NNS	_	6	ppmod	_	_
11	did	do	VBD	_	13	aux	_	_
12	not	not	RB	_	13	neg	_	_
13	affect	affect	VB	_	1	acl	_	_
14	the	the	DT	_	15	det	_	_
15	pharmacokinetics	pharmacokinetics	NNS	_	13	obj	_	_
16	of	of	IN	_	17	case	_	_
17	drug3	drug0	NN	_	15	ppmod	_	_
18	-	-	:	_	17	p	_	_
19	or	or	CC	_	17	cc	_	_
20	drug4	drug0	NN	_	17	conj	_	_
21	,	,	,	_	13	p	_	_
22	nor	nor	CC	_	13	cc	_	_
23	were	be	VBD	_	13	conj	_	_
24	there	there	RB	_	23	adv	_	_
25	any	any	DT	_	26	det	_	_
26	changes	change	NNS	_	23	obj	_	_
27	in	in	IN	_	30	case	_	_
28	the	the	DT	_	30	det	_	_
29	pharmacodynamic	pharmacodynamic	JJ	_	30	attr	_	_
30	profile	profile	NN	_	26	ppmod	_	_
31	(	-lrb-	-LRB-	_	33	p	_	_
32	prothrombin	prothrombin	NN	_	33	com	_	_
33	time	time	NN	_	30	prn	_	_
34	)	-rrb-	-RRB-	_	33	p	_	_
35	following	follow	VBG	_	41	adv	_	_
36	a	a	DT	_	41	det	_	_
37	single	single	JJ	_	41	attr	_	_
38	25	0	CD	_	41	num	_	_
39	mg	mg	NN	_	41	attr	_	_
40	oral	oral	JJ	_	41	attr	_	_
41	dose	dose	NN	_	26	ppmod	_	_
42	of	of	IN	_	43	case	_	_
43	drug5	drug0	NN	_	41	ppmod	_	_

1	.	.	.	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	Elevated	elevated	JJ	_	3	attr	_	_
2	plasma	plasma	NN	_	3	com	_	_
3	levels	level	NNS	_	8	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	have	have	VBP	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	reported	report	VBN	_	0	root	_	_
9	with	with	IN	_	12	case	_	_
10	concomitant	concomitant	JJ	_	12	attr	_	_
11	drug2	drug0	NN	_	12	com	_	_
12	use	use	NN	_	8	ppmod	_	_
13	.	.	.	_	8	p	_	_

1	There	there	EX	_	3	dep	_	_
2	have	have	VBP	_	3	aux	_	_
3	been	be	VBN	_	0	root	_	_
4	reports	report	NNS	_	3	obj	_	_
5	of	of	IN	_	9	case	_	_
6	drug1	drug0	JJ	_	9	attr	_	_
7	-related	-related	JJ	_	9	attr	_	_
8	side	side	JJ	_	9	attr	_	_
9	effects	effect	NNS	_	4	ppmod	_	_
10	in	in	IN	_	11	case	_	_
11	patients	patient	NNS	_	9	ppmod	_	_
12	on	on	IN	_	14	case	_	_
13	concomitant	concomitant	JJ	_	14	attr	_	_
14	therapy	therapy	NN	_	11	ppmod	_	_
15	with	with	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	drug3	drug0	NN	_	16	conj	_	_
19	.	.	.	_	3	p	_	_

1	Therefore	therefore	RB	_	10	adv	_	_
2	,	,	,	_	10	p	_	_
3	monitoring	monitoring	NN	_	10	dep	_	_
4	of	of	IN	_	7	case	_	_
5	drug1	drug0	NN	_	7	com	_	_
6	plasma	plasma	NN	_	7	com	_	_
7	levels	level	NNS	_	3	ppmod	_	_
8	should	should	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	considered	consider	VBN	_	0	root	_	_
11	and	and	CC	_	10	cc	_	_
12	dosage	dosage	NN	_	15	dep	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	adjusted	adjust	VBN	_	10	conj	_	_
16	as	as	IN	_	17	case	_	_
17	required	require	VBN	_	15	ppmod	_	_
18	.	.	.	_	10	p	_	_

1	Elevated	elevated	JJ	_	3	attr	_	_
2	serum	serum	NN	_	3	com	_	_
3	levels	level	NNS	_	8	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	have	have	VBP	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	reported	report	VBN	_	0	root	_	_
9	with	with	IN	_	11	case	_	_
10	concomitant	concomitant	JJ	_	11	attr	_	_
11	use	use	NN	_	8	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	with	with	IN	_	15	case	_	_
15	drug3	drug0	NN	_	11	ppmod	_	_
16	.	.	.	_	8	p	_	_

1	Therefore	therefore	RB	_	8	adv	_	_
2	,	,	,	_	8	p	_	_
3	drug1	drug0	NN	_	5	com	_	_
4	serum	serum	NN	_	5	com	_	_
5	levels	level	NNS	_	8	dep	_	_
6	should	should	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	monitored	monitor	VBN	_	0	root	_	_
9	and	and	CC	_	8	cc	_	_
10	appropriate	appropriate	JJ	_	13	attr	_	_
11	drug2	drug0	NN	_	13	com	_	_
12	dosage	dosage	NN	_	13	com	_	_
13	adjustments	adjustment	NNS	_	14	dep	_	_
14	made	make	VBD	_	8	conj	_	_
15	when	when	WRB	_	19	adv	_	_
16	these	these	DT	_	17	det	_	_
17	drugs	drug	NNS	_	19	dep	_	_
18	are	be	VBP	_	19	aux	_	_
19	used	use	VBN	_	14	comp	_	_
20	concomitantly	concomitantly	RB	_	19	adv	_	_
21	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	7	dep	_	_
2	,	,	,	_	1	p	_	_
3	including	include	VBG	_	4	adv	_	_
4	drug2	drug0	NN	_	1	ppmod	_	_
5	,	,	,	_	1	p	_	_
6	may	may	MD	_	7	modal	_	_
7	enhance	enhance	VB	_	0	root	_	_
8	the	the	DT	_	9	det	_	_
9	effects	effect	NNS	_	7	obj	_	_
10	of	of	IN	_	12	case	_	_
11	oral	oral	JJ	_	12	attr	_	_
12	drug3	drug0	NN	_	9	ppmod	_	_
13	,	,	,	_	9	p	_	_
14	including	include	VBG	_	15	adv	_	_
15	drug4	drug0	NN	_	9	ppmod	_	_
16	or	or	CC	_	15	cc	_	_
17	its	its	PRP$	_	18	poss	_	_
18	derivatives	derivative	NNS	_	15	conj	_	_
19	or	or	CC	_	18	cc	_	_
20	similar	similar	JJ	_	21	attr	_	_
21	agents	agent	NNS	_	18	conj	_	_
22	.	.	.	_	7	p	_	_

1	When	when	WRB	_	5	adv	_	_
2	these	these	DT	_	3	det	_	_
3	products	product	NNS	_	5	dep	_	_
4	are	be	VBP	_	5	aux	_	_
5	administered	administer	VBN	_	18	advcl	_	_
6	concomitantly	concomitantly	RB	_	5	adv	_	_
7	,	,	,	_	18	p	_	_
8	prothrombin	prothrombin	NN	_	9	com	_	_
9	time	time	NN	_	18	dep	_	_
10	or	or	CC	_	9	cc	_	_
11	other	other	JJ	_	14	attr	_	_
12	suitable	suitable	JJ	_	14	attr	_	_
13	coagulation	coagulation	NN	_	14	com	_	_
14	tests	test	NNS	_	9	conj	_	_
15	should	should	MD	_	18	modal	_	_
16	be	be	VB	_	18	aux	_	_
17	closely	closely	RB	_	18	adv	_	_
18	monitored	monitor	VBN	_	0	root	_	_
19	.	.	.	_	18	p	_	_

1	The	the	DT	_	3	det	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	administration	administration	NN	_	20	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	including	include	VBG	_	7	adv	_	_
7	drug2	drug0	NN	_	3	ppmod	_	_
8	with	with	IN	_	9	case	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_
10	(	-lrb-	-LRB-	_	12	p	_	_
11	a	a	DT	_	12	det	_	_
12	drug4	drug0	NN	_	9	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	has	have	VBZ	_	20	aux	_	_
15	,	,	,	_	20	p	_	_
16	on	on	IN	_	18	case	_	_
17	rare	rare	JJ	_	18	attr	_	_
18	occasions	occasion	NNS	_	20	ppmod	_	_
19	,	,	,	_	20	p	_	_
20	resulted	result	VBD	_	0	root	_	_
21	in	in	IN	_	23	case	_	_
22	severe	severe	JJ	_	23	attr	_	_
23	hypoglycemia	hypoglycemia	NN	_	20	ppmod	_	_
24	.	.	.	_	20	p	_	_

1	Therefore	therefore	RB	_	8	adv	_	_
2	,	,	,	_	8	p	_	_
3	monitoring	monitoring	NN	_	8	dep	_	_
4	of	of	IN	_	6	case	_	_
5	blood	blood	NN	_	6	com	_	_
6	glucose	glucose	NN	_	3	ppmod	_	_
7	is	be	VBZ	_	8	aux	_	_
8	recommended	recommend	VBN	_	0	root	_	_
9	when	when	WRB	_	12	adv	_	_
10	these	these	DT	_	11	det	_	_
11	agents	agent	NNS	_	12	dep	_	_
12	are	be	VBP	_	8	comp	_	_
13	co-administered	co-administered	NN	_	12	obj	_	_
14	.	.	.	_	8	p	_	_

1	Diminished	diminish	VBN	_	3	attr	_	_
2	urinary	urinary	JJ	_	3	attr	_	_
3	excretion	excretion	NN	_	8	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	has	have	VBZ	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	reported	report	VBN	_	0	root	_	_
9	during	during	IN	_	12	case	_	_
10	the	the	DT	_	12	det	_	_
11	concomitant	concomitant	JJ	_	12	attr	_	_
12	administration	administration	NN	_	8	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	drug3	drug0	NN	_	14	conj	_	_
17	.	.	.	_	8	p	_	_

1	The	the	DT	_	3	det	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	use	use	NN	_	8	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	is	be	VBZ	_	8	aux	_	_
7	not	not	RB	_	8	neg	_	_
8	recommended	recommend	VBN	_	0	root	_	_
9	since	since	IN	_	12	mark	_	_
10	drug2	drug0	NN	_	12	dep	_	_
11	may	may	MD	_	12	modal	_	_
12	antagonize	antagonize	VB	_	8	comp	_	_
13	the	the	DT	_	15	det	_	_
14	antibacterial	antibacterial	JJ	_	15	attr	_	_
15	effect	effect	NN	_	12	obj	_	_
16	of	of	IN	_	17	case	_	_
17	drug3	drug0	NN	_	15	ppmod	_	_
18	in	in	IN	_	21	case	_	_
19	the	the	DT	_	21	det	_	_
20	urinary	urinary	JJ	_	21	attr	_	_
21	tract	tract	NN	_	15	ppmod	_	_
22	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	17	dep	_	_
2	,	,	,	_	1	p	_	_
3	or	or	CC	_	1	cc	_	_
4	other	other	JJ	_	5	attr	_	_
5	products	product	NNS	_	1	conj	_	_
6	containing	contain	VBG	_	1	acl	_	_
7	drug2	drug0	NN	_	6	obj	_	_
8	or	or	CC	_	7	cc	_	_
9	drug3	drug0	NN	_	7	conj	_	_
10	,	,	,	_	9	p	_	_
11	drug4	drug0	NN	_	9	conj	_	_
12	or	or	CC	_	11	cc	_	_
13	drug5	drug0	NN	_	9	conj	_	_
14	should	should	MD	_	17	modal	_	_
15	not	not	RB	_	17	neg	_	_
16	be	be	VB	_	17	aux	_	_
17	administered	administer	VBN	_	0	root	_	_
18	concomitantly	concomitantly	RB	_	17	adv	_	_
19	with	with	IN	_	17	ppmod	_	_
20	,	,	,	_	19	p	_	_
21	or	or	CC	_	19	cc	_	_
22	within	within	IN	_	24	case	_	_
23	2	0	CD	_	24	num	_	_
24	hours	hour	NNS	_	19	conj	_	_
25	of	of	IN	_	24	case	_	_
26	,	,	,	_	24	p	_	_
27	the	the	DT	_	28	det	_	_
28	administration	administration	NN	_	24	appo	_	_
29	of	of	IN	_	30	case	_	_
30	drug6	drug0	NN	_	28	ppmod	_	_
31	,	,	,	_	17	p	_	_
32	because	because	IN	_	35	mark	_	_
33	they	they	PRP	_	35	dep	_	_
34	may	may	MD	_	35	modal	_	_
35	interfere	interfere	VB	_	17	comp	_	_
36	with	with	IN	_	37	case	_	_
37	absorption	absorption	NN	_	35	ppmod	_	_
38	resulting	result	VBG	_	37	acl	_	_
39	in	in	IN	_	41	case	_	_
40	lower	low	JJR	_	41	attr	_	_
41	serum	serum	NN	_	38	ppmod	_	_
42	and	and	CC	_	41	cc	_	_
43	urine	urine	NN	_	44	com	_	_
44	levels	level	NNS	_	41	conj	_	_
45	of	of	IN	_	46	case	_	_
46	drug7	drug0	NN	_	41	ppmod	_	_
47	.	.	.	_	17	p	_	_

1	drug1	drug0	NN	_	6	attr	_	_
2	(	-lrb-	-LRB-	_	6	p	_	_
3	drug2	drug0	NN	_	6	attr	_	_
4	)	-rrb-	-RRB-	_	6	p	_	_
5	chewable/buffered	chewable/buffered	JJ	_	6	attr	_	_
6	tablets	tablet	NNS	_	17	dep	_	_
7	or	or	CC	_	6	cc	_	_
8	the	the	DT	_	10	det	_	_
9	pediatric	pediatric	JJ	_	10	attr	_	_
10	powder	powder	NN	_	6	conj	_	_
11	for	for	IN	_	13	case	_	_
12	oral	oral	JJ	_	13	attr	_	_
13	solution	solution	NN	_	6	ppmod	_	_
14	should	should	MD	_	17	modal	_	_
15	not	not	RB	_	17	neg	_	_
16	be	be	VB	_	17	aux	_	_
17	administered	administer	VBN	_	0	root	_	_
18	concomitantly	concomitantly	RB	_	17	adv	_	_
19	with	with	IN	_	17	ppmod	_	_
20	,	,	,	_	19	p	_	_
21	or	or	CC	_	19	cc	_	_
22	within	within	IN	_	24	case	_	_
23	2	0	CD	_	24	num	_	_
24	hours	hour	NNS	_	19	conj	_	_
25	of	of	IN	_	24	case	_	_
26	,	,	,	_	24	p	_	_
27	the	the	DT	_	28	det	_	_
28	administration	administration	NN	_	24	appo	_	_
29	of	of	IN	_	30	case	_	_
30	drug3	drug0	NN	_	28	ppmod	_	_
31	,	,	,	_	17	p	_	_
32	because	because	IN	_	36	mark	_	_
33	these	these	DT	_	34	det	_	_
34	products	product	NNS	_	36	dep	_	_
35	may	may	MD	_	36	modal	_	_
36	interfere	interfere	VB	_	17	comp	_	_
37	with	with	IN	_	38	case	_	_
38	absorption	absorption	NN	_	36	ppmod	_	_
39	resulting	result	VBG	_	38	acl	_	_
40	in	in	IN	_	42	case	_	_
41	lower	low	JJR	_	42	attr	_	_
42	serum	serum	NN	_	39	ppmod	_	_
43	and	and	CC	_	42	cc	_	_
44	urine	urine	NN	_	45	com	_	_
45	levels	level	NNS	_	42	conj	_	_
46	of	of	IN	_	47	case	_	_
47	drug4	drug0	NN	_	42	ppmod	_	_
48	.	.	.	_	17	p	_	_

1	Some	some	DT	_	2	det	_	_
2	drug1	drug0	NNS	_	6	dep	_	_
3	have	have	VBP	_	6	aux	_	_
4	also	also	RB	_	6	adv	_	_
5	been	be	VBN	_	6	aux	_	_
6	shown	show	VBN	_	0	root	_	_
7	to	to	TO	_	8	aux	_	_
8	interfere	interfere	VB	_	6	comp	_	_
9	with	with	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	metabolism	metabolism	NN	_	8	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	.	.	.	_	6	p	_	_

1	This	this	DT	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	lead	lead	VB	_	0	root	_	_
4	to	to	TO	_	6	aux	_	_
5	reduced	reduce	VBN	_	6	attr	_	_
6	clearance	clearance	NN	_	3	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	6	cc	_	_
10	a	a	DT	_	11	det	_	_
11	prolongation	prolongation	NN	_	6	conj	_	_
12	of	of	IN	_	15	case	_	_
13	its	its	PRP$	_	15	poss	_	_
14	plasma	plasma	NN	_	15	com	_	_
15	half-life	half-life	NN	_	11	ppmod	_	_
16	.	.	.	_	3	p	_	_

1	No	no	DT	_	5	det	_	_
2	pharmacokinetic-based	pharmacokinetic-based	JJ	_	5	attr	_	_
3	drug-drug	drug-drug	JJ	_	5	attr	_	_
4	interaction	interaction	NN	_	5	com	_	_
5	studies	study	NNS	_	8	dep	_	_
6	have	have	VBP	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	conducted	conduct	VBN	_	0	root	_	_
9	with	with	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	8	p	_	_

1	However	however	RB	_	42	adv	_	_
2	,	,	,	_	42	p	_	_
3	because	because	IN	_	5	mark	_	_
4	drug1	drug0	NN	_	5	dep	_	_
5	is	be	VBZ	_	42	advcl	_	_
6	a	a	DT	_	7	det	_	_
7	peptide	peptide	NN	_	5	obj	_	_
8	that	that	WDT	_	11	dep	_	_
9	is	be	VBZ	_	11	aux	_	_
10	primarily	primarily	RB	_	11	adv	_	_
11	degraded	degrade	VBN	_	7	relcl	_	_
12	by	by	IN	_	13	case	_	_
13	peptidase	peptidase	NN	_	11	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	not	not	RB	_	19	neg	_	_
16	by	by	IN	_	19	case	_	_
17	cytochrome	cytochrome	NN	_	18	com	_	_
18	P-450	p-0	NN	_	19	com	_	_
19	enzymes	enzyme	NNS	_	13	conj	_	_
20	,	,	,	_	5	p	_	_
21	and	and	CC	_	5	cc	_	_
22	the	the	DT	_	23	det	_	_
23	drug	drug	NN	_	24	dep	_	_
24	is	be	VBZ	_	5	conj	_	_
25	only	only	RB	_	24	adv	_	_
26	about	about	RB	_	27	adv	_	_
27	80	0	CD	_	24	obj	_	_
28	%	%	NN	_	27	meta	_	_
29	bound	bind	VBD	_	27	acl	_	_
30	to	to	TO	_	32	aux	_	_
31	plasma	plasma	NN	_	32	com	_	_
32	proteins	protein	NNS	_	29	ppmod	_	_
33	at	at	IN	_	35	case	_	_
34	4	0	CD	_	35	num	_	_
35	C	c	NN	_	29	ppmod	_	_
36	,	,	,	_	42	p	_	_
37	drug	drug	NN	_	38	com	_	_
38	interactions	interaction	NNS	_	42	dep	_	_
39	would	would	MD	_	42	modal	_	_
40	not	not	RB	_	42	neg	_	_
41	be	be	VB	_	42	aux	_	_
42	expected	expect	VBN	_	0	root	_	_
43	to	to	TO	_	44	aux	_	_
44	occur	occur	VB	_	42	comp	_	_
45	.	.	.	_	42	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	Reports	report	NNS	_	3	dep	_	_
3	suggest	suggest	VBP	_	0	root	_	_
4	that	that	IN	_	7	mark	_	_
5	drug2	drug0	NN	_	7	dep	_	_
6	may	may	MD	_	7	modal	_	_
7	diminish	diminish	VB	_	3	comp	_	_
8	the	the	DT	_	10	det	_	_
9	antihypertensive	antihypertensive	JJ	_	10	attr	_	_
10	effect	effect	NN	_	7	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	3	p	_	_

1	This	this	DT	_	2	det	_	_
2	interaction	interaction	NN	_	6	dep	_	_
3	should	should	MD	_	6	modal	_	_
4	be	be	VB	_	6	aux	_	_
5	given	give	VBN	_	6	lv	_	_
6	consideration	consideration	NN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	6	ppmod	_	_
9	taking	take	VBG	_	8	acl	_	_
10	drug1	drug0	NN	_	9	obj	_	_
11	concomitantly	concomitantly	RB	_	6	adv	_	_
12	with	with	IN	_	13	case	_	_
13	drug2	drug0	NN	_	6	ppmod	_	_
14	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	5	det	_	_
4	concomitant	concomitant	JJ	_	5	attr	_	_
5	administration	administration	NN	_	8	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	has	have	VBZ	_	1	acl	_	_
9	no	no	DT	_	11	det	_	_
10	apparent	apparent	JJ	_	11	attr	_	_
11	effect	effect	NN	_	8	obj	_	_
12	on	on	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	extent	extent	NN	_	8	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	absorption	absorption	NN	_	14	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug3	drug0	NN	_	16	ppmod	_	_
19	.	.	.	_	1	p	_	_

1	However	however	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	drug1	drug0	NN	_	5	dep	_	_
4	can	can	MD	_	5	modal	_	_
5	decrease	decrease	VB	_	0	root	_	_
6	the	the	DT	_	8	det	_	_
7	peak	peak	JJ	_	8	attr	_	_
8	concentration	concentration	NN	_	5	obj	_	_
9	reached	reach	VBN	_	8	acl	_	_
10	by	by	IN	_	11	case	_	_
11	15	0	CD	_	9	ppmod	_	_
12	%	%	NN	_	11	meta	_	_
13	to	to	TO	_	11	cc	_	_
14	20	0	CD	_	11	conj	_	_
15	%	%	NN	_	11	meta	_	_
16	but	but	CC	_	5	cc	_	_
17	have	have	VB	_	5	conj	_	_
18	no	no	DT	_	20	det	_	_
19	detectable	detectable	JJ	_	20	attr	_	_
20	effect	effect	NN	_	17	obj	_	_
21	on	on	IN	_	23	case	_	_
22	the	the	DT	_	23	det	_	_
23	time-to-peak	time-to-peak	NN	_	17	ppmod	_	_
24	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	When	when	WRB	_	6	adv	_	_
4	drug2	drug0	NN	_	6	dep	_	_
5	is	be	VBZ	_	6	aux	_	_
6	administered	administer	VBN	_	14	advcl	_	_
7	with	with	IN	_	8	case	_	_
8	drug3	drug0	NN	_	6	ppmod	_	_
9	,	,	,	_	14	p	_	_
10	its	its	PRP$	_	12	poss	_	_
11	protein	protein	NN	_	12	com	_	_
12	binding	binding	NN	_	14	dep	_	_
13	is	be	VBZ	_	14	aux	_	_
14	reduced	reduce	VBN	_	1	acl	_	_
15	,	,	,	_	14	p	_	_
16	although	although	IN	_	24	mark	_	_
17	the	the	DT	_	18	det	_	_
18	clearance	clearance	NN	_	24	dep	_	_
19	of	of	IN	_	21	case	_	_
20	free	free	JJ	_	21	attr	_	_
21	drug4	drug0	NNS	_	18	ppmod	_	_
22	is	be	VBZ	_	24	aux	_	_
23	not	not	RB	_	24	neg	_	_
24	altered	alter	VBN	_	14	comp	_	_
25	.	.	.	_	1	p	_	_

1	The	the	DT	_	3	det	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	significance	significance	NN	_	9	dep	_	_
4	of	of	IN	_	6	case	_	_
5	this	this	DT	_	6	det	_	_
6	interaction	interaction	NN	_	3	ppmod	_	_
7	is	be	VBZ	_	9	aux	_	_
8	not	not	RB	_	9	neg	_	_
9	known	know	VBN	_	0	root	_	_
10	;	;	:	_	9	p	_	_

1	however	however	RB	_	17	adv	_	_
2	,	,	,	_	17	p	_	_
3	as	as	IN	_	6	case	_	_
4	with	with	IN	_	6	case	_	_
5	other	other	JJ	_	6	attr	_	_
6	drug1	drug0	NN	_	17	ppmod	_	_
7	,	,	,	_	17	p	_	_
8	concomitant	concomitant	JJ	_	9	attr	_	_
9	administration	administration	NN	_	17	dep	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	drug3	drug0	NN	_	11	conj	_	_
14	is	be	VBZ	_	17	aux	_	_
15	not	not	RB	_	17	neg	_	_
16	generally	generally	RB	_	17	adv	_	_
17	recommended	recommend	VBN	_	0	root	_	_
18	because	because	IN	_	21	case	_	_
19	of	of	IN	_	21	case	_	_
20	the	the	DT	_	21	det	_	_
21	potential	potential	NN	_	17	ppmod	_	_
22	of	of	IN	_	25	case	_	_
23	increased	increase	VBN	_	25	attr	_	_
24	adverse	adverse	JJ	_	25	attr	_	_
25	effects	effect	NNS	_	21	ppmod	_	_
26	.	.	.	_	17	p	_	_

1	Cyclosporine	cyclosporine	NN	_	19	dep	_	_
2	,	,	,	_	1	p	_	_
3	Digoxin	digoxin	NN	_	1	appo	_	_
4	,	,	,	_	1	p	_	_
5	Methotrexate	methotrexate	NN	_	6	com	_	_
6	drug1	drug0	NN	_	1	appo	_	_
7	,	,	,	_	1	p	_	_
8	like	like	IN	_	10	case	_	_
9	other	other	JJ	_	10	attr	_	_
10	drug2	drug0	NN	_	19	ppmod	_	_
11	,	,	,	_	19	p	_	_
12	through	through	IN	_	13	case	_	_
13	effects	effect	NNS	_	19	ppmod	_	_
14	on	on	IN	_	16	case	_	_
15	renal	renal	JJ	_	16	attr	_	_
16	prostaglandins	prostaglandin	NNS	_	13	ppmod	_	_
17	,	,	,	_	19	p	_	_
18	may	may	MD	_	19	modal	_	_
19	cause	cause	VB	_	0	root	_	_
20	changes	change	NNS	_	19	obj	_	_
21	in	in	IN	_	23	case	_	_
22	the	the	DT	_	23	det	_	_
23	elimination	elimination	NN	_	20	ppmod	_	_
24	of	of	IN	_	26	case	_	_
25	these	these	DT	_	26	det	_	_
26	drugs	drug	NNS	_	23	ppmod	_	_
27	leading	lead	VBG	_	26	acl	_	_
28	to	to	TO	_	31	aux	_	_
29	elevated	elevated	JJ	_	31	attr	_	_
30	serum	serum	NN	_	31	com	_	_
31	levels	level	NNS	_	27	ppmod	_	_
32	of	of	IN	_	33	case	_	_
33	drug3	drug0	NN	_	31	ppmod	_	_
34	,	,	,	_	33	p	_	_
35	drug4	drug0	NN	_	33	conj	_	_
36	,	,	,	_	35	p	_	_
37	drug5	drug0	NN	_	33	conj	_	_
38	,	,	,	_	37	p	_	_
39	and	and	CC	_	37	cc	_	_
40	increased	increase	VBN	_	41	attr	_	_
41	toxicity	toxicity	NN	_	33	conj	_	_
42	.	.	.	_	19	p	_	_

1	Nephrotoxicity	nephrotoxicity	NN	_	8	dep	_	_
2	associated	associate	VBN	_	1	acl	_	_
3	with	with	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	may	may	MD	_	8	modal	_	_
6	also	also	RB	_	8	adv	_	_
7	be	be	VB	_	8	aux	_	_
8	enhanced	enhance	VBN	_	0	root	_	_
9	.	.	.	_	8	p	_	_

1	Patients	patient	NNS	_	26	dep	_	_
2	receiving	receive	VBG	_	1	acl	_	_
3	these	these	DT	_	4	det	_	_
4	drugs	drug	NNS	_	2	obj	_	_
5	who	who	WP	_	7	dep	_	_
6	are	be	VBP	_	7	aux	_	_
7	given	give	VBN	_	4	relcl	_	_
8	drug1	drug0	NN	_	7	obj	_	_
9	,	,	,	_	4	p	_	_
10	or	or	CC	_	4	cc	_	_
11	any	any	DT	_	13	det	_	_
12	other	other	JJ	_	13	attr	_	_
13	drug2	drug0	NNS	_	4	conj	_	_
14	,	,	,	_	1	p	_	_
15	and	and	CC	_	1	cc	_	_
16	particularly	particularly	RB	_	15	com	_	_
17	those	those	DT	_	18	det	_	_
18	patients	patient	NNS	_	1	conj	_	_
19	with	with	IN	_	22	case	_	_
20	altered	altered	JJ	_	22	attr	_	_
21	renal	renal	JJ	_	22	attr	_	_
22	function	function	NN	_	18	ppmod	_	_
23	,	,	,	_	18	p	_	_
24	should	should	MD	_	26	modal	_	_
25	be	be	VB	_	26	aux	_	_
26	observed	observe	VBN	_	0	root	_	_
27	for	for	IN	_	29	case	_	_
28	the	the	DT	_	29	det	_	_
29	development	development	NN	_	26	ppmod	_	_
30	of	of	IN	_	33	case	_	_
31	the	the	DT	_	33	det	_	_
32	specific	specific	JJ	_	33	attr	_	_
33	toxicities	toxicity	NNS	_	29	ppmod	_	_
34	of	of	IN	_	36	case	_	_
35	these	these	DT	_	36	det	_	_
36	drugs	drug	NNS	_	33	ppmod	_	_
37	.	.	.	_	26	p	_	_

1	drug1	drug0	NN	_	8	dep	_	_
2	:	:	:	_	1	p	_	_
3	Etodolac	etodolac	NN	_	1	appo	_	_
4	has	have	VBZ	_	8	lv	_	_
5	no	no	DT	_	8	det	_	_
6	apparent	apparent	JJ	_	8	attr	_	_
7	pharmacokinetic	pharmacokinetic	JJ	_	8	attr	_	_
8	interaction	interaction	NN	_	0	root	_	_
9	when	when	WRB	_	10	adv	_	_
10	administered	administer	VBN	_	8	comp	_	_
11	with	with	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	or	or	CC	_	12	cc	_	_
14	drug3	drug0	NN	_	12	conj	_	_
15	.	.	.	_	8	p	_	_

1	Nevertheless	nevertheless	RB	_	12	adv	_	_
2	,	,	,	_	12	p	_	_
3	clinical	clinical	JJ	_	4	attr	_	_
4	studies	study	NNS	_	12	dep	_	_
5	,	,	,	_	4	p	_	_
6	as	as	RB	_	7	com	_	_
7	well	well	RB	_	4	cc	_	_
8	as	as	IN	_	7	com	_	_
9	postmarketing	postmarketing	VBG	_	4	conj	_	_
10	observations	observation	NNS	_	9	obj	_	_
11	have	have	VBP	_	12	aux	_	_
12	shown	show	VBN	_	0	root	_	_
13	that	that	IN	_	16	mark	_	_
14	drug1	drug0	NN	_	16	dep	_	_
15	can	can	MD	_	16	modal	_	_
16	reduce	reduce	VB	_	12	comp	_	_
17	the	the	DT	_	19	det	_	_
18	natriuretic	natriuretic	JJ	_	19	attr	_	_
19	effect	effect	NN	_	16	obj	_	_
20	of	of	IN	_	21	case	_	_
21	drug2	drug0	NN	_	19	ppmod	_	_
22	and	and	CC	_	21	cc	_	_
23	drug3	drug0	NN	_	21	conj	_	_
24	in	in	IN	_	26	case	_	_
25	some	some	DT	_	26	det	_	_
26	patients	patient	NNS	_	19	ppmod	_	_
27	.	.	.	_	12	p	_	_

1	This	this	DT	_	2	det	_	_
2	response	response	NN	_	5	dep	_	_
3	has	have	VBZ	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	attributed	attribute	VBN	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	inhibition	inhibition	NN	_	5	ppmod	_	_
8	of	of	IN	_	11	case	_	_
9	renal	renal	JJ	_	11	attr	_	_
10	prostaglandin	prostaglandin	NN	_	11	com	_	_
11	synthesis	synthesis	NN	_	7	ppmod	_	_
12	.	.	.	_	5	p	_	_

1	During	during	IN	_	3	case	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	therapy	therapy	NN	_	11	ppmod	_	_
4	with	with	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	,	,	,	_	11	p	_	_
7	the	the	DT	_	8	det	_	_
8	patient	patient	NN	_	11	dep	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	observed	observe	VBN	_	0	root	_	_
12	closely	closely	RB	_	11	adv	_	_
13	for	for	IN	_	14	case	_	_
14	signs	sign	NNS	_	11	ppmod	_	_
15	of	of	IN	_	17	case	_	_
16	renal	renal	JJ	_	17	attr	_	_
17	failure	failure	NN	_	14	ppmod	_	_
18	,	,	,	_	11	p	_	_
19	as	as	RB	_	20	com	_	_
20	well	well	RB	_	23	cc	_	_
21	as	as	IN	_	20	com	_	_
22	to	to	TO	_	23	aux	_	_
23	assure	assure	VB	_	11	comp	_	_
24	diuretic	diuretic	JJ	_	25	attr	_	_
25	efficacy	efficacy	NN	_	23	obj	_	_
26	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	8	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	has	have	VBZ	_	8	lv	_	_
5	no	no	DT	_	8	det	_	_
6	apparent	apparent	JJ	_	8	attr	_	_
7	pharmacokinetic	pharmacokinetic	JJ	_	8	attr	_	_
8	interaction	interaction	NN	_	0	root	_	_
9	when	when	WRB	_	10	adv	_	_
10	administered	administer	VBN	_	8	comp	_	_
11	with	with	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	have	have	VBP	_	5	aux	_	_
5	produced	produce	VBN	_	0	root	_	_
6	an	an	DT	_	7	det	_	_
7	elevation	elevation	NN	_	5	obj	_	_
8	of	of	IN	_	11	case	_	_
9	plasma	plasma	NN	_	11	com	_	_
10	drug3	drug0	NN	_	11	com	_	_
11	levels	level	NNS	_	7	ppmod	_	_
12	and	and	CC	_	7	cc	_	_
13	a	a	DT	_	14	det	_	_
14	reduction	reduction	NN	_	7	conj	_	_
15	in	in	IN	_	18	case	_	_
16	renal	renal	JJ	_	18	attr	_	_
17	drug4	drug0	NN	_	18	com	_	_
18	clearance	clearance	NN	_	14	ppmod	_	_
19	.	.	.	_	5	p	_	_

1	The	the	DT	_	5	det	_	_
2	mean	mean	JJ	_	5	attr	_	_
3	minimum	minimum	JJ	_	5	attr	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	concentration	concentration	NN	_	6	dep	_	_
6	increased	increase	VBD	_	0	root	_	_
7	15	0	CD	_	6	obj	_	_
8	%	%	NN	_	7	meta	_	_
9	and	and	CC	_	6	cc	_	_
10	the	the	DT	_	12	det	_	_
11	renal	renal	JJ	_	12	attr	_	_
12	clearance	clearance	NN	_	14	dep	_	_
13	was	be	VBD	_	14	aux	_	_
14	decreased	decrease	VBN	_	6	conj	_	_
15	by	by	IN	_	17	case	_	_
16	approximately	approximately	RB	_	17	adv	_	_
17	20	0	CD	_	14	ppmod	_	_
18	%	%	NN	_	17	meta	_	_
19	.	.	.	_	6	p	_	_

1	These	these	DT	_	2	det	_	_
2	effects	effect	NNS	_	5	dep	_	_
3	have	have	VBP	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	attributed	attribute	VBN	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	inhibition	inhibition	NN	_	5	ppmod	_	_
8	of	of	IN	_	11	case	_	_
9	renal	renal	JJ	_	11	attr	_	_
10	prostaglandin	prostaglandin	NN	_	11	com	_	_
11	synthesis	synthesis	NN	_	7	ppmod	_	_
12	by	by	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	drug1	drug0	NN	_	7	ppmod	_	_
15	.	.	.	_	5	p	_	_

1	Thus	thus	RB	_	14	adv	_	_
2	,	,	,	_	14	p	_	_
3	when	when	WRB	_	8	adv	_	_
4	drug1	drug0	NN	_	8	dep	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	are	be	VBP	_	8	aux	_	_
8	administered	administer	VBN	_	14	advcl	_	_
9	concurrently	concurrently	RB	_	8	adv	_	_
10	,	,	,	_	14	p	_	_
11	subjects	subject	NNS	_	14	dep	_	_
12	should	should	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	observed	observe	VBN	_	0	root	_	_
15	carefully	carefully	RB	_	14	adv	_	_
16	for	for	IN	_	17	case	_	_
17	signs	sign	NNS	_	14	ppmod	_	_
18	of	of	IN	_	20	case	_	_
19	drug3	drug0	NN	_	20	com	_	_
20	toxicity	toxicity	NN	_	17	ppmod	_	_
21	.	.	.	_	14	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	4	dep	_	_
4	causes	cause	VBZ	_	1	acl	_	_
5	increase	increase	NN	_	4	obj	_	_
6	(	-lrb-	-LRB-	_	9	p	_	_
7	by	by	IN	_	9	case	_	_
8	about	about	RB	_	9	adv	_	_
9	80	0	CD	_	5	num	_	_
10	%	%	NN	_	9	meta	_	_
11	)	-rrb-	-RRB-	_	9	p	_	_
12	in	in	IN	_	15	case	_	_
13	the	the	DT	_	15	det	_	_
14	free	free	JJ	_	15	attr	_	_
15	fraction	fraction	NN	_	4	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	drug3	drug0	NN	_	15	ppmod	_	_
18	.	.	.	_	1	p	_	_

1	Although	although	IN	_	8	mark	_	_
2	in	in	FW	_	3	adv	_	_
3	vivo	vivo	FW	_	4	attr	_	_
4	studies	study	NNS	_	8	dep	_	_
5	have	have	VBP	_	8	aux	_	_
6	not	not	RB	_	8	neg	_	_
7	been	be	VBN	_	8	aux	_	_
8	done	do	VBN	_	24	advcl	_	_
9	to	to	TO	_	10	aux	_	_
10	see	see	VB	_	8	comp	_	_
11	if	if	IN	_	15	mark	_	_
12	drug1	drug0	NN	_	13	com	_	_
13	clearance	clearance	NN	_	15	dep	_	_
14	is	be	VBZ	_	15	aux	_	_
15	changed	change	VBN	_	10	comp	_	_
16	by	by	IN	_	17	case	_	_
17	coadministration	coadministration	NN	_	15	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug2	drug0	NNS	_	17	ppmod	_	_
20	,	,	,	_	24	p	_	_
21	it	it	PRP	_	24	dep	_	_
22	is	be	VBZ	_	24	aux	_	_
23	not	not	RB	_	24	neg	_	_
24	recommended	recommend	VBN	_	0	root	_	_
25	that	that	IN	_	28	mark	_	_
26	they	they	PRP	_	28	dep	_	_
27	be	be	VB	_	28	aux	_	_
28	coadministered	coadministered	VBN	_	24	comp	_	_
29	.	.	.	_	24	p	_	_

1	drug1	drug0	NN	_	8	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	has	have	VBZ	_	8	lv	_	_
5	no	no	DT	_	8	det	_	_
6	apparent	apparent	JJ	_	8	attr	_	_
7	pharmacokinetic	pharmacokinetic	JJ	_	8	attr	_	_
8	interaction	interaction	NN	_	0	root	_	_
9	when	when	WRB	_	10	adv	_	_
10	administered	administer	VBN	_	8	comp	_	_
11	with	with	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	effects	effect	NNS	_	12	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	on	on	IN	_	11	case	_	_
10	GI	gi	JJ	_	11	attr	_	_
11	bleeding	bleeding	JJ	_	4	ppmod	_	_
12	are	be	VBP	_	1	acl	_	_
13	synergistic	synergistic	JJ	_	12	dep	_	_
14	,	,	,	_	12	p	_	_
15	such	such	JJ	_	24	dep	_	_
16	that	that	IN	_	24	mark	_	_
17	users	user	NNS	_	24	dep	_	_
18	of	of	IN	_	20	case	_	_
19	both	both	DT	_	20	det	_	_
20	drugs	drug	NNS	_	17	ppmod	_	_
21	together	together	RB	_	24	adv	_	_
22	have	have	VBP	_	24	lv	_	_
23	a	a	DT	_	24	det	_	_
24	risk	risk	NN	_	12	comp	_	_
25	of	of	IN	_	28	case	_	_
26	serious	serious	JJ	_	28	attr	_	_
27	GI	gi	JJ	_	28	attr	_	_
28	bleeding	bleeding	JJ	_	24	ppmod	_	_
29	higher	high	JJR	_	24	attr	_	_
30	than	than	IN	_	31	case	_	_
31	that	that	DT	_	29	ppmod	_	_
32	of	of	IN	_	33	case	_	_
33	users	user	NNS	_	31	ppmod	_	_
34	of	of	IN	_	36	case	_	_
35	either	either	DT	_	36	det	_	_
36	drug	drug	NN	_	33	ppmod	_	_
37	alone	alone	RB	_	36	adv	_	_
38	.	.	.	_	1	p	_	_

1	Short-term	short-term	JJ	_	3	attr	_	_
2	pharmacokinetic	pharmacokinetic	JJ	_	3	attr	_	_
3	studies	study	NNS	_	5	dep	_	_
4	have	have	VBP	_	5	aux	_	_
5	demonstrated	demonstrate	VBN	_	0	root	_	_
6	that	that	IN	_	19	mark	_	_
7	concomitant	concomitant	JJ	_	8	attr	_	_
8	administration	administration	NN	_	19	dep	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug2	drug0	NNS	_	10	conj	_	_
13	(	-lrb-	-LRB-	_	15	p	_	_
14	drug3	drug0	NN	_	15	com	_	_
15	capsules	capsule	NNS	_	12	prn	_	_
16	and	and	CC	_	15	cc	_	_
17	tablets	tablet	NNS	_	15	conj	_	_
18	)	-rrb-	-RRB-	_	15	p	_	_
19	results	result	VBZ	_	5	comp	_	_
20	in	in	IN	_	23	case	_	_
21	reduced	reduce	VBN	_	23	attr	_	_
22	protein	protein	NN	_	23	com	_	_
23	binding	binding	NN	_	19	ppmod	_	_
24	of	of	IN	_	25	case	_	_
25	drug4	drug0	NN	_	23	ppmod	_	_
26	,	,	,	_	5	p	_	_
27	but	but	CC	_	5	cc	_	_
28	there	there	EX	_	29	dep	_	_
29	was	be	VBD	_	5	conj	_	_
30	no	no	DT	_	31	det	_	_
31	change	change	NN	_	29	obj	_	_
32	in	in	IN	_	34	case	_	_
33	the	the	DT	_	34	det	_	_
34	clearance	clearance	NN	_	31	ppmod	_	_
35	of	of	IN	_	37	case	_	_
36	free	free	JJ	_	37	attr	_	_
37	drug5	drug0	NN	_	34	ppmod	_	_
38	.	.	.	_	5	p	_	_

1	There	there	EX	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	no	no	DT	_	5	det	_	_
4	significant	significant	JJ	_	5	attr	_	_
5	difference	difference	NN	_	2	obj	_	_
6	in	in	IN	_	9	case	_	_
7	the	the	DT	_	9	det	_	_
8	pharmacodynamic	pharmacodynamic	JJ	_	9	attr	_	_
9	effect	effect	NN	_	2	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	administered	administer	VBN	_	11	acl	_	_
13	alone	alone	RB	_	12	adv	_	_
14	and	and	CC	_	2	cc	_	_
15	drug2	drug0	NN	_	16	dep	_	_
16	administered	administer	VBN	_	2	conj	_	_
17	with	with	IN	_	18	case	_	_
18	drug3	drug0	NN	_	16	ppmod	_	_
19	as	as	IN	_	20	mark	_	_
20	measured	measure	VBN	_	16	comp	_	_
21	by	by	IN	_	23	case	_	_
22	prothrombin	prothrombin	NN	_	23	com	_	_
23	time	time	NN	_	20	ppmod	_	_
24	.	.	.	_	2	p	_	_

1	Thus	thus	RB	_	11	adv	_	_
2	,	,	,	_	11	p	_	_
3	concomitant	concomitant	JJ	_	4	attr	_	_
4	therapy	therapy	NN	_	11	dep	_	_
5	with	with	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	should	should	MD	_	11	modal	_	_
10	not	not	RB	_	11	neg	_	_
11	require	require	VBP	_	0	root	_	_
12	dosage	dosage	JJ	_	13	attr	_	_
13	adjustment	adjustment	NN	_	11	obj	_	_
14	of	of	IN	_	16	case	_	_
15	either	either	DT	_	16	det	_	_
16	drug	drug	NN	_	13	ppmod	_	_
17	.	.	.	_	11	p	_	_

1	However	however	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	caution	caution	NN	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	exercised	exercise	VBN	_	0	root	_	_
7	because	because	IN	_	10	mark	_	_
8	there	there	EX	_	10	dep	_	_
9	have	have	VBP	_	10	aux	_	_
10	been	be	VBN	_	6	comp	_	_
11	a	a	DT	_	14	det	_	_
12	few	few	JJ	_	14	attr	_	_
13	spontaneous	spontaneous	JJ	_	14	attr	_	_
14	reports	report	NNS	_	10	obj	_	_
15	of	of	IN	_	18	case	_	_
16	prolonged	prolonged	JJ	_	18	attr	_	_
17	prothrombin	prothrombin	NN	_	18	com	_	_
18	times	time	NNS	_	14	ppmod	_	_
19	,	,	,	_	10	p	_	_
20	with	with	IN	_	10	ppmod	_	_
21	or	or	CC	_	20	cc	_	_
22	without	without	IN	_	23	case	_	_
23	bleeding	bleeding	JJ	_	20	conj	_	_
24	,	,	,	_	10	p	_	_
25	in	in	IN	_	28	case	_	_
26	drug1	drug0	JJ	_	28	attr	_	_
27	-treated	-treated	JJ	_	28	attr	_	_
28	patients	patient	NNS	_	10	ppmod	_	_
29	receiving	receive	VBG	_	28	acl	_	_
30	concomitant	concomitant	JJ	_	32	attr	_	_
31	drug2	drug0	NN	_	32	com	_	_
32	therapy	therapy	NN	_	29	obj	_	_
33	.	.	.	_	6	p	_	_

1	Drug/Laboratory	drug/laboratory	JJ	_	3	attr	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	15	dep	_	_
4	The	the	DT	_	5	det	_	_
5	urine	urine	NN	_	3	attr	_	_
6	of	of	IN	_	7	case	_	_
7	patients	patient	NNS	_	5	ppmod	_	_
8	who	who	WP	_	9	dep	_	_
9	take	take	VBP	_	7	relcl	_	_
10	drug1	drug0	NN	_	9	obj	_	_
11	can	can	MD	_	15	modal	_	_
12	give	give	VBP	_	15	lv	_	_
13	a	a	DT	_	15	det	_	_
14	false-positive	false-positive	JJ	_	15	attr	_	_
15	reaction	reaction	NN	_	0	root	_	_
16	for	for	IN	_	18	case	_	_
17	urinary	urinary	JJ	_	18	attr	_	_
18	bilirubin	bilirubin	NN	_	15	ppmod	_	_
19	(	-lrb-	-LRB-	_	20	p	_	_
20	urobilin	urobilin	NN	_	18	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	due	due	JJ	_	25	adv	_	_
23	to	to	TO	_	25	aux	_	_
24	the	the	DT	_	25	det	_	_
25	presence	presence	NN	_	15	ppmod	_	_
26	of	of	IN	_	28	case	_	_
27	phenolic	phenolic	JJ	_	28	attr	_	_
28	metabolites	metabolite	NNS	_	25	ppmod	_	_
29	of	of	IN	_	30	case	_	_
30	drug2	drug0	NN	_	28	ppmod	_	_
31	.	.	.	_	15	p	_	_

1	Diagnostic	diagnostic	JJ	_	3	attr	_	_
2	dip-stick	dip-stick	JJ	_	3	attr	_	_
3	methodology	methodology	NN	_	14	dep	_	_
4	,	,	,	_	3	p	_	_
5	used	use	VBN	_	3	acl	_	_
6	to	to	TO	_	7	aux	_	_
7	detect	detect	VB	_	5	comp	_	_
8	ketone	ketone	NN	_	9	com	_	_
9	bodies	body	NNS	_	7	obj	_	_
10	in	in	IN	_	11	case	_	_
11	urine	urine	NN	_	7	ppmod	_	_
12	,	,	,	_	3	p	_	_
13	has	have	VBZ	_	14	aux	_	_
14	resulted	result	VBD	_	0	root	_	_
15	in	in	IN	_	17	case	_	_
16	false-positive	false-positive	JJ	_	17	attr	_	_
17	findings	finding	NNS	_	14	ppmod	_	_
18	in	in	IN	_	20	case	_	_
19	some	some	DT	_	20	det	_	_
20	patients	patient	NNS	_	17	ppmod	_	_
21	treated	treat	VBN	_	20	acl	_	_
22	with	with	IN	_	23	case	_	_
23	drug1	drug0	NN	_	21	ppmod	_	_
24	.	.	.	_	14	p	_	_

1	Generally	generally	RB	_	8	adv	_	_
2	,	,	,	_	8	p	_	_
3	this	this	DT	_	4	det	_	_
4	phenomenon	phenomenon	NN	_	8	dep	_	_
5	has	have	VBZ	_	8	aux	_	_
6	not	not	RB	_	8	neg	_	_
7	been	be	VBN	_	8	aux	_	_
8	associated	associate	VBN	_	0	root	_	_
9	with	with	IN	_	13	case	_	_
10	other	other	JJ	_	13	attr	_	_
11	clinically	clinically	RB	_	12	adv	_	_
12	significant	significant	JJ	_	13	attr	_	_
13	events	event	NNS	_	8	ppmod	_	_
14	.	.	.	_	8	p	_	_

1	No	no	DT	_	3	det	_	_
2	dose	dose	NN	_	3	com	_	_
3	relationship	relationship	NN	_	6	dep	_	_
4	has	have	VBZ	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	observed	observe	VBN	_	0	root	_	_
7	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	treatment	treatment	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	associated	associate	VBN	_	0	root	_	_
5	with	with	IN	_	8	case	_	_
6	a	a	DT	_	8	det	_	_
7	small	small	JJ	_	8	attr	_	_
8	decrease	decrease	NN	_	4	ppmod	_	_
9	in	in	IN	_	13	case	_	_
10	serum	serum	NN	_	13	attr	_	_
11	uric	uric	JJ	_	13	attr	_	_
12	acid	acid	NN	_	13	com	_	_
13	levels	level	NNS	_	8	ppmod	_	_
14	.	.	.	_	4	p	_	_

1	In	in	IN	_	3	case	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	trials	trial	NNS	_	13	ppmod	_	_
4	,	,	,	_	13	p	_	_
5	mean	mean	JJ	_	6	attr	_	_
6	decreases	decrease	NNS	_	13	dep	_	_
7	of	of	IN	_	11	case	_	_
8	1	0	CD	_	11	num	_	_
9	to	to	TO	_	8	cc	_	_
10	2	0	CD	_	8	conj	_	_
11	mg/dL	mg/dl	NN	_	6	ppmod	_	_
12	were	be	VBD	_	13	aux	_	_
13	observed	observe	VBN	_	0	root	_	_
14	in	in	IN	_	16	case	_	_
15	arthritic	arthritic	JJ	_	16	attr	_	_
16	patients	patient	NNS	_	13	ppmod	_	_
17	receiving	receive	VBG	_	16	acl	_	_
18	drug1	drug0	NN	_	17	obj	_	_
19	(	-lrb-	-LRB-	_	24	p	_	_
20	600	0	CD	_	24	num	_	_
21	mg	mg	NN	_	24	attr	_	_
22	to	to	TO	_	24	attr	_	_
23	1000	0	CD	_	24	num	_	_
24	mg/day	mg/day	NN	_	18	prn	_	_
25	)	-rrb-	-RRB-	_	24	p	_	_
26	after	after	IN	_	28	case	_	_
27	4	0	CD	_	28	num	_	_
28	weeks	week	NNS	_	17	ppmod	_	_
29	of	of	IN	_	30	case	_	_
30	therapy	therapy	NN	_	28	ppmod	_	_
31	.	.	.	_	13	p	_	_

1	These	these	DT	_	2	det	_	_
2	levels	level	NNS	_	4	dep	_	_
3	then	then	RB	_	4	adv	_	_
4	remained	remain	VBD	_	0	root	_	_
5	stable	stable	JJ	_	4	dep	_	_
6	for	for	IN	_	10	case	_	_
7	up	up	RB	_	9	adv	_	_
8	to	to	TO	_	9	attr	_	_
9	1	0	CD	_	10	num	_	_
10	year	year	NN	_	4	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	therapy	therapy	NN	_	10	ppmod	_	_
13	.	.	.	_	4	p	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	Drug-drug	drug-drug	JJ	_	2	attr	_	_
2	interactions	interaction	NNS	_	8	dep	_	_
3	with	with	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	have	have	VBP	_	8	aux	_	_
6	not	not	RB	_	8	neg	_	_
7	been	be	VBN	_	8	aux	_	_
8	explored	explore	VBN	_	0	root	_	_
9	in	in	IN	_	10	case	_	_
10	detail	detail	NN	_	8	ppmod	_	_
11	.	.	.	_	8	p	_	_

1	There	there	EX	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	one	#crd#	CD	_	4	num	_	_
4	report	report	NN	_	2	obj	_	_
5	of	of	IN	_	7	case	_	_
6	cardiopulmonary	cardiopulmonary	NN	_	7	com	_	_
7	arrest	arrest	NN	_	4	ppmod	_	_
8	,	,	,	_	2	p	_	_
9	with	with	IN	_	11	case	_	_
10	full	full	JJ	_	11	attr	_	_
11	recovery	recovery	NN	_	2	ppmod	_	_
12	,	,	,	_	2	p	_	_
13	in	in	IN	_	15	case	_	_
14	a	a	DT	_	15	det	_	_
15	patient	patient	NN	_	2	ppmod	_	_
16	who	who	WP	_	18	dep	_	_
17	was	be	VBD	_	18	aux	_	_
18	taking	take	VBG	_	15	relcl	_	_
19	a	a	DT	_	20	det	_	_
20	drug1	drug0	NN	_	18	obj	_	_
21	(	-lrb-	-LRB-	_	22	p	_	_
22	drug2	drug0	NN	_	20	prn	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	effects	effect	NNS	_	13	dep	_	_
3	of	of	IN	_	4	case	_	_
4	Mefloquineuine	mefloquineuine	NN	_	2	ppmod	_	_
5	on	on	IN	_	9	case	_	_
6	the	the	DT	_	9	det	_	_
7	compromised	compromise	VBN	_	9	attr	_	_
8	cardiovascular	cardiovascular	JJ	_	9	attr	_	_
9	system	system	NN	_	2	ppmod	_	_
10	have	have	VBP	_	13	aux	_	_
11	not	not	RB	_	13	neg	_	_
12	been	be	VBN	_	13	aux	_	_
13	evaluated	evaluate	VBN	_	0	root	_	_
14	.	.	.	_	13	p	_	_

1	The	the	DT	_	2	det	_	_
2	benefits	benefit	NNS	_	8	dep	_	_
3	of	of	IN	_	5	case	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	therapy	therapy	NN	_	2	ppmod	_	_
6	should	should	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	weighed	weigh	VBN	_	0	root	_	_
9	against	against	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	possibility	possibility	NN	_	8	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	adverse	adverse	JJ	_	14	attr	_	_
14	effects	effect	NNS	_	11	ppmod	_	_
15	in	in	IN	_	16	case	_	_
16	patients	patient	NNS	_	14	ppmod	_	_
17	with	with	IN	_	19	case	_	_
18	cardiac	cardiac	JJ	_	19	attr	_	_
19	disease	disease	NN	_	16	ppmod	_	_
20	.	.	.	_	8	p	_	_

1	Because	because	IN	_	4	case	_	_
2	of	of	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	danger	danger	NN	_	19	ppmod	_	_
5	of	of	IN	_	9	case	_	_
6	a	a	DT	_	9	det	_	_
7	potentially	potentially	RB	_	8	adv	_	_
8	fatal	fatal	JJ	_	9	attr	_	_
9	prolongation	prolongation	NN	_	4	ppmod	_	_
10	of	of	IN	_	13	case	_	_
11	the	the	DT	_	13	det	_	_
12	QTc	qtc	NN	_	13	com	_	_
13	interval	interval	NN	_	9	ppmod	_	_
14	,	,	,	_	19	p	_	_
15	drug1	drug0	NN	_	19	dep	_	_
16	must	must	MD	_	19	modal	_	_
17	not	not	RB	_	19	neg	_	_
18	be	be	VB	_	19	aux	_	_
19	given	give	VBN	_	0	root	_	_
20	simultaneously	simultaneously	RB	_	19	adv	_	_
21	with	with	IN	_	22	case	_	_
22	or	or	NN	_	19	ppmod	_	_
23	subsequent	subsequent	JJ	_	22	attr	_	_
24	to	to	TO	_	25	aux	_	_
25	drug2	drug0	NN	_	23	ppmod	_	_
26	.	.	.	_	19	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	administration	administration	NN	_	19	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	other	other	JJ	_	8	attr	_	_
7	related	related	JJ	_	8	attr	_	_
8	compounds	compound	NNS	_	4	conj	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	eg	eg	NN	_	8	prn	_	_
11	,	,	,	_	10	p	_	_
12	drug2	drug0	NN	_	10	conj	_	_
13	,	,	,	_	12	p	_	_
14	drug3	drug0	NN	_	10	conj	_	_
15	and	and	CC	_	14	cc	_	_
16	drug4	drug0	NN	_	10	conj	_	_
17	)	-rrb-	-RRB-	_	10	p	_	_
18	may	may	MD	_	19	modal	_	_
19	produce	produce	VB	_	0	root	_	_
20	electrocardiographic	electrocardiographic	JJ	_	21	attr	_	_
21	abnormalities	abnormality	NNS	_	19	obj	_	_
22	and	and	CC	_	19	cc	_	_
23	increase	increase	VB	_	19	conj	_	_
24	the	the	DT	_	25	det	_	_
25	risk	risk	NN	_	23	obj	_	_
26	of	of	IN	_	27	case	_	_
27	convulsions	convulsion	NNS	_	25	ppmod	_	_
28	.	.	.	_	19	p	_	_

1	If	if	IN	_	4	mark	_	_
2	these	these	DT	_	3	det	_	_
3	drugs	drug	NNS	_	4	dep	_	_
4	are	be	VBP	_	20	advcl	_	_
5	to	to	TO	_	7	aux	_	_
6	be	be	VB	_	7	aux	_	_
7	used	use	VBN	_	4	comp	_	_
8	in	in	IN	_	11	case	_	_
9	the	the	DT	_	11	det	_	_
10	initial	initial	JJ	_	11	attr	_	_
11	treatment	treatment	NN	_	7	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	severe	severe	JJ	_	14	attr	_	_
14	malaria	malaria	NN	_	11	ppmod	_	_
15	,	,	,	_	20	p	_	_
16	drug1	drug0	NN	_	17	com	_	_
17	administration	administration	NN	_	20	dep	_	_
18	should	should	MD	_	20	modal	_	_
19	be	be	VB	_	20	aux	_	_
20	delayed	delay	VBN	_	0	root	_	_
21	at	at	IN	_	23	case	_	_
22	least	least	JJS	_	23	attr	_	_
23	12	0	CD	_	24	num	_	_
24	hours	hour	NNS	_	28	dat	_	_
25	after	after	IN	_	28	case	_	_
26	the	the	DT	_	28	det	_	_
27	last	last	JJ	_	28	attr	_	_
28	dose	dose	NN	_	20	ppmod	_	_
29	.	.	.	_	20	p	_	_

1	There	there	EX	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	evidence	evidence	NN	_	2	obj	_	_
4	that	that	IN	_	11	mark	_	_
5	the	the	DT	_	6	det	_	_
6	use	use	NN	_	11	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	after	after	IN	_	10	case	_	_
10	Mefloquineuine	mefloquineuine	NN	_	6	ppmod	_	_
11	causes	cause	VBZ	_	3	acl	_	_
12	a	a	DT	_	14	det	_	_
13	significant	significant	JJ	_	14	attr	_	_
14	lengthening	lengthening	NN	_	11	obj	_	_
15	of	of	IN	_	18	case	_	_
16	the	the	DT	_	18	det	_	_
17	QTc	qtc	NN	_	18	com	_	_
18	interval	interval	NN	_	14	ppmod	_	_
19	.	.	.	_	2	p	_	_

1	Clinically	clinically	RB	_	2	adv	_	_
2	significant	significant	JJ	_	4	attr	_	_
3	QTc	qtc	NN	_	4	com	_	_
4	prolongation	prolongation	NN	_	8	dep	_	_
5	has	have	VBZ	_	8	aux	_	_
6	not	not	RB	_	8	neg	_	_
7	been	be	VBN	_	8	aux	_	_
8	found	find	VBN	_	0	root	_	_
9	with	with	IN	_	10	case	_	_
10	Mefloquineuine	mefloquineuine	NN	_	8	ppmod	_	_
11	alone	alone	RB	_	10	adv	_	_
12	.	.	.	_	8	p	_	_

1	This	this	DT	_	2	dep	_	_
2	appears	appear	VBZ	_	0	root	_	_
3	to	to	TO	_	4	aux	_	_
4	be	be	VB	_	2	comp	_	_
5	the	the	DT	_	9	det	_	_
6	only	only	RB	_	8	adv	_	_
7	clinically	clinically	RB	_	8	adv	_	_
8	relevant	relevant	JJ	_	9	attr	_	_
9	interaction	interaction	NN	_	4	obj	_	_
10	of	of	IN	_	12	case	_	_
11	this	this	DT	_	12	det	_	_
12	kind	kind	NN	_	9	ppmod	_	_
13	with	with	IN	_	14	case	_	_
14	drug1	drug0	NN	_	9	ppmod	_	_
15	,	,	,	_	2	p	_	_
16	although	although	IN	_	47	mark	_	_
17	theoretically	theoretically	RB	_	47	adv	_	_
18	,	,	,	_	47	p	_	_
19	coadministration	coadministration	NN	_	47	dep	_	_
20	of	of	IN	_	22	case	_	_
21	other	other	JJ	_	22	attr	_	_
22	drugs	drug	NNS	_	19	ppmod	_	_
23	known	know	VBN	_	22	acl	_	_
24	to	to	TO	_	25	aux	_	_
25	alter	alter	VB	_	23	comp	_	_
26	cardiac	cardiac	JJ	_	27	attr	_	_
27	conduction	conduction	NN	_	25	obj	_	_
28	(	-lrb-	-LRB-	_	41	p	_	_
29	eg	eg	NN	_	41	dep	_	_
30	,	,	,	_	29	p	_	_
31	drug2	drug0	NN	_	29	conj	_	_
32	or	or	CC	_	31	cc	_	_
33	drug3	drug0	NN	_	29	conj	_	_
34	,	,	,	_	41	p	_	_
35	drug4	drug0	NN	_	41	dep	_	_
36	,	,	,	_	35	p	_	_
37	drug5	drug0	NN	_	35	conj	_	_
38	or	or	CC	_	37	cc	_	_
39	drug6	drug0	NN	_	35	conj	_	_
40	,	,	,	_	41	p	_	_
41	drug7	drug0	NN	_	25	prn	_	_
42	and	and	CC	_	41	cc	_	_
43	drug8	drug0	NN	_	41	conj	_	_
44	)	-rrb-	-RRB-	_	41	p	_	_
45	might	might	MD	_	47	modal	_	_
46	also	also	RB	_	47	adv	_	_
47	contribute	contribute	VB	_	2	comp	_	_
48	to	to	TO	_	50	aux	_	_
49	a	a	DT	_	50	det	_	_
50	prolongation	prolongation	NN	_	47	ppmod	_	_
51	of	of	IN	_	54	case	_	_
52	the	the	DT	_	54	det	_	_
53	QTc	qtc	NN	_	54	com	_	_
54	interval	interval	NN	_	50	ppmod	_	_
55	.	.	.	_	2	p	_	_

1	There	there	EX	_	2	dep	_	_
2	are	be	VBP	_	0	root	_	_
3	no	no	DT	_	4	det	_	_
4	data	datum	NNS	_	2	obj	_	_
5	that	that	WDT	_	7	dep	_	_
6	conclusively	conclusively	RB	_	7	adv	_	_
7	establish	establish	VBP	_	4	relcl	_	_
8	whether	whether	IN	_	19	mark	_	_
9	the	the	DT	_	11	det	_	_
10	concomitant	concomitant	JJ	_	11	attr	_	_
11	administration	administration	NN	_	19	dep	_	_
12	of	of	IN	_	13	case	_	_
13	Mefloquineuine	mefloquineuine	NN	_	11	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	the	the	DT	_	18	det	_	_
16	above	above	JJ	_	18	attr	_	_
17	listed	listed	JJ	_	18	attr	_	_
18	agents	agent	NNS	_	13	conj	_	_
19	has	have	VBZ	_	7	comp	_	_
20	an	an	DT	_	21	det	_	_
21	effect	effect	NN	_	19	obj	_	_
22	on	on	IN	_	24	case	_	_
23	cardiac	cardiac	JJ	_	24	attr	_	_
24	function	function	NN	_	21	ppmod	_	_
25	.	.	.	_	2	p	_	_

1	In	in	IN	_	2	case	_	_
2	patients	patient	NNS	_	24	ppmod	_	_
3	taking	take	VBG	_	2	acl	_	_
4	an	an	DT	_	5	det	_	_
5	drug1	drug0	NN	_	3	obj	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	eg	eg	NN	_	5	prn	_	_
8	,	,	,	_	7	p	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	,	,	,	_	9	p	_	_
11	drug3	drug0	NN	_	7	conj	_	_
12	,	,	,	_	11	p	_	_
13	drug4	drug0	NN	_	7	conj	_	_
14	or	or	CC	_	13	cc	_	_
15	drug5	drug0	NN	_	7	conj	_	_
16	)	-rrb-	-RRB-	_	7	p	_	_
17	,	,	,	_	24	p	_	_
18	the	the	DT	_	20	det	_	_
19	concomitant	concomitant	JJ	_	20	attr	_	_
20	use	use	NN	_	24	dep	_	_
21	of	of	IN	_	22	case	_	_
22	drug6	drug0	NN	_	20	ppmod	_	_
23	may	may	MD	_	24	modal	_	_
24	reduce	reduce	VB	_	0	root	_	_
25	seizure	seizure	NN	_	26	com	_	_
26	control	control	NN	_	24	obj	_	_
27	by	by	IN	_	28	case	_	_
28	lowering	lower	VBG	_	24	ppmod	_	_
29	the	the	DT	_	31	det	_	_
30	plasma	plasma	NN	_	31	com	_	_
31	levels	level	NNS	_	28	obj	_	_
32	of	of	IN	_	34	case	_	_
33	the	the	DT	_	34	det	_	_
34	drug7	drug0	NN	_	31	ppmod	_	_
35	.	.	.	_	24	p	_	_

1	Therefore	therefore	RB	_	11	adv	_	_
2	,	,	,	_	11	p	_	_
3	patients	patient	NNS	_	11	dep	_	_
4	concurrently	concurrently	RB	_	7	adv	_	_
5	taking	take	VBG	_	7	lv	_	_
6	antiseizure	antiseizure	NN	_	7	com	_	_
7	medication	medication	NN	_	3	acl	_	_
8	and	and	CC	_	7	cc	_	_
9	drug1	drug0	NN	_	7	conj	_	_
10	should	should	MD	_	11	modal	_	_
11	have	have	VBP	_	0	root	_	_
12	the	the	DT	_	14	det	_	_
13	blood	blood	NN	_	14	com	_	_
14	level	level	NN	_	11	obj	_	_
15	of	of	IN	_	18	case	_	_
16	their	their	PRP$	_	18	poss	_	_
17	antiseizure	antiseizure	JJ	_	18	attr	_	_
18	medication	medication	NN	_	14	ppmod	_	_
19	monitored	monitor	VBN	_	18	acl	_	_
20	and	and	CC	_	18	cc	_	_
21	the	the	DT	_	22	det	_	_
22	dosage	dosage	NN	_	18	conj	_	_
23	adjusted	adjust	VBN	_	22	acl	_	_
24	appropriately	appropriately	RB	_	23	adv	_	_
25	.	.	.	_	11	p	_	_

1	When	when	WRB	_	4	adv	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	taken	take	VBN	_	15	advcl	_	_
5	concurrently	concurrently	RB	_	4	adv	_	_
6	with	with	IN	_	8	case	_	_
7	oral	oral	JJ	_	8	attr	_	_
8	drug2	drug0	NN	_	4	ppmod	_	_
9	,	,	,	_	15	p	_	_
10	attenuation	attenuation	NN	_	15	dep	_	_
11	of	of	IN	_	12	case	_	_
12	immunization	immunization	NN	_	10	ppmod	_	_
13	cannot	cannot	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	excluded	exclude	VBN	_	0	root	_	_
16	.	.	.	_	15	p	_	_

1	Vaccinations	vaccination	NNS	_	9	dep	_	_
2	with	with	IN	_	5	case	_	_
3	attenuated	attenuate	VBN	_	5	attr	_	_
4	live	live	JJ	_	5	attr	_	_
5	bacteria	bacteria	NNS	_	1	ppmod	_	_
6	should	should	MD	_	9	modal	_	_
7	therefore	therefore	RB	_	9	adv	_	_
8	be	be	VB	_	9	aux	_	_
9	completed	complete	VBN	_	0	root	_	_
10	at	at	IN	_	12	case	_	_
11	least	least	JJS	_	12	attr	_	_
12	3	0	CD	_	13	num	_	_
13	days	day	NNS	_	9	obj	_	_
14	before	before	IN	_	17	case	_	_
15	the	the	DT	_	17	det	_	_
16	first	#ord#	JJ	_	17	attr	_	_
17	dose	dose	NN	_	9	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug1	drug0	NN	_	17	ppmod	_	_
20	.	.	.	_	9	p	_	_

1	No	no	DT	_	4	det	_	_
2	other	other	JJ	_	4	attr	_	_
3	drug	drug	NN	_	4	com	_	_
4	interactions	interaction	NNS	_	6	dep	_	_
5	are	be	VBP	_	6	aux	_	_
6	known	know	VBN	_	0	root	_	_
7	.	.	.	_	6	p	_	_

1	Nevertheless	nevertheless	RB	_	21	adv	_	_
2	,	,	,	_	21	p	_	_
3	the	the	DT	_	4	det	_	_
4	effects	effect	NNS	_	21	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	on	on	IN	_	8	case	_	_
8	travelers	traveler	NNS	_	4	ppmod	_	_
9	receiving	receive	VBG	_	8	acl	_	_
10	comedication	comedication	NN	_	9	obj	_	_
11	,	,	,	_	10	p	_	_
12	particularly	particularly	RB	_	13	adv	_	_
13	diabetics	diabetic	NNS	_	10	appo	_	_
14	or	or	CC	_	13	cc	_	_
15	patients	patient	NNS	_	13	conj	_	_
16	using	use	VBG	_	15	acl	_	_
17	drug2	drug0	NN	_	16	obj	_	_
18	,	,	,	_	10	p	_	_
19	should	should	MD	_	21	modal	_	_
20	be	be	VB	_	21	aux	_	_
21	checked	check	VBN	_	0	root	_	_
22	before	before	IN	_	23	case	_	_
23	departure	departure	NN	_	21	ppmod	_	_
24	.	.	.	_	21	p	_	_

1	In	in	IN	_	3	case	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	trials	trial	NNS	_	14	ppmod	_	_
4	,	,	,	_	14	p	_	_
5	the	the	DT	_	7	det	_	_
6	concomitant	concomitant	JJ	_	7	attr	_	_
7	administration	administration	NN	_	14	dep	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	drug2	drug0	NN	_	9	conj	_	_
12	did	do	VBD	_	14	aux	_	_
13	not	not	RB	_	14	neg	_	_
14	alter	alter	VB	_	0	root	_	_
15	the	the	DT	_	18	det	_	_
16	adverse	adverse	JJ	_	18	attr	_	_
17	reaction	reaction	NN	_	18	com	_	_
18	profile	profile	NN	_	14	obj	_	_
19	.	.	.	_	14	p	_	_

1	The	the	DT	_	2	det	_	_
2	risk	risk	NN	_	16	dep	_	_
3	of	of	IN	_	6	case	_	_
4	a	a	DT	_	6	det	_	_
5	potential	potential	JJ	_	6	attr	_	_
6	interaction	interaction	NN	_	2	ppmod	_	_
7	between	between	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	drug2	drug0	NN	_	11	com	_	_
11	concentrates	concentrate	NNS	_	8	conj	_	_
12	has	have	VBZ	_	16	aux	_	_
13	not	not	RB	_	16	neg	_	_
14	been	be	VBN	_	16	aux	_	_
15	adequately	adequately	RB	_	16	adv	_	_
16	evaluated	evaluate	VBN	_	0	root	_	_
17	in	in	IN	_	21	case	_	_
18	preclinical	preclinical	JJ	_	21	attr	_	_
19	or	or	CC	_	18	cc	_	_
20	clinical	clinical	JJ	_	18	conj	_	_
21	studies	study	NNS	_	16	ppmod	_	_
22	.	.	.	_	16	p	_	_

1	Simultaneous	simultaneous	JJ	_	2	attr	_	_
2	use	use	NN	_	9	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	or	or	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	should	should	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	avoided	avoid	VBN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	Although	although	IN	_	8	mark	_	_
2	the	the	DT	_	5	det	_	_
3	specific	specific	JJ	_	5	attr	_	_
4	drug	drug	NN	_	5	com	_	_
5	interaction	interaction	NN	_	8	dep	_	_
6	was	be	VBD	_	8	aux	_	_
7	not	not	RB	_	8	neg	_	_
8	studied	study	VBN	_	16	advcl	_	_
9	in	in	IN	_	12	case	_	_
10	a	a	DT	_	12	det	_	_
11	clinical	clinical	JJ	_	12	attr	_	_
12	trial	trial	NN	_	8	ppmod	_	_
13	,	,	,	_	16	p	_	_
14	there	there	EX	_	16	dep	_	_
15	have	have	VBP	_	16	aux	_	_
16	been	be	VBN	_	0	root	_	_
17	more	more	JJR	_	19	attr	_	_
18	than	than	IN	_	17	com	_	_
19	50	0	CD	_	20	num	_	_
20	episodes	episode	NNS	_	16	obj	_	_
21	of	of	IN	_	23	case	_	_
22	concomitant	concomitant	JJ	_	23	attr	_	_
23	use	use	NN	_	20	ppmod	_	_
24	of	of	IN	_	26	case	_	_
25	antifibrinolytic	antifibrinolytic	JJ	_	26	attr	_	_
26	therapies	therapy	NNS	_	23	ppmod	_	_
27	(	-lrb-	-LRB-	_	32	p	_	_
28	i.e.	i.e.	FW	_	30	adv	_	_
29	,	,	,	_	30	p	_	_
30	drug1	drug0	NN	_	32	ppmod	_	_
31	,	,	,	_	32	p	_	_
32	drug2	drug0	NNS	_	26	prn	_	_
33	)	-rrb-	-RRB-	_	32	p	_	_
34	and	and	CC	_	23	cc	_	_
35	drug3	drug0	NN	_	23	conj	_	_
36	.	.	.	_	16	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	should	should	MD	_	5	modal	_	_
3	not	not	RB	_	5	neg	_	_
4	be	be	VB	_	5	aux	_	_
5	mixed	mix	VBN	_	0	root	_	_
6	with	with	IN	_	8	case	_	_
7	infusion	infusion	NN	_	8	com	_	_
8	solutions	solution	NNS	_	5	ppmod	_	_
9	until	until	IN	_	12	mark	_	_
10	clinical	clinical	JJ	_	11	attr	_	_
11	data	datum	NNS	_	12	dep	_	_
12	are	be	VBP	_	5	comp	_	_
13	available	available	JJ	_	12	dep	_	_
14	to	to	TO	_	15	aux	_	_
15	direct	direct	VB	_	13	comp	_	_
16	this	this	DT	_	17	det	_	_
17	use	use	NN	_	15	obj	_	_
18	.	.	.	_	5	p	_	_

1	When	when	WRB	_	6	adv	_	_
2	drug1	drug0	NN	_	6	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	drug2	drug0	NN	_	2	conj	_	_
5	are	be	VBP	_	6	aux	_	_
6	used	use	VBN	_	28	advcl	_	_
7	together	together	RB	_	6	adv	_	_
8	,	,	,	_	28	p	_	_
9	the	the	DT	_	10	det	_	_
10	signs	sign	NNS	_	28	dep	_	_
11	of	of	IN	_	12	case	_	_
12	atropinization	atropinization	NN	_	10	ppmod	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	flushing	flushing	NN	_	12	prn	_	_
15	,	,	,	_	14	p	_	_
16	mydriasis	mydriasis	NN	_	14	conj	_	_
17	,	,	,	_	16	p	_	_
18	tachycardia	tachycardia	NN	_	14	conj	_	_
19	,	,	,	_	18	p	_	_
20	dryness	dryness	NN	_	14	conj	_	_
21	of	of	IN	_	23	case	_	_
22	the	the	DT	_	23	det	_	_
23	mouth	mouth	NN	_	20	ppmod	_	_
24	and	and	CC	_	20	cc	_	_
25	nose	nose	NN	_	14	conj	_	_
26	)	-rrb-	-RRB-	_	14	p	_	_
27	may	may	MD	_	28	modal	_	_
28	occur	occur	VB	_	0	root	_	_
29	earlier	early	RBR	_	28	adv	_	_
30	than	than	IN	_	33	case	_	_
31	might	might	MD	_	33	modal	_	_
32	be	be	VB	_	33	aux	_	_
33	expected	expect	VBN	_	28	ppmod	_	_
34	than	than	IN	_	38	case	_	_
35	when	when	WRB	_	38	adv	_	_
36	drug3	drug0	NN	_	38	dep	_	_
37	is	be	VBZ	_	38	aux	_	_
38	used	use	VBN	_	33	ppmod	_	_
39	alone	alone	RB	_	38	adv	_	_
40	because	because	IN	_	43	mark	_	_
41	drug4	drug0	NN	_	43	dep	_	_
42	may	may	MD	_	43	modal	_	_
43	potentiate	potentiate	VB	_	38	comp	_	_
44	the	the	DT	_	45	det	_	_
45	effect	effect	NN	_	43	obj	_	_
46	of	of	IN	_	47	case	_	_
47	drug5	drug0	NN	_	45	ppmod	_	_
48	.	.	.	_	28	p	_	_

1	The	the	DT	_	3	det	_	_
2	following	following	JJ	_	3	attr	_	_
3	precautions	precaution	NNS	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	kept	keep	VBN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	mind	mind	NN	_	6	ppmod	_	_
9	in	in	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	treatment	treatment	NN	_	6	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	anticholinesterase	anticholinesterase	NN	_	14	com	_	_
14	poisoning	poisoning	NN	_	11	ppmod	_	_
15	although	although	IN	_	19	mark	_	_
16	they	they	PRP	_	19	dep	_	_
17	do	do	VBP	_	19	aux	_	_
18	not	not	RB	_	19	neg	_	_
19	bear	bear	VB	_	6	comp	_	_
20	directly	directly	RB	_	19	adv	_	_
21	on	on	IN	_	23	case	_	_
22	the	the	DT	_	23	det	_	_
23	use	use	NN	_	19	ppmod	_	_
24	of	of	IN	_	25	case	_	_
25	drug1	drug0	NN	_	23	ppmod	_	_
26	and	and	CC	_	25	cc	_	_
27	drug2	drug0	NN	_	25	conj	_	_
28	.	.	.	_	6	p	_	_

1	Since	since	IN	_	4	mark	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	are	be	VBP	_	4	aux	_	_
4	potentiated	potentiate	VBN	_	12	advcl	_	_
5	by	by	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	drug2	drug0	NN	_	4	ppmod	_	_
8	,	,	,	_	12	p	_	_
9	they	they	PRP	_	12	dep	_	_
10	should	should	MD	_	12	modal	_	_
11	be	be	VB	_	12	aux	_	_
12	used	use	VBN	_	0	root	_	_
13	cautiously	cautiously	RB	_	12	adv	_	_
14	in	in	IN	_	16	case	_	_
15	the	the	DT	_	16	det	_	_
16	treatment	treatment	NN	_	12	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	convulsions	convulsion	NNS	_	16	ppmod	_	_
19	.	.	.	_	12	p	_	_

1	Drugs	drug	NNS	_	2	dep	_	_
2	Metabolized	metabolize	VBN	_	23	advcl	_	_
3	by	by	IN	_	5	case	_	_
4	P450	p0	NN	_	5	com	_	_
5	2D6	0d0	NN	_	2	ppmod	_	_
6	:	:	:	_	23	p	_	_
7	The	the	DT	_	9	det	_	_
8	biochemical	biochemical	JJ	_	9	attr	_	_
9	activity	activity	NN	_	23	dep	_	_
10	of	of	IN	_	17	case	_	_
11	the	the	DT	_	17	det	_	_
12	drug	drug	NN	_	17	com	_	_
13	metabolizing	metabolizing	NN	_	17	com	_	_
14	isozyme	isozyme	NN	_	17	com	_	_
15	cytochrome	cytochrome	NN	_	17	com	_	_
16	P450	p0	NN	_	17	com	_	_
17	2D6	0d0	NN	_	9	ppmod	_	_
18	(	-lrb-	-LRB-	_	20	p	_	_
19	debrisoquin	debrisoquin	NN	_	20	com	_	_
20	hydroxylase	hydroxylase	NN	_	17	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	is	be	VBZ	_	23	aux	_	_
23	reduced	reduce	VBN	_	0	root	_	_
24	in	in	IN	_	26	case	_	_
25	a	a	DT	_	26	det	_	_
26	subset	subset	NN	_	23	ppmod	_	_
27	of	of	IN	_	30	case	_	_
28	the	the	DT	_	30	det	_	_
29	Caucasian	caucasian	NN	_	30	com	_	_
30	population	population	NN	_	26	ppmod	_	_
31	(	-lrb-	-LRB-	_	37	p	_	_
32	about	about	RB	_	33	adv	_	_
33	7-10	0	CD	_	37	num	_	_
34	%	%	NN	_	33	meta	_	_
35	of	of	IN	_	36	case	_	_
36	Caucasians	caucasian	NNS	_	33	ppmod	_	_
37	are	be	VBP	_	23	prn	_	_
38	so-called	so-called	JJ	_	40	attr	_	_
39	poor	poor	JJ	_	40	attr	_	_
40	metabolizers	metabolizers	NNS	_	37	obj	_	_
41	)	-rrb-	-RRB-	_	37	p	_	_
42	;	;	:	_	23	p	_	_

1	reliable	reliable	JJ	_	2	attr	_	_
2	estimates	estimate	NNS	_	19	dep	_	_
3	of	of	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	prevalence	prevalence	NN	_	2	ppmod	_	_
6	of	of	IN	_	11	case	_	_
7	reduced	reduce	VBN	_	11	attr	_	_
8	P450	p0	NN	_	11	com	_	_
9	2D6	0d0	NN	_	11	com	_	_
10	isozyme	isozyme	NN	_	11	com	_	_
11	activity	activity	NN	_	5	ppmod	_	_
12	among	among	IN	_	18	case	_	_
13	Asian	asian	JJ	_	18	attr	_	_
14	,	,	,	_	13	p	_	_
15	African	african	JJ	_	13	conj	_	_
16	and	and	CC	_	15	cc	_	_
17	other	other	JJ	_	13	conj	_	_
18	populations	population	NNS	_	5	ppmod	_	_
19	are	be	VBP	_	0	root	_	_
20	not	not	RB	_	19	neg	_	_
21	yet	yet	RB	_	19	adv	_	_
22	available	available	JJ	_	19	dep	_	_
23	.	.	.	_	19	p	_	_

1	Poor	poor	JJ	_	2	attr	_	_
2	metabolizers	metabolizers	NNS	_	8	dep	_	_
3	have	have	VBP	_	8	lv	_	_
4	higher	high	JJR	_	8	attr	_	_
5	than	than	IN	_	8	case	_	_
6	expected	expect	VBN	_	8	attr	_	_
7	plasma	plasma	NN	_	8	com	_	_
8	concentrations	concentration	NNS	_	0	root	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	drug2	drug0	NN	_	10	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	when	when	WRB	_	15	adv	_	_
15	given	give	VBN	_	8	comp	_	_
16	usual	usual	JJ	_	17	attr	_	_
17	doses	dose	NNS	_	15	obj	_	_
18	.	.	.	_	8	p	_	_

1	Depending	depend	VBG	_	4	adv	_	_
2	on	on	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	fraction	fraction	NN	_	18	ppmod	_	_
5	of	of	IN	_	6	case	_	_
6	drug	drug	NN	_	4	ppmod	_	_
7	metabolized	metabolize	VBN	_	6	acl	_	_
8	by	by	IN	_	10	case	_	_
9	P450	p0	NN	_	10	com	_	_
10	2D6	0d0	NN	_	7	ppmod	_	_
11	,	,	,	_	18	p	_	_
12	the	the	DT	_	13	det	_	_
13	increase	increase	NN	_	18	dep	_	_
14	in	in	IN	_	16	case	_	_
15	plasma	plasma	NN	_	16	com	_	_
16	concentration	concentration	NN	_	13	ppmod	_	_
17	may	may	MD	_	18	modal	_	_
18	be	be	VB	_	0	root	_	_
19	small	small	JJ	_	18	dep	_	_
20	,	,	,	_	19	p	_	_
21	or	or	CC	_	19	cc	_	_
22	quite	quite	RB	_	23	adv	_	_
23	large	large	JJ	_	19	conj	_	_
24	(	-lrb-	-LRB-	_	26	p	_	_
25	8-fold	0-fold	JJ	_	26	attr	_	_
26	increase	increase	NN	_	23	prn	_	_
27	in	in	IN	_	29	case	_	_
28	plasma	plasma	NN	_	29	com	_	_
29	AUC	auc	NN	_	26	ppmod	_	_
30	of	of	IN	_	32	case	_	_
31	the	the	DT	_	32	det	_	_
32	TCA	tca	NN	_	29	ppmod	_	_
33	)	-rrb-	-RRB-	_	26	p	_	_
34	.	.	.	_	18	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	16	ppmod	_	_
3	,	,	,	_	16	p	_	_
4	certain	certain	JJ	_	5	attr	_	_
5	drugs	drug	NNS	_	16	dep	_	_
6	inhibit	inhibit	VB	_	16	dep	_	_
7	the	the	DT	_	8	det	_	_
8	activity	activity	NN	_	6	obj	_	_
9	of	of	IN	_	11	case	_	_
10	this	this	DT	_	11	det	_	_
11	isozyme	isozyme	NN	_	8	ppmod	_	_
12	and	and	CC	_	6	cc	_	_
13	make	make	VB	_	6	conj	_	_
14	normal	normal	JJ	_	15	attr	_	_
15	metabolizers	metabolizers	NNS	_	13	obj	_	_
16	resemble	resemble	VBP	_	0	root	_	_
17	poor	poor	JJ	_	18	attr	_	_
18	metabolizers	metabolizers	NNS	_	16	obj	_	_
19	.	.	.	_	16	p	_	_

1	An	an	DT	_	2	det	_	_
2	individual	individual	JJ	_	13	dep	_	_
3	who	who	WP	_	4	dep	_	_
4	is	be	VBZ	_	2	relcl	_	_
5	stable	stable	JJ	_	4	dep	_	_
6	on	on	IN	_	9	case	_	_
7	a	a	DT	_	9	det	_	_
8	given	given	JJ	_	9	attr	_	_
9	dose	dose	NN	_	5	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	may	may	MD	_	13	modal	_	_
13	become	become	VB	_	0	root	_	_
14	abruptly	abruptly	RB	_	15	adv	_	_
15	toxic	toxic	JJ	_	13	dep	_	_
16	when	when	WRB	_	17	adv	_	_
17	given	give	VBN	_	13	comp	_	_
18	one	#crd#	CD	_	17	obj	_	_
19	of	of	IN	_	22	case	_	_
20	these	these	DT	_	22	det	_	_
21	inhibiting	inhibiting	JJ	_	22	attr	_	_
22	drugs	drug	NNS	_	18	ppmod	_	_
23	as	as	IN	_	25	case	_	_
24	concomitant	concomitant	JJ	_	25	attr	_	_
25	therapy	therapy	NN	_	22	ppmod	_	_
26	.	.	.	_	13	p	_	_

1	The	the	DT	_	2	det	_	_
2	drugs	drug	NNS	_	8	dep	_	_
3	that	that	WDT	_	4	dep	_	_
4	inhibit	inhibit	VBP	_	2	relcl	_	_
5	cytochrome	cytochrome	NN	_	7	com	_	_
6	P450	p0	NN	_	7	com	_	_
7	2D6	0d0	NN	_	4	obj	_	_
8	include	include	VBP	_	0	root	_	_
9	some	some	DT	_	8	obj	_	_
10	that	that	WDT	_	13	dep	_	_
11	are	be	VBP	_	13	aux	_	_
12	not	not	RB	_	13	neg	_	_
13	metabolized	metabolize	VBN	_	9	relcl	_	_
14	by	by	IN	_	18	case	_	_
15	the	the	DT	_	18	det	_	_
16	enzyme	enzyme	NN	_	18	attr	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	drug1	drug0	NN	_	13	ppmod	_	_
19	;	;	:	_	8	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	)	-rrb-	-RRB-	_	1	p	_	_
3	and	and	CC	_	1	cc	_	_
4	many	many	JJ	_	1	conj	_	_
5	that	that	WDT	_	6	dep	_	_
6	are	be	VBP	_	4	relcl	_	_
7	substrates	substrate	NNS	_	6	obj	_	_
8	for	for	IN	_	10	case	_	_
9	P450	p0	NN	_	10	com	_	_
10	2D6	0d0	NN	_	7	ppmod	_	_
11	(	-lrb-	-LRB-	_	14	p	_	_
12	many	many	JJ	_	14	attr	_	_
13	other	other	JJ	_	14	attr	_	_
14	drug2	drug0	NN	_	10	prn	_	_
15	,	,	,	_	14	p	_	_
16	drug3	drug0	NN	_	14	conj	_	_
17	,	,	,	_	16	p	_	_
18	and	and	CC	_	16	cc	_	_
19	the	the	DT	_	21	det	_	_
20	drug4	drug0	NN	_	21	com	_	_
21	drug5	drug0	NN	_	14	conj	_	_
22	and	and	CC	_	21	cc	_	_
23	drug6	drug0	NN	_	21	conj	_	_
24	)	-rrb-	-RRB-	_	14	p	_	_
25	.	.	.	_	1	p	_	_

1	While	while	IN	_	22	mark	_	_
2	all	all	PDT	_	4	det	_	_
3	the	the	DT	_	4	det	_	_
4	drug1	drug0	NN	_	22	dep	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	drug2	drug0	NN	_	4	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	,	,	,	_	4	p	_	_
9	e.g.	e.g.	FW	_	11	adv	_	_
10	,	,	,	_	11	p	_	_
11	drug3	drug0	NN	_	4	ppmod	_	_
12	,	,	,	_	11	p	_	_
13	drug4	drug0	NN	_	11	conj	_	_
14	,	,	,	_	13	p	_	_
15	drug5	drug0	NN	_	11	conj	_	_
16	,	,	,	_	15	p	_	_
17	drug6	drug0	NN	_	11	conj	_	_
18	,	,	,	_	17	p	_	_
19	and	and	CC	_	17	cc	_	_
20	drug7	drug0	NN	_	11	conj	_	_
21	,	,	,	_	4	p	_	_
22	inhibit	inhibit	VBP	_	28	advcl	_	_
23	P450	p0	NN	_	24	com	_	_
24	2D6	0d0	NN	_	22	obj	_	_
25	,	,	,	_	28	p	_	_
26	they	they	PRP	_	28	dep	_	_
27	may	may	MD	_	28	modal	_	_
28	vary	vary	VB	_	0	root	_	_
29	in	in	IN	_	31	case	_	_
30	the	the	DT	_	31	det	_	_
31	extent	extent	NN	_	28	ppmod	_	_
32	of	of	IN	_	33	case	_	_
33	inhibition	inhibition	NN	_	31	ppmod	_	_
34	.	.	.	_	28	p	_	_

1	The	the	DT	_	2	det	_	_
2	extent	extent	NN	_	14	dep	_	_
3	to	to	TO	_	4	aux	_	_
4	which	which	WDT	_	10	ppmod	_	_
5	drug1	drug0	NN	_	8	attr	_	_
6	-	-	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	interactions	interaction	NNS	_	10	dep	_	_
9	may	may	MD	_	10	modal	_	_
10	pose	pose	VBP	_	2	relcl	_	_
11	clinical	clinical	JJ	_	12	attr	_	_
12	problems	problem	NNS	_	10	obj	_	_
13	will	will	MD	_	14	modal	_	_
14	depend	depend	VB	_	0	root	_	_
15	on	on	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	degree	degree	NN	_	14	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	inhibition	inhibition	NN	_	17	ppmod	_	_
20	and	and	CC	_	17	cc	_	_
21	the	the	DT	_	22	det	_	_
22	pharmacokinetics	pharmacokinetics	NNS	_	17	conj	_	_
23	of	of	IN	_	25	case	_	_
24	the	the	DT	_	25	det	_	_
25	drug3	drug0	NN	_	22	ppmod	_	_
26	involved	involve	VBN	_	25	acl	_	_
27	.	.	.	_	14	p	_	_

1	Nevertheless	nevertheless	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	caution	caution	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	indicated	indicate	VBN	_	0	root	_	_
6	in	in	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	co-administration	co-administration	NN	_	5	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	with	with	IN	_	12	case	_	_
12	any	any	DT	_	8	ppmod	_	_
13	of	of	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	drug2	drug0	NN	_	12	ppmod	_	_
16	and	and	CC	_	8	cc	_	_
17	also	also	RB	_	19	adv	_	_
18	in	in	IN	_	19	case	_	_
19	switching	switching	NN	_	8	conj	_	_
20	from	from	IN	_	22	case	_	_
21	one	#crd#	CD	_	22	num	_	_
22	class	class	NN	_	19	ppmod	_	_
23	to	to	TO	_	25	aux	_	_
24	the	the	DT	_	25	det	_	_
25	other	other	JJ	_	19	ppmod	_	_
26	.	.	.	_	5	p	_	_

1	Of	of	IN	_	3	case	_	_
2	particular	particular	JJ	_	3	attr	_	_
3	importance	importance	NN	_	8	ppmod	_	_
4	,	,	,	_	8	p	_	_
5	sufficient	sufficient	JJ	_	6	attr	_	_
6	time	time	NN	_	8	dep	_	_
7	must	must	MD	_	8	modal	_	_
8	elapse	elapse	VB	_	0	root	_	_
9	before	before	IN	_	10	case	_	_
10	initiating	initiate	VBG	_	8	ppmod	_	_
11	TCA	tca	NN	_	12	com	_	_
12	treatment	treatment	NN	_	10	obj	_	_
13	in	in	IN	_	15	case	_	_
14	a	a	DT	_	15	det	_	_
15	patient	patient	NN	_	10	ppmod	_	_
16	being	be	VBG	_	17	aux	_	_
17	withdrawn	withdraw	VBN	_	15	acl	_	_
18	from	from	IN	_	19	case	_	_
19	drug1	drug0	NN	_	17	ppmod	_	_
20	,	,	,	_	19	p	_	_
21	given	give	VBN	_	19	acl	_	_
22	the	the	DT	_	24	det	_	_
23	long	long	JJ	_	24	attr	_	_
24	half-life	half-life	NN	_	21	obj	_	_
25	of	of	IN	_	27	case	_	_
26	the	the	DT	_	27	det	_	_
27	parent	parent	NN	_	24	ppmod	_	_
28	and	and	CC	_	19	cc	_	_
29	active	active	JJ	_	30	attr	_	_
30	metabolite	metabolite	NN	_	19	conj	_	_
31	(	-lrb-	-LRB-	_	35	p	_	_
32	at	at	IN	_	34	case	_	_
33	least	least	JJS	_	34	attr	_	_
34	5	0	CD	_	35	num	_	_
35	weeks	week	NNS	_	30	prn	_	_
36	may	may	MD	_	37	modal	_	_
37	be	be	VB	_	35	acl	_	_
38	necessary	necessary	JJ	_	37	dep	_	_
39	)	-rrb-	-RRB-	_	35	p	_	_
40	.	.	.	_	8	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	use	use	NN	_	14	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	with	with	IN	_	6	case	_	_
6	drugs	drug	NNS	_	2	ppmod	_	_
7	that	that	WDT	_	9	dep	_	_
8	can	can	MD	_	9	modal	_	_
9	inhibit	inhibit	VB	_	6	relcl	_	_
10	cytochrome	cytochrome	NN	_	12	com	_	_
11	P450	p0	NN	_	12	com	_	_
12	2D6	0d0	NN	_	9	obj	_	_
13	may	may	MD	_	14	modal	_	_
14	require	require	VB	_	0	root	_	_
15	lower	low	JJR	_	16	attr	_	_
16	doses	dose	NNS	_	14	obj	_	_
17	than	than	IN	_	18	case	_	_
18	usually	usually	RB	_	19	adv	_	_
19	prescribed	prescribe	VBN	_	16	acl	_	_
20	for	for	IN	_	23	case	_	_
21	either	either	CC	_	23	cc	_	_
22	the	the	DT	_	23	det	_	_
23	drug2	drug0	NN	_	19	ppmod	_	_
24	or	or	CC	_	23	cc	_	_
25	the	the	DT	_	27	det	_	_
26	other	other	JJ	_	27	attr	_	_
27	drug	drug	NN	_	23	conj	_	_
28	.	.	.	_	14	p	_	_

1	Furthermore	furthermore	RB	_	21	adv	_	_
2	,	,	,	_	21	p	_	_
3	whenever	whenever	RB	_	10	adv	_	_
4	one	#crd#	CD	_	10	num	_	_
5	of	of	IN	_	8	case	_	_
6	these	these	DT	_	8	det	_	_
7	other	other	JJ	_	8	attr	_	_
8	drugs	drug	NNS	_	4	ppmod	_	_
9	is	be	VBZ	_	10	aux	_	_
10	withdrawn	withdraw	VBN	_	21	advcl	_	_
11	from	from	IN	_	12	case	_	_
12	co-therapy	co-therapy	NN	_	10	ppmod	_	_
13	,	,	,	_	21	p	_	_
14	an	an	DT	_	16	det	_	_
15	increased	increase	VBN	_	16	attr	_	_
16	dose	dose	NN	_	21	dep	_	_
17	of	of	IN	_	18	case	_	_
18	drug1	drug0	NN	_	16	ppmod	_	_
19	may	may	MD	_	21	modal	_	_
20	be	be	VB	_	21	aux	_	_
21	required	require	VBN	_	0	root	_	_
22	.	.	.	_	21	p	_	_

1	It	it	PRP	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	desirable	desirable	JJ	_	2	dep	_	_
4	to	to	TO	_	5	aux	_	_
5	monitor	monitor	VB	_	2	comp	_	_
6	drug1	drug0	NN	_	8	com	_	_
7	plasma	plasma	NN	_	8	com	_	_
8	levels	level	NNS	_	5	obj	_	_
9	whenever	whenever	RB	_	12	adv	_	_
10	a	a	DT	_	11	det	_	_
11	drug2	drug0	NN	_	12	dep	_	_
12	is	be	VBZ	_	5	comp	_	_
13	going	going	JJ	_	12	dep	_	_
14	to	to	TO	_	16	aux	_	_
15	be	be	VB	_	16	aux	_	_
16	co-administered	co-administered	VBN	_	13	comp	_	_
17	with	with	IN	_	19	case	_	_
18	another	another	DT	_	19	det	_	_
19	drug	drug	NN	_	16	ppmod	_	_
20	known	know	VBN	_	19	acl	_	_
21	to	to	TO	_	22	aux	_	_
22	be	be	VB	_	20	comp	_	_
23	an	an	DT	_	24	det	_	_
24	inhibitor	inhibitor	NN	_	22	obj	_	_
25	of	of	IN	_	27	case	_	_
26	P450	p0	NN	_	27	com	_	_
27	2D6	0d0	NN	_	24	ppmod	_	_
28	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	primarily	primarily	RB	_	4	adv	_	_
4	metabolized	metabolize	VBN	_	0	root	_	_
5	by	by	IN	_	6	case	_	_
6	CYP2D6	cyp0d0	NN	_	4	ppmod	_	_
7	(	-lrb-	-LRB-	_	14	p	_	_
8	with	with	IN	_	9	case	_	_
9	CYP1A2	cyp0a0	NN	_	14	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	CYP3A4	cyp0a0	NN	_	9	conj	_	_
12	as	as	IN	_	14	case	_	_
13	minor	minor	JJ	_	14	attr	_	_
14	pathways	pathway	NNS	_	6	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	.	.	.	_	4	p	_	_

1	Inhibitors	inhibitor	NNS	_	17	dep	_	_
2	or	or	CC	_	1	cc	_	_
3	substrates	substrate	NNS	_	1	conj	_	_
4	of	of	IN	_	5	case	_	_
5	CYP2D6	cyp0d0	NN	_	1	ppmod	_	_
6	(	-lrb-	-LRB-	_	9	p	_	_
7	i.e.	i.e.	FW	_	9	ppmod	_	_
8	,	,	,	_	9	p	_	_
9	drug1	drug0	NN	_	5	prn	_	_
10	,	,	,	_	9	p	_	_
11	drug2	drug0	NN	_	9	appo	_	_
12	[	-lsb-	-LRB-	_	11	p	_	_
13	drug3	drug0	CD	_	11	num	_	_
14	]	-rsb-	-RRB-	_	11	p	_	_
15	)	-rrb-	-RRB-	_	9	p	_	_
16	may	may	MD	_	17	modal	_	_
17	increase	increase	VB	_	0	root	_	_
18	the	the	DT	_	20	det	_	_
19	plasma	plasma	NN	_	20	com	_	_
20	concentration	concentration	NN	_	17	obj	_	_
21	of	of	IN	_	22	case	_	_
22	drug4	drug0	NN	_	20	ppmod	_	_
23	when	when	WRB	_	24	adv	_	_
24	administered	administer	VBN	_	17	comp	_	_
25	concomitantly	concomitantly	RB	_	24	adv	_	_
26	.	.	.	_	17	p	_	_

1	The	the	DT	_	2	det	_	_
2	extent	extent	NN	_	5	dep	_	_
3	of	of	IN	_	4	case	_	_
4	interaction	interaction	NN	_	2	ppmod	_	_
5	depends	depend	VBZ	_	0	root	_	_
6	on	on	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	variability	variability	NN	_	5	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	effect	effect	NN	_	8	ppmod	_	_
11	on	on	IN	_	12	case	_	_
12	CYP2D6	cyp0d0	NN	_	8	ppmod	_	_
13	.	.	.	_	5	p	_	_

1	The	the	DT	_	3	det	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	significance	significance	NN	_	13	dep	_	_
4	of	of	IN	_	6	case	_	_
5	this	this	DT	_	6	det	_	_
6	interaction	interaction	NN	_	3	ppmod	_	_
7	with	with	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	has	have	VBZ	_	13	aux	_	_
10	not	not	RB	_	13	neg	_	_
11	been	be	VBN	_	13	aux	_	_
12	systematically	systematically	RB	_	13	adv	_	_
13	evaluated	evaluate	VBN	_	0	root	_	_
14	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Serious	serious	JJ	_	5	attr	_	_
4	side	side	JJ	_	5	attr	_	_
5	effects	effect	NNS	_	11	dep	_	_
6	and	and	CC	_	5	cc	_	_
7	even	even	JJ	_	8	attr	_	_
8	death	death	NN	_	5	conj	_	_
9	have	have	VBP	_	11	aux	_	_
10	been	be	VBN	_	11	aux	_	_
11	reported	report	VBN	_	1	acl	_	_
12	following	follow	VBG	_	15	adv	_	_
13	the	the	DT	_	15	det	_	_
14	concomitant	concomitant	JJ	_	15	attr	_	_
15	use	use	NN	_	11	ppmod	_	_
16	of	of	IN	_	18	case	_	_
17	certain	certain	JJ	_	18	attr	_	_
18	drugs	drug	NNS	_	15	ppmod	_	_
19	with	with	IN	_	20	case	_	_
20	drug2	drug0	NN	_	18	ppmod	_	_
21	.	.	.	_	1	p	_	_

1	Therefore	therefore	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	drug1	drug0	NN	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	discontinued	discontinue	VBN	_	0	root	_	_
7	at	at	IN	_	9	case	_	_
8	least	least	JJS	_	9	attr	_	_
9	two	#crd#	CD	_	10	num	_	_
10	weeks	week	NNS	_	6	obj	_	_
11	prior	prior	JJ	_	10	attr	_	_
12	to	to	TO	_	15	aux	_	_
13	the	the	DT	_	15	det	_	_
14	cautious	cautious	JJ	_	15	attr	_	_
15	initiation	initiation	NN	_	11	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	therapy	therapy	NN	_	15	ppmod	_	_
18	with	with	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	.	.	.	_	6	p	_	_

1	The	the	DT	_	3	det	_	_
2	exact	exact	JJ	_	3	attr	_	_
3	length	length	NN	_	7	dep	_	_
4	of	of	IN	_	5	case	_	_
5	time	time	NN	_	3	ppmod	_	_
6	may	may	MD	_	7	modal	_	_
7	vary	vary	VB	_	0	root	_	_
8	and	and	CC	_	7	cc	_	_
9	is	be	VBZ	_	7	conj	_	_
10	dependent	dependent	JJ	_	9	dep	_	_
11	upon	upon	IN	_	14	case	_	_
12	the	the	DT	_	14	det	_	_
13	particular	particular	JJ	_	14	attr	_	_
14	drug1	drug0	NN	_	10	ppmod	_	_
15	being	be	VBG	_	16	aux	_	_
16	used	use	VBN	_	14	acl	_	_
17	,	,	,	_	14	p	_	_
18	the	the	DT	_	19	det	_	_
19	length	length	NN	_	14	conj	_	_
20	of	of	IN	_	21	case	_	_
21	time	time	NN	_	19	ppmod	_	_
22	it	it	PRP	_	25	dep	_	_
23	has	have	VBZ	_	25	aux	_	_
24	been	be	VBN	_	25	aux	_	_
25	administered	administer	VBN	_	19	acl	_	_
26	,	,	,	_	19	p	_	_
27	and	and	CC	_	19	cc	_	_
28	the	the	DT	_	29	det	_	_
29	dosage	dosage	NN	_	14	conj	_	_
30	involved	involve	VBN	_	29	acl	_	_
31	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	has	have	VBZ	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	reported	report	VBN	_	0	root	_	_
7	to	to	TO	_	8	aux	_	_
8	produce	produce	VB	_	6	comp	_	_
9	clinically	clinically	RB	_	10	adv	_	_
10	significant	significant	JJ	_	11	attr	_	_
11	fluctuations	fluctuation	NNS	_	8	obj	_	_
12	in	in	IN	_	15	case	_	_
13	steady-state	steady-state	JJ	_	15	attr	_	_
14	serum	serum	NN	_	15	com	_	_
15	concentrations	concentration	NNS	_	11	ppmod	_	_
16	of	of	IN	_	18	case	_	_
17	various	various	JJ	_	18	attr	_	_
18	drug3	drug0	NNS	_	15	ppmod	_	_
19	.	.	.	_	6	p	_	_

1	Serious	serious	JJ	_	3	attr	_	_
2	anticholinergic	anticholinergic	JJ	_	3	attr	_	_
3	symptoms	symptom	NNS	_	19	dep	_	_
4	(	-lrb-	-LRB-	_	9	p	_	_
5	i.e.	i.e.	FW	_	9	adv	_	_
6	,	,	,	_	9	p	_	_
7	severe	severe	JJ	_	9	attr	_	_
8	dry	dry	JJ	_	9	attr	_	_
9	mouth	mouth	NN	_	3	prn	_	_
10	,	,	,	_	9	p	_	_
11	urinary	urinary	JJ	_	12	attr	_	_
12	retention	retention	NN	_	9	conj	_	_
13	and	and	CC	_	12	cc	_	_
14	blurred	blurred	JJ	_	15	attr	_	_
15	vision	vision	NN	_	9	conj	_	_
16	)	-rrb-	-RRB-	_	9	p	_	_
17	have	have	VBP	_	19	aux	_	_
18	been	be	VBN	_	19	aux	_	_
19	associated	associate	VBN	_	0	root	_	_
20	with	with	IN	_	21	case	_	_
21	elevations	elevation	NNS	_	19	ppmod	_	_
22	in	in	IN	_	25	case	_	_
23	the	the	DT	_	25	det	_	_
24	serum	serum	NN	_	25	com	_	_
25	levels	level	NNS	_	21	ppmod	_	_
26	of	of	IN	_	27	case	_	_
27	drug1	drug0	NN	_	25	ppmod	_	_
28	when	when	WRB	_	32	adv	_	_
29	drug2	drug0	NN	_	30	com	_	_
30	therapy	therapy	NN	_	32	dep	_	_
31	is	be	VBZ	_	32	aux	_	_
32	initiated	initiate	VBN	_	19	comp	_	_
33	.	.	.	_	19	p	_	_

1	Additionally	additionally	RB	_	10	adv	_	_
2	,	,	,	_	10	p	_	_
3	higher	high	JJR	_	7	attr	_	_
4	than	than	IN	_	7	case	_	_
5	expected	expect	VBN	_	7	attr	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	levels	level	NNS	_	10	dep	_	_
8	have	have	VBP	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	observed	observe	VBN	_	0	root	_	_
11	when	when	WRB	_	14	adv	_	_
12	they	they	PRP	_	14	dep	_	_
13	are	be	VBP	_	14	aux	_	_
14	begun	begin	VBN	_	10	comp	_	_
15	in	in	IN	_	16	case	_	_
16	patients	patient	NNS	_	14	ppmod	_	_
17	already	already	RB	_	18	adv	_	_
18	taking	take	VBG	_	16	acl	_	_
19	drug2	drug0	NN	_	18	obj	_	_
20	.	.	.	_	10	p	_	_

1	In	in	IN	_	2	case	_	_
2	patients	patient	NNS	_	23	ppmod	_	_
3	who	who	WP	_	6	dep	_	_
4	have	have	VBP	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	reported	report	VBN	_	2	relcl	_	_
7	to	to	TO	_	10	aux	_	_
8	be	be	VB	_	10	aux	_	_
9	well	well	RB	_	10	adv	_	_
10	controlled	control	VBN	_	6	comp	_	_
11	on	on	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	receiving	receive	VBG	_	12	acl	_	_
14	concurrent	concurrent	JJ	_	16	attr	_	_
15	drug2	drug0	NN	_	16	com	_	_
16	therapy	therapy	NN	_	13	obj	_	_
17	,	,	,	_	23	p	_	_
18	discontinuation	discontinuation	NN	_	23	dep	_	_
19	of	of	IN	_	20	case	_	_
20	drug3	drug0	NN	_	18	ppmod	_	_
21	has	have	VBZ	_	23	aux	_	_
22	been	be	VBN	_	23	aux	_	_
23	reported	report	VBN	_	0	root	_	_
24	to	to	TO	_	25	aux	_	_
25	decrease	decrease	VB	_	23	comp	_	_
26	established	established	JJ	_	30	attr	_	_
27	steady-state	steady-state	JJ	_	30	attr	_	_
28	serum	serum	NN	_	30	com	_	_
29	drug4	drug0	NN	_	30	com	_	_
30	levels	level	NNS	_	25	obj	_	_
31	and	and	CC	_	25	cc	_	_
32	compromise	compromise	VB	_	25	conj	_	_
33	their	their	PRP$	_	35	poss	_	_
34	therapeutic	therapeutic	JJ	_	35	attr	_	_
35	effects	effect	NNS	_	32	obj	_	_
36	.	.	.	_	23	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	It	it	PRP	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	borne	bear	VBN	_	1	acl	_	_
7	in	in	IN	_	8	case	_	_
8	mind	mind	NN	_	6	ppmod	_	_
9	that	that	IN	_	13	mark	_	_
10	drug2	drug0	NN	_	11	com	_	_
11	ingestion	ingestion	NN	_	13	dep	_	_
12	may	may	MD	_	13	modal	_	_
13	increase	increase	VB	_	6	comp	_	_
14	the	the	DT	_	15	det	_	_
15	danger	danger	NN	_	13	obj	_	_
16	inherent	inherent	JJ	_	15	attr	_	_
17	in	in	IN	_	23	case	_	_
18	any	any	DT	_	23	det	_	_
19	intentional	intentional	JJ	_	23	attr	_	_
20	or	or	CC	_	19	cc	_	_
21	unintentional	unintentional	JJ	_	19	conj	_	_
22	drug3	drug0	NN	_	23	com	_	_
23	overdosage	overdosage	NN	_	16	ppmod	_	_
24	.	.	.	_	1	p	_	_

1	This	this	DT	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	especially	especially	RB	_	4	adv	_	_
4	important	important	JJ	_	2	dep	_	_
5	in	in	IN	_	6	case	_	_
6	patients	patient	NNS	_	4	ppmod	_	_
7	who	who	WP	_	9	dep	_	_
8	may	may	MD	_	9	modal	_	_
9	use	use	VB	_	6	relcl	_	_
10	drug1	drug0	NN	_	9	obj	_	_
11	excessively	excessively	RB	_	9	adv	_	_
12	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	A	a	DT	_	4	det	_	_
4	case	case	NN	_	10	dep	_	_
5	of	of	IN	_	7	case	_	_
6	severe	severe	JJ	_	7	attr	_	_
7	hypoglycemia	hypoglycemia	NN	_	4	ppmod	_	_
8	has	have	VBZ	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	reported	report	VBN	_	1	acl	_	_
11	in	in	IN	_	16	case	_	_
12	a	a	DT	_	16	det	_	_
13	type	type	NN	_	16	attr	_	_
14	II	ii	CD	_	16	num	_	_
15	diabetic	diabetic	JJ	_	16	attr	_	_
16	patient	patient	NN	_	10	ppmod	_	_
17	maintained	maintain	VBN	_	16	acl	_	_
18	on	on	IN	_	25	case	_	_
19	drug2	drug0	NN	_	25	attr	_	_
20	(	-lrb-	-LRB-	_	22	p	_	_
21	1	0	CD	_	22	num	_	_
22	gm/day	gm/day	NN	_	19	prn	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	11	0	CD	_	25	num	_	_
25	days	day	NNS	_	17	ppmod	_	_
26	after	after	IN	_	28	case	_	_
27	the	the	DT	_	28	det	_	_
28	addition	addition	NN	_	25	ppmod	_	_
29	of	of	IN	_	30	case	_	_
30	drug3	drug0	NN	_	28	ppmod	_	_
31	(	-lrb-	-LRB-	_	33	p	_	_
32	75	0	CD	_	33	num	_	_
33	mg/day	mg/day	NN	_	30	prn	_	_
34	)	-rrb-	-RRB-	_	33	p	_	_
35	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	should	should	MD	_	5	modal	_	_
3	not	not	RB	_	5	neg	_	_
4	be	be	VB	_	5	aux	_	_
5	used	use	VBN	_	0	root	_	_
6	in	in	IN	_	7	case	_	_
7	patients	patient	NNS	_	5	ppmod	_	_
8	receiving	receive	VBG	_	7	acl	_	_
9	drug2	drug0	NN	_	8	obj	_	_
10	.	.	.	_	5	p	_	_
11	.	.	.	_	5	p	_	_

1	Although	although	IN	_	14	mark	_	_
2	no	no	DT	_	5	det	_	_
3	specific	specific	JJ	_	5	attr	_	_
4	drug	drug	NN	_	5	com	_	_
5	interactions	interaction	NNS	_	14	dep	_	_
6	with	with	IN	_	9	case	_	_
7	topical	topical	JJ	_	9	attr	_	_
8	glaucoma	glaucoma	NN	_	9	com	_	_
9	drugs	drug	NNS	_	5	ppmod	_	_
10	or	or	CC	_	9	cc	_	_
11	systemic	systemic	JJ	_	12	attr	_	_
12	medications	medication	NNS	_	9	conj	_	_
13	were	be	VBD	_	14	aux	_	_
14	identified	identify	VBN	_	48	advcl	_	_
15	in	in	IN	_	17	case	_	_
16	clinical	clinical	JJ	_	17	attr	_	_
17	studies	study	NNS	_	14	ppmod	_	_
18	of	of	IN	_	23	case	_	_
19	drug1	drug0	JJ	_	23	attr	_	_
20	0.5	0	CD	_	23	num	_	_
21	%	%	NN	_	20	meta	_	_
22	Ophthalmic	ophthalmic	JJ	_	23	attr	_	_
23	Solution	solution	NN	_	17	ppmod	_	_
24	,	,	,	_	48	p	_	_
25	the	the	DT	_	26	det	_	_
26	possibility	possibility	NN	_	48	dep	_	_
27	of	of	IN	_	32	case	_	_
28	an	an	DT	_	32	det	_	_
29	additive	additive	JJ	_	32	attr	_	_
30	or	or	NN	_	32	com	_	_
31	potentiating	potentiating	NN	_	32	com	_	_
32	effect	effect	NN	_	26	ppmod	_	_
33	with	with	IN	_	34	case	_	_
34	drug2	drug0	NN	_	32	ppmod	_	_
35	(	-lrb-	-LRB-	_	36	p	_	_
36	drug3	drug0	NN	_	34	prn	_	_
37	,	,	,	_	36	p	_	_
38	drug4	drug0	NN	_	36	appo	_	_
39	,	,	,	_	36	p	_	_
40	drug5	drug0	NN	_	36	appo	_	_
41	,	,	,	_	36	p	_	_
42	drug6	drug0	NN	_	36	appo	_	_
43	,	,	,	_	36	p	_	_
44	drug7	drug0	NN	_	36	appo	_	_
45	)	-rrb-	-RRB-	_	36	p	_	_
46	should	should	MD	_	48	modal	_	_
47	be	be	VB	_	48	aux	_	_
48	considered	consider	VBN	_	0	root	_	_
49	.	.	.	_	48	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	have	have	VBP	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	reported	report	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	blunt	blunt	VB	_	4	comp	_	_
7	the	the	DT	_	9	det	_	_
8	hypotensive	hypotensive	JJ	_	9	attr	_	_
9	effect	effect	NN	_	6	obj	_	_
10	of	of	IN	_	12	case	_	_
11	systemic	systemic	JJ	_	12	attr	_	_
12	drug2	drug0	NN	_	9	ppmod	_	_
13	.	.	.	_	4	p	_	_

1	It	it	PRP	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	known	know	VBN	_	0	root	_	_
5	whether	whether	IN	_	15	mark	_	_
6	the	the	DT	_	8	det	_	_
7	concurrent	concurrent	JJ	_	8	attr	_	_
8	use	use	NN	_	15	dep	_	_
9	of	of	IN	_	11	case	_	_
10	these	these	DT	_	11	det	_	_
11	agents	agent	NNS	_	8	ppmod	_	_
12	with	with	IN	_	13	case	_	_
13	drug1	drug0	NN	_	8	ppmod	_	_
14	can	can	MD	_	15	modal	_	_
15	lead	lead	VB	_	4	comp	_	_
16	to	to	TO	_	18	aux	_	_
17	a	a	DT	_	18	det	_	_
18	reduction	reduction	NN	_	15	ppmod	_	_
19	in	in	IN	_	22	case	_	_
20	IOP	iop	NN	_	22	attr	_	_
21	lowering	lowering	JJ	_	22	attr	_	_
22	effect	effect	NN	_	18	ppmod	_	_
23	.	.	.	_	4	p	_	_

1	No	no	DT	_	2	det	_	_
2	data	datum	NNS	_	12	dep	_	_
3	on	on	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	level	level	NN	_	2	ppmod	_	_
6	of	of	IN	_	8	case	_	_
7	circulating	circulating	JJ	_	8	attr	_	_
8	catecholamines	catecholamine	NNS	_	5	ppmod	_	_
9	after	after	IN	_	11	case	_	_
10	drug1	drug0	NN	_	11	com	_	_
11	withdrawal	withdrawal	NN	_	5	ppmod	_	_
12	are	be	VBP	_	0	root	_	_
13	available	available	JJ	_	12	dep	_	_
14	.	.	.	_	12	p	_	_

1	Caution	caution	NN	_	6	dep	_	_
2	,	,	,	_	6	p	_	_
3	however	however	RB	_	6	adv	_	_
4	,	,	,	_	6	p	_	_
5	is	be	VBZ	_	6	aux	_	_
6	advised	advise	VBN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	6	ppmod	_	_
9	taking	take	VBG	_	8	acl	_	_
10	drug1	drug0	NN	_	9	obj	_	_
11	which	which	WDT	_	13	dep	_	_
12	can	can	MD	_	13	modal	_	_
13	affect	affect	VB	_	10	relcl	_	_
14	the	the	DT	_	15	det	_	_
15	metabolism	metabolism	NN	_	13	obj	_	_
16	and	and	CC	_	15	cc	_	_
17	uptake	uptake	NN	_	15	conj	_	_
18	of	of	IN	_	20	case	_	_
19	circulating	circulate	VBG	_	20	attr	_	_
20	amines	amine	NNS	_	15	ppmod	_	_
21	.	.	.	_	6	p	_	_

1	An	an	DT	_	4	det	_	_
2	additive	additive	JJ	_	4	attr	_	_
3	hypotensive	hypotensive	JJ	_	4	attr	_	_
4	effect	effect	NN	_	7	dep	_	_
5	has	have	VBZ	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	reported	report	VBN	_	0	root	_	_
8	with	with	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	combination	combination	NN	_	7	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	systemic	systemic	JJ	_	13	attr	_	_
13	drug1	drug0	NN	_	10	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	drug2	drug0	JJ	_	16	attr	_	_
16	therapy	therapy	NN	_	13	conj	_	_
17	.	.	.	_	7	p	_	_

1	Systemic	systemic	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	inhibit	inhibit	VB	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	production	production	NN	_	4	obj	_	_
7	of	of	IN	_	8	case	_	_
8	catecholamines	catecholamine	NNS	_	6	ppmod	_	_
9	in	in	IN	_	10	case	_	_
10	response	response	NN	_	6	ppmod	_	_
11	to	to	TO	_	13	aux	_	_
12	insulin-induced	insulin-induced	JJ	_	13	attr	_	_
13	hypoglycemia	hypoglycemia	NN	_	10	ppmod	_	_
14	and	and	CC	_	4	cc	_	_
15	mask	mask	VB	_	4	conj	_	_
16	the	the	DT	_	17	det	_	_
17	signs	sign	NNS	_	15	obj	_	_
18	and	and	CC	_	17	cc	_	_
19	symptoms	symptom	NNS	_	17	conj	_	_
20	of	of	IN	_	21	case	_	_
21	hypoglycemia	hypoglycemia	NN	_	17	ppmod	_	_
22	.	.	.	_	4	p	_	_

1	Since	since	IN	_	4	mark	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	reduce	reduce	VB	_	27	advcl	_	_
5	pulse	pulse	NN	_	4	obj	_	_
6	and	and	CC	_	5	cc	_	_
7	blood	blood	NN	_	8	com	_	_
8	pressure	pressure	NN	_	5	conj	_	_
9	,	,	,	_	27	p	_	_
10	caution	caution	NN	_	27	dep	_	_
11	in	in	IN	_	12	case	_	_
12	using	use	VBG	_	10	ppmod	_	_
13	drugs	drug	NNS	_	12	obj	_	_
14	such	such	JJ	_	16	adv	_	_
15	as	as	IN	_	16	case	_	_
16	drug2	drug0	NN	_	13	ppmod	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	ophthalmic	ophthalmic	JJ	_	16	prn	_	_
19	and	and	CC	_	18	cc	_	_
20	systemic	systemic	JJ	_	18	conj	_	_
21	)	-rrb-	-RRB-	_	18	p	_	_
22	,	,	,	_	16	p	_	_
23	drug3	drug0	NN	_	16	conj	_	_
24	,	,	,	_	23	p	_	_
25	and	and	CC	_	23	cc	_	_
26	drug4	drug0	NN	_	16	conj	_	_
27	is	be	VBZ	_	0	root	_	_
28	advised	advised	JJ	_	27	dep	_	_
29	.	.	.	_	27	p	_	_

1	Patients	patient	NNS	_	13	dep	_	_
2	using	use	VBG	_	1	acl	_	_
3	cardiovascular	cardiovascular	JJ	_	4	attr	_	_
4	drugs	drug	NNS	_	2	obj	_	_
5	concurrently	concurrently	RB	_	11	adv	_	_
6	with	with	IN	_	11	case	_	_
7	drug1	drug0	JJ	_	11	attr	_	_
8	0.5	0	CD	_	11	num	_	_
9	%	%	NN	_	8	meta	_	_
10	Ophthalmic	ophthalmic	JJ	_	11	attr	_	_
11	Solution	solution	NN	_	4	ppmod	_	_
12	should	should	MD	_	13	modal	_	_
13	have	have	VB	_	0	root	_	_
14	pulse	pulse	NN	_	19	dep	_	_
15	and	and	CC	_	14	cc	_	_
16	blood	blood	NN	_	17	com	_	_
17	pressures	pressure	NNS	_	14	conj	_	_
18	frequently	frequently	RB	_	19	adv	_	_
19	monitored	monitor	VBN	_	13	comp	_	_
20	.	.	.	_	13	p	_	_

1	Caution	caution	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	exercised	exercise	VBN	_	0	root	_	_
5	with	with	IN	_	7	case	_	_
6	simultaneous	simultaneous	JJ	_	7	attr	_	_
7	use	use	NN	_	4	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	and	and	CC	_	7	cc	_	_
11	other	other	JJ	_	14	attr	_	_
12	similar	similar	JJ	_	14	attr	_	_
13	pharmacologic	pharmacologic	JJ	_	14	attr	_	_
14	agents	agent	NNS	_	7	conj	_	_

1	.	.	.	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	Immediate	immediate	JJ	_	5	attr	_	_
2	and	and	CC	_	1	cc	_	_
3	Extended	extended	JJ	_	1	conj	_	_
4	Release	release	NN	_	5	com	_	_
5	Tablets	tablet	NNS	_	0	root	_	_
6	The	the	DT	_	8	det	_	_
7	hypoglycemic	hypoglycemic	JJ	_	8	attr	_	_
8	action	action	NN	_	13	dep	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	may	may	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	potentiated	potentiate	VBN	_	5	acl	_	_
14	by	by	IN	_	16	case	_	_
15	certain	certain	JJ	_	16	attr	_	_
16	drugs	drug	NNS	_	13	ppmod	_	_
17	including	include	VBG	_	18	adv	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	,	,	,	_	18	p	_	_
20	some	some	DT	_	21	det	_	_
21	drug3	drug0	NN	_	18	conj	_	_
22	and	and	CC	_	21	cc	_	_
23	other	other	JJ	_	24	attr	_	_
24	drugs	drug	NNS	_	21	conj	_	_
25	that	that	WDT	_	29	dep	_	_
26	are	be	VBP	_	29	aux	_	_
27	highly	highly	RB	_	29	adv	_	_
28	protein	protein	NN	_	29	dep	_	_
29	bound	bind	VBN	_	21	relcl	_	_
30	,	,	,	_	21	p	_	_
31	drug4	drug0	NN	_	18	conj	_	_
32	,	,	,	_	31	p	_	_
33	drug5	drug0	NN	_	18	conj	_	_
34	,	,	,	_	33	p	_	_
35	drug6	drug0	NN	_	18	conj	_	_
36	,	,	,	_	35	p	_	_
37	drug7	drug0	NN	_	18	conj	_	_
38	,	,	,	_	37	p	_	_
39	drug8	drug0	NN	_	18	conj	_	_
40	,	,	,	_	39	p	_	_
41	drug9	drug0	NN	_	18	conj	_	_
42	,	,	,	_	41	p	_	_
43	and	and	CC	_	41	cc	_	_
44	drug10	drug0	NN	_	18	conj	_	_
45	.	.	.	_	5	p	_	_

1	When	when	WRB	_	5	adv	_	_
2	such	such	JJ	_	3	attr	_	_
3	drugs	drug	NNS	_	5	dep	_	_
4	are	be	VBP	_	5	aux	_	_
5	administered	administer	VBN	_	16	advcl	_	_
6	to	to	TO	_	8	aux	_	_
7	a	a	DT	_	8	det	_	_
8	patient	patient	NN	_	5	ppmod	_	_
9	receiving	receive	VBG	_	8	acl	_	_
10	drug1	drug0	NN	_	9	obj	_	_
11	,	,	,	_	16	p	_	_
12	the	the	DT	_	13	det	_	_
13	patient	patient	NN	_	16	dep	_	_
14	should	should	MD	_	16	modal	_	_
15	be	be	VB	_	16	aux	_	_
16	observed	observe	VBN	_	0	root	_	_
17	closely	closely	RB	_	16	adv	_	_
18	for	for	IN	_	19	case	_	_
19	hypoglycemia	hypoglycemia	NN	_	16	ppmod	_	_
20	.	.	.	_	16	p	_	_

1	When	when	WRB	_	5	adv	_	_
2	such	such	JJ	_	3	attr	_	_
3	drugs	drug	NNS	_	5	dep	_	_
4	are	be	VBP	_	5	aux	_	_
5	withdrawn	withdraw	VBN	_	16	advcl	_	_
6	from	from	IN	_	8	case	_	_
7	a	a	DT	_	8	det	_	_
8	patient	patient	NN	_	5	ppmod	_	_
9	receiving	receive	VBG	_	8	acl	_	_
10	drug1	drug0	NN	_	9	obj	_	_
11	,	,	,	_	16	p	_	_
12	the	the	DT	_	13	det	_	_
13	patient	patient	NN	_	16	dep	_	_
14	should	should	MD	_	16	modal	_	_
15	be	be	VB	_	16	aux	_	_
16	observed	observe	VBN	_	0	root	_	_
17	closely	closely	RB	_	16	adv	_	_
18	for	for	IN	_	19	case	_	_
19	loss	loss	NN	_	16	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	control	control	NN	_	19	ppmod	_	_
22	.	.	.	_	16	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	4	attr	_	_
3	binding	binding	NN	_	4	com	_	_
4	studies	study	NNS	_	9	dep	_	_
5	with	with	IN	_	8	case	_	_
6	human	human	JJ	_	8	attr	_	_
7	serum	serum	NN	_	8	com	_	_
8	proteins	protein	NNS	_	4	ppmod	_	_
9	indicate	indicate	VBP	_	0	root	_	_
10	that	that	IN	_	12	mark	_	_
11	drug1	drug0	NN	_	12	dep	_	_
12	binds	bind	VBZ	_	9	comp	_	_
13	differently	differently	RB	_	12	adv	_	_
14	than	than	IN	_	15	case	_	_
15	drug2	drug0	NN	_	12	ppmod	_	_
16	and	and	CC	_	12	cc	_	_
17	does	do	VBZ	_	19	aux	_	_
18	not	not	RB	_	19	neg	_	_
19	interact	interact	VB	_	12	conj	_	_
20	with	with	IN	_	21	case	_	_
21	drug3	drug0	NN	_	19	ppmod	_	_
22	or	or	CC	_	21	cc	_	_
23	drug4	drug0	NN	_	21	conj	_	_
24	.	.	.	_	9	p	_	_

1	However	however	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	caution	caution	NN	_	6	dep	_	_
4	must	must	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	exercised	exercise	VBN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	extrapolating	extrapolate	VBG	_	6	ppmod	_	_
9	these	these	DT	_	10	det	_	_
10	findings	finding	NNS	_	8	obj	_	_
11	to	to	TO	_	14	aux	_	_
12	the	the	DT	_	14	det	_	_
13	clinical	clinical	JJ	_	14	attr	_	_
14	situation	situation	NN	_	8	ppmod	_	_
15	and	and	CC	_	8	cc	_	_
16	in	in	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	use	use	NN	_	8	conj	_	_
19	of	of	IN	_	20	case	_	_
20	drug1	drug0	NN	_	18	ppmod	_	_
21	with	with	IN	_	23	case	_	_
22	these	these	DT	_	23	det	_	_
23	drugs	drug	NNS	_	18	ppmod	_	_
24	.	.	.	_	6	p	_	_

1	Certain	certain	JJ	_	2	attr	_	_
2	drugs	drug	NNS	_	3	dep	_	_
3	tend	tend	VBP	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	produce	produce	VB	_	3	comp	_	_
6	hyperglycemia	hyperglycemia	NN	_	5	obj	_	_
7	and	and	CC	_	5	cc	_	_
8	may	may	MD	_	9	modal	_	_
9	lead	lead	VB	_	5	conj	_	_
10	to	to	TO	_	11	aux	_	_
11	loss	loss	NN	_	9	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	control	control	NN	_	11	ppmod	_	_
14	.	.	.	_	3	p	_	_

1	These	these	DT	_	2	det	_	_
2	drugs	drug	NNS	_	3	dep	_	_
3	include	include	VBP	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	drug1	drug0	NN	_	3	obj	_	_
6	and	and	CC	_	5	cc	_	_
7	other	other	JJ	_	8	attr	_	_
8	drug2	drug0	NNS	_	5	conj	_	_
9	,	,	,	_	5	p	_	_
10	drug3	drug0	NN	_	5	appo	_	_
11	,	,	,	_	10	p	_	_
12	drug4	drug0	NN	_	10	conj	_	_
13	,	,	,	_	12	p	_	_
14	drug5	drug0	NN	_	10	conj	_	_
15	,	,	,	_	14	p	_	_
16	drug6	drug0	NN	_	10	conj	_	_
17	,	,	,	_	16	p	_	_
18	oral	oral	JJ	_	19	attr	_	_
19	drug7	drug0	NN	_	10	conj	_	_
20	,	,	,	_	19	p	_	_
21	drug8	drug0	NN	_	10	conj	_	_
22	,	,	,	_	21	p	_	_
23	drug9	drug0	NN	_	10	conj	_	_
24	,	,	,	_	23	p	_	_
25	drug10	drug0	NN	_	10	conj	_	_
26	,	,	,	_	25	p	_	_
27	drug11	drug0	NN	_	10	conj	_	_
28	,	,	,	_	27	p	_	_
29	and	and	CC	_	27	cc	_	_
30	drug12	drug0	NN	_	10	conj	_	_
31	.	.	.	_	3	p	_	_

1	When	when	WRB	_	5	adv	_	_
2	such	such	JJ	_	3	attr	_	_
3	drugs	drug	NNS	_	5	dep	_	_
4	are	be	VBP	_	5	aux	_	_
5	administered	administer	VBN	_	17	advcl	_	_
6	to	to	TO	_	8	aux	_	_
7	a	a	DT	_	8	det	_	_
8	patient	patient	NN	_	5	ppmod	_	_
9	receiving	receive	VBG	_	8	acl	_	_
10	drug1	drug0	NN	_	9	obj	_	_
11	,	,	,	_	17	p	_	_
12	the	the	DT	_	13	det	_	_
13	patient	patient	NN	_	17	dep	_	_
14	should	should	MD	_	17	modal	_	_
15	be	be	VB	_	17	aux	_	_
16	closely	closely	RB	_	17	adv	_	_
17	observed	observe	VBN	_	0	root	_	_
18	for	for	IN	_	19	case	_	_
19	loss	loss	NN	_	17	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	control	control	NN	_	19	ppmod	_	_
22	.	.	.	_	17	p	_	_

1	When	when	WRB	_	5	adv	_	_
2	such	such	JJ	_	3	attr	_	_
3	drugs	drug	NNS	_	5	dep	_	_
4	are	be	VBP	_	5	aux	_	_
5	withdrawn	withdraw	VBN	_	16	advcl	_	_
6	from	from	IN	_	8	case	_	_
7	a	a	DT	_	8	det	_	_
8	patient	patient	NN	_	5	ppmod	_	_
9	receiving	receive	VBG	_	8	acl	_	_
10	drug1	drug0	NN	_	9	obj	_	_
11	,	,	,	_	16	p	_	_
12	the	the	DT	_	13	det	_	_
13	patient	patient	NN	_	16	dep	_	_
14	should	should	MD	_	16	modal	_	_
15	be	be	VB	_	16	aux	_	_
16	observed	observe	VBN	_	0	root	_	_
17	closely	closely	RB	_	16	adv	_	_
18	for	for	IN	_	19	case	_	_
19	hypoglycemia	hypoglycemia	NN	_	16	ppmod	_	_
20	.	.	.	_	16	p	_	_

1	A	a	DT	_	3	det	_	_
2	potential	potential	JJ	_	3	attr	_	_
3	interaction	interaction	NN	_	16	dep	_	_
4	between	between	IN	_	6	case	_	_
5	oral	oral	JJ	_	6	attr	_	_
6	drug1	drug0	NN	_	3	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	oral	oral	JJ	_	9	attr	_	_
9	drug2	drug0	NN	_	6	conj	_	_
10	leading	lead	VBG	_	6	acl	_	_
11	to	to	TO	_	13	aux	_	_
12	severe	severe	JJ	_	13	attr	_	_
13	hypoglycemia	hypoglycemia	NN	_	10	ppmod	_	_
14	has	have	VBZ	_	16	aux	_	_
15	been	be	VBN	_	16	aux	_	_
16	reported	report	VBN	_	0	root	_	_
17	.	.	.	_	16	p	_	_

1	Whether	whether	IN	_	5	mark	_	_
2	this	this	DT	_	3	det	_	_
3	interaction	interaction	NN	_	5	dep	_	_
4	also	also	RB	_	5	adv	_	_
5	occurs	occur	VBZ	_	19	advcl	_	_
6	with	with	IN	_	14	case	_	_
7	the	the	DT	_	14	det	_	_
8	intravenous	intravenous	JJ	_	14	attr	_	_
9	,	,	,	_	8	p	_	_
10	topical	topical	JJ	_	8	conj	_	_
11	,	,	,	_	10	p	_	_
12	or	or	CC	_	10	cc	_	_
13	vaginal	vaginal	JJ	_	8	conj	_	_
14	preparations	preparation	NNS	_	5	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	is	be	VBZ	_	19	aux	_	_
18	not	not	RB	_	19	neg	_	_
19	known	know	VBN	_	0	root	_	_
20	.	.	.	_	19	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	12	dep	_	_
3	of	of	IN	_	5	case	_	_
4	concomitant	concomitant	JJ	_	5	attr	_	_
5	administration	administration	NN	_	2	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	has	have	VBZ	_	12	aux	_	_
11	been	be	VBN	_	12	aux	_	_
12	demonstrated	demonstrate	VBN	_	0	root	_	_
13	in	in	IN	_	17	case	_	_
14	a	a	DT	_	17	det	_	_
15	placebo-controlled	placebo-controlled	JJ	_	17	attr	_	_
16	crossover	crossover	NN	_	17	com	_	_
17	study	study	NN	_	12	ppmod	_	_
18	in	in	IN	_	20	case	_	_
19	normal	normal	JJ	_	20	attr	_	_
20	volunteers	volunteer	NNS	_	17	ppmod	_	_
21	.	.	.	_	12	p	_	_

1	All	all	DT	_	2	det	_	_
2	subjects	subject	NNS	_	3	dep	_	_
3	received	receive	VBD	_	0	root	_	_
4	drug1	drug0	NN	_	3	obj	_	_
5	alone	alone	RB	_	4	adv	_	_
6	and	and	CC	_	4	cc	_	_
7	following	follow	VBG	_	8	attr	_	_
8	treatment	treatment	NN	_	4	conj	_	_
9	with	with	IN	_	11	case	_	_
10	100	0	CD	_	11	num	_	_
11	mg	mg	NN	_	8	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	as	as	IN	_	19	case	_	_
15	a	a	DT	_	19	det	_	_
16	single	single	JJ	_	19	attr	_	_
17	daily	daily	JJ	_	19	attr	_	_
18	oral	oral	JJ	_	19	attr	_	_
19	dose	dose	NN	_	3	ppmod	_	_
20	for	for	IN	_	22	case	_	_
21	seven	#crd#	CD	_	22	num	_	_
22	days	day	NNS	_	19	ppmod	_	_
23	.	.	.	_	3	p	_	_

1	The	the	DT	_	4	det	_	_
2	mean	mean	JJ	_	4	attr	_	_
3	percentage	percentage	NN	_	4	com	_	_
4	increase	increase	NN	_	12	dep	_	_
5	in	in	IN	_	8	case	_	_
6	the	the	DT	_	8	det	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	AUC	auc	NN	_	4	ppmod	_	_
9	after	after	IN	_	11	case	_	_
10	drug2	drug0	NN	_	11	com	_	_
11	administration	administration	NN	_	4	ppmod	_	_
12	was	be	VBD	_	0	root	_	_
13	56.9	0	CD	_	12	obj	_	_
14	%	%	NN	_	13	meta	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	range	range	NN	_	13	prn	_	_
17	:	:	:	_	16	p	_	_
18	35	0	CD	_	20	num	_	_
19	to	to	TO	_	20	attr	_	_
20	81	0	CD	_	16	appo	_	_
21	)	-rrb-	-RRB-	_	16	p	_	_
22	.	.	.	_	12	p	_	_

1	Intravenous	intravenous	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	9	dep	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	drug2	drug0	NN	_	2	prn	_	_
5	)	-rrb-	-RRB-	_	4	p	_	_
6	has	have	VBZ	_	9	aux	_	_
7	been	be	VBN	_	9	aux	_	_
8	effectively	effectively	RB	_	9	adv	_	_
9	administered	administer	VBN	_	0	root	_	_
10	in	in	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	presence	presence	NN	_	9	ppmod	_	_
13	of	of	IN	_	16	case	_	_
14	other	other	JJ	_	16	attr	_	_
15	cardioactive	cardioactive	JJ	_	16	attr	_	_
16	drugs	drug	NNS	_	12	ppmod	_	_
17	,	,	,	_	16	p	_	_
18	such	such	JJ	_	20	adv	_	_
19	as	as	IN	_	20	case	_	_
20	drug3	drug0	NN	_	16	ppmod	_	_
21	,	,	,	_	20	p	_	_
22	drug4	drug0	NN	_	20	conj	_	_
23	,	,	,	_	22	p	_	_
24	drug5	drug0	NN	_	20	conj	_	_
25	,	,	,	_	24	p	_	_
26	and	and	CC	_	24	cc	_	_
27	drug6	drug0	NN	_	20	conj	_	_
28	,	,	,	_	9	p	_	_
29	without	without	IN	_	31	case	_	_
30	any	any	DT	_	31	det	_	_
31	change	change	NN	_	9	ppmod	_	_
32	in	in	IN	_	36	case	_	_
33	the	the	DT	_	36	det	_	_
34	adverse	adverse	JJ	_	36	attr	_	_
35	reaction	reaction	NN	_	36	com	_	_
36	profile	profile	NN	_	31	ppmod	_	_
37	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	8	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	4	com	_	_
4	use	use	NN	_	1	conj	_	_
5	may	may	MD	_	8	modal	_	_
6	be	be	VB	_	8	aux	_	_
7	rarely	rarely	RB	_	8	adv	_	_
8	associated	associate	VBN	_	0	root	_	_
9	with	with	IN	_	11	case	_	_
10	ventricular	ventricular	JJ	_	11	attr	_	_
11	fibrillation	fibrillation	NN	_	8	ppmod	_	_
12	when	when	WRB	_	13	adv	_	_
13	combined	combine	VBN	_	8	comp	_	_
14	with	with	IN	_	15	case	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	8	p	_	_

1	Because	because	IN	_	4	case	_	_
2	of	of	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	potential	potential	NN	_	23	ppmod	_	_
5	for	for	IN	_	10	case	_	_
6	additive	additive	JJ	_	10	attr	_	_
7	or	or	CC	_	6	cc	_	_
8	synergistic	synergistic	JJ	_	6	conj	_	_
9	depressant	depressant	NN	_	10	com	_	_
10	effects	effect	NNS	_	4	ppmod	_	_
11	on	on	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	SA	sa	NN	_	10	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	AV	av	NN	_	16	com	_	_
16	nodes	node	NNS	_	13	conj	_	_
17	,	,	,	_	23	p	_	_
18	however	however	RB	_	23	adv	_	_
19	,	,	,	_	23	p	_	_
20	drug1	drug0	NN	_	23	dep	_	_
21	should	should	MD	_	23	modal	_	_
22	be	be	VB	_	23	aux	_	_
23	used	use	VBN	_	0	root	_	_
24	with	with	IN	_	25	case	_	_
25	caution	caution	NN	_	23	ppmod	_	_
26	in	in	IN	_	28	case	_	_
27	the	the	DT	_	28	det	_	_
28	presence	presence	NN	_	23	ppmod	_	_
29	of	of	IN	_	31	case	_	_
30	these	these	DT	_	31	det	_	_
31	agents	agent	NNS	_	28	ppmod	_	_
32	.	.	.	_	23	p	_	_

1	The	the	DT	_	2	det	_	_
2	use	use	NN	_	12	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	in	in	IN	_	6	case	_	_
6	patients	patient	NNS	_	2	ppmod	_	_
7	receiving	receive	VBG	_	6	acl	_	_
8	drug2	drug0	NN	_	7	obj	_	_
9	may	may	MD	_	12	modal	_	_
10	be	be	VB	_	12	aux	_	_
11	rarely	rarely	RB	_	12	adv	_	_
12	associated	associate	VBN	_	0	root	_	_
13	with	with	IN	_	15	case	_	_
14	ventricular	ventricular	JJ	_	15	attr	_	_
15	fibrillation	fibrillation	NN	_	12	ppmod	_	_
16	.	.	.	_	12	p	_	_

1	The	the	DT	_	2	det	_	_
2	effects	effect	NNS	_	6	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	are	be	VBP	_	6	aux	_	_
6	antagonized	antagonize	VBN	_	0	root	_	_
7	by	by	IN	_	8	case	_	_
8	drug2	drug0	NNS	_	6	ppmod	_	_
9	such	such	JJ	_	11	adv	_	_
10	as	as	IN	_	11	case	_	_
11	drug3	drug0	NN	_	8	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	drug4	drug0	NN	_	11	conj	_	_
14	.	.	.	_	6	p	_	_

1	In	in	IN	_	3	case	_	_
2	the	the	DT	_	3	det	_	_
3	presence	presence	NN	_	14	ppmod	_	_
4	of	of	IN	_	6	case	_	_
5	these	these	DT	_	6	det	_	_
6	drug1	drug0	NN	_	3	ppmod	_	_
7	,	,	,	_	14	p	_	_
8	larger	large	JJR	_	9	attr	_	_
9	doses	dose	NNS	_	14	dep	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	may	may	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	required	require	VBN	_	0	root	_	_
15	or	or	CC	_	14	cc	_	_
16	drug3	drug0	NN	_	19	dep	_	_
17	may	may	MD	_	19	modal	_	_
18	not	not	RB	_	19	neg	_	_
19	be	be	VB	_	14	conj	_	_
20	effective	effective	JJ	_	19	dep	_	_
21	.	.	.	_	14	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	effects	effect	NNS	_	4	dep	_	_
3	are	be	VBP	_	4	aux	_	_
4	potentiated	potentiate	VBN	_	0	root	_	_
5	by	by	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	.	.	.	_	4	p	_	_

1	Thus	thus	RB	_	8	adv	_	_
2	,	,	,	_	8	p	_	_
3	smaller	small	JJR	_	4	attr	_	_
4	doses	dose	NNS	_	8	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	may	may	MD	_	8	modal	_	_
8	be	be	VB	_	0	root	_	_
9	effective	effective	JJ	_	8	dep	_	_
10	in	in	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	presence	presence	NN	_	9	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	reported	report	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	increase	increase	VB	_	4	comp	_	_
7	the	the	DT	_	8	det	_	_
8	degree	degree	NN	_	6	obj	_	_
9	of	of	IN	_	11	case	_	_
10	heart	heart	NN	_	11	com	_	_
11	block	block	NN	_	8	ppmod	_	_
12	produced	produce	VBN	_	11	acl	_	_
13	by	by	IN	_	15	case	_	_
14	other	other	JJ	_	15	attr	_	_
15	agents	agent	NNS	_	12	ppmod	_	_
16	.	.	.	_	4	p	_	_

1	As	as	IN	_	7	mark	_	_
2	the	the	DT	_	4	det	_	_
3	primary	primary	JJ	_	4	attr	_	_
4	effect	effect	NN	_	7	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	is	be	VBZ	_	23	advcl	_	_
8	to	to	TO	_	9	aux	_	_
9	decrease	decrease	VB	_	7	comp	_	_
10	conduction	conduction	NN	_	9	obj	_	_
11	through	through	IN	_	14	case	_	_
12	the	the	DT	_	14	det	_	_
13	A-V	a-v	NN	_	14	com	_	_
14	node	node	NN	_	9	ppmod	_	_
15	,	,	,	_	23	p	_	_
16	higher	high	JJR	_	17	attr	_	_
17	degrees	degree	NNS	_	23	dep	_	_
18	of	of	IN	_	20	case	_	_
19	heart	heart	NN	_	20	com	_	_
20	block	block	NN	_	17	ppmod	_	_
21	may	may	MD	_	23	modal	_	_
22	be	be	VB	_	23	aux	_	_
23	produced	produce	VBN	_	0	root	_	_
24	in	in	IN	_	26	case	_	_
25	the	the	DT	_	26	det	_	_
26	presence	presence	NN	_	23	ppmod	_	_
27	of	of	IN	_	28	case	_	_
28	drug2	drug0	NN	_	26	ppmod	_	_
29	.	.	.	_	23	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	potentiates	potentiate	VBZ	_	0	root	_	_
3	the	the	DT	_	6	det	_	_
4	muscle	muscle	NN	_	6	attr	_	_
5	relaxant	relaxant	JJ	_	6	attr	_	_
6	effect	effect	NN	_	2	obj	_	_
7	of	of	IN	_	9	case	_	_
8	all	all	DT	_	9	det	_	_
9	drug2	drug0	NNS	_	6	ppmod	_	_
10	,	,	,	_	9	p	_	_
11	most	most	RBS	_	12	com	_	_
12	notably	notably	RB	_	9	adv	_	_
13	drug3	drug0	NN	_	9	appo	_	_
14	,	,	,	_	2	p	_	_
15	and	and	CC	_	2	cc	_	_
16	MAC	mac	NN	_	23	dep	_	_
17	(	-lrb-	-LRB-	_	20	p	_	_
18	minimum	minimum	JJ	_	20	attr	_	_
19	alveolar	alveolar	JJ	_	20	attr	_	_
20	concentration	concentration	NN	_	16	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	is	be	VBZ	_	23	aux	_	_
23	reduced	reduce	VBN	_	2	conj	_	_
24	by	by	IN	_	26	case	_	_
25	concomitant	concomitant	JJ	_	26	attr	_	_
26	administration	administration	NN	_	23	ppmod	_	_
27	of	of	IN	_	29	case	_	_
28	N	n	NN	_	29	com	_	_
29	2O	0o	NN	_	26	ppmod	_	_
30	.	.	.	_	2	p	_	_

1	See	see	VB	_	0	root	_	_
2	CLINICAL	clinical	JJ	_	3	attr	_	_
3	PHARMACOLOGY	pharmacology	NN	_	1	obj	_	_
4	.	.	.	_	1	p	_	_

1	Oral	oral	JJ	_	2	attr	_	_
2	doses	dose	NNS	_	16	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	(	-lrb-	-LRB-	_	7	p	_	_
6	10-20	0	CD	_	7	num	_	_
7	mg/kg	mg/kg	NN	_	4	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	,	,	,	_	2	p	_	_
10	via	via	IN	_	13	case	_	_
11	alcohol	alcohol	NN	_	12	com	_	_
12	dehydrogenase	dehydrogenase	NN	_	13	com	_	_
13	inhibition	inhibition	NN	_	2	ppmod	_	_
14	,	,	,	_	2	p	_	_
15	significantly	significantly	RB	_	16	adv	_	_
16	reduced	reduce	VBD	_	0	root	_	_
17	the	the	DT	_	18	det	_	_
18	rate	rate	NN	_	16	obj	_	_
19	of	of	IN	_	20	case	_	_
20	elimination	elimination	NN	_	18	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	drug2	drug0	NN	_	20	ppmod	_	_
23	(	-lrb-	-LRB-	_	26	p	_	_
24	by	by	IN	_	26	case	_	_
25	approximately	approximately	RB	_	26	adv	_	_
26	40	0	CD	_	18	num	_	_
27	%	%	NN	_	26	meta	_	_
28	)	-rrb-	-RRB-	_	26	p	_	_
29	given	give	VBN	_	18	acl	_	_
30	to	to	TO	_	32	aux	_	_
31	healthy	healthy	JJ	_	32	attr	_	_
32	volunteers	volunteer	NNS	_	29	ppmod	_	_
33	in	in	IN	_	35	case	_	_
34	moderate	moderate	JJ	_	35	attr	_	_
35	doses	dose	NNS	_	32	ppmod	_	_
36	.	.	.	_	16	p	_	_

1	Similarly	similarly	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	drug1	drug0	NN	_	4	dep	_	_
4	decreased	decrease	VBD	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	rate	rate	NN	_	4	obj	_	_
7	of	of	IN	_	8	case	_	_
8	elimination	elimination	NN	_	6	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	(	-lrb-	-LRB-	_	14	p	_	_
12	by	by	IN	_	14	case	_	_
13	approximately	approximately	RB	_	14	adv	_	_
14	50	0	CD	_	10	num	_	_
15	%	%	NN	_	14	meta	_	_
16	)	-rrb-	-RRB-	_	14	p	_	_
17	by	by	IN	_	20	case	_	_
18	the	the	DT	_	20	det	_	_
19	same	same	JJ	_	20	attr	_	_
20	mechanism	mechanism	NN	_	4	ppmod	_	_
21	.	.	.	_	4	p	_	_

1	Reciprocal	reciprocal	JJ	_	2	attr	_	_
2	interactions	interaction	NNS	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	occur	occur	VB	_	37	advcl	_	_
5	with	with	IN	_	7	case	_	_
6	concomitant	concomitant	JJ	_	7	attr	_	_
7	use	use	NN	_	4	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	and	and	CC	_	7	cc	_	_
11	drugs	drug	NNS	_	7	conj	_	_
12	that	that	WDT	_	13	dep	_	_
13	increase	increase	VBP	_	11	relcl	_	_
14	or	or	CC	_	13	cc	_	_
15	inhibit	inhibit	VBP	_	13	conj	_	_
16	the	the	DT	_	19	det	_	_
17	cytochrome	cytochrome	NN	_	19	com	_	_
18	P450	p0	NN	_	19	com	_	_
19	system	system	NN	_	15	obj	_	_
20	(	-lrb-	-LRB-	_	23	p	_	_
21	e.g.	e.g.	FW	_	23	ppmod	_	_
22	,	,	,	_	23	p	_	_
23	drug2	drug0	NN	_	13	prn	_	_
24	,	,	,	_	23	p	_	_
25	drug3	drug0	NN	_	23	appo	_	_
26	,	,	,	_	23	p	_	_
27	drug4	drug0	NN	_	23	appo	_	_
28	,	,	,	_	23	p	_	_
29	drug5	drug0	NN	_	23	appo	_	_
30	)	-rrb-	-RRB-	_	23	p	_	_
31	,	,	,	_	37	p	_	_
32	though	though	IN	_	37	case	_	_
33	this	this	DT	_	37	dep	_	_
34	has	have	VBZ	_	37	aux	_	_
35	not	not	RB	_	37	neg	_	_
36	been	be	VBN	_	37	aux	_	_
37	studied	study	VBN	_	0	root	_	_

1	.	.	.	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	Drug	drug	NN	_	2	com	_	_
2	Interaction	interaction	NN	_	10	dep	_	_
3	During	during	IN	_	4	case	_	_
4	Pregnancy	pregnancy	NN	_	2	ppmod	_	_
5	:	:	:	_	2	p	_	_
6	drug1	drug0	NN	_	2	appo	_	_
7	and	and	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	were	be	VBD	_	10	aux	_	_
10	studied	study	VBN	_	0	root	_	_
11	following	follow	VBG	_	13	adv	_	_
12	subcutaneous	subcutaneous	JJ	_	13	attr	_	_
13	injections	injection	NNS	_	10	ppmod	_	_
14	in	in	IN	_	16	case	_	_
15	pregnant	pregnant	JJ	_	16	attr	_	_
16	mice	mouse	NNS	_	13	ppmod	_	_
17	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	28	dep	_	_
2	alone	alone	RB	_	1	adv	_	_
3	in	in	IN	_	4	case	_	_
4	doses	dose	NNS	_	1	ppmod	_	_
5	up	up	RB	_	7	adv	_	_
6	to	to	TO	_	7	attr	_	_
7	540	0	CD	_	8	num	_	_
8	mg/kg/day	mg/kg/day	NN	_	4	appo	_	_
9	(	-lrb-	-LRB-	_	8	p	_	_
10	approximately	approximately	RB	_	11	adv	_	_
11	340	0	CD	_	18	num	_	_
12	times	time	NNS	_	11	attr	_	_
13	the	the	DT	_	18	det	_	_
14	maximum	maximum	JJ	_	18	attr	_	_
15	recommended	recommend	VBN	_	18	attr	_	_
16	daily	daily	JJ	_	18	attr	_	_
17	inhalation	inhalation	NN	_	18	com	_	_
18	dose	dose	NN	_	8	appo	_	_
19	in	in	IN	_	20	case	_	_
20	adults	adult	NNS	_	18	ppmod	_	_
21	on	on	IN	_	24	case	_	_
22	a	a	DT	_	24	det	_	_
23	mg/m2	mg/m0	NN	_	24	com	_	_
24	basis	basis	NN	_	20	ppmod	_	_
25	)	-rrb-	-RRB-	_	8	p	_	_
26	did	do	VBD	_	28	aux	_	_
27	not	not	RB	_	28	neg	_	_
28	cause	cause	VB	_	0	root	_	_
29	significant	significant	JJ	_	30	attr	_	_
30	increases	increase	NNS	_	28	obj	_	_
31	in	in	IN	_	32	case	_	_
32	resorptions	resorption	NNS	_	30	ppmod	_	_
33	or	or	CC	_	32	cc	_	_
34	major	major	JJ	_	35	attr	_	_
35	malformations	malformation	NNS	_	32	conj	_	_
36	.	.	.	_	28	p	_	_

1	drug1	drug0	NN	_	26	dep	_	_
2	alone	alone	RB	_	1	adv	_	_
3	at	at	IN	_	5	case	_	_
4	a	a	DT	_	5	det	_	_
5	dose	dose	NN	_	1	ppmod	_	_
6	of	of	IN	_	8	case	_	_
7	2.7	0	CD	_	8	num	_	_
8	mg/kg/day	mg/kg/day	NN	_	5	ppmod	_	_
9	(	-lrb-	-LRB-	_	8	p	_	_
10	approximately	approximately	RB	_	11	adv	_	_
11	7	0	CD	_	18	num	_	_
12	times	time	NNS	_	11	attr	_	_
13	the	the	DT	_	18	det	_	_
14	maximum	maximum	JJ	_	18	attr	_	_
15	recommended	recommend	VBN	_	18	attr	_	_
16	daily	daily	JJ	_	18	attr	_	_
17	inhalation	inhalation	NN	_	18	com	_	_
18	dose	dose	NN	_	8	appo	_	_
19	in	in	IN	_	20	case	_	_
20	adults	adult	NNS	_	18	ppmod	_	_
21	on	on	IN	_	24	case	_	_
22	a	a	DT	_	24	det	_	_
23	mg/m2	mg/m0	JJ	_	24	attr	_	_
24	basis	basis	NN	_	8	ppmod	_	_
25	)	-rrb-	-RRB-	_	8	p	_	_
26	increased	increase	VBD	_	0	root	_	_
27	both	both	CC	_	28	cc	_	_
28	resorptions	resorption	NNS	_	26	obj	_	_
29	and	and	CC	_	28	cc	_	_
30	malformations	malformation	NNS	_	28	conj	_	_
31	.	.	.	_	26	p	_	_

1	The	the	DT	_	2	det	_	_
2	addition	addition	NN	_	47	dep	_	_
3	of	of	IN	_	5	case	_	_
4	540	0	CD	_	5	num	_	_
5	mg/kg/day	mg/kg/day	NN	_	2	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	(	-lrb-	-LRB-	_	5	p	_	_
9	approximately	approximately	RB	_	10	adv	_	_
10	340	0	CD	_	17	num	_	_
11	times	time	NNS	_	10	attr	_	_
12	the	the	DT	_	17	det	_	_
13	maximum	maximum	JJ	_	17	attr	_	_
14	recommended	recommend	VBN	_	17	attr	_	_
15	daily	daily	JJ	_	17	attr	_	_
16	inhalation	inhalation	NN	_	17	com	_	_
17	dose	dose	NN	_	5	appo	_	_
18	in	in	IN	_	19	case	_	_
19	adults	adult	NNS	_	17	ppmod	_	_
20	on	on	IN	_	23	case	_	_
21	a	a	DT	_	23	det	_	_
22	mg/m2	mg/m0	NN	_	23	com	_	_
23	basis	basis	NN	_	17	ppmod	_	_
24	)	-rrb-	-RRB-	_	5	p	_	_
25	to	to	TO	_	27	aux	_	_
26	2.7	0	CD	_	27	num	_	_
27	mg/kg/day	mg/kg/day	NN	_	2	ppmod	_	_
28	of	of	IN	_	29	case	_	_
29	drug2	drug0	NN	_	27	ppmod	_	_
30	(	-lrb-	-LRB-	_	27	p	_	_
31	approximately	approximately	RB	_	32	adv	_	_
32	7	0	CD	_	39	num	_	_
33	times	time	NNS	_	32	attr	_	_
34	the	the	DT	_	39	det	_	_
35	maximum	maximum	JJ	_	39	attr	_	_
36	recommended	recommend	VBN	_	39	attr	_	_
37	daily	daily	JJ	_	39	attr	_	_
38	inhalation	inhalation	NN	_	39	com	_	_
39	dose	dose	NN	_	27	appo	_	_
40	in	in	IN	_	41	case	_	_
41	adults	adult	NNS	_	39	ppmod	_	_
42	on	on	IN	_	45	case	_	_
43	a	a	DT	_	45	det	_	_
44	mg/m2	mg/m0	NN	_	45	com	_	_
45	basis	basis	NN	_	39	ppmod	_	_
46	)	-rrb-	-RRB-	_	27	p	_	_
47	appears	appear	VBZ	_	0	root	_	_
48	to	to	TO	_	50	aux	_	_
49	have	have	VB	_	50	aux	_	_
50	increased	increase	VBD	_	47	comp	_	_
51	the	the	DT	_	52	det	_	_
52	incidence	incidence	NN	_	50	obj	_	_
53	of	of	IN	_	55	case	_	_
54	both	both	CC	_	55	cc	_	_
55	resorptions	resorption	NNS	_	52	ppmod	_	_
56	and	and	CC	_	55	cc	_	_
57	malformations	malformation	NNS	_	55	conj	_	_
58	.	.	.	_	47	p	_	_

1	LABORATORY	laboratory	NN	_	3	com	_	_
2	TEST	test	NN	_	3	com	_	_
3	FINDINGS	finding	NNS	_	4	advnp	_	_
4	Asymptomatic	asymptomatic	JJ	_	6	adv	_	_
5	,	,	,	_	6	p	_	_
6	transitory	transitory	JJ	_	7	attr	_	_
7	changes	change	NNS	_	13	dep	_	_
8	in	in	IN	_	10	case	_	_
9	serum	serum	NN	_	10	com	_	_
10	iron	iron	NN	_	7	ppmod	_	_
11	have	have	VBP	_	13	aux	_	_
12	been	be	VBN	_	13	aux	_	_
13	observed	observe	VBN	_	0	root	_	_
14	.	.	.	_	13	p	_	_

1	The	the	DT	_	3	det	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	significance	significance	NN	_	4	dep	_	_
4	is	be	VBZ	_	0	root	_	_
5	unknown	unknown	JJ	_	4	dep	_	_
6	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	interferes	interfere	VBZ	_	0	root	_	_
3	with	with	IN	_	6	case	_	_
4	serum	serum	NN	_	6	com	_	_
5	calcium	calcium	NN	_	6	com	_	_
6	measurements	measurement	NNS	_	2	ppmod	_	_
7	with	with	IN	_	13	case	_	_
8	some	some	DT	_	13	det	_	_
9	colorimetric	colorimetric	JJ	_	13	attr	_	_
10	(	-lrb-	-LRB-	_	13	p	_	_
11	complexometric	complexometric	JJ	_	13	attr	_	_
12	)	-rrb-	-RRB-	_	13	p	_	_
13	methods	method	NNS	_	2	ppmod	_	_
14	commonly	commonly	RB	_	15	adv	_	_
15	used	use	VBN	_	13	acl	_	_
16	in	in	IN	_	17	case	_	_
17	hospitals	hospital	NNS	_	15	ppmod	_	_
18	,	,	,	_	2	p	_	_
19	resulting	result	VBG	_	2	comp	_	_
20	in	in	IN	_	23	case	_	_
21	serum	serum	NN	_	23	com	_	_
22	calcium	calcium	NN	_	23	com	_	_
23	concentrations	concentration	NNS	_	19	ppmod	_	_
24	lower	low	JJR	_	23	attr	_	_
25	than	than	IN	_	28	case	_	_
26	the	the	DT	_	28	det	_	_
27	true	true	JJ	_	28	attr	_	_
28	values	value	NNS	_	24	ppmod	_	_
29	.	.	.	_	2	p	_	_

1	Thus	thus	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	it	it	PRP	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	recommended	recommend	VBN	_	0	root	_	_
6	not	not	RB	_	8	neg	_	_
7	to	to	TO	_	8	aux	_	_
8	use	use	VB	_	5	comp	_	_
9	such	such	JJ	_	10	attr	_	_
10	methods	method	NNS	_	8	obj	_	_
11	for	for	IN	_	13	case	_	_
12	12-24	0	CD	_	13	num	_	_
13	hours	hour	NNS	_	8	ppmod	_	_
14	after	after	IN	_	15	case	_	_
15	administration	administration	NN	_	8	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	drug1	drug0	NN	_	15	ppmod	_	_
18	.	.	.	_	5	p	_	_

1	If	if	IN	_	4	mark	_	_
2	such	such	JJ	_	3	attr	_	_
3	measurements	measurement	NNS	_	4	dep	_	_
4	are	be	VBP	_	13	advcl	_	_
5	necessary	necessary	JJ	_	4	dep	_	_
6	,	,	,	_	13	p	_	_
7	the	the	DT	_	8	det	_	_
8	use	use	NN	_	13	dep	_	_
9	of	of	IN	_	11	case	_	_
10	other	other	JJ	_	11	attr	_	_
11	methods	method	NNS	_	8	ppmod	_	_
12	is	be	VBZ	_	13	aux	_	_
13	recommended	recommend	VBN	_	0	root	_	_
14	.	.	.	_	13	p	_	_

1	All	all	DT	_	2	det	_	_
2	patients	patient	NNS	_	9	dep	_	_
3	in	in	IN	_	4	case	_	_
4	whom	whom	WP	_	8	ppmod	_	_
5	this	this	DT	_	6	det	_	_
6	effect	effect	NN	_	8	dep	_	_
7	was	be	VBD	_	8	aux	_	_
8	observed	observe	VBN	_	2	relcl	_	_
9	remained	remain	VBD	_	0	root	_	_
10	asymptomatic	asymptomatic	JJ	_	9	dep	_	_
11	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	increase	increase	VB	_	0	root	_	_
4	the	the	DT	_	6	det	_	_
5	ototoxic	ototoxic	JJ	_	6	attr	_	_
6	potential	potential	NN	_	3	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	,	,	,	_	3	p	_	_
10	especially	especially	RB	_	17	adv	_	_
11	in	in	IN	_	17	case	_	_
12	the	the	DT	_	17	det	_	_
13	presence	presence	NN	_	17	advnp	_	_
14	of	of	IN	_	17	case	_	_
15	impaired	impaired	JJ	_	17	attr	_	_
16	renal	renal	JJ	_	17	attr	_	_
17	function	function	NN	_	3	ppmod	_	_
18	.	.	.	_	3	p	_	_

1	Except	except	IN	_	4	case	_	_
2	in	in	IN	_	4	case	_	_
3	life-threatening	life-threatening	JJ	_	4	attr	_	_
4	situations	situation	NNS	_	6	ppmod	_	_
5	,	,	,	_	6	p	_	_
6	avoid	avoid	VB	_	0	root	_	_
7	this	this	DT	_	8	det	_	_
8	combination	combination	NN	_	6	obj	_	_
9	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	should	should	MD	_	5	modal	_	_
3	not	not	RB	_	5	neg	_	_
4	be	be	VB	_	5	aux	_	_
5	used	use	VBN	_	0	root	_	_
6	concomitantly	concomitantly	RB	_	5	adv	_	_
7	with	with	IN	_	8	case	_	_
8	drug2	drug0	NN	_	5	ppmod	_	_
9	because	because	IN	_	12	case	_	_
10	of	of	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	possibility	possibility	NN	_	5	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	ototoxicity	ototoxicity	NN	_	12	ppmod	_	_
15	.	.	.	_	5	p	_	_

1	Patients	patient	NNS	_	17	dep	_	_
2	receiving	receive	VBG	_	1	acl	_	_
3	high	high	JJ	_	4	attr	_	_
4	doses	dose	NNS	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	concomitantly	concomitantly	RB	_	9	adv	_	_
8	with	with	IN	_	9	case	_	_
9	drug2	drug0	NN	_	1	ppmod	_	_
10	,	,	,	_	17	p	_	_
11	as	as	IN	_	14	case	_	_
12	in	in	IN	_	14	case	_	_
13	rheumatic	rheumatic	JJ	_	14	attr	_	_
14	disease	disease	NN	_	17	ppmod	_	_
15	,	,	,	_	17	p	_	_
16	may	may	MD	_	17	modal	_	_
17	experience	experience	VBP	_	0	root	_	_
18	drug3	drug0	NN	_	19	com	_	_
19	toxicity	toxicity	NN	_	17	obj	_	_
20	at	at	IN	_	22	case	_	_
21	lower	low	JJR	_	22	attr	_	_
22	doses	dose	NNS	_	17	ppmod	_	_
23	because	because	IN	_	28	case	_	_
24	of	of	IN	_	28	case	_	_
25	competitive	competitive	JJ	_	28	attr	_	_
26	renal	renal	JJ	_	28	attr	_	_
27	excretory	excretory	NN	_	28	com	_	_
28	sites	site	NNS	_	22	ppmod	_	_
29	.	.	.	_	17	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	has	have	VBZ	_	0	root	_	_
3	a	a	DT	_	4	det	_	_
4	tendency	tendency	NN	_	2	obj	_	_
5	to	to	TO	_	6	aux	_	_
6	antagonize	antagonize	VB	_	4	acl	_	_
7	the	the	DT	_	11	det	_	_
8	skeletal	skeletal	JJ	_	11	attr	_	_
9	muscle	muscle	NN	_	11	com	_	_
10	relaxing	relaxing	NN	_	11	com	_	_
11	effect	effect	NN	_	6	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	and	and	CC	_	2	cc	_	_
15	may	may	MD	_	16	modal	_	_
16	potentiate	potentiate	VB	_	2	conj	_	_
17	the	the	DT	_	18	det	_	_
18	action	action	NN	_	16	obj	_	_
19	of	of	IN	_	20	case	_	_
20	drug3	drug0	NN	_	18	ppmod	_	_
21	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	generally	generally	RB	_	6	adv	_	_
3	should	should	MD	_	6	modal	_	_
4	not	not	RB	_	6	neg	_	_
5	be	be	VB	_	6	aux	_	_
6	given	give	VBN	_	0	root	_	_
7	with	with	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	because	because	IN	_	11	mark	_	_
10	they	they	PRP	_	11	dep	_	_
11	reduce	reduce	VBP	_	6	comp	_	_
12	drug3	drug0	NN	_	15	attr	_	_
13	s	s	NN	_	15	attr	_	_
14	renal	renal	JJ	_	15	attr	_	_
15	clearance	clearance	NN	_	11	obj	_	_
16	and	and	CC	_	11	cc	_	_
17	add	add	VBP	_	11	conj	_	_
18	a	a	DT	_	20	det	_	_
19	high	high	JJ	_	20	attr	_	_
20	risk	risk	NN	_	17	obj	_	_
21	of	of	IN	_	23	case	_	_
22	drug4	drug0	NN	_	23	com	_	_
23	toxicity	toxicity	NN	_	20	ppmod	_	_
24	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	add	add	VBP	_	0	root	_	_
4	to	to	TO	_	3	ppmod	_	_
5	or	or	CC	_	3	cc	_	_
6	potentiate	potentiate	VB	_	3	conj	_	_
7	the	the	DT	_	9	det	_	_
8	therapeutic	therapeutic	JJ	_	9	attr	_	_
9	effect	effect	NN	_	6	obj	_	_
10	of	of	IN	_	12	case	_	_
11	other	other	JJ	_	12	attr	_	_
12	drug2	drug0	NNS	_	9	ppmod	_	_
13	.	.	.	_	3	p	_	_

1	Potentiation	potentiation	NN	_	2	dep	_	_
2	occurs	occur	VBZ	_	0	root	_	_
3	with	with	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	or	or	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	decrease	decrease	VB	_	0	root	_	_
4	arterial	arterial	JJ	_	5	attr	_	_
5	responsiveness	responsiveness	NN	_	3	obj	_	_
6	to	to	TO	_	7	aux	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	.	.	.	_	3	p	_	_

1	However	however	RB	_	7	adv	_	_
2	,	,	,	_	7	p	_	_
3	drug1	drug0	NN	_	7	dep	_	_
4	may	may	MD	_	7	modal	_	_
5	still	still	RB	_	7	adv	_	_
6	be	be	VB	_	7	aux	_	_
7	used	use	VBN	_	0	root	_	_
8	effectively	effectively	RB	_	7	adv	_	_
9	.	.	.	_	7	p	_	_

1	Tablets	tablet	NNS	_	3	attr	_	_
2	Simultaneous	simultaneous	JJ	_	3	attr	_	_
3	administration	administration	NN	_	10	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	8	com	_	_
8	tablets	tablet	NNS	_	5	conj	_	_
9	may	may	MD	_	10	modal	_	_
10	reduce	reduce	VB	_	0	root	_	_
11	the	the	DT	_	15	det	_	_
12	natriuretic	natriuretic	JJ	_	15	attr	_	_
13	and	and	CC	_	12	cc	_	_
14	antihypertensive	antihypertensive	JJ	_	12	conj	_	_
15	effects	effect	NNS	_	10	obj	_	_
16	of	of	IN	_	17	case	_	_
17	drug3	drug0	NN	_	15	ppmod	_	_
18	.	.	.	_	10	p	_	_

1	Patients	patient	NNS	_	7	dep	_	_
2	receiving	receive	VBG	_	1	acl	_	_
3	both	both	DT	_	4	det	_	_
4	drugs	drug	NNS	_	2	obj	_	_
5	should	should	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	observed	observe	VBN	_	0	root	_	_
8	closely	closely	RB	_	7	adv	_	_
9	to	to	TO	_	10	aux	_	_
10	determine	determine	VB	_	7	comp	_	_
11	if	if	IN	_	21	mark	_	_
12	the	the	DT	_	17	det	_	_
13	desired	desired	JJ	_	17	attr	_	_
14	diuretic	diuretic	JJ	_	17	attr	_	_
15	and/or	and/or	CC	_	14	cc	_	_
16	antihypertensive	antihypertensive	JJ	_	14	conj	_	_
17	effect	effect	NN	_	21	dep	_	_
18	of	of	IN	_	19	case	_	_
19	drug1	drug0	NN	_	17	ppmod	_	_
20	is	be	VBZ	_	21	aux	_	_
21	achieved	achieve	VBN	_	10	comp	_	_
22	.	.	.	_	7	p	_	_

1	The	the	DT	_	2	det	_	_
2	intake	intake	NN	_	9	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	should	should	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	separated	separate	VBN	_	0	root	_	_
10	by	by	IN	_	14	case	_	_
11	at	at	IN	_	13	case	_	_
12	least	least	JJS	_	13	attr	_	_
13	two	#crd#	CD	_	14	num	_	_
14	hours	hour	NNS	_	9	ppmod	_	_
15	.	.	.	_	9	p	_	_

1	Tablets	tablet	NNS	_	13	dep	_	_
2	,	,	,	_	1	p	_	_
3	Injection	injection	NN	_	1	conj	_	_
4	,	,	,	_	3	p	_	_
5	and	and	CC	_	3	cc	_	_
6	Oral	oral	JJ	_	9	attr	_	_
7	Solution	solution	NN	_	9	attr	_	_
8	One	#crd#	CD	_	9	num	_	_
9	study	study	NN	_	1	conj	_	_
10	in	in	IN	_	12	case	_	_
11	six	#crd#	CD	_	12	num	_	_
12	subjects	subject	NNS	_	1	ppmod	_	_
13	demonstrated	demonstrate	VBD	_	0	root	_	_
14	that	that	IN	_	22	mark	_	_
15	the	the	DT	_	16	det	_	_
16	combination	combination	NN	_	22	dep	_	_
17	of	of	IN	_	18	case	_	_
18	drug1	drug0	NN	_	16	ppmod	_	_
19	and	and	CC	_	18	cc	_	_
20	drug2	drug0	NN	_	18	conj	_	_
21	temporarily	temporarily	RB	_	22	adv	_	_
22	reduced	reduce	VBD	_	13	comp	_	_
23	creatinine	creatinine	NN	_	24	com	_	_
24	clearance	clearance	NN	_	22	obj	_	_
25	in	in	IN	_	26	case	_	_
26	patients	patient	NNS	_	22	ppmod	_	_
27	with	with	IN	_	30	case	_	_
28	chronic	chronic	JJ	_	30	attr	_	_
29	renal	renal	JJ	_	30	attr	_	_
30	insufficiency	insufficiency	NN	_	26	ppmod	_	_
31	.	.	.	_	13	p	_	_

1	There	there	EX	_	2	dep	_	_
2	are	be	VBP	_	0	root	_	_
3	case	case	NN	_	4	com	_	_
4	reports	report	NNS	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	patients	patient	NNS	_	4	ppmod	_	_
7	who	who	WP	_	8	dep	_	_
8	developed	develop	VBD	_	6	relcl	_	_
9	increased	increase	VBN	_	10	attr	_	_
10	BUN	bun	NN	_	8	obj	_	_
11	,	,	,	_	10	p	_	_
12	serum	serum	NN	_	13	com	_	_
13	creatinine	creatinine	NN	_	10	conj	_	_
14	and	and	CC	_	13	cc	_	_
15	serum	serum	NN	_	17	com	_	_
16	potassium	potassium	NN	_	17	com	_	_
17	levels	level	NNS	_	10	conj	_	_
18	,	,	,	_	10	p	_	_
19	and	and	CC	_	10	cc	_	_
20	weight	weight	NN	_	21	com	_	_
21	gain	gain	NN	_	10	conj	_	_
22	when	when	WRB	_	25	adv	_	_
23	drug1	drug0	NN	_	25	dep	_	_
24	was	be	VBD	_	25	aux	_	_
25	used	use	VBN	_	8	comp	_	_
26	in	in	IN	_	27	case	_	_
27	conjunction	conjunction	NN	_	25	ppmod	_	_
28	with	with	IN	_	29	case	_	_
29	drug2	drug0	NN	_	27	ppmod	_	_
30	.	.	.	_	2	p	_	_

1	Literature	literature	NN	_	2	com	_	_
2	reports	report	NNS	_	3	dep	_	_
3	indicate	indicate	VBP	_	0	root	_	_
4	that	that	IN	_	9	mark	_	_
5	coadministration	coadministration	NN	_	9	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	may	may	MD	_	9	modal	_	_
9	reduce	reduce	VB	_	3	comp	_	_
10	the	the	DT	_	14	det	_	_
11	natriuretic	natriuretic	JJ	_	14	attr	_	_
12	and	and	CC	_	11	cc	_	_
13	antihypertensive	antihypertensive	JJ	_	11	conj	_	_
14	effects	effect	NNS	_	9	obj	_	_
15	of	of	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	in	in	IN	_	19	case	_	_
18	some	some	DT	_	19	det	_	_
19	patients	patient	NNS	_	14	ppmod	_	_
20	by	by	IN	_	21	case	_	_
21	inhibiting	inhibit	VBG	_	9	ppmod	_	_
22	prostaglandin	prostaglandin	NN	_	23	com	_	_
23	synthesis	synthesis	NN	_	21	obj	_	_
24	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	may	may	MD	_	4	modal	_	_
3	also	also	RB	_	4	adv	_	_
4	affect	affect	VB	_	0	root	_	_
5	plasma	plasma	NN	_	7	com	_	_
6	renin	renin	NN	_	7	com	_	_
7	levels	level	NNS	_	4	obj	_	_
8	,	,	,	_	7	p	_	_
9	aldosterone	aldosterone	NN	_	10	com	_	_
10	excretion	excretion	NN	_	7	conj	_	_
11	,	,	,	_	10	p	_	_
12	and	and	CC	_	10	cc	_	_
13	renin	renin	NN	_	15	com	_	_
14	profile	profile	NN	_	15	com	_	_
15	evaluation	evaluation	NN	_	7	conj	_	_
16	.	.	.	_	4	p	_	_

1	Patients	patient	NNS	_	9	dep	_	_
2	receiving	receive	VBG	_	1	acl	_	_
3	both	both	CC	_	4	cc	_	_
4	drug1	drug0	NN	_	2	obj	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	should	should	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	observed	observe	VBN	_	0	root	_	_
10	closely	closely	RB	_	9	adv	_	_
11	to	to	TO	_	12	aux	_	_
12	determine	determine	VB	_	9	comp	_	_
13	if	if	IN	_	23	mark	_	_
14	the	the	DT	_	19	det	_	_
15	desired	desired	JJ	_	19	attr	_	_
16	diuretic	diuretic	JJ	_	19	attr	_	_
17	and/or	and/or	CC	_	16	cc	_	_
18	antihypertensive	antihypertensive	JJ	_	16	conj	_	_
19	effect	effect	NN	_	23	dep	_	_
20	of	of	IN	_	21	case	_	_
21	drug3	drug0	NN	_	19	ppmod	_	_
22	is	be	VBZ	_	23	aux	_	_
23	achieved	achieve	VBN	_	12	comp	_	_
24	.	.	.	_	9	p	_	_

1	After	after	IN	_	3	case	_	_
2	multiple	multiple	JJ	_	3	attr	_	_
3	dosing	dosing	NN	_	14	ppmod	_	_
4	,	,	,	_	14	p	_	_
5	drug1	drug0	NN	_	14	dep	_	_
6	(	-lrb-	-LRB-	_	10	p	_	_
7	drug2	drug0	NN	_	10	attr	_	_
8	30	0	CD	_	10	num	_	_
9	mcg	mcg	NN	_	10	com	_	_
10	IM	im	NN	_	5	prn	_	_
11	once	once	RB	_	12	com	_	_
12	weekly	weekly	RB	_	10	adv	_	_
13	)	-rrb-	-RRB-	_	10	p	_	_
14	reduced	reduce	VBD	_	0	root	_	_
15	drug3	drug0	NN	_	16	com	_	_
16	clearance	clearance	NN	_	14	obj	_	_
17	by	by	IN	_	19	case	_	_
18	approximately	approximately	RB	_	19	adv	_	_
19	30	0	CD	_	14	ppmod	_	_
20	%	%	NN	_	19	meta	_	_
21	.	.	.	_	14	p	_	_

1	The	the	DT	_	2	det	_	_
2	similarity	similarity	NN	_	26	dep	_	_
3	of	of	IN	_	9	case	_	_
4	the	the	DT	_	9	det	_	_
5	drug1	drug0	NN	_	6	advnp	_	_
6	-associated	-associated	JJ	_	9	attr	_	_
7	adverse	adverse	JJ	_	9	attr	_	_
8	event	event	NN	_	9	com	_	_
9	profile	profile	NN	_	2	ppmod	_	_
10	between	between	IN	_	11	case	_	_
11	Study	study	NN	_	2	ppmod	_	_
12	1	0	CD	_	11	num	_	_
13	(	-lrb-	-LRB-	_	16	p	_	_
14	without	without	IN	_	16	case	_	_
15	co-administered	co-administered	NN	_	16	com	_	_
16	drug2	drug0	NN	_	11	prn	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	and	and	CC	_	11	cc	_	_
19	Study	study	NN	_	11	conj	_	_
20	2	0	CD	_	19	num	_	_
21	(	-lrb-	-LRB-	_	24	p	_	_
22	with	with	IN	_	24	case	_	_
23	co-administered	co-administered	NN	_	24	com	_	_
24	drug3	drug0	NN	_	19	prn	_	_
25	)	-rrb-	-RRB-	_	24	p	_	_
26	indicates	indicate	VBZ	_	0	root	_	_
27	that	that	IN	_	34	mark	_	_
28	this	this	DT	_	29	det	_	_
29	alteration	alteration	NN	_	34	dep	_	_
30	in	in	IN	_	31	case	_	_
31	clearance	clearance	NN	_	29	ppmod	_	_
32	does	do	VBZ	_	34	aux	_	_
33	not	not	RB	_	34	neg	_	_
34	necessitate	necessitate	VBP	_	26	comp	_	_
35	reduction	reduction	NN	_	34	obj	_	_
36	of	of	IN	_	39	case	_	_
37	the	the	DT	_	39	det	_	_
38	drug4	drug0	NN	_	39	com	_	_
39	dose	dose	NN	_	35	ppmod	_	_
40	to	to	TO	_	41	aux	_	_
41	maintain	maintain	VB	_	35	acl	_	_
42	safety	safety	NN	_	41	obj	_	_
43	,	,	,	_	44	p	_	_
44	General	general	JJ	_	41	prn	_	_
45	)	-rrb-	-RRB-	_	44	p	_	_
46	.	.	.	_	26	p	_	_

1	Results	result	NNS	_	23	dep	_	_
2	of	of	IN	_	3	case	_	_
3	studies	study	NNS	_	1	ppmod	_	_
4	in	in	IN	_	7	case	_	_
5	multiple	multiple	JJ	_	6	attr	_	_
6	sclerosis	sclerosis	NN	_	7	com	_	_
7	patients	patient	NNS	_	3	ppmod	_	_
8	taking	take	VBG	_	7	acl	_	_
9	drug1	drug0	NN	_	8	obj	_	_
10	and	and	CC	_	9	cc	_	_
11	concomitant	concomitant	JJ	_	12	attr	_	_
12	drug2	drug0	NN	_	9	conj	_	_
13	(	-lrb-	-LRB-	_	17	p	_	_
14	drug3	drug0	NN	_	17	attr	_	_
15	30	0	CD	_	17	num	_	_
16	mcg	mcg	NN	_	17	com	_	_
17	IM	im	NN	_	9	prn	_	_
18	once	once	RB	_	19	com	_	_
19	weekly	weekly	RB	_	17	adv	_	_
20	)	-rrb-	-RRB-	_	17	p	_	_
21	or	or	CC	_	9	cc	_	_
22	drug4	drug0	NN	_	9	conj	_	_
23	were	be	VBD	_	0	root	_	_
24	inconclusive	inconclusive	JJ	_	23	dep	_	_
25	with	with	IN	_	26	case	_	_
26	regard	regard	NN	_	24	ppmod	_	_
27	to	to	TO	_	29	aux	_	_
28	the	the	DT	_	29	det	_	_
29	need	need	NN	_	26	ppmod	_	_
30	for	for	IN	_	32	case	_	_
31	dose	dose	NN	_	32	com	_	_
32	adjustment	adjustment	NN	_	29	ppmod	_	_
33	of	of	IN	_	35	case	_	_
34	the	the	DT	_	35	det	_	_
35	drug5	drug0	NN	_	32	ppmod	_	_
36	or	or	CC	_	35	cc	_	_
37	drug6	drug0	NN	_	35	conj	_	_
38	.	.	.	_	23	p	_	_

1	Use	use	NN	_	13	dep	_	_
2	with	with	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	:	:	:	_	3	p	_	_
5	The	the	DT	_	7	det	_	_
6	principal	principal	JJ	_	7	attr	_	_
7	pathway	pathway	NN	_	3	appo	_	_
8	for	for	IN	_	9	case	_	_
9	detoxification	detoxification	NN	_	7	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	is	be	VBZ	_	13	aux	_	_
13	inhibited	inhibit	VBN	_	0	root	_	_
14	by	by	IN	_	15	case	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	13	p	_	_

1	Patients	patient	NNS	_	11	dep	_	_
2	receiving	receive	VBG	_	1	acl	_	_
3	drug1	drug0	NN	_	2	obj	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	concomitantly	concomitantly	RB	_	3	adv	_	_
7	should	should	MD	_	11	modal	_	_
8	have	have	VB	_	11	lv	_	_
9	a	a	DT	_	11	det	_	_
10	dose	dose	NN	_	11	com	_	_
11	reduction	reduction	NN	_	0	root	_	_
12	of	of	IN	_	13	case	_	_
13	drug3	drug0	NN	_	11	ppmod	_	_
14	,	,	,	_	11	p	_	_
15	to	to	TO	_	22	aux	_	_
16	approximately	approximately	RB	_	17	adv	_	_
17	1/3	0	CD	_	22	num	_	_
18	to	to	TO	_	17	cc	_	_
19	1/4	0	CD	_	17	conj	_	_
20	the	the	DT	_	22	det	_	_
21	usual	usual	JJ	_	22	attr	_	_
22	dose	dose	NN	_	11	ppmod	_	_
23	.	.	.	_	11	p	_	_

1	Use	use	NN	_	0	root	_	_
2	with	with	IN	_	4	case	_	_
3	Other	other	JJ	_	4	attr	_	_
4	Agents	agent	NNS	_	1	ppmod	_	_
5	Affecting	affect	VBG	_	4	acl	_	_
6	Myelopoesis	myelopoesis	NN	_	5	obj	_	_
7	:	:	:	_	1	p	_	_
8	Drugs	drug	NNS	_	19	dep	_	_
9	which	which	WDT	_	11	dep	_	_
10	may	may	MD	_	11	modal	_	_
11	affect	affect	VB	_	8	relcl	_	_
12	leukocyte	leukocyte	NN	_	13	com	_	_
13	production	production	NN	_	11	obj	_	_
14	,	,	,	_	8	p	_	_
15	including	include	VBG	_	16	adv	_	_
16	drug1	drug0	NN	_	8	ppmod	_	_
17	,	,	,	_	8	p	_	_
18	may	may	MD	_	19	modal	_	_
19	lead	lead	VB	_	1	acl	_	_
20	to	to	TO	_	22	aux	_	_
21	exaggerated	exaggerated	JJ	_	22	attr	_	_
22	leukopenia	leukopenia	NN	_	19	ppmod	_	_
23	,	,	,	_	19	p	_	_
24	especially	especially	RB	_	28	adv	_	_
25	in	in	IN	_	28	case	_	_
26	renal	renal	JJ	_	28	attr	_	_
27	transplant	transplant	NN	_	28	com	_	_
28	recipients	recipient	NNS	_	19	ppmod	_	_
29	.	.	.	_	1	p	_	_

1	Use	use	NN	_	0	root	_	_
2	with	with	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	:	:	:	_	1	p	_	_
5	The	the	DT	_	6	det	_	_
6	use	use	NN	_	18	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	to	to	TO	_	11	aux	_	_
10	control	control	NN	_	11	com	_	_
11	hypertension	hypertension	NN	_	6	ppmod	_	_
12	in	in	IN	_	13	case	_	_
13	patients	patient	NNS	_	11	ppmod	_	_
14	on	on	IN	_	15	case	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	has	have	VBZ	_	18	aux	_	_
17	been	be	VBN	_	18	aux	_	_
18	reported	report	VBN	_	1	acl	_	_
19	to	to	TO	_	20	aux	_	_
20	induce	induce	VB	_	18	comp	_	_
21	severe	severe	JJ	_	22	attr	_	_
22	leukopenia	leukopenia	NN	_	20	obj	_	_
23	.	.	.	_	1	p	_	_

1	Interaction	interaction	NN	_	11	dep	_	_
2	with	with	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	other	other	JJ	_	5	com	_	_
5	than	than	IN	_	3	cc	_	_
6	drug2	drug0	NN	_	3	conj	_	_
7	has	have	VBZ	_	11	aux	_	_
8	not	not	RB	_	11	neg	_	_
9	been	be	VBN	_	11	aux	_	_
10	specifically	specifically	RB	_	11	adv	_	_
11	studied	study	VBN	_	0	root	_	_
12	;	;	:	_	11	p	_	_

1	however	however	RB	_	7	adv	_	_
2	,	,	,	_	7	p	_	_
3	no	no	DT	_	5	det	_	_
4	deleterious	deleterious	JJ	_	5	attr	_	_
5	interactions	interaction	NNS	_	7	dep	_	_
6	were	be	VBD	_	7	aux	_	_
7	seen	see	VBN	_	0	root	_	_
8	when	when	WRB	_	11	adv	_	_
9	drug1	drug0	NN	_	11	dep	_	_
10	was	be	VBD	_	11	aux	_	_
11	administered	administer	VBN	_	7	comp	_	_
12	after	after	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	,	,	,	_	13	p	_	_
15	inhalational	inhalational	JJ	_	16	attr	_	_
16	drug3	drug0	NN	_	13	conj	_	_
17	,	,	,	_	16	p	_	_
18	drug4	drug0	NN	_	13	conj	_	_
19	and	and	CC	_	18	cc	_	_
20	muscle	muscle	NN	_	22	com	_	_
21	relaxant	relaxant	NN	_	22	com	_	_
22	antagonists	antagonist	NNS	_	13	conj	_	_
23	administered	administer	VBN	_	13	acl	_	_
24	in	in	IN	_	25	case	_	_
25	conjunction	conjunction	NN	_	23	ppmod	_	_
26	with	with	IN	_	27	case	_	_
27	sedation	sedation	NN	_	25	ppmod	_	_
28	or	or	CC	_	27	cc	_	_
29	anesthesia	anesthesia	NN	_	27	conj	_	_
30	.	.	.	_	7	p	_	_

1	Particular	particular	JJ	_	2	attr	_	_
2	caution	caution	NN	_	3	dep	_	_
3	is	be	VBZ	_	0	root	_	_
4	necessary	necessary	JJ	_	3	dep	_	_
5	when	when	WRB	_	6	adv	_	_
6	using	use	VBG	_	4	comp	_	_
7	drug1	drug0	NN	_	6	obj	_	_
8	in	in	IN	_	9	case	_	_
9	cases	case	NNS	_	7	ppmod	_	_
10	of	of	IN	_	13	case	_	_
11	mixed	mixed	JJ	_	13	attr	_	_
12	drug	drug	NN	_	13	com	_	_
13	overdosage	overdosage	NN	_	9	ppmod	_	_
14	since	since	IN	_	37	mark	_	_
15	the	the	DT	_	17	det	_	_
16	toxic	toxic	JJ	_	17	attr	_	_
17	effects	effect	NNS	_	37	dep	_	_
18	(	-lrb-	-LRB-	_	19	p	_	_
19	such	such	JJ	_	17	prn	_	_
20	as	as	IN	_	21	case	_	_
21	convulsions	convulsions	NN	_	19	ppmod	_	_
22	and	and	CC	_	21	cc	_	_
23	cardiac	cardiac	JJ	_	24	attr	_	_
24	dysrhythmias	dysrhythmia	NNS	_	21	conj	_	_
25	)	-rrb-	-RRB-	_	19	p	_	_
26	of	of	IN	_	28	case	_	_
27	other	other	JJ	_	28	attr	_	_
28	drugs	drug	NNS	_	17	ppmod	_	_
29	taken	take	VBN	_	28	acl	_	_
30	in	in	IN	_	31	case	_	_
31	overdose	overdose	NN	_	29	ppmod	_	_
32	(	-lrb-	-LRB-	_	34	p	_	_
33	especially	especially	RB	_	34	adv	_	_
34	drug2	drug0	NN	_	29	prn	_	_
35	)	-rrb-	-RRB-	_	34	p	_	_
36	may	may	MD	_	37	modal	_	_
37	emerge	emerge	VB	_	3	comp	_	_
38	with	with	IN	_	40	case	_	_
39	the	the	DT	_	40	det	_	_
40	reversal	reversal	NN	_	37	ppmod	_	_
41	of	of	IN	_	44	case	_	_
42	the	the	DT	_	44	det	_	_
43	drug3	drug0	NN	_	44	com	_	_
44	effect	effect	NN	_	40	ppmod	_	_
45	by	by	IN	_	46	case	_	_
46	drug4	drug0	NN	_	40	ppmod	_	_
47	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	use	use	NN	_	7	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	is	be	VBZ	_	7	aux	_	_
6	not	not	RB	_	7	neg	_	_
7	recommended	recommend	VBN	_	0	root	_	_
8	in	in	IN	_	10	case	_	_
9	epileptic	epileptic	JJ	_	10	attr	_	_
10	patients	patient	NNS	_	7	ppmod	_	_
11	who	who	WP	_	14	dep	_	_
12	have	have	VBP	_	14	aux	_	_
13	been	be	VBN	_	14	aux	_	_
14	receiving	receive	VBG	_	10	relcl	_	_
15	benzodiazepine	benzodiazepine	NN	_	16	com	_	_
16	treatment	treatment	NN	_	14	obj	_	_
17	for	for	IN	_	20	case	_	_
18	a	a	DT	_	20	det	_	_
19	prolonged	prolonged	JJ	_	20	attr	_	_
20	period	period	NN	_	14	ppmod	_	_
21	.	.	.	_	7	p	_	_

1	Although	although	IN	_	3	mark	_	_
2	drug1	drug0	NN	_	3	dep	_	_
3	exerts	exert	VBZ	_	22	advcl	_	_
4	a	a	DT	_	8	det	_	_
5	slight	slight	JJ	_	8	attr	_	_
6	intrinsic	intrinsic	JJ	_	8	attr	_	_
7	anticonvulsant	anticonvulsant	JJ	_	8	attr	_	_
8	effect	effect	NN	_	3	obj	_	_
9	,	,	,	_	22	p	_	_
10	its	its	PRP$	_	12	poss	_	_
11	abrupt	abrupt	JJ	_	12	attr	_	_
12	suppression	suppression	NN	_	22	dep	_	_
13	of	of	IN	_	16	case	_	_
14	the	the	DT	_	16	det	_	_
15	protective	protective	JJ	_	16	attr	_	_
16	effect	effect	NN	_	12	ppmod	_	_
17	of	of	IN	_	20	case	_	_
18	a	a	DT	_	20	det	_	_
19	drug2	drug0	NN	_	20	com	_	_
20	agonist	agonist	NN	_	16	ppmod	_	_
21	can	can	MD	_	22	modal	_	_
22	give	give	VBP	_	0	root	_	_
23	rise	rise	NN	_	22	obj	_	_
24	to	to	TO	_	25	aux	_	_
25	convulsions	convulsion	NNS	_	22	ppmod	_	_
26	in	in	IN	_	28	case	_	_
27	epileptic	epileptic	JJ	_	28	attr	_	_
28	patients	patient	NNS	_	25	ppmod	_	_
29	.	.	.	_	22	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	blocks	block	VBZ	_	0	root	_	_
3	the	the	DT	_	5	det	_	_
4	central	central	JJ	_	5	attr	_	_
5	effects	effect	NNS	_	2	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	by	by	IN	_	10	case	_	_
9	competitive	competitive	JJ	_	10	attr	_	_
10	interaction	interaction	NN	_	2	ppmod	_	_
11	at	at	IN	_	14	case	_	_
12	the	the	DT	_	14	det	_	_
13	receptor	receptor	NN	_	14	com	_	_
14	level	level	NN	_	10	ppmod	_	_
15	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	effects	effect	NNS	_	20	dep	_	_
3	of	of	IN	_	5	case	_	_
4	nonbenzodiazepine	nonbenzodiazepine	NN	_	5	com	_	_
5	agonists	agonist	NNS	_	2	ppmod	_	_
6	at	at	IN	_	8	case	_	_
7	benzodiazepine	benzodiazepine	NN	_	8	com	_	_
8	receptors	receptor	NNS	_	2	ppmod	_	_
9	,	,	,	_	8	p	_	_
10	such	such	JJ	_	12	adv	_	_
11	as	as	IN	_	12	case	_	_
12	drug1	drug0	NN	_	8	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	triazolopyridazines	triazolopyridazines	NN	_	12	conj	_	_
15	and	and	CC	_	14	cc	_	_
16	others	other	NNS	_	12	conj	_	_
17	,	,	,	_	8	p	_	_
18	are	be	VBP	_	20	aux	_	_
19	also	also	RB	_	20	adv	_	_
20	blocked	block	VBN	_	0	root	_	_
21	by	by	IN	_	22	case	_	_
22	drug2	drug0	NN	_	20	ppmod	_	_
23	.	.	.	_	20	p	_	_

1	The	the	DT	_	2	det	_	_
2	pharmacokinetics	pharmacokinetics	NNS	_	5	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	are	be	VBP	_	0	root	_	_
6	unaltered	unaltered	JJ	_	5	dep	_	_
7	in	in	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	presence	presence	NN	_	6	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	6	cc	_	_
13	vice	vice	RB	_	14	com	_	_
14	versa	versa	RB	_	6	conj	_	_
15	.	.	.	_	5	p	_	_

1	There	there	EX	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	no	no	DT	_	5	det	_	_
4	pharmacokinetic	pharmacokinetic	JJ	_	5	attr	_	_
5	interaction	interaction	NN	_	2	obj	_	_
6	between	between	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	.	.	.	_	2	p	_	_

1	Use	use	NN	_	10	dep	_	_
2	in	in	IN	_	4	case	_	_
3	Ambulatory	ambulatory	JJ	_	4	attr	_	_
4	Patients	patient	NNS	_	1	ppmod	_	_
5	The	the	DT	_	6	det	_	_
6	effects	effect	NNS	_	1	appo	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	may	may	MD	_	10	modal	_	_
10	wear	wear	JJ	_	0	root	_	_
11	off	off	RP	_	10	prt	_	_
12	before	before	IN	_	17	mark	_	_
13	a	a	DT	_	14	det	_	_
14	drug2	drug0	NN	_	17	dep	_	_
15	is	be	VBZ	_	17	aux	_	_
16	completely	completely	RB	_	17	adv	_	_
17	cleared	clear	VBN	_	10	comp	_	_
18	from	from	IN	_	20	case	_	_
19	the	the	DT	_	20	det	_	_
20	body	body	NN	_	17	ppmod	_	_
21	.	.	.	_	10	p	_	_

1	In	in	IN	_	2	case	_	_
2	general	general	JJ	_	28	ppmod	_	_
3	,	,	,	_	28	p	_	_
4	if	if	IN	_	7	mark	_	_
5	a	a	DT	_	6	det	_	_
6	patient	patient	NN	_	7	dep	_	_
7	shows	show	VBZ	_	28	advcl	_	_
8	no	no	DT	_	9	det	_	_
9	signs	sign	NNS	_	7	obj	_	_
10	of	of	IN	_	11	case	_	_
11	sedation	sedation	NN	_	9	ppmod	_	_
12	within	within	IN	_	14	case	_	_
13	2	0	CD	_	14	num	_	_
14	hours	hour	NNS	_	7	ppmod	_	_
15	after	after	IN	_	18	case	_	_
16	a	a	DT	_	18	det	_	_
17	1-mg	0-mg	JJ	_	18	attr	_	_
18	dose	dose	NN	_	14	ppmod	_	_
19	of	of	IN	_	20	case	_	_
20	drug1	drug0	NN	_	18	ppmod	_	_
21	,	,	,	_	28	p	_	_
22	serious	serious	JJ	_	23	attr	_	_
23	resedation	resedation	NN	_	28	dep	_	_
24	at	at	IN	_	27	case	_	_
25	a	a	DT	_	27	det	_	_
26	later	late	JJ	_	27	attr	_	_
27	time	time	NN	_	23	ppmod	_	_
28	is	be	VBZ	_	0	root	_	_
29	unlikely	unlikely	JJ	_	28	dep	_	_
30	.	.	.	_	28	p	_	_

1	An	an	DT	_	3	det	_	_
2	adequate	adequate	JJ	_	3	attr	_	_
3	period	period	NN	_	8	dep	_	_
4	of	of	IN	_	5	case	_	_
5	observation	observation	NN	_	3	ppmod	_	_
6	must	must	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	provided	provided	VBN	_	0	root	_	_
9	for	for	IN	_	11	case	_	_
10	any	any	DT	_	11	det	_	_
11	patient	patient	NN	_	8	ppmod	_	_
12	in	in	IN	_	13	case	_	_
13	whom	whom	WP	_	36	ppmod	_	_
14	either	either	CC	_	15	cc	_	_
15	drug1	drug0	NN	_	36	dep	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	such	such	JJ	_	15	prn	_	_
18	as	as	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	)	-rrb-	-RRB-	_	17	p	_	_
21	or	or	CC	_	15	cc	_	_
22	large	large	JJ	_	23	attr	_	_
23	doses	dose	NNS	_	15	conj	_	_
24	of	of	IN	_	25	case	_	_
25	drug3	drug0	NN	_	23	ppmod	_	_
26	(	-lrb-	-LRB-	_	30	p	_	_
27	such	such	JJ	_	28	com	_	_
28	as	as	IN	_	30	cc	_	_
29	10	0	CD	_	30	num	_	_
30	mg	mg	NN	_	23	prn	_	_
31	of	of	IN	_	32	case	_	_
32	drug4	drug0	NN	_	30	ppmod	_	_
33	)	-rrb-	-RRB-	_	30	p	_	_
34	have	have	VBP	_	36	aux	_	_
35	been	be	VBN	_	36	aux	_	_
36	used	use	VBN	_	11	relcl	_	_
37	.	.	.	_	8	p	_	_

1	Because	because	IN	_	5	case	_	_
2	of	of	IN	_	5	case	_	_
3	the	the	DT	_	5	det	_	_
4	increased	increase	VBN	_	5	attr	_	_
5	risk	risk	NN	_	22	ppmod	_	_
6	of	of	IN	_	8	case	_	_
7	adverse	adverse	JJ	_	8	attr	_	_
8	reactions	reaction	NNS	_	5	ppmod	_	_
9	in	in	IN	_	10	case	_	_
10	patients	patient	NNS	_	5	ppmod	_	_
11	who	who	WP	_	13	dep	_	_
12	have	have	VBP	_	13	aux	_	_
13	been	be	VBN	_	10	relcl	_	_
14	taking	take	VBG	_	13	comp	_	_
15	drug1	drug0	NN	_	14	obj	_	_
16	on	on	IN	_	19	case	_	_
17	a	a	DT	_	19	det	_	_
18	regular	regular	JJ	_	19	attr	_	_
19	basis	basis	NN	_	14	ppmod	_	_
20	,	,	,	_	22	p	_	_
21	it	it	PRP	_	22	dep	_	_
22	is	be	VBZ	_	0	root	_	_
23	particularly	particularly	RB	_	24	adv	_	_
24	important	important	JJ	_	22	dep	_	_
25	that	that	IN	_	27	mark	_	_
26	physicians	physician	NNS	_	27	dep	_	_
27	query	query	VB	_	22	comp	_	_
28	patients	patient	NNS	_	27	obj	_	_
29	or	or	CC	_	28	cc	_	_
30	their	their	PRP$	_	31	poss	_	_
31	guardians	guardian	NNS	_	28	conj	_	_
32	carefully	carefully	RB	_	27	adv	_	_
33	about	about	IN	_	34	case	_	_
34	drug2	drug0	NN	_	27	ppmod	_	_
35	,	,	,	_	34	p	_	_
36	drug3	drug0	NN	_	34	conj	_	_
37	and	and	CC	_	36	cc	_	_
38	drug4	drug0	NN	_	39	com	_	_
39	use	use	NN	_	34	conj	_	_
40	as	as	IN	_	41	case	_	_
41	part	part	NN	_	27	ppmod	_	_
42	of	of	IN	_	44	case	_	_
43	the	the	DT	_	44	det	_	_
44	history	history	NN	_	41	ppmod	_	_
45	prior	prior	RB	_	44	adv	_	_
46	to	to	TO	_	48	aux	_	_
47	any	any	DT	_	48	det	_	_
48	procedure	procedure	NN	_	45	ppmod	_	_
49	in	in	IN	_	50	case	_	_
50	which	which	WDT	_	56	ppmod	_	_
51	the	the	DT	_	52	det	_	_
52	use	use	NN	_	56	dep	_	_
53	of	of	IN	_	54	case	_	_
54	drug5	drug0	NN	_	52	ppmod	_	_
55	is	be	VBZ	_	56	aux	_	_
56	planned	plan	VBN	_	48	relcl	_	_
57	.	.	.	_	22	p	_	_

1	Substrate	substrate	NN	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	CYP2D6	cyp0d0	NNS	_	1	ppmod	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	minor	minor	JJ	_	3	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	,	,	,	_	1	p	_	_
8	3A4	0a0	NN	_	1	appo	_	_
9	(	-lrb-	-LRB-	_	8	p	_	_
10	major	major	JJ	_	8	attr	_	_
11	)	-rrb-	-RRB-	_	8	p	_	_
12	;	;	:	_	8	p	_	_

1	Inhibits	inhibit	VBZ	_	0	root	_	_
2	CYP2D6	cyp0d0	NN	_	1	obj	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	weak	weak	JJ	_	2	prn	_	_
5	)	-rrb-	-RRB-	_	4	p	_	_
6	.	.	.	_	1	p	_	_

1	Increased	increase	VBN	_	2	attr	_	_
2	toxicity	toxicity	NN	_	0	root	_	_
3	(	-lrb-	-LRB-	_	5	p	_	_
4	CNS	cns	NN	_	5	com	_	_
5	depression	depression	NN	_	2	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	:	:	:	_	2	p	_	_
8	drug1	drug0	NN	_	2	appo	_	_
9	,	,	,	_	8	p	_	_
10	drug2	drug0	NN	_	8	appo	_	_
11	,	,	,	_	8	p	_	_
12	drug3	drug0	NN	_	8	appo	_	_
13	,	,	,	_	8	p	_	_
14	drug4	drug0	NN	_	8	appo	_	_
15	.	.	.	_	2	p	_	_

1	CYP3A4	cyp0a0	JJ	_	2	attr	_	_
2	inhibitors	inhibitor	NNS	_	5	dep	_	_
3	:	:	:	_	2	p	_	_
4	May	may	MD	_	5	modal	_	_
5	increase	increase	VB	_	0	root	_	_
6	the	the	DT	_	7	det	_	_
7	levels/effects	levels/effects	NNS	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	.	.	.	_	5	p	_	_

1	Example	example	NN	_	2	com	_	_
2	inhibitors	inhibitor	NNS	_	3	dep	_	_
3	include	include	VBP	_	0	root	_	_
4	drug1	drug0	NN	_	3	obj	_	_
5	,	,	,	_	4	p	_	_
6	drug2	drug0	NN	_	4	appo	_	_
7	,	,	,	_	6	p	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	,	,	,	_	8	p	_	_
10	drug4	drug0	NN	_	6	conj	_	_
11	,	,	,	_	10	p	_	_
12	drug5	drug0	NN	_	6	conj	_	_
13	,	,	,	_	12	p	_	_
14	drug6	drug0	NN	_	6	conj	_	_
15	,	,	,	_	14	p	_	_
16	drug7	drug0	NN	_	6	conj	_	_
17	,	,	,	_	16	p	_	_
18	drug8	drug0	NN	_	6	conj	_	_
19	,	,	,	_	18	p	_	_
20	drug9	drug0	NN	_	6	conj	_	_
21	,	,	,	_	20	p	_	_
22	drug10	drug0	NN	_	6	conj	_	_
23	,	,	,	_	22	p	_	_
24	drug11	drug0	NN	_	6	conj	_	_
25	,	,	,	_	24	p	_	_
26	drug12	drug0	NN	_	6	conj	_	_
27	,	,	,	_	26	p	_	_
28	drug13	drug0	NN	_	6	conj	_	_
29	,	,	,	_	28	p	_	_
30	and	and	CC	_	28	cc	_	_
31	drug14	drug0	NN	_	6	conj	_	_
32	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	19	attr	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	drug3	drug0	NN	_	3	prn	_	_
6	,	,	,	_	5	p	_	_
7	drug4	drug0	NN	_	5	conj	_	_
8	,	,	,	_	7	p	_	_
9	drug5	drug0	NN	_	5	conj	_	_
10	,	,	,	_	9	p	_	_
11	drug6	drug0	NN	_	5	conj	_	_
12	,	,	,	_	11	p	_	_
13	fruit	fruit	NN	_	14	com	_	_
14	juices	juice	NNS	_	5	conj	_	_
15	,	,	,	_	14	p	_	_
16	etc.	etc.	NN	_	5	conj	_	_
17	)	-rrb-	-RRB-	_	5	p	_	_
18	lower	low	JJR	_	19	attr	_	_
19	absorption	absorption	NN	_	1	appo	_	_
20	of	of	IN	_	21	case	_	_
21	drug7	drug0	NN	_	19	ppmod	_	_
22	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	9	dep	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	drug2	drug0	NN	_	1	prn	_	_
4	,	,	,	_	3	p	_	_
5	drug3	drug0	NN	_	3	conj	_	_
6	,	,	,	_	5	p	_	_
7	etc.	etc.	NN	_	3	conj	_	_
8	)	-rrb-	-RRB-	_	3	p	_	_
9	increase	increase	VBP	_	0	root	_	_
10	the	the	DT	_	11	det	_	_
11	concentration	concentration	NN	_	9	obj	_	_
12	of	of	IN	_	15	case	_	_
13	the	the	DT	_	15	det	_	_
14	ionized	ionize	VBN	_	15	attr	_	_
15	species	species	NNS	_	11	ppmod	_	_
16	of	of	IN	_	19	case	_	_
17	the	the	DT	_	19	det	_	_
18	drug4	drug0	NN	_	19	com	_	_
19	molecule	molecule	NN	_	15	ppmod	_	_
20	,	,	,	_	9	p	_	_
21	thereby	thereby	RB	_	22	adv	_	_
22	increasing	increase	VBG	_	9	comp	_	_
23	urinary	urinary	JJ	_	24	attr	_	_
24	excretion	excretion	NN	_	22	obj	_	_
25	.	.	.	_	9	p	_	_

1	Both	both	CC	_	2	cc	_	_
2	groups	group	NNS	_	5	dep	_	_
3	of	of	IN	_	4	case	_	_
4	agents	agent	NNS	_	2	ppmod	_	_
5	lower	low	JJR	_	0	root	_	_
6	blood	blood	NN	_	7	com	_	_
7	levels	level	NNS	_	5	obj	_	_
8	and	and	CC	_	7	cc	_	_
9	efficacy	efficacy	NN	_	7	conj	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	are	be	VBP	_	5	aux	_	_
5	inhibited	inhibit	VBN	_	0	root	_	_
6	by	by	IN	_	7	case	_	_
7	drug3	drug0	NN	_	5	ppmod	_	_
8	.	.	.	_	5	p	_	_

1	Alkalinizing	alkalinizing	NN	_	2	com	_	_
2	agents	agent	NNS	_	12	dep	_	_
3	:	:	:	_	2	p	_	_
4	Gastrointestinal	gastrointestinal	JJ	_	6	attr	_	_
5	alkalinizing	alkalinizing	NN	_	6	com	_	_
6	agents	agent	NNS	_	2	appo	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	drug1	drug0	NN	_	6	prn	_	_
9	,	,	,	_	8	p	_	_
10	etc.	etc.	NN	_	8	conj	_	_
11	)	-rrb-	-RRB-	_	8	p	_	_
12	increase	increase	VBP	_	0	root	_	_
13	absorption	absorption	NN	_	12	obj	_	_
14	of	of	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	12	p	_	_

1	Urinary	urinary	JJ	_	3	attr	_	_
2	alkalinizing	alkalinizing	NN	_	3	com	_	_
3	agents	agent	NNS	_	10	dep	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	drug1	drug0	NN	_	3	prn	_	_
6	,	,	,	_	5	p	_	_
7	some	some	DT	_	8	det	_	_
8	drug2	drug0	NNS	_	5	appo	_	_
9	)	-rrb-	-RRB-	_	5	p	_	_
10	increase	increase	VBP	_	0	root	_	_
11	the	the	DT	_	12	det	_	_
12	concentration	concentration	NN	_	10	obj	_	_
13	of	of	IN	_	16	case	_	_
14	the	the	DT	_	16	det	_	_
15	non-ionized	non-ionized	JJ	_	16	attr	_	_
16	species	species	NNS	_	12	ppmod	_	_
17	of	of	IN	_	20	case	_	_
18	the	the	DT	_	20	det	_	_
19	drug3	drug0	NN	_	20	com	_	_
20	molecule	molecule	NN	_	16	ppmod	_	_
21	,	,	,	_	10	p	_	_
22	thereby	thereby	RB	_	23	adv	_	_
23	decreasing	decrease	VBG	_	10	comp	_	_
24	urinary	urinary	JJ	_	25	attr	_	_
25	excretion	excretion	NN	_	23	obj	_	_
26	.	.	.	_	10	p	_	_

1	Both	both	DT	_	2	det	_	_
2	groups	group	NNS	_	5	dep	_	_
3	of	of	IN	_	4	case	_	_
4	agents	agent	NNS	_	2	ppmod	_	_
5	increase	increase	VBP	_	0	root	_	_
6	blood	blood	NN	_	7	com	_	_
7	levels	level	NNS	_	5	obj	_	_
8	and	and	CC	_	5	cc	_	_
9	therefore	therefore	RB	_	10	adv	_	_
10	potentiate	potentiate	VB	_	5	conj	_	_
11	the	the	DT	_	12	det	_	_
12	actions	action	NNS	_	10	obj	_	_
13	of	of	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	,	,	,	_	3	p	_	_
3	drug2	drug0	NN	_	7	comp	_	_
4	:	:	:	_	7	p	_	_
5	drug3	drug0	NN	_	7	dep	_	_
6	may	may	MD	_	7	modal	_	_
7	enhance	enhance	VB	_	0	root	_	_
8	the	the	DT	_	9	det	_	_
9	activity	activity	NN	_	7	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug4	drug0	NN	_	9	ppmod	_	_
12	or	or	CC	_	11	cc	_	_
13	drug5	drug0	NN	_	11	conj	_	_
14	;	;	:	_	7	p	_	_

1	drug1	drug0	NN	_	10	dep	_	_
2	with	with	IN	_	3	case	_	_
3	drug2	drug0	NN	_	1	ppmod	_	_
4	or	or	CC	_	3	cc	_	_
5	drug3	drug0	NN	_	3	conj	_	_
6	and	and	CC	_	1	cc	_	_
7	possibly	possibly	RB	_	9	adv	_	_
8	other	other	JJ	_	9	attr	_	_
9	drug4	drug0	NNS	_	1	conj	_	_
10	cause	cause	VBP	_	0	root	_	_
11	striking	striking	JJ	_	14	attr	_	_
12	and	and	CC	_	11	cc	_	_
13	sustained	sustained	JJ	_	11	conj	_	_
14	increases	increase	NNS	_	10	obj	_	_
15	in	in	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	concentration	concentration	NN	_	14	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug5	drug0	NN	_	17	ppmod	_	_
20	in	in	IN	_	22	case	_	_
21	the	the	DT	_	22	det	_	_
22	brain	brain	NN	_	17	ppmod	_	_
23	;	;	:	_	10	p	_	_

1	cardiovascular	cardiovascular	JJ	_	2	attr	_	_
2	effects	effect	NNS	_	5	dep	_	_
3	can	can	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	potentiated	potentiate	VBN	_	0	root	_	_
6	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	,	,	,	_	3	p	_	_
5	as	as	RB	_	6	com	_	_
6	well	well	RB	_	3	cc	_	_
7	as	as	IN	_	6	com	_	_
8	a	a	DT	_	9	det	_	_
9	metabolite	metabolite	NN	_	3	conj	_	_
10	of	of	IN	_	11	case	_	_
11	drug3	drug0	NN	_	9	ppmod	_	_
12	,	,	,	_	9	p	_	_
13	slow	slow	JJ	_	15	attr	_	_
14	drug4	drug0	NN	_	15	com	_	_
15	metabolism	metabolism	NN	_	9	appo	_	_
16	.	.	.	_	1	p	_	_

1	This	this	DT	_	2	det	_	_
2	slowing	slowing	NN	_	3	dep	_	_
3	potentiates	potentiate	VBZ	_	0	root	_	_
4	drug1	drug0	NN	_	3	obj	_	_
5	,	,	,	_	3	p	_	_
6	increasing	increase	VBG	_	3	comp	_	_
7	their	their	PRP$	_	8	poss	_	_
8	effect	effect	NN	_	6	obj	_	_
9	on	on	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	release	release	NN	_	8	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	norepinephrine	norepinephrine	NN	_	11	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	other	other	JJ	_	16	attr	_	_
16	monoamines	monoamine	NNS	_	13	conj	_	_
17	from	from	IN	_	20	case	_	_
18	adrenergic	adrenergic	JJ	_	20	attr	_	_
19	nerve	nerve	NN	_	20	com	_	_
20	endings	ending	NNS	_	11	ppmod	_	_
21	;	;	:	_	3	p	_	_

1	this	this	DT	_	3	dep	_	_
2	can	can	MD	_	3	modal	_	_
3	cause	cause	VB	_	0	root	_	_
4	headaches	headache	NNS	_	3	obj	_	_
5	and	and	CC	_	4	cc	_	_
6	other	other	JJ	_	7	attr	_	_
7	signs	sign	NNS	_	4	conj	_	_
8	of	of	IN	_	10	case	_	_
9	hypertensive	hypertensive	JJ	_	10	attr	_	_
10	crisis	crisis	NN	_	4	ppmod	_	_
11	.	.	.	_	3	p	_	_

1	A	a	DT	_	2	det	_	_
2	variety	variety	NN	_	11	dep	_	_
3	of	of	IN	_	6	case	_	_
4	neurological	neurological	JJ	_	6	attr	_	_
5	toxic	toxic	JJ	_	6	attr	_	_
6	effects	effect	NNS	_	2	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	malignant	malignant	JJ	_	9	attr	_	_
9	hyperpyrexia	hyperpyrexia	NN	_	6	conj	_	_
10	can	can	MD	_	11	modal	_	_
11	occur	occur	VB	_	0	root	_	_
12	,	,	,	_	11	p	_	_
13	sometimes	sometimes	RB	_	16	adv	_	_
14	with	with	IN	_	16	case	_	_
15	fatal	fatal	JJ	_	16	attr	_	_
16	results	result	NNS	_	11	ppmod	_	_
17	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	may	may	MD	_	5	modal	_	_
5	counteract	counteract	VB	_	0	root	_	_
6	the	the	DT	_	8	det	_	_
7	sedative	sedative	JJ	_	8	attr	_	_
8	effect	effect	NN	_	5	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug3	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	may	may	MD	_	5	modal	_	_
5	antagonize	antagonize	VB	_	0	root	_	_
6	the	the	DT	_	8	det	_	_
7	hypotensive	hypotensive	JJ	_	8	attr	_	_
8	effects	effect	NNS	_	5	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug3	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	4	dep	_	_
4	blocks	block	VBZ	_	1	acl	_	_
5	dopamine	dopamine	NN	_	4	obj	_	_
6	and	and	CC	_	5	cc	_	_
7	norepinephrine	norepinephrine	NN	_	8	com	_	_
8	reuptake	reuptake	NN	_	5	conj	_	_
9	,	,	,	_	4	p	_	_
10	thus	thus	RB	_	11	adv	_	_
11	inhibiting	inhibit	VBG	_	4	comp	_	_
12	the	the	DT	_	15	det	_	_
13	central	central	JJ	_	15	attr	_	_
14	stimulant	stimulant	NN	_	15	com	_	_
15	effects	effect	NNS	_	11	obj	_	_
16	of	of	IN	_	17	case	_	_
17	drug3	drug0	NN	_	15	ppmod	_	_
18	,	,	,	_	4	p	_	_
19	and	and	CC	_	4	cc	_	_
20	can	can	MD	_	22	modal	_	_
21	be	be	VB	_	22	aux	_	_
22	used	use	VBN	_	4	conj	_	_
23	to	to	TO	_	24	aux	_	_
24	treat	treat	VB	_	22	comp	_	_
25	drug4	drug0	NN	_	26	com	_	_
26	poisoning	poisoning	NN	_	24	obj	_	_
27	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	may	may	MD	_	5	modal	_	_
5	delay	delay	VB	_	0	root	_	_
6	intestinal	intestinal	JJ	_	7	attr	_	_
7	absorption	absorption	NN	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_
10	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	blocks	block	VBZ	_	0	root	_	_
5	dopamine	dopamine	NN	_	4	obj	_	_
6	and	and	CC	_	5	cc	_	_
7	norepinephrine	norepinephrine	NN	_	8	com	_	_
8	reuptake	reuptake	NN	_	5	conj	_	_
9	,	,	,	_	4	p	_	_
10	thus	thus	RB	_	11	adv	_	_
11	inhibiting	inhibit	VBG	_	4	comp	_	_
12	the	the	DT	_	15	det	_	_
13	central	central	JJ	_	15	attr	_	_
14	stimulant	stimulant	JJ	_	15	attr	_	_
15	effects	effect	NNS	_	11	obj	_	_
16	of	of	IN	_	17	case	_	_
17	drug3	drug0	NN	_	15	ppmod	_	_
18	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	10	dep	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	5	det	_	_
4	stimulatory	stimulatory	JJ	_	5	attr	_	_
5	effects	effect	NNS	_	1	appo	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	may	may	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	inhibited	inhibit	VBN	_	0	root	_	_
11	by	by	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	potentiate	potentiate	VB	_	0	root	_	_
5	the	the	DT	_	7	det	_	_
6	analgesic	analgesic	JJ	_	7	attr	_	_
7	effect	effect	NN	_	4	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_
10	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	therapy	therapy	NN	_	9	dep	_	_
3	:	:	:	_	9	p	_	_
4	Urinary	urinary	JJ	_	5	attr	_	_
5	excretion	excretion	NN	_	9	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	is	be	VBZ	_	9	aux	_	_
9	increased	increase	VBN	_	0	root	_	_
10	,	,	,	_	9	p	_	_
11	and	and	CC	_	9	cc	_	_
12	efficacy	efficacy	NN	_	14	dep	_	_
13	is	be	VBZ	_	14	aux	_	_
14	reduced	reduce	VBN	_	9	conj	_	_
15	,	,	,	_	14	p	_	_
16	by	by	IN	_	17	case	_	_
17	drug3	drug0	NN	_	14	ppmod	_	_
18	used	use	VBN	_	17	acl	_	_
19	in	in	IN	_	21	case	_	_
20	drug4	drug0	NN	_	21	com	_	_
21	therapy	therapy	NN	_	18	ppmod	_	_
22	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	enhance	enhance	VBP	_	0	root	_	_
5	the	the	DT	_	7	det	_	_
6	adrenergic	adrenergic	JJ	_	7	attr	_	_
7	effect	effect	NN	_	4	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_
10	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	delay	delay	VB	_	1	acl	_	_
6	intestinal	intestinal	JJ	_	7	attr	_	_
7	absorption	absorption	NN	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_
10	;	;	:	_	1	p	_	_

1	co-administration	co-administration	NN	_	5	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	may	may	MD	_	5	modal	_	_
5	produce	produce	VB	_	0	root	_	_
6	a	a	DT	_	9	det	_	_
7	synergistic	synergistic	JJ	_	9	attr	_	_
8	anticonvulsant	anticonvulsant	JJ	_	9	attr	_	_
9	action	action	NN	_	5	obj	_	_
10	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	delay	delay	VB	_	1	acl	_	_
6	intestinal	intestinal	JJ	_	7	attr	_	_
7	absorption	absorption	NN	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_
10	;	;	:	_	1	p	_	_

1	co-administration	co-administration	NN	_	5	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	may	may	MD	_	5	modal	_	_
5	produce	produce	VB	_	0	root	_	_
6	a	a	DT	_	9	det	_	_
7	synergistic	synergistic	JJ	_	9	attr	_	_
8	anticonvulsant	anticonvulsant	JJ	_	9	attr	_	_
9	action	action	NN	_	5	obj	_	_
10	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	4	case	_	_
4	cases	case	NNS	_	13	ppmod	_	_
5	of	of	IN	_	7	case	_	_
6	drug2	drug0	NN	_	7	com	_	_
7	overdosage	overdosage	NN	_	4	ppmod	_	_
8	,	,	,	_	13	p	_	_
9	drug3	drug0	NN	_	11	com	_	_
10	CNS	cns	NN	_	11	com	_	_
11	stimulation	stimulation	NN	_	13	dep	_	_
12	is	be	VBZ	_	13	aux	_	_
13	potentiated	potentiate	VBN	_	1	acl	_	_
14	and	and	CC	_	13	cc	_	_
15	fatal	fatal	JJ	_	16	attr	_	_
16	convulsions	convulsion	NNS	_	18	dep	_	_
17	can	can	MD	_	18	modal	_	_
18	occur	occur	VB	_	13	conj	_	_
19	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	inhibit	inhibit	VBP	_	0	root	_	_
5	the	the	DT	_	7	det	_	_
6	hypotensive	hypotensive	JJ	_	7	attr	_	_
7	effect	effect	NN	_	4	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_
10	.	.	.	_	4	p	_	_

1	Drug/Laboratory	drug/laboratory	JJ	_	3	attr	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	7	dep	_	_
4	:	:	:	_	3	p	_	_
5	drug1	drug0	NN	_	3	appo	_	_
6	can	can	MD	_	7	modal	_	_
7	cause	cause	VB	_	0	root	_	_
8	a	a	DT	_	10	det	_	_
9	significant	significant	JJ	_	10	attr	_	_
10	elevation	elevation	NN	_	7	obj	_	_
11	in	in	IN	_	14	case	_	_
12	plasma	plasma	NN	_	14	com	_	_
13	drug2	drug0	NN	_	14	com	_	_
14	levels	level	NNS	_	10	ppmod	_	_
15	.	.	.	_	7	p	_	_

1	This	this	DT	_	2	det	_	_
2	increase	increase	NN	_	3	dep	_	_
3	is	be	VBZ	_	0	root	_	_
4	greatest	great	JJS	_	3	dep	_	_
5	in	in	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	evening	evening	NN	_	4	ppmod	_	_
8	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	interfere	interfere	VB	_	0	root	_	_
4	with	with	IN	_	7	case	_	_
5	urinary	urinary	JJ	_	7	attr	_	_
6	steroid	steroid	NN	_	7	com	_	_
7	determinations	determination	NNS	_	3	ppmod	_	_
8	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	metabolized	metabolize	VBN	_	0	root	_	_
4	mainly	mainly	RB	_	3	adv	_	_
5	via	via	IN	_	9	case	_	_
6	the	the	DT	_	9	det	_	_
7	cytochrome	cytochrome	NN	_	9	com	_	_
8	P450	p0	NN	_	9	com	_	_
9	3A4	0a0	NN	_	3	ppmod	_	_
10	enzyme	enzyme	NN	_	9	appo	_	_
11	.	.	.	_	3	p	_	_

1	In	in	IN	_	3	case	_	_
2	some	some	DT	_	3	det	_	_
3	cases	case	NNS	_	38	ppmod	_	_
4	where	where	WRB	_	17	adv	_	_
5	serious	serious	JJ	_	7	attr	_	_
6	ventricular	ventricular	JJ	_	7	attr	_	_
7	arrhythmias	arrhythmia	NNS	_	17	dep	_	_
8	,	,	,	_	7	p	_	_
9	QT	qt	NN	_	10	com	_	_
10	prolongation	prolongation	NN	_	7	conj	_	_
11	,	,	,	_	10	p	_	_
12	and	and	CC	_	10	cc	_	_
13	torsades	torsades	NNS	_	7	conj	_	_
14	de	de	FW	_	15	adv	_	_
15	pointes	pointes	FW	_	13	attr	_	_
16	have	have	VBP	_	17	aux	_	_
17	occurred	occur	VBN	_	3	relcl	_	_
18	when	when	WRB	_	21	adv	_	_
19	drug1	drug0	NN	_	21	dep	_	_
20	was	be	VBD	_	21	aux	_	_
21	taken	take	VBN	_	17	comp	_	_
22	in	in	IN	_	23	case	_	_
23	conjunction	conjunction	NN	_	21	ppmod	_	_
24	with	with	IN	_	25	case	_	_
25	one	#crd#	CD	_	23	ppmod	_	_
26	of	of	IN	_	31	case	_	_
27	the	the	DT	_	30	det	_	_
28	cytochrome	cytochrome	NN	_	30	com	_	_
29	P450	p0	NN	_	30	com	_	_
30	3A4	0a0	NN	_	31	com	_	_
31	inhibitors	inhibitor	NNS	_	25	ppmod	_	_
32	,	,	,	_	38	p	_	_
33	elevated	elevated	JJ	_	36	attr	_	_
34	blood	blood	NN	_	36	com	_	_
35	drug2	drug0	NN	_	36	com	_	_
36	levels	level	NNS	_	38	dep	_	_
37	were	be	VBD	_	38	aux	_	_
38	noted	note	VBN	_	0	root	_	_
39	at	at	IN	_	41	case	_	_
40	the	the	DT	_	41	det	_	_
41	time	time	NN	_	38	ppmod	_	_
42	of	of	IN	_	45	case	_	_
43	the	the	DT	_	45	det	_	_
44	QT	qt	NN	_	45	com	_	_
45	prolongation	prolongation	NN	_	41	ppmod	_	_
46	.	.	.	_	38	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	FW	_	4	adv	_	_
4	vitro	vitro	FW	_	8	attr	_	_
5	and/or	and/or	CC	_	4	cc	_	_
6	in	in	FW	_	7	adv	_	_
7	vivo	vivo	FW	_	4	conj	_	_
8	data	datum	NNS	_	9	dep	_	_
9	show	show	VBP	_	1	acl	_	_
10	that	that	IN	_	18	mark	_	_
11	drug2	drug0	NN	_	18	dep	_	_
12	,	,	,	_	11	p	_	_
13	drug3	drug0	NN	_	11	conj	_	_
14	,	,	,	_	13	p	_	_
15	and	and	CC	_	13	cc	_	_
16	drug4	drug0	NN	_	11	conj	_	_
17	markedly	markedly	RB	_	18	adv	_	_
18	inhibit	inhibit	VBP	_	9	comp	_	_
19	the	the	DT	_	20	det	_	_
20	metabolism	metabolism	NN	_	18	obj	_	_
21	of	of	IN	_	22	case	_	_
22	drug5	drug0	NN	_	20	ppmod	_	_
23	,	,	,	_	20	p	_	_
24	which	which	WDT	_	26	dep	_	_
25	can	can	MD	_	26	modal	_	_
26	result	result	VB	_	20	relcl	_	_
27	in	in	IN	_	29	case	_	_
28	an	an	DT	_	29	det	_	_
29	increase	increase	NN	_	26	ppmod	_	_
30	in	in	IN	_	33	case	_	_
31	plasma	plasma	NN	_	33	com	_	_
32	drug6	drug0	NN	_	33	com	_	_
33	levels	level	NNS	_	29	ppmod	_	_
34	and	and	CC	_	29	cc	_	_
35	prolongation	prolongation	NN	_	29	conj	_	_
36	of	of	IN	_	39	case	_	_
37	the	the	DT	_	39	det	_	_
38	QT	qt	JJ	_	39	attr	_	_
39	interval	interval	NN	_	35	ppmod	_	_
40	on	on	IN	_	42	case	_	_
41	the	the	DT	_	42	det	_	_
42	ECG	ecg	NN	_	39	ppmod	_	_
43	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Concurrent	concurrent	JJ	_	4	attr	_	_
4	administration	administration	NN	_	17	dep	_	_
5	of	of	IN	_	7	case	_	_
6	certain	certain	JJ	_	7	attr	_	_
7	drug2	drug0	NNS	_	4	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	such	such	JJ	_	11	adv	_	_
10	as	as	IN	_	11	case	_	_
11	drug3	drug0	NN	_	7	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	drug4	drug0	NN	_	11	conj	_	_
14	,	,	,	_	7	p	_	_
15	would	would	MD	_	17	modal	_	_
16	be	be	VB	_	17	aux	_	_
17	expected	expect	VBN	_	1	acl	_	_
18	to	to	TO	_	19	aux	_	_
19	compromise	compromise	VB	_	17	comp	_	_
20	the	the	DT	_	22	det	_	_
21	beneficial	beneficial	JJ	_	22	attr	_	_
22	effects	effect	NNS	_	19	obj	_	_
23	of	of	IN	_	24	case	_	_
24	drug5	drug0	NN	_	22	ppmod	_	_
25	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	16	dep	_	_
2	(	-lrb-	-LRB-	_	1	p	_	_
3	Oral	oral	JJ	_	1	attr	_	_
4	)	-rrb-	-RRB-	_	1	p	_	_
5	:	:	:	_	1	p	_	_
6	In	in	IN	_	7	case	_	_
7	patients	patient	NNS	_	1	ppmod	_	_
8	receiving	receive	VBG	_	7	acl	_	_
9	oral	oral	JJ	_	10	attr	_	_
10	drug2	drug0	NN	_	8	obj	_	_
11	,	,	,	_	7	p	_	_
12	the	the	DT	_	14	det	_	_
13	coagulation	coagulation	NN	_	14	com	_	_
14	times	time	NNS	_	7	appo	_	_
15	were	be	VBD	_	16	aux	_	_
16	increased	increase	VBN	_	0	root	_	_
17	in	in	IN	_	19	case	_	_
18	some	some	DT	_	19	det	_	_
19	cases	case	NNS	_	16	ppmod	_	_
20	.	.	.	_	16	p	_	_

1	It	it	PRP	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	advisable	advisable	JJ	_	2	dep	_	_
4	to	to	TO	_	5	aux	_	_
5	check	check	VB	_	3	comp	_	_
6	coagulation	coagulation	NN	_	7	com	_	_
7	time	time	NN	_	5	obj	_	_
8	within	within	IN	_	12	case	_	_
9	the	the	DT	_	12	det	_	_
10	first	#ord#	JJ	_	12	attr	_	_
11	few	few	JJ	_	12	attr	_	_
12	days	day	NNS	_	5	ppmod	_	_
13	after	after	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	start	start	NN	_	12	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	discontinuation	discontinuation	NN	_	15	conj	_	_
18	of	of	IN	_	20	case	_	_
19	drug1	drug0	NN	_	20	com	_	_
20	therapy	therapy	NN	_	15	ppmod	_	_
21	,	,	,	_	5	p	_	_
22	with	with	IN	_	25	case	_	_
23	an	an	DT	_	25	det	_	_
24	appropriate	appropriate	JJ	_	25	attr	_	_
25	adjustment	adjustment	NN	_	5	ppmod	_	_
26	of	of	IN	_	29	case	_	_
27	the	the	DT	_	29	det	_	_
28	drug2	drug0	NN	_	29	com	_	_
29	dose	dose	NN	_	25	ppmod	_	_
30	,	,	,	_	5	p	_	_
31	if	if	IN	_	32	mark	_	_
32	necessary	necessary	JJ	_	5	comp	_	_
33	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	FW	_	4	adv	_	_
4	vitro	vitro	FW	_	5	attr	_	_
5	data	datum	NNS	_	6	dep	_	_
6	indicate	indicate	VBP	_	1	acl	_	_
7	that	that	IN	_	9	mark	_	_
8	drug2	drug0	NN	_	9	dep	_	_
9	inhibits	inhibit	VBZ	_	6	comp	_	_
10	the	the	DT	_	11	det	_	_
11	metabolism	metabolism	NN	_	9	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug3	drug0	NN	_	11	ppmod	_	_
14	,	,	,	_	11	p	_	_
15	which	which	WDT	_	17	dep	_	_
16	can	can	MD	_	17	modal	_	_
17	result	result	VB	_	11	relcl	_	_
18	in	in	IN	_	20	case	_	_
19	an	an	DT	_	20	det	_	_
20	increase	increase	NN	_	17	ppmod	_	_
21	in	in	IN	_	24	case	_	_
22	plasma	plasma	NN	_	24	com	_	_
23	drug4	drug0	NN	_	24	com	_	_
24	levels	level	NNS	_	20	ppmod	_	_
25	and	and	CC	_	20	cc	_	_
26	prolongation	prolongation	NN	_	20	conj	_	_
27	of	of	IN	_	30	case	_	_
28	the	the	DT	_	30	det	_	_
29	QT	qt	JJ	_	30	attr	_	_
30	interval	interval	NN	_	26	ppmod	_	_
31	on	on	IN	_	33	case	_	_
32	the	the	DT	_	33	det	_	_
33	ECG	ecg	NN	_	30	ppmod	_	_
34	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	FW	_	4	adv	_	_
4	vitro	vitro	FW	_	8	attr	_	_
5	and/or	and/or	CC	_	4	cc	_	_
6	in	in	FW	_	7	adv	_	_
7	vivo	vivo	FW	_	4	conj	_	_
8	data	datum	NNS	_	9	dep	_	_
9	indicate	indicate	VBP	_	1	acl	_	_
10	that	that	IN	_	19	mark	_	_
11	drug2	drug0	NN	_	19	dep	_	_
12	,	,	,	_	11	p	_	_
13	drug3	drug0	NN	_	11	conj	_	_
14	,	,	,	_	13	p	_	_
15	and	and	CC	_	13	cc	_	_
16	oral	oral	JJ	_	17	attr	_	_
17	drug4	drug0	NN	_	11	conj	_	_
18	markedly	markedly	RB	_	19	adv	_	_
19	inhibit	inhibit	VBP	_	9	comp	_	_
20	the	the	DT	_	21	det	_	_
21	metabolism	metabolism	NN	_	19	obj	_	_
22	of	of	IN	_	23	case	_	_
23	drug5	drug0	NN	_	21	ppmod	_	_
24	,	,	,	_	21	p	_	_
25	which	which	WDT	_	27	dep	_	_
26	can	can	MD	_	27	modal	_	_
27	result	result	VB	_	21	relcl	_	_
28	in	in	IN	_	30	case	_	_
29	an	an	DT	_	30	det	_	_
30	increase	increase	NN	_	27	ppmod	_	_
31	in	in	IN	_	34	case	_	_
32	plasma	plasma	NN	_	34	com	_	_
33	drug6	drug0	NN	_	34	com	_	_
34	levels	level	NNS	_	30	ppmod	_	_
35	and	and	CC	_	30	cc	_	_
36	prolongation	prolongation	NN	_	30	conj	_	_
37	of	of	IN	_	40	case	_	_
38	the	the	DT	_	40	det	_	_
39	QT	qt	JJ	_	40	attr	_	_
40	interval	interval	NN	_	36	ppmod	_	_
41	on	on	IN	_	43	case	_	_
42	the	the	DT	_	43	det	_	_
43	ECG	ecg	NN	_	40	ppmod	_	_
44	.	.	.	_	1	p	_	_

1	Human	human	JJ	_	3	attr	_	_
2	pharmacokinetic	pharmacokinetic	JJ	_	3	attr	_	_
3	data	datum	NNS	_	4	dep	_	_
4	indicate	indicate	VBP	_	0	root	_	_
5	that	that	IN	_	9	mark	_	_
6	oral	oral	JJ	_	7	attr	_	_
7	drug1	drug0	NN	_	9	dep	_	_
8	markedly	markedly	RB	_	9	adv	_	_
9	inhibits	inhibit	VBZ	_	4	comp	_	_
10	the	the	DT	_	11	det	_	_
11	metabolism	metabolism	NN	_	9	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	,	,	,	_	9	p	_	_
15	resulting	result	VBG	_	9	comp	_	_
16	in	in	IN	_	20	case	_	_
17	a	a	DT	_	20	det	_	_
18	mean	mean	NN	_	19	advnp	_	_
19	eight-fold	eight-fold	JJ	_	20	attr	_	_
20	increase	increase	NN	_	15	ppmod	_	_
21	in	in	IN	_	22	case	_	_
22	AUC	auc	NN	_	20	ppmod	_	_
23	of	of	IN	_	24	case	_	_
24	drug3	drug0	NN	_	22	ppmod	_	_
25	.	.	.	_	4	p	_	_

1	A	a	DT	_	2	det	_	_
2	study	study	NN	_	10	dep	_	_
3	in	in	IN	_	9	case	_	_
4	14	0	CD	_	9	num	_	_
5	normal	normal	JJ	_	9	attr	_	_
6	male	male	JJ	_	9	attr	_	_
7	and	and	CC	_	6	cc	_	_
8	female	female	JJ	_	6	conj	_	_
9	volunteers	volunteer	NNS	_	2	ppmod	_	_
10	suggests	suggest	VBZ	_	0	root	_	_
11	that	that	IN	_	18	mark	_	_
12	coadministration	coadministration	NN	_	18	dep	_	_
13	of	of	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	drug2	drug0	NN	_	14	conj	_	_
17	can	can	MD	_	18	modal	_	_
18	result	result	VB	_	10	comp	_	_
19	in	in	IN	_	20	case	_	_
20	prolongation	prolongation	NN	_	18	ppmod	_	_
21	of	of	IN	_	24	case	_	_
22	the	the	DT	_	24	det	_	_
23	QT	qt	JJ	_	24	attr	_	_
24	interval	interval	NN	_	20	ppmod	_	_
25	on	on	IN	_	27	case	_	_
26	the	the	DT	_	27	det	_	_
27	ECG	ecg	NN	_	24	ppmod	_	_
28	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	4	com	_	_
4	coadministration	coadministration	NN	_	5	dep	_	_
5	leads	lead	VBZ	_	18	advcl	_	_
6	to	to	TO	_	11	aux	_	_
7	an	an	DT	_	11	det	_	_
8	increased	increase	VBN	_	11	attr	_	_
9	peak	peak	JJ	_	11	attr	_	_
10	plasma	plasma	NN	_	11	com	_	_
11	concentration	concentration	NN	_	5	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	AUC	auc	NN	_	11	conj	_	_
14	of	of	IN	_	15	case	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	,	,	,	_	18	p	_	_
17	there	there	EX	_	18	dep	_	_
18	is	be	VBZ	_	1	acl	_	_
19	no	no	DT	_	20	det	_	_
20	effect	effect	NN	_	18	obj	_	_
21	on	on	IN	_	23	case	_	_
22	drug4	drug0	NN	_	23	com	_	_
23	absorption	absorption	NN	_	20	ppmod	_	_
24	when	when	WRB	_	27	adv	_	_
25	it	it	PRP	_	27	dep	_	_
26	is	be	VBZ	_	27	aux	_	_
27	coadministered	coadministered	VBN	_	18	comp	_	_
28	with	with	IN	_	29	case	_	_
29	drug5	drug0	NN	_	27	ppmod	_	_
30	.	.	.	_	1	p	_	_

1	The	the	DT	_	3	det	_	_
2	gastrointestinal	gastrointestinal	JJ	_	3	attr	_	_
3	absorption	absorption	NN	_	9	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	is	be	VBZ	_	9	aux	_	_
9	accelerated	accelerate	VBN	_	0	root	_	_
10	when	when	WRB	_	13	adv	_	_
11	they	they	PRP	_	13	dep	_	_
12	are	be	VBP	_	13	aux	_	_
13	coadministered	coadministered	VBN	_	9	comp	_	_
14	with	with	IN	_	15	case	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	FW	_	4	adv	_	_
4	vitro	vitro	FW	_	5	attr	_	_
5	data	datum	NNS	_	6	dep	_	_
6	indicate	indicate	VBP	_	1	acl	_	_
7	that	that	IN	_	12	mark	_	_
8	drug2	drug0	NN	_	12	dep	_	_
9	and	and	CC	_	8	cc	_	_
10	drug3	drug0	NN	_	8	conj	_	_
11	markedly	markedly	RB	_	12	adv	_	_
12	inhibit	inhibit	VBP	_	6	comp	_	_
13	the	the	DT	_	14	det	_	_
14	metabolism	metabolism	NN	_	12	obj	_	_
15	of	of	IN	_	16	case	_	_
16	drug4	drug0	NN	_	14	ppmod	_	_
17	which	which	WDT	_	19	dep	_	_
18	can	can	MD	_	19	modal	_	_
19	result	result	VB	_	14	relcl	_	_
20	in	in	IN	_	22	case	_	_
21	an	an	DT	_	22	det	_	_
22	increase	increase	NN	_	19	ppmod	_	_
23	in	in	IN	_	26	case	_	_
24	plasma	plasma	NN	_	26	com	_	_
25	drug5	drug0	NN	_	26	com	_	_
26	levels	level	NNS	_	22	ppmod	_	_
27	and	and	CC	_	22	cc	_	_
28	prolongation	prolongation	NN	_	22	conj	_	_
29	of	of	IN	_	32	case	_	_
30	the	the	DT	_	32	det	_	_
31	QT	qt	JJ	_	32	attr	_	_
32	interval	interval	NN	_	28	ppmod	_	_
33	on	on	IN	_	35	case	_	_
34	the	the	DT	_	35	det	_	_
35	ECG	ecg	NN	_	32	ppmod	_	_
36	.	.	.	_	1	p	_	_

1	Other	other	JJ	_	3	attr	_	_
2	:	:	:	_	1	p	_	_
3	Coadministration	coadministration	NN	_	9	dep	_	_
4	of	of	IN	_	6	case	_	_
5	grapefruit	grapefruit	NN	_	6	com	_	_
6	juice	juice	NN	_	3	ppmod	_	_
7	with	with	IN	_	8	case	_	_
8	drug1	drug0	NN	_	3	ppmod	_	_
9	increases	increase	VBZ	_	0	root	_	_
10	the	the	DT	_	11	det	_	_
11	bioavailability	bioavailability	NN	_	9	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	and	and	CC	_	9	cc	_	_
15	concomitant	concomitant	JJ	_	16	attr	_	_
16	use	use	NN	_	19	dep	_	_
17	should	should	MD	_	19	modal	_	_
18	be	be	VB	_	19	aux	_	_
19	avoided	avoid	VBN	_	9	conj	_	_
20	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	should	should	MD	_	5	modal	_	_
3	not	not	RB	_	5	neg	_	_
4	be	be	VB	_	5	aux	_	_
5	used	use	VBN	_	0	root	_	_
6	concomitantly	concomitantly	RB	_	5	adv	_	_
7	with	with	IN	_	9	case	_	_
8	other	other	JJ	_	9	attr	_	_
9	drugs	drug	NNS	_	5	ppmod	_	_
10	known	know	VBN	_	9	acl	_	_
11	to	to	TO	_	12	aux	_	_
12	prolong	prolong	VB	_	10	comp	_	_
13	the	the	DT	_	15	det	_	_
14	QT	qt	JJ	_	15	attr	_	_
15	interval	interval	NN	_	12	obj	_	_
16	:	:	:	_	5	p	_	_
17	certain	certain	JJ	_	18	attr	_	_
18	drug2	drug0	NNS	_	5	dep	_	_
19	,	,	,	_	18	p	_	_
20	including	include	VBG	_	21	adv	_	_
21	those	those	DT	_	18	ppmod	_	_
22	of	of	IN	_	23	case	_	_
23	Class	class	NN	_	21	ppmod	_	_
24	IA	ia	CD	_	23	num	_	_
25	(	-lrb-	-LRB-	_	26	p	_	_
26	such	such	JJ	_	23	prn	_	_
27	as	as	IN	_	28	case	_	_
28	drug3	drug0	NN	_	26	ppmod	_	_
29	and	and	CC	_	28	cc	_	_
30	drug4	drug0	NN	_	28	conj	_	_
31	)	-rrb-	-RRB-	_	26	p	_	_
32	and	and	CC	_	23	cc	_	_
33	Class	class	NN	_	23	conj	_	_
34	III	iii	CD	_	33	num	_	_
35	(	-lrb-	-LRB-	_	36	p	_	_
36	such	such	JJ	_	33	prn	_	_
37	as	as	IN	_	38	case	_	_
38	drug5	drug0	NN	_	36	ppmod	_	_
39	)	-rrb-	-RRB-	_	36	p	_	_
40	;	;	:	_	5	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	such	such	JJ	_	1	prn	_	_
4	as	as	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	)	-rrb-	-RRB-	_	3	p	_	_
7	;	;	:	_	1	p	_	_

1	certain	certain	JJ	_	2	attr	_	_
2	drug1	drug0	JJ	_	0	root	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	such	such	JJ	_	2	prn	_	_
5	as	as	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	)	-rrb-	-RRB-	_	4	p	_	_
8	;	;	:	_	2	p	_	_

1	certain	certain	JJ	_	2	attr	_	_
2	drug1	drug0	JJ	_	0	root	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	such	such	JJ	_	2	prn	_	_
5	as	as	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	)	-rrb-	-RRB-	_	4	p	_	_
8	;	;	:	_	2	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	,	,	,	_	3	p	_	_
5	drug3	drug0	NN	_	1	conj	_	_
6	,	,	,	_	5	p	_	_
7	and	and	CC	_	5	cc	_	_
8	drug4	drug0	NN	_	1	conj	_	_
9	.	.	.	_	1	p	_	_

1	The	the	DT	_	3	det	_	_
2	preceding	preceding	JJ	_	3	attr	_	_
3	lists	list	NNS	_	6	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drugs	drug	NNS	_	3	ppmod	_	_
6	are	be	VBP	_	0	root	_	_
7	not	not	RB	_	6	neg	_	_
8	comprehensive	comprehensive	JJ	_	6	dep	_	_
9	.	.	.	_	6	p	_	_

1	The	the	DT	_	2	det	_	_
2	acceleration	acceleration	NN	_	9	dep	_	_
3	of	of	IN	_	5	case	_	_
4	gastric	gastric	JJ	_	5	attr	_	_
5	emptying	emptying	NN	_	2	ppmod	_	_
6	by	by	IN	_	7	case	_	_
7	drug1	drug0	NN	_	2	ppmod	_	_
8	could	could	MD	_	9	modal	_	_
9	affect	affect	VB	_	0	root	_	_
10	the	the	DT	_	11	det	_	_
11	rate	rate	NN	_	9	obj	_	_
12	of	of	IN	_	13	case	_	_
13	absorption	absorption	NN	_	11	ppmod	_	_
14	of	of	IN	_	16	case	_	_
15	other	other	JJ	_	16	attr	_	_
16	drugs	drug	NNS	_	13	ppmod	_	_
17	.	.	.	_	9	p	_	_

1	Patients	patient	NNS	_	16	dep	_	_
2	receiving	receive	VBG	_	1	acl	_	_
3	narrow	narrow	JJ	_	6	attr	_	_
4	therapeutic	therapeutic	JJ	_	6	attr	_	_
5	ratio	ratio	NN	_	6	com	_	_
6	drugs	drug	NNS	_	2	obj	_	_
7	or	or	CC	_	6	cc	_	_
8	other	other	JJ	_	9	attr	_	_
9	drugs	drug	NNS	_	6	conj	_	_
10	that	that	WDT	_	11	dep	_	_
11	require	require	VBP	_	6	relcl	_	_
12	careful	careful	JJ	_	13	attr	_	_
13	titration	titration	NN	_	11	obj	_	_
14	should	should	MD	_	16	modal	_	_
15	be	be	VB	_	16	aux	_	_
16	followed	followed	VBN	_	0	root	_	_
17	closely	closely	RB	_	16	adv	_	_
18	;	;	:	_	16	p	_	_

1	if	if	IN	_	6	mark	_	_
2	plasma	plasma	NN	_	3	com	_	_
3	levels	level	NNS	_	6	dep	_	_
4	are	be	VBP	_	6	aux	_	_
5	being	be	VBG	_	6	aux	_	_
6	monitored	monitor	VBN	_	11	advcl	_	_
7	,	,	,	_	11	p	_	_
8	they	they	PRP	_	11	dep	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	reassessed	reassess	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	The	the	DT	_	2	det	_	_
2	risks	risk	NNS	_	15	dep	_	_
3	of	of	IN	_	4	case	_	_
4	using	use	VBG	_	2	ppmod	_	_
5	drug1	drug0	NN	_	4	obj	_	_
6	in	in	IN	_	7	case	_	_
7	combination	combination	NN	_	4	ppmod	_	_
8	with	with	IN	_	10	case	_	_
9	other	other	JJ	_	10	attr	_	_
10	drugs	drug	NNS	_	7	ppmod	_	_
11	have	have	VBP	_	15	aux	_	_
12	not	not	RB	_	15	neg	_	_
13	been	be	VBN	_	15	aux	_	_
14	systematically	systematically	RB	_	15	adv	_	_
15	evaluated	evaluate	VBN	_	0	root	_	_
16	.	.	.	_	15	p	_	_

1	Given	given	IN	_	5	case	_	_
2	the	the	DT	_	5	det	_	_
3	primary	primary	JJ	_	5	attr	_	_
4	CNS	cns	NN	_	5	com	_	_
5	effects	effect	NNS	_	11	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	,	,	,	_	11	p	_	_
9	caution	caution	NN	_	11	dep	_	_
10	is	be	VBZ	_	11	aux	_	_
11	advised	advise	VBN	_	0	root	_	_
12	in	in	IN	_	13	case	_	_
13	using	use	VBG	_	11	ppmod	_	_
14	it	it	PRP	_	13	obj	_	_
15	concomitantly	concomitantly	RB	_	14	adv	_	_
16	with	with	IN	_	19	case	_	_
17	other	other	JJ	_	19	attr	_	_
18	CNS-active	cns-active	JJ	_	19	attr	_	_
19	drugs	drug	NNS	_	14	ppmod	_	_
20	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	should	should	MD	_	5	modal	_	_
3	not	not	RB	_	5	neg	_	_
4	be	be	VB	_	5	aux	_	_
5	used	use	VBN	_	0	root	_	_
6	with	with	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	.	.	.	_	5	p	_	_

1	Close	close	JJ	_	2	attr	_	_
2	supervision	supervision	NN	_	9	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	careful	careful	JJ	_	5	attr	_	_
5	adjustment	adjustment	NN	_	2	conj	_	_
6	of	of	IN	_	7	case	_	_
7	dosage	dosage	NN	_	2	ppmod	_	_
8	are	be	VBP	_	9	aux	_	_
9	required	require	VBN	_	0	root	_	_
10	when	when	WRB	_	13	adv	_	_
11	drug1	drug0	NN	_	13	dep	_	_
12	is	be	VBZ	_	13	aux	_	_
13	administered	administer	VBN	_	9	comp	_	_
14	with	with	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	or	or	CC	_	15	cc	_	_
17	drug3	drug0	NN	_	15	conj	_	_
18	.	.	.	_	9	p	_	_

1	Several	several	JJ	_	2	attr	_	_
2	drug1	drug0	NNS	_	5	dep	_	_
3	have	have	VBP	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	reported	report	VBN	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	block	block	VB	_	5	comp	_	_
8	the	the	DT	_	10	det	_	_
9	pharmacologic	pharmacologic	JJ	_	10	attr	_	_
10	effects	effect	NNS	_	7	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	drug3	drug0	NN	_	12	conj	_	_
15	,	,	,	_	14	p	_	_
16	or	or	CC	_	14	cc	_	_
17	similar	similar	JJ	_	18	attr	_	_
18	agents	agent	NNS	_	12	conj	_	_
19	,	,	,	_	5	p	_	_
20	and	and	CC	_	5	cc	_	_
21	such	such	PDT	_	23	det	_	_
22	an	an	DT	_	23	det	_	_
23	effect	effect	NN	_	26	dep	_	_
24	may	may	MD	_	26	modal	_	_
25	be	be	VB	_	26	aux	_	_
26	anticipated	anticipate	VBN	_	5	conj	_	_
27	with	with	IN	_	28	case	_	_
28	drug4	drug0	NN	_	26	ppmod	_	_
29	because	because	IN	_	33	case	_	_
30	of	of	IN	_	33	case	_	_
31	its	its	PRP$	_	33	poss	_	_
32	structural	structural	JJ	_	33	attr	_	_
33	similarity	similarity	NN	_	26	ppmod	_	_
34	to	to	TO	_	36	aux	_	_
35	other	other	JJ	_	36	attr	_	_
36	drug5	drug0	NNS	_	33	ppmod	_	_
37	.	.	.	_	5	p	_	_

1	The	the	DT	_	3	det	_	_
2	plasma	plasma	NN	_	3	com	_	_
3	concentration	concentration	NN	_	8	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	has	have	VBZ	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	reported	report	VBN	_	0	root	_	_
9	to	to	TO	_	11	aux	_	_
10	be	be	VB	_	11	aux	_	_
11	increased	increase	VBN	_	8	comp	_	_
12	by	by	IN	_	15	case	_	_
13	the	the	DT	_	15	det	_	_
14	concomitant	concomitant	JJ	_	15	attr	_	_
15	administration	administration	NN	_	11	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	;	;	:	_	8	p	_	_

1	plasma	plasma	NN	_	2	com	_	_
2	levels	level	NNS	_	10	dep	_	_
3	of	of	IN	_	7	case	_	_
4	several	several	JJ	_	7	attr	_	_
5	closely	closely	RB	_	6	adv	_	_
6	related	related	JJ	_	7	attr	_	_
7	drug1	drug0	NNS	_	2	ppmod	_	_
8	have	have	VBP	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	reported	report	VBN	_	0	root	_	_
11	to	to	TO	_	13	aux	_	_
12	be	be	VB	_	13	aux	_	_
13	increased	increase	VBN	_	10	comp	_	_
14	by	by	IN	_	17	case	_	_
15	the	the	DT	_	17	det	_	_
16	concomitant	concomitant	JJ	_	17	attr	_	_
17	administration	administration	NN	_	13	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	or	or	CC	_	19	cc	_	_
21	hepatic	hepatic	JJ	_	23	attr	_	_
22	enzyme	enzyme	NN	_	23	com	_	_
23	inhibitors	inhibitor	NNS	_	19	conj	_	_
24	(	-lrb-	-LRB-	_	29	p	_	_
25	e.g.	e.g.	FW	_	27	adv	_	_
26	,	,	,	_	27	p	_	_
27	drug3	drug0	NN	_	29	ppmod	_	_
28	,	,	,	_	29	p	_	_
29	drug4	drug0	NNS	_	23	prn	_	_
30	)	-rrb-	-RRB-	_	29	p	_	_
31	and	and	CC	_	13	cc	_	_
32	decreased	decrease	VBN	_	13	conj	_	_
33	by	by	IN	_	36	case	_	_
34	the	the	DT	_	36	det	_	_
35	concomitant	concomitant	JJ	_	36	attr	_	_
36	administration	administration	NN	_	32	ppmod	_	_
37	of	of	IN	_	40	case	_	_
38	hepatic	hepatic	JJ	_	40	attr	_	_
39	enzyme	enzyme	NN	_	40	com	_	_
40	inducers	inducer	NNS	_	36	ppmod	_	_
41	(	-lrb-	-LRB-	_	46	p	_	_
42	e.g.	e.g.	FW	_	44	adv	_	_
43	,	,	,	_	44	p	_	_
44	drug5	drug0	NN	_	46	ppmod	_	_
45	,	,	,	_	46	p	_	_
46	drug6	drug0	NNS	_	40	prn	_	_
47	)	-rrb-	-RRB-	_	46	p	_	_
48	,	,	,	_	10	p	_	_
49	and	and	CC	_	10	cc	_	_
50	such	such	PDT	_	52	det	_	_
51	an	an	DT	_	52	det	_	_
52	effect	effect	NN	_	55	dep	_	_
53	may	may	MD	_	55	modal	_	_
54	be	be	VB	_	55	aux	_	_
55	anticipated	anticipate	VBN	_	10	conj	_	_
56	with	with	IN	_	57	case	_	_
57	drug7	drug0	NN	_	55	ppmod	_	_
58	as	as	IN	_	59	case	_	_
59	well	well	NN	_	55	ppmod	_	_
60	.	.	.	_	55	p	_	_

1	Administration	administration	NN	_	6	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	has	have	VBZ	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	reported	report	VBN	_	0	root	_	_
7	to	to	TO	_	8	aux	_	_
8	increase	increase	VB	_	6	comp	_	_
9	the	the	DT	_	11	det	_	_
10	plasma	plasma	NN	_	11	com	_	_
11	levels	level	NNS	_	8	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	,	,	,	_	6	p	_	_
15	if	if	IN	_	16	mark	_	_
16	given	give	VBN	_	6	comp	_	_
17	concomitantly	concomitantly	RB	_	16	adv	_	_
18	.	.	.	_	6	p	_	_

1	Drugs	drug	NNS	_	2	dep	_	_
2	Metabolized	metabolize	VBN	_	23	advcl	_	_
3	by	by	IN	_	5	case	_	_
4	P450	p0	NN	_	5	com	_	_
5	2D6	0d0	NN	_	2	ppmod	_	_
6	:	:	:	_	23	p	_	_
7	The	the	DT	_	9	det	_	_
8	biochemical	biochemical	JJ	_	9	attr	_	_
9	activity	activity	NN	_	23	dep	_	_
10	of	of	IN	_	17	case	_	_
11	the	the	DT	_	17	det	_	_
12	drug	drug	NN	_	17	com	_	_
13	metabolizing	metabolizing	NN	_	17	com	_	_
14	isozyme	isozyme	NN	_	17	com	_	_
15	cytochrome	cytochrome	NN	_	17	com	_	_
16	P450	p0	NN	_	17	com	_	_
17	2D6	0d0	NN	_	9	ppmod	_	_
18	(	-lrb-	-LRB-	_	20	p	_	_
19	debrisoquin	debrisoquin	NN	_	20	com	_	_
20	hydroxylase	hydroxylase	NN	_	17	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	is	be	VBZ	_	23	aux	_	_
23	reduced	reduce	VBN	_	0	root	_	_
24	in	in	IN	_	26	case	_	_
25	a	a	DT	_	26	det	_	_
26	subset	subset	NN	_	23	ppmod	_	_
27	of	of	IN	_	30	case	_	_
28	the	the	DT	_	30	det	_	_
29	aucasian	aucasian	JJ	_	30	attr	_	_
30	population	population	NN	_	26	ppmod	_	_
31	(	-lrb-	-LRB-	_	35	p	_	_
32	about	about	RB	_	33	adv	_	_
33	7	0	CD	_	35	num	_	_
34	%	%	NN	_	35	meta	_	_
35	-10	0	CD	_	30	num	_	_
36	%	%	NN	_	35	meta	_	_
37	of	of	IN	_	38	case	_	_
38	Caucasians	caucasians	NNP	_	35	ppmod	_	_
39	are	be	VBP	_	38	acl	_	_
40	so-called	so-called	JJ	_	42	attr	_	_
41	poor	poor	JJ	_	42	attr	_	_
42	metabolizers	metabolizers	NNS	_	39	obj	_	_
43	)	-rrb-	-RRB-	_	35	p	_	_
44	;	;	:	_	23	p	_	_

1	reliable	reliable	JJ	_	2	attr	_	_
2	estimates	estimate	NNS	_	19	dep	_	_
3	of	of	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	prevalence	prevalence	NN	_	2	ppmod	_	_
6	of	of	IN	_	11	case	_	_
7	reduced	reduce	VBN	_	11	attr	_	_
8	P450	p0	NN	_	11	com	_	_
9	2D6	0d0	NN	_	11	com	_	_
10	isozyme	isozyme	NN	_	11	com	_	_
11	activity	activity	NN	_	5	ppmod	_	_
12	among	among	IN	_	18	case	_	_
13	Asian	asian	JJ	_	18	attr	_	_
14	,	,	,	_	13	p	_	_
15	African	african	JJ	_	13	conj	_	_
16	and	and	CC	_	15	cc	_	_
17	other	other	JJ	_	13	conj	_	_
18	populations	population	NNS	_	5	ppmod	_	_
19	are	be	VBP	_	0	root	_	_
20	not	not	RB	_	19	neg	_	_
21	yet	yet	RB	_	19	adv	_	_
22	available	available	JJ	_	19	dep	_	_
23	.	.	.	_	19	p	_	_

1	Poor	poor	JJ	_	2	attr	_	_
2	metabolizers	metabolizers	NNS	_	8	dep	_	_
3	have	have	VBP	_	8	lv	_	_
4	higher	high	JJR	_	8	attr	_	_
5	than	than	IN	_	8	case	_	_
6	expected	expect	VBN	_	8	attr	_	_
7	lasma	lasma	NN	_	8	com	_	_
8	concentrations	concentration	NNS	_	0	root	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	drug2	drug0	NN	_	10	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	when	when	WRB	_	15	adv	_	_
15	given	give	VBN	_	8	comp	_	_
16	usual	usual	JJ	_	17	attr	_	_
17	doses	dose	NNS	_	15	obj	_	_
18	.	.	.	_	8	p	_	_

1	Depending	depend	VBG	_	4	adv	_	_
2	on	on	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	fraction	fraction	NN	_	18	ppmod	_	_
5	of	of	IN	_	6	case	_	_
6	drug	drug	NN	_	4	ppmod	_	_
7	metabolized	metabolize	VBN	_	6	acl	_	_
8	by	by	IN	_	10	case	_	_
9	P450	p0	NN	_	10	com	_	_
10	2D6	0d0	NN	_	7	ppmod	_	_
11	,	,	,	_	18	p	_	_
12	the	the	DT	_	13	det	_	_
13	increase	increase	NN	_	18	dep	_	_
14	in	in	IN	_	16	case	_	_
15	plasma	plasma	NN	_	16	com	_	_
16	concentration	concentration	NN	_	13	ppmod	_	_
17	may	may	MD	_	18	modal	_	_
18	be	be	VB	_	0	root	_	_
19	small	small	JJ	_	18	dep	_	_
20	,	,	,	_	19	p	_	_
21	or	or	CC	_	19	cc	_	_
22	quite	quite	RB	_	23	adv	_	_
23	large	large	JJ	_	19	conj	_	_
24	(	-lrb-	-LRB-	_	27	p	_	_
25	8	0	CD	_	26	num	_	_
26	fold	fold	JJ	_	27	attr	_	_
27	increase	increase	NN	_	23	prn	_	_
28	in	in	IN	_	30	case	_	_
29	plasma	plasma	NN	_	30	com	_	_
30	AUC	auc	NN	_	27	ppmod	_	_
31	of	of	IN	_	33	case	_	_
32	the	the	DT	_	33	det	_	_
33	drug1	drug0	NN	_	30	ppmod	_	_
34	)	-rrb-	-RRB-	_	27	p	_	_
35	.	.	.	_	18	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	16	ppmod	_	_
3	,	,	,	_	16	p	_	_
4	certain	certain	JJ	_	5	attr	_	_
5	drugs	drug	NNS	_	16	dep	_	_
6	inhibit	inhibit	VB	_	16	dep	_	_
7	the	the	DT	_	8	det	_	_
8	activity	activity	NN	_	6	obj	_	_
9	of	of	IN	_	11	case	_	_
10	this	this	DT	_	11	det	_	_
11	isozyme	isozyme	NN	_	8	ppmod	_	_
12	and	and	CC	_	6	cc	_	_
13	make	make	VB	_	6	conj	_	_
14	normal	normal	JJ	_	15	attr	_	_
15	metabolizers	metabolizers	NNS	_	13	obj	_	_
16	resemble	resemble	VBP	_	0	root	_	_
17	poor	poor	JJ	_	18	attr	_	_
18	metabolizers	metabolizers	NNS	_	16	obj	_	_
19	.	.	.	_	16	p	_	_

1	An	an	DT	_	2	det	_	_
2	individual	individual	JJ	_	13	dep	_	_
3	who	who	WP	_	4	dep	_	_
4	is	be	VBZ	_	2	relcl	_	_
5	stable	stable	JJ	_	4	dep	_	_
6	on	on	IN	_	9	case	_	_
7	a	a	DT	_	9	det	_	_
8	given	given	JJ	_	9	attr	_	_
9	dose	dose	NN	_	5	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	may	may	MD	_	13	modal	_	_
13	become	become	VB	_	0	root	_	_
14	abruptly	abruptly	RB	_	15	adv	_	_
15	toxic	toxic	JJ	_	13	dep	_	_
16	when	when	WRB	_	17	adv	_	_
17	given	give	VBN	_	13	comp	_	_
18	one	#crd#	CD	_	17	obj	_	_
19	of	of	IN	_	22	case	_	_
20	these	these	DT	_	22	det	_	_
21	inhibiting	inhibiting	JJ	_	22	attr	_	_
22	drugs	drug	NNS	_	18	ppmod	_	_
23	as	as	IN	_	25	case	_	_
24	concomitant	concomitant	JJ	_	25	attr	_	_
25	therapy	therapy	NN	_	22	ppmod	_	_
26	.	.	.	_	13	p	_	_

1	The	the	DT	_	2	det	_	_
2	drugs	drug	NNS	_	8	dep	_	_
3	that	that	WDT	_	4	dep	_	_
4	inhibit	inhibit	VBP	_	2	relcl	_	_
5	cytochrome	cytochrome	NN	_	7	com	_	_
6	P450	p0	NN	_	7	com	_	_
7	2D6	0d0	NN	_	4	obj	_	_
8	include	include	VBP	_	0	root	_	_
9	some	some	DT	_	8	obj	_	_
10	that	that	WDT	_	13	dep	_	_
11	are	be	VBP	_	13	aux	_	_
12	not	not	RB	_	13	neg	_	_
13	metabolized	metabolize	VBN	_	9	relcl	_	_
14	by	by	IN	_	18	case	_	_
15	the	the	DT	_	18	det	_	_
16	enzyme	enzyme	NN	_	18	attr	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	drug1	drug0	NN	_	13	ppmod	_	_
19	;	;	:	_	8	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	)	-rrb-	-RRB-	_	1	p	_	_
3	and	and	CC	_	1	cc	_	_
4	many	many	JJ	_	1	conj	_	_
5	that	that	WDT	_	6	dep	_	_
6	are	be	VBP	_	4	relcl	_	_
7	substrates	substrate	NNS	_	6	obj	_	_
8	for	for	IN	_	10	case	_	_
9	P450	p0	NN	_	10	com	_	_
10	2D6	0d0	NN	_	7	ppmod	_	_
11	(	-lrb-	-LRB-	_	14	p	_	_
12	many	many	JJ	_	14	attr	_	_
13	other	other	JJ	_	14	attr	_	_
14	drug2	drug0	NN	_	10	prn	_	_
15	,	,	,	_	14	p	_	_
16	drug3	drug0	NN	_	14	conj	_	_
17	,	,	,	_	16	p	_	_
18	and	and	CC	_	16	cc	_	_
19	the	the	DT	_	21	det	_	_
20	drug4	drug0	NN	_	21	com	_	_
21	drug5	drug0	NN	_	14	conj	_	_
22	and	and	CC	_	21	cc	_	_
23	drug6	drug0	NN	_	21	conj	_	_
24	)	-rrb-	-RRB-	_	14	p	_	_
25	.	.	.	_	1	p	_	_

1	While	while	IN	_	20	mark	_	_
2	all	all	PDT	_	4	det	_	_
3	the	the	DT	_	4	det	_	_
4	drug1	drug0	NN	_	20	dep	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	drug2	drug0	NN	_	4	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	,	,	,	_	4	p	_	_
9	e.g.	e.g.	FW	_	11	adv	_	_
10	,	,	,	_	11	p	_	_
11	drug3	drug0	NN	_	4	ppmod	_	_
12	,	,	,	_	11	p	_	_
13	drug4	drug0	NN	_	11	conj	_	_
14	,	,	,	_	13	p	_	_
15	drug5	drug0	NN	_	11	conj	_	_
16	,	,	,	_	15	p	_	_
17	and	and	CC	_	15	cc	_	_
18	drug6	drug0	NN	_	11	conj	_	_
19	,	,	,	_	4	p	_	_
20	inhibit	inhibit	VBP	_	26	advcl	_	_
21	P450	p0	NN	_	22	com	_	_
22	2D6	0d0	NN	_	20	obj	_	_
23	,	,	,	_	26	p	_	_
24	they	they	PRP	_	26	dep	_	_
25	may	may	MD	_	26	modal	_	_
26	vary	vary	VB	_	0	root	_	_
27	in	in	IN	_	29	case	_	_
28	the	the	DT	_	29	det	_	_
29	extent	extent	NN	_	26	ppmod	_	_
30	of	of	IN	_	31	case	_	_
31	inhibition	inhibition	NN	_	29	ppmod	_	_
32	.	.	.	_	26	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	has	have	VBZ	_	5	aux	_	_
3	also	also	RB	_	5	adv	_	_
4	been	be	VBN	_	5	aux	_	_
5	shown	show	VBN	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	inhibit	inhibit	VB	_	5	comp	_	_
8	P450	p0	NN	_	9	com	_	_
9	1A2	0a0	NN	_	7	obj	_	_
10	,	,	,	_	9	p	_	_
11	an	an	DT	_	12	det	_	_
12	isoform	isoform	NN	_	9	appo	_	_
13	also	also	RB	_	14	adv	_	_
14	involved	involve	VBN	_	12	acl	_	_
15	in	in	IN	_	17	case	_	_
16	drug2	drug0	NN	_	17	com	_	_
17	metabolism	metabolism	NN	_	14	ppmod	_	_
18	.	.	.	_	5	p	_	_

1	The	the	DT	_	2	det	_	_
2	extent	extent	NN	_	14	dep	_	_
3	to	to	TO	_	4	aux	_	_
4	which	which	WDT	_	10	ppmod	_	_
5	drug1	drug0	NN	_	8	attr	_	_
6	-	-	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	interactions	interaction	NNS	_	10	dep	_	_
9	may	may	MD	_	10	modal	_	_
10	pose	pose	VBP	_	2	relcl	_	_
11	clinical	clinical	JJ	_	12	attr	_	_
12	problems	problem	NNS	_	10	obj	_	_
13	will	will	MD	_	14	modal	_	_
14	depend	depend	VB	_	0	root	_	_
15	on	on	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	degree	degree	NN	_	14	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	inhibition	inhibition	NN	_	17	ppmod	_	_
20	and	and	CC	_	17	cc	_	_
21	the	the	DT	_	22	det	_	_
22	pharmacokinetics	pharmacokinetics	NNS	_	17	conj	_	_
23	of	of	IN	_	25	case	_	_
24	the	the	DT	_	25	det	_	_
25	drug3	drug0	NN	_	22	ppmod	_	_
26	involved	involve	VBN	_	25	acl	_	_
27	.	.	.	_	14	p	_	_

1	Nevertheless	nevertheless	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	caution	caution	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	indicated	indicate	VBN	_	0	root	_	_
6	in	in	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	co-administration	co-administration	NN	_	5	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	with	with	IN	_	12	case	_	_
12	any	any	DT	_	8	ppmod	_	_
13	of	of	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	drug2	drug0	NN	_	12	ppmod	_	_
16	and	and	CC	_	8	cc	_	_
17	also	also	RB	_	19	adv	_	_
18	in	in	IN	_	19	case	_	_
19	switching	switching	NN	_	8	conj	_	_
20	from	from	IN	_	22	case	_	_
21	one	#crd#	CD	_	22	num	_	_
22	class	class	NN	_	19	ppmod	_	_
23	to	to	TO	_	25	aux	_	_
24	the	the	DT	_	25	det	_	_
25	other	other	JJ	_	19	ppmod	_	_
26	.	.	.	_	5	p	_	_

1	Of	of	IN	_	3	case	_	_
2	particular	particular	JJ	_	3	attr	_	_
3	importance	importance	NN	_	8	ppmod	_	_
4	,	,	,	_	8	p	_	_
5	sufficient	sufficient	JJ	_	6	attr	_	_
6	time	time	NN	_	8	dep	_	_
7	must	must	MD	_	8	modal	_	_
8	elapse	elapse	VB	_	0	root	_	_
9	before	before	IN	_	10	case	_	_
10	initiating	initiate	VBG	_	8	ppmod	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	treatment	treatment	NN	_	10	obj	_	_
13	in	in	IN	_	15	case	_	_
14	a	a	DT	_	15	det	_	_
15	patient	patient	NN	_	10	ppmod	_	_
16	being	be	VBG	_	17	aux	_	_
17	withdrawn	withdraw	VBN	_	15	acl	_	_
18	from	from	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	,	,	,	_	19	p	_	_
21	given	give	VBN	_	19	acl	_	_
22	the	the	DT	_	24	det	_	_
23	long	long	JJ	_	24	attr	_	_
24	half-life	half-life	NN	_	21	obj	_	_
25	of	of	IN	_	27	case	_	_
26	the	the	DT	_	27	det	_	_
27	parent	parent	NN	_	24	ppmod	_	_
28	and	and	CC	_	19	cc	_	_
29	active	active	JJ	_	30	attr	_	_
30	metabolite	metabolite	NN	_	19	conj	_	_
31	(	-lrb-	-LRB-	_	35	p	_	_
32	at	at	IN	_	34	case	_	_
33	least	least	JJS	_	34	attr	_	_
34	5	0	CD	_	35	num	_	_
35	weeks	week	NNS	_	30	prn	_	_
36	may	may	MD	_	37	modal	_	_
37	be	be	VB	_	35	acl	_	_
38	necessary	necessary	JJ	_	37	dep	_	_
39	)	-rrb-	-RRB-	_	35	p	_	_
40	.	.	.	_	8	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	use	use	NN	_	22	dep	_	_
3	of	of	IN	_	4	case	_	_
4	agents	agent	NNS	_	2	ppmod	_	_
5	in	in	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	drug1	drug0	NN	_	4	ppmod	_	_
8	(	-lrb-	-LRB-	_	7	p	_	_
9	which	which	WDT	_	10	dep	_	_
10	includes	include	VBZ	_	7	relcl	_	_
11	drug2	drug0	NN	_	10	obj	_	_
12	)	-rrb-	-RRB-	_	7	p	_	_
13	with	with	IN	_	14	case	_	_
14	drugs	drug	NNS	_	2	ppmod	_	_
15	that	that	WDT	_	17	dep	_	_
16	can	can	MD	_	17	modal	_	_
17	inhibit	inhibit	VB	_	14	relcl	_	_
18	cytochrome	cytochrome	NN	_	20	com	_	_
19	P450	p0	NN	_	20	com	_	_
20	2D6	0d0	NN	_	17	obj	_	_
21	may	may	MD	_	22	modal	_	_
22	require	require	VB	_	0	root	_	_
23	lower	low	JJR	_	24	attr	_	_
24	doses	dose	NNS	_	22	obj	_	_
25	than	than	IN	_	26	case	_	_
26	usually	usually	RB	_	27	adv	_	_
27	prescribed	prescribe	VBN	_	24	acl	_	_
28	for	for	IN	_	31	case	_	_
29	either	either	CC	_	31	cc	_	_
30	the	the	DT	_	31	det	_	_
31	drug3	drug0	NN	_	27	ppmod	_	_
32	or	or	CC	_	31	cc	_	_
33	the	the	DT	_	35	det	_	_
34	other	other	JJ	_	35	attr	_	_
35	drug	drug	NN	_	31	conj	_	_
36	.	.	.	_	22	p	_	_

1	Furthermore	furthermore	RB	_	20	adv	_	_
2	,	,	,	_	20	p	_	_
3	whenever	whenever	RB	_	9	adv	_	_
4	one	#crd#	CD	_	9	num	_	_
5	of	of	IN	_	7	case	_	_
6	these	these	DT	_	7	det	_	_
7	drugs	drug	NNS	_	4	ppmod	_	_
8	is	be	VBZ	_	9	aux	_	_
9	withdrawn	withdraw	VBN	_	20	advcl	_	_
10	from	from	IN	_	11	case	_	_
11	co-therapy	co-therapy	NN	_	9	ppmod	_	_
12	,	,	,	_	20	p	_	_
13	an	an	DT	_	15	det	_	_
14	increased	increase	VBN	_	15	attr	_	_
15	dose	dose	NN	_	20	dep	_	_
16	of	of	IN	_	17	case	_	_
17	drug1	drug0	NN	_	15	ppmod	_	_
18	may	may	MD	_	20	modal	_	_
19	be	be	VB	_	20	aux	_	_
20	required	require	VBN	_	0	root	_	_
21	.	.	.	_	20	p	_	_

1	It	it	PRP	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	desirable	desirable	JJ	_	2	dep	_	_
4	to	to	TO	_	5	aux	_	_
5	monitor	monitor	VB	_	3	comp	_	_
6	drug1	drug0	NN	_	8	com	_	_
7	plasma	plasma	NN	_	8	com	_	_
8	levels	level	NNS	_	5	obj	_	_
9	whenever	whenever	RB	_	17	adv	_	_
10	an	an	DT	_	11	det	_	_
11	agent	agent	NN	_	17	dep	_	_
12	of	of	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	drug2	drug0	NNS	_	11	ppmod	_	_
15	including	include	VBG	_	16	adv	_	_
16	drug3	drug0	NN	_	14	ppmod	_	_
17	is	be	VBZ	_	5	comp	_	_
18	going	going	JJ	_	17	dep	_	_
19	to	to	TO	_	21	aux	_	_
20	be	be	VB	_	21	aux	_	_
21	co-administered	co-administered	VBN	_	18	comp	_	_
22	with	with	IN	_	24	case	_	_
23	another	another	DT	_	24	det	_	_
24	drug	drug	NN	_	21	ppmod	_	_
25	known	know	VBN	_	24	acl	_	_
26	to	to	TO	_	27	aux	_	_
27	be	be	VB	_	25	comp	_	_
28	an	an	DT	_	29	det	_	_
29	inhibitor	inhibitor	NN	_	27	obj	_	_
30	of	of	IN	_	32	case	_	_
31	P450	p0	NN	_	32	com	_	_
32	2D6	0d0	NN	_	29	ppmod	_	_
33	(	-lrb-	-LRB-	_	32	p	_	_
34	and/or	and/or	CC	_	32	cc	_	_
35	P450	p0	NN	_	36	com	_	_
36	1A2	0a0	NN	_	32	conj	_	_
37	)	-rrb-	-RRB-	_	36	p	_	_
38	.	.	.	_	2	p	_	_

1	Because	because	IN	_	5	mark	_	_
2	drug1	drug0	NN	_	5	dep	_	_
3	is	be	VBZ	_	5	aux	_	_
4	highly	highly	RB	_	5	adv	_	_
5	bound	bind	VBN	_	33	advcl	_	_
6	to	to	TO	_	8	aux	_	_
7	serum	serum	NN	_	8	com	_	_
8	protein	protein	NN	_	5	ppmod	_	_
9	,	,	,	_	33	p	_	_
10	the	the	DT	_	11	det	_	_
11	administration	administration	NN	_	33	dep	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	to	to	TO	_	15	aux	_	_
15	patients	patient	NNS	_	11	ppmod	_	_
16	taking	take	VBG	_	15	acl	_	_
17	other	other	JJ	_	18	attr	_	_
18	drugs	drug	NNS	_	16	obj	_	_
19	that	that	WDT	_	22	dep	_	_
20	are	be	VBP	_	22	aux	_	_
21	highly	highly	RB	_	22	adv	_	_
22	bound	bind	VBN	_	18	relcl	_	_
23	to	to	TO	_	24	aux	_	_
24	protein	protein	NN	_	22	ppmod	_	_
25	(	-lrb-	-LRB-	_	30	p	_	_
26	e.g.	e.g.	FW	_	28	adv	_	_
27	,	,	,	_	28	p	_	_
28	drug3	drug0	NN	_	30	ppmod	_	_
29	,	,	,	_	30	p	_	_
30	drug4	drug0	NNS	_	18	prn	_	_
31	)	-rrb-	-RRB-	_	30	p	_	_
32	may	may	MD	_	33	modal	_	_
33	cause	cause	VB	_	0	root	_	_
34	an	an	DT	_	35	det	_	_
35	increase	increase	NN	_	33	obj	_	_
36	in	in	IN	_	38	case	_	_
37	plasma	plasma	NN	_	38	com	_	_
38	concentrations	concentration	NNS	_	35	ppmod	_	_
39	of	of	IN	_	41	case	_	_
40	these	these	DT	_	41	det	_	_
41	drugs	drug	NNS	_	38	ppmod	_	_
42	,	,	,	_	33	p	_	_
43	potentially	potentially	RB	_	44	adv	_	_
44	resulting	result	VBG	_	33	comp	_	_
45	in	in	IN	_	47	case	_	_
46	adverse	adverse	JJ	_	47	attr	_	_
47	effects	effect	NNS	_	44	ppmod	_	_
48	.	.	.	_	33	p	_	_

1	Conversely	conversely	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	adverse	adverse	JJ	_	4	attr	_	_
4	effects	effect	NNS	_	6	dep	_	_
5	may	may	MD	_	6	modal	_	_
6	result	result	VB	_	0	root	_	_
7	from	from	IN	_	8	case	_	_
8	displacement	displacement	NN	_	6	ppmod	_	_
9	of	of	IN	_	11	case	_	_
10	protein-bound	protein-bound	JJ	_	11	attr	_	_
11	drug1	drug0	NN	_	8	ppmod	_	_
12	by	by	IN	_	16	case	_	_
13	other	other	JJ	_	16	attr	_	_
14	highly	highly	RB	_	15	adv	_	_
15	bound	bind	VBN	_	16	attr	_	_
16	drugs	drug	NNS	_	8	ppmod	_	_
17	.	.	.	_	6	p	_	_

1	No	no	DT	_	2	det	_	_
2	trials	trial	NNS	_	11	dep	_	_
3	specifically	specifically	RB	_	4	adv	_	_
4	examining	examine	VBG	_	2	acl	_	_
5	potential	potential	JJ	_	7	attr	_	_
6	drug	drug	NN	_	7	com	_	_
7	interactions	interaction	NNS	_	4	obj	_	_
8	with	with	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	were	be	VBD	_	11	aux	_	_
11	conducted	conduct	VBN	_	0	root	_	_
12	,	,	,	_	11	p	_	_
13	although	although	IN	_	18	mark	_	_
14	many	many	JJ	_	16	attr	_	_
15	concomitant	concomitant	JJ	_	16	attr	_	_
16	drugs	drug	NNS	_	18	dep	_	_
17	were	be	VBD	_	18	aux	_	_
18	used	use	VBN	_	11	comp	_	_
19	in	in	IN	_	21	case	_	_
20	clinical	clinical	JJ	_	21	attr	_	_
21	trials	trial	NNS	_	18	ppmod	_	_
22	.	.	.	_	11	p	_	_

1	No	no	DT	_	3	det	_	_
2	drug	drug	NN	_	3	com	_	_
3	interactions	interaction	NNS	_	5	dep	_	_
4	were	be	VBD	_	5	aux	_	_
5	detected	detect	VBN	_	0	root	_	_
6	except	except	IN	_	9	case	_	_
7	for	for	IN	_	9	case	_	_
8	an	an	DT	_	9	det	_	_
9	increase	increase	NN	_	5	ppmod	_	_
10	in	in	IN	_	12	case	_	_
11	symptomatic	symptomatic	JJ	_	12	attr	_	_
12	hypotension	hypotension	NN	_	9	ppmod	_	_
13	in	in	IN	_	14	case	_	_
14	patients	patient	NNS	_	12	ppmod	_	_
15	receiving	receive	VBG	_	14	acl	_	_
16	oral	oral	JJ	_	17	attr	_	_
17	drug1	drug0	NN	_	15	obj	_	_
18	.	.	.	_	5	p	_	_

1	The	the	DT	_	2	det	_	_
2	co-administration	co-administration	NN	_	22	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	with	with	IN	_	7	case	_	_
6	IV	iv	NN	_	7	com	_	_
7	drug2	drug0	NNS	_	2	ppmod	_	_
8	such	such	JJ	_	10	adv	_	_
9	as	as	IN	_	10	case	_	_
10	drug3	drug0	NN	_	7	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	drug4	drug0	NN	_	10	conj	_	_
13	,	,	,	_	12	p	_	_
14	drug5	drug0	NN	_	10	conj	_	_
15	,	,	,	_	14	p	_	_
16	or	or	CC	_	14	cc	_	_
17	IV	iv	CD	_	18	num	_	_
18	drug6	drug0	NN	_	10	conj	_	_
19	has	have	VBZ	_	22	aux	_	_
20	not	not	RB	_	22	neg	_	_
21	been	be	VBN	_	22	aux	_	_
22	evaluated	evaluate	VBN	_	0	root	_	_
23	(	-lrb-	-LRB-	_	28	p	_	_
24	these	these	DT	_	25	det	_	_
25	drugs	drug	NNS	_	28	dep	_	_
26	were	be	VBD	_	28	aux	_	_
27	not	not	RB	_	28	neg	_	_
28	co-administered	co-administered	VBN	_	22	prn	_	_
29	with	with	IN	_	30	case	_	_
30	drug7	drug0	NN	_	28	ppmod	_	_
31	in	in	IN	_	33	case	_	_
32	clinical	clinical	JJ	_	33	attr	_	_
33	trials	trial	NNS	_	28	ppmod	_	_
34	)	-rrb-	-RRB-	_	28	p	_	_
35	.	.	.	_	22	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	interact	interact	VB	_	0	root	_	_
4	with	with	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	or	or	CC	_	5	cc	_	_
7	other	other	JJ	_	8	attr	_	_
8	drug3	drug0	NN	_	5	conj	_	_
9	,	,	,	_	3	p	_	_
10	causing	cause	VBG	_	3	comp	_	_
11	increased	increase	VBN	_	13	attr	_	_
12	sedative	sedative	JJ	_	13	attr	_	_
13	effects	effect	NNS	_	10	obj	_	_
14	.	.	.	_	3	p	_	_

1	It	it	PRP	_	4	dep	_	_
2	may	may	MD	_	4	modal	_	_
3	also	also	RB	_	4	adv	_	_
4	interact	interact	VB	_	0	root	_	_
5	with	with	IN	_	9	case	_	_
6	drug1	drug0	JJ	_	9	attr	_	_
7	or	or	CC	_	6	cc	_	_
8	other	other	JJ	_	6	conj	_	_
9	drug2	drug0	NN	_	4	ppmod	_	_
10	or	or	CC	_	9	cc	_	_
11	drug3	drug0	NN	_	9	conj	_	_
12	,	,	,	_	9	p	_	_
13	which	which	WDT	_	15	dep	_	_
14	may	may	MD	_	15	modal	_	_
15	intensify	intensify	VB	_	9	relcl	_	_
16	the	the	DT	_	18	det	_	_
17	anticholinergic	anticholinergic	JJ	_	18	attr	_	_
18	action	action	NN	_	15	obj	_	_
19	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	can	can	MD	_	3	modal	_	_
3	interact	interact	VB	_	0	root	_	_
4	with	with	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	,	,	,	_	3	p	_	_
7	increasing	increase	VBG	_	3	comp	_	_
8	the	the	DT	_	9	det	_	_
9	metabolism	metabolism	NN	_	7	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug3	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	3	p	_	_

1	Additional	additional	JJ	_	2	attr	_	_
2	reductions	reduction	NNS	_	7	dep	_	_
3	in	in	IN	_	5	case	_	_
4	blood	blood	NN	_	5	com	_	_
5	pressure	pressure	NN	_	2	ppmod	_	_
6	may	may	MD	_	7	modal	_	_
7	occur	occur	VB	_	0	root	_	_
8	when	when	WRB	_	11	adv	_	_
9	drug1	drug0	NN	_	11	dep	_	_
10	is	be	VBZ	_	11	aux	_	_
11	administered	administer	VBN	_	7	comp	_	_
12	with	with	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	,	,	,	_	13	p	_	_
15	drug3	drug0	NN	_	13	conj	_	_
16	,	,	,	_	15	p	_	_
17	or	or	CC	_	15	cc	_	_
18	other	other	JJ	_	19	attr	_	_
19	drug4	drug0	NN	_	13	conj	_	_
20	.	.	.	_	7	p	_	_

1	When	when	WRB	_	7	adv	_	_
2	other	other	JJ	_	3	attr	_	_
3	drug1	drug0	NN	_	7	dep	_	_
4	or	or	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	are	be	VBP	_	7	aux	_	_
7	used	use	VBN	_	11	advcl	_	_
8	concomitantly	concomitantly	RB	_	7	adv	_	_
9	,	,	,	_	11	p	_	_
10	there	there	EX	_	11	dep	_	_
11	is	be	VBZ	_	0	root	_	_
12	the	the	DT	_	13	det	_	_
13	potential	potential	NN	_	11	obj	_	_
14	for	for	IN	_	15	case	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	to	to	TO	_	17	aux	_	_
17	increase	increase	VB	_	13	acl	_	_
18	the	the	DT	_	19	det	_	_
19	risk	risk	NN	_	17	obj	_	_
20	of	of	IN	_	21	case	_	_
21	bleeding	bleeding	JJ	_	19	ppmod	_	_
22	.	.	.	_	11	p	_	_

1	However	however	RB	_	12	adv	_	_
2	,	,	,	_	12	p	_	_
3	patients	patient	NNS	_	12	dep	_	_
4	receiving	receive	VBG	_	3	acl	_	_
5	infusions	infusion	NNS	_	4	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	in	in	IN	_	10	case	_	_
9	clinical	clinical	JJ	_	10	attr	_	_
10	trials	trial	NNS	_	4	ppmod	_	_
11	were	be	VBD	_	12	aux	_	_
12	maintained	maintain	VBN	_	0	root	_	_
13	on	on	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	without	without	IN	_	16	case	_	_
16	evidence	evidence	NN	_	12	ppmod	_	_
17	of	of	IN	_	19	case	_	_
18	increased	increase	VBN	_	19	attr	_	_
19	bleeding	bleeding	JJ	_	16	ppmod	_	_
20	.	.	.	_	12	p	_	_

1	In	in	IN	_	3	case	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	trials	trial	NNS	_	7	ppmod	_	_
4	,	,	,	_	7	p	_	_
5	drug1	drug0	NN	_	7	dep	_	_
6	was	be	VBD	_	7	aux	_	_
7	used	use	VBN	_	0	root	_	_
8	with	with	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	9	p	_	_
11	drug3	drug0	NN	_	9	conj	_	_
12	,	,	,	_	11	p	_	_
13	drug4	drug0	NN	_	9	conj	_	_
14	,	,	,	_	13	p	_	_
15	oral	oral	JJ	_	16	attr	_	_
16	drug5	drug0	NN	_	9	conj	_	_
17	,	,	,	_	16	p	_	_
18	and	and	CC	_	16	cc	_	_
19	supplemental	supplemental	JJ	_	21	attr	_	_
20	drug6	drug0	NN	_	21	com	_	_
21	.In	.in	NN	_	24	attr	_	_
22	a	a	DT	_	24	det	_	_
23	pharmacokinetic	pharmacokinetic	JJ	_	24	attr	_	_
24	substudy	substudy	NN	_	9	conj	_	_
25	in	in	IN	_	26	case	_	_
26	patients	patient	NNS	_	9	ppmod	_	_
27	with	with	IN	_	30	case	_	_
28	congestive	congestive	JJ	_	30	attr	_	_
29	heart	heart	NN	_	30	com	_	_
30	failure	failure	NN	_	26	ppmod	_	_
31	receiving	receive	VBG	_	26	acl	_	_
32	drug7	drug0	NN	_	31	obj	_	_
33	or	or	CC	_	32	cc	_	_
34	drug8	drug0	NN	_	32	conj	_	_
35	in	in	IN	_	36	case	_	_
36	whom	whom	WP	_	62	ppmod	_	_
37	therapy	therapy	NN	_	41	dep	_	_
38	with	with	IN	_	39	case	_	_
39	drug9	drug0	NN	_	37	ppmod	_	_
40	was	be	VBD	_	41	aux	_	_
41	initiated	initiate	VBN	_	62	advcl	_	_
42	,	,	,	_	62	p	_	_
43	apparent	apparent	JJ	_	46	attr	_	_
44	oral	oral	JJ	_	46	attr	_	_
45	clearance	clearance	NN	_	46	com	_	_
46	values	value	NNS	_	62	dep	_	_
47	for	for	IN	_	48	case	_	_
48	drug10	drug0	NN	_	46	ppmod	_	_
49	(	-lrb-	-LRB-	_	50	p	_	_
50	n	n	NN	_	48	prn	_	_
51	=	=	JJ	_	50	attr	_	_
52	23	0	CD	_	50	num	_	_
53	)	-rrb-	-RRB-	_	50	p	_	_
54	and	and	CC	_	46	cc	_	_
55	drug11	drug0	NN	_	46	conj	_	_
56	(	-lrb-	-LRB-	_	57	p	_	_
57	n	n	NN	_	46	prn	_	_
58	=	=	JJ	_	57	attr	_	_
59	30	0	CD	_	57	num	_	_
60	)	-rrb-	-RRB-	_	57	p	_	_
61	were	be	VBD	_	62	aux	_	_
62	decreased	decrease	VBN	_	32	relcl	_	_
63	by	by	IN	_	64	case	_	_
64	13	0	CD	_	62	ppmod	_	_
65	%	%	NN	_	64	meta	_	_
66	and	and	CC	_	64	cc	_	_
67	15	0	CD	_	64	conj	_	_
68	%	%	NN	_	67	meta	_	_
69	,	,	,	_	62	p	_	_
70	respectively	respectively	RB	_	62	adv	_	_
71	,	,	,	_	62	p	_	_
72	on	on	IN	_	75	case	_	_
73	the	the	DT	_	75	det	_	_
74	second	#ord#	JJ	_	75	attr	_	_
75	day	day	NN	_	62	ppmod	_	_
76	of	of	IN	_	77	case	_	_
77	therapy	therapy	NN	_	75	ppmod	_	_
78	and	and	CC	_	62	cc	_	_
79	had	have	VBD	_	80	aux	_	_
80	returned	return	VBD	_	62	conj	_	_
81	to	to	TO	_	83	aux	_	_
82	baseline	baseline	NN	_	83	com	_	_
83	values	value	NNS	_	80	ppmod	_	_
84	by	by	IN	_	85	case	_	_
85	day	day	NN	_	80	ppmod	_	_
86	87	0	CD	_	85	num	_	_
87	.	.	.	_	7	p	_	_

1	The	the	DT	_	2	det	_	_
2	change	change	NN	_	7	dep	_	_
3	in	in	IN	_	6	case	_	_
4	drug1	drug0	NN	_	6	com	_	_
5	clearance	clearance	NN	_	6	com	_	_
6	value	value	NN	_	2	ppmod	_	_
7	is	be	VBZ	_	0	root	_	_
8	not	not	RB	_	7	neg	_	_
9	likely	likely	JJ	_	7	dep	_	_
10	to	to	TO	_	11	aux	_	_
11	be	be	VB	_	9	comp	_	_
12	clinically	clinically	RB	_	13	adv	_	_
13	significant	significant	JJ	_	11	dep	_	_
14	.	.	.	_	7	p	_	_

1	However	however	RB	_	7	adv	_	_
2	,	,	,	_	7	p	_	_
3	patients	patient	NNS	_	7	dep	_	_
4	on	on	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	may	may	MD	_	7	modal	_	_
7	show	show	VB	_	0	root	_	_
8	elevations	elevation	NNS	_	7	obj	_	_
9	of	of	IN	_	11	case	_	_
10	drug2	drug0	NN	_	11	com	_	_
11	concentrations	concentration	NNS	_	8	ppmod	_	_
12	after	after	IN	_	13	case	_	_
13	initiation	initiation	NN	_	7	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	therapy	therapy	NN	_	13	ppmod	_	_
16	with	with	IN	_	17	case	_	_
17	drug3	drug0	NN	_	13	ppmod	_	_
18	,	,	,	_	17	p	_	_
19	which	which	WDT	_	21	dep	_	_
20	may	may	MD	_	21	modal	_	_
21	be	be	VB	_	17	relcl	_	_
22	clinically	clinically	RB	_	23	adv	_	_
23	significant	significant	JJ	_	21	dep	_	_
24	in	in	IN	_	25	case	_	_
25	patients	patient	NNS	_	23	ppmod	_	_
26	prone	prone	JJ	_	25	attr	_	_
27	to	to	TO	_	29	aux	_	_
28	drug4	drug0	NN	_	29	com	_	_
29	toxicity	toxicity	NN	_	26	ppmod	_	_
30	.	.	.	_	7	p	_	_

1	Specific	specific	JJ	_	4	attr	_	_
2	drug	drug	NN	_	4	com	_	_
3	interaction	interaction	NN	_	4	com	_	_
4	studies	study	NNS	_	8	dep	_	_
5	have	have	VBP	_	8	aux	_	_
6	not	not	RB	_	8	neg	_	_
7	been	be	VBN	_	8	aux	_	_
8	conducted	conduct	VBN	_	0	root	_	_
9	with	with	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	8	p	_	_

1	However	however	RB	_	11	adv	_	_
2	,	,	,	_	11	p	_	_
3	the	the	DT	_	5	det	_	_
4	systemic	systemic	JJ	_	5	attr	_	_
5	administration	administration	NN	_	11	dep	_	_
6	of	of	IN	_	8	case	_	_
7	some	some	DT	_	8	det	_	_
8	drug1	drug0	NN	_	5	ppmod	_	_
9	has	have	VBZ	_	11	aux	_	_
10	been	be	VBN	_	11	aux	_	_
11	shown	show	VBN	_	0	root	_	_
12	to	to	TO	_	13	aux	_	_
13	elevate	elevate	VBP	_	11	comp	_	_
14	plasma	plasma	NN	_	15	com	_	_
15	concentrations	concentration	NNS	_	13	obj	_	_
16	of	of	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	,	,	,	_	13	p	_	_
19	interfere	interfere	VB	_	13	conj	_	_
20	with	with	IN	_	22	case	_	_
21	the	the	DT	_	22	det	_	_
22	metabolism	metabolism	NN	_	19	ppmod	_	_
23	of	of	IN	_	24	case	_	_
24	drug3	drug0	NN	_	22	ppmod	_	_
25	,	,	,	_	19	p	_	_
26	and	and	CC	_	19	cc	_	_
27	enhance	enhance	VBP	_	13	conj	_	_
28	the	the	DT	_	29	det	_	_
29	effects	effect	NNS	_	27	obj	_	_
30	of	of	IN	_	34	case	_	_
31	the	the	DT	_	34	det	_	_
32	oral	oral	JJ	_	34	attr	_	_
33	drug4	drug0	NN	_	34	com	_	_
34	drug5	drug0	NN	_	29	ppmod	_	_
35	and	and	CC	_	34	cc	_	_
36	its	its	PRP$	_	37	poss	_	_
37	derivatives	derivative	NNS	_	34	conj	_	_
38	,	,	,	_	11	p	_	_
39	and	and	CC	_	11	cc	_	_
40	has	have	VBZ	_	42	aux	_	_
41	been	be	VBN	_	42	aux	_	_
42	associated	associate	VBN	_	11	conj	_	_
43	with	with	IN	_	45	case	_	_
44	transient	transient	JJ	_	45	attr	_	_
45	elevations	elevation	NNS	_	42	ppmod	_	_
46	in	in	IN	_	48	case	_	_
47	serum	serum	NN	_	48	com	_	_
48	creatinine	creatinine	NN	_	45	ppmod	_	_
49	in	in	IN	_	50	case	_	_
50	patients	patient	NNS	_	48	ppmod	_	_
51	receiving	receive	VBG	_	50	acl	_	_
52	systemic	systemic	JJ	_	53	attr	_	_
53	drug6	drug0	NN	_	51	obj	_	_
54	concomitantly	concomitantly	RB	_	53	adv	_	_
55	.	.	.	_	11	p	_	_

1	No	no	DT	_	10	det	_	_
2	drug	drug	NN	_	10	attr	_	_
3	,	,	,	_	2	p	_	_
4	nutritional	nutritional	JJ	_	5	attr	_	_
5	supplement	supplement	NN	_	2	conj	_	_
6	,	,	,	_	5	p	_	_
7	food	food	NN	_	2	conj	_	_
8	or	or	CC	_	7	cc	_	_
9	herb	herb	NN	_	2	conj	_	_
10	interactions	interaction	NNS	_	12	dep	_	_
11	are	be	VBP	_	12	aux	_	_
12	known	know	VBN	_	0	root	_	_
13	.	.	.	_	12	p	_	_

1	Before	before	IN	_	2	case	_	_
2	using	use	VBG	_	17	ppmod	_	_
3	this	this	DT	_	4	det	_	_
4	medication	medication	NN	_	2	obj	_	_
5	,	,	,	_	17	p	_	_
6	tell	tell	NN	_	8	com	_	_
7	your	your	NN	_	8	com	_	_
8	doctor	doctor	NN	_	17	dep	_	_
9	or	or	CC	_	8	cc	_	_
10	pharmacist	pharmacist	NN	_	8	conj	_	_
11	of	of	IN	_	13	case	_	_
12	all	all	DT	_	13	det	_	_
13	prescription	prescription	NN	_	8	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	nonprescription	nonprescription	NN	_	16	com	_	_
16	products	product	NNS	_	13	conj	_	_
17	you	you	VBZ	_	0	root	_	_
18	may	may	MD	_	19	modal	_	_
19	use	use	VBP	_	17	comp	_	_
20	,	,	,	_	19	p	_	_
21	especially	especially	RB	_	24	adv	_	_
22	of	of	IN	_	24	case	_	_
23	:	:	:	_	24	p	_	_
24	drug1	drug0	NN	_	19	ppmod	_	_
25	(	-lrb-	-LRB-	_	30	p	_	_
26	e.g.	e.g.	FW	_	28	adv	_	_
27	,	,	,	_	28	p	_	_
28	drug2	drug0	NN	_	30	ppmod	_	_
29	,	,	,	_	30	p	_	_
30	drug3	drug0	NN	_	24	prn	_	_
31	)	-rrb-	-RRB-	_	30	p	_	_
32	,	,	,	_	24	p	_	_
33	drug4	drug0	NN	_	24	appo	_	_
34	,	,	,	_	24	p	_	_
35	drug5	drug0	NN	_	24	appo	_	_
36	,	,	,	_	24	p	_	_
37	drug6	drug0	JJ	_	38	attr	_	_
38	drugs	drug	NNS	_	24	appo	_	_
39	(	-lrb-	-LRB-	_	42	p	_	_
40	e.g.	e.g.	FW	_	42	adv	_	_
41	,	,	,	_	42	p	_	_
42	drug7	drug0	NN	_	38	prn	_	_
43	)	-rrb-	-RRB-	_	42	p	_	_
44	,	,	,	_	24	p	_	_
45	drug8	drug0	NN	_	24	appo	_	_
46	,	,	,	_	24	p	_	_
47	drug9	drug0	NN	_	24	appo	_	_
48	.	.	.	_	17	p	_	_

1	Do	do	VBP	_	3	aux	_	_
2	not	not	RB	_	3	neg	_	_
3	start	start	VBP	_	0	root	_	_
4	or	or	CC	_	3	cc	_	_
5	stop	stop	NN	_	3	conj	_	_
6	any	any	DT	_	7	det	_	_
7	medicine	medicine	NN	_	5	obj	_	_
8	without	without	IN	_	9	case	_	_
9	doctor	doctor	NN	_	5	ppmod	_	_
10	or	or	CC	_	9	cc	_	_
11	pharmacist	pharmacist	NN	_	12	com	_	_
12	approval	approval	NN	_	9	conj	_	_
13	.	.	.	_	3	p	_	_

1	The	the	DT	_	3	det	_	_
2	hypoglycemic	hypoglycemic	JJ	_	3	attr	_	_
3	action	action	NN	_	8	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	may	may	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	potentiated	potentiate	VBN	_	0	root	_	_
9	by	by	IN	_	11	case	_	_
10	certain	certain	JJ	_	11	attr	_	_
11	drugs	drug	NNS	_	8	ppmod	_	_
12	including	include	VBG	_	13	adv	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	other	other	JJ	_	16	attr	_	_
16	drugs	drug	NNS	_	13	conj	_	_
17	that	that	WDT	_	21	dep	_	_
18	are	be	VBP	_	21	aux	_	_
19	highly	highly	RB	_	21	adv	_	_
20	protein	protein	NN	_	21	dep	_	_
21	bound	bind	VBN	_	13	relcl	_	_
22	,	,	,	_	13	p	_	_
23	drug3	drug0	NN	_	13	conj	_	_
24	,	,	,	_	23	p	_	_
25	drug4	drug0	NN	_	13	conj	_	_
26	,	,	,	_	25	p	_	_
27	drug5	drug0	NN	_	13	conj	_	_
28	,	,	,	_	27	p	_	_
29	drug6	drug0	NN	_	13	conj	_	_
30	,	,	,	_	29	p	_	_
31	drug7	drug0	NN	_	13	conj	_	_
32	,	,	,	_	31	p	_	_
33	drug8	drug0	NN	_	13	conj	_	_
34	,	,	,	_	33	p	_	_
35	and	and	CC	_	33	cc	_	_
36	drug9	drug0	NN	_	13	conj	_	_
37	.	.	.	_	8	p	_	_

1	When	when	WRB	_	5	adv	_	_
2	such	such	JJ	_	3	attr	_	_
3	drugs	drug	NNS	_	5	dep	_	_
4	are	be	VBP	_	5	aux	_	_
5	administered	administer	VBN	_	16	advcl	_	_
6	to	to	TO	_	8	aux	_	_
7	a	a	DT	_	8	det	_	_
8	patient	patient	NN	_	5	ppmod	_	_
9	receiving	receive	VBG	_	8	acl	_	_
10	drug1	drug0	NN	_	9	obj	_	_
11	,	,	,	_	16	p	_	_
12	the	the	DT	_	13	det	_	_
13	patient	patient	NN	_	16	dep	_	_
14	should	should	MD	_	16	modal	_	_
15	be	be	VB	_	16	aux	_	_
16	observed	observe	VBN	_	0	root	_	_
17	closely	closely	RB	_	16	adv	_	_
18	for	for	IN	_	19	case	_	_
19	hypoglycemia	hypoglycemia	NN	_	16	ppmod	_	_
20	.	.	.	_	16	p	_	_

1	When	when	WRB	_	5	adv	_	_
2	such	such	JJ	_	3	attr	_	_
3	drugs	drug	NNS	_	5	dep	_	_
4	are	be	VBP	_	5	aux	_	_
5	withdrawn	withdraw	VBN	_	16	advcl	_	_
6	from	from	IN	_	8	case	_	_
7	a	a	DT	_	8	det	_	_
8	patient	patient	NN	_	5	ppmod	_	_
9	receiving	receive	VBG	_	8	acl	_	_
10	drug1	drug0	NN	_	9	obj	_	_
11	,	,	,	_	16	p	_	_
12	the	the	DT	_	13	det	_	_
13	patient	patient	NN	_	16	dep	_	_
14	should	should	MD	_	16	modal	_	_
15	be	be	VB	_	16	aux	_	_
16	observed	observe	VBN	_	0	root	_	_
17	closely	closely	RB	_	16	adv	_	_
18	for	for	IN	_	19	case	_	_
19	loss	loss	NN	_	16	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	control	control	NN	_	19	ppmod	_	_
22	.	.	.	_	16	p	_	_

1	Certain	certain	JJ	_	2	attr	_	_
2	drugs	drug	NNS	_	3	dep	_	_
3	tend	tend	VBP	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	produce	produce	VB	_	3	comp	_	_
6	hyperglycemia	hyperglycemia	NN	_	5	obj	_	_
7	and	and	CC	_	5	cc	_	_
8	may	may	MD	_	9	modal	_	_
9	lead	lead	VB	_	5	conj	_	_
10	to	to	TO	_	11	aux	_	_
11	loss	loss	NN	_	9	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	control	control	NN	_	11	ppmod	_	_
14	.	.	.	_	3	p	_	_

1	These	these	DT	_	2	det	_	_
2	drugs	drug	NNS	_	3	dep	_	_
3	include	include	VBP	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	drug1	drug0	NN	_	3	obj	_	_
6	and	and	CC	_	5	cc	_	_
7	other	other	JJ	_	8	attr	_	_
8	drug2	drug0	NNS	_	5	conj	_	_
9	,	,	,	_	5	p	_	_
10	drug3	drug0	NN	_	5	appo	_	_
11	,	,	,	_	10	p	_	_
12	drug4	drug0	NN	_	10	conj	_	_
13	,	,	,	_	12	p	_	_
14	thyroid	thyroid	NN	_	15	com	_	_
15	products	product	NNS	_	10	conj	_	_
16	,	,	,	_	15	p	_	_
17	drug5	drug0	NN	_	10	conj	_	_
18	,	,	,	_	17	p	_	_
19	oral	oral	JJ	_	20	attr	_	_
20	drug6	drug0	NN	_	10	conj	_	_
21	,	,	,	_	20	p	_	_
22	drug7	drug0	NN	_	10	conj	_	_
23	,	,	,	_	22	p	_	_
24	drug8	drug0	NN	_	10	conj	_	_
25	,	,	,	_	24	p	_	_
26	drug9	drug0	NN	_	10	conj	_	_
27	,	,	,	_	26	p	_	_
28	drug10	drug0	NN	_	10	conj	_	_
29	,	,	,	_	28	p	_	_
30	and	and	CC	_	28	cc	_	_
31	drug11	drug0	NN	_	10	conj	_	_
32	.	.	.	_	3	p	_	_

1	When	when	WRB	_	5	adv	_	_
2	such	such	JJ	_	3	attr	_	_
3	drugs	drug	NNS	_	5	dep	_	_
4	are	be	VBP	_	5	aux	_	_
5	administered	administer	VBN	_	17	advcl	_	_
6	to	to	TO	_	8	aux	_	_
7	a	a	DT	_	8	det	_	_
8	patient	patient	NN	_	5	ppmod	_	_
9	receiving	receive	VBG	_	8	acl	_	_
10	drug1	drug0	NN	_	9	obj	_	_
11	,	,	,	_	17	p	_	_
12	the	the	DT	_	13	det	_	_
13	patient	patient	NN	_	17	dep	_	_
14	should	should	MD	_	17	modal	_	_
15	be	be	VB	_	17	aux	_	_
16	closely	closely	RB	_	17	adv	_	_
17	observed	observe	VBN	_	0	root	_	_
18	for	for	IN	_	19	case	_	_
19	loss	loss	NN	_	17	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	control	control	NN	_	19	ppmod	_	_
22	.	.	.	_	17	p	_	_

1	When	when	WRB	_	5	adv	_	_
2	such	such	JJ	_	3	attr	_	_
3	drugs	drug	NNS	_	5	dep	_	_
4	are	be	VBP	_	5	aux	_	_
5	withdrawn	withdraw	VBN	_	16	advcl	_	_
6	from	from	IN	_	8	case	_	_
7	a	a	DT	_	8	det	_	_
8	patient	patient	NN	_	5	ppmod	_	_
9	receiving	receive	VBG	_	8	acl	_	_
10	drug1	drug0	NN	_	9	obj	_	_
11	,	,	,	_	16	p	_	_
12	the	the	DT	_	13	det	_	_
13	patient	patient	NN	_	16	dep	_	_
14	should	should	MD	_	16	modal	_	_
15	be	be	VB	_	16	aux	_	_
16	observed	observe	VBN	_	0	root	_	_
17	closely	closely	RB	_	16	adv	_	_
18	for	for	IN	_	19	case	_	_
19	hypoglycemia	hypoglycemia	NN	_	16	ppmod	_	_
20	.	.	.	_	16	p	_	_

1	Since	since	IN	_	4	mark	_	_
2	animal	animal	NN	_	3	com	_	_
3	studies	study	NNS	_	4	dep	_	_
4	suggest	suggest	VBP	_	21	advcl	_	_
5	that	that	IN	_	11	mark	_	_
6	the	the	DT	_	7	det	_	_
7	action	action	NN	_	11	dep	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	may	may	MD	_	11	modal	_	_
11	be	be	VB	_	4	comp	_	_
12	prolonged	prolonged	JJ	_	11	dep	_	_
13	by	by	IN	_	14	case	_	_
14	therapy	therapy	NN	_	12	ppmod	_	_
15	with	with	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	,	,	,	_	21	p	_	_
18	drug3	drug0	NN	_	21	dep	_	_
19	should	should	MD	_	21	modal	_	_
20	be	be	VB	_	21	aux	_	_
21	employed	employ	VBN	_	0	root	_	_
22	with	with	IN	_	23	case	_	_
23	caution	caution	NN	_	21	ppmod	_	_
24	.	.	.	_	21	p	_	_

1	In	in	IN	_	3	case	_	_
2	some	some	DT	_	3	det	_	_
3	patients	patient	NNS	_	11	ppmod	_	_
4	,	,	,	_	11	p	_	_
5	a	a	DT	_	8	det	_	_
6	drug1	drug0	JJ	_	8	attr	_	_
7	-like	-like	JJ	_	8	attr	_	_
8	reaction	reaction	NN	_	11	dep	_	_
9	may	may	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	produced	produce	VBN	_	0	root	_	_
12	by	by	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	ingestion	ingestion	NN	_	11	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	.	.	.	_	11	p	_	_

1	A	a	DT	_	3	det	_	_
2	potential	potential	JJ	_	3	attr	_	_
3	interaction	interaction	NN	_	16	dep	_	_
4	between	between	IN	_	6	case	_	_
5	oral	oral	JJ	_	6	attr	_	_
6	drug1	drug0	NN	_	3	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	oral	oral	JJ	_	9	attr	_	_
9	drug2	drug0	NN	_	6	conj	_	_
10	leading	lead	VBG	_	6	acl	_	_
11	to	to	TO	_	13	aux	_	_
12	severe	severe	JJ	_	13	attr	_	_
13	hypoglycemia	hypoglycemia	NN	_	10	ppmod	_	_
14	has	have	VBZ	_	16	aux	_	_
15	been	be	VBN	_	16	aux	_	_
16	reported	report	VBN	_	0	root	_	_
17	.	.	.	_	16	p	_	_

1	Whether	whether	IN	_	5	mark	_	_
2	this	this	DT	_	3	det	_	_
3	interaction	interaction	NN	_	5	dep	_	_
4	also	also	RB	_	5	adv	_	_
5	occurs	occur	VBZ	_	19	advcl	_	_
6	with	with	IN	_	14	case	_	_
7	the	the	DT	_	14	det	_	_
8	intravenous	intravenous	JJ	_	14	attr	_	_
9	,	,	,	_	8	p	_	_
10	topical	topical	JJ	_	8	conj	_	_
11	,	,	,	_	10	p	_	_
12	or	or	CC	_	10	cc	_	_
13	vaginal	vaginal	JJ	_	8	conj	_	_
14	preparations	preparation	NNS	_	5	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	is	be	VBZ	_	19	aux	_	_
18	not	not	RB	_	19	neg	_	_
19	known	know	VBN	_	0	root	_	_
20	.	.	.	_	19	p	_	_

1	Concurrent	concurrent	JJ	_	2	attr	_	_
2	use	use	NN	_	20	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	with	with	IN	_	6	case	_	_
6	drug2	drug0	NNS	_	2	ppmod	_	_
7	(	-lrb-	-LRB-	_	10	p	_	_
8	e.g.	e.g.	FW	_	10	adv	_	_
9	,	,	,	_	10	p	_	_
10	drug3	drug0	NN	_	6	prn	_	_
11	,	,	,	_	10	p	_	_
12	drug4	drug0	NN	_	10	conj	_	_
13	,	,	,	_	12	p	_	_
14	drug5	drug0	NN	_	10	conj	_	_
15	,	,	,	_	14	p	_	_
16	and	and	CC	_	14	cc	_	_
17	drug6	drug0	NN	_	10	conj	_	_
18	)	-rrb-	-RRB-	_	10	p	_	_
19	may	may	MD	_	20	modal	_	_
20	result	result	VB	_	0	root	_	_
21	in	in	IN	_	24	case	_	_
22	increased	increase	VBN	_	24	attr	_	_
23	drug7	drug0	NN	_	24	com	_	_
24	effects	effect	NNS	_	20	ppmod	_	_
25	.	.	.	_	20	p	_	_

1	When	when	WRB	_	2	adv	_	_
2	used	use	VBN	_	13	advcl	_	_
3	concurrently	concurrently	RB	_	2	adv	_	_
4	with	with	IN	_	6	case	_	_
5	such	such	JJ	_	6	attr	_	_
6	drugs	drug	NNS	_	2	ppmod	_	_
7	,	,	,	_	13	p	_	_
8	the	the	DT	_	9	det	_	_
9	dose	dose	NN	_	13	dep	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	should	should	MD	_	13	modal	_	_
13	be	be	VB	_	0	root	_	_
14	the	the	DT	_	17	det	_	_
15	smallest	smallest	JJ	_	17	attr	_	_
16	effective	effective	JJ	_	17	attr	_	_
17	dose	dose	NN	_	13	obj	_	_
18	and	and	CC	_	13	cc	_	_
19	the	the	DT	_	20	det	_	_
20	frequency	frequency	NN	_	23	dep	_	_
21	of	of	IN	_	22	case	_	_
22	dosing	dosing	NN	_	20	ppmod	_	_
23	reduced	reduce	VBD	_	13	conj	_	_
24	as	as	RB	_	25	com	_	_
25	much	much	RB	_	27	adv	_	_
26	as	as	RB	_	27	adv	_	_
27	possible	possible	JJ	_	23	dep	_	_
28	when	when	WRB	_	29	adv	_	_
29	administered	administer	VBN	_	23	comp	_	_
30	concomitantly	concomitantly	RB	_	29	adv	_	_
31	with	with	IN	_	32	case	_	_
32	drugs	drug	NNS	_	29	ppmod	_	_
33	that	that	WDT	_	34	dep	_	_
34	potentiate	potentiate	VB	_	32	relcl	_	_
35	the	the	DT	_	36	det	_	_
36	action	action	NN	_	34	obj	_	_
37	of	of	IN	_	38	case	_	_
38	drug2	drug0	NN	_	36	ppmod	_	_
39	.	.	.	_	23	p	_	_

1	In	in	IN	_	3	case	_	_
2	healthy	healthy	JJ	_	3	attr	_	_
3	volunteers	volunteer	NNS	_	18	ppmod	_	_
4	,	,	,	_	18	p	_	_
5	the	the	DT	_	6	det	_	_
6	pharmacokinetics	pharmacokinetics	NNS	_	18	dep	_	_
7	of	of	IN	_	10	case	_	_
8	a	a	DT	_	10	det	_	_
9	1-mg	0-mg	JJ	_	10	attr	_	_
10	dose	dose	NN	_	6	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	administered	administer	VBN	_	10	acl	_	_
14	as	as	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	were	be	VBD	_	18	aux	_	_
17	not	not	RB	_	18	neg	_	_
18	affected	affect	VBN	_	0	root	_	_
19	by	by	IN	_	21	case	_	_
20	the	the	DT	_	21	det	_	_
21	coadministration	coadministration	NN	_	18	ppmod	_	_
22	of	of	IN	_	27	case	_	_
23	a	a	DT	_	27	det	_	_
24	single	single	JJ	_	27	attr	_	_
25	6-mg	0-mg	JJ	_	27	attr	_	_
26	subcutaneous	subcutaneous	NN	_	27	com	_	_
27	dose	dose	NN	_	21	ppmod	_	_
28	of	of	IN	_	29	case	_	_
29	drug3	drug0	NN	_	27	ppmod	_	_
30	.	.	.	_	18	p	_	_

1	However	however	RB	_	16	adv	_	_
2	,	,	,	_	16	p	_	_
3	in	in	IN	_	5	case	_	_
4	another	another	DT	_	5	det	_	_
5	study	study	NN	_	16	ppmod	_	_
6	in	in	IN	_	8	case	_	_
7	healthy	healthy	JJ	_	8	attr	_	_
8	volunteers	volunteer	NNS	_	5	ppmod	_	_
9	,	,	,	_	16	p	_	_
10	the	the	DT	_	11	det	_	_
11	pharmacokinetics	pharmacokinetics	NNS	_	16	dep	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	were	be	VBD	_	16	aux	_	_
15	significantly	significantly	RB	_	16	adv	_	_
16	altered	alter	VBN	_	0	root	_	_
17	(	-lrb-	-LRB-	_	20	p	_	_
18	29	0	CD	_	20	num	_	_
19	%	%	NN	_	18	meta	_	_
20	decrease	decrease	NN	_	16	prn	_	_
21	in	in	IN	_	22	case	_	_
22	AUC	auc	NN	_	20	ppmod	_	_
23	and	and	CC	_	20	cc	_	_
24	38	0	CD	_	26	num	_	_
25	%	%	NN	_	24	meta	_	_
26	decrease	decrease	NN	_	20	conj	_	_
27	in	in	IN	_	28	case	_	_
28	Cmax	cmax	NN	_	26	ppmod	_	_
29	)	-rrb-	-RRB-	_	20	p	_	_
30	when	when	WRB	_	37	adv	_	_
31	a	a	DT	_	33	det	_	_
32	1-mg	0-mg	JJ	_	33	attr	_	_
33	dose	dose	NN	_	37	dep	_	_
34	of	of	IN	_	35	case	_	_
35	drug2	drug0	NN	_	33	ppmod	_	_
36	was	be	VBD	_	37	aux	_	_
37	administered	administer	VBN	_	16	comp	_	_
38	1	0	CD	_	39	num	_	_
39	minute	minute	NN	_	43	dat	_	_
40	after	after	IN	_	43	case	_	_
41	a	a	DT	_	43	det	_	_
42	20-mg	0-mg	JJ	_	43	attr	_	_
43	dose	dose	NN	_	37	ppmod	_	_
44	of	of	IN	_	47	case	_	_
45	drug3	drug0	NN	_	47	attr	_	_
46	nasal	nasal	JJ	_	47	attr	_	_
47	spray	spray	NN	_	43	ppmod	_	_
48	.	.	.	_	16	p	_	_

1	(	-lrb-	-LRB-	_	6	p	_	_
2	The	the	DT	_	4	det	_	_
3	two	#crd#	CD	_	4	num	_	_
4	drugs	drug	NNS	_	6	dep	_	_
5	were	be	VBD	_	6	aux	_	_
6	administered	administer	VBN	_	0	root	_	_
7	in	in	IN	_	9	case	_	_
8	opposite	opposite	JJ	_	9	attr	_	_
9	nostrils	nostril	NNS	_	6	ppmod	_	_
10	.	.	.	_	6	p	_	_
11	)	-rrb-	-RRB-	_	6	p	_	_

1	When	when	WRB	_	5	adv	_	_
2	the	the	DT	_	3	det	_	_
3	drug1	drug0	NN	_	5	dep	_	_
4	was	be	VBD	_	5	aux	_	_
5	administered	administer	VBN	_	18	advcl	_	_
6	30	0	CD	_	7	num	_	_
7	minutes	minute	NNS	_	12	dat	_	_
8	after	after	IN	_	12	case	_	_
9	the	the	DT	_	12	det	_	_
10	drug2	drug0	NN	_	12	attr	_	_
11	nasal	nasal	JJ	_	12	attr	_	_
12	spray	spray	NN	_	5	ppmod	_	_
13	,	,	,	_	18	p	_	_
14	the	the	DT	_	15	det	_	_
15	AUC	auc	NN	_	18	dep	_	_
16	of	of	IN	_	17	case	_	_
17	drug3	drug0	NN	_	15	ppmod	_	_
18	increased	increase	VBD	_	0	root	_	_
19	11	0	CD	_	18	obj	_	_
20	%	%	NN	_	19	meta	_	_
21	and	and	CC	_	18	cc	_	_
22	Cmax	cmax	NN	_	23	dep	_	_
23	decreased	decrease	VBD	_	18	conj	_	_
24	18	0	CD	_	23	obj	_	_
25	%	%	NN	_	24	meta	_	_
26	.	.	.	_	18	p	_	_

1	In	in	NN	_	4	dep	_	_
2	neither	neither	CC	_	1	cc	_	_
3	case	case	NN	_	1	conj	_	_
4	were	be	VBD	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	pharmacokinetics	pharmacokinetics	NNS	_	4	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	affected	affect	VBN	_	8	acl	_	_
10	by	by	IN	_	11	case	_	_
11	coadministration	coadministration	NN	_	9	ppmod	_	_
12	with	with	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	.	.	.	_	4	p	_	_

1	These	these	DT	_	2	det	_	_
2	results	result	NNS	_	3	dep	_	_
3	suggest	suggest	VBP	_	0	root	_	_
4	that	that	IN	_	12	mark	_	_
5	the	the	DT	_	7	det	_	_
6	analgesic	analgesic	JJ	_	7	attr	_	_
7	effect	effect	NN	_	12	dep	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	may	may	MD	_	12	modal	_	_
11	be	be	VB	_	12	aux	_	_
12	diminished	diminish	VBN	_	3	comp	_	_
13	when	when	WRB	_	16	adv	_	_
14	it	it	PRP	_	16	dep	_	_
15	is	be	VBZ	_	16	aux	_	_
16	administered	administer	VBN	_	12	comp	_	_
17	shortly	shortly	RB	_	16	adv	_	_
18	after	after	IN	_	21	case	_	_
19	drug2	drug0	NN	_	21	attr	_	_
20	nasal	nasal	JJ	_	21	attr	_	_
21	spray	spray	NN	_	16	ppmod	_	_
22	,	,	,	_	12	p	_	_
23	but	but	CC	_	12	cc	_	_
24	by	by	IN	_	26	case	_	_
25	30	0	CD	_	26	num	_	_
26	minutes	minute	NNS	_	33	ppmod	_	_
27	any	any	DT	_	29	det	_	_
28	such	such	JJ	_	29	attr	_	_
29	reduction	reduction	NN	_	33	dep	_	_
30	in	in	IN	_	31	case	_	_
31	effect	effect	NN	_	29	ppmod	_	_
32	should	should	MD	_	33	modal	_	_
33	be	be	VB	_	12	conj	_	_
34	minimal	minimal	JJ	_	33	dep	_	_
35	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	safety	safety	NN	_	22	dep	_	_
3	of	of	IN	_	4	case	_	_
4	using	use	VBG	_	2	ppmod	_	_
5	drug1	drug0	NN	_	4	obj	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	12	attr	_	_
8	(	-lrb-	-LRB-	_	12	p	_	_
9	drug3	drug0	NN	_	12	attr	_	_
10	)	-rrb-	-RRB-	_	12	p	_	_
11	Nasal	nasal	JJ	_	12	attr	_	_
12	Spray	spray	NN	_	5	conj	_	_
13	during	during	IN	_	16	case	_	_
14	the	the	DT	_	16	det	_	_
15	same	same	JJ	_	16	attr	_	_
16	episode	episode	NN	_	4	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	migraine	migraine	NN	_	16	ppmod	_	_
19	has	have	VBZ	_	22	aux	_	_
20	not	not	RB	_	22	neg	_	_
21	been	be	VBN	_	22	aux	_	_
22	established	establish	VBN	_	0	root	_	_
23	.	.	.	_	22	p	_	_

1	However	however	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	it	it	PRP	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	noted	note	VBN	_	0	root	_	_
7	that	that	IN	_	10	mark	_	_
8	both	both	DT	_	9	det	_	_
9	products	product	NNS	_	10	dep	_	_
10	are	be	VBP	_	6	comp	_	_
11	capable	capable	JJ	_	10	dep	_	_
12	of	of	IN	_	13	case	_	_
13	producing	produce	VBG	_	11	ppmod	_	_
14	transient	transient	JJ	_	15	attr	_	_
15	increases	increase	NNS	_	13	obj	_	_
16	in	in	IN	_	18	case	_	_
17	blood	blood	NN	_	18	com	_	_
18	pressure	pressure	NN	_	15	ppmod	_	_
19	.	.	.	_	6	p	_	_

1	The	the	DT	_	2	det	_	_
2	pharmacokinetics	pharmacokinetics	NNS	_	14	dep	_	_
3	of	of	IN	_	6	case	_	_
4	a	a	DT	_	6	det	_	_
5	1-mg	0-mg	JJ	_	6	attr	_	_
6	dose	dose	NN	_	2	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	administered	administer	VBN	_	6	acl	_	_
10	as	as	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	were	be	VBD	_	14	aux	_	_
13	not	not	RB	_	14	neg	_	_
14	affected	affect	VBN	_	0	root	_	_
15	by	by	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	coadministration	coadministration	NN	_	14	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug3	drug0	NN	_	17	ppmod	_	_
20	(	-lrb-	-LRB-	_	22	p	_	_
21	300	0	CD	_	22	num	_	_
22	mg	mg	NN	_	19	prn	_	_
23	QID	qid	JJ	_	22	attr	_	_
24	)	-rrb-	-RRB-	_	22	p	_	_
25	.	.	.	_	14	p	_	_

1	Conversely	conversely	RB	_	15	adv	_	_
2	,	,	,	_	15	p	_	_
3	the	the	DT	_	4	det	_	_
4	administration	administration	NN	_	15	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	(	-lrb-	-LRB-	_	9	p	_	_
8	1	0	CD	_	9	num	_	_
9	mg	mg	NN	_	6	prn	_	_
10	drug2	drug0	JJ	_	9	attr	_	_
11	QID	qid	JJ	_	9	attr	_	_
12	)	-rrb-	-RRB-	_	9	p	_	_
13	did	do	VBD	_	15	aux	_	_
14	not	not	RB	_	15	neg	_	_
15	alter	alter	VB	_	0	root	_	_
16	the	the	DT	_	17	det	_	_
17	pharmacokinetics	pharmacokinetics	NNS	_	15	obj	_	_
18	of	of	IN	_	21	case	_	_
19	a	a	DT	_	21	det	_	_
20	300-mg	0-mg	JJ	_	21	attr	_	_
21	dose	dose	NN	_	17	ppmod	_	_
22	of	of	IN	_	23	case	_	_
23	drug3	drug0	NN	_	21	ppmod	_	_
24	.	.	.	_	15	p	_	_

1	It	it	PRP	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	known	know	VBN	_	0	root	_	_
5	if	if	IN	_	11	mark	_	_
6	the	the	DT	_	7	det	_	_
7	effects	effect	NNS	_	11	dep	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	are	be	VBP	_	11	aux	_	_
11	altered	alter	VBN	_	4	comp	_	_
12	by	by	IN	_	14	case	_	_
13	concomitant	concomitant	JJ	_	14	attr	_	_
14	medications	medication	NNS	_	11	ppmod	_	_
15	that	that	WDT	_	16	dep	_	_
16	affect	affect	VBP	_	14	relcl	_	_
17	hepatic	hepatic	JJ	_	18	attr	_	_
18	metabolism	metabolism	NN	_	16	obj	_	_
19	of	of	IN	_	20	case	_	_
20	drugs	drug	NNS	_	18	ppmod	_	_
21	(	-lrb-	-LRB-	_	22	p	_	_
22	drug2	drug0	NN	_	20	prn	_	_
23	,	,	,	_	22	p	_	_
24	etc.	etc.	NN	_	22	conj	_	_
25	)	-rrb-	-RRB-	_	22	p	_	_
26	,	,	,	_	11	p	_	_
27	but	but	CC	_	11	cc	_	_
28	physicians	physician	NNS	_	30	dep	_	_
29	should	should	MD	_	30	modal	_	_
30	be	be	VB	_	11	conj	_	_
31	alert	alert	JJ	_	30	dep	_	_
32	to	to	TO	_	34	aux	_	_
33	the	the	DT	_	34	det	_	_
34	possibility	possibility	NN	_	31	ppmod	_	_
35	that	that	IN	_	47	mark	_	_
36	a	a	DT	_	39	det	_	_
37	smaller	small	JJR	_	39	attr	_	_
38	initial	initial	JJ	_	39	attr	_	_
39	dose	dose	NN	_	47	dep	_	_
40	and	and	CC	_	39	cc	_	_
41	longer	long	JJR	_	42	attr	_	_
42	intervals	interval	NNS	_	39	conj	_	_
43	between	between	IN	_	44	case	_	_
44	doses	dose	NNS	_	42	ppmod	_	_
45	may	may	MD	_	47	modal	_	_
46	be	be	VB	_	47	aux	_	_
47	needed	need	VBN	_	34	acl	_	_
48	.	.	.	_	4	p	_	_

1	The	the	DT	_	2	det	_	_
2	fraction	fraction	NN	_	7	dep	_	_
3	of	of	IN	_	5	case	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	absorbed	absorbed	NN	_	2	ppmod	_	_
6	is	be	VBZ	_	7	aux	_	_
7	unaffected	unaffected	VBN	_	0	root	_	_
8	by	by	IN	_	11	case	_	_
9	the	the	DT	_	11	det	_	_
10	concomitant	concomitant	JJ	_	11	attr	_	_
11	administration	administration	NN	_	7	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	a	a	DT	_	14	det	_	_
14	drug2	drug0	NN	_	11	ppmod	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	drug3	drug0	NN	_	14	prn	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	,	,	,	_	7	p	_	_
19	but	but	CC	_	7	cc	_	_
20	the	the	DT	_	21	det	_	_
21	rate	rate	NN	_	25	dep	_	_
22	of	of	IN	_	23	case	_	_
23	absorption	absorption	NN	_	21	ppmod	_	_
24	is	be	VBZ	_	25	aux	_	_
25	decreased	decrease	VBN	_	7	conj	_	_
26	.	.	.	_	7	p	_	_

1	Therefore	therefore	RB	_	8	adv	_	_
2	,	,	,	_	8	p	_	_
3	a	a	DT	_	5	det	_	_
4	slower	slow	JJR	_	5	attr	_	_
5	onset	onset	NN	_	8	dep	_	_
6	can	can	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	anticipated	anticipate	VBN	_	0	root	_	_
9	if	if	IN	_	12	mark	_	_
10	drug1	drug0	NN	_	12	dep	_	_
11	is	be	VBZ	_	12	aux	_	_
12	administered	administer	VBN	_	8	comp	_	_
13	concomitantly	concomitantly	RB	_	12	adv	_	_
14	with	with	IN	_	12	ppmod	_	_
15	,	,	,	_	14	p	_	_
16	or	or	CC	_	14	cc	_	_
17	immediately	immediately	RB	_	14	conj	_	_
18	following	follow	VBG	_	17	adv	_	_
19	,	,	,	_	12	p	_	_
20	a	a	DT	_	21	det	_	_
21	drug2	drug0	NN	_	12	obj	_	_
22	.	.	.	_	8	p	_	_

1	No	no	DT	_	2	det	_	_
2	information	information	NN	_	3	dep	_	_
3	is	be	VBZ	_	0	root	_	_
4	available	available	JJ	_	3	dep	_	_
5	about	about	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	use	use	NN	_	4	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	concurrently	concurrently	RB	_	12	adv	_	_
11	with	with	IN	_	12	case	_	_
12	drug2	drug0	NN	_	7	ppmod	_	_
13	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	used	use	VBN	_	0	root	_	_
5	cautiously	cautiously	RB	_	4	adv	_	_
6	in	in	IN	_	7	case	_	_
7	patients	patient	NNS	_	4	ppmod	_	_
8	with	with	IN	_	9	case	_	_
9	hyperthyroidism	hyperthyroidism	NN	_	7	ppmod	_	_
10	,	,	,	_	9	p	_	_
11	hypertension	hypertension	NN	_	9	conj	_	_
12	and	and	CC	_	11	cc	_	_
13	cardiac	cardiac	JJ	_	14	attr	_	_
14	arrhythmias	arrhythmia	NNS	_	9	conj	_	_
15	.	.	.	_	4	p	_	_

1	All	all	DT	_	2	det	_	_
2	drug1	drug0	NN	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	used	use	VBN	_	0	root	_	_
6	cautiously	cautiously	RB	_	5	adv	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	5	ppmod	_	_
9	taking	take	VBG	_	8	acl	_	_
10	drug2	drug0	NN	_	9	obj	_	_
11	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	should	should	MD	_	5	modal	_	_
3	not	not	RB	_	5	neg	_	_
4	be	be	VB	_	5	aux	_	_
5	administered	administer	VBN	_	0	root	_	_
6	concomitantly	concomitantly	RB	_	5	adv	_	_
7	with	with	IN	_	9	case	_	_
8	other	other	JJ	_	9	attr	_	_
9	drug2	drug0	NNS	_	5	ppmod	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	such	such	JJ	_	9	prn	_	_
12	as	as	IN	_	13	case	_	_
13	drug3	drug0	NN	_	11	ppmod	_	_
14	)	-rrb-	-RRB-	_	11	p	_	_
15	because	because	IN	_	19	case	_	_
16	of	of	IN	_	19	case	_	_
17	possible	possible	JJ	_	19	attr	_	_
18	additive	additive	JJ	_	19	attr	_	_
19	effects	effect	NNS	_	5	ppmod	_	_
20	and	and	CC	_	19	cc	_	_
21	increased	increase	VBN	_	22	attr	_	_
22	toxicity	toxicity	NN	_	19	conj	_	_
23	.	.	.	_	5	p	_	_

1	Combined	combined	JJ	_	2	attr	_	_
2	effects	effect	NNS	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	induce	induce	VB	_	0	root	_	_
5	serious	serious	JJ	_	7	attr	_	_
6	cardiac	cardiac	JJ	_	7	attr	_	_
7	arrhythmias	arrhythmia	NNS	_	4	obj	_	_
8	.	.	.	_	4	p	_	_

1	They	they	PRP	_	4	dep	_	_
2	may	may	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	administered	administer	VBN	_	0	root	_	_
5	alternately	alternately	RB	_	4	adv	_	_
6	when	when	WRB	_	15	adv	_	_
7	the	the	DT	_	9	det	_	_
8	preceding	preceding	JJ	_	9	attr	_	_
9	effect	effect	NN	_	15	dep	_	_
10	of	of	IN	_	13	case	_	_
11	other	other	JJ	_	13	attr	_	_
12	such	such	JJ	_	13	attr	_	_
13	drug	drug	NN	_	9	ppmod	_	_
14	has	have	VBZ	_	15	aux	_	_
15	subsided	subside	VBN	_	4	comp	_	_
16	.	.	.	_	4	p	_	_

1	Administration	administration	NN	_	19	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	to	to	TO	_	5	aux	_	_
5	patients	patient	NNS	_	1	ppmod	_	_
6	receiving	receive	VBG	_	5	acl	_	_
7	drug2	drug0	NN	_	6	obj	_	_
8	or	or	CC	_	7	cc	_	_
9	drug3	drug0	NN	_	7	conj	_	_
10	such	such	JJ	_	12	adv	_	_
11	as	as	IN	_	12	case	_	_
12	drug4	drug0	NN	_	7	ppmod	_	_
13	which	which	WDT	_	14	dep	_	_
14	sensitize	sensitize	VB	_	7	relcl	_	_
15	the	the	DT	_	16	det	_	_
16	myocardium	myocardium	NN	_	14	obj	_	_
17	,	,	,	_	7	p	_	_
18	may	may	MD	_	19	modal	_	_
19	induce	induce	VB	_	0	root	_	_
20	cardiac	cardiac	JJ	_	21	attr	_	_
21	arrhythmia	arrhythmia	NN	_	19	obj	_	_
22	.	.	.	_	19	p	_	_
23	.	.	.	_	19	p	_	_

1	When	when	WRB	_	2	adv	_	_
2	encountered	encounter	VBN	_	7	advcl	_	_
3	,	,	,	_	7	p	_	_
4	such	such	JJ	_	5	attr	_	_
5	arrhythmias	arrhythmia	NNS	_	7	dep	_	_
6	may	may	MD	_	7	modal	_	_
7	respond	respond	VB	_	0	root	_	_
8	to	to	TO	_	9	aux	_	_
9	administration	administration	NN	_	7	ppmod	_	_
10	of	of	IN	_	12	case	_	_
11	a	a	DT	_	12	det	_	_
12	drug1	drug0	NN	_	9	ppmod	_	_
13	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	also	also	RB	_	5	adv	_	_
3	should	should	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	used	use	VBN	_	0	root	_	_
6	cautiously	cautiously	RB	_	5	adv	_	_
7	with	with	IN	_	9	case	_	_
8	other	other	JJ	_	9	attr	_	_
9	drugs	drug	NNS	_	5	ppmod	_	_
10	(	-lrb-	-LRB-	_	15	p	_	_
11	e.g.	e.g.	FW	_	13	adv	_	_
12	,	,	,	_	13	p	_	_
13	drug2	drug0	NN	_	15	ppmod	_	_
14	,	,	,	_	15	p	_	_
15	drug3	drug0	NNS	_	9	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	that	that	WDT	_	18	dep	_	_
18	sensitize	sensitize	VB	_	9	relcl	_	_
19	the	the	DT	_	20	det	_	_
20	myocardium	myocardium	NN	_	18	obj	_	_
21	to	to	TO	_	23	aux	_	_
22	the	the	DT	_	23	det	_	_
23	actions	action	NNS	_	18	ppmod	_	_
24	of	of	IN	_	25	case	_	_
25	drug4	drug0	NN	_	23	ppmod	_	_
26	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	decrease	decrease	VB	_	0	root	_	_
4	vascular	vascular	JJ	_	5	attr	_	_
5	response	response	NN	_	3	obj	_	_
6	to	to	TO	_	8	aux	_	_
7	pressor	pressor	JJ	_	8	attr	_	_
8	drugs	drug	NNS	_	5	ppmod	_	_
9	such	such	JJ	_	11	adv	_	_
10	as	as	IN	_	11	case	_	_
11	drug2	drug0	NN	_	8	ppmod	_	_
12	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	antagonize	antagonize	VB	_	0	root	_	_
4	the	the	DT	_	6	det	_	_
5	neuron	neuron	NN	_	6	com	_	_
6	blockade	blockade	NN	_	3	obj	_	_
7	produced	produce	VBN	_	6	acl	_	_
8	by	by	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	resulting	result	VBG	_	9	acl	_	_
11	in	in	IN	_	14	case	_	_
12	decreased	decrease	VBN	_	14	attr	_	_
13	antihypertensive	antihypertensive	JJ	_	14	attr	_	_
14	effect	effect	NN	_	10	ppmod	_	_
15	and	and	CC	_	10	cc	_	_
16	requiring	require	VBG	_	10	conj	_	_
17	increased	increase	VBN	_	18	attr	_	_
18	dosage	dosage	NN	_	16	obj	_	_
19	of	of	IN	_	21	case	_	_
20	the	the	DT	_	21	det	_	_
21	latter	latter	JJ	_	18	ppmod	_	_
22	.	.	.	_	3	p	_	_

1	May	may	MD	_	2	modal	_	_
2	interact	interact	VB	_	0	root	_	_
3	drug1	drug0	NN	_	2	obj	_	_
4	(	-lrb-	-LRB-	_	7	p	_	_
5	altered	altered	JJ	_	7	attr	_	_
6	hypo-prothrombinemic	hypo-prothrombinemic	JJ	_	7	attr	_	_
7	effect	effect	NN	_	3	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	,	,	,	_	3	p	_	_
10	drug2	drug0	NN	_	3	conj	_	_
11	,	,	,	_	10	p	_	_
12	drug3	drug0	NN	_	3	conj	_	_
13	and	and	CC	_	12	cc	_	_
14	other	other	JJ	_	15	attr	_	_
15	inducers	inducer	NNS	_	3	conj	_	_
16	of	of	IN	_	21	case	_	_
17	hepatic	hepatic	JJ	_	21	attr	_	_
18	microsomal	microsomal	JJ	_	21	attr	_	_
19	enzyme	enzyme	NN	_	21	com	_	_
20	oxidation	oxidation	NN	_	21	com	_	_
21	system	system	NN	_	15	ppmod	_	_
22	(	-lrb-	-LRB-	_	24	p	_	_
23	decreased	decrease	VBN	_	24	attr	_	_
24	effect	effect	NN	_	21	prn	_	_
25	of	of	IN	_	26	case	_	_
26	drug4	drug0	NNS	_	24	ppmod	_	_
27	)	-rrb-	-RRB-	_	24	p	_	_
28	,	,	,	_	15	p	_	_
29	drug5	drug0	NN	_	15	appo	_	_
30	(	-lrb-	-LRB-	_	34	p	_	_
31	increased	increase	VBN	_	34	attr	_	_
32	effect	effect	NN	_	34	attr	_	_
33	of	of	IN	_	34	case	_	_
34	drug6	drug0	NN	_	29	prn	_	_
35	)	-rrb-	-RRB-	_	34	p	_	_
36	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Concomitant	concomitant	JJ	_	4	attr	_	_
4	administration	administration	NN	_	11	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	is	be	VBZ	_	11	aux	_	_
10	not	not	RB	_	11	neg	_	_
11	recommended	recommend	VBN	_	1	acl	_	_
12	because	because	IN	_	15	mark	_	_
13	drug4	drug0	NN	_	15	dep	_	_
14	is	be	VBZ	_	15	aux	_	_
15	displaced	displace	VBN	_	11	comp	_	_
16	from	from	IN	_	19	case	_	_
17	its	its	PRP$	_	19	poss	_	_
18	binding	binding	NN	_	19	com	_	_
19	sites	site	NNS	_	15	ppmod	_	_
20	during	during	IN	_	23	case	_	_
21	the	the	DT	_	23	det	_	_
22	concomitant	concomitant	JJ	_	23	attr	_	_
23	administration	administration	NN	_	15	ppmod	_	_
24	of	of	IN	_	25	case	_	_
25	drug5	drug0	NN	_	23	ppmod	_	_
26	,	,	,	_	15	p	_	_
27	resulting	result	VBG	_	15	comp	_	_
28	in	in	IN	_	31	case	_	_
29	lower	low	JJR	_	31	attr	_	_
30	plasma	plasma	NN	_	31	com	_	_
31	concentrations	concentration	NNS	_	27	ppmod	_	_
32	,	,	,	_	31	p	_	_
33	peak	peak	NN	_	35	com	_	_
34	plasma	plasma	NN	_	35	com	_	_
35	levels	level	NNS	_	31	conj	_	_
36	,	,	,	_	35	p	_	_
37	and	and	CC	_	35	cc	_	_
38	AUC	auc	NN	_	39	com	_	_
39	values	value	NNS	_	31	conj	_	_
40	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	While	while	IN	_	7	mark	_	_
4	studies	study	NNS	_	7	dep	_	_
5	have	have	VBP	_	7	aux	_	_
6	not	not	RB	_	7	neg	_	_
7	shown	show	VBN	_	17	advcl	_	_
8	drug2	drug0	NN	_	7	obj	_	_
9	to	to	TO	_	10	aux	_	_
10	interact	interact	VB	_	7	comp	_	_
11	with	with	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	,	,	,	_	17	p	_	_
14	caution	caution	NN	_	17	dep	_	_
15	should	should	MD	_	17	modal	_	_
16	be	be	VB	_	17	aux	_	_
17	exercised	exercise	VBN	_	1	acl	_	_
18	,	,	,	_	17	p	_	_
19	nonetheless	nonetheless	RB	_	17	adv	_	_
20	,	,	,	_	17	p	_	_
21	since	since	IN	_	25	mark	_	_
22	interactions	interaction	NNS	_	25	dep	_	_
23	have	have	VBP	_	25	aux	_	_
24	been	be	VBN	_	25	aux	_	_
25	seen	see	VBN	_	17	comp	_	_
26	with	with	IN	_	28	case	_	_
27	other	other	JJ	_	28	attr	_	_
28	drug4	drug0	NN	_	25	ppmod	_	_
29	.	.	.	_	1	p	_	_

1	Because	because	IN	_	3	mark	_	_
2	prostaglandins	prostaglandin	NNS	_	3	dep	_	_
3	play	play	VBP	_	29	advcl	_	_
4	an	an	DT	_	6	det	_	_
5	important	important	JJ	_	6	attr	_	_
6	role	role	NN	_	3	obj	_	_
7	in	in	IN	_	8	case	_	_
8	hemostasis	hemostasis	NN	_	3	ppmod	_	_
9	,	,	,	_	3	p	_	_
10	and	and	CC	_	3	cc	_	_
11	drug1	drug0	NN	_	12	dep	_	_
12	affect	affect	VBP	_	3	conj	_	_
13	platelet	platelet	NN	_	14	com	_	_
14	function	function	NN	_	12	obj	_	_
15	as	as	IN	_	16	case	_	_
16	well	well	NN	_	12	ppmod	_	_
17	,	,	,	_	29	p	_	_
18	concurrent	concurrent	JJ	_	19	attr	_	_
19	therapy	therapy	NN	_	29	dep	_	_
20	with	with	IN	_	22	case	_	_
21	all	all	DT	_	22	det	_	_
22	drug2	drug0	NNS	_	19	ppmod	_	_
23	,	,	,	_	22	p	_	_
24	including	include	VBG	_	25	adv	_	_
25	drug3	drug0	NN	_	22	ppmod	_	_
26	,	,	,	_	22	p	_	_
27	and	and	CC	_	22	cc	_	_
28	drug4	drug0	NNS	_	22	conj	_	_
29	requires	require	VBZ	_	0	root	_	_
30	close	close	JJ	_	31	attr	_	_
31	monitoring	monitoring	NN	_	29	obj	_	_
32	of	of	IN	_	33	case	_	_
33	patients	patient	NNS	_	31	ppmod	_	_
34	to	to	TO	_	35	aux	_	_
35	be	be	VB	_	29	comp	_	_
36	certain	certain	JJ	_	35	dep	_	_
37	that	that	IN	_	45	mark	_	_
38	no	no	DT	_	39	det	_	_
39	change	change	NN	_	45	dep	_	_
40	in	in	IN	_	43	case	_	_
41	their	their	PRP$	_	43	poss	_	_
42	drug5	drug0	NN	_	43	com	_	_
43	dosage	dosage	NN	_	39	ppmod	_	_
44	is	be	VBZ	_	45	aux	_	_
45	required	require	VBN	_	36	comp	_	_
46	.	.	.	_	29	p	_	_

1	drug1	drug0	NN	_	14	dep	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	,	,	,	_	1	p	_	_
5	drug3	drug0	NN	_	1	appo	_	_
6	:	:	:	_	1	p	_	_
7	drug4	drug0	NN	_	1	appo	_	_
8	,	,	,	_	14	p	_	_
9	like	like	IN	_	11	case	_	_
10	other	other	JJ	_	11	attr	_	_
11	drug5	drug0	NN	_	14	ppmod	_	_
12	,	,	,	_	14	p	_	_
13	may	may	MD	_	14	modal	_	_
14	affect	affect	VB	_	0	root	_	_
15	renal	renal	JJ	_	16	attr	_	_
16	prostaglandins	prostaglandin	NNS	_	14	obj	_	_
17	and	and	CC	_	14	cc	_	_
18	increase	increase	VB	_	14	conj	_	_
19	the	the	DT	_	20	det	_	_
20	toxicity	toxicity	NN	_	18	obj	_	_
21	of	of	IN	_	23	case	_	_
22	certain	certain	JJ	_	23	attr	_	_
23	drugs	drug	NNS	_	20	ppmod	_	_
24	.	.	.	_	14	p	_	_

1	Ingestion	ingestion	NN	_	5	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	may	may	MD	_	5	modal	_	_
5	increase	increase	VB	_	0	root	_	_
6	serum	serum	NN	_	7	com	_	_
7	concentrations	concentration	NNS	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	drug3	drug0	NN	_	9	conj	_	_
12	and	and	CC	_	5	cc	_	_
13	increase	increase	VB	_	5	conj	_	_
14	drug4	drug0	NN	_	16	com	_	_
15	s	s	NN	_	16	com	_	_
16	nephrotoxicity	nephrotoxicity	NN	_	13	obj	_	_
17	.	.	.	_	5	p	_	_

1	Patients	patient	NNS	_	25	dep	_	_
2	who	who	WP	_	4	dep	_	_
3	begin	begin	VBP	_	4	aux	_	_
4	taking	take	VBG	_	1	advcl	_	_
5	drug1	drug0	NN	_	4	obj	_	_
6	or	or	CC	_	4	cc	_	_
7	who	who	WP	_	8	dep	_	_
8	increase	increase	VBP	_	4	conj	_	_
9	their	their	PRP$	_	11	poss	_	_
10	drug2	drug0	NN	_	11	com	_	_
11	dose	dose	NN	_	8	obj	_	_
12	or	or	CC	_	11	cc	_	_
13	any	any	DT	_	15	det	_	_
14	other	other	JJ	_	15	attr	_	_
15	drug3	drug0	NN	_	11	conj	_	_
16	while	while	IN	_	17	mark	_	_
17	taking	take	VBG	_	8	comp	_	_
18	drug4	drug0	NN	_	17	obj	_	_
19	,	,	,	_	18	p	_	_
20	drug5	drug0	NN	_	18	conj	_	_
21	,	,	,	_	20	p	_	_
22	or	or	CC	_	20	cc	_	_
23	drug6	drug0	NN	_	18	conj	_	_
24	may	may	MD	_	25	modal	_	_
25	develop	develop	VBP	_	0	root	_	_
26	toxicity	toxicity	NN	_	27	com	_	_
27	characteristics	characteristic	NNS	_	25	obj	_	_
28	for	for	IN	_	30	case	_	_
29	these	these	DT	_	30	det	_	_
30	drugs	drug	NNS	_	27	ppmod	_	_
31	.	.	.	_	25	p	_	_

1	They	they	PRP	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	observed	observe	VBN	_	0	root	_	_
5	closely	closely	RB	_	4	adv	_	_
6	,	,	,	_	4	p	_	_
7	particularly	particularly	RB	_	12	adv	_	_
8	if	if	IN	_	12	mark	_	_
9	renal	renal	JJ	_	10	attr	_	_
10	function	function	NN	_	12	dep	_	_
11	is	be	VBZ	_	12	aux	_	_
12	impaired	impair	VBN	_	4	comp	_	_
13	.	.	.	_	4	p	_	_

1	In	in	IN	_	3	case	_	_
2	the	the	DT	_	3	det	_	_
3	case	case	NN	_	11	ppmod	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	,	,	,	_	11	p	_	_
7	serum	serum	NN	_	8	com	_	_
8	levels	level	NNS	_	11	dep	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	monitored	monitor	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	decreases	decrease	VBZ	_	0	root	_	_
5	drug3	drug0	NN	_	7	attr	_	_
6	renal	renal	JJ	_	7	attr	_	_
7	clearance	clearance	NN	_	4	obj	_	_
8	and	and	CC	_	4	cc	_	_
9	increases	increase	VBZ	_	4	conj	_	_
10	drug4	drug0	NN	_	12	com	_	_
11	plasma	plasma	NN	_	12	com	_	_
12	levels	level	NNS	_	9	obj	_	_
13	.	.	.	_	4	p	_	_

1	In	in	IN	_	2	case	_	_
2	patients	patient	NNS	_	12	ppmod	_	_
3	taking	take	VBG	_	2	acl	_	_
4	drug1	drug0	NN	_	3	obj	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	concomitantly	concomitantly	RB	_	4	adv	_	_
8	,	,	,	_	12	p	_	_
9	drug3	drug0	NN	_	10	com	_	_
10	toxicity	toxicity	NN	_	12	dep	_	_
11	may	may	MD	_	12	modal	_	_
12	develop	develop	VB	_	0	root	_	_
13	.	.	.	_	12	p	_	_

1	Oral	oral	JJ	_	4	attr	_	_
2	drug1	drug0	NN	_	4	attr	_	_
3	:	:	:	_	4	p	_	_
4	drug2	drug0	NN	_	7	dep	_	_
5	does	do	VBZ	_	7	aux	_	_
6	not	not	RB	_	7	neg	_	_
7	alter	alter	VB	_	0	root	_	_
8	glucose	glucose	NN	_	9	com	_	_
9	metabolism	metabolism	NN	_	7	obj	_	_
10	in	in	IN	_	12	case	_	_
11	normal	normal	JJ	_	12	attr	_	_
12	subjects	subject	NNS	_	9	ppmod	_	_
13	nor	nor	CC	_	7	cc	_	_
14	does	do	VBZ	_	7	conj	_	_
15	it	it	PRP	_	14	obj	_	_
16	alter	alter	VBP	_	15	acl	_	_
17	the	the	DT	_	18	det	_	_
18	effects	effect	NNS	_	16	obj	_	_
19	of	of	IN	_	21	case	_	_
20	oral	oral	JJ	_	21	attr	_	_
21	drug3	drug0	NN	_	18	ppmod	_	_
22	.	.	.	_	7	p	_	_

1	There	there	EX	_	2	dep	_	_
2	are	be	VBP	_	0	root	_	_
3	rare	rare	JJ	_	4	attr	_	_
4	reports	report	NNS	_	2	obj	_	_
5	,	,	,	_	4	p	_	_
6	however	however	RB	_	4	adv	_	_
7	,	,	,	_	4	p	_	_
8	from	from	IN	_	10	case	_	_
9	marketing	marketing	JJ	_	10	attr	_	_
10	experiences	experience	NNS	_	4	ppmod	_	_
11	,	,	,	_	4	p	_	_
12	of	of	IN	_	13	case	_	_
13	changes	change	NNS	_	4	ppmod	_	_
14	in	in	IN	_	15	case	_	_
15	effects	effect	NNS	_	13	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	drug1	drug0	NN	_	15	ppmod	_	_
18	or	or	CC	_	17	cc	_	_
19	oral	oral	JJ	_	20	attr	_	_
20	drug2	drug0	NN	_	17	conj	_	_
21	in	in	IN	_	23	case	_	_
22	the	the	DT	_	23	det	_	_
23	presence	presence	NN	_	15	ppmod	_	_
24	of	of	IN	_	25	case	_	_
25	drug3	drug0	NN	_	23	ppmod	_	_
26	that	that	WDT	_	27	dep	_	_
27	necessitated	necessitate	VBD	_	25	relcl	_	_
28	changes	change	NNS	_	27	obj	_	_
29	in	in	IN	_	31	case	_	_
30	the	the	DT	_	31	det	_	_
31	doses	dose	NNS	_	28	ppmod	_	_
32	of	of	IN	_	34	case	_	_
33	such	such	JJ	_	34	attr	_	_
34	agents	agent	NNS	_	31	ppmod	_	_
35	.	.	.	_	2	p	_	_

1	Both	both	CC	_	2	cc	_	_
2	hypo-	hypo-	JJ	_	5	attr	_	_
3	and	and	CC	_	2	cc	_	_
4	hyperglycemic	hyperglycemic	JJ	_	2	conj	_	_
5	effects	effect	NNS	_	8	dep	_	_
6	have	have	VBP	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	reported	report	VBN	_	0	root	_	_
9	.	.	.	_	8	p	_	_

1	A	a	DT	_	4	det	_	_
2	direct	direct	JJ	_	4	attr	_	_
3	causal	causal	JJ	_	4	attr	_	_
4	relationship	relationship	NN	_	8	dep	_	_
5	has	have	VBZ	_	8	aux	_	_
6	not	not	RB	_	8	neg	_	_
7	been	be	VBN	_	8	aux	_	_
8	established	establish	VBN	_	0	root	_	_
9	,	,	,	_	8	p	_	_
10	but	but	CC	_	8	cc	_	_
11	physicians	physician	NNS	_	13	dep	_	_
12	should	should	MD	_	13	modal	_	_
13	consider	consider	VB	_	8	conj	_	_
14	the	the	DT	_	15	det	_	_
15	possibility	possibility	NN	_	13	obj	_	_
16	that	that	IN	_	19	mark	_	_
17	drug1	drug0	NN	_	19	dep	_	_
18	may	may	MD	_	19	modal	_	_
19	alter	alter	VB	_	15	acl	_	_
20	a	a	DT	_	24	det	_	_
21	diabetic	diabetic	JJ	_	24	attr	_	_
22	patient	patient	NN	_	24	com	_	_
23	s	s	NN	_	24	com	_	_
24	response	response	NN	_	19	obj	_	_
25	to	to	TO	_	26	aux	_	_
26	drug2	drug0	NN	_	24	ppmod	_	_
27	or	or	CC	_	26	cc	_	_
28	oral	oral	JJ	_	29	attr	_	_
29	drug3	drug0	NN	_	26	conj	_	_
30	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	8	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	and	and	CC	_	3	cc	_	_
5	other	other	JJ	_	6	attr	_	_
6	drug3	drug0	NN	_	1	conj	_	_
7	can	can	MD	_	8	modal	_	_
8	inhibit	inhibit	VB	_	0	root	_	_
9	the	the	DT	_	10	det	_	_
10	activity	activity	NN	_	8	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug4	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	8	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	treatment	treatment	NN	_	7	dep	_	_
3	with	with	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	may	may	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	associated	associate	VBN	_	0	root	_	_
8	with	with	IN	_	12	case	_	_
9	increased	increase	VBN	_	12	attr	_	_
10	serum	serum	NN	_	12	com	_	_
11	potassium	potassium	NN	_	12	com	_	_
12	levels	level	NNS	_	7	ppmod	_	_
13	.	.	.	_	7	p	_	_

1	Other	other	JJ	_	2	attr	_	_
2	Drugs	drug	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	In	in	IN	_	6	case	_	_
5	small	small	JJ	_	6	attr	_	_
6	groups	group	NNS	_	35	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	patients	patient	NNS	_	6	ppmod	_	_
9	(	-lrb-	-LRB-	_	11	p	_	_
10	7-10/interaction	0/interaction	JJ	_	11	attr	_	_
11	study	study	NN	_	8	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	,	,	,	_	35	p	_	_
14	the	the	DT	_	16	det	_	_
15	concomitant	concomitant	JJ	_	16	attr	_	_
16	administration	administration	NN	_	35	dep	_	_
17	of	of	IN	_	18	case	_	_
18	drug1	drug0	NN	_	16	ppmod	_	_
19	,	,	,	_	18	p	_	_
20	drug2	drug0	NN	_	18	conj	_	_
21	,	,	,	_	20	p	_	_
22	drug3	drug0	NN	_	18	conj	_	_
23	,	,	,	_	22	p	_	_
24	drug4	drug0	NN	_	18	conj	_	_
25	,	,	,	_	24	p	_	_
26	drug5	drug0	NN	_	18	conj	_	_
27	,	,	,	_	26	p	_	_
28	drug6	drug0	NN	_	18	conj	_	_
29	,	,	,	_	28	p	_	_
30	or	or	CC	_	28	cc	_	_
31	drug7	drug0	NN	_	18	conj	_	_
32	did	do	VBD	_	35	aux	_	_
33	not	not	RB	_	35	neg	_	_
34	significantly	significantly	RB	_	35	adv	_	_
35	affect	affect	VB	_	2	acl	_	_
36	the	the	DT	_	38	det	_	_
37	peak	peak	NN	_	38	com	_	_
38	levels	level	NNS	_	35	obj	_	_
39	and	and	CC	_	38	cc	_	_
40	AUC	auc	NN	_	41	com	_	_
41	values	value	NNS	_	38	conj	_	_
42	of	of	IN	_	43	case	_	_
43	drug8	drug0	NN	_	41	ppmod	_	_
44	.	.	.	_	2	p	_	_

1	drug1	drug0	JJ	_	2	attr	_	_
2	toxicity	toxicity	NN	_	5	dep	_	_
3	has	have	VBZ	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	reported	report	VBN	_	0	root	_	_
6	to	to	TO	_	8	aux	_	_
7	have	have	VB	_	8	aux	_	_
8	occurred	occur	VBN	_	5	comp	_	_
9	in	in	IN	_	11	case	_	_
10	a	a	DT	_	11	det	_	_
11	patient	patient	NN	_	8	ppmod	_	_
12	on	on	IN	_	15	case	_	_
13	chronic	chronic	JJ	_	15	attr	_	_
14	drug2	drug0	NN	_	15	com	_	_
15	treatment	treatment	NN	_	11	ppmod	_	_
16	following	follow	VBG	_	18	adv	_	_
17	the	the	DT	_	18	det	_	_
18	initiation	initiation	NN	_	15	ppmod	_	_
19	of	of	IN	_	21	case	_	_
20	drug3	drug0	NN	_	21	com	_	_
21	therapy	therapy	NN	_	18	ppmod	_	_
22	.	.	.	_	5	p	_	_

1	Protein	protein	NN	_	2	com	_	_
2	Binding	binding	NN	_	7	dep	_	_
3	In	in	FW	_	4	adv	_	_
4	vitro	vitro	FW	_	2	adv	_	_
5	,	,	,	_	2	p	_	_
6	drug1	drug0	NN	_	2	appo	_	_
7	interferes	interfere	VBZ	_	0	root	_	_
8	minimally	minimally	RB	_	7	adv	_	_
9	or	or	CC	_	8	cc	_	_
10	not	not	RB	_	12	neg	_	_
11	at	at	IN	_	12	case	_	_
12	all	all	DT	_	8	conj	_	_
13	with	with	IN	_	16	case	_	_
14	the	the	DT	_	16	det	_	_
15	protein	protein	NN	_	16	com	_	_
16	binding	binding	NN	_	12	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	(	-lrb-	-LRB-	_	22	p	_	_
20	20	0	CD	_	22	num	_	_
21	%	%	NN	_	20	meta	_	_
22	decrease	decrease	NN	_	18	prn	_	_
23	in	in	IN	_	24	case	_	_
24	binding	binding	NN	_	22	ppmod	_	_
25	)	-rrb-	-RRB-	_	22	p	_	_
26	,	,	,	_	18	p	_	_
27	drug3	drug0	NN	_	18	conj	_	_
28	,	,	,	_	27	p	_	_
29	drug4	drug0	NN	_	18	conj	_	_
30	(	-lrb-	-LRB-	_	33	p	_	_
31	10	0	CD	_	33	num	_	_
32	%	%	NN	_	31	meta	_	_
33	decrease	decrease	NN	_	29	prn	_	_
34	in	in	IN	_	35	case	_	_
35	binding	binding	NN	_	33	ppmod	_	_
36	)	-rrb-	-RRB-	_	33	p	_	_
37	,	,	,	_	29	p	_	_
38	or	or	CC	_	29	cc	_	_
39	drug5	drug0	NN	_	18	conj	_	_
40	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	19	dep	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	,	,	,	_	3	p	_	_
5	drug3	drug0	NN	_	1	conj	_	_
6	,	,	,	_	5	p	_	_
7	drug4	drug0	NN	_	1	conj	_	_
8	,	,	,	_	7	p	_	_
9	drug5	drug0	NN	_	1	conj	_	_
10	,	,	,	_	9	p	_	_
11	drug6	drug0	NN	_	1	conj	_	_
12	,	,	,	_	11	p	_	_
13	drug7	drug0	NN	_	1	conj	_	_
14	,	,	,	_	13	p	_	_
15	and	and	CC	_	13	cc	_	_
16	drug8	drug0	NN	_	1	conj	_	_
17	have	have	VBP	_	19	lv	_	_
18	no	no	DT	_	19	det	_	_
19	influence	influence	NN	_	0	root	_	_
20	in	in	FW	_	21	adv	_	_
21	vitro	vitro	FW	_	19	adv	_	_
22	on	on	IN	_	25	case	_	_
23	the	the	DT	_	25	det	_	_
24	protein	protein	NN	_	25	com	_	_
25	binding	binding	NN	_	19	ppmod	_	_
26	of	of	IN	_	27	case	_	_
27	drug9	drug0	NN	_	25	ppmod	_	_
28	in	in	IN	_	30	case	_	_
29	human	human	JJ	_	30	attr	_	_
30	serum	serum	NN	_	25	ppmod	_	_
31	.	.	.	_	19	p	_	_

1	Drug/Laboratory	drug/laboratory	NN	_	3	com	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	4	com	_	_
4	Effect	effect	NN	_	10	advcl	_	_
5	on	on	IN	_	7	case	_	_
6	Blood	blood	NN	_	7	com	_	_
7	Coagulation	coagulation	NN	_	4	ppmod	_	_
8	:	:	:	_	10	p	_	_
9	drug1	drug0	NN	_	10	dep	_	_
10	increases	increase	VBZ	_	0	root	_	_
11	platelet	platelet	NN	_	12	com	_	_
12	aggregation	aggregation	NN	_	13	com	_	_
13	time	time	NN	_	10	obj	_	_
14	but	but	CC	_	10	cc	_	_
15	does	do	VBZ	_	17	aux	_	_
16	not	not	RB	_	17	neg	_	_
17	affect	affect	VB	_	10	conj	_	_
18	bleeding	bleeding	JJ	_	19	attr	_	_
19	time	time	NN	_	17	obj	_	_
20	,	,	,	_	19	p	_	_
21	plasma	plasma	NN	_	24	com	_	_
22	thrombin	thrombin	NN	_	24	com	_	_
23	clotting	clotting	NN	_	24	com	_	_
24	time	time	NN	_	19	conj	_	_
25	,	,	,	_	24	p	_	_
26	plasma	plasma	NN	_	27	com	_	_
27	fibrinogen	fibrinogen	NN	_	19	conj	_	_
28	,	,	,	_	27	p	_	_
29	or	or	CC	_	27	cc	_	_
30	factors	factor	NNS	_	19	conj	_	_
31	V	v	CD	_	30	num	_	_
32	and	and	CC	_	31	cc	_	_
33	VII	vii	NN	_	31	conj	_	_
34	to	to	TO	_	35	aux	_	_
35	XII	xii	NN	_	30	ppmod	_	_
36	.	.	.	_	10	p	_	_

1	Statistically	statistically	RB	_	2	adv	_	_
2	significant	significant	JJ	_	3	attr	_	_
3	changes	change	NNS	_	12	dep	_	_
4	in	in	IN	_	9	case	_	_
5	prothrombin	prothrombin	JJ	_	9	attr	_	_
6	and	and	CC	_	5	cc	_	_
7	partial	partial	JJ	_	5	conj	_	_
8	thromboplastin	thromboplastin	NN	_	9	com	_	_
9	times	time	NNS	_	3	ppmod	_	_
10	have	have	VBP	_	12	aux	_	_
11	been	be	VBN	_	12	aux	_	_
12	reported	report	VBN	_	0	root	_	_
13	in	in	IN	_	15	case	_	_
14	normal	normal	JJ	_	15	attr	_	_
15	volunteers	volunteer	NNS	_	12	ppmod	_	_
16	.	.	.	_	12	p	_	_

1	The	the	DT	_	3	det	_	_
2	mean	mean	JJ	_	3	attr	_	_
3	changes	change	NNS	_	5	dep	_	_
4	were	be	VBD	_	5	aux	_	_
5	observed	observe	VBN	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	be	be	VB	_	5	comp	_	_
8	less	less	RBR	_	7	adv	_	_
9	than	than	IN	_	11	case	_	_
10	1	0	CD	_	11	com	_	_
11	second	#ord#	NN	_	8	ppmod	_	_
12	in	in	IN	_	14	case	_	_
13	both	both	DT	_	14	det	_	_
14	instances	instance	NNS	_	8	ppmod	_	_
15	,	,	,	_	8	p	_	_
16	however	however	RB	_	8	adv	_	_
17	,	,	,	_	5	p	_	_
18	and	and	CC	_	5	cc	_	_
19	are	be	VBP	_	5	conj	_	_
20	unlikely	unlikely	JJ	_	19	dep	_	_
21	to	to	TO	_	22	aux	_	_
22	be	be	VB	_	20	comp	_	_
23	clinically	clinically	RB	_	24	adv	_	_
24	important	important	JJ	_	22	dep	_	_
25	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	a	a	DT	_	6	det	_	_
4	prostaglandin	prostaglandin	NN	_	6	com	_	_
5	synthetase	synthetase	NN	_	6	com	_	_
6	inhibitor	inhibitor	NN	_	2	obj	_	_
7	,	,	,	_	6	p	_	_
8	however	however	RB	_	6	appo	_	_
9	,	,	,	_	2	p	_	_
10	and	and	CC	_	2	cc	_	_
11	all	all	DT	_	12	det	_	_
12	drugs	drug	NNS	_	17	dep	_	_
13	that	that	WDT	_	14	dep	_	_
14	inhibit	inhibit	VBP	_	12	relcl	_	_
15	prostaglandin	prostaglandin	NN	_	16	com	_	_
16	synthesis	synthesis	NN	_	14	obj	_	_
17	interfere	interfere	VBP	_	2	conj	_	_
18	with	with	IN	_	20	case	_	_
19	platelet	platelet	NN	_	20	com	_	_
20	function	function	NN	_	17	ppmod	_	_
21	to	to	TO	_	23	aux	_	_
22	some	some	DT	_	23	det	_	_
23	degree	degree	NN	_	17	ppmod	_	_
24	;	;	:	_	17	p	_	_

1	therefore	therefore	RB	_	16	adv	_	_
2	,	,	,	_	16	p	_	_
3	patients	patient	NNS	_	16	dep	_	_
4	who	who	WP	_	8	dep	_	_
5	may	may	MD	_	8	modal	_	_
6	be	be	VB	_	8	aux	_	_
7	adversely	adversely	RB	_	8	adv	_	_
8	affected	affect	VBN	_	3	relcl	_	_
9	by	by	IN	_	12	case	_	_
10	such	such	PDT	_	12	det	_	_
11	an	an	DT	_	12	det	_	_
12	action	action	NN	_	8	ppmod	_	_
13	should	should	MD	_	16	modal	_	_
14	be	be	VB	_	16	aux	_	_
15	carefully	carefully	RB	_	16	adv	_	_
16	observed	observe	VBN	_	0	root	_	_
17	.	.	.	_	16	p	_	_

1	Certain	certain	JJ	_	3	attr	_	_
2	other	other	JJ	_	3	attr	_	_
3	drug1	drug0	NNS	_	12	dep	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	drug2	drug0	NN	_	3	prn	_	_
6	and	and	CC	_	5	cc	_	_
7	drug3	drug0	NN	_	5	conj	_	_
8	)	-rrb-	-RRB-	_	5	p	_	_
9	have	have	VBP	_	12	aux	_	_
10	also	also	RB	_	12	adv	_	_
11	been	be	VBN	_	12	aux	_	_
12	reported	report	VBN	_	0	root	_	_
13	to	to	TO	_	14	aux	_	_
14	interfere	interfere	VB	_	12	comp	_	_
15	with	with	IN	_	18	case	_	_
16	the	the	DT	_	18	det	_	_
17	nerve	nerve	NN	_	18	com	_	_
18	transmission	transmission	NN	_	14	ppmod	_	_
19	at	at	IN	_	22	case	_	_
20	the	the	DT	_	22	det	_	_
21	neuromuscular	neuromuscular	JJ	_	22	attr	_	_
22	junction	junction	NN	_	14	ppmod	_	_
23	.	.	.	_	12	p	_	_

1	Based	base	VBN	_	5	adv	_	_
2	on	on	IN	_	5	case	_	_
3	this	this	DT	_	5	det	_	_
4	reported	report	VBN	_	5	attr	_	_
5	activity	activity	NN	_	11	ppmod	_	_
6	,	,	,	_	11	p	_	_
7	they	they	PRP	_	11	dep	_	_
8	should	should	MD	_	11	modal	_	_
9	not	not	RB	_	11	neg	_	_
10	be	be	VB	_	11	aux	_	_
11	given	give	VBN	_	0	root	_	_
12	concomitantly	concomitantly	RB	_	11	adv	_	_
13	with	with	IN	_	14	case	_	_
14	drug1	drug0	NN	_	11	ppmod	_	_
15	Parenteral	parenteral	JJ	_	14	attr	_	_
16	except	except	IN	_	20	case	_	_
17	with	with	IN	_	20	case	_	_
18	the	the	DT	_	20	det	_	_
19	greatest	great	JJS	_	20	attr	_	_
20	caution	caution	NN	_	11	ppmod	_	_
21	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	22	dep	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	eg	eg	NN	_	1	prn	_	_
4	,	,	,	_	3	p	_	_
5	drug2	drug0	NN	_	3	appo	_	_
6	)	-rrb-	-RRB-	_	3	p	_	_
7	and	and	CC	_	1	cc	_	_
8	other	other	JJ	_	9	attr	_	_
9	drugs	drug	NNS	_	1	conj	_	_
10	,	,	,	_	9	p	_	_
11	including	include	VBG	_	12	adv	_	_
12	ether	ether	NN	_	9	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	drug3	drug0	NN	_	12	conj	_	_
15	,	,	,	_	14	p	_	_
16	drug4	drug0	NN	_	12	conj	_	_
17	,	,	,	_	16	p	_	_
18	drug5	drug0	NN	_	12	conj	_	_
19	and	and	CC	_	18	cc	_	_
20	drug6	drug0	NN	_	12	conj	_	_
21	,	,	,	_	9	p	_	_
22	potentiate	potentiate	VB	_	0	root	_	_
23	the	the	DT	_	26	det	_	_
24	neuromuscular	neuromuscular	JJ	_	26	attr	_	_
25	blocking	blocking	NN	_	26	com	_	_
26	effect	effect	NN	_	22	obj	_	_
27	and	and	CC	_	22	cc	_	_
28	should	should	MD	_	30	modal	_	_
29	be	be	VB	_	30	aux	_	_
30	used	use	VBN	_	22	conj	_	_
31	with	with	IN	_	33	case	_	_
32	extreme	extreme	JJ	_	33	attr	_	_
33	caution	caution	NN	_	30	ppmod	_	_
34	in	in	IN	_	35	case	_	_
35	patients	patient	NNS	_	33	ppmod	_	_
36	being	be	VBG	_	37	aux	_	_
37	treated	treat	VBN	_	35	acl	_	_
38	with	with	IN	_	39	case	_	_
39	drug7	drug0	NN	_	37	ppmod	_	_
40	Parenteral	parenteral	JJ	_	39	attr	_	_
41	.	.	.	_	22	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	enhance	enhance	VB	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	nephrotoxicity	nephrotoxicity	NN	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	Parenteral	parenteral	JJ	_	7	attr	_	_
9	.	.	.	_	3	p	_	_

1	The	the	DT	_	3	det	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	use	use	NN	_	11	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	Parenteral	parenteral	JJ	_	7	attr	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	avoided	avoid	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	Antiacid	antiacid	NN	_	0	root	_	_
2	,	,	,	_	1	p	_	_
3	drug1	drug0	NN	_	1	appo	_	_
4	,	,	,	_	1	p	_	_
5	drug2	drug0	NN	_	1	appo	_	_
6	,	,	,	_	1	p	_	_
7	drug3	drug0	NN	_	1	appo	_	_
8	,	,	,	_	1	p	_	_
9	drug4	drug0	NN	_	1	appo	_	_
10	,	,	,	_	1	p	_	_
11	Indanavir	indanavir	NNP	_	25	attr	_	_
12	,	,	,	_	25	p	_	_
13	drug5	drug0	NN	_	25	attr	_	_
14	,	,	,	_	25	p	_	_
15	drug6	drug0	NN	_	25	attr	_	_
16	,	,	,	_	25	p	_	_
17	Phenobarbitol	phenobarbitol	NN	_	25	attr	_	_
18	,	,	,	_	25	p	_	_
19	drug7	drug0	NN	_	25	attr	_	_
20	,	,	,	_	25	p	_	_
21	drug8	drug0	NN	_	25	attr	_	_
22	,	,	,	_	25	p	_	_
23	drug9	drug0	NN	_	25	attr	_	_
24	,	,	,	_	25	p	_	_
25	Ritanovir	ritanovir	NNP	_	1	appo	_	_
26	,	,	,	_	1	p	_	_
27	drug10	drug0	NN	_	1	appo	_	_
28	.	.	.	_	1	p	_	_

1	Although	although	IN	_	5	mark	_	_
2	drug1	drug0	NN	_	5	dep	_	_
3	used	use	VBN	_	2	acl	_	_
4	alone	alone	RB	_	3	adv	_	_
5	has	have	VBZ	_	24	advcl	_	_
6	little	little	JJ	_	5	obj	_	_
7	or	or	CC	_	6	cc	_	_
8	no	no	DT	_	9	det	_	_
9	effect	effect	NN	_	6	conj	_	_
10	on	on	IN	_	12	case	_	_
11	pupil	pupil	NN	_	12	com	_	_
12	size	size	NN	_	9	ppmod	_	_
13	,	,	,	_	24	p	_	_
14	mydriasis	mydriasis	NNS	_	24	dep	_	_
15	resulting	result	VBG	_	14	acl	_	_
16	from	from	IN	_	18	case	_	_
17	concomitant	concomitant	JJ	_	18	attr	_	_
18	therapy	therapy	NN	_	15	ppmod	_	_
19	with	with	IN	_	20	case	_	_
20	drug2	drug0	NN	_	18	ppmod	_	_
21	and	and	CC	_	20	cc	_	_
22	drug3	drug0	NN	_	20	conj	_	_
23	may	may	MD	_	24	modal	_	_
24	occur	occur	VB	_	0	root	_	_
25	.	.	.	_	24	p	_	_

1	Close	close	JJ	_	2	attr	_	_
2	observation	observation	NN	_	7	dep	_	_
3	of	of	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	patient	patient	NN	_	2	ppmod	_	_
6	is	be	VBZ	_	7	aux	_	_
7	recommended	recommend	VBN	_	0	root	_	_
8	when	when	WRB	_	12	adv	_	_
9	a	a	DT	_	10	det	_	_
10	drug1	drug0	NN	_	12	dep	_	_
11	is	be	VBZ	_	12	aux	_	_
12	administered	administer	VBN	_	7	comp	_	_
13	to	to	TO	_	14	aux	_	_
14	patients	patient	NNS	_	12	ppmod	_	_
15	receiving	receive	VBG	_	14	acl	_	_
16	catecholamine-depleting	catecholamine-depleting	JJ	_	17	attr	_	_
17	drugs	drug	NNS	_	15	obj	_	_
18	such	such	JJ	_	20	adv	_	_
19	as	as	IN	_	20	case	_	_
20	drug2	drug0	NN	_	17	ppmod	_	_
21	,	,	,	_	17	p	_	_
22	because	because	IN	_	26	case	_	_
23	of	of	IN	_	26	case	_	_
24	possible	possible	JJ	_	26	attr	_	_
25	additive	additive	JJ	_	26	attr	_	_
26	effects	effect	NNS	_	17	ppmod	_	_
27	and	and	CC	_	26	cc	_	_
28	the	the	DT	_	29	det	_	_
29	production	production	NN	_	26	conj	_	_
30	of	of	IN	_	31	case	_	_
31	hypotension	hypotension	NN	_	29	ppmod	_	_
32	and/or	and/or	CC	_	31	cc	_	_
33	marked	marked	JJ	_	34	attr	_	_
34	bradycardia	bradycardia	NN	_	31	conj	_	_
35	,	,	,	_	17	p	_	_
36	which	which	WDT	_	38	dep	_	_
37	may	may	MD	_	38	modal	_	_
38	produce	produce	VB	_	17	relcl	_	_
39	vertigo	vertigo	NN	_	38	obj	_	_
40	,	,	,	_	39	p	_	_
41	syncope	syncope	NN	_	39	conj	_	_
42	or	or	CC	_	41	cc	_	_
43	postural	postural	JJ	_	44	attr	_	_
44	hypotension	hypotension	NN	_	39	conj	_	_
45	.	.	.	_	7	p	_	_

1	Patients	patient	NNS	_	13	dep	_	_
2	receiving	receive	VBG	_	1	acl	_	_
3	drug1	drug0	NN	_	2	obj	_	_
4	along	along	IN	_	10	case	_	_
5	with	with	IN	_	10	case	_	_
6	either	either	CC	_	7	cc	_	_
7	oral	oral	JJ	_	10	attr	_	_
8	or	or	CC	_	7	cc	_	_
9	intravenous	intravenous	JJ	_	7	conj	_	_
10	drug2	drug0	NNS	_	2	ppmod	_	_
11	should	should	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	monitored	monitor	VBN	_	0	root	_	_
14	for	for	IN	_	18	case	_	_
15	possible	possible	JJ	_	18	attr	_	_
16	atrioventricular	atrioventricular	JJ	_	18	attr	_	_
17	conduction	conduction	NN	_	18	com	_	_
18	disturbances	disturbance	NNS	_	13	ppmod	_	_
19	,	,	,	_	18	p	_	_
20	left	left	JJ	_	22	attr	_	_
21	ventricular	ventricular	JJ	_	22	attr	_	_
22	failure	failure	NN	_	18	conj	_	_
23	and	and	CC	_	22	cc	_	_
24	hypotension	hypotension	NN	_	18	conj	_	_
25	.	.	.	_	13	p	_	_

1	In	in	IN	_	2	case	_	_
2	patients	patient	NNS	_	12	ppmod	_	_
3	with	with	IN	_	6	case	_	_
4	impaired	impaired	JJ	_	6	attr	_	_
5	cardiac	cardiac	JJ	_	6	attr	_	_
6	function	function	NN	_	2	ppmod	_	_
7	,	,	,	_	12	p	_	_
8	simultaneous	simultaneous	JJ	_	9	attr	_	_
9	use	use	NN	_	12	dep	_	_
10	should	should	MD	_	12	modal	_	_
11	be	be	VB	_	12	aux	_	_
12	avoided	avoid	VBN	_	0	root	_	_
13	altogether	altogether	RB	_	12	adv	_	_
14	.	.	.	_	12	p	_	_

1	The	the	DT	_	3	det	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	use	use	NN	_	12	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	with	with	IN	_	10	case	_	_
7	drug2	drug0	NN	_	10	attr	_	_
8	and	and	CC	_	7	cc	_	_
9	drug3	drug0	NN	_	7	conj	_	_
10	s	s	NNS	_	3	ppmod	_	_
11	may	may	MD	_	12	modal	_	_
12	have	have	VB	_	0	root	_	_
13	additive	additive	JJ	_	14	attr	_	_
14	effects	effect	NNS	_	12	obj	_	_
15	on	on	IN	_	16	case	_	_
16	prolonging	prolong	VBG	_	12	ppmod	_	_
17	atrioventricular	atrioventricular	JJ	_	19	attr	_	_
18	conduction	conduction	NN	_	19	com	_	_
19	time	time	NN	_	16	obj	_	_
20	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	may	may	MD	_	5	modal	_	_
5	have	have	VB	_	0	root	_	_
6	additive	additive	JJ	_	8	attr	_	_
7	hypotensite	hypotensite	JJ	_	8	attr	_	_
8	effects	effect	NNS	_	5	obj	_	_
9	due	due	JJ	_	12	adv	_	_
10	to	to	TO	_	12	aux	_	_
11	the	the	DT	_	12	det	_	_
12	inhibition	inhibition	NN	_	5	ppmod	_	_
13	of	of	IN	_	17	case	_	_
14	each	each	DT	_	17	det	_	_
15	other	other	JJ	_	17	attr	_	_
16	s	s	NN	_	17	com	_	_
17	metabolism	metabolism	NN	_	12	ppmod	_	_
18	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	concurrent	concurrent	JJ	_	4	attr	_	_
4	use	use	NN	_	6	dep	_	_
5	may	may	MD	_	6	modal	_	_
6	blunt	blunt	VB	_	1	acl	_	_
7	the	the	DT	_	8	det	_	_
8	response	response	NN	_	6	obj	_	_
9	to	to	TO	_	10	aux	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	withdrawn	withdraw	VBN	_	0	root	_	_
5	at	at	IN	_	8	case	_	_
6	least	least	JJS	_	7	attr	_	_
7	48	0	CD	_	8	num	_	_
8	hours	hour	NNS	_	4	ppmod	_	_
9	before	before	IN	_	10	case	_	_
10	conducting	conduct	VBG	_	4	ppmod	_	_
11	an	an	DT	_	15	det	_	_
12	drug2	drug0	JJ	_	15	attr	_	_
13	-mediated	-mediated	JJ	_	15	attr	_	_
14	stress	stress	NN	_	15	com	_	_
15	test	test	NN	_	10	obj	_	_
16	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	(	-lrb-	-LRB-	_	5	p	_	_
3	such	such	JJ	_	4	com	_	_
4	as	as	IN	_	5	cc	_	_
5	drug2	drug0	NN	_	1	prn	_	_
6	,	,	,	_	5	p	_	_
7	drug3	drug0	NN	_	5	conj	_	_
8	,	,	,	_	7	p	_	_
9	or	or	CC	_	7	cc	_	_
10	drug4	drug0	NN	_	5	conj	_	_
11	)	-rrb-	-RRB-	_	5	p	_	_
12	:	:	:	_	1	p	_	_
13	concurrent	concurrent	JJ	_	14	attr	_	_
14	use	use	NN	_	18	dep	_	_
15	with	with	IN	_	16	case	_	_
16	drug5	drug0	NN	_	14	ppmod	_	_
17	may	may	MD	_	18	modal	_	_
18	have	have	VB	_	1	acl	_	_
19	a	a	DT	_	21	det	_	_
20	proarrhythmic	proarrhythmic	JJ	_	21	attr	_	_
21	effect	effect	NN	_	18	obj	_	_
22	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	drug2	drug0	NN	_	1	prn	_	_
4	)	-rrb-	-RRB-	_	3	p	_	_
5	,	,	,	_	1	p	_	_
6	drug3	drug0	JJ	_	9	attr	_	_
7	or	or	CC	_	6	cc	_	_
8	other	other	JJ	_	6	conj	_	_
9	drug4	drug0	NN	_	1	conj	_	_
10	,	,	,	_	9	p	_	_
11	or	or	CC	_	9	cc	_	_
12	drug5	drug0	NN	_	1	conj	_	_
13	:	:	:	_	1	p	_	_
14	concurrent	concurrent	JJ	_	15	attr	_	_
15	use	use	NN	_	19	dep	_	_
16	with	with	IN	_	17	case	_	_
17	drug6	drug0	NN	_	15	ppmod	_	_
18	may	may	MD	_	19	modal	_	_
19	produce	produce	VB	_	1	acl	_	_
20	additive	additive	JJ	_	24	attr	_	_
21	inotropic	inotropic	JJ	_	24	attr	_	_
22	and/or	and/or	CC	_	21	cc	_	_
23	chronotropic	chronotropic	JJ	_	21	conj	_	_
24	effects	effect	NNS	_	19	obj	_	_
25	.	.	.	_	1	p	_	_

1	Other	other	JJ	_	2	attr	_	_
2	drug1	drug0	NNS	_	14	dep	_	_
3	(	-lrb-	-LRB-	_	5	p	_	_
4	e.g.	e.g.	FW	_	5	adv	_	_
5	drug2	drug0	NN	_	2	prn	_	_
6	,	,	,	_	5	p	_	_
7	drug3	drug0	NN	_	5	conj	_	_
8	,	,	,	_	7	p	_	_
9	drug4	drug0	NN	_	5	conj	_	_
10	and	and	CC	_	9	cc	_	_
11	general	general	JJ	_	12	attr	_	_
12	drug5	drug0	NN	_	5	conj	_	_
13	)	-rrb-	-RRB-	_	5	p	_	_
14	have	have	VBP	_	0	root	_	_
15	additive	additive	JJ	_	18	attr	_	_
16	or	or	CC	_	18	cc	_	_
17	potentiating	potentiating	NN	_	18	com	_	_
18	effects	effect	NNS	_	14	obj	_	_
19	with	with	IN	_	20	case	_	_
20	drug6	drug0	NN	_	14	ppmod	_	_
21	.	.	.	_	14	p	_	_

1	When	when	WRB	_	4	adv	_	_
2	patients	patient	NNS	_	4	dep	_	_
3	have	have	VBP	_	4	aux	_	_
4	received	receive	VBN	_	14	advcl	_	_
5	such	such	JJ	_	6	attr	_	_
6	drugs	drug	NNS	_	4	obj	_	_
7	,	,	,	_	14	p	_	_
8	the	the	DT	_	9	det	_	_
9	dose	dose	NN	_	14	dep	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	required	require	VBN	_	11	acl	_	_
13	will	will	MD	_	14	modal	_	_
14	be	be	VB	_	0	root	_	_
15	less	less	JJR	_	14	dep	_	_
16	than	than	IN	_	17	case	_	_
17	usual	usual	JJ	_	15	ppmod	_	_
18	.	.	.	_	14	p	_	_

1	Following	follow	VBG	_	3	adv	_	_
2	the	the	DT	_	3	det	_	_
3	administration	administration	NN	_	14	ppmod	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	,	,	,	_	14	p	_	_
7	the	the	DT	_	8	det	_	_
8	dose	dose	NN	_	14	dep	_	_
9	of	of	IN	_	11	case	_	_
10	other	other	JJ	_	11	attr	_	_
11	drug2	drug0	NNS	_	8	ppmod	_	_
12	should	should	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	reduced	reduce	VBN	_	0	root	_	_
15	.	.	.	_	14	p	_	_

1	There	there	EX	_	2	dep	_	_
2	are	be	VBP	_	0	root	_	_
3	no	no	DT	_	6	det	_	_
4	known	known	JJ	_	6	attr	_	_
5	drug/drug	drug/drug	NN	_	6	com	_	_
6	interactions	interaction	NNS	_	2	obj	_	_
7	with	with	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	shown	show	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	have	have	VBP	_	4	comp	_	_
7	neuromuscular	neuromuscular	JJ	_	9	attr	_	_
8	blocking	blocking	NN	_	9	com	_	_
9	properties	property	NNS	_	6	obj	_	_
10	that	that	WDT	_	12	dep	_	_
11	may	may	MD	_	12	modal	_	_
12	enhance	enhance	VB	_	9	relcl	_	_
13	the	the	DT	_	14	det	_	_
14	action	action	NN	_	12	obj	_	_
15	of	of	IN	_	17	case	_	_
16	other	other	JJ	_	17	attr	_	_
17	drug2	drug0	NN	_	14	ppmod	_	_
18	.	.	.	_	4	p	_	_

1	Therefore	therefore	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	it	it	PRP	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	used	use	VBN	_	0	root	_	_
7	with	with	IN	_	8	case	_	_
8	caution	caution	NN	_	6	ppmod	_	_
9	in	in	IN	_	10	case	_	_
10	patients	patient	NNS	_	6	ppmod	_	_
11	receiving	receive	VBG	_	10	acl	_	_
12	such	such	JJ	_	13	attr	_	_
13	agents	agent	NNS	_	11	obj	_	_
14	.	.	.	_	6	p	_	_

1	Antagonism	antagonism	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	demonstrated	demonstrate	VBN	_	0	root	_	_
5	between	between	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	in	in	FW	_	10	adv	_	_
10	vitro	vitro	FW	_	4	adv	_	_
11	.	.	.	_	4	p	_	_

1	Because	because	IN	_	5	case	_	_
2	of	of	IN	_	5	case	_	_
3	possible	possible	JJ	_	5	attr	_	_
4	clinical	clinical	JJ	_	5	attr	_	_
5	significance	significance	NN	_	13	ppmod	_	_
6	,	,	,	_	13	p	_	_
7	these	these	DT	_	9	det	_	_
8	two	#crd#	CD	_	9	num	_	_
9	drugs	drug	NNS	_	13	dep	_	_
10	should	should	MD	_	13	modal	_	_
11	not	not	RB	_	13	neg	_	_
12	be	be	VB	_	13	aux	_	_
13	administered	administer	VBN	_	0	root	_	_
14	concurrently	concurrently	RB	_	13	adv	_	_
15	.	.	.	_	13	p	_	_

1	Interactions	interaction	NNS	_	0	root	_	_
2	with	with	IN	_	5	case	_	_
3	Other	other	JJ	_	5	attr	_	_
4	CNS	cns	NN	_	5	com	_	_
5	Agents	agent	NNS	_	1	ppmod	_	_
6	:	:	:	_	1	p	_	_
7	Concurrent	concurrent	JJ	_	8	attr	_	_
8	use	use	NN	_	42	dep	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	with	with	IN	_	13	case	_	_
12	all	all	DT	_	13	det	_	_
13	drug2	drug0	NN	_	8	ppmod	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	eg	eg	NN	_	13	prn	_	_
16	,	,	,	_	15	p	_	_
17	drug3	drug0	NN	_	15	conj	_	_
18	,	,	,	_	17	p	_	_
19	drug4	drug0	NN	_	15	conj	_	_
20	,	,	,	_	19	p	_	_
21	drug5	drug0	NN	_	15	conj	_	_
22	,	,	,	_	21	p	_	_
23	other	other	JJ	_	24	attr	_	_
24	drug6	drug0	NN	_	15	conj	_	_
25	,	,	,	_	24	p	_	_
26	general	general	JJ	_	27	attr	_	_
27	drug7	drug0	NN	_	15	conj	_	_
28	,	,	,	_	27	p	_	_
29	drug8	drug0	NN	_	15	conj	_	_
30	,	,	,	_	29	p	_	_
31	drug9	drug0	NN	_	15	conj	_	_
32	,	,	,	_	31	p	_	_
33	drug10	drug0	NN	_	15	conj	_	_
34	,	,	,	_	33	p	_	_
35	drug11	drug0	NN	_	15	conj	_	_
36	,	,	,	_	35	p	_	_
37	drug12	drug0	NN	_	15	conj	_	_
38	and	and	CC	_	37	cc	_	_
39	drug13	drug0	NN	_	15	conj	_	_
40	)	-rrb-	-RRB-	_	15	p	_	_
41	may	may	MD	_	42	modal	_	_
42	result	result	VB	_	1	acl	_	_
43	in	in	IN	_	49	case	_	_
44	additive	additive	JJ	_	49	attr	_	_
45	central	central	JJ	_	49	attr	_	_
46	nervous	nervous	JJ	_	49	attr	_	_
47	system	system	NN	_	49	com	_	_
48	depressant	depressant	NN	_	49	com	_	_
49	effects	effect	NNS	_	42	ppmod	_	_
50	.	.	.	_	1	p	_	_

1	Respiratory	respiratory	JJ	_	2	attr	_	_
2	depression	depression	NN	_	12	dep	_	_
3	,	,	,	_	2	p	_	_
4	hypotension	hypotension	NN	_	2	conj	_	_
5	,	,	,	_	4	p	_	_
6	and	and	CC	_	4	cc	_	_
7	profound	profound	JJ	_	8	attr	_	_
8	sedation	sedation	NN	_	2	conj	_	_
9	or	or	CC	_	8	cc	_	_
10	coma	coma	NN	_	8	conj	_	_
11	may	may	MD	_	12	modal	_	_
12	occur	occur	VB	_	0	root	_	_
13	.	.	.	_	12	p	_	_

1	When	when	WRB	_	6	adv	_	_
2	such	such	JJ	_	4	attr	_	_
3	combined	combined	JJ	_	4	attr	_	_
4	therapy	therapy	NN	_	6	dep	_	_
5	is	be	VBZ	_	6	aux	_	_
6	contemplated	contemplate	VBN	_	17	advcl	_	_
7	,	,	,	_	17	p	_	_
8	the	the	DT	_	9	det	_	_
9	dose	dose	NN	_	17	dep	_	_
10	of	of	IN	_	11	case	_	_
11	one	#crd#	CD	_	9	ppmod	_	_
12	or	or	CC	_	11	cc	_	_
13	both	both	DT	_	14	attr	_	_
14	agents	agent	NNS	_	11	conj	_	_
15	should	should	MD	_	17	modal	_	_
16	be	be	VB	_	17	aux	_	_
17	reduced	reduce	VBN	_	0	root	_	_
18	.	.	.	_	17	p	_	_

1	Although	although	IN	_	10	mark	_	_
2	no	no	DT	_	3	det	_	_
3	interaction	interaction	NN	_	10	dep	_	_
4	between	between	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	has	have	VBZ	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	observed	observe	VBN	_	15	advcl	_	_
11	,	,	,	_	15	p	_	_
12	it	it	PRP	_	15	dep	_	_
13	is	be	VBZ	_	15	aux	_	_
14	not	not	RB	_	15	neg	_	_
15	recommended	recommend	VBN	_	0	root	_	_
16	for	for	IN	_	17	case	_	_
17	use	use	NN	_	15	ppmod	_	_
18	with	with	IN	_	19	case	_	_
19	drug3	drug0	NN	_	17	ppmod	_	_
20	.	.	.	_	15	p	_	_

1	Most	most	JJS	_	2	attr	_	_
2	cases	case	NNS	_	19	dep	_	_
3	of	of	IN	_	8	case	_	_
4	serious	serious	JJ	_	8	attr	_	_
5	or	or	CC	_	8	cc	_	_
6	fatal	fatal	JJ	_	8	attr	_	_
7	adverse	adverse	JJ	_	8	attr	_	_
8	events	event	NNS	_	2	ppmod	_	_
9	involving	involve	VBG	_	8	acl	_	_
10	drug1	drug0	NN	_	9	obj	_	_
11	reported	report	VBN	_	10	acl	_	_
12	to	to	TO	_	14	aux	_	_
13	the	the	DT	_	14	det	_	_
14	manufacturer	manufacturer	NN	_	11	ppmod	_	_
15	or	or	CC	_	14	cc	_	_
16	the	the	DT	_	17	det	_	_
17	FDA	fda	NN	_	14	conj	_	_
18	have	have	VBP	_	19	aux	_	_
19	involved	involve	VBN	_	0	root	_	_
20	either	either	CC	_	22	cc	_	_
21	the	the	DT	_	22	det	_	_
22	administration	administration	NN	_	19	obj	_	_
23	of	of	IN	_	26	case	_	_
24	large	large	JJ	_	26	attr	_	_
25	initial	initial	JJ	_	26	attr	_	_
26	doses	dose	NNS	_	22	ppmod	_	_
27	or	or	CC	_	26	cc	_	_
28	too	too	RB	_	29	adv	_	_
29	frequent	frequent	JJ	_	30	attr	_	_
30	doses	dose	NNS	_	26	conj	_	_
31	of	of	IN	_	33	case	_	_
32	the	the	DT	_	33	det	_	_
33	drug	drug	NN	_	26	ppmod	_	_
34	to	to	TO	_	37	aux	_	_
35	nonopioid	nonopioid	JJ	_	37	attr	_	_
36	tolerant	tolerant	JJ	_	37	attr	_	_
37	patients	patient	NNS	_	22	ppmod	_	_
38	,	,	,	_	22	p	_	_
39	or	or	CC	_	22	cc	_	_
40	the	the	DT	_	42	det	_	_
41	simultaneous	simultaneous	JJ	_	42	attr	_	_
42	administration	administration	NN	_	22	conj	_	_
43	of	of	IN	_	44	case	_	_
44	drug2	drug0	NN	_	42	ppmod	_	_
45	with	with	IN	_	47	case	_	_
46	other	other	JJ	_	47	attr	_	_
47	drugs	drug	NNS	_	44	ppmod	_	_
48	affecting	affect	VBG	_	47	acl	_	_
49	respiration	respiration	NN	_	48	obj	_	_
50	.	.	.	_	19	p	_	_

1	The	the	DT	_	3	det	_	_
2	initial	initial	JJ	_	3	attr	_	_
3	dose	dose	NN	_	8	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	should	should	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	reduced	reduce	VBN	_	0	root	_	_
9	by	by	IN	_	11	case	_	_
10	approximately	approximately	RB	_	11	adv	_	_
11	50	0	CD	_	8	ppmod	_	_
12	%	%	NN	_	11	meta	_	_
13	or	or	CC	_	11	cc	_	_
14	more	more	JJR	_	11	conj	_	_
15	when	when	WRB	_	18	adv	_	_
16	it	it	PRP	_	18	dep	_	_
17	is	be	VBZ	_	18	aux	_	_
18	given	give	VBN	_	8	comp	_	_
19	to	to	TO	_	20	aux	_	_
20	patients	patient	NNS	_	18	ppmod	_	_
21	along	along	IN	_	24	case	_	_
22	with	with	IN	_	24	case	_	_
23	another	another	DT	_	24	det	_	_
24	drug	drug	NN	_	18	ppmod	_	_
25	affecting	affect	VBG	_	24	acl	_	_
26	respiration	respiration	NN	_	25	obj	_	_
27	.	.	.	_	8	p	_	_

1	Interactions	interaction	NNS	_	22	dep	_	_
2	with	with	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	:	:	:	_	1	p	_	_
5	drug2	drug0	NN	_	1	appo	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	eg	eg	NN	_	5	prn	_	_
8	,	,	,	_	7	p	_	_
9	drug3	drug0	NN	_	7	conj	_	_
10	,	,	,	_	9	p	_	_
11	drug4	drug0	NN	_	7	conj	_	_
12	,	,	,	_	11	p	_	_
13	drug5	drug0	NN	_	7	conj	_	_
14	,	,	,	_	13	p	_	_
15	drug6	drug0	NN	_	7	conj	_	_
16	and	and	CC	_	15	cc	_	_
17	drug7	drug0	NN	_	7	conj	_	_
18	)	-rrb-	-RRB-	_	7	p	_	_
19	should	should	MD	_	22	modal	_	_
20	NOT	not	RB	_	22	neg	_	_
21	be	be	VB	_	22	aux	_	_
22	administered	administer	VBN	_	0	root	_	_
23	to	to	TO	_	25	aux	_	_
24	a	a	DT	_	25	det	_	_
25	patient	patient	NN	_	22	ppmod	_	_
26	who	who	WP	_	28	dep	_	_
27	has	have	VBZ	_	28	aux	_	_
28	received	receive	VBN	_	25	relcl	_	_
29	or	or	CC	_	28	cc	_	_
30	is	be	VBZ	_	31	aux	_	_
31	receiving	receive	VBG	_	28	conj	_	_
32	a	a	DT	_	33	det	_	_
33	course	course	NN	_	31	obj	_	_
34	of	of	IN	_	35	case	_	_
35	therapy	therapy	NN	_	33	ppmod	_	_
36	with	with	IN	_	38	case	_	_
37	a	a	DT	_	38	det	_	_
38	drug8	drug0	NN	_	35	ppmod	_	_
39	such	such	JJ	_	41	adv	_	_
40	as	as	IN	_	41	case	_	_
41	drug9	drug0	NN	_	38	ppmod	_	_
42	.	.	.	_	22	p	_	_

1	In	in	IN	_	4	case	_	_
2	drug1	drug0	JJ	_	4	attr	_	_
3	-dependent	-dependent	JJ	_	4	attr	_	_
4	patients	patient	NNS	_	8	ppmod	_	_
5	,	,	,	_	8	p	_	_
6	drug2	drug0	NN	_	8	dep	_	_
7	may	may	MD	_	8	modal	_	_
8	precipitate	precipitate	VB	_	0	root	_	_
9	withdrawal	withdrawal	NN	_	10	com	_	_
10	symptoms	symptom	NNS	_	8	obj	_	_
11	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	10	dep	_	_
2	(	-lrb-	-LRB-	_	4	p	_	_
3	10	0	CD	_	4	num	_	_
4	mg	mg	NN	_	1	prn	_	_
5	once	once	RB	_	6	adv	_	_
6	daily	daily	JJ	_	4	attr	_	_
7	)	-rrb-	-RRB-	_	4	p	_	_
8	has	have	VBZ	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	coadministered	coadministered	VBN	_	0	root	_	_
11	with	with	IN	_	13	case	_	_
12	therapeutic	therapeutic	JJ	_	13	attr	_	_
13	doses	dose	NNS	_	10	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	,	,	,	_	15	p	_	_
17	drug3	drug0	NN	_	15	conj	_	_
18	,	,	,	_	17	p	_	_
19	and	and	CC	_	17	cc	_	_
20	drug4	drug0	NN	_	15	conj	_	_
21	in	in	IN	_	25	case	_	_
22	controlled	controlled	JJ	_	25	attr	_	_
23	clinical	clinical	JJ	_	25	attr	_	_
24	pharmacology	pharmacology	NN	_	25	com	_	_
25	studies	study	NNS	_	15	ppmod	_	_
26	in	in	IN	_	28	case	_	_
27	adult	adult	JJ	_	28	attr	_	_
28	volunteers	volunteer	NNS	_	25	ppmod	_	_
29	.	.	.	_	10	p	_	_

1	Although	although	IN	_	15	mark	_	_
2	increased	increase	VBN	_	4	attr	_	_
3	plasma	plasma	NN	_	4	com	_	_
4	concentrations	concentration	NNS	_	15	dep	_	_
5	(	-lrb-	-LRB-	_	8	p	_	_
6	AUC	auc	NN	_	8	attr	_	_
7	0-24	0	CD	_	8	num	_	_
8	hrs	hr	NNS	_	4	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	4	ppmod	_	_
12	and/or	and/or	CC	_	11	cc	_	_
13	drug2	drug0	NN	_	11	conj	_	_
14	were	be	VBD	_	15	aux	_	_
15	observed	observe	VBN	_	38	advcl	_	_
16	following	follow	VBG	_	17	adv	_	_
17	coadministration	coadministration	NN	_	15	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug3	drug0	NN	_	17	ppmod	_	_
20	with	with	IN	_	21	case	_	_
21	each	each	DT	_	19	ppmod	_	_
22	of	of	IN	_	24	case	_	_
23	these	these	DT	_	24	det	_	_
24	drugs	drug	NNS	_	21	ppmod	_	_
25	in	in	IN	_	27	case	_	_
26	normal	normal	JJ	_	27	attr	_	_
27	volunteers	volunteer	NNS	_	19	ppmod	_	_
28	(	-lrb-	-LRB-	_	29	p	_	_
29	n	n	NN	_	27	prn	_	_
30	=	=	JJ	_	29	attr	_	_
31	24	0	CD	_	29	num	_	_
32	in	in	IN	_	34	case	_	_
33	each	each	DT	_	34	det	_	_
34	study	study	NN	_	29	ppmod	_	_
35	)	-rrb-	-RRB-	_	29	p	_	_
36	,	,	,	_	38	p	_	_
37	there	there	EX	_	38	dep	_	_
38	were	be	VBD	_	0	root	_	_
39	no	no	DT	_	42	det	_	_
40	clinically	clinically	RB	_	41	adv	_	_
41	relevant	relevant	JJ	_	42	attr	_	_
42	changes	change	NNS	_	38	obj	_	_
43	in	in	IN	_	46	case	_	_
44	the	the	DT	_	46	det	_	_
45	safety	safety	NN	_	46	com	_	_
46	profile	profile	NN	_	38	ppmod	_	_
47	of	of	IN	_	48	case	_	_
48	drug4	drug0	NN	_	46	ppmod	_	_
49	,	,	,	_	38	p	_	_
50	as	as	IN	_	51	mark	_	_
51	assessed	assess	VBN	_	38	comp	_	_
52	by	by	IN	_	54	case	_	_
53	electrocardiographic	electrocardiographic	JJ	_	54	attr	_	_
54	parameters	parameter	NNS	_	51	ppmod	_	_
55	,	,	,	_	54	p	_	_
56	clinical	clinical	JJ	_	58	attr	_	_
57	laboratory	laboratory	NN	_	58	com	_	_
58	tests	test	NNS	_	54	conj	_	_
59	,	,	,	_	58	p	_	_
60	vital	vital	JJ	_	61	attr	_	_
61	signs	sign	NNS	_	54	conj	_	_
62	,	,	,	_	61	p	_	_
63	and	and	CC	_	61	cc	_	_
64	adverse	adverse	JJ	_	65	attr	_	_
65	events	event	NNS	_	54	conj	_	_
66	.	.	.	_	38	p	_	_

1	There	there	EX	_	2	dep	_	_
2	were	be	VBD	_	0	root	_	_
3	no	no	DT	_	5	det	_	_
4	significant	significant	JJ	_	5	attr	_	_
5	effects	effect	NNS	_	2	obj	_	_
6	on	on	IN	_	8	case	_	_
7	QTc	qtc	NN	_	8	com	_	_
8	intervals	interval	NNS	_	5	ppmod	_	_
9	,	,	,	_	5	p	_	_
10	and	and	CC	_	5	cc	_	_
11	no	no	DT	_	12	det	_	_
12	reports	report	NNS	_	5	conj	_	_
13	of	of	IN	_	14	case	_	_
14	sedation	sedation	NN	_	12	ppmod	_	_
15	or	or	CC	_	14	cc	_	_
16	syncope	syncope	NN	_	14	conj	_	_
17	.	.	.	_	2	p	_	_

1	No	no	DT	_	2	det	_	_
2	effects	effect	NNS	_	11	dep	_	_
3	on	on	IN	_	5	case	_	_
4	plasma	plasma	NN	_	5	com	_	_
5	concentrations	concentration	NNS	_	2	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	or	or	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	were	be	VBD	_	11	aux	_	_
11	observed	observe	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	Plasma	plasma	NN	_	2	com	_	_
2	concentrations	concentration	NNS	_	10	dep	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	AUC	auc	NN	_	6	attr	_	_
5	0-24	0	NN	_	6	num	_	_
6	hrs	hr	NNS	_	2	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	2	ppmod	_	_
10	decreased	decrease	VBD	_	0	root	_	_
11	15	0	CD	_	10	obj	_	_
12	%	%	NN	_	11	meta	_	_
13	with	with	IN	_	14	case	_	_
14	coadministration	coadministration	NN	_	10	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug2	drug0	NNS	_	14	ppmod	_	_
17	relative	relative	JJ	_	16	attr	_	_
18	to	to	TO	_	19	aux	_	_
19	that	that	DT	_	17	ppmod	_	_
20	observed	observe	VBN	_	19	acl	_	_
21	with	with	IN	_	22	case	_	_
22	drug3	drug0	NN	_	20	ppmod	_	_
23	alone	alone	RB	_	22	adv	_	_
24	.	.	.	_	10	p	_	_

1	The	the	DT	_	3	det	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	relevance	relevance	NN	_	7	dep	_	_
4	of	of	IN	_	6	case	_	_
5	this	this	DT	_	6	det	_	_
6	difference	difference	NN	_	3	ppmod	_	_
7	is	be	VBZ	_	0	root	_	_
8	unknown	unknown	JJ	_	7	dep	_	_
9	.	.	.	_	7	p	_	_

1	These	these	DT	_	3	det	_	_
2	above	above	JJ	_	3	attr	_	_
3	findings	finding	NNS	_	5	dep	_	_
4	are	be	VBP	_	5	aux	_	_
5	summarized	summarize	VBN	_	0	root	_	_
6	in	in	IN	_	7	case	_	_
7	TABLE	table	NN	_	5	ppmod	_	_
8	1	0	CD	_	7	num	_	_
9	.	.	.	_	5	p	_	_

1	TABLE	table	NN	_	3	attr	_	_
2	1	0	CD	_	3	num	_	_
3	Effects	effect	NNS	_	0	root	_	_
4	on	on	IN	_	6	case	_	_
5	Plasma	plasma	NN	_	6	com	_	_
6	Concentrations	concentration	NNS	_	3	ppmod	_	_
7	(	-lrb-	-LRB-	_	10	p	_	_
8	AUC	auc	NN	_	10	attr	_	_
9	0-24	0	NN	_	10	num	_	_
10	hrs	hr	NNS	_	6	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	6	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	drug2	drug0	NN	_	13	conj	_	_
16	After	after	IN	_	18	case	_	_
17	10	0	CD	_	18	num	_	_
18	Days	day	NNS	_	13	ppmod	_	_
19	of	of	IN	_	20	case	_	_
20	Coadministration	coadministration	NN	_	18	ppmod	_	_
21	(	-lrb-	-LRB-	_	24	p	_	_
22	drug3	drug0	NN	_	24	attr	_	_
23	10	0	CD	_	24	num	_	_
24	mg	mg	NN	_	20	prn	_	_
25	)	-rrb-	-RRB-	_	24	p	_	_
26	in	in	IN	_	28	case	_	_
27	Normal	normal	JJ	_	28	attr	_	_
28	Volunteers	volunteer	NNS	_	3	ppmod	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	drug2	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	(	-lrb-	-LRB-	_	5	p	_	_
3	500	0	CD	_	5	num	_	_
4	mg	mg	NN	_	5	com	_	_
5	q8h	q0h	NN	_	1	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	+	+	CC	_	1	cc	_	_
8	40	0	CD	_	10	num	_	_
9	%	%	NN	_	10	meta	_	_
10	+46	0	CD	_	1	conj	_	_
11	%	%	NN	_	10	meta	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	(	-lrb-	-LRB-	_	4	p	_	_
3	300	0	CD	_	4	num	_	_
4	mg	mg	NN	_	1	prn	_	_
5	qid	qid	JJ	_	4	attr	_	_
6	)	-rrb-	-RRB-	_	4	p	_	_
7	+103	0	CD	_	1	appo	_	_
8	%	%	NN	_	7	meta	_	_
9	+	+	CC	_	7	cc	_	_
10	6	0	CD	_	7	conj	_	_
11	%	%	NN	_	10	meta	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	(	-lrb-	-LRB-	_	4	p	_	_
3	200	0	CD	_	4	num	_	_
4	mg	mg	NN	_	1	prn	_	_
5	q12h	q0h	IN	_	4	case	_	_
6	)	-rrb-	-RRB-	_	4	p	_	_
7	+307	0	NN	_	1	appo	_	_
8	%	%	NN	_	7	meta	_	_
9	+73	0	CD	_	7	num	_	_
10	%	%	NN	_	7	meta	_	_

1	There	there	EX	_	4	dep	_	_
2	does	do	VBZ	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	appear	appear	VB	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	be	be	VB	_	4	comp	_	_
7	an	an	DT	_	8	det	_	_
8	increase	increase	NN	_	6	obj	_	_
9	in	in	IN	_	11	case	_	_
10	adverse	adverse	JJ	_	11	attr	_	_
11	events	event	NNS	_	8	ppmod	_	_
12	in	in	IN	_	13	case	_	_
13	subjects	subject	NNS	_	11	ppmod	_	_
14	who	who	WP	_	15	dep	_	_
15	received	receive	VBD	_	13	relcl	_	_
16	oral	oral	JJ	_	17	attr	_	_
17	drug1	drug0	NN	_	15	obj	_	_
18	and	and	CC	_	17	cc	_	_
19	drug2	drug0	NN	_	17	conj	_	_
20	.	.	.	_	4	p	_	_

1	No	no	DT	_	3	det	_	_
2	drug	drug	NN	_	3	com	_	_
3	interactions	interaction	NNS	_	6	dep	_	_
4	have	have	VBP	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	reported	report	VBN	_	0	root	_	_
7	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	known	know	VBN	_	1	acl	_	_
6	to	to	TO	_	7	aux	_	_
7	interact	interact	VB	_	5	comp	_	_
8	with	with	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	metabolism	metabolism	NN	_	7	ppmod	_	_
11	or	or	CC	_	10	cc	_	_
12	renal	renal	JJ	_	14	attr	_	_
13	tubular	tubular	JJ	_	14	attr	_	_
14	excretion	excretion	NN	_	10	conj	_	_
15	of	of	IN	_	17	case	_	_
16	many	many	JJ	_	17	attr	_	_
17	drugs	drug	NNS	_	10	ppmod	_	_
18	(	-lrb-	-LRB-	_	21	p	_	_
19	e.g.	e.g.	FW	_	21	adv	_	_
20	,	,	,	_	21	p	_	_
21	drug3	drug0	NN	_	17	prn	_	_
22	,	,	,	_	21	p	_	_
23	drug4	drug0	NN	_	21	conj	_	_
24	,	,	,	_	23	p	_	_
25	drug5	drug0	NN	_	21	conj	_	_
26	,	,	,	_	25	p	_	_
27	drug6	drug0	NN	_	21	conj	_	_
28	,	,	,	_	27	p	_	_
29	drug7	drug0	NN	_	21	conj	_	_
30	,	,	,	_	29	p	_	_
31	drug8	drug0	NN	_	21	conj	_	_
32	,	,	,	_	31	p	_	_
33	drug9	drug0	NN	_	21	conj	_	_
34	,	,	,	_	33	p	_	_
35	drug10	drug0	NN	_	21	conj	_	_
36	,	,	,	_	35	p	_	_
37	drug11	drug0	CD	_	43	num	_	_
38	,	,	,	_	43	p	_	_
39	drug12	drug0	CD	_	43	num	_	_
40	,	,	,	_	43	p	_	_
41	drug13	drug0	CD	_	43	num	_	_
42	,	,	,	_	43	p	_	_
43	drug14	drug0	CD	_	44	num	_	_
44	agents	agent	NNS	_	21	conj	_	_
45	,	,	,	_	44	p	_	_
46	drug15	drug0	NN	_	21	conj	_	_
47	,	,	,	_	46	p	_	_
48	and	and	CC	_	46	cc	_	_
49	drug16	drug0	NN	_	21	conj	_	_
50	)	-rrb-	-RRB-	_	21	p	_	_
51	.	.	.	_	1	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	medications	medication	NNS	_	6	dep	_	_
3	should	should	MD	_	6	modal	_	_
4	be	be	VB	_	6	aux	_	_
5	carefully	carefully	RB	_	6	adv	_	_
6	assessed	assess	VBN	_	0	root	_	_
7	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	should	should	MD	_	6	modal	_	_
3	either	either	RB	_	6	adv	_	_
4	be	be	VB	_	6	aux	_	_
5	temporarily	temporarily	RB	_	6	adv	_	_
6	discontinued	discontinue	VBN	_	0	root	_	_
7	or	or	CC	_	6	cc	_	_
8	decreased	decrease	VBD	_	6	conj	_	_
9	by	by	IN	_	10	case	_	_
10	50	0	CD	_	8	ppmod	_	_
11	%	%	NN	_	10	meta	_	_
12	when	when	WRB	_	13	adv	_	_
13	coadministered	coadministered	VBN	_	8	comp	_	_
14	with	with	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	on	on	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	day	day	NN	_	13	ppmod	_	_
19	of	of	IN	_	21	case	_	_
20	drug3	drug0	NN	_	21	com	_	_
21	infusion	infusion	NN	_	18	ppmod	_	_
22	.	.	.	_	6	p	_	_

1	Nephrotoxic	nephrotoxic	JJ	_	2	attr	_	_
2	agents	agent	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	Concomitant	concomitant	JJ	_	5	attr	_	_
5	administration	administration	NN	_	41	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	agents	agent	NNS	_	7	conj	_	_
10	with	with	IN	_	13	case	_	_
11	nephrotoxic	nephrotoxic	JJ	_	13	attr	_	_
12	potential	potential	JJ	_	13	attr	_	_
13	-LSB-e.g.	-lsb-e.g.	NN	_	5	ppmod	_	_
14	,	,	,	_	13	p	_	_
15	intravenous	intravenous	JJ	_	16	attr	_	_
16	drug2	drug0	NN	_	13	conj	_	_
17	(	-lrb-	-LRB-	_	20	p	_	_
18	e.g.	e.g.	FW	_	20	adv	_	_
19	,	,	,	_	20	p	_	_
20	drug3	drug0	NN	_	16	prn	_	_
21	,	,	,	_	20	p	_	_
22	drug4	drug0	NN	_	20	conj	_	_
23	,	,	,	_	22	p	_	_
24	and	and	CC	_	22	cc	_	_
25	drug5	drug0	NN	_	20	conj	_	_
26	)	-rrb-	-RRB-	_	20	p	_	_
27	,	,	,	_	16	p	_	_
28	drug6	drug0	NN	_	13	conj	_	_
29	,	,	,	_	28	p	_	_
30	drug7	drug0	NN	_	13	conj	_	_
31	,	,	,	_	30	p	_	_
32	intravenous	intravenous	JJ	_	33	attr	_	_
33	drug8	drug0	NN	_	13	conj	_	_
34	,	,	,	_	33	p	_	_
35	drug9	drug0	NN	_	13	conj	_	_
36	,	,	,	_	35	p	_	_
37	and	and	CC	_	35	cc	_	_
38	drug10	drug0	NN	_	13	conj	_	_
39	]	-rsb-	-RRB-	_	38	p	_	_
40	is	be	VBZ	_	41	aux	_	_
41	contraindicated	contraindicate	VBN	_	2	acl	_	_
42	.	.	.	_	2	p	_	_

1	Such	such	JJ	_	2	attr	_	_
2	agents	agent	NNS	_	5	dep	_	_
3	must	must	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	discontinued	discontinue	VBN	_	0	root	_	_
6	at	at	IN	_	8	case	_	_
7	least	least	JJS	_	8	attr	_	_
8	seven	#crd#	CD	_	9	num	_	_
9	days	day	NNS	_	5	obj	_	_
10	prior	prior	JJ	_	9	attr	_	_
11	to	to	TO	_	12	aux	_	_
12	starting	start	VBG	_	10	ppmod	_	_
13	therapy	therapy	NN	_	12	obj	_	_
14	with	with	IN	_	15	case	_	_
15	drug1	drug0	NN	_	12	ppmod	_	_
16	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	7	dep	_	_
2	,	,	,	_	1	p	_	_
3	a	a	DT	_	4	det	_	_
4	drug2	drug0	NN	_	1	appo	_	_
5	,	,	,	_	1	p	_	_
6	may	may	MD	_	7	modal	_	_
7	antagonize	antagonize	VB	_	0	root	_	_
8	the	the	DT	_	10	det	_	_
9	bactericidal	bactericidal	JJ	_	10	attr	_	_
10	effect	effect	NN	_	7	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	and	and	CC	_	7	cc	_	_
14	concurrent	concurrent	JJ	_	15	attr	_	_
15	use	use	NN	_	21	dep	_	_
16	of	of	IN	_	18	case	_	_
17	these	these	DT	_	18	det	_	_
18	drugs	drug	NNS	_	15	ppmod	_	_
19	should	should	MD	_	21	modal	_	_
20	be	be	VB	_	21	aux	_	_
21	avoided	avoid	VBN	_	7	conj	_	_
22	.	.	.	_	7	p	_	_

1	The	the	DT	_	3	det	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	use	use	NN	_	10	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	or	or	CC	_	5	cc	_	_
7	other	other	JJ	_	8	attr	_	_
8	drug2	drug0	NNS	_	5	conj	_	_
9	may	may	MD	_	10	modal	_	_
10	have	have	VB	_	0	root	_	_
11	an	an	DT	_	13	det	_	_
12	additive	additive	JJ	_	13	attr	_	_
13	effect	effect	NN	_	10	obj	_	_
14	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	There	there	EX	_	4	dep	_	_
4	is	be	VBZ	_	1	acl	_	_
5	no	no	DT	_	8	det	_	_
6	significant	significant	JJ	_	8	attr	_	_
7	pharmacokinetic	pharmacokinetic	JJ	_	8	attr	_	_
8	interaction	interaction	NN	_	4	obj	_	_
9	between	between	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug3	drug0	NN	_	10	conj	_	_
13	which	which	WDT	_	16	dep	_	_
14	has	have	VBZ	_	16	aux	_	_
15	been	be	VBN	_	16	aux	_	_
16	confirmed	confirm	VBN	_	8	relcl	_	_
17	clinically	clinically	RB	_	16	adv	_	_
18	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	also	also	RB	_	3	adv	_	_
3	has	have	VBZ	_	0	root	_	_
4	no	no	DT	_	6	det	_	_
5	significant	significant	JJ	_	6	attr	_	_
6	effect	effect	NN	_	3	obj	_	_
7	on	on	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	intracellular	intracellular	JJ	_	10	attr	_	_
10	phosphorylation	phosphorylation	NN	_	3	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	,	,	,	_	3	p	_	_
14	as	as	IN	_	15	mark	_	_
15	shown	show	VBN	_	3	comp	_	_
16	in	in	FW	_	17	adv	_	_
17	vitro	vitro	FW	_	15	adv	_	_
18	in	in	IN	_	22	case	_	_
19	peripheral	peripheral	JJ	_	22	attr	_	_
20	blood	blood	NN	_	22	attr	_	_
21	mononuclear	mononuclear	JJ	_	22	attr	_	_
22	cells	cell	NNS	_	15	ppmod	_	_
23	or	or	CC	_	22	cc	_	_
24	in	in	IN	_	28	case	_	_
25	two	#crd#	CD	_	28	num	_	_
26	other	other	JJ	_	28	attr	_	_
27	cell	cell	NN	_	28	com	_	_
28	lines	line	NNS	_	22	conj	_	_
29	(	-lrb-	-LRB-	_	30	p	_	_
30	U937	u0	NN	_	28	prn	_	_
31	and	and	CC	_	30	cc	_	_
32	Molt-4	molt-0	NN	_	30	conj	_	_
33	)	-rrb-	-RRB-	_	30	p	_	_
34	.	.	.	_	3	p	_	_

1	In	in	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	same	same	JJ	_	4	attr	_	_
4	study	study	NN	_	7	ppmod	_	_
5	it	it	PRP	_	7	dep	_	_
6	was	be	VBD	_	7	aux	_	_
7	shown	show	VBN	_	0	root	_	_
8	that	that	IN	_	12	mark	_	_
9	drug1	drug0	NN	_	12	dep	_	_
10	and	and	CC	_	9	cc	_	_
11	drug2	drug0	NN	_	9	conj	_	_
12	had	have	VBD	_	7	comp	_	_
13	no	no	DT	_	15	det	_	_
14	significant	significant	JJ	_	15	attr	_	_
15	effect	effect	NN	_	12	obj	_	_
16	on	on	IN	_	19	case	_	_
17	the	the	DT	_	19	det	_	_
18	intracellular	intracellular	JJ	_	19	attr	_	_
19	phosphorylation	phosphorylation	NN	_	12	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	drug3	drug0	NN	_	19	ppmod	_	_
22	in	in	IN	_	26	case	_	_
23	peripheral	peripheral	JJ	_	26	attr	_	_
24	blood	blood	NN	_	26	attr	_	_
25	mononuclear	mononuclear	JJ	_	26	attr	_	_
26	cells	cell	NNS	_	19	ppmod	_	_
27	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	FW	_	4	adv	_	_
4	vitro	vitro	FW	_	5	attr	_	_
5	studies	study	NNS	_	16	dep	_	_
6	in	in	IN	_	10	case	_	_
7	peripheral	peripheral	JJ	_	10	attr	_	_
8	blood	blood	NN	_	10	attr	_	_
9	mononuclear	mononuclear	JJ	_	10	attr	_	_
10	cells	cell	NNS	_	5	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	U937	u0	NN	_	10	conj	_	_
13	and	and	CC	_	12	cc	_	_
14	Molt-4	molt-0	NN	_	15	com	_	_
15	cells	cell	NNS	_	10	conj	_	_
16	revealed	reveal	VBD	_	1	acl	_	_
17	that	that	IN	_	20	mark	_	_
18	drug2	drug0	NN	_	20	dep	_	_
19	significantly	significantly	RB	_	20	adv	_	_
20	inhibited	inhibit	VBD	_	16	comp	_	_
21	drug3	drug0	NN	_	22	com	_	_
22	phosphorylation	phosphorylation	NN	_	20	obj	_	_
23	in	in	IN	_	27	case	_	_
24	a	a	DT	_	27	det	_	_
25	dose	dose	NN	_	26	advnp	_	_
26	dependent	dependent	JJ	_	27	attr	_	_
27	manner	manner	NN	_	20	ppmod	_	_
28	.	.	.	_	1	p	_	_

1	Effects	effect	NNS	_	4	dep	_	_
2	were	be	VBD	_	4	aux	_	_
3	already	already	RB	_	4	adv	_	_
4	seen	see	VBN	_	0	root	_	_
5	with	with	IN	_	6	case	_	_
6	doses	dose	NNS	_	4	ppmod	_	_
7	corresponding	correspond	VBG	_	6	acl	_	_
8	to	to	TO	_	11	aux	_	_
9	relevant	relevant	JJ	_	11	attr	_	_
10	plasma	plasma	NN	_	11	com	_	_
11	levels	level	NNS	_	7	ppmod	_	_
12	in	in	IN	_	13	case	_	_
13	humans	human	NNS	_	11	ppmod	_	_
14	,	,	,	_	4	p	_	_
15	and	and	CC	_	4	cc	_	_
16	the	the	DT	_	18	det	_	_
17	intracellular	intracellular	JJ	_	18	attr	_	_
18	phosphorylation	phosphorylation	NN	_	35	dep	_	_
19	of	of	IN	_	20	case	_	_
20	drug1	drug0	NN	_	18	ppmod	_	_
21	to	to	TO	_	24	aux	_	_
22	its	its	PRP$	_	24	poss	_	_
23	three	#crd#	CD	_	24	num	_	_
24	metabolites	metabolite	NNS	_	18	ppmod	_	_
25	(	-lrb-	-LRB-	_	26	p	_	_
26	including	include	VBG	_	24	prn	_	_
27	the	the	DT	_	31	det	_	_
28	active	active	JJ	_	31	attr	_	_
29	zalcitabine	zalcitabine	NN	_	31	com	_	_
30	triphosphate	triphosphate	NN	_	31	com	_	_
31	metabolite	metabolite	NN	_	26	obj	_	_
32	)	-rrb-	-RRB-	_	26	p	_	_
33	was	be	VBD	_	35	aux	_	_
34	significantly	significantly	RB	_	35	adv	_	_
35	inhibited	inhibit	VBN	_	4	conj	_	_
36	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	inhibited	inhibit	VBD	_	0	root	_	_
3	drug2	drug0	NN	_	4	com	_	_
4	phosphorylation	phosphorylation	NN	_	2	obj	_	_
5	at	at	IN	_	8	case	_	_
6	high	high	JJ	_	8	attr	_	_
7	concentration	concentration	NN	_	8	com	_	_
8	ratios	ratio	NNS	_	2	ppmod	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	10	0	CD	_	2	num	_	_
11	and	and	CC	_	10	cc	_	_
12	100	0	CD	_	10	conj	_	_
13	)	-rrb-	-RRB-	_	10	p	_	_
14	;	;	:	_	2	p	_	_

1	however	however	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	it	it	PRP	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	considered	consider	VBN	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	be	be	VB	_	5	comp	_	_
8	unlikely	unlikely	JJ	_	7	dep	_	_
9	that	that	IN	_	16	mark	_	_
10	this	this	DT	_	11	det	_	_
11	decrease	decrease	NN	_	16	dep	_	_
12	of	of	IN	_	15	case	_	_
13	phosphorylated	phosphorylated	VBN	_	15	attr	_	_
14	drug1	drug0	NN	_	15	com	_	_
15	concentration	concentration	NN	_	11	ppmod	_	_
16	is	be	VBZ	_	8	comp	_	_
17	of	of	IN	_	19	case	_	_
18	clinical	clinical	JJ	_	19	attr	_	_
19	significance	significance	NN	_	16	ppmod	_	_
20	,	,	,	_	16	p	_	_
21	as	as	IN	_	23	mark	_	_
22	drug2	drug0	NN	_	23	dep	_	_
23	is	be	VBZ	_	16	comp	_	_
24	a	a	DT	_	27	det	_	_
25	more	more	RBR	_	26	adv	_	_
26	efficient	efficient	JJ	_	27	attr	_	_
27	substrate	substrate	NN	_	23	obj	_	_
28	for	for	IN	_	30	case	_	_
29	deoxycytidine	deoxycytidine	NN	_	30	com	_	_
30	kinase	kinase	NN	_	27	ppmod	_	_
31	than	than	IN	_	32	case	_	_
32	drug3	drug0	NN	_	27	ppmod	_	_
33	.	.	.	_	5	p	_	_

1	These	these	DT	_	4	det	_	_
2	in	in	FW	_	3	adv	_	_
3	vitro	vitro	FW	_	4	attr	_	_
4	studies	study	NNS	_	5	dep	_	_
5	suggest	suggest	VBP	_	0	root	_	_
6	that	that	IN	_	16	mark	_	_
7	concomitant	concomitant	JJ	_	8	attr	_	_
8	administration	administration	NN	_	16	dep	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug2	drug0	NN	_	10	conj	_	_
13	in	in	IN	_	14	case	_	_
14	humans	human	NNS	_	8	ppmod	_	_
15	may	may	MD	_	16	modal	_	_
16	result	result	VB	_	5	comp	_	_
17	in	in	IN	_	19	case	_	_
18	sub-therapeutic	sub-therapeutic	JJ	_	19	attr	_	_
19	concentrations	concentration	NNS	_	16	ppmod	_	_
20	of	of	IN	_	23	case	_	_
21	active	active	JJ	_	23	attr	_	_
22	phosphorylated	phosphorylated	JJ	_	23	attr	_	_
23	drug3	drug0	NN	_	19	ppmod	_	_
24	,	,	,	_	23	p	_	_
25	which	which	WDT	_	27	dep	_	_
26	may	may	MD	_	27	modal	_	_
27	lead	lead	VB	_	23	relcl	_	_
28	to	to	TO	_	32	aux	_	_
29	a	a	DT	_	32	det	_	_
30	decreased	decrease	VBN	_	32	attr	_	_
31	drug4	drug0	NN	_	32	com	_	_
32	effect	effect	NN	_	27	ppmod	_	_
33	of	of	IN	_	34	case	_	_
34	drug5	drug0	NN	_	32	ppmod	_	_
35	.	.	.	_	5	p	_	_

1	It	it	PRP	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	unknown	unknown	JJ	_	2	dep	_	_
4	how	how	WRB	_	13	adv	_	_
5	the	the	DT	_	6	det	_	_
6	effect	effect	NN	_	13	dep	_	_
7	seen	see	VBN	_	6	acl	_	_
8	in	in	IN	_	12	case	_	_
9	these	these	DT	_	12	det	_	_
10	in	in	FW	_	11	adv	_	_
11	vitro	vitro	FW	_	12	attr	_	_
12	studies	study	NNS	_	7	ppmod	_	_
13	translates	translate	VBZ	_	2	comp	_	_
14	into	into	IN	_	16	case	_	_
15	clinical	clinical	JJ	_	16	attr	_	_
16	consequences	consequence	NNS	_	13	ppmod	_	_
17	.	.	.	_	2	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	use	use	NN	_	9	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	is	be	VBZ	_	9	aux	_	_
8	not	not	RB	_	9	neg	_	_
9	recommended	recommend	VBN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	combination	combination	NN	_	14	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	,	,	,	_	6	p	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	,	,	,	_	8	p	_	_
10	and	and	CC	_	8	cc	_	_
11	drug4	drug0	NN	_	6	conj	_	_
12	has	have	VBZ	_	14	aux	_	_
13	been	be	VBN	_	14	aux	_	_
14	studied	study	VBN	_	1	acl	_	_
15	(	-lrb-	-LRB-	_	18	p	_	_
16	as	as	IN	_	18	case	_	_
17	triple	triple	JJ	_	18	attr	_	_
18	combination	combination	NN	_	14	prn	_	_
19	)	-rrb-	-RRB-	_	18	p	_	_
20	in	in	IN	_	21	case	_	_
21	adults	adult	NNS	_	14	ppmod	_	_
22	.	.	.	_	1	p	_	_

1	Pharmacokinetic	pharmacokinetic	JJ	_	2	attr	_	_
2	data	datum	NNS	_	3	dep	_	_
3	suggest	suggest	VBP	_	0	root	_	_
4	that	that	IN	_	16	mark	_	_
5	absorption	absorption	NN	_	16	dep	_	_
6	,	,	,	_	5	p	_	_
7	metabolism	metabolism	NN	_	5	conj	_	_
8	,	,	,	_	7	p	_	_
9	and	and	CC	_	7	cc	_	_
10	elimination	elimination	NN	_	5	conj	_	_
11	of	of	IN	_	12	case	_	_
12	each	each	DT	_	5	ppmod	_	_
13	of	of	IN	_	15	case	_	_
14	these	these	DT	_	15	det	_	_
15	drugs	drug	NNS	_	12	ppmod	_	_
16	are	be	VBP	_	3	comp	_	_
17	unchanged	unchanged	JJ	_	16	dep	_	_
18	when	when	WRB	_	21	adv	_	_
19	they	they	PRP	_	21	dep	_	_
20	are	be	VBP	_	21	aux	_	_
21	used	use	VBN	_	16	comp	_	_
22	together	together	RB	_	21	adv	_	_
23	.	.	.	_	3	p	_	_

1	Drugs	drug	NNS	_	0	root	_	_
2	Associated	associate	VBN	_	1	acl	_	_
3	With	with	IN	_	5	case	_	_
4	Peripheral	peripheral	JJ	_	5	attr	_	_
5	Neuropathy	neuropathy	NN	_	2	ppmod	_	_
6	:	:	:	_	1	p	_	_
7	The	the	DT	_	9	det	_	_
8	concomitant	concomitant	JJ	_	9	attr	_	_
9	use	use	NN	_	24	dep	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	with	with	IN	_	13	case	_	_
13	drugs	drug	NNS	_	9	ppmod	_	_
14	that	that	WDT	_	15	dep	_	_
15	have	have	VBP	_	13	relcl	_	_
16	the	the	DT	_	17	det	_	_
17	potential	potential	NN	_	15	obj	_	_
18	to	to	TO	_	19	aux	_	_
19	cause	cause	VB	_	17	acl	_	_
20	peripheral	peripheral	JJ	_	21	attr	_	_
21	neuropathy	neuropathy	NN	_	19	obj	_	_
22	should	should	MD	_	24	modal	_	_
23	be	be	VB	_	24	aux	_	_
24	avoided	avoid	VBN	_	1	acl	_	_
25	where	where	WRB	_	26	adv	_	_
26	possible	possible	JJ	_	24	comp	_	_
27	.	.	.	_	1	p	_	_

1	Drugs	drug	NNS	_	0	root	_	_
2	that	that	WDT	_	5	dep	_	_
3	have	have	VBP	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	associated	associate	VBN	_	1	relcl	_	_
6	with	with	IN	_	8	case	_	_
7	peripheral	peripheral	JJ	_	8	attr	_	_
8	neuropathy	neuropathy	NN	_	5	ppmod	_	_
9	include	include	VBP	_	5	comp	_	_
10	drug1	drug0	NN	_	9	obj	_	_
11	,	,	,	_	10	p	_	_
12	drug2	drug0	NN	_	10	appo	_	_
13	,	,	,	_	12	p	_	_
14	drug3	drug0	NN	_	12	conj	_	_
15	,	,	,	_	14	p	_	_
16	drug4	drug0	NN	_	12	conj	_	_
17	,	,	,	_	16	p	_	_
18	drug5	drug0	NN	_	12	conj	_	_
19	,	,	,	_	18	p	_	_
20	drug6	drug0	NN	_	12	conj	_	_
21	,	,	,	_	20	p	_	_
22	drug7	drug0	NN	_	12	conj	_	_
23	,	,	,	_	22	p	_	_
24	drug8	drug0	NN	_	12	conj	_	_
25	,	,	,	_	24	p	_	_
26	drug9	drug0	NN	_	12	conj	_	_
27	,	,	,	_	26	p	_	_
28	drug10	drug0	NN	_	12	conj	_	_
29	,	,	,	_	28	p	_	_
30	drug11	drug0	NN	_	12	conj	_	_
31	,	,	,	_	30	p	_	_
32	drug12	drug0	NN	_	12	conj	_	_
33	,	,	,	_	32	p	_	_
34	drug13	drug0	NN	_	12	conj	_	_
35	,	,	,	_	34	p	_	_
36	drug14	drug0	NN	_	12	conj	_	_
37	,	,	,	_	36	p	_	_
38	drug15	drug0	NN	_	12	conj	_	_
39	,	,	,	_	38	p	_	_
40	and	and	CC	_	38	cc	_	_
41	drug16	drug0	NN	_	12	conj	_	_
42	.	.	.	_	1	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	use	use	NN	_	9	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	with	with	IN	_	6	case	_	_
6	drug2	drug0	NN	_	2	ppmod	_	_
7	is	be	VBZ	_	9	aux	_	_
8	not	not	RB	_	9	neg	_	_
9	recommended	recommend	VBN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	Intravenous	intravenous	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	Treatment	treatment	NN	_	9	dep	_	_
5	with	with	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	should	should	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	interrupted	interrupt	VBN	_	2	acl	_	_
10	when	when	WRB	_	24	adv	_	_
11	the	the	DT	_	12	det	_	_
12	use	use	NN	_	24	dep	_	_
13	of	of	IN	_	15	case	_	_
14	a	a	DT	_	15	det	_	_
15	drug	drug	NN	_	12	ppmod	_	_
16	that	that	WDT	_	17	dep	_	_
17	has	have	VBZ	_	15	relcl	_	_
18	the	the	DT	_	19	det	_	_
19	potential	potential	NN	_	17	obj	_	_
20	to	to	TO	_	21	aux	_	_
21	cause	cause	VB	_	19	acl	_	_
22	pancreatitis	pancreatitis	NN	_	21	obj	_	_
23	is	be	VBZ	_	24	aux	_	_
24	required	require	VBN	_	9	comp	_	_
25	.	.	.	_	2	p	_	_

1	Death	death	NN	_	15	dep	_	_
2	due	due	IN	_	5	case	_	_
3	to	to	TO	_	5	aux	_	_
4	fulminant	fulminant	JJ	_	5	attr	_	_
5	pancreatitis	pancreatitis	NN	_	1	ppmod	_	_
6	possibly	possibly	RB	_	7	adv	_	_
7	related	related	JJ	_	1	attr	_	_
8	to	to	TO	_	10	aux	_	_
9	intravenous	intravenous	JJ	_	10	attr	_	_
10	drug1	drug0	NN	_	7	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug2	drug0	NN	_	10	conj	_	_
13	has	have	VBZ	_	15	aux	_	_
14	been	be	VBN	_	15	aux	_	_
15	reported	report	VBN	_	0	root	_	_
16	.	.	.	_	15	p	_	_

1	If	if	IN	_	5	mark	_	_
2	intravenous	intravenous	JJ	_	3	attr	_	_
3	drug1	drug0	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	required	require	VBN	_	17	advcl	_	_
6	to	to	TO	_	7	aux	_	_
7	treat	treat	VB	_	5	comp	_	_
8	Pneumocystis	pneumocystis	NN	_	10	com	_	_
9	carinii	carinii	NN	_	10	com	_	_
10	pneumonia	pneumonia	NNS	_	7	obj	_	_
11	,	,	,	_	17	p	_	_
12	treatment	treatment	NN	_	17	dep	_	_
13	with	with	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	should	should	MD	_	17	modal	_	_
16	be	be	VB	_	17	aux	_	_
17	interrupted	interrupt	VBN	_	0	root	_	_
18	.	.	.	_	17	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	,	,	,	_	3	p	_	_
5	and	and	CC	_	3	cc	_	_
6	drug3	drug0	NN	_	1	conj	_	_
7	:	:	:	_	1	p	_	_
8	Drugs	drug	NNS	_	18	dep	_	_
9	such	such	JJ	_	11	adv	_	_
10	as	as	IN	_	11	case	_	_
11	drug4	drug0	NN	_	8	ppmod	_	_
12	,	,	,	_	11	p	_	_
13	drug5	drug0	NN	_	11	conj	_	_
14	,	,	,	_	13	p	_	_
15	and	and	CC	_	13	cc	_	_
16	drug6	drug0	NN	_	11	conj	_	_
17	may	may	MD	_	18	modal	_	_
18	increase	increase	VB	_	1	acl	_	_
19	the	the	DT	_	20	det	_	_
20	risk	risk	NN	_	18	obj	_	_
21	of	of	IN	_	22	case	_	_
22	developing	develop	VBG	_	20	ppmod	_	_
23	peripheral	peripheral	JJ	_	24	attr	_	_
24	neuropathy	neuropathy	NN	_	30	attr	_	_
25	or	or	CC	_	24	cc	_	_
26	other	other	JJ	_	27	attr	_	_
27	drug7	drug0	NN	_	24	conj	_	_
28	-associated	-associated	JJ	_	30	attr	_	_
29	adverse	adverse	JJ	_	30	attr	_	_
30	events	event	NNS	_	22	obj	_	_
31	by	by	IN	_	32	case	_	_
32	interfering	interfere	VBG	_	22	ppmod	_	_
33	with	with	IN	_	36	case	_	_
34	the	the	DT	_	36	det	_	_
35	renal	renal	JJ	_	36	attr	_	_
36	clearance	clearance	NN	_	32	ppmod	_	_
37	of	of	IN	_	38	case	_	_
38	drug8	drug0	NN	_	36	ppmod	_	_
39	(	-lrb-	-LRB-	_	41	p	_	_
40	thereby	thereby	RB	_	41	adv	_	_
41	raising	raise	VBG	_	36	prn	_	_
42	systemic	systemic	JJ	_	43	attr	_	_
43	exposure	exposure	NN	_	41	obj	_	_
44	)	-rrb-	-RRB-	_	41	p	_	_
45	.	.	.	_	1	p	_	_

1	Patients	patient	NNS	_	19	dep	_	_
2	who	who	WP	_	3	dep	_	_
3	require	require	VBP	_	1	relcl	_	_
4	the	the	DT	_	5	det	_	_
5	use	use	NN	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	one	#crd#	CD	_	5	ppmod	_	_
8	of	of	IN	_	10	case	_	_
9	these	these	DT	_	10	det	_	_
10	drugs	drug	NNS	_	7	ppmod	_	_
11	with	with	IN	_	12	case	_	_
12	drug1	drug0	NN	_	5	ppmod	_	_
13	should	should	MD	_	19	modal	_	_
14	have	have	VBP	_	19	lv	_	_
15	frequent	frequent	JJ	_	19	attr	_	_
16	clinical	clinical	JJ	_	19	attr	_	_
17	and	and	CC	_	16	cc	_	_
18	laboratory	laboratory	JJ	_	16	conj	_	_
19	monitoring	monitoring	NN	_	0	root	_	_
20	with	with	IN	_	22	case	_	_
21	dosage	dosage	JJ	_	22	attr	_	_
22	adjustment	adjustment	NN	_	19	ppmod	_	_
23	for	for	IN	_	26	case	_	_
24	any	any	DT	_	26	det	_	_
25	significant	significant	JJ	_	26	attr	_	_
26	change	change	NN	_	22	ppmod	_	_
27	in	in	IN	_	29	case	_	_
28	renal	renal	JJ	_	29	attr	_	_
29	function	function	NN	_	26	ppmod	_	_
30	.	.	.	_	19	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	or	or	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	:	:	:	_	1	p	_	_
5	Concomitant	concomitant	JJ	_	6	attr	_	_
6	administration	administration	NN	_	11	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug3	drug0	NN	_	6	ppmod	_	_
9	or	or	CC	_	8	cc	_	_
10	drug4	drug0	NN	_	8	conj	_	_
11	decreases	decrease	VBZ	_	1	acl	_	_
12	the	the	DT	_	13	det	_	_
13	elimination	elimination	NN	_	11	obj	_	_
14	of	of	IN	_	15	case	_	_
15	drug5	drug0	NN	_	13	ppmod	_	_
16	,	,	,	_	11	p	_	_
17	most	most	RBS	_	18	com	_	_
18	likely	likely	RB	_	20	adv	_	_
19	by	by	IN	_	20	case	_	_
20	inhibition	inhibition	NN	_	11	ppmod	_	_
21	of	of	IN	_	24	case	_	_
22	renal	renal	JJ	_	24	attr	_	_
23	tubular	tubular	JJ	_	24	attr	_	_
24	secretion	secretion	NN	_	20	ppmod	_	_
25	of	of	IN	_	26	case	_	_
26	drug6	drug0	NN	_	24	ppmod	_	_
27	.	.	.	_	1	p	_	_

1	Patients	patient	NNS	_	11	dep	_	_
2	receiving	receive	VBG	_	1	acl	_	_
3	these	these	DT	_	4	det	_	_
4	drugs	drug	NNS	_	2	obj	_	_
5	in	in	IN	_	6	case	_	_
6	combination	combination	NN	_	2	ppmod	_	_
7	with	with	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	monitored	monitor	VBN	_	0	root	_	_
12	for	for	IN	_	13	case	_	_
13	signs	sign	NNS	_	11	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	toxicity	toxicity	NN	_	13	ppmod	_	_
16	and	and	CC	_	11	cc	_	_
17	the	the	DT	_	18	det	_	_
18	dose	dose	NN	_	21	dep	_	_
19	of	of	IN	_	20	case	_	_
20	drug2	drug0	NN	_	18	ppmod	_	_
21	reduced	reduce	VBD	_	11	conj	_	_
22	if	if	IN	_	23	mark	_	_
23	warranted	warrant	VBN	_	21	comp	_	_
24	.	.	.	_	21	p	_	_

1	drug1	drug0	NN	_	12	dep	_	_
2	/	/	:	_	1	p	_	_
3	drug2	drug0	NN	_	5	attr	_	_
4	-containing	-containing	JJ	_	5	attr	_	_
5	drug3	drug0	NN	_	1	appo	_	_
6	:	:	:	_	1	p	_	_
7	Absorption	absorption	NN	_	1	appo	_	_
8	of	of	IN	_	9	case	_	_
9	drug4	drug0	NN	_	7	ppmod	_	_
10	is	be	VBZ	_	12	aux	_	_
11	moderately	moderately	RB	_	12	adv	_	_
12	reduced	reduce	VBN	_	0	root	_	_
13	(	-lrb-	-LRB-	_	15	p	_	_
14	approximately	approximately	RB	_	15	adv	_	_
15	25	0	CD	_	12	num	_	_
16	%	%	NN	_	15	meta	_	_
17	)	-rrb-	-RRB-	_	15	p	_	_
18	when	when	WRB	_	19	adv	_	_
19	coadministered	coadministered	VBN	_	12	comp	_	_
20	with	with	IN	_	25	case	_	_
21	drug5	drug0	NN	_	25	attr	_	_
22	/	/	:	_	25	p	_	_
23	drug6	drug0	NN	_	25	attr	_	_
24	-containing	-containing	JJ	_	25	attr	_	_
25	drug7	drug0	NN	_	19	ppmod	_	_
26	.	.	.	_	12	p	_	_

1	The	the	DT	_	3	det	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	significance	significance	NN	_	9	dep	_	_
4	of	of	IN	_	6	case	_	_
5	this	this	DT	_	6	det	_	_
6	reduction	reduction	NN	_	3	ppmod	_	_
7	is	be	VBZ	_	9	aux	_	_
8	not	not	RB	_	9	neg	_	_
9	known	know	VBN	_	15	advcl	_	_
10	,	,	,	_	15	p	_	_
11	hence	hence	RB	_	15	adv	_	_
12	drug1	drug0	NN	_	15	dep	_	_
13	is	be	VBZ	_	15	aux	_	_
14	not	not	RB	_	15	neg	_	_
15	recommended	recommend	VBN	_	0	root	_	_
16	to	to	TO	_	18	aux	_	_
17	be	be	VB	_	18	aux	_	_
18	ingested	ingest	VBN	_	15	comp	_	_
19	simultaneously	simultaneously	RB	_	18	adv	_	_
20	with	with	IN	_	25	case	_	_
21	drug2	drug0	NN	_	25	attr	_	_
22	/	/	:	_	25	p	_	_
23	drug3	drug0	NN	_	25	attr	_	_
24	-containing	-containing	JJ	_	25	attr	_	_
25	drug4	drug0	NN	_	18	ppmod	_	_
26	.	.	.	_	15	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	:	:	:	_	1	p	_	_
3	Bioavailability	bioavailability	NN	_	1	appo	_	_
4	is	be	VBZ	_	6	aux	_	_
5	mildly	mildly	RB	_	6	adv	_	_
6	reduced	reduce	VBN	_	0	root	_	_
7	(	-lrb-	-LRB-	_	9	p	_	_
8	approximately	approximately	RB	_	9	adv	_	_
9	10	0	CD	_	6	num	_	_
10	%	%	NN	_	9	meta	_	_
11	)	-rrb-	-RRB-	_	9	p	_	_
12	when	when	WRB	_	17	adv	_	_
13	drug2	drug0	NN	_	17	dep	_	_
14	and	and	CC	_	13	cc	_	_
15	drug3	drug0	NN	_	13	conj	_	_
16	are	be	VBP	_	17	aux	_	_
17	coadministered	coadministered	VBN	_	6	comp	_	_
18	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	4	dep	_	_
4	caused	cause	VBD	_	1	acl	_	_
5	a	a	DT	_	6	det	_	_
6	decrease	decrease	NN	_	4	obj	_	_
7	in	in	IN	_	9	case	_	_
8	drug3	drug0	NN	_	9	com	_	_
9	phosphorylation	phosphorylation	NN	_	6	ppmod	_	_
10	(	-lrb-	-LRB-	_	6	p	_	_
11	50	0	CD	_	13	num	_	_
12	%	%	NN	_	11	meta	_	_
13	inhibition	inhibition	NN	_	6	appo	_	_
14	of	of	IN	_	17	case	_	_
15	total	total	JJ	_	17	attr	_	_
16	phosphate	phosphate	NN	_	17	com	_	_
17	formation	formation	NN	_	13	ppmod	_	_
18	)	-rrb-	-RRB-	_	6	p	_	_
19	in	in	IN	_	22	case	_	_
20	U937/Molt	u0/molt	NN	_	22	attr	_	_
21	4	0	CD	_	22	num	_	_
22	cells	cell	NNS	_	4	ppmod	_	_
23	.	.	.	_	1	p	_	_

1	Although	although	IN	_	4	mark	_	_
2	there	there	EX	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	be	be	VB	_	25	advcl	_	_
5	decreased	decrease	VBN	_	7	attr	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	activity	activity	NN	_	4	obj	_	_
8	because	because	IN	_	13	case	_	_
9	of	of	IN	_	13	case	_	_
10	lessened	lessened	JJ	_	13	attr	_	_
11	active	active	JJ	_	13	attr	_	_
12	metabolite	metabolite	NN	_	13	com	_	_
13	formation	formation	NN	_	4	ppmod	_	_
14	,	,	,	_	25	p	_	_
15	the	the	DT	_	17	det	_	_
16	clinical	clinical	JJ	_	17	attr	_	_
17	relevance	relevance	NN	_	25	dep	_	_
18	of	of	IN	_	22	case	_	_
19	these	these	DT	_	22	det	_	_
20	in	in	FW	_	21	adv	_	_
21	vitro	vitro	FW	_	22	attr	_	_
22	results	result	NNS	_	17	ppmod	_	_
23	are	be	VBP	_	25	aux	_	_
24	not	not	RB	_	25	neg	_	_
25	known	know	VBN	_	0	root	_	_
26	.	.	.	_	25	p	_	_

1	No	no	DT	_	2	det	_	_
2	Information	information	NN	_	0	root	_	_
3	Provided	provided	VBN	_	2	acl	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	add	add	VBP	_	0	root	_	_
4	to	to	TO	_	3	ppmod	_	_
5	or	or	CC	_	3	cc	_	_
6	potentiate	potentiate	VB	_	3	conj	_	_
7	the	the	DT	_	8	det	_	_
8	action	action	NN	_	6	obj	_	_
9	of	of	IN	_	11	case	_	_
10	other	other	JJ	_	11	attr	_	_
11	drug2	drug0	NNS	_	8	ppmod	_	_
12	.	.	.	_	3	p	_	_

1	Potentiation	potentiation	NN	_	2	dep	_	_
2	occurs	occur	VBZ	_	0	root	_	_
3	with	with	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	.	.	.	_	2	p	_	_

1	Medication	medication	NN	_	7	dep	_	_
2	such	such	JJ	_	4	adv	_	_
3	as	as	IN	_	4	case	_	_
4	drug1	drug0	NN	_	1	ppmod	_	_
5	may	may	MD	_	7	modal	_	_
6	also	also	RB	_	7	adv	_	_
7	influence	influence	VB	_	0	root	_	_
8	serum	serum	NN	_	9	com	_	_
9	electrolytes	electrolyte	NNS	_	7	obj	_	_
10	.	.	.	_	7	p	_	_

1	Warning	warning	JJ	_	2	attr	_	_
2	signs	sign	NNS	_	8	dep	_	_
3	,	,	,	_	2	p	_	_
4	irrespective	irrespective	JJ	_	2	attr	_	_
5	of	of	IN	_	6	case	_	_
6	cause	cause	NN	_	4	ppmod	_	_
7	,	,	,	_	2	p	_	_
8	are	be	VBP	_	0	root	_	_
9	:	:	:	_	8	p	_	_
10	dryness	dryness	NN	_	8	obj	_	_
11	of	of	IN	_	12	case	_	_
12	mouth	mouth	NN	_	10	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	thirst	thirst	NN	_	12	conj	_	_
15	,	,	,	_	14	p	_	_
16	weakness	weakness	NN	_	12	conj	_	_
17	,	,	,	_	16	p	_	_
18	lethargy	lethargy	NN	_	12	conj	_	_
19	,	,	,	_	18	p	_	_
20	drowsiness	drowsiness	NN	_	12	conj	_	_
21	,	,	,	_	20	p	_	_
22	restlessness	restlessness	NN	_	12	conj	_	_
23	,	,	,	_	22	p	_	_
24	muscle	muscle	NN	_	25	com	_	_
25	pains	pain	NNS	_	12	conj	_	_
26	or	or	CC	_	25	cc	_	_
27	cramps	cramps	NN	_	12	conj	_	_
28	,	,	,	_	10	p	_	_
29	muscular	muscular	JJ	_	30	attr	_	_
30	fatigue	fatigue	NN	_	10	conj	_	_
31	,	,	,	_	30	p	_	_
32	hypotension	hypotension	NN	_	10	conj	_	_
33	,	,	,	_	32	p	_	_
34	oliguria	oliguria	NN	_	10	conj	_	_
35	,	,	,	_	34	p	_	_
36	tachycardia	tachycardia	NN	_	10	conj	_	_
37	,	,	,	_	36	p	_	_
38	and	and	CC	_	36	cc	_	_
39	gastrointestinal	gastrointestinal	JJ	_	40	attr	_	_
40	disturbances	disturbance	NNS	_	10	conj	_	_
41	such	such	JJ	_	43	adv	_	_
42	as	as	IN	_	43	case	_	_
43	nausea	nausea	NN	_	10	ppmod	_	_
44	and	and	CC	_	43	cc	_	_
45	vomiting	vomiting	NN	_	43	conj	_	_
46	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	requirements	requirement	NNS	_	7	dep	_	_
3	in	in	IN	_	5	case	_	_
4	diabetic	diabetic	JJ	_	5	attr	_	_
5	patients	patient	NNS	_	2	ppmod	_	_
6	may	may	MD	_	7	modal	_	_
7	be	be	VB	_	0	root	_	_
8	increased	increase	VBN	_	7	dep	_	_
9	,	,	,	_	8	p	_	_
10	decreased	decrease	VBN	_	8	conj	_	_
11	,	,	,	_	10	p	_	_
12	or	or	CC	_	10	cc	_	_
13	unchanged	unchanged	JJ	_	8	conj	_	_
14	.	.	.	_	7	p	_	_

1	Higher	high	JJR	_	2	attr	_	_
2	dosage	dosage	NN	_	8	dep	_	_
3	of	of	IN	_	5	case	_	_
4	oral	oral	JJ	_	5	attr	_	_
5	drug1	drug0	NN	_	2	ppmod	_	_
6	may	may	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	required	require	VBN	_	0	root	_	_
9	.	.	.	_	8	p	_	_

1	Latent	latent	JJ	_	3	attr	_	_
2	diabetes	diabetes	NN	_	3	com	_	_
3	mellitus	mellitus	NN	_	6	dep	_	_
4	may	may	MD	_	6	modal	_	_
5	become	become	VB	_	6	aux	_	_
6	manifest	manifest	VBP	_	0	root	_	_
7	during	during	IN	_	9	case	_	_
8	drug1	drug0	NN	_	9	com	_	_
9	administration	administration	NN	_	6	ppmod	_	_
10	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	related	related	JJ	_	4	attr	_	_
4	drugs	drug	NNS	_	1	conj	_	_
5	may	may	MD	_	6	modal	_	_
6	increase	increase	VB	_	0	root	_	_
7	the	the	DT	_	8	det	_	_
8	responsiveness	responsiveness	NN	_	6	obj	_	_
9	to	to	TO	_	10	aux	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	related	related	JJ	_	4	attr	_	_
4	drugs	drug	NNS	_	1	conj	_	_
5	may	may	MD	_	6	modal	_	_
6	decrease	decrease	VB	_	0	root	_	_
7	arterial	arterial	JJ	_	8	attr	_	_
8	responsiveness	responsiveness	NN	_	6	obj	_	_
9	to	to	TO	_	10	aux	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	6	p	_	_

1	This	this	DT	_	2	det	_	_
2	diminution	diminution	NN	_	3	dep	_	_
3	is	be	VBZ	_	0	root	_	_
4	not	not	RB	_	3	neg	_	_
5	sufficient	sufficient	JJ	_	3	dep	_	_
6	to	to	TO	_	7	aux	_	_
7	preclude	preclude	VB	_	5	comp	_	_
8	effectiveness	effectiveness	NN	_	7	obj	_	_
9	of	of	IN	_	12	case	_	_
10	the	the	DT	_	12	det	_	_
11	pressor	pressor	JJ	_	12	attr	_	_
12	agent	agent	NN	_	8	ppmod	_	_
13	for	for	IN	_	15	case	_	_
14	therapeutic	therapeutic	JJ	_	15	attr	_	_
15	use	use	NN	_	12	ppmod	_	_
16	.	.	.	_	3	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	studies	study	NNS	_	5	dep	_	_
4	have	have	VBP	_	5	aux	_	_
5	shown	show	VBN	_	0	root	_	_
6	drug1	drug0	NN	_	8	dep	_	_
7	can	can	MD	_	8	modal	_	_
8	displace	displace	VB	_	5	comp	_	_
9	drug2	drug0	NN	_	10	com	_	_
10	s	s	NNS	_	8	obj	_	_
11	,	,	,	_	8	p	_	_
12	such	such	JJ	_	14	adv	_	_
13	as	as	IN	_	14	case	_	_
14	drug3	drug0	NN	_	8	ppmod	_	_
15	,	,	,	_	8	p	_	_
16	from	from	IN	_	19	case	_	_
17	their	their	PRP$	_	19	poss	_	_
18	protein-binding	protein-binding	JJ	_	19	attr	_	_
19	sites	site	NNS	_	8	ppmod	_	_
20	.	.	.	_	5	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	recommended	recommend	VBN	_	0	root	_	_
4	that	that	IN	_	20	mark	_	_
5	if	if	IN	_	8	mark	_	_
6	drug1	drug0	NN	_	8	dep	_	_
7	is	be	VBZ	_	8	aux	_	_
8	started	start	VBN	_	20	advcl	_	_
9	in	in	IN	_	10	case	_	_
10	patients	patient	NNS	_	8	ppmod	_	_
11	already	already	RB	_	12	adv	_	_
12	receiving	receive	VBG	_	10	acl	_	_
13	drug2	drug0	NN	_	12	obj	_	_
14	,	,	,	_	20	p	_	_
15	prothrombin	prothrombin	NN	_	16	com	_	_
16	times	time	NNS	_	20	dep	_	_
17	should	should	MD	_	20	modal	_	_
18	be	be	VB	_	20	aux	_	_
19	closely	closely	RB	_	20	adv	_	_
20	monitored	monitor	VBN	_	3	comp	_	_
21	and	and	CC	_	20	cc	_	_
22	adjustment	adjustment	NN	_	28	dep	_	_
23	of	of	IN	_	26	case	_	_
24	the	the	DT	_	26	det	_	_
25	drug3	drug0	NN	_	26	com	_	_
26	dose	dose	NN	_	22	ppmod	_	_
27	may	may	MD	_	28	modal	_	_
28	be	be	VB	_	20	conj	_	_
29	necessary	necessary	JJ	_	28	dep	_	_
30	.	.	.	_	3	p	_	_

1	Prior	prior	JJ	_	2	attr	_	_
2	administration	administration	NN	_	5	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	has	have	VBZ	_	0	root	_	_
6	no	no	DT	_	9	det	_	_
7	clinically	clinically	RB	_	8	adv	_	_
8	important	important	JJ	_	9	attr	_	_
9	effect	effect	NN	_	5	obj	_	_
10	on	on	IN	_	14	case	_	_
11	the	the	DT	_	14	det	_	_
12	neuromuscular	neuromuscular	JJ	_	14	attr	_	_
13	blocking	blocking	NN	_	14	com	_	_
14	action	action	NN	_	5	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	.	.	.	_	5	p	_	_

1	The	the	DT	_	2	det	_	_
2	use	use	NN	_	19	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	before	before	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	to	to	TO	_	8	aux	_	_
8	attenuate	attenuate	VB	_	2	acl	_	_
9	some	some	DT	_	8	obj	_	_
10	of	of	IN	_	13	case	_	_
11	the	the	DT	_	13	det	_	_
12	side	side	JJ	_	13	attr	_	_
13	effects	effect	NNS	_	9	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug3	drug0	NNS	_	13	ppmod	_	_
16	has	have	VBZ	_	19	aux	_	_
17	not	not	RB	_	19	neg	_	_
18	been	be	VBN	_	19	aux	_	_
19	studied	study	VBN	_	0	root	_	_
20	.	.	.	_	19	p	_	_

1	There	there	EX	_	2	dep	_	_
2	are	be	VBP	_	0	root	_	_
3	no	no	DT	_	5	det	_	_
4	clinical	clinical	JJ	_	5	attr	_	_
5	data	datum	NNS	_	2	obj	_	_
6	on	on	IN	_	8	case	_	_
7	concomitant	concomitant	JJ	_	8	attr	_	_
8	use	use	NN	_	5	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	other	other	JJ	_	14	attr	_	_
13	nondepolarizing	nondepolarizing	JJ	_	14	attr	_	_
14	drug2	drug0	NNS	_	10	conj	_	_
15	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	7	dep	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	,	,	,	_	3	p	_	_
5	and	and	CC	_	3	cc	_	_
6	drug3	drug0	NN	_	1	conj	_	_
7	decrease	decrease	VBP	_	0	root	_	_
8	the	the	DT	_	9	det	_	_
9	ED50	ed0	NN	_	7	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug4	drug0	NN	_	9	ppmod	_	_
12	by	by	IN	_	16	case	_	_
13	30	0	CD	_	16	num	_	_
14	%	%	NN	_	16	meta	_	_
15	to	to	TO	_	16	attr	_	_
16	45	0	CD	_	7	ppmod	_	_
17	%	%	NN	_	16	meta	_	_
18	.	.	.	_	7	p	_	_

1	These	these	DT	_	2	det	_	_
2	agents	agent	NNS	_	5	dep	_	_
3	may	may	MD	_	5	modal	_	_
4	also	also	RB	_	5	adv	_	_
5	prolong	prolong	VB	_	0	root	_	_
6	the	the	DT	_	9	det	_	_
7	clinically	clinically	RB	_	8	adv	_	_
8	effective	effective	JJ	_	9	attr	_	_
9	duration	duration	NN	_	5	obj	_	_
10	of	of	IN	_	11	case	_	_
11	action	action	NN	_	9	ppmod	_	_
12	by	by	IN	_	15	case	_	_
13	up	up	RB	_	15	adv	_	_
14	to	to	TO	_	15	attr	_	_
15	25	0	CD	_	5	ppmod	_	_
16	%	%	NN	_	15	meta	_	_
17	.	.	.	_	5	p	_	_

1	Other	other	JJ	_	2	attr	_	_
2	drugs	drug	NNS	_	16	dep	_	_
3	which	which	WDT	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	enhance	enhance	VB	_	2	relcl	_	_
6	the	the	DT	_	9	det	_	_
7	neuromuscular	neuromuscular	JJ	_	9	attr	_	_
8	blocking	blocking	NN	_	9	com	_	_
9	action	action	NN	_	5	obj	_	_
10	of	of	IN	_	12	case	_	_
11	nondepolarizing	nondepolarizing	JJ	_	12	attr	_	_
12	agents	agent	NNS	_	9	ppmod	_	_
13	such	such	JJ	_	15	adv	_	_
14	as	as	IN	_	15	case	_	_
15	drug1	drug0	NN	_	12	ppmod	_	_
16	include	include	VBP	_	0	root	_	_
17	certain	certain	JJ	_	18	attr	_	_
18	drug2	drug0	NN	_	16	obj	_	_
19	(	-lrb-	-LRB-	_	23	p	_	_
20	e.	e.	FW	_	21	attr	_	_
21	g.	g.	FW	_	23	dep	_	_
22	,	,	,	_	23	p	_	_
23	drug3	drug0	NN	_	18	prn	_	_
24	,	,	,	_	23	p	_	_
25	drug4	drug0	NN	_	23	conj	_	_
26	,	,	,	_	25	p	_	_
27	drug5	drug0	NN	_	23	conj	_	_
28	,	,	,	_	27	p	_	_
29	drug6	drug0	NN	_	23	conj	_	_
30	,	,	,	_	29	p	_	_
31	drug7	drug0	NN	_	23	conj	_	_
32	,	,	,	_	31	p	_	_
33	drug8	drug0	NN	_	23	conj	_	_
34	,	,	,	_	33	p	_	_
35	drug9	drug0	NN	_	23	conj	_	_
36	,	,	,	_	35	p	_	_
37	and	and	CC	_	35	cc	_	_
38	drug10	drug0	CD	_	23	conj	_	_
39	)	-rrb-	-RRB-	_	23	p	_	_
40	,	,	,	_	18	p	_	_
41	drug11	drug0	NN	_	42	com	_	_
42	salts	salt	NNS	_	18	conj	_	_
43	,	,	,	_	42	p	_	_
44	drug12	drug0	NN	_	18	conj	_	_
45	,	,	,	_	44	p	_	_
46	local	local	JJ	_	47	attr	_	_
47	drug13	drug0	NN	_	18	conj	_	_
48	,	,	,	_	47	p	_	_
49	drug14	drug0	NN	_	18	conj	_	_
50	,	,	,	_	49	p	_	_
51	and	and	CC	_	49	cc	_	_
52	drug15	drug0	NN	_	18	conj	_	_
53	.	.	.	_	16	p	_	_

1	As	as	IN	_	5	case	_	_
2	with	with	IN	_	5	case	_	_
3	some	some	DT	_	5	det	_	_
4	other	other	JJ	_	5	attr	_	_
5	drug1	drug0	NN	_	18	ppmod	_	_
6	,	,	,	_	18	p	_	_
7	the	the	DT	_	8	det	_	_
8	time	time	NN	_	18	dep	_	_
9	of	of	IN	_	10	case	_	_
10	onset	onset	NN	_	8	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	neuromuscular	neuromuscular	JJ	_	13	attr	_	_
13	block	block	NN	_	10	ppmod	_	_
14	induced	induce	VBN	_	13	acl	_	_
15	by	by	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	is	be	VBZ	_	18	aux	_	_
18	lengthened	lengthen	VBN	_	0	root	_	_
19	and	and	CC	_	18	cc	_	_
20	the	the	DT	_	21	det	_	_
21	duration	duration	NN	_	25	dep	_	_
22	of	of	IN	_	23	case	_	_
23	block	block	NN	_	21	ppmod	_	_
24	is	be	VBZ	_	25	aux	_	_
25	shortened	shorten	VBD	_	18	conj	_	_
26	in	in	IN	_	27	case	_	_
27	patients	patient	NNS	_	25	ppmod	_	_
28	receiving	receive	VBG	_	27	acl	_	_
29	drug3	drug0	NN	_	28	obj	_	_
30	or	or	CC	_	29	cc	_	_
31	drug4	drug0	NN	_	29	conj	_	_
32	.	.	.	_	18	p	_	_

1	Oils	oil	NNS	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	enhance	enhance	VB	_	0	root	_	_
4	absorption	absorption	NN	_	3	obj	_	_
5	.	.	.	_	3	p	_	_

1	Therefore	therefore	RB	_	13	adv	_	_
2	,	,	,	_	13	p	_	_
3	simultaneous	simultaneous	JJ	_	4	attr	_	_
4	use	use	NN	_	13	dep	_	_
5	of	of	IN	_	6	case	_	_
6	creams	cream	NNS	_	4	ppmod	_	_
7	,	,	,	_	6	p	_	_
8	ointments	ointment	NNS	_	6	conj	_	_
9	or	or	CC	_	8	cc	_	_
10	oils	oil	NNS	_	6	conj	_	_
11	should	should	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	avoided	avoid	VBN	_	0	root	_	_
14	.	.	.	_	13	p	_	_

1	Inhibitors	inhibitor	NNS	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	CYP2D6	cyp0d0	NN	_	1	ppmod	_	_
4	;	;	:	_	1	p	_	_

1	poor	poor	JJ	_	2	attr	_	_
2	metabolizers	metabolizers	NNS	_	0	root	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	:	:	:	_	2	p	_	_
6	Interactions	interaction	NNS	_	29	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	with	with	IN	_	11	case	_	_
10	strong	strong	JJ	_	11	attr	_	_
11	inhibitors	inhibitor	NNS	_	6	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	CYP2D6	cyp0d0	NNS	_	11	ppmod	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	such	such	JJ	_	13	prn	_	_
16	as	as	IN	_	17	case	_	_
17	drug3	drug0	NN	_	15	ppmod	_	_
18	,	,	,	_	17	p	_	_
19	drug4	drug0	NN	_	17	conj	_	_
20	,	,	,	_	19	p	_	_
21	drug5	drug0	NN	_	17	conj	_	_
22	,	,	,	_	21	p	_	_
23	and	and	CC	_	21	cc	_	_
24	drug6	drug0	NN	_	17	conj	_	_
25	)	-rrb-	-RRB-	_	15	p	_	_
26	have	have	VBP	_	29	aux	_	_
27	not	not	RB	_	29	neg	_	_
28	been	be	VBN	_	29	aux	_	_
29	studied	study	VBN	_	2	acl	_	_
30	,	,	,	_	29	p	_	_
31	but	but	CC	_	29	cc	_	_
32	these	these	DT	_	33	det	_	_
33	drugs	drug	NNS	_	36	dep	_	_
34	would	would	MD	_	36	modal	_	_
35	be	be	VB	_	36	aux	_	_
36	expected	expect	VBN	_	29	conj	_	_
37	to	to	TO	_	38	aux	_	_
38	increase	increase	VB	_	36	comp	_	_
39	blood	blood	NN	_	40	com	_	_
40	levels	level	NNS	_	38	obj	_	_
41	of	of	IN	_	47	case	_	_
42	the	the	DT	_	47	det	_	_
43	R	r	NN	_	47	attr	_	_
44	(	-lrb-	-LRB-	_	43	p	_	_
45	+	+	CC	_	43	cc	_	_
46	)	-rrb-	-RRB-	_	43	p	_	_
47	enantiomer	enantiomer	NN	_	40	ppmod	_	_
48	of	of	IN	_	49	case	_	_
49	drug7	drug0	NN	_	47	ppmod	_	_
50	.	.	.	_	2	p	_	_

1	Retrospective	retrospective	JJ	_	2	attr	_	_
2	analysis	analysis	NN	_	9	dep	_	_
3	of	of	IN	_	5	case	_	_
4	side	side	JJ	_	5	attr	_	_
5	effects	effect	NNS	_	2	ppmod	_	_
6	in	in	IN	_	8	case	_	_
7	clinical	clinical	JJ	_	8	attr	_	_
8	trials	trial	NNS	_	5	ppmod	_	_
9	showed	show	VBD	_	0	root	_	_
10	that	that	IN	_	14	mark	_	_
11	poor	poor	JJ	_	13	attr	_	_
12	2D6	0d0	NN	_	13	com	_	_
13	metabolizers	metabolizers	NNS	_	14	dep	_	_
14	had	have	VBD	_	9	comp	_	_
15	a	a	DT	_	17	det	_	_
16	higher	high	JJR	_	17	attr	_	_
17	rate	rate	NN	_	14	obj	_	_
18	of	of	IN	_	19	case	_	_
19	dizziness	dizziness	NN	_	17	ppmod	_	_
20	during	during	IN	_	21	case	_	_
21	up-titration	up-titration	NN	_	14	ppmod	_	_
22	,	,	,	_	14	p	_	_
23	presumably	presumably	RB	_	24	adv	_	_
24	resulting	result	VBG	_	14	comp	_	_
25	from	from	IN	_	27	case	_	_
26	vasodilating	vasodilating	JJ	_	27	attr	_	_
27	effects	effect	NNS	_	24	ppmod	_	_
28	of	of	IN	_	31	case	_	_
29	the	the	DT	_	31	det	_	_
30	higher	high	JJR	_	31	attr	_	_
31	concentrations	concentration	NNS	_	27	ppmod	_	_
32	of	of	IN	_	39	case	_	_
33	the	the	DT	_	39	det	_	_
34	a-blocking	a-blocking	JJ	_	39	attr	_	_
35	R	r	NN	_	39	attr	_	_
36	(	-lrb-	-LRB-	_	35	p	_	_
37	+	+	CC	_	35	cc	_	_
38	)	-rrb-	-RRB-	_	35	p	_	_
39	enantiomer	enantiomer	NN	_	31	ppmod	_	_
40	.	.	.	_	9	p	_	_

1	Catecholamine-depleting	catecholamine-depleting	JJ	_	2	attr	_	_
2	Agents	agent	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	Patients	patient	NNS	_	24	dep	_	_
5	taking	take	VBG	_	4	acl	_	_
6	both	both	CC	_	7	cc	_	_
7	drug1	drug0	NN	_	5	obj	_	_
8	and	and	CC	_	7	cc	_	_
9	a	a	DT	_	10	det	_	_
10	drug	drug	NN	_	7	conj	_	_
11	that	that	WDT	_	13	dep	_	_
12	can	can	MD	_	13	modal	_	_
13	deplete	deplete	VB	_	7	relcl	_	_
14	catecholamines	catecholamine	NNS	_	13	obj	_	_
15	(	-lrb-	-LRB-	_	18	p	_	_
16	e.g.	e.g.	FW	_	18	adv	_	_
17	,	,	,	_	18	p	_	_
18	drug2	drug0	NN	_	4	prn	_	_
19	and	and	CC	_	18	cc	_	_
20	drug3	drug0	NN	_	18	conj	_	_
21	)	-rrb-	-RRB-	_	18	p	_	_
22	should	should	MD	_	24	modal	_	_
23	be	be	VB	_	24	aux	_	_
24	observed	observe	VBN	_	2	acl	_	_
25	closely	closely	RB	_	24	adv	_	_
26	for	for	IN	_	27	case	_	_
27	signs	sign	NNS	_	24	ppmod	_	_
28	of	of	IN	_	29	case	_	_
29	hypotension	hypotension	NN	_	27	ppmod	_	_
30	and/or	and/or	CC	_	29	cc	_	_
31	severe	severe	JJ	_	32	attr	_	_
32	bradycardia	bradycardia	NN	_	29	conj	_	_
33	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Concomitant	concomitant	JJ	_	4	attr	_	_
4	administration	administration	NN	_	10	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	with	with	IN	_	8	case	_	_
8	drug3	drug0	NN	_	4	ppmod	_	_
9	may	may	MD	_	10	modal	_	_
10	potentiate	potentiate	VB	_	1	acl	_	_
11	blood-pressure-	blood-pressure-	JJ	_	14	attr	_	_
12	and	and	CC	_	11	cc	_	_
13	heart-rate-lowering	heart-rate-lowering	JJ	_	11	conj	_	_
14	effects	effect	NNS	_	10	obj	_	_
15	.	.	.	_	1	p	_	_

1	When	when	WRB	_	8	adv	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	treatment	treatment	NN	_	8	dep	_	_
4	with	with	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	is	be	VBZ	_	17	advcl	_	_
9	to	to	TO	_	11	aux	_	_
10	be	be	VB	_	11	aux	_	_
11	terminated	terminate	VBN	_	8	comp	_	_
12	,	,	,	_	17	p	_	_
13	the	the	DT	_	14	det	_	_
14	drug3	drug0	NN	_	17	dep	_	_
15	should	should	MD	_	17	modal	_	_
16	be	be	VB	_	17	aux	_	_
17	discontinued	discontinue	VBN	_	0	root	_	_
18	first	#ord#	RB	_	17	adv	_	_
19	.	.	.	_	17	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	therapy	therapy	NN	_	6	dep	_	_
3	can	can	MD	_	6	modal	_	_
4	then	then	RB	_	6	adv	_	_
5	be	be	VB	_	6	aux	_	_
6	discontinued	discontinue	VBN	_	0	root	_	_
7	several	several	JJ	_	8	attr	_	_
8	days	day	NNS	_	9	advnp	_	_
9	later	later	RB	_	6	adv	_	_
10	by	by	IN	_	12	case	_	_
11	gradually	gradually	RB	_	12	adv	_	_
12	decreasing	decrease	VBG	_	6	ppmod	_	_
13	the	the	DT	_	14	det	_	_
14	dosage	dosage	NN	_	12	obj	_	_
15	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Modest	modest	JJ	_	4	attr	_	_
4	increases	increase	NNS	_	11	dep	_	_
5	in	in	IN	_	9	case	_	_
6	mean	mean	JJ	_	9	attr	_	_
7	trough	trough	NN	_	9	com	_	_
8	drug2	drug0	NN	_	9	com	_	_
9	concentrations	concentration	NNS	_	4	ppmod	_	_
10	were	be	VBD	_	11	aux	_	_
11	observed	observe	VBN	_	1	acl	_	_
12	following	follow	VBG	_	13	adv	_	_
13	initiation	initiation	NN	_	11	ppmod	_	_
14	of	of	IN	_	16	case	_	_
15	drug3	drug0	NN	_	16	com	_	_
16	treatment	treatment	NN	_	13	ppmod	_	_
17	in	in	IN	_	21	case	_	_
18	21	0	CD	_	21	num	_	_
19	renal	renal	JJ	_	21	attr	_	_
20	transplant	transplant	NN	_	21	com	_	_
21	patients	patient	NNS	_	13	ppmod	_	_
22	suffering	suffer	VBG	_	21	acl	_	_
23	from	from	IN	_	26	case	_	_
24	chronic	chronic	JJ	_	26	attr	_	_
25	vascular	vascular	JJ	_	26	attr	_	_
26	rejection	rejection	NN	_	22	ppmod	_	_
27	.	.	.	_	1	p	_	_

1	In	in	IN	_	3	case	_	_
2	about	about	RB	_	3	adv	_	_
3	30	0	CD	_	12	ppmod	_	_
4	%	%	NN	_	3	meta	_	_
5	of	of	IN	_	6	case	_	_
6	patients	patient	NNS	_	3	ppmod	_	_
7	,	,	,	_	12	p	_	_
8	the	the	DT	_	9	det	_	_
9	dose	dose	NN	_	12	dep	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	had	have	VBD	_	0	root	_	_
13	to	to	TO	_	15	aux	_	_
14	be	be	VB	_	15	aux	_	_
15	reduced	reduce	VBN	_	12	comp	_	_
16	in	in	IN	_	19	mark	_	_
17	order	order	NN	_	19	dep	_	_
18	to	to	TO	_	19	aux	_	_
19	maintain	maintain	VB	_	15	comp	_	_
20	drug2	drug0	NN	_	21	com	_	_
21	concentrations	concentration	NNS	_	19	obj	_	_
22	within	within	IN	_	25	case	_	_
23	the	the	DT	_	25	det	_	_
24	therapeutic	therapeutic	JJ	_	25	attr	_	_
25	range	range	NN	_	19	ppmod	_	_
26	,	,	,	_	12	p	_	_
27	while	while	IN	_	34	mark	_	_
28	in	in	IN	_	30	case	_	_
29	the	the	DT	_	30	det	_	_
30	remainder	remainder	NN	_	34	ppmod	_	_
31	no	no	DT	_	32	det	_	_
32	adjustment	adjustment	NN	_	34	dep	_	_
33	was	be	VBD	_	34	aux	_	_
34	needed	need	VBN	_	12	comp	_	_
35	.	.	.	_	12	p	_	_

1	On	on	IN	_	3	case	_	_
2	the	the	DT	_	3	det	_	_
3	average	average	NN	_	13	ppmod	_	_
4	for	for	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	group	group	NN	_	3	ppmod	_	_
7	,	,	,	_	13	p	_	_
8	the	the	DT	_	9	det	_	_
9	dose	dose	NN	_	13	dep	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	was	be	VBD	_	13	aux	_	_
13	reduced	reduce	VBN	_	0	root	_	_
14	about	about	RB	_	15	adv	_	_
15	20	0	CD	_	13	obj	_	_
16	%	%	NN	_	15	meta	_	_
17	in	in	IN	_	19	case	_	_
18	these	these	DT	_	19	det	_	_
19	patients	patient	NNS	_	13	ppmod	_	_
20	.	.	.	_	13	p	_	_

1	Due	due	JJ	_	5	adv	_	_
2	to	to	TO	_	5	aux	_	_
3	wide	wide	JJ	_	5	attr	_	_
4	interindividual	interindividual	JJ	_	5	attr	_	_
5	variability	variability	NN	_	14	ppmod	_	_
6	in	in	IN	_	9	case	_	_
7	the	the	DT	_	9	det	_	_
8	dose	dose	NN	_	9	com	_	_
9	adjustment	adjustment	NN	_	5	ppmod	_	_
10	required	require	VBN	_	9	acl	_	_
11	,	,	,	_	14	p	_	_
12	it	it	PRP	_	14	dep	_	_
13	is	be	VBZ	_	14	aux	_	_
14	recommended	recommend	VBN	_	0	root	_	_
15	that	that	IN	_	19	mark	_	_
16	drug1	drug0	NN	_	17	com	_	_
17	concentrations	concentration	NNS	_	19	dep	_	_
18	be	be	VB	_	19	aux	_	_
19	monitored	monitor	VBN	_	14	advcl	_	_
20	closely	closely	RB	_	19	adv	_	_
21	after	after	IN	_	22	case	_	_
22	initiation	initiation	NN	_	19	ppmod	_	_
23	of	of	IN	_	25	case	_	_
24	drug2	drug0	NN	_	25	com	_	_
25	therapy	therapy	NN	_	22	ppmod	_	_
26	and	and	CC	_	19	cc	_	_
27	that	that	IN	_	33	mark	_	_
28	the	the	DT	_	29	det	_	_
29	dose	dose	NN	_	33	dep	_	_
30	of	of	IN	_	31	case	_	_
31	drug3	drug0	NN	_	29	ppmod	_	_
32	be	be	VB	_	33	aux	_	_
33	adjusted	adjust	VBN	_	19	conj	_	_
34	as	as	IN	_	35	case	_	_
35	appropriate	appropriate	JJ	_	33	ppmod	_	_
36	.	.	.	_	14	p	_	_

1	drug1	drug0	NN	_	4	attr	_	_
2	:	:	:	_	4	p	_	_
3	drug2	drug0	NN	_	4	com	_	_
4	concentrations	concentration	NNS	_	6	dep	_	_
5	are	be	VBP	_	6	aux	_	_
6	increased	increase	VBN	_	0	root	_	_
7	by	by	IN	_	9	case	_	_
8	about	about	RB	_	9	adv	_	_
9	15	0	CD	_	6	ppmod	_	_
10	%	%	NN	_	9	meta	_	_
11	when	when	WRB	_	16	adv	_	_
12	drug3	drug0	NN	_	16	dep	_	_
13	and	and	CC	_	12	cc	_	_
14	drug4	drug0	NN	_	12	conj	_	_
15	are	be	VBP	_	16	aux	_	_
16	administered	administer	VBN	_	6	comp	_	_
17	concomitantly	concomitantly	RB	_	16	adv	_	_
18	.	.	.	_	6	p	_	_

1	Both	both	CC	_	2	cc	_	_
2	drug1	drug0	NN	_	5	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	drug2	drug0	NN	_	2	conj	_	_
5	slow	slow	JJ	_	0	root	_	_
6	AV	av	NN	_	7	com	_	_
7	conduction	conduction	NN	_	5	obj	_	_
8	.	.	.	_	5	p	_	_

1	Therefore	therefore	RB	_	8	adv	_	_
2	,	,	,	_	8	p	_	_
3	increased	increase	VBN	_	4	attr	_	_
4	monitoring	monitoring	NN	_	8	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	is	be	VBZ	_	8	aux	_	_
8	recommended	recommend	VBN	_	0	root	_	_
9	when	when	WRB	_	10	adv	_	_
10	initiating	initiate	VBG	_	8	comp	_	_
11	,	,	,	_	10	p	_	_
12	adjusting	adjust	VBG	_	10	conj	_	_
13	,	,	,	_	12	p	_	_
14	or	or	CC	_	12	cc	_	_
15	discontinuing	discontinue	VBG	_	10	conj	_	_
16	drug2	drug0	NN	_	15	obj	_	_
17	.	.	.	_	8	p	_	_

1	Inducers	inducer	NNS	_	0	root	_	_
2	and	and	CC	_	1	cc	_	_
3	Inhibitors	inhibitor	NNS	_	1	conj	_	_
4	of	of	IN	_	6	case	_	_
5	Hepatic	hepatic	JJ	_	6	attr	_	_
6	Metabolism	metabolism	NN	_	1	ppmod	_	_
7	:	:	:	_	1	p	_	_
8	drug1	drug0	NN	_	9	dep	_	_
9	reduced	reduce	VBD	_	1	acl	_	_
10	plasma	plasma	NN	_	11	com	_	_
11	concentrations	concentration	NNS	_	9	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	by	by	IN	_	16	case	_	_
15	about	about	RB	_	16	adv	_	_
16	70	0	CD	_	9	ppmod	_	_
17	%	%	NN	_	16	meta	_	_
18	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	increased	increase	VBD	_	0	root	_	_
3	AUC	auc	NN	_	2	obj	_	_
4	by	by	IN	_	6	case	_	_
5	about	about	RB	_	6	adv	_	_
6	30	0	CD	_	2	ppmod	_	_
7	%	%	NN	_	6	meta	_	_
8	but	but	CC	_	2	cc	_	_
9	caused	cause	VBD	_	2	conj	_	_
10	no	no	DT	_	11	det	_	_
11	change	change	NN	_	9	obj	_	_
12	in	in	IN	_	13	case	_	_
13	Cmax	cmax	NN	_	9	ppmod	_	_
14	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Isolated	isolate	VBN	_	4	attr	_	_
4	cases	case	NNS	_	16	dep	_	_
5	of	of	IN	_	7	case	_	_
6	conduction	conduction	NN	_	7	com	_	_
7	disturbance	disturbance	NN	_	4	ppmod	_	_
8	(	-lrb-	-LRB-	_	12	p	_	_
9	rarely	rarely	RB	_	12	adv	_	_
10	with	with	IN	_	12	case	_	_
11	hemodynamic	hemodynamic	JJ	_	12	attr	_	_
12	compromise	compromise	VB	_	7	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	have	have	VBP	_	16	aux	_	_
15	been	be	VBN	_	16	aux	_	_
16	observed	observe	VBN	_	1	acl	_	_
17	when	when	WRB	_	20	adv	_	_
18	drug2	drug0	NN	_	20	dep	_	_
19	is	be	VBZ	_	20	aux	_	_
20	co-administered	co-administered	VBN	_	16	comp	_	_
21	with	with	IN	_	22	case	_	_
22	drug3	drug0	NN	_	20	ppmod	_	_
23	.	.	.	_	1	p	_	_

1	As	as	IN	_	4	case	_	_
2	with	with	IN	_	4	case	_	_
3	other	other	JJ	_	4	attr	_	_
4	drug1	drug0	NN	_	24	ppmod	_	_
5	,	,	,	_	24	p	_	_
6	if	if	IN	_	8	mark	_	_
7	drug2	drug0	NN	_	8	dep	_	_
8	is	be	VBZ	_	24	advcl	_	_
9	to	to	TO	_	11	aux	_	_
10	be	be	VB	_	11	aux	_	_
11	administered	administer	VBN	_	8	comp	_	_
12	orally	orally	RB	_	11	adv	_	_
13	with	with	IN	_	14	case	_	_
14	drug3	drug0	NN	_	11	ppmod	_	_
15	of	of	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	drug4	drug0	NN	_	14	ppmod	_	_
18	or	or	CC	_	17	cc	_	_
19	drug5	drug0	NN	_	20	com	_	_
20	type	type	NN	_	17	conj	_	_
21	,	,	,	_	24	p	_	_
22	it	it	PRP	_	24	dep	_	_
23	is	be	VBZ	_	24	aux	_	_
24	recommended	recommend	VBN	_	0	root	_	_
25	that	that	IN	_	31	mark	_	_
26	ECG	ecg	NN	_	31	dep	_	_
27	and	and	CC	_	26	cc	_	_
28	blood	blood	NN	_	29	com	_	_
29	pressure	pressure	NN	_	26	conj	_	_
30	be	be	VB	_	31	aux	_	_
31	monitored	monitor	VBN	_	24	comp	_	_
32	.	.	.	_	24	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	or	or	CC	_	1	cc	_	_
3	Oral	oral	JJ	_	4	attr	_	_
4	drug2	drug0	NN	_	1	conj	_	_
5	:	:	:	_	1	p	_	_
6	drug3	drug0	NN	_	8	dep	_	_
7	may	may	MD	_	8	modal	_	_
8	enhance	enhance	VB	_	1	acl	_	_
9	the	the	DT	_	11	det	_	_
10	blood-sugar-reducing	blood-sugar-reducing	JJ	_	11	attr	_	_
11	effect	effect	NN	_	8	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug4	drug0	NN	_	11	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	oral	oral	JJ	_	16	attr	_	_
16	drug5	drug0	NN	_	13	conj	_	_
17	.	.	.	_	1	p	_	_

1	Therefore	therefore	RB	_	17	adv	_	_
2	,	,	,	_	17	p	_	_
3	in	in	IN	_	4	case	_	_
4	patients	patient	NNS	_	17	ppmod	_	_
5	taking	take	VBG	_	4	acl	_	_
6	drug1	drug0	NN	_	5	obj	_	_
7	or	or	CC	_	6	cc	_	_
8	oral	oral	JJ	_	9	attr	_	_
9	drug2	drug0	NN	_	6	conj	_	_
10	,	,	,	_	17	p	_	_
11	regular	regular	JJ	_	12	attr	_	_
12	monitoring	monitoring	NN	_	17	dep	_	_
13	of	of	IN	_	15	case	_	_
14	blood	blood	NN	_	15	com	_	_
15	glucose	glucose	NN	_	12	ppmod	_	_
16	is	be	VBZ	_	17	aux	_	_
17	recommended	recommend	VBN	_	0	root	_	_
18	.	.	.	_	17	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	principally	principally	RB	_	4	adv	_	_
4	metabolized	metabolize	VBN	_	0	root	_	_
5	by	by	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	liver	liver	NN	_	4	ppmod	_	_
8	via	via	IN	_	12	case	_	_
9	the	the	DT	_	12	det	_	_
10	cytochrome	cytochrome	NN	_	12	com	_	_
11	P450	p0	NN	_	12	com	_	_
12	isoenzymes	isoenzymes	NNS	_	4	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	3A4	0a0	NN	_	12	appo	_	_
15	and	and	CC	_	14	cc	_	_
16	2B6	0b0	NN	_	14	conj	_	_
17	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	known	know	VBN	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	be	be	VB	_	3	comp	_	_
6	an	an	DT	_	7	det	_	_
7	inducer	inducer	NN	_	5	obj	_	_
8	of	of	IN	_	10	case	_	_
9	these	these	DT	_	10	det	_	_
10	enzymes	enzyme	NNS	_	7	ppmod	_	_
11	.	.	.	_	3	p	_	_

1	As	as	IN	_	3	case	_	_
2	a	a	DT	_	3	det	_	_
3	result	result	NN	_	14	ppmod	_	_
4	,	,	,	_	14	p	_	_
5	drugs	drug	NNS	_	14	dep	_	_
6	that	that	WDT	_	8	dep	_	_
7	are	be	VBP	_	8	aux	_	_
8	metabolized	metabolize	VBN	_	5	relcl	_	_
9	by	by	IN	_	12	case	_	_
10	these	these	DT	_	12	det	_	_
11	enzyme	enzyme	NN	_	12	com	_	_
12	systems	system	NNS	_	8	ppmod	_	_
13	may	may	MD	_	14	modal	_	_
14	have	have	VBP	_	0	root	_	_
15	lower	low	JJR	_	19	attr	_	_
16	than	than	IN	_	19	case	_	_
17	expected	expect	VBN	_	19	attr	_	_
18	plasma	plasma	NN	_	19	com	_	_
19	levels	level	NNS	_	14	obj	_	_
20	when	when	WRB	_	21	adv	_	_
21	coadministered	coadministered	VBN	_	14	comp	_	_
22	with	with	IN	_	23	case	_	_
23	drug1	drug0	NN	_	21	ppmod	_	_
24	.	.	.	_	14	p	_	_

1	The	the	DT	_	4	det	_	_
2	specific	specific	JJ	_	4	attr	_	_
3	pharmacokinetic	pharmacokinetic	JJ	_	4	attr	_	_
4	changes	change	NNS	_	15	dep	_	_
5	that	that	WDT	_	6	dep	_	_
6	occur	occur	VBP	_	4	relcl	_	_
7	with	with	IN	_	8	case	_	_
8	co-administration	co-administration	NN	_	6	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	other	other	JJ	_	13	attr	_	_
13	drugs	drug	NNS	_	10	conj	_	_
14	are	be	VBP	_	15	aux	_	_
15	listed	list	VBN	_	0	root	_	_
16	in	in	IN	_	18	case	_	_
17	CLINICAL	clinical	JJ	_	18	attr	_	_
18	PHARMACOLOGY	pharmacology	NN	_	15	ppmod	_	_
19	,	,	,	_	18	p	_	_
20	Table	table	NN	_	18	appo	_	_
21	1	0	CD	_	20	num	_	_
22	.	.	.	_	15	p	_	_

1	Clinical	clinical	JJ	_	2	attr	_	_
2	comments	comment	NNS	_	13	dep	_	_
3	about	about	IN	_	6	case	_	_
4	possible	possible	JJ	_	6	attr	_	_
5	dosage	dosage	NN	_	6	com	_	_
6	modifications	modification	NNS	_	2	ppmod	_	_
7	based	base	VBN	_	6	acl	_	_
8	on	on	IN	_	11	case	_	_
9	these	these	DT	_	11	det	_	_
10	pharmacokinetic	pharmacokinetic	JJ	_	11	attr	_	_
11	changes	change	NNS	_	7	ppmod	_	_
12	are	be	VBP	_	13	aux	_	_
13	listed	list	VBN	_	0	root	_	_
14	in	in	IN	_	15	case	_	_
15	Table	table	NN	_	13	ppmod	_	_
16	3	0	CD	_	15	num	_	_
17	.	.	.	_	13	p	_	_

1	The	the	DT	_	3	det	_	_
2	data	data	NN	_	3	com	_	_
3	inTables	intables	NNS	_	8	dep	_	_
4	1	0	CD	_	3	num	_	_
5	and	and	CC	_	4	cc	_	_
6	3	0	CD	_	4	conj	_	_
7	are	be	VBP	_	8	aux	_	_
8	based	base	VBN	_	0	root	_	_
9	on	on	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	results	result	NNS	_	8	ppmod	_	_
12	of	of	IN	_	15	case	_	_
13	drug	drug	NN	_	15	com	_	_
14	interaction	interaction	NN	_	15	com	_	_
15	studies	study	NNS	_	11	ppmod	_	_
16	conducted	conduct	VBN	_	15	acl	_	_
17	in	in	IN	_	20	case	_	_
18	HIV-1	hiv-0	NN	_	20	attr	_	_
19	seropositive	seropositive	JJ	_	20	attr	_	_
20	subjects	subject	NNS	_	16	ppmod	_	_
21	unless	unless	IN	_	23	mark	_	_
22	otherwise	otherwise	RB	_	23	adv	_	_
23	indicated	indicate	VBN	_	16	comp	_	_
24	.	.	.	_	8	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	10	ppmod	_	_
3	to	to	TO	_	6	aux	_	_
4	established	established	JJ	_	6	attr	_	_
5	drug	drug	NN	_	6	com	_	_
6	interactions	interaction	NNS	_	2	ppmod	_	_
7	,	,	,	_	10	p	_	_
8	there	there	EX	_	10	dep	_	_
9	may	may	MD	_	10	modal	_	_
10	be	be	VB	_	0	root	_	_
11	potential	potential	JJ	_	13	attr	_	_
12	pharmacokinetic	pharmacokinetic	JJ	_	13	attr	_	_
13	interactions	interaction	NNS	_	10	obj	_	_
14	between	between	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	other	other	JJ	_	19	attr	_	_
18	drug	drug	NN	_	19	com	_	_
19	classes	class	NNS	_	15	conj	_	_
20	that	that	WDT	_	22	dep	_	_
21	are	be	VBP	_	22	aux	_	_
22	metabolized	metabolize	VBN	_	13	relcl	_	_
23	by	by	IN	_	27	case	_	_
24	the	the	DT	_	27	det	_	_
25	cytochrome	cytochrome	NN	_	27	com	_	_
26	P450	p0	NN	_	27	com	_	_
27	system	system	NN	_	22	ppmod	_	_
28	.	.	.	_	10	p	_	_

1	These	these	DT	_	4	det	_	_
2	potential	potential	JJ	_	4	attr	_	_
3	drug	drug	NN	_	4	com	_	_
4	interactions	interaction	NNS	_	6	dep	_	_
5	are	be	VBP	_	6	aux	_	_
6	listed	list	VBN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	Table	table	NN	_	6	ppmod	_	_
9	4	0	CD	_	8	num	_	_
10	.	.	.	_	6	p	_	_

1	Although	although	IN	_	13	mark	_	_
2	specific	specific	JJ	_	5	attr	_	_
3	drug	drug	NN	_	5	com	_	_
4	interaction	interaction	NN	_	5	com	_	_
5	studies	study	NNS	_	13	dep	_	_
6	in	in	IN	_	9	case	_	_
7	HIV-1	hiv-0	NN	_	9	attr	_	_
8	seropositive	seropositive	JJ	_	9	attr	_	_
9	subjects	subject	NNS	_	5	ppmod	_	_
10	have	have	VBP	_	13	aux	_	_
11	not	not	RB	_	13	neg	_	_
12	been	be	VBN	_	13	aux	_	_
13	conducted	conduct	VBN	_	29	advcl	_	_
14	for	for	IN	_	16	case	_	_
15	the	the	DT	_	16	det	_	_
16	classes	class	NNS	_	13	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drugs	drug	NNS	_	16	ppmod	_	_
19	listed	list	VBN	_	18	acl	_	_
20	in	in	IN	_	21	case	_	_
21	Table	table	NN	_	19	ppmod	_	_
22	4	0	CD	_	21	num	_	_
23	,	,	,	_	29	p	_	_
24	additional	additional	JJ	_	26	attr	_	_
25	clinical	clinical	JJ	_	26	attr	_	_
26	monitoring	monitoring	NN	_	29	dep	_	_
27	may	may	MD	_	29	modal	_	_
28	be	be	VB	_	29	aux	_	_
29	warranted	warrant	VBN	_	0	root	_	_
30	when	when	WRB	_	31	adv	_	_
31	co-administering	co-administering	JJ	_	29	comp	_	_
32	these	these	DT	_	33	det	_	_
33	drugs	drug	NNS	_	31	obj	_	_
34	.	.	.	_	29	p	_	_

1	The	the	DT	_	4	det	_	_
2	in	in	FW	_	3	adv	_	_
3	vitro	vitro	FW	_	4	attr	_	_
4	interaction	interaction	NN	_	11	dep	_	_
5	between	between	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	the	the	DT	_	10	det	_	_
9	drug2	drug0	NN	_	10	com	_	_
10	drug3	drug0	NN	_	6	conj	_	_
11	is	be	VBZ	_	0	root	_	_
12	complex	complex	NN	_	11	obj	_	_
13	.	.	.	_	11	p	_	_

1	As	as	IN	_	3	case	_	_
2	a	a	DT	_	3	det	_	_
3	result	result	NN	_	15	ppmod	_	_
4	,	,	,	_	15	p	_	_
5	when	when	WRB	_	6	adv	_	_
6	giving	give	VBG	_	15	advcl	_	_
7	these	these	DT	_	8	det	_	_
8	drugs	drug	NNS	_	6	obj	_	_
9	concomitantly	concomitantly	RB	_	6	adv	_	_
10	,	,	,	_	15	p	_	_
11	plasma	plasma	NN	_	13	com	_	_
12	drug1	drug0	NN	_	13	com	_	_
13	levels	level	NNS	_	15	dep	_	_
14	may	may	MD	_	15	modal	_	_
15	change	change	VB	_	0	root	_	_
16	with	with	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	potential	potential	NN	_	15	ppmod	_	_
19	for	for	IN	_	20	case	_	_
20	increases	increase	NNS	_	18	ppmod	_	_
21	in	in	IN	_	23	case	_	_
22	coagulation	coagulation	NN	_	23	com	_	_
23	time	time	NN	_	20	ppmod	_	_
24	.	.	.	_	15	p	_	_

1	When	when	WRB	_	4	adv	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	co-administered	co-administered	VBN	_	12	advcl	_	_
5	with	with	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	,	,	,	_	12	p	_	_
8	anticoagulation	anticoagulation	NN	_	9	com	_	_
9	levels	level	NNS	_	12	dep	_	_
10	should	should	MD	_	12	modal	_	_
11	be	be	VB	_	12	aux	_	_
12	monitored	monitor	VBN	_	0	root	_	_
13	frequently	frequently	RB	_	12	adv	_	_
14	.	.	.	_	12	p	_	_

1	Table	table	NN	_	5	attr	_	_
2	3	0	CD	_	5	num	_	_
3	Established	established	JJ	_	5	attr	_	_
4	Drug	drug	NN	_	5	com	_	_
5	Interactions	interaction	NNS	_	0	root	_	_
6	:	:	:	_	5	p	_	_
7	Alteration	alteration	NN	_	14	dep	_	_
8	in	in	IN	_	9	case	_	_
9	Dose	dose	NN	_	7	ppmod	_	_
10	or	or	CC	_	9	cc	_	_
11	Regimen	regimen	NN	_	9	conj	_	_
12	May	may	MD	_	14	modal	_	_
13	Be	be	VB	_	14	aux	_	_
14	Recommended	recommend	VBN	_	5	acl	_	_
15	Based	base	VBN	_	19	adv	_	_
16	on	on	IN	_	19	case	_	_
17	Drug	drug	NN	_	19	com	_	_
18	Interaction	interaction	NN	_	19	com	_	_
19	Studies	study	NNS	_	14	ppmod	_	_

1	Drug	drug	NN	_	2	com	_	_
2	Name	name	NN	_	0	root	_	_

1	Effect	effect	NN	_	0	root	_	_
2	on	on	IN	_	3	case	_	_
3	Concentration	concentration	NN	_	1	ppmod	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	1	ppmod	_	_
6	or	or	CC	_	5	cc	_	_
7	Concomitant	concomitant	JJ	_	8	attr	_	_
8	Drug	drug	NN	_	5	conj	_	_

1	Clinical	clinical	JJ	_	2	attr	_	_
2	Comment	comment	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	3	com	_	_
2	14OH-	0oh-	NN	_	3	com	_	_
3	clarithromycin	clarithromycin	NN	_	0	root	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	exposure	exposure	NN	_	5	dep	_	_
3	was	be	VBD	_	5	aux	_	_
4	significantly	significantly	RB	_	5	adv	_	_
5	decreased	decrease	VBN	_	0	root	_	_
6	by	by	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	;	;	:	_	5	p	_	_

1	however	however	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	14-OH	0-oh	NN	_	5	com	_	_
4	metabolite	metabolite	NN	_	5	com	_	_
5	concentrations	concentration	NNS	_	6	dep	_	_
6	were	be	VBD	_	0	root	_	_
7	increased.Because	#hlink#	JJ	_	6	dep	_	_
8	drug1	drug0	IN	_	13	mark	_	_
9	active	active	JJ	_	10	attr	_	_
10	metabolite	metabolite	NN	_	13	dep	_	_
11	has	have	VBZ	_	13	lv	_	_
12	reduced	reduce	VBN	_	13	attr	_	_
13	activity	activity	NN	_	6	comp	_	_
14	against	against	IN	_	16	case	_	_
15	Mycobacteriumavium-intracellulare	mycobacteriumavium-intracellulare	NN	_	16	com	_	_
16	complex	complex	NN	_	13	ppmod	_	_
17	,	,	,	_	13	p	_	_
18	overallactivity	overallactivity	NN	_	23	dep	_	_
19	against	against	IN	_	21	case	_	_
20	this	this	DT	_	21	det	_	_
21	pathogen	pathogen	NN	_	18	ppmod	_	_
22	may	may	MD	_	23	modal	_	_
23	bealtered	bealtered	JJ	_	13	comp	_	_
24	.	.	.	_	6	p	_	_

1	Alternatives	alternative	NNS	_	11	dep	_	_
2	to	to	TO	_	3	aux	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	,	,	,	_	1	p	_	_
5	such	such	JJ	_	7	adv	_	_
6	as	as	IN	_	7	case	_	_
7	drug2	drug0	NN	_	1	ppmod	_	_
8	,	,	,	_	1	p	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	considered	consider	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	Appropriate	appropriate	JJ	_	2	attr	_	_
2	doses	dose	NNS	_	8	dep	_	_
3	for	for	IN	_	5	case	_	_
4	this	this	DT	_	5	det	_	_
5	combination	combination	NN	_	2	ppmod	_	_
6	are	be	VBP	_	8	aux	_	_
7	not	not	RB	_	8	neg	_	_
8	established	establish	VBN	_	0	root	_	_
9	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	drug2	drug0	NN	_	0	root	_	_

1	Oral	oral	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	11	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	other	other	JJ	_	5	attr	_	_
5	hormonalmethods	hormonalmethods	NNS	_	2	conj	_	_
6	of	of	IN	_	8	case	_	_
7	birth	birth	NN	_	8	com	_	_
8	control	control	NN	_	2	ppmod	_	_
9	should	should	MD	_	11	modal	_	_
10	not	not	RB	_	11	neg	_	_
11	be	be	VB	_	0	root	_	_
12	usedas	usedas	NN	_	11	dep	_	_
13	the	the	DT	_	15	det	_	_
14	sole	sole	JJ	_	15	attr	_	_
15	method	method	NN	_	11	obj	_	_
16	of	of	IN	_	17	case	_	_
17	contraception	contraception	NN	_	15	ppmod	_	_
18	inwomen	inwomen	CD	_	17	num	_	_
19	taking	take	VBG	_	17	acl	_	_
20	drug2	drug0	NN	_	19	obj	_	_
21	,	,	,	_	11	p	_	_
22	since	since	IN	_	24	mark	_	_
23	nevirapinemay	nevirapinemay	NN	_	24	dep	_	_
24	lower	low	JJR	_	11	comp	_	_
25	the	the	DT	_	27	det	_	_
26	plasma	plasma	NN	_	27	com	_	_
27	levels	level	NNS	_	24	obj	_	_
28	of	of	IN	_	29	case	_	_
29	thesemedications	thesemedications	NNS	_	27	ppmod	_	_
30	.	.	.	_	11	p	_	_

1	An	an	DT	_	5	det	_	_
2	alternative	alternative	JJ	_	5	attr	_	_
3	or	or	CC	_	2	cc	_	_
4	additional	additional	JJ	_	2	conj	_	_
5	method	method	NN	_	9	dep	_	_
6	of	of	IN	_	7	case	_	_
7	contraception	contraception	NN	_	5	ppmod	_	_
8	is	be	VBZ	_	9	aux	_	_
9	recommended	recommend	VBN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	Because	because	IN	_	4	case	_	_
2	of	of	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	risk	risk	NN	_	14	ppmod	_	_
5	of	of	IN	_	7	case	_	_
6	increased	increase	VBN	_	7	attr	_	_
7	exposure	exposure	NN	_	4	ppmod	_	_
8	to	to	TO	_	9	aux	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	14	p	_	_
11	caution	caution	NN	_	14	dep	_	_
12	should	should	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	used	use	VBN	_	0	root	_	_
15	inconcomitant	inconcomitant	NN	_	16	com	_	_
16	administration	administration	NN	_	14	obj	_	_
17	,	,	,	_	14	p	_	_
18	and	and	CC	_	14	cc	_	_
19	patients	patient	NNS	_	22	dep	_	_
20	should	should	MD	_	22	modal	_	_
21	be	be	VB	_	22	aux	_	_
22	monitored	monitor	VBN	_	14	conj	_	_
23	closely	closely	RB	_	22	adv	_	_
24	for	for	IN	_	27	case	_	_
25	nevirapine-associated	nevirapine-associated	JJ	_	27	attr	_	_
26	adverse	adverse	JJ	_	27	attr	_	_
27	events	event	NNS	_	22	ppmod	_	_
28	.	.	.	_	14	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	Appropriate	appropriate	JJ	_	2	attr	_	_
2	doses	dose	NNS	_	7	dep	_	_
3	for	for	IN	_	6	case	_	_
4	this	this	DT	_	6	det	_	_
5	combination	combination	NN	_	6	com	_	_
6	arenot	arenot	NN	_	2	ppmod	_	_
7	established	establish	VBN	_	0	root	_	_
8	,	,	,	_	7	p	_	_
9	but	but	CC	_	7	cc	_	_
10	an	an	DT	_	11	det	_	_
11	increase	increase	NN	_	18	dep	_	_
12	in	in	IN	_	13	case	_	_
13	thedosage	thedosage	NN	_	11	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	may	may	MD	_	18	modal	_	_
17	be	be	VB	_	18	aux	_	_
18	required	require	VBN	_	7	conj	_	_
19	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	should	should	MD	_	6	modal	_	_
5	not	not	RB	_	6	neg	_	_
6	beadministered	beadministered	VB	_	0	root	_	_
7	concomitantly	concomitantly	RB	_	6	adv	_	_
8	becausedecreases	becausedecreases	NNS	_	6	obj	_	_
9	in	in	IN	_	11	case	_	_
10	drug3	drug0	NN	_	11	com	_	_
11	plasmaconcentrations	plasmaconcentrations	NNS	_	8	ppmod	_	_
12	may	may	MD	_	13	modal	_	_
13	reduce	reduce	VB	_	11	acl	_	_
14	the	the	DT	_	15	det	_	_
15	efficacy	efficacy	NN	_	13	obj	_	_
16	of	of	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	drug	drug	NN	_	15	ppmod	_	_
19	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	/	/	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	A	a	DT	_	3	det	_	_
2	dose	dose	NN	_	3	com	_	_
3	increase	increase	NN	_	0	root	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	/	/	:	_	3	p	_	_
7	drug2	drug0	NN	_	10	attr	_	_
8	to	to	TO	_	10	attr	_	_
9	533/133	0	CD	_	10	num	_	_
10	mg	mg	NN	_	3	appo	_	_
11	twice	twice	RB	_	12	adv	_	_
12	daily	daily	JJ	_	10	attr	_	_
13	with	with	IN	_	14	case	_	_
14	food	food	NN	_	12	ppmod	_	_
15	isrecommended	isrecommended	VBN	_	14	acl	_	_
16	in	in	IN	_	17	case	_	_
17	combination	combination	NN	_	15	ppmod	_	_
18	with	with	IN	_	19	case	_	_
19	drug3	drug0	NN	_	17	ppmod	_	_
20	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	Methadonea	methadonea	NN	_	0	root	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	levels	level	NNS	_	5	dep	_	_
3	may	may	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	decreased	decrease	VBN	_	11	advcl	_	_
6	;	;	:	_	11	p	_	_
7	increased	increase	VBN	_	8	attr	_	_
8	dosages	dosage	NNS	_	11	dep	_	_
9	may	may	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	required	require	VBN	_	0	root	_	_
12	to	to	TO	_	13	aux	_	_
13	prevent	prevent	VB	_	11	comp	_	_
14	symptoms	symptom	NNS	_	13	obj	_	_
15	of	of	IN	_	26	case	_	_
16	drug2	drug0	NN	_	20	attr	_	_
17	withdrawal.	withdrawal.	CD	_	20	num	_	_
18	drug3	drug0	NN	_	20	attr	_	_
19	maintained	maintained	JJ	_	20	attr	_	_
20	patients	patient	NNS	_	26	dep	_	_
21	beginning	begin	VBG	_	20	acl	_	_
22	drug4	drug0	NN	_	23	com	_	_
23	therapy	therapy	NN	_	21	obj	_	_
24	should	should	MD	_	26	modal	_	_
25	be	be	VB	_	26	aux	_	_
26	monitored	monitor	VBN	_	14	ppmod	_	_
27	forevidence	forevidence	NN	_	26	obj	_	_
28	of	of	IN	_	29	case	_	_
29	withdrawal	withdrawal	NN	_	27	ppmod	_	_
30	and	and	CC	_	26	cc	_	_
31	drug5	drug0	NN	_	32	com	_	_
32	dose	dose	NN	_	35	dep	_	_
33	should	should	MD	_	35	modal	_	_
34	be	be	VB	_	35	aux	_	_
35	adjusted	adjust	VBN	_	26	conj	_	_
36	accordingly	accordingly	RB	_	35	adv	_	_
37	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NNP	_	2	com	_	_
2	M8	m0	NNP	_	0	root	_	_

1	The	the	DT	_	3	det	_	_
2	appropriate	appropriate	JJ	_	3	attr	_	_
3	dose	dose	NN	_	19	dep	_	_
4	for	for	IN	_	6	case	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	incombination	incombination	NN	_	3	ppmod	_	_
7	with	with	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	,	,	,	_	3	p	_	_
10	with	with	IN	_	11	case	_	_
11	respectto	respectto	NN	_	3	ppmod	_	_
12	safety	safety	NN	_	11	attr	_	_
13	and	and	CC	_	12	cc	_	_
14	efficacy	efficacy	NN	_	12	conj	_	_
15	,	,	,	_	3	p	_	_
16	has	have	VBZ	_	19	aux	_	_
17	not	not	RB	_	19	neg	_	_
18	been	be	VBN	_	19	aux	_	_
19	established	establish	VBN	_	0	root	_	_
20	.	.	.	_	19	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	7	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	its	its	PRP$	_	4	poss	_	_
4	metabolite	metabolite	NN	_	1	conj	_	_
5	concentrationswere	concentrationswere	VBD	_	7	aux	_	_
6	moderately	moderately	RB	_	7	adv	_	_
7	increased	increase	VBN	_	0	root	_	_
8	.	.	.	_	7	p	_	_

1	Due	due	IN	_	4	case	_	_
2	to	to	TO	_	4	aux	_	_
3	highintersubject	highintersubject	NN	_	4	com	_	_
4	variability	variability	NN	_	10	ppmod	_	_
5	,	,	,	_	10	p	_	_
6	however	however	RB	_	10	adv	_	_
7	,	,	,	_	10	p	_	_
8	somepatients	somepatients	NNS	_	10	dep	_	_
9	may	may	MD	_	10	modal	_	_
10	experience	experience	VBP	_	0	root	_	_
11	large	large	JJ	_	12	attr	_	_
12	increases	increase	NNS	_	10	obj	_	_
13	in	in	IN	_	15	case	_	_
14	drug1	drug0	NN	_	15	com	_	_
15	exposure	exposure	NN	_	12	ppmod	_	_
16	and	and	CC	_	10	cc	_	_
17	may	may	MD	_	18	modal	_	_
18	be	be	VB	_	10	conj	_	_
19	at	at	IN	_	23	case	_	_
20	higher	high	JJR	_	23	attr	_	_
21	riskfor	riskfor	NN	_	23	com	_	_
22	rifabutin	rifabutin	NN	_	23	com	_	_
23	toxicity	toxicity	NN	_	18	ppmod	_	_
24	.	.	.	_	10	p	_	_

1	Therefore	therefore	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	caution	caution	NN	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	used	use	VBN	_	0	root	_	_
7	in	in	IN	_	9	case	_	_
8	concomitant	concomitant	JJ	_	9	attr	_	_
9	administration	administration	NN	_	6	ppmod	_	_
10	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	should	should	MD	_	6	modal	_	_
5	not	not	RB	_	6	neg	_	_
6	beadministered	beadministered	VB	_	0	root	_	_
7	concomitantly	concomitantly	RB	_	6	adv	_	_
8	becausedecreases	becausedecreases	NNS	_	6	obj	_	_
9	in	in	IN	_	11	case	_	_
10	drug3	drug0	NN	_	11	com	_	_
11	plasmaconcentrations	plasmaconcentrations	NNS	_	8	ppmod	_	_
12	may	may	MD	_	13	modal	_	_
13	reduce	reduce	VB	_	11	acl	_	_
14	the	the	DT	_	17	det	_	_
15	efficacy	efficacy	NN	_	17	com	_	_
16	ofthe	ofthe	NN	_	17	com	_	_
17	drug	drug	NN	_	13	obj	_	_
18	.	.	.	_	6	p	_	_

1	Physicians	physician	NNS	_	2	dep	_	_
2	needing	need	VBG	_	0	root	_	_
3	to	to	TO	_	4	aux	_	_
4	treatpatients	treatpatients	NNS	_	2	ppmod	_	_
5	co-infected	co-infected	VBN	_	4	acl	_	_
6	with	with	IN	_	7	case	_	_
7	tuberculosis	tuberculosis	NN	_	5	ppmod	_	_
8	andusing	andusing	VBG	_	7	acl	_	_
9	a	a	DT	_	10	det	_	_
10	drug1	drug0	NN	_	8	obj	_	_
11	containing	contain	VBG	_	10	acl	_	_
12	regimen	regimen	NN	_	14	com	_	_
13	mayuse	mayuse	NN	_	14	com	_	_
14	drug2	drug0	NN	_	11	obj	_	_
15	instead	instead	RB	_	14	adv	_	_
16	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	Appropriate	appropriate	JJ	_	2	attr	_	_
2	doses	dose	NNS	_	7	dep	_	_
3	for	for	IN	_	6	case	_	_
4	this	this	DT	_	6	det	_	_
5	combination	combination	NN	_	6	com	_	_
6	arenot	arenot	NN	_	2	ppmod	_	_
7	established	establish	VBN	_	0	root	_	_
8	,	,	,	_	7	p	_	_
9	but	but	CC	_	7	cc	_	_
10	an	an	DT	_	11	det	_	_
11	increase	increase	NN	_	18	dep	_	_
12	in	in	IN	_	13	case	_	_
13	thedosage	thedosage	NN	_	11	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	may	may	MD	_	18	modal	_	_
17	be	be	VB	_	18	aux	_	_
18	required	require	VBN	_	7	conj	_	_
19	.	.	.	_	7	p	_	_

1	aBased	abase	VBN	_	0	root	_	_
2	on	on	IN	_	3	case	_	_
3	reports	report	NNS	_	1	ppmod	_	_
4	of	of	IN	_	7	case	_	_
5	narcotic	narcotic	JJ	_	7	attr	_	_
6	withdrawal	withdrawal	NN	_	7	com	_	_
7	syndrome	syndrome	NN	_	3	ppmod	_	_
8	in	in	IN	_	9	case	_	_
9	patients	patient	NNS	_	7	ppmod	_	_
10	treated	treat	VBN	_	9	acl	_	_
11	with	with	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	drug2	drug0	NN	_	12	conj	_	_
15	concurrently	concurrently	RB	_	10	adv	_	_
16	,	,	,	_	3	p	_	_
17	and	and	CC	_	3	cc	_	_
18	evidence	evidence	NN	_	3	conj	_	_
19	of	of	IN	_	22	case	_	_
20	decreased	decrease	VBN	_	22	attr	_	_
21	plasma	plasma	NN	_	22	com	_	_
22	concentrations	concentration	NNS	_	18	ppmod	_	_
23	of	of	IN	_	24	case	_	_
24	drug3	drug0	NN	_	22	ppmod	_	_
25	.	.	.	_	1	p	_	_

1	Table	table	NN	_	5	attr	_	_
2	4	0	CD	_	5	num	_	_
3	Potential	potential	JJ	_	5	attr	_	_
4	Drug	drug	NN	_	5	com	_	_
5	Interactions	interaction	NNS	_	0	root	_	_
6	:	:	:	_	5	p	_	_
7	Use	use	NN	_	18	dep	_	_
8	With	with	IN	_	9	case	_	_
9	Caution	caution	NN	_	7	ppmod	_	_
10	,	,	,	_	9	p	_	_
11	Dose	dose	NN	_	12	com	_	_
12	Adjustment	adjustment	NN	_	9	appo	_	_
13	of	of	IN	_	15	case	_	_
14	Co-administered	co-administered	NN	_	15	com	_	_
15	Drug	drug	NN	_	12	ppmod	_	_
16	May	may	MD	_	18	modal	_	_
17	Be	be	VB	_	18	aux	_	_
18	Needed	need	VBN	_	5	acl	_	_
19	due	due	JJ	_	22	adv	_	_
20	to	to	TO	_	22	aux	_	_
21	Possible	possible	JJ	_	22	attr	_	_
22	Decrease	decrease	NN	_	18	ppmod	_	_
23	in	in	IN	_	25	case	_	_
24	Clinical	clinical	JJ	_	25	attr	_	_
25	Effect	effect	NN	_	22	ppmod	_	_

1	Examples	example	NNS	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	Drugs	drug	NNS	_	1	ppmod	_	_
4	in	in	IN	_	5	case	_	_
5	Which	which	WDT	_	10	ppmod	_	_
6	Plasma	plasma	NN	_	7	com	_	_
7	Concentrations	concentration	NNS	_	10	dep	_	_
8	May	may	MD	_	10	modal	_	_
9	Be	be	VB	_	10	aux	_	_
10	Decreased	decrease	VBN	_	1	relcl	_	_
11	By	by	IN	_	12	case	_	_
12	Co-administration	co-administration	NN	_	10	ppmod	_	_
13	With	with	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_

1	Drug	drug	NN	_	3	com	_	_
2	Class	class	NN	_	3	com	_	_
3	Examples	example	NNS	_	0	root	_	_
4	of	of	IN	_	5	case	_	_
5	Drugs	drug	NNS	_	3	ppmod	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	,	,	,	_	1	p	_	_
5	drug3	drug0	NN	_	1	appo	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	,	,	,	_	1	p	_	_
5	drug3	drug0	NN	_	1	appo	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	,	,	,	_	1	p	_	_
5	drug3	drug0	NN	_	1	appo	_	_

1	Cancer	cancer	NN	_	2	com	_	_
2	chemotherapy	chemotherapy	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	,	,	,	_	1	p	_	_
5	drug3	drug0	NN	_	1	appo	_	_

1	Motility	motility	NN	_	2	com	_	_
2	agents	agent	NNS	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	Examples	example	NNS	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	Drugs	drug	NNS	_	1	ppmod	_	_
4	in	in	IN	_	5	case	_	_
5	Which	which	WDT	_	10	ppmod	_	_
6	Plasma	plasma	NN	_	7	com	_	_
7	Concentrations	concentration	NNS	_	10	dep	_	_
8	May	may	MD	_	10	modal	_	_
9	Be	be	VB	_	10	aux	_	_
10	Increased	increase	VBN	_	1	relcl	_	_
11	By	by	IN	_	12	case	_	_
12	Co-administration	co-administration	NN	_	10	ppmod	_	_
13	With	with	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	Potential	potential	JJ	_	2	attr	_	_
2	effect	effect	NN	_	0	root	_	_
3	on	on	IN	_	4	case	_	_
4	anticoagulation	anticoagulation	NN	_	2	ppmod	_	_
5	.	.	.	_	2	p	_	_

1	Monitoring	monitoring	NN	_	6	dep	_	_
2	of	of	IN	_	4	case	_	_
3	anticoagulation	anticoagulation	NN	_	4	com	_	_
4	levels	level	NNS	_	1	ppmod	_	_
5	is	be	VBZ	_	6	aux	_	_
6	recommended	recommend	VBN	_	0	root	_	_
7	.	.	.	_	6	p	_	_

1	Fat	fat	JJ	_	2	attr	_	_
2	redistribution	redistribution	NN	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	Redistribution/accumulation	redistribution/accumulation	NN	_	34	dep	_	_
5	of	of	IN	_	7	case	_	_
6	body	body	NN	_	7	com	_	_
7	fat	fat	NN	_	4	ppmod	_	_
8	including	include	VBG	_	10	adv	_	_
9	central	central	JJ	_	10	attr	_	_
10	obesity	obesity	NN	_	4	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	dorsocervical	dorsocervical	JJ	_	14	attr	_	_
13	fat	fat	JJ	_	14	attr	_	_
14	enlargement	enlargement	NN	_	10	conj	_	_
15	(	-lrb-	-LRB-	_	17	p	_	_
16	buffalo	buffalo	JJ	_	17	attr	_	_
17	hump	hump	NN	_	14	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	,	,	,	_	14	p	_	_
20	peripheral	peripheral	JJ	_	21	attr	_	_
21	wasting	wasting	NN	_	10	conj	_	_
22	,	,	,	_	21	p	_	_
23	facial	facial	NN	_	24	com	_	_
24	wasting	wasting	NN	_	10	conj	_	_
25	,	,	,	_	24	p	_	_
26	breast	breast	NN	_	27	com	_	_
27	enlargement	enlargement	NN	_	10	conj	_	_
28	,	,	,	_	27	p	_	_
29	and	and	CC	_	27	cc	_	_
30	cushingoid	cushingoid	JJ	_	31	attr	_	_
31	appearance	appearance	NN	_	10	conj	_	_
32	have	have	VBP	_	34	aux	_	_
33	been	be	VBN	_	34	aux	_	_
34	observed	observe	VBN	_	2	acl	_	_
35	in	in	IN	_	36	case	_	_
36	patients	patient	NNS	_	34	ppmod	_	_
37	receiving	receive	VBG	_	36	acl	_	_
38	drug1	drug0	NN	_	39	com	_	_
39	therapy	therapy	NN	_	37	obj	_	_
40	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	mechanism	mechanism	NN	_	9	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	long-term	long-term	JJ	_	5	attr	_	_
5	consequences	consequence	NNS	_	2	conj	_	_
6	of	of	IN	_	8	case	_	_
7	these	these	DT	_	8	det	_	_
8	events	event	NNS	_	2	ppmod	_	_
9	are	be	VBP	_	0	root	_	_
10	currently	currently	RB	_	9	adv	_	_
11	unknown	unknown	JJ	_	9	dep	_	_
12	.	.	.	_	9	p	_	_

1	A	a	DT	_	3	det	_	_
2	causal	causal	JJ	_	3	attr	_	_
3	relationship	relationship	NN	_	7	dep	_	_
4	has	have	VBZ	_	7	aux	_	_
5	not	not	RB	_	7	neg	_	_
6	been	be	VBN	_	7	aux	_	_
7	established	establish	VBN	_	0	root	_	_

1	.	.	.	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	Physiological	physiological	JJ	_	2	attr	_	_
2	changes	change	NNS	_	15	dep	_	_
3	resulting	result	VBG	_	2	acl	_	_
4	from	from	IN	_	6	case	_	_
5	smoking	smoking	NN	_	6	com	_	_
6	cessation	cessation	NN	_	3	ppmod	_	_
7	,	,	,	_	2	p	_	_
8	with	with	IN	_	2	ppmod	_	_
9	or	or	CC	_	8	cc	_	_
10	without	without	IN	_	12	case	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	replacement	replacement	NN	_	8	conj	_	_
13	,	,	,	_	2	p	_	_
14	may	may	MD	_	15	modal	_	_
15	alter	alter	VB	_	0	root	_	_
16	the	the	DT	_	17	det	_	_
17	pharmacokinetics	pharmacokinetics	NNS	_	15	obj	_	_
18	of	of	IN	_	21	case	_	_
19	certain	certain	JJ	_	21	attr	_	_
20	concomitant	concomitant	JJ	_	21	attr	_	_
21	medications	medication	NNS	_	17	ppmod	_	_
22	,	,	,	_	21	p	_	_
23	such	such	JJ	_	25	adv	_	_
24	as	as	IN	_	25	case	_	_
25	drug2	drug0	NN	_	21	ppmod	_	_
26	and	and	CC	_	25	cc	_	_
27	drug3	drug0	NN	_	25	conj	_	_
28	.	.	.	_	15	p	_	_

1	Doses	dose	NNS	_	9	dep	_	_
2	of	of	IN	_	7	case	_	_
3	these	these	DT	_	7	attr	_	_
4	and	and	CC	_	3	cc	_	_
5	perhaps	perhaps	RB	_	6	adv	_	_
6	other	other	JJ	_	3	conj	_	_
7	medications	medication	NNS	_	1	ppmod	_	_
8	may	may	MD	_	9	modal	_	_
9	need	need	VBP	_	0	root	_	_
10	to	to	TO	_	12	aux	_	_
11	be	be	VB	_	12	aux	_	_
12	adjusted	adjust	VBN	_	9	comp	_	_
13	in	in	IN	_	14	case	_	_
14	patients	patient	NNS	_	12	ppmod	_	_
15	who	who	WP	_	17	dep	_	_
16	successfully	successfully	RB	_	17	adv	_	_
17	quit	quit	VB	_	14	relcl	_	_
18	smoking	smoking	NN	_	17	obj	_	_
19	.	.	.	_	9	p	_	_

1	The	the	DT	_	2	det	_	_
2	risk	risk	NN	_	15	dep	_	_
3	of	of	IN	_	4	case	_	_
4	using	use	VBG	_	2	ppmod	_	_
5	drug1	drug0	NN	_	4	obj	_	_
6	in	in	IN	_	7	case	_	_
7	combination	combination	NN	_	4	ppmod	_	_
8	with	with	IN	_	10	case	_	_
9	other	other	JJ	_	10	attr	_	_
10	drugs	drug	NNS	_	7	ppmod	_	_
11	has	have	VBZ	_	15	aux	_	_
12	not	not	RB	_	15	neg	_	_
13	been	be	VBN	_	15	aux	_	_
14	systematically	systematically	RB	_	15	adv	_	_
15	evaluated	evaluate	VBN	_	0	root	_	_
16	,	,	,	_	15	p	_	_
17	but	but	CC	_	15	cc	_	_
18	drug2	drug0	NN	_	20	dep	_	_
19	may	may	MD	_	20	modal	_	_
20	potentiate	potentiate	VB	_	15	conj	_	_
21	the	the	DT	_	23	det	_	_
22	side	side	JJ	_	23	attr	_	_
23	effects	effect	NNS	_	20	obj	_	_
24	of	of	IN	_	25	case	_	_
25	drug3	drug0	NN	_	23	ppmod	_	_
26	.	.	.	_	15	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	interact	interact	VB	_	0	root	_	_
4	with	with	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	,	,	,	_	5	p	_	_
7	drug3	drug0	NN	_	5	conj	_	_
8	,	,	,	_	7	p	_	_
9	and	and	CC	_	7	cc	_	_
10	certain	certain	JJ	_	12	attr	_	_
11	other	other	JJ	_	12	attr	_	_
12	agents	agent	NNS	_	5	conj	_	_
13	.	.	.	_	3	p	_	_

1	Compounds	compound	NNS	_	5	dep	_	_
2	in	in	IN	_	4	case	_	_
3	these	these	DT	_	4	det	_	_
4	categories	category	NNS	_	1	ppmod	_	_
5	result	result	VBP	_	0	root	_	_
6	in	in	IN	_	9	case	_	_
7	a	a	DT	_	9	det	_	_
8	decreased	decrease	VBN	_	9	attr	_	_
9	efficacy	efficacy	NN	_	5	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	:	:	:	_	9	p	_	_
13	drug2	drug0	NN	_	9	appo	_	_
14	,	,	,	_	13	p	_	_
15	drug3	drug0	NN	_	13	appo	_	_
16	,	,	,	_	13	p	_	_
17	drug4	drug0	NN	_	13	appo	_	_
18	,	,	,	_	13	p	_	_
19	drug5	drug0	NN	_	13	appo	_	_
20	.	.	.	_	5	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	use	use	NN	_	10	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	with	with	IN	_	7	case	_	_
6	other	other	JJ	_	7	attr	_	_
7	drug2	drug0	NNS	_	2	ppmod	_	_
8	is	be	VBZ	_	10	aux	_	_
9	not	not	RB	_	10	neg	_	_
10	recommended	recommend	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	Drug-Drug	drug-drug	JJ	_	2	attr	_	_
2	Interactions	interaction	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	The	the	DT	_	8	det	_	_
5	pharmacokinetic	pharmacokinetic	JJ	_	8	attr	_	_
6	and	and	CC	_	5	cc	_	_
7	pharmacodynamic	pharmacodynamic	JJ	_	5	conj	_	_
8	interactions	interaction	NNS	_	17	dep	_	_
9	between	between	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	other	other	JJ	_	13	attr	_	_
13	drug2	drug0	NN	_	10	conj	_	_
14	have	have	VBP	_	17	aux	_	_
15	not	not	RB	_	17	neg	_	_
16	been	be	VBN	_	17	aux	_	_
17	determined	determine	VBN	_	2	acl	_	_
18	.	.	.	_	2	p	_	_

1	However	however	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	interactions	interaction	NNS	_	6	dep	_	_
4	may	may	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	expected	expect	VBN	_	0	root	_	_
7	,	,	,	_	6	p	_	_
8	and	and	CC	_	6	cc	_	_
9	drug1	drug0	NN	_	13	dep	_	_
10	should	should	MD	_	13	modal	_	_
11	NOT	not	RB	_	13	neg	_	_
12	be	be	VB	_	13	aux	_	_
13	used	use	VBN	_	6	conj	_	_
14	in	in	IN	_	15	case	_	_
15	combination	combination	NN	_	13	ppmod	_	_
16	with	with	IN	_	18	case	_	_
17	other	other	JJ	_	18	attr	_	_
18	drug2	drug0	NNS	_	15	ppmod	_	_
19	.	.	.	_	6	p	_	_

1	Animal	animal	NN	_	2	com	_	_
2	studies	study	NNS	_	3	dep	_	_
3	indicate	indicate	VBP	_	0	root	_	_
4	that	that	IN	_	7	mark	_	_
5	drug1	drug0	NN	_	7	dep	_	_
6	may	may	MD	_	7	modal	_	_
7	be	be	VB	_	3	comp	_	_
8	ineffective	ineffective	JJ	_	7	dep	_	_
9	if	if	IN	_	14	mark	_	_
10	the	the	DT	_	11	det	_	_
11	patient	patient	NN	_	14	dep	_	_
12	has	have	VBZ	_	14	aux	_	_
13	recently	recently	RB	_	14	adv	_	_
14	received	receive	VBN	_	7	comp	_	_
15	a	a	DT	_	16	det	_	_
16	drug2	drug0	NN	_	14	obj	_	_
17	.	.	.	_	3	p	_	_

1	In	in	IN	_	4	case	_	_
2	such	such	PDT	_	4	det	_	_
3	a	a	DT	_	4	det	_	_
4	case	case	NN	_	11	ppmod	_	_
5	,	,	,	_	11	p	_	_
6	the	the	DT	_	9	det	_	_
7	peripheral	peripheral	JJ	_	9	attr	_	_
8	vascular	vascular	JJ	_	9	attr	_	_
9	resistance	resistance	NN	_	11	dep	_	_
10	may	may	MD	_	11	modal	_	_
11	increase	increase	VB	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	Preliminary	preliminary	JJ	_	2	attr	_	_
2	studies	study	NNS	_	3	dep	_	_
3	indicate	indicate	VBP	_	0	root	_	_
4	that	that	IN	_	12	mark	_	_
5	the	the	DT	_	7	det	_	_
6	concomitant	concomitant	JJ	_	7	attr	_	_
7	use	use	NN	_	12	dep	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	drug2	drug0	NN	_	9	conj	_	_
12	results	result	VBZ	_	3	comp	_	_
13	in	in	IN	_	17	case	_	_
14	a	a	DT	_	17	det	_	_
15	higher	high	JJR	_	17	attr	_	_
16	cardiac	cardiac	JJ	_	17	attr	_	_
17	output	output	NN	_	12	ppmod	_	_
18	and	and	CC	_	17	cc	_	_
19	,	,	,	_	17	p	_	_
20	usually	usually	RB	_	17	adv	_	_
21	,	,	,	_	17	p	_	_
22	a	a	DT	_	26	det	_	_
23	lower	low	JJR	_	26	attr	_	_
24	pulmonary	pulmonary	JJ	_	26	attr	_	_
25	wedge	wedge	NN	_	26	com	_	_
26	pressure	pressure	NN	_	17	conj	_	_
27	than	than	IN	_	32	case	_	_
28	when	when	WRB	_	32	adv	_	_
29	either	either	DT	_	30	det	_	_
30	drug	drug	NN	_	32	dep	_	_
31	is	be	VBZ	_	32	aux	_	_
32	used	use	VBN	_	26	ppmod	_	_
33	alone	alone	RB	_	32	adv	_	_
34	.	.	.	_	3	p	_	_

1	There	there	EX	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	no	no	DT	_	4	det	_	_
4	evidence	evidence	NN	_	2	obj	_	_
5	of	of	IN	_	7	case	_	_
6	drug	drug	NN	_	7	com	_	_
7	interactions	interaction	NNS	_	4	ppmod	_	_
8	in	in	IN	_	10	case	_	_
9	clinical	clinical	JJ	_	10	attr	_	_
10	studies	study	NNS	_	7	ppmod	_	_
11	in	in	IN	_	12	case	_	_
12	which	which	WDT	_	15	ppmod	_	_
13	drug1	drug0	NN	_	15	dep	_	_
14	was	be	VBD	_	15	aux	_	_
15	administered	administer	VBN	_	10	relcl	_	_
16	concurrently	concurrently	RB	_	15	adv	_	_
17	with	with	IN	_	19	case	_	_
18	other	other	JJ	_	19	attr	_	_
19	drugs	drug	NNS	_	15	ppmod	_	_
20	,	,	,	_	19	p	_	_
21	including	include	VBG	_	22	adv	_	_
22	drug2	drug0	NN	_	19	ppmod	_	_
23	,	,	,	_	22	p	_	_
24	drug3	drug0	NN	_	22	conj	_	_
25	,	,	,	_	24	p	_	_
26	drug4	drug0	NN	_	22	conj	_	_
27	,	,	,	_	26	p	_	_
28	drug5	drug0	NN	_	22	conj	_	_
29	,	,	,	_	28	p	_	_
30	drug6	drug0	NN	_	22	conj	_	_
31	,	,	,	_	30	p	_	_
32	drug7	drug0	NN	_	22	conj	_	_
33	,	,	,	_	32	p	_	_
34	drug8	drug0	NN	_	22	conj	_	_
35	,	,	,	_	34	p	_	_
36	drug9	drug0	NN	_	22	conj	_	_
37	,	,	,	_	36	p	_	_
38	drug10	drug0	NN	_	22	conj	_	_
39	,	,	,	_	38	p	_	_
40	drug11	drug0	NN	_	22	conj	_	_
41	,	,	,	_	40	p	_	_
42	drug12	drug0	NN	_	22	conj	_	_
43	,	,	,	_	42	p	_	_
44	drug13	drug0	NN	_	22	conj	_	_
45	,	,	,	_	44	p	_	_
46	and	and	CC	_	44	cc	_	_
47	drug14	drug0	NN	_	22	conj	_	_
48	.	.	.	_	2	p	_	_

1	No	no	DT	_	4	det	_	_
2	drug-drug	drug-drug	JJ	_	4	attr	_	_
3	interaction	interaction	NN	_	4	com	_	_
4	studies	study	NNS	_	10	dep	_	_
5	in	in	IN	_	7	case	_	_
6	human	human	JJ	_	7	attr	_	_
7	subjects	subject	NNS	_	4	ppmod	_	_
8	have	have	VBP	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	conducted	conduct	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	Toxicologic	toxicologic	JJ	_	4	attr	_	_
2	and	and	CC	_	1	cc	_	_
3	toxicokinetic	toxicokinetic	JJ	_	1	conj	_	_
4	studies	study	NNS	_	9	dep	_	_
5	in	in	IN	_	6	case	_	_
6	rats	rat	NNS	_	4	ppmod	_	_
7	did	do	VBD	_	9	aux	_	_
8	not	not	RB	_	9	neg	_	_
9	demonstrate	demonstrate	VB	_	0	root	_	_
10	any	any	DT	_	11	det	_	_
11	alterations	alteration	NNS	_	9	obj	_	_
12	in	in	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	clearance	clearance	NN	_	11	ppmod	_	_
15	or	or	CC	_	14	cc	_	_
16	toxicologic	toxicologic	JJ	_	17	attr	_	_
17	profile	profile	NN	_	14	conj	_	_
18	of	of	IN	_	20	case	_	_
19	either	either	CC	_	20	cc	_	_
20	drug1	drug0	NN	_	14	ppmod	_	_
21	or	or	CC	_	20	cc	_	_
22	drug2	drug0	NN	_	20	conj	_	_
23	when	when	WRB	_	28	adv	_	_
24	the	the	DT	_	26	det	_	_
25	two	#crd#	CD	_	26	num	_	_
26	agents	agent	NNS	_	28	dep	_	_
27	were	be	VBD	_	28	aux	_	_
28	administered	administer	VBN	_	9	comp	_	_
29	together	together	RB	_	28	adv	_	_
30	.	.	.	_	9	p	_	_

1	In	in	IN	_	3	case	_	_
2	a	a	DT	_	3	det	_	_
3	study	study	NN	_	32	ppmod	_	_
4	in	in	IN	_	5	case	_	_
5	which	which	WDT	_	11	ppmod	_	_
6	patients	patient	NNS	_	11	dep	_	_
7	with	with	IN	_	9	case	_	_
8	active	active	JJ	_	9	attr	_	_
9	RA	ra	NN	_	6	ppmod	_	_
10	were	be	VBD	_	11	aux	_	_
11	treated	treat	VBN	_	3	relcl	_	_
12	for	for	IN	_	16	case	_	_
13	up	up	RB	_	15	adv	_	_
14	to	to	TO	_	15	attr	_	_
15	24	0	CD	_	16	num	_	_
16	weeks	week	NNS	_	11	ppmod	_	_
17	with	with	IN	_	19	case	_	_
18	concurrent	concurrent	JJ	_	19	attr	_	_
19	drug1	drug0	NN	_	11	ppmod	_	_
20	and	and	CC	_	19	cc	_	_
21	drug2	drug0	JJ	_	22	attr	_	_
22	therapy	therapy	NN	_	19	conj	_	_
23	,	,	,	_	32	p	_	_
24	a	a	DT	_	27	det	_	_
25	7	0	CD	_	27	num	_	_
26	%	%	NN	_	25	meta	_	_
27	rate	rate	NN	_	32	dep	_	_
28	of	of	IN	_	30	case	_	_
29	serious	serious	JJ	_	30	attr	_	_
30	infections	infection	NNS	_	27	ppmod	_	_
31	was	be	VBD	_	32	aux	_	_
32	observed	observe	VBN	_	0	root	_	_
33	,	,	,	_	32	p	_	_
34	which	which	WDT	_	35	dep	_	_
35	was	be	VBD	_	32	comp	_	_
36	higher	high	JJR	_	35	dep	_	_
37	than	than	IN	_	38	case	_	_
38	that	that	DT	_	36	ppmod	_	_
39	observed	observe	VBN	_	38	acl	_	_
40	with	with	IN	_	41	case	_	_
41	drug3	drug0	NN	_	39	ppmod	_	_
42	alone	alone	RB	_	41	adv	_	_
43	(	-lrb-	-LRB-	_	44	p	_	_
44	0	0	CD	_	35	num	_	_
45	%	%	NN	_	44	meta	_	_
46	)	-rrb-	-RRB-	_	44	p	_	_
47	.	.	.	_	32	p	_	_

1	Two	#crd#	CD	_	2	num	_	_
2	percent	percent	NN	_	11	dep	_	_
3	of	of	IN	_	4	case	_	_
4	patients	patient	NNS	_	2	ppmod	_	_
5	treated	treat	VBN	_	4	acl	_	_
6	concurrently	concurrently	RB	_	5	adv	_	_
7	with	with	IN	_	8	case	_	_
8	drug1	drug0	NN	_	5	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	drug2	drug0	NN	_	8	conj	_	_
11	developed	develop	VBD	_	0	root	_	_
12	neutropenia	neutropenia	NN	_	11	obj	_	_
13	(	-lrb-	-LRB-	_	17	p	_	_
14	ANC	anc	NN	_	17	attr	_	_
15	1	0	CD	_	17	num	_	_
16	x	x	NN	_	17	com	_	_
17	109/L	0/l	NN	_	12	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	3	com	_	_
2	containing	containing	NN	_	3	com	_	_
3	drug2	drug0	NNS	_	11	dep	_	_
4	,	,	,	_	3	p	_	_
5	when	when	WRB	_	6	adv	_	_
6	administered	administer	VBN	_	3	relcl	_	_
7	concomitantly	concomitantly	RB	_	6	adv	_	_
8	with	with	IN	_	9	case	_	_
9	drug3	drug0	NN	_	6	ppmod	_	_
10	,	,	,	_	3	p	_	_
11	reduce	reduce	VBP	_	0	root	_	_
12	both	both	CC	_	14	cc	_	_
13	the	the	DT	_	14	det	_	_
14	rate	rate	NN	_	11	obj	_	_
15	and	and	CC	_	14	cc	_	_
16	extent	extent	NN	_	14	conj	_	_
17	of	of	IN	_	18	case	_	_
18	absorption	absorption	NN	_	14	ppmod	_	_
19	.	.	.	_	11	p	_	_

1	The	the	DT	_	2	det	_	_
2	mechanism	mechanism	NN	_	7	dep	_	_
3	for	for	IN	_	5	case	_	_
4	this	this	DT	_	5	det	_	_
5	interaction	interaction	NN	_	2	ppmod	_	_
6	probably	probably	RB	_	7	adv	_	_
7	is	be	VBZ	_	0	root	_	_
8	adsorption	adsorption	NN	_	7	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	onto	onto	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	surface	surface	NN	_	8	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	10	dep	_	_
2	,	,	,	_	1	p	_	_
3	such	such	JJ	_	5	adv	_	_
4	as	as	IN	_	5	case	_	_
5	drug2	drug0	NN	_	1	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug3	drug0	NN	_	5	conj	_	_
8	,	,	,	_	1	p	_	_
9	can	can	MD	_	10	modal	_	_
10	inhibit	inhibit	VB	_	0	root	_	_
11	renal	renal	JJ	_	13	attr	_	_
12	tubular	tubular	JJ	_	13	attr	_	_
13	secretion	secretion	NN	_	10	obj	_	_
14	of	of	IN	_	15	case	_	_
15	drug4	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	10	p	_	_

1	The	the	DT	_	3	det	_	_
2	resulting	result	VBG	_	3	attr	_	_
3	increase	increase	NN	_	9	dep	_	_
4	in	in	IN	_	7	case	_	_
5	drug1	drug0	NN	_	7	com	_	_
6	serum	serum	NN	_	7	com	_	_
7	levels	level	NNS	_	3	ppmod	_	_
8	may	may	MD	_	9	modal	_	_
9	increase	increase	VB	_	0	root	_	_
10	toxicity	toxicity	NN	_	9	obj	_	_
11	,	,	,	_	9	p	_	_
12	and	and	CC	_	9	cc	_	_
13	the	the	DT	_	16	det	_	_
14	decreased	decrease	VBN	_	16	attr	_	_
15	urinary	urinary	JJ	_	16	attr	_	_
16	levels	level	NNS	_	18	dep	_	_
17	could	could	MD	_	18	modal	_	_
18	lessen	lessen	VB	_	9	conj	_	_
19	its	its	PRP$	_	20	poss	_	_
20	efficacy	efficacy	NN	_	18	obj	_	_
21	as	as	IN	_	25	case	_	_
22	a	a	DT	_	25	det	_	_
23	urinary	urinary	JJ	_	25	attr	_	_
24	tract	tract	NN	_	25	com	_	_
25	drug2	drug0	NN	_	18	ppmod	_	_
26	.	.	.	_	9	p	_	_

1	Drug/Laboratory	drug/laboratory	JJ	_	3	attr	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	22	dep	_	_
4	As	as	IN	_	6	case	_	_
5	a	a	DT	_	6	det	_	_
6	result	result	NN	_	3	ppmod	_	_
7	of	of	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	presence	presence	NN	_	6	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	,	,	,	_	11	p	_	_
13	a	a	DT	_	15	det	_	_
14	false-positive	false-positive	JJ	_	15	attr	_	_
15	reaction	reaction	NN	_	11	appo	_	_
16	for	for	IN	_	17	case	_	_
17	glucose	glucose	NN	_	15	ppmod	_	_
18	in	in	IN	_	20	case	_	_
19	the	the	DT	_	20	det	_	_
20	urine	urine	NN	_	15	ppmod	_	_
21	may	may	MD	_	22	modal	_	_
22	occur	occur	VB	_	0	root	_	_
23	.	.	.	_	22	p	_	_

1	This	this	DT	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	observed	observe	VBN	_	0	root	_	_
5	with	with	IN	_	11	case	_	_
6	Benedict	benedict	NNP	_	7	com	_	_
7	s	s	NNP	_	11	attr	_	_
8	and	and	CC	_	7	cc	_	_
9	Fehling	fehling	NNP	_	10	com	_	_
10	s	s	NNP	_	7	conj	_	_
11	solutions	solution	NNS	_	4	ppmod	_	_
12	but	but	CC	_	11	cc	_	_
13	not	not	RB	_	18	neg	_	_
14	with	with	IN	_	18	case	_	_
15	the	the	DT	_	18	det	_	_
16	glucose	glucose	NN	_	18	attr	_	_
17	enzymatic	enzymatic	JJ	_	18	attr	_	_
18	test	test	NN	_	11	conj	_	_
19	.	.	.	_	4	p	_	_

1	In	in	IN	_	2	case	_	_
2	evaluating	evaluate	VBG	_	27	ppmod	_	_
3	the	the	DT	_	4	det	_	_
4	potential	potential	NN	_	2	obj	_	_
5	for	for	IN	_	6	case	_	_
6	interactions	interaction	NNS	_	4	ppmod	_	_
7	among	among	IN	_	10	case	_	_
8	co-administered	co-administered	NN	_	10	com	_	_
9	antiepilepsy	antiepilepsy	NN	_	10	com	_	_
10	drugs	drug	NNS	_	6	ppmod	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	drug1	drug0	NN	_	10	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	,	,	,	_	27	p	_	_
15	whether	whether	IN	_	20	mark	_	_
16	or	or	CC	_	20	cc	_	_
17	not	not	RB	_	20	neg	_	_
18	an	an	DT	_	19	det	_	_
19	drug2	drug0	NN	_	20	dep	_	_
20	induces	induce	VBZ	_	27	advcl	_	_
21	or	or	CC	_	20	cc	_	_
22	does	do	VBZ	_	24	aux	_	_
23	not	not	RB	_	24	neg	_	_
24	induce	induce	VB	_	20	conj	_	_
25	metabolic	metabolic	JJ	_	26	attr	_	_
26	enzymes	enzyme	NNS	_	24	obj	_	_
27	is	be	VBZ	_	0	root	_	_
28	an	an	DT	_	30	det	_	_
29	important	important	JJ	_	30	attr	_	_
30	consideration	consideration	NN	_	27	obj	_	_
31	.	.	.	_	27	p	_	_

1	drug1	drug0	NN	_	9	dep	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	and	and	CC	_	3	cc	_	_
5	drug3	drug0	NN	_	1	conj	_	_
6	are	be	VBP	_	9	aux	_	_
7	ge	ge	NN	_	8	advnp	_	_
8	nerally	nerally	RB	_	9	adv	_	_
9	classified	classify	VBN	_	0	root	_	_
10	as	as	IN	_	12	case	_	_
11	enzyme	enzyme	NN	_	12	com	_	_
12	inducers	inducer	NNS	_	9	ppmod	_	_
13	;	;	:	_	9	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	are	be	VBP	_	0	root	_	_
5	not	not	RB	_	4	neg	_	_
6	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	considered	consider	VBN	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	be	be	VB	_	3	comp	_	_
6	a	a	DT	_	9	det	_	_
7	non-enzyme	non-enzyme	JJ	_	9	attr	_	_
8	inducing	inducing	NN	_	9	com	_	_
9	drug2	drug0	NN	_	5	obj	_	_
10	.	.	.	_	3	p	_	_

1	The	the	DT	_	4	det	_	_
2	drug	drug	NN	_	4	com	_	_
3	interaction	interaction	NN	_	4	com	_	_
4	data	datum	NNS	_	10	dep	_	_
5	described	describe	VBN	_	4	acl	_	_
6	in	in	IN	_	8	case	_	_
7	this	this	DT	_	8	det	_	_
8	section	section	NN	_	5	ppmod	_	_
9	were	be	VBD	_	10	aux	_	_
10	obtained	obtain	VBN	_	0	root	_	_
11	from	from	IN	_	12	case	_	_
12	studies	study	NNS	_	10	ppmod	_	_
13	involving	involve	VBG	_	12	acl	_	_
14	either	either	CC	_	16	cc	_	_
15	healthy	healthy	JJ	_	16	attr	_	_
16	subjects	subject	NNS	_	13	obj	_	_
17	or	or	CC	_	16	cc	_	_
18	patients	patient	NNS	_	16	conj	_	_
19	with	with	IN	_	20	case	_	_
20	epilepsy	epilepsy	NN	_	18	ppmod	_	_
21	.	.	.	_	10	p	_	_

1	Effects	effect	NNS	_	15	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	on	on	IN	_	7	case	_	_
5	other	other	JJ	_	7	attr	_	_
6	Antiepilepsy	antiepilepsy	NN	_	7	com	_	_
7	Drugs	drug	NNS	_	1	ppmod	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	drug2	drug0	NN	_	7	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	:	:	:	_	7	p	_	_
12	drug3	drug0	NN	_	7	appo	_	_
13	:	:	:	_	7	p	_	_
14	drug4	drug0	NNS	_	7	appo	_	_
15	had	have	VBD	_	0	root	_	_
16	no	no	DT	_	17	det	_	_
17	effect	effect	NN	_	15	obj	_	_
18	on	on	IN	_	22	case	_	_
19	the	the	DT	_	22	det	_	_
20	steady-state	steady-state	JJ	_	22	attr	_	_
21	plasma	plasma	NN	_	22	com	_	_
22	concentrations	concentration	NNS	_	15	ppmod	_	_
23	of	of	IN	_	24	case	_	_
24	drug5	drug0	NN	_	22	ppmod	_	_
25	in	in	IN	_	26	case	_	_
26	patients	patient	NNS	_	24	ppmod	_	_
27	with	with	IN	_	28	case	_	_
28	epilepsy	epilepsy	NN	_	26	ppmod	_	_
29	.	.	.	_	15	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	4	dep	_	_
4	had	have	VBD	_	1	acl	_	_
5	no	no	DT	_	6	det	_	_
6	effect	effect	NN	_	4	obj	_	_
7	on	on	IN	_	11	case	_	_
8	the	the	DT	_	11	det	_	_
9	steady-state	steady-state	JJ	_	11	attr	_	_
10	plasma	plasma	NN	_	11	com	_	_
11	concentrations	concentration	NNS	_	4	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug3	drug0	NN	_	11	ppmod	_	_
14	or	or	CC	_	11	cc	_	_
15	its	its	PRP$	_	17	poss	_	_
16	epoxide	epoxide	NN	_	17	com	_	_
17	metabolite	metabolite	NN	_	11	conj	_	_
18	in	in	IN	_	19	case	_	_
19	patients	patient	NNS	_	17	ppmod	_	_
20	with	with	IN	_	21	case	_	_
21	epilepsy	epilepsy	NN	_	19	ppmod	_	_
22	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	causes	cause	VBZ	_	0	root	_	_
5	a	a	DT	_	7	det	_	_
6	slight	slight	JJ	_	7	attr	_	_
7	decrease	decrease	NN	_	4	obj	_	_
8	(	-lrb-	-LRB-	_	10	p	_	_
9	about	about	RB	_	10	adv	_	_
10	10	0	CD	_	7	num	_	_
11	%	%	NN	_	10	meta	_	_
12	)	-rrb-	-RRB-	_	10	p	_	_
13	in	in	IN	_	16	case	_	_
14	steady-state	steady-state	JJ	_	16	attr	_	_
15	drug3	drug0	NN	_	16	com	_	_
16	concentrations	concentration	NNS	_	4	ppmod	_	_
17	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	or	or	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	:	:	:	_	1	p	_	_
5	No	no	DT	_	8	det	_	_
6	formal	formal	JJ	_	8	attr	_	_
7	pharmacokinetic	pharmacokinetic	JJ	_	8	attr	_	_
8	studies	study	NNS	_	11	dep	_	_
9	have	have	VBP	_	11	aux	_	_
10	been	be	VBN	_	11	aux	_	_
11	performed	performed	VBN	_	1	acl	_	_
12	examining	examine	VBG	_	11	comp	_	_
13	the	the	DT	_	14	det	_	_
14	addition	addition	NN	_	12	obj	_	_
15	of	of	IN	_	16	case	_	_
16	drug3	drug0	NN	_	14	ppmod	_	_
17	to	to	TO	_	18	aux	_	_
18	regimens	regimen	NNS	_	14	ppmod	_	_
19	containing	contain	VBG	_	18	acl	_	_
20	drug4	drug0	NN	_	19	obj	_	_
21	or	or	CC	_	20	cc	_	_
22	drug5	drug0	NN	_	20	conj	_	_
23	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	addition	addition	NN	_	15	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	in	in	IN	_	8	case	_	_
6	a	a	DT	_	8	det	_	_
7	limited	limited	JJ	_	8	attr	_	_
8	number	number	NN	_	2	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	patients	patient	NNS	_	8	ppmod	_	_
11	in	in	IN	_	14	case	_	_
12	three	#crd#	CD	_	14	num	_	_
13	well-controlled	well-controlled	JJ	_	14	attr	_	_
14	studies	study	NNS	_	10	ppmod	_	_
15	caused	cause	VBD	_	0	root	_	_
16	no	no	DT	_	18	det	_	_
17	systematic	systematic	JJ	_	18	attr	_	_
18	changes	change	NNS	_	15	obj	_	_
19	in	in	IN	_	20	case	_	_
20	drug2	drug0	NN	_	15	ppmod	_	_
21	or	or	CC	_	20	cc	_	_
22	drug3	drug0	NN	_	23	com	_	_
23	concentrations	concentration	NNS	_	20	conj	_	_
24	when	when	WRB	_	25	adv	_	_
25	compared	compare	VBN	_	15	comp	_	_
26	to	to	TO	_	27	aux	_	_
27	placebo	placebo	NN	_	25	ppmod	_	_
28	.	.	.	_	15	p	_	_

1	Effects	effect	NNS	_	12	dep	_	_
2	of	of	IN	_	5	case	_	_
3	other	other	JJ	_	5	attr	_	_
4	Antiepilepsy	antiepilepsy	NN	_	5	com	_	_
5	Drugs	drug	NNS	_	1	ppmod	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	drug1	drug0	NN	_	5	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	on	on	IN	_	10	case	_	_
10	drug2	drug0	NN	_	1	ppmod	_	_
11	:	:	:	_	12	p	_	_
12	drug3	drug0	NN	_	0	root	_	_
13	:	:	:	_	12	p	_	_
14	Population	population	NN	_	16	attr	_	_
15	pharmacokinetic	pharmacokinetic	JJ	_	16	attr	_	_
16	analyses	analysis	NNS	_	17	dep	_	_
17	indicate	indicate	VBP	_	12	acl	_	_
18	that	that	IN	_	21	mark	_	_
19	drug4	drug0	NN	_	20	com	_	_
20	clearance	clearance	NN	_	21	dep	_	_
21	is	be	VBZ	_	17	comp	_	_
22	60	0	CD	_	24	num	_	_
23	%	%	NN	_	22	meta	_	_
24	greater	great	JJR	_	21	dep	_	_
25	in	in	IN	_	26	case	_	_
26	patients	patient	NNS	_	24	ppmod	_	_
27	taking	take	VBG	_	26	acl	_	_
28	drug5	drug0	NN	_	27	obj	_	_
29	with	with	IN	_	27	ppmod	_	_
30	or	or	CC	_	29	cc	_	_
31	without	without	IN	_	35	case	_	_
32	other	other	JJ	_	35	attr	_	_
33	enzyme-	enzyme-	NN	_	35	com	_	_
34	inducing	inducing	NN	_	35	com	_	_
35	drug6	drug0	NN	_	29	conj	_	_
36	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Population	population	NN	_	5	attr	_	_
4	pharmacokinetic	pharmacokinetic	JJ	_	5	attr	_	_
5	analyses	analysis	NNS	_	6	dep	_	_
6	indicate	indicate	VBP	_	1	acl	_	_
7	that	that	IN	_	10	mark	_	_
8	drug2	drug0	NN	_	9	com	_	_
9	clearance	clearance	NN	_	10	dep	_	_
10	is	be	VBZ	_	6	comp	_	_
11	60	0	CD	_	13	num	_	_
12	%	%	NN	_	11	meta	_	_
13	greater	great	JJR	_	10	dep	_	_
14	in	in	IN	_	15	case	_	_
15	patients	patient	NNS	_	13	ppmod	_	_
16	taking	take	VBG	_	15	acl	_	_
17	drug3	drug0	NN	_	16	obj	_	_
18	with	with	IN	_	16	ppmod	_	_
19	or	or	CC	_	18	cc	_	_
20	without	without	IN	_	24	case	_	_
21	other	other	JJ	_	24	attr	_	_
22	enzyme-	enzyme-	NN	_	24	com	_	_
23	inducing	inducing	NN	_	24	com	_	_
24	drug4	drug0	NN	_	18	conj	_	_
25	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	drug2	drug0	NN	_	1	prn	_	_
4	)	-rrb-	-RRB-	_	3	p	_	_
5	:	:	:	_	1	p	_	_
6	Population	population	NN	_	8	attr	_	_
7	pharmacokinetic	pharmacokinetic	JJ	_	8	attr	_	_
8	analyses	analysis	NNS	_	9	dep	_	_
9	indicate	indicate	VBP	_	1	acl	_	_
10	that	that	IN	_	13	mark	_	_
11	drug3	drug0	NN	_	12	com	_	_
12	clearance	clearance	NN	_	13	dep	_	_
13	is	be	VBZ	_	9	comp	_	_
14	60	0	CD	_	16	num	_	_
15	%	%	NN	_	14	meta	_	_
16	greater	great	JJR	_	13	dep	_	_
17	in	in	IN	_	18	case	_	_
18	patients	patient	NNS	_	16	ppmod	_	_
19	taking	take	VBG	_	18	acl	_	_
20	drug4	drug0	NN	_	19	obj	_	_
21	(	-lrb-	-LRB-	_	22	p	_	_
22	drug5	drug0	NN	_	20	prn	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	with	with	IN	_	19	ppmod	_	_
25	or	or	CC	_	24	cc	_	_
26	without	without	IN	_	29	case	_	_
27	other	other	JJ	_	29	attr	_	_
28	enzyme-inducing	enzyme-inducing	JJ	_	29	attr	_	_
29	drug6	drug0	NN	_	24	conj	_	_
30	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	addition	addition	NN	_	12	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	to	to	TO	_	8	aux	_	_
8	patients	patient	NNS	_	4	ppmod	_	_
9	taking	take	VBG	_	8	acl	_	_
10	drug3	drug0	NN	_	9	obj	_	_
11	chronically	chronically	RB	_	12	adv	_	_
12	had	have	VBD	_	1	acl	_	_
13	no	no	DT	_	14	det	_	_
14	effect	effect	NN	_	12	obj	_	_
15	on	on	IN	_	17	case	_	_
16	drug4	drug0	NN	_	17	com	_	_
17	pharmacokinetics	pharmacokinetics	NNS	_	12	ppmod	_	_
18	,	,	,	_	12	p	_	_
19	but	but	CC	_	12	cc	_	_
20	drug5	drug0	NN	_	22	dep	_	_
21	significantly	significantly	RB	_	22	adv	_	_
22	decreased	decrease	VBD	_	12	conj	_	_
23	drug6	drug0	NN	_	24	com	_	_
24	binding	binding	NN	_	22	obj	_	_
25	in	in	FW	_	26	adv	_	_
26	vitro	vitro	FW	_	22	adv	_	_
27	from	from	IN	_	28	case	_	_
28	96.3	0	CD	_	22	ppmod	_	_
29	to	to	TO	_	28	cc	_	_
30	94.8	0	CD	_	28	conj	_	_
31	%	%	NN	_	28	meta	_	_
32	,	,	,	_	28	p	_	_
33	which	which	WDT	_	34	dep	_	_
34	resulted	result	VBD	_	28	relcl	_	_
35	in	in	IN	_	37	case	_	_
36	an	an	DT	_	37	det	_	_
37	increase	increase	NN	_	34	ppmod	_	_
38	of	of	IN	_	40	case	_	_
39	approximately	approximately	RB	_	40	adv	_	_
40	40	0	CD	_	37	ppmod	_	_
41	%	%	NN	_	40	meta	_	_
42	in	in	IN	_	46	case	_	_
43	the	the	DT	_	46	det	_	_
44	free	free	JJ	_	46	attr	_	_
45	tiagabine	tiagabine	NN	_	46	com	_	_
46	concentration	concentration	NN	_	37	ppmod	_	_
47	.	.	.	_	1	p	_	_

1	The	the	DT	_	3	det	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	relevance	relevance	NN	_	9	dep	_	_
4	of	of	IN	_	8	case	_	_
5	this	this	DT	_	8	det	_	_
6	in	in	FW	_	7	adv	_	_
7	vitro	vitro	FW	_	8	attr	_	_
8	finding	finding	NN	_	3	ppmod	_	_
9	is	be	VBZ	_	0	root	_	_
10	unknown	unknown	JJ	_	9	dep	_	_
11	.	.	.	_	9	p	_	_

1	Interaction	interaction	NN	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	6	case	_	_
5	Other	other	JJ	_	6	attr	_	_
6	Drugs	drug	NNS	_	1	ppmod	_	_
7	:	:	:	_	1	p	_	_
8	drug2	drug0	NN	_	1	appo	_	_
9	:	:	:	_	1	p	_	_
10	Co-administration	co-administration	NN	_	22	dep	_	_
11	of	of	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	(	-lrb-	-LRB-	_	15	p	_	_
14	800	0	CD	_	15	num	_	_
15	mg/day	mg/day	NN	_	12	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	to	to	TO	_	18	aux	_	_
18	patients	patient	NNS	_	10	ppmod	_	_
19	taking	take	VBG	_	18	acl	_	_
20	drug4	drug0	NN	_	19	obj	_	_
21	chronically	chronically	RB	_	22	adv	_	_
22	had	have	VBD	_	1	acl	_	_
23	no	no	DT	_	24	det	_	_
24	effect	effect	NN	_	22	obj	_	_
25	on	on	IN	_	27	case	_	_
26	drug5	drug0	NN	_	27	com	_	_
27	pharmacokinetics	pharmacokinetics	NNS	_	22	ppmod	_	_
28	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	12	dep	_	_
2	:	:	:	_	1	p	_	_
3	A	a	DT	_	7	det	_	_
4	single	single	JJ	_	7	attr	_	_
5	10	0	CD	_	6	num	_	_
6	mg	mg	NN	_	7	com	_	_
7	dose	dose	NN	_	1	appo	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	did	do	VBD	_	12	aux	_	_
11	not	not	RB	_	12	neg	_	_
12	affect	affect	VB	_	0	root	_	_
13	the	the	DT	_	14	det	_	_
14	pharmacokinetics	pharmacokinetics	NNS	_	12	obj	_	_
15	of	of	IN	_	16	case	_	_
16	drug3	drug0	NN	_	14	ppmod	_	_
17	at	at	IN	_	19	case	_	_
18	steady	steady	JJ	_	19	attr	_	_
19	state	state	NN	_	14	ppmod	_	_
20	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	No	no	DT	_	5	det	_	_
4	significant	significant	JJ	_	5	attr	_	_
5	differences	difference	NNS	_	7	dep	_	_
6	were	be	VBD	_	7	aux	_	_
7	observed	observe	VBN	_	1	acl	_	_
8	in	in	IN	_	11	case	_	_
9	the	the	DT	_	11	det	_	_
10	steady-state	steady-state	JJ	_	11	attr	_	_
11	pharmacokinetics	pharmacokinetics	NNS	_	7	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	or	or	CC	_	13	cc	_	_
15	drug3	drug0	NN	_	13	conj	_	_
16	with	with	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	addition	addition	NN	_	11	ppmod	_	_
19	of	of	IN	_	20	case	_	_
20	drug4	drug0	NNS	_	18	ppmod	_	_
21	given	give	VBN	_	20	acl	_	_
22	as	as	IN	_	25	case	_	_
23	a	a	DT	_	25	det	_	_
24	single	single	JJ	_	25	attr	_	_
25	dose	dose	NN	_	21	ppmod	_	_
26	.	.	.	_	1	p	_	_

1	Prothrombin	prothrombin	NN	_	2	com	_	_
2	times	time	NNS	_	5	dep	_	_
3	were	be	VBD	_	5	aux	_	_
4	not	not	RB	_	5	neg	_	_
5	affected	affect	VBN	_	0	root	_	_
6	by	by	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Concomitant	concomitant	JJ	_	4	attr	_	_
4	administration	administration	NN	_	9	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	did	do	VBD	_	9	aux	_	_
8	not	not	RB	_	9	neg	_	_
9	affect	affect	VB	_	1	acl	_	_
10	the	the	DT	_	12	det	_	_
11	steady-state	steady-state	JJ	_	12	attr	_	_
12	pharmacokinetics	pharmacokinetics	NNS	_	9	obj	_	_
13	of	of	IN	_	14	case	_	_
14	drug3	drug0	NN	_	12	ppmod	_	_
15	or	or	CC	_	12	cc	_	_
16	the	the	DT	_	21	det	_	_
17	mean	mean	JJ	_	21	attr	_	_
18	daily	daily	JJ	_	21	attr	_	_
19	trough	trough	NN	_	21	com	_	_
20	serum	serum	NN	_	21	com	_	_
21	level	level	NN	_	12	conj	_	_
22	of	of	IN	_	23	case	_	_
23	drug4	drug0	NN	_	21	ppmod	_	_
24	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	or	or	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	:	:	:	_	1	p	_	_
5	No	no	DT	_	7	det	_	_
6	significant	significant	JJ	_	7	attr	_	_
7	differences	difference	NNS	_	9	dep	_	_
8	were	be	VBD	_	9	aux	_	_
9	observed	observe	VBN	_	1	acl	_	_
10	in	in	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	pharmacokinetics	pharmacokinetics	NNS	_	9	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug3	drug0	NN	_	12	ppmod	_	_
15	(	-lrb-	-LRB-	_	17	p	_	_
16	0.125	0	CD	_	17	num	_	_
17	mg	mg	NN	_	14	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	and	and	CC	_	14	cc	_	_
20	drug4	drug0	NN	_	14	conj	_	_
21	(	-lrb-	-LRB-	_	23	p	_	_
22	10	0	CD	_	23	num	_	_
23	mg	mg	NN	_	20	prn	_	_
24	)	-rrb-	-RRB-	_	23	p	_	_
25	when	when	WRB	_	26	adv	_	_
26	given	give	VBN	_	9	comp	_	_
27	together	together	RB	_	26	adv	_	_
28	as	as	IN	_	31	case	_	_
29	a	a	DT	_	31	det	_	_
30	single	single	JJ	_	31	attr	_	_
31	dose	dose	NN	_	26	ppmod	_	_
32	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	pharmacokinetics	pharmacokinetics	NNS	_	7	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	were	be	VBD	_	7	aux	_	_
6	not	not	RB	_	7	neg	_	_
7	affected	affect	VBN	_	0	root	_	_
8	by	by	IN	_	10	case	_	_
9	multiple-dose	multiple-dose	JJ	_	10	attr	_	_
10	administration	administration	NN	_	7	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	has	have	VBZ	_	3	aux	_	_
3	shown	show	VBN	_	0	root	_	_
4	no	no	DT	_	7	det	_	_
5	clinically	clinically	RB	_	6	adv	_	_
6	important	important	JJ	_	7	attr	_	_
7	potentiation	potentiation	NN	_	3	obj	_	_
8	of	of	IN	_	11	case	_	_
9	the	the	DT	_	11	det	_	_
10	pharmacodynamic	pharmacodynamic	JJ	_	11	attr	_	_
11	effects	effect	NNS	_	7	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	triazo	triazo	NN	_	14	com	_	_
14	lam	lam	NN	_	11	ppmod	_	_
15	or	or	CC	_	14	cc	_	_
16	drug2	drug0	NN	_	14	conj	_	_
17	.	.	.	_	3	p	_	_

1	Because	because	IN	_	6	case	_	_
2	of	of	IN	_	6	case	_	_
3	the	the	DT	_	6	det	_	_
4	possible	possible	JJ	_	6	attr	_	_
5	additive	additive	JJ	_	6	attr	_	_
6	effects	effect	NNS	_	21	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drugs	drug	NNS	_	6	ppmod	_	_
9	that	that	WDT	_	11	dep	_	_
10	may	may	MD	_	11	modal	_	_
11	depress	depress	VB	_	8	relcl	_	_
12	the	the	DT	_	14	det	_	_
13	nervous	nervous	JJ	_	14	attr	_	_
14	system	system	NN	_	11	obj	_	_
15	,	,	,	_	21	p	_	_
16	drug1	drug0	NN	_	21	dep	_	_
17	or	or	CC	_	16	cc	_	_
18	drug2	drug0	NN	_	16	conj	_	_
19	should	should	MD	_	21	modal	_	_
20	be	be	VB	_	21	aux	_	_
21	used	use	VBN	_	0	root	_	_
22	cautiously	cautiously	RB	_	21	adv	_	_
23	in	in	IN	_	24	case	_	_
24	combination	combination	NN	_	21	ppmod	_	_
25	with	with	IN	_	26	case	_	_
26	drug3	drug0	NN	_	24	ppmod	_	_
27	.	.	.	_	21	p	_	_

1	Oral	oral	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	Multiple	multiple	JJ	_	6	attr	_	_
5	dose	dose	NN	_	6	com	_	_
6	administration	administration	NN	_	16	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	(	-lrb-	-LRB-	_	12	p	_	_
10	8	0	CD	_	12	num	_	_
11	mg/day	mg/day	NN	_	12	com	_	_
12	monotherapy	monotherapy	NN	_	8	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	did	do	VBD	_	16	aux	_	_
15	not	not	RB	_	16	neg	_	_
16	alter	alter	VB	_	2	acl	_	_
17	the	the	DT	_	18	det	_	_
18	pharmacokinetics	pharmacokinetics	NNS	_	16	obj	_	_
19	of	of	IN	_	21	case	_	_
20	oral	oral	JJ	_	21	attr	_	_
21	drug3	drug0	NN	_	18	ppmod	_	_
22	in	in	IN	_	24	case	_	_
23	healthy	healthy	JJ	_	24	attr	_	_
24	women	woman	NNS	_	18	ppmod	_	_
25	of	of	IN	_	27	case	_	_
26	childbearing	childbearing	JJ	_	27	attr	_	_
27	age	age	NN	_	24	ppmod	_	_
28	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	4	com	_	_
4	pharmacokinetics	pharmacokinetics	NNS	_	5	dep	_	_
5	were	be	VBD	_	1	acl	_	_
6	not	not	RB	_	5	neg	_	_
7	significantly	significantly	RB	_	8	adv	_	_
8	different	different	JJ	_	5	dep	_	_
9	before	before	IN	_	5	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	after	after	IN	_	14	case	_	_
12	drug3	drug0	NN	_	14	com	_	_
13	multiple-dose	multiple-dose	NN	_	14	com	_	_
14	regimens	regimen	NNS	_	9	conj	_	_
15	.	.	.	_	1	p	_	_

1	This	this	DT	_	2	dep	_	_
2	indicates	indicate	VBZ	_	0	root	_	_
3	that	that	IN	_	7	mark	_	_
4	drug1	drug0	NN	_	7	dep	_	_
5	does	do	VBZ	_	7	aux	_	_
6	not	not	RB	_	7	neg	_	_
7	cause	cause	VB	_	2	comp	_	_
8	induction	induction	NN	_	7	obj	_	_
9	or	or	CC	_	8	cc	_	_
10	inhibition	inhibition	NN	_	8	conj	_	_
11	of	of	IN	_	16	case	_	_
12	the	the	DT	_	16	det	_	_
13	hepatic	hepatic	JJ	_	16	attr	_	_
14	microsomal	microsomal	JJ	_	16	attr	_	_
15	enzyme	enzyme	NN	_	16	com	_	_
16	systems	system	NNS	_	8	ppmod	_	_
17	responsible	responsible	JJ	_	16	attr	_	_
18	for	for	IN	_	20	case	_	_
19	the	the	DT	_	20	det	_	_
20	metabolism	metabolism	NN	_	17	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	drug2	drug0	NN	_	20	ppmod	_	_
23	.	.	.	_	2	p	_	_

1	Interaction	interaction	NN	_	13	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	8	case	_	_
5	Highly	highly	RB	_	7	adv	_	_
6	Protein	protein	NN	_	7	advnp	_	_
7	Bound	bound	JJ	_	8	attr	_	_
8	Drugs	drug	NNS	_	1	ppmod	_	_
9	:	:	:	_	8	p	_	_
10	In	in	FW	_	11	adv	_	_
11	vitro	vitro	FW	_	12	attr	_	_
12	data	datum	NNS	_	8	appo	_	_
13	showed	show	VBD	_	0	root	_	_
14	that	that	IN	_	16	mark	_	_
15	drug2	drug0	NN	_	16	dep	_	_
16	is	be	VBZ	_	13	comp	_	_
17	96	0	CD	_	16	obj	_	_
18	%	%	NN	_	17	meta	_	_
19	bound	bind	VBD	_	17	acl	_	_
20	to	to	TO	_	23	aux	_	_
21	human	human	JJ	_	23	attr	_	_
22	plasma	plasma	NN	_	23	com	_	_
23	protein	protein	NN	_	19	ppmod	_	_
24	and	and	CC	_	16	cc	_	_
25	therefore	therefore	RB	_	26	adv	_	_
26	has	have	VBZ	_	16	conj	_	_
27	the	the	DT	_	28	det	_	_
28	potential	potential	NN	_	26	obj	_	_
29	to	to	TO	_	30	aux	_	_
30	interact	interact	VB	_	28	acl	_	_
31	with	with	IN	_	36	case	_	_
32	other	other	JJ	_	36	attr	_	_
33	highly	highly	RB	_	35	adv	_	_
34	protein	protein	NN	_	35	advnp	_	_
35	bound	bound	JJ	_	36	attr	_	_
36	compounds	compound	NNS	_	30	ppmod	_	_
37	.	.	.	_	13	p	_	_

1	Such	such	PDT	_	3	det	_	_
2	an	an	DT	_	3	det	_	_
3	interaction	interaction	NN	_	6	dep	_	_
4	can	can	MD	_	6	modal	_	_
5	potentially	potentially	RB	_	6	adv	_	_
6	lead	lead	VB	_	0	root	_	_
7	to	to	TO	_	10	aux	_	_
8	higher	high	JJR	_	10	attr	_	_
9	free	free	JJ	_	10	attr	_	_
10	fractions	fraction	NNS	_	6	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	either	either	CC	_	13	cc	_	_
13	drug1	drug0	NN	_	10	ppmod	_	_
14	or	or	CC	_	13	cc	_	_
15	the	the	DT	_	17	det	_	_
16	competing	compete	VBG	_	17	attr	_	_
17	drug	drug	NN	_	13	conj	_	_
18	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	15	dep	_	_
2	dosed	dose	VBN	_	1	acl	_	_
3	as	as	IN	_	8	case	_	_
4	a	a	DT	_	8	det	_	_
5	1.0	0	CD	_	6	num	_	_
6	mg/kg	mg/kg	NN	_	8	com	_	_
7	subcutaneous	subcutaneous	NN	_	8	com	_	_
8	injection	injection	NN	_	2	ppmod	_	_
9	q12h	q0h	IN	_	12	case	_	_
10	for	for	IN	_	12	case	_	_
11	four	#crd#	CD	_	12	num	_	_
12	doses	dose	NNS	_	8	ppmod	_	_
13	did	do	VBD	_	15	aux	_	_
14	not	not	RB	_	15	neg	_	_
15	alter	alter	VB	_	0	root	_	_
16	the	the	DT	_	17	det	_	_
17	pharmacokinetics	pharmacokinetics	NNS	_	15	obj	_	_
18	of	of	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	or	or	CC	_	19	cc	_	_
21	the	the	DT	_	22	det	_	_
22	level	level	NN	_	19	conj	_	_
23	of	of	IN	_	25	case	_	_
24	platelet	platelet	NN	_	25	com	_	_
25	aggregation	aggregation	NN	_	22	ppmod	_	_
26	in	in	IN	_	28	case	_	_
27	healthy	healthy	JJ	_	28	attr	_	_
28	adults	adult	NNS	_	17	ppmod	_	_
29	.	.	.	_	15	p	_	_

1	The	the	DT	_	3	det	_	_
2	adverse	adverse	JJ	_	3	attr	_	_
3	effects	effect	NNS	_	15	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	,	,	,	_	3	p	_	_
7	such	such	JJ	_	3	attr	_	_
8	as	as	IN	_	9	case	_	_
9	myelosuppression	myelosuppression	NN	_	7	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	diarrhea	diarrhea	NN	_	9	conj	_	_
12	,	,	,	_	3	p	_	_
13	would	would	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	expected	expect	VBN	_	0	root	_	_
16	to	to	TO	_	17	aux	_	_
17	be	be	VB	_	15	comp	_	_
18	exacerbated	exacerbated	JJ	_	17	dep	_	_
19	by	by	IN	_	21	case	_	_
20	other	other	JJ	_	21	attr	_	_
21	drug2	drug0	NNS	_	18	ppmod	_	_
22	having	have	VBG	_	21	acl	_	_
23	similar	similar	JJ	_	25	attr	_	_
24	adverse	adverse	JJ	_	25	attr	_	_
25	effects	effect	NNS	_	22	obj	_	_
26	.	.	.	_	15	p	_	_

1	Patients	patient	NNS	_	9	dep	_	_
2	who	who	WP	_	5	dep	_	_
3	have	have	VBP	_	5	aux	_	_
4	previously	previously	RB	_	5	adv	_	_
5	received	receive	VBN	_	1	relcl	_	_
6	pelvic/	pelvic/	NN	_	8	attr	_	_
7	abdominal	abdominal	JJ	_	8	attr	_	_
8	irradiation	irradiation	NN	_	5	obj	_	_
9	are	be	VBP	_	0	root	_	_
10	at	at	IN	_	12	case	_	_
11	increased	increase	VBN	_	12	attr	_	_
12	risk	risk	NN	_	9	ppmod	_	_
13	of	of	IN	_	15	case	_	_
14	severe	severe	JJ	_	15	attr	_	_
15	myelosuppression	myelosuppression	NN	_	12	ppmod	_	_
16	following	follow	VBG	_	18	adv	_	_
17	the	the	DT	_	18	det	_	_
18	administration	administration	NN	_	9	ppmod	_	_
19	of	of	IN	_	20	case	_	_
20	drug1	drug0	NN	_	18	ppmod	_	_
21	.	.	.	_	9	p	_	_

1	The	the	DT	_	3	det	_	_
2	concurrent	concurrent	JJ	_	3	attr	_	_
3	administration	administration	NN	_	12	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	irradiation	irradiation	NN	_	3	ppmod	_	_
8	has	have	VBZ	_	12	aux	_	_
9	not	not	RB	_	12	neg	_	_
10	been	be	VBN	_	12	aux	_	_
11	adequately	adequately	RB	_	12	adv	_	_
12	studied	study	VBN	_	0	root	_	_
13	and	and	CC	_	12	cc	_	_
14	is	be	VBZ	_	16	aux	_	_
15	not	not	RB	_	16	neg	_	_
16	recommended	recommend	VBN	_	12	conj	_	_
17	.	.	.	_	12	p	_	_

1	Lymphocytopenia	lymphocytopenia	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	reported	report	VBN	_	0	root	_	_
5	in	in	IN	_	6	case	_	_
6	patients	patient	NNS	_	4	ppmod	_	_
7	receiving	receive	VBG	_	6	acl	_	_
8	drug1	drug0	NN	_	7	obj	_	_
9	,	,	,	_	4	p	_	_
10	and	and	CC	_	4	cc	_	_
11	it	it	PRP	_	12	dep	_	_
12	is	be	VBZ	_	4	conj	_	_
13	possible	possible	JJ	_	12	dep	_	_
14	that	that	IN	_	24	mark	_	_
15	the	the	DT	_	16	det	_	_
16	administration	administration	NN	_	24	dep	_	_
17	of	of	IN	_	18	case	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	as	as	IN	_	21	case	_	_
20	antiemetic	antiemetic	JJ	_	21	attr	_	_
21	prophylaxis	prophylaxis	NNS	_	18	ppmod	_	_
22	may	may	MD	_	24	modal	_	_
23	have	have	VB	_	24	aux	_	_
24	enhanced	enhance	VBD	_	12	comp	_	_
25	the	the	DT	_	26	det	_	_
26	likelihood	likelihood	NN	_	24	obj	_	_
27	of	of	IN	_	29	case	_	_
28	this	this	DT	_	29	det	_	_
29	effect	effect	NN	_	26	ppmod	_	_
30	.	.	.	_	4	p	_	_

1	However	however	RB	_	9	adv	_	_
2	,	,	,	_	9	p	_	_
3	serious	serious	JJ	_	5	attr	_	_
4	opportunistic	opportunistic	JJ	_	5	attr	_	_
5	infections	infection	NNS	_	9	dep	_	_
6	have	have	VBP	_	9	aux	_	_
7	not	not	RB	_	9	neg	_	_
8	been	be	VBN	_	9	aux	_	_
9	observed	observe	VBN	_	0	root	_	_
10	,	,	,	_	9	p	_	_
11	and	and	CC	_	9	cc	_	_
12	no	no	DT	_	13	det	_	_
13	complications	complication	NNS	_	17	dep	_	_
14	have	have	VBP	_	17	aux	_	_
15	specifically	specifically	RB	_	17	adv	_	_
16	been	be	VBN	_	17	aux	_	_
17	attributed	attribute	VBN	_	9	conj	_	_
18	to	to	TO	_	19	aux	_	_
19	lymphocytopenia	lymphocytopenia	NN	_	17	ppmod	_	_
20	.	.	.	_	9	p	_	_

1	Hyperglycemia	hyperglycemia	NN	_	5	dep	_	_
2	has	have	VBZ	_	5	aux	_	_
3	also	also	RB	_	5	adv	_	_
4	been	be	VBN	_	5	aux	_	_
5	reported	report	VBN	_	0	root	_	_
6	in	in	IN	_	7	case	_	_
7	patients	patient	NNS	_	5	ppmod	_	_
8	receiving	receive	VBG	_	7	acl	_	_
9	drug1	drug0	NN	_	8	obj	_	_
10	.	.	.	_	5	p	_	_

1	Usually	usually	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	this	this	DT	_	6	dep	_	_
4	has	have	VBZ	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	observed	observe	VBN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	6	ppmod	_	_
9	with	with	IN	_	11	case	_	_
10	a	a	DT	_	11	det	_	_
11	history	history	NN	_	8	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	diabetes	diabetes	NN	_	14	com	_	_
14	mellitus	mellitus	NN	_	11	ppmod	_	_
15	or	or	CC	_	11	cc	_	_
16	evidence	evidence	NN	_	11	conj	_	_
17	of	of	IN	_	19	case	_	_
18	glucose	glucose	NN	_	19	com	_	_
19	intolerance	intolerance	NN	_	16	ppmod	_	_
20	prior	prior	JJ	_	19	attr	_	_
21	to	to	TO	_	22	aux	_	_
22	administration	administration	NN	_	20	ppmod	_	_
23	of	of	IN	_	24	case	_	_
24	drug1	drug0	NN	_	22	ppmod	_	_
25	.	.	.	_	6	p	_	_

1	It	it	PRP	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	probable	probable	JJ	_	2	dep	_	_
4	that	that	IN	_	12	mark	_	_
5	drug1	drug0	NN	_	12	dep	_	_
6	,	,	,	_	5	p	_	_
7	given	give	VBN	_	5	acl	_	_
8	as	as	IN	_	10	case	_	_
9	antiemetic	antiemetic	NN	_	10	com	_	_
10	prophylaxis	prophylaxis	NN	_	7	ppmod	_	_
11	,	,	,	_	5	p	_	_
12	contributed	contribute	VBD	_	2	comp	_	_
13	to	to	TO	_	14	aux	_	_
14	hyperglycemia	hyperglycemia	NN	_	12	ppmod	_	_
15	in	in	IN	_	17	case	_	_
16	some	some	DT	_	17	det	_	_
17	patients	patient	NNS	_	14	ppmod	_	_
18	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	incidence	incidence	NN	_	13	dep	_	_
3	of	of	IN	_	4	case	_	_
4	akathisia	akathisia	NN	_	2	ppmod	_	_
5	in	in	IN	_	7	case	_	_
6	clinical	clinical	JJ	_	7	attr	_	_
7	trials	trial	NNS	_	2	ppmod	_	_
8	of	of	IN	_	12	case	_	_
9	the	the	DT	_	12	det	_	_
10	weekly	weekly	JJ	_	12	attr	_	_
11	dosage	dosage	NN	_	12	com	_	_
12	schedule	schedule	NN	_	7	ppmod	_	_
13	was	be	VBD	_	0	root	_	_
14	greater	great	JJR	_	13	dep	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	8.5	0	CD	_	14	num	_	_
17	%	%	NN	_	16	meta	_	_
18	,	,	,	_	16	p	_	_
19	4/47	0	CD	_	20	num	_	_
20	patients	patient	NNS	_	16	appo	_	_
21	)	-rrb-	-RRB-	_	16	p	_	_
22	when	when	WRB	_	25	adv	_	_
23	drug1	drug0	NN	_	25	dep	_	_
24	was	be	VBD	_	25	aux	_	_
25	administered	administer	VBN	_	13	comp	_	_
26	on	on	IN	_	29	case	_	_
27	the	the	DT	_	29	det	_	_
28	same	same	JJ	_	29	attr	_	_
29	day	day	NN	_	25	ppmod	_	_
30	as	as	IN	_	31	case	_	_
31	drug2	drug0	NN	_	25	ppmod	_	_
32	than	than	IN	_	37	case	_	_
33	when	when	WRB	_	37	adv	_	_
34	these	these	DT	_	35	det	_	_
35	drugs	drug	NNS	_	37	dep	_	_
36	were	be	VBD	_	37	aux	_	_
37	given	give	VBN	_	31	ppmod	_	_
38	on	on	IN	_	40	case	_	_
39	separate	separate	JJ	_	40	attr	_	_
40	days	day	NNS	_	37	ppmod	_	_
41	(	-lrb-	-LRB-	_	46	p	_	_
42	1.3	0	CD	_	46	num	_	_
43	%	%	NN	_	42	meta	_	_
44	,	,	,	_	46	p	_	_
45	1/80	0	CD	_	46	num	_	_
46	patients	patient	NNS	_	40	prn	_	_
47	)	-rrb-	-RRB-	_	46	p	_	_
48	.	.	.	_	13	p	_	_

1	The	the	DT	_	4	det	_	_
2	8.5	0	CD	_	4	num	_	_
3	%	%	NN	_	2	meta	_	_
4	incidence	incidence	NN	_	10	dep	_	_
5	of	of	IN	_	6	case	_	_
6	akathisia	akathisia	NN	_	4	ppmod	_	_
7	,	,	,	_	10	p	_	_
8	however	however	RB	_	10	adv	_	_
9	,	,	,	_	10	p	_	_
10	is	be	VBZ	_	0	root	_	_
11	within	within	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	range	range	NN	_	10	ppmod	_	_
14	reported	report	VBN	_	13	acl	_	_
15	for	for	IN	_	16	case	_	_
16	use	use	NN	_	14	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug1	drug0	NN	_	16	ppmod	_	_
19	when	when	WRB	_	20	adv	_	_
20	given	give	VBN	_	10	comp	_	_
21	as	as	IN	_	23	case	_	_
22	a	a	DT	_	23	det	_	_
23	premedication	premedication	NN	_	20	ppmod	_	_
24	for	for	IN	_	26	case	_	_
25	other	other	JJ	_	26	attr	_	_
26	chemotherapies	chemotherapy	NNS	_	23	ppmod	_	_
27	.	.	.	_	10	p	_	_

1	It	it	PRP	_	4	dep	_	_
2	would	would	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	expected	expect	VBN	_	0	root	_	_
5	that	that	IN	_	13	mark	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	use	use	NN	_	13	dep	_	_
8	during	during	IN	_	9	case	_	_
9	therapy	therapy	NN	_	7	ppmod	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NN	_	7	ppmod	_	_
12	would	would	MD	_	13	modal	_	_
13	worsen	worsen	VB	_	4	comp	_	_
14	the	the	DT	_	15	det	_	_
15	incidence	incidence	NN	_	13	obj	_	_
16	or	or	CC	_	15	cc	_	_
17	severity	severity	NN	_	15	conj	_	_
18	of	of	IN	_	19	case	_	_
19	diarrhea	diarrhea	NN	_	15	ppmod	_	_
20	,	,	,	_	13	p	_	_
21	but	but	CC	_	13	cc	_	_
22	this	this	DT	_	26	dep	_	_
23	has	have	VBZ	_	26	aux	_	_
24	not	not	RB	_	26	neg	_	_
25	been	be	VBN	_	26	aux	_	_
26	studied	study	VBN	_	13	conj	_	_
27	.	.	.	_	4	p	_	_

1	In	in	IN	_	2	case	_	_
2	view	view	NN	_	21	ppmod	_	_
3	of	of	IN	_	6	case	_	_
4	the	the	DT	_	6	det	_	_
5	potential	potential	JJ	_	6	attr	_	_
6	risk	risk	NN	_	2	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	dehydration	dehydration	NN	_	6	ppmod	_	_
9	secondary	secondary	JJ	_	8	attr	_	_
10	to	to	TO	_	11	aux	_	_
11	vomiting	vomiting	NN	_	9	ppmod	_	_
12	and/or	and/or	CC	_	11	cc	_	_
13	diarrhea	diarrhea	NN	_	11	conj	_	_
14	induced	induce	VBN	_	11	acl	_	_
15	by	by	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	,	,	,	_	21	p	_	_
18	the	the	DT	_	19	det	_	_
19	physician	physician	NN	_	21	dep	_	_
20	may	may	MD	_	21	modal	_	_
21	wish	wish	VB	_	0	root	_	_
22	to	to	TO	_	24	aux	_	_
23	withhold	withhold	JJ	_	24	attr	_	_
24	drug2	drug0	NN	_	21	ppmod	_	_
25	during	during	IN	_	26	case	_	_
26	dosing	dosing	NN	_	21	ppmod	_	_
27	with	with	IN	_	28	case	_	_
28	drug3	drug0	NN	_	26	ppmod	_	_
29	and	and	CC	_	21	cc	_	_
30	,	,	,	_	21	p	_	_
31	certainly	certainly	RB	_	21	adv	_	_
32	,	,	,	_	21	p	_	_
33	during	during	IN	_	34	case	_	_
34	periods	period	NNS	_	21	conj	_	_
35	of	of	IN	_	37	case	_	_
36	active	active	JJ	_	37	attr	_	_
37	vomiting	vomiting	NN	_	34	ppmod	_	_
38	or	or	CC	_	37	cc	_	_
39	diarrhea	diarrhea	NN	_	37	conj	_	_
40	.	.	.	_	21	p	_	_

1	Drug-Laboratory	drug-laboratory	JJ	_	3	attr	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	5	dep	_	_
4	There	there	RB	_	5	adv	_	_
5	are	be	VBP	_	0	root	_	_
6	no	no	DT	_	8	det	_	_
7	known	known	JJ	_	8	attr	_	_
8	interactions	interaction	NNS	_	5	obj	_	_
9	between	between	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	laboratory	laboratory	NN	_	13	com	_	_
13	tests	test	NNS	_	10	conj	_	_
14	.	.	.	_	5	p	_	_

1	No	no	DT	_	3	det	_	_
2	specific	specific	JJ	_	3	attr	_	_
3	information	information	NN	_	0	root	_	_
4	available	available	JJ	_	3	attr	_	_

1	.	.	.	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	decrease	decrease	VB	_	0	root	_	_
4	renal	renal	JJ	_	6	attr	_	_
5	tubular	tubular	JJ	_	6	attr	_	_
6	secretion	secretion	NN	_	3	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	when	when	WRB	_	10	adv	_	_
10	used	use	VBN	_	3	comp	_	_
11	concurrently	concurrently	RB	_	10	adv	_	_
12	,	,	,	_	3	p	_	_
13	resulting	result	VBG	_	3	comp	_	_
14	in	in	IN	_	21	case	_	_
15	increased	increase	VBN	_	21	attr	_	_
16	and	and	CC	_	15	cc	_	_
17	more	more	RBR	_	18	adv	_	_
18	prolonged	prolonged	JJ	_	15	conj	_	_
19	drug3	drug0	NN	_	21	com	_	_
20	blood	blood	NN	_	21	com	_	_
21	levels	level	NNS	_	13	ppmod	_	_
22	.	.	.	_	3	p	_	_

1	Drug/Laboratory	drug/laboratory	NN	_	3	com	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	0	root	_	_
4	A	a	DT	_	7	det	_	_
5	false	false	JJ	_	6	adv	_	_
6	positive	positive	JJ	_	7	attr	_	_
7	reaction	reaction	NN	_	14	dep	_	_
8	for	for	IN	_	9	case	_	_
9	glucose	glucose	NN	_	7	ppmod	_	_
10	in	in	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	urine	urine	NN	_	7	ppmod	_	_
13	may	may	MD	_	14	modal	_	_
14	occur	occur	VB	_	3	acl	_	_
15	with	with	IN	_	17	case	_	_
16	Benedicts	benedicts	NN	_	17	com	_	_
17	solution	solution	NN	_	14	ppmod	_	_
18	,	,	,	_	17	p	_	_
19	Fehlings	fehlings	NN	_	20	com	_	_
20	solution	solution	NN	_	17	appo	_	_
21	or	or	CC	_	24	cc	_	_
22	with	with	IN	_	24	case	_	_
23	CLINITEST	clinitest	JJ	_	24	attr	_	_
24	tablets	tablet	NNS	_	14	ppmod	_	_
25	,	,	,	_	24	p	_	_
26	but	but	CC	_	24	cc	_	_
27	not	not	RB	_	30	neg	_	_
28	with	with	IN	_	30	case	_	_
29	enzyme-based	enzyme-based	JJ	_	30	attr	_	_
30	tests	test	NNS	_	24	conj	_	_
31	such	such	JJ	_	33	adv	_	_
32	as	as	IN	_	33	case	_	_
33	CLINISTIX	clinistix	NN	_	30	ppmod	_	_
34	.	.	.	_	3	p	_	_

1	Positive	positive	JJ	_	9	attr	_	_
2	direct	direct	JJ	_	9	attr	_	_
3	and	and	CC	_	2	cc	_	_
4	indirect	indirect	JJ	_	2	conj	_	_
5	antiglobulin	antiglobulin	NN	_	9	attr	_	_
6	(	-lrb-	-LRB-	_	9	p	_	_
7	Coombs	coombs	NN	_	9	attr	_	_
8	)	-rrb-	-RRB-	_	9	p	_	_
9	tests	test	NNS	_	11	dep	_	_
10	have	have	VBP	_	11	aux	_	_
11	occurred	occur	VBN	_	0	root	_	_
12	;	;	:	_	11	p	_	_

1	these	these	DT	_	4	dep	_	_
2	may	may	MD	_	4	modal	_	_
3	also	also	RB	_	4	adv	_	_
4	occur	occur	VB	_	0	root	_	_
5	in	in	IN	_	6	case	_	_
6	neonates	neonate	NNS	_	4	ppmod	_	_
7	whose	whose	WP$	_	8	poss	_	_
8	mothers	mother	NNS	_	9	dep	_	_
9	received	receive	VBD	_	6	relcl	_	_
10	drug1	drug0	NN	_	9	obj	_	_
11	before	before	IN	_	12	case	_	_
12	delivery	delivery	NN	_	9	ppmod	_	_
13	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	should	should	MD	_	5	modal	_	_
3	not	not	RB	_	5	neg	_	_
4	be	be	VB	_	5	aux	_	_
5	administered	administer	VBN	_	0	root	_	_
6	concurrently	concurrently	RB	_	5	adv	_	_
7	with	with	IN	_	8	case	_	_
8	D2-antagonists	d0-antagonists	NNS	_	5	ppmod	_	_
9	,	,	,	_	8	p	_	_
10	such	such	JJ	_	12	adv	_	_
11	as	as	IN	_	12	case	_	_
12	drug2	drug0	NN	_	8	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	drug3	drug0	NN	_	12	conj	_	_
15	,	,	,	_	14	p	_	_
16	drug4	drug0	NN	_	12	conj	_	_
17	,	,	,	_	16	p	_	_
18	or	or	CC	_	16	cc	_	_
19	drug5	drug0	NN	_	12	conj	_	_
20	.	.	.	_	5	p	_	_

1	Oral	oral	JJ	_	3	attr	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	CAUTION	caution	NN	_	6	dep	_	_
4	SHOULD	should	MD	_	6	modal	_	_
5	BE	be	VB	_	6	aux	_	_
6	EXERCISED	exercise	VBN	_	0	root	_	_
7	WHEN	when	WRB	_	10	adv	_	_
8	drug2	drug0	NN	_	10	dep	_	_
9	ARE	be	VBP	_	10	aux	_	_
10	GIVEN	give	VBN	_	6	comp	_	_
11	IN	in	IN	_	12	case	_	_
12	CONJUNCTION	conjunction	NN	_	10	ppmod	_	_
13	WITH	with	IN	_	14	case	_	_
14	drug3	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	6	p	_	_

1	THE	the	DT	_	2	det	_	_
2	DOSAGE	dosage	NN	_	8	dep	_	_
3	OF	of	IN	_	5	case	_	_
4	THE	the	DT	_	5	det	_	_
5	drug1	drug0	NN	_	2	ppmod	_	_
6	SHOULD	should	MD	_	8	modal	_	_
7	BE	be	VB	_	8	aux	_	_
8	REDUCED	reduce	VBN	_	0	root	_	_
9	TO	to	TO	_	10	aux	_	_
10	MAINTAIN	maintain	VB	_	8	comp	_	_
11	THE	the	DT	_	13	det	_	_
12	PROTHROMBIN	prothrombin	NN	_	13	com	_	_
13	TIME/INR	time/inr	NN	_	10	obj	_	_
14	AT	at	IN	_	17	case	_	_
15	THE	the	DT	_	17	det	_	_
16	DESIRED	desired	JJ	_	17	attr	_	_
17	LEVEL	level	NN	_	13	ppmod	_	_
18	TO	to	TO	_	19	aux	_	_
19	PREVENT	prevent	VB	_	13	acl	_	_
20	BLEEDING	bleeding	JJ	_	21	attr	_	_
21	COMPLICATIONS	complication	NNS	_	19	obj	_	_
22	.	.	.	_	8	p	_	_

1	FREQUENT	frequent	JJ	_	4	attr	_	_
2	PROTHROMBIN	prothrombin	NN	_	4	com	_	_
3	TIME/INR	time/inr	NN	_	4	com	_	_
4	DETERMINATIONS	determination	NNS	_	5	dep	_	_
5	ARE	be	VBP	_	0	root	_	_
6	ADVISABLE	advisable	JJ	_	5	dep	_	_
7	UNTIL	until	IN	_	12	mark	_	_
8	IT	it	PRP	_	12	dep	_	_
9	HAS	have	VBZ	_	12	aux	_	_
10	BEEN	be	VBN	_	12	aux	_	_
11	DEFINITELY	definitely	RB	_	12	adv	_	_
12	DETERMINED	determine	VBN	_	6	comp	_	_
13	THAT	that	IN	_	18	mark	_	_
14	THE	the	DT	_	16	det	_	_
15	PROTHROMBIN	prothrombin	NN	_	16	com	_	_
16	TIME/INR	time/inr	NN	_	18	dep	_	_
17	HAS	have	VBZ	_	18	aux	_	_
18	STABILIZED	stabilize	VBN	_	12	comp	_	_
19	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	5	det	_	_
4	combined	combined	JJ	_	5	attr	_	_
5	use	use	NN	_	12	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug3	drug0	NN	_	7	conj	_	_
10	should	should	MD	_	12	modal	_	_
11	be	be	VB	_	12	aux	_	_
12	avoided	avoid	VBN	_	1	acl	_	_
13	unless	unless	IN	_	22	mark	_	_
14	the	the	DT	_	15	det	_	_
15	benefit	benefit	NN	_	22	dep	_	_
16	of	of	IN	_	18	case	_	_
17	further	far	JJ	_	18	attr	_	_
18	alterations	alteration	NNS	_	15	ppmod	_	_
19	in	in	IN	_	21	case	_	_
20	lipid	lipid	NN	_	21	com	_	_
21	levels	level	NNS	_	15	ppmod	_	_
22	is	be	VBZ	_	12	comp	_	_
23	likely	likely	JJ	_	22	dep	_	_
24	to	to	TO	_	25	aux	_	_
25	outweigh	outweigh	VB	_	23	comp	_	_
26	the	the	DT	_	28	det	_	_
27	increased	increase	VBN	_	28	attr	_	_
28	risk	risk	NN	_	25	obj	_	_
29	of	of	IN	_	32	case	_	_
30	this	this	DT	_	32	det	_	_
31	drug	drug	NN	_	32	com	_	_
32	combination	combination	NN	_	28	ppmod	_	_
33	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Since	since	IN	_	6	mark	_	_
4	drug2	drug0	NN	_	6	dep	_	_
5	may	may	MD	_	6	modal	_	_
6	bind	bind	VB	_	14	advcl	_	_
7	other	other	JJ	_	8	attr	_	_
8	drugs	drug	NNS	_	6	obj	_	_
9	given	give	VBN	_	8	acl	_	_
10	concurrently	concurrently	RB	_	9	adv	_	_
11	,	,	,	_	14	p	_	_
12	patients	patient	NNS	_	14	dep	_	_
13	should	should	MD	_	14	modal	_	_
14	take	take	VB	_	1	acl	_	_
15	drug3	drug0	NN	_	14	obj	_	_
16	at	at	IN	_	18	case	_	_
17	least	least	JJS	_	18	attr	_	_
18	1	0	CD	_	19	num	_	_
19	hour	hour	NN	_	23	dat	_	_
20	before	before	IN	_	23	case	_	_
21	or	or	CC	_	23	cc	_	_
22	4-6	0	CD	_	23	num	_	_
23	hours	hour	NNS	_	14	ppmod	_	_
24	after	after	IN	_	26	case	_	_
25	a	a	DT	_	26	det	_	_
26	drug4	drug0	NN	_	23	ppmod	_	_
27	to	to	TO	_	28	aux	_	_
28	avoid	avoid	VB	_	26	acl	_	_
29	impeding	impede	VBG	_	28	comp	_	_
30	its	its	PRP$	_	31	poss	_	_
31	absorption	absorption	NN	_	29	obj	_	_
32	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Because	because	IN	_	6	mark	_	_
4	drug2	drug0	NN	_	6	dep	_	_
5	can	can	MD	_	6	modal	_	_
6	produce	produce	VB	_	34	advcl	_	_
7	nephrotoxicity	nephrotoxicity	NN	_	6	obj	_	_
8	with	with	IN	_	9	case	_	_
9	decreases	decrease	NNS	_	6	ppmod	_	_
10	in	in	IN	_	12	case	_	_
11	creatinine	creatinine	NN	_	12	com	_	_
12	clearance	clearance	NN	_	9	ppmod	_	_
13	and	and	CC	_	6	cc	_	_
14	rises	rise	VBZ	_	6	conj	_	_
15	in	in	IN	_	17	case	_	_
16	serum	serum	NN	_	17	com	_	_
17	creatinine	creatinine	NN	_	14	ppmod	_	_
18	,	,	,	_	6	p	_	_
19	and	and	CC	_	6	cc	_	_
20	because	because	IN	_	23	mark	_	_
21	renal	renal	JJ	_	22	attr	_	_
22	excretion	excretion	NN	_	23	dep	_	_
23	is	be	VBZ	_	6	conj	_	_
24	the	the	DT	_	27	det	_	_
25	primary	primary	JJ	_	27	attr	_	_
26	elimination	elimination	NN	_	27	com	_	_
27	route	route	NN	_	23	obj	_	_
28	of	of	IN	_	29	case	_	_
29	drug3	drug0	NNS	_	27	ppmod	_	_
30	including	include	VBG	_	31	adv	_	_
31	drug4	drug0	NN	_	29	ppmod	_	_
32	,	,	,	_	34	p	_	_
33	there	there	EX	_	34	dep	_	_
34	is	be	VBZ	_	1	acl	_	_
35	a	a	DT	_	36	det	_	_
36	risk	risk	NN	_	34	obj	_	_
37	that	that	IN	_	41	mark	_	_
38	an	an	DT	_	39	det	_	_
39	interaction	interaction	NN	_	41	dep	_	_
40	will	will	MD	_	41	modal	_	_
41	lead	lead	VB	_	36	acl	_	_
42	to	to	TO	_	43	aux	_	_
43	deterioration	deterioration	NN	_	41	ppmod	_	_
44	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	benefits	benefit	NNS	_	18	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	risks	risk	NNS	_	2	conj	_	_
5	of	of	IN	_	7	case	_	_
6	using	use	VBG	_	7	attr	_	_
7	drug1	drug0	NN	_	2	ppmod	_	_
8	with	with	IN	_	9	case	_	_
9	drug2	drug0	NN	_	2	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	other	other	JJ	_	14	attr	_	_
12	potentially	potentially	RB	_	13	adv	_	_
13	nephrotoxic	nephrotoxic	JJ	_	14	attr	_	_
14	agents	agent	NNS	_	9	conj	_	_
15	should	should	MD	_	18	modal	_	_
16	be	be	VB	_	18	aux	_	_
17	carefully	carefully	RB	_	18	adv	_	_
18	considered	consider	VBN	_	0	root	_	_
19	,	,	,	_	18	p	_	_
20	and	and	CC	_	18	cc	_	_
21	the	the	DT	_	24	det	_	_
22	lowest	low	JJS	_	23	adv	_	_
23	effective	effective	JJ	_	24	attr	_	_
24	dose	dose	NN	_	25	dep	_	_
25	employed	employ	VBN	_	18	conj	_	_

1	.	.	.	_	0	root	_	_

1	Drug-drug	drug-drug	JJ	_	2	attr	_	_
2	interactions	interaction	NNS	_	0	root	_	_
3	In	in	FW	_	4	adv	_	_
4	vitro	vitro	FW	_	5	attr	_	_
5	studies	study	NNS	_	10	dep	_	_
6	using	use	VBG	_	5	acl	_	_
7	human	human	JJ	_	9	attr	_	_
8	liver	liver	NN	_	9	com	_	_
9	microsomes	microsome	NNS	_	6	obj	_	_
10	indicate	indicate	VBP	_	2	acl	_	_
11	that	that	IN	_	15	mark	_	_
12	drug1	drug0	NN	_	15	dep	_	_
13	and	and	CC	_	12	cc	_	_
14	drug2	drug0	NN	_	12	conj	_	_
15	are	be	VBP	_	10	comp	_	_
16	not	not	RB	_	15	neg	_	_
17	inhibitors	inhibitor	NNS	_	15	obj	_	_
18	of	of	IN	_	24	case	_	_
19	cytochrome	cytochrome	NN	_	24	attr	_	_
20	(	-lrb-	-LRB-	_	24	p	_	_
21	CYP	cyp	NN	_	24	attr	_	_
22	)	-rrb-	-RRB-	_	24	p	_	_
23	P450	p0	NN	_	24	com	_	_
24	isoforms	isoforms	NNS	_	17	ppmod	_	_
25	CYP3A4	cyp0a0	NN	_	24	attr	_	_
26	,	,	,	_	25	p	_	_
27	CYP2D6	cyp0d0	NN	_	25	conj	_	_
28	,	,	,	_	27	p	_	_
29	CYP2E1	cyp0e0	NN	_	25	conj	_	_
30	,	,	,	_	29	p	_	_
31	or	or	CC	_	29	cc	_	_
32	CYP1A2	cyp0a0	NN	_	25	conj	_	_
33	.	.	.	_	2	p	_	_

1	They	they	PRP	_	2	dep	_	_
2	are	be	VBP	_	0	root	_	_
3	weak	weak	JJ	_	4	attr	_	_
4	inhibitors	inhibitor	NNS	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	CYP2C19	cyp0c0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	CYP2A6	cyp0a0	NN	_	6	conj	_	_
9	,	,	,	_	4	p	_	_
10	and	and	CC	_	4	cc	_	_
11	mild-to-moderate	mild-to-moderate	JJ	_	12	attr	_	_
12	inhibitors	inhibitor	NNS	_	4	conj	_	_
13	of	of	IN	_	14	case	_	_
14	CYP2C9	cyp0c0	NN	_	12	ppmod	_	_
15	at	at	IN	_	17	case	_	_
16	therapeutic	therapeutic	JJ	_	17	attr	_	_
17	concentrations	concentration	NNS	_	2	ppmod	_	_
18	.	.	.	_	2	p	_	_

1	Potentiation	potentiation	NN	_	6	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	has	have	VBZ	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	observed	observe	VBN	_	0	root	_	_
7	with	with	IN	_	8	case	_	_
8	prolongation	prolongation	NN	_	6	ppmod	_	_
9	of	of	IN	_	12	case	_	_
10	the	the	DT	_	12	det	_	_
11	prothrombin	prothrombin	NN	_	12	com	_	_
12	time/INR	time/inr	NN	_	8	ppmod	_	_
13	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	have	have	VBP	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	shown	show	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	bind	bind	VB	_	4	comp	_	_
7	other	other	JJ	_	8	attr	_	_
8	drugs	drug	NNS	_	6	obj	_	_
9	given	give	VBN	_	8	acl	_	_
10	concurrently	concurrently	RB	_	9	adv	_	_
11	.	.	.	_	4	p	_	_

1	Therefore	therefore	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	drug1	drug0	NN	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	taken	take	VBN	_	0	root	_	_
7	at	at	IN	_	9	case	_	_
8	least	least	JJS	_	9	attr	_	_
9	1	0	CD	_	10	num	_	_
10	hour	hour	NN	_	14	dat	_	_
11	before	before	IN	_	14	case	_	_
12	or	or	CC	_	14	cc	_	_
13	4-6	0	CD	_	14	num	_	_
14	hours	hour	NNS	_	6	ppmod	_	_
15	after	after	IN	_	17	case	_	_
16	a	a	DT	_	17	det	_	_
17	drug2	drug0	NN	_	14	ppmod	_	_
18	to	to	TO	_	19	aux	_	_
19	avoid	avoid	VB	_	17	acl	_	_
20	impeding	impede	VBG	_	19	comp	_	_
21	its	its	PRP$	_	22	poss	_	_
22	absorption	absorption	NN	_	20	obj	_	_
23	.	.	.	_	6	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	administration	administration	NN	_	24	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	(	-lrb-	-LRB-	_	9	p	_	_
6	equivalent	equivalent	JJ	_	9	attr	_	_
7	to	to	TO	_	8	aux	_	_
8	145mg	0mg	NN	_	6	ppmod	_	_
9	drug2	drug0	NN	_	4	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	with	with	IN	_	12	case	_	_
12	drug3	drug0	NN	_	2	ppmod	_	_
13	(	-lrb-	-LRB-	_	15	p	_	_
14	40	0	CD	_	15	num	_	_
15	mg	mg	NN	_	12	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	once	once	RB	_	18	adv	_	_
18	daily	daily	JJ	_	12	attr	_	_
19	for	for	IN	_	21	case	_	_
20	10	0	CD	_	21	num	_	_
21	days	day	NNS	_	18	ppmod	_	_
22	has	have	VBZ	_	24	aux	_	_
23	been	be	VBN	_	24	aux	_	_
24	shown	show	VBN	_	0	root	_	_
25	to	to	TO	_	26	aux	_	_
26	increase	increase	VB	_	24	comp	_	_
27	the	the	DT	_	29	det	_	_
28	mean	mean	NN	_	29	com	_	_
29	Cmax	cmax	NN	_	26	obj	_	_
30	and	and	CC	_	29	cc	_	_
31	AUC	auc	NN	_	32	com	_	_
32	values	value	NNS	_	29	conj	_	_
33	for	for	IN	_	34	case	_	_
34	drug4	drug0	NN	_	29	ppmod	_	_
35	by	by	IN	_	36	case	_	_
36	36	0	CD	_	34	ppmod	_	_
37	%	%	NN	_	36	meta	_	_
38	(	-lrb-	-LRB-	_	39	p	_	_
39	range	range	NN	_	36	prn	_	_
40	from	from	IN	_	43	case	_	_
41	69	0	CD	_	43	num	_	_
42	%	%	NN	_	41	meta	_	_
43	decrease	decrease	NN	_	39	ppmod	_	_
44	to	to	TO	_	47	aux	_	_
45	321	0	CD	_	47	num	_	_
46	%	%	NN	_	45	meta	_	_
47	increase	increase	NN	_	43	ppmod	_	_
48	)	-rrb-	-RRB-	_	39	p	_	_
49	and	and	CC	_	36	cc	_	_
50	28	0	CD	_	36	conj	_	_
51	%	%	NN	_	50	meta	_	_
52	(	-lrb-	-LRB-	_	53	p	_	_
53	range	range	NN	_	50	prn	_	_
54	from	from	IN	_	57	case	_	_
55	54	0	CD	_	57	num	_	_
56	%	%	NN	_	55	meta	_	_
57	decrease	decrease	NN	_	53	ppmod	_	_
58	to	to	TO	_	61	aux	_	_
59	128	0	CD	_	61	num	_	_
60	%	%	NN	_	59	meta	_	_
61	increase	increase	NN	_	57	ppmod	_	_
62	)	-rrb-	-RRB-	_	53	p	_	_
63	,	,	,	_	50	p	_	_
64	respectively	respectively	RB	_	36	conj	_	_
65	,	,	,	_	34	p	_	_
66	and	and	CC	_	34	cc	_	_
67	for	for	IN	_	69	case	_	_
68	3	0	CD	_	69	num	_	_
69	-hydroxy-iso-pravastatin	-hydroxy-iso-pravastatin	NN	_	34	conj	_	_
70	by	by	IN	_	71	case	_	_
71	55	0	CD	_	26	ppmod	_	_
72	%	%	NN	_	71	meta	_	_
73	(	-lrb-	-LRB-	_	74	p	_	_
74	range	range	NN	_	71	prn	_	_
75	from	from	IN	_	78	case	_	_
76	32	0	CD	_	78	num	_	_
77	%	%	NN	_	76	meta	_	_
78	decrease	decrease	NN	_	74	ppmod	_	_
79	to	to	TO	_	82	aux	_	_
80	314	0	CD	_	82	num	_	_
81	%	%	NN	_	80	meta	_	_
82	increase	increase	NN	_	78	ppmod	_	_
83	)	-rrb-	-RRB-	_	74	p	_	_
84	and	and	CC	_	71	cc	_	_
85	39	0	CD	_	71	conj	_	_
86	%	%	NN	_	85	meta	_	_
87	(	-lrb-	-LRB-	_	88	p	_	_
88	range	range	NN	_	85	prn	_	_
89	from	from	IN	_	92	case	_	_
90	24	0	CD	_	92	num	_	_
91	%	%	NN	_	90	meta	_	_
92	decrease	decrease	NN	_	88	ppmod	_	_
93	to	to	TO	_	96	aux	_	_
94	261	0	CD	_	96	num	_	_
95	%	%	NN	_	94	meta	_	_
96	increase	increase	NN	_	92	ppmod	_	_
97	)	-rrb-	-RRB-	_	88	p	_	_
98	,	,	,	_	85	p	_	_
99	respectively	respectively	RB	_	71	conj	_	_
100	in	in	IN	_	103	case	_	_
101	23	0	CD	_	103	num	_	_
102	healthy	healthy	JJ	_	103	attr	_	_
103	adults	adult	NNS	_	26	ppmod	_	_
104	.	.	.	_	24	p	_	_

1	A	a	DT	_	3	det	_	_
2	single	single	JJ	_	3	attr	_	_
3	dose	dose	NN	_	6	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	had	have	VBD	_	0	root	_	_
7	no	no	DT	_	10	det	_	_
8	clinically	clinically	RB	_	9	adv	_	_
9	important	important	JJ	_	10	attr	_	_
10	effect	effect	NN	_	6	obj	_	_
11	on	on	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	pharmacokinetics	pharmacokinetics	NNS	_	6	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	6	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	administration	administration	NN	_	23	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	(	-lrb-	-LRB-	_	4	p	_	_
6	equivalent	equivalent	JJ	_	4	attr	_	_
7	to	to	TO	_	10	aux	_	_
8	145	0	CD	_	9	num	_	_
9	mg	mg	NN	_	10	com	_	_
10	drug2	drug0	NN	_	6	ppmod	_	_
11	)	-rrb-	-RRB-	_	4	p	_	_
12	with	with	IN	_	13	case	_	_
13	drug3	drug0	NN	_	2	ppmod	_	_
14	(	-lrb-	-LRB-	_	16	p	_	_
15	20	0	CD	_	16	num	_	_
16	mg	mg	NN	_	13	prn	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	once	once	RB	_	19	adv	_	_
19	daily	daily	JJ	_	13	attr	_	_
20	for	for	IN	_	22	case	_	_
21	10	0	CD	_	22	num	_	_
22	days	day	NNS	_	19	ppmod	_	_
23	resulted	result	VBD	_	0	root	_	_
24	in	in	IN	_	28	case	_	_
25	approximately	approximately	RB	_	26	adv	_	_
26	17	0	CD	_	28	num	_	_
27	%	%	NN	_	26	meta	_	_
28	decrease	decrease	NN	_	23	ppmod	_	_
29	(	-lrb-	-LRB-	_	30	p	_	_
30	range	range	NN	_	28	prn	_	_
31	from	from	IN	_	34	case	_	_
32	67	0	CD	_	34	num	_	_
33	%	%	NN	_	32	meta	_	_
34	decrease	decrease	NN	_	30	ppmod	_	_
35	to	to	TO	_	38	aux	_	_
36	44	0	CD	_	38	num	_	_
37	%	%	NN	_	36	meta	_	_
38	increase	increase	NN	_	34	ppmod	_	_
39	)	-rrb-	-RRB-	_	30	p	_	_
40	in	in	IN	_	43	case	_	_
41	drug4	drug0	NN	_	43	com	_	_
42	AUC	auc	NN	_	43	com	_	_
43	values	value	NNS	_	28	ppmod	_	_
44	in	in	IN	_	47	case	_	_
45	22	0	CD	_	47	num	_	_
46	healthy	healthy	JJ	_	47	attr	_	_
47	males	male	NNS	_	28	ppmod	_	_
48	.	.	.	_	23	p	_	_

1	The	the	DT	_	4	det	_	_
2	drug1	drug0	JJ	_	4	attr	_	_
3	Cmax	cmax	NN	_	4	com	_	_
4	values	value	NNS	_	8	dep	_	_
5	were	be	VBD	_	8	aux	_	_
6	not	not	RB	_	8	neg	_	_
7	significantly	significantly	RB	_	8	adv	_	_
8	affected	affect	VBN	_	0	root	_	_
9	by	by	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	8	p	_	_

1	The	the	DT	_	2	det	_	_
2	pharmacokinetics	pharmacokinetics	NNS	_	8	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	were	be	VBD	_	8	aux	_	_
6	not	not	RB	_	8	neg	_	_
7	significantly	significantly	RB	_	8	adv	_	_
8	affected	affect	VBN	_	0	root	_	_
9	by	by	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_

1	.	.	.	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	If	if	IN	_	4	mark	_	_
2	additional	additional	JJ	_	3	attr	_	_
3	drug1	drug0	NNS	_	4	dep	_	_
4	are	be	VBP	_	15	advcl	_	_
5	to	to	TO	_	7	aux	_	_
6	be	be	VB	_	7	aux	_	_
7	administered	administer	VBN	_	4	comp	_	_
8	by	by	IN	_	10	case	_	_
9	any	any	DT	_	10	det	_	_
10	route	route	NN	_	7	ppmod	_	_
11	,	,	,	_	15	p	_	_
12	they	they	PRP	_	15	dep	_	_
13	should	should	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	used	use	VBN	_	0	root	_	_
16	with	with	IN	_	17	case	_	_
17	caution	caution	NN	_	15	ppmod	_	_
18	because	because	IN	_	28	mark	_	_
19	the	the	DT	_	23	det	_	_
20	pharmacologically	pharmacologically	RB	_	21	adv	_	_
21	predictable	predictable	JJ	_	23	attr	_	_
22	sympathetic	sympathetic	JJ	_	23	attr	_	_
23	effects	effect	NNS	_	28	dep	_	_
24	of	of	IN	_	25	case	_	_
25	drug2	drug0	NN	_	23	ppmod	_	_
26	may	may	MD	_	28	modal	_	_
27	be	be	VB	_	28	aux	_	_
28	potentiated	potentiate	VBN	_	15	comp	_	_
29	.	.	.	_	15	p	_	_

1	When	when	WRB	_	11	adv	_	_
2	drug1	drug0	NN	_	11	dep	_	_
3	,	,	,	_	2	p	_	_
4	a	a	DT	_	6	det	_	_
5	potent	potent	JJ	_	6	attr	_	_
6	inhibitor	inhibitor	NN	_	2	appo	_	_
7	of	of	IN	_	8	case	_	_
8	CYP2D6	cyp0d0	NN	_	6	ppmod	_	_
9	,	,	,	_	2	p	_	_
10	was	be	VBD	_	11	aux	_	_
11	co-administered	co-administered	VBN	_	23	advcl	_	_
12	with	with	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	at	at	IN	_	15	case	_	_
15	steady-state	steady-state	NN	_	11	ppmod	_	_
16	,	,	,	_	23	p	_	_
17	exposure	exposure	NN	_	23	dep	_	_
18	to	to	TO	_	20	aux	_	_
19	either	either	DT	_	20	det	_	_
20	drug	drug	NN	_	17	ppmod	_	_
21	was	be	VBD	_	23	aux	_	_
22	not	not	RB	_	23	neg	_	_
23	altered	alter	VBN	_	0	root	_	_
24	.	.	.	_	23	p	_	_

1	Dosage	dosage	NN	_	2	com	_	_
2	adjustments	adjustment	NNS	_	5	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	are	be	VBP	_	0	root	_	_
6	not	not	RB	_	5	neg	_	_
7	necessary	necessary	JJ	_	5	dep	_	_
8	when	when	WRB	_	12	adv	_	_
9	the	the	DT	_	10	det	_	_
10	drug	drug	NN	_	12	dep	_	_
11	is	be	VBZ	_	12	aux	_	_
12	given	give	VBN	_	5	comp	_	_
13	concomitantly	concomitantly	RB	_	12	adv	_	_
14	with	with	IN	_	17	case	_	_
15	potent	potent	JJ	_	17	attr	_	_
16	CYP2D6	cyp0d0	NN	_	17	com	_	_
17	inhibitors	inhibitor	NNS	_	12	ppmod	_	_
18	.	.	.	_	5	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	treatment	treatment	NN	_	16	dep	_	_
3	with	with	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	drug2	drug0	NN	_	4	prn	_	_
7	,	,	,	_	6	p	_	_
8	drug3	drug0	NN	_	6	appo	_	_
9	)	-rrb-	-RRB-	_	6	p	_	_
10	,	,	,	_	4	p	_	_
11	drug4	drug0	NN	_	4	conj	_	_
12	,	,	,	_	11	p	_	_
13	or	or	CC	_	11	cc	_	_
14	drug5	drug0	NN	_	4	conj	_	_
15	may	may	MD	_	16	modal	_	_
16	potentiate	potentiate	VB	_	0	root	_	_
17	any	any	DT	_	19	det	_	_
18	hypokalemic	hypokalemic	JJ	_	19	attr	_	_
19	effect	effect	NN	_	16	obj	_	_
20	of	of	IN	_	21	case	_	_
21	drug6	drug0	NN	_	19	ppmod	_	_
22	.	.	.	_	16	p	_	_

1	The	the	DT	_	3	det	_	_
2	ECG	ecg	NN	_	3	com	_	_
3	changes	change	NNS	_	24	dep	_	_
4	and/or	and/or	CC	_	3	cc	_	_
5	hypokalemia	hypokalemia	NN	_	3	conj	_	_
6	that	that	WDT	_	8	dep	_	_
7	may	may	MD	_	8	modal	_	_
8	result	result	VB	_	3	relcl	_	_
9	from	from	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	administration	administration	NN	_	8	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	such	such	JJ	_	13	prn	_	_
16	as	as	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	or	or	CC	_	17	cc	_	_
19	drug3	drug0	NN	_	17	conj	_	_
20	)	-rrb-	-RRB-	_	15	p	_	_
21	can	can	MD	_	24	modal	_	_
22	be	be	VB	_	24	aux	_	_
23	acutely	acutely	RB	_	24	adv	_	_
24	worsened	worsen	VBN	_	0	root	_	_
25	by	by	IN	_	26	case	_	_
26	drug4	drug0	NN	_	24	ppmod	_	_
27	,	,	,	_	24	p	_	_
28	especially	especially	RB	_	29	com	_	_
29	when	when	WRB	_	37	adv	_	_
30	the	the	DT	_	32	det	_	_
31	recommended	recommend	VBN	_	32	attr	_	_
32	dose	dose	NN	_	37	dep	_	_
33	of	of	IN	_	35	case	_	_
34	the	the	DT	_	35	det	_	_
35	drug5	drug0	NN	_	32	ppmod	_	_
36	is	be	VBZ	_	37	aux	_	_
37	exceeded	exceed	VBD	_	24	comp	_	_
38	.	.	.	_	24	p	_	_

1	Although	although	IN	_	10	mark	_	_
2	the	the	DT	_	4	det	_	_
3	clinical	clinical	JJ	_	4	attr	_	_
4	significance	significance	NN	_	10	dep	_	_
5	of	of	IN	_	7	case	_	_
6	these	these	DT	_	7	det	_	_
7	effects	effect	NNS	_	4	ppmod	_	_
8	is	be	VBZ	_	10	aux	_	_
9	not	not	RB	_	10	neg	_	_
10	known	know	VBN	_	14	advcl	_	_
11	,	,	,	_	14	p	_	_
12	caution	caution	NN	_	14	dep	_	_
13	is	be	VBZ	_	14	aux	_	_
14	advised	advise	VBN	_	0	root	_	_
15	in	in	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	co-administration	co-administration	NN	_	14	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug1	drug0	NN	_	17	ppmod	_	_
20	with	with	IN	_	21	case	_	_
21	drug2	drug0	NN	_	17	ppmod	_	_
22	.	.	.	_	14	p	_	_

1	drug1	drug0	NN	_	10	dep	_	_
2	,	,	,	_	1	p	_	_
3	as	as	RB	_	1	cc	_	_
4	with	with	IN	_	3	com	_	_
5	other	other	JJ	_	6	attr	_	_
6	drug2	drug0	NNS	_	1	conj	_	_
7	,	,	,	_	6	p	_	_
8	should	should	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	administered	administer	VBN	_	0	root	_	_
11	with	with	IN	_	13	case	_	_
12	extreme	extreme	JJ	_	13	attr	_	_
13	caution	caution	NN	_	10	ppmod	_	_
14	to	to	TO	_	15	aux	_	_
15	patients	patient	NNS	_	13	ppmod	_	_
16	being	be	VBG	_	17	aux	_	_
17	treated	treat	VBN	_	15	acl	_	_
18	with	with	IN	_	19	case	_	_
19	drug3	drug0	NN	_	17	ppmod	_	_
20	,	,	,	_	19	p	_	_
21	drug4	drug0	NN	_	19	conj	_	_
22	,	,	,	_	21	p	_	_
23	or	or	CC	_	21	cc	_	_
24	drugs	drug	NNS	_	19	conj	_	_
25	known	know	VBN	_	24	acl	_	_
26	to	to	TO	_	27	aux	_	_
27	prolong	prolong	VB	_	25	comp	_	_
28	the	the	DT	_	30	det	_	_
29	QTc	qtc	NN	_	30	com	_	_
30	interval	interval	NN	_	27	obj	_	_
31	because	because	IN	_	42	mark	_	_
32	the	the	DT	_	33	det	_	_
33	action	action	NN	_	42	dep	_	_
34	of	of	IN	_	35	case	_	_
35	drug5	drug0	NN	_	33	ppmod	_	_
36	on	on	IN	_	39	case	_	_
37	the	the	DT	_	39	det	_	_
38	cardiovascular	cardiovascular	JJ	_	39	attr	_	_
39	system	system	NN	_	33	ppmod	_	_
40	may	may	MD	_	42	modal	_	_
41	be	be	VB	_	42	aux	_	_
42	potentiated	potentiate	VBN	_	27	comp	_	_
43	by	by	IN	_	45	case	_	_
44	these	these	DT	_	45	det	_	_
45	agents	agent	NNS	_	42	ppmod	_	_
46	.	.	.	_	10	p	_	_

1	Drugs	drug	NNS	_	13	dep	_	_
2	that	that	WDT	_	4	dep	_	_
3	are	be	VBP	_	4	aux	_	_
4	known	know	VBN	_	1	relcl	_	_
5	to	to	TO	_	6	aux	_	_
6	prolong	prolong	VB	_	4	comp	_	_
7	the	the	DT	_	9	det	_	_
8	QTc	qtc	NN	_	9	com	_	_
9	interval	interval	NN	_	6	obj	_	_
10	have	have	VBP	_	13	lv	_	_
11	an	an	DT	_	13	det	_	_
12	increased	increase	VBN	_	13	attr	_	_
13	risk	risk	NN	_	0	root	_	_
14	of	of	IN	_	16	case	_	_
15	ventricular	ventricular	JJ	_	16	attr	_	_
16	arrhythmias	arrhythmia	NNS	_	13	ppmod	_	_
17	.	.	.	_	13	p	_	_

1	The	the	DT	_	3	det	_	_
2	concurrent	concurrent	JJ	_	3	attr	_	_
3	use	use	NN	_	25	dep	_	_
4	of	of	IN	_	9	case	_	_
5	intravenously	intravenously	RB	_	8	adv	_	_
6	or	or	CC	_	8	cc	_	_
7	orally	orally	RB	_	8	adv	_	_
8	administered	administer	VBN	_	9	attr	_	_
9	drug1	drug0	NN	_	3	ppmod	_	_
10	(	-lrb-	-LRB-	_	15	p	_	_
11	e.g.	e.g.	FW	_	13	adv	_	_
12	,	,	,	_	13	p	_	_
13	drug2	drug0	NN	_	15	ppmod	_	_
14	,	,	,	_	15	p	_	_
15	drug3	drug0	NN	_	9	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	by	by	IN	_	18	case	_	_
18	patients	patient	NNS	_	3	ppmod	_	_
19	receiving	receive	VBG	_	18	acl	_	_
20	drug4	drug0	NN	_	19	obj	_	_
21	has	have	VBZ	_	25	aux	_	_
22	not	not	RB	_	25	neg	_	_
23	been	be	VBN	_	25	aux	_	_
24	completely	completely	RB	_	25	adv	_	_
25	evaluated	evaluate	VBN	_	0	root	_	_
26	.	.	.	_	25	p	_	_

1	In	in	IN	_	7	case	_	_
2	two	#crd#	CD	_	7	num	_	_
3	combined	combined	JJ	_	7	attr	_	_
4	12-week	0-week	JJ	_	7	attr	_	_
5	placebo	placebo	NN	_	7	attr	_	_
6	controlled	controlled	JJ	_	7	attr	_	_
7	trials	trial	NNS	_	35	ppmod	_	_
8	that	that	WDT	_	9	dep	_	_
9	included	include	VBD	_	7	relcl	_	_
10	drug1	drug0	NN	_	11	com	_	_
11	doses	dose	NNS	_	9	obj	_	_
12	of	of	IN	_	14	case	_	_
13	15	0	CD	_	14	num	_	_
14	mcg	mcg	NN	_	11	ppmod	_	_
15	twice	twice	RB	_	16	com	_	_
16	daily	daily	RB	_	14	adv	_	_
17	,	,	,	_	14	p	_	_
18	25	0	CD	_	19	num	_	_
19	mcg	mcg	NN	_	14	conj	_	_
20	twice	twice	RB	_	21	com	_	_
21	daily	daily	RB	_	19	adv	_	_
22	,	,	,	_	19	p	_	_
23	and	and	CC	_	19	cc	_	_
24	50	0	CD	_	25	num	_	_
25	mcg	mcg	NN	_	14	conj	_	_
26	once	once	RB	_	27	com	_	_
27	daily	daily	RB	_	25	adv	_	_
28	,	,	,	_	35	p	_	_
29	54	0	CD	_	35	num	_	_
30	of	of	IN	_	34	case	_	_
31	873	0	CD	_	34	num	_	_
32	drug2	drug0	JJ	_	34	attr	_	_
33	-treated	-treated	JJ	_	34	attr	_	_
34	subjects	subject	NNS	_	29	ppmod	_	_
35	received	receive	VBD	_	0	root	_	_
36	concomitant	concomitant	JJ	_	37	attr	_	_
37	drug3	drug0	NN	_	35	obj	_	_
38	at	at	IN	_	40	case	_	_
39	study	study	NN	_	40	com	_	_
40	entry	entry	NN	_	35	ppmod	_	_
41	.	.	.	_	35	p	_	_

1	In	in	IN	_	5	case	_	_
2	a	a	DT	_	5	det	_	_
3	12-month	0-month	JJ	_	5	attr	_	_
4	controlled	controlled	JJ	_	5	attr	_	_
5	trial	trial	NN	_	23	ppmod	_	_
6	that	that	WDT	_	7	dep	_	_
7	included	include	VBD	_	5	relcl	_	_
8	a	a	DT	_	14	det	_	_
9	50	0	CD	_	14	num	_	_
10	mcg	mcg	NN	_	14	attr	_	_
11	once	once	RB	_	12	adv	_	_
12	daily	daily	JJ	_	14	attr	_	_
13	drug1	drug0	NN	_	14	com	_	_
14	dose	dose	NN	_	7	obj	_	_
15	,	,	,	_	23	p	_	_
16	30	0	CD	_	23	num	_	_
17	of	of	IN	_	22	case	_	_
18	the	the	DT	_	22	det	_	_
19	528	0	CD	_	22	num	_	_
20	drug2	drug0	JJ	_	22	attr	_	_
21	-treated	-treated	JJ	_	22	attr	_	_
22	subjects	subject	NNS	_	16	ppmod	_	_
23	received	receive	VBD	_	0	root	_	_
24	concomitant	concomitant	JJ	_	25	attr	_	_
25	drug3	drug0	NN	_	23	obj	_	_
26	at	at	IN	_	28	case	_	_
27	study	study	NN	_	28	com	_	_
28	entry	entry	NN	_	23	ppmod	_	_
29	.	.	.	_	23	p	_	_

1	In	in	IN	_	3	case	_	_
2	these	these	DT	_	3	det	_	_
3	trials	trial	NNS	_	11	ppmod	_	_
4	,	,	,	_	11	p	_	_
5	heart	heart	NN	_	6	com	_	_
6	rate	rate	NN	_	11	dep	_	_
7	and	and	CC	_	6	cc	_	_
8	systolic	systolic	JJ	_	10	attr	_	_
9	blood	blood	NN	_	10	com	_	_
10	pressure	pressure	NN	_	6	conj	_	_
11	were	be	VBD	_	0	root	_	_
12	approximately	approximately	RB	_	13	adv	_	_
13	2-3	0	CD	_	14	num	_	_
14	bpm	bpm	NN	_	19	advnp	_	_
15	and	and	CC	_	14	cc	_	_
16	6-8	0	CD	_	17	num	_	_
17	mm	mm	NN	_	18	com	_	_
18	Hg	hg	NN	_	14	conj	_	_
19	higher	high	JJR	_	11	dep	_	_
20	,	,	,	_	11	p	_	_
21	respectively	respectively	RB	_	11	adv	_	_
22	,	,	,	_	11	p	_	_
23	in	in	IN	_	24	case	_	_
24	subjects	subject	NNS	_	11	ppmod	_	_
25	on	on	IN	_	27	case	_	_
26	concomitant	concomitant	JJ	_	27	attr	_	_
27	drug1	drug0	NN	_	24	ppmod	_	_
28	compared	compare	VBN	_	32	adv	_	_
29	with	with	IN	_	32	case	_	_
30	the	the	DT	_	32	det	_	_
31	overall	overall	JJ	_	32	attr	_	_
32	population	population	NN	_	27	ppmod	_	_
33	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	8	dep	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	drug2	drug0	NN	_	1	prn	_	_
4	)	-rrb-	-RRB-	_	3	p	_	_
5	and	and	CC	_	1	cc	_	_
6	drug3	drug0	NN	_	1	conj	_	_
7	may	may	MD	_	8	modal	_	_
8	interfere	interfere	VB	_	0	root	_	_
9	with	with	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	effect	effect	NN	_	8	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	each	each	DT	_	14	det	_	_
14	other	other	JJ	_	11	ppmod	_	_
15	when	when	WRB	_	16	adv	_	_
16	administered	administer	VBN	_	8	comp	_	_
17	concurrently	concurrently	RB	_	16	adv	_	_
18	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	not	not	RB	_	3	com	_	_
3	only	only	RB	_	4	cc	_	_
4	block	block	VBP	_	0	root	_	_
5	the	the	DT	_	7	det	_	_
6	therapeutic	therapeutic	JJ	_	7	attr	_	_
7	effects	effect	NNS	_	4	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	4	p	_	_
11	but	but	CC	_	4	cc	_	_
12	may	may	MD	_	13	modal	_	_
13	produce	produce	VB	_	4	conj	_	_
14	severe	severe	JJ	_	15	attr	_	_
15	bronchospasm	bronchospasm	NN	_	13	obj	_	_
16	in	in	IN	_	18	case	_	_
17	COPD	copd	NN	_	18	com	_	_
18	patients	patient	NNS	_	15	ppmod	_	_
19	.	.	.	_	4	p	_	_

1	Therefore	therefore	RB	_	10	adv	_	_
2	,	,	,	_	10	p	_	_
3	patients	patient	NNS	_	10	dep	_	_
4	with	with	IN	_	5	case	_	_
5	COPD	copd	NN	_	3	ppmod	_	_
6	should	should	MD	_	10	modal	_	_
7	not	not	RB	_	10	neg	_	_
8	normally	normally	RB	_	10	adv	_	_
9	be	be	VB	_	10	aux	_	_
10	treated	treat	VBN	_	0	root	_	_
11	with	with	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	10	p	_	_

1	However	however	RB	_	17	adv	_	_
2	,	,	,	_	17	p	_	_
3	under	under	IN	_	5	case	_	_
4	certain	certain	JJ	_	5	attr	_	_
5	circumstances	circumstance	NNS	_	17	ppmod	_	_
6	,	,	,	_	5	p	_	_
7	e.g.	e.g.	FW	_	5	ppmod	_	_
8	,	,	,	_	17	p	_	_
9	as	as	IN	_	10	case	_	_
10	prophylaxis	prophylaxis	NN	_	17	ppmod	_	_
11	after	after	IN	_	13	case	_	_
12	myocardial	myocardial	JJ	_	13	attr	_	_
13	infarction	infarction	NN	_	10	ppmod	_	_
14	,	,	,	_	17	p	_	_
15	there	there	EX	_	17	dep	_	_
16	may	may	MD	_	17	modal	_	_
17	be	be	VB	_	0	root	_	_
18	no	no	DT	_	20	det	_	_
19	acceptable	acceptable	JJ	_	20	attr	_	_
20	alternatives	alternative	NNS	_	17	obj	_	_
21	to	to	TO	_	23	aux	_	_
22	the	the	DT	_	23	det	_	_
23	use	use	NN	_	20	ppmod	_	_
24	of	of	IN	_	25	case	_	_
25	drug1	drug0	NN	_	23	ppmod	_	_
26	in	in	IN	_	27	case	_	_
27	patients	patient	NNS	_	23	ppmod	_	_
28	with	with	IN	_	29	case	_	_
29	COPD	copd	NN	_	27	ppmod	_	_
30	.	.	.	_	17	p	_	_

1	In	in	IN	_	3	case	_	_
2	this	this	DT	_	3	det	_	_
3	setting	setting	NN	_	8	ppmod	_	_
4	,	,	,	_	8	p	_	_
5	drug1	drug0	NN	_	8	dep	_	_
6	could	could	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	considered	consider	VBN	_	0	root	_	_
9	,	,	,	_	8	p	_	_
10	although	although	IN	_	14	mark	_	_
11	they	they	PRP	_	14	dep	_	_
12	should	should	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	administered	administer	VBN	_	8	comp	_	_
15	with	with	IN	_	16	case	_	_
16	caution	caution	NN	_	14	ppmod	_	_
17	.	.	.	_	8	p	_	_

1	Reduced	reduce	VBN	_	2	attr	_	_
2	efficacy	efficacy	NN	_	14	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	increased	increase	VBN	_	5	attr	_	_
5	incidence	incidence	NN	_	2	conj	_	_
6	of	of	IN	_	8	case	_	_
7	breakthrough	breakthrough	JJ	_	8	attr	_	_
8	bleeding	bleeding	JJ	_	2	ppmod	_	_
9	and	and	CC	_	2	cc	_	_
10	menstrual	menstrual	JJ	_	11	attr	_	_
11	irregularities	irregularity	NNS	_	2	conj	_	_
12	have	have	VBP	_	14	aux	_	_
13	been	be	VBN	_	14	aux	_	_
14	associated	associate	VBN	_	0	root	_	_
15	with	with	IN	_	17	case	_	_
16	concomitant	concomitant	JJ	_	17	attr	_	_
17	use	use	NN	_	14	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug1	drug0	NN	_	17	ppmod	_	_
20	.	.	.	_	14	p	_	_

1	A	a	DT	_	3	det	_	_
2	similar	similar	JJ	_	3	attr	_	_
3	association	association	NN	_	11	dep	_	_
4	,	,	,	_	3	p	_	_
5	though	though	RB	_	7	adv	_	_
6	less	less	RBR	_	7	adv	_	_
7	marked	marked	JJ	_	3	attr	_	_
8	,	,	,	_	3	p	_	_
9	has	have	VBZ	_	11	aux	_	_
10	been	be	VBN	_	11	aux	_	_
11	suggested	suggest	VBN	_	0	root	_	_
12	with	with	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	,	,	,	_	13	p	_	_
15	phenyl-butazone	phenyl-butazone	NN	_	13	conj	_	_
16	,	,	,	_	15	p	_	_
17	drug2	drug0	NN	_	13	conj	_	_
18	,	,	,	_	17	p	_	_
19	drug3	drug0	NN	_	13	conj	_	_
20	and	and	CC	_	19	cc	_	_
21	possibly	possibly	RB	_	23	adv	_	_
22	with	with	IN	_	23	case	_	_
23	drug4	drug0	NN	_	13	conj	_	_
24	,	,	,	_	23	p	_	_
25	drug5	drug0	NN	_	23	conj	_	_
26	,	,	,	_	25	p	_	_
27	and	and	CC	_	25	cc	_	_
28	drug6	drug0	NN	_	23	conj	_	_
29	(	-lrb-	-LRB-	_	28	p	_	_
30	72	0	CD	_	28	num	_	_
31	)	-rrb-	-RRB-	_	28	p	_	_

1	.	.	.	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	increase	increase	VB	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	action	action	NN	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	drug3	drug0	NN	_	7	conj	_	_
10	,	,	,	_	9	p	_	_
11	drug4	drug0	NN	_	7	conj	_	_
12	,	,	,	_	11	p	_	_
13	and	and	CC	_	11	cc	_	_
14	drug5	drug0	NN	_	7	conj	_	_
15	.	.	.	_	3	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	increase	increase	VB	_	0	root	_	_
4	excretion	excretion	NN	_	3	obj	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	,	,	,	_	6	p	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	,	,	,	_	8	p	_	_
10	and	and	CC	_	8	cc	_	_
11	drug3	drug0	NN	_	6	conj	_	_
12	and	and	CC	_	3	cc	_	_
13	may	may	MD	_	15	modal	_	_
14	also	also	RB	_	15	adv	_	_
15	increase	increase	VB	_	3	conj	_	_
16	the	the	DT	_	17	det	_	_
17	toxicity	toxicity	NN	_	15	obj	_	_
18	of	of	IN	_	19	case	_	_
19	drug4	drug0	NN	_	17	ppmod	_	_
20	.	.	.	_	3	p	_	_

1	Coadministration	coadministration	NN	_	13	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	6	case	_	_
5	other	other	JJ	_	6	attr	_	_
6	drug2	drug0	NN	_	1	ppmod	_	_
7	,	,	,	_	6	p	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	,	,	,	_	8	p	_	_
10	and	and	CC	_	8	cc	_	_
11	drug4	drug0	NN	_	6	conj	_	_
12	may	may	MD	_	13	modal	_	_
13	cause	cause	VB	_	0	root	_	_
14	hypokalemia	hypokalemia	NN	_	13	obj	_	_
15	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	administered	administer	VBN	_	0	root	_	_
5	with	with	IN	_	6	case	_	_
6	caution	caution	NN	_	4	ppmod	_	_
7	to	to	TO	_	8	aux	_	_
8	patients	patient	NNS	_	4	ppmod	_	_
9	taking	take	VBG	_	8	acl	_	_
10	drug2	drug0	NN	_	9	obj	_	_
11	,	,	,	_	4	p	_	_
12	because	because	IN	_	15	case	_	_
13	of	of	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	possibility	possibility	NN	_	4	ppmod	_	_
16	of	of	IN	_	18	case	_	_
17	conduction	conduction	NN	_	18	com	_	_
18	disturbances	disturbance	NNS	_	15	ppmod	_	_
19	.	.	.	_	4	p	_	_

1	Drugs	drug	NNS	_	11	dep	_	_
2	with	with	IN	_	4	case	_	_
3	parasympathomimetic	parasympathomimetic	JJ	_	4	attr	_	_
4	effects	effect	NNS	_	1	ppmod	_	_
5	administered	administer	VBN	_	4	acl	_	_
6	concurrently	concurrently	RB	_	5	adv	_	_
7	with	with	IN	_	8	case	_	_
8	drug1	drug0	NN	_	5	ppmod	_	_
9	can	can	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	expected	expect	VBN	_	0	root	_	_
12	to	to	TO	_	13	aux	_	_
13	have	have	VB	_	11	comp	_	_
14	additive	additive	JJ	_	15	attr	_	_
15	effects	effect	NNS	_	13	obj	_	_
16	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	might	might	MD	_	3	modal	_	_
3	interfere	interfere	VB	_	0	root	_	_
4	with	with	IN	_	7	case	_	_
5	desirable	desirable	JJ	_	7	attr	_	_
6	antimuscarinic	antimuscarinic	JJ	_	7	attr	_	_
7	effects	effect	NNS	_	3	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drugs	drug	NNS	_	7	ppmod	_	_
10	used	use	VBN	_	9	acl	_	_
11	concomitantly	concomitantly	RB	_	10	adv	_	_
12	.	.	.	_	3	p	_	_

1	Drugs	drug	NNS	_	8	dep	_	_
2	which	which	WDT	_	3	dep	_	_
3	inhibit	inhibit	VBP	_	1	relcl	_	_
4	CYP2D6	cyp0d0	NN	_	3	obj	_	_
5	and	and	CC	_	4	cc	_	_
6	CYP3A3/4	cyp0a0	NN	_	4	conj	_	_
7	also	also	RB	_	8	adv	_	_
8	inhibit	inhibit	VBP	_	0	root	_	_
9	the	the	DT	_	10	det	_	_
10	metabolism	metabolism	NN	_	8	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	used	use	VBN	_	0	root	_	_
5	with	with	IN	_	6	case	_	_
6	caution	caution	NN	_	4	ppmod	_	_
7	in	in	IN	_	8	case	_	_
8	individuals	individual	NNS	_	6	ppmod	_	_
9	known	know	VBN	_	8	attr	_	_
10	or	or	CC	_	9	cc	_	_
11	suspected	suspect	VBN	_	9	conj	_	_
12	to	to	TO	_	13	aux	_	_
13	be	be	VB	_	6	acl	_	_
14	deficient	deficient	JJ	_	13	dep	_	_
15	in	in	IN	_	17	case	_	_
16	CYP2D6	cyp0d0	NN	_	17	com	_	_
17	activity	activity	NN	_	14	ppmod	_	_
18	,	,	,	_	17	p	_	_
19	based	base	VBN	_	17	acl	_	_
20	on	on	IN	_	22	case	_	_
21	previous	previous	JJ	_	22	attr	_	_
22	experience	experience	VBP	_	19	ppmod	_	_
23	,	,	,	_	13	p	_	_
24	as	as	IN	_	27	mark	_	_
25	they	they	PRP	_	27	dep	_	_
26	may	may	MD	_	27	modal	_	_
27	be	be	VB	_	13	comp	_	_
28	at	at	IN	_	31	case	_	_
29	a	a	DT	_	31	det	_	_
30	higher	high	JJR	_	31	attr	_	_
31	risk	risk	NN	_	27	ppmod	_	_
32	of	of	IN	_	34	case	_	_
33	adverse	adverse	JJ	_	34	attr	_	_
34	events	event	NNS	_	31	ppmod	_	_
35	.	.	.	_	4	p	_	_

1	In	in	IN	_	5	case	_	_
2	an	an	DT	_	5	det	_	_
3	in	in	FW	_	4	adv	_	_
4	vitro	vitro	FW	_	5	attr	_	_
5	study	study	NN	_	26	ppmod	_	_
6	,	,	,	_	26	p	_	_
7	cytochrome	cytochrome	NN	_	9	com	_	_
8	P450	p0	NN	_	9	com	_	_
9	isozymes	isozymes	NNS	_	26	dep	_	_
10	1A2	0a0	NN	_	9	attr	_	_
11	,	,	,	_	10	p	_	_
12	2A6	0a0	NN	_	10	conj	_	_
13	,	,	,	_	12	p	_	_
14	2C9	0c0	NN	_	10	conj	_	_
15	,	,	,	_	14	p	_	_
16	2C19	0c0	NN	_	10	conj	_	_
17	,	,	,	_	16	p	_	_
18	2D6	0d0	NN	_	10	conj	_	_
19	,	,	,	_	18	p	_	_
20	2E1	0e0	NN	_	10	conj	_	_
21	,	,	,	_	20	p	_	_
22	and	and	CC	_	20	cc	_	_
23	3A4	0a0	NN	_	10	conj	_	_
24	were	be	VBD	_	26	aux	_	_
25	not	not	RB	_	26	neg	_	_
26	inhibited	inhibit	VBN	_	0	root	_	_
27	by	by	IN	_	28	case	_	_
28	exposure	exposure	NN	_	26	ppmod	_	_
29	to	to	TO	_	30	aux	_	_
30	drug1	drug0	NN	_	28	ppmod	_	_
31	.	.	.	_	26	p	_	_

1	In	in	IN	_	5	case	_	_
2	a	a	DT	_	5	det	_	_
3	Phase	phase	NN	_	5	com	_	_
4	I	i	NN	_	5	com	_	_
5	trial	trial	NN	_	29	ppmod	_	_
6	using	use	VBG	_	5	acl	_	_
7	escalating	escalating	JJ	_	8	attr	_	_
8	doses	dose	NNS	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	(	-lrb-	-LRB-	_	13	p	_	_
12	110-200	0	CD	_	13	num	_	_
13	mg/m2	mg/m0	NN	_	10	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	and	and	CC	_	10	cc	_	_
16	drug2	drug0	NN	_	10	conj	_	_
17	(	-lrb-	-LRB-	_	21	p	_	_
18	50	0	CD	_	21	num	_	_
19	or	or	CC	_	18	cc	_	_
20	75	0	CD	_	18	conj	_	_
21	mg/m2	mg/m0	NN	_	16	prn	_	_
22	)	-rrb-	-RRB-	_	21	p	_	_
23	given	give	VBN	_	8	acl	_	_
24	as	as	IN	_	26	case	_	_
25	sequential	sequential	JJ	_	26	attr	_	_
26	infusions	infusion	NNS	_	23	ppmod	_	_
27	,	,	,	_	29	p	_	_
28	myelosuppression	myelosuppression	NN	_	29	dep	_	_
29	was	be	VBD	_	0	root	_	_
30	more	more	RBR	_	31	adv	_	_
31	profound	profound	JJ	_	29	dep	_	_
32	when	when	WRB	_	35	adv	_	_
33	drug3	drug0	NN	_	35	dep	_	_
34	was	be	VBD	_	35	aux	_	_
35	given	give	VBN	_	29	comp	_	_
36	after	after	IN	_	37	case	_	_
37	drug4	drug0	NN	_	35	ppmod	_	_
38	than	than	IN	_	42	case	_	_
39	with	with	IN	_	42	case	_	_
40	the	the	DT	_	42	det	_	_
41	alternate	alternate	JJ	_	42	attr	_	_
42	sequence	sequence	NN	_	35	ppmod	_	_
43	(	-lrb-	-LRB-	_	46	p	_	_
44	ie	ie	FW	_	46	ppmod	_	_
45	,	,	,	_	46	p	_	_
46	drug5	drug0	NN	_	42	prn	_	_
47	before	before	IN	_	48	case	_	_
48	drug6	drug0	NN	_	46	ppmod	_	_
49	)	-rrb-	-RRB-	_	46	p	_	_
50	.	.	.	_	29	p	_	_

1	Pharmacokinetic	pharmacokinetic	JJ	_	2	attr	_	_
2	data	datum	NNS	_	6	dep	_	_
3	from	from	IN	_	5	case	_	_
4	these	these	DT	_	5	det	_	_
5	patients	patient	NNS	_	2	ppmod	_	_
6	demonstrated	demonstrate	VBD	_	0	root	_	_
7	a	a	DT	_	8	det	_	_
8	decrease	decrease	NN	_	6	obj	_	_
9	in	in	IN	_	11	case	_	_
10	drug1	drug0	NN	_	11	com	_	_
11	clearance	clearance	NN	_	8	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	approximately	approximately	RB	_	14	adv	_	_
14	33	0	CD	_	11	ppmod	_	_
15	%	%	NN	_	14	meta	_	_
16	when	when	WRB	_	19	adv	_	_
17	drug2	drug0	NN	_	19	dep	_	_
18	was	be	VBD	_	19	aux	_	_
19	administered	administer	VBN	_	6	comp	_	_
20	following	follow	VBG	_	21	adv	_	_
21	drug3	drug0	NN	_	19	ppmod	_	_
22	.	.	.	_	6	p	_	_

1	The	the	DT	_	2	det	_	_
2	metabolism	metabolism	NN	_	6	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	is	be	VBZ	_	6	aux	_	_
6	catalyzed	catalyze	VBN	_	0	root	_	_
7	by	by	IN	_	10	case	_	_
8	cytochrome	cytochrome	NN	_	10	com	_	_
9	P450	p0	NN	_	10	com	_	_
10	isoen-zymes	isoen-zymes	NNS	_	6	ppmod	_	_
11	CYP2C8	cyp0c0	NN	_	10	attr	_	_
12	and	and	CC	_	11	cc	_	_
13	CYP3A4	cyp0a0	NN	_	11	conj	_	_
14	.	.	.	_	6	p	_	_

1	In	in	IN	_	9	case	_	_
2	the	the	DT	_	9	det	_	_
3	absence	absence	NN	_	9	advnp	_	_
4	of	of	IN	_	9	case	_	_
5	formal	formal	JJ	_	9	attr	_	_
6	clinical	clinical	JJ	_	9	attr	_	_
7	drug	drug	NN	_	9	com	_	_
8	interaction	interaction	NN	_	9	com	_	_
9	studies	study	NNS	_	14	ppmod	_	_
10	,	,	,	_	14	p	_	_
11	caution	caution	NN	_	14	dep	_	_
12	should	should	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	exercised	exercise	VBN	_	0	root	_	_
15	when	when	WRB	_	16	adv	_	_
16	administering	administer	VBG	_	14	comp	_	_
17	drug1	drug0	NN	_	16	obj	_	_
18	concomitantly	concomitantly	RB	_	21	adv	_	_
19	with	with	IN	_	21	case	_	_
20	known	known	JJ	_	21	attr	_	_
21	substrates	substrate	NNS	_	16	ppmod	_	_
22	or	or	CC	_	21	cc	_	_
23	inhibitors	inhibitor	NNS	_	21	conj	_	_
24	of	of	IN	_	28	case	_	_
25	the	the	DT	_	28	det	_	_
26	cytochrome	cytochrome	NN	_	28	com	_	_
27	P450	p0	NN	_	28	com	_	_
28	isoenzymes	isoenzymes	NNS	_	23	ppmod	_	_
29	CYP2C8	cyp0c0	NN	_	28	attr	_	_
30	and	and	CC	_	29	cc	_	_
31	CYP3A4	cyp0a0	NN	_	29	conj	_	_
32	.	.	.	_	14	p	_	_

1	Potential	potential	JJ	_	2	attr	_	_
2	interactions	interaction	NNS	_	35	dep	_	_
3	between	between	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	,	,	,	_	4	p	_	_
6	a	a	DT	_	7	det	_	_
7	substrate	substrate	NN	_	4	conj	_	_
8	of	of	IN	_	9	case	_	_
9	CYP3A4	cyp0a0	NN	_	7	ppmod	_	_
10	,	,	,	_	7	p	_	_
11	and	and	CC	_	7	cc	_	_
12	drug2	drug0	NN	_	4	conj	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	drug3	drug0	NN	_	12	prn	_	_
15	,	,	,	_	14	p	_	_
16	drug4	drug0	NN	_	14	conj	_	_
17	,	,	,	_	16	p	_	_
18	drug5	drug0	NN	_	14	conj	_	_
19	,	,	,	_	18	p	_	_
20	and	and	CC	_	18	cc	_	_
21	drug6	drug0	NN	_	14	conj	_	_
22	)	-rrb-	-RRB-	_	14	p	_	_
23	,	,	,	_	2	p	_	_
24	which	which	WDT	_	25	dep	_	_
25	are	be	VBP	_	2	relcl	_	_
26	substrates	substrate	NNS	_	25	obj	_	_
27	and/or	and/or	CC	_	26	cc	_	_
28	inhibitors	inhibitor	NNS	_	26	conj	_	_
29	of	of	IN	_	30	case	_	_
30	CYP3A4	cyp0a0	NN	_	26	ppmod	_	_
31	,	,	,	_	2	p	_	_
32	have	have	VBP	_	35	aux	_	_
33	not	not	RB	_	35	neg	_	_
34	been	be	VBN	_	35	aux	_	_
35	evaluated	evaluate	VBN	_	0	root	_	_
36	in	in	IN	_	38	case	_	_
37	clinical	clinical	JJ	_	38	attr	_	_
38	trials	trial	NNS	_	35	ppmod	_	_
39	.	.	.	_	35	p	_	_

1	Reports	report	NNS	_	5	dep	_	_
2	in	in	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	literature	literature	NN	_	1	ppmod	_	_
5	suggest	suggest	VBP	_	0	root	_	_
6	that	that	IN	_	20	mark	_	_
7	plasma	plasma	NN	_	8	com	_	_
8	levels	level	NNS	_	20	dep	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	(	-lrb-	-LRB-	_	8	p	_	_
12	and	and	CC	_	8	cc	_	_
13	its	its	PRP$	_	16	poss	_	_
14	active	active	JJ	_	16	attr	_	_
15	metabolite	metabolite	NN	_	16	com	_	_
16	drug2	drug0	NN	_	8	conj	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	may	may	MD	_	20	modal	_	_
19	be	be	VB	_	20	aux	_	_
20	increased	increase	VBN	_	5	comp	_	_
21	when	when	WRB	_	26	adv	_	_
22	drug3	drug0	NN	_	26	dep	_	_
23	and	and	CC	_	22	cc	_	_
24	drug4	drug0	NN	_	22	conj	_	_
25	are	be	VBP	_	26	aux	_	_
26	used	use	VBN	_	20	comp	_	_
27	in	in	IN	_	28	case	_	_
28	combination	combination	NN	_	26	ppmod	_	_
29	.	.	.	_	5	p	_	_

1	Hematology	hematology	NNP	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	therapy	therapy	NN	_	8	dep	_	_
5	should	should	MD	_	8	modal	_	_
6	not	not	RB	_	8	neg	_	_
7	be	be	VB	_	8	aux	_	_
8	administered	administer	VBN	_	1	acl	_	_
9	to	to	TO	_	10	aux	_	_
10	patients	patient	NNS	_	8	ppmod	_	_
11	with	with	IN	_	14	case	_	_
12	baseline	baseline	NN	_	14	com	_	_
13	neutrophil	neutrophil	NN	_	14	com	_	_
14	counts	count	NNS	_	10	ppmod	_	_
15	of	of	IN	_	19	case	_	_
16	less	less	JJR	_	18	attr	_	_
17	than	than	IN	_	16	com	_	_
18	1,500	0	CD	_	19	num	_	_
19	cells/mm3	cells/mm0	NN	_	14	ppmod	_	_
20	.	.	.	_	1	p	_	_

1	In	in	IN	_	4	mark	_	_
2	order	order	NN	_	4	dep	_	_
3	to	to	TO	_	4	aux	_	_
4	monitor	monitor	VB	_	12	advcl	_	_
5	the	the	DT	_	6	det	_	_
6	occurrence	occurrence	NN	_	4	obj	_	_
7	of	of	IN	_	8	case	_	_
8	myelotoxicity	myelotoxicity	NN	_	6	ppmod	_	_
9	,	,	,	_	12	p	_	_
10	it	it	PRP	_	12	dep	_	_
11	is	be	VBZ	_	12	aux	_	_
12	recommended	recommend	VBN	_	0	root	_	_
13	that	that	IN	_	20	mark	_	_
14	frequent	frequent	JJ	_	18	attr	_	_
15	peripheral	peripheral	JJ	_	18	attr	_	_
16	blood	blood	NN	_	18	com	_	_
17	cell	cell	NN	_	18	com	_	_
18	counts	count	NNS	_	20	dep	_	_
19	be	be	VB	_	20	aux	_	_
20	performed	performed	VBN	_	12	comp	_	_
21	on	on	IN	_	23	case	_	_
22	all	all	DT	_	23	det	_	_
23	patients	patient	NNS	_	20	ppmod	_	_
24	receiving	receive	VBG	_	23	acl	_	_
25	drug1	drug0	NN	_	24	obj	_	_
26	.	.	.	_	12	p	_	_

1	Patients	patient	NNS	_	5	dep	_	_
2	should	should	MD	_	5	modal	_	_
3	not	not	RB	_	5	neg	_	_
4	be	be	VB	_	5	aux	_	_
5	re-treated	re-treated	VBN	_	0	root	_	_
6	with	with	IN	_	8	case	_	_
7	subsequent	subsequent	JJ	_	8	attr	_	_
8	cycles	cycle	NNS	_	5	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	until	until	IN	_	13	mark	_	_
12	neutrophils	neutrophil	NNS	_	13	dep	_	_
13	recover	recover	VBP	_	5	comp	_	_
14	to	to	TO	_	16	aux	_	_
15	a	a	DT	_	16	det	_	_
16	level	level	NN	_	13	ppmod	_	_
17	1500	0	CD	_	18	num	_	_
18	cells/mm3	cells/mm0	NN	_	16	attr	_	_
19	and	and	CC	_	13	cc	_	_
20	platelets	platelet	NNS	_	21	dep	_	_
21	recover	recover	VBP	_	13	conj	_	_
22	to	to	TO	_	24	aux	_	_
23	a	a	DT	_	24	det	_	_
24	level	level	NN	_	21	ppmod	_	_
25	100,000	0	CD	_	26	num	_	_
26	cells/mm3	cells/mm0	NN	_	24	attr	_	_
27	.	.	.	_	5	p	_	_

1	In	in	IN	_	3	case	_	_
2	the	the	DT	_	3	det	_	_
3	case	case	NN	_	35	ppmod	_	_
4	of	of	IN	_	6	case	_	_
5	severe	severe	JJ	_	6	attr	_	_
6	neutropenia	neutropenia	NN	_	3	ppmod	_	_
7	(	-lrb-	-LRB-	_	9	p	_	_
8	500	0	CD	_	9	num	_	_
9	cells/mm3	cells/mm0	NN	_	6	prn	_	_
10	for	for	IN	_	12	case	_	_
11	seven	#crd#	CD	_	12	num	_	_
12	days	day	NNS	_	9	ppmod	_	_
13	or	or	CC	_	12	cc	_	_
14	more	more	JJR	_	12	conj	_	_
15	)	-rrb-	-RRB-	_	9	p	_	_
16	during	during	IN	_	18	case	_	_
17	a	a	DT	_	18	det	_	_
18	course	course	NN	_	3	ppmod	_	_
19	of	of	IN	_	21	case	_	_
20	drug1	drug0	NN	_	21	com	_	_
21	therapy	therapy	NN	_	18	ppmod	_	_
22	,	,	,	_	35	p	_	_
23	a	a	DT	_	26	det	_	_
24	20	0	CD	_	26	num	_	_
25	%	%	NN	_	26	meta	_	_
26	reduction	reduction	NN	_	35	dep	_	_
27	in	in	IN	_	28	case	_	_
28	dose	dose	NN	_	26	ppmod	_	_
29	for	for	IN	_	31	case	_	_
30	subsequent	subsequent	JJ	_	31	attr	_	_
31	courses	course	NNS	_	26	ppmod	_	_
32	of	of	IN	_	33	case	_	_
33	therapy	therapy	NN	_	31	ppmod	_	_
34	is	be	VBZ	_	35	aux	_	_
35	recommended	recommend	VBN	_	0	root	_	_
36	.	.	.	_	35	p	_	_

1	For	for	IN	_	2	case	_	_
2	patients	patient	NNS	_	26	ppmod	_	_
3	with	with	IN	_	6	case	_	_
4	advanced	advanced	JJ	_	6	attr	_	_
5	HIV	hiv	NN	_	6	com	_	_
6	disease	disease	NN	_	2	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	poor-risk	poor-risk	JJ	_	12	attr	_	_
9	AIDS-related	aids-related	JJ	_	12	attr	_	_
10	Kaposi	kaposi	NN	_	12	com	_	_
11	s	s	NN	_	12	com	_	_
12	sarcoma	sarcoma	NN	_	6	conj	_	_
13	,	,	,	_	26	p	_	_
14	drug1	drug0	NN	_	26	dep	_	_
15	,	,	,	_	14	p	_	_
16	at	at	IN	_	19	case	_	_
17	the	the	DT	_	19	det	_	_
18	recommended	recommend	VBN	_	19	attr	_	_
19	dose	dose	NN	_	14	ppmod	_	_
20	for	for	IN	_	22	case	_	_
21	this	this	DT	_	22	det	_	_
22	disease	disease	NN	_	19	ppmod	_	_
23	,	,	,	_	14	p	_	_
24	can	can	MD	_	26	modal	_	_
25	be	be	VB	_	26	aux	_	_
26	initiated	initiate	VBN	_	0	root	_	_
27	and	and	CC	_	26	cc	_	_
28	repeated	repeat	VBN	_	26	conj	_	_
29	if	if	IN	_	33	mark	_	_
30	the	the	DT	_	32	det	_	_
31	neutrophil	neutrophil	NN	_	32	com	_	_
32	count	count	NN	_	33	dep	_	_
33	is	be	VBZ	_	28	comp	_	_
34	at	at	IN	_	36	case	_	_
35	least	least	JJS	_	36	attr	_	_
36	1000	0	CD	_	37	num	_	_
37	cells/mm3	cells/mm0	NN	_	33	obj	_	_
38	.	.	.	_	26	p	_	_

1	Hypersensitivity	hypersensitivity	NN	_	2	com	_	_
2	Reactions	reaction	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	Patients	patient	NNS	_	33	dep	_	_
5	with	with	IN	_	7	case	_	_
6	a	a	DT	_	7	det	_	_
7	history	history	NN	_	4	ppmod	_	_
8	of	of	IN	_	11	case	_	_
9	severe	severe	JJ	_	11	attr	_	_
10	hypersensitivity	hypersensitivity	NN	_	11	com	_	_
11	reactions	reaction	NNS	_	7	ppmod	_	_
12	to	to	TO	_	13	aux	_	_
13	products	product	NNS	_	11	ppmod	_	_
14	containing	contain	VBG	_	13	acl	_	_
15	Cremophor	cremophor	NN	_	16	com	_	_
16	EL	el	NN	_	14	obj	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	eg	eg	NN	_	16	prn	_	_
19	,	,	,	_	18	p	_	_
20	drug1	drug0	CD	_	18	appo	_	_
21	for	for	IN	_	23	case	_	_
22	injection	injection	NN	_	23	com	_	_
23	concentrate	concentrate	NN	_	20	ppmod	_	_
24	and	and	CC	_	20	cc	_	_
25	drug2	drug0	CD	_	20	conj	_	_
26	for	for	IN	_	28	case	_	_
27	injection	injection	NN	_	28	com	_	_
28	concentrate	concentrate	NN	_	25	ppmod	_	_
29	)	-rrb-	-RRB-	_	18	p	_	_
30	should	should	MD	_	33	modal	_	_
31	not	not	RB	_	33	neg	_	_
32	be	be	VB	_	33	aux	_	_
33	treated	treat	VBN	_	2	acl	_	_
34	with	with	IN	_	35	case	_	_
35	drug3	drug0	NN	_	33	ppmod	_	_
36	.	.	.	_	2	p	_	_

1	In	in	IN	_	4	mark	_	_
2	order	order	NN	_	4	dep	_	_
3	to	to	TO	_	4	aux	_	_
4	avoid	avoid	VB	_	19	advcl	_	_
5	the	the	DT	_	6	det	_	_
6	occurrence	occurrence	NN	_	4	obj	_	_
7	of	of	IN	_	10	case	_	_
8	severe	severe	JJ	_	10	attr	_	_
9	hypersensitivity	hypersensitivity	NN	_	10	com	_	_
10	reactions	reaction	NNS	_	6	ppmod	_	_
11	,	,	,	_	19	p	_	_
12	all	all	DT	_	13	det	_	_
13	patients	patient	NNS	_	19	dep	_	_
14	treated	treat	VBN	_	13	acl	_	_
15	with	with	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	should	should	MD	_	19	modal	_	_
18	be	be	VB	_	19	aux	_	_
19	premedicated	premedicated	VBN	_	0	root	_	_
20	with	with	IN	_	21	case	_	_
21	drug2	drug0	NN	_	19	ppmod	_	_
22	(	-lrb-	-LRB-	_	23	p	_	_
23	such	such	JJ	_	21	prn	_	_
24	as	as	IN	_	25	case	_	_
25	drug3	drug0	NN	_	23	ppmod	_	_
26	)	-rrb-	-RRB-	_	23	p	_	_
27	,	,	,	_	21	p	_	_
28	diphen-hydramine	diphen-hydramine	NN	_	21	conj	_	_
29	and	and	CC	_	28	cc	_	_
30	drug4	drug0	NN	_	21	conj	_	_
31	(	-lrb-	-LRB-	_	32	p	_	_
32	such	such	JJ	_	30	prn	_	_
33	as	as	IN	_	34	case	_	_
34	drug5	drug0	NN	_	32	ppmod	_	_
35	or	or	CC	_	34	cc	_	_
36	drug6	drug0	NN	_	34	conj	_	_
37	)	-rrb-	-RRB-	_	32	p	_	_
38	.	.	.	_	19	p	_	_

1	Minor	minor	JJ	_	2	attr	_	_
2	symptoms	symptom	NNS	_	18	dep	_	_
3	such	such	JJ	_	5	adv	_	_
4	as	as	IN	_	5	case	_	_
5	flushing	flushing	NN	_	2	ppmod	_	_
6	,	,	,	_	5	p	_	_
7	skin	skin	NN	_	8	com	_	_
8	reactions	reaction	NNS	_	5	conj	_	_
9	,	,	,	_	8	p	_	_
10	dyspnea	dyspnea	NN	_	5	conj	_	_
11	,	,	,	_	10	p	_	_
12	hypotension	hypotension	NN	_	5	conj	_	_
13	,	,	,	_	12	p	_	_
14	or	or	CC	_	12	cc	_	_
15	tachycardia	tachycardia	NN	_	5	conj	_	_
16	do	do	VBP	_	18	aux	_	_
17	not	not	RB	_	18	neg	_	_
18	require	require	VB	_	0	root	_	_
19	interruption	interruption	NN	_	18	obj	_	_
20	of	of	IN	_	21	case	_	_
21	therapy	therapy	NN	_	19	ppmod	_	_
22	.	.	.	_	18	p	_	_

1	However	however	RB	_	21	adv	_	_
2	,	,	,	_	21	p	_	_
3	severe	severe	JJ	_	4	attr	_	_
4	reactions	reaction	NNS	_	21	dep	_	_
5	,	,	,	_	4	p	_	_
6	such	such	JJ	_	8	adv	_	_
7	as	as	IN	_	8	case	_	_
8	hypotension	hypotension	NN	_	4	ppmod	_	_
9	requiring	require	VBG	_	8	acl	_	_
10	treatment	treatment	NN	_	9	obj	_	_
11	,	,	,	_	10	p	_	_
12	dyspnea	dyspnea	NN	_	10	conj	_	_
13	requiring	require	VBG	_	12	acl	_	_
14	drug1	drug0	NN	_	13	obj	_	_
15	,	,	,	_	12	p	_	_
16	angioedema	angioedema	NN	_	10	conj	_	_
17	,	,	,	_	16	p	_	_
18	or	or	CC	_	16	cc	_	_
19	generalized	generalize	VBN	_	20	attr	_	_
20	urticaria	urticaria	NN	_	10	conj	_	_
21	require	require	VBP	_	0	root	_	_
22	immediate	immediate	JJ	_	23	attr	_	_
23	discontinuation	discontinuation	NN	_	21	obj	_	_
24	of	of	IN	_	25	case	_	_
25	drug2	drug0	NN	_	23	ppmod	_	_
26	and	and	CC	_	25	cc	_	_
27	aggressive	aggressive	JJ	_	29	attr	_	_
28	symptomatic	symptomatic	JJ	_	29	attr	_	_
29	therapy	therapy	NN	_	25	conj	_	_
30	.	.	.	_	21	p	_	_

1	Patients	patient	NNS	_	11	dep	_	_
2	who	who	WP	_	4	dep	_	_
3	have	have	VBP	_	4	aux	_	_
4	developed	develop	VBN	_	1	relcl	_	_
5	severe	severe	JJ	_	7	attr	_	_
6	hypersensitivity	hypersensitivity	NN	_	7	com	_	_
7	reactions	reaction	NNS	_	4	obj	_	_
8	should	should	MD	_	11	modal	_	_
9	not	not	RB	_	11	neg	_	_
10	be	be	VB	_	11	aux	_	_
11	rechallenged	rechallenged	VBN	_	0	root	_	_
12	with	with	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	.	.	.	_	11	p	_	_

1	Cardiovascular	cardiovascular	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Hypotension	hypotension	NN	_	11	dep	_	_
4	,	,	,	_	3	p	_	_
5	bradycardia	bradycardia	NN	_	3	conj	_	_
6	,	,	,	_	5	p	_	_
7	and	and	CC	_	5	cc	_	_
8	hypertension	hypertension	NN	_	3	conj	_	_
9	have	have	VBP	_	11	aux	_	_
10	been	be	VBN	_	11	aux	_	_
11	observed	observe	VBN	_	1	acl	_	_
12	during	during	IN	_	13	case	_	_
13	administration	administration	NN	_	11	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	,	,	,	_	11	p	_	_
17	but	but	CC	_	11	cc	_	_
18	generally	generally	RB	_	21	adv	_	_
19	do	do	VBP	_	21	aux	_	_
20	not	not	RB	_	21	neg	_	_
21	require	require	VB	_	11	conj	_	_
22	treatment	treatment	NN	_	21	obj	_	_
23	.	.	.	_	1	p	_	_

1	Occasionally	occasionally	RB	_	6	adv	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	infusions	infusion	NNS	_	6	dep	_	_
4	must	must	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	interrupted	interrupt	VBN	_	0	root	_	_
7	or	or	CC	_	6	cc	_	_
8	discontinued	discontinue	VBD	_	6	conj	_	_
9	because	because	IN	_	14	case	_	_
10	of	of	IN	_	14	case	_	_
11	initial	initial	JJ	_	14	attr	_	_
12	or	or	CC	_	11	cc	_	_
13	recurrent	recurrent	JJ	_	11	conj	_	_
14	hypertension	hypertension	NN	_	8	ppmod	_	_
15	.	.	.	_	6	p	_	_

1	Frequent	frequent	JJ	_	4	attr	_	_
2	vital	vital	JJ	_	4	attr	_	_
3	sign	sign	NN	_	4	com	_	_
4	monitoring	monitoring	NN	_	16	dep	_	_
5	,	,	,	_	4	p	_	_
6	particularly	particularly	RB	_	4	adv	_	_
7	during	during	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	first	#ord#	JJ	_	10	attr	_	_
10	hour	hour	NN	_	4	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	drug1	drug0	NN	_	13	com	_	_
13	infusion	infusion	NN	_	10	ppmod	_	_
14	,	,	,	_	4	p	_	_
15	is	be	VBZ	_	16	aux	_	_
16	recommended	recommend	VBN	_	0	root	_	_
17	.	.	.	_	16	p	_	_

1	Continuous	continuous	JJ	_	3	attr	_	_
2	cardiac	cardiac	JJ	_	3	attr	_	_
3	monitoring	monitoring	NN	_	6	dep	_	_
4	is	be	VBZ	_	6	aux	_	_
5	not	not	RB	_	6	neg	_	_
6	required	require	VBN	_	0	root	_	_
7	except	except	IN	_	9	case	_	_
8	for	for	IN	_	9	case	_	_
9	patients	patient	NNS	_	6	ppmod	_	_
10	with	with	IN	_	13	case	_	_
11	serious	serious	JJ	_	13	attr	_	_
12	conduction	conduction	NN	_	13	com	_	_
13	abnormalities	abnormality	NNS	_	9	ppmod	_	_
14	.	.	.	_	6	p	_	_

1	Nervous	nervous	JJ	_	2	attr	_	_
2	System	system	NN	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	Although	although	IN	_	10	mark	_	_
5	the	the	DT	_	6	det	_	_
6	occurrence	occurrence	NN	_	10	dep	_	_
7	of	of	IN	_	9	case	_	_
8	peripheral	peripheral	JJ	_	9	attr	_	_
9	neuropathy	neuropathy	NN	_	6	ppmod	_	_
10	is	be	VBZ	_	18	advcl	_	_
11	frequent	frequent	JJ	_	10	dep	_	_
12	,	,	,	_	18	p	_	_
13	the	the	DT	_	14	det	_	_
14	development	development	NN	_	18	dep	_	_
15	of	of	IN	_	17	case	_	_
16	severe	severe	JJ	_	17	attr	_	_
17	symptomatology	symptomatology	NN	_	14	ppmod	_	_
18	is	be	VBZ	_	2	acl	_	_
19	unusual	unusual	JJ	_	18	dep	_	_
20	and	and	CC	_	18	cc	_	_
21	requires	require	VBZ	_	18	conj	_	_
22	a	a	DT	_	24	det	_	_
23	dose	dose	NN	_	24	com	_	_
24	reduction	reduction	NN	_	21	obj	_	_
25	of	of	IN	_	26	case	_	_
26	20	0	CD	_	24	ppmod	_	_
27	%	%	NN	_	26	meta	_	_
28	for	for	IN	_	30	case	_	_
29	all	all	DT	_	30	det	_	_
30	subsequentcourses	subsequentcourses	NNS	_	24	ppmod	_	_
31	of	of	IN	_	32	case	_	_
32	drug1	drug0	NN	_	30	ppmod	_	_
33	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	contains	contain	VBZ	_	0	root	_	_
3	dehydrated	dehydrated	JJ	_	5	attr	_	_
4	alcohol	alcohol	NN	_	5	com	_	_
5	USP	usp	NN	_	2	obj	_	_
6	,	,	,	_	5	p	_	_
7	396	0	CD	_	8	num	_	_
8	mg/mL	mg/ml	NN	_	5	appo	_	_
9	;	;	:	_	2	p	_	_

1	consideration	consideration	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	given	give	VBN	_	0	root	_	_
5	to	to	TO	_	7	aux	_	_
6	possible	possible	JJ	_	7	attr	_	_
7	CNS	cn	NNS	_	4	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	other	other	JJ	_	10	attr	_	_
10	effects	effect	NNS	_	7	conj	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	7	ppmod	_	_
13	.	.	.	_	4	p	_	_

1	Hepatic	hepatic	JJ	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	There	there	EX	_	4	dep	_	_
4	is	be	VBZ	_	1	acl	_	_
5	limited	limited	JJ	_	6	attr	_	_
6	evidence	evidence	NN	_	4	obj	_	_
7	that	that	IN	_	13	mark	_	_
8	the	the	DT	_	9	det	_	_
9	myelotoxicity	myelotoxicity	NN	_	13	dep	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	may	may	MD	_	13	modal	_	_
13	be	be	VB	_	6	acl	_	_
14	exacerbated	exacerbated	JJ	_	13	dep	_	_
15	in	in	IN	_	16	case	_	_
16	patients	patient	NNS	_	14	ppmod	_	_
17	with	with	IN	_	23	case	_	_
18	serum	serum	NN	_	23	attr	_	_
19	total	total	JJ	_	23	attr	_	_
20	bilirubin	bilirubin	NN	_	23	attr	_	_
21	2	0	CD	_	23	num	_	_
22	times	time	NNS	_	23	com	_	_
23	ULN	uln	NN	_	16	ppmod	_	_
24	.	.	.	_	1	p	_	_

1	Extreme	extreme	JJ	_	2	attr	_	_
2	caution	caution	NN	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	exercised	exercise	VBN	_	0	root	_	_
6	when	when	WRB	_	7	adv	_	_
7	administering	administer	VBG	_	5	comp	_	_
8	drug1	drug0	NN	_	7	obj	_	_
9	to	to	TO	_	11	aux	_	_
10	such	such	JJ	_	11	attr	_	_
11	patients	patient	NNS	_	7	ppmod	_	_
12	,	,	,	_	5	p	_	_
13	with	with	IN	_	15	case	_	_
14	dose	dose	NN	_	15	com	_	_
15	reduction	reduction	NN	_	5	ppmod	_	_
16	as	as	IN	_	17	mark	_	_
17	recommended	recommend	VBN	_	5	comp	_	_
18	in	in	IN	_	19	case	_	_
19	DOSAGE	dosage	NN	_	17	ppmod	_	_
20	AND	and	CC	_	19	cc	_	_
21	ADMINISTRATION	administration	NN	_	19	conj	_	_
22	,	,	,	_	21	p	_	_
23	Table	table	NN	_	21	appo	_	_
24	17	0	CD	_	23	num	_	_
25	.	.	.	_	5	p	_	_

1	InjectionSite	injectionsite	NN	_	2	com	_	_
2	Reaction	reaction	NN	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	Injection	injection	NN	_	6	com	_	_
5	site	site	NN	_	6	com	_	_
6	reactions	reaction	NNS	_	14	dep	_	_
7	,	,	,	_	6	p	_	_
8	including	include	VBG	_	9	adv	_	_
9	reactions	reaction	NNS	_	6	ppmod	_	_
10	secondary	secondary	JJ	_	9	attr	_	_
11	to	to	TO	_	12	aux	_	_
12	extravasation	extravasation	NN	_	10	ppmod	_	_
13	,	,	,	_	6	p	_	_
14	were	be	VBD	_	2	acl	_	_
15	usually	usually	RB	_	16	adv	_	_
16	mild	mild	JJ	_	14	dep	_	_
17	and	and	CC	_	14	cc	_	_
18	consisted	consist	VBD	_	14	conj	_	_
19	of	of	IN	_	20	case	_	_
20	erythema	erythema	NN	_	18	ppmod	_	_
21	,	,	,	_	20	p	_	_
22	tenderness	tenderness	NN	_	20	conj	_	_
23	,	,	,	_	22	p	_	_
24	skin	skin	NN	_	25	com	_	_
25	discoloration	discoloration	NN	_	20	conj	_	_
26	,	,	,	_	25	p	_	_
27	or	or	CC	_	25	cc	_	_
28	swelling	swelling	NN	_	20	conj	_	_
29	at	at	IN	_	32	case	_	_
30	the	the	DT	_	32	det	_	_
31	injection	injection	NN	_	32	com	_	_
32	site	site	NN	_	18	ppmod	_	_
33	.	.	.	_	2	p	_	_

1	These	these	DT	_	2	det	_	_
2	reactions	reaction	NNS	_	5	dep	_	_
3	have	have	VBP	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	observed	observe	VBN	_	0	root	_	_
6	more	more	RBR	_	7	com	_	_
7	frequently	frequently	RB	_	5	adv	_	_
8	with	with	IN	_	11	case	_	_
9	the	the	DT	_	11	det	_	_
10	24-hour	0-hour	JJ	_	11	attr	_	_
11	infusion	infusion	NN	_	5	ppmod	_	_
12	than	than	IN	_	16	case	_	_
13	with	with	IN	_	16	case	_	_
14	the	the	DT	_	16	det	_	_
15	3-hour	0-hour	JJ	_	16	attr	_	_
16	infusion	infusion	NN	_	5	ppmod	_	_
17	.	.	.	_	5	p	_	_

1	Recurrence	recurrence	NN	_	26	dep	_	_
2	of	of	IN	_	4	case	_	_
3	skin	skin	NN	_	4	com	_	_
4	reactions	reaction	NNS	_	1	ppmod	_	_
5	at	at	IN	_	7	case	_	_
6	a	a	DT	_	7	det	_	_
7	site	site	NN	_	1	ppmod	_	_
8	of	of	IN	_	10	case	_	_
9	previous	previous	JJ	_	10	attr	_	_
10	extravasation	extravasation	NN	_	7	ppmod	_	_
11	following	follow	VBG	_	12	adv	_	_
12	administration	administration	NN	_	7	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	at	at	IN	_	18	case	_	_
16	a	a	DT	_	18	det	_	_
17	different	different	JJ	_	18	attr	_	_
18	site	site	NN	_	12	ppmod	_	_
19	,	,	,	_	1	p	_	_
20	ie	ie	FW	_	22	adv	_	_
21	,	,	,	_	22	p	_	_
22	recall	recall	NN	_	1	ppmod	_	_
23	,	,	,	_	1	p	_	_
24	has	have	VBZ	_	26	aux	_	_
25	been	be	VBN	_	26	aux	_	_
26	reported	report	VBN	_	0	root	_	_
27	rarely	rarely	RB	_	26	adv	_	_
28	.	.	.	_	26	p	_	_

1	Rare	rare	JJ	_	2	attr	_	_
2	reports	report	NNS	_	24	dep	_	_
3	of	of	IN	_	6	case	_	_
4	more	more	RBR	_	5	adv	_	_
5	severe	severe	JJ	_	6	attr	_	_
6	events	event	NNS	_	2	ppmod	_	_
7	such	such	JJ	_	9	adv	_	_
8	as	as	IN	_	9	case	_	_
9	phlebitis	phlebitis	NN	_	6	ppmod	_	_
10	,	,	,	_	9	p	_	_
11	cellulitis	cellulitis	NN	_	9	conj	_	_
12	,	,	,	_	11	p	_	_
13	induration	induration	NN	_	9	conj	_	_
14	,	,	,	_	13	p	_	_
15	skin	skin	NN	_	16	com	_	_
16	exfoliation	exfoliation	NN	_	9	conj	_	_
17	,	,	,	_	16	p	_	_
18	necrosis	necrosis	NN	_	9	conj	_	_
19	,	,	,	_	18	p	_	_
20	and	and	CC	_	18	cc	_	_
21	fibrosis	fibrosis	NN	_	9	conj	_	_
22	have	have	VBP	_	24	aux	_	_
23	been	be	VBN	_	24	aux	_	_
24	received	receive	VBN	_	0	root	_	_
25	as	as	IN	_	26	case	_	_
26	part	part	NN	_	24	ppmod	_	_
27	of	of	IN	_	30	case	_	_
28	the	the	DT	_	30	det	_	_
29	continuing	continue	VBG	_	30	attr	_	_
30	surveillance	surveillance	NN	_	26	ppmod	_	_
31	of	of	IN	_	33	case	_	_
32	drug1	drug0	NN	_	33	com	_	_
33	safety	safety	NN	_	30	ppmod	_	_
34	.	.	.	_	24	p	_	_

1	In	in	IN	_	3	case	_	_
2	some	some	DT	_	3	det	_	_
3	cases	case	NNS	_	12	ppmod	_	_
4	the	the	DT	_	5	det	_	_
5	onset	onset	NN	_	12	dep	_	_
6	of	of	IN	_	10	case	_	_
7	the	the	DT	_	10	det	_	_
8	injection	injection	NN	_	10	com	_	_
9	site	site	NN	_	10	com	_	_
10	reaction	reaction	NN	_	5	ppmod	_	_
11	either	either	RB	_	12	adv	_	_
12	occurred	occur	VBD	_	0	root	_	_
13	during	during	IN	_	16	case	_	_
14	a	a	DT	_	16	det	_	_
15	prolonged	prolonged	JJ	_	16	attr	_	_
16	infusion	infusion	NN	_	12	ppmod	_	_
17	or	or	CC	_	12	cc	_	_
18	was	be	VBD	_	19	aux	_	_
19	delayed	delay	VBN	_	12	conj	_	_
20	by	by	IN	_	22	case	_	_
21	a	a	DT	_	22	det	_	_
22	week	week	NN	_	19	ppmod	_	_
23	to	to	TO	_	25	aux	_	_
24	ten	#crd#	CD	_	25	num	_	_
25	days	day	NNS	_	22	ppmod	_	_
26	.	.	.	_	12	p	_	_

1	A	a	DT	_	3	det	_	_
2	specific	specific	JJ	_	3	attr	_	_
3	treatment	treatment	NN	_	7	dep	_	_
4	for	for	IN	_	6	case	_	_
5	extravasation	extravasation	NN	_	6	com	_	_
6	reactions	reaction	NNS	_	3	ppmod	_	_
7	is	be	VBZ	_	0	root	_	_
8	unknown	unknown	JJ	_	7	dep	_	_
9	at	at	IN	_	11	case	_	_
10	this	this	DT	_	11	det	_	_
11	time	time	NN	_	7	ppmod	_	_
12	.	.	.	_	7	p	_	_

1	Given	given	IN	_	3	case	_	_
2	the	the	DT	_	3	det	_	_
3	possibility	possibility	NN	_	8	ppmod	_	_
4	of	of	IN	_	5	case	_	_
5	extravasation	extravasation	NN	_	3	ppmod	_	_
6	,	,	,	_	8	p	_	_
7	it	it	PRP	_	8	dep	_	_
8	is	be	VBZ	_	0	root	_	_
9	advisable	advisable	JJ	_	8	dep	_	_
10	to	to	TO	_	12	aux	_	_
11	closely	closely	RB	_	12	adv	_	_
12	monitor	monitor	VB	_	9	comp	_	_
13	the	the	DT	_	15	det	_	_
14	infusion	infusion	NN	_	15	com	_	_
15	site	site	NN	_	12	obj	_	_
16	for	for	IN	_	18	case	_	_
17	possible	possible	JJ	_	18	attr	_	_
18	infiltration	infiltration	NN	_	15	ppmod	_	_
19	during	during	IN	_	21	case	_	_
20	drug	drug	NN	_	21	com	_	_
21	administration	administration	NN	_	18	ppmod	_	_
22	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	metabolized	metabolize	VBN	_	0	root	_	_
4	by	by	IN	_	5	case	_	_
5	CYP2C9	cyp0c0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	CYP3A4	cyp0a0	NN	_	5	conj	_	_
8	.	.	.	_	3	p	_	_

1	Inhibition	inhibition	NN	_	6	dep	_	_
2	of	of	IN	_	4	case	_	_
3	these	these	DT	_	4	det	_	_
4	isoenzymes	isoenzymes	NNS	_	1	ppmod	_	_
5	may	may	MD	_	6	modal	_	_
6	increase	increase	VB	_	0	root	_	_
7	the	the	DT	_	9	det	_	_
8	plasma	plasma	NN	_	9	com	_	_
9	concentration	concentration	NN	_	6	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	an	an	DT	_	4	det	_	_
4	inducer	inducer	NN	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	CYP3A4	cyp0a0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	CYP2C9	cyp0c0	NN	_	6	conj	_	_
9	.	.	.	_	2	p	_	_

1	Consequently	consequently	RB	_	14	adv	_	_
2	,	,	,	_	14	p	_	_
3	plasma	plasma	NN	_	4	com	_	_
4	concentrations	concentration	NNS	_	14	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drugs	drug	NNS	_	4	ppmod	_	_
7	metabolized	metabolize	VBN	_	6	acl	_	_
8	by	by	IN	_	11	case	_	_
9	these	these	DT	_	11	det	_	_
10	two	#crd#	CD	_	11	num	_	_
11	isoenzymes	isoenzymes	NNS	_	7	ppmod	_	_
12	will	will	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	decreased	decrease	VBN	_	0	root	_	_
15	when	when	WRB	_	17	adv	_	_
16	drug1	drug0	NN	_	17	dep	_	_
17	is	be	VBZ	_	14	comp	_	_
18	co-administered	co-administered	NN	_	17	obj	_	_
19	.	.	.	_	14	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	had	have	VBD	_	0	root	_	_
3	no	no	DT	_	6	det	_	_
4	relevant	relevant	JJ	_	6	attr	_	_
5	inhibitory	inhibitory	JJ	_	6	attr	_	_
6	effect	effect	NN	_	2	obj	_	_
7	on	on	IN	_	10	case	_	_
8	any	any	DT	_	10	det	_	_
9	CYP	cyp	JJ	_	10	attr	_	_
10	isoenzymes	isoenzymes	NNS	_	2	ppmod	_	_
11	tested	test	VBN	_	10	acl	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	CYP1A2	cyp0a0	NN	_	11	prn	_	_
14	,	,	,	_	13	p	_	_
15	CYP2C9	cyp0c0	NN	_	13	appo	_	_
16	,	,	,	_	13	p	_	_
17	CYP2C19	cyp0c0	NN	_	13	appo	_	_
18	,	,	,	_	13	p	_	_
19	CYP2D6	cyp0d0	NN	_	13	appo	_	_
20	,	,	,	_	13	p	_	_
21	CYP3A4	cyp0a0	NN	_	13	appo	_	_
22	)	-rrb-	-RRB-	_	13	p	_	_
23	.	.	.	_	2	p	_	_

1	Consequently	consequently	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	drug1	drug0	NN	_	6	dep	_	_
4	is	be	VBZ	_	6	aux	_	_
5	not	not	RB	_	6	neg	_	_
6	expected	expect	VBN	_	0	root	_	_
7	to	to	TO	_	8	aux	_	_
8	increase	increase	VB	_	6	comp	_	_
9	the	the	DT	_	11	det	_	_
10	plasma	plasma	NN	_	11	com	_	_
11	concentrations	concentration	NNS	_	8	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drugs	drug	NNS	_	11	ppmod	_	_
14	metabolized	metabolize	VBN	_	13	acl	_	_
15	by	by	IN	_	17	case	_	_
16	these	these	DT	_	17	det	_	_
17	enzymes	enzyme	NNS	_	14	ppmod	_	_
18	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	,	,	,	_	3	p	_	_
3	Including	include	VBG	_	17	advcl	_	_
4	Oral	oral	JJ	_	12	attr	_	_
5	,	,	,	_	4	p	_	_
6	Injectable	injectable	JJ	_	4	conj	_	_
7	,	,	,	_	6	p	_	_
8	Transdermal	transdermal	JJ	_	4	conj	_	_
9	,	,	,	_	8	p	_	_
10	and	and	CC	_	8	cc	_	_
11	Implantable	implantable	JJ	_	4	conj	_	_
12	drug2	drug0	NNS	_	3	obj	_	_
13	:	:	:	_	17	p	_	_
14	An	an	DT	_	16	det	_	_
15	interaction	interaction	NN	_	16	com	_	_
16	study	study	NN	_	17	dep	_	_
17	demonstrated	demonstrate	VBD	_	0	root	_	_
18	that	that	IN	_	27	mark	_	_
19	co-administration	co-administration	NN	_	27	dep	_	_
20	of	of	IN	_	21	case	_	_
21	drug3	drug0	NN	_	19	ppmod	_	_
22	and	and	CC	_	19	cc	_	_
23	the	the	DT	_	26	det	_	_
24	oral	oral	JJ	_	26	attr	_	_
25	drug4	drug0	NN	_	26	com	_	_
26	drug5	drug0	NN	_	19	conj	_	_
27	produced	produce	VBD	_	17	comp	_	_
28	average	average	JJ	_	29	attr	_	_
29	decreases	decrease	NNS	_	27	obj	_	_
30	of	of	IN	_	31	case	_	_
31	drug6	drug0	NN	_	29	ppmod	_	_
32	and	and	CC	_	29	cc	_	_
33	drug7	drug0	NN	_	34	com	_	_
34	levels	level	NNS	_	29	conj	_	_
35	of	of	IN	_	36	case	_	_
36	14	0	CD	_	34	ppmod	_	_
37	%	%	NN	_	36	meta	_	_
38	and	and	CC	_	36	cc	_	_
39	31	0	CD	_	36	conj	_	_
40	%	%	NN	_	39	meta	_	_
41	,	,	,	_	39	p	_	_
42	respectively	respectively	RB	_	36	conj	_	_
43	.	.	.	_	17	p	_	_

1	However	however	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	decreases	decrease	NNS	_	6	dep	_	_
4	in	in	IN	_	5	case	_	_
5	exposure	exposure	NN	_	3	ppmod	_	_
6	were	be	VBD	_	0	root	_	_
7	as	as	RB	_	10	adv	_	_
8	much	much	JJ	_	10	attr	_	_
9	as	as	IN	_	10	case	_	_
10	56	0	CD	_	6	obj	_	_
11	%	%	NN	_	10	meta	_	_
12	and	and	CC	_	10	cc	_	_
13	66	0	CD	_	10	conj	_	_
14	%	%	NN	_	13	meta	_	_
15	,	,	,	_	13	p	_	_
16	respectively	respectively	RB	_	10	conj	_	_
17	,	,	,	_	6	p	_	_
18	in	in	IN	_	20	case	_	_
19	individual	individual	JJ	_	20	attr	_	_
20	subjects	subject	NNS	_	6	ppmod	_	_
21	.	.	.	_	6	p	_	_

1	Therefore	therefore	RB	_	18	adv	_	_
2	,	,	,	_	18	p	_	_
3	drug1	drug0	NN	_	18	dep	_	_
4	,	,	,	_	3	p	_	_
5	including	include	VBG	_	14	adv	_	_
6	oral	oral	JJ	_	14	attr	_	_
7	,	,	,	_	6	p	_	_
8	injectable	injectable	JJ	_	6	conj	_	_
9	,	,	,	_	8	p	_	_
10	transdermal	transdermal	JJ	_	6	conj	_	_
11	,	,	,	_	10	p	_	_
12	and	and	CC	_	10	cc	_	_
13	implantable	implantable	JJ	_	6	conj	_	_
14	forms	form	NNS	_	3	ppmod	_	_
15	,	,	,	_	3	p	_	_
16	may	may	MD	_	18	modal	_	_
17	not	not	RB	_	18	neg	_	_
18	be	be	VB	_	0	root	_	_
19	reliable	reliable	JJ	_	18	dep	_	_
20	when	when	WRB	_	22	adv	_	_
21	drug2	drug0	NN	_	22	dep	_	_
22	is	be	VBZ	_	19	comp	_	_
23	co-administered	co-administered	NN	_	22	obj	_	_
24	.	.	.	_	18	p	_	_

1	Women	woman	NNS	_	3	dep	_	_
2	should	should	MD	_	3	modal	_	_
3	practice	practice	NN	_	0	root	_	_
4	additional	additional	JJ	_	5	attr	_	_
5	methods	method	NNS	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	contraception	contraception	NN	_	5	ppmod	_	_
8	and	and	CC	_	3	cc	_	_
9	not	not	RB	_	10	neg	3:neg	_
10	rely	rely	VBP	_	3	conj	_	_
11	on	on	IN	_	13	case	_	_
12	hormonal	hormonal	JJ	_	13	attr	_	_
13	contraception	contraception	NN	_	10	ppmod	_	_
14	alone	alone	RB	_	13	adv	_	_
15	when	when	WRB	_	16	adv	_	_
16	taking	take	VBG	_	10	comp	_	_
17	drug1	drug0	NN	_	16	obj	_	_
18	.	.	.	_	3	p	_	_

1	Specific	specific	JJ	_	3	attr	_	_
2	interaction	interaction	NN	_	3	com	_	_
3	studies	study	NNS	_	5	dep	_	_
4	have	have	VBP	_	5	aux	_	_
5	demonstrated	demonstrate	VBN	_	0	root	_	_
6	the	the	DT	_	7	det	_	_
7	following	following	NN	_	5	obj	_	_
8	:	:	:	_	7	p	_	_
9	drug1	drug0	NN	_	24	dep	_	_
10	:	:	:	_	24	p	_	_
11	During	during	IN	_	14	case	_	_
12	the	the	DT	_	14	det	_	_
13	first	#ord#	JJ	_	14	attr	_	_
14	day	day	NN	_	24	ppmod	_	_
15	of	of	IN	_	17	case	_	_
16	concomitant	concomitant	JJ	_	17	attr	_	_
17	administration	administration	NN	_	14	ppmod	_	_
18	,	,	,	_	24	p	_	_
19	trough	trough	NN	_	20	com	_	_
20	concentrations	concentration	NNS	_	24	dep	_	_
21	of	of	IN	_	22	case	_	_
22	drug2	drug0	NN	_	20	ppmod	_	_
23	were	be	VBD	_	24	aux	_	_
24	increased	increase	VBN	_	7	acl	_	_
25	by	by	IN	_	27	case	_	_
26	about	about	RB	_	27	com	_	_
27	30-fold	0-fold	RB	_	24	ppmod	_	_
28	.	.	.	_	5	p	_	_

1	Steady-state	steady-state	JJ	_	4	attr	_	_
2	drug1	drug0	NN	_	4	com	_	_
3	plasma	plasma	NN	_	4	com	_	_
4	concentrations	concentration	NNS	_	5	dep	_	_
5	were	be	VBD	_	0	root	_	_
6	3-	0-	CD	_	9	num	_	_
7	to	to	TO	_	6	attr	_	_
8	4-fold	0-fold	RB	_	6	adv	_	_
9	higher	high	JJR	_	5	dep	_	_
10	than	than	IN	_	13	case	_	_
11	in	in	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	absence	absence	NN	_	9	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	5	p	_	_

1	The	the	DT	_	3	det	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	administration	administration	NN	_	9	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	is	be	VBZ	_	9	aux	_	_
9	contraindicated	contraindicate	VBN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	Co-administration	co-administration	NN	_	4	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	decreased	decrease	VBD	_	0	root	_	_
5	the	the	DT	_	7	det	_	_
6	plasma	plasma	NN	_	7	com	_	_
7	concentrations	concentration	NNS	_	4	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	(	-lrb-	-LRB-	_	13	p	_	_
11	a	a	DT	_	13	det	_	_
12	CYP3A4	cyp0a0	NN	_	13	com	_	_
13	substrate	substrate	NN	_	9	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	by	by	IN	_	17	case	_	_
16	approximately	approximately	RB	_	17	adv	_	_
17	50	0	CD	_	4	ppmod	_	_
18	%	%	NN	_	17	meta	_	_
19	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	3	attr	_	_
2	:	:	:	_	3	p	_	_
3	Co-administration	co-administration	NN	_	11	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug3	drug0	NN	_	5	conj	_	_
8	has	have	VBZ	_	11	aux	_	_
9	not	not	RB	_	11	neg	_	_
10	been	be	VBN	_	11	aux	_	_
11	studied	study	VBN	_	0	root	_	_
12	in	in	IN	_	13	case	_	_
13	man	man	NN	_	11	ppmod	_	_
14	.	.	.	_	11	p	_	_

1	Co-administration	co-administration	NN	_	6	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	resulted	result	VBD	_	0	root	_	_
7	in	in	IN	_	11	case	_	_
8	markedly	markedly	RB	_	9	adv	_	_
9	increased	increase	VBN	_	11	attr	_	_
10	plasma	plasma	NN	_	11	com	_	_
11	concentrations	concentration	NNS	_	6	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug3	drug0	NN	_	11	ppmod	_	_
14	in	in	IN	_	15	case	_	_
15	animals	animal	NNS	_	13	ppmod	_	_
16	.	.	.	_	6	p	_	_

1	Caution	caution	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	exercised	exercise	VBN	_	0	root	_	_
5	if	if	IN	_	10	mark	_	_
6	drug1	drug0	NN	_	10	dep	_	_
7	and	and	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	are	be	VBP	_	10	aux	_	_
10	used	use	VBN	_	4	comp	_	_
11	together	together	RB	_	10	adv	_	_
12	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	An	an	DT	_	5	det	_	_
4	increased	increase	VBN	_	5	attr	_	_
5	risk	risk	NN	_	11	dep	_	_
6	of	of	IN	_	9	case	_	_
7	elevated	elevated	JJ	_	9	attr	_	_
8	liver	liver	NN	_	9	com	_	_
9	aminotransferases	aminotransferase	NNS	_	5	ppmod	_	_
10	was	be	VBD	_	11	aux	_	_
11	observed	observe	VBN	_	1	acl	_	_
12	in	in	IN	_	13	case	_	_
13	patients	patient	NNS	_	11	ppmod	_	_
14	receiving	receive	VBG	_	13	acl	_	_
15	concomitant	concomitant	JJ	_	16	attr	_	_
16	therapy	therapy	NN	_	14	obj	_	_
17	with	with	IN	_	18	case	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	.	.	.	_	1	p	_	_

1	Therefore	therefore	RB	_	11	adv	_	_
2	,	,	,	_	11	p	_	_
3	the	the	DT	_	5	det	_	_
4	concomitant	concomitant	JJ	_	5	attr	_	_
5	administration	administration	NN	_	11	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	is	be	VBZ	_	11	aux	_	_
11	contraindicated	contraindicate	VBN	_	0	root	_	_
12	,	,	,	_	11	p	_	_
13	and	and	CC	_	11	cc	_	_
14	alternative	alternative	JJ	_	15	attr	_	_
15	drug3	drug0	NN	_	18	dep	_	_
16	should	should	MD	_	18	modal	_	_
17	be	be	VB	_	18	aux	_	_
18	considered	consider	VBN	_	11	conj	_	_
19	.	.	.	_	11	p	_	_

1	Co-administration	co-administration	NN	_	4	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	decreased	decrease	VBD	_	0	root	_	_
5	the	the	DT	_	7	det	_	_
6	plasma	plasma	NN	_	7	com	_	_
7	concentrations	concentration	NNS	_	4	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	by	by	IN	_	12	case	_	_
11	approximately	approximately	RB	_	12	adv	_	_
12	40	0	CD	_	4	ppmod	_	_
13	%	%	NN	_	12	meta	_	_
14	.	.	.	_	4	p	_	_

1	The	the	DT	_	3	det	_	_
2	plasma	plasma	NN	_	3	com	_	_
3	concentrations	concentration	NNS	_	8	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	were	be	VBD	_	8	aux	_	_
7	also	also	RB	_	8	adv	_	_
8	decreased	decrease	VBN	_	0	root	_	_
9	by	by	IN	_	11	case	_	_
10	approximately	approximately	RB	_	11	adv	_	_
11	30	0	CD	_	8	ppmod	_	_
12	%	%	NN	_	11	meta	_	_
13	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	also	also	RB	_	4	adv	_	_
4	expected	expect	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	reduce	reduce	VB	_	4	comp	_	_
7	plasma	plasma	NN	_	8	com	_	_
8	concentrations	concentration	NNS	_	6	obj	_	_
9	of	of	IN	_	12	case	_	_
10	other	other	JJ	_	12	attr	_	_
11	oral	oral	JJ	_	12	attr	_	_
12	drug2	drug0	NNS	_	8	ppmod	_	_
13	that	that	WDT	_	16	dep	_	_
14	are	be	VBP	_	16	aux	_	_
15	predominantly	predominantly	RB	_	16	adv	_	_
16	metabolized	metabolize	VBN	_	12	relcl	_	_
17	by	by	IN	_	18	case	_	_
18	CYP2C9	cyp0c0	NN	_	16	ppmod	_	_
19	or	or	CC	_	18	cc	_	_
20	CYP3A4	cyp0a0	NN	_	18	conj	_	_
21	.	.	.	_	4	p	_	_

1	The	the	DT	_	2	det	_	_
2	possibility	possibility	NN	_	14	dep	_	_
3	of	of	IN	_	6	case	_	_
4	worsened	worsened	JJ	_	6	attr	_	_
5	glucose	glucose	NN	_	6	com	_	_
6	control	control	NN	_	2	ppmod	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	2	ppmod	_	_
9	using	use	VBG	_	8	acl	_	_
10	these	these	DT	_	11	det	_	_
11	agents	agent	NNS	_	9	obj	_	_
12	should	should	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	considered	consider	VBN	_	0	root	_	_
15	.	.	.	_	14	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Co-administration	co-administration	NN	_	17	dep	_	_
4	of	of	IN	_	8	case	_	_
5	drug2	drug0	NN	_	8	attr	_	_
6	125	0	CD	_	8	num	_	_
7	mg	mg	NN	_	8	com	_	_
8	b.i.d.	b.i.d.	NN	_	3	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	drug3	drug0	NN	_	8	conj	_	_
11	,	,	,	_	10	p	_	_
12	a	a	DT	_	15	det	_	_
13	potent	potent	JJ	_	15	attr	_	_
14	CYP3A4	cyp0a0	NN	_	15	com	_	_
15	inhibitor	inhibitor	NN	_	10	appo	_	_
16	,	,	,	_	10	p	_	_
17	increased	increase	VBD	_	1	acl	_	_
18	the	the	DT	_	20	det	_	_
19	plasma	plasma	NN	_	20	com	_	_
20	concentrations	concentration	NNS	_	17	obj	_	_
21	of	of	IN	_	22	case	_	_
22	drug4	drug0	NN	_	20	ppmod	_	_
23	by	by	IN	_	25	case	_	_
24	approximately	approximately	RB	_	25	com	_	_
25	2-fold	0-fold	RB	_	17	ppmod	_	_
26	.	.	.	_	1	p	_	_

1	No	no	DT	_	3	det	_	_
2	dose	dose	NN	_	3	com	_	_
3	adjustment	adjustment	NN	_	6	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	is	be	VBZ	_	0	root	_	_
7	necessary	necessary	JJ	_	6	dep	_	_
8	,	,	,	_	6	p	_	_
9	but	but	CC	_	6	cc	_	_
10	increased	increase	VBN	_	11	attr	_	_
11	effects	effect	NNS	_	16	dep	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	should	should	MD	_	16	modal	_	_
15	be	be	VB	_	16	aux	_	_
16	considered	consider	VBN	_	6	conj	_	_
17	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	and	and	CC	_	1	cc	_	_
3	Other	other	JJ	_	4	attr	_	_
4	drug2	drug0	NN	_	1	conj	_	_
5	:	:	:	_	1	p	_	_
6	Co-administration	co-administration	NN	_	9	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug3	drug0	NN	_	6	ppmod	_	_
9	decreased	decrease	VBD	_	1	acl	_	_
10	the	the	DT	_	12	det	_	_
11	plasma	plasma	NN	_	12	com	_	_
12	concentrations	concentration	NNS	_	9	obj	_	_
13	of	of	IN	_	14	case	_	_
14	drug4	drug0	NN	_	12	ppmod	_	_
15	(	-lrb-	-LRB-	_	18	p	_	_
16	a	a	DT	_	18	det	_	_
17	CYP3A4	cyp0a0	NN	_	18	com	_	_
18	substrate	substrate	NN	_	14	prn	_	_
19	)	-rrb-	-RRB-	_	18	p	_	_
20	,	,	,	_	14	p	_	_
21	and	and	CC	_	14	cc	_	_
22	its	its	PRP$	_	26	poss	_	_
23	active	active	JJ	_	26	attr	_	_
24	-hydroxy	-hydroxy	NN	_	26	com	_	_
25	acid	acid	NN	_	26	com	_	_
26	metabolite	metabolite	NN	_	14	conj	_	_
27	,	,	,	_	9	p	_	_
28	by	by	IN	_	30	case	_	_
29	approximately	approximately	RB	_	30	adv	_	_
30	50	0	CD	_	9	ppmod	_	_
31	%	%	NN	_	30	meta	_	_
32	.	.	.	_	1	p	_	_

1	The	the	DT	_	3	det	_	_
2	plasma	plasma	NN	_	3	com	_	_
3	concentrations	concentration	NNS	_	8	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	were	be	VBD	_	8	aux	_	_
7	not	not	RB	_	8	neg	_	_
8	affected	affect	VBN	_	0	root	_	_
9	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	also	also	RB	_	4	adv	_	_
4	expected	expect	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	reduce	reduce	VB	_	4	comp	_	_
7	plasma	plasma	NN	_	8	com	_	_
8	concentrations	concentration	NNS	_	6	obj	_	_
9	of	of	IN	_	11	case	_	_
10	other	other	JJ	_	11	attr	_	_
11	drug2	drug0	NNS	_	8	ppmod	_	_
12	that	that	WDT	_	15	dep	_	_
13	have	have	VBP	_	15	lv	_	_
14	significant	significant	JJ	_	15	attr	_	_
15	metabolism	metabolism	NN	_	11	relcl	_	_
16	by	by	IN	_	17	case	_	_
17	CYP3A4	cyp0a0	NN	_	15	ppmod	_	_
18	,	,	,	_	11	p	_	_
19	such	such	JJ	_	21	adv	_	_
20	as	as	IN	_	21	case	_	_
21	drug3	drug0	NN	_	11	ppmod	_	_
22	and	and	CC	_	21	cc	_	_
23	drug4	drug0	NN	_	21	conj	_	_
24	.	.	.	_	4	p	_	_

1	The	the	DT	_	2	det	_	_
2	possibility	possibility	NN	_	9	dep	_	_
3	of	of	IN	_	6	case	_	_
4	reduced	reduce	VBN	_	6	attr	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	efficacy	efficacy	NN	_	2	ppmod	_	_
7	should	should	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	considered	consider	VBN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	Patients	patient	NNS	_	7	dep	_	_
2	using	use	VBG	_	1	acl	_	_
3	CYP3A4	cyp0a0	NN	_	5	com	_	_
4	metabolized	metabolized	NN	_	5	com	_	_
5	drug1	drug0	NN	_	2	obj	_	_
6	should	should	MD	_	7	modal	_	_
7	have	have	VB	_	14	advcl	_	_
8	cholesterol	cholesterol	NN	_	9	com	_	_
9	levels	level	NNS	_	7	obj	_	_
10	monitored	monitor	VBN	_	9	acl	_	_
11	after	after	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	is	be	VBZ	_	14	aux	_	_
14	initiated	initiate	VBN	_	0	root	_	_
15	to	to	TO	_	16	aux	_	_
16	see	see	VB	_	14	comp	_	_
17	whether	whether	IN	_	21	mark	_	_
18	the	the	DT	_	20	det	_	_
19	drug3	drug0	NN	_	20	com	_	_
20	dose	dose	NN	_	21	dep	_	_
21	needs	need	VBZ	_	16	comp	_	_
22	adjustment	adjustment	NN	_	21	obj	_	_
23	.	.	.	_	14	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Co-administration	co-administration	NN	_	12	dep	_	_
4	of	of	IN	_	8	case	_	_
5	drug2	drug0	NN	_	8	attr	_	_
6	500	0	CD	_	8	num	_	_
7	mg	mg	NN	_	8	com	_	_
8	b.i.d.	b.i.d.	NN	_	3	ppmod	_	_
9	for	for	IN	_	11	case	_	_
10	6	0	CD	_	11	num	_	_
11	days	day	NNS	_	8	ppmod	_	_
12	decreased	decrease	VBD	_	1	acl	_	_
13	the	the	DT	_	15	det	_	_
14	plasma	plasma	NN	_	15	com	_	_
15	concentrations	concentration	NNS	_	12	obj	_	_
16	of	of	IN	_	18	case	_	_
17	both	both	CC	_	18	cc	_	_
18	drug3	drug0	NN	_	15	ppmod	_	_
19	(	-lrb-	-LRB-	_	22	p	_	_
20	a	a	DT	_	22	det	_	_
21	CYP2C9	cyp0c0	NN	_	22	com	_	_
22	substrate	substrate	NN	_	18	prn	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	and	and	CC	_	18	cc	_	_
25	drug4	drug0	NN	_	18	conj	_	_
26	(	-lrb-	-LRB-	_	29	p	_	_
27	a	a	DT	_	29	det	_	_
28	CYP3A4	cyp0a0	NN	_	29	com	_	_
29	substrate	substrate	NN	_	25	prn	_	_
30	)	-rrb-	-RRB-	_	29	p	_	_
31	by	by	IN	_	32	case	_	_
32	29	0	CD	_	12	ppmod	_	_
33	and	and	CC	_	32	cc	_	_
34	38	0	CD	_	32	conj	_	_
35	%	%	NN	_	32	meta	_	_
36	,	,	,	_	12	p	_	_
37	respectively	respectively	RB	_	12	adv	_	_
38	.	.	.	_	1	p	_	_

1	Clinical	clinical	JJ	_	2	dep	_	_
2	experience	experience	VBP	_	0	root	_	_
3	with	with	IN	_	18	mark	_	_
4	concomitant	concomitant	JJ	_	5	attr	_	_
5	administration	administration	NN	_	18	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	in	in	IN	_	11	case	_	_
11	patients	patient	NNS	_	7	ppmod	_	_
12	with	with	IN	_	15	case	_	_
13	pulmonary	pulmonary	JJ	_	15	attr	_	_
14	arterial	arterial	JJ	_	15	attr	_	_
15	hypertension	hypertension	NN	_	11	ppmod	_	_
16	did	do	VBD	_	18	aux	_	_
17	not	not	RB	_	18	neg	_	_
18	show	show	VB	_	2	comp	_	_
19	clinically	clinically	RB	_	20	adv	_	_
20	relevant	relevant	JJ	_	21	attr	_	_
21	changes	change	NNS	_	18	obj	_	_
22	in	in	IN	_	23	case	_	_
23	INR	inr	NN	_	21	ppmod	_	_
24	or	or	CC	_	23	cc	_	_
25	drug3	drug0	NN	_	26	com	_	_
26	dose	dose	NN	_	23	conj	_	_
27	(	-lrb-	-LRB-	_	28	p	_	_
28	baseline	baseline	NN	_	23	prn	_	_
29	vs.	vs.	CC	_	28	cc	_	_
30	end	end	NN	_	28	conj	_	_
31	of	of	IN	_	34	case	_	_
32	the	the	DT	_	34	det	_	_
33	clinical	clinical	JJ	_	34	attr	_	_
34	studies	study	NNS	_	30	ppmod	_	_
35	)	-rrb-	-RRB-	_	28	p	_	_
36	,	,	,	_	18	p	_	_
37	and	and	CC	_	18	cc	_	_
38	the	the	DT	_	39	det	_	_
39	need	need	NN	_	58	dep	_	_
40	to	to	TO	_	41	aux	_	_
41	change	change	VB	_	39	acl	_	_
42	the	the	DT	_	44	det	_	_
43	drug4	drug0	NN	_	44	com	_	_
44	dose	dose	NN	_	41	obj	_	_
45	during	during	IN	_	47	case	_	_
46	the	the	DT	_	47	det	_	_
47	trials	trial	NNS	_	41	ppmod	_	_
48	due	due	JJ	_	47	attr	_	_
49	to	to	TO	_	50	aux	_	_
50	changes	change	NNS	_	48	ppmod	_	_
51	in	in	IN	_	52	case	_	_
52	INR	inr	NN	_	50	ppmod	_	_
53	or	or	CC	_	48	cc	_	_
54	due	due	JJ	_	48	conj	_	_
55	to	to	TO	_	57	aux	_	_
56	adverse	adverse	JJ	_	57	attr	_	_
57	events	event	NNS	_	54	ppmod	_	_
58	was	be	VBD	_	18	conj	_	_
59	similar	similar	JJ	_	58	dep	_	_
60	among	among	IN	_	61	case	_	_
61	drug5	drug0	NN	_	59	ppmod	_	_
62	-	-	:	_	2	p	_	_
63	and	and	CC	_	2	cc	_	_
64	placebo-treated	placebo-treated	JJ	_	65	attr	_	_
65	patients	patient	NNS	_	2	conj	_	_
66	.	.	.	_	65	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	and	and	CC	_	3	cc	_	_
5	drug3	drug0	NN	_	1	conj	_	_
6	:	:	:	_	1	p	_	_
7	drug4	drug0	NN	_	12	dep	_	_
8	has	have	VBZ	_	12	lv	_	_
9	no	no	DT	_	12	det	_	_
10	significant	significant	JJ	_	12	attr	_	_
11	pharmacokinetic	pharmacokinetic	JJ	_	12	attr	_	_
12	interactions	interaction	NNS	_	1	acl	_	_
13	with	with	IN	_	14	case	_	_
14	drug5	drug0	NN	_	12	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	drug6	drug0	NN	_	14	conj	_	_
17	,	,	,	_	12	p	_	_
18	and	and	CC	_	12	cc	_	_
19	drug7	drug0	NN	_	20	dep	_	_
20	has	have	VBZ	_	12	conj	_	_
21	no	no	DT	_	23	det	_	_
22	significant	significant	JJ	_	23	attr	_	_
23	effect	effect	NN	_	20	obj	_	_
24	on	on	IN	_	26	case	_	_
25	plasma	plasma	NN	_	26	com	_	_
26	levels	level	NNS	_	20	ppmod	_	_
27	of	of	IN	_	28	case	_	_
28	drug8	drug0	NN	_	26	ppmod	_	_
29	.	.	.	_	1	p	_	_

1	No	no	DT	_	3	det	_	_
2	drug	drug	NN	_	3	com	_	_
3	interactions	interaction	NNS	_	6	dep	_	_
4	have	have	VBP	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	reported	report	VBN	_	0	root	_	_
7	between	between	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	the	the	DT	_	11	det	_	_
11	therapy	therapy	NN	_	8	conj	_	_
12	standard	standard	JJ	_	11	attr	_	_
13	in	in	IN	_	14	case	_	_
14	neonates	neonate	NNS	_	11	ppmod	_	_
15	with	with	IN	_	21	case	_	_
16	restricted	restricted	JJ	_	21	attr	_	_
17	pulmonary	pulmonary	JJ	_	21	attr	_	_
18	or	or	CC	_	17	cc	_	_
19	systemic	systemic	JJ	_	17	conj	_	_
20	blood	blood	NN	_	21	com	_	_
21	flow	flow	NN	_	11	ppmod	_	_
22	.	.	.	_	6	p	_	_

1	Standard	standard	JJ	_	2	attr	_	_
2	therapy	therapy	NN	_	3	dep	_	_
3	includes	include	VBZ	_	0	root	_	_
4	drug1	drug0	NN	_	3	obj	_	_
5	,	,	,	_	3	p	_	_
6	such	such	JJ	_	8	adv	_	_
7	as	as	IN	_	8	case	_	_
8	drug2	drug0	NN	_	3	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	drug3	drug0	NN	_	8	conj	_	_
11	;	;	:	_	3	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	,	,	,	_	1	p	_	_
3	such	such	JJ	_	1	appo	_	_
4	as	as	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug3	drug0	NN	_	5	conj	_	_
8	;	;	:	_	3	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	and	and	CC	_	2	cc	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	,	,	,	_	2	p	_	_
4	such	such	JJ	_	6	adv	_	_
5	as	as	IN	_	6	case	_	_
6	drug2	drug0	NN	_	2	ppmod	_	_
7	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	18	dep	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	potential	potential	NN	_	1	appo	_	_
5	for	for	IN	_	8	case	_	_
6	pharmacokinetic	pharmacokinetic	JJ	_	8	attr	_	_
7	drug-drug	drug-drug	JJ	_	8	attr	_	_
8	interactions	interaction	NNS	_	4	ppmod	_	_
9	between	between	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	other	other	JJ	_	13	attr	_	_
13	agents	agent	NNS	_	10	conj	_	_
14	has	have	VBZ	_	18	aux	_	_
15	not	not	RB	_	18	neg	_	_
16	been	be	VBN	_	18	aux	_	_
17	formally	formally	RB	_	18	adv	_	_
18	studied	study	VBN	_	0	root	_	_
19	.	.	.	_	18	p	_	_

1	When	when	WRB	_	6	adv	_	_
2	drug1	drug0	NN	_	6	dep	_	_
3	or	or	CC	_	2	cc	_	_
4	drug2	drug0	NN	_	2	conj	_	_
5	is	be	VBZ	_	6	aux	_	_
6	used	use	VBN	_	21	advcl	_	_
7	at	at	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	same	same	JJ	_	10	attr	_	_
10	time	time	NN	_	6	ppmod	_	_
11	as	as	IN	_	13	case	_	_
12	other	other	JJ	_	13	attr	_	_
13	medicines	medicine	NNS	_	6	ppmod	_	_
14	or	or	CC	_	13	cc	_	_
15	substances	substance	NNS	_	13	conj	_	_
16	the	the	DT	_	18	det	_	_
17	following	following	JJ	_	18	attr	_	_
18	interactions	interaction	NNS	_	21	dep	_	_
19	must	must	MD	_	21	modal	_	_
20	be	be	VB	_	21	aux	_	_
21	taken	take	VBN	_	30	advcl	_	_
22	into	into	IN	_	23	case	_	_
23	account	account	NN	_	21	ppmod	_	_
24	:	:	:	_	30	p	_	_
25	-	-	CC	_	26	cc	_	_
26	drug3	drug0	NN	_	30	dep	_	_
27	and	and	CC	_	26	cc	_	_
28	drug4	drug0	NN	_	26	conj	_	_
29	may	may	MD	_	30	modal	_	_
30	enhance	enhance	VB	_	0	root	_	_
31	the	the	DT	_	32	det	_	_
32	action	action	NN	_	30	obj	_	_
33	of	of	IN	_	34	case	_	_
34	drug5	drug0	NN	_	32	ppmod	_	_
35	.	.	.	_	30	p	_	_

1	For	for	IN	_	3	case	_	_
2	this	this	DT	_	3	det	_	_
3	reason	reason	NN	_	12	ppmod	_	_
4	,	,	,	_	12	p	_	_
5	the	the	DT	_	6	det	_	_
6	dose	dose	NN	_	12	dep	_	_
7	of	of	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	drug1	drug0	NN	_	6	ppmod	_	_
10	should	should	MD	_	12	modal	_	_
11	be	be	VB	_	12	aux	_	_
12	reduced	reduce	VBN	_	0	root	_	_
13	by	by	IN	_	14	case	_	_
14	30	0	CD	_	12	ppmod	_	_
15	-	-	TO	_	14	cc	_	_
16	50	0	CD	_	14	conj	_	_
17	%	%	NN	_	14	meta	_	_
18	at	at	IN	_	20	case	_	_
19	the	the	DT	_	20	det	_	_
20	start	start	NN	_	12	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	treatment	treatment	NN	_	20	ppmod	_	_
23	with	with	IN	_	24	case	_	_
24	drug2	drug0	NN	_	22	ppmod	_	_
25	or	or	CC	_	24	cc	_	_
26	drug3	drug0	NN	_	24	conj	_	_
27	retard	retard	VB	_	26	acl	_	_
28	and	and	CC	_	12	cc	_	_
29	then	then	RB	_	30	adv	_	_
30	titrated	titrate	VBN	_	12	conj	_	_
31	according	accord	VBG	_	36	adv	_	_
32	to	to	TO	_	36	aux	_	_
33	the	the	DT	_	36	det	_	_
34	blood	blood	NN	_	36	com	_	_
35	clotting	clotting	NN	_	36	com	_	_
36	parameters	parameter	NNS	_	30	ppmod	_	_

1	.	.	.	_	0	root	_	_

1	-	-	CC	_	3	cc	_	_
2	The	the	DT	_	3	det	_	_
3	action	action	NN	_	10	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	may	may	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	enhanced	enhance	VBN	_	0	root	_	_
11	by	by	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	or	or	CC	_	12	cc	_	_
14	drug4	drug0	NN	_	12	conj	_	_
15	.	.	.	_	10	p	_	_

1	This	this	DT	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	be	be	VB	_	0	root	_	_
4	due	due	JJ	_	3	dep	_	_
5	to	to	TO	_	9	aux	_	_
6	an	an	DT	_	9	det	_	_
7	improved	improved	JJ	_	9	attr	_	_
8	glucose	glucose	NN	_	9	com	_	_
9	utilization	utilization	NN	_	4	ppmod	_	_
10	with	with	IN	_	12	case	_	_
11	simultaneous	simultaneous	JJ	_	12	attr	_	_
12	reduction	reduction	NN	_	9	ppmod	_	_
13	in	in	IN	_	15	case	_	_
14	drug1	drug0	NN	_	15	com	_	_
15	requirement	requirement	NN	_	12	ppmod	_	_

1	.	.	.	_	0	root	_	_

1	-	-	CC	_	4	cc	_	_
2	In	in	IN	_	4	case	_	_
3	isolated	isolate	VBN	_	4	attr	_	_
4	cases	case	NNS	_	29	ppmod	_	_
5	,	,	,	_	29	p	_	_
6	a	a	DT	_	11	det	_	_
7	pronounced	pronounced	JJ	_	9	adv	_	_
8	though	though	RB	_	9	adv	_	_
9	reversible	reversible	JJ	_	11	attr	_	_
10	,	,	,	_	11	p	_	_
11	impairment	impairment	NN	_	29	dep	_	_
12	of	of	IN	_	14	case	_	_
13	renal	renal	JJ	_	14	attr	_	_
14	function	function	NN	_	11	ppmod	_	_
15	(	-lrb-	-LRB-	_	11	p	_	_
16	accompanied	accompany	VBN	_	11	acl	_	_
17	by	by	IN	_	20	case	_	_
18	a	a	DT	_	20	det	_	_
19	corresponding	corresponding	JJ	_	20	attr	_	_
20	increase	increase	NN	_	16	ppmod	_	_
21	in	in	IN	_	25	case	_	_
22	the	the	DT	_	25	det	_	_
23	serum	serum	NN	_	25	com	_	_
24	creatinine	creatinine	NN	_	25	com	_	_
25	level	level	NN	_	20	ppmod	_	_
26	)	-rrb-	-RRB-	_	11	p	_	_
27	has	have	VBZ	_	29	aux	_	_
28	been	be	VBN	_	29	aux	_	_
29	reported	report	VBN	_	0	root	_	_
30	in	in	IN	_	33	case	_	_
31	organ	organ	NN	_	33	com	_	_
32	transplant	transplant	NN	_	33	com	_	_
33	patients	patient	NNS	_	29	ppmod	_	_
34	receiving	receive	VBG	_	33	acl	_	_
35	drug1	drug0	NN	_	36	com	_	_
36	therapy	therapy	NN	_	34	obj	_	_
37	and	and	CC	_	36	cc	_	_
38	concomitant	concomitant	JJ	_	39	attr	_	_
39	drug2	drug0	NN	_	36	conj	_	_
40	.	.	.	_	29	p	_	_

1	Accordingly	accordingly	RB	_	8	adv	_	_
2	,	,	,	_	8	p	_	_
3	renal	renal	JJ	_	4	attr	_	_
4	function	function	NN	_	8	dep	_	_
5	should	should	MD	_	8	modal	_	_
6	be	be	VB	_	8	aux	_	_
7	closely	closely	RB	_	8	adv	_	_
8	monitored	monitor	VBN	_	0	root	_	_
9	in	in	IN	_	11	case	_	_
10	these	these	DT	_	11	det	_	_
11	patients	patient	NNS	_	8	ppmod	_	_
12	and	and	CC	_	8	cc	_	_
13	,	,	,	_	8	p	_	_
14	in	in	IN	_	16	case	_	_
15	the	the	DT	_	16	det	_	_
16	event	event	NN	_	32	ppmod	_	_
17	of	of	IN	_	20	case	_	_
18	relevant	relevant	JJ	_	20	attr	_	_
19	significant	significant	JJ	_	20	attr	_	_
20	changes	change	NNS	_	16	ppmod	_	_
21	in	in	IN	_	23	case	_	_
22	laboratory	laboratory	JJ	_	23	attr	_	_
23	parameters	parameter	NNS	_	20	ppmod	_	_
24	,	,	,	_	32	p	_	_
25	drug1	drug0	NN	_	32	dep	_	_
26	should	should	MD	_	32	modal	_	_
27	,	,	,	_	32	p	_	_
28	if	if	IN	_	29	case	_	_
29	necessary	necessary	JJ	_	32	ppmod	_	_
30	,	,	,	_	32	p	_	_
31	be	be	VB	_	32	aux	_	_
32	discontinued	discontinue	VBN	_	8	conj	_	_

1	.	.	.	_	0	root	_	_

1	-	-	CC	_	7	cc	_	_
2	When	when	WRB	_	7	adv	_	_
3	drug1	drug0	NN	_	7	dep	_	_
4	or	or	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	is	be	VBZ	_	7	aux	_	_
7	used	use	VBN	_	0	root	_	_
8	concurrently	concurrently	RB	_	7	adv	_	_
9	with	with	IN	_	10	case	_	_
10	drug3	drug0	NN	_	7	ppmod	_	_
11	(	-lrb-	-LRB-	_	13	p	_	_
12	e.g.	e.g.	FW	_	13	ppmod	_	_
13	drug4	drug0	NNS	_	10	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	,	,	,	_	10	p	_	_
16	an	an	DT	_	17	det	_	_
17	interval	interval	NN	_	10	appo	_	_
18	of	of	IN	_	22	case	_	_
19	at	at	IN	_	21	case	_	_
20	least	least	JJS	_	21	attr	_	_
21	2	0	CD	_	22	num	_	_
22	hours	hour	NNS	_	17	ppmod	_	_
23	should	should	MD	_	25	modal	_	_
24	be	be	VB	_	25	aux	_	_
25	maintained	maintain	VBN	_	22	acl	_	_
26	between	between	IN	_	29	case	_	_
27	the	the	DT	_	29	det	_	_
28	two	#crd#	CD	_	29	num	_	_
29	medicines	medicine	NNS	_	25	ppmod	_	_
30	,	,	,	_	7	p	_	_
31	since	since	IN	_	39	mark	_	_
32	the	the	DT	_	33	det	_	_
33	absorption	absorption	NN	_	39	dep	_	_
34	of	of	IN	_	35	case	_	_
35	drug5	drug0	NN	_	33	ppmod	_	_
36	or	or	CC	_	35	cc	_	_
37	drug6	drug0	NN	_	35	conj	_	_
38	is	be	VBZ	_	39	aux	_	_
39	impaired	impair	VBN	_	7	comp	_	_

1	.	.	.	_	0	root	_	_

1	-	-	CC	_	2	cc	_	_
2	drug1	drug0	NN	_	13	dep	_	_
3	or	or	CC	_	2	cc	_	_
4	drug2	drug0	NN	_	2	conj	_	_
5	(	-lrb-	-LRB-	_	8	p	_	_
6	with	with	IN	_	8	case	_	_
7	hepatotoxic	hepatotoxic	JJ	_	8	attr	_	_
8	potential	potential	NN	_	2	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	must	must	MD	_	13	modal	_	_
11	not	not	RB	_	13	neg	_	_
12	be	be	VB	_	13	aux	_	_
13	administered	administer	VBN	_	0	root	_	_
14	together	together	RB	_	13	adv	_	_
15	with	with	IN	_	16	case	_	_
16	drug3	drug0	NN	_	13	ppmod	_	_
17	or	or	CC	_	16	cc	_	_
18	drug4	drug0	NN	_	16	conj	_	_
19	.	.	.	_	13	p	_	_

1	Care	care	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	given	give	VBN	_	0	root	_	_
5	when	when	WRB	_	6	adv	_	_
6	administering	administer	VBG	_	4	comp	_	_
7	this	this	DT	_	8	det	_	_
8	drug	drug	NN	_	6	obj	_	_
9	to	to	TO	_	10	aux	_	_
10	patients	patient	NNS	_	6	ppmod	_	_
11	with	with	IN	_	12	case	_	_
12	symptoms	symptom	NNS	_	10	ppmod	_	_
13	of	of	IN	_	15	case	_	_
14	myasthenic	myasthenic	JJ	_	15	attr	_	_
15	weakness	weakness	NN	_	12	ppmod	_	_
16	who	who	WP	_	17	dep	_	_
17	are	be	VBP	_	10	relcl	_	_
18	also	also	RB	_	17	adv	_	_
19	on	on	IN	_	20	case	_	_
20	drug1	drug0	NN	_	17	ppmod	_	_
21	.	.	.	_	4	p	_	_

1	Since	since	IN	_	11	mark	_	_
2	symptoms	symptom	NNS	_	11	dep	_	_
3	of	of	IN	_	5	case	_	_
4	anticholinesterase	anticholinesterase	NN	_	5	com	_	_
5	overdose	overdose	NN	_	2	ppmod	_	_
6	(	-lrb-	-LRB-	_	8	p	_	_
7	cholinergic	cholinergic	JJ	_	8	attr	_	_
8	crisis	crisis	NN	_	5	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	may	may	MD	_	11	modal	_	_
11	mimic	mimic	VB	_	22	advcl	_	_
12	underdosage	underdosage	NN	_	11	obj	_	_
13	(	-lrb-	-LRB-	_	15	p	_	_
14	myasthenic	myasthenic	JJ	_	15	attr	_	_
15	weakness	weakness	NN	_	12	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	,	,	,	_	22	p	_	_
18	their	their	PRP$	_	19	poss	_	_
19	condition	condition	NN	_	22	dep	_	_
20	may	may	MD	_	22	modal	_	_
21	be	be	VB	_	22	aux	_	_
22	worsened	worsen	VBN	_	0	root	_	_
23	by	by	IN	_	25	case	_	_
24	the	the	DT	_	25	det	_	_
25	use	use	NN	_	22	ppmod	_	_
26	of	of	IN	_	28	case	_	_
27	this	this	DT	_	28	det	_	_
28	drug	drug	NN	_	25	ppmod	_	_
29	.	.	.	_	22	p	_	_

1	May	may	MD	_	2	modal	_	_
2	interact	interact	VB	_	0	root	_	_
3	with	with	IN	_	5	case	_	_
4	thyroid	thyroid	NN	_	5	com	_	_
5	medication	medication	NN	_	2	ppmod	_	_
6	(	-lrb-	-LRB-	_	9	p	_	_
7	e.g.	e.g.	FW	_	9	ppmod	_	_
8	,	,	,	_	9	p	_	_
9	drug1	drug0	NN	_	5	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	,	,	,	_	5	p	_	_
12	drug2	drug0	JJ	_	14	attr	_	_
13	-containing	-containing	JJ	_	14	attr	_	_
14	products	product	NNS	_	5	conj	_	_
15	,	,	,	_	14	p	_	_
16	drug3	drug0	NN	_	5	conj	_	_
17	,	,	,	_	16	p	_	_
18	drug4	drug0	NN	_	5	conj	_	_
19	(	-lrb-	-LRB-	_	24	p	_	_
20	e.g.	e.g.	FW	_	22	adv	_	_
21	,	,	,	_	22	p	_	_
22	drug5	drug0	NN	_	24	ppmod	_	_
23	,	,	,	_	24	p	_	_
24	drug6	drug0	NN	_	18	prn	_	_
25	)	-rrb-	-RRB-	_	24	p	_	_
26	,	,	,	_	18	p	_	_
27	and	and	CC	_	18	cc	_	_
28	drug7	drug0	NN	_	5	conj	_	_
29	(	-lrb-	-LRB-	_	34	p	_	_
30	e.g.	e.g.	FW	_	32	adv	_	_
31	,	,	,	_	32	p	_	_
32	drug8	drug0	NN	_	34	ppmod	_	_
33	,	,	,	_	34	p	_	_
34	drug9	drug0	NNS	_	28	prn	_	_
35	)	-rrb-	-RRB-	_	34	p	_	_
36	.	.	.	_	2	p	_	_

1	This	this	DT	_	2	det	_	_
2	product	product	NN	_	4	dep	_	_
3	can	can	MD	_	4	modal	_	_
4	affect	affect	VB	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	results	result	NNS	_	4	obj	_	_
7	of	of	IN	_	10	case	_	_
8	certain	certain	JJ	_	10	attr	_	_
9	lab	lab	NN	_	10	com	_	_
10	tests	test	NNS	_	6	ppmod	_	_
11	.	.	.	_	4	p	_	_

1	Drug/LaboratoryTest	drug/laboratorytest	NN	_	2	com	_	_
2	Interactions	interaction	NNS	_	5	dep	_	_
3	drug1	drug0	CD	_	2	num	_	_
4	may	may	MD	_	5	modal	_	_
5	interfere	interfere	VB	_	0	root	_	_
6	with	with	IN	_	8	case	_	_
7	bioassay	bioassay	NN	_	8	com	_	_
8	procedures	procedure	NNS	_	5	ppmod	_	_
9	for	for	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	determination	determination	NN	_	8	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	drug2	drug0	NN	_	14	com	_	_
14	levels	level	NNS	_	11	ppmod	_	_
15	.	.	.	_	5	p	_	_

1	Since	since	IN	_	5	mark	_	_
2	drug1	drug0	NN	_	5	dep	_	_
3	is	be	VBZ	_	5	aux	_	_
4	primarily	primarily	RB	_	5	adv	_	_
5	eliminated	eliminate	VBN	_	26	advcl	_	_
6	by	by	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	kidneys	kidney	NNS	_	5	ppmod	_	_
9	,	,	,	_	26	p	_	_
10	coadministration	coadministration	NN	_	26	dep	_	_
11	of	of	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	with	with	IN	_	14	case	_	_
14	drugs	drug	NNS	_	10	ppmod	_	_
15	that	that	WDT	_	16	dep	_	_
16	reduce	reduce	VBP	_	14	relcl	_	_
17	renal	renal	JJ	_	18	attr	_	_
18	function	function	NN	_	16	obj	_	_
19	or	or	CC	_	16	cc	_	_
20	compete	compete	VBP	_	16	conj	_	_
21	for	for	IN	_	24	case	_	_
22	active	active	JJ	_	24	attr	_	_
23	tubular	tubular	JJ	_	24	attr	_	_
24	secretion	secretion	NN	_	20	ppmod	_	_
25	may	may	MD	_	26	modal	_	_
26	increase	increase	VB	_	0	root	_	_
27	serum	serum	NN	_	28	com	_	_
28	concentrations	concentration	NNS	_	26	obj	_	_
29	of	of	IN	_	31	case	_	_
30	either	either	CC	_	31	cc	_	_
31	drug3	drug0	NN	_	28	ppmod	_	_
32	or	or	CC	_	31	cc	_	_
33	the	the	DT	_	35	det	_	_
34	coadministered	coadministered	JJ	_	35	attr	_	_
35	drug	drug	NN	_	31	conj	_	_
36	.	.	.	_	26	p	_	_

1	Coadministration	coadministration	NN	_	13	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	5	case	_	_
5	drug2	drug0	NN	_	1	ppmod	_	_
6	,	,	,	_	5	p	_	_
7	drug3	drug0	NN	_	5	conj	_	_
8	,	,	,	_	7	p	_	_
9	or	or	CC	_	7	cc	_	_
10	drug4	drug0	NN	_	5	conj	_	_
11	did	do	VBD	_	13	aux	_	_
12	not	not	RB	_	13	neg	_	_
13	result	result	VB	_	0	root	_	_
14	in	in	IN	_	17	case	_	_
15	significant	significant	JJ	_	17	attr	_	_
16	drug	drug	NN	_	17	com	_	_
17	interactions	interaction	NNS	_	13	ppmod	_	_
18	.	.	.	_	13	p	_	_

1	The	the	DT	_	2	det	_	_
2	effects	effect	NNS	_	24	dep	_	_
3	of	of	IN	_	4	case	_	_
4	coadministration	coadministration	NN	_	2	ppmod	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	with	with	IN	_	9	case	_	_
8	other	other	JJ	_	9	attr	_	_
9	drugs	drug	NNS	_	4	ppmod	_	_
10	that	that	WDT	_	13	dep	_	_
11	are	be	VBP	_	13	aux	_	_
12	renally	renally	RB	_	13	adv	_	_
13	eliminated	eliminate	VBN	_	9	relcl	_	_
14	or	or	CC	_	13	cc	_	_
15	are	be	VBP	_	16	aux	_	_
16	known	know	VBN	_	13	conj	_	_
17	to	to	TO	_	18	aux	_	_
18	affect	affect	VB	_	16	comp	_	_
19	renal	renal	JJ	_	20	attr	_	_
20	function	function	NN	_	18	obj	_	_
21	have	have	VBP	_	24	aux	_	_
22	not	not	RB	_	24	neg	_	_
23	been	be	VBN	_	24	aux	_	_
24	evaluated	evaluate	VBN	_	0	root	_	_
25	,	,	,	_	24	p	_	_
26	and	and	CC	_	24	cc	_	_
27	patients	patient	NNS	_	30	dep	_	_
28	should	should	MD	_	30	modal	_	_
29	be	be	VB	_	30	aux	_	_
30	monitored	monitor	VBN	_	24	conj	_	_
31	closely	closely	RB	_	30	adv	_	_
32	for	for	IN	_	34	case	_	_
33	adverse	adverse	JJ	_	34	attr	_	_
34	events	event	NNS	_	30	ppmod	_	_
35	when	when	WRB	_	38	adv	_	_
36	drug2	drug0	NN	_	38	dep	_	_
37	is	be	VBZ	_	38	aux	_	_
38	coadministered	coadministered	VBN	_	30	comp	_	_
39	with	with	IN	_	41	case	_	_
40	such	such	JJ	_	41	attr	_	_
41	drugs	drug	NNS	_	38	ppmod	_	_
42	.	.	.	_	24	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	has	have	VBZ	_	0	root	_	_
3	additive	additive	JJ	_	4	attr	_	_
4	effects	effect	NNS	_	2	obj	_	_
5	with	with	IN	_	6	case	_	_
6	drug2	drug0	NN	_	2	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	other	other	JJ	_	9	attr	_	_
9	drug3	drug0	NN	_	6	conj	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	drug4	drug0	NN	_	9	prn	_	_
12	,	,	,	_	11	p	_	_
13	drug5	drug0	NN	_	11	appo	_	_
14	,	,	,	_	11	p	_	_
15	drug6	drug0	NN	_	11	appo	_	_
16	,	,	,	_	11	p	_	_
17	etc	etc	NN	_	11	appo	_	_
18	)	-rrb-	-RRB-	_	11	p	_	_
19	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	prolong	prolong	VBP	_	0	root	_	_
3	and	and	CC	_	2	cc	_	_
4	intensify	intensify	VBP	_	2	conj	_	_
5	the	the	DT	_	10	det	_	_
6	anticholinergic	anticholinergic	JJ	_	10	attr	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	drying	drying	NN	_	6	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	effects	effect	NNS	_	4	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	2	p	_	_

1	Formal	formal	JJ	_	4	attr	_	_
2	drug	drug	NN	_	4	com	_	_
3	interaction	interaction	NN	_	4	com	_	_
4	studies	study	NNS	_	8	dep	_	_
5	have	have	VBP	_	8	aux	_	_
6	not	not	RB	_	8	neg	_	_
7	been	be	VBN	_	8	aux	_	_
8	conducted	conduct	VBN	_	0	root	_	_
9	with	with	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	8	p	_	_

1	Population	population	NN	_	3	attr	_	_
2	pharmacokinetic	pharmacokinetic	JJ	_	3	attr	_	_
3	analyses	analysis	NNS	_	4	dep	_	_
4	revealed	reveal	VBD	_	0	root	_	_
5	that	that	IN	_	16	mark	_	_
6	drug1	drug0	NN	_	16	dep	_	_
7	,	,	,	_	6	p	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	,	,	,	_	8	p	_	_
10	drug3	drug0	NN	_	6	conj	_	_
11	,	,	,	_	10	p	_	_
12	and	and	CC	_	10	cc	_	_
13	drug4	drug0	NN	_	6	conj	_	_
14	did	do	VBD	_	16	aux	_	_
15	not	not	RB	_	16	neg	_	_
16	influence	influence	VB	_	4	comp	_	_
17	drug5	drug0	NN	_	18	com	_	_
18	clearance	clearance	NN	_	16	obj	_	_
19	.	.	.	_	4	p	_	_

1	The	the	DT	_	2	det	_	_
2	majority	majority	NN	_	9	dep	_	_
3	of	of	IN	_	4	case	_	_
4	patients	patient	NNS	_	2	ppmod	_	_
5	in	in	IN	_	8	case	_	_
6	RA	ra	NN	_	8	attr	_	_
7	clinical	clinical	JJ	_	8	attr	_	_
8	studies	study	NNS	_	4	ppmod	_	_
9	received	receive	VBD	_	0	root	_	_
10	one	#crd#	CD	_	9	obj	_	_
11	or	or	CC	_	10	cc	_	_
12	more	more	JJR	_	10	conj	_	_
13	of	of	IN	_	17	case	_	_
14	the	the	DT	_	17	det	_	_
15	following	follow	VBG	_	17	attr	_	_
16	concomitant	concomitant	JJ	_	17	attr	_	_
17	medications	medication	NNS	_	10	ppmod	_	_
18	with	with	IN	_	19	case	_	_
19	drug1	drug0	NN	_	17	ppmod	_	_
20	:	:	:	_	17	p	_	_
21	drug2	drug0	NN	_	17	appo	_	_
22	,	,	,	_	21	p	_	_
23	drug3	drug0	NN	_	21	conj	_	_
24	,	,	,	_	23	p	_	_
25	drug4	drug0	NN	_	21	conj	_	_
26	,	,	,	_	25	p	_	_
27	drug5	drug0	NN	_	21	conj	_	_
28	,	,	,	_	27	p	_	_
29	drug6	drug0	NN	_	21	conj	_	_
30	,	,	,	_	29	p	_	_
31	drug7	drug0	NN	_	21	conj	_	_
32	,	,	,	_	31	p	_	_
33	drug8	drug0	NN	_	21	conj	_	_
34	,	,	,	_	33	p	_	_
35	drug9	drug0	NN	_	21	conj	_	_
36	,	,	,	_	35	p	_	_
37	drug10	drug0	NN	_	21	conj	_	_
38	,	,	,	_	37	p	_	_
39	drug11	drug0	NN	_	21	conj	_	_
40	,	,	,	_	39	p	_	_
41	and	and	CC	_	39	cc	_	_
42	drug12	drug0	NN	_	21	conj	_	_
43	.	.	.	_	9	p	_	_

1	Concurrent	concurrent	JJ	_	2	attr	_	_
2	administration	administration	NN	_	10	dep	_	_
3	of	of	IN	_	5	case	_	_
4	a	a	DT	_	5	det	_	_
5	drug1	drug0	NN	_	2	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	has	have	VBZ	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	associated	associate	VBN	_	0	root	_	_
11	with	with	IN	_	14	case	_	_
12	an	an	DT	_	14	det	_	_
13	increased	increase	VBN	_	14	attr	_	_
14	risk	risk	NN	_	10	ppmod	_	_
15	of	of	IN	_	17	case	_	_
16	serious	serious	JJ	_	17	attr	_	_
17	infections	infection	NNS	_	14	ppmod	_	_
18	and	and	CC	_	14	cc	_	_
19	no	no	DT	_	22	det	_	_
20	significant	significant	JJ	_	22	attr	_	_
21	additional	additional	JJ	_	22	attr	_	_
22	efficacy	efficacy	NN	_	14	conj	_	_
23	over	over	IN	_	24	case	_	_
24	use	use	NN	_	22	ppmod	_	_
25	of	of	IN	_	27	case	_	_
26	the	the	DT	_	27	det	_	_
27	drug3	drug0	NN	_	24	ppmod	_	_
28	alone	alone	RB	_	27	adv	_	_
29	.	.	.	_	10	p	_	_

1	Concurrent	concurrent	JJ	_	2	attr	_	_
2	therapy	therapy	NN	_	9	dep	_	_
3	with	with	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	is	be	VBZ	_	9	aux	_	_
8	not	not	RB	_	9	neg	_	_
9	recommended	recommend	VBN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	There	there	EX	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	insufficient	insufficient	JJ	_	2	dep	_	_
4	experience	experience	VBP	_	3	comp	_	_
5	to	to	TO	_	6	aux	_	_
6	assess	assess	VB	_	4	comp	_	_
7	the	the	DT	_	8	det	_	_
8	safety	safety	NN	_	6	obj	_	_
9	and	and	CC	_	8	cc	_	_
10	efficacy	efficacy	NN	_	8	conj	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	8	ppmod	_	_
13	administered	administer	VBN	_	12	acl	_	_
14	concurrently	concurrently	RB	_	13	adv	_	_
15	with	with	IN	_	16	case	_	_
16	drug2	drug0	NNS	_	13	ppmod	_	_
17	,	,	,	_	2	p	_	_
18	and	and	CC	_	2	cc	_	_
19	therefore	therefore	RB	_	24	adv	_	_
20	such	such	JJ	_	21	attr	_	_
21	use	use	NN	_	24	dep	_	_
22	is	be	VBZ	_	24	aux	_	_
23	not	not	RB	_	24	neg	_	_
24	recommended	recommend	VBN	_	2	conj	_	_
25	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	interfere	interfere	VB	_	0	root	_	_
4	with	with	IN	_	7	case	_	_
5	the	the	DT	_	7	det	_	_
6	anti-glaucoma	anti-glaucoma	NN	_	7	com	_	_
7	action	action	NN	_	3	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	or	or	CC	_	9	cc	_	_
11	drug3	drug0	NN	_	9	conj	_	_
12	;	;	:	_	3	p	_	_

1	also	also	RB	_	9	adv	_	_
2	,	,	,	_	9	p	_	_
3	concurrent	concurrent	JJ	_	4	attr	_	_
4	use	use	NN	_	9	dep	_	_
5	of	of	IN	_	7	case	_	_
6	this	this	DT	_	7	det	_	_
7	medication	medication	NN	_	4	ppmod	_	_
8	may	may	MD	_	9	modal	_	_
9	antagonise	antagonise	VB	_	0	root	_	_
10	the	the	DT	_	11	det	_	_
11	anti-glaucoma	anti-glaucoma	NN	_	9	obj	_	_
12	and	and	CC	_	11	cc	_	_
13	miotic	miotic	JJ	_	14	attr	_	_
14	actions	action	NNS	_	11	conj	_	_
15	of	of	IN	_	17	case	_	_
16	ophthalmic	ophthalmic	JJ	_	17	attr	_	_
17	drug1	drug0	NN	_	11	ppmod	_	_
18	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	These	these	DT	_	4	det	_	_
4	drugs	drug	NNS	_	7	dep	_	_
5	have	have	VBP	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	reported	report	VBN	_	1	acl	_	_
8	to	to	TO	_	9	aux	_	_
9	cause	cause	VB	_	7	comp	_	_
10	prolonged	prolonged	JJ	_	12	attr	_	_
11	vasospastic	vasospastic	JJ	_	12	attr	_	_
12	reactions	reaction	NNS	_	9	obj	_	_
13	.	.	.	_	1	p	_	_

1	Because	because	IN	_	3	mark	_	_
2	there	there	EX	_	3	dep	_	_
3	is	be	VBZ	_	36	advcl	_	_
4	a	a	DT	_	6	det	_	_
5	theoretical	theoretical	JJ	_	6	attr	_	_
6	basis	basis	NN	_	3	obj	_	_
7	that	that	IN	_	11	mark	_	_
8	these	these	DT	_	9	det	_	_
9	effects	effect	NNS	_	11	dep	_	_
10	may	may	MD	_	11	modal	_	_
11	be	be	VB	_	6	acl	_	_
12	additive	additive	JJ	_	11	dep	_	_
13	,	,	,	_	36	p	_	_
14	use	use	NN	_	36	dep	_	_
15	of	of	IN	_	19	case	_	_
16	drug1	drug0	JJ	_	17	adv	_	_
17	-containing	-containing	JJ	_	19	attr	_	_
18	or	or	CC	_	17	cc	_	_
19	drug2	drug0	NN	_	14	ppmod	_	_
20	(	-lrb-	-LRB-	_	22	p	_	_
21	like	like	IN	_	22	case	_	_
22	drug3	drug0	NN	_	19	prn	_	_
23	or	or	CC	_	22	cc	_	_
24	drug4	drug0	NN	_	22	conj	_	_
25	)	-rrb-	-RRB-	_	22	p	_	_
26	and	and	CC	_	19	cc	_	_
27	drug5	drug0	NN	_	19	conj	_	_
28	within	within	IN	_	30	case	_	_
29	24	0	CD	_	30	num	_	_
30	hours	hour	NNS	_	14	ppmod	_	_
31	of	of	IN	_	33	case	_	_
32	each	each	DT	_	33	det	_	_
33	other	other	JJ	_	30	ppmod	_	_
34	should	should	MD	_	36	modal	_	_
35	be	be	VB	_	36	aux	_	_
36	avoided	avoid	VBN	_	0	root	_	_
37	.	.	.	_	36	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Coadministration	coadministration	NN	_	6	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	resulted	result	VBD	_	1	acl	_	_
7	in	in	IN	_	11	case	_	_
8	a	a	DT	_	11	det	_	_
9	27	0	CD	_	11	num	_	_
10	%	%	NN	_	9	meta	_	_
11	decrease	decrease	NN	_	6	ppmod	_	_
12	in	in	IN	_	14	case	_	_
13	drug3	drug0	NN	_	14	com	_	_
14	clearance	clearance	NN	_	11	ppmod	_	_
15	and	and	CC	_	11	cc	_	_
16	an	an	DT	_	17	det	_	_
17	increase	increase	NN	_	11	conj	_	_
18	in	in	IN	_	19	case	_	_
19	Cmax	cmax	NN	_	17	ppmod	_	_
20	of	of	IN	_	22	case	_	_
21	approximately	approximately	RB	_	22	adv	_	_
22	6	0	CD	_	19	ppmod	_	_
23	%	%	NN	_	22	meta	_	_
24	.	.	.	_	1	p	_	_

1	No	no	DT	_	3	det	_	_
2	dose	dose	NN	_	3	com	_	_
3	adjustment	adjustment	NN	_	4	dep	_	_
4	is	be	VBZ	_	0	root	_	_
5	necessary	necessary	JJ	_	4	dep	_	_
6	.	.	.	_	4	p	_	_

1	Other	other	JJ	_	4	attr	_	_
2	drug1	drug0	NN	_	4	attr	_	_
3	Concomitant	concomitant	JJ	_	4	attr	_	_
4	use	use	NN	_	16	dep	_	_
5	of	of	IN	_	7	case	_	_
6	other	other	JJ	_	7	attr	_	_
7	drug2	drug0	NNS	_	4	ppmod	_	_
8	within	within	IN	_	10	case	_	_
9	24	0	CD	_	10	num	_	_
10	hours	hour	NNS	_	7	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	treatment	treatment	NN	_	10	ppmod	_	_
13	with	with	IN	_	14	case	_	_
14	drug3	drug0	NN	_	12	ppmod	_	_
15	is	be	VBZ	_	16	aux	_	_
16	contraindicated	contraindicate	VBN	_	0	root	_	_
17	.	.	.	_	16	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	pharmacokinetics	pharmacokinetics	NNS	_	9	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	were	be	VBD	_	9	aux	_	_
8	not	not	RB	_	9	neg	_	_
9	affected	affect	VBN	_	1	acl	_	_
10	by	by	IN	_	11	case	_	_
11	coadministration	coadministration	NN	_	9	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug3	drug0	NN	_	11	ppmod	_	_
14	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	21	dep	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	drug2	drug0	NN	_	1	prn	_	_
4	)	-rrb-	-RRB-	_	3	p	_	_
5	:	:	:	_	1	p	_	_
6	drug3	drug0	NN	_	1	appo	_	_
7	(	-lrb-	-LRB-	_	10	p	_	_
8	e.g.	e.g.	FW	_	10	ppmod	_	_
9	,	,	,	_	10	p	_	_
10	drug4	drug0	NN	_	6	prn	_	_
11	,	,	,	_	10	p	_	_
12	drug5	drug0	NN	_	10	appo	_	_
13	,	,	,	_	10	p	_	_
14	drug6	drug0	NN	_	10	appo	_	_
15	,	,	,	_	10	p	_	_
16	drug7	drug0	NN	_	10	appo	_	_
17	)	-rrb-	-RRB-	_	10	p	_	_
18	have	have	VBP	_	21	aux	_	_
19	been	be	VBN	_	21	aux	_	_
20	rarely	rarely	RB	_	21	adv	_	_
21	reported	report	VBN	_	0	root	_	_
22	to	to	TO	_	23	aux	_	_
23	cause	cause	VB	_	21	comp	_	_
24	weakness	weakness	NN	_	23	obj	_	_
25	,	,	,	_	24	p	_	_
26	hyperreflexia	hyperreflexia	NN	_	24	conj	_	_
27	,	,	,	_	26	p	_	_
28	and	and	CC	_	26	cc	_	_
29	incoordination	incoordination	NN	_	24	conj	_	_
30	when	when	WRB	_	31	adv	_	_
31	coadministered	coadministered	VBN	_	23	comp	_	_
32	with	with	IN	_	33	case	_	_
33	drug8	drug0	NN	_	31	ppmod	_	_
34	.	.	.	_	21	p	_	_

1	If	if	IN	_	11	mark	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	treatment	treatment	NN	_	11	dep	_	_
4	with	with	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	an	an	DT	_	8	det	_	_
8	drug2	drug0	NN	_	5	conj	_	_
9	is	be	VBZ	_	11	aux	_	_
10	clinically	clinically	RB	_	11	adv	_	_
11	warranted	warrant	VBN	_	19	advcl	_	_
12	,	,	,	_	19	p	_	_
13	appropriate	appropriate	JJ	_	14	attr	_	_
14	observation	observation	NN	_	19	dep	_	_
15	of	of	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	patient	patient	NN	_	14	ppmod	_	_
18	is	be	VBZ	_	19	aux	_	_
19	advised	advise	VBN	_	0	root	_	_
20	.	.	.	_	19	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Coadministration	coadministration	NN	_	8	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug3	drug0	NN	_	5	conj	_	_
8	resulted	result	VBD	_	1	acl	_	_
9	in	in	IN	_	13	case	_	_
10	a	a	DT	_	13	det	_	_
11	24	0	CD	_	13	num	_	_
12	%	%	NN	_	11	meta	_	_
13	increase	increase	NN	_	8	ppmod	_	_
14	in	in	IN	_	16	case	_	_
15	plasma	plasma	NN	_	16	com	_	_
16	concentrations	concentration	NNS	_	13	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug4	drug0	NN	_	16	ppmod	_	_
19	.	.	.	_	1	p	_	_

1	No	no	DT	_	3	det	_	_
2	dose	dose	NN	_	3	com	_	_
3	adjustment	adjustment	NN	_	4	dep	_	_
4	is	be	VBZ	_	0	root	_	_
5	necessary	necessary	JJ	_	4	dep	_	_
6	.	.	.	_	4	p	_	_

1	Coadministration	coadministration	NN	_	18	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	the	the	DT	_	9	det	_	_
6	potent	potent	JJ	_	9	attr	_	_
7	CYP3A4	cyp0a0	NN	_	9	com	_	_
8	inhibitor	inhibitor	NN	_	9	com	_	_
9	drug2	drug0	NN	_	3	conj	_	_
10	(	-lrb-	-LRB-	_	13	p	_	_
11	400	0	CD	_	12	num	_	_
12	mg	mg	NN	_	13	com	_	_
13	q.d.	q.d.	NN	_	9	prn	_	_
14	for	for	IN	_	16	case	_	_
15	3	0	CD	_	16	num	_	_
16	days	day	NNS	_	13	ppmod	_	_
17	)	-rrb-	-RRB-	_	13	p	_	_
18	resulted	result	VBD	_	0	root	_	_
19	in	in	IN	_	24	case	_	_
20	an	an	DT	_	24	det	_	_
21	approximately	approximately	RB	_	22	adv	_	_
22	60	0	CD	_	24	num	_	_
23	%	%	NN	_	22	meta	_	_
24	increase	increase	NN	_	18	ppmod	_	_
25	in	in	IN	_	27	case	_	_
26	the	the	DT	_	27	det	_	_
27	area	area	NN	_	24	ppmod	_	_
28	under	under	IN	_	32	case	_	_
29	the	the	DT	_	32	det	_	_
30	plasma	plasma	NN	_	32	com	_	_
31	concentration-time	concentration-time	NN	_	32	com	_	_
32	curve	curve	NN	_	27	ppmod	_	_
33	and	and	CC	_	27	cc	_	_
34	maximal	maximal	JJ	_	36	attr	_	_
35	plasma	plasma	NN	_	36	com	_	_
36	concentrations	concentration	NNS	_	27	conj	_	_
37	of	of	IN	_	38	case	_	_
38	drug3	drug0	NN	_	36	ppmod	_	_
39	.	.	.	_	18	p	_	_

1	Although	although	IN	_	24	mark	_	_
2	the	the	DT	_	3	det	_	_
3	interaction	interaction	NN	_	24	dep	_	_
4	between	between	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	other	other	JJ	_	10	attr	_	_
8	potent	potent	JJ	_	10	attr	_	_
9	CYP3A4	cyp0a0	JJ	_	10	attr	_	_
10	inhibitors	inhibitor	NNS	_	5	conj	_	_
11	(	-lrb-	-LRB-	_	14	p	_	_
12	e.g.	e.g.	FW	_	14	adv	_	_
13	,	,	,	_	14	p	_	_
14	drug2	drug0	NN	_	10	prn	_	_
15	,	,	,	_	14	p	_	_
16	drug3	drug0	NN	_	14	conj	_	_
17	,	,	,	_	16	p	_	_
18	and	and	CC	_	16	cc	_	_
19	drug4	drug0	NN	_	14	conj	_	_
20	)	-rrb-	-RRB-	_	14	p	_	_
21	has	have	VBZ	_	24	aux	_	_
22	not	not	RB	_	24	neg	_	_
23	been	be	VBN	_	24	aux	_	_
24	studied	study	VBN	_	32	advcl	_	_
25	,	,	,	_	32	p	_	_
26	increased	increase	VBN	_	27	attr	_	_
27	exposures	exposure	NNS	_	32	dep	_	_
28	to	to	TO	_	29	aux	_	_
29	drug5	drug0	NN	_	27	ppmod	_	_
30	may	may	MD	_	32	modal	_	_
31	be	be	VB	_	32	aux	_	_
32	expected	expect	VBN	_	0	root	_	_
33	when	when	WRB	_	36	adv	_	_
34	drug6	drug0	NN	_	36	dep	_	_
35	is	be	VBZ	_	36	aux	_	_
36	used	use	VBN	_	32	comp	_	_
37	concomitantly	concomitantly	RB	_	36	adv	_	_
38	with	with	IN	_	40	case	_	_
39	these	these	DT	_	40	det	_	_
40	medications	medication	NNS	_	36	ppmod	_	_
41	.	.	.	_	32	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	known	know	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	interfere	interfere	VB	_	4	comp	_	_
7	with	with	IN	_	12	case	_	_
8	commonly	commonly	RB	_	9	adv	_	_
9	employed	employ	VBN	_	12	attr	_	_
10	clinical	clinical	JJ	_	12	attr	_	_
11	laboratory	laboratory	NN	_	12	com	_	_
12	tests	test	NNS	_	6	ppmod	_	_
13	.	.	.	_	4	p	_	_

1	No	no	DT	_	5	det	_	_
2	formal	formal	JJ	_	5	attr	_	_
3	drug	drug	NN	_	5	com	_	_
4	interaction	interaction	NN	_	5	com	_	_
5	studies	study	NNS	_	8	dep	_	_
6	have	have	VBP	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	conducted	conduct	VBN	_	0	root	_	_
9	.	.	.	_	8	p	_	_

1	D	d	NN	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	Drug	drug	NN	_	6	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	Laboratory	laboratory	NN	_	5	com	_	_
4	Test	test	NN	_	5	com	_	_
5	Interactions	interaction	NNS	_	1	conj	_	_
6	1	0	CD	_	0	root	_	_
7	.	.	.	_	6	p	_	_

1	Accelerated	accelerate	VBN	_	3	attr	_	_
2	prothrombin	prothrombin	NN	_	3	com	_	_
3	time	time	NN	_	0	root	_	_
4	,	,	,	_	3	p	_	_
5	partial	partial	JJ	_	7	attr	_	_
6	thromboplastin	thromboplastin	NN	_	7	com	_	_
7	time	time	NN	_	3	conj	_	_
8	,	,	,	_	7	p	_	_
9	and	and	CC	_	7	cc	_	_
10	platelet	platelet	NN	_	12	com	_	_
11	aggregation	aggregation	NN	_	12	com	_	_
12	time	time	NN	_	3	conj	_	_
13	;	;	:	_	12	p	_	_

1	increased	increase	VBN	_	3	attr	_	_
2	platelet	platelet	NN	_	3	com	_	_
3	count	count	NN	_	0	root	_	_
4	;	;	:	_	3	p	_	_

1	increased	increase	VBN	_	2	attr	_	_
2	factors	factor	NNS	_	0	root	_	_
3	II	ii	CD	_	2	num	_	_
4	,	,	,	_	2	p	_	_
5	VII	vii	NN	_	6	com	_	_
6	antigen	antigen	NN	_	2	appo	_	_
7	,	,	,	_	6	p	_	_
8	VIII	viii	NN	_	9	com	_	_
9	antigen	antigen	NN	_	6	conj	_	_
10	,	,	,	_	9	p	_	_
11	VIII	viii	NN	_	13	com	_	_
12	coagulant	coagulant	NN	_	13	com	_	_
13	activity	activity	NN	_	6	conj	_	_
14	,	,	,	_	13	p	_	_
15	IX	ix	NN	_	6	conj	_	_
16	,	,	,	_	15	p	_	_
17	X	x	NN	_	6	conj	_	_
18	,	,	,	_	17	p	_	_
19	XII	xii	NN	_	6	conj	_	_
20	,	,	,	_	19	p	_	_
21	VII-X	vii-x	NN	_	22	com	_	_
22	complex	complex	NN	_	6	conj	_	_
23	,	,	,	_	22	p	_	_
24	II-VII-X	ii-vii-x	NN	_	25	com	_	_
25	complex	complex	NN	_	6	conj	_	_
26	,	,	,	_	25	p	_	_
27	and	and	CC	_	25	cc	_	_
28	beta-thromboglobulin	beta-thromboglobulin	NN	_	6	conj	_	_
29	;	;	:	_	2	p	_	_

1	decreased	decrease	VBN	_	2	attr	_	_
2	levels	level	NNS	_	10	dep	_	_
3	of	of	IN	_	5	case	_	_
4	anti-factor	anti-factor	NN	_	5	com	_	_
5	Xa	xa	NN	_	2	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	antithrombin	antithrombin	NN	_	5	conj	_	_
8	III	iii	CD	_	7	num	_	_
9	,	,	,	_	2	p	_	_
10	decreased	decrease	VBD	_	0	root	_	_
11	antithrombin	antithrombin	NN	_	13	attr	_	_
12	III	iii	CD	_	13	num	_	_
13	activity	activity	NN	_	10	obj	_	_
14	;	;	:	_	10	p	_	_

1	increased	increase	VBN	_	2	attr	_	_
2	levels	level	NNS	_	0	root	_	_
3	of	of	IN	_	4	case	_	_
4	fibrinogen	fibrinogen	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	fibrinogen	fibrinogen	NN	_	7	com	_	_
7	activity	activity	NN	_	4	conj	_	_
8	;	;	:	_	2	p	_	_

1	increased	increase	VBN	_	3	attr	_	_
2	plasminogen	plasminogen	NN	_	3	com	_	_
3	antigen	antigen	NN	_	0	root	_	_
4	and	and	CC	_	3	cc	_	_
5	activity	activity	NN	_	3	conj	_	_
6	.	.	.	_	3	p	_	_

1	2	0	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	Increased	increase	VBN	_	0	root	_	_
2	thyroid-binding	thyroid-binding	JJ	_	3	attr	_	_
3	globulin	globulin	NN	_	1	obj	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	TBG	tbg	NN	_	3	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	leading	lead	VBG	_	3	acl	_	_
8	to	to	TO	_	14	aux	_	_
9	increased	increase	VBN	_	14	attr	_	_
10	circulating	circulating	JJ	_	14	attr	_	_
11	total	total	JJ	_	14	attr	_	_
12	thyroid	thyroid	NN	_	14	com	_	_
13	hormone	hormone	NN	_	14	com	_	_
14	levels	level	NNS	_	7	ppmod	_	_
15	,	,	,	_	1	p	_	_
16	as	as	IN	_	17	mark	_	_
17	measured	measure	VBN	_	1	comp	_	_
18	by	by	IN	_	20	case	_	_
19	protein-bound	protein-bound	JJ	_	20	attr	_	_
20	iodine	iodine	NN	_	17	ppmod	_	_
21	(	-lrb-	-LRB-	_	22	p	_	_
22	PBI	pbi	NN	_	20	prn	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	,	,	,	_	20	p	_	_
25	T4	t0	NN	_	26	com	_	_
26	levels	level	NNS	_	20	conj	_	_
27	(	-lrb-	-LRB-	_	29	p	_	_
28	by	by	IN	_	29	case	_	_
29	column	column	NN	_	26	prn	_	_
30	or	or	CC	_	29	cc	_	_
31	by	by	IN	_	32	case	_	_
32	radioimmunoassay	radioimmunoassay	NN	_	29	conj	_	_
33	)	-rrb-	-RRB-	_	29	p	_	_
34	or	or	CC	_	26	cc	_	_
35	T3	t0	NN	_	36	com	_	_
36	levels	level	NNS	_	20	conj	_	_
37	by	by	IN	_	38	case	_	_
38	radioimmunoassay	radioimmunoassay	NN	_	17	ppmod	_	_
39	.	.	.	_	1	p	_	_

1	T3	t0	NN	_	3	com	_	_
2	resin	resin	NN	_	3	com	_	_
3	uptake	uptake	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	decreased	decrease	VBN	_	0	root	_	_
6	,	,	,	_	5	p	_	_
7	reflecting	reflect	VBG	_	5	comp	_	_
8	the	the	DT	_	10	det	_	_
9	elevated	elevated	JJ	_	10	attr	_	_
10	TBG	tbg	NN	_	7	obj	_	_
11	.	.	.	_	5	p	_	_

1	Free	free	JJ	_	5	attr	_	_
2	T4	t0	NN	_	5	attr	_	_
3	and	and	CC	_	2	cc	_	_
4	T3	t0	NN	_	2	conj	_	_
5	concentrations	concentration	NNS	_	6	dep	_	_
6	are	be	VBP	_	0	root	_	_
7	unaltered	unaltered	JJ	_	6	dep	_	_
8	.	.	.	_	6	p	_	_

1	Patients	patient	NNS	_	7	dep	_	_
2	on	on	IN	_	5	case	_	_
3	thyroid	thyroid	NN	_	5	com	_	_
4	replacement	replacement	NN	_	5	com	_	_
5	therapy	therapy	NN	_	1	ppmod	_	_
6	may	may	MD	_	7	modal	_	_
7	require	require	VBP	_	0	root	_	_
8	higher	high	JJR	_	9	attr	_	_
9	doses	dose	NNS	_	7	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	7	p	_	_

1	3	0	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	Other	other	JJ	_	3	attr	_	_
2	binding	binding	NN	_	3	com	_	_
3	proteins	protein	NNS	_	6	dep	_	_
4	may	may	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	elevated	elevate	VBN	_	0	root	_	_
7	in	in	IN	_	10	case	_	_
8	serum	serum	NN	_	10	attr	_	_
9	,	,	,	_	10	p	_	_
10	i.e.	i.e.	FW	_	6	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	corticosteroid	corticosteroid	NN	_	14	com	_	_
13	binding	binding	NN	_	14	com	_	_
14	globulin	globulin	NN	_	8	appo	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	CBG	cbg	NN	_	14	prn	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	,	,	,	_	10	p	_	_
19	sex	sex	NN	_	21	com	_	_
20	hormone-binding	hormone-binding	NN	_	21	com	_	_
21	globulin	globulin	NN	_	8	appo	_	_
22	(	-lrb-	-LRB-	_	23	p	_	_
23	SHBG	shbg	NN	_	21	prn	_	_
24	)	-rrb-	-RRB-	_	23	p	_	_
25	,	,	,	_	6	p	_	_
26	leading	lead	VBG	_	6	comp	_	_
27	to	to	TO	_	31	aux	_	_
28	increased	increase	VBN	_	31	attr	_	_
29	total	total	JJ	_	31	attr	_	_
30	circulating	circulating	JJ	_	31	attr	_	_
31	drug1	drug0	NN	_	26	ppmod	_	_
32	and	and	CC	_	31	cc	_	_
33	drug2	drug0	NN	_	31	conj	_	_
34	,	,	,	_	26	p	_	_
35	respectively	respectively	RB	_	26	adv	_	_
36	.	.	.	_	6	p	_	_

1	Free	free	JJ	_	3	attr	_	_
2	hormone	hormone	NN	_	3	com	_	_
3	concentrations	concentration	NNS	_	6	dep	_	_
4	may	may	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	decreased	decrease	VBN	_	0	root	_	_
7	.	.	.	_	6	p	_	_

1	Other	other	JJ	_	3	attr	_	_
2	plasma	plasma	NN	_	3	com	_	_
3	proteins	protein	NNS	_	6	dep	_	_
4	may	may	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	increased	increase	VBN	_	0	root	_	_
7	(	-lrb-	-LRB-	_	9	p	_	_
8	angiotensinogen/renin	angiotensinogen/renin	NN	_	9	com	_	_
9	substrate	substrate	NN	_	6	prn	_	_
10	,	,	,	_	9	p	_	_
11	alpha-1-antitrypsin	alpha-0-antitrypsin	JJ	_	9	appo	_	_
12	,	,	,	_	9	p	_	_
13	ceruloplasmin	ceruloplasmin	NN	_	9	appo	_	_
14	)	-rrb-	-RRB-	_	9	p	_	_
15	.	.	.	_	6	p	_	_

1	4	0	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	Increased	increase	VBN	_	3	attr	_	_
2	plasma	plasma	NN	_	3	com	_	_
3	HDL	hdl	NN	_	10	dep	_	_
4	and	and	CC	_	3	cc	_	_
5	HDL2	hdl0	NN	_	8	com	_	_
6	cholesterol	cholesterol	NN	_	8	com	_	_
7	subfraction	subfraction	NN	_	8	com	_	_
8	concentrations	concentration	NNS	_	3	conj	_	_
9	,	,	,	_	10	p	_	_
10	reduced	reduce	VBD	_	0	root	_	_
11	LDL	ldl	NN	_	13	com	_	_
12	cholesterol	cholesterol	NN	_	13	com	_	_
13	concentration	concentration	NN	_	10	obj	_	_
14	,	,	,	_	10	p	_	_
15	increased	increase	VBD	_	10	dep	_	_
16	triglyceride	triglyceride	NN	_	17	com	_	_
17	levels	level	NNS	_	15	obj	_	_
18	.	.	.	_	10	p	_	_

1	5	0	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	Impaired	impaired	JJ	_	3	attr	_	_
2	glucose	glucose	NN	_	3	com	_	_
3	tolerance	tolerance	NN	_	0	root	_	_
4	.	.	.	_	3	p	_	_

1	6	0	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	Reduced	reduce	VBN	_	0	root	_	_
2	response	response	NN	_	1	obj	_	_
3	to	to	TO	_	5	aux	_	_
4	metyrapone	metyrapone	NN	_	5	com	_	_
5	test	test	NN	_	2	ppmod	_	_
6	.	.	.	_	1	p	_	_

1	http	http	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	//www.rxlist.com/cgi/generic3/guanethidine_od.htm	#hlink#	NN	_	1	appo	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	5	case	_	_
4	healthy	healthy	JJ	_	5	attr	_	_
5	subjects	subject	NNS	_	22	ppmod	_	_
6	given	give	VBN	_	5	acl	_	_
7	single	single	JJ	_	10	attr	_	_
8	500	0	CD	_	10	num	_	_
9	mg	mg	NN	_	10	com	_	_
10	doses	dose	NNS	_	6	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	drug3	drug0	NN	_	12	conj	_	_
15	,	,	,	_	22	p	_	_
16	plasma	plasma	NN	_	19	com	_	_
17	drug4	drug0	NN	_	19	com	_	_
18	mean	mean	NN	_	19	com	_	_
19	cmax	cmax	NN	_	22	dep	_	_
20	and	and	CC	_	19	cc	_	_
21	AUC	auc	NN	_	19	conj	_	_
22	increased	increase	VBD	_	1	acl	_	_
23	by	by	IN	_	25	case	_	_
24	an	an	DT	_	25	det	_	_
25	average	average	NN	_	22	ppmod	_	_
26	of	of	IN	_	27	case	_	_
27	34	0	CD	_	25	ppmod	_	_
28	%	%	NN	_	27	meta	_	_
29	and	and	CC	_	27	cc	_	_
30	24	0	CD	_	27	conj	_	_
31	%	%	NN	_	30	meta	_	_
32	,	,	,	_	30	p	_	_
33	respectively	respectively	RB	_	27	conj	_	_
34	,	,	,	_	22	p	_	_
35	and	and	CC	_	22	cc	_	_
36	drug5	drug0	VBN	_	39	attr	_	_
37	mean	mean	JJ	_	39	attr	_	_
38	renal	renal	JJ	_	39	attr	_	_
39	clearance	clearance	NN	_	40	dep	_	_
40	decreased	decrease	VBD	_	22	conj	_	_
41	by	by	IN	_	42	case	_	_
42	14	0	CD	_	40	ppmod	_	_
43	%	%	NN	_	42	meta	_	_
44	.	.	.	_	1	p	_	_

1	No	no	DT	_	2	det	_	_
2	information	information	NN	_	3	dep	_	_
3	is	be	VBZ	_	0	root	_	_
4	available	available	JJ	_	3	dep	_	_
5	about	about	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	interaction	interaction	NN	_	4	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	drug2	drug0	NN	_	9	conj	_	_
12	following	follow	VBG	_	14	adv	_	_
13	multiple	multiple	JJ	_	14	attr	_	_
14	doses	dose	NNS	_	7	ppmod	_	_
15	of	of	IN	_	17	case	_	_
16	either	either	DT	_	17	det	_	_
17	drug	drug	NN	_	14	ppmod	_	_
18	.	.	.	_	3	p	_	_

1	Although	although	IN	_	3	mark	_	_
2	not	not	RB	_	3	neg	_	_
3	observed	observe	VBN	_	12	advcl	_	_
4	in	in	IN	_	6	case	_	_
5	this	this	DT	_	6	det	_	_
6	study	study	NN	_	3	ppmod	_	_
7	,	,	,	_	12	p	_	_
8	adverse	adverse	JJ	_	9	attr	_	_
9	effects	effect	NNS	_	12	dep	_	_
10	could	could	MD	_	12	modal	_	_
11	potentially	potentially	RB	_	12	adv	_	_
12	arise	arise	VB	_	0	root	_	_
13	from	from	IN	_	14	case	_	_
14	co-administration	co-administration	NN	_	12	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	drug2	drug0	NN	_	16	conj	_	_
19	by	by	IN	_	20	case	_	_
20	inhibition	inhibition	NN	_	12	ppmod	_	_
21	of	of	IN	_	23	case	_	_
22	tubular	tubular	JJ	_	23	attr	_	_
23	secretion	secretion	NN	_	20	ppmod	_	_
24	via	via	IN	_	28	case	_	_
25	organic	organic	JJ	_	28	attr	_	_
26	cationic	cationic	JJ	_	28	attr	_	_
27	transporter	transporter	NN	_	28	com	_	_
28	systems	system	NNS	_	23	ppmod	_	_
29	.	.	.	_	12	p	_	_

1	Accordingly	accordingly	RB	_	12	adv	_	_
2	,	,	,	_	12	p	_	_
3	careful	careful	JJ	_	5	attr	_	_
4	patient	patient	NN	_	5	com	_	_
5	monitoring	monitoring	NN	_	12	dep	_	_
6	and	and	CC	_	5	cc	_	_
7	dose	dose	NN	_	8	com	_	_
8	adjustment	adjustment	NN	_	5	conj	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	5	ppmod	_	_
11	is	be	VBZ	_	12	aux	_	_
12	recommended	recommend	VBN	_	0	root	_	_
13	in	in	IN	_	14	case	_	_
14	patients	patient	NNS	_	12	ppmod	_	_
15	concomitantly	concomitantly	RB	_	16	adv	_	_
16	taking	take	VBG	_	14	acl	_	_
17	drug2	drug0	NN	_	16	obj	_	_
18	and	and	CC	_	17	cc	_	_
19	drug3	drug0	NN	_	17	conj	_	_
20	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	14	dep	_	_
2	:	:	:	_	14	p	_	_
3	As	as	IN	_	6	case	_	_
4	with	with	IN	_	6	case	_	_
5	other	other	JJ	_	6	attr	_	_
6	drug2	drug0	NNS	_	14	ppmod	_	_
7	,	,	,	_	14	p	_	_
8	the	the	DT	_	10	det	_	_
9	renal	renal	JJ	_	10	attr	_	_
10	excretion	excretion	NN	_	14	dep	_	_
11	of	of	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	is	be	VBZ	_	14	aux	_	_
14	inhibited	inhibit	VBN	_	0	root	_	_
15	by	by	IN	_	16	case	_	_
16	drug4	drug0	NN	_	14	ppmod	_	_
17	.	.	.	_	14	p	_	_

1	Drug	drug	NN	_	5	attr	_	_
2	/	/	:	_	5	p	_	_
3	Laboratory	laboratory	NN	_	5	com	_	_
4	Test	test	NN	_	5	com	_	_
5	Interactions	interaction	NNS	_	23	dep	_	_
6	As	as	IN	_	8	case	_	_
7	a	a	DT	_	8	det	_	_
8	result	result	NN	_	5	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	administration	administration	NN	_	8	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	a	a	DT	_	16	det	_	_
15	false-positive	false-positive	JJ	_	16	attr	_	_
16	reaction	reaction	NN	_	12	appo	_	_
17	for	for	IN	_	18	case	_	_
18	glucose	glucose	NN	_	16	ppmod	_	_
19	in	in	IN	_	21	case	_	_
20	the	the	DT	_	21	det	_	_
21	urine	urine	NN	_	16	ppmod	_	_
22	may	may	MD	_	23	modal	_	_
23	occur	occur	VB	_	0	root	_	_
24	.	.	.	_	23	p	_	_

1	This	this	DT	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	observed	observe	VBN	_	0	root	_	_
5	with	with	IN	_	11	case	_	_
6	Benedict	benedict	NNP	_	7	com	_	_
7	s	s	NNP	_	11	attr	_	_
8	and	and	CC	_	7	cc	_	_
9	Fehling	fehling	NNP	_	10	com	_	_
10	s	s	NNP	_	7	conj	_	_
11	solutions	solution	NNS	_	4	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	also	also	RB	_	16	adv	_	_
14	with	with	IN	_	16	case	_	_
15	Clinitest	clinitest	JJ	_	16	attr	_	_
16	tablets	tablet	NNS	_	11	conj	_	_
17	.	.	.	_	4	p	_	_

1	May	may	MD	_	2	modal	_	_
2	interact	interact	VB	_	15	advcl	_	_
3	with	with	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	following	following	NN	_	2	ppmod	_	_
6	:	:	:	_	15	p	_	_
7	drug1	drug0	NN	_	15	dep	_	_
8	,	,	,	_	7	p	_	_
9	drug2	drug0	NN	_	11	attr	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	use	use	NN	_	7	appo	_	_
12	with	with	IN	_	13	case	_	_
13	drug3	drug0	NN	_	7	ppmod	_	_
14	may	may	MD	_	15	modal	_	_
15	prevent	prevent	VB	_	0	root	_	_
16	the	the	DT	_	17	det	_	_
17	drug4	drug0	NN	_	15	obj	_	_
18	from	from	IN	_	19	case	_	_
19	working	working	NNP	_	17	ppmod	_	_
20	properly	properly	RB	_	15	adv	_	_
21	;	;	:	_	15	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	metabolized	metabolize	VBN	_	0	root	_	_
4	by	by	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	liver	liver	NN	_	3	ppmod	_	_
7	,	,	,	_	3	p	_	_
8	and	and	CC	_	3	cc	_	_
9	it	it	PRP	_	10	dep	_	_
10	is	be	VBZ	_	3	conj	_	_
11	theoretically	theoretically	RB	_	12	adv	_	_
12	possible	possible	JJ	_	10	dep	_	_
13	that	that	IN	_	18	mark	_	_
14	its	its	PRP$	_	15	poss	_	_
15	metabolism	metabolism	NN	_	18	dep	_	_
16	may	may	MD	_	18	modal	_	_
17	be	be	VB	_	18	aux	_	_
18	enhanced	enhance	VBN	_	10	comp	_	_
19	by	by	IN	_	20	case	_	_
20	drugs	drug	NNS	_	18	ppmod	_	_
21	known	know	VBN	_	20	acl	_	_
22	to	to	TO	_	23	aux	_	_
23	induce	induce	VB	_	21	comp	_	_
24	hepatic	hepatic	JJ	_	26	attr	_	_
25	microsomal	microsomal	JJ	_	26	attr	_	_
26	enzymes	enzyme	NNS	_	23	obj	_	_
27	.	.	.	_	3	p	_	_

1	However	however	RB	_	7	adv	_	_
2	,	,	,	_	7	p	_	_
3	neither	neither	CC	_	4	cc	_	_
4	drug1	drug0	NN	_	7	dep	_	_
5	nor	nor	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	appears	appear	VBZ	_	0	root	_	_
8	to	to	TO	_	9	aux	_	_
9	affect	affect	VB	_	7	comp	_	_
10	drug3	drug0	NN	_	11	com	_	_
11	metabolism	metabolism	NN	_	9	obj	_	_
12	.	.	.	_	7	p	_	_

1	Binding	binding	NN	_	8	dep	_	_
2	to	to	TO	_	4	aux	_	_
3	plasma	plasma	NN	_	4	com	_	_
4	protein	protein	NN	_	1	ppmod	_	_
5	is	be	VBZ	_	8	aux	_	_
6	not	not	RB	_	8	neg	_	_
7	significantly	significantly	RB	_	8	adv	_	_
8	altered	alter	VBN	_	0	root	_	_
9	by	by	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	drug2	drug0	NN	_	10	conj	_	_
13	,	,	,	_	12	p	_	_
14	or	or	CC	_	12	cc	_	_
15	drug3	drug0	NN	_	10	conj	_	_
16	.	.	.	_	8	p	_	_

1	Binding	binding	NN	_	6	dep	_	_
2	to	to	TO	_	4	aux	_	_
3	plasma	plasma	NN	_	4	com	_	_
4	proteins	protein	NNS	_	1	ppmod	_	_
5	is	be	VBZ	_	6	aux	_	_
6	reduced	reduce	VBN	_	0	root	_	_
7	by	by	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	clotibrate	clotibrate	NN	_	8	conj	_	_
11	and	and	CC	_	6	cc	_	_
12	increased	increase	VBN	_	6	conj	_	_
13	by	by	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	6	p	_	_

1	Cardiovascular	cardiovascular	JJ	_	2	attr	_	_
2	collapse	collapse	NN	_	11	dep	_	_
3	in	in	IN	_	4	case	_	_
4	patients	patient	NNS	_	2	ppmod	_	_
5	treated	treat	VBN	_	4	acl	_	_
6	simultaneously	simultaneously	RB	_	5	adv	_	_
7	with	with	IN	_	8	case	_	_
8	varapamil	varapamil	NN	_	5	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	drug1	drug0	NN	_	8	conj	_	_
11	is	be	VBZ	_	0	root	_	_
12	rare	rare	NN	_	11	obj	_	_
13	.	.	.	_	11	p	_	_

1	The	the	DT	_	2	det	_	_
2	combination	combination	NN	_	17	dep	_	_
3	of	of	IN	_	5	case	_	_
4	therapeutic	therapeutic	JJ	_	5	attr	_	_
5	doses	dose	NNS	_	2	ppmod	_	_
6	of	of	IN	_	8	case	_	_
7	intravenous	intravenous	JJ	_	8	attr	_	_
8	drug1	drug0	NN	_	5	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	drug2	drug0	NN	_	8	conj	_	_
11	in	in	IN	_	15	case	_	_
12	drug3	drug0	NN	_	15	attr	_	_
13	a-chloralose	a-chloralose	JJ	_	15	attr	_	_
14	anesthetized	anesthetized	JJ	_	15	attr	_	_
15	swine	swine	NN	_	8	ppmod	_	_
16	has	have	VBZ	_	17	aux	_	_
17	resulted	result	VBD	_	0	root	_	_
18	in	in	IN	_	20	case	_	_
19	ventricular	ventricular	NN	_	20	com	_	_
20	fibrillation	fibrillation	NN	_	17	ppmod	_	_
21	and	and	CC	_	20	cc	_	_
22	cardiovascular	cardiovascular	JJ	_	23	attr	_	_
23	collapse	collapse	NN	_	20	conj	_	_
24	in	in	IN	_	25	case	_	_
25	association	association	NN	_	17	ppmod	_	_
26	with	with	IN	_	28	case	_	_
27	marked	marked	JJ	_	28	attr	_	_
28	hyperkalemia	hyperkalemia	NN	_	25	ppmod	_	_
29	.	.	.	_	17	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	recommended	recommend	VBN	_	0	root	_	_
4	that	that	IN	_	19	mark	_	_
5	the	the	DT	_	6	det	_	_
6	combination	combination	NN	_	19	dep	_	_
7	of	of	IN	_	9	case	_	_
8	intravenous	intravenous	JJ	_	9	attr	_	_
9	drug1	drug0	NN	_	6	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	drug2	drug0	NN	_	9	conj	_	_
12	,	,	,	_	11	p	_	_
13	such	such	JJ	_	14	com	_	_
14	as	as	IN	_	11	cc	_	_
15	drug3	drug0	NN	_	9	conj	_	_
16	,	,	,	_	15	p	_	_
17	not	not	RB	_	19	neg	_	_
18	be	be	VB	_	19	aux	_	_
19	used	use	VBN	_	3	comp	_	_
20	together	together	RB	_	19	adv	_	_
21	during	during	IN	_	23	case	_	_
22	the	the	DT	_	23	det	_	_
23	management	management	NN	_	19	ppmod	_	_
24	of	of	IN	_	27	case	_	_
25	malignant	malignant	JJ	_	26	attr	_	_
26	hyperthermia	hyperthermia	NN	_	27	com	_	_
27	crisis	crisis	NN	_	23	ppmod	_	_
28	until	until	IN	_	37	mark	_	_
29	the	the	DT	_	30	det	_	_
30	relevance	relevance	NN	_	37	dep	_	_
31	of	of	IN	_	33	case	_	_
32	these	these	DT	_	33	det	_	_
33	findings	finding	NNS	_	30	ppmod	_	_
34	to	to	TO	_	35	aux	_	_
35	humans	human	NNS	_	30	ppmod	_	_
36	is	be	VBZ	_	37	aux	_	_
37	established	establish	VBN	_	19	comp	_	_
38	.	.	.	_	3	p	_	_

1	Administration	administration	NN	_	5	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	may	may	MD	_	5	modal	_	_
5	potentiate	potentiate	VB	_	0	root	_	_
6	drug2	drug0	JJ	_	9	attr	_	_
7	-induced	-induced	JJ	_	9	attr	_	_
8	neuromuscular	neuromuscular	NN	_	9	com	_	_
9	block	block	NN	_	5	obj	_	_
10	.	.	.	_	5	p	_	_

1	The	the	DT	_	2	det	_	_
2	effectiveness	effectiveness	NN	_	8	dep	_	_
3	of	of	IN	_	6	case	_	_
4	drug1	drug0	NN	_	6	com	_	_
5	-only	-only	NN	_	6	com	_	_
6	pills	pill	NNS	_	2	ppmod	_	_
7	is	be	VBZ	_	8	aux	_	_
8	reduced	reduce	VBN	_	0	root	_	_
9	by	by	IN	_	12	case	_	_
10	hepatic	hepatic	JJ	_	12	attr	_	_
11	enzyme-inducing	enzyme-inducing	JJ	_	12	attr	_	_
12	drugs	drug	NNS	_	8	ppmod	_	_
13	such	such	JJ	_	17	adv	_	_
14	as	as	IN	_	17	case	_	_
15	the	the	DT	_	17	det	_	_
16	drug2	drug0	NN	_	17	com	_	_
17	drug3	drug0	NN	_	12	ppmod	_	_
18	,	,	,	_	17	p	_	_
19	drug4	drug0	NN	_	17	conj	_	_
20	,	,	,	_	19	p	_	_
21	and	and	CC	_	19	cc	_	_
22	drug5	drug0	NN	_	17	conj	_	_
23	,	,	,	_	22	p	_	_
24	and	and	CC	_	22	cc	_	_
25	the	the	DT	_	27	det	_	_
26	drug6	drug0	NN	_	27	com	_	_
27	drug7	drug0	NN	_	17	conj	_	_
28	.	.	.	_	8	p	_	_

1	No	no	DT	_	3	det	_	_
2	significant	significant	JJ	_	3	attr	_	_
3	interaction	interaction	NN	_	6	dep	_	_
4	has	have	VBZ	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	found	find	VBN	_	0	root	_	_
7	with	with	IN	_	9	case	_	_
8	broad-spectrum	broad-spectrum	NN	_	9	com	_	_
9	drug1	drug0	NN	_	6	ppmod	_	_
10	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	can	can	MD	_	3	modal	_	_
3	inhibit	inhibit	VB	_	0	root	_	_
4	CYP2C19	cyp0c0	NN	_	3	obj	_	_
5	and	and	CC	_	3	cc	_	_
6	induce	induce	VB	_	3	conj	_	_
7	CYP3A4/5	cyp0a0	NN	_	6	obj	_	_
8	with	with	IN	_	11	case	_	_
9	potentially	potentially	RB	_	10	adv	_	_
10	important	important	JJ	_	11	attr	_	_
11	effects	effect	NNS	_	7	ppmod	_	_
12	on	on	IN	_	14	case	_	_
13	plasma	plasma	NN	_	14	com	_	_
14	concentrations	concentration	NNS	_	11	ppmod	_	_
15	of	of	IN	_	17	case	_	_
16	other	other	JJ	_	17	attr	_	_
17	drugs	drug	NNS	_	14	ppmod	_	_
18	.	.	.	_	3	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	13	ppmod	_	_
3	,	,	,	_	13	p	_	_
4	several	several	JJ	_	6	attr	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	s	s	NNS	_	13	dep	_	_
7	that	that	WDT	_	8	dep	_	_
8	are	be	VBP	_	6	relcl	_	_
9	cytochrome	cytochrome	NN	_	10	com	_	_
10	P450	p0	NN	_	11	com	_	_
11	inducers	inducer	NNS	_	8	obj	_	_
12	can	can	MD	_	13	modal	_	_
13	decrease	decrease	VBP	_	0	root	_	_
14	plasma	plasma	NN	_	15	com	_	_
15	concentrations	concentration	NNS	_	13	obj	_	_
16	of	of	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	and	and	CC	_	17	cc	_	_
19	drug3	drug0	NN	_	17	conj	_	_
20	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	was	be	VBD	_	3	aux	_	_
3	evaluated	evaluate	VBN	_	0	root	_	_
4	in	in	IN	_	7	case	_	_
5	human	human	JJ	_	7	attr	_	_
6	liver	liver	NN	_	7	com	_	_
7	microsomes	microsome	NNS	_	3	ppmod	_	_
8	to	to	TO	_	9	aux	_	_
9	determine	determine	VB	_	3	comp	_	_
10	its	its	PRP$	_	11	poss	_	_
11	capacity	capacity	NN	_	9	obj	_	_
12	to	to	TO	_	13	aux	_	_
13	inhibit	inhibit	VB	_	11	acl	_	_
14	the	the	DT	_	18	det	_	_
15	major	major	JJ	_	18	attr	_	_
16	cytochrome	cytochrome	NN	_	18	com	_	_
17	P450	p0	NN	_	18	com	_	_
18	enzymes	enzyme	NNS	_	13	obj	_	_
19	responsible	responsible	JJ	_	18	attr	_	_
20	for	for	IN	_	22	case	_	_
21	the	the	DT	_	22	det	_	_
22	metabolism	metabolism	NN	_	19	ppmod	_	_
23	of	of	IN	_	25	case	_	_
24	other	other	JJ	_	25	attr	_	_
25	drugs	drug	NNS	_	22	ppmod	_	_
26	.	.	.	_	3	p	_	_

1	Results	result	NNS	_	2	dep	_	_
2	demonstrate	demonstrate	VBP	_	0	root	_	_
3	that	that	IN	_	14	mark	_	_
4	drug1	drug0	NN	_	14	dep	_	_
5	and	and	CC	_	4	cc	_	_
6	its	its	PRP$	_	10	poss	_	_
7	pharmacologically	pharmacologically	RB	_	8	adv	_	_
8	active	active	JJ	_	10	attr	_	_
9	10-monohydroxy	0-monohydroxy	JJ	_	10	attr	_	_
10	metabolite	metabolite	NN	_	4	conj	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	drug2	drug0	NN	_	10	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	have	have	VBP	_	2	comp	_	_
15	little	little	JJ	_	14	obj	_	_
16	or	or	CC	_	15	cc	_	_
17	no	no	DT	_	18	det	_	_
18	capacity	capacity	NN	_	15	conj	_	_
19	to	to	TO	_	20	aux	_	_
20	function	function	VB	_	18	acl	_	_
21	as	as	IN	_	22	case	_	_
22	inhibitors	inhibitor	NNS	_	20	ppmod	_	_
23	for	for	IN	_	24	case	_	_
24	most	most	JJS	_	22	ppmod	_	_
25	of	of	IN	_	30	case	_	_
26	the	the	DT	_	29	det	_	_
27	human	human	JJ	_	29	attr	_	_
28	cytochrome	cytochrome	NN	_	29	com	_	_
29	P450	p0	NN	_	30	com	_	_
30	enzymes	enzyme	NNS	_	24	ppmod	_	_
31	evaluated	evaluate	VBN	_	30	acl	_	_
32	(	-lrb-	-LRB-	_	33	p	_	_
33	CYP1A2	cyp0a0	NN	_	31	prn	_	_
34	,	,	,	_	33	p	_	_
35	CYP2A6	cyp0a0	NN	_	33	conj	_	_
36	,	,	,	_	35	p	_	_
37	CYP2C9	cyp0c0	NN	_	33	conj	_	_
38	,	,	,	_	37	p	_	_
39	CYP2D6	cyp0d0	NN	_	33	conj	_	_
40	,	,	,	_	39	p	_	_
41	CYP2E1	cyp0e0	NN	_	33	conj	_	_
42	,	,	,	_	41	p	_	_
43	CYP4A9	cyp0a0	NN	_	33	conj	_	_
44	and	and	CC	_	43	cc	_	_
45	CYP4A11	cyp0a0	NN	_	33	conj	_	_
46	)	-rrb-	-RRB-	_	33	p	_	_
47	with	with	IN	_	49	case	_	_
48	the	the	DT	_	49	det	_	_
49	exception	exception	NN	_	31	ppmod	_	_
50	of	of	IN	_	51	case	_	_
51	CYP2C19	cyp0c0	NN	_	49	ppmod	_	_
52	and	and	CC	_	51	cc	_	_
53	CYP3A4/5	cyp0a0	NN	_	51	conj	_	_
54	.	.	.	_	2	p	_	_

1	Although	although	IN	_	11	mark	_	_
2	inhibition	inhibition	NN	_	11	dep	_	_
3	of	of	IN	_	5	case	_	_
4	CYP	cyp	NN	_	5	com	_	_
5	3A4/5	0a0	NN	_	2	ppmod	_	_
6	by	by	IN	_	7	case	_	_
7	drug1	drug0	NN	_	2	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	did	do	VBD	_	11	aux	_	_
11	occur	occur	VB	_	17	advcl	_	_
12	at	at	IN	_	14	case	_	_
13	high	high	JJ	_	14	attr	_	_
14	concentrations	concentration	NNS	_	11	ppmod	_	_
15	,	,	,	_	17	p	_	_
16	it	it	PRP	_	17	dep	_	_
17	is	be	VBZ	_	0	root	_	_
18	not	not	RB	_	17	neg	_	_
19	likely	likely	JJ	_	17	dep	_	_
20	to	to	TO	_	21	aux	_	_
21	be	be	VB	_	19	comp	_	_
22	of	of	IN	_	24	case	_	_
23	clinical	clinical	JJ	_	24	attr	_	_
24	significance	significance	NN	_	21	ppmod	_	_
25	.	.	.	_	17	p	_	_

1	The	the	DT	_	2	det	_	_
2	inhibition	inhibition	NN	_	12	dep	_	_
3	of	of	IN	_	4	case	_	_
4	CYP-2C19	cyp-0c0	NN	_	2	ppmod	_	_
5	by	by	IN	_	6	case	_	_
6	drug1	drug0	NN	_	2	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	,	,	,	_	12	p	_	_
10	however	however	RB	_	12	adv	_	_
11	,	,	,	_	12	p	_	_
12	is	be	VBZ	_	0	root	_	_
13	clinically	clinically	RB	_	14	adv	_	_
14	relevant	relevant	JJ	_	12	dep	_	_
15	.	.	.	_	12	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	9	adv	_	_
3	,	,	,	_	9	p	_	_
4	the	the	DT	_	7	det	_	_
5	UDP-glucuronyl	udp-glucuronyl	JJ	_	7	attr	_	_
6	transferase	transferase	NN	_	7	com	_	_
7	level	level	NN	_	9	dep	_	_
8	was	be	VBD	_	9	aux	_	_
9	increased	increase	VBN	_	0	root	_	_
10	,	,	,	_	9	p	_	_
11	indicating	indicate	VBG	_	9	comp	_	_
12	induction	induction	NN	_	11	obj	_	_
13	of	of	IN	_	15	case	_	_
14	this	this	DT	_	15	det	_	_
15	enzyme	enzyme	NN	_	12	ppmod	_	_
16	.	.	.	_	9	p	_	_

1	Increases	increase	NNS	_	13	dep	_	_
2	of	of	IN	_	3	case	_	_
3	22	0	CD	_	1	ppmod	_	_
4	%	%	NN	_	3	meta	_	_
5	with	with	IN	_	6	case	_	_
6	drug1	drug0	NN	_	3	ppmod	_	_
7	and	and	CC	_	3	cc	_	_
8	47	0	CD	_	3	conj	_	_
9	%	%	NN	_	8	meta	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NN	_	8	ppmod	_	_
12	were	be	VBD	_	13	aux	_	_
13	observed	observe	VBN	_	0	root	_	_
14	.	.	.	_	13	p	_	_

1	As	as	IN	_	9	mark	_	_
2	drug1	drug0	NN	_	9	dep	_	_
3	,	,	,	_	2	p	_	_
4	the	the	DT	_	7	det	_	_
5	predominant	predominant	JJ	_	7	attr	_	_
6	plasma	plasma	NN	_	7	com	_	_
7	substrate	substrate	NN	_	2	appo	_	_
8	,	,	,	_	2	p	_	_
9	is	be	VBZ	_	19	advcl	_	_
10	only	only	RB	_	9	adv	_	_
11	a	a	DT	_	13	det	_	_
12	weak	weak	JJ	_	13	attr	_	_
13	inducer	inducer	NN	_	9	obj	_	_
14	of	of	IN	_	16	case	_	_
15	UDP-glucuronyl	udp-glucuronyl	NN	_	16	com	_	_
16	transferase	transferase	NN	_	13	ppmod	_	_
17	,	,	,	_	19	p	_	_
18	it	it	PRP	_	19	dep	_	_
19	is	be	VBZ	_	0	root	_	_
20	unlikely	unlikely	JJ	_	19	dep	_	_
21	to	to	TO	_	22	aux	_	_
22	have	have	VB	_	20	comp	_	_
23	an	an	DT	_	24	det	_	_
24	effect	effect	NN	_	22	obj	_	_
25	on	on	IN	_	26	case	_	_
26	drugs	drug	NNS	_	22	ppmod	_	_
27	that	that	WDT	_	30	dep	_	_
28	are	be	VBP	_	30	aux	_	_
29	mainly	mainly	RB	_	30	adv	_	_
30	eliminated	eliminate	VBN	_	26	relcl	_	_
31	by	by	IN	_	32	case	_	_
32	conjugation	conjugation	NN	_	30	ppmod	_	_
33	through	through	IN	_	35	case	_	_
34	UDP-glucuronyl	udp-glucuronyl	JJ	_	35	attr	_	_
35	transferase	transferase	NN	_	30	ppmod	_	_
36	(	-lrb-	-LRB-	_	41	p	_	_
37	e.g.	e.g.	FW	_	39	adv	_	_
38	,	,	,	_	39	p	_	_
39	drug2	drug0	NN	_	41	ppmod	_	_
40	,	,	,	_	41	p	_	_
41	drug3	drug0	NN	_	35	prn	_	_
42	)	-rrb-	-RRB-	_	41	p	_	_
43	.	.	.	_	19	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	7	ppmod	_	_
3	,	,	,	_	7	p	_	_
4	drug1	drug0	NN	_	7	dep	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	induce	induce	VBP	_	0	root	_	_
8	a	a	DT	_	9	det	_	_
9	subgroup	subgroup	NN	_	7	obj	_	_
10	of	of	IN	_	15	case	_	_
11	the	the	DT	_	15	det	_	_
12	cytochrome	cytochrome	NN	_	15	com	_	_
13	P450	p0	NN	_	15	com	_	_
14	3A	0a	NN	_	15	com	_	_
15	family	family	NN	_	9	ppmod	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	CYP3A4	cyp0a0	NN	_	9	prn	_	_
18	and	and	CC	_	17	cc	_	_
19	CYP3A5	cyp0a0	NN	_	17	conj	_	_
20	)	-rrb-	-RRB-	_	17	p	_	_
21	responsible	responsible	JJ	_	9	attr	_	_
22	for	for	IN	_	24	case	_	_
23	the	the	DT	_	24	det	_	_
24	metabolism	metabolism	NN	_	21	ppmod	_	_
25	of	of	IN	_	26	case	_	_
26	drug3	drug0	NN	_	24	ppmod	_	_
27	and	and	CC	_	26	cc	_	_
28	oral	oral	JJ	_	29	attr	_	_
29	drug4	drug0	NN	_	26	conj	_	_
30	,	,	,	_	7	p	_	_
31	resulting	result	VBG	_	7	comp	_	_
32	in	in	IN	_	36	case	_	_
33	a	a	DT	_	36	det	_	_
34	lower	low	JJR	_	36	attr	_	_
35	plasma	plasma	NN	_	36	com	_	_
36	concentration	concentration	NN	_	31	ppmod	_	_
37	of	of	IN	_	39	case	_	_
38	these	these	DT	_	39	det	_	_
39	drugs	drug	NNS	_	36	ppmod	_	_
40	.	.	.	_	7	p	_	_

1	As	as	IN	_	8	mark	_	_
2	binding	binding	NN	_	8	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	to	to	TO	_	7	aux	_	_
6	plasma	plasma	NN	_	7	com	_	_
7	proteins	protein	NNS	_	2	ppmod	_	_
8	is	be	VBZ	_	27	advcl	_	_
9	low	low	JJ	_	8	dep	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	40	0	CD	_	9	num	_	_
12	%	%	NN	_	11	meta	_	_
13	)	-rrb-	-RRB-	_	11	p	_	_
14	,	,	,	_	27	p	_	_
15	clinically	clinically	RB	_	16	adv	_	_
16	significant	significant	JJ	_	17	attr	_	_
17	interactions	interaction	NNS	_	27	dep	_	_
18	with	with	IN	_	20	case	_	_
19	other	other	JJ	_	20	attr	_	_
20	drugs	drug	NNS	_	17	ppmod	_	_
21	through	through	IN	_	22	case	_	_
22	competition	competition	NN	_	17	ppmod	_	_
23	for	for	IN	_	26	case	_	_
24	protein	protein	NN	_	26	com	_	_
25	binding	binding	NN	_	26	com	_	_
26	sites	site	NNS	_	22	ppmod	_	_
27	are	be	VBP	_	0	root	_	_
28	unlikely	unlikely	JJ	_	27	dep	_	_
29	.	.	.	_	27	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Potential	potential	JJ	_	4	attr	_	_
4	interactions	interaction	NNS	_	11	dep	_	_
5	between	between	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	other	other	JJ	_	9	attr	_	_
9	drug3	drug0	NN	_	6	conj	_	_
10	were	be	VBD	_	11	aux	_	_
11	assessed	assess	VBN	_	1	acl	_	_
12	in	in	IN	_	14	case	_	_
13	clinical	clinical	JJ	_	14	attr	_	_
14	studies	study	NNS	_	11	ppmod	_	_
15	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	12	dep	_	_
3	of	of	IN	_	5	case	_	_
4	these	these	DT	_	5	det	_	_
5	interactions	interaction	NNS	_	2	ppmod	_	_
6	on	on	IN	_	8	case	_	_
7	mean	mean	JJ	_	8	attr	_	_
8	AUCs	auc	NNS	_	2	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	Cmin	cmin	NN	_	8	conj	_	_
11	are	be	VBP	_	12	aux	_	_
12	summarized	summarize	VBN	_	0	root	_	_
13	in	in	IN	_	14	case	_	_
14	Table	table	NN	_	12	ppmod	_	_
15	2	0	CD	_	14	num	_	_
16	:	:	:	_	12	p	_	_
17	Table	table	NN	_	12	dep	_	_
18	2	0	CD	_	17	num	_	_
19	:	:	:	_	12	p	_	_
20	Summary	summary	NN	_	12	dep	_	_
21	of	of	IN	_	23	case	_	_
22	AED	aed	JJ	_	23	attr	_	_
23	interactions	interaction	NNS	_	20	ppmod	_	_
24	with	with	IN	_	25	case	_	_
25	drug1	drug0	NN	_	23	ppmod	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	Co-administered	co-administered	NN	_	0	root	_	_

1	Dose	dose	NN	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	mg/day	mg/day	NN	_	1	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	dose	dose	NN	_	0	root	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	mg/day	mg/day	NN	_	2	prn	_	_
5	)	-rrb-	-RRB-	_	4	p	_	_

1	Influence	influence	NN	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	on	on	IN	_	6	case	_	_
5	drug2	drug0	NN	_	6	com	_	_
6	Concentration	concentration	NN	_	1	ppmod	_	_
7	(	-lrb-	-LRB-	_	9	p	_	_
8	Mean	mean	NN	_	9	com	_	_
9	change	change	NN	_	6	prn	_	_
10	,	,	,	_	9	p	_	_
11	90	0	CD	_	14	num	_	_
12	%	%	NN	_	11	meta	_	_
13	Confidence	confidence	NN	_	14	com	_	_
14	Interval	interval	NN	_	9	appo	_	_
15	)	-rrb-	-RRB-	_	9	p	_	_

1	Influence	influence	NN	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	On	on	IN	_	6	case	_	_
5	drug2	drug0	NN	_	6	com	_	_
6	Concentration	concentration	NN	_	1	ppmod	_	_
7	(	-lrb-	-LRB-	_	9	p	_	_
8	Mean	mean	NN	_	9	com	_	_
9	change	change	NN	_	6	prn	_	_
10	,	,	,	_	9	p	_	_
11	90	0	CD	_	14	num	_	_
12	%	%	NN	_	11	meta	_	_
13	Confidence	confidence	NN	_	14	com	_	_
14	Interval	interval	NN	_	9	appo	_	_
15	)	-rrb-	-RRB-	_	9	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	400-2000	0	NN	_	0	root	_	_

1	900	0	CD	_	0	root	_	_

1	nc1	nc0	NN	_	0	root	_	_
2	40	0	CD	_	4	num	_	_
3	%	%	NN	_	4	meta	_	_
4	decrease	decrease	NN	_	13	dep	_	_
5	-LSB-CI	-lsb-ci	CD	_	4	num	_	_
6	:	:	:	_	13	p	_	_
7	17	0	CD	_	9	num	_	_
8	%	%	NN	_	9	meta	_	_
9	decrease	decrease	NN	_	13	dep	_	_
10	,	,	,	_	13	p	_	_
11	57	0	CD	_	13	num	_	_
12	%	%	NN	_	13	meta	_	_
13	decrease	decrease	NN	_	1	prn	_	_
14	]	-rsb-	-RRB-	_	13	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	100-150	0	CD	_	0	root	_	_

1	600-1800	0	NN	_	0	root	_	_

1	14	0	CD	_	4	num	_	_
2	%	%	NN	_	1	meta	_	_
3	increase	increase	NN	_	4	com	_	_
4	-LSB-CI	-lsb-ci	NN	_	0	root	_	_
5	:	:	:	_	25	p	_	_
6	2	0	CD	_	8	num	_	_
7	%	%	NN	_	6	meta	_	_
8	increase	increase	NN	_	25	dep	_	_
9	,	,	,	_	25	p	_	_
10	24	0	CD	_	16	num	_	_
11	%	%	NN	_	16	meta	_	_
12	increase	increase	NN	_	16	attr	_	_
13	]	-rsb-	-RRB-	_	16	p	_	_
14	25	0	CD	_	16	num	_	_
15	%	%	NN	_	16	meta	_	_
16	decrease	decrease	NN	_	25	dep	_	_
17	-LSB-CI	-lsb-ci	CD	_	16	num	_	_
18	:	:	:	_	25	p	_	_
19	12	0	CD	_	21	num	_	_
20	%	%	NN	_	19	meta	_	_
21	decrease	decrease	NN	_	25	dep	_	_
22	,	,	,	_	25	p	_	_
23	51	0	CD	_	25	num	_	_
24	%	%	NN	_	25	meta	_	_
25	decrease	decrease	NN	_	4	prn	_	_
26	]	-rsb-	-RRB-	_	25	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	250-500	0	CD	_	0	root	_	_

1	600-1800	0	NN	_	0	root	_	_

1	nc1,2	nc0	NN	_	0	root	_	_
2	30	0	CD	_	4	num	_	_
3	%	%	NN	_	4	meta	_	_
4	decrease	decrease	NN	_	13	dep	_	_
5	-LSB-CI	-lsb-ci	CD	_	4	num	_	_
6	:	:	:	_	13	p	_	_
7	3	0	CD	_	9	num	_	_
8	%	%	NN	_	9	meta	_	_
9	decrease	decrease	NN	_	13	dep	_	_
10	,	,	,	_	13	p	_	_
11	48	0	CD	_	13	num	_	_
12	%	%	NN	_	13	meta	_	_
13	decrease	decrease	NN	_	1	prn	_	_
14	]	-rsb-	-RRB-	_	13	p	_	_

1	1200-2400	0	CD	_	11	num	_	_
2	up	up	RP	_	1	prt	_	_
3	to	to	TO	_	1	cc	_	_
4	40	0	CD	_	1	conj	_	_
5	%	%	NN	_	11	meta	_	_
6	increase3	increase0	NN	_	11	attr	_	_
7	-LSB-CI	-lsb-ci	NN	_	11	attr	_	_
8	:	:	:	_	11	p	_	_
9	12	0	CD	_	11	num	_	_
10	%	%	NN	_	11	meta	_	_
11	increase	increase	NN	_	15	dep	_	_
12	,	,	,	_	15	p	_	_
13	60	0	CD	_	15	num	_	_
14	%	%	NN	_	13	meta	_	_
15	increase	increase	NN	_	0	root	_	_
16	]	-rsb-	-RRB-	_	15	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	400-2800	0	NN	_	0	root	_	_

1	600-1800	0	NN	_	0	root	_	_

1	nc1	nc0	NN	_	5	attr	_	_
2	18	0	CD	_	5	num	_	_
3	%	%	NN	_	5	meta	_	_
4	decrease	decrease	NN	_	5	com	_	_
5	-LSB-CI	-lsb-ci	NN	_	0	root	_	_
6	:	:	:	_	13	p	_	_
7	13	0	CD	_	9	num	_	_
8	%	%	NN	_	9	meta	_	_
9	decrease	decrease	NN	_	13	dep	_	_
10	,	,	,	_	13	p	_	_
11	40	0	CD	_	13	num	_	_
12	%	%	NN	_	11	meta	_	_
13	decrease	decrease	NN	_	5	prn	_	_
14	]	-rsb-	-RRB-	_	13	p	_	_

1	1-	0-	CD	_	2	num	_	_
2	nc	nc	NN	_	3	dep	_	_
3	denotes	denote	VBZ	_	31	advcl	_	_
4	a	a	DT	_	6	det	_	_
5	mean	mean	JJ	_	6	attr	_	_
6	change	change	NN	_	3	obj	_	_
7	of	of	IN	_	16	case	_	_
8	less	less	JJR	_	10	attr	_	_
9	than	than	IN	_	8	com	_	_
10	10	0	CD	_	16	num	_	_
11	%	%	NN	_	16	meta	_	_
12	2-	0-	CD	_	16	num	_	_
13	Pediatrics	pediatrics	NN	_	16	attr	_	_
14	3-	0-	CD	_	16	num	_	_
15	Mean	mean	NN	_	16	com	_	_
16	increase	increase	NN	_	6	ppmod	_	_
17	in	in	IN	_	18	case	_	_
18	adults	adult	NNS	_	16	ppmod	_	_
19	at	at	IN	_	22	case	_	_
20	high	high	JJ	_	22	attr	_	_
21	drug1	drug0	NN	_	22	com	_	_
22	doses	dose	NNS	_	16	ppmod	_	_
23	In	in	FW	_	24	adv	_	_
24	vivo	vivo	FW	_	3	adv	_	_
25	,	,	,	_	31	p	_	_
26	the	the	DT	_	28	det	_	_
27	plasma	plasma	NN	_	28	com	_	_
28	levels	level	NNS	_	31	dep	_	_
29	of	of	IN	_	30	case	_	_
30	drug2	drug0	NN	_	28	ppmod	_	_
31	increased	increase	VBD	_	0	root	_	_
32	by	by	IN	_	35	case	_	_
33	up	up	RB	_	35	adv	_	_
34	to	to	TO	_	35	attr	_	_
35	40	0	CD	_	31	ppmod	_	_
36	%	%	NN	_	35	meta	_	_
37	,	,	,	_	31	p	_	_
38	when	when	WRB	_	41	adv	_	_
39	drug3	drug0	NN	_	41	dep	_	_
40	was	be	VBD	_	41	aux	_	_
41	given	give	VBN	_	31	comp	_	_
42	at	at	IN	_	43	case	_	_
43	doses	dose	NNS	_	41	ppmod	_	_
44	above	above	IN	_	46	case	_	_
45	1200	0	CD	_	46	num	_	_
46	mg/day	mg/day	NN	_	43	ppmod	_	_
47	.	.	.	_	31	p	_	_

1	Therefore	therefore	RB	_	25	adv	_	_
2	,	,	,	_	25	p	_	_
3	when	when	WRB	_	4	adv	_	_
4	using	use	VBG	_	25	advcl	_	_
5	doses	dose	NNS	_	4	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	greater	great	JJR	_	10	attr	_	_
9	than	than	IN	_	8	com	_	_
10	1200	0	CD	_	11	num	_	_
11	mg/day	mg/day	NN	_	5	attr	_	_
12	during	during	IN	_	14	case	_	_
13	adjunctive	adjunctive	JJ	_	14	attr	_	_
14	therapy	therapy	NN	_	4	ppmod	_	_
15	,	,	,	_	25	p	_	_
16	a	a	DT	_	17	det	_	_
17	decrease	decrease	NN	_	25	dep	_	_
18	in	in	IN	_	20	case	_	_
19	the	the	DT	_	20	det	_	_
20	dose	dose	NN	_	17	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	drug2	drug0	NN	_	20	ppmod	_	_
23	may	may	MD	_	25	modal	_	_
24	be	be	VB	_	25	aux	_	_
25	required	require	VBN	_	0	root	_	_
26	.	.	.	_	25	p	_	_

1	The	the	DT	_	2	det	_	_
2	increase	increase	NN	_	9	dep	_	_
3	of	of	IN	_	5	case	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	level	level	NN	_	2	ppmod	_	_
6	,	,	,	_	9	p	_	_
7	however	however	RB	_	9	adv	_	_
8	,	,	,	_	9	p	_	_
9	is	be	VBZ	_	0	root	_	_
10	small	small	JJ	_	9	dep	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	15	0	CD	_	10	num	_	_
13	%	%	NN	_	12	meta	_	_
14	)	-rrb-	-RRB-	_	12	p	_	_
15	when	when	WRB	_	16	adv	_	_
16	given	give	VBN	_	9	comp	_	_
17	with	with	IN	_	18	case	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	.	.	.	_	9	p	_	_

1	Strong	strong	JJ	_	2	attr	_	_
2	inducers	inducer	NNS	_	17	dep	_	_
3	of	of	IN	_	6	case	_	_
4	cytochrome	cytochrome	NN	_	6	com	_	_
5	P450	p0	NN	_	6	com	_	_
6	enzymes	enzyme	NNS	_	2	ppmod	_	_
7	(	-lrb-	-LRB-	_	9	p	_	_
8	i.e.	i.e.	FW	_	9	ppmod	_	_
9	drug1	drug0	NN	_	6	prn	_	_
10	,	,	,	_	9	p	_	_
11	drug2	drug0	NN	_	9	conj	_	_
12	and	and	CC	_	11	cc	_	_
13	drug3	drug0	NN	_	9	conj	_	_
14	)	-rrb-	-RRB-	_	9	p	_	_
15	have	have	VBP	_	17	aux	_	_
16	been	be	VBN	_	17	aux	_	_
17	shown	show	VBN	_	0	root	_	_
18	to	to	TO	_	19	aux	_	_
19	decrease	decrease	VB	_	17	comp	_	_
20	the	the	DT	_	22	det	_	_
21	plasma	plasma	NN	_	22	com	_	_
22	levels	level	NNS	_	19	obj	_	_
23	of	of	IN	_	24	case	_	_
24	drug4	drug0	NN	_	22	ppmod	_	_
25	(	-lrb-	-LRB-	_	26	p	_	_
26	29-40	0	CD	_	24	num	_	_
27	%	%	NN	_	26	meta	_	_
28	)	-rrb-	-RRB-	_	26	p	_	_
29	.	.	.	_	17	p	_	_

1	No	no	DT	_	2	det	_	_
2	autoinduction	autoinduction	NN	_	5	dep	_	_
3	has	have	VBZ	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	observed	observe	VBN	_	0	root	_	_
6	with	with	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	.	.	.	_	5	p	_	_

1	Hormonal	hormonal	JJ	_	3	attr	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	Co-administration	co-administration	NN	_	12	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	with	with	IN	_	9	case	_	_
7	an	an	DT	_	9	det	_	_
8	oral	oral	JJ	_	9	attr	_	_
9	drug3	drug0	NN	_	3	ppmod	_	_
10	has	have	VBZ	_	12	aux	_	_
11	been	be	VBN	_	12	aux	_	_
12	shown	show	VBN	_	0	root	_	_
13	to	to	TO	_	14	aux	_	_
14	influence	influence	VB	_	12	comp	_	_
15	the	the	DT	_	17	det	_	_
16	plasma	plasma	NN	_	17	com	_	_
17	concentrations	concentration	NNS	_	14	obj	_	_
18	of	of	IN	_	22	case	_	_
19	the	the	DT	_	22	det	_	_
20	two	#crd#	CD	_	22	num	_	_
21	hormonal	hormonal	JJ	_	22	attr	_	_
22	components	component	NNS	_	17	ppmod	_	_
23	,	,	,	_	22	p	_	_
24	drug4	drug0	NN	_	22	appo	_	_
25	(	-lrb-	-LRB-	_	26	p	_	_
26	EE	ee	NN	_	24	prn	_	_
27	)	-rrb-	-RRB-	_	26	p	_	_
28	and	and	CC	_	24	cc	_	_
29	drug5	drug0	NN	_	24	conj	_	_
30	(	-lrb-	-LRB-	_	31	p	_	_
31	LNG	lng	NN	_	29	prn	_	_
32	)	-rrb-	-RRB-	_	31	p	_	_
33	.	.	.	_	12	p	_	_

1	The	the	DT	_	4	det	_	_
2	mean	mean	JJ	_	4	attr	_	_
3	AUC	auc	NN	_	4	com	_	_
4	values	value	NNS	_	8	dep	_	_
5	of	of	IN	_	6	case	_	_
6	EE	ee	NN	_	4	ppmod	_	_
7	were	be	VBD	_	8	aux	_	_
8	decreased	decrease	VBN	_	0	root	_	_
9	by	by	IN	_	16	case	_	_
10	48	0	CD	_	16	num	_	_
11	%	%	NN	_	16	meta	_	_
12	-LSB-90	-lsb-0	CD	_	16	num	_	_
13	%	%	NN	_	16	meta	_	_
14	CI	ci	CD	_	16	num	_	_
15	:	:	:	_	16	p	_	_
16	22-65	0	CD	_	8	ppmod	_	_
17	]	-rsb-	-RRB-	_	16	p	_	_
18	in	in	IN	_	20	case	_	_
19	one	#crd#	CD	_	20	num	_	_
20	study	study	NN	_	16	ppmod	_	_
21	and	and	CC	_	16	cc	_	_
22	52	0	CD	_	28	num	_	_
23	%	%	NN	_	28	meta	_	_
24	-LSB-90	-lsb-0	CD	_	28	num	_	_
25	%	%	NN	_	28	meta	_	_
26	CI	ci	CD	_	28	num	_	_
27	:	:	:	_	28	p	_	_
28	38-52	0	CD	_	16	conj	_	_
29	]	-rsb-	-RRB-	_	28	p	_	_
30	in	in	IN	_	33	case	_	_
31	another	another	DT	_	33	det	_	_
32	study	study	NN	_	33	com	_	_
33	-LSB-1,2	-lsb-0	NN	_	28	ppmod	_	_
34	]	-rsb-	-RRB-	_	28	p	_	_
35	.	.	.	_	8	p	_	_

1	The	the	DT	_	4	det	_	_
2	mean	mean	JJ	_	4	attr	_	_
3	AUC	auc	NN	_	4	com	_	_
4	values	value	NNS	_	8	dep	_	_
5	of	of	IN	_	6	case	_	_
6	LNG	lng	NN	_	4	ppmod	_	_
7	were	be	VBD	_	8	aux	_	_
8	decreased	decrease	VBN	_	0	root	_	_
9	by	by	IN	_	16	case	_	_
10	32	0	CD	_	16	num	_	_
11	%	%	NN	_	16	meta	_	_
12	-LSB-90	-lsb-0	CD	_	16	num	_	_
13	%	%	NN	_	16	meta	_	_
14	CI	ci	CD	_	16	num	_	_
15	:	:	:	_	16	p	_	_
16	20-45	0	CD	_	8	ppmod	_	_
17	]	-rsb-	-RRB-	_	16	p	_	_
18	in	in	IN	_	20	case	_	_
19	one	#crd#	CD	_	20	num	_	_
20	study	study	NN	_	16	ppmod	_	_
21	and	and	CC	_	16	cc	_	_
22	52	0	CD	_	16	conj	_	_
23	%	%	NN	_	22	meta	_	_
24	-LSB-90	-lsb-0	CD	_	28	num	_	_
25	%	%	NN	_	28	meta	_	_
26	CI	ci	CD	_	28	num	_	_
27	:	:	:	_	28	p	_	_
28	42-52	0	CD	_	22	appo	_	_
29	]	-rsb-	-RRB-	_	28	p	_	_
30	in	in	IN	_	32	case	_	_
31	another	another	DT	_	32	det	_	_
32	study	study	NN	_	22	ppmod	_	_
33	.	.	.	_	8	p	_	_

1	Therefore	therefore	RB	_	10	adv	_	_
2	,	,	,	_	10	p	_	_
3	concurrent	concurrent	JJ	_	4	attr	_	_
4	use	use	NN	_	10	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	with	with	IN	_	8	case	_	_
8	drug2	drug0	NN	_	4	ppmod	_	_
9	may	may	MD	_	10	modal	_	_
10	render	render	VB	_	0	root	_	_
11	these	these	DT	_	12	det	_	_
12	drug3	drug0	NNS	_	10	obj	_	_
13	less	less	RBR	_	14	adv	_	_
14	effective	effective	JJ	_	12	attr	_	_
15	.	.	.	_	10	p	_	_

1	Studies	study	NNS	_	11	dep	_	_
2	with	with	IN	_	7	case	_	_
3	other	other	JJ	_	7	attr	_	_
4	oral	oral	JJ	_	7	attr	_	_
5	or	or	CC	_	4	cc	_	_
6	implant	implant	JJ	_	4	conj	_	_
7	drug1	drug0	NNS	_	1	ppmod	_	_
8	have	have	VBP	_	11	aux	_	_
9	not	not	RB	_	11	neg	_	_
10	been	be	VBN	_	11	aux	_	_
11	conducted	conduct	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	s	s	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	After	after	IN	_	6	case	_	_
5	repeated	repeated	JJ	_	6	attr	_	_
6	co-administration	co-administration	NN	_	15	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	,	,	,	_	15	p	_	_
10	the	the	DT	_	11	det	_	_
11	AUC	auc	NN	_	15	dep	_	_
12	of	of	IN	_	13	case	_	_
13	drug3	drug0	NN	_	11	ppmod	_	_
14	was	be	VBD	_	15	aux	_	_
15	lowered	lower	VBN	_	2	acl	_	_
16	by	by	IN	_	23	case	_	_
17	28	0	CD	_	19	num	_	_
18	%	%	NN	_	19	meta	_	_
19	-LSB-90	-lsb-0	CD	_	23	num	_	_
20	%	%	NN	_	19	meta	_	_
21	CI	ci	CD	_	23	num	_	_
22	:	:	:	_	23	p	_	_
23	20-33	0	CD	_	15	ppmod	_	_
24	]	-rsb-	-RRB-	_	23	p	_	_
25	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	produced	produce	VBD	_	0	root	_	_
3	a	a	DT	_	4	det	_	_
4	decrease	decrease	NN	_	2	obj	_	_
5	of	of	IN	_	12	case	_	_
6	20	0	CD	_	12	num	_	_
7	%	%	NN	_	12	meta	_	_
8	-LSB-90	-lsb-0	CD	_	12	num	_	_
9	%	%	NN	_	12	meta	_	_
10	CI	ci	CD	_	12	num	_	_
11	:	:	:	_	12	p	_	_
12	18-27	0	CD	_	4	ppmod	_	_
13	]	-rsb-	-RRB-	_	12	p	_	_
14	of	of	IN	_	17	case	_	_
15	the	the	DT	_	17	det	_	_
16	plasma	plasma	NN	_	17	com	_	_
17	levels	level	NNS	_	12	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	.	.	.	_	2	p	_	_

1	Other	other	JJ	_	3	attr	_	_
2	drug	drug	NN	_	3	com	_	_
3	interactions	interaction	NNS	_	9	dep	_	_
4	drug1	drug0	NN	_	3	attr	_	_
5	,	,	,	_	4	p	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	and	and	CC	_	6	cc	_	_
8	drug3	drug0	NN	_	4	conj	_	_
9	had	have	VBD	_	0	root	_	_
10	no	no	DT	_	11	det	_	_
11	effect	effect	NN	_	9	obj	_	_
12	on	on	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	pharmacokinetics	pharmacokinetics	NNS	_	9	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug4	drug0	NN	_	14	ppmod	_	_
17	.	.	.	_	9	p	_	_

1	Results	result	NNS	_	4	dep	_	_
2	with	with	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	wshow	wshow	VBP	_	0	root	_	_
5	no	no	DT	_	6	det	_	_
6	evidence	evidence	NN	_	4	obj	_	_
7	of	of	IN	_	8	case	_	_
8	interaction	interaction	NN	_	6	ppmod	_	_
9	with	with	IN	_	14	case	_	_
10	either	either	CC	_	11	cc	_	_
11	single	single	JJ	_	14	attr	_	_
12	or	or	CC	_	11	cc	_	_
13	repeated	repeated	JJ	_	11	conj	_	_
14	doses	dose	NNS	_	8	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	.	.	.	_	4	p	_	_

1	THE	the	DT	_	3	det	_	_
2	POTENTIATING	potentiating	NN	_	3	com	_	_
3	ACTION	action	NN	_	8	dep	_	_
4	OF	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	MUST	must	MD	_	8	modal	_	_
7	BE	be	VB	_	8	aux	_	_
8	CONSIDERED	consider	VBN	_	0	root	_	_
9	WHEN	when	WRB	_	13	adv	_	_
10	THE	the	DT	_	11	det	_	_
11	DRUG	drug	NN	_	13	dep	_	_
12	IS	be	VBZ	_	13	aux	_	_
13	USED	use	VBN	_	8	comp	_	_
14	IN	in	IN	_	15	case	_	_
15	CONJUNCTION	conjunction	NN	_	13	ppmod	_	_
16	WITH	with	IN	_	17	case	_	_
17	drug2	drug0	NNS	_	15	ppmod	_	_
18	SUCH	such	JJ	_	20	adv	_	_
19	AS	as	IN	_	20	case	_	_
20	drug3	drug0	NN	_	17	ppmod	_	_
21	,	,	,	_	20	p	_	_
22	drug4	drug0	NN	_	20	conj	_	_
23	AND	and	CC	_	22	cc	_	_
24	drug5	drug0	NN	_	20	conj	_	_
25	.	.	.	_	8	p	_	_

1	Therefore	therefore	RB	_	13	adv	_	_
2	when	when	WRB	_	5	adv	_	_
3	drug1	drug0	NN	_	5	dep	_	_
4	are	be	VBP	_	5	aux	_	_
5	administered	administer	VBN	_	13	advcl	_	_
6	concomitantly	concomitantly	RB	_	5	adv	_	_
7	with	with	IN	_	8	case	_	_
8	drug2	drug0	NN	_	5	ppmod	_	_
9	their	their	PRP$	_	10	poss	_	_
10	dosage	dosage	NN	_	13	dep	_	_
11	should	should	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	reduced	reduce	VBN	_	0	root	_	_
14	.	.	.	_	13	p	_	_

1	Since	since	IN	_	4	mark	_	_
2	drowsiness	drowsiness	NN	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	occur	occur	VB	_	14	advcl	_	_
5	with	with	IN	_	6	case	_	_
6	use	use	NN	_	4	ppmod	_	_
7	of	of	IN	_	9	case	_	_
8	this	this	DT	_	9	det	_	_
9	drug	drug	NN	_	6	ppmod	_	_
10	,	,	,	_	14	p	_	_
11	patients	patient	NNS	_	14	dep	_	_
12	should	should	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	warned	warn	VBN	_	0	root	_	_
15	of	of	IN	_	17	case	_	_
16	this	this	DT	_	17	det	_	_
17	possibility	possibility	NN	_	14	ppmod	_	_
18	and	and	CC	_	14	cc	_	_
19	cautioned	caution	VBN	_	14	conj	_	_
20	against	against	IN	_	21	case	_	_
21	driving	drive	VBG	_	19	ppmod	_	_
22	a	a	DT	_	23	det	_	_
23	car	car	NN	_	21	obj	_	_
24	or	or	CC	_	21	cc	_	_
25	operating	operate	VBG	_	21	conj	_	_
26	dangerous	dangerous	NN	_	27	com	_	_
27	machinery	machinery	NN	_	25	obj	_	_
28	while	while	IN	_	29	case	_	_
29	taking	take	VBG	_	25	ppmod	_	_
30	drug1	drug0	NN	_	29	obj	_	_
31	.	.	.	_	14	p	_	_

1	Patients	patient	NNS	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	advised	advise	VBN	_	0	root	_	_
5	against	against	IN	_	8	case	_	_
6	the	the	DT	_	8	det	_	_
7	simultaneous	simultaneous	JJ	_	8	attr	_	_
8	use	use	NN	_	4	ppmod	_	_
9	of	of	IN	_	11	case	_	_
10	other	other	JJ	_	11	attr	_	_
11	drug1	drug0	NN	_	8	ppmod	_	_
12	,	,	,	_	4	p	_	_
13	and	and	CC	_	4	cc	_	_
14	cautioned	caution	VBN	_	4	conj	_	_
15	that	that	IN	_	22	mark	_	_
16	the	the	DT	_	17	det	_	_
17	effect	effect	NN	_	22	dep	_	_
18	of	of	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	may	may	MD	_	22	modal	_	_
21	be	be	VB	_	22	aux	_	_
22	increased	increase	VBN	_	14	comp	_	_
23	.	.	.	_	4	p	_	_

1	Additive	additive	JJ	_	3	attr	_	_
2	CNS	cns	NN	_	3	com	_	_
3	depression	depression	NN	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	occur	occur	VB	_	0	root	_	_
6	when	when	WRB	_	9	adv	_	_
7	drug1	drug0	NN	_	9	dep	_	_
8	are	be	VBP	_	9	aux	_	_
9	administered	administer	VBN	_	5	comp	_	_
10	concomitantly	concomitantly	RB	_	9	adv	_	_
11	with	with	IN	_	13	case	_	_
12	other	other	JJ	_	13	attr	_	_
13	drug2	drug0	NNS	_	9	ppmod	_	_
14	including	include	VBG	_	15	adv	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	,	,	,	_	15	p	_	_
17	drug4	drug0	NN	_	15	conj	_	_
18	,	,	,	_	17	p	_	_
19	and	and	CC	_	17	cc	_	_
20	drug5	drug0	NN	_	15	conj	_	_
21	.	.	.	_	5	p	_	_

1	Patients	patient	NNS	_	6	dep	_	_
2	receiving	receive	VBG	_	1	acl	_	_
3	drug1	drug0	NN	_	2	obj	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	advised	advise	VBN	_	0	root	_	_
7	against	against	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	concurrent	concurrent	JJ	_	10	attr	_	_
10	use	use	NN	_	6	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	other	other	JJ	_	13	attr	_	_
13	drug2	drug0	NNS	_	10	ppmod	_	_
14	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	prolong	prolong	VBP	_	0	root	_	_
3	and	and	CC	_	2	cc	_	_
4	intensify	intensify	VBP	_	2	conj	_	_
5	the	the	DT	_	7	det	_	_
6	anticholinergic	anticholinergic	JJ	_	7	attr	_	_
7	effects	effect	NNS	_	4	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	.	.	.	_	2	p	_	_

1	It	it	PRP	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	possible	possible	JJ	_	2	dep	_	_
4	that	that	IN	_	13	mark	_	_
5	the	the	DT	_	7	det	_	_
6	cardiovascular	cardiovascular	JJ	_	7	attr	_	_
7	action	action	NN	_	13	dep	_	_
8	of	of	IN	_	10	case	_	_
9	other	other	JJ	_	10	attr	_	_
10	drug1	drug0	NN	_	7	ppmod	_	_
11	could	could	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	enhanced	enhance	VBN	_	2	comp	_	_
14	by	by	IN	_	16	case	_	_
15	the	the	DT	_	16	det	_	_
16	addition	addition	NN	_	13	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	.	.	.	_	2	p	_	_

1	In	in	IN	_	2	case	_	_
2	Europe	europe	NN	_	6	ppmod	_	_
3	,	,	,	_	6	p	_	_
4	drug1	drug0	NN	_	6	dep	_	_
5	was	be	VBD	_	6	aux	_	_
6	observed	observe	VBN	_	0	root	_	_
7	to	to	TO	_	9	aux	_	_
8	occasionally	occasionally	RB	_	9	adv	_	_
9	intensify	intensify	VB	_	6	comp	_	_
10	the	the	DT	_	11	det	_	_
11	effect	effect	NN	_	9	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NNS	_	11	ppmod	_	_
14	taken	take	VBN	_	13	acl	_	_
15	concomitantly	concomitantly	RB	_	14	adv	_	_
16	by	by	IN	_	17	case	_	_
17	patients	patient	NNS	_	14	ppmod	_	_
18	suffering	suffer	VBG	_	17	acl	_	_
19	from	from	IN	_	20	case	_	_
20	hypertension	hypertension	NN	_	18	ppmod	_	_
21	;	;	:	_	6	p	_	_

1	this	this	DT	_	2	det	_	_
2	phenomenon	phenomenon	NN	_	5	dep	_	_
3	was	be	VBD	_	5	aux	_	_
4	not	not	RB	_	5	neg	_	_
5	observed	observe	VBN	_	0	root	_	_
6	in	in	IN	_	10	case	_	_
7	North	north	NNP	_	8	com	_	_
8	American	american	NNP	_	10	attr	_	_
9	clinical	clinical	JJ	_	10	attr	_	_
10	trials	trial	NNS	_	5	ppmod	_	_
11	.	.	.	_	5	p	_	_

1	A	a	DT	_	2	det	_	_
2	study	study	NN	_	8	dep	_	_
3	in	in	IN	_	6	case	_	_
4	eight	#crd#	CD	_	6	num	_	_
5	healthy	healthy	JJ	_	6	attr	_	_
6	volunteers	volunteer	NNS	_	2	ppmod	_	_
7	has	have	VBZ	_	8	aux	_	_
8	shown	show	VBN	_	0	root	_	_
9	a	a	DT	_	12	det	_	_
10	50	0	CD	_	12	num	_	_
11	%	%	NN	_	10	meta	_	_
12	increase	increase	NN	_	8	obj	_	_
13	in	in	IN	_	18	case	_	_
14	mean	mean	JJ	_	18	attr	_	_
15	peak	peak	NN	_	18	com	_	_
16	drug1	drug0	NN	_	18	com	_	_
17	plasma	plasma	NN	_	18	com	_	_
18	concentrations	concentration	NNS	_	12	ppmod	_	_
19	and	and	CC	_	12	cc	_	_
20	a	a	DT	_	23	det	_	_
21	90	0	CD	_	23	num	_	_
22	%	%	NN	_	21	meta	_	_
23	increase	increase	NN	_	12	conj	_	_
24	in	in	IN	_	26	case	_	_
25	mean	mean	NN	_	26	com	_	_
26	area	area	NN	_	23	ppmod	_	_
27	under	under	IN	_	29	case	_	_
28	the	the	DT	_	29	det	_	_
29	curve	curve	NN	_	26	ppmod	_	_
30	,	,	,	_	8	p	_	_
31	after	after	IN	_	35	case	_	_
32	a	a	DT	_	35	det	_	_
33	one	#crd#	CD	_	35	num	_	_
34	week	week	NN	_	35	com	_	_
35	course	course	NN	_	8	ppmod	_	_
36	of	of	IN	_	37	case	_	_
37	drug2	drug0	NN	_	35	ppmod	_	_
38	at	at	IN	_	40	case	_	_
39	1,000	0	CD	_	40	num	_	_
40	mg/day	mg/day	NN	_	37	ppmod	_	_
41	and	and	CC	_	40	cc	_	_
42	drug3	drug0	NN	_	40	conj	_	_
43	at	at	IN	_	45	case	_	_
44	90	0	CD	_	45	num	_	_
45	mg/day	mg/day	NN	_	40	ppmod	_	_
46	.	.	.	_	8	p	_	_

1	This	this	DT	_	2	det	_	_
2	effect	effect	NN	_	5	dep	_	_
3	may	may	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	mediated	mediate	VBN	_	0	root	_	_
6	by	by	IN	_	9	case	_	_
7	the	the	DT	_	9	det	_	_
8	known	known	JJ	_	9	attr	_	_
9	inhibition	inhibition	NN	_	5	ppmod	_	_
10	of	of	IN	_	13	case	_	_
11	hepatic	hepatic	JJ	_	13	attr	_	_
12	cytochrome	cytochrome	NN	_	13	com	_	_
13	P-	p-	NN	_	9	ppmod	_	_
14	450	0	CD	_	13	num	_	_
15	by	by	IN	_	16	case	_	_
16	drug1	drug0	NN	_	9	ppmod	_	_
17	,	,	,	_	16	p	_	_
18	which	which	WDT	_	20	dep	_	_
19	could	could	MD	_	20	modal	_	_
20	decrease	decrease	VB	_	16	relcl	_	_
21	first	#ord#	JJ	_	23	attr	_	_
22	pass	pass	NN	_	23	com	_	_
23	metabolism	metabolism	NN	_	20	obj	_	_
24	of	of	IN	_	25	case	_	_
25	drug2	drug0	NN	_	23	ppmod	_	_
26	.	.	.	_	5	p	_	_

1	Taking	take	VBG	_	16	advcl	_	_
2	a	a	DT	_	3	det	_	_
3	drug1	drug0	NN	_	1	obj	_	_
4	while	while	IN	_	7	mark	_	_
5	you	you	RB	_	7	adv	_	_
6	are	be	VBP	_	7	aux	_	_
7	taking	take	VBG	_	3	acl	_	_
8	or	or	CC	_	11	cc	_	_
9	within	within	IN	_	11	case	_	_
10	2	0	CD	_	11	num	_	_
11	weeks	week	NNS	_	7	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	taking	take	VBG	_	14	attr	_	_
14	drug2	drug0	NNS	_	11	ppmod	_	_
15	may	may	MD	_	16	modal	_	_
16	increase	increase	VB	_	0	root	_	_
17	the	the	DT	_	18	det	_	_
18	risk	risk	NN	_	16	obj	_	_
19	of	of	IN	_	23	case	_	_
20	central	central	JJ	_	22	attr	_	_
21	nervous	nervous	JJ	_	22	attr	_	_
22	system	system	NN	_	23	com	_	_
23	depression	depression	NN	_	18	ppmod	_	_
24	or	or	CC	_	16	cc	_	_
25	may	may	MD	_	26	modal	_	_
26	cause	cause	VB	_	16	conj	_	_
27	a	a	DT	_	31	det	_	_
28	severe	severe	JJ	_	31	attr	_	_
29	high	high	JJ	_	31	attr	_	_
30	blood	blood	NN	_	31	com	_	_
31	pressure	pressure	NN	_	32	com	_	_
32	reaction	reaction	NN	_	26	obj	_	_
33	.	.	.	_	16	p	_	_

1	No	no	DT	_	5	det	_	_
2	formal	formal	JJ	_	5	attr	_	_
3	drug	drug	NN	_	5	com	_	_
4	interaction	interaction	NN	_	5	com	_	_
5	studies	study	NNS	_	10	dep	_	_
6	with	with	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	have	have	VBP	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	conducted	conduct	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	In	in	IN	_	2	case	_	_
2	Study	study	NN	_	10	ppmod	_	_
3	1	0	CD	_	2	num	_	_
4	,	,	,	_	10	p	_	_
5	patients	patient	NNS	_	10	dep	_	_
6	with	with	IN	_	8	case	_	_
7	colorectal	colorectal	JJ	_	8	attr	_	_
8	cancer	cancer	NN	_	5	ppmod	_	_
9	were	be	VBD	_	10	aux	_	_
10	given	give	VBN	_	0	root	_	_
11	drug1	drug0	NN	_	10	obj	_	_
12	/	/	:	_	11	p	_	_
13	drug2	drug0	NN	_	11	appo	_	_
14	/	/	:	_	11	p	_	_
15	drug3	drug0	NN	_	11	appo	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	bolus-IFL	bolus-ifl	NN	_	15	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	with	with	IN	_	10	ppmod	_	_
20	or	or	CC	_	19	cc	_	_
21	without	without	IN	_	22	case	_	_
22	drug4	drug0	NN	_	19	conj	_	_
23	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	concentrations	concentration	NNS	_	3	dep	_	_
3	were	be	VBD	_	0	root	_	_
4	similar	similar	JJ	_	3	dep	_	_
5	in	in	IN	_	6	case	_	_
6	patients	patient	NNS	_	4	ppmod	_	_
7	receiving	receive	VBG	_	6	acl	_	_
8	bolus-IFL	bolus-ifl	NN	_	7	obj	_	_
9	alone	alone	RB	_	3	adv	_	_
10	and	and	CC	_	9	cc	_	_
11	in	in	IN	_	12	case	_	_
12	combination	combination	NN	_	9	conj	_	_
13	with	with	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	concentrations	concentration	NNS	_	12	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	,	,	,	_	4	p	_	_
6	the	the	DT	_	8	det	_	_
7	active	active	JJ	_	8	attr	_	_
8	metabolite	metabolite	NN	_	4	appo	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	,	,	,	_	4	p	_	_
12	were	be	VBD	_	0	root	_	_
13	on	on	IN	_	14	case	_	_
14	average	average	NN	_	12	ppmod	_	_
15	33	0	CD	_	17	num	_	_
16	%	%	NN	_	15	meta	_	_
17	higher	high	JJR	_	12	dep	_	_
18	in	in	IN	_	19	case	_	_
19	patients	patient	NNS	_	17	ppmod	_	_
20	receiving	receive	VBG	_	19	acl	_	_
21	bolus-IFL	bolus-ifl	NN	_	20	obj	_	_
22	in	in	IN	_	23	case	_	_
23	combination	combination	NN	_	20	ppmod	_	_
24	with	with	IN	_	25	case	_	_
25	drug3	drug0	NN	_	23	ppmod	_	_
26	when	when	WRB	_	27	adv	_	_
27	compared	compare	VBN	_	12	comp	_	_
28	with	with	IN	_	29	case	_	_
29	bolus-IFL	bolus-ifl	NN	_	27	ppmod	_	_
30	alone	alone	RB	_	29	adv	_	_
31	.	.	.	_	12	p	_	_

1	In	in	IN	_	2	case	_	_
2	Study	study	NN	_	10	ppmod	_	_
3	1	0	CD	_	2	num	_	_
4	,	,	,	_	10	p	_	_
5	patients	patient	NNS	_	10	dep	_	_
6	receiving	receive	VBG	_	5	acl	_	_
7	bolus-IFL	bolus-ifl	NN	_	6	obj	_	_
8	plus	plus	CC	_	7	cc	_	_
9	drug1	drug0	NN	_	7	conj	_	_
10	had	have	VBD	_	0	root	_	_
11	a	a	DT	_	13	det	_	_
12	higher	high	JJR	_	13	attr	_	_
13	incidence	incidence	NN	_	10	obj	_	_
14	of	of	IN	_	17	case	_	_
15	Grade	grade	NN	_	17	attr	_	_
16	3-4	0	JJ	_	17	num	_	_
17	diarrhea	diarrhea	NN	_	13	ppmod	_	_
18	and	and	CC	_	17	cc	_	_
19	neutropenia	neutropenia	NN	_	17	conj	_	_
20	.	.	.	_	10	p	_	_

1	Due	due	JJ	_	5	adv	_	_
2	to	to	TO	_	5	aux	_	_
3	high	high	JJ	_	5	attr	_	_
4	inter-patient	inter-patient	JJ	_	5	attr	_	_
5	variability	variability	NN	_	25	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	limited	limited	JJ	_	8	attr	_	_
8	sampling	sampling	NN	_	5	conj	_	_
9	,	,	,	_	25	p	_	_
10	the	the	DT	_	11	det	_	_
11	extent	extent	NN	_	25	dep	_	_
12	of	of	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	increase	increase	NN	_	11	ppmod	_	_
15	in	in	IN	_	17	case	_	_
16	drug1	drug0	NN	_	17	com	_	_
17	levels	level	NNS	_	14	ppmod	_	_
18	in	in	IN	_	19	case	_	_
19	patients	patient	NNS	_	17	ppmod	_	_
20	receiving	receive	VBG	_	19	acl	_	_
21	concurrent	concurrent	JJ	_	22	attr	_	_
22	drug2	drug0	NN	_	20	obj	_	_
23	and	and	CC	_	22	cc	_	_
24	drug3	drug0	NN	_	22	conj	_	_
25	is	be	VBZ	_	0	root	_	_
26	uncertain	uncertain	JJ	_	25	dep	_	_
27	.	.	.	_	25	p	_	_

1	A	a	DT	_	2	det	_	_
2	number	number	NN	_	5	dep	_	_
3	of	of	IN	_	4	case	_	_
4	substances	substance	NNS	_	2	ppmod	_	_
5	affect	affect	VBP	_	0	root	_	_
6	glucose	glucose	NN	_	7	com	_	_
7	metabolism	metabolism	NN	_	5	obj	_	_
8	and	and	CC	_	5	cc	_	_
9	may	may	MD	_	10	modal	_	_
10	require	require	VBP	_	5	conj	_	_
11	drug1	drug0	NN	_	13	com	_	_
12	dose	dose	NN	_	13	com	_	_
13	adjustment	adjustment	NN	_	10	obj	_	_
14	and	and	CC	_	13	cc	_	_
15	particularly	particularly	RB	_	17	adv	_	_
16	close	close	JJ	_	17	attr	_	_
17	monitoring	monitoring	NN	_	13	conj	_	_
18	.	.	.	_	5	p	_	_

1	The	the	DT	_	2	det	_	_
2	following	following	NN	_	3	dep	_	_
3	are	be	VBP	_	0	root	_	_
4	examples	example	NNS	_	3	obj	_	_
5	of	of	IN	_	6	case	_	_
6	substances	substance	NNS	_	4	ppmod	_	_
7	that	that	WDT	_	9	dep	_	_
8	may	may	MD	_	9	modal	_	_
9	increase	increase	VB	_	6	relcl	_	_
10	the	the	DT	_	12	det	_	_
11	blood-glucose-lowering	blood-glucose-lowering	JJ	_	12	attr	_	_
12	effect	effect	NN	_	9	obj	_	_
13	and	and	CC	_	12	cc	_	_
14	susceptibility	susceptibility	NN	_	12	conj	_	_
15	to	to	TO	_	16	aux	_	_
16	hypoglycemia	hypoglycemia	NN	_	14	ppmod	_	_
17	:	:	:	_	4	p	_	_
18	oral	oral	JJ	_	19	attr	_	_
19	drug1	drug0	NN	_	4	appo	_	_
20	,	,	,	_	19	p	_	_
21	drug2	drug0	NN	_	19	appo	_	_
22	,	,	,	_	19	p	_	_
23	drug3	drug0	NN	_	19	appo	_	_
24	,	,	,	_	19	p	_	_
25	drug4	drug0	NN	_	19	appo	_	_
26	,	,	,	_	19	p	_	_
27	drug5	drug0	NN	_	19	appo	_	_
28	,	,	,	_	19	p	_	_
29	drug6	drug0	NN	_	19	appo	_	_
30	,	,	,	_	19	p	_	_
31	drug7	drug0	NN	_	19	appo	_	_
32	,	,	,	_	19	p	_	_
33	drug8	drug0	NN	_	19	appo	_	_
34	,	,	,	_	19	p	_	_
35	drug9	drug0	NN	_	19	appo	_	_
36	(	-lrb-	-LRB-	_	39	p	_	_
37	e.g.	e.g.	FW	_	39	adv	_	_
38	,	,	,	_	39	p	_	_
39	drug10	drug0	NN	_	35	prn	_	_
40	)	-rrb-	-RRB-	_	39	p	_	_
41	,	,	,	_	19	p	_	_
42	drug11	drug0	NN	_	19	appo	_	_
43	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	following	following	NN	_	3	dep	_	_
3	are	be	VBP	_	0	root	_	_
4	examples	example	NNS	_	3	obj	_	_
5	of	of	IN	_	6	case	_	_
6	substances	substance	NNS	_	4	ppmod	_	_
7	that	that	WDT	_	9	dep	_	_
8	may	may	MD	_	9	modal	_	_
9	reduce	reduce	VB	_	6	relcl	_	_
10	the	the	DT	_	12	det	_	_
11	blood-glucose-lowering	blood-glucose-lowering	JJ	_	12	attr	_	_
12	effect	effect	NN	_	9	obj	_	_
13	:	:	:	_	4	p	_	_
14	drug1	drug0	NN	_	4	appo	_	_
15	,	,	,	_	14	p	_	_
16	drug2	drug0	NN	_	14	appo	_	_
17	,	,	,	_	14	p	_	_
18	drug3	drug0	NN	_	14	appo	_	_
19	,	,	,	_	14	p	_	_
20	drug4	drug0	NN	_	14	appo	_	_
21	,	,	,	_	14	p	_	_
22	drug5	drug0	NN	_	14	appo	_	_
23	(	-lrb-	-LRB-	_	24	p	_	_
24	e.g.	e.g.	FW	_	22	prn	_	_
25	,	,	,	_	24	p	_	_
26	drug6	drug0	NN	_	24	attr	_	_
27	,	,	,	_	24	p	_	_
28	drug7	drug0	NN	_	26	appo	_	_
29	,	,	,	_	24	p	_	_
30	drug8	drug0	NN	_	26	appo	_	_
31	)	-rrb-	-RRB-	_	24	p	_	_
32	,	,	,	_	14	p	_	_
33	drug9	drug0	NN	_	14	appo	_	_
34	,	,	,	_	14	p	_	_
35	drug10	drug0	NN	_	14	appo	_	_
36	,	,	,	_	14	p	_	_
37	drug11	drug0	NN	_	14	appo	_	_
38	,	,	,	_	14	p	_	_
39	drug12	drug0	NN	_	14	appo	_	_
40	,	,	,	_	14	p	_	_
41	drug13	drug0	NN	_	14	appo	_	_
42	,	,	,	_	14	p	_	_
43	drug14	drug0	NN	_	14	appo	_	_
44	(	-lrb-	-LRB-	_	49	p	_	_
45	e.g.	e.g.	FW	_	49	ppmod	_	_
46	,	,	,	_	49	p	_	_
47	in	in	IN	_	49	case	_	_
48	oral	oral	JJ	_	49	attr	_	_
49	drug15	drug0	NN	_	3	prn	_	_
50	)	-rrb-	-RRB-	_	49	p	_	_
51	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	12	dep	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	,	,	,	_	3	p	_	_
5	drug3	drug0	NN	_	6	com	_	_
6	salts	salt	NNS	_	1	conj	_	_
7	,	,	,	_	6	p	_	_
8	and	and	CC	_	6	cc	_	_
9	drug4	drug0	NN	_	1	conj	_	_
10	may	may	MD	_	12	modal	_	_
11	either	either	CC	_	12	cc	_	_
12	potentiate	potentiate	VB	_	0	root	_	_
13	or	or	CC	_	12	cc	_	_
14	weaken	weaken	VB	_	12	conj	_	_
15	the	the	DT	_	17	det	_	_
16	blood-glucose-lowering	blood-glucose-lowering	JJ	_	17	attr	_	_
17	effect	effect	NN	_	14	obj	_	_
18	of	of	IN	_	19	case	_	_
19	drug5	drug0	NN	_	17	ppmod	_	_
20	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	cause	cause	VB	_	0	root	_	_
4	hypoglycemia	hypoglycemia	NN	_	3	obj	_	_
5	,	,	,	_	4	p	_	_
6	which	which	WDT	_	10	dep	_	_
7	may	may	MD	_	10	modal	_	_
8	sometimes	sometimes	RB	_	10	adv	_	_
9	be	be	VB	_	10	aux	_	_
10	followed	followed	VBN	_	4	relcl	_	_
11	by	by	IN	_	12	case	_	_
12	hyperglycemia	hyperglycemia	NN	_	10	ppmod	_	_
13	.	.	.	_	3	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	28	ppmod	_	_
3	,	,	,	_	28	p	_	_
4	under	under	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	influence	influence	NN	_	28	ppmod	_	_
7	of	of	IN	_	10	case	_	_
8	sympatholytic	sympatholytic	JJ	_	10	attr	_	_
9	medicinal	medicinal	NN	_	10	com	_	_
10	products	product	NNS	_	6	ppmod	_	_
11	such	such	JJ	_	13	adv	_	_
12	as	as	IN	_	13	case	_	_
13	drug1	drug0	NN	_	10	ppmod	_	_
14	,	,	,	_	13	p	_	_
15	drug2	drug0	NN	_	13	conj	_	_
16	,	,	,	_	15	p	_	_
17	drug3	drug0	NN	_	13	conj	_	_
18	,	,	,	_	17	p	_	_
19	and	and	CC	_	17	cc	_	_
20	drug4	drug0	NN	_	13	conj	_	_
21	,	,	,	_	28	p	_	_
22	the	the	DT	_	23	det	_	_
23	signs	sign	NNS	_	28	dep	_	_
24	of	of	IN	_	25	case	_	_
25	hypoglycemia	hypoglycemia	NN	_	23	ppmod	_	_
26	may	may	MD	_	28	modal	_	_
27	be	be	VB	_	28	aux	_	_
28	reduced	reduce	VBN	_	0	root	_	_
29	or	or	CC	_	28	cc	_	_
30	absent	absent	JJ	_	28	conj	_	_
31	.	.	.	_	28	p	_	_

1	Mixing	mixing	NN	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_

1	A	a	DT	_	3	det	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	study	study	NN	_	11	dep	_	_
4	in	in	IN	_	7	case	_	_
5	healthy	healthy	JJ	_	7	attr	_	_
6	male	male	JJ	_	7	attr	_	_
7	volunteers	volunteer	NNS	_	3	ppmod	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	n=24	n=0	NN	_	7	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	demonstrated	demonstrate	VBD	_	0	root	_	_
12	that	that	IN	_	20	mark	_	_
13	mixing	mixing	JJ	_	14	attr	_	_
14	drug1	drug0	NN	_	20	dep	_	_
15	with	with	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	immediately	immediately	RB	_	19	adv	_	_
18	before	before	IN	_	19	case	_	_
19	injection	injection	NN	_	16	ppmod	_	_
20	produced	produce	VBD	_	11	advcl	_	_
21	some	some	DT	_	22	det	_	_
22	attenuation	attenuation	NN	_	20	obj	_	_
23	in	in	IN	_	26	case	_	_
24	the	the	DT	_	26	det	_	_
25	peak	peak	JJ	_	26	attr	_	_
26	concentration	concentration	NN	_	22	ppmod	_	_
27	of	of	IN	_	28	case	_	_
28	drug3	drug0	NN	_	26	ppmod	_	_
29	,	,	,	_	20	p	_	_
30	but	but	CC	_	20	cc	_	_
31	that	that	IN	_	45	mark	_	_
32	the	the	DT	_	33	det	_	_
33	time	time	NN	_	45	dep	_	_
34	to	to	TO	_	35	aux	_	_
35	peak	peak	NN	_	33	ppmod	_	_
36	and	and	CC	_	33	cc	_	_
37	the	the	DT	_	39	det	_	_
38	total	total	JJ	_	39	attr	_	_
39	bioavailability	bioavailability	NN	_	33	conj	_	_
40	of	of	IN	_	41	case	_	_
41	drug4	drug0	NN	_	39	ppmod	_	_
42	were	be	VBD	_	45	aux	_	_
43	not	not	RB	_	45	neg	_	_
44	significantly	significantly	RB	_	45	adv	_	_
45	affected	affect	VBN	_	20	conj	_	_
46	.	.	.	_	11	p	_	_

1	If	if	IN	_	4	mark	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	mixed	mix	VBN	_	11	advcl	_	_
5	with	with	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	,	,	,	_	11	p	_	_
8	drug3	drug0	NN	_	11	dep	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	drawn	draw	VBN	_	0	root	_	_
12	into	into	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	syringe	syringe	NN	_	11	ppmod	_	_
15	first	#ord#	JJ	_	14	attr	_	_
16	.	.	.	_	11	p	_	_

1	The	the	DT	_	2	det	_	_
2	injection	injection	NN	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	made	make	VBN	_	0	root	_	_
6	immediately	immediately	RB	_	8	adv	_	_
7	after	after	IN	_	8	case	_	_
8	mixing	mixing	NN	_	5	ppmod	_	_
9	.	.	.	_	5	p	_	_

1	Because	because	IN	_	3	mark	_	_
2	there	there	EX	_	3	dep	_	_
3	are	be	VBP	_	20	advcl	_	_
4	no	no	DT	_	5	det	_	_
5	data	datum	NNS	_	3	obj	_	_
6	on	on	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	compatibility	compatibility	NN	_	5	ppmod	_	_
9	of	of	IN	_	14	case	_	_
10	drug1	drug0	NN	_	14	attr	_	_
11	and	and	CC	_	10	cc	_	_
12	crystalline	crystalline	NN	_	13	com	_	_
13	drug2	drug0	NN	_	10	conj	_	_
14	preparations	preparation	NNS	_	8	ppmod	_	_
15	,	,	,	_	20	p	_	_
16	drug3	drug0	NN	_	20	dep	_	_
17	should	should	MD	_	20	modal	_	_
18	not	not	RB	_	20	neg	_	_
19	be	be	VB	_	20	aux	_	_
20	mixed	mix	VBN	_	0	root	_	_
21	with	with	IN	_	23	case	_	_
22	these	these	DT	_	23	det	_	_
23	preparations	preparation	NNS	_	20	ppmod	_	_
24	.	.	.	_	20	p	_	_

1	The	the	DT	_	2	det	_	_
2	effects	effect	NNS	_	21	dep	_	_
3	of	of	IN	_	5	case	_	_
4	mixing	mixing	NN	_	5	com	_	_
5	drug1	drug0	NN	_	2	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drug2	drug0	NN	_	2	ppmod	_	_
8	of	of	IN	_	10	case	_	_
9	animal	animal	NN	_	10	com	_	_
10	source	source	NN	_	7	ppmod	_	_
11	or	or	CC	_	10	cc	_	_
12	drug3	drug0	NN	_	13	com	_	_
13	preparations	preparation	NNS	_	10	conj	_	_
14	produced	produce	VBN	_	10	acl	_	_
15	by	by	IN	_	17	case	_	_
16	other	other	JJ	_	17	attr	_	_
17	manufacturers	manufacturer	NNS	_	14	ppmod	_	_
18	have	have	VBP	_	21	aux	_	_
19	not	not	RB	_	21	neg	_	_
20	been	be	VBN	_	21	aux	_	_
21	studied	study	VBN	_	0	root	_	_
22	.	.	.	_	21	p	_	_

1	Mixtures	mixtures	NN	_	5	dep	_	_
2	should	should	MD	_	5	modal	_	_
3	not	not	RB	_	5	neg	_	_
4	be	be	VB	_	5	aux	_	_
5	administered	administer	VBN	_	0	root	_	_
6	intravenously	intravenously	RB	_	5	adv	_	_
7	.	.	.	_	5	p	_	_

1	When	when	WRB	_	2	adv	_	_
2	used	use	VBN	_	15	advcl	_	_
3	in	in	IN	_	6	case	_	_
4	external	external	JJ	_	6	attr	_	_
5	subcutaneous	subcutaneous	JJ	_	6	attr	_	_
6	infusion	infusion	NN	_	2	ppmod	_	_
7	pumps	pump	VBZ	_	6	attr	_	_
8	for	for	IN	_	9	case	_	_
9	drug1	drug0	NN	_	6	ppmod	_	_
10	,	,	,	_	15	p	_	_
11	drug2	drug0	NN	_	15	dep	_	_
12	should	should	MD	_	15	modal	_	_
13	not	not	RB	_	15	neg	_	_
14	be	be	VB	_	15	aux	_	_
15	mixed	mix	VBN	_	0	root	_	_
16	with	with	IN	_	19	case	_	_
17	any	any	DT	_	19	det	_	_
18	other	other	JJ	_	19	attr	_	_
19	drug3	drug0	NN	_	15	ppmod	_	_
20	or	or	CC	_	19	cc	_	_
21	diluent	diluent	NN	_	19	conj	_	_
22	.	.	.	_	15	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	may	may	MD	_	5	modal	_	_
5	diminish	diminish	VB	_	0	root	_	_
6	adrenal	adrenal	JJ	_	7	attr	_	_
7	suppression	suppression	NN	_	5	obj	_	_
8	by	by	IN	_	9	case	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_
10	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	injection	injection	NN	_	0	root	_	_
3	and	and	CC	_	2	cc	_	_
4	potassium-depleting	potassium-depleting	JJ	_	5	attr	_	_
5	agents	agent	NNS	_	2	conj	_	_
6	:	:	:	_	2	p	_	_
7	When	when	WRB	_	10	adv	_	_
8	drug2	drug0	NNS	_	10	dep	_	_
9	are	be	VBP	_	10	aux	_	_
10	administered	administer	VBN	_	26	advcl	_	_
11	concomitantly	concomitantly	RB	_	10	adv	_	_
12	with	with	IN	_	14	case	_	_
13	potassium-depleting	potassium-depleting	JJ	_	14	attr	_	_
14	agents	agent	NNS	_	10	ppmod	_	_
15	(	-lrb-	-LRB-	_	20	p	_	_
16	e.g.	e.g.	FW	_	18	adv	_	_
17	,	,	,	_	18	p	_	_
18	drug3	drug0	NN	_	20	ppmod	_	_
19	,	,	,	_	20	p	_	_
20	drug4	drug0	NNS	_	10	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	,	,	,	_	26	p	_	_
23	patients	patient	NNS	_	26	dep	_	_
24	should	should	MD	_	26	modal	_	_
25	be	be	VB	_	26	aux	_	_
26	observed	observe	VBN	_	2	acl	_	_
27	closely	closely	RB	_	26	adv	_	_
28	for	for	IN	_	29	case	_	_
29	development	development	NN	_	26	ppmod	_	_
30	of	of	IN	_	31	case	_	_
31	hypokalemia	hypokalemia	NN	_	29	ppmod	_	_
32	.	.	.	_	2	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	6	ppmod	_	_
3	,	,	,	_	6	p	_	_
4	there	there	EX	_	6	dep	_	_
5	have	have	VBP	_	6	aux	_	_
6	been	be	VBN	_	0	root	_	_
7	cases	case	NNS	_	6	obj	_	_
8	reported	report	VBN	_	7	acl	_	_
9	in	in	IN	_	10	case	_	_
10	which	which	WDT	_	18	ppmod	_	_
11	concomitant	concomitant	JJ	_	12	attr	_	_
12	use	use	NN	_	18	dep	_	_
13	of	of	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	drug2	drug0	NN	_	14	conj	_	_
17	was	be	VBD	_	18	aux	_	_
18	followed	followed	VBN	_	7	relcl	_	_
19	by	by	IN	_	21	case	_	_
20	cardiac	cardiac	JJ	_	21	attr	_	_
21	enlargement	enlargement	NN	_	18	ppmod	_	_
22	and	and	CC	_	21	cc	_	_
23	congestive	congestive	JJ	_	25	attr	_	_
24	heart	heart	NN	_	25	com	_	_
25	failure	failure	NN	_	21	conj	_	_
26	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	have	have	VBP	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	reported	report	VBN	_	0	root	_	_
7	to	to	TO	_	8	aux	_	_
8	cause	cause	VB	_	6	comp	_	_
9	a	a	DT	_	11	det	_	_
10	significant	significant	JJ	_	11	attr	_	_
11	decrease	decrease	NN	_	8	obj	_	_
12	in	in	IN	_	14	case	_	_
13	drug3	drug0	NN	_	14	com	_	_
14	clearance	clearance	NN	_	11	ppmod	_	_
15	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Concomitant	concomitant	JJ	_	4	attr	_	_
4	use	use	NN	_	10	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	may	may	MD	_	10	modal	_	_
10	produce	produce	VB	_	1	acl	_	_
11	severe	severe	JJ	_	12	attr	_	_
12	weakness	weakness	NN	_	10	obj	_	_
13	in	in	IN	_	14	case	_	_
14	patients	patient	NNS	_	12	ppmod	_	_
15	with	with	IN	_	17	case	_	_
16	myasthenia	myasthenia	JJ	_	17	attr	_	_
17	gravis	gravis	NNS	_	14	ppmod	_	_
18	.	.	.	_	1	p	_	_

1	If	if	IN	_	2	mark	_	_
2	possible	possible	JJ	_	7	advcl	_	_
3	,	,	,	_	7	p	_	_
4	drug1	drug0	NN	_	7	dep	_	_
5	should	should	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	withdrawn	withdraw	VBN	_	0	root	_	_
8	at	at	IN	_	11	case	_	_
9	least	least	JJS	_	10	attr	_	_
10	24	0	CD	_	11	num	_	_
11	hours	hour	NNS	_	7	ppmod	_	_
12	before	before	IN	_	13	case	_	_
13	initiating	initiate	VBG	_	7	ppmod	_	_
14	drug2	drug0	NN	_	15	com	_	_
15	therapy	therapy	NN	_	13	obj	_	_
16	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	11	dep	_	_
2	,	,	,	_	1	p	_	_
3	oral	oral	JJ	_	1	appo	_	_
4	:	:	:	_	1	p	_	_
5	Co-administration	co-administration	NN	_	1	appo	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug3	drug0	NN	_	7	conj	_	_
10	usually	usually	RB	_	11	adv	_	_
11	results	result	VBZ	_	0	root	_	_
12	in	in	IN	_	13	case	_	_
13	inhibition	inhibition	NN	_	11	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	response	response	NN	_	13	ppmod	_	_
16	to	to	TO	_	17	aux	_	_
17	drug4	drug0	NN	_	15	ppmod	_	_
18	,	,	,	_	11	p	_	_
19	although	although	IN	_	22	mark	_	_
20	there	there	EX	_	22	dep	_	_
21	have	have	VBP	_	22	aux	_	_
22	been	be	VBN	_	11	comp	_	_
23	some	some	DT	_	25	det	_	_
24	conflicting	conflict	VBG	_	25	attr	_	_
25	reports	report	NNS	_	22	obj	_	_
26	.	.	.	_	11	p	_	_

1	Therefore	therefore	RB	_	7	adv	_	_
2	,	,	,	_	7	p	_	_
3	coagulation	coagulation	NN	_	4	com	_	_
4	indices	index	NNS	_	7	dep	_	_
5	should	should	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	monitored	monitor	VBN	_	0	root	_	_
8	frequently	frequently	RB	_	7	adv	_	_
9	to	to	TO	_	10	aux	_	_
10	maintain	maintain	VB	_	7	comp	_	_
11	the	the	DT	_	14	det	_	_
12	desired	desired	JJ	_	14	attr	_	_
13	anticoagulant	anticoagulant	JJ	_	14	attr	_	_
14	effect	effect	NN	_	10	obj	_	_
15	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Because	because	IN	_	6	mark	_	_
4	drug2	drug0	NN	_	6	dep	_	_
5	may	may	MD	_	6	modal	_	_
6	increase	increase	VB	_	17	advcl	_	_
7	blood	blood	NN	_	9	com	_	_
8	glucose	glucose	NN	_	9	com	_	_
9	concentrations	concentration	NNS	_	6	obj	_	_
10	,	,	,	_	17	p	_	_
11	dosage	dosage	NN	_	12	com	_	_
12	adjustments	adjustment	NNS	_	17	dep	_	_
13	of	of	IN	_	14	case	_	_
14	drug3	drug0	NN	_	12	ppmod	_	_
15	may	may	MD	_	17	modal	_	_
16	be	be	VB	_	17	aux	_	_
17	required	require	VBN	_	1	acl	_	_
18	.	.	.	_	1	p	_	_

1	Antitubercular	antitubercular	JJ	_	2	attr	_	_
2	drugs	drug	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	Serum	serum	NN	_	5	com	_	_
5	concentrations	concentration	NNS	_	10	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	may	may	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	decreased	decrease	VBN	_	2	acl	_	_
11	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	may	may	MD	_	5	modal	_	_
5	increase	increase	VB	_	0	root	_	_
6	the	the	DT	_	7	det	_	_
7	clearance	clearance	NN	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_
10	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Increased	increase	VBN	_	4	attr	_	_
4	activity	activity	NN	_	11	dep	_	_
5	of	of	IN	_	7	case	_	_
6	both	both	CC	_	7	cc	_	_
7	drug2	drug0	NN	_	4	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug3	drug0	NN	_	7	conj	_	_
10	may	may	MD	_	11	modal	_	_
11	occur	occur	VB	_	1	acl	_	_
12	when	when	WRB	_	16	adv	_	_
13	the	the	DT	_	14	det	_	_
14	two	#crd#	CD	_	16	num	_	_
15	are	be	VBP	_	16	aux	_	_
16	used	use	VBN	_	11	comp	_	_
17	concurrently	concurrently	RB	_	16	adv	_	_
18	.	.	.	_	1	p	_	_

1	Convulsions	convulsion	NNS	_	4	dep	_	_
2	have	have	VBP	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	reported	report	VBN	_	0	root	_	_
5	with	with	IN	_	8	case	_	_
6	this	this	DT	_	8	det	_	_
7	concurrent	concurrent	JJ	_	8	attr	_	_
8	use	use	NN	_	4	ppmod	_	_
9	.	.	.	_	4	p	_	_

1	Dexamethasone	dexamethasone	NN	_	3	com	_	_
2	suppression	suppression	NN	_	3	com	_	_
3	test	test	NN	_	9	attr	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	DST	dst	NN	_	3	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	:	:	:	_	9	p	_	_
8	False-negative	false-negative	JJ	_	9	attr	_	_
9	results	result	NNS	_	26	dep	_	_
10	in	in	IN	_	14	case	_	_
11	the	the	DT	_	14	det	_	_
12	dexamethasone	dexamethasone	NN	_	14	com	_	_
13	suppression	suppression	NN	_	14	com	_	_
14	test	test	NN	_	9	ppmod	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	DST	dst	NN	_	14	prn	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	in	in	IN	_	19	case	_	_
19	patients	patient	NNS	_	14	ppmod	_	_
20	being	be	VBG	_	21	aux	_	_
21	treated	treat	VBN	_	19	acl	_	_
22	with	with	IN	_	23	case	_	_
23	drug1	drug0	NN	_	21	ppmod	_	_
24	have	have	VBP	_	26	aux	_	_
25	been	be	VBN	_	26	aux	_	_
26	reported	report	VBN	_	0	root	_	_
27	.	.	.	_	26	p	_	_

1	Thus	thus	RB	_	9	adv	_	_
2	,	,	,	_	9	p	_	_
3	results	result	NNS	_	9	dep	_	_
4	of	of	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	DST	dst	NN	_	3	ppmod	_	_
7	should	should	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	interpreted	interpret	VBN	_	0	root	_	_
10	with	with	IN	_	11	case	_	_
11	caution	caution	NN	_	9	ppmod	_	_
12	in	in	IN	_	14	case	_	_
13	these	these	DT	_	14	det	_	_
14	patients	patient	NNS	_	9	ppmod	_	_
15	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Patients	patient	NNS	_	7	dep	_	_
4	on	on	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	may	may	MD	_	7	modal	_	_
7	be	be	VB	_	1	acl	_	_
8	at	at	IN	_	10	case	_	_
9	increased	increase	VBN	_	10	attr	_	_
10	risk	risk	NN	_	7	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	arrhythmias	arrhythmias	NN	_	10	ppmod	_	_
13	due	due	IN	_	15	case	_	_
14	to	to	TO	_	15	aux	_	_
15	hypokalemia	hypokalemia	NN	_	10	ppmod	_	_
16	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	enhance	enhance	VB	_	1	acl	_	_
6	the	the	DT	_	8	det	_	_
7	metabolic	metabolic	JJ	_	8	attr	_	_
8	clearance	clearance	NN	_	5	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug3	drug0	NN	_	8	ppmod	_	_
11	,	,	,	_	5	p	_	_
12	resulting	result	VBG	_	5	comp	_	_
13	in	in	IN	_	16	case	_	_
14	decreased	decrease	VBN	_	16	attr	_	_
15	blood	blood	NN	_	16	com	_	_
16	levels	level	NNS	_	12	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	lessened	lessened	JJ	_	20	attr	_	_
19	physiologic	physiologic	JJ	_	20	attr	_	_
20	activity	activity	NN	_	16	conj	_	_
21	,	,	,	_	5	p	_	_
22	thus	thus	RB	_	23	adv	_	_
23	requiring	require	VBG	_	5	comp	_	_
24	an	an	DT	_	25	det	_	_
25	increase	increase	NN	_	23	obj	_	_
26	in	in	IN	_	28	case	_	_
27	drug4	drug0	JJ	_	28	attr	_	_
28	dosage	dosage	NN	_	25	ppmod	_	_
29	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	9	dep	_	_
2	,	,	,	_	1	p	_	_
3	including	include	VBG	_	5	adv	_	_
4	oral	oral	JJ	_	5	attr	_	_
5	drug2	drug0	NN	_	1	ppmod	_	_
6	:	:	:	_	1	p	_	_
7	drug3	drug0	NN	_	1	appo	_	_
8	may	may	MD	_	9	modal	_	_
9	decrease	decrease	VB	_	0	root	_	_
10	the	the	DT	_	12	det	_	_
11	hepatic	hepatic	JJ	_	12	attr	_	_
12	metabolism	metabolism	NN	_	9	obj	_	_
13	of	of	IN	_	15	case	_	_
14	certain	certain	JJ	_	15	attr	_	_
15	drug4	drug0	NNS	_	12	ppmod	_	_
16	,	,	,	_	9	p	_	_
17	thereby	thereby	RB	_	18	adv	_	_
18	increasing	increase	VBG	_	9	comp	_	_
19	their	their	PRP$	_	20	poss	_	_
20	effect	effect	NN	_	18	obj	_	_
21	.	.	.	_	9	p	_	_

1	Hepatic	hepatic	JJ	_	3	attr	_	_
2	Enzyme	enzyme	NN	_	3	com	_	_
3	Inducers	inducer	NNS	_	0	root	_	_
4	,	,	,	_	3	p	_	_
5	Inhibitors	inhibitor	NNS	_	3	conj	_	_
6	and	and	CC	_	5	cc	_	_
7	Substrates	substrate	NNS	_	3	conj	_	_
8	:	:	:	_	3	p	_	_
9	Drugs	drug	NNS	_	33	dep	_	_
10	which	which	WDT	_	11	dep	_	_
11	induce	induce	VBP	_	9	relcl	_	_
12	cytochrome	cytochrome	NN	_	14	com	_	_
13	P450	p0	NN	_	14	com	_	_
14	3A4	0a0	NN	_	20	attr	_	_
15	(	-lrb-	-LRB-	_	17	p	_	_
16	CYP	cyp	CD	_	17	num	_	_
17	3A4	0a0	NN	_	14	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	enzyme	enzyme	NN	_	20	com	_	_
20	activity	activity	NN	_	11	obj	_	_
21	(	-lrb-	-LRB-	_	24	p	_	_
22	e.g.	e.g.	FW	_	24	ppmod	_	_
23	,	,	,	_	24	p	_	_
24	drug1	drug0	NN	_	20	prn	_	_
25	,	,	,	_	24	p	_	_
26	drug2	drug0	NN	_	24	appo	_	_
27	,	,	,	_	24	p	_	_
28	drug3	drug0	NN	_	24	appo	_	_
29	,	,	,	_	24	p	_	_
30	drug4	drug0	NN	_	24	appo	_	_
31	)	-rrb-	-RRB-	_	24	p	_	_
32	may	may	MD	_	33	modal	_	_
33	enhance	enhance	VB	_	3	acl	_	_
34	the	the	DT	_	35	det	_	_
35	metabolism	metabolism	NN	_	33	obj	_	_
36	of	of	IN	_	37	case	_	_
37	drug5	drug0	NN	_	35	ppmod	_	_
38	and	and	CC	_	33	cc	_	_
39	require	require	VB	_	33	conj	_	_
40	that	that	IN	_	47	mark	_	_
41	the	the	DT	_	42	det	_	_
42	dosage	dosage	NN	_	47	dep	_	_
43	of	of	IN	_	45	case	_	_
44	the	the	DT	_	45	det	_	_
45	drug6	drug0	NN	_	42	ppmod	_	_
46	be	be	VB	_	47	aux	_	_
47	increased	increase	VBN	_	39	comp	_	_
48	.	.	.	_	3	p	_	_

1	Drugs	drug	NNS	_	16	dep	_	_
2	which	which	WDT	_	3	dep	_	_
3	inhibit	inhibit	VBP	_	1	relcl	_	_
4	CYP	cyp	NN	_	5	com	_	_
5	3A4	0a0	NN	_	3	obj	_	_
6	(	-lrb-	-LRB-	_	11	p	_	_
7	e.g.	e.g.	FW	_	9	adv	_	_
8	,	,	,	_	9	p	_	_
9	drug1	drug0	NN	_	11	ppmod	_	_
10	,	,	,	_	11	p	_	_
11	drug2	drug0	NNS	_	1	prn	_	_
12	such	such	JJ	_	14	adv	_	_
13	as	as	IN	_	14	case	_	_
14	drug3	drug0	NN	_	11	ppmod	_	_
15	)	-rrb-	-RRB-	_	11	p	_	_
16	have	have	VBP	_	0	root	_	_
17	the	the	DT	_	18	det	_	_
18	potential	potential	NN	_	16	obj	_	_
19	to	to	TO	_	20	aux	_	_
20	result	result	VB	_	18	acl	_	_
21	in	in	IN	_	24	case	_	_
22	increased	increase	VBN	_	24	attr	_	_
23	plasma	plasma	NN	_	24	com	_	_
24	concentrations	concentration	NNS	_	20	ppmod	_	_
25	of	of	IN	_	26	case	_	_
26	drug4	drug0	NN	_	24	ppmod	_	_
27	.	.	.	_	16	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	a	a	DT	_	5	det	_	_
4	moderate	moderate	JJ	_	5	attr	_	_
5	inducer	inducer	NN	_	2	obj	_	_
6	of	of	IN	_	8	case	_	_
7	CYP	cyp	NN	_	8	com	_	_
8	3A4	0a0	NN	_	5	ppmod	_	_
9	.	.	.	_	2	p	_	_

1	Co-administration	co-administration	NN	_	19	dep	_	_
2	with	with	IN	_	4	case	_	_
3	other	other	JJ	_	4	attr	_	_
4	drugs	drug	NNS	_	1	ppmod	_	_
5	that	that	WDT	_	7	dep	_	_
6	are	be	VBP	_	7	aux	_	_
7	metabolized	metabolize	VBN	_	4	relcl	_	_
8	by	by	IN	_	10	case	_	_
9	CYP	cyp	NN	_	10	com	_	_
10	3A4	0a0	NN	_	7	ppmod	_	_
11	(	-lrb-	-LRB-	_	16	p	_	_
12	e.g.	e.g.	FW	_	14	adv	_	_
13	,	,	,	_	14	p	_	_
14	drug1	drug0	NN	_	16	ppmod	_	_
15	,	,	,	_	16	p	_	_
16	drug2	drug0	NNS	_	10	prn	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	may	may	MD	_	19	modal	_	_
19	increase	increase	VB	_	0	root	_	_
20	their	their	PRP$	_	21	poss	_	_
21	clearance	clearance	NN	_	19	obj	_	_
22	,	,	,	_	19	p	_	_
23	resulting	result	VBG	_	19	comp	_	_
24	in	in	IN	_	27	case	_	_
25	decreased	decrease	VBN	_	27	attr	_	_
26	plasma	plasma	NN	_	27	com	_	_
27	concentration	concentration	NN	_	23	ppmod	_	_
28	.	.	.	_	19	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	6	dep	_	_
4	has	have	VBZ	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	reported	report	VBN	_	1	acl	_	_
7	to	to	TO	_	8	aux	_	_
8	decrease	decrease	VB	_	6	comp	_	_
9	the	the	DT	_	10	det	_	_
10	metabolism	metabolism	NN	_	8	obj	_	_
11	of	of	IN	_	13	case	_	_
12	certain	certain	JJ	_	13	attr	_	_
13	drug3	drug0	NNS	_	10	ppmod	_	_
14	by	by	IN	_	17	case	_	_
15	up	up	RB	_	17	adv	_	_
16	to	to	TO	_	17	attr	_	_
17	60	0	CD	_	10	ppmod	_	_
18	%	%	NN	_	17	meta	_	_
19	,	,	,	_	6	p	_	_
20	leading	lead	VBG	_	6	comp	_	_
21	to	to	TO	_	23	aux	_	_
22	increased	increase	VBN	_	23	attr	_	_
23	risk	risk	NN	_	20	ppmod	_	_
24	of	of	IN	_	27	case	_	_
25	drug4	drug0	JJ	_	27	attr	_	_
26	side	side	JJ	_	27	attr	_	_
27	effects	effect	NNS	_	23	ppmod	_	_
28	.	.	.	_	1	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	7	ppmod	_	_
3	,	,	,	_	7	p	_	_
4	drug1	drug0	NN	_	7	dep	_	_
5	alone	alone	RB	_	4	adv	_	_
6	can	can	MD	_	7	modal	_	_
7	inhibit	inhibit	VB	_	0	root	_	_
8	adrenal	adrenal	JJ	_	10	attr	_	_
9	drug2	drug0	NN	_	10	com	_	_
10	synthesis	synthesis	NN	_	7	obj	_	_
11	and	and	CC	_	7	cc	_	_
12	may	may	MD	_	13	modal	_	_
13	cause	cause	VBP	_	7	conj	_	_
14	adrenal	adrenal	JJ	_	15	attr	_	_
15	insufficiency	insufficiency	NN	_	13	obj	_	_
16	during	during	IN	_	18	case	_	_
17	corticosteroid	corticosteroid	NN	_	18	com	_	_
18	withdrawal	withdrawal	NN	_	13	ppmod	_	_
19	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	drug2	drug0	NN	_	1	prn	_	_
4	)	-rrb-	-RRB-	_	3	p	_	_
5	:	:	:	_	1	p	_	_
6	Concomitant	concomitant	JJ	_	7	attr	_	_
7	use	use	NN	_	17	dep	_	_
8	of	of	IN	_	9	case	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_
10	(	-lrb-	-LRB-	_	13	p	_	_
11	or	or	CC	_	13	cc	_	_
12	other	other	JJ	_	13	attr	_	_
13	drug4	drug0	NN	_	7	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	and	and	CC	_	7	cc	_	_
16	drug5	drug0	NN	_	7	conj	_	_
17	increases	increase	VBZ	_	1	acl	_	_
18	the	the	DT	_	19	det	_	_
19	risk	risk	NN	_	17	obj	_	_
20	of	of	IN	_	23	case	_	_
21	gastrointestinal	gastrointestinal	JJ	_	23	attr	_	_
22	side	side	JJ	_	23	attr	_	_
23	effects	effect	NNS	_	19	ppmod	_	_
24	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	used	use	VBN	_	0	root	_	_
5	cautiously	cautiously	RB	_	4	adv	_	_
6	in	in	IN	_	7	case	_	_
7	conjunction	conjunction	NN	_	4	ppmod	_	_
8	with	with	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	in	in	IN	_	11	case	_	_
11	hypoprothrombinemia	hypoprothrombinemia	NN	_	9	ppmod	_	_
12	.	.	.	_	4	p	_	_

1	The	the	DT	_	2	det	_	_
2	clearance	clearance	NN	_	7	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	may	may	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	increased	increase	VBN	_	0	root	_	_
8	with	with	IN	_	10	case	_	_
9	concurrent	concurrent	JJ	_	10	attr	_	_
10	use	use	NN	_	7	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	5	case	_	_
4	post-marketing	post-marketing	JJ	_	5	attr	_	_
5	experience	experience	VBP	_	9	ppmod	_	_
6	,	,	,	_	9	p	_	_
7	there	there	EX	_	9	dep	_	_
8	have	have	VBP	_	9	aux	_	_
9	been	be	VBN	_	1	acl	_	_
10	reports	report	NNS	_	9	obj	_	_
11	of	of	IN	_	13	case	_	_
12	both	both	CC	_	13	cc	_	_
13	increases	increase	NNS	_	10	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	decreases	decrease	NNS	_	13	conj	_	_
16	in	in	IN	_	18	case	_	_
17	drug2	drug0	NN	_	18	com	_	_
18	levels	level	NNS	_	13	ppmod	_	_
19	with	with	IN	_	21	case	_	_
20	drug3	drug0	NN	_	21	com	_	_
21	co-administration	co-administration	NN	_	18	ppmod	_	_
22	,	,	,	_	9	p	_	_
23	leading	lead	VBG	_	9	comp	_	_
24	to	to	TO	_	25	aux	_	_
25	alterations	alteration	NNS	_	23	ppmod	_	_
26	in	in	IN	_	28	case	_	_
27	seizure	seizure	NN	_	28	com	_	_
28	control	control	NN	_	25	ppmod	_	_
29	.	.	.	_	1	p	_	_

1	Skin	skin	NN	_	2	com	_	_
2	tests	test	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	drug1	drug0	NN	_	6	dep	_	_
5	may	may	MD	_	6	modal	_	_
6	suppress	suppress	VB	_	2	acl	_	_
7	reactions	reaction	NNS	_	6	obj	_	_
8	to	to	TO	_	10	aux	_	_
9	skin	skin	NN	_	10	com	_	_
10	tests	test	NNS	_	7	ppmod	_	_
11	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	17	dep	_	_
2	:	:	:	_	1	p	_	_
3	Co-administration	co-administration	NN	_	8	dep	_	_
4	with	with	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	should	should	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	employed	employ	VBN	_	1	acl	_	_
9	cautiously	cautiously	RB	_	8	adv	_	_
10	,	,	,	_	8	p	_	_
11	as	as	IN	_	14	case	_	_
12	toxic	toxic	JJ	_	14	attr	_	_
13	epidermal	epidermal	JJ	_	14	attr	_	_
14	necrolysis	necrolysis	NNS	_	8	ppmod	_	_
15	has	have	VBZ	_	17	aux	_	_
16	been	be	VBN	_	17	aux	_	_
17	reported	report	VBN	_	0	root	_	_
18	with	with	IN	_	20	case	_	_
19	concomitant	concomitant	JJ	_	20	attr	_	_
20	use	use	NN	_	17	ppmod	_	_
21	.	.	.	_	17	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Patients	patient	NNS	_	8	dep	_	_
4	on	on	IN	_	6	case	_	_
5	drug2	drug0	NN	_	6	com	_	_
6	therapy	therapy	NN	_	3	ppmod	_	_
7	may	may	MD	_	8	modal	_	_
8	exhibit	exhibit	VBP	_	1	acl	_	_
9	a	a	DT	_	11	det	_	_
10	diminished	diminish	VBN	_	11	attr	_	_
11	response	response	NN	_	8	obj	_	_
12	to	to	TO	_	13	aux	_	_
13	toxoids	toxoids	NN	_	11	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	drug3	drug0	NN	_	13	conj	_	_
16	or	or	CC	_	15	cc	_	_
17	drug4	drug0	NN	_	15	conj	_	_
18	due	due	IN	_	20	case	_	_
19	to	to	TO	_	20	aux	_	_
20	inhibition	inhibition	NN	_	8	ppmod	_	_
21	of	of	IN	_	23	case	_	_
22	antibody	antibody	NN	_	23	com	_	_
23	response	response	NN	_	20	ppmod	_	_
24	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	may	may	MD	_	4	modal	_	_
3	also	also	RB	_	4	adv	_	_
4	potentiate	potentiate	VB	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	replication	replication	NN	_	4	obj	_	_
7	of	of	IN	_	9	case	_	_
8	some	some	DT	_	9	det	_	_
9	organisms	organism	NNS	_	6	ppmod	_	_
10	contained	contain	VBN	_	9	acl	_	_
11	in	in	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	4	p	_	_

1	Routine	routine	JJ	_	2	attr	_	_
2	administration	administration	NN	_	9	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	or	or	CC	_	4	cc	_	_
6	toxoids	toxoids	NN	_	4	conj	_	_
7	should	should	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	deferred	defer	VBN	_	0	root	_	_
10	until	until	IN	_	14	mark	_	_
11	drug2	drug0	NN	_	12	com	_	_
12	therapy	therapy	NN	_	14	dep	_	_
13	is	be	VBZ	_	14	aux	_	_
14	discontinued	discontinue	VBN	_	9	comp	_	_
15	if	if	IN	_	16	mark	_	_
16	possible	possible	JJ	_	14	comp	_	_
17	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Coadministration	coadministration	NN	_	14	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	,	,	,	_	5	p	_	_
7	a	a	DT	_	9	det	_	_
8	P-glycoprotein	p-glycoprotein	NN	_	9	com	_	_
9	substrate	substrate	NN	_	5	appo	_	_
10	,	,	,	_	5	p	_	_
11	with	with	IN	_	13	case	_	_
12	oral	oral	JJ	_	13	attr	_	_
13	drug3	drug0	NN	_	3	ppmod	_	_
14	resulted	result	VBD	_	1	acl	_	_
15	in	in	IN	_	17	case	_	_
16	a	a	DT	_	17	det	_	_
17	reduction	reduction	NN	_	14	ppmod	_	_
18	in	in	IN	_	19	case	_	_
19	clearance	clearance	NN	_	17	ppmod	_	_
20	and	and	CC	_	17	cc	_	_
21	an	an	DT	_	22	det	_	_
22	increase	increase	NN	_	17	conj	_	_
23	in	in	IN	_	25	case	_	_
24	drug4	drug0	NN	_	25	com	_	_
25	Cmax	cmax	NN	_	22	ppmod	_	_
26	and	and	CC	_	25	cc	_	_
27	AUC	auc	NN	_	28	com	_	_
28	values	value	NNS	_	25	conj	_	_
29	.	.	.	_	1	p	_	_

1	Therefore	therefore	RB	_	13	adv	_	_
2	,	,	,	_	13	p	_	_
3	if	if	IN	_	6	mark	_	_
4	drug1	drug0	NN	_	6	dep	_	_
5	is	be	VBZ	_	6	aux	_	_
6	administered	administer	VBN	_	13	advcl	_	_
7	with	with	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	,	,	,	_	13	p	_	_
10	the	the	DT	_	11	det	_	_
11	clinician	clinician	NN	_	13	dep	_	_
12	should	should	MD	_	13	modal	_	_
13	be	be	VB	_	0	root	_	_
14	alert	alert	JJ	_	13	dep	_	_
15	to	to	TO	_	17	aux	_	_
16	the	the	DT	_	17	det	_	_
17	possibility	possibility	NN	_	14	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	increases	increase	NNS	_	17	ppmod	_	_
20	in	in	IN	_	22	case	_	_
21	drug3	drug0	NN	_	22	com	_	_
22	levels	level	NNS	_	19	ppmod	_	_
23	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	Inhibitors	inhibitor	NNS	_	3	com	_	_
3	Felodipine	felodipine	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	metabolized	metabolize	VBN	_	0	root	_	_
6	by	by	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	.	.	.	_	5	p	_	_

1	Co-administration	co-administration	NN	_	22	dep	_	_
2	of	of	IN	_	4	case	_	_
3	CYP3A4	cyp0a0	JJ	_	4	attr	_	_
4	inhibitors	inhibitor	NNS	_	1	ppmod	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	eg	eg	NN	_	4	prn	_	_
7	,	,	,	_	6	p	_	_
8	drug1	drug0	NN	_	6	appo	_	_
9	,	,	,	_	6	p	_	_
10	drug2	drug0	NN	_	6	appo	_	_
11	,	,	,	_	6	p	_	_
12	drug3	drug0	NN	_	6	appo	_	_
13	,	,	,	_	6	p	_	_
14	grapefruit	grapefruit	NN	_	15	com	_	_
15	juice	juice	NN	_	6	appo	_	_
16	,	,	,	_	6	p	_	_
17	drug4	drug0	NN	_	6	appo	_	_
18	)	-rrb-	-RRB-	_	6	p	_	_
19	with	with	IN	_	20	case	_	_
20	drug5	drug0	NN	_	1	ppmod	_	_
21	may	may	MD	_	22	modal	_	_
22	lead	lead	VB	_	0	root	_	_
23	to	to	TO	_	26	aux	_	_
24	several-	several-	JJ	_	26	attr	_	_
25	fold	fold	NN	_	26	com	_	_
26	increases	increase	NNS	_	22	ppmod	_	_
27	in	in	IN	_	30	case	_	_
28	the	the	DT	_	30	det	_	_
29	plasma	plasma	NN	_	30	com	_	_
30	levels	level	NNS	_	22	ppmod	_	_
31	of	of	IN	_	32	case	_	_
32	drug6	drug0	NN	_	30	ppmod	_	_
33	,	,	,	_	22	p	_	_
34	either	either	CC	_	35	cc	_	_
35	due	due	JJ	_	22	dep	_	_
36	to	to	TO	_	38	aux	_	_
37	an	an	DT	_	38	det	_	_
38	increase	increase	NN	_	35	ppmod	_	_
39	in	in	IN	_	40	case	_	_
40	bioavailability	bioavailability	NN	_	38	ppmod	_	_
41	or	or	CC	_	35	cc	_	_
42	due	due	JJ	_	35	conj	_	_
43	to	to	TO	_	45	aux	_	_
44	a	a	DT	_	45	det	_	_
45	decrease	decrease	NN	_	42	ppmod	_	_
46	in	in	IN	_	47	case	_	_
47	metabolism	metabolism	NN	_	45	ppmod	_	_
48	.	.	.	_	22	p	_	_

1	These	these	DT	_	2	det	_	_
2	increases	increase	NNS	_	6	dep	_	_
3	in	in	IN	_	4	case	_	_
4	concentration	concentration	NN	_	2	ppmod	_	_
5	may	may	MD	_	6	modal	_	_
6	lead	lead	VB	_	0	root	_	_
7	to	to	TO	_	9	aux	_	_
8	increased	increase	VBN	_	9	attr	_	_
9	effects	effect	NNS	_	6	ppmod	_	_
10	,	,	,	_	14	p	_	_
11	(	-lrb-	-LRB-	_	14	p	_	_
12	lower	low	JJR	_	14	attr	_	_
13	blood	blood	NN	_	14	com	_	_
14	pressure	pressure	NN	_	9	prn	_	_
15	and	and	CC	_	14	cc	_	_
16	increased	increase	VBN	_	18	attr	_	_
17	heart	heart	NN	_	18	com	_	_
18	rate	rate	NN	_	14	conj	_	_
19	)	-rrb-	-RRB-	_	14	p	_	_
20	.	.	.	_	6	p	_	_

1	These	these	DT	_	2	det	_	_
2	effects	effect	NNS	_	5	dep	_	_
3	have	have	VBP	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	observed	observe	VBN	_	0	root	_	_
6	with	with	IN	_	7	case	_	_
7	co-administration	co-administration	NN	_	5	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	(	-lrb-	-LRB-	_	14	p	_	_
11	a	a	DT	_	14	det	_	_
12	potent	potent	JJ	_	14	attr	_	_
13	drug2	drug0	NN	_	14	com	_	_
14	inhibitor	inhibitor	NN	_	9	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	.	.	.	_	5	p	_	_

1	Caution	caution	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	used	use	VBN	_	0	root	_	_
5	when	when	WRB	_	9	adv	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	inhibitors	inhibitor	NNS	_	9	dep	_	_
8	are	be	VBP	_	9	aux	_	_
9	co-administered	co-administered	VBN	_	4	comp	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	4	p	_	_

1	A	a	DT	_	3	det	_	_
2	conservative	conservative	JJ	_	3	attr	_	_
3	approach	approach	NN	_	9	dep	_	_
4	to	to	TO	_	6	aux	_	_
5	dosing	dosing	NN	_	6	com	_	_
6	drug1	drug0	NN	_	3	ppmod	_	_
7	should	should	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	taken	take	VBN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	The	the	DT	_	4	det	_	_
2	following	following	JJ	_	4	attr	_	_
3	specific	specific	JJ	_	4	attr	_	_
4	interactions	interaction	NNS	_	7	dep	_	_
5	have	have	VBP	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	reported	report	VBN	_	20	advcl	_	_
8	:	:	:	_	20	p	_	_
9	Itraconazole	itraconazole	NN	_	10	com	_	_
10	Co-administration	co-administration	NN	_	20	dep	_	_
11	of	of	IN	_	15	case	_	_
12	another	another	DT	_	15	det	_	_
13	extended	extend	VBN	_	15	attr	_	_
14	release	release	NN	_	15	com	_	_
15	formulation	formulation	NN	_	10	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	drug1	drug0	NN	_	15	ppmod	_	_
18	with	with	IN	_	19	case	_	_
19	drug2	drug0	NN	_	10	ppmod	_	_
20	resulted	result	VBD	_	0	root	_	_
21	in	in	IN	_	24	case	_	_
22	approximately	approximately	RB	_	23	adv	_	_
23	8-fold	0-fold	JJ	_	24	attr	_	_
24	increase	increase	NN	_	20	ppmod	_	_
25	in	in	IN	_	27	case	_	_
26	the	the	DT	_	27	det	_	_
27	AUC	auc	NN	_	24	ppmod	_	_
28	,	,	,	_	24	p	_	_
29	more	more	JJR	_	31	attr	_	_
30	than	than	IN	_	29	com	_	_
31	6-	0-	CD	_	32	num	_	_
32	fold	fold	JJ	_	33	attr	_	_
33	increase	increase	NN	_	24	conj	_	_
34	in	in	IN	_	36	case	_	_
35	the	the	DT	_	36	det	_	_
36	Cmax	cmax	NN	_	33	ppmod	_	_
37	,	,	,	_	33	p	_	_
38	and	and	CC	_	33	cc	_	_
39	2-fold	0-fold	JJ	_	40	attr	_	_
40	prolongation	prolongation	NN	_	24	conj	_	_
41	in	in	IN	_	44	case	_	_
42	the	the	DT	_	44	det	_	_
43	half-	half-	JJ	_	44	attr	_	_
44	life	life	NN	_	40	ppmod	_	_
45	of	of	IN	_	46	case	_	_
46	drug3	drug0	NN	_	44	ppmod	_	_
47	.	.	.	_	20	p	_	_

1	Erythromycin	erythromycin	NN	_	2	com	_	_
2	Co-administration	co-administration	NN	_	10	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	drug2	drug0	NN	_	4	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	with	with	IN	_	9	case	_	_
9	drug3	drug0	NN	_	2	ppmod	_	_
10	resulted	result	VBD	_	0	root	_	_
11	in	in	IN	_	15	case	_	_
12	approximately	approximately	RB	_	13	adv	_	_
13	2.5-	0-	CD	_	14	num	_	_
14	fold	fold	JJ	_	15	attr	_	_
15	increase	increase	NN	_	10	ppmod	_	_
16	in	in	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	AUC	auc	NN	_	15	ppmod	_	_
19	and	and	CC	_	18	cc	_	_
20	Cmax	cmax	NN	_	18	conj	_	_
21	,	,	,	_	15	p	_	_
22	and	and	CC	_	15	cc	_	_
23	about	about	RB	_	24	adv	_	_
24	2-	0-	CD	_	25	num	_	_
25	fold	fold	NN	_	26	com	_	_
26	prolongation	prolongation	NN	_	15	conj	_	_
27	in	in	IN	_	30	case	_	_
28	the	the	DT	_	30	det	_	_
29	half-	half-	JJ	_	30	attr	_	_
30	life	life	NN	_	26	ppmod	_	_
31	of	of	IN	_	32	case	_	_
32	drug4	drug0	NN	_	30	ppmod	_	_
33	.	.	.	_	10	p	_	_

1	Grapefruit	grapefruit	NN	_	3	com	_	_
2	juice	juice	NN	_	3	com	_	_
3	Co-administration	co-administration	NN	_	9	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	with	with	IN	_	8	case	_	_
7	grapefruit	grapefruit	NN	_	8	com	_	_
8	juice	juice	NN	_	3	ppmod	_	_
9	resulted	result	VBD	_	0	root	_	_
10	in	in	IN	_	14	case	_	_
11	more	more	JJR	_	13	adv	_	_
12	than	than	IN	_	13	case	_	_
13	2-fold	0-fold	JJ	_	14	attr	_	_
14	increase	increase	NN	_	9	ppmod	_	_
15	in	in	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	AUC	auc	NN	_	14	ppmod	_	_
18	and	and	CC	_	17	cc	_	_
19	Cmax	cmax	NN	_	17	conj	_	_
20	,	,	,	_	14	p	_	_
21	but	but	CC	_	14	cc	_	_
22	no	no	DT	_	23	det	_	_
23	prolongation	prolongation	NN	_	14	conj	_	_
24	in	in	IN	_	27	case	_	_
25	the	the	DT	_	27	det	_	_
26	half-	half-	JJ	_	27	attr	_	_
27	life	life	NN	_	23	ppmod	_	_
28	of	of	IN	_	29	case	_	_
29	drug2	drug0	NN	_	27	ppmod	_	_
30	.	.	.	_	9	p	_	_

1	Cimetidine	cimetidine	NN	_	2	com	_	_
2	Co-administration	co-administration	NN	_	13	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	with	with	IN	_	6	case	_	_
6	drug2	drug0	NN	_	2	ppmod	_	_
7	(	-lrb-	-LRB-	_	11	p	_	_
8	a	a	DT	_	11	det	_	_
9	non-specific	non-specific	JJ	_	11	attr	_	_
10	CYP-450	cyp-0	NN	_	11	com	_	_
11	inhibitor	inhibitor	NN	_	6	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	resulted	result	VBD	_	0	root	_	_
14	in	in	IN	_	16	case	_	_
15	an	an	DT	_	16	det	_	_
16	increase	increase	NN	_	13	ppmod	_	_
17	of	of	IN	_	19	case	_	_
18	approximately	approximately	RB	_	19	adv	_	_
19	50	0	CD	_	16	ppmod	_	_
20	%	%	NN	_	19	meta	_	_
21	in	in	IN	_	23	case	_	_
22	the	the	DT	_	23	det	_	_
23	AUC	auc	NN	_	16	ppmod	_	_
24	and	and	CC	_	23	cc	_	_
25	the	the	DT	_	26	det	_	_
26	Cmax	cmax	NN	_	23	conj	_	_
27	,	,	,	_	26	p	_	_
28	of	of	IN	_	29	case	_	_
29	drug3	drug0	NN	_	26	ppmod	_	_
30	.	.	.	_	13	p	_	_

1	Beta-Blocking	beta-blocking	JJ	_	2	attr	_	_
2	Agents	agent	NNS	_	12	dep	_	_
3	A	a	DT	_	5	det	_	_
4	pharmacokinetic	pharmacokinetic	JJ	_	5	attr	_	_
5	study	study	NN	_	2	appo	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	in	in	IN	_	9	case	_	_
9	conjunction	conjunction	NN	_	5	ppmod	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	demonstrated	demonstrate	VBD	_	0	root	_	_
13	no	no	DT	_	15	det	_	_
14	significant	significant	JJ	_	15	attr	_	_
15	effects	effect	NNS	_	12	obj	_	_
16	on	on	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	pharmacokinetics	pharmacokinetics	NNS	_	15	ppmod	_	_
19	of	of	IN	_	20	case	_	_
20	drug3	drug0	NN	_	18	ppmod	_	_
21	.	.	.	_	12	p	_	_

1	The	the	DT	_	2	det	_	_
2	AUC	auc	NN	_	11	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	Cmax	cmax	NN	_	2	conj	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	2	ppmod	_	_
7	,	,	,	_	11	p	_	_
8	however	however	RB	_	11	adv	_	_
9	,	,	,	_	11	p	_	_
10	were	be	VBD	_	11	aux	_	_
11	increased	increase	VBN	_	0	root	_	_
12	approximately	approximately	RB	_	13	adv	_	_
13	31	0	CD	_	11	obj	_	_
14	and	and	CC	_	13	cc	_	_
15	38	0	CD	_	13	conj	_	_
16	%	%	NN	_	13	meta	_	_
17	,	,	,	_	11	p	_	_
18	respectively	respectively	RB	_	11	adv	_	_
19	.	.	.	_	11	p	_	_

1	In	in	IN	_	4	case	_	_
2	controlled	controlled	JJ	_	4	attr	_	_
3	clinical	clinical	JJ	_	4	attr	_	_
4	trials	trial	NNS	_	13	ppmod	_	_
5	,	,	,	_	13	p	_	_
6	however	however	RB	_	13	adv	_	_
7	,	,	,	_	13	p	_	_
8	drug1	drug0	NN	_	13	dep	_	_
9	including	include	VBG	_	10	adv	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	were	be	VBD	_	13	aux	_	_
12	concurrently	concurrently	RB	_	13	adv	_	_
13	administered	administer	VBN	_	0	root	_	_
14	with	with	IN	_	15	case	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	and	and	CC	_	13	cc	_	_
17	were	be	VBD	_	19	aux	_	_
18	well	well	RB	_	19	adv	_	_
19	tolerated	tolerate	VBN	_	13	conj	_	_
20	.	.	.	_	13	p	_	_

1	Digoxin	digoxin	NN	_	19	dep	_	_
2	When	when	WRB	_	3	adv	_	_
3	given	give	VBN	_	1	relcl	_	_
4	concomitantly	concomitantly	RB	_	3	adv	_	_
5	with	with	IN	_	6	case	_	_
6	drug1	drug0	NN	_	3	ppmod	_	_
7	the	the	DT	_	8	det	_	_
8	pharmacokinetics	pharmacokinetics	NNS	_	1	appo	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	in	in	IN	_	12	case	_	_
12	patients	patient	NNS	_	1	ppmod	_	_
13	with	with	IN	_	15	case	_	_
14	heart	heart	NN	_	15	com	_	_
15	failure	failure	NN	_	12	ppmod	_	_
16	were	be	VBD	_	19	aux	_	_
17	not	not	RB	_	19	neg	_	_
18	significantly	significantly	RB	_	19	adv	_	_
19	altered	alter	VBN	_	0	root	_	_
20	.	.	.	_	19	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	6	case	_	_
4	a	a	DT	_	6	det	_	_
5	pharmacokinetic	pharmacokinetic	JJ	_	6	attr	_	_
6	study	study	NN	_	13	ppmod	_	_
7	,	,	,	_	13	p	_	_
8	maximum	maximum	JJ	_	10	attr	_	_
9	plasma	plasma	NN	_	10	com	_	_
10	concentrations	concentration	NNS	_	13	dep	_	_
11	of	of	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	were	be	VBD	_	1	acl	_	_
14	considerably	considerably	RB	_	15	adv	_	_
15	lower	low	JJR	_	13	dep	_	_
16	in	in	IN	_	18	case	_	_
17	epileptic	epileptic	JJ	_	18	attr	_	_
18	patients	patient	NNS	_	15	ppmod	_	_
19	on	on	IN	_	22	case	_	_
20	long-term	long-term	JJ	_	22	attr	_	_
21	drug3	drug0	NN	_	22	com	_	_
22	therapy	therapy	NN	_	18	ppmod	_	_
23	(	-lrb-	-LRB-	_	24	p	_	_
24	eg	eg	NN	_	22	prn	_	_
25	,	,	,	_	24	p	_	_
26	drug4	drug0	NN	_	24	conj	_	_
27	,	,	,	_	26	p	_	_
28	drug5	drug0	NN	_	24	conj	_	_
29	,	,	,	_	28	p	_	_
30	or	or	CC	_	28	cc	_	_
31	drug6	drug0	NN	_	24	conj	_	_
32	)	-rrb-	-RRB-	_	24	p	_	_
33	than	than	IN	_	36	case	_	_
34	in	in	IN	_	36	case	_	_
35	healthy	healthy	JJ	_	36	attr	_	_
36	volunteers	volunteer	NNS	_	15	ppmod	_	_
37	.	.	.	_	1	p	_	_

1	In	in	IN	_	3	case	_	_
2	such	such	JJ	_	3	attr	_	_
3	patients	patient	NNS	_	16	ppmod	_	_
4	,	,	,	_	16	p	_	_
5	the	the	DT	_	7	det	_	_
6	mean	mean	JJ	_	7	attr	_	_
7	area	area	NN	_	16	dep	_	_
8	under	under	IN	_	13	case	_	_
9	the	the	DT	_	13	det	_	_
10	drug1	drug0	NN	_	13	com	_	_
11	plasma	plasma	NN	_	13	com	_	_
12	concentration-time	concentration-time	NN	_	13	com	_	_
13	curve	curve	NN	_	7	ppmod	_	_
14	was	be	VBD	_	16	aux	_	_
15	also	also	RB	_	16	adv	_	_
16	reduced	reduce	VBN	_	0	root	_	_
17	to	to	TO	_	19	aux	_	_
18	approximately	approximately	RB	_	19	adv	_	_
19	6	0	CD	_	16	ppmod	_	_
20	%	%	NN	_	19	meta	_	_
21	of	of	IN	_	22	case	_	_
22	that	that	DT	_	19	ppmod	_	_
23	observed	observe	VBN	_	22	acl	_	_
24	in	in	IN	_	26	case	_	_
25	healthy	healthy	JJ	_	26	attr	_	_
26	volunteers	volunteer	NNS	_	23	ppmod	_	_
27	.	.	.	_	16	p	_	_

1	Since	since	IN	_	8	mark	_	_
2	a	a	DT	_	5	det	_	_
3	clinically	clinically	RB	_	4	adv	_	_
4	significant	significant	JJ	_	5	attr	_	_
5	interaction	interaction	NN	_	8	dep	_	_
6	may	may	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	anticipated	anticipate	VBN	_	15	advcl	_	_
9	,	,	,	_	15	p	_	_
10	alternative	alternative	JJ	_	12	attr	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	therapy	therapy	NN	_	15	dep	_	_
13	should	should	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	considered	consider	VBN	_	0	root	_	_
16	in	in	IN	_	18	case	_	_
17	these	these	DT	_	18	det	_	_
18	patients	patient	NNS	_	15	ppmod	_	_
19	.	.	.	_	15	p	_	_

1	Tacrolimus	tacrolimus	NN	_	2	com	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	increase	increase	VB	_	0	root	_	_
5	the	the	DT	_	7	det	_	_
6	blood	blood	NN	_	7	com	_	_
7	concentration	concentration	NN	_	4	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	.	.	.	_	4	p	_	_

1	When	when	WRB	_	2	adv	_	_
2	given	give	VBN	_	13	advcl	_	_
3	concomitantly	concomitantly	RB	_	2	adv	_	_
4	with	with	IN	_	5	case	_	_
5	drug1	drug0	NN	_	2	ppmod	_	_
6	,	,	,	_	13	p	_	_
7	the	the	DT	_	10	det	_	_
8	drug2	drug0	NN	_	10	com	_	_
9	blood	blood	NN	_	10	com	_	_
10	concentration	concentration	NN	_	13	dep	_	_
11	should	should	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	followed	followed	VBN	_	0	root	_	_
14	and	and	CC	_	13	cc	_	_
15	the	the	DT	_	17	det	_	_
16	tacrolimus	tacrolimus	NN	_	17	com	_	_
17	dose	dose	NN	_	19	dep	_	_
18	may	may	MD	_	19	modal	_	_
19	need	need	VBP	_	13	conj	_	_
20	to	to	TO	_	22	aux	_	_
21	be	be	VB	_	22	aux	_	_
22	adjusted	adjust	VBN	_	19	comp	_	_
23	.	.	.	_	13	p	_	_

1	Other	other	JJ	_	3	attr	_	_
2	Concomitant	concomitant	JJ	_	3	attr	_	_
3	Therapy	therapy	NN	_	8	dep	_	_
4	In	in	IN	_	6	case	_	_
5	healthy	healthy	JJ	_	6	attr	_	_
6	subjects	subject	NNS	_	3	ppmod	_	_
7	there	there	RB	_	8	adv	_	_
8	were	be	VBD	_	0	root	_	_
9	no	no	DT	_	12	det	_	_
10	clinically	clinically	RB	_	11	adv	_	_
11	significant	significant	JJ	_	12	attr	_	_
12	interactions	interaction	NNS	_	8	obj	_	_
13	when	when	WRB	_	16	adv	_	_
14	drug1	drug0	NN	_	16	dep	_	_
15	was	be	VBD	_	16	aux	_	_
16	given	give	VBN	_	8	comp	_	_
17	concomitantly	concomitantly	RB	_	16	adv	_	_
18	with	with	IN	_	19	case	_	_
19	drug2	drug0	NN	_	16	ppmod	_	_
20	or	or	CC	_	19	cc	_	_
21	drug3	drug0	NN	_	19	conj	_	_
22	.	.	.	_	8	p	_	_

1	Interaction	interaction	NN	_	4	dep	_	_
2	with	with	IN	_	3	case	_	_
3	Food	food	NN	_	1	ppmod	_	_
4	See	see	VB	_	0	root	_	_
5	CLINICAL	clinical	JJ	_	6	attr	_	_
6	PHARMACOLOGY	pharmacology	NN	_	4	obj	_	_
7	,	,	,	_	6	p	_	_
8	Pharmacokinetics	pharmacokinetics	NNS	_	6	conj	_	_
9	and	and	CC	_	8	cc	_	_
10	Metabolism	metabolism	NN	_	6	conj	_	_
11	.	.	.	_	4	p	_	_

1	DRUG/LABORATORY	drug/laboratory	NN	_	2	dep	_	_
2	TEST	test	VB	_	0	root	_	_
3	INTERACTIONS	interaction	NNS	_	2	obj	_	_
4	1	0	CD	_	3	num	_	_
5	.	.	.	_	2	p	_	_

1	Accelerated	accelerate	VBN	_	3	attr	_	_
2	prothrombin	prothrombin	NN	_	3	com	_	_
3	time	time	NN	_	0	root	_	_
4	,	,	,	_	3	p	_	_
5	partial	partial	JJ	_	7	attr	_	_
6	thromboplastin	thromboplastin	NN	_	7	com	_	_
7	time	time	NN	_	3	conj	_	_
8	,	,	,	_	7	p	_	_
9	and	and	CC	_	7	cc	_	_
10	platelet	platelet	NN	_	12	com	_	_
11	aggregation	aggregation	NN	_	12	com	_	_
12	time	time	NN	_	3	conj	_	_
13	;	;	:	_	12	p	_	_

1	increased	increase	VBN	_	3	attr	_	_
2	platelet	platelet	NN	_	3	com	_	_
3	count	count	NN	_	0	root	_	_
4	;	;	:	_	3	p	_	_

1	increased	increase	VBN	_	2	attr	_	_
2	factors	factor	NNS	_	0	root	_	_
3	II	ii	CD	_	2	num	_	_
4	,	,	,	_	2	p	_	_
5	VII	vii	NN	_	6	com	_	_
6	antigen	antigen	NN	_	2	appo	_	_
7	,	,	,	_	6	p	_	_
8	VIII	viii	NN	_	9	com	_	_
9	antigen	antigen	NN	_	6	conj	_	_
10	,	,	,	_	9	p	_	_
11	VIII	viii	NN	_	13	com	_	_
12	coagulant	coagulant	NN	_	13	com	_	_
13	activity	activity	NN	_	6	conj	_	_
14	,	,	,	_	13	p	_	_
15	IX	ix	NN	_	6	conj	_	_
16	,	,	,	_	15	p	_	_
17	X	x	NN	_	6	conj	_	_
18	,	,	,	_	17	p	_	_
19	XII	xii	NN	_	6	conj	_	_
20	,	,	,	_	19	p	_	_
21	VII-X	vii-x	NN	_	22	com	_	_
22	complex	complex	NN	_	6	conj	_	_
23	,	,	,	_	22	p	_	_
24	II-VII-X	ii-vii-x	NN	_	25	com	_	_
25	complex	complex	NN	_	6	conj	_	_
26	,	,	,	_	25	p	_	_
27	and	and	CC	_	25	cc	_	_
28	beta-thromboglobulin	beta-thromboglobulin	NN	_	6	conj	_	_
29	;	;	:	_	2	p	_	_

1	decreased	decrease	VBN	_	2	attr	_	_
2	levels	level	NNS	_	9	dep	_	_
3	of	of	IN	_	5	case	_	_
4	anti-factor	anti-factor	NN	_	5	com	_	_
5	Xa	xa	NN	_	2	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug1	drug0	NN	_	5	conj	_	_
8	,	,	,	_	2	p	_	_
9	decreased	decrease	VBD	_	0	root	_	_
10	drug2	drug0	NN	_	11	com	_	_
11	activity	activity	NN	_	9	obj	_	_
12	;	;	:	_	9	p	_	_

1	increased	increase	VBN	_	2	attr	_	_
2	levels	level	NNS	_	0	root	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	7	com	_	_
7	activity	activity	NN	_	4	conj	_	_
8	;	;	:	_	2	p	_	_

1	increased	increase	VBN	_	3	attr	_	_
2	plasminogen	plasminogen	NN	_	3	com	_	_
3	antigen	antigen	NN	_	0	root	_	_
4	and	and	CC	_	3	cc	_	_
5	activity	activity	NN	_	3	conj	_	_
6	.	.	.	_	3	p	_	_

1	2	0	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	Increased	increase	VBN	_	0	root	_	_
2	thyroid-binding	thyroid-binding	JJ	_	3	attr	_	_
3	globulin	globulin	NN	_	7	attr	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	TBG	tbg	NN	_	3	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	levels	level	NNS	_	1	obj	_	_
8	leading	lead	VBG	_	7	acl	_	_
9	to	to	TO	_	15	aux	_	_
10	increased	increase	VBN	_	15	attr	_	_
11	circulating	circulating	JJ	_	15	attr	_	_
12	total	total	JJ	_	15	attr	_	_
13	thyroid	thyroid	NN	_	15	com	_	_
14	hormone	hormone	NN	_	15	com	_	_
15	levels	level	NNS	_	8	ppmod	_	_
16	as	as	IN	_	17	mark	_	_
17	measured	measure	VBN	_	1	comp	_	_
18	by	by	IN	_	20	case	_	_
19	protein-bound	protein-bound	JJ	_	20	attr	_	_
20	drug1	drug0	NN	_	17	ppmod	_	_
21	(	-lrb-	-LRB-	_	22	p	_	_
22	PBI	pbi	NN	_	20	prn	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	,	,	,	_	20	p	_	_
25	T4	t0	NN	_	26	com	_	_
26	levels	level	NNS	_	20	conj	_	_
27	(	-lrb-	-LRB-	_	29	p	_	_
28	by	by	IN	_	29	case	_	_
29	column	column	NN	_	26	prn	_	_
30	or	or	CC	_	29	cc	_	_
31	by	by	IN	_	32	case	_	_
32	radioimmunoassay	radioimmunoassay	NN	_	29	conj	_	_
33	)	-rrb-	-RRB-	_	29	p	_	_
34	or	or	CC	_	26	cc	_	_
35	T3	t0	NN	_	36	com	_	_
36	levels	level	NNS	_	20	conj	_	_
37	by	by	IN	_	38	case	_	_
38	radioimmunoassay	radioimmunoassay	NN	_	17	ppmod	_	_
39	.	.	.	_	1	p	_	_

1	T3	t0	NN	_	3	com	_	_
2	resin	resin	NN	_	3	com	_	_
3	uptake	uptake	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	decreased	decrease	VBN	_	0	root	_	_
6	,	,	,	_	5	p	_	_
7	reflecting	reflect	VBG	_	5	comp	_	_
8	the	the	DT	_	10	det	_	_
9	elevated	elevated	JJ	_	10	attr	_	_
10	TBG	tbg	NN	_	7	obj	_	_
11	.	.	.	_	5	p	_	_

1	Free	free	JJ	_	2	attr	_	_
2	T4	t0	NN	_	6	attr	_	_
3	and	and	CC	_	2	cc	_	_
4	free	free	JJ	_	5	attr	_	_
5	T3	t0	NN	_	2	conj	_	_
6	concentrations	concentration	NNS	_	7	dep	_	_
7	are	be	VBP	_	0	root	_	_
8	unaltered	unaltered	JJ	_	7	dep	_	_
9	.	.	.	_	7	p	_	_

1	Patients	patient	NNS	_	7	dep	_	_
2	on	on	IN	_	5	case	_	_
3	thyroid	thyroid	NN	_	5	com	_	_
4	replacement	replacement	NN	_	5	com	_	_
5	therapy	therapy	NN	_	1	ppmod	_	_
6	may	may	MD	_	7	modal	_	_
7	require	require	VBP	_	0	root	_	_
8	higher	high	JJR	_	9	attr	_	_
9	doses	dose	NNS	_	7	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	7	p	_	_

1	3	0	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	Other	other	JJ	_	3	attr	_	_
2	binding	binding	NN	_	3	com	_	_
3	proteins	protein	NNS	_	6	dep	_	_
4	may	may	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	elevated	elevate	VBN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	serum	serum	NN	_	6	ppmod	_	_
9	,	,	,	_	6	p	_	_
10	(	-lrb-	-LRB-	_	15	p	_	_
11	i.e.	i.e.	FW	_	15	ppmod	_	_
12	,	,	,	_	15	p	_	_
13	corticosteroid	corticosteroid	NN	_	15	com	_	_
14	binding	binding	NN	_	15	com	_	_
15	globulin	globulin	NN	_	28	prn	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	CBG	cbg	NN	_	15	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	,	,	,	_	15	p	_	_
20	sex	sex	NN	_	23	com	_	_
21	hormone	hormone	NN	_	23	com	_	_
22	binding	binding	NN	_	23	com	_	_
23	globulin	globulin	NN	_	15	appo	_	_
24	(	-lrb-	-LRB-	_	25	p	_	_
25	SHBG	shbg	NN	_	23	prn	_	_
26	)	-rrb-	-RRB-	_	25	p	_	_
27	)	-rrb-	-RRB-	_	15	p	_	_
28	leading	lead	VBG	_	6	comp	_	_
29	to	to	TO	_	33	aux	_	_
30	increased	increase	VBN	_	33	attr	_	_
31	total	total	JJ	_	33	attr	_	_
32	circulating	circulating	JJ	_	33	attr	_	_
33	drug1	drug0	NN	_	28	ppmod	_	_
34	and	and	CC	_	33	cc	_	_
35	drug2	drug0	NN	_	33	conj	_	_
36	,	,	,	_	28	p	_	_
37	respectively	respectively	RB	_	28	adv	_	_
38	.	.	.	_	6	p	_	_

1	Free	free	JJ	_	3	attr	_	_
2	hormone	hormone	NN	_	3	com	_	_
3	concentrations	concentration	NNS	_	6	dep	_	_
4	may	may	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	decreased	decrease	VBN	_	0	root	_	_
7	.	.	.	_	6	p	_	_

1	Other	other	JJ	_	3	attr	_	_
2	plasma	plasma	NN	_	3	com	_	_
3	proteins	protein	NNS	_	6	dep	_	_
4	may	may	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	increased	increase	VBN	_	0	root	_	_
7	(	-lrb-	-LRB-	_	9	p	_	_
8	angiotensinogen/renin	angiotensinogen/renin	NN	_	9	com	_	_
9	substrate	substrate	NN	_	6	prn	_	_
10	,	,	,	_	9	p	_	_
11	alpha-1-antitrypsin	alpha-0-antitrypsin	JJ	_	9	appo	_	_
12	,	,	,	_	9	p	_	_
13	ceruloplasmin	ceruloplasmin	NN	_	9	appo	_	_
14	)	-rrb-	-RRB-	_	9	p	_	_
15	.	.	.	_	6	p	_	_

1	4	0	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	Increased	increase	VBN	_	3	attr	_	_
2	plasma	plasma	NN	_	3	com	_	_
3	HDL	hdl	NN	_	10	dep	_	_
4	and	and	CC	_	3	cc	_	_
5	HDL2	hdl0	NN	_	8	com	_	_
6	cholesterol	cholesterol	NN	_	8	com	_	_
7	subfraction	subfraction	NN	_	8	com	_	_
8	concentrations	concentration	NNS	_	3	conj	_	_
9	,	,	,	_	10	p	_	_
10	reduced	reduce	VBD	_	0	root	_	_
11	LDL	ldl	NN	_	13	com	_	_
12	cholesterol	cholesterol	NN	_	13	com	_	_
13	concentration	concentration	NN	_	10	obj	_	_
14	,	,	,	_	10	p	_	_
15	increased	increase	VBD	_	10	dep	_	_
16	triglyceride	triglyceride	NN	_	17	com	_	_
17	levels	level	NNS	_	15	obj	_	_
18	.	.	.	_	10	p	_	_

1	5	0	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	Impaired	impaired	JJ	_	3	attr	_	_
2	glucose	glucose	NN	_	3	com	_	_
3	tolerance	tolerance	NN	_	0	root	_	_
4	.	.	.	_	3	p	_	_

1	6	0	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	Reduced	reduce	VBN	_	0	root	_	_
2	response	response	NN	_	1	obj	_	_
3	to	to	TO	_	5	aux	_	_
4	metyrapone	metyrapone	NN	_	5	com	_	_
5	test	test	NN	_	2	ppmod	_	_
6	.	.	.	_	1	p	_	_

1	When	when	WRB	_	2	adv	_	_
2	administered	administer	VBN	_	9	advcl	_	_
3	concurrently	concurrently	RB	_	2	adv	_	_
4	,	,	,	_	9	p	_	_
5	the	the	DT	_	7	det	_	_
6	following	following	JJ	_	7	attr	_	_
7	drugs	drug	NNS	_	9	dep	_	_
8	may	may	MD	_	9	modal	_	_
9	interact	interact	VB	_	16	advcl	_	_
10	with	with	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	:	:	:	_	16	p	_	_
13	drug2	drug0	NN	_	16	dep	_	_
14	:	:	:	_	13	p	_	_
15	may	may	MD	_	16	modal	_	_
16	enhance	enhance	VB	_	0	root	_	_
17	the	the	DT	_	18	det	_	_
18	potential	potential	NN	_	16	obj	_	_
19	for	for	IN	_	21	case	_	_
20	renal	renal	JJ	_	21	attr	_	_
21	toxicity	toxicity	NN	_	18	ppmod	_	_
22	,	,	,	_	21	p	_	_
23	bronchospasm	bronchospasm	NN	_	21	conj	_	_
24	and	and	CC	_	23	cc	_	_
25	hypotension	hypotension	NN	_	21	conj	_	_
26	.	.	.	_	16	p	_	_

1	drug1	drug0	NN	_	12	dep	_	_
2	(	-lrb-	-LRB-	_	4	p	_	_
3	e.	e.	FW	_	4	attr	_	_
4	g.	g.	FW	_	1	prn	_	_
5	,	,	,	_	4	p	_	_
6	drug2	drug0	NN	_	4	attr	_	_
7	,	,	,	_	4	p	_	_
8	etc.	etc.	NN	_	4	conj	_	_
9	)	-rrb-	-RRB-	_	4	p	_	_
10	should	should	MD	_	12	modal	_	_
11	be	be	VB	_	12	aux	_	_
12	given	give	VBN	_	0	root	_	_
13	concomitantly	concomitantly	RB	_	12	adv	_	_
14	only	only	RB	_	17	adv	_	_
15	with	with	IN	_	17	case	_	_
16	great	great	JJ	_	17	attr	_	_
17	caution	caution	NN	_	12	ppmod	_	_
18	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	drug3	drug0	NN	_	1	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	:	:	:	_	1	p	_	_
8	may	may	MD	_	9	modal	_	_
9	potentiate	potentiate	VB	_	1	acl	_	_
10	drug4	drug0	NN	_	9	obj	_	_
11	-	-	CC	_	10	cc	_	_
12	induced	induce	VBN	_	13	attr	_	_
13	hypokalemia	hypokalemia	NN	_	10	conj	_	_
14	which	which	WDT	_	16	dep	_	_
15	may	may	MD	_	16	modal	_	_
16	predispose	predispose	VB	_	10	relcl	_	_
17	the	the	DT	_	18	det	_	_
18	patient	patient	NN	_	16	obj	_	_
19	to	to	TO	_	21	aux	_	_
20	cardiac	cardiac	JJ	_	21	attr	_	_
21	dysfunction	dysfunction	NN	_	16	ppmod	_	_
22	.	.	.	_	1	p	_	_

1	Avoid	avoid	VB	_	0	root	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	use	use	NN	_	1	obj	_	_
4	unless	unless	IN	_	5	case	_	_
5	necessary	necessary	JJ	_	3	ppmod	_	_
6	to	to	TO	_	7	aux	_	_
7	control	control	VB	_	3	acl	_	_
8	side	side	JJ	_	9	attr	_	_
9	effects	effect	NNS	_	7	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	1	p	_	_

1	If	if	IN	_	2	mark	_	_
2	used	use	VBN	_	6	advcl	_	_
3	concomitantly	concomitantly	RB	_	2	adv	_	_
4	,	,	,	_	6	p	_	_
5	closely	closely	RB	_	6	adv	_	_
6	monitor	monitor	VB	_	0	root	_	_
7	serum	serum	NN	_	8	com	_	_
8	electrolytes	electrolyte	NNS	_	6	obj	_	_
9	and	and	CC	_	8	cc	_	_
10	cardiac	cardiac	JJ	_	11	attr	_	_
11	function	function	NN	_	8	conj	_	_
12	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	7	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	5	attr	_	_
4	-induced	-induced	JJ	_	5	attr	_	_
5	hypokalemia	hypokalemia	NN	_	1	appo	_	_
6	may	may	MD	_	7	modal	_	_
7	potentiate	potentiate	VB	_	0	root	_	_
8	drug3	drug0	NN	_	9	com	_	_
9	toxicity	toxicity	NN	_	7	obj	_	_
10	.	.	.	_	7	p	_	_

1	Serum	serum	NN	_	3	com	_	_
2	potassium	potassium	NN	_	3	com	_	_
3	levels	level	NNS	_	10	dep	_	_
4	and	and	CC	_	3	cc	_	_
5	cardiac	cardiac	JJ	_	6	attr	_	_
6	function	function	NN	_	3	conj	_	_
7	should	should	MD	_	10	modal	_	_
8	be	be	VB	_	10	aux	_	_
9	closely	closely	RB	_	10	adv	_	_
10	monitored	monitor	VBN	_	0	root	_	_
11	and	and	CC	_	10	cc	_	_
12	any	any	DT	_	13	det	_	_
13	deficit	deficit	NN	_	15	dep	_	_
14	promptly	promptly	RB	_	15	adv	_	_
15	corrected	correct	VBN	_	10	conj	_	_
16	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	while	while	IN	_	11	mark	_	_
4	a	a	DT	_	6	det	_	_
5	synergistic	synergistic	JJ	_	6	attr	_	_
6	relationship	relationship	NN	_	11	dep	_	_
7	with	with	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	has	have	VBZ	_	11	aux	_	_
10	been	be	VBN	_	11	aux	_	_
11	reported	report	VBN	_	16	advcl	_	_
12	,	,	,	_	16	p	_	_
13	concomitant	concomitant	JJ	_	14	attr	_	_
14	use	use	NN	_	16	dep	_	_
15	may	may	MD	_	16	modal	_	_
16	increase	increase	VB	_	1	acl	_	_
17	the	the	DT	_	18	det	_	_
18	toxicity	toxicity	NN	_	16	obj	_	_
19	of	of	IN	_	20	case	_	_
20	drug3	drug0	NN	_	18	ppmod	_	_
21	by	by	IN	_	23	case	_	_
22	possibly	possibly	RB	_	23	adv	_	_
23	increasing	increase	VBG	_	16	ppmod	_	_
24	its	its	PRP$	_	26	poss	_	_
25	cellular	cellular	JJ	_	26	attr	_	_
26	uptake	uptake	NN	_	23	obj	_	_
27	and/or	and/or	CC	_	23	cc	_	_
28	impairing	impair	VBG	_	23	conj	_	_
29	its	its	PRP$	_	31	poss	_	_
30	renal	renal	JJ	_	31	attr	_	_
31	excretion	excretion	NN	_	28	obj	_	_
32	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	(	-lrb-	-LRB-	_	6	p	_	_
3	e.	e.	NNP	_	4	com	_	_
4	g.	g.	NNP	_	6	dep	_	_
5	,	,	,	_	6	p	_	_
6	drug2	drug0	NN	_	1	prn	_	_
7	,	,	,	_	6	p	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	,	,	,	_	8	p	_	_
10	drug4	drug0	NN	_	6	conj	_	_
11	,	,	,	_	10	p	_	_
12	drug5	drug0	NN	_	6	conj	_	_
13	,	,	,	_	12	p	_	_
14	etc.	etc.	NN	_	6	conj	_	_
15	)	-rrb-	-RRB-	_	6	p	_	_
16	:	:	:	_	1	p	_	_
17	in	in	FW	_	18	adv	_	_
18	vitro	vitro	FW	_	21	attr	_	_
19	and	and	CC	_	18	cc	_	_
20	animal	animal	JJ	_	18	conj	_	_
21	studies	study	NNS	_	29	dep	_	_
22	with	with	IN	_	24	case	_	_
23	the	the	DT	_	24	det	_	_
24	combination	combination	NN	_	21	ppmod	_	_
25	of	of	IN	_	26	case	_	_
26	drug6	drug0	NN	_	24	ppmod	_	_
27	and	and	CC	_	26	cc	_	_
28	drug7	drug0	NN	_	26	conj	_	_
29	suggest	suggest	VBP	_	1	acl	_	_
30	that	that	IN	_	33	mark	_	_
31	drug8	drug0	NN	_	33	dep	_	_
32	may	may	MD	_	33	modal	_	_
33	induce	induce	VB	_	29	comp	_	_
34	fungal	fungal	JJ	_	35	attr	_	_
35	resistance	resistance	NN	_	33	obj	_	_
36	to	to	TO	_	37	aux	_	_
37	drug9	drug0	NN	_	35	ppmod	_	_
38	.	.	.	_	1	p	_	_

1	Combination	combination	NN	_	2	com	_	_
2	therapy	therapy	NN	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	administered	administer	VBN	_	0	root	_	_
6	with	with	IN	_	7	case	_	_
7	caution	caution	NN	_	5	ppmod	_	_
8	,	,	,	_	5	p	_	_
9	especially	especially	RB	_	12	adv	_	_
10	in	in	IN	_	12	case	_	_
11	immunocompromised	immunocompromised	JJ	_	12	attr	_	_
12	patients	patient	NNS	_	5	ppmod	_	_
13	.	.	.	_	5	p	_	_

1	Other	other	JJ	_	3	attr	_	_
2	nephrotoxic	nephrotoxic	JJ	_	3	attr	_	_
3	medications	medication	NNS	_	0	root	_	_
4	:	:	:	_	3	p	_	_
5	agents	agent	NNS	_	15	dep	_	_
6	such	such	JJ	_	8	adv	_	_
7	as	as	IN	_	8	case	_	_
8	drug1	drug0	NN	_	5	ppmod	_	_
9	,	,	,	_	8	p	_	_
10	drug2	drug0	NN	_	8	conj	_	_
11	,	,	,	_	10	p	_	_
12	and	and	CC	_	10	cc	_	_
13	drug3	drug0	NN	_	8	conj	_	_
14	may	may	MD	_	15	modal	_	_
15	enhance	enhance	VB	_	3	acl	_	_
16	the	the	DT	_	17	det	_	_
17	potential	potential	NN	_	15	obj	_	_
18	for	for	IN	_	21	case	_	_
19	drug-induced	drug-induced	JJ	_	21	attr	_	_
20	renal	renal	JJ	_	21	attr	_	_
21	toxicity	toxicity	NN	_	17	ppmod	_	_
22	,	,	,	_	15	p	_	_
23	and	and	CC	_	15	cc	_	_
24	should	should	MD	_	26	modal	_	_
25	be	be	VB	_	26	aux	_	_
26	used	use	VBN	_	15	conj	_	_
27	concomitantly	concomitantly	RB	_	26	adv	_	_
28	only	only	RB	_	31	adv	_	_
29	with	with	IN	_	31	case	_	_
30	great	great	JJ	_	31	attr	_	_
31	caution	caution	NN	_	26	ppmod	_	_
32	.	.	.	_	3	p	_	_

1	Intensive	intensive	JJ	_	2	attr	_	_
2	monitoring	monitoring	NN	_	7	dep	_	_
3	of	of	IN	_	5	case	_	_
4	renal	renal	JJ	_	5	attr	_	_
5	function	function	NN	_	2	ppmod	_	_
6	is	be	VBZ	_	7	aux	_	_
7	recommended	recommend	VBN	_	0	root	_	_
8	in	in	IN	_	9	case	_	_
9	patients	patient	NNS	_	7	ppmod	_	_
10	requiring	require	VBG	_	9	acl	_	_
11	any	any	DT	_	12	det	_	_
12	combination	combination	NN	_	10	obj	_	_
13	of	of	IN	_	15	case	_	_
14	nephrotoxic	nephrotoxic	JJ	_	15	attr	_	_
15	medications	medication	NNS	_	12	ppmod	_	_
16	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	5	attr	_	_
4	-induced	-induced	JJ	_	5	attr	_	_
5	hypokalemia	hypokalemia	NN	_	7	dep	_	_
6	may	may	MD	_	7	modal	_	_
7	enhance	enhance	VB	_	1	acl	_	_
8	the	the	DT	_	10	det	_	_
9	curariform	curariform	JJ	_	10	attr	_	_
10	effect	effect	NN	_	7	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	(	-lrb-	-LRB-	_	16	p	_	_
14	e.g.	e.g.	FW	_	16	ppmod	_	_
15	,	,	,	_	16	p	_	_
16	drug4	drug0	NN	_	7	prn	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	.	.	.	_	1	p	_	_

1	Serum	serum	NN	_	3	com	_	_
2	potassium	potassium	NN	_	3	com	_	_
3	levels	level	NNS	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	monitored	monitor	VBN	_	0	root	_	_
7	and	and	CC	_	6	cc	_	_
8	deficiencies	deficiency	NNS	_	9	dep	_	_
9	corrected	correct	VBN	_	6	conj	_	_
10	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	8	dep	_	_
2	:	:	:	_	1	p	_	_
3	acute	acute	JJ	_	5	attr	_	_
4	pulmonary	pulmonary	JJ	_	5	attr	_	_
5	toxicity	toxicity	NN	_	1	appo	_	_
6	has	have	VBZ	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	reported	report	VBN	_	0	root	_	_
9	in	in	IN	_	10	case	_	_
10	patients	patient	NNS	_	8	ppmod	_	_
11	receiving	receive	VBG	_	10	acl	_	_
12	intravenous	intravenous	JJ	_	13	attr	_	_
13	drug2	drug0	NN	_	11	obj	_	_
14	and	and	CC	_	13	cc	_	_
15	drug3	drug0	NN	_	13	conj	_	_
16	.	.	.	_	8	p	_	_

1	Drugs	drug	NNS	_	12	dep	_	_
2	that	that	WDT	_	3	dep	_	_
3	inhibit	inhibit	VBP	_	1	relcl	_	_
4	or	or	CC	_	3	cc	_	_
5	Induce	induce	VBP	_	3	conj	_	_
6	CYP	cyp	NN	_	7	com	_	_
7	2D6	0d0	NN	_	5	obj	_	_
8	and	and	CC	_	7	cc	_	_
9	CYP	cyp	NN	_	10	com	_	_
10	3A4	0a0	NN	_	7	conj	_	_
11	may	may	MD	_	12	modal	_	_
12	affect	affect	VB	_	0	root	_	_
13	the	the	DT	_	14	det	_	_
14	concentration	concentration	NN	_	12	obj	_	_
15	on	on	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	used	use	VBN	_	0	root	_	_
5	with	with	IN	_	6	case	_	_
6	caution	caution	NN	_	4	ppmod	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	4	ppmod	_	_
9	receiving	receive	VBG	_	8	acl	_	_
10	other	other	JJ	_	12	attr	_	_
11	local	local	JJ	_	12	attr	_	_
12	drug2	drug0	NNS	_	9	obj	_	_
13	or	or	CC	_	12	cc	_	_
14	agents	agent	NNS	_	12	conj	_	_
15	structurally	structurally	RB	_	16	adv	_	_
16	related	related	JJ	_	12	attr	_	_
17	to	to	TO	_	20	aux	_	_
18	amide-type	amide-type	JJ	_	20	attr	_	_
19	local	local	JJ	_	20	attr	_	_
20	anesthetics	anesthetic	NNS	_	16	ppmod	_	_
21	since	since	IN	_	29	mark	_	_
22	the	the	DT	_	24	det	_	_
23	toxic	toxic	JJ	_	24	attr	_	_
24	effects	effect	NNS	_	29	dep	_	_
25	of	of	IN	_	27	case	_	_
26	these	these	DT	_	27	det	_	_
27	drugs	drug	NNS	_	24	ppmod	_	_
28	could	could	MD	_	29	modal	_	_
29	be	be	VB	_	4	comp	_	_
30	additive	additive	JJ	_	29	dep	_	_
31	.	.	.	_	4	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	studies	study	NNS	_	4	dep	_	_
4	indicate	indicate	VBP	_	0	root	_	_
5	CYP3A4	cyp0a0	NN	_	6	com	_	_
6	isoform	isoform	NN	_	10	dep	_	_
7	and	and	CC	_	6	cc	_	_
8	CYP1A2	cyp0a0	NN	_	9	com	_	_
9	isoform	isoform	NN	_	6	conj	_	_
10	mediate	mediate	VBP	_	4	comp	_	_
11	the	the	DT	_	12	det	_	_
12	metabolism	metabolism	NN	_	10	obj	_	_
13	of	of	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	to	to	TO	_	16	aux	_	_
16	drug2	drug0	NN	_	12	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	drug3	drug0	NN	_	16	conj	_	_
19	,	,	,	_	10	p	_	_
20	respectively	respectively	RB	_	10	adv	_	_
21	.	.	.	_	4	p	_	_

1	Thus	thus	RB	_	19	adv	_	_
2	agents	agent	NNS	_	19	dep	_	_
3	likely	likely	RB	_	7	adv	_	_
4	to	to	TO	_	7	aux	_	_
5	be	be	VB	_	7	aux	_	_
6	concomitantly	concomitantly	RB	_	7	adv	_	_
7	administered	administer	VBN	_	2	acl	_	_
8	with	with	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	that	that	WDT	_	12	dep	_	_
11	are	be	VBP	_	12	aux	_	_
12	metabolized	metabolize	VBN	_	9	relcl	_	_
13	by	by	IN	_	16	case	_	_
14	this	this	DT	_	16	det	_	_
15	isoenzyme	isoenzyme	NN	_	16	com	_	_
16	family	family	NN	_	12	ppmod	_	_
17	may	may	MD	_	19	modal	_	_
18	potentially	potentially	RB	_	19	adv	_	_
19	interact	interact	VB	_	0	root	_	_
20	with	with	IN	_	21	case	_	_
21	drug2	drug0	NN	_	19	ppmod	_	_
22	.	.	.	_	19	p	_	_

1	Although	although	IN	_	7	mark	_	_
2	no	no	DT	_	4	det	_	_
3	clinical	clinical	JJ	_	4	attr	_	_
4	studies	study	NNS	_	7	dep	_	_
5	have	have	VBP	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	conducted	conduct	VBN	_	10	advcl	_	_
8	,	,	,	_	10	p	_	_
9	it	it	PRP	_	10	dep	_	_
10	is	be	VBZ	_	0	root	_	_
11	likely	likely	JJ	_	10	dep	_	_
12	that	that	IN	_	19	mark	_	_
13	the	the	DT	_	14	det	_	_
14	metabolism	metabolism	NN	_	19	dep	_	_
15	of	of	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	may	may	MD	_	19	modal	_	_
18	be	be	VB	_	19	aux	_	_
19	affected	affect	VBN	_	11	comp	_	_
20	by	by	IN	_	24	case	_	_
21	the	the	DT	_	24	det	_	_
22	known	known	JJ	_	24	attr	_	_
23	CYP3A4	cyp0a0	NN	_	24	com	_	_
24	inducers	inducer	NNS	_	19	ppmod	_	_
25	(	-lrb-	-LRB-	_	28	p	_	_
26	such	such	JJ	_	27	com	_	_
27	as	as	IN	_	28	cc	_	_
28	drug2	drug0	NN	_	24	prn	_	_
29	,	,	,	_	28	p	_	_
30	drug3	drug0	NN	_	28	appo	_	_
31	,	,	,	_	28	p	_	_
32	drug4	drug0	NN	_	28	appo	_	_
33	)	-rrb-	-RRB-	_	28	p	_	_
34	,	,	,	_	24	p	_	_
35	CYP3A4	cyp0a0	JJ	_	36	attr	_	_
36	inhibitors	inhibitor	NNS	_	24	appo	_	_
37	(	-lrb-	-LRB-	_	39	p	_	_
38	azole	azole	JJ	_	39	attr	_	_
39	antimycotics	antimycotic	NNS	_	36	prn	_	_
40	e.g.	e.g.	FW	_	39	ppmod	_	_
41	,	,	,	_	24	p	_	_
42	drug5	drug0	NN	_	24	appo	_	_
43	;	;	:	_	10	p	_	_

1	certain	certain	JJ	_	2	attr	_	_
2	drug1	drug0	NNS	_	0	root	_	_
3	e.g.	e.g.	FW	_	5	adv	_	_
4	,	,	,	_	5	p	_	_
5	ritanovir	ritanovir	NN	_	2	ppmod	_	_
6	;	;	:	_	2	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	e.g.	e.g.	FW	_	1	attr	_	_
3	,	,	,	_	1	p	_	_
4	drug2	drug0	NN	_	1	attr	_	_
5	;	;	:	_	4	p	_	_

1	and	and	CC	_	2	cc	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	e.g.	e.g.	FW	_	5	adv	_	_
4	,	,	,	_	5	p	_	_
5	drug2	drug0	NN	_	2	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	,	,	,	_	2	p	_	_
8	CYP1A2	cyp0a0	NN	_	9	com	_	_
9	inducers	inducer	NNS	_	2	conj	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	drug3	drug0	NN	_	9	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	and	and	CC	_	9	cc	_	_
14	CYP1A2	cyp0a0	NN	_	15	com	_	_
15	inhibitors	inhibitor	NNS	_	2	conj	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	drug4	drug0	NN	_	15	prn	_	_
18	and	and	CC	_	17	cc	_	_
19	drug5	drug0	NN	_	17	conj	_	_
20	)	-rrb-	-RRB-	_	17	p	_	_
21	.	.	.	_	2	p	_	_

1	Dosage	dosage	NN	_	2	com	_	_
2	adjustment	adjustment	NN	_	5	dep	_	_
3	may	may	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	warranted	warrant	VBN	_	0	root	_	_
6	when	when	WRB	_	10	adv	_	_
7	drug1	drug0	NN	_	10	dep	_	_
8	is	be	VBZ	_	10	aux	_	_
9	concurrently	concurrently	RB	_	10	adv	_	_
10	administered	administer	VBN	_	5	comp	_	_
11	with	with	IN	_	13	case	_	_
12	CYP3A4	cyp0a0	JJ	_	13	attr	_	_
13	inhibitors	inhibitor	NNS	_	10	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	CYP1A2	cyp0a0	NN	_	16	com	_	_
16	inhibitors	inhibitor	NNS	_	13	conj	_	_
17	as	as	IN	_	22	mark	_	_
18	systemic	systemic	JJ	_	20	attr	_	_
19	drug2	drug0	NN	_	20	com	_	_
20	levels	level	NNS	_	22	dep	_	_
21	may	may	MD	_	22	modal	_	_
22	rise	rise	VB	_	10	comp	_	_
23	resulting	result	VBG	_	22	comp	_	_
24	in	in	IN	_	25	case	_	_
25	toxicity	toxicity	NN	_	23	ppmod	_	_
26	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Steady-state	steady-state	JJ	_	5	attr	_	_
4	trough	trough	NN	_	5	com	_	_
5	concentrations	concentration	NNS	_	8	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	were	be	VBD	_	1	acl	_	_
9	about	about	RB	_	10	adv	_	_
10	56	0	CD	_	12	num	_	_
11	%	%	NN	_	10	meta	_	_
12	higher	high	JJR	_	8	dep	_	_
13	when	when	WRB	_	18	adv	_	_
14	8	0	CD	_	15	num	_	_
15	mg	mg	NN	_	16	com	_	_
16	drug3	drug0	NN	_	18	dep	_	_
17	was	be	VBD	_	18	aux	_	_
18	coadministered	coadministered	VBN	_	8	comp	_	_
19	with	with	IN	_	21	case	_	_
20	each	each	DT	_	21	det	_	_
21	dose	dose	NN	_	18	ppmod	_	_
22	of	of	IN	_	23	case	_	_
23	drug4	drug0	NN	_	21	ppmod	_	_
24	(	-lrb-	-LRB-	_	26	p	_	_
25	15	0	CD	_	26	num	_	_
26	mg/kg/day	mg/kg/day	NN	_	23	prn	_	_
27	)	-rrb-	-RRB-	_	26	p	_	_
28	in	in	IN	_	31	case	_	_
29	eight	#crd#	CD	_	31	num	_	_
30	neurocysticercosis	neurocysticercosis	NN	_	31	com	_	_
31	patients	patient	NNS	_	21	ppmod	_	_
32	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	6	case	_	_
4	the	the	DT	_	6	det	_	_
5	fed	fed	JJ	_	6	attr	_	_
6	state	state	NN	_	13	ppmod	_	_
7	,	,	,	_	13	p	_	_
8	drug2	drug0	NN	_	13	dep	_	_
9	(	-lrb-	-LRB-	_	11	p	_	_
10	40	0	CD	_	11	num	_	_
11	mg/kg	mg/kg	NN	_	8	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	increased	increase	VBD	_	1	acl	_	_
14	mean	mean	NN	_	17	com	_	_
15	maximum	maximum	NN	_	17	com	_	_
16	plasma	plasma	NN	_	17	com	_	_
17	concentration	concentration	NN	_	13	obj	_	_
18	and	and	CC	_	17	cc	_	_
19	area	area	NN	_	17	conj	_	_
20	under	under	IN	_	22	case	_	_
21	the	the	DT	_	22	det	_	_
22	curve	curve	NN	_	19	ppmod	_	_
23	of	of	IN	_	24	case	_	_
24	drug3	drug0	NN	_	22	ppmod	_	_
25	by	by	IN	_	27	case	_	_
26	about	about	RB	_	27	adv	_	_
27	50	0	CD	_	13	ppmod	_	_
28	%	%	NN	_	27	meta	_	_
29	in	in	IN	_	31	case	_	_
30	healthy	healthy	JJ	_	31	attr	_	_
31	subjects	subject	NNS	_	27	ppmod	_	_
32	(	-lrb-	-LRB-	_	33	p	_	_
33	n=10	n=0	NN	_	31	prn	_	_
34	)	-rrb-	-RRB-	_	33	p	_	_
35	compared	compare	VBN	_	39	adv	_	_
36	with	with	IN	_	39	case	_	_
37	a	a	DT	_	39	det	_	_
38	separate	separate	JJ	_	39	attr	_	_
39	group	group	NN	_	13	ppmod	_	_
40	of	of	IN	_	41	case	_	_
41	subjects	subject	NNS	_	39	ppmod	_	_
42	(	-lrb-	-LRB-	_	43	p	_	_
43	n=6	n=0	NN	_	41	prn	_	_
44	)	-rrb-	-RRB-	_	43	p	_	_
45	given	given	IN	_	46	case	_	_
46	drug4	drug0	NN	_	41	ppmod	_	_
47	alone	alone	RB	_	46	adv	_	_
48	.	.	.	_	1	p	_	_

1	Mean	mean	NN	_	3	com	_	_
2	T	t	NN	_	3	com	_	_
3	max	max	NN	_	11	dep	_	_
4	and	and	CC	_	3	cc	_	_
5	mean	mean	NN	_	8	com	_	_
6	plasma	plasma	NN	_	8	com	_	_
7	elimination	elimination	NN	_	8	com	_	_
8	half-life	half-life	NN	_	3	conj	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	3	ppmod	_	_
11	were	be	VBD	_	0	root	_	_
12	unchanged	unchanged	JJ	_	11	dep	_	_
13	.	.	.	_	11	p	_	_

1	The	the	DT	_	2	det	_	_
2	pharmacokinetics	pharmacokinetics	NNS	_	5	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	were	be	VBD	_	0	root	_	_
6	unchanged	unchanged	JJ	_	5	dep	_	_
7	following	follow	VBG	_	8	adv	_	_
8	coadministration	coadministration	NN	_	5	ppmod	_	_
9	with	with	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	(	-lrb-	-LRB-	_	13	p	_	_
12	400	0	CD	_	13	num	_	_
13	mg	mg	NN	_	10	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	4	com	_	_
4	concentrations	concentration	NNS	_	11	dep	_	_
5	in	in	IN	_	6	case	_	_
6	bile	bile	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	cystic	cystic	JJ	_	9	attr	_	_
9	fluid	fluid	NN	_	6	conj	_	_
10	were	be	VBD	_	11	aux	_	_
11	increased	increase	VBN	_	1	acl	_	_
12	(	-lrb-	-LRB-	_	14	p	_	_
13	about	about	RB	_	14	com	_	_
14	2-fold	0-fold	RB	_	11	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	in	in	IN	_	19	case	_	_
17	hydatid	hydatid	JJ	_	19	attr	_	_
18	cyst	cyst	NN	_	19	com	_	_
19	patients	patient	NNS	_	11	ppmod	_	_
20	treated	treat	VBN	_	19	acl	_	_
21	with	with	IN	_	22	case	_	_
22	drug3	drug0	NN	_	20	ppmod	_	_
23	(	-lrb-	-LRB-	_	25	p	_	_
24	10	0	CD	_	25	num	_	_
25	mg/kg/day	mg/kg/day	NN	_	22	prn	_	_
26	)	-rrb-	-RRB-	_	25	p	_	_
27	(	-lrb-	-LRB-	_	28	p	_	_
28	n=7	n=0	NN	_	22	prn	_	_
29	)	-rrb-	-RRB-	_	28	p	_	_
30	compared	compare	VBN	_	32	adv	_	_
31	with	with	IN	_	32	case	_	_
32	drug4	drug0	NN	_	20	ppmod	_	_
33	(	-lrb-	-LRB-	_	35	p	_	_
34	20	0	CD	_	35	num	_	_
35	mg/kg/day	mg/kg/day	NN	_	32	prn	_	_
36	)	-rrb-	-RRB-	_	35	p	_	_
37	alone	alone	RB	_	32	adv	_	_
38	(	-lrb-	-LRB-	_	39	p	_	_
39	n=12	n=0	NN	_	32	prn	_	_
40	)	-rrb-	-RRB-	_	39	p	_	_
41	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	3	com	_	_
2	plasma	plasma	NN	_	3	com	_	_
3	concentrations	concentration	NNS	_	4	dep	_	_
4	were	be	VBD	_	0	root	_	_
5	unchanged	unchanged	JJ	_	4	dep	_	_
6	4	0	CD	_	7	num	_	_
7	hours	hour	NNS	_	9	dat	_	_
8	after	after	IN	_	9	case	_	_
9	dosing	dosing	NN	_	4	ppmod	_	_
10	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	pharmacokinetics	pharmacokinetics	NNS	_	16	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	(	-lrb-	-LRB-	_	10	p	_	_
8	drug3	drug0	NN	_	10	attr	_	_
9	5.8	0	CD	_	10	num	_	_
10	mg/kg	mg/kg	NN	_	6	prn	_	_
11	infused	infuse	VBN	_	10	acl	_	_
12	over	over	IN	_	14	case	_	_
13	20	0	CD	_	14	num	_	_
14	minutes	minute	NNS	_	11	ppmod	_	_
15	)	-rrb-	-RRB-	_	10	p	_	_
16	were	be	VBD	_	1	acl	_	_
17	unchanged	unchanged	JJ	_	16	dep	_	_
18	following	follow	VBG	_	22	adv	_	_
19	a	a	DT	_	22	det	_	_
20	single	single	JJ	_	22	attr	_	_
21	oral	oral	JJ	_	22	attr	_	_
22	dose	dose	NN	_	16	ppmod	_	_
23	of	of	IN	_	24	case	_	_
24	drug4	drug0	NN	_	22	ppmod	_	_
25	(	-lrb-	-LRB-	_	27	p	_	_
26	400	0	CD	_	27	num	_	_
27	mg	mg	NN	_	22	prn	_	_
28	)	-rrb-	-RRB-	_	27	p	_	_
29	in	in	IN	_	32	case	_	_
30	6	0	CD	_	32	num	_	_
31	healthy	healthy	JJ	_	32	attr	_	_
32	subjects	subject	NNS	_	16	ppmod	_	_
33	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	8	dep	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	,	,	,	_	3	p	_	_
5	and	and	CC	_	3	cc	_	_
6	drug3	drug0	NN	_	1	conj	_	_
7	may	may	MD	_	8	modal	_	_
8	increase	increase	VB	_	0	root	_	_
9	anticholinergic	anticholinergic	JJ	_	10	attr	_	_
10	effect	effect	NN	_	8	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug4	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	decrease	decrease	VB	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	effect	effect	NN	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	drug3	drug0	NN	_	7	conj	_	_
10	,	,	,	_	9	p	_	_
11	and	and	CC	_	9	cc	_	_
12	drug4	drug0	NN	_	7	conj	_	_
13	.	.	.	_	3	p	_	_

1	Co-administration	co-administration	NN	_	21	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	or	or	CC	_	3	cc	_	_
7	other	other	JJ	_	8	attr	_	_
8	agents	agent	NNS	_	3	conj	_	_
9	interfering	interfere	VBG	_	8	acl	_	_
10	with	with	IN	_	12	case	_	_
11	neuromuscular	neuromuscular	JJ	_	12	attr	_	_
12	transmission	transmission	NN	_	9	ppmod	_	_
13	(	-lrb-	-LRB-	_	16	p	_	_
14	e.g.	e.g.	FW	_	16	ppmod	_	_
15	,	,	,	_	16	p	_	_
16	drug3	drug0	NNS	_	8	prn	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	should	should	MD	_	21	modal	_	_
19	only	only	RB	_	21	adv	_	_
20	be	be	VB	_	21	aux	_	_
21	performed	performed	VBN	_	0	root	_	_
22	with	with	IN	_	23	case	_	_
23	caution	caution	NN	_	21	ppmod	_	_
24	as	as	IN	_	32	mark	_	_
25	the	the	DT	_	26	det	_	_
26	effect	effect	NN	_	32	dep	_	_
27	of	of	IN	_	29	case	_	_
28	the	the	DT	_	29	det	_	_
29	drug4	drug0	NNS	_	26	ppmod	_	_
30	may	may	MD	_	32	modal	_	_
31	be	be	VB	_	32	aux	_	_
32	potentiated	potentiate	VBN	_	21	comp	_	_
33	.	.	.	_	21	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	21	dep	_	_
3	of	of	IN	_	4	case	_	_
4	administering	administer	VBG	_	2	ppmod	_	_
5	different	different	JJ	_	7	attr	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	serotypes	serotype	NNS	_	4	obj	_	_
8	at	at	IN	_	11	case	_	_
9	the	the	DT	_	11	det	_	_
10	same	same	JJ	_	11	attr	_	_
11	time	time	NN	_	4	ppmod	_	_
12	or	or	CC	_	11	cc	_	_
13	within	within	IN	_	17	case	_	_
14	less	less	JJR	_	16	attr	_	_
15	than	than	IN	_	14	com	_	_
16	4	0	CD	_	17	num	_	_
17	months	month	NNS	_	11	conj	_	_
18	of	of	IN	_	20	case	_	_
19	each	each	DT	_	20	det	_	_
20	other	other	JJ	_	17	ppmod	_	_
21	is	be	VBZ	_	0	root	_	_
22	unknown	unknown	JJ	_	21	dep	_	_
23	.	.	.	_	21	p	_	_

1	However	however	RB	_	7	adv	_	_
2	,	,	,	_	7	p	_	_
3	neuromuscular	neuromuscular	NN	_	4	com	_	_
4	paralysis	paralysis	NN	_	7	dep	_	_
5	may	may	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	potentiated	potentiate	VBN	_	0	root	_	_
8	by	by	IN	_	9	case	_	_
9	co-administration	co-administration	NN	_	7	ppmod	_	_
10	or	or	CC	_	9	cc	_	_
11	overlapping	overlapping	JJ	_	12	attr	_	_
12	administration	administration	NN	_	9	conj	_	_
13	of	of	IN	_	16	case	_	_
14	different	different	JJ	_	16	attr	_	_
15	drug1	drug0	NN	_	16	com	_	_
16	serotypes	serotype	NNS	_	9	ppmod	_	_
17	.	.	.	_	7	p	_	_

1	As	as	IN	_	4	case	_	_
2	with	with	IN	_	4	case	_	_
3	all	all	DT	_	4	det	_	_
4	drugs	drug	NNS	_	8	ppmod	_	_
5	,	,	,	_	8	p	_	_
6	the	the	DT	_	7	det	_	_
7	potential	potential	NN	_	8	dep	_	_
8	exists	exist	VBZ	_	0	root	_	_
9	for	for	IN	_	10	case	_	_
10	interaction	interaction	NN	_	8	ppmod	_	_
11	with	with	IN	_	13	case	_	_
12	other	other	JJ	_	13	attr	_	_
13	drugs	drug	NNS	_	10	ppmod	_	_
14	by	by	IN	_	16	case	_	_
15	a	a	DT	_	16	det	_	_
16	variety	variety	NN	_	8	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	mechanisms	mechanism	NNS	_	16	ppmod	_	_
19	.	.	.	_	8	p	_	_

1	CNS-Active	cns-active	JJ	_	3	attr	_	_
2	Drugs	drug	NNS	_	3	com	_	_
3	drug1	drug0	NN	_	0	root	_	_
4	:	:	:	_	3	p	_	_
5	drug2	drug0	NN	_	7	attr	_	_
6	10	0	CD	_	7	num	_	_
7	mg	mg	NN	_	8	dep	_	_
8	potentiated	potentiate	VBD	_	3	acl	_	_
9	the	the	DT	_	11	det	_	_
10	CNS-impairing	cns-impairing	JJ	_	11	attr	_	_
11	effects	effect	NNS	_	8	obj	_	_
12	of	of	IN	_	15	case	_	_
13	drug3	drug0	NN	_	15	attr	_	_
14	0.75	0	CD	_	15	num	_	_
15	g/kg	g/kg	NNS	_	11	ppmod	_	_
16	on	on	IN	_	18	case	_	_
17	balance	balance	NN	_	18	com	_	_
18	testing	testing	NN	_	11	ppmod	_	_
19	and	and	CC	_	18	cc	_	_
20	reaction	reaction	NN	_	21	com	_	_
21	time	time	NN	_	18	conj	_	_
22	for	for	IN	_	24	case	_	_
23	1	0	CD	_	24	num	_	_
24	hour	hour	NN	_	18	ppmod	_	_
25	after	after	IN	_	27	case	_	_
26	drug4	drug0	NN	_	27	com	_	_
27	administration	administration	NN	_	18	ppmod	_	_
28	and	and	CC	_	18	cc	_	_
29	on	on	IN	_	34	case	_	_
30	the	the	DT	_	34	det	_	_
31	digit	digit	NN	_	34	com	_	_
32	symbol	symbol	NN	_	34	com	_	_
33	substitution	substitution	NN	_	34	com	_	_
34	test	test	NN	_	18	conj	_	_
35	(	-lrb-	-LRB-	_	36	p	_	_
36	DSST	dsst	NN	_	34	prn	_	_
37	)	-rrb-	-RRB-	_	36	p	_	_
38	,	,	,	_	34	p	_	_
39	symbol	symbol	NN	_	41	com	_	_
40	copying	copying	NN	_	41	com	_	_
41	test	test	NN	_	34	conj	_	_
42	,	,	,	_	41	p	_	_
43	and	and	CC	_	41	cc	_	_
44	the	the	DT	_	46	det	_	_
45	variability	variability	NN	_	46	com	_	_
46	component	component	NN	_	34	conj	_	_
47	of	of	IN	_	51	case	_	_
48	the	the	DT	_	51	det	_	_
49	divided	divided	JJ	_	51	attr	_	_
50	attention	attention	NN	_	51	com	_	_
51	test	test	NN	_	46	ppmod	_	_
52	for	for	IN	_	54	case	_	_
53	2.5	0	CD	_	54	num	_	_
54	hours	hour	NNS	_	46	ppmod	_	_
55	after	after	IN	_	57	case	_	_
56	drug5	drug0	NN	_	57	com	_	_
57	administration	administration	NN	_	54	ppmod	_	_
58	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	potentiation	potentiation	NN	_	3	dep	_	_
3	resulted	result	VBD	_	0	root	_	_
4	from	from	IN	_	8	case	_	_
5	a	a	DT	_	8	det	_	_
6	CNS	cns	NN	_	8	attr	_	_
7	pharmacodynamic	pharmacodynamic	JJ	_	8	attr	_	_
8	interaction	interaction	NN	_	3	ppmod	_	_
9	;	;	:	_	3	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	did	do	VBD	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	affect	affect	VB	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	pharmacokinetics	pharmacokinetics	NNS	_	4	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Coadministration	coadministration	NN	_	15	dep	_	_
4	of	of	IN	_	6	case	_	_
5	single	single	JJ	_	6	attr	_	_
6	doses	dose	NNS	_	3	ppmod	_	_
7	of	of	IN	_	10	case	_	_
8	drug2	drug0	NN	_	10	attr	_	_
9	20	0	CD	_	10	num	_	_
10	mg	mg	NN	_	6	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug3	drug0	NN	_	14	attr	_	_
13	75	0	CD	_	14	num	_	_
14	mg	mg	NN	_	10	conj	_	_
15	produced	produce	VBD	_	1	acl	_	_
16	additive	additive	JJ	_	17	attr	_	_
17	effects	effect	NNS	_	15	obj	_	_
18	on	on	IN	_	20	case	_	_
19	decreased	decrease	VBN	_	20	attr	_	_
20	alertness	alertness	NN	_	17	ppmod	_	_
21	and	and	CC	_	20	cc	_	_
22	impaired	impaired	JJ	_	24	attr	_	_
23	psychomotor	psychomotor	NN	_	24	com	_	_
24	performance	performance	NN	_	20	conj	_	_
25	for	for	IN	_	29	case	_	_
26	2	0	CD	_	29	num	_	_
27	to	to	TO	_	26	cc	_	_
28	4	0	CD	_	26	conj	_	_
29	hours	hour	NNS	_	17	ppmod	_	_
30	after	after	IN	_	31	case	_	_
31	administration	administration	NN	_	15	ppmod	_	_
32	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	interaction	interaction	NN	_	3	dep	_	_
3	was	be	VBD	_	0	root	_	_
4	pharmacodynamic	pharmacodynamic	JJ	_	3	dep	_	_
5	with	with	IN	_	7	case	_	_
6	no	no	DT	_	7	det	_	_
7	alteration	alteration	NN	_	4	ppmod	_	_
8	of	of	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	pharmacokinetics	pharmacokinetics	NNS	_	7	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	either	either	DT	_	13	det	_	_
13	drug	drug	NN	_	10	ppmod	_	_
14	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Coadministration	coadministration	NN	_	22	dep	_	_
4	of	of	IN	_	7	case	_	_
5	a	a	DT	_	7	det	_	_
6	single	single	JJ	_	7	attr	_	_
7	dose	dose	NN	_	3	ppmod	_	_
8	of	of	IN	_	11	case	_	_
9	drug2	drug0	NN	_	11	attr	_	_
10	20	0	CD	_	11	num	_	_
11	mg	mg	NN	_	7	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	drug3	drug0	NN	_	15	attr	_	_
14	20	0	CD	_	15	num	_	_
15	mg	mg	NN	_	11	conj	_	_
16	daily	daily	RB	_	15	adv	_	_
17	for	for	IN	_	19	case	_	_
18	7	0	CD	_	19	num	_	_
19	days	day	NNS	_	15	ppmod	_	_
20	did	do	VBD	_	22	aux	_	_
21	not	not	RB	_	22	neg	_	_
22	produce	produce	VB	_	1	acl	_	_
23	any	any	DT	_	24	det	_	_
24	interaction	interaction	NN	_	22	obj	_	_
25	on	on	IN	_	27	case	_	_
26	psychomotor	psychomotor	NN	_	27	com	_	_
27	performance	performance	NN	_	24	ppmod	_	_
28	.	.	.	_	1	p	_	_

1	Additionally	additionally	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	drug1	drug0	NN	_	6	dep	_	_
4	did	do	VBD	_	6	aux	_	_
5	not	not	RB	_	6	neg	_	_
6	alter	alter	VB	_	0	root	_	_
7	the	the	DT	_	8	det	_	_
8	pharmacokinetics	pharmacokinetics	NNS	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	,	,	,	_	6	p	_	_
12	reflecting	reflect	VBG	_	6	comp	_	_
13	the	the	DT	_	14	det	_	_
14	absence	absence	NN	_	12	obj	_	_
15	of	of	IN	_	17	case	_	_
16	a	a	DT	_	17	det	_	_
17	role	role	NN	_	14	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	CYP2D6	cyp0d0	NN	_	17	ppmod	_	_
20	in	in	IN	_	23	case	_	_
21	drug3	drug0	NN	_	23	com	_	_
22	s	s	NN	_	23	com	_	_
23	metabolism	metabolism	NN	_	17	ppmod	_	_
24	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Coadministration	coadministration	NN	_	15	dep	_	_
4	of	of	IN	_	6	case	_	_
5	single	single	JJ	_	6	attr	_	_
6	doses	dose	NNS	_	3	ppmod	_	_
7	of	of	IN	_	10	case	_	_
8	drug2	drug0	NN	_	10	attr	_	_
9	20	0	CD	_	10	num	_	_
10	mg	mg	NN	_	6	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug3	drug0	NN	_	14	attr	_	_
13	50	0	CD	_	14	num	_	_
14	mg	mg	NN	_	10	conj	_	_
15	produced	produce	VBD	_	1	acl	_	_
16	additive	additive	JJ	_	17	attr	_	_
17	effects	effect	NNS	_	15	obj	_	_
18	on	on	IN	_	20	case	_	_
19	decreased	decrease	VBN	_	20	attr	_	_
20	alertness	alertness	NN	_	17	ppmod	_	_
21	and	and	CC	_	20	cc	_	_
22	impaired	impaired	JJ	_	24	attr	_	_
23	psychomotor	psychomotor	NN	_	24	com	_	_
24	performance	performance	NN	_	20	conj	_	_
25	for	for	IN	_	29	case	_	_
26	2	0	CD	_	29	num	_	_
27	to	to	TO	_	26	cc	_	_
28	4	0	CD	_	26	conj	_	_
29	hours	hour	NNS	_	17	ppmod	_	_
30	after	after	IN	_	31	case	_	_
31	administration	administration	NN	_	15	ppmod	_	_
32	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	interaction	interaction	NN	_	3	dep	_	_
3	was	be	VBD	_	0	root	_	_
4	pharmacodynamic	pharmacodynamic	JJ	_	3	dep	_	_
5	with	with	IN	_	7	case	_	_
6	no	no	DT	_	7	det	_	_
7	alteration	alteration	NN	_	4	ppmod	_	_
8	of	of	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	pharmacokinetics	pharmacokinetics	NNS	_	7	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	either	either	DT	_	13	det	_	_
13	drug	drug	NN	_	10	ppmod	_	_
14	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Coadministration	coadministration	NN	_	26	dep	_	_
4	of	of	IN	_	7	case	_	_
5	a	a	DT	_	7	det	_	_
6	single	single	JJ	_	7	attr	_	_
7	dose	dose	NN	_	3	ppmod	_	_
8	of	of	IN	_	11	case	_	_
9	drug2	drug0	NN	_	11	attr	_	_
10	10	0	CD	_	11	num	_	_
11	mg	mg	NN	_	7	ppmod	_	_
12	and	and	CC	_	7	cc	_	_
13	multiple	multiple	JJ	_	14	attr	_	_
14	doses	dose	NNS	_	7	conj	_	_
15	of	of	IN	_	23	case	_	_
16	drug3	drug0	NN	_	23	attr	_	_
17	ER	er	NN	_	23	attr	_	_
18	(	-lrb-	-LRB-	_	23	p	_	_
19	extended	extended	JJ	_	23	attr	_	_
20	release	release	NN	_	23	attr	_	_
21	)	-rrb-	-RRB-	_	23	p	_	_
22	150	0	CD	_	23	num	_	_
23	mg	mg	NN	_	14	ppmod	_	_
24	did	do	VBD	_	26	aux	_	_
25	not	not	RB	_	26	neg	_	_
26	result	result	VB	_	1	acl	_	_
27	in	in	IN	_	30	case	_	_
28	any	any	DT	_	30	det	_	_
29	significant	significant	JJ	_	30	attr	_	_
30	changes	change	NNS	_	26	ppmod	_	_
31	in	in	IN	_	33	case	_	_
32	the	the	DT	_	33	det	_	_
33	pharmacokinetics	pharmacokinetics	NNS	_	30	ppmod	_	_
34	of	of	IN	_	36	case	_	_
35	either	either	CC	_	36	cc	_	_
36	drug4	drug0	NN	_	33	ppmod	_	_
37	or	or	CC	_	36	cc	_	_
38	drug5	drug0	NN	_	36	conj	_	_
39	.	.	.	_	1	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	5	ppmod	_	_
3	,	,	,	_	5	p	_	_
4	there	there	EX	_	5	dep	_	_
5	was	be	VBD	_	0	root	_	_
6	no	no	DT	_	8	det	_	_
7	pharmacodynamic	pharmacodynamic	JJ	_	8	attr	_	_
8	interaction	interaction	NN	_	5	obj	_	_
9	as	as	IN	_	11	case	_	_
10	a	a	DT	_	11	det	_	_
11	result	result	NN	_	5	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	coadministration	coadministration	NN	_	11	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	drug2	drug0	NN	_	18	com	_	_
18	ER	er	NN	_	15	conj	_	_
19	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Coadministration	coadministration	NN	_	20	dep	_	_
4	of	of	IN	_	7	case	_	_
5	a	a	DT	_	7	det	_	_
6	single	single	JJ	_	7	attr	_	_
7	dose	dose	NN	_	3	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	drug3	drug0	NN	_	9	conj	_	_
12	(	-lrb-	-LRB-	_	16	p	_	_
13	10	0	CD	_	16	num	_	_
14	and	and	CC	_	13	cc	_	_
15	25	0	CD	_	13	conj	_	_
16	mg	mg	NN	_	7	prn	_	_
17	,	,	,	_	16	p	_	_
18	respectively	respectively	RB	_	16	adv	_	_
19	)	-rrb-	-RRB-	_	16	p	_	_
20	resulted	result	VBD	_	1	acl	_	_
21	in	in	IN	_	25	case	_	_
22	a	a	DT	_	25	det	_	_
23	15	0	CD	_	25	num	_	_
24	%	%	NN	_	23	meta	_	_
25	decrease	decrease	NN	_	20	ppmod	_	_
26	in	in	IN	_	29	case	_	_
27	maximal	maximal	JJ	_	29	attr	_	_
28	plasma	plasma	NN	_	29	com	_	_
29	concentrations	concentration	NNS	_	25	ppmod	_	_
30	of	of	IN	_	31	case	_	_
31	drug4	drug0	NN	_	29	ppmod	_	_
32	,	,	,	_	25	p	_	_
33	but	but	CC	_	25	cc	_	_
34	no	no	DT	_	35	det	_	_
35	change	change	NN	_	25	conj	_	_
36	in	in	IN	_	38	case	_	_
37	the	the	DT	_	38	det	_	_
38	area	area	NN	_	35	ppmod	_	_
39	under	under	IN	_	43	case	_	_
40	the	the	DT	_	43	det	_	_
41	plasma	plasma	NN	_	43	com	_	_
42	concentration-time	concentration-time	NN	_	43	com	_	_
43	curve	curve	NN	_	38	ppmod	_	_
44	.	.	.	_	1	p	_	_

1	However	however	RB	_	14	adv	_	_
2	,	,	,	_	14	p	_	_
3	the	the	DT	_	4	det	_	_
4	pharmacodynamics	pharmacodynamics	NNS	_	14	dep	_	_
5	of	of	IN	_	6	case	_	_
6	coadministration	coadministration	NN	_	4	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	drug2	drug0	NN	_	8	conj	_	_
11	have	have	VBP	_	14	aux	_	_
12	not	not	RB	_	14	neg	_	_
13	been	be	VBN	_	14	aux	_	_
14	evaluated	evaluate	VBN	_	0	root	_	_
15	.	.	.	_	14	p	_	_

1	Caution	caution	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	exercised	exercise	VBN	_	0	root	_	_
5	when	when	WRB	_	10	adv	_	_
6	these	these	DT	_	8	det	_	_
7	2	0	CD	_	8	num	_	_
8	agents	agent	NNS	_	10	dep	_	_
9	are	be	VBP	_	10	aux	_	_
10	coadministered	coadministered	VBN	_	4	comp	_	_
11	.	.	.	_	4	p	_	_

1	Drugs	drug	NNS	_	0	root	_	_
2	That	that	WDT	_	3	dep	_	_
3	Induce	induce	VBP	_	1	relcl	_	_
4	CYP3A4	cyp0a0	NN	_	5	com	_	_
5	drug1	drug0	NN	_	3	obj	_	_
6	:	:	:	_	1	p	_	_
7	CYP3A4	cyp0a0	NN	_	8	dep	_	_
8	is	be	VBZ	_	1	acl	_	_
9	ordinarily	ordinarily	RB	_	8	adv	_	_
10	a	a	DT	_	13	det	_	_
11	minor	minor	JJ	_	13	attr	_	_
12	metabolizing	metabolizing	NN	_	13	com	_	_
13	enzyme	enzyme	NN	_	8	obj	_	_
14	of	of	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	1	p	_	_

1	Multiple-dose	multiple-dose	JJ	_	2	attr	_	_
2	administration	administration	NN	_	25	dep	_	_
3	of	of	IN	_	8	case	_	_
4	the	the	DT	_	8	det	_	_
5	potent	potent	JJ	_	8	attr	_	_
6	CYP3A4	cyp0a0	NN	_	8	com	_	_
7	inducer	inducer	NN	_	8	com	_	_
8	drug1	drug0	NN	_	2	ppmod	_	_
9	(	-lrb-	-LRB-	_	11	p	_	_
10	600	0	CD	_	11	num	_	_
11	mg	mg	NN	_	8	prn	_	_
12	every	every	DT	_	14	det	_	_
13	24	0	CD	_	14	num	_	_
14	hours	hour	NNS	_	11	attr	_	_
15	,	,	,	_	14	p	_	_
16	q24h	q0h	NN	_	14	appo	_	_
17	,	,	,	_	14	p	_	_
18	for	for	IN	_	20	case	_	_
19	14	0	CD	_	20	num	_	_
20	days	day	NNS	_	11	ppmod	_	_
21	)	-rrb-	-RRB-	_	11	p	_	_
22	,	,	,	_	25	p	_	_
23	however	however	RB	_	25	adv	_	_
24	,	,	,	_	25	p	_	_
25	reduced	reduce	VBD	_	0	root	_	_
26	drug2	drug0	NN	_	27	com	_	_
27	Cmax	cmax	NN	_	25	obj	_	_
28	and	and	CC	_	27	cc	_	_
29	AUC	auc	NN	_	27	conj	_	_
30	by	by	IN	_	32	case	_	_
31	approximately	approximately	RB	_	32	adv	_	_
32	80	0	CD	_	25	ppmod	_	_
33	%	%	NN	_	32	meta	_	_
34	.	.	.	_	25	p	_	_

1	The	the	DT	_	2	det	_	_
2	coadministration	coadministration	NN	_	19	dep	_	_
3	of	of	IN	_	8	case	_	_
4	a	a	DT	_	8	det	_	_
5	potent	potent	JJ	_	8	attr	_	_
6	CYP3A4	cyp0a0	NN	_	8	com	_	_
7	enzyme	enzyme	NN	_	8	com	_	_
8	inducer	inducer	NN	_	2	ppmod	_	_
9	,	,	,	_	19	p	_	_
10	although	although	IN	_	12	mark	_	_
11	not	not	RB	_	12	neg	_	_
12	posing	pose	VBG	_	19	advcl	_	_
13	a	a	DT	_	15	det	_	_
14	safety	safety	NN	_	15	com	_	_
15	concern	concern	NN	_	12	obj	_	_
16	,	,	,	_	19	p	_	_
17	thus	thus	RB	_	19	adv	_	_
18	could	could	MD	_	19	modal	_	_
19	lead	lead	VB	_	0	root	_	_
20	to	to	TO	_	21	aux	_	_
21	ineffectiveness	ineffectiveness	NN	_	19	ppmod	_	_
22	of	of	IN	_	23	case	_	_
23	drug1	drug0	NN	_	21	ppmod	_	_
24	.	.	.	_	19	p	_	_

1	An	an	DT	_	5	det	_	_
2	alternative	alternative	JJ	_	5	attr	_	_
3	non-CYP3A4	non-cyp0a0	NN	_	5	com	_	_
4	substrate	substrate	NN	_	5	com	_	_
5	drug1	drug0	NN	_	8	dep	_	_
6	may	may	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	considered	consider	VBN	_	0	root	_	_
9	in	in	IN	_	10	case	_	_
10	patients	patient	NNS	_	8	ppmod	_	_
11	taking	take	VBG	_	10	acl	_	_
12	CYP3A4	cyp0a0	JJ	_	13	attr	_	_
13	inducers	inducer	NNS	_	11	obj	_	_
14	such	such	JJ	_	16	adv	_	_
15	as	as	IN	_	16	case	_	_
16	drug2	drug0	NN	_	13	ppmod	_	_
17	,	,	,	_	16	p	_	_
18	drug3	drug0	NN	_	16	conj	_	_
19	,	,	,	_	18	p	_	_
20	drug4	drug0	NN	_	16	conj	_	_
21	,	,	,	_	20	p	_	_
22	and	and	CC	_	20	cc	_	_
23	drug5	drug0	NN	_	16	conj	_	_
24	.	.	.	_	8	p	_	_

1	Drugs	drug	NNS	_	36	dep	_	_
2	That	that	WDT	_	3	dep	_	_
3	Inhibit	inhibit	VBP	_	1	relcl	_	_
4	CYP3A4	cyp0a0	NN	_	5	com	_	_
5	CYP3A4	cyp0a0	NN	_	3	obj	_	_
6	is	be	VBZ	_	5	acl	_	_
7	a	a	DT	_	10	det	_	_
8	minor	minor	JJ	_	10	attr	_	_
9	metabolic	metabolic	JJ	_	10	attr	_	_
10	pathway	pathway	NN	_	6	obj	_	_
11	for	for	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	elimination	elimination	NN	_	10	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	because	because	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	sum	sum	NN	_	6	ppmod	_	_
19	of	of	IN	_	20	case	_	_
20	desethylzaleplon	desethylzaleplon	NN	_	18	ppmod	_	_
21	(	-lrb-	-LRB-	_	18	p	_	_
22	formed	form	VBN	_	18	acl	_	_
23	via	via	IN	_	24	case	_	_
24	CYP3A4	cyp0a0	NN	_	22	ppmod	_	_
25	in	in	FW	_	26	adv	_	_
26	vitro	vitro	FW	_	22	adv	_	_
27	)	-rrb-	-RRB-	_	18	p	_	_
28	and	and	CC	_	5	cc	_	_
29	its	its	PRP$	_	30	poss	_	_
30	metabolites	metabolite	NNS	_	5	conj	_	_
31	,	,	,	_	1	p	_	_
32	drug2	drug0	NN	_	1	appo	_	_
33	and	and	CC	_	32	cc	_	_
34	drug3	drug0	NN	_	32	conj	_	_
35	,	,	,	_	1	p	_	_
36	account	account	VBP	_	0	root	_	_
37	for	for	IN	_	39	case	_	_
38	only	only	RB	_	39	adv	_	_
39	9	0	CD	_	36	ppmod	_	_
40	%	%	NN	_	39	meta	_	_
41	of	of	IN	_	44	case	_	_
42	the	the	DT	_	44	det	_	_
43	urinary	urinary	JJ	_	44	attr	_	_
44	recovery	recovery	NN	_	39	ppmod	_	_
45	of	of	IN	_	48	case	_	_
46	a	a	DT	_	48	det	_	_
47	drug4	drug0	NN	_	48	com	_	_
48	dose	dose	NN	_	44	ppmod	_	_
49	.	.	.	_	36	p	_	_

1	Coadministration	coadministration	NN	_	27	dep	_	_
2	of	of	IN	_	6	case	_	_
3	single	single	JJ	_	5	adv	_	_
4	,	,	,	_	5	p	_	_
5	oral	oral	JJ	_	6	attr	_	_
6	doses	dose	NNS	_	1	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	with	with	IN	_	10	case	_	_
10	drug2	drug0	NN	_	1	ppmod	_	_
11	(	-lrb-	-LRB-	_	13	p	_	_
12	10	0	CD	_	13	num	_	_
13	mg	mg	NN	_	10	prn	_	_
14	and	and	CC	_	13	cc	_	_
15	800	0	CD	_	16	num	_	_
16	mg	mg	NN	_	13	conj	_	_
17	,	,	,	_	13	p	_	_
18	respectively	respectively	RB	_	13	adv	_	_
19	)	-rrb-	-RRB-	_	13	p	_	_
20	,	,	,	_	10	p	_	_
21	a	a	DT	_	26	det	_	_
22	strong	strong	JJ	_	24	adv	_	_
23	,	,	,	_	24	p	_	_
24	selective	selective	JJ	_	26	attr	_	_
25	CYP3A4	cyp0a0	NN	_	26	com	_	_
26	inhibitor	inhibitor	NN	_	10	appo	_	_
27	produced	produce	VBD	_	0	root	_	_
28	a	a	DT	_	31	det	_	_
29	34	0	CD	_	31	num	_	_
30	%	%	NN	_	29	meta	_	_
31	increase	increase	NN	_	27	obj	_	_
32	in	in	IN	_	37	case	_	_
33	drug3	drug0	NN	_	37	attr	_	_
34	s	s	NN	_	37	attr	_	_
35	maximal	maximal	JJ	_	37	attr	_	_
36	plasma	plasma	NN	_	37	com	_	_
37	concentrations	concentration	NNS	_	31	ppmod	_	_
38	and	and	CC	_	31	cc	_	_
39	a	a	DT	_	42	det	_	_
40	20	0	CD	_	42	num	_	_
41	%	%	NN	_	40	meta	_	_
42	increase	increase	NN	_	31	conj	_	_
43	in	in	IN	_	45	case	_	_
44	the	the	DT	_	45	det	_	_
45	area	area	NN	_	42	ppmod	_	_
46	under	under	IN	_	50	case	_	_
47	the	the	DT	_	50	det	_	_
48	plasma	plasma	NN	_	50	com	_	_
49	concentration-time	concentration-time	NN	_	50	com	_	_
50	curve	curve	NN	_	45	ppmod	_	_
51	.	.	.	_	27	p	_	_

1	The	the	DT	_	2	det	_	_
2	magnitude	magnitude	NN	_	10	dep	_	_
3	of	of	IN	_	4	case	_	_
4	interaction	interaction	NN	_	2	ppmod	_	_
5	with	with	IN	_	7	case	_	_
6	multiple	multiple	JJ	_	7	attr	_	_
7	doses	dose	NNS	_	4	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	is	be	VBZ	_	0	root	_	_
11	unknown	unknown	JJ	_	10	dep	_	_
12	.	.	.	_	10	p	_	_

1	Other	other	JJ	_	5	attr	_	_
2	strong	strong	JJ	_	5	attr	_	_
3	selective	selective	JJ	_	5	attr	_	_
4	CYP3A4	cyp0a0	JJ	_	5	attr	_	_
5	inhibitors	inhibitor	NNS	_	12	dep	_	_
6	such	such	JJ	_	8	adv	_	_
7	as	as	IN	_	8	case	_	_
8	drug1	drug0	NN	_	5	ppmod	_	_
9	can	can	MD	_	12	modal	_	_
10	also	also	RB	_	12	adv	_	_
11	be	be	VB	_	12	aux	_	_
12	expected	expect	VBN	_	0	root	_	_
13	to	to	TO	_	14	aux	_	_
14	increase	increase	VB	_	12	comp	_	_
15	the	the	DT	_	16	det	_	_
16	exposure	exposure	NN	_	14	obj	_	_
17	of	of	IN	_	18	case	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	.	.	.	_	12	p	_	_

1	A	a	DT	_	4	det	_	_
2	routine	routine	JJ	_	4	attr	_	_
3	dosage	dosage	NN	_	4	com	_	_
4	adjustment	adjustment	NN	_	9	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	is	be	VBZ	_	9	aux	_	_
8	not	not	RB	_	9	neg	_	_
9	considered	consider	VBN	_	0	root	_	_
10	necessary	necessary	JJ	_	9	dep	_	_
11	.	.	.	_	9	p	_	_

1	Drugs	drug	NNS	_	10	attr	_	_
2	That	that	WDT	_	3	dep	_	_
3	Inhibit	inhibit	VBP	_	1	relcl	_	_
4	Aldehyde	aldehyde	NN	_	5	com	_	_
5	Oxidase	oxidase	NN	_	3	obj	_	_
6	The	the	DT	_	9	det	_	_
7	aldehyde	aldehyde	NN	_	9	com	_	_
8	oxidase	oxidase	NN	_	9	com	_	_
9	enzyme	enzyme	NN	_	10	com	_	_
10	system	system	NN	_	14	dep	_	_
11	is	be	VBZ	_	14	aux	_	_
12	less	less	RBR	_	13	com	_	_
13	well	well	RB	_	14	adv	_	_
14	studied	study	VBN	_	0	root	_	_
15	than	than	IN	_	20	case	_	_
16	the	the	DT	_	20	det	_	_
17	cytochrome	cytochrome	NN	_	20	com	_	_
18	P450	p0	NN	_	20	com	_	_
19	enzyme	enzyme	NN	_	20	com	_	_
20	system	system	NN	_	14	ppmod	_	_
21	.	.	.	_	14	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	reported	report	VBN	_	1	acl	_	_
6	to	to	TO	_	7	aux	_	_
7	be	be	VB	_	5	comp	_	_
8	a	a	DT	_	10	det	_	_
9	weak	weak	JJ	_	10	attr	_	_
10	inhibitor	inhibitor	NN	_	7	obj	_	_
11	of	of	IN	_	13	case	_	_
12	aldehyde	aldehyde	NN	_	13	com	_	_
13	oxidase	oxidase	NN	_	10	ppmod	_	_
14	in	in	IN	_	16	case	_	_
15	rat	rat	NN	_	16	com	_	_
16	liver	liver	NN	_	10	ppmod	_	_
17	,	,	,	_	5	p	_	_
18	but	but	CC	_	5	cc	_	_
19	its	its	PRP$	_	21	poss	_	_
20	inhibitory	inhibitory	JJ	_	21	attr	_	_
21	effects	effect	NNS	_	27	dep	_	_
22	in	in	IN	_	24	case	_	_
23	human	human	JJ	_	24	attr	_	_
24	liver	liver	NN	_	21	ppmod	_	_
25	are	be	VBP	_	27	aux	_	_
26	not	not	RB	_	27	neg	_	_
27	known	know	VBN	_	5	conj	_	_
28	.	.	.	_	1	p	_	_

1	There	there	EX	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	no	no	DT	_	5	det	_	_
4	pharmacokinetic	pharmacokinetic	JJ	_	5	attr	_	_
5	interaction	interaction	NN	_	2	obj	_	_
6	between	between	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	following	follow	VBG	_	12	adv	_	_
11	the	the	DT	_	12	det	_	_
12	administration	administration	NN	_	7	ppmod	_	_
13	of	of	IN	_	16	case	_	_
14	a	a	DT	_	16	det	_	_
15	single	single	JJ	_	16	attr	_	_
16	dose	dose	NN	_	12	ppmod	_	_
17	(	-lrb-	-LRB-	_	19	p	_	_
18	10	0	CD	_	19	num	_	_
19	mg	mg	NN	_	16	prn	_	_
20	and	and	CC	_	19	cc	_	_
21	50	0	CD	_	22	num	_	_
22	mg	mg	NN	_	19	conj	_	_
23	,	,	,	_	19	p	_	_
24	respectively	respectively	RB	_	19	adv	_	_
25	)	-rrb-	-RRB-	_	19	p	_	_
26	of	of	IN	_	28	case	_	_
27	each	each	DT	_	28	det	_	_
28	drug	drug	NN	_	16	ppmod	_	_
29	.	.	.	_	2	p	_	_

1	However	however	RB	_	16	adv	_	_
2	,	,	,	_	16	p	_	_
3	because	because	IN	_	8	mark	_	_
4	both	both	DT	_	8	dep	_	_
5	of	of	IN	_	7	case	_	_
6	these	these	DT	_	7	det	_	_
7	compounds	compound	NNS	_	4	ppmod	_	_
8	have	have	VBP	_	16	advcl	_	_
9	CNS	cns	NN	_	10	com	_	_
10	effects	effect	NNS	_	8	obj	_	_
11	,	,	,	_	16	p	_	_
12	an	an	DT	_	15	det	_	_
13	additive	additive	JJ	_	15	attr	_	_
14	pharmacodynamic	pharmacodynamic	JJ	_	15	attr	_	_
15	effect	effect	NN	_	16	dep	_	_
16	is	be	VBZ	_	0	root	_	_
17	possible	possible	JJ	_	16	dep	_	_
18	.	.	.	_	16	p	_	_

1	Drugs	drug	NNS	_	0	root	_	_
2	That	that	IN	_	3	mark	_	_
3	Inhibit	inhibit	VBP	_	1	acl	_	_
4	Both	both	DT	_	6	det	_	_
5	Aldehyde	aldehyde	NN	_	6	com	_	_
6	Oxidase	oxidase	NN	_	3	obj	_	_
7	and	and	CC	_	1	cc	_	_
8	CYP3A4	cyp0a0	NN	_	9	com	_	_
9	drug1	drug0	NN	_	1	conj	_	_
10	:	:	:	_	1	p	_	_
11	drug2	drug0	NN	_	12	dep	_	_
12	inhibits	inhibit	VBZ	_	1	acl	_	_
13	both	both	CC	_	15	cc	_	_
14	aldehyde	aldehyde	NN	_	15	com	_	_
15	oxidase	oxidase	NN	_	12	dat	_	_
16	(	-lrb-	-LRB-	_	18	p	_	_
17	in	in	FW	_	18	attr	_	_
18	vitro	vitro	FW	_	15	prn	_	_
19	)	-rrb-	-RRB-	_	18	p	_	_
20	and	and	CC	_	15	cc	_	_
21	CYP3A4	cyp0a0	NN	_	15	conj	_	_
22	(	-lrb-	-LRB-	_	24	p	_	_
23	in	in	FW	_	24	attr	_	_
24	vitro	vitro	FW	_	12	prn	_	_
25	and	and	CC	_	24	cc	_	_
26	in	in	FW	_	27	attr	_	_
27	vivo	vivo	FW	_	24	conj	_	_
28	)	-rrb-	-RRB-	_	24	p	_	_
29	,	,	,	_	12	p	_	_
30	the	the	DT	_	34	det	_	_
31	primary	primary	JJ	_	34	attr	_	_
32	and	and	CC	_	31	cc	_	_
33	secondary	secondary	JJ	_	31	conj	_	_
34	enzymes	enzyme	NNS	_	12	obj	_	_
35	,	,	,	_	34	p	_	_
36	respectively	respectively	RB	_	34	adv	_	_
37	,	,	,	_	34	p	_	_
38	responsible	responsible	JJ	_	34	attr	_	_
39	for	for	IN	_	41	case	_	_
40	drug3	drug0	NN	_	41	com	_	_
41	metabolism	metabolism	NN	_	38	ppmod	_	_
42	.	.	.	_	1	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	administration	administration	NN	_	15	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	(	-lrb-	-LRB-	_	7	p	_	_
6	10	0	CD	_	7	num	_	_
7	mg	mg	NN	_	4	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	and	and	CC	_	4	cc	_	_
10	drug2	drug0	NN	_	4	conj	_	_
11	(	-lrb-	-LRB-	_	13	p	_	_
12	800	0	CD	_	13	num	_	_
13	mg	mg	NN	_	10	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	produced	produce	VBD	_	0	root	_	_
16	an	an	DT	_	19	det	_	_
17	85	0	CD	_	19	num	_	_
18	%	%	NN	_	17	meta	_	_
19	increase	increase	NN	_	15	obj	_	_
20	in	in	IN	_	23	case	_	_
21	the	the	DT	_	23	det	_	_
22	mean	mean	JJ	_	23	attr	_	_
23	Cmax	cmax	NN	_	19	ppmod	_	_
24	and	and	CC	_	23	cc	_	_
25	AUC	auc	NN	_	23	conj	_	_
26	of	of	IN	_	27	case	_	_
27	drug3	drug0	NN	_	23	ppmod	_	_
28	.	.	.	_	15	p	_	_

1	An	an	DT	_	3	det	_	_
2	initial	initial	JJ	_	3	attr	_	_
3	dose	dose	NN	_	9	dep	_	_
4	of	of	IN	_	6	case	_	_
5	5	0	CD	_	6	num	_	_
6	mg	mg	NN	_	3	ppmod	_	_
7	should	should	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	given	give	VBN	_	0	root	_	_
10	to	to	TO	_	11	aux	_	_
11	patients	patient	NNS	_	9	ppmod	_	_
12	who	who	WP	_	16	dep	_	_
13	are	be	VBP	_	16	aux	_	_
14	concomitantly	concomitantly	RB	_	16	adv	_	_
15	being	be	VBG	_	16	aux	_	_
16	treated	treat	VBN	_	11	relcl	_	_
17	with	with	IN	_	18	case	_	_
18	drug1	drug0	NN	_	16	ppmod	_	_
19	.	.	.	_	9	p	_	_

1	Drugs	drug	NNS	_	11	dep	_	_
2	Highly	highly	RB	_	3	adv	_	_
3	Bound	bind	VBN	_	1	acl	_	_
4	to	to	TO	_	7	aux	_	_
5	Plasma	plasma	NN	_	7	com	_	_
6	Protein	protein	NN	_	7	com	_	_
7	drug1	drug0	NN	_	3	ppmod	_	_
8	is	be	VBZ	_	11	aux	_	_
9	not	not	RB	_	11	neg	_	_
10	highly	highly	RB	_	11	adv	_	_
11	bound	bind	VBN	_	0	root	_	_
12	to	to	TO	_	14	aux	_	_
13	plasma	plasma	NN	_	14	com	_	_
14	proteins	protein	NNS	_	11	ppmod	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	fraction	fraction	NN	_	14	prn	_	_
17	bound	bound	JJ	_	16	attr	_	_
18	60	0	CD	_	16	num	_	_
19	%	%	NN	_	16	meta	_	_
20	15	0	CD	_	16	num	_	_
21	%	%	NN	_	16	meta	_	_
22	)	-rrb-	-RRB-	_	16	p	_	_
23	;	;	:	_	11	p	_	_

1	therefore	therefore	RB	_	9	adv	_	_
2	,	,	,	_	9	p	_	_
3	the	the	DT	_	4	det	_	_
4	disposition	disposition	NN	_	9	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	is	be	VBZ	_	9	aux	_	_
8	not	not	RB	_	9	neg	_	_
9	expected	expect	VBN	_	0	root	_	_
10	to	to	TO	_	11	aux	_	_
11	be	be	VB	_	9	comp	_	_
12	sensitive	sensitive	JJ	_	11	dep	_	_
13	to	to	TO	_	14	aux	_	_
14	alterations	alteration	NNS	_	12	ppmod	_	_
15	in	in	IN	_	17	case	_	_
16	protein	protein	NN	_	17	com	_	_
17	binding	binding	NN	_	14	ppmod	_	_
18	.	.	.	_	9	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	20	ppmod	_	_
3	,	,	,	_	20	p	_	_
4	administration	administration	NN	_	20	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	to	to	TO	_	9	aux	_	_
8	a	a	DT	_	9	det	_	_
9	patient	patient	NN	_	4	ppmod	_	_
10	taking	take	VBG	_	9	acl	_	_
11	another	another	DT	_	12	det	_	_
12	drug	drug	NN	_	10	obj	_	_
13	that	that	WDT	_	17	dep	_	_
14	is	be	VBZ	_	17	aux	_	_
15	highly	highly	RB	_	17	adv	_	_
16	protein	protein	NN	_	17	dep	_	_
17	bound	bind	VBN	_	12	relcl	_	_
18	should	should	MD	_	20	modal	_	_
19	not	not	RB	_	20	neg	_	_
20	cause	cause	VB	_	0	root	_	_
21	transient	transient	JJ	_	22	attr	_	_
22	increase	increase	NN	_	20	obj	_	_
23	in	in	IN	_	25	case	_	_
24	free	free	JJ	_	25	attr	_	_
25	concentrations	concentration	NNS	_	22	ppmod	_	_
26	of	of	IN	_	29	case	_	_
27	the	the	DT	_	29	det	_	_
28	other	other	JJ	_	29	attr	_	_
29	drug	drug	NN	_	25	ppmod	_	_
30	.	.	.	_	20	p	_	_

1	Drugs	drug	NNS	_	16	dep	_	_
2	with	with	IN	_	7	case	_	_
3	a	a	DT	_	7	det	_	_
4	Narrow	narrow	JJ	_	7	attr	_	_
5	Therapeutic	therapeutic	JJ	_	7	attr	_	_
6	Index	index	NN	_	7	com	_	_
7	drug1	drug0	NN	_	1	ppmod	_	_
8	:	:	:	_	7	p	_	_
9	drug2	drug0	NN	_	7	appo	_	_
10	(	-lrb-	-LRB-	_	12	p	_	_
11	10	0	CD	_	12	num	_	_
12	mg	mg	NN	_	9	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	did	do	VBD	_	16	aux	_	_
15	not	not	RB	_	16	neg	_	_
16	affect	affect	VB	_	0	root	_	_
17	the	the	DT	_	21	det	_	_
18	pharmacokinetic	pharmacokinetic	JJ	_	21	attr	_	_
19	or	or	CC	_	18	cc	_	_
20	pharmacodynamic	pharmacodynamic	JJ	_	18	conj	_	_
21	profile	profile	NN	_	16	obj	_	_
22	of	of	IN	_	23	case	_	_
23	drug3	drug0	NN	_	21	ppmod	_	_
24	(	-lrb-	-LRB-	_	27	p	_	_
25	0.375	0	CD	_	27	num	_	_
26	mg	mg	NN	_	27	com	_	_
27	q24h	q0h	NN	_	23	prn	_	_
28	for	for	IN	_	30	case	_	_
29	8	0	CD	_	30	num	_	_
30	days	day	NNS	_	27	ppmod	_	_
31	)	-rrb-	-RRB-	_	27	p	_	_
32	.	.	.	_	16	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Multiple	multiple	JJ	_	5	attr	_	_
4	oral	oral	JJ	_	5	attr	_	_
5	doses	dose	NNS	_	18	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	(	-lrb-	-LRB-	_	11	p	_	_
9	20	0	CD	_	10	num	_	_
10	mg	mg	NN	_	11	com	_	_
11	q24h	q0h	NN	_	7	prn	_	_
12	for	for	IN	_	14	case	_	_
13	13	0	CD	_	14	num	_	_
14	days	day	NNS	_	11	ppmod	_	_
15	)	-rrb-	-RRB-	_	11	p	_	_
16	did	do	VBD	_	18	aux	_	_
17	not	not	RB	_	18	neg	_	_
18	affect	affect	VB	_	1	acl	_	_
19	the	the	DT	_	20	det	_	_
20	pharmacokinetics	pharmacokinetics	NNS	_	18	obj	_	_
21	of	of	IN	_	22	case	_	_
22	drug3	drug0	NN	_	20	ppmod	_	_
23	(	-lrb-	-LRB-	_	24	p	_	_
24	R+	r+	JJ	_	22	prn	_	_
25	)	-rrb-	-RRB-	_	24	p	_	_
26	-	-	:	_	22	p	_	_
27	or	or	CC	_	22	cc	_	_
28	(	-lrb-	-LRB-	_	31	p	_	_
29	S-	s-	NN	_	31	attr	_	_
30	)	-rrb-	-RRB-	_	31	p	_	_
31	-enantiomers	-enantiomers	NNS	_	22	conj	_	_
32	or	or	CC	_	20	cc	_	_
33	the	the	DT	_	34	det	_	_
34	pharmacodynamics	pharmacodynamics	NNS	_	20	conj	_	_
35	(	-lrb-	-LRB-	_	37	p	_	_
36	prothrombin	prothrombin	NN	_	37	com	_	_
37	time	time	NN	_	34	prn	_	_
38	)	-rrb-	-RRB-	_	37	p	_	_
39	following	follow	VBG	_	44	adv	_	_
40	a	a	DT	_	44	det	_	_
41	single	single	JJ	_	44	attr	_	_
42	25-mg	0-mg	JJ	_	44	attr	_	_
43	oral	oral	JJ	_	44	attr	_	_
44	dose	dose	NN	_	34	ppmod	_	_
45	of	of	IN	_	46	case	_	_
46	drug4	drug0	NN	_	44	ppmod	_	_
47	.	.	.	_	1	p	_	_

1	Drugs	drug	NNS	_	0	root	_	_
2	That	that	WDT	_	3	dep	_	_
3	Alter	alter	VBP	_	1	relcl	_	_
4	Renal	renal	JJ	_	6	attr	_	_
5	Excretion	excretion	NN	_	6	com	_	_
6	drug1	drug0	NN	_	3	obj	_	_
7	:	:	:	_	1	p	_	_
8	drug2	drug0	NN	_	10	dep	_	_
9	is	be	VBZ	_	10	aux	_	_
10	known	know	VBN	_	1	acl	_	_
11	to	to	TO	_	12	aux	_	_
12	affect	affect	VB	_	10	comp	_	_
13	renal	renal	JJ	_	14	attr	_	_
14	function	function	NN	_	12	obj	_	_
15	and	and	CC	_	12	cc	_	_
16	,	,	,	_	12	p	_	_
17	consequently	consequently	RB	_	12	adv	_	_
18	,	,	,	_	12	p	_	_
19	alter	alter	VB	_	12	conj	_	_
20	the	the	DT	_	22	det	_	_
21	renal	renal	JJ	_	22	attr	_	_
22	excretion	excretion	NN	_	19	obj	_	_
23	of	of	IN	_	25	case	_	_
24	other	other	JJ	_	25	attr	_	_
25	drugs	drug	NNS	_	22	ppmod	_	_
26	.	.	.	_	1	p	_	_

1	There	there	EX	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	no	no	DT	_	6	det	_	_
4	apparent	apparent	JJ	_	6	attr	_	_
5	pharmacokinetic	pharmacokinetic	JJ	_	6	attr	_	_
6	interaction	interaction	NN	_	2	obj	_	_
7	between	between	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	drug2	drug0	NN	_	8	conj	_	_
11	following	follow	VBG	_	14	adv	_	_
12	single	single	JJ	_	14	attr	_	_
13	dose	dose	NN	_	14	com	_	_
14	administration	administration	NN	_	2	ppmod	_	_
15	(	-lrb-	-LRB-	_	17	p	_	_
16	10	0	CD	_	17	num	_	_
17	mg	mg	NN	_	14	prn	_	_
18	and	and	CC	_	17	cc	_	_
19	600	0	CD	_	20	num	_	_
20	mg	mg	NN	_	17	conj	_	_
21	,	,	,	_	17	p	_	_
22	respectively	respectively	RB	_	17	adv	_	_
23	)	-rrb-	-RRB-	_	17	p	_	_
24	of	of	IN	_	26	case	_	_
25	each	each	DT	_	26	det	_	_
26	drug	drug	NN	_	14	ppmod	_	_
27	.	.	.	_	2	p	_	_

1	This	this	DT	_	3	dep	_	_
2	was	be	VBD	_	3	aux	_	_
3	expected	expect	VBN	_	0	root	_	_
4	because	because	IN	_	8	mark	_	_
5	drug1	drug0	NN	_	8	dep	_	_
6	is	be	VBZ	_	8	aux	_	_
7	primarily	primarily	RB	_	8	adv	_	_
8	metabolized	metabolize	VBN	_	3	comp	_	_
9	and	and	CC	_	8	cc	_	_
10	renal	renal	JJ	_	11	attr	_	_
11	excretion	excretion	NN	_	15	dep	_	_
12	of	of	IN	_	14	case	_	_
13	unchanged	unchanged	JJ	_	14	attr	_	_
14	drug2	drug0	NNS	_	11	ppmod	_	_
15	accounts	account	VBZ	_	8	conj	_	_
16	for	for	IN	_	19	case	_	_
17	less	less	JJR	_	19	attr	_	_
18	than	than	IN	_	17	com	_	_
19	1	0	CD	_	15	ppmod	_	_
20	%	%	NN	_	19	meta	_	_
21	of	of	IN	_	24	case	_	_
22	the	the	DT	_	24	det	_	_
23	administered	administer	VBN	_	24	attr	_	_
24	dose	dose	NN	_	19	ppmod	_	_
25	.	.	.	_	3	p	_	_

1	Because	because	IN	_	4	mark	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	metabolized	metabolize	VBN	_	16	advcl	_	_
5	by	by	IN	_	7	case	_	_
6	monoamine	monoamine	NN	_	7	com	_	_
7	oxidase	oxidase	NN	_	4	ppmod	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	MAO	mao	NN	_	7	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	,	,	,	_	16	p	_	_
12	inhibition	inhibition	NN	_	16	dep	_	_
13	of	of	IN	_	15	case	_	_
14	this	this	DT	_	15	det	_	_
15	enzyme	enzyme	NN	_	12	ppmod	_	_
16	prolongs	prolong	VBZ	_	0	root	_	_
17	and	and	CC	_	16	cc	_	_
18	potentiates	potentiate	VBZ	_	16	conj	_	_
19	the	the	DT	_	20	det	_	_
20	effect	effect	NN	_	18	obj	_	_
21	of	of	IN	_	22	case	_	_
22	drug2	drug0	NN	_	20	ppmod	_	_
23	.	.	.	_	16	p	_	_

1	Patients	patient	NNS	_	20	dep	_	_
2	who	who	WP	_	5	dep	_	_
3	have	have	VBP	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	treated	treat	VBN	_	1	relcl	_	_
6	with	with	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	within	within	IN	_	12	case	_	_
9	two	#crd#	CD	_	12	num	_	_
10	to	to	TO	_	9	cc	_	_
11	three	#crd#	CD	_	9	conj	_	_
12	weeks	week	NNS	_	5	ppmod	_	_
13	prior	prior	JJ	_	12	attr	_	_
14	to	to	TO	_	16	aux	_	_
15	the	the	DT	_	16	det	_	_
16	administration	administration	NN	_	13	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	should	should	MD	_	20	modal	_	_
20	receive	receive	VBP	_	0	root	_	_
21	initial	initial	JJ	_	22	attr	_	_
22	doses	dose	NNS	_	20	obj	_	_
23	of	of	IN	_	24	case	_	_
24	drug3	drug0	NN	_	22	ppmod	_	_
25	no	no	RB	_	26	neg	_	_
26	greater	great	JJR	_	22	attr	_	_
27	than	than	IN	_	28	case	_	_
28	one-tenth	one-tenth	CD	_	26	ppmod	_	_
29	(	-lrb-	-LRB-	_	30	p	_	_
30	1/10	0	CD	_	28	num	_	_
31	)	-rrb-	-RRB-	_	30	p	_	_
32	of	of	IN	_	35	case	_	_
33	the	the	DT	_	35	det	_	_
34	usual	usual	JJ	_	35	attr	_	_
35	dose	dose	NN	_	28	ppmod	_	_
36	.	.	.	_	20	p	_	_

1	Concurrent	concurrent	JJ	_	2	attr	_	_
2	administration	administration	NN	_	9	dep	_	_
3	of	of	IN	_	5	case	_	_
4	low-dose	low-dose	JJ	_	5	attr	_	_
5	drug1	drug0	NN	_	2	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	may	may	MD	_	9	modal	_	_
9	produce	produce	VB	_	0	root	_	_
10	an	an	DT	_	14	det	_	_
11	additive	additive	JJ	_	14	attr	_	_
12	or	or	NN	_	14	com	_	_
13	potentiating	potentiating	NN	_	14	com	_	_
14	effect	effect	NN	_	9	obj	_	_
15	on	on	IN	_	17	case	_	_
16	urine	urine	NN	_	17	com	_	_
17	flow	flow	NN	_	14	ppmod	_	_
18	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	potentiate	potentiate	VB	_	0	root	_	_
4	the	the	DT	_	6	det	_	_
5	cardiovascular	cardiovascular	JJ	_	6	attr	_	_
6	effects	effect	NNS	_	3	obj	_	_
7	of	of	IN	_	9	case	_	_
8	adreneric	adreneric	JJ	_	9	attr	_	_
9	agents	agent	NNS	_	6	ppmod	_	_
10	.	.	.	_	3	p	_	_

1	Cardiac	cardiac	JJ	_	2	attr	_	_
2	effects	effect	NNS	_	6	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	are	be	VBP	_	6	aux	_	_
6	antagonized	antagonize	VBN	_	0	root	_	_
7	by	by	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	,	,	,	_	6	p	_	_
10	such	such	JJ	_	12	adv	_	_
11	as	as	IN	_	12	case	_	_
12	drug3	drug0	NN	_	6	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	drug4	drug0	NN	_	12	conj	_	_
15	.	.	.	_	6	p	_	_

1	The	the	DT	_	3	det	_	_
2	peripheral	peripheral	JJ	_	3	attr	_	_
3	vasoconstriction	vasoconstriction	NN	_	11	dep	_	_
4	caused	cause	VBN	_	3	acl	_	_
5	by	by	IN	_	7	case	_	_
6	high	high	JJ	_	7	attr	_	_
7	doses	dose	NNS	_	4	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	is	be	VBZ	_	11	aux	_	_
11	antagonized	antagonize	VBN	_	0	root	_	_
12	by	by	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	2	advnp	_	_
2	-induced	-induced	JJ	_	6	attr	_	_
3	renal	renal	JJ	_	6	attr	_	_
4	and	and	CC	_	3	cc	_	_
5	mesenteric	mesenteric	JJ	_	3	conj	_	_
6	vasodilation	vasodilation	NN	_	9	dep	_	_
7	is	be	VBZ	_	9	aux	_	_
8	not	not	RB	_	9	neg	_	_
9	antagonized	antagonize	VBN	_	0	root	_	_
10	by	by	IN	_	12	case	_	_
11	either	either	CC	_	12	cc	_	_
12	drug2	drug0	NN	_	9	ppmod	_	_
13	or	or	CC	_	12	cc	_	_
14	drug3	drug0	NN	_	12	conj	_	_
15	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	10	dep	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	such	such	JJ	_	1	prn	_	_
4	as	as	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	)	-rrb-	-RRB-	_	3	p	_	_
7	and	and	CC	_	1	cc	_	_
8	drug3	drug0	NN	_	1	conj	_	_
9	can	can	MD	_	10	modal	_	_
10	suppress	suppress	VB	_	0	root	_	_
11	the	the	DT	_	17	det	_	_
12	drug4	drug0	NN	_	17	attr	_	_
13	rgic	rgic	JJ	_	17	attr	_	_
14	renal	renal	JJ	_	17	attr	_	_
15	and	and	CC	_	14	cc	_	_
16	mesenteric	mesenteric	JJ	_	14	conj	_	_
17	vasodilation	vasodilation	NN	_	10	obj	_	_
18	induced	induce	VBN	_	17	acl	_	_
19	with	with	IN	_	23	case	_	_
20	low	low	JJ	_	23	attr	_	_
21	dose	dose	NN	_	23	com	_	_
22	dopamine	dopamine	NN	_	23	com	_	_
23	infusion	infusion	NN	_	18	ppmod	_	_
24	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	or	or	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	increase	increase	VBP	_	0	root	_	_
5	cardiac	cardiac	JJ	_	7	attr	_	_
6	autonomic	autonomic	JJ	_	7	attr	_	_
7	irritability	irritability	NN	_	4	obj	_	_
8	and	and	CC	_	4	cc	_	_
9	may	may	MD	_	10	modal	_	_
10	sensitize	sensitize	VB	_	4	conj	_	_
11	the	the	DT	_	12	det	_	_
12	myocardium	myocardium	NN	_	10	obj	_	_
13	to	to	TO	_	15	aux	_	_
14	the	the	DT	_	15	det	_	_
15	action	action	NN	_	10	ppmod	_	_
16	of	of	IN	_	20	case	_	_
17	certain	certain	JJ	_	20	attr	_	_
18	intravenously	intravenously	RB	_	19	adv	_	_
19	administered	administer	VBN	_	20	attr	_	_
20	drug3	drug0	NNS	_	15	ppmod	_	_
21	,	,	,	_	20	p	_	_
22	such	such	JJ	_	24	adv	_	_
23	as	as	IN	_	24	case	_	_
24	drug4	drug0	NN	_	20	ppmod	_	_
25	.	.	.	_	4	p	_	_

1	This	this	DT	_	2	det	_	_
2	interaction	interaction	NN	_	3	dep	_	_
3	appears	appear	VBZ	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	be	be	VB	_	3	comp	_	_
6	related	related	JJ	_	5	dep	_	_
7	both	both	CC	_	10	cc	_	_
8	to	to	TO	_	10	aux	_	_
9	pressor	pressor	NN	_	10	com	_	_
10	activity	activity	NN	_	6	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	to	to	TO	_	15	aux	_	_
13	beta-adrenergic	beta-adrenergic	JJ	_	15	attr	_	_
14	stimulating	stimulating	JJ	_	15	attr	_	_
15	properties	property	NNS	_	10	conj	_	_
16	of	of	IN	_	18	case	_	_
17	these	these	DT	_	18	det	_	_
18	drug1	drug0	NN	_	15	ppmod	_	_
19	and	and	CC	_	3	cc	_	_
20	may	may	MD	_	21	modal	_	_
21	produce	produce	VB	_	3	conj	_	_
22	ventricular	ventricular	JJ	_	23	attr	_	_
23	arrhythmias	arrhythmia	NNS	_	21	obj	_	_
24	and	and	CC	_	23	cc	_	_
25	hypertension	hypertension	NN	_	23	conj	_	_
26	.	.	.	_	3	p	_	_

1	Therefore	therefore	RB	_	7	adv	_	_
2	,	,	,	_	7	p	_	_
3	EXTREME	extreme	JJ	_	4	attr	_	_
4	CAUTION	caution	NN	_	7	dep	_	_
5	should	should	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	exercised	exercise	VBN	_	0	root	_	_
8	when	when	WRB	_	9	adv	_	_
9	administering	administer	VBG	_	7	comp	_	_
10	drug1	drug0	NN	_	9	obj	_	_
11	to	to	TO	_	12	aux	_	_
12	patients	patient	NNS	_	9	ppmod	_	_
13	receiving	receive	VBG	_	12	acl	_	_
14	drug2	drug0	NN	_	13	obj	_	_
15	or	or	CC	_	14	cc	_	_
16	drug3	drug0	NN	_	14	conj	_	_
17	.	.	.	_	7	p	_	_

1	It	it	PRP	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	reported	report	VBN	_	0	root	_	_
5	that	that	IN	_	11	mark	_	_
6	results	result	NNS	_	11	dep	_	_
7	of	of	IN	_	8	case	_	_
8	studies	study	NNS	_	6	ppmod	_	_
9	in	in	IN	_	10	case	_	_
10	animals	animal	NNS	_	8	ppmod	_	_
11	indicate	indicate	VBP	_	4	comp	_	_
12	that	that	IN	_	21	mark	_	_
13	drug1	drug0	NN	_	16	attr	_	_
14	-induced	-induced	JJ	_	16	attr	_	_
15	ventricular	ventricular	JJ	_	16	attr	_	_
16	arrhythmias	arrhythmia	NNS	_	21	dep	_	_
17	during	during	IN	_	18	case	_	_
18	anesthesia	anesthesia	NN	_	16	ppmod	_	_
19	can	can	MD	_	21	modal	_	_
20	be	be	VB	_	21	aux	_	_
21	reversed	reverse	VBN	_	11	comp	_	_
22	by	by	IN	_	23	case	_	_
23	drug2	drug0	NN	_	21	ppmod	_	_
24	.	.	.	_	4	p	_	_

1	The	the	DT	_	3	det	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	use	use	NN	_	19	dep	_	_
4	of	of	IN	_	6	case	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	s	s	NNS	_	3	ppmod	_	_
7	,	,	,	_	6	p	_	_
8	vasoconstricting	vasoconstricting	VBG	_	9	attr	_	_
9	agents	agent	NNS	_	6	conj	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	such	such	JJ	_	9	prn	_	_
12	as	as	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	)	-rrb-	-RRB-	_	11	p	_	_
15	and	and	CC	_	9	cc	_	_
16	some	some	DT	_	17	det	_	_
17	drug3	drug0	NNS	_	6	conj	_	_
18	may	may	MD	_	19	modal	_	_
19	result	result	VB	_	0	root	_	_
20	in	in	IN	_	22	case	_	_
21	severe	severe	JJ	_	22	attr	_	_
22	hypertension	hypertension	NN	_	19	ppmod	_	_
23	.	.	.	_	19	p	_	_

1	Administration	administration	NN	_	10	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	to	to	TO	_	5	aux	_	_
5	patients	patient	NNS	_	1	ppmod	_	_
6	receiving	receive	VBG	_	5	acl	_	_
7	drug2	drug0	NN	_	6	obj	_	_
8	has	have	VBZ	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	reported	report	VBN	_	0	root	_	_
11	to	to	TO	_	12	aux	_	_
12	lead	lead	VB	_	10	comp	_	_
13	to	to	TO	_	14	aux	_	_
14	hypotension	hypotension	NN	_	12	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	bradycardia	bradycardia	NN	_	14	conj	_	_
17	.	.	.	_	10	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	suggested	suggest	VBN	_	0	root	_	_
4	that	that	IN	_	15	mark	_	_
5	in	in	IN	_	6	case	_	_
6	patients	patient	NNS	_	15	ppmod	_	_
7	receiving	receive	VBG	_	6	acl	_	_
8	drug1	drug0	NN	_	7	obj	_	_
9	,	,	,	_	15	p	_	_
10	alternatives	alternative	NNS	_	15	dep	_	_
11	to	to	TO	_	12	aux	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	should	should	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	used	use	VBN	_	3	comp	_	_
16	if	if	IN	_	20	mark	_	_
17	drug3	drug0	NN	_	18	com	_	_
18	therapy	therapy	NN	_	20	dep	_	_
19	is	be	VBZ	_	20	aux	_	_
20	needed	need	VBN	_	15	comp	_	_
21	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	10	dep	_	_
2	-	-	:	_	1	p	_	_
3	Taking	take	VBG	_	1	acl	_	_
4	drug2	drug0	NN	_	3	obj	_	_
5	and	and	CC	_	4	cc	_	_
6	a	a	DT	_	7	det	_	_
7	drug3	drug0	NN	_	4	conj	_	_
8	together	together	RB	_	7	adv	_	_
9	may	may	MD	_	10	modal	_	_
10	increase	increase	VB	_	0	root	_	_
11	the	the	DT	_	12	det	_	_
12	risk	risk	NN	_	10	obj	_	_
13	of	of	IN	_	14	case	_	_
14	convulsions	convulsion	NNS	_	12	ppmod	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	seizures	seizure	NNS	_	14	prn	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	(	-lrb-	-LRB-	_	5	p	_	_
3	e.g.	e.g.	FW	_	5	ppmod	_	_
4	,	,	,	_	5	p	_	_
5	drug2	drug0	NN	_	1	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	-	-	:	_	1	p	_	_
8	Taking	take	VBG	_	14	advcl	_	_
9	drug3	drug0	NN	_	8	obj	_	_
10	and	and	CC	_	9	cc	_	_
11	drug4	drug0	NN	_	9	conj	_	_
12	together	together	RB	_	8	adv	_	_
13	may	may	MD	_	14	modal	_	_
14	decrease	decrease	VB	_	1	acl	_	_
15	the	the	DT	_	16	det	_	_
16	effects	effect	NNS	_	14	obj	_	_
17	of	of	IN	_	18	case	_	_
18	drug5	drug0	NN	_	16	ppmod	_	_
19	.	.	.	_	1	p	_	_

1	There	there	EX	_	3	dep	_	_
2	have	have	VBP	_	3	aux	_	_
3	been	be	VBN	_	0	root	_	_
4	isolated	isolate	VBN	_	5	attr	_	_
5	reports	report	NNS	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	patients	patient	NNS	_	5	ppmod	_	_
8	experiencing	experience	VBG	_	7	acl	_	_
9	increases	increase	NNS	_	8	obj	_	_
10	in	in	IN	_	13	case	_	_
11	their	their	PRP$	_	13	poss	_	_
12	prothrombin	prothrombin	NN	_	13	com	_	_
13	times	time	NNS	_	9	ppmod	_	_
14	when	when	WRB	_	17	adv	_	_
15	drug1	drug0	NN	_	17	dep	_	_
16	was	be	VBD	_	17	aux	_	_
17	added	add	VBN	_	13	relcl	_	_
18	to	to	TO	_	20	aux	_	_
19	drug2	drug0	NN	_	20	com	_	_
20	therapy	therapy	NN	_	17	ppmod	_	_
21	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	majority	majority	NN	_	6	dep	_	_
3	of	of	IN	_	5	case	_	_
4	these	these	DT	_	5	det	_	_
5	reports	report	NNS	_	2	ppmod	_	_
6	concerned	concern	VBD	_	0	root	_	_
7	variable	variable	JJ	_	8	attr	_	_
8	elevations	elevation	NNS	_	6	obj	_	_
9	in	in	IN	_	11	case	_	_
10	prothrombin	prothrombin	NN	_	11	com	_	_
11	times	time	NNS	_	8	ppmod	_	_
12	without	without	IN	_	15	case	_	_
13	clinically	clinically	RB	_	14	adv	_	_
14	significant	significant	JJ	_	15	attr	_	_
15	sequelae	sequelae	NN	_	11	ppmod	_	_
16	.	.	.	_	6	p	_	_

1	Although	although	IN	_	13	mark	_	_
2	the	the	DT	_	3	det	_	_
3	relevance	relevance	NN	_	13	dep	_	_
4	of	of	IN	_	6	case	_	_
5	these	these	DT	_	6	det	_	_
6	reports	report	NNS	_	3	ppmod	_	_
7	and	and	CC	_	3	cc	_	_
8	any	any	DT	_	9	det	_	_
9	mechanism	mechanism	NN	_	3	conj	_	_
10	of	of	IN	_	12	case	_	_
11	coagulation	coagulation	NN	_	12	com	_	_
12	alterations	alteration	NNS	_	9	ppmod	_	_
13	is	be	VBZ	_	20	advcl	_	_
14	unclear	unclear	JJ	_	13	dep	_	_
15	,	,	,	_	20	p	_	_
16	patients	patient	NNS	_	20	dep	_	_
17	on	on	IN	_	18	case	_	_
18	drug1	drug0	NN	_	16	ppmod	_	_
19	should	should	MD	_	20	modal	_	_
20	have	have	VB	_	0	root	_	_
21	their	their	PRP$	_	23	poss	_	_
22	prothrombin	prothrombin	NN	_	23	com	_	_
23	time	time	NN	_	20	obj	_	_
24	monitored	monitor	VBN	_	23	acl	_	_
25	.	.	.	_	20	p	_	_

1	The	the	DT	_	4	det	_	_
2	drug	drug	NN	_	4	com	_	_
3	interaction	interaction	NN	_	4	com	_	_
4	studies	study	NNS	_	8	dep	_	_
5	with	with	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	were	be	VBD	_	8	aux	_	_
8	performed	performed	VBN	_	0	root	_	_
9	both	both	CC	_	11	cc	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NN	_	8	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	a	a	DT	_	17	det	_	_
14	rapidly	rapidly	RB	_	15	adv	_	_
15	hydrolyzed	hydrolyzed	JJ	_	17	attr	_	_
16	intravenous	intravenous	JJ	_	17	attr	_	_
17	prodrug	prodrug	NN	_	18	com	_	_
18	form	form	NN	_	11	conj	_	_
19	.	.	.	_	8	p	_	_

1	The	the	DT	_	2	det	_	_
2	results	result	NNS	_	10	dep	_	_
3	from	from	IN	_	4	case	_	_
4	trials	trial	NNS	_	2	ppmod	_	_
5	using	use	VBG	_	4	acl	_	_
6	the	the	DT	_	8	det	_	_
7	intravenous	intravenous	JJ	_	8	attr	_	_
8	prodrug	prodrug	NN	_	5	obj	_	_
9	are	be	VBP	_	10	aux	_	_
10	reported	report	VBN	_	0	root	_	_
11	in	in	IN	_	13	case	_	_
12	this	this	DT	_	13	det	_	_
13	section	section	NN	_	10	ppmod	_	_
14	as	as	IN	_	16	mark	_	_
15	they	they	PRP	_	16	dep	_	_
16	relate	relate	VB	_	10	comp	_	_
17	to	to	TO	_	19	aux	_	_
18	the	the	DT	_	19	det	_	_
19	role	role	NN	_	16	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	drug1	drug0	NN	_	19	ppmod	_	_
22	in	in	IN	_	24	case	_	_
23	drug	drug	NN	_	24	com	_	_
24	interactions	interaction	NNS	_	19	ppmod	_	_
25	.	.	.	_	10	p	_	_

1	General	general	JJ	_	10	dep	_	_
2	:	:	:	_	10	p	_	_
3	In	in	IN	_	4	case	_	_
4	humans	human	NNS	_	10	ppmod	_	_
5	,	,	,	_	10	p	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	metabolism	metabolism	NN	_	10	dep	_	_
8	is	be	VBZ	_	10	aux	_	_
9	predominantly	predominantly	RB	_	10	adv	_	_
10	mediated	mediate	VBN	_	0	root	_	_
11	via	via	IN	_	12	case	_	_
12	CYP	cyp	VBG	_	10	ppmod	_	_
13	3A4	0a0	NN	_	12	obj	_	_
14	and	and	CC	_	13	cc	_	_
15	2C9	0c0	NN	_	13	conj	_	_
16	with	with	IN	_	18	case	_	_
17	glucuronidation	glucuronidation	NN	_	18	dep	_	_
18	being	be	VBG	_	12	ppmod	_	_
19	a	a	DT	_	25	det	_	_
20	further	far	JJ	_	25	attr	_	_
21	(	-lrb-	-LRB-	_	22	p	_	_
22	20	0	CD	_	20	num	_	_
23	%	%	NN	_	22	meta	_	_
24	)	-rrb-	-RRB-	_	22	p	_	_
25	route	route	NN	_	18	obj	_	_
26	of	of	IN	_	27	case	_	_
27	metabolism	metabolism	NN	_	25	ppmod	_	_
28	.	.	.	_	10	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	studies	study	NNS	_	4	dep	_	_
4	indicate	indicate	VBP	_	0	root	_	_
5	that	that	IN	_	7	mark	_	_
6	drug1	drug0	NN	_	7	dep	_	_
7	is	be	VBZ	_	4	comp	_	_
8	a	a	DT	_	10	det	_	_
9	moderate	moderate	JJ	_	10	attr	_	_
10	inhibitor	inhibitor	NN	_	7	obj	_	_
11	of	of	IN	_	13	case	_	_
12	CYP	cyp	NN	_	13	com	_	_
13	2C19	0c0	NN	_	10	ppmod	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	IC50	ic0	NN	_	10	prn	_	_
16	=	=	JJ	_	15	attr	_	_
17	6	0	CD	_	21	num	_	_
18	g/mL	g/ml	NN	_	17	attr	_	_
19	or	or	CC	_	17	cc	_	_
20	19	0	CD	_	17	conj	_	_
21	M	m	NN	_	16	advnp	_	_
22	)	-rrb-	-RRB-	_	15	p	_	_
23	and	and	CC	_	10	cc	_	_
24	2C9	0c0	NN	_	10	conj	_	_
25	(	-lrb-	-LRB-	_	26	p	_	_
26	IC50	ic0	NN	_	10	prn	_	_
27	=	=	JJ	_	26	attr	_	_
28	13	0	CD	_	32	num	_	_
29	g/mL	g/ml	NN	_	28	attr	_	_
30	or	or	CC	_	28	cc	_	_
31	41	0	CD	_	28	conj	_	_
32	M	m	NN	_	27	advnp	_	_
33	)	-rrb-	-RRB-	_	26	p	_	_
34	,	,	,	_	10	p	_	_
35	and	and	CC	_	10	cc	_	_
36	a	a	DT	_	38	det	_	_
37	weak	weak	JJ	_	38	attr	_	_
38	inhibitor	inhibitor	NN	_	10	conj	_	_
39	of	of	IN	_	41	case	_	_
40	CYP	cyp	NN	_	41	com	_	_
41	2D6	0d0	NN	_	38	ppmod	_	_
42	(	-lrb-	-LRB-	_	43	p	_	_
43	IC50	ic0	NN	_	38	prn	_	_
44	=	=	JJ	_	43	attr	_	_
45	31	0	CD	_	49	num	_	_
46	g/mL	g/ml	NN	_	45	attr	_	_
47	or	or	CC	_	45	cc	_	_
48	100	0	CD	_	45	conj	_	_
49	M	m	NN	_	44	advnp	_	_
50	)	-rrb-	-RRB-	_	43	p	_	_
51	and	and	CC	_	38	cc	_	_
52	3A4	0a0	NN	_	38	conj	_	_
53	(	-lrb-	-LRB-	_	54	p	_	_
54	IC50	ic0	NN	_	38	prn	_	_
55	=	=	JJ	_	54	attr	_	_
56	44	0	CD	_	60	num	_	_
57	g/mL	g/ml	NN	_	56	attr	_	_
58	or	or	CC	_	56	cc	_	_
59	141	0	CD	_	56	conj	_	_
60	M	m	NN	_	55	advnp	_	_
61	)	-rrb-	-RRB-	_	54	p	_	_
62	.	.	.	_	4	p	_	_
63	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Concomitant	concomitant	JJ	_	4	attr	_	_
4	administration	administration	NN	_	10	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	with	with	IN	_	8	case	_	_
8	drug3	drug0	NN	_	4	ppmod	_	_
9	may	may	MD	_	10	modal	_	_
10	result	result	VB	_	1	acl	_	_
11	in	in	IN	_	14	case	_	_
12	an	an	DT	_	14	det	_	_
13	increased	increase	VBN	_	14	attr	_	_
14	risk	risk	NN	_	10	ppmod	_	_
15	of	of	IN	_	17	case	_	_
16	GI	gi	NN	_	17	com	_	_
17	ulceration	ulceration	NN	_	14	ppmod	_	_
18	and	and	CC	_	17	cc	_	_
19	complications	complication	NNS	_	17	conj	_	_
20	compared	compare	VBN	_	22	adv	_	_
21	to	to	TO	_	22	aux	_	_
22	drug4	drug0	NN	_	10	ppmod	_	_
23	alone	alone	RB	_	22	adv	_	_
24	.	.	.	_	1	p	_	_

1	Because	because	IN	_	4	case	_	_
2	of	of	IN	_	4	case	_	_
3	its	its	PRP$	_	4	poss	_	_
4	lack	lack	NN	_	12	ppmod	_	_
5	of	of	IN	_	8	case	_	_
6	anti-platelet	anti-platelet	JJ	_	8	attr	_	_
7	effect	effect	NN	_	8	com	_	_
8	drug1	drug0	NN	_	4	ppmod	_	_
9	is	be	VBZ	_	12	aux	_	_
10	not	not	RB	_	12	neg	_	_
11	a	a	DT	_	12	det	_	_
12	substitute	substitute	VB	_	0	root	_	_
13	for	for	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	for	for	IN	_	17	case	_	_
16	cardiovascular	cardiovascular	JJ	_	17	attr	_	_
17	prophylaxis	prophylaxis	NN	_	12	ppmod	_	_
18	.	.	.	_	12	p	_	_

1	In	in	IN	_	7	case	_	_
2	a	a	DT	_	7	det	_	_
3	parallel	parallel	JJ	_	7	attr	_	_
4	group	group	NN	_	7	com	_	_
5	drug	drug	NN	_	7	com	_	_
6	interaction	interaction	NN	_	7	com	_	_
7	study	study	NN	_	29	ppmod	_	_
8	comparing	compare	VBG	_	7	acl	_	_
9	the	the	DT	_	12	det	_	_
10	intravenous	intravenous	JJ	_	12	attr	_	_
11	prodrug	prodrug	NN	_	12	com	_	_
12	form	form	NN	_	8	obj	_	_
13	of	of	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	at	at	IN	_	17	case	_	_
16	40	0	CD	_	17	num	_	_
17	mg	mg	NN	_	8	ppmod	_	_
18	BID	bid	JJ	_	17	attr	_	_
19	(	-lrb-	-LRB-	_	20	p	_	_
20	n=10	n=0	NN	_	17	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	vs	vs	CC	_	17	cc	_	_
23	placebo	placebo	NN	_	17	conj	_	_
24	(	-lrb-	-LRB-	_	25	p	_	_
25	n=9	n=0	NN	_	23	prn	_	_
26	)	-rrb-	-RRB-	_	25	p	_	_
27	,	,	,	_	29	p	_	_
28	drug2	drug0	NN	_	29	dep	_	_
29	had	have	VBD	_	0	root	_	_
30	no	no	DT	_	31	det	_	_
31	effect	effect	NN	_	29	obj	_	_
32	on	on	IN	_	37	case	_	_
33	in	in	FW	_	34	adv	_	_
34	vitro	vitro	FW	_	35	attr	_	_
35	drug3	drug0	NN	_	36	advnp	_	_
36	-mediated	-mediated	JJ	_	37	attr	_	_
37	inhibition	inhibition	NN	_	29	ppmod	_	_
38	of	of	IN	_	39	case	_	_
39	arachidonate-	arachidonate-	NN	_	37	ppmod	_	_
40	or	or	CC	_	39	cc	_	_
41	collagen-stimulated	collagen-stimulated	JJ	_	43	attr	_	_
42	platelet	platelet	NN	_	43	com	_	_
43	aggregation	aggregation	NN	_	39	conj	_	_
44	.	.	.	_	29	p	_	_

1	drug1	drug0	NN	_	4	attr	_	_
2	:	:	:	_	4	p	_	_
3	drug2	drug0	NN	_	4	com	_	_
4	BID	bid	NN	_	7	dep	_	_
5	did	do	VBD	_	7	aux	_	_
6	not	not	RB	_	7	neg	_	_
7	show	show	VB	_	0	root	_	_
8	a	a	DT	_	10	det	_	_
9	significant	significant	JJ	_	10	attr	_	_
10	effect	effect	NN	_	7	obj	_	_
11	on	on	IN	_	14	case	_	_
12	the	the	DT	_	14	det	_	_
13	plasma	plasma	NN	_	14	com	_	_
14	exposure	exposure	NN	_	10	ppmod	_	_
15	or	or	CC	_	14	cc	_	_
16	renal	renal	JJ	_	17	attr	_	_
17	clearance	clearance	NN	_	14	conj	_	_
18	of	of	IN	_	19	case	_	_
19	drug3	drug0	NN	_	17	ppmod	_	_
20	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Reports	report	NNS	_	4	dep	_	_
4	suggest	suggest	VBP	_	1	acl	_	_
5	that	that	IN	_	8	mark	_	_
6	drug2	drug0	NN	_	8	dep	_	_
7	may	may	MD	_	8	modal	_	_
8	diminish	diminish	VB	_	4	comp	_	_
9	the	the	DT	_	11	det	_	_
10	antihypertensive	antihypertensive	JJ	_	11	attr	_	_
11	effect	effect	NN	_	8	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug3	drug0	NN	_	11	ppmod	_	_
14	.	.	.	_	1	p	_	_

1	This	this	DT	_	2	det	_	_
2	interaction	interaction	NN	_	6	dep	_	_
3	should	should	MD	_	6	modal	_	_
4	be	be	VB	_	6	aux	_	_
5	given	give	VBN	_	6	lv	_	_
6	consideration	consideration	NN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	6	ppmod	_	_
9	taking	take	VBG	_	8	acl	_	_
10	drug1	drug0	NN	_	9	obj	_	_
11	concomitantly	concomitantly	RB	_	6	adv	_	_
12	with	with	IN	_	13	case	_	_
13	drug2	drug0	NN	_	6	ppmod	_	_
14	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Clinical	clinical	JJ	_	4	attr	_	_
4	studies	study	NNS	_	13	dep	_	_
5	,	,	,	_	4	p	_	_
6	as	as	RB	_	7	com	_	_
7	well	well	RB	_	4	cc	_	_
8	as	as	IN	_	7	com	_	_
9	post-marketing	post-marketing	JJ	_	10	attr	_	_
10	observations	observation	NNS	_	4	conj	_	_
11	,	,	,	_	10	p	_	_
12	have	have	VBP	_	13	aux	_	_
13	shown	show	VBN	_	1	acl	_	_
14	that	that	IN	_	17	mark	_	_
15	drug2	drug0	NN	_	17	dep	_	_
16	can	can	MD	_	17	modal	_	_
17	reduce	reduce	VB	_	13	comp	_	_
18	the	the	DT	_	20	det	_	_
19	natriuretic	natriuretic	JJ	_	20	attr	_	_
20	effect	effect	NN	_	17	obj	_	_
21	of	of	IN	_	22	case	_	_
22	drug3	drug0	NN	_	20	ppmod	_	_
23	and	and	CC	_	22	cc	_	_
24	drug4	drug0	NN	_	22	conj	_	_
25	in	in	IN	_	27	case	_	_
26	some	some	DT	_	27	det	_	_
27	patients	patient	NNS	_	20	ppmod	_	_
28	.	.	.	_	1	p	_	_

1	This	this	DT	_	2	det	_	_
2	response	response	NN	_	5	dep	_	_
3	has	have	VBZ	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	attributed	attribute	VBN	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	inhibition	inhibition	NN	_	5	ppmod	_	_
8	of	of	IN	_	11	case	_	_
9	renal	renal	JJ	_	11	attr	_	_
10	prostaglandin	prostaglandin	NN	_	11	com	_	_
11	synthesis	synthesis	NN	_	7	ppmod	_	_
12	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	drug2	drug0	NN	_	1	prn	_	_
4	)	-rrb-	-RRB-	_	3	p	_	_
5	:	:	:	_	1	p	_	_
6	Steady	steady	JJ	_	9	attr	_	_
7	state	state	NN	_	9	com	_	_
8	plasma	plasma	NN	_	9	com	_	_
9	exposure	exposure	NN	_	24	dep	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	AUC	auc	NN	_	9	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	of	of	IN	_	14	case	_	_
14	drug3	drug0	NN	_	9	ppmod	_	_
15	(	-lrb-	-LRB-	_	18	p	_	_
16	40	0	CD	_	17	num	_	_
17	mg	mg	NN	_	18	com	_	_
18	BID	bid	NN	_	14	prn	_	_
19	for	for	IN	_	21	case	_	_
20	12	0	CD	_	21	num	_	_
21	days	day	NNS	_	18	ppmod	_	_
22	)	-rrb-	-RRB-	_	18	p	_	_
23	was	be	VBD	_	24	aux	_	_
24	decreased	decrease	VBN	_	1	acl	_	_
25	by	by	IN	_	26	case	_	_
26	27	0	CD	_	24	ppmod	_	_
27	%	%	NN	_	26	meta	_	_
28	when	when	WRB	_	29	adv	_	_
29	co-administered	co-administered	VBN	_	24	comp	_	_
30	with	with	IN	_	32	case	_	_
31	multiple	multiple	JJ	_	32	attr	_	_
32	doses	dose	NNS	_	29	ppmod	_	_
33	(	-lrb-	-LRB-	_	36	p	_	_
34	300	0	CD	_	35	num	_	_
35	mg	mg	NN	_	36	com	_	_
36	QD	qd	NN	_	32	prn	_	_
37	for	for	IN	_	39	case	_	_
38	12	0	CD	_	39	num	_	_
39	days	day	NNS	_	36	ppmod	_	_
40	)	-rrb-	-RRB-	_	36	p	_	_
41	of	of	IN	_	42	case	_	_
42	drug4	drug0	NN	_	32	ppmod	_	_
43	(	-lrb-	-LRB-	_	47	p	_	_
44	a	a	DT	_	47	det	_	_
45	CYP	cyp	NN	_	47	com	_	_
46	3A4	0a0	NN	_	47	com	_	_
47	inducer	inducer	NN	_	42	prn	_	_
48	)	-rrb-	-RRB-	_	47	p	_	_
49	.	.	.	_	1	p	_	_

1	Patients	patient	NNS	_	9	dep	_	_
2	already	already	RB	_	3	adv	_	_
3	stabilized	stabilize	VBN	_	1	acl	_	_
4	on	on	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	should	should	MD	_	9	modal	_	_
7	be	be	VB	_	9	aux	_	_
8	closely	closely	RB	_	9	adv	_	_
9	monitored	monitor	VBN	_	0	root	_	_
10	for	for	IN	_	11	case	_	_
11	loss	loss	NN	_	9	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	symptom	symptom	JJ	_	14	attr	_	_
14	control	control	NN	_	11	ppmod	_	_
15	with	with	IN	_	17	case	_	_
16	drug2	drug0	NN	_	17	com	_	_
17	coadministration	coadministration	NN	_	14	ppmod	_	_
18	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	did	do	VBD	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	have	have	VB	_	0	root	_	_
5	a	a	DT	_	8	det	_	_
6	statistically	statistically	RB	_	7	adv	_	_
7	significant	significant	JJ	_	8	attr	_	_
8	effect	effect	NN	_	4	obj	_	_
9	on	on	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	pharmacokinetics	pharmacokinetics	NNS	_	8	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	(	-lrb-	-LRB-	_	17	p	_	_
15	a	a	DT	_	17	det	_	_
16	CYP	cyp	NN	_	17	com	_	_
17	2C9	0c0	NN	_	13	prn	_	_
18	and	and	CC	_	17	cc	_	_
19	CYP	cyp	NN	_	21	com	_	_
20	2C19	0c0	NN	_	21	com	_	_
21	substrate	substrate	NN	_	17	conj	_	_
22	)	-rrb-	-RRB-	_	17	p	_	_
23	.	.	.	_	4	p	_	_

1	Drug	drug	NN	_	3	com	_	_
2	interaction	interaction	NN	_	3	com	_	_
3	studies	study	NNS	_	10	dep	_	_
4	with	with	IN	_	6	case	_	_
5	other	other	JJ	_	6	attr	_	_
6	drug1	drug0	NN	_	3	ppmod	_	_
7	have	have	VBP	_	10	aux	_	_
8	not	not	RB	_	10	neg	_	_
9	been	be	VBN	_	10	aux	_	_
10	conducted	conduct	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	Routine	routine	JJ	_	2	attr	_	_
2	monitoring	monitoring	NN	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	performed	performed	VBN	_	0	root	_	_
6	when	when	WRB	_	12	adv	_	_
7	therapy	therapy	NN	_	12	dep	_	_
8	with	with	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	is	be	VBZ	_	12	aux	_	_
11	either	either	CC	_	12	cc	_	_
12	initiated	initiate	VBN	_	5	comp	_	_
13	or	or	CC	_	12	cc	_	_
14	discontinued	discontinue	VBN	_	12	conj	_	_
15	in	in	IN	_	16	case	_	_
16	patients	patient	NNS	_	14	ppmod	_	_
17	on	on	IN	_	19	case	_	_
18	anticonvulsant	anticonvulsant	JJ	_	19	attr	_	_
19	therapy	therapy	NN	_	16	ppmod	_	_
20	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	is	be	VBZ	_	6	aux	_	_
5	primarily	primarily	RB	_	6	adv	_	_
6	metabolized	metabolize	VBN	_	0	root	_	_
7	by	by	IN	_	9	case	_	_
8	CYP	cyp	NN	_	9	com	_	_
9	2D6	0d0	NN	_	6	ppmod	_	_
10	and	and	CC	_	6	cc	_	_
11	to	to	TO	_	14	aux	_	_
12	a	a	DT	_	14	det	_	_
13	lesser	less	JJR	_	14	attr	_	_
14	extent	extent	NN	_	6	conj	_	_
15	by	by	IN	_	16	case	_	_
16	3A4	0a0	NN	_	14	ppmod	_	_
17	.	.	.	_	6	p	_	_

1	Coadministration	coadministration	NN	_	12	dep	_	_
2	with	with	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	(	-lrb-	-LRB-	_	6	p	_	_
5	40	0	CD	_	6	num	_	_
6	mg	mg	NN	_	3	prn	_	_
7	BID	bid	JJ	_	6	attr	_	_
8	for	for	IN	_	10	case	_	_
9	7	0	CD	_	10	num	_	_
10	days	day	NNS	_	7	ppmod	_	_
11	)	-rrb-	-RRB-	_	6	p	_	_
12	resulted	result	VBD	_	0	root	_	_
13	in	in	IN	_	16	case	_	_
14	a	a	DT	_	16	det	_	_
15	significant	significant	JJ	_	16	attr	_	_
16	increase	increase	NN	_	12	ppmod	_	_
17	in	in	IN	_	20	case	_	_
18	drug2	drug0	NN	_	20	com	_	_
19	plasma	plasma	NN	_	20	com	_	_
20	levels	level	NNS	_	16	ppmod	_	_
21	suggesting	suggest	VBG	_	12	comp	_	_
22	that	that	IN	_	29	mark	_	_
23	,	,	,	_	29	p	_	_
24	at	at	IN	_	26	case	_	_
25	these	these	DT	_	26	det	_	_
26	doses	dose	NNS	_	29	ppmod	_	_
27	,	,	,	_	29	p	_	_
28	drug3	drug0	NN	_	29	dep	_	_
29	is	be	VBZ	_	21	comp	_	_
30	a	a	DT	_	32	det	_	_
31	weak	weak	JJ	_	32	attr	_	_
32	inhibitor	inhibitor	NN	_	29	obj	_	_
33	of	of	IN	_	34	case	_	_
34	2D6	0d0	NN	_	32	ppmod	_	_
35	.	.	.	_	12	p	_	_

1	Even	even	RB	_	2	com	_	_
2	so	so	RB	_	14	adv	_	_
3	drug1	drug0	NN	_	5	com	_	_
4	plasma	plasma	NN	_	5	com	_	_
5	concentrations	concentration	NNS	_	14	dep	_	_
6	in	in	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	presence	presence	NN	_	5	ppmod	_	_
9	of	of	IN	_	11	case	_	_
10	high	high	JJ	_	11	attr	_	_
11	doses	dose	NNS	_	8	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	were	be	VBD	_	0	root	_	_
15	almost	almost	RB	_	16	com	_	_
16	5-fold	0-fold	RB	_	17	adv	_	_
17	lower	low	JJR	_	14	dep	_	_
18	than	than	IN	_	19	case	_	_
19	those	those	DT	_	17	ppmod	_	_
20	seen	see	VBN	_	19	acl	_	_
21	in	in	IN	_	25	case	_	_
22	CYP	cyp	NN	_	23	com	_	_
23	2D6	0d0	NN	_	25	attr	_	_
24	poor	poor	JJ	_	25	attr	_	_
25	metabolizers	metabolizers	NNS	_	20	ppmod	_	_
26	suggesting	suggest	VBG	_	25	acl	_	_
27	that	that	IN	_	30	mark	_	_
28	dose	dose	NN	_	29	com	_	_
29	adjustment	adjustment	NN	_	30	dep	_	_
30	is	be	VBZ	_	26	comp	_	_
31	not	not	RB	_	30	neg	_	_
32	necessary	necessary	JJ	_	30	dep	_	_
33	.	.	.	_	14	p	_	_

1	drug1	drug0	NN	_	10	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	6	attr	_	_
4	40	0	CD	_	5	num	_	_
5	mg	mg	NN	_	6	com	_	_
6	BID	bid	NN	_	1	appo	_	_
7	for	for	IN	_	9	case	_	_
8	7	0	CD	_	9	num	_	_
9	days	day	NNS	_	6	ppmod	_	_
10	produced	produce	VBD	_	0	root	_	_
11	significant	significant	JJ	_	12	attr	_	_
12	decreases	decrease	NNS	_	10	obj	_	_
13	in	in	IN	_	16	case	_	_
14	drug3	drug0	NN	_	16	com	_	_
15	serum	serum	NN	_	16	com	_	_
16	clearance	clearance	NN	_	12	ppmod	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	25	0	CD	_	16	num	_	_
19	%	%	NN	_	18	meta	_	_
20	)	-rrb-	-RRB-	_	18	p	_	_
21	and	and	CC	_	16	cc	_	_
22	renal	renal	JJ	_	23	attr	_	_
23	clearance	clearance	NN	_	16	conj	_	_
24	(	-lrb-	-LRB-	_	25	p	_	_
25	30	0	CD	_	23	num	_	_
26	%	%	NN	_	25	meta	_	_
27	)	-rrb-	-RRB-	_	25	p	_	_
28	with	with	IN	_	34	case	_	_
29	a	a	DT	_	34	det	_	_
30	34	0	CD	_	32	num	_	_
31	%	%	NN	_	30	meta	_	_
32	higher	high	JJR	_	34	attr	_	_
33	serum	serum	NN	_	34	com	_	_
34	exposure	exposure	NN	_	10	ppmod	_	_
35	compared	compare	VBN	_	37	adv	_	_
36	to	to	TO	_	37	aux	_	_
37	drug4	drug0	NN	_	34	ppmod	_	_
38	alone	alone	RB	_	37	adv	_	_
39	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	3	com	_	_
2	serum	serum	NN	_	3	com	_	_
3	concentrations	concentration	NNS	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	monitored	monitor	VBN	_	0	root	_	_
7	closely	closely	RB	_	6	adv	_	_
8	when	when	WRB	_	9	adv	_	_
9	initiating	initiate	VBG	_	6	comp	_	_
10	or	or	CC	_	9	cc	_	_
11	changing	change	VBG	_	9	conj	_	_
12	therapy	therapy	NN	_	11	obj	_	_
13	with	with	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	in	in	IN	_	16	case	_	_
16	patients	patient	NNS	_	12	ppmod	_	_
17	receiving	receive	VBG	_	16	acl	_	_
18	drug3	drug0	NN	_	17	obj	_	_
19	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	10	dep	_	_
2	(	-lrb-	-LRB-	_	4	p	_	_
3	450	0	CD	_	4	num	_	_
4	mg	mg	NN	_	1	prn	_	_
5	BID	bid	JJ	_	4	attr	_	_
6	for	for	IN	_	8	case	_	_
7	7	0	CD	_	8	num	_	_
8	days	day	NNS	_	5	ppmod	_	_
9	)	-rrb-	-RRB-	_	4	p	_	_
10	had	have	VBD	_	0	root	_	_
11	no	no	DT	_	12	det	_	_
12	effect	effect	NN	_	10	obj	_	_
13	on	on	IN	_	15	case	_	_
14	drug2	drug0	NN	_	15	com	_	_
15	pharmacokinetics	pharmacokinetics	NNS	_	10	ppmod	_	_
16	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	effect	effect	NN	_	20	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	on	on	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	anticoagulant	anticoagulant	JJ	_	10	attr	_	_
10	effect	effect	NN	_	4	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	(	-lrb-	-LRB-	_	17	p	_	_
14	1	0	CD	_	16	num	_	_
15	-	-	:	_	16	p	_	_
16	8	0	CD	_	17	num	_	_
17	mg/day	mg/day	NN	_	12	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	was	be	VBD	_	20	aux	_	_
20	studied	study	VBN	_	1	acl	_	_
21	in	in	IN	_	23	case	_	_
22	healthy	healthy	JJ	_	23	attr	_	_
23	subjects	subject	NNS	_	20	ppmod	_	_
24	by	by	IN	_	25	case	_	_
25	coadministration	coadministration	NN	_	20	ppmod	_	_
26	of	of	IN	_	30	case	_	_
27	drug4	drug0	NN	_	30	attr	_	_
28	40	0	CD	_	30	num	_	_
29	mg	mg	NN	_	30	com	_	_
30	BID	bid	NN	_	25	ppmod	_	_
31	for	for	IN	_	33	case	_	_
32	7	0	CD	_	33	num	_	_
33	days	day	NNS	_	20	ppmod	_	_
34	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	caused	cause	VBD	_	0	root	_	_
3	a	a	DT	_	6	det	_	_
4	statistically	statistically	RB	_	5	adv	_	_
5	significant	significant	JJ	_	6	attr	_	_
6	increase	increase	NN	_	2	obj	_	_
7	in	in	IN	_	9	case	_	_
8	plasma	plasma	NN	_	9	com	_	_
9	exposures	exposure	NNS	_	6	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	drug3	drug0	NN	_	11	conj	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	12	0	CD	_	13	num	_	_
16	%	%	NN	_	15	meta	_	_
17	and	and	CC	_	15	cc	_	_
18	15	0	CD	_	15	conj	_	_
19	%	%	NN	_	18	meta	_	_
20	,	,	,	_	15	p	_	_
21	respectively	respectively	RB	_	15	adv	_	_
22	)	-rrb-	-RRB-	_	15	p	_	_
23	,	,	,	_	9	p	_	_
24	and	and	CC	_	9	cc	_	_
25	in	in	IN	_	28	case	_	_
26	the	the	DT	_	28	det	_	_
27	pharmacodynamic	pharmacodynamic	JJ	_	28	attr	_	_
28	effects	effect	NNS	_	9	conj	_	_
29	(	-lrb-	-LRB-	_	31	p	_	_
30	prothrombin	prothrombin	NN	_	31	com	_	_
31	time	time	NN	_	28	prn	_	_
32	,	,	,	_	31	p	_	_
33	measured	measure	VBN	_	31	acl	_	_
34	as	as	IN	_	35	case	_	_
35	INR	inr	NN	_	33	ppmod	_	_
36	)	-rrb-	-RRB-	_	31	p	_	_
37	of	of	IN	_	38	case	_	_
38	drug4	drug0	NN	_	28	ppmod	_	_
39	.	.	.	_	2	p	_	_

1	While	while	IN	_	8	mark	_	_
2	mean	mean	NN	_	4	com	_	_
3	INR	inr	NN	_	4	com	_	_
4	values	value	NNS	_	8	dep	_	_
5	were	be	VBD	_	8	aux	_	_
6	only	only	RB	_	7	com	_	_
7	slightly	slightly	RB	_	8	adv	_	_
8	increased	increase	VBN	_	22	advcl	_	_
9	with	with	IN	_	10	case	_	_
10	coadministration	coadministration	NN	_	8	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	,	,	,	_	22	p	_	_
14	the	the	DT	_	16	det	_	_
15	day-to-day	day-to-day	JJ	_	16	attr	_	_
16	variability	variability	NN	_	22	dep	_	_
17	in	in	IN	_	20	case	_	_
18	individual	individual	JJ	_	20	attr	_	_
19	INR	inr	NN	_	20	com	_	_
20	values	value	NNS	_	16	ppmod	_	_
21	was	be	VBD	_	22	aux	_	_
22	increased	increase	VBN	_	0	root	_	_
23	.	.	.	_	22	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	therapy	therapy	NN	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	monitored	monitor	VBN	_	0	root	_	_
6	,	,	,	_	5	p	_	_
7	particularly	particularly	RB	_	12	adv	_	_
8	during	during	IN	_	12	case	_	_
9	the	the	DT	_	12	det	_	_
10	first	#ord#	JJ	_	12	attr	_	_
11	few	few	JJ	_	12	attr	_	_
12	weeks	week	NNS	_	5	ppmod	_	_
13	,	,	,	_	5	p	_	_
14	after	after	IN	_	15	case	_	_
15	initiating	initiate	VBG	_	5	ppmod	_	_
16	therapy	therapy	NN	_	15	obj	_	_
17	with	with	IN	_	18	case	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	in	in	IN	_	20	case	_	_
20	patients	patient	NNS	_	16	ppmod	_	_
21	receiving	receive	VBG	_	20	acl	_	_
22	drug3	drug0	JJ	_	25	attr	_	_
23	or	or	CC	_	22	cc	_	_
24	similar	similar	JJ	_	22	conj	_	_
25	agents	agent	NNS	_	21	obj	_	_
26	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	:	:	:	_	1	p	_	_
5	drug3	drug0	NN	_	8	dep	_	_
6	and	and	CC	_	5	cc	_	_
7	drug4	drug0	NN	_	5	conj	_	_
8	are	be	VBP	_	1	acl	_	_
9	predominantly	predominantly	RB	_	10	adv	_	_
10	CYP	cyp	JJ	_	14	attr	_	_
11	3A4	0a0	NN	_	14	attr	_	_
12	and	and	CC	_	11	cc	_	_
13	2C9	0c0	NN	_	11	conj	_	_
14	inhibitors	inhibitor	NNS	_	8	obj	_	_
15	,	,	,	_	8	p	_	_
16	respectively	respectively	RB	_	8	adv	_	_
17	.	.	.	_	1	p	_	_

1	Concomitant	concomitant	JJ	_	4	attr	_	_
2	single	single	JJ	_	4	attr	_	_
3	dose	dose	NN	_	4	com	_	_
4	administration	administration	NN	_	16	dep	_	_
5	of	of	IN	_	8	case	_	_
6	drug1	drug0	NN	_	8	attr	_	_
7	20	0	CD	_	8	num	_	_
8	mg	mg	NN	_	4	ppmod	_	_
9	with	with	IN	_	11	case	_	_
10	multiple	multiple	JJ	_	11	attr	_	_
11	doses	dose	NNS	_	4	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	drug3	drug0	NN	_	13	conj	_	_
16	produced	produce	VBD	_	0	root	_	_
17	a	a	DT	_	19	det	_	_
18	significant	significant	JJ	_	19	attr	_	_
19	increase	increase	NN	_	16	obj	_	_
20	in	in	IN	_	21	case	_	_
21	exposure	exposure	NN	_	19	ppmod	_	_
22	of	of	IN	_	23	case	_	_
23	drug4	drug0	NN	_	21	ppmod	_	_
24	.	.	.	_	16	p	_	_

1	Plasma	plasma	NN	_	2	com	_	_
2	exposure	exposure	NN	_	9	dep	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	AUC	auc	NN	_	2	prn	_	_
5	)	-rrb-	-RRB-	_	4	p	_	_
6	to	to	TO	_	7	aux	_	_
7	drug1	drug0	NN	_	2	ppmod	_	_
8	was	be	VBD	_	9	aux	_	_
9	increased	increase	VBN	_	0	root	_	_
10	62	0	CD	_	9	obj	_	_
11	%	%	NN	_	10	meta	_	_
12	when	when	WRB	_	13	adv	_	_
13	coadministered	coadministered	VBN	_	10	relcl	_	_
14	with	with	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	and	and	CC	_	10	cc	_	_
17	38	0	CD	_	10	conj	_	_
18	%	%	NN	_	17	meta	_	_
19	when	when	WRB	_	20	adv	_	_
20	coadministered	coadministered	VBN	_	17	relcl	_	_
21	with	with	IN	_	22	case	_	_
22	drug3	drug0	NN	_	20	ppmod	_	_
23	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	is	be	VBZ	_	0	root	_	_
5	a	a	DT	_	8	det	_	_
6	CYP	cyp	NN	_	8	com	_	_
7	2C9	0c0	NN	_	8	com	_	_
8	substrate	substrate	NN	_	4	obj	_	_
9	.	.	.	_	4	p	_	_

1	Coadministration	coadministration	NN	_	25	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	(	-lrb-	-LRB-	_	7	p	_	_
5	10	0	CD	_	6	num	_	_
6	mg	mg	NN	_	7	com	_	_
7	BID	bid	NN	_	3	prn	_	_
8	for	for	IN	_	10	case	_	_
9	7	0	CD	_	10	num	_	_
10	days	day	NNS	_	7	ppmod	_	_
11	)	-rrb-	-RRB-	_	7	p	_	_
12	with	with	IN	_	13	case	_	_
13	drug2	drug0	NN	_	1	ppmod	_	_
14	(	-lrb-	-LRB-	_	17	p	_	_
15	5	0	CD	_	16	num	_	_
16	mg	mg	NN	_	17	com	_	_
17	QD	qd	NN	_	13	prn	_	_
18	or	or	CC	_	17	cc	_	_
19	10	0	CD	_	20	num	_	_
20	mg	mg	NN	_	21	com	_	_
21	BID	bid	NN	_	17	conj	_	_
22	)	-rrb-	-RRB-	_	17	p	_	_
23	did	do	VBD	_	25	aux	_	_
24	not	not	RB	_	25	neg	_	_
25	affect	affect	VB	_	0	root	_	_
26	the	the	DT	_	27	det	_	_
27	pharmacokinetics	pharmacokinetics	NNS	_	25	obj	_	_
28	(	-lrb-	-LRB-	_	29	p	_	_
29	exposure	exposure	NN	_	27	prn	_	_
30	)	-rrb-	-RRB-	_	29	p	_	_
31	of	of	IN	_	32	case	_	_
32	drug3	drug0	NN	_	27	ppmod	_	_
33	.	.	.	_	25	p	_	_

1	Coadministration	coadministration	NN	_	30	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	(	-lrb-	-LRB-	_	6	p	_	_
5	40	0	CD	_	6	num	_	_
6	mg	mg	NN	_	3	prn	_	_
7	BID	bid	JJ	_	6	attr	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	day	day	NN	_	6	prn	_	_
10	1	0	CD	_	9	num	_	_
11	)	-rrb-	-RRB-	_	9	p	_	_
12	and	and	CC	_	6	cc	_	_
13	40	0	CD	_	14	num	_	_
14	mg	mg	NN	_	15	com	_	_
15	QD	qd	NN	_	6	conj	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	days	day	NNS	_	15	prn	_	_
18	2-7	0	CD	_	17	num	_	_
19	)	-rrb-	-RRB-	_	17	p	_	_
20	)	-rrb-	-RRB-	_	6	p	_	_
21	with	with	IN	_	22	case	_	_
22	drug2	drug0	NN	_	1	ppmod	_	_
23	(	-lrb-	-LRB-	_	26	p	_	_
24	5	0	CD	_	25	num	_	_
25	mg	mg	NN	_	26	com	_	_
26	QD	qd	NN	_	22	prn	_	_
27	)	-rrb-	-RRB-	_	26	p	_	_
28	did	do	VBD	_	30	aux	_	_
29	not	not	RB	_	30	neg	_	_
30	affect	affect	VB	_	0	root	_	_
31	either	either	CC	_	33	cc	_	_
32	the	the	DT	_	33	det	_	_
33	pharmacokinetics	pharmacokinetics	NNS	_	30	obj	_	_
34	(	-lrb-	-LRB-	_	35	p	_	_
35	exposure	exposure	NN	_	33	prn	_	_
36	)	-rrb-	-RRB-	_	35	p	_	_
37	or	or	CC	_	33	cc	_	_
38	the	the	DT	_	39	det	_	_
39	pharmacodynamics	pharmacodynamics	NNS	_	33	conj	_	_
40	(	-lrb-	-LRB-	_	42	p	_	_
41	blood	blood	NN	_	42	com	_	_
42	glucose	glucose	NN	_	39	prn	_	_
43	and	and	CC	_	42	cc	_	_
44	insulin	insulin	NN	_	45	com	_	_
45	levels	level	NNS	_	42	conj	_	_
46	)	-rrb-	-RRB-	_	42	p	_	_
47	of	of	IN	_	48	case	_	_
48	drug3	drug0	NN	_	39	ppmod	_	_
49	.	.	.	_	30	p	_	_

1	Coadministration	coadministration	NN	_	29	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	(	-lrb-	-LRB-	_	6	p	_	_
5	40	0	CD	_	6	num	_	_
6	mg	mg	NN	_	3	prn	_	_
7	BID	bid	JJ	_	6	attr	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	day	day	NN	_	6	prn	_	_
10	1	0	CD	_	9	num	_	_
11	)	-rrb-	-RRB-	_	9	p	_	_
12	and	and	CC	_	6	cc	_	_
13	40	0	CD	_	14	num	_	_
14	mg	mg	NN	_	15	com	_	_
15	QD	qd	NN	_	6	conj	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	days	day	NNS	_	15	prn	_	_
18	2-7	0	CD	_	17	num	_	_
19	)	-rrb-	-RRB-	_	17	p	_	_
20	)	-rrb-	-RRB-	_	6	p	_	_
21	with	with	IN	_	22	case	_	_
22	drug2	drug0	NN	_	1	ppmod	_	_
23	(	-lrb-	-LRB-	_	27	p	_	_
24	10	0	CD	_	25	num	_	_
25	mg	mg	NN	_	27	com	_	_
26	drug3	drug0	NN	_	27	com	_	_
27	BID	bid	NN	_	22	prn	_	_
28	)	-rrb-	-RRB-	_	27	p	_	_
29	resulted	result	VBD	_	0	root	_	_
30	in	in	IN	_	33	case	_	_
31	21	0	CD	_	33	num	_	_
32	%	%	NN	_	31	meta	_	_
33	increase	increase	NN	_	29	ppmod	_	_
34	in	in	IN	_	35	case	_	_
35	drug4	drug0	NN	_	33	ppmod	_	_
36	AUC0-12	auc0	CD	_	35	num	_	_
37	and	and	CC	_	33	cc	_	_
38	a	a	DT	_	41	det	_	_
39	16	0	CD	_	41	num	_	_
40	%	%	NN	_	41	meta	_	_
41	increase	increase	NN	_	33	conj	_	_
42	in	in	IN	_	44	case	_	_
43	drug5	drug0	NN	_	44	com	_	_
44	Cmax	cmax	NN	_	41	ppmod	_	_
45	leading	lead	VBG	_	44	acl	_	_
46	to	to	TO	_	50	aux	_	_
47	a	a	DT	_	50	det	_	_
48	16	0	CD	_	50	num	_	_
49	%	%	NN	_	48	meta	_	_
50	decrease	decrease	NN	_	45	ppmod	_	_
51	in	in	IN	_	52	case	_	_
52	glucose	glucose	NN	_	50	ppmod	_	_
53	AUC0-24	auc0	CD	_	52	num	_	_
54	.	.	.	_	29	p	_	_

1	Insulin	insulin	NN	_	2	com	_	_
2	parameters	parameter	NNS	_	5	dep	_	_
3	were	be	VBD	_	5	aux	_	_
4	not	not	RB	_	5	neg	_	_
5	affected	affect	VBN	_	0	root	_	_
6	.	.	.	_	5	p	_	_

1	Because	because	IN	_	9	mark	_	_
2	changes	change	NNS	_	9	dep	_	_
3	in	in	IN	_	5	case	_	_
4	glucose	glucose	NN	_	5	com	_	_
5	concentrations	concentration	NNS	_	2	ppmod	_	_
6	with	with	IN	_	8	case	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	coadministration	coadministration	NN	_	5	ppmod	_	_
9	were	be	VBD	_	50	advcl	_	_
10	within	within	IN	_	13	case	_	_
11	the	the	DT	_	13	det	_	_
12	normal	normal	JJ	_	13	attr	_	_
13	variability	variability	NN	_	9	ppmod	_	_
14	and	and	CC	_	9	cc	_	_
15	individual	individual	JJ	_	17	attr	_	_
16	glucose	glucose	NN	_	17	com	_	_
17	concentrations	concentration	NNS	_	18	dep	_	_
18	were	be	VBD	_	9	conj	_	_
19	above	above	RB	_	18	adv	_	_
20	or	or	CC	_	19	cc	_	_
21	near	near	IN	_	23	case	_	_
22	70	0	CD	_	23	num	_	_
23	mg/dL	mg/dl	NN	_	19	conj	_	_
24	,	,	,	_	50	p	_	_
25	dose	dose	NN	_	26	com	_	_
26	adjustment	adjustment	NN	_	50	dep	_	_
27	for	for	IN	_	28	case	_	_
28	drug2	drug0	NN	_	26	ppmod	_	_
29	(	-lrb-	-LRB-	_	32	p	_	_
30	5	0	CD	_	31	num	_	_
31	mg	mg	NN	_	32	com	_	_
32	QD	qd	NN	_	28	prn	_	_
33	and	and	CC	_	32	cc	_	_
34	10	0	CD	_	35	num	_	_
35	mg	mg	NN	_	36	com	_	_
36	BID	bid	NN	_	32	conj	_	_
37	)	-rrb-	-RRB-	_	32	p	_	_
38	with	with	IN	_	40	case	_	_
39	drug3	drug0	NN	_	40	com	_	_
40	coadministration	coadministration	NN	_	28	ppmod	_	_
41	(	-lrb-	-LRB-	_	46	p	_	_
42	up	up	RB	_	44	adv	_	_
43	to	to	TO	_	44	attr	_	_
44	40	0	CD	_	46	num	_	_
45	mg	mg	NN	_	46	com	_	_
46	QD	qd	NN	_	40	prn	_	_
47	)	-rrb-	-RRB-	_	46	p	_	_
48	is	be	VBZ	_	50	aux	_	_
49	not	not	RB	_	50	neg	_	_
50	indicated	indicate	VBN	_	0	root	_	_
51	.	.	.	_	50	p	_	_

1	Coadministration	coadministration	NN	_	21	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	5	case	_	_
5	doses	dose	NNS	_	1	ppmod	_	_
6	higher	high	JJR	_	5	attr	_	_
7	than	than	IN	_	10	case	_	_
8	40	0	CD	_	9	num	_	_
9	mg	mg	NN	_	10	com	_	_
10	drug2	drug0	NN	_	6	ppmod	_	_
11	(	-lrb-	-LRB-	_	16	p	_	_
12	e.g.	e.g.	FW	_	16	adv	_	_
13	,	,	,	_	16	p	_	_
14	40	0	CD	_	15	num	_	_
15	mg	mg	NN	_	16	com	_	_
16	BID	bid	NN	_	10	prn	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	have	have	VBP	_	21	aux	_	_
19	not	not	RB	_	21	neg	_	_
20	been	be	VBN	_	21	aux	_	_
21	studied	study	VBN	_	0	root	_	_
22	.	.	.	_	21	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	4	dep	_	_
4	is	be	VBZ	_	1	acl	_	_
5	a	a	DT	_	8	det	_	_
6	CYP	cyp	JJ	_	8	attr	_	_
7	3A4	0a0	NN	_	8	com	_	_
8	substrate	substrate	NN	_	4	obj	_	_
9	and	and	CC	_	8	cc	_	_
10	CYP	cyp	NN	_	12	com	_	_
11	2C19	0c0	NN	_	12	com	_	_
12	substrate	substrate	NN	_	8	conj	_	_
13	and	and	CC	_	12	cc	_	_
14	inhibitor	inhibitor	NN	_	12	conj	_	_
15	.	.	.	_	1	p	_	_

1	drug1	drug0	JJ	_	5	attr	_	_
2	steady	steady	JJ	_	5	attr	_	_
3	state	state	NN	_	5	com	_	_
4	plasma	plasma	NN	_	5	com	_	_
5	concentrations	concentration	NNS	_	13	dep	_	_
6	(	-lrb-	-LRB-	_	8	p	_	_
7	40	0	CD	_	8	num	_	_
8	mg	mg	NN	_	5	prn	_	_
9	BID	bid	JJ	_	8	attr	_	_
10	)	-rrb-	-RRB-	_	8	p	_	_
11	were	be	VBD	_	13	aux	_	_
12	not	not	RB	_	13	neg	_	_
13	affected	affect	VBN	_	0	root	_	_
14	significantly	significantly	RB	_	13	adv	_	_
15	with	with	IN	_	17	case	_	_
16	multiple	multiple	JJ	_	17	attr	_	_
17	doses	dose	NNS	_	13	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	(	-lrb-	-LRB-	_	23	p	_	_
21	40	0	CD	_	22	num	_	_
22	mg	mg	NN	_	23	com	_	_
23	QD	qd	NN	_	19	prn	_	_
24	)	-rrb-	-RRB-	_	23	p	_	_
25	.	.	.	_	13	p	_	_

1	Coadministration	coadministration	NN	_	4	dep	_	_
2	with	with	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	increased	increase	VBD	_	0	root	_	_
5	exposure	exposure	NN	_	4	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	AUC	auc	NN	_	7	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	by	by	IN	_	12	case	_	_
12	46	0	CD	_	4	ppmod	_	_
13	%	%	NN	_	12	meta	_	_
14	.	.	.	_	4	p	_	_

1	Drugs	drug	NNS	_	11	dep	_	_
2	whose	whose	WP$	_	3	poss	_	_
3	absorption	absorption	NN	_	4	dep	_	_
4	is	be	VBZ	_	1	relcl	_	_
5	sensitive	sensitive	JJ	_	4	dep	_	_
6	to	to	TO	_	7	aux	_	_
7	pH	ph	NN	_	5	ppmod	_	_
8	may	may	MD	_	11	modal	_	_
9	be	be	VB	_	11	aux	_	_
10	negatively	negatively	RB	_	11	adv	_	_
11	impacted	impact	VBN	_	0	root	_	_
12	by	by	IN	_	14	case	_	_
13	concomitant	concomitant	JJ	_	14	attr	_	_
14	administration	administration	NN	_	11	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	drug2	drug0	NN	_	16	conj	_	_
19	.	.	.	_	11	p	_	_

1	However	however	RB	_	30	adv	_	_
2	,	,	,	_	30	p	_	_
3	because	because	IN	_	16	mark	_	_
4	higher	high	JJR	_	5	attr	_	_
5	doses	dose	NNS	_	16	dep	_	_
6	(	-lrb-	-LRB-	_	11	p	_	_
7	up	up	RB	_	9	adv	_	_
8	to	to	TO	_	9	attr	_	_
9	360	0	CD	_	11	num	_	_
10	mg	mg	NN	_	11	com	_	_
11	QD	qd	NN	_	5	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	of	of	IN	_	14	case	_	_
14	drug1	drug0	NN	_	5	ppmod	_	_
15	are	be	VBP	_	16	aux	_	_
16	tolerated	tolerate	VBN	_	30	advcl	_	_
17	in	in	IN	_	22	case	_	_
18	Zollinger-Ellison	zollinger-ellison	NN	_	22	attr	_	_
19	(	-lrb-	-LRB-	_	20	p	_	_
20	ZE	ze	NN	_	18	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	patients	patient	NNS	_	16	ppmod	_	_
23	,	,	,	_	30	p	_	_
24	no	no	DT	_	26	det	_	_
25	dose	dose	NN	_	26	com	_	_
26	adjustment	adjustment	NN	_	30	dep	_	_
27	for	for	IN	_	28	case	_	_
28	drug2	drug0	NN	_	26	ppmod	_	_
29	is	be	VBZ	_	30	aux	_	_
30	recommended	recommend	VBN	_	0	root	_	_
31	at	at	IN	_	33	case	_	_
32	current	current	JJ	_	33	attr	_	_
33	doses	dose	NNS	_	30	ppmod	_	_
34	.	.	.	_	30	p	_	_

1	Coadministration	coadministration	NN	_	15	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	5	case	_	_
5	doses	dose	NNS	_	1	ppmod	_	_
6	higher	high	JJR	_	5	attr	_	_
7	than	than	IN	_	11	case	_	_
8	40	0	CD	_	9	num	_	_
9	mg	mg	NN	_	11	com	_	_
10	QD	qd	NN	_	11	com	_	_
11	drug2	drug0	NN	_	6	ppmod	_	_
12	has	have	VBZ	_	15	aux	_	_
13	not	not	RB	_	15	neg	_	_
14	been	be	VBN	_	15	aux	_	_
15	studied	study	VBN	_	0	root	_	_
16	.	.	.	_	15	p	_	_

1	Oral	oral	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	drug2	drug0	NN	_	12	dep	_	_
5	(	-lrb-	-LRB-	_	8	p	_	_
6	40	0	CD	_	7	num	_	_
7	mg	mg	NN	_	8	com	_	_
8	BID	bid	NN	_	4	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	did	do	VBD	_	12	aux	_	_
11	not	not	RB	_	12	neg	_	_
12	induce	induce	VB	_	2	acl	_	_
13	the	the	DT	_	14	det	_	_
14	metabolism	metabolism	NN	_	12	obj	_	_
15	of	of	IN	_	20	case	_	_
16	the	the	DT	_	20	det	_	_
17	combination	combination	NN	_	20	attr	_	_
18	oral	oral	JJ	_	20	attr	_	_
19	drug3	drug0	NN	_	20	com	_	_
20	drug4	drug0	NN	_	14	ppmod	_	_
21	/	/	:	_	14	p	_	_
22	drug5	drug0	NN	_	14	appo	_	_
23	(	-lrb-	-LRB-	_	25	p	_	_
24	1	0	CD	_	25	num	_	_
25	mg	mg	NN	_	22	prn	_	_
26	/35	0	CD	_	28	num	_	_
27	mcg	mcg	NN	_	28	com	_	_
28	combination	combination	NN	_	25	appo	_	_
29	,	,	,	_	25	p	_	_
30	drug6	drug0	NN	_	31	com	_	_
31	1/35	0	NN	_	25	appo	_	_
32	)	-rrb-	-RRB-	_	25	p	_	_
33	.	.	.	_	2	p	_	_

1	Coadministration	coadministration	NN	_	7	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	1/35	0	RB	_	7	num	_	_
7	increased	increase	VBD	_	0	root	_	_
8	the	the	DT	_	9	det	_	_
9	exposure	exposure	NN	_	7	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug3	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	drug4	drug0	NN	_	11	conj	_	_
14	by	by	IN	_	15	case	_	_
15	20	0	CD	_	7	ppmod	_	_
16	%	%	NN	_	15	meta	_	_
17	and	and	CC	_	15	cc	_	_
18	34	0	CD	_	15	conj	_	_
19	%	%	NN	_	18	meta	_	_
20	,	,	,	_	18	p	_	_
21	respectively	respectively	RB	_	15	conj	_	_
22	.	.	.	_	7	p	_	_

1	Although	although	IN	_	3	mark	_	_
2	there	there	EX	_	3	dep	_	_
3	is	be	VBZ	_	25	advcl	_	_
4	little	little	JJ	_	5	attr	_	_
5	risk	risk	NN	_	3	obj	_	_
6	for	for	IN	_	7	case	_	_
7	loss	loss	NN	_	5	ppmod	_	_
8	of	of	IN	_	10	case	_	_
9	contraceptive	contraceptive	JJ	_	10	attr	_	_
10	efficacy	efficacy	NN	_	7	ppmod	_	_
11	,	,	,	_	25	p	_	_
12	the	the	DT	_	14	det	_	_
13	clinical	clinical	JJ	_	14	attr	_	_
14	significance	significance	NN	_	25	dep	_	_
15	of	of	IN	_	18	case	_	_
16	these	these	DT	_	18	det	_	_
17	increased	increase	VBN	_	18	attr	_	_
18	exposures	exposure	NNS	_	14	ppmod	_	_
19	in	in	IN	_	20	case	_	_
20	terms	term	NNS	_	14	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	safety	safety	NN	_	20	ppmod	_	_
23	is	be	VBZ	_	25	aux	_	_
24	not	not	RB	_	25	neg	_	_
25	known	know	VBN	_	0	root	_	_
26	.	.	.	_	25	p	_	_

1	These	these	DT	_	3	det	_	_
2	increased	increase	VBN	_	3	attr	_	_
3	exposures	exposure	NNS	_	10	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	should	should	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	taken	take	VBN	_	0	root	_	_
11	into	into	IN	_	12	case	_	_
12	consideration	consideration	NN	_	10	ppmod	_	_
13	when	when	WRB	_	14	adv	_	_
14	selecting	select	VBG	_	10	comp	_	_
15	an	an	DT	_	17	det	_	_
16	oral	oral	JJ	_	17	attr	_	_
17	drug3	drug0	NN	_	14	obj	_	_
18	for	for	IN	_	19	case	_	_
19	women	woman	NNS	_	17	ppmod	_	_
20	taking	take	VBG	_	19	acl	_	_
21	drug4	drug0	NN	_	20	obj	_	_
22	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	7	dep	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	drug3	drug0	NN	_	3	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	is	be	VBZ	_	1	acl	_	_
8	a	a	DT	_	10	det	_	_
9	CYP	cyp	NN	_	10	com	_	_
10	3A4	0a0	NN	_	7	obj	_	_
11	and	and	CC	_	10	cc	_	_
12	CYP	cyp	NN	_	14	com	_	_
13	2C19	0c0	NN	_	14	com	_	_
14	substrate	substrate	NN	_	10	conj	_	_
15	.	.	.	_	1	p	_	_

1	Plasma	plasma	NN	_	2	com	_	_
2	exposure	exposure	NN	_	11	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	(	-lrb-	-LRB-	_	8	p	_	_
6	10	0	CD	_	7	num	_	_
7	mg	mg	NN	_	8	com	_	_
8	BID	bid	NN	_	4	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	was	be	VBD	_	11	aux	_	_
11	increased	increase	VBN	_	0	root	_	_
12	by	by	IN	_	13	case	_	_
13	28	0	CD	_	11	ppmod	_	_
14	%	%	NN	_	13	meta	_	_
15	following	follow	VBG	_	16	adv	_	_
16	administration	administration	NN	_	11	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	(	-lrb-	-LRB-	_	22	p	_	_
20	40	0	CD	_	21	num	_	_
21	mg	mg	NN	_	22	com	_	_
22	BID	bid	NN	_	18	prn	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	for	for	IN	_	26	case	_	_
25	12	0	CD	_	26	num	_	_
26	days	day	NNS	_	18	ppmod	_	_
27	,	,	,	_	11	p	_	_
28	while	while	IN	_	41	mark	_	_
29	plasma	plasma	NN	_	30	com	_	_
30	exposure	exposure	NN	_	41	dep	_	_
31	of	of	IN	_	32	case	_	_
32	drug3	drug0	NN	_	30	ppmod	_	_
33	(	-lrb-	-LRB-	_	36	p	_	_
34	40	0	CD	_	35	num	_	_
35	mg	mg	NN	_	36	com	_	_
36	BID	bid	NN	_	32	prn	_	_
37	)	-rrb-	-RRB-	_	36	p	_	_
38	was	be	VBD	_	41	aux	_	_
39	not	not	RB	_	41	neg	_	_
40	substantially	substantially	RB	_	41	adv	_	_
41	increased	increase	VBN	_	11	comp	_	_
42	following	follow	VBG	_	43	adv	_	_
43	administration	administration	NN	_	41	ppmod	_	_
44	of	of	IN	_	45	case	_	_
45	drug4	drug0	NN	_	43	ppmod	_	_
46	(	-lrb-	-LRB-	_	49	p	_	_
47	10	0	CD	_	48	num	_	_
48	mg	mg	NN	_	49	com	_	_
49	BID	bid	NN	_	45	prn	_	_
50	)	-rrb-	-RRB-	_	49	p	_	_
51	for	for	IN	_	53	case	_	_
52	12	0	CD	_	53	num	_	_
53	days	day	NNS	_	45	ppmod	_	_
54	.	.	.	_	11	p	_	_

1	Although	although	IN	_	14	mark	_	_
2	the	the	DT	_	3	det	_	_
3	magnitude	magnitude	NN	_	14	dep	_	_
4	of	of	IN	_	5	case	_	_
5	changes	change	NNS	_	3	ppmod	_	_
6	in	in	IN	_	9	case	_	_
7	drug1	drug0	JJ	_	9	attr	_	_
8	plasma	plasma	NN	_	9	com	_	_
9	exposure	exposure	NN	_	5	ppmod	_	_
10	when	when	WRB	_	11	adv	_	_
11	coadministered	coadministered	VBN	_	5	relcl	_	_
12	with	with	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	were	be	VBD	_	24	advcl	_	_
15	not	not	RB	_	14	neg	_	_
16	sufficient	sufficient	JJ	_	14	dep	_	_
17	to	to	TO	_	18	aux	_	_
18	warrant	warrant	VBP	_	16	comp	_	_
19	dosage	dosage	NN	_	20	com	_	_
20	adjustments	adjustment	NNS	_	18	obj	_	_
21	,	,	,	_	24	p	_	_
22	patients	patient	NNS	_	24	dep	_	_
23	may	may	MD	_	24	modal	_	_
24	experience	experience	VBP	_	0	root	_	_
25	enhanced	enhance	VBN	_	28	attr	_	_
26	sedative	sedative	JJ	_	28	attr	_	_
27	side	side	JJ	_	28	attr	_	_
28	effects	effect	NNS	_	24	obj	_	_
29	caused	cause	VBN	_	28	acl	_	_
30	by	by	IN	_	32	case	_	_
31	increased	increase	VBN	_	32	attr	_	_
32	exposure	exposure	NN	_	29	ppmod	_	_
33	of	of	IN	_	34	case	_	_
34	drug3	drug0	NN	_	32	ppmod	_	_
35	under	under	IN	_	37	case	_	_
36	this	this	DT	_	37	det	_	_
37	circumstance	circumstance	NN	_	32	ppmod	_	_
38	.	.	.	_	24	p	_	_

1	Patients	patient	NNS	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	cautioned	caution	VBN	_	0	root	_	_
5	against	against	IN	_	6	case	_	_
6	engaging	engaging	NN	_	4	ppmod	_	_
7	in	in	IN	_	9	case	_	_
8	hazardous	hazardous	JJ	_	9	attr	_	_
9	activities	activity	NNS	_	6	ppmod	_	_
10	requiring	require	VBG	_	9	acl	_	_
11	complete	complete	JJ	_	13	attr	_	_
12	mental	mental	JJ	_	13	attr	_	_
13	alertness	alertness	NN	_	10	obj	_	_
14	such	such	JJ	_	17	adv	_	_
15	as	as	IN	_	17	case	_	_
16	operating	operate	VBG	_	17	attr	_	_
17	machinery	machinery	NN	_	13	ppmod	_	_
18	or	or	CC	_	10	cc	_	_
19	driving	drive	VBG	_	10	conj	_	_
20	a	a	DT	_	22	det	_	_
21	motor	motor	NN	_	22	com	_	_
22	vehicle	vehicle	NN	_	19	obj	_	_
23	.	.	.	_	4	p	_	_

1	When	when	WRB	_	4	adv	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	co-administered	co-administered	VBN	_	17	advcl	_	_
5	with	with	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	(	-lrb-	-LRB-	_	10	p	_	_
8	500	0	CD	_	9	num	_	_
9	mg	mg	NN	_	10	com	_	_
10	p.o.	p.o.	NN	_	6	prn	_	_
11	every	every	DT	_	13	det	_	_
12	6	0	CD	_	13	num	_	_
13	hours	hour	NNS	_	10	appo	_	_
14	)	-rrb-	-RRB-	_	10	p	_	_
15	,	,	,	_	17	p	_	_
16	drug3	drug0	NN	_	17	dep	_	_
17	competes	compete	VBZ	_	0	root	_	_
18	for	for	IN	_	21	case	_	_
19	active	active	JJ	_	21	attr	_	_
20	tubular	tubular	JJ	_	21	attr	_	_
21	secretion	secretion	NN	_	17	ppmod	_	_
22	and	and	CC	_	17	cc	_	_
23	reduces	reduce	VBZ	_	17	conj	_	_
24	the	the	DT	_	26	det	_	_
25	renal	renal	JJ	_	26	attr	_	_
26	clearance	clearance	NN	_	23	obj	_	_
27	of	of	IN	_	28	case	_	_
28	drug4	drug0	NN	_	26	ppmod	_	_
29	.	.	.	_	17	p	_	_

1	Based	base	VBN	_	5	adv	_	_
2	on	on	IN	_	5	case	_	_
3	total	total	JJ	_	5	attr	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	concentrations	concentration	NNS	_	8	ppmod	_	_
6	,	,	,	_	8	p	_	_
7	drug2	drug0	NN	_	8	dep	_	_
8	increased	increase	VBD	_	0	root	_	_
9	the	the	DT	_	10	det	_	_
10	AUC	auc	NN	_	8	obj	_	_
11	by	by	IN	_	12	case	_	_
12	25	0	CD	_	8	ppmod	_	_
13	%	%	NN	_	12	meta	_	_
14	and	and	CC	_	8	cc	_	_
15	reduced	reduce	VBD	_	8	conj	_	_
16	the	the	DT	_	17	det	_	_
17	plasma	plasma	NN	_	15	obj	_	_
18	and	and	CC	_	17	cc	_	_
19	renal	renal	JJ	_	20	attr	_	_
20	clearances	clearance	NNS	_	17	conj	_	_
21	by	by	IN	_	22	case	_	_
22	20	0	CD	_	15	ppmod	_	_
23	%	%	NN	_	22	meta	_	_
24	and	and	CC	_	22	cc	_	_
25	35	0	CD	_	22	conj	_	_
26	%	%	NN	_	25	meta	_	_
27	,	,	,	_	25	p	_	_
28	respectively	respectively	RB	_	22	conj	_	_
29	.	.	.	_	8	p	_	_

1	The	the	DT	_	2	det	_	_
2	half-life	half-life	NN	_	3	dep	_	_
3	increased	increase	VBD	_	0	root	_	_
4	from	from	IN	_	8	case	_	_
5	4.0	0	CD	_	8	num	_	_
6	to	to	TO	_	5	cc	_	_
7	4.8	0	CD	_	5	conj	_	_
8	hours	hour	NNS	_	3	ppmod	_	_
9	.	.	.	_	3	p	_	_

1	Because	because	IN	_	5	case	_	_
2	of	of	IN	_	5	case	_	_
3	the	the	DT	_	5	det	_	_
4	small	small	JJ	_	5	attr	_	_
5	effect	effect	NN	_	21	ppmod	_	_
6	on	on	IN	_	7	case	_	_
7	half-life	half-life	NN	_	5	ppmod	_	_
8	,	,	,	_	21	p	_	_
9	the	the	DT	_	10	det	_	_
10	coadministration	coadministration	NN	_	21	dep	_	_
11	with	with	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	to	to	TO	_	14	aux	_	_
14	extend	extend	VB	_	10	acl	_	_
15	the	the	DT	_	16	det	_	_
16	half-life	half-life	NN	_	14	obj	_	_
17	of	of	IN	_	18	case	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	is	be	VBZ	_	21	aux	_	_
20	not	not	RB	_	21	neg	_	_
21	recommended	recommend	VBN	_	0	root	_	_
22	.	.	.	_	21	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	studies	study	NNS	_	4	dep	_	_
4	indicate	indicate	VBP	_	0	root	_	_
5	that	that	IN	_	9	mark	_	_
6	drug1	drug0	NN	_	9	dep	_	_
7	does	do	VBZ	_	9	aux	_	_
8	not	not	RB	_	9	neg	_	_
9	inhibit	inhibit	VB	_	4	advcl	_	_
10	P-glycoprotein-mediated	p-glycoprotein-mediated	JJ	_	11	attr	_	_
11	transport	transport	NN	_	9	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	or	or	CC	_	13	cc	_	_
15	drug3	drug0	NN	_	13	conj	_	_
16	and	and	CC	_	9	cc	_	_
17	that	that	IN	_	19	mark	_	_
18	drug4	drug0	NN	_	19	dep	_	_
19	is	be	VBZ	_	9	conj	_	_
20	not	not	RB	_	19	neg	_	_
21	a	a	DT	_	22	det	_	_
22	substrate	substrate	NN	_	19	obj	_	_
23	for	for	IN	_	25	case	_	_
24	P-glycoprotein-mediated	p-glycoprotein-mediated	JJ	_	25	attr	_	_
25	transport	transport	NN	_	22	ppmod	_	_
26	.	.	.	_	4	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	studies	study	NNS	_	8	dep	_	_
4	in	in	IN	_	7	case	_	_
5	human	human	JJ	_	7	attr	_	_
6	liver	liver	NN	_	7	com	_	_
7	microsomes	microsome	NNS	_	3	ppmod	_	_
8	indicate	indicate	VBP	_	0	root	_	_
9	that	that	IN	_	13	mark	_	_
10	drug1	drug0	NN	_	13	dep	_	_
11	does	do	VBZ	_	13	aux	_	_
12	not	not	RB	_	13	neg	_	_
13	inhibit	inhibit	VB	_	8	comp	_	_
14	metabolism	metabolism	NN	_	13	obj	_	_
15	mediated	mediate	VBN	_	14	acl	_	_
16	by	by	IN	_	17	case	_	_
17	any	any	DT	_	15	ppmod	_	_
18	of	of	IN	_	27	case	_	_
19	the	the	DT	_	27	det	_	_
20	following	following	JJ	_	27	attr	_	_
21	six	#crd#	CD	_	23	num	_	_
22	cytochrome	cytochrome	NN	_	23	com	_	_
23	p450	p0	NN	_	27	attr	_	_
24	(	-lrb-	-LRB-	_	25	p	_	_
25	CYP	cyp	NN	_	23	prn	_	_
26	)	-rrb-	-RRB-	_	25	p	_	_
27	isoforms	isoforms	NNS	_	17	ppmod	_	_
28	:	:	:	_	27	p	_	_
29	1A2	0a0	NN	_	27	appo	_	_
30	,	,	,	_	29	p	_	_
31	2C9	0c0	NN	_	29	conj	_	_
32	,	,	,	_	31	p	_	_
33	2C19	0c0	NN	_	29	conj	_	_
34	,	,	,	_	33	p	_	_
35	2D6	0d0	NN	_	29	conj	_	_
36	,	,	,	_	35	p	_	_
37	2E1	0e0	NN	_	29	conj	_	_
38	and	and	CC	_	37	cc	_	_
39	3A4	0a0	NN	_	29	conj	_	_
40	.	.	.	_	8	p	_	_

1	Drug	drug	NN	_	2	com	_	_
2	interactions	interaction	NNS	_	18	dep	_	_
3	caused	cause	VBN	_	2	acl	_	_
4	by	by	IN	_	5	case	_	_
5	inhibition	inhibition	NN	_	3	ppmod	_	_
6	of	of	IN	_	9	case	_	_
7	P-glycoprotein-mediated	p-glycoprotein-mediated	JJ	_	9	attr	_	_
8	drug	drug	NN	_	9	com	_	_
9	clearance	clearance	NN	_	5	ppmod	_	_
10	or	or	CC	_	9	cc	_	_
11	CYP-mediated	cyp-mediated	JJ	_	13	attr	_	_
12	drug	drug	NN	_	13	com	_	_
13	clearance	clearance	NN	_	9	conj	_	_
14	with	with	IN	_	17	case	_	_
15	the	the	DT	_	17	det	_	_
16	listed	listed	JJ	_	17	attr	_	_
17	isoforms	isoforms	NNS	_	5	ppmod	_	_
18	are	be	VBP	_	0	root	_	_
19	unlikely	unlikely	JJ	_	18	dep	_	_
20	.	.	.	_	18	p	_	_

1	Other	other	JJ	_	14	adv	_	_
2	than	than	IN	_	4	case	_	_
3	with	with	IN	_	4	case	_	_
4	drug1	drug0	NN	_	1	ppmod	_	_
5	,	,	,	_	14	p	_	_
6	no	no	DT	_	11	det	_	_
7	specific	specific	JJ	_	11	attr	_	_
8	clinical	clinical	JJ	_	11	attr	_	_
9	drug	drug	NN	_	11	com	_	_
10	interaction	interaction	NN	_	11	com	_	_
11	studies	study	NNS	_	14	dep	_	_
12	have	have	VBP	_	14	aux	_	_
13	been	be	VBN	_	14	aux	_	_
14	conducted	conduct	VBN	_	0	root	_	_

1	.	.	.	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	Caution	caution	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	taken	take	VBN	_	0	root	_	_
5	in	in	IN	_	9	case	_	_
6	concurrent	concurrent	JJ	_	9	attr	_	_
7	or	or	CC	_	6	cc	_	_
8	serial	serial	JJ	_	6	conj	_	_
9	use	use	NN	_	4	ppmod	_	_
10	of	of	IN	_	13	case	_	_
11	other	other	JJ	_	13	attr	_	_
12	neurotoxic	neurotoxic	JJ	_	13	attr	_	_
13	and/	and/	NN	_	9	ppmod	_	_
14	or	or	CC	_	13	cc	_	_
15	nephrotoxic	nephrotoxic	JJ	_	16	attr	_	_
16	drugs	drug	NNS	_	13	conj	_	_
17	because	because	IN	_	20	case	_	_
18	of	of	IN	_	20	case	_	_
19	possible	possible	JJ	_	20	attr	_	_
20	enhancement	enhancement	NN	_	13	ppmod	_	_
21	of	of	IN	_	23	case	_	_
22	the	the	DT	_	23	det	_	_
23	nephrotoxicity	nephrotoxicity	NN	_	20	ppmod	_	_
24	and/or	and/or	CC	_	23	cc	_	_
25	ototoxicity	ototoxicity	NN	_	23	conj	_	_
26	of	of	IN	_	27	case	_	_
27	drug1	drug0	NN	_	23	ppmod	_	_
28	.	.	.	_	4	p	_	_

1	Caution	caution	NN	_	5	dep	_	_
2	should	should	MD	_	5	modal	_	_
3	also	also	RB	_	5	adv	_	_
4	be	be	VB	_	5	aux	_	_
5	taken	take	VBN	_	0	root	_	_
6	in	in	IN	_	10	case	_	_
7	concurrent	concurrent	JJ	_	10	attr	_	_
8	or	or	CC	_	7	cc	_	_
9	serial	serial	JJ	_	7	conj	_	_
10	use	use	NN	_	5	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	other	other	JJ	_	13	attr	_	_
13	drug1	drug0	NN	_	10	ppmod	_	_
14	and	and	CC	_	10	cc	_	_
15	drug2	drug0	NN	_	10	conj	_	_
16	because	because	IN	_	19	mark	_	_
17	they	they	PRP	_	19	dep	_	_
18	may	may	MD	_	19	modal	_	_
19	enhance	enhance	VB	_	5	comp	_	_
20	neomycin	neomycin	NN	_	22	com	_	_
21	s	s	NN	_	22	com	_	_
22	nephrotoxicity	nephrotoxicity	NN	_	19	obj	_	_
23	and/or	and/or	CC	_	22	cc	_	_
24	ototoxicity	ototoxicity	NN	_	22	conj	_	_
25	and	and	CC	_	19	cc	_	_
26	potentiate	potentiate	VB	_	19	conj	_	_
27	drug3	drug0	NN	_	30	com	_	_
28	neuromuscular	neuromuscular	NN	_	30	com	_	_
29	blocking	blocking	NN	_	30	com	_	_
30	effects	effect	NNS	_	26	obj	_	_
31	.	.	.	_	5	p	_	_

1	Oral	oral	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	3	dep	_	_
3	inhibits	inhibit	VBZ	_	0	root	_	_
4	the	the	DT	_	6	det	_	_
5	gastrointestinal	gastrointestinal	JJ	_	6	attr	_	_
6	absorption	absorption	NN	_	3	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	,	,	,	_	8	p	_	_
10	oral	oral	JJ	_	11	attr	_	_
11	drug3	drug0	NN	_	8	conj	_	_
12	,	,	,	_	11	p	_	_
13	drug4	drug0	NN	_	8	conj	_	_
14	and	and	CC	_	13	cc	_	_
15	drug5	drug0	NN	_	8	conj	_	_
16	.	.	.	_	3	p	_	_

1	The	the	DT	_	3	det	_	_
2	gastrointestinal	gastrointestinal	JJ	_	3	attr	_	_
3	absorption	absorption	NN	_	7	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	also	also	RB	_	7	adv	_	_
7	appears	appear	VBZ	_	0	root	_	_
8	to	to	TO	_	10	aux	_	_
9	be	be	VB	_	10	aux	_	_
10	inhibited	inhibit	VBN	_	7	comp	_	_
11	.	.	.	_	7	p	_	_

1	Therefore	therefore	RB	_	8	adv	_	_
2	,	,	,	_	8	p	_	_
3	drug1	drug0	NN	_	5	com	_	_
4	serum	serum	NN	_	5	com	_	_
5	levels	level	NNS	_	8	dep	_	_
6	should	should	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	monitored	monitor	VBN	_	0	root	_	_
9	.	.	.	_	8	p	_	_

1	Oral	oral	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	enhance	enhance	VB	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	effect	effect	NN	_	4	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	in	in	IN	_	10	case	_	_
10	drug3	drug0	NN	_	6	ppmod	_	_
11	by	by	IN	_	12	case	_	_
12	decreasing	decrease	VBG	_	4	ppmod	_	_
13	vitamin	vitamin	NN	_	15	com	_	_
14	K	k	NN	_	15	com	_	_
15	availability	availability	NN	_	12	obj	_	_
16	.	.	.	_	4	p	_	_

1	-	-	CC	_	2	cc	_	_
2	Drugs	drug	NNS	_	0	root	_	_
3	with	with	IN	_	5	case	_	_
4	ototoxic	ototoxic	JJ	_	5	attr	_	_
5	potential	potential	NN	_	2	ppmod	_	_
6	:	:	:	_	2	p	_	_
7	Especially	especially	RB	_	14	adv	_	_
8	in	in	IN	_	14	case	_	_
9	the	the	DT	_	14	det	_	_
10	presence	presence	NN	_	14	advnp	_	_
11	of	of	IN	_	14	case	_	_
12	impaired	impaired	JJ	_	14	attr	_	_
13	renal	renal	JJ	_	14	attr	_	_
14	function	function	NN	_	33	ppmod	_	_
15	,	,	,	_	33	p	_	_
16	the	the	DT	_	17	det	_	_
17	use	use	NN	_	33	dep	_	_
18	of	of	IN	_	21	case	_	_
19	parenterally	parenterally	RB	_	20	adv	_	_
20	administered	administer	VBN	_	21	attr	_	_
21	drug1	drug0	NN	_	17	ppmod	_	_
22	in	in	IN	_	23	case	_	_
23	patients	patient	NNS	_	17	ppmod	_	_
24	to	to	TO	_	26	aux	_	_
25	whom	whom	WP	_	26	det	_	_
26	drug2	drug0	NN	_	30	ppmod	_	_
27	are	be	VBP	_	30	aux	_	_
28	also	also	RB	_	30	adv	_	_
29	being	be	VBG	_	30	aux	_	_
30	given	give	VBN	_	23	relcl	_	_
31	should	should	MD	_	33	modal	_	_
32	be	be	VB	_	33	aux	_	_
33	avoided	avoid	VBN	_	2	acl	_	_
34	,	,	,	_	33	p	_	_
35	except	except	IN	_	38	case	_	_
36	in	in	IN	_	38	case	_	_
37	life-threatening	life-threatening	JJ	_	38	attr	_	_
38	conditions	condition	NNS	_	33	ppmod	_	_
39	.	.	.	_	2	p	_	_

1	-	-	CC	_	2	cc	_	_
2	Drugs	drug	NNS	_	0	root	_	_
3	with	with	IN	_	5	case	_	_
4	nephrotoxic	nephrotoxic	JJ	_	5	attr	_	_
5	potential	potential	NN	_	2	ppmod	_	_
6	:	:	:	_	2	p	_	_
7	There	there	EX	_	9	dep	_	_
8	has	have	VBZ	_	9	aux	_	_
9	been	be	VBN	_	2	acl	_	_
10	no	no	DT	_	9	obj	_	_
11	experience	experience	VBP	_	15	adv	_	_
12	on	on	IN	_	15	case	_	_
13	the	the	DT	_	15	det	_	_
14	concurrent	concurrent	JJ	_	15	attr	_	_
15	use	use	NN	_	10	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	drug1	drug0	NN	_	15	ppmod	_	_
18	with	with	IN	_	19	case	_	_
19	drugs	drug	NNS	_	15	ppmod	_	_
20	known	know	VBN	_	19	acl	_	_
21	to	to	TO	_	22	aux	_	_
22	have	have	VB	_	20	comp	_	_
23	a	a	DT	_	25	det	_	_
24	nephrotoxic	nephrotoxic	JJ	_	25	attr	_	_
25	potential	potential	NN	_	22	obj	_	_
26	.	.	.	_	2	p	_	_

1	Therefore	therefore	RB	_	11	adv	_	_
2	,	,	,	_	11	p	_	_
3	the	the	DT	_	5	det	_	_
4	simultaneous	simultaneous	JJ	_	5	attr	_	_
5	administration	administration	NN	_	11	dep	_	_
6	of	of	IN	_	8	case	_	_
7	these	these	DT	_	8	det	_	_
8	drugs	drug	NNS	_	5	ppmod	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	avoided	avoid	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	-	-	CC	_	2	cc	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	drug2	drug0	NN	_	9	dep	_	_
5	should	should	MD	_	9	modal	_	_
6	generally	generally	RB	_	9	adv	_	_
7	not	not	RB	_	9	neg	_	_
8	be	be	VB	_	9	aux	_	_
9	given	give	VBN	_	2	acl	_	_
10	with	with	IN	_	11	case	_	_
11	drug3	drug0	NN	_	9	ppmod	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	such	such	JJ	_	11	prn	_	_
14	as	as	IN	_	15	case	_	_
15	drug4	drug0	NN	_	13	ppmod	_	_
16	)	-rrb-	-RRB-	_	13	p	_	_
17	because	because	IN	_	19	mark	_	_
18	they	they	PRP	_	19	dep	_	_
19	reduce	reduce	VBP	_	9	comp	_	_
20	its	its	PRP$	_	22	poss	_	_
21	renal	renal	JJ	_	22	attr	_	_
22	clearance	clearance	NN	_	19	obj	_	_
23	and	and	CC	_	19	cc	_	_
24	add	add	VBP	_	19	conj	_	_
25	a	a	DT	_	27	det	_	_
26	high	high	JJ	_	27	attr	_	_
27	risk	risk	NN	_	24	obj	_	_
28	of	of	IN	_	30	case	_	_
29	drug5	drug0	NN	_	30	com	_	_
30	toxicity	toxicity	NN	_	27	ppmod	_	_
31	.	.	.	_	2	p	_	_

1	-	-	CC	_	2	cc	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	Pretreatment	pretreatment	NN	_	7	dep	_	_
5	with	with	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	reduces	reduce	VBZ	_	2	acl	_	_
8	both	both	CC	_	10	cc	_	_
9	the	the	DT	_	10	det	_	_
10	natriuresis	natriuresis	NN	_	7	obj	_	_
11	and	and	CC	_	10	cc	_	_
12	hyperreninemia	hyperreninemia	NN	_	10	conj	_	_
13	produced	produce	VBN	_	10	acl	_	_
14	by	by	IN	_	15	case	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	2	p	_	_

1	This	this	DT	_	3	det	_	_
2	antagonistic	antagonistic	JJ	_	3	attr	_	_
3	effect	effect	NN	_	9	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	on	on	IN	_	8	case	_	_
7	drug2	drug0	NN	_	8	com	_	_
8	natriuresis	natriuresis	NN	_	3	ppmod	_	_
9	is	be	VBZ	_	0	root	_	_
10	not	not	RB	_	9	neg	_	_
11	due	due	JJ	_	9	dep	_	_
12	to	to	TO	_	15	aux	_	_
13	a	a	DT	_	15	det	_	_
14	direct	direct	JJ	_	15	attr	_	_
15	action	action	NN	_	11	ppmod	_	_
16	on	on	IN	_	18	case	_	_
17	sodium	sodium	NN	_	18	com	_	_
18	excretion	excretion	NN	_	15	ppmod	_	_
19	but	but	CC	_	9	cc	_	_
20	is	be	VBZ	_	9	conj	_	_
21	probably	probably	RB	_	20	adv	_	_
22	secondary	secondary	JJ	_	20	dep	_	_
23	to	to	TO	_	26	aux	_	_
24	its	its	PRP$	_	26	poss	_	_
25	inhibitory	inhibitory	JJ	_	26	attr	_	_
26	effect	effect	NN	_	22	ppmod	_	_
27	on	on	IN	_	30	case	_	_
28	renal	renal	JJ	_	30	attr	_	_
29	tubular	tubular	JJ	_	30	attr	_	_
30	secretion	secretion	NN	_	26	ppmod	_	_
31	of	of	IN	_	32	case	_	_
32	drug3	drug0	NN	_	30	ppmod	_	_
33	.	.	.	_	9	p	_	_

1	Thus	thus	RB	_	7	adv	_	_
2	,	,	,	_	7	p	_	_
3	drug1	drug0	NN	_	7	dep	_	_
4	should	should	MD	_	7	modal	_	_
5	not	not	RB	_	7	neg	_	_
6	be	be	VB	_	7	aux	_	_
7	administered	administer	VBN	_	0	root	_	_
8	concurrently	concurrently	RB	_	7	adv	_	_
9	with	with	IN	_	10	case	_	_
10	drug2	drug0	NN	_	7	ppmod	_	_
11	.	.	.	_	7	p	_	_

1	-	-	CC	_	2	cc	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	drug2	drug0	NN	_	5	dep	_	_
5	blunts	blunt	VBZ	_	2	acl	_	_
6	the	the	DT	_	7	det	_	_
7	increases	increase	NNS	_	5	obj	_	_
8	in	in	IN	_	10	case	_	_
9	urine	urine	NN	_	10	com	_	_
10	volume	volume	NN	_	7	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	sodium	sodium	NN	_	13	com	_	_
13	excretion	excretion	NN	_	10	conj	_	_
14	seen	see	VBN	_	10	acl	_	_
15	during	during	IN	_	17	case	_	_
16	drug3	drug0	NN	_	17	com	_	_
17	treatment	treatment	NN	_	14	ppmod	_	_
18	and	and	CC	_	5	cc	_	_
19	inhibits	inhibit	VBZ	_	5	conj	_	_
20	the	the	DT	_	23	det	_	_
21	drug4	drug0	NN	_	22	advnp	_	_
22	-induced	-induced	JJ	_	23	attr	_	_
23	increase	increase	NN	_	19	obj	_	_
24	in	in	IN	_	27	case	_	_
25	plasma	plasma	NN	_	26	com	_	_
26	renin	renin	NN	_	27	com	_	_
27	activity	activity	NN	_	23	ppmod	_	_
28	.	.	.	_	2	p	_	_

1	Concurrent	concurrent	JJ	_	2	attr	_	_
2	therapy	therapy	NN	_	8	dep	_	_
3	with	with	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	is	be	VBZ	_	8	aux	_	_
6	thus	thus	RB	_	8	adv	_	_
7	not	not	RB	_	8	neg	_	_
8	recommended	recommend	VBN	_	0	root	_	_
9	.	.	.	_	8	p	_	_

1	-	-	CC	_	2	cc	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	drug2	drug0	NN	_	6	dep	_	_
5	may	may	MD	_	6	modal	_	_
6	potentiate	potentiate	VB	_	2	acl	_	_
7	the	the	DT	_	8	det	_	_
8	effect	effect	NN	_	6	obj	_	_
9	of	of	IN	_	11	case	_	_
10	various	various	JJ	_	11	attr	_	_
11	drug3	drug0	NNS	_	8	ppmod	_	_
12	,	,	,	_	6	p	_	_
13	necessitating	necessitate	VBG	_	6	comp	_	_
14	a	a	DT	_	15	det	_	_
15	reduction	reduction	NN	_	13	obj	_	_
16	in	in	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	dosage	dosage	NN	_	15	ppmod	_	_
19	of	of	IN	_	21	case	_	_
20	these	these	DT	_	21	det	_	_
21	drugs	drug	NNS	_	18	ppmod	_	_
22	.	.	.	_	2	p	_	_

1	-	-	CC	_	2	cc	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	Interaction	interaction	NN	_	5	com	_	_
5	studies	study	NNS	_	9	dep	_	_
6	in	in	IN	_	7	case	_	_
7	humans	human	NNS	_	5	ppmod	_	_
8	have	have	VBP	_	9	aux	_	_
9	shown	show	VBN	_	2	acl	_	_
10	no	no	DT	_	11	det	_	_
11	effect	effect	NN	_	9	obj	_	_
12	on	on	IN	_	15	case	_	_
13	drug2	drug0	NN	_	15	com	_	_
14	blood	blood	NN	_	15	com	_	_
15	levels	level	NNS	_	11	ppmod	_	_
16	.	.	.	_	2	p	_	_

1	-	-	CC	_	2	cc	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	Interaction	interaction	NN	_	5	com	_	_
5	studies	study	NNS	_	9	dep	_	_
6	in	in	IN	_	7	case	_	_
7	humans	human	NNS	_	5	ppmod	_	_
8	have	have	VBP	_	9	aux	_	_
9	shown	show	VBN	_	2	acl	_	_
10	drug2	drug0	NN	_	9	obj	_	_
11	to	to	TO	_	12	aux	_	_
12	have	have	VB	_	9	comp	_	_
13	no	no	DT	_	14	det	_	_
14	effect	effect	NN	_	12	obj	_	_
15	on	on	IN	_	17	case	_	_
16	drug3	drug0	NN	_	17	com	_	_
17	metabolism	metabolism	NN	_	12	ppmod	_	_
18	or	or	CC	_	17	cc	_	_
19	on	on	IN	_	22	case	_	_
20	plasma	plasma	NN	_	22	com	_	_
21	prothrombin	prothrombin	NN	_	22	com	_	_
22	activity	activity	NN	_	17	conj	_	_
23	.	.	.	_	2	p	_	_

1	Administration	administration	NN	_	13	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	to	to	TO	_	5	aux	_	_
5	patients	patient	NNS	_	1	ppmod	_	_
6	who	who	WP	_	8	dep	_	_
7	are	be	VBP	_	8	aux	_	_
8	receiving	receive	VBG	_	5	relcl	_	_
9	drug2	drug0	NN	_	8	obj	_	_
10	or	or	CC	_	9	cc	_	_
11	drug3	drug0	NN	_	9	conj	_	_
12	may	may	MD	_	13	modal	_	_
13	result	result	VB	_	0	root	_	_
14	in	in	IN	_	18	case	_	_
15	an	an	DT	_	18	det	_	_
16	additive	additive	JJ	_	18	attr	_	_
17	pressor	pressor	JJ	_	18	attr	_	_
18	effect	effect	NN	_	13	ppmod	_	_
19	.	.	.	_	13	p	_	_

1	In	in	IN	_	2	case	_	_
2	patients	patient	NNS	_	11	ppmod	_	_
3	who	who	WP	_	5	dep	_	_
4	have	have	VBP	_	5	aux	_	_
5	received	receive	VBN	_	2	relcl	_	_
6	drug1	drug0	NN	_	5	obj	_	_
7	,	,	,	_	11	p	_	_
8	drug2	drug0	NN	_	11	dep	_	_
9	may	may	MD	_	11	modal	_	_
10	temporarily	temporarily	RB	_	11	adv	_	_
11	mask	mask	VB	_	0	root	_	_
12	the	the	DT	_	14	det	_	_
13	residual	residual	JJ	_	14	attr	_	_
14	effects	effect	NNS	_	11	obj	_	_
15	of	of	IN	_	16	case	_	_
16	drug3	drug0	NN	_	14	ppmod	_	_
17	.	.	.	_	11	p	_	_

1	In	in	IN	_	2	case	_	_
2	patients	patient	NNS	_	25	ppmod	_	_
3	who	who	WP	_	5	dep	_	_
4	have	have	VBP	_	5	aux	_	_
5	received	receive	VBN	_	2	relcl	_	_
6	general	general	JJ	_	7	attr	_	_
7	anesthesia	anesthesia	NN	_	5	obj	_	_
8	utilizing	utilize	VBG	_	7	acl	_	_
9	a	a	DT	_	11	det	_	_
10	volatile	volatile	JJ	_	11	attr	_	_
11	agent	agent	NN	_	8	obj	_	_
12	known	know	VBN	_	11	acl	_	_
13	to	to	TO	_	14	aux	_	_
14	sensitize	sensitize	VB	_	12	comp	_	_
15	the	the	DT	_	16	det	_	_
16	myocardium	myocardium	NN	_	14	obj	_	_
17	to	to	TO	_	18	aux	_	_
18	catecholamines	catecholamine	NNS	_	16	ppmod	_	_
19	,	,	,	_	25	p	_	_
20	administration	administration	NN	_	25	dep	_	_
21	of	of	IN	_	22	case	_	_
22	drug1	drug0	NN	_	20	ppmod	_	_
23	should	should	MD	_	25	modal	_	_
24	be	be	VB	_	25	aux	_	_
25	delayed	delay	VBN	_	0	root	_	_
26	until	until	IN	_	32	mark	_	_
27	the	the	DT	_	29	det	_	_
28	volatile	volatile	JJ	_	29	attr	_	_
29	agent	agent	NN	_	32	dep	_	_
30	has	have	VBZ	_	32	aux	_	_
31	been	be	VBN	_	32	aux	_	_
32	excreted	excrete	VBN	_	25	comp	_	_
33	in	in	IN	_	36	mark	_	_
34	order	order	NN	_	36	dep	_	_
35	to	to	TO	_	36	aux	_	_
36	lessen	lessen	VB	_	32	comp	_	_
37	the	the	DT	_	38	det	_	_
38	potential	potential	NN	_	36	obj	_	_
39	for	for	IN	_	40	case	_	_
40	arrhythmias	arrhythmia	NNS	_	38	ppmod	_	_
41	,	,	,	_	40	p	_	_
42	including	include	VBG	_	44	adv	_	_
43	ventricular	ventricular	JJ	_	44	attr	_	_
44	tachycardia	tachycardia	NN	_	40	ppmod	_	_
45	and	and	CC	_	44	cc	_	_
46	ventricular	ventricular	JJ	_	47	attr	_	_
47	fibrillation	fibrillation	NN	_	44	conj	_	_
48	.	.	.	_	25	p	_	_

1	Effect	effect	NN	_	14	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	on	on	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	Pharmacokinetics	pharmacokinetics	NNS	_	1	ppmod	_	_
7	of	of	IN	_	9	case	_	_
8	Other	other	JJ	_	9	attr	_	_
9	Drugs	drug	NNS	_	6	ppmod	_	_
10	:	:	:	_	14	p	_	_
11	drug2	drug0	NN	_	14	dep	_	_
12	does	do	VBZ	_	14	aux	_	_
13	not	not	RB	_	14	neg	_	_
14	appear	appear	VB	_	0	root	_	_
15	to	to	TO	_	16	aux	_	_
16	alter	alter	VB	_	14	comp	_	_
17	the	the	DT	_	18	det	_	_
18	pharmacokinetics	pharmacokinetics	NNS	_	16	obj	_	_
19	of	of	IN	_	20	case	_	_
20	drug3	drug0	NN	_	18	ppmod	_	_
21	,	,	,	_	20	p	_	_
22	drug4	drug0	NN	_	20	conj	_	_
23	,	,	,	_	22	p	_	_
24	or	or	CC	_	22	cc	_	_
25	drug5	drug0	NN	_	20	conj	_	_
26	.	.	.	_	14	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	14	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	on	on	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	metabolism	metabolism	NN	_	2	ppmod	_	_
8	of	of	IN	_	10	case	_	_
9	other	other	JJ	_	10	attr	_	_
10	drugs	drug	NNS	_	7	ppmod	_	_
11	has	have	VBZ	_	14	aux	_	_
12	not	not	RB	_	14	neg	_	_
13	been	be	VBN	_	14	aux	_	_
14	investigated	investigate	VBN	_	0	root	_	_
15	.	.	.	_	14	p	_	_

1	Effect	effect	NN	_	13	dep	_	_
2	of	of	IN	_	4	case	_	_
3	Other	other	JJ	_	4	attr	_	_
4	Drugs	drug	NNS	_	1	ppmod	_	_
5	on	on	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	Pharmacokinetics	pharmacokinetics	NNS	_	1	ppmod	_	_
8	of	of	IN	_	12	case	_	_
9	drug1	drug0	NN	_	12	attr	_	_
10	:	:	:	_	12	p	_	_
11	Literature	literature	NN	_	12	com	_	_
12	reports	report	NNS	_	7	ppmod	_	_
13	suggest	suggest	VBP	_	0	root	_	_
14	that	that	IN	_	27	mark	_	_
15	drug2	drug0	NN	_	27	dep	_	_
16	,	,	,	_	15	p	_	_
17	an	an	DT	_	18	det	_	_
18	agent	agent	NN	_	15	appo	_	_
19	that	that	WDT	_	20	dep	_	_
20	decreases	decrease	VBZ	_	18	relcl	_	_
21	stomach	stomach	NN	_	22	com	_	_
22	acidity	acidity	NN	_	20	obj	_	_
23	,	,	,	_	15	p	_	_
24	does	do	VBZ	_	27	aux	_	_
25	not	not	RB	_	27	neg	_	_
26	greatly	greatly	RB	_	27	adv	_	_
27	alter	alter	VB	_	13	comp	_	_
28	drug3	drug0	NN	_	29	com	_	_
29	pharmacokinetics	pharmacokinetics	NNS	_	27	obj	_	_
30	.	.	.	_	13	p	_	_

1	In	in	IN	_	3	case	_	_
2	a	a	DT	_	3	det	_	_
3	study	study	NN	_	47	ppmod	_	_
4	in	in	IN	_	5	case	_	_
5	which	which	WDT	_	14	ppmod	_	_
6	the	the	DT	_	9	det	_	_
7	2	0	CD	_	8	num	_	_
8	mg	mg	NN	_	9	com	_	_
9	drug1	drug0	NN	_	14	dep	_	_
10	orally	orally	RB	_	11	adv	_	_
11	disintegrating	disintegrate	VBG	_	9	acl	_	_
12	tablet	tablet	NN	_	11	obj	_	_
13	was	be	VBD	_	14	aux	_	_
14	administered	administer	VBN	_	3	relcl	_	_
15	with	with	IN	_	14	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	without	without	IN	_	18	case	_	_
18	drug2	drug0	NN	_	15	conj	_	_
19	(	-lrb-	-LRB-	_	21	p	_	_
20	an	an	DT	_	21	det	_	_
21	drug3	drug0	NN	_	18	prn	_	_
22	with	with	IN	_	24	case	_	_
23	multiple	multiple	JJ	_	24	attr	_	_
24	effects	effect	NNS	_	21	ppmod	_	_
25	on	on	IN	_	28	case	_	_
26	the	the	DT	_	28	det	_	_
27	GI	gi	JJ	_	28	attr	_	_
28	tract	tract	NN	_	24	ppmod	_	_
29	)	-rrb-	-RRB-	_	21	p	_	_
30	to	to	TO	_	32	aux	_	_
31	healthy	healthy	JJ	_	32	attr	_	_
32	volunteers	volunteer	NNS	_	14	ppmod	_	_
33	,	,	,	_	47	p	_	_
34	the	the	DT	_	35	det	_	_
35	AUC	auc	NN	_	47	dep	_	_
36	of	of	IN	_	37	case	_	_
37	drug4	drug0	NNS	_	35	ppmod	_	_
38	was	be	VBD	_	37	acl	_	_
39	10	0	CD	_	41	num	_	_
40	%	%	NN	_	39	meta	_	_
41	lower	low	JJR	_	38	dep	_	_
42	and	and	CC	_	35	cc	_	_
43	the	the	DT	_	44	det	_	_
44	Cmax	cmax	NN	_	35	conj	_	_
45	of	of	IN	_	46	case	_	_
46	drug5	drug0	NN	_	44	ppmod	_	_
47	was	be	VBD	_	0	root	_	_
48	20	0	CD	_	50	num	_	_
49	%	%	NN	_	48	meta	_	_
50	lower	low	JJR	_	47	dep	_	_
51	when	when	WRB	_	57	adv	_	_
52	the	the	DT	_	55	det	_	_
53	orally	orally	RB	_	54	adv	_	_
54	disintegrating	disintegrating	JJ	_	55	attr	_	_
55	tablet	tablet	NN	_	57	dep	_	_
56	was	be	VBD	_	57	aux	_	_
57	given	give	VBN	_	47	comp	_	_
58	with	with	IN	_	59	case	_	_
59	drug6	drug0	NN	_	57	ppmod	_	_
60	compared	compare	VBN	_	65	adv	_	_
61	to	to	TO	_	65	aux	_	_
62	when	when	WRB	_	65	adv	_	_
63	it	it	PRP	_	65	dep	_	_
64	was	be	VBD	_	65	aux	_	_
65	given	give	VBN	_	57	ppmod	_	_
66	alone	alone	RB	_	65	adv	_	_
67	.	.	.	_	47	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	does	do	VBZ	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	affect	affect	VB	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	pharmacokinetics	pharmacokinetics	NNS	_	4	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	.	.	.	_	4	p	_	_

1	Cytochrome	cytochrome	NN	_	2	com	_	_
2	P-450	p-0	NN	_	3	com	_	_
3	inducers	inducer	NNS	_	13	dep	_	_
4	,	,	,	_	3	p	_	_
5	such	such	JJ	_	7	adv	_	_
6	as	as	IN	_	7	case	_	_
7	drug1	drug0	NN	_	3	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	and	and	CC	_	9	cc	_	_
11	drug3	drug0	NN	_	7	conj	_	_
12	,	,	,	_	3	p	_	_
13	induce	induce	VBP	_	0	root	_	_
14	drug4	drug0	NN	_	15	com	_	_
15	metabolism	metabolism	NN	_	13	obj	_	_
16	,	,	,	_	13	p	_	_
17	causing	cause	VBG	_	13	comp	_	_
18	an	an	DT	_	22	det	_	_
19	approximately	approximately	RB	_	20	adv	_	_
20	30	0	CD	_	22	num	_	_
21	%	%	NN	_	20	meta	_	_
22	decrease	decrease	NN	_	17	obj	_	_
23	in	in	IN	_	26	case	_	_
24	plasma	plasma	NN	_	26	com	_	_
25	drug5	drug0	NN	_	26	com	_	_
26	levels	level	NNS	_	22	ppmod	_	_
27	.	.	.	_	13	p	_	_

1	Although	although	IN	_	7	mark	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	studies	study	NNS	_	7	dep	_	_
4	have	have	VBP	_	7	aux	_	_
5	not	not	RB	_	7	neg	_	_
6	been	be	VBN	_	7	aux	_	_
7	performed	performed	VBN	_	35	advcl	_	_
8	,	,	,	_	7	p	_	_
9	based	base	VBN	_	12	adv	_	_
10	on	on	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	involvement	involvement	NN	_	7	ppmod	_	_
13	of	of	IN	_	18	case	_	_
14	the	the	DT	_	18	det	_	_
15	cytochrome	cytochrome	NN	_	16	com	_	_
16	P-450	p-0	NN	_	18	com	_	_
17	3A	0a	NN	_	18	com	_	_
18	family	family	NN	_	12	ppmod	_	_
19	in	in	IN	_	21	case	_	_
20	drug1	drug0	NN	_	21	com	_	_
21	metabolism	metabolism	NN	_	12	ppmod	_	_
22	,	,	,	_	35	p	_	_
23	inhibitors	inhibitor	NNS	_	35	dep	_	_
24	of	of	IN	_	27	case	_	_
25	this	this	DT	_	27	det	_	_
26	enzyme	enzyme	NN	_	27	com	_	_
27	system	system	NN	_	23	ppmod	_	_
28	,	,	,	_	23	p	_	_
29	notably	notably	RB	_	31	adv	_	_
30	oral	oral	JJ	_	31	attr	_	_
31	drug2	drug0	NN	_	23	appo	_	_
32	,	,	,	_	23	p	_	_
33	should	should	MD	_	35	modal	_	_
34	be	be	VB	_	35	aux	_	_
35	used	use	VBN	_	0	root	_	_
36	cautiously	cautiously	RB	_	35	adv	_	_
37	in	in	IN	_	38	case	_	_
38	patients	patient	NNS	_	35	ppmod	_	_
39	receiving	receive	VBG	_	38	acl	_	_
40	drug3	drug0	NN	_	39	obj	_	_
41	.	.	.	_	35	p	_	_

1	Pharmacodynamic	pharmacodynamic	JJ	_	2	attr	_	_
2	Interactions	interaction	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	The	the	DT	_	6	det	_	_
5	CNS-depressant	cns-depressant	JJ	_	6	attr	_	_
6	action	action	NN	_	14	dep	_	_
7	of	of	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	drug1	drug0	NN	_	6	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drugs	drug	NNS	_	9	ppmod	_	_
12	may	may	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	potentiated	potentiate	VBN	_	2	acl	_	_
15	by	by	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	,	,	,	_	16	p	_	_
18	drug3	drug0	NN	_	16	conj	_	_
19	,	,	,	_	18	p	_	_
20	drug4	drug0	NN	_	16	conj	_	_
21	,	,	,	_	20	p	_	_
22	drug5	drug0	NN	_	16	conj	_	_
23	,	,	,	_	22	p	_	_
24	drug6	drug0	NN	_	16	conj	_	_
25	,	,	,	_	24	p	_	_
26	the	the	DT	_	27	det	_	_
27	drug7	drug0	NN	_	16	conj	_	_
28	,	,	,	_	27	p	_	_
29	drug8	drug0	NN	_	16	conj	_	_
30	and	and	CC	_	29	cc	_	_
31	drug9	drug0	NN	_	16	conj	_	_
32	,	,	,	_	31	p	_	_
33	drug10	drug0	NN	_	16	conj	_	_
34	and	and	CC	_	33	cc	_	_
35	the	the	DT	_	36	det	_	_
36	drug11	drug0	NN	_	16	conj	_	_
37	,	,	,	_	16	p	_	_
38	and	and	CC	_	16	cc	_	_
39	by	by	IN	_	41	case	_	_
40	other	other	JJ	_	41	attr	_	_
41	drug12	drug0	NN	_	16	conj	_	_
42	.	.	.	_	2	p	_	_

1	Hypotension	hypotension	NN	_	0	root	_	_
2	-	-	:	_	1	p	_	_
3	Patients	patient	NNS	_	25	dep	_	_
4	on	on	IN	_	6	case	_	_
5	Diuretic	diuretic	JJ	_	6	attr	_	_
6	Therapy	therapy	NN	_	3	ppmod	_	_
7	:	:	:	_	3	p	_	_
8	Patients	patient	NNS	_	3	conj	_	_
9	on	on	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	,	,	,	_	8	p	_	_
12	and	and	CC	_	8	cc	_	_
13	especially	especially	RB	_	14	adv	_	_
14	those	those	DT	_	3	conj	_	_
15	in	in	IN	_	16	case	_	_
16	whom	whom	WP	_	21	ppmod	_	_
17	diuretic	diuretic	JJ	_	18	attr	_	_
18	therapy	therapy	NN	_	21	dep	_	_
19	was	be	VBD	_	21	aux	_	_
20	recently	recently	RB	_	21	adv	_	_
21	instituted	institute	VBN	_	14	relcl	_	_
22	,	,	,	_	14	p	_	_
23	may	may	MD	_	25	modal	_	_
24	occasionally	occasionally	RB	_	25	adv	_	_
25	experience	experience	VBP	_	1	acl	_	_
26	an	an	DT	_	28	det	_	_
27	excessive	excessive	JJ	_	28	attr	_	_
28	reduction	reduction	NN	_	25	obj	_	_
29	of	of	IN	_	31	case	_	_
30	blood	blood	NN	_	31	com	_	_
31	pressure	pressure	NN	_	28	ppmod	_	_
32	after	after	IN	_	33	case	_	_
33	initiation	initiation	NN	_	28	ppmod	_	_
34	of	of	IN	_	35	case	_	_
35	therapy	therapy	NN	_	33	ppmod	_	_
36	with	with	IN	_	37	case	_	_
37	drug2	drug0	NN	_	35	ppmod	_	_
38	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	possibility	possibility	NN	_	10	dep	_	_
3	of	of	IN	_	5	case	_	_
4	hypotensive	hypotensive	JJ	_	5	attr	_	_
5	effects	effect	NNS	_	2	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	can	can	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	minimized	minimize	VBN	_	0	root	_	_
11	by	by	IN	_	13	case	_	_
12	either	either	CC	_	13	cc	_	_
13	discontinuing	discontinue	VBG	_	10	ppmod	_	_
14	the	the	DT	_	15	det	_	_
15	drug2	drug0	NN	_	13	obj	_	_
16	or	or	CC	_	13	cc	_	_
17	increasing	increase	VBG	_	13	conj	_	_
18	the	the	DT	_	20	det	_	_
19	salt	salt	NN	_	20	com	_	_
20	intake	intake	NN	_	17	obj	_	_
21	prior	prior	JJ	_	20	attr	_	_
22	to	to	TO	_	23	aux	_	_
23	initiation	initiation	NN	_	21	ppmod	_	_
24	of	of	IN	_	25	case	_	_
25	treatment	treatment	NN	_	23	ppmod	_	_
26	with	with	IN	_	27	case	_	_
27	drug3	drug0	NN	_	25	ppmod	_	_
28	.	.	.	_	10	p	_	_

1	If	if	IN	_	3	mark	_	_
2	it	it	PRP	_	3	dep	_	_
3	is	be	VBZ	_	35	advcl	_	_
4	necessary	necessary	JJ	_	3	dep	_	_
5	to	to	TO	_	6	aux	_	_
6	continue	continue	VB	_	4	comp	_	_
7	the	the	DT	_	8	det	_	_
8	drug1	drug0	NN	_	6	obj	_	_
9	,	,	,	_	6	p	_	_
10	initiate	initiate	VB	_	6	conj	_	_
11	therapy	therapy	NN	_	10	obj	_	_
12	with	with	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	at	at	IN	_	16	case	_	_
15	a	a	DT	_	16	det	_	_
16	dose	dose	NN	_	10	ppmod	_	_
17	of	of	IN	_	19	case	_	_
18	5	0	CD	_	19	num	_	_
19	mg	mg	NN	_	16	ppmod	_	_
20	daily	daily	RB	_	19	adv	_	_
21	,	,	,	_	10	p	_	_
22	and	and	CC	_	10	cc	_	_
23	provide	provide	VB	_	6	conj	_	_
24	close	close	JJ	_	26	attr	_	_
25	medical	medical	JJ	_	26	attr	_	_
26	supervision	supervision	NN	_	23	obj	_	_
27	after	after	IN	_	30	case	_	_
28	the	the	DT	_	30	det	_	_
29	initial	initial	JJ	_	30	attr	_	_
30	dose	dose	NN	_	26	ppmod	_	_
31	until	until	IN	_	33	case	_	_
32	blood	blood	NN	_	33	com	_	_
33	pressure	pressure	NN	_	23	ppmod	_	_
34	has	have	VBZ	_	35	aux	_	_
35	stabilized	stabilize	VBN	_	0	root	_	_
36	.	.	.	_	35	p	_	_

1	When	when	WRB	_	5	adv	_	_
2	a	a	DT	_	3	det	_	_
3	drug1	drug0	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	added	add	VBN	_	21	advcl	_	_
6	to	to	TO	_	8	aux	_	_
7	the	the	DT	_	8	det	_	_
8	therapy	therapy	NN	_	5	ppmod	_	_
9	of	of	IN	_	11	case	_	_
10	a	a	DT	_	11	det	_	_
11	patient	patient	NN	_	8	ppmod	_	_
12	receiving	receive	VBG	_	11	acl	_	_
13	drug2	drug0	NN	_	12	obj	_	_
14	,	,	,	_	21	p	_	_
15	an	an	DT	_	18	det	_	_
16	additional	additional	JJ	_	18	attr	_	_
17	antihypertensive	antihypertensive	JJ	_	18	attr	_	_
18	effect	effect	NN	_	21	dep	_	_
19	is	be	VBZ	_	21	aux	_	_
20	usually	usually	RB	_	21	adv	_	_
21	observed	observe	VBN	_	0	root	_	_
22	.	.	.	_	21	p	_	_

1	Studies	study	NNS	_	8	dep	_	_
2	with	with	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	in	in	IN	_	5	case	_	_
5	combination	combination	NN	_	1	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	indicate	indicate	VBP	_	0	root	_	_
9	that	that	IN	_	17	mark	_	_
10	the	the	DT	_	11	det	_	_
11	dose	dose	NN	_	17	dep	_	_
12	of	of	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	drug3	drug0	NN	_	11	ppmod	_	_
15	can	can	MD	_	17	modal	_	_
16	be	be	VB	_	17	aux	_	_
17	reduced	reduce	VBN	_	8	comp	_	_
18	when	when	WRB	_	21	adv	_	_
19	it	it	PRP	_	21	dep	_	_
20	is	be	VBZ	_	21	aux	_	_
21	given	give	VBN	_	17	comp	_	_
22	with	with	IN	_	24	case	_	_
23	a	a	DT	_	24	det	_	_
24	drug4	drug0	NN	_	21	ppmod	_	_
25	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	5	case	_	_
4	some	some	DT	_	5	det	_	_
5	patients	patient	NNS	_	22	ppmod	_	_
6	with	with	IN	_	9	case	_	_
7	compromised	compromise	VBN	_	9	attr	_	_
8	renal	renal	JJ	_	9	attr	_	_
9	function	function	NN	_	5	ppmod	_	_
10	who	who	WP	_	13	dep	_	_
11	are	be	VBP	_	13	aux	_	_
12	being	be	VBG	_	13	aux	_	_
13	treated	treat	VBN	_	5	relcl	_	_
14	with	with	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	,	,	,	_	22	p	_	_
17	the	the	DT	_	18	det	_	_
18	co-administration	co-administration	NN	_	22	dep	_	_
19	of	of	IN	_	20	case	_	_
20	drug3	drug0	NN	_	18	ppmod	_	_
21	may	may	MD	_	22	modal	_	_
22	result	result	VB	_	1	acl	_	_
23	in	in	IN	_	26	case	_	_
24	a	a	DT	_	26	det	_	_
25	further	far	JJ	_	26	attr	_	_
26	deterioration	deterioration	NN	_	22	ppmod	_	_
27	of	of	IN	_	29	case	_	_
28	renal	renal	JJ	_	29	attr	_	_
29	function	function	NN	_	26	ppmod	_	_
30	.	.	.	_	1	p	_	_

1	These	these	DT	_	2	det	_	_
2	effects	effect	NNS	_	3	dep	_	_
3	are	be	VBP	_	0	root	_	_
4	usually	usually	RB	_	3	adv	_	_
5	reversible	reversible	JJ	_	3	dep	_	_
6	.	.	.	_	3	p	_	_

1	Reports	report	NNS	_	2	dep	_	_
2	suggest	suggest	VBP	_	0	root	_	_
3	that	that	IN	_	6	mark	_	_
4	drug1	drug0	NN	_	6	dep	_	_
5	may	may	MD	_	6	modal	_	_
6	diminish	diminish	VB	_	2	comp	_	_
7	the	the	DT	_	9	det	_	_
8	antihypertensive	antihypertensive	JJ	_	9	attr	_	_
9	effect	effect	NN	_	6	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	,	,	,	_	6	p	_	_
13	including	include	VBG	_	14	adv	_	_
14	drug3	drug0	NN	_	6	ppmod	_	_
15	.	.	.	_	2	p	_	_

1	This	this	DT	_	2	det	_	_
2	interaction	interaction	NN	_	6	dep	_	_
3	should	should	MD	_	6	modal	_	_
4	be	be	VB	_	6	aux	_	_
5	given	give	VBN	_	6	lv	_	_
6	consideration	consideration	NN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	6	ppmod	_	_
9	taking	take	VBG	_	8	acl	_	_
10	drug1	drug0	NN	_	9	obj	_	_
11	concomitantly	concomitantly	RB	_	6	adv	_	_
12	with	with	IN	_	13	case	_	_
13	drug2	drug0	NN	_	6	ppmod	_	_
14	.	.	.	_	6	p	_	_

1	In	in	IN	_	3	case	_	_
2	a	a	DT	_	3	det	_	_
3	study	study	NN	_	33	ppmod	_	_
4	in	in	IN	_	6	case	_	_
5	36	0	CD	_	6	num	_	_
6	patients	patient	NNS	_	3	ppmod	_	_
7	with	with	IN	_	11	case	_	_
8	mild	mild	JJ	_	10	adv	_	_
9	to	to	TO	_	10	adv	_	_
10	moderate	moderate	JJ	_	11	attr	_	_
11	hypertension	hypertension	NN	_	6	ppmod	_	_
12	where	where	WRB	_	20	adv	_	_
13	the	the	DT	_	15	det	_	_
14	antihypertensive	antihypertensive	JJ	_	15	attr	_	_
15	effects	effect	NNS	_	20	dep	_	_
16	of	of	IN	_	17	case	_	_
17	drug1	drug0	NN	_	15	ppmod	_	_
18	alone	alone	RB	_	17	adv	_	_
19	were	be	VBD	_	20	aux	_	_
20	compared	compare	VBN	_	11	relcl	_	_
21	to	to	TO	_	22	aux	_	_
22	drug2	drug0	NNS	_	20	ppmod	_	_
23	given	give	VBN	_	22	acl	_	_
24	concomitantly	concomitantly	RB	_	23	adv	_	_
25	with	with	IN	_	26	case	_	_
26	drug3	drug0	NN	_	23	ppmod	_	_
27	,	,	,	_	33	p	_	_
28	the	the	DT	_	29	det	_	_
29	use	use	NN	_	33	dep	_	_
30	of	of	IN	_	31	case	_	_
31	drug4	drug0	NN	_	29	ppmod	_	_
32	was	be	VBD	_	33	aux	_	_
33	associated	associate	VBN	_	0	root	_	_
34	with	with	IN	_	38	case	_	_
35	a	a	DT	_	38	det	_	_
36	reduced	reduce	VBN	_	38	attr	_	_
37	antihypertensive	antihypertensive	JJ	_	38	attr	_	_
38	effect	effect	NN	_	33	ppmod	_	_
39	,	,	,	_	33	p	_	_
40	although	although	IN	_	47	mark	_	_
41	the	the	DT	_	42	det	_	_
42	difference	difference	NN	_	47	dep	_	_
43	between	between	IN	_	46	case	_	_
44	the	the	DT	_	46	det	_	_
45	two	#crd#	CD	_	46	num	_	_
46	regimens	regimen	NNS	_	42	ppmod	_	_
47	was	be	VBD	_	33	comp	_	_
48	not	not	RB	_	47	neg	_	_
49	significant	significant	JJ	_	47	dep	_	_
50	.	.	.	_	33	p	_	_

1	Other	other	JJ	_	2	attr	_	_
2	Agents	agent	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	drug1	drug0	NN	_	7	dep	_	_
5	has	have	VBZ	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	used	use	VBN	_	2	acl	_	_
8	concomitantly	concomitantly	RB	_	7	adv	_	_
9	with	with	IN	_	10	case	_	_
10	drug2	drug0	NN	_	7	ppmod	_	_
11	and/or	and/or	CC	_	10	cc	_	_
12	drug3	drug0	NN	_	10	conj	_	_
13	without	without	IN	_	14	case	_	_
14	evidence	evidence	NN	_	7	ppmod	_	_
15	of	of	IN	_	19	case	_	_
16	clinically	clinically	RB	_	17	adv	_	_
17	significant	significant	JJ	_	19	attr	_	_
18	adverse	adverse	JJ	_	19	attr	_	_
19	interactions	interaction	NNS	_	14	ppmod	_	_
20	.	.	.	_	2	p	_	_

1	This	this	DT	_	2	dep	_	_
2	included	include	VBD	_	0	root	_	_
3	post	post	JJ	_	6	attr	_	_
4	myocardial	myocardial	JJ	_	6	attr	_	_
5	infarction	infarction	NN	_	6	com	_	_
6	patients	patient	NNS	_	2	obj	_	_
7	who	who	WP	_	9	dep	_	_
8	were	be	VBD	_	9	aux	_	_
9	receiving	receive	VBG	_	6	relcl	_	_
10	intravenous	intravenous	JJ	_	13	attr	_	_
11	or	or	CC	_	10	cc	_	_
12	transdermal	transdermal	JJ	_	10	conj	_	_
13	drug1	drug0	NN	_	9	obj	_	_
14	.	.	.	_	2	p	_	_

1	No	no	DT	_	5	det	_	_
2	clinically	clinically	RB	_	3	adv	_	_
3	important	important	JJ	_	5	attr	_	_
4	pharmacokinetic	pharmacokinetic	JJ	_	5	attr	_	_
5	interactions	interaction	NNS	_	6	dep	_	_
6	occurred	occur	VBD	_	0	root	_	_
7	when	when	WRB	_	10	adv	_	_
8	drug1	drug0	NN	_	10	dep	_	_
9	was	be	VBD	_	10	aux	_	_
10	used	use	VBN	_	6	comp	_	_
11	concomitantly	concomitantly	RB	_	10	adv	_	_
12	with	with	IN	_	13	case	_	_
13	drug2	drug0	NN	_	10	ppmod	_	_
14	or	or	CC	_	13	cc	_	_
15	drug3	drug0	NN	_	13	conj	_	_
16	.	.	.	_	6	p	_	_

1	The	the	DT	_	2	det	_	_
2	presence	presence	NN	_	10	dep	_	_
3	of	of	IN	_	4	case	_	_
4	food	food	NN	_	2	ppmod	_	_
5	in	in	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	stomach	stomach	NN	_	2	ppmod	_	_
8	does	do	VBZ	_	10	aux	_	_
9	not	not	RB	_	10	neg	_	_
10	alter	alter	VB	_	0	root	_	_
11	the	the	DT	_	12	det	_	_
12	bioavailability	bioavailability	NN	_	10	obj	_	_
13	of	of	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	10	p	_	_

1	Agents	agent	NNS	_	2	dep	_	_
2	Increasing	increase	VBG	_	7	advcl	_	_
3	Serum	serum	NN	_	4	com	_	_
4	Potassium	potassium	NN	_	2	obj	_	_
5	:	:	:	_	7	p	_	_
6	drug1	drug0	NN	_	7	dep	_	_
7	attenuates	attenuate	VBZ	_	0	root	_	_
8	potassium	potassium	NN	_	9	com	_	_
9	loss	loss	NN	_	7	obj	_	_
10	caused	cause	VBN	_	9	acl	_	_
11	by	by	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	7	p	_	_

1	Use	use	NN	_	25	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	5	case	_	_
5	drug2	drug0	NN	_	1	ppmod	_	_
6	(	-lrb-	-LRB-	_	9	p	_	_
7	e.g.	e.g.	FW	_	9	adv	_	_
8	,	,	,	_	9	p	_	_
9	drug3	drug0	NN	_	5	prn	_	_
10	,	,	,	_	9	p	_	_
11	drug4	drug0	NN	_	9	conj	_	_
12	,	,	,	_	11	p	_	_
13	or	or	CC	_	11	cc	_	_
14	drug5	drug0	NN	_	9	conj	_	_
15	)	-rrb-	-RRB-	_	9	p	_	_
16	,	,	,	_	5	p	_	_
17	drug6	drug0	NN	_	18	com	_	_
18	supplements	supplement	NNS	_	5	conj	_	_
19	,	,	,	_	18	p	_	_
20	or	or	CC	_	18	cc	_	_
21	potassium-containing	potassium-containing	JJ	_	22	attr	_	_
22	salt	salt	NN	_	5	conj	_	_
23	substitutes	substitute	VBZ	_	22	attr	_	_
24	may	may	MD	_	25	modal	_	_
25	lead	lead	VB	_	0	root	_	_
26	to	to	TO	_	28	aux	_	_
27	significant	significant	JJ	_	28	attr	_	_
28	increases	increase	NNS	_	25	ppmod	_	_
29	in	in	IN	_	31	case	_	_
30	serum	serum	NN	_	31	com	_	_
31	potassium	potassium	NN	_	28	ppmod	_	_
32	.	.	.	_	25	p	_	_

1	Therefore	therefore	RB	_	19	adv	_	_
2	,	,	,	_	19	p	_	_
3	if	if	IN	_	10	mark	_	_
4	concomitant	concomitant	JJ	_	5	attr	_	_
5	use	use	NN	_	10	dep	_	_
6	of	of	IN	_	8	case	_	_
7	these	these	DT	_	8	det	_	_
8	agents	agent	NNS	_	5	ppmod	_	_
9	is	be	VBZ	_	10	aux	_	_
10	indicated	indicate	VBN	_	19	advcl	_	_
11	because	because	IN	_	14	case	_	_
12	of	of	IN	_	14	case	_	_
13	demonstrated	demonstrate	VBN	_	14	attr	_	_
14	hypokalemia	hypokalemia	NN	_	10	ppmod	_	_
15	,	,	,	_	19	p	_	_
16	they	they	PRP	_	19	dep	_	_
17	should	should	MD	_	19	modal	_	_
18	be	be	VB	_	19	aux	_	_
19	used	use	VBN	_	0	root	_	_
20	with	with	IN	_	21	case	_	_
21	caution	caution	NN	_	19	ppmod	_	_
22	and	and	CC	_	21	cc	_	_
23	with	with	IN	_	25	case	_	_
24	frequent	frequent	JJ	_	25	attr	_	_
25	monitoring	monitoring	NN	_	21	conj	_	_
26	of	of	IN	_	28	case	_	_
27	serum	serum	NN	_	28	com	_	_
28	potassium	potassium	NN	_	25	ppmod	_	_
29	.	.	.	_	19	p	_	_

1	Potassium	potassium	NN	_	3	com	_	_
2	sparing	sparing	NN	_	3	com	_	_
3	agents	agent	NNS	_	8	dep	_	_
4	should	should	MD	_	8	modal	_	_
5	generally	generally	RB	_	8	adv	_	_
6	not	not	RB	_	8	neg	_	_
7	be	be	VB	_	8	aux	_	_
8	used	use	VBN	_	0	root	_	_
9	in	in	IN	_	10	case	_	_
10	patients	patient	NNS	_	8	ppmod	_	_
11	with	with	IN	_	13	case	_	_
12	heart	heart	NN	_	13	com	_	_
13	failure	failure	NN	_	10	ppmod	_	_
14	who	who	WP	_	16	dep	_	_
15	are	be	VBP	_	16	aux	_	_
16	receiving	receive	VBG	_	10	relcl	_	_
17	drug1	drug0	NN	_	16	obj	_	_
18	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	JJ	_	4	attr	_	_
4	toxicity	toxicity	NN	_	7	dep	_	_
5	has	have	VBZ	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	reported	report	VBN	_	1	acl	_	_
8	in	in	IN	_	9	case	_	_
9	patients	patient	NNS	_	7	ppmod	_	_
10	receiving	receive	VBG	_	9	acl	_	_
11	drug3	drug0	NN	_	10	obj	_	_
12	concomitantly	concomitantly	RB	_	14	adv	_	_
13	with	with	IN	_	14	case	_	_
14	drugs	drug	NNS	_	9	ppmod	_	_
15	which	which	WDT	_	16	dep	_	_
16	cause	cause	VBP	_	14	relcl	_	_
17	elimination	elimination	NN	_	16	obj	_	_
18	of	of	IN	_	19	case	_	_
19	sodium	sodium	NN	_	17	ppmod	_	_
20	,	,	,	_	14	p	_	_
21	including	include	VBG	_	22	adv	_	_
22	drug4	drug0	NN	_	14	ppmod	_	_
23	.	.	.	_	1	p	_	_

1	drug1	drug0	JJ	_	2	attr	_	_
2	toxicity	toxicity	NN	_	3	dep	_	_
3	was	be	VBD	_	0	root	_	_
4	usually	usually	RB	_	5	adv	_	_
5	reversible	reversible	JJ	_	3	dep	_	_
6	upon	upon	IN	_	7	case	_	_
7	discontinuation	discontinuation	NN	_	5	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	the	the	DT	_	12	det	_	_
12	drug3	drug0	NN	_	9	conj	_	_
13	.	.	.	_	3	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	recommended	recommend	VBN	_	0	root	_	_
4	that	that	IN	_	9	mark	_	_
5	serum	serum	NN	_	7	com	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	levels	level	NNS	_	9	dep	_	_
8	be	be	VB	_	9	aux	_	_
9	monitored	monitor	VBN	_	3	comp	_	_
10	frequently	frequently	RB	_	9	adv	_	_
11	if	if	IN	_	14	mark	_	_
12	drug2	drug0	NN	_	14	dep	_	_
13	is	be	VBZ	_	14	aux	_	_
14	administered	administer	VBN	_	9	comp	_	_
15	concomitantly	concomitantly	RB	_	14	adv	_	_
16	with	with	IN	_	17	case	_	_
17	drug3	drug0	NN	_	14	ppmod	_	_
18	.	.	.	_	3	p	_	_

1	If	if	IN	_	3	mark	_	_
2	drug1	drug0	NN	_	3	dep	_	_
3	is	be	VBZ	_	21	advcl	_	_
4	to	to	TO	_	6	aux	_	_
5	be	be	VB	_	6	aux	_	_
6	combined	combine	VBN	_	3	comp	_	_
7	with	with	IN	_	9	case	_	_
8	other	other	JJ	_	9	attr	_	_
9	drugs	drug	NNS	_	6	ppmod	_	_
10	acting	act	VBG	_	9	acl	_	_
11	on	on	IN	_	15	case	_	_
12	the	the	DT	_	15	det	_	_
13	central	central	JJ	_	15	attr	_	_
14	nervous	nervous	JJ	_	15	attr	_	_
15	system	system	NN	_	10	ppmod	_	_
16	,	,	,	_	21	p	_	_
17	careful	careful	JJ	_	18	attr	_	_
18	consideration	consideration	NN	_	21	dep	_	_
19	should	should	MD	_	21	modal	_	_
20	be	be	VB	_	21	aux	_	_
21	given	give	VBN	_	0	root	_	_
22	to	to	TO	_	24	aux	_	_
23	the	the	DT	_	24	det	_	_
24	pharmacology	pharmacology	NN	_	21	ppmod	_	_
25	of	of	IN	_	27	case	_	_
26	the	the	DT	_	27	det	_	_
27	agents	agent	NNS	_	24	ppmod	_	_
28	to	to	TO	_	30	aux	_	_
29	be	be	VB	_	30	aux	_	_
30	employed	employ	VBN	_	24	acl	_	_
31	.	.	.	_	21	p	_	_

1	Animal	animal	JJ	_	2	attr	_	_
2	experience	experience	VBP	_	3	dep	_	_
3	indicates	indicate	VBZ	_	0	root	_	_
4	that	that	IN	_	6	mark	_	_
5	drug1	drug0	NN	_	6	dep	_	_
6	prolongs	prolong	VBZ	_	3	comp	_	_
7	the	the	DT	_	9	det	_	_
8	sleeping	sleeping	JJ	_	9	attr	_	_
9	time	time	NN	_	6	obj	_	_
10	after	after	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	or	or	CC	_	11	cc	_	_
13	after	after	IN	_	14	case	_	_
14	drug3	drug0	NN	_	11	conj	_	_
15	,	,	,	_	6	p	_	_
16	increases	increase	VBZ	_	6	conj	_	_
17	the	the	DT	_	19	det	_	_
18	inhibitory	inhibitory	JJ	_	19	attr	_	_
19	effects	effect	NNS	_	16	obj	_	_
20	of	of	IN	_	21	case	_	_
21	drug4	drug0	NN	_	19	ppmod	_	_
22	,	,	,	_	16	p	_	_
23	but	but	CC	_	16	cc	_	_
24	does	do	VBZ	_	26	aux	_	_
25	not	not	RB	_	26	neg	_	_
26	exhibit	exhibit	VB	_	6	conj	_	_
27	monoamine	monoamine	NN	_	28	com	_	_
28	oxidase	oxidase	NN	_	29	com	_	_
29	inhibition	inhibition	NN	_	26	obj	_	_
30	.	.	.	_	3	p	_	_

1	Clinical	clinical	JJ	_	2	attr	_	_
2	studies	study	NNS	_	4	dep	_	_
3	have	have	VBP	_	4	aux	_	_
4	shown	show	VBN	_	0	root	_	_
5	increased	increase	VBN	_	6	attr	_	_
6	sedation	sedation	NN	_	4	obj	_	_
7	with	with	IN	_	9	case	_	_
8	concurrent	concurrent	JJ	_	9	attr	_	_
9	drug1	drug0	NN	_	6	ppmod	_	_
10	.	.	.	_	4	p	_	_

1	The	the	DT	_	2	det	_	_
2	actions	action	NNS	_	8	dep	_	_
3	of	of	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	drug1	drug0	NN	_	2	ppmod	_	_
6	may	may	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	potentiated	potentiate	VBN	_	0	root	_	_
9	by	by	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	drug3	drug0	NN	_	10	conj	_	_
13	,	,	,	_	12	p	_	_
14	drug4	drug0	NN	_	10	conj	_	_
15	,	,	,	_	14	p	_	_
16	drug5	drug0	NN	_	10	conj	_	_
17	or	or	CC	_	16	cc	_	_
18	other	other	JJ	_	19	attr	_	_
19	drug6	drug0	NN	_	10	conj	_	_
20	.	.	.	_	8	p	_	_

1	If	if	IN	_	5	mark	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	tablets	tablet	NNS	_	5	dep	_	_
4	are	be	VBP	_	5	aux	_	_
5	used	use	VBN	_	18	advcl	_	_
6	to	to	TO	_	7	aux	_	_
7	treat	treat	VB	_	5	comp	_	_
8	anxiety	anxiety	NN	_	7	obj	_	_
9	associated	associate	VBN	_	8	acl	_	_
10	with	with	IN	_	13	case	_	_
11	somatic	somatic	JJ	_	13	attr	_	_
12	disease	disease	NN	_	13	com	_	_
13	states	state	NNS	_	9	ppmod	_	_
14	,	,	,	_	18	p	_	_
15	careful	careful	JJ	_	16	attr	_	_
16	attention	attention	NN	_	18	dep	_	_
17	must	must	MD	_	18	modal	_	_
18	be	be	VB	_	0	root	_	_
19	paid	paid	JJ	_	18	dep	_	_
20	to	to	TO	_	23	aux	_	_
21	possible	possible	JJ	_	23	attr	_	_
22	drug	drug	NN	_	23	com	_	_
23	interaction	interaction	NN	_	19	ppmod	_	_
24	with	with	IN	_	26	case	_	_
25	concomitant	concomitant	JJ	_	26	attr	_	_
26	medication	medication	NN	_	23	ppmod	_	_
27	.	.	.	_	18	p	_	_

1	In	in	IN	_	3	case	_	_
2	bioavailability	bioavailability	JJ	_	3	attr	_	_
3	studies	study	NNS	_	19	ppmod	_	_
4	with	with	IN	_	6	case	_	_
5	normal	normal	JJ	_	6	attr	_	_
6	subjects	subject	NNS	_	3	ppmod	_	_
7	,	,	,	_	19	p	_	_
8	the	the	DT	_	10	det	_	_
9	concurrent	concurrent	JJ	_	10	attr	_	_
10	administration	administration	NN	_	19	dep	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	at	at	IN	_	15	case	_	_
14	therapeutic	therapeutic	JJ	_	15	attr	_	_
15	levels	level	NNS	_	10	ppmod	_	_
16	did	do	VBD	_	19	aux	_	_
17	not	not	RB	_	19	neg	_	_
18	significantly	significantly	RB	_	19	adv	_	_
19	influence	influence	VB	_	0	root	_	_
20	the	the	DT	_	21	det	_	_
21	bioavailability	bioavailability	NN	_	19	obj	_	_
22	of	of	IN	_	24	case	_	_
23	drug2	drug0	JJ	_	24	attr	_	_
24	tablets	tablet	NNS	_	21	ppmod	_	_
25	.	.	.	_	19	p	_	_

1	Although	although	IN	_	6	mark	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	studies	study	NNS	_	6	dep	_	_
4	have	have	VBP	_	6	aux	_	_
5	not	not	RB	_	6	neg	_	_
6	established	establish	VBN	_	15	advcl	_	_
7	a	a	DT	_	8	det	_	_
8	cause	cause	NN	_	6	obj	_	_
9	and	and	CC	_	8	cc	_	_
10	effect	effect	NN	_	11	com	_	_
11	relationship	relationship	NN	_	8	conj	_	_
12	,	,	,	_	15	p	_	_
13	physicians	physician	NNS	_	15	dep	_	_
14	should	should	MD	_	15	modal	_	_
15	be	be	VB	_	0	root	_	_
16	aware	aware	NN	_	15	obj	_	_
17	that	that	IN	_	25	mark	_	_
18	variable	variable	JJ	_	19	attr	_	_
19	effects	effect	NNS	_	25	dep	_	_
20	an	an	DT	_	22	det	_	_
21	blood	blood	NN	_	22	com	_	_
22	coagulation	coagulation	NN	_	19	appo	_	_
23	have	have	VBP	_	25	aux	_	_
24	been	be	VBN	_	25	aux	_	_
25	reported	report	VBN	_	15	comp	_	_
26	very	very	RB	_	27	com	_	_
27	rarely	rarely	RB	_	25	adv	_	_
28	in	in	IN	_	29	case	_	_
29	patients	patient	NNS	_	25	ppmod	_	_
30	receiving	receive	VBG	_	29	acl	_	_
31	oral	oral	JJ	_	32	attr	_	_
32	drug1	drug0	NN	_	30	obj	_	_
33	and	and	CC	_	32	cc	_	_
34	drug2	drug0	NN	_	32	conj	_	_
35	.	.	.	_	15	p	_	_

1	The	the	DT	_	3	det	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	use	use	NN	_	10	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	or	or	CC	_	5	cc	_	_
7	other	other	JJ	_	8	attr	_	_
8	drug2	drug0	NNS	_	5	conj	_	_
9	may	may	MD	_	10	modal	_	_
10	have	have	VB	_	0	root	_	_
11	an	an	DT	_	13	det	_	_
12	additive	additive	JJ	_	13	attr	_	_
13	effect	effect	NN	_	10	obj	_	_
14	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Concomitant	concomitant	JJ	_	4	attr	_	_
4	administration	administration	NN	_	27	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	(	-lrb-	-LRB-	_	9	p	_	_
8	6	0	CD	_	9	num	_	_
9	mg/kg	mg/kg	NN	_	6	prn	_	_
10	once	once	IN	_	13	case	_	_
11	every	every	DT	_	13	det	_	_
12	24	0	CD	_	13	num	_	_
13	hours	hour	NNS	_	9	ppmod	_	_
14	for	for	IN	_	16	case	_	_
15	5	0	CD	_	16	num	_	_
16	days	day	NNS	_	9	ppmod	_	_
17	)	-rrb-	-RRB-	_	9	p	_	_
18	and	and	CC	_	6	cc	_	_
19	drug3	drug0	NN	_	6	conj	_	_
20	(	-lrb-	-LRB-	_	25	p	_	_
21	25	0	CD	_	25	num	_	_
22	mg	mg	NN	_	25	attr	_	_
23	single	single	JJ	_	25	attr	_	_
24	oral	oral	JJ	_	25	attr	_	_
25	dose	dose	NN	_	19	prn	_	_
26	)	-rrb-	-RRB-	_	25	p	_	_
27	had	have	VBD	_	1	acl	_	_
28	no	no	DT	_	30	det	_	_
29	significant	significant	JJ	_	30	attr	_	_
30	effect	effect	NN	_	27	obj	_	_
31	on	on	IN	_	33	case	_	_
32	the	the	DT	_	33	det	_	_
33	pharmacokinetics	pharmacokinetics	NNS	_	27	ppmod	_	_
34	of	of	IN	_	36	case	_	_
35	either	either	DT	_	36	det	_	_
36	drug	drug	NN	_	33	ppmod	_	_
37	,	,	,	_	27	p	_	_
38	and	and	CC	_	27	cc	_	_
39	the	the	DT	_	40	det	_	_
40	INR	inr	NN	_	44	dep	_	_
41	was	be	VBD	_	44	aux	_	_
42	not	not	RB	_	44	neg	_	_
43	significantly	significantly	RB	_	44	adv	_	_
44	altered	alter	VBN	_	27	conj	_	_
45	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	may	may	MD	_	5	modal	_	_
5	cause	cause	VB	_	0	root	_	_
6	myopathy	myopathy	NN	_	5	obj	_	_
7	,	,	,	_	6	p	_	_
8	which	which	WDT	_	10	dep	_	_
9	is	be	VBZ	_	10	aux	_	_
10	manifested	manifest	VBN	_	6	relcl	_	_
11	as	as	IN	_	13	case	_	_
12	muscle	muscle	NN	_	13	com	_	_
13	pain	pain	NN	_	10	ppmod	_	_
14	or	or	CC	_	13	cc	_	_
15	weakness	weakness	NN	_	13	conj	_	_
16	associated	associate	VBN	_	13	acl	_	_
17	with	with	IN	_	19	case	_	_
18	elevated	elevated	JJ	_	19	attr	_	_
19	levels	level	NNS	_	16	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	CPK	cpk	NN	_	19	ppmod	_	_
22	.	.	.	_	5	p	_	_

1	There	there	EX	_	2	dep	_	_
2	were	be	VBD	_	0	root	_	_
3	no	no	DT	_	4	det	_	_
4	reports	report	NNS	_	2	obj	_	_
5	of	of	IN	_	7	case	_	_
6	skeletal	skeletal	JJ	_	7	attr	_	_
7	myopathy	myopathy	NN	_	4	ppmod	_	_
8	in	in	IN	_	13	case	_	_
9	a	a	DT	_	13	det	_	_
10	placebo-controlled	placebo-controlled	JJ	_	13	attr	_	_
11	Phase	phase	NN	_	13	com	_	_
12	I	i	NN	_	13	com	_	_
13	trial	trial	NN	_	2	ppmod	_	_
14	in	in	IN	_	15	case	_	_
15	which	which	WDT	_	24	ppmod	_	_
16	10	0	CD	_	18	num	_	_
17	healthy	healthy	JJ	_	18	attr	_	_
18	subjects	subject	NNS	_	24	dep	_	_
19	on	on	IN	_	22	case	_	_
20	stable	stable	JJ	_	22	attr	_	_
21	drug1	drug0	NN	_	22	com	_	_
22	therapy	therapy	NN	_	18	ppmod	_	_
23	were	be	VBD	_	24	aux	_	_
24	treated	treat	VBN	_	13	relcl	_	_
25	concurrently	concurrently	RB	_	24	adv	_	_
26	with	with	IN	_	27	case	_	_
27	drug2	drug0	NN	_	24	ppmod	_	_
28	(	-lrb-	-LRB-	_	30	p	_	_
29	4	0	CD	_	30	num	_	_
30	mg/kg	mg/kg	NN	_	27	prn	_	_
31	once	once	RB	_	30	adv	_	_
32	every	every	DT	_	34	det	_	_
33	24	0	CD	_	34	num	_	_
34	hours	hour	NNS	_	30	attr	_	_
35	)	-rrb-	-RRB-	_	30	p	_	_
36	for	for	IN	_	38	case	_	_
37	14	0	CD	_	38	num	_	_
38	days	day	NNS	_	24	ppmod	_	_
39	.	.	.	_	2	p	_	_

1	Experience	experience	VBP	_	0	root	_	_
2	with	with	IN	_	11	mark	_	_
3	co-administration	co-administration	NN	_	11	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	in	in	IN	_	9	case	_	_
9	patients	patient	NNS	_	3	ppmod	_	_
10	is	be	VBZ	_	11	aux	_	_
11	limited	limit	VBN	_	1	comp	_	_
12	,	,	,	_	1	p	_	_
13	therefore	therefore	RB	_	18	adv	_	_
14	,	,	,	_	18	p	_	_
15	consideration	consideration	NN	_	18	dep	_	_
16	should	should	MD	_	18	modal	_	_
17	be	be	VB	_	18	aux	_	_
18	given	give	VBN	_	1	comp	_	_
19	to	to	TO	_	22	aux	_	_
20	temporarily	temporarily	RB	_	21	adv	_	_
21	suspending	suspending	JJ	_	22	attr	_	_
22	use	use	NN	_	18	ppmod	_	_
23	of	of	IN	_	24	case	_	_
24	drug3	drug0	NN	_	22	ppmod	_	_
25	in	in	IN	_	26	case	_	_
26	patients	patient	NNS	_	22	ppmod	_	_
27	receiving	receive	VBG	_	26	acl	_	_
28	drug4	drug0	NN	_	27	obj	_	_
29	.	.	.	_	1	p	_	_

1	Drug-Laboratory	drug-laboratory	JJ	_	3	attr	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	6	dep	_	_
4	:	:	:	_	6	p	_	_
5	There	there	EX	_	6	dep	_	_
6	are	be	VBP	_	0	root	_	_
7	no	no	DT	_	11	det	_	_
8	reported	report	VBN	_	11	attr	_	_
9	drug-laboratory	drug-laboratory	JJ	_	11	attr	_	_
10	test	test	NN	_	11	com	_	_
11	interactions	interaction	NNS	_	6	obj	_	_
12	.	.	.	_	6	p	_	_

1	If	if	IN	_	4	mark	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	given	give	VBN	_	20	advcl	_	_
5	concomitantly	concomitantly	RB	_	4	adv	_	_
6	with	with	IN	_	8	case	_	_
7	other	other	JJ	_	8	attr	_	_
8	drugs	drug	NNS	_	4	ppmod	_	_
9	acting	act	VBG	_	8	acl	_	_
10	on	on	IN	_	14	case	_	_
11	the	the	DT	_	14	det	_	_
12	central	central	JJ	_	14	attr	_	_
13	nervous	nervous	JJ	_	14	attr	_	_
14	system	system	NN	_	9	ppmod	_	_
15	,	,	,	_	20	p	_	_
16	careful	careful	JJ	_	17	attr	_	_
17	consideration	consideration	NN	_	20	dep	_	_
18	should	should	MD	_	20	modal	_	_
19	be	be	VB	_	20	aux	_	_
20	given	give	VBN	_	0	root	_	_
21	to	to	TO	_	23	aux	_	_
22	the	the	DT	_	23	det	_	_
23	pharmacology	pharmacology	NN	_	20	ppmod	_	_
24	of	of	IN	_	26	case	_	_
25	all	all	DT	_	26	det	_	_
26	agents	agent	NNS	_	23	ppmod	_	_
27	.	.	.	_	20	p	_	_

1	The	the	DT	_	2	det	_	_
2	action	action	NN	_	8	dep	_	_
3	of	of	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	drug1	drug0	NN	_	2	ppmod	_	_
6	may	may	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	potentiated	potentiate	VBN	_	0	root	_	_
9	by	by	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	drug3	drug0	NN	_	10	conj	_	_
13	,	,	,	_	12	p	_	_
14	drug4	drug0	NN	_	10	conj	_	_
15	,	,	,	_	14	p	_	_
16	drug5	drug0	NN	_	10	conj	_	_
17	,	,	,	_	16	p	_	_
18	drug6	drug0	NN	_	10	conj	_	_
19	,	,	,	_	18	p	_	_
20	drug7	drug0	NN	_	10	conj	_	_
21	,	,	,	_	20	p	_	_
22	drug8	drug0	NN	_	10	conj	_	_
23	,	,	,	_	22	p	_	_
24	drug9	drug0	NN	_	10	conj	_	_
25	,	,	,	_	24	p	_	_
26	or	or	CC	_	24	cc	_	_
27	other	other	JJ	_	28	attr	_	_
28	drugs	drug	NNS	_	10	conj	_	_
29	that	that	WDT	_	30	dep	_	_
30	produce	produce	VBP	_	28	relcl	_	_
31	CNS	cns	NN	_	32	com	_	_
32	depression	depression	NN	_	30	obj	_	_
33	.	.	.	_	8	p	_	_

1	Smokers	smoker	NNS	_	2	dep	_	_
2	have	have	VBP	_	0	root	_	_
3	an	an	DT	_	5	det	_	_
4	increased	increase	VBN	_	5	attr	_	_
5	clearance	clearance	NN	_	2	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	as	as	IN	_	9	mark	_	_
9	compared	compare	VBN	_	2	comp	_	_
10	to	to	TO	_	11	aux	_	_
11	nonsmokers	nonsmoker	NNS	_	9	ppmod	_	_
12	;	;	:	_	2	p	_	_

1	this	this	DT	_	3	dep	_	_
2	was	be	VBD	_	3	aux	_	_
3	seen	see	VBN	_	0	root	_	_
4	in	in	IN	_	5	case	_	_
5	studies	study	NNS	_	3	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	.	.	.	_	3	p	_	_

1	While	while	IN	_	9	mark	_	_
2	no	no	DT	_	7	det	_	_
3	in	in	FW	_	4	adv	_	_
4	vivo	vivo	FW	_	7	attr	_	_
5	drug-drug	drug-drug	JJ	_	7	attr	_	_
6	interaction	interaction	NN	_	7	com	_	_
7	studies	study	NNS	_	9	dep	_	_
8	were	be	VBD	_	9	aux	_	_
9	conducted	conduct	VBN	_	37	advcl	_	_
10	between	between	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	inducers	inducer	NNS	_	11	conj	_	_
14	of	of	IN	_	15	case	_	_
15	CYP3A	cyp0a	NN	_	13	ppmod	_	_
16	,	,	,	_	37	p	_	_
17	compounds	compound	NNS	_	37	dep	_	_
18	that	that	WDT	_	19	dep	_	_
19	are	be	VBP	_	17	relcl	_	_
20	potent	potent	JJ	_	22	attr	_	_
21	CYP3A	cyp0a	NN	_	22	com	_	_
22	inducers	inducer	NNS	_	19	obj	_	_
23	(	-lrb-	-LRB-	_	24	p	_	_
24	such	such	JJ	_	22	prn	_	_
25	as	as	IN	_	26	case	_	_
26	drug2	drug0	NN	_	24	ppmod	_	_
27	,	,	,	_	26	p	_	_
28	drug3	drug0	NN	_	26	conj	_	_
29	,	,	,	_	28	p	_	_
30	drug4	drug0	NN	_	26	conj	_	_
31	,	,	,	_	30	p	_	_
32	and	and	CC	_	30	cc	_	_
33	drug5	drug0	NN	_	26	conj	_	_
34	)	-rrb-	-RRB-	_	24	p	_	_
35	would	would	MD	_	37	modal	_	_
36	be	be	VB	_	37	aux	_	_
37	expected	expect	VBN	_	0	root	_	_
38	to	to	TO	_	39	aux	_	_
39	decrease	decrease	VB	_	37	comp	_	_
40	drug6	drug0	NN	_	41	com	_	_
41	concentrations	concentration	NNS	_	39	obj	_	_
42	.	.	.	_	37	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Interaction	interaction	NN	_	1	appo	_	_
4	with	with	IN	_	5	case	_	_
5	Drugs	drug	NNS	_	3	ppmod	_	_
6	that	that	WDT	_	7	dep	_	_
7	Inhibit	inhibit	VBP	_	5	relcl	_	_
8	Metabolism	metabolism	NN	_	7	obj	_	_
9	via	via	IN	_	11	case	_	_
10	Cytochrome	cytochrome	NN	_	11	com	_	_
11	P450	p0	NN	_	7	ppmod	_	_
12	3A	0a	NN	_	11	attr	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	CYP3A	cyp0a	NN	_	12	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	:	:	:	_	1	p	_	_
17	The	the	DT	_	18	det	_	_
18	metabolism	metabolism	NN	_	34	dep	_	_
19	of	of	IN	_	20	case	_	_
20	drug2	drug0	NN	_	18	ppmod	_	_
21	to	to	TO	_	26	aux	_	_
22	the	the	DT	_	26	det	_	_
23	major	major	JJ	_	26	attr	_	_
24	circulating	circulating	JJ	_	26	attr	_	_
25	metabolite	metabolite	NN	_	26	com	_	_
26	drug3	drug0	NN	_	18	ppmod	_	_
27	and	and	CC	_	26	cc	_	_
28	the	the	DT	_	29	det	_	_
29	metabolism	metabolism	NN	_	26	conj	_	_
30	of	of	IN	_	32	case	_	_
31	other	other	JJ	_	32	attr	_	_
32	drug4	drug0	NNS	_	29	ppmod	_	_
33	is	be	VBZ	_	34	aux	_	_
34	catalyzed	catalyze	VBN	_	1	acl	_	_
35	by	by	IN	_	36	case	_	_
36	CYP3A	cyp0a	NN	_	34	ppmod	_	_
37	.	.	.	_	1	p	_	_

1	Consequently	consequently	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	drug1	drug0	NN	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	avoided	avoid	VBN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	6	ppmod	_	_
9	receiving	receive	VBG	_	8	acl	_	_
10	drug2	drug0	NN	_	9	obj	_	_
11	and	and	CC	_	10	cc	_	_
12	drug3	drug0	NN	_	10	conj	_	_
13	,	,	,	_	10	p	_	_
14	which	which	WDT	_	15	dep	_	_
15	are	be	VBP	_	10	relcl	_	_
16	very	very	RB	_	17	adv	_	_
17	potent	potent	JJ	_	18	attr	_	_
18	inhibitors	inhibitor	NNS	_	15	obj	_	_
19	of	of	IN	_	20	case	_	_
20	CYP3A	cyp0a	NN	_	18	ppmod	_	_
21	.	.	.	_	6	p	_	_

1	With	with	IN	_	2	case	_	_
2	drugs	drug	NNS	_	17	ppmod	_	_
3	inhibiting	inhibit	VBG	_	2	acl	_	_
4	CYP3A	cyp0a	NN	_	3	obj	_	_
5	to	to	TO	_	12	aux	_	_
6	a	a	DT	_	12	det	_	_
7	lesser	less	JJR	_	12	attr	_	_
8	,	,	,	_	7	p	_	_
9	but	but	CC	_	7	cc	_	_
10	still	still	RB	_	11	adv	_	_
11	significant	significant	JJ	_	7	conj	_	_
12	degree	degree	NN	_	3	ppmod	_	_
13	,	,	,	_	17	p	_	_
14	drug1	drug0	NN	_	17	dep	_	_
15	should	should	MD	_	17	modal	_	_
16	be	be	VB	_	17	aux	_	_
17	used	use	VBN	_	0	root	_	_
18	only	only	RB	_	17	adv	_	_
19	with	with	IN	_	20	case	_	_
20	caution	caution	NN	_	17	ppmod	_	_
21	and	and	CC	_	20	cc	_	_
22	consideration	consideration	NN	_	20	conj	_	_
23	of	of	IN	_	26	case	_	_
24	appropriate	appropriate	JJ	_	26	attr	_	_
25	dosage	dosage	NN	_	26	com	_	_
26	reduction	reduction	NN	_	22	ppmod	_	_
27	.	.	.	_	17	p	_	_

1	The	the	DT	_	2	det	_	_
2	following	following	NN	_	3	dep	_	_
3	are	be	VBP	_	0	root	_	_
4	examples	example	NNS	_	3	obj	_	_
5	of	of	IN	_	6	case	_	_
6	drugs	drug	NNS	_	4	ppmod	_	_
7	known	know	VBN	_	6	acl	_	_
8	to	to	TO	_	9	aux	_	_
9	inhibit	inhibit	VB	_	7	comp	_	_
10	the	the	DT	_	11	det	_	_
11	metabolism	metabolism	NN	_	9	obj	_	_
12	of	of	IN	_	15	case	_	_
13	other	other	JJ	_	15	attr	_	_
14	related	related	JJ	_	15	attr	_	_
15	drug1	drug0	NN	_	11	ppmod	_	_
16	,	,	,	_	9	p	_	_
17	presumably	presumably	RB	_	19	adv	_	_
18	through	through	IN	_	19	case	_	_
19	inhibition	inhibition	NN	_	9	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	CYP3A	cyp0a	NN	_	19	ppmod	_	_
22	:	:	:	_	4	p	_	_
23	drug2	drug0	NN	_	4	appo	_	_
24	,	,	,	_	23	p	_	_
25	drug3	drug0	NN	_	23	conj	_	_
26	,	,	,	_	25	p	_	_
27	drug4	drug0	NN	_	23	conj	_	_
28	,	,	,	_	27	p	_	_
29	drug5	drug0	NN	_	23	conj	_	_
30	,	,	,	_	29	p	_	_
31	drug6	drug0	NN	_	23	conj	_	_
32	,	,	,	_	31	p	_	_
33	and	and	CC	_	31	cc	_	_
34	some	some	DT	_	35	det	_	_
35	drug7	drug0	NN	_	23	conj	_	_
36	.	.	.	_	3	p	_	_

1	Drug	drug	NN	_	2	com	_	_
2	Interaction	interaction	NN	_	0	root	_	_
3	with	with	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	:	:	:	_	2	p	_	_
6	A	a	DT	_	8	det	_	_
7	multiple-dose	multiple-dose	JJ	_	8	attr	_	_
8	study	study	NN	_	10	dep	_	_
9	was	be	VBD	_	10	aux	_	_
10	conducted	conduct	VBN	_	2	acl	_	_
11	to	to	TO	_	12	aux	_	_
12	assess	assess	VB	_	10	comp	_	_
13	the	the	DT	_	14	det	_	_
14	effect	effect	NN	_	12	obj	_	_
15	of	of	IN	_	19	case	_	_
16	drug2	drug0	NN	_	19	attr	_	_
17	20	0	CD	_	18	num	_	_
18	mg	mg	NN	_	19	com	_	_
19	BID	bid	NN	_	14	ppmod	_	_
20	on	on	IN	_	22	case	_	_
21	the	the	DT	_	22	det	_	_
22	pharmacokinetics	pharmacokinetics	NNS	_	14	ppmod	_	_
23	of	of	IN	_	27	case	_	_
24	drug3	drug0	NN	_	27	attr	_	_
25	2	0	CD	_	27	num	_	_
26	mg	mg	NN	_	27	com	_	_
27	QHS	qhs	NNS	_	22	ppmod	_	_
28	after	after	IN	_	30	case	_	_
29	seven	#crd#	CD	_	30	num	_	_
30	days	day	NNS	_	12	ppmod	_	_
31	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	pharmacokinetics	pharmacokinetics	NNS	_	12	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	Cmax	cmax	NN	_	4	prn	_	_
7	and	and	CC	_	6	cc	_	_
8	AUC	auc	NN	_	6	conj	_	_
9	)	-rrb-	-RRB-	_	6	p	_	_
10	were	be	VBD	_	12	aux	_	_
11	not	not	RB	_	12	neg	_	_
12	affected	affect	VBN	_	0	root	_	_
13	during	during	IN	_	15	case	_	_
14	multiple-dose	multiple-dose	NN	_	15	com	_	_
15	drug2	drug0	NN	_	12	ppmod	_	_
16	,	,	,	_	12	p	_	_
17	suggesting	suggest	VBG	_	12	comp	_	_
18	no	no	DT	_	22	det	_	_
19	clinically	clinically	RB	_	20	adv	_	_
20	significant	significant	JJ	_	22	attr	_	_
21	pharmacokinetic	pharmacokinetic	JJ	_	22	attr	_	_
22	interaction	interaction	NN	_	17	obj	_	_
23	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Interaction	interaction	NN	_	1	appo	_	_
4	with	with	IN	_	6	case	_	_
5	Other	other	JJ	_	6	attr	_	_
6	Drugs	drug	NNS	_	3	ppmod	_	_
7	that	that	WDT	_	9	dep	_	_
8	are	be	VBP	_	9	aux	_	_
9	Metabolized	metabolize	VBN	_	6	relcl	_	_
10	by	by	IN	_	12	case	_	_
11	Cytochrome	cytochrome	NN	_	12	com	_	_
12	P450	p0	NN	_	9	ppmod	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	CYP	cyp	NN	_	12	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	:	:	:	_	1	p	_	_
17	At	at	IN	_	20	case	_	_
18	clinically	clinically	RB	_	19	adv	_	_
19	relevant	relevant	JJ	_	20	attr	_	_
20	concentrations	concentration	NNS	_	25	ppmod	_	_
21	,	,	,	_	25	p	_	_
22	in	in	FW	_	23	adv	_	_
23	vitro	vitro	FW	_	24	attr	_	_
24	studies	study	NNS	_	25	dep	_	_
25	indicate	indicate	VBP	_	1	acl	_	_
26	that	that	IN	_	32	mark	_	_
27	drug2	drug0	NN	_	32	dep	_	_
28	(	-lrb-	-LRB-	_	30	p	_	_
29	0.6	0	CD	_	30	num	_	_
30	M	m	NN	_	27	prn	_	_
31	)	-rrb-	-RRB-	_	30	p	_	_
32	was	be	VBD	_	25	comp	_	_
33	not	not	RB	_	32	neg	_	_
34	inhibitory	inhibitory	JJ	_	32	dep	_	_
35	towards	towards	IN	_	41	case	_	_
36	the	the	DT	_	41	det	_	_
37	major	major	JJ	_	41	attr	_	_
38	cytochrome	cytochrome	NN	_	41	com	_	_
39	P450	p0	NN	_	41	com	_	_
40	isoforms	isoforms	NNS	_	41	com	_	_
41	CYP1A2	cyp0a0	NN	_	34	ppmod	_	_
42	,	,	,	_	41	p	_	_
43	CYP2A6	cyp0a0	NN	_	41	conj	_	_
44	,	,	,	_	43	p	_	_
45	CYP2C9	cyp0c0	NN	_	41	conj	_	_
46	,	,	,	_	45	p	_	_
47	CYP2C19	cyp0c0	NN	_	41	conj	_	_
48	,	,	,	_	47	p	_	_
49	CYP2D6	cyp0d0	NN	_	41	conj	_	_
50	,	,	,	_	49	p	_	_
51	CYP2E1	cyp0e0	NN	_	41	conj	_	_
52	,	,	,	_	51	p	_	_
53	and	and	CC	_	51	cc	_	_
54	CYP3A	cyp0a	NN	_	41	conj	_	_
55	.	.	.	_	1	p	_	_

1	Therefore	therefore	RB	_	11	adv	_	_
2	,	,	,	_	11	p	_	_
3	based	base	VBN	_	8	adv	_	_
4	on	on	IN	_	8	case	_	_
5	these	these	DT	_	8	det	_	_
6	in	in	FW	_	7	adv	_	_
7	vitro	vitro	FW	_	8	attr	_	_
8	data	datum	NNS	_	11	ppmod	_	_
9	,	,	,	_	11	p	_	_
10	drug1	drug0	NN	_	11	dep	_	_
11	is	be	VBZ	_	0	root	_	_
12	very	very	RB	_	13	adv	_	_
13	unlikely	unlikely	JJ	_	11	dep	_	_
14	to	to	TO	_	15	aux	_	_
15	inhibit	inhibit	VB	_	13	comp	_	_
16	the	the	DT	_	17	det	_	_
17	biotransformation	biotransformation	NN	_	15	obj	_	_
18	of	of	IN	_	20	case	_	_
19	other	other	JJ	_	20	attr	_	_
20	drugs	drug	NNS	_	17	ppmod	_	_
21	metabolized	metabolize	VBN	_	20	acl	_	_
22	by	by	IN	_	25	case	_	_
23	these	these	DT	_	25	det	_	_
24	CYP	cyp	JJ	_	25	attr	_	_
25	isoforms	isoforms	NNS	_	21	ppmod	_	_

1	.	.	.	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	drug1	drug0	NN	_	11	dep	_	_
2	:	:	:	_	1	p	_	_
3	Elevated	elevated	JJ	_	5	attr	_	_
4	drug2	drug0	NN	_	5	com	_	_
5	levels	level	NNS	_	8	dep	_	_
6	have	have	VBP	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	reported	report	VBN	_	1	acl	_	_
9	in	in	IN	_	10	case	_	_
10	postmarketing	postmarketing	NN	_	8	ppmod	_	_
11	experience	experience	VBP	_	0	root	_	_
12	when	when	WRB	_	15	adv	_	_
13	drug3	drug0	NN	_	15	dep	_	_
14	is	be	VBZ	_	15	aux	_	_
15	administered	administer	VBN	_	11	comp	_	_
16	concomitantly	concomitantly	RB	_	15	adv	_	_
17	.	.	.	_	11	p	_	_

1	Drug	drug	NN	_	2	com	_	_
2	monitoring	monitoring	NN	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	be	be	VB	_	0	root	_	_
5	of	of	IN	_	6	case	_	_
6	assistance	assistance	NN	_	4	ppmod	_	_
7	in	in	IN	_	8	case	_	_
8	detecting	detect	VBG	_	4	ppmod	_	_
9	alterations	alteration	NNS	_	8	obj	_	_
10	in	in	IN	_	13	case	_	_
11	drug1	drug0	NN	_	13	com	_	_
12	plasma	plasma	NN	_	13	com	_	_
13	concentrations	concentration	NNS	_	9	ppmod	_	_
14	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	17	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	:	:	:	_	3	p	_	_
5	Increased	increase	VBN	_	7	attr	_	_
6	prothrombin	prothrombin	NN	_	7	com	_	_
7	time	time	NN	_	1	conj	_	_
8	,	,	,	_	1	p	_	_
9	with	with	IN	_	1	ppmod	_	_
10	or	or	CC	_	9	cc	_	_
11	without	without	IN	_	13	case	_	_
12	clinical	clinical	JJ	_	13	attr	_	_
13	bleeding	bleeding	JJ	_	9	conj	_	_
14	,	,	,	_	1	p	_	_
15	has	have	VBZ	_	17	aux	_	_
16	been	be	VBN	_	17	aux	_	_
17	reported	report	VBN	_	0	root	_	_
18	when	when	WRB	_	21	adv	_	_
19	drug3	drug0	NN	_	21	dep	_	_
20	is	be	VBZ	_	21	aux	_	_
21	administered	administer	VBN	_	17	comp	_	_
22	concomitantly	concomitantly	RB	_	21	adv	_	_
23	.	.	.	_	17	p	_	_

1	Drug/Laboratory	drug/laboratory	JJ	_	3	attr	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	13	dep	_	_
4	A	a	DT	_	6	det	_	_
5	false-positive	false-positive	JJ	_	6	attr	_	_
6	reaction	reaction	NN	_	3	attr	_	_
7	for	for	IN	_	8	case	_	_
8	ketones	ketone	NNS	_	6	ppmod	_	_
9	in	in	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	urine	urine	NN	_	8	ppmod	_	_
12	may	may	MD	_	13	modal	_	_
13	occur	occur	VB	_	0	root	_	_
14	with	with	IN	_	15	case	_	_
15	tests	test	NNS	_	13	ppmod	_	_
16	using	use	VBG	_	15	acl	_	_
17	drug1	drug0	NN	_	16	obj	_	_
18	but	but	CC	_	15	cc	_	_
19	not	not	RB	_	21	neg	_	_
20	with	with	IN	_	21	case	_	_
21	those	those	DT	_	15	conj	_	_
22	using	use	VBG	_	21	acl	_	_
23	drug2	drug0	NN	_	22	obj	_	_
24	.	.	.	_	13	p	_	_

1	The	the	DT	_	2	det	_	_
2	administration	administration	NN	_	6	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	may	may	MD	_	6	modal	_	_
6	result	result	VB	_	0	root	_	_
7	in	in	IN	_	10	case	_	_
8	a	a	DT	_	10	det	_	_
9	false-positive	false-positive	JJ	_	10	attr	_	_
10	reaction	reaction	NN	_	6	ppmod	_	_
11	for	for	IN	_	12	case	_	_
12	glucose	glucose	NN	_	10	ppmod	_	_
13	in	in	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	urine	urine	NN	_	10	ppmod	_	_
16	using	use	VBG	_	15	acl	_	_
17	Clinitest	clinitest	NNP	_	22	attr	_	_
18	**	**	NN	_	22	attr	_	_
19	,	,	,	_	22	p	_	_
20	Benedict	benedict	NNP	_	22	com	_	_
21	s	s	NNP	_	22	com	_	_
22	solution	solution	NN	_	16	obj	_	_
23	,	,	,	_	22	p	_	_
24	or	or	CC	_	22	cc	_	_
25	Fehling	fehling	JJ	_	27	attr	_	_
26	s	s	NN	_	27	com	_	_
27	solution	solution	NN	_	22	conj	_	_
28	.	.	.	_	6	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	recommended	recommend	VBN	_	0	root	_	_
4	that	that	IN	_	24	mark	_	_
5	glucose	glucose	NN	_	6	com	_	_
6	tests	test	NNS	_	24	dep	_	_
7	based	base	VBN	_	6	acl	_	_
8	on	on	IN	_	12	case	_	_
9	enzymatic	enzymatic	JJ	_	12	attr	_	_
10	glucose	glucose	NN	_	12	com	_	_
11	oxidase	oxidase	NN	_	12	com	_	_
12	reactions	reaction	NNS	_	7	ppmod	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	such	such	JJ	_	12	prn	_	_
15	as	as	IN	_	18	case	_	_
16	Clinistix	clinistix	NN	_	18	com	_	_
17	*	*	NN	_	18	com	_	_
18	*	*	NN	_	14	ppmod	_	_
19	or	or	CC	_	18	cc	_	_
20	Tes-Tape	tes-tape	JJ	_	21	attr	_	_
21	**	**	NN	_	18	conj	_	_
22	)	-rrb-	-RRB-	_	14	p	_	_
23	be	be	VB	_	24	aux	_	_
24	used	use	VBN	_	3	comp	_	_
25	.	.	.	_	3	p	_	_

1	A	a	DT	_	5	det	_	_
2	false-positive	false-positive	JJ	_	5	attr	_	_
3	direct	direct	JJ	_	5	attr	_	_
4	Coombs	coombs	NN	_	5	com	_	_
5	test	test	NN	_	8	dep	_	_
6	has	have	VBZ	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	reported	report	VBN	_	0	root	_	_
9	during	during	IN	_	10	case	_	_
10	treatment	treatment	NN	_	8	ppmod	_	_
11	with	with	IN	_	13	case	_	_
12	other	other	JJ	_	13	attr	_	_
13	drug1	drug0	NN	_	10	ppmod	_	_
14	;	;	:	_	8	p	_	_

1	therefore	therefore	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	it	it	PRP	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	recognized	recognize	VBN	_	0	root	_	_
7	that	that	IN	_	13	mark	_	_
8	a	a	DT	_	11	det	_	_
9	positive	positive	JJ	_	11	attr	_	_
10	Coombs	coombs	NN	_	11	com	_	_
11	test	test	NN	_	13	dep	_	_
12	may	may	MD	_	13	modal	_	_
13	be	be	VB	_	6	comp	_	_
14	due	due	JJ	_	13	dep	_	_
15	to	to	TO	_	17	aux	_	_
16	the	the	DT	_	17	det	_	_
17	drug	drug	NN	_	14	ppmod	_	_
18	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	an	an	DT	_	4	det	_	_
4	inhibitor	inhibitor	NN	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	CYP3A	cyp0a	NN	_	4	ppmod	_	_
7	(	-lrb-	-LRB-	_	10	p	_	_
8	cytochrome	cytochrome	NN	_	10	com	_	_
9	P450	p0	NN	_	10	com	_	_
10	3A	0a	NN	_	4	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	.	.	.	_	2	p	_	_

1	Coadministration	coadministration	NN	_	16	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	drugs	drug	NNS	_	3	conj	_	_
6	primarily	primarily	RB	_	7	adv	_	_
7	metabolized	metabolize	VBN	_	5	acl	_	_
8	by	by	IN	_	9	case	_	_
9	CYP3A	cyp0a	NN	_	7	ppmod	_	_
10	(	-lrb-	-LRB-	_	13	p	_	_
11	e.g.	e.g.	FW	_	13	ppmod	_	_
12	,	,	,	_	13	p	_	_
13	drug2	drug0	NNS	_	5	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	may	may	MD	_	16	modal	_	_
16	result	result	VB	_	0	root	_	_
17	in	in	IN	_	20	case	_	_
18	increased	increase	VBN	_	20	attr	_	_
19	plasma	plasma	NN	_	20	com	_	_
20	concentrations	concentration	NNS	_	16	ppmod	_	_
21	of	of	IN	_	24	case	_	_
22	the	the	DT	_	24	det	_	_
23	other	other	JJ	_	24	attr	_	_
24	drug	drug	NN	_	20	ppmod	_	_
25	that	that	WDT	_	27	dep	_	_
26	could	could	MD	_	27	modal	_	_
27	increase	increase	VB	_	24	relcl	_	_
28	or	or	CC	_	27	cc	_	_
29	prolong	prolong	VB	_	27	conj	_	_
30	both	both	DT	_	35	det	_	_
31	its	its	PRP$	_	35	poss	_	_
32	therapeutic	therapeutic	JJ	_	35	attr	_	_
33	and	and	CC	_	32	cc	_	_
34	adverse	adverse	JJ	_	32	conj	_	_
35	effects	effect	NNS	_	29	obj	_	_
36	.	.	.	_	16	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	metabolized	metabolize	VBN	_	0	root	_	_
4	in	in	IN	_	5	case	_	_
5	proof	proof	NN	_	3	ppmod	_	_
6	by	by	IN	_	7	case	_	_
7	C.P.A.	c.p.a.	NN	_	3	ppmod	_	_

1	Coadministration	coadministration	NN	_	10	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NNS	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	drugs	drug	NNS	_	3	conj	_	_
6	that	that	WDT	_	7	dep	_	_
7	induce	induce	VBP	_	3	relcl	_	_
8	CYP3A	cyp0a	NN	_	7	obj	_	_
9	may	may	MD	_	10	modal	_	_
10	decrease	decrease	VB	_	0	root	_	_
11	drug2	drug0	NN	_	13	com	_	_
12	plasma	plasma	NN	_	13	com	_	_
13	concentrations	concentration	NNS	_	10	obj	_	_
14	and	and	CC	_	10	cc	_	_
15	reduce	reduce	VB	_	10	conj	_	_
16	its	its	PRP$	_	18	poss	_	_
17	therapeutic	therapeutic	JJ	_	18	attr	_	_
18	effect	effect	NN	_	15	obj	_	_
19	.	.	.	_	10	p	_	_

1	Coadministration	coadministration	NN	_	10	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NNS	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	drugs	drug	NNS	_	3	conj	_	_
6	that	that	WDT	_	7	dep	_	_
7	inhibit	inhibit	VBP	_	3	relcl	_	_
8	CYP3A	cyp0a	NN	_	7	obj	_	_
9	may	may	MD	_	10	modal	_	_
10	increase	increase	VB	_	0	root	_	_
11	drug2	drug0	NN	_	13	com	_	_
12	plasma	plasma	NN	_	13	com	_	_
13	concentrations	concentration	NNS	_	10	obj	_	_
14	.	.	.	_	10	p	_	_

1	Based	base	VBN	_	5	adv	_	_
2	on	on	IN	_	5	case	_	_
3	known	known	JJ	_	5	attr	_	_
4	metabolic	metabolic	JJ	_	5	attr	_	_
5	profiles	profile	NNS	_	13	ppmod	_	_
6	,	,	,	_	13	p	_	_
7	clinically	clinically	RB	_	8	adv	_	_
8	significant	significant	JJ	_	10	attr	_	_
9	drug	drug	NN	_	10	com	_	_
10	interactions	interaction	NNS	_	13	dep	_	_
11	are	be	VBP	_	13	aux	_	_
12	not	not	RB	_	13	neg	_	_
13	expected	expect	VBN	_	0	root	_	_
14	between	between	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	drug2	drug0	NN	_	15	conj	_	_
18	,	,	,	_	15	p	_	_
19	drug3	drug0	NN	_	15	appo	_	_
20	/	/	:	_	19	p	_	_
21	drug4	drug0	NN	_	19	conj	_	_
22	,	,	,	_	21	p	_	_
23	drug5	drug0	NN	_	19	conj	_	_
24	,	,	,	_	23	p	_	_
25	drug6	drug0	NN	_	19	conj	_	_
26	,	,	,	_	25	p	_	_
27	drug7	drug0	NN	_	19	conj	_	_
28	or	or	CC	_	27	cc	_	_
29	drug8	drug0	NN	_	19	conj	_	_
30	.	.	.	_	13	p	_	_

1	Drugs	drug	NNS	_	0	root	_	_
2	That	that	WDT	_	6	dep	_	_
3	Should	should	MD	_	6	modal	_	_
4	Not	not	RB	_	6	neg	_	_
5	Be	be	VB	_	6	aux	_	_
6	Coadministered	coadministered	VBN	_	1	relcl	_	_
7	With	with	IN	_	9	case	_	_
8	drug1	drug0	NN	_	9	com	_	_
9	drug2	drug0	NN	_	6	ppmod	_	_
10	:	:	:	_	1	p	_	_
11	drug3	drug0	NN	_	1	appo	_	_
12	,	,	,	_	11	p	_	_
13	drug4	drug0	NN	_	14	com	_	_
14	drug5	drug0	NN	_	11	appo	_	_
15	:	:	:	_	11	p	_	_
16	drug6	drug0	NN	_	11	appo	_	_
17	,	,	,	_	11	p	_	_
18	drug7	drug0	NN	_	19	com	_	_
19	Antimigraine	antimigraine	NN	_	11	appo	_	_
20	:	:	:	_	11	p	_	_
21	drug8	drug0	NN	_	22	com	_	_
22	drug9	drug0	NN	_	11	appo	_	_
23	:	:	:	_	11	p	_	_
24	drug10	drug0	CD	_	25	num	_	_
25	drug11	drug0	NN	_	11	appo	_	_
26	drug12	drug0	CD	_	25	num	_	_
27	,	,	,	_	25	p	_	_
28	drug13	drug0	CD	_	31	num	_	_
29	GI	gi	NN	_	31	com	_	_
30	motility	motility	NN	_	31	com	_	_
31	agents	agent	NNS	_	25	appo	_	_
32	:	:	:	_	11	p	_	_
33	drug14	drug0	NN	_	11	appo	_	_

1	Drugs	drug	NNS	_	0	root	_	_
2	Which	which	WDT	_	3	dep	_	_
3	Require	require	VBP	_	1	relcl	_	_
4	a	a	DT	_	6	det	_	_
5	Dose	dose	NN	_	6	com	_	_
6	Reduction	reduction	NN	_	3	obj	_	_
7	When	when	WRB	_	8	adv	_	_
8	Coadminstered	coadminstered	VBN	_	6	relcl	_	_
9	With	with	IN	_	11	case	_	_
10	drug1	drug0	NN	_	11	com	_	_
11	drug2	drug0	NN	_	8	ppmod	_	_
12	:	:	:	_	1	p	_	_
13	drug3	drug0	NN	_	1	appo	_	_

1	*	*	RB	_	4	adv	_	_
2	This	this	DT	_	3	det	_	_
3	table	table	NN	_	4	dep	_	_
4	is	be	VBZ	_	0	root	_	_
5	not	not	RB	_	4	neg	_	_
6	all	all	DT	_	10	det	_	_
7	inclusive	inclusive	JJ	_	10	attr	_	_
8	*	*	NN	_	10	com	_	_
9	*	*	NN	_	10	com	_	_
10	drug1	drug0	NN	_	4	obj	_	_
11	may	may	MD	_	13	modal	_	_
12	not	not	RB	_	13	neg	_	_
13	be	be	VB	_	10	acl	_	_
14	effective	effective	JJ	_	13	dep	_	_
15	due	due	JJ	_	20	adv	_	_
16	to	to	TO	_	20	aux	_	_
17	decreased	decrease	VBN	_	20	attr	_	_
18	drug2	drug0	NN	_	20	com	_	_
19	plasma	plasma	NN	_	20	com	_	_
20	concentrations	concentration	NNS	_	14	ppmod	_	_
21	in	in	IN	_	22	case	_	_
22	patients	patient	NNS	_	20	ppmod	_	_
23	taking	take	VBG	_	22	acl	_	_
24	these	these	DT	_	25	det	_	_
25	agents	agent	NNS	_	23	obj	_	_
26	concomitantly	concomitantly	RB	_	4	adv	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Administration	administration	NN	_	8	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drug3	drug0	NN	_	3	ppmod	_	_
8	resulted	result	VBD	_	1	acl	_	_
9	in	in	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	appearance	appearance	NN	_	8	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	unchanged	unchanged	JJ	_	14	attr	_	_
14	drug4	drug0	NNS	_	11	ppmod	_	_
15	in	in	IN	_	16	case	_	_
16	plasma	plasma	NN	_	11	ppmod	_	_
17	;	;	:	_	1	p	_	_

1	therefore	therefore	RB	_	7	adv	_	_
2	,	,	,	_	7	p	_	_
3	drug1	drug0	NN	_	7	dep	_	_
4	should	should	MD	_	7	modal	_	_
5	not	not	RB	_	7	neg	_	_
6	be	be	VB	_	7	aux	_	_
7	administered	administer	VBN	_	0	root	_	_
8	concurrently	concurrently	RB	_	7	adv	_	_
9	with	with	IN	_	10	case	_	_
10	drug2	drug0	NN	_	7	ppmod	_	_
11	because	because	IN	_	14	case	_	_
12	of	of	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	potential	potential	NN	_	7	ppmod	_	_
15	for	for	IN	_	20	case	_	_
16	serious	serious	JJ	_	20	attr	_	_
17	and/or	and/or	CC	_	16	cc	_	_
18	life-threatening	life-threatening	JJ	_	16	conj	_	_
19	cardiac	cardiac	JJ	_	20	attr	_	_
20	arrhythmias	arrhythmia	NNS	_	14	ppmod	_	_
21	.	.	.	_	7	p	_	_

1	Because	because	IN	_	5	mark	_	_
2	a	a	DT	_	4	det	_	_
3	similar	similar	JJ	_	4	attr	_	_
4	interaction	interaction	NN	_	5	dep	_	_
5	is	be	VBZ	_	13	advcl	_	_
6	likely	likely	JJ	_	5	dep	_	_
7	,	,	,	_	13	p	_	_
8	drug1	drug0	NN	_	13	dep	_	_
9	should	should	MD	_	13	modal	_	_
10	also	also	RB	_	13	adv	_	_
11	not	not	RB	_	13	neg	_	_
12	be	be	VB	_	13	aux	_	_
13	administered	administer	VBN	_	0	root	_	_
14	concurrently	concurrently	RB	_	13	adv	_	_
15	with	with	IN	_	16	case	_	_
16	drug2	drug0	NN	_	13	ppmod	_	_
17	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Coadministration	coadministration	NN	_	8	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drug3	drug0	NN	_	3	ppmod	_	_
8	resulted	result	VBD	_	1	acl	_	_
9	in	in	IN	_	13	case	_	_
10	an	an	DT	_	13	det	_	_
11	83	0	CD	_	13	num	_	_
12	%	%	NN	_	11	meta	_	_
13	increase	increase	NN	_	8	ppmod	_	_
14	in	in	IN	_	17	case	_	_
15	drug4	drug0	NN	_	17	com	_	_
16	plasma	plasma	NN	_	17	com	_	_
17	AUC	auc	NN	_	13	ppmod	_	_
18	and	and	CC	_	13	cc	_	_
19	a	a	DT	_	22	det	_	_
20	51	0	CD	_	22	num	_	_
21	%	%	NN	_	20	meta	_	_
22	increase	increase	NN	_	13	conj	_	_
23	in	in	IN	_	26	case	_	_
24	drug5	drug0	NN	_	26	com	_	_
25	plasma	plasma	NN	_	26	com	_	_
26	A.C.	a.c.	NN	_	22	ppmod	_	_

1	Currently	currently	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	there	there	EX	_	4	dep	_	_
4	are	be	VBP	_	0	root	_	_
5	no	no	DT	_	9	det	_	_
6	safety	safety	NN	_	9	attr	_	_
7	and	and	CC	_	6	cc	_	_
8	efficacy	efficacy	NN	_	6	conj	_	_
9	data	datum	NNS	_	4	obj	_	_
10	available	available	JJ	_	9	attr	_	_
11	from	from	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	use	use	NN	_	10	ppmod	_	_
14	of	of	IN	_	16	case	_	_
15	this	this	DT	_	16	det	_	_
16	combination	combination	NN	_	13	ppmod	_	_
17	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Coadministration	coadministration	NN	_	8	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drug3	drug0	NN	_	3	ppmod	_	_
8	resulted	result	VBD	_	1	acl	_	_
9	in	in	IN	_	13	case	_	_
10	a	a	DT	_	13	det	_	_
11	152	0	CD	_	13	num	_	_
12	%	%	NN	_	11	meta	_	_
13	increase	increase	NN	_	8	ppmod	_	_
14	in	in	IN	_	17	case	_	_
15	drug4	drug0	NN	_	17	com	_	_
16	plasma	plasma	NN	_	17	com	_	_
17	AUC	auc	NN	_	13	ppmod	_	_
18	and	and	CC	_	13	cc	_	_
19	very	very	RB	_	20	adv	_	_
20	little	little	JJ	_	21	attr	_	_
21	change	change	NN	_	13	conj	_	_
22	in	in	IN	_	25	case	_	_
23	drug5	drug0	NN	_	25	com	_	_
24	plasma	plasma	NN	_	25	com	_	_
25	A.C.	a.c.	NN	_	21	ppmod	_	_

1	Currently	currently	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	there	there	EX	_	4	dep	_	_
4	are	be	VBP	_	0	root	_	_
5	no	no	DT	_	9	det	_	_
6	safety	safety	NN	_	9	attr	_	_
7	and	and	CC	_	6	cc	_	_
8	efficacy	efficacy	NN	_	6	conj	_	_
9	data	datum	NNS	_	4	obj	_	_
10	available	available	JJ	_	9	attr	_	_
11	from	from	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	use	use	NN	_	10	ppmod	_	_
14	of	of	IN	_	16	case	_	_
15	this	this	DT	_	16	det	_	_
16	combination	combination	NN	_	13	ppmod	_	_
17	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Coadministration	coadministration	NN	_	19	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	(	-lrb-	-LRB-	_	3	p	_	_
7	using	use	VBG	_	3	acl	_	_
8	an	an	DT	_	12	det	_	_
9	experimental	experimental	JJ	_	12	attr	_	_
10	soft-gelatin	soft-gelatin	NN	_	12	com	_	_
11	capsule	capsule	NN	_	12	com	_	_
12	formulation	formulation	NN	_	7	obj	_	_
13	of	of	IN	_	15	case	_	_
14	drug3	drug0	NN	_	15	com	_	_
15	1200mg	0mg	NN	_	12	ppmod	_	_
16	)	-rrb-	-RRB-	_	3	p	_	_
17	with	with	IN	_	18	case	_	_
18	drug4	drug0	NN	_	3	ppmod	_	_
19	resulted	result	VBD	_	1	acl	_	_
20	in	in	IN	_	24	case	_	_
21	an	an	DT	_	24	det	_	_
22	18	0	CD	_	24	num	_	_
23	%	%	NN	_	22	meta	_	_
24	increase	increase	NN	_	19	ppmod	_	_
25	in	in	IN	_	28	case	_	_
26	drug5	drug0	NN	_	28	com	_	_
27	plasma	plasma	NN	_	28	com	_	_
28	AUC	auc	NN	_	24	ppmod	_	_
29	and	and	CC	_	24	cc	_	_
30	a	a	DT	_	32	det	_	_
31	4-fold	0-fold	JJ	_	32	attr	_	_
32	increase	increase	NN	_	24	conj	_	_
33	in	in	IN	_	36	case	_	_
34	drug6	drug0	NN	_	36	com	_	_
35	plasma	plasma	NN	_	36	com	_	_
36	A.C.	a.c.	NN	_	32	ppmod	_	_

1	If	if	IN	_	2	mark	_	_
2	used	use	VBN	_	23	advcl	_	_
3	in	in	IN	_	4	case	_	_
4	combination	combination	NN	_	2	ppmod	_	_
5	with	with	IN	_	9	case	_	_
6	drug1	drug0	NN	_	9	com	_	_
7	hard	hard	NN	_	9	com	_	_
8	gelatin	gelatin	NN	_	9	com	_	_
9	capsules	capsule	NNS	_	4	ppmod	_	_
10	at	at	IN	_	13	case	_	_
11	the	the	DT	_	13	det	_	_
12	recommended	recommend	VBN	_	13	attr	_	_
13	dose	dose	NN	_	9	ppmod	_	_
14	of	of	IN	_	17	case	_	_
15	600	0	CD	_	16	num	_	_
16	mg	mg	NN	_	17	com	_	_
17	tid	tid	NN	_	13	ppmod	_	_
18	,	,	,	_	23	p	_	_
19	no	no	DT	_	21	det	_	_
20	dose	dose	NN	_	21	com	_	_
21	adjustments	adjustment	NNS	_	23	dep	_	_
22	are	be	VBP	_	23	aux	_	_
23	needed	need	VBN	_	0	root	_	_
24	.	.	.	_	23	p	_	_

1	Currently	currently	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	there	there	EX	_	4	dep	_	_
4	are	be	VBP	_	0	root	_	_
5	no	no	DT	_	9	det	_	_
6	safety	safety	NN	_	9	attr	_	_
7	and	and	CC	_	6	cc	_	_
8	efficacy	efficacy	NN	_	6	conj	_	_
9	data	datum	NNS	_	4	obj	_	_
10	available	available	JJ	_	9	attr	_	_
11	from	from	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	use	use	NN	_	10	ppmod	_	_
14	of	of	IN	_	16	case	_	_
15	this	this	DT	_	16	det	_	_
16	combination	combination	NN	_	13	ppmod	_	_
17	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Coadministration	coadministration	NN	_	8	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drug3	drug0	NN	_	3	ppmod	_	_
8	resulted	result	VBD	_	1	acl	_	_
9	in	in	IN	_	13	case	_	_
10	a	a	DT	_	13	det	_	_
11	35	0	CD	_	13	num	_	_
12	%	%	NN	_	11	meta	_	_
13	increase	increase	NN	_	8	ppmod	_	_
14	in	in	IN	_	17	case	_	_
15	drug4	drug0	NN	_	17	com	_	_
16	plasma	plasma	NN	_	17	com	_	_
17	A.C.	a.c.	NN	_	13	ppmod	_	_

1	This	this	DT	_	2	det	_	_
2	change	change	NN	_	5	dep	_	_
3	was	be	VBD	_	5	aux	_	_
4	not	not	RB	_	5	neg	_	_
5	considered	consider	VBN	_	0	root	_	_
6	clinically	clinically	RB	_	7	adv	_	_
7	significant	significant	JJ	_	5	dep	_	_
8	and	and	CC	_	5	cc	_	_
9	no	no	DT	_	11	det	_	_
10	dose	dose	NN	_	11	com	_	_
11	adjustment	adjustment	NN	_	13	dep	_	_
12	is	be	VBZ	_	13	aux	_	_
13	needed	need	VBN	_	5	conj	_	_
14	when	when	WRB	_	19	adv	_	_
15	drug1	drug0	NN	_	19	dep	_	_
16	and	and	CC	_	15	cc	_	_
17	drug2	drug0	NN	_	15	conj	_	_
18	are	be	VBP	_	19	aux	_	_
19	coadministered	coadministered	VBN	_	13	comp	_	_
20	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	It	it	PRP	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	recommended	recommend	VBN	_	1	acl	_	_
6	that	that	IN	_	9	mark	_	_
7	drug2	drug0	NN	_	9	dep	_	_
8	be	be	VB	_	9	aux	_	_
9	administered	administer	VBN	_	5	comp	_	_
10	on	on	IN	_	13	case	_	_
11	an	an	DT	_	13	det	_	_
12	empty	empty	JJ	_	13	attr	_	_
13	stomach	stomach	NN	_	9	ppmod	_	_
14	;	;	:	_	1	p	_	_

1	therefore	therefore	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	drug1	drug0	NN	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	administered	administer	VBN	_	0	root	_	_
7	(	-lrb-	-LRB-	_	9	p	_	_
8	with	with	IN	_	9	case	_	_
9	food	food	NN	_	6	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	one	#crd#	CD	_	12	num	_	_
12	hour	hour	NN	_	18	dat	_	_
13	after	after	IN	_	18	case	_	_
14	or	or	CC	_	17	cc	_	_
15	more	more	JJR	_	17	attr	_	_
16	than	than	IN	_	15	com	_	_
17	two	#crd#	CD	_	18	num	_	_
18	hours	hour	NNS	_	6	ppmod	_	_
19	before	before	IN	_	20	case	_	_
20	drug2	drug0	NN	_	18	ppmod	_	_
21	.	.	.	_	6	p	_	_

1	A	a	DT	_	3	det	_	_
2	dose	dose	NN	_	3	com	_	_
3	adjustment	adjustment	NN	_	6	dep	_	_
4	is	be	VBZ	_	6	aux	_	_
5	not	not	RB	_	6	neg	_	_
6	needed	need	VBN	_	0	root	_	_
7	when	when	WRB	_	10	adv	_	_
8	drug1	drug0	NN	_	10	dep	_	_
9	is	be	VBZ	_	10	aux	_	_
10	administered	administer	VBN	_	6	comp	_	_
11	with	with	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	6	p	_	_

1	Little	little	JJ	_	12	dep	_	_
2	or	or	CC	_	1	cc	_	_
3	no	no	DT	_	4	det	_	_
4	change	change	NN	_	1	conj	_	_
5	in	in	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	pharmacokinetics	pharmacokinetics	NNS	_	4	ppmod	_	_
8	of	of	IN	_	10	case	_	_
9	either	either	DT	_	10	det	_	_
10	drug	drug	NN	_	7	ppmod	_	_
11	was	be	VBD	_	12	aux	_	_
12	observed	observe	VBN	_	0	root	_	_
13	when	when	WRB	_	16	adv	_	_
14	drug1	drug0	NN	_	16	dep	_	_
15	was	be	VBD	_	16	aux	_	_
16	coadministered	coadministered	VBN	_	12	comp	_	_
17	with	with	IN	_	18	case	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	or	or	CC	_	18	cc	_	_
20	drug3	drug0	NN	_	18	conj	_	_
21	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Coadministration	coadministration	NN	_	8	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug3	drug0	NN	_	5	conj	_	_
8	resulted	result	VBD	_	1	acl	_	_
9	in	in	IN	_	13	case	_	_
10	a	a	DT	_	13	det	_	_
11	32	0	CD	_	13	num	_	_
12	%	%	NN	_	11	meta	_	_
13	decrease	decrease	NN	_	8	ppmod	_	_
14	in	in	IN	_	17	case	_	_
15	drug4	drug0	NN	_	17	com	_	_
16	plasma	plasma	NN	_	17	com	_	_
17	AUC	auc	NN	_	13	ppmod	_	_
18	and	and	CC	_	13	cc	_	_
19	a	a	DT	_	22	det	_	_
20	207	0	CD	_	22	num	_	_
21	%	%	NN	_	20	meta	_	_
22	increase	increase	NN	_	13	conj	_	_
23	in	in	IN	_	26	case	_	_
24	drug5	drug0	NN	_	26	com	_	_
25	plasma	plasma	NN	_	26	com	_	_
26	A.C.	a.c.	NN	_	22	ppmod	_	_

1	It	it	PRP	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	recommended	recommend	VBN	_	0	root	_	_
4	that	that	IN	_	10	mark	_	_
5	the	the	DT	_	6	det	_	_
6	dose	dose	NN	_	10	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	be	be	VB	_	10	aux	_	_
10	reduced	reduce	VBN	_	3	comp	_	_
11	to	to	TO	_	12	aux	_	_
12	one-half	one-half	NN	_	10	ppmod	_	_
13	the	the	DT	_	15	det	_	_
14	usual	usual	JJ	_	15	attr	_	_
15	dose	dose	NN	_	12	attr	_	_
16	when	when	WRB	_	17	adv	_	_
17	administered	administer	VBN	_	10	comp	_	_
18	with	with	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Coadministration	coadministration	NN	_	8	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug3	drug0	NN	_	5	conj	_	_
8	resulted	result	VBD	_	1	acl	_	_
9	in	in	IN	_	13	case	_	_
10	an	an	DT	_	13	det	_	_
11	82	0	CD	_	13	num	_	_
12	%	%	NN	_	11	meta	_	_
13	decrease	decrease	NN	_	8	ppmod	_	_
14	in	in	IN	_	17	case	_	_
15	drug4	drug0	NN	_	17	com	_	_
16	plasma	plasma	NN	_	17	com	_	_
17	A.C.	a.c.	NN	_	13	ppmod	_	_

1	drug1	drug0	NN	_	7	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	should	should	MD	_	7	modal	_	_
5	not	not	RB	_	7	neg	_	_
6	be	be	VB	_	7	aux	_	_
7	coadministered	coadministered	VBN	_	0	root	_	_
8	.	.	.	_	7	p	_	_

1	Oral	oral	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	:	:	:	_	1	p	_	_
5	Coadministration	coadministration	NN	_	10	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug3	drug0	NN	_	5	ppmod	_	_
8	with	with	IN	_	9	case	_	_
9	drug4	drug0	NN	_	5	ppmod	_	_
10	resulted	result	VBD	_	1	acl	_	_
11	in	in	IN	_	15	case	_	_
12	a	a	DT	_	15	det	_	_
13	47	0	CD	_	15	num	_	_
14	%	%	NN	_	13	meta	_	_
15	decrease	decrease	NN	_	10	ppmod	_	_
16	in	in	IN	_	17	case	_	_
17	drug5	drug0	NN	_	15	ppmod	_	_
18	and	and	CC	_	15	cc	_	_
19	an	an	DT	_	22	det	_	_
20	18	0	CD	_	22	num	_	_
21	%	%	NN	_	20	meta	_	_
22	decrease	decrease	NN	_	15	conj	_	_
23	in	in	IN	_	26	case	_	_
24	drug6	drug0	NN	_	26	com	_	_
25	plasma	plasma	NN	_	26	com	_	_
26	concentrations	concentration	NNS	_	22	ppmod	_	_
27	.	.	.	_	1	p	_	_

1	Alternate	alternate	JJ	_	5	attr	_	_
2	or	or	CC	_	5	cc	_	_
3	additional	additional	JJ	_	5	attr	_	_
4	contraceptive	contraceptive	NN	_	5	com	_	_
5	measures	measure	NNS	_	8	dep	_	_
6	should	should	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	used	use	VBN	_	0	root	_	_
9	during	during	IN	_	10	case	_	_
10	therapy	therapy	NN	_	8	ppmod	_	_
11	with	with	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_

1	Specific	specific	JJ	_	4	attr	_	_
2	drug	drug	NN	_	4	com	_	_
3	interaction	interaction	NN	_	4	com	_	_
4	studies	study	NNS	_	8	dep	_	_
5	have	have	VBP	_	8	aux	_	_
6	not	not	RB	_	8	neg	_	_
7	been	be	VBN	_	8	aux	_	_
8	conducted	conduct	VBN	_	0	root	_	_
9	with	with	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	8	p	_	_

1	However	however	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	it	it	PRP	_	5	dep	_	_
4	was	be	VBD	_	5	aux	_	_
5	observed	observe	VBN	_	0	root	_	_
6	that	that	IN	_	11	mark	_	_
7	the	the	DT	_	8	det	_	_
8	pharmacokinetics	pharmacokinetics	NNS	_	11	dep	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	was	be	VBD	_	5	comp	_	_
12	unaltered	unaltered	JJ	_	11	dep	_	_
13	by	by	IN	_	15	case	_	_
14	concomitant	concomitant	JJ	_	15	attr	_	_
15	drug2	drug0	NN	_	12	ppmod	_	_
16	in	in	IN	_	19	case	_	_
17	rheumatoid	rheumatoid	JJ	_	19	attr	_	_
18	arthritis	arthritis	NN	_	19	com	_	_
19	patients	patient	NNS	_	15	ppmod	_	_
20	.	.	.	_	5	p	_	_

1	In	in	IN	_	3	case	_	_
2	a	a	DT	_	3	det	_	_
3	study	study	NN	_	32	ppmod	_	_
4	in	in	IN	_	5	case	_	_
5	which	which	WDT	_	11	ppmod	_	_
6	patients	patient	NNS	_	11	dep	_	_
7	with	with	IN	_	9	case	_	_
8	active	active	JJ	_	9	attr	_	_
9	RA	ra	NN	_	6	ppmod	_	_
10	were	be	VBD	_	11	aux	_	_
11	treated	treat	VBN	_	3	relcl	_	_
12	for	for	IN	_	16	case	_	_
13	up	up	RB	_	15	adv	_	_
14	to	to	TO	_	15	attr	_	_
15	24	0	CD	_	16	num	_	_
16	weeks	week	NNS	_	11	ppmod	_	_
17	with	with	IN	_	19	case	_	_
18	concurrent	concurrent	JJ	_	19	attr	_	_
19	drug1	drug0	NN	_	11	ppmod	_	_
20	and	and	CC	_	19	cc	_	_
21	drug2	drug0	JJ	_	22	attr	_	_
22	therapy	therapy	NN	_	19	conj	_	_
23	,	,	,	_	32	p	_	_
24	a	a	DT	_	27	det	_	_
25	7	0	CD	_	27	num	_	_
26	%	%	NN	_	25	meta	_	_
27	rate	rate	NN	_	32	dep	_	_
28	of	of	IN	_	30	case	_	_
29	serious	serious	JJ	_	30	attr	_	_
30	infections	infection	NNS	_	27	ppmod	_	_
31	was	be	VBD	_	32	aux	_	_
32	observed	observe	VBN	_	0	root	_	_
33	,	,	,	_	32	p	_	_
34	which	which	WDT	_	35	dep	_	_
35	was	be	VBD	_	32	comp	_	_
36	higher	high	JJR	_	35	dep	_	_
37	than	than	IN	_	38	case	_	_
38	that	that	DT	_	36	ppmod	_	_
39	observed	observe	VBN	_	38	acl	_	_
40	with	with	IN	_	41	case	_	_
41	drug3	drug0	NN	_	39	ppmod	_	_
42	alone	alone	RB	_	41	adv	_	_
43	(	-lrb-	-LRB-	_	44	p	_	_
44	0	0	CD	_	35	num	_	_
45	%	%	NN	_	44	meta	_	_
46	)	-rrb-	-RRB-	_	44	p	_	_
47	.	.	.	_	32	p	_	_

1	Two	#crd#	CD	_	2	num	_	_
2	percent	percent	NN	_	11	dep	_	_
3	of	of	IN	_	4	case	_	_
4	patients	patient	NNS	_	2	ppmod	_	_
5	treated	treat	VBN	_	4	acl	_	_
6	concurrently	concurrently	RB	_	5	adv	_	_
7	with	with	IN	_	8	case	_	_
8	drug1	drug0	NN	_	5	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	drug2	drug0	NN	_	8	conj	_	_
11	developed	develop	VBD	_	0	root	_	_
12	neutropenia	neutropenia	NN	_	11	obj	_	_
13	(	-lrb-	-LRB-	_	17	p	_	_
14	ANC	anc	NN	_	17	attr	_	_
15	1	0	CD	_	17	num	_	_
16	x	x	NN	_	17	com	_	_
17	109/L	0/l	NN	_	12	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	.	.	.	_	11	p	_	_

1	Patients	patient	NNS	_	21	dep	_	_
2	in	in	IN	_	5	case	_	_
3	a	a	DT	_	5	det	_	_
4	clinical	clinical	JJ	_	5	attr	_	_
5	study	study	NN	_	1	ppmod	_	_
6	who	who	WP	_	7	dep	_	_
7	were	be	VBD	_	1	relcl	_	_
8	on	on	IN	_	10	case	_	_
9	established	established	JJ	_	10	attr	_	_
10	therapy	therapy	NN	_	7	ppmod	_	_
11	with	with	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	to	to	TO	_	15	aux	_	_
15	which	which	WDT	_	18	ppmod	_	_
16	drug2	drug0	NN	_	18	dep	_	_
17	was	be	VBD	_	18	aux	_	_
18	added	add	VBN	_	12	relcl	_	_
19	,	,	,	_	12	p	_	_
20	were	be	VBD	_	21	aux	_	_
21	noted	note	VBN	_	0	root	_	_
22	to	to	TO	_	23	aux	_	_
23	develop	develop	VB	_	21	comp	_	_
24	a	a	DT	_	26	det	_	_
25	mild	mild	JJ	_	26	attr	_	_
26	decrease	decrease	NN	_	23	obj	_	_
27	in	in	IN	_	30	case	_	_
28	mean	mean	NN	_	30	com	_	_
29	neutrophil	neutrophil	NN	_	30	com	_	_
30	counts	count	NNS	_	26	ppmod	_	_
31	in	in	IN	_	32	case	_	_
32	comparison	comparison	NN	_	30	ppmod	_	_
33	to	to	TO	_	34	aux	_	_
34	groups	group	NNS	_	32	ppmod	_	_
35	treated	treat	VBN	_	34	acl	_	_
36	with	with	IN	_	38	case	_	_
37	either	either	CC	_	38	cc	_	_
38	drug3	drug0	NN	_	35	ppmod	_	_
39	CI	ci	CD	_	38	num	_	_
40	or	or	CC	_	38	cc	_	_
41	drug4	drug0	NN	_	38	conj	_	_
42	alone	alone	RB	_	35	adv	_	_
43	.	.	.	_	21	p	_	_

1	The	the	DT	_	3	det	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	significance	significance	NN	_	7	dep	_	_
4	of	of	IN	_	6	case	_	_
5	this	this	DT	_	6	det	_	_
6	observation	observation	NN	_	3	ppmod	_	_
7	is	be	VBZ	_	0	root	_	_
8	unknown	unknown	JJ	_	7	dep	_	_
9	.	.	.	_	7	p	_	_

1	This	this	DT	_	2	det	_	_
2	drug	drug	NN	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	interact	interact	VB	_	0	root	_	_
5	with	with	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	or	or	CC	_	6	cc	_	_
8	other	other	JJ	_	9	attr	_	_
9	drug2	drug0	NNS	_	6	conj	_	_
10	(	-lrb-	-LRB-	_	9	p	_	_
11	may	may	MD	_	12	modal	_	_
12	potentiate	potentiate	VB	_	9	acl	_	_
13	the	the	DT	_	16	det	_	_
14	CNS	cns	NN	_	16	com	_	_
15	depressant	depressant	NN	_	16	com	_	_
16	effects	effect	NNS	_	12	obj	_	_
17	of	of	IN	_	20	case	_	_
18	either	either	CC	_	20	cc	_	_
19	these	these	DT	_	20	det	_	_
20	medications	medication	NNS	_	16	ppmod	_	_
21	or	or	CC	_	20	cc	_	_
22	drug3	drug0	NN	_	20	conj	_	_
23	)	-rrb-	-RRB-	_	9	p	_	_
24	,	,	,	_	9	p	_	_
25	drug4	drug0	NN	_	9	conj	_	_
26	or	or	CC	_	25	cc	_	_
27	other	other	JJ	_	28	attr	_	_
28	medications	medication	NNS	_	9	conj	_	_
29	with	with	IN	_	31	case	_	_
30	anticholinergic	anticholinergic	JJ	_	31	attr	_	_
31	activity	activity	NN	_	4	ppmod	_	_
32	(	-lrb-	-LRB-	_	37	p	_	_
33	anticholinergic	anticholinergic	JJ	_	34	attr	_	_
34	effects	effect	NNS	_	37	dep	_	_
35	may	may	MD	_	37	modal	_	_
36	be	be	VB	_	37	aux	_	_
37	potentiated	potentiate	VBN	_	31	prn	_	_
38	when	when	WRB	_	42	adv	_	_
39	these	these	DT	_	40	det	_	_
40	medications	medication	NNS	_	42	dep	_	_
41	are	be	VBP	_	42	aux	_	_
42	used	use	VBN	_	37	comp	_	_
43	concurrently	concurrently	RB	_	42	adv	_	_
44	with	with	IN	_	45	case	_	_
45	drug5	drug0	NN	_	42	ppmod	_	_
46	)	-rrb-	-RRB-	_	37	p	_	_
47	,	,	,	_	31	p	_	_
48	and	and	CC	_	31	cc	_	_
49	drug6	drug0	NN	_	31	conj	_	_
50	(	-lrb-	-LRB-	_	56	p	_	_
51	concurrent	concurrent	JJ	_	52	attr	_	_
52	use	use	NN	_	56	dep	_	_
53	with	with	IN	_	54	case	_	_
54	drug7	drug0	NN	_	52	ppmod	_	_
55	may	may	MD	_	56	modal	_	_
56	prolong	prolong	VB	_	49	prn	_	_
57	and	and	CC	_	56	cc	_	_
58	intensify	intensify	VB	_	56	conj	_	_
59	the	the	DT	_	64	det	_	_
60	anticholinergic	anticholinergic	JJ	_	64	attr	_	_
61	and	and	CC	_	64	cc	_	_
62	CNS	cns	NN	_	64	com	_	_
63	depressant	depressant	NN	_	64	com	_	_
64	effects	effect	NNS	_	58	obj	_	_
65	of	of	IN	_	66	case	_	_
66	drug8	drug0	NN	_	64	ppmod	_	_
67	)	-rrb-	-RRB-	_	56	p	_	_
68	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	,	,	,	_	1	p	_	_
5	drug3	drug0	NN	_	1	appo	_	_
6	,	,	,	_	1	p	_	_
7	drug4	drug0	NN	_	1	appo	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	use	use	NN	_	9	dep	_	_
3	of	of	IN	_	5	case	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	supplements	supplement	NNS	_	2	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NNS	_	5	conj	_	_
8	may	may	MD	_	9	modal	_	_
9	increase	increase	VB	_	0	root	_	_
10	drug3	drug0	NN	_	11	com	_	_
11	absorption	absorption	NN	_	9	obj	_	_

1	Since	since	IN	_	3	mark	_	_
2	drug1	drug0	NN	_	3	dep	_	_
3	is	be	VBZ	_	9	advcl	_	_
4	an	an	DT	_	5	det	_	_
5	drug2	drug0	NN	_	3	obj	_	_
6	,	,	,	_	9	p	_	_
7	it	it	PRP	_	9	dep	_	_
8	may	may	MD	_	9	modal	_	_
9	have	have	VB	_	0	root	_	_
10	a	a	DT	_	12	det	_	_
11	strong	strong	JJ	_	12	attr	_	_
12	affinity	affinity	NN	_	9	obj	_	_
13	for	for	IN	_	14	case	_	_
14	anions	anion	NNS	_	12	ppmod	_	_
15	other	other	JJ	_	14	attr	_	_
16	than	than	IN	_	19	case	_	_
17	the	the	DT	_	19	det	_	_
18	bile	bile	JJ	_	19	attr	_	_
19	acids	acid	NNS	_	15	ppmod	_	_
20	.	.	.	_	9	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	studies	study	NNS	_	5	dep	_	_
4	have	have	VBP	_	5	aux	_	_
5	indicated	indicate	VBN	_	0	root	_	_
6	that	that	IN	_	8	mark	_	_
7	drug1	drug0	NN	_	8	dep	_	_
8	binds	bind	VBZ	_	5	comp	_	_
9	a	a	DT	_	10	det	_	_
10	number	number	NN	_	8	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drugs	drug	NNS	_	10	ppmod	_	_
13	.	.	.	_	5	p	_	_

1	Therefore	therefore	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	Tablets	tablet	NNS	_	6	dep	_	_
5	may	may	MD	_	6	modal	_	_
6	delay	delay	VB	_	0	root	_	_
7	or	or	CC	_	6	cc	_	_
8	reduce	reduce	VB	_	6	conj	_	_
9	the	the	DT	_	10	det	_	_
10	absorption	absorption	NN	_	8	obj	_	_
11	of	of	IN	_	14	case	_	_
12	concomitant	concomitant	JJ	_	14	attr	_	_
13	oral	oral	JJ	_	14	attr	_	_
14	medication	medication	NN	_	10	ppmod	_	_
15	.	.	.	_	6	p	_	_

1	The	the	DT	_	2	det	_	_
2	interval	interval	NN	_	14	dep	_	_
3	between	between	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	administration	administration	NN	_	2	ppmod	_	_
6	of	of	IN	_	8	case	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	Tablets	tablet	NNS	_	5	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	any	any	DT	_	12	det	_	_
11	other	other	JJ	_	12	attr	_	_
12	medication	medication	NN	_	8	conj	_	_
13	should	should	MD	_	14	modal	_	_
14	be	be	VB	_	0	root	_	_
15	as	as	RB	_	16	adv	_	_
16	long	long	JJ	_	14	dep	_	_
17	as	as	IN	_	18	case	_	_
18	possible	possible	JJ	_	16	ppmod	_	_
19	.	.	.	_	14	p	_	_

1	Patients	patient	NNS	_	3	dep	_	_
2	should	should	MD	_	3	modal	_	_
3	take	take	VB	_	0	root	_	_
4	other	other	JJ	_	5	attr	_	_
5	drugs	drug	NNS	_	3	obj	_	_
6	at	at	IN	_	8	case	_	_
7	least	least	JJS	_	8	attr	_	_
8	one	#crd#	CD	_	9	num	_	_
9	hour	hour	NN	_	13	dat	_	_
10	before	before	IN	_	13	case	_	_
11	or	or	CC	_	13	cc	_	_
12	four	#crd#	CD	_	13	num	_	_
13	hours	hour	NNS	_	3	ppmod	_	_
14	after	after	IN	_	16	case	_	_
15	drug1	drug0	JJ	_	16	attr	_	_
16	Tablets	tablet	NNS	_	13	ppmod	_	_
17	to	to	TO	_	18	aux	_	_
18	avoid	avoid	VB	_	3	comp	_	_
19	impeding	impede	VBG	_	18	comp	_	_
20	their	their	PRP$	_	21	poss	_	_
21	absorption	absorption	NN	_	19	obj	_	_
22	.	.	.	_	3	p	_	_

1	Repeated	repeated	JJ	_	2	attr	_	_
2	doses	dose	NNS	_	18	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	given	give	VBN	_	4	acl	_	_
6	prior	prior	JJ	_	10	adv	_	_
7	to	to	TO	_	10	aux	_	_
8	a	a	DT	_	10	det	_	_
9	single	single	JJ	_	10	attr	_	_
10	dose	dose	NN	_	5	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	in	in	IN	_	15	case	_	_
14	human	human	JJ	_	15	attr	_	_
15	trials	trial	NNS	_	12	ppmod	_	_
16	have	have	VBP	_	18	aux	_	_
17	been	be	VBN	_	18	aux	_	_
18	reported	report	VBN	_	0	root	_	_
19	to	to	TO	_	20	aux	_	_
20	decrease	decrease	VB	_	18	comp	_	_
21	drug3	drug0	NN	_	22	com	_	_
22	absorption	absorption	NN	_	20	obj	_	_
23	.	.	.	_	18	p	_	_

1	However	however	RB	_	28	adv	_	_
2	,	,	,	_	28	p	_	_
3	in	in	IN	_	6	case	_	_
4	a	a	DT	_	6	det	_	_
5	follow-up	follow-up	JJ	_	6	attr	_	_
6	study	study	NN	_	28	ppmod	_	_
7	in	in	IN	_	9	case	_	_
8	normal	normal	JJ	_	9	attr	_	_
9	subjects	subject	NNS	_	6	ppmod	_	_
10	,	,	,	_	28	p	_	_
11	single-dose	single-dose	JJ	_	12	attr	_	_
12	administration	administration	NN	_	28	dep	_	_
13	of	of	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	drug2	drug0	NN	_	14	conj	_	_
17	and	and	CC	_	12	cc	_	_
18	twice-a-day	twice-a-day	JJ	_	19	attr	_	_
19	administration	administration	NN	_	12	conj	_	_
20	for	for	IN	_	22	case	_	_
21	5	0	CD	_	22	num	_	_
22	days	day	NNS	_	19	ppmod	_	_
23	of	of	IN	_	25	case	_	_
24	both	both	DT	_	25	det	_	_
25	agents	agent	NNS	_	22	ppmod	_	_
26	did	do	VBD	_	28	aux	_	_
27	not	not	RB	_	28	neg	_	_
28	affect	affect	VB	_	0	root	_	_
29	the	the	DT	_	30	det	_	_
30	extent	extent	NN	_	28	obj	_	_
31	of	of	IN	_	33	case	_	_
32	drug3	drug0	NN	_	33	com	_	_
33	absorption	absorption	NN	_	30	ppmod	_	_
34	,	,	,	_	28	p	_	_
35	but	but	CC	_	28	cc	_	_
36	had	have	VBD	_	28	conj	_	_
37	a	a	DT	_	42	det	_	_
38	small	small	JJ	_	42	attr	_	_
39	yet	yet	CC	_	38	cc	_	_
40	statistically	statistically	RB	_	41	adv	_	_
41	significant	significant	JJ	_	38	conj	_	_
42	effect	effect	NN	_	36	obj	_	_
43	on	on	IN	_	45	case	_	_
44	its	its	PRP$	_	45	poss	_	_
45	rate	rate	NN	_	36	ppmod	_	_
46	of	of	IN	_	47	case	_	_
47	absorption	absorption	NN	_	45	ppmod	_	_
48	;	;	:	_	28	p	_	_

1	the	the	DT	_	2	det	_	_
2	time	time	NN	_	8	dep	_	_
3	to	to	TO	_	4	aux	_	_
4	reach	reach	VB	_	2	acl	_	_
5	maximum	maximum	NN	_	6	com	_	_
6	concentration	concentration	NN	_	4	obj	_	_
7	was	be	VBD	_	8	aux	_	_
8	delayed	delay	VBN	_	0	root	_	_
9	approximately	approximately	RB	_	10	adv	_	_
10	30	0	CD	_	11	num	_	_
11	minutes	minute	NNS	_	8	obj	_	_
12	.	.	.	_	8	p	_	_

1	Effects	effect	NNS	_	11	dep	_	_
2	on	on	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	absorption	absorption	NN	_	1	ppmod	_	_
5	of	of	IN	_	7	case	_	_
6	other	other	JJ	_	7	attr	_	_
7	drug1	drug0	NN	_	4	ppmod	_	_
8	have	have	VBP	_	11	aux	_	_
9	not	not	RB	_	11	neg	_	_
10	been	be	VBN	_	11	aux	_	_
11	determined	determine	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	Therefore	therefore	RB	_	8	adv	_	_
2	,	,	,	_	8	p	_	_
3	patients	patient	NNS	_	8	dep	_	_
4	on	on	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	should	should	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	observed	observe	VBN	_	0	root	_	_
9	when	when	WRB	_	14	adv	_	_
10	drug2	drug0	NN	_	11	com	_	_
11	Tablets	tablet	NNS	_	14	dep	_	_
12	are	be	VBP	_	14	aux	_	_
13	either	either	CC	_	14	cc	_	_
14	added	add	VBN	_	8	comp	_	_
15	or	or	CC	_	14	cc	_	_
16	deleted	delete	VBN	_	14	conj	_	_
17	from	from	IN	_	20	case	_	_
18	a	a	DT	_	20	det	_	_
19	therapeutic	therapeutic	JJ	_	20	attr	_	_
20	regimen	regimen	NNS	_	16	ppmod	_	_
21	.	.	.	_	8	p	_	_

1	Studies	study	NNS	_	4	dep	_	_
2	in	in	IN	_	3	case	_	_
3	humans	human	NNS	_	1	ppmod	_	_
4	show	show	VBP	_	0	root	_	_
5	that	that	IN	_	17	mark	_	_
6	the	the	DT	_	7	det	_	_
7	absorption	absorption	NN	_	17	dep	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	as	as	IN	_	11	mark	_	_
11	reflected	reflect	VBN	_	7	acl	_	_
12	in	in	IN	_	14	case	_	_
13	urinary	urinary	JJ	_	14	attr	_	_
14	excretion	excretion	NN	_	11	ppmod	_	_
15	is	be	VBZ	_	17	aux	_	_
16	markedly	markedly	RB	_	17	adv	_	_
17	decreased	decrease	VBN	_	4	comp	_	_
18	even	even	RB	_	19	com	_	_
19	when	when	WRB	_	20	adv	_	_
20	administered	administer	VBN	_	17	comp	_	_
21	one	#crd#	CD	_	22	num	_	_
22	hour	hour	NN	_	24	dat	_	_
23	before	before	IN	_	24	case	_	_
24	drug2	drug0	NN	_	20	ppmod	_	_
25	.	.	.	_	4	p	_	_

1	The	the	DT	_	2	det	_	_
2	absorption	absorption	NN	_	16	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	,	,	,	_	4	p	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	,	,	,	_	6	p	_	_
8	drug3	drug0	NN	_	4	conj	_	_
9	,	,	,	_	8	p	_	_
10	drug4	drug0	NN	_	4	conj	_	_
11	,	,	,	_	10	p	_	_
12	and	and	CC	_	10	cc	_	_
13	drug5	drug0	NN	_	4	conj	_	_
14	was	be	VBD	_	16	aux	_	_
15	significantly	significantly	RB	_	16	adv	_	_
16	decreased	decrease	VBN	_	0	root	_	_
17	when	when	WRB	_	18	adv	_	_
18	given	give	VBN	_	16	comp	_	_
19	simultaneously	simultaneously	RB	_	18	adv	_	_
20	with	with	IN	_	21	case	_	_
21	drug6	drug0	NN	_	18	ppmod	_	_
22	;	;	:	_	16	p	_	_

1	these	these	DT	_	2	det	_	_
2	drugs	drug	NNS	_	5	dep	_	_
3	were	be	VBD	_	5	aux	_	_
4	not	not	RB	_	5	neg	_	_
5	tested	test	VBN	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	determine	determine	VB	_	5	comp	_	_
8	the	the	DT	_	9	det	_	_
9	effect	effect	NN	_	7	obj	_	_
10	of	of	IN	_	11	case	_	_
11	administration	administration	NN	_	9	ppmod	_	_
12	one	#crd#	CD	_	13	num	_	_
13	hour	hour	NN	_	15	dat	_	_
14	before	before	IN	_	15	case	_	_
15	drug1	drug0	NN	_	9	ppmod	_	_
16	.	.	.	_	5	p	_	_

1	No	no	DT	_	3	det	_	_
2	depressant	depressant	JJ	_	3	attr	_	_
3	effect	effect	NN	_	10	dep	_	_
4	on	on	IN	_	6	case	_	_
5	blood	blood	NN	_	6	com	_	_
6	levels	level	NNS	_	3	ppmod	_	_
7	in	in	IN	_	8	case	_	_
8	humans	human	NNS	_	6	ppmod	_	_
9	was	be	VBD	_	10	aux	_	_
10	noted	note	VBN	_	0	root	_	_
11	when	when	WRB	_	14	adv	_	_
12	drug1	drug0	NN	_	14	dep	_	_
13	was	be	VBD	_	14	aux	_	_
14	administered	administer	VBN	_	10	comp	_	_
15	with	with	IN	_	16	case	_	_
16	any	any	DT	_	14	ppmod	_	_
17	of	of	IN	_	20	case	_	_
18	the	the	DT	_	20	det	_	_
19	following	following	JJ	_	20	attr	_	_
20	drugs	drug	NNS	_	16	ppmod	_	_
21	:	:	:	_	20	p	_	_
22	drug2	drug0	NN	_	20	appo	_	_
23	,	,	,	_	22	p	_	_
24	drug3	drug0	NN	_	22	conj	_	_
25	,	,	,	_	24	p	_	_
26	drug4	drug0	NN	_	22	conj	_	_
27	,	,	,	_	26	p	_	_
28	drug5	drug0	NN	_	22	conj	_	_
29	,	,	,	_	28	p	_	_
30	drug6	drug0	NN	_	22	conj	_	_
31	(	-lrb-	-LRB-	_	32	p	_	_
32	drug7	drug0	NN	_	30	prn	_	_
33	)	-rrb-	-RRB-	_	32	p	_	_
34	,	,	,	_	30	p	_	_
35	drug8	drug0	NN	_	22	conj	_	_
36	,	,	,	_	35	p	_	_
37	drug9	drug0	NN	_	22	conj	_	_
38	or	or	CC	_	37	cc	_	_
39	drug10	drug0	NN	_	22	conj	_	_
40	.	.	.	_	10	p	_	_

1	Particular	particular	JJ	_	2	attr	_	_
2	caution	caution	NN	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	observed	observe	VBN	_	0	root	_	_
6	with	with	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	since	since	IN	_	10	mark	_	_
9	there	there	EX	_	10	dep	_	_
10	are	be	VBP	_	5	comp	_	_
11	conflicting	conflict	VBG	_	12	attr	_	_
12	results	result	NNS	_	10	obj	_	_
13	for	for	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	effect	effect	NN	_	10	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	on	on	IN	_	20	case	_	_
19	the	the	DT	_	20	det	_	_
20	availability	availability	NN	_	15	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	drug3	drug0	NN	_	20	ppmod	_	_
23	and	and	CC	_	22	cc	_	_
24	drug4	drug0	NN	_	22	conj	_	_
25	.	.	.	_	5	p	_	_

1	The	the	DT	_	2	det	_	_
2	potential	potential	NN	_	11	dep	_	_
3	for	for	IN	_	4	case	_	_
4	binding	binding	NN	_	2	ppmod	_	_
5	of	of	IN	_	7	case	_	_
6	these	these	DT	_	7	det	_	_
7	drugs	drug	NNS	_	4	ppmod	_	_
8	if	if	IN	_	9	mark	_	_
9	given	give	VBN	_	11	advcl	_	_
10	concomitantly	concomitantly	RB	_	9	adv	_	_
11	is	be	VBZ	_	0	root	_	_
12	present	present	JJ	_	11	dep	_	_
13	.	.	.	_	11	p	_	_

1	Discontinuing	discontinuing	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	could	could	MD	_	4	modal	_	_
4	pose	pose	VB	_	0	root	_	_
5	a	a	DT	_	6	det	_	_
6	hazard	hazard	NN	_	4	obj	_	_
7	to	to	TO	_	8	aux	_	_
8	health	health	NN	_	6	ppmod	_	_
9	if	if	IN	_	23	mark	_	_
10	a	a	DT	_	13	det	_	_
11	potentially	potentially	RB	_	12	adv	_	_
12	toxic	toxic	JJ	_	13	attr	_	_
13	drug	drug	NN	_	23	dep	_	_
14	that	that	WDT	_	17	dep	_	_
15	is	be	VBZ	_	17	aux	_	_
16	significantly	significantly	RB	_	17	adv	_	_
17	bound	bind	VBN	_	13	relcl	_	_
18	to	to	TO	_	20	aux	_	_
19	the	the	DT	_	20	det	_	_
20	drug2	drug0	NN	_	17	ppmod	_	_
21	has	have	VBZ	_	23	aux	_	_
22	been	be	VBN	_	23	aux	_	_
23	titrated	titrate	VBN	_	4	comp	_	_
24	to	to	TO	_	27	aux	_	_
25	a	a	DT	_	27	det	_	_
26	maintenance	maintenance	NN	_	27	com	_	_
27	level	level	NN	_	23	ppmod	_	_
28	while	while	IN	_	32	mark	_	_
29	the	the	DT	_	30	det	_	_
30	patient	patient	NN	_	32	dep	_	_
31	was	be	VBD	_	32	aux	_	_
32	taking	take	VBG	_	23	comp	_	_
33	drug3	drug0	NN	_	32	obj	_	_
34	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	may	may	MD	_	4	modal	_	_
3	also	also	RB	_	4	adv	_	_
4	interfere	interfere	VB	_	0	root	_	_
5	with	with	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	absorption	absorption	NN	_	4	ppmod	_	_
8	of	of	IN	_	11	case	_	_
9	oral	oral	JJ	_	11	attr	_	_
10	drug2	drug0	NN	_	11	com	_	_
11	supplements	supplement	NNS	_	7	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	drug3	drug0	NN	_	11	conj	_	_
14	.	.	.	_	4	p	_	_

1	Studies	study	NNS	_	16	dep	_	_
2	to	to	TO	_	3	aux	_	_
3	evaluate	evaluate	VB	_	1	acl	_	_
4	possible	possible	JJ	_	5	attr	_	_
5	interactions	interaction	NNS	_	3	obj	_	_
6	between	between	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drugs	drug	NNS	_	7	conj	_	_
10	other	other	JJ	_	9	attr	_	_
11	than	than	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	have	have	VBP	_	16	aux	_	_
14	not	not	RB	_	16	neg	_	_
15	been	be	VBN	_	16	aux	_	_
16	performed	performed	VBN	_	0	root	_	_
17	.	.	.	_	16	p	_	_

1	Consequently	consequently	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	caution	caution	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	advised	advise	VBN	_	0	root	_	_
6	if	if	IN	_	16	mark	_	_
7	the	the	DT	_	9	det	_	_
8	concomitant	concomitant	JJ	_	9	attr	_	_
9	administration	administration	NN	_	16	dep	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	other	other	JJ	_	14	attr	_	_
14	drugs	drug	NNS	_	11	conj	_	_
15	is	be	VBZ	_	16	aux	_	_
16	required	require	VBN	_	5	comp	_	_
17	.	.	.	_	5	p	_	_

1	The	the	DT	_	2	det	_	_
2	safety	safety	NN	_	12	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	efficacy	efficacy	NN	_	2	conj	_	_
5	of	of	IN	_	7	case	_	_
6	concomitant	concomitant	JJ	_	7	attr	_	_
7	use	use	NN	_	2	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	drug2	drug0	NN	_	9	conj	_	_
12	is	be	VBZ	_	0	root	_	_
13	unknown	unknown	JJ	_	12	dep	_	_
14	,	,	,	_	12	p	_	_
15	and	and	CC	_	12	cc	_	_
16	the	the	DT	_	18	det	_	_
17	concomitant	concomitant	JJ	_	18	attr	_	_
18	use	use	NN	_	27	dep	_	_
19	of	of	IN	_	23	case	_	_
20	two	#crd#	CD	_	23	num	_	_
21	potentially	potentially	RB	_	22	adv	_	_
22	hepatotoxic	hepatotoxic	JJ	_	23	attr	_	_
23	medications	medication	NNS	_	18	ppmod	_	_
24	is	be	VBZ	_	27	aux	_	_
25	not	not	RB	_	27	neg	_	_
26	ordinarily	ordinarily	RB	_	27	adv	_	_
27	recommended	recommend	VBN	_	12	conj	_	_
28	unless	unless	IN	_	32	mark	_	_
29	the	the	DT	_	31	det	_	_
30	probable	probable	JJ	_	31	attr	_	_
31	benefits	benefit	NNS	_	32	dep	_	_
32	outweigh	outweigh	VBP	_	27	comp	_	_
33	the	the	DT	_	35	det	_	_
34	known	known	JJ	_	35	attr	_	_
35	risks	risk	NNS	_	32	obj	_	_
36	.	.	.	_	12	p	_	_

1	Lethargy	lethargy	NN	_	6	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	somnolence	somnolence	NN	_	1	conj	_	_
4	have	have	VBP	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	reported	report	VBN	_	0	root	_	_
7	following	follow	VBG	_	8	adv	_	_
8	doses	dose	NNS	_	6	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug2	drug0	NN	_	10	conj	_	_
13	.	.	.	_	6	p	_	_

1	Patients	patient	NNS	_	6	dep	_	_
2	taking	take	VBG	_	1	acl	_	_
3	drug1	drug0	NN	_	2	obj	_	_
4	may	may	MD	_	6	modal	_	_
5	not	not	RB	_	6	neg	_	_
6	benefit	benefit	VB	_	0	root	_	_
7	from	from	IN	_	8	case	_	_
8	drug2	drug0	NNS	_	6	ppmod	_	_
9	containing	contain	VBG	_	8	acl	_	_
10	medicines	medicine	NNS	_	9	obj	_	_
11	,	,	,	_	8	p	_	_
12	such	such	JJ	_	14	adv	_	_
13	as	as	IN	_	14	case	_	_
14	cough	cough	NN	_	8	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	cold	cold	JJ	_	17	attr	_	_
17	preparations	preparation	NNS	_	14	conj	_	_
18	,	,	,	_	8	p	_	_
19	antidiarrheal	antidiarrheal	JJ	_	20	attr	_	_
20	preparations	preparation	NNS	_	8	conj	_	_
21	,	,	,	_	20	p	_	_
22	and	and	CC	_	20	cc	_	_
23	drug3	drug0	NN	_	8	conj	_	_
24	.	.	.	_	6	p	_	_

1	In	in	IN	_	4	case	_	_
2	an	an	DT	_	4	det	_	_
3	emergency	emergency	NN	_	4	com	_	_
4	situation	situation	NN	_	23	ppmod	_	_
5	when	when	WRB	_	10	adv	_	_
6	opioid	opioid	NN	_	7	com	_	_
7	analgesia	analgesia	NN	_	10	dep	_	_
8	must	must	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	administered	administer	VBN	_	4	relcl	_	_
11	to	to	TO	_	13	aux	_	_
12	a	a	DT	_	13	det	_	_
13	patient	patient	NN	_	10	ppmod	_	_
14	receiving	receive	VBG	_	13	acl	_	_
15	drug1	drug0	NN	_	14	obj	_	_
16	,	,	,	_	23	p	_	_
17	the	the	DT	_	18	det	_	_
18	amount	amount	NN	_	23	dep	_	_
19	of	of	IN	_	20	case	_	_
20	drug2	drug0	NN	_	18	ppmod	_	_
21	required	require	VBN	_	18	acl	_	_
22	may	may	MD	_	23	modal	_	_
23	be	be	VB	_	0	root	_	_
24	greater	great	JJR	_	23	dep	_	_
25	than	than	IN	_	26	case	_	_
26	usual	usual	JJ	_	24	ppmod	_	_
27	,	,	,	_	23	p	_	_
28	and	and	CC	_	23	cc	_	_
29	the	the	DT	_	32	det	_	_
30	resulting	result	VBG	_	32	attr	_	_
31	respiratory	respiratory	JJ	_	32	attr	_	_
32	depression	depression	NN	_	34	dep	_	_
33	may	may	MD	_	34	modal	_	_
34	be	be	VB	_	23	conj	_	_
35	deeper	deep	JJR	_	34	dep	_	_
36	and	and	CC	_	35	cc	_	_
37	more	more	RBR	_	38	adv	_	_
38	prolonged	prolonged	JJ	_	35	conj	_	_
39	.	.	.	_	23	p	_	_

1	Administration	administration	NN	_	7	dep	_	_
2	of	of	IN	_	4	case	_	_
3	repeat	repeat	NN	_	4	com	_	_
4	doses	dose	NNS	_	1	ppmod	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	had	have	VBD	_	0	root	_	_
8	no	no	DT	_	9	det	_	_
9	effect	effect	NN	_	7	obj	_	_
10	on	on	IN	_	14	case	_	_
11	the	the	DT	_	14	det	_	_
12	repeat	repeat	NN	_	14	com	_	_
13	dose	dose	NN	_	14	com	_	_
14	pharmacokinetics	pharmacokinetics	NNS	_	7	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	,	,	,	_	16	p	_	_
18	drug3	drug0	NN	_	16	conj	_	_
19	or	or	CC	_	18	cc	_	_
20	an	an	DT	_	24	det	_	_
21	drug4	drug0	NN	_	24	attr	_	_
22	/levonorgestrol	/levonorgestrol	NN	_	24	attr	_	_
23	oral	oral	JJ	_	24	attr	_	_
24	drug5	drug0	NN	_	16	conj	_	_
25	in	in	IN	_	27	case	_	_
26	healthy	healthy	JJ	_	27	attr	_	_
27	subjects	subject	NNS	_	24	ppmod	_	_
28	.	.	.	_	7	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	administration	administration	NN	_	19	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	,	,	,	_	6	p	_	_
8	drug3	drug0	NN	_	4	conj	_	_
9	,	,	,	_	8	p	_	_
10	drug4	drug0	NN	_	4	conj	_	_
11	,	,	,	_	10	p	_	_
12	or	or	CC	_	10	cc	_	_
13	an	an	DT	_	18	det	_	_
14	drug5	drug0	NN	_	18	attr	_	_
15	/	/	:	_	18	p	_	_
16	drug6	drug0	NN	_	18	attr	_	_
17	oral	oral	JJ	_	18	attr	_	_
18	drug7	drug0	NN	_	4	conj	_	_
19	produced	produce	VBD	_	0	root	_	_
20	minor	minor	JJ	_	21	attr	_	_
21	changes	change	NNS	_	19	obj	_	_
22	in	in	IN	_	24	case	_	_
23	the	the	DT	_	24	det	_	_
24	pharmacokinetics	pharmacokinetics	NNS	_	21	ppmod	_	_
25	of	of	IN	_	26	case	_	_
26	drug8	drug0	NN	_	24	ppmod	_	_
27	,	,	,	_	21	p	_	_
28	which	which	WDT	_	30	dep	_	_
29	were	be	VBD	_	30	aux	_	_
30	considered	consider	VBN	_	21	relcl	_	_
31	to	to	TO	_	32	aux	_	_
32	be	be	VB	_	30	comp	_	_
33	without	without	IN	_	35	case	_	_
34	clinical	clinical	JJ	_	35	attr	_	_
35	significance	significance	NN	_	32	ppmod	_	_
36	.	.	.	_	19	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	administration	administration	NN	_	7	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	with	with	IN	_	6	case	_	_
6	drug2	drug0	NN	_	2	ppmod	_	_
7	resulted	result	VBD	_	0	root	_	_
8	in	in	IN	_	12	case	_	_
9	a	a	DT	_	12	det	_	_
10	45	0	CD	_	12	num	_	_
11	%	%	NN	_	10	meta	_	_
12	increase	increase	NN	_	7	ppmod	_	_
13	in	in	IN	_	15	case	_	_
14	systemic	systemic	JJ	_	15	attr	_	_
15	exposure	exposure	NN	_	12	ppmod	_	_
16	to	to	TO	_	17	aux	_	_
17	drug3	drug0	NN	_	15	ppmod	_	_
18	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	had	have	VBD	_	0	root	_	_
3	no	no	DT	_	5	det	_	_
4	significant	significant	JJ	_	5	attr	_	_
5	effect	effect	NN	_	2	obj	_	_
6	on	on	IN	_	9	case	_	_
7	the	the	DT	_	9	det	_	_
8	anticoagulant	anticoagulant	JJ	_	9	attr	_	_
9	effect	effect	NN	_	2	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	in	in	IN	_	14	case	_	_
13	healthy	healthy	JJ	_	14	attr	_	_
14	subjects	subject	NNS	_	11	ppmod	_	_
15	on	on	IN	_	18	case	_	_
16	stable	stable	JJ	_	18	attr	_	_
17	drug3	drug0	NN	_	18	com	_	_
18	therapy	therapy	NN	_	9	ppmod	_	_
19	.	.	.	_	2	p	_	_

1	However	however	RB	_	33	adv	_	_
2	,	,	,	_	33	p	_	_
3	because	because	IN	_	8	mark	_	_
4	some	some	DT	_	5	det	_	_
5	drug1	drug0	NNS	_	8	dep	_	_
6	have	have	VBP	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	reported	report	VBN	_	33	advcl	_	_
9	to	to	TO	_	10	aux	_	_
10	enhance	enhance	VB	_	8	comp	_	_
11	the	the	DT	_	13	det	_	_
12	anticoagulant	anticoagulant	JJ	_	13	attr	_	_
13	effects	effect	NNS	_	10	obj	_	_
14	of	of	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	or	or	CC	_	15	cc	_	_
17	its	its	PRP$	_	18	poss	_	_
18	derivatives	derivative	NNS	_	15	conj	_	_
19	in	in	IN	_	20	case	_	_
20	patients	patient	NNS	_	13	ppmod	_	_
21	,	,	,	_	33	p	_	_
22	the	the	DT	_	24	det	_	_
23	prothrombin	prothrombin	NN	_	24	com	_	_
24	time	time	NN	_	33	dep	_	_
25	or	or	CC	_	24	cc	_	_
26	other	other	JJ	_	29	attr	_	_
27	suitable	suitable	JJ	_	29	attr	_	_
28	coagulation	coagulation	NN	_	29	com	_	_
29	test	test	NN	_	24	conj	_	_
30	should	should	MD	_	33	modal	_	_
31	be	be	VB	_	33	aux	_	_
32	closely	closely	RB	_	33	adv	_	_
33	monitored	monitor	VBN	_	0	root	_	_
34	if	if	IN	_	38	mark	_	_
35	a	a	DT	_	36	det	_	_
36	drug3	drug0	NN	_	38	dep	_	_
37	is	be	VBZ	_	38	aux	_	_
38	administered	administer	VBN	_	33	comp	_	_
39	concomitantly	concomitantly	RB	_	38	adv	_	_
40	with	with	IN	_	41	case	_	_
41	drug4	drug0	NN	_	38	ppmod	_	_
42	or	or	CC	_	41	cc	_	_
43	its	its	PRP$	_	44	poss	_	_
44	derivatives	derivative	NNS	_	41	conj	_	_
45	.	.	.	_	33	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	form	form	VBP	_	0	root	_	_
3	chelates	chelate	NNS	_	2	obj	_	_
4	with	with	IN	_	6	case	_	_
5	alkaline	alkaline	NN	_	6	com	_	_
6	earth	earth	NN	_	2	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	transition	transition	NN	_	9	com	_	_
9	metals	metal	NNS	_	6	conj	_	_
10	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	absorption	absorption	NN	_	8	dep	_	_
3	of	of	IN	_	5	case	_	_
4	oral	oral	JJ	_	5	attr	_	_
5	drug1	drug0	NN	_	2	ppmod	_	_
6	is	be	VBZ	_	8	aux	_	_
7	significantly	significantly	RB	_	8	adv	_	_
8	reduced	reduce	VBN	_	0	root	_	_
9	by	by	IN	_	12	case	_	_
10	the	the	DT	_	12	det	_	_
11	concomitant	concomitant	JJ	_	12	attr	_	_
12	administration	administration	NN	_	8	ppmod	_	_
13	of	of	IN	_	15	case	_	_
14	an	an	DT	_	15	det	_	_
15	drug2	drug0	NN	_	12	ppmod	_	_
16	containing	contain	VBG	_	15	acl	_	_
17	drug3	drug0	NN	_	16	obj	_	_
18	and	and	CC	_	17	cc	_	_
19	drug4	drug0	NN	_	17	conj	_	_
20	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	-	-	:	_	1	p	_	_
3	and/or	and/or	CC	_	6	cc	_	_
4	drug2	drug0	NN	_	6	attr	_	_
5	-containing	-containing	JJ	_	6	attr	_	_
6	drug3	drug0	NN	_	40	dep	_	_
7	,	,	,	_	6	p	_	_
8	products	product	NNS	_	6	appo	_	_
9	containing	contain	VBG	_	8	acl	_	_
10	drug4	drug0	NN	_	9	obj	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	drug5	drug0	NN	_	10	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	,	,	,	_	10	p	_	_
15	drug6	drug0	NN	_	10	conj	_	_
16	containing	contain	VBG	_	15	acl	_	_
17	drug7	drug0	NN	_	16	obj	_	_
18	or	or	CC	_	17	cc	_	_
19	other	other	JJ	_	21	attr	_	_
20	metal	metal	JJ	_	21	attr	_	_
21	cations	cation	NNS	_	17	conj	_	_
22	,	,	,	_	15	p	_	_
23	or	or	CC	_	15	cc	_	_
24	drug8	drug0	NN	_	28	advnp	_	_
25	(	-lrb-	-LRB-	_	28	p	_	_
26	drug9	drug0	NN	_	28	advnp	_	_
27	)	-rrb-	-RRB-	_	28	p	_	_
28	chewable/buffered	chewable/buffered	JJ	_	29	attr	_	_
29	tablets	tablet	NNS	_	10	conj	_	_
30	or	or	CC	_	6	cc	_	_
31	the	the	DT	_	33	det	_	_
32	pediatric	pediatric	JJ	_	33	attr	_	_
33	powder	powder	NN	_	6	conj	_	_
34	for	for	IN	_	36	case	_	_
35	oral	oral	JJ	_	36	attr	_	_
36	solution	solution	NN	_	33	ppmod	_	_
37	should	should	MD	_	40	modal	_	_
38	not	not	RB	_	40	neg	_	_
39	be	be	VB	_	40	aux	_	_
40	taken	take	VBN	_	1	acl	_	_
41	within	within	IN	_	43	case	_	_
42	3	0	CD	_	43	num	_	_
43	hours	hour	NNS	_	40	ppmod	_	_
44	before	before	IN	_	43	case	_	_
45	or	or	CC	_	43	cc	_	_
46	2	0	CD	_	47	num	_	_
47	hours	hour	NNS	_	43	conj	_	_
48	after	after	IN	_	49	case	_	_
49	drug10	drug0	NN	_	47	ppmod	_	_
50	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	should	should	MD	_	5	modal	_	_
3	not	not	RB	_	5	neg	_	_
4	be	be	VB	_	5	aux	_	_
5	taken	take	VBN	_	0	root	_	_
6	within	within	IN	_	8	case	_	_
7	2	0	CD	_	8	num	_	_
8	hours	hour	NNS	_	5	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	5	p	_	_

1	Although	although	IN	_	7	mark	_	_
2	the	the	DT	_	4	det	_	_
3	pressor	pressor	JJ	_	4	attr	_	_
4	activity	activity	NN	_	7	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	is	be	VBZ	_	23	advcl	_	_
8	very	very	RB	_	9	adv	_	_
9	low	low	JJ	_	7	dep	_	_
10	compared	compare	VBN	_	14	adv	_	_
11	to	to	TO	_	14	aux	_	_
12	its	its	PRP$	_	14	poss	_	_
13	antidiuretic	antidiuretic	JJ	_	14	attr	_	_
14	activity	activity	NN	_	9	ppmod	_	_
15	,	,	,	_	23	p	_	_
16	large	large	JJ	_	17	attr	_	_
17	doses	dose	NNS	_	23	dep	_	_
18	of	of	IN	_	20	case	_	_
19	drug2	drug0	NN	_	20	com	_	_
20	Tablets	tablet	NNS	_	17	ppmod	_	_
21	should	should	MD	_	23	modal	_	_
22	be	be	VB	_	23	aux	_	_
23	used	use	VBN	_	0	root	_	_
24	with	with	IN	_	27	case	_	_
25	other	other	JJ	_	27	attr	_	_
26	pressor	pressor	JJ	_	27	attr	_	_
27	agents	agent	NNS	_	23	ppmod	_	_
28	only	only	RB	_	32	adv	_	_
29	with	with	IN	_	32	case	_	_
30	careful	careful	JJ	_	32	attr	_	_
31	patient	patient	NN	_	32	com	_	_
32	monitoring	monitoring	NN	_	27	ppmod	_	_
33	.	.	.	_	23	p	_	_

1	None	none	NN	_	2	dep	_	_
2	known	know	VBN	_	0	root	_	_
3	.	.	.	_	2	p	_	_

1	Studies	study	NNS	_	4	dep	_	_
2	in	in	FW	_	3	adv	_	_
3	vitro	vitro	FW	_	1	adv	_	_
4	show	show	VBP	_	0	root	_	_
5	that	that	IN	_	7	mark	_	_
6	drug1	drug0	NN	_	7	dep	_	_
7	is	be	VBZ	_	4	comp	_	_
8	not	not	RB	_	7	neg	_	_
9	an	an	DT	_	10	det	_	_
10	inhibitor	inhibitor	NN	_	7	obj	_	_
11	of	of	IN	_	13	case	_	_
12	any	any	DT	_	13	det	_	_
13	enzyme	enzyme	NN	_	10	ppmod	_	_
14	in	in	IN	_	21	case	_	_
15	the	the	DT	_	21	det	_	_
16	cytochrome	cytochrome	NN	_	17	com	_	_
17	P450	p0	NN	_	21	attr	_	_
18	(	-lrb-	-LRB-	_	19	p	_	_
19	CYP	cyp	NN	_	17	prn	_	_
20	)	-rrb-	-RRB-	_	19	p	_	_
21	system	system	NN	_	10	ppmod	_	_
22	.	.	.	_	4	p	_	_

1	In	in	IN	_	3	case	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	studies	study	NNS	_	8	ppmod	_	_
4	,	,	,	_	8	p	_	_
5	drug1	drug0	NN	_	8	dep	_	_
6	did	do	VBD	_	8	aux	_	_
7	not	not	RB	_	8	neg	_	_
8	induce	induce	VB	_	0	root	_	_
9	the	the	DT	_	11	det	_	_
10	CYP3A4	cyp0a0	NN	_	11	com	_	_
11	metabolism	metabolism	NN	_	8	obj	_	_
12	of	of	IN	_	14	case	_	_
13	other	other	JJ	_	14	attr	_	_
14	drugs	drug	NNS	_	11	ppmod	_	_
15	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	not	not	RB	_	2	neg	_	_
4	a	a	DT	_	5	det	_	_
5	substrate	substrate	NN	_	2	obj	_	_
6	for	for	IN	_	7	case	_	_
7	P-glycoprotein	p-glycoprotein	NN	_	5	ppmod	_	_
8	and	and	CC	_	2	cc	_	_
9	is	be	VBZ	_	2	conj	_	_
10	a	a	DT	_	12	det	_	_
11	poor	poor	JJ	_	12	attr	_	_
12	substrate	substrate	NN	_	9	obj	_	_
13	for	for	IN	_	16	case	_	_
14	cytochrome	cytochrome	NN	_	16	com	_	_
15	P450	p0	NN	_	16	com	_	_
16	enzymes	enzyme	NNS	_	12	ppmod	_	_
17	.	.	.	_	2	p	_	_

1	Clinical	clinical	JJ	_	2	attr	_	_
2	studies	study	NNS	_	6	dep	_	_
3	in	in	IN	_	5	case	_	_
4	healthy	healthy	JJ	_	5	attr	_	_
5	volunteers	volunteer	NNS	_	2	ppmod	_	_
6	show	show	VBP	_	0	root	_	_
7	that	that	IN	_	14	mark	_	_
8	the	the	DT	_	9	det	_	_
9	pharmacokinetics	pharmacokinetics	NNS	_	14	dep	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	are	be	VBP	_	14	aux	_	_
13	not	not	RB	_	14	neg	_	_
14	altered	alter	VBN	_	6	comp	_	_
15	by	by	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	,	,	,	_	16	p	_	_
18	drug3	drug0	NN	_	16	conj	_	_
19	,	,	,	_	18	p	_	_
20	drug4	drug0	NN	_	16	conj	_	_
21	,	,	,	_	20	p	_	_
22	drug5	drug0	NN	_	16	conj	_	_
23	,	,	,	_	22	p	_	_
24	or	or	CC	_	22	cc	_	_
25	drug6	drug0	NN	_	16	conj	_	_
26	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	has	have	VBZ	_	0	root	_	_
3	no	no	DT	_	4	det	_	_
4	effect	effect	NN	_	2	obj	_	_
5	on	on	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	pharmacokinetics	pharmacokinetics	NNS	_	2	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	9	p	_	_
11	drug3	drug0	NN	_	9	conj	_	_
12	,	,	,	_	11	p	_	_
13	or	or	CC	_	11	cc	_	_
14	the	the	DT	_	16	det	_	_
15	active	active	JJ	_	16	attr	_	_
16	metabolite	metabolite	NN	_	9	conj	_	_
17	of	of	IN	_	18	case	_	_
18	mycophenolate	mycophenolate	NN	_	16	ppmod	_	_
19	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	reduced	reduce	VBD	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	blood	blood	NN	_	2	obj	_	_
5	AUC0-12	auc0	CD	_	4	num	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	4	ppmod	_	_
8	by	by	IN	_	10	case	_	_
9	approximately	approximately	RB	_	10	adv	_	_
10	20	0	CD	_	7	ppmod	_	_
11	%	%	NN	_	10	meta	_	_
12	,	,	,	_	7	p	_	_
13	peak	peak	JJ	_	15	attr	_	_
14	blood	blood	NN	_	15	com	_	_
15	concentration	concentration	NN	_	7	conj	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	Cmax	cmax	NN	_	15	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	by	by	IN	_	20	case	_	_
20	16	0	CD	_	15	ppmod	_	_
21	%	%	NN	_	20	meta	_	_
22	,	,	,	_	15	p	_	_
23	and	and	CC	_	15	cc	_	_
24	12-hour	0-hour	JJ	_	26	attr	_	_
25	blood	blood	NN	_	26	com	_	_
26	concentration	concentration	NN	_	7	conj	_	_
27	(	-lrb-	-LRB-	_	28	p	_	_
28	C12hr	c0hr	NN	_	26	prn	_	_
29	)	-rrb-	-RRB-	_	28	p	_	_
30	by	by	IN	_	31	case	_	_
31	26	0	CD	_	2	ppmod	_	_
32	%	%	NN	_	31	meta	_	_
33	in	in	IN	_	35	case	_	_
34	healthy	healthy	JJ	_	35	attr	_	_
35	subjects	subject	NNS	_	31	ppmod	_	_
36	when	when	WRB	_	49	adv	_	_
37	drug3	drug0	NN	_	49	dep	_	_
38	(	-lrb-	-LRB-	_	40	p	_	_
39	2	0	CD	_	40	num	_	_
40	doses	dose	NNS	_	37	prn	_	_
41	of	of	IN	_	45	case	_	_
42	0.1	0	CD	_	44	num	_	_
43	mg/kg	mg/kg	NN	_	44	attr	_	_
44	12	0	CD	_	45	num	_	_
45	hours	hour	NNS	_	40	ppmod	_	_
46	apart	apart	RB	_	40	adv	_	_
47	)	-rrb-	-RRB-	_	40	p	_	_
48	was	be	VBD	_	49	aux	_	_
49	administered	administer	VBN	_	2	comp	_	_
50	on	on	IN	_	53	case	_	_
51	the	the	DT	_	53	det	_	_
52	10th	#ord#	JJ	_	53	attr	_	_
53	day	day	NN	_	49	ppmod	_	_
54	of	of	IN	_	57	case	_	_
55	drug4	drug0	NN	_	57	attr	_	_
56	70	0	CD	_	57	num	_	_
57	mg	mg	NN	_	53	ppmod	_	_
58	daily	daily	RB	_	57	adv	_	_
59	,	,	,	_	49	p	_	_
60	as	as	IN	_	61	mark	_	_
61	compared	compare	VBN	_	49	comp	_	_
62	to	to	TO	_	63	aux	_	_
63	results	result	NNS	_	61	ppmod	_	_
64	from	from	IN	_	67	case	_	_
65	a	a	DT	_	67	det	_	_
66	control	control	NN	_	67	com	_	_
67	period	period	NN	_	63	ppmod	_	_
68	in	in	IN	_	69	case	_	_
69	which	which	WDT	_	72	ppmod	_	_
70	drug5	drug0	NN	_	72	dep	_	_
71	was	be	VBD	_	72	aux	_	_
72	administered	administer	VBN	_	67	relcl	_	_
73	alone	alone	RB	_	72	adv	_	_
74	.	.	.	_	2	p	_	_

1	For	for	IN	_	2	case	_	_
2	patients	patient	NNS	_	19	ppmod	_	_
3	receiving	receive	VBG	_	2	acl	_	_
4	both	both	DT	_	5	det	_	_
5	therapies	therapy	NNS	_	3	obj	_	_
6	,	,	,	_	19	p	_	_
7	standard	standard	JJ	_	8	attr	_	_
8	monitoring	monitoring	NN	_	19	dep	_	_
9	of	of	IN	_	12	case	_	_
10	drug1	drug0	NN	_	12	com	_	_
11	blood	blood	NN	_	12	com	_	_
12	concentrations	concentration	NNS	_	8	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	appropriate	appropriate	JJ	_	17	attr	_	_
15	drug2	drug0	NN	_	17	com	_	_
16	dosage	dosage	NN	_	17	com	_	_
17	adjustments	adjustment	NNS	_	12	conj	_	_
18	are	be	VBP	_	19	aux	_	_
19	recommended	recommend	VBN	_	0	root	_	_
20	.	.	.	_	19	p	_	_

1	In	in	IN	_	4	case	_	_
2	two	#crd#	CD	_	4	num	_	_
3	clinical	clinical	JJ	_	4	attr	_	_
4	studies	study	NNS	_	18	ppmod	_	_
5	,	,	,	_	18	p	_	_
6	drug1	drug0	NN	_	18	dep	_	_
7	(	-lrb-	-LRB-	_	11	p	_	_
8	one	#crd#	CD	_	11	num	_	_
9	4	0	CD	_	10	num	_	_
10	mg/kg	mg/kg	NN	_	11	com	_	_
11	dose	dose	NN	_	6	prn	_	_
12	or	or	CC	_	11	cc	_	_
13	two	#crd#	CD	_	16	num	_	_
14	3	0	CD	_	16	num	_	_
15	mg/kg	mg/kg	NN	_	16	com	_	_
16	doses	dose	NNS	_	11	conj	_	_
17	)	-rrb-	-RRB-	_	11	p	_	_
18	increased	increase	VBD	_	0	root	_	_
19	the	the	DT	_	20	det	_	_
20	AUC	auc	NN	_	18	obj	_	_
21	of	of	IN	_	22	case	_	_
22	drug2	drug0	NN	_	20	ppmod	_	_
23	by	by	IN	_	25	case	_	_
24	approximately	approximately	RB	_	25	adv	_	_
25	35	0	CD	_	18	ppmod	_	_
26	%	%	NN	_	25	meta	_	_
27	.	.	.	_	18	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	did	do	VBD	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	increase	increase	VB	_	0	root	_	_
5	the	the	DT	_	7	det	_	_
6	plasma	plasma	NN	_	7	com	_	_
7	levels	level	NNS	_	4	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	.	.	.	_	4	p	_	_

1	There	there	EX	_	2	dep	_	_
2	were	be	VBD	_	0	root	_	_
3	transient	transient	JJ	_	4	attr	_	_
4	increases	increase	NNS	_	2	obj	_	_
5	in	in	IN	_	7	case	_	_
6	liver	liver	NN	_	7	com	_	_
7	ALT	alt	NN	_	4	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	AST	ast	NN	_	7	conj	_	_
10	when	when	WRB	_	15	adv	_	_
11	drug1	drug0	NN	_	15	dep	_	_
12	and	and	CC	_	11	cc	_	_
13	drug2	drug0	NN	_	11	conj	_	_
14	were	be	VBD	_	15	aux	_	_
15	co-administered	co-administered	VBN	_	2	comp	_	_
16	.	.	.	_	2	p	_	_

1	A	a	DT	_	4	det	_	_
2	drug-drug	drug-drug	JJ	_	4	attr	_	_
3	interaction	interaction	NN	_	4	com	_	_
4	study	study	NN	_	11	dep	_	_
5	with	with	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	in	in	IN	_	9	case	_	_
8	healthy	healthy	JJ	_	9	attr	_	_
9	volunteers	volunteer	NNS	_	4	ppmod	_	_
10	has	have	VBZ	_	11	aux	_	_
11	shown	show	VBN	_	0	root	_	_
12	a	a	DT	_	15	det	_	_
13	30	0	CD	_	15	num	_	_
14	%	%	NN	_	13	meta	_	_
15	decrease	decrease	NN	_	11	obj	_	_
16	in	in	IN	_	19	case	_	_
17	drug2	drug0	NN	_	19	com	_	_
18	trough	trough	NN	_	19	com	_	_
19	concentrations	concentration	NNS	_	15	ppmod	_	_
20	.	.	.	_	11	p	_	_

1	Patients	patient	NNS	_	5	dep	_	_
2	on	on	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	should	should	MD	_	5	modal	_	_
5	receive	receive	VBP	_	0	root	_	_
6	70	0	CD	_	7	num	_	_
7	mg	mg	NN	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	daily	daily	RB	_	5	adv	_	_
11	.	.	.	_	5	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	12	ppmod	_	_
3	,	,	,	_	12	p	_	_
4	results	result	NNS	_	12	dep	_	_
5	from	from	IN	_	7	case	_	_
6	regression	regression	NN	_	7	com	_	_
7	analyses	analysis	NNS	_	4	ppmod	_	_
8	of	of	IN	_	11	case	_	_
9	patient	patient	NN	_	11	attr	_	_
10	pharmacokinetic	pharmacokinetic	JJ	_	11	attr	_	_
11	data	datum	NNS	_	7	ppmod	_	_
12	suggest	suggest	VBP	_	0	root	_	_
13	that	that	IN	_	36	mark	_	_
14	co-administration	co-administration	NN	_	36	dep	_	_
15	of	of	IN	_	17	case	_	_
16	other	other	JJ	_	17	attr	_	_
17	inducers	inducer	NNS	_	14	ppmod	_	_
18	of	of	IN	_	20	case	_	_
19	drug	drug	NN	_	20	com	_	_
20	clearance	clearance	NN	_	17	ppmod	_	_
21	(	-lrb-	-LRB-	_	22	p	_	_
22	drug1	drug0	NN	_	20	prn	_	_
23	,	,	,	_	22	p	_	_
24	drug2	drug0	NN	_	22	conj	_	_
25	,	,	,	_	24	p	_	_
26	drug3	drug0	NN	_	22	conj	_	_
27	,	,	,	_	26	p	_	_
28	drug4	drug0	NN	_	22	conj	_	_
29	,	,	,	_	28	p	_	_
30	or	or	CC	_	28	cc	_	_
31	drug5	drug0	NN	_	22	conj	_	_
32	)	-rrb-	-RRB-	_	22	p	_	_
33	with	with	IN	_	34	case	_	_
34	drug6	drug0	NN	_	14	ppmod	_	_
35	may	may	MD	_	36	modal	_	_
36	result	result	VB	_	12	comp	_	_
37	in	in	IN	_	40	case	_	_
38	clinically	clinically	RB	_	39	adv	_	_
39	meaningful	meaningful	JJ	_	40	attr	_	_
40	reductions	reduction	NNS	_	36	ppmod	_	_
41	in	in	IN	_	43	case	_	_
42	drug7	drug0	NN	_	43	com	_	_
43	concentrations	concentration	NNS	_	40	ppmod	_	_
44	.	.	.	_	12	p	_	_

1	It	it	PRP	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	known	know	VBN	_	0	root	_	_
5	which	which	WDT	_	14	dep	_	_
6	drug	drug	NN	_	8	com	_	_
7	clearance	clearance	NN	_	8	com	_	_
8	mechanism	mechanism	NN	_	14	dep	_	_
9	involved	involve	VBN	_	8	acl	_	_
10	in	in	IN	_	12	case	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	disposition	disposition	NN	_	9	ppmod	_	_
13	may	may	MD	_	14	modal	_	_
14	be	be	VB	_	4	comp	_	_
15	inducible	inducible	JJ	_	14	dep	_	_
16	.	.	.	_	4	p	_	_

1	When	when	WRB	_	4	adv	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	co-administered	co-administered	VBN	_	36	advcl	_	_
5	with	with	IN	_	6	case	_	_
6	inducers	inducer	NNS	_	4	ppmod	_	_
7	of	of	IN	_	9	case	_	_
8	drug	drug	NN	_	9	com	_	_
9	clearance	clearance	NN	_	6	ppmod	_	_
10	,	,	,	_	6	p	_	_
11	such	such	JJ	_	13	adv	_	_
12	as	as	IN	_	13	case	_	_
13	drug2	drug0	NN	_	6	ppmod	_	_
14	,	,	,	_	13	p	_	_
15	drug3	drug0	NN	_	13	conj	_	_
16	,	,	,	_	15	p	_	_
17	drug4	drug0	NN	_	13	conj	_	_
18	,	,	,	_	17	p	_	_
19	drug5	drug0	NN	_	13	conj	_	_
20	,	,	,	_	19	p	_	_
21	or	or	CC	_	19	cc	_	_
22	drug6	drug0	NN	_	13	conj	_	_
23	,	,	,	_	36	p	_	_
24	use	use	NN	_	36	dep	_	_
25	of	of	IN	_	28	case	_	_
26	a	a	DT	_	28	det	_	_
27	daily	daily	JJ	_	28	attr	_	_
28	dose	dose	NN	_	24	ppmod	_	_
29	of	of	IN	_	31	case	_	_
30	70	0	CD	_	31	num	_	_
31	mg	mg	NN	_	28	ppmod	_	_
32	of	of	IN	_	33	case	_	_
33	drug7	drug0	NN	_	31	ppmod	_	_
34	should	should	MD	_	36	modal	_	_
35	be	be	VB	_	36	aux	_	_
36	considered	consider	VBN	_	0	root	_	_

1	.	.	.	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	As	as	IN	_	6	case	_	_
4	with	with	IN	_	6	case	_	_
5	other	other	JJ	_	6	attr	_	_
6	drug2	drug0	NN	_	13	ppmod	_	_
7	,	,	,	_	13	p	_	_
8	renal	renal	JJ	_	9	attr	_	_
9	excretion	excretion	NN	_	13	dep	_	_
10	of	of	IN	_	11	case	_	_
11	drug3	drug0	NN	_	9	ppmod	_	_
12	is	be	VBZ	_	13	aux	_	_
13	inhibited	inhibit	VBN	_	1	acl	_	_
14	by	by	IN	_	15	case	_	_
15	drug4	drug0	NN	_	13	ppmod	_	_
16	and	and	CC	_	13	cc	_	_
17	resulted	result	VBD	_	13	conj	_	_
18	in	in	IN	_	23	case	_	_
19	an	an	DT	_	23	det	_	_
20	approximate	approximate	JJ	_	23	attr	_	_
21	80	0	CD	_	23	num	_	_
22	%	%	NN	_	21	meta	_	_
23	increase	increase	NN	_	17	ppmod	_	_
24	in	in	IN	_	26	case	_	_
25	the	the	DT	_	26	det	_	_
26	AUC	auc	NN	_	23	ppmod	_	_
27	for	for	IN	_	28	case	_	_
28	drug5	drug0	NN	_	26	ppmod	_	_
29	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	requirements	requirement	NNS	_	10	dep	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	i.e.	i.e.	FW	_	6	ppmod	_	_
5	,	,	,	_	6	p	_	_
6	drug2	drug0	NNS	_	2	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	may	may	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	altered	alter	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	Concurrent	concurrent	JJ	_	2	attr	_	_
2	use	use	NN	_	7	dep	_	_
3	with	with	IN	_	5	case	_	_
4	general	general	JJ	_	5	attr	_	_
5	drug1	drug0	NN	_	2	ppmod	_	_
6	may	may	MD	_	7	modal	_	_
7	result	result	VB	_	0	root	_	_
8	in	in	IN	_	9	case	_	_
9	arrhythmias	arrhythmias	NN	_	7	ppmod	_	_
10	.	.	.	_	7	p	_	_

1	The	the	DT	_	3	det	_	_
2	pressor	pressor	JJ	_	3	attr	_	_
3	effects	effect	NNS	_	12	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	3	cc	_	_
7	those	those	DT	_	3	conj	_	_
8	of	of	IN	_	10	case	_	_
9	other	other	JJ	_	10	attr	_	_
10	drugs	drug	NNS	_	7	ppmod	_	_
11	may	may	MD	_	12	modal	_	_
12	be	be	VB	_	0	root	_	_
13	additive	additive	JJ	_	12	dep	_	_
14	when	when	WRB	_	18	adv	_	_
15	the	the	DT	_	16	det	_	_
16	drugs	drug	NNS	_	18	dep	_	_
17	are	be	VBP	_	18	aux	_	_
18	used	use	VBN	_	12	comp	_	_
19	concomitantly	concomitantly	RB	_	18	adv	_	_
20	;	;	:	_	12	p	_	_

1	conversely	conversely	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	drug1	drug0	NN	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	interfere	interfere	VB	_	0	root	_	_
6	with	with	IN	_	7	case	_	_
7	drug2	drug0	NNS	_	5	ppmod	_	_
8	(	-lrb-	-LRB-	_	13	p	_	_
9	i.e.	i.e.	FW	_	11	adv	_	_
10	,	,	,	_	11	p	_	_
11	drug3	drug0	NN	_	13	ppmod	_	_
12	,	,	,	_	13	p	_	_
13	drug4	drug0	NNS	_	7	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	.	.	.	_	5	p	_	_

1	Concurrent	concurrent	JJ	_	2	attr	_	_
2	use	use	NN	_	6	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	may	may	MD	_	6	modal	_	_
6	antagonize	antagonize	VB	_	0	root	_	_
7	the	the	DT	_	9	det	_	_
8	anorectic	anorectic	JJ	_	9	attr	_	_
9	effect	effect	NN	_	6	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Clinical	clinical	JJ	_	4	attr	_	_
4	evidence	evidence	NN	_	6	dep	_	_
5	has	have	VBZ	_	6	aux	_	_
6	shown	show	VBN	_	1	acl	_	_
7	that	that	IN	_	11	mark	_	_
8	drug2	drug0	NN	_	11	dep	_	_
9	can	can	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	formed	form	VBN	_	6	comp	_	_
12	with	with	IN	_	14	case	_	_
13	concurrent	concurrent	JJ	_	14	attr	_	_
14	ingestion	ingestion	NN	_	11	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug3	drug0	NN	_	14	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	drug4	drug0	NN	_	16	conj	_	_
19	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	5	case	_	_
4	a	a	DT	_	5	det	_	_
5	study	study	NN	_	14	ppmod	_	_
6	of	of	IN	_	10	case	_	_
7	7	0	CD	_	10	num	_	_
8	healthy	healthy	JJ	_	10	attr	_	_
9	male	male	JJ	_	10	attr	_	_
10	volunteers	volunteer	NNS	_	5	ppmod	_	_
11	,	,	,	_	14	p	_	_
12	drug2	drug0	NN	_	13	com	_	_
13	treatment	treatment	NN	_	14	dep	_	_
14	potentiated	potentiate	VBD	_	1	acl	_	_
15	the	the	DT	_	19	det	_	_
16	blood	blood	NN	_	19	attr	_	_
17	glucose	glucose	NN	_	19	attr	_	_
18	lowering	lowering	JJ	_	19	attr	_	_
19	effect	effect	NN	_	14	obj	_	_
20	of	of	IN	_	21	case	_	_
21	drug3	drug0	NN	_	19	ppmod	_	_
22	(	-lrb-	-LRB-	_	24	p	_	_
23	a	a	DT	_	24	det	_	_
24	drug4	drug0	NN	_	21	prn	_	_
25	similar	similar	JJ	_	24	attr	_	_
26	to	to	TO	_	27	aux	_	_
27	drug5	drug0	NN	_	25	ppmod	_	_
28	)	-rrb-	-RRB-	_	24	p	_	_
29	in	in	IN	_	30	case	_	_
30	3	0	CD	_	19	ppmod	_	_
31	of	of	IN	_	34	case	_	_
32	the	the	DT	_	34	det	_	_
33	7	0	CD	_	34	num	_	_
34	subjects	subject	NNS	_	30	ppmod	_	_
35	.	.	.	_	1	p	_	_

1	Repeating	repeat	VBG	_	16	advcl	_	_
2	the	the	DT	_	3	det	_	_
3	study	study	NN	_	1	obj	_	_
4	with	with	IN	_	8	case	_	_
5	6	0	CD	_	8	num	_	_
6	healthy	healthy	JJ	_	8	attr	_	_
7	male	male	JJ	_	8	attr	_	_
8	volunteers	volunteer	NNS	_	3	ppmod	_	_
9	in	in	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	absence	absence	NN	_	3	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	did	do	VBD	_	16	aux	_	_
15	not	not	RB	_	16	neg	_	_
16	detect	detect	VB	_	0	root	_	_
17	an	an	DT	_	18	det	_	_
18	effect	effect	NN	_	16	obj	_	_
19	of	of	IN	_	20	case	_	_
20	drug2	drug0	NN	_	18	ppmod	_	_
21	on	on	IN	_	23	case	_	_
22	glucose	glucose	NN	_	23	com	_	_
23	tolerance	tolerance	NN	_	18	ppmod	_	_
24	.	.	.	_	16	p	_	_

1	Careful	careful	JJ	_	2	attr	_	_
2	supervision	supervision	NN	_	11	dep	_	_
3	of	of	IN	_	5	case	_	_
4	diabetic	diabetic	JJ	_	5	attr	_	_
5	patients	patient	NNS	_	2	ppmod	_	_
6	under	under	IN	_	7	case	_	_
7	treatment	treatment	NN	_	2	ppmod	_	_
8	with	with	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	is	be	VBZ	_	11	aux	_	_
11	recommended	recommend	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	It	it	PRP	_	7	dep	_	_
4	has	have	VBZ	_	7	aux	_	_
5	not	not	RB	_	7	neg	_	_
6	been	be	VBN	_	7	aux	_	_
7	established	establish	VBN	_	1	acl	_	_
8	if	if	IN	_	10	mark	_	_
9	there	there	EX	_	10	dep	_	_
10	is	be	VBZ	_	7	comp	_	_
11	a	a	DT	_	13	det	_	_
12	pharmacokinetic	pharmacokinetic	JJ	_	13	attr	_	_
13	interaction	interaction	NN	_	10	obj	_	_
14	between	between	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	drug3	drug0	NN	_	15	conj	_	_
18	.	.	.	_	1	p	_	_

1	However	however	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	it	it	PRP	_	6	dep	_	_
4	has	have	VBZ	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	established	establish	VBN	_	0	root	_	_
7	that	that	IN	_	9	mark	_	_
8	drug1	drug0	NN	_	9	dep	_	_
9	interferes	interfere	VBZ	_	6	comp	_	_
10	with	with	IN	_	13	case	_	_
11	the	the	DT	_	13	det	_	_
12	contraceptive	contraceptive	JJ	_	13	attr	_	_
13	effect	effect	NN	_	9	ppmod	_	_
14	of	of	IN	_	18	case	_	_
15	microdosed	microdosed	JJ	_	18	attr	_	_
16	drug2	drug0	NN	_	18	com	_	_
17	minipill	minipill	NN	_	18	com	_	_
18	preparations	preparation	NNS	_	13	ppmod	_	_
19	.	.	.	_	6	p	_	_

1	Microdosed	microdosed	JJ	_	4	attr	_	_
2	minipill	minipill	NN	_	4	com	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	preparations	preparation	NNS	_	7	dep	_	_
5	are	be	VBP	_	7	aux	_	_
6	not	not	RB	_	7	neg	_	_
7	recommended	recommend	VBN	_	0	root	_	_
8	for	for	IN	_	9	case	_	_
9	use	use	NN	_	7	ppmod	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	7	p	_	_

1	It	it	PRP	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	known	know	VBN	_	0	root	_	_
5	whether	whether	IN	_	15	mark	_	_
6	other	other	JJ	_	7	attr	_	_
7	drug1	drug0	NNS	_	15	dep	_	_
8	,	,	,	_	7	p	_	_
9	such	such	JJ	_	11	adv	_	_
10	as	as	IN	_	11	case	_	_
11	implants	implant	NNS	_	7	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	injectables	injectables	NNS	_	11	conj	_	_
14	,	,	,	_	7	p	_	_
15	are	be	VBP	_	4	comp	_	_
16	adequate	adequate	JJ	_	17	attr	_	_
17	methods	method	NNS	_	15	obj	_	_
18	of	of	IN	_	19	case	_	_
19	contraception	contraception	NN	_	17	ppmod	_	_
20	during	during	IN	_	22	case	_	_
21	drug2	drug0	NN	_	22	com	_	_
22	therapy	therapy	NN	_	15	ppmod	_	_
23	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	10	dep	_	_
2	:	:	:	_	1	p	_	_
3	An	an	DT	_	5	det	_	_
4	increased	increase	VBN	_	5	attr	_	_
5	risk	risk	NN	_	1	appo	_	_
6	of	of	IN	_	7	case	_	_
7	hepatitis	hepatitis	NN	_	5	ppmod	_	_
8	has	have	VBZ	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	reported	report	VBN	_	0	root	_	_
11	to	to	TO	_	12	aux	_	_
12	result	result	VB	_	10	comp	_	_
13	from	from	IN	_	15	case	_	_
14	combined	combined	JJ	_	15	attr	_	_
15	use	use	NN	_	12	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	and	and	CC	_	17	cc	_	_
19	drug3	drug0	NN	_	17	conj	_	_
20	.	.	.	_	10	p	_	_

1	Consequently	consequently	RB	_	11	adv	_	_
2	,	,	,	_	11	p	_	_
3	the	the	DT	_	4	det	_	_
4	combination	combination	NN	_	11	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	with	with	IN	_	8	case	_	_
8	drug2	drug0	NN	_	4	ppmod	_	_
9	is	be	VBZ	_	11	aux	_	_
10	also	also	RB	_	11	adv	_	_
11	contraindicated	contraindicate	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	If	if	IN	_	6	mark	_	_
4	drug2	drug0	NN	_	6	dep	_	_
5	is	be	VBZ	_	6	aux	_	_
6	given	give	VBN	_	18	advcl	_	_
7	concurrently	concurrently	RB	_	6	adv	_	_
8	with	with	IN	_	9	case	_	_
9	drug3	drug0	NN	_	6	ppmod	_	_
10	,	,	,	_	18	p	_	_
11	the	the	DT	_	13	det	_	_
12	protein	protein	NN	_	13	com	_	_
13	binding	binding	NN	_	18	dep	_	_
14	of	of	IN	_	15	case	_	_
15	drug4	drug0	NN	_	13	ppmod	_	_
16	may	may	MD	_	18	modal	_	_
17	be	be	VB	_	18	aux	_	_
18	reduced	reduce	VBN	_	1	acl	_	_
19	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Since	since	IN	_	9	mark	_	_
4	both	both	CC	_	5	cc	_	_
5	drug2	drug0	NN	_	9	dep	_	_
6	and	and	CC	_	5	cc	_	_
7	drug3	drug0	NN	_	5	conj	_	_
8	can	can	MD	_	9	modal	_	_
9	cause	cause	VB	_	18	advcl	_	_
10	increased	increase	VBN	_	12	attr	_	_
11	intracranial	intracranial	JJ	_	12	attr	_	_
12	pressure	pressure	NN	_	9	obj	_	_
13	,	,	,	_	18	p	_	_
14	their	their	PRP$	_	16	poss	_	_
15	combined	combined	JJ	_	16	attr	_	_
16	use	use	NN	_	18	dep	_	_
17	is	be	VBZ	_	18	aux	_	_
18	contraindicated	contraindicate	VBN	_	1	acl	_	_
19	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	and	and	CC	_	1	cc	_	_
3	oral	oral	JJ	_	4	attr	_	_
4	drug2	drug0	NN	_	1	conj	_	_
5	:	:	:	_	1	p	_	_
6	Concomitant	concomitant	JJ	_	7	attr	_	_
7	administration	administration	NN	_	18	dep	_	_
8	of	of	IN	_	9	case	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_
10	and/or	and/or	CC	_	7	cc	_	_
11	other	other	JJ	_	13	attr	_	_
12	oral	oral	JJ	_	13	attr	_	_
13	drug4	drug0	NNS	_	7	conj	_	_
14	with	with	IN	_	15	case	_	_
15	drug5	drug0	NN	_	13	ppmod	_	_
16	must	must	MD	_	18	modal	_	_
17	be	be	VB	_	18	aux	_	_
18	avoided	avoid	VBN	_	1	acl	_	_
19	because	because	IN	_	22	case	_	_
20	of	of	IN	_	22	case	_	_
21	the	the	DT	_	22	det	_	_
22	risk	risk	NN	_	18	ppmod	_	_
23	of	of	IN	_	25	case	_	_
24	hypervitaminosis	hypervitaminosis	NN	_	25	com	_	_
25	A	a	NN	_	22	ppmod	_	_
26	.	.	.	_	1	p	_	_

1	Other	other	JJ	_	4	dep	_	_
2	:	:	:	_	1	p	_	_
3	There	there	EX	_	1	attr	_	_
4	appears	appear	VBZ	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	be	be	VB	_	4	comp	_	_
7	no	no	DT	_	9	det	_	_
8	pharmacokinetic	pharmacokinetic	JJ	_	9	attr	_	_
9	interaction	interaction	NN	_	6	obj	_	_
10	between	between	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	drug2	drug0	NN	_	11	conj	_	_
14	,	,	,	_	13	p	_	_
15	drug3	drug0	NN	_	11	conj	_	_
16	,	,	,	_	15	p	_	_
17	or	or	CC	_	15	cc	_	_
18	drug4	drug0	NN	_	11	conj	_	_
19	.	.	.	_	4	p	_	_

1	Investigations	investigation	NNS	_	16	dep	_	_
2	into	into	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	effect	effect	NN	_	1	ppmod	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	on	on	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	protein	protein	NN	_	10	com	_	_
10	binding	binding	NN	_	4	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	drug3	drug0	NN	_	12	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	revealed	reveal	VBD	_	0	root	_	_
17	no	no	DT	_	18	det	_	_
18	interaction	interaction	NN	_	16	obj	_	_
19	.	.	.	_	16	p	_	_

1	Laboratory	laboratory	NN	_	2	com	_	_
2	Tests	test	NNS	_	9	dep	_	_
3	If	if	IN	_	7	case	_	_
4	significant	significant	JJ	_	7	attr	_	_
5	abnormal	abnormal	JJ	_	7	attr	_	_
6	laboratory	laboratory	NN	_	7	com	_	_
7	results	result	NNS	_	2	ppmod	_	_
8	are	be	VBP	_	9	aux	_	_
9	obtained	obtain	VBN	_	0	root	_	_
10	,	,	,	_	9	p	_	_
11	either	either	CC	_	9	cc	_	_
12	dosage	dosage	NN	_	13	com	_	_
13	reduction	reduction	NN	_	21	dep	_	_
14	with	with	IN	_	16	case	_	_
15	careful	careful	JJ	_	16	attr	_	_
16	monitoring	monitoring	NN	_	13	ppmod	_	_
17	or	or	CC	_	16	cc	_	_
18	treatment	treatment	NN	_	19	com	_	_
19	discontinuation	discontinuation	NN	_	16	conj	_	_
20	is	be	VBZ	_	21	aux	_	_
21	recommended	recommend	VBN	_	9	conj	_	_
22	,	,	,	_	21	p	_	_
23	depending	depend	VBG	_	26	adv	_	_
24	on	on	IN	_	26	case	_	_
25	clinical	clinical	JJ	_	26	attr	_	_
26	judgement	judgement	NN	_	21	ppmod	_	_
27	.	.	.	_	9	p	_	_

1	Blood	blood	NN	_	2	com	_	_
2	Sugar	sugar	NN	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	Some	some	DT	_	5	det	_	_
5	patients	patient	NNS	_	9	dep	_	_
6	receiving	receive	VBG	_	5	acl	_	_
7	drug1	drug0	NN	_	6	obj	_	_
8	have	have	VBP	_	9	aux	_	_
9	experienced	experience	VBN	_	2	acl	_	_
10	problems	problem	NNS	_	9	obj	_	_
11	with	with	IN	_	14	case	_	_
12	blood	blood	NN	_	14	com	_	_
13	sugar	sugar	NN	_	14	com	_	_
14	control	control	NN	_	9	ppmod	_	_
15	.	.	.	_	2	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	10	ppmod	_	_
3	,	,	,	_	10	p	_	_
4	new	new	JJ	_	5	attr	_	_
5	cases	case	NNS	_	10	dep	_	_
6	of	of	IN	_	7	case	_	_
7	diabetes	diabetes	NNS	_	5	ppmod	_	_
8	have	have	VBP	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	diagnosed	diagnose	VBN	_	0	root	_	_
11	during	during	IN	_	13	case	_	_
12	drug1	drug0	NN	_	13	com	_	_
13	therapy	therapy	NN	_	10	ppmod	_	_
14	,	,	,	_	10	p	_	_
15	including	include	VBG	_	17	adv	_	_
16	diabetic	diabetic	JJ	_	17	attr	_	_
17	ketoacidosis	ketoacidosis	NN	_	10	ppmod	_	_
18	.	.	.	_	10	p	_	_

1	In	in	IN	_	2	case	_	_
2	diabetics	diabetics	NN	_	8	ppmod	_	_
3	,	,	,	_	8	p	_	_
4	blood-sugar	blood-sugar	JJ	_	5	attr	_	_
5	levels	level	NNS	_	8	dep	_	_
6	should	should	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	monitored	monitor	VBN	_	0	root	_	_
9	very	very	RB	_	10	com	_	_
10	carefully	carefully	RB	_	8	adv	_	_
11	.	.	.	_	8	p	_	_

1	Lipids	lipid	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	5	case	_	_
4	clinical	clinical	JJ	_	5	attr	_	_
5	studies	study	NNS	_	11	ppmod	_	_
6	,	,	,	_	11	p	_	_
7	the	the	DT	_	8	det	_	_
8	incidence	incidence	NN	_	11	dep	_	_
9	of	of	IN	_	10	case	_	_
10	hypertriglyceridemia	hypertriglyceridemia	NNS	_	8	ppmod	_	_
11	was	be	VBD	_	1	acl	_	_
12	66	0	CD	_	11	obj	_	_
13	%	%	NN	_	12	meta	_	_
14	,	,	,	_	11	p	_	_
15	hypercholesterolemia	hypercholesterolemia	NN	_	16	dep	_	_
16	was	be	VBD	_	11	conj	_	_
17	33	0	CD	_	16	obj	_	_
18	%	%	NN	_	17	meta	_	_
19	and	and	CC	_	16	cc	_	_
20	that	that	DT	_	24	dep	_	_
21	of	of	IN	_	23	case	_	_
22	decreased	decrease	VBN	_	23	attr	_	_
23	HDL	hdl	NN	_	20	ppmod	_	_
24	was	be	VBD	_	11	conj	_	_
25	40	0	CD	_	24	obj	_	_
26	%	%	NN	_	25	meta	_	_
27	.	.	.	_	1	p	_	_

1	Pretreatment	pretreatment	NN	_	4	attr	_	_
2	and	and	CC	_	1	cc	_	_
3	follow-up	follow-up	NN	_	1	conj	_	_
4	measurements	measurement	NNS	_	7	dep	_	_
5	should	should	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	obtained	obtain	VBN	_	0	root	_	_
8	under	under	IN	_	10	case	_	_
9	fasting	fasting	JJ	_	10	attr	_	_
10	conditions	condition	NNS	_	7	ppmod	_	_
11	.	.	.	_	7	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	recommended	recommend	VBN	_	0	root	_	_
4	that	that	IN	_	8	mark	_	_
5	these	these	DT	_	6	det	_	_
6	tests	test	NNS	_	8	dep	_	_
7	be	be	VB	_	8	aux	_	_
8	performed	performed	VBN	_	3	comp	_	_
9	weekly	weekly	RB	_	8	adv	_	_
10	or	or	CC	_	8	cc	_	_
11	every	every	DT	_	13	det	_	_
12	other	other	JJ	_	13	attr	_	_
13	week	week	NN	_	21	dep	_	_
14	until	until	IN	_	17	case	_	_
15	the	the	DT	_	17	det	_	_
16	lipid	lipid	NN	_	17	com	_	_
17	response	response	NN	_	13	ppmod	_	_
18	to	to	TO	_	19	aux	_	_
19	drug1	drug0	NN	_	17	ppmod	_	_
20	has	have	VBZ	_	21	aux	_	_
21	stabilized	stabilize	VBN	_	8	conj	_	_
22	.	.	.	_	3	p	_	_

1	Liver	liver	NN	_	3	com	_	_
2	Function	function	NN	_	3	com	_	_
3	Tests	test	NNS	_	0	root	_	_
4	:	:	:	_	3	p	_	_
5	Elevations	elevation	NNS	_	19	dep	_	_
6	of	of	IN	_	7	case	_	_
7	AST	ast	NN	_	5	ppmod	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	SGOT	sgot	NN	_	7	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	,	,	,	_	7	p	_	_
12	ALT	alt	NN	_	7	conj	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	SGPT	sgpt	NN	_	12	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	or	or	CC	_	12	cc	_	_
17	LDH	ldh	NN	_	7	conj	_	_
18	were	be	VBD	_	19	aux	_	_
19	experienced	experience	VBN	_	3	acl	_	_
20	by	by	IN	_	22	case	_	_
21	approximately	approximately	RB	_	22	adv	_	_
22	1	0	CD	_	19	ppmod	_	_
23	in	in	IN	_	25	case	_	_
24	3	0	CD	_	25	num	_	_
25	patients	patient	NNS	_	22	ppmod	_	_
26	treated	treat	VBN	_	25	acl	_	_
27	with	with	IN	_	28	case	_	_
28	drug1	drug0	NN	_	26	ppmod	_	_
29	.	.	.	_	3	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	recommended	recommend	VBN	_	0	root	_	_
4	that	that	IN	_	8	mark	_	_
5	these	these	DT	_	6	det	_	_
6	tests	test	NNS	_	8	dep	_	_
7	be	be	VB	_	8	aux	_	_
8	performed	performed	VBN	_	3	comp	_	_
9	prior	prior	RB	_	8	adv	_	_
10	to	to	TO	_	11	aux	_	_
11	initiation	initiation	NN	_	9	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	drug1	drug0	NN	_	14	com	_	_
14	therapy	therapy	NN	_	11	ppmod	_	_
15	,	,	,	_	8	p	_	_
16	at	at	IN	_	20	case	_	_
17	1-	0-	CD	_	20	num	_	_
18	to	to	TO	_	20	attr	_	_
19	2-week	0-week	JJ	_	20	attr	_	_
20	intervals	interval	NNS	_	8	ppmod	_	_
21	until	until	IN	_	22	case	_	_
22	stable	stable	JJ	_	20	ppmod	_	_
23	and	and	CC	_	20	cc	_	_
24	thereafter	thereafter	RB	_	26	adv	_	_
25	at	at	IN	_	26	case	_	_
26	intervals	interval	NNS	_	20	conj	_	_
27	as	as	IN	_	29	mark	_	_
28	clinically	clinically	RB	_	29	adv	_	_
29	indicated	indicate	VBN	_	8	comp	_	_
30	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	highly	highly	RB	_	4	adv	_	_
4	bound	bind	VBN	_	0	root	_	_
5	to	to	TO	_	7	aux	_	_
6	plasma	plasma	NN	_	7	com	_	_
7	protein	protein	NN	_	4	ppmod	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	99.9	0	CD	_	7	num	_	_
10	%	%	NN	_	9	meta	_	_
11	)	-rrb-	-RRB-	_	9	p	_	_
12	.	.	.	_	4	p	_	_

1	Therefore	therefore	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	caution	caution	NN	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	used	use	VBN	_	0	root	_	_
7	when	when	WRB	_	8	adv	_	_
8	administering	administer	VBG	_	6	comp	_	_
9	drug1	drug0	NN	_	8	obj	_	_
10	concurrently	concurrently	RB	_	16	adv	_	_
11	with	with	IN	_	16	case	_	_
12	other	other	JJ	_	16	attr	_	_
13	highly	highly	RB	_	15	adv	_	_
14	plasma	plasma	NN	_	15	advnp	_	_
15	protein-bound	protein-bound	JJ	_	16	attr	_	_
16	drugs	drug	NNS	_	9	ppmod	_	_
17	with	with	IN	_	20	case	_	_
18	narrow	narrow	JJ	_	20	attr	_	_
19	therapeutic	therapeutic	JJ	_	20	attr	_	_
20	indices	index	NNS	_	8	ppmod	_	_
21	,	,	,	_	6	p	_	_
22	as	as	IN	_	28	mark	_	_
23	competition	competition	NN	_	28	dep	_	_
24	for	for	IN	_	26	case	_	_
25	binding	binding	NN	_	26	com	_	_
26	sites	site	NNS	_	23	ppmod	_	_
27	may	may	MD	_	28	modal	_	_
28	occur	occur	VB	_	6	comp	_	_
29	(	-lrb-	-LRB-	_	32	p	_	_
30	e.g.	e.g.	FW	_	32	ppmod	_	_
31	,	,	,	_	32	p	_	_
32	drug2	drug0	NN	_	6	prn	_	_
33	)	-rrb-	-RRB-	_	32	p	_	_
34	.	.	.	_	6	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	4	attr	_	_
3	metabolism	metabolism	NN	_	4	com	_	_
4	studies	study	NNS	_	6	dep	_	_
5	have	have	VBP	_	6	aux	_	_
6	demonstrated	demonstrate	VBN	_	0	root	_	_
7	that	that	IN	_	9	mark	_	_
8	drug1	drug0	NN	_	9	dep	_	_
9	has	have	VBZ	_	6	comp	_	_
10	no	no	DT	_	13	det	_	_
11	significant	significant	JJ	_	13	attr	_	_
12	inhibitory	inhibitory	JJ	_	13	attr	_	_
13	effect	effect	NN	_	9	obj	_	_
14	on	on	IN	_	17	case	_	_
15	cytochrome	cytochrome	NN	_	17	com	_	_
16	P450	p0	NN	_	17	com	_	_
17	enzymes	enzyme	NNS	_	9	ppmod	_	_
18	.	.	.	_	6	p	_	_

1	Although	although	IN	_	8	mark	_	_
2	no	no	DT	_	5	det	_	_
3	drug-drug	drug-drug	JJ	_	5	attr	_	_
4	interaction	interaction	NN	_	5	com	_	_
5	studies	study	NNS	_	8	dep	_	_
6	have	have	VBP	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	conducted	conduct	VBN	_	14	advcl	_	_
9	in	in	FW	_	10	adv	_	_
10	vivo	vivo	FW	_	8	adv	_	_
11	,	,	,	_	14	p	_	_
12	it	it	PRP	_	14	dep	_	_
13	is	be	VBZ	_	14	aux	_	_
14	expected	expect	VBN	_	0	root	_	_
15	that	that	IN	_	20	mark	_	_
16	no	no	DT	_	18	det	_	_
17	significant	significant	JJ	_	18	attr	_	_
18	interaction	interaction	NN	_	20	dep	_	_
19	would	would	MD	_	20	modal	_	_
20	occur	occur	VB	_	14	comp	_	_
21	when	when	WRB	_	24	adv	_	_
22	drug1	drug0	NN	_	24	dep	_	_
23	is	be	VBZ	_	24	aux	_	_
24	co-administered	co-administered	VBN	_	20	comp	_	_
25	with	with	IN	_	26	case	_	_
26	drugs	drug	NNS	_	24	ppmod	_	_
27	that	that	WDT	_	30	dep	_	_
28	either	either	RB	_	30	adv	_	_
29	are	be	VBP	_	30	aux	_	_
30	metabolized	metabolize	VBN	_	26	relcl	_	_
31	by	by	IN	_	30	case	_	_
32	or	or	CC	_	30	cc	_	_
33	inhibit	inhibit	VB	_	30	conj	_	_
34	cytochrome	cytochrome	NN	_	36	com	_	_
35	P450	p0	NN	_	36	com	_	_
36	enzymes	enzyme	NNS	_	33	obj	_	_
37	.	.	.	_	14	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	increase	increase	VB	_	0	root	_	_
4	sensitivity	sensitivity	NN	_	3	obj	_	_
5	to	to	TO	_	7	aux	_	_
6	oral	oral	JJ	_	7	attr	_	_
7	anticoagulahts	anticoagulahts	NNS	_	4	ppmod	_	_
8	.	.	.	_	3	p	_	_

1	Dosage	dosage	NN	_	6	dep	_	_
2	of	of	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	drug1	drug0	NN	_	1	ppmod	_	_
5	may	may	MD	_	6	modal	_	_
6	require	require	VB	_	0	root	_	_
7	reduction	reduction	NN	_	6	obj	_	_
8	in	in	IN	_	11	mark	_	_
9	order	order	NN	_	11	dep	_	_
10	to	to	TO	_	11	aux	_	_
11	maintain	maintain	VB	_	6	comp	_	_
12	satisfactory	satisfactory	JJ	_	14	attr	_	_
13	therapeutic	therapeutic	JJ	_	14	attr	_	_
14	hypoprothrombinemia	hypoprothrombinemia	NN	_	11	obj	_	_
15	.	.	.	_	6	p	_	_

1	Concurrent	concurrent	JJ	_	2	attr	_	_
2	administration	administration	NN	_	8	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	may	may	MD	_	8	modal	_	_
8	result	result	VB	_	0	root	_	_
9	in	in	IN	_	12	case	_	_
10	elevated	elevated	JJ	_	12	attr	_	_
11	serum	serum	NN	_	12	com	_	_
12	levels	level	NNS	_	8	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug3	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	8	p	_	_

1	In	in	IN	_	3	case	_	_
2	diabetic	diabetic	JJ	_	3	attr	_	_
3	patients	patient	NNS	_	11	ppmod	_	_
4	,	,	,	_	11	p	_	_
5	the	the	DT	_	7	det	_	_
6	metabolic	metabolic	JJ	_	7	attr	_	_
7	effects	effect	NNS	_	11	dep	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	may	may	MD	_	11	modal	_	_
11	decrease	decrease	VB	_	0	root	_	_
12	blood	blood	NN	_	13	com	_	_
13	glucose	glucose	NN	_	11	obj	_	_
14	and	and	CC	_	11	cc	_	_
15	therefore	therefore	RB	_	11	adv	_	_
16	,	,	,	_	11	p	_	_
17	drug2	drug0	NN	_	18	com	_	_
18	requirements	requirement	NNS	_	11	conj	_	_
19	.	.	.	_	11	p	_	_

1	When	when	WRB	_	5	adv	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	HCl	hcl	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	administered	administer	VBN	_	17	advcl	_	_
6	concomitantly	concomitantly	RB	_	5	adv	_	_
7	with	with	IN	_	9	case	_	_
8	an	an	DT	_	9	det	_	_
9	drug2	drug0	NN	_	5	ppmod	_	_
10	,	,	,	_	17	p	_	_
11	the	the	DT	_	12	det	_	_
12	risk	risk	NN	_	17	dep	_	_
13	of	of	IN	_	14	case	_	_
14	hyperkalemia	hyperkalemia	NN	_	12	ppmod	_	_
15	may	may	MD	_	17	modal	_	_
16	be	be	VB	_	17	aux	_	_
17	increased	increase	VBN	_	0	root	_	_
18	.	.	.	_	17	p	_	_

1	Therefore	therefore	RB	_	19	adv	_	_
2	,	,	,	_	19	p	_	_
3	if	if	IN	_	10	mark	_	_
4	concomitant	concomitant	JJ	_	5	attr	_	_
5	use	use	NN	_	10	dep	_	_
6	of	of	IN	_	8	case	_	_
7	these	these	DT	_	8	det	_	_
8	agents	agent	NNS	_	5	ppmod	_	_
9	is	be	VBZ	_	10	aux	_	_
10	indicated	indicate	VBN	_	19	advcl	_	_
11	because	because	IN	_	14	case	_	_
12	of	of	IN	_	14	case	_	_
13	demonstrated	demonstrate	VBN	_	14	attr	_	_
14	hypokalemia	hypokalemia	NN	_	10	ppmod	_	_
15	,	,	,	_	19	p	_	_
16	they	they	PRP	_	19	dep	_	_
17	should	should	MD	_	19	modal	_	_
18	be	be	VB	_	19	aux	_	_
19	used	use	VBN	_	0	root	_	_
20	with	with	IN	_	21	case	_	_
21	caution	caution	NN	_	19	ppmod	_	_
22	and	and	CC	_	21	cc	_	_
23	with	with	IN	_	25	case	_	_
24	frequent	frequent	JJ	_	25	attr	_	_
25	monitoring	monitoring	NN	_	21	conj	_	_
26	of	of	IN	_	28	case	_	_
27	serum	serum	NN	_	28	com	_	_
28	potassium	potassium	NN	_	25	ppmod	_	_
29	.	.	.	_	19	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	generally	generally	RB	_	6	adv	_	_
3	should	should	MD	_	6	modal	_	_
4	not	not	RB	_	6	neg	_	_
5	be	be	VB	_	6	aux	_	_
6	given	give	VBN	_	0	root	_	_
7	with	with	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	because	because	IN	_	11	mark	_	_
10	they	they	PRP	_	11	dep	_	_
11	reduce	reduce	VBP	_	6	comp	_	_
12	its	its	PRP$	_	14	poss	_	_
13	renal	renal	JJ	_	14	attr	_	_
14	clearance	clearance	NN	_	11	obj	_	_
15	and	and	CC	_	11	cc	_	_
16	add	add	VBP	_	11	conj	_	_
17	a	a	DT	_	19	det	_	_
18	high	high	JJ	_	19	attr	_	_
19	risk	risk	NN	_	16	obj	_	_
20	of	of	IN	_	22	case	_	_
21	lithium	lithium	NN	_	22	com	_	_
22	toxicity	toxicity	NN	_	19	ppmod	_	_
23	.	.	.	_	6	p	_	_

1	Read	read	VBN	_	2	dep	_	_
2	circulars	circulars	VBZ	_	0	root	_	_
3	for	for	IN	_	5	case	_	_
4	drug1	drug0	JJ	_	5	attr	_	_
5	preparations	preparation	NNS	_	2	ppmod	_	_
6	before	before	IN	_	7	case	_	_
7	use	use	NN	_	5	ppmod	_	_
8	of	of	IN	_	11	case	_	_
9	such	such	JJ	_	11	attr	_	_
10	concomitant	concomitant	JJ	_	11	attr	_	_
11	therapy	therapy	NN	_	7	ppmod	_	_
12	.	.	.	_	2	p	_	_

1	In	in	IN	_	3	case	_	_
2	some	some	DT	_	3	det	_	_
3	patients	patient	NNS	_	11	ppmod	_	_
4	,	,	,	_	11	p	_	_
5	the	the	DT	_	6	det	_	_
6	administration	administration	NN	_	11	dep	_	_
7	of	of	IN	_	9	case	_	_
8	a	a	DT	_	9	det	_	_
9	drug1	drug0	NN	_	6	ppmod	_	_
10	can	can	MD	_	11	modal	_	_
11	reduce	reduce	VB	_	0	root	_	_
12	the	the	DT	_	19	det	_	_
13	diuretic	diuretic	JJ	_	19	attr	_	_
14	,	,	,	_	13	p	_	_
15	natriuretic	natriuretic	JJ	_	13	conj	_	_
16	,	,	,	_	15	p	_	_
17	and	and	CC	_	15	cc	_	_
18	antihypertensive	antihypertensive	JJ	_	13	conj	_	_
19	effects	effect	NNS	_	11	obj	_	_
20	of	of	IN	_	21	case	_	_
21	drug2	drug0	NN	_	19	ppmod	_	_
22	,	,	,	_	21	p	_	_
23	drug3	drug0	NN	_	21	conj	_	_
24	and	and	CC	_	23	cc	_	_
25	drug4	drug0	NN	_	21	conj	_	_
26	.	.	.	_	11	p	_	_

1	Therefore	therefore	RB	_	15	adv	_	_
2	,	,	,	_	15	p	_	_
3	when	when	WRB	_	8	adv	_	_
4	drug1	drug0	NN	_	8	dep	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	are	be	VBP	_	8	aux	_	_
8	used	use	VBN	_	15	advcl	_	_
9	concomitantly	concomitantly	RB	_	8	adv	_	_
10	,	,	,	_	15	p	_	_
11	the	the	DT	_	12	det	_	_
12	patient	patient	NN	_	15	dep	_	_
13	should	should	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	observed	observe	VBN	_	0	root	_	_
16	closely	closely	RB	_	15	adv	_	_
17	to	to	TO	_	18	aux	_	_
18	determine	determine	VB	_	15	comp	_	_
19	if	if	IN	_	27	mark	_	_
20	the	the	DT	_	22	det	_	_
21	desired	desired	JJ	_	22	attr	_	_
22	effect	effect	NN	_	27	dep	_	_
23	of	of	IN	_	25	case	_	_
24	the	the	DT	_	25	det	_	_
25	drug3	drug0	NN	_	22	ppmod	_	_
26	is	be	VBZ	_	27	aux	_	_
27	obtained	obtain	VBN	_	18	comp	_	_
28	.	.	.	_	15	p	_	_

1	Since	since	IN	_	12	mark	_	_
2	drug1	drug0	NN	_	12	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	drug2	drug0	NN	_	2	conj	_	_
5	,	,	,	_	2	p	_	_
6	including	include	VBG	_	7	adv	_	_
7	drug3	drug0	NN	_	2	ppmod	_	_
8	,	,	,	_	2	p	_	_
9	may	may	MD	_	12	modal	_	_
10	each	each	DT	_	12	det	_	_
11	be	be	VB	_	12	aux	_	_
12	associated	associate	VBN	_	30	advcl	_	_
13	with	with	IN	_	17	case	_	_
14	increased	increase	VBN	_	17	attr	_	_
15	serum	serum	NN	_	17	com	_	_
16	potassium	potassium	NN	_	17	com	_	_
17	levels	level	NNS	_	12	ppmod	_	_
18	,	,	,	_	30	p	_	_
19	the	the	DT	_	21	det	_	_
20	potential	potential	JJ	_	21	attr	_	_
21	effects	effect	NNS	_	30	dep	_	_
22	on	on	IN	_	24	case	_	_
23	potassium	potassium	NN	_	24	com	_	_
24	kinetics	kinetics	NNS	_	21	ppmod	_	_
25	and	and	CC	_	24	cc	_	_
26	renal	renal	JJ	_	27	attr	_	_
27	function	function	NN	_	24	conj	_	_
28	should	should	MD	_	30	modal	_	_
29	be	be	VB	_	30	aux	_	_
30	considered	consider	VBN	_	0	root	_	_
31	when	when	WRB	_	35	adv	_	_
32	these	these	DT	_	33	det	_	_
33	agents	agent	NNS	_	35	dep	_	_
34	are	be	VBP	_	35	aux	_	_
35	administered	administer	VBN	_	30	comp	_	_
36	concurrently	concurrently	RB	_	35	adv	_	_
37	.	.	.	_	30	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Based	base	VBN	_	48	advcl	_	_
4	on	on	IN	_	5	case	_	_
5	reports	report	NNS	_	3	ppmod	_	_
6	of	of	IN	_	8	case	_	_
7	profound	profound	JJ	_	8	attr	_	_
8	hypotension	hypotension	NN	_	5	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	loss	loss	NN	_	8	conj	_	_
11	of	of	IN	_	12	case	_	_
12	consciousness	consciousness	NN	_	10	ppmod	_	_
13	when	when	WRB	_	16	adv	_	_
14	drug2	drug0	NN	_	16	dep	_	_
15	was	be	VBD	_	16	aux	_	_
16	administered	administer	VBN	_	3	comp	_	_
17	with	with	IN	_	18	case	_	_
18	drug3	drug0	NN	_	16	ppmod	_	_
19	,	,	,	_	48	p	_	_
20	the	the	DT	_	22	det	_	_
21	concomitant	concomitant	JJ	_	22	attr	_	_
22	use	use	NN	_	48	dep	_	_
23	of	of	IN	_	24	case	_	_
24	drug4	drug0	NN	_	22	ppmod	_	_
25	with	with	IN	_	26	case	_	_
26	drugs	drug	NNS	_	22	ppmod	_	_
27	of	of	IN	_	29	case	_	_
28	the	the	DT	_	29	det	_	_
29	drug5	drug0	NN	_	26	ppmod	_	_
30	(	-lrb-	-LRB-	_	31	p	_	_
31	including	include	VBG	_	29	prn	_	_
32	,	,	,	_	31	p	_	_
33	for	for	IN	_	34	case	_	_
34	example	example	NN	_	31	ppmod	_	_
35	,	,	,	_	34	p	_	_
36	drug6	drug0	NN	_	34	conj	_	_
37	,	,	,	_	36	p	_	_
38	drug7	drug0	NN	_	34	conj	_	_
39	,	,	,	_	38	p	_	_
40	drug8	drug0	NN	_	34	conj	_	_
41	,	,	,	_	40	p	_	_
42	drug9	drug0	NN	_	34	conj	_	_
43	,	,	,	_	42	p	_	_
44	and	and	CC	_	42	cc	_	_
45	drug10	drug0	NN	_	34	conj	_	_
46	)	-rrb-	-RRB-	_	31	p	_	_
47	is	be	VBZ	_	48	aux	_	_
48	contraindicated	contraindicate	VBN	_	1	acl	_	_
49	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	s	s	NNS	_	0	root	_	_
3	and	and	CC	_	2	cc	_	_
4	drug2	drug0	NN	_	2	conj	_	_
5	:	:	:	_	2	p	_	_
6	The	the	DT	_	9	det	_	_
7	following	following	JJ	_	9	attr	_	_
8	adverse	adverse	JJ	_	9	attr	_	_
9	events	event	NNS	_	11	dep	_	_
10	were	be	VBD	_	11	aux	_	_
11	experienced	experience	VBN	_	2	acl	_	_
12	more	more	RBR	_	13	com	_	_
13	commonly	commonly	RB	_	11	adv	_	_
14	in	in	IN	_	15	case	_	_
15	patients	patient	NNS	_	11	ppmod	_	_
16	receiving	receive	VBG	_	15	acl	_	_
17	concomitant	concomitant	JJ	_	18	attr	_	_
18	drug3	drug0	NN	_	16	obj	_	_
19	or	or	CC	_	18	cc	_	_
20	drug4	drug0	NN	_	18	conj	_	_
21	(	-lrb-	-LRB-	_	22	p	_	_
22	n	n	NN	_	20	prn	_	_
23	=	=	JJ	_	22	attr	_	_
24	94	0	CD	_	22	num	_	_
25	)	-rrb-	-RRB-	_	22	p	_	_
26	compared	compare	VBN	_	28	adv	_	_
27	to	to	TO	_	28	aux	_	_
28	patients	patient	NNS	_	16	ppmod	_	_
29	not	not	RB	_	30	neg	_	_
30	receiving	receive	VBG	_	28	acl	_	_
31	these	these	DT	_	33	det	_	_
32	concomitant	concomitant	JJ	_	33	attr	_	_
33	drugs	drug	NNS	_	30	obj	_	_
34	(	-lrb-	-LRB-	_	35	p	_	_
35	n	n	NN	_	33	prn	_	_
36	=	=	JJ	_	35	attr	_	_
37	456	0	CD	_	35	num	_	_
38	)	-rrb-	-RRB-	_	35	p	_	_
39	:	:	:	_	33	p	_	_
40	hypotension	hypotension	NN	_	33	appo	_	_
41	10	0	CD	_	40	num	_	_
42	%	%	NN	_	40	meta	_	_
43	vs	vs	CC	_	40	cc	_	_
44	4	0	CD	_	40	conj	_	_
45	%	%	NN	_	44	meta	_	_
46	,	,	,	_	40	p	_	_
47	myocardial	myocardial	JJ	_	48	attr	_	_
48	infarction	infarction	NN	_	40	conj	_	_
49	3	0	CD	_	48	num	_	_
50	%	%	NN	_	48	meta	_	_
51	vs	vs	CC	_	48	cc	_	_
52	1	0	CD	_	48	conj	_	_
53	%	%	NN	_	52	meta	_	_
54	,	,	,	_	48	p	_	_
55	serious	serious	JJ	_	56	attr	_	_
56	pneumonia	pneumonia	NN	_	40	conj	_	_
57	5	0	CD	_	56	num	_	_
58	%	%	NN	_	56	meta	_	_
59	vs	vs	CC	_	56	cc	_	_
60	3	0	CD	_	56	conj	_	_
61	%	%	NN	_	60	meta	_	_
62	,	,	,	_	56	p	_	_
63	serious	serious	JJ	_	64	attr	_	_
64	falls	fall	NNS	_	65	attr	_	_
65	9	0	CD	_	40	conj	_	_
66	%	%	NN	_	65	meta	_	_
67	vs	vs	CC	_	65	cc	_	_
68	3	0	CD	_	65	conj	_	_
69	%	%	NN	_	68	meta	_	_
70	,	,	,	_	65	p	_	_
71	and	and	CC	_	65	cc	_	_
72	bone	bone	NN	_	40	conj	_	_
73	and	and	CC	_	72	cc	_	_
74	joint	joint	NN	_	75	com	_	_
75	injuries	injury	NNS	_	72	conj	_	_
76	6	0	CD	_	75	num	_	_
77	%	%	NN	_	76	meta	_	_
78	vs	vs	CC	_	76	cc	_	_
79	2	0	CD	_	76	conj	_	_
80	%	%	NN	_	79	meta	_	_
81	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	mechanism	mechanism	NN	_	8	dep	_	_
3	underlying	underlie	VBG	_	2	acl	_	_
4	many	many	JJ	_	3	obj	_	_
5	of	of	IN	_	7	case	_	_
6	these	these	DT	_	7	det	_	_
7	events	event	NNS	_	4	ppmod	_	_
8	is	be	VBZ	_	0	root	_	_
9	unknown	unknown	JJ	_	8	dep	_	_
10	,	,	,	_	8	p	_	_
11	but	but	CC	_	8	cc	_	_
12	may	may	MD	_	13	modal	_	_
13	represent	represent	VB	_	8	conj	_	_
14	increased	increase	VBN	_	15	attr	_	_
15	hypotension	hypotension	NN	_	13	obj	_	_
16	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Since	since	IN	_	5	mark	_	_
4	drug2	drug0	NN	_	5	dep	_	_
5	is	be	VBZ	_	10	advcl	_	_
6	a	a	DT	_	7	det	_	_
7	drug3	drug0	NN	_	5	obj	_	_
8	,	,	,	_	10	p	_	_
9	it	it	PRP	_	10	dep	_	_
10	is	be	VBZ	_	1	acl	_	_
11	possible	possible	JJ	_	10	dep	_	_
12	that	that	IN	_	30	mark	_	_
13	drug4	drug0	NNS	_	30	dep	_	_
14	,	,	,	_	13	p	_	_
15	such	such	JJ	_	18	adv	_	_
16	as	as	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	drug5	drug0	NN	_	13	ppmod	_	_
19	(	-lrb-	-LRB-	_	20	p	_	_
20	drug6	drug0	NN	_	18	prn	_	_
21	,	,	,	_	20	p	_	_
22	drug7	drug0	NN	_	20	appo	_	_
23	,	,	,	_	20	p	_	_
24	drug8	drug0	NN	_	20	appo	_	_
25	)	-rrb-	-RRB-	_	20	p	_	_
26	or	or	CC	_	18	cc	_	_
27	drug9	drug0	NN	_	18	conj	_	_
28	,	,	,	_	13	p	_	_
29	may	may	MD	_	30	modal	_	_
30	diminish	diminish	VB	_	10	comp	_	_
31	the	the	DT	_	32	det	_	_
32	effectiveness	effectiveness	NN	_	30	obj	_	_
33	of	of	IN	_	34	case	_	_
34	drug10	drug0	NN	_	32	ppmod	_	_
35	.	.	.	_	1	p	_	_

1	Patients	patient	NNS	_	13	dep	_	_
2	with	with	IN	_	5	case	_	_
3	major	major	JJ	_	5	attr	_	_
4	psychotic	psychotic	JJ	_	5	attr	_	_
5	disorders	disorder	NNS	_	1	ppmod	_	_
6	,	,	,	_	1	p	_	_
7	treated	treat	VBN	_	1	acl	_	_
8	with	with	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	1	p	_	_
11	should	should	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	treated	treat	VBN	_	0	root	_	_
14	with	with	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	only	only	RB	_	21	adv	_	_
17	if	if	IN	_	21	mark	_	_
18	the	the	DT	_	20	det	_	_
19	potential	potential	JJ	_	20	attr	_	_
20	benefits	benefit	NNS	_	21	dep	_	_
21	outweigh	outweigh	VBP	_	13	comp	_	_
22	the	the	DT	_	23	det	_	_
23	risks	risk	NNS	_	21	obj	_	_
24	.	.	.	_	13	p	_	_

1	Drugs	drug	NNS	_	9	dep	_	_
2	Prolonging	prolong	VBG	_	1	acl	_	_
3	the	the	DT	_	6	det	_	_
4	QT/QTc	qt/qtc	NN	_	6	com	_	_
5	Interval	interval	NN	_	6	com	_	_
6	Caution	caution	NN	_	2	obj	_	_
7	should	should	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	exercised	exercise	VBN	_	0	root	_	_
10	when	when	WRB	_	11	adv	_	_
11	prescribing	prescribe	VBG	_	9	comp	_	_
12	drug1	drug0	NN	_	11	obj	_	_
13	concomitantly	concomitantly	RB	_	11	adv	_	_
14	with	with	IN	_	15	case	_	_
15	drugs	drug	NNS	_	11	ppmod	_	_
16	that	that	WDT	_	17	dep	_	_
17	prolong	prolong	VBP	_	15	relcl	_	_
18	the	the	DT	_	20	det	_	_
19	QT/QTc	qt/qtc	NN	_	20	com	_	_
20	interval	interval	NN	_	17	obj	_	_
21	.	.	.	_	9	p	_	_

1	Drug/Laboratory	drug/laboratory	JJ	_	3	attr	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	5	dep	_	_
4	There	there	RB	_	5	adv	_	_
5	are	be	VBP	_	0	root	_	_
6	no	no	DT	_	8	det	_	_
7	known	known	JJ	_	8	attr	_	_
8	interactions	interaction	NNS	_	5	obj	_	_
9	between	between	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	laboratory	laboratory	NN	_	13	com	_	_
13	tests	test	NNS	_	10	conj	_	_
14	.	.	.	_	5	p	_	_

1	Since	since	IN	_	5	mark	_	_
2	drug1	drug0	NN	_	5	dep	_	_
3	is	be	VBZ	_	5	aux	_	_
4	extensively	extensively	RB	_	5	adv	_	_
5	metabolized	metabolize	VBN	_	14	advcl	_	_
6	by	by	IN	_	9	case	_	_
7	cytochrome	cytochrome	NN	_	8	com	_	_
8	P-450	p-0	NN	_	9	com	_	_
9	isoenzymes	isoenzymes	NNS	_	5	ppmod	_	_
10	,	,	,	_	14	p	_	_
11	caution	caution	NN	_	14	dep	_	_
12	should	should	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	exercised	exercise	VBN	_	0	root	_	_
15	when	when	WRB	_	18	adv	_	_
16	drug2	drug0	NN	_	18	dep	_	_
17	is	be	VBZ	_	18	aux	_	_
18	coadministered	coadministered	VBN	_	14	comp	_	_
19	with	with	IN	_	20	case	_	_
20	inhibitors	inhibitor	NNS	_	18	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	C.P.A.	c.p.a.	NNP	_	20	ppmod	_	_
23	such	such	JJ	_	25	adv	_	_
24	as	as	IN	_	25	case	_	_
25	drug3	drug0	NN	_	20	ppmod	_	_
26	and	and	CC	_	25	cc	_	_
27	drug4	drug0	NN	_	25	conj	_	_
28	or	or	CC	_	20	cc	_	_
29	inhibitors	inhibitor	NNS	_	20	conj	_	_
30	of	of	IN	_	31	case	_	_
31	CYP2C19	cyp0c0	NN	_	29	ppmod	_	_
32	such	such	JJ	_	34	adv	_	_
33	as	as	IN	_	34	case	_	_
34	drug5	drug0	NN	_	29	ppmod	_	_
35	.	.	.	_	14	p	_	_

1	Pharmacokinetic	pharmacokinetic	JJ	_	2	attr	_	_
2	studies	study	NNS	_	4	dep	_	_
3	have	have	VBP	_	4	aux	_	_
4	demonstrated	demonstrate	VBN	_	0	root	_	_
5	that	that	IN	_	10	mark	_	_
6	drug1	drug0	NN	_	10	dep	_	_
7	and	and	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	significantly	significantly	RB	_	10	adv	_	_
10	increased	increase	VBD	_	4	comp	_	_
11	the	the	DT	_	13	det	_	_
12	systemic	systemic	JJ	_	13	attr	_	_
13	exposure	exposure	NN	_	10	obj	_	_
14	of	of	IN	_	15	case	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	and/or	and/or	CC	_	15	cc	_	_
17	its	its	PRP$	_	19	poss	_	_
18	major	major	JJ	_	19	attr	_	_
19	metabolites	metabolite	NNS	_	15	conj	_	_
20	.	.	.	_	4	p	_	_

1	Population	population	NN	_	3	attr	_	_
2	pharmacokinetic	pharmacokinetic	JJ	_	3	attr	_	_
3	studies	study	NNS	_	4	dep	_	_
4	showed	show	VBD	_	0	root	_	_
5	higher	high	JJR	_	6	attr	_	_
6	concentrations	concentration	NNS	_	4	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	among	among	IN	_	10	case	_	_
10	patients	patient	NNS	_	4	ppmod	_	_
11	concurrently	concurrently	RB	_	12	adv	_	_
12	treated	treat	VBN	_	10	acl	_	_
13	with	with	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	,	,	,	_	14	p	_	_
16	an	an	DT	_	17	det	_	_
17	inhibitor	inhibitor	NN	_	14	appo	_	_
18	of	of	IN	_	19	case	_	_
19	C.P.A.	c.p.a.	NN	_	17	ppmod	_	_
20	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	does	do	VBZ	_	7	advcl	_	_
3	not	not	RB	_	2	neg	_	_
4	,	,	,	_	7	p	_	_
5	however	however	RB	_	7	adv	_	_
6	,	,	,	_	7	p	_	_
7	appear	appear	VBP	_	0	root	_	_
8	to	to	TO	_	9	aux	_	_
9	cause	cause	VB	_	7	comp	_	_
10	increased	increase	VBN	_	12	attr	_	_
11	blood	blood	NN	_	12	com	_	_
12	levels	level	NNS	_	9	obj	_	_
13	of	of	IN	_	14	case	_	_
14	drugs	drug	NNS	_	12	ppmod	_	_
15	metabolized	metabolize	VBN	_	14	acl	_	_
16	by	by	IN	_	17	case	_	_
17	CYP3A4	cyp0a0	NN	_	15	ppmod	_	_
18	,	,	,	_	7	p	_	_
19	as	as	IN	_	21	mark	_	_
20	it	it	PRP	_	21	dep	_	_
21	had	have	VBD	_	7	comp	_	_
22	no	no	DT	_	23	det	_	_
23	effect	effect	NN	_	21	obj	_	_
24	on	on	IN	_	25	case	_	_
25	drug2	drug0	NN	_	21	ppmod	_	_
26	,	,	,	_	25	p	_	_
27	a	a	DT	_	28	det	_	_
28	drug	drug	NN	_	25	appo	_	_
29	with	with	IN	_	30	case	_	_
30	metabolism	metabolism	NN	_	28	ppmod	_	_
31	very	very	RB	_	32	adv	_	_
32	sensitive	sensitive	JJ	_	30	attr	_	_
33	to	to	TO	_	35	aux	_	_
34	C.P.A.	c.p.a.	NN	_	35	com	_	_
35	inhibition	inhibition	NN	_	32	ppmod	_	_
36	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	17	dep	_	_
2	used	use	VBN	_	1	acl	_	_
3	in	in	IN	_	4	case	_	_
4	combination	combination	NN	_	2	ppmod	_	_
5	with	with	IN	_	7	case	_	_
6	other	other	JJ	_	7	attr	_	_
7	drugs	drug	NNS	_	4	ppmod	_	_
8	known	know	VBN	_	7	acl	_	_
9	to	to	TO	_	11	aux	_	_
10	adversely	adversely	RB	_	11	adv	_	_
11	affect	affect	VB	_	8	comp	_	_
12	the	the	DT	_	14	det	_	_
13	hematopoietic	hematopoietic	JJ	_	14	attr	_	_
14	system	system	NN	_	11	obj	_	_
15	should	should	MD	_	17	modal	_	_
16	be	be	VB	_	17	aux	_	_
17	avoided	avoid	VBN	_	0	root	_	_
18	if	if	IN	_	19	mark	_	_
19	possible	possible	JJ	_	17	comp	_	_
20	.	.	.	_	17	p	_	_

1	Considerable	considerable	JJ	_	2	attr	_	_
2	caution	caution	NN	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	exercised	exercise	VBN	_	0	root	_	_
6	if	if	IN	_	9	mark	_	_
7	drug1	drug0	NN	_	9	dep	_	_
8	is	be	VBZ	_	9	aux	_	_
9	administered	administer	VBN	_	5	comp	_	_
10	concurrently	concurrently	RB	_	9	adv	_	_
11	with	with	IN	_	12	case	_	_
12	drug2	drug0	NN	_	9	ppmod	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	drug3	drug0	NN	_	12	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	since	since	IN	_	21	mark	_	_
17	paranoid	paranoid	JJ	_	18	attr	_	_
18	symptoms	symptom	NNS	_	21	dep	_	_
19	have	have	VBP	_	21	aux	_	_
20	been	be	VBN	_	21	aux	_	_
21	reported	report	VBN	_	9	comp	_	_
22	during	during	IN	_	23	case	_	_
23	therapy	therapy	NN	_	21	ppmod	_	_
24	with	with	IN	_	26	case	_	_
25	this	this	DT	_	26	det	_	_
26	combination	combination	NN	_	23	ppmod	_	_
27	.	.	.	_	5	p	_	_

1	A	a	DT	_	3	det	_	_
2	two-way	two-way	JJ	_	3	attr	_	_
3	interaction	interaction	NN	_	16	dep	_	_
4	between	between	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	drug1	drug0	NN	_	3	ppmod	_	_
7	,	,	,	_	6	p	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	,	,	,	_	8	p	_	_
10	and	and	CC	_	8	cc	_	_
11	the	the	DT	_	13	det	_	_
12	drug3	drug0	NN	_	13	com	_	_
13	s	s	NNS	_	6	conj	_	_
14	has	have	VBZ	_	16	aux	_	_
15	been	be	VBN	_	16	aux	_	_
16	suggested	suggest	VBN	_	0	root	_	_
17	.	.	.	_	16	p	_	_

1	Presumably	presumably	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	drug1	drug0	NN	_	4	dep	_	_
4	acts	act	VBZ	_	0	root	_	_
5	as	as	IN	_	7	case	_	_
6	a	a	DT	_	7	det	_	_
7	stimulator	stimulator	NN	_	4	ppmod	_	_
8	of	of	IN	_	10	case	_	_
9	drug2	drug0	NN	_	10	com	_	_
10	metabolism	metabolism	NN	_	7	ppmod	_	_
11	and	and	CC	_	4	cc	_	_
12	has	have	VBZ	_	14	aux	_	_
13	been	be	VBN	_	14	aux	_	_
14	reported	report	VBN	_	4	conj	_	_
15	to	to	TO	_	16	aux	_	_
16	cause	cause	VB	_	14	comp	_	_
17	decreased	decrease	VBN	_	19	attr	_	_
18	serum	serum	NN	_	19	com	_	_
19	levels	level	NNS	_	16	obj	_	_
20	of	of	IN	_	22	case	_	_
21	the	the	DT	_	22	det	_	_
22	drug3	drug0	NN	_	19	ppmod	_	_
23	and	and	CC	_	19	cc	_	_
24	increased	increase	VBN	_	26	attr	_	_
25	prothrombin-proconvertin	prothrombin-proconvertin	NN	_	26	com	_	_
26	concentrations	concentration	NNS	_	19	conj	_	_
27	.	.	.	_	4	p	_	_

1	Conversely	conversely	RB	_	7	adv	_	_
2	,	,	,	_	7	p	_	_
3	the	the	DT	_	4	det	_	_
4	drug1	drug0	NNS	_	7	dep	_	_
5	have	have	VBP	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	reported	report	VBN	_	0	root	_	_
8	to	to	TO	_	9	aux	_	_
9	increase	increase	VB	_	7	comp	_	_
10	the	the	DT	_	12	det	_	_
11	serum	serum	NN	_	12	com	_	_
12	levels	level	NNS	_	9	obj	_	_
13	and	and	CC	_	9	cc	_	_
14	prolong	prolong	VB	_	9	conj	_	_
15	the	the	DT	_	17	det	_	_
16	serum	serum	NN	_	17	com	_	_
17	half-life	half-life	NN	_	14	obj	_	_
18	of	of	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	by	by	IN	_	21	case	_	_
21	inhibiting	inhibit	VBG	_	9	ppmod	_	_
22	its	its	PRP$	_	23	poss	_	_
23	metabolism	metabolism	NN	_	21	obj	_	_
24	.	.	.	_	7	p	_	_

1	Although	although	IN	_	3	mark	_	_
2	there	there	EX	_	3	dep	_	_
3	is	be	VBZ	_	18	advcl	_	_
4	no	no	DT	_	5	det	_	_
5	documentation	documentation	NN	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	such	such	JJ	_	5	ppmod	_	_
8	,	,	,	_	18	p	_	_
9	a	a	DT	_	11	det	_	_
10	similar	similar	JJ	_	11	attr	_	_
11	interaction	interaction	NN	_	18	dep	_	_
12	between	between	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	the	the	DT	_	16	det	_	_
16	drug2	drug0	NN	_	13	conj	_	_
17	may	may	MD	_	18	modal	_	_
18	occur	occur	VB	_	0	root	_	_
19	.	.	.	_	18	p	_	_

1	Caution	caution	NN	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	therefore	therefore	RB	_	4	adv	_	_
4	advised	advise	VBN	_	0	root	_	_
5	when	when	WRB	_	6	adv	_	_
6	administering	administer	VBG	_	4	comp	_	_
7	drug1	drug0	NN	_	6	obj	_	_
8	to	to	TO	_	9	aux	_	_
9	patients	patient	NNS	_	6	ppmod	_	_
10	receiving	receive	VBG	_	9	acl	_	_
11	drug2	drug0	NN	_	10	obj	_	_
12	.	.	.	_	4	p	_	_

1	Reduced	reduce	VBN	_	2	attr	_	_
2	efficacy	efficacy	NN	_	14	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	increased	increase	VBN	_	5	attr	_	_
5	incidence	incidence	NN	_	2	conj	_	_
6	of	of	IN	_	8	case	_	_
7	breakthrough	breakthrough	JJ	_	8	attr	_	_
8	bleeding	bleeding	JJ	_	2	ppmod	_	_
9	and	and	CC	_	2	cc	_	_
10	menstrual	menstrual	JJ	_	11	attr	_	_
11	irregularities	irregularity	NNS	_	2	conj	_	_
12	have	have	VBP	_	14	aux	_	_
13	been	be	VBN	_	14	aux	_	_
14	associated	associate	VBN	_	0	root	_	_
15	with	with	IN	_	17	case	_	_
16	concomitant	concomitant	JJ	_	17	attr	_	_
17	use	use	NN	_	14	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug1	drug0	NN	_	17	ppmod	_	_
20	.	.	.	_	14	p	_	_

1	A	a	DT	_	3	det	_	_
2	similar	similar	JJ	_	3	attr	_	_
3	association	association	NN	_	11	dep	_	_
4	,	,	,	_	3	p	_	_
5	though	though	RB	_	7	adv	_	_
6	less	less	RBR	_	7	adv	_	_
7	marked	marked	JJ	_	3	attr	_	_
8	,	,	,	_	3	p	_	_
9	has	have	VBZ	_	11	aux	_	_
10	been	be	VBN	_	11	aux	_	_
11	suggested	suggest	VBN	_	0	root	_	_
12	with	with	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	,	,	,	_	13	p	_	_
15	drug2	drug0	NN	_	13	conj	_	_
16	,	,	,	_	15	p	_	_
17	drug3	drug0	NN	_	13	conj	_	_
18	,	,	,	_	17	p	_	_
19	drug4	drug0	NN	_	13	conj	_	_
20	,	,	,	_	19	p	_	_
21	drug5	drug0	NN	_	13	conj	_	_
22	,	,	,	_	21	p	_	_
23	drug6	drug0	NN	_	13	conj	_	_
24	,	,	,	_	23	p	_	_
25	and	and	CC	_	23	cc	_	_
26	possibly	possibly	RB	_	28	adv	_	_
27	with	with	IN	_	28	case	_	_
28	drug7	drug0	NN	_	13	conj	_	_
29	and	and	CC	_	28	cc	_	_
30	drug8	drug0	NN	_	28	conj	_	_
31	72	0	CD	_	30	num	_	_
32	.	.	.	_	11	p	_	_

1	A	a	DT	_	3	det	_	_
2	possible	possible	JJ	_	3	attr	_	_
3	interaction	interaction	NN	_	6	dep	_	_
4	has	have	VBZ	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	suggested	suggest	VBN	_	0	root	_	_
7	with	with	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	the	the	DT	_	13	det	_	_
11	herbal	herbal	JJ	_	13	attr	_	_
12	supplement	supplement	JJ	_	13	attr	_	_
13	St.	st.	NN	_	15	com	_	_
14	Johns	johns	NNP	_	15	com	_	_
15	Wort	wort	NNP	_	8	conj	_	_
16	based	base	VBN	_	8	acl	_	_
17	on	on	IN	_	19	case	_	_
18	some	some	DT	_	19	det	_	_
19	reports	report	NNS	_	16	ppmod	_	_
20	of	of	IN	_	23	case	_	_
21	oral	oral	JJ	_	23	attr	_	_
22	drug2	drug0	NN	_	23	com	_	_
23	users	user	NNS	_	19	ppmod	_	_
24	experiencing	experience	VBG	_	23	acl	_	_
25	breakthrough	breakthrough	JJ	_	26	attr	_	_
26	bleeding	bleeding	JJ	_	24	obj	_	_
27	shortly	shortly	RB	_	29	adv	_	_
28	after	after	IN	_	29	case	_	_
29	starting	start	VBG	_	24	ppmod	_	_
30	St.	st.	NN	_	29	obj	_	_
31	Johns	johns	NNP	_	32	com	_	_
32	Wort	wort	NNP	_	30	attr	_	_
33	.	.	.	_	6	p	_	_

1	Pregnancies	pregnancy	NNS	_	4	dep	_	_
2	have	have	VBP	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	reported	report	VBN	_	0	root	_	_
5	by	by	IN	_	6	case	_	_
6	users	user	NNS	_	4	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	who	who	WP	_	11	dep	_	_
10	also	also	RB	_	11	adv	_	_
11	used	use	VBD	_	6	relcl	_	_
12	some	some	DT	_	13	det	_	_
13	form	form	NN	_	11	obj	_	_
14	of	of	IN	_	17	case	_	_
15	St.	st.	NN	_	17	com	_	_
16	Johns	johns	NNP	_	17	com	_	_
17	Wort	wort	NNP	_	13	ppmod	_	_
18	.	.	.	_	4	p	_	_

1	Healthcare	healthcare	NN	_	2	com	_	_
2	prescribers	prescriber	NNS	_	4	dep	_	_
3	are	be	VBP	_	4	aux	_	_
4	advised	advise	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	consult	consult	VB	_	4	comp	_	_
7	the	the	DT	_	9	det	_	_
8	package	package	JJ	_	9	attr	_	_
9	inserts	insert	NNS	_	6	obj	_	_
10	of	of	IN	_	11	case	_	_
11	medication	medication	NN	_	9	ppmod	_	_
12	administered	administer	VBN	_	11	acl	_	_
13	concomitantly	concomitantly	RB	_	12	adv	_	_
14	with	with	IN	_	16	case	_	_
15	oral	oral	JJ	_	16	attr	_	_
16	drug1	drug0	NN	_	12	ppmod	_	_
17	.	.	.	_	4	p	_	_

1	Combination	combination	NN	_	2	com	_	_
2	Therapy	therapy	NN	_	26	dep	_	_
3	:	:	:	_	2	p	_	_
4	Any	any	DT	_	5	det	_	_
5	form	form	NN	_	2	appo	_	_
6	of	of	IN	_	7	case	_	_
7	therapy	therapy	NN	_	5	ppmod	_	_
8	which	which	WDT	_	9	dep	_	_
9	adds	add	VBZ	_	5	relcl	_	_
10	to	to	TO	_	12	aux	_	_
11	the	the	DT	_	12	det	_	_
12	stress	stress	NN	_	9	ppmod	_	_
13	of	of	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	patient	patient	NN	_	12	ppmod	_	_
16	,	,	,	_	9	p	_	_
17	interferes	interfere	VBZ	_	9	conj	_	_
18	with	with	IN	_	19	case	_	_
19	nutrition	nutrition	NN	_	17	ppmod	_	_
20	or	or	CC	_	17	cc	_	_
21	depresses	depress	VBZ	_	9	conj	_	_
22	bone	bone	NN	_	23	com	_	_
23	marrow	marrow	NN	_	24	com	_	_
24	function	function	NN	_	21	obj	_	_
25	will	will	MD	_	26	modal	_	_
26	increase	increase	VB	_	0	root	_	_
27	the	the	DT	_	28	det	_	_
28	toxicity	toxicity	NN	_	26	obj	_	_
29	of	of	IN	_	30	case	_	_
30	drug1	drug0	NN	_	28	ppmod	_	_
31	.	.	.	_	26	p	_	_

1	Based	base	VBN	_	5	adv	_	_
2	on	on	IN	_	5	case	_	_
3	in	in	FW	_	4	adv	_	_
4	vitro	vitro	FW	_	5	attr	_	_
5	studies	study	NNS	_	12	ppmod	_	_
6	in	in	IN	_	9	case	_	_
7	human	human	JJ	_	9	attr	_	_
8	liver	liver	NN	_	9	com	_	_
9	microsomes	microsome	NNS	_	5	ppmod	_	_
10	,	,	,	_	12	p	_	_
11	drug1	drug0	NN	_	12	dep	_	_
12	appears	appear	VBZ	_	0	root	_	_
13	to	to	TO	_	14	aux	_	_
14	have	have	VB	_	12	comp	_	_
15	no	no	DT	_	19	det	_	_
16	inhibitory	inhibitory	JJ	_	19	attr	_	_
17	or	or	NN	_	19	com	_	_
18	induction	induction	NN	_	19	com	_	_
19	potential	potential	NN	_	14	obj	_	_
20	on	on	IN	_	22	case	_	_
21	the	the	DT	_	22	det	_	_
22	metabolism	metabolism	NN	_	14	ppmod	_	_
23	of	of	IN	_	25	case	_	_
24	other	other	JJ	_	25	attr	_	_
25	drugs	drug	NNS	_	22	ppmod	_	_
26	metabolized	metabolize	VBN	_	25	acl	_	_
27	by	by	IN	_	28	case	_	_
28	CYP	cyp	VBG	_	26	ppmod	_	_
29	450	0	CD	_	30	num	_	_
30	enzymes	enzyme	NNS	_	28	obj	_	_
31	.	.	.	_	12	p	_	_

1	The	the	DT	_	3	det	_	_
2	inhibitory	inhibitory	JJ	_	3	attr	_	_
3	potential	potential	NN	_	12	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	on	on	IN	_	8	case	_	_
7	CYP450	cyp0	NN	_	8	com	_	_
8	isoenzymes	isoenzymes	NNS	_	3	ppmod	_	_
9	has	have	VBZ	_	12	aux	_	_
10	not	not	RB	_	12	neg	_	_
11	been	be	VBN	_	12	aux	_	_
12	studied	study	VBN	_	0	root	_	_
13	.	.	.	_	12	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	studies	study	NNS	_	4	dep	_	_
4	demonstrated	demonstrate	VBD	_	0	root	_	_
5	that	that	IN	_	14	mark	_	_
6	the	the	DT	_	9	det	_	_
7	plasma	plasma	NN	_	9	com	_	_
8	protein	protein	NN	_	9	com	_	_
9	binding	binding	NN	_	14	dep	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	was	be	VBD	_	14	aux	_	_
13	not	not	RB	_	14	neg	_	_
14	affected	affect	VBN	_	4	comp	_	_
15	by	by	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	or	or	CC	_	16	cc	_	_
18	drug3	drug0	NN	_	16	conj	_	_
19	,	,	,	_	14	p	_	_
20	indicating	indicate	VBG	_	14	comp	_	_
21	no	no	DT	_	22	det	_	_
22	potential	potential	NN	_	20	obj	_	_
23	for	for	IN	_	27	case	_	_
24	protein	protein	NN	_	27	attr	_	_
25	binding-based	binding-based	JJ	_	27	attr	_	_
26	drug	drug	NN	_	27	com	_	_
27	interactions	interaction	NNS	_	22	ppmod	_	_
28	.	.	.	_	4	p	_	_

1	In	in	IN	_	5	case	_	_
2	a	a	DT	_	5	det	_	_
3	drug	drug	NN	_	5	com	_	_
4	interaction	interaction	NN	_	5	com	_	_
5	study	study	NN	_	23	ppmod	_	_
6	,	,	,	_	23	p	_	_
7	co-administration	co-administration	NN	_	23	dep	_	_
8	of	of	IN	_	11	case	_	_
9	orally	orally	RB	_	10	adv	_	_
10	inhaled	inhale	VBN	_	11	attr	_	_
11	drug1	drug0	NN	_	7	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	oral	oral	JJ	_	14	attr	_	_
14	drug2	drug0	NN	_	11	conj	_	_
15	,	,	,	_	11	p	_	_
16	an	an	DT	_	17	det	_	_
17	inhibitor	inhibitor	NN	_	11	appo	_	_
18	of	of	IN	_	21	case	_	_
19	cytochrome	cytochrome	NN	_	21	com	_	_
20	P450	p0	NN	_	21	com	_	_
21	3A4	0a0	NN	_	17	ppmod	_	_
22	,	,	,	_	11	p	_	_
23	had	have	VBD	_	0	root	_	_
24	no	no	DT	_	25	det	_	_
25	effect	effect	NN	_	23	obj	_	_
26	on	on	IN	_	28	case	_	_
27	the	the	DT	_	28	det	_	_
28	pharmacokinetics	pharmacokinetics	NNS	_	23	ppmod	_	_
29	of	of	IN	_	31	case	_	_
30	either	either	CC	_	31	cc	_	_
31	drug3	drug0	NN	_	28	ppmod	_	_
32	or	or	CC	_	31	cc	_	_
33	drug4	drug0	NN	_	31	conj	_	_
34	.	.	.	_	23	p	_	_

1	In	in	IN	_	5	case	_	_
2	another	another	DT	_	5	det	_	_
3	drug	drug	NN	_	5	com	_	_
4	interaction	interaction	NN	_	5	com	_	_
5	study	study	NN	_	24	ppmod	_	_
6	,	,	,	_	24	p	_	_
7	co-administration	co-administration	NN	_	24	dep	_	_
8	of	of	IN	_	11	case	_	_
9	orally	orally	RB	_	10	adv	_	_
10	inhaled	inhale	VBN	_	11	attr	_	_
11	drug1	drug0	NN	_	7	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	oral	oral	JJ	_	14	attr	_	_
14	drug2	drug0	NN	_	11	conj	_	_
15	,	,	,	_	11	p	_	_
16	a	a	DT	_	18	det	_	_
17	potent	potent	JJ	_	18	attr	_	_
18	inhibitor	inhibitor	NN	_	11	appo	_	_
19	of	of	IN	_	22	case	_	_
20	cytochrome	cytochrome	NN	_	22	com	_	_
21	P450	p0	NN	_	22	com	_	_
22	3A4	0a0	NN	_	18	ppmod	_	_
23	,	,	,	_	11	p	_	_
24	increased	increase	VBD	_	0	root	_	_
25	the	the	DT	_	26	det	_	_
26	exposure	exposure	NN	_	24	obj	_	_
27	(	-lrb-	-LRB-	_	28	p	_	_
28	AUC	auc	NN	_	26	prn	_	_
29	)	-rrb-	-RRB-	_	28	p	_	_
30	of	of	IN	_	31	case	_	_
31	drug3	drug0	NN	_	26	ppmod	_	_
32	by	by	IN	_	34	case	_	_
33	approximately	approximately	RB	_	34	adv	_	_
34	3.6-fold	0-fold	NN	_	24	ppmod	_	_
35	at	at	IN	_	37	case	_	_
36	steady	steady	JJ	_	37	attr	_	_
37	state	state	NN	_	34	ppmod	_	_
38	,	,	,	_	24	p	_	_
39	while	while	IN	_	43	mark	_	_
40	levels	level	NNS	_	43	dep	_	_
41	of	of	IN	_	42	case	_	_
42	drug4	drug0	NN	_	40	ppmod	_	_
43	remained	remain	VBD	_	24	comp	_	_
44	unchanged	unchanged	JJ	_	43	dep	_	_
45	.	.	.	_	24	p	_	_

1	Therefore	therefore	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	drug1	drug0	NN	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	administered	administer	VBN	_	0	root	_	_
7	with	with	IN	_	8	case	_	_
8	caution	caution	NN	_	6	ppmod	_	_
9	with	with	IN	_	11	case	_	_
10	intranasal	intranasal	JJ	_	11	attr	_	_
11	drug2	drug0	NN	_	6	ppmod	_	_
12	.	.	.	_	6	p	_	_

1	No	no	DT	_	5	det	_	_
2	clinically	clinically	RB	_	3	adv	_	_
3	significant	significant	JJ	_	5	attr	_	_
4	adverse	adverse	JJ	_	5	attr	_	_
5	interactions	interaction	NNS	_	28	dep	_	_
6	with	with	IN	_	10	case	_	_
7	commonly	commonly	RB	_	8	adv	_	_
8	used	use	VBN	_	10	attr	_	_
9	preanesthetic	preanesthetic	JJ	_	10	attr	_	_
10	drugs	drug	NNS	_	5	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	or	or	CC	_	10	cc	_	_
13	drugs	drug	NNS	_	10	conj	_	_
14	used	use	VBN	_	13	acl	_	_
15	during	during	IN	_	16	case	_	_
16	anesthesia	anesthesia	NN	_	14	ppmod	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	drug1	drug0	NN	_	13	prn	_	_
19	,	,	,	_	18	p	_	_
20	intravenous	intravenous	JJ	_	21	attr	_	_
21	agents	agent	NNS	_	18	conj	_	_
22	,	,	,	_	21	p	_	_
23	and	and	CC	_	21	cc	_	_
24	local	local	JJ	_	25	attr	_	_
25	drug2	drug0	NN	_	18	conj	_	_
26	)	-rrb-	-RRB-	_	18	p	_	_
27	were	be	VBD	_	28	aux	_	_
28	reported	report	VBN	_	0	root	_	_
29	in	in	IN	_	31	case	_	_
30	clinical	clinical	JJ	_	31	attr	_	_
31	trials	trial	NNS	_	28	ppmod	_	_
32	.	.	.	_	28	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	14	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	on	on	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	disposition	disposition	NN	_	2	ppmod	_	_
8	of	of	IN	_	10	case	_	_
9	other	other	JJ	_	10	attr	_	_
10	drugs	drug	NNS	_	7	ppmod	_	_
11	has	have	VBZ	_	14	aux	_	_
12	not	not	RB	_	14	neg	_	_
13	been	be	VBN	_	14	aux	_	_
14	determined	determine	VBN	_	0	root	_	_
15	.	.	.	_	14	p	_	_

1	Like	like	IN	_	2	case	_	_
2	drug1	drug0	NN	_	7	ppmod	_	_
3	,	,	,	_	7	p	_	_
4	drug2	drug0	NN	_	7	dep	_	_
5	does	do	VBZ	_	7	aux	_	_
6	not	not	RB	_	7	neg	_	_
7	predispose	predispose	VB	_	0	root	_	_
8	to	to	TO	_	11	aux	_	_
9	premature	premature	JJ	_	11	attr	_	_
10	ventricular	ventricular	JJ	_	11	attr	_	_
11	arrhythmias	arrhythmia	NNS	_	7	ppmod	_	_
12	in	in	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	presence	presence	NN	_	7	ppmod	_	_
15	of	of	IN	_	18	case	_	_
16	exogenously	exogenously	RB	_	17	adv	_	_
17	infused	infuse	VBN	_	18	attr	_	_
18	drug3	drug0	NN	_	14	ppmod	_	_
19	in	in	IN	_	20	case	_	_
20	swine	swine	NN	_	14	ppmod	_	_
21	.	.	.	_	7	p	_	_

1	Because	because	IN	_	4	mark	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	metabolized	metabolize	VBN	_	21	advcl	_	_
5	by	by	IN	_	7	case	_	_
6	a	a	DT	_	7	det	_	_
7	variety	variety	NN	_	4	ppmod	_	_
8	of	of	IN	_	12	case	_	_
9	hepatic	hepatic	JJ	_	12	attr	_	_
10	CYP	cyp	JJ	_	12	attr	_	_
11	drug-metabolizing	drug-metabolizing	JJ	_	12	attr	_	_
12	enzymes	enzyme	NNS	_	7	ppmod	_	_
13	,	,	,	_	21	p	_	_
14	inducers	inducer	NNS	_	21	dep	_	_
15	or	or	CC	_	14	cc	_	_
16	inhibitors	inhibitor	NNS	_	14	conj	_	_
17	of	of	IN	_	19	case	_	_
18	these	these	DT	_	19	det	_	_
19	enzymes	enzyme	NNS	_	14	ppmod	_	_
20	may	may	MD	_	21	modal	_	_
21	change	change	VB	_	0	root	_	_
22	the	the	DT	_	23	det	_	_
23	clearance	clearance	NN	_	21	obj	_	_
24	of	of	IN	_	25	case	_	_
25	drug2	drug0	NN	_	23	ppmod	_	_
26	.	.	.	_	21	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	a	a	DT	_	6	det	_	_
4	known	known	JJ	_	6	attr	_	_
5	strong	strong	JJ	_	6	attr	_	_
6	inhibitor	inhibitor	NN	_	2	obj	_	_
7	of	of	IN	_	8	case	_	_
8	CYP1A2	cyp0a0	NN	_	6	ppmod	_	_
9	and	and	CC	_	2	cc	_	_
10	also	also	RB	_	11	adv	_	_
11	inhibits	inhibit	VBZ	_	2	conj	_	_
12	CYP3A4	cyp0a0	NN	_	11	obj	_	_
13	,	,	,	_	12	p	_	_
14	CYP2C9	cyp0c0	NN	_	12	conj	_	_
15	,	,	,	_	14	p	_	_
16	and	and	CC	_	14	cc	_	_
17	CYP2C19	cyp0c0	NN	_	12	conj	_	_
18	.	.	.	_	2	p	_	_

1	In	in	IN	_	4	case	_	_
2	a	a	DT	_	4	det	_	_
3	pharmacokinetic	pharmacokinetic	JJ	_	4	attr	_	_
4	study	study	NN	_	10	ppmod	_	_
5	,	,	,	_	10	p	_	_
6	40	0	CD	_	9	num	_	_
7	healthy	healthy	JJ	_	9	attr	_	_
8	female	female	NN	_	9	com	_	_
9	subjects	subject	NNS	_	10	dep	_	_
10	received	receive	VBD	_	0	root	_	_
11	drug1	drug0	NN	_	10	obj	_	_
12	in	in	IN	_	14	case	_	_
13	escalating	escalating	JJ	_	14	attr	_	_
14	doses	dose	NNS	_	11	ppmod	_	_
15	from	from	IN	_	19	case	_	_
16	50	0	CD	_	19	num	_	_
17	to	to	TO	_	16	cc	_	_
18	200	0	CD	_	16	conj	_	_
19	mg	mg	NN	_	14	ppmod	_	_
20	per	per	IN	_	21	case	_	_
21	day	day	NN	_	19	ppmod	_	_
22	for	for	IN	_	24	case	_	_
23	16	0	CD	_	24	num	_	_
24	days	day	NNS	_	19	ppmod	_	_
25	,	,	,	_	10	p	_	_
26	with	with	IN	_	27	case	_	_
27	coadministration	coadministration	NN	_	10	ppmod	_	_
28	of	of	IN	_	31	case	_	_
29	drug2	drug0	NN	_	31	attr	_	_
30	1	0	CD	_	31	num	_	_
31	mg	mg	NN	_	27	ppmod	_	_
32	on	on	IN	_	35	case	_	_
33	the	the	DT	_	35	det	_	_
34	last	last	JJ	_	35	attr	_	_
35	day	day	NN	_	31	ppmod	_	_
36	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	increased	increase	VBD	_	0	root	_	_
3	mean	mean	JJ	_	6	attr	_	_
4	drug2	drug0	NN	_	6	com	_	_
5	plasma	plasma	NN	_	6	com	_	_
6	concentrations	concentration	NNS	_	2	obj	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	AUC	auc	NN	_	6	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	approximately	approximately	RB	_	11	com	_	_
11	6-fold	0-fold	RB	_	2	adv	_	_
12	and	and	CC	_	2	cc	_	_
13	prolonged	prolong	VBD	_	2	conj	_	_
14	the	the	DT	_	15	det	_	_
15	half-life	half-life	NN	_	13	obj	_	_
16	by	by	IN	_	18	case	_	_
17	approximately	approximately	RB	_	18	com	_	_
18	3-fold	0-fold	RB	_	13	ppmod	_	_
19	.	.	.	_	2	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	administration	administration	NN	_	8	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	is	be	VBZ	_	8	aux	_	_
8	contraindicated	contraindicate	VBN	_	0	root	_	_
9	.	.	.	_	8	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	administration	administration	NN	_	18	dep	_	_
3	of	of	IN	_	8	case	_	_
4	drug1	drug0	JJ	_	8	attr	_	_
5	and	and	CC	_	4	cc	_	_
6	moderate	moderate	JJ	_	4	conj	_	_
7	CYP1A2	cyp0a0	NN	_	8	com	_	_
8	inhibitors	inhibitor	NNS	_	2	ppmod	_	_
9	,	,	,	_	8	p	_	_
10	including	include	VBG	_	11	adv	_	_
11	drug2	drug0	NN	_	8	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	drug3	drug0	NN	_	11	conj	_	_
14	,	,	,	_	8	p	_	_
15	has	have	VBZ	_	18	aux	_	_
16	not	not	RB	_	18	neg	_	_
17	been	be	VBN	_	18	aux	_	_
18	evaluated	evaluate	VBN	_	0	root	_	_
19	,	,	,	_	18	p	_	_
20	but	but	CC	_	18	cc	_	_
21	should	should	MD	_	23	modal	_	_
22	be	be	VB	_	23	aux	_	_
23	avoided	avoid	VBN	_	18	conj	_	_
24	unless	unless	IN	_	26	case	_	_
25	clinically	clinically	RB	_	26	adv	_	_
26	necessary	necessary	JJ	_	23	ppmod	_	_
27	because	because	IN	_	32	case	_	_
28	of	of	IN	_	32	case	_	_
29	similar	similar	JJ	_	32	attr	_	_
30	potential	potential	JJ	_	32	attr	_	_
31	drug	drug	NN	_	32	com	_	_
32	interactions	interaction	NNS	_	23	ppmod	_	_
33	.	.	.	_	18	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	a	a	DT	_	6	det	_	_
4	known	known	JJ	_	6	attr	_	_
5	strong	strong	JJ	_	6	attr	_	_
6	inhibitor	inhibitor	NN	_	2	obj	_	_
7	of	of	IN	_	8	case	_	_
8	CYP3A4	cyp0a0	NN	_	6	ppmod	_	_
9	.	.	.	_	2	p	_	_

1	In	in	IN	_	4	case	_	_
2	a	a	DT	_	4	det	_	_
3	pharmacokinetic	pharmacokinetic	JJ	_	4	attr	_	_
4	study	study	NN	_	10	ppmod	_	_
5	,	,	,	_	10	p	_	_
6	38	0	CD	_	9	num	_	_
7	healthy	healthy	JJ	_	9	attr	_	_
8	female	female	JJ	_	9	attr	_	_
9	subjects	subject	NNS	_	10	dep	_	_
10	received	receive	VBD	_	0	root	_	_
11	drug1	drug0	NN	_	13	attr	_	_
12	200	0	CD	_	13	num	_	_
13	mg	mg	NN	_	10	obj	_	_
14	twice	twice	RB	_	15	adv	_	_
15	daily	daily	JJ	_	13	attr	_	_
16	for	for	IN	_	18	case	_	_
17	7	0	CD	_	18	num	_	_
18	days	day	NNS	_	15	ppmod	_	_
19	,	,	,	_	10	p	_	_
20	with	with	IN	_	21	case	_	_
21	coadministration	coadministration	NN	_	10	ppmod	_	_
22	of	of	IN	_	25	case	_	_
23	drug2	drug0	NN	_	25	attr	_	_
24	1	0	CD	_	25	num	_	_
25	mg	mg	NN	_	21	ppmod	_	_
26	on	on	IN	_	29	case	_	_
27	the	the	DT	_	29	det	_	_
28	last	last	JJ	_	29	attr	_	_
29	day	day	NN	_	25	ppmod	_	_
30	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	increased	increase	VBD	_	0	root	_	_
3	mean	mean	JJ	_	6	attr	_	_
4	drug2	drug0	NN	_	6	com	_	_
5	plasma	plasma	NN	_	6	com	_	_
6	concentrations	concentration	NNS	_	2	obj	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	AUC	auc	NN	_	6	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	by	by	IN	_	11	case	_	_
11	29	0	CD	_	2	ppmod	_	_
12	%	%	NN	_	11	meta	_	_
13	.	.	.	_	2	p	_	_

1	Caution	caution	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	used	use	VBN	_	0	root	_	_
5	when	when	WRB	_	10	adv	_	_
6	drug1	drug0	NN	_	10	dep	_	_
7	and	and	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	are	be	VBP	_	10	aux	_	_
10	administered	administer	VBN	_	4	comp	_	_
11	concomitantly	concomitantly	RB	_	10	adv	_	_
12	.	.	.	_	4	p	_	_

1	Coadministration	coadministration	NN	_	24	dep	_	_
2	of	of	IN	_	7	case	_	_
3	drug1	drug0	JJ	_	7	attr	_	_
4	and	and	CC	_	3	cc	_	_
5	strong	strong	JJ	_	3	conj	_	_
6	CYP3A4	cyp0a0	JJ	_	7	attr	_	_
7	inhibitors	inhibitor	NNS	_	1	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	such	such	JJ	_	11	adv	_	_
10	as	as	IN	_	11	case	_	_
11	drug2	drug0	NN	_	7	ppmod	_	_
12	,	,	,	_	11	p	_	_
13	drug3	drug0	NN	_	11	conj	_	_
14	,	,	,	_	13	p	_	_
15	drug4	drug0	NN	_	11	conj	_	_
16	,	,	,	_	15	p	_	_
17	drug5	drug0	NN	_	11	conj	_	_
18	,	,	,	_	17	p	_	_
19	and	and	CC	_	17	cc	_	_
20	drug6	drug0	NN	_	11	conj	_	_
21	has	have	VBZ	_	24	aux	_	_
22	not	not	RB	_	24	neg	_	_
23	been	be	VBN	_	24	aux	_	_
24	evaluated	evaluate	VBN	_	0	root	_	_
25	but	but	CC	_	24	cc	_	_
26	should	should	MD	_	28	modal	_	_
27	be	be	VB	_	28	aux	_	_
28	undertaken	undertake	VBN	_	24	conj	_	_
29	with	with	IN	_	30	case	_	_
30	caution	caution	NN	_	28	ppmod	_	_
31	because	because	IN	_	36	case	_	_
32	of	of	IN	_	36	case	_	_
33	similar	similar	JJ	_	36	attr	_	_
34	potential	potential	JJ	_	36	attr	_	_
35	drug	drug	NN	_	36	com	_	_
36	interactions	interaction	NNS	_	28	ppmod	_	_
37	.	.	.	_	24	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	19	dep	_	_
3	of	of	IN	_	4	case	_	_
4	induction	induction	NN	_	2	ppmod	_	_
5	or	or	CC	_	4	cc	_	_
6	inhibition	inhibition	NN	_	4	conj	_	_
7	of	of	IN	_	9	case	_	_
8	other	other	JJ	_	9	attr	_	_
9	pathways	pathway	NNS	_	4	ppmod	_	_
10	on	on	IN	_	11	case	_	_
11	exposure	exposure	NN	_	2	ppmod	_	_
12	to	to	TO	_	13	aux	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	its	its	PRP$	_	16	poss	_	_
16	metabolites	metabolite	NNS	_	13	conj	_	_
17	is	be	VBZ	_	19	aux	_	_
18	not	not	RB	_	19	neg	_	_
19	known	know	VBN	_	0	root	_	_
20	.	.	.	_	19	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	6	attr	_	_
3	human	human	JJ	_	6	attr	_	_
4	liver	liver	NN	_	6	com	_	_
5	microsome	microsome	NN	_	6	com	_	_
6	studies	study	NNS	_	14	dep	_	_
7	and	and	CC	_	6	cc	_	_
8	an	an	DT	_	13	det	_	_
9	in	in	FW	_	10	adv	_	_
10	vivo	vivo	FW	_	13	attr	_	_
11	metabolic	metabolic	JJ	_	13	attr	_	_
12	probe	probe	NN	_	13	com	_	_
13	study	study	NN	_	6	conj	_	_
14	demonstrated	demonstrate	VBD	_	0	root	_	_
15	that	that	IN	_	19	mark	_	_
16	drug1	drug0	NN	_	19	dep	_	_
17	did	do	VBD	_	19	aux	_	_
18	not	not	RB	_	19	neg	_	_
19	inhibit	inhibit	VB	_	14	comp	_	_
20	CYP	cyp	JJ	_	21	attr	_	_
21	enzymes	enzyme	NNS	_	19	obj	_	_
22	2D6	0d0	NN	_	21	attr	_	_
23	,	,	,	_	22	p	_	_
24	3A4	0a0	NN	_	22	conj	_	_
25	,	,	,	_	24	p	_	_
26	2C9	0c0	NN	_	22	conj	_	_
27	,	,	,	_	26	p	_	_
28	or	or	CC	_	26	cc	_	_
29	2C19	0c0	NN	_	22	conj	_	_
30	.	.	.	_	14	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	21	adv	_	_
3	,	,	,	_	21	p	_	_
4	at	at	IN	_	7	case	_	_
5	total	total	JJ	_	7	attr	_	_
6	drug	drug	NN	_	7	com	_	_
7	concentrations	concentration	NNS	_	21	ppmod	_	_
8	27-fold	0-fold	RB	_	9	adv	_	_
9	higher	high	JJR	_	7	attr	_	_
10	than	than	IN	_	13	case	_	_
11	peak	peak	NN	_	13	com	_	_
12	plasma	plasma	NN	_	13	com	_	_
13	concentrations	concentration	NNS	_	9	ppmod	_	_
14	observed	observe	VBN	_	13	acl	_	_
15	with	with	IN	_	18	case	_	_
16	the	the	DT	_	18	det	_	_
17	1-mg	0-mg	JJ	_	18	attr	_	_
18	dosage	dosage	NN	_	14	ppmod	_	_
19	,	,	,	_	21	p	_	_
20	drug1	drug0	NN	_	21	dep	_	_
21	inhibited	inhibit	VBD	_	0	root	_	_
22	CYP	cyp	CD	_	24	num	_	_
23	enzymes	enzyme	NNS	_	24	com	_	_
24	1A2	0a0	NN	_	21	obj	_	_
25	(	-lrb-	-LRB-	_	26	p	_	_
26	60	0	CD	_	24	num	_	_
27	%	%	NN	_	26	meta	_	_
28	)	-rrb-	-RRB-	_	26	p	_	_
29	and	and	CC	_	24	cc	_	_
30	2E1	0e0	NN	_	24	conj	_	_
31	(	-lrb-	-LRB-	_	32	p	_	_
32	50	0	CD	_	30	num	_	_
33	%	%	NN	_	32	meta	_	_
34	)	-rrb-	-RRB-	_	32	p	_	_
35	.	.	.	_	21	p	_	_

1	In	in	IN	_	7	case	_	_
2	an	an	DT	_	7	det	_	_
3	in	in	FW	_	4	adv	_	_
4	vivo	vivo	FW	_	7	attr	_	_
5	metabolic	metabolic	JJ	_	7	attr	_	_
6	probe	probe	NN	_	7	com	_	_
7	study	study	NN	_	12	ppmod	_	_
8	,	,	,	_	12	p	_	_
9	drug1	drug0	NN	_	12	dep	_	_
10	did	do	VBD	_	12	aux	_	_
11	not	not	RB	_	12	neg	_	_
12	inhibit	inhibit	VB	_	0	root	_	_
13	CYP2E1	cyp0e0	NN	_	12	obj	_	_
14	but	but	CC	_	12	cc	_	_
15	did	do	VBD	_	16	aux	_	_
16	produce	produce	VB	_	12	conj	_	_
17	30	0	CD	_	19	num	_	_
18	%	%	NN	_	17	meta	_	_
19	inhibition	inhibition	NN	_	16	obj	_	_
20	of	of	IN	_	22	case	_	_
21	both	both	CC	_	22	cc	_	_
22	CYP1A2	cyp0a0	NN	_	19	ppmod	_	_
23	and	and	CC	_	22	cc	_	_
24	N-acetyltransferase	n-acetyltransferase	NN	_	22	conj	_	_
25	.	.	.	_	12	p	_	_

1	Although	although	IN	_	3	mark	_	_
2	not	not	RB	_	3	neg	_	_
3	studied	study	VBN	_	11	advcl	_	_
4	with	with	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	,	,	,	_	11	p	_	_
7	inhibition	inhibition	NN	_	11	dep	_	_
8	of	of	IN	_	9	case	_	_
9	N-acetyltransferase	n-acetyltransferase	NN	_	7	ppmod	_	_
10	may	may	MD	_	11	modal	_	_
11	have	have	VB	_	0	root	_	_
12	clinically	clinically	RB	_	13	adv	_	_
13	relevant	relevant	JJ	_	14	attr	_	_
14	consequences	consequence	NNS	_	11	obj	_	_
15	for	for	IN	_	16	case	_	_
16	drugs	drug	NNS	_	11	ppmod	_	_
17	such	such	JJ	_	19	adv	_	_
18	as	as	IN	_	19	case	_	_
19	drug2	drug0	NN	_	16	ppmod	_	_
20	,	,	,	_	19	p	_	_
21	drug3	drug0	NN	_	19	conj	_	_
22	,	,	,	_	21	p	_	_
23	and	and	CC	_	21	cc	_	_
24	drug4	drug0	NN	_	19	conj	_	_
25	.	.	.	_	11	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	6	dep	_	_
3	on	on	IN	_	4	case	_	_
4	CYP1A2	cyp0a0	NN	_	2	ppmod	_	_
5	was	be	VBD	_	6	aux	_	_
6	explored	explore	VBN	_	0	root	_	_
7	further	far	RB	_	6	adv	_	_
8	in	in	IN	_	12	case	_	_
9	a	a	DT	_	12	det	_	_
10	clinical	clinical	JJ	_	12	attr	_	_
11	interaction	interaction	NN	_	12	com	_	_
12	study	study	NN	_	6	ppmod	_	_
13	with	with	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	and	and	CC	_	6	cc	_	_
16	no	no	DT	_	17	det	_	_
17	effect	effect	NN	_	21	dep	_	_
18	on	on	IN	_	19	case	_	_
19	metabolism	metabolism	NN	_	17	ppmod	_	_
20	was	be	VBD	_	21	aux	_	_
21	observed	observe	VBN	_	6	conj	_	_
22	.	.	.	_	6	p	_	_

1	Another	another	DT	_	2	det	_	_
2	study	study	NN	_	3	dep	_	_
3	showed	show	VBD	_	0	root	_	_
4	that	that	IN	_	6	mark	_	_
5	drug1	drug0	NN	_	6	dep	_	_
6	had	have	VBD	_	3	comp	_	_
7	no	no	DT	_	10	det	_	_
8	clinically	clinically	RB	_	9	adv	_	_
9	significant	significant	JJ	_	10	attr	_	_
10	effect	effect	NN	_	6	obj	_	_
11	on	on	IN	_	13	case	_	_
12	plasma	plasma	NN	_	13	com	_	_
13	concentrations	concentration	NNS	_	6	ppmod	_	_
14	of	of	IN	_	18	case	_	_
15	the	the	DT	_	18	det	_	_
16	oral	oral	JJ	_	18	attr	_	_
17	drug2	drug0	NN	_	18	com	_	_
18	drug3	drug0	NN	_	13	ppmod	_	_
19	and	and	CC	_	18	cc	_	_
20	drug4	drug0	NNS	_	18	conj	_	_
21	(	-lrb-	-LRB-	_	23	p	_	_
22	CYP3A4	cyp0a0	NN	_	23	com	_	_
23	substrates	substrate	NNS	_	20	prn	_	_
24	)	-rrb-	-RRB-	_	23	p	_	_
25	.	.	.	_	3	p	_	_

1	A	a	DT	_	4	det	_	_
2	clinical	clinical	JJ	_	4	attr	_	_
3	interaction	interaction	NN	_	4	com	_	_
4	study	study	NN	_	7	dep	_	_
5	was	be	VBD	_	7	aux	_	_
6	also	also	RB	_	7	adv	_	_
7	conducted	conduct	VBN	_	0	root	_	_
8	with	with	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	the	the	DT	_	14	det	_	_
12	CYP3A4	cyp0a0	NN	_	14	com	_	_
13	substrate	substrate	NN	_	14	com	_	_
14	drug2	drug0	NN	_	9	conj	_	_
15	.	.	.	_	7	p	_	_

1	No	no	DT	_	3	det	_	_
2	significant	significant	JJ	_	3	attr	_	_
3	effects	effect	NNS	_	11	dep	_	_
4	on	on	IN	_	6	case	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	metabolism	metabolism	NN	_	3	ppmod	_	_
7	or	or	CC	_	6	cc	_	_
8	QT	qt	NN	_	9	com	_	_
9	interval	interval	NN	_	6	conj	_	_
10	were	be	VBD	_	11	aux	_	_
11	noted	note	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	21	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	on	on	IN	_	7	case	_	_
6	monoamine	monoamine	NN	_	7	com	_	_
7	oxidases	oxidase	NNS	_	2	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	on	on	IN	_	12	case	_	_
10	intestinal	intestinal	JJ	_	12	attr	_	_
11	first	#ord#	JJ	_	12	attr	_	_
12	pass	pass	NN	_	7	conj	_	_
13	secondary	secondary	JJ	_	12	attr	_	_
14	to	to	TO	_	17	aux	_	_
15	high	high	JJ	_	17	attr	_	_
16	intraluminal	intraluminal	JJ	_	17	attr	_	_
17	concentrations	concentration	NNS	_	13	ppmod	_	_
18	have	have	VBP	_	21	aux	_	_
19	not	not	RB	_	21	neg	_	_
20	been	be	VBN	_	21	aux	_	_
21	examined	examine	VBN	_	0	root	_	_
22	.	.	.	_	21	p	_	_

1	Based	base	VBN	_	5	adv	_	_
2	on	on	IN	_	5	case	_	_
3	the	the	DT	_	5	det	_	_
4	above	above	JJ	_	5	attr	_	_
5	data	datum	NNS	_	15	ppmod	_	_
6	from	from	IN	_	12	case	_	_
7	in	in	FW	_	8	adv	_	_
8	vitro	vitro	FW	_	12	attr	_	_
9	and	and	CC	_	8	cc	_	_
10	in	in	FW	_	11	adv	_	_
11	vivo	vivo	FW	_	8	conj	_	_
12	studies	study	NNS	_	5	ppmod	_	_
13	,	,	,	_	15	p	_	_
14	it	it	PRP	_	15	dep	_	_
15	is	be	VBZ	_	0	root	_	_
16	unlikely	unlikely	JJ	_	15	dep	_	_
17	that	that	IN	_	20	mark	_	_
18	drug1	drug0	NN	_	20	dep	_	_
19	will	will	MD	_	20	modal	_	_
20	inhibit	inhibit	VB	_	16	comp	_	_
21	the	the	DT	_	24	det	_	_
22	hepatic	hepatic	JJ	_	24	attr	_	_
23	metabolic	metabolic	JJ	_	24	attr	_	_
24	clearance	clearance	NN	_	20	obj	_	_
25	of	of	IN	_	26	case	_	_
26	drugs	drug	NNS	_	24	ppmod	_	_
27	metabolized	metabolize	VBN	_	26	acl	_	_
28	by	by	IN	_	33	case	_	_
29	the	the	DT	_	33	det	_	_
30	major	major	JJ	_	33	attr	_	_
31	CYP	cyp	NN	_	33	com	_	_
32	enzyme	enzyme	NN	_	33	com	_	_
33	3A4	0a0	NN	_	27	ppmod	_	_
34	,	,	,	_	33	p	_	_
35	as	as	RB	_	36	com	_	_
36	well	well	RB	_	33	cc	_	_
37	as	as	IN	_	36	com	_	_
38	the	the	DT	_	41	det	_	_
39	CYP	cyp	NN	_	41	com	_	_
40	enzymes	enzyme	NNS	_	41	com	_	_
41	2D6	0d0	NN	_	33	conj	_	_
42	,	,	,	_	41	p	_	_
43	2C9	0c0	NN	_	33	conj	_	_
44	,	,	,	_	43	p	_	_
45	2C19	0c0	NN	_	33	conj	_	_
46	,	,	,	_	45	p	_	_
47	2E1	0e0	NN	_	33	conj	_	_
48	,	,	,	_	47	p	_	_
49	or	or	CC	_	47	cc	_	_
50	1A2	0a0	NN	_	33	conj	_	_
51	.	.	.	_	15	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	does	do	VBZ	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	appear	appear	VB	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	induce	induce	VB	_	4	comp	_	_
7	the	the	DT	_	10	det	_	_
8	major	major	JJ	_	10	attr	_	_
9	cytochrome	cytochrome	NN	_	10	com	_	_
10	P450	p0	NN	_	6	obj	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	CYP	cyp	NN	_	10	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	drug	drug	NN	_	17	com	_	_
15	metabolizing	metabolizing	NN	_	17	com	_	_
16	enzyme	enzyme	NN	_	17	com	_	_
17	3A	0a	NN	_	10	appo	_	_
18	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	also	also	RB	_	5	adv	_	_
3	does	do	VBZ	_	5	aux	_	_
4	not	not	RB	_	5	neg	_	_
5	appear	appear	VB	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	induce	induce	VB	_	5	comp	_	_
8	CYP	cyp	JJ	_	9	attr	_	_
9	enzymes	enzyme	NNS	_	7	obj	_	_
10	2E1	0e0	NN	_	9	attr	_	_
11	or	or	CC	_	10	cc	_	_
12	2C19	0c0	NN	_	10	conj	_	_
13	.	.	.	_	5	p	_	_

1	It	it	PRP	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	known	know	VBN	_	0	root	_	_
5	whether	whether	IN	_	8	mark	_	_
6	drug1	drug0	NN	_	8	dep	_	_
7	might	might	MD	_	8	modal	_	_
8	induce	induce	VBP	_	4	comp	_	_
9	other	other	JJ	_	10	attr	_	_
10	enzymes	enzyme	NNS	_	8	obj	_	_
11	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	-	-	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	was	be	VBD	_	5	aux	_	_
5	observed	observe	VBN	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	enhance	enhance	VBP	_	5	comp	_	_
8	(	-lrb-	-LRB-	_	11	p	_	_
9	in	in	IN	_	11	case	_	_
10	tissue	tissue	NN	_	11	com	_	_
11	culture	culture	NN	_	7	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	the	the	DT	_	14	det	_	_
14	effect	effect	NN	_	7	obj	_	_
15	of	of	IN	_	16	case	_	_
16	drug3	drug0	NN	_	14	ppmod	_	_
17	in	in	IN	_	18	case	_	_
18	reducing	reduce	VBG	_	14	ppmod	_	_
19	the	the	DT	_	20	det	_	_
20	number	number	NN	_	18	obj	_	_
21	of	of	IN	_	25	case	_	_
22	human	human	JJ	_	25	attr	_	_
23	breast	breast	NN	_	25	com	_	_
24	cancer	cancer	NN	_	25	com	_	_
25	cells	cell	NNS	_	20	ppmod	_	_
26	that	that	WDT	_	27	dep	_	_
27	were	be	VBD	_	25	relcl	_	_
28	in	in	IN	_	31	case	_	_
29	the	the	DT	_	31	det	_	_
30	S	s	NN	_	31	com	_	_
31	phase	phase	NN	_	27	ppmod	_	_
32	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	-	-	:	_	1	p	_	_
5	Although	although	IN	_	7	mark	_	_
6	not	not	RB	_	7	neg	_	_
7	reported	report	VBN	_	18	advcl	_	_
8	,	,	,	_	18	p	_	_
9	drug3	drug0	NN	_	18	dep	_	_
10	,	,	,	_	9	p	_	_
11	via	via	IN	_	13	case	_	_
12	its	its	PRP$	_	13	poss	_	_
13	metabolism	metabolism	NN	_	9	ppmod	_	_
14	to	to	TO	_	15	aux	_	_
15	histamine	histamine	NN	_	13	ppmod	_	_
16	,	,	,	_	9	p	_	_
17	might	might	MD	_	18	modal	_	_
18	decrease	decrease	VB	_	1	acl	_	_
19	the	the	DT	_	20	det	_	_
20	efficacy	efficacy	NN	_	18	obj	_	_
21	of	of	IN	_	22	case	_	_
22	drug4	drug0	NN	_	20	ppmod	_	_
23	and	and	CC	_	22	cc	_	_
24	drug5	drug0	NN	_	22	conj	_	_
25	.	.	.	_	1	p	_	_

1	May	may	MD	_	2	modal	_	_
2	interact	interact	VB	_	0	root	_	_
3	with	with	IN	_	5	case	_	_
4	skin	skin	NN	_	5	com	_	_
5	products	product	NNS	_	2	ppmod	_	_
6	or	or	CC	_	5	cc	_	_
7	shampoos	shampoo	NNS	_	5	conj	_	_
8	for	for	IN	_	9	case	_	_
9	dandruff	dandruff	NN	_	7	ppmod	_	_
10	or	or	CC	_	9	cc	_	_
11	psoriasis	psoriasis	NN	_	9	conj	_	_
12	.	.	.	_	2	p	_	_

1	Most	most	JJS	_	11	dep	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	98	0	CD	_	1	num	_	_
4	%	%	NN	_	3	meta	_	_
5	)	-rrb-	-RRB-	_	3	p	_	_
6	of	of	IN	_	8	case	_	_
7	plasma	plasma	NN	_	8	com	_	_
8	drug1	drug0	NN	_	1	ppmod	_	_
9	is	be	VBZ	_	11	aux	_	_
10	protein	protein	NN	_	11	dep	_	_
11	bound	bind	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	data	datum	NNS	_	7	dep	_	_
4	in	in	IN	_	6	case	_	_
5	human	human	JJ	_	6	attr	_	_
6	plasma	plasma	NN	_	3	ppmod	_	_
7	indicate	indicate	VBP	_	0	root	_	_
8	that	that	IN	_	10	mark	_	_
9	drug1	drug0	NN	_	10	dep	_	_
10	has	have	VBZ	_	7	comp	_	_
11	no	no	DT	_	12	det	_	_
12	effect	effect	NN	_	10	obj	_	_
13	on	on	IN	_	15	case	_	_
14	protein	protein	NN	_	15	com	_	_
15	binding	binding	NN	_	10	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	,	,	,	_	17	p	_	_
19	drug3	drug0	NN	_	17	conj	_	_
20	,	,	,	_	19	p	_	_
21	drug4	drug0	NN	_	17	conj	_	_
22	or	or	CC	_	21	cc	_	_
23	drug5	drug0	NN	_	17	conj	_	_
24	.	.	.	_	7	p	_	_

1	There	there	EX	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	no	no	DT	_	4	det	_	_
4	information	information	NN	_	2	obj	_	_
5	on	on	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	effect	effect	NN	_	4	ppmod	_	_
8	of	of	IN	_	14	case	_	_
9	other	other	JJ	_	14	attr	_	_
10	highly	highly	RB	_	13	adv	_	_
11	plasma	plasma	NN	_	12	com	_	_
12	protein	protein	NN	_	13	advnp	_	_
13	bound	bind	VBN	_	14	attr	_	_
14	drugs	drug	NNS	_	7	ppmod	_	_
15	on	on	IN	_	17	case	_	_
16	drug1	drug0	NN	_	17	com	_	_
17	binding	binding	NN	_	7	ppmod	_	_
18	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	administered	administer	VBN	_	0	root	_	_
5	without	without	IN	_	7	case	_	_
6	any	any	DT	_	7	det	_	_
7	evidence	evidence	NN	_	4	ppmod	_	_
8	of	of	IN	_	12	case	_	_
9	an	an	DT	_	12	det	_	_
10	adverse	adverse	JJ	_	12	attr	_	_
11	drug	drug	NN	_	12	com	_	_
12	interaction	interaction	NN	_	7	ppmod	_	_
13	to	to	TO	_	14	aux	_	_
14	patients	patient	NNS	_	12	ppmod	_	_
15	receiving	receive	VBG	_	14	acl	_	_
16	drug2	drug0	NN	_	15	obj	_	_
17	,	,	,	_	16	p	_	_
18	drug3	drug0	NN	_	19	com	_	_
19	s	s	NN	_	16	conj	_	_
20	,	,	,	_	19	p	_	_
21	and	and	CC	_	19	cc	_	_
22	drug4	drug0	NN	_	16	conj	_	_
23	.	.	.	_	4	p	_	_

1	In	in	IN	_	4	case	_	_
2	a	a	DT	_	4	det	_	_
3	placebo-controlled	placebo-controlled	JJ	_	4	attr	_	_
4	trial	trial	NN	_	35	ppmod	_	_
5	in	in	IN	_	7	case	_	_
6	normal	normal	JJ	_	7	attr	_	_
7	volunteers	volunteer	NNS	_	4	ppmod	_	_
8	,	,	,	_	35	p	_	_
9	the	the	DT	_	10	det	_	_
10	administration	administration	NN	_	35	dep	_	_
11	of	of	IN	_	16	case	_	_
12	a	a	DT	_	16	det	_	_
13	single	single	JJ	_	16	attr	_	_
14	1	0	CD	_	15	num	_	_
15	mg	mg	NN	_	16	com	_	_
16	dose	dose	NN	_	10	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug1	drug0	NN	_	16	ppmod	_	_
19	on	on	IN	_	20	case	_	_
20	day	day	NN	_	18	ppmod	_	_
21	1	0	CD	_	20	num	_	_
22	of	of	IN	_	25	case	_	_
23	a	a	DT	_	25	det	_	_
24	four-day	four-day	JJ	_	25	attr	_	_
25	regimen	regimen	NN	_	20	ppmod	_	_
26	of	of	IN	_	28	case	_	_
27	oral	oral	JJ	_	28	attr	_	_
28	drug2	drug0	NN	_	25	ppmod	_	_
29	(	-lrb-	-LRB-	_	31	p	_	_
30	400	0	CD	_	31	num	_	_
31	mg	mg	NN	_	16	prn	_	_
32	twice	twice	RB	_	33	com	_	_
33	daily	daily	RB	_	31	adv	_	_
34	)	-rrb-	-RRB-	_	31	p	_	_
35	resulted	result	VBD	_	0	root	_	_
36	in	in	IN	_	40	case	_	_
37	a	a	DT	_	40	det	_	_
38	10	0	CD	_	40	num	_	_
39	%	%	NN	_	38	meta	_	_
40	increase	increase	NN	_	35	ppmod	_	_
41	in	in	IN	_	43	case	_	_
42	mean	mean	JJ	_	43	attr	_	_
43	AUC	auc	NN	_	40	ppmod	_	_
44	of	of	IN	_	45	case	_	_
45	drug3	drug0	NN	_	43	ppmod	_	_
46	(	-lrb-	-LRB-	_	47	p	_	_
47	p=0.006	p=0	NN	_	45	prn	_	_
48	)	-rrb-	-RRB-	_	47	p	_	_
49	,	,	,	_	40	p	_	_
50	and	and	CC	_	40	cc	_	_
51	a	a	DT	_	57	det	_	_
52	slight	slight	JJ	_	57	attr	_	_
53	but	but	CC	_	52	cc	_	_
54	not	not	RB	_	56	neg	_	_
55	statistically	statistically	RB	_	56	adv	_	_
56	significant	significant	JJ	_	52	conj	_	_
57	increase	increase	NN	_	40	conj	_	_
58	in	in	IN	_	60	case	_	_
59	mean	mean	JJ	_	60	attr	_	_
60	Cmax	cmax	NN	_	57	ppmod	_	_
61	and	and	CC	_	60	cc	_	_
62	mean	mean	JJ	_	63	attr	_	_
63	half-life	half-life	NN	_	60	conj	_	_
64	of	of	IN	_	65	case	_	_
65	drug4	drug0	NN	_	60	ppmod	_	_
66	.	.	.	_	35	p	_	_

1	The	the	DT	_	3	det	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	significance	significance	NN	_	10	dep	_	_
4	of	of	IN	_	6	case	_	_
5	this	this	DT	_	6	det	_	_
6	increase	increase	NN	_	3	ppmod	_	_
7	in	in	IN	_	9	case	_	_
8	drug1	drug0	NN	_	9	com	_	_
9	AUC	auc	NN	_	3	ppmod	_	_
10	is	be	VBZ	_	0	root	_	_
11	unknown	unknown	JJ	_	10	dep	_	_
12	.	.	.	_	10	p	_	_

1	In	in	IN	_	3	case	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	trials	trial	NNS	_	9	ppmod	_	_
4	,	,	,	_	9	p	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	tablets	tablet	NNS	_	9	dep	_	_
7	have	have	VBP	_	9	aux	_	_
8	been	be	VBN	_	9	aux	_	_
9	administered	administer	VBN	_	0	root	_	_
10	to	to	TO	_	11	aux	_	_
11	patients	patient	NNS	_	9	ppmod	_	_
12	on	on	IN	_	14	case	_	_
13	a	a	DT	_	14	det	_	_
14	variety	variety	NN	_	9	ppmod	_	_
15	of	of	IN	_	17	case	_	_
16	concomitant	concomitant	JJ	_	17	attr	_	_
17	medications	medication	NNS	_	14	ppmod	_	_
18	;	;	:	_	9	p	_	_

1	while	while	IN	_	8	mark	_	_
2	no	no	DT	_	5	det	_	_
3	formal	formal	JJ	_	5	attr	_	_
4	interaction	interaction	NN	_	5	com	_	_
5	studies	study	NNS	_	8	dep	_	_
6	have	have	VBP	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	conducted	conduct	VBN	_	13	advcl	_	_
9	,	,	,	_	13	p	_	_
10	no	no	DT	_	11	det	_	_
11	interactions	interaction	NNS	_	13	dep	_	_
12	were	be	VBD	_	13	aux	_	_
13	observed	observe	VBN	_	0	root	_	_
14	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	tablets	tablet	NNS	_	5	dep	_	_
3	have	have	VBP	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	used	use	VBN	_	0	root	_	_
6	with	with	IN	_	9	case	_	_
7	the	the	DT	_	9	det	_	_
8	following	following	JJ	_	9	attr	_	_
9	drugs	drug	NNS	_	5	ppmod	_	_
10	or	or	CC	_	9	cc	_	_
11	drug	drug	NN	_	12	com	_	_
12	classes	class	NNS	_	9	conj	_	_
13	:	:	:	_	12	p	_	_
14	1	0	CD	_	9	conj	_	_
15	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	/	/	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	(	-lrb-	-LRB-	_	16	p	_	_
5	e.g.	e.g.	FW	_	7	adv	_	_
6	,	,	,	_	7	p	_	_
7	drug3	drug0	NN	_	16	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	drug4	drug0	NN	_	7	conj	_	_
10	,	,	,	_	9	p	_	_
11	drug5	drug0	NN	_	7	conj	_	_
12	and	and	CC	_	11	cc	_	_
13	drug6	drug0	NN	_	14	com	_	_
14	combinations	combination	NNS	_	7	conj	_	_
15	,	,	,	_	16	p	_	_
16	drug7	drug0	NN	_	3	prn	_	_
17	,	,	,	_	16	p	_	_
18	drug8	drug0	NN	_	16	appo	_	_
19	)	-rrb-	-RRB-	_	16	p	_	_
20	.	.	.	_	1	p	_	_

1	2	0	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	(	-lrb-	-LRB-	_	11	p	_	_
3	e.g.	e.g.	FW	_	5	adv	_	_
4	,	,	,	_	5	p	_	_
5	drug2	drug0	NN	_	11	ppmod	_	_
6	,	,	,	_	5	p	_	_
7	drug3	drug0	NN	_	5	conj	_	_
8	and	and	CC	_	7	cc	_	_
9	drug4	drug0	NN	_	5	conj	_	_
10	,	,	,	_	11	p	_	_
11	drug5	drug0	NN	_	1	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	.	.	.	_	1	p	_	_

1	3	0	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	(	-lrb-	-LRB-	_	5	p	_	_
3	e.g.	e.g.	FW	_	5	adv	_	_
4	,	,	,	_	5	p	_	_
5	drug2	drug0	NN	_	1	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	.	.	.	_	1	p	_	_

1	4	0	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	Cardiovascular	cardiovascular	JJ	_	2	attr	_	_
2	agents	agent	NNS	_	0	root	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	e.g.	e.g.	FW	_	6	adv	_	_
5	,	,	,	_	6	p	_	_
6	drug1	drug0	NN	_	2	prn	_	_
7	,	,	,	_	6	p	_	_
8	drug2	drug0	NN	_	6	appo	_	_
9	,	,	,	_	6	p	_	_
10	drug3	drug0	NN	_	6	appo	_	_
11	)	-rrb-	-RRB-	_	6	p	_	_
12	.	.	.	_	2	p	_	_

1	5	0	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	6	0	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	Gastrointestinal	gastrointestinal	JJ	_	2	attr	_	_
2	agents	agent	NNS	_	0	root	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	e.g.	e.g.	FW	_	6	adv	_	_
5	,	,	,	_	6	p	_	_
6	drug1	drug0	NN	_	2	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	.	.	.	_	2	p	_	_

1	7	0	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	drug1	drug0	JJ	_	4	attr	_	_
2	and	and	CC	_	1	cc	_	_
3	endocrine	endocrine	JJ	_	1	conj	_	_
4	drugs	drug	NNS	_	0	root	_	_
5	.	.	.	_	4	p	_	_

1	8	0	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	(	-lrb-	-LRB-	_	7	p	_	_
5	e.g.	e.g.	FW	_	7	adv	_	_
6	,	,	,	_	7	p	_	_
7	drug3	drug0	NN	_	1	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	.	.	.	_	1	p	_	_

1	9	0	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	Cold	cold	NN	_	4	attr	_	_
2	and	and	CC	_	1	cc	_	_
3	flu	flu	NN	_	1	conj	_	_
4	remedies	remedy	NNS	_	0	root	_	_
5	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	modifies	modify	VBZ	_	0	root	_	_
3	drug2	drug0	NN	_	4	com	_	_
4	metabolism	metabolism	NN	_	2	obj	_	_
5	with	with	IN	_	8	case	_	_
6	increased	increase	VBN	_	8	attr	_	_
7	serum	serum	NN	_	8	com	_	_
8	levels	level	NNS	_	2	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug3	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	2	p	_	_

1	This	this	DT	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	increase	increase	VB	_	0	root	_	_
4	or	or	CC	_	3	cc	_	_
5	enhance	enhance	VB	_	3	conj	_	_
6	the	the	DT	_	7	det	_	_
7	occurrence	occurrence	NN	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	osteomalacia	osteomalacia	NN	_	7	ppmod	_	_
10	in	in	IN	_	12	case	_	_
11	some	some	DT	_	12	det	_	_
12	patients	patient	NNS	_	7	ppmod	_	_
13	receiving	receive	VBG	_	12	acl	_	_
14	chronic	chronic	JJ	_	16	attr	_	_
15	drug1	drug0	NN	_	16	com	_	_
16	therapy	therapy	NN	_	13	obj	_	_
17	.	.	.	_	3	p	_	_

1	Caution	caution	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	advised	advise	VBN	_	0	root	_	_
4	in	in	IN	_	5	case	_	_
5	patients	patient	NNS	_	3	ppmod	_	_
6	receiving	receive	VBG	_	5	acl	_	_
7	chronic	chronic	JJ	_	9	attr	_	_
8	concomitant	concomitant	JJ	_	9	attr	_	_
9	therapy	therapy	NN	_	6	obj	_	_
10	.	.	.	_	3	p	_	_

1	By	by	IN	_	2	case	_	_
2	decreasing	decrease	VBG	_	11	ppmod	_	_
3	the	the	DT	_	5	det	_	_
4	gastrointestinal	gastrointestinal	JJ	_	5	attr	_	_
5	absorption	absorption	NN	_	2	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	,	,	,	_	11	p	_	_
9	drug2	drug0	NN	_	11	dep	_	_
10	may	may	MD	_	11	modal	_	_
11	decrease	decrease	VB	_	0	root	_	_
12	serum	serum	NN	_	13	com	_	_
13	concentrations	concentration	NNS	_	11	obj	_	_
14	of	of	IN	_	15	case	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	its	its	PRP$	_	18	poss	_	_
18	metabolites	metabolite	NNS	_	15	conj	_	_
19	,	,	,	_	11	p	_	_
20	with	with	IN	_	24	case	_	_
21	a	a	DT	_	24	det	_	_
22	consequent	consequent	JJ	_	24	attr	_	_
23	possible	possible	JJ	_	24	attr	_	_
24	decrease	decrease	NN	_	11	ppmod	_	_
25	in	in	IN	_	27	case	_	_
26	anticonvulsant	anticonvulsant	JJ	_	27	attr	_	_
27	effect	effect	NN	_	24	ppmod	_	_
28	.	.	.	_	11	p	_	_

1	Caution	caution	NN	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	advised	advised	JJ	_	2	dep	_	_
4	when	when	WRB	_	5	adv	_	_
5	beginning	begin	VBG	_	2	comp	_	_
6	,	,	,	_	5	p	_	_
7	discontinuing	discontinue	VBG	_	5	conj	_	_
8	,	,	,	_	7	p	_	_
9	or	or	CC	_	7	cc	_	_
10	changing	change	VBG	_	5	conj	_	_
11	the	the	DT	_	12	det	_	_
12	dose	dose	NN	_	10	obj	_	_
13	of	of	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	in	in	IN	_	16	case	_	_
16	patients	patient	NNS	_	12	ppmod	_	_
17	receiving	receive	VBG	_	16	acl	_	_
18	drug2	drug0	NN	_	17	obj	_	_
19	.	.	.	_	2	p	_	_

1	Because	because	IN	_	5	case	_	_
2	of	of	IN	_	5	case	_	_
3	possible	possible	JJ	_	5	attr	_	_
4	additive	additive	JJ	_	5	attr	_	_
5	effects	effect	NNS	_	12	ppmod	_	_
6	with	with	IN	_	8	case	_	_
7	other	other	JJ	_	8	attr	_	_
8	drug1	drug0	NN	_	5	ppmod	_	_
9	,	,	,	_	12	p	_	_
10	concomitant	concomitant	JJ	_	11	attr	_	_
11	use	use	NN	_	12	dep	_	_
12	is	be	VBZ	_	0	root	_	_
13	not	not	RB	_	12	neg	_	_
14	advisable	advisable	JJ	_	12	dep	_	_
15	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	increase	increase	VB	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	effects	effect	NNS	_	3	obj	_	_
6	of	of	IN	_	8	case	_	_
7	other	other	JJ	_	8	attr	_	_
8	drug2	drug0	NNS	_	5	ppmod	_	_
9	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	increase	increase	VB	_	0	root	_	_
4	or	or	CC	_	3	cc	_	_
5	decrease	decrease	VB	_	3	conj	_	_
6	blood	blood	NN	_	8	com	_	_
7	glucose	glucose	NN	_	8	com	_	_
8	levels	level	NNS	_	5	obj	_	_
9	.	.	.	_	3	p	_	_

1	Consideration	consideration	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	taken	take	VBN	_	0	root	_	_
5	in	in	IN	_	6	case	_	_
6	patients	patient	NNS	_	4	ppmod	_	_
7	being	be	VBG	_	8	aux	_	_
8	treated	treat	VBN	_	6	acl	_	_
9	with	with	IN	_	11	case	_	_
10	drug1	drug0	JJ	_	11	attr	_	_
11	agents	agent	NNS	_	8	ppmod	_	_
12	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	decreases	decrease	VBZ	_	0	root	_	_
3	urinary	urinary	JJ	_	4	attr	_	_
4	excretion	excretion	NN	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	2	cc	_	_
8	may	may	MD	_	9	modal	_	_
9	enhance	enhance	VB	_	2	conj	_	_
10	the	the	DT	_	11	det	_	_
11	magnitude	magnitude	NN	_	9	obj	_	_
12	and	and	CC	_	11	cc	_	_
13	duration	duration	NN	_	11	conj	_	_
14	of	of	IN	_	16	case	_	_
15	their	their	PRP$	_	16	poss	_	_
16	effect	effect	NN	_	11	ppmod	_	_
17	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	reduces	reduce	VBZ	_	0	root	_	_
3	urinary	urinary	JJ	_	4	attr	_	_
4	excretion	excretion	NN	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	2	cc	_	_
8	may	may	MD	_	9	modal	_	_
9	enhance	enhance	VB	_	2	conj	_	_
10	its	its	PRP$	_	11	poss	_	_
11	effect	effect	NN	_	9	obj	_	_
12	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	prevent	prevent	VB	_	0	root	_	_
4	the	the	DT	_	7	det	_	_
5	urinary	urinary	JJ	_	7	attr	_	_
6	antiseptic	antiseptic	JJ	_	7	attr	_	_
7	effect	effect	NN	_	3	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	increases	increase	VBZ	_	0	root	_	_
3	drug2	drug0	NN	_	4	com	_	_
4	excretion	excretion	NN	_	2	obj	_	_
5	and	and	CC	_	2	cc	_	_
6	the	the	DT	_	7	det	_	_
7	drug3	drug0	NN	_	10	dep	_	_
8	may	may	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	decreased	decrease	VBN	_	2	conj	_	_
11	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	used	use	VBN	_	1	acl	_	_
5	concurrently	concurrently	RB	_	6	adv	_	_
6	increases	increase	VBZ	_	0	root	_	_
7	the	the	DT	_	8	det	_	_
8	risk	risk	NN	_	6	obj	_	_
9	of	of	IN	_	12	case	_	_
10	renal	renal	JJ	_	12	attr	_	_
11	calculus	calculus	NNS	_	12	com	_	_
12	formation	formation	NN	_	8	ppmod	_	_
13	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	elevate	elevate	VBP	_	0	root	_	_
4	drug2	drug0	NN	_	5	com	_	_
5	levels	level	NNS	_	3	obj	_	_
6	.	.	.	_	3	p	_	_

1	The	the	DT	_	3	det	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	test	test	NN	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	conducted	conduct	VBN	_	0	root	_	_
7	in	in	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	absence	absence	NN	_	6	ppmod	_	_
10	of	of	IN	_	12	case	_	_
11	other	other	JJ	_	12	attr	_	_
12	drugs	drug	NNS	_	9	ppmod	_	_
13	which	which	WDT	_	15	dep	_	_
14	directly	directly	RB	_	15	adv	_	_
15	affect	affect	VBP	_	12	relcl	_	_
16	the	the	DT	_	18	det	_	_
17	pituitary	pituitary	JJ	_	18	attr	_	_
18	secretion	secretion	NN	_	15	obj	_	_
19	of	of	IN	_	21	case	_	_
20	the	the	DT	_	21	det	_	_
21	gonadotropins	gonadotropin	NNS	_	18	ppmod	_	_
22	.	.	.	_	6	p	_	_

1	These	these	DT	_	3	dep	_	_
2	would	would	MD	_	3	modal	_	_
3	include	include	VBP	_	0	root	_	_
4	a	a	DT	_	5	det	_	_
5	variety	variety	NN	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	preparations	preparation	NNS	_	5	ppmod	_	_
8	which	which	WDT	_	9	dep	_	_
9	contain	contain	VBP	_	7	relcl	_	_
10	drug1	drug0	NN	_	9	obj	_	_
11	,	,	,	_	10	p	_	_
12	drug2	drug0	NN	_	10	conj	_	_
13	,	,	,	_	12	p	_	_
14	drug3	drug0	NN	_	10	conj	_	_
15	,	,	,	_	14	p	_	_
16	or	or	CC	_	14	cc	_	_
17	drug4	drug0	NN	_	10	conj	_	_
18	.	.	.	_	3	p	_	_

1	The	the	DT	_	3	det	_	_
2	gonadotropin	gonadotropin	NN	_	3	com	_	_
3	levels	level	NNS	_	7	dep	_	_
4	may	may	MD	_	7	modal	_	_
5	be	be	VB	_	7	aux	_	_
6	transiently	transiently	RB	_	7	adv	_	_
7	elevated	elevate	VBN	_	0	root	_	_
8	by	by	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	7	p	_	_
11	minimally	minimally	RB	_	12	adv	_	_
12	elevated	elevate	VBN	_	7	conj	_	_
13	by	by	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	,	,	,	_	12	p	_	_
16	and	and	CC	_	12	cc	_	_
17	suppressed	suppress	VBN	_	7	conj	_	_
18	by	by	IN	_	20	case	_	_
19	oral	oral	JJ	_	20	attr	_	_
20	drug3	drug0	NN	_	17	ppmod	_	_
21	and	and	CC	_	20	cc	_	_
22	drug4	drug0	NN	_	20	conj	_	_
23	.	.	.	_	7	p	_	_

1	The	the	DT	_	2	det	_	_
2	response	response	NN	_	7	dep	_	_
3	to	to	TO	_	4	aux	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	may	may	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	blunted	blunt	VBN	_	0	root	_	_
8	by	by	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	drug3	drug0	NN	_	9	conj	_	_
12	which	which	WDT	_	13	dep	_	_
13	cause	cause	VBP	_	9	relcl	_	_
14	a	a	DT	_	15	det	_	_
15	rise	rise	NN	_	13	obj	_	_
16	in	in	IN	_	17	case	_	_
17	prolactin	prolactin	NN	_	15	ppmod	_	_
18	.	.	.	_	7	p	_	_

1	As	as	IN	_	4	mark	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	Gel	gel	NN	_	4	dep	_	_
4	has	have	VBZ	_	57	advcl	_	_
5	the	the	DT	_	6	det	_	_
6	potential	potential	NN	_	4	obj	_	_
7	to	to	TO	_	8	aux	_	_
8	produce	produce	VB	_	6	acl	_	_
9	local	local	JJ	_	10	attr	_	_
10	irritation	irritation	NN	_	8	obj	_	_
11	in	in	IN	_	13	case	_	_
12	some	some	DT	_	13	det	_	_
13	patients	patient	NNS	_	8	ppmod	_	_
14	,	,	,	_	57	p	_	_
15	concomitant	concomitant	JJ	_	16	attr	_	_
16	use	use	NN	_	57	dep	_	_
17	of	of	IN	_	22	case	_	_
18	other	other	JJ	_	22	attr	_	_
19	potentially	potentially	RB	_	20	adv	_	_
20	irritating	irritating	JJ	_	22	attr	_	_
21	topical	topical	JJ	_	22	attr	_	_
22	products	product	NNS	_	16	ppmod	_	_
23	(	-lrb-	-LRB-	_	27	p	_	_
24	medicated	medicated	JJ	_	27	attr	_	_
25	or	or	CC	_	24	cc	_	_
26	abrasive	abrasive	JJ	_	24	conj	_	_
27	soaps	soap	NNS	_	22	prn	_	_
28	and	and	CC	_	27	cc	_	_
29	cleansers	cleanser	NNS	_	27	conj	_	_
30	,	,	,	_	27	p	_	_
31	soaps	soap	NNS	_	27	conj	_	_
32	and	and	CC	_	31	cc	_	_
33	cosmetics	cosmetic	NNS	_	31	conj	_	_
34	that	that	WDT	_	35	dep	_	_
35	have	have	VBP	_	31	relcl	_	_
36	a	a	DT	_	39	det	_	_
37	strong	strong	JJ	_	39	attr	_	_
38	drying	drying	NN	_	39	com	_	_
39	effect	effect	NN	_	35	obj	_	_
40	,	,	,	_	31	p	_	_
41	and	and	CC	_	31	cc	_	_
42	products	product	NNS	_	27	conj	_	_
43	with	with	IN	_	45	case	_	_
44	high	high	JJ	_	45	attr	_	_
45	concentrations	concentration	NNS	_	27	ppmod	_	_
46	of	of	IN	_	47	case	_	_
47	alcohol	alcohol	NN	_	45	ppmod	_	_
48	,	,	,	_	27	p	_	_
49	astringents	astringent	NNS	_	27	conj	_	_
50	,	,	,	_	49	p	_	_
51	spices	spice	NNS	_	27	conj	_	_
52	or	or	CC	_	51	cc	_	_
53	lime	lime	NN	_	27	conj	_	_
54	)	-rrb-	-RRB-	_	27	p	_	_
55	should	should	MD	_	57	modal	_	_
56	be	be	VB	_	57	aux	_	_
57	approached	approach	VBN	_	0	root	_	_
58	with	with	IN	_	59	case	_	_
59	caution	caution	NN	_	57	ppmod	_	_
60	.	.	.	_	57	p	_	_

1	Particular	particular	JJ	_	2	attr	_	_
2	caution	caution	NN	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	exercised	exercise	VBN	_	0	root	_	_
6	in	in	IN	_	7	case	_	_
7	using	use	VBG	_	5	ppmod	_	_
8	preparations	preparation	NNS	_	7	obj	_	_
9	containing	contain	VBG	_	8	acl	_	_
10	drug1	drug0	NN	_	9	obj	_	_
11	,	,	,	_	10	p	_	_
12	drug2	drug0	NN	_	10	conj	_	_
13	,	,	,	_	12	p	_	_
14	or	or	CC	_	12	cc	_	_
15	drug3	drug0	NN	_	10	conj	_	_
16	in	in	IN	_	17	case	_	_
17	combination	combination	NN	_	9	ppmod	_	_
18	with	with	IN	_	20	case	_	_
19	drug4	drug0	NN	_	20	com	_	_
20	Gel	gel	NN	_	17	ppmod	_	_
21	.	.	.	_	5	p	_	_

1	If	if	IN	_	6	mark	_	_
2	these	these	DT	_	3	det	_	_
3	preparations	preparation	NNS	_	6	dep	_	_
4	have	have	VBP	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	used	use	VBN	_	8	advcl	_	_
7	it	it	PRP	_	8	dep	_	_
8	is	be	VBZ	_	0	root	_	_
9	advisable	advisable	JJ	_	8	dep	_	_
10	not	not	RB	_	13	neg	_	_
11	to	to	TO	_	13	aux	_	_
12	start	start	NN	_	13	com	_	_
13	therapy	therapy	NN	_	9	ppmod	_	_
14	with	with	IN	_	16	case	_	_
15	drug1	drug0	NN	_	16	com	_	_
16	Gel	gel	NN	_	13	ppmod	_	_
17	until	until	IN	_	27	mark	_	_
18	the	the	DT	_	19	det	_	_
19	effects	effect	NNS	_	27	dep	_	_
20	of	of	IN	_	22	case	_	_
21	such	such	JJ	_	22	attr	_	_
22	preparations	preparation	NNS	_	19	ppmod	_	_
23	in	in	IN	_	25	case	_	_
24	the	the	DT	_	25	det	_	_
25	skin	skin	NN	_	19	ppmod	_	_
26	have	have	VBP	_	27	aux	_	_
27	subsided	subside	VBN	_	8	comp	_	_
28	.	.	.	_	8	p	_	_

1	There	there	EX	_	3	dep	_	_
2	have	have	VBP	_	3	aux	_	_
3	been	be	VBN	_	0	root	_	_
4	no	no	DT	_	7	det	_	_
5	formal	formal	JJ	_	7	attr	_	_
6	clinical	clinical	JJ	_	7	attr	_	_
7	studies	study	NNS	_	3	obj	_	_
8	to	to	TO	_	9	aux	_	_
9	evaluate	evaluate	VB	_	3	comp	_	_
10	the	the	DT	_	12	det	_	_
11	drug	drug	NN	_	12	com	_	_
12	interactions	interaction	NNS	_	9	obj	_	_
13	of	of	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	with	with	IN	_	17	case	_	_
16	other	other	JJ	_	17	attr	_	_
17	medications	medication	NNS	_	12	ppmod	_	_
18	.	.	.	_	3	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	studies	study	NNS	_	5	dep	_	_
4	have	have	VBP	_	5	aux	_	_
5	shown	show	VBN	_	0	root	_	_
6	that	that	IN	_	13	mark	_	_
7	the	the	DT	_	8	det	_	_
8	metabolism	metabolism	NN	_	13	dep	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	may	may	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	modified	modify	VBN	_	5	comp	_	_
14	by	by	IN	_	17	case	_	_
15	the	the	DT	_	17	det	_	_
16	concomitant	concomitant	JJ	_	17	attr	_	_
17	administration	administration	NN	_	13	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	compounds	compound	NNS	_	17	ppmod	_	_
20	that	that	WDT	_	21	dep	_	_
21	induce	induce	VBP	_	19	relcl	_	_
22	,	,	,	_	21	p	_	_
23	inhibit	inhibit	VBP	_	21	conj	_	_
24	,	,	,	_	23	p	_	_
25	or	or	CC	_	23	cc	_	_
26	are	be	VBP	_	27	aux	_	_
27	metabolized	metabolize	VBN	_	21	conj	_	_
28	by	by	IN	_	31	case	_	_
29	cytochrome	cytochrome	NN	_	31	com	_	_
30	P450	p0	NN	_	31	com	_	_
31	3A4	0a0	NN	_	27	ppmod	_	_
32	,	,	,	_	19	p	_	_
33	such	such	JJ	_	35	adv	_	_
34	as	as	IN	_	35	case	_	_
35	drug2	drug0	NN	_	19	ppmod	_	_
36	,	,	,	_	35	p	_	_
37	drug3	drug0	NN	_	35	conj	_	_
38	,	,	,	_	37	p	_	_
39	drug4	drug0	NN	_	35	conj	_	_
40	,	,	,	_	39	p	_	_
41	drug5	drug0	NN	_	35	conj	_	_
42	,	,	,	_	41	p	_	_
43	and	and	CC	_	41	cc	_	_
44	drug6	drug0	NN	_	35	conj	_	_
45	.	.	.	_	5	p	_	_

1	Caution	caution	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	exercised	exercise	VBN	_	0	root	_	_
5	with	with	IN	_	7	case	_	_
6	these	these	DT	_	7	det	_	_
7	drugs	drug	NNS	_	4	ppmod	_	_
8	when	when	WRB	_	9	adv	_	_
9	treating	treat	VBG	_	4	comp	_	_
10	patients	patient	NNS	_	9	obj	_	_
11	receiving	receive	VBG	_	10	acl	_	_
12	drug1	drug0	NN	_	11	obj	_	_
13	as	as	IN	_	15	mark	_	_
14	there	there	EX	_	15	dep	_	_
15	is	be	VBZ	_	12	acl	_	_
16	a	a	DT	_	17	det	_	_
17	potential	potential	NN	_	15	obj	_	_
18	for	for	IN	_	21	case	_	_
19	a	a	DT	_	21	det	_	_
20	significant	significant	JJ	_	21	attr	_	_
21	interaction	interaction	NN	_	17	ppmod	_	_
22	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	accelerates	accelerate	VBZ	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	metabolism	metabolism	NN	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	;	;	:	_	2	p	_	_

1	therefore	therefore	RB	_	12	adv	_	_
2	,	,	,	_	12	p	_	_
3	if	if	IN	_	7	mark	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	replacement	replacement	NN	_	7	dep	_	_
6	is	be	VBZ	_	7	aux	_	_
7	needed	need	VBN	_	12	advcl	_	_
8	,	,	,	_	12	p	_	_
9	drug2	drug0	NN	_	12	dep	_	_
10	should	should	MD	_	12	modal	_	_
11	be	be	VB	_	12	aux	_	_
12	prescribed	prescribe	VBN	_	0	root	_	_
13	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	diminishes	diminish	VBZ	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	effect	effect	NN	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	14	dep	_	_
2	:	:	:	_	1	p	_	_
3	Experience	experience	VBP	_	1	acl	_	_
4	in	in	IN	_	7	case	_	_
5	over	over	IN	_	6	case	_	_
6	1400	0	CD	_	7	num	_	_
7	patients	patient	NNS	_	3	ppmod	_	_
8	in	in	IN	_	12	case	_	_
9	a	a	DT	_	12	det	_	_
10	non-comparative	non-comparative	JJ	_	12	attr	_	_
11	clinical	clinical	JJ	_	12	attr	_	_
12	trial	trial	NN	_	3	ppmod	_	_
13	has	have	VBZ	_	14	aux	_	_
14	shown	show	VBN	_	0	root	_	_
15	that	that	IN	_	25	mark	_	_
16	concomitant	concomitant	JJ	_	17	attr	_	_
17	administration	administration	NN	_	25	dep	_	_
18	of	of	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	and	and	CC	_	19	cc	_	_
21	drug3	drug0	NN	_	19	conj	_	_
22	is	be	VBZ	_	25	aux	_	_
23	usually	usually	RB	_	25	adv	_	_
24	well	well	RB	_	25	adv	_	_
25	tolerated	tolerate	VBN	_	14	comp	_	_
26	,	,	,	_	14	p	_	_
27	but	but	CC	_	14	cc	_	_
28	there	there	EX	_	30	dep	_	_
29	have	have	VBP	_	30	aux	_	_
30	been	be	VBN	_	14	conj	_	_
31	occasional	occasional	JJ	_	33	attr	_	_
32	literature	literature	NN	_	33	com	_	_
33	reports	report	NNS	_	30	obj	_	_
34	suggesting	suggest	VBG	_	33	acl	_	_
35	that	that	IN	_	39	mark	_	_
36	the	the	DT	_	37	det	_	_
37	combination	combination	NN	_	39	dep	_	_
38	may	may	MD	_	39	modal	_	_
39	increase	increase	VB	_	34	comp	_	_
40	the	the	DT	_	41	det	_	_
41	likelihood	likelihood	NN	_	39	obj	_	_
42	of	of	IN	_	45	case	_	_
43	congestive	congestive	JJ	_	45	attr	_	_
44	heart	heart	NN	_	45	com	_	_
45	failure	failure	NN	_	41	ppmod	_	_
46	,	,	,	_	45	p	_	_
47	severe	severe	JJ	_	48	attr	_	_
48	hypotension	hypotension	NN	_	45	conj	_	_
49	or	or	CC	_	48	cc	_	_
50	exacerbation	exacerbation	NN	_	45	conj	_	_
51	of	of	IN	_	52	case	_	_
52	angina	angina	NN	_	50	ppmod	_	_
53	.	.	.	_	14	p	_	_

1	Long	long	JJ	_	3	attr	_	_
2	Acting	acting	NN	_	3	com	_	_
3	drug1	drug0	NN	_	0	root	_	_
4	:	:	:	_	3	p	_	_
5	drug2	drug0	NN	_	9	dep	_	_
6	may	may	MD	_	9	modal	_	_
7	be	be	VB	_	9	aux	_	_
8	safely	safely	RB	_	9	adv	_	_
9	co-administered	co-administered	VBN	_	3	acl	_	_
10	with	with	IN	_	11	case	_	_
11	drug3	drug0	NN	_	9	ppmod	_	_
12	,	,	,	_	9	p	_	_
13	but	but	CC	_	9	cc	_	_
14	there	there	EX	_	16	dep	_	_
15	have	have	VBP	_	16	aux	_	_
16	been	be	VBN	_	9	conj	_	_
17	no	no	DT	_	19	det	_	_
18	controlled	controlled	JJ	_	19	attr	_	_
19	studies	study	NNS	_	16	obj	_	_
20	to	to	TO	_	21	aux	_	_
21	evaluate	evaluate	VB	_	16	comp	_	_
22	the	the	DT	_	24	det	_	_
23	antianginal	antianginal	JJ	_	24	attr	_	_
24	effectiveness	effectiveness	NN	_	21	obj	_	_
25	of	of	IN	_	27	case	_	_
26	this	this	DT	_	27	det	_	_
27	combination	combination	NN	_	24	ppmod	_	_
28	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Immediate	immediate	JJ	_	5	attr	_	_
4	Release	release	NN	_	5	com	_	_
5	Capsules	capsule	NNS	_	1	attr	_	_
6	:	:	:	_	1	p	_	_
7	Since	since	IN	_	10	mark	_	_
8	there	there	EX	_	10	dep	_	_
9	have	have	VBP	_	10	aux	_	_
10	been	be	VBN	_	33	advcl	_	_
11	isolated	isolate	VBN	_	12	attr	_	_
12	reports	report	NNS	_	10	obj	_	_
13	of	of	IN	_	14	case	_	_
14	patients	patient	NNS	_	12	ppmod	_	_
15	with	with	IN	_	18	case	_	_
16	elevated	elevated	JJ	_	18	attr	_	_
17	drug2	drug0	NN	_	18	com	_	_
18	levels	level	NNS	_	14	ppmod	_	_
19	,	,	,	_	10	p	_	_
20	and	and	CC	_	10	cc	_	_
21	there	there	EX	_	22	dep	_	_
22	is	be	VBZ	_	10	conj	_	_
23	a	a	DT	_	25	det	_	_
24	possible	possible	JJ	_	25	attr	_	_
25	interaction	interaction	NN	_	22	obj	_	_
26	between	between	IN	_	27	case	_	_
27	drug3	drug0	NN	_	25	ppmod	_	_
28	and	and	CC	_	27	cc	_	_
29	drug4	drug0	NN	_	27	conj	_	_
30	,	,	,	_	33	p	_	_
31	it	it	PRP	_	33	dep	_	_
32	is	be	VBZ	_	33	aux	_	_
33	recommended	recommend	VBN	_	1	acl	_	_
34	that	that	IN	_	38	mark	_	_
35	drug5	drug0	NN	_	36	com	_	_
36	levels	level	NNS	_	38	dep	_	_
37	be	be	VB	_	38	aux	_	_
38	monitored	monitor	VBN	_	33	comp	_	_
39	when	when	WRB	_	40	adv	_	_
40	initiating	initiate	VBG	_	38	comp	_	_
41	,	,	,	_	40	p	_	_
42	adjusting	adjust	VBG	_	40	conj	_	_
43	,	,	,	_	42	p	_	_
44	and	and	CC	_	42	cc	_	_
45	discontinuing	discontinue	VBG	_	40	conj	_	_
46	drug6	drug0	NN	_	45	obj	_	_
47	to	to	TO	_	48	aux	_	_
48	avoid	avoid	VB	_	45	comp	_	_
49	possible	possible	JJ	_	50	attr	_	_
50	over-	over-	NN	_	48	obj	_	_
51	or	or	CC	_	50	cc	_	_
52	under-digitalization	under-digitalization	NN	_	50	conj	_	_
53	.	.	.	_	1	p	_	_

1	Extended	extended	JJ	_	3	attr	_	_
2	Release	release	NN	_	3	com	_	_
3	Tablets	tablet	NNS	_	0	root	_	_
4	:	:	:	_	3	p	_	_
5	Administration	administration	NN	_	10	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	with	with	IN	_	9	case	_	_
9	drug2	drug0	NN	_	5	ppmod	_	_
10	increased	increase	VBD	_	3	acl	_	_
11	drug3	drug0	NN	_	12	com	_	_
12	levels	level	NNS	_	10	obj	_	_
13	in	in	IN	_	14	case	_	_
14	9	0	CD	_	10	ppmod	_	_
15	of	of	IN	_	18	case	_	_
16	12	0	CD	_	18	num	_	_
17	normal	normal	JJ	_	18	attr	_	_
18	volunteers	volunteer	NNS	_	14	ppmod	_	_
19	.	.	.	_	3	p	_	_

1	The	the	DT	_	3	det	_	_
2	average	average	JJ	_	3	attr	_	_
3	increase	increase	NN	_	4	dep	_	_
4	was	be	VBD	_	0	root	_	_
5	45	0	CD	_	4	obj	_	_
6	%	%	NN	_	5	meta	_	_
7	.	.	.	_	4	p	_	_

1	Another	another	DT	_	2	det	_	_
2	investigator	investigator	NN	_	3	dep	_	_
3	found	find	VBD	_	0	root	_	_
4	no	no	DT	_	5	det	_	_
5	increase	increase	NN	_	3	obj	_	_
6	in	in	IN	_	8	case	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	levels	level	NNS	_	5	ppmod	_	_
9	in	in	IN	_	11	case	_	_
10	13	0	CD	_	11	num	_	_
11	patients	patient	NNS	_	8	ppmod	_	_
12	with	with	IN	_	15	case	_	_
13	coronary	coronary	JJ	_	15	attr	_	_
14	artery	artery	NN	_	15	com	_	_
15	disease	disease	NN	_	11	ppmod	_	_
16	.	.	.	_	3	p	_	_

1	In	in	IN	_	4	case	_	_
2	an	an	DT	_	4	det	_	_
3	uncontrolled	uncontrolled	JJ	_	4	attr	_	_
4	study	study	NN	_	26	ppmod	_	_
5	of	of	IN	_	8	case	_	_
6	over	over	IN	_	7	case	_	_
7	200	0	CD	_	8	num	_	_
8	patients	patient	NNS	_	4	ppmod	_	_
9	with	with	IN	_	12	case	_	_
10	congestive	congestive	JJ	_	12	attr	_	_
11	heart	heart	NN	_	12	com	_	_
12	failure	failure	NN	_	8	ppmod	_	_
13	during	during	IN	_	14	case	_	_
14	which	which	WDT	_	20	ppmod	_	_
15	drug1	drug0	NN	_	17	com	_	_
16	blood	blood	NN	_	17	com	_	_
17	levels	level	NNS	_	20	dep	_	_
18	were	be	VBD	_	20	aux	_	_
19	not	not	RB	_	20	neg	_	_
20	measured	measure	VBN	_	8	relcl	_	_
21	,	,	,	_	26	p	_	_
22	digitalis	digitalis	NN	_	23	com	_	_
23	toxicity	toxicity	NN	_	26	dep	_	_
24	was	be	VBD	_	26	aux	_	_
25	not	not	RB	_	26	neg	_	_
26	observed	observe	VBN	_	0	root	_	_
27	.	.	.	_	26	p	_	_

1	Since	since	IN	_	4	mark	_	_
2	there	there	EX	_	4	dep	_	_
3	have	have	VBP	_	4	aux	_	_
4	been	be	VBN	_	16	advcl	_	_
5	isolated	isolate	VBN	_	6	attr	_	_
6	reports	report	NNS	_	4	obj	_	_
7	of	of	IN	_	8	case	_	_
8	patients	patient	NNS	_	6	ppmod	_	_
9	with	with	IN	_	12	case	_	_
10	elevated	elevated	JJ	_	12	attr	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	levels	level	NNS	_	8	ppmod	_	_
13	,	,	,	_	16	p	_	_
14	it	it	PRP	_	16	dep	_	_
15	is	be	VBZ	_	16	aux	_	_
16	recommended	recommend	VBN	_	0	root	_	_
17	that	that	IN	_	21	mark	_	_
18	drug2	drug0	NN	_	19	com	_	_
19	levels	level	NNS	_	21	dep	_	_
20	be	be	VB	_	21	aux	_	_
21	monitored	monitor	VBN	_	16	comp	_	_
22	when	when	WRB	_	23	adv	_	_
23	initiating	initiate	VBG	_	21	comp	_	_
24	,	,	,	_	23	p	_	_
25	adjusting	adjust	VBG	_	23	conj	_	_
26	,	,	,	_	25	p	_	_
27	and	and	CC	_	25	cc	_	_
28	discontinuing	discontinue	VBG	_	23	conj	_	_
29	drug3	drug0	NN	_	28	obj	_	_
30	to	to	TO	_	31	aux	_	_
31	avoid	avoid	VB	_	28	comp	_	_
32	possible	possible	JJ	_	33	attr	_	_
33	over-	over-	NN	_	31	obj	_	_
34	or	or	CC	_	33	cc	_	_
35	under-digitalization	under-digitalization	NN	_	33	conj	_	_
36	.	.	.	_	16	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Immediate	immediate	JJ	_	5	attr	_	_
4	Release	release	NN	_	5	com	_	_
5	Capsules	capsule	NNS	_	1	attr	_	_
6	:	:	:	_	1	p	_	_
7	There	there	EX	_	9	dep	_	_
8	have	have	VBP	_	9	aux	_	_
9	been	be	VBN	_	1	acl	_	_
10	rare	rare	JJ	_	11	attr	_	_
11	reports	report	NNS	_	9	obj	_	_
12	of	of	IN	_	14	case	_	_
13	an	an	DT	_	14	det	_	_
14	interaction	interaction	NN	_	11	ppmod	_	_
15	between	between	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	drug3	drug0	NN	_	16	conj	_	_
19	(	-lrb-	-LRB-	_	14	p	_	_
20	with	with	IN	_	24	case	_	_
21	a	a	DT	_	24	det	_	_
22	decreased	decrease	VBN	_	24	attr	_	_
23	plasma	plasma	NN	_	24	com	_	_
24	level	level	NN	_	14	ppmod	_	_
25	of	of	IN	_	26	case	_	_
26	drug4	drug0	NN	_	24	ppmod	_	_
27	)	-rrb-	-RRB-	_	14	p	_	_
28	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	There	there	EX	_	5	dep	_	_
4	have	have	VBP	_	5	aux	_	_
5	been	be	VBN	_	1	acl	_	_
6	rare	rare	JJ	_	7	attr	_	_
7	reports	report	NNS	_	5	obj	_	_
8	of	of	IN	_	11	case	_	_
9	increased	increase	VBN	_	11	attr	_	_
10	prothrombin	prothrombin	NN	_	11	com	_	_
11	time	time	NN	_	7	ppmod	_	_
12	in	in	IN	_	13	case	_	_
13	patients	patient	NNS	_	7	ppmod	_	_
14	taking	take	VBG	_	13	acl	_	_
15	drug2	drug0	NN	_	14	obj	_	_
16	to	to	TO	_	17	aux	_	_
17	whom	whom	WP	_	20	ppmod	_	_
18	drug3	drug0	NN	_	20	dep	_	_
19	was	be	VBD	_	20	aux	_	_
20	administered	administer	VBN	_	15	relcl	_	_
21	.	.	.	_	1	p	_	_

1	However	however	RB	_	8	adv	_	_
2	,	,	,	_	8	p	_	_
3	the	the	DT	_	4	det	_	_
4	relationship	relationship	NN	_	8	dep	_	_
5	to	to	TO	_	7	aux	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	therapy	therapy	NN	_	4	ppmod	_	_
8	is	be	VBZ	_	0	root	_	_
9	uncertain	uncertain	JJ	_	8	dep	_	_
10	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	A	a	DT	_	4	det	_	_
4	study	study	NN	_	10	dep	_	_
5	in	in	IN	_	8	case	_	_
6	6	0	CD	_	8	num	_	_
7	healthy	healthy	JJ	_	8	attr	_	_
8	volunteers	volunteer	NNS	_	4	ppmod	_	_
9	has	have	VBZ	_	10	aux	_	_
10	shown	show	VBN	_	1	acl	_	_
11	a	a	DT	_	13	det	_	_
12	significant	significant	JJ	_	13	attr	_	_
13	increase	increase	NN	_	10	obj	_	_
14	in	in	IN	_	18	case	_	_
15	peak	peak	NN	_	18	com	_	_
16	drug2	drug0	NN	_	18	com	_	_
17	plasma	plasma	NN	_	18	com	_	_
18	levels	level	NNS	_	13	ppmod	_	_
19	(	-lrb-	-LRB-	_	20	p	_	_
20	80	0	CD	_	18	num	_	_
21	%	%	NN	_	20	meta	_	_
22	)	-rrb-	-RRB-	_	20	p	_	_
23	and	and	CC	_	18	cc	_	_
24	area-under-the-curve	area-under-the-curve	JJ	_	18	conj	_	_
25	(	-lrb-	-LRB-	_	26	p	_	_
26	74	0	CD	_	24	num	_	_
27	%	%	NN	_	26	meta	_	_
28	)	-rrb-	-RRB-	_	26	p	_	_
29	after	after	IN	_	33	case	_	_
30	a	a	DT	_	33	det	_	_
31	1	0	CD	_	33	num	_	_
32	week	week	NN	_	33	com	_	_
33	course	course	NN	_	10	ppmod	_	_
34	of	of	IN	_	35	case	_	_
35	drug3	drug0	NN	_	33	ppmod	_	_
36	at	at	IN	_	38	case	_	_
37	1000	0	CD	_	38	num	_	_
38	mg	mg	NN	_	35	ppmod	_	_
39	per	per	IN	_	40	case	_	_
40	day	day	NN	_	38	ppmod	_	_
41	and	and	CC	_	40	cc	_	_
42	drug4	drug0	NN	_	40	conj	_	_
43	at	at	IN	_	45	case	_	_
44	40	0	CD	_	45	num	_	_
45	mg	mg	NN	_	38	ppmod	_	_
46	per	per	IN	_	47	case	_	_
47	day	day	NN	_	45	ppmod	_	_
48	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	produced	produce	VBD	_	0	root	_	_
3	smaller	small	JJR	_	5	adv	_	_
4	,	,	,	_	5	p	_	_
5	non-significant	non-significant	JJ	_	6	attr	_	_
6	increases	increase	NNS	_	2	obj	_	_
7	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	5	dep	_	_
3	may	may	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	mediated	mediate	VBN	_	0	root	_	_
6	by	by	IN	_	9	case	_	_
7	the	the	DT	_	9	det	_	_
8	known	known	JJ	_	9	attr	_	_
9	inhibition	inhibition	NN	_	5	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	on	on	IN	_	15	case	_	_
13	hepatic	hepatic	JJ	_	15	attr	_	_
14	cytochrome	cytochrome	NN	_	15	com	_	_
15	P-450	p-0	NN	_	9	ppmod	_	_
16	,	,	,	_	15	p	_	_
17	the	the	DT	_	19	det	_	_
18	enzyme	enzyme	NN	_	19	com	_	_
19	system	system	NN	_	15	appo	_	_
20	probably	probably	RB	_	21	adv	_	_
21	responsible	responsible	JJ	_	19	attr	_	_
22	for	for	IN	_	25	case	_	_
23	the	the	DT	_	25	det	_	_
24	first-pass	first-pass	NN	_	25	com	_	_
25	metabolism	metabolism	NN	_	21	ppmod	_	_
26	of	of	IN	_	27	case	_	_
27	drug2	drug0	NN	_	25	ppmod	_	_
28	.	.	.	_	5	p	_	_

1	If	if	IN	_	5	mark	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	therapy	therapy	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	initiated	initiate	VBN	_	16	advcl	_	_
6	in	in	IN	_	8	case	_	_
7	a	a	DT	_	8	det	_	_
8	patient	patient	NN	_	5	ppmod	_	_
9	currently	currently	RB	_	10	adv	_	_
10	receiving	receive	VBG	_	8	acl	_	_
11	drug2	drug0	NN	_	10	obj	_	_
12	,	,	,	_	16	p	_	_
13	cautious	cautious	JJ	_	14	attr	_	_
14	titration	titration	NN	_	16	dep	_	_
15	is	be	VBZ	_	16	aux	_	_
16	advised	advise	VBN	_	0	root	_	_
17	.	.	.	_	16	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	avoided	avoid	VBN	_	0	root	_	_
5	by	by	IN	_	6	case	_	_
6	patients	patient	NNS	_	4	ppmod	_	_
7	with	with	IN	_	9	case	_	_
8	a	a	DT	_	9	det	_	_
9	history	history	NN	_	6	ppmod	_	_
10	of	of	IN	_	12	case	_	_
11	serious	serious	JJ	_	12	attr	_	_
12	reaction	reaction	NN	_	9	ppmod	_	_
13	to	to	TO	_	15	aux	_	_
14	any	any	DT	_	15	det	_	_
15	drug2	drug0	NNS	_	9	ppmod	_	_
16	,	,	,	_	15	p	_	_
17	including	include	VBG	_	18	adv	_	_
18	drug3	drug0	NN	_	15	ppmod	_	_
19	and	and	CC	_	18	cc	_	_
20	drug4	drug0	NN	_	18	conj	_	_
21	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	should	should	MD	_	5	modal	_	_
3	not	not	RB	_	5	neg	_	_
4	be	be	VB	_	5	aux	_	_
5	used	use	VBN	_	0	root	_	_
6	together	together	RB	_	5	adv	_	_
7	with	with	IN	_	8	case	_	_
8	drug2	drug0	NN	_	5	ppmod	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	drug3	drug0	NN	_	8	prn	_	_
11	,	,	,	_	10	p	_	_
12	drug4	drug0	NN	_	10	appo	_	_
13	)	-rrb-	-RRB-	_	10	p	_	_
14	,	,	,	_	8	p	_	_
15	another	another	DT	_	17	det	_	_
16	arthritis	arthritis	NN	_	17	com	_	_
17	medication	medication	NN	_	8	appo	_	_
18	.	.	.	_	5	p	_	_

1	It	it	PRP	_	5	dep	_	_
2	should	should	MD	_	5	modal	_	_
3	also	also	RB	_	5	adv	_	_
4	be	be	VB	_	5	aux	_	_
5	avoided	avoid	VBN	_	0	root	_	_
6	in	in	IN	_	7	case	_	_
7	patients	patient	NNS	_	5	ppmod	_	_
8	with	with	IN	_	9	case	_	_
9	blood	blood	NN	_	7	ppmod	_	_
10	,	,	,	_	9	p	_	_
11	liver	liver	NN	_	9	conj	_	_
12	or	or	CC	_	11	cc	_	_
13	kidney	kidney	NN	_	14	com	_	_
14	diseases	disease	NNS	_	9	conj	_	_
15	,	,	,	_	14	p	_	_
16	recent	recent	JJ	_	18	attr	_	_
17	radiation	radiation	NN	_	18	com	_	_
18	treatment	treatment	NN	_	9	conj	_	_
19	,	,	,	_	18	p	_	_
20	or	or	CC	_	18	cc	_	_
21	uncontrolled	uncontrolled	JJ	_	22	attr	_	_
22	diabetes	diabetes	NN	_	9	conj	_	_
23	.	.	.	_	5	p	_	_

1	Patients	patient	NNS	_	3	dep	_	_
2	should	should	MD	_	3	modal	_	_
3	report	report	VBP	_	0	root	_	_
4	to	to	TO	_	6	aux	_	_
5	their	their	PRP$	_	6	poss	_	_
6	practitioners	practitioner	NNS	_	3	ppmod	_	_
7	any	any	DT	_	9	det	_	_
8	new	new	JJ	_	9	attr	_	_
9	rashes	rashes	NN	_	6	appo	_	_
10	,	,	,	_	9	p	_	_
11	itching	itching	NN	_	9	conj	_	_
12	,	,	,	_	11	p	_	_
13	mouth	mouth	NN	_	14	com	_	_
14	sores	sore	NNS	_	9	conj	_	_
15	,	,	,	_	14	p	_	_
16	or	or	CC	_	14	cc	_	_
17	unusual	unusual	JJ	_	18	attr	_	_
18	taste	taste	NN	_	9	conj	_	_
19	while	while	IN	_	20	mark	_	_
20	taking	take	VBG	_	3	comp	_	_
21	drug1	drug0	NN	_	20	obj	_	_
22	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	excreted	excrete	VBN	_	0	root	_	_
4	slowly	slowly	RB	_	3	adv	_	_
5	from	from	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	body	body	NN	_	3	ppmod	_	_
8	.	.	.	_	3	p	_	_

1	Safety	safety	NN	_	9	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	effectiveness	effectiveness	NN	_	1	conj	_	_
4	in	in	IN	_	5	case	_	_
5	children	child	NNS	_	1	ppmod	_	_
6	has	have	VBZ	_	9	aux	_	_
7	not	not	RB	_	9	neg	_	_
8	been	be	VBN	_	9	aux	_	_
9	established	establish	VBN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	The	the	DT	_	2	det	_	_
2	potential	potential	NN	_	10	dep	_	_
3	for	for	IN	_	5	case	_	_
4	drug	drug	NN	_	5	com	_	_
5	interactions	interaction	NNS	_	2	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	has	have	VBZ	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	studied	study	VBN	_	0	root	_	_
11	in	in	IN	_	12	case	_	_
12	combination	combination	NN	_	10	ppmod	_	_
13	with	with	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	,	,	,	_	14	p	_	_
16	drug3	drug0	NN	_	14	conj	_	_
17	,	,	,	_	16	p	_	_
18	drug4	drug0	NN	_	14	conj	_	_
19	,	,	,	_	18	p	_	_
20	and	and	CC	_	18	cc	_	_
21	drug5	drug0	NN	_	14	conj	_	_
22	.	.	.	_	10	p	_	_

1	There	there	EX	_	2	dep	_	_
2	were	be	VBD	_	0	root	_	_
3	no	no	DT	_	7	det	_	_
4	clinically	clinically	RB	_	5	adv	_	_
5	significant	significant	JJ	_	7	attr	_	_
6	drug	drug	NN	_	7	com	_	_
7	interactions	interaction	NNS	_	2	obj	_	_
8	for	for	IN	_	9	case	_	_
9	any	any	DT	_	7	ppmod	_	_
10	of	of	IN	_	12	case	_	_
11	these	these	DT	_	12	det	_	_
12	drugs	drug	NNS	_	9	ppmod	_	_

1	.	.	.	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	May	may	MD	_	2	modal	_	_
2	interact	interact	VB	_	0	root	_	_
3	with	with	IN	_	5	case	_	_
4	addictive	addictive	JJ	_	5	attr	_	_
5	medications	medication	NNS	_	2	ppmod	_	_
6	,	,	,	_	5	p	_	_
7	especially	especially	RB	_	5	adv	_	_
8	drug1	drug0	NN	_	5	appo	_	_
9	with	with	IN	_	11	case	_	_
10	habituating	habituating	JJ	_	11	attr	_	_
11	potential	potential	NN	_	2	ppmod	_	_
12	(	-lrb-	-LRB-	_	17	p	_	_
13	prolonged	prolonged	JJ	_	15	attr	_	_
14	concurrent	concurrent	JJ	_	15	attr	_	_
15	use	use	NN	_	17	dep	_	_
16	may	may	MD	_	17	modal	_	_
17	increase	increase	VB	_	11	prn	_	_
18	the	the	DT	_	19	det	_	_
19	risk	risk	NN	_	17	obj	_	_
20	of	of	IN	_	21	case	_	_
21	habituation	habituation	NN	_	19	ppmod	_	_
22	)	-rrb-	-RRB-	_	17	p	_	_
23	,	,	,	_	11	p	_	_
24	drug2	drug0	NN	_	11	appo	_	_
25	or	or	CC	_	24	cc	_	_
26	CNS	cns	NN	_	27	com	_	_
27	depression	depression	NN	_	24	conj	_	_
28	producing	produce	VBG	_	24	acl	_	_
29	medications	medication	NNS	_	28	obj	_	_
30	(	-lrb-	-LRB-	_	34	p	_	_
31	concurrent	concurrent	JJ	_	32	attr	_	_
32	use	use	NN	_	34	dep	_	_
33	may	may	MD	_	34	modal	_	_
34	increase	increase	VB	_	29	prn	_	_
35	the	the	DT	_	38	det	_	_
36	CNS	cns	NN	_	38	com	_	_
37	depressant	depressant	NN	_	38	com	_	_
38	effects	effect	NNS	_	34	obj	_	_
39	of	of	IN	_	42	case	_	_
40	either	either	CC	_	42	cc	_	_
41	these	these	DT	_	42	det	_	_
42	medications	medication	NNS	_	38	ppmod	_	_
43	or	or	CC	_	42	cc	_	_
44	drug3	drug0	NNS	_	42	conj	_	_
45	)	-rrb-	-RRB-	_	34	p	_	_
46	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	potentiates	potentiate	VBZ	_	0	root	_	_
3	other	other	JJ	_	4	attr	_	_
4	drug2	drug0	NNS	_	2	obj	_	_
5	such	such	JJ	_	7	adv	_	_
6	as	as	IN	_	7	case	_	_
7	drug3	drug0	NN	_	4	ppmod	_	_
8	or	or	CC	_	7	cc	_	_
9	drug4	drug0	NN	_	7	conj	_	_
10	and	and	CC	_	9	cc	_	_
11	drug5	drug0	NN	_	12	com	_	_
12	s	s	NN	_	9	conj	_	_
13	.	.	.	_	2	p	_	_

1	Patients	patient	NNS	_	8	dep	_	_
2	undergoing	undergo	VBG	_	1	acl	_	_
3	systemic	systemic	JJ	_	5	attr	_	_
4	anticholinesterase	anticholinesterase	NN	_	5	com	_	_
5	treatment	treatment	NN	_	2	obj	_	_
6	should	should	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	warned	warn	VBN	_	0	root	_	_
9	of	of	IN	_	13	case	_	_
10	the	the	DT	_	13	det	_	_
11	possible	possible	JJ	_	13	attr	_	_
12	additive	additive	JJ	_	13	attr	_	_
13	effects	effect	NNS	_	8	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	8	p	_	_

1	Renal	renal	JJ	_	2	attr	_	_
2	function	function	NN	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	monitored	monitor	VBN	_	0	root	_	_
6	carefully	carefully	RB	_	5	adv	_	_
7	if	if	IN	_	12	mark	_	_
8	high	high	JJ	_	9	attr	_	_
9	doses	dose	NNS	_	12	dep	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	are	be	VBP	_	5	comp	_	_
13	to	to	TO	_	15	aux	_	_
14	be	be	VB	_	15	aux	_	_
15	administered	administer	VBN	_	12	comp	_	_
16	with	with	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	because	because	IN	_	22	case	_	_
19	of	of	IN	_	22	case	_	_
20	the	the	DT	_	22	det	_	_
21	increased	increase	VBN	_	22	attr	_	_
22	potential	potential	NN	_	15	ppmod	_	_
23	of	of	IN	_	24	case	_	_
24	nephrotoxicity	nephrotoxicity	NN	_	22	ppmod	_	_
25	and	and	CC	_	24	cc	_	_
26	ototoxicity	ototoxicity	NN	_	24	conj	_	_
27	of	of	IN	_	28	case	_	_
28	drug3	drug0	NN	_	24	ppmod	_	_
29	.	.	.	_	5	p	_	_

1	Nephrotoxicity	nephrotoxicity	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	reported	report	VBN	_	0	root	_	_
5	following	follow	VBG	_	7	adv	_	_
6	concomitant	concomitant	JJ	_	7	attr	_	_
7	administration	administration	NN	_	4	ppmod	_	_
8	of	of	IN	_	10	case	_	_
9	other	other	JJ	_	10	attr	_	_
10	drug1	drug0	NN	_	7	ppmod	_	_
11	with	with	IN	_	13	case	_	_
12	potent	potent	JJ	_	13	attr	_	_
13	drug2	drug0	NNS	_	7	ppmod	_	_
14	such	such	JJ	_	16	adv	_	_
15	as	as	IN	_	16	case	_	_
16	drug3	drug0	NN	_	13	ppmod	_	_
17	.	.	.	_	4	p	_	_

1	Drug/Laboratory	drug/laboratory	NN	_	3	com	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	0	root	_	_
4	The	the	DT	_	5	det	_	_
5	administration	administration	NN	_	9	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	may	may	MD	_	9	modal	_	_
9	result	result	VB	_	3	acl	_	_
10	in	in	IN	_	13	case	_	_
11	a	a	DT	_	13	det	_	_
12	false-positive	false-positive	JJ	_	13	attr	_	_
13	reaction	reaction	NN	_	9	ppmod	_	_
14	for	for	IN	_	15	case	_	_
15	glucose	glucose	NN	_	13	ppmod	_	_
16	in	in	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	urine	urine	NN	_	13	ppmod	_	_
19	when	when	WRB	_	20	adv	_	_
20	using	use	VBG	_	9	comp	_	_
21	Clinitest	clinitest	NN	_	22	com	_	_
22	tablets	tablet	NNS	_	20	obj	_	_
23	.	.	.	_	3	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	recommended	recommend	VBN	_	0	root	_	_
4	that	that	IN	_	21	mark	_	_
5	glucose	glucose	NN	_	6	com	_	_
6	tests	test	NNS	_	21	dep	_	_
7	based	base	VBN	_	6	acl	_	_
8	on	on	IN	_	12	case	_	_
9	enzymatic	enzymatic	JJ	_	12	attr	_	_
10	glucose	glucose	NN	_	12	com	_	_
11	oxidase	oxidase	NN	_	12	com	_	_
12	reactions	reaction	NNS	_	7	ppmod	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	such	such	JJ	_	12	prn	_	_
15	as	as	IN	_	16	case	_	_
16	Clinistix	clinistix	NN	_	14	ppmod	_	_
17	or	or	CC	_	16	cc	_	_
18	Tes-Tape	tes-tape	NN	_	16	conj	_	_
19	)	-rrb-	-RRB-	_	14	p	_	_
20	be	be	VB	_	21	aux	_	_
21	used	use	VBN	_	3	comp	_	_
22	.	.	.	_	3	p	_	_

1	There	there	EX	_	3	dep	_	_
2	have	have	VBP	_	3	aux	_	_
3	been	be	VBN	_	0	root	_	_
4	no	no	DT	_	6	det	_	_
5	formal	formal	JJ	_	6	attr	_	_
6	studies	study	NNS	_	3	obj	_	_
7	of	of	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	interaction	interaction	NN	_	6	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	for	for	IN	_	14	case	_	_
13	Topical	topical	JJ	_	14	attr	_	_
14	Solution	solution	NN	_	11	ppmod	_	_
15	with	with	IN	_	18	case	_	_
16	any	any	DT	_	18	det	_	_
17	other	other	JJ	_	18	attr	_	_
18	drugs	drug	NNS	_	14	ppmod	_	_
19	,	,	,	_	3	p	_	_
20	and	and	CC	_	3	cc	_	_
21	no	no	DT	_	23	det	_	_
22	drug-specific	drug-specific	JJ	_	23	attr	_	_
23	interactions	interaction	NNS	_	25	dep	_	_
24	were	be	VBD	_	25	aux	_	_
25	noted	note	VBN	_	3	conj	_	_
26	during	during	IN	_	27	case	_	_
27	any	any	DT	_	25	ppmod	_	_
28	of	of	IN	_	32	case	_	_
29	the	the	DT	_	32	det	_	_
30	controlled	controlled	JJ	_	32	attr	_	_
31	clinical	clinical	JJ	_	32	attr	_	_
32	trials	trial	NNS	_	27	ppmod	_	_
33	.	.	.	_	3	p	_	_

1	It	it	PRP	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	,	,	,	_	2	p	_	_
4	however	however	RB	_	2	adv	_	_
5	,	,	,	_	2	p	_	_
6	possible	possible	JJ	_	2	dep	_	_
7	that	that	IN	_	28	mark	_	_
8	concomitant	concomitant	JJ	_	9	attr	_	_
9	use	use	NN	_	28	dep	_	_
10	of	of	IN	_	13	case	_	_
11	other	other	JJ	_	13	attr	_	_
12	known	known	JJ	_	13	attr	_	_
13	drug1	drug0	NN	_	9	ppmod	_	_
14	such	such	JJ	_	16	adv	_	_
15	as	as	IN	_	16	case	_	_
16	drug2	drug0	NN	_	9	ppmod	_	_
17	,	,	,	_	16	p	_	_
18	drug3	drug0	NN	_	16	conj	_	_
19	,	,	,	_	18	p	_	_
20	drug4	drug0	NN	_	16	conj	_	_
21	,	,	,	_	20	p	_	_
22	drug5	drug0	NN	_	16	conj	_	_
23	,	,	,	_	22	p	_	_
24	drug6	drug0	NN	_	16	conj	_	_
25	and	and	CC	_	24	cc	_	_
26	drug7	drug0	NN	_	16	conj	_	_
27	might	might	MD	_	28	modal	_	_
28	increase	increase	VB	_	2	comp	_	_
29	the	the	DT	_	31	det	_	_
30	photosensitivity	photosensitivity	NN	_	31	com	_	_
31	reaction	reaction	NN	_	28	obj	_	_
32	of	of	IN	_	34	case	_	_
33	actinic	actinic	JJ	_	34	attr	_	_
34	keratoses	keratoses	NNS	_	31	ppmod	_	_
35	treated	treat	VBN	_	34	acl	_	_
36	with	with	IN	_	38	case	_	_
37	the	the	DT	_	38	det	_	_
38	drug8	drug0	NN	_	35	ppmod	_	_
39	for	for	IN	_	41	case	_	_
40	Topical	topical	JJ	_	41	attr	_	_
41	Solution	solution	NN	_	35	ppmod	_	_
42	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	metabolized	metabolize	VBN	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	by	by	IN	_	9	case	_	_
7	cytochrome	cytochrome	NN	_	9	com	_	_
8	CYP	cyp	NN	_	9	com	_	_
9	3A4	0a0	NN	_	3	ppmod	_	_
10	.	.	.	_	3	p	_	_

1	Because	because	IN	_	6	mark	_	_
2	CYP	cyp	NN	_	4	com	_	_
3	3A4	0a0	NN	_	4	com	_	_
4	inhibitors	inhibitor	NNS	_	6	dep	_	_
5	may	may	MD	_	6	modal	_	_
6	increase	increase	VB	_	0	root	_	_
7	plasma	plasma	NN	_	8	com	_	_
8	concentrations	concentration	NNS	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	,	,	,	_	6	p	_	_
12	patients	patient	NNS	_	6	dep	_	_
13	already	already	RB	_	6	adv	_	_
14	on	on	IN	_	17	case	_	_
15	CYP	cyp	NN	_	17	com	_	_
16	3A4	0a0	NN	_	17	com	_	_
17	inhibitors	inhibitor	NNS	_	6	ppmod	_	_
18	such	such	JJ	_	20	adv	_	_
19	as	as	IN	_	20	case	_	_
20	drug2	drug0	NN	_	17	ppmod	_	_
21	(	-lrb-	-LRB-	_	22	p	_	_
22	e.g.	e.g.	FW	_	20	prn	_	_

1	drug1	drug0	NN	_	21	dep	_	_
2	)	-rrb-	-RRB-	_	1	p	_	_
3	,	,	,	_	1	p	_	_
4	drug2	drug0	NN	_	1	conj	_	_
5	(	-lrb-	-LRB-	_	7	p	_	_
6	e.g.	e.g.	FW	_	7	ppmod	_	_
7	drug3	drug0	NN	_	4	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	,	,	,	_	4	p	_	_
10	and	and	CC	_	4	cc	_	_
11	drug4	drug0	NN	_	1	conj	_	_
12	(	-lrb-	-LRB-	_	14	p	_	_
13	e.g.	e.g.	FW	_	14	ppmod	_	_
14	drug5	drug0	NN	_	11	prn	_	_
15	,	,	,	_	14	p	_	_
16	drug6	drug0	NN	_	14	conj	_	_
17	and	and	CC	_	16	cc	_	_
18	drug7	drug0	NN	_	14	conj	_	_
19	)	-rrb-	-RRB-	_	14	p	_	_
20	should	should	MD	_	21	modal	_	_
21	have	have	VB	_	0	root	_	_
22	their	their	PRP$	_	23	poss	_	_
23	dose	dose	NN	_	21	obj	_	_
24	of	of	IN	_	25	case	_	_
25	drug8	drug0	NN	_	23	ppmod	_	_
26	or	or	CC	_	25	cc	_	_
27	drug9	drug0	NN	_	25	conj	_	_
28	adjusted	adjust	VBN	_	25	acl	_	_
29	.	.	.	_	21	p	_	_

1	Based	base	VBN	_	4	adv	_	_
2	on	on	IN	_	4	case	_	_
3	anecdotal	anecdotal	JJ	_	4	attr	_	_
4	reports	report	NNS	_	8	ppmod	_	_
5	,	,	,	_	8	p	_	_
6	there	there	EX	_	8	dep	_	_
7	may	may	MD	_	8	modal	_	_
8	be	be	VB	_	0	root	_	_
9	an	an	DT	_	10	det	_	_
10	interaction	interaction	NN	_	8	obj	_	_
11	between	between	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	drug2	drug0	NN	_	12	conj	_	_
15	.	.	.	_	8	p	_	_

1	There	there	EX	_	3	dep	_	_
2	have	have	VBP	_	3	aux	_	_
3	been	be	VBN	_	0	root	_	_
4	a	a	DT	_	5	det	_	_
5	number	number	NN	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	reports	report	NNS	_	5	ppmod	_	_
8	in	in	IN	_	11	case	_	_
9	the	the	DT	_	11	det	_	_
10	post-marketing	post-marketing	JJ	_	11	attr	_	_
11	experience	experience	VBP	_	7	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	coma	coma	NN	_	11	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	death	death	NN	_	13	conj	_	_
16	associated	associate	VBN	_	13	acl	_	_
17	with	with	IN	_	21	case	_	_
18	the	the	DT	_	21	det	_	_
19	concomitant	concomitant	JJ	_	21	attr	_	_
20	intravenous	intravenous	JJ	_	21	attr	_	_
21	misuse	misuse	NN	_	16	ppmod	_	_
22	of	of	IN	_	23	case	_	_
23	drug1	drug0	NN	_	21	ppmod	_	_
24	and	and	CC	_	23	cc	_	_
25	drug2	drug0	NN	_	23	conj	_	_
26	by	by	IN	_	27	case	_	_
27	addicts	addict	NNS	_	23	ppmod	_	_
28	.	.	.	_	3	p	_	_

1	In	in	IN	_	2	case	_	_
2	many	many	JJ	_	8	ppmod	_	_
3	of	of	IN	_	5	case	_	_
4	these	these	DT	_	5	det	_	_
5	cases	case	NNS	_	2	ppmod	_	_
6	,	,	,	_	8	p	_	_
7	drug1	drug0	NN	_	8	dep	_	_
8	was	be	VBD	_	0	root	_	_
9	misused	misused	JJ	_	8	dep	_	_
10	by	by	IN	_	11	case	_	_
11	self-injection	self-injection	NN	_	9	ppmod	_	_
12	of	of	IN	_	15	case	_	_
13	crushed	crushed	JJ	_	15	attr	_	_
14	drug2	drug0	NN	_	15	com	_	_
15	tablets	tablet	NNS	_	11	ppmod	_	_
16	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	prescribed	prescribe	VBN	_	0	root	_	_
7	with	with	IN	_	8	case	_	_
8	caution	caution	NN	_	6	ppmod	_	_
9	to	to	TO	_	10	aux	_	_
10	patients	patient	NNS	_	8	ppmod	_	_
11	on	on	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	or	or	CC	_	12	cc	_	_
14	other	other	JJ	_	15	attr	_	_
15	drugs	drug	NNS	_	12	conj	_	_
16	that	that	WDT	_	17	dep	_	_
17	act	act	VBP	_	10	relcl	_	_
18	on	on	IN	_	22	case	_	_
19	the	the	DT	_	22	det	_	_
20	central	central	JJ	_	22	attr	_	_
21	nervous	nervous	JJ	_	22	attr	_	_
22	system	system	NN	_	17	ppmod	_	_
23	,	,	,	_	6	p	_	_
24	regardless	regardless	RB	_	6	adv	_	_
25	of	of	IN	_	30	case	_	_
26	whether	whether	IN	_	30	mark	_	_
27	these	these	DT	_	28	det	_	_
28	drugs	drug	NNS	_	30	dep	_	_
29	are	be	VBP	_	30	aux	_	_
30	taken	take	VBN	_	24	ppmod	_	_
31	on	on	IN	_	33	case	_	_
32	the	the	DT	_	33	det	_	_
33	advice	advice	NN	_	30	ppmod	_	_
34	of	of	IN	_	36	case	_	_
35	a	a	DT	_	36	det	_	_
36	physician	physician	NN	_	33	ppmod	_	_
37	or	or	CC	_	30	cc	_	_
38	are	be	VBP	_	39	aux	_	_
39	taken	take	VBN	_	30	conj	_	_
40	as	as	IN	_	41	case	_	_
41	drugs	drug	NNS	_	39	ppmod	_	_
42	of	of	IN	_	43	case	_	_
43	abuse	abuse	NN	_	41	ppmod	_	_
44	.	.	.	_	6	p	_	_

1	Patients	patient	NNS	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	warned	warn	VBN	_	0	root	_	_
5	of	of	IN	_	8	case	_	_
6	the	the	DT	_	8	det	_	_
7	potential	potential	JJ	_	8	attr	_	_
8	danger	danger	NN	_	4	ppmod	_	_
9	of	of	IN	_	12	case	_	_
10	the	the	DT	_	12	det	_	_
11	intravenous	intravenous	JJ	_	12	attr	_	_
12	self-administration	self-administration	NN	_	8	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	while	while	IN	_	17	case	_	_
16	under	under	IN	_	17	case	_	_
17	treatment	treatment	NN	_	4	ppmod	_	_
18	with	with	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	or	or	CC	_	19	cc	_	_
21	drug3	drug0	NN	_	19	conj	_	_
22	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	7	dep	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	drug2	drug0	NN	_	1	prn	_	_
4	)	-rrb-	-RRB-	_	3	p	_	_
5	has	have	VBZ	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	reported	report	VBN	_	0	root	_	_
8	to	to	TO	_	9	aux	_	_
9	produce	produce	VB	_	7	comp	_	_
10	ANTABUSE-like	antabuse-like	JJ	_	12	attr	_	_
11	side	side	JJ	_	12	attr	_	_
12	effects	effect	NNS	_	9	obj	_	_
13	when	when	WRB	_	14	adv	_	_
14	given	give	VBN	_	9	comp	_	_
15	concomitantly	concomitantly	RB	_	14	adv	_	_
16	with	with	IN	_	17	case	_	_
17	drug3	drug0	NN	_	14	ppmod	_	_
18	.	.	.	_	7	p	_	_

1	The	the	DT	_	2	det	_	_
2	physician	physician	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	advised	advise	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	monitor	monitor	VB	_	4	comp	_	_
7	plasma	plasma	NN	_	8	com	_	_
8	levels	level	NNS	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	6	cc	_	_
12	to	to	TO	_	13	aux	_	_
13	decrease	decrease	VB	_	6	conj	_	_
14	the	the	DT	_	15	det	_	_
15	dose	dose	NN	_	13	obj	_	_
16	if	if	IN	_	17	mark	_	_
17	necessary	necessary	JJ	_	15	acl	_	_
18	.	.	.	_	4	p	_	_

1	Because	because	IN	_	3	case	_	_
2	of	of	IN	_	3	case	_	_
3	reports	report	NNS	_	24	ppmod	_	_
4	of	of	IN	_	5	case	_	_
5	prolongation	prolongation	NN	_	3	ppmod	_	_
6	of	of	IN	_	9	case	_	_
7	the	the	DT	_	9	det	_	_
8	prothrombin	prothrombin	NN	_	9	com	_	_
9	time	time	NN	_	5	ppmod	_	_
10	beyond	beyond	IN	_	13	case	_	_
11	the	the	DT	_	13	det	_	_
12	therapeutic	therapeutic	JJ	_	13	attr	_	_
13	range	range	NN	_	9	ppmod	_	_
14	in	in	IN	_	15	case	_	_
15	patients	patient	NNS	_	13	ppmod	_	_
16	taking	take	VBG	_	15	acl	_	_
17	concurrent	concurrent	JJ	_	18	attr	_	_
18	drug1	drug0	NN	_	16	obj	_	_
19	and	and	CC	_	18	cc	_	_
20	drug2	drug0	NN	_	18	conj	_	_
21	,	,	,	_	24	p	_	_
22	it	it	PRP	_	24	dep	_	_
23	is	be	VBZ	_	24	aux	_	_
24	suggested	suggest	VBN	_	0	root	_	_
25	that	that	IN	_	30	mark	_	_
26	the	the	DT	_	28	det	_	_
27	prothrombin	prothrombin	NN	_	28	com	_	_
28	time	time	NN	_	30	dep	_	_
29	be	be	VB	_	30	aux	_	_
30	monitored	monitor	VBN	_	24	comp	_	_
31	carefully	carefully	RB	_	30	adv	_	_
32	,	,	,	_	30	p	_	_
33	and	and	CC	_	30	cc	_	_
34	the	the	DT	_	35	det	_	_
35	dose	dose	NN	_	45	dep	_	_
36	of	of	IN	_	37	case	_	_
37	drug3	drug0	NN	_	35	ppmod	_	_
38	or	or	CC	_	37	cc	_	_
39	other	other	JJ	_	42	attr	_	_
40	drug4	drug0	NN	_	42	attr	_	_
41	-like	-like	JJ	_	42	attr	_	_
42	drugs	drug	NNS	_	37	conj	_	_
43	should	should	MD	_	45	modal	_	_
44	be	be	VB	_	45	aux	_	_
45	adjusted	adjust	VBN	_	30	conj	_	_
46	accordingly	accordingly	RB	_	45	adv	_	_
47	,	,	,	_	45	p	_	_
48	in	in	IN	_	49	case	_	_
49	patients	patient	NNS	_	45	ppmod	_	_
50	taking	take	VBG	_	49	acl	_	_
51	both	both	DT	_	52	det	_	_
52	drugs	drug	NNS	_	50	obj	_	_
53	.	.	.	_	24	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	a	a	DT	_	4	det	_	_
4	substrate	substrate	NN	_	2	obj	_	_
5	,	,	,	_	4	p	_	_
6	a	a	DT	_	8	det	_	_
7	moderate	moderate	JJ	_	8	attr	_	_
8	inhibitor	inhibitor	NN	_	4	conj	_	_
9	,	,	,	_	8	p	_	_
10	and	and	CC	_	8	cc	_	_
11	an	an	DT	_	12	det	_	_
12	inducer	inducer	NN	_	4	conj	_	_
13	of	of	IN	_	14	case	_	_
14	CYP3A4	cyp0a0	NN	_	12	ppmod	_	_
15	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	also	also	RB	_	2	adv	_	_
4	an	an	DT	_	5	det	_	_
5	inducer	inducer	NN	_	2	obj	_	_
6	of	of	IN	_	7	case	_	_
7	CYP2C9	cyp0c0	NN	_	5	ppmod	_	_
8	.	.	.	_	2	p	_	_

1	Effect	effect	NN	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	on	on	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	pharmacokinetics	pharmacokinetics	NNS	_	1	ppmod	_	_
7	of	of	IN	_	9	case	_	_
8	other	other	JJ	_	9	attr	_	_
9	agents	agent	NNS	_	6	ppmod	_	_

1	As	as	IN	_	4	case	_	_
2	a	a	DT	_	4	det	_	_
3	moderate	moderate	JJ	_	4	attr	_	_
4	inhibitor	inhibitor	NN	_	10	ppmod	_	_
5	of	of	IN	_	6	case	_	_
6	CYP3A4	cyp0a0	NN	_	4	ppmod	_	_
7	,	,	,	_	10	p	_	_
8	drug1	drug0	NN	_	10	dep	_	_
9	can	can	MD	_	10	modal	_	_
10	increase	increase	VB	_	0	root	_	_
11	plasma	plasma	NN	_	12	com	_	_
12	concentrations	concentration	NNS	_	10	obj	_	_
13	of	of	IN	_	16	case	_	_
14	coadministered	coadministered	JJ	_	16	attr	_	_
15	medicinal	medicinal	NN	_	16	com	_	_
16	products	product	NNS	_	12	ppmod	_	_
17	that	that	WDT	_	19	dep	_	_
18	are	be	VBP	_	19	aux	_	_
19	metabolized	metabolize	VBN	_	16	relcl	_	_
20	through	through	IN	_	21	case	_	_
21	CYP3A4	cyp0a0	NN	_	19	ppmod	_	_
22	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	shown	show	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	induce	induce	VB	_	4	comp	_	_
7	the	the	DT	_	8	det	_	_
8	metabolism	metabolism	NN	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug3	drug0	NN	_	10	conj	_	_
13	,	,	,	_	10	p	_	_
14	which	which	WDT	_	16	dep	_	_
15	are	be	VBP	_	16	aux	_	_
16	metabolized	metabolize	VBN	_	10	relcl	_	_
17	through	through	IN	_	18	case	_	_
18	CYP2C9	cyp0c0	NN	_	16	ppmod	_	_
19	.	.	.	_	4	p	_	_

1	Coadministration	coadministration	NN	_	24	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	6	case	_	_
5	these	these	DT	_	6	det	_	_
6	drugs	drug	NNS	_	1	ppmod	_	_
7	or	or	CC	_	6	cc	_	_
8	other	other	JJ	_	9	attr	_	_
9	drugs	drug	NNS	_	6	conj	_	_
10	that	that	WDT	_	12	dep	_	_
11	are	be	VBP	_	12	aux	_	_
12	known	know	VBN	_	6	relcl	_	_
13	to	to	TO	_	15	aux	_	_
14	be	be	VB	_	15	aux	_	_
15	metabolized	metabolize	VBN	_	12	comp	_	_
16	by	by	IN	_	17	case	_	_
17	CYP2C9	cyp0c0	NN	_	15	ppmod	_	_
18	,	,	,	_	6	p	_	_
19	such	such	JJ	_	21	adv	_	_
20	as	as	IN	_	21	case	_	_
21	drug2	drug0	NN	_	6	ppmod	_	_
22	,	,	,	_	6	p	_	_
23	may	may	MD	_	24	modal	_	_
24	result	result	VB	_	0	root	_	_
25	in	in	IN	_	28	case	_	_
26	lower	low	JJR	_	28	attr	_	_
27	plasma	plasma	NN	_	28	com	_	_
28	concentrations	concentration	NNS	_	24	ppmod	_	_
29	of	of	IN	_	31	case	_	_
30	these	these	DT	_	31	det	_	_
31	drugs	drug	NNS	_	28	ppmod	_	_
32	.	.	.	_	24	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	unlikely	unlikely	JJ	_	2	dep	_	_
4	to	to	TO	_	5	aux	_	_
5	interact	interact	VB	_	3	comp	_	_
6	with	with	IN	_	7	case	_	_
7	drugs	drug	NNS	_	5	ppmod	_	_
8	that	that	WDT	_	9	dep	_	_
9	are	be	VBP	_	7	relcl	_	_
10	substrates	substrate	NNS	_	9	obj	_	_
11	for	for	IN	_	14	case	_	_
12	the	the	DT	_	14	det	_	_
13	P-glycoprotein	p-glycoprotein	NN	_	14	com	_	_
14	transporter	transporter	NN	_	10	ppmod	_	_
15	,	,	,	_	9	p	_	_
16	as	as	IN	_	17	mark	_	_
17	demonstrated	demonstrate	VBN	_	9	comp	_	_
18	by	by	IN	_	20	case	_	_
19	the	the	DT	_	20	det	_	_
20	lack	lack	NN	_	17	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	interaction	interaction	NN	_	20	ppmod	_	_
23	of	of	IN	_	24	case	_	_
24	drug2	drug0	NN	_	22	ppmod	_	_
25	with	with	IN	_	26	case	_	_
26	drug3	drug0	NN	_	22	ppmod	_	_
27	in	in	IN	_	32	case	_	_
28	a	a	DT	_	32	det	_	_
29	clinical	clinical	JJ	_	32	attr	_	_
30	drug	drug	NN	_	32	com	_	_
31	interaction	interaction	NN	_	32	com	_	_
32	study	study	NN	_	20	ppmod	_	_
33	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	7	case	_	_
4	clinical	clinical	JJ	_	7	attr	_	_
5	drug	drug	NN	_	7	com	_	_
6	interaction	interaction	NN	_	7	com	_	_
7	studies	study	NNS	_	12	ppmod	_	_
8	,	,	,	_	12	p	_	_
9	drug2	drug0	NN	_	12	dep	_	_
10	did	do	VBD	_	12	aux	_	_
11	not	not	RB	_	12	neg	_	_
12	have	have	VB	_	1	acl	_	_
13	clinically	clinically	RB	_	14	adv	_	_
14	important	important	JJ	_	15	attr	_	_
15	effects	effect	NNS	_	12	obj	_	_
16	on	on	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	pharmacokinetics	pharmacokinetics	NNS	_	12	ppmod	_	_
19	of	of	IN	_	20	case	_	_
20	drug3	drug0	NN	_	18	ppmod	_	_
21	or	or	CC	_	20	cc	_	_
22	drug4	drug0	NN	_	20	conj	_	_
23	.	.	.	_	1	p	_	_

1	No	no	DT	_	6	det	_	_
2	clinical	clinical	JJ	_	6	attr	_	_
3	or	or	NN	_	6	com	_	_
4	drug	drug	NN	_	6	com	_	_
5	interaction	interaction	NN	_	6	com	_	_
6	study	study	NN	_	8	dep	_	_
7	was	be	VBD	_	8	aux	_	_
8	conducted	conduct	VBN	_	0	root	_	_
9	with	with	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	45	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	:	:	:	_	3	p	_	_
5	drug3	drug0	NN	_	1	conj	_	_
6	,	,	,	_	5	p	_	_
7	when	when	WRB	_	8	adv	_	_
8	given	give	VBN	_	5	relcl	_	_
9	as	as	IN	_	11	case	_	_
10	a	a	DT	_	11	det	_	_
11	regimen	regimen	NN	_	8	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	125mg	0mg	NN	_	11	ppmod	_	_
14	with	with	IN	_	15	case	_	_
15	drug4	drug0	NN	_	13	ppmod	_	_
16	coadministered	coadministered	VBN	_	15	acl	_	_
17	orally	orally	RB	_	16	adv	_	_
18	as	as	IN	_	20	case	_	_
19	20	0	CD	_	20	num	_	_
20	mg	mg	NN	_	16	ppmod	_	_
21	on	on	IN	_	22	case	_	_
22	Day	day	NN	_	20	ppmod	_	_
23	1	0	CD	_	22	num	_	_
24	,	,	,	_	5	p	_	_
25	and	and	CC	_	5	cc	_	_
26	drug5	drug0	NN	_	1	conj	_	_
27	when	when	WRB	_	28	adv	_	_
28	given	give	VBN	_	45	advcl	_	_
29	as	as	IN	_	31	case	_	_
30	80	0	CD	_	31	num	_	_
31	mg/day	mg/day	NN	_	28	ppmod	_	_
32	with	with	IN	_	33	case	_	_
33	drug6	drug0	NN	_	28	ppmod	_	_
34	coadministered	coadministered	VBN	_	33	acl	_	_
35	orally	orally	RB	_	34	adv	_	_
36	as	as	IN	_	38	case	_	_
37	8	0	CD	_	38	num	_	_
38	mg	mg	NN	_	34	ppmod	_	_
39	on	on	IN	_	40	case	_	_
40	Days	day	NNS	_	38	ppmod	_	_
41	2	0	CD	_	43	num	_	_
42	through	through	IN	_	43	case	_	_
43	5	0	CD	_	40	num	_	_
44	,	,	,	_	45	p	_	_
45	increased	increase	VBD	_	0	root	_	_
46	the	the	DT	_	47	det	_	_
47	AUC	auc	NN	_	45	obj	_	_
48	of	of	IN	_	49	case	_	_
49	drug7	drug0	NN	_	47	ppmod	_	_
50	,	,	,	_	49	p	_	_
51	a	a	DT	_	53	det	_	_
52	CYP3A4	cyp0a0	NN	_	53	com	_	_
53	substrate	substrate	NN	_	49	appo	_	_
54	by	by	IN	_	55	case	_	_
55	2.2-fold	0-fold	NN	_	53	ppmod	_	_
56	,	,	,	_	49	p	_	_
57	on	on	IN	_	58	case	_	_
58	Days	day	NNS	_	45	ppmod	_	_
59	1	0	CD	_	58	num	_	_
60	and	and	CC	_	58	cc	_	_
61	5	0	CD	_	58	conj	_	_
62	.	.	.	_	45	p	_	_

1	The	the	DT	_	4	det	_	_
2	oral	oral	JJ	_	4	attr	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	doses	dose	NNS	_	7	dep	_	_
5	should	should	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	reduced	reduce	VBN	_	0	root	_	_
8	by	by	IN	_	10	case	_	_
9	approximately	approximately	RB	_	10	adv	_	_
10	50	0	CD	_	7	ppmod	_	_
11	%	%	NN	_	10	meta	_	_
12	when	when	WRB	_	13	adv	_	_
13	coadministered	coadministered	VBN	_	7	comp	_	_
14	with	with	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	,	,	,	_	13	p	_	_
17	to	to	TO	_	18	aux	_	_
18	achieve	achieve	VB	_	13	comp	_	_
19	exposures	exposure	NNS	_	18	obj	_	_
20	of	of	IN	_	21	case	_	_
21	drug3	drug0	NN	_	19	ppmod	_	_
22	similar	similar	JJ	_	19	attr	_	_
23	to	to	TO	_	24	aux	_	_
24	those	those	DT	_	22	ppmod	_	_
25	obtained	obtain	VBN	_	24	acl	_	_
26	when	when	WRB	_	29	adv	_	_
27	it	it	PRP	_	29	dep	_	_
28	is	be	VBZ	_	29	aux	_	_
29	given	give	VBN	_	25	comp	_	_
30	without	without	IN	_	31	case	_	_
31	drug4	drug0	NN	_	29	ppmod	_	_
32	.	.	.	_	7	p	_	_

1	The	the	DT	_	3	det	_	_
2	daily	daily	JJ	_	3	attr	_	_
3	dose	dose	NN	_	12	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	administered	administer	VBN	_	3	acl	_	_
7	in	in	IN	_	9	case	_	_
8	clinical	clinical	JJ	_	9	attr	_	_
9	studies	study	NNS	_	6	ppmod	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	reflects	reflect	VBZ	_	0	root	_	_
13	an	an	DT	_	17	det	_	_
14	approximate	approximate	JJ	_	17	attr	_	_
15	50	0	CD	_	17	num	_	_
16	%	%	NN	_	15	meta	_	_
17	reduction	reduction	NN	_	12	obj	_	_
18	of	of	IN	_	20	case	_	_
19	the	the	DT	_	20	det	_	_
20	dose	dose	NN	_	17	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	drug3	drug0	NN	_	20	ppmod	_	_
23	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	23	dep	_	_
2	,	,	,	_	1	p	_	_
3	when	when	WRB	_	4	adv	_	_
4	given	give	VBN	_	1	relcl	_	_
5	as	as	IN	_	7	case	_	_
6	a	a	DT	_	7	det	_	_
7	regimen	regimen	NN	_	4	ppmod	_	_
8	of	of	IN	_	10	case	_	_
9	125	0	CD	_	10	num	_	_
10	mg	mg	NN	_	7	ppmod	_	_
11	on	on	IN	_	12	case	_	_
12	Day	day	NN	_	4	ppmod	_	_
13	1	0	CD	_	12	num	_	_
14	and	and	CC	_	12	cc	_	_
15	80	0	CD	_	16	num	_	_
16	mg/day	mg/day	NN	_	12	conj	_	_
17	on	on	IN	_	18	case	_	_
18	Days	day	NNS	_	12	ppmod	_	_
19	2	0	CD	_	18	num	_	_
20	and	and	CC	_	18	cc	_	_
21	3	0	CD	_	18	conj	_	_
22	,	,	,	_	1	p	_	_
23	increased	increase	VBD	_	0	root	_	_
24	the	the	DT	_	25	det	_	_
25	AUC	auc	NN	_	23	obj	_	_
26	of	of	IN	_	27	case	_	_
27	drug2	drug0	NN	_	25	ppmod	_	_
28	,	,	,	_	27	p	_	_
29	a	a	DT	_	31	det	_	_
30	CYP3A4	cyp0a0	NN	_	31	com	_	_
31	substrate	substrate	NN	_	27	appo	_	_
32	,	,	,	_	27	p	_	_
33	by	by	IN	_	34	case	_	_
34	1.34-fold	0-fold	JJ	_	23	ppmod	_	_
35	on	on	IN	_	36	case	_	_
36	Day	day	NN	_	34	ppmod	_	_
37	1	0	CD	_	36	num	_	_
38	and	and	CC	_	36	cc	_	_
39	by	by	IN	_	40	case	_	_
40	2.5-fold	0-fold	RB	_	36	conj	_	_
41	on	on	IN	_	42	case	_	_
42	Day	day	NN	_	40	ppmod	_	_
43	3	0	CD	_	42	num	_	_
44	,	,	,	_	42	p	_	_
45	when	when	WRB	_	48	adv	_	_
46	drug3	drug0	NN	_	48	dep	_	_
47	was	be	VBD	_	48	aux	_	_
48	coadministered	coadministered	VBN	_	42	relcl	_	_
49	intravenously	intravenously	RB	_	48	adv	_	_
50	as	as	IN	_	52	case	_	_
51	125	0	CD	_	52	num	_	_
52	mg	mg	NN	_	48	ppmod	_	_
53	on	on	IN	_	54	case	_	_
54	Day	day	NN	_	52	ppmod	_	_
55	1	0	CD	_	54	num	_	_
56	and	and	CC	_	52	cc	_	_
57	orally	orally	RB	_	60	adv	_	_
58	as	as	IN	_	60	case	_	_
59	40	0	CD	_	60	num	_	_
60	mg	mg	NN	_	52	conj	_	_
61	on	on	IN	_	62	case	_	_
62	Days	day	NNS	_	60	ppmod	_	_
63	2	0	CD	_	62	num	_	_
64	and	and	CC	_	62	cc	_	_
65	3	0	CD	_	62	conj	_	_
66	.	.	.	_	23	p	_	_

1	The	the	DT	_	4	det	_	_
2	IV	iv	NN	_	4	com	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	dose	dose	NN	_	7	dep	_	_
5	should	should	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	reduced	reduce	VBN	_	0	root	_	_
8	by	by	IN	_	10	case	_	_
9	approximately	approximately	RB	_	10	adv	_	_
10	25	0	CD	_	7	ppmod	_	_
11	%	%	NN	_	10	meta	_	_
12	,	,	,	_	7	p	_	_
13	and	and	CC	_	7	cc	_	_
14	the	the	DT	_	17	det	_	_
15	oral	oral	JJ	_	17	attr	_	_
16	drug2	drug0	NN	_	17	com	_	_
17	dose	dose	NN	_	20	dep	_	_
18	should	should	MD	_	20	modal	_	_
19	be	be	VB	_	20	aux	_	_
20	reduced	reduce	VBN	_	7	conj	_	_
21	by	by	IN	_	23	case	_	_
22	approximately	approximately	RB	_	23	adv	_	_
23	50	0	CD	_	20	ppmod	_	_
24	%	%	NN	_	23	meta	_	_
25	when	when	WRB	_	26	adv	_	_
26	coadministered	coadministered	VBN	_	20	comp	_	_
27	with	with	IN	_	28	case	_	_
28	drug3	drug0	NN	_	26	ppmod	_	_
29	to	to	TO	_	30	aux	_	_
30	achieve	achieve	VB	_	26	comp	_	_
31	exposures	exposure	NNS	_	30	obj	_	_
32	of	of	IN	_	33	case	_	_
33	drug4	drug0	NN	_	31	ppmod	_	_
34	similar	similar	JJ	_	33	attr	_	_
35	to	to	TO	_	36	aux	_	_
36	those	those	DT	_	34	ppmod	_	_
37	obtained	obtain	VBN	_	36	acl	_	_
38	when	when	WRB	_	41	adv	_	_
39	it	it	PRP	_	41	dep	_	_
40	is	be	VBZ	_	41	aux	_	_
41	given	give	VBN	_	37	comp	_	_
42	without	without	IN	_	43	case	_	_
43	drug5	drug0	NN	_	41	ppmod	_	_
44	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	A	a	DT	_	6	det	_	_
4	single	single	JJ	_	6	attr	_	_
5	125-mg	0-mg	NN	_	6	com	_	_
6	dose	dose	NN	_	10	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	was	be	VBD	_	10	aux	_	_
10	administered	administer	VBN	_	1	acl	_	_
11	on	on	IN	_	12	case	_	_
12	Day	day	NN	_	10	ppmod	_	_
13	1	0	CD	_	12	num	_	_
14	and	and	CC	_	12	cc	_	_
15	80	0	CD	_	16	num	_	_
16	mg/day	mg/day	NN	_	12	conj	_	_
17	on	on	IN	_	18	case	_	_
18	Days	day	NNS	_	16	ppmod	_	_
19	2	0	CD	_	18	num	_	_
20	and	and	CC	_	18	cc	_	_
21	3	0	CD	_	18	conj	_	_
22	to	to	TO	_	24	aux	_	_
23	healthy	healthy	JJ	_	24	attr	_	_
24	subjects	subject	NNS	_	16	ppmod	_	_
25	who	who	WP	_	27	dep	_	_
26	were	be	VBD	_	27	aux	_	_
27	stabilized	stabilize	VBN	_	24	relcl	_	_
28	on	on	IN	_	31	case	_	_
29	chronic	chronic	JJ	_	31	attr	_	_
30	drug3	drug0	NN	_	31	com	_	_
31	therapy	therapy	NN	_	27	ppmod	_	_
32	.	.	.	_	1	p	_	_

1	Although	although	IN	_	3	mark	_	_
2	there	there	EX	_	3	dep	_	_
3	was	be	VBD	_	22	advcl	_	_
4	no	no	DT	_	5	det	_	_
5	effect	effect	NN	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	on	on	IN	_	11	case	_	_
9	the	the	DT	_	11	det	_	_
10	plasma	plasma	NN	_	11	com	_	_
11	AUC	auc	NN	_	5	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	or	or	CC	_	13	cc	_	_
15	drug3	drug0	NN	_	13	conj	_	_
16	determined	determine	VBN	_	11	acl	_	_
17	on	on	IN	_	18	case	_	_
18	Day	day	NN	_	16	ppmod	_	_
19	3	0	CD	_	18	num	_	_
20	,	,	,	_	22	p	_	_
21	there	there	EX	_	22	dep	_	_
22	was	be	VBD	_	0	root	_	_
23	a	a	DT	_	26	det	_	_
24	34	0	CD	_	26	num	_	_
25	%	%	NN	_	24	meta	_	_
26	decrease	decrease	NN	_	22	obj	_	_
27	in	in	IN	_	35	case	_	_
28	drug4	drug0	NN	_	35	attr	_	_
29	(	-lrb-	-LRB-	_	32	p	_	_
30	a	a	DT	_	32	det	_	_
31	CYP2C9	cyp0c0	NN	_	32	com	_	_
32	substrate	substrate	NN	_	28	prn	_	_
33	)	-rrb-	-RRB-	_	32	p	_	_
34	trough	trough	NN	_	35	com	_	_
35	concentration	concentration	NN	_	26	ppmod	_	_
36	accompanied	accompany	VBN	_	35	acl	_	_
37	by	by	IN	_	41	case	_	_
38	a	a	DT	_	41	det	_	_
39	14	0	CD	_	41	num	_	_
40	%	%	NN	_	39	meta	_	_
41	decrease	decrease	NN	_	36	ppmod	_	_
42	in	in	IN	_	45	case	_	_
43	the	the	DT	_	45	det	_	_
44	prothrombin	prothrombin	NN	_	45	com	_	_
45	time	time	NN	_	41	ppmod	_	_
46	(	-lrb-	-LRB-	_	47	p	_	_
47	reported	report	VBN	_	45	prn	_	_
48	as	as	IN	_	51	case	_	_
49	International	international	NNP	_	51	attr	_	_
50	Normalized	normalize	VBN	_	51	attr	_	_
51	Ratio	ratio	NN	_	47	ppmod	_	_
52	or	or	CC	_	51	cc	_	_
53	INR	inr	NN	_	51	conj	_	_
54	)	-rrb-	-RRB-	_	47	p	_	_
55	5	0	CD	_	56	num	_	_
56	days	day	NNS	_	45	appo	_	_
57	after	after	IN	_	58	case	_	_
58	completion	completion	NN	_	56	ppmod	_	_
59	of	of	IN	_	60	case	_	_
60	dosing	dosing	NN	_	58	ppmod	_	_
61	with	with	IN	_	62	case	_	_
62	drug5	drug0	NN	_	60	ppmod	_	_
63	.	.	.	_	22	p	_	_

1	In	in	IN	_	2	case	_	_
2	patients	patient	NNS	_	17	ppmod	_	_
3	on	on	IN	_	6	case	_	_
4	chronic	chronic	JJ	_	6	attr	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	therapy	therapy	NN	_	2	ppmod	_	_
7	,	,	,	_	17	p	_	_
8	the	the	DT	_	10	det	_	_
9	prothrombin	prothrombin	NN	_	10	com	_	_
10	time	time	NN	_	17	dep	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	INR	inr	NN	_	10	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	should	should	MD	_	17	modal	_	_
15	be	be	VB	_	17	aux	_	_
16	closely	closely	RB	_	17	adv	_	_
17	monitored	monitor	VBN	_	0	root	_	_
18	in	in	IN	_	21	case	_	_
19	the	the	DT	_	21	det	_	_
20	2-week	0-week	JJ	_	21	attr	_	_
21	period	period	NN	_	17	ppmod	_	_
22	,	,	,	_	17	p	_	_
23	particularly	particularly	RB	_	28	adv	_	_
24	at	at	IN	_	28	case	_	_
25	7	0	CD	_	28	num	_	_
26	to	to	TO	_	25	cc	_	_
27	10	0	CD	_	25	conj	_	_
28	days	day	NNS	_	17	ppmod	_	_
29	,	,	,	_	17	p	_	_
30	following	follow	VBG	_	31	adv	_	_
31	initiation	initiation	NN	_	17	ppmod	_	_
32	of	of	IN	_	35	case	_	_
33	the	the	DT	_	35	det	_	_
34	3-day	0-day	JJ	_	35	attr	_	_
35	regimen	regimen	NN	_	31	ppmod	_	_
36	of	of	IN	_	37	case	_	_
37	drug2	drug0	NN	_	35	ppmod	_	_
38	with	with	IN	_	41	case	_	_
39	each	each	DT	_	41	det	_	_
40	chemotherapy	chemotherapy	NN	_	41	com	_	_
41	cycle	cycle	NN	_	31	ppmod	_	_
42	.	.	.	_	17	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	,	,	,	_	3	p	_	_
5	when	when	WRB	_	6	adv	_	_
6	given	give	VBN	_	3	relcl	_	_
7	as	as	IN	_	9	case	_	_
8	125	0	CD	_	9	num	_	_
9	mg	mg	NN	_	6	ppmod	_	_
10	on	on	IN	_	11	case	_	_
11	Day	day	NN	_	9	ppmod	_	_
12	1	0	CD	_	11	num	_	_
13	and	and	CC	_	11	cc	_	_
14	80	0	CD	_	15	num	_	_
15	mg/day	mg/day	NN	_	11	conj	_	_
16	on	on	IN	_	17	case	_	_
17	Days	day	NNS	_	11	ppmod	_	_
18	2	0	CD	_	17	num	_	_
19	and	and	CC	_	17	cc	_	_
20	3	0	CD	_	17	conj	_	_
21	,	,	,	_	11	p	_	_
22	decreased	decrease	VBD	_	11	acl	_	_
23	the	the	DT	_	24	det	_	_
24	AUC	auc	NN	_	22	obj	_	_
25	of	of	IN	_	26	case	_	_
26	drug3	drug0	NN	_	24	ppmod	_	_
27	(	-lrb-	-LRB-	_	30	p	_	_
28	a	a	DT	_	30	det	_	_
29	CYP2C9	cyp0c0	NN	_	30	com	_	_
30	substrate	substrate	NN	_	26	prn	_	_
31	)	-rrb-	-RRB-	_	30	p	_	_
32	by	by	IN	_	33	case	_	_
33	23	0	CD	_	22	ppmod	_	_
34	%	%	NN	_	33	meta	_	_
35	on	on	IN	_	36	case	_	_
36	Day	day	NN	_	33	ppmod	_	_
37	4	0	CD	_	36	num	_	_
38	,	,	,	_	33	p	_	_
39	28	0	CD	_	33	conj	_	_
40	%	%	NN	_	39	meta	_	_
41	on	on	IN	_	42	case	_	_
42	Day	day	NN	_	39	ppmod	_	_
43	8	0	CD	_	42	num	_	_
44	,	,	,	_	39	p	_	_
45	and	and	CC	_	39	cc	_	_
46	15	0	CD	_	33	conj	_	_
47	%	%	NN	_	46	meta	_	_
48	on	on	IN	_	49	case	_	_
49	Day	day	NN	_	33	ppmod	_	_
50	15	0	CD	_	49	num	_	_
51	,	,	,	_	22	p	_	_
52	when	when	WRB	_	60	adv	_	_
53	a	a	DT	_	55	det	_	_
54	single	single	JJ	_	55	attr	_	_
55	dose	dose	NN	_	60	dep	_	_
56	of	of	IN	_	59	case	_	_
57	drug4	drug0	NN	_	59	attr	_	_
58	500	0	CD	_	59	num	_	_
59	mg	mg	NN	_	55	ppmod	_	_
60	was	be	VBD	_	22	comp	_	_
61	admini	admini	NNS	_	60	obj	_	_
62	,	,	,	_	11	p	_	_
63	stered	stered	JJ	_	11	attr	_	_
64	orally	orally	RB	_	65	adv	_	_
65	prior	prior	JJ	_	11	attr	_	_
66	to	to	TO	_	68	aux	_	_
67	the	the	DT	_	68	det	_	_
68	administration	administration	NN	_	65	ppmod	_	_
69	of	of	IN	_	72	case	_	_
70	the	the	DT	_	72	det	_	_
71	3-day	0-day	JJ	_	72	attr	_	_
72	regimen	regimen	NN	_	68	ppmod	_	_
73	of	of	IN	_	74	case	_	_
74	drug5	drug0	NN	_	72	ppmod	_	_
75	and	and	CC	_	11	cc	_	_
76	on	on	IN	_	77	case	_	_
77	Days	day	NNS	_	11	conj	_	_
78	4,8	0	NN	_	77	num	_	_
79	,	,	,	_	77	p	_	_
80	and	and	CC	_	77	cc	_	_
81	15	0	CD	_	77	conj	_	_
82	.	.	.	_	1	p	_	_

1	Oral	oral	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	drug2	drug0	NN	_	32	dep	_	_
5	,	,	,	_	32	p	_	_
6	when	when	WRB	_	7	adv	_	_
7	given	give	VBN	_	32	advcl	_	_
8	once	once	RB	_	9	com	_	_
9	daily	daily	RB	_	7	adv	_	_
10	for	for	IN	_	12	case	_	_
11	14	0	CD	_	12	num	_	_
12	days	day	NNS	_	7	ppmod	_	_
13	as	as	IN	_	16	case	_	_
14	a	a	DT	_	16	det	_	_
15	100-mg	0-mg	JJ	_	16	attr	_	_
16	capsule	capsule	NN	_	7	ppmod	_	_
17	with	with	IN	_	20	case	_	_
18	an	an	DT	_	20	det	_	_
19	oral	oral	JJ	_	20	attr	_	_
20	drug3	drug0	NN	_	16	ppmod	_	_
21	containing	contain	VBG	_	20	acl	_	_
22	35	0	CD	_	23	num	_	_
23	mcg	mcg	NN	_	21	obj	_	_
24	of	of	IN	_	25	case	_	_
25	drug4	drug0	NN	_	23	ppmod	_	_
26	and	and	CC	_	23	cc	_	_
27	1	0	CD	_	28	num	_	_
28	mg	mg	NN	_	23	conj	_	_
29	of	of	IN	_	30	case	_	_
30	drug5	drug0	NN	_	28	ppmod	_	_
31	,	,	,	_	32	p	_	_
32	decreased	decrease	VBD	_	2	acl	_	_
33	the	the	DT	_	34	det	_	_
34	AUC	auc	NN	_	32	obj	_	_
35	of	of	IN	_	36	case	_	_
36	drug6	drug0	NN	_	34	ppmod	_	_
37	by	by	IN	_	38	case	_	_
38	43	0	CD	_	32	ppmod	_	_
39	%	%	NN	_	38	meta	_	_
40	,	,	,	_	32	p	_	_
41	and	and	CC	_	32	cc	_	_
42	decreased	decrease	VBD	_	32	conj	_	_
43	the	the	DT	_	44	det	_	_
44	AUC	auc	NN	_	42	obj	_	_
45	of	of	IN	_	46	case	_	_
46	drug7	drug0	NN	_	44	ppmod	_	_
47	by	by	IN	_	48	case	_	_
48	8	0	CD	_	42	ppmod	_	_
49	%	%	NN	_	48	meta	_	_
50	;	;	:	_	2	p	_	_

1	therefore	therefore	RB	_	14	adv	_	_
2	,	,	,	_	14	p	_	_
3	the	the	DT	_	4	det	_	_
4	efficacy	efficacy	NN	_	14	dep	_	_
5	of	of	IN	_	7	case	_	_
6	oral	oral	JJ	_	7	attr	_	_
7	drug1	drug0	NN	_	4	ppmod	_	_
8	during	during	IN	_	9	case	_	_
9	administration	administration	NN	_	4	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	may	may	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	reduced	reduce	VBN	_	0	root	_	_
15	.	.	.	_	14	p	_	_

1	Although	although	IN	_	15	mark	_	_
2	a	a	DT	_	4	det	_	_
3	3-day	0-day	JJ	_	4	attr	_	_
4	regimen	regimen	NN	_	15	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	given	give	VBN	_	4	acl	_	_
8	concomitantly	concomitantly	RB	_	7	adv	_	_
9	with	with	IN	_	11	case	_	_
10	oral	oral	JJ	_	11	attr	_	_
11	drug2	drug0	NN	_	7	ppmod	_	_
12	has	have	VBZ	_	15	aux	_	_
13	not	not	RB	_	15	neg	_	_
14	been	be	VBN	_	15	aux	_	_
15	studied	study	VBN	_	25	advcl	_	_
16	,	,	,	_	25	p	_	_
17	alternative	alternative	JJ	_	20	attr	_	_
18	or	or	CC	_	17	cc	_	_
19	back-up	back-up	JJ	_	17	conj	_	_
20	methods	method	NNS	_	25	dep	_	_
21	of	of	IN	_	22	case	_	_
22	contraception	contraception	NN	_	20	ppmod	_	_
23	should	should	MD	_	25	modal	_	_
24	be	be	VB	_	25	aux	_	_
25	used	use	VBN	_	0	root	_	_
26	.	.	.	_	25	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	4	dep	_	_
4	increased	increase	VBD	_	1	acl	_	_
5	the	the	DT	_	6	det	_	_
6	AUC	auc	NN	_	4	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug3	drug0	NN	_	6	ppmod	_	_
9	,	,	,	_	8	p	_	_
10	a	a	DT	_	13	det	_	_
11	sensitive	sensitive	JJ	_	13	attr	_	_
12	CYP3A4	cyp0a0	NN	_	13	com	_	_
13	substrate	substrate	NN	_	8	appo	_	_
14	,	,	,	_	8	p	_	_
15	by	by	IN	_	16	case	_	_
16	2.3-fold	0-fold	NN	_	4	ppmod	_	_
17	on	on	IN	_	18	case	_	_
18	Day	day	NN	_	4	ppmod	_	_
19	1	0	CD	_	18	num	_	_
20	and	and	CC	_	18	cc	_	_
21	3.3-fold	0-fold	RB	_	23	adv	_	_
22	on	on	IN	_	23	case	_	_
23	Day	day	NN	_	18	conj	_	_
24	5	0	CD	_	23	num	_	_
25	,	,	,	_	4	p	_	_
26	when	when	WRB	_	36	adv	_	_
27	a	a	DT	_	30	det	_	_
28	single	single	JJ	_	30	attr	_	_
29	oral	oral	JJ	_	30	attr	_	_
30	dose	dose	NN	_	36	dep	_	_
31	of	of	IN	_	34	case	_	_
32	drug4	drug0	NN	_	34	attr	_	_
33	2	0	CD	_	34	num	_	_
34	mg	mg	NN	_	30	ppmod	_	_
35	was	be	VBD	_	36	aux	_	_
36	coadministered	coadministered	VBN	_	4	comp	_	_
37	on	on	IN	_	38	case	_	_
38	Day	day	NN	_	36	ppmod	_	_
39	1	0	CD	_	38	num	_	_
40	and	and	CC	_	38	cc	_	_
41	Day	day	NN	_	38	conj	_	_
42	5	0	CD	_	41	num	_	_
43	of	of	IN	_	45	case	_	_
44	a	a	DT	_	45	det	_	_
45	regimen	regimen	NN	_	38	ppmod	_	_
46	of	of	IN	_	49	case	_	_
47	drug5	drug0	NN	_	49	attr	_	_
48	125	0	CD	_	49	num	_	_
49	mg	mg	NN	_	45	ppmod	_	_
50	on	on	IN	_	51	case	_	_
51	Day	day	NN	_	49	ppmod	_	_
52	1	0	CD	_	51	num	_	_
53	and	and	CC	_	51	cc	_	_
54	80	0	CD	_	55	num	_	_
55	mg/day	mg/day	NN	_	51	conj	_	_
56	on	on	IN	_	57	case	_	_
57	Days	day	NNS	_	51	ppmod	_	_
58	2	0	CD	_	60	num	_	_
59	through	through	IN	_	60	case	_	_
60	5	0	CD	_	57	num	_	_
61	.	.	.	_	1	p	_	_

1	The	the	DT	_	3	det	_	_
2	potential	potential	JJ	_	3	attr	_	_
3	effects	effect	NNS	_	23	dep	_	_
4	of	of	IN	_	7	case	_	_
5	increased	increase	VBN	_	7	attr	_	_
6	plasma	plasma	NN	_	7	com	_	_
7	concentrations	concentration	NNS	_	3	ppmod	_	_
8	of	of	IN	_	12	case	_	_
9	drug1	drug0	JJ	_	12	attr	_	_
10	or	or	CC	_	9	cc	_	_
11	other	other	JJ	_	9	conj	_	_
12	drug2	drug0	NNS	_	7	ppmod	_	_
13	metabolized	metabolize	VBN	_	12	acl	_	_
14	via	via	IN	_	15	case	_	_
15	CYP3A4	cyp0a0	NN	_	13	ppmod	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	drug3	drug0	NN	_	15	prn	_	_
18	,	,	,	_	17	p	_	_
19	drug4	drug0	NN	_	17	appo	_	_
20	)	-rrb-	-RRB-	_	17	p	_	_
21	should	should	MD	_	23	modal	_	_
22	be	be	VB	_	23	aux	_	_
23	considered	consider	VBN	_	0	root	_	_
24	when	when	WRB	_	25	adv	_	_
25	coadministering	coadministering	VBG	_	23	comp	_	_
26	these	these	DT	_	27	det	_	_
27	agents	agent	NNS	_	25	obj	_	_
28	with	with	IN	_	29	case	_	_
29	drug5	drug0	NN	_	25	ppmod	_	_
30	.	.	.	_	23	p	_	_

1	In	in	IN	_	3	case	_	_
2	another	another	DT	_	3	det	_	_
3	study	study	NN	_	12	ppmod	_	_
4	with	with	IN	_	6	case	_	_
5	intravenous	intravenous	JJ	_	6	attr	_	_
6	administration	administration	NN	_	3	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	,	,	,	_	12	p	_	_
10	drug2	drug0	NN	_	12	dep	_	_
11	was	be	VBD	_	12	aux	_	_
12	given	give	VBN	_	0	root	_	_
13	as	as	IN	_	15	case	_	_
14	125	0	CD	_	15	num	_	_
15	mg	mg	NN	_	12	ppmod	_	_
16	on	on	IN	_	17	case	_	_
17	Day	day	NN	_	15	ppmod	_	_
18	1	0	CD	_	17	num	_	_
19	and	and	CC	_	15	cc	_	_
20	80	0	CD	_	21	num	_	_
21	mg/day	mg/day	NN	_	15	conj	_	_
22	on	on	IN	_	23	case	_	_
23	Days	day	NNS	_	12	ppmod	_	_
24	2	0	CD	_	23	num	_	_
25	and	and	CC	_	23	cc	_	_
26	3	0	CD	_	23	conj	_	_
27	,	,	,	_	12	p	_	_
28	and	and	CC	_	12	cc	_	_
29	drug3	drug0	NN	_	31	attr	_	_
30	2	0	CD	_	31	num	_	_
31	mg	mg	NN	_	34	dep	_	_
32	IV	iv	CD	_	31	num	_	_
33	was	be	VBD	_	34	aux	_	_
34	given	give	VBN	_	12	conj	_	_
35	prior	prior	JJ	_	38	adv	_	_
36	to	to	TO	_	38	aux	_	_
37	the	the	DT	_	38	det	_	_
38	administration	administration	NN	_	34	ppmod	_	_
39	of	of	IN	_	42	case	_	_
40	the	the	DT	_	42	det	_	_
41	3-day	0-day	JJ	_	42	attr	_	_
42	regimen	regimen	NN	_	38	ppmod	_	_
43	of	of	IN	_	44	case	_	_
44	drug4	drug0	NN	_	42	ppmod	_	_
45	and	and	CC	_	42	cc	_	_
46	on	on	IN	_	47	case	_	_
47	Days	day	NNS	_	42	conj	_	_
48	4	0	CD	_	47	num	_	_
49	,	,	,	_	48	p	_	_
50	8	0	CD	_	48	conj	_	_
51	,	,	,	_	50	p	_	_
52	and	and	CC	_	50	cc	_	_
53	15	0	CD	_	48	conj	_	_
54	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	increased	increase	VBD	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	AUC	auc	NN	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	by	by	IN	_	8	case	_	_
8	25	0	CD	_	2	ppmod	_	_
9	%	%	NN	_	8	meta	_	_
10	on	on	IN	_	11	case	_	_
11	Day	day	NN	_	8	ppmod	_	_
12	4	0	CD	_	11	num	_	_
13	and	and	CC	_	2	cc	_	_
14	decreased	decrease	VBD	_	2	conj	_	_
15	the	the	DT	_	16	det	_	_
16	AUC	auc	NN	_	14	obj	_	_
17	of	of	IN	_	18	case	_	_
18	drug3	drug0	NN	_	16	ppmod	_	_
19	by	by	IN	_	20	case	_	_
20	19	0	CD	_	14	ppmod	_	_
21	%	%	NN	_	20	meta	_	_
22	on	on	IN	_	23	case	_	_
23	Day	day	NN	_	20	ppmod	_	_
24	8	0	CD	_	23	num	_	_
25	relative	relative	JJ	_	23	attr	_	_
26	to	to	TO	_	28	aux	_	_
27	the	the	DT	_	28	det	_	_
28	dosing	dosing	NN	_	25	ppmod	_	_
29	of	of	IN	_	30	case	_	_
30	drug4	drug0	NN	_	28	ppmod	_	_
31	on	on	IN	_	32	case	_	_
32	Days	day	NNS	_	30	ppmod	_	_
33	1	0	CD	_	35	num	_	_
34	through	through	IN	_	35	case	_	_
35	3	0	CD	_	32	num	_	_
36	.	.	.	_	2	p	_	_

1	These	these	DT	_	2	det	_	_
2	effects	effect	NNS	_	5	dep	_	_
3	were	be	VBD	_	5	aux	_	_
4	not	not	RB	_	5	neg	_	_
5	considered	consider	VBN	_	0	root	_	_
6	clinically	clinically	RB	_	7	adv	_	_
7	important	important	JJ	_	5	comp	_	_
8	.	.	.	_	5	p	_	_

1	The	the	DT	_	2	det	_	_
2	AUC	auc	NN	_	8	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	on	on	IN	_	6	case	_	_
6	Day	day	NN	_	2	ppmod	_	_
7	15	0	CD	_	6	num	_	_
8	was	be	VBD	_	0	root	_	_
9	similar	similar	JJ	_	8	dep	_	_
10	to	to	TO	_	11	aux	_	_
11	that	that	DT	_	9	ppmod	_	_
12	observed	observe	VBN	_	11	acl	_	_
13	at	at	IN	_	14	case	_	_
14	baseline	baseline	NN	_	12	ppmod	_	_
15	.	.	.	_	8	p	_	_

1	Effect	effect	NN	_	0	root	_	_
2	of	of	IN	_	4	case	_	_
3	other	other	JJ	_	4	attr	_	_
4	agents	agent	NNS	_	1	ppmod	_	_
5	on	on	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	pharmacokinefics	pharmacokinefics	NNS	_	1	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	a	a	DT	_	4	det	_	_
4	substrate	substrate	NN	_	2	obj	_	_
5	for	for	IN	_	6	case	_	_
6	CYP3A4	cyp0a0	NN	_	4	ppmod	_	_
7	;	;	:	_	2	p	_	_

1	therefore	therefore	RB	_	13	adv	_	_
2	,	,	,	_	13	p	_	_
3	coadministration	coadministration	NN	_	13	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drugs	drug	NNS	_	3	ppmod	_	_
8	that	that	WDT	_	9	dep	_	_
9	inhibit	inhibit	VBP	_	7	relcl	_	_
10	CYP3A4	cyp0a0	NN	_	11	com	_	_
11	activity	activity	NN	_	9	obj	_	_
12	may	may	MD	_	13	modal	_	_
13	result	result	VB	_	0	root	_	_
14	in	in	IN	_	17	case	_	_
15	increased	increase	VBN	_	17	attr	_	_
16	plasma	plasma	NN	_	17	com	_	_
17	concentrations	concentration	NNS	_	13	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	.	.	.	_	13	p	_	_

1	Consequently	consequently	RB	_	30	adv	_	_
2	,	,	,	_	30	p	_	_
3	concomitant	concomitant	JJ	_	4	attr	_	_
4	administration	administration	NN	_	30	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	with	with	IN	_	10	case	_	_
8	strong	strong	JJ	_	10	attr	_	_
9	CYP3A4	cyp0a0	JJ	_	10	attr	_	_
10	inhibitors	inhibitor	NNS	_	4	ppmod	_	_
11	(	-lrb-	-LRB-	_	14	p	_	_
12	e.g.	e.g.	FW	_	14	adv	_	_
13	,	,	,	_	14	p	_	_
14	drug2	drug0	NN	_	10	prn	_	_
15	,	,	,	_	14	p	_	_
16	drug3	drug0	NN	_	14	appo	_	_
17	,	,	,	_	14	p	_	_
18	drug4	drug0	NN	_	14	appo	_	_
19	,	,	,	_	14	p	_	_
20	drug5	drug0	NN	_	14	appo	_	_
21	,	,	,	_	14	p	_	_
22	drug6	drug0	NN	_	14	appo	_	_
23	,	,	,	_	14	p	_	_
24	drug7	drug0	NN	_	14	appo	_	_
25	,	,	,	_	14	p	_	_
26	drug8	drug0	NN	_	14	appo	_	_
27	)	-rrb-	-RRB-	_	14	p	_	_
28	should	should	MD	_	30	modal	_	_
29	be	be	VB	_	30	aux	_	_
30	approached	approach	VBN	_	0	root	_	_
31	with	with	IN	_	32	case	_	_
32	caution	caution	NN	_	30	ppmod	_	_
33	.	.	.	_	30	p	_	_

1	Because	because	IN	_	10	mark	_	_
2	moderate	moderate	JJ	_	4	attr	_	_
3	CYP3A4	cyp0a0	JJ	_	4	attr	_	_
4	inhibitors	inhibitor	NNS	_	10	dep	_	_
5	(	-lrb-	-LRB-	_	8	p	_	_
6	e.g.	e.g.	FW	_	8	adv	_	_
7	,	,	,	_	8	p	_	_
8	drug1	drug0	NN	_	4	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	result	result	VBP	_	25	advcl	_	_
11	in	in	IN	_	13	case	_	_
12	2-fold	0-fold	JJ	_	13	attr	_	_
13	increase	increase	NN	_	10	ppmod	_	_
14	in	in	IN	_	16	case	_	_
15	plasma	plasma	NN	_	16	com	_	_
16	concentrations	concentration	NNS	_	13	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	,	,	,	_	25	p	_	_
20	concomitant	concomitant	JJ	_	21	attr	_	_
21	administration	administration	NN	_	25	dep	_	_
22	should	should	MD	_	25	modal	_	_
23	also	also	RB	_	25	adv	_	_
24	be	be	VB	_	25	aux	_	_
25	approached	approach	VBN	_	0	root	_	_
26	with	with	IN	_	27	case	_	_
27	caution	caution	NN	_	25	ppmod	_	_
28	.	.	.	_	25	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	a	a	DT	_	4	det	_	_
4	substrate	substrate	NN	_	2	obj	_	_
5	for	for	IN	_	6	case	_	_
6	CYP3A4	cyp0a0	NN	_	4	ppmod	_	_
7	;	;	:	_	2	p	_	_

1	therefore	therefore	RB	_	23	adv	_	_
2	,	,	,	_	23	p	_	_
3	coadministration	coadministration	NN	_	23	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drugs	drug	NNS	_	3	ppmod	_	_
8	that	that	WDT	_	10	dep	_	_
9	strongly	strongly	RB	_	10	adv	_	_
10	induce	induce	VBP	_	7	relcl	_	_
11	CYP3A4	cyp0a0	NN	_	12	com	_	_
12	activity	activity	NN	_	10	obj	_	_
13	(	-lrb-	-LRB-	_	16	p	_	_
14	e.g.	e.g.	FW	_	16	ppmod	_	_
15	,	,	,	_	16	p	_	_
16	drug2	drug0	NN	_	12	prn	_	_
17	,	,	,	_	16	p	_	_
18	drug3	drug0	NN	_	16	appo	_	_
19	,	,	,	_	16	p	_	_
20	drug4	drug0	NN	_	16	appo	_	_
21	)	-rrb-	-RRB-	_	16	p	_	_
22	may	may	MD	_	23	modal	_	_
23	result	result	VB	_	0	root	_	_
24	in	in	IN	_	27	case	_	_
25	reduced	reduce	VBN	_	27	attr	_	_
26	plasma	plasma	NN	_	27	com	_	_
27	concentrations	concentration	NNS	_	23	ppmod	_	_
28	of	of	IN	_	29	case	_	_
29	drug5	drug0	NN	_	27	ppmod	_	_
30	that	that	WDT	_	32	dep	_	_
31	may	may	MD	_	32	modal	_	_
32	result	result	VB	_	27	relcl	_	_
33	in	in	IN	_	35	case	_	_
34	decreased	decrease	VBN	_	35	attr	_	_
35	efficacy	efficacy	NN	_	32	ppmod	_	_
36	of	of	IN	_	37	case	_	_
37	drug6	drug0	NN	_	35	ppmod	_	_
38	.	.	.	_	23	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	When	when	WRB	_	11	adv	_	_
4	a	a	DT	_	7	det	_	_
5	single	single	JJ	_	7	attr	_	_
6	125-mg	0-mg	NN	_	7	com	_	_
7	dose	dose	NN	_	11	dep	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	was	be	VBD	_	11	aux	_	_
11	administered	administer	VBN	_	1	relcl	_	_
12	on	on	IN	_	13	case	_	_
13	Day5	day0	NN	_	11	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	a	a	NN	_	13	ppmod	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	When	when	WRB	_	11	adv	_	_
4	a	a	DT	_	7	det	_	_
5	single	single	JJ	_	7	attr	_	_
6	125-mg	0-mg	NN	_	7	com	_	_
7	dose	dose	NN	_	11	dep	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	was	be	VBD	_	11	aux	_	_
11	administered	administer	VBN	_	33	advcl	_	_
12	on	on	IN	_	13	case	_	_
13	Day5	day0	NN	_	11	ppmod	_	_
14	of	of	IN	_	17	case	_	_
15	a	a	DT	_	17	det	_	_
16	10-day	0-day	JJ	_	17	attr	_	_
17	regimen	regimen	NN	_	13	ppmod	_	_
18	of	of	IN	_	20	case	_	_
19	400	0	CD	_	20	num	_	_
20	mg/day	mg/day	NN	_	17	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	drug3	drug0	NN	_	20	ppmod	_	_
23	,	,	,	_	22	p	_	_
24	a	a	DT	_	27	det	_	_
25	strong	strong	JJ	_	27	attr	_	_
26	CYP3A4	cyp0a0	NN	_	27	com	_	_
27	inhibitor	inhibitor	NN	_	22	appo	_	_
28	,	,	,	_	33	p	_	_
29	the	the	DT	_	30	det	_	_
30	AUC	auc	NN	_	33	dep	_	_
31	of	of	IN	_	32	case	_	_
32	drug4	drug0	NN	_	30	ppmod	_	_
33	increased	increase	VBD	_	1	acl	_	_
34	approximately	approximately	RB	_	35	com	_	_
35	5-fold	0-fold	RB	_	33	adv	_	_
36	and	and	CC	_	33	cc	_	_
37	the	the	DT	_	40	det	_	_
38	mean	mean	JJ	_	40	attr	_	_
39	terminal	terminal	JJ	_	40	attr	_	_
40	half-life	half-life	NN	_	43	dep	_	_
41	of	of	IN	_	42	case	_	_
42	drug5	drug0	NN	_	40	ppmod	_	_
43	increased	increase	VBD	_	33	conj	_	_
44	approximately	approximately	RB	_	45	com	_	_
45	3-fold	0-fold	RB	_	43	adv	_	_
46	.	.	.	_	1	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	administration	administration	NN	_	11	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	with	with	IN	_	8	case	_	_
6	strong	strong	JJ	_	8	attr	_	_
7	CYP3A4	cyp0a0	JJ	_	8	attr	_	_
8	inhibitors	inhibitor	NNS	_	2	ppmod	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	approached	approach	VBN	_	0	root	_	_
12	cautiously	cautiously	RB	_	11	adv	_	_
13	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	When	when	WRB	_	11	adv	_	_
4	a	a	DT	_	7	det	_	_
5	single	single	JJ	_	7	attr	_	_
6	375-mg	0-mg	JJ	_	7	attr	_	_
7	dose	dose	NN	_	11	dep	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	was	be	VBD	_	11	aux	_	_
11	administered	administer	VBN	_	33	advcl	_	_
12	on	on	IN	_	13	case	_	_
13	Day9	day0	NN	_	11	ppmod	_	_
14	of	of	IN	_	17	case	_	_
15	a	a	DT	_	17	det	_	_
16	14-day	0-day	JJ	_	17	attr	_	_
17	regimen	regimen	NN	_	13	ppmod	_	_
18	of	of	IN	_	20	case	_	_
19	600	0	CD	_	20	num	_	_
20	mg/day	mg/day	NN	_	17	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	drug3	drug0	NN	_	20	ppmod	_	_
23	,	,	,	_	22	p	_	_
24	a	a	DT	_	27	det	_	_
25	strong	strong	JJ	_	27	attr	_	_
26	CYP3A4	cyp0a0	NN	_	27	com	_	_
27	inducer	inducer	NN	_	22	appo	_	_
28	,	,	,	_	33	p	_	_
29	the	the	DT	_	30	det	_	_
30	AUC	auc	NN	_	33	dep	_	_
31	of	of	IN	_	32	case	_	_
32	drug4	drug0	NN	_	30	ppmod	_	_
33	decreased	decrease	VBD	_	1	acl	_	_
34	approximately	approximately	RB	_	35	com	_	_
35	11-fold	0-fold	RB	_	33	adv	_	_
36	and	and	CC	_	33	cc	_	_
37	the	the	DT	_	40	det	_	_
38	mean	mean	JJ	_	40	attr	_	_
39	terminal	terminal	JJ	_	40	attr	_	_
40	half-life	half-life	NN	_	41	dep	_	_
41	decreased	decrease	VBD	_	33	conj	_	_
42	approximately	approximately	RB	_	43	com	_	_
43	3-fold	0-fold	RB	_	41	adv	_	_
44	.	.	.	_	1	p	_	_

1	Coadministration	coadministration	NN	_	11	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	5	case	_	_
5	drugs	drug	NNS	_	1	ppmod	_	_
6	that	that	WDT	_	7	dep	_	_
7	induce	induce	VBP	_	5	relcl	_	_
8	CYP3A4	cyp0a0	NN	_	9	com	_	_
9	activity	activity	NN	_	7	obj	_	_
10	may	may	MD	_	11	modal	_	_
11	result	result	VB	_	0	root	_	_
12	in	in	IN	_	15	case	_	_
13	reduced	reduce	VBN	_	15	attr	_	_
14	plasma	plasma	NN	_	15	com	_	_
15	concentrations	concentration	NNS	_	11	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	decreased	decrease	VBN	_	18	attr	_	_
18	efficacy	efficacy	NN	_	15	conj	_	_
19	of	of	IN	_	20	case	_	_
20	drug2	drug0	NN	_	18	ppmod	_	_
21	.	.	.	_	11	p	_	_

1	Additional	additional	JJ	_	2	attr	_	_
2	interactions	interaction	NNS	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	4	case	_	_
4	patients	patient	NNS	_	41	ppmod	_	_
5	with	with	IN	_	9	case	_	_
6	mild	mild	JJ	_	8	adv	_	_
7	to	to	TO	_	8	adv	_	_
8	moderate	moderate	JJ	_	9	attr	_	_
9	hypertension	hypertension	NN	_	4	ppmod	_	_
10	,	,	,	_	41	p	_	_
11	administration	administration	NN	_	41	dep	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NNS	_	11	ppmod	_	_
14	once	once	RB	_	15	adv	_	_
15	daily	daily	JJ	_	13	attr	_	_
16	,	,	,	_	13	p	_	_
17	as	as	IN	_	20	case	_	_
18	a	a	DT	_	20	det	_	_
19	tablet	tablet	NN	_	20	com	_	_
20	formulation	formulation	NN	_	13	ppmod	_	_
21	comparable	comparable	JJ	_	20	attr	_	_
22	to	to	TO	_	24	aux	_	_
23	230	0	CD	_	24	num	_	_
24	mg	mg	NN	_	21	ppmod	_	_
25	of	of	IN	_	28	case	_	_
26	the	the	DT	_	28	det	_	_
27	capsule	capsule	JJ	_	28	attr	_	_
28	formulation	formulation	NN	_	24	ppmod	_	_
29	,	,	,	_	41	p	_	_
30	with	with	IN	_	35	case	_	_
31	drug3	drug0	NN	_	35	attr	_	_
32	120	0	CD	_	35	num	_	_
33	mg	mg	NN	_	35	attr	_	_
34	3	0	CD	_	35	num	_	_
35	times	time	NNS	_	41	ppmod	_	_
36	daily	daily	JJ	_	35	attr	_	_
37	for	for	IN	_	39	case	_	_
38	5	0	CD	_	39	num	_	_
39	days	day	NNS	_	36	ppmod	_	_
40	,	,	,	_	41	p	_	_
41	resulted	result	VBD	_	1	acl	_	_
42	in	in	IN	_	45	case	_	_
43	a	a	DT	_	45	det	_	_
44	2-fold	0-fold	JJ	_	45	attr	_	_
45	increase	increase	NN	_	41	ppmod	_	_
46	of	of	IN	_	48	case	_	_
47	drug4	drug0	NN	_	48	com	_	_
48	AUC	auc	NN	_	45	ppmod	_	_
49	and	and	CC	_	45	cc	_	_
50	a	a	DT	_	53	det	_	_
51	simultaneous	simultaneous	JJ	_	53	attr	_	_
52	1.7-fold	0-fold	JJ	_	53	attr	_	_
53	increase	increase	NN	_	45	conj	_	_
54	of	of	IN	_	56	case	_	_
55	drug5	drug0	NN	_	56	com	_	_
56	AUC	auc	NN	_	53	ppmod	_	_
57	.	.	.	_	1	p	_	_

1	These	these	DT	_	3	det	_	_
2	pharmacokinetic	pharmacokinetic	JJ	_	3	attr	_	_
3	effects	effect	NNS	_	6	dep	_	_
4	did	do	VBD	_	6	aux	_	_
5	not	not	RB	_	6	neg	_	_
6	result	result	VB	_	0	root	_	_
7	in	in	IN	_	10	case	_	_
8	clinically	clinically	RB	_	9	adv	_	_
9	meaningful	meaningful	JJ	_	10	attr	_	_
10	changes	change	NNS	_	6	ppmod	_	_
11	in	in	IN	_	12	case	_	_
12	ECG	ecg	NN	_	10	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	heart	heart	NN	_	15	com	_	_
15	rate	rate	NN	_	12	conj	_	_
16	or	or	CC	_	15	cc	_	_
17	blood	blood	NN	_	18	com	_	_
18	pressure	pressure	NN	_	12	conj	_	_
19	beyond	beyond	IN	_	21	case	_	_
20	those	those	DT	_	21	det	_	_
21	changes	change	NNS	_	6	ppmod	_	_
22	induced	induce	VBN	_	21	acl	_	_
23	by	by	IN	_	24	case	_	_
24	drug1	drug0	NN	_	22	ppmod	_	_
25	alone	alone	RB	_	24	adv	_	_
26	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Coadministration	coadministration	NN	_	34	dep	_	_
4	of	of	IN	_	7	case	_	_
5	once	once	RB	_	6	adv	_	_
6	daily	daily	JJ	_	7	attr	_	_
7	doses	dose	NNS	_	3	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	3	p	_	_
11	as	as	IN	_	14	case	_	_
12	a	a	DT	_	14	det	_	_
13	tablet	tablet	NN	_	14	com	_	_
14	formulation	formulation	NN	_	3	ppmod	_	_
15	comparable	comparable	JJ	_	14	attr	_	_
16	to	to	TO	_	18	aux	_	_
17	85	0	CD	_	18	num	_	_
18	mg	mg	NN	_	15	ppmod	_	_
19	or	or	CC	_	18	cc	_	_
20	170	0	CD	_	21	num	_	_
21	mg	mg	NN	_	18	conj	_	_
22	of	of	IN	_	25	case	_	_
23	the	the	DT	_	25	det	_	_
24	capsule	capsule	JJ	_	25	attr	_	_
25	formulation	formulation	NN	_	18	ppmod	_	_
26	,	,	,	_	3	p	_	_
27	with	with	IN	_	30	case	_	_
28	drug3	drug0	NN	_	30	attr	_	_
29	20	0	CD	_	30	num	_	_
30	mg	mg	NN	_	3	ppmod	_	_
31	once	once	RB	_	32	adv	_	_
32	daily	daily	JJ	_	30	attr	_	_
33	,	,	,	_	3	p	_	_
34	resulted	result	VBD	_	1	acl	_	_
35	in	in	IN	_	37	case	_	_
36	a	a	DT	_	37	det	_	_
37	decrease	decrease	NN	_	34	ppmod	_	_
38	in	in	IN	_	39	case	_	_
39	AUC	auc	NN	_	37	ppmod	_	_
40	by	by	IN	_	42	case	_	_
41	approximately	approximately	RB	_	42	adv	_	_
42	25	0	CD	_	39	ppmod	_	_
43	%	%	NN	_	42	meta	_	_
44	and	and	CC	_	39	cc	_	_
45	Cmax	cmax	NN	_	39	conj	_	_
46	,	,	,	_	34	p	_	_
47	by	by	IN	_	49	case	_	_
48	approximately	approximately	RB	_	49	adv	_	_
49	20	0	CD	_	34	ppmod	_	_
50	%	%	NN	_	49	meta	_	_
51	of	of	IN	_	53	case	_	_
52	both	both	CC	_	53	cc	_	_
53	drug4	drug0	NN	_	49	ppmod	_	_
54	and	and	CC	_	53	cc	_	_
55	drug5	drug0	NN	_	53	conj	_	_
56	.	.	.	_	1	p	_	_

1	No	no	DT	_	2	det	_	_
2	information	information	NN	_	0	root	_	_
3	provided	provided	VBN	_	2	acl	_	_

1	Interactions	interaction	NNS	_	0	root	_	_
2	for	for	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	drug2	drug0	NN	_	1	prn	_	_
6	,	,	,	_	5	p	_	_
7	drug3	drug0	NN	_	5	conj	_	_
8	,	,	,	_	7	p	_	_
9	drug4	drug0	NN	_	5	conj	_	_
10	,	,	,	_	9	p	_	_
11	and	and	CC	_	9	cc	_	_
12	drug5	drug0	NN	_	5	conj	_	_
13	)	-rrb-	-RRB-	_	5	p	_	_
14	:	:	:	_	1	p	_	_
15	drug6	drug0	NN	_	1	appo	_	_
16	:	:	:	_	15	p	_	_
17	drug7	drug0	NN	_	20	dep	_	_
18	has	have	VBZ	_	20	aux	_	_
19	been	be	VBN	_	20	aux	_	_
20	reported	report	VBN	_	15	acl	_	_
21	to	to	TO	_	22	aux	_	_
22	reduce	reduce	VB	_	20	comp	_	_
23	intestinal	intestinal	JJ	_	24	attr	_	_
24	absorption	absorption	NN	_	22	obj	_	_
25	of	of	IN	_	26	case	_	_
26	drug8	drug0	NN	_	24	ppmod	_	_
27	;	;	:	_	1	p	_	_

1	as	as	IN	_	2	case	_	_
2	such	such	JJ	_	5	ppmod	_	_
3	it	it	PRP	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	impair	impair	VB	_	0	root	_	_
6	intestinal	intestinal	JJ	_	7	attr	_	_
7	absorption	absorption	NN	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	any	any	DT	_	7	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	13	dep	_	_
2	/	/	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	:	:	:	_	1	p	_	_
5	The	the	DT	_	6	det	_	_
6	coadministration	coadministration	NN	_	1	appo	_	_
7	of	of	IN	_	8	case	_	_
8	drug3	drug0	NN	_	6	ppmod	_	_
9	or	or	CC	_	8	cc	_	_
10	drug4	drug0	NN	_	8	conj	_	_
11	will	will	MD	_	13	modal	_	_
12	not	not	RB	_	13	neg	_	_
13	affect	affect	VB	_	0	root	_	_
14	plasma	plasma	NN	_	15	com	_	_
15	concentrations	concentration	NNS	_	13	obj	_	_
16	of	of	IN	_	17	case	_	_
17	drug5	drug0	NN	_	15	ppmod	_	_
18	,	,	,	_	13	p	_	_
19	but	but	CC	_	13	cc	_	_
20	may	may	MD	_	21	modal	_	_
21	reduce	reduce	VB	_	13	conj	_	_
22	endogenous	endogenous	JJ	_	24	attr	_	_
23	plasma	plasma	NN	_	24	com	_	_
24	levels	level	NNS	_	21	obj	_	_
25	of	of	IN	_	27	case	_	_
26	drug6	drug0	NN	_	27	com	_	_
27	/ergocalcitriol	/ergocalcitriol	NN	_	24	ppmod	_	_
28	by	by	IN	_	29	case	_	_
29	accelerating	accelerate	VBG	_	21	ppmod	_	_
30	metabolism	metabolism	NN	_	29	obj	_	_
31	.	.	.	_	13	p	_	_

1	Since	since	IN	_	9	mark	_	_
2	blood	blood	NN	_	3	com	_	_
3	level	level	NN	_	9	dep	_	_
4	of	of	IN	_	6	case	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	/ergocalcitriol	/ergocalcitriol	NN	_	3	ppmod	_	_
7	will	will	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	reduced	reduce	VBN	_	16	advcl	_	_
10	,	,	,	_	16	p	_	_
11	higher	high	JJR	_	12	attr	_	_
12	doses	dose	NNS	_	16	dep	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	may	may	MD	_	16	modal	_	_
16	be	be	VB	_	0	root	_	_
17	necessary	necessary	JJ	_	16	dep	_	_
18	if	if	IN	_	22	mark	_	_
19	these	these	DT	_	20	det	_	_
20	drugs	drug	NNS	_	22	dep	_	_
21	are	be	VBP	_	22	aux	_	_
22	administered	administer	VBN	_	16	comp	_	_
23	simultaneously	simultaneously	RB	_	22	adv	_	_
24	.	.	.	_	16	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	are	be	VBP	_	5	aux	_	_
5	known	know	VBN	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	induce	induce	VB	_	5	comp	_	_
8	hypercalcemia	hypercalcemia	NN	_	7	obj	_	_
9	by	by	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	reduction	reduction	NN	_	7	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	drug3	drug0	NN	_	14	com	_	_
14	excretion	excretion	NN	_	11	ppmod	_	_
15	in	in	IN	_	16	case	_	_
16	urine	urine	NN	_	11	ppmod	_	_
17	.	.	.	_	5	p	_	_

1	Some	some	DT	_	2	det	_	_
2	reports	report	NNS	_	4	dep	_	_
3	have	have	VBP	_	4	aux	_	_
4	shown	show	VBN	_	0	root	_	_
5	that	that	IN	_	13	mark	_	_
6	the	the	DT	_	8	det	_	_
7	concomitant	concomitant	JJ	_	8	attr	_	_
8	administration	administration	NN	_	13	dep	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	with	with	IN	_	12	case	_	_
12	drug2	drug0	NN	_	8	ppmod	_	_
13	causes	cause	VBZ	_	4	comp	_	_
14	hypercalcemia	hypercalcemia	NN	_	13	obj	_	_
15	.	.	.	_	4	p	_	_

1	Therefore	therefore	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	precaution	precaution	NN	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	taken	take	VBN	_	0	root	_	_
7	when	when	WRB	_	9	adv	_	_
8	coadministration	coadministration	NN	_	9	dep	_	_
9	is	be	VBZ	_	6	comp	_	_
10	necessary	necessary	JJ	_	9	dep	_	_
11	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	4	com	_	_
4	dosage	dosage	NN	_	7	dep	_	_
5	must	must	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	determined	determine	VBN	_	1	acl	_	_
8	with	with	IN	_	9	case	_	_
9	care	care	NN	_	7	ppmod	_	_
10	in	in	IN	_	11	case	_	_
11	patients	patient	NNS	_	7	ppmod	_	_
12	undergoing	undergo	VBG	_	11	acl	_	_
13	treatment	treatment	NN	_	12	obj	_	_
14	with	with	IN	_	15	case	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	,	,	,	_	7	p	_	_
17	as	as	IN	_	23	mark	_	_
18	hypercalcemia	hypercalcemia	NN	_	23	dep	_	_
19	in	in	IN	_	21	case	_	_
20	such	such	JJ	_	21	attr	_	_
21	patients	patient	NNS	_	18	ppmod	_	_
22	may	may	MD	_	23	modal	_	_
23	precipitate	precipitate	VB	_	7	comp	_	_
24	cardiac	cardiac	JJ	_	25	attr	_	_
25	arrhythmias	arrhythmias	NN	_	23	obj	_	_
26	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	inhibit	inhibit	VB	_	1	acl	_	_
6	both	both	CC	_	7	cc	_	_
7	synthetic	synthetic	JJ	_	10	attr	_	_
8	and	and	CC	_	7	cc	_	_
9	catabolic	catabolic	JJ	_	7	conj	_	_
10	enzymes	enzyme	NNS	_	5	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	1	p	_	_

1	Reductions	reduction	NNS	_	10	dep	_	_
2	in	in	IN	_	7	case	_	_
3	serum	serum	NN	_	7	attr	_	_
4	endogenous	endogenous	JJ	_	6	attr	_	_
5	vitamin	vitamin	NN	_	6	com	_	_
6	D	d	NN	_	7	com	_	_
7	concentrations	concentration	NNS	_	1	ppmod	_	_
8	have	have	VBP	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	observed	observe	VBN	_	0	root	_	_
11	following	follow	VBG	_	13	adv	_	_
12	the	the	DT	_	13	det	_	_
13	administration	administration	NN	_	10	ppmod	_	_
14	of	of	IN	_	16	case	_	_
15	300	0	CD	_	16	num	_	_
16	mg/day	mg/day	NN	_	13	ppmod	_	_
17	to	to	TO	_	20	aux	_	_
18	1200	0	CD	_	19	num	_	_
19	mg/day	mg/day	NN	_	20	com	_	_
20	drug1	drug0	NN	_	13	ppmod	_	_
21	for	for	IN	_	23	case	_	_
22	a	a	DT	_	23	det	_	_
23	week	week	NN	_	20	ppmod	_	_
24	to	to	TO	_	26	aux	_	_
25	healthy	healthy	JJ	_	26	attr	_	_
26	men	man	NNS	_	23	ppmod	_	_
27	.	.	.	_	10	p	_	_

1	However	however	RB	_	15	adv	_	_
2	,	,	,	_	15	p	_	_
3	in	in	FW	_	4	adv	_	_
4	vivo	vivo	FW	_	7	attr	_	_
5	drug	drug	NN	_	7	com	_	_
6	interaction	interaction	NN	_	7	com	_	_
7	studies	study	NNS	_	15	dep	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NN	_	7	ppmod	_	_
12	have	have	VBP	_	15	aux	_	_
13	not	not	RB	_	15	neg	_	_
14	been	be	VBN	_	15	aux	_	_
15	investigated	investigate	VBN	_	0	root	_	_
16	.	.	.	_	15	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	A	a	DT	_	4	det	_	_
4	relationship	relationship	NN	_	8	dep	_	_
5	of	of	IN	_	7	case	_	_
6	functional	functional	JJ	_	7	attr	_	_
7	antagonism	antagonism	NN	_	4	ppmod	_	_
8	exists	exist	VBZ	_	1	acl	_	_
9	between	between	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	which	which	WDT	_	13	dep	_	_
13	promote	promote	VBP	_	10	relcl	_	_
14	calcium	calcium	NN	_	15	com	_	_
15	absorption	absorption	NN	_	13	obj	_	_
16	,	,	,	_	10	p	_	_
17	and	and	CC	_	10	cc	_	_
18	drug3	drug0	NN	_	10	conj	_	_
19	,	,	,	_	10	p	_	_
20	which	which	WDT	_	21	dep	_	_
21	inhibit	inhibit	VBP	_	10	relcl	_	_
22	calcium	calcium	NN	_	23	com	_	_
23	absorption	absorption	NN	_	21	obj	_	_
24	.	.	.	_	1	p	_	_

1	Phosphate-Binding	phosphate-binding	JJ	_	2	attr	_	_
2	Agents	agent	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	Since	since	IN	_	7	mark	_	_
5	drug1	drug0	NN	_	7	dep	_	_
6	also	also	RB	_	7	adv	_	_
7	has	have	VBZ	_	28	advcl	_	_
8	an	an	DT	_	9	det	_	_
9	effect	effect	NN	_	7	obj	_	_
10	on	on	IN	_	12	case	_	_
11	phosphate	phosphate	NN	_	12	com	_	_
12	transport	transport	NN	_	9	ppmod	_	_
13	in	in	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	intestine	intestine	NN	_	7	ppmod	_	_
16	,	,	,	_	15	p	_	_
17	kidneys	kidneys	NN	_	15	conj	_	_
18	and	and	CC	_	17	cc	_	_
19	bones	bones	NN	_	15	conj	_	_
20	,	,	,	_	28	p	_	_
21	the	the	DT	_	22	det	_	_
22	dosage	dosage	NN	_	28	dep	_	_
23	of	of	IN	_	25	case	_	_
24	phosphate-binding	phosphate-binding	JJ	_	25	attr	_	_
25	agents	agent	NNS	_	22	ppmod	_	_
26	must	must	MD	_	28	modal	_	_
27	be	be	VB	_	28	aux	_	_
28	adjusted	adjust	VBN	_	2	acl	_	_
29	in	in	IN	_	30	case	_	_
30	accordance	accordance	NN	_	28	ppmod	_	_
31	with	with	IN	_	35	case	_	_
32	the	the	DT	_	35	det	_	_
33	serum	serum	NN	_	35	com	_	_
34	phosphate	phosphate	NN	_	35	com	_	_
35	concentration	concentration	NN	_	30	ppmod	_	_
36	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	coadministration	coadministration	NN	_	12	dep	_	_
5	of	of	IN	_	6	case	_	_
6	any	any	DT	_	4	ppmod	_	_
7	of	of	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	drug2	drug0	NNS	_	6	ppmod	_	_
10	should	should	MD	_	12	modal	_	_
11	be	be	VB	_	12	aux	_	_
12	avoided	avoid	VBN	_	1	acl	_	_
13	as	as	IN	_	16	mark	_	_
14	this	this	DT	_	16	dep	_	_
15	could	could	MD	_	16	modal	_	_
16	create	create	VB	_	12	comp	_	_
17	possible	possible	JJ	_	19	attr	_	_
18	additive	additive	JJ	_	19	attr	_	_
19	effects	effect	NNS	_	16	obj	_	_
20	and	and	CC	_	19	cc	_	_
21	hypercalcemia	hypercalcemia	NN	_	19	conj	_	_
22	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	Supplements	supplement	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	Uncontrolled	uncontrolled	JJ	_	5	attr	_	_
5	intake	intake	NN	_	13	dep	_	_
6	of	of	IN	_	10	case	_	_
7	additional	additional	JJ	_	10	attr	_	_
8	drug2	drug0	NN	_	10	attr	_	_
9	-containing	-containing	JJ	_	10	attr	_	_
10	preparations	preparation	NNS	_	5	ppmod	_	_
11	should	should	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	avoided	avoid	VBN	_	2	acl	_	_
14	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	5	attr	_	_
4	-containing	-containing	JJ	_	5	attr	_	_
5	preparations	preparation	NNS	_	12	dep	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	eg	eg	NN	_	5	prn	_	_
8	,	,	,	_	7	p	_	_
9	drug3	drug0	NN	_	7	appo	_	_
10	)	-rrb-	-RRB-	_	7	p	_	_
11	may	may	MD	_	12	modal	_	_
12	cause	cause	VB	_	1	acl	_	_
13	hypermagnesemia	hypermagnesemia	NN	_	12	obj	_	_
14	and	and	CC	_	12	cc	_	_
15	should	should	MD	_	19	modal	_	_
16	therefore	therefore	RB	_	19	adv	_	_
17	not	not	RB	_	19	neg	_	_
18	be	be	VB	_	19	aux	_	_
19	taken	take	VBN	_	12	conj	_	_
20	during	during	IN	_	21	case	_	_
21	therapy	therapy	NN	_	19	ppmod	_	_
22	with	with	IN	_	23	case	_	_
23	drug4	drug0	NN	_	19	ppmod	_	_
24	by	by	IN	_	25	case	_	_
25	patients	patient	NNS	_	19	ppmod	_	_
26	on	on	IN	_	29	case	_	_
27	chronic	chronic	JJ	_	29	attr	_	_
28	renal	renal	JJ	_	29	attr	_	_
29	dialysis	dialysis	NN	_	25	ppmod	_	_
30	.	.	.	_	1	p	_	_

1	It	it	PRP	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	known	know	VBN	_	0	root	_	_
5	if	if	IN	_	8	mark	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	Gel	gel	NN	_	8	dep	_	_
8	interacts	interact	VBZ	_	4	comp	_	_
9	with	with	IN	_	12	case	_	_
10	other	other	JJ	_	12	attr	_	_
11	topical	topical	JJ	_	12	attr	_	_
12	medications	medication	NNS	_	8	ppmod	_	_
13	applied	apply	VBN	_	12	acl	_	_
14	to	to	TO	_	17	aux	_	_
15	the	the	DT	_	17	det	_	_
16	ulcer	ulcer	NN	_	17	com	_	_
17	site	site	NN	_	13	ppmod	_	_
18	.	.	.	_	4	p	_	_

1	The	the	DT	_	2	det	_	_
2	use	use	NN	_	13	dep	_	_
3	of	of	IN	_	5	case	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	Gel	gel	NN	_	2	ppmod	_	_
6	with	with	IN	_	9	case	_	_
7	other	other	JJ	_	9	attr	_	_
8	topical	topical	JJ	_	9	attr	_	_
9	drugs	drug	NNS	_	5	ppmod	_	_
10	has	have	VBZ	_	13	aux	_	_
11	not	not	RB	_	13	neg	_	_
12	been	be	VBN	_	13	aux	_	_
13	studied	study	VBN	_	0	root	_	_
14	.	.	.	_	13	p	_	_

1	1	0	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	Drugs	drug	NNS	_	2	dep	_	_
2	Metabolized	metabolize	VBN	_	23	advcl	_	_
3	by	by	IN	_	5	case	_	_
4	P450	p0	NN	_	5	com	_	_
5	2D6	0d0	NN	_	2	ppmod	_	_
6	:	:	:	_	23	p	_	_
7	The	the	DT	_	9	det	_	_
8	biochemical	biochemical	JJ	_	9	attr	_	_
9	activity	activity	NN	_	23	dep	_	_
10	of	of	IN	_	17	case	_	_
11	the	the	DT	_	17	det	_	_
12	drug	drug	NN	_	17	com	_	_
13	metabolizing	metabolizing	NN	_	17	com	_	_
14	isozyme	isozyme	NN	_	17	com	_	_
15	cytochrome	cytochrome	NN	_	17	com	_	_
16	P450	p0	NN	_	17	com	_	_
17	2D6	0d0	NN	_	9	ppmod	_	_
18	(	-lrb-	-LRB-	_	20	p	_	_
19	debrisoquin	debrisoquin	NN	_	20	com	_	_
20	hydroxylase	hydroxylase	NN	_	17	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	is	be	VBZ	_	23	aux	_	_
23	reduced	reduce	VBN	_	0	root	_	_
24	in	in	IN	_	26	case	_	_
25	a	a	DT	_	26	det	_	_
26	subset	subset	NN	_	23	ppmod	_	_
27	of	of	IN	_	30	case	_	_
28	the	the	DT	_	30	det	_	_
29	caucasian	caucasian	NN	_	30	com	_	_
30	population	population	NN	_	26	ppmod	_	_
31	(	-lrb-	-LRB-	_	41	p	_	_
32	about	about	RB	_	33	adv	_	_
33	7	0	CD	_	41	num	_	_
34	to	to	TO	_	33	cc	_	_
35	10	0	CD	_	33	conj	_	_
36	%	%	NN	_	33	meta	_	_
37	of	of	IN	_	38	case	_	_
38	caucasians	caucasian	NNS	_	33	ppmod	_	_
39	are	be	VBP	_	41	aux	_	_
40	so	so	RB	_	41	adv	_	_
41	called	call	VBN	_	23	prn	_	_
42	poor	poor	JJ	_	43	attr	_	_
43	metabolizers	metabolizers	NNS	_	41	obj	_	_
44	)	-rrb-	-RRB-	_	41	p	_	_
45	;	;	:	_	23	p	_	_

1	reliable	reliable	JJ	_	2	attr	_	_
2	estimates	estimate	NNS	_	19	dep	_	_
3	of	of	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	prevalence	prevalence	NN	_	2	ppmod	_	_
6	of	of	IN	_	11	case	_	_
7	reduced	reduce	VBN	_	11	attr	_	_
8	P450	p0	NN	_	11	com	_	_
9	2D6	0d0	NN	_	11	com	_	_
10	isozyme	isozyme	NN	_	11	com	_	_
11	activity	activity	NN	_	5	ppmod	_	_
12	among	among	IN	_	18	case	_	_
13	Asian	asian	JJ	_	18	attr	_	_
14	,	,	,	_	13	p	_	_
15	African	african	JJ	_	13	conj	_	_
16	and	and	CC	_	15	cc	_	_
17	other	other	JJ	_	13	conj	_	_
18	populations	population	NNS	_	5	ppmod	_	_
19	are	be	VBP	_	0	root	_	_
20	not	not	RB	_	19	neg	_	_
21	yet	yet	RB	_	19	adv	_	_
22	available	available	JJ	_	19	dep	_	_
23	.	.	.	_	19	p	_	_

1	Poor	poor	JJ	_	2	attr	_	_
2	metabolizers	metabolizers	NNS	_	8	dep	_	_
3	have	have	VBP	_	8	lv	_	_
4	higher	high	JJR	_	8	attr	_	_
5	than	than	IN	_	8	case	_	_
6	expected	expect	VBN	_	8	attr	_	_
7	plasma	plasma	NN	_	8	com	_	_
8	concentrations	concentration	NNS	_	0	root	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	drug2	drug0	NN	_	10	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	when	when	WRB	_	15	adv	_	_
15	given	give	VBN	_	8	comp	_	_
16	usual	usual	JJ	_	17	attr	_	_
17	doses	dose	NNS	_	15	obj	_	_
18	.	.	.	_	8	p	_	_

1	Depending	depend	VBG	_	4	adv	_	_
2	on	on	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	traction	traction	NN	_	18	ppmod	_	_
5	of	of	IN	_	7	case	_	_
6	drug	drug	NN	_	7	com	_	_
7	metabolized	metabolized	NN	_	4	ppmod	_	_
8	by	by	IN	_	10	case	_	_
9	P450	p0	NN	_	10	com	_	_
10	2D6	0d0	NN	_	4	ppmod	_	_
11	,	,	,	_	18	p	_	_
12	the	the	DT	_	13	det	_	_
13	increase	increase	NN	_	18	dep	_	_
14	in	in	IN	_	16	case	_	_
15	plasma	plasma	NN	_	16	com	_	_
16	concentration	concentration	NN	_	13	ppmod	_	_
17	may	may	MD	_	18	modal	_	_
18	be	be	VB	_	0	root	_	_
19	small	small	JJ	_	18	dep	_	_
20	,	,	,	_	19	p	_	_
21	or	or	CC	_	19	cc	_	_
22	quite	quite	RB	_	23	adv	_	_
23	large	large	JJ	_	19	conj	_	_
24	(	-lrb-	-LRB-	_	27	p	_	_
25	8	0	CD	_	26	num	_	_
26	fold	fold	JJ	_	27	attr	_	_
27	increase	increase	NN	_	23	prn	_	_
28	in	in	IN	_	30	case	_	_
29	plasma	plasma	NN	_	30	com	_	_
30	AUC	auc	NN	_	27	ppmod	_	_
31	of	of	IN	_	33	case	_	_
32	the	the	DT	_	33	det	_	_
33	drug1	drug0	NN	_	30	ppmod	_	_
34	)	-rrb-	-RRB-	_	27	p	_	_
35	.	.	.	_	18	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	16	ppmod	_	_
3	,	,	,	_	16	p	_	_
4	certain	certain	JJ	_	5	attr	_	_
5	drugs	drug	NNS	_	16	dep	_	_
6	inhibit	inhibit	VB	_	16	dep	_	_
7	the	the	DT	_	8	det	_	_
8	activity	activity	NN	_	6	obj	_	_
9	of	of	IN	_	11	case	_	_
10	this	this	DT	_	11	det	_	_
11	isozyme	isozyme	NN	_	8	ppmod	_	_
12	and	and	CC	_	6	cc	_	_
13	make	make	VB	_	6	conj	_	_
14	normal	normal	JJ	_	15	attr	_	_
15	metabolizers	metabolizers	NNS	_	13	obj	_	_
16	resemble	resemble	VBP	_	0	root	_	_
17	p.o.	p.o.	NN	_	16	obj	_	_

1	metabolizers	metabolizers	NN	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	An	an	DT	_	2	det	_	_
2	individual	individual	JJ	_	13	dep	_	_
3	who	who	WP	_	4	dep	_	_
4	is	be	VBZ	_	2	relcl	_	_
5	stable	stable	JJ	_	4	dep	_	_
6	on	on	IN	_	9	case	_	_
7	a	a	DT	_	9	det	_	_
8	given	given	JJ	_	9	attr	_	_
9	dose	dose	NN	_	5	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	may	may	MD	_	13	modal	_	_
13	become	become	VB	_	0	root	_	_
14	abruptly	abruptly	RB	_	15	adv	_	_
15	toxic	toxic	JJ	_	13	dep	_	_
16	when	when	WRB	_	17	adv	_	_
17	given	give	VBN	_	13	comp	_	_
18	one	#crd#	CD	_	17	obj	_	_
19	of	of	IN	_	22	case	_	_
20	these	these	DT	_	22	det	_	_
21	inhibiting	inhibiting	JJ	_	22	attr	_	_
22	drugs	drug	NNS	_	18	ppmod	_	_
23	as	as	IN	_	25	case	_	_
24	concomitant	concomitant	JJ	_	25	attr	_	_
25	therapy	therapy	NN	_	22	ppmod	_	_
26	.	.	.	_	13	p	_	_

1	The	the	DT	_	2	det	_	_
2	drugs	drug	NNS	_	8	dep	_	_
3	that	that	WDT	_	4	dep	_	_
4	inhibit	inhibit	VBP	_	2	relcl	_	_
5	cytochrome	cytochrome	NN	_	7	com	_	_
6	P450	p0	NN	_	7	com	_	_
7	2D6	0d0	NN	_	4	obj	_	_
8	include	include	VBP	_	0	root	_	_
9	some	some	DT	_	8	obj	_	_
10	that	that	WDT	_	13	dep	_	_
11	are	be	VBP	_	13	aux	_	_
12	not	not	RB	_	13	neg	_	_
13	metabolized	metabolize	VBN	_	9	relcl	_	_
14	by	by	IN	_	18	case	_	_
15	the	the	DT	_	18	det	_	_
16	enzyme	enzyme	NN	_	18	attr	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	drug1	drug0	NN	_	13	ppmod	_	_
19	;	;	:	_	8	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	)	-rrb-	-RRB-	_	1	p	_	_
3	and	and	CC	_	1	cc	_	_
4	many	many	JJ	_	1	conj	_	_
5	that	that	WDT	_	6	dep	_	_
6	are	be	VBP	_	4	relcl	_	_
7	substrates	substrate	NNS	_	6	obj	_	_
8	for	for	IN	_	10	case	_	_
9	P450	p0	NN	_	10	com	_	_
10	2D6	0d0	NN	_	7	ppmod	_	_
11	(	-lrb-	-LRB-	_	14	p	_	_
12	many	many	JJ	_	14	attr	_	_
13	other	other	JJ	_	14	attr	_	_
14	drug2	drug0	NNS	_	10	prn	_	_
15	,	,	,	_	14	p	_	_
16	drug3	drug0	NN	_	14	conj	_	_
17	,	,	,	_	16	p	_	_
18	and	and	CC	_	16	cc	_	_
19	the	the	DT	_	22	det	_	_
20	Type	type	NN	_	22	com	_	_
21	1C	0c	NN	_	22	com	_	_
22	antiarrhythrnics	antiarrhythrnics	NNS	_	14	conj	_	_
23	propatenone	propatenone	NN	_	22	appo	_	_
24	and	and	CC	_	23	cc	_	_
25	drug4	drug0	NN	_	23	conj	_	_
26	)	-rrb-	-RRB-	_	14	p	_	_
27	.	.	.	_	1	p	_	_

1	While	while	IN	_	18	mark	_	_
2	all	all	PDT	_	4	det	_	_
3	the	the	DT	_	4	det	_	_
4	drug1	drug0	NNS	_	18	dep	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	drug2	drug0	NN	_	4	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	,	,	,	_	4	p	_	_
9	e.g.	e.g.	FW	_	11	adv	_	_
10	,	,	,	_	11	p	_	_
11	drug3	drug0	NN	_	4	ppmod	_	_
12	,	,	,	_	11	p	_	_
13	seriraline	seriraline	NN	_	11	conj	_	_
14	,	,	,	_	13	p	_	_
15	and	and	CC	_	13	cc	_	_
16	drug4	drug0	NN	_	11	conj	_	_
17	,	,	,	_	4	p	_	_
18	inhibit	inhibit	VBP	_	24	advcl	_	_
19	P450	p0	NN	_	20	com	_	_
20	2D6	0d0	NN	_	18	obj	_	_
21	,	,	,	_	24	p	_	_
22	they	they	PRP	_	24	dep	_	_
23	may	may	MD	_	24	modal	_	_
24	vary	vary	VB	_	0	root	_	_
25	in	in	IN	_	27	case	_	_
26	the	the	DT	_	27	det	_	_
27	extent	extent	NN	_	24	ppmod	_	_
28	of	of	IN	_	29	case	_	_
29	inhibition	inhibition	NN	_	27	ppmod	_	_
30	.	.	.	_	24	p	_	_

1	The	the	DT	_	2	det	_	_
2	extent	extent	NN	_	14	dep	_	_
3	to	to	TO	_	4	aux	_	_
4	which	which	WDT	_	10	ppmod	_	_
5	drug1	drug0	NN	_	8	attr	_	_
6	-	-	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	interactions	interaction	NNS	_	10	dep	_	_
9	may	may	MD	_	10	modal	_	_
10	pose	pose	VBP	_	2	relcl	_	_
11	clinical	clinical	JJ	_	12	attr	_	_
12	problems	problem	NNS	_	10	obj	_	_
13	will	will	MD	_	14	modal	_	_
14	depend	depend	VB	_	0	root	_	_
15	on	on	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	degree	degree	NN	_	14	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	inhibition	inhibition	NN	_	17	ppmod	_	_
20	and	and	CC	_	17	cc	_	_
21	the	the	DT	_	22	det	_	_
22	pharmacokinetics	pharmacokinetics	NNS	_	17	conj	_	_
23	of	of	IN	_	25	case	_	_
24	the	the	DT	_	25	det	_	_
25	drug3	drug0	NN	_	22	ppmod	_	_
26	involved	involve	VBN	_	25	acl	_	_
27	.	.	.	_	14	p	_	_

1	Nevertheless	nevertheless	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	caution	caution	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	indicated	indicate	VBN	_	0	root	_	_
6	in	in	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	co-administration	co-administration	NN	_	5	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	with	with	IN	_	12	case	_	_
12	any	any	DT	_	8	ppmod	_	_
13	of	of	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	drug2	drug0	NN	_	12	ppmod	_	_
16	and	and	CC	_	8	cc	_	_
17	also	also	RB	_	19	adv	_	_
18	in	in	IN	_	19	case	_	_
19	switching	switching	NN	_	8	conj	_	_
20	from	from	IN	_	22	case	_	_
21	one	#crd#	CD	_	22	num	_	_
22	class	class	NN	_	19	ppmod	_	_
23	to	to	TO	_	25	aux	_	_
24	the	the	DT	_	25	det	_	_
25	other	other	JJ	_	19	ppmod	_	_
26	.	.	.	_	5	p	_	_

1	Of	of	IN	_	3	case	_	_
2	particular	particular	JJ	_	3	attr	_	_
3	importance	importance	NN	_	8	ppmod	_	_
4	,	,	,	_	8	p	_	_
5	sufficient	sufficient	JJ	_	6	attr	_	_
6	time	time	NN	_	8	dep	_	_
7	must	must	MD	_	8	modal	_	_
8	elapse	elapse	VB	_	0	root	_	_
9	before	before	IN	_	10	case	_	_
10	initiating	initiate	VBG	_	8	ppmod	_	_
11	TCA	tca	NN	_	12	com	_	_
12	treatment	treatment	NN	_	10	obj	_	_
13	in	in	IN	_	15	case	_	_
14	a	a	DT	_	15	det	_	_
15	patient	patient	NN	_	10	ppmod	_	_
16	being	be	VBG	_	17	aux	_	_
17	withdrawn	withdraw	VBN	_	15	acl	_	_
18	from	from	IN	_	19	case	_	_
19	drug1	drug0	NN	_	17	ppmod	_	_
20	,	,	,	_	19	p	_	_
21	given	give	VBN	_	19	acl	_	_
22	the	the	DT	_	24	det	_	_
23	long	long	JJ	_	24	attr	_	_
24	half-life	half-life	NN	_	21	obj	_	_
25	of	of	IN	_	27	case	_	_
26	the	the	DT	_	27	det	_	_
27	parent	parent	NN	_	24	ppmod	_	_
28	and	and	CC	_	19	cc	_	_
29	active	active	JJ	_	30	attr	_	_
30	metabolite	metabolite	NN	_	19	conj	_	_
31	(	-lrb-	-LRB-	_	35	p	_	_
32	at	at	IN	_	34	case	_	_
33	least	least	JJS	_	34	attr	_	_
34	5	0	CD	_	35	num	_	_
35	weeks	week	NNS	_	30	prn	_	_
36	may	may	MD	_	37	modal	_	_
37	be	be	VB	_	35	acl	_	_
38	necessary	necessary	JJ	_	37	dep	_	_
39	)	-rrb-	-RRB-	_	35	p	_	_
40	.	.	.	_	8	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	use	use	NN	_	14	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	with	with	IN	_	6	case	_	_
6	drugs	drug	NNS	_	2	ppmod	_	_
7	that	that	WDT	_	9	dep	_	_
8	can	can	MD	_	9	modal	_	_
9	inhibit	inhibit	VB	_	6	relcl	_	_
10	cytochrome	cytochrome	NN	_	12	com	_	_
11	P450	p0	NN	_	12	com	_	_
12	2D6	0d0	NN	_	9	obj	_	_
13	may	may	MD	_	14	modal	_	_
14	require	require	VB	_	0	root	_	_
15	lower	low	JJR	_	16	attr	_	_
16	doses	dose	NNS	_	14	obj	_	_
17	than	than	IN	_	18	case	_	_
18	usually	usually	RB	_	19	adv	_	_
19	prescribed	prescribe	VBN	_	16	acl	_	_
20	for	for	IN	_	23	case	_	_
21	either	either	CC	_	23	cc	_	_
22	the	the	DT	_	23	det	_	_
23	drug2	drug0	NN	_	19	ppmod	_	_
24	or	or	CC	_	23	cc	_	_
25	the	the	DT	_	27	det	_	_
26	other	other	JJ	_	27	attr	_	_
27	drug	drug	NN	_	23	conj	_	_
28	.	.	.	_	14	p	_	_

1	Furthermore	furthermore	RB	_	21	adv	_	_
2	,	,	,	_	21	p	_	_
3	whenever	whenever	RB	_	10	adv	_	_
4	one	#crd#	CD	_	10	num	_	_
5	of	of	IN	_	8	case	_	_
6	these	these	DT	_	8	det	_	_
7	other	other	JJ	_	8	attr	_	_
8	drugs	drug	NNS	_	4	ppmod	_	_
9	is	be	VBZ	_	10	aux	_	_
10	withdrawn	withdraw	VBN	_	21	advcl	_	_
11	from	from	IN	_	12	case	_	_
12	co-therapy	co-therapy	NN	_	10	ppmod	_	_
13	,	,	,	_	21	p	_	_
14	an	an	DT	_	16	det	_	_
15	increased	increase	VBN	_	16	attr	_	_
16	dose	dose	NN	_	21	dep	_	_
17	of	of	IN	_	18	case	_	_
18	drug1	drug0	NN	_	16	ppmod	_	_
19	may	may	MD	_	21	modal	_	_
20	be	be	VB	_	21	aux	_	_
21	required	require	VBN	_	0	root	_	_
22	.	.	.	_	21	p	_	_

1	It	it	PRP	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	desirable	desirable	JJ	_	2	dep	_	_
4	to	to	TO	_	5	aux	_	_
5	monitor	monitor	VB	_	2	comp	_	_
6	drug1	drug0	NN	_	8	com	_	_
7	plasma	plasma	NN	_	8	com	_	_
8	levels	level	NNS	_	5	obj	_	_
9	whenever	whenever	RB	_	12	adv	_	_
10	a	a	DT	_	11	det	_	_
11	drug2	drug0	NN	_	12	dep	_	_
12	is	be	VBZ	_	5	comp	_	_
13	going	going	JJ	_	12	dep	_	_
14	to	to	TO	_	16	aux	_	_
15	be	be	VB	_	16	aux	_	_
16	co-administered	co-administered	VBN	_	13	comp	_	_
17	with	with	IN	_	19	case	_	_
18	another	another	DT	_	19	det	_	_
19	drug	drug	NN	_	16	ppmod	_	_
20	known	know	VBN	_	19	acl	_	_
21	to	to	TO	_	22	aux	_	_
22	be	be	VB	_	20	comp	_	_
23	an	an	DT	_	24	det	_	_
24	inhibitor	inhibitor	NN	_	22	obj	_	_
25	of	of	IN	_	27	case	_	_
26	P450	p0	NN	_	27	com	_	_
27	2D6	0d0	NN	_	24	ppmod	_	_
28	.	.	.	_	2	p	_	_

1	2	0	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	Close	close	JJ	_	2	attr	_	_
2	supervision	supervision	NN	_	9	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	careful	careful	JJ	_	5	attr	_	_
5	adjustment	adjustment	NN	_	2	conj	_	_
6	of	of	IN	_	7	case	_	_
7	dosage	dosage	NN	_	2	ppmod	_	_
8	are	be	VBP	_	9	aux	_	_
9	required	require	VBN	_	0	root	_	_
10	when	when	WRB	_	14	adv	_	_
11	this	this	DT	_	12	det	_	_
12	drug	drug	NN	_	14	dep	_	_
13	is	be	VBZ	_	14	aux	_	_
14	given	give	VBN	_	9	comp	_	_
15	concomitantly	concomitantly	RB	_	14	adv	_	_
16	with	with	IN	_	17	case	_	_
17	drug1	drug0	NN	_	14	ppmod	_	_
18	or	or	CC	_	17	cc	_	_
19	drug2	drug0	NN	_	17	conj	_	_
20	.	.	.	_	9	p	_	_

1	3	0	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	Clinical	clinical	JJ	_	2	dep	_	_
2	experience	experience	VBP	_	0	root	_	_
3	in	in	IN	_	12	mark	_	_
4	the	the	DT	_	6	det	_	_
5	concurrent	concurrent	JJ	_	6	attr	_	_
6	administration	administration	NN	_	12	dep	_	_
7	of	of	IN	_	8	case	_	_
8	ECT	ect	NN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	drug1	drug0	NN	_	8	conj	_	_
11	is	be	VBZ	_	12	aux	_	_
12	limited	limit	VBN	_	2	comp	_	_
13	.	.	.	_	2	p	_	_

1	Thus	thus	RB	_	19	adv	_	_
2	,	,	,	_	19	p	_	_
3	if	if	IN	_	6	mark	_	_
4	such	such	JJ	_	5	attr	_	_
5	treatment	treatment	NN	_	6	dep	_	_
6	is	be	VBZ	_	19	advcl	_	_
7	essential	essential	JJ	_	6	dep	_	_
8	,	,	,	_	19	p	_	_
9	the	the	DT	_	10	det	_	_
10	possibility	possibility	NN	_	19	dep	_	_
11	of	of	IN	_	13	case	_	_
12	increased	increase	VBN	_	13	attr	_	_
13	risk	risk	NN	_	10	ppmod	_	_
14	relative	relative	JJ	_	13	attr	_	_
15	to	to	TO	_	16	aux	_	_
16	benefits	benefit	NNS	_	14	ppmod	_	_
17	should	should	MD	_	19	modal	_	_
18	be	be	VB	_	19	aux	_	_
19	considered	consider	VBN	_	0	root	_	_
20	.	.	.	_	19	p	_	_

1	4	0	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	If	if	IN	_	3	mark	_	_
2	drug1	drug0	NN	_	3	dep	_	_
3	is	be	VBZ	_	22	advcl	_	_
4	to	to	TO	_	6	aux	_	_
5	be	be	VB	_	6	aux	_	_
6	combined	combine	VBN	_	3	comp	_	_
7	with	with	IN	_	9	case	_	_
8	other	other	JJ	_	9	attr	_	_
9	drug2	drug0	NNS	_	6	ppmod	_	_
10	such	such	JJ	_	12	adv	_	_
11	as	as	IN	_	12	case	_	_
12	drug3	drug0	NN	_	9	ppmod	_	_
13	or	or	CC	_	12	cc	_	_
14	drug4	drug0	NN	_	12	conj	_	_
15	/	/	:	_	6	p	_	_
16	drug5	drug0	NN	_	6	obj	_	_
17	,	,	,	_	22	p	_	_
18	careful	careful	JJ	_	19	attr	_	_
19	consideration	consideration	NN	_	22	dep	_	_
20	should	should	MD	_	22	modal	_	_
21	be	be	VB	_	22	aux	_	_
22	given	give	VBN	_	0	root	_	_
23	to	to	TO	_	25	aux	_	_
24	the	the	DT	_	25	det	_	_
25	pharmacology	pharmacology	NN	_	22	ppmod	_	_
26	of	of	IN	_	28	case	_	_
27	the	the	DT	_	28	det	_	_
28	agents	agent	NNS	_	25	ppmod	_	_
29	employed	employ	VBN	_	28	acl	_	_
30	since	since	IN	_	45	mark	_	_
31	the	the	DT	_	33	det	_	_
32	sedative	sedative	JJ	_	33	attr	_	_
33	effects	effect	NNS	_	45	dep	_	_
34	of	of	IN	_	35	case	_	_
35	drug6	drug0	NN	_	33	ppmod	_	_
36	and	and	CC	_	35	cc	_	_
37	drug7	drug0	NN	_	35	conj	_	_
38	(	-lrb-	-LRB-	_	41	p	_	_
39	e.g.	e.g.	FW	_	41	adv	_	_
40	,	,	,	_	41	p	_	_
41	drug8	drug0	NN	_	35	prn	_	_
42	or	or	CC	_	41	cc	_	_
43	drug9	drug0	NN	_	41	conj	_	_
44	)	-rrb-	-RRB-	_	41	p	_	_
45	are	be	VBP	_	29	comp	_	_
46	additive	additive	JJ	_	45	dep	_	_
47	.	.	.	_	22	p	_	_

1	Both	both	CC	_	6	cc	_	_
2	the	the	DT	_	6	det	_	_
3	sedative	sedative	JJ	_	6	attr	_	_
4	and	and	CC	_	3	cc	_	_
5	anticholinergic	anticholinergic	JJ	_	3	conj	_	_
6	effects	effect	NNS	_	10	dep	_	_
7	of	of	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	drug1	drug0	NN	_	6	ppmod	_	_
10	are	be	VBP	_	0	root	_	_
11	also	also	RB	_	10	adv	_	_
12	additive	additive	JJ	_	10	dep	_	_
13	to	to	TO	_	14	aux	_	_
14	those	those	DT	_	12	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	.	.	.	_	10	p	_	_

1	5	0	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	Concurrent	concurrent	JJ	_	2	attr	_	_
2	administration	administration	NN	_	8	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	can	can	MD	_	8	modal	_	_
8	produce	produce	VBP	_	0	root	_	_
9	clinically	clinically	RB	_	10	adv	_	_
10	significant	significant	JJ	_	11	attr	_	_
11	increases	increase	NNS	_	8	obj	_	_
12	in	in	IN	_	15	case	_	_
13	the	the	DT	_	15	det	_	_
14	plasma	plasma	NN	_	15	com	_	_
15	levels	level	NNS	_	11	ppmod	_	_
16	of	of	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	drug3	drug0	NN	_	15	ppmod	_	_
19	.	.	.	_	8	p	_	_

1	Conversely	conversely	RB	_	12	adv	_	_
2	,	,	,	_	12	p	_	_
3	decreases	decrease	NNS	_	12	dep	_	_
4	in	in	IN	_	6	case	_	_
5	plasma	plasma	NN	_	6	com	_	_
6	levels	level	NNS	_	3	ppmod	_	_
7	of	of	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	drug1	drug0	NN	_	6	ppmod	_	_
10	have	have	VBP	_	12	aux	_	_
11	been	be	VBN	_	12	aux	_	_
12	reported	report	VBN	_	0	root	_	_
13	upon	upon	IN	_	14	case	_	_
14	discontinuation	discontinuation	NN	_	12	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	which	which	WDT	_	19	dep	_	_
18	may	may	MD	_	19	modal	_	_
19	result	result	VB	_	16	relcl	_	_
20	in	in	IN	_	22	case	_	_
21	the	the	DT	_	22	det	_	_
22	loss	loss	NN	_	19	ppmod	_	_
23	of	of	IN	_	26	case	_	_
24	the	the	DT	_	26	det	_	_
25	therapeutic	therapeutic	JJ	_	26	attr	_	_
26	efficacy	efficacy	NN	_	22	ppmod	_	_
27	of	of	IN	_	29	case	_	_
28	the	the	DT	_	29	det	_	_
29	drug3	drug0	NN	_	26	ppmod	_	_
30	6	0	CD	_	29	num	_	_
31	.	.	.	_	12	p	_	_

1	There	there	EX	_	3	dep	_	_
2	have	have	VBP	_	3	aux	_	_
3	been	be	VBN	_	0	root	_	_
4	greater	great	JJR	_	3	dep	_	_
5	than	than	IN	_	7	case	_	_
6	two-fold	two-fold	JJ	_	7	attr	_	_
7	increases	increase	NNS	_	4	ppmod	_	_
8	of	of	IN	_	12	case	_	_
9	previously	previously	RB	_	10	adv	_	_
10	stable	stable	JJ	_	12	attr	_	_
11	plasma	plasma	NN	_	12	com	_	_
12	levels	level	NNS	_	7	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	when	when	WRB	_	19	adv	_	_
16	drug2	drug0	NN	_	19	dep	_	_
17	has	have	VBZ	_	19	aux	_	_
18	been	be	VBN	_	19	aux	_	_
19	administered	administer	VBN	_	3	comp	_	_
20	in	in	IN	_	21	case	_	_
21	combination	combination	NN	_	19	ppmod	_	_
22	with	with	IN	_	24	case	_	_
23	these	these	DT	_	24	det	_	_
24	agents	agent	NNS	_	21	ppmod	_	_
25	.	.	.	_	3	p	_	_

1	Potential	potential	JJ	_	3	attr	_	_
2	drug	drug	NN	_	3	com	_	_
3	interactions	interaction	NNS	_	6	dep	_	_
4	for	for	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	include	include	VBP	_	0	root	_	_
7	,	,	,	_	6	p	_	_
8	increased	increase	VBN	_	9	attr	_	_
9	sedation	sedation	NN	_	6	obj	_	_
10	if	if	IN	_	13	mark	_	_
11	drug2	drug0	NN	_	13	dep	_	_
12	is	be	VBZ	_	13	aux	_	_
13	combined	combine	VBN	_	9	acl	_	_
14	with	with	IN	_	16	case	_	_
15	other	other	JJ	_	16	attr	_	_
16	drug3	drug0	NN	_	13	ppmod	_	_
17	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	may	may	MD	_	4	modal	_	_
3	partially	partially	RB	_	4	adv	_	_
4	counteract	counteract	VB	_	0	root	_	_
5	the	the	DT	_	7	det	_	_
6	anticoagulation	anticoagulation	NN	_	7	com	_	_
7	effects	effect	NNS	_	4	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	or	or	CC	_	9	cc	_	_
11	drug3	drug0	NN	_	9	conj	_	_
12	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	enhance	enhance	VB	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	effects	effect	NNS	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	8	dep	_	_
2	,	,	,	_	1	p	_	_
3	such	such	JJ	_	5	adv	_	_
4	as	as	IN	_	5	case	_	_
5	drug2	drug0	NN	_	1	ppmod	_	_
6	,	,	,	_	1	p	_	_
7	may	may	MD	_	8	modal	_	_
8	have	have	VB	_	0	root	_	_
9	an	an	DT	_	11	det	_	_
10	additive	additive	JJ	_	11	attr	_	_
11	effect	effect	NN	_	8	obj	_	_
12	when	when	WRB	_	13	adv	_	_
13	given	give	VBN	_	8	comp	_	_
14	with	with	IN	_	15	case	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	8	p	_	_

1	Patients	patient	NNS	_	12	dep	_	_
2	treated	treat	VBN	_	1	acl	_	_
3	with	with	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	plus	plus	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	should	should	MD	_	12	modal	_	_
8	,	,	,	_	12	p	_	_
9	therefore	therefore	RB	_	12	adv	_	_
10	,	,	,	_	12	p	_	_
11	be	be	VB	_	12	aux	_	_
12	observed	observe	VBN	_	0	root	_	_
13	closely	closely	RB	_	12	adv	_	_
14	for	for	IN	_	15	case	_	_
15	evidence	evidence	NN	_	12	ppmod	_	_
16	of	of	IN	_	18	case	_	_
17	marked	marked	JJ	_	18	attr	_	_
18	bradycardia	bradycardia	NN	_	15	ppmod	_	_
19	or	or	CC	_	18	cc	_	_
20	hypotension	hypotension	NN	_	18	conj	_	_
21	which	which	WDT	_	23	dep	_	_
22	may	may	MD	_	23	modal	_	_
23	present	present	VBP	_	18	relcl	_	_
24	as	as	IN	_	25	case	_	_
25	vertigo	vertigo	NN	_	23	ppmod	_	_
26	,	,	,	_	25	p	_	_
27	syncope/presyncope	syncope/presyncope	NN	_	25	conj	_	_
28	,	,	,	_	27	p	_	_
29	or	or	CC	_	27	cc	_	_
30	orthostatic	orthostatic	JJ	_	31	attr	_	_
31	changes	change	NNS	_	25	conj	_	_
32	in	in	IN	_	34	case	_	_
33	blood	blood	NN	_	34	com	_	_
34	pressure	pressure	NN	_	31	ppmod	_	_
35	without	without	IN	_	37	case	_	_
36	compensatory	compensatory	JJ	_	37	attr	_	_
37	tachycardia	tachycardia	NN	_	31	ppmod	_	_
38	.	.	.	_	12	p	_	_

1	Exaggerated	exaggerated	JJ	_	3	attr	_	_
2	hypertensive	hypertensive	JJ	_	3	attr	_	_
3	responses	response	NNS	_	6	dep	_	_
4	have	have	VBP	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	reported	report	VBN	_	0	root	_	_
7	from	from	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	combined	combined	JJ	_	10	attr	_	_
10	use	use	NN	_	6	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	drug2	drug0	NN	_	12	conj	_	_
15	,	,	,	_	6	p	_	_
16	including	include	VBG	_	17	adv	_	_
17	those	those	DT	_	6	ppmod	_	_
18	contained	contain	VBN	_	17	acl	_	_
19	in	in	IN	_	22	case	_	_
20	proprietary	proprietary	JJ	_	22	attr	_	_
21	cold	cold	JJ	_	22	attr	_	_
22	remedies	remedy	NNS	_	18	ppmod	_	_
23	and	and	CC	_	22	cc	_	_
24	vasoconstrictive	vasoconstrictive	JJ	_	26	attr	_	_
25	nasal	nasal	JJ	_	26	attr	_	_
26	drops	drops	NN	_	22	conj	_	_
27	.	.	.	_	6	p	_	_

1	Patients	patient	NNS	_	6	dep	_	_
2	receiving	receive	VBG	_	1	acl	_	_
3	drug1	drug0	NN	_	2	obj	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	warned	warn	VBN	_	0	root	_	_
7	of	of	IN	_	10	case	_	_
8	this	this	DT	_	10	det	_	_
9	potential	potential	JJ	_	10	attr	_	_
10	hazard	hazard	NN	_	6	ppmod	_	_
11	.	.	.	_	6	p	_	_

1	Blunting	blunting	NN	_	12	dep	_	_
2	of	of	IN	_	5	case	_	_
3	the	the	DT	_	5	det	_	_
4	antihypertensive	antihypertensive	JJ	_	5	attr	_	_
5	effect	effect	NN	_	1	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	by	by	IN	_	9	case	_	_
9	drug2	drug0	NN	_	1	ppmod	_	_
10	has	have	VBZ	_	12	aux	_	_
11	been	be	VBN	_	12	aux	_	_
12	reported	report	VBN	_	0	root	_	_
13	.	.	.	_	12	p	_	_

1	No	no	DT	_	3	det	_	_
2	significant	significant	JJ	_	3	attr	_	_
3	interactions	interaction	NNS	_	22	dep	_	_
4	with	with	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	,	,	,	_	5	p	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	,	,	,	_	7	p	_	_
9	drug3	drug0	NN	_	5	conj	_	_
10	,	,	,	_	9	p	_	_
11	drug4	drug0	NN	_	5	conj	_	_
12	,	,	,	_	11	p	_	_
13	oral	oral	JJ	_	14	attr	_	_
14	drug5	drug0	NN	_	5	conj	_	_
15	,	,	,	_	14	p	_	_
16	drug6	drug0	NN	_	5	conj	_	_
17	,	,	,	_	16	p	_	_
18	or	or	CC	_	16	cc	_	_
19	drug7	drug0	NN	_	5	conj	_	_
20	have	have	VBP	_	22	aux	_	_
21	been	be	VBN	_	22	aux	_	_
22	observed	observe	VBN	_	0	root	_	_
23	.	.	.	_	22	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	enhance	enhance	VB	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	effects	effect	NNS	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	drug3	drug0	NN	_	7	conj	_	_
10	,	,	,	_	9	p	_	_
11	drug4	drug0	NN	_	7	conj	_	_
12	,	,	,	_	11	p	_	_
13	and	and	CC	_	11	cc	_	_
14	other	other	JJ	_	15	attr	_	_
15	drug5	drug0	NN	_	7	conj	_	_
16	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	prolong	prolong	VBP	_	0	root	_	_
3	and	and	CC	_	2	cc	_	_
4	intensify	intensify	VBP	_	2	conj	_	_
5	the	the	DT	_	7	det	_	_
6	anticholinergic	anticholinergic	JJ	_	7	attr	_	_
7	effects	effect	NNS	_	4	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	reduce	reduce	VB	_	0	root	_	_
4	the	the	DT	_	6	det	_	_
5	antihypertensive	antihypertensive	JJ	_	6	attr	_	_
6	effects	effect	NNS	_	3	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	,	,	,	_	8	p	_	_
10	drug3	drug0	NN	_	8	conj	_	_
11	,	,	,	_	10	p	_	_
12	drug4	drug0	NN	_	8	conj	_	_
13	and	and	CC	_	12	cc	_	_
14	drug5	drug0	NN	_	8	conj	_	_
15	.	.	.	_	3	p	_	_

1	Effects	effect	NNS	_	5	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	are	be	VBP	_	5	aux	_	_
5	increased	increase	VBN	_	0	root	_	_
6	with	with	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug3	drug0	NN	_	7	conj	_	_
10	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	such	such	JJ	_	0	root	_	_
3	as	as	IN	_	4	case	_	_
4	drug2	drug0	NN	_	2	ppmod	_	_
5	or	or	CC	_	4	cc	_	_
6	drug3	drug0	NN	_	4	conj	_	_
7	;	;	:	_	2	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	No	no	DT	_	3	det	_	_
2	separate	separate	JJ	_	3	attr	_	_
3	information	information	NN	_	0	root	_	_
4	available	available	JJ	_	3	attr	_	_

1	Patients	patient	NNS	_	10	dep	_	_
2	who	who	WP	_	4	dep	_	_
3	are	be	VBP	_	4	aux	_	_
4	applying	apply	VBG	_	1	relcl	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	gel	gel	NN	_	4	obj	_	_
7	should	should	MD	_	10	modal	_	_
8	not	not	RB	_	10	neg	_	_
9	concurrently	concurrently	RB	_	10	adv	_	_
10	use	use	VB	_	0	root	_	_
11	products	product	NNS	_	10	obj	_	_
12	that	that	WDT	_	13	dep	_	_
13	contain	contain	VBP	_	11	relcl	_	_
14	drug2	drug0	NN	_	13	obj	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	N	n	NN	_	14	prn	_	_
17	,	,	,	_	16	p	_	_
18	drug3	drug0	NN	_	16	appo	_	_
19	)	-rrb-	-RRB-	_	16	p	_	_
20	,	,	,	_	14	p	_	_
21	a	a	DT	_	23	det	_	_
22	common	common	JJ	_	23	attr	_	_
23	component	component	NN	_	14	appo	_	_
24	of	of	IN	_	27	case	_	_
25	insect	insect	NN	_	27	com	_	_
26	repellent	repellent	NN	_	27	com	_	_
27	products	product	NNS	_	23	ppmod	_	_
28	.	.	.	_	10	p	_	_

1	Animal	animal	NN	_	3	com	_	_
2	toxicology	toxicology	NN	_	3	com	_	_
3	studies	study	NNS	_	4	dep	_	_
4	showed	show	VBD	_	0	root	_	_
5	increased	increase	VBN	_	7	attr	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	toxicity	toxicity	NN	_	4	obj	_	_
8	when	when	WRB	_	11	adv	_	_
9	drug2	drug0	NN	_	11	dep	_	_
10	was	be	VBD	_	11	aux	_	_
11	included	include	VBN	_	4	comp	_	_
12	as	as	IN	_	13	case	_	_
13	proof	proof	NN	_	11	ppmod	_	_
14	of	of	IN	_	16	case	_	_
15	the	the	DT	_	16	det	_	_
16	formulation	formulation	NN	_	13	ppmod	_	_
17	.	.	.	_	4	p	_	_

1	Although	although	IN	_	3	mark	_	_
2	there	there	EX	_	3	dep	_	_
3	was	be	VBD	_	40	advcl	_	_
4	no	no	DT	_	6	det	_	_
5	clinical	clinical	JJ	_	6	attr	_	_
6	evidence	evidence	NN	_	3	obj	_	_
7	in	in	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	vehicle-controlled	vehicle-controlled	JJ	_	10	attr	_	_
10	studies	study	NNS	_	3	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	drug	drug	NN	_	13	com	_	_
13	interactions	interaction	NNS	_	10	ppmod	_	_
14	with	with	IN	_	16	case	_	_
15	systemic	systemic	JJ	_	16	attr	_	_
16	drug1	drug0	NN	_	13	ppmod	_	_
17	,	,	,	_	10	p	_	_
18	including	include	VBG	_	19	adv	_	_
19	drug2	drug0	NN	_	10	ppmod	_	_
20	,	,	,	_	19	p	_	_
21	drug3	drug0	NN	_	19	conj	_	_
22	,	,	,	_	21	p	_	_
23	and	and	CC	_	21	cc	_	_
24	drug4	drug0	NN	_	19	conj	_	_
25	,	,	,	_	40	p	_	_
26	the	the	DT	_	27	det	_	_
27	effect	effect	NN	_	40	dep	_	_
28	of	of	IN	_	30	case	_	_
29	drug5	drug0	NN	_	30	com	_	_
30	gel	gel	NN	_	27	ppmod	_	_
31	on	on	IN	_	34	case	_	_
32	the	the	DT	_	34	det	_	_
33	steady-state	steady-state	JJ	_	34	attr	_	_
34	concentrations	concentration	NNS	_	27	ppmod	_	_
35	of	of	IN	_	37	case	_	_
36	these	these	DT	_	37	det	_	_
37	drugs	drug	NNS	_	34	ppmod	_	_
38	is	be	VBZ	_	40	aux	_	_
39	not	not	RB	_	40	neg	_	_
40	known	know	VBN	_	0	root	_	_
41	.	.	.	_	40	p	_	_

1	No	no	DT	_	4	det	_	_
2	drug	drug	NN	_	4	com	_	_
3	interaction	interaction	NN	_	4	com	_	_
4	data	datum	NNS	_	5	dep	_	_
5	are	be	VBP	_	0	root	_	_
6	available	available	JJ	_	5	dep	_	_
7	on	on	IN	_	9	case	_	_
8	concomitant	concomitant	JJ	_	9	attr	_	_
9	administration	administration	NN	_	6	ppmod	_	_
10	of	of	IN	_	12	case	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	gel	gel	NN	_	9	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	systemic	systemic	JJ	_	16	attr	_	_
15	anti-KS	anti-ks	JJ	_	16	attr	_	_
16	agents	agent	NNS	_	12	conj	_	_
17	.	.	.	_	5	p	_	_

1	Pharmacokinetic	pharmacokinetic	JJ	_	3	attr	_	_
2	interaction	interaction	NN	_	3	com	_	_
3	studies	study	NNS	_	9	dep	_	_
4	with	with	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	in	in	IN	_	7	case	_	_
7	adults	adult	NNS	_	5	ppmod	_	_
8	were	be	VBD	_	9	aux	_	_
9	conducted	conduct	VBN	_	0	root	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	,	,	,	_	11	p	_	_
13	drug3	drug0	NN	_	11	conj	_	_
14	,	,	,	_	13	p	_	_
15	drug4	drug0	NN	_	11	conj	_	_
16	,	,	,	_	15	p	_	_
17	drug5	drug0	NN	_	11	conj	_	_
18	and	and	CC	_	17	cc	_	_
19	drug6	drug0	NN	_	11	conj	_	_
20	.	.	.	_	9	p	_	_

1	No	no	DT	_	2	det	_	_
2	interactions	interaction	NNS	_	4	dep	_	_
3	were	be	VBD	_	4	aux	_	_
4	observed	observe	VBN	_	0	root	_	_
5	.	.	.	_	4	p	_	_

1	In	in	IN	_	5	case	_	_
2	a	a	DT	_	5	det	_	_
3	multiple	multiple	JJ	_	5	attr	_	_
4	dose	dose	NN	_	5	com	_	_
5	study	study	NN	_	39	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	(	-lrb-	-LRB-	_	10	p	_	_
9	400	0	CD	_	10	num	_	_
10	mg	mg	NN	_	7	prn	_	_
11	once	once	RB	_	12	adv	_	_
12	daily	daily	JJ	_	10	attr	_	_
13	for	for	IN	_	15	case	_	_
14	3	0	CD	_	15	num	_	_
15	days	day	NNS	_	12	ppmod	_	_
16	)	-rrb-	-RRB-	_	10	p	_	_
17	and	and	CC	_	7	cc	_	_
18	drug2	drug0	NN	_	7	conj	_	_
19	(	-lrb-	-LRB-	_	21	p	_	_
20	20	0	CD	_	21	num	_	_
21	mg	mg	NN	_	18	prn	_	_
22	once	once	RB	_	23	adv	_	_
23	daily	daily	JJ	_	21	attr	_	_
24	for	for	IN	_	26	case	_	_
25	3	0	CD	_	26	num	_	_
26	days	day	NNS	_	23	ppmod	_	_
27	)	-rrb-	-RRB-	_	21	p	_	_
28	,	,	,	_	39	p	_	_
29	a	a	DT	_	32	det	_	_
30	16	0	CD	_	32	num	_	_
31	%	%	NN	_	30	meta	_	_
32	decrease	decrease	NN	_	39	dep	_	_
33	in	in	IN	_	35	case	_	_
34	the	the	DT	_	35	det	_	_
35	clearance	clearance	NN	_	32	ppmod	_	_
36	of	of	IN	_	37	case	_	_
37	drug3	drug0	NN	_	35	ppmod	_	_
38	was	be	VBD	_	39	aux	_	_
39	observed	observe	VBN	_	0	root	_	_
40	.	.	.	_	39	p	_	_

1	The	the	DT	_	2	det	_	_
2	disposition	disposition	NN	_	7	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	was	be	VBD	_	7	aux	_	_
6	not	not	RB	_	7	neg	_	_
7	altered	alter	VBN	_	0	root	_	_
8	by	by	IN	_	11	case	_	_
9	concomitant	concomitant	JJ	_	11	attr	_	_
10	drug2	drug0	NN	_	11	com	_	_
11	administration	administration	NN	_	7	ppmod	_	_
12	.	.	.	_	7	p	_	_

1	Drug-Drug	drug-drug	JJ	_	2	attr	_	_
2	Interactions	interaction	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	No	no	DT	_	8	det	_	_
5	clinically	clinically	RB	_	6	adv	_	_
6	significant	significant	JJ	_	8	attr	_	_
7	drug	drug	NN	_	8	com	_	_
8	interactions	interaction	NNS	_	11	dep	_	_
9	have	have	VBP	_	11	aux	_	_
10	been	be	VBN	_	11	aux	_	_
11	found	find	VBN	_	2	acl	_	_
12	with	with	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	at	at	IN	_	17	case	_	_
15	a	a	DT	_	17	det	_	_
16	low	low	JJ	_	17	attr	_	_
17	dose	dose	NN	_	11	ppmod	_	_
18	,	,	,	_	17	p	_	_
19	drug2	drug0	NN	_	17	conj	_	_
20	,	,	,	_	19	p	_	_
21	drug3	drug0	NN	_	17	conj	_	_
22	,	,	,	_	21	p	_	_
23	drug4	drug0	NN	_	17	conj	_	_
24	,	,	,	_	23	p	_	_
25	or	or	CC	_	23	cc	_	_
26	drug5	drug0	NN	_	17	conj	_	_
27	.	.	.	_	2	p	_	_

1	There	there	EX	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	a	a	DT	_	5	det	_	_
4	small	small	JJ	_	5	attr	_	_
5	decrease	decrease	NN	_	2	obj	_	_
6	in	in	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	clearance	clearance	NN	_	5	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	caused	cause	VBN	_	10	acl	_	_
12	by	by	IN	_	15	case	_	_
13	a	a	DT	_	15	det	_	_
14	400-mg	0-mg	JJ	_	15	attr	_	_
15	dose	dose	NN	_	11	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	;	;	:	_	2	p	_	_

1	it	it	PRP	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	possible	possible	JJ	_	2	dep	_	_
4	that	that	IN	_	9	mark	_	_
5	larger	large	JJR	_	7	attr	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	doses	dose	NNS	_	9	dep	_	_
8	could	could	MD	_	9	modal	_	_
9	have	have	VB	_	2	comp	_	_
10	a	a	DT	_	12	det	_	_
11	greater	great	JJR	_	12	attr	_	_
12	effect	effect	NN	_	9	obj	_	_
13	.	.	.	_	2	p	_	_

1	The	the	DT	_	3	det	_	_
2	hypotensive	hypotensive	JJ	_	3	attr	_	_
3	effect	effect	NN	_	7	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	is	be	VBZ	_	7	aux	_	_
7	augmented	augment	VBN	_	0	root	_	_
8	by	by	IN	_	9	case	_	_
9	that	that	DT	_	7	ppmod	_	_
10	of	of	IN	_	13	case	_	_
11	most	most	JJ	_	13	attr	_	_
12	other	other	JJ	_	13	attr	_	_
13	drug2	drug0	NNS	_	9	ppmod	_	_
14	,	,	,	_	13	p	_	_
15	including	include	VBG	_	16	adv	_	_
16	drug3	drug0	NN	_	13	ppmod	_	_
17	,	,	,	_	16	p	_	_
18	negative	negative	JJ	_	20	attr	_	_
19	inotropic	inotropic	JJ	_	20	attr	_	_
20	agents	agent	NNS	_	16	conj	_	_
21	,	,	,	_	20	p	_	_
22	and	and	CC	_	20	cc	_	_
23	inhaled	inhaled	JJ	_	24	attr	_	_
24	drug4	drug0	NN	_	16	conj	_	_
25	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	16	dep	_	_
2	:	:	:	_	16	p	_	_
3	drug2	drug0	NN	_	16	dep	_	_
4	,	,	,	_	3	p	_	_
5	given	give	VBN	_	3	acl	_	_
6	concomitantly	concomitantly	RB	_	5	adv	_	_
7	with	with	IN	_	8	case	_	_
8	drug3	drug0	NN	_	5	ppmod	_	_
9	or	or	CC	_	8	cc	_	_
10	60	0	CD	_	11	num	_	_
11	minutes	minute	NNS	_	8	conj	_	_
12	following	follow	VBG	_	14	adv	_	_
13	drug4	drug0	NN	_	14	com	_	_
14	administration	administration	NN	_	5	ppmod	_	_
15	,	,	,	_	3	p	_	_
16	decreased	decrease	VBN	_	0	root	_	_
17	drug5	drug0	NN	_	18	com	_	_
18	bioavailability	bioavailability	NN	_	16	obj	_	_
19	by	by	IN	_	21	case	_	_
20	approximately	approximately	RB	_	21	adv	_	_
21	25	0	CD	_	16	ppmod	_	_
22	%	%	NN	_	21	meta	_	_
23	.	.	.	_	16	p	_	_

1	Thus	thus	RB	_	11	adv	_	_
2	,	,	,	_	11	p	_	_
3	concomitant	concomitant	JJ	_	4	attr	_	_
4	administration	administration	NN	_	11	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	avoided	avoid	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	is	be	VBZ	_	0	root	_	_
5	a	a	DT	_	7	det	_	_
6	potent	potent	JJ	_	7	attr	_	_
7	inhibitor	inhibitor	NN	_	4	obj	_	_
8	of	of	IN	_	12	case	_	_
9	the	the	DT	_	12	det	_	_
10	cytochrome	cytochrome	NN	_	11	com	_	_
11	P-450	p-0	NN	_	12	com	_	_
12	isozymes	isozymes	NNS	_	7	ppmod	_	_
13	responsible	responsible	JJ	_	12	attr	_	_
14	for	for	IN	_	16	case	_	_
15	the	the	DT	_	16	det	_	_
16	metabolism	metabolism	NN	_	13	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug3	drug0	NN	_	16	ppmod	_	_
19	.	.	.	_	4	p	_	_

1	In	in	IN	_	4	case	_	_
2	a	a	DT	_	4	det	_	_
3	multiple-dose	multiple-dose	JJ	_	4	attr	_	_
4	study	study	NN	_	7	ppmod	_	_
5	,	,	,	_	7	p	_	_
6	drug1	drug0	NN	_	7	dep	_	_
7	caused	cause	VBD	_	0	root	_	_
8	a	a	DT	_	10	det	_	_
9	dose-related	dose-related	JJ	_	10	attr	_	_
10	increase	increase	NN	_	7	obj	_	_
11	in	in	IN	_	15	case	_	_
12	the	the	DT	_	15	det	_	_
13	mean	mean	JJ	_	15	attr	_	_
14	elimination	elimination	NN	_	15	com	_	_
15	half-life	half-life	NN	_	10	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	,	,	,	_	7	p	_	_
19	thereby	thereby	RB	_	20	adv	_	_
20	decreasing	decrease	VBG	_	7	comp	_	_
21	the	the	DT	_	22	det	_	_
22	clearance	clearance	NN	_	20	obj	_	_
23	of	of	IN	_	24	case	_	_
24	drug3	drug0	NN	_	22	ppmod	_	_
25	by	by	IN	_	28	case	_	_
26	up	up	RB	_	28	adv	_	_
27	to	to	TO	_	28	attr	_	_
28	80	0	CD	_	20	ppmod	_	_
29	%	%	NN	_	28	meta	_	_
30	and	and	CC	_	20	cc	_	_
31	leading	lead	VBG	_	20	conj	_	_
32	to	to	TO	_	35	aux	_	_
33	a	a	DT	_	35	det	_	_
34	five-fold	five-fold	JJ	_	35	attr	_	_
35	increase	increase	NN	_	31	ppmod	_	_
36	in	in	IN	_	38	case	_	_
37	the	the	DT	_	38	det	_	_
38	AUC	auc	NN	_	35	ppmod	_	_
39	and	and	CC	_	35	cc	_	_
40	the	the	DT	_	41	det	_	_
41	half-life	half-life	NN	_	35	conj	_	_
42	of	of	IN	_	43	case	_	_
43	drug4	drug0	NN	_	41	ppmod	_	_
44	.	.	.	_	7	p	_	_

1	Trough	trough	NN	_	4	com	_	_
2	plasma	plasma	NN	_	4	com	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	levels	level	NNS	_	5	dep	_	_
5	were	be	VBD	_	0	root	_	_
6	also	also	RB	_	5	adv	_	_
7	20	0	CD	_	9	num	_	_
8	%	%	NN	_	7	meta	_	_
9	higher	high	JJR	_	5	dep	_	_
10	when	when	WRB	_	15	adv	_	_
11	drug2	drug0	NN	_	15	dep	_	_
12	and	and	CC	_	11	cc	_	_
13	drug3	drug0	NN	_	11	conj	_	_
14	were	be	VBD	_	15	aux	_	_
15	administered	administer	VBN	_	5	comp	_	_
16	concomitantly	concomitantly	RB	_	15	adv	_	_
17	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	4	attr	_	_
2	-related	-related	JJ	_	4	attr	_	_
3	adverse	adverse	JJ	_	4	attr	_	_
4	effects	effect	NNS	_	6	dep	_	_
5	have	have	VBP	_	6	aux	_	_
6	occurred	occur	VBN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	6	ppmod	_	_
9	consuming	consume	VBG	_	8	acl	_	_
10	drug2	drug0	NN	_	9	obj	_	_
11	while	while	IN	_	13	case	_	_
12	on	on	IN	_	13	case	_	_
13	therapy	therapy	NN	_	9	ppmod	_	_
14	with	with	IN	_	15	case	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Elevated	elevated	JJ	_	5	attr	_	_
4	serum	serum	NN	_	5	com	_	_
5	levels	level	NNS	_	10	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	have	have	VBP	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	reported	report	VBN	_	1	acl	_	_
11	with	with	IN	_	13	case	_	_
12	concomitant	concomitant	JJ	_	13	attr	_	_
13	use	use	NN	_	10	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	with	with	IN	_	18	case	_	_
17	other	other	JJ	_	18	attr	_	_
18	members	member	NNS	_	13	ppmod	_	_
19	of	of	IN	_	21	case	_	_
20	the	the	DT	_	21	det	_	_
21	drug4	drug0	NN	_	18	ppmod	_	_
22	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	may	may	MD	_	5	modal	_	_
5	raise	raise	VBP	_	0	root	_	_
6	serum	serum	NN	_	8	com	_	_
7	drug3	drug0	NN	_	8	com	_	_
8	levels	level	NNS	_	5	obj	_	_
9	in	in	IN	_	11	case	_	_
10	some	some	DT	_	11	det	_	_
11	individuals	individual	NNS	_	5	ppmod	_	_
12	.	.	.	_	5	p	_	_

1	If	if	IN	_	9	mark	_	_
2	signs	sign	NNS	_	9	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	symptoms	symptom	NNS	_	2	conj	_	_
5	suggestive	suggestive	JJ	_	4	adv	_	_
6	of	of	IN	_	8	case	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	toxicity	toxicity	NN	_	5	ppmod	_	_
9	occur	occur	VBP	_	20	advcl	_	_
10	when	when	WRB	_	15	adv	_	_
11	drug2	drug0	NN	_	15	dep	_	_
12	and	and	CC	_	11	cc	_	_
13	drug3	drug0	NN	_	11	conj	_	_
14	are	be	VBP	_	15	aux	_	_
15	given	give	VBN	_	9	comp	_	_
16	concomitantly	concomitantly	RB	_	15	adv	_	_
17	,	,	,	_	20	p	_	_
18	physicians	physician	NNS	_	20	dep	_	_
19	are	be	VBP	_	20	aux	_	_
20	advised	advise	VBN	_	0	root	_	_
21	to	to	TO	_	22	aux	_	_
22	obtain	obtain	VB	_	20	comp	_	_
23	serum	serum	NN	_	25	com	_	_
24	drug4	drug0	NN	_	25	com	_	_
25	levels	level	NNS	_	22	obj	_	_
26	and	and	CC	_	22	cc	_	_
27	adjust	adjust	VB	_	22	conj	_	_
28	drug5	drug0	NN	_	29	com	_	_
29	doses	dose	NNS	_	27	obj	_	_
30	appropriately	appropriately	RB	_	27	adv	_	_
31	.	.	.	_	20	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Seizures	seizure	NNS	_	6	dep	_	_
4	have	have	VBP	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	reported	report	VBN	_	1	acl	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	6	ppmod	_	_
9	taking	take	VBG	_	8	acl	_	_
10	drug2	drug0	NN	_	9	obj	_	_
11	concomitantly	concomitantly	RB	_	15	adv	_	_
12	with	with	IN	_	15	case	_	_
13	the	the	DT	_	15	det	_	_
14	drug3	drug0	NN	_	15	com	_	_
15	drug4	drug0	NN	_	9	ppmod	_	_
16	.	.	.	_	1	p	_	_

1	Animal	animal	NN	_	2	com	_	_
2	studies	study	NNS	_	4	dep	_	_
3	also	also	RB	_	4	adv	_	_
4	suggest	suggest	VBP	_	0	root	_	_
5	an	an	DT	_	7	det	_	_
6	increased	increase	VBN	_	7	attr	_	_
7	potential	potential	NN	_	4	obj	_	_
8	for	for	IN	_	9	case	_	_
9	seizures	seizure	NNS	_	7	ppmod	_	_
10	when	when	WRB	_	15	adv	_	_
11	these	these	DT	_	13	det	_	_
12	two	#crd#	CD	_	13	num	_	_
13	drugs	drug	NNS	_	15	dep	_	_
14	are	be	VBP	_	15	aux	_	_
15	given	give	VBN	_	4	comp	_	_
16	concomitantly	concomitantly	RB	_	15	adv	_	_
17	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	not	not	RB	_	2	neg	_	_
4	approved	approved	JJ	_	2	dep	_	_
5	in	in	IN	_	8	case	_	_
6	the	the	DT	_	8	det	_	_
7	United	united	JJ	_	8	attr	_	_
8	States	state	NNS	_	2	ppmod	_	_
9	at	at	IN	_	11	case	_	_
10	this	this	DT	_	11	det	_	_
11	time	time	NN	_	2	ppmod	_	_
12	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	:	:	:	_	1	p	_	_
5	drug3	drug0	NN	_	1	appo	_	_
6	form	form	VBP	_	0	root	_	_
7	chelates	chelate	NNS	_	6	obj	_	_
8	with	with	IN	_	10	case	_	_
9	metal	metal	JJ	_	10	attr	_	_
10	cations	cation	NNS	_	6	ppmod	_	_
11	.	.	.	_	6	p	_	_

1	Therefore	therefore	RB	_	8	adv	_	_
2	,	,	,	_	8	p	_	_
3	administration	administration	NN	_	8	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drug2	drug0	NN	_	3	ppmod	_	_
8	containing	contain	VBG	_	0	root	_	_
9	drug3	drug0	NN	_	8	obj	_	_
10	,	,	,	_	9	p	_	_
11	drug4	drug0	NN	_	9	conj	_	_
12	,	,	,	_	11	p	_	_
13	or	or	CC	_	11	cc	_	_
14	drug5	drug0	NN	_	9	conj	_	_
15	;	;	:	_	8	p	_	_

1	with	with	IN	_	2	case	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	;	;	:	_	2	p	_	_

1	with	with	IN	_	5	case	_	_
2	divalent	divalent	JJ	_	5	attr	_	_
3	or	or	CC	_	2	cc	_	_
4	trivalent	trivalent	JJ	_	2	conj	_	_
5	cations	cation	NNS	_	0	root	_	_
6	such	such	JJ	_	8	adv	_	_
7	as	as	IN	_	8	case	_	_
8	drug1	drug0	NN	_	5	ppmod	_	_
9	;	;	:	_	5	p	_	_

1	or	or	NN	_	8	dep	_	_
2	with	with	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	containing	contain	VBG	_	3	acl	_	_
5	drug2	drug0	NN	_	4	obj	_	_
6	may	may	MD	_	8	modal	_	_
7	substantially	substantially	RB	_	8	adv	_	_
8	interfere	interfere	VB	_	0	root	_	_
9	with	with	IN	_	11	case	_	_
10	drug	drug	NN	_	11	com	_	_
11	absorption	absorption	NN	_	8	ppmod	_	_
12	and	and	CC	_	8	cc	_	_
13	result	result	VB	_	8	conj	_	_
14	in	in	IN	_	16	case	_	_
15	insufficient	insufficient	JJ	_	16	attr	_	_
16	plasma	plasma	NN	_	13	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	tissue	tissue	NN	_	20	com	_	_
19	drug3	drug0	NN	_	20	com	_	_
20	concentrations	concentration	NNS	_	16	conj	_	_
21	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	containing	contain	VBG	_	1	acl	_	_
3	drug2	drug0	NN	_	2	obj	_	_
4	and	and	CC	_	3	cc	_	_
5	drug3	drug0	NN	_	3	conj	_	_
6	reduce	reduce	VBP	_	0	root	_	_
7	the	the	DT	_	9	det	_	_
8	oral	oral	JJ	_	9	attr	_	_
9	absorption	absorption	NN	_	6	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug4	drug0	NN	_	9	ppmod	_	_
12	by	by	IN	_	13	case	_	_
13	75	0	CD	_	6	ppmod	_	_
14	%	%	NN	_	13	meta	_	_
15	.	.	.	_	6	p	_	_

1	The	the	DT	_	3	det	_	_
2	oral	oral	JJ	_	3	attr	_	_
3	bioavailability	bioavailability	NN	_	7	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	is	be	VBZ	_	7	aux	_	_
7	reduced	reduce	VBN	_	0	root	_	_
8	by	by	IN	_	9	case	_	_
9	60	0	CD	_	7	ppmod	_	_
10	%	%	NN	_	9	meta	_	_
11	with	with	IN	_	12	case	_	_
12	coadministration	coadministration	NN	_	7	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	7	p	_	_

1	These	these	DT	_	2	det	_	_
2	agents	agent	NNS	_	6	dep	_	_
3	should	should	MD	_	6	modal	_	_
4	not	not	RB	_	6	neg	_	_
5	be	be	VB	_	6	aux	_	_
6	taken	take	VBN	_	0	root	_	_
7	for	for	IN	_	9	case	_	_
8	8	0	CD	_	9	num	_	_
9	hours	hour	NNS	_	6	ppmod	_	_
10	before	before	IN	_	6	ppmod	_	_
11	or	or	CC	_	10	cc	_	_
12	for	for	IN	_	14	case	_	_
13	2	0	CD	_	14	num	_	_
14	hours	hour	NNS	_	17	ppmod	_	_
15	after	after	IN	_	17	case	_	_
16	drug1	drug0	NN	_	17	com	_	_
17	administration	administration	NN	_	10	conj	_	_
18	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	is	be	VBZ	_	0	root	_	_
5	a	a	DT	_	7	det	_	_
6	potent	potent	JJ	_	7	attr	_	_
7	inhibitor	inhibitor	NN	_	4	obj	_	_
8	of	of	IN	_	12	case	_	_
9	the	the	DT	_	12	det	_	_
10	cytochrome	cytochrome	NN	_	11	com	_	_
11	P-450	p-0	NN	_	12	com	_	_
12	isozymes	isozymes	NNS	_	7	ppmod	_	_
13	responsible	responsible	JJ	_	12	attr	_	_
14	for	for	IN	_	16	case	_	_
15	the	the	DT	_	16	det	_	_
16	metabolism	metabolism	NN	_	13	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug3	drug0	NN	_	16	ppmod	_	_
19	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	interferes	interfere	VBZ	_	0	root	_	_
3	with	with	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	metabolism	metabolism	NN	_	2	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	resulting	result	VBG	_	7	acl	_	_
9	in	in	IN	_	17	case	_	_
10	a	a	DT	_	17	det	_	_
11	42	0	CD	_	14	num	_	_
12	%	%	NN	_	14	meta	_	_
13	to	to	TO	_	14	attr	_	_
14	74	0	CD	_	16	num	_	_
15	%	%	NN	_	14	meta	_	_
16	dose-related	dose-related	JJ	_	17	attr	_	_
17	decrease	decrease	NN	_	8	ppmod	_	_
18	in	in	IN	_	20	case	_	_
19	drug3	drug0	NN	_	20	com	_	_
20	clearance	clearance	NN	_	17	ppmod	_	_
21	and	and	CC	_	17	cc	_	_
22	a	a	DT	_	29	det	_	_
23	subsequent	subsequent	JJ	_	29	attr	_	_
24	260	0	CD	_	29	num	_	_
25	%	%	NN	_	29	meta	_	_
26	to	to	TO	_	29	attr	_	_
27	350	0	CD	_	29	num	_	_
28	%	%	NN	_	29	meta	_	_
29	increase	increase	NN	_	17	conj	_	_
30	in	in	IN	_	33	case	_	_
31	serum	serum	NN	_	33	com	_	_
32	theophylline	theophylline	NN	_	33	com	_	_
33	levels	level	NNS	_	29	ppmod	_	_
34	.	.	.	_	2	p	_	_

1	drug1	drug0	JJ	_	4	attr	_	_
2	-related	-related	JJ	_	4	attr	_	_
3	adverse	adverse	JJ	_	4	attr	_	_
4	effects	effect	NNS	_	6	dep	_	_
5	have	have	VBP	_	6	aux	_	_
6	occurred	occur	VBN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	6	ppmod	_	_
9	when	when	WRB	_	14	adv	_	_
10	drug2	drug0	NN	_	14	dep	_	_
11	and	and	CC	_	10	cc	_	_
12	drug3	drug0	NN	_	10	conj	_	_
13	were	be	VBD	_	14	aux	_	_
14	coadministered	coadministered	VBN	_	6	comp	_	_
15	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	8	dep	_	_
4	,	,	,	_	3	p	_	_
5	including	include	VBG	_	6	adv	_	_
6	drug3	drug0	NN	_	3	ppmod	_	_
7	,	,	,	_	3	p	_	_
8	decrease	decrease	VBP	_	1	acl	_	_
9	the	the	DT	_	10	det	_	_
10	clearance	clearance	NN	_	8	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug4	drug0	NN	_	10	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	the	the	DT	_	17	det	_	_
15	less	less	RBR	_	16	adv	_	_
16	active	active	JJ	_	17	attr	_	_
17	isomer	isomer	NN	_	12	appo	_	_
18	of	of	IN	_	20	case	_	_
19	racemic	racemic	JJ	_	20	attr	_	_
20	drug5	drug0	NN	_	17	ppmod	_	_
21	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	does	do	VBZ	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	affect	affect	VB	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	clearance	clearance	NN	_	4	obj	_	_
7	of	of	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	active	active	JJ	_	10	attr	_	_
10	S-isomer	s-isomer	NN	_	6	ppmod	_	_
11	,	,	,	_	4	p	_	_
12	and	and	CC	_	4	cc	_	_
13	changes	change	NNS	_	20	dep	_	_
14	in	in	IN	_	16	case	_	_
15	clotting	clotting	NN	_	16	com	_	_
16	time	time	NN	_	13	ppmod	_	_
17	have	have	VBP	_	20	aux	_	_
18	not	not	RB	_	20	neg	_	_
19	been	be	VBN	_	20	aux	_	_
20	observed	observe	VBN	_	4	conj	_	_
21	when	when	WRB	_	26	adv	_	_
22	drug2	drug0	NN	_	26	dep	_	_
23	and	and	CC	_	22	cc	_	_
24	drug3	drug0	NN	_	22	conj	_	_
25	were	be	VBD	_	26	aux	_	_
26	coadministered	coadministered	VBN	_	20	comp	_	_
27	.	.	.	_	4	p	_	_

1	Nevertheless	nevertheless	RB	_	13	adv	_	_
2	,	,	,	_	13	p	_	_
3	the	the	DT	_	5	det	_	_
4	prothrombin	prothrombin	NN	_	5	com	_	_
5	time	time	NN	_	13	dep	_	_
6	or	or	CC	_	5	cc	_	_
7	other	other	JJ	_	10	attr	_	_
8	suitable	suitable	JJ	_	10	attr	_	_
9	coagulation	coagulation	NN	_	10	com	_	_
10	test	test	NN	_	5	conj	_	_
11	should	should	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	monitored	monitor	VBN	_	0	root	_	_
14	when	when	WRB	_	22	adv	_	_
15	drug1	drug0	NN	_	22	dep	_	_
16	or	or	CC	_	15	cc	_	_
17	its	its	PRP$	_	18	poss	_	_
18	derivatives	derivative	NNS	_	15	conj	_	_
19	and	and	CC	_	15	cc	_	_
20	drug2	drug0	NN	_	15	conj	_	_
21	are	be	VBP	_	22	aux	_	_
22	given	give	VBN	_	13	comp	_	_
23	concomitantly	concomitantly	RB	_	22	adv	_	_
24	.	.	.	_	13	p	_	_

1	Patients	patient	NNS	_	24	dep	_	_
2	receiving	receive	VBG	_	1	acl	_	_
3	other	other	JJ	_	4	attr	_	_
4	drug1	drug0	NN	_	2	obj	_	_
5	,	,	,	_	4	p	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	,	,	,	_	6	p	_	_
8	drug3	drug0	NN	_	4	conj	_	_
9	,	,	,	_	8	p	_	_
10	or	or	CC	_	8	cc	_	_
11	other	other	JJ	_	12	attr	_	_
12	drug4	drug0	NNS	_	4	conj	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	including	include	VBG	_	12	prn	_	_
15	drug5	drug0	NN	_	14	obj	_	_
16	)	-rrb-	-RRB-	_	14	p	_	_
17	concomitantly	concomitantly	RB	_	19	adv	_	_
18	with	with	IN	_	19	case	_	_
19	drug6	drug0	NN	_	2	ppmod	_	_
20	and	and	CC	_	19	cc	_	_
21	drug7	drug0	NN	_	22	com	_	_
22	tablets	tablet	NNS	_	19	conj	_	_
23	may	may	MD	_	24	modal	_	_
24	exhibit	exhibit	VBP	_	0	root	_	_
25	an	an	DT	_	28	det	_	_
26	additive	additive	JJ	_	28	attr	_	_
27	CNS	cns	NN	_	28	com	_	_
28	depression	depression	NN	_	24	obj	_	_
29	.	.	.	_	24	p	_	_

1	When	when	WRB	_	5	adv	_	_
2	combined	combined	JJ	_	3	attr	_	_
3	therapy	therapy	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	contemplated	contemplate	VBN	_	16	advcl	_	_
6	,	,	,	_	16	p	_	_
7	the	the	DT	_	8	det	_	_
8	dose	dose	NN	_	16	dep	_	_
9	of	of	IN	_	10	case	_	_
10	one	#crd#	CD	_	8	ppmod	_	_
11	or	or	CC	_	10	cc	_	_
12	both	both	DT	_	13	attr	_	_
13	agents	agent	NNS	_	10	conj	_	_
14	should	should	MD	_	16	modal	_	_
15	be	be	VB	_	16	aux	_	_
16	reduced	reduce	VBN	_	0	root	_	_
17	.	.	.	_	16	p	_	_

1	The	the	DT	_	2	det	_	_
2	use	use	NN	_	11	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	or	or	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	with	with	IN	_	9	case	_	_
8	drug3	drug0	NN	_	9	com	_	_
9	preparations	preparation	NNS	_	2	ppmod	_	_
10	may	may	MD	_	11	modal	_	_
11	increase	increase	VB	_	0	root	_	_
12	the	the	DT	_	13	det	_	_
13	effect	effect	NN	_	11	obj	_	_
14	of	of	IN	_	17	case	_	_
15	either	either	CC	_	17	cc	_	_
16	the	the	DT	_	17	det	_	_
17	drug4	drug0	NN	_	13	ppmod	_	_
18	or	or	CC	_	17	cc	_	_
19	drug5	drug0	NN	_	17	conj	_	_
20	.	.	.	_	11	p	_	_

1	The	the	DT	_	3	det	_	_
2	concurrent	concurrent	JJ	_	3	attr	_	_
3	use	use	NN	_	9	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drug2	drug0	NN	_	3	ppmod	_	_
8	may	may	MD	_	9	modal	_	_
9	produce	produce	VB	_	0	root	_	_
10	paralytic	paralytic	JJ	_	11	attr	_	_
11	ileus	ileus	NN	_	9	obj	_	_
12	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	use	use	NN	_	14	dep	_	_
3	in	in	IN	_	4	case	_	_
4	patients	patient	NNS	_	2	ppmod	_	_
5	who	who	WP	_	7	dep	_	_
6	are	be	VBP	_	7	aux	_	_
7	receiving	receive	VBG	_	4	relcl	_	_
8	high	high	JJ	_	9	attr	_	_
9	doses	dose	NNS	_	7	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	may	may	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	associated	associate	VBN	_	0	root	_	_
15	with	with	IN	_	17	case	_	_
16	an	an	DT	_	17	det	_	_
17	increase	increase	NN	_	14	ppmod	_	_
18	in	in	IN	_	21	case	_	_
19	serum	serum	NN	_	21	com	_	_
20	drug3	drug0	NN	_	21	com	_	_
21	levels	level	NNS	_	17	ppmod	_	_
22	and	and	CC	_	21	cc	_	_
23	potential	potential	JJ	_	25	attr	_	_
24	drug4	drug0	NN	_	25	com	_	_
25	toxicity	toxicity	NN	_	21	conj	_	_
26	.	.	.	_	14	p	_	_

1	In	in	IN	_	2	case	_	_
2	case	case	NN	_	18	ppmod	_	_
3	of	of	IN	_	5	case	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	toxicity	toxicity	NN	_	2	ppmod	_	_
6	and/or	and/or	CC	_	5	cc	_	_
7	elevated	elevated	JJ	_	10	attr	_	_
8	serum	serum	NN	_	10	com	_	_
9	drug2	drug0	NN	_	10	com	_	_
10	levels	level	NNS	_	5	conj	_	_
11	,	,	,	_	18	p	_	_
12	the	the	DT	_	13	det	_	_
13	dose	dose	NN	_	18	dep	_	_
14	of	of	IN	_	15	case	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	should	should	MD	_	18	modal	_	_
17	be	be	VB	_	18	aux	_	_
18	reduced	reduce	VBN	_	0	root	_	_
19	while	while	IN	_	23	mark	_	_
20	the	the	DT	_	21	det	_	_
21	patient	patient	NN	_	23	dep	_	_
22	is	be	VBZ	_	23	aux	_	_
23	receiving	receive	VBG	_	18	comp	_	_
24	concomitant	concomitant	JJ	_	26	attr	_	_
25	drug4	drug0	NN	_	26	com	_	_
26	therapy	therapy	NN	_	23	obj	_	_
27	.	.	.	_	18	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	administration	administration	NN	_	9	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	has	have	VBZ	_	9	aux	_	_
8	been	be	VBN	_	9	aux	_	_
9	reported	report	VBN	_	0	root	_	_
10	to	to	TO	_	11	aux	_	_
11	result	result	VB	_	9	comp	_	_
12	in	in	IN	_	16	case	_	_
13	elevated	elevated	JJ	_	16	attr	_	_
14	drug3	drug0	NN	_	16	com	_	_
15	serum	serum	NN	_	16	com	_	_
16	levels	level	NNS	_	11	ppmod	_	_
17	.	.	.	_	9	p	_	_

1	There	there	EX	_	3	dep	_	_
2	have	have	VBP	_	3	aux	_	_
3	been	be	VBN	_	0	root	_	_
4	reports	report	NNS	_	3	obj	_	_
5	of	of	IN	_	8	case	_	_
6	increased	increase	VBN	_	8	attr	_	_
7	anticoagulant	anticoagulant	JJ	_	8	attr	_	_
8	effects	effect	NNS	_	4	ppmod	_	_
9	when	when	WRB	_	15	adv	_	_
10	drug1	drug0	NN	_	15	dep	_	_
11	and	and	CC	_	10	cc	_	_
12	oral	oral	JJ	_	13	attr	_	_
13	drug2	drug0	NN	_	10	conj	_	_
14	were	be	VBD	_	15	aux	_	_
15	used	use	VBN	_	3	comp	_	_
16	concomitantly	concomitantly	RB	_	15	adv	_	_
17	.	.	.	_	3	p	_	_

1	Increased	increase	VBN	_	3	attr	_	_
2	anticoagulation	anticoagulation	NN	_	3	com	_	_
3	effects	effect	NNS	_	14	dep	_	_
4	due	due	JJ	_	3	attr	_	_
5	to	to	TO	_	6	aux	_	_
6	interactions	interaction	NNS	_	4	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	with	with	IN	_	12	case	_	_
10	various	various	JJ	_	12	attr	_	_
11	oral	oral	JJ	_	12	attr	_	_
12	anticoagulents	anticoagulents	NNS	_	6	ppmod	_	_
13	may	may	MD	_	14	modal	_	_
14	be	be	VB	_	0	root	_	_
15	more	more	RBR	_	16	adv	_	_
16	pronounced	pronounced	JJ	_	14	dep	_	_
17	in	in	IN	_	19	case	_	_
18	the	the	DT	_	19	det	_	_
19	elderly	elderly	JJ	_	14	ppmod	_	_
20	.	.	.	_	14	p	_	_

1	Concurrent	concurrent	JJ	_	2	attr	_	_
2	use	use	NN	_	11	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	or	or	CC	_	6	cc	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	has	have	VBZ	_	11	aux	_	_
10	been	be	VBN	_	11	aux	_	_
11	associated	associate	VBN	_	0	root	_	_
12	in	in	IN	_	14	case	_	_
13	some	some	DT	_	14	det	_	_
14	patients	patient	NNS	_	11	ppmod	_	_
15	with	with	IN	_	18	case	_	_
16	acute	acute	JJ	_	18	attr	_	_
17	ergot	ergot	NN	_	18	com	_	_
18	toxicity	toxicity	NN	_	14	ppmod	_	_
19	characterized	characterize	VBN	_	18	acl	_	_
20	by	by	IN	_	23	case	_	_
21	severe	severe	JJ	_	23	attr	_	_
22	peripheral	peripheral	JJ	_	23	attr	_	_
23	vasospasm	vasospasm	NN	_	19	ppmod	_	_
24	and	and	CC	_	23	cc	_	_
25	dysesthesia	dysesthesia	NN	_	23	conj	_	_
26	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	reported	report	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	decrease	decrease	VB	_	4	comp	_	_
7	the	the	DT	_	8	det	_	_
8	clearance	clearance	NN	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug3	drug0	NN	_	10	conj	_	_
13	and	and	CC	_	4	cc	_	_
14	thus	thus	RB	_	16	adv	_	_
15	may	may	MD	_	16	modal	_	_
16	increase	increase	VB	_	4	conj	_	_
17	the	the	DT	_	19	det	_	_
18	pharmacologic	pharmacologic	JJ	_	19	attr	_	_
19	effect	effect	NN	_	16	obj	_	_
20	of	of	IN	_	22	case	_	_
21	these	these	DT	_	22	det	_	_
22	drug4	drug0	NNS	_	19	ppmod	_	_
23	.	.	.	_	4	p	_	_

1	The	the	DT	_	2	det	_	_
2	use	use	NN	_	18	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	in	in	IN	_	6	case	_	_
6	patients	patient	NNS	_	2	ppmod	_	_
7	concurrently	concurrently	RB	_	8	adv	_	_
8	taking	take	VBG	_	6	acl	_	_
9	drugs	drug	NNS	_	8	obj	_	_
10	metabolized	metabolize	VBN	_	9	acl	_	_
11	by	by	IN	_	15	case	_	_
12	the	the	DT	_	15	det	_	_
13	cytochrome	cytochrome	NN	_	15	com	_	_
14	P450	p0	NN	_	15	com	_	_
15	system	system	NN	_	10	ppmod	_	_
16	may	may	MD	_	18	modal	_	_
17	be	be	VB	_	18	aux	_	_
18	associated	associate	VBN	_	0	root	_	_
19	with	with	IN	_	20	case	_	_
20	elevations	elevation	NNS	_	18	ppmod	_	_
21	in	in	IN	_	23	case	_	_
22	serum	serum	NN	_	23	com	_	_
23	levels	level	NNS	_	20	ppmod	_	_
24	of	of	IN	_	27	case	_	_
25	these	these	DT	_	27	det	_	_
26	other	other	JJ	_	27	attr	_	_
27	drugs	drug	NNS	_	23	ppmod	_	_
28	.	.	.	_	18	p	_	_

1	There	there	EX	_	3	dep	_	_
2	have	have	VBP	_	3	aux	_	_
3	been	be	VBN	_	0	root	_	_
4	reports	report	NNS	_	3	obj	_	_
5	of	of	IN	_	6	case	_	_
6	interactions	interaction	NNS	_	4	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	with	with	IN	_	10	case	_	_
10	drug2	drug0	NN	_	6	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	drug3	drug0	NN	_	10	conj	_	_
13	,	,	,	_	12	p	_	_
14	drug4	drug0	NN	_	10	conj	_	_
15	,	,	,	_	14	p	_	_
16	drug5	drug0	NN	_	10	conj	_	_
17	,	,	,	_	16	p	_	_
18	drug6	drug0	NN	_	10	conj	_	_
19	,	,	,	_	18	p	_	_
20	drug7	drug0	NN	_	10	conj	_	_
21	,	,	,	_	20	p	_	_
22	drug8	drug0	NN	_	10	conj	_	_
23	,	,	,	_	22	p	_	_
24	drug9	drug0	NN	_	10	conj	_	_
25	,	,	,	_	24	p	_	_
26	drug10	drug0	NN	_	10	conj	_	_
27	,	,	,	_	26	p	_	_
28	drug11	drug0	NN	_	10	conj	_	_
29	,	,	,	_	28	p	_	_
30	drug12	drug0	NN	_	10	conj	_	_
31	,	,	,	_	30	p	_	_
32	drug13	drug0	NN	_	10	conj	_	_
33	,	,	,	_	32	p	_	_
34	and	and	CC	_	32	cc	_	_
35	drug14	drug0	NN	_	10	conj	_	_
36	.	.	.	_	3	p	_	_

1	Serum	serum	NN	_	2	com	_	_
2	concentrations	concentration	NNS	_	13	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drugs	drug	NNS	_	2	ppmod	_	_
5	metabolized	metabolize	VBN	_	4	acl	_	_
6	by	by	IN	_	10	case	_	_
7	the	the	DT	_	10	det	_	_
8	cytochrome	cytochrome	NN	_	10	com	_	_
9	P450	p0	NN	_	10	com	_	_
10	system	system	NN	_	5	ppmod	_	_
11	should	should	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	monitored	monitor	VBN	_	0	root	_	_
14	closely	closely	RB	_	13	adv	_	_
15	in	in	IN	_	16	case	_	_
16	patients	patient	NNS	_	13	ppmod	_	_
17	concurrently	concurrently	RB	_	18	adv	_	_
18	receiving	receive	VBG	_	16	acl	_	_
19	drug1	drug0	NN	_	18	obj	_	_
20	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	reported	report	VBN	_	0	root	_	_
5	to	to	TO	_	7	aux	_	_
6	significantly	significantly	RB	_	7	adv	_	_
7	alter	alter	VB	_	4	comp	_	_
8	the	the	DT	_	9	det	_	_
9	metabolism	metabolism	NN	_	7	obj	_	_
10	of	of	IN	_	13	case	_	_
11	nonsedating	nonsedating	JJ	_	13	attr	_	_
12	drug2	drug0	NN	_	13	com	_	_
13	drug3	drug0	NN	_	9	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	drug4	drug0	NN	_	13	conj	_	_
16	when	when	WRB	_	17	adv	_	_
17	taken	take	VBN	_	7	comp	_	_
18	concomitantly	concomitantly	RB	_	17	adv	_	_
19	.	.	.	_	4	p	_	_

1	Rare	rare	JJ	_	2	attr	_	_
2	cases	case	NNS	_	28	dep	_	_
3	of	of	IN	_	7	case	_	_
4	serious	serious	JJ	_	7	attr	_	_
5	cardiovascular	cardiovascular	JJ	_	7	attr	_	_
6	adverse	adverse	JJ	_	7	attr	_	_
7	events	event	NNS	_	2	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	including	include	VBG	_	13	adv	_	_
10	electrocardiographic	electrocardiographic	JJ	_	13	attr	_	_
11	QT/QTc	qt/qtc	NN	_	13	com	_	_
12	interval	interval	NN	_	13	com	_	_
13	prolongation	prolongation	NN	_	7	ppmod	_	_
14	,	,	,	_	13	p	_	_
15	cardiac	cardiac	JJ	_	16	attr	_	_
16	arrest	arrest	NN	_	13	conj	_	_
17	,	,	,	_	16	p	_	_
18	torsades	torsades	NNS	_	13	conj	_	_
19	de	de	FW	_	20	adv	_	_
20	pointes	pointes	FW	_	18	attr	_	_
21	,	,	,	_	18	p	_	_
22	and	and	CC	_	18	cc	_	_
23	other	other	JJ	_	25	attr	_	_
24	ventricular	ventricular	JJ	_	25	attr	_	_
25	arrhythmias	arrhythmia	NNS	_	13	conj	_	_
26	have	have	VBP	_	28	aux	_	_
27	been	be	VBN	_	28	aux	_	_
28	observed	observe	VBN	_	0	root	_	_
29	.	.	.	_	28	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	7	ppmod	_	_
3	,	,	,	_	7	p	_	_
4	deaths	death	NNS	_	7	dep	_	_
5	have	have	VBP	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	reported	report	VBN	_	0	root	_	_
8	rarely	rarely	RB	_	7	adv	_	_
9	with	with	IN	_	11	case	_	_
10	concomitant	concomitant	JJ	_	11	attr	_	_
11	administration	administration	NN	_	7	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	drug2	drug0	NN	_	13	conj	_	_
16	.	.	.	_	7	p	_	_

1	There	there	EX	_	3	dep	_	_
2	have	have	VBP	_	3	aux	_	_
3	been	be	VBN	_	0	root	_	_
4	postmarketing	postmarketing	JJ	_	5	attr	_	_
5	reports	report	NNS	_	3	obj	_	_
6	of	of	IN	_	8	case	_	_
7	drug	drug	NN	_	8	com	_	_
8	interactions	interaction	NNS	_	5	ppmod	_	_
9	when	when	WRB	_	12	adv	_	_
10	drug1	drug0	NN	_	12	dep	_	_
11	is	be	VBZ	_	12	aux	_	_
12	coadministered	coadministered	VBN	_	8	relcl	_	_
13	with	with	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	,	,	,	_	12	p	_	_
16	resulting	result	VBG	_	12	comp	_	_
17	in	in	IN	_	19	case	_	_
18	QT	qt	NN	_	19	com	_	_
19	prolongation	prolongation	NN	_	16	ppmod	_	_
20	,	,	,	_	19	p	_	_
21	cardiac	cardiac	JJ	_	22	attr	_	_
22	arrythmias	arrythmias	NN	_	19	conj	_	_
23	,	,	,	_	22	p	_	_
24	ventricular	ventricular	JJ	_	25	attr	_	_
25	tachycardia	tachycardia	NN	_	19	conj	_	_
26	,	,	,	_	25	p	_	_
27	ventricular	ventricular	JJ	_	28	attr	_	_
28	fibrulation	fibrulation	NN	_	19	conj	_	_
29	,	,	,	_	28	p	_	_
30	and	and	CC	_	28	cc	_	_
31	torsades	torsades	NNS	_	19	conj	_	_
32	de	de	FW	_	33	adv	_	_
33	pointes	pointes	FW	_	31	attr	_	_
34	,	,	,	_	16	p	_	_
35	most	most	RBS	_	16	adv	_	_
36	like	like	IN	_	37	case	_	_
37	due	due	JJ	_	16	ppmod	_	_
38	to	to	TO	_	39	aux	_	_
39	inhibition	inhibition	NN	_	37	ppmod	_	_
40	of	of	IN	_	42	case	_	_
41	hepatic	hepatic	JJ	_	42	attr	_	_
42	metabolism	metabolism	NN	_	39	ppmod	_	_
43	of	of	IN	_	44	case	_	_
44	drug3	drug0	NN	_	42	ppmod	_	_
45	by	by	IN	_	46	case	_	_
46	drug4	drug0	NN	_	39	ppmod	_	_
47	.	.	.	_	3	p	_	_

1	Fatalities	fatality	NNS	_	4	dep	_	_
2	have	have	VBP	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	reported	report	VBN	_	0	root	_	_
5	.	.	.	_	4	p	_	_

1	Patients	patient	NNS	_	10	dep	_	_
2	receiving	receive	VBG	_	1	acl	_	_
3	concomitant	concomitant	JJ	_	4	attr	_	_
4	drug1	drug0	NN	_	2	obj	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	should	should	MD	_	10	modal	_	_
8	be	be	VB	_	10	aux	_	_
9	carefully	carefully	RB	_	10	adv	_	_
10	monitored	monitor	VBN	_	0	root	_	_
11	;	;	:	_	10	p	_	_

1	cases	case	NNS	_	6	dep	_	_
2	of	of	IN	_	3	case	_	_
3	rhabdomyolysis	rhabdomyolysis	NN	_	1	ppmod	_	_
4	have	have	VBP	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	reported	report	VBN	_	0	root	_	_
7	in	in	IN	_	10	case	_	_
8	seriously	seriously	RB	_	9	adv	_	_
9	ill	ill	JJ	_	10	attr	_	_
10	patients	patient	NNS	_	6	ppmod	_	_
11	.	.	.	_	6	p	_	_

1	The	the	DT	_	2	det	_	_
2	use	use	NN	_	6	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	may	may	MD	_	6	modal	_	_
6	result	result	VB	_	0	root	_	_
7	in	in	IN	_	11	case	_	_
8	additive	additive	JJ	_	11	attr	_	_
9	CNS	cns	NN	_	11	com	_	_
10	depressant	depressant	NN	_	11	com	_	_
11	effects	effect	NNS	_	6	ppmod	_	_
12	when	when	WRB	_	13	adv	_	_
13	coadministered	coadministered	VBN	_	11	relcl	_	_
14	with	with	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	,	,	,	_	15	p	_	_
17	drug3	drug0	NN	_	15	conj	_	_
18	,	,	,	_	17	p	_	_
19	drug4	drug0	NN	_	15	conj	_	_
20	or	or	CC	_	19	cc	_	_
21	other	other	JJ	_	22	attr	_	_
22	drugs	drug	NNS	_	15	conj	_	_
23	that	that	WDT	_	24	dep	_	_
24	produce	produce	VBP	_	15	relcl	_	_
25	CNS	cns	NN	_	26	com	_	_
26	depression	depression	NN	_	24	obj	_	_
27	.	.	.	_	6	p	_	_

1	Serious	serious	JJ	_	2	attr	_	_
2	toxicity	toxicity	NN	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	result	result	VB	_	0	root	_	_
5	if	if	IN	_	8	mark	_	_
6	drug1	drug0	NN	_	8	dep	_	_
7	is	be	VBZ	_	8	aux	_	_
8	coadministered	coadministered	VBN	_	4	comp	_	_
9	with	with	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	drug3	drug0	NN	_	10	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	.	.	.	_	4	p	_	_

1	The	the	DT	_	2	det	_	_
2	use	use	NN	_	6	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	may	may	MD	_	6	modal	_	_
6	result	result	VB	_	0	root	_	_
7	in	in	IN	_	11	case	_	_
8	additive	additive	JJ	_	11	attr	_	_
9	CNS	cns	NN	_	11	com	_	_
10	depressant	depressant	NN	_	11	com	_	_
11	effects	effect	NNS	_	6	ppmod	_	_
12	when	when	WRB	_	13	adv	_	_
13	coadministered	coadministered	VBN	_	11	relcl	_	_
14	with	with	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	,	,	,	_	15	p	_	_
17	drug3	drug0	NN	_	15	conj	_	_
18	,	,	,	_	17	p	_	_
19	drug4	drug0	NN	_	15	conj	_	_
20	or	or	CC	_	19	cc	_	_
21	other	other	JJ	_	22	attr	_	_
22	drugs	drug	NNS	_	15	conj	_	_
23	that	that	WDT	_	24	dep	_	_
24	produce	produce	VBP	_	15	relcl	_	_
25	CNS	cns	NN	_	26	com	_	_
26	depression	depression	NN	_	24	obj	_	_
27	.	.	.	_	6	p	_	_

1	Preliminary	preliminary	JJ	_	2	attr	_	_
2	data	datum	NNS	_	17	dep	_	_
3	which	which	WDT	_	4	dep	_	_
4	suggest	suggest	VBP	_	2	relcl	_	_
5	that	that	IN	_	8	mark	_	_
6	drug1	drug0	NN	_	8	dep	_	_
7	may	may	MD	_	8	modal	_	_
8	inhibit	inhibit	VB	_	4	comp	_	_
9	the	the	DT	_	11	det	_	_
10	anti-inflammatory	anti-inflammatory	JJ	_	11	attr	_	_
11	activity	activity	NN	_	8	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NNS	_	11	ppmod	_	_
14	have	have	VBP	_	17	aux	_	_
15	not	not	RB	_	17	neg	_	_
16	been	be	VBN	_	17	aux	_	_
17	confirmed	confirm	VBN	_	0	root	_	_
18	.	.	.	_	17	p	_	_

1	If	if	IN	_	5	mark	_	_
2	leprosy-associated	leprosy-associated	JJ	_	4	attr	_	_
3	inflammatory	inflammatory	JJ	_	4	attr	_	_
4	reactions	reaction	NNS	_	5	dep	_	_
5	develop	develop	VBP	_	16	advcl	_	_
6	in	in	IN	_	7	case	_	_
7	patients	patient	NNS	_	5	ppmod	_	_
8	being	be	VBG	_	9	aux	_	_
9	treated	treat	VBN	_	7	acl	_	_
10	with	with	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	drug2	drug0	NN	_	11	conj	_	_
14	,	,	,	_	16	p	_	_
15	it	it	PRP	_	16	dep	_	_
16	is	be	VBZ	_	0	root	_	_
17	still	still	RB	_	16	adv	_	_
18	advisable	advisable	JJ	_	16	dep	_	_
19	to	to	TO	_	20	aux	_	_
20	continue	continue	VBP	_	18	comp	_	_
21	treatment	treatment	NN	_	20	obj	_	_
22	with	with	IN	_	24	case	_	_
23	both	both	DT	_	24	det	_	_
24	drugs	drug	NNS	_	21	ppmod	_	_
25	.	.	.	_	16	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	As	as	IN	_	6	case	_	_
4	with	with	IN	_	6	case	_	_
5	other	other	JJ	_	6	attr	_	_
6	drug2	drug0	NNS	_	17	ppmod	_	_
7	,	,	,	_	17	p	_	_
8	concomitant	concomitant	JJ	_	9	attr	_	_
9	administration	administration	NN	_	17	dep	_	_
10	of	of	IN	_	11	case	_	_
11	drug3	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	drug4	drug0	NN	_	11	conj	_	_
14	is	be	VBZ	_	17	aux	_	_
15	not	not	RB	_	17	neg	_	_
16	generally	generally	RB	_	17	adv	_	_
17	recommended	recommend	VBN	_	1	acl	_	_
18	because	because	IN	_	21	case	_	_
19	of	of	IN	_	21	case	_	_
20	the	the	DT	_	21	det	_	_
21	potential	potential	NN	_	17	ppmod	_	_
22	of	of	IN	_	25	case	_	_
23	increased	increase	VBN	_	25	attr	_	_
24	adverse	adverse	JJ	_	25	attr	_	_
25	effects	effect	NNS	_	21	ppmod	_	_
26	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	have	have	VBP	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	reported	report	VBN	_	0	root	_	_
7	to	to	TO	_	9	aux	_	_
8	competitively	competitively	RB	_	9	adv	_	_
9	inhibit	inhibit	VB	_	6	comp	_	_
10	drug3	drug0	NN	_	11	com	_	_
11	accumulation	accumulation	NN	_	9	obj	_	_
12	in	in	IN	_	15	case	_	_
13	rabbit	rabbit	NN	_	15	com	_	_
14	kidney	kidney	NN	_	15	com	_	_
15	slices	slice	NNS	_	11	ppmod	_	_
16	.	.	.	_	6	p	_	_

1	This	this	DT	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	indicate	indicate	VB	_	0	root	_	_
4	that	that	IN	_	7	mark	_	_
5	they	they	PRP	_	7	dep	_	_
6	could	could	MD	_	7	modal	_	_
7	enhance	enhance	VB	_	3	comp	_	_
8	the	the	DT	_	9	det	_	_
9	toxicity	toxicity	NN	_	7	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	3	p	_	_

1	Caution	caution	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	used	use	VBN	_	0	root	_	_
5	when	when	WRB	_	8	adv	_	_
6	drug1	drug0	NN	_	8	dep	_	_
7	are	be	VBP	_	8	aux	_	_
8	administered	administer	VBN	_	4	comp	_	_
9	concomitantly	concomitantly	RB	_	8	adv	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NN	_	8	ppmod	_	_
12	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Reports	report	NNS	_	4	dep	_	_
4	suggest	suggest	VBP	_	1	acl	_	_
5	that	that	IN	_	8	mark	_	_
6	drug2	drug0	NN	_	8	dep	_	_
7	may	may	MD	_	8	modal	_	_
8	diminish	diminish	VB	_	4	comp	_	_
9	the	the	DT	_	11	det	_	_
10	antihypertensive	antihypertensive	JJ	_	11	attr	_	_
11	effect	effect	NN	_	8	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug3	drug0	NN	_	11	ppmod	_	_
14	.	.	.	_	1	p	_	_

1	This	this	DT	_	2	det	_	_
2	interaction	interaction	NN	_	6	dep	_	_
3	should	should	MD	_	6	modal	_	_
4	be	be	VB	_	6	aux	_	_
5	given	give	VBN	_	6	lv	_	_
6	consideration	consideration	NN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	6	ppmod	_	_
9	taking	take	VBG	_	8	acl	_	_
10	drug1	drug0	NN	_	9	obj	_	_
11	concomitantly	concomitantly	RB	_	6	adv	_	_
12	with	with	IN	_	13	case	_	_
13	drug2	drug0	NN	_	6	ppmod	_	_
14	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Clinical	clinical	JJ	_	4	attr	_	_
4	studies	study	NNS	_	13	dep	_	_
5	,	,	,	_	4	p	_	_
6	as	as	RB	_	7	com	_	_
7	well	well	RB	_	4	cc	_	_
8	as	as	IN	_	7	com	_	_
9	post-marketing	post-marketing	JJ	_	10	attr	_	_
10	observations	observation	NNS	_	4	conj	_	_
11	,	,	,	_	10	p	_	_
12	have	have	VBP	_	13	aux	_	_
13	shown	show	VBN	_	1	acl	_	_
14	that	that	IN	_	17	mark	_	_
15	drug2	drug0	NN	_	17	dep	_	_
16	can	can	MD	_	17	modal	_	_
17	reduce	reduce	VB	_	13	comp	_	_
18	the	the	DT	_	20	det	_	_
19	natriuretic	natriuretic	JJ	_	20	attr	_	_
20	effect	effect	NN	_	17	obj	_	_
21	of	of	IN	_	22	case	_	_
22	drug3	drug0	NN	_	20	ppmod	_	_
23	and	and	CC	_	22	cc	_	_
24	drug4	drug0	NN	_	22	conj	_	_
25	in	in	IN	_	27	case	_	_
26	some	some	DT	_	27	det	_	_
27	patients	patient	NNS	_	20	ppmod	_	_
28	.	.	.	_	1	p	_	_

1	This	this	DT	_	2	det	_	_
2	response	response	NN	_	5	dep	_	_
3	has	have	VBZ	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	attributed	attribute	VBN	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	inhibition	inhibition	NN	_	5	ppmod	_	_
8	of	of	IN	_	11	case	_	_
9	renal	renal	JJ	_	11	attr	_	_
10	prostaglandin	prostaglandin	NN	_	11	com	_	_
11	synthesis	synthesis	NN	_	7	ppmod	_	_
12	.	.	.	_	5	p	_	_

1	During	during	IN	_	3	case	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	therapy	therapy	NN	_	13	ppmod	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drug2	drug0	NN	_	3	ppmod	_	_
8	,	,	,	_	13	p	_	_
9	the	the	DT	_	10	det	_	_
10	patient	patient	NN	_	13	dep	_	_
11	should	should	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	observed	observe	VBN	_	0	root	_	_
14	closely	closely	RB	_	13	adv	_	_
15	for	for	IN	_	16	case	_	_
16	signs	sign	NNS	_	13	ppmod	_	_
17	of	of	IN	_	19	case	_	_
18	renal	renal	JJ	_	19	attr	_	_
19	failure	failure	NN	_	16	ppmod	_	_
20	,	,	,	_	13	p	_	_
21	as	as	RB	_	22	com	_	_
22	well	well	RB	_	25	cc	_	_
23	as	as	IN	_	22	com	_	_
24	to	to	TO	_	25	aux	_	_
25	assure	assure	VB	_	13	comp	_	_
26	diuretic	diuretic	JJ	_	27	attr	_	_
27	efficacy	efficacy	NN	_	25	obj	_	_
28	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	have	have	VBP	_	5	aux	_	_
5	produced	produce	VBN	_	0	root	_	_
6	an	an	DT	_	7	det	_	_
7	elevation	elevation	NN	_	5	obj	_	_
8	of	of	IN	_	11	case	_	_
9	plasma	plasma	NN	_	11	com	_	_
10	drug3	drug0	NN	_	11	com	_	_
11	levels	level	NNS	_	7	ppmod	_	_
12	and	and	CC	_	7	cc	_	_
13	a	a	DT	_	14	det	_	_
14	reduction	reduction	NN	_	7	conj	_	_
15	in	in	IN	_	18	case	_	_
16	renal	renal	JJ	_	18	attr	_	_
17	drug4	drug0	NN	_	18	com	_	_
18	clearance	clearance	NN	_	14	ppmod	_	_
19	.	.	.	_	5	p	_	_

1	The	the	DT	_	5	det	_	_
2	mean	mean	JJ	_	5	attr	_	_
3	minimum	minimum	JJ	_	5	attr	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	concentration	concentration	NN	_	6	dep	_	_
6	increased	increase	VBD	_	0	root	_	_
7	15	0	CD	_	6	obj	_	_
8	%	%	NN	_	7	meta	_	_
9	and	and	CC	_	6	cc	_	_
10	the	the	DT	_	12	det	_	_
11	renal	renal	JJ	_	12	attr	_	_
12	clearance	clearance	NN	_	14	dep	_	_
13	was	be	VBD	_	14	aux	_	_
14	decreased	decrease	VBN	_	6	conj	_	_
15	by	by	IN	_	17	case	_	_
16	approximately	approximately	RB	_	17	adv	_	_
17	20	0	CD	_	14	ppmod	_	_
18	%	%	NN	_	17	meta	_	_
19	.	.	.	_	6	p	_	_

1	These	these	DT	_	2	det	_	_
2	effects	effect	NNS	_	5	dep	_	_
3	have	have	VBP	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	attributed	attribute	VBN	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	inhibition	inhibition	NN	_	5	ppmod	_	_
8	of	of	IN	_	11	case	_	_
9	renal	renal	JJ	_	11	attr	_	_
10	prostaglandin	prostaglandin	NN	_	11	com	_	_
11	synthesis	synthesis	NN	_	7	ppmod	_	_
12	by	by	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	drug1	drug0	NN	_	7	ppmod	_	_
15	.	.	.	_	5	p	_	_

1	Thus	thus	RB	_	14	adv	_	_
2	,	,	,	_	14	p	_	_
3	when	when	WRB	_	8	adv	_	_
4	drug1	drug0	NN	_	8	dep	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	are	be	VBP	_	8	aux	_	_
8	administered	administer	VBN	_	14	advcl	_	_
9	concurrently	concurrently	RB	_	8	adv	_	_
10	,	,	,	_	14	p	_	_
11	subjects	subject	NNS	_	14	dep	_	_
12	should	should	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	observed	observe	VBN	_	0	root	_	_
15	carefully	carefully	RB	_	14	adv	_	_
16	for	for	IN	_	17	case	_	_
17	signs	sign	NNS	_	14	ppmod	_	_
18	of	of	IN	_	20	case	_	_
19	drug3	drug0	NN	_	20	com	_	_
20	toxicity	toxicity	NN	_	17	ppmod	_	_
21	.	.	.	_	14	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	effects	effect	NNS	_	12	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	on	on	IN	_	11	case	_	_
10	GI	gi	JJ	_	11	attr	_	_
11	bleeding	bleeding	JJ	_	4	ppmod	_	_
12	are	be	VBP	_	1	acl	_	_
13	synergistic	synergistic	JJ	_	12	dep	_	_
14	,	,	,	_	12	p	_	_
15	such	such	JJ	_	24	dep	_	_
16	that	that	IN	_	24	mark	_	_
17	users	user	NNS	_	24	dep	_	_
18	of	of	IN	_	20	case	_	_
19	both	both	DT	_	20	det	_	_
20	drugs	drug	NNS	_	17	ppmod	_	_
21	together	together	RB	_	24	adv	_	_
22	have	have	VBP	_	24	lv	_	_
23	a	a	DT	_	24	det	_	_
24	risk	risk	NN	_	12	comp	_	_
25	of	of	IN	_	28	case	_	_
26	serious	serious	JJ	_	28	attr	_	_
27	GI	gi	JJ	_	28	attr	_	_
28	bleeding	bleeding	JJ	_	24	ppmod	_	_
29	higher	high	JJR	_	24	attr	_	_
30	than	than	IN	_	31	case	_	_
31	users	user	NNS	_	29	ppmod	_	_
32	of	of	IN	_	34	case	_	_
33	either	either	DT	_	34	det	_	_
34	drug	drug	NN	_	31	ppmod	_	_
35	alone	alone	RB	_	34	adv	_	_
36	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	7	case	_	_
4	a	a	DT	_	7	det	_	_
5	single	single	JJ	_	7	attr	_	_
6	dose	dose	NN	_	7	com	_	_
7	study	study	NN	_	24	ppmod	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	n=6	n=0	NN	_	7	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	,	,	,	_	24	p	_	_
12	ingestion	ingestion	NN	_	24	dep	_	_
13	of	of	IN	_	15	case	_	_
14	an	an	DT	_	15	det	_	_
15	drug2	drug0	NN	_	12	ppmod	_	_
16	containing	contain	VBG	_	15	acl	_	_
17	1.7-gram	0-gram	NN	_	16	obj	_	_
18	of	of	IN	_	19	case	_	_
19	drug3	drug0	NN	_	17	ppmod	_	_
20	with	with	IN	_	21	case	_	_
21	500-mg	0-mg	NN	_	17	ppmod	_	_
22	of	of	IN	_	23	case	_	_
23	drug4	drug0	NN	_	21	ppmod	_	_
24	increased	increase	VBD	_	1	acl	_	_
25	the	the	DT	_	26	det	_	_
26	Cmax	cmax	NN	_	24	obj	_	_
27	and	and	CC	_	26	cc	_	_
28	AUC	auc	NN	_	26	conj	_	_
29	of	of	IN	_	30	case	_	_
30	drug5	drug0	NN	_	26	ppmod	_	_
31	by	by	IN	_	32	case	_	_
32	125	0	CD	_	24	ppmod	_	_
33	%	%	NN	_	32	meta	_	_
34	and	and	CC	_	32	cc	_	_
35	36	0	CD	_	32	conj	_	_
36	%	%	NN	_	35	meta	_	_
37	,	,	,	_	24	p	_	_
38	respectively.	respectively.	IN	_	43	mark	_	_
39	A	a	DT	_	40	det	_	_
40	number	number	NN	_	43	dep	_	_
41	of	of	IN	_	42	case	_	_
42	compounds	compound	NNS	_	40	ppmod	_	_
43	are	be	VBP	_	24	comp	_	_
44	inhibitors	inhibitor	NNS	_	43	obj	_	_
45	of	of	IN	_	46	case	_	_
46	CYP2C9	cyp0c0	NN	_	44	ppmod	_	_
47	including	include	VBG	_	48	adv	_	_
48	drug6	drug0	NN	_	44	ppmod	_	_
49	,	,	,	_	48	p	_	_
50	drug7	drug0	NN	_	48	conj	_	_
51	and	and	CC	_	50	cc	_	_
52	drug8	drug0	NN	_	48	conj	_	_
53	.	.	.	_	1	p	_	_

1	Drug	drug	NN	_	3	com	_	_
2	interaction	interaction	NN	_	3	com	_	_
3	studies	study	NNS	_	12	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	these	these	DT	_	8	det	_	_
8	compounds	compound	NNS	_	5	conj	_	_
9	have	have	VBP	_	12	aux	_	_
10	not	not	RB	_	12	neg	_	_
11	been	be	VBN	_	12	aux	_	_
12	conducted	conduct	VBN	_	0	root	_	_
13	.	.	.	_	12	p	_	_

1	The	the	DT	_	2	det	_	_
2	possibility	possibility	NN	_	10	dep	_	_
3	of	of	IN	_	5	case	_	_
4	altered	altered	JJ	_	5	attr	_	_
5	safety	safety	NN	_	2	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	efficacy	efficacy	NN	_	5	conj	_	_
8	should	should	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	considered	consider	VBN	_	0	root	_	_
11	when	when	WRB	_	14	adv	_	_
12	drug1	drug0	NN	_	14	dep	_	_
13	is	be	VBZ	_	14	aux	_	_
14	used	use	VBN	_	10	comp	_	_
15	concomitantly	concomitantly	RB	_	14	adv	_	_
16	with	with	IN	_	18	case	_	_
17	these	these	DT	_	18	det	_	_
18	drugs	drug	NNS	_	14	ppmod	_	_
19	.	.	.	_	10	p	_	_

1	Drug	drug	NN	_	2	com	_	_
2	Interactions	interaction	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	The	the	DT	_	7	det	_	_
5	central	central	JJ	_	7	attr	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	syndrome	syndrome	NN	_	9	dep	_	_
8	can	can	MD	_	9	modal	_	_
9	occur	occur	VB	_	2	acl	_	_
10	when	when	WRB	_	17	adv	_	_
11	anticholinergic	anticholinergic	JJ	_	12	attr	_	_
12	agents	agent	NNS	_	17	dep	_	_
13	such	such	JJ	_	15	adv	_	_
14	as	as	IN	_	15	case	_	_
15	drug2	drug0	NN	_	12	ppmod	_	_
16	are	be	VBP	_	17	aux	_	_
17	administered	administer	VBN	_	9	comp	_	_
18	concomitantly	concomitantly	RB	_	17	adv	_	_
19	with	with	IN	_	20	case	_	_
20	drugs	drug	NNS	_	17	ppmod	_	_
21	that	that	WDT	_	22	dep	_	_
22	have	have	VBP	_	20	relcl	_	_
23	secondary	secondary	JJ	_	25	attr	_	_
24	anticholinergic	anticholinergic	JJ	_	25	attr	_	_
25	actions	action	NNS	_	22	dat	_	_
26	,	,	,	_	22	p	_	_
27	e.g.	e.g.	FW	_	22	ppmod	_	_
28	,	,	,	_	22	p	_	_
29	certain	certain	JJ	_	30	attr	_	_
30	drug3	drug0	NNS	_	22	obj	_	_
31	such	such	JJ	_	33	adv	_	_
32	as	as	IN	_	33	case	_	_
33	drug4	drug0	NN	_	30	ppmod	_	_
34	,	,	,	_	33	p	_	_
35	the	the	DT	_	36	det	_	_
36	drug5	drug0	NN	_	33	conj	_	_
37	and	and	CC	_	36	cc	_	_
38	other	other	JJ	_	39	attr	_	_
39	drug6	drug0	NN	_	36	conj	_	_
40	,	,	,	_	36	p	_	_
41	drug7	drug0	NN	_	33	conj	_	_
42	,	,	,	_	41	p	_	_
43	certain	certain	JJ	_	44	attr	_	_
44	drug8	drug0	NNS	_	33	conj	_	_
45	such	such	JJ	_	49	adv	_	_
46	as	as	IN	_	49	case	_	_
47	the	the	DT	_	49	det	_	_
48	drug9	drug0	NN	_	49	com	_	_
49	salts	salt	NNS	_	44	ppmod	_	_
50	,	,	,	_	44	p	_	_
51	and	and	CC	_	44	cc	_	_
52	drug10	drug0	NN	_	33	conj	_	_
53	.	.	.	_	2	p	_	_

1	No	no	DT	_	4	det	_	_
2	drug/drug	drug/drug	JJ	_	4	attr	_	_
3	interaction	interaction	NN	_	4	com	_	_
4	studies	study	NNS	_	7	dep	_	_
5	have	have	VBP	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	performed	performed	VBN	_	0	root	_	_
8	.	.	.	_	7	p	_	_

1	There	there	EX	_	3	dep	_	_
2	have	have	VBP	_	3	aux	_	_
3	been	be	VBN	_	0	root	_	_
4	no	no	DT	_	7	det	_	_
5	formal	formal	JJ	_	7	attr	_	_
6	drug-interaction	drug-interaction	NN	_	7	com	_	_
7	studies	study	NNS	_	3	obj	_	_
8	performed	performed	VBN	_	7	acl	_	_
9	with	with	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	potential	potential	NN	_	16	dep	_	_
3	for	for	IN	_	5	case	_	_
4	drug-drug	drug-drug	JJ	_	5	attr	_	_
5	interaction	interaction	NN	_	2	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drugs	drug	NNS	_	5	ppmod	_	_
8	affected	affect	VBN	_	7	acl	_	_
9	by	by	IN	_	12	case	_	_
10	cytochrome	cytochrome	NN	_	12	com	_	_
11	P450	p0	NN	_	12	com	_	_
12	enzymes	enzyme	NNS	_	8	ppmod	_	_
13	may	may	MD	_	16	modal	_	_
14	not	not	RB	_	16	neg	_	_
15	be	be	VB	_	16	aux	_	_
16	ruled	rule	VBN	_	0	root	_	_
17	out	out	RP	_	16	prt	_	_
18	.	.	.	_	16	p	_	_

1	Laboratory	laboratory	NN	_	3	com	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	0	root	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	known	know	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	interfere	interfere	VB	_	4	comp	_	_
7	with	with	IN	_	11	case	_	_
8	any	any	DT	_	11	det	_	_
9	routine	routine	NN	_	11	attr	_	_
10	diagnostic	diagnostic	JJ	_	11	attr	_	_
11	tests	test	NNS	_	6	ppmod	_	_
12	.	.	.	_	4	p	_	_

1	Interactions	interaction	NNS	_	16	dep	_	_
2	for	for	IN	_	4	case	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	analogues	analogue	NNS	_	1	ppmod	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	drug2	drug0	NN	_	4	prn	_	_
7	,	,	,	_	6	p	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	,	,	,	_	8	p	_	_
10	drug4	drug0	NN	_	6	conj	_	_
11	,	,	,	_	10	p	_	_
12	and	and	CC	_	10	cc	_	_
13	drug5	drug0	NN	_	6	conj	_	_
14	)	-rrb-	-RRB-	_	6	p	_	_
15	:	:	:	_	16	p	_	_
16	drug6	drug0	NN	_	21	comp	_	_
17	:	:	:	_	21	p	_	_
18	drug7	drug0	NN	_	21	dep	_	_
19	has	have	VBZ	_	21	aux	_	_
20	been	be	VBN	_	21	aux	_	_
21	reported	report	VBN	_	0	root	_	_
22	to	to	TO	_	23	aux	_	_
23	reduce	reduce	VB	_	21	comp	_	_
24	intestinal	intestinal	JJ	_	25	attr	_	_
25	absorption	absorption	NN	_	23	obj	_	_
26	of	of	IN	_	27	case	_	_
27	drug8	drug0	NN	_	25	ppmod	_	_
28	;	;	:	_	21	p	_	_

1	as	as	IN	_	2	case	_	_
2	such	such	JJ	_	5	ppmod	_	_
3	it	it	PRP	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	impair	impair	VB	_	0	root	_	_
6	intestinal	intestinal	JJ	_	7	attr	_	_
7	absorption	absorption	NN	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	any	any	DT	_	7	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	13	dep	_	_
2	/	/	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	:	:	:	_	1	p	_	_
5	The	the	DT	_	6	det	_	_
6	coadministration	coadministration	NN	_	1	appo	_	_
7	of	of	IN	_	8	case	_	_
8	drug3	drug0	NN	_	6	ppmod	_	_
9	or	or	CC	_	8	cc	_	_
10	drug4	drug0	NN	_	8	conj	_	_
11	will	will	MD	_	13	modal	_	_
12	not	not	RB	_	13	neg	_	_
13	affect	affect	VB	_	0	root	_	_
14	plasma	plasma	NN	_	15	com	_	_
15	concentrations	concentration	NNS	_	13	obj	_	_
16	of	of	IN	_	17	case	_	_
17	drug5	drug0	NN	_	15	ppmod	_	_
18	,	,	,	_	13	p	_	_
19	but	but	CC	_	13	cc	_	_
20	may	may	MD	_	21	modal	_	_
21	reduce	reduce	VB	_	13	conj	_	_
22	endogenous	endogenous	JJ	_	24	attr	_	_
23	plasma	plasma	NN	_	24	com	_	_
24	levels	level	NNS	_	21	obj	_	_
25	of	of	IN	_	27	case	_	_
26	drug6	drug0	NN	_	27	com	_	_
27	/ergocalcitriol	/ergocalcitriol	NN	_	24	ppmod	_	_
28	by	by	IN	_	29	case	_	_
29	accelerating	accelerate	VBG	_	21	ppmod	_	_
30	metabolism	metabolism	NN	_	29	obj	_	_
31	.	.	.	_	13	p	_	_

1	Since	since	IN	_	9	mark	_	_
2	blood	blood	NN	_	3	com	_	_
3	level	level	NN	_	9	dep	_	_
4	of	of	IN	_	6	case	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	/ergocalcitriol	/ergocalcitriol	NN	_	3	ppmod	_	_
7	will	will	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	reduced	reduce	VBN	_	16	advcl	_	_
10	,	,	,	_	16	p	_	_
11	higher	high	JJR	_	12	attr	_	_
12	doses	dose	NNS	_	16	dep	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	may	may	MD	_	16	modal	_	_
16	be	be	VB	_	0	root	_	_
17	necessary	necessary	JJ	_	16	dep	_	_
18	if	if	IN	_	22	mark	_	_
19	these	these	DT	_	20	det	_	_
20	drugs	drug	NNS	_	22	dep	_	_
21	are	be	VBP	_	22	aux	_	_
22	administered	administer	VBN	_	16	comp	_	_
23	simultaneously	simultaneously	RB	_	22	adv	_	_
24	.	.	.	_	16	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	are	be	VBP	_	5	aux	_	_
5	known	know	VBN	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	induce	induce	VB	_	5	comp	_	_
8	hypercalcemia	hypercalcemia	NN	_	7	obj	_	_
9	by	by	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	reduction	reduction	NN	_	7	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	calcium	calcium	NN	_	14	com	_	_
14	excretion	excretion	NN	_	11	ppmod	_	_
15	in	in	IN	_	16	case	_	_
16	urine	urine	NN	_	11	ppmod	_	_
17	.	.	.	_	5	p	_	_

1	Some	some	DT	_	2	det	_	_
2	reports	report	NNS	_	4	dep	_	_
3	have	have	VBP	_	4	aux	_	_
4	shown	show	VBN	_	0	root	_	_
5	that	that	IN	_	13	mark	_	_
6	the	the	DT	_	8	det	_	_
7	concomitant	concomitant	JJ	_	8	attr	_	_
8	administration	administration	NN	_	13	dep	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	with	with	IN	_	12	case	_	_
12	drug2	drug0	NN	_	8	ppmod	_	_
13	causes	cause	VBZ	_	4	comp	_	_
14	hypercalcemia	hypercalcemia	NN	_	13	obj	_	_
15	.	.	.	_	4	p	_	_

1	Therefore	therefore	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	precaution	precaution	NN	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	taken	take	VBN	_	0	root	_	_
7	when	when	WRB	_	9	adv	_	_
8	coadministration	coadministration	NN	_	9	dep	_	_
9	is	be	VBZ	_	6	comp	_	_
10	necessary	necessary	JJ	_	9	dep	_	_
11	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	4	com	_	_
4	dosage	dosage	NN	_	7	dep	_	_
5	must	must	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	determined	determine	VBN	_	1	acl	_	_
8	with	with	IN	_	9	case	_	_
9	care	care	NN	_	7	ppmod	_	_
10	in	in	IN	_	11	case	_	_
11	patients	patient	NNS	_	7	ppmod	_	_
12	undergoing	undergo	VBG	_	11	acl	_	_
13	treatment	treatment	NN	_	12	obj	_	_
14	with	with	IN	_	15	case	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	,	,	,	_	7	p	_	_
17	as	as	IN	_	23	mark	_	_
18	hypercalcemia	hypercalcemia	NN	_	23	dep	_	_
19	in	in	IN	_	21	case	_	_
20	such	such	JJ	_	21	attr	_	_
21	patients	patient	NNS	_	18	ppmod	_	_
22	may	may	MD	_	23	modal	_	_
23	precipitate	precipitate	VB	_	7	comp	_	_
24	cardiac	cardiac	JJ	_	25	attr	_	_
25	arrhythmias	arrhythmias	NN	_	23	obj	_	_
26	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	inhibit	inhibit	VB	_	1	acl	_	_
6	both	both	CC	_	7	cc	_	_
7	synthetic	synthetic	JJ	_	10	attr	_	_
8	and	and	CC	_	7	cc	_	_
9	catabolic	catabolic	JJ	_	7	conj	_	_
10	enzymes	enzyme	NNS	_	5	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	1	p	_	_

1	Reductions	reduction	NNS	_	10	dep	_	_
2	in	in	IN	_	7	case	_	_
3	serum	serum	NN	_	7	attr	_	_
4	endogenous	endogenous	JJ	_	6	attr	_	_
5	vitamin	vitamin	NN	_	6	com	_	_
6	D	d	NN	_	7	com	_	_
7	concentrations	concentration	NNS	_	1	ppmod	_	_
8	have	have	VBP	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	observed	observe	VBN	_	0	root	_	_
11	following	follow	VBG	_	13	adv	_	_
12	the	the	DT	_	13	det	_	_
13	administration	administration	NN	_	10	ppmod	_	_
14	of	of	IN	_	16	case	_	_
15	300	0	CD	_	16	num	_	_
16	mg/day	mg/day	NN	_	13	ppmod	_	_
17	to	to	TO	_	20	aux	_	_
18	1200	0	CD	_	19	num	_	_
19	mg/day	mg/day	NN	_	20	com	_	_
20	drug1	drug0	NN	_	13	ppmod	_	_
21	for	for	IN	_	23	case	_	_
22	a	a	DT	_	23	det	_	_
23	week	week	NN	_	20	ppmod	_	_
24	to	to	TO	_	26	aux	_	_
25	healthy	healthy	JJ	_	26	attr	_	_
26	men	man	NNS	_	23	ppmod	_	_
27	.	.	.	_	10	p	_	_

1	However	however	RB	_	15	adv	_	_
2	,	,	,	_	15	p	_	_
3	in	in	FW	_	4	adv	_	_
4	vivo	vivo	FW	_	7	attr	_	_
5	drug	drug	NN	_	7	com	_	_
6	interaction	interaction	NN	_	7	com	_	_
7	studies	study	NNS	_	15	dep	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NN	_	7	ppmod	_	_
12	have	have	VBP	_	15	aux	_	_
13	not	not	RB	_	15	neg	_	_
14	been	be	VBN	_	15	aux	_	_
15	investigated	investigate	VBN	_	0	root	_	_
16	.	.	.	_	15	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	A	a	DT	_	4	det	_	_
4	relationship	relationship	NN	_	8	dep	_	_
5	of	of	IN	_	7	case	_	_
6	functional	functional	JJ	_	7	attr	_	_
7	antagonism	antagonism	NN	_	4	ppmod	_	_
8	exists	exist	VBZ	_	1	acl	_	_
9	between	between	IN	_	11	case	_	_
10	drug2	drug0	NN	_	11	com	_	_
11	analogues	analogue	NNS	_	8	ppmod	_	_
12	,	,	,	_	11	p	_	_
13	which	which	WDT	_	14	dep	_	_
14	promote	promote	VBP	_	11	relcl	_	_
15	calcium	calcium	NN	_	16	com	_	_
16	absorption	absorption	NN	_	14	obj	_	_
17	,	,	,	_	11	p	_	_
18	and	and	CC	_	11	cc	_	_
19	drug3	drug0	NN	_	11	conj	_	_
20	,	,	,	_	19	p	_	_
21	which	which	WDT	_	22	dep	_	_
22	inhibit	inhibit	VBP	_	19	relcl	_	_
23	calcium	calcium	NN	_	24	com	_	_
24	absorption	absorption	NN	_	22	obj	_	_
25	.	.	.	_	1	p	_	_

1	Phosphate-Binding	phosphate-binding	JJ	_	2	attr	_	_
2	Agents	agent	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	Since	since	IN	_	7	mark	_	_
5	drug1	drug0	NN	_	7	dep	_	_
6	also	also	RB	_	7	adv	_	_
7	has	have	VBZ	_	28	advcl	_	_
8	an	an	DT	_	9	det	_	_
9	effect	effect	NN	_	7	obj	_	_
10	on	on	IN	_	12	case	_	_
11	phosphate	phosphate	NN	_	12	com	_	_
12	transport	transport	NN	_	9	ppmod	_	_
13	in	in	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	intestine	intestine	NN	_	7	ppmod	_	_
16	,	,	,	_	15	p	_	_
17	kidneys	kidneys	NN	_	15	conj	_	_
18	and	and	CC	_	17	cc	_	_
19	bones	bones	NN	_	15	conj	_	_
20	,	,	,	_	28	p	_	_
21	the	the	DT	_	22	det	_	_
22	dosage	dosage	NN	_	28	dep	_	_
23	of	of	IN	_	25	case	_	_
24	phosphate-binding	phosphate-binding	JJ	_	25	attr	_	_
25	agents	agent	NNS	_	22	ppmod	_	_
26	must	must	MD	_	28	modal	_	_
27	be	be	VB	_	28	aux	_	_
28	adjusted	adjust	VBN	_	2	acl	_	_
29	in	in	IN	_	30	case	_	_
30	accordance	accordance	NN	_	28	ppmod	_	_
31	with	with	IN	_	35	case	_	_
32	the	the	DT	_	35	det	_	_
33	serum	serum	NN	_	35	com	_	_
34	phosphate	phosphate	NN	_	35	com	_	_
35	concentration	concentration	NN	_	30	ppmod	_	_
36	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	coadministration	coadministration	NN	_	13	dep	_	_
5	of	of	IN	_	6	case	_	_
6	any	any	DT	_	4	ppmod	_	_
7	of	of	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	drug2	drug0	JJ	_	10	attr	_	_
10	analogues	analogue	NNS	_	6	ppmod	_	_
11	should	should	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	avoided	avoid	VBN	_	1	acl	_	_
14	as	as	IN	_	17	mark	_	_
15	this	this	DT	_	17	dep	_	_
16	could	could	MD	_	17	modal	_	_
17	create	create	VB	_	13	comp	_	_
18	possible	possible	JJ	_	20	attr	_	_
19	additive	additive	JJ	_	20	attr	_	_
20	effects	effect	NNS	_	17	obj	_	_
21	and	and	CC	_	20	cc	_	_
22	hypercalcemia	hypercalcemia	NN	_	20	conj	_	_
23	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	Supplements	supplement	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	Uncontrolled	uncontrolled	JJ	_	5	attr	_	_
5	intake	intake	NN	_	13	dep	_	_
6	of	of	IN	_	10	case	_	_
7	additional	additional	JJ	_	10	attr	_	_
8	drug2	drug0	NN	_	10	attr	_	_
9	-containing	-containing	JJ	_	10	attr	_	_
10	preparations	preparation	NNS	_	5	ppmod	_	_
11	should	should	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	avoided	avoid	VBN	_	2	acl	_	_
14	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	5	attr	_	_
4	-containing	-containing	JJ	_	5	attr	_	_
5	preparations	preparation	NNS	_	12	dep	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	eg	eg	NN	_	5	prn	_	_
8	,	,	,	_	7	p	_	_
9	drug3	drug0	NN	_	7	appo	_	_
10	)	-rrb-	-RRB-	_	7	p	_	_
11	may	may	MD	_	12	modal	_	_
12	cause	cause	VB	_	1	acl	_	_
13	hypermagnesemia	hypermagnesemia	NN	_	12	obj	_	_
14	and	and	CC	_	12	cc	_	_
15	should	should	MD	_	19	modal	_	_
16	therefore	therefore	RB	_	19	adv	_	_
17	not	not	RB	_	19	neg	_	_
18	be	be	VB	_	19	aux	_	_
19	taken	take	VBN	_	12	conj	_	_
20	during	during	IN	_	21	case	_	_
21	therapy	therapy	NN	_	19	ppmod	_	_
22	with	with	IN	_	23	case	_	_
23	drug4	drug0	NN	_	19	ppmod	_	_
24	by	by	IN	_	25	case	_	_
25	patients	patient	NNS	_	19	ppmod	_	_
26	on	on	IN	_	29	case	_	_
27	chronic	chronic	JJ	_	29	attr	_	_
28	renal	renal	JJ	_	29	attr	_	_
29	dialysis	dialysis	NN	_	25	ppmod	_	_
30	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	may	may	MD	_	5	modal	_	_
5	decrease	decrease	VB	_	0	root	_	_
6	hypoprothrombinemic	hypoprothrombinemic	JJ	_	7	attr	_	_
7	effect	effect	NN	_	5	obj	_	_
8	.	.	.	_	5	p	_	_

1	Other	other	JJ	_	2	attr	_	_
2	depressasnts	depressasnts	NNS	_	12	dep	_	_
3	such	such	JJ	_	5	adv	_	_
4	as	as	IN	_	5	case	_	_
5	drug1	drug0	NN	_	2	ppmod	_	_
6	,	,	,	_	5	p	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	,	,	,	_	7	p	_	_
9	and	and	CC	_	7	cc	_	_
10	drug3	drug0	NN	_	5	conj	_	_
11	may	may	MD	_	12	modal	_	_
12	enhance	enhance	VB	_	0	root	_	_
13	CNS	cns	NN	_	14	com	_	_
14	depression	depression	NN	_	12	obj	_	_
15	when	when	WRB	_	16	adv	_	_
16	administered	administer	VBN	_	12	comp	_	_
17	with	with	IN	_	18	case	_	_
18	drug4	drug0	NN	_	16	ppmod	_	_
19	.	.	.	_	12	p	_	_

1	May	may	MD	_	2	modal	_	_
2	interact	interact	VB	_	0	root	_	_
3	with	with	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	,	,	,	_	4	p	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	,	,	,	_	6	p	_	_
8	drug3	drug0	NN	_	4	conj	_	_
9	,	,	,	_	8	p	_	_
10	drug4	drug0	NN	_	4	conj	_	_
11	,	,	,	_	10	p	_	_
12	and	and	CC	_	10	cc	_	_
13	drug5	drug0	NN	_	4	conj	_	_
14	.	.	.	_	2	p	_	_

1	Drug/Laboratory	drug/laboratory	NN	_	2	com	_	_
2	Interactions	interaction	NNS	_	10	dep	_	_
3	No	no	DT	_	7	det	_	_
4	formal	formal	JJ	_	7	attr	_	_
5	drug	drug	NN	_	7	com	_	_
6	interaction	interaction	NN	_	7	com	_	_
7	studies	study	NNS	_	2	appo	_	_
8	have	have	VBP	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	performed	performed	VBN	_	0	root	_	_
11	with	with	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	10	p	_	_

1	An	an	DT	_	3	det	_	_
2	immune	immune	JJ	_	3	attr	_	_
3	response	response	NN	_	7	dep	_	_
4	to	to	TO	_	5	aux	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	may	may	MD	_	7	modal	_	_
7	interfere	interfere	VB	_	0	root	_	_
8	with	with	IN	_	12	case	_	_
9	subsequent	subsequent	JJ	_	12	attr	_	_
10	diagnostic	diagnostic	JJ	_	12	attr	_	_
11	serum	serum	NN	_	12	com	_	_
12	tests	test	NNS	_	7	ppmod	_	_
13	that	that	WDT	_	14	dep	_	_
14	utilize	utilize	VBP	_	12	relcl	_	_
15	drug2	drug0	NN	_	14	obj	_	_

1	.	.	.	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	No	no	DT	_	5	det	_	_
2	formal	formal	JJ	_	5	attr	_	_
3	drug	drug	NN	_	5	com	_	_
4	interaction	interaction	NN	_	5	com	_	_
5	studies	study	NNS	_	8	dep	_	_
6	have	have	VBP	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	performed	performed	VBN	_	0	root	_	_
9	with	with	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	8	p	_	_

1	Due	due	IN	_	5	case	_	_
2	to	to	TO	_	5	aux	_	_
3	the	the	DT	_	5	det	_	_
4	frequent	frequent	JJ	_	5	attr	_	_
5	occurrence	occurrence	NN	_	26	ppmod	_	_
6	of	of	IN	_	10	case	_	_
7	severe	severe	JJ	_	10	attr	_	_
8	and	and	CC	_	7	cc	_	_
9	prolonged	prolonged	JJ	_	7	conj	_	_
10	thrombocytopenia	thrombocytopenia	NN	_	5	ppmod	_	_
11	,	,	,	_	26	p	_	_
12	the	the	DT	_	14	det	_	_
13	potential	potential	JJ	_	14	attr	_	_
14	benefits	benefit	NNS	_	26	dep	_	_
15	of	of	IN	_	16	case	_	_
16	medications	medication	NNS	_	14	ppmod	_	_
17	which	which	WDT	_	18	dep	_	_
18	interfere	interfere	VBP	_	16	relcl	_	_
19	with	with	IN	_	21	case	_	_
20	platelet	platelet	NN	_	21	com	_	_
21	function	function	NN	_	18	ppmod	_	_
22	and/or	and/or	CC	_	21	cc	_	_
23	anticoagulation	anticoagulation	NN	_	21	conj	_	_
24	should	should	MD	_	26	modal	_	_
25	be	be	VB	_	26	aux	_	_
26	weighed	weigh	VBN	_	0	root	_	_
27	against	against	IN	_	31	case	_	_
28	the	the	DT	_	31	det	_	_
29	potential	potential	JJ	_	31	attr	_	_
30	increased	increase	VBN	_	31	attr	_	_
31	risks	risk	NNS	_	26	ppmod	_	_
32	of	of	IN	_	33	case	_	_
33	bleeding	bleeding	JJ	_	31	ppmod	_	_
34	and	and	CC	_	33	cc	_	_
35	hemorrhage	hemorrhage	JJ	_	33	conj	_	_
36	.	.	.	_	26	p	_	_

1	Patients	patient	NNS	_	16	dep	_	_
2	receiving	receive	VBG	_	1	acl	_	_
3	medications	medication	NNS	_	2	obj	_	_
4	that	that	WDT	_	5	dep	_	_
5	interfere	interfere	VBP	_	3	relcl	_	_
6	with	with	IN	_	8	case	_	_
7	platelet	platelet	NN	_	8	com	_	_
8	function	function	NN	_	5	ppmod	_	_
9	or	or	CC	_	8	cc	_	_
10	coagulation	coagulation	NN	_	8	conj	_	_
11	should	should	MD	_	16	modal	_	_
12	have	have	VB	_	16	lv	_	_
13	more	more	RBR	_	14	adv	_	_
14	frequent	frequent	JJ	_	16	attr	_	_
15	laboratory	laboratory	NN	_	16	com	_	_
16	monitoring	monitoring	NN	_	0	root	_	_
17	for	for	IN	_	18	case	_	_
18	thrombocytopenia	thrombocytopenia	NN	_	16	ppmod	_	_
19	.	.	.	_	16	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	11	ppmod	_	_
3	,	,	,	_	11	p	_	_
4	the	the	DT	_	6	det	_	_
5	transfusion	transfusion	NN	_	6	com	_	_
6	practices	practice	NNS	_	11	dep	_	_
7	for	for	IN	_	9	case	_	_
8	such	such	JJ	_	9	attr	_	_
9	patients	patient	NNS	_	6	ppmod	_	_
10	may	may	MD	_	11	modal	_	_
11	need	need	VBP	_	0	root	_	_
12	to	to	TO	_	14	aux	_	_
13	be	be	VB	_	14	aux	_	_
14	modified	modify	VBN	_	11	comp	_	_
15	given	given	IN	_	18	case	_	_
16	the	the	DT	_	18	det	_	_
17	increased	increase	VBN	_	18	attr	_	_
18	risk	risk	NN	_	14	ppmod	_	_
19	of	of	IN	_	20	case	_	_
20	bleeding	bleeding	JJ	_	18	ppmod	_	_
21	.	.	.	_	11	p	_	_

1	Patients	patient	NNS	_	6	dep	_	_
2	in	in	IN	_	4	case	_	_
3	clinical	clinical	JJ	_	4	attr	_	_
4	studies	study	NNS	_	1	ppmod	_	_
5	were	be	VBD	_	6	aux	_	_
6	prohibited	prohibit	VBD	_	0	root	_	_
7	from	from	IN	_	8	case	_	_
8	receiving	receive	VBG	_	6	ppmod	_	_
9	growth	growth	NN	_	10	com	_	_
10	factor	factor	NN	_	11	com	_	_
11	treatment	treatment	NN	_	8	obj	_	_
12	for	for	IN	_	14	case	_	_
13	2	0	CD	_	14	num	_	_
14	weeks	week	NNS	_	11	ppmod	_	_
15	prior	prior	JJ	_	14	attr	_	_
16	to	to	TO	_	20	aux	_	_
17	the	the	DT	_	20	det	_	_
18	drug1	drug0	JJ	_	20	attr	_	_
19	therapeutic	therapeutic	JJ	_	20	attr	_	_
20	regimen	regimen	NN	_	15	ppmod	_	_
21	as	as	RB	_	22	com	_	_
22	well	well	RB	_	20	cc	_	_
23	as	as	IN	_	22	com	_	_
24	for	for	IN	_	26	case	_	_
25	2	0	CD	_	26	num	_	_
26	weeks	week	NNS	_	20	conj	_	_
27	following	follow	VBG	_	28	adv	_	_
28	completion	completion	NN	_	26	ppmod	_	_
29	of	of	IN	_	31	case	_	_
30	the	the	DT	_	31	det	_	_
31	regimen	regimen	NN	_	28	ppmod	_	_
32	.	.	.	_	6	p	_	_

1	Because	because	IN	_	6	mark	_	_
2	the	the	DT	_	3	det	_	_
3	drug1	drug0	NNS	_	6	dep	_	_
4	have	have	VBP	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	shown	show	VBN	_	20	advcl	_	_
7	to	to	TO	_	8	aux	_	_
8	depress	depress	VB	_	6	comp	_	_
9	plasma	plasma	NN	_	11	com	_	_
10	prothrombin	prothrombin	NN	_	11	com	_	_
11	activity	activity	NN	_	8	obj	_	_
12	,	,	,	_	20	p	_	_
13	patients	patient	NNS	_	20	dep	_	_
14	who	who	WP	_	15	dep	_	_
15	are	be	VBP	_	13	relcl	_	_
16	on	on	IN	_	18	case	_	_
17	drug2	drug0	NN	_	18	com	_	_
18	therapy	therapy	NN	_	15	ppmod	_	_
19	may	may	MD	_	20	modal	_	_
20	require	require	VBP	_	0	root	_	_
21	downward	downward	JJ	_	22	attr	_	_
22	adjustment	adjustment	NN	_	20	obj	_	_
23	of	of	IN	_	26	case	_	_
24	their	their	PRP$	_	26	poss	_	_
25	drug3	drug0	NN	_	26	com	_	_
26	dosage	dosage	NN	_	22	ppmod	_	_
27	.	.	.	_	20	p	_	_

1	Since	since	IN	_	13	mark	_	_
2	bacteriostatic	bacteriostatic	JJ	_	3	attr	_	_
3	drugs	drug	NNS	_	13	dep	_	_
4	,	,	,	_	3	p	_	_
5	such	such	JJ	_	8	adv	_	_
6	as	as	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	drug1	drug0	NN	_	3	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	,	,	,	_	3	p	_	_
12	may	may	MD	_	13	modal	_	_
13	interfere	interfere	VB	_	22	advcl	_	_
14	with	with	IN	_	17	case	_	_
15	the	the	DT	_	17	det	_	_
16	bactericidal	bactericidal	JJ	_	17	attr	_	_
17	action	action	NN	_	13	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug3	drug0	NN	_	17	ppmod	_	_
20	,	,	,	_	22	p	_	_
21	it	it	PRP	_	22	dep	_	_
22	is	be	VBZ	_	0	root	_	_
23	not	not	RB	_	22	neg	_	_
24	advisable	advisable	JJ	_	22	dep	_	_
25	to	to	TO	_	26	aux	_	_
26	administer	administer	VB	_	24	comp	_	_
27	these	these	DT	_	28	det	_	_
28	drugs	drug	NNS	_	26	obj	_	_
29	concomitantly	concomitantly	RB	_	26	adv	_	_
30	.	.	.	_	22	p	_	_

1	Concurrent	concurrent	JJ	_	2	attr	_	_
2	use	use	NN	_	9	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	with	with	IN	_	7	case	_	_
6	oral	oral	JJ	_	7	attr	_	_
7	drug2	drug0	NN	_	2	ppmod	_	_
8	may	may	MD	_	9	modal	_	_
9	render	render	VB	_	0	root	_	_
10	oral	oral	JJ	_	11	attr	_	_
11	drug3	drug0	NN	_	9	obj	_	_
12	less	less	RBR	_	13	adv	_	_
13	effective	effective	JJ	_	11	attr	_	_
14	.	.	.	_	9	p	_	_

1	Breakthrough	breakthrough	JJ	_	2	attr	_	_
2	bleeding	bleeding	JJ	_	5	dep	_	_
3	has	have	VBZ	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	reported	report	VBN	_	0	root	_	_

1	drug1	drug0	NN	_	13	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	7	attr	_	_
4	(	-lrb-	-LRB-	_	7	p	_	_
5	drug3	drug0	NN	_	7	attr	_	_
6	)	-rrb-	-RRB-	_	7	p	_	_
7	Injection	injection	NN	_	1	appo	_	_
8	,	,	,	_	1	p	_	_
9	USP	usp	NN	_	1	appo	_	_
10	should	should	MD	_	13	modal	_	_
11	not	not	RB	_	13	neg	_	_
12	be	be	VB	_	13	aux	_	_
13	used	use	VBN	_	0	root	_	_
14	with	with	IN	_	15	case	_	_
15	drug4	drug0	NN	_	13	ppmod	_	_
16	because	because	IN	_	20	mark	_	_
17	the	the	DT	_	18	det	_	_
18	combination	combination	NN	_	20	dep	_	_
19	may	may	MD	_	20	modal	_	_
20	cause	cause	VB	_	13	comp	_	_
21	synergistic	synergistic	JJ	_	22	attr	_	_
22	elevation	elevation	NN	_	20	obj	_	_
23	of	of	IN	_	25	case	_	_
24	blood	blood	NN	_	25	com	_	_
25	pressure	pressure	NN	_	22	ppmod	_	_
26	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	6	dep	_	_
4	has	have	VBZ	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	reported	report	VBN	_	1	acl	_	_
7	to	to	TO	_	8	aux	_	_
8	cause	cause	VB	_	6	comp	_	_
9	coronary	coronary	JJ	_	11	attr	_	_
10	artery	artery	NN	_	11	com	_	_
11	vasospasm	vasospasm	NN	_	8	obj	_	_
12	,	,	,	_	6	p	_	_
13	and	and	CC	_	6	cc	_	_
14	its	its	PRP$	_	15	poss	_	_
15	effect	effect	NN	_	17	dep	_	_
16	could	could	MD	_	17	modal	_	_
17	be	be	VB	_	6	conj	_	_
18	additive	additive	JJ	_	17	dep	_	_
19	with	with	IN	_	24	case	_	_
20	drug3	drug0	NN	_	24	attr	_	_
21	(	-lrb-	-LRB-	_	24	p	_	_
22	drug4	drug0	NN	_	24	attr	_	_
23	)	-rrb-	-RRB-	_	24	p	_	_
24	Injection	injection	NN	_	18	ppmod	_	_
25	,	,	,	_	24	p	_	_
26	USP	usp	NN	_	24	appo	_	_
27	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	7	attr	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	drug3	drug0	NN	_	1	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	Injection	injection	NN	_	13	dep	_	_
8	,	,	,	_	7	p	_	_
9	USP	usp	NN	_	7	appo	_	_
10	should	should	MD	_	13	modal	_	_
11	not	not	RB	_	13	neg	_	_
12	be	be	VB	_	13	aux	_	_
13	taken	take	VBN	_	0	root	_	_
14	within	within	IN	_	16	case	_	_
15	24	0	CD	_	16	num	_	_
16	hours	hour	NNS	_	13	ppmod	_	_
17	of	of	IN	_	19	case	_	_
18	each	each	DT	_	19	det	_	_
19	other	other	JJ	_	16	ppmod	_	_
20	.	.	.	_	13	p	_	_
21	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Although	although	IN	_	12	mark	_	_
4	the	the	DT	_	5	det	_	_
5	results	result	NNS	_	12	dep	_	_
6	of	of	IN	_	9	case	_	_
7	a	a	DT	_	9	det	_	_
8	clinical	clinical	JJ	_	9	attr	_	_
9	study	study	NN	_	5	ppmod	_	_
10	did	do	VBD	_	12	aux	_	_
11	not	not	RB	_	12	neg	_	_
12	indicate	indicate	VB	_	36	advcl	_	_
13	a	a	DT	_	15	det	_	_
14	safe	safe	JJ	_	15	attr	_	_
15	problem	problem	NN	_	12	obj	_	_
16	associated	associate	VBN	_	15	acl	_	_
17	with	with	IN	_	19	case	_	_
18	the	the	DT	_	19	det	_	_
19	administration	administration	NN	_	16	ppmod	_	_
20	of	of	IN	_	25	case	_	_
21	drug2	drug0	NN	_	25	attr	_	_
22	(	-lrb-	-LRB-	_	25	p	_	_
23	drug3	drug0	NN	_	25	attr	_	_
24	)	-rrb-	-RRB-	_	25	p	_	_
25	Injection	injection	NN	_	19	ppmod	_	_
26	,	,	,	_	15	p	_	_
27	USP	usp	NN	_	15	appo	_	_
28	to	to	TO	_	29	aux	_	_
29	subjects	subject	NNS	_	27	ppmod	_	_
30	already	already	RB	_	31	adv	_	_
31	receiving	receive	VBG	_	29	acl	_	_
32	drug4	drug0	NN	_	31	obj	_	_
33	,	,	,	_	36	p	_	_
34	there	there	EX	_	36	dep	_	_
35	have	have	VBP	_	36	aux	_	_
36	been	be	VBN	_	1	acl	_	_
37	reports	report	NNS	_	36	obj	_	_
38	that	that	IN	_	41	mark	_	_
39	drug5	drug0	NN	_	41	dep	_	_
40	may	may	MD	_	41	modal	_	_
41	potentiate	potentiate	VB	_	37	acl	_	_
42	the	the	DT	_	44	det	_	_
43	vasoconstrictive	vasoconstrictive	JJ	_	44	attr	_	_
44	action	action	NN	_	41	obj	_	_
45	of	of	IN	_	46	case	_	_
46	drug6	drug0	NN	_	44	ppmod	_	_
47	by	by	IN	_	48	case	_	_
48	blocking	block	VBG	_	41	ppmod	_	_
49	the	the	DT	_	51	det	_	_
50	vasodilating	vasodilating	JJ	_	51	attr	_	_
51	property	property	NN	_	48	obj	_	_
52	of	of	IN	_	53	case	_	_
53	epinephrine	epinephrine	NN	_	51	ppmod	_	_
54	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	provoke	provoke	VB	_	1	acl	_	_
6	vasoconstriction	vasoconstriction	NN	_	5	obj	_	_
7	in	in	IN	_	9	case	_	_
8	some	some	DT	_	9	det	_	_
9	patients	patient	NNS	_	5	ppmod	_	_
10	,	,	,	_	5	p	_	_
11	predisposing	predispose	VBG	_	16	adv	_	_
12	to	to	TO	_	16	aux	_	_
13	a	a	DT	_	16	det	_	_
14	greater	great	JJR	_	16	attr	_	_
15	ischemic	ischemic	JJ	_	16	attr	_	_
16	response	response	NN	_	5	ppmod	_	_
17	to	to	TO	_	19	aux	_	_
18	drug3	drug0	NN	_	19	com	_	_
19	therapy	therapy	NN	_	16	ppmod	_	_
20	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	(	-lrb-	-LRB-	_	5	p	_	_
3	e.	e.	FW	_	5	attr	_	_
4	g.	g.	FW	_	5	attr	_	_
5	drug2	drug0	NN	_	1	prn	_	_
6	and	and	CC	_	5	cc	_	_
7	drug3	drug0	NN	_	5	conj	_	_
8	)	-rrb-	-RRB-	_	5	p	_	_
9	:	:	:	_	1	p	_	_
10	Agents	agent	NNS	_	30	dep	_	_
11	of	of	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	drug4	drug0	NNS	_	10	ppmod	_	_
14	,	,	,	_	13	p	_	_
15	of	of	IN	_	16	case	_	_
16	which	which	WDT	_	24	ppmod	_	_
17	drug5	drug0	NN	_	21	attr	_	_
18	(	-lrb-	-LRB-	_	21	p	_	_
19	drug6	drug0	NN	_	21	attr	_	_
20	)	-rrb-	-RRB-	_	21	p	_	_
21	Injection	injection	NN	_	24	dep	_	_
22	,	,	,	_	21	p	_	_
23	USP	usp	NN	_	21	appo	_	_
24	is	be	VBZ	_	13	relcl	_	_
25	a	a	DT	_	26	det	_	_
26	member	member	NN	_	24	obj	_	_
27	,	,	,	_	13	p	_	_
28	have	have	VBP	_	30	aux	_	_
29	been	be	VBN	_	30	aux	_	_
30	shown	show	VBN	_	1	acl	_	_
31	to	to	TO	_	32	aux	_	_
32	interact	interact	VB	_	30	comp	_	_
33	with	with	IN	_	34	case	_	_
34	drug7	drug0	NN	_	32	ppmod	_	_
35	of	of	IN	_	37	case	_	_
36	the	the	DT	_	37	det	_	_
37	drug8	drug0	NN	_	34	ppmod	_	_
38	,	,	,	_	32	p	_	_
39	resulting	result	VBG	_	32	comp	_	_
40	in	in	IN	_	43	case	_	_
41	increased	increase	VBN	_	43	attr	_	_
42	plasma	plasma	NN	_	43	com	_	_
43	levels	level	NNS	_	39	ppmod	_	_
44	of	of	IN	_	46	case	_	_
45	unchanged	unchanged	JJ	_	46	attr	_	_
46	alkaloids	alkaloid	NNS	_	43	ppmod	_	_
47	and	and	CC	_	46	cc	_	_
48	peripheral	peripheral	JJ	_	49	attr	_	_
49	vasoconstriction	vasoconstriction	NN	_	46	conj	_	_
50	.	.	.	_	1	p	_	_

1	Vasospastic	vasospastic	JJ	_	2	attr	_	_
2	reactions	reaction	NNS	_	5	dep	_	_
3	have	have	VBP	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	reported	report	VBN	_	0	root	_	_
6	with	with	IN	_	8	case	_	_
7	therapeutic	therapeutic	JJ	_	8	attr	_	_
8	doses	dose	NNS	_	5	ppmod	_	_
9	of	of	IN	_	12	case	_	_
10	drug1	drug0	JJ	_	12	attr	_	_
11	-containing	-containing	JJ	_	12	attr	_	_
12	drugs	drug	NNS	_	8	ppmod	_	_
13	when	when	WRB	_	14	adv	_	_
14	co-administered	co-administered	VBN	_	5	comp	_	_
15	with	with	IN	_	17	case	_	_
16	these	these	DT	_	17	det	_	_
17	drug2	drug0	NNS	_	14	ppmod	_	_
18	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Weakness	weakness	NN	_	4	com	_	_
4	hyperreflexia	hyperreflexia	NN	_	10	dep	_	_
5	,	,	,	_	4	p	_	_
6	and	and	CC	_	4	cc	_	_
7	incoordination	incoordination	NN	_	4	conj	_	_
8	have	have	VBP	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	reported	report	VBN	_	1	acl	_	_
11	rarely	rarely	RB	_	10	adv	_	_
12	when	when	WRB	_	16	adv	_	_
13	drug2	drug0	NNS	_	16	dep	_	_
14	have	have	VBP	_	16	aux	_	_
15	been	be	VBN	_	16	aux	_	_
16	co-administered	co-administered	VBN	_	10	comp	_	_
17	with	with	IN	_	18	case	_	_
18	drug3	drug0	NN	_	16	ppmod	_	_
19	(	-lrb-	-LRB-	_	20	p	_	_
20	e.	e.	NNP	_	16	prn	_	_
21	g	g	NN	_	20	appo	_	_
22	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	,	,	,	_	1	p	_	_
5	drug3	drug0	NN	_	1	appo	_	_
6	,	,	,	_	7	p	_	_
7	drug4	drug0	NN	_	5	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	.	.	.	_	1	p	_	_

1	There	there	EX	_	3	dep	_	_
2	have	have	VBP	_	3	aux	_	_
3	been	be	VBN	_	0	root	_	_
4	no	no	DT	_	6	det	_	_
5	reported	report	VBN	_	6	attr	_	_
6	cases	case	NNS	_	3	obj	_	_
7	from	from	IN	_	9	case	_	_
8	spontaneous	spontaneous	JJ	_	9	attr	_	_
9	reports	report	NNS	_	6	ppmod	_	_
10	of	of	IN	_	12	case	_	_
11	drug	drug	NN	_	12	com	_	_
12	interaction	interaction	NN	_	9	ppmod	_	_
13	between	between	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	drug2	drug0	NN	_	14	conj	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	drug3	drug0	NN	_	16	prn	_	_
19	)	-rrb-	-RRB-	_	18	p	_	_
20	Injection	injection	NN	_	16	appo	_	_
21	,	,	,	_	16	p	_	_
22	USP	usp	NN	_	16	appo	_	_
23	.	.	.	_	3	p	_	_

1	Oral	oral	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	The	the	DT	_	5	det	_	_
5	effect	effect	NN	_	23	dep	_	_
6	of	of	IN	_	8	case	_	_
7	oral	oral	JJ	_	8	attr	_	_
8	drug2	drug0	NN	_	5	ppmod	_	_
9	on	on	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	pharmacokinetics	pharmacokinetics	NNS	_	5	ppmod	_	_
12	of	of	IN	_	17	case	_	_
13	drug3	drug0	NN	_	17	attr	_	_
14	(	-lrb-	-LRB-	_	17	p	_	_
15	drug4	drug0	NN	_	17	attr	_	_
16	)	-rrb-	-RRB-	_	17	p	_	_
17	Injection	injection	NN	_	11	ppmod	_	_
18	,	,	,	_	17	p	_	_
19	USP	usp	NN	_	17	appo	_	_
20	has	have	VBZ	_	23	aux	_	_
21	not	not	RB	_	23	neg	_	_
22	been	be	VBN	_	23	aux	_	_
23	studied	study	VBN	_	2	acl	_	_
24	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	magnitude	magnitude	NN	_	11	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	relative	relative	JJ	_	5	attr	_	_
5	importance	importance	NN	_	2	conj	_	_
6	of	of	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	effects	effect	NNS	_	2	ppmod	_	_
9	noted	note	VBN	_	8	acl	_	_
10	below	below	IN	_	9	case	_	_
11	are	be	VBP	_	0	root	_	_
12	likely	likely	JJ	_	11	dep	_	_
13	to	to	TO	_	14	aux	_	_
14	be	be	VB	_	12	comp	_	_
15	patient	patient	NN	_	16	advnp	_	_
16	specific	specific	JJ	_	14	dep	_	_
17	and	and	CC	_	14	cc	_	_
18	may	may	MD	_	19	modal	_	_
19	vary	vary	VB	_	14	conj	_	_
20	by	by	IN	_	22	case	_	_
21	such	such	JJ	_	22	attr	_	_
22	factors	factor	NNS	_	19	ppmod	_	_
23	as	as	IN	_	24	case	_	_
24	age	age	NN	_	22	ppmod	_	_
25	,	,	,	_	24	p	_	_
26	gender	gender	NN	_	24	conj	_	_
27	,	,	,	_	26	p	_	_
28	race	race	NN	_	24	conj	_	_
29	,	,	,	_	28	p	_	_
30	intercurrent	intercurrent	NN	_	31	com	_	_
31	illnesses	illness	NNS	_	24	conj	_	_
32	,	,	,	_	31	p	_	_
33	dose	dose	NN	_	24	conj	_	_
34	of	of	IN	_	36	case	_	_
35	either	either	DT	_	36	det	_	_
36	agent	agent	NN	_	33	ppmod	_	_
37	,	,	,	_	33	p	_	_
38	additional	additional	JJ	_	40	attr	_	_
39	concomitant	concomitant	JJ	_	40	attr	_	_
40	medications	medication	NNS	_	24	conj	_	_
41	,	,	,	_	40	p	_	_
42	and	and	CC	_	40	cc	_	_
43	timing	timing	NN	_	24	conj	_	_
44	of	of	IN	_	46	case	_	_
45	drug	drug	NN	_	46	com	_	_
46	administration	administration	NN	_	43	ppmod	_	_
47	.	.	.	_	11	p	_	_

1	Any	any	DT	_	2	det	_	_
2	agent	agent	NN	_	23	dep	_	_
3	that	that	WDT	_	4	dep	_	_
4	alters	alter	VBZ	_	2	relcl	_	_
5	thyroid	thyroid	NN	_	7	com	_	_
6	hormone	hormone	NN	_	7	com	_	_
7	synthesis	synthesis	NN	_	4	obj	_	_
8	,	,	,	_	7	p	_	_
9	secretion	secretion	NN	_	7	conj	_	_
10	,	,	,	_	9	p	_	_
11	distribution	distribution	NN	_	7	conj	_	_
12	,	,	,	_	11	p	_	_
13	effect	effect	NN	_	7	conj	_	_
14	on	on	IN	_	16	case	_	_
15	target	target	NN	_	16	com	_	_
16	tissues	tissue	NNS	_	13	ppmod	_	_
17	,	,	,	_	13	p	_	_
18	metabolism	metabolism	NN	_	7	conj	_	_
19	,	,	,	_	18	p	_	_
20	or	or	CC	_	18	cc	_	_
21	elimination	elimination	NN	_	7	conj	_	_
22	may	may	MD	_	23	modal	_	_
23	alter	alter	VB	_	0	root	_	_
24	the	the	DT	_	27	det	_	_
25	optimal	optimal	JJ	_	27	attr	_	_
26	therapeutic	therapeutic	JJ	_	27	attr	_	_
27	dose	dose	NN	_	23	obj	_	_
28	of	of	IN	_	30	case	_	_
29	drug1	drug0	NN	_	30	com	_	_
30	sodium	sodium	NN	_	27	ppmod	_	_
31	.	.	.	_	23	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	Absorption	absorption	NN	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	The	the	DT	_	6	det	_	_
5	following	following	JJ	_	6	attr	_	_
6	agents	agent	NNS	_	8	dep	_	_
7	may	may	MD	_	8	modal	_	_
8	bind	bind	VB	_	2	acl	_	_
9	and	and	CC	_	8	cc	_	_
10	decrease	decrease	VB	_	8	conj	_	_
11	absorption	absorption	NN	_	10	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	from	from	IN	_	17	case	_	_
15	the	the	DT	_	17	det	_	_
16	gastrointestinal	gastrointestinal	JJ	_	17	attr	_	_
17	tract	tract	NN	_	11	ppmod	_	_
18	:	:	:	_	2	p	_	_
19	drug3	drug0	NN	_	2	appo	_	_
20	,	,	,	_	19	p	_	_
21	drug4	drug0	NN	_	22	com	_	_
22	resin	resin	NN	_	19	appo	_	_
23	,	,	,	_	19	p	_	_
24	drug5	drug0	NN	_	19	appo	_	_
25	,	,	,	_	19	p	_	_
26	drug6	drug0	NN	_	19	appo	_	_
27	,	,	,	_	19	p	_	_
28	drug7	drug0	NN	_	19	appo	_	_
29	,	,	,	_	19	p	_	_
30	soybean	soybean	NN	_	31	com	_	_
31	flour	flour	NN	_	19	appo	_	_
32	(	-lrb-	-LRB-	_	36	p	_	_
33	e.g.	e.g.	FW	_	36	ppmod	_	_
34	,	,	,	_	36	p	_	_
35	infant	infant	NN	_	36	com	_	_
36	formula	formula	NNS	_	19	prn	_	_
37	)	-rrb-	-RRB-	_	36	p	_	_
38	,	,	,	_	2	p	_	_
39	drug8	drug0	NN	_	2	appo	_	_
40	.	.	.	_	2	p	_	_

1	Binding	bind	VBG	_	0	root	_	_
2	to	to	TO	_	26	aux	_	_
3	Serum	serum	NN	_	4	com	_	_
4	Proteins	protein	NNS	_	26	attr	_	_
5	:	:	:	_	4	p	_	_
6	The	the	DT	_	8	det	_	_
7	following	follow	VBG	_	8	attr	_	_
8	agents	agent	NNS	_	11	dep	_	_
9	may	may	MD	_	11	modal	_	_
10	either	either	CC	_	11	cc	_	_
11	inhibit	inhibit	VB	_	4	acl	_	_
12	drug1	drug0	NN	_	13	com	_	_
13	binding	binding	NN	_	11	obj	_	_
14	to	to	TO	_	16	aux	_	_
15	serum	serum	NN	_	16	com	_	_
16	proteins	protein	NNS	_	13	ppmod	_	_
17	or	or	CC	_	11	cc	_	_
18	alter	alter	VB	_	11	conj	_	_
19	the	the	DT	_	20	det	_	_
20	concentrations	concentration	NNS	_	18	obj	_	_
21	of	of	IN	_	24	case	_	_
22	serum	serum	NN	_	24	com	_	_
23	binding	binding	NN	_	24	com	_	_
24	proteins	protein	NNS	_	20	ppmod	_	_
25	:	:	:	_	4	p	_	_
26	drug2	drug0	NN	_	1	ppmod	_	_
27	and	and	CC	_	26	cc	_	_
28	related	related	JJ	_	29	attr	_	_
29	drug3	drug0	NN	_	26	conj	_	_
30	,	,	,	_	29	p	_	_
31	drug4	drug0	NN	_	26	conj	_	_
32	,	,	,	_	31	p	_	_
33	drug5	drug0	NN	_	26	conj	_	_
34	,	,	,	_	33	p	_	_
35	drug6	drug0	NN	_	26	conj	_	_
36	and	and	CC	_	35	cc	_	_
37	drug7	drug0	NN	_	35	conj	_	_
38	,	,	,	_	35	p	_	_
39	drug8	drug0	NN	_	26	conj	_	_
40	,	,	,	_	39	p	_	_
41	drug9	drug0	NN	_	26	conj	_	_
42	,	,	,	_	41	p	_	_
43	drug10	drug0	NN	_	26	conj	_	_
44	,	,	,	_	43	p	_	_
45	drug11	drug0	CD	_	26	conj	_	_
46	,	,	,	_	45	p	_	_
47	drug12	drug0	CD	_	45	appo	_	_
48	,	,	,	_	45	p	_	_
49	drug13	drug0	CD	_	45	appo	_	_
50	,	,	,	_	45	p	_	_
51	drug14	drug0	CD	_	45	appo	_	_
52	,	,	,	_	45	p	_	_
53	drug15	drug0	CD	_	45	appo	_	_
54	,	,	,	_	45	p	_	_
55	drug16	drug0	CD	_	45	appo	_	_
56	,	,	,	_	45	p	_	_
57	drug17	drug0	CD	_	45	appo	_	_
58	,	,	,	_	45	p	_	_
59	drug18	drug0	CD	_	45	appo	_	_
60	.	.	.	_	1	p	_	_

1	Thyroid	thyroid	NN	_	2	com	_	_
2	Physiology	physiology	NN	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	The	the	DT	_	6	det	_	_
5	following	following	JJ	_	6	attr	_	_
6	agents	agent	NNS	_	8	dep	_	_
7	may	may	MD	_	8	modal	_	_
8	alter	alter	VB	_	2	acl	_	_
9	thyroid	thyroid	NN	_	10	com	_	_
10	hormone	hormone	NN	_	8	obj	_	_
11	or	or	CC	_	10	cc	_	_
12	TSH	tsh	NN	_	13	com	_	_
13	levels	level	NNS	_	10	conj	_	_
14	,	,	,	_	8	p	_	_
15	generally	generally	RB	_	8	adv	_	_
16	by	by	IN	_	122	case	_	_
17	effects	effect	NNS	_	57	attr	_	_
18	on	on	IN	_	21	case	_	_
19	thyroid	thyroid	NN	_	21	com	_	_
20	hormone	hormone	NN	_	21	com	_	_
21	synthesis	synthesis	NN	_	17	ppmod	_	_
22	,	,	,	_	21	p	_	_
23	secretion	secretion	NN	_	21	conj	_	_
24	,	,	,	_	23	p	_	_
25	distribution	distribution	NN	_	21	conj	_	_
26	,	,	,	_	25	p	_	_
27	metabolism	metabolism	NN	_	21	conj	_	_
28	,	,	,	_	27	p	_	_
29	hormone	hormone	NN	_	30	com	_	_
30	action	action	NN	_	21	conj	_	_
31	,	,	,	_	30	p	_	_
32	or	or	CC	_	30	cc	_	_
33	elimination	elimination	NN	_	21	conj	_	_
34	,	,	,	_	33	p	_	_
35	or	or	CC	_	33	cc	_	_
36	altered	altered	JJ	_	38	attr	_	_
37	TSH	tsh	NN	_	38	com	_	_
38	secretion	secretion	NN	_	21	conj	_	_
39	:	:	:	_	17	p	_	_
40	drug1	drug0	NN	_	17	appo	_	_
41	,	,	,	_	40	p	_	_
42	drug2	drug0	NN	_	40	conj	_	_
43	,	,	,	_	42	p	_	_
44	drug3	drug0	NN	_	40	conj	_	_
45	,	,	,	_	44	p	_	_
46	drug4	drug0	NN	_	40	conj	_	_
47	and	and	CC	_	46	cc	_	_
48	related	related	JJ	_	50	attr	_	_
49	anabolic	anabolic	JJ	_	50	attr	_	_
50	hormones	hormone	NNS	_	40	conj	_	_
51	,	,	,	_	17	p	_	_
52	complex	complex	JJ	_	53	attr	_	_
53	anions	anion	NNS	_	17	appo	_	_
54	(	-lrb-	-LRB-	_	17	p	_	_
55	drug5	drug0	NN	_	17	appo	_	_
56	,	,	,	_	17	p	_	_
57	drug6	drug0	NN	_	122	attr	_	_
58	,	,	,	_	59	p	_	_
59	drug7	drug0	NN	_	57	prn	_	_
60	)	-rrb-	-RRB-	_	59	p	_	_
61	,	,	,	_	57	p	_	_
62	drug8	drug0	NN	_	57	appo	_	_
63	,	,	,	_	57	p	_	_
64	drug9	drug0	NN	_	57	appo	_	_
65	,	,	,	_	57	p	_	_
66	drug10	drug0	CD	_	57	appo	_	_
67	,	,	,	_	66	p	_	_
68	drug11	drug0	CD	_	66	conj	_	_
69	,	,	,	_	68	p	_	_
70	drug12	drug0	CD	_	66	conj	_	_
71	,	,	,	_	70	p	_	_
72	drug13	drug0	CD	_	66	conj	_	_
73	and	and	CC	_	72	cc	_	_
74	drug14	drug0	CD	_	66	conj	_	_
75	,	,	,	_	66	p	_	_
76	drug15	drug0	CD	_	66	appo	_	_
77	,	,	,	_	66	p	_	_
78	drug16	drug0	CD	_	66	appo	_	_
79	,	,	,	_	66	p	_	_
80	drug17	drug0	CD	_	66	appo	_	_
81	,	,	,	_	66	p	_	_
82	hepatic	hepatic	JJ	_	84	attr	_	_
83	enzyme	enzyme	NN	_	84	com	_	_
84	inducers	inducer	NNS	_	66	appo	_	_
85	,	,	,	_	66	p	_	_
86	drug18	drug0	NN	_	66	appo	_	_
87	,	,	,	_	66	p	_	_
88	iodinated	iodinated	JJ	_	90	attr	_	_
89	cholestographic	cholestographic	JJ	_	90	attr	_	_
90	agents	agent	NNS	_	66	appo	_	_
91	,	,	,	_	66	p	_	_
92	drug19	drug0	NN	_	66	appo	_	_
93	,	,	,	_	66	p	_	_
94	drug20	drug0	CD	_	66	appo	_	_
95	,	,	,	_	66	p	_	_
96	drug21	drug0	CD	_	66	appo	_	_
97	,	,	,	_	66	p	_	_
98	drug22	drug0	CD	_	66	appo	_	_
99	,	,	,	_	57	p	_	_
100	drug23	drug0	CD	_	122	num	_	_
101	,	,	,	_	122	p	_	_
102	drug24	drug0	CD	_	122	num	_	_
103	,	,	,	_	122	p	_	_
104	drug25	drug0	CD	_	122	num	_	_
105	,	,	,	_	122	p	_	_
106	drug26	drug0	CD	_	122	num	_	_
107	,	,	,	_	122	p	_	_
108	drug27	drug0	CD	_	122	num	_	_
109	,	,	,	_	122	p	_	_
110	drug28	drug0	CD	_	122	num	_	_
111	,	,	,	_	122	p	_	_
112	drug29	drug0	CD	_	122	num	_	_
113	,	,	,	_	122	p	_	_
114	drug30	drug0	CD	_	122	num	_	_
115	,	,	,	_	122	p	_	_
116	drug31	drug0	CD	_	122	num	_	_
117	,	,	,	_	122	p	_	_
118	drug32	drug0	CD	_	122	num	_	_
119	,	,	,	_	122	p	_	_
120	drug33	drug0	CD	_	122	num	_	_
121	,	,	,	_	122	p	_	_
122	drug34	drug0	CD	_	8	ppmod	_	_
123	.	.	.	_	2	p	_	_

1	Adrenocorticoids	adrenocorticoids	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Metabolic	metabolic	JJ	_	4	attr	_	_
4	clearance	clearance	NN	_	8	dep	_	_
5	of	of	IN	_	6	case	_	_
6	adrenocorticoids	adrenocorticoids	NNS	_	4	ppmod	_	_
7	is	be	VBZ	_	8	aux	_	_
8	decreased	decrease	VBN	_	1	acl	_	_
9	in	in	IN	_	11	case	_	_
10	hypothyroid	hypothyroid	JJ	_	11	attr	_	_
11	patients	patient	NNS	_	8	ppmod	_	_
12	and	and	CC	_	8	cc	_	_
13	increased	increase	VBN	_	8	conj	_	_
14	in	in	IN	_	16	case	_	_
15	hyperthyroid	hyperthyroid	JJ	_	16	attr	_	_
16	patients	patient	NNS	_	13	ppmod	_	_
17	,	,	,	_	8	p	_	_
18	and	and	CC	_	8	cc	_	_
19	may	may	MD	_	21	modal	_	_
20	therefore	therefore	RB	_	21	adv	_	_
21	change	change	VB	_	8	conj	_	_
22	with	with	IN	_	23	case	_	_
23	changing	change	VBG	_	21	ppmod	_	_
24	thyroid	thyroid	NN	_	25	com	_	_
25	status	status	NN	_	23	obj	_	_
26	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	4	attr	_	_
2	:	:	:	_	4	p	_	_
3	drug2	drug0	NN	_	4	com	_	_
4	therapy	therapy	NN	_	7	dep	_	_
5	alone	alone	RB	_	4	adv	_	_
6	can	can	MD	_	7	modal	_	_
7	cause	cause	VB	_	0	root	_	_
8	hypothyroidism	hypothyroidism	NN	_	7	obj	_	_
9	or	or	CC	_	8	cc	_	_
10	hyperthyroidism	hyperthyroidism	NN	_	8	conj	_	_
11	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	Oral	oral	JJ	_	1	prn	_	_
4	)	-rrb-	-RRB-	_	3	p	_	_
5	:	:	:	_	1	p	_	_
6	The	the	DT	_	8	det	_	_
7	hypoprothrombinemic	hypoprothrombinemic	JJ	_	8	attr	_	_
8	effect	effect	NN	_	13	dep	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	may	may	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	potentiated	potentiate	VBN	_	1	acl	_	_
14	,	,	,	_	13	p	_	_
15	apparently	apparently	RB	_	13	adv	_	_
16	by	by	IN	_	18	case	_	_
17	increased	increase	VBN	_	18	attr	_	_
18	catabloism	catabloism	NN	_	13	ppmod	_	_
19	of	of	IN	_	23	case	_	_
20	vitamin	vitamin	NN	_	23	com	_	_
21	K-dependent	k-dependent	NN	_	23	com	_	_
22	clotting	clotting	NN	_	23	com	_	_
23	factors	factor	NNS	_	18	ppmod	_	_
24	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	drug2	drug0	NN	_	1	prn	_	_
4	,	,	,	_	3	p	_	_
5	drug3	drug0	NN	_	3	appo	_	_
6	)	-rrb-	-RRB-	_	3	p	_	_
7	:	:	:	_	1	p	_	_
8	Requirements	requirement	NNS	_	16	dep	_	_
9	for	for	IN	_	10	case	_	_
10	drug4	drug0	NN	_	8	ppmod	_	_
11	or	or	CC	_	10	cc	_	_
12	oral	oral	JJ	_	13	attr	_	_
13	drug5	drug0	NN	_	10	conj	_	_
14	may	may	MD	_	16	modal	_	_
15	be	be	VB	_	16	aux	_	_
16	reduced	reduce	VBN	_	1	acl	_	_
17	in	in	IN	_	19	case	_	_
18	hypothyroid	hypothyroid	JJ	_	19	attr	_	_
19	patients	patient	NNS	_	16	ppmod	_	_
20	with	with	IN	_	22	case	_	_
21	diabetes	diabetes	NN	_	22	com	_	_
22	mellitus	mellitus	NN	_	19	ppmod	_	_
23	and	and	CC	_	16	cc	_	_
24	may	may	MD	_	26	modal	_	_
25	subsequently	subsequently	RB	_	26	adv	_	_
26	increase	increase	VB	_	16	conj	_	_
27	with	with	IN	_	29	case	_	_
28	the	the	DT	_	29	det	_	_
29	initiation	initiation	NN	_	26	ppmod	_	_
30	of	of	IN	_	34	case	_	_
31	thyroid	thyroid	NN	_	34	com	_	_
32	hormone	hormone	NN	_	34	com	_	_
33	replacement	replacement	NN	_	34	com	_	_
34	therapy	therapy	NN	_	29	ppmod	_	_
35	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Actions	action	NNS	_	10	dep	_	_
4	of	of	IN	_	5	case	_	_
5	some	some	DT	_	3	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	may	may	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	impaired	impair	VBN	_	1	acl	_	_
11	when	when	WRB	_	14	adv	_	_
12	hypothyroid	hypothyroid	JJ	_	13	attr	_	_
13	patients	patient	NNS	_	14	dep	_	_
14	become	become	VBP	_	10	comp	_	_
15	euthyroid	euthyroid	JJ	_	14	dep	_	_
16	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	11	dep	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	drug2	drug0	NN	_	1	prn	_	_
4	,	,	,	_	3	p	_	_
5	drug3	drug0	NN	_	3	appo	_	_
6	)	-rrb-	-RRB-	_	3	p	_	_
7	:	:	:	_	1	p	_	_
8	drug4	drug0	NN	_	1	appo	_	_
9	have	have	VBP	_	11	aux	_	_
10	been	be	VBN	_	11	aux	_	_
11	reported	report	VBN	_	0	root	_	_
12	to	to	TO	_	13	aux	_	_
13	induce	induce	VB	_	11	comp	_	_
14	both	both	CC	_	15	cc	_	_
15	hyperthyroidism	hyperthyroidism	NN	_	13	obj	_	_
16	and	and	CC	_	15	cc	_	_
17	hypothyroidism	hypothyroidism	NN	_	15	conj	_	_
18	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	4	attr	_	_
2	:	:	:	_	4	p	_	_
3	Therapeutic	therapeutic	JJ	_	4	attr	_	_
4	effects	effect	NNS	_	9	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	may	may	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	reduced	reduce	VBN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	Serum	serum	NN	_	3	com	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	levels	level	NNS	_	6	dep	_	_
4	may	may	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	decreased	decrease	VBN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	hyperthyroidism	hyperthyroidism	NN	_	6	ppmod	_	_
9	or	or	CC	_	14	cc	_	_
10	when	when	WRB	_	14	adv	_	_
11	a	a	DT	_	13	det	_	_
12	hypothyroid	hypothyroid	JJ	_	13	attr	_	_
13	patient	patient	NN	_	14	dep	_	_
14	becomes	become	VBZ	_	6	advcl	_	_
15	euthyroid	euthyroid	NN	_	14	obj	_	_
16	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Marked	marked	JJ	_	4	attr	_	_
4	hypertension	hypertension	NN	_	9	dep	_	_
5	and	and	CC	_	4	cc	_	_
6	tachycardia	tachycardia	NN	_	4	conj	_	_
7	have	have	VBP	_	9	aux	_	_
8	been	be	VBN	_	9	aux	_	_
9	reported	report	VBN	_	1	acl	_	_
10	in	in	IN	_	11	case	_	_
11	association	association	NN	_	9	ppmod	_	_
12	with	with	IN	_	14	case	_	_
13	concomitant	concomitant	JJ	_	14	attr	_	_
14	administration	administration	NN	_	11	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	drug3	drug0	NN	_	16	conj	_	_
19	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	3	attr	_	_
2	:	:	:	_	3	p	_	_
3	Risk	risk	NN	_	8	dep	_	_
4	of	of	IN	_	6	case	_	_
5	cardiac	cardiac	JJ	_	6	attr	_	_
6	arrhythmias	arrhythmia	NNS	_	3	ppmod	_	_
7	may	may	MD	_	8	modal	_	_
8	increase	increase	VB	_	0	root	_	_
9	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	16	dep	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	123I	0i	NN	_	1	prn	_	_
4	and	and	CC	_	3	cc	_	_
5	131I	0i	NN	_	3	conj	_	_
6	)	-rrb-	-RRB-	_	3	p	_	_
7	,	,	,	_	1	p	_	_
8	drug2	drug0	NN	_	1	appo	_	_
9	:	:	:	_	1	p	_	_
10	Uptake	uptake	NN	_	1	appo	_	_
11	of	of	IN	_	13	case	_	_
12	radiolabeled	radiolabeled	VBN	_	13	attr	_	_
13	ions	ion	NNS	_	10	ppmod	_	_
14	may	may	MD	_	16	modal	_	_
15	be	be	VB	_	16	aux	_	_
16	decreased	decrease	VBN	_	0	root	_	_
17	.	.	.	_	16	p	_	_

1	drug1	drug0	NN	_	11	dep	_	_
2	/	/	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	:	:	:	_	1	p	_	_
5	Excessive	excessive	JJ	_	7	attr	_	_
6	concurrent	concurrent	JJ	_	7	attr	_	_
7	use	use	NN	_	1	appo	_	_
8	of	of	IN	_	9	case	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_
10	may	may	MD	_	11	modal	_	_
11	accelerate	accelerate	VB	_	0	root	_	_
12	epiphyseal	epiphyseal	JJ	_	13	attr	_	_
13	closure	closure	NN	_	11	obj	_	_
14	.	.	.	_	11	p	_	_

1	Untreated	untreated	JJ	_	2	attr	_	_
2	hypothyroidism	hypothyroidism	NN	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	interfere	interfere	VB	_	0	root	_	_
5	with	with	IN	_	8	case	_	_
6	the	the	DT	_	8	det	_	_
7	growth	growth	NN	_	8	com	_	_
8	response	response	NN	_	4	ppmod	_	_
9	to	to	TO	_	10	aux	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	or	or	CC	_	10	cc	_	_
12	drug2	drug0	NN	_	10	conj	_	_
13	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	4	com	_	_
4	clearance	clearance	NN	_	6	dep	_	_
5	may	may	MD	_	6	modal	_	_
6	decrease	decrease	VB	_	1	acl	_	_
7	in	in	IN	_	9	case	_	_
8	hypothyroid	hypothyroid	JJ	_	9	attr	_	_
9	patients	patient	NNS	_	6	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	return	return	NN	_	9	conj	_	_
12	toward	toward	IN	_	13	case	_	_
13	normal	normal	JJ	_	6	ppmod	_	_
14	when	when	WRB	_	19	adv	_	_
15	a	a	DT	_	17	det	_	_
16	euthyroid	euthyroid	JJ	_	17	attr	_	_
17	state	state	NN	_	19	dep	_	_
18	is	be	VBZ	_	19	aux	_	_
19	achieved	achieve	VBN	_	6	comp	_	_
20	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Concurrent	concurrent	JJ	_	4	attr	_	_
4	use	use	NN	_	6	dep	_	_
5	may	may	MD	_	6	modal	_	_
6	increase	increase	VB	_	1	acl	_	_
7	the	the	DT	_	11	det	_	_
8	therapeutic	therapeutic	JJ	_	11	attr	_	_
9	and	and	CC	_	8	cc	_	_
10	toxic	toxic	JJ	_	8	conj	_	_
11	effects	effect	NNS	_	6	obj	_	_
12	of	of	IN	_	14	case	_	_
13	both	both	DT	_	14	det	_	_
14	drugs	drug	NNS	_	11	ppmod	_	_
15	,	,	,	_	6	p	_	_
16	possibly	possibly	RB	_	21	adv	_	_
17	due	due	JJ	_	21	adv	_	_
18	to	to	TO	_	21	aux	_	_
19	increased	increase	VBN	_	21	attr	_	_
20	catecholamine	catecholamine	NN	_	21	com	_	_
21	sensitivity	sensitivity	NN	_	6	ppmod	_	_
22	.	.	.	_	1	p	_	_

1	Onset	onset	NN	_	8	dep	_	_
2	of	of	IN	_	3	case	_	_
3	action	action	NN	_	1	ppmod	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	may	may	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	accelerated	accelerate	VBN	_	0	root	_	_
9	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	:	:	:	_	5	p	_	_
3	Possible	possible	JJ	_	5	attr	_	_
4	increased	increase	VBN	_	5	attr	_	_
5	risk	risk	NN	_	0	root	_	_
6	of	of	IN	_	8	case	_	_
7	coronary	coronary	JJ	_	8	attr	_	_
8	insufficiency	insufficiency	NN	_	5	ppmod	_	_
9	in	in	IN	_	10	case	_	_
10	patients	patient	NNS	_	5	ppmod	_	_
11	with	with	IN	_	14	case	_	_
12	coronary	coronary	JJ	_	14	attr	_	_
13	artery	artery	NN	_	14	com	_	_
14	disease	disease	NN	_	10	ppmod	_	_
15	.	.	.	_	5	p	_	_

1	In	in	IN	_	3	case	_	_
2	one	#crd#	CD	_	3	num	_	_
3	survey	survey	NN	_	15	ppmod	_	_
4	,	,	,	_	15	p	_	_
5	2.3	0	CD	_	15	num	_	_
6	%	%	NN	_	5	meta	_	_
7	of	of	IN	_	8	case	_	_
8	patients	patient	NNS	_	5	ppmod	_	_
9	taking	take	VBG	_	8	acl	_	_
10	drug1	drug0	NN	_	9	obj	_	_
11	in	in	IN	_	12	case	_	_
12	combination	combination	NN	_	9	ppmod	_	_
13	with	with	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	experienced	experience	VBN	_	0	root	_	_
16	tremor	tremor	NN	_	15	obj	_	_
17	,	,	,	_	15	p	_	_
18	as	as	IN	_	19	mark	_	_
19	compared	compare	VBN	_	15	comp	_	_
20	to	to	TO	_	21	aux	_	_
21	0.7	0	CD	_	19	ppmod	_	_
22	%	%	NN	_	21	meta	_	_
23	reported	report	VBN	_	21	acl	_	_
24	to	to	TO	_	25	aux	_	_
25	occur	occur	VB	_	23	comp	_	_
26	with	with	IN	_	27	case	_	_
27	drug3	drug0	NN	_	25	ppmod	_	_
28	alone	alone	RB	_	27	adv	_	_
29	.	.	.	_	15	p	_	_

1	The	the	DT	_	2	det	_	_
2	contribution	contribution	NN	_	12	dep	_	_
3	of	of	IN	_	4	case	_	_
4	each	each	DT	_	2	ppmod	_	_
5	of	of	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	treatments	treatment	NNS	_	4	ppmod	_	_
8	to	to	TO	_	11	aux	_	_
9	this	this	DT	_	11	det	_	_
10	adverse	adverse	JJ	_	11	attr	_	_
11	reaction	reaction	NN	_	2	ppmod	_	_
12	is	be	VBZ	_	0	root	_	_
13	unknown	unknown	JJ	_	12	dep	_	_
14	but	but	CC	_	12	cc	_	_
15	the	the	DT	_	16	det	_	_
16	possibility	possibility	NN	_	23	dep	_	_
17	of	of	IN	_	20	case	_	_
18	a	a	DT	_	20	det	_	_
19	drug	drug	NN	_	20	com	_	_
20	interaction	interaction	NN	_	16	ppmod	_	_
21	cannot	cannot	MD	_	23	modal	_	_
22	be	be	VB	_	23	aux	_	_
23	excluded	exclude	VBN	_	12	conj	_	_
24	.	.	.	_	12	p	_	_

1	Drugs	drug	NNS	_	6	dep	_	_
2	possessing	possess	VBG	_	1	acl	_	_
3	beta-blocking	beta-blocking	JJ	_	4	attr	_	_
4	properties	property	NNS	_	2	obj	_	_
5	can	can	MD	_	6	modal	_	_
6	blunt	blunt	VB	_	0	root	_	_
7	the	the	DT	_	9	det	_	_
8	bronchodilator	bronchodilator	NN	_	9	com	_	_
9	effect	effect	NN	_	6	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	in	in	IN	_	13	case	_	_
13	patients	patient	NNS	_	9	ppmod	_	_
14	with	with	IN	_	15	case	_	_
15	bronchospasm	bronchospasm	NN	_	13	ppmod	_	_
16	;	;	:	_	6	p	_	_

1	therefore	therefore	RB	_	14	adv	_	_
2	,	,	,	_	14	p	_	_
3	doses	dose	NNS	_	14	dep	_	_
4	greater	great	JJR	_	3	attr	_	_
5	than	than	IN	_	9	case	_	_
6	the	the	DT	_	9	det	_	_
7	normal	normal	JJ	_	9	attr	_	_
8	antiasthmatic	antiasthmatic	JJ	_	9	attr	_	_
9	dose	dose	NN	_	4	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	may	may	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	required	require	VBN	_	0	root	_	_
15	.	.	.	_	14	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	shown	show	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	increase	increase	VB	_	4	comp	_	_
7	the	the	DT	_	8	det	_	_
8	bioavailability	bioavailability	NN	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	4	p	_	_

1	Since	since	IN	_	5	mark	_	_
2	this	this	DT	_	5	dep	_	_
3	could	could	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	explained	explain	VBN	_	24	advcl	_	_
6	either	either	CC	_	9	cc	_	_
7	by	by	IN	_	9	case	_	_
8	enhanced	enhance	VBN	_	9	attr	_	_
9	absorption	absorption	NN	_	5	ppmod	_	_
10	or	or	CC	_	9	cc	_	_
11	by	by	IN	_	13	case	_	_
12	an	an	DT	_	13	det	_	_
13	alteration	alteration	NN	_	9	conj	_	_
14	of	of	IN	_	16	case	_	_
15	hepatic	hepatic	JJ	_	16	attr	_	_
16	metabolism	metabolism	NN	_	13	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug1	drug0	NN	_	16	ppmod	_	_
19	,	,	,	_	24	p	_	_
20	special	special	JJ	_	21	attr	_	_
21	care	care	NN	_	24	dep	_	_
22	should	should	MD	_	24	modal	_	_
23	be	be	VB	_	24	aux	_	_
24	used	use	VBN	_	0	root	_	_
25	in	in	IN	_	26	case	_	_
26	establishing	establish	VBG	_	24	ppmod	_	_
27	the	the	DT	_	28	det	_	_
28	dose	dose	NN	_	26	obj	_	_
29	required	require	VBN	_	28	acl	_	_
30	for	for	IN	_	33	case	_	_
31	blood	blood	NN	_	33	com	_	_
32	pressure	pressure	NN	_	33	com	_	_
33	control	control	NN	_	29	ppmod	_	_
34	in	in	IN	_	36	case	_	_
35	such	such	JJ	_	36	attr	_	_
36	patients	patient	NNS	_	33	ppmod	_	_
37	.	.	.	_	24	p	_	_

1	Synergism	synergism	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	shown	show	VBN	_	0	root	_	_
5	between	between	IN	_	7	case	_	_
6	drug1	drug0	JJ	_	7	attr	_	_
7	anesthesia	anesthesia	NN	_	4	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	intravenously	intravenously	RB	_	10	adv	_	_
10	administered	administer	VBN	_	11	attr	_	_
11	drug2	drug0	NN	_	7	conj	_	_
12	.	.	.	_	4	p	_	_

1	During	during	IN	_	4	case	_	_
2	controlled	controlled	JJ	_	4	attr	_	_
3	hypotensive	hypotensive	JJ	_	4	attr	_	_
4	anesthesia	anesthesia	NN	_	25	ppmod	_	_
5	using	use	VBG	_	4	acl	_	_
6	drug1	drug0	NN	_	5	obj	_	_
7	in	in	IN	_	8	case	_	_
8	association	association	NN	_	5	ppmod	_	_
9	with	with	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	,	,	,	_	25	p	_	_
12	high	high	JJ	_	13	attr	_	_
13	concentrations	concentration	NNS	_	25	dep	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	3	0	CD	_	13	num	_	_
16	%	%	NN	_	15	meta	_	_
17	or	or	CC	_	15	cc	_	_
18	above	above	JJ	_	15	conj	_	_
19	)	-rrb-	-RRB-	_	15	p	_	_
20	of	of	IN	_	21	case	_	_
21	drug3	drug0	NN	_	13	ppmod	_	_
22	should	should	MD	_	25	modal	_	_
23	not	not	RB	_	25	neg	_	_
24	be	be	VB	_	25	aux	_	_
25	used	use	VBN	_	0	root	_	_
26	because	because	IN	_	33	mark	_	_
27	the	the	DT	_	28	det	_	_
28	degree	degree	NN	_	33	dep	_	_
29	of	of	IN	_	30	case	_	_
30	hypotension	hypotension	NN	_	28	ppmod	_	_
31	will	will	MD	_	33	modal	_	_
32	be	be	VB	_	33	aux	_	_
33	increased	increase	VBN	_	25	comp	_	_
34	and	and	CC	_	33	cc	_	_
35	because	because	IN	_	38	case	_	_
36	of	of	IN	_	38	case	_	_
37	the	the	DT	_	38	det	_	_
38	possibility	possibility	NN	_	33	conj	_	_
39	of	of	IN	_	42	case	_	_
40	a	a	DT	_	42	det	_	_
41	large	large	JJ	_	42	attr	_	_
42	reduction	reduction	NN	_	38	ppmod	_	_
43	in	in	IN	_	45	case	_	_
44	cardiac	cardiac	JJ	_	45	attr	_	_
45	output	output	NN	_	42	ppmod	_	_
46	and	and	CC	_	42	cc	_	_
47	an	an	DT	_	48	det	_	_
48	increase	increase	NN	_	42	conj	_	_
49	in	in	IN	_	52	case	_	_
50	central	central	JJ	_	52	attr	_	_
51	venous	venous	JJ	_	52	attr	_	_
52	pressure	pressure	NN	_	48	ppmod	_	_
53	.	.	.	_	25	p	_	_

1	The	the	DT	_	2	det	_	_
2	anesthesiologist	anesthesiologist	NN	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	informed	inform	VBN	_	0	root	_	_
6	when	when	WRB	_	10	adv	_	_
7	a	a	DT	_	8	det	_	_
8	patient	patient	NN	_	10	dep	_	_
9	is	be	VBZ	_	10	aux	_	_
10	receiving	receive	VBG	_	5	comp	_	_
11	drug1	drug0	NN	_	10	obj	_	_
12	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	blunts	blunt	VBZ	_	0	root	_	_
3	the	the	DT	_	5	det	_	_
4	reflex	reflex	NN	_	5	com	_	_
5	tachycardia	tachycardia	NN	_	2	obj	_	_
6	produced	produce	VBN	_	5	acl	_	_
7	by	by	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	without	without	IN	_	10	case	_	_
10	preventing	prevent	VBG	_	2	ppmod	_	_
11	its	its	PRP$	_	13	poss	_	_
12	hypotensive	hypotensive	JJ	_	13	attr	_	_
13	effect	effect	NN	_	10	obj	_	_
14	.	.	.	_	2	p	_	_

1	If	if	IN	_	4	mark	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	used	use	VBN	_	17	advcl	_	_
5	with	with	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	4	ppmod	_	_
9	with	with	IN	_	11	case	_	_
10	angina	angina	NN	_	11	com	_	_
11	pectoris	pectoris	NNS	_	8	ppmod	_	_
12	,	,	,	_	17	p	_	_
13	additional	additional	JJ	_	15	attr	_	_
14	antihypertensive	antihypertensive	JJ	_	15	attr	_	_
15	effects	effect	NNS	_	17	dep	_	_
16	may	may	MD	_	17	modal	_	_
17	occur	occur	VB	_	0	root	_	_
18	.	.	.	_	17	p	_	_

1	Care	care	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	taken	take	VBN	_	0	root	_	_
5	if	if	IN	_	8	mark	_	_
6	drug1	drug0	NN	_	8	dep	_	_
7	is	be	VBZ	_	8	aux	_	_
8	used	use	VBN	_	4	comp	_	_
9	concomitantly	concomitantly	RB	_	8	adv	_	_
10	with	with	IN	_	12	case	_	_
11	drug2	drug0	NN	_	12	com	_	_
12	s	s	NNS	_	8	ppmod	_	_
13	of	of	IN	_	16	case	_	_
14	the	the	DT	_	16	det	_	_
15	drug3	drug0	NN	_	16	com	_	_
16	type	type	NN	_	12	ppmod	_	_
17	.	.	.	_	4	p	_	_

1	Risk	risk	NN	_	23	dep	_	_
2	of	of	IN	_	4	case	_	_
3	Anaphylactic	anaphylactic	JJ	_	4	attr	_	_
4	Reaction	reaction	NN	_	1	ppmod	_	_
5	While	while	IN	_	6	mark	_	_
6	taking	take	VBG	_	23	advcl	_	_
7	drug1	drug0	NN	_	6	obj	_	_
8	,	,	,	_	23	p	_	_
9	patients	patient	NNS	_	23	dep	_	_
10	with	with	IN	_	12	case	_	_
11	a	a	DT	_	12	det	_	_
12	history	history	NN	_	9	ppmod	_	_
13	of	of	IN	_	16	case	_	_
14	severe	severe	JJ	_	16	attr	_	_
15	anaphylactic	anaphylactic	JJ	_	16	attr	_	_
16	reaction	reaction	NN	_	12	ppmod	_	_
17	to	to	TO	_	19	aux	_	_
18	a	a	DT	_	19	det	_	_
19	variety	variety	NN	_	16	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	allergens	allergen	NNS	_	19	ppmod	_	_
22	may	may	MD	_	23	modal	_	_
23	be	be	VB	_	0	root	_	_
24	more	more	RBR	_	25	adv	_	_
25	reactive	reactive	JJ	_	23	dep	_	_
26	to	to	TO	_	28	aux	_	_
27	repeated	repeated	JJ	_	28	attr	_	_
28	challenge	challenge	NN	_	25	ppmod	_	_
29	,	,	,	_	28	p	_	_
30	either	either	CC	_	31	cc	_	_
31	accidental	accidental	JJ	_	28	dep	_	_
32	,	,	,	_	31	p	_	_
33	diagnostic	diagnostic	JJ	_	31	conj	_	_
34	,	,	,	_	33	p	_	_
35	or	or	CC	_	33	cc	_	_
36	therapeutic	therapeutic	JJ	_	31	conj	_	_
37	.	.	.	_	23	p	_	_

1	Such	such	JJ	_	2	attr	_	_
2	patients	patient	NNS	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	be	be	VB	_	0	root	_	_
5	unresponsive	unresponsive	JJ	_	4	dep	_	_
6	to	to	TO	_	9	aux	_	_
7	the	the	DT	_	9	det	_	_
8	usual	usual	JJ	_	9	attr	_	_
9	doses	dose	NNS	_	5	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	used	use	VBN	_	9	acl	_	_
13	to	to	TO	_	14	aux	_	_
14	treat	treat	VB	_	12	comp	_	_
15	allergic	allergic	JJ	_	16	attr	_	_
16	reaction	reaction	NN	_	14	obj	_	_
17	.	.	.	_	4	p	_	_

1	Drug/Laboratory	drug/laboratory	NN	_	3	com	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	0	root	_	_
4	The	the	DT	_	5	det	_	_
5	presence	presence	NN	_	13	dep	_	_
6	of	of	IN	_	8	case	_	_
7	labetalol	labetalol	NN	_	8	com	_	_
8	metabolites	metabolite	NNS	_	5	ppmod	_	_
9	in	in	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	urine	urine	NN	_	5	ppmod	_	_
12	may	may	MD	_	13	modal	_	_
13	result	result	VB	_	3	acl	_	_
14	in	in	IN	_	17	case	_	_
15	falsely	falsely	RB	_	16	adv	_	_
16	elevated	elevated	JJ	_	17	attr	_	_
17	levels	level	NNS	_	13	ppmod	_	_
18	of	of	IN	_	20	case	_	_
19	urinary	urinary	JJ	_	20	attr	_	_
20	catecholamines	catecholamine	NNS	_	17	ppmod	_	_
21	,	,	,	_	17	p	_	_
22	metanephrine	metanephrine	NN	_	17	appo	_	_
23	,	,	,	_	22	p	_	_
24	normetanephrine	normetanephrine	NN	_	22	conj	_	_
25	and	and	CC	_	24	cc	_	_
26	vanillylmandelic	vanillylmandelic	JJ	_	27	attr	_	_
27	acid	acid	NN	_	22	conj	_	_
28	when	when	WRB	_	29	adv	_	_
29	measured	measure	VBN	_	13	comp	_	_
30	by	by	IN	_	34	case	_	_
31	fluorimetric	fluorimetric	JJ	_	34	attr	_	_
32	or	or	CC	_	31	cc	_	_
33	photometric	photometric	JJ	_	31	conj	_	_
34	methods	method	NNS	_	29	ppmod	_	_
35	.	.	.	_	3	p	_	_

1	In	in	IN	_	3	case	_	_
2	screening	screening	JJ	_	3	attr	_	_
3	patients	patient	NNS	_	40	ppmod	_	_
4	suspected	suspect	VBN	_	3	acl	_	_
5	of	of	IN	_	6	case	_	_
6	having	have	VBG	_	4	ppmod	_	_
7	a	a	DT	_	8	det	_	_
8	pheochromocytoma	pheochromocytoma	NN	_	6	obj	_	_
9	and	and	CC	_	6	cc	_	_
10	being	be	VBG	_	11	aux	_	_
11	treated	treat	VBN	_	6	conj	_	_
12	with	with	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	,	,	,	_	40	p	_	_
15	a	a	DT	_	17	det	_	_
16	specific	specific	JJ	_	17	attr	_	_
17	method	method	NN	_	40	dep	_	_
18	,	,	,	_	17	p	_	_
19	such	such	JJ	_	17	attr	_	_
20	as	as	IN	_	26	case	_	_
21	a	a	DT	_	26	det	_	_
22	high	high	JJ	_	26	attr	_	_
23	performance	performance	NN	_	26	attr	_	_
24	liquid	liquid	JJ	_	26	attr	_	_
25	chromatographic	chromatographic	JJ	_	26	attr	_	_
26	assay	assay	NN	_	19	ppmod	_	_
27	with	with	IN	_	30	case	_	_
28	solid	solid	JJ	_	30	attr	_	_
29	phase	phase	NN	_	30	com	_	_
30	extraction	extraction	NN	_	26	ppmod	_	_
31	(	-lrb-	-LRB-	_	35	p	_	_
32	e.g.	e.g.	FW	_	35	ppmod	_	_
33	,	,	,	_	35	p	_	_
34	J	j	NNP	_	35	com	_	_
35	Chromatogr	chromatogr	NNP	_	30	prn	_	_
36	385:241,1987	0	CD	_	35	num	_	_
37	)	-rrb-	-RRB-	_	35	p	_	_
38	should	should	MD	_	40	modal	_	_
39	be	be	VB	_	40	aux	_	_
40	employed	employ	VBN	_	0	root	_	_
41	in	in	IN	_	42	case	_	_
42	determining	determine	VBG	_	40	ppmod	_	_
43	levels	level	NNS	_	42	obj	_	_
44	of	of	IN	_	45	case	_	_
45	catecholamines	catecholamine	NNS	_	43	ppmod	_	_
46	.	.	.	_	40	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	has	have	VBZ	_	5	aux	_	_
3	also	also	RB	_	5	adv	_	_
4	been	be	VBN	_	5	aux	_	_
5	reported	report	VBN	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	produce	produce	VB	_	5	comp	_	_
8	a	a	DT	_	11	det	_	_
9	false	false	JJ	_	11	attr	_	_
10	positive	positive	JJ	_	11	attr	_	_
11	test	test	NN	_	7	obj	_	_
12	for	for	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	when	when	WRB	_	15	adv	_	_
15	screening	screen	VBG	_	7	comp	_	_
16	urine	urine	NN	_	15	obj	_	_
17	for	for	IN	_	19	case	_	_
18	the	the	DT	_	19	det	_	_
19	presence	presence	NN	_	15	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	drugs	drug	NNS	_	19	ppmod	_	_
22	using	use	VBG	_	21	acl	_	_
23	the	the	DT	_	27	det	_	_
24	commercially	commercially	RB	_	25	adv	_	_
25	available	available	JJ	_	27	attr	_	_
26	assay	assay	NN	_	27	com	_	_
27	methods	method	NNS	_	22	obj	_	_
28	Toxi-Lab	toxi-lab	NN	_	29	com	_	_
29	A	a	NN	_	27	attr	_	_
30	(	-lrb-	-LRB-	_	33	p	_	_
31	thin-layer	thin-layer	NN	_	33	attr	_	_
32	chromatographic	chromatographic	JJ	_	33	attr	_	_
33	assay	assay	NN	_	29	prn	_	_
34	)	-rrb-	-RRB-	_	33	p	_	_
35	and	and	CC	_	29	cc	_	_
36	Emit-d.a.u.	emit-d.a.u.	NN	_	29	conj	_	_
37	(	-lrb-	-LRB-	_	39	p	_	_
38	radioenzymatic	radioenzymatic	JJ	_	39	attr	_	_
39	assay	assay	NN	_	36	prn	_	_
40	)	-rrb-	-RRB-	_	39	p	_	_
41	.	.	.	_	5	p	_	_

1	When	when	WRB	_	7	adv	_	_
2	patients	patient	NNS	_	7	dep	_	_
3	being	be	VBG	_	4	aux	_	_
4	treated	treat	VBN	_	2	acl	_	_
5	with	with	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	have	have	VBP	_	14	advcl	_	_
8	a	a	DT	_	11	det	_	_
9	positive	positive	JJ	_	11	attr	_	_
10	urine	urine	NN	_	11	com	_	_
11	test	test	NN	_	7	obj	_	_
12	for	for	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	using	use	VBG	_	20	advcl	_	_
15	these	these	DT	_	16	det	_	_
16	techniques	technique	NNS	_	14	obj	_	_
17	confirmation	confirmation	NN	_	20	dep	_	_
18	should	should	MD	_	20	modal	_	_
19	be	be	VB	_	20	aux	_	_
20	made	make	VBN	_	0	root	_	_
21	by	by	IN	_	22	case	_	_
22	using	use	VBG	_	20	ppmod	_	_
23	more	more	RBR	_	24	adv	_	_
24	specific	specific	JJ	_	25	attr	_	_
25	methods	method	NNS	_	22	obj	_	_
26	such	such	JJ	_	32	adv	_	_
27	as	as	IN	_	32	case	_	_
28	a	a	DT	_	32	det	_	_
29	gas	gas	NN	_	32	com	_	_
30	chromatographic-mass	chromatographic-mass	NN	_	32	com	_	_
31	spectrometer	spectrometer	NN	_	32	com	_	_
32	technique	technique	NN	_	25	ppmod	_	_
33	.	.	.	_	20	p	_	_

1	The	the	DT	_	4	det	_	_
2	following	following	JJ	_	4	attr	_	_
3	drug	drug	NN	_	4	com	_	_
4	interactions	interaction	NNS	_	6	dep	_	_
5	were	be	VBD	_	6	aux	_	_
6	observed	observe	VBN	_	0	root	_	_
7	in	in	IN	_	9	case	_	_
8	some	some	DT	_	9	det	_	_
9	patients	patient	NNS	_	6	ppmod	_	_
10	undergoing	undergo	VBG	_	9	acl	_	_
11	treatment	treatment	NN	_	10	obj	_	_
12	with	with	IN	_	14	case	_	_
13	oral	oral	JJ	_	14	attr	_	_
14	drug1	drug0	NN	_	11	ppmod	_	_
15	.	.	.	_	6	p	_	_

1	Although	although	IN	_	9	mark	_	_
2	the	the	DT	_	3	det	_	_
3	pattern	pattern	NN	_	9	dep	_	_
4	of	of	IN	_	5	case	_	_
5	use	use	NN	_	3	ppmod	_	_
6	for	for	IN	_	8	case	_	_
7	oral	oral	JJ	_	8	attr	_	_
8	drug1	drug0	NN	_	3	ppmod	_	_
9	includes	include	VBZ	_	23	advcl	_	_
10	longer	long	JJR	_	12	attr	_	_
11	term	term	NN	_	12	com	_	_
12	therapy	therapy	NN	_	9	obj	_	_
13	,	,	,	_	12	p	_	_
14	particularly	particularly	RB	_	12	adv	_	_
15	for	for	IN	_	16	case	_	_
16	gout	gout	NN	_	12	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	renal	renal	JJ	_	19	attr	_	_
19	calculi	calculi	NN	_	16	conj	_	_
20	,	,	,	_	23	p	_	_
21	the	the	DT	_	23	dep	_	_
22	experience	experience	VBP	_	23	aux	_	_
23	gained	gain	VBN	_	0	root	_	_
24	may	may	MD	_	25	modal	_	_
25	be	be	VB	_	23	comp	_	_
26	relevant	relevant	JJ	_	25	dep	_	_
27	.	.	.	_	23	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	/	/	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	:	:	:	_	1	p	_	_
5	drug3	drug0	NN	_	1	appo	_	_
6	inhibits	inhibit	VBZ	_	0	root	_	_
7	the	the	DT	_	9	det	_	_
8	enzymatic	enzymatic	JJ	_	9	attr	_	_
9	oxidation	oxidation	NN	_	6	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug4	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	drug5	drug0	NN	_	11	conj	_	_
14	to	to	TO	_	15	aux	_	_
15	drug6	drug0	NN	_	9	ppmod	_	_
16	.	.	.	_	6	p	_	_

1	This	this	DT	_	2	det	_	_
2	oxidation	oxidation	NN	_	11	dep	_	_
3	,	,	,	_	2	p	_	_
4	which	which	WDT	_	6	dep	_	_
5	is	be	VBZ	_	6	aux	_	_
6	catalyzed	catalyze	VBN	_	2	relcl	_	_
7	by	by	IN	_	9	case	_	_
8	xanthine	xanthine	NN	_	9	com	_	_
9	oxidase	oxidase	NN	_	6	ppmod	_	_
10	,	,	,	_	2	p	_	_
11	inactivates	inactivate	VBZ	_	0	root	_	_
12	drug1	drug0	NN	_	11	obj	_	_
13	.	.	.	_	11	p	_	_

1	In	in	IN	_	2	case	_	_
2	patients	patient	NNS	_	25	ppmod	_	_
3	receiving	receive	VBG	_	2	acl	_	_
4	drug1	drug0	NN	_	3	obj	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	drug2	drug0	NN	_	4	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	or	or	CC	_	4	cc	_	_
9	drug3	drug0	NN	_	4	conj	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	drug4	drug0	NN	_	9	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	,	,	,	_	25	p	_	_
14	the	the	DT	_	16	det	_	_
15	concomitant	concomitant	JJ	_	16	attr	_	_
16	administration	administration	NN	_	25	dep	_	_
17	of	of	IN	_	19	case	_	_
18	300-600	0	CD	_	19	num	_	_
19	mg	mg	NN	_	16	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	drug5	drug0	NN	_	19	ppmod	_	_
22	per	per	IN	_	23	case	_	_
23	day	day	NN	_	19	ppmod	_	_
24	will	will	MD	_	25	modal	_	_
25	require	require	VB	_	0	root	_	_
26	a	a	DT	_	27	det	_	_
27	reduction	reduction	NN	_	25	obj	_	_
28	in	in	IN	_	29	case	_	_
29	dose	dose	NN	_	27	ppmod	_	_
30	to	to	TO	_	34	aux	_	_
31	approximately	approximately	RB	_	34	adv	_	_
32	one-third	one-third	CD	_	34	num	_	_
33	to	to	TO	_	34	attr	_	_
34	one-fourth	one-fourth	CD	_	27	ppmod	_	_
35	of	of	IN	_	38	case	_	_
36	the	the	DT	_	38	det	_	_
37	usual	usual	JJ	_	38	attr	_	_
38	dose	dose	NN	_	34	ppmod	_	_
39	of	of	IN	_	40	case	_	_
40	drug6	drug0	NN	_	38	ppmod	_	_
41	or	or	CC	_	40	cc	_	_
42	drug7	drug0	NN	_	40	conj	_	_
43	.	.	.	_	25	p	_	_

1	Subsequent	subsequent	JJ	_	2	attr	_	_
2	adjustment	adjustment	NN	_	11	dep	_	_
3	of	of	IN	_	4	case	_	_
4	doses	dose	NNS	_	2	ppmod	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	or	or	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	made	make	VBN	_	0	root	_	_
12	on	on	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	basis	basis	NN	_	11	ppmod	_	_
15	of	of	IN	_	17	case	_	_
16	therapeutic	therapeutic	JJ	_	17	attr	_	_
17	response	response	NN	_	14	ppmod	_	_
18	and	and	CC	_	14	cc	_	_
19	the	the	DT	_	20	det	_	_
20	appearance	appearance	NN	_	14	conj	_	_
21	of	of	IN	_	23	case	_	_
22	toxic	toxic	JJ	_	23	attr	_	_
23	effects	effect	NNS	_	20	ppmod	_	_
24	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	It	it	PRP	_	6	dep	_	_
4	has	have	VBZ	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	reported	report	VBN	_	1	acl	_	_
7	that	that	IN	_	9	mark	_	_
8	drug2	drug0	NN	_	9	dep	_	_
9	prolongs	prolong	VBZ	_	6	comp	_	_
10	the	the	DT	_	11	det	_	_
11	half-life	half-life	NN	_	9	obj	_	_
12	of	of	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	drug3	drug0	NN	_	11	ppmod	_	_
15	,	,	,	_	14	p	_	_
16	drug4	drug0	NN	_	14	appo	_	_
17	.	.	.	_	1	p	_	_

1	The	the	DT	_	3	det	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	basis	basis	NN	_	11	dep	_	_
4	of	of	IN	_	7	case	_	_
5	this	this	DT	_	7	det	_	_
6	drug	drug	NN	_	7	com	_	_
7	interaction	interaction	NN	_	3	ppmod	_	_
8	has	have	VBZ	_	11	aux	_	_
9	not	not	RB	_	11	neg	_	_
10	been	be	VBN	_	11	aux	_	_
11	established	establish	VBN	_	0	root	_	_
12	but	but	CC	_	11	cc	_	_
13	should	should	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	noted	note	VBN	_	11	conj	_	_
16	when	when	WRB	_	19	adv	_	_
17	drug1	drug0	NN	_	19	dep	_	_
18	is	be	VBZ	_	19	aux	_	_
19	given	give	VBN	_	15	comp	_	_
20	to	to	TO	_	21	aux	_	_
21	patients	patient	NNS	_	19	ppmod	_	_
22	already	already	RB	_	25	adv	_	_
23	on	on	IN	_	25	case	_	_
24	drug2	drug0	NN	_	25	com	_	_
25	therapy	therapy	NN	_	19	ppmod	_	_
26	.	.	.	_	11	p	_	_

1	Consequently	consequently	RB	_	7	adv	_	_
2	,	,	,	_	7	p	_	_
3	prothrombin	prothrombin	NN	_	4	com	_	_
4	time	time	NN	_	7	dep	_	_
5	should	should	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	reassessed	reassess	VBN	_	0	root	_	_
8	periodically	periodically	RB	_	7	adv	_	_
9	in	in	IN	_	10	case	_	_
10	patients	patient	NNS	_	7	ppmod	_	_
11	receiving	receive	VBG	_	10	acl	_	_
12	both	both	DT	_	13	det	_	_
13	drugs	drug	NNS	_	11	obj	_	_
14	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Since	since	IN	_	8	mark	_	_
4	the	the	DT	_	5	det	_	_
5	excretion	excretion	NN	_	8	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	is	be	VBZ	_	24	advcl	_	_
9	similar	similar	JJ	_	8	dep	_	_
10	to	to	TO	_	11	aux	_	_
11	that	that	DT	_	9	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	urate	urate	NN	_	11	ppmod	_	_
14	,	,	,	_	24	p	_	_
15	drug3	drug0	NN	_	24	dep	_	_
16	,	,	,	_	15	p	_	_
17	which	which	WDT	_	18	dep	_	_
18	increase	increase	VBP	_	15	relcl	_	_
19	the	the	DT	_	20	det	_	_
20	excretion	excretion	NN	_	18	obj	_	_
21	of	of	IN	_	22	case	_	_
22	urate	urate	NN	_	20	ppmod	_	_
23	,	,	,	_	15	p	_	_
24	are	be	VBP	_	1	acl	_	_
25	also	also	RB	_	24	adv	_	_
26	likely	likely	JJ	_	24	dep	_	_
27	to	to	TO	_	28	aux	_	_
28	increase	increase	VB	_	26	comp	_	_
29	the	the	DT	_	30	det	_	_
30	excretion	excretion	NN	_	28	obj	_	_
31	of	of	IN	_	32	case	_	_
32	drug4	drug0	NN	_	30	ppmod	_	_
33	and	and	CC	_	28	cc	_	_
34	thus	thus	RB	_	35	adv	_	_
35	lower	low	JJR	_	28	conj	_	_
36	the	the	DT	_	37	det	_	_
37	degree	degree	NN	_	35	obj	_	_
38	of	of	IN	_	39	case	_	_
39	inhibition	inhibition	NN	_	37	ppmod	_	_
40	of	of	IN	_	42	case	_	_
41	xanthine	xanthine	NN	_	42	com	_	_
42	oxidase	oxidase	NN	_	39	ppmod	_	_
43	.	.	.	_	1	p	_	_

1	The	the	DT	_	3	det	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	administration	administration	NN	_	10	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	has	have	VBZ	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	associated	associate	VBN	_	0	root	_	_
11	with	with	IN	_	13	case	_	_
12	a	a	DT	_	13	det	_	_
13	decrease	decrease	NN	_	10	ppmod	_	_
14	in	in	IN	_	16	case	_	_
15	the	the	DT	_	16	det	_	_
16	excretion	excretion	NN	_	13	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	oxypurines	oxypurines	NNS	_	16	ppmod	_	_
19	(	-lrb-	-LRB-	_	20	p	_	_
20	hypoxanthine	hypoxanthine	NN	_	18	prn	_	_
21	and	and	CC	_	20	cc	_	_
22	xanthine	xanthine	NN	_	20	conj	_	_
23	)	-rrb-	-RRB-	_	20	p	_	_
24	and	and	CC	_	13	cc	_	_
25	an	an	DT	_	26	det	_	_
26	increase	increase	NN	_	13	conj	_	_
27	in	in	IN	_	31	case	_	_
28	urinary	urinary	JJ	_	31	attr	_	_
29	uric	uric	JJ	_	31	attr	_	_
30	acid	acid	NN	_	31	com	_	_
31	excretion	excretion	NN	_	26	ppmod	_	_
32	compared	compare	VBN	_	34	adv	_	_
33	with	with	IN	_	34	case	_	_
34	that	that	DT	_	31	ppmod	_	_
35	observed	observe	VBN	_	34	acl	_	_
36	with	with	IN	_	37	case	_	_
37	drug3	drug0	NN	_	35	ppmod	_	_
38	alone	alone	RB	_	37	adv	_	_
39	.	.	.	_	10	p	_	_

1	Although	although	IN	_	8	mark	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	evidence	evidence	NN	_	8	dep	_	_
4	to	to	TO	_	5	aux	_	_
5	date	date	NN	_	3	ppmod	_	_
6	has	have	VBZ	_	8	aux	_	_
7	not	not	RB	_	8	neg	_	_
8	demonstrated	demonstrate	VBN	_	29	advcl	_	_
9	renal	renal	JJ	_	10	attr	_	_
10	precipitation	precipitation	NN	_	8	obj	_	_
11	of	of	IN	_	12	case	_	_
12	oxypurines	oxypurines	NNS	_	10	ppmod	_	_
13	in	in	IN	_	14	case	_	_
14	patients	patient	NNS	_	10	ppmod	_	_
15	either	either	CC	_	14	cc	_	_
16	on	on	IN	_	17	case	_	_
17	drug1	drug0	NN	_	14	conj	_	_
18	alone	alone	RB	_	10	adv	_	_
19	or	or	CC	_	18	cc	_	_
20	in	in	IN	_	21	case	_	_
21	combination	combination	NN	_	18	conj	_	_
22	with	with	IN	_	23	case	_	_
23	drug2	drug0	NN	_	21	ppmod	_	_
24	,	,	,	_	29	p	_	_
25	the	the	DT	_	26	det	_	_
26	possibility	possibility	NN	_	29	dep	_	_
27	should	should	MD	_	29	modal	_	_
28	be	be	VB	_	29	aux	_	_
29	kept	keep	VBN	_	0	root	_	_
30	in	in	IN	_	31	case	_	_
31	mind	mind	NN	_	29	ppmod	_	_
32	.	.	.	_	29	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	reports	report	NNS	_	26	dep	_	_
5	that	that	IN	_	14	mark	_	_
6	the	the	DT	_	8	det	_	_
7	concomitant	concomitant	JJ	_	8	attr	_	_
8	use	use	NN	_	14	dep	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug3	drug0	NN	_	10	conj	_	_
13	may	may	MD	_	14	modal	_	_
14	contribute	contribute	VB	_	4	acl	_	_
15	to	to	TO	_	17	aux	_	_
16	the	the	DT	_	17	det	_	_
17	enhancement	enhancement	NN	_	14	ppmod	_	_
18	of	of	IN	_	20	case	_	_
19	drug4	drug0	NN	_	20	com	_	_
20	toxicity	toxicity	NN	_	17	ppmod	_	_
21	in	in	IN	_	23	case	_	_
22	some	some	DT	_	23	det	_	_
23	patients	patient	NNS	_	17	ppmod	_	_
24	have	have	VBP	_	26	aux	_	_
25	been	be	VBN	_	26	aux	_	_
26	reviewed	review	VBN	_	1	acl	_	_
27	in	in	IN	_	29	case	_	_
28	an	an	DT	_	29	det	_	_
29	attempt	attempt	NN	_	26	ppmod	_	_
30	to	to	TO	_	31	aux	_	_
31	establish	establish	VB	_	29	acl	_	_
32	a	a	DT	_	34	det	_	_
33	cause-and-effect	cause-and-effect	JJ	_	34	attr	_	_
34	relationship	relationship	NN	_	31	obj	_	_
35	and	and	CC	_	34	cc	_	_
36	a	a	DT	_	37	det	_	_
37	mechanism	mechanism	NN	_	34	conj	_	_
38	of	of	IN	_	39	case	_	_
39	causation	causation	NN	_	37	ppmod	_	_
40	.	.	.	_	1	p	_	_

1	Review	review	NN	_	6	dep	_	_
2	of	of	IN	_	5	case	_	_
3	these	these	DT	_	5	det	_	_
4	case	case	NN	_	5	com	_	_
5	reports	report	NNS	_	1	ppmod	_	_
6	indicates	indicate	VBZ	_	0	root	_	_
7	that	that	IN	_	12	mark	_	_
8	the	the	DT	_	9	det	_	_
9	patients	patient	NNS	_	12	dep	_	_
10	were	be	VBD	_	12	aux	_	_
11	mainly	mainly	RB	_	12	adv	_	_
12	receiving	receive	VBG	_	6	advcl	_	_
13	drug1	drug0	NN	_	12	obj	_	_
14	for	for	IN	_	15	case	_	_
15	hypertension	hypertension	NN	_	13	ppmod	_	_
16	and	and	CC	_	12	cc	_	_
17	that	that	IN	_	32	mark	_	_
18	tests	test	NNS	_	32	dep	_	_
19	to	to	TO	_	20	aux	_	_
20	rule	rule	NN	_	18	ppmod	_	_
21	out	out	IN	_	24	case	_	_
22	decreased	decrease	VBN	_	24	attr	_	_
23	renal	renal	JJ	_	24	attr	_	_
24	function	function	NN	_	20	ppmod	_	_
25	secondary	secondary	JJ	_	24	attr	_	_
26	to	to	TO	_	28	aux	_	_
27	hypertensive	hypertensive	NN	_	28	com	_	_
28	nephropathy	nephropathy	NN	_	25	ppmod	_	_
29	were	be	VBD	_	32	aux	_	_
30	not	not	RB	_	32	neg	_	_
31	often	often	RB	_	32	adv	_	_
32	performed	performed	VBN	_	12	conj	_	_
33	.	.	.	_	6	p	_	_

1	In	in	IN	_	3	case	_	_
2	those	those	DT	_	3	det	_	_
3	patients	patient	NNS	_	23	ppmod	_	_
4	in	in	IN	_	5	case	_	_
5	whom	whom	WP	_	9	ppmod	_	_
6	renal	renal	JJ	_	7	attr	_	_
7	insufficiency	insufficiency	NN	_	9	dep	_	_
8	was	be	VBD	_	9	aux	_	_
9	documented	document	VBN	_	3	relcl	_	_
10	,	,	,	_	23	p	_	_
11	however	however	RB	_	23	adv	_	_
12	,	,	,	_	23	p	_	_
13	the	the	DT	_	14	det	_	_
14	recommendation	recommendation	NN	_	23	dep	_	_
15	to	to	TO	_	16	aux	_	_
16	lower	lower	VB	_	14	acl	_	_
17	the	the	DT	_	18	det	_	_
18	dose	dose	NN	_	16	obj	_	_
19	of	of	IN	_	20	case	_	_
20	drug1	drug0	NN	_	18	ppmod	_	_
21	was	be	VBD	_	23	aux	_	_
22	not	not	RB	_	23	neg	_	_
23	followed	followed	VBN	_	0	root	_	_
24	.	.	.	_	23	p	_	_

1	Although	although	IN	_	12	mark	_	_
2	a	a	DT	_	4	det	_	_
3	causal	causal	JJ	_	4	attr	_	_
4	mechanism	mechanism	NN	_	12	dep	_	_
5	and	and	CC	_	4	cc	_	_
6	a	a	DT	_	8	det	_	_
7	cause-and-effect	cause-and-effect	JJ	_	8	attr	_	_
8	relationship	relationship	NN	_	4	conj	_	_
9	have	have	VBP	_	12	aux	_	_
10	not	not	RB	_	12	neg	_	_
11	been	be	VBN	_	12	aux	_	_
12	established	establish	VBN	_	16	advcl	_	_
13	,	,	,	_	16	p	_	_
14	current	current	JJ	_	15	attr	_	_
15	evidence	evidence	NN	_	16	dep	_	_
16	suggests	suggest	VBZ	_	0	root	_	_
17	that	that	IN	_	22	mark	_	_
18	renal	renal	JJ	_	19	attr	_	_
19	function	function	NN	_	22	dep	_	_
20	should	should	MD	_	22	modal	_	_
21	be	be	VB	_	22	aux	_	_
22	monitored	monitor	VBN	_	16	comp	_	_
23	in	in	IN	_	24	case	_	_
24	patients	patient	NNS	_	22	ppmod	_	_
25	on	on	IN	_	26	case	_	_
26	drug1	drug0	NN	_	24	ppmod	_	_
27	and	and	CC	_	26	cc	_	_
28	drug2	drug0	NN	_	26	conj	_	_
29	even	even	RB	_	32	adv	_	_
30	in	in	IN	_	32	case	_	_
31	the	the	DT	_	32	det	_	_
32	absence	absence	NN	_	22	ppmod	_	_
33	of	of	IN	_	35	case	_	_
34	renal	renal	JJ	_	35	attr	_	_
35	failure	failure	NN	_	32	ppmod	_	_
36	,	,	,	_	22	p	_	_
37	and	and	CC	_	22	cc	_	_
38	dosage	dosage	NN	_	39	com	_	_
39	levels	level	NNS	_	45	dep	_	_
40	should	should	MD	_	45	modal	_	_
41	be	be	VB	_	45	aux	_	_
42	even	even	RB	_	44	com	_	_
43	more	more	RBR	_	44	com	_	_
44	conservatively	conservatively	RB	_	45	adv	_	_
45	adjusted	adjust	VBN	_	22	conj	_	_
46	in	in	IN	_	48	case	_	_
47	those	those	DT	_	48	det	_	_
48	patients	patient	NNS	_	45	ppmod	_	_
49	on	on	IN	_	52	case	_	_
50	such	such	JJ	_	52	attr	_	_
51	combined	combined	JJ	_	52	attr	_	_
52	therapy	therapy	NN	_	48	ppmod	_	_
53	if	if	IN	_	58	mark	_	_
54	diminished	diminish	VBN	_	56	attr	_	_
55	renal	renal	JJ	_	56	attr	_	_
56	function	function	NN	_	58	dep	_	_
57	is	be	VBZ	_	58	aux	_	_
58	detected	detect	VBN	_	45	comp	_	_
59	.	.	.	_	16	p	_	_
60	.	.	.	_	16	p	_	_

1	drug1	drug0	NN	_	15	dep	_	_
2	/	/	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	:	:	:	_	1	p	_	_
5	An	an	DT	_	6	det	_	_
6	increase	increase	NN	_	1	appo	_	_
7	in	in	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	frequency	frequency	NN	_	6	ppmod	_	_
10	of	of	IN	_	12	case	_	_
11	skin	skin	NN	_	12	com	_	_
12	rash	rash	NN	_	9	ppmod	_	_
13	has	have	VBZ	_	15	aux	_	_
14	been	be	VBN	_	15	aux	_	_
15	reported	report	VBN	_	0	root	_	_
16	among	among	IN	_	17	case	_	_
17	patients	patient	NNS	_	15	ppmod	_	_
18	receiving	receive	VBG	_	17	acl	_	_
19	drug3	drug0	NN	_	18	obj	_	_
20	or	or	CC	_	19	cc	_	_
21	drug4	drug0	NN	_	19	conj	_	_
22	concurrently	concurrently	RB	_	24	adv	_	_
23	with	with	IN	_	24	case	_	_
24	drug5	drug0	NN	_	19	ppmod	_	_
25	compared	compare	VBN	_	27	adv	_	_
26	to	to	TO	_	27	aux	_	_
27	patients	patient	NNS	_	19	ppmod	_	_
28	who	who	WP	_	31	dep	_	_
29	are	be	VBP	_	31	aux	_	_
30	not	not	RB	_	31	neg	_	_
31	receiving	receive	VBG	_	27	relcl	_	_
32	both	both	DT	_	33	det	_	_
33	drugs	drug	NNS	_	31	obj	_	_
34	.	.	.	_	15	p	_	_

1	The	the	DT	_	2	det	_	_
2	cause	cause	NN	_	10	dep	_	_
3	of	of	IN	_	6	case	_	_
4	the	the	DT	_	6	det	_	_
5	reported	report	VBN	_	6	attr	_	_
6	association	association	NN	_	2	ppmod	_	_
7	has	have	VBZ	_	10	aux	_	_
8	not	not	RB	_	10	neg	_	_
9	been	be	VBN	_	10	aux	_	_
10	established	establish	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Enhanced	enhance	VBN	_	5	attr	_	_
4	bone	bone	NN	_	5	com	_	_
5	marrow	marrow	NN	_	6	com	_	_
6	suppression	suppression	NN	_	14	dep	_	_
7	by	by	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	other	other	JJ	_	11	attr	_	_
11	drug3	drug0	NNS	_	8	conj	_	_
12	has	have	VBZ	_	14	aux	_	_
13	been	be	VBN	_	14	aux	_	_
14	reported	report	VBN	_	1	acl	_	_
15	among	among	IN	_	16	case	_	_
16	patients	patient	NNS	_	14	ppmod	_	_
17	with	with	IN	_	19	case	_	_
18	neoplastic	neoplastic	JJ	_	19	attr	_	_
19	disease	disease	NN	_	16	ppmod	_	_
20	,	,	,	_	14	p	_	_
21	except	except	IN	_	22	case	_	_
22	leukemia	leukemia	NN	_	14	ppmod	_	_
23	,	,	,	_	14	p	_	_
24	in	in	IN	_	26	case	_	_
25	the	the	DT	_	26	det	_	_
26	presence	presence	NN	_	14	ppmod	_	_
27	of	of	IN	_	28	case	_	_
28	drug4	drug0	NN	_	26	ppmod	_	_
29	.	.	.	_	1	p	_	_

1	However	however	RB	_	18	adv	_	_
2	,	,	,	_	18	p	_	_
3	in	in	IN	_	6	case	_	_
4	a	a	DT	_	6	det	_	_
5	well-controlled	well-controlled	JJ	_	6	attr	_	_
6	study	study	NN	_	18	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	patients	patient	NNS	_	6	ppmod	_	_
9	with	with	IN	_	10	case	_	_
10	lymphoma	lymphoma	NN	_	8	ppmod	_	_
11	on	on	IN	_	13	case	_	_
12	combination	combination	NN	_	13	com	_	_
13	therapy	therapy	NN	_	6	ppmod	_	_
14	,	,	,	_	18	p	_	_
15	drug1	drug0	NN	_	18	dep	_	_
16	did	do	VBD	_	18	aux	_	_
17	not	not	RB	_	18	neg	_	_
18	increase	increase	VB	_	0	root	_	_
19	the	the	DT	_	21	det	_	_
20	marrow	marrow	NN	_	21	com	_	_
21	toxicity	toxicity	NN	_	18	obj	_	_
22	of	of	IN	_	23	case	_	_
23	patients	patient	NNS	_	21	ppmod	_	_
24	treated	treat	VBN	_	23	acl	_	_
25	with	with	IN	_	26	case	_	_
26	drug2	drug0	NN	_	24	ppmod	_	_
27	,	,	,	_	26	p	_	_
28	drug3	drug0	NN	_	26	conj	_	_
29	,	,	,	_	28	p	_	_
30	drug4	drug0	NN	_	26	conj	_	_
31	,	,	,	_	30	p	_	_
32	drug5	drug0	NN	_	26	conj	_	_
33	and/or	and/or	CC	_	32	cc	_	_
34	drug6	drug0	NN	_	26	conj	_	_
35	.	.	.	_	18	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	6	com	_	_
4	s	s	NN	_	6	com	_	_
5	plasma	plasma	NN	_	6	com	_	_
6	half-life	half-life	NN	_	8	dep	_	_
7	may	may	MD	_	8	modal	_	_
8	be	be	VB	_	1	acl	_	_
9	prolonged	prolonged	JJ	_	8	dep	_	_
10	by	by	IN	_	11	case	_	_
11	drug3	drug0	NN	_	9	ppmod	_	_
12	,	,	,	_	8	p	_	_
13	since	since	IN	_	18	mark	_	_
14	drug4	drug0	NN	_	18	dep	_	_
15	and	and	CC	_	14	cc	_	_
16	drug5	drug0	NN	_	14	conj	_	_
17	may	may	MD	_	18	modal	_	_
18	compete	compete	VB	_	8	comp	_	_
19	for	for	IN	_	20	case	_	_
20	excretion	excretion	NN	_	18	ppmod	_	_
21	in	in	IN	_	24	case	_	_
22	the	the	DT	_	24	det	_	_
23	renal	renal	JJ	_	24	attr	_	_
24	tubule	tubule	NN	_	18	ppmod	_	_
25	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	risk	risk	NN	_	11	dep	_	_
3	of	of	IN	_	4	case	_	_
4	hypoglycemia	hypoglycemia	NN	_	2	ppmod	_	_
5	secondary	secondary	JJ	_	4	attr	_	_
6	to	to	TO	_	8	aux	_	_
7	this	this	DT	_	8	det	_	_
8	mechanism	mechanism	NN	_	5	ppmod	_	_
9	may	may	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	increased	increase	VBN	_	0	root	_	_
12	if	if	IN	_	17	mark	_	_
13	drug1	drug0	NN	_	17	dep	_	_
14	and	and	CC	_	13	cc	_	_
15	drug2	drug0	NN	_	13	conj	_	_
16	are	be	VBP	_	17	aux	_	_
17	given	give	VBN	_	11	comp	_	_
18	concomitantly	concomitantly	RB	_	17	adv	_	_
19	in	in	IN	_	21	case	_	_
20	the	the	DT	_	21	det	_	_
21	presence	presence	NN	_	17	ppmod	_	_
22	of	of	IN	_	24	case	_	_
23	renal	renal	JJ	_	24	attr	_	_
24	insufficiency	insufficiency	NN	_	21	ppmod	_	_
25	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Reports	report	NNS	_	4	dep	_	_
4	indicate	indicate	VBP	_	1	acl	_	_
5	that	that	IN	_	10	mark	_	_
6	drug2	drug0	NN	_	7	com	_	_
7	levels	level	NNS	_	10	dep	_	_
8	may	may	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	increased	increase	VBN	_	4	comp	_	_
11	during	during	IN	_	13	case	_	_
12	concomitant	concomitant	JJ	_	13	attr	_	_
13	treatment	treatment	NN	_	10	ppmod	_	_
14	with	with	IN	_	15	case	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	for	for	IN	_	17	case	_	_
17	injection	injection	NN	_	13	ppmod	_	_
18	.	.	.	_	1	p	_	_

1	Monitoring	monitoring	NN	_	13	dep	_	_
2	of	of	IN	_	4	case	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	levels	level	NNS	_	1	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	possible	possible	JJ	_	7	attr	_	_
7	adjustment	adjustment	NN	_	4	conj	_	_
8	of	of	IN	_	10	case	_	_
9	drug2	drug0	NN	_	10	com	_	_
10	dosage	dosage	NN	_	7	ppmod	_	_
11	should	should	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	considered	consider	VBN	_	0	root	_	_
14	when	when	WRB	_	18	adv	_	_
15	these	these	DT	_	16	det	_	_
16	drugs	drug	NNS	_	18	dep	_	_
17	are	be	VBP	_	18	aux	_	_
18	co-administered	co-administered	VBN	_	13	comp	_	_
19	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	3	com	_	_
2	s	s	NN	_	3	com	_	_
3	conversion	conversion	NN	_	9	dep	_	_
4	to	to	TO	_	6	aux	_	_
5	inactive	inactive	JJ	_	6	attr	_	_
6	metabolites	metabolite	NNS	_	3	ppmod	_	_
7	has	have	VBZ	_	9	aux	_	_
8	been	be	VBN	_	9	aux	_	_
9	shown	show	VBN	_	0	root	_	_
10	to	to	TO	_	12	aux	_	_
11	be	be	VB	_	12	aux	_	_
12	catalyzed	catalyze	VBN	_	9	comp	_	_
13	by	by	IN	_	15	case	_	_
14	xanthine	xanthine	NN	_	15	com	_	_
15	oxidase	oxidase	NN	_	12	ppmod	_	_
16	from	from	IN	_	18	case	_	_
17	rat	rat	NN	_	18	com	_	_
18	liver	liver	NN	_	15	ppmod	_	_
19	.	.	.	_	9	p	_	_

1	The	the	DT	_	3	det	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	significance	significance	NN	_	11	dep	_	_
4	,	,	,	_	6	p	_	_
5	if	if	IN	_	6	mark	_	_
6	any	any	DT	_	3	prn	_	_
7	,	,	,	_	6	p	_	_
8	of	of	IN	_	10	case	_	_
9	these	these	DT	_	10	det	_	_
10	observations	observation	NNS	_	3	ppmod	_	_
11	is	be	VBZ	_	0	root	_	_
12	unknown	unknown	JJ	_	11	dep	_	_
13	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	generally	generally	RB	_	6	adv	_	_
3	should	should	MD	_	6	modal	_	_
4	not	not	RB	_	6	neg	_	_
5	be	be	VB	_	6	aux	_	_
6	given	give	VBN	_	0	root	_	_
7	with	with	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	because	because	IN	_	11	mark	_	_
10	they	they	PRP	_	11	dep	_	_
11	reduce	reduce	VBP	_	6	comp	_	_
12	its	its	PRP$	_	14	poss	_	_
13	renal	renal	JJ	_	14	attr	_	_
14	clearance	clearance	NN	_	11	obj	_	_
15	and	and	CC	_	11	cc	_	_
16	add	add	VBP	_	11	conj	_	_
17	a	a	DT	_	19	det	_	_
18	high	high	JJ	_	19	attr	_	_
19	risk	risk	NN	_	16	obj	_	_
20	of	of	IN	_	22	case	_	_
21	drug3	drug0	NN	_	22	com	_	_
22	toxicity	toxicity	NN	_	19	ppmod	_	_
23	.	.	.	_	6	p	_	_

1	Read	read	VBN	_	2	dep	_	_
2	circulars	circulars	VBZ	_	0	root	_	_
3	for	for	IN	_	5	case	_	_
4	drug1	drug0	JJ	_	5	attr	_	_
5	preparations	preparation	NNS	_	2	ppmod	_	_
6	before	before	IN	_	7	case	_	_
7	use	use	NN	_	5	ppmod	_	_
8	of	of	IN	_	11	case	_	_
9	such	such	JJ	_	11	attr	_	_
10	concomitant	concomitant	JJ	_	11	attr	_	_
11	therapy	therapy	NN	_	7	ppmod	_	_
12	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	increase	increase	VB	_	0	root	_	_
4	the	the	DT	_	6	det	_	_
5	ototoxic	ototoxic	JJ	_	6	attr	_	_
6	potential	potential	NN	_	3	obj	_	_
7	of	of	IN	_	9	case	_	_
8	other	other	JJ	_	9	attr	_	_
9	drugs	drug	NNS	_	6	ppmod	_	_
10	such	such	JJ	_	12	adv	_	_
11	as	as	IN	_	12	case	_	_
12	drug2	drug0	NN	_	9	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	some	some	DT	_	15	det	_	_
15	drug3	drug0	NN	_	12	conj	_	_
16	.	.	.	_	3	p	_	_

1	Their	their	PRP$	_	3	poss	_	_
2	concurrent	concurrent	JJ	_	3	attr	_	_
3	use	use	NN	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	avoided	avoid	VBN	_	0	root	_	_
7	.	.	.	_	6	p	_	_

1	A	a	DT	_	2	det	_	_
2	number	number	NN	_	11	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drugs	drug	NNS	_	2	ppmod	_	_
5	,	,	,	_	4	p	_	_
6	including	include	VBG	_	7	adv	_	_
7	drug1	drug0	NN	_	4	ppmod	_	_
8	,	,	,	_	4	p	_	_
9	have	have	VBP	_	11	aux	_	_
10	been	be	VBN	_	11	aux	_	_
11	shown	show	VBN	_	0	root	_	_
12	to	to	TO	_	13	aux	_	_
13	displace	displace	VB	_	11	comp	_	_
14	drug2	drug0	NN	_	13	obj	_	_
15	from	from	IN	_	17	case	_	_
16	plasma	plasma	NN	_	17	com	_	_
17	protein	protein	NN	_	13	ppmod	_	_
18	;	;	:	_	11	p	_	_

1	a	a	DT	_	2	det	_	_
2	reduction	reduction	NN	_	10	dep	_	_
3	in	in	IN	_	7	case	_	_
4	the	the	DT	_	7	det	_	_
5	usual	usual	JJ	_	7	attr	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	dosage	dosage	NN	_	2	ppmod	_	_
8	may	may	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	required	require	VBN	_	0	root	_	_
11	in	in	IN	_	12	case	_	_
12	patients	patient	NNS	_	10	ppmod	_	_
13	receiving	receive	VBG	_	12	acl	_	_
14	both	both	DT	_	15	det	_	_
15	drugs	drug	NNS	_	13	obj	_	_
16	.	.	.	_	10	p	_	_

1	In	in	IN	_	3	case	_	_
2	some	some	DT	_	3	det	_	_
3	patients	patient	NNS	_	11	ppmod	_	_
4	,	,	,	_	11	p	_	_
5	the	the	DT	_	6	det	_	_
6	administration	administration	NN	_	11	dep	_	_
7	of	of	IN	_	9	case	_	_
8	a	a	DT	_	9	det	_	_
9	drug1	drug0	NN	_	6	ppmod	_	_
10	can	can	MD	_	11	modal	_	_
11	reduce	reduce	VB	_	0	root	_	_
12	the	the	DT	_	19	det	_	_
13	diuretic	diuretic	JJ	_	19	attr	_	_
14	,	,	,	_	13	p	_	_
15	natriuretic	natriuretic	JJ	_	13	conj	_	_
16	,	,	,	_	15	p	_	_
17	and	and	CC	_	15	cc	_	_
18	antihypertensive	antihypertensive	JJ	_	13	conj	_	_
19	effects	effect	NNS	_	11	obj	_	_
20	of	of	IN	_	21	case	_	_
21	drug2	drug0	NN	_	19	ppmod	_	_
22	,	,	,	_	21	p	_	_
23	drug3	drug0	NN	_	21	conj	_	_
24	and	and	CC	_	23	cc	_	_
25	drug4	drug0	NN	_	21	conj	_	_
26	.	.	.	_	11	p	_	_

1	Therefore	therefore	RB	_	15	adv	_	_
2	,	,	,	_	15	p	_	_
3	when	when	WRB	_	8	adv	_	_
4	drug1	drug0	NN	_	8	dep	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	are	be	VBP	_	8	aux	_	_
8	used	use	VBN	_	15	advcl	_	_
9	concomitantly	concomitantly	RB	_	8	adv	_	_
10	,	,	,	_	15	p	_	_
11	the	the	DT	_	12	det	_	_
12	patient	patient	NN	_	15	dep	_	_
13	should	should	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	observed	observe	VBN	_	0	root	_	_
16	closely	closely	RB	_	15	adv	_	_
17	to	to	TO	_	18	aux	_	_
18	determine	determine	VB	_	15	comp	_	_
19	if	if	IN	_	27	mark	_	_
20	the	the	DT	_	22	det	_	_
21	desired	desired	JJ	_	22	attr	_	_
22	effect	effect	NN	_	27	dep	_	_
23	of	of	IN	_	25	case	_	_
24	the	the	DT	_	25	det	_	_
25	drug3	drug0	NN	_	22	ppmod	_	_
26	is	be	VBZ	_	27	aux	_	_
27	obtained	obtain	VBN	_	18	comp	_	_
28	.	.	.	_	15	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Several	several	JJ	_	6	attr	_	_
4	short-term	short-term	JJ	_	6	attr	_	_
5	controlled	controlled	JJ	_	6	attr	_	_
6	studies	study	NNS	_	7	dep	_	_
7	failed	fail	VBD	_	1	acl	_	_
8	to	to	TO	_	9	aux	_	_
9	wshow	wshow	VB	_	7	comp	_	_
10	that	that	IN	_	13	mark	_	_
11	drug2	drug0	NN	_	13	dep	_	_
12	significantly	significantly	RB	_	13	adv	_	_
13	affected	affect	VBD	_	9	comp	_	_
14	prothrombin	prothrombin	NN	_	15	com	_	_
15	times	time	NNS	_	13	obj	_	_
16	or	or	CC	_	15	cc	_	_
17	a	a	DT	_	18	det	_	_
18	variety	variety	NN	_	15	conj	_	_
19	of	of	IN	_	22	case	_	_
20	other	other	JJ	_	22	attr	_	_
21	clotting	clotting	NN	_	22	com	_	_
22	factors	factor	NNS	_	18	ppmod	_	_
23	when	when	WRB	_	24	adv	_	_
24	administered	administer	VBN	_	13	comp	_	_
25	to	to	TO	_	26	aux	_	_
26	individuals	individual	NNS	_	24	ppmod	_	_
27	on	on	IN	_	28	case	_	_
28	drug3	drug0	NN	_	26	ppmod	_	_
29	.	.	.	_	1	p	_	_

1	However	however	RB	_	24	adv	_	_
2	,	,	,	_	24	p	_	_
3	because	because	IN	_	7	mark	_	_
4	bleeding	bleeding	JJ	_	7	dep	_	_
5	has	have	VBZ	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	reported	report	VBN	_	24	advcl	_	_
8	when	when	WRB	_	15	adv	_	_
9	drug1	drug0	NN	_	15	dep	_	_
10	and	and	CC	_	9	cc	_	_
11	other	other	JJ	_	12	attr	_	_
12	drug2	drug0	NN	_	9	conj	_	_
13	have	have	VBP	_	15	aux	_	_
14	been	be	VBN	_	15	aux	_	_
15	administered	administer	VBN	_	7	comp	_	_
16	to	to	TO	_	17	aux	_	_
17	patients	patient	NNS	_	15	ppmod	_	_
18	on	on	IN	_	19	case	_	_
19	drug3	drug0	NN	_	15	ppmod	_	_
20	,	,	,	_	24	p	_	_
21	the	the	DT	_	22	det	_	_
22	physician	physician	NN	_	24	dep	_	_
23	should	should	MD	_	24	modal	_	_
24	be	be	VB	_	0	root	_	_
25	cautious	cautious	JJ	_	24	dep	_	_
26	when	when	WRB	_	27	adv	_	_
27	administering	administer	VBG	_	24	comp	_	_
28	drug4	drug0	NN	_	27	obj	_	_
29	to	to	TO	_	30	aux	_	_
30	patients	patient	NNS	_	27	ppmod	_	_
31	on	on	IN	_	32	case	_	_
32	drug5	drug0	NN	_	30	ppmod	_	_
33	.	.	.	_	24	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Animal	animal	NN	_	4	com	_	_
4	studies	study	NNS	_	5	dep	_	_
5	wshow	wshow	VBP	_	1	acl	_	_
6	that	that	IN	_	15	mark	_	_
7	drug2	drug0	NN	_	15	dep	_	_
8	given	give	VBN	_	7	acl	_	_
9	with	with	IN	_	10	case	_	_
10	drug3	drug0	NN	_	8	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	including	include	VBG	_	13	adv	_	_
13	drug4	drug0	NN	_	10	ppmod	_	_
14	,	,	,	_	10	p	_	_
15	yields	yield	VBZ	_	5	comp	_	_
16	a	a	DT	_	18	det	_	_
17	net	net	JJ	_	18	attr	_	_
18	decrease	decrease	NN	_	15	obj	_	_
19	in	in	IN	_	21	case	_	_
20	anti-inflammatory	anti-inflammatory	JJ	_	21	attr	_	_
21	activity	activity	NN	_	18	ppmod	_	_
22	with	with	IN	_	25	case	_	_
23	lowered	lowered	JJ	_	25	attr	_	_
24	blood	blood	NN	_	25	com	_	_
25	levels	level	NNS	_	21	ppmod	_	_
26	of	of	IN	_	29	case	_	_
27	the	the	DT	_	29	det	_	_
28	non-aspirin	non-aspirin	JJ	_	29	attr	_	_
29	drug	drug	NN	_	25	ppmod	_	_
30	.	.	.	_	1	p	_	_

1	Single	single	JJ	_	4	attr	_	_
2	dose	dose	NN	_	4	com	_	_
3	bioavailability	bioavailability	NN	_	4	com	_	_
4	studies	study	NNS	_	9	dep	_	_
5	in	in	IN	_	7	case	_	_
6	normal	normal	JJ	_	7	attr	_	_
7	volunteers	volunteer	NNS	_	4	ppmod	_	_
8	have	have	VBP	_	9	aux	_	_
9	failed	fail	VBN	_	0	root	_	_
10	to	to	TO	_	11	aux	_	_
11	wshow	wshow	VB	_	9	comp	_	_
12	an	an	DT	_	13	det	_	_
13	effect	effect	NN	_	11	obj	_	_
14	of	of	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	on	on	IN	_	19	case	_	_
17	drug2	drug0	NN	_	19	com	_	_
18	blood	blood	NN	_	19	com	_	_
19	levels	level	NNS	_	13	ppmod	_	_
20	.	.	.	_	9	p	_	_

1	Correlative	correlative	JJ	_	3	attr	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	studies	study	NNS	_	7	dep	_	_
4	have	have	VBP	_	7	aux	_	_
5	not	not	RB	_	7	neg	_	_
6	been	be	VBN	_	7	aux	_	_
7	performed	performed	VBN	_	0	root	_	_
8	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	12	dep	_	_
4	,	,	,	_	3	p	_	_
5	as	as	RB	_	6	com	_	_
6	well	well	RB	_	3	cc	_	_
7	as	as	IN	_	6	com	_	_
8	other	other	JJ	_	9	attr	_	_
9	drug3	drug0	NN	_	3	conj	_	_
10	,	,	,	_	9	p	_	_
11	probably	probably	RB	_	12	adv	_	_
12	reduces	reduce	VBZ	_	1	acl	_	_
13	the	the	DT	_	15	det	_	_
14	tubular	tubular	JJ	_	15	attr	_	_
15	secretion	secretion	NN	_	12	obj	_	_
16	of	of	IN	_	17	case	_	_
17	drug4	drug0	NN	_	15	ppmod	_	_
18	based	base	VBN	_	22	adv	_	_
19	on	on	IN	_	22	case	_	_
20	in	in	FW	_	21	adv	_	_
21	vitro	vitro	FW	_	22	attr	_	_
22	studies	study	NNS	_	15	ppmod	_	_
23	in	in	IN	_	26	case	_	_
24	rabbit	rabbit	NN	_	26	com	_	_
25	kidney	kidney	NN	_	26	com	_	_
26	slices	slice	NNS	_	22	ppmod	_	_
27	.	.	.	_	1	p	_	_

1	This	this	DT	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	indicate	indicate	VB	_	0	root	_	_
4	that	that	IN	_	7	mark	_	_
5	drug1	drug0	NN	_	7	dep	_	_
6	could	could	MD	_	7	modal	_	_
7	enhance	enhance	VB	_	3	comp	_	_
8	the	the	DT	_	9	det	_	_
9	toxicity	toxicity	NN	_	7	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	3	p	_	_

1	Caution	caution	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	used	use	VBN	_	0	root	_	_
5	if	if	IN	_	8	mark	_	_
6	drug1	drug0	NN	_	8	dep	_	_
7	is	be	VBZ	_	8	aux	_	_
8	administered	administer	VBN	_	4	comp	_	_
9	concomitantly	concomitantly	RB	_	8	adv	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NN	_	8	ppmod	_	_
12	.	.	.	_	4	p	_	_

1	H-2	h-0	NN	_	2	com	_	_
2	Antagonists	antagonist	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	In	in	IN	_	5	case	_	_
5	studies	study	NNS	_	17	ppmod	_	_
6	with	with	IN	_	8	case	_	_
7	human	human	JJ	_	8	attr	_	_
8	volunteers	volunteer	NNS	_	5	ppmod	_	_
9	,	,	,	_	17	p	_	_
10	co-administration	co-administration	NN	_	17	dep	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	or	or	CC	_	12	cc	_	_
14	drug2	drug0	NN	_	12	conj	_	_
15	with	with	IN	_	16	case	_	_
16	drug3	drug0	NN	_	10	ppmod	_	_
17	had	have	VBD	_	2	acl	_	_
18	no	no	DT	_	20	det	_	_
19	substantive	substantive	JJ	_	20	attr	_	_
20	effect	effect	NN	_	17	obj	_	_
21	on	on	IN	_	24	case	_	_
22	drug4	drug0	NN	_	24	com	_	_
23	serum	serum	NN	_	24	com	_	_
24	concentrations	concentration	NNS	_	17	ppmod	_	_
25	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Clinical	clinical	JJ	_	4	attr	_	_
4	studies	study	NNS	_	13	dep	_	_
5	,	,	,	_	4	p	_	_
6	as	as	RB	_	7	com	_	_
7	well	well	RB	_	4	cc	_	_
8	as	as	IN	_	7	com	_	_
9	random	random	JJ	_	10	attr	_	_
10	observations	observation	NNS	_	4	conj	_	_
11	,	,	,	_	10	p	_	_
12	have	have	VBP	_	13	aux	_	_
13	shown	show	VBN	_	1	acl	_	_
14	that	that	IN	_	17	mark	_	_
15	drug2	drug0	NN	_	17	dep	_	_
16	can	can	MD	_	17	modal	_	_
17	reduce	reduce	VB	_	13	comp	_	_
18	the	the	DT	_	20	det	_	_
19	natriuretic	natriuretic	JJ	_	20	attr	_	_
20	effect	effect	NN	_	17	obj	_	_
21	of	of	IN	_	22	case	_	_
22	drug3	drug0	NN	_	20	ppmod	_	_
23	and	and	CC	_	22	cc	_	_
24	drug4	drug0	NN	_	22	conj	_	_
25	in	in	IN	_	27	case	_	_
26	some	some	DT	_	27	det	_	_
27	patients	patient	NNS	_	20	ppmod	_	_
28	.	.	.	_	1	p	_	_

1	This	this	DT	_	2	det	_	_
2	response	response	NN	_	5	dep	_	_
3	has	have	VBZ	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	attributed	attribute	VBN	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	inhibition	inhibition	NN	_	5	ppmod	_	_
8	of	of	IN	_	11	case	_	_
9	renal	renal	JJ	_	11	attr	_	_
10	prostaglandin	prostaglandin	NN	_	11	com	_	_
11	synthesis	synthesis	NN	_	7	ppmod	_	_
12	.	.	.	_	5	p	_	_

1	During	during	IN	_	3	case	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	therapy	therapy	NN	_	11	ppmod	_	_
4	with	with	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	,	,	,	_	11	p	_	_
7	the	the	DT	_	8	det	_	_
8	patient	patient	NN	_	11	dep	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	observed	observe	VBN	_	0	root	_	_
12	closely	closely	RB	_	11	adv	_	_
13	for	for	IN	_	14	case	_	_
14	signs	sign	NNS	_	11	ppmod	_	_
15	of	of	IN	_	17	case	_	_
16	renal	renal	JJ	_	17	attr	_	_
17	failure	failure	NN	_	14	ppmod	_	_
18	,	,	,	_	11	p	_	_
19	as	as	RB	_	20	com	_	_
20	well	well	RB	_	23	cc	_	_
21	as	as	IN	_	20	com	_	_
22	to	to	TO	_	23	aux	_	_
23	assure	assure	VB	_	11	comp	_	_
24	drug2	drug0	NN	_	25	com	_	_
25	efficacy	efficacy	NN	_	23	obj	_	_
26	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	produced	produce	VBD	_	0	root	_	_
5	an	an	DT	_	6	det	_	_
6	elevation	elevation	NN	_	4	obj	_	_
7	of	of	IN	_	10	case	_	_
8	plasma	plasma	NN	_	10	com	_	_
9	drug3	drug0	NN	_	10	com	_	_
10	levels	level	NNS	_	6	ppmod	_	_
11	and	and	CC	_	6	cc	_	_
12	a	a	DT	_	13	det	_	_
13	reduction	reduction	NN	_	6	conj	_	_
14	in	in	IN	_	17	case	_	_
15	renal	renal	JJ	_	17	attr	_	_
16	drug4	drug0	NN	_	17	com	_	_
17	clearance	clearance	NN	_	13	ppmod	_	_
18	in	in	IN	_	20	case	_	_
19	a	a	DT	_	20	det	_	_
20	study	study	NN	_	4	ppmod	_	_
21	of	of	IN	_	24	case	_	_
22	eleven	#crd#	CD	_	24	num	_	_
23	normal	normal	JJ	_	24	attr	_	_
24	volunteers	volunteer	NNS	_	20	ppmod	_	_
25	.	.	.	_	4	p	_	_

1	The	the	DT	_	5	det	_	_
2	mean	mean	JJ	_	5	attr	_	_
3	minimum	minimum	JJ	_	5	attr	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	concentration	concentration	NN	_	6	dep	_	_
6	increased	increase	VBD	_	0	root	_	_
7	15	0	CD	_	6	obj	_	_
8	%	%	NN	_	7	meta	_	_
9	and	and	CC	_	6	cc	_	_
10	the	the	DT	_	12	det	_	_
11	renal	renal	JJ	_	12	attr	_	_
12	clearance	clearance	NN	_	16	dep	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	was	be	VBD	_	16	aux	_	_
16	decreased	decrease	VBN	_	6	conj	_	_
17	by	by	IN	_	18	case	_	_
18	19	0	CD	_	16	ppmod	_	_
19	%	%	NN	_	18	meta	_	_
20	during	during	IN	_	22	case	_	_
21	this	this	DT	_	22	det	_	_
22	period	period	NN	_	16	ppmod	_	_
23	of	of	IN	_	26	case	_	_
24	concomitant	concomitant	JJ	_	26	attr	_	_
25	drug	drug	NN	_	26	com	_	_
26	administration	administration	NN	_	22	ppmod	_	_
27	.	.	.	_	6	p	_	_

1	This	this	DT	_	2	det	_	_
2	effect	effect	NN	_	5	dep	_	_
3	has	have	VBZ	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	attributed	attribute	VBN	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	inhibition	inhibition	NN	_	5	ppmod	_	_
8	of	of	IN	_	11	case	_	_
9	renal	renal	JJ	_	11	attr	_	_
10	prostaglandin	prostaglandin	NN	_	11	com	_	_
11	synthesis	synthesis	NN	_	7	ppmod	_	_
12	by	by	IN	_	13	case	_	_
13	drug1	drug0	NN	_	7	ppmod	_	_
14	.	.	.	_	5	p	_	_

1	Thus	thus	RB	_	14	adv	_	_
2	,	,	,	_	14	p	_	_
3	when	when	WRB	_	8	adv	_	_
4	drug1	drug0	NN	_	8	dep	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	are	be	VBP	_	8	aux	_	_
8	administered	administer	VBN	_	14	advcl	_	_
9	concurrently	concurrently	RB	_	8	adv	_	_
10	,	,	,	_	14	p	_	_
11	subjects	subject	NNS	_	14	dep	_	_
12	should	should	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	observed	observe	VBN	_	0	root	_	_
15	carefully	carefully	RB	_	14	adv	_	_
16	for	for	IN	_	17	case	_	_
17	signs	sign	NNS	_	14	ppmod	_	_
18	of	of	IN	_	20	case	_	_
19	drug3	drug0	NN	_	20	com	_	_
20	toxicity	toxicity	NN	_	17	ppmod	_	_
21	.	.	.	_	14	p	_	_

1	(	-lrb-	-LRB-	_	3	p	_	_
2	Read	read	VBN	_	3	attr	_	_
3	circulars	circulars	NN	_	0	root	_	_
4	for	for	IN	_	6	case	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	preparation	preparation	NN	_	3	ppmod	_	_
7	before	before	IN	_	8	case	_	_
8	use	use	NN	_	3	ppmod	_	_
9	of	of	IN	_	12	case	_	_
10	such	such	JJ	_	12	attr	_	_
11	concurrent	concurrent	JJ	_	12	attr	_	_
12	therapy	therapy	NN	_	8	ppmod	_	_
13	)	-rrb-	-RRB-	_	3	p	_	_
14	.	.	.	_	3	p	_	_

1	Renal	renal	JJ	_	3	attr	_	_
2	clearance	clearance	NN	_	3	com	_	_
3	measurements	measurement	NNS	_	8	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	cannot	cannot	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	made	make	VBN	_	0	root	_	_
9	with	with	IN	_	12	case	_	_
10	any	any	DT	_	12	det	_	_
11	significant	significant	JJ	_	12	attr	_	_
12	accuracy	accuracy	NN	_	8	ppmod	_	_
13	in	in	IN	_	14	case	_	_
14	patients	patient	NNS	_	12	ppmod	_	_
15	receiving	receive	VBG	_	14	acl	_	_
16	drug2	drug0	NN	_	15	obj	_	_
17	,	,	,	_	16	p	_	_
18	drug3	drug0	NN	_	16	conj	_	_
19	,	,	,	_	18	p	_	_
20	or	or	CC	_	18	cc	_	_
21	drug4	drug0	NN	_	16	conj	_	_
22	.	.	.	_	8	p	_	_

1	These	these	DT	_	2	det	_	_
2	compounds	compound	NNS	_	3	dep	_	_
3	interfere	interfere	VBP	_	0	root	_	_
4	with	with	IN	_	7	case	_	_
5	chemical	chemical	JJ	_	7	attr	_	_
6	color	color	NN	_	7	com	_	_
7	development	development	NN	_	3	ppmod	_	_
8	essential	essential	JJ	_	7	attr	_	_
9	to	to	TO	_	12	aux	_	_
10	the	the	DT	_	12	det	_	_
11	analytical	analytical	JJ	_	12	attr	_	_
12	procedures	procedure	NNS	_	8	ppmod	_	_
13	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	depresses	depress	VBZ	_	0	root	_	_
3	tubular	tubular	JJ	_	4	attr	_	_
4	secretion	secretion	NN	_	2	obj	_	_
5	of	of	IN	_	8	case	_	_
6	certain	certain	JJ	_	8	attr	_	_
7	weak	weak	JJ	_	8	attr	_	_
8	acids	acid	NNS	_	4	ppmod	_	_
9	such	such	JJ	_	11	adv	_	_
10	as	as	IN	_	11	case	_	_
11	drug2	drug0	NN	_	8	ppmod	_	_
12	.	.	.	_	2	p	_	_

1	Therefore	therefore	RB	_	7	adv	_	_
2	,	,	,	_	7	p	_	_
3	patients	patient	NNS	_	7	dep	_	_
4	receiving	receive	VBG	_	3	acl	_	_
5	drug1	drug0	NN	_	4	obj	_	_
6	will	will	MD	_	7	modal	_	_
7	have	have	VB	_	0	root	_	_
8	erroneously	erroneously	RB	_	9	adv	_	_
9	low	low	JJ	_	10	attr	_	_
10	ERPF	erpf	NN	_	7	obj	_	_
11	and	and	CC	_	10	cc	_	_
12	Tm	tm	NN	_	14	com	_	_
13	drug2	drug0	NN	_	14	com	_	_
14	values	value	NNS	_	10	conj	_	_
15	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	should	should	MD	_	5	modal	_	_
3	not	not	RB	_	5	neg	_	_
4	be	be	VB	_	5	aux	_	_
5	administered	administer	VBN	_	0	root	_	_
6	concomitantly	concomitantly	RB	_	5	adv	_	_
7	with	with	IN	_	9	case	_	_
8	potent	potent	JJ	_	9	attr	_	_
9	drug2	drug0	NNS	_	5	ppmod	_	_
10	such	such	JJ	_	12	adv	_	_
11	as	as	IN	_	12	case	_	_
12	drug3	drug0	NN	_	9	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	drug4	drug0	NN	_	12	conj	_	_
15	as	as	IN	_	21	mark	_	_
16	the	the	DT	_	17	det	_	_
17	potential	potential	NN	_	21	dep	_	_
18	for	for	IN	_	19	case	_	_
19	ototoxicity	ototoxicity	NN	_	17	ppmod	_	_
20	is	be	VBZ	_	21	aux	_	_
21	enhanced	enhance	VBN	_	5	comp	_	_
22	by	by	IN	_	24	case	_	_
23	the	the	DT	_	24	det	_	_
24	combination	combination	NN	_	21	ppmod	_	_
25	.	.	.	_	5	p	_	_

1	No	no	DT	_	5	det	_	_
2	formal	formal	JJ	_	5	attr	_	_
3	drug	drug	NN	_	5	com	_	_
4	interaction	interaction	NN	_	5	com	_	_
5	studies	study	NNS	_	8	dep	_	_
6	have	have	VBP	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	conducted	conduct	VBN	_	0	root	_	_
9	with	with	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	8	p	_	_

1	The	the	DT	_	3	det	_	_
2	concurrent	concurrent	JJ	_	3	attr	_	_
3	administration	administration	NN	_	8	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	increases	increase	VBZ	_	0	root	_	_
9	substantially	substantially	RB	_	8	adv	_	_
10	the	the	DT	_	11	det	_	_
11	incidence	incidence	NN	_	8	obj	_	_
12	of	of	IN	_	13	case	_	_
13	rashes	rash	NNS	_	11	ppmod	_	_
14	in	in	IN	_	15	case	_	_
15	patients	patient	NNS	_	11	ppmod	_	_
16	receiving	receive	VBG	_	15	acl	_	_
17	both	both	DT	_	18	det	_	_
18	drugs	drug	NNS	_	16	obj	_	_
19	as	as	IN	_	20	mark	_	_
20	compared	compare	VBN	_	8	comp	_	_
21	to	to	TO	_	22	aux	_	_
22	patients	patient	NNS	_	20	ppmod	_	_
23	receiving	receive	VBG	_	22	acl	_	_
24	drug3	drug0	NN	_	23	obj	_	_
25	alone	alone	RB	_	20	adv	_	_
26	.	.	.	_	8	p	_	_

1	It	it	PRP	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	known	know	VBN	_	0	root	_	_
5	whether	whether	IN	_	11	mark	_	_
6	this	this	DT	_	7	det	_	_
7	potentiation	potentiation	NN	_	11	dep	_	_
8	of	of	IN	_	10	case	_	_
9	drug1	drug0	NN	_	10	com	_	_
10	rashes	rash	NNS	_	7	ppmod	_	_
11	is	be	VBZ	_	4	comp	_	_
12	due	due	JJ	_	11	dep	_	_
13	to	to	TO	_	14	aux	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	or	or	CC	_	14	cc	_	_
16	the	the	DT	_	17	det	_	_
17	hyperuricemia	hyperuricemia	NN	_	14	conj	_	_
18	present	present	JJ	_	14	attr	_	_
19	in	in	IN	_	21	case	_	_
20	these	these	DT	_	21	det	_	_
21	patients	patient	NNS	_	18	ppmod	_	_
22	.	.	.	_	4	p	_	_

1	In	in	IN	_	4	case	_	_
2	controlled	controlled	JJ	_	4	attr	_	_
3	clinical	clinical	JJ	_	4	attr	_	_
4	trials	trial	NNS	_	10	ppmod	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	,	,	,	_	10	p	_	_
8	22	0	CD	_	9	num	_	_
9	patients	patient	NNS	_	10	dep	_	_
10	received	receive	VBD	_	0	root	_	_
11	concomitant	concomitant	JJ	_	12	attr	_	_
12	drug2	drug0	NN	_	10	obj	_	_
13	and	and	CC	_	12	cc	_	_
14	drug3	drug0	NN	_	12	conj	_	_
15	.	.	.	_	10	p	_	_

1	No	no	DT	_	2	det	_	_
2	rashes	rash	NNS	_	4	dep	_	_
3	were	be	VBD	_	4	aux	_	_
4	reported	report	VBN	_	0	root	_	_
5	in	in	IN	_	7	case	_	_
6	these	these	DT	_	7	det	_	_
7	patients	patient	NNS	_	4	ppmod	_	_
8	.	.	.	_	4	p	_	_

1	However	however	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	this	this	DT	_	5	det	_	_
4	sample	sample	NN	_	5	com	_	_
5	size	size	NN	_	6	dep	_	_
6	is	be	VBZ	_	0	root	_	_
7	too	too	RB	_	8	adv	_	_
8	small	small	JJ	_	6	dep	_	_
9	to	to	TO	_	10	aux	_	_
10	allow	allow	VB	_	8	comp	_	_
11	for	for	IN	_	16	mark	_	_
12	any	any	DT	_	13	det	_	_
13	conclusions	conclusion	NNS	_	16	dep	_	_
14	to	to	TO	_	16	aux	_	_
15	be	be	VB	_	16	aux	_	_
16	drawn	draw	VBN	_	10	comp	_	_
17	regarding	regard	VBG	_	19	adv	_	_
18	the	the	DT	_	19	det	_	_
19	risk	risk	NN	_	16	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	rashes	rash	NNS	_	19	ppmod	_	_
22	with	with	IN	_	24	case	_	_
23	concomitant	concomitant	JJ	_	24	attr	_	_
24	drug1	drug0	NN	_	21	ppmod	_	_
25	and	and	CC	_	24	cc	_	_
26	drug2	drug0	NN	_	27	com	_	_
27	use	use	NN	_	24	conj	_	_
28	.	.	.	_	6	p	_	_

1	In	in	IN	_	5	case	_	_
2	common	common	NN	_	5	advnp	_	_
3	with	with	IN	_	5	case	_	_
4	other	other	JJ	_	5	attr	_	_
5	drug1	drug0	NN	_	9	ppmod	_	_
6	,	,	,	_	9	p	_	_
7	drug2	drug0	NN	_	9	dep	_	_
8	may	may	MD	_	9	modal	_	_
9	reduce	reduce	VB	_	0	root	_	_
10	the	the	DT	_	11	det	_	_
11	efficacy	efficacy	NN	_	9	obj	_	_
12	of	of	IN	_	14	case	_	_
13	oral	oral	JJ	_	14	attr	_	_
14	drug3	drug0	NN	_	11	ppmod	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	drug2	drug0	NN	_	1	prn	_	_
4	-	-	:	_	3	p	_	_
5	or	or	CC	_	3	cc	_	_
6	drug3	drug0	NN	_	3	conj	_	_
7	-containing	-containing	JJ	_	6	attr	_	_
8	)	-rrb-	-RRB-	_	3	p	_	_
9	:	:	:	_	1	p	_	_
10	Concomitant	concomitant	JJ	_	11	attr	_	_
11	administration	administration	NN	_	21	dep	_	_
12	of	of	IN	_	15	case	_	_
13	300-mg	0-mg	NN	_	15	com	_	_
14	drug4	drug0	NN	_	15	com	_	_
15	capsules	capsule	NNS	_	11	ppmod	_	_
16	with	with	IN	_	20	case	_	_
17	30	0	CD	_	18	num	_	_
18	mL	ml	NN	_	20	com	_	_
19	drug5	drug0	NN	_	20	com	_	_
20	suspension	suspension	NN	_	15	ppmod	_	_
21	reduces	reduce	VBZ	_	1	acl	_	_
22	the	the	DT	_	23	det	_	_
23	rate	rate	NN	_	21	obj	_	_
24	(	-lrb-	-LRB-	_	25	p	_	_
25	Cmax	cmax	NN	_	23	prn	_	_
26	)	-rrb-	-RRB-	_	25	p	_	_
27	and	and	CC	_	23	cc	_	_
28	extent	extent	NN	_	23	conj	_	_
29	(	-lrb-	-LRB-	_	30	p	_	_
30	AUC	auc	NN	_	28	prn	_	_
31	)	-rrb-	-RRB-	_	30	p	_	_
32	of	of	IN	_	33	case	_	_
33	absorption	absorption	NN	_	23	ppmod	_	_
34	by	by	IN	_	36	case	_	_
35	approximately	approximately	RB	_	36	adv	_	_
36	40	0	CD	_	21	ppmod	_	_
37	%	%	NN	_	36	meta	_	_
38	.	.	.	_	1	p	_	_

1	Time	time	NN	_	7	dep	_	_
2	to	to	TO	_	3	aux	_	_
3	reach	reach	VB	_	1	acl	_	_
4	Cmax	cmax	NN	_	3	obj	_	_
5	is	be	VBZ	_	7	aux	_	_
6	also	also	RB	_	7	adv	_	_
7	prolonged	prolong	VBD	_	0	root	_	_
8	by	by	IN	_	10	case	_	_
9	1	0	CD	_	10	num	_	_
10	hour	hour	NN	_	7	ppmod	_	_
11	.	.	.	_	7	p	_	_

1	There	there	EX	_	2	dep	_	_
2	are	be	VBP	_	0	root	_	_
3	no	no	DT	_	5	det	_	_
4	significant	significant	JJ	_	5	attr	_	_
5	effects	effect	NNS	_	2	obj	_	_
6	on	on	IN	_	8	case	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	pharmacokinetics	pharmacokinetics	NNS	_	5	ppmod	_	_
9	if	if	IN	_	13	mark	_	_
10	the	the	DT	_	11	det	_	_
11	drug2	drug0	NN	_	13	dep	_	_
12	is	be	VBZ	_	13	aux	_	_
13	administered	administer	VBN	_	2	comp	_	_
14	2	0	CD	_	15	num	_	_
15	hours	hour	NNS	_	13	obj	_	_
16	before	before	IN	_	15	case	_	_
17	or	or	CC	_	15	cc	_	_
18	2	0	CD	_	19	num	_	_
19	hours	hour	NNS	_	15	conj	_	_
20	after	after	IN	_	21	case	_	_
21	drug3	drug0	NN	_	19	ppmod	_	_
22	.	.	.	_	2	p	_	_

1	If	if	IN	_	4	mark	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	are	be	VBP	_	4	aux	_	_
4	required	require	VBN	_	12	advcl	_	_
5	during	during	IN	_	7	case	_	_
6	drug2	drug0	NN	_	7	com	_	_
7	therapy	therapy	NN	_	4	ppmod	_	_
8	,	,	,	_	12	p	_	_
9	drug3	drug0	NN	_	12	dep	_	_
10	should	should	MD	_	12	modal	_	_
11	be	be	VB	_	12	aux	_	_
12	taken	take	VBN	_	0	root	_	_
13	at	at	IN	_	15	case	_	_
14	least	least	JJS	_	15	attr	_	_
15	2	0	CD	_	16	num	_	_
16	hours	hour	NNS	_	12	ppmod	_	_
17	before	before	IN	_	16	case	_	_
18	or	or	CC	_	16	cc	_	_
19	after	after	IN	_	21	case	_	_
20	the	the	DT	_	21	det	_	_
21	drug4	drug0	NN	_	16	conj	_	_
22	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	As	as	IN	_	6	case	_	_
4	with	with	IN	_	6	case	_	_
5	other	other	JJ	_	6	attr	_	_
6	drug2	drug0	NNS	_	9	ppmod	_	_
7	,	,	,	_	9	p	_	_
8	drug3	drug0	NN	_	9	dep	_	_
9	inhibits	inhibit	VBZ	_	1	acl	_	_
10	the	the	DT	_	12	det	_	_
11	renal	renal	JJ	_	12	attr	_	_
12	excretion	excretion	NN	_	9	obj	_	_
13	of	of	IN	_	14	case	_	_
14	drug4	drug0	NN	_	12	ppmod	_	_
15	,	,	,	_	9	p	_	_
16	resulting	result	VBG	_	9	comp	_	_
17	in	in	IN	_	20	case	_	_
18	an	an	DT	_	20	det	_	_
19	approximate	approximate	JJ	_	20	attr	_	_
20	doubling	doubling	JJ	_	16	ppmod	_	_
21	in	in	IN	_	22	case	_	_
22	A.C.	a.c.	NNP	_	20	ppmod	_	_
23	a	a	DT	_	26	det	_	_
24	54	0	CD	_	26	num	_	_
25	%	%	NN	_	24	meta	_	_
26	increase	increase	NN	_	16	obj	_	_
27	in	in	IN	_	31	case	_	_
28	peak	peak	NN	_	31	com	_	_
29	drug5	drug0	NN	_	31	com	_	_
30	plasma	plasma	NN	_	31	com	_	_
31	levels	level	NNS	_	26	ppmod	_	_
32	,	,	,	_	26	p	_	_
33	and	and	CC	_	26	cc	_	_
34	a	a	DT	_	37	det	_	_
35	50	0	CD	_	37	num	_	_
36	%	%	NN	_	35	meta	_	_
37	prolongation	prolongation	NN	_	26	conj	_	_
38	in	in	IN	_	42	case	_	_
39	the	the	DT	_	42	det	_	_
40	apparent	apparent	JJ	_	42	attr	_	_
41	elimination	elimination	NN	_	42	com	_	_
42	half-life	half-life	NN	_	37	ppmod	_	_
43	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	34	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	Foods	foods	NN	_	1	conj	_	_
4	Fortified	fortify	VBN	_	1	acl	_	_
5	With	with	IN	_	8	case	_	_
6	drug2	drug0	JJ	_	8	attr	_	_
7	Concomitant	concomitant	JJ	_	8	attr	_	_
8	administration	administration	NN	_	4	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug3	drug0	NN	_	8	ppmod	_	_
11	with	with	IN	_	14	case	_	_
12	a	a	DT	_	14	det	_	_
13	therapeutic	therapeutic	JJ	_	14	attr	_	_
14	drug4	drug0	NN	_	4	ppmod	_	_
15	containing	contain	VBG	_	14	acl	_	_
16	60	0	CD	_	17	num	_	_
17	mg	mg	NN	_	15	obj	_	_
18	of	of	IN	_	20	case	_	_
19	elemental	elemental	JJ	_	20	attr	_	_
20	drug5	drug0	NN	_	17	ppmod	_	_
21	(	-lrb-	-LRB-	_	23	p	_	_
22	as	as	IN	_	23	case	_	_
23	FeSO4	feso0	NN	_	20	prn	_	_
24	)	-rrb-	-RRB-	_	23	p	_	_
25	or	or	CC	_	20	cc	_	_
26	drug6	drug0	NN	_	20	conj	_	_
27	supplemented	supplement	VBN	_	26	acl	_	_
28	with	with	IN	_	30	case	_	_
29	10	0	CD	_	30	num	_	_
30	mg	mg	NN	_	27	ppmod	_	_
31	of	of	IN	_	33	case	_	_
32	elemental	elemental	JJ	_	33	attr	_	_
33	drug7	drug0	NN	_	30	ppmod	_	_
34	reduced	reduce	VBD	_	0	root	_	_
35	extent	extent	NN	_	34	obj	_	_
36	of	of	IN	_	37	case	_	_
37	absorption	absorption	NN	_	35	ppmod	_	_
38	by	by	IN	_	39	case	_	_
39	80	0	CD	_	34	ppmod	_	_
40	%	%	NN	_	39	meta	_	_
41	and	and	CC	_	39	cc	_	_
42	31	0	CD	_	39	conj	_	_
43	%	%	NN	_	42	meta	_	_
44	,	,	,	_	42	p	_	_
45	respectively	respectively	RB	_	39	conj	_	_
46	.	.	.	_	34	p	_	_

1	If	if	IN	_	4	mark	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	are	be	VBP	_	4	aux	_	_
4	required	require	VBN	_	12	advcl	_	_
5	during	during	IN	_	7	case	_	_
6	drug2	drug0	NN	_	7	com	_	_
7	therapy	therapy	NN	_	4	ppmod	_	_
8	,	,	,	_	12	p	_	_
9	drug3	drug0	NN	_	12	dep	_	_
10	should	should	MD	_	12	modal	_	_
11	be	be	VB	_	12	aux	_	_
12	taken	take	VBN	_	0	root	_	_
13	at	at	IN	_	15	case	_	_
14	least	least	JJS	_	15	attr	_	_
15	2	0	CD	_	16	num	_	_
16	hours	hour	NNS	_	12	ppmod	_	_
17	before	before	IN	_	16	case	_	_
18	or	or	CC	_	16	cc	_	_
19	after	after	IN	_	21	case	_	_
20	the	the	DT	_	21	det	_	_
21	supplement	supplement	NN	_	16	conj	_	_
22	.	.	.	_	12	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	23	dep	_	_
3	of	of	IN	_	4	case	_	_
4	foods	food	NNS	_	2	ppmod	_	_
5	highly	highly	RB	_	6	adv	_	_
6	fortified	fortify	VBN	_	4	acl	_	_
7	with	with	IN	_	9	case	_	_
8	elemental	elemental	JJ	_	9	attr	_	_
9	drug1	drug0	NN	_	6	ppmod	_	_
10	(	-lrb-	-LRB-	_	12	p	_	_
11	primarily	primarily	RB	_	12	adv	_	_
12	drug2	drug0	VBP	_	9	prn	_	_
13	-fortified	-fortified	JJ	_	15	attr	_	_
14	breakfast	breakfast	NN	_	15	com	_	_
15	cereals	cereal	NNS	_	12	obj	_	_
16	)	-rrb-	-RRB-	_	12	p	_	_
17	on	on	IN	_	19	case	_	_
18	drug3	drug0	NN	_	19	com	_	_
19	absorption	absorption	NN	_	2	ppmod	_	_
20	has	have	VBZ	_	23	aux	_	_
21	not	not	RB	_	23	neg	_	_
22	been	be	VBN	_	23	aux	_	_
23	studied	study	VBN	_	0	root	_	_
24	.	.	.	_	23	p	_	_

1	Concomitantly	concomitantly	RB	_	2	adv	_	_
2	administered	administer	VBN	_	6	attr	_	_
3	drug1	drug0	NN	_	6	attr	_	_
4	-fortified	-fortified	JJ	_	6	attr	_	_
5	infant	infant	NN	_	6	com	_	_
6	formula	formula	NN	_	15	dep	_	_
7	(	-lrb-	-LRB-	_	13	p	_	_
8	2.2	0	CD	_	13	num	_	_
9	mg	mg	NN	_	13	attr	_	_
10	elemental	elemental	NN	_	13	attr	_	_
11	drug2	drug0	NN	_	13	attr	_	_
12	/6	0	NN	_	13	num	_	_
13	oz	oz	NN	_	6	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	has	have	VBZ	_	0	root	_	_
16	no	no	DT	_	18	det	_	_
17	significant	significant	JJ	_	18	attr	_	_
18	effect	effect	NN	_	15	obj	_	_
19	on	on	IN	_	21	case	_	_
20	drug3	drug0	NN	_	21	com	_	_
21	pharmacokinetics	pharmacokinetics	NNS	_	15	ppmod	_	_
22	.	.	.	_	15	p	_	_

1	Therefore	therefore	RB	_	9	adv	_	_
2	,	,	,	_	9	p	_	_
3	drug1	drug0	NN	_	9	dep	_	_
4	for	for	IN	_	6	case	_	_
5	Oral	oral	JJ	_	6	attr	_	_
6	Suspension	suspension	NN	_	3	ppmod	_	_
7	can	can	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	administered	administer	VBN	_	0	root	_	_
10	with	with	IN	_	14	case	_	_
11	drug2	drug0	JJ	_	14	attr	_	_
12	-fortified	-fortified	JJ	_	14	attr	_	_
13	infant	infant	NN	_	14	com	_	_
14	formula	formula	NN	_	9	ppmod	_	_
15	.	.	.	_	9	p	_	_

1	There	there	EX	_	3	dep	_	_
2	have	have	VBP	_	3	aux	_	_
3	been	be	VBN	_	0	root	_	_
4	rare	rare	JJ	_	5	attr	_	_
5	reports	report	NNS	_	3	obj	_	_
6	of	of	IN	_	8	case	_	_
7	reddish	reddish	NN	_	8	com	_	_
8	stools	stool	NNS	_	5	ppmod	_	_
9	in	in	IN	_	10	case	_	_
10	patients	patient	NNS	_	5	ppmod	_	_
11	who	who	WP	_	13	dep	_	_
12	have	have	VBP	_	13	aux	_	_
13	received	receive	VBN	_	10	relcl	_	_
14	drug1	drug0	NN	_	13	obj	_	_
15	in	in	IN	_	16	case	_	_
16	Japan	japan	NNP	_	13	ppmod	_	_
17	.	.	.	_	3	p	_	_

1	The	the	DT	_	3	det	_	_
2	reddish	reddish	NN	_	3	com	_	_
3	color	color	NN	_	4	dep	_	_
4	is	be	VBZ	_	0	root	_	_
5	due	due	JJ	_	4	dep	_	_
6	to	to	TO	_	8	aux	_	_
7	the	the	DT	_	8	det	_	_
8	formation	formation	NN	_	5	ppmod	_	_
9	of	of	IN	_	12	case	_	_
10	a	a	DT	_	12	det	_	_
11	nonabsorbable	nonabsorbable	JJ	_	12	attr	_	_
12	complex	complex	NN	_	8	ppmod	_	_
13	between	between	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	or	or	CC	_	14	cc	_	_
16	its	its	PRP$	_	18	poss	_	_
17	breakdown	breakdown	NN	_	18	com	_	_
18	products	product	NNS	_	14	conj	_	_
19	and	and	CC	_	12	cc	_	_
20	drug2	drug0	NN	_	12	conj	_	_
21	in	in	IN	_	24	case	_	_
22	the	the	DT	_	24	det	_	_
23	gastrointestinal	gastrointestinal	JJ	_	24	attr	_	_
24	tract	tract	NN	_	20	ppmod	_	_
25	.	.	.	_	4	p	_	_

1	Drug/Laboratory	drug/laboratory	JJ	_	3	attr	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	13	dep	_	_
4	A	a	DT	_	6	det	_	_
5	false-positive	false-positive	JJ	_	6	attr	_	_
6	reaction	reaction	NN	_	3	attr	_	_
7	for	for	IN	_	8	case	_	_
8	ketones	ketone	NNS	_	6	ppmod	_	_
9	in	in	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	urine	urine	NN	_	8	ppmod	_	_
12	may	may	MD	_	13	modal	_	_
13	occur	occur	VB	_	0	root	_	_
14	with	with	IN	_	15	case	_	_
15	tests	test	NNS	_	13	ppmod	_	_
16	using	use	VBG	_	15	acl	_	_
17	drug1	drug0	NN	_	16	obj	_	_
18	,	,	,	_	15	p	_	_
19	but	but	CC	_	15	cc	_	_
20	not	not	RB	_	22	neg	_	_
21	with	with	IN	_	22	case	_	_
22	those	those	DT	_	15	conj	_	_
23	using	use	VBG	_	22	acl	_	_
24	drug2	drug0	NN	_	23	obj	_	_
25	.	.	.	_	13	p	_	_

1	The	the	DT	_	2	det	_	_
2	administration	administration	NN	_	6	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	may	may	MD	_	6	modal	_	_
6	result	result	VB	_	0	root	_	_
7	in	in	IN	_	10	case	_	_
8	a	a	DT	_	10	det	_	_
9	false-positive	false-positive	JJ	_	10	attr	_	_
10	reaction	reaction	NN	_	6	ppmod	_	_
11	for	for	IN	_	12	case	_	_
12	glucose	glucose	NN	_	10	ppmod	_	_
13	in	in	IN	_	14	case	_	_
14	urine	urine	NN	_	10	ppmod	_	_
15	using	use	VBG	_	14	acl	_	_
16	Clinitest	clinitest	NNP	_	20	attr	_	_
17	,	,	,	_	20	p	_	_
18	Benedict	benedict	NNP	_	20	com	_	_
19	s	s	NNP	_	20	com	_	_
20	solution	solution	NN	_	15	obj	_	_
21	,	,	,	_	20	p	_	_
22	or	or	CC	_	20	cc	_	_
23	Fehlings	fehlings	NN	_	24	com	_	_
24	solution	solution	NN	_	20	conj	_	_
25	.	.	.	_	6	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	recommended	recommend	VBN	_	0	root	_	_
4	that	that	IN	_	21	mark	_	_
5	glucose	glucose	NN	_	6	com	_	_
6	tests	test	NNS	_	21	dep	_	_
7	based	base	VBN	_	6	acl	_	_
8	on	on	IN	_	12	case	_	_
9	enzymatic	enzymatic	JJ	_	12	attr	_	_
10	glucose	glucose	NN	_	12	com	_	_
11	oxidase	oxidase	NN	_	12	com	_	_
12	reactions	reaction	NNS	_	7	ppmod	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	such	such	JJ	_	12	prn	_	_
15	as	as	IN	_	16	case	_	_
16	Clinistix	clinistix	NN	_	14	ppmod	_	_
17	or	or	CC	_	16	cc	_	_
18	Tes-Tape	tes-tape	NN	_	16	conj	_	_
19	)	-rrb-	-RRB-	_	14	p	_	_
20	be	be	VB	_	21	aux	_	_
21	used	use	VBN	_	3	comp	_	_
22	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	are	be	VBP	_	3	aux	_	_
3	known	know	VBN	_	0	root	_	_
4	to	to	TO	_	6	aux	_	_
5	occasionally	occasionally	RB	_	6	adv	_	_
6	induce	induce	VB	_	3	comp	_	_
7	a	a	DT	_	11	det	_	_
8	positive	positive	JJ	_	11	attr	_	_
9	direct	direct	JJ	_	11	attr	_	_
10	Coombs	coombs	NN	_	11	com	_	_
11	test	test	NN	_	6	obj	_	_
12	.	.	.	_	3	p	_	_

1	No	no	DT	_	2	det	_	_
2	information	information	NN	_	3	dep	_	_
3	available	available	JJ	_	0	root	_	_
4	.	.	.	_	3	p	_	_

1	Catecholamine-depleting	catecholamine-depleting	JJ	_	2	attr	_	_
2	drugs	drug	NNS	_	9	dep	_	_
3	,	,	,	_	2	p	_	_
4	e.g.	e.g.	FW	_	6	adv	_	_
5	,	,	,	_	6	p	_	_
6	drug1	drug0	NN	_	2	ppmod	_	_
7	,	,	,	_	2	p	_	_
8	may	may	MD	_	9	modal	_	_
9	have	have	VB	_	0	root	_	_
10	an	an	DT	_	12	det	_	_
11	additive	additive	JJ	_	12	attr	_	_
12	effect	effect	NN	_	9	obj	_	_
13	when	when	WRB	_	14	adv	_	_
14	given	give	VBN	_	9	comp	_	_
15	with	with	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	.	.	.	_	9	p	_	_

1	Patients	patient	NNS	_	17	dep	_	_
2	treated	treat	VBN	_	1	acl	_	_
3	concurrently	concurrently	RB	_	2	adv	_	_
4	with	with	IN	_	5	case	_	_
5	drug1	drug0	NN	_	2	ppmod	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	drug2	drug0	NN	_	5	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	and	and	CC	_	5	cc	_	_
10	a	a	DT	_	12	det	_	_
11	catecholamine	catecholamine	NN	_	12	com	_	_
12	depletor	depletor	NN	_	5	conj	_	_
13	should	should	MD	_	17	modal	_	_
14	therefore	therefore	RB	_	17	adv	_	_
15	be	be	VB	_	17	aux	_	_
16	closely	closely	RB	_	17	adv	_	_
17	observed	observe	VBN	_	0	root	_	_
18	for	for	IN	_	19	case	_	_
19	evidence	evidence	NN	_	17	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	hypotension	hypotension	NN	_	19	ppmod	_	_
22	or	or	CC	_	21	cc	_	_
23	marked	marked	JJ	_	24	attr	_	_
24	bradycardia	bradycardia	NN	_	21	conj	_	_
25	,	,	,	_	21	p	_	_
26	which	which	WDT	_	28	dep	_	_
27	may	may	MD	_	28	modal	_	_
28	result	result	VB	_	21	relcl	_	_
29	in	in	IN	_	30	case	_	_
30	vertigo	vertigo	NN	_	28	ppmod	_	_
31	,	,	,	_	30	p	_	_
32	syncope	syncope	NN	_	30	conj	_	_
33	,	,	,	_	32	p	_	_
34	or	or	CC	_	32	cc	_	_
35	postural	postural	JJ	_	36	attr	_	_
36	hypotension	hypotension	NN	_	30	conj	_	_
37	.	.	.	_	17	p	_	_

1	A	a	DT	_	2	det	_	_
2	study	study	NN	_	9	dep	_	_
3	of	of	IN	_	4	case	_	_
4	interaction	interaction	NN	_	2	ppmod	_	_
5	between	between	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	showed	show	VBD	_	0	root	_	_
10	that	that	IN	_	19	mark	_	_
11	concomitant	concomitant	JJ	_	12	attr	_	_
12	administration	administration	NN	_	19	dep	_	_
13	of	of	IN	_	14	case	_	_
14	drug3	drug0	NN	_	12	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	drug4	drug0	NN	_	14	conj	_	_
17	does	do	VBZ	_	19	aux	_	_
18	not	not	RB	_	19	neg	_	_
19	alter	alter	VB	_	9	comp	_	_
20	drug5	drug0	NN	_	22	com	_	_
21	plasma	plasma	NN	_	22	com	_	_
22	levels	level	NNS	_	19	obj	_	_
23	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	concentrations	concentration	NNS	_	3	dep	_	_
3	were	be	VBD	_	0	root	_	_
4	equivocally	equivocally	RB	_	5	adv	_	_
5	higher	high	JJR	_	3	dep	_	_
6	when	when	WRB	_	7	adv	_	_
7	given	give	VBN	_	3	comp	_	_
8	with	with	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	3	p	_	_
11	but	but	CC	_	3	cc	_	_
12	this	this	DT	_	13	dep	_	_
13	is	be	VBZ	_	3	conj	_	_
14	not	not	RB	_	13	neg	_	_
15	likely	likely	JJ	_	13	dep	_	_
16	to	to	TO	_	17	aux	_	_
17	be	be	VB	_	15	comp	_	_
18	clinically	clinically	RB	_	19	adv	_	_
19	important	important	JJ	_	17	dep	_	_
20	.	.	.	_	3	p	_	_

1	When	when	WRB	_	7	adv	_	_
2	drug1	drug0	NN	_	7	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	drug2	drug0	NN	_	2	conj	_	_
5	were	be	VBD	_	7	aux	_	_
6	concomitantly	concomitantly	RB	_	7	adv	_	_
7	administered	administer	VBN	_	14	advcl	_	_
8	intravenously	intravenously	RB	_	7	adv	_	_
9	to	to	TO	_	11	aux	_	_
10	normal	normal	JJ	_	11	attr	_	_
11	volunteers	volunteer	NNS	_	7	ppmod	_	_
12	,	,	,	_	14	p	_	_
13	there	there	EX	_	14	dep	_	_
14	was	be	VBD	_	0	root	_	_
15	a	a	DT	_	18	det	_	_
16	10-20	0	CD	_	18	num	_	_
17	%	%	NN	_	16	meta	_	_
18	increase	increase	NN	_	14	obj	_	_
19	in	in	IN	_	22	case	_	_
20	drug3	drug0	NN	_	22	com	_	_
21	blood	blood	NN	_	22	com	_	_
22	levels	level	NNS	_	18	ppmod	_	_
23	at	at	IN	_	26	case	_	_
24	some	some	DT	_	26	det	_	_
25	time	time	NN	_	26	com	_	_
26	points	point	NNS	_	14	ppmod	_	_
27	.	.	.	_	14	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	did	do	VBD	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	affect	affect	VB	_	0	root	_	_
5	drug2	drug0	NN	_	6	com	_	_
6	pharmacokinetics	pharmacokinetics	NNS	_	4	obj	_	_
7	.	.	.	_	4	p	_	_

1	When	when	WRB	_	8	adv	_	_
2	intravenous	intravenous	JJ	_	3	attr	_	_
3	drug1	drug0	NN	_	8	dep	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	were	be	VBD	_	8	aux	_	_
7	concomitantly	concomitantly	RB	_	8	adv	_	_
8	administered	administer	VBN	_	20	advcl	_	_
9	in	in	IN	_	11	case	_	_
10	normal	normal	JJ	_	11	attr	_	_
11	subjects	subject	NNS	_	8	ppmod	_	_
12	,	,	,	_	20	p	_	_
13	no	no	DT	_	14	det	_	_
14	effect	effect	NN	_	20	dep	_	_
15	on	on	IN	_	18	case	_	_
16	drug3	drug0	NN	_	18	com	_	_
17	blood	blood	NN	_	18	com	_	_
18	levels	level	NNS	_	14	ppmod	_	_
19	was	be	VBD	_	20	aux	_	_
20	seen	see	VBN	_	0	root	_	_
21	,	,	,	_	20	p	_	_
22	but	but	CC	_	20	cc	_	_
23	drug4	drug0	NN	_	26	attr	_	_
24	steady-state	steady-state	JJ	_	26	attr	_	_
25	blood	blood	NN	_	26	com	_	_
26	levels	level	NNS	_	28	dep	_	_
27	were	be	VBD	_	28	aux	_	_
28	increased	increase	VBN	_	20	conj	_	_
29	by	by	IN	_	30	case	_	_
30	46	0	CD	_	28	ppmod	_	_
31	%	%	NN	_	30	meta	_	_
32	in	in	IN	_	34	case	_	_
33	the	the	DT	_	34	det	_	_
34	presence	presence	NN	_	28	ppmod	_	_
35	of	of	IN	_	36	case	_	_
36	drug5	drug0	NN	_	34	ppmod	_	_
37	.	.	.	_	20	p	_	_

1	No	no	DT	_	4	det	_	_
2	other	other	JJ	_	4	attr	_	_
3	pharmacokinetic	pharmacokinetic	JJ	_	4	attr	_	_
4	parameters	parameter	NNS	_	6	dep	_	_
5	were	be	VBD	_	6	aux	_	_
6	changed	change	VBN	_	0	root	_	_
7	.	.	.	_	6	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	14	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	on	on	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	duration	duration	NN	_	2	ppmod	_	_
8	of	of	IN	_	12	case	_	_
9	drug2	drug0	NN	_	12	attr	_	_
10	-induced	-induced	JJ	_	12	attr	_	_
11	neuromuscular	neuromuscular	JJ	_	12	attr	_	_
12	blockade	blockade	NN	_	7	ppmod	_	_
13	was	be	VBD	_	14	aux	_	_
14	studied	study	VBN	_	0	root	_	_
15	in	in	IN	_	16	case	_	_
16	patients	patient	NNS	_	14	ppmod	_	_
17	undergoing	undergo	VBG	_	16	acl	_	_
18	surgery	surgery	NN	_	17	obj	_	_
19	.	.	.	_	14	p	_	_

1	The	the	DT	_	2	det	_	_
2	onset	onset	NN	_	9	dep	_	_
3	of	of	IN	_	5	case	_	_
4	neuromuscular	neuromuscular	JJ	_	5	attr	_	_
5	blockade	blockade	NN	_	2	ppmod	_	_
6	by	by	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	was	be	VBD	_	9	aux	_	_
9	unaffected	unaffected	VBN	_	0	root	_	_
10	by	by	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	,	,	,	_	9	p	_	_
13	but	but	CC	_	9	cc	_	_
14	the	the	DT	_	15	det	_	_
15	duration	duration	NN	_	20	dep	_	_
16	of	of	IN	_	18	case	_	_
17	neuromuscular	neuromuscular	JJ	_	18	attr	_	_
18	blockade	blockade	NN	_	15	ppmod	_	_
19	was	be	VBD	_	20	aux	_	_
20	prolonged	prolong	VBD	_	9	conj	_	_
21	from	from	IN	_	23	case	_	_
22	5	0	CD	_	23	num	_	_
23	minutes	minute	NNS	_	20	ppmod	_	_
24	to	to	TO	_	26	aux	_	_
25	8	0	CD	_	26	num	_	_
26	minutes	minute	NNS	_	23	ppmod	_	_
27	.	.	.	_	9	p	_	_

1	Although	although	IN	_	10	mark	_	_
2	the	the	DT	_	3	det	_	_
3	interactions	interaction	NNS	_	10	dep	_	_
4	observed	observe	VBN	_	3	acl	_	_
5	in	in	IN	_	7	case	_	_
6	these	these	DT	_	7	det	_	_
7	studies	study	NNS	_	4	ppmod	_	_
8	do	do	VBP	_	10	aux	_	_
9	not	not	RB	_	10	neg	_	_
10	appear	appear	VB	_	21	advcl	_	_
11	to	to	TO	_	12	aux	_	_
12	be	be	VB	_	10	comp	_	_
13	of	of	IN	_	16	case	_	_
14	major	major	JJ	_	16	attr	_	_
15	clinical	clinical	JJ	_	16	attr	_	_
16	importance	importance	NN	_	12	ppmod	_	_
17	,	,	,	_	21	p	_	_
18	drug1	drug0	NN	_	21	dep	_	_
19	should	should	MD	_	21	modal	_	_
20	be	be	VB	_	21	aux	_	_
21	titrated	titrate	VBN	_	0	root	_	_
22	with	with	IN	_	23	case	_	_
23	caution	caution	NN	_	21	ppmod	_	_
24	in	in	IN	_	25	case	_	_
25	patients	patient	NNS	_	23	ppmod	_	_
26	being	be	VBG	_	27	aux	_	_
27	treated	treat	VBN	_	25	acl	_	_
28	concurrently	concurrently	RB	_	27	adv	_	_
29	with	with	IN	_	30	case	_	_
30	drug2	drug0	NN	_	27	ppmod	_	_
31	,	,	,	_	30	p	_	_
32	drug3	drug0	NN	_	30	conj	_	_
33	,	,	,	_	32	p	_	_
34	drug4	drug0	NN	_	30	conj	_	_
35	or	or	CC	_	34	cc	_	_
36	drug5	drug0	NN	_	30	conj	_	_
37	.	.	.	_	21	p	_	_

1	While	while	IN	_	2	mark	_	_
2	taking	take	VBG	_	19	advcl	_	_
3	drug1	drug0	NN	_	2	obj	_	_
4	,	,	,	_	19	p	_	_
5	patients	patient	NNS	_	19	dep	_	_
6	with	with	IN	_	8	case	_	_
7	a	a	DT	_	8	det	_	_
8	history	history	NN	_	5	ppmod	_	_
9	of	of	IN	_	12	case	_	_
10	severe	severe	JJ	_	12	attr	_	_
11	anaphylactic	anaphylactic	JJ	_	12	attr	_	_
12	reaction	reaction	NN	_	8	ppmod	_	_
13	to	to	TO	_	15	aux	_	_
14	a	a	DT	_	15	det	_	_
15	variety	variety	NN	_	12	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	allergens	allergen	NNS	_	15	ppmod	_	_
18	may	may	MD	_	19	modal	_	_
19	be	be	VB	_	0	root	_	_
20	more	more	RBR	_	21	adv	_	_
21	reactive	reactive	JJ	_	19	dep	_	_
22	to	to	TO	_	24	aux	_	_
23	repeated	repeated	JJ	_	24	attr	_	_
24	challenge	challenge	NN	_	21	ppmod	_	_
25	,	,	,	_	21	p	_	_
26	either	either	CC	_	21	cc	_	_
27	accidental	accidental	JJ	_	21	conj	_	_
28	,	,	,	_	27	p	_	_
29	diagnostic	diagnostic	JJ	_	21	conj	_	_
30	,	,	,	_	29	p	_	_
31	or	or	CC	_	29	cc	_	_
32	therapeutic	therapeutic	JJ	_	21	conj	_	_
33	.	.	.	_	19	p	_	_

1	Such	such	JJ	_	2	attr	_	_
2	patients	patient	NNS	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	be	be	VB	_	0	root	_	_
5	unresponsive	unresponsive	JJ	_	4	dep	_	_
6	to	to	TO	_	9	aux	_	_
7	the	the	DT	_	9	det	_	_
8	usual	usual	JJ	_	9	attr	_	_
9	doses	dose	NNS	_	5	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	used	use	VBN	_	9	acl	_	_
13	to	to	TO	_	14	aux	_	_
14	treat	treat	VB	_	12	comp	_	_
15	allergic	allergic	JJ	_	16	attr	_	_
16	reaction	reaction	NN	_	14	obj	_	_
17	.	.	.	_	4	p	_	_

1	Caution	caution	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	exercised	exercise	VBN	_	0	root	_	_
5	when	when	WRB	_	6	adv	_	_
6	considering	consider	VBG	_	4	comp	_	_
7	the	the	DT	_	8	det	_	_
8	use	use	NN	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug2	drug0	NN	_	10	conj	_	_
13	in	in	IN	_	14	case	_	_
14	patients	patient	NNS	_	8	ppmod	_	_
15	with	with	IN	_	18	case	_	_
16	depressed	depressed	JJ	_	18	attr	_	_
17	myocardial	myocardial	JJ	_	18	attr	_	_
18	function	function	NN	_	14	ppmod	_	_
19	.	.	.	_	4	p	_	_

1	Fatal	fatal	JJ	_	2	attr	_	_
2	cardiac	cardiac	JJ	_	5	dep	_	_
3	arrests	arrest	VBZ	_	2	attr	_	_
4	have	have	VBP	_	5	aux	_	_
5	occurred	occur	VBN	_	0	root	_	_
6	in	in	IN	_	7	case	_	_
7	patients	patient	NNS	_	5	ppmod	_	_
8	receiving	receive	VBG	_	7	acl	_	_
9	both	both	DT	_	10	det	_	_
10	drugs	drug	NNS	_	8	obj	_	_
11	.	.	.	_	5	p	_	_

1	Additionally	additionally	RB	_	7	adv	_	_
2	,	,	,	_	7	p	_	_
3	drug1	drug0	NN	_	7	dep	_	_
4	should	should	MD	_	7	modal	_	_
5	not	not	RB	_	7	neg	_	_
6	be	be	VB	_	7	aux	_	_
7	used	use	VBN	_	0	root	_	_
8	to	to	TO	_	9	aux	_	_
9	control	control	VB	_	7	comp	_	_
10	supraventricular	supraventricular	JJ	_	11	attr	_	_
11	tachycardia	tachycardia	NN	_	9	obj	_	_
12	in	in	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	presence	presence	NN	_	9	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	agents	agent	NNS	_	14	ppmod	_	_
17	which	which	WDT	_	18	dep	_	_
18	are	be	VBP	_	16	relcl	_	_
19	vasoconstrictive	vasoconstrictive	JJ	_	18	dep	_	_
20	and	and	CC	_	19	cc	_	_
21	inotropic	inotropic	JJ	_	19	conj	_	_
22	such	such	JJ	_	24	adv	_	_
23	as	as	IN	_	24	case	_	_
24	drug2	drug0	NN	_	18	ppmod	_	_
25	,	,	,	_	24	p	_	_
26	drug3	drug0	NN	_	24	conj	_	_
27	,	,	,	_	26	p	_	_
28	and	and	CC	_	26	cc	_	_
29	drug4	drug0	NN	_	24	conj	_	_
30	because	because	IN	_	33	case	_	_
31	of	of	IN	_	33	case	_	_
32	the	the	DT	_	33	det	_	_
33	danger	danger	NN	_	18	ppmod	_	_
34	of	of	IN	_	35	case	_	_
35	blocking	block	VBG	_	33	ppmod	_	_
36	cardiac	cardiac	JJ	_	37	attr	_	_
37	contractility	contractility	NN	_	35	obj	_	_
38	when	when	WRB	_	42	adv	_	_
39	systemic	systemic	JJ	_	41	attr	_	_
40	vascular	vascular	JJ	_	41	attr	_	_
41	resistance	resistance	NN	_	42	dep	_	_
42	is	be	VBZ	_	9	comp	_	_
43	high	high	JJ	_	42	dep	_	_
44	.	.	.	_	7	p	_	_

1	In	in	IN	_	2	case	_	_
2	patients	patient	NNS	_	34	ppmod	_	_
3	receiving	receive	VBG	_	2	acl	_	_
4	nonselective	nonselective	JJ	_	5	attr	_	_
5	drug1	drug0	NN	_	3	obj	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	drug2	drug0	NN	_	5	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	(	-lrb-	-LRB-	_	12	p	_	_
10	e.g.	e.g.	FW	_	12	adv	_	_
11	,	,	,	_	12	p	_	_
12	drug3	drug0	NN	_	5	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	in	in	IN	_	15	case	_	_
15	combination	combination	NN	_	3	ppmod	_	_
16	with	with	IN	_	17	case	_	_
17	drug4	drug0	NN	_	15	ppmod	_	_
18	(	-lrb-	-LRB-	_	21	p	_	_
19	e.g.	e.g.	FW	_	21	ppmod	_	_
20	,	,	,	_	21	p	_	_
21	drug5	drug0	NN	_	17	prn	_	_
22	,	,	,	_	21	p	_	_
23	drug6	drug0	NN	_	21	appo	_	_
24	,	,	,	_	21	p	_	_
25	drug7	drug0	NN	_	21	appo	_	_
26	,	,	,	_	21	p	_	_
27	drug8	drug0	NN	_	21	appo	_	_
28	,	,	,	_	21	p	_	_
29	drug9	drug0	NN	_	21	appo	_	_
30	)	-rrb-	-RRB-	_	21	p	_	_
31	,	,	,	_	34	p	_	_
32	there	there	EX	_	34	dep	_	_
33	have	have	VBP	_	34	aux	_	_
34	been	be	VBN	_	0	root	_	_
35	reports	report	NNS	_	34	obj	_	_
36	of	of	IN	_	42	case	_	_
37	serious	serious	JJ	_	42	attr	_	_
38	,	,	,	_	42	p	_	_
39	sometimes	sometimes	RB	_	40	adv	_	_
40	fatal	fatal	JJ	_	42	attr	_	_
41	,	,	,	_	42	p	_	_
42	reactions	reaction	NNS	_	35	ppmod	_	_
43	.	.	.	_	34	p	_	_

1	Because	because	IN	_	3	mark	_	_
2	drug1	drug0	NN	_	3	dep	_	_
3	is	be	VBZ	_	15	advcl	_	_
4	a	a	DT	_	6	det	_	_
5	serotonin	serotonin	NN	_	6	com	_	_
6	releaser	releaser	NN	_	3	obj	_	_
7	and	and	CC	_	6	cc	_	_
8	reuptake	reuptake	NN	_	9	com	_	_
9	inhibitor	inhibitor	NN	_	6	conj	_	_
10	,	,	,	_	15	p	_	_
11	drug2	drug0	NN	_	15	dep	_	_
12	should	should	MD	_	15	modal	_	_
13	not	not	RB	_	15	neg	_	_
14	be	be	VB	_	15	aux	_	_
15	used	use	VBN	_	0	root	_	_
16	concomitantly	concomitantly	RB	_	15	adv	_	_
17	with	with	IN	_	19	case	_	_
18	a	a	DT	_	19	det	_	_
19	drug3	drug0	NN	_	15	ppmod	_	_
20	.	.	.	_	15	p	_	_

1	At	at	IN	_	3	case	_	_
2	least	least	JJS	_	3	attr	_	_
3	14	0	CD	_	4	num	_	_
4	days	day	NNS	_	6	dep	_	_
5	should	should	MD	_	6	modal	_	_
6	elapse	elapse	VB	_	0	root	_	_
7	between	between	IN	_	8	case	_	_
8	discontinuation	discontinuation	NN	_	6	ppmod	_	_
9	of	of	IN	_	11	case	_	_
10	a	a	DT	_	11	det	_	_
11	drug1	drug0	NN	_	8	ppmod	_	_
12	and	and	CC	_	8	cc	_	_
13	initiation	initiation	NN	_	8	conj	_	_
14	of	of	IN	_	15	case	_	_
15	treatment	treatment	NN	_	13	ppmod	_	_
16	with	with	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	.	.	.	_	6	p	_	_

1	At	at	IN	_	3	case	_	_
2	least	least	JJS	_	3	attr	_	_
3	3	0	CD	_	4	num	_	_
4	weeks	week	NNS	_	6	dep	_	_
5	should	should	MD	_	6	modal	_	_
6	elapse	elapse	VB	_	0	root	_	_
7	between	between	IN	_	8	case	_	_
8	discontinuation	discontinuation	NN	_	6	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	8	cc	_	_
12	initiation	initiation	NN	_	8	conj	_	_
13	of	of	IN	_	14	case	_	_
14	treatment	treatment	NN	_	12	ppmod	_	_
15	with	with	IN	_	17	case	_	_
16	a	a	DT	_	17	det	_	_
17	drug2	drug0	NN	_	14	ppmod	_	_
18	.	.	.	_	6	p	_	_

1	A	a	DT	_	7	det	_	_
2	rare	rare	JJ	_	7	attr	_	_
3	,	,	,	_	2	p	_	_
4	but	but	CC	_	2	cc	_	_
5	serious	serious	JJ	_	2	conj	_	_
6	,	,	,	_	5	p	_	_
7	constellation	constellation	NN	_	17	dep	_	_
8	of	of	IN	_	9	case	_	_
9	symptoms	symptom	NNS	_	7	ppmod	_	_
10	,	,	,	_	7	p	_	_
11	termed	term	VBN	_	7	acl	_	_
12	serotonin	serotonin	NN	_	13	com	_	_
13	syndrome	syndrome	NN	_	11	obj	_	_
14	,	,	,	_	7	p	_	_
15	has	have	VBZ	_	17	aux	_	_
16	been	be	VBN	_	17	aux	_	_
17	reported	report	VBN	_	0	root	_	_
18	with	with	IN	_	21	case	_	_
19	the	the	DT	_	21	det	_	_
20	concomitant	concomitant	JJ	_	21	attr	_	_
21	use	use	NN	_	17	ppmod	_	_
22	of	of	IN	_	23	case	_	_
23	drug1	drug0	NN	_	21	ppmod	_	_
24	(	-lrb-	-LRB-	_	25	p	_	_
25	drug2	drug0	NN	_	23	prn	_	_
26	)	-rrb-	-RRB-	_	25	p	_	_
27	and	and	CC	_	23	cc	_	_
28	agents	agent	NNS	_	23	conj	_	_
29	for	for	IN	_	31	case	_	_
30	migraine	migraine	NN	_	31	com	_	_
31	therapy	therapy	NN	_	28	ppmod	_	_
32	,	,	,	_	28	p	_	_
33	such	such	JJ	_	35	adv	_	_
34	as	as	IN	_	35	case	_	_
35	drug3	drug0	NN	_	28	ppmod	_	_
36	(	-lrb-	-LRB-	_	37	p	_	_
37	drug4	drug0	NN	_	35	prn	_	_
38	)	-rrb-	-RRB-	_	37	p	_	_
39	and	and	CC	_	35	cc	_	_
40	drug5	drug0	NN	_	35	conj	_	_
41	.	.	.	_	17	p	_	_

1	The	the	DT	_	2	det	_	_
2	syndrome	syndrome	NN	_	3	dep	_	_
3	requires	require	VBZ	_	0	root	_	_
4	immediate	immediate	JJ	_	6	attr	_	_
5	medical	medical	JJ	_	6	attr	_	_
6	attention	attention	NN	_	3	obj	_	_
7	and	and	CC	_	3	cc	_	_
8	may	may	MD	_	9	modal	_	_
9	include	include	VB	_	3	conj	_	_
10	one	#crd#	CD	_	32	num	_	_
11	or	or	CC	_	10	cc	_	_
12	more	more	JJR	_	10	conj	_	_
13	of	of	IN	_	32	case	_	_
14	the	the	DT	_	16	det	_	_
15	following	follow	VBG	_	16	attr	_	_
16	symptoms	symptom	NNS	_	32	attr	_	_
17	:	:	:	_	16	p	_	_
18	excitement	excitement	NN	_	16	appo	_	_
19	,	,	,	_	16	p	_	_
20	hypomania	hypomania	NN	_	16	appo	_	_
21	,	,	,	_	16	p	_	_
22	restlessness	restlessness	NN	_	16	appo	_	_
23	,	,	,	_	16	p	_	_
24	loss	loss	NN	_	16	appo	_	_
25	of	of	IN	_	26	case	_	_
26	consciousness	consciousness	NN	_	24	ppmod	_	_
27	,	,	,	_	16	p	_	_
28	confusion	confusion	NN	_	16	appo	_	_
29	,	,	,	_	16	p	_	_
30	disorientation	disorientation	NN	_	16	appo	_	_
31	,	,	,	_	16	p	_	_
32	anxiety	anxiety	NN	_	9	obj	_	_
33	,	,	,	_	32	p	_	_
34	agitation	agitation	NN	_	32	conj	_	_
35	,	,	,	_	34	p	_	_
36	motor	motor	NN	_	37	com	_	_
37	weakness	weakness	NN	_	32	conj	_	_
38	,	,	,	_	37	p	_	_
39	myoclonus	myoclonus	NN	_	32	conj	_	_
40	,	,	,	_	39	p	_	_
41	tremor	tremor	NN	_	32	conj	_	_
42	,	,	,	_	41	p	_	_
43	hemiballismus	hemiballismus	NN	_	32	conj	_	_
44	,	,	,	_	43	p	_	_
45	hyperreflexia	hyperreflexia	NN	_	32	conj	_	_
46	,	,	,	_	45	p	_	_
47	ataxia	ataxia	NN	_	32	conj	_	_
48	,	,	,	_	47	p	_	_
49	dysarthria	dysarthria	NN	_	32	conj	_	_
50	,	,	,	_	49	p	_	_
51	incoordination	incoordination	NN	_	32	conj	_	_
52	,	,	,	_	51	p	_	_
53	hyperthermia	hyperthermia	NN	_	32	conj	_	_
54	,	,	,	_	53	p	_	_
55	shivering	shivering	NN	_	32	conj	_	_
56	,	,	,	_	55	p	_	_
57	pupillary	pupillary	JJ	_	58	attr	_	_
58	dilation	dilation	NN	_	32	conj	_	_
59	,	,	,	_	58	p	_	_
60	diaphoresis	diaphoresis	NN	_	32	conj	_	_
61	,	,	,	_	60	p	_	_
62	emesis	emesis	NN	_	32	conj	_	_
63	,	,	,	_	62	p	_	_
64	and	and	CC	_	62	cc	_	_
65	tachycardia	tachycardia	NN	_	32	conj	_	_
66	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	should	should	MD	_	5	modal	_	_
3	not	not	RB	_	5	neg	_	_
4	be	be	VB	_	5	aux	_	_
5	administered	administer	VBN	_	0	root	_	_
6	with	with	IN	_	8	case	_	_
7	other	other	JJ	_	8	attr	_	_
8	drug2	drug0	NN	_	5	ppmod	_	_
9	.	.	.	_	5	p	_	_

1	The	the	DT	_	3	det	_	_
2	appropriate	appropriate	JJ	_	3	attr	_	_
3	interval	interval	NN	_	14	dep	_	_
4	between	between	IN	_	5	case	_	_
5	administration	administration	NN	_	3	ppmod	_	_
6	of	of	IN	_	8	case	_	_
7	these	these	DT	_	8	det	_	_
8	agents	agent	NNS	_	5	ppmod	_	_
9	and	and	CC	_	5	cc	_	_
10	drug1	drug0	NN	_	5	conj	_	_
11	has	have	VBZ	_	14	aux	_	_
12	not	not	RB	_	14	neg	_	_
13	been	be	VBN	_	14	aux	_	_
14	established	establish	VBN	_	0	root	_	_
15	.	.	.	_	14	p	_	_

1	The	the	DT	_	2	det	_	_
2	use	use	NN	_	13	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	with	with	IN	_	8	case	_	_
6	other	other	JJ	_	8	attr	_	_
7	CNS-active	cns-active	JJ	_	8	attr	_	_
8	drugs	drug	NNS	_	2	ppmod	_	_
9	has	have	VBZ	_	13	aux	_	_
10	not	not	RB	_	13	neg	_	_
11	been	be	VBN	_	13	aux	_	_
12	systematically	systematically	RB	_	13	adv	_	_
13	evaluated	evaluate	VBN	_	0	root	_	_
14	;	;	:	_	13	p	_	_

1	consequently	consequently	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	caution	caution	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	advised	advise	VBN	_	0	root	_	_
6	if	if	IN	_	12	mark	_	_
7	drug1	drug0	NN	_	12	dep	_	_
8	and	and	CC	_	7	cc	_	_
9	such	such	JJ	_	10	attr	_	_
10	drugs	drug	NNS	_	7	conj	_	_
11	are	be	VBP	_	12	aux	_	_
12	prescribed	prescribe	VBN	_	5	comp	_	_
13	concurrently	concurrently	RB	_	12	adv	_	_
14	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	highly	highly	RB	_	4	adv	_	_
4	bound	bind	VBN	_	0	root	_	_
5	to	to	TO	_	7	aux	_	_
6	plasma	plasma	NN	_	7	com	_	_
7	protein	protein	NN	_	4	ppmod	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	99.9	0	CD	_	7	num	_	_
10	%	%	NN	_	9	meta	_	_
11	)	-rrb-	-RRB-	_	9	p	_	_
12	.	.	.	_	4	p	_	_

1	Therefore	therefore	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	caution	caution	NN	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	used	use	VBN	_	0	root	_	_
7	when	when	WRB	_	8	adv	_	_
8	administering	administer	VBG	_	6	comp	_	_
9	drug1	drug0	NN	_	8	obj	_	_
10	concurrently	concurrently	RB	_	17	adv	_	_
11	with	with	IN	_	17	case	_	_
12	other	other	JJ	_	17	attr	_	_
13	highly	highly	RB	_	16	adv	_	_
14	plasma	plasma	NN	_	15	com	_	_
15	protein-	protein-	NN	_	16	advnp	_	_
16	bound	bind	VBN	_	17	attr	_	_
17	drugs	drug	NNS	_	9	ppmod	_	_
18	with	with	IN	_	21	case	_	_
19	narrow	narrow	JJ	_	21	attr	_	_
20	therapeutic	therapeutic	JJ	_	21	attr	_	_
21	indices	index	NNS	_	8	ppmod	_	_
22	,	,	,	_	6	p	_	_
23	as	as	IN	_	29	mark	_	_
24	competition	competition	NN	_	29	dep	_	_
25	for	for	IN	_	27	case	_	_
26	binding	binding	NN	_	27	com	_	_
27	sites	site	NNS	_	24	ppmod	_	_
28	may	may	MD	_	29	modal	_	_
29	occur	occur	VB	_	6	comp	_	_
30	.	.	.	_	6	p	_	_

1	The	the	DT	_	2	det	_	_
2	extent	extent	NN	_	14	dep	_	_
3	of	of	IN	_	6	case	_	_
4	plasma	plasma	NN	_	6	com	_	_
5	protein	protein	NN	_	6	com	_	_
6	binding	binding	NN	_	2	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	in	in	IN	_	11	case	_	_
10	human	human	JJ	_	11	attr	_	_
11	plasma	plasma	NN	_	8	ppmod	_	_
12	is	be	VBZ	_	14	aux	_	_
13	not	not	RB	_	14	neg	_	_
14	affected	affect	VBN	_	0	root	_	_
15	by	by	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	presence	presence	NN	_	14	ppmod	_	_
18	of	of	IN	_	20	case	_	_
19	therapeutic	therapeutic	JJ	_	20	attr	_	_
20	concentrations	concentration	NNS	_	17	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	drug2	drug0	NN	_	20	ppmod	_	_
23	(	-lrb-	-LRB-	_	26	p	_	_
24	15	0	CD	_	26	num	_	_
25	mcg/	mcg/	NN	_	26	com	_	_
26	mL	ml	NN	_	22	prn	_	_
27	)	-rrb-	-RRB-	_	26	p	_	_
28	,	,	,	_	14	p	_	_
29	nor	nor	CC	_	14	cc	_	_
30	is	be	VBZ	_	14	conj	_	_
31	the	the	DT	_	32	det	_	_
32	binding	binding	NN	_	30	obj	_	_
33	of	of	IN	_	34	case	_	_
34	drug3	drug0	NN	_	32	ppmod	_	_
35	affected	affect	VBN	_	34	acl	_	_
36	by	by	IN	_	38	case	_	_
37	the	the	DT	_	38	det	_	_
38	presence	presence	NN	_	35	ppmod	_	_
39	of	of	IN	_	40	case	_	_
40	drug4	drug0	NN	_	38	ppmod	_	_
41	.	.	.	_	14	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Coadministration	coadministration	NN	_	9	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug3	drug0	NN	_	8	com	_	_
8	Suspension	suspension	NN	_	5	conj	_	_
9	results	result	VBZ	_	1	acl	_	_
10	in	in	IN	_	13	case	_	_
11	a	a	DT	_	13	det	_	_
12	significant	significant	JJ	_	13	attr	_	_
13	decrease	decrease	NN	_	9	ppmod	_	_
14	in	in	IN	_	20	case	_	_
15	average	average	JJ	_	20	attr	_	_
16	steady-	steady-	JJ	_	20	attr	_	_
17	state	state	NN	_	20	com	_	_
18	plasma	plasma	NN	_	20	com	_	_
19	drug4	drug0	NN	_	20	com	_	_
20	concentrations	concentration	NNS	_	13	ppmod	_	_
21	.	.	.	_	1	p	_	_

1	Alternatives	alternative	NNS	_	6	dep	_	_
2	to	to	TO	_	3	aux	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	considered	consider	VBN	_	0	root	_	_
7	during	during	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	course	course	NN	_	6	ppmod	_	_
10	of	of	IN	_	12	case	_	_
11	PCP	pcp	NN	_	12	com	_	_
12	treatment	treatment	NN	_	9	ppmod	_	_
13	with	with	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	,	,	,	_	1	p	_	_
3	another	another	DT	_	4	det	_	_
4	drug2	drug0	NN	_	1	appo	_	_
5	,	,	,	_	1	p	_	_
6	is	be	VBZ	_	0	root	_	_
7	structurally	structurally	RB	_	8	adv	_	_
8	similar	similar	JJ	_	6	dep	_	_
9	to	to	TO	_	10	aux	_	_
10	drug3	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	6	cc	_	_
12	may	may	MD	_	14	modal	_	_
13	possibly	possibly	RB	_	14	adv	_	_
14	have	have	VB	_	6	conj	_	_
15	some	some	DT	_	14	obj	_	_
16	of	of	IN	_	20	case	_	_
17	the	the	DT	_	20	det	_	_
18	same	same	JJ	_	20	attr	_	_
19	drug	drug	NN	_	20	com	_	_
20	interactions	interaction	NNS	_	15	ppmod	_	_
21	as	as	IN	_	22	case	_	_
22	drug4	drug0	NN	_	20	ppmod	_	_
23	.	.	.	_	6	p	_	_

1	No	no	NN	_	3	com	_	_
2	interaction	interaction	NN	_	3	com	_	_
3	trials	trial	NNS	_	6	dep	_	_
4	have	have	VBP	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	conducted	conduct	VBN	_	0	root	_	_
7	with	with	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	drug2	drug0	NN	_	8	conj	_	_
11	.	.	.	_	6	p	_	_

1	Drug/	drug/	NN	_	4	com	_	_
2	Laboratory	laboratory	NN	_	4	com	_	_
3	Test	test	NN	_	4	com	_	_
4	Interactions	interaction	NNS	_	0	root	_	_
5	:	:	:	_	4	p	_	_
6	It	it	PRP	_	9	dep	_	_
7	is	be	VBZ	_	9	aux	_	_
8	not	not	RB	_	9	neg	_	_
9	known	know	VBN	_	4	acl	_	_
10	if	if	IN	_	12	mark	_	_
11	drug1	drug0	NN	_	12	dep	_	_
12	interferes	interfere	VBZ	_	9	comp	_	_
13	with	with	IN	_	19	case	_	_
14	clinical	clinical	JJ	_	19	attr	_	_
15	laboratory	laboratory	JJ	_	19	attr	_	_
16	test	test	NN	_	19	com	_	_
17	or	or	NN	_	19	com	_	_
18	assay	assay	NN	_	19	com	_	_
19	results	result	NNS	_	12	ppmod	_	_
20	.	.	.	_	4	p	_	_

1	Medications	medication	NNS	_	13	dep	_	_
2	that	that	WDT	_	3	dep	_	_
3	interfere	interfere	VBP	_	1	relcl	_	_
4	with	with	IN	_	7	case	_	_
5	your	your	NN	_	7	com	_	_
6	bodys	bodys	NN	_	7	com	_	_
7	ability	ability	NN	_	3	ppmod	_	_
8	to	to	TO	_	9	aux	_	_
9	use	use	VB	_	7	acl	_	_
10	folate	folate	NN	_	9	obj	_	_
11	may	may	MD	_	13	modal	_	_
12	also	also	RB	_	13	adv	_	_
13	increase	increase	VBP	_	0	root	_	_
14	the	the	DT	_	15	det	_	_
15	need	need	NN	_	13	obj	_	_
16	for	for	IN	_	18	case	_	_
17	this	this	DT	_	18	det	_	_
18	drug1	drug0	NN	_	15	ppmod	_	_
19	.	.	.	_	13	p	_	_

1	Medications	medication	NNS	_	3	dep	_	_
2	can	can	MD	_	3	modal	_	_
3	interfere	interfere	VB	_	55	advcl	_	_
4	with	with	IN	_	6	case	_	_
5	folate	folate	NN	_	6	com	_	_
6	utilization	utilization	NN	_	3	ppmod	_	_
7	,	,	,	_	3	p	_	_
8	including	include	VBG	_	3	comp	_	_
9	:	:	:	_	55	p	_	_
10	drug1	drug0	NN	_	19	attr	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	such	such	JJ	_	19	prn	_	_
13	as	as	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	,	,	,	_	14	p	_	_
16	and	and	CC	_	14	cc	_	_
17	drug3	drug0	NN	_	14	conj	_	_
18	)	-rrb-	-RRB-	_	12	p	_	_
19	drug4	drug0	NNS	_	32	dep	_	_
20	(	-lrb-	-LRB-	_	22	p	_	_
21	sometimes	sometimes	RB	_	22	adv	_	_
22	prescribed	prescribe	VBN	_	19	prn	_	_
23	to	to	TO	_	24	aux	_	_
24	control	control	VB	_	22	comp	_	_
25	blood	blood	NN	_	26	com	_	_
26	sugar	sugar	NN	_	24	obj	_	_
27	in	in	IN	_	30	case	_	_
28	type	type	NN	_	30	attr	_	_
29	2	0	CD	_	30	num	_	_
30	diabetes	diabetes	NNS	_	26	ppmod	_	_
31	)	-rrb-	-RRB-	_	22	p	_	_
32	drug5	drug0	VBN	_	55	advcl	_	_
33	(	-lrb-	-LRB-	_	34	p	_	_
34	used	use	VBN	_	46	prn	_	_
35	to	to	TO	_	36	aux	_	_
36	control	control	VB	_	34	comp	_	_
37	inflammation	inflammation	NN	_	36	obj	_	_
38	associated	associate	VBN	_	37	acl	_	_
39	with	with	IN	_	41	case	_	_
40	Crohns	crohns	NN	_	41	com	_	_
41	disease	disease	NN	_	38	ppmod	_	_
42	and	and	CC	_	41	cc	_	_
43	ulcerative	ulcerative	JJ	_	44	attr	_	_
44	colitis	colitis	NN	_	41	conj	_	_
45	)	-rrb-	-RRB-	_	34	p	_	_
46	drug6	drug0	NN	_	32	obj	_	_
47	(	-lrb-	-LRB-	_	49	p	_	_
48	a	a	DT	_	49	det	_	_
49	drug7	drug0	NN	_	46	prn	_	_
50	)	-rrb-	-RRB-	_	49	p	_	_
51	drug8	drug0	:	_	55	p	_	_
52	There	there	EX	_	55	dep	_	_
53	has	have	VBZ	_	55	aux	_	_
54	been	be	VBN	_	55	aux	_	_
55	concern	concern	VBN	_	0	root	_	_
56	about	about	IN	_	58	case	_	_
57	the	the	DT	_	58	det	_	_
58	interaction	interaction	NN	_	55	ppmod	_	_
59	between	between	IN	_	60	case	_	_
60	drug9	drug0	NN	_	58	ppmod	_	_
61	and	and	CC	_	60	cc	_	_
62	drug10	drug0	NN	_	60	conj	_	_
63	.	.	.	_	55	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	supplements	supplement	NNS	_	4	dep	_	_
3	can	can	MD	_	4	modal	_	_
4	correct	correct	VB	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	anemia	anemia	NN	_	4	obj	_	_
7	associated	associate	VBN	_	6	acl	_	_
8	with	with	IN	_	11	case	_	_
9	vitamin	vitamin	NN	_	11	com	_	_
10	B12	b0	NN	_	11	com	_	_
11	deficiency	deficiency	NN	_	7	ppmod	_	_
12	.	.	.	_	4	p	_	_

1	Unfortunately	unfortunately	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	drug1	drug0	NN	_	6	dep	_	_
4	will	will	MD	_	6	modal	_	_
5	not	not	RB	_	6	neg	_	_
6	correct	correct	VB	_	0	root	_	_
7	changes	change	NNS	_	6	obj	_	_
8	in	in	IN	_	11	case	_	_
9	the	the	DT	_	11	det	_	_
10	nervous	nervous	JJ	_	11	attr	_	_
11	system	system	NN	_	7	ppmod	_	_
12	that	that	WDT	_	13	dep	_	_
13	result	result	VBP	_	7	relcl	_	_
14	from	from	IN	_	17	case	_	_
15	vitamin	vitamin	NN	_	17	com	_	_
16	B12	b0	NN	_	17	com	_	_
17	deficiency	deficiency	NN	_	13	ppmod	_	_
18	.	.	.	_	6	p	_	_

1	Permanent	permanent	JJ	_	3	attr	_	_
2	nerve	nerve	NN	_	3	com	_	_
3	damage	damage	NN	_	6	dep	_	_
4	could	could	MD	_	6	modal	_	_
5	theoretically	theoretically	RB	_	6	adv	_	_
6	occur	occur	VB	_	0	root	_	_
7	if	if	IN	_	13	mark	_	_
8	vitamin	vitamin	NN	_	10	com	_	_
9	B12	b0	NN	_	10	com	_	_
10	deficiency	deficiency	NN	_	13	dep	_	_
11	is	be	VBZ	_	13	aux	_	_
12	not	not	RB	_	13	neg	_	_
13	treated	treat	VBN	_	6	comp	_	_
14	.	.	.	_	6	p	_	_

1	Therefore	therefore	RB	_	9	adv	_	_
2	,	,	,	_	9	p	_	_
3	intake	intake	NN	_	9	dep	_	_
4	of	of	IN	_	6	case	_	_
5	supplemental	supplemental	JJ	_	6	attr	_	_
6	drug1	drug0	NN	_	3	ppmod	_	_
7	should	should	MD	_	9	modal	_	_
8	not	not	RB	_	9	neg	_	_
9	exceed	exceed	VB	_	0	root	_	_
10	1000	0	CD	_	11	num	_	_
11	micrograms	microgram	NNS	_	9	obj	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	g	g	NN	_	11	prn	_	_
14	,	,	,	_	13	p	_	_
15	sometimes	sometimes	RB	_	13	adv	_	_
16	mcg	mcg	NN	_	13	appo	_	_
17	)	-rrb-	-RRB-	_	13	p	_	_
18	per	per	IN	_	19	case	_	_
19	day	day	NN	_	11	ppmod	_	_
20	to	to	TO	_	21	aux	_	_
21	prevent	prevent	VB	_	9	comp	_	_
22	drug2	drug0	NN	_	21	obj	_	_
23	from	from	IN	_	25	case	_	_
24	masking	masking	JJ	_	25	attr	_	_
25	symptoms	symptom	NNS	_	21	ppmod	_	_
26	of	of	IN	_	29	case	_	_
27	vitamin	vitamin	NN	_	29	com	_	_
28	B12	b0	NN	_	29	com	_	_
29	deficiency	deficiency	NN	_	25	ppmod	_	_
30	.	.	.	_	9	p	_	_

1	It	it	PRP	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	important	important	JJ	_	2	dep	_	_
4	for	for	IN	_	8	case	_	_
5	older	old	JJR	_	6	attr	_	_
6	adults	adult	NNS	_	8	dep	_	_
7	to	to	TO	_	8	aux	_	_
8	be	be	VB	_	3	ppmod	_	_
9	aware	aware	NN	_	8	obj	_	_
10	of	of	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	relationship	relationship	NN	_	9	ppmod	_	_
13	between	between	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	drug2	drug0	NN	_	14	conj	_	_
17	because	because	IN	_	19	mark	_	_
18	they	they	PRP	_	19	dep	_	_
19	are	be	VBP	_	8	comp	_	_
20	at	at	IN	_	22	case	_	_
21	greater	great	JJR	_	22	attr	_	_
22	risk	risk	NN	_	19	ppmod	_	_
23	of	of	IN	_	24	case	_	_
24	having	have	VBG	_	22	ppmod	_	_
25	a	a	DT	_	28	det	_	_
26	vitamin	vitamin	NN	_	28	com	_	_
27	B12	b0	NN	_	28	com	_	_
28	deficiency	deficiency	NN	_	24	obj	_	_
29	.	.	.	_	2	p	_	_

1	If	if	IN	_	3	mark	_	_
2	you	you	RB	_	3	adv	_	_
3	are	be	VBP	_	11	advcl	_	_
4	50	0	CD	_	5	num	_	_
5	years	year	NNS	_	9	advnp	_	_
6	of	of	IN	_	7	case	_	_
7	age	age	NN	_	5	ppmod	_	_
8	or	or	CC	_	9	cc	_	_
9	older	old	JJR	_	3	dep	_	_
10	,	,	,	_	11	p	_	_
11	ask	ask	VB	_	0	root	_	_
12	your	your	NN	_	13	com	_	_
13	physician	physician	NN	_	15	dep	_	_
14	to	to	TO	_	15	aux	_	_
15	check	check	VB	_	11	comp	_	_
16	your	your	JJ	_	18	attr	_	_
17	B12	b0	NN	_	18	com	_	_
18	status	status	NN	_	15	obj	_	_
19	before	before	IN	_	21	mark	_	_
20	you	you	VBN	_	21	aux	_	_
21	take	take	VB	_	15	comp	_	_
22	a	a	DT	_	23	det	_	_
23	supplement	supplement	NN	_	21	obj	_	_
24	that	that	WDT	_	25	dep	_	_
25	contains	contain	VBZ	_	23	relcl	_	_
26	drug1	drug0	NN	_	25	obj	_	_
27	.	.	.	_	11	p	_	_

1	Ergot-containing	ergot-containing	JJ	_	2	attr	_	_
2	drugs	drug	NNS	_	5	dep	_	_
3	have	have	VBP	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	reported	report	VBN	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	cause	cause	VB	_	5	comp	_	_
8	prolonged	prolonged	JJ	_	10	attr	_	_
9	vasospastic	vasospastic	JJ	_	10	attr	_	_
10	reactions	reaction	NNS	_	7	obj	_	_
11	.	.	.	_	5	p	_	_

1	Due	due	IN	_	5	case	_	_
2	to	to	TO	_	5	aux	_	_
3	a	a	DT	_	5	det	_	_
4	theoretical	theoretical	JJ	_	5	attr	_	_
5	risk	risk	NN	_	33	ppmod	_	_
6	of	of	IN	_	9	case	_	_
7	a	a	DT	_	9	det	_	_
8	pharmacodynamic	pharmacodynamic	JJ	_	9	attr	_	_
9	interaction	interaction	NN	_	5	ppmod	_	_
10	,	,	,	_	33	p	_	_
11	use	use	NN	_	33	dep	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	-containing	-containing	JJ	_	13	attr	_	_
15	or	or	CC	_	13	cc	_	_
16	drug2	drug0	NN	_	13	conj	_	_
17	(	-lrb-	-LRB-	_	19	p	_	_
18	like	like	IN	_	19	case	_	_
19	drug3	drug0	NN	_	13	prn	_	_
20	or	or	CC	_	19	cc	_	_
21	drug4	drug0	NN	_	19	conj	_	_
22	)	-rrb-	-RRB-	_	19	p	_	_
23	and	and	CC	_	13	cc	_	_
24	drug5	drug0	NN	_	13	conj	_	_
25	within	within	IN	_	27	case	_	_
26	24	0	CD	_	27	num	_	_
27	hours	hour	NNS	_	11	ppmod	_	_
28	of	of	IN	_	30	case	_	_
29	each	each	DT	_	30	det	_	_
30	other	other	JJ	_	27	ppmod	_	_
31	should	should	MD	_	33	modal	_	_
32	be	be	VB	_	33	aux	_	_
33	avoided	avoid	VBN	_	0	root	_	_
34	(	-lrb-	-LRB-	_	35	p	_	_
35	see	see	VB	_	33	prn	_	_
36	a	a	DT	_	39	det	_	_
37	href=	href=	JJ	_	39	attr	_	_
38	frova_od.htm	#hlink#	NN	_	39	com	_	_
39	#	#	NN	_	41	attr	_	_
40	CI	ci	CD	_	39	num	_	_
41	CONTRAINDICATIONS	contraindication	NNS	_	35	obj	_	_
42	)	-rrb-	-RRB-	_	35	p	_	_
43	.	.	.	_	33	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	use	use	NN	_	15	dep	_	_
3	of	of	IN	_	6	case	_	_
4	other	other	JJ	_	6	attr	_	_
5	5-HT1B/1D	0-ht0b/0d	JJ	_	6	attr	_	_
6	agonists	agonist	NNS	_	2	ppmod	_	_
7	within	within	IN	_	9	case	_	_
8	24	0	CD	_	9	num	_	_
9	hours	hour	NNS	_	2	ppmod	_	_
10	of	of	IN	_	12	case	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	treatment	treatment	NN	_	9	ppmod	_	_
13	is	be	VBZ	_	15	aux	_	_
14	not	not	RB	_	15	neg	_	_
15	recommended	recommend	VBN	_	0	root	_	_
16	.	.	.	_	15	p	_	_

1	drug1	drug0	NN	_	18	dep	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	drug2	drug0	NN	_	1	prn	_	_
4	)	-rrb-	-RRB-	_	3	p	_	_
5	(	-lrb-	-LRB-	_	8	p	_	_
6	e.g.	e.g.	FW	_	8	ppmod	_	_
7	,	,	,	_	8	p	_	_
8	drug3	drug0	NN	_	1	prn	_	_
9	,	,	,	_	8	p	_	_
10	drug4	drug0	NN	_	8	appo	_	_
11	,	,	,	_	8	p	_	_
12	drug5	drug0	NN	_	8	appo	_	_
13	,	,	,	_	8	p	_	_
14	drug6	drug0	NN	_	8	appo	_	_
15	)	-rrb-	-RRB-	_	8	p	_	_
16	have	have	VBP	_	18	aux	_	_
17	been	be	VBN	_	18	aux	_	_
18	reported	report	VBN	_	0	root	_	_
19	,	,	,	_	18	p	_	_
20	rarely	rarely	RB	_	18	adv	_	_
21	,	,	,	_	18	p	_	_
22	to	to	TO	_	23	aux	_	_
23	cause	cause	VB	_	18	comp	_	_
24	weakness	weakness	NN	_	23	obj	_	_
25	,	,	,	_	24	p	_	_
26	hyperreflexia	hyperreflexia	NN	_	24	conj	_	_
27	,	,	,	_	26	p	_	_
28	and	and	CC	_	26	cc	_	_
29	incoordination	incoordination	NN	_	24	conj	_	_
30	when	when	WRB	_	31	adv	_	_
31	coadministered	coadministered	VBN	_	23	comp	_	_
32	with	with	IN	_	33	case	_	_
33	drug7	drug0	NN	_	31	ppmod	_	_
34	.	.	.	_	18	p	_	_

1	If	if	IN	_	11	mark	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	treatment	treatment	NN	_	11	dep	_	_
4	with	with	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	an	an	DT	_	8	det	_	_
8	drug2	drug0	NN	_	5	conj	_	_
9	is	be	VBZ	_	11	aux	_	_
10	clinically	clinically	RB	_	11	adv	_	_
11	warranted	warrant	VBN	_	19	advcl	_	_
12	,	,	,	_	19	p	_	_
13	appropriate	appropriate	JJ	_	14	attr	_	_
14	observation	observation	NN	_	19	dep	_	_
15	of	of	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	patient	patient	NN	_	14	ppmod	_	_
18	is	be	VBZ	_	19	aux	_	_
19	advised	advise	VBN	_	0	root	_	_
20	.	.	.	_	19	p	_	_

1	Drug/Laboratory	drug/laboratory	JJ	_	4	attr	_	_
2	Test	test	NN	_	4	com	_	_
3	Interactions	interaction	NNS	_	4	com	_	_
4	drug1	drug0	NN	_	7	dep	_	_
5	is	be	VBZ	_	7	aux	_	_
6	not	not	RB	_	7	neg	_	_
7	known	know	VBN	_	0	root	_	_
8	to	to	TO	_	9	aux	_	_
9	interfere	interfere	VB	_	7	comp	_	_
10	with	with	IN	_	15	case	_	_
11	commonly	commonly	RB	_	12	adv	_	_
12	employed	employ	VBN	_	15	attr	_	_
13	clinical	clinical	JJ	_	15	attr	_	_
14	laboratory	laboratory	NN	_	15	com	_	_
15	tests	test	NNS	_	9	ppmod	_	_
16	.	.	.	_	7	p	_	_

1	Elevated	elevated	JJ	_	3	attr	_	_
2	plasma	plasma	NN	_	3	com	_	_
3	levels	level	NNS	_	8	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	have	have	VBP	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	reported	report	VBN	_	0	root	_	_
9	with	with	IN	_	12	case	_	_
10	concomitant	concomitant	JJ	_	12	attr	_	_
11	drug2	drug0	NN	_	12	com	_	_
12	use	use	NN	_	8	ppmod	_	_
13	.	.	.	_	8	p	_	_

1	There	there	EX	_	3	dep	_	_
2	have	have	VBP	_	3	aux	_	_
3	been	be	VBN	_	0	root	_	_
4	reports	report	NNS	_	3	obj	_	_
5	of	of	IN	_	9	case	_	_
6	drug1	drug0	JJ	_	9	attr	_	_
7	-related	-related	JJ	_	9	attr	_	_
8	side	side	JJ	_	9	attr	_	_
9	effects	effect	NNS	_	4	ppmod	_	_
10	in	in	IN	_	11	case	_	_
11	patients	patient	NNS	_	9	ppmod	_	_
12	on	on	IN	_	14	case	_	_
13	concomitant	concomitant	JJ	_	14	attr	_	_
14	therapy	therapy	NN	_	11	ppmod	_	_
15	with	with	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	drug3	drug0	NN	_	16	conj	_	_
19	.	.	.	_	3	p	_	_

1	Therefore	therefore	RB	_	10	adv	_	_
2	,	,	,	_	10	p	_	_
3	monitoring	monitoring	NN	_	10	dep	_	_
4	of	of	IN	_	7	case	_	_
5	drug1	drug0	NN	_	7	com	_	_
6	plasma	plasma	NN	_	7	com	_	_
7	levels	level	NNS	_	3	ppmod	_	_
8	should	should	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	considered	consider	VBN	_	0	root	_	_
11	and	and	CC	_	10	cc	_	_
12	dosage	dosage	NN	_	10	conj	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	adjusted	adjust	VBN	_	14	acl	_	_
16	,	,	,	_	12	p	_	_
17	as	as	IN	_	18	mark	_	_
18	required	require	VBN	_	12	comp	_	_
19	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	have	have	VBP	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	shown	show	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	interfere	interfere	VB	_	4	comp	_	_
7	with	with	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	metabolism	metabolism	NN	_	6	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	4	p	_	_

1	This	this	DT	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	lead	lead	VB	_	0	root	_	_
4	to	to	TO	_	6	aux	_	_
5	reduced	reduce	VBN	_	6	attr	_	_
6	clearance	clearance	NN	_	3	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	6	cc	_	_
10	the	the	DT	_	11	det	_	_
11	prolongation	prolongation	NN	_	6	conj	_	_
12	of	of	IN	_	15	case	_	_
13	its	its	PRP$	_	15	poss	_	_
14	plasma	plasma	NN	_	15	com	_	_
15	half-life	half-life	NN	_	11	ppmod	_	_
16	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	7	dep	_	_
2	,	,	,	_	1	p	_	_
3	including	include	VBG	_	4	adv	_	_
4	drug2	drug0	NN	_	1	ppmod	_	_
5	,	,	,	_	1	p	_	_
6	may	may	MD	_	7	modal	_	_
7	enhance	enhance	VB	_	0	root	_	_
8	the	the	DT	_	9	det	_	_
9	effects	effect	NNS	_	7	obj	_	_
10	of	of	IN	_	14	case	_	_
11	the	the	DT	_	14	det	_	_
12	oral	oral	JJ	_	14	attr	_	_
13	drug3	drug0	NN	_	14	com	_	_
14	drug4	drug0	NN	_	9	ppmod	_	_
15	or	or	CC	_	14	cc	_	_
16	its	its	PRP$	_	17	poss	_	_
17	derivatives	derivative	NNS	_	14	conj	_	_
18	.	.	.	_	7	p	_	_

1	When	when	WRB	_	5	adv	_	_
2	these	these	DT	_	3	det	_	_
3	products	product	NNS	_	5	dep	_	_
4	are	be	VBP	_	5	aux	_	_
5	administered	administer	VBN	_	18	advcl	_	_
6	concomitantly	concomitantly	RB	_	5	adv	_	_
7	,	,	,	_	18	p	_	_
8	prothrombin	prothrombin	NN	_	9	com	_	_
9	time	time	NN	_	18	dep	_	_
10	or	or	CC	_	9	cc	_	_
11	other	other	JJ	_	14	attr	_	_
12	suitable	suitable	JJ	_	14	attr	_	_
13	coagulation	coagulation	NN	_	14	com	_	_
14	test	test	NN	_	9	conj	_	_
15	should	should	MD	_	18	modal	_	_
16	be	be	VB	_	18	aux	_	_
17	closely	closely	RB	_	18	adv	_	_
18	monitored	monitor	VBN	_	0	root	_	_
19	.	.	.	_	18	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	interferes	interfere	VBZ	_	0	root	_	_
3	with	with	IN	_	6	case	_	_
4	the	the	DT	_	6	det	_	_
5	therapeutic	therapeutic	JJ	_	6	attr	_	_
6	action	action	NN	_	2	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	containing	contain	VBG	_	0	root	_	_
3	drug2	drug0	NN	_	2	obj	_	_
4	,	,	,	_	3	p	_	_
5	drug3	drug0	NN	_	3	conj	_	_
6	,	,	,	_	5	p	_	_
7	or	or	CC	_	5	cc	_	_
8	drug4	drug0	NN	_	3	conj	_	_
9	;	;	:	_	2	p	_	_

1	drug1	drug0	NN	_	6	attr	_	_
2	or	or	CC	_	3	cc	_	_
3	divalent	divalent	JJ	_	6	attr	_	_
4	or	or	CC	_	3	cc	_	_
5	trivalent	trivalent	JJ	_	3	conj	_	_
6	cations	cation	NNS	_	0	root	_	_
7	such	such	JJ	_	9	adv	_	_
8	as	as	IN	_	9	case	_	_
9	drug2	drug0	NN	_	6	ppmod	_	_
10	;	;	:	_	6	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	containing	contain	VBG	_	0	root	_	_
3	drug2	drug0	NN	_	2	obj	_	_
4	;	;	:	_	2	p	_	_

1	and	and	CC	_	2	cc	_	_
2	drug1	drug0	NN	_	19	dep	_	_
3	,	,	,	_	2	p	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	drug2	drug0	NN	_	2	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	,	,	,	_	2	p	_	_
8	chewable/buffered	chewable/buffered	JJ	_	9	attr	_	_
9	tablets	tablet	NNS	_	2	conj	_	_
10	or	or	CC	_	9	cc	_	_
11	the	the	DT	_	13	det	_	_
12	pediatric	pediatric	JJ	_	13	attr	_	_
13	powder	powder	NN	_	2	conj	_	_
14	for	for	IN	_	16	case	_	_
15	oral	oral	JJ	_	16	attr	_	_
16	solution	solution	NN	_	2	ppmod	_	_
17	may	may	MD	_	19	modal	_	_
18	substantially	substantially	RB	_	19	adv	_	_
19	interfere	interfere	VB	_	0	root	_	_
20	with	with	IN	_	22	case	_	_
21	the	the	DT	_	22	det	_	_
22	absorption	absorption	NN	_	19	ppmod	_	_
23	of	of	IN	_	24	case	_	_
24	drug3	drug0	NN	_	22	ppmod	_	_
25	,	,	,	_	19	p	_	_
26	resulting	result	VBG	_	19	comp	_	_
27	in	in	IN	_	29	case	_	_
28	systemic	systemic	JJ	_	29	attr	_	_
29	levels	level	NNS	_	26	ppmod	_	_
30	considerably	considerably	RB	_	31	adv	_	_
31	lower	low	JJR	_	29	attr	_	_
32	than	than	IN	_	33	mark	_	_
33	desired	desire	VBN	_	31	comp	_	_
34	.	.	.	_	19	p	_	_

1	These	these	DT	_	2	det	_	_
2	agents	agent	NNS	_	6	dep	_	_
3	should	should	MD	_	6	modal	_	_
4	not	not	RB	_	6	neg	_	_
5	be	be	VB	_	6	aux	_	_
6	taken	take	VBN	_	0	root	_	_
7	within	within	IN	_	11	case	_	_
8	the	the	DT	_	11	det	_	_
9	two	#crd#	CD	_	10	num	_	_
10	hour	hour	NN	_	11	com	_	_
11	period	period	NN	_	6	ppmod	_	_
12	before	before	IN	_	6	ppmod	_	_
13	or	or	CC	_	12	cc	_	_
14	within	within	IN	_	17	case	_	_
15	the	the	DT	_	17	det	_	_
16	two-hour	two-hour	JJ	_	17	attr	_	_
17	period	period	NN	_	12	conj	_	_
18	after	after	IN	_	20	case	_	_
19	drug1	drug0	NN	_	20	com	_	_
20	administration	administration	NN	_	17	ppmod	_	_
21	.	.	.	_	6	p	_	_

1	Elevated	elevated	JJ	_	3	attr	_	_
2	serum	serum	NN	_	3	com	_	_
3	levels	level	NNS	_	8	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	have	have	VBP	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	reported	report	VBN	_	0	root	_	_
9	with	with	IN	_	12	case	_	_
10	the	the	DT	_	12	det	_	_
11	concomitant	concomitant	JJ	_	12	attr	_	_
12	use	use	NN	_	8	ppmod	_	_
13	of	of	IN	_	15	case	_	_
14	some	some	DT	_	15	det	_	_
15	drug2	drug0	NN	_	12	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	drug3	drug0	NN	_	15	conj	_	_
18	.	.	.	_	8	p	_	_

1	Therefore	therefore	RB	_	8	adv	_	_
2	,	,	,	_	8	p	_	_
3	drug1	drug0	NN	_	5	com	_	_
4	serum	serum	NN	_	5	com	_	_
5	levels	level	NNS	_	8	dep	_	_
6	should	should	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	monitored	monitor	VBN	_	0	root	_	_
9	and	and	CC	_	8	cc	_	_
10	appropriate	appropriate	JJ	_	13	attr	_	_
11	drug2	drug0	NN	_	13	com	_	_
12	dosage	dosage	NN	_	13	com	_	_
13	adjustments	adjustment	NNS	_	14	dep	_	_
14	made	make	VBD	_	8	conj	_	_
15	when	when	WRB	_	19	adv	_	_
16	these	these	DT	_	17	det	_	_
17	drugs	drug	NNS	_	19	dep	_	_
18	are	be	VBP	_	19	aux	_	_
19	used	use	VBN	_	14	comp	_	_
20	concomitantly	concomitantly	RB	_	19	adv	_	_
21	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	11	dep	_	_
2	when	when	WRB	_	3	adv	_	_
3	used	use	VBN	_	1	relcl	_	_
4	in	in	IN	_	5	case	_	_
5	combination	combination	NN	_	3	ppmod	_	_
6	with	with	IN	_	9	case	_	_
7	other	other	JJ	_	9	attr	_	_
8	cytotoxic	cytotoxic	JJ	_	9	attr	_	_
9	drugs	drug	NNS	_	5	ppmod	_	_
10	may	may	MD	_	11	modal	_	_
11	show	show	VB	_	0	root	_	_
12	on-treatment	on-treatment	JJ	_	14	attr	_	_
13	additive	additive	JJ	_	14	attr	_	_
14	toxicity	toxicity	NN	_	11	obj	_	_
15	,	,	,	_	14	p	_	_
16	especially	especially	RB	_	20	adv	_	_
17	hematologic	hematologic	JJ	_	20	attr	_	_
18	and	and	CC	_	17	cc	_	_
19	gastrointestinal	gastrointestinal	JJ	_	17	conj	_	_
20	effects	effect	NNS	_	14	appo	_	_
21	.	.	.	_	11	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	use	use	NN	_	20	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	with	with	IN	_	8	case	_	_
6	other	other	JJ	_	8	attr	_	_
7	cardioactive	cardioactive	JJ	_	8	attr	_	_
8	compounds	compound	NNS	_	4	ppmod	_	_
9	that	that	WDT	_	11	dep	_	_
10	could	could	MD	_	11	modal	_	_
11	cause	cause	VB	_	8	relcl	_	_
12	heart	heart	NN	_	13	com	_	_
13	failure	failure	NN	_	11	obj	_	_
14	(	-lrb-	-LRB-	_	17	p	_	_
15	e.g.	e.g.	FW	_	17	ppmod	_	_
16	,	,	,	_	17	p	_	_
17	drug2	drug0	NNS	_	13	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	,	,	,	_	2	p	_	_
20	requires	require	VBZ	_	0	root	_	_
21	close	close	JJ	_	22	attr	_	_
22	monitoring	monitoring	NN	_	20	obj	_	_
23	of	of	IN	_	25	case	_	_
24	cardiac	cardiac	JJ	_	25	attr	_	_
25	function	function	NN	_	22	ppmod	_	_
26	throughout	throughout	IN	_	27	case	_	_
27	treatment	treatment	NN	_	20	ppmod	_	_
28	.	.	.	_	20	p	_	_

1	There	there	EX	_	2	dep	_	_
2	are	be	VBP	_	0	root	_	_
3	few	few	JJ	_	4	attr	_	_
4	data	datum	NNS	_	2	obj	_	_
5	regarding	regard	VBG	_	7	adv	_	_
6	the	the	DT	_	7	det	_	_
7	coadministration	coadministration	NN	_	4	ppmod	_	_
8	of	of	IN	_	10	case	_	_
9	radiation	radiation	NN	_	10	com	_	_
10	therapy	therapy	NN	_	7	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug1	drug0	NN	_	10	conj	_	_
13	.	.	.	_	2	p	_	_

1	In	in	IN	_	3	case	_	_
2	adjuvant	adjuvant	JJ	_	3	attr	_	_
3	trials	trial	NNS	_	15	ppmod	_	_
4	of	of	IN	_	7	case	_	_
5	drug1	drug0	NN	_	6	advnp	_	_
6	-containing	-containing	JJ	_	7	attr	_	_
7	CEF-120	cef-0	NN	_	3	ppmod	_	_
8	or	or	CC	_	3	cc	_	_
9	FEC-100	fec-0	CD	_	10	num	_	_
10	chemotherapies	chemotherapy	NNS	_	3	conj	_	_
11	,	,	,	_	15	p	_	_
12	breast	breast	NN	_	13	com	_	_
13	irradiation	irradiation	NN	_	15	dep	_	_
14	was	be	VBD	_	15	aux	_	_
15	delayed	delay	VBN	_	0	root	_	_
16	until	until	IN	_	20	mark	_	_
17	after	after	IN	_	18	case	_	_
18	chemotherapy	chemotherapy	NN	_	20	ppmod	_	_
19	was	be	VBD	_	20	aux	_	_
20	completed	complete	VBN	_	15	comp	_	_
21	.	.	.	_	15	p	_	_

1	This	this	DT	_	2	det	_	_
2	practice	practice	NN	_	3	dep	_	_
3	resulted	result	VBD	_	0	root	_	_
4	in	in	IN	_	7	case	_	_
5	no	no	DT	_	7	det	_	_
6	apparent	apparent	JJ	_	7	attr	_	_
7	increase	increase	NN	_	3	ppmod	_	_
8	in	in	IN	_	12	case	_	_
9	local	local	JJ	_	12	attr	_	_
10	breast	breast	NN	_	12	com	_	_
11	cancer	cancer	NN	_	12	com	_	_
12	recurrence	recurrence	NN	_	7	ppmod	_	_
13	relative	relative	JJ	_	12	attr	_	_
14	to	to	TO	_	16	aux	_	_
15	published	publish	VBN	_	16	attr	_	_
16	accounts	account	VBZ	_	13	ppmod	_	_
17	in	in	IN	_	19	case	_	_
18	the	the	DT	_	19	det	_	_
19	literature	literature	NN	_	16	ppmod	_	_
20	.	.	.	_	3	p	_	_

1	A	a	DT	_	3	det	_	_
2	small	small	JJ	_	3	attr	_	_
3	number	number	NN	_	6	dep	_	_
4	of	of	IN	_	5	case	_	_
5	patients	patient	NNS	_	3	ppmod	_	_
6	received	receive	VBD	_	0	root	_	_
7	drug1	drug0	NN	_	9	attr	_	_
8	-based	-based	JJ	_	9	attr	_	_
9	chemotherapy	chemotherapy	NN	_	6	obj	_	_
10	concomitantly	concomitantly	RB	_	6	adv	_	_
11	with	with	IN	_	13	case	_	_
12	radiation	radiation	NN	_	13	com	_	_
13	therapy	therapy	NN	_	6	ppmod	_	_
14	but	but	CC	_	6	cc	_	_
15	had	have	VBD	_	6	conj	_	_
16	chemotherapy	chemotherapy	NN	_	15	obj	_	_
17	interrupted	interrupt	VBN	_	16	acl	_	_
18	in	in	IN	_	21	mark	_	_
19	order	order	NN	_	21	dep	_	_
20	to	to	TO	_	21	aux	_	_
21	avoid	avoid	VB	_	17	comp	_	_
22	potential	potential	JJ	_	24	attr	_	_
23	overlapping	overlap	VBG	_	24	attr	_	_
24	toxicities	toxicity	NNS	_	21	obj	_	_
25	.	.	.	_	6	p	_	_

1	It	it	PRP	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	likely	likely	JJ	_	2	dep	_	_
4	that	that	IN	_	11	mark	_	_
5	use	use	NN	_	11	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	with	with	IN	_	9	case	_	_
9	radiotherapy	radiotherapy	NN	_	5	ppmod	_	_
10	may	may	MD	_	11	modal	_	_
11	sensitize	sensitize	VB	_	3	comp	_	_
12	tissues	tissue	NNS	_	11	obj	_	_
13	to	to	TO	_	16	aux	_	_
14	the	the	DT	_	16	det	_	_
15	cytotoxic	cytotoxic	JJ	_	16	attr	_	_
16	actions	action	NNS	_	11	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	irradiation	irradiation	NN	_	16	ppmod	_	_
19	.	.	.	_	2	p	_	_

1	Administration	administration	NN	_	9	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	after	after	IN	_	7	case	_	_
5	previous	previous	JJ	_	7	attr	_	_
6	radiation	radiation	NN	_	7	com	_	_
7	therapy	therapy	NN	_	1	ppmod	_	_
8	may	may	MD	_	9	modal	_	_
9	induce	induce	VB	_	0	root	_	_
10	an	an	DT	_	13	det	_	_
11	inflammatory	inflammatory	JJ	_	13	attr	_	_
12	recall	recall	NN	_	13	com	_	_
13	reaction	reaction	NN	_	9	obj	_	_
14	at	at	IN	_	16	case	_	_
15	the	the	DT	_	16	det	_	_
16	site	site	NN	_	9	ppmod	_	_
17	of	of	IN	_	19	case	_	_
18	the	the	DT	_	19	det	_	_
19	irradiation	irradiation	NN	_	16	ppmod	_	_
20	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	extensively	extensively	RB	_	4	adv	_	_
4	metabolized	metabolize	VBN	_	0	root	_	_
5	by	by	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	liver	liver	NN	_	4	ppmod	_	_
8	.	.	.	_	4	p	_	_

1	Changes	change	NNS	_	10	dep	_	_
2	in	in	IN	_	4	case	_	_
3	hepatic	hepatic	JJ	_	4	attr	_	_
4	function	function	NN	_	1	ppmod	_	_
5	induced	induce	VBN	_	1	acl	_	_
6	by	by	IN	_	8	case	_	_
7	concomitant	concomitant	JJ	_	8	attr	_	_
8	therapies	therapy	NNS	_	5	ppmod	_	_
9	may	may	MD	_	10	modal	_	_
10	affect	affect	VBP	_	0	root	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	metabolism	metabolism	NN	_	10	obj	_	_
13	,	,	,	_	12	p	_	_
14	pharmacokinetics	pharmacokinetics	NNS	_	12	conj	_	_
15	,	,	,	_	14	p	_	_
16	therapeutic	therapeutic	JJ	_	17	attr	_	_
17	efficacy	efficacy	NN	_	12	conj	_	_
18	,	,	,	_	17	p	_	_
19	and/or	and/or	CC	_	17	cc	_	_
20	toxicity	toxicity	NN	_	12	conj	_	_
21	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	increased	increase	VBD	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	AUC	auc	NN	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	by	by	IN	_	8	case	_	_
8	50	0	CD	_	2	ppmod	_	_
9	%	%	NN	_	8	meta	_	_
10	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	treatment	treatment	NN	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	stopped	stop	VBN	_	0	root	_	_
6	during	during	IN	_	7	case	_	_
7	treatment	treatment	NN	_	5	ppmod	_	_
8	with	with	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	.	.	.	_	5	p	_	_

1	Drug-Laboratory	drug-laboratory	JJ	_	3	attr	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	5	dep	_	_
4	There	there	RB	_	5	adv	_	_
5	are	be	VBP	_	0	root	_	_
6	no	no	DT	_	8	det	_	_
7	known	known	JJ	_	8	attr	_	_
8	interactions	interaction	NNS	_	5	obj	_	_
9	between	between	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	laboratory	laboratory	NN	_	13	com	_	_
13	tests	test	NNS	_	10	conj	_	_
14	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	:	:	:	_	1	p	_	_
5	drug3	drug0	NN	_	9	dep	_	_
6	and	and	CC	_	5	cc	_	_
7	drug4	drug0	NN	_	5	conj	_	_
8	can	can	MD	_	9	modal	_	_
9	reduce	reduce	VB	_	1	acl	_	_
10	absorption	absorption	NN	_	9	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug5	drug0	NN	_	10	ppmod	_	_
13	;	;	:	_	1	p	_	_

1	an	an	DT	_	2	det	_	_
2	interval	interval	NN	_	17	dep	_	_
3	of	of	IN	_	7	case	_	_
4	at	at	IN	_	6	case	_	_
5	least	least	JJS	_	6	attr	_	_
6	4	0	CD	_	7	num	_	_
7	hours	hour	NNS	_	2	ppmod	_	_
8	between	between	IN	_	9	case	_	_
9	intake	intake	NN	_	2	ppmod	_	_
10	of	of	IN	_	12	case	_	_
11	these	these	DT	_	12	det	_	_
12	agents	agent	NNS	_	9	ppmod	_	_
13	and	and	CC	_	9	cc	_	_
14	drug1	drug0	NN	_	9	conj	_	_
15	should	should	MD	_	17	modal	_	_
16	be	be	VB	_	17	aux	_	_
17	observed	observe	VBN	_	0	root	_	_
18	.	.	.	_	17	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	can	can	MD	_	5	modal	_	_
5	inhibit	inhibit	VB	_	0	root	_	_
6	the	the	DT	_	7	det	_	_
7	metabolism	metabolism	NN	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	5	p	_	_
11	increasing	increase	VBG	_	5	comp	_	_
12	its	its	PRP$	_	14	poss	_	_
13	plasma	plasma	NN	_	14	com	_	_
14	level	level	NN	_	11	obj	_	_
15	.	.	.	_	5	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	use	use	NN	_	7	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	should	should	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	avoided	avoid	VBN	_	0	root	_	_
8	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	12	dep	_	_
2	:	:	:	_	12	p	_	_
3	In	in	IN	_	5	case	_	_
4	a	a	DT	_	5	det	_	_
5	study	study	NN	_	12	ppmod	_	_
6	of	of	IN	_	8	case	_	_
7	healthy	healthy	JJ	_	8	attr	_	_
8	volunteers	volunteer	NNS	_	5	ppmod	_	_
9	,	,	,	_	12	p	_	_
10	drug2	drug0	NN	_	12	dep	_	_
11	significantly	significantly	RB	_	12	adv	_	_
12	reduced	reduce	VBD	_	0	root	_	_
13	the	the	DT	_	14	det	_	_
14	bioavailability	bioavailability	NN	_	12	obj	_	_
15	of	of	IN	_	16	case	_	_
16	drug3	drug0	NN	_	14	ppmod	_	_
17	.	.	.	_	12	p	_	_

1	An	an	DT	_	2	det	_	_
2	interval	interval	NN	_	17	dep	_	_
3	of	of	IN	_	7	case	_	_
4	at	at	IN	_	6	case	_	_
5	least	least	JJS	_	6	attr	_	_
6	two	#crd#	CD	_	7	num	_	_
7	hours	hour	NNS	_	2	ppmod	_	_
8	between	between	IN	_	9	case	_	_
9	intake	intake	NN	_	2	ppmod	_	_
10	of	of	IN	_	12	case	_	_
11	this	this	DT	_	12	det	_	_
12	agent	agent	NN	_	9	ppmod	_	_
13	and	and	CC	_	9	cc	_	_
14	drug1	drug0	NN	_	9	conj	_	_
15	should	should	MD	_	17	modal	_	_
16	be	be	VB	_	17	aux	_	_
17	observed	observe	VBN	_	0	root	_	_
18	.	.	.	_	17	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	After	after	IN	_	4	case	_	_
4	introduction	introduction	NN	_	21	ppmod	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	(	-lrb-	-LRB-	_	9	p	_	_
8	oral	oral	JJ	_	9	attr	_	_
9	form	form	NN	_	6	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	,	,	,	_	21	p	_	_
12	a	a	DT	_	14	det	_	_
13	sudden	sudden	JJ	_	14	attr	_	_
14	increase	increase	NN	_	21	dep	_	_
15	in	in	IN	_	18	case	_	_
16	serum	serum	NN	_	18	com	_	_
17	drug3	drug0	NN	_	18	com	_	_
18	level	level	NN	_	14	ppmod	_	_
19	has	have	VBZ	_	21	aux	_	_
20	been	be	VBN	_	21	aux	_	_
21	reported	report	VBN	_	1	acl	_	_
22	.	.	.	_	1	p	_	_

1	Therefore	therefore	RB	_	10	adv	_	_
2	,	,	,	_	10	p	_	_
3	close	close	JJ	_	4	attr	_	_
4	monitoring	monitoring	NN	_	10	dep	_	_
5	of	of	IN	_	8	case	_	_
6	serum	serum	NN	_	8	com	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	level	level	NN	_	4	ppmod	_	_
9	is	be	VBZ	_	10	aux	_	_
10	recommended	recommend	VBN	_	0	root	_	_
11	and	and	CC	_	10	cc	_	_
12	,	,	,	_	19	p	_	_
13	if	if	IN	_	14	mark	_	_
14	necessary	necessary	JJ	_	19	advcl	_	_
15	,	,	,	_	19	p	_	_
16	drug2	drug0	NN	_	19	dep	_	_
17	should	should	MD	_	19	modal	_	_
18	be	be	VB	_	19	aux	_	_
19	discontinued	discontinue	VBN	_	10	conj	_	_
20	.	.	.	_	10	p	_	_

1	Intravenous	intravenous	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	was	be	VBD	_	4	aux	_	_
4	shown	show	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	double	double	JJ	_	4	comp	_	_
7	the	the	DT	_	8	det	_	_
8	bioavailability	bioavailability	NN	_	6	obj	_	_
9	of	of	IN	_	11	case	_	_
10	oral	oral	JJ	_	11	attr	_	_
11	drug2	drug0	NN	_	8	ppmod	_	_
12	.	.	.	_	4	p	_	_

1	The	the	DT	_	3	det	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	significance	significance	NN	_	13	dep	_	_
4	of	of	IN	_	7	case	_	_
5	this	this	DT	_	7	det	_	_
6	increased	increase	VBN	_	7	attr	_	_
7	bioavailability	bioavailability	NN	_	3	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	whether	whether	IN	_	11	case	_	_
10	similar	similar	JJ	_	11	attr	_	_
11	increases	increase	NNS	_	7	conj	_	_
12	will	will	MD	_	13	modal	_	_
13	occur	occur	VB	_	0	root	_	_
14	in	in	IN	_	15	case	_	_
15	patients	patient	NNS	_	13	ppmod	_	_
16	given	given	IN	_	19	mark	_	_
17	oral	oral	JJ	_	18	attr	_	_
18	drug1	drug0	NN	_	19	dep	_	_
19	is	be	VBZ	_	13	comp	_	_
20	unknown	unknown	JJ	_	19	dep	_	_
21	;	;	:	_	13	p	_	_

1	no	no	DT	_	6	det	_	_
2	other	other	JJ	_	6	attr	_	_
3	specific	specific	JJ	_	6	attr	_	_
4	drug	drug	NN	_	6	com	_	_
5	interaction	interaction	NN	_	6	com	_	_
6	studies	study	NNS	_	8	dep	_	_
7	were	be	VBD	_	8	aux	_	_
8	performed	performed	VBN	_	0	root	_	_
9	.	.	.	_	8	p	_	_

1	Products	product	NNS	_	9	dep	_	_
2	containing	contain	VBG	_	1	acl	_	_
3	drug1	drug0	NN	_	2	obj	_	_
4	and	and	CC	_	3	cc	_	_
5	other	other	JJ	_	6	attr	_	_
6	drug2	drug0	NN	_	3	conj	_	_
7	likely	likely	RB	_	9	adv	_	_
8	will	will	MD	_	9	modal	_	_
9	interfere	interfere	VB	_	0	root	_	_
10	with	with	IN	_	11	case	_	_
11	absorption	absorption	NN	_	9	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug3	drug0	NN	_	11	ppmod	_	_
14	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	metabolized	metabolize	VBN	_	0	root	_	_
4	through	through	IN	_	8	case	_	_
5	the	the	DT	_	8	det	_	_
6	cytochrome	cytochrome	NN	_	8	com	_	_
7	P450	p0	NN	_	8	com	_	_
8	system	system	NN	_	3	ppmod	_	_
9	,	,	,	_	3	p	_	_
10	specifically	specifically	RB	_	13	adv	_	_
11	through	through	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	CYP3A	cyp0a	NN	_	3	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	CYP2C19	cyp0c0	NN	_	16	com	_	_
16	isozymes	isozymes	NNS	_	13	conj	_	_
17	.	.	.	_	3	p	_	_

1	Studies	study	NNS	_	3	dep	_	_
2	have	have	VBP	_	3	aux	_	_
3	shown	show	VBN	_	0	root	_	_
4	that	that	IN	_	11	mark	_	_
5	drug1	drug0	NN	_	11	dep	_	_
6	does	do	VBZ	_	11	aux	_	_
7	not	not	RB	_	11	neg	_	_
8	have	have	VB	_	11	lv	_	_
9	clinically	clinically	RB	_	10	adv	_	_
10	significant	significant	JJ	_	11	attr	_	_
11	interactions	interaction	NNS	_	3	comp	_	_
12	with	with	IN	_	14	case	_	_
13	other	other	JJ	_	14	attr	_	_
14	drugs	drug	NNS	_	11	ppmod	_	_
15	metabolized	metabolize	VBN	_	14	acl	_	_
16	by	by	IN	_	20	case	_	_
17	the	the	DT	_	20	det	_	_
18	cytochrome	cytochrome	NN	_	20	com	_	_
19	P450	p0	NN	_	20	com	_	_
20	system	system	NN	_	15	ppmod	_	_
21	,	,	,	_	14	p	_	_
22	such	such	JJ	_	24	adv	_	_
23	as	as	IN	_	24	case	_	_
24	drug2	drug0	NN	_	14	ppmod	_	_
25	,	,	,	_	24	p	_	_
26	drug3	drug0	NN	_	24	conj	_	_
27	,	,	,	_	26	p	_	_
28	drug4	drug0	NN	_	24	conj	_	_
29	,	,	,	_	28	p	_	_
30	drug5	drug0	NN	_	24	conj	_	_
31	,	,	,	_	30	p	_	_
32	drug6	drug0	NN	_	24	conj	_	_
33	,	,	,	_	32	p	_	_
34	drug7	drug0	NN	_	24	conj	_	_
35	,	,	,	_	34	p	_	_
36	drug8	drug0	NN	_	24	conj	_	_
37	,	,	,	_	36	p	_	_
38	drug9	drug0	NN	_	24	conj	_	_
39	,	,	,	_	38	p	_	_
40	drug10	drug0	NN	_	24	conj	_	_
41	,	,	,	_	40	p	_	_
42	or	or	CC	_	40	cc	_	_
43	drug11	drug0	NN	_	24	conj	_	_
44	in	in	IN	_	46	case	_	_
45	healthy	healthy	JJ	_	46	attr	_	_
46	subjects	subject	NNS	_	24	ppmod	_	_
47	.	.	.	_	3	p	_	_

1	These	these	DT	_	2	det	_	_
2	compounds	compound	NNS	_	4	dep	_	_
3	are	be	VBP	_	4	aux	_	_
4	metabolized	metabolize	VBN	_	0	root	_	_
5	through	through	IN	_	9	case	_	_
6	various	various	JJ	_	9	attr	_	_
7	cytochrome	cytochrome	NN	_	9	com	_	_
8	P450	p0	NN	_	9	com	_	_
9	isozymes	isozymes	NNS	_	4	ppmod	_	_
10	including	include	VBG	_	11	adv	_	_
11	CYP1A2	cyp0a0	NN	_	9	ppmod	_	_
12	,	,	,	_	11	p	_	_
13	CYP2C9	cyp0c0	NN	_	11	conj	_	_
14	,	,	,	_	13	p	_	_
15	CYP2C19	cyp0c0	NN	_	11	conj	_	_
16	,	,	,	_	15	p	_	_
17	CYP2D6	cyp0d0	NN	_	11	conj	_	_
18	,	,	,	_	17	p	_	_
19	and	and	CC	_	17	cc	_	_
20	CYP3A	cyp0a	NN	_	11	conj	_	_
21	.	.	.	_	4	p	_	_

1	When	when	WRB	_	4	adv	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	was	be	VBD	_	4	aux	_	_
4	administered	administer	VBN	_	27	advcl	_	_
5	concomitantly	concomitantly	RB	_	4	adv	_	_
6	with	with	IN	_	7	case	_	_
7	drug2	drug0	NN	_	4	ppmod	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	CYP1A2	cyp0a0	NN	_	7	prn	_	_
10	,	,	,	_	9	p	_	_
11	CYP3A	cyp0a	NN	_	9	appo	_	_
12	)	-rrb-	-RRB-	_	9	p	_	_
13	,	,	,	_	27	p	_	_
14	a	a	DT	_	16	det	_	_
15	minor	minor	JJ	_	16	attr	_	_
16	increase	increase	NN	_	27	dep	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	10	0	CD	_	16	num	_	_
19	%	%	NN	_	18	meta	_	_
20	)	-rrb-	-RRB-	_	18	p	_	_
21	in	in	IN	_	23	case	_	_
22	the	the	DT	_	23	det	_	_
23	clearance	clearance	NN	_	16	ppmod	_	_
24	of	of	IN	_	25	case	_	_
25	drug3	drug0	NN	_	23	ppmod	_	_
26	was	be	VBD	_	27	aux	_	_
27	seen	see	VBN	_	0	root	_	_
28	.	.	.	_	27	p	_	_

1	Because	because	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	small	small	JJ	_	4	attr	_	_
4	magnitude	magnitude	NN	_	17	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	the	the	DT	_	7	det	_	_
7	direction	direction	NN	_	4	conj	_	_
8	of	of	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	effect	effect	NN	_	7	ppmod	_	_
11	on	on	IN	_	13	case	_	_
12	drug1	drug0	NN	_	13	com	_	_
13	clearance	clearance	NN	_	10	ppmod	_	_
14	,	,	,	_	17	p	_	_
15	this	this	DT	_	16	det	_	_
16	interaction	interaction	NN	_	17	dep	_	_
17	is	be	VBZ	_	0	root	_	_
18	unlikely	unlikely	JJ	_	17	dep	_	_
19	to	to	TO	_	20	aux	_	_
20	be	be	VB	_	18	comp	_	_
21	clinical	clinical	JJ	_	22	attr	_	_
22	concern	concern	NN	_	20	obj	_	_
23	.	.	.	_	17	p	_	_

1	Nonetheless	nonetheless	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	individual	individual	JJ	_	4	attr	_	_
4	patients	patient	NNS	_	6	dep	_	_
5	may	may	MD	_	6	modal	_	_
6	require	require	VB	_	0	root	_	_
7	additional	additional	JJ	_	8	attr	_	_
8	titration	titration	NN	_	6	obj	_	_
9	of	of	IN	_	12	case	_	_
10	their	their	PRP$	_	12	poss	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	dosage	dosage	NN	_	8	ppmod	_	_
13	when	when	WRB	_	16	adv	_	_
14	drug2	drug0	NN	_	16	dep	_	_
15	is	be	VBZ	_	16	aux	_	_
16	started	start	VBN	_	6	comp	_	_
17	or	or	CC	_	16	cc	_	_
18	stopped	stop	VBN	_	16	conj	_	_
19	to	to	TO	_	20	aux	_	_
20	ensure	ensure	VB	_	18	comp	_	_
21	clinically	clinically	RB	_	22	adv	_	_
22	effective	effective	JJ	_	24	attr	_	_
23	blood	blood	NN	_	24	com	_	_
24	levels	level	NNS	_	20	obj	_	_
25	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	has	have	VBZ	_	5	aux	_	_
3	also	also	RB	_	5	adv	_	_
4	been	be	VBN	_	5	aux	_	_
5	shown	show	VBN	_	0	root	_	_
6	to	to	TO	_	11	aux	_	_
7	have	have	VBP	_	11	lv	_	_
8	no	no	DT	_	11	det	_	_
9	clinically	clinically	RB	_	10	adv	_	_
10	significant	significant	JJ	_	11	attr	_	_
11	interaction	interaction	NN	_	5	comp	_	_
12	with	with	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	.	.	.	_	5	p	_	_

1	In	in	IN	_	5	case	_	_
2	a	a	DT	_	5	det	_	_
3	single-dose	single-dose	JJ	_	5	attr	_	_
4	crossover	crossover	NN	_	5	com	_	_
5	study	study	NN	_	29	ppmod	_	_
6	examining	examine	VBG	_	5	acl	_	_
7	drug1	drug0	NN	_	9	attr	_	_
8	30	0	CD	_	9	num	_	_
9	mg	mg	NN	_	6	obj	_	_
10	and	and	CC	_	9	cc	_	_
11	drug2	drug0	NN	_	13	attr	_	_
12	20	0	CD	_	13	num	_	_
13	mg	mg	NN	_	9	conj	_	_
14	each	each	DT	_	9	appo	_	_
15	administered	administer	VBN	_	9	acl	_	_
16	alone	alone	RB	_	15	adv	_	_
17	and	and	CC	_	16	cc	_	_
18	concomitantly	concomitantly	RB	_	16	conj	_	_
19	with	with	IN	_	22	case	_	_
20	drug3	drug0	NN	_	22	attr	_	_
21	1	0	CD	_	22	num	_	_
22	gram	gram	NN	_	15	ppmod	_	_
23	,	,	,	_	29	p	_	_
24	absorption	absorption	NN	_	29	dep	_	_
25	of	of	IN	_	27	case	_	_
26	the	the	DT	_	27	det	_	_
27	drug4	drug0	NN	_	24	ppmod	_	_
28	was	be	VBD	_	29	aux	_	_
29	delayed	delay	VBN	_	0	root	_	_
30	and	and	CC	_	29	cc	_	_
31	their	their	PRP$	_	32	poss	_	_
32	bioavailability	bioavailability	NN	_	34	dep	_	_
33	was	be	VBD	_	34	aux	_	_
34	reduced	reduce	VBN	_	29	conj	_	_
35	by	by	IN	_	36	case	_	_
36	17	0	CD	_	34	ppmod	_	_
37	%	%	NN	_	36	meta	_	_
38	and	and	CC	_	36	cc	_	_
39	16	0	CD	_	36	conj	_	_
40	%	%	NN	_	39	meta	_	_
41	,	,	,	_	39	p	_	_
42	respectively	respectively	RB	_	36	conj	_	_
43	,	,	,	_	34	p	_	_
44	when	when	WRB	_	45	adv	_	_
45	administered	administer	VBN	_	34	comp	_	_
46	concomitantly	concomitantly	RB	_	45	adv	_	_
47	with	with	IN	_	48	case	_	_
48	drug5	drug0	NN	_	45	ppmod	_	_
49	.	.	.	_	34	p	_	_

1	Therefore	therefore	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	drug1	drug0	NN	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	taken	take	VBN	_	0	root	_	_
7	at	at	IN	_	9	case	_	_
8	least	least	JJS	_	9	attr	_	_
9	30	0	CD	_	10	num	_	_
10	minutes	minute	NNS	_	11	advnp	_	_
11	prior	prior	RB	_	6	adv	_	_
12	to	to	TO	_	13	aux	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	.	.	.	_	6	p	_	_

1	In	in	IN	_	3	case	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	trials	trial	NNS	_	7	ppmod	_	_
4	,	,	,	_	7	p	_	_
5	drug1	drug0	NN	_	7	dep	_	_
6	were	be	VBD	_	7	aux	_	_
7	administered	administer	VBN	_	0	root	_	_
8	concomitantly	concomitantly	RB	_	7	adv	_	_
9	with	with	IN	_	12	case	_	_
10	drug2	drug0	NN	_	12	com	_	_
11	delayed-release	delayed-release	NN	_	12	com	_	_
12	capsules	capsule	NNS	_	7	ppmod	_	_
13	;	;	:	_	7	p	_	_

1	this	this	DT	_	4	dep	_	_
2	did	do	VBD	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	interfere	interfere	VB	_	0	root	_	_
5	with	with	IN	_	7	case	_	_
6	its	its	PRP$	_	7	poss	_	_
7	effect	effect	NN	_	4	ppmod	_	_
8	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	causes	cause	VBZ	_	0	root	_	_
3	a	a	DT	_	8	det	_	_
4	profound	profound	JJ	_	8	attr	_	_
5	and	and	CC	_	4	cc	_	_
6	long	long	JJ	_	4	conj	_	_
7	lasting	lasting	NN	_	8	com	_	_
8	inhibition	inhibition	NN	_	2	obj	_	_
9	of	of	IN	_	12	case	_	_
10	gastric	gastric	JJ	_	12	attr	_	_
11	acid	acid	NN	_	12	com	_	_
12	secretion	secretion	NN	_	8	ppmod	_	_
13	;	;	:	_	2	p	_	_

1	therefore	therefore	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	it	it	PRP	_	4	dep	_	_
4	is	be	VBZ	_	0	root	_	_
5	theoretically	theoretically	RB	_	6	adv	_	_
6	possible	possible	JJ	_	4	dep	_	_
7	that	that	IN	_	10	mark	_	_
8	drug1	drug0	NN	_	10	dep	_	_
9	may	may	MD	_	10	modal	_	_
10	interfere	interfere	VB	_	4	comp	_	_
11	with	with	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	absorption	absorption	NN	_	10	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drugs	drug	NNS	_	13	ppmod	_	_
16	where	where	WRB	_	19	adv	_	_
17	gastric	gastric	JJ	_	18	attr	_	_
18	pH	ph	NN	_	19	dep	_	_
19	is	be	VBZ	_	15	relcl	_	_
20	an	an	DT	_	22	det	_	_
21	important	important	JJ	_	22	attr	_	_
22	determinant	determinant	NN	_	19	obj	_	_
23	of	of	IN	_	24	case	_	_
24	bioavailability	bioavailability	NN	_	22	ppmod	_	_
25	(	-lrb-	-LRB-	_	27	p	_	_
26	e.g.	e.g.	FW	_	27	ppmod	_	_
27	drug2	drug0	NNS	_	24	prn	_	_
28	,	,	,	_	27	p	_	_
29	drug3	drug0	NN	_	30	com	_	_
30	esters	ester	NNS	_	27	appo	_	_
31	,	,	,	_	27	p	_	_
32	drug4	drug0	NN	_	33	com	_	_
33	salts	salt	NNS	_	27	appo	_	_
34	,	,	,	_	27	p	_	_
35	drug5	drug0	NN	_	27	appo	_	_
36	)	-rrb-	-RRB-	_	27	p	_	_
37	.	.	.	_	4	p	_	_

1	APRD00513_IN	aprd0_in	NN	_	0	root	_	_
2	,	,	,	_	1	p	_	_
3	txt	txt	NN	_	1	appo	_	_

1	No	no	DT	_	5	det	_	_
2	formal	formal	JJ	_	5	attr	_	_
3	drug	drug	NN	_	5	com	_	_
4	interaction	interaction	NN	_	5	com	_	_
5	studies	study	NNS	_	8	dep	_	_
6	have	have	VBP	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	conducted	conduct	VBN	_	0	root	_	_
9	with	with	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	8	p	_	_

1	Due	due	JJ	_	4	adv	_	_
2	to	to	TO	_	4	aux	_	_
3	its	its	PRP$	_	4	poss	_	_
4	potential	potential	NN	_	16	ppmod	_	_
5	to	to	TO	_	6	aux	_	_
6	cause	cause	VB	_	4	acl	_	_
7	neutropenia	neutropenia	NN	_	6	obj	_	_
8	and	and	CC	_	7	cc	_	_
9	lymphopenia	lymphopenia	NN	_	7	conj	_	_
10	,	,	,	_	16	p	_	_
11	proper	proper	JJ	_	12	attr	_	_
12	monitoring	monitoring	NN	_	16	dep	_	_
13	of	of	IN	_	14	case	_	_
14	patients	patient	NNS	_	12	ppmod	_	_
15	is	be	VBZ	_	16	aux	_	_
16	required	require	VBN	_	0	root	_	_
17	if	if	IN	_	20	mark	_	_
18	drug1	drug0	NN	_	20	dep	_	_
19	is	be	VBZ	_	20	aux	_	_
20	given	give	VBN	_	16	comp	_	_
21	in	in	IN	_	22	case	_	_
22	combination	combination	NN	_	20	ppmod	_	_
23	with	with	IN	_	25	case	_	_
24	myelosuppressive	myelosuppressive	JJ	_	25	attr	_	_
25	agents	agent	NNS	_	22	ppmod	_	_
26	.	.	.	_	16	p	_	_

1	Also	also	RB	_	10	adv	_	_
2	,	,	,	_	10	p	_	_
3	the	the	DT	_	4	det	_	_
4	potential	potential	NN	_	10	dep	_	_
5	for	for	IN	_	7	case	_	_
6	hepatic	hepatic	JJ	_	7	attr	_	_
7	injury	injury	NN	_	4	ppmod	_	_
8	should	should	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	considered	consider	VBN	_	0	root	_	_
11	when	when	WRB	_	14	adv	_	_
12	drug1	drug0	NN	_	14	dep	_	_
13	is	be	VBZ	_	14	aux	_	_
14	used	use	VBN	_	10	advcl	_	_
15	in	in	IN	_	16	case	_	_
16	combination	combination	NN	_	14	ppmod	_	_
17	with	with	IN	_	19	case	_	_
18	other	other	JJ	_	19	attr	_	_
19	products	product	NNS	_	16	ppmod	_	_
20	associated	associate	VBN	_	19	acl	_	_
21	with	with	IN	_	23	case	_	_
22	hepatic	hepatic	JJ	_	23	attr	_	_
23	injury	injury	NN	_	20	ppmod	_	_
24	,	,	,	_	14	p	_	_
25	or	or	CC	_	14	cc	_	_
26	when	when	WRB	_	30	adv	_	_
27	new	new	JJ	_	28	attr	_	_
28	agents	agent	NNS	_	30	dep	_	_
29	are	be	VBP	_	30	aux	_	_
30	added	add	VBN	_	14	conj	_	_
31	to	to	TO	_	33	aux	_	_
32	the	the	DT	_	33	det	_	_
33	regimen	regimen	NN	_	30	ppmod	_	_
34	of	of	IN	_	35	case	_	_
35	patients	patient	NNS	_	33	ppmod	_	_
36	already	already	RB	_	35	adv	_	_
37	on	on	IN	_	38	case	_	_
38	drug2	drug0	NN	_	30	ppmod	_	_
39	.	.	.	_	10	p	_	_

1	The	the	DT	_	4	det	_	_
2	drug	drug	NN	_	4	com	_	_
3	interaction	interaction	NN	_	4	com	_	_
4	data	datum	NNS	_	10	dep	_	_
5	described	describe	VBN	_	4	acl	_	_
6	in	in	IN	_	8	case	_	_
7	this	this	DT	_	8	det	_	_
8	section	section	NN	_	5	ppmod	_	_
9	were	be	VBD	_	10	aux	_	_
10	obtained	obtain	VBN	_	0	root	_	_
11	from	from	IN	_	14	case	_	_
12	controlled	controlled	JJ	_	14	attr	_	_
13	clinical	clinical	JJ	_	14	attr	_	_
14	trials	trial	NNS	_	10	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	studies	study	NNS	_	14	conj	_	_
17	involving	involve	VBG	_	16	acl	_	_
18	otherwise	otherwise	RB	_	19	adv	_	_
19	healthy	healthy	JJ	_	20	attr	_	_
20	adults	adult	NNS	_	17	obj	_	_
21	with	with	IN	_	22	case	_	_
22	epilepsy	epilepsy	NN	_	20	ppmod	_	_
23	.	.	.	_	10	p	_	_

1	Use	use	NN	_	17	dep	_	_
2	in	in	IN	_	3	case	_	_
3	Conjunction	conjunction	NN	_	1	ppmod	_	_
4	with	with	IN	_	6	case	_	_
5	Other	other	JJ	_	6	attr	_	_
6	drug1	drug0	NN	_	3	ppmod	_	_
7	:	:	:	_	17	p	_	_
8	The	the	DT	_	9	det	_	_
9	addition	addition	NN	_	17	dep	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	to	to	TO	_	13	aux	_	_
13	drug3	drug0	NN	_	9	ppmod	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	drug4	drug0	NN	_	13	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	affects	affect	VBZ	_	0	root	_	_
18	the	the	DT	_	21	det	_	_
19	steady-state	steady-state	JJ	_	21	attr	_	_
20	plasma	plasma	NN	_	21	com	_	_
21	concentrations	concentration	NNS	_	17	obj	_	_
22	of	of	IN	_	23	case	_	_
23	drug5	drug0	NN	_	21	ppmod	_	_
24	.	.	.	_	17	p	_	_

1	The	the	DT	_	3	det	_	_
2	net	net	JJ	_	3	attr	_	_
3	effect	effect	NN	_	8	dep	_	_
4	of	of	IN	_	6	case	_	_
5	these	these	DT	_	6	det	_	_
6	interactions	interaction	NNS	_	3	ppmod	_	_
7	is	be	VBZ	_	8	aux	_	_
8	summarized	summarize	VBN	_	15	advcl	_	_
9	in	in	IN	_	12	case	_	_
10	the	the	DT	_	12	det	_	_
11	following	following	JJ	_	12	attr	_	_
12	table	table	NN	_	8	ppmod	_	_
13	:	:	:	_	15	p	_	_
14	drug1	drug0	NN	_	15	dep	_	_
15	drug2	drug0	VBP	_	0	root	_	_
16	drug3	drug0	NN	_	15	obj	_	_

1	Coadministered	coadministered	JJ	_	3	attr	_	_
2	Concentration	concentration	NN	_	3	com	_	_
3	Concentration	concentration	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	3	com	_	_
2	*	*	NN	_	3	com	_	_
3	*	*	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	drug2	drug0	NN	_	1	prn	_	_
4	)	-rrb-	-RRB-	_	3	p	_	_

1	*	*	NN	_	3	com	_	_
2	CBZ	cbz	NN	_	3	com	_	_
3	epoxide	epoxide	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	*	*	NN	_	3	dep	_	_
2	Not	not	RB	_	3	neg	_	_
3	administered	administer	VBN	_	0	root	_	_
4	,	,	,	_	3	p	_	_
5	but	but	CC	_	3	cc	_	_
6	an	an	DT	_	8	det	_	_
7	active	active	JJ	_	8	attr	_	_
8	metabolite	metabolite	NN	_	3	conj	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	3	p	_	_

1	**	**	NN	_	4	dep	_	_
2	No	no	DT	_	4	det	_	_
3	significant	significant	JJ	_	4	attr	_	_
4	effect	effect	NN	_	0	root	_	_
5	.	.	.	_	4	p	_	_

1	Specific	specific	JJ	_	2	attr	_	_
2	Effects	effect	NNS	_	0	root	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	on	on	IN	_	8	case	_	_
6	Other	other	JJ	_	8	attr	_	_
7	drug2	drug0	NN	_	8	com	_	_
8	drug3	drug0	NN	_	2	ppmod	_	_
9	:	:	:	_	2	p	_	_
10	drug4	drug0	NN	_	2	appo	_	_
11	causes	cause	VBZ	_	10	acl	_	_
12	an	an	DT	_	13	det	_	_
13	increase	increase	NN	_	11	obj	_	_
14	in	in	IN	_	18	case	_	_
15	steady-state	steady-state	JJ	_	18	attr	_	_
16	drug5	drug0	NN	_	18	com	_	_
17	plasma	plasma	NN	_	18	com	_	_
18	concentrations	concentration	NNS	_	13	ppmod	_	_
19	.	.	.	_	2	p	_	_

1	In	in	IN	_	5	case	_	_
2	10	0	CD	_	5	num	_	_
3	otherwise	otherwise	JJ	_	5	attr	_	_
4	healthy	healthy	JJ	_	5	attr	_	_
5	subjects	subject	NNS	_	20	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	epilepsy	epilepsy	NN	_	5	ppmod	_	_
8	ingesting	ingest	VBG	_	7	acl	_	_
9	drug1	drug0	NN	_	8	obj	_	_
10	,	,	,	_	20	p	_	_
11	the	the	DT	_	19	det	_	_
12	steadystate	steadystate	JJ	_	19	attr	_	_
13	trough	trough	NN	_	19	attr	_	_
14	(	-lrb-	-LRB-	_	19	p	_	_
15	Cmin	cmin	NN	_	19	attr	_	_
16	)	-rrb-	-RRB-	_	19	p	_	_
17	drug2	drug0	NN	_	19	com	_	_
18	plasma	plasma	NN	_	19	com	_	_
19	concentration	concentration	NN	_	20	dep	_	_
20	was	be	VBD	_	0	root	_	_
21	17	0	CD	_	23	num	_	_
22	5	0	CD	_	23	num	_	_
23	micrograms/mL	micrograms/ml	NN	_	20	dep	_	_
24	.	.	.	_	20	p	_	_

1	The	the	DT	_	3	det	_	_
2	steady-state	steady-state	JJ	_	3	attr	_	_
3	Cmin	cmin	NN	_	4	dep	_	_
4	increased	increase	VBD	_	0	root	_	_
5	to	to	TO	_	8	aux	_	_
6	21	0	CD	_	8	num	_	_
7	5	0	CD	_	8	num	_	_
8	micrograms/mL	micrograms/ml	NNS	_	4	ppmod	_	_
9	when	when	WRB	_	15	adv	_	_
10	1200	0	CD	_	11	num	_	_
11	mg/day	mg/day	NN	_	15	dep	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	was	be	VBD	_	15	aux	_	_
15	coadministered	coadministered	VBN	_	4	comp	_	_
16	.	.	.	_	4	p	_	_

1	Increasing	increase	VBG	_	13	advcl	_	_
2	the	the	DT	_	4	det	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	dose	dose	NN	_	1	obj	_	_
5	to	to	TO	_	7	aux	_	_
6	1800	0	CD	_	7	num	_	_
7	mg/day	mg/day	NN	_	1	ppmod	_	_
8	in	in	IN	_	9	case	_	_
9	six	#crd#	CD	_	1	ppmod	_	_
10	of	of	IN	_	12	case	_	_
11	these	these	DT	_	12	det	_	_
12	subjects	subject	NNS	_	9	ppmod	_	_
13	increased	increase	VBD	_	0	root	_	_
14	the	the	DT	_	17	det	_	_
15	steady-state	steady-state	JJ	_	17	attr	_	_
16	drug2	drug0	NN	_	17	com	_	_
17	Cmin	cmin	NN	_	13	obj	_	_
18	to	to	TO	_	21	aux	_	_
19	25	0	CD	_	20	com	_	_
20	7	0	CD	_	21	num	_	_
21	micrograms/mL	micrograms/ml	NNS	_	17	ppmod	_	_
22	.	.	.	_	13	p	_	_

1	In	in	IN	_	4	mark	_	_
2	order	order	NN	_	4	dep	_	_
3	to	to	TO	_	4	aux	_	_
4	maintain	maintain	VB	_	29	advcl	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	levels	level	NNS	_	4	obj	_	_
7	,	,	,	_	4	p	_	_
8	limit	limit	VB	_	4	conj	_	_
9	adverse	adverse	JJ	_	10	attr	_	_
10	experiences	experience	NNS	_	8	obj	_	_
11	,	,	,	_	8	p	_	_
12	and	and	CC	_	8	cc	_	_
13	achieve	achieve	VB	_	4	conj	_	_
14	the	the	DT	_	16	det	_	_
15	drug2	drug0	NN	_	16	com	_	_
16	dose	dose	NN	_	13	obj	_	_
17	of	of	IN	_	19	case	_	_
18	3600	0	CD	_	19	num	_	_
19	mg/day	mg/day	NN	_	16	ppmod	_	_
20	,	,	,	_	29	p	_	_
21	a	a	DT	_	24	det	_	_
22	drug3	drug0	NN	_	24	com	_	_
23	dose	dose	NN	_	24	com	_	_
24	reduction	reduction	NN	_	29	dep	_	_
25	of	of	IN	_	27	case	_	_
26	approximately	approximately	RB	_	27	adv	_	_
27	40	0	CD	_	24	ppmod	_	_
28	%	%	NN	_	27	meta	_	_
29	was	be	VBD	_	0	root	_	_
30	necessary	necessary	JJ	_	29	dep	_	_
31	for	for	IN	_	32	case	_	_
32	eight	#crd#	CD	_	30	ppmod	_	_
33	of	of	IN	_	36	case	_	_
34	these	these	DT	_	36	det	_	_
35	10	0	CD	_	36	num	_	_
36	subjects	subject	NNS	_	32	ppmod	_	_
37	.	.	.	_	29	p	_	_

1	In	in	IN	_	5	case	_	_
2	a	a	DT	_	5	det	_	_
3	controlled	controlled	JJ	_	5	attr	_	_
4	clinical	clinical	JJ	_	5	attr	_	_
5	trial	trial	NN	_	21	ppmod	_	_
6	,	,	,	_	21	p	_	_
7	a	a	DT	_	10	det	_	_
8	20	0	CD	_	10	num	_	_
9	%	%	NN	_	10	meta	_	_
10	reduction	reduction	NN	_	21	dep	_	_
11	of	of	IN	_	14	case	_	_
12	the	the	DT	_	14	det	_	_
13	drug1	drug0	JJ	_	14	attr	_	_
14	dose	dose	NN	_	10	ppmod	_	_
15	at	at	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	initiation	initiation	NN	_	14	ppmod	_	_
18	of	of	IN	_	20	case	_	_
19	drug2	drug0	NN	_	20	com	_	_
20	therapy	therapy	NN	_	17	ppmod	_	_
21	resulted	result	VBD	_	0	root	_	_
22	in	in	IN	_	24	case	_	_
23	drug3	drug0	NN	_	24	com	_	_
24	levels	level	NNS	_	21	ppmod	_	_
25	comparable	comparable	JJ	_	24	attr	_	_
26	to	to	TO	_	27	aux	_	_
27	those	those	DT	_	25	ppmod	_	_
28	prior	prior	JJ	_	27	attr	_	_
29	to	to	TO	_	31	aux	_	_
30	drug4	drug0	NN	_	31	com	_	_
31	administration	administration	NN	_	28	ppmod	_	_
32	.	.	.	_	21	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	causes	cause	VBZ	_	0	root	_	_
5	a	a	DT	_	6	det	_	_
6	decrease	decrease	NN	_	4	obj	_	_
7	in	in	IN	_	12	case	_	_
8	the	the	DT	_	12	det	_	_
9	steady-state	steady-state	JJ	_	12	attr	_	_
10	drug3	drug0	NN	_	12	com	_	_
11	plasma	plasma	NN	_	12	com	_	_
12	concentrations	concentration	NNS	_	6	ppmod	_	_
13	and	and	CC	_	6	cc	_	_
14	an	an	DT	_	15	det	_	_
15	increase	increase	NN	_	6	conj	_	_
16	in	in	IN	_	21	case	_	_
17	the	the	DT	_	21	det	_	_
18	steady-state	steady-state	JJ	_	21	attr	_	_
19	drug4	drug0	NN	_	21	com	_	_
20	plasma	plasma	NN	_	21	com	_	_
21	concentration	concentration	NN	_	15	ppmod	_	_
22	.	.	.	_	4	p	_	_

1	In	in	IN	_	5	case	_	_
2	nine	#crd#	CD	_	5	num	_	_
3	otherwise	otherwise	JJ	_	5	attr	_	_
4	healthy	healthy	JJ	_	5	attr	_	_
5	subjects	subject	NNS	_	19	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	epilepsy	epilepsy	NN	_	5	ppmod	_	_
8	ingesting	ingest	VBG	_	7	acl	_	_
9	drug1	drug0	NN	_	8	obj	_	_
10	,	,	,	_	19	p	_	_
11	the	the	DT	_	18	det	_	_
12	steady-state	steady-state	JJ	_	18	attr	_	_
13	trough	trough	NN	_	18	attr	_	_
14	(	-lrb-	-LRB-	_	18	p	_	_
15	Cmin	cmin	NN	_	18	attr	_	_
16	)	-rrb-	-RRB-	_	18	p	_	_
17	drug2	drug0	NN	_	18	com	_	_
18	concentration	concentration	NN	_	19	dep	_	_
19	was	be	VBD	_	0	root	_	_
20	8	0	CD	_	22	num	_	_
21	2	0	CD	_	22	num	_	_
22	micrograms/mL	micrograms/ml	NN	_	19	dep	_	_
23	.	.	.	_	19	p	_	_

1	The	the	DT	_	4	det	_	_
2	drug1	drug0	NN	_	4	com	_	_
3	steady-state	steady-state	NN	_	4	com	_	_
4	Cmin	cmin	NN	_	5	dep	_	_
5	decreased	decrease	VBD	_	0	root	_	_
6	31	0	CD	_	5	obj	_	_
7	%	%	NN	_	6	meta	_	_
8	to	to	TO	_	11	aux	_	_
9	5	0	CD	_	11	num	_	_
10	1	0	CD	_	11	num	_	_
11	micrograms/mL	micrograms/ml	NNS	_	5	ppmod	_	_
12	when	when	WRB	_	24	adv	_	_
13	drug2	drug0	NN	_	24	dep	_	_
14	(	-lrb-	-LRB-	_	16	p	_	_
15	3000	0	CD	_	16	num	_	_
16	mg/day	mg/day	NN	_	13	prn	_	_
17	,	,	,	_	16	p	_	_
18	divided	divide	VBN	_	16	acl	_	_
19	into	into	IN	_	21	case	_	_
20	three	#crd#	CD	_	21	num	_	_
21	doses	dose	NNS	_	18	ppmod	_	_
22	)	-rrb-	-RRB-	_	16	p	_	_
23	was	be	VBD	_	24	aux	_	_
24	coadministered	coadministered	VBN	_	5	comp	_	_
25	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	4	attr	_	_
2	steady-state	steady-state	JJ	_	4	attr	_	_
3	Cmin	cmin	NN	_	4	com	_	_
4	concentrations	concentration	NNS	_	5	dep	_	_
5	increased	increase	VBD	_	0	root	_	_
6	57	0	CD	_	5	obj	_	_
7	%	%	NN	_	6	meta	_	_
8	from	from	IN	_	14	case	_	_
9	1.0	0	CD	_	14	num	_	_
10	0.3	0	CD	_	14	num	_	_
11	to	to	TO	_	10	cc	_	_
12	1.6	0	CD	_	13	com	_	_
13	0.4	0	CD	_	10	conj	_	_
14	micrograms/mL	micrograms/ml	NNS	_	5	ppmod	_	_
15	with	with	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	addition	addition	NN	_	14	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	.	.	.	_	5	p	_	_

1	In	in	IN	_	3	case	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	trials	trial	NNS	_	12	ppmod	_	_
4	,	,	,	_	12	p	_	_
5	similar	similar	JJ	_	6	attr	_	_
6	changes	change	NNS	_	12	dep	_	_
7	in	in	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	drug2	drug0	NN	_	8	conj	_	_
11	were	be	VBD	_	12	aux	_	_
12	seen	see	VBN	_	0	root	_	_
13	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	causes	cause	VBZ	_	0	root	_	_
5	an	an	DT	_	6	det	_	_
6	increase	increase	NN	_	4	obj	_	_
7	in	in	IN	_	10	case	_	_
8	steady-state	steady-state	JJ	_	10	attr	_	_
9	drug3	drug0	NN	_	10	com	_	_
10	concentrations	concentration	NNS	_	6	ppmod	_	_
11	.	.	.	_	4	p	_	_

1	In	in	IN	_	3	case	_	_
2	four	#crd#	CD	_	3	num	_	_
3	subjects	subject	NNS	_	18	ppmod	_	_
4	with	with	IN	_	5	case	_	_
5	epilepsy	epilepsy	NN	_	3	ppmod	_	_
6	ingesting	ingest	VBG	_	5	acl	_	_
7	drug1	drug0	NN	_	6	obj	_	_
8	,	,	,	_	18	p	_	_
9	the	the	DT	_	17	det	_	_
10	steady-state	steady-state	JJ	_	17	attr	_	_
11	trough	trough	NN	_	17	attr	_	_
12	(	-lrb-	-LRB-	_	17	p	_	_
13	Cmin	cmin	NN	_	17	attr	_	_
14	)	-rrb-	-RRB-	_	17	p	_	_
15	drug2	drug0	NN	_	17	com	_	_
16	plasma	plasma	NN	_	17	com	_	_
17	concentration	concentration	NN	_	18	dep	_	_
18	was	be	VBD	_	0	root	_	_
19	63	0	CD	_	21	num	_	_
20	16	0	CD	_	21	num	_	_
21	micrograms/mL	micrograms/ml	NN	_	18	dep	_	_
22	.	.	.	_	18	p	_	_

1	The	the	DT	_	3	det	_	_
2	steady-state	steady-state	JJ	_	3	attr	_	_
3	Cmin	cmin	NN	_	4	dep	_	_
4	increased	increase	VBD	_	0	root	_	_
5	to	to	TO	_	8	aux	_	_
6	78	0	CD	_	7	com	_	_
7	14	0	CD	_	8	num	_	_
8	micrograms/mL	micrograms/ml	NNS	_	4	ppmod	_	_
9	when	when	WRB	_	15	adv	_	_
10	1200	0	CD	_	11	num	_	_
11	mg/day	mg/day	NN	_	15	dep	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	was	be	VBD	_	15	aux	_	_
15	coadministered	coadministered	VBN	_	4	comp	_	_
16	.	.	.	_	4	p	_	_

1	Increasing	increase	VBG	_	8	advcl	_	_
2	the	the	DT	_	4	det	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	dose	dose	NN	_	1	obj	_	_
5	to	to	TO	_	7	aux	_	_
6	2400	0	CD	_	7	num	_	_
7	mg/day	mg/day	NN	_	1	ppmod	_	_
8	increased	increase	VBD	_	0	root	_	_
9	the	the	DT	_	12	det	_	_
10	steadystate	steadystate	JJ	_	12	attr	_	_
11	drug2	drug0	NN	_	12	com	_	_
12	Cmin	cmin	NN	_	8	obj	_	_
13	to	to	TO	_	16	aux	_	_
14	96	0	CD	_	15	com	_	_
15	25	0	CD	_	16	num	_	_
16	micrograms/mL	micrograms/ml	NNS	_	12	ppmod	_	_
17	.	.	.	_	8	p	_	_

1	Corresponding	corresponding	JJ	_	2	attr	_	_
2	values	value	NNS	_	8	dep	_	_
3	for	for	IN	_	7	case	_	_
4	free	free	JJ	_	7	attr	_	_
5	drug1	drug0	NN	_	7	com	_	_
6	Cmin	cmin	NN	_	7	com	_	_
7	concentrations	concentration	NNS	_	2	ppmod	_	_
8	were	be	VBD	_	0	root	_	_
9	7	0	CD	_	18	num	_	_
10	3	0	CD	_	9	num	_	_
11	,	,	,	_	10	p	_	_
12	9	0	CD	_	13	com	_	_
13	4	0	CD	_	10	conj	_	_
14	,	,	,	_	13	p	_	_
15	and	and	CC	_	13	cc	_	_
16	11	0	CD	_	17	com	_	_
17	6	0	CD	_	10	conj	_	_
18	micrograms/mL	micrograms/ml	NNS	_	8	obj	_	_
19	for	for	IN	_	27	case	_	_
20	0	0	CD	_	27	num	_	_
21	,	,	,	_	20	p	_	_
22	1200	0	CD	_	20	conj	_	_
23	,	,	,	_	22	p	_	_
24	and	and	CC	_	22	cc	_	_
25	2400	0	CD	_	20	conj	_	_
26	mg/day	mg/day	NN	_	27	com	_	_
27	drug2	drug0	NN	_	18	ppmod	_	_
28	,	,	,	_	8	p	_	_
29	respectively	respectively	RB	_	8	adv	_	_
30	.	.	.	_	8	p	_	_

1	The	the	DT	_	2	det	_	_
2	ratios	ratio	NNS	_	16	dep	_	_
3	of	of	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	AUCs	auc	NNS	_	2	ppmod	_	_
6	of	of	IN	_	8	case	_	_
7	unbound	unbound	JJ	_	8	attr	_	_
8	drug1	drug0	NN	_	5	ppmod	_	_
9	to	to	TO	_	11	aux	_	_
10	the	the	DT	_	11	det	_	_
11	AUCs	auc	NNS	_	2	ppmod	_	_
12	of	of	IN	_	15	case	_	_
13	the	the	DT	_	15	det	_	_
14	total	total	JJ	_	15	attr	_	_
15	drug2	drug0	NN	_	11	ppmod	_	_
16	were	be	VBD	_	0	root	_	_
17	11.1	0	CD	_	16	obj	_	_
18	%	%	NN	_	17	meta	_	_
19	,	,	,	_	17	p	_	_
20	13.0	0	CD	_	17	conj	_	_
21	%	%	NN	_	20	meta	_	_
22	,	,	,	_	20	p	_	_
23	and	and	CC	_	20	cc	_	_
24	11.5	0	CD	_	17	conj	_	_
25	%	%	NN	_	24	meta	_	_
26	,	,	,	_	16	p	_	_
27	with	with	IN	_	28	case	_	_
28	coadministration	coadministration	NN	_	16	ppmod	_	_
29	of	of	IN	_	36	case	_	_
30	0	0	CD	_	36	num	_	_
31	,	,	,	_	30	p	_	_
32	1200	0	CD	_	30	conj	_	_
33	,	,	,	_	32	p	_	_
34	and	and	CC	_	32	cc	_	_
35	2400	0	CD	_	30	conj	_	_
36	mg/day	mg/day	NN	_	28	ppmod	_	_
37	of	of	IN	_	38	case	_	_
38	drug3	drug0	NN	_	36	ppmod	_	_
39	,	,	,	_	16	p	_	_
40	respectively	respectively	RB	_	16	adv	_	_
41	.	.	.	_	16	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Coadministration	coadministration	NN	_	8	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drug3	drug0	NN	_	3	ppmod	_	_
8	causes	cause	VBZ	_	1	acl	_	_
9	an	an	DT	_	10	det	_	_
10	increase	increase	NN	_	8	obj	_	_
11	in	in	IN	_	14	case	_	_
12	drug4	drug0	NN	_	14	com	_	_
13	plasma	plasma	NN	_	14	com	_	_
14	concentrations	concentration	NNS	_	10	ppmod	_	_
15	,	,	,	_	8	p	_	_
16	In	in	IN	_	21	case	_	_
17	12	0	CD	_	21	num	_	_
18	otherwise	otherwise	RB	_	19	adv	_	_
19	healthy	healthy	JJ	_	21	attr	_	_
20	male	male	JJ	_	21	attr	_	_
21	volunteers	volunteer	NNS	_	8	ppmod	_	_
22	ingesting	ingest	VBG	_	21	acl	_	_
23	drug5	drug0	NN	_	22	obj	_	_
24	,	,	,	_	23	p	_	_
25	the	the	DT	_	32	det	_	_
26	steady-state	steady-state	JJ	_	32	attr	_	_
27	trough	trough	NN	_	32	attr	_	_
28	(	-lrb-	-LRB-	_	32	p	_	_
29	Cmin	cmin	NN	_	32	attr	_	_
30	)	-rrb-	-RRB-	_	32	p	_	_
31	drug6	drug0	NN	_	32	com	_	_
32	concentration	concentration	NN	_	23	appo	_	_
33	was	be	VBD	_	32	acl	_	_
34	14.2	0	CD	_	35	num	_	_
35	micrograms/mL	micrograms/ml	NN	_	33	obj	_	_
36	.	.	.	_	1	p	_	_

1	The	the	DT	_	4	det	_	_
2	steady-state	steady-state	JJ	_	4	attr	_	_
3	Cmin	cmin	NN	_	4	com	_	_
4	concentration	concentration	NN	_	5	dep	_	_
5	increased	increase	VBD	_	0	root	_	_
6	to	to	TO	_	8	aux	_	_
7	17.8	0	CD	_	8	num	_	_
8	micrograms/mL	micrograms/ml	NNS	_	5	ppmod	_	_
9	when	when	WRB	_	15	adv	_	_
10	2400	0	CD	_	11	num	_	_
11	mg/day	mg/day	NN	_	15	dep	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	was	be	VBD	_	15	aux	_	_
15	coadministered	coadministered	VBN	_	5	comp	_	_
16	for	for	IN	_	18	case	_	_
17	one	#crd#	CD	_	18	num	_	_
18	week	week	NN	_	15	ppmod	_	_
19	.	.	.	_	5	p	_	_

1	Effects	effect	NNS	_	0	root	_	_
2	of	of	IN	_	4	case	_	_
3	Other	other	JJ	_	4	attr	_	_
4	drug1	drug0	NN	_	1	ppmod	_	_
5	on	on	IN	_	7	case	_	_
6	drug2	drug0	NN	_	7	com	_	_
7	drug3	drug0	NN	_	1	ppmod	_	_
8	:	:	:	_	1	p	_	_
9	drug4	drug0	NN	_	10	dep	_	_
10	causes	cause	VBZ	_	1	acl	_	_
11	an	an	DT	_	13	det	_	_
12	approximate	approximate	JJ	_	13	attr	_	_
13	doubling	doubling	JJ	_	10	obj	_	_
14	of	of	IN	_	16	case	_	_
15	the	the	DT	_	16	det	_	_
16	clearance	clearance	NN	_	13	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug5	drug0	NN	_	16	ppmod	_	_
19	(	-lrb-	-LRB-	_	20	p	_	_
20	drug6	drug0	NN	_	18	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	at	at	IN	_	24	case	_	_
23	steady	steady	JJ	_	24	attr	_	_
24	state	state	NN	_	16	ppmod	_	_
25	and	and	CC	_	10	cc	_	_
26	,	,	,	_	10	p	_	_
27	therefore	therefore	RB	_	33	adv	_	_
28	,	,	,	_	33	p	_	_
29	the	the	DT	_	30	det	_	_
30	addition	addition	NN	_	33	dep	_	_
31	of	of	IN	_	32	case	_	_
32	drug7	drug0	NN	_	30	ppmod	_	_
33	causes	cause	VBZ	_	10	conj	_	_
34	an	an	DT	_	38	det	_	_
35	approximate	approximate	JJ	_	38	attr	_	_
36	45	0	CD	_	38	num	_	_
37	%	%	NN	_	36	meta	_	_
38	decrease	decrease	NN	_	33	obj	_	_
39	in	in	IN	_	43	case	_	_
40	the	the	DT	_	43	det	_	_
41	steady-state	steady-state	JJ	_	43	attr	_	_
42	trough	trough	NN	_	43	com	_	_
43	concentrations	concentration	NNS	_	38	ppmod	_	_
44	of	of	IN	_	45	case	_	_
45	drug8	drug0	NN	_	43	ppmod	_	_
46	as	as	IN	_	47	mark	_	_
47	compared	compare	VBN	_	33	comp	_	_
48	to	to	TO	_	51	aux	_	_
49	the	the	DT	_	51	det	_	_
50	same	same	JJ	_	51	attr	_	_
51	dose	dose	NN	_	47	ppmod	_	_
52	of	of	IN	_	53	case	_	_
53	drug9	drug0	NN	_	51	ppmod	_	_
54	given	give	VBN	_	51	acl	_	_
55	as	as	IN	_	56	case	_	_
56	monotherapy	monotherapy	NN	_	54	ppmod	_	_
57	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	4	dep	_	_
4	causes	cause	VBZ	_	1	acl	_	_
5	an	an	DT	_	9	det	_	_
6	approximate	approximate	JJ	_	9	attr	_	_
7	50	0	CD	_	9	num	_	_
8	%	%	NN	_	7	meta	_	_
9	increase	increase	NN	_	4	obj	_	_
10	in	in	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	clearance	clearance	NN	_	9	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug3	drug0	NN	_	12	ppmod	_	_
15	at	at	IN	_	17	case	_	_
16	steady	steady	JJ	_	17	attr	_	_
17	state	state	NN	_	12	ppmod	_	_
18	and	and	CC	_	4	cc	_	_
19	,	,	,	_	4	p	_	_
20	therefore	therefore	RB	_	26	adv	_	_
21	,	,	,	_	26	p	_	_
22	the	the	DT	_	23	det	_	_
23	addition	addition	NN	_	26	dep	_	_
24	of	of	IN	_	25	case	_	_
25	drug4	drug0	NN	_	23	ppmod	_	_
26	results	result	VBZ	_	4	conj	_	_
27	in	in	IN	_	32	case	_	_
28	an	an	DT	_	32	det	_	_
29	approximate	approximate	JJ	_	32	attr	_	_
30	40	0	CD	_	32	num	_	_
31	%	%	NN	_	30	meta	_	_
32	decrease	decrease	NN	_	26	ppmod	_	_
33	in	in	IN	_	37	case	_	_
34	the	the	DT	_	37	det	_	_
35	steady-state	steady-state	JJ	_	37	attr	_	_
36	trough	trough	NN	_	37	com	_	_
37	concentrations	concentration	NNS	_	32	ppmod	_	_
38	of	of	IN	_	39	case	_	_
39	drug5	drug0	NN	_	37	ppmod	_	_
40	as	as	IN	_	41	mark	_	_
41	compared	compare	VBN	_	26	comp	_	_
42	to	to	TO	_	45	aux	_	_
43	the	the	DT	_	45	det	_	_
44	same	same	JJ	_	45	attr	_	_
45	dose	dose	NN	_	41	ppmod	_	_
46	of	of	IN	_	47	case	_	_
47	drug6	drug0	NN	_	45	ppmod	_	_
48	given	give	VBN	_	45	acl	_	_
49	as	as	IN	_	50	case	_	_
50	monotherapy	monotherapy	NN	_	48	ppmod	_	_
51	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Available	available	JJ	_	4	attr	_	_
4	data	datum	NNS	_	5	dep	_	_
5	suggest	suggest	VBP	_	1	acl	_	_
6	that	that	IN	_	31	mark	_	_
7	there	there	EX	_	8	dep	_	_
8	is	be	VBZ	_	31	advcl	_	_
9	no	no	DT	_	11	det	_	_
10	significant	significant	JJ	_	11	attr	_	_
11	effect	effect	NN	_	8	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	on	on	IN	_	16	case	_	_
15	the	the	DT	_	16	det	_	_
16	clearance	clearance	NN	_	11	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug3	drug0	NN	_	16	ppmod	_	_
19	at	at	IN	_	21	case	_	_
20	steady	steady	JJ	_	21	attr	_	_
21	state	state	NN	_	16	ppmod	_	_
22	,	,	,	_	31	p	_	_
23	Therefore	therefore	RB	_	31	adv	_	_
24	,	,	,	_	31	p	_	_
25	the	the	DT	_	26	det	_	_
26	addition	addition	NN	_	31	dep	_	_
27	of	of	IN	_	28	case	_	_
28	drug4	drug0	NN	_	26	ppmod	_	_
29	is	be	VBZ	_	31	aux	_	_
30	not	not	RB	_	31	neg	_	_
31	expected	expect	VBN	_	5	comp	_	_
32	to	to	TO	_	33	aux	_	_
33	cause	cause	VB	_	31	comp	_	_
34	a	a	DT	_	37	det	_	_
35	clinically	clinically	RB	_	36	adv	_	_
36	important	important	JJ	_	37	attr	_	_
37	effect	effect	NN	_	33	obj	_	_
38	on	on	IN	_	44	case	_	_
39	drug5	drug0	NN	_	44	attr	_	_
40	(	-lrb-	-LRB-	_	44	p	_	_
41	drug6	drug0	NN	_	44	attr	_	_
42	)	-rrb-	-RRB-	_	44	p	_	_
43	plasma	plasma	NN	_	44	com	_	_
44	concentrations	concentration	NNS	_	37	ppmod	_	_
45	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	It	it	PRP	_	4	dep	_	_
4	appears	appear	VBZ	_	1	acl	_	_
5	that	that	IN	_	8	mark	_	_
6	drug2	drug0	NN	_	8	dep	_	_
7	may	may	MD	_	8	modal	_	_
8	reduce	reduce	VB	_	4	comp	_	_
9	plasma	plasma	NN	_	11	com	_	_
10	drug3	drug0	NN	_	11	com	_	_
11	concentrations	concentration	NNS	_	8	obj	_	_
12	.	.	.	_	1	p	_	_

1	Steady-state	steady-state	JJ	_	4	attr	_	_
2	plasma	plasma	NN	_	4	com	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	concentrations	concentration	NNS	_	6	dep	_	_
5	were	be	VBD	_	6	aux	_	_
6	found	find	VBN	_	0	root	_	_
7	to	to	TO	_	8	aux	_	_
8	be	be	VB	_	6	comp	_	_
9	29	0	CD	_	11	num	_	_
10	%	%	NN	_	9	meta	_	_
11	lower	low	JJR	_	8	dep	_	_
12	than	than	IN	_	15	case	_	_
13	the	the	DT	_	15	det	_	_
14	mean	mean	JJ	_	15	attr	_	_
15	concentrations	concentration	NNS	_	11	ppmod	_	_
16	of	of	IN	_	18	case	_	_
17	a	a	DT	_	18	det	_	_
18	group	group	NN	_	15	ppmod	_	_
19	of	of	IN	_	22	case	_	_
20	newly	newly	RB	_	21	adv	_	_
21	diagnosed	diagnose	VBN	_	22	attr	_	_
22	subjects	subject	NNS	_	18	ppmod	_	_
23	with	with	IN	_	24	case	_	_
24	epilepsy	epilepsy	NN	_	22	ppmod	_	_
25	also	also	RB	_	26	adv	_	_
26	receiving	receive	VBG	_	22	acl	_	_
27	2400	0	CD	_	28	num	_	_
28	mg	mg	NN	_	26	obj	_	_
29	of	of	IN	_	32	case	_	_
30	drug2	drug0	NN	_	32	com	_	_
31	a	a	NN	_	32	com	_	_
32	day	day	NN	_	28	ppmod	_	_
33	.	.	.	_	6	p	_	_

1	Effects	effect	NNS	_	26	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	on	on	IN	_	5	case	_	_
5	drug2	drug0	NN	_	1	ppmod	_	_
6	The	the	DT	_	7	det	_	_
7	rate	rate	NN	_	5	attr	_	_
8	and	and	CC	_	7	cc	_	_
9	extent	extent	NN	_	7	conj	_	_
10	of	of	IN	_	11	case	_	_
11	absorption	absorption	NN	_	5	ppmod	_	_
12	of	of	IN	_	16	case	_	_
13	a	a	DT	_	16	det	_	_
14	2400	0	CD	_	15	num	_	_
15	mg	mg	NN	_	16	com	_	_
16	dose	dose	NN	_	11	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug3	drug0	NN	_	16	ppmod	_	_
19	as	as	IN	_	20	case	_	_
20	monotherapy	monotherapy	NN	_	18	ppmod	_	_
21	given	give	VBN	_	16	acl	_	_
22	as	as	IN	_	23	case	_	_
23	tablets	tablet	NNS	_	21	ppmod	_	_
24	was	be	VBD	_	26	aux	_	_
25	not	not	RB	_	26	neg	_	_
26	affected	affect	VBN	_	0	root	_	_
27	when	when	WRB	_	28	adv	_	_
28	coadministered	coadministered	VBN	_	26	comp	_	_
29	with	with	IN	_	30	case	_	_
30	drug4	drug0	NN	_	28	ppmod	_	_
31	.	.	.	_	26	p	_	_

1	Effects	effect	NNS	_	19	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	on	on	IN	_	5	case	_	_
5	drug2	drug0	NN	_	1	ppmod	_	_
6	The	the	DT	_	7	det	_	_
7	coadministration	coadministration	NN	_	5	appo	_	_
8	of	of	IN	_	9	case	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_
10	(	-lrb-	-LRB-	_	12	p	_	_
11	1000	0	CD	_	12	num	_	_
12	mg/day	mg/day	NN	_	9	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	for	for	IN	_	16	case	_	_
15	10	0	CD	_	16	num	_	_
16	days	day	NNS	_	9	ppmod	_	_
17	did	do	VBD	_	19	aux	_	_
18	not	not	RB	_	19	neg	_	_
19	alter	alter	VB	_	0	root	_	_
20	the	the	DT	_	22	det	_	_
21	pharmacokinetic	pharmacokinetic	JJ	_	22	attr	_	_
22	parameters	parameter	NNS	_	19	obj	_	_
23	of	of	IN	_	24	case	_	_
24	Cmax	cmax	NN	_	22	ppmod	_	_
25	,	,	,	_	24	p	_	_
26	Cmin	cmin	NN	_	24	conj	_	_
27	,	,	,	_	26	p	_	_
28	AUC	auc	NN	_	24	conj	_	_
29	,	,	,	_	28	p	_	_
30	CI/kg	ci/kg	NN	_	24	conj	_	_
31	or	or	CC	_	30	cc	_	_
32	tmax	tmax	NN	_	24	conj	_	_
33	at	at	IN	_	36	case	_	_
34	drug4	drug0	NN	_	36	attr	_	_
35	daily	daily	JJ	_	36	attr	_	_
36	doses	dose	NNS	_	24	ppmod	_	_
37	of	of	IN	_	41	case	_	_
38	3000	0	CD	_	41	num	_	_
39	or	or	CC	_	38	cc	_	_
40	3600	0	CD	_	38	conj	_	_
41	mg/day	mg/day	NN	_	36	ppmod	_	_
42	in	in	IN	_	46	case	_	_
43	10	0	CD	_	46	num	_	_
44	otherwise	otherwise	JJ	_	46	attr	_	_
45	healthy	healthy	JJ	_	46	attr	_	_
46	subjects	subject	NNS	_	24	ppmod	_	_
47	with	with	IN	_	48	case	_	_
48	epilepsy	epilepsy	NN	_	46	ppmod	_	_
49	.	.	.	_	19	p	_	_

1	Effects	effect	NNS	_	36	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	on	on	IN	_	6	case	_	_
5	Low-Dose	low-dose	JJ	_	6	attr	_	_
6	drug2	drug0	NNS	_	1	ppmod	_	_
7	A	a	DT	_	8	det	_	_
8	group	group	NN	_	6	appo	_	_
9	of	of	IN	_	16	case	_	_
10	24	0	CD	_	16	num	_	_
11	nonsmoking	nonsmoking	JJ	_	16	attr	_	_
12	,	,	,	_	16	p	_	_
13	healthy	healthy	JJ	_	16	attr	_	_
14	white	white	JJ	_	16	attr	_	_
15	female	female	JJ	_	16	attr	_	_
16	volunteers	volunteer	NNS	_	8	ppmod	_	_
17	established	establish	VBN	_	6	acl	_	_
18	on	on	IN	_	22	case	_	_
19	an	an	DT	_	22	det	_	_
20	oral	oral	JJ	_	22	attr	_	_
21	drug3	drug0	NN	_	22	com	_	_
22	regimen	regimen	NN	_	17	ppmod	_	_
23	containing	contain	VBG	_	22	acl	_	_
24	30	0	CD	_	25	num	_	_
25	mg	mg	NN	_	26	com	_	_
26	drug4	drug0	NN	_	23	obj	_	_
27	and	and	CC	_	26	cc	_	_
28	75	0	CD	_	29	num	_	_
29	mg	mg	NN	_	30	com	_	_
30	drug5	drug0	NN	_	26	conj	_	_
31	for	for	IN	_	35	case	_	_
32	at	at	IN	_	34	case	_	_
33	least	least	JJS	_	34	attr	_	_
34	3	0	CD	_	35	num	_	_
35	months	month	NNS	_	26	ppmod	_	_
36	received	receive	VBD	_	0	root	_	_
37	2400	0	CD	_	38	num	_	_
38	mg/day	mg/day	NN	_	36	obj	_	_
39	of	of	IN	_	40	case	_	_
40	drug6	drug0	NN	_	38	ppmod	_	_
41	from	from	IN	_	42	case	_	_
42	midcycle	midcycle	NN	_	36	ppmod	_	_
43	(	-lrb-	-LRB-	_	44	p	_	_
44	day	day	NN	_	42	prn	_	_
45	15	0	CD	_	44	num	_	_
46	)	-rrb-	-RRB-	_	44	p	_	_
47	to	to	TO	_	48	aux	_	_
48	midcycle	midcycle	NN	_	42	ppmod	_	_
49	(	-lrb-	-LRB-	_	50	p	_	_
50	day	day	NN	_	48	prn	_	_
51	14	0	CD	_	50	num	_	_
52	)	-rrb-	-RRB-	_	50	p	_	_
53	of	of	IN	_	58	case	_	_
54	two	#crd#	CD	_	58	num	_	_
55	consecutive	consecutive	JJ	_	58	attr	_	_
56	oral	oral	JJ	_	58	attr	_	_
57	drug7	drug0	NN	_	58	com	_	_
58	cycles	cycle	NNS	_	48	ppmod	_	_
59	.	.	.	_	36	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	treatment	treatment	NN	_	3	dep	_	_
3	resulted	result	VBD	_	0	root	_	_
4	in	in	IN	_	8	case	_	_
5	a	a	DT	_	8	det	_	_
6	42	0	CD	_	8	num	_	_
7	%	%	NN	_	6	meta	_	_
8	decrease	decrease	NN	_	3	ppmod	_	_
9	in	in	IN	_	12	case	_	_
10	the	the	DT	_	12	det	_	_
11	drug2	drug0	NN	_	12	com	_	_
12	AUC	auc	NN	_	8	ppmod	_	_
13	0-24	0	CD	_	12	num	_	_
14	,	,	,	_	3	p	_	_
15	but	but	CC	_	3	cc	_	_
16	no	no	DT	_	19	det	_	_
17	clinically	clinically	RB	_	18	adv	_	_
18	relevant	relevant	JJ	_	19	attr	_	_
19	effect	effect	NN	_	21	dep	_	_
20	was	be	VBD	_	21	aux	_	_
21	observed	observe	VBN	_	3	conj	_	_
22	on	on	IN	_	25	case	_	_
23	the	the	DT	_	25	det	_	_
24	pharmacokinetic	pharmacokinetic	JJ	_	25	attr	_	_
25	parameters	parameter	NNS	_	21	ppmod	_	_
26	of	of	IN	_	27	case	_	_
27	drug3	drug0	NN	_	25	ppmod	_	_
28	.	.	.	_	3	p	_	_

1	No	no	DT	_	2	det	_	_
2	volunteer	volunteer	NN	_	3	dep	_	_
3	showed	show	VBD	_	0	root	_	_
4	hormonal	hormonal	JJ	_	5	attr	_	_
5	evidence	evidence	NN	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	ovulation	ovulation	NN	_	5	ppmod	_	_
8	,	,	,	_	3	p	_	_
9	but	but	CC	_	3	cc	_	_
10	one	#crd#	CD	_	11	num	_	_
11	volunteer	volunteer	NN	_	12	dep	_	_
12	reported	report	VBD	_	3	conj	_	_
13	intermenstrual	intermenstrual	JJ	_	14	adv	_	_
14	bleeding	bleeding	JJ	_	12	dep	_	_
15	during	during	IN	_	17	case	_	_
16	drug1	drug0	NN	_	17	com	_	_
17	treatment	treatment	NN	_	12	ppmod	_	_
18	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	extensively	extensively	RB	_	4	adv	_	_
4	metabolized	metabolize	VBN	_	0	root	_	_
5	by	by	IN	_	7	case	_	_
6	CYP	cyp	NN	_	7	com	_	_
7	3A4	0a0	NN	_	4	ppmod	_	_
8	,	,	,	_	4	p	_	_
9	but	but	CC	_	4	cc	_	_
10	coadministration	coadministration	NN	_	21	dep	_	_
11	of	of	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	a	a	DT	_	16	det	_	_
15	potent	potent	JJ	_	16	attr	_	_
16	inhibitor	inhibitor	NN	_	12	appo	_	_
17	of	of	IN	_	19	case	_	_
18	CYP	cyp	NN	_	19	com	_	_
19	3A4	0a0	NN	_	16	ppmod	_	_
20	,	,	,	_	12	p	_	_
21	has	have	VBZ	_	4	conj	_	_
22	no	no	DT	_	24	det	_	_
23	significant	significant	JJ	_	24	attr	_	_
24	effect	effect	NN	_	21	obj	_	_
25	on	on	IN	_	27	case	_	_
26	drug3	drug0	NN	_	27	com	_	_
27	pharmacokinetics	pharmacokinetics	NNS	_	21	ppmod	_	_
28	.	.	.	_	4	p	_	_

1	Significant	significant	JJ	_	3	attr	_	_
2	pharmacokinetic	pharmacokinetic	JJ	_	3	attr	_	_
3	interactions	interaction	NNS	_	11	dep	_	_
4	mediated	mediate	VBN	_	3	acl	_	_
5	by	by	IN	_	6	case	_	_
6	inhibition	inhibition	NN	_	4	ppmod	_	_
7	of	of	IN	_	9	case	_	_
8	CYP	cyp	NN	_	9	com	_	_
9	isoenzymes	isoenzymes	NNS	_	6	ppmod	_	_
10	therefore	therefore	RB	_	11	adv	_	_
11	appear	appear	VBP	_	0	root	_	_
12	unlikely	unlikely	JJ	_	11	dep	_	_
13	.	.	.	_	11	p	_	_

1	Co-medications	co-medications	NNS	_	25	dep	_	_
2	that	that	WDT	_	3	dep	_	_
3	induce	induce	VBP	_	1	relcl	_	_
4	CYP	cyp	NN	_	5	com	_	_
5	3A4	0a0	NN	_	3	obj	_	_
6	(	-lrb-	-LRB-	_	9	p	_	_
7	e.g.	e.g.	FW	_	9	adv	_	_
8	,	,	,	_	9	p	_	_
9	drug1	drug0	NN	_	5	prn	_	_
10	,	,	,	_	9	p	_	_
11	drug2	drug0	NN	_	9	conj	_	_
12	,	,	,	_	11	p	_	_
13	drug3	drug0	NN	_	9	conj	_	_
14	,	,	,	_	13	p	_	_
15	drug4	drug0	NN	_	9	conj	_	_
16	,	,	,	_	15	p	_	_
17	or	or	CC	_	15	cc	_	_
18	St.	st.	NN	_	21	com	_	_
19	John	john	NN	_	21	com	_	_
20	s	s	NN	_	21	com	_	_
21	wort	wort	NN	_	9	conj	_	_
22	)	-rrb-	-RRB-	_	9	p	_	_
23	may	may	MD	_	25	modal	_	_
24	significantly	significantly	RB	_	25	adv	_	_
25	decrease	decrease	VB	_	0	root	_	_
26	exposure	exposure	NN	_	25	obj	_	_
27	to	to	TO	_	28	aux	_	_
28	drug5	drug0	NN	_	26	ppmod	_	_
29	.	.	.	_	25	p	_	_

1	Dose	dose	NN	_	2	com	_	_
2	modification	modification	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	recommended	recommend	VBN	_	0	root	_	_
5	for	for	IN	_	6	case	_	_
6	patients	patient	NNS	_	4	ppmod	_	_
7	who	who	WP	_	10	dep	_	_
8	are	be	VBP	_	10	aux	_	_
9	also	also	RB	_	10	adv	_	_
10	receiving	receive	VBG	_	6	relcl	_	_
11	a	a	DT	_	15	det	_	_
12	potent	potent	JJ	_	15	attr	_	_
13	CYP	cyp	NN	_	15	com	_	_
14	3A4	0a0	NN	_	15	com	_	_
15	inducer	inducer	NN	_	10	obj	_	_
16	.	.	.	_	4	p	_	_

1	Drug/Laboratory	drug/laboratory	JJ	_	2	attr	_	_
2	Tests	test	NNS	_	17	dep	_	_
3	Interactions	interaction	NNS	_	2	acl	_	_
4	No	no	DT	_	7	det	_	_
5	clinically	clinically	RB	_	6	adv	_	_
6	relevant	relevant	JJ	_	7	attr	_	_
7	changes	change	NNS	_	3	obj	_	_
8	in	in	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	results	result	NNS	_	3	ppmod	_	_
11	of	of	IN	_	14	case	_	_
12	clinical	clinical	JJ	_	14	attr	_	_
13	laboratory	laboratory	NN	_	14	com	_	_
14	tests	test	NNS	_	10	ppmod	_	_
15	have	have	VBP	_	17	aux	_	_
16	been	be	VBN	_	17	aux	_	_
17	observed	observe	VBN	_	0	root	_	_
18	.	.	.	_	17	p	_	_

1	No	no	DT	_	10	det	_	_
2	drug	drug	NN	_	10	attr	_	_
3	,	,	,	_	2	p	_	_
4	nutritional	nutritional	JJ	_	5	attr	_	_
5	supplement	supplement	NN	_	2	conj	_	_
6	,	,	,	_	5	p	_	_
7	food	food	NN	_	2	conj	_	_
8	or	or	CC	_	7	cc	_	_
9	herb	herb	NN	_	2	conj	_	_
10	interactions	interaction	NNS	_	14	dep	_	_
11	have	have	VBP	_	14	aux	_	_
12	yet	yet	RB	_	14	adv	_	_
13	been	be	VBN	_	14	aux	_	_
14	reported	report	VBN	_	0	root	_	_
15	.	.	.	_	14	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	metabolized	metabolize	VBN	_	0	root	_	_
4	in	in	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	liver	liver	NN	_	3	ppmod	_	_
7	by	by	IN	_	12	case	_	_
8	the	the	DT	_	12	det	_	_
9	cytochrome	cytochrome	NN	_	12	com	_	_
10	P450	p0	NN	_	12	com	_	_
11	enzyme	enzyme	NN	_	12	com	_	_
12	system	system	NN	_	3	ppmod	_	_
13	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	inhibits	inhibit	VBZ	_	0	root	_	_
3	CYP3A4	cyp0a0	NN	_	2	obj	_	_
4	.	.	.	_	2	p	_	_

1	Caution	caution	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	used	use	VBN	_	0	root	_	_
5	when	when	WRB	_	6	adv	_	_
6	coadministering	coadministering	VBG	_	4	comp	_	_
7	medications	medication	NNS	_	6	obj	_	_
8	that	that	WDT	_	9	dep	_	_
9	are	be	VBP	_	7	relcl	_	_
10	substrates	substrate	NNS	_	9	obj	_	_
11	,	,	,	_	10	p	_	_
12	inhibitors	inhibitor	NNS	_	10	conj	_	_
13	,	,	,	_	12	p	_	_
14	or	or	CC	_	12	cc	_	_
15	inducers	inducer	NNS	_	12	conj	_	_
16	of	of	IN	_	17	case	_	_
17	CYP3A4	cyp0a0	NN	_	12	ppmod	_	_
18	,	,	,	_	12	p	_	_
19	or	or	CC	_	12	cc	_	_
20	potentially	potentially	RB	_	21	adv	_	_
21	toxic	toxic	JJ	_	22	attr	_	_
22	medications	medication	NNS	_	10	conj	_	_
23	that	that	WDT	_	25	dep	_	_
24	are	be	VBP	_	25	aux	_	_
25	metabolized	metabolize	VBN	_	22	relcl	_	_
26	by	by	IN	_	27	case	_	_
27	CYP3A4	cyp0a0	NN	_	25	ppmod	_	_
28	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	does	do	VBZ	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	inhibit	inhibit	VB	_	0	root	_	_
5	CYP2D6	cyp0d0	NN	_	4	obj	_	_
6	,	,	,	_	5	p	_	_
7	CYP1A2	cyp0a0	NN	_	5	conj	_	_
8	,	,	,	_	7	p	_	_
9	CYP2C9	cyp0c0	NN	_	5	conj	_	_
10	,	,	,	_	9	p	_	_
11	CYP2C19	cyp0c0	NN	_	5	conj	_	_
12	,	,	,	_	11	p	_	_
13	CYP2E1	cyp0e0	NN	_	5	conj	_	_
14	,	,	,	_	13	p	_	_
15	or	or	CC	_	13	cc	_	_
16	uridine	uridine	NN	_	17	com	_	_
17	glucuronosyltransferase	glucuronosyltransferase	NN	_	5	conj	_	_
18	(	-lrb-	-LRB-	_	19	p	_	_
19	UDPGT	udpgt	NN	_	17	prn	_	_
20	)	-rrb-	-RRB-	_	19	p	_	_
21	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	effect	effect	NN	_	20	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	on	on	IN	_	10	case	_	_
8	total	total	JJ	_	10	attr	_	_
9	drug	drug	NN	_	10	com	_	_
10	concentrations	concentration	NNS	_	4	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	other	other	JJ	_	13	attr	_	_
13	drug3	drug0	NNS	_	10	ppmod	_	_
14	in	in	IN	_	15	case	_	_
15	subjects	subject	NNS	_	13	ppmod	_	_
16	receiving	receive	VBG	_	15	acl	_	_
17	both	both	DT	_	18	det	_	_
18	agents	agent	NNS	_	16	obj	_	_
19	was	be	VBD	_	20	aux	_	_
20	evaluated	evaluate	VBN	_	1	acl	_	_
21	using	use	VBG	_	20	comp	_	_
22	comparisons	comparison	NNS	_	21	obj	_	_
23	to	to	TO	_	25	aux	_	_
24	historical	historical	JJ	_	25	attr	_	_
25	data	datum	NNS	_	22	ppmod	_	_
26	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	3	attr	_	_
2	steady-state	steady-state	JJ	_	3	attr	_	_
3	Cmax	cmax	NN	_	9	dep	_	_
4	,	,	,	_	3	p	_	_
5	A.C.	a.c.	NNP	_	3	conj	_	_
6	and	and	CC	_	5	cc	_	_
7	Cmin	cmin	NN	_	3	conj	_	_
8	were	be	VBD	_	9	aux	_	_
9	decreased	decrease	VBN	_	0	root	_	_
10	by	by	IN	_	11	case	_	_
11	22	0	CD	_	9	ppmod	_	_
12	%	%	NN	_	11	meta	_	_
13	,	,	,	_	11	p	_	_
14	38	0	CD	_	11	conj	_	_
15	%	%	NN	_	14	meta	_	_
16	,	,	,	_	14	p	_	_
17	and	and	CC	_	14	cc	_	_
18	27	0	CD	_	11	conj	_	_
19	%	%	NN	_	18	meta	_	_
20	,	,	,	_	18	p	_	_
21	respectively	respectively	RB	_	11	conj	_	_
22	,	,	,	_	9	p	_	_
23	by	by	IN	_	25	case	_	_
24	concomitant	concomitant	JJ	_	25	attr	_	_
25	drug2	drug0	NN	_	9	ppmod	_	_
26	.	.	.	_	9	p	_	_

1	Similar	similar	JJ	_	2	attr	_	_
2	decreases	decrease	NNS	_	8	dep	_	_
3	in	in	IN	_	4	case	_	_
4	Cmax	cmax	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	AUC	auc	NN	_	4	conj	_	_
7	were	be	VBD	_	8	aux	_	_
8	seen	see	VBN	_	0	root	_	_
9	after	after	IN	_	12	case	_	_
10	the	the	DT	_	12	det	_	_
11	first	#ord#	JJ	_	12	attr	_	_
12	dose	dose	NN	_	8	ppmod	_	_
13	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	3	attr	_	_
2	steady-state	steady-state	JJ	_	3	attr	_	_
3	Cmax	cmax	NN	_	9	dep	_	_
4	,	,	,	_	3	p	_	_
5	A.C.	a.c.	NN	_	3	conj	_	_
6	and	and	CC	_	5	cc	_	_
7	Cmin	cmin	NN	_	3	conj	_	_
8	were	be	VBD	_	9	aux	_	_
9	increased	increase	VBN	_	0	root	_	_
10	21	0	CD	_	9	obj	_	_
11	%	%	NN	_	10	meta	_	_
12	,	,	,	_	9	p	_	_
13	decreased	decrease	VBN	_	9	conj	_	_
14	19	0	CD	_	13	obj	_	_
15	%	%	NN	_	14	meta	_	_
16	,	,	,	_	13	p	_	_
17	and	and	CC	_	13	cc	_	_
18	decreased	decrease	VBN	_	9	conj	_	_
19	48	0	CD	_	18	obj	_	_
20	%	%	NN	_	19	meta	_	_
21	,	,	,	_	19	p	_	_
22	respectively	respectively	RB	_	19	adv	_	_
23	,	,	,	_	18	p	_	_
24	by	by	IN	_	26	case	_	_
25	concomitant	concomitant	JJ	_	26	attr	_	_
26	drug2	drug0	NN	_	9	conj	_	_
27	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	3	attr	_	_
2	steady-state	steady-state	JJ	_	3	attr	_	_
3	Cmax	cmax	NN	_	9	dep	_	_
4	,	,	,	_	3	p	_	_
5	A.C.	a.c.	NNP	_	3	conj	_	_
6	and	and	CC	_	5	cc	_	_
7	Cmin	cmin	NN	_	3	conj	_	_
8	were	be	VBD	_	9	aux	_	_
9	increased	increase	VBN	_	0	root	_	_
10	by	by	IN	_	11	case	_	_
11	12	0	CD	_	9	ppmod	_	_
12	%	%	NN	_	11	meta	_	_
13	,	,	,	_	11	p	_	_
14	15	0	CD	_	11	conj	_	_
15	%	%	NN	_	14	meta	_	_
16	,	,	,	_	14	p	_	_
17	and	and	CC	_	14	cc	_	_
18	14	0	CD	_	11	conj	_	_
19	%	%	NN	_	18	meta	_	_
20	,	,	,	_	18	p	_	_
21	respectively	respectively	RB	_	11	conj	_	_
22	,	,	,	_	9	p	_	_
23	by	by	IN	_	25	case	_	_
24	concomitant	concomitant	JJ	_	25	attr	_	_
25	drug2	drug0	NN	_	9	ppmod	_	_
26	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Coadministration	coadministration	NN	_	9	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug3	drug0	NN	_	5	conj	_	_
8	can	can	MD	_	9	modal	_	_
9	decrease	decrease	VB	_	1	acl	_	_
10	plasma	plasma	NN	_	11	com	_	_
11	levels	level	NNS	_	9	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug4	drug0	NN	_	11	ppmod	_	_
14	.	.	.	_	1	p	_	_

1	Coadministration	coadministration	NN	_	13	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	as	as	IN	_	7	mark	_	_
7	compared	compare	VBN	_	1	acl	_	_
8	to	to	TO	_	12	aux	_	_
9	a	a	DT	_	12	det	_	_
10	non-matched	non-matched	JJ	_	12	attr	_	_
11	historicalcontrol	historicalcontrol	NN	_	12	com	_	_
12	group	group	NN	_	7	ppmod	_	_
13	resulted	result	VBD	_	0	root	_	_
14	in	in	IN	_	25	case	_	_
15	a	a	DT	_	25	det	_	_
16	30	0	CD	_	25	num	_	_
17	%	%	NN	_	16	meta	_	_
18	,	,	,	_	16	p	_	_
19	27	0	CD	_	16	conj	_	_
20	%	%	NN	_	19	meta	_	_
21	,	,	,	_	19	p	_	_
22	and	and	CC	_	19	cc	_	_
23	25	0	CD	_	16	conj	_	_
24	%	%	NN	_	23	meta	_	_
25	decrease	decrease	NN	_	13	ppmod	_	_
26	in	in	IN	_	29	case	_	_
27	serum	serum	NN	_	29	com	_	_
28	drug3	drug0	NN	_	29	com	_	_
29	AUC	auc	NN	_	25	ppmod	_	_
30	,	,	,	_	29	p	_	_
31	Cmax	cmax	NN	_	29	appo	_	_
32	,	,	,	_	29	p	_	_
33	andCmin	andcmin	NN	_	29	appo	_	_
34	,	,	,	_	13	p	_	_
35	respectively	respectively	RB	_	13	adv	_	_
36	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	an	an	DT	_	4	det	_	_
4	inhibitor	inhibitor	NN	_	2	obj	_	_
5	of	of	IN	_	9	case	_	_
6	cytochrome	cytochrome	NN	_	7	com	_	_
7	P450	p0	NN	_	9	com	_	_
8	C.P.A.	c.p.a.	NNP	_	9	com	_	_
9	metabolism	metabolism	NN	_	4	ppmod	_	_
10	and	and	CC	_	2	cc	_	_
11	therefore	therefore	RB	_	15	adv	_	_
12	should	should	MD	_	15	modal	_	_
13	not	not	RB	_	15	neg	_	_
14	be	be	VB	_	15	aux	_	_
15	administered	administer	VBN	_	2	conj	_	_
16	concurrently	concurrently	RB	_	15	adv	_	_
17	with	with	IN	_	18	case	_	_
18	medications	medication	NNS	_	15	ppmod	_	_
19	with	with	IN	_	22	case	_	_
20	narrow	narrow	JJ	_	21	adv	_	_
21	therapeutic	therapeutic	JJ	_	22	attr	_	_
22	windows	window	NNS	_	18	ppmod	_	_
23	that	that	WDT	_	24	dep	_	_
24	are	be	VBP	_	22	relcl	_	_
25	substrates	substrate	NNS	_	24	obj	_	_
26	of	of	IN	_	27	case	_	_
27	CYP3A4	cyp0a0	NN	_	25	ppmod	_	_
28	.	.	.	_	2	p	_	_

1	There	there	EX	_	2	dep	_	_
2	are	be	VBP	_	0	root	_	_
3	other	other	JJ	_	4	attr	_	_
4	agents	agent	NNS	_	2	obj	_	_
5	that	that	WDT	_	7	dep	_	_
6	may	may	MD	_	7	modal	_	_
7	result	result	VB	_	4	relcl	_	_
8	in	in	IN	_	13	case	_	_
9	serious	serious	JJ	_	13	attr	_	_
10	and/or	and/or	CC	_	9	cc	_	_
11	life-threatening	life-threatening	JJ	_	9	conj	_	_
12	drug	drug	NN	_	13	com	_	_
13	interactions	interaction	NNS	_	7	ppmod	_	_
14	.	.	.	_	2	p	_	_

1	Laboratory	laboratory	NN	_	2	com	_	_
2	Tests	test	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	The	the	DT	_	5	det	_	_
5	combination	combination	NN	_	13	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	low-dose	low-dose	JJ	_	10	attr	_	_
10	drug2	drug0	NN	_	7	conj	_	_
11	has	have	VBZ	_	13	aux	_	_
12	been	be	VBN	_	13	aux	_	_
13	associated	associate	VBN	_	2	acl	_	_
14	with	with	IN	_	15	case	_	_
15	elevations	elevation	NNS	_	13	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	cholesterol	cholesterol	NN	_	15	ppmod	_	_
18	and	and	CC	_	17	cc	_	_
19	triglycerides	triglyceride	NNS	_	17	conj	_	_
20	,	,	,	_	17	p	_	_
21	SGOT	sgot	NN	_	17	conj	_	_
22	(	-lrb-	-LRB-	_	23	p	_	_
23	AST	ast	NN	_	21	prn	_	_
24	)	-rrb-	-RRB-	_	23	p	_	_
25	,	,	,	_	21	p	_	_
26	and	and	CC	_	21	cc	_	_
27	SGPT	sgpt	NN	_	17	conj	_	_
28	(	-lrb-	-LRB-	_	29	p	_	_
29	ALT	alt	NN	_	27	prn	_	_
30	)	-rrb-	-RRB-	_	29	p	_	_
31	in	in	IN	_	33	case	_	_
32	some	some	DT	_	33	det	_	_
33	patients	patient	NNS	_	15	ppmod	_	_
34	.	.	.	_	2	p	_	_

1	Appropriate	appropriate	JJ	_	3	attr	_	_
2	laboratory	laboratory	NN	_	3	com	_	_
3	testing	testing	NN	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	considered	consider	VBN	_	0	root	_	_
7	prior	prior	JJ	_	11	adv	_	_
8	to	to	TO	_	11	aux	_	_
9	initiating	initiate	VBG	_	11	attr	_	_
10	combination	combination	NN	_	11	com	_	_
11	therapy	therapy	NN	_	6	ppmod	_	_
12	with	with	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	drug2	drug0	NN	_	13	conj	_	_
16	and	and	CC	_	13	cc	_	_
17	at	at	IN	_	19	case	_	_
18	periodic	periodic	JJ	_	19	attr	_	_
19	intervals	interval	NNS	_	13	conj	_	_
20	or	or	CC	_	6	cc	_	_
21	if	if	IN	_	34	mark	_	_
22	any	any	DT	_	24	det	_	_
23	clinical	clinical	JJ	_	24	attr	_	_
24	signs	sign	NNS	_	34	dep	_	_
25	or	or	CC	_	24	cc	_	_
26	symptoms	symptom	NNS	_	24	conj	_	_
27	of	of	IN	_	28	case	_	_
28	hyperlipidemia	hyperlipidemia	NN	_	24	ppmod	_	_
29	or	or	CC	_	24	cc	_	_
30	elevated	elevated	JJ	_	33	attr	_	_
31	liver	liver	NN	_	33	com	_	_
32	function	function	NN	_	33	com	_	_
33	tests	test	NNS	_	24	conj	_	_
34	occur	occur	VBP	_	6	conj	_	_
35	during	during	IN	_	36	case	_	_
36	therapy	therapy	NN	_	34	ppmod	_	_
37	.	.	.	_	6	p	_	_

1	For	for	IN	_	3	case	_	_
2	comprehensive	comprehensive	JJ	_	3	attr	_	_
3	information	information	NN	_	14	ppmod	_	_
4	concerning	concern	VBG	_	3	acl	_	_
5	laboratory	laboratory	NN	_	7	com	_	_
6	test	test	NN	_	7	com	_	_
7	alterations	alteration	NNS	_	4	obj	_	_
8	associated	associate	VBN	_	7	acl	_	_
9	with	with	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	,	,	,	_	14	p	_	_
12	physicians	physician	NNS	_	14	dep	_	_
13	should	should	MD	_	14	modal	_	_
14	refer	refer	VBP	_	0	root	_	_
15	to	to	TO	_	19	aux	_	_
16	the	the	DT	_	19	det	_	_
17	complete	complete	JJ	_	19	attr	_	_
18	prescribing	prescribing	NN	_	19	com	_	_
19	information	information	NN	_	14	ppmod	_	_
20	for	for	IN	_	21	case	_	_
21	drug2	drug0	NN	_	19	ppmod	_	_
22	(	-lrb-	-LRB-	_	23	p	_	_
23	drug3	drug0	NN	_	21	prn	_	_
24	)	-rrb-	-RRB-	_	23	p	_	_
25	.	.	.	_	14	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	studies	study	NNS	_	5	dep	_	_
4	were	be	VBD	_	5	aux	_	_
5	conducted	conduct	VBN	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	investigate	investigate	VB	_	5	comp	_	_
8	the	the	DT	_	9	det	_	_
9	potential	potential	NN	_	7	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	to	to	TO	_	13	aux	_	_
13	inhibit	inhibit	VB	_	9	acl	_	_
14	the	the	DT	_	18	det	_	_
15	major	major	JJ	_	18	attr	_	_
16	cytochrome	cytochrome	NN	_	18	com	_	_
17	P450	p0	NN	_	18	com	_	_
18	enzymes	enzyme	NNS	_	13	obj	_	_
19	(	-lrb-	-LRB-	_	20	p	_	_
20	CYP1A2	cyp0a0	NN	_	18	prn	_	_
21	,	,	,	_	20	p	_	_
22	CYP2A6	cyp0a0	NN	_	20	conj	_	_
23	,	,	,	_	22	p	_	_
24	CYP2C9	cyp0c0	NN	_	20	conj	_	_
25	,	,	,	_	24	p	_	_
26	CYP2C19	cyp0c0	NN	_	20	conj	_	_
27	,	,	,	_	26	p	_	_
28	CYP2D6	cyp0d0	NN	_	20	conj	_	_
29	,	,	,	_	28	p	_	_
30	CYP2E1	cyp0e0	NN	_	20	conj	_	_
31	,	,	,	_	30	p	_	_
32	and	and	CC	_	30	cc	_	_
33	CYP3A4	cyp0a0	NN	_	20	conj	_	_
34	)	-rrb-	-RRB-	_	20	p	_	_
35	that	that	WDT	_	36	dep	_	_
36	mediate	mediate	VBP	_	18	relcl	_	_
37	drug	drug	NN	_	36	obj	_	_
38	and	and	CC	_	37	cc	_	_
39	xenobiotic	xenobiotic	JJ	_	40	attr	_	_
40	metabolism	metabolism	NN	_	37	conj	_	_
41	using	use	VBG	_	37	acl	_	_
42	isoform	isoform	NN	_	45	attr	_	_
43	selective	selective	JJ	_	45	attr	_	_
44	marker	marker	NN	_	45	com	_	_
45	substrates	substrate	NNS	_	41	obj	_	_
46	and	and	CC	_	45	cc	_	_
47	human	human	JJ	_	50	attr	_	_
48	liver	liver	NN	_	50	attr	_	_
49	microsomal	microsomal	JJ	_	50	attr	_	_
50	preparations	preparation	NNS	_	45	conj	_	_
51	.	.	.	_	5	p	_	_

1	Only	only	JJ	_	8	attr	_	_
2	at	at	IN	_	5	case	_	_
3	the	the	DT	_	5	det	_	_
4	highest	high	JJS	_	5	attr	_	_
5	concentration	concentration	NN	_	8	ppmod	_	_
6	tested	test	VBN	_	5	acl	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	171	0	CD	_	0	root	_	_

1	g/mL	g/ml	NN	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	1	0	CD	_	2	num	_	_
2	mM	mm	NN	_	4	dep	_	_
3	)	-rrb-	-RRB-	_	2	p	_	_
4	was	be	VBD	_	0	root	_	_
5	a	a	DT	_	7	det	_	_
6	slight	slight	JJ	_	7	attr	_	_
7	degree	degree	NN	_	4	obj	_	_
8	of	of	IN	_	9	case	_	_
9	inhibition	inhibition	NN	_	7	ppmod	_	_
10	(	-lrb-	-LRB-	_	13	p	_	_
11	14	0	CD	_	13	num	_	_
12	%	%	NN	_	13	meta	_	_
13	-30	0	CD	_	9	num	_	_
14	%	%	NN	_	13	meta	_	_
15	)	-rrb-	-RRB-	_	13	p	_	_
16	of	of	IN	_	18	case	_	_
17	isoform	isoform	NN	_	18	com	_	_
18	CYP2A6	cyp0a0	NN	_	9	ppmod	_	_
19	observed	observe	VBN	_	18	acl	_	_
20	.	.	.	_	4	p	_	_

1	No	no	DT	_	2	det	_	_
2	inhibition	inhibition	NN	_	11	dep	_	_
3	of	of	IN	_	4	case	_	_
4	any	any	DT	_	2	ppmod	_	_
5	of	of	IN	_	8	case	_	_
6	the	the	DT	_	8	det	_	_
7	other	other	JJ	_	8	attr	_	_
8	isoforms	isoforms	NNS	_	4	ppmod	_	_
9	tested	test	VBN	_	8	acl	_	_
10	was	be	VBD	_	11	aux	_	_
11	observed	observe	VBN	_	0	root	_	_
12	at	at	IN	_	14	case	_	_
13	drug1	drug0	JJ	_	14	attr	_	_
14	concentrations	concentration	NNS	_	11	ppmod	_	_
15	up	up	RB	_	17	adv	_	_
16	to	to	TO	_	17	attr	_	_
17	171	0	CD	_	18	num	_	_
18	mg/mL	mg/ml	NN	_	14	attr	_	_
19	(	-lrb-	-LRB-	_	22	p	_	_
20	approximately	approximately	RB	_	21	adv	_	_
21	15	0	CD	_	22	num	_	_
22	times	time	NNS	_	11	prn	_	_
23	the	the	DT	_	24	det	_	_
24	Cmax	cmax	NN	_	22	appo	_	_
25	at	at	IN	_	27	case	_	_
26	3600	0	CD	_	27	num	_	_
27	mg/day	mg/day	NN	_	24	ppmod	_	_
28	)	-rrb-	-RRB-	_	22	p	_	_
29	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	is	be	VBZ	_	5	aux	_	_
3	not	not	RB	_	5	neg	_	_
4	appreciably	appreciably	RB	_	5	adv	_	_
5	metabolized	metabolize	VBN	_	0	root	_	_
6	nor	nor	CC	_	5	cc	_	_
7	does	do	VBZ	_	9	aux	_	_
8	it	it	PRP	_	9	obj	_	_
9	interfere	interfere	VB	_	5	conj	_	_
10	with	with	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	metabolism	metabolism	NN	_	9	ppmod	_	_
13	of	of	IN	_	16	case	_	_
14	commonly	commonly	RB	_	15	adv	_	_
15	coadministered	coadministered	VBN	_	16	attr	_	_
16	drug2	drug0	NN	_	12	ppmod	_	_
17	.	.	.	_	5	p	_	_

1	The	the	DT	_	4	det	_	_
2	drug	drug	NN	_	4	com	_	_
3	interaction	interaction	NN	_	4	com	_	_
4	data	datum	NNS	_	10	dep	_	_
5	described	describe	VBN	_	4	acl	_	_
6	in	in	IN	_	8	case	_	_
7	this	this	DT	_	8	det	_	_
8	section	section	NN	_	5	ppmod	_	_
9	were	be	VBD	_	10	aux	_	_
10	obtained	obtain	VBN	_	0	root	_	_
11	from	from	IN	_	12	case	_	_
12	studies	study	NNS	_	10	ppmod	_	_
13	involving	involve	VBG	_	12	acl	_	_
14	healthy	healthy	JJ	_	15	attr	_	_
15	adults	adult	NNS	_	13	obj	_	_
16	and	and	CC	_	15	cc	_	_
17	adult	adult	JJ	_	18	attr	_	_
18	patients	patient	NNS	_	15	conj	_	_
19	with	with	IN	_	20	case	_	_
20	epilepsy	epilepsy	NN	_	15	ppmod	_	_
21	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	18	case	_	_
4	a	a	DT	_	12	det	_	_
5	single	single	JJ	_	12	attr	_	_
6	(	-lrb-	-LRB-	_	8	p	_	_
7	400	0	CD	_	8	num	_	_
8	mg	mg	NN	_	5	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	and	and	CC	_	5	cc	_	_
11	multiple	multiple	JJ	_	5	conj	_	_
12	dose	dose	NN	_	18	attr	_	_
13	(	-lrb-	-LRB-	_	15	p	_	_
14	400	0	CD	_	15	num	_	_
15	mg	mg	NN	_	12	prn	_	_
16	TID	tid	JJ	_	15	attr	_	_
17	)	-rrb-	-RRB-	_	15	p	_	_
18	study	study	NN	_	38	ppmod	_	_
19	of	of	IN	_	20	case	_	_
20	drug2	drug0	NN	_	18	ppmod	_	_
21	in	in	IN	_	23	case	_	_
22	epileptic	epileptic	JJ	_	23	attr	_	_
23	patients	patient	NNS	_	18	ppmod	_	_
24	(	-lrb-	-LRB-	_	25	p	_	_
25	N=8	n=0	NN	_	23	prn	_	_
26	)	-rrb-	-RRB-	_	25	p	_	_
27	maintained	maintain	VBN	_	23	acl	_	_
28	on	on	IN	_	30	case	_	_
29	drug3	drug0	NN	_	30	com	_	_
30	monotherapy	monotherapy	NN	_	27	ppmod	_	_
31	for	for	IN	_	35	case	_	_
32	at	at	IN	_	34	case	_	_
33	least	least	JJS	_	34	attr	_	_
34	2	0	CD	_	35	num	_	_
35	months	month	NNS	_	27	ppmod	_	_
36	,	,	,	_	38	p	_	_
37	drug4	drug0	NN	_	38	dep	_	_
38	had	have	VBD	_	1	acl	_	_
39	no	no	DT	_	40	det	_	_
40	effect	effect	NN	_	38	obj	_	_
41	on	on	IN	_	46	case	_	_
42	the	the	DT	_	46	det	_	_
43	steady-state	steady-state	JJ	_	46	attr	_	_
44	trough	trough	NN	_	46	com	_	_
45	plasma	plasma	NN	_	46	com	_	_
46	concentrations	concentration	NNS	_	38	ppmod	_	_
47	of	of	IN	_	48	case	_	_
48	drug5	drug0	NN	_	46	ppmod	_	_
49	and	and	CC	_	38	cc	_	_
50	drug6	drug0	NN	_	51	dep	_	_
51	had	have	VBD	_	38	conj	_	_
52	no	no	DT	_	53	det	_	_
53	effect	effect	NN	_	51	obj	_	_
54	on	on	IN	_	56	case	_	_
55	drug7	drug0	NN	_	56	com	_	_
56	pharmacokinetics	pharmacokinetics	NNS	_	51	ppmod	_	_
57	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Steady-state	steady-state	JJ	_	6	attr	_	_
4	trough	trough	NN	_	6	com	_	_
5	plasma	plasma	NN	_	6	com	_	_
6	drug2	drug0	NN	_	12	dep	_	_
7	and	and	CC	_	6	cc	_	_
8	drug3	drug0	NN	_	9	com	_	_
9	concentrations	concentration	NNS	_	6	conj	_	_
10	were	be	VBD	_	12	aux	_	_
11	not	not	RB	_	12	neg	_	_
12	affected	affect	VBN	_	1	acl	_	_
13	by	by	IN	_	15	case	_	_
14	concomitant	concomitant	JJ	_	15	attr	_	_
15	drug4	drug0	NNS	_	12	ppmod	_	_
16	(	-lrb-	-LRB-	_	19	p	_	_
17	400	0	CD	_	18	num	_	_
18	mg	mg	NN	_	19	com	_	_
19	TID	tid	NN	_	15	prn	_	_
20	;	;	:	_	12	p	_	_

1	N=12	n=0	CD	_	3	num	_	_
2	)	-rrb-	-RRB-	_	3	p	_	_
3	administration	administration	NN	_	0	root	_	_
4	.	.	.	_	3	p	_	_

1	Likewise	likewise	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	pharmacokinetics	pharmacokinetics	NNS	_	5	dep	_	_
5	were	be	VBD	_	0	root	_	_
6	unaltered	unaltered	JJ	_	5	dep	_	_
7	by	by	IN	_	9	case	_	_
8	drug2	drug0	NN	_	9	com	_	_
9	administration	administration	NN	_	6	ppmod	_	_
10	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	9	det	_	_
4	mean	mean	JJ	_	9	attr	_	_
5	steady-state	steady-state	JJ	_	9	attr	_	_
6	trough	trough	NN	_	9	com	_	_
7	serum	serum	NN	_	9	com	_	_
8	drug2	drug0	NN	_	9	com	_	_
9	concentrations	concentration	NNS	_	1	appo	_	_
10	prior	prior	RB	_	9	adv	_	_
11	to	to	TO	_	16	aux	_	_
12	and	and	CC	_	16	cc	_	_
13	during	during	IN	_	16	case	_	_
14	concomitant	concomitant	JJ	_	16	attr	_	_
15	drug3	drug0	NN	_	16	com	_	_
16	administration	administration	NN	_	10	ppmod	_	_
17	(	-lrb-	-LRB-	_	9	p	_	_
18	400	0	CD	_	19	num	_	_
19	mg	mg	NN	_	20	com	_	_
20	TID	tid	NN	_	9	appo	_	_
21	;	;	:	_	1	p	_	_

1	N=17	n=0	NN	_	3	dep	_	_
2	)	-rrb-	-RRB-	_	1	p	_	_
3	were	be	VBD	_	0	root	_	_
4	not	not	RB	_	3	neg	_	_
5	different	different	JJ	_	3	dep	_	_
6	and	and	CC	_	3	cc	_	_
7	neither	neither	DT	_	8	dep	_	_
8	were	be	VBD	_	3	conj	_	_
9	drug1	drug0	NN	_	11	attr	_	_
10	pharmacokinetic	pharmacokinetic	JJ	_	11	attr	_	_
11	parameters	parameter	NNS	_	8	obj	_	_
12	affected	affect	VBN	_	11	acl	_	_
13	by	by	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Estimates	estimates	NN	_	1	appo	_	_
4	of	of	IN	_	7	case	_	_
5	steady-state	steady-state	JJ	_	7	attr	_	_
6	pharmacokinetic	pharmacokinetic	JJ	_	7	attr	_	_
7	parameters	parameter	NNS	_	3	ppmod	_	_
8	for	for	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	or	or	CC	_	9	cc	_	_
11	drug3	drug0	NN	_	9	conj	_	_
12	(	-lrb-	-LRB-	_	3	p	_	_
13	300	0	CD	_	14	num	_	_
14	mg	mg	NN	_	15	com	_	_
15	TID	tid	NN	_	3	appo	_	_
16	;	;	:	_	1	p	_	_

1	N=12	n=0	CD	_	3	num	_	_
2	)	-rrb-	-RRB-	_	1	p	_	_
3	are	be	VBP	_	0	root	_	_
4	identical	identical	JJ	_	3	dep	_	_
5	whether	whether	IN	_	9	mark	_	_
6	the	the	DT	_	7	det	_	_
7	drugs	drug	NNS	_	9	dep	_	_
8	are	be	VBP	_	9	aux	_	_
9	administered	administer	VBN	_	4	comp	_	_
10	alone	alone	RB	_	9	adv	_	_
11	or	or	CC	_	10	cc	_	_
12	together	together	RB	_	10	conj	_	_
13	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Coadministration	coadministration	NN	_	20	dep	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	N=18	n=0	NN	_	3	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	of	of	IN	_	9	case	_	_
8	drug2	drug0	JJ	_	9	attr	_	_
9	capsules	capsule	NNS	_	3	ppmod	_	_
10	(	-lrb-	-LRB-	_	12	p	_	_
11	250	0	CD	_	12	num	_	_
12	mg	mg	NN	_	9	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	with	with	IN	_	15	case	_	_
15	drug3	drug0	NN	_	3	ppmod	_	_
16	(	-lrb-	-LRB-	_	18	p	_	_
17	125	0	CD	_	18	num	_	_
18	mg	mg	NN	_	15	prn	_	_
19	)	-rrb-	-RRB-	_	18	p	_	_
20	appears	appear	VBZ	_	1	acl	_	_
21	to	to	TO	_	22	aux	_	_
22	increase	increase	VB	_	20	comp	_	_
23	the	the	DT	_	24	det	_	_
24	amount	amount	NN	_	22	obj	_	_
25	of	of	IN	_	26	case	_	_
26	drug4	drug0	NNS	_	24	ppmod	_	_
27	absorbed	absorb	VBN	_	26	acl	_	_
28	by	by	IN	_	29	case	_	_
29	12	0	CD	_	27	ppmod	_	_
30	%	%	NN	_	29	meta	_	_
31	to	to	TO	_	29	cc	_	_
32	15	0	CD	_	29	conj	_	_
33	%	%	NN	_	29	meta	_	_
34	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	had	have	VBD	_	0	root	_	_
3	no	no	DT	_	4	det	_	_
4	effect	effect	NN	_	2	obj	_	_
5	on	on	IN	_	8	case	_	_
6	drug2	drug0	JJ	_	8	attr	_	_
7	pharmacokinetic	pharmacokinetic	JJ	_	8	attr	_	_
8	parameters	parameter	NNS	_	2	ppmod	_	_
9	.	.	.	_	2	p	_	_

1	These	these	DT	_	2	det	_	_
2	doses	dose	NNS	_	3	dep	_	_
3	are	be	VBP	_	0	root	_	_
4	lower	low	JJR	_	3	dep	_	_
5	than	than	IN	_	8	case	_	_
6	the	the	DT	_	8	det	_	_
7	therapeutic	therapeutic	JJ	_	8	attr	_	_
8	doses	dose	NNS	_	4	ppmod	_	_
9	for	for	IN	_	11	case	_	_
10	both	both	DT	_	11	det	_	_
11	drugs	drug	NNS	_	8	ppmod	_	_
12	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	magnitude	magnitude	NN	_	15	dep	_	_
3	of	of	IN	_	4	case	_	_
4	interaction	interaction	NN	_	2	ppmod	_	_
5	within	within	IN	_	9	case	_	_
6	the	the	DT	_	9	det	_	_
7	recommended	recommend	VBN	_	9	attr	_	_
8	dose	dose	NN	_	9	com	_	_
9	ranges	range	NNS	_	2	ppmod	_	_
10	of	of	IN	_	12	case	_	_
11	either	either	DT	_	12	det	_	_
12	drug	drug	NN	_	9	ppmod	_	_
13	is	be	VBZ	_	15	aux	_	_
14	not	not	RB	_	15	neg	_	_
15	known	know	VBN	_	0	root	_	_
16	.	.	.	_	15	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Coadministration	coadministration	NN	_	1	appo	_	_
4	of	of	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	(	-lrb-	-LRB-	_	3	p	_	_
7	125	0	CD	_	10	num	_	_
8	to	to	TO	_	7	cc	_	_
9	500	0	CD	_	7	conj	_	_
10	mg	mg	NN	_	3	appo	_	_
11	;	;	:	_	1	p	_	_

1	N=48	n=0	NN	_	3	dep	_	_
2	)	-rrb-	-RRB-	_	1	p	_	_
3	decreases	decrease	VBZ	_	0	root	_	_
4	drug1	drug0	NN	_	3	obj	_	_
5	(	-lrb-	-LRB-	_	4	p	_	_
6	10	0	CD	_	7	num	_	_
7	mg	mg	NN	_	4	appo	_	_
8	;	;	:	_	3	p	_	_

1	N=50	n=0	NN	_	3	attr	_	_
2	)	-rrb-	-RRB-	_	3	p	_	_
3	Cmax	cmax	NN	_	0	root	_	_
4	and	and	CC	_	3	cc	_	_
5	AUC	auc	NN	_	6	com	_	_
6	values	value	NNS	_	3	conj	_	_
7	in	in	IN	_	10	case	_	_
8	a	a	DT	_	10	det	_	_
9	dose-dependent	dose-dependent	JJ	_	10	attr	_	_
10	manner	manner	NN	_	3	ppmod	_	_
11	relative	relative	JJ	_	10	attr	_	_
12	to	to	TO	_	13	aux	_	_
13	administration	administration	NN	_	11	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	alone	alone	RB	_	15	adv	_	_
17	;	;	:	_	3	p	_	_

1	Cmax	cmax	NN	_	5	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	AUC	auc	NN	_	4	com	_	_
4	values	value	NNS	_	1	conj	_	_
5	are	be	VBP	_	0	root	_	_
6	3	0	CD	_	9	num	_	_
7	%	%	NN	_	9	meta	_	_
8	to	to	TO	_	9	attr	_	_
9	4	0	CD	_	11	num	_	_
10	%	%	NN	_	9	meta	_	_
11	lower	low	JJR	_	5	dep	_	_
12	,	,	,	_	11	p	_	_
13	respectively	respectively	RB	_	11	adv	_	_
14	,	,	,	_	11	p	_	_
15	after	after	IN	_	16	case	_	_
16	administration	administration	NN	_	11	ppmod	_	_
17	of	of	IN	_	20	case	_	_
18	125	0	CD	_	19	num	_	_
19	mg	mg	NN	_	20	com	_	_
20	drug1	drug0	NN	_	16	ppmod	_	_
21	and	and	CC	_	11	cc	_	_
22	21	0	CD	_	25	num	_	_
23	%	%	NN	_	25	meta	_	_
24	to	to	TO	_	25	attr	_	_
25	22	0	CD	_	27	num	_	_
26	%	%	NN	_	25	meta	_	_
27	lower	low	JJR	_	11	conj	_	_
28	,	,	,	_	27	p	_	_
29	respectively	respectively	RB	_	27	adv	_	_
30	,	,	,	_	27	p	_	_
31	after	after	IN	_	32	case	_	_
32	administration	administration	NN	_	27	ppmod	_	_
33	of	of	IN	_	36	case	_	_
34	500	0	CD	_	35	num	_	_
35	mg	mg	NN	_	36	com	_	_
36	drug2	drug0	NN	_	32	ppmod	_	_
37	.	.	.	_	5	p	_	_

1	The	the	DT	_	2	det	_	_
2	mechanism	mechanism	NN	_	6	dep	_	_
3	for	for	IN	_	5	case	_	_
4	this	this	DT	_	5	det	_	_
5	interaction	interaction	NN	_	2	ppmod	_	_
6	is	be	VBZ	_	0	root	_	_
7	unknown	unknown	JJ	_	6	dep	_	_
8	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	increases	increase	VBZ	_	0	root	_	_
3	drug2	drug0	NN	_	5	com	_	_
4	AUC	auc	NN	_	5	com	_	_
5	values	value	NNS	_	2	obj	_	_
6	by	by	IN	_	7	case	_	_
7	14	0	CD	_	2	ppmod	_	_
8	%	%	NN	_	7	meta	_	_
9	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	magnitude	magnitude	NN	_	10	dep	_	_
3	of	of	IN	_	4	case	_	_
4	interaction	interaction	NN	_	2	ppmod	_	_
5	at	at	IN	_	7	case	_	_
6	other	other	JJ	_	7	attr	_	_
7	doses	dose	NNS	_	2	ppmod	_	_
8	is	be	VBZ	_	10	aux	_	_
9	not	not	RB	_	10	neg	_	_
10	known	know	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	A	a	DT	_	5	det	_	_
4	literature	literature	NN	_	5	com	_	_
5	article	article	NN	_	6	dep	_	_
6	reported	report	VBD	_	1	acl	_	_
7	that	that	IN	_	31	mark	_	_
8	when	when	WRB	_	15	adv	_	_
9	a	a	DT	_	13	det	_	_
10	60-mg	0-mg	JJ	_	13	attr	_	_
11	controlled-release	controlled-release	JJ	_	13	attr	_	_
12	drug2	drug0	NN	_	13	com	_	_
13	capsule	capsule	NN	_	15	dep	_	_
14	was	be	VBD	_	15	aux	_	_
15	administered	administer	VBN	_	31	advcl	_	_
16	2	0	CD	_	17	num	_	_
17	hours	hour	NNS	_	18	advnp	_	_
18	prior	prior	RB	_	15	adv	_	_
19	to	to	TO	_	23	aux	_	_
20	a	a	DT	_	23	det	_	_
21	600-mg	0-mg	JJ	_	23	attr	_	_
22	drug3	drug0	NN	_	23	com	_	_
23	capsule	capsule	NN	_	15	ppmod	_	_
24	(	-lrb-	-LRB-	_	25	p	_	_
25	N=12	n=0	NN	_	23	prn	_	_
26	)	-rrb-	-RRB-	_	25	p	_	_
27	,	,	,	_	31	p	_	_
28	mean	mean	JJ	_	30	attr	_	_
29	drug4	drug0	NN	_	30	com	_	_
30	AUC	auc	NN	_	31	dep	_	_
31	increased	increase	VBD	_	6	comp	_	_
32	by	by	IN	_	33	case	_	_
33	44	0	CD	_	31	ppmod	_	_
34	%	%	NN	_	33	meta	_	_
35	compared	compare	VBN	_	37	adv	_	_
36	to	to	TO	_	37	aux	_	_
37	drug5	drug0	NN	_	31	ppmod	_	_
38	administered	administer	VBN	_	37	acl	_	_
39	without	without	IN	_	40	case	_	_
40	drug6	drug0	NN	_	38	ppmod	_	_
41	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	4	attr	_	_
2	pharmacokinetic	pharmacokinetic	JJ	_	4	attr	_	_
3	parameter	parameter	NN	_	4	com	_	_
4	values	value	NNS	_	7	dep	_	_
5	were	be	VBD	_	7	aux	_	_
6	not	not	RB	_	7	neg	_	_
7	affected	affect	VBN	_	0	root	_	_
8	by	by	IN	_	9	case	_	_
9	administration	administration	NN	_	7	ppmod	_	_
10	of	of	IN	_	13	case	_	_
11	drug2	drug0	NN	_	13	attr	_	_
12	2	0	CD	_	13	num	_	_
13	hours	hour	NNS	_	9	ppmod	_	_
14	after	after	IN	_	15	case	_	_
15	drug3	drug0	NN	_	9	ppmod	_	_
16	.	.	.	_	7	p	_	_

1	The	the	DT	_	2	det	_	_
2	magnitude	magnitude	NN	_	10	dep	_	_
3	of	of	IN	_	4	case	_	_
4	interaction	interaction	NN	_	2	ppmod	_	_
5	at	at	IN	_	7	case	_	_
6	other	other	JJ	_	7	attr	_	_
7	doses	dose	NNS	_	2	ppmod	_	_
8	is	be	VBZ	_	10	aux	_	_
9	not	not	RB	_	10	neg	_	_
10	known	know	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	presence	presence	NN	_	29	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	at	at	IN	_	10	case	_	_
9	300	0	CD	_	10	num	_	_
10	mg	mg	NN	_	5	ppmod	_	_
11	QID	qid	JJ	_	10	attr	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	N=12	n=0	NN	_	10	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	the	the	DT	_	19	det	_	_
16	mean	mean	JJ	_	19	attr	_	_
17	apparent	apparent	JJ	_	19	attr	_	_
18	oral	oral	JJ	_	19	attr	_	_
19	clearance	clearance	NN	_	29	dep	_	_
20	of	of	IN	_	22	case	_	_
21	drug3	drug0	NN	_	22	com	_	_
22	fell	fell	NN	_	19	ppmod	_	_
23	by	by	IN	_	24	case	_	_
24	14	0	CD	_	19	ppmod	_	_
25	%	%	NN	_	24	meta	_	_
26	and	and	CC	_	19	cc	_	_
27	creatinine	creatinine	NN	_	28	com	_	_
28	clearance	clearance	NN	_	19	conj	_	_
29	fell	fall	VBP	_	1	acl	_	_
30	by	by	IN	_	31	case	_	_
31	10	0	CD	_	29	ppmod	_	_
32	%	%	NN	_	31	meta	_	_
33	.	.	.	_	1	p	_	_

1	Thus	thus	RB	_	3	adv	_	_
2	drug1	drug0	NN	_	3	dep	_	_
3	appeared	appear	VBD	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	alter	alter	VB	_	3	comp	_	_
6	the	the	DT	_	8	det	_	_
7	renal	renal	JJ	_	8	attr	_	_
8	excretion	excretion	NN	_	5	obj	_	_
9	of	of	IN	_	11	case	_	_
10	both	both	CC	_	11	cc	_	_
11	drug2	drug0	NN	_	8	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	creatinine	creatinine	NN	_	11	conj	_	_
14	,	,	,	_	11	p	_	_
15	an	an	DT	_	17	det	_	_
16	endogenous	endogenous	JJ	_	17	attr	_	_
17	marker	marker	NN	_	11	appo	_	_
18	of	of	IN	_	20	case	_	_
19	renal	renal	JJ	_	20	attr	_	_
20	function	function	NN	_	17	ppmod	_	_
21	.	.	.	_	3	p	_	_

1	This	this	DT	_	3	det	_	_
2	small	small	JJ	_	3	attr	_	_
3	decrease	decrease	NN	_	12	dep	_	_
4	in	in	IN	_	5	case	_	_
5	excretion	excretion	NN	_	3	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	by	by	IN	_	9	case	_	_
9	drug2	drug0	NN	_	5	ppmod	_	_
10	is	be	VBZ	_	12	aux	_	_
11	not	not	RB	_	12	neg	_	_
12	expected	expect	VBN	_	0	root	_	_
13	to	to	TO	_	14	aux	_	_
14	be	be	VB	_	12	comp	_	_
15	of	of	IN	_	17	case	_	_
16	clinical	clinical	JJ	_	17	attr	_	_
17	importance	importance	NN	_	14	ppmod	_	_
18	.	.	.	_	12	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	9	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	on	on	IN	_	6	case	_	_
6	drug2	drug0	NN	_	2	ppmod	_	_
7	was	be	VBD	_	9	aux	_	_
8	not	not	RB	_	9	neg	_	_
9	evaluated	evaluate	VBN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	Oral	oral	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	Based	base	VBN	_	6	adv	_	_
5	on	on	IN	_	6	case	_	_
6	AUC	auc	NN	_	31	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	half-life	half-life	NN	_	6	conj	_	_
9	,	,	,	_	31	p	_	_
10	multiple-dose	multiple-dose	JJ	_	12	attr	_	_
11	pharmacokinetic	pharmacokinetic	JJ	_	12	attr	_	_
12	profiles	profile	NNS	_	31	dep	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	drug3	drug0	NN	_	14	conj	_	_
17	following	follow	VBG	_	18	adv	_	_
18	administration	administration	NN	_	14	ppmod	_	_
19	of	of	IN	_	20	case	_	_
20	tablets	tablet	NNS	_	18	ppmod	_	_
21	containing	contain	VBG	_	20	acl	_	_
22	2.5	0	CD	_	23	num	_	_
23	mg	mg	NN	_	21	obj	_	_
24	of	of	IN	_	25	case	_	_
25	drug4	drug0	NN	_	23	ppmod	_	_
26	and	and	CC	_	25	cc	_	_
27	50	0	CD	_	28	num	_	_
28	mcg	mcg	NN	_	25	conj	_	_
29	of	of	IN	_	30	case	_	_
30	drug5	drug0	NN	_	25	ppmod	_	_
31	were	be	VBD	_	2	acl	_	_
32	similar	similar	JJ	_	31	dep	_	_
33	with	with	IN	_	31	ppmod	_	_
34	and	and	CC	_	33	cc	_	_
35	without	without	IN	_	36	case	_	_
36	coadministration	coadministration	NN	_	33	conj	_	_
37	of	of	IN	_	38	case	_	_
38	drug6	drug0	NN	_	36	ppmod	_	_
39	(	-lrb-	-LRB-	_	42	p	_	_
40	400	0	CD	_	41	num	_	_
41	mg	mg	NN	_	42	com	_	_
42	TID	tid	NN	_	31	prn	_	_
43	;	;	:	_	31	p	_	_

1	N=13	n=0	NN	_	0	root	_	_
2	)	-rrb-	-RRB-	_	1	p	_	_
3	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	Cmax	cmax	NN	_	5	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	was	be	VBD	_	0	root	_	_
6	13	0	CD	_	8	num	_	_
7	%	%	NN	_	6	meta	_	_
8	higher	high	JJR	_	5	dep	_	_
9	when	when	WRB	_	12	adv	_	_
10	it	it	PRP	_	12	dep	_	_
11	was	be	VBD	_	12	aux	_	_
12	coadministered	coadministered	VBN	_	5	comp	_	_
13	with	with	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	;	;	:	_	5	p	_	_

1	this	this	DT	_	2	det	_	_
2	interaction	interaction	NN	_	5	dep	_	_
3	is	be	VBZ	_	5	aux	_	_
4	not	not	RB	_	5	neg	_	_
5	expected	expect	VBN	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	be	be	VB	_	5	comp	_	_
8	of	of	IN	_	10	case	_	_
9	clinical	clinical	JJ	_	10	attr	_	_
10	importance	importance	NN	_	7	ppmod	_	_
11	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	7	dep	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	drug2	drug0	NN	_	1	prn	_	_
4	)	-rrb-	-RRB-	_	3	p	_	_
5	:	:	:	_	1	p	_	_
6	drug3	drug0	NN	_	1	appo	_	_
7	reduced	reduce	VBD	_	0	root	_	_
8	the	the	DT	_	9	det	_	_
9	bioavailability	bioavailability	NN	_	7	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug4	drug0	NN	_	9	ppmod	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	N=16	n=0	NN	_	11	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	by	by	IN	_	17	case	_	_
16	about	about	RB	_	17	adv	_	_
17	20	0	CD	_	7	ppmod	_	_
18	%	%	NN	_	17	meta	_	_
19	.	.	.	_	7	p	_	_

1	This	this	DT	_	2	det	_	_
2	decrease	decrease	NN	_	5	dep	_	_
3	in	in	IN	_	4	case	_	_
4	bioavailability	bioavailability	NN	_	2	ppmod	_	_
5	was	be	VBD	_	0	root	_	_
6	about	about	RB	_	7	adv	_	_
7	5	0	CD	_	5	obj	_	_
8	%	%	NN	_	7	meta	_	_
9	when	when	WRB	_	12	adv	_	_
10	drug1	drug0	NN	_	12	dep	_	_
11	was	be	VBD	_	12	aux	_	_
12	administered	administer	VBN	_	5	comp	_	_
13	2	0	CD	_	14	num	_	_
14	hours	hour	NNS	_	16	dat	_	_
15	after	after	IN	_	16	case	_	_
16	drug2	drug0	NN	_	12	ppmod	_	_
17	.	.	.	_	5	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	recommended	recommend	VBN	_	0	root	_	_
4	that	that	IN	_	7	mark	_	_
5	drug1	drug0	NN	_	7	dep	_	_
6	be	be	VB	_	7	aux	_	_
7	taken	take	VBN	_	3	comp	_	_
8	at	at	IN	_	10	case	_	_
9	least	least	JJS	_	10	attr	_	_
10	2	0	CD	_	11	num	_	_
11	hours	hour	NNS	_	14	dat	_	_
12	following	follow	VBG	_	14	adv	_	_
13	drug2	drug0	NN	_	14	com	_	_
14	administration	administration	NN	_	7	ppmod	_	_
15	.	.	.	_	3	p	_	_

1	Effect	effect	NN	_	6	dep	_	_
2	of	of	IN	_	5	case	_	_
3	drug1	drug0	NN	_	5	attr	_	_
4	:	:	:	_	5	p	_	_
5	drug2	drug0	NN	_	1	ppmod	_	_
6	is	be	VBZ	_	0	root	_	_
7	a	a	DT	_	8	det	_	_
8	blocker	blocker	NN	_	6	obj	_	_
9	of	of	IN	_	12	case	_	_
10	renal	renal	JJ	_	12	attr	_	_
11	tubular	tubular	JJ	_	12	attr	_	_
12	secretion	secretion	NN	_	8	ppmod	_	_
13	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	3	attr	_	_
2	pharmacokinetic	pharmacokinetic	JJ	_	3	attr	_	_
3	parameters	parameter	NNS	_	8	dep	_	_
4	without	without	IN	_	3	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	with	with	IN	_	7	case	_	_
7	drug2	drug0	NN	_	4	conj	_	_
8	were	be	VBD	_	0	root	_	_
9	comparable	comparable	JJ	_	8	dep	_	_
10	.	.	.	_	8	p	_	_

1	This	this	DT	_	2	dep	_	_
2	indicates	indicate	VBZ	_	0	root	_	_
3	that	that	IN	_	7	mark	_	_
4	drug1	drug0	NN	_	7	dep	_	_
5	does	do	VBZ	_	7	aux	_	_
6	not	not	RB	_	7	neg	_	_
7	undergo	undergo	VB	_	2	comp	_	_
8	renal	renal	JJ	_	10	attr	_	_
9	tubular	tubular	JJ	_	10	attr	_	_
10	secretion	secretion	NN	_	7	obj	_	_
11	by	by	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	pathway	pathway	NN	_	7	ppmod	_	_
14	that	that	WDT	_	16	dep	_	_
15	is	be	VBZ	_	16	aux	_	_
16	blocked	block	VBN	_	13	relcl	_	_
17	by	by	IN	_	18	case	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	.	.	.	_	2	p	_	_

1	Drug/Laboratory	drug/laboratory	NN	_	2	com	_	_
2	Tests	test	NNS	_	0	root	_	_
3	Interactions	interaction	NNS	_	2	obj	_	_
4	Because	because	IN	_	9	mark	_	_
5	false	false	JJ	_	6	adv	_	_
6	positive	positive	JJ	_	7	attr	_	_
7	readings	reading	NNS	_	9	dep	_	_
8	were	be	VBD	_	9	aux	_	_
9	reported	report	VBN	_	2	comp	_	_
10	with	with	IN	_	16	case	_	_
11	the	the	DT	_	16	det	_	_
12	Ames	ames	NN	_	16	attr	_	_
13	N-Multistix	n-multistix	JJ	_	16	attr	_	_
14	SG	sg	NN	_	16	com	_	_
15	dipstick	dipstick	NN	_	16	com	_	_
16	test	test	NN	_	9	ppmod	_	_
17	for	for	IN	_	19	case	_	_
18	urinary	urinary	JJ	_	19	attr	_	_
19	protein	protein	NN	_	16	ppmod	_	_
20	when	when	WRB	_	23	adv	_	_
21	drug1	drug0	NN	_	23	dep	_	_
22	was	be	VBD	_	23	aux	_	_
23	added	add	VBN	_	9	comp	_	_
24	to	to	TO	_	26	aux	_	_
25	other	other	JJ	_	26	attr	_	_
26	drug2	drug0	NN	_	23	ppmod	_	_
27	,	,	,	_	23	p	_	_
28	the	the	DT	_	34	det	_	_
29	more	more	RBR	_	30	adv	_	_
30	specific	specific	JJ	_	34	attr	_	_
31	sulfosalicylic	sulfosalicylic	JJ	_	34	attr	_	_
32	acid	acid	NN	_	34	com	_	_
33	precipitation	precipitation	NN	_	34	com	_	_
34	procedure	procedure	NN	_	36	dep	_	_
35	is	be	VBZ	_	36	aux	_	_
36	recommended	recommend	VBN	_	23	comp	_	_
37	to	to	TO	_	38	aux	_	_
38	determine	determine	VB	_	36	comp	_	_
39	the	the	DT	_	40	det	_	_
40	presence	presence	NN	_	38	obj	_	_
41	of	of	IN	_	43	case	_	_
42	urine	urine	NN	_	43	com	_	_
43	protein	protein	NN	_	40	ppmod	_	_

1	.	.	.	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	accentuate	accentuate	VB	_	0	root	_	_
4	the	the	DT	_	6	det	_	_
5	electrolyte	electrolyte	NN	_	6	com	_	_
6	loss	loss	NN	_	3	obj	_	_
7	associated	associate	VBN	_	6	acl	_	_
8	with	with	IN	_	10	case	_	_
9	drug2	drug0	NN	_	10	com	_	_
10	therapy	therapy	NN	_	7	ppmod	_	_
11	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	3	com	_	_
2	Supplements/	supplements/	NN	_	3	com	_	_
3	drug2	drug0	NN	_	0	root	_	_

1	Products	product	NNS	_	17	dep	_	_
2	containing	contain	VBG	_	1	acl	_	_
3	drug1	drug0	NN	_	2	obj	_	_
4	and	and	CC	_	3	cc	_	_
5	other	other	JJ	_	7	attr	_	_
6	multivalent	multivalent	JJ	_	7	attr	_	_
7	cations	cation	NNS	_	3	conj	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	such	such	JJ	_	7	prn	_	_
10	as	as	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	,	,	,	_	11	p	_	_
13	drug3	drug0	NN	_	11	appo	_	_
14	,	,	,	_	11	p	_	_
15	drug4	drug0	NN	_	11	appo	_	_
16	)	-rrb-	-RRB-	_	9	p	_	_
17	are	be	VBP	_	0	root	_	_
18	likely	likely	JJ	_	17	dep	_	_
19	to	to	TO	_	20	aux	_	_
20	interfere	interfere	VB	_	18	comp	_	_
21	with	with	IN	_	22	case	_	_
22	absorption	absorption	NN	_	20	ppmod	_	_
23	of	of	IN	_	24	case	_	_
24	drug5	drug0	NN	_	22	ppmod	_	_
25	.	.	.	_	17	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	taken	take	VBN	_	0	root	_	_
5	at	at	IN	_	7	case	_	_
6	least	least	JJS	_	7	attr	_	_
7	60	0	CD	_	8	num	_	_
8	minutes	minute	NNS	_	12	dat	_	_
9	before	before	IN	_	12	case	_	_
10	any	any	DT	_	12	det	_	_
11	oral	oral	JJ	_	12	attr	_	_
12	medications	medication	NNS	_	4	ppmod	_	_
13	containing	contain	VBG	_	12	acl	_	_
14	multivalent	multivalent	JJ	_	15	attr	_	_
15	cations	cation	NNS	_	13	obj	_	_
16	(	-lrb-	-LRB-	_	18	p	_	_
17	including	include	VBG	_	18	adv	_	_
18	drug2	drug0	NN	_	15	prn	_	_
19	,	,	,	_	18	p	_	_
20	supplements	supplement	NNS	_	18	conj	_	_
21	or	or	CC	_	20	cc	_	_
22	drug3	drug0	NN	_	18	conj	_	_
23	)	-rrb-	-RRB-	_	18	p	_	_
24	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	drug3	drug0	NN	_	1	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_

1	Of	of	IN	_	4	case	_	_
2	over	over	IN	_	4	case	_	_
3	3500	0	CD	_	4	num	_	_
4	patients	patient	NNS	_	17	ppmod	_	_
5	enrolled	enrol	VBN	_	4	acl	_	_
6	in	in	IN	_	10	case	_	_
7	the	the	DT	_	10	det	_	_
8	drug1	drug0	JJ	_	10	attr	_	_
9	osteoporosis	osteoporosis	NN	_	10	com	_	_
10	Treatment	treatment	NN	_	5	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	Prevention	prevention	NN	_	13	com	_	_
13	Studies	study	NNS	_	10	conj	_	_
14	,	,	,	_	17	p	_	_
15	15	0	CD	_	17	num	_	_
16	%	%	NN	_	15	meta	_	_
17	used	use	VBD	_	0	root	_	_
18	anti-peptic	anti-peptic	JJ	_	19	attr	_	_
19	agents	agent	NNS	_	17	obj	_	_
20	(	-lrb-	-LRB-	_	22	p	_	_
21	primarily	primarily	RB	_	22	adv	_	_
22	drug2	drug0	NN	_	19	prn	_	_
23	and	and	CC	_	22	cc	_	_
24	drug3	drug0	NN	_	22	conj	_	_
25	)	-rrb-	-RRB-	_	22	p	_	_
26	.	.	.	_	17	p	_	_

1	Among	among	IN	_	3	case	_	_
2	these	these	DT	_	3	det	_	_
3	patients	patient	NNS	_	18	ppmod	_	_
4	,	,	,	_	18	p	_	_
5	the	the	DT	_	6	det	_	_
6	incidence	incidence	NN	_	18	dep	_	_
7	of	of	IN	_	11	case	_	_
8	upper	upper	JJ	_	11	attr	_	_
9	gastrointestinal	gastrointestinal	JJ	_	11	attr	_	_
10	adverse	adverse	JJ	_	11	attr	_	_
11	experiences	experience	NNS	_	6	ppmod	_	_
12	in	in	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	patients	patient	NNS	_	6	ppmod	_	_
15	treated	treat	VBN	_	14	acl	_	_
16	with	with	IN	_	17	case	_	_
17	drug1	drug0	NN	_	15	ppmod	_	_
18	was	be	VBD	_	0	root	_	_
19	similar	similar	JJ	_	18	dep	_	_
20	to	to	TO	_	21	aux	_	_
21	that	that	DT	_	19	ppmod	_	_
22	in	in	IN	_	24	case	_	_
23	placebo-treated	placebo-treated	JJ	_	24	attr	_	_
24	patients	patient	NNS	_	21	ppmod	_	_
25	.	.	.	_	18	p	_	_

1	Similarly	similarly	RB	_	7	adv	_	_
2	,	,	,	_	7	p	_	_
3	of	of	IN	_	5	case	_	_
4	over	over	IN	_	5	case	_	_
5	1600	0	CD	_	6	num	_	_
6	patients	patient	NNS	_	7	dep	_	_
7	enrolled	enrol	VBN	_	0	root	_	_
8	in	in	IN	_	10	case	_	_
9	a	a	DT	_	10	det	_	_
10	study	study	NN	_	7	ppmod	_	_
11	comparing	compare	VBG	_	10	acl	_	_
12	once-monthly	once-monthly	JJ	_	26	attr	_	_
13	with	with	IN	_	16	case	_	_
14	daily	daily	JJ	_	16	attr	_	_
15	dosing	dosing	NN	_	16	com	_	_
16	regimens	regimen	NNS	_	12	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug1	drug0	NN	_	16	ppmod	_	_
19	,	,	,	_	18	p	_	_
20	14	0	CD	_	18	appo	_	_
21	%	%	NN	_	20	meta	_	_
22	of	of	IN	_	23	case	_	_
23	patients	patient	NNS	_	20	ppmod	_	_
24	used	use	VBN	_	26	attr	_	_
25	anti-peptic	anti-peptic	JJ	_	26	attr	_	_
26	agents	agent	NNS	_	11	obj	_	_
27	.	.	.	_	7	p	_	_

1	Among	among	IN	_	3	case	_	_
2	these	these	DT	_	3	det	_	_
3	patients	patient	NNS	_	22	ppmod	_	_
4	,	,	,	_	22	p	_	_
5	the	the	DT	_	6	det	_	_
6	incidence	incidence	NN	_	22	dep	_	_
7	of	of	IN	_	11	case	_	_
8	upper	upper	JJ	_	11	attr	_	_
9	gastrointestinal	gastrointestinal	JJ	_	11	attr	_	_
10	adverse	adverse	JJ	_	11	attr	_	_
11	experiences	experience	NNS	_	6	ppmod	_	_
12	in	in	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	patients	patient	NNS	_	6	ppmod	_	_
15	treated	treat	VBN	_	14	acl	_	_
16	with	with	IN	_	19	case	_	_
17	drug1	drug0	NN	_	19	attr	_	_
18	150	0	CD	_	19	num	_	_
19	mg	mg	NN	_	15	ppmod	_	_
20	once	once	RB	_	21	com	_	_
21	monthly	monthly	RB	_	19	adv	_	_
22	was	be	VBD	_	0	root	_	_
23	similar	similar	JJ	_	22	dep	_	_
24	to	to	TO	_	25	aux	_	_
25	that	that	DT	_	23	ppmod	_	_
26	in	in	IN	_	27	case	_	_
27	patients	patient	NNS	_	25	ppmod	_	_
28	treated	treat	VBN	_	27	acl	_	_
29	with	with	IN	_	32	case	_	_
30	drug2	drug0	NN	_	32	attr	_	_
31	2.5	0	CD	_	32	num	_	_
32	mg	mg	NN	_	28	ppmod	_	_
33	once	once	RB	_	34	com	_	_
34	daily	daily	RB	_	32	adv	_	_
35	.	.	.	_	22	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	/	/	:	_	1	p	_	_
3	drug2	drug0	NN	_	4	com	_	_
4	s	s	NN	_	1	appo	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	drug3	drug0	NN	_	4	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_

1	In	in	IN	_	8	case	_	_
2	the	the	DT	_	8	det	_	_
3	large	large	JJ	_	5	adv	_	_
4	,	,	,	_	5	p	_	_
5	placebo-controlled	placebo-controlled	JJ	_	8	attr	_	_
6	osteoporosis	osteoporosis	NN	_	8	com	_	_
7	Treatment	treatment	NN	_	8	com	_	_
8	Study	study	NN	_	14	ppmod	_	_
9	,	,	,	_	14	p	_	_
10	drug1	drug0	NN	_	14	dep	_	_
11	and	and	CC	_	10	cc	_	_
12	drug2	drug0	NN	_	10	conj	_	_
13	were	be	VBD	_	14	aux	_	_
14	taken	take	VBN	_	0	root	_	_
15	by	by	IN	_	16	case	_	_
16	62	0	CD	_	14	ppmod	_	_
17	%	%	NN	_	16	meta	_	_
18	of	of	IN	_	21	case	_	_
19	the	the	DT	_	21	det	_	_
20	2946	0	CD	_	21	num	_	_
21	patients	patient	NNS	_	16	ppmod	_	_
22	.	.	.	_	14	p	_	_

1	Among	among	IN	_	5	case	_	_
2	drug1	drug0	NN	_	5	attr	_	_
3	or	or	CC	_	2	cc	_	_
4	drug2	drug0	NN	_	2	conj	_	_
5	users	user	NNS	_	26	ppmod	_	_
6	,	,	,	_	26	p	_	_
7	the	the	DT	_	8	det	_	_
8	incidence	incidence	NN	_	26	dep	_	_
9	of	of	IN	_	13	case	_	_
10	upper	upper	JJ	_	13	attr	_	_
11	gastrointestinal	gastrointestinal	JJ	_	13	attr	_	_
12	adverse	adverse	JJ	_	13	attr	_	_
13	events	event	NNS	_	8	ppmod	_	_
14	in	in	IN	_	15	case	_	_
15	patients	patient	NNS	_	13	ppmod	_	_
16	treated	treat	VBN	_	15	acl	_	_
17	with	with	IN	_	20	case	_	_
18	drug3	drug0	NN	_	20	attr	_	_
19	2.5	0	CD	_	20	num	_	_
20	mg	mg	NN	_	16	ppmod	_	_
21	daily	daily	RB	_	20	adv	_	_
22	(	-lrb-	-LRB-	_	23	p	_	_
23	28.9	0	CD	_	20	num	_	_
24	%	%	NN	_	23	meta	_	_
25	)	-rrb-	-RRB-	_	23	p	_	_
26	was	be	VBD	_	0	root	_	_
27	similar	similar	JJ	_	26	dep	_	_
28	to	to	TO	_	29	aux	_	_
29	that	that	DT	_	27	ppmod	_	_
30	in	in	IN	_	32	case	_	_
31	placebo-treated	placebo-treated	JJ	_	32	attr	_	_
32	patients	patient	NNS	_	29	ppmod	_	_
33	(	-lrb-	-LRB-	_	34	p	_	_
34	30.7	0	CD	_	32	num	_	_
35	%	%	NN	_	34	meta	_	_
36	)	-rrb-	-RRB-	_	34	p	_	_
37	.	.	.	_	26	p	_	_

1	Similarly	similarly	RB	_	14	adv	_	_
2	,	,	,	_	14	p	_	_
3	in	in	IN	_	8	case	_	_
4	the	the	DT	_	8	det	_	_
5	1-year	0-year	JJ	_	8	attr	_	_
6	monthly	monthly	JJ	_	8	attr	_	_
7	comparison	comparison	NN	_	8	com	_	_
8	study	study	NN	_	14	ppmod	_	_
9	,	,	,	_	14	p	_	_
10	drug1	drug0	NN	_	14	dep	_	_
11	and	and	CC	_	10	cc	_	_
12	drug2	drug0	NN	_	10	conj	_	_
13	were	be	VBD	_	14	aux	_	_
14	taken	take	VBN	_	0	root	_	_
15	by	by	IN	_	16	case	_	_
16	39	0	CD	_	14	ppmod	_	_
17	%	%	NN	_	16	meta	_	_
18	of	of	IN	_	21	case	_	_
19	the	the	DT	_	21	det	_	_
20	1602	0	CD	_	21	num	_	_
21	patients	patient	NNS	_	16	ppmod	_	_
22	.	.	.	_	14	p	_	_

1	The	the	DT	_	2	det	_	_
2	incidence	incidence	NN	_	14	dep	_	_
3	of	of	IN	_	6	case	_	_
4	upper	upper	JJ	_	6	attr	_	_
5	gastrointestinal	gastrointestinal	JJ	_	6	attr	_	_
6	events	event	NNS	_	2	ppmod	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	6	ppmod	_	_
9	concomitantly	concomitantly	RB	_	10	adv	_	_
10	taking	take	VBG	_	8	acl	_	_
11	drug1	drug0	NN	_	10	obj	_	_
12	or	or	CC	_	11	cc	_	_
13	drug2	drug0	NN	_	11	conj	_	_
14	was	be	VBD	_	0	root	_	_
15	similar	similar	JJ	_	14	dep	_	_
16	in	in	IN	_	17	case	_	_
17	patients	patient	NNS	_	15	ppmod	_	_
18	taking	take	VBG	_	17	acl	_	_
19	drug3	drug0	NN	_	21	attr	_	_
20	2.5	0	CD	_	21	num	_	_
21	mg	mg	NN	_	18	obj	_	_
22	daily	daily	RB	_	21	adv	_	_
23	(	-lrb-	-LRB-	_	24	p	_	_
24	21.7	0	CD	_	21	num	_	_
25	%	%	NN	_	24	meta	_	_
26	)	-rrb-	-RRB-	_	24	p	_	_
27	and	and	CC	_	21	cc	_	_
28	150	0	CD	_	29	num	_	_
29	mg	mg	NN	_	21	conj	_	_
30	once	once	RB	_	29	adv	_	_
31	monthly	monthly	RB	_	29	adv	_	_
32	(	-lrb-	-LRB-	_	33	p	_	_
33	22.0	0	CD	_	29	num	_	_
34	%	%	NN	_	33	meta	_	_
35	)	-rrb-	-RRB-	_	33	p	_	_
36	.	.	.	_	14	p	_	_

1	However	however	RB	_	20	adv	_	_
2	,	,	,	_	20	p	_	_
3	since	since	IN	_	12	mark	_	_
4	drug1	drug0	NN	_	12	dep	_	_
5	,	,	,	_	4	p	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	,	,	,	_	6	p	_	_
8	and	and	CC	_	6	cc	_	_
9	drug3	drug0	NN	_	4	conj	_	_
10	are	be	VBP	_	12	aux	_	_
11	all	all	RB	_	12	adv	_	_
12	associated	associate	VBN	_	20	advcl	_	_
13	with	with	IN	_	15	case	_	_
14	gastrointestinal	gastrointestinal	JJ	_	15	attr	_	_
15	irritation	irritation	NN	_	12	ppmod	_	_
16	,	,	,	_	20	p	_	_
17	caution	caution	NN	_	20	dep	_	_
18	should	should	MD	_	20	modal	_	_
19	be	be	VB	_	20	aux	_	_
20	exercised	exercise	VBN	_	0	root	_	_
21	in	in	IN	_	24	case	_	_
22	the	the	DT	_	24	det	_	_
23	concomitant	concomitant	JJ	_	24	attr	_	_
24	use	use	NN	_	20	ppmod	_	_
25	of	of	IN	_	26	case	_	_
26	drug4	drug0	NN	_	24	ppmod	_	_
27	or	or	CC	_	26	cc	_	_
28	drug5	drug0	NN	_	26	conj	_	_
29	with	with	IN	_	30	case	_	_
30	drug6	drug0	NN	_	24	ppmod	_	_
31	.	.	.	_	20	p	_	_

1	Drug/Laboratory	drug/laboratory	NN	_	3	com	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	0	root	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	are	be	VBP	_	3	aux	_	_
3	known	know	VBN	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	interfere	interfere	VB	_	3	comp	_	_
6	with	with	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	use	use	NN	_	5	ppmod	_	_
9	of	of	IN	_	11	case	_	_
10	bone-imaging	bone-imaging	JJ	_	11	attr	_	_
11	agents	agent	NNS	_	8	ppmod	_	_
12	.	.	.	_	3	p	_	_

1	Specific	specific	JJ	_	2	attr	_	_
2	studies	study	NNS	_	8	dep	_	_
3	with	with	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	have	have	VBP	_	8	aux	_	_
6	not	not	RB	_	8	neg	_	_
7	been	be	VBN	_	8	aux	_	_
8	performed	performed	VBN	_	0	root	_	_
9	.	.	.	_	8	p	_	_

1	Monoamine	monoamine	NN	_	2	com	_	_
2	Oxidase	oxidase	NN	_	3	com	_	_
3	Inhibition	inhibition	NN	_	6	dep	_	_
4	:	:	:	_	3	p	_	_
5	drug1	drug0	NN	_	3	appo	_	_
6	is	be	VBZ	_	0	root	_	_
7	a	a	DT	_	11	det	_	_
8	reversible	reversible	JJ	_	10	adv	_	_
9	,	,	,	_	10	p	_	_
10	nonselective	nonselective	JJ	_	11	attr	_	_
11	inhibitor	inhibitor	NN	_	6	obj	_	_
12	of	of	IN	_	14	case	_	_
13	monoamine	monoamine	NN	_	14	com	_	_
14	oxidase	oxidase	NN	_	11	ppmod	_	_
15	.	.	.	_	6	p	_	_

1	Therefore	therefore	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	drug1	drug0	NN	_	4	dep	_	_
4	has	have	VBZ	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	potential	potential	NN	_	4	obj	_	_
7	for	for	IN	_	8	case	_	_
8	interaction	interaction	NN	_	6	ppmod	_	_
9	with	with	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug3	drug0	NN	_	10	conj	_	_
13	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Some	some	DT	_	4	det	_	_
4	individuals	individual	NNS	_	8	dep	_	_
5	receiving	receive	VBG	_	4	acl	_	_
6	drug2	drug0	NN	_	5	obj	_	_
7	may	may	MD	_	8	modal	_	_
8	experience	experience	VBP	_	1	acl	_	_
9	a	a	DT	_	11	det	_	_
10	reversible	reversible	JJ	_	11	attr	_	_
11	enhancement	enhancement	NN	_	8	obj	_	_
12	of	of	IN	_	15	case	_	_
13	the	the	DT	_	15	det	_	_
14	pressor	pressor	JJ	_	15	attr	_	_
15	response	response	NN	_	11	ppmod	_	_
16	to	to	TO	_	18	aux	_	_
17	indirect-acting	indirect-acting	JJ	_	18	attr	_	_
18	drug3	drug0	NN	_	15	ppmod	_	_
19	,	,	,	_	18	p	_	_
20	drug4	drug0	NN	_	18	conj	_	_
21	or	or	CC	_	20	cc	_	_
22	drug5	drug0	NN	_	18	conj	_	_
23	.	.	.	_	1	p	_	_

1	Commonly	commonly	RB	_	2	adv	_	_
2	used	use	VBN	_	3	attr	_	_
3	drugs	drug	NNS	_	12	dep	_	_
4	such	such	JJ	_	6	adv	_	_
5	as	as	IN	_	6	case	_	_
6	drug1	drug0	NN	_	3	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	have	have	VBP	_	12	aux	_	_
10	been	be	VBN	_	12	aux	_	_
11	specifically	specifically	RB	_	12	adv	_	_
12	studied	study	VBN	_	0	root	_	_
13	.	.	.	_	12	p	_	_

1	Initial	initial	JJ	_	2	attr	_	_
2	doses	dose	NNS	_	14	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	,	,	,	_	2	p	_	_
6	such	such	JJ	_	8	adv	_	_
7	as	as	IN	_	8	case	_	_
8	drug2	drug0	NN	_	2	ppmod	_	_
9	or	or	CC	_	8	cc	_	_
10	drug3	drug0	NN	_	8	conj	_	_
11	,	,	,	_	2	p	_	_
12	should	should	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	reduced	reduce	VBN	_	0	root	_	_
15	and	and	CC	_	14	cc	_	_
16	titrated	titrate	VBN	_	14	conj	_	_
17	to	to	TO	_	18	aux	_	_
18	achieve	achieve	VB	_	16	comp	_	_
19	the	the	DT	_	21	det	_	_
20	desired	desired	JJ	_	21	attr	_	_
21	response	response	NN	_	18	obj	_	_
22	.	.	.	_	14	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Co-administration	co-administration	NN	_	10	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug3	drug0	NN	_	5	conj	_	_
8	was	be	VBD	_	10	aux	_	_
9	not	not	RB	_	10	neg	_	_
10	associated	associate	VBN	_	1	acl	_	_
11	with	with	IN	_	13	case	_	_
12	serotonin	serotonin	NN	_	13	com	_	_
13	syndrome	syndrome	NN	_	10	ppmod	_	_
14	in	in	IN	_	15	case	_	_
15	Phase	phase	NN	_	13	ppmod	_	_
16	1	0	CD	_	15	num	_	_
17	,	,	,	_	13	p	_	_
18	2	0	CD	_	21	num	_	_
19	or	or	CC	_	18	cc	_	_
20	3	0	CD	_	18	conj	_	_
21	studies	study	NNS	_	13	appo	_	_
22	.	.	.	_	1	p	_	_

1	Spontaneous	spontaneous	JJ	_	2	attr	_	_
2	reports	report	NNS	_	25	dep	_	_
3	of	of	IN	_	5	case	_	_
4	serotonin	serotonin	NN	_	5	com	_	_
5	syndrome	syndrome	NN	_	2	ppmod	_	_
6	associated	associate	VBN	_	5	acl	_	_
7	with	with	IN	_	8	case	_	_
8	co-administration	co-administration	NN	_	6	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug2	drug0	NN	_	10	conj	_	_
13	,	,	,	_	2	p	_	_
14	including	include	VBG	_	15	adv	_	_
15	drug3	drug0	NN	_	2	ppmod	_	_
16	such	such	JJ	_	17	com	_	_
17	as	as	IN	_	15	cc	_	_
18	drug4	drug0	NN	_	15	conj	_	_
19	(	-lrb-	-LRB-	_	20	p	_	_
20	drug5	drug0	NN	_	18	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	,	,	,	_	2	p	_	_
23	have	have	VBP	_	25	aux	_	_
24	been	be	VBN	_	25	aux	_	_
25	reported	report	VBN	_	0	root	_	_
26	.	.	.	_	25	p	_	_

1	Patients	patient	NNS	_	13	dep	_	_
2	who	who	WP	_	4	dep	_	_
3	are	be	VBP	_	4	aux	_	_
4	treated	treat	VBN	_	1	relcl	_	_
5	with	with	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	concomitant	concomitant	JJ	_	9	attr	_	_
9	drug2	drug0	NN	_	6	conj	_	_
10	should	should	MD	_	13	modal	_	_
11	be	be	VB	_	13	aux	_	_
12	closely	closely	RB	_	13	adv	_	_
13	observed	observe	VBN	_	0	root	_	_
14	for	for	IN	_	15	case	_	_
15	signs	sign	NNS	_	13	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	symptoms	symptom	NNS	_	15	conj	_	_
18	of	of	IN	_	20	case	_	_
19	serotonin	serotonin	NN	_	20	com	_	_
20	syndrome	syndrome	NN	_	15	ppmod	_	_
21	(	-lrb-	-LRB-	_	27	p	_	_
22	e.g.	e.g.	FW	_	25	adv	_	_
23	,	,	,	_	25	p	_	_
24	cognitive	cognitive	JJ	_	25	attr	_	_
25	dysfunction	dysfunction	NN	_	27	ppmod	_	_
26	,	,	,	_	27	p	_	_
27	hyperpyrexia	hyperpyrexia	NN	_	20	prn	_	_
28	,	,	,	_	27	p	_	_
29	hyperreflexia	hyperreflexia	NN	_	27	appo	_	_
30	,	,	,	_	27	p	_	_
31	incoordination	incoordination	NN	_	27	appo	_	_
32	)	-rrb-	-RRB-	_	27	p	_	_
33	.	.	.	_	13	p	_	_

1	If	if	IN	_	6	mark	_	_
2	any	any	DT	_	3	det	_	_
3	signs	sign	NNS	_	6	dep	_	_
4	or	or	CC	_	3	cc	_	_
5	symptoms	symptom	NNS	_	3	conj	_	_
6	occur	occur	VBP	_	9	advcl	_	_
7	physicians	physician	NNS	_	9	dep	_	_
8	should	should	MD	_	9	modal	_	_
9	consider	consider	VB	_	0	root	_	_
10	discontinuation	discontinuation	NN	_	9	obj	_	_
11	of	of	IN	_	13	case	_	_
12	either	either	CC	_	13	cc	_	_
13	one	#crd#	CD	_	10	ppmod	_	_
14	or	or	CC	_	13	cc	_	_
15	both	both	DT	_	16	attr	_	_
16	agents	agent	NNS	_	13	conj	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	drug1	drug0	NN	_	16	prn	_	_
19	or	or	CC	_	18	cc	_	_
20	concomitant	concomitant	JJ	_	21	attr	_	_
21	drug2	drug0	NN	_	18	conj	_	_
22	)	-rrb-	-RRB-	_	18	p	_	_
23	.	.	.	_	9	p	_	_

1	Drug-Laboratory	drug-laboratory	JJ	_	3	attr	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	5	dep	_	_
4	There	there	RB	_	5	adv	_	_
5	are	be	VBP	_	0	root	_	_
6	no	no	DT	_	10	det	_	_
7	reported	report	VBN	_	10	attr	_	_
8	drug-laboratory	drug-laboratory	JJ	_	10	attr	_	_
9	test	test	NN	_	10	com	_	_
10	interactions	interaction	NNS	_	5	obj	_	_
11	.	.	.	_	5	p	_	_

1	Increases	increase	NNS	_	7	dep	_	_
2	in	in	IN	_	4	case	_	_
3	prothrombin	prothrombin	NN	_	4	com	_	_
4	time	time	NN	_	1	ppmod	_	_
5	have	have	VBP	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	noted	note	VBN	_	0	root	_	_
8	in	in	IN	_	9	case	_	_
9	patients	patient	NNS	_	7	ppmod	_	_
10	receiving	receive	VBG	_	9	acl	_	_
11	long-	long-	NN	_	14	com	_	_
12	term	term	NN	_	14	com	_	_
13	drug1	drug0	NN	_	14	com	_	_
14	therapy	therapy	NN	_	10	obj	_	_
15	after	after	IN	_	16	case	_	_
16	drug2	drug0	NN	_	10	ppmod	_	_
17	was	be	VBD	_	16	acl	_	_
18	initiated	initiate	VBN	_	17	dep	_	_
19	.	.	.	_	7	p	_	_

1	Therefore	therefore	RB	_	9	adv	_	_
2	,	,	,	_	9	p	_	_
3	close	close	JJ	_	4	attr	_	_
4	monitoring	monitoring	NN	_	9	dep	_	_
5	of	of	IN	_	7	case	_	_
6	prothrombin	prothrombin	NN	_	7	com	_	_
7	time	time	NN	_	4	ppmod	_	_
8	is	be	VBZ	_	9	aux	_	_
9	recommended	recommend	VBN	_	0	root	_	_
10	and	and	CC	_	9	cc	_	_
11	adjustment	adjustment	NN	_	17	dep	_	_
12	of	of	IN	_	15	case	_	_
13	the	the	DT	_	15	det	_	_
14	drug1	drug0	NN	_	15	com	_	_
15	dose	dose	NN	_	11	ppmod	_	_
16	may	may	MD	_	17	modal	_	_
17	be	be	VB	_	9	conj	_	_
18	necessary	necessary	JJ	_	17	dep	_	_
19	when	when	WRB	_	23	adv	_	_
20	drug2	drug0	NN	_	21	com	_	_
21	Capsules	capsule	NNS	_	23	dep	_	_
22	are	be	VBP	_	23	aux	_	_
23	administered	administer	VBN	_	18	comp	_	_
24	concomitantly	concomitantly	RB	_	23	adv	_	_
25	with	with	IN	_	26	case	_	_
26	drug3	drug0	NN	_	23	ppmod	_	_
27	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	may	may	MD	_	5	modal	_	_
5	decrease	decrease	VB	_	0	root	_	_
6	the	the	DT	_	7	det	_	_
7	effects	effect	NNS	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	9	p	_	_
11	drug4	drug0	NN	_	9	conj	_	_
12	,	,	,	_	11	p	_	_
13	and	and	CC	_	11	cc	_	_
14	drug5	drug0	NN	_	9	conj	_	_
15	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	:	:	:	_	1	p	_	_
3	Has	have	VBZ	_	0	root	_	_
4	a	a	DT	_	6	det	_	_
5	synergistic	synergistic	JJ	_	6	attr	_	_
6	effect	effect	NN	_	3	obj	_	_
7	with	with	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	in	in	IN	_	10	case	_	_
10	causing	cause	VBG	_	3	ppmod	_	_
11	gastrointestinal	gastrointestinal	JJ	_	12	attr	_	_
12	bleeding	bleeding	JJ	_	10	obj	_	_
13	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Concomitant	concomitant	JJ	_	4	attr	_	_
4	administration	administration	NN	_	8	dep	_	_
5	with	with	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	may	may	MD	_	8	modal	_	_
8	increase	increase	VB	_	1	acl	_	_
9	the	the	DT	_	10	det	_	_
10	risk	risk	NN	_	8	obj	_	_
11	of	of	IN	_	13	case	_	_
12	gastrointestinal	gastrointestinal	JJ	_	13	attr	_	_
13	ulceration	ulceration	NN	_	10	ppmod	_	_
14	and	and	CC	_	8	cc	_	_
15	may	may	MD	_	16	modal	_	_
16	reduce	reduce	VB	_	8	conj	_	_
17	serum	serum	NN	_	19	com	_	_
18	salicylate	salicylate	NN	_	19	com	_	_
19	levels	level	NNS	_	16	obj	_	_
20	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	drug2	drug0	NN	_	1	prn	_	_
4	,	,	,	_	3	p	_	_
5	drug3	drug0	NN	_	3	conj	_	_
6	,	,	,	_	5	p	_	_
7	and	and	CC	_	5	cc	_	_
8	possibly	possibly	RB	_	9	adv	_	_
9	drug4	drug0	NN	_	3	conj	_	_
10	)	-rrb-	-RRB-	_	3	p	_	_
11	:	:	:	_	1	p	_	_
12	Concomitant	concomitant	JJ	_	13	attr	_	_
13	administration	administration	NN	_	17	dep	_	_
14	with	with	IN	_	15	case	_	_
15	drug5	drug0	NN	_	13	ppmod	_	_
16	may	may	MD	_	17	modal	_	_
17	increase	increase	VB	_	1	acl	_	_
18	the	the	DT	_	19	det	_	_
19	risk	risk	NN	_	17	obj	_	_
20	of	of	IN	_	22	case	_	_
21	gastrointestinal	gastrointestinal	JJ	_	22	attr	_	_
22	ulceration	ulceration	NN	_	19	ppmod	_	_
23	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	Agents	agent	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	drug2	drug0	NN	_	6	dep	_	_
5	is	be	VBZ	_	6	aux	_	_
6	contraindicated	contraindicate	VBN	_	2	acl	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	6	ppmod	_	_
9	who	who	WP	_	10	dep	_	_
10	are	be	VBP	_	8	relcl	_	_
11	hypersensitive	hypersensitive	JJ	_	10	dep	_	_
12	to	to	TO	_	14	aux	_	_
13	drug3	drug0	JJ	_	14	attr	_	_
14	agents	agent	NNS	_	11	ppmod	_	_
15	.	.	.	_	2	p	_	_

1	Urinary	urinary	JJ	_	2	attr	_	_
2	Alkalinizers	alkalinizers	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	Decrease	decrease	VB	_	2	acl	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	effectiveness	effectiveness	NN	_	4	obj	_	_
7	by	by	IN	_	8	case	_	_
8	increasing	increase	VBG	_	4	ppmod	_	_
9	the	the	DT	_	10	det	_	_
10	rate	rate	NN	_	8	obj	_	_
11	of	of	IN	_	14	case	_	_
12	drug2	drug0	JJ	_	14	attr	_	_
13	renal	renal	JJ	_	14	attr	_	_
14	excretion	excretion	NN	_	10	ppmod	_	_
15	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	:	:	:	_	1	p	_	_
3	Decreases	decrease	VBZ	_	0	root	_	_
4	drug2	drug0	NN	_	5	com	_	_
5	effectiveness	effectiveness	NN	_	3	obj	_	_
6	by	by	IN	_	8	case	_	_
7	enzyme	enzyme	NN	_	8	com	_	_
8	induction	induction	NN	_	3	ppmod	_	_
9	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	5	attr	_	_
2	:	:	:	_	5	p	_	_
3	Serum	serum	NN	_	5	com	_	_
4	drug2	drug0	NN	_	5	com	_	_
5	levels	level	NNS	_	8	dep	_	_
6	may	may	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	increased	increase	VBN	_	0	root	_	_
9	by	by	IN	_	10	case	_	_
10	drug3	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	:	:	:	_	1	p	_	_
3	May	may	MD	_	4	modal	_	_
4	decrease	decrease	VB	_	0	root	_	_
5	drug2	drug0	NN	_	7	attr	_	_
6	anti-inflammatory	anti-inflammatory	JJ	_	7	attr	_	_
7	action	action	NN	_	4	obj	_	_
8	by	by	IN	_	9	case	_	_
9	competing	compete	VBG	_	4	ppmod	_	_
10	for	for	IN	_	13	case	_	_
11	the	the	DT	_	13	det	_	_
12	same	same	JJ	_	13	attr	_	_
13	receptors	receptor	NNS	_	9	ppmod	_	_
14	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Enteric	enteric	JJ	_	5	attr	_	_
4	Coated	coated	JJ	_	5	attr	_	_
5	drug2	drug0	NNS	_	9	dep	_	_
6	should	should	MD	_	9	modal	_	_
7	not	not	RB	_	9	neg	_	_
8	be	be	VB	_	9	aux	_	_
9	given	give	VBN	_	1	acl	_	_
10	concurrently	concurrently	RB	_	9	adv	_	_
11	with	with	IN	_	12	case	_	_
12	drug3	drug0	NN	_	9	ppmod	_	_
13	,	,	,	_	9	p	_	_
14	since	since	IN	_	24	mark	_	_
15	an	an	DT	_	16	det	_	_
16	increase	increase	NN	_	24	dep	_	_
17	in	in	IN	_	19	case	_	_
18	the	the	DT	_	19	det	_	_
19	pH	ph	NN	_	16	ppmod	_	_
20	of	of	IN	_	22	case	_	_
21	the	the	DT	_	22	det	_	_
22	stomach	stomach	NN	_	19	ppmod	_	_
23	may	may	MD	_	24	modal	_	_
24	effect	effect	VB	_	9	comp	_	_
25	the	the	DT	_	27	det	_	_
26	enteric	enteric	JJ	_	27	attr	_	_
27	coating	coating	NN	_	24	obj	_	_
28	of	of	IN	_	30	case	_	_
29	the	the	DT	_	30	det	_	_
30	tablets	tablet	NNS	_	27	ppmod	_	_
31	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	use	use	NN	_	13	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	FOR	for	IN	_	6	case	_	_
6	INJECTION	injection	NN	_	2	ppmod	_	_
7	in	in	IN	_	8	case	_	_
8	combination	combination	NN	_	2	ppmod	_	_
9	with	with	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	is	be	VBZ	_	13	aux	_	_
12	not	not	RB	_	13	neg	_	_
13	recommended	recommend	VBN	_	0	root	_	_
14	due	due	JJ	_	17	adv	_	_
15	to	to	TO	_	17	aux	_	_
16	the	the	DT	_	17	det	_	_
17	risk	risk	NN	_	13	ppmod	_	_
18	of	of	IN	_	21	case	_	_
19	severe	severe	JJ	_	21	attr	_	_
20	pulmonary	pulmonary	JJ	_	21	attr	_	_
21	toxicity	toxicity	NN	_	17	ppmod	_	_
22	.	.	.	_	13	p	_	_

1	No	no	DT	_	5	det	_	_
2	clinically	clinically	RB	_	3	adv	_	_
3	relevant	relevant	JJ	_	5	attr	_	_
4	drug-drug	drug-drug	JJ	_	5	attr	_	_
5	interactions	interaction	NNS	_	8	dep	_	_
6	have	have	VBP	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	observed	observe	VBN	_	0	root	_	_
9	with	with	IN	_	14	mark	_	_
10	drugs	drug	NNS	_	14	dep	_	_
11	likely	likely	RB	_	14	adv	_	_
12	to	to	TO	_	14	aux	_	_
13	be	be	VB	_	14	aux	_	_
14	co-administered	co-administered	VBN	_	8	comp	_	_
15	with	with	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	interact	interact	VB	_	0	root	_	_
4	with	with	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	,	,	,	_	5	p	_	_
7	drug3	drug0	NN	_	5	conj	_	_
8	,	,	,	_	7	p	_	_
9	drug4	drug0	NN	_	5	conj	_	_
10	,	,	,	_	9	p	_	_
11	drug5	drug0	NN	_	5	conj	_	_
12	,	,	,	_	11	p	_	_
13	drug6	drug0	NN	_	14	com	_	_
14	supplements	supplement	NNS	_	5	conj	_	_
15	,	,	,	_	14	p	_	_
16	drug7	drug0	NN	_	5	conj	_	_
17	,	,	,	_	16	p	_	_
18	drug8	drug0	NN	_	5	conj	_	_
19	,	,	,	_	18	p	_	_
20	drug9	drug0	NN	_	5	conj	_	_
21	,	,	,	_	20	p	_	_
22	drug10	drug0	NN	_	5	conj	_	_
23	,	,	,	_	22	p	_	_
24	drug11	drug0	NN	_	5	conj	_	_
25	,	,	,	_	24	p	_	_
26	drug12	drug0	NN	_	5	conj	_	_
27	,	,	,	_	26	p	_	_
28	drug13	drug0	NN	_	5	conj	_	_
29	,	,	,	_	28	p	_	_
30	and	and	CC	_	28	cc	_	_
31	drug14	drug0	NN	_	5	conj	_	_
32	.	.	.	_	3	p	_	_

1	Drug/Laboratory	drug/laboratory	NN	_	3	com	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	0	root	_	_
4	:	:	:	_	3	p	_	_
5	A	a	DT	_	7	det	_	_
6	false-positive	false-positive	JJ	_	7	attr	_	_
7	reaction	reaction	NN	_	14	dep	_	_
8	for	for	IN	_	9	case	_	_
9	glucose	glucose	NN	_	7	ppmod	_	_
10	in	in	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	urine	urine	NN	_	7	ppmod	_	_
13	may	may	MD	_	14	modal	_	_
14	occur	occur	VB	_	3	acl	_	_
15	with	with	IN	_	18	case	_	_
16	copper	copper	NN	_	18	com	_	_
17	reduction	reduction	NN	_	18	com	_	_
18	tests	test	NNS	_	14	ppmod	_	_
19	(	-lrb-	-LRB-	_	21	p	_	_
20	Benedict	benedict	NN	_	21	com	_	_
21	s	s	NN	_	18	prn	_	_
22	or	or	CC	_	21	cc	_	_
23	Fehling	fehling	JJ	_	25	attr	_	_
24	s	s	NN	_	25	com	_	_
25	solution	solution	NN	_	21	conj	_	_
26	or	or	CC	_	21	cc	_	_
27	with	with	IN	_	29	case	_	_
28	Clinitest	clinitest	JJ	_	29	attr	_	_
29	tablets	tablet	NNS	_	21	conj	_	_
30	)	-rrb-	-RRB-	_	29	p	_	_
31	but	but	CC	_	18	cc	_	_
32	not	not	RB	_	35	neg	_	_
33	with	with	IN	_	35	case	_	_
34	enzyme-based	enzyme-based	JJ	_	35	attr	_	_
35	tests	test	NNS	_	18	conj	_	_
36	for	for	IN	_	37	case	_	_
37	glycosuria	glycosuria	NN	_	35	ppmod	_	_
38	.	.	.	_	3	p	_	_

1	As	as	IN	_	6	mark	_	_
2	a	a	DT	_	4	det	_	_
3	false-negative	false-negative	JJ	_	4	attr	_	_
4	result	result	NN	_	6	dep	_	_
5	may	may	MD	_	6	modal	_	_
6	occur	occur	VB	_	14	advcl	_	_
7	in	in	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	ferricyanide	ferricyanide	NN	_	10	com	_	_
10	test	test	NN	_	6	ppmod	_	_
11	,	,	,	_	14	p	_	_
12	it	it	PRP	_	14	dep	_	_
13	is	be	VBZ	_	14	aux	_	_
14	recommended	recommend	VBN	_	0	root	_	_
15	that	that	IN	_	24	mark	_	_
16	either	either	CC	_	19	cc	_	_
17	the	the	DT	_	19	det	_	_
18	glucose	glucose	NN	_	19	com	_	_
19	oxidase	oxidase	NN	_	24	dep	_	_
20	or	or	CC	_	19	cc	_	_
21	hexokinase	hexokinase	NN	_	22	com	_	_
22	method	method	NN	_	19	conj	_	_
23	be	be	VB	_	24	aux	_	_
24	used	use	VBN	_	14	comp	_	_
25	to	to	TO	_	26	aux	_	_
26	determine	determine	VB	_	24	comp	_	_
27	blood	blood	NN	_	30	com	_	_
28	plasma	plasma	NN	_	30	com	_	_
29	glucose	glucose	NN	_	30	com	_	_
30	levels	level	NNS	_	26	obj	_	_
31	in	in	IN	_	32	case	_	_
32	patients	patient	NNS	_	30	ppmod	_	_
33	receiving	receive	VBG	_	32	acl	_	_
34	drug1	drug0	NN	_	33	obj	_	_
35	.	.	.	_	14	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	does	do	VBZ	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	interfere	interfere	VB	_	0	root	_	_
5	with	with	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	assay	assay	NN	_	4	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	serum	serum	NN	_	7	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	urine	urine	NN	_	12	com	_	_
12	creatinine	creatinine	NN	_	9	conj	_	_
13	by	by	IN	_	17	case	_	_
14	the	the	DT	_	17	det	_	_
15	alkaline	alkaline	NN	_	17	com	_	_
16	picrate	picrate	NN	_	17	com	_	_
17	method	method	NN	_	4	ppmod	_	_
18	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	prolong	prolong	VBP	_	0	root	_	_
3	and	and	CC	_	2	cc	_	_
4	intensify	intensify	VBP	_	2	conj	_	_
5	the	the	DT	_	6	det	_	_
6	effects	effect	NNS	_	4	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	.	.	.	_	2	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	use	use	NN	_	16	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	with	with	IN	_	6	case	_	_
6	drug2	drug0	NN	_	2	ppmod	_	_
7	,	,	,	_	6	p	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	,	,	,	_	8	p	_	_
10	drug4	drug0	NN	_	6	conj	_	_
11	,	,	,	_	10	p	_	_
12	or	or	CC	_	10	cc	_	_
13	other	other	JJ	_	14	attr	_	_
14	drug5	drug0	NN	_	6	conj	_	_
15	may	may	MD	_	16	modal	_	_
16	have	have	VB	_	0	root	_	_
17	an	an	DT	_	19	det	_	_
18	additive	additive	JJ	_	19	attr	_	_
19	effect	effect	NN	_	16	obj	_	_
20	.	.	.	_	16	p	_	_

1	When	when	WRB	_	4	adv	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	are	be	VBP	_	4	aux	_	_
4	given	give	VBN	_	18	advcl	_	_
5	to	to	TO	_	6	aux	_	_
6	patients	patient	NNS	_	4	ppmod	_	_
7	receiving	receive	VBG	_	6	acl	_	_
8	drug2	drug0	NN	_	7	obj	_	_
9	,	,	,	_	18	p	_	_
10	hypertensive	hypertensive	JJ	_	11	attr	_	_
11	reactions	reaction	NNS	_	18	dep	_	_
12	,	,	,	_	11	p	_	_
13	including	include	VBG	_	15	adv	_	_
14	hypertensive	hypertensive	JJ	_	15	attr	_	_
15	crises	crisis	NNS	_	11	ppmod	_	_
16	,	,	,	_	11	p	_	_
17	may	may	MD	_	18	modal	_	_
18	occur	occur	VB	_	0	root	_	_
19	.	.	.	_	18	p	_	_

1	The	the	DT	_	3	det	_	_
2	antihypertensive	antihypertensive	JJ	_	3	attr	_	_
3	effects	effect	NNS	_	15	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	,	,	,	_	5	p	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	,	,	,	_	7	p	_	_
9	drug3	drug0	NN	_	5	conj	_	_
10	,	,	,	_	9	p	_	_
11	and	and	CC	_	9	cc	_	_
12	drug4	drug0	NN	_	5	conj	_	_
13	may	may	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	reduced	reduce	VBN	_	0	root	_	_
16	by	by	IN	_	17	case	_	_
17	drug5	drug0	NN	_	15	ppmod	_	_
18	.	.	.	_	15	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	may	may	MD	_	4	modal	_	_
3	also	also	RB	_	4	adv	_	_
4	interact	interact	VB	_	0	root	_	_
5	with	with	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	.	.	.	_	4	p	_	_

1	Increased	increase	VBN	_	4	attr	_	_
2	ectopic	ectopic	JJ	_	4	attr	_	_
3	pacemaker	pacemaker	NN	_	4	com	_	_
4	activity	activity	NN	_	6	dep	_	_
5	can	can	MD	_	6	modal	_	_
6	occur	occur	VB	_	0	root	_	_
7	when	when	WRB	_	10	adv	_	_
8	drug1	drug0	NN	_	10	dep	_	_
9	is	be	VBZ	_	10	aux	_	_
10	used	use	VBN	_	6	comp	_	_
11	concomitantly	concomitantly	RB	_	10	adv	_	_
12	with	with	IN	_	13	case	_	_
13	drug2	drug0	NN	_	10	ppmod	_	_
14	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	increase	increase	VBP	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	rate	rate	NN	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	absorption	absorption	NN	_	4	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	,	,	,	_	2	p	_	_
10	while	while	IN	_	12	mark	_	_
11	drug3	drug0	NN	_	12	dep	_	_
12	decreases	decrease	VBZ	_	2	comp	_	_
13	it	it	PRP	_	12	obj	_	_
14	.	.	.	_	2	p	_	_

1	Co-administration	co-administration	NN	_	11	dep	_	_
2	with	with	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	such	such	JJ	_	6	adv	_	_
5	as	as	IN	_	6	case	_	_
6	drug2	drug0	NN	_	1	ppmod	_	_
7	or	or	CC	_	6	cc	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	is	be	VBZ	_	11	aux	_	_
10	not	not	RB	_	11	neg	_	_
11	recommended	recommend	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	,	,	,	_	1	p	_	_
5	drug3	drug0	NN	_	1	appo	_	_
6	(	-lrb-	-LRB-	_	10	p	_	_
7	consider	consider	VB	_	10	attr	_	_
8	drug4	drug0	NN	_	10	com	_	_
9	dose	dose	NN	_	10	com	_	_
10	reduction	reduction	NN	_	5	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	,	,	,	_	1	p	_	_
5	drug3	drug0	NN	_	1	appo	_	_
6	,	,	,	_	1	p	_	_
7	drug4	drug0	NN	_	1	appo	_	_
8	,	,	,	_	1	p	_	_
9	drug5	drug0	NN	_	1	appo	_	_
10	(	-lrb-	-LRB-	_	12	p	_	_
11	exercise	exercise	NN	_	12	com	_	_
12	caution	caution	NN	_	9	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	are	be	VBP	_	0	root	_	_
3	a	a	DT	_	6	det	_	_
4	major	major	JJ	_	6	attr	_	_
5	contributing	contribute	VBG	_	6	attr	_	_
6	factor	factor	NN	_	2	obj	_	_
7	to	to	TO	_	9	aux	_	_
8	drug2	drug0	NN	_	9	com	_	_
9	toxicity	toxicity	NN	_	6	ppmod	_	_
10	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	13	dep	_	_
2	,	,	,	_	13	p	_	_
3	particularly	particularly	RB	_	5	adv	_	_
4	if	if	IN	_	5	mark	_	_
5	administered	administer	VBN	_	13	advcl	_	_
6	rapidly	rapidly	RB	_	5	adv	_	_
7	by	by	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	intravenous	intravenous	JJ	_	10	attr	_	_
10	route	route	NN	_	5	ppmod	_	_
11	,	,	,	_	13	p	_	_
12	may	may	MD	_	13	modal	_	_
13	produce	produce	VB	_	0	root	_	_
14	serious	serious	JJ	_	15	attr	_	_
15	arrhythmias	arrhythmia	NNS	_	13	obj	_	_
16	in	in	IN	_	18	case	_	_
17	digitalized	digitalized	JJ	_	18	attr	_	_
18	patients	patient	NNS	_	15	ppmod	_	_
19	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	17	dep	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	,	,	,	_	3	p	_	_
5	drug3	drug0	NN	_	1	conj	_	_
6	,	,	,	_	5	p	_	_
7	drug4	drug0	NN	_	1	conj	_	_
8	,	,	,	_	7	p	_	_
9	drug5	drug0	NN	_	1	conj	_	_
10	,	,	,	_	9	p	_	_
11	drug6	drug0	NN	_	1	conj	_	_
12	,	,	,	_	11	p	_	_
13	drug7	drug0	NN	_	1	conj	_	_
14	,	,	,	_	13	p	_	_
15	and	and	CC	_	13	cc	_	_
16	drug8	drug0	NN	_	1	conj	_	_
17	raise	raise	VBP	_	0	root	_	_
18	the	the	DT	_	21	det	_	_
19	serum	serum	NN	_	21	com	_	_
20	drug9	drug0	NN	_	21	com	_	_
21	concentration	concentration	NN	_	17	obj	_	_
22	due	due	JJ	_	21	attr	_	_
23	to	to	TO	_	25	aux	_	_
24	a	a	DT	_	25	det	_	_
25	reduction	reduction	NN	_	22	ppmod	_	_
26	in	in	IN	_	27	case	_	_
27	clearance	clearance	NN	_	25	ppmod	_	_
28	and/or	and/or	CC	_	27	cc	_	_
29	in	in	IN	_	30	case	_	_
30	volume	volume	NN	_	27	conj	_	_
31	of	of	IN	_	32	case	_	_
32	distribution	distribution	NN	_	30	ppmod	_	_
33	of	of	IN	_	35	case	_	_
34	the	the	DT	_	35	det	_	_
35	drug	drug	NN	_	32	ppmod	_	_
36	,	,	,	_	32	p	_	_
37	with	with	IN	_	44	mark	_	_
38	the	the	DT	_	39	det	_	_
39	implication	implication	NN	_	44	dep	_	_
40	that	that	IN	_	42	case	_	_
41	drug10	drug0	NN	_	42	com	_	_
42	intoxication	intoxication	NN	_	39	ppmod	_	_
43	may	may	MD	_	44	modal	_	_
44	result	result	VB	_	32	acl	_	_
45	.	.	.	_	17	p	_	_

1	drug1	drug0	NN	_	13	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	(	-lrb-	-LRB-	_	8	p	_	_
5	and	and	CC	_	8	cc	_	_
6	possibly	possibly	RB	_	8	adv	_	_
7	other	other	JJ	_	8	attr	_	_
8	drug3	drug0	NN	_	1	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	and	and	CC	_	1	cc	_	_
11	drug4	drug0	NN	_	1	conj	_	_
12	may	may	MD	_	13	modal	_	_
13	increase	increase	VB	_	0	root	_	_
14	drug5	drug0	NN	_	15	com	_	_
15	absorption	absorption	NN	_	13	obj	_	_
16	in	in	IN	_	17	case	_	_
17	patients	patient	NNS	_	13	ppmod	_	_
18	who	who	WP	_	19	dep	_	_
19	inactivate	inactivate	VBP	_	17	relcl	_	_
20	drug6	drug0	NN	_	19	obj	_	_
21	by	by	IN	_	23	case	_	_
22	bacterial	bacterial	JJ	_	23	attr	_	_
23	metabolism	metabolism	NN	_	19	ppmod	_	_
24	in	in	IN	_	27	case	_	_
25	the	the	DT	_	27	det	_	_
26	lower	low	JJR	_	27	attr	_	_
27	intestine	intestine	NN	_	19	ppmod	_	_
28	,	,	,	_	19	p	_	_
29	so	so	IN	_	34	mark	_	_
30	that	that	IN	_	34	mark	_	_
31	drug7	drug0	NN	_	32	com	_	_
32	intoxication	intoxication	NN	_	34	dep	_	_
33	may	may	MD	_	34	modal	_	_
34	result	result	VB	_	19	comp	_	_
35	.	.	.	_	13	p	_	_

1	The	the	DT	_	2	det	_	_
2	risk	risk	NN	_	8	dep	_	_
3	of	of	IN	_	5	case	_	_
4	this	this	DT	_	5	det	_	_
5	interaction	interaction	NN	_	2	ppmod	_	_
6	may	may	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	reduced	reduce	VBN	_	0	root	_	_
9	if	if	IN	_	12	mark	_	_
10	drug1	drug0	NN	_	12	dep	_	_
11	is	be	VBZ	_	12	aux	_	_
12	given	give	VBN	_	8	comp	_	_
13	as	as	IN	_	14	case	_	_
14	capsules	capsule	NNS	_	12	ppmod	_	_
15	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	11	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	,	,	,	_	11	p	_	_
5	by	by	IN	_	6	case	_	_
6	decreasing	decrease	VBG	_	11	ppmod	_	_
7	gut	gut	NN	_	8	com	_	_
8	motility	motility	NN	_	6	obj	_	_
9	,	,	,	_	11	p	_	_
10	may	may	MD	_	11	modal	_	_
11	increase	increase	VB	_	0	root	_	_
12	drug3	drug0	NN	_	13	com	_	_
13	absorption	absorption	NN	_	11	obj	_	_
14	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	19	dep	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	4	com	_	_
4	-pectin	-pectin	NN	_	1	conj	_	_
5	,	,	,	_	4	p	_	_
6	drug3	drug0	NN	_	1	conj	_	_
7	,	,	,	_	6	p	_	_
8	drug4	drug0	NN	_	1	conj	_	_
9	,	,	,	_	8	p	_	_
10	drug5	drug0	NN	_	1	conj	_	_
11	,	,	,	_	10	p	_	_
12	certain	certain	JJ	_	14	attr	_	_
13	anticancer	anticancer	JJ	_	14	attr	_	_
14	drugs	drug	NNS	_	1	conj	_	_
15	,	,	,	_	14	p	_	_
16	and	and	CC	_	14	cc	_	_
17	drug6	drug0	NN	_	1	conj	_	_
18	may	may	MD	_	19	modal	_	_
19	interfere	interfere	VB	_	0	root	_	_
20	with	with	IN	_	23	case	_	_
21	intestinal	intestinal	JJ	_	23	attr	_	_
22	drug7	drug0	NN	_	23	com	_	_
23	absorption	absorption	NN	_	19	ppmod	_	_
24	,	,	,	_	19	p	_	_
25	resulting	result	VBG	_	19	comp	_	_
26	in	in	IN	_	30	case	_	_
27	unexpectedly	unexpectedly	RB	_	28	adv	_	_
28	low	low	JJ	_	30	attr	_	_
29	serum	serum	NN	_	30	com	_	_
30	concentrations	concentration	NNS	_	25	ppmod	_	_
31	.	.	.	_	19	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	decrease	decrease	VB	_	0	root	_	_
4	serum	serum	NN	_	6	com	_	_
5	drug2	drug0	NN	_	6	com	_	_
6	concentration	concentration	NN	_	3	obj	_	_
7	,	,	,	_	3	p	_	_
8	especially	especially	RB	_	10	adv	_	_
9	in	in	IN	_	10	case	_	_
10	patients	patient	NNS	_	3	ppmod	_	_
11	with	with	IN	_	13	case	_	_
12	renal	renal	JJ	_	13	attr	_	_
13	dysfunction	dysfunction	NN	_	10	ppmod	_	_
14	,	,	,	_	3	p	_	_
15	by	by	IN	_	16	case	_	_
16	increasing	increase	VBG	_	3	ppmod	_	_
17	the	the	DT	_	19	det	_	_
18	non-renal	non-renal	JJ	_	19	attr	_	_
19	clearance	clearance	NN	_	16	obj	_	_
20	of	of	IN	_	21	case	_	_
21	drug3	drug0	NN	_	19	ppmod	_	_
22	.	.	.	_	3	p	_	_

1	There	there	EX	_	3	dep	_	_
2	have	have	VBP	_	3	aux	_	_
3	been	be	VBN	_	0	root	_	_
4	inconsistent	inconsistent	JJ	_	5	attr	_	_
5	reports	report	NNS	_	3	obj	_	_
6	regarding	regard	VBG	_	5	acl	_	_
7	the	the	DT	_	8	det	_	_
8	effects	effect	NNS	_	6	obj	_	_
9	of	of	IN	_	11	case	_	_
10	other	other	JJ	_	11	attr	_	_
11	drugs	drug	NNS	_	8	ppmod	_	_
12	(	-lrb-	-LRB-	_	17	p	_	_
13	e.g.	e.g.	FW	_	15	adv	_	_
14	,	,	,	_	15	p	_	_
15	drug1	drug0	NN	_	17	ppmod	_	_
16	,	,	,	_	17	p	_	_
17	drug2	drug0	NNS	_	11	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	on	on	IN	_	22	case	_	_
20	serum	serum	NN	_	22	com	_	_
21	drug3	drug0	NN	_	22	com	_	_
22	concentration	concentration	NN	_	8	ppmod	_	_
23	.	.	.	_	3	p	_	_

1	drug1	drug0	JJ	_	2	attr	_	_
2	administration	administration	NN	_	10	dep	_	_
3	to	to	TO	_	8	aux	_	_
4	a	a	DT	_	8	det	_	_
5	digitalized	digitalized	JJ	_	7	adv	_	_
6	,	,	,	_	7	p	_	_
7	hypothyroid	hypothyroid	JJ	_	8	attr	_	_
8	patient	patient	NN	_	2	ppmod	_	_
9	may	may	MD	_	10	modal	_	_
10	increase	increase	VB	_	0	root	_	_
11	the	the	DT	_	13	det	_	_
12	dose	dose	NN	_	13	com	_	_
13	requirement	requirement	NN	_	10	obj	_	_
14	of	of	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	10	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	use	use	NN	_	7	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	increases	increase	VBZ	_	0	root	_	_
8	the	the	DT	_	9	det	_	_
9	risk	risk	NN	_	7	obj	_	_
10	of	of	IN	_	12	case	_	_
11	cardiac	cardiac	JJ	_	12	attr	_	_
12	arrhythmias	arrhythmia	NNS	_	9	ppmod	_	_
13	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	cause	cause	VB	_	0	root	_	_
4	a	a	DT	_	6	det	_	_
5	sudden	sudden	JJ	_	6	attr	_	_
6	extrusion	extrusion	NN	_	3	obj	_	_
7	of	of	IN	_	8	case	_	_
8	potassium	potassium	NN	_	6	ppmod	_	_
9	from	from	IN	_	11	case	_	_
10	muscle	muscle	NN	_	11	com	_	_
11	cells	cell	NNS	_	6	ppmod	_	_
12	,	,	,	_	3	p	_	_
13	and	and	CC	_	3	cc	_	_
14	may	may	MD	_	16	modal	_	_
15	thereby	thereby	RB	_	16	adv	_	_
16	cause	cause	VB	_	3	conj	_	_
17	arrhythmias	arrhythmia	NNS	_	16	obj	_	_
18	in	in	IN	_	20	case	_	_
19	digitalized	digitalized	JJ	_	20	attr	_	_
20	patients	patient	NNS	_	17	ppmod	_	_
21	.	.	.	_	3	p	_	_

1	Although	although	IN	_	8	mark	_	_
2	drug1	drug0	NN	_	8	dep	_	_
3	or	or	CC	_	2	cc	_	_
4	drug2	drug0	NN	_	2	conj	_	_
5	and	and	CC	_	4	cc	_	_
6	drug3	drug0	NN	_	4	conj	_	_
7	may	may	MD	_	8	modal	_	_
8	be	be	VB	_	25	advcl	_	_
9	useful	useful	JJ	_	8	dep	_	_
10	in	in	IN	_	11	case	_	_
11	combination	combination	NN	_	9	ppmod	_	_
12	to	to	TO	_	13	aux	_	_
13	control	control	VB	_	8	comp	_	_
14	atrial	atrial	NN	_	15	com	_	_
15	fibrillation	fibrillation	NN	_	13	obj	_	_
16	,	,	,	_	25	p	_	_
17	their	their	PRP$	_	19	poss	_	_
18	additive	additive	JJ	_	19	attr	_	_
19	effects	effect	NNS	_	25	dep	_	_
20	on	on	IN	_	23	case	_	_
21	AV	av	NN	_	23	com	_	_
22	node	node	NN	_	23	com	_	_
23	conduction	conduction	NN	_	19	ppmod	_	_
24	can	can	MD	_	25	modal	_	_
25	result	result	VB	_	0	root	_	_
26	in	in	IN	_	31	case	_	_
27	advanced	advanced	JJ	_	31	attr	_	_
28	or	or	CC	_	27	cc	_	_
29	complete	complete	JJ	_	27	conj	_	_
30	heart	heart	NN	_	31	com	_	_
31	block	block	NN	_	25	ppmod	_	_
32	.	.	.	_	25	p	_	_

1	Due	due	IN	_	5	case	_	_
2	to	to	TO	_	5	aux	_	_
3	the	the	DT	_	5	det	_	_
4	considerable	considerable	JJ	_	5	attr	_	_
5	variability	variability	NN	_	16	ppmod	_	_
6	of	of	IN	_	8	case	_	_
7	these	these	DT	_	8	det	_	_
8	interactions	interaction	NNS	_	5	ppmod	_	_
9	,	,	,	_	16	p	_	_
10	the	the	DT	_	11	det	_	_
11	dosage	dosage	NN	_	16	dep	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	should	should	MD	_	16	modal	_	_
15	be	be	VB	_	16	aux	_	_
16	individualized	individualize	VBN	_	0	root	_	_
17	when	when	WRB	_	19	adv	_	_
18	patients	patient	NNS	_	19	dep	_	_
19	receive	receive	VBP	_	16	comp	_	_
20	these	these	DT	_	21	det	_	_
21	medications	medication	NNS	_	19	obj	_	_
22	concurrently	concurrently	RB	_	19	adv	_	_
23	.	.	.	_	16	p	_	_

1	Furthermore	furthermore	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	caution	caution	NN	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	exercised	exercise	VBN	_	0	root	_	_
7	when	when	WRB	_	8	adv	_	_
8	combining	combine	VBG	_	6	comp	_	_
9	drug1	drug0	NN	_	8	obj	_	_
10	with	with	IN	_	12	case	_	_
11	any	any	DT	_	12	det	_	_
12	drug	drug	NN	_	8	ppmod	_	_
13	that	that	WDT	_	15	dep	_	_
14	may	may	MD	_	15	modal	_	_
15	cause	cause	VB	_	12	relcl	_	_
16	a	a	DT	_	18	det	_	_
17	significant	significant	JJ	_	18	attr	_	_
18	deterioration	deterioration	NN	_	15	obj	_	_
19	in	in	IN	_	21	case	_	_
20	renal	renal	JJ	_	21	attr	_	_
21	function	function	NN	_	15	ppmod	_	_
22	,	,	,	_	15	p	_	_
23	since	since	IN	_	33	mark	_	_
24	a	a	DT	_	25	det	_	_
25	decline	decline	NN	_	33	dep	_	_
26	in	in	IN	_	28	case	_	_
27	glomerular	glomerular	JJ	_	28	attr	_	_
28	filtration	filtration	NN	_	25	ppmod	_	_
29	or	or	CC	_	28	cc	_	_
30	tubular	tubular	JJ	_	31	attr	_	_
31	secretion	secretion	NN	_	28	conj	_	_
32	may	may	MD	_	33	modal	_	_
33	impair	impair	VB	_	15	comp	_	_
34	the	the	DT	_	35	det	_	_
35	excretion	excretion	NN	_	33	obj	_	_
36	of	of	IN	_	37	case	_	_
37	drug2	drug0	NN	_	35	ppmod	_	_
38	.	.	.	_	6	p	_	_

1	Drug	drug	NN	_	2	com	_	_
2	interactions	interaction	NNS	_	10	dep	_	_
3	with	with	IN	_	6	case	_	_
4	drug1	drug0	CD	_	6	num	_	_
5	tablets	tablet	NNS	_	6	com	_	_
6	USP	usp	NN	_	2	ppmod	_	_
7	have	have	VBP	_	10	aux	_	_
8	not	not	RB	_	10	neg	_	_
9	been	be	VBN	_	10	aux	_	_
10	documented	document	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	Administration	administration	NN	_	15	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	to	to	TO	_	6	aux	_	_
5	hypoparathyroid	hypoparathyroid	JJ	_	6	attr	_	_
6	patients	patient	NNS	_	1	ppmod	_	_
7	who	who	WP	_	11	dep	_	_
8	are	be	VBP	_	11	aux	_	_
9	concurrently	concurrently	RB	_	11	adv	_	_
10	being	be	VBG	_	11	aux	_	_
11	treated	treat	VBN	_	6	relcl	_	_
12	with	with	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	may	may	MD	_	15	modal	_	_
15	cause	cause	VB	_	0	root	_	_
16	hypercalcemia	hypercalcemia	NN	_	15	obj	_	_
17	.	.	.	_	15	p	_	_

1	drug1	drug0	NN	_	8	dep	_	_
2	,	,	,	_	1	p	_	_
3	a	a	DT	_	4	det	_	_
4	drug2	drug0	NN	_	1	appo	_	_
5	,	,	,	_	1	p	_	_
6	has	have	VBZ	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	reported	report	VBN	_	0	root	_	_
9	to	to	TO	_	10	aux	_	_
10	inactivate	inactivate	VB	_	8	comp	_	_
11	the	the	DT	_	13	det	_	_
12	antifungal	antifungal	JJ	_	13	attr	_	_
13	activity	activity	NN	_	10	obj	_	_
14	of	of	IN	_	15	case	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	by	by	IN	_	18	case	_	_
17	competitive	competitive	JJ	_	18	attr	_	_
18	inhibition	inhibition	NN	_	13	ppmod	_	_
19	.	.	.	_	8	p	_	_

1	Drugs	drug	NNS	_	7	dep	_	_
2	which	which	WDT	_	3	dep	_	_
3	impair	impair	VBP	_	1	relcl	_	_
4	glomerular	glomerular	JJ	_	5	attr	_	_
5	filtration	filtration	NN	_	3	obj	_	_
6	may	may	MD	_	7	modal	_	_
7	prolong	prolong	VB	_	0	root	_	_
8	the	the	DT	_	10	det	_	_
9	biological	biological	JJ	_	10	attr	_	_
10	half-life	half-life	NN	_	7	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	7	p	_	_

1	Drug/Laboratory	drug/laboratory	NN	_	3	com	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	0	root	_	_
4	:	:	:	_	3	p	_	_
5	Measurement	measurement	NN	_	12	dep	_	_
6	of	of	IN	_	9	case	_	_
7	serum	serum	NN	_	9	com	_	_
8	creatinine	creatinine	NN	_	9	com	_	_
9	levels	level	NNS	_	5	ppmod	_	_
10	should	should	MD	_	12	modal	_	_
11	be	be	VB	_	12	aux	_	_
12	determined	determine	VBN	_	3	acl	_	_
13	by	by	IN	_	16	case	_	_
14	the	the	DT	_	16	det	_	_
15	Jaffe	jaffe	NN	_	16	com	_	_
16	reaction	reaction	NN	_	12	ppmod	_	_
17	,	,	,	_	12	p	_	_
18	since	since	IN	_	22	mark	_	_
19	drug1	drug0	NN	_	22	dep	_	_
20	does	do	VBZ	_	22	aux	_	_
21	not	not	RB	_	22	neg	_	_
22	interfere	interfere	VB	_	12	comp	_	_
23	with	with	IN	_	25	case	_	_
24	the	the	DT	_	25	det	_	_
25	determination	determination	NN	_	22	ppmod	_	_
26	of	of	IN	_	28	case	_	_
27	creatinine	creatinine	NN	_	28	com	_	_
28	values	value	NNS	_	25	ppmod	_	_
29	by	by	IN	_	31	case	_	_
30	this	this	DT	_	31	det	_	_
31	method	method	NN	_	25	ppmod	_	_
32	.	.	.	_	3	p	_	_

1	Most	most	JJ	_	3	attr	_	_
2	automated	automated	JJ	_	3	attr	_	_
3	equipment	equipment	NN	_	9	dep	_	_
4	for	for	IN	_	5	case	_	_
5	measurement	measurement	NN	_	3	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	creatinine	creatinine	NN	_	5	ppmod	_	_
8	makes	make	VBZ	_	9	lv	_	_
9	use	use	NN	_	0	root	_	_
10	of	of	IN	_	13	case	_	_
11	the	the	DT	_	13	det	_	_
12	Jaffe	jaffe	NN	_	13	com	_	_
13	reaction	reaction	NN	_	9	ppmod	_	_
14	.	.	.	_	9	p	_	_

1	-	-	:	_	4	p	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	enhance	enhance	VB	_	0	root	_	_
5	the	the	DT	_	8	det	_	_
6	CNS	cns	NN	_	8	attr	_	_
7	depressive	depressive	JJ	_	8	attr	_	_
8	effects	effect	NNS	_	4	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	drug3	drug0	NN	_	10	conj	_	_
13	and	and	CC	_	12	cc	_	_
14	other	other	JJ	_	15	attr	_	_
15	drug4	drug0	NNS	_	10	conj	_	_

1	.	.	.	_	0	root	_	_

1	-	-	:	_	4	p	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	enhance	enhance	VB	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	effects	effect	NNS	_	4	obj	_	_
7	of	of	IN	_	9	case	_	_
8	drug2	drug0	NN	_	9	com	_	_
9	therapy	therapy	NN	_	6	ppmod	_	_

1	.	.	.	_	0	root	_	_

1	-	-	CC	_	3	cc	_	_
2	Concomitant	concomitant	JJ	_	3	attr	_	_
3	use	use	NN	_	7	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	may	may	MD	_	7	modal	_	_
7	reduce	reduce	VB	_	0	root	_	_
8	the	the	DT	_	9	det	_	_
9	efficacy	efficacy	NN	_	7	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	7	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	studies	study	NNS	_	8	dep	_	_
4	of	of	IN	_	7	case	_	_
5	human	human	JJ	_	7	attr	_	_
6	CYP	cyp	JJ	_	7	attr	_	_
7	enzymes	enzyme	NNS	_	3	ppmod	_	_
8	showed	show	VBD	_	0	root	_	_
9	that	that	IN	_	11	mark	_	_
10	drug1	drug0	NN	_	11	dep	_	_
11	inhibited	inhibit	VBD	_	8	comp	_	_
12	the	the	DT	_	14	det	_	_
13	CYP	cyp	JJ	_	14	attr	_	_
14	enzymes	enzyme	NNS	_	11	obj	_	_
15	1A2	0a0	NN	_	14	appo	_	_
16	,	,	,	_	15	p	_	_
17	2A6	0a0	NN	_	15	conj	_	_
18	,	,	,	_	17	p	_	_
19	2C9	0c0	NN	_	15	conj	_	_
20	,	,	,	_	19	p	_	_
21	2C19	0c0	NN	_	15	conj	_	_
22	,	,	,	_	21	p	_	_
23	2D6	0d0	NN	_	15	conj	_	_
24	,	,	,	_	23	p	_	_
25	2E1	0e0	NN	_	15	conj	_	_
26	and	and	CC	_	25	cc	_	_
27	3A	0a	NN	_	15	conj	_	_
28	only	only	RB	_	11	adv	_	_
29	at	at	IN	_	32	case	_	_
30	very	very	RB	_	31	adv	_	_
31	high	high	JJ	_	32	attr	_	_
32	concentrations	concentration	NNS	_	11	ppmod	_	_
33	(	-lrb-	-LRB-	_	34	p	_	_
34	IC50	ic0	NN	_	32	prn	_	_
35	from	from	IN	_	40	case	_	_
36	200	0	CD	_	40	num	_	_
37	to	to	TO	_	36	cc	_	_
38	over	over	IN	_	39	case	_	_
39	1000	0	CD	_	36	conj	_	_
40	uM	um	NN	_	34	ppmod	_	_
41	;	;	:	_	8	p	_	_

1	an	an	DT	_	5	det	_	_
2	oral	oral	JJ	_	5	attr	_	_
3	200	0	CD	_	4	num	_	_
4	mg	mg	NN	_	5	com	_	_
5	dose	dose	NN	_	6	dep	_	_
6	achieves	achieve	VBZ	_	0	root	_	_
7	a	a	DT	_	9	det	_	_
8	highest	high	JJS	_	9	attr	_	_
9	level	level	NN	_	6	obj	_	_
10	of	of	IN	_	13	case	_	_
11	approximately	approximately	RB	_	12	adv	_	_
12	5	0	CD	_	13	num	_	_
13	uM	um	NN	_	9	ppmod	_	_
14	in	in	IN	_	15	case	_	_
15	people	people	NN	_	9	ppmod	_	_
16	)	-rrb-	-RRB-	_	9	p	_	_
17	;	;	:	_	6	p	_	_

1	these	these	DT	_	2	det	_	_
2	enzymes	enzyme	NNS	_	7	dep	_	_
3	would	would	MD	_	7	modal	_	_
4	therefore	therefore	RB	_	7	adv	_	_
5	not	not	RB	_	7	neg	_	_
6	be	be	VB	_	7	aux	_	_
7	expected	expect	VBN	_	0	root	_	_
8	to	to	TO	_	10	aux	_	_
9	be	be	VB	_	10	aux	_	_
10	inhibited	inhibit	VBN	_	7	comp	_	_
11	in	in	IN	_	13	case	_	_
12	clinical	clinical	JJ	_	13	attr	_	_
13	use	use	NN	_	10	ppmod	_	_
14	.	.	.	_	7	p	_	_

1	Protein	protein	NN	_	2	com	_	_
2	Binding	binding	NN	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	drug1	drug0	NN	_	5	dep	_	_
5	is	be	VBZ	_	2	acl	_	_
6	highly	highly	RB	_	5	adv	_	_
7	protein	protein	NN	_	8	advnp	_	_
8	bound	bind	VBN	_	5	dep	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	98	0	CD	_	8	num	_	_
11	%	%	NN	_	10	meta	_	_
12	)	-rrb-	-RRB-	_	10	p	_	_
13	.	.	.	_	2	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	studies	study	NNS	_	5	dep	_	_
4	have	have	VBP	_	5	aux	_	_
5	shown	show	VBN	_	0	root	_	_
6	no	no	DT	_	8	det	_	_
7	binding	bind	VBG	_	8	attr	_	_
8	displacement	displacement	NN	_	5	obj	_	_
9	between	between	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	other	other	JJ	_	15	attr	_	_
13	highly	highly	RB	_	14	adv	_	_
14	bound	bind	VBN	_	15	attr	_	_
15	drugs	drug	NNS	_	10	conj	_	_
16	,	,	,	_	15	p	_	_
17	such	such	JJ	_	19	adv	_	_
18	as	as	IN	_	19	case	_	_
19	drug2	drug0	NN	_	15	ppmod	_	_
20	,	,	,	_	15	p	_	_
21	drug3	drug0	NN	_	15	appo	_	_
22	,	,	,	_	21	p	_	_
23	drug4	drug0	NN	_	21	conj	_	_
24	,	,	,	_	23	p	_	_
25	and	and	CC	_	23	cc	_	_
26	drug5	drug0	NN	_	21	conj	_	_
27	.	.	.	_	5	p	_	_

1	Drugs	drug	NNS	_	0	root	_	_
2	Metabolized	metabolize	VBN	_	1	acl	_	_
3	by	by	IN	_	10	case	_	_
4	Catechol-O-methyltransferase	catechol-o-methyltransferase	NN	_	10	attr	_	_
5	(	-lrb-	-LRB-	_	10	p	_	_
6	COMT	comt	NN	_	10	attr	_	_
7	)	-rrb-	-RRB-	_	10	p	_	_
8	:	:	:	_	10	p	_	_
9	Hormone	hormone	NN	_	10	com	_	_
10	levels	level	NNS	_	2	ppmod	_	_
11	:	:	:	_	1	p	_	_
12	drug1	drug0	NN	_	14	dep	_	_
13	is	be	VBZ	_	14	aux	_	_
14	known	know	VBN	_	1	acl	_	_
15	to	to	TO	_	16	aux	_	_
16	depress	depress	VB	_	14	comp	_	_
17	prolactin	prolactin	NN	_	18	com	_	_
18	secretion	secretion	NN	_	16	obj	_	_
19	and	and	CC	_	16	cc	_	_
20	increase	increase	VB	_	16	conj	_	_
21	growth	growth	NN	_	23	com	_	_
22	hormone	hormone	NN	_	23	com	_	_
23	levels	level	NNS	_	20	obj	_	_
24	.	.	.	_	1	p	_	_

1	Treatment	treatment	NN	_	11	dep	_	_
2	with	with	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	coadministered	coadministered	VBN	_	1	acl	_	_
5	with	with	IN	_	8	case	_	_
6	drug2	drug0	NN	_	8	attr	_	_
7	/	/	:	_	8	p	_	_
8	drug3	drug0	NN	_	4	ppmod	_	_
9	does	do	VBZ	_	11	aux	_	_
10	not	not	RB	_	11	neg	_	_
11	change	change	VB	_	0	root	_	_
12	these	these	DT	_	13	det	_	_
13	effects	effect	NNS	_	11	obj	_	_
14	.	.	.	_	11	p	_	_

1	No	no	DT	_	2	det	_	_
2	interaction	interaction	NN	_	4	dep	_	_
3	was	be	VBD	_	4	aux	_	_
4	noted	note	VBN	_	0	root	_	_
5	with	with	IN	_	8	case	_	_
6	the	the	DT	_	8	det	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	drug2	drug0	NN	_	4	ppmod	_	_
9	in	in	IN	_	13	case	_	_
10	two	#crd#	CD	_	13	num	_	_
11	multiple-dose	multiple-dose	NN	_	13	com	_	_
12	interaction	interaction	NN	_	13	com	_	_
13	studies	study	NNS	_	4	ppmod	_	_
14	when	when	WRB	_	17	adv	_	_
15	drug3	drug0	NN	_	17	dep	_	_
16	was	be	VBD	_	17	aux	_	_
17	coadministered	coadministered	VBN	_	4	comp	_	_
18	with	with	IN	_	20	case	_	_
19	a	a	DT	_	20	det	_	_
20	drug4	drug0	NN	_	17	ppmod	_	_
21	/	/	:	_	20	p	_	_
22	drug5	drug0	NN	_	20	appo	_	_
23	(	-lrb-	-LRB-	_	24	p	_	_
24	n=29	n=0	NN	_	22	prn	_	_
25	)	-rrb-	-RRB-	_	24	p	_	_
26	.	.	.	_	4	p	_	_

1	More	more	JJR	_	3	attr	_	_
2	than	than	IN	_	1	com	_	_
3	600	0	CD	_	6	num	_	_
4	Parkinsons	parkinsons	NN	_	6	com	_	_
5	disease	disease	NN	_	6	com	_	_
6	patients	patient	NNS	_	11	dep	_	_
7	in	in	IN	_	9	case	_	_
8	clinical	clinical	JJ	_	9	attr	_	_
9	trials	trial	NNS	_	6	ppmod	_	_
10	have	have	VBP	_	11	aux	_	_
11	used	use	VBN	_	0	root	_	_
12	drug1	drug0	NN	_	11	obj	_	_
13	in	in	IN	_	14	case	_	_
14	combination	combination	NN	_	11	ppmod	_	_
15	with	with	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	drug3	drug0	NN	_	16	conj	_	_
19	/	/	:	_	16	p	_	_
20	drug4	drug0	NN	_	16	appo	_	_
21	.	.	.	_	11	p	_	_

1	As	as	IN	_	5	mark	_	_
2	most	most	JJ	_	4	attr	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	excretion	excretion	NN	_	5	dep	_	_
5	is	be	VBZ	_	13	advcl	_	_
6	via	via	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	bile	bile	NN	_	5	ppmod	_	_
9	,	,	,	_	13	p	_	_
10	caution	caution	NN	_	13	dep	_	_
11	should	should	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	exercised	exercise	VBN	_	0	root	_	_
14	when	when	WRB	_	29	adv	_	_
15	drugs	drug	NNS	_	29	dep	_	_
16	known	know	VBN	_	15	acl	_	_
17	to	to	TO	_	18	aux	_	_
18	interfere	interfere	VB	_	16	comp	_	_
19	with	with	IN	_	21	case	_	_
20	biliary	biliary	JJ	_	21	attr	_	_
21	excretion	excretion	NN	_	18	ppmod	_	_
22	,	,	,	_	21	p	_	_
23	glucuronidation	glucuronidation	NN	_	21	conj	_	_
24	,	,	,	_	23	p	_	_
25	and	and	CC	_	23	cc	_	_
26	intestinal	intestinal	JJ	_	27	attr	_	_
27	beta-glucuronidase	beta-glucuronidase	NN	_	21	conj	_	_
28	are	be	VBP	_	29	aux	_	_
29	given	give	VBN	_	13	comp	_	_
30	concurrently	concurrently	RB	_	29	adv	_	_
31	with	with	IN	_	32	case	_	_
32	drug2	drug0	NN	_	29	ppmod	_	_
33	.	.	.	_	13	p	_	_

1	These	these	DT	_	2	dep	_	_
2	include	include	VBP	_	0	root	_	_
3	drug1	drug0	NN	_	2	obj	_	_
4	,	,	,	_	3	p	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	,	,	,	_	5	p	_	_
7	and	and	CC	_	5	cc	_	_
8	some	some	DT	_	9	det	_	_
9	drug3	drug0	NN	_	3	conj	_	_
10	(	-lrb-	-LRB-	_	12	p	_	_
11	e.g.	e.g.	FW	_	12	ppmod	_	_
12	drug4	drug0	NN	_	9	prn	_	_
13	,	,	,	_	12	p	_	_
14	rifamipicin	rifamipicin	NN	_	12	conj	_	_
15	,	,	,	_	14	p	_	_
16	drug5	drug0	NN	_	12	conj	_	_
17	and	and	CC	_	16	cc	_	_
18	drug6	drug0	NN	_	12	conj	_	_
19	)	-rrb-	-RRB-	_	12	p	_	_
20	.	.	.	_	2	p	_	_

1	No	no	DT	_	2	det	_	_
2	interaction	interaction	NN	_	8	dep	_	_
3	with	with	IN	_	6	case	_	_
4	the	the	DT	_	6	det	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	drug2	drug0	NN	_	2	ppmod	_	_
7	was	be	VBD	_	8	aux	_	_
8	shown	show	VBN	_	0	root	_	_
9	in	in	IN	_	12	case	_	_
10	a	a	DT	_	12	det	_	_
11	single-dose	single-dose	JJ	_	12	attr	_	_
12	study	study	NN	_	8	ppmod	_	_
13	with	with	IN	_	14	case	_	_
14	drug3	drug0	NN	_	12	ppmod	_	_
15	without	without	IN	_	19	case	_	_
16	coadministered	coadministered	JJ	_	19	attr	_	_
17	drug4	drug0	NN	_	19	attr	_	_
18	/	/	:	_	19	p	_	_
19	drug5	drug0	NN	_	14	ppmod	_	_
20	.	.	.	_	8	p	_	_

1	Co-treatment	co-treatment	NN	_	8	dep	_	_
2	with	with	IN	_	7	case	_	_
3	the	the	DT	_	7	det	_	_
4	potent	potent	JJ	_	7	attr	_	_
5	CYP3A4	cyp0a0	NN	_	7	com	_	_
6	inhibitor	inhibitor	NN	_	7	com	_	_
7	drug1	drug0	NN	_	1	ppmod	_	_
8	increases	increase	VBZ	_	0	root	_	_
9	drug2	drug0	NN	_	10	com	_	_
10	AUC	auc	NN	_	8	obj	_	_
11	by	by	IN	_	12	case	_	_
12	2/3	0	CD	_	8	ppmod	_	_
13	.	.	.	_	8	p	_	_

1	Caution	caution	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	used	use	VBN	_	0	root	_	_
5	when	when	WRB	_	6	adv	_	_
6	administering	administer	VBG	_	4	comp	_	_
7	or	or	CC	_	9	cc	_	_
8	taking	take	VBG	_	9	attr	_	_
9	drug1	drug0	NN	_	6	obj	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NN	_	6	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	other	other	JJ	_	16	attr	_	_
14	strong	strong	JJ	_	16	attr	_	_
15	CYP3A4	cyp0a0	JJ	_	16	attr	_	_
16	inhibitors	inhibitor	NNS	_	11	conj	_	_
17	such	such	JJ	_	25	attr	_	_
18	as	as	IN	_	17	case	_	_
19	,	,	,	_	17	p	_	_
20	but	but	CC	_	17	cc	_	_
21	not	not	RB	_	20	com	_	_
22	limited	limited	JJ	_	17	conj	_	_
23	to	to	TO	_	22	ppmod	_	_
24	,	,	,	_	22	p	_	_
25	drug3	drug0	NN	_	16	appo	_	_
26	,	,	,	_	25	p	_	_
27	drug4	drug0	NN	_	25	conj	_	_
28	,	,	,	_	27	p	_	_
29	drug5	drug0	NN	_	25	conj	_	_
30	,	,	,	_	29	p	_	_
31	drug6	drug0	NN	_	25	conj	_	_
32	,	,	,	_	31	p	_	_
33	drug7	drug0	NN	_	25	conj	_	_
34	,	,	,	_	33	p	_	_
35	drug8	drug0	NN	_	25	conj	_	_
36	,	,	,	_	35	p	_	_
37	drug9	drug0	NN	_	25	conj	_	_
38	,	,	,	_	37	p	_	_
39	drug10	drug0	NN	_	25	conj	_	_
40	,	,	,	_	39	p	_	_
41	drug11	drug0	NN	_	25	conj	_	_
42	,	,	,	_	41	p	_	_
43	drug12	drug0	NN	_	25	conj	_	_
44	(	-lrb-	-LRB-	_	43	p	_	_
45	drug13	drug0	CD	_	43	num	_	_
46	)	-rrb-	-RRB-	_	43	p	_	_
47	,	,	,	_	43	p	_	_
48	and	and	CC	_	43	cc	_	_
49	drug14	drug0	NN	_	25	conj	_	_
50	.	.	.	_	4	p	_	_

1	Pre-treatment	pre-treatment	NN	_	7	dep	_	_
2	with	with	IN	_	6	case	_	_
3	the	the	DT	_	6	det	_	_
4	CYP3A4	cyp0a0	NN	_	6	com	_	_
5	inducer	inducer	NN	_	6	com	_	_
6	drug1	drug0	NN	_	1	ppmod	_	_
7	decreased	decrease	VBD	_	0	root	_	_
8	drug2	drug0	NN	_	9	com	_	_
9	AUC	auc	NN	_	7	obj	_	_
10	by	by	IN	_	12	case	_	_
11	about	about	RB	_	12	adv	_	_
12	2/3	0	CD	_	7	ppmod	_	_
13	.	.	.	_	7	p	_	_

1	Alternate	alternate	JJ	_	2	attr	_	_
2	treatments	treatment	NNS	_	9	dep	_	_
3	lacking	lack	VBG	_	2	acl	_	_
4	CYP3A4	cyp0a0	NN	_	6	com	_	_
5	inducing	inducing	NN	_	6	com	_	_
6	activity	activity	NN	_	3	obj	_	_
7	should	should	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	considered	consider	VBN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	If	if	IN	_	5	mark	_	_
2	an	an	DT	_	4	det	_	_
3	alternative	alternative	JJ	_	4	attr	_	_
4	treatment	treatment	NN	_	5	dep	_	_
5	is	be	VBZ	_	17	advcl	_	_
6	unavailable	unavailable	JJ	_	5	dep	_	_
7	,	,	,	_	17	p	_	_
8	a	a	DT	_	10	det	_	_
9	drug1	drug0	JJ	_	10	attr	_	_
10	dose	dose	NN	_	17	dep	_	_
11	greater	great	JJR	_	13	attr	_	_
12	than	than	IN	_	11	com	_	_
13	150	0	CD	_	14	num	_	_
14	mg	mg	NN	_	10	attr	_	_
15	should	should	MD	_	17	modal	_	_
16	be	be	VB	_	17	aux	_	_
17	considered	consider	VBN	_	0	root	_	_
18	for	for	IN	_	20	case	_	_
19	NSCLC	nsclc	NN	_	20	com	_	_
20	patients	patient	NNS	_	17	ppmod	_	_
21	,	,	,	_	20	p	_	_
22	and	and	CC	_	20	cc	_	_
23	greater	great	JJR	_	20	conj	_	_
24	than	than	IN	_	26	case	_	_
25	100	0	CD	_	26	num	_	_
26	mg	mg	NN	_	23	ppmod	_	_
27	considered	consider	VBN	_	20	acl	_	_
28	for	for	IN	_	31	case	_	_
29	pancreatic	pancreatic	JJ	_	31	attr	_	_
30	cancer	cancer	NN	_	31	com	_	_
31	patients	patient	NNS	_	27	ppmod	_	_
32	.	.	.	_	17	p	_	_

1	If	if	IN	_	6	mark	_	_
2	the	the	DT	_	4	det	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	dose	dose	NN	_	6	dep	_	_
5	is	be	VBZ	_	6	aux	_	_
6	adjusted	adjust	VBN	_	12	advcl	_	_
7	upward	upward	NN	_	6	comp	_	_
8	,	,	,	_	12	p	_	_
9	the	the	DT	_	10	det	_	_
10	dose	dose	NN	_	12	dep	_	_
11	will	will	MD	_	12	modal	_	_
12	need	need	VBP	_	0	root	_	_
13	to	to	TO	_	15	aux	_	_
14	be	be	VB	_	15	aux	_	_
15	reduced	reduce	VBN	_	12	comp	_	_
16	upon	upon	IN	_	17	case	_	_
17	discontinuation	discontinuation	NN	_	15	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	or	or	CC	_	19	cc	_	_
21	other	other	JJ	_	22	attr	_	_
22	inducers	inducer	NNS	_	19	conj	_	_
23	.	.	.	_	12	p	_	_

1	Other	other	JJ	_	3	attr	_	_
2	CYP3A4	cyp0a0	NN	_	3	com	_	_
3	inducers	inducer	NNS	_	4	dep	_	_
4	include	include	VBP	_	0	root	_	_
5	,	,	,	_	4	p	_	_
6	but	but	CC	_	4	cc	_	_
7	are	be	VBP	_	4	conj	_	_
8	not	not	RB	_	7	neg	_	_
9	limited	limited	JJ	_	7	dep	_	_
10	to	to	TO	_	12	aux	_	_
11	,	,	,	_	12	p	_	_
12	drug1	drug0	NN	_	9	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	drug2	drug0	NN	_	12	conj	_	_
15	,	,	,	_	14	p	_	_
16	drug3	drug0	NN	_	12	conj	_	_
17	,	,	,	_	16	p	_	_
18	drug4	drug0	NN	_	12	conj	_	_
19	,	,	,	_	18	p	_	_
20	drug5	drug0	NN	_	12	conj	_	_
21	and	and	CC	_	20	cc	_	_
22	St.	st.	NN	_	24	com	_	_
23	Johns	johns	NNP	_	24	com	_	_
24	Wort	wort	NNP	_	12	conj	_	_
25	.	.	.	_	4	p	_	_

1	Hepatotoxicity	hepatotoxicity	NN	_	3	attr	_	_
2	Asymptomatic	asymptomatic	JJ	_	3	attr	_	_
3	increases	increase	NNS	_	9	dep	_	_
4	in	in	IN	_	6	case	_	_
5	liver	liver	NN	_	6	com	_	_
6	transaminases	transaminase	NNS	_	3	ppmod	_	_
7	have	have	VBP	_	9	aux	_	_
8	been	be	VBN	_	9	aux	_	_
9	observed	observe	VBN	_	0	root	_	_
10	in	in	IN	_	13	case	_	_
11	drug1	drug0	JJ	_	13	attr	_	_
12	treated	treated	JJ	_	13	attr	_	_
13	patients	patient	NNS	_	9	ppmod	_	_
14	;	;	:	_	9	p	_	_

1	therefore	therefore	RB	_	18	adv	_	_
2	,	,	,	_	18	p	_	_
3	periodic	periodic	JJ	_	6	attr	_	_
4	liver	liver	NN	_	6	com	_	_
5	function	function	NN	_	6	com	_	_
6	testing	testing	NN	_	18	dep	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	transaminases	transaminases	NN	_	6	prn	_	_
9	,	,	,	_	8	p	_	_
10	bilirubin	bilirubin	NN	_	8	conj	_	_
11	,	,	,	_	10	p	_	_
12	and	and	CC	_	10	cc	_	_
13	alkaline	alkaline	NN	_	14	com	_	_
14	phosphatase	phosphatase	NN	_	8	conj	_	_
15	)	-rrb-	-RRB-	_	8	p	_	_
16	should	should	MD	_	18	modal	_	_
17	be	be	VB	_	18	aux	_	_
18	considered	consider	VBN	_	0	root	_	_
19	.	.	.	_	18	p	_	_

1	Dose	dose	NN	_	2	com	_	_
2	reduction	reduction	NN	_	9	dep	_	_
3	or	or	CC	_	2	cc	_	_
4	interruption	interruption	NN	_	2	conj	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	should	should	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	considered	consider	VBN	_	0	root	_	_
10	if	if	IN	_	15	mark	_	_
11	changes	change	NNS	_	15	dep	_	_
12	in	in	IN	_	14	case	_	_
13	liver	liver	NN	_	14	com	_	_
14	function	function	NN	_	11	ppmod	_	_
15	are	be	VBP	_	9	comp	_	_
16	severe	severe	JJ	_	15	dep	_	_
17	.	.	.	_	9	p	_	_

1	Patients	patient	NNS	_	11	dep	_	_
2	with	with	IN	_	4	case	_	_
3	Hepatic	hepatic	JJ	_	4	attr	_	_
4	Impairment	impairment	NN	_	1	ppmod	_	_
5	In	in	FW	_	6	adv	_	_
6	vitro	vitro	FW	_	4	adv	_	_
7	and	and	CC	_	1	cc	_	_
8	in	in	FW	_	9	adv	_	_
9	vivo	vivo	FW	_	10	attr	_	_
10	evidence	evidence	NN	_	1	conj	_	_
11	suggest	suggest	VBP	_	0	root	_	_
12	that	that	IN	_	15	mark	_	_
13	drug1	drug0	NN	_	15	dep	_	_
14	is	be	VBZ	_	15	aux	_	_
15	cleared	clear	VBN	_	11	comp	_	_
16	primarily	primarily	RB	_	15	adv	_	_
17	by	by	IN	_	19	case	_	_
18	the	the	DT	_	19	det	_	_
19	liver	liver	NN	_	15	ppmod	_	_
20	.	.	.	_	11	p	_	_

1	Therefore	therefore	RB	_	7	adv	_	_
2	,	,	,	_	7	p	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	exposure	exposure	NN	_	7	dep	_	_
5	may	may	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	increased	increase	VBN	_	0	root	_	_
8	in	in	IN	_	9	case	_	_
9	patients	patient	NNS	_	7	ppmod	_	_
10	with	with	IN	_	12	case	_	_
11	hepatic	hepatic	JJ	_	12	attr	_	_
12	dysfunction	dysfunction	NN	_	9	ppmod	_	_
13	.	.	.	_	7	p	_	_

1	Elevated	elevated	JJ	_	4	attr	_	_
2	International	international	NNP	_	4	attr	_	_
3	Normalized	normalize	VBN	_	4	attr	_	_
4	Ratio	ratio	NN	_	14	attr	_	_
5	and	and	CC	_	4	cc	_	_
6	Potential	potential	JJ	_	10	attr	_	_
7	Bleeding	bleeding	JJ	_	10	attr	_	_
8	International	international	NNP	_	10	attr	_	_
9	Normalized	normalize	VBN	_	10	attr	_	_
10	Ratio	ratio	NN	_	4	conj	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	INR	inr	NN	_	10	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	elevations	elevation	NNS	_	28	dep	_	_
15	and	and	CC	_	14	cc	_	_
16	infrequent	infrequent	JJ	_	17	attr	_	_
17	reports	report	NNS	_	14	conj	_	_
18	of	of	IN	_	20	case	_	_
19	bleeding	bleeding	JJ	_	20	attr	_	_
20	events	event	NNS	_	17	ppmod	_	_
21	including	include	VBG	_	25	adv	_	_
22	gastrointestinal	gastrointestinal	JJ	_	25	attr	_	_
23	and	and	CC	_	22	cc	_	_
24	non-gastrointestinal	non-gastrointestinal	JJ	_	22	conj	_	_
25	bleedings	bleeding	NNS	_	20	ppmod	_	_
26	have	have	VBP	_	28	aux	_	_
27	been	be	VBN	_	28	aux	_	_
28	reported	report	VBN	_	0	root	_	_
29	in	in	IN	_	31	case	_	_
30	clinical	clinical	JJ	_	31	attr	_	_
31	studies	study	NNS	_	28	ppmod	_	_
32	,	,	,	_	31	p	_	_
33	some	some	DT	_	31	appo	_	_
34	associated	associate	VBN	_	33	acl	_	_
35	with	with	IN	_	38	case	_	_
36	concomitant	concomitant	JJ	_	38	attr	_	_
37	drug1	drug0	NN	_	38	com	_	_
38	administration	administration	NN	_	34	ppmod	_	_
39	.	.	.	_	28	p	_	_

1	Patients	patient	NNS	_	0	root	_	_
2	taking	take	VBG	_	1	acl	_	_
3	drug1	drug0	NN	_	2	obj	_	_
4	or	or	CC	_	1	cc	_	_
5	other	other	JJ	_	6	attr	_	_
6	drug2	drug0	NNS	_	1	conj	_	_
7	should	should	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	monitored	monitor	VBN	_	6	acl	_	_
10	regularly	regularly	RB	_	9	adv	_	_
11	for	for	IN	_	12	case	_	_
12	changes	change	NNS	_	9	ppmod	_	_
13	in	in	IN	_	15	case	_	_
14	prothrombin	prothrombin	NN	_	15	com	_	_
15	time	time	NN	_	12	ppmod	_	_
16	or	or	CC	_	15	cc	_	_
17	INR	inr	NN	_	15	conj	_	_

1	.	.	.	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	decrease	decrease	VB	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	effectiveness	effectiveness	NN	_	3	obj	_	_
6	of	of	IN	_	8	case	_	_
7	oral	oral	JJ	_	8	attr	_	_
8	drug2	drug0	NN	_	5	ppmod	_	_
9	,	,	,	_	8	p	_	_
10	certain	certain	JJ	_	11	attr	_	_
11	drug3	drug0	NN	_	8	conj	_	_
12	,	,	,	_	11	p	_	_
13	drug4	drug0	NN	_	8	conj	_	_
14	,	,	,	_	13	p	_	_
15	drug5	drug0	NN	_	8	conj	_	_
16	,	,	,	_	15	p	_	_
17	drug6	drug0	NN	_	8	conj	_	_
18	,	,	,	_	17	p	_	_
19	drug7	drug0	NN	_	8	conj	_	_
20	,	,	,	_	19	p	_	_
21	and	and	CC	_	19	cc	_	_
22	drug8	drug0	NN	_	8	conj	_	_
23	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	a	a	DT	_	5	det	_	_
4	potent	potent	JJ	_	5	attr	_	_
5	inhibitor	inhibitor	NN	_	2	obj	_	_
6	of	of	IN	_	12	case	_	_
7	the	the	DT	_	12	det	_	_
8	cytochrome	cytochrome	NN	_	10	com	_	_
9	P450	p0	NN	_	10	com	_	_
10	3A4	0a0	NN	_	12	com	_	_
11	enzyme	enzyme	NN	_	12	com	_	_
12	system	system	NN	_	5	ppmod	_	_
13	.	.	.	_	2	p	_	_

1	Coadministration	coadministration	NN	_	17	dep	_	_
2	of	of	IN	_	4	case	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	Tablets	tablet	NNS	_	1	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drugs	drug	NNS	_	4	conj	_	_
7	primarily	primarily	RB	_	8	adv	_	_
8	metabolized	metabolize	VBN	_	4	acl	_	_
9	by	by	IN	_	15	case	_	_
10	the	the	DT	_	15	det	_	_
11	cytochrome	cytochrome	NN	_	13	com	_	_
12	P450	p0	NN	_	13	com	_	_
13	3A4	0a0	NN	_	15	com	_	_
14	enzyme	enzyme	NN	_	15	com	_	_
15	system	system	NN	_	8	ppmod	_	_
16	may	may	MD	_	17	modal	_	_
17	result	result	VB	_	0	root	_	_
18	in	in	IN	_	21	case	_	_
19	increased	increase	VBN	_	21	attr	_	_
20	plasma	plasma	NN	_	21	com	_	_
21	concentrations	concentration	NNS	_	17	ppmod	_	_
22	of	of	IN	_	24	case	_	_
23	the	the	DT	_	24	det	_	_
24	drugs	drug	NNS	_	21	ppmod	_	_
25	that	that	WDT	_	27	dep	_	_
26	could	could	MD	_	27	modal	_	_
27	increase	increase	VB	_	24	relcl	_	_
28	or	or	CC	_	27	cc	_	_
29	prolong	prolong	VB	_	27	conj	_	_
30	both	both	CC	_	31	cc	_	_
31	therapeutic	therapeutic	JJ	_	34	attr	_	_
32	and	and	CC	_	31	cc	_	_
33	adverse	adverse	JJ	_	31	conj	_	_
34	effects	effect	NNS	_	29	obj	_	_
35	.	.	.	_	17	p	_	_

1	Therefore	therefore	RB	_	11	adv	_	_
2	,	,	,	_	11	p	_	_
3	unless	unless	IN	_	5	mark	_	_
4	otherwise	otherwise	RB	_	5	adv	_	_
5	specified	specify	VBN	_	11	advcl	_	_
6	,	,	,	_	11	p	_	_
7	appropriate	appropriate	JJ	_	9	attr	_	_
8	dosage	dosage	NN	_	9	com	_	_
9	adjustments	adjustment	NNS	_	11	dep	_	_
10	may	may	MD	_	11	modal	_	_
11	be	be	VB	_	0	root	_	_
12	necessary	necessary	JJ	_	11	dep	_	_
13	.	.	.	_	11	p	_	_

1	The	the	DT	_	4	det	_	_
2	following	following	JJ	_	4	attr	_	_
3	drug	drug	NN	_	4	com	_	_
4	interactions	interaction	NNS	_	7	dep	_	_
5	have	have	VBP	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	identified	identify	VBN	_	25	advcl	_	_
8	involving	involve	VBG	_	7	comp	_	_
9	drug1	drug0	NN	_	10	com	_	_
10	Tablets	tablet	NNS	_	8	obj	_	_
11	and	and	CC	_	10	cc	_	_
12	other	other	JJ	_	13	attr	_	_
13	drugs	drug	NNS	_	10	conj	_	_
14	metabolized	metabolize	VBN	_	10	acl	_	_
15	by	by	IN	_	21	case	_	_
16	the	the	DT	_	19	det	_	_
17	cytochrome	cytochrome	NN	_	19	com	_	_
18	P450	p0	NN	_	19	com	_	_
19	3A4	0a0	NN	_	21	com	_	_
20	enzyme	enzyme	NN	_	21	com	_	_
21	system	system	NN	_	14	ppmod	_	_
22	:	:	:	_	25	p	_	_
23	drug2	drug0	NN	_	24	com	_	_
24	tablets	tablet	NNS	_	25	dep	_	_
25	inhibit	inhibit	VBP	_	0	root	_	_
26	the	the	DT	_	27	det	_	_
27	metabolism	metabolism	NN	_	25	obj	_	_
28	of	of	IN	_	29	case	_	_
29	drug3	drug0	NN	_	27	ppmod	_	_
30	,	,	,	_	25	p	_	_
31	resulting	result	VBG	_	25	comp	_	_
32	in	in	IN	_	36	case	_	_
33	an	an	DT	_	36	det	_	_
34	increased	increase	VBN	_	36	attr	_	_
35	plasma	plasma	NN	_	36	com	_	_
36	concentration	concentration	NN	_	31	ppmod	_	_
37	of	of	IN	_	38	case	_	_
38	drug4	drug0	NN	_	36	ppmod	_	_
39	and	and	CC	_	36	cc	_	_
40	a	a	DT	_	41	det	_	_
41	delay	delay	NN	_	36	conj	_	_
42	in	in	IN	_	44	case	_	_
43	the	the	DT	_	44	det	_	_
44	elimination	elimination	NN	_	41	ppmod	_	_
45	of	of	IN	_	48	case	_	_
46	its	its	PRP$	_	48	poss	_	_
47	acid	acid	NN	_	48	com	_	_
48	metabolite	metabolite	NN	_	44	ppmod	_	_
49	.	.	.	_	25	p	_	_

1	The	the	DT	_	4	det	_	_
2	increased	increase	VBN	_	4	attr	_	_
3	plasma	plasma	NN	_	4	com	_	_
4	concentration	concentration	NN	_	11	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	or	or	CC	_	6	cc	_	_
8	its	its	PRP$	_	9	poss	_	_
9	metabolite	metabolite	NN	_	6	conj	_	_
10	may	may	MD	_	11	modal	_	_
11	result	result	VB	_	0	root	_	_
12	in	in	IN	_	15	case	_	_
13	prolonged	prolonged	JJ	_	15	attr	_	_
14	QT	qt	VBG	_	15	attr	_	_
15	intervals	interval	NNS	_	11	ppmod	_	_
16	.	.	.	_	11	p	_	_

1	Pharmacokinetic	pharmacokinetic	JJ	_	2	attr	_	_
2	data	datum	NNS	_	3	dep	_	_
3	indicate	indicate	VBP	_	0	root	_	_
4	that	that	IN	_	7	mark	_	_
5	oral	oral	JJ	_	6	attr	_	_
6	drug1	drug0	NN	_	7	dep	_	_
7	inhibits	inhibit	VBZ	_	3	comp	_	_
8	the	the	DT	_	9	det	_	_
9	metabolism	metabolism	NN	_	7	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	,	,	,	_	7	p	_	_
13	resulting	result	VBG	_	7	comp	_	_
14	in	in	IN	_	17	case	_	_
15	elevated	elevated	JJ	_	17	attr	_	_
16	plasma	plasma	NN	_	17	com	_	_
17	levels	level	NNS	_	13	ppmod	_	_
18	of	of	IN	_	24	case	_	_
19	drug3	drug0	NN	_	24	attr	_	_
20	and	and	CC	_	19	cc	_	_
21	its	its	PRP$	_	23	poss	_	_
22	active	active	JJ	_	23	attr	_	_
23	metabolite	metabolite	NN	_	19	conj	_	_
24	drug4	drug0	NNS	_	17	ppmod	_	_
25	which	which	WDT	_	27	dep	_	_
26	may	may	MD	_	27	modal	_	_
27	prolong	prolong	VB	_	24	relcl	_	_
28	QT	qt	VBG	_	29	attr	_	_
29	intervals	interval	NNS	_	27	obj	_	_
30	.	.	.	_	3	p	_	_

1	Coadministration	coadministration	NN	_	9	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	6	case	_	_
5	drug2	drug0	NN	_	6	com	_	_
6	tablets	tablet	NNS	_	1	ppmod	_	_
7	is	be	VBZ	_	9	aux	_	_
8	therefore	therefore	RB	_	9	adv	_	_
9	contraindicated	contraindicate	VBN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	Human	human	JJ	_	3	attr	_	_
2	pharmacokinetics	pharmacokinetics	NNS	_	3	com	_	_
3	data	datum	NNS	_	4	dep	_	_
4	indicate	indicate	VBP	_	0	root	_	_
5	that	that	IN	_	9	mark	_	_
6	oral	oral	JJ	_	7	attr	_	_
7	drug1	drug0	NN	_	9	dep	_	_
8	potently	potently	RB	_	9	adv	_	_
9	inhibits	inhibit	VBZ	_	4	comp	_	_
10	the	the	DT	_	11	det	_	_
11	metabolism	metabolism	NN	_	9	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	resulting	result	VBG	_	13	acl	_	_
15	in	in	IN	_	19	case	_	_
16	a	a	DT	_	19	det	_	_
17	mean	mean	NN	_	18	advnp	_	_
18	eight-fold	eight-fold	JJ	_	19	attr	_	_
19	increase	increase	NN	_	14	ppmod	_	_
20	in	in	IN	_	21	case	_	_
21	AUC	auc	NN	_	19	ppmod	_	_
22	of	of	IN	_	23	case	_	_
23	drug3	drug0	NN	_	21	ppmod	_	_
24	.	.	.	_	4	p	_	_

1	Data	datum	NNS	_	2	dep	_	_
2	suggest	suggest	VBP	_	0	root	_	_
3	that	that	IN	_	11	mark	_	_
4	coadministration	coadministration	NN	_	11	dep	_	_
5	of	of	IN	_	7	case	_	_
6	oral	oral	JJ	_	7	attr	_	_
7	drug1	drug0	NN	_	4	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	can	can	MD	_	11	modal	_	_
11	result	result	VB	_	2	comp	_	_
12	in	in	IN	_	13	case	_	_
13	prolongation	prolongation	NN	_	11	ppmod	_	_
14	of	of	IN	_	17	case	_	_
15	the	the	DT	_	17	det	_	_
16	QT	qt	JJ	_	17	attr	_	_
17	interval	interval	NN	_	13	ppmod	_	_
18	on	on	IN	_	20	case	_	_
19	the	the	DT	_	20	det	_	_
20	ECG	ecg	NN	_	17	ppmod	_	_
21	.	.	.	_	2	p	_	_

1	Therefore	therefore	RB	_	10	adv	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	administration	administration	NN	_	10	dep	_	_
4	of	of	IN	_	6	case	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	tablets	tablet	NNS	_	3	ppmod	_	_
7	with	with	IN	_	8	case	_	_
8	drug2	drug0	NN	_	3	ppmod	_	_
9	is	be	VBZ	_	10	aux	_	_
10	contraindicated	contraindicate	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	tablets	tablet	NNS	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	alter	alter	VB	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	metabolism	metabolism	NN	_	4	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	,	,	,	_	8	p	_	_
10	drug3	drug0	NN	_	8	conj	_	_
11	,	,	,	_	10	p	_	_
12	and	and	CC	_	10	cc	_	_
13	drug4	drug0	NN	_	8	conj	_	_
14	,	,	,	_	4	p	_	_
15	resulting	result	VBG	_	4	comp	_	_
16	in	in	IN	_	19	case	_	_
17	elevated	elevated	JJ	_	19	attr	_	_
18	plasma	plasma	NN	_	19	com	_	_
19	concentrations	concentration	NNS	_	15	ppmod	_	_
20	of	of	IN	_	23	case	_	_
21	the	the	DT	_	23	det	_	_
22	latter	latter	JJ	_	23	attr	_	_
23	drugs	drug	NNS	_	19	ppmod	_	_
24	.	.	.	_	4	p	_	_

1	Dosage	dosage	JJ	_	2	attr	_	_
2	adjustment	adjustment	NN	_	5	dep	_	_
3	may	may	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	required	require	VBN	_	0	root	_	_
6	if	if	IN	_	14	mark	_	_
7	drug1	drug0	NN	_	14	dep	_	_
8	,	,	,	_	7	p	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	,	,	,	_	9	p	_	_
11	or	or	CC	_	9	cc	_	_
12	drug3	drug0	NN	_	7	conj	_	_
13	are	be	VBP	_	14	aux	_	_
14	given	give	VBN	_	5	comp	_	_
15	concomitantly	concomitantly	RB	_	14	adv	_	_
16	with	with	IN	_	18	case	_	_
17	drug4	drug0	JJ	_	18	attr	_	_
18	Tablets	tablet	NNS	_	14	ppmod	_	_
19	.	.	.	_	5	p	_	_

1	Coadministration	coadministration	NN	_	10	dep	_	_
2	of	of	IN	_	4	case	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	Tablets	tablet	NNS	_	1	ppmod	_	_
5	with	with	IN	_	6	case	_	_
6	drug2	drug0	NN	_	1	ppmod	_	_
7	or	or	CC	_	6	cc	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	has	have	VBZ	_	10	aux	_	_
10	resulted	result	VBD	_	0	root	_	_
11	in	in	IN	_	14	case	_	_
12	elevated	elevated	JJ	_	14	attr	_	_
13	plasma	plasma	NN	_	14	com	_	_
14	concentrations	concentration	NNS	_	10	ppmod	_	_
15	of	of	IN	_	19	case	_	_
16	the	the	DT	_	19	det	_	_
17	latter	latter	JJ	_	19	attr	_	_
18	two	#crd#	CD	_	19	num	_	_
19	drugs	drug	NNS	_	14	ppmod	_	_
20	.	.	.	_	10	p	_	_

1	This	this	DT	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	potentiate	potentiate	VB	_	0	root	_	_
4	and	and	CC	_	3	cc	_	_
5	prolong	prolong	VB	_	3	conj	_	_
6	hypnotic	hypnotic	NN	_	5	obj	_	_
7	and	and	CC	_	6	cc	_	_
8	sedative	sedative	JJ	_	9	attr	_	_
9	effects	effect	NNS	_	6	conj	_	_
10	,	,	,	_	6	p	_	_
11	especially	especially	RB	_	6	adv	_	_
12	with	with	IN	_	14	case	_	_
13	repeated	repeated	JJ	_	14	attr	_	_
14	dosing	dosing	NN	_	6	ppmod	_	_
15	or	or	CC	_	14	cc	_	_
16	chronic	chronic	JJ	_	17	attr	_	_
17	administration	administration	NN	_	14	conj	_	_
18	of	of	IN	_	20	case	_	_
19	these	these	DT	_	20	det	_	_
20	agents	agent	NNS	_	14	ppmod	_	_
21	.	.	.	_	3	p	_	_

1	These	these	DT	_	2	det	_	_
2	agents	agent	NNS	_	6	dep	_	_
3	should	should	MD	_	6	modal	_	_
4	not	not	RB	_	6	neg	_	_
5	be	be	VB	_	6	aux	_	_
6	used	use	VBN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	6	ppmod	_	_
9	treated	treat	VBN	_	8	acl	_	_
10	with	with	IN	_	12	case	_	_
11	drug1	drug0	JJ	_	12	attr	_	_
12	Tablets	tablet	NNS	_	9	ppmod	_	_
13	.	.	.	_	6	p	_	_

1	If	if	IN	_	4	mark	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	administered	administer	VBN	_	10	advcl	_	_
5	parenterally	parenterally	RB	_	4	adv	_	_
6	,	,	,	_	10	p	_	_
7	special	special	JJ	_	8	attr	_	_
8	precaution	precaution	NN	_	10	dep	_	_
9	is	be	VBZ	_	10	aux	_	_
10	required	require	VBN	_	0	root	_	_
11	since	since	IN	_	16	mark	_	_
12	the	the	DT	_	14	det	_	_
13	sedative	sedative	JJ	_	14	attr	_	_
14	effect	effect	NN	_	16	dep	_	_
15	may	may	MD	_	16	modal	_	_
16	be	be	VB	_	10	comp	_	_
17	prolonged	prolonged	JJ	_	16	dep	_	_
18	.	.	.	_	10	p	_	_

1	Rare	rare	JJ	_	2	attr	_	_
2	cases	case	NNS	_	11	dep	_	_
3	of	of	IN	_	6	case	_	_
4	elevated	elevated	JJ	_	6	attr	_	_
5	plasma	plasma	NN	_	6	com	_	_
6	concentrations	concentration	NNS	_	2	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	have	have	VBP	_	11	aux	_	_
10	been	be	VBN	_	11	aux	_	_
11	reported	report	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	It	it	PRP	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	not	not	RB	_	2	neg	_	_
4	clear	clear	JJ	_	2	dep	_	_
5	whether	whether	IN	_	7	mark	_	_
6	this	this	DT	_	7	dep	_	_
7	was	be	VBD	_	2	comp	_	_
8	due	due	JJ	_	7	dep	_	_
9	to	to	TO	_	11	aux	_	_
10	the	the	DT	_	11	det	_	_
11	combination	combination	NN	_	8	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	therapy	therapy	NN	_	11	ppmod	_	_
14	.	.	.	_	2	p	_	_

1	It	it	PRP	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	,	,	,	_	2	p	_	_
4	therefore	therefore	RB	_	2	adv	_	_
5	,	,	,	_	2	p	_	_
6	advisable	advisable	JJ	_	2	dep	_	_
7	to	to	TO	_	8	aux	_	_
8	monitor	monitor	VB	_	6	comp	_	_
9	drug1	drug0	NN	_	10	com	_	_
10	concentrations	concentration	NNS	_	8	obj	_	_
11	in	in	IN	_	12	case	_	_
12	patients	patient	NNS	_	10	ppmod	_	_
13	receiving	receive	VBG	_	12	acl	_	_
14	drug2	drug0	NN	_	13	obj	_	_
15	.	.	.	_	2	p	_	_

1	When	when	WRB	_	2	adv	_	_
2	taken	take	VBN	_	9	advcl	_	_
3	orally	orally	RB	_	2	adv	_	_
4	,	,	,	_	9	p	_	_
5	drug1	drug0	NN	_	9	dep	_	_
6	like	like	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	may	may	MD	_	9	modal	_	_
9	enhance	enhance	VB	_	0	root	_	_
10	the	the	DT	_	12	det	_	_
11	anticoagulant	anticoagulant	JJ	_	12	attr	_	_
12	effect	effect	NN	_	9	obj	_	_
13	of	of	IN	_	16	case	_	_
14	drug3	drug0	JJ	_	16	attr	_	_
15	-like	-like	JJ	_	16	attr	_	_
16	drugs	drug	NNS	_	12	ppmod	_	_
17	.	.	.	_	9	p	_	_

1	In	in	IN	_	3	case	_	_
2	simultaneous	simultaneous	JJ	_	3	attr	_	_
3	treatment	treatment	NN	_	15	ppmod	_	_
4	with	with	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	,	,	,	_	15	p	_	_
9	the	the	DT	_	11	det	_	_
10	anticoagulant	anticoagulant	JJ	_	11	attr	_	_
11	effect	effect	NN	_	15	dep	_	_
12	should	should	MD	_	15	modal	_	_
13	be	be	VB	_	15	aux	_	_
14	carefully	carefully	RB	_	15	adv	_	_
15	titrated	titrate	VBN	_	0	root	_	_
16	and	and	CC	_	15	cc	_	_
17	monitored	monitor	VBN	_	15	conj	_	_
18	.	.	.	_	15	p	_	_

1	Because	because	IN	_	6	mark	_	_
2	severe	severe	JJ	_	3	attr	_	_
3	hypoglycemia	hypoglycemia	NN	_	6	dep	_	_
4	has	have	VBZ	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	reported	report	VBN	_	42	advcl	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	6	ppmod	_	_
9	concomitantly	concomitantly	RB	_	10	adv	_	_
10	receiving	receive	VBG	_	8	acl	_	_
11	oral	oral	JJ	_	12	attr	_	_
12	drug1	drug0	NN	_	10	obj	_	_
13	(	-lrb-	-LRB-	_	15	p	_	_
14	an	an	DT	_	15	det	_	_
15	drug2	drug0	NN	_	12	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	and	and	CC	_	12	cc	_	_
18	oral	oral	JJ	_	19	attr	_	_
19	drug3	drug0	NN	_	12	conj	_	_
20	,	,	,	_	42	p	_	_
21	such	such	PDT	_	24	det	_	_
22	a	a	DT	_	24	det	_	_
23	potential	potential	JJ	_	24	attr	_	_
24	interaction	interaction	NN	_	42	dep	_	_
25	involving	involve	VBG	_	24	acl	_	_
26	the	the	DT	_	28	det	_	_
27	latter	latter	JJ	_	28	attr	_	_
28	agents	agent	NNS	_	25	obj	_	_
29	when	when	WRB	_	30	adv	_	_
30	used	use	VBN	_	28	relcl	_	_
31	concomitantly	concomitantly	RB	_	30	adv	_	_
32	with	with	IN	_	34	case	_	_
33	drug4	drug0	NN	_	34	com	_	_
34	tablets	tablet	NNS	_	30	ppmod	_	_
35	(	-lrb-	-LRB-	_	37	p	_	_
36	an	an	DT	_	37	det	_	_
37	drug5	drug0	NN	_	34	prn	_	_
38	)	-rrb-	-RRB-	_	37	p	_	_
39	can	can	MD	_	42	modal	_	_
40	not	not	RB	_	42	neg	_	_
41	be	be	VB	_	42	aux	_	_
42	ruled	rule	VBN	_	0	root	_	_
43	out	out	RP	_	42	prt	_	_
44	.	.	.	_	42	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	administration	administration	NN	_	9	dep	_	_
3	of	of	IN	_	5	case	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	tablets	tablet	NNS	_	2	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drug2	drug0	NN	_	2	ppmod	_	_
8	may	may	MD	_	9	modal	_	_
9	alter	alter	VB	_	0	root	_	_
10	the	the	DT	_	11	det	_	_
11	metabolism	metabolism	NN	_	9	obj	_	_
12	of	of	IN	_	13	case	_	_
13	one	#crd#	CD	_	11	ppmod	_	_
14	or	or	CC	_	13	cc	_	_
15	both	both	DT	_	13	conj	_	_
16	of	of	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	drugs	drug	NNS	_	13	ppmod	_	_
19	.	.	.	_	9	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	suggested	suggest	VBN	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	monitor	monitor	VB	_	3	comp	_	_
6	both	both	CC	_	7	cc	_	_
7	drug1	drug0	NN	_	5	obj	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	.	.	.	_	3	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	administration	administration	NN	_	8	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	with	with	IN	_	7	case	_	_
6	drug2	drug0	NN	_	7	com	_	_
7	tablets	tablet	NNS	_	2	ppmod	_	_
8	reduces	reduce	VBZ	_	0	root	_	_
9	the	the	DT	_	11	det	_	_
10	blood	blood	NN	_	11	com	_	_
11	levels	level	NNS	_	8	obj	_	_
12	of	of	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	latter	latter	JJ	_	11	ppmod	_	_
15	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	7	dep	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	drug2	drug0	NN	_	1	prn	_	_
4	)	-rrb-	-RRB-	_	3	p	_	_
5	is	be	VBZ	_	7	aux	_	_
6	also	also	RB	_	7	adv	_	_
7	reported	report	VBN	_	0	root	_	_
8	to	to	TO	_	9	aux	_	_
9	affect	affect	VB	_	7	comp	_	_
10	drug3	drug0	NN	_	11	com	_	_
11	concentrations	concentration	NNS	_	9	obj	_	_
12	adversely	adversely	RB	_	9	adv	_	_
13	.	.	.	_	7	p	_	_

1	These	these	DT	_	2	det	_	_
2	drugs	drug	NNS	_	6	dep	_	_
3	should	should	MD	_	6	modal	_	_
4	not	not	RB	_	6	neg	_	_
5	be	be	VB	_	6	aux	_	_
6	given	give	VBN	_	0	root	_	_
7	concomitantly	concomitantly	RB	_	6	adv	_	_
8	.	.	.	_	6	p	_	_

1	After	after	IN	_	3	case	_	_
2	the	the	DT	_	3	det	_	_
3	coadministration	coadministration	NN	_	28	ppmod	_	_
4	of	of	IN	_	8	case	_	_
5	200	0	CD	_	6	num	_	_
6	mg	mg	NN	_	8	attr	_	_
7	oral	oral	JJ	_	8	attr	_	_
8	drug1	drug0	NN	_	3	ppmod	_	_
9	twice	twice	RB	_	10	com	_	_
10	daily	daily	RB	_	8	adv	_	_
11	and	and	CC	_	8	cc	_	_
12	one	#crd#	CD	_	15	num	_	_
13	20	0	CD	_	14	num	_	_
14	mg	mg	NN	_	15	com	_	_
15	dose	dose	NN	_	8	conj	_	_
16	of	of	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	to	to	TO	_	20	aux	_	_
19	11	0	CD	_	20	num	_	_
20	subjects	subject	NNS	_	15	ppmod	_	_
21	,	,	,	_	28	p	_	_
22	the	the	DT	_	23	det	_	_
23	AUC	auc	NN	_	28	dep	_	_
24	and	and	CC	_	23	cc	_	_
25	Cmax	cmax	NN	_	23	conj	_	_
26	of	of	IN	_	27	case	_	_
27	drug3	drug0	NN	_	23	ppmod	_	_
28	averaged	average	VBD	_	0	root	_	_
29	302	0	CD	_	28	obj	_	_
30	%	%	NN	_	29	meta	_	_
31	(	-lrb-	-LRB-	_	33	p	_	_
32	142	0	CD	_	33	num	_	_
33	S.D.	s.d.	NN	_	29	prn	_	_
34	)	-rrb-	-RRB-	_	33	p	_	_
35	and	and	CC	_	29	cc	_	_
36	251	0	CD	_	29	conj	_	_
37	%	%	NN	_	36	meta	_	_
38	(	-lrb-	-LRB-	_	40	p	_	_
39	68	0	CD	_	40	num	_	_
40	S.D.	s.d.	NN	_	36	prn	_	_
41	)	-rrb-	-RRB-	_	40	p	_	_
42	,	,	,	_	36	p	_	_
43	respectively	respectively	RB	_	36	adv	_	_
44	,	,	,	_	36	p	_	_
45	of	of	IN	_	46	case	_	_
46	those	those	DT	_	29	conj	_	_
47	obtained	obtain	VBN	_	46	acl	_	_
48	after	after	IN	_	49	case	_	_
49	co-treatment	co-treatment	NN	_	47	ppmod	_	_
50	with	with	IN	_	51	case	_	_
51	placebo	placebo	NN	_	49	ppmod	_	_
52	.	.	.	_	28	p	_	_

1	The	the	DT	_	2	det	_	_
2	AUC	auc	NN	_	12	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	Cmax	cmax	NN	_	2	conj	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	2	ppmod	_	_
7	,	,	,	_	6	p	_	_
8	an	an	DT	_	10	det	_	_
9	active	active	JJ	_	10	attr	_	_
10	metabolite	metabolite	NN	_	6	appo	_	_
11	,	,	,	_	6	p	_	_
12	averaged	average	VBD	_	0	root	_	_
13	155	0	CD	_	12	obj	_	_
14	%	%	NN	_	13	meta	_	_
15	(	-lrb-	-LRB-	_	17	p	_	_
16	27	0	CD	_	17	num	_	_
17	S.D.	s.d.	NN	_	13	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	and	and	CC	_	13	cc	_	_
20	141	0	CD	_	13	conj	_	_
21	%	%	NN	_	20	meta	_	_
22	(	-lrb-	-LRB-	_	24	p	_	_
23	35	0	CD	_	24	num	_	_
24	S.D.	s.d.	NN	_	20	prn	_	_
25	)	-rrb-	-RRB-	_	24	p	_	_
26	,	,	,	_	20	p	_	_
27	respectively	respectively	RB	_	13	conj	_	_
28	.	.	.	_	12	p	_	_

1	However	however	RB	_	7	adv	_	_
2	,	,	,	_	7	p	_	_
3	no	no	DT	_	5	det	_	_
4	related	related	JJ	_	5	attr	_	_
5	changes	change	NNS	_	7	dep	_	_
6	were	be	VBD	_	7	aux	_	_
7	noted	note	VBN	_	0	root	_	_
8	in	in	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	QT0	qt0	NNS	_	7	ppmod	_	_
11	on	on	IN	_	12	case	_	_
12	ECG	ecg	NN	_	10	ppmod	_	_
13	taken	take	VBN	_	12	acl	_	_
14	at	at	IN	_	21	case	_	_
15	2	0	CD	_	21	num	_	_
16	,	,	,	_	15	p	_	_
17	6	0	CD	_	15	conj	_	_
18	,	,	,	_	17	p	_	_
19	and	and	CC	_	17	cc	_	_
20	24	0	CD	_	15	conj	_	_
21	hours	hour	NNS	_	13	ppmod	_	_
22	after	after	IN	_	24	case	_	_
23	the	the	DT	_	24	det	_	_
24	coadministration	coadministration	NN	_	21	ppmod	_	_
25	.	.	.	_	7	p	_	_

1	Also	also	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	there	there	EX	_	4	dep	_	_
4	were	be	VBD	_	0	root	_	_
5	no	no	DT	_	8	det	_	_
6	clinically	clinically	RB	_	7	adv	_	_
7	significant	significant	JJ	_	8	attr	_	_
8	differences	difference	NNS	_	4	obj	_	_
9	in	in	IN	_	11	case	_	_
10	adverse	adverse	JJ	_	11	attr	_	_
11	events	event	NNS	_	8	ppmod	_	_
12	when	when	WRB	_	15	adv	_	_
13	drug1	drug0	NN	_	15	dep	_	_
14	was	be	VBD	_	15	aux	_	_
15	administered	administer	VBN	_	4	comp	_	_
16	with	with	IN	_	15	ppmod	_	_
17	or	or	CC	_	16	cc	_	_
18	without	without	IN	_	19	case	_	_
19	drug2	drug0	NN	_	16	conj	_	_
20	.	.	.	_	4	p	_	_

1	Rare	rare	JJ	_	2	attr	_	_
2	cases	case	NNS	_	11	dep	_	_
3	of	of	IN	_	6	case	_	_
4	a	a	DT	_	6	det	_	_
5	disulfiram-like	disulfiram-like	JJ	_	6	attr	_	_
6	reaction	reaction	NN	_	2	ppmod	_	_
7	to	to	TO	_	8	aux	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	have	have	VBP	_	11	aux	_	_
10	been	be	VBN	_	11	aux	_	_
11	reported	report	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	These	these	DT	_	2	det	_	_
2	experiences	experience	NNS	_	5	dep	_	_
3	have	have	VBP	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	characterized	characterize	VBN	_	0	root	_	_
6	by	by	IN	_	7	case	_	_
7	flushing	flushing	NN	_	5	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	rash	rash	NN	_	7	conj	_	_
10	,	,	,	_	9	p	_	_
11	peripheral	peripheral	JJ	_	12	attr	_	_
12	edema	edema	NN	_	7	conj	_	_
13	,	,	,	_	12	p	_	_
14	nausea	nausea	NN	_	7	conj	_	_
15	,	,	,	_	14	p	_	_
16	and	and	CC	_	14	cc	_	_
17	headache	headache	NN	_	7	conj	_	_
18	.	.	.	_	5	p	_	_

1	Symptoms	symptom	NNS	_	2	dep	_	_
2	resolved	resolve	VBN	_	0	root	_	_
3	within	within	IN	_	6	case	_	_
4	a	a	DT	_	6	det	_	_
5	few	few	JJ	_	6	attr	_	_
6	hours	hour	NNS	_	2	ppmod	_	_
7	.	.	.	_	2	p	_	_

1	The	the	DT	_	3	det	_	_
2	daily	daily	JJ	_	3	attr	_	_
3	dose	dose	NN	_	8	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	should	should	MD	_	8	modal	_	_
7	not	not	RB	_	8	neg	_	_
8	exceed	exceed	VB	_	0	root	_	_
9	7.5	0	CD	_	10	num	_	_
10	mg	mg	NN	_	8	obj	_	_
11	when	when	WRB	_	12	adv	_	_
12	coadministered	coadministered	VBN	_	8	comp	_	_
13	with	with	IN	_	16	case	_	_
14	potent	potent	JJ	_	16	attr	_	_
15	CYP3A4	cyp0a0	JJ	_	16	attr	_	_
16	inhibitors	inhibitor	NNS	_	12	ppmod	_	_
17	(	-lrb-	-LRB-	_	20	p	_	_
18	e.g.	e.g.	FW	_	20	adv	_	_
19	,	,	,	_	20	p	_	_
20	drug2	drug0	NN	_	16	prn	_	_
21	,	,	,	_	20	p	_	_
22	drug3	drug0	NN	_	20	conj	_	_
23	,	,	,	_	22	p	_	_
24	drug4	drug0	NN	_	20	conj	_	_
25	,	,	,	_	24	p	_	_
26	drug5	drug0	NN	_	20	conj	_	_
27	,	,	,	_	26	p	_	_
28	drug6	drug0	NN	_	20	conj	_	_
29	and	and	CC	_	28	cc	_	_
30	nefazadone	nefazadone	NN	_	20	conj	_	_
31	)	-rrb-	-RRB-	_	20	p	_	_
32	.	.	.	_	8	p	_	_

1	Caution	caution	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	taken	take	VBN	_	0	root	_	_
5	when	when	WRB	_	8	adv	_	_
6	drug1	drug0	NN	_	8	dep	_	_
7	is	be	VBZ	_	8	aux	_	_
8	used	use	VBN	_	4	comp	_	_
9	concomitantly	concomitantly	RB	_	8	adv	_	_
10	with	with	IN	_	11	case	_	_
11	medications	medication	NNS	_	8	ppmod	_	_
12	that	that	WDT	_	15	dep	_	_
13	are	be	VBP	_	15	aux	_	_
14	predominantly	predominantly	RB	_	15	adv	_	_
15	metabolized	metabolize	VBN	_	11	advcl	_	_
16	by	by	IN	_	17	case	_	_
17	CYP2D6	cyp0d0	NN	_	15	ppmod	_	_
18	and	and	CC	_	15	cc	_	_
19	which	which	WDT	_	20	dep	_	_
20	have	have	VBP	_	15	conj	_	_
21	a	a	DT	_	24	det	_	_
22	narrow	narrow	JJ	_	24	attr	_	_
23	therapeutic	therapeutic	JJ	_	24	attr	_	_
24	window	window	NN	_	20	obj	_	_
25	,	,	,	_	11	p	_	_
26	such	such	JJ	_	28	adv	_	_
27	as	as	IN	_	28	case	_	_
28	drug2	drug0	NN	_	11	ppmod	_	_
29	,	,	,	_	28	p	_	_
30	drug3	drug0	NN	_	28	conj	_	_
31	and	and	CC	_	30	cc	_	_
32	drug4	drug0	NN	_	28	conj	_	_
33	(	-lrb-	-LRB-	_	34	p	_	_
34	see	see	VB	_	28	prn	_	_
35	CLINICAL	clinical	JJ	_	36	attr	_	_
36	PHARMACOLOGY	pharmacology	NN	_	34	obj	_	_
37	)	-rrb-	-RRB-	_	34	p	_	_
38	.	.	.	_	4	p	_	_

1	The	the	DT	_	3	det	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	use	use	NN	_	10	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	with	with	IN	_	8	case	_	_
7	other	other	JJ	_	8	attr	_	_
8	drug2	drug0	NNS	_	3	ppmod	_	_
9	may	may	MD	_	10	modal	_	_
10	increase	increase	VB	_	0	root	_	_
11	the	the	DT	_	12	det	_	_
12	frequency	frequency	NN	_	10	obj	_	_
13	and/or	and/or	CC	_	12	cc	_	_
14	severity	severity	NN	_	12	conj	_	_
15	of	of	IN	_	17	case	_	_
16	dry	dry	JJ	_	17	attr	_	_
17	mouth	mouth	NN	_	12	ppmod	_	_
18	,	,	,	_	17	p	_	_
19	constipation	constipation	NN	_	17	conj	_	_
20	,	,	,	_	19	p	_	_
21	blurred	blurred	JJ	_	22	attr	_	_
22	vision	vision	NN	_	17	conj	_	_
23	and	and	CC	_	22	cc	_	_
24	other	other	JJ	_	27	attr	_	_
25	anticholinergic	anticholinergic	JJ	_	27	attr	_	_
26	pharmacological	pharmacological	JJ	_	27	attr	_	_
27	effects	effect	NNS	_	17	conj	_	_
28	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	may	may	MD	_	4	modal	_	_
3	potentially	potentially	RB	_	4	adv	_	_
4	alter	alter	VB	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	absorption	absorption	NN	_	4	obj	_	_
7	of	of	IN	_	11	case	_	_
8	some	some	DT	_	11	det	_	_
9	concomitantly	concomitantly	RB	_	10	adv	_	_
10	administered	administer	VBN	_	11	attr	_	_
11	drugs	drug	NNS	_	6	ppmod	_	_
12	due	due	JJ	_	11	attr	_	_
13	to	to	TO	_	14	aux	_	_
14	effects	effect	NNS	_	12	ppmod	_	_
15	on	on	IN	_	17	case	_	_
16	gastrointestinal	gastrointestinal	JJ	_	17	attr	_	_
17	motility	motility	NN	_	14	ppmod	_	_
18	.	.	.	_	4	p	_	_

1	Drug	drug	NN	_	5	com	_	_
2	Laboratory	laboratory	NN	_	5	com	_	_
3	Test	test	NN	_	5	com	_	_
4	Interactions	interaction	NNS	_	5	com	_	_
5	Interactions	interaction	NNS	_	14	dep	_	_
6	between	between	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	laboratory	laboratory	NN	_	10	com	_	_
10	tests	test	NNS	_	7	conj	_	_
11	have	have	VBP	_	14	aux	_	_
12	not	not	RB	_	14	neg	_	_
13	been	be	VBN	_	14	aux	_	_
14	studied	study	VBN	_	0	root	_	_
15	.	.	.	_	14	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	5	attr	_	_
3	drug	drug	NN	_	5	com	_	_
4	metabolism	metabolism	NN	_	5	com	_	_
5	studies	study	NNS	_	6	dep	_	_
6	indicate	indicate	VBP	_	0	root	_	_
7	that	that	IN	_	11	mark	_	_
8	drug1	drug0	NN	_	11	dep	_	_
9	is	be	VBZ	_	11	aux	_	_
10	predominantly	predominantly	RB	_	11	adv	_	_
11	metabolized	metabolize	VBN	_	6	comp	_	_
12	by	by	IN	_	15	case	_	_
13	the	the	DT	_	15	det	_	_
14	cytochrome	cytochrome	NN	_	15	com	_	_
15	P450	p0	NN	_	11	ppmod	_	_
16	isozyme	isozyme	NN	_	17	com	_	_
17	CYP2C9	cyp0c0	NN	_	15	attr	_	_
18	(	-lrb-	-LRB-	_	19	p	_	_
19	70	0	CD	_	17	num	_	_
20	%	%	NN	_	19	meta	_	_
21	)	-rrb-	-RRB-	_	19	p	_	_
22	and	and	CC	_	26	cc	_	_
23	to	to	TO	_	26	aux	_	_
24	a	a	DT	_	26	det	_	_
25	lesser	less	JJR	_	26	attr	_	_
26	extent	extent	NN	_	11	ppmod	_	_
27	CYP3A4	cyp0a0	NN	_	26	obj	_	_
28	(	-lrb-	-LRB-	_	29	p	_	_
29	30	0	CD	_	27	num	_	_
30	%	%	NN	_	29	meta	_	_
31	)	-rrb-	-RRB-	_	29	p	_	_
32	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	a	a	DT	_	5	det	_	_
4	potential	potential	JJ	_	5	attr	_	_
5	inhibitor	inhibitor	NN	_	2	obj	_	_
6	of	of	IN	_	9	case	_	_
7	the	the	DT	_	9	det	_	_
8	CYP2C9	cyp0c0	NN	_	9	com	_	_
9	isoenzyme	isoenzyme	NN	_	5	ppmod	_	_
10	in	in	FW	_	11	adv	_	_
11	vivo	vivo	FW	_	2	adv	_	_
12	as	as	IN	_	13	mark	_	_
13	indicated	indicate	VBN	_	2	comp	_	_
14	by	by	IN	_	16	case	_	_
15	its	its	PRP$	_	16	poss	_	_
16	ability	ability	NN	_	13	ppmod	_	_
17	to	to	TO	_	18	aux	_	_
18	inhibit	inhibit	VB	_	16	acl	_	_
19	the	the	DT	_	22	det	_	_
20	in	in	FW	_	21	adv	_	_
21	vitro	vitro	FW	_	22	attr	_	_
22	metabolism	metabolism	NN	_	18	obj	_	_
23	of	of	IN	_	24	case	_	_
24	drug2	drug0	NN	_	22	ppmod	_	_
25	.	.	.	_	2	p	_	_

1	Inhibition	inhibition	NN	_	8	dep	_	_
2	of	of	IN	_	5	case	_	_
3	CYP3A4	cyp0a0	JJ	_	5	attr	_	_
4	metabolic	metabolic	JJ	_	5	attr	_	_
5	reactions	reaction	NNS	_	1	ppmod	_	_
6	was	be	VBD	_	8	aux	_	_
7	not	not	RB	_	8	neg	_	_
8	detected	detect	VBN	_	0	root	_	_
9	in	in	IN	_	12	case	_	_
10	in	in	FW	_	11	adv	_	_
11	vitro	vitro	FW	_	12	attr	_	_
12	experiments	experiment	NNS	_	8	ppmod	_	_
13	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	9	case	_	_
4	a	a	DT	_	9	det	_	_
5	randomized	randomized	JJ	_	7	adv	_	_
6	,	,	,	_	7	p	_	_
7	multiple-dose	multiple-dose	JJ	_	9	attr	_	_
8	crossover	crossover	NN	_	9	com	_	_
9	study	study	NN	_	17	ppmod	_	_
10	,	,	,	_	17	p	_	_
11	patients	patient	NNS	_	17	dep	_	_
12	with	with	IN	_	15	case	_	_
13	Type	type	NN	_	15	attr	_	_
14	2	0	CD	_	15	num	_	_
15	diabetes	diabetes	NNS	_	11	ppmod	_	_
16	were	be	VBD	_	17	aux	_	_
17	administered	administer	VBN	_	1	acl	_	_
18	120	0	CD	_	22	num	_	_
19	mg	mg	NN	_	22	attr	_	_
20	drug2	drug0	NN	_	22	attr	_	_
21	three	#crd#	CD	_	22	num	_	_
22	times	time	NNS	_	17	obj	_	_
23	a	a	DT	_	24	det	_	_
24	day	day	NN	_	22	appo	_	_
25	before	before	IN	_	26	case	_	_
26	meals	meals	NN	_	24	ppmod	_	_
27	for	for	IN	_	29	case	_	_
28	1	0	CD	_	29	num	_	_
29	day	day	NN	_	24	ppmod	_	_
30	in	in	IN	_	31	case	_	_
31	combination	combination	NN	_	17	ppmod	_	_
32	with	with	IN	_	35	case	_	_
33	drug3	drug0	NN	_	35	attr	_	_
34	10	0	CD	_	35	num	_	_
35	mg	mg	NN	_	31	ppmod	_	_
36	daily	daily	RB	_	35	adv	_	_
37	.	.	.	_	1	p	_	_

1	There	there	EX	_	2	dep	_	_
2	were	be	VBD	_	0	root	_	_
3	no	no	DT	_	6	det	_	_
4	clinically	clinically	RB	_	5	adv	_	_
5	relevant	relevant	JJ	_	6	attr	_	_
6	alterations	alteration	NNS	_	2	obj	_	_
7	in	in	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	pharmacokinetics	pharmacokinetics	NNS	_	6	ppmod	_	_
10	of	of	IN	_	12	case	_	_
11	either	either	DT	_	12	det	_	_
12	agent	agent	NN	_	9	ppmod	_	_
13	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	When	when	WRB	_	13	adv	_	_
4	drug2	drug0	NN	_	6	attr	_	_
5	120	0	CD	_	6	num	_	_
6	mg	mg	NN	_	13	dep	_	_
7	three	#crd#	CD	_	8	num	_	_
8	times	time	NNS	_	9	advnp	_	_
9	daily	daily	RB	_	6	adv	_	_
10	before	before	IN	_	11	case	_	_
11	meals	meals	NN	_	9	ppmod	_	_
12	was	be	VBD	_	13	aux	_	_
13	administered	administer	VBN	_	31	advcl	_	_
14	in	in	IN	_	15	case	_	_
15	combination	combination	NN	_	13	ppmod	_	_
16	with	with	IN	_	21	case	_	_
17	drug3	drug0	NN	_	21	attr	_	_
18	500	0	CD	_	21	num	_	_
19	mg	mg	NN	_	21	attr	_	_
20	three	#crd#	CD	_	21	num	_	_
21	times	time	NNS	_	15	ppmod	_	_
22	daily	daily	JJ	_	21	attr	_	_
23	to	to	TO	_	24	aux	_	_
24	patients	patient	NNS	_	22	ppmod	_	_
25	with	with	IN	_	28	case	_	_
26	Type	type	NN	_	28	attr	_	_
27	2	0	CD	_	28	num	_	_
28	diabetes	diabetes	NNS	_	24	ppmod	_	_
29	,	,	,	_	31	p	_	_
30	there	there	EX	_	31	dep	_	_
31	were	be	VBD	_	1	acl	_	_
32	no	no	DT	_	35	det	_	_
33	clinically	clinically	RB	_	34	adv	_	_
34	relevant	relevant	JJ	_	35	attr	_	_
35	changes	change	NNS	_	31	obj	_	_
36	in	in	IN	_	38	case	_	_
37	the	the	DT	_	38	det	_	_
38	pharmacokinetics	pharmacokinetics	NNS	_	35	ppmod	_	_
39	of	of	IN	_	41	case	_	_
40	either	either	DT	_	41	det	_	_
41	agent	agent	NN	_	38	ppmod	_	_
42	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	When	when	WRB	_	10	adv	_	_
4	drug2	drug0	NN	_	6	attr	_	_
5	120	0	CD	_	6	num	_	_
6	mg	mg	NN	_	10	dep	_	_
7	before	before	IN	_	8	case	_	_
8	meals	meals	NN	_	6	ppmod	_	_
9	was	be	VBD	_	10	aux	_	_
10	administered	administer	VBN	_	25	advcl	_	_
11	in	in	IN	_	12	case	_	_
12	combination	combination	NN	_	10	ppmod	_	_
13	with	with	IN	_	17	case	_	_
14	a	a	DT	_	17	det	_	_
15	single	single	JJ	_	17	attr	_	_
16	1-mg	0-mg	JJ	_	17	attr	_	_
17	dose	dose	NN	_	12	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug3	drug0	NN	_	17	ppmod	_	_
20	to	to	TO	_	22	aux	_	_
21	healthy	healthy	JJ	_	22	attr	_	_
22	volunteers	volunteer	NNS	_	17	ppmod	_	_
23	,	,	,	_	25	p	_	_
24	there	there	EX	_	25	dep	_	_
25	were	be	VBD	_	1	acl	_	_
26	no	no	DT	_	29	det	_	_
27	clinically	clinically	RB	_	28	adv	_	_
28	relevant	relevant	JJ	_	29	attr	_	_
29	changes	change	NNS	_	25	obj	_	_
30	in	in	IN	_	32	case	_	_
31	the	the	DT	_	32	det	_	_
32	pharmacokinetics	pharmacokinetics	NNS	_	29	ppmod	_	_
33	of	of	IN	_	35	case	_	_
34	either	either	DT	_	35	det	_	_
35	agent	agent	NN	_	32	ppmod	_	_
36	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	When	when	WRB	_	7	adv	_	_
4	healthy	healthy	JJ	_	5	attr	_	_
5	subjects	subject	NNS	_	7	dep	_	_
6	were	be	VBD	_	7	aux	_	_
7	administered	administer	VBN	_	34	advcl	_	_
8	drug2	drug0	NN	_	12	attr	_	_
9	120	0	CD	_	12	num	_	_
10	mg	mg	NN	_	12	attr	_	_
11	three	#crd#	CD	_	12	num	_	_
12	times	time	NNS	_	13	advnp	_	_
13	daily	daily	RB	_	7	adv	_	_
14	before	before	IN	_	15	case	_	_
15	meals	meals	NN	_	7	ppmod	_	_
16	for	for	IN	_	18	case	_	_
17	four	#crd#	CD	_	18	num	_	_
18	days	day	NNS	_	7	ppmod	_	_
19	in	in	IN	_	20	case	_	_
20	combination	combination	NN	_	18	ppmod	_	_
21	with	with	IN	_	24	case	_	_
22	a	a	DT	_	24	det	_	_
23	single	single	JJ	_	24	attr	_	_
24	dose	dose	NN	_	20	ppmod	_	_
25	of	of	IN	_	28	case	_	_
26	drug3	drug0	NN	_	28	attr	_	_
27	30	0	CD	_	28	num	_	_
28	mg	mg	NN	_	24	ppmod	_	_
29	on	on	IN	_	30	case	_	_
30	day	day	NN	_	28	ppmod	_	_
31	2	0	CD	_	30	num	_	_
32	,	,	,	_	34	p	_	_
33	there	there	EX	_	34	dep	_	_
34	were	be	VBD	_	1	acl	_	_
35	no	no	DT	_	36	det	_	_
36	alterations	alteration	NNS	_	34	obj	_	_
37	in	in	IN	_	39	case	_	_
38	the	the	DT	_	39	det	_	_
39	pharmacokinetics	pharmacokinetics	NNS	_	34	ppmod	_	_
40	of	of	IN	_	42	case	_	_
41	either	either	DT	_	42	det	_	_
42	agent	agent	NN	_	39	ppmod	_	_
43	.	.	.	_	1	p	_	_

1	Prothrombin	prothrombin	NN	_	2	com	_	_
2	time	time	NN	_	5	dep	_	_
3	was	be	VBD	_	5	aux	_	_
4	not	not	RB	_	5	neg	_	_
5	affected	affect	VBN	_	0	root	_	_
6	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Administration	administration	NN	_	25	dep	_	_
4	of	of	IN	_	8	case	_	_
5	morning	morning	NN	_	8	attr	_	_
6	and	and	CC	_	5	cc	_	_
7	lunch	lunch	NN	_	5	conj	_	_
8	doses	dose	NNS	_	3	ppmod	_	_
9	of	of	IN	_	12	case	_	_
10	drug2	drug0	NN	_	12	attr	_	_
11	120	0	CD	_	12	num	_	_
12	mg	mg	NN	_	8	ppmod	_	_
13	in	in	IN	_	14	case	_	_
14	combination	combination	NN	_	12	ppmod	_	_
15	with	with	IN	_	19	case	_	_
16	a	a	DT	_	19	det	_	_
17	single	single	JJ	_	19	attr	_	_
18	75-mg	0-mg	NN	_	19	com	_	_
19	dose	dose	NN	_	14	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	drug3	drug0	NN	_	19	ppmod	_	_
22	in	in	IN	_	24	case	_	_
23	healthy	healthy	JJ	_	24	attr	_	_
24	volunteers	volunteer	NNS	_	19	ppmod	_	_
25	resulted	result	VBD	_	1	acl	_	_
26	in	in	IN	_	29	case	_	_
27	no	no	DT	_	29	det	_	_
28	significant	significant	JJ	_	29	attr	_	_
29	changes	change	NNS	_	25	ppmod	_	_
30	to	to	TO	_	32	aux	_	_
31	the	the	DT	_	32	det	_	_
32	pharmacokinetics	pharmacokinetics	NNS	_	29	ppmod	_	_
33	of	of	IN	_	35	case	_	_
34	either	either	DT	_	35	det	_	_
35	agent	agent	NN	_	32	ppmod	_	_
36	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	highly	highly	RB	_	4	adv	_	_
4	bound	bind	VBN	_	0	root	_	_
5	to	to	TO	_	7	aux	_	_
6	plasma	plasma	NN	_	7	com	_	_
7	proteins	protein	NNS	_	4	ppmod	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	98	0	CD	_	7	num	_	_
10	%	%	NN	_	9	meta	_	_
11	)	-rrb-	-RRB-	_	9	p	_	_
12	,	,	,	_	7	p	_	_
13	mainly	mainly	RB	_	14	adv	_	_
14	albumin	albumin	NN	_	7	appo	_	_
15	.	.	.	_	4	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	4	attr	_	_
3	displacement	displacement	NN	_	4	com	_	_
4	studies	study	NNS	_	33	dep	_	_
5	with	with	IN	_	8	case	_	_
6	highly	highly	RB	_	7	adv	_	_
7	protein-bound	protein-bound	JJ	_	8	attr	_	_
8	drugs	drug	NNS	_	4	ppmod	_	_
9	such	such	JJ	_	11	adv	_	_
10	as	as	IN	_	11	case	_	_
11	drug1	drug0	NN	_	8	ppmod	_	_
12	,	,	,	_	11	p	_	_
13	drug2	drug0	NN	_	11	conj	_	_
14	,	,	,	_	13	p	_	_
15	drug3	drug0	NN	_	11	conj	_	_
16	,	,	,	_	15	p	_	_
17	drug4	drug0	NN	_	11	conj	_	_
18	,	,	,	_	17	p	_	_
19	drug5	drug0	NN	_	11	conj	_	_
20	,	,	,	_	19	p	_	_
21	drug6	drug0	NN	_	11	conj	_	_
22	,	,	,	_	21	p	_	_
23	drug7	drug0	NN	_	11	conj	_	_
24	,	,	,	_	23	p	_	_
25	drug8	drug0	NN	_	11	conj	_	_
26	,	,	,	_	25	p	_	_
27	drug9	drug0	NN	_	11	conj	_	_
28	,	,	,	_	27	p	_	_
29	drug10	drug0	NN	_	11	conj	_	_
30	,	,	,	_	29	p	_	_
31	and	and	CC	_	29	cc	_	_
32	drug11	drug0	NN	_	11	conj	_	_
33	showed	show	VBD	_	0	root	_	_
34	no	no	DT	_	35	det	_	_
35	influence	influence	NN	_	33	obj	_	_
36	on	on	IN	_	38	case	_	_
37	the	the	DT	_	38	det	_	_
38	extent	extent	NN	_	35	ppmod	_	_
39	of	of	IN	_	42	case	_	_
40	drug12	drug0	NN	_	42	com	_	_
41	protein	protein	NN	_	42	com	_	_
42	binding	binding	NN	_	38	ppmod	_	_
43	.	.	.	_	33	p	_	_

1	Similarly	similarly	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	drug1	drug0	NN	_	6	dep	_	_
4	had	have	VBD	_	6	lv	_	_
5	no	no	DT	_	6	det	_	_
6	influence	influence	NN	_	0	root	_	_
7	on	on	IN	_	11	case	_	_
8	the	the	DT	_	11	det	_	_
9	serum	serum	NN	_	11	com	_	_
10	protein	protein	NN	_	11	com	_	_
11	binding	binding	NN	_	6	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	,	,	,	_	13	p	_	_
15	drug3	drug0	NN	_	13	conj	_	_
16	,	,	,	_	15	p	_	_
17	drug4	drug0	NN	_	13	conj	_	_
18	,	,	,	_	17	p	_	_
19	drug5	drug0	NN	_	13	conj	_	_
20	,	,	,	_	19	p	_	_
21	drug6	drug0	NN	_	13	conj	_	_
22	,	,	,	_	21	p	_	_
23	drug7	drug0	NN	_	13	conj	_	_
24	,	,	,	_	23	p	_	_
25	and	and	CC	_	23	cc	_	_
26	drug8	drug0	NN	_	13	conj	_	_
27	in	in	FW	_	28	adv	_	_
28	vitro	vitro	FW	_	6	adv	_	_
29	.	.	.	_	6	p	_	_

1	However	however	RB	_	9	adv	_	_
2	,	,	,	_	9	p	_	_
3	prudent	prudent	JJ	_	4	attr	_	_
4	evaluation	evaluation	NN	_	9	dep	_	_
5	of	of	IN	_	7	case	_	_
6	individual	individual	JJ	_	7	attr	_	_
7	cases	case	NNS	_	4	ppmod	_	_
8	is	be	VBZ	_	9	aux	_	_
9	warranted	warrant	VBN	_	0	root	_	_
10	in	in	IN	_	13	case	_	_
11	the	the	DT	_	13	det	_	_
12	clinical	clinical	JJ	_	13	attr	_	_
13	setting	setting	NN	_	9	ppmod	_	_
14	.	.	.	_	9	p	_	_

1	Certain	certain	JJ	_	2	attr	_	_
2	drugs	drug	NNS	_	17	dep	_	_
3	,	,	,	_	2	p	_	_
4	including	include	VBG	_	5	adv	_	_
5	drug1	drug0	NN	_	2	ppmod	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	drug2	drug0	NN	_	5	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	,	,	,	_	5	p	_	_
10	drug3	drug0	NN	_	5	conj	_	_
11	,	,	,	_	10	p	_	_
12	drug4	drug0	NN	_	5	conj	_	_
13	,	,	,	_	12	p	_	_
14	and	and	CC	_	12	cc	_	_
15	drug5	drug0	NN	_	5	conj	_	_
16	may	may	MD	_	17	modal	_	_
17	potentiate	potentiate	VB	_	0	root	_	_
18	the	the	DT	_	20	det	_	_
19	hypoglycemic	hypoglycemic	JJ	_	20	attr	_	_
20	action	action	NN	_	17	obj	_	_
21	of	of	IN	_	22	case	_	_
22	drug6	drug0	NN	_	20	ppmod	_	_
23	and	and	CC	_	22	cc	_	_
24	other	other	JJ	_	26	attr	_	_
25	oral	oral	JJ	_	26	attr	_	_
26	drug7	drug0	NNS	_	22	conj	_	_
27	.	.	.	_	17	p	_	_

1	Certain	certain	JJ	_	2	attr	_	_
2	drugs	drug	NNS	_	13	dep	_	_
3	including	include	VBG	_	4	adv	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	,	,	,	_	4	p	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	,	,	,	_	6	p	_	_
8	drug3	drug0	NN	_	4	conj	_	_
9	,	,	,	_	8	p	_	_
10	and	and	CC	_	8	cc	_	_
11	drug4	drug0	NN	_	4	conj	_	_
12	may	may	MD	_	13	modal	_	_
13	reduce	reduce	VB	_	0	root	_	_
14	the	the	DT	_	16	det	_	_
15	hypoglycemic	hypoglycemic	JJ	_	16	attr	_	_
16	action	action	NN	_	13	obj	_	_
17	of	of	IN	_	18	case	_	_
18	drug5	drug0	NN	_	16	ppmod	_	_
19	and	and	CC	_	18	cc	_	_
20	other	other	JJ	_	22	attr	_	_
21	oral	oral	JJ	_	22	attr	_	_
22	drug6	drug0	NN	_	18	conj	_	_
23	.	.	.	_	13	p	_	_

1	When	when	WRB	_	5	adv	_	_
2	these	these	DT	_	3	det	_	_
3	drugs	drug	NNS	_	5	dep	_	_
4	are	be	VBP	_	5	aux	_	_
5	administered	administer	VBN	_	18	advcl	_	_
6	to	to	TO	_	5	ppmod	_	_
7	or	or	CC	_	5	cc	_	_
8	withdrawn	withdraw	VBN	_	5	conj	_	_
9	from	from	IN	_	10	case	_	_
10	patients	patient	NNS	_	8	ppmod	_	_
11	receiving	receive	VBG	_	10	acl	_	_
12	drug1	drug0	NN	_	11	obj	_	_
13	,	,	,	_	18	p	_	_
14	the	the	DT	_	15	det	_	_
15	patient	patient	NN	_	18	dep	_	_
16	should	should	MD	_	18	modal	_	_
17	be	be	VB	_	18	aux	_	_
18	observed	observe	VBN	_	0	root	_	_
19	closely	closely	RB	_	18	adv	_	_
20	for	for	IN	_	21	case	_	_
21	changes	change	NNS	_	18	ppmod	_	_
22	in	in	IN	_	24	case	_	_
23	glycemic	glycemic	JJ	_	24	attr	_	_
24	control	control	NN	_	21	ppmod	_	_
25	.	.	.	_	18	p	_	_

1	Additive	additive	JJ	_	3	attr	_	_
2	depressant	depressant	JJ	_	3	attr	_	_
3	effect	effect	NN	_	5	dep	_	_
4	when	when	WRB	_	5	adv	_	_
5	used	use	VBN	_	0	root	_	_
6	with	with	IN	_	8	case	_	_
7	general	general	JJ	_	8	attr	_	_
8	drug1	drug0	NN	_	5	ppmod	_	_
9	,	,	,	_	8	p	_	_
10	drug2	drug0	NN	_	8	conj	_	_
11	,	,	,	_	10	p	_	_
12	drug3	drug0	NN	_	8	conj	_	_
13	,	,	,	_	12	p	_	_
14	drug4	drug0	NN	_	8	conj	_	_
15	,	,	,	_	14	p	_	_
16	drug5	drug0	NN	_	8	conj	_	_
17	,	,	,	_	16	p	_	_
18	and	and	CC	_	16	cc	_	_
19	other	other	JJ	_	20	attr	_	_
20	drug6	drug0	NN	_	8	conj	_	_
21	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	mixing	mixing	NN	_	13	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	with	with	IN	_	9	case	_	_
8	an	an	DT	_	9	det	_	_
9	drug3	drug0	NN	_	4	ppmod	_	_
10	in	in	IN	_	11	case	_	_
11	vitro	vitro	FW	_	9	ppmod	_	_
12	can	can	MD	_	13	modal	_	_
13	result	result	VB	_	1	acl	_	_
14	in	in	IN	_	16	case	_	_
15	substantial	substantial	JJ	_	16	attr	_	_
16	inactivation	inactivation	NN	_	13	ppmod	_	_
17	of	of	IN	_	19	case	_	_
18	the	the	DT	_	19	det	_	_
19	drug4	drug0	NN	_	16	ppmod	_	_
20	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	When	when	WRB	_	4	adv	_	_
4	used	use	VBN	_	13	advcl	_	_
5	in	in	IN	_	8	case	_	_
6	the	the	DT	_	8	det	_	_
7	perioperative	perioperative	JJ	_	8	attr	_	_
8	period	period	NN	_	4	ppmod	_	_
9	,	,	,	_	13	p	_	_
10	drug2	drug0	NN	_	13	dep	_	_
11	has	have	VBZ	_	13	aux	_	_
12	been	be	VBN	_	13	aux	_	_
13	implicated	implicate	VBN	_	1	acl	_	_
14	in	in	IN	_	16	case	_	_
15	the	the	DT	_	16	det	_	_
16	prolongation	prolongation	NN	_	13	ppmod	_	_
17	of	of	IN	_	20	case	_	_
18	the	the	DT	_	20	det	_	_
19	neuromuscular	neuromuscular	JJ	_	20	attr	_	_
20	blockade	blockade	NN	_	16	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	drug3	drug0	NN	_	20	ppmod	_	_
23	.	.	.	_	1	p	_	_

1	Caution	caution	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	indicated	indicate	VBN	_	0	root	_	_
4	when	when	WRB	_	7	adv	_	_
5	drug1	drug0	NN	_	7	dep	_	_
6	is	be	VBZ	_	7	aux	_	_
7	used	use	VBN	_	3	comp	_	_
8	perioperatively	perioperatively	NN	_	7	obj	_	_
9	.	.	.	_	3	p	_	_

1	In	in	IN	_	5	case	_	_
2	one	#crd#	CD	_	5	num	_	_
3	controlled	controlled	JJ	_	5	attr	_	_
4	clinical	clinical	JJ	_	5	attr	_	_
5	study	study	NN	_	14	ppmod	_	_
6	,	,	,	_	14	p	_	_
7	the	the	DT	_	8	det	_	_
8	ureidopenicillins	ureidopenicillins	NNS	_	14	dep	_	_
9	,	,	,	_	8	p	_	_
10	including	include	VBG	_	11	adv	_	_
11	drug1	drug0	NN	_	8	ppmod	_	_
12	,	,	,	_	8	p	_	_
13	were	be	VBD	_	14	aux	_	_
14	reported	report	VBN	_	0	root	_	_
15	to	to	TO	_	16	aux	_	_
16	prolong	prolong	VB	_	14	comp	_	_
17	the	the	DT	_	18	det	_	_
18	action	action	NN	_	16	obj	_	_
19	of	of	IN	_	20	case	_	_
20	drug2	drug0	NN	_	18	ppmod	_	_
21	.	.	.	_	14	p	_	_

1	Due	due	JJ	_	5	adv	_	_
2	to	to	TO	_	5	aux	_	_
3	their	their	PRP$	_	5	poss	_	_
4	similar	similar	JJ	_	5	attr	_	_
5	mechanism	mechanism	NN	_	11	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	action	action	NN	_	5	ppmod	_	_
8	,	,	,	_	11	p	_	_
9	it	it	PRP	_	11	dep	_	_
10	is	be	VBZ	_	11	aux	_	_
11	expected	expect	VBN	_	0	root	_	_
12	that	that	IN	_	24	mark	_	_
13	the	the	DT	_	15	det	_	_
14	neuromuscular	neuromuscular	JJ	_	15	attr	_	_
15	blockade	blockade	NN	_	24	dep	_	_
16	produced	produce	VBN	_	15	acl	_	_
17	by	by	IN	_	18	case	_	_
18	any	any	DT	_	16	ppmod	_	_
19	of	of	IN	_	21	case	_	_
20	the	the	DT	_	21	det	_	_
21	drug1	drug0	NN	_	18	ppmod	_	_
22	could	could	MD	_	24	modal	_	_
23	be	be	VB	_	24	aux	_	_
24	prolonged	prolong	VBD	_	11	comp	_	_
25	in	in	IN	_	27	case	_	_
26	the	the	DT	_	27	det	_	_
27	presence	presence	NN	_	24	ppmod	_	_
28	of	of	IN	_	29	case	_	_
29	drug2	drug0	NN	_	27	ppmod	_	_
30	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	5	det	_	_
4	oral	oral	JJ	_	5	attr	_	_
5	combination	combination	NN	_	13	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	before	before	IN	_	10	case	_	_
9	intramuscular	intramuscular	JJ	_	10	attr	_	_
10	injection	injection	NN	_	5	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	produces	produce	VBZ	_	1	acl	_	_
14	an	an	DT	_	15	det	_	_
15	increase	increase	NN	_	13	obj	_	_
16	in	in	IN	_	20	case	_	_
17	drug4	drug0	JJ	_	20	attr	_	_
18	peak	peak	JJ	_	20	attr	_	_
19	serum	serum	NN	_	20	com	_	_
20	level	level	NN	_	15	ppmod	_	_
21	of	of	IN	_	23	case	_	_
22	about	about	RB	_	23	adv	_	_
23	30	0	CD	_	20	ppmod	_	_
24	%	%	NN	_	23	meta	_	_
25	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Coagulation	coagulation	NN	_	4	com	_	_
4	parameters	parameter	NNS	_	7	dep	_	_
5	should	should	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	tested	test	VBN	_	1	acl	_	_
8	more	more	RBR	_	9	com	_	_
9	frequently	frequently	RB	_	7	adv	_	_
10	and	and	CC	_	7	cc	_	_
11	monitored	monitor	VBN	_	7	conj	_	_
12	regularly	regularly	RB	_	11	adv	_	_
13	during	during	IN	_	15	case	_	_
14	simultaneous	simultaneous	JJ	_	15	attr	_	_
15	administration	administration	NN	_	11	ppmod	_	_
16	of	of	IN	_	18	case	_	_
17	high	high	JJ	_	18	attr	_	_
18	doses	dose	NNS	_	15	ppmod	_	_
19	of	of	IN	_	20	case	_	_
20	drug2	drug0	NN	_	18	ppmod	_	_
21	,	,	,	_	20	p	_	_
22	oral	oral	JJ	_	23	attr	_	_
23	drug3	drug0	NN	_	20	conj	_	_
24	,	,	,	_	23	p	_	_
25	or	or	CC	_	23	cc	_	_
26	other	other	JJ	_	27	attr	_	_
27	drugs	drug	NNS	_	20	conj	_	_
28	that	that	WDT	_	30	dep	_	_
29	may	may	MD	_	30	modal	_	_
30	affect	affect	VB	_	27	relcl	_	_
31	the	the	DT	_	34	det	_	_
32	blood	blood	NN	_	34	com	_	_
33	coagulation	coagulation	NN	_	34	com	_	_
34	system	system	NN	_	30	obj	_	_
35	or	or	CC	_	34	cc	_	_
36	the	the	DT	_	38	det	_	_
37	thrombocyte	thrombocyte	JJ	_	38	attr	_	_
38	function	function	NN	_	34	conj	_	_
39	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	may	may	MD	_	5	modal	_	_
5	reduce	reduce	VB	_	0	root	_	_
6	the	the	DT	_	7	det	_	_
7	excretion	excretion	NN	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_
10	.	.	.	_	5	p	_	_

1	Therefore	therefore	RB	_	9	adv	_	_
2	,	,	,	_	9	p	_	_
3	serum	serum	NN	_	4	com	_	_
4	levels	level	NNS	_	9	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	should	should	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	monitored	monitor	VBN	_	0	root	_	_
10	in	in	IN	_	11	case	_	_
11	patients	patient	NNS	_	9	ppmod	_	_
12	to	to	TO	_	13	aux	_	_
13	avoid	avoid	VB	_	9	comp	_	_
14	drug	drug	NN	_	15	com	_	_
15	toxicity	toxicity	NN	_	13	obj	_	_
16	.	.	.	_	9	p	_	_

1	Drug/Laboratory	drug/laboratory	JJ	_	3	attr	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	14	dep	_	_
4	As	as	IN	_	7	case	_	_
5	with	with	IN	_	7	case	_	_
6	other	other	JJ	_	7	attr	_	_
7	drug1	drug0	NN	_	14	ppmod	_	_
8	,	,	,	_	14	p	_	_
9	the	the	DT	_	10	det	_	_
10	administration	administration	NN	_	14	dep	_	_
11	of	of	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	may	may	MD	_	14	modal	_	_
14	result	result	VB	_	0	root	_	_
15	in	in	IN	_	18	case	_	_
16	a	a	DT	_	18	det	_	_
17	false-positive	false-positive	JJ	_	18	attr	_	_
18	reaction	reaction	NN	_	14	ppmod	_	_
19	for	for	IN	_	20	case	_	_
20	glucose	glucose	NN	_	18	ppmod	_	_
21	in	in	IN	_	23	case	_	_
22	the	the	DT	_	23	det	_	_
23	urine	urine	NN	_	18	ppmod	_	_
24	using	use	VBG	_	23	acl	_	_
25	a	a	DT	_	27	det	_	_
26	copper-reduction	copper-reduction	NN	_	27	com	_	_
27	method	method	NN	_	24	obj	_	_
28	.	.	.	_	14	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	recommended	recommend	VBN	_	0	root	_	_
4	that	that	IN	_	14	mark	_	_
5	glucose	glucose	NN	_	6	com	_	_
6	tests	test	NNS	_	14	dep	_	_
7	based	base	VBN	_	6	acl	_	_
8	on	on	IN	_	12	case	_	_
9	enzymatic	enzymatic	JJ	_	12	attr	_	_
10	glucose	glucose	NN	_	12	com	_	_
11	oxidase	oxidase	NN	_	12	com	_	_
12	reactions	reaction	NNS	_	7	ppmod	_	_
13	be	be	VB	_	14	aux	_	_
14	used	use	VBN	_	3	comp	_	_
15	.	.	.	_	3	p	_	_

1	There	there	EX	_	3	dep	_	_
2	have	have	VBP	_	3	aux	_	_
3	been	be	VBN	_	0	root	_	_
4	reports	report	NNS	_	3	obj	_	_
5	of	of	IN	_	8	case	_	_
6	positive	positive	JJ	_	8	attr	_	_
7	test	test	NN	_	8	com	_	_
8	results	result	NNS	_	4	ppmod	_	_
9	using	use	VBG	_	3	comp	_	_
10	the	the	DT	_	16	det	_	_
11	Bio-Rad	bio-rad	JJ	_	12	attr	_	_
12	Laboratories	laboratory	NNS	_	16	com	_	_
13	Platelia	platelia	NN	_	16	com	_	_
14	Aspergillus	aspergillus	NN	_	16	com	_	_
15	EIA	eia	NN	_	16	com	_	_
16	test	test	NN	_	9	obj	_	_
17	in	in	IN	_	18	case	_	_
18	patients	patient	NNS	_	16	ppmod	_	_
19	receiving	receive	VBG	_	18	acl	_	_
20	drug1	drug0	NN	_	23	attr	_	_
21	/	/	:	_	23	p	_	_
22	drug2	drug0	NN	_	23	com	_	_
23	injection	injection	NN	_	19	obj	_	_
24	who	who	WP	_	27	dep	_	_
25	were	be	VBD	_	27	aux	_	_
26	subsequently	subsequently	RB	_	27	adv	_	_
27	found	find	VBN	_	18	relcl	_	_
28	to	to	TO	_	29	aux	_	_
29	be	be	VB	_	27	comp	_	_
30	free	free	JJ	_	29	dep	_	_
31	of	of	IN	_	33	case	_	_
32	Aspergillus	aspergillus	JJ	_	33	attr	_	_
33	infection	infection	NN	_	30	ppmod	_	_
34	.	.	.	_	3	p	_	_

1	Cross-reactions	cross-reactions	NNS	_	17	dep	_	_
2	with	with	IN	_	4	case	_	_
3	non-Aspergillus	non-aspergillus	JJ	_	4	attr	_	_
4	polysaccharides	polysaccharide	NNS	_	1	ppmod	_	_
5	and	and	CC	_	1	cc	_	_
6	polyfuranoses	polyfuranoses	NNS	_	14	attr	_	_
7	with	with	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	Bio-Rad	bio-rad	JJ	_	10	attr	_	_
10	Laboratories	laboratory	NNS	_	6	ppmod	_	_
11	Platelia	platelia	FW	_	12	adv	_	_
12	Aspergillus	aspergillus	FW	_	14	attr	_	_
13	EIA	eia	NN	_	14	com	_	_
14	test	test	NN	_	1	conj	_	_
15	have	have	VBP	_	17	aux	_	_
16	been	be	VBN	_	17	aux	_	_
17	reported	report	VBN	_	0	root	_	_
18	.	.	.	_	17	p	_	_

1	Therefore	therefore	RB	_	12	adv	_	_
2	,	,	,	_	12	p	_	_
3	positive	positive	JJ	_	5	attr	_	_
4	test	test	NN	_	5	com	_	_
5	results	result	NNS	_	12	dep	_	_
6	in	in	IN	_	7	case	_	_
7	patients	patient	NNS	_	5	ppmod	_	_
8	receiving	receive	VBG	_	7	acl	_	_
9	drug1	drug0	NN	_	8	obj	_	_
10	should	should	MD	_	12	modal	_	_
11	be	be	VB	_	12	aux	_	_
12	interpreted	interpret	VBN	_	0	root	_	_
13	cautiously	cautiously	RB	_	12	adv	_	_
14	and	and	CC	_	12	cc	_	_
15	confirmed	confirm	VBN	_	12	conj	_	_
16	by	by	IN	_	19	case	_	_
17	other	other	JJ	_	19	attr	_	_
18	diagnostic	diagnostic	JJ	_	19	attr	_	_
19	methods	method	NNS	_	15	ppmod	_	_
20	.	.	.	_	12	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	recommended	recommend	VBN	_	0	root	_	_
4	that	that	IN	_	8	mark	_	_
5	drug1	drug0	NN	_	8	dep	_	_
6	not	not	RB	_	8	neg	_	_
7	be	be	VB	_	8	aux	_	_
8	used	use	VBN	_	3	comp	_	_
9	concomitantly	concomitantly	RB	_	8	adv	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NN	_	8	ppmod	_	_
12	Because	because	IN	_	27	mark	_	_
13	the	the	DT	_	14	det	_	_
14	effects	effect	NNS	_	27	dep	_	_
15	of	of	IN	_	17	case	_	_
16	concomitant	concomitant	JJ	_	17	attr	_	_
17	administration	administration	NN	_	14	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug3	drug0	NN	_	17	ppmod	_	_
20	with	with	IN	_	23	case	_	_
21	most	most	JJS	_	23	attr	_	_
22	other	other	JJ	_	23	attr	_	_
23	drug4	drug0	NNS	_	14	ppmod	_	_
24	have	have	VBP	_	27	aux	_	_
25	not	not	RB	_	27	neg	_	_
26	been	be	VBN	_	27	aux	_	_
27	studied	study	VBN	_	40	advcl	_	_
28	,	,	,	_	40	p	_	_
29	the	the	DT	_	31	det	_	_
30	concomitant	concomitant	JJ	_	31	attr	_	_
31	use	use	NN	_	40	dep	_	_
32	of	of	IN	_	33	case	_	_
33	drug5	drug0	NN	_	31	ppmod	_	_
34	with	with	IN	_	37	case	_	_
35	other	other	JJ	_	37	attr	_	_
36	CNS-active	cns-active	JJ	_	37	attr	_	_
37	drugs	drug	NNS	_	33	ppmod	_	_
38	should	should	MD	_	40	modal	_	_
39	be	be	VB	_	40	aux	_	_
40	approached	approach	VBN	_	11	acl	_	_
41	with	with	IN	_	42	case	_	_
42	caution	caution	NN	_	40	ppmod	_	_
43	.	.	.	_	3	p	_	_

1	There	there	EX	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	one	#crd#	CD	_	4	num	_	_
4	report	report	NN	_	2	obj	_	_
5	suggesting	suggest	VBG	_	4	acl	_	_
6	that	that	IN	_	19	mark	_	_
7	the	the	DT	_	9	det	_	_
8	concomitant	concomitant	JJ	_	9	attr	_	_
9	use	use	NN	_	19	dep	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	drug2	drug0	NN	_	11	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	and	and	CC	_	11	cc	_	_
16	drug3	drug0	NN	_	11	conj	_	_
17	may	may	MD	_	19	modal	_	_
18	have	have	VB	_	19	aux	_	_
19	caused	cause	VBD	_	5	comp	_	_
20	3-	0-	CD	_	23	num	_	_
21	to	to	TO	_	20	attr	_	_
22	6-fold	0-fold	RB	_	20	adv	_	_
23	elevations	elevation	NNS	_	19	obj	_	_
24	on	on	IN	_	25	case	_	_
25	SGPT	sgpt	NN	_	23	ppmod	_	_
26	(	-lrb-	-LRB-	_	27	p	_	_
27	ALT	alt	NN	_	25	prn	_	_
28	)	-rrb-	-RRB-	_	27	p	_	_
29	in	in	IN	_	32	case	_	_
30	a	a	DT	_	32	det	_	_
31	few	few	JJ	_	32	attr	_	_
32	patients	patient	NNS	_	19	ppmod	_	_
33	.	.	.	_	2	p	_	_

1	In	in	IN	_	4	case	_	_
2	a	a	DT	_	4	det	_	_
3	similar	similar	JJ	_	4	attr	_	_
4	study	study	NN	_	19	ppmod	_	_
5	,	,	,	_	19	p	_	_
6	attempting	attempt	VBG	_	19	advcl	_	_
7	to	to	TO	_	8	aux	_	_
8	replicate	replicate	VB	_	6	comp	_	_
9	this	this	DT	_	10	det	_	_
10	finding	finding	NN	_	8	obj	_	_
11	,	,	,	_	19	p	_	_
12	no	no	DT	_	14	det	_	_
13	interactive	interactive	JJ	_	14	attr	_	_
14	effect	effect	NN	_	19	dep	_	_
15	on	on	IN	_	17	case	_	_
16	hepatic	hepatic	JJ	_	17	attr	_	_
17	transaminases	transaminase	NNS	_	14	ppmod	_	_
18	was	be	VBD	_	19	aux	_	_
19	identified	identify	VBN	_	0	root	_	_
20	.	.	.	_	19	p	_	_

1	In	in	IN	_	3	case	_	_
2	a	a	DT	_	3	det	_	_
3	study	study	NN	_	14	ppmod	_	_
4	in	in	IN	_	6	case	_	_
5	normal	normal	JJ	_	6	attr	_	_
6	volunteers	volunteer	NNS	_	3	ppmod	_	_
7	,	,	,	_	14	p	_	_
8	concomitant	concomitant	JJ	_	9	attr	_	_
9	administration	administration	NN	_	14	dep	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	drug2	drug0	NN	_	11	conj	_	_
14	resulted	result	VBD	_	0	root	_	_
15	in	in	IN	_	19	case	_	_
16	increased	increase	VBN	_	19	attr	_	_
17	serum	serum	NN	_	19	com	_	_
18	drug3	drug0	NN	_	19	com	_	_
19	concentrations	concentration	NNS	_	14	ppmod	_	_
20	.	.	.	_	14	p	_	_

1	The	the	DT	_	3	det	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	significance	significance	NN	_	7	dep	_	_
4	of	of	IN	_	6	case	_	_
5	this	this	DT	_	6	det	_	_
6	finding	finding	NN	_	3	ppmod	_	_
7	is	be	VBZ	_	0	root	_	_
8	not	not	RB	_	7	neg	_	_
9	clear	clear	JJ	_	7	dep	_	_
10	.	.	.	_	7	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	7	adv	_	_
3	,	,	,	_	7	p	_	_
4	drug1	drug0	NN	_	7	dep	_	_
5	does	do	VBZ	_	7	aux	_	_
6	not	not	RB	_	7	neg	_	_
7	displace	displace	VB	_	0	root	_	_
8	tightly	tightly	RB	_	9	adv	_	_
9	bound	bind	VBN	_	10	attr	_	_
10	drugs	drug	NNS	_	7	obj	_	_
11	like	like	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	drug3	drug0	NN	_	12	conj	_	_
15	,	,	,	_	14	p	_	_
16	and	and	CC	_	14	cc	_	_
17	drug4	drug0	NN	_	12	conj	_	_
18	from	from	IN	_	20	case	_	_
19	serum	serum	NN	_	20	com	_	_
20	proteins	protein	NNS	_	12	ppmod	_	_
21	.	.	.	_	7	p	_	_

1	However	however	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	there	there	EX	_	5	dep	_	_
4	has	have	VBZ	_	5	aux	_	_
5	been	be	VBN	_	0	root	_	_
6	one	#crd#	CD	_	7	num	_	_
7	report	report	NN	_	5	obj	_	_
8	of	of	IN	_	11	case	_	_
9	prolonged	prolonged	JJ	_	11	attr	_	_
10	prothrombin	prothrombin	NN	_	11	com	_	_
11	time	time	NN	_	7	ppmod	_	_
12	when	when	WRB	_	15	adv	_	_
13	drug1	drug0	NN	_	15	dep	_	_
14	was	be	VBD	_	15	aux	_	_
15	added	add	VBN	_	5	comp	_	_
16	to	to	TO	_	18	aux	_	_
17	the	the	DT	_	18	det	_	_
18	regimen	regimen	NN	_	15	ppmod	_	_
19	of	of	IN	_	21	case	_	_
20	a	a	DT	_	21	det	_	_
21	patient	patient	NN	_	18	ppmod	_	_
22	treated	treat	VBN	_	21	acl	_	_
23	with	with	IN	_	24	case	_	_
24	drug2	drug0	NN	_	22	ppmod	_	_
25	.	.	.	_	5	p	_	_

1	The	the	DT	_	2	det	_	_
2	patient	patient	NN	_	6	dep	_	_
3	was	be	VBD	_	6	aux	_	_
4	also	also	RB	_	6	adv	_	_
5	chronically	chronically	RB	_	6	adv	_	_
6	receiving	receive	VBG	_	0	root	_	_
7	drug1	drug0	NN	_	6	obj	_	_
8	,	,	,	_	7	p	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	,	,	,	_	9	p	_	_
11	drug3	drug0	NN	_	7	conj	_	_
12	,	,	,	_	11	p	_	_
13	and	and	CC	_	11	cc	_	_
14	drug4	drug0	NN	_	7	conj	_	_
15	.	.	.	_	6	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	6	adv	_	_
3	,	,	,	_	6	p	_	_
4	drug1	drug0	NN	_	6	dep	_	_
5	may	may	MD	_	6	modal	_	_
6	displace	displace	VB	_	0	root	_	_
7	less	less	RBR	_	8	com	_	_
8	firmly	firmly	RB	_	10	adv	_	_
9	bound	bind	VBN	_	10	attr	_	_
10	drugs	drug	NNS	_	6	obj	_	_
11	like	like	IN	_	12	case	_	_
12	drug2	drug0	NN	_	6	ppmod	_	_
13	.	.	.	_	6	p	_	_

1	The	the	DT	_	3	det	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	significance	significance	NN	_	7	dep	_	_
4	of	of	IN	_	6	case	_	_
5	this	this	DT	_	6	det	_	_
6	property	property	NN	_	3	ppmod	_	_
7	is	be	VBZ	_	0	root	_	_
8	unknown	unknown	JJ	_	7	dep	_	_
9	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	24	dep	_	_
2	in	in	IN	_	3	case	_	_
3	combination	combination	NN	_	1	ppmod	_	_
4	with	with	IN	_	6	case	_	_
5	other	other	JJ	_	6	attr	_	_
6	drug2	drug0	NN	_	3	ppmod	_	_
7	,	,	,	_	6	p	_	_
8	general	general	JJ	_	9	attr	_	_
9	drug3	drug0	NN	_	6	conj	_	_
10	,	,	,	_	9	p	_	_
11	drug4	drug0	NN	_	6	conj	_	_
12	,	,	,	_	11	p	_	_
13	drug5	drug0	NN	_	6	conj	_	_
14	,	,	,	_	13	p	_	_
15	drug6	drug0	NN	_	6	conj	_	_
16	,	,	,	_	15	p	_	_
17	or	or	CC	_	15	cc	_	_
18	other	other	JJ	_	19	attr	_	_
19	drug7	drug0	NNS	_	6	conj	_	_
20	(	-lrb-	-LRB-	_	21	p	_	_
21	including	include	VBG	_	19	prn	_	_
22	drug8	drug0	NN	_	21	obj	_	_
23	)	-rrb-	-RRB-	_	21	p	_	_
24	has	have	VBZ	_	0	root	_	_
25	additive	additive	JJ	_	27	attr	_	_
26	depressant	depressant	NN	_	27	com	_	_
27	effects	effect	NNS	_	24	obj	_	_
28	.	.	.	_	24	p	_	_

1	When	when	IN	_	2	case	_	_
2	s.c.	s.c.	NN	_	0	root	_	_

1	combination	combination	NN	_	2	com	_	_
2	therapy	therapy	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	contemplated	contemplate	VBN	_	0	root	_	_
5	,	,	,	_	4	p	_	_
6	the	the	DT	_	7	det	_	_
7	dosage	dosage	NN	_	4	obj	_	_
8	of	of	IN	_	9	case	_	_
9	one	#crd#	CD	_	7	ppmod	_	_
10	or	or	CC	_	4	cc	_	_
11	both	both	DT	_	12	det	_	_
12	agents	agent	NNS	_	15	dep	_	_
13	should	should	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	reduced	reduce	VBN	_	4	conj	_	_
16	.	.	.	_	4	p	_	_

1	The	the	DT	_	3	det	_	_
2	vasodilating	vasodilating	JJ	_	3	attr	_	_
3	effects	effect	NNS	_	7	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	may	may	MD	_	7	modal	_	_
7	be	be	VB	_	0	root	_	_
8	additive	additive	JJ	_	7	dep	_	_
9	with	with	IN	_	10	case	_	_
10	those	those	DT	_	8	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	other	other	JJ	_	13	attr	_	_
13	drug2	drug0	NNS	_	10	ppmod	_	_
14	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	8	dep	_	_
2	,	,	,	_	1	p	_	_
3	in	in	IN	_	4	case	_	_
4	particular	particular	JJ	_	1	ppmod	_	_
5	,	,	,	_	1	p	_	_
6	has	have	VBZ	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	found	find	VBN	_	0	root	_	_
9	to	to	TO	_	10	aux	_	_
10	exhibit	exhibit	VBP	_	8	comp	_	_
11	additive	additive	JJ	_	12	attr	_	_
12	effects	effect	NNS	_	10	obj	_	_
13	of	of	IN	_	15	case	_	_
14	this	this	DT	_	15	det	_	_
15	variety	variety	NN	_	12	ppmod	_	_
16	.	.	.	_	8	p	_	_

1	Drug	drug	NN	_	2	com	_	_
2	Interaction	interaction	NN	_	10	dep	_	_
3	with	with	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	7	com	_	_
7	drug3	drug0	NN	_	4	conj	_	_
8	has	have	VBZ	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	shown	show	VBN	_	0	root	_	_
11	to	to	TO	_	12	aux	_	_
12	exhibit	exhibit	VB	_	10	comp	_	_
13	minimal	minimal	JJ	_	19	attr	_	_
14	(	-lrb-	-LRB-	_	16	p	_	_
15	ca.	ca.	FW	_	16	ppmod	_	_
16	5	0	CD	_	13	num	_	_
17	%	%	NN	_	16	meta	_	_
18	)	-rrb-	-RRB-	_	16	p	_	_
19	metabolism	metabolism	NN	_	12	obj	_	_
20	.	.	.	_	10	p	_	_

1	However	however	RB	_	12	adv	_	_
2	,	,	,	_	12	p	_	_
3	co	co	NN	_	4	com	_	_
4	administration	administration	NN	_	12	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	with	with	IN	_	9	case	_	_
8	either	either	CC	_	9	cc	_	_
9	drug2	drug0	NN	_	4	ppmod	_	_
10	or	or	CC	_	9	cc	_	_
11	drug3	drug0	NN	_	9	conj	_	_
12	led	lead	VBD	_	0	root	_	_
13	to	to	TO	_	16	aux	_	_
14	increased	increase	VBN	_	16	attr	_	_
15	plasma	plasma	NN	_	16	com	_	_
16	concentrations	concentration	NNS	_	12	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug4	drug0	NN	_	16	ppmod	_	_
19	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	had	have	VBD	_	0	root	_	_
3	no	no	DT	_	4	det	_	_
4	effect	effect	NN	_	2	obj	_	_
5	on	on	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	pharmacokinetics	pharmacokinetics	NNS	_	2	ppmod	_	_
8	of	of	IN	_	10	case	_	_
9	either	either	CC	_	10	cc	_	_
10	drug2	drug0	NN	_	7	ppmod	_	_
11	or	or	CC	_	10	cc	_	_
12	drug3	drug0	NN	_	10	conj	_	_
13	.	.	.	_	2	p	_	_

1	In	in	IN	_	4	case	_	_
2	2	0	CD	_	4	num	_	_
3	separate	separate	JJ	_	4	attr	_	_
4	studies	study	NNS	_	19	ppmod	_	_
5	,	,	,	_	19	p	_	_
6	drug1	drug0	NN	_	8	attr	_	_
7	120	0	CD	_	8	num	_	_
8	mg	mg	NN	_	19	dep	_	_
9	twice	twice	RB	_	10	com	_	_
10	daily	daily	RB	_	8	adv	_	_
11	(	-lrb-	-LRB-	_	16	p	_	_
12	240	0	CD	_	16	num	_	_
13	mg	mg	NN	_	16	attr	_	_
14	total	total	JJ	_	16	attr	_	_
15	daily	daily	JJ	_	16	attr	_	_
16	dose	dose	NN	_	8	prn	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	was	be	VBD	_	19	aux	_	_
19	co-administered	co-administered	VBN	_	0	root	_	_
20	with	with	IN	_	24	case	_	_
21	either	either	CC	_	24	cc	_	_
22	drug2	drug0	NN	_	24	attr	_	_
23	500	0	CD	_	24	num	_	_
24	mg	mg	NN	_	19	ppmod	_	_
25	every	every	DT	_	27	det	_	_
26	8	0	CD	_	27	num	_	_
27	hours	hour	NNS	_	24	appo	_	_
28	or	or	CC	_	24	cc	_	_
29	drug3	drug0	NN	_	31	attr	_	_
30	400	0	CD	_	31	num	_	_
31	mg	mg	NN	_	24	conj	_	_
32	once	once	RB	_	33	adv	_	_
33	daily	daily	JJ	_	31	attr	_	_
34	under	under	IN	_	36	case	_	_
35	steady-state	steady-state	JJ	_	36	attr	_	_
36	conditions	condition	NNS	_	33	ppmod	_	_
37	to	to	TO	_	39	aux	_	_
38	healthy	healthy	JJ	_	39	attr	_	_
39	volunteers	volunteer	NNS	_	36	ppmod	_	_
40	(	-lrb-	-LRB-	_	41	p	_	_
41	n=24	n=0	NN	_	39	prn	_	_
42	,	,	,	_	41	p	_	_
43	each	each	DT	_	44	det	_	_
44	study	study	NN	_	41	appo	_	_
45	)	-rrb-	-RRB-	_	41	p	_	_
46	.	.	.	_	19	p	_	_

1	No	no	DT	_	2	det	_	_
2	differences	difference	NNS	_	10	dep	_	_
3	in	in	IN	_	5	case	_	_
4	adverse	adverse	JJ	_	5	attr	_	_
5	events	event	NNS	_	2	ppmod	_	_
6	or	or	CC	_	5	cc	_	_
7	QTc	qtc	NN	_	8	com	_	_
8	interval	interval	NN	_	5	conj	_	_
9	were	be	VBD	_	10	aux	_	_
10	observed	observe	VBN	_	0	root	_	_
11	when	when	WRB	_	14	adv	_	_
12	subjects	subject	NNS	_	14	dep	_	_
13	were	be	VBD	_	14	aux	_	_
14	administered	administer	VBN	_	10	comp	_	_
15	drug1	drug0	NN	_	14	obj	_	_
16	alone	alone	RB	_	14	adv	_	_
17	or	or	CC	_	16	cc	_	_
18	in	in	IN	_	19	case	_	_
19	combination	combination	NN	_	16	conj	_	_
20	with	with	IN	_	22	case	_	_
21	either	either	CC	_	22	cc	_	_
22	drug2	drug0	NN	_	19	ppmod	_	_
23	or	or	CC	_	22	cc	_	_
24	drug3	drug0	NN	_	22	conj	_	_
25	.	.	.	_	10	p	_	_

1	The	the	DT	_	2	det	_	_
2	findings	finding	NNS	_	7	dep	_	_
3	of	of	IN	_	5	case	_	_
4	these	these	DT	_	5	det	_	_
5	studies	study	NNS	_	2	ppmod	_	_
6	are	be	VBP	_	7	aux	_	_
7	summarized	summarize	VBN	_	0	root	_	_
8	in	in	IN	_	11	case	_	_
9	the	the	DT	_	11	det	_	_
10	following	follow	VBG	_	11	attr	_	_
11	table	table	NN	_	7	ppmod	_	_
12	:	:	:	_	7	p	_	_
13	Effects	effect	NNS	_	7	dep	_	_
14	on	on	IN	_	17	case	_	_
15	steady-state	steady-state	JJ	_	17	attr	_	_
16	drug1	drug0	NN	_	17	com	_	_
17	pharmacokinetics	pharmacokinetics	NNS	_	13	ppmod	_	_
18	after	after	IN	_	20	case	_	_
19	7	0	CD	_	20	num	_	_
20	days	day	NNS	_	17	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	co-administration	co-administration	NN	_	20	ppmod	_	_
23	with	with	IN	_	26	case	_	_
24	drug2	drug0	NN	_	26	attr	_	_
25	120	0	CD	_	26	num	_	_
26	mg	mg	NN	_	22	ppmod	_	_
27	every	every	DT	_	29	det	_	_
28	12	0	CD	_	29	num	_	_
29	hours	hour	NNS	_	26	appo	_	_
30	(	-lrb-	-LRB-	_	32	p	_	_
31	two	#crd#	CD	_	32	num	_	_
32	times	time	NNS	_	29	prn	_	_
33	the	the	DT	_	37	det	_	_
34	recommended	recommend	VBN	_	37	attr	_	_
35	twice	twice	RB	_	37	adv	_	_
36	daily	daily	JJ	_	37	attr	_	_
37	dose	dose	NN	_	32	appo	_	_
38	)	-rrb-	-RRB-	_	32	p	_	_
39	in	in	IN	_	41	case	_	_
40	healthy	healthy	JJ	_	41	attr	_	_
41	volunteers	volunteer	NNS	_	7	ppmod	_	_
42	(	-lrb-	-LRB-	_	43	p	_	_
43	n=24	n=0	NN	_	41	prn	_	_
44	)	-rrb-	-RRB-	_	43	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	Drug	drug	NN	_	0	root	_	_

1	cmaxSS	cmaxss	NN	_	0	root	_	_
2	(	-lrb-	-LRB-	_	5	p	_	_
3	Peak	peak	NN	_	5	com	_	_
4	plasma	plasma	NN	_	5	com	_	_
5	concentration	concentration	NN	_	1	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_

1	AUCss	aucss	NN	_	0	root	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	0-12h	0h	NN	_	1	prn	_	_
4	)	-rrb-	-RRB-	_	3	p	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	Extent	extent	NN	_	1	prn	_	_
7	of	of	IN	_	9	case	_	_
8	systemic	systemic	JJ	_	9	attr	_	_
9	exposure	exposure	NN	_	6	ppmod	_	_
10	)	-rrb-	-RRB-	_	6	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	(	-lrb-	-LRB-	_	4	p	_	_
3	500	0	CD	_	4	num	_	_
4	mg	mg	NN	_	1	prn	_	_
5	every	every	DT	_	7	det	_	_
6	8	0	CD	_	7	num	_	_
7	hrs	hr	NNS	_	4	attr	_	_
8	)	-rrb-	-RRB-	_	4	p	_	_

1	+82	0	CD	_	0	root	_	_
2	%	%	NN	_	1	meta	_	_

1	+109	0	CD	_	0	root	_	_
2	%	%	NN	_	1	meta	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	(	-lrb-	-LRB-	_	4	p	_	_
3	400	0	CD	_	4	num	_	_
4	mg	mg	NN	_	1	prn	_	_
5	once	once	RB	_	6	adv	_	_
6	daily	daily	JJ	_	4	attr	_	_
7	)	-rrb-	-RRB-	_	4	p	_	_

1	+135	0	CD	_	0	root	_	_
2	%	%	NN	_	1	meta	_	_

1	+164	0	CD	_	0	root	_	_
2	%	%	NN	_	1	meta	_	_

1	The	the	DT	_	2	det	_	_
2	changes	change	NNS	_	6	dep	_	_
3	in	in	IN	_	5	case	_	_
4	plasma	plasma	NN	_	5	com	_	_
5	levels	level	NNS	_	2	ppmod	_	_
6	were	be	VBD	_	0	root	_	_
7	within	within	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	range	range	NN	_	6	ppmod	_	_
10	of	of	IN	_	12	case	_	_
11	plasma	plasma	NN	_	12	com	_	_
12	levels	level	NNS	_	9	ppmod	_	_
13	achieved	achieve	VBN	_	12	acl	_	_
14	in	in	IN	_	19	case	_	_
15	adequate	adequate	JJ	_	19	attr	_	_
16	and	and	CC	_	15	cc	_	_
17	well-controlled	well-controlled	JJ	_	15	conj	_	_
18	clinical	clinical	JJ	_	19	attr	_	_
19	trials	trial	NNS	_	13	ppmod	_	_
20	.	.	.	_	6	p	_	_

1	The	the	DT	_	2	det	_	_
2	mechanism	mechanism	NN	_	8	dep	_	_
3	of	of	IN	_	5	case	_	_
4	these	these	DT	_	5	det	_	_
5	interactions	interaction	NNS	_	2	ppmod	_	_
6	has	have	VBZ	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	evaluated	evaluate	VBN	_	0	root	_	_
9	in	in	IN	_	20	case	_	_
10	in	in	FW	_	11	adv	_	_
11	vitro	vitro	FW	_	20	attr	_	_
12	,	,	,	_	11	p	_	_
13	in	in	FW	_	14	adv	_	_
14	situ	situ	FW	_	11	conj	_	_
15	,	,	,	_	14	p	_	_
16	and	and	CC	_	14	cc	_	_
17	in	in	FW	_	18	adv	_	_
18	vivo	vivo	FW	_	11	conj	_	_
19	animal	animal	NN	_	20	com	_	_
20	models	model	NNS	_	8	ppmod	_	_
21	.	.	.	_	8	p	_	_

1	These	these	DT	_	2	det	_	_
2	studies	study	NNS	_	3	dep	_	_
3	indicate	indicate	VBP	_	0	root	_	_
4	that	that	IN	_	9	mark	_	_
5	drug1	drug0	NN	_	9	dep	_	_
6	or	or	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	8	com	_	_
8	co-administration	co-administration	NN	_	5	conj	_	_
9	enhances	enhance	VBZ	_	3	comp	_	_
10	drug3	drug0	NN	_	12	attr	_	_
11	gastrointestinal	gastrointestinal	JJ	_	12	attr	_	_
12	absorption	absorption	NN	_	9	obj	_	_
13	.	.	.	_	3	p	_	_

1	This	this	DT	_	3	det	_	_
2	observed	observe	VBN	_	3	attr	_	_
3	increase	increase	NN	_	10	dep	_	_
4	in	in	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	bioavailability	bioavailability	NN	_	3	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	may	may	MD	_	10	modal	_	_
10	be	be	VB	_	0	root	_	_
11	due	due	JJ	_	10	dep	_	_
12	to	to	TO	_	14	aux	_	_
13	transport-related	transport-related	JJ	_	14	attr	_	_
14	effects	effect	NNS	_	11	ppmod	_	_
15	,	,	,	_	14	p	_	_
16	such	such	JJ	_	14	appo	_	_
17	as	as	IN	_	24	mark	_	_
18	p-glycoprotein.	p-glycoprotein.	JJ	_	22	attr	_	_
19	in	in	FW	_	20	adv	_	_
20	vivo	vivo	FW	_	22	attr	_	_
21	animal	animal	NN	_	22	com	_	_
22	studies	study	NNS	_	24	dep	_	_
23	also	also	RB	_	24	adv	_	_
24	suggest	suggest	VBP	_	16	acl	_	_
25	that	that	IN	_	33	mark	_	_
26	in	in	IN	_	27	case	_	_
27	addition	addition	NN	_	33	ppmod	_	_
28	to	to	TO	_	27	aux	_	_
29	enhancing	enhance	VBG	_	27	comp	_	_
30	absorption	absorption	NN	_	29	obj	_	_
31	,	,	,	_	33	p	_	_
32	drug2	drug0	NN	_	33	dep	_	_
33	decreases	decrease	VBZ	_	24	comp	_	_
34	drug3	drug0	NN	_	36	attr	_	_
35	gastrointestinal	gastrointestinal	JJ	_	36	attr	_	_
36	secretion	secretion	NN	_	33	obj	_	_
37	,	,	,	_	33	p	_	_
38	while	while	IN	_	42	mark	_	_
39	drug4	drug0	NN	_	42	dep	_	_
40	may	may	MD	_	42	modal	_	_
41	also	also	RB	_	42	adv	_	_
42	decrease	decrease	VB	_	33	comp	_	_
43	biliary	biliary	JJ	_	44	attr	_	_
44	excretion	excretion	NN	_	42	obj	_	_
45	.	.	.	_	10	p	_	_

1	Drug	drug	NN	_	2	com	_	_
2	Interactions	interaction	NNS	_	31	dep	_	_
3	with	with	IN	_	5	case	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	Administration	administration	NN	_	2	ppmod	_	_
6	of	of	IN	_	8	case	_	_
7	120	0	CD	_	8	num	_	_
8	mg	mg	NN	_	5	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	(	-lrb-	-LRB-	_	15	p	_	_
12	2	0	CD	_	15	num	_	_
13	x	x	CC	_	15	cc	_	_
14	60	0	CD	_	15	num	_	_
15	mg	mg	NN	_	10	prn	_	_
16	capsule	capsule	JJ	_	15	attr	_	_
17	)	-rrb-	-RRB-	_	15	p	_	_
18	within	within	IN	_	20	case	_	_
19	15	0	CD	_	20	num	_	_
20	minutes	minute	NNS	_	2	ppmod	_	_
21	of	of	IN	_	23	case	_	_
22	an	an	DT	_	23	det	_	_
23	drug3	drug0	NN	_	20	ppmod	_	_
24	and	and	CC	_	23	cc	_	_
25	drug4	drug0	NN	_	23	conj	_	_
26	containing	contain	VBG	_	23	acl	_	_
27	drug5	drug0	NN	_	26	obj	_	_
28	(	-lrb-	-LRB-	_	29	p	_	_
29	drug6	drug0	NN	_	27	prn	_	_
30	)	-rrb-	-RRB-	_	29	p	_	_
31	decreased	decrease	VBD	_	0	root	_	_
32	drug7	drug0	NN	_	33	com	_	_
33	AUC	auc	NN	_	31	obj	_	_
34	by	by	IN	_	35	case	_	_
35	41	0	CD	_	33	ppmod	_	_
36	%	%	NN	_	35	meta	_	_
37	and	and	CC	_	33	cc	_	_
38	cmax	cmax	NN	_	33	conj	_	_
39	by	by	IN	_	40	case	_	_
40	43	0	CD	_	31	ppmod	_	_
41	%	%	NN	_	40	meta	_	_
42	.	.	.	_	31	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	should	should	MD	_	5	modal	_	_
3	not	not	RB	_	5	neg	_	_
4	be	be	VB	_	5	aux	_	_
5	taken	take	VBN	_	0	root	_	_
6	closely	closely	RB	_	5	adv	_	_
7	in	in	IN	_	8	case	_	_
8	time	time	NN	_	5	ppmod	_	_
9	with	with	IN	_	10	case	_	_
10	drug2	drug0	NN	_	5	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug3	drug0	NN	_	10	conj	_	_
13	containing	contain	VBG	_	10	acl	_	_
14	drug4	drug0	NN	_	13	obj	_	_
15	.	.	.	_	5	p	_	_

1	Interactions	interaction	NNS	_	15	dep	_	_
2	with	with	IN	_	6	case	_	_
3	Fruit	fruit	NN	_	6	com	_	_
4	Juices	juice	NNS	_	6	com	_	_
5	Fruit	fruit	NN	_	6	com	_	_
6	juices	juice	NNS	_	1	ppmod	_	_
7	such	such	JJ	_	9	adv	_	_
8	as	as	IN	_	9	case	_	_
9	grapefruit	grapefruit	NN	_	6	ppmod	_	_
10	,	,	,	_	9	p	_	_
11	orange	orange	NN	_	9	conj	_	_
12	and	and	CC	_	11	cc	_	_
13	apple	apple	NN	_	9	conj	_	_
14	may	may	MD	_	15	modal	_	_
15	reduce	reduce	VB	_	0	root	_	_
16	the	the	DT	_	17	det	_	_
17	bioavailability	bioavailability	NN	_	15	obj	_	_
18	and	and	CC	_	17	cc	_	_
19	exposure	exposure	NN	_	17	conj	_	_
20	of	of	IN	_	21	case	_	_
21	drug1	drug0	NN	_	17	ppmod	_	_
22	.	.	.	_	15	p	_	_

1	This	this	DT	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	based	base	VBN	_	0	root	_	_
4	on	on	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	results	result	NNS	_	3	ppmod	_	_
7	from	from	IN	_	10	case	_	_
8	3	0	CD	_	10	num	_	_
9	clinical	clinical	JJ	_	10	attr	_	_
10	studies	study	NNS	_	6	ppmod	_	_
11	using	use	VBG	_	10	acl	_	_
12	drug1	drug0	NN	_	15	attr	_	_
13	induced	induced	JJ	_	15	attr	_	_
14	skin	skin	NN	_	15	com	_	_
15	wheals	wheal	NNS	_	11	obj	_	_
16	and	and	CC	_	15	cc	_	_
17	flares	flare	NNS	_	15	conj	_	_
18	coupled	couple	VBN	_	15	acl	_	_
19	with	with	IN	_	22	case	_	_
20	population	population	NN	_	22	attr	_	_
21	pharmacokinetic	pharmacokinetic	JJ	_	22	attr	_	_
22	analysis	analysis	NN	_	18	ppmod	_	_
23	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	size	size	NN	_	7	dep	_	_
3	of	of	IN	_	4	case	_	_
4	wheal	wheal	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	flare	flare	NN	_	4	conj	_	_
7	were	be	VBD	_	0	root	_	_
8	significantly	significantly	RB	_	9	adv	_	_
9	larger	large	JJR	_	7	dep	_	_
10	when	when	WRB	_	13	adv	_	_
11	drug1	drug0	NN	_	13	dep	_	_
12	was	be	VBD	_	13	aux	_	_
13	administered	administer	VBN	_	7	comp	_	_
14	with	with	IN	_	16	case	_	_
15	either	either	CC	_	16	cc	_	_
16	grapefruit	grapefruit	NN	_	13	ppmod	_	_
17	or	or	CC	_	16	cc	_	_
18	orange	orange	NN	_	19	com	_	_
19	juices	juice	NNS	_	16	conj	_	_
20	compared	compare	VBN	_	22	adv	_	_
21	to	to	TO	_	22	aux	_	_
22	water	water	NN	_	13	ppmod	_	_
23	.	.	.	_	7	p	_	_

1	Based	base	VBN	_	5	adv	_	_
2	on	on	IN	_	5	case	_	_
3	the	the	DT	_	5	det	_	_
4	literature	literature	NN	_	5	com	_	_
5	reports	report	NNS	_	12	ppmod	_	_
6	,	,	,	_	12	p	_	_
7	the	the	DT	_	9	det	_	_
8	same	same	JJ	_	9	attr	_	_
9	effects	effect	NNS	_	12	dep	_	_
10	may	may	MD	_	12	modal	_	_
11	be	be	VB	_	12	aux	_	_
12	extrapolated	extrapolate	VBN	_	0	root	_	_
13	to	to	TO	_	16	aux	_	_
14	other	other	JJ	_	16	attr	_	_
15	fruit	fruit	NN	_	16	com	_	_
16	juices	juice	NNS	_	12	ppmod	_	_
17	such	such	JJ	_	20	adv	_	_
18	as	as	IN	_	20	case	_	_
19	apple	apple	JJ	_	20	attr	_	_
20	juice	juice	NN	_	16	ppmod	_	_
21	.	.	.	_	12	p	_	_

1	The	the	DT	_	3	det	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	significance	significance	NN	_	7	dep	_	_
4	of	of	IN	_	6	case	_	_
5	these	these	DT	_	6	det	_	_
6	observations	observation	NNS	_	3	ppmod	_	_
7	is	be	VBZ	_	0	root	_	_
8	unknown	unknown	JJ	_	7	dep	_	_
9	.	.	.	_	7	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	33	ppmod	_	_
3	,	,	,	_	33	p	_	_
4	based	base	VBN	_	8	adv	_	_
5	on	on	IN	_	8	case	_	_
6	the	the	DT	_	8	det	_	_
7	population	population	NN	_	8	com	_	_
8	pharmacokinetics	pharmacokinetics	NNS	_	33	ppmod	_	_
9	analysis	analysis	NN	_	33	dep	_	_
10	of	of	IN	_	13	case	_	_
11	the	the	DT	_	13	det	_	_
12	combined	combined	JJ	_	13	attr	_	_
13	data	datum	NNS	_	9	ppmod	_	_
14	from	from	IN	_	19	case	_	_
15	grapefruit	grapefruit	NN	_	19	attr	_	_
16	and	and	CC	_	15	cc	_	_
17	orange	orange	NN	_	18	com	_	_
18	juices	juice	NNS	_	15	conj	_	_
19	studies	study	NNS	_	13	ppmod	_	_
20	with	with	IN	_	22	case	_	_
21	the	the	DT	_	22	det	_	_
22	data	datum	NNS	_	19	ppmod	_	_
23	from	from	IN	_	26	case	_	_
24	a	a	DT	_	26	det	_	_
25	bioequivalence	bioequivalence	NN	_	26	com	_	_
26	study	study	NN	_	22	ppmod	_	_
27	,	,	,	_	26	p	_	_
28	the	the	DT	_	29	det	_	_
29	bioavailability	bioavailability	NN	_	26	appo	_	_
30	of	of	IN	_	31	case	_	_
31	drug1	drug0	NN	_	29	ppmod	_	_
32	was	be	VBD	_	33	aux	_	_
33	reduced	reduce	VBN	_	0	root	_	_
34	by	by	IN	_	35	case	_	_
35	36	0	CD	_	33	ppmod	_	_
36	%	%	NN	_	35	meta	_	_
37	.	.	.	_	33	p	_	_

1	Therefore	therefore	RB	_	12	adv	_	_
2	,	,	,	_	12	p	_	_
3	to	to	TO	_	4	aux	_	_
4	maximize	maximize	VB	_	12	advcl	_	_
5	the	the	DT	_	6	det	_	_
6	effects	effect	NNS	_	4	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	,	,	,	_	12	p	_	_
10	it	it	PRP	_	12	dep	_	_
11	is	be	VBZ	_	12	aux	_	_
12	recommended	recommend	VBN	_	0	root	_	_
13	that	that	IN	_	17	mark	_	_
14	drug2	drug0	NN	_	17	dep	_	_
15	should	should	MD	_	17	modal	_	_
16	be	be	VB	_	17	aux	_	_
17	taken	take	VBN	_	12	comp	_	_
18	with	with	IN	_	19	case	_	_
19	water	water	NN	_	17	ppmod	_	_

1	.	.	.	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	No	no	DT	_	3	det	_	_
2	formal	formal	JJ	_	3	attr	_	_
3	studies	study	NNS	_	12	dep	_	_
4	to	to	TO	_	5	aux	_	_
5	evaluate	evaluate	VB	_	3	acl	_	_
6	drug	drug	NN	_	7	com	_	_
7	interactions	interaction	NNS	_	5	obj	_	_
8	with	with	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	have	have	VBP	_	12	aux	_	_
11	been	be	VBN	_	12	aux	_	_
12	conducted	conduct	VBN	_	0	root	_	_
13	.	.	.	_	12	p	_	_

1	drug1	drug0	JJ	_	3	attr	_	_
2	oxidative	oxidative	JJ	_	3	attr	_	_
3	metabolites	metabolite	NNS	_	4	dep	_	_
4	appear	appear	VBP	_	0	root	_	_
5	to	to	TO	_	7	aux	_	_
6	be	be	VB	_	7	aux	_	_
7	formed	form	VBN	_	4	comp	_	_
8	by	by	IN	_	11	case	_	_
9	cytochrome	cytochrome	NN	_	11	com	_	_
10	P450	p0	NN	_	11	com	_	_
11	3A4	0a0	NN	_	7	ppmod	_	_
12	.	.	.	_	4	p	_	_

1	On	on	IN	_	6	case	_	_
2	the	the	DT	_	6	det	_	_
3	basis	basis	NN	_	6	advnp	_	_
4	of	of	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	metabolism	metabolism	NN	_	34	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	by	by	IN	_	12	case	_	_
10	cytochrome	cytochrome	NN	_	12	com	_	_
11	P450	p0	NN	_	12	com	_	_
12	3A4	0a0	NN	_	8	ppmod	_	_
13	,	,	,	_	34	p	_	_
14	drug2	drug0	NN	_	34	dep	_	_
15	,	,	,	_	14	p	_	_
16	drug3	drug0	NN	_	14	conj	_	_
17	,	,	,	_	16	p	_	_
18	drug4	drug0	NN	_	14	conj	_	_
19	,	,	,	_	18	p	_	_
20	drug5	drug0	NN	_	14	conj	_	_
21	,	,	,	_	20	p	_	_
22	grapefruit	grapefruit	NN	_	23	com	_	_
23	juice	juice	NN	_	14	conj	_	_
24	,	,	,	_	23	p	_	_
25	and	and	CC	_	23	cc	_	_
26	other	other	JJ	_	27	attr	_	_
27	inhibitors	inhibitor	NNS	_	14	conj	_	_
28	of	of	IN	_	31	case	_	_
29	cytochrome	cytochrome	NN	_	31	com	_	_
30	P450	p0	NN	_	31	com	_	_
31	3A4	0a0	NN	_	14	ppmod	_	_
32	would	would	MD	_	34	modal	_	_
33	be	be	VB	_	34	aux	_	_
34	expected	expect	VBN	_	0	root	_	_
35	to	to	TO	_	36	aux	_	_
36	lead	lead	VB	_	34	comp	_	_
37	to	to	TO	_	39	aux	_	_
38	an	an	DT	_	39	det	_	_
39	increase	increase	NN	_	36	ppmod	_	_
40	in	in	IN	_	43	case	_	_
41	plasma	plasma	NN	_	43	com	_	_
42	drug6	drug0	NN	_	43	com	_	_
43	concentrations	concentration	NNS	_	39	ppmod	_	_
44	.	.	.	_	34	p	_	_

1	Furthermore	furthermore	RB	_	17	adv	_	_
2	,	,	,	_	17	p	_	_
3	drug1	drug0	NN	_	17	dep	_	_
4	,	,	,	_	3	p	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	,	,	,	_	5	p	_	_
7	drug3	drug0	NN	_	3	conj	_	_
8	,	,	,	_	7	p	_	_
9	and	and	CC	_	7	cc	_	_
10	other	other	JJ	_	11	attr	_	_
11	inducers	inducer	NNS	_	3	conj	_	_
12	of	of	IN	_	15	case	_	_
13	cytochrome	cytochrome	NN	_	15	com	_	_
14	P450	p0	NN	_	15	com	_	_
15	3A4	0a0	NN	_	3	ppmod	_	_
16	may	may	MD	_	17	modal	_	_
17	cause	cause	VB	_	0	root	_	_
18	a	a	DT	_	19	det	_	_
19	reduction	reduction	NN	_	17	obj	_	_
20	in	in	IN	_	23	case	_	_
21	plasma	plasma	NN	_	23	com	_	_
22	drug4	drug0	NN	_	23	com	_	_
23	concentrations	concentration	NNS	_	19	ppmod	_	_
24	.	.	.	_	17	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	administration	administration	NN	_	8	dep	_	_
3	of	of	IN	_	5	case	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	capsules	capsule	NNS	_	2	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NNS	_	5	conj	_	_
8	resulted	result	VBD	_	0	root	_	_
9	in	in	IN	_	11	case	_	_
10	substantial	substantial	JJ	_	11	attr	_	_
11	increases	increase	NNS	_	8	ppmod	_	_
12	in	in	IN	_	14	case	_	_
13	plasma	plasma	NN	_	14	com	_	_
14	concentrations	concentration	NNS	_	11	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug3	drug0	NN	_	14	ppmod	_	_
17	,	,	,	_	8	p	_	_
18	probably	probably	RB	_	8	adv	_	_
19	at	at	IN	_	20	case	_	_
20	least	least	JJS	_	21	adv	_	_
21	partially	partially	RB	_	22	adv	_	_
22	related	related	JJ	_	8	dep	_	_
23	to	to	TO	_	27	aux	_	_
24	cytochrome	cytochrome	NN	_	26	com	_	_
25	P450	p0	NN	_	26	com	_	_
26	3A4	0a0	NN	_	27	com	_	_
27	inhibition	inhibition	NN	_	22	ppmod	_	_
28	by	by	IN	_	29	case	_	_
29	drug4	drug0	NN	_	27	ppmod	_	_
30	.	.	.	_	8	p	_	_

1	Under	under	IN	_	3	case	_	_
2	similar	similar	JJ	_	3	attr	_	_
3	conditions	condition	NNS	_	9	ppmod	_	_
4	,	,	,	_	9	p	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	concentrations	concentration	NNS	_	9	dep	_	_
7	were	be	VBD	_	9	aux	_	_
8	not	not	RB	_	9	neg	_	_
9	affected	affect	VBN	_	0	root	_	_
10	by	by	IN	_	13	case	_	_
11	concomitant	concomitant	JJ	_	13	attr	_	_
12	drug2	drug0	NN	_	13	com	_	_
13	administration	administration	NN	_	9	ppmod	_	_
14	.	.	.	_	9	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	administration	administration	NN	_	10	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	with	with	IN	_	7	case	_	_
6	drug2	drug0	NN	_	7	com	_	_
7	capsules	capsule	NNS	_	2	ppmod	_	_
8	is	be	VBZ	_	10	aux	_	_
9	not	not	RB	_	10	neg	_	_
10	recommended	recommend	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	6	case	_	_
4	controlled	controlled	JJ	_	6	attr	_	_
5	clinical	clinical	JJ	_	6	attr	_	_
6	studies	study	NNS	_	12	ppmod	_	_
7	,	,	,	_	12	p	_	_
8	drug2	drug0	NNS	_	12	dep	_	_
9	have	have	VBP	_	12	aux	_	_
10	been	be	VBN	_	12	aux	_	_
11	frequently	frequently	RB	_	12	adv	_	_
12	administered	administer	VBN	_	1	acl	_	_
13	concomitantly	concomitantly	RB	_	12	adv	_	_
14	with	with	IN	_	15	case	_	_
15	drug3	drug0	NN	_	12	ppmod	_	_
16	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	combination	combination	NN	_	5	dep	_	_
3	is	be	VBZ	_	5	aux	_	_
4	well	well	RB	_	5	adv	_	_
5	tolerated	tolerate	VBN	_	0	root	_	_
6	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	increases	increase	VBZ	_	0	root	_	_
5	drug3	drug0	NN	_	7	com	_	_
6	plasma	plasma	NN	_	7	com	_	_
7	levels	level	NNS	_	4	obj	_	_
8	.	.	.	_	4	p	_	_

1	Patients	patient	NNS	_	10	dep	_	_
2	receiving	receive	VBG	_	1	acl	_	_
3	the	the	DT	_	5	det	_	_
4	two	#crd#	CD	_	5	num	_	_
5	drugs	drug	NNS	_	2	obj	_	_
6	concomitantly	concomitantly	RB	_	10	adv	_	_
7	should	should	MD	_	10	modal	_	_
8	be	be	VB	_	10	aux	_	_
9	carefully	carefully	RB	_	10	adv	_	_
10	monitored	monitor	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Some	some	DT	_	4	det	_	_
4	drug2	drug0	NNS	_	6	dep	_	_
5	may	may	MD	_	6	modal	_	_
6	increase	increase	VB	_	1	acl	_	_
7	the	the	DT	_	8	det	_	_
8	concentration	concentration	NN	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug3	drug0	NN	_	8	ppmod	_	_
11	in	in	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	blood	blood	NN	_	8	ppmod	_	_
14	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	usually	usually	RB	_	5	adv	_	_
3	does	do	VBZ	_	5	aux	_	_
4	not	not	RB	_	5	neg	_	_
5	alter	alter	VB	_	19	advcl	_	_
6	the	the	DT	_	8	det	_	_
7	plasma	plasma	NN	_	8	com	_	_
8	levels	level	NNS	_	5	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	,	,	,	_	19	p	_	_
12	however	however	RB	_	19	adv	_	_
13	,	,	,	_	19	p	_	_
14	serum	serum	NN	_	16	com	_	_
15	drug3	drug0	NN	_	16	com	_	_
16	levels	level	NNS	_	19	dep	_	_
17	should	should	MD	_	19	modal	_	_
18	be	be	VB	_	19	aux	_	_
19	evaluated	evaluate	VBN	_	0	root	_	_
20	after	after	IN	_	22	case	_	_
21	concomitant	concomitant	JJ	_	22	attr	_	_
22	therapy	therapy	NN	_	19	ppmod	_	_
23	with	with	IN	_	26	mark	_	_
24	drug4	drug0	NN	_	26	dep	_	_
25	is	be	VBZ	_	26	aux	_	_
26	initiated	initiate	VBN	_	22	acl	_	_
27	.	.	.	_	19	p	_	_

1	drug1	drug0	NN	_	3	com	_	_
2	*	*	NN	_	3	com	_	_
3	Coadministration	coadministration	NN	_	6	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	had	have	VBD	_	0	root	_	_
7	no	no	DT	_	8	det	_	_
8	effect	effect	NN	_	6	obj	_	_
9	on	on	IN	_	11	case	_	_
10	drug3	drug0	NN	_	11	com	_	_
11	absorption	absorption	NN	_	6	ppmod	_	_
12	.	.	.	_	6	p	_	_

1	Even	even	RB	_	7	adv	_	_
2	though	though	IN	_	7	mark	_	_
3	such	such	JJ	_	4	attr	_	_
4	interactions	interaction	NNS	_	7	dep	_	_
5	were	be	VBD	_	7	aux	_	_
6	not	not	RB	_	7	neg	_	_
7	seen	see	VBN	_	22	advcl	_	_
8	during	during	IN	_	10	case	_	_
9	clinical	clinical	JJ	_	10	attr	_	_
10	studies	study	NNS	_	7	ppmod	_	_
11	with	with	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	,	,	,	_	22	p	_	_
14	an	an	DT	_	16	det	_	_
15	increased	increase	VBN	_	16	attr	_	_
16	volume	volume	NN	_	22	dep	_	_
17	of	of	IN	_	19	case	_	_
18	circulating	circulating	JJ	_	19	attr	_	_
19	fluids	fluid	NNS	_	16	ppmod	_	_
20	might	might	MD	_	22	modal	_	_
21	be	be	VB	_	22	aux	_	_
22	required	require	VBN	_	0	root	_	_
23	if	if	IN	_	27	mark	_	_
24	such	such	PDT	_	26	det	_	_
25	an	an	DT	_	26	det	_	_
26	interaction	interaction	NN	_	27	dep	_	_
27	were	be	VBD	_	22	comp	_	_
28	to	to	TO	_	29	aux	_	_
29	occur	occur	VB	_	27	comp	_	_
30	.	.	.	_	22	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Concomitant	concomitant	JJ	_	4	attr	_	_
4	administration	administration	NN	_	1	appo	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug3	drug0	NN	_	9	com	_	_
9	levels	level	NNS	_	6	conj	_	_
10	.	.	.	_	1	p	_	_

1	Plasma	plasma	NN	_	2	com	_	_
2	concentrations	concentration	NNS	_	9	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	should	should	MD	_	9	modal	_	_
6	therefore	therefore	RB	_	9	adv	_	_
7	be	be	VB	_	9	aux	_	_
8	closely	closely	RB	_	9	adv	_	_
9	monitored	monitor	VBN	_	0	root	_	_
10	,	,	,	_	9	p	_	_
11	and	and	CC	_	9	cc	_	_
12	its	its	PRP$	_	13	poss	_	_
13	dosage	dosage	NN	_	14	dep	_	_
14	reduced	reduce	VBD	_	9	conj	_	_
15	accordingly	accordingly	RB	_	14	adv	_	_
16	,	,	,	_	14	p	_	_
17	in	in	IN	_	18	case	_	_
18	patients	patient	NNS	_	14	ppmod	_	_
19	treated	treat	VBN	_	18	acl	_	_
20	with	with	IN	_	21	case	_	_
21	drug2	drug0	NN	_	19	ppmod	_	_
22	.	.	.	_	9	p	_	_

1	When	when	WRB	_	18	adv	_	_
2	therapeutic	therapeutic	JJ	_	3	attr	_	_
3	concentrations	concentration	NNS	_	18	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	,	,	,	_	5	p	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	,	,	,	_	7	p	_	_
9	drug3	drug0	NN	_	5	conj	_	_
10	,	,	,	_	9	p	_	_
11	drug4	drug0	NN	_	5	conj	_	_
12	,	,	,	_	11	p	_	_
13	drug5	drug0	NN	_	5	conj	_	_
14	,	,	,	_	13	p	_	_
15	or	or	CC	_	13	cc	_	_
16	drug6	drug0	NN	_	5	conj	_	_
17	were	be	VBD	_	18	aux	_	_
18	added	add	VBN	_	35	advcl	_	_
19	to	to	TO	_	21	aux	_	_
20	human	human	JJ	_	21	attr	_	_
21	plasma	plasma	NN	_	18	ppmod	_	_
22	(	-lrb-	-LRB-	_	24	p	_	_
23	in	in	FW	_	24	attr	_	_
24	vitro	vitro	FW	_	21	prn	_	_
25	)	-rrb-	-RRB-	_	24	p	_	_
26	,	,	,	_	35	p	_	_
27	the	the	DT	_	30	det	_	_
28	plasma	plasma	NN	_	30	com	_	_
29	protein	protein	NN	_	30	com	_	_
30	binding	binding	NN	_	35	dep	_	_
31	of	of	IN	_	32	case	_	_
32	drug7	drug0	NN	_	30	ppmod	_	_
33	was	be	VBD	_	35	aux	_	_
34	not	not	RB	_	35	neg	_	_
35	altered	alter	VBN	_	0	root	_	_
36	.	.	.	_	35	p	_	_

1	Drugs	drug	NNS	_	11	dep	_	_
2	which	which	WDT	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	enhance	enhance	VB	_	1	relcl	_	_
5	the	the	DT	_	8	det	_	_
6	neuromuscular	neuromuscular	JJ	_	8	attr	_	_
7	blocking	blocking	NN	_	8	com	_	_
8	action	action	NN	_	4	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	include	include	VBP	_	0	root	_	_
12	:	:	:	_	11	p	_	_
13	drug2	drug0	NN	_	11	obj	_	_
14	;	;	:	_	11	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	certain	certain	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	,	,	,	_	2	p	_	_
4	especially	especially	RB	_	6	adv	_	_
5	the	the	DT	_	6	det	_	_
6	drug2	drug0	NN	_	2	appo	_	_
7	and	and	CC	_	6	cc	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	;	;	:	_	2	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	salts	salt	NNS	_	0	root	_	_
3	;	;	:	_	2	p	_	_

1	drug1	drug0	NNP	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	Drugs	drug	NNS	_	0	root	_	_
2	which	which	WDT	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	enhance	enhance	VB	_	1	relcl	_	_
5	the	the	DT	_	8	det	_	_
6	neuromuscular	neuromuscular	JJ	_	8	attr	_	_
7	blocking	blocking	NN	_	8	com	_	_
8	action	action	NN	_	4	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	include	include	VBP	_	4	comp	_	_
12	:	:	:	_	11	p	_	_
13	drug2	drug0	NN	_	11	obj	_	_
14	;	;	:	_	13	p	_	_
15	drug3	drug0	NN	_	13	conj	_	_
16	;	;	:	_	15	p	_	_
17	drug4	drug0	NN	_	13	conj	_	_
18	;	;	:	_	17	p	_	_
19	certain	certain	JJ	_	20	attr	_	_
20	drug5	drug0	NN	_	13	conj	_	_
21	,	,	,	_	20	p	_	_
22	especially	especially	RB	_	20	adv	_	_
23	the	the	DT	_	24	det	_	_
24	drug6	drug0	NN	_	20	appo	_	_
25	and	and	CC	_	24	cc	_	_
26	drug7	drug0	NN	_	24	conj	_	_
27	;	;	:	_	20	p	_	_
28	drug8	drug0	NN	_	13	conj	_	_
29	;	;	:	_	28	p	_	_
30	drug9	drug0	NN	_	31	com	_	_
31	salts	salt	NNS	_	13	conj	_	_
32	;	;	:	_	31	p	_	_
33	drug10	drug0	CD	_	13	conj	_	_
34	;	;	:	_	33	p	_	_
35	and	and	CC	_	33	cc	_	_
36	drug11	drug0	NN	_	13	conj	_	_
37	.	.	.	_	1	p	_	_

1	If	if	IN	_	5	mark	_	_
2	other	other	JJ	_	3	attr	_	_
3	drug1	drug0	NNS	_	5	dep	_	_
4	are	be	VBP	_	5	aux	_	_
5	used	use	VBN	_	21	advcl	_	_
6	during	during	IN	_	9	case	_	_
7	the	the	DT	_	9	det	_	_
8	same	same	JJ	_	9	attr	_	_
9	procedure	procedure	NN	_	5	ppmod	_	_
10	,	,	,	_	21	p	_	_
11	the	the	DT	_	12	det	_	_
12	possibility	possibility	NN	_	21	dep	_	_
13	of	of	IN	_	18	case	_	_
14	a	a	DT	_	18	det	_	_
15	synergistic	synergistic	JJ	_	18	attr	_	_
16	or	or	NN	_	18	com	_	_
17	antagonist	antagonist	NN	_	18	com	_	_
18	effect	effect	NN	_	12	ppmod	_	_
19	should	should	MD	_	21	modal	_	_
20	be	be	VB	_	21	aux	_	_
21	considered	consider	VBN	_	0	root	_	_
22	.	.	.	_	21	p	_	_

1	The	the	DT	_	3	det	_	_
2	prior	prior	JJ	_	3	attr	_	_
3	administration	administration	NN	_	8	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	does	do	VBZ	_	8	aux	_	_
7	not	not	RB	_	8	neg	_	_
8	enhance	enhance	VB	_	0	root	_	_
9	the	the	DT	_	10	det	_	_
10	duration	duration	NN	_	8	obj	_	_
11	,	,	,	_	8	p	_	_
12	but	but	CC	_	8	cc	_	_
13	quickens	quicken	VBZ	_	8	conj	_	_
14	the	the	DT	_	15	det	_	_
15	onset	onset	NN	_	13	obj	_	_
16	and	and	CC	_	13	cc	_	_
17	may	may	MD	_	18	modal	_	_
18	increase	increase	VB	_	8	conj	_	_
19	the	the	DT	_	20	det	_	_
20	depth	depth	NN	_	18	obj	_	_
21	,	,	,	_	20	p	_	_
22	of	of	IN	_	24	case	_	_
23	neuromuscular	neuromuscular	JJ	_	24	attr	_	_
24	block	block	NN	_	20	ppmod	_	_
25	induced	induce	VBN	_	24	acl	_	_
26	by	by	IN	_	27	case	_	_
27	drug2	drug0	NN	_	25	ppmod	_	_
28	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	should	should	MD	_	5	modal	_	_
3	not	not	RB	_	5	neg	_	_
4	be	be	VB	_	5	aux	_	_
5	administered	administer	VBN	_	0	root	_	_
6	until	until	IN	_	10	mark	_	_
7	a	a	DT	_	8	det	_	_
8	patient	patient	NN	_	10	dep	_	_
9	has	have	VBZ	_	10	aux	_	_
10	recovered	recover	VBN	_	5	comp	_	_
11	from	from	IN	_	15	case	_	_
12	drug2	drug0	NN	_	15	attr	_	_
13	-induced	-induced	JJ	_	15	attr	_	_
14	neuromuscular	neuromuscular	JJ	_	15	attr	_	_
15	block	block	NN	_	10	ppmod	_	_
16	.	.	.	_	5	p	_	_

1	No	no	DT	_	3	det	_	_
2	formal	formal	JJ	_	3	attr	_	_
3	assessments	assessment	NNS	_	15	dep	_	_
4	of	of	IN	_	7	case	_	_
5	pharmacokinetic	pharmacokinetic	JJ	_	7	attr	_	_
6	drug-drug	drug-drug	JJ	_	7	attr	_	_
7	interactions	interaction	NNS	_	3	ppmod	_	_
8	between	between	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	other	other	JJ	_	12	attr	_	_
12	agents	agent	NNS	_	9	conj	_	_
13	have	have	VBP	_	15	aux	_	_
14	been	be	VBN	_	15	aux	_	_
15	conducted	conduct	VBN	_	0	root	_	_
16	.	.	.	_	15	p	_	_

1	Caution	caution	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	advised	advise	VBN	_	0	root	_	_
4	when	when	WRB	_	7	adv	_	_
5	drug1	drug0	NN	_	7	dep	_	_
6	is	be	VBZ	_	7	aux	_	_
7	coadministered	coadministered	VBN	_	3	comp	_	_
8	with	with	IN	_	10	case	_	_
9	other	other	JJ	_	10	attr	_	_
10	medications	medication	NNS	_	7	ppmod	_	_
11	that	that	WDT	_	13	dep	_	_
12	can	can	MD	_	13	modal	_	_
13	prolong	prolong	VB	_	10	relcl	_	_
14	the	the	DT	_	16	det	_	_
15	QT	qt	JJ	_	16	attr	_	_
16	interval	interval	NN	_	13	obj	_	_
17	(	-lrb-	-LRB-	_	20	p	_	_
18	e.g.	e.g.	FW	_	20	adv	_	_
19	certain	certain	JJ	_	20	attr	_	_
20	drug2	drug0	NN	_	16	prn	_	_
21	or	or	CC	_	20	cc	_	_
22	drug3	drug0	NN	_	20	conj	_	_
23	)	-rrb-	-RRB-	_	20	p	_	_
24	or	or	CC	_	13	cc	_	_
25	lead	lead	VB	_	13	conj	_	_
26	to	to	TO	_	28	aux	_	_
27	electrolyte	electrolyte	NN	_	28	com	_	_
28	abnormalities	abnormality	NNS	_	25	ppmod	_	_
29	(	-lrb-	-LRB-	_	30	p	_	_
30	such	such	JJ	_	28	prn	_	_
31	as	as	IN	_	32	case	_	_
32	drug4	drug0	NN	_	30	ppmod	_	_
33	or	or	CC	_	32	cc	_	_
34	drug5	drug0	NN	_	32	conj	_	_
35	)	-rrb-	-RRB-	_	30	p	_	_
36	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	interferes	interfere	VBZ	_	0	root	_	_
3	with	with	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	absorption	absorption	NN	_	2	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	including	include	VBG	_	10	adv	_	_
10	drug3	drug0	NN	_	7	ppmod	_	_
11	.	.	.	_	2	p	_	_

1	Administration	administration	NN	_	15	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	to	to	TO	_	6	aux	_	_
5	hypoparathyroid	hypoparathyroid	JJ	_	6	attr	_	_
6	patients	patient	NNS	_	1	ppmod	_	_
7	who	who	WP	_	11	dep	_	_
8	are	be	VBP	_	11	aux	_	_
9	concurrently	concurrently	RB	_	11	adv	_	_
10	being	be	VBG	_	11	aux	_	_
11	treated	treat	VBN	_	6	relcl	_	_
12	with	with	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	may	may	MD	_	15	modal	_	_
15	cause	cause	VB	_	0	root	_	_
16	hypercalcemia	hypercalcemia	NN	_	15	obj	_	_
17	.	.	.	_	15	p	_	_

1	drug1	drug0	NN	_	5	attr	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	CNS	cns	NN	_	1	prn	_	_
4	)	-rrb-	-RRB-	_	3	p	_	_
5	drugs	drug	NNS	_	0	root	_	_
6	including	include	VBG	_	7	adv	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	drug3	drug0	NN	_	7	conj	_	_
10	,	,	,	_	9	p	_	_
11	drug4	drug0	NN	_	7	conj	_	_
12	,	,	,	_	11	p	_	_
13	drug5	drug0	NN	_	7	conj	_	_
14	,	,	,	_	13	p	_	_
15	blood	blood	NN	_	17	com	_	_
16	pressure	pressure	NN	_	17	com	_	_
17	medications	medication	NNS	_	7	conj	_	_
18	(	-lrb-	-LRB-	_	19	p	_	_
19	drug6	drug0	NN	_	17	prn	_	_
20	,	,	,	_	19	p	_	_
21	drug7	drug0	NN	_	19	appo	_	_
22	,	,	,	_	19	p	_	_
23	drug8	drug0	NN	_	19	appo	_	_
24	)	-rrb-	-RRB-	_	19	p	_	_
25	,	,	,	_	17	p	_	_
26	motion	motion	NN	_	28	com	_	_
27	sickness	sickness	NN	_	28	com	_	_
28	medications	medication	NNS	_	7	conj	_	_
29	,	,	,	_	28	p	_	_
30	drug9	drug0	NN	_	7	conj	_	_
31	,	,	,	_	30	p	_	_
32	drug10	drug0	NN	_	7	conj	_	_
33	,	,	,	_	32	p	_	_
34	drug11	drug0	NN	_	7	conj	_	_
35	,	,	,	_	34	p	_	_
36	sleeping	sleeping	NN	_	37	com	_	_
37	pills	pill	NNS	_	7	conj	_	_
38	and	and	CC	_	37	cc	_	_
39	drug12	drug0	NN	_	7	conj	_	_

1	Although	although	IN	_	9	mark	_	_
2	no	no	DT	_	6	det	_	_
3	clinical	clinical	JJ	_	6	attr	_	_
4	drug-drug	drug-drug	JJ	_	6	attr	_	_
5	interaction	interaction	NN	_	6	com	_	_
6	studies	study	NNS	_	9	dep	_	_
7	have	have	VBP	_	9	aux	_	_
8	been	be	VBN	_	9	aux	_	_
9	conducted	conduct	VBN	_	27	advcl	_	_
10	to	to	TO	_	11	aux	_	_
11	date	date	NN	_	9	ppmod	_	_
12	,	,	,	_	27	p	_	_
13	on	on	IN	_	20	case	_	_
14	the	the	DT	_	20	det	_	_
15	basis	basis	NN	_	20	advnp	_	_
16	of	of	IN	_	20	case	_	_
17	the	the	DT	_	20	det	_	_
18	in	in	FW	_	19	adv	_	_
19	vitro	vitro	FW	_	20	attr	_	_
20	studies	study	NNS	_	27	ppmod	_	_
21	,	,	,	_	27	p	_	_
22	cytochrome	cytochrome	NN	_	24	com	_	_
23	p450	p0	NN	_	24	com	_	_
24	inhibitors	inhibitor	NNS	_	27	dep	_	_
25	and	and	CC	_	24	cc	_	_
26	inducers	inducer	NNS	_	24	conj	_	_
27	are	be	VBP	_	0	root	_	_
28	unlikely	unlikely	JJ	_	27	dep	_	_
29	to	to	TO	_	30	aux	_	_
30	affect	affect	VB	_	28	comp	_	_
31	the	the	DT	_	32	det	_	_
32	metabolism	metabolism	NN	_	30	obj	_	_
33	of	of	IN	_	34	case	_	_
34	drug1	drug0	NN	_	32	ppmod	_	_
35	.	.	.	_	27	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	15	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	on	on	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	metabolism	metabolism	NN	_	2	ppmod	_	_
8	of	of	IN	_	11	case	_	_
9	cytochrome	cytochrome	NN	_	11	com	_	_
10	p450	p0	NN	_	11	com	_	_
11	substrates	substrate	NNS	_	7	ppmod	_	_
12	has	have	VBZ	_	15	aux	_	_
13	not	not	RB	_	15	neg	_	_
14	been	be	VBN	_	15	aux	_	_
15	studied	study	VBN	_	0	root	_	_
16	.	.	.	_	15	p	_	_

1	Drug/Laboratory	drug/laboratory	JJ	_	3	attr	_	_
2	Tests	test	NNS	_	3	com	_	_
3	Interactions	interaction	NNS	_	0	root	_	_
4	There	there	EX	_	5	dep	_	_
5	are	be	VBP	_	3	acl	_	_
6	no	no	DT	_	10	det	_	_
7	known	known	JJ	_	10	attr	_	_
8	clinically	clinically	RB	_	9	adv	_	_
9	significant	significant	JJ	_	10	attr	_	_
10	interactions	interaction	NNS	_	5	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	with	with	IN	_	15	case	_	_
14	other	other	JJ	_	15	attr	_	_
15	medications	medication	NNS	_	10	ppmod	_	_
16	or	or	CC	_	15	cc	_	_
17	laboratory	laboratory	NN	_	18	com	_	_
18	tests	test	NNS	_	15	conj	_	_
19	.	.	.	_	3	p	_	_

1	No	no	DT	_	6	det	_	_
2	formal	formal	JJ	_	6	attr	_	_
3	drug/laboratory	drug/laboratory	NN	_	6	com	_	_
4	test	test	NN	_	6	com	_	_
5	interaction	interaction	NN	_	6	com	_	_
6	studies	study	NNS	_	9	dep	_	_
7	have	have	VBP	_	9	aux	_	_
8	been	be	VBN	_	9	aux	_	_
9	conducted	conduct	VBN	_	0	root	_	_
10	with	with	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	9	p	_	_

1	Unless	unless	IN	_	3	mark	_	_
2	really	really	RB	_	3	adv	_	_
3	needed	need	VBN	_	15	advcl	_	_
4	,	,	,	_	15	p	_	_
5	agents	agent	NNS	_	15	dep	_	_
6	which	which	WDT	_	8	dep	_	_
7	may	may	MD	_	8	modal	_	_
8	enhance	enhance	VB	_	5	relcl	_	_
9	the	the	DT	_	10	det	_	_
10	risk	risk	NN	_	8	obj	_	_
11	of	of	IN	_	12	case	_	_
12	hemorrhage	hemorrhage	NN	_	10	ppmod	_	_
13	should	should	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	discontinued	discontinue	VBN	_	0	root	_	_
16	prior	prior	JJ	_	18	adv	_	_
17	to	to	TO	_	18	aux	_	_
18	initiation	initiation	NN	_	15	ppmod	_	_
19	of	of	IN	_	22	case	_	_
20	drug1	drug0	NN	_	22	com	_	_
21	Injection	injection	NN	_	22	com	_	_
22	therapy	therapy	NN	_	18	ppmod	_	_
23	.	.	.	_	15	p	_	_

1	These	these	DT	_	2	det	_	_
2	agents	agent	NNS	_	3	dep	_	_
3	include	include	VBP	_	0	root	_	_
4	medications	medication	NNS	_	3	obj	_	_
5	such	such	JJ	_	8	adv	_	_
6	as	as	IN	_	8	case	_	_
7	:	:	:	_	8	p	_	_
8	drug1	drug0	NN	_	4	ppmod	_	_
9	,	,	,	_	8	p	_	_
10	drug2	drug0	NN	_	8	appo	_	_
11	including	include	VBG	_	12	adv	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	sali-cylates	sali-cylates	NN	_	12	conj	_	_
15	,	,	,	_	14	p	_	_
16	drug4	drug0	NN	_	12	conj	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	including	include	VBG	_	16	prn	_	_
19	drug5	drug0	NN	_	18	obj	_	_
20	)	-rrb-	-RRB-	_	18	p	_	_
21	,	,	,	_	16	p	_	_
22	drug6	drug0	NN	_	12	conj	_	_
23	,	,	,	_	22	p	_	_
24	or	or	CC	_	22	cc	_	_
25	drug7	drug0	NN	_	12	conj	_	_
26	.	.	.	_	3	p	_	_

1	If	if	IN	_	3	mark	_	_
2	co-administration	co-administration	NN	_	3	dep	_	_
3	is	be	VBZ	_	6	advcl	_	_
4	essential	essential	JJ	_	3	dep	_	_
5	,	,	,	_	6	p	_	_
6	conduct	conduct	VBP	_	0	root	_	_
7	close	close	JJ	_	11	attr	_	_
8	clinical	clinical	JJ	_	11	attr	_	_
9	and	and	CC	_	8	cc	_	_
10	laboratory	laboratory	JJ	_	8	conj	_	_
11	monitoring	monitoring	NN	_	6	obj	_	_

1	.	.	.	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	No	no	DT	_	2	det	_	_
2	interactions	interaction	NNS	_	5	dep	_	_
3	have	have	VBP	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	observed	observe	VBN	_	0	root	_	_
6	between	between	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	,	,	,	_	9	p	_	_
11	drug3	drug0	NN	_	7	conj	_	_
12	,	,	,	_	11	p	_	_
13	drug4	drug0	NN	_	7	conj	_	_
14	,	,	,	_	13	p	_	_
15	drug5	drug0	NN	_	7	conj	_	_
16	,	,	,	_	15	p	_	_
17	drug6	drug0	NN	_	7	conj	_	_
18	,	,	,	_	17	p	_	_
19	and	and	CC	_	17	cc	_	_
20	drug7	drug0	NN	_	7	conj	_	_
21	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	does	do	VBZ	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	inhibit	inhibit	VB	_	0	root	_	_
5	the	the	DT	_	10	det	_	_
6	cytochrome	cytochrome	NN	_	10	attr	_	_
7	P-450-linked	p-0-linked	JJ	_	10	attr	_	_
8	drug-metabolizing	drug-metabolizing	NN	_	10	com	_	_
9	enzyme	enzyme	NN	_	10	com	_	_
10	system	system	NN	_	4	obj	_	_
11	;	;	:	_	4	p	_	_

1	therefore	therefore	RB	_	13	adv	_	_
2	,	,	,	_	13	p	_	_
3	drug	drug	NN	_	4	com	_	_
4	interactions	interaction	NNS	_	13	dep	_	_
5	mediated	mediate	VBN	_	4	acl	_	_
6	by	by	IN	_	7	case	_	_
7	inhibition	inhibition	NN	_	5	ppmod	_	_
8	of	of	IN	_	10	case	_	_
9	hepatic	hepatic	JJ	_	10	attr	_	_
10	metabolism	metabolism	NN	_	7	ppmod	_	_
11	are	be	VBP	_	13	aux	_	_
12	not	not	RB	_	13	neg	_	_
13	expected	expect	VBN	_	0	root	_	_
14	to	to	TO	_	15	aux	_	_
15	occur	occur	VB	_	13	comp	_	_
16	.	.	.	_	13	p	_	_

1	In	in	IN	_	2	case	_	_
2	patients	patient	NNS	_	21	ppmod	_	_
3	given	given	IN	_	6	case	_	_
4	very	very	RB	_	5	adv	_	_
5	high	high	JJ	_	6	attr	_	_
6	doses	dose	NNS	_	2	ppmod	_	_
7	(	-lrb-	-LRB-	_	9	p	_	_
8	3900	0	NN	_	9	num	_	_
9	mg	mg	NN	_	6	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	6	ppmod	_	_
13	daily	daily	RB	_	12	adv	_	_
14	,	,	,	_	21	p	_	_
15	increases	increase	NNS	_	21	dep	_	_
16	in	in	IN	_	19	case	_	_
17	serum	serum	NN	_	19	com	_	_
18	drug2	drug0	NN	_	19	com	_	_
19	levels	level	NNS	_	15	ppmod	_	_
20	were	be	VBD	_	21	aux	_	_
21	seen	see	VBN	_	0	root	_	_
22	when	when	WRB	_	30	adv	_	_
23	drug3	drug0	NN	_	30	dep	_	_
24	,	,	,	_	23	p	_	_
25	150	0	CD	_	26	num	_	_
26	mg	mg	NN	_	27	com	_	_
27	b.i.d.	b.i.d.	NN	_	23	appo	_	_
28	,	,	,	_	23	p	_	_
29	was	be	VBD	_	30	aux	_	_
30	administered	administer	VBN	_	21	comp	_	_
31	concurrently	concurrently	RB	_	30	adv	_	_
32	.	.	.	_	21	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	should	should	MD	_	5	modal	_	_
3	not	not	RB	_	5	neg	_	_
4	be	be	VB	_	5	aux	_	_
5	combined	combine	VBN	_	0	root	_	_
6	with	with	IN	_	8	case	_	_
7	other	other	JJ	_	8	attr	_	_
8	drug2	drug0	NN	_	5	ppmod	_	_
9	.	.	.	_	5	p	_	_

1	Patients	patient	NNS	_	15	dep	_	_
2	receiving	receive	VBG	_	1	acl	_	_
3	catecholamine-depleting	catecholamine-depleting	JJ	_	4	attr	_	_
4	drugs	drug	NNS	_	2	obj	_	_
5	,	,	,	_	4	p	_	_
6	such	such	JJ	_	8	adv	_	_
7	as	as	IN	_	8	case	_	_
8	drug1	drug0	NN	_	4	ppmod	_	_
9	or	or	CC	_	8	cc	_	_
10	drug2	drug0	NN	_	8	conj	_	_
11	,	,	,	_	4	p	_	_
12	should	should	MD	_	15	modal	_	_
13	be	be	VB	_	15	aux	_	_
14	closely	closely	RB	_	15	adv	_	_
15	monitored	monitor	VBN	_	0	root	_	_
16	,	,	,	_	15	p	_	_
17	because	because	IN	_	26	mark	_	_
18	the	the	DT	_	22	det	_	_
19	added	add	VBN	_	22	attr	_	_
20	beta-adrenergic	beta-adrenergic	JJ	_	22	attr	_	_
21	blocking	blocking	NN	_	22	com	_	_
22	action	action	NN	_	26	dep	_	_
23	of	of	IN	_	24	case	_	_
24	drug3	drug0	NN	_	22	ppmod	_	_
25	may	may	MD	_	26	modal	_	_
26	produce	produce	VB	_	15	comp	_	_
27	excessive	excessive	JJ	_	28	attr	_	_
28	reduction	reduction	NN	_	26	obj	_	_
29	of	of	IN	_	31	case	_	_
30	sympathetic	sympathetic	JJ	_	31	attr	_	_
31	activity	activity	NN	_	28	ppmod	_	_
32	.	.	.	_	15	p	_	_

1	In	in	IN	_	2	case	_	_
2	patients	patient	NNS	_	18	ppmod	_	_
3	receiving	receive	VBG	_	2	acl	_	_
4	concurrent	concurrent	JJ	_	5	attr	_	_
5	therapy	therapy	NN	_	3	obj	_	_
6	with	with	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	,	,	,	_	18	p	_	_
9	if	if	IN	_	11	mark	_	_
10	therapy	therapy	NN	_	11	dep	_	_
11	is	be	VBZ	_	18	advcl	_	_
12	to	to	TO	_	14	aux	_	_
13	be	be	VB	_	14	aux	_	_
14	discontinued	discontinue	VBN	_	11	comp	_	_
15	,	,	,	_	18	p	_	_
16	it	it	PRP	_	18	dep	_	_
17	is	be	VBZ	_	18	aux	_	_
18	suggested	suggest	VBN	_	0	root	_	_
19	that	that	IN	_	22	mark	_	_
20	drug2	drug0	NN	_	22	dep	_	_
21	be	be	VB	_	22	aux	_	_
22	discontinued	discontinue	VBN	_	18	comp	_	_
23	for	for	IN	_	25	case	_	_
24	several	several	JJ	_	25	attr	_	_
25	days	day	NNS	_	22	ppmod	_	_
26	before	before	IN	_	28	case	_	_
27	the	the	DT	_	28	det	_	_
28	withdrawal	withdrawal	NN	_	25	ppmod	_	_
29	of	of	IN	_	30	case	_	_
30	drug3	drug0	NN	_	28	ppmod	_	_
31	.	.	.	_	18	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	used	use	VBN	_	0	root	_	_
5	with	with	IN	_	6	case	_	_
6	care	care	NN	_	4	ppmod	_	_
7	when	when	WRB	_	43	adv	_	_
8	drug2	drug0	NNS	_	43	dep	_	_
9	or	or	CC	_	8	cc	_	_
10	inhibitors	inhibitor	NNS	_	8	conj	_	_
11	of	of	IN	_	13	case	_	_
12	AV	av	NN	_	13	com	_	_
13	conduction	conduction	NN	_	8	ppmod	_	_
14	,	,	,	_	8	p	_	_
15	such	such	JJ	_	18	adv	_	_
16	as	as	IN	_	18	case	_	_
17	certain	certain	JJ	_	18	attr	_	_
18	drug3	drug0	NN	_	8	ppmod	_	_
19	(	-lrb-	-LRB-	_	23	p	_	_
20	particularly	particularly	RB	_	23	adv	_	_
21	of	of	IN	_	23	case	_	_
22	the	the	DT	_	23	det	_	_
23	drug4	drug0	NN	_	18	prn	_	_
24	[	-lsb-	-LRB-	_	25	p	_	_
25	drug5	drug0	NN	_	23	prn	_	_
26	]	-rsb-	-RRB-	_	25	p	_	_
27	and	and	CC	_	23	cc	_	_
28	drug6	drug0	NN	_	32	attr	_	_
29	[	-lsb-	-LRB-	_	32	p	_	_
30	drug7	drug0	NN	_	32	attr	_	_
31	]	-rsb-	-RRB-	_	32	p	_	_
32	classes	class	NNS	_	23	conj	_	_
33	)	-rrb-	-RRB-	_	23	p	_	_
34	,	,	,	_	18	p	_	_
35	or	or	CC	_	18	cc	_	_
36	drug8	drug0	NN	_	18	conj	_	_
37	,	,	,	_	8	p	_	_
38	such	such	JJ	_	40	adv	_	_
39	as	as	IN	_	40	case	_	_
40	drug9	drug0	NN	_	8	ppmod	_	_
41	,	,	,	_	8	p	_	_
42	are	be	VBP	_	43	aux	_	_
43	used	use	VBN	_	4	comp	_	_
44	concurrently	concurrently	RB	_	43	adv	_	_
45	.	.	.	_	4	p	_	_

1	Concurrent	concurrent	JJ	_	2	attr	_	_
2	use	use	NN	_	5	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	increases	increase	VBZ	_	0	root	_	_
6	the	the	DT	_	8	det	_	_
7	metabolic	metabolic	JJ	_	8	attr	_	_
8	clearance	clearance	NN	_	5	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	,	,	,	_	5	p	_	_
12	resulting	result	VBG	_	5	comp	_	_
13	in	in	IN	_	17	case	_	_
14	a	a	DT	_	17	det	_	_
15	shortened	shorten	VBD	_	17	attr	_	_
16	elimination	elimination	NN	_	17	com	_	_
17	half-life	half-life	NN	_	12	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug3	drug0	NN	_	17	ppmod	_	_
20	.	.	.	_	5	p	_	_

1	However	however	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	initial	initial	JJ	_	5	attr	_	_
4	dose	dose	NN	_	5	com	_	_
5	modification	modification	NN	_	6	dep	_	_
6	is	be	VBZ	_	0	root	_	_
7	generally	generally	RB	_	6	adv	_	_
8	not	not	RB	_	6	neg	_	_
9	necessary	necessary	JJ	_	6	dep	_	_
10	.	.	.	_	6	p	_	_

1	Pharmacokinetic	pharmacokinetic	JJ	_	2	attr	_	_
2	studies	study	NNS	_	3	dep	_	_
3	document	document	VBP	_	0	root	_	_
4	no	no	DT	_	7	det	_	_
5	clinically	clinically	RB	_	6	adv	_	_
6	relevant	relevant	JJ	_	7	attr	_	_
7	interactions	interaction	NNS	_	3	obj	_	_
8	with	with	IN	_	10	case	_	_
9	other	other	JJ	_	10	attr	_	_
10	agents	agent	NNS	_	7	ppmod	_	_
11	given	give	VBN	_	10	acl	_	_
12	concomitantly	concomitantly	RB	_	11	adv	_	_
13	,	,	,	_	10	p	_	_
14	including	include	VBG	_	15	adv	_	_
15	drug1	drug0	NN	_	10	ppmod	_	_
16	,	,	,	_	15	p	_	_
17	drug2	drug0	NN	_	15	conj	_	_
18	,	,	,	_	17	p	_	_
19	and	and	CC	_	17	cc	_	_
20	drug3	drug0	NN	_	15	conj	_	_
21	.	.	.	_	3	p	_	_

1	There	there	EX	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	no	no	DT	_	4	det	_	_
4	effect	effect	NN	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	on	on	IN	_	9	case	_	_
8	prothrombin	prothrombin	NN	_	9	com	_	_
9	time	time	NN	_	4	ppmod	_	_
10	in	in	IN	_	11	case	_	_
11	patients	patient	NNS	_	9	ppmod	_	_
12	on	on	IN	_	14	case	_	_
13	stable	stable	JJ	_	14	attr	_	_
14	doses	dose	NNS	_	11	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	.	.	.	_	2	p	_	_

1	Risk	risk	NN	_	0	root	_	_
2	of	of	IN	_	4	case	_	_
3	Anaphylactic	anaphylactic	JJ	_	4	attr	_	_
4	Reaction	reaction	NN	_	1	ppmod	_	_
5	:	:	:	_	1	p	_	_
6	While	while	IN	_	7	mark	_	_
7	taking	take	VBG	_	24	advcl	_	_
8	drug1	drug0	NN	_	7	obj	_	_
9	,	,	,	_	24	p	_	_
10	patients	patient	NNS	_	24	dep	_	_
11	with	with	IN	_	13	case	_	_
12	a	a	DT	_	13	det	_	_
13	history	history	NN	_	10	ppmod	_	_
14	of	of	IN	_	17	case	_	_
15	severe	severe	JJ	_	17	attr	_	_
16	anaphylactic	anaphylactic	JJ	_	17	attr	_	_
17	reaction	reaction	NN	_	13	ppmod	_	_
18	to	to	TO	_	20	aux	_	_
19	a	a	DT	_	20	det	_	_
20	variety	variety	NN	_	17	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	allergens	allergen	NNS	_	20	ppmod	_	_
23	may	may	MD	_	24	modal	_	_
24	be	be	VB	_	1	acl	_	_
25	more	more	RBR	_	26	adv	_	_
26	reactive	reactive	JJ	_	24	dep	_	_
27	to	to	TO	_	29	aux	_	_
28	repeated	repeated	JJ	_	29	attr	_	_
29	challenge	challenge	NN	_	26	ppmod	_	_
30	,	,	,	_	26	p	_	_
31	either	either	CC	_	26	cc	_	_
32	accidental	accidental	JJ	_	26	conj	_	_
33	,	,	,	_	32	p	_	_
34	diagnostic	diagnostic	JJ	_	26	conj	_	_
35	,	,	,	_	34	p	_	_
36	or	or	CC	_	34	cc	_	_
37	therapeutic	therapeutic	JJ	_	26	conj	_	_
38	.	.	.	_	1	p	_	_

1	Such	such	JJ	_	2	attr	_	_
2	patients	patient	NNS	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	be	be	VB	_	0	root	_	_
5	unresponsive	unresponsive	JJ	_	4	dep	_	_
6	to	to	TO	_	9	aux	_	_
7	the	the	DT	_	9	det	_	_
8	usual	usual	JJ	_	9	attr	_	_
9	doses	dose	NNS	_	5	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	used	use	VBN	_	9	acl	_	_
13	to	to	TO	_	14	aux	_	_
14	treat	treat	VB	_	12	comp	_	_
15	allergic	allergic	JJ	_	16	attr	_	_
16	reactions	reaction	NNS	_	14	obj	_	_
17	.	.	.	_	4	p	_	_

1	Hypertensive	hypertensive	NN	_	2	com	_	_
2	crises	crisis	NNS	_	3	dep	_	_
3	have	have	VBP	_	0	root	_	_
4	resulted	result	VBD	_	3	comp	_	_
5	when	when	WRB	_	9	adv	_	_
6	drug1	drug0	NN	_	9	dep	_	_
7	have	have	VBP	_	9	aux	_	_
8	been	be	VBN	_	9	aux	_	_
9	used	use	VBN	_	4	comp	_	_
10	concomitantly	concomitantly	RB	_	9	adv	_	_
11	within14	within0	CD	_	12	num	_	_
12	days	day	NNS	_	14	dat	_	_
13	following	follow	VBG	_	14	adv	_	_
14	use	use	NN	_	9	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	should	should	MD	_	5	modal	_	_
3	not	not	RB	_	5	neg	_	_
4	be	be	VB	_	5	aux	_	_
5	used	use	VBN	_	0	root	_	_
6	concomitantly	concomitantly	RB	_	5	adv	_	_
7	with	with	IN	_	9	case	_	_
8	other	other	JJ	_	9	attr	_	_
9	drug2	drug0	NNS	_	5	ppmod	_	_
10	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	decrease	decrease	VB	_	0	root	_	_
4	the	the	DT	_	6	det	_	_
5	hypotensive	hypotensive	JJ	_	6	attr	_	_
6	effect	effect	NN	_	3	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	enhance	enhance	VB	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	effects	effect	NNS	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	.	.	.	_	3	p	_	_

1	Urinary	urinary	JJ	_	3	attr	_	_
2	alkalinizing	alkalinizing	NN	_	3	com	_	_
3	agents	agent	NNS	_	4	dep	_	_
4	increase	increase	VBP	_	0	root	_	_
5	blood	blood	NN	_	6	com	_	_
6	levels	level	NNS	_	4	obj	_	_
7	and	and	CC	_	4	cc	_	_
8	decrease	decrease	VBP	_	4	conj	_	_
9	excretion	excretion	NN	_	8	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	agents	agent	NNS	_	3	dep	_	_
3	decrease	decrease	VB	_	0	root	_	_
4	blood	blood	NN	_	5	com	_	_
5	levels	level	NNS	_	3	obj	_	_
6	and	and	CC	_	3	cc	_	_
7	increase	increase	VB	_	3	conj	_	_
8	excretion	excretion	NN	_	7	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	3	p	_	_

1	drug1	drug0	JJ	_	3	attr	_	_
2	-containing	-containing	JJ	_	3	attr	_	_
3	drugs	drug	NNS	_	6	dep	_	_
4	have	have	VBP	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	reported	report	VBN	_	0	root	_	_
7	to	to	TO	_	8	aux	_	_
8	cause	cause	VB	_	6	comp	_	_
9	prolonged	prolonged	JJ	_	11	attr	_	_
10	vasospastic	vasospastic	JJ	_	11	attr	_	_
11	reactions	reaction	NNS	_	8	obj	_	_
12	.	.	.	_	6	p	_	_

1	Because	because	IN	_	3	mark	_	_
2	there	there	EX	_	3	dep	_	_
3	is	be	VBZ	_	32	advcl	_	_
4	a	a	DT	_	6	det	_	_
5	theoretical	theoretical	JJ	_	6	attr	_	_
6	basis	basis	NN	_	3	obj	_	_
7	that	that	IN	_	11	mark	_	_
8	these	these	DT	_	9	det	_	_
9	effects	effect	NNS	_	11	dep	_	_
10	may	may	MD	_	11	modal	_	_
11	be	be	VB	_	6	acl	_	_
12	additive	additive	JJ	_	11	dep	_	_
13	,	,	,	_	32	p	_	_
14	use	use	NN	_	32	dep	_	_
15	of	of	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	-containing	-containing	JJ	_	16	attr	_	_
18	or	or	CC	_	17	cc	_	_
19	drug2	drug0	JJ	_	17	conj	_	_
20	(	-lrb-	-LRB-	_	22	p	_	_
21	like	like	IN	_	22	case	_	_
22	drug3	drug0	NN	_	16	prn	_	_
23	or	or	CC	_	22	cc	_	_
24	drug4	drug0	NN	_	22	conj	_	_
25	)	-rrb-	-RRB-	_	22	p	_	_
26	and	and	CC	_	16	cc	_	_
27	drug5	drug0	NN	_	16	conj	_	_
28	within	within	IN	_	30	case	_	_
29	24	0	CD	_	30	num	_	_
30	hours	hour	NNS	_	14	ppmod	_	_
31	is	be	VBZ	_	32	aux	_	_
32	contraindicated	contraindicate	VBN	_	0	root	_	_
33	.	.	.	_	32	p	_	_

1	The	the	DT	_	2	det	_	_
2	administration	administration	NN	_	11	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	with	with	IN	_	7	case	_	_
6	other	other	JJ	_	7	attr	_	_
7	drug2	drug0	NNS	_	2	ppmod	_	_
8	has	have	VBZ	_	11	aux	_	_
9	not	not	RB	_	11	neg	_	_
10	been	be	VBN	_	11	aux	_	_
11	evaluated	evaluate	VBN	_	0	root	_	_
12	in	in	IN	_	14	case	_	_
13	migraine	migraine	NN	_	14	com	_	_
14	patients	patient	NNS	_	11	ppmod	_	_
15	.	.	.	_	11	p	_	_

1	Because	because	IN	_	6	mark	_	_
2	their	their	PRP$	_	4	poss	_	_
3	vasospastic	vasospastic	JJ	_	4	attr	_	_
4	effects	effect	NNS	_	6	dep	_	_
5	may	may	MD	_	6	modal	_	_
6	be	be	VB	_	23	advcl	_	_
7	additive	additive	JJ	_	6	dep	_	_
8	,	,	,	_	23	p	_	_
9	coadministration	coadministration	NN	_	23	dep	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	other	other	JJ	_	14	attr	_	_
14	drug2	drug0	NN	_	11	conj	_	_
15	within	within	IN	_	17	case	_	_
16	24	0	CD	_	17	num	_	_
17	hours	hour	NNS	_	9	ppmod	_	_
18	of	of	IN	_	20	case	_	_
19	each	each	DT	_	20	det	_	_
20	other	other	JJ	_	17	ppmod	_	_
21	is	be	VBZ	_	23	aux	_	_
22	not	not	RB	_	23	neg	_	_
23	recommended	recommend	VBN	_	0	root	_	_
24	.	.	.	_	23	p	_	_

1	drug1	drug0	NN	_	18	dep	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	drug2	drug0	NN	_	1	prn	_	_
4	)	-rrb-	-RRB-	_	3	p	_	_
5	(	-lrb-	-LRB-	_	8	p	_	_
6	e.g.	e.g.	FW	_	8	ppmod	_	_
7	,	,	,	_	8	p	_	_
8	drug3	drug0	NN	_	1	prn	_	_
9	,	,	,	_	8	p	_	_
10	drug4	drug0	NN	_	8	appo	_	_
11	,	,	,	_	8	p	_	_
12	drug5	drug0	NN	_	8	appo	_	_
13	,	,	,	_	8	p	_	_
14	drug6	drug0	NN	_	8	appo	_	_
15	)	-rrb-	-RRB-	_	8	p	_	_
16	have	have	VBP	_	18	aux	_	_
17	been	be	VBN	_	18	aux	_	_
18	reported	report	VBN	_	0	root	_	_
19	,	,	,	_	18	p	_	_
20	rarely	rarely	RB	_	18	adv	_	_
21	,	,	,	_	18	p	_	_
22	to	to	TO	_	23	aux	_	_
23	cause	cause	VB	_	18	comp	_	_
24	weakness	weakness	NN	_	23	obj	_	_
25	,	,	,	_	24	p	_	_
26	hyperreflexia	hyperreflexia	NN	_	24	conj	_	_
27	,	,	,	_	26	p	_	_
28	and	and	CC	_	26	cc	_	_
29	incoordination	incoordination	NN	_	24	conj	_	_
30	when	when	WRB	_	31	adv	_	_
31	coadministered	coadministered	VBN	_	23	comp	_	_
32	with	with	IN	_	34	case	_	_
33	5-HTv	0-htv	JJ	_	34	attr	_	_
34	agonists	agonist	NNS	_	31	ppmod	_	_
35	.	.	.	_	18	p	_	_

1	If	if	IN	_	11	mark	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	treatment	treatment	NN	_	11	dep	_	_
4	with	with	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	an	an	DT	_	8	det	_	_
8	drug2	drug0	NN	_	5	conj	_	_
9	is	be	VBZ	_	11	aux	_	_
10	clinically	clinically	RB	_	11	adv	_	_
11	warranted	warrant	VBN	_	19	advcl	_	_
12	,	,	,	_	19	p	_	_
13	appropriate	appropriate	JJ	_	14	attr	_	_
14	observation	observation	NN	_	19	dep	_	_
15	of	of	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	patient	patient	NN	_	14	ppmod	_	_
18	is	be	VBZ	_	19	aux	_	_
19	advised	advise	VBN	_	0	root	_	_
20	.	.	.	_	19	p	_	_

1	Drug/	drug/	NN	_	4	com	_	_
2	Laboratory	laboratory	NN	_	4	com	_	_
3	Test	test	NN	_	4	com	_	_
4	Interactions	interaction	NNS	_	9	dep	_	_
5	drug1	drug0	IN	_	6	case	_	_
6	Tablets	tablet	NNS	_	4	ppmod	_	_
7	are	be	VBP	_	9	aux	_	_
8	not	not	RB	_	9	neg	_	_
9	known	know	VBN	_	0	root	_	_
10	to	to	TO	_	11	aux	_	_
11	interfere	interfere	VB	_	9	comp	_	_
12	with	with	IN	_	17	case	_	_
13	commonly	commonly	RB	_	14	adv	_	_
14	employed	employ	VBN	_	17	attr	_	_
15	clinical	clinical	JJ	_	17	attr	_	_
16	laboratory	laboratory	NN	_	17	com	_	_
17	tests	test	NNS	_	11	ppmod	_	_
18	.	.	.	_	9	p	_	_

1	The	the	DT	_	3	det	_	_
2	vasodilating	vasodilating	JJ	_	3	attr	_	_
3	effects	effect	NNS	_	7	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	may	may	MD	_	7	modal	_	_
7	be	be	VB	_	0	root	_	_
8	additive	additive	JJ	_	7	dep	_	_
9	with	with	IN	_	10	case	_	_
10	those	those	DT	_	8	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	other	other	JJ	_	13	attr	_	_
13	drug2	drug0	NNS	_	10	ppmod	_	_
14	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	8	dep	_	_
2	,	,	,	_	1	p	_	_
3	in	in	IN	_	4	case	_	_
4	particular	particular	JJ	_	1	ppmod	_	_
5	,	,	,	_	1	p	_	_
6	has	have	VBZ	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	found	find	VBN	_	0	root	_	_
9	to	to	TO	_	10	aux	_	_
10	exhibit	exhibit	VBP	_	8	comp	_	_
11	additive	additive	JJ	_	12	attr	_	_
12	effects	effect	NNS	_	10	obj	_	_
13	of	of	IN	_	15	case	_	_
14	this	this	DT	_	15	det	_	_
15	variety	variety	NN	_	12	ppmod	_	_
16	.	.	.	_	8	p	_	_

1	Marked	marked	JJ	_	4	attr	_	_
2	symptomatic	symptomatic	JJ	_	4	attr	_	_
3	orthostatic	orthostatic	JJ	_	4	attr	_	_
4	hypotension	hypotension	NN	_	7	dep	_	_
5	has	have	VBZ	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	reported	report	VBN	_	0	root	_	_
8	when	when	WRB	_	13	adv	_	_
9	drug1	drug0	NN	_	13	dep	_	_
10	and	and	CC	_	9	cc	_	_
11	drug2	drug0	NN	_	9	conj	_	_
12	were	be	VBD	_	13	aux	_	_
13	used	use	VBN	_	7	comp	_	_
14	in	in	IN	_	15	case	_	_
15	combination	combination	NN	_	13	ppmod	_	_
16	.	.	.	_	7	p	_	_

1	Dose	dose	NN	_	2	com	_	_
2	adjustments	adjustment	NNS	_	9	dep	_	_
3	of	of	IN	_	5	case	_	_
4	either	either	DT	_	5	det	_	_
5	class	class	NN	_	2	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	agents	agent	NNS	_	5	ppmod	_	_
8	may	may	MD	_	9	modal	_	_
9	be	be	VB	_	0	root	_	_
10	necessary	necessary	JJ	_	9	dep	_	_
11	.	.	.	_	9	p	_	_

1	The	the	DT	_	2	det	_	_
2	risks	risk	NNS	_	15	dep	_	_
3	of	of	IN	_	4	case	_	_
4	using	use	VBG	_	2	ppmod	_	_
5	drug1	drug0	NN	_	4	obj	_	_
6	in	in	IN	_	7	case	_	_
7	combination	combination	NN	_	4	ppmod	_	_
8	with	with	IN	_	10	case	_	_
9	other	other	JJ	_	10	attr	_	_
10	drugs	drug	NNS	_	7	ppmod	_	_
11	have	have	VBP	_	15	aux	_	_
12	not	not	RB	_	15	neg	_	_
13	been	be	VBN	_	15	aux	_	_
14	systematically	systematically	RB	_	15	adv	_	_
15	evaluated	evaluate	VBN	_	0	root	_	_
16	.	.	.	_	15	p	_	_

1	Pharmacodynamic-related	pharmacodynamic-related	JJ	_	2	attr	_	_
2	Interactions	interaction	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	The	the	DT	_	5	det	_	_
5	mechanism	mechanism	NN	_	10	dep	_	_
6	of	of	IN	_	9	case	_	_
7	drug1	drug0	NN	_	9	attr	_	_
8	induced	induced	JJ	_	9	attr	_	_
9	agranulocytosis	agranulocytosis	NN	_	5	ppmod	_	_
10	is	be	VBZ	_	2	acl	_	_
11	unknown	unknown	JJ	_	10	dep	_	_
12	;	;	:	_	2	p	_	_

1	nonetheless	nonetheless	RB	_	21	adv	_	_
2	,	,	,	_	21	p	_	_
3	the	the	DT	_	4	det	_	_
4	possibility	possibility	NN	_	21	dep	_	_
5	that	that	IN	_	12	mark	_	_
6	causative	causative	JJ	_	7	attr	_	_
7	factors	factor	NNS	_	12	dep	_	_
8	may	may	MD	_	12	modal	_	_
9	interact	interact	VB	_	12	aux	_	_
10	synergistically	synergistically	RB	_	12	adv	_	_
11	to	to	TO	_	12	aux	_	_
12	increase	increase	VB	_	4	acl	_	_
13	the	the	DT	_	14	det	_	_
14	risk	risk	NN	_	12	obj	_	_
15	and/or	and/or	CC	_	14	cc	_	_
16	severity	severity	NN	_	14	conj	_	_
17	of	of	IN	_	20	case	_	_
18	bone	bone	NN	_	19	com	_	_
19	marrow	marrow	NN	_	20	com	_	_
20	suppression	suppression	NN	_	14	ppmod	_	_
21	warrants	warrant	VBZ	_	0	root	_	_
22	consideration	consideration	NN	_	21	obj	_	_
23	.	.	.	_	21	p	_	_

1	Therefore	therefore	RB	_	7	adv	_	_
2	,	,	,	_	7	p	_	_
3	drug1	drug0	NN	_	7	dep	_	_
4	should	should	MD	_	7	modal	_	_
5	not	not	RB	_	7	neg	_	_
6	be	be	VB	_	7	aux	_	_
7	used	use	VBN	_	0	root	_	_
8	with	with	IN	_	10	case	_	_
9	other	other	JJ	_	10	attr	_	_
10	agents	agent	NNS	_	7	ppmod	_	_
11	having	have	VBG	_	10	acl	_	_
12	a	a	DT	_	14	det	_	_
13	well-known	well-known	JJ	_	14	attr	_	_
14	potential	potential	NN	_	11	obj	_	_
15	to	to	TO	_	16	aux	_	_
16	suppress	suppress	VB	_	14	acl	_	_
17	bone	bone	NN	_	18	com	_	_
18	marrow	marrow	NN	_	19	com	_	_
19	function	function	NN	_	16	obj	_	_
20	.	.	.	_	7	p	_	_

1	Given	given	IN	_	5	case	_	_
2	the	the	DT	_	5	det	_	_
3	primary	primary	JJ	_	5	attr	_	_
4	CNS	cns	NN	_	5	com	_	_
5	effects	effect	NNS	_	11	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	,	,	,	_	11	p	_	_
9	caution	caution	NN	_	11	dep	_	_
10	is	be	VBZ	_	11	aux	_	_
11	advised	advise	VBN	_	0	root	_	_
12	in	in	IN	_	13	case	_	_
13	using	use	VBG	_	11	ppmod	_	_
14	it	it	PRP	_	13	obj	_	_
15	concomitantly	concomitantly	RB	_	14	adv	_	_
16	with	with	IN	_	19	case	_	_
17	other	other	JJ	_	19	attr	_	_
18	CNS-active	cns-active	JJ	_	19	attr	_	_
19	drugs	drug	NNS	_	14	ppmod	_	_
20	or	or	CC	_	19	cc	_	_
21	drug2	drug0	NN	_	19	conj	_	_
22	.	.	.	_	11	p	_	_

1	Orthostatic	orthostatic	JJ	_	2	attr	_	_
2	hypotension	hypotension	NN	_	22	dep	_	_
3	in	in	IN	_	4	case	_	_
4	patients	patient	NNS	_	2	ppmod	_	_
5	taking	take	VBG	_	4	acl	_	_
6	drug1	drug0	NN	_	5	obj	_	_
7	can	can	MD	_	22	modal	_	_
8	,	,	,	_	22	p	_	_
9	in	in	IN	_	11	case	_	_
10	rare	rare	JJ	_	11	attr	_	_
11	cases	case	NNS	_	22	ppmod	_	_
12	(	-lrb-	-LRB-	_	15	p	_	_
13	approximately	approximately	RB	_	14	adv	_	_
14	1	0	CD	_	15	num	_	_
15	case	case	NN	_	11	prn	_	_
16	per	per	IN	_	18	case	_	_
17	3,000	0	CD	_	18	num	_	_
18	patients	patient	NNS	_	15	ppmod	_	_
19	)	-rrb-	-RRB-	_	15	p	_	_
20	,	,	,	_	22	p	_	_
21	be	be	VB	_	22	aux	_	_
22	accompanied	accompany	VBN	_	0	root	_	_
23	by	by	IN	_	25	case	_	_
24	profound	profound	JJ	_	25	attr	_	_
25	collapse	collapse	NN	_	22	ppmod	_	_
26	and	and	CC	_	25	cc	_	_
27	respiratory	respiratory	JJ	_	30	attr	_	_
28	and/or	and/or	CC	_	27	cc	_	_
29	cardiac	cardiac	JJ	_	27	conj	_	_
30	arrest	arrest	NN	_	25	conj	_	_
31	.	.	.	_	22	p	_	_

1	Some	some	DT	_	12	dep	_	_
2	of	of	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	cases	case	NNS	_	1	ppmod	_	_
5	of	of	IN	_	8	case	_	_
6	collapse/respiratory	collapse/respiratory	JJ	_	8	attr	_	_
7	arrest/cardiac	arrest/cardiac	NN	_	8	com	_	_
8	arrest	arrest	NN	_	4	ppmod	_	_
9	during	during	IN	_	11	case	_	_
10	initial	initial	JJ	_	11	attr	_	_
11	treatment	treatment	NN	_	8	ppmod	_	_
12	occurred	occur	VBD	_	0	root	_	_
13	in	in	IN	_	14	case	_	_
14	patients	patient	NNS	_	12	ppmod	_	_
15	who	who	WP	_	18	dep	_	_
16	were	be	VBD	_	18	aux	_	_
17	being	be	VBG	_	18	aux	_	_
18	administered	administer	VBN	_	14	relcl	_	_
19	drug1	drug0	NN	_	18	obj	_	_
20	;	;	:	_	12	p	_	_

1	similar	similar	JJ	_	2	attr	_	_
2	events	event	NNS	_	5	dep	_	_
3	have	have	VBP	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	reported	report	VBN	_	0	root	_	_
6	in	in	IN	_	7	case	_	_
7	patients	patient	NNS	_	5	ppmod	_	_
8	taking	take	VBG	_	7	acl	_	_
9	other	other	JJ	_	10	attr	_	_
10	drug1	drug0	NN	_	8	obj	_	_
11	or	or	CC	_	8	cc	_	_
12	even	even	RB	_	13	adv	_	_
13	drug2	drug0	VBN	_	8	conj	_	_
14	by	by	IN	_	15	case	_	_
15	itself	itself	PRP	_	13	ppmod	_	_
16	.	.	.	_	5	p	_	_

1	Although	although	IN	_	6	mark	_	_
2	it	it	PRP	_	6	dep	_	_
3	has	have	VBZ	_	6	aux	_	_
4	not	not	RB	_	6	neg	_	_
5	been	be	VBN	_	6	aux	_	_
6	established	establish	VBN	_	22	advcl	_	_
7	that	that	IN	_	9	mark	_	_
8	there	there	EX	_	9	dep	_	_
9	is	be	VBZ	_	6	comp	_	_
10	an	an	DT	_	11	det	_	_
11	interaction	interaction	NN	_	9	obj	_	_
12	between	between	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	drug2	drug0	NN	_	13	conj	_	_
16	or	or	CC	_	13	cc	_	_
17	other	other	JJ	_	18	attr	_	_
18	drug3	drug0	NN	_	13	conj	_	_
19	,	,	,	_	22	p	_	_
20	caution	caution	NN	_	22	dep	_	_
21	is	be	VBZ	_	22	aux	_	_
22	advised	advise	VBN	_	0	root	_	_
23	when	when	WRB	_	26	adv	_	_
24	drug4	drug0	NN	_	26	dep	_	_
25	is	be	VBZ	_	26	aux	_	_
26	initiated	initiate	VBN	_	22	comp	_	_
27	in	in	IN	_	28	case	_	_
28	patients	patient	NNS	_	26	ppmod	_	_
29	taking	take	VBG	_	28	acl	_	_
30	a	a	DT	_	31	det	_	_
31	drug5	drug0	NN	_	29	obj	_	_
32	or	or	CC	_	31	cc	_	_
33	any	any	DT	_	35	det	_	_
34	other	other	JJ	_	35	attr	_	_
35	drug6	drug0	NN	_	31	conj	_	_
36	.	.	.	_	22	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	potentiate	potentiate	VB	_	0	root	_	_
4	the	the	DT	_	6	det	_	_
5	hypotensive	hypotensive	JJ	_	6	attr	_	_
6	effects	effect	NNS	_	3	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	6	cc	_	_
10	the	the	DT	_	12	det	_	_
11	anticholinergic	anticholinergic	JJ	_	12	attr	_	_
12	effects	effect	NNS	_	6	conj	_	_
13	of	of	IN	_	16	case	_	_
14	drug3	drug0	NN	_	16	com	_	_
15	-type	-type	NN	_	16	com	_	_
16	drugs	drug	NNS	_	12	ppmod	_	_
17	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	administration	administration	NN	_	7	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	should	should	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	avoided	avoid	VBN	_	0	root	_	_
8	in	in	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	treatment	treatment	NN	_	7	ppmod	_	_
11	of	of	IN	_	14	case	_	_
12	drug	drug	NN	_	13	advnp	_	_
13	induced	induce	VBN	_	14	attr	_	_
14	hypotension	hypotension	NN	_	10	ppmod	_	_
15	because	because	IN	_	21	case	_	_
16	of	of	IN	_	21	case	_	_
17	a	a	DT	_	21	det	_	_
18	possible	possible	JJ	_	21	attr	_	_
19	reverse	reverse	JJ	_	21	attr	_	_
20	drug2	drug0	NN	_	21	com	_	_
21	effect	effect	NN	_	7	ppmod	_	_
22	.	.	.	_	7	p	_	_

1	Pharmacokinetic-related	pharmacokinetic-related	JJ	_	2	attr	_	_
2	Interactions	interaction	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	drug1	drug0	NN	_	5	dep	_	_
5	is	be	VBZ	_	2	acl	_	_
6	a	a	DT	_	7	det	_	_
7	substrate	substrate	NN	_	5	obj	_	_
8	for	for	IN	_	12	case	_	_
9	many	many	JJ	_	12	attr	_	_
10	CYP	cyp	NN	_	12	attr	_	_
11	450	0	CD	_	12	num	_	_
12	isozymes	isozymes	NNS	_	7	ppmod	_	_
13	,	,	,	_	5	p	_	_
14	in	in	IN	_	16	case	_	_
15	particular	particular	JJ	_	16	attr	_	_
16	1A2	0a0	NN	_	5	ppmod	_	_
17	,	,	,	_	16	p	_	_
18	2D6	0d0	NN	_	16	conj	_	_
19	,	,	,	_	18	p	_	_
20	and	and	CC	_	18	cc	_	_
21	3A4	0a0	NN	_	16	conj	_	_
22	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	risk	risk	NN	_	16	dep	_	_
3	of	of	IN	_	5	case	_	_
4	metabolic	metabolic	JJ	_	5	attr	_	_
5	interactions	interaction	NNS	_	2	ppmod	_	_
6	caused	cause	VBN	_	2	acl	_	_
7	by	by	IN	_	9	case	_	_
8	an	an	DT	_	9	det	_	_
9	effect	effect	NN	_	6	ppmod	_	_
10	on	on	IN	_	13	case	_	_
11	an	an	DT	_	13	det	_	_
12	individual	individual	JJ	_	13	attr	_	_
13	isoform	isoform	NN	_	9	ppmod	_	_
14	is	be	VBZ	_	16	aux	_	_
15	therefore	therefore	RB	_	16	adv	_	_
16	minimized	minimize	VBN	_	0	root	_	_
17	.	.	.	_	16	p	_	_

1	Nevertheless	nevertheless	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	caution	caution	NN	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	used	use	VBN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	6	ppmod	_	_
9	receiving	receive	VBG	_	8	acl	_	_
10	concomitant	concomitant	JJ	_	11	attr	_	_
11	treatment	treatment	NN	_	9	obj	_	_
12	with	with	IN	_	14	case	_	_
13	other	other	JJ	_	14	attr	_	_
14	drugs	drug	NNS	_	11	ppmod	_	_
15	that	that	WDT	_	16	dep	_	_
16	are	be	VBP	_	14	relcl	_	_
17	either	either	CC	_	18	cc	_	_
18	inhibitors	inhibitor	NNS	_	16	obj	_	_
19	or	or	CC	_	18	cc	_	_
20	inducers	inducer	NNS	_	18	conj	_	_
21	of	of	IN	_	23	case	_	_
22	these	these	DT	_	23	det	_	_
23	enzymes	enzyme	NNS	_	18	ppmod	_	_
24	.	.	.	_	6	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	administration	administration	NN	_	12	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drugs	drug	NNS	_	2	ppmod	_	_
5	known	know	VBN	_	4	acl	_	_
6	to	to	TO	_	7	aux	_	_
7	induce	induce	VB	_	5	comp	_	_
8	cytochrome	cytochrome	NN	_	10	com	_	_
9	P450	p0	NN	_	10	com	_	_
10	enzymes	enzyme	NNS	_	7	obj	_	_
11	may	may	MD	_	12	modal	_	_
12	decrease	decrease	VB	_	0	root	_	_
13	the	the	DT	_	15	det	_	_
14	plasma	plasma	NN	_	15	com	_	_
15	levels	level	NNS	_	12	obj	_	_
16	of	of	IN	_	17	case	_	_
17	drug1	drug0	NN	_	15	ppmod	_	_
18	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	8	dep	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	,	,	,	_	3	p	_	_
5	and	and	CC	_	3	cc	_	_
6	drug3	drug0	NN	_	1	conj	_	_
7	may	may	MD	_	8	modal	_	_
8	decrease	decrease	VB	_	0	root	_	_
9	drug4	drug0	NN	_	11	com	_	_
10	plasma	plasma	NN	_	11	com	_	_
11	levels	level	NNS	_	8	obj	_	_
12	,	,	,	_	8	p	_	_
13	resulting	result	VBG	_	8	comp	_	_
14	in	in	IN	_	16	case	_	_
15	a	a	DT	_	16	det	_	_
16	decrease	decrease	NN	_	13	ppmod	_	_
17	in	in	IN	_	18	case	_	_
18	effectiveness	effectiveness	NN	_	16	ppmod	_	_
19	of	of	IN	_	24	case	_	_
20	a	a	DT	_	24	det	_	_
21	previously	previously	RB	_	22	adv	_	_
22	effective	effective	JJ	_	24	attr	_	_
23	drug5	drug0	NN	_	24	com	_	_
24	dose	dose	NN	_	18	ppmod	_	_
25	.	.	.	_	8	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	administration	administration	NN	_	15	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drugs	drug	NNS	_	2	ppmod	_	_
5	known	know	VBN	_	4	acl	_	_
6	to	to	TO	_	7	aux	_	_
7	inhibit	inhibit	VB	_	5	comp	_	_
8	the	the	DT	_	9	det	_	_
9	activity	activity	NN	_	7	obj	_	_
10	of	of	IN	_	13	case	_	_
11	cytochrome	cytochrome	NN	_	13	com	_	_
12	P450	p0	NN	_	13	com	_	_
13	isozymes	isozymes	NNS	_	9	ppmod	_	_
14	may	may	MD	_	15	modal	_	_
15	increase	increase	VB	_	0	root	_	_
16	the	the	DT	_	18	det	_	_
17	plasma	plasma	NN	_	18	com	_	_
18	levels	level	NNS	_	15	obj	_	_
19	of	of	IN	_	20	case	_	_
20	drug1	drug0	NN	_	18	ppmod	_	_
21	.	.	.	_	15	p	_	_

1	drug1	drug0	NN	_	8	dep	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	,	,	,	_	3	p	_	_
5	and	and	CC	_	3	cc	_	_
6	drug3	drug0	NN	_	1	conj	_	_
7	may	may	MD	_	8	modal	_	_
8	increase	increase	VB	_	0	root	_	_
9	plasma	plasma	NN	_	10	com	_	_
10	levels	level	NNS	_	8	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug4	drug0	NN	_	10	ppmod	_	_
13	,	,	,	_	8	p	_	_
14	potentially	potentially	RB	_	15	adv	_	_
15	resulting	result	VBG	_	8	comp	_	_
16	in	in	IN	_	18	case	_	_
17	adverse	adverse	JJ	_	18	attr	_	_
18	effects	effect	NNS	_	15	ppmod	_	_
19	.	.	.	_	8	p	_	_

1	Although	although	IN	_	10	mark	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	use	use	NN	_	10	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	is	be	VBZ	_	10	aux	_	_
9	not	not	RB	_	10	neg	_	_
10	recommended	recommend	VBN	_	15	advcl	_	_
11	,	,	,	_	15	p	_	_
12	it	it	PRP	_	15	dep	_	_
13	should	should	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	noted	note	VBN	_	0	root	_	_
16	that	that	IN	_	23	mark	_	_
17	discontinuation	discontinuation	NN	_	23	dep	_	_
18	of	of	IN	_	21	case	_	_
19	concomitant	concomitant	JJ	_	21	attr	_	_
20	drug3	drug0	NN	_	21	com	_	_
21	administration	administration	NN	_	17	ppmod	_	_
22	may	may	MD	_	23	modal	_	_
23	result	result	VB	_	15	comp	_	_
24	in	in	IN	_	26	case	_	_
25	an	an	DT	_	26	det	_	_
26	increase	increase	NN	_	23	ppmod	_	_
27	in	in	IN	_	30	case	_	_
28	drug4	drug0	NN	_	30	com	_	_
29	plasma	plasma	NN	_	30	com	_	_
30	levels	level	NNS	_	26	ppmod	_	_
31	.	.	.	_	15	p	_	_

1	In	in	IN	_	3	case	_	_
2	a	a	DT	_	3	det	_	_
3	study	study	NN	_	19	ppmod	_	_
4	of	of	IN	_	6	case	_	_
5	schizophrenic	schizophrenic	JJ	_	6	attr	_	_
6	patients	patient	NNS	_	3	ppmod	_	_
7	who	who	WP	_	8	dep	_	_
8	received	receive	VBD	_	6	relcl	_	_
9	drug1	drug0	NN	_	8	obj	_	_
10	under	under	IN	_	13	case	_	_
11	steady	steady	JJ	_	13	attr	_	_
12	state	state	NN	_	13	com	_	_
13	conditions	condition	NNS	_	8	ppmod	_	_
14	,	,	,	_	19	p	_	_
15	drug2	drug0	NN	_	19	dep	_	_
16	or	or	CC	_	15	cc	_	_
17	drug3	drug0	NN	_	15	conj	_	_
18	was	be	VBD	_	19	aux	_	_
19	added	add	VBN	_	0	root	_	_
20	in	in	IN	_	24	case	_	_
21	16	0	CD	_	24	num	_	_
22	and	and	CC	_	21	cc	_	_
23	14	0	CD	_	21	conj	_	_
24	patients	patient	NNS	_	19	ppmod	_	_
25	,	,	,	_	19	p	_	_
26	respectively	respectively	RB	_	19	adv	_	_
27	.	.	.	_	19	p	_	_

1	After	after	IN	_	3	case	_	_
2	14	0	CD	_	3	num	_	_
3	days	day	NNS	_	21	ppmod	_	_
4	of	of	IN	_	5	case	_	_
5	co-administration	co-administration	NN	_	3	ppmod	_	_
6	,	,	,	_	21	p	_	_
7	mean	mean	NN	_	9	com	_	_
8	trough	trough	NN	_	9	com	_	_
9	concentrations	concentration	NNS	_	21	dep	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	9	cc	_	_
13	its	its	PRP$	_	14	poss	_	_
14	metabolites	metabolite	NNS	_	9	conj	_	_
15	,	,	,	_	14	p	_	_
16	drug2	drug0	NN	_	14	appo	_	_
17	and	and	CC	_	16	cc	_	_
18	drug3	drug0	NN	_	16	conj	_	_
19	,	,	,	_	14	p	_	_
20	were	be	VBD	_	21	aux	_	_
21	elevated	elevate	VBN	_	0	root	_	_
22	with	with	IN	_	23	case	_	_
23	drug4	drug0	NN	_	21	ppmod	_	_
24	by	by	IN	_	26	case	_	_
25	about	about	RB	_	26	com	_	_
26	three-fold	three-fold	RB	_	21	ppmod	_	_
27	compared	compare	VBN	_	26	acl	_	_
28	to	to	TO	_	30	aux	_	_
29	baseline	baseline	NN	_	30	com	_	_
30	concentrations	concentration	NNS	_	27	ppmod	_	_
31	.	.	.	_	21	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	produced	produce	VBD	_	0	root	_	_
3	only	only	RB	_	4	adv	_	_
4	minor	minor	JJ	_	5	attr	_	_
5	changes	change	NNS	_	2	obj	_	_
6	in	in	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	levels	level	NNS	_	2	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	its	its	PRP$	_	13	poss	_	_
13	metabolites	metabolite	NNS	_	10	conj	_	_
14	.	.	.	_	2	p	_	_

1	However	however	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	other	other	JJ	_	5	attr	_	_
4	published	publish	VBN	_	5	attr	_	_
5	reports	report	NNS	_	6	dep	_	_
6	describe	describe	VBP	_	0	root	_	_
7	modest	modest	JJ	_	8	attr	_	_
8	elevations	elevation	NNS	_	6	obj	_	_
9	(	-lrb-	-LRB-	_	12	p	_	_
10	less	less	JJR	_	12	adv	_	_
11	than	than	IN	_	12	case	_	_
12	two-fold	two-fold	JJ	_	8	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	of	of	IN	_	15	case	_	_
15	drug1	drug0	NN	_	8	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	metabolite	metabolite	NN	_	18	com	_	_
18	concentrations	concentration	NNS	_	15	conj	_	_
19	when	when	WRB	_	22	adv	_	_
20	drug2	drug0	NN	_	22	dep	_	_
21	was	be	VBD	_	22	aux	_	_
22	taken	take	VBN	_	6	comp	_	_
23	with	with	IN	_	24	case	_	_
24	drug3	drug0	NN	_	22	ppmod	_	_
25	,	,	,	_	24	p	_	_
26	drug4	drug0	NN	_	24	conj	_	_
27	,	,	,	_	26	p	_	_
28	and	and	CC	_	26	cc	_	_
29	drug5	drug0	NN	_	24	conj	_	_
30	.	.	.	_	6	p	_	_

1	Therefore	therefore	RB	_	8	adv	_	_
2	,	,	,	_	8	p	_	_
3	such	such	JJ	_	5	attr	_	_
4	combined	combined	JJ	_	5	attr	_	_
5	treatment	treatment	NN	_	8	dep	_	_
6	should	should	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	approached	approach	VBN	_	0	root	_	_
9	with	with	IN	_	10	case	_	_
10	caution	caution	NN	_	8	ppmod	_	_
11	and	and	CC	_	8	cc	_	_
12	patients	patient	NNS	_	15	dep	_	_
13	should	should	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	monitored	monitor	VBN	_	8	conj	_	_
16	closely	closely	RB	_	15	adv	_	_
17	when	when	WRB	_	20	adv	_	_
18	drug1	drug0	NN	_	20	dep	_	_
19	is	be	VBZ	_	20	aux	_	_
20	combined	combine	VBN	_	15	comp	_	_
21	with	with	IN	_	23	case	_	_
22	these	these	DT	_	23	det	_	_
23	drugs	drug	NNS	_	20	ppmod	_	_
24	,	,	,	_	20	p	_	_
25	particularly	particularly	RB	_	27	adv	_	_
26	with	with	IN	_	27	case	_	_
27	drug2	drug0	NN	_	20	ppmod	_	_
28	.	.	.	_	8	p	_	_

1	A	a	DT	_	4	det	_	_
2	reduced	reduce	VBN	_	4	attr	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	dose	dose	NN	_	7	dep	_	_
5	should	should	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	considered	consider	VBN	_	0	root	_	_
8	.	.	.	_	7	p	_	_

1	A	a	DT	_	2	det	_	_
2	subset	subset	NN	_	14	dep	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	3	0	CD	_	6	num	_	_
5	%	%	NN	_	6	meta	_	_
6	-10	0	CD	_	2	num	_	_
7	%	%	NN	_	6	meta	_	_
8	)	-rrb-	-RRB-	_	6	p	_	_
9	of	of	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	population	population	NN	_	2	ppmod	_	_
12	has	have	VBZ	_	14	lv	_	_
13	reduced	reduce	VBN	_	14	attr	_	_
14	activity	activity	NN	_	0	root	_	_
15	of	of	IN	_	19	case	_	_
16	certain	certain	JJ	_	19	attr	_	_
17	drug	drug	NN	_	19	com	_	_
18	metabolizing	metabolizing	NN	_	19	com	_	_
19	enzymes	enzyme	NNS	_	14	ppmod	_	_
20	such	such	JJ	_	27	adv	_	_
21	as	as	IN	_	27	case	_	_
22	the	the	DT	_	27	det	_	_
23	cytochrome	cytochrome	NN	_	27	com	_	_
24	P450	p0	NN	_	27	com	_	_
25	isozyme	isozyme	NN	_	27	com	_	_
26	P450	p0	NN	_	27	com	_	_
27	2D6	0d0	NN	_	19	ppmod	_	_
28	.	.	.	_	14	p	_	_

1	Such	such	JJ	_	2	attr	_	_
2	individuals	individual	NNS	_	4	dep	_	_
3	are	be	VBP	_	4	aux	_	_
4	referred	refer	VBN	_	0	root	_	_
5	to	to	TO	_	4	ppmod	_	_
6	as	as	IN	_	8	case	_	_
7	poor	poor	JJ	_	8	attr	_	_
8	metabolizers	metabolizers	NNS	_	4	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drugs	drug	NNS	_	8	ppmod	_	_
11	such	such	JJ	_	13	adv	_	_
12	as	as	IN	_	13	case	_	_
13	drug1	drug0	NN	_	10	ppmod	_	_
14	,	,	,	_	13	p	_	_
15	drug2	drug0	NN	_	13	conj	_	_
16	,	,	,	_	15	p	_	_
17	the	the	DT	_	18	det	_	_
18	drug3	drug0	NN	_	13	conj	_	_
19	,	,	,	_	18	p	_	_
20	and	and	CC	_	18	cc	_	_
21	drug4	drug0	NN	_	13	conj	_	_
22	.	.	.	_	4	p	_	_

1	These	these	DT	_	2	det	_	_
2	individuals	individual	NNS	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	develop	develop	VBP	_	0	root	_	_
5	higher	high	JJR	_	9	attr	_	_
6	than	than	IN	_	9	case	_	_
7	expected	expect	VBN	_	9	attr	_	_
8	plasma	plasma	NN	_	9	com	_	_
9	concentrations	concentration	NNS	_	4	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	when	when	WRB	_	13	adv	_	_
13	given	give	VBN	_	4	comp	_	_
14	usual	usual	JJ	_	15	attr	_	_
15	doses	dose	NNS	_	13	obj	_	_
16	.	.	.	_	4	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	26	ppmod	_	_
3	,	,	,	_	26	p	_	_
4	certain	certain	JJ	_	5	attr	_	_
5	drugs	drug	NNS	_	26	dep	_	_
6	that	that	WDT	_	8	dep	_	_
7	are	be	VBP	_	8	aux	_	_
8	metabolized	metabolize	VBN	_	5	relcl	_	_
9	by	by	IN	_	11	case	_	_
10	this	this	DT	_	11	det	_	_
11	isozyme	isozyme	NN	_	8	ppmod	_	_
12	,	,	,	_	5	p	_	_
13	including	include	VBG	_	15	adv	_	_
14	many	many	JJ	_	15	attr	_	_
15	drug1	drug0	NNS	_	5	ppmod	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	drug2	drug0	NN	_	15	prn	_	_
18	,	,	,	_	17	p	_	_
19	drug3	drug0	NN	_	17	conj	_	_
20	,	,	,	_	19	p	_	_
21	and	and	CC	_	19	cc	_	_
22	others	other	NNS	_	17	conj	_	_
23	)	-rrb-	-RRB-	_	17	p	_	_
24	,	,	,	_	5	p	_	_
25	may	may	MD	_	26	modal	_	_
26	inhibit	inhibit	VB	_	0	root	_	_
27	the	the	DT	_	28	det	_	_
28	activity	activity	NN	_	26	obj	_	_
29	of	of	IN	_	31	case	_	_
30	this	this	DT	_	31	det	_	_
31	isozyme	isozyme	NN	_	28	ppmod	_	_
32	,	,	,	_	26	p	_	_
33	and	and	CC	_	26	cc	_	_
34	thus	thus	RB	_	36	adv	_	_
35	may	may	MD	_	36	modal	_	_
36	make	make	VB	_	26	conj	_	_
37	normal	normal	JJ	_	38	attr	_	_
38	metabolizers	metabolizers	NNS	_	39	dep	_	_
39	resemble	resemble	VBP	_	36	comp	_	_
40	poor	poor	JJ	_	41	attr	_	_
41	metabolizers	metabolizers	NNS	_	39	obj	_	_
42	with	with	IN	_	43	case	_	_
43	regard	regard	NN	_	39	ppmod	_	_
44	to	to	TO	_	46	aux	_	_
45	concomitant	concomitant	JJ	_	46	attr	_	_
46	therapy	therapy	NN	_	43	ppmod	_	_
47	with	with	IN	_	49	case	_	_
48	other	other	JJ	_	49	attr	_	_
49	drugs	drug	NNS	_	46	ppmod	_	_
50	metabolized	metabolize	VBN	_	49	acl	_	_
51	by	by	IN	_	54	case	_	_
52	this	this	DT	_	54	det	_	_
53	enzyme	enzyme	NN	_	54	com	_	_
54	system	system	NN	_	50	ppmod	_	_
55	,	,	,	_	39	p	_	_
56	leading	lead	VBG	_	39	comp	_	_
57	to	to	TO	_	59	aux	_	_
58	drug	drug	NN	_	59	com	_	_
59	interaction	interaction	NN	_	56	ppmod	_	_
60	.	.	.	_	26	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	use	use	NN	_	14	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	with	with	IN	_	7	case	_	_
6	other	other	JJ	_	7	attr	_	_
7	drugs	drug	NNS	_	2	ppmod	_	_
8	metabolized	metabolize	VBN	_	7	acl	_	_
9	by	by	IN	_	12	case	_	_
10	cytochrome	cytochrome	NN	_	12	com	_	_
11	P450	p0	NN	_	12	com	_	_
12	2D6	0d0	NN	_	8	ppmod	_	_
13	may	may	MD	_	14	modal	_	_
14	require	require	VBP	_	0	root	_	_
15	lower	low	JJR	_	16	attr	_	_
16	doses	dose	NNS	_	14	obj	_	_
17	than	than	IN	_	18	case	_	_
18	usually	usually	RB	_	19	adv	_	_
19	prescribed	prescribe	VBN	_	16	acl	_	_
20	for	for	IN	_	22	case	_	_
21	either	either	CC	_	22	cc	_	_
22	drug2	drug0	NN	_	19	ppmod	_	_
23	or	or	CC	_	22	cc	_	_
24	the	the	DT	_	26	det	_	_
25	other	other	JJ	_	26	attr	_	_
26	drug	drug	NN	_	22	conj	_	_
27	.	.	.	_	14	p	_	_

1	Therefore	therefore	RB	_	48	adv	_	_
2	,	,	,	_	48	p	_	_
3	co-administration	co-administration	NN	_	48	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	with	with	IN	_	8	case	_	_
7	other	other	JJ	_	8	attr	_	_
8	drugs	drug	NNS	_	3	ppmod	_	_
9	that	that	WDT	_	11	dep	_	_
10	are	be	VBP	_	11	aux	_	_
11	metabolized	metabolize	VBN	_	8	relcl	_	_
12	by	by	IN	_	14	case	_	_
13	this	this	DT	_	14	det	_	_
14	isozyme	isozyme	NN	_	11	ppmod	_	_
15	,	,	,	_	8	p	_	_
16	including	include	VBG	_	17	adv	_	_
17	drug2	drug0	NN	_	8	ppmod	_	_
18	,	,	,	_	17	p	_	_
19	drug3	drug0	NN	_	17	conj	_	_
20	,	,	,	_	19	p	_	_
21	drug4	drug0	NN	_	17	conj	_	_
22	,	,	,	_	21	p	_	_
23	and	and	CC	_	21	cc	_	_
24	drug5	drug0	NN	_	17	conj	_	_
25	(	-lrb-	-LRB-	_	28	p	_	_
26	e.g.	e.g.	FW	_	28	adv	_	_
27	,	,	,	_	28	p	_	_
28	drug6	drug0	NN	_	24	prn	_	_
29	,	,	,	_	28	p	_	_
30	drug7	drug0	NN	_	28	conj	_	_
31	and	and	CC	_	30	cc	_	_
32	drug8	drug0	NN	_	28	conj	_	_
33	)	-rrb-	-RRB-	_	28	p	_	_
34	,	,	,	_	8	p	_	_
35	or	or	CC	_	37	cc	_	_
36	that	that	WDT	_	37	dep	_	_
37	inhibit	inhibit	VBP	_	8	relcl	_	_
38	this	this	DT	_	39	det	_	_
39	enzyme	enzyme	NN	_	37	obj	_	_
40	(	-lrb-	-LRB-	_	43	p	_	_
41	e.g.	e.g.	FW	_	43	ppmod	_	_
42	,	,	,	_	43	p	_	_
43	drug9	drug0	NN	_	39	prn	_	_
44	)	-rrb-	-RRB-	_	43	p	_	_
45	,	,	,	_	8	p	_	_
46	should	should	MD	_	48	modal	_	_
47	be	be	VB	_	48	aux	_	_
48	approached	approach	VBN	_	0	root	_	_
49	with	with	IN	_	50	case	_	_
50	caution	caution	NN	_	48	ppmod	_	_
51	.	.	.	_	48	p	_	_

1	Milk	milk	NN	_	13	dep	_	_
2	,	,	,	_	1	p	_	_
3	milk	milk	NN	_	4	com	_	_
4	products	product	NNS	_	1	conj	_	_
5	,	,	,	_	4	p	_	_
6	and	and	CC	_	4	cc	_	_
7	drug1	drug0	CD	_	1	conj	_	_
8	-rich	-rich	JJ	_	7	attr	_	_
9	foods	food	NNS	_	7	attr	_	_
10	or	or	CC	_	7	cc	_	_
11	drugs	drug	NNS	_	7	conj	_	_
12	may	may	MD	_	13	modal	_	_
13	impair	impair	VB	_	0	root	_	_
14	the	the	DT	_	15	det	_	_
15	absorption	absorption	NN	_	13	obj	_	_
16	of	of	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	.	.	.	_	13	p	_	_

1	Do	do	VBP	_	3	aux	_	_
2	not	not	RB	_	3	neg	_	_
3	take	take	VB	_	0	root	_	_
4	this	this	DT	_	5	det	_	_
5	medicine	medicine	NN	_	3	obj	_	_
6	with	with	IN	_	7	case	_	_
7	thioridizine	thioridizine	NN	_	3	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	or	or	CC	_	7	cc	_	_
10	within	within	IN	_	12	case	_	_
11	5	0	CD	_	12	num	_	_
12	weeks	week	NNS	_	7	conj	_	_
13	of	of	IN	_	15	case	_	_
14	taking	take	VBG	_	15	attr	_	_
15	drug1	drug0	NN	_	12	ppmod	_	_
16	.	.	.	_	3	p	_	_

1	Talk	talk	NN	_	8	dep	_	_
2	to	to	TO	_	4	aux	_	_
3	your	your	NN	_	4	com	_	_
4	doctor	doctor	NN	_	1	ppmod	_	_
5	if	if	IN	_	6	case	_	_
6	you	you	NN	_	1	ppmod	_	_
7	are	be	VBP	_	8	aux	_	_
8	taking	take	VBG	_	0	root	_	_
9	certain	certain	JJ	_	10	attr	_	_
10	drug1	drug0	NNS	_	8	obj	_	_
11	such	such	JJ	_	13	adv	_	_
12	as	as	IN	_	13	case	_	_
13	drug2	drug0	NN	_	10	ppmod	_	_
14	,	,	,	_	13	p	_	_
15	drug3	drug0	NN	_	13	conj	_	_
16	or	or	CC	_	15	cc	_	_
17	drug4	drug0	NN	_	13	conj	_	_
18	.	.	.	_	8	p	_	_

1	This	this	DT	_	2	det	_	_
2	medicine	medicine	NN	_	6	dep	_	_
3	should	should	MD	_	6	modal	_	_
4	not	not	RB	_	6	neg	_	_
5	be	be	VB	_	6	aux	_	_
6	taken	take	VBN	_	0	root	_	_
7	with	with	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	.	.	.	_	6	p	_	_

1	Caution	caution	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	exercised	exercise	VBN	_	0	root	_	_
5	when	when	WRB	_	6	adv	_	_
6	taking	take	VBG	_	4	comp	_	_
7	this	this	DT	_	10	det	_	_
8	medicine	medicine	NN	_	10	attr	_	_
9	certain	certain	JJ	_	10	attr	_	_
10	drug1	drug0	NN	_	6	obj	_	_
11	,	,	,	_	4	p	_	_
12	such	such	JJ	_	14	adv	_	_
13	as	as	IN	_	14	case	_	_
14	drug2	drug0	NN	_	4	ppmod	_	_
15	,	,	,	_	14	p	_	_
16	drug3	drug0	NN	_	14	conj	_	_
17	,	,	,	_	16	p	_	_
18	or	or	CC	_	16	cc	_	_
19	drug4	drug0	NN	_	14	conj	_	_
20	.	.	.	_	4	p	_	_

1	This	this	DT	_	2	det	_	_
2	medicine	medicine	NN	_	6	dep	_	_
3	should	should	MD	_	6	modal	_	_
4	not	not	RB	_	6	neg	_	_
5	be	be	VB	_	6	aux	_	_
6	taken	take	VBN	_	0	root	_	_
7	with	with	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	.	.	.	_	6	p	_	_

1	If	if	IN	_	3	mark	_	_
2	you	you	VBN	_	3	aux	_	_
3	think	think	VBP	_	6	advcl	_	_
4	you	you	RB	_	3	adv	_	_
5	are	be	VBP	_	6	aux	_	_
6	taking	take	VBG	_	0	root	_	_
7	an	an	DT	_	9	det	_	_
8	drug1	drug0	NN	_	9	com	_	_
9	talk	talk	NN	_	6	obj	_	_
10	to	to	TO	_	12	aux	_	_
11	your	your	NN	_	12	com	_	_
12	doctor	doctor	NN	_	6	ppmod	_	_
13	or	or	CC	_	12	cc	_	_
14	pharmacist	pharmacist	NN	_	12	conj	_	_
15	.	.	.	_	6	p	_	_

1	Do	do	VBP	_	3	aux	_	_
2	not	not	RB	_	3	neg	_	_
3	take	take	VB	_	0	root	_	_
4	this	this	DT	_	5	det	_	_
5	medicine	medicine	NN	_	3	obj	_	_
6	with	with	IN	_	9	case	_	_
7	St.	st.	NN	_	9	com	_	_
8	Johns	johns	NNP	_	9	com	_	_
9	Wort	wort	NNP	_	5	ppmod	_	_
10	because	because	IN	_	14	case	_	_
11	of	of	IN	_	14	case	_	_
12	the	the	DT	_	14	det	_	_
13	additive	additive	JJ	_	14	attr	_	_
14	effects	effect	NNS	_	3	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	sertonin	sertonin	NN	_	14	ppmod	_	_
17	.	.	.	_	3	p	_	_

1	This	this	DT	_	2	det	_	_
2	medication	medication	NN	_	6	dep	_	_
3	should	should	MD	_	6	modal	_	_
4	not	not	RB	_	6	neg	_	_
5	be	be	VB	_	6	aux	_	_
6	taken	take	VBN	_	0	root	_	_
7	with	with	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	.	.	.	_	6	p	_	_

1	Your	your	NN	_	2	com	_	_
2	doctor	doctor	NN	_	6	dep	_	_
3	or	or	CC	_	2	cc	_	_
4	pharmacist	pharmacist	NN	_	2	conj	_	_
5	can	can	MD	_	6	modal	_	_
6	give	give	VB	_	0	root	_	_
7	you	you	RB	_	8	adv	_	_
8	more	more	JJR	_	9	attr	_	_
9	information	information	NN	_	6	obj	_	_
10	on	on	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	6	p	_	_

1	Wait	wait	VBP	_	0	root	_	_
2	5	0	CD	_	3	num	_	_
3	weeks	week	NNS	_	1	obj	_	_
4	after	after	IN	_	5	case	_	_
5	stopping	stop	VBG	_	3	ppmod	_	_
6	drug1	drug0	NN	_	5	obj	_	_
7	before	before	IN	_	8	case	_	_
8	starting	start	VBG	_	5	ppmod	_	_
9	a	a	DT	_	10	det	_	_
10	drug2	drug0	NN	_	8	obj	_	_
11	.	.	.	_	1	p	_	_

1	Wait	wait	VBP	_	0	root	_	_
2	2	0	CD	_	3	num	_	_
3	weeks	week	NNS	_	1	obj	_	_
4	after	after	IN	_	5	case	_	_
5	stopping	stop	VBG	_	3	ppmod	_	_
6	an	an	DT	_	7	det	_	_
7	drug1	drug0	NN	_	5	obj	_	_
8	before	before	IN	_	9	case	_	_
9	starting	start	VBG	_	5	ppmod	_	_
10	drug2	drug0	NN	_	9	obj	_	_
11	.	.	.	_	1	p	_	_

1	If	if	IN	_	2	mark	_	_
2	you	you	VBN	_	5	advcl	_	_
3	are	be	VBP	_	5	aux	_	_
4	taking	take	VBG	_	5	lv	_	_
5	medications	medication	NNS	_	0	root	_	_
6	for	for	IN	_	7	case	_	_
7	migraines	migraine	NNS	_	5	ppmod	_	_
8	such	such	JJ	_	10	adv	_	_
9	as	as	IN	_	10	case	_	_
10	drug1	drug0	NN	_	7	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	talk	talk	NN	_	10	appo	_	_
13	to	to	TO	_	15	aux	_	_
14	your	your	NN	_	15	com	_	_
15	doctor	doctor	NN	_	12	ppmod	_	_
16	before	before	IN	_	17	case	_	_
17	starting	start	VBG	_	12	ppmod	_	_
18	this	this	DT	_	19	det	_	_
19	medicine	medicine	NN	_	17	obj	_	_
20	.	.	.	_	5	p	_	_

1	If	if	IN	_	2	mark	_	_
2	you	you	VBN	_	4	advcl	_	_
3	are	be	VBP	_	4	aux	_	_
4	taking	take	VBG	_	0	root	_	_
5	a	a	DT	_	6	det	_	_
6	drug1	drug0	NN	_	4	obj	_	_
7	,	,	,	_	6	p	_	_
8	talk	talk	NN	_	6	appo	_	_
9	to	to	TO	_	11	aux	_	_
10	your	your	NN	_	11	com	_	_
11	doctor	doctor	NN	_	8	ppmod	_	_
12	before	before	IN	_	13	case	_	_
13	taking	take	VBG	_	4	ppmod	_	_
14	this	this	DT	_	15	det	_	_
15	medicine	medicine	NN	_	13	obj	_	_
16	.	.	.	_	4	p	_	_

1	St.	st.	NN	_	4	com	_	_
2	John	john	NNP	_	4	com	_	_
3	s	s	NNP	_	4	com	_	_
4	Wort	wort	NNP	_	7	dep	_	_
5	should	should	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	avoided	avoid	VBN	_	0	root	_	_
8	while	while	IN	_	9	mark	_	_
9	taking	take	VBG	_	7	comp	_	_
10	this	this	DT	_	11	det	_	_
11	medicine	medicine	NN	_	9	obj	_	_
12	due	due	JJ	_	11	attr	_	_
13	to	to	TO	_	16	aux	_	_
14	the	the	DT	_	16	det	_	_
15	additive	additive	JJ	_	16	attr	_	_
16	effects	effect	NNS	_	12	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	serotonin	serotonin	NN	_	16	ppmod	_	_
19	.	.	.	_	7	p	_	_

1	Tell	tell	NN	_	3	com	_	_
2	your	your	NN	_	3	com	_	_
3	doctor	doctor	NN	_	0	root	_	_
4	if	if	IN	_	53	mark	_	_
5	you	you	RB	_	53	adv	_	_
6	are	be	VBP	_	53	aux	_	_
7	taking	take	VBG	_	53	lv	_	_
8	any	any	DT	_	52	attr	_	_
9	of	of	IN	_	12	case	_	_
10	the	the	DT	_	12	det	_	_
11	following	follow	VBG	_	12	attr	_	_
12	drugs	drug	NNS	_	8	ppmod	_	_
13	:	:	:	_	8	p	_	_
14	drug1	drug0	NN	_	49	attr	_	_
15	s	s	NN	_	49	attr	_	_
16	(	-lrb-	-LRB-	_	49	p	_	_
17	drug2	drug0	NN	_	49	attr	_	_
18	)	-rrb-	-RRB-	_	49	p	_	_
19	other	other	JJ	_	49	attr	_	_
20	drug3	drug0	NN	_	49	attr	_	_
21	drug4	drug0	NN	_	49	attr	_	_
22	drug5	drug0	NN	_	49	attr	_	_
23	drug6	drug0	NN	_	49	attr	_	_
24	(	-lrb-	-LRB-	_	49	p	_	_
25	drug7	drug0	NN	_	49	attr	_	_
26	)	-rrb-	-RRB-	_	49	p	_	_
27	drug8	drug0	NN	_	49	attr	_	_
28	(	-lrb-	-LRB-	_	49	p	_	_
29	drug9	drug0	NN	_	49	attr	_	_
30	)	-rrb-	-RRB-	_	49	p	_	_
31	drug10	drug0	NN	_	49	attr	_	_
32	drug11	drug0	NN	_	49	attr	_	_
33	(	-lrb-	-LRB-	_	49	p	_	_
34	drug12	drug0	CD	_	49	num	_	_
35	)	-rrb-	-RRB-	_	49	p	_	_
36	intraconazole	intraconazole	NN	_	49	attr	_	_
37	(	-lrb-	-LRB-	_	49	p	_	_
38	drug13	drug0	CD	_	49	num	_	_
39	)	-rrb-	-RRB-	_	49	p	_	_
40	drug14	drug0	NN	_	49	attr	_	_
41	(	-lrb-	-LRB-	_	49	p	_	_
42	drug15	drug0	CD	_	49	num	_	_
43	)	-rrb-	-RRB-	_	49	p	_	_
44	drug16	drug0	NN	_	49	attr	_	_
45	drug17	drug0	NN	_	49	attr	_	_
46	drug18	drug0	CD	_	49	num	_	_
47	birth	birth	NN	_	49	com	_	_
48	control	control	NN	_	49	com	_	_
49	pills	pill	NNS	_	8	appo	_	_
50	sleeping	sleeping	JJ	_	51	attr	_	_
51	pills	pill	NNS	_	8	appo	_	_
52	thyroid	thyroid	NN	_	53	com	_	_
53	medications	medication	NNS	_	3	acl	_	_

1	Increases	increase	NNS	_	6	dep	_	_
2	in	in	IN	_	4	case	_	_
3	serum	serum	NN	_	4	com	_	_
4	creatinine	creatinine	NN	_	1	ppmod	_	_
5	have	have	VBP	_	6	aux	_	_
6	occurred	occur	VBN	_	0	root	_	_
7	when	when	WRB	_	10	adv	_	_
8	drug1	drug0	NN	_	10	dep	_	_
9	was	be	VBD	_	10	aux	_	_
10	given	give	VBN	_	6	comp	_	_
11	alone	alone	RB	_	10	adv	_	_
12	.	.	.	_	6	p	_	_

1	If	if	IN	_	7	mark	_	_
2	drug1	drug0	NN	_	7	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	an	an	DT	_	5	det	_	_
5	drug2	drug0	NN	_	2	conj	_	_
6	are	be	VBP	_	7	aux	_	_
7	used	use	VBN	_	15	advcl	_	_
8	concomitantly	concomitantly	RB	_	7	adv	_	_
9	,	,	,	_	15	p	_	_
10	renal	renal	JJ	_	11	attr	_	_
11	function	function	NN	_	15	dep	_	_
12	should	should	MD	_	15	modal	_	_
13	be	be	VB	_	15	aux	_	_
14	carefully	carefully	RB	_	15	adv	_	_
15	monitored	monitor	VBN	_	0	root	_	_
16	,	,	,	_	15	p	_	_
17	because	because	IN	_	21	mark	_	_
18	nephrotoxicity	nephrotoxicity	NN	_	21	dep	_	_
19	may	may	MD	_	21	modal	_	_
20	be	be	VB	_	21	aux	_	_
21	potentiated	potentiate	VBN	_	15	comp	_	_
22	.	.	.	_	15	p	_	_

1	Drug/Laboratory	drug/laboratory	NN	_	3	com	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	0	root	_	_
4	:	:	:	_	3	p	_	_
5	The	the	DT	_	6	det	_	_
6	administration	administration	NN	_	10	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	may	may	MD	_	10	modal	_	_
10	result	result	VB	_	3	acl	_	_
11	in	in	IN	_	15	case	_	_
12	a	a	DT	_	15	det	_	_
13	false	false	JJ	_	14	adv	_	_
14	positive	positive	JJ	_	15	attr	_	_
15	reaction	reaction	NN	_	10	ppmod	_	_
16	for	for	IN	_	17	case	_	_
17	glucose	glucose	NN	_	15	ppmod	_	_
18	in	in	IN	_	20	case	_	_
19	the	the	DT	_	20	det	_	_
20	urine	urine	NN	_	15	ppmod	_	_
21	using	use	VBG	_	20	acl	_	_
22	Clinitest	clinitest	NNP	_	25	attr	_	_
23	,	,	,	_	25	p	_	_
24	Benedicts	benedicts	NNP	_	25	com	_	_
25	solution	solution	NN	_	21	obj	_	_
26	,	,	,	_	25	p	_	_
27	or	or	CC	_	25	cc	_	_
28	Fehlings	fehlings	NN	_	29	com	_	_
29	solution	solution	NN	_	25	conj	_	_
30	.	.	.	_	3	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	recommended	recommend	VBN	_	0	root	_	_
4	that	that	IN	_	13	mark	_	_
5	glucose	glucose	NN	_	6	com	_	_
6	tests	test	NNS	_	13	dep	_	_
7	based	base	VBN	_	6	acl	_	_
8	on	on	IN	_	11	case	_	_
9	enzymatic	enzymatic	JJ	_	11	attr	_	_
10	glucose	glucose	NN	_	11	com	_	_
11	oxidase	oxidase	NN	_	7	ppmod	_	_
12	be	be	VB	_	13	aux	_	_
13	used	use	VBN	_	3	comp	_	_
14	.	.	.	_	3	p	_	_

1	As	as	IN	_	4	case	_	_
2	with	with	IN	_	4	case	_	_
3	other	other	JJ	_	4	attr	_	_
4	drug1	drug0	NN	_	11	ppmod	_	_
5	,	,	,	_	11	p	_	_
6	high	high	JJ	_	7	attr	_	_
7	concentrations	concentration	NNS	_	11	dep	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	may	may	MD	_	11	modal	_	_
11	interfere	interfere	VB	_	0	root	_	_
12	with	with	IN	_	13	case	_	_
13	measurement	measurement	NN	_	11	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	serum	serum	NN	_	13	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	urine	urine	NN	_	19	com	_	_
18	creatinine	creatinine	NN	_	19	com	_	_
19	levels	level	NNS	_	15	conj	_	_
20	by	by	IN	_	22	case	_	_
21	Jaffe	jaffe	NN	_	22	com	_	_
22	reaction	reaction	NN	_	11	ppmod	_	_
23	and	and	CC	_	11	cc	_	_
24	produce	produce	VB	_	11	conj	_	_
25	false	false	JJ	_	26	attr	_	_
26	increases	increase	NNS	_	24	obj	_	_
27	in	in	IN	_	29	case	_	_
28	the	the	DT	_	29	det	_	_
29	levels	level	NNS	_	26	ppmod	_	_
30	of	of	IN	_	31	case	_	_
31	creatinine	creatinine	NN	_	29	ppmod	_	_
32	reported	report	VBD	_	31	acl	_	_
33	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	interact	interact	VB	_	0	root	_	_
4	with	with	IN	_	7	case	_	_
5	the	the	DT	_	7	det	_	_
6	following	following	JJ	_	7	attr	_	_
7	medications	medication	NNS	_	3	ppmod	_	_
8	:	:	:	_	7	p	_	_
9	drug2	drug0	NN	_	7	appo	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	drug3	drug0	NN	_	9	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	,	,	,	_	7	p	_	_
14	drug4	drug0	NN	_	7	appo	_	_
15	such	such	JJ	_	17	adv	_	_
16	as	as	IN	_	17	case	_	_
17	drug5	drug0	NN	_	14	ppmod	_	_
18	and	and	CC	_	17	cc	_	_
19	drug6	drug0	NN	_	17	conj	_	_
20	,	,	,	_	7	p	_	_
21	drug7	drug0	NN	_	7	appo	_	_
22	(	-lrb-	-LRB-	_	23	p	_	_
23	drug8	drug0	NN	_	21	prn	_	_
24	,	,	,	_	23	p	_	_
25	drug9	drug0	NN	_	23	appo	_	_
26	,	,	,	_	23	p	_	_
27	drug10	drug0	NN	_	23	appo	_	_
28	,	,	,	_	23	p	_	_
29	drug11	drug0	NN	_	23	appo	_	_
30	,	,	,	_	23	p	_	_
31	drug12	drug0	NN	_	23	appo	_	_
32	,	,	,	_	23	p	_	_
33	drug13	drug0	NN	_	23	appo	_	_
34	)	-rrb-	-RRB-	_	23	p	_	_
35	,	,	,	_	7	p	_	_
36	drug14	drug0	CD	_	42	num	_	_
37	(	-lrb-	-LRB-	_	42	p	_	_
38	drug15	drug0	CD	_	42	num	_	_
39	,	,	,	_	42	p	_	_
40	drug16	drug0	CD	_	42	num	_	_
41	,	,	,	_	42	p	_	_
42	drug17	drug0	CD	_	7	appo	_	_
43	)	-rrb-	-RRB-	_	42	p	_	_
44	,	,	,	_	7	p	_	_
45	drug18	drug0	CD	_	47	num	_	_
46	(	-lrb-	-LRB-	_	47	p	_	_
47	drug19	drug0	CD	_	7	appo	_	_
48	)	-rrb-	-RRB-	_	47	p	_	_
49	,	,	,	_	47	p	_	_
50	drug20	drug0	CD	_	52	num	_	_
51	(	-lrb-	-LRB-	_	52	p	_	_
52	drug21	drug0	CD	_	47	appo	_	_
53	)	-rrb-	-RRB-	_	52	p	_	_
54	,	,	,	_	47	p	_	_
55	drug22	drug0	CD	_	59	num	_	_
56	(	-lrb-	-LRB-	_	59	p	_	_
57	drug23	drug0	CD	_	59	num	_	_
58	,	,	,	_	59	p	_	_
59	drug24	drug0	CD	_	47	appo	_	_
60	)	-rrb-	-RRB-	_	59	p	_	_
61	,	,	,	_	47	p	_	_
62	HIV	hiv	NN	_	63	com	_	_
63	drugs	drug	NNS	_	47	appo	_	_
64	classified	classify	VBN	_	63	acl	_	_
65	as	as	IN	_	80	case	_	_
66	drug25	drug0	CD	_	80	num	_	_
67	(	-lrb-	-LRB-	_	80	p	_	_
68	drug26	drug0	CD	_	80	num	_	_
69	,	,	,	_	80	p	_	_
70	drug27	drug0	CD	_	80	num	_	_
71	,	,	,	_	80	p	_	_
72	drug28	drug0	CD	_	80	num	_	_
73	,	,	,	_	80	p	_	_
74	drug29	drug0	CD	_	80	num	_	_
75	,	,	,	_	80	p	_	_
76	drug30	drug0	CD	_	80	num	_	_
77	,	,	,	_	80	p	_	_
78	drug31	drug0	CD	_	80	num	_	_
79	,	,	,	_	80	p	_	_
80	drug32	drug0	CD	_	64	ppmod	_	_
81	)	-rrb-	-RRB-	_	80	p	_	_
82	,	,	,	_	47	p	_	_
83	drug33	drug0	CD	_	89	num	_	_
84	(	-lrb-	-LRB-	_	89	p	_	_
85	drug34	drug0	CD	_	89	num	_	_
86	,	,	,	_	89	p	_	_
87	drug35	drug0	CD	_	89	num	_	_
88	,	,	,	_	89	p	_	_
89	drug36	drug0	CD	_	47	appo	_	_
90	)	-rrb-	-RRB-	_	89	p	_	_
91	,	,	,	_	47	p	_	_
92	drug37	drug0	CD	_	47	appo	_	_
93	,	,	,	_	47	p	_	_
94	drug38	drug0	CD	_	47	appo	_	_
95	(	-lrb-	-LRB-	_	96	p	_	_
96	drug39	drug0	CD	_	94	num	_	_
97	)	-rrb-	-RRB-	_	96	p	_	_
98	,	,	,	_	47	p	_	_
99	drug40	drug0	CD	_	101	num	_	_
100	(	-lrb-	-LRB-	_	101	p	_	_
101	drug41	drug0	CD	_	47	appo	_	_
102	)	-rrb-	-RRB-	_	101	p	_	_
103	,	,	,	_	47	p	_	_
104	St.	st.	NN	_	47	appo	_	_
105	Johns	johns	NNP	_	106	com	_	_
106	wort	wort	NNP	_	47	appo	_	_
107	,	,	,	_	47	p	_	_
108	drug42	drug0	CD	_	47	conj	_	_
109	,	,	,	_	108	p	_	_
110	drug43	drug0	CD	_	47	conj	_	_
111	(	-lrb-	-LRB-	_	112	p	_	_
112	drug44	drug0	CD	_	110	num	_	_
113	)	-rrb-	-RRB-	_	112	p	_	_
114	,	,	,	_	110	p	_	_
115	and	and	CC	_	110	cc	_	_
116	drug45	drug0	CD	_	47	conj	_	_
117	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Substrate	substrate	NN	_	1	appo	_	_
4	of	of	IN	_	5	case	_	_
5	CYP3A4	cyp0a0	NN	_	3	ppmod	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	major	major	JJ	_	5	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	,	,	,	_	5	p	_	_
10	3A5-7	0a0	NN	_	5	appo	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	minor	minor	JJ	_	10	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	;	;	:	_	1	p	_	_

1	Inhibits	inhibit	VBZ	_	0	root	_	_
2	CYP1A2	cyp0a0	NN	_	1	obj	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	weak	weak	JJ	_	2	prn	_	_
5	)	-rrb-	-RRB-	_	4	p	_	_
6	,	,	,	_	2	p	_	_
7	2B6	0b0	NN	_	2	appo	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	weak	weak	JJ	_	7	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	,	,	,	_	7	p	_	_
12	2C19	0c0	NN	_	7	appo	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	weak	weak	JJ	_	12	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	,	,	,	_	7	p	_	_
17	3A4	0a0	NN	_	7	appo	_	_
18	(	-lrb-	-LRB-	_	19	p	_	_
19	weak	weak	JJ	_	7	prn	_	_
20	)	-rrb-	-RRB-	_	19	p	_	_
21	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	:	:	:	_	1	p	_	_
3	May	may	MD	_	4	modal	_	_
4	increase	increase	VB	_	0	root	_	_
5	plasma	plasma	NN	_	6	com	_	_
6	concentration	concentration	NN	_	4	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	,	,	,	_	4	p	_	_
10	possibly	possibly	RB	_	12	adv	_	_
11	by	by	IN	_	12	case	_	_
12	inhibiting	inhibit	VBG	_	4	ppmod	_	_
13	conjugation	conjugation	NN	_	12	obj	_	_
14	.	.	.	_	4	p	_	_

1	Combination	combination	NN	_	2	com	_	_
2	drug1	drug0	NN	_	5	dep	_	_
3	may	may	MD	_	5	modal	_	_
4	also	also	RB	_	5	adv	_	_
5	decrease	decrease	VB	_	0	root	_	_
6	the	the	DT	_	8	det	_	_
7	plasma	plasma	NN	_	8	com	_	_
8	concentration	concentration	NN	_	5	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	:	:	:	_	1	p	_	_
3	Interferes	interfere	VBZ	_	0	root	_	_
4	with	with	IN	_	7	case	_	_
5	the	the	DT	_	7	det	_	_
6	contraceptive	contraceptive	JJ	_	7	attr	_	_
7	effect	effect	NN	_	3	ppmod	_	_
8	of	of	IN	_	13	case	_	_
9	microdosed	microdosed	JJ	_	13	attr	_	_
10	drug2	drug0	NN	_	13	attr	_	_
11	-containing	-containing	JJ	_	13	attr	_	_
12	minipill	minipill	NN	_	13	com	_	_
13	preparations	preparation	NNS	_	7	ppmod	_	_
14	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	13	dep	_	_
3	on	on	IN	_	5	case	_	_
4	other	other	JJ	_	5	attr	_	_
5	drug1	drug0	NN	_	2	ppmod	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	eg	eg	NN	_	5	prn	_	_
8	,	,	,	_	7	p	_	_
9	implants	implant	NNS	_	7	appo	_	_
10	,	,	,	_	7	p	_	_
11	injectables	injectables	NN	_	7	appo	_	_
12	)	-rrb-	-RRB-	_	7	p	_	_
13	is	be	VBZ	_	0	root	_	_
14	unknown	unknown	JJ	_	13	dep	_	_
15	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	:	:	:	_	1	p	_	_
3	May	may	MD	_	4	modal	_	_
4	increase	increase	VB	_	0	root	_	_
5	CYP	cyp	NN	_	6	com	_	_
6	metabolism	metabolism	NN	_	4	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	leading	lead	VBG	_	8	acl	_	_
10	to	to	TO	_	12	aux	_	_
11	possible	possible	JJ	_	12	attr	_	_
12	decrease	decrease	NN	_	9	ppmod	_	_
13	in	in	IN	_	15	case	_	_
14	contraceptive	contraceptive	JJ	_	15	attr	_	_
15	effectiveness	effectiveness	NN	_	12	ppmod	_	_
16	.	.	.	_	4	p	_	_

1	Use	use	NN	_	6	dep	_	_
2	of	of	IN	_	4	case	_	_
3	a	a	DT	_	4	det	_	_
4	drug1	drug0	NN	_	1	ppmod	_	_
5	is	be	VBZ	_	6	aux	_	_
6	recommended	recommend	VBN	_	0	root	_	_
7	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	22	dep	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	drug2	drug0	NN	_	1	prn	_	_
4	,	,	,	_	3	p	_	_
5	drug3	drug0	NN	_	3	appo	_	_
6	)	-rrb-	-RRB-	_	3	p	_	_
7	:	:	:	_	1	p	_	_
8	Pregnancy	pregnancy	NN	_	11	dep	_	_
9	has	have	VBZ	_	11	aux	_	_
10	been	be	VBN	_	11	aux	_	_
11	reported	report	VBN	_	1	acl	_	_
12	following	follow	VBG	_	14	adv	_	_
13	concomitant	concomitant	JJ	_	14	attr	_	_
14	use	use	NN	_	11	ppmod	_	_
15	,	,	,	_	22	p	_	_
16	however	however	RB	_	22	adv	_	_
17	,	,	,	_	22	p	_	_
18	pharmacokinetic	pharmacokinetic	JJ	_	19	attr	_	_
19	studies	study	NNS	_	22	dep	_	_
20	have	have	VBP	_	22	aux	_	_
21	not	not	RB	_	22	neg	_	_
22	shown	show	VBN	_	0	root	_	_
23	consistent	consistent	JJ	_	24	attr	_	_
24	effects	effect	NNS	_	22	obj	_	_
25	with	with	IN	_	27	case	_	_
26	these	these	DT	_	27	det	_	_
27	drug4	drug0	NNS	_	24	ppmod	_	_
28	on	on	IN	_	30	case	_	_
29	plasma	plasma	NN	_	30	com	_	_
30	concentrations	concentration	NNS	_	24	ppmod	_	_
31	of	of	IN	_	32	case	_	_
32	drug5	drug0	NN	_	30	ppmod	_	_
33	.	.	.	_	22	p	_	_

1	Use	use	NN	_	6	dep	_	_
2	of	of	IN	_	4	case	_	_
3	a	a	DT	_	4	det	_	_
4	drug1	drug0	NN	_	1	ppmod	_	_
5	is	be	VBZ	_	6	aux	_	_
6	recommended	recommend	VBN	_	0	root	_	_
7	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	4	attr	_	_
2	:	:	:	_	4	p	_	_
3	Combination	combination	NN	_	4	com	_	_
4	drug2	drug0	NN	_	6	dep	_	_
5	may	may	MD	_	6	modal	_	_
6	increase	increase	VB	_	0	root	_	_
7	or	or	CC	_	6	cc	_	_
8	decrease	decrease	VB	_	6	conj	_	_
9	the	the	DT	_	10	det	_	_
10	effects	effect	NNS	_	8	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	6	p	_	_

1	Combination	combination	NN	_	2	com	_	_
2	drug1	drug0	NN	_	5	dep	_	_
3	may	may	MD	_	5	modal	_	_
4	also	also	RB	_	5	adv	_	_
5	increase	increase	VB	_	0	root	_	_
6	risk	risk	NN	_	5	obj	_	_
7	of	of	IN	_	9	case	_	_
8	thromboembolic	thromboembolic	JJ	_	9	attr	_	_
9	disorders	disorder	NNS	_	6	ppmod	_	_
10	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	drug2	drug0	NN	_	1	prn	_	_
4	,	,	,	_	3	p	_	_
5	drug3	drug0	NN	_	3	appo	_	_
6	,	,	,	_	3	p	_	_
7	drug4	drug0	NN	_	3	appo	_	_
8	,	,	,	_	3	p	_	_
9	drug5	drug0	NN	_	3	appo	_	_
10	,	,	,	_	3	p	_	_
11	drug6	drug0	NN	_	3	appo	_	_
12	)	-rrb-	-RRB-	_	3	p	_	_
13	:	:	:	_	1	p	_	_
14	Increase	increase	NN	_	1	appo	_	_
15	the	the	DT	_	16	det	_	_
16	metabolism	metabolism	NN	_	14	appo	_	_
17	of	of	IN	_	18	case	_	_
18	drug7	drug0	NN	_	16	ppmod	_	_
19	and/or	and/or	CC	_	18	cc	_	_
20	some	some	DT	_	21	det	_	_
21	drug8	drug0	NN	_	18	conj	_	_
22	,	,	,	_	21	p	_	_
23	leading	lead	VBG	_	21	acl	_	_
24	to	to	TO	_	26	aux	_	_
25	possible	possible	JJ	_	26	attr	_	_
26	decrease	decrease	NN	_	23	ppmod	_	_
27	in	in	IN	_	29	case	_	_
28	contraceptive	contraceptive	JJ	_	29	attr	_	_
29	effectiveness	effectiveness	NN	_	26	ppmod	_	_
30	.	.	.	_	1	p	_	_

1	Use	use	NN	_	6	dep	_	_
2	of	of	IN	_	4	case	_	_
3	a	a	DT	_	4	det	_	_
4	drug1	drug0	NN	_	1	ppmod	_	_
5	is	be	VBZ	_	6	aux	_	_
6	recommended	recommend	VBN	_	0	root	_	_
7	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Doses	dose	NNS	_	13	dep	_	_
4	of	of	IN	_	10	case	_	_
5	drug2	drug0	NN	_	10	attr	_	_
6	(	-lrb-	-LRB-	_	10	p	_	_
7	drug3	drug0	NN	_	10	attr	_	_
8	)	-rrb-	-RRB-	_	10	p	_	_
9	1	0	CD	_	10	num	_	_
10	g/day	g/day	NN	_	3	ppmod	_	_
11	have	have	VBP	_	13	aux	_	_
12	been	be	VBN	_	13	aux	_	_
13	reported	report	VBN	_	1	acl	_	_
14	to	to	TO	_	15	aux	_	_
15	increase	increase	VB	_	13	comp	_	_
16	plasma	plasma	NN	_	17	com	_	_
17	concentration	concentration	NN	_	15	obj	_	_
18	of	of	IN	_	19	case	_	_
19	drug4	drug0	NN	_	17	ppmod	_	_
20	by	by	IN	_	21	case	_	_
21	~47	~0	CD	_	15	ppmod	_	_
22	%	%	NN	_	21	meta	_	_
23	,	,	,	_	15	p	_	_
24	possibly	possibly	RB	_	26	adv	_	_
25	by	by	IN	_	26	case	_	_
26	inhibiting	inhibit	VBG	_	15	ppmod	_	_
27	conjugation	conjugation	NN	_	26	obj	_	_
28	;	;	:	_	1	p	_	_

1	clinical	clinical	JJ	_	2	attr	_	_
2	implications	implication	NNS	_	3	dep	_	_
3	are	be	VBP	_	0	root	_	_
4	unclear	unclear	JJ	_	3	dep	_	_
5	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	increases	increase	VBZ	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	AUC	auc	NN	_	4	obj	_	_
7	for	for	IN	_	8	case	_	_
8	drug3	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	drug4	drug0	NN	_	8	conj	_	_
11	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	4	attr	_	_
2	:	:	:	_	4	p	_	_
3	Combination	combination	NN	_	4	com	_	_
4	drug2	drug0	NN	_	6	dep	_	_
5	may	may	MD	_	6	modal	_	_
6	decrease	decrease	VB	_	0	root	_	_
7	the	the	DT	_	8	det	_	_
8	clearance	clearance	NN	_	6	obj	_	_
9	of	of	IN	_	11	case	_	_
10	some	some	DT	_	11	det	_	_
11	drug3	drug0	NN	_	8	ppmod	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	drug4	drug0	NN	_	11	prn	_	_
14	,	,	,	_	13	p	_	_
15	drug5	drug0	NN	_	13	appo	_	_
16	,	,	,	_	13	p	_	_
17	drug6	drug0	NN	_	13	appo	_	_
18	)	-rrb-	-RRB-	_	13	p	_	_
19	and	and	CC	_	6	cc	_	_
20	increase	increase	VB	_	6	conj	_	_
21	the	the	DT	_	22	det	_	_
22	clearance	clearance	NN	_	20	obj	_	_
23	of	of	IN	_	24	case	_	_
24	others	other	NNS	_	22	ppmod	_	_
25	(	-lrb-	-LRB-	_	26	p	_	_
26	drug7	drug0	NN	_	24	prn	_	_
27	,	,	,	_	26	p	_	_
28	drug8	drug0	NN	_	26	appo	_	_
29	,	,	,	_	26	p	_	_
30	drug9	drug0	NN	_	26	appo	_	_
31	)	-rrb-	-RRB-	_	26	p	_	_
32	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	4	attr	_	_
2	:	:	:	_	4	p	_	_
3	Combination	combination	NN	_	4	com	_	_
4	drug2	drug0	NN	_	6	dep	_	_
5	may	may	MD	_	6	modal	_	_
6	increase	increase	VB	_	0	root	_	_
7	the	the	DT	_	8	det	_	_
8	clearance	clearance	NN	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug3	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	4	attr	_	_
2	:	:	:	_	4	p	_	_
3	Combination	combination	NN	_	4	com	_	_
4	drug2	drug0	NN	_	6	dep	_	_
5	may	may	MD	_	6	modal	_	_
6	inhibit	inhibit	VB	_	0	root	_	_
7	the	the	DT	_	8	det	_	_
8	metabolism	metabolism	NN	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug3	drug0	NN	_	8	ppmod	_	_
11	,	,	,	_	6	p	_	_
12	leading	lead	VBG	_	6	comp	_	_
13	to	to	TO	_	16	aux	_	_
14	increased	increase	VBN	_	16	attr	_	_
15	plasma	plasma	NN	_	16	com	_	_
16	concentrations	concentration	NNS	_	12	ppmod	_	_
17	;	;	:	_	6	p	_	_

1	monitor	monitor	VB	_	0	root	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	levels	level	NNS	_	1	obj	_	_
4	.	.	.	_	1	p	_	_

1	CYP3A4	cyp0a0	JJ	_	2	attr	_	_
2	inducers	inducer	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	CYP3A4	cyp0a0	NN	_	5	com	_	_
5	inducers	inducer	NNS	_	7	dep	_	_
6	may	may	MD	_	7	modal	_	_
7	decrease	decrease	VB	_	2	acl	_	_
8	the	the	DT	_	9	det	_	_
9	levels/effects	levels/effects	NNS	_	7	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	2	p	_	_

1	Example	example	NN	_	2	com	_	_
2	inducers	inducer	NNS	_	3	dep	_	_
3	include	include	VBP	_	0	root	_	_
4	drug1	drug0	NN	_	3	obj	_	_
5	,	,	,	_	4	p	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	,	,	,	_	6	p	_	_
8	drug3	drug0	NN	_	4	conj	_	_
9	,	,	,	_	8	p	_	_
10	drug4	drug0	NN	_	4	conj	_	_
11	,	,	,	_	10	p	_	_
12	drug5	drug0	NN	_	4	conj	_	_
13	,	,	,	_	12	p	_	_
14	drug6	drug0	NN	_	4	conj	_	_
15	,	,	,	_	14	p	_	_
16	and	and	CC	_	14	cc	_	_
17	drug7	drug0	NN	_	4	conj	_	_
18	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	induce	induce	VB	_	1	acl	_	_
6	the	the	DT	_	7	det	_	_
7	metabolism	metabolism	NN	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_
10	causing	cause	VBG	_	9	acl	_	_
11	menstrual	menstrual	JJ	_	12	attr	_	_
12	changes	change	NNS	_	10	obj	_	_
13	;	;	:	_	1	p	_	_

1	pregnancies	pregnancy	NNS	_	4	dep	_	_
2	have	have	VBP	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	reported	report	VBN	_	0	root	_	_
5	.	.	.	_	4	p	_	_

1	Use	use	NN	_	8	dep	_	_
2	of	of	IN	_	4	case	_	_
3	barrier	barrier	NN	_	4	com	_	_
4	form	form	NN	_	1	ppmod	_	_
5	of	of	IN	_	6	case	_	_
6	contraception	contraception	NN	_	4	ppmod	_	_
7	is	be	VBZ	_	8	aux	_	_
8	suggested	suggest	VBN	_	0	root	_	_
9	while	while	IN	_	12	case	_	_
10	on	on	IN	_	12	case	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	therapy	therapy	NN	_	8	ppmod	_	_
13	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	4	attr	_	_
2	:	:	:	_	4	p	_	_
3	Combination	combination	NN	_	4	com	_	_
4	drug2	drug0	NN	_	6	dep	_	_
5	may	may	MD	_	6	modal	_	_
6	increase	increase	VB	_	0	root	_	_
7	the	the	DT	_	8	det	_	_
8	clearance	clearance	NN	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug3	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	drug2	drug0	NN	_	1	prn	_	_
4	)	-rrb-	-RRB-	_	3	p	_	_
5	:	:	:	_	1	p	_	_
6	drug3	drug0	NN	_	8	dep	_	_
7	may	may	MD	_	8	modal	_	_
8	decrease	decrease	VB	_	1	acl	_	_
9	plasma	plasma	NN	_	10	com	_	_
10	levels	level	NNS	_	8	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug4	drug0	NN	_	10	ppmod	_	_
13	;	;	:	_	1	p	_	_

1	use	use	NN	_	6	dep	_	_
2	of	of	IN	_	4	case	_	_
3	a	a	DT	_	4	det	_	_
4	drug1	drug0	NN	_	1	ppmod	_	_
5	is	be	VBZ	_	6	aux	_	_
6	recommended	recommend	VBN	_	0	root	_	_
7	.	.	.	_	6	p	_	_

1	No	no	DT	_	2	det	_	_
2	data	datum	NNS	_	0	root	_	_
3	for	for	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	;	;	:	_	2	p	_	_

1	incomplete	incomplete	JJ	_	2	attr	_	_
2	data	datum	NNS	_	0	root	_	_
3	for	for	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	may	may	MD	_	5	modal	_	_
5	inhibit	inhibit	VB	_	0	root	_	_
6	the	the	DT	_	7	det	_	_
7	metabolism	metabolism	NN	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	5	p	_	_
11	leading	lead	VBG	_	5	comp	_	_
12	to	to	TO	_	15	aux	_	_
13	increased	increase	VBN	_	15	attr	_	_
14	plasma	plasma	NN	_	15	com	_	_
15	concentrations	concentration	NNS	_	11	ppmod	_	_
16	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	13	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	,	,	,	_	3	p	_	_
5	drug3	drug0	NN	_	1	conj	_	_
6	,	,	,	_	5	p	_	_
7	drug4	drug0	NN	_	1	conj	_	_
8	,	,	,	_	7	p	_	_
9	and	and	CC	_	7	cc	_	_
10	drug5	drug0	NN	_	1	conj	_	_
11	have	have	VBP	_	13	aux	_	_
12	been	be	VBN	_	13	aux	_	_
13	shown	show	VBN	_	0	root	_	_
14	to	to	TO	_	15	aux	_	_
15	decrease	decrease	VB	_	13	comp	_	_
16	plasma	plasma	NN	_	17	com	_	_
17	levels	level	NNS	_	15	obj	_	_
18	of	of	IN	_	19	case	_	_
19	drug6	drug0	NN	_	17	ppmod	_	_
20	;	;	:	_	13	p	_	_

1	use	use	NN	_	6	dep	_	_
2	of	of	IN	_	4	case	_	_
3	a	a	DT	_	4	det	_	_
4	drug1	drug0	NN	_	1	ppmod	_	_
5	is	be	VBZ	_	6	aux	_	_
6	recommended	recommend	VBN	_	0	root	_	_
7	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	shown	show	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	increase	increase	VB	_	4	comp	_	_
7	plasma	plasma	NN	_	8	com	_	_
8	levels	level	NNS	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	4	p	_	_

1	No	no	DT	_	2	det	_	_
2	data	datum	NNS	_	0	root	_	_
3	for	for	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	4	dep	_	_
4	increases	increase	VBZ	_	1	acl	_	_
5	the	the	DT	_	6	det	_	_
6	metabolism	metabolism	NN	_	4	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug3	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	some	some	DT	_	11	det	_	_
11	drug4	drug0	NNS	_	8	conj	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	drug5	drug0	NN	_	11	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	resulting	result	VBG	_	11	acl	_	_
16	in	in	IN	_	19	case	_	_
17	decreased	decrease	VBN	_	19	attr	_	_
18	contraceptive	contraceptive	JJ	_	19	attr	_	_
19	effectiveness	effectiveness	NN	_	15	ppmod	_	_
20	and	and	CC	_	19	cc	_	_
21	increased	increase	VBN	_	23	attr	_	_
22	menstrual	menstrual	JJ	_	23	attr	_	_
23	irregularities	irregularity	NNS	_	19	conj	_	_
24	.	.	.	_	1	p	_	_

1	Use	use	NN	_	6	dep	_	_
2	of	of	IN	_	4	case	_	_
3	a	a	DT	_	4	det	_	_
4	drug1	drug0	NN	_	1	ppmod	_	_
5	is	be	VBZ	_	6	aux	_	_
6	recommended	recommend	VBN	_	0	root	_	_
7	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	4	attr	_	_
2	:	:	:	_	4	p	_	_
3	Combination	combination	NN	_	4	com	_	_
4	drug2	drug0	NN	_	6	dep	_	_
5	may	may	MD	_	6	modal	_	_
6	increase	increase	VB	_	0	root	_	_
7	the	the	DT	_	8	det	_	_
8	clearance	clearance	NN	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug3	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	may	may	MD	_	5	modal	_	_
5	increase	increase	VB	_	0	root	_	_
6	the	the	DT	_	8	det	_	_
7	serum	serum	NN	_	8	com	_	_
8	concentration	concentration	NN	_	5	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug3	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	may	may	MD	_	5	modal	_	_
5	inhibit	inhibit	VB	_	0	root	_	_
6	the	the	DT	_	7	det	_	_
7	metabolism	metabolism	NN	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	5	p	_	_
11	leading	lead	VBG	_	5	comp	_	_
12	to	to	TO	_	15	aux	_	_
13	increased	increase	VBN	_	15	attr	_	_
14	plasma	plasma	NN	_	15	com	_	_
15	concentrations	concentration	NNS	_	11	ppmod	_	_
16	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	13	comp	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	drug2	drug0	NN	_	1	prn	_	_
4	,	,	,	_	3	p	_	_
5	drug3	drug0	NN	_	3	appo	_	_
6	,	,	,	_	3	p	_	_
7	drug4	drug0	NN	_	3	appo	_	_
8	)	-rrb-	-RRB-	_	3	p	_	_
9	:	:	:	_	13	p	_	_
10	Metabolism	metabolism	NN	_	13	dep	_	_
11	may	may	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	inhibited	inhibit	VBN	_	0	root	_	_
14	by	by	IN	_	15	case	_	_
15	drug5	drug0	NN	_	13	ppmod	_	_
16	,	,	,	_	13	p	_	_
17	increasing	increase	VBG	_	13	comp	_	_
18	plasma	plasma	NN	_	19	com	_	_
19	levels	level	NNS	_	17	obj	_	_
20	of	of	IN	_	21	case	_	_
21	drug6	drug0	NN	_	19	ppmod	_	_
22	;	;	:	_	13	p	_	_

1	use	use	VBP	_	0	root	_	_
2	caution	caution	NN	_	1	obj	_	_
3	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	/	/	:	_	1	p	_	_
3	NUTRITION	nutrition	NN	_	1	appo	_	_
4	/	/	:	_	1	p	_	_
5	HERB	herb	NN	_	6	com	_	_
6	INTERACTIONS	interaction	NNS	_	1	appo	_	_
7	:	:	:	_	1	p	_	_
8	Food	food	NN	_	1	appo	_	_
9	:	:	:	_	1	p	_	_
10	CNS	cns	NN	_	11	com	_	_
11	effects	effect	NNS	_	16	dep	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	may	may	MD	_	16	modal	_	_
15	be	be	VB	_	16	aux	_	_
16	enhanced	enhance	VBN	_	1	acl	_	_
17	if	if	IN	_	20	mark	_	_
18	drug3	drug0	NN	_	20	dep	_	_
19	are	be	VBP	_	20	aux	_	_
20	used	use	VBN	_	16	comp	_	_
21	concurrently	concurrently	RB	_	20	adv	_	_
22	with	with	IN	_	23	case	_	_
23	drug4	drug0	NN	_	20	ppmod	_	_
24	.	.	.	_	1	p	_	_

1	Grapefruit	grapefruit	NN	_	2	com	_	_
2	juice	juice	NN	_	3	dep	_	_
3	increases	increase	VBZ	_	0	root	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	concentrations	concentration	NNS	_	3	obj	_	_
6	and	and	CC	_	3	cc	_	_
7	would	would	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	expected	expect	VBN	_	3	conj	_	_
10	to	to	TO	_	11	aux	_	_
11	increase	increase	VB	_	9	comp	_	_
12	drug2	drug0	NN	_	14	com	_	_
13	serum	serum	NN	_	14	com	_	_
14	levels	level	NNS	_	11	obj	_	_
15	as	as	IN	_	16	case	_	_
16	well	well	NN	_	11	ppmod	_	_
17	;	;	:	_	3	p	_	_

1	clinical	clinical	JJ	_	2	attr	_	_
2	implications	implication	NNS	_	3	dep	_	_
3	are	be	VBP	_	0	root	_	_
4	unclear	unclear	JJ	_	3	dep	_	_
5	.	.	.	_	3	p	_	_

1	Herb/Nutraceutical	herb/nutraceutical	NN	_	7	dep	_	_
2	:	:	:	_	1	p	_	_
3	St	st	JJ	_	5	attr	_	_
4	Johns	johns	NNP	_	5	com	_	_
5	wort	wort	NN	_	1	appo	_	_
6	may	may	MD	_	7	modal	_	_
7	decrease	decrease	VB	_	0	root	_	_
8	the	the	DT	_	9	det	_	_
9	effectiveness	effectiveness	NN	_	7	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	by	by	IN	_	13	case	_	_
13	inducing	induce	VBG	_	7	ppmod	_	_
14	hepatic	hepatic	JJ	_	15	attr	_	_
15	enzymes	enzyme	NNS	_	13	obj	_	_
16	.	.	.	_	7	p	_	_

1	Avoid	avoid	VB	_	0	root	_	_
2	dong	dong	JJ	_	3	attr	_	_
3	quai	quai	NN	_	1	obj	_	_
4	and	and	CC	_	3	cc	_	_
5	black	black	JJ	_	6	attr	_	_
6	cohosh	cohosh	NN	_	3	conj	_	_
7	(	-lrb-	-LRB-	_	10	p	_	_
8	have	have	VBP	_	10	lv	_	_
9	estrogen	estrogen	NN	_	10	com	_	_
10	activity	activity	NN	_	1	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	.	.	.	_	1	p	_	_

1	Avoid	avoid	VB	_	0	root	_	_
2	saw	see	VB	_	1	comp	_	_
3	palmetto	palmetto	NN	_	2	obj	_	_
4	,	,	,	_	3	p	_	_
5	red	red	JJ	_	6	attr	_	_
6	clover	clover	NN	_	3	appo	_	_
7	,	,	,	_	3	p	_	_
8	ginseng	ginseng	NN	_	3	appo	_	_
9	.	.	.	_	1	p	_	_

1	No	no	DT	_	4	det	_	_
2	drug	drug	NN	_	4	com	_	_
3	interaction	interaction	NN	_	4	com	_	_
4	studies	study	NNS	_	7	dep	_	_
5	have	have	VBP	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	conducted	conduct	VBN	_	22	advcl	_	_
8	for	for	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	22	p	_	_
11	however	however	RB	_	22	adv	_	_
12	the	the	DT	_	13	det	_	_
13	use	use	NN	_	22	dep	_	_
14	of	of	IN	_	17	case	_	_
15	orally	orally	RB	_	16	adv	_	_
16	administered	administer	VBN	_	17	attr	_	_
17	drug2	drug0	NN	_	13	ppmod	_	_
18	could	could	MD	_	22	modal	_	_
19	,	,	,	_	22	p	_	_
20	theoretically	theoretically	RB	_	22	adv	_	_
21	,	,	,	_	22	p	_	_
22	interfere	interfere	VB	_	0	root	_	_
23	with	with	IN	_	25	case	_	_
24	the	the	DT	_	25	det	_	_
25	release	release	NN	_	22	ppmod	_	_
26	of	of	IN	_	27	case	_	_
27	drug3	drug0	NN	_	25	ppmod	_	_
28	in	in	IN	_	30	case	_	_
29	the	the	DT	_	30	det	_	_
30	colon	colon	NN	_	25	ppmod	_	_
31	.	.	.	_	22	p	_	_

1	The	the	DT	_	3	det	_	_
2	pharmacokinetic	pharmacokinetic	JJ	_	3	attr	_	_
3	interactions	interaction	NNS	_	6	dep	_	_
4	listed	list	VBN	_	3	acl	_	_
5	below	below	IN	_	4	case	_	_
6	are	be	VBP	_	0	root	_	_
7	potentially	potentially	RB	_	9	adv	_	_
8	clinically	clinically	RB	_	9	adv	_	_
9	important	important	JJ	_	6	dep	_	_
10	.	.	.	_	6	p	_	_

1	Drugs	drug	NNS	_	14	dep	_	_
2	that	that	WDT	_	3	dep	_	_
3	induce	induce	VBP	_	1	relcl	_	_
4	hepatic	hepatic	JJ	_	5	attr	_	_
5	enzymes	enzyme	NNS	_	3	obj	_	_
6	such	such	JJ	_	8	adv	_	_
7	as	as	IN	_	8	case	_	_
8	drug1	drug0	NN	_	5	ppmod	_	_
9	,	,	,	_	8	p	_	_
10	drug2	drug0	NN	_	8	conj	_	_
11	and	and	CC	_	10	cc	_	_
12	drug3	drug0	NN	_	8	conj	_	_
13	may	may	MD	_	14	modal	_	_
14	increase	increase	VB	_	0	root	_	_
15	the	the	DT	_	16	det	_	_
16	clearance	clearance	NN	_	14	obj	_	_
17	of	of	IN	_	18	case	_	_
18	drug4	drug0	NN	_	16	ppmod	_	_
19	and	and	CC	_	14	cc	_	_
20	may	may	MD	_	21	modal	_	_
21	require	require	VB	_	14	conj	_	_
22	increases	increase	NNS	_	21	obj	_	_
23	in	in	IN	_	25	case	_	_
24	drug5	drug0	NN	_	25	com	_	_
25	dose	dose	NN	_	22	ppmod	_	_
26	to	to	TO	_	27	aux	_	_
27	achieve	achieve	VB	_	21	comp	_	_
28	the	the	DT	_	30	det	_	_
29	desired	desired	JJ	_	30	attr	_	_
30	response	response	NN	_	27	obj	_	_
31	.	.	.	_	14	p	_	_

1	Drugs	drug	NNS	_	8	dep	_	_
2	such	such	JJ	_	4	adv	_	_
3	as	as	IN	_	4	case	_	_
4	drug1	drug0	NN	_	1	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	may	may	MD	_	8	modal	_	_
8	inhibit	inhibit	VB	_	0	root	_	_
9	the	the	DT	_	10	det	_	_
10	metabolism	metabolism	NN	_	8	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	and	and	CC	_	8	cc	_	_
14	thus	thus	RB	_	15	adv	_	_
15	decrease	decrease	VB	_	8	conj	_	_
16	their	their	PRP$	_	17	poss	_	_
17	clearance	clearance	NN	_	15	obj	_	_
18	.	.	.	_	8	p	_	_

1	Therefore	therefore	RB	_	9	adv	_	_
2	,	,	,	_	9	p	_	_
3	the	the	DT	_	4	det	_	_
4	dose	dose	NN	_	9	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	should	should	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	titrated	titrate	VBN	_	0	root	_	_
10	to	to	TO	_	11	aux	_	_
11	avoid	avoid	VB	_	9	comp	_	_
12	steroid	steroid	NN	_	13	com	_	_
13	toxicity	toxicity	NN	_	11	obj	_	_
14	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	increase	increase	VB	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	clearance	clearance	NN	_	3	obj	_	_
6	of	of	IN	_	10	case	_	_
7	chronic	chronic	JJ	_	10	attr	_	_
8	high	high	JJ	_	10	attr	_	_
9	dose	dose	NN	_	10	com	_	_
10	drug2	drug0	NN	_	5	ppmod	_	_
11	.	.	.	_	3	p	_	_

1	This	this	DT	_	3	dep	_	_
2	could	could	MD	_	3	modal	_	_
3	lead	lead	VB	_	0	root	_	_
4	to	to	TO	_	8	aux	_	_
5	decreased	decrease	VBN	_	8	attr	_	_
6	drug1	drug0	NN	_	8	com	_	_
7	serum	serum	NN	_	8	com	_	_
8	levels	level	NNS	_	3	ppmod	_	_
9	or	or	CC	_	3	cc	_	_
10	increase	increase	VBP	_	3	conj	_	_
11	the	the	DT	_	12	det	_	_
12	risk	risk	NN	_	10	obj	_	_
13	of	of	IN	_	15	case	_	_
14	drug2	drug0	NN	_	15	com	_	_
15	toxicity	toxicity	NN	_	12	ppmod	_	_
16	when	when	WRB	_	19	adv	_	_
17	drug3	drug0	NN	_	19	dep	_	_
18	is	be	VBZ	_	19	aux	_	_
19	withdrawn	withdraw	VBN	_	10	comp	_	_
20	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	used	use	VBN	_	0	root	_	_
5	cautiously	cautiously	RB	_	4	adv	_	_
6	in	in	IN	_	7	case	_	_
7	conjunction	conjunction	NN	_	4	ppmod	_	_
8	with	with	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	in	in	IN	_	11	case	_	_
11	patients	patient	NNS	_	9	ppmod	_	_
12	suffering	suffer	VBG	_	11	acl	_	_
13	from	from	IN	_	14	case	_	_
14	hypopro-thrombinemia	hypopro-thrombinemia	NN	_	12	ppmod	_	_
15	.	.	.	_	4	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	8	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	on	on	IN	_	7	case	_	_
6	oral	oral	JJ	_	7	attr	_	_
7	drug2	drug0	NNS	_	2	ppmod	_	_
8	is	be	VBZ	_	0	root	_	_
9	variable	variable	NN	_	8	obj	_	_
10	.	.	.	_	8	p	_	_

1	There	there	EX	_	2	dep	_	_
2	are	be	VBP	_	0	root	_	_
3	reports	report	NNS	_	2	obj	_	_
4	of	of	IN	_	5	case	_	_
5	enhanced	enhance	VBN	_	3	ppmod	_	_
6	as	as	RB	_	7	com	_	_
7	well	well	RB	_	5	cc	_	_
8	as	as	IN	_	7	com	_	_
9	diminished	diminish	VBN	_	10	attr	_	_
10	effects	effect	NNS	_	5	conj	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	when	when	WRB	_	14	adv	_	_
14	given	give	VBN	_	2	comp	_	_
15	concurrently	concurrently	RB	_	14	adv	_	_
16	with	with	IN	_	17	case	_	_
17	drug2	drug0	NN	_	14	ppmod	_	_
18	.	.	.	_	2	p	_	_

1	Therefore	therefore	RB	_	7	adv	_	_
2	,	,	,	_	7	p	_	_
3	coagulation	coagulation	NN	_	4	com	_	_
4	indices	index	NNS	_	7	dep	_	_
5	should	should	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	monitored	monitor	VBN	_	0	root	_	_
8	to	to	TO	_	9	aux	_	_
9	maintain	maintain	VB	_	7	comp	_	_
10	the	the	DT	_	13	det	_	_
11	desired	desired	JJ	_	13	attr	_	_
12	anticoagulant	anticoagulant	JJ	_	13	attr	_	_
13	effect	effect	NN	_	9	obj	_	_
14	.	.	.	_	7	p	_	_

1	Drug	drug	NN	_	2	com	_	_
2	Interactions	interaction	NNS	_	15	dep	_	_
3	:	:	:	_	2	p	_	_
4	a.	a.	FW	_	8	attr	_	_
5	Drugs	drug	NNS	_	8	com	_	_
6	Enhancing	enhancing	NN	_	8	com	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	Effect	effect	NN	_	2	appo	_	_
9	:	:	:	_	2	p	_	_
10	Oral	oral	JJ	_	11	attr	_	_
11	drug2	drug0	NN	_	2	appo	_	_
12	:	:	:	_	2	p	_	_
13	drug3	drug0	NN	_	2	appo	_	_
14	may	may	MD	_	15	modal	_	_
15	prolong	prolong	VB	_	0	root	_	_
16	the	the	DT	_	19	det	_	_
17	one-stage	one-stage	JJ	_	19	attr	_	_
18	prothrombin	prothrombin	NN	_	19	com	_	_
19	time	time	NN	_	15	obj	_	_
20	.	.	.	_	15	p	_	_

1	Therefore	therefore	RB	_	33	adv	_	_
2	,	,	,	_	33	p	_	_
3	when	when	WRB	_	6	adv	_	_
4	drug1	drug0	NN	_	6	dep	_	_
5	is	be	VBZ	_	6	aux	_	_
6	given	give	VBN	_	33	advcl	_	_
7	with	with	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	or	or	CC	_	8	cc	_	_
10	drug3	drug0	NN	_	8	conj	_	_
11	,	,	,	_	33	p	_	_
12	a	a	DT	_	13	det	_	_
13	period	period	NN	_	33	dep	_	_
14	of	of	IN	_	18	case	_	_
15	at	at	IN	_	17	case	_	_
16	least	least	JJS	_	17	attr	_	_
17	5	0	CD	_	18	num	_	_
18	hours	hour	NNS	_	13	ppmod	_	_
19	after	after	IN	_	23	case	_	_
20	the	the	DT	_	23	det	_	_
21	last	last	JJ	_	23	attr	_	_
22	intravenous	intravenous	JJ	_	23	attr	_	_
23	dose	dose	NN	_	18	ppmod	_	_
24	or	or	CC	_	18	cc	_	_
25	24	0	CD	_	26	num	_	_
26	hours	hour	NNS	_	18	conj	_	_
27	after	after	IN	_	31	case	_	_
28	the	the	DT	_	31	det	_	_
29	last	last	JJ	_	31	attr	_	_
30	subcutaneous	subcutaneous	NN	_	31	com	_	_
31	dose	dose	NN	_	26	ppmod	_	_
32	should	should	MD	_	33	modal	_	_
33	elapse	elapse	VB	_	0	root	_	_
34	before	before	IN	_	37	mark	_	_
35	blood	blood	NN	_	37	dep	_	_
36	is	be	VBZ	_	37	aux	_	_
37	drawn	draw	VBN	_	33	comp	_	_
38	if	if	IN	_	43	mark	_	_
39	a	a	DT	_	42	det	_	_
40	valid	valid	JJ	_	42	attr	_	_
41	prothrombin	prothrombin	NN	_	42	com	_	_
42	time	time	NN	_	43	dep	_	_
43	is	be	VBZ	_	37	comp	_	_
44	to	to	TO	_	46	aux	_	_
45	be	be	VB	_	46	aux	_	_
46	obtained	obtain	VBN	_	43	comp	_	_
47	.	.	.	_	33	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Drugs	drug	NNS	_	36	dep	_	_
4	such	such	JJ	_	6	adv	_	_
5	as	as	IN	_	6	case	_	_
6	drug2	drug0	NN	_	3	ppmod	_	_
7	,	,	,	_	6	p	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	,	,	,	_	8	p	_	_
10	drug4	drug0	NN	_	6	conj	_	_
11	,	,	,	_	10	p	_	_
12	drug5	drug0	NN	_	6	conj	_	_
13	,	,	,	_	12	p	_	_
14	drug6	drug0	NN	_	6	conj	_	_
15	,	,	,	_	14	p	_	_
16	drug7	drug0	NN	_	6	conj	_	_
17	,	,	,	_	16	p	_	_
18	drug8	drug0	NN	_	6	conj	_	_
19	and	and	CC	_	18	cc	_	_
20	others	other	NNS	_	6	conj	_	_
21	that	that	WDT	_	22	dep	_	_
22	interfere	interfere	VBP	_	20	relcl	_	_
23	with	with	IN	_	25	case	_	_
24	platelet-aggregation	platelet-aggregation	JJ	_	25	attr	_	_
25	reactions	reaction	NNS	_	22	ppmod	_	_
26	(	-lrb-	-LRB-	_	30	p	_	_
27	the	the	DT	_	30	det	_	_
28	main	main	JJ	_	30	attr	_	_
29	hemostatic	hemostatic	JJ	_	30	attr	_	_
30	defense	defense	NN	_	25	prn	_	_
31	of	of	IN	_	33	case	_	_
32	heparinized	heparinized	JJ	_	33	attr	_	_
33	patients	patient	NNS	_	30	ppmod	_	_
34	)	-rrb-	-RRB-	_	30	p	_	_
35	may	may	MD	_	36	modal	_	_
36	induce	induce	VB	_	1	acl	_	_
37	bleeding	bleeding	JJ	_	36	dep	_	_
38	and	and	CC	_	36	cc	_	_
39	should	should	MD	_	41	modal	_	_
40	be	be	VB	_	41	aux	_	_
41	used	use	VBN	_	36	conj	_	_
42	with	with	IN	_	43	case	_	_
43	caution	caution	NN	_	41	ppmod	_	_
44	in	in	IN	_	45	case	_	_
45	patients	patient	NNS	_	41	ppmod	_	_
46	receiving	receive	VBG	_	45	acl	_	_
47	drug9	drug0	NN	_	46	obj	_	_
48	.	.	.	_	1	p	_	_

1	The	the	DT	_	3	det	_	_
2	anticoagulant	anticoagulant	JJ	_	3	attr	_	_
3	effect	effect	NN	_	7	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	is	be	VBZ	_	7	aux	_	_
7	enhanced	enhance	VBN	_	0	root	_	_
8	by	by	IN	_	10	case	_	_
9	concurrent	concurrent	JJ	_	10	attr	_	_
10	treatment	treatment	NN	_	7	ppmod	_	_
11	with	with	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	human	human	NN	_	12	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	in	in	IN	_	17	case	_	_
17	patients	patient	NNS	_	12	ppmod	_	_
18	with	with	IN	_	22	case	_	_
19	hereditary	hereditary	JJ	_	22	attr	_	_
20	antithrombin	antithrombin	NN	_	22	attr	_	_
21	III	iii	CD	_	22	num	_	_
22	deficiency	deficiency	NN	_	17	ppmod	_	_
23	.	.	.	_	7	p	_	_

1	Thus	thus	RB	_	13	adv	_	_
2	in	in	IN	_	5	mark	_	_
3	order	order	NN	_	5	dep	_	_
4	to	to	TO	_	5	aux	_	_
5	avoid	avoid	VB	_	13	advcl	_	_
6	bleeding	bleeding	JJ	_	5	dep	_	_
7	,	,	,	_	13	p	_	_
8	reduced	reduce	VBN	_	9	attr	_	_
9	dosage	dosage	NN	_	13	dep	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	is	be	VBZ	_	13	aux	_	_
13	recommended	recommend	VBN	_	0	root	_	_
14	during	during	IN	_	15	case	_	_
15	treatment	treatment	NN	_	13	ppmod	_	_
16	with	with	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	(	-lrb-	-LRB-	_	19	p	_	_
19	human	human	NN	_	17	prn	_	_
20	)	-rrb-	-RRB-	_	19	p	_	_
21	.	.	.	_	13	p	_	_

1	b	b	NN	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	Drugs	drug	NNS	_	16	dep	_	_
2	Decreasing	decrease	VBG	_	1	acl	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	Effect	effect	NN	_	2	obj	_	_
5	:	:	:	_	1	p	_	_
6	drug2	drug0	NN	_	1	appo	_	_
7	,	,	,	_	6	p	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	,	,	,	_	8	p	_	_
10	drug4	drug0	NN	_	6	conj	_	_
11	,	,	,	_	10	p	_	_
12	or	or	CC	_	10	cc	_	_
13	drug5	drug0	NN	_	6	conj	_	_
14	may	may	MD	_	16	modal	_	_
15	partially	partially	RB	_	16	adv	_	_
16	counteract	counteract	VB	_	0	root	_	_
17	the	the	DT	_	19	det	_	_
18	anticoagulant	anticoagulant	JJ	_	19	attr	_	_
19	action	action	NN	_	16	obj	_	_
20	of	of	IN	_	21	case	_	_
21	drug6	drug0	NN	_	19	ppmod	_	_
22	.	.	.	_	16	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	Injection	injection	NN	_	6	dep	_	_
3	should	should	MD	_	6	modal	_	_
4	not	not	RB	_	6	neg	_	_
5	be	be	VB	_	6	aux	_	_
6	mixed	mix	VBN	_	0	root	_	_
7	with	with	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	,	,	,	_	8	p	_	_
10	drug3	drug0	NN	_	8	conj	_	_
11	,	,	,	_	10	p	_	_
12	drug4	drug0	NN	_	8	conj	_	_
13	,	,	,	_	12	p	_	_
14	or	or	CC	_	12	cc	_	_
15	drug5	drug0	NN	_	8	conj	_	_
16	,	,	,	_	6	p	_	_
17	since	since	IN	_	21	mark	_	_
18	it	it	PRP	_	21	dep	_	_
19	has	have	VBZ	_	21	aux	_	_
20	been	be	VBN	_	21	aux	_	_
21	reported	report	VBN	_	6	comp	_	_
22	that	that	IN	_	25	mark	_	_
23	these	these	DT	_	24	det	_	_
24	drugs	drug	NNS	_	25	dep	_	_
25	are	be	VBP	_	21	comp	_	_
26	incompatible	incompatible	JJ	_	25	dep	_	_
27	with	with	IN	_	28	case	_	_
28	drug6	drug0	NN	_	26	ppmod	_	_
29	and	and	CC	_	25	cc	_	_
30	a	a	DT	_	31	det	_	_
31	precipitate	precipitate	NN	_	33	dep	_	_
32	may	may	MD	_	33	modal	_	_
33	form	form	VB	_	25	conj	_	_
34	.	.	.	_	6	p	_	_

1	Drug/	drug/	NN	_	3	com	_	_
2	Laboratory	laboratory	NN	_	3	com	_	_
3	Tests	test	NNS	_	4	com	_	_
4	Interactions	interaction	NNS	_	22	advcl	_	_
5	Hyperaminotransferasemia	hyperaminotransferasemia	NN	_	4	obj	_	_
6	:	:	:	_	22	p	_	_
7	Significant	significant	JJ	_	8	attr	_	_
8	elevations	elevation	NNS	_	22	dep	_	_
9	of	of	IN	_	10	case	_	_
10	aminotransferase	aminotransferase	NN	_	8	ppmod	_	_
11	(	-lrb-	-LRB-	_	13	p	_	_
12	SGOT	sgot	NN	_	13	com	_	_
13	-LSB-S-AST	-lsb-s-ast	NN	_	10	prn	_	_
14	]	-rsb-	-RRB-	_	13	p	_	_
15	and	and	CC	_	10	cc	_	_
16	SGPT	sgpt	NN	_	20	attr	_	_
17	-LSB-S-ALT	-lsb-s-alt	NN	_	16	prn	_	_
18	]	-rsb-	-RRB-	_	17	p	_	_
19	)	-rrb-	-RRB-	_	17	p	_	_
20	levels	level	NNS	_	10	conj	_	_
21	have	have	VBP	_	22	aux	_	_
22	occurred	occur	VBN	_	0	root	_	_
23	in	in	IN	_	26	case	_	_
24	a	a	DT	_	26	det	_	_
25	high	high	JJ	_	26	attr	_	_
26	percentage	percentage	NN	_	22	ppmod	_	_
27	of	of	IN	_	28	case	_	_
28	patients	patient	NNS	_	26	ppmod	_	_
29	(	-lrb-	-LRB-	_	28	p	_	_
30	and	and	CC	_	28	cc	_	_
31	healthy	healthy	JJ	_	32	attr	_	_
32	subjects	subject	NNS	_	28	conj	_	_
33	)	-rrb-	-RRB-	_	32	p	_	_
34	who	who	WP	_	36	dep	_	_
35	have	have	VBP	_	36	aux	_	_
36	received	receive	VBN	_	28	relcl	_	_
37	drug1	drug0	NN	_	36	obj	_	_
38	.	.	.	_	22	p	_	_

1	Since	since	IN	_	4	mark	_	_
2	aminotransferase	aminotransferase	NN	_	3	com	_	_
3	determinations	determination	NNS	_	4	dep	_	_
4	are	be	VBP	_	32	advcl	_	_
5	important	important	JJ	_	4	dep	_	_
6	in	in	IN	_	9	case	_	_
7	the	the	DT	_	9	det	_	_
8	differential	differential	JJ	_	9	attr	_	_
9	diagnosis	diagnosis	NN	_	5	ppmod	_	_
10	of	of	IN	_	12	case	_	_
11	myocardial	myocardial	JJ	_	12	attr	_	_
12	infarction	infarction	NN	_	9	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	liver	liver	NN	_	15	com	_	_
15	disease	disease	NN	_	12	conj	_	_
16	and	and	CC	_	15	cc	_	_
17	pulmonary	pulmonary	JJ	_	18	attr	_	_
18	emboli	embolus	NNS	_	12	conj	_	_
19	,	,	,	_	32	p	_	_
20	rises	rise	VBZ	_	32	dep	_	_
21	that	that	WDT	_	24	dep	_	_
22	might	might	MD	_	24	modal	_	_
23	be	be	VB	_	24	aux	_	_
24	caused	cause	VBN	_	20	relcl	_	_
25	by	by	IN	_	26	case	_	_
26	drugs	drug	NNS	_	24	ppmod	_	_
27	(	-lrb-	-LRB-	_	28	p	_	_
28	drug1	drug0	NN	_	26	prn	_	_
29	)	-rrb-	-RRB-	_	28	p	_	_
30	should	should	MD	_	32	modal	_	_
31	be	be	VB	_	32	aux	_	_
32	interpreted	interpret	VBN	_	0	root	_	_
33	with	with	IN	_	34	case	_	_
34	caution	caution	NN	_	32	ppmod	_	_
35	.	.	.	_	32	p	_	_

1	The	the	DT	_	3	det	_	_
2	following	following	JJ	_	3	attr	_	_
3	drugs	drug	NNS	_	6	dep	_	_
4	have	have	VBP	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	coadministered	coadministered	VBN	_	0	root	_	_
7	with	with	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	6	cc	_	_
10	have	have	VBP	_	12	aux	_	_
11	not	not	RB	_	12	neg	_	_
12	altered	alter	VBN	_	6	conj	_	_
13	its	its	PRP$	_	14	poss	_	_
14	pharmacokinetics	pharmacokinetics	NNS	_	12	obj	_	_
15	:	:	:	_	14	p	_	_
16	drug2	drug0	NN	_	14	appo	_	_
17	,	,	,	_	16	p	_	_
18	drug3	drug0	NN	_	16	conj	_	_
19	,	,	,	_	18	p	_	_
20	drug4	drug0	NN	_	16	conj	_	_
21	,	,	,	_	20	p	_	_
22	and	and	CC	_	20	cc	_	_
23	drug5	drug0	NN	_	16	conj	_	_
24	.	.	.	_	6	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	administration	administration	NN	_	12	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	with	with	IN	_	9	case	_	_
6	the	the	DT	_	9	det	_	_
7	oral	oral	JJ	_	9	attr	_	_
8	drug2	drug0	NN	_	9	com	_	_
9	drug3	drug0	NN	_	2	ppmod	_	_
10	has	have	VBZ	_	12	aux	_	_
11	been	be	VBN	_	12	aux	_	_
12	shown	show	VBN	_	0	root	_	_
13	not	not	RB	_	15	neg	_	_
14	to	to	TO	_	15	aux	_	_
15	potentiate	potentiate	VB	_	12	comp	_	_
16	the	the	DT	_	18	det	_	_
17	anticoagulant	anticoagulant	JJ	_	18	attr	_	_
18	effect	effect	NN	_	15	obj	_	_
19	of	of	IN	_	20	case	_	_
20	drug4	drug0	NN	_	18	ppmod	_	_
21	.	.	.	_	12	p	_	_

1	Catecholamine-depleting	catecholamine-depleting	JJ	_	2	attr	_	_
2	drugs	drug	NNS	_	9	dep	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	e.g.	e.g.	FW	_	6	adv	_	_
5	,	,	,	_	6	p	_	_
6	drug1	drug0	NN	_	2	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	may	may	MD	_	9	modal	_	_
9	have	have	VB	_	0	root	_	_
10	an	an	DT	_	12	det	_	_
11	additive	additive	JJ	_	12	attr	_	_
12	effect	effect	NN	_	9	obj	_	_
13	when	when	WRB	_	14	adv	_	_
14	given	give	VBN	_	9	comp	_	_
15	with	with	IN	_	17	case	_	_
16	drug2	drug0	JJ	_	17	attr	_	_
17	agents	agent	NNS	_	14	ppmod	_	_
18	.	.	.	_	9	p	_	_

1	Patients	patient	NNS	_	14	dep	_	_
2	treated	treat	VBN	_	1	acl	_	_
3	with	with	IN	_	5	case	_	_
4	a	a	DT	_	5	det	_	_
5	drug1	drug0	NN	_	2	ppmod	_	_
6	plus	plus	CC	_	5	cc	_	_
7	a	a	DT	_	9	det	_	_
8	catecholamine	catecholamine	NN	_	9	com	_	_
9	depletor	depletor	NN	_	5	conj	_	_
10	should	should	MD	_	14	modal	_	_
11	therefore	therefore	RB	_	14	adv	_	_
12	be	be	VB	_	14	aux	_	_
13	closely	closely	RB	_	14	adv	_	_
14	observed	observe	VBN	_	0	root	_	_
15	for	for	IN	_	16	case	_	_
16	evidence	evidence	NN	_	14	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	hypotension	hypotension	NN	_	16	ppmod	_	_
19	or	or	CC	_	18	cc	_	_
20	marked	marked	JJ	_	21	attr	_	_
21	bradycardia	bradycardia	NN	_	18	conj	_	_
22	,	,	,	_	18	p	_	_
23	which	which	WDT	_	25	dep	_	_
24	may	may	MD	_	25	modal	_	_
25	produce	produce	VB	_	18	relcl	_	_
26	vertigo	vertigo	NN	_	25	obj	_	_
27	,	,	,	_	26	p	_	_
28	syncope	syncope	NN	_	26	conj	_	_
29	,	,	,	_	28	p	_	_
30	or	or	CC	_	28	cc	_	_
31	postural	postural	JJ	_	32	attr	_	_
32	hypotension	hypotension	NN	_	26	conj	_	_
33	.	.	.	_	14	p	_	_

1	Should	should	MD	_	4	modal	_	_
2	it	it	PRP	_	4	obj	_	_
3	be	be	VB	_	4	aux	_	_
4	decided	decide	VBN	_	20	comp	_	_
5	to	to	TO	_	7	aux	_	_
6	discontinue	discontinue	NN	_	7	com	_	_
7	therapy	therapy	NN	_	4	ppmod	_	_
8	in	in	IN	_	9	case	_	_
9	patients	patient	NNS	_	7	ppmod	_	_
10	receiving	receive	VBG	_	9	acl	_	_
11	drug1	drug0	NN	_	10	obj	_	_
12	and	and	CC	_	11	cc	_	_
13	drug2	drug0	NN	_	11	conj	_	_
14	concurrently	concurrently	RB	_	4	adv	_	_
15	,	,	,	_	20	p	_	_
16	the	the	DT	_	17	det	_	_
17	drug3	drug0	NN	_	20	dep	_	_
18	should	should	MD	_	20	modal	_	_
19	be	be	VB	_	20	aux	_	_
20	discontinued	discontinue	VBN	_	0	root	_	_
21	slowly	slowly	RB	_	20	adv	_	_
22	over	over	IN	_	24	case	_	_
23	several	several	JJ	_	24	attr	_	_
24	days	day	NNS	_	20	ppmod	_	_
25	before	before	IN	_	28	case	_	_
26	the	the	DT	_	28	det	_	_
27	gradual	gradual	JJ	_	28	attr	_	_
28	withdrawal	withdrawal	NN	_	24	ppmod	_	_
29	of	of	IN	_	30	case	_	_
30	drug4	drug0	NN	_	28	ppmod	_	_
31	.	.	.	_	20	p	_	_

1	Literature	literature	NN	_	2	com	_	_
2	reports	report	NNS	_	3	dep	_	_
3	suggest	suggest	VBP	_	0	root	_	_
4	that	that	IN	_	9	mark	_	_
5	oral	oral	JJ	_	6	attr	_	_
6	drug1	drug0	NN	_	9	dep	_	_
7	may	may	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	used	use	VBN	_	3	comp	_	_
10	in	in	IN	_	11	case	_	_
11	combination	combination	NN	_	9	ppmod	_	_
12	with	with	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	when	when	WRB	_	17	adv	_	_
15	heart	heart	NN	_	16	com	_	_
16	function	function	NN	_	17	dep	_	_
17	is	be	VBZ	_	9	comp	_	_
18	normal	normal	JJ	_	17	dep	_	_
19	,	,	,	_	9	p	_	_
20	but	but	CC	_	9	cc	_	_
21	should	should	MD	_	23	modal	_	_
22	be	be	VB	_	23	aux	_	_
23	avoided	avoid	VBN	_	9	conj	_	_
24	in	in	IN	_	25	case	_	_
25	patients	patient	NNS	_	23	ppmod	_	_
26	with	with	IN	_	29	case	_	_
27	impaired	impaired	JJ	_	29	attr	_	_
28	cardiac	cardiac	JJ	_	29	attr	_	_
29	function	function	NN	_	25	ppmod	_	_
30	.	.	.	_	3	p	_	_

1	Hypotension	hypotension	NN	_	13	dep	_	_
2	,	,	,	_	1	p	_	_
3	AV	av	NN	_	5	com	_	_
4	conduction	conduction	NN	_	5	com	_	_
5	disturbances	disturbance	NNS	_	1	conj	_	_
6	,	,	,	_	5	p	_	_
7	and	and	CC	_	5	cc	_	_
8	left	left	JJ	_	10	attr	_	_
9	ventricular	ventricular	JJ	_	10	attr	_	_
10	failure	failure	NN	_	1	conj	_	_
11	have	have	VBP	_	13	aux	_	_
12	been	be	VBN	_	13	aux	_	_
13	reported	report	VBN	_	0	root	_	_
14	in	in	IN	_	16	case	_	_
15	some	some	DT	_	16	det	_	_
16	patients	patient	NNS	_	13	ppmod	_	_
17	receiving	receive	VBG	_	16	acl	_	_
18	drug1	drug0	NN	_	17	obj	_	_
19	when	when	WRB	_	24	adv	_	_
20	an	an	DT	_	22	det	_	_
21	oral	oral	JJ	_	22	attr	_	_
22	drug2	drug0	NN	_	24	dep	_	_
23	was	be	VBD	_	24	aux	_	_
24	added	add	VBN	_	13	comp	_	_
25	to	to	TO	_	28	aux	_	_
26	the	the	DT	_	28	det	_	_
27	treatment	treatment	NN	_	28	com	_	_
28	regimen	regimen	NN	_	24	ppmod	_	_
29	.	.	.	_	13	p	_	_

1	Hypotension	hypotension	NN	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	more	more	RBR	_	4	adv	_	_
4	likely	likely	JJ	_	2	dep	_	_
5	to	to	TO	_	6	aux	_	_
6	occur	occur	VB	_	2	comp	_	_
7	if	if	IN	_	10	mark	_	_
8	the	the	DT	_	9	det	_	_
9	drug1	drug0	NN	_	10	dep	_	_
10	were	be	VBD	_	6	comp	_	_
11	a	a	DT	_	12	det	_	_
12	drug2	drug0	NN	_	10	obj	_	_
13	,	,	,	_	10	p	_	_
14	e.g.	e.g.	FW	_	16	adv	_	_
15	,	,	,	_	16	p	_	_
16	drug3	drug0	NN	_	10	ppmod	_	_
17	,	,	,	_	10	p	_	_
18	while	while	IN	_	32	mark	_	_
19	left	left	JJ	_	20	attr	_	_
20	ventricular	ventricular	NN	_	21	com	_	_
21	failure	failure	NN	_	32	dep	_	_
22	and	and	CC	_	21	cc	_	_
23	AV	av	NN	_	25	com	_	_
24	conduction	conduction	NN	_	25	com	_	_
25	disturbances	disturbance	NNS	_	21	conj	_	_
26	,	,	,	_	21	p	_	_
27	including	include	VBG	_	30	adv	_	_
28	complete	complete	JJ	_	30	attr	_	_
29	heart	heart	NN	_	30	com	_	_
30	block	block	NN	_	21	ppmod	_	_
31	,	,	,	_	21	p	_	_
32	were	be	VBD	_	10	comp	_	_
33	more	more	RBR	_	34	adv	_	_
34	likely	likely	JJ	_	32	dep	_	_
35	to	to	TO	_	36	aux	_	_
36	occur	occur	VB	_	32	comp	_	_
37	with	with	IN	_	39	case	_	_
38	either	either	CC	_	39	cc	_	_
39	drug4	drug0	NN	_	36	ppmod	_	_
40	or	or	CC	_	39	cc	_	_
41	drug5	drug0	NN	_	39	conj	_	_
42	.	.	.	_	2	p	_	_

1	Risk	risk	NN	_	0	root	_	_
2	of	of	IN	_	4	case	_	_
3	Anaphylactic	anaphylactic	JJ	_	4	attr	_	_
4	Reaction	reaction	NN	_	1	ppmod	_	_
5	:	:	:	_	1	p	_	_
6	Although	although	IN	_	9	mark	_	_
7	it	it	PRP	_	9	dep	_	_
8	is	be	VBZ	_	9	aux	_	_
9	known	know	VBN	_	15	advcl	_	_
10	that	that	IN	_	11	case	_	_
11	patients	patient	NNS	_	9	ppmod	_	_
12	on	on	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	may	may	MD	_	15	modal	_	_
15	be	be	VB	_	1	acl	_	_
16	refractory	refractory	JJ	_	15	dep	_	_
17	to	to	TO	_	18	aux	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	in	in	IN	_	21	case	_	_
20	the	the	DT	_	21	det	_	_
21	treatment	treatment	NN	_	18	ppmod	_	_
22	of	of	IN	_	24	case	_	_
23	anaphylactic	anaphylactic	NN	_	24	com	_	_
24	shock	shock	NN	_	21	ppmod	_	_
25	,	,	,	_	18	p	_	_
26	drug3	drug0	WDT	_	32	dep	_	_
27	can	can	MD	_	32	modal	_	_
28	,	,	,	_	32	p	_	_
29	in	in	IN	_	30	case	_	_
30	addition	addition	NN	_	32	ppmod	_	_
31	,	,	,	_	32	p	_	_
32	interfere	interfere	VB	_	18	relcl	_	_
33	with	with	IN	_	35	case	_	_
34	the	the	DT	_	35	det	_	_
35	modulation	modulation	NN	_	32	ppmod	_	_
36	of	of	IN	_	38	case	_	_
37	allergic	allergic	JJ	_	38	attr	_	_
38	reaction	reaction	NN	_	35	ppmod	_	_
39	and	and	CC	_	32	cc	_	_
40	lead	lead	VB	_	32	conj	_	_
41	to	to	TO	_	44	aux	_	_
42	an	an	DT	_	44	det	_	_
43	increased	increase	VBN	_	44	attr	_	_
44	severity	severity	NN	_	40	ppmod	_	_
45	and/or	and/or	CC	_	44	cc	_	_
46	frequency	frequency	NN	_	44	conj	_	_
47	of	of	IN	_	48	case	_	_
48	attacks	attack	NNS	_	44	ppmod	_	_
49	.	.	.	_	1	p	_	_

1	Severe	severe	JJ	_	3	attr	_	_
2	allergic	allergic	JJ	_	3	attr	_	_
3	reactions	reaction	NNS	_	8	dep	_	_
4	including	include	VBG	_	5	adv	_	_
5	anaphylaxis	anaphylaxis	NN	_	3	ppmod	_	_
6	have	have	VBP	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	reported	report	VBN	_	0	root	_	_
9	in	in	IN	_	10	case	_	_
10	patients	patient	NNS	_	8	ppmod	_	_
11	exposed	expose	VBN	_	10	acl	_	_
12	to	to	TO	_	14	aux	_	_
13	a	a	DT	_	14	det	_	_
14	variety	variety	NN	_	11	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	allergens	allergen	NNS	_	14	ppmod	_	_
17	either	either	CC	_	20	cc	_	_
18	by	by	IN	_	20	case	_	_
19	repeated	repeated	JJ	_	20	attr	_	_
20	challenge	challenge	NN	_	11	ppmod	_	_
21	,	,	,	_	20	p	_	_
22	or	or	CC	_	20	cc	_	_
23	accidental	accidental	JJ	_	24	attr	_	_
24	contact	contact	NN	_	20	conj	_	_
25	,	,	,	_	20	p	_	_
26	and	and	CC	_	20	cc	_	_
27	with	with	IN	_	31	case	_	_
28	diagnostic	diagnostic	JJ	_	31	attr	_	_
29	or	or	CC	_	28	cc	_	_
30	therapeutic	therapeutic	JJ	_	28	conj	_	_
31	agents	agent	NNS	_	20	conj	_	_
32	while	while	IN	_	33	mark	_	_
33	receiving	receive	VBG	_	11	comp	_	_
34	drug1	drug0	NN	_	33	obj	_	_
35	.	.	.	_	8	p	_	_

1	Such	such	JJ	_	2	attr	_	_
2	patients	patient	NNS	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	be	be	VB	_	0	root	_	_
5	unresponsive	unresponsive	JJ	_	4	dep	_	_
6	to	to	TO	_	9	aux	_	_
7	the	the	DT	_	9	det	_	_
8	usual	usual	JJ	_	9	attr	_	_
9	doses	dose	NNS	_	5	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	used	use	VBN	_	9	acl	_	_
13	to	to	TO	_	14	aux	_	_
14	treat	treat	VB	_	12	comp	_	_
15	allergic	allergic	JJ	_	16	attr	_	_
16	reaction	reaction	NN	_	14	obj	_	_
17	.	.	.	_	4	p	_	_

1	)	-rrb-	-RRB-	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	Clinical	clinical	JJ	_	2	attr	_	_
2	Laboratory	laboratory	NN	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	increased	increase	VBN	_	2	attr	_	_
2	creatine	creatine	NN	_	0	root	_	_

1	positive	positive	JJ	_	2	attr	_	_
2	antinuclear	antinuclear	NN	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	phosphokinase	phosphokinase	NN	_	0	root	_	_

1	antibody	antibody	NN	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	increased	increase	VBN	_	2	attr	_	_
2	bilirubin	bilirubin	NN	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	increased	increase	VBN	_	2	attr	_	_
2	liver	liver	NN	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	transaminases	transaminase	NNS	_	0	root	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	AST	ast	NN	_	1	prn	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	(	-lrb-	-LRB-	_	2	p	_	_
2	SGOT	sgot	NN	_	5	prn	_	_
3	)	-rrb-	-RRB-	_	2	p	_	_
4	,	,	,	_	5	p	_	_
5	ALT	alt	NN	_	0	root	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	SGPT	sgpt	NN	_	5	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	increased	increase	VBN	_	2	attr	_	_
2	alkaline	alkaline	NN	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	phophatase	phophatase	NN	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	Hematopoietic	hematopoietic	JJ	_	0	root	_	_

1	anemia	anemia	NN	_	0	root	_	_

1	thrombocytopenia	thrombocytopenia	NN	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	leukopenia	leukopenia	NN	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	bone	bone	NN	_	3	com	_	_
2	marrow	marrow	NN	_	3	com	_	_
3	hypoplasia	hypoplasia	NNS	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	eosinophilia	eosinophilia	NN	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	Immunologic	immunologic	JJ	_	0	root	_	_

1	angioedema	angioedema	NN	_	0	root	_	_

1	anaphylaxis	anaphylaxis	NN	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	laryngeal	laryngeal	JJ	_	2	attr	_	_
2	edema	edema	NN	_	0	root	_	_

1	Lupus-like	lupus-like	JJ	_	2	attr	_	_
2	syndrome	syndrome	NN	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	urticaria	urticaria	NN	_	0	root	_	_

1	vasculitis	vasculitis	NN	_	0	root	_	_

1	Integumentary	integumentary	JJ	_	0	root	_	_

1	exfoliative	exfoliative	JJ	_	2	attr	_	_
2	dermatitis	dermatitis	NN	_	0	root	_	_

1	alopecia	alopecia	NN	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	rash	rash	NN	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	dermatitis	dermatitis	NN	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	pruritus	pruritus	NN	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	No	no	DT	_	4	det	_	_
2	formal	formal	JJ	_	4	attr	_	_
3	interaction	interaction	NN	_	4	com	_	_
4	studies	study	NNS	_	7	dep	_	_
5	have	have	VBP	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	performed	performed	VBN	_	0	root	_	_
8	.	.	.	_	7	p	_	_

1	The	the	DT	_	2	det	_	_
2	duration	duration	NN	_	21	dep	_	_
3	of	of	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	period	period	NN	_	2	ppmod	_	_
6	following	follow	VBG	_	7	adv	_	_
7	treatment	treatment	NN	_	5	ppmod	_	_
8	with	with	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	before	before	IN	_	13	mark	_	_
11	one	#crd#	PRP	_	13	dep	_	_
12	should	should	MD	_	13	modal	_	_
13	consider	consider	VB	_	9	acl	_	_
14	starting	start	VBG	_	13	comp	_	_
15	other	other	JJ	_	17	attr	_	_
16	drug2	drug0	NN	_	17	com	_	_
17	therapy	therapy	NN	_	14	obj	_	_
18	has	have	VBZ	_	21	aux	_	_
19	not	not	RB	_	21	neg	_	_
20	been	be	VBN	_	21	aux	_	_
21	evaluated	evaluate	VBN	_	0	root	_	_
22	.	.	.	_	21	p	_	_

1	Carcinogenesis	carcinogenesis	NN	_	0	root	_	_
2	,	,	,	_	1	p	_	_
3	Mutagenesis	mutagenesis	NN	_	1	conj	_	_
4	,	,	,	_	3	p	_	_
5	and	and	CC	_	3	cc	_	_
6	Fertility	fertility	NN	_	1	conj	_	_

1	In	in	IN	_	5	case	_	_
2	a	a	DT	_	5	det	_	_
3	chronic	chronic	JJ	_	5	attr	_	_
4	toxicity	toxicity	NN	_	5	com	_	_
5	study	study	NN	_	10	ppmod	_	_
6	,	,	,	_	10	p	_	_
7	cynomolgus	cynomolgus	NN	_	8	com	_	_
8	monkeys	monkey	NNS	_	10	dep	_	_
9	were	be	VBD	_	10	aux	_	_
10	dosed	dose	VBN	_	0	root	_	_
11	weekly	weekly	RB	_	10	adv	_	_
12	for	for	IN	_	14	case	_	_
13	52	0	CD	_	14	num	_	_
14	weeks	week	NNS	_	10	ppmod	_	_
15	with	with	IN	_	17	case	_	_
16	intravenous	intravenous	JJ	_	17	attr	_	_
17	drug1	drug0	NN	_	14	ppmod	_	_
18	at	at	IN	_	20	case	_	_
19	1	0	CD	_	20	num	_	_
20	mg/kg/dose	mg/kg/dose	NN	_	10	ppmod	_	_
21	or	or	CC	_	20	cc	_	_
22	20	0	CD	_	23	num	_	_
23	mg/kg/dose	mg/kg/dose	NN	_	20	conj	_	_
24	.	.	.	_	10	p	_	_

1	One	#crd#	CD	_	2	num	_	_
2	animal	animal	NN	_	8	dep	_	_
3	in	in	IN	_	7	case	_	_
4	the	the	DT	_	7	det	_	_
5	high	high	JJ	_	7	attr	_	_
6	dose	dose	NN	_	7	com	_	_
7	group	group	NN	_	2	ppmod	_	_
8	developed	develop	VBD	_	0	root	_	_
9	a	a	DT	_	11	det	_	_
10	B-cell	b-cell	NN	_	11	com	_	_
11	lymphoma	lymphoma	NN	_	8	obj	_	_
12	that	that	WDT	_	14	dep	_	_
13	was	be	VBD	_	14	aux	_	_
14	detected	detect	VBN	_	11	relcl	_	_
15	after	after	IN	_	17	case	_	_
16	28	0	CD	_	17	num	_	_
17	weeks	week	NNS	_	14	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	dosing	dosing	NN	_	17	ppmod	_	_
20	.	.	.	_	8	p	_	_

1	Additional	additional	JJ	_	2	attr	_	_
2	animals	animal	NNS	_	7	dep	_	_
3	in	in	IN	_	6	case	_	_
4	both	both	DT	_	6	det	_	_
5	dose	dose	NN	_	6	com	_	_
6	groups	group	NNS	_	2	ppmod	_	_
7	developed	develop	VBD	_	0	root	_	_
8	B-cell	b-cell	NN	_	9	com	_	_
9	hyperplasia	hyperplasia	NN	_	7	obj	_	_
10	of	of	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	spleen	spleen	NN	_	9	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	lymph	lymph	NN	_	15	com	_	_
15	nodes	node	NNS	_	12	conj	_	_
16	.	.	.	_	7	p	_	_

1	All	all	DT	_	2	det	_	_
2	animals	animal	NNS	_	6	dep	_	_
3	in	in	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	study	study	NN	_	2	ppmod	_	_
6	were	be	VBD	_	0	root	_	_
7	positive	positive	JJ	_	6	dep	_	_
8	for	for	IN	_	13	case	_	_
9	an	an	DT	_	13	det	_	_
10	endemic	endemic	JJ	_	13	attr	_	_
11	primate	primate	JJ	_	13	attr	_	_
12	gammaherpes	gammaherpes	NN	_	13	com	_	_
13	virus	virus	NN	_	7	ppmod	_	_
14	also	also	RB	_	15	adv	_	_
15	known	know	VBN	_	13	acl	_	_
16	as	as	IN	_	17	case	_	_
17	lymphocryptovirus	lymphocryptovirus	NN	_	15	ppmod	_	_
18	(	-lrb-	-LRB-	_	19	p	_	_
19	LCV	lcv	NN	_	17	prn	_	_
20	)	-rrb-	-RRB-	_	19	p	_	_
21	.	.	.	_	6	p	_	_

1	Latent	latent	JJ	_	3	attr	_	_
2	LCV	lcv	NN	_	3	com	_	_
3	infection	infection	NN	_	4	dep	_	_
4	is	be	VBZ	_	0	root	_	_
5	generally	generally	RB	_	4	adv	_	_
6	asymptomatic	asymptomatic	JJ	_	4	dep	_	_
7	,	,	,	_	4	p	_	_
8	but	but	CC	_	4	cc	_	_
9	can	can	MD	_	10	modal	_	_
10	lead	lead	VB	_	4	conj	_	_
11	to	to	TO	_	13	aux	_	_
12	B-cell	b-cell	NN	_	13	com	_	_
13	lymphomas	lymphoma	NNS	_	10	ppmod	_	_
14	when	when	WRB	_	18	adv	_	_
15	animals	animal	NNS	_	18	dep	_	_
16	are	be	VBP	_	18	aux	_	_
17	immune	immune	JJ	_	18	adv	_	_
18	suppressed	suppress	VBN	_	10	comp	_	_
19	.	.	.	_	4	p	_	_

1	In	in	IN	_	4	case	_	_
2	a	a	DT	_	4	det	_	_
3	separate	separate	JJ	_	4	attr	_	_
4	study	study	NN	_	19	ppmod	_	_
5	,	,	,	_	19	p	_	_
6	baboons	baboon	NNS	_	19	dep	_	_
7	given	give	VBN	_	6	acl	_	_
8	3	0	CD	_	9	num	_	_
9	doses	dose	NNS	_	7	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	at	at	IN	_	14	case	_	_
13	1	0	CD	_	14	num	_	_
14	mg/kg	mg/kg	NN	_	7	ppmod	_	_
15	every	every	DT	_	17	det	_	_
16	8	0	CD	_	17	num	_	_
17	weeks	week	NNS	_	6	appo	_	_
18	were	be	VBD	_	19	aux	_	_
19	found	find	VBN	_	0	root	_	_
20	to	to	TO	_	23	aux	_	_
21	have	have	VB	_	23	lv	_	_
22	centroblast	centroblast	JJ	_	23	attr	_	_
23	proliferation	proliferation	NN	_	19	comp	_	_
24	in	in	IN	_	27	case	_	_
25	B-cell	b-cell	NN	_	27	attr	_	_
26	dependent	dependent	JJ	_	27	attr	_	_
27	areas	area	NNS	_	23	ppmod	_	_
28	in	in	IN	_	31	case	_	_
29	the	the	DT	_	31	det	_	_
30	germinal	germinal	JJ	_	31	attr	_	_
31	centers	center	NNS	_	27	ppmod	_	_
32	of	of	IN	_	34	case	_	_
33	the	the	DT	_	34	det	_	_
34	spleen	spleen	NN	_	31	ppmod	_	_
35	following	follow	VBG	_	39	adv	_	_
36	a	a	DT	_	39	det	_	_
37	116-day	0-day	JJ	_	39	attr	_	_
38	washout	washout	NN	_	39	com	_	_
39	period	period	NN	_	23	ppmod	_	_
40	.	.	.	_	19	p	_	_

1	The	the	DT	_	2	det	_	_
2	role	role	NN	_	24	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	in	in	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	development	development	NN	_	2	ppmod	_	_
8	of	of	IN	_	11	case	_	_
9	the	the	DT	_	11	det	_	_
10	lymphoid	lymphoid	JJ	_	11	attr	_	_
11	malignancy	malignancy	NN	_	7	ppmod	_	_
12	and	and	CC	_	7	cc	_	_
13	the	the	DT	_	14	det	_	_
14	hyperplasia	hyperplasia	NN	_	7	conj	_	_
15	observed	observe	VBN	_	14	acl	_	_
16	in	in	IN	_	18	case	_	_
17	non-human	non-human	JJ	_	18	attr	_	_
18	primates	primate	NNS	_	15	ppmod	_	_
19	and	and	CC	_	2	cc	_	_
20	the	the	DT	_	21	det	_	_
21	relevance	relevance	NN	_	2	conj	_	_
22	to	to	TO	_	23	aux	_	_
23	humans	human	NNS	_	21	ppmod	_	_
24	is	be	VBZ	_	0	root	_	_
25	unknown	unknown	JJ	_	24	dep	_	_
26	.	.	.	_	24	p	_	_

1	Immunodeficiency-associated	immunodeficiency-associated	JJ	_	3	attr	_	_
2	lymphocyte	lymphocyte	NN	_	3	com	_	_
3	disorders	disorder	NNS	_	15	dep	_	_
4	(	-lrb-	-LRB-	_	6	p	_	_
5	plasmacytic	plasmacytic	JJ	_	6	attr	_	_
6	hyperplasia	hyperplasia	NN	_	3	prn	_	_
7	,	,	,	_	6	p	_	_
8	polymorphic	polymorphic	JJ	_	9	attr	_	_
9	proliferation	proliferation	NN	_	6	conj	_	_
10	,	,	,	_	9	p	_	_
11	and	and	CC	_	9	cc	_	_
12	B-cell	b-cell	NN	_	13	com	_	_
13	lymphomas	lymphoma	NNS	_	6	conj	_	_
14	)	-rrb-	-RRB-	_	6	p	_	_
15	occur	occur	VBP	_	0	root	_	_
16	in	in	IN	_	17	case	_	_
17	patients	patient	NNS	_	15	ppmod	_	_
18	who	who	WP	_	19	dep	_	_
19	have	have	VBP	_	17	relcl	_	_
20	congenital	congenital	JJ	_	23	attr	_	_
21	or	or	CC	_	20	cc	_	_
22	acquired	acquired	JJ	_	20	conj	_	_
23	immunodeficiencies	immunodeficiency	NNS	_	19	obj	_	_
24	including	include	VBG	_	25	adv	_	_
25	those	those	DT	_	23	ppmod	_	_
26	resulting	result	VBG	_	25	acl	_	_
27	from	from	IN	_	29	case	_	_
28	drug1	drug0	NN	_	29	com	_	_
29	therapy	therapy	NN	_	26	ppmod	_	_
30	.	.	.	_	15	p	_	_

1	No	no	DT	_	2	det	_	_
2	carcinogenicity	carcinogenicity	NN	_	7	dep	_	_
3	or	or	CC	_	2	cc	_	_
4	fertility	fertility	NN	_	5	com	_	_
5	studies	study	NNS	_	2	conj	_	_
6	were	be	VBD	_	7	aux	_	_
7	conducted	conduct	VBN	_	0	root	_	_
8	.	.	.	_	7	p	_	_

1	Mutagenicity	mutagenicity	NN	_	2	com	_	_
2	studies	study	NNS	_	4	dep	_	_
3	were	be	VBD	_	4	aux	_	_
4	conducted	conduct	VBN	_	0	root	_	_
5	in	in	FW	_	6	adv	_	_
6	vitro	vitro	FW	_	4	adv	_	_
7	and	and	CC	_	6	cc	_	_
8	in	in	FW	_	9	adv	_	_
9	vivo	vivo	FW	_	6	conj	_	_
10	;	;	:	_	4	p	_	_

1	no	no	DT	_	2	det	_	_
2	evidence	evidence	NN	_	6	dep	_	_
3	of	of	IN	_	4	case	_	_
4	mutagenicity	mutagenicity	NN	_	2	ppmod	_	_
5	was	be	VBD	_	6	aux	_	_
6	observed	observe	VBN	_	0	root	_	_
7	.	.	.	_	6	p	_	_

1	Pregnancy	pregnancy	NN	_	0	root	_	_
2	(	-lrb-	-LRB-	_	4	p	_	_
3	Category	category	NN	_	4	com	_	_
4	B	b	NN	_	1	prn	_	_
5	)	-rrb-	-RRB-	_	4	p	_	_

1	Women	woman	NNS	_	5	dep	_	_
2	of	of	IN	_	4	case	_	_
3	childbearing	childbearing	JJ	_	4	attr	_	_
4	potential	potential	NN	_	1	ppmod	_	_
5	make	make	VBP	_	0	root	_	_
6	up	up	RP	_	5	prt	_	_
7	a	a	DT	_	9	det	_	_
8	considerable	considerable	JJ	_	9	attr	_	_
9	segment	segment	NN	_	5	obj	_	_
10	of	of	IN	_	13	case	_	_
11	the	the	DT	_	13	det	_	_
12	patient	patient	NN	_	13	com	_	_
13	population	population	NN	_	9	ppmod	_	_
14	affected	affect	VBN	_	13	acl	_	_
15	by	by	IN	_	16	case	_	_
16	psoriasis	psoriasis	NN	_	14	ppmod	_	_
17	.	.	.	_	5	p	_	_

1	Since	since	IN	_	19	mark	_	_
2	the	the	DT	_	3	det	_	_
3	effect	effect	NN	_	19	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	on	on	IN	_	7	case	_	_
7	pregnancy	pregnancy	NN	_	3	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	fetal	fetal	JJ	_	10	attr	_	_
10	development	development	NN	_	7	conj	_	_
11	,	,	,	_	7	p	_	_
12	including	include	VBG	_	15	adv	_	_
13	immune	immune	JJ	_	14	attr	_	_
14	system	system	NN	_	15	com	_	_
15	development	development	NN	_	7	ppmod	_	_
16	,	,	,	_	7	p	_	_
17	is	be	VBZ	_	19	aux	_	_
18	not	not	RB	_	19	neg	_	_
19	known	know	VBN	_	25	advcl	_	_
20	,	,	,	_	25	p	_	_
21	health	health	NN	_	23	com	_	_
22	care	care	NN	_	23	com	_	_
23	providers	provider	NNS	_	25	dep	_	_
24	are	be	VBP	_	25	aux	_	_
25	encouraged	encourage	VBN	_	0	root	_	_
26	to	to	TO	_	27	aux	_	_
27	enroll	enroll	VBP	_	25	comp	_	_
28	patients	patient	NNS	_	27	obj	_	_
29	currently	currently	RB	_	30	adv	_	_
30	taking	take	VBG	_	28	acl	_	_
31	drug2	drug0	NN	_	30	obj	_	_
32	who	who	WP	_	33	dep	_	_
33	become	become	VBP	_	28	relcl	_	_
34	pregnant	pregnant	JJ	_	33	dep	_	_
35	into	into	IN	_	39	case	_	_
36	the	the	DT	_	39	det	_	_
37	Biogen	biogen	NN	_	39	com	_	_
38	Pregnancy	pregnancy	NN	_	39	com	_	_
39	Registry	registry	NN	_	33	ppmod	_	_
40	by	by	IN	_	41	case	_	_
41	calling	call	VBG	_	33	ppmod	_	_
42	1-866-	0-	NN	_	43	com	_	_
43	drug3	drug0	NN	_	41	obj	_	_
44	(	-lrb-	-LRB-	_	45	p	_	_
45	1-866-263-8483	0	NN	_	43	num	_	_
46	)	-rrb-	-RRB-	_	45	p	_	_
47	.	.	.	_	25	p	_	_

1	Reproductive	reproductive	JJ	_	3	attr	_	_
2	toxicology	toxicology	NN	_	3	com	_	_
3	studies	study	NNS	_	6	dep	_	_
4	have	have	VBP	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	performed	performed	VBN	_	0	root	_	_
7	in	in	IN	_	9	case	_	_
8	cynomolgus	cynomolgus	JJ	_	9	attr	_	_
9	monkeys	monkey	NNS	_	6	ppmod	_	_
10	at	at	IN	_	11	case	_	_
11	doses	dose	NNS	_	6	ppmod	_	_
12	up	up	RB	_	14	adv	_	_
13	to	to	TO	_	14	attr	_	_
14	5	0	CD	_	15	num	_	_
15	mg/kg/week	mg/kg/week	NN	_	11	attr	_	_
16	(	-lrb-	-LRB-	_	22	p	_	_
17	about	about	RB	_	18	adv	_	_
18	62	0	CD	_	22	num	_	_
19	times	time	NNS	_	18	attr	_	_
20	the	the	DT	_	22	det	_	_
21	human	human	JJ	_	22	attr	_	_
22	dose	dose	NN	_	15	prn	_	_
23	based	base	VBN	_	22	acl	_	_
24	on	on	IN	_	26	case	_	_
25	body	body	NN	_	26	com	_	_
26	weight	weight	NN	_	23	ppmod	_	_
27	)	-rrb-	-RRB-	_	22	p	_	_
28	and	and	CC	_	6	cc	_	_
29	have	have	VBP	_	30	aux	_	_
30	revealed	reveal	VBN	_	6	conj	_	_
31	no	no	DT	_	32	det	_	_
32	evidence	evidence	NN	_	30	obj	_	_
33	of	of	IN	_	35	case	_	_
34	impaired	impaired	JJ	_	35	attr	_	_
35	fertility	fertility	NN	_	32	ppmod	_	_
36	or	or	CC	_	35	cc	_	_
37	harm	harm	NN	_	35	conj	_	_
38	to	to	TO	_	40	aux	_	_
39	the	the	DT	_	40	det	_	_
40	fetus	fetus	NN	_	37	ppmod	_	_
41	due	due	JJ	_	40	attr	_	_
42	to	to	TO	_	43	aux	_	_
43	drug1	drug0	NN	_	41	ppmod	_	_
44	.	.	.	_	6	p	_	_

1	No	no	DT	_	5	det	_	_
2	abortifacient	abortifacient	JJ	_	5	attr	_	_
3	or	or	CC	_	2	cc	_	_
4	teratogenic	teratogenic	JJ	_	2	conj	_	_
5	effects	effect	NNS	_	7	dep	_	_
6	were	be	VBD	_	7	aux	_	_
7	observed	observe	VBN	_	0	root	_	_
8	in	in	IN	_	10	case	_	_
9	cynomolgus	cynomolgus	JJ	_	10	attr	_	_
10	monkeys	monkey	NNS	_	7	ppmod	_	_
11	following	follow	VBG	_	14	adv	_	_
12	intravenous	intravenous	JJ	_	14	attr	_	_
13	bolus	bolus	NN	_	14	com	_	_
14	injections	injection	NNS	_	7	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	administered	administer	VBN	_	14	acl	_	_
18	weekly	weekly	RB	_	17	adv	_	_
19	during	during	IN	_	21	case	_	_
20	the	the	DT	_	21	det	_	_
21	period	period	NN	_	17	ppmod	_	_
22	of	of	IN	_	23	case	_	_
23	organogenesis	organogenesis	NN	_	21	ppmod	_	_
24	to	to	TO	_	25	aux	_	_
25	gestation	gestation	NN	_	21	ppmod	_	_
26	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	underwent	undergo	VBD	_	0	root	_	_
3	trans-placental	trans-placental	JJ	_	4	attr	_	_
4	passage	passage	NN	_	2	obj	_	_
5	and	and	CC	_	2	cc	_	_
6	produced	produce	VBD	_	2	conj	_	_
7	in	in	FW	_	8	adv	_	_
8	utero	utero	FW	_	9	attr	_	_
9	exposure	exposure	NN	_	6	obj	_	_
10	in	in	IN	_	13	case	_	_
11	the	the	DT	_	13	det	_	_
12	developing	develop	VBG	_	13	attr	_	_
13	monkeys	monkey	NNS	_	9	ppmod	_	_
14	.	.	.	_	2	p	_	_

1	In	in	IN	_	2	case	_	_
2	utero	utero	NN	_	11	ppmod	_	_
3	,	,	,	_	11	p	_	_
4	serum	serum	NN	_	5	com	_	_
5	levels	level	NNS	_	11	dep	_	_
6	of	of	IN	_	7	case	_	_
7	exposure	exposure	NN	_	5	ppmod	_	_
8	in	in	IN	_	10	case	_	_
9	these	these	DT	_	10	det	_	_
10	monkeys	monkey	NNS	_	5	ppmod	_	_
11	were	be	VBD	_	0	root	_	_
12	23	0	CD	_	11	obj	_	_
13	%	%	NN	_	12	meta	_	_
14	of	of	IN	_	17	case	_	_
15	maternal	maternal	JJ	_	17	attr	_	_
16	serum	serum	NN	_	17	com	_	_
17	levels	level	NNS	_	12	ppmod	_	_
18	.	.	.	_	11	p	_	_

1	No	no	DT	_	2	det	_	_
2	evidence	evidence	NN	_	14	dep	_	_
3	of	of	IN	_	5	case	_	_
4	fetal	fetal	JJ	_	5	attr	_	_
5	toxicity	toxicity	NN	_	2	ppmod	_	_
6	including	include	VBG	_	8	adv	_	_
7	adverse	adverse	JJ	_	8	attr	_	_
8	effects	effect	NNS	_	2	ppmod	_	_
9	on	on	IN	_	12	case	_	_
10	immune	immune	JJ	_	12	attr	_	_
11	system	system	NN	_	12	com	_	_
12	development	development	NN	_	8	ppmod	_	_
13	was	be	VBD	_	14	aux	_	_
14	observed	observe	VBN	_	0	root	_	_
15	in	in	IN	_	16	case	_	_
16	any	any	DT	_	14	ppmod	_	_
17	of	of	IN	_	19	case	_	_
18	these	these	DT	_	19	det	_	_
19	animals	animal	NNS	_	16	ppmod	_	_
20	.	.	.	_	14	p	_	_

1	Animal	animal	NN	_	3	com	_	_
2	reproduction	reproduction	NN	_	3	com	_	_
3	studies	study	NNS	_	7	dep	_	_
4	,	,	,	_	7	p	_	_
5	however	however	RB	_	7	adv	_	_
6	,	,	,	_	7	p	_	_
7	are	be	VBP	_	0	root	_	_
8	not	not	RB	_	7	neg	_	_
9	always	always	RB	_	7	adv	_	_
10	predictive	predictive	JJ	_	7	dep	_	_
11	of	of	IN	_	13	case	_	_
12	human	human	JJ	_	13	attr	_	_
13	response	response	NN	_	10	ppmod	_	_
14	and	and	CC	_	7	cc	_	_
15	there	there	EX	_	16	dep	_	_
16	are	be	VBP	_	7	conj	_	_
17	no	no	DT	_	21	det	_	_
18	adequate	adequate	JJ	_	21	attr	_	_
19	and	and	CC	_	18	cc	_	_
20	well-controlled	well-controlled	JJ	_	18	conj	_	_
21	studies	study	NNS	_	16	obj	_	_
22	in	in	IN	_	24	case	_	_
23	pregnant	pregnant	JJ	_	24	attr	_	_
24	women	woman	NNS	_	21	ppmod	_	_
25	.	.	.	_	7	p	_	_

1	Because	because	IN	_	18	mark	_	_
2	the	the	DT	_	3	det	_	_
3	risk	risk	NN	_	18	dep	_	_
4	to	to	TO	_	6	aux	_	_
5	the	the	DT	_	6	det	_	_
6	development	development	NN	_	3	ppmod	_	_
7	of	of	IN	_	11	case	_	_
8	the	the	DT	_	11	det	_	_
9	fetal	fetal	JJ	_	11	attr	_	_
10	immune	immune	JJ	_	11	attr	_	_
11	system	system	NN	_	6	ppmod	_	_
12	and	and	CC	_	6	cc	_	_
13	postnatal	postnatal	JJ	_	15	attr	_	_
14	immune	immune	JJ	_	15	attr	_	_
15	function	function	NN	_	6	conj	_	_
16	in	in	IN	_	17	case	_	_
17	humans	human	NNS	_	15	ppmod	_	_
18	is	be	VBZ	_	24	advcl	_	_
19	unknown	unknown	JJ	_	18	dep	_	_
20	,	,	,	_	24	p	_	_
21	drug1	drug0	NN	_	24	dep	_	_
22	should	should	MD	_	24	modal	_	_
23	be	be	VB	_	24	aux	_	_
24	used	use	VBN	_	0	root	_	_
25	during	during	IN	_	26	case	_	_
26	pregnancy	pregnancy	NN	_	24	ppmod	_	_
27	only	only	RB	_	30	adv	_	_
28	if	if	IN	_	30	mark	_	_
29	clearly	clearly	RB	_	30	adv	_	_
30	needed	need	VBN	_	24	comp	_	_
31	.	.	.	_	24	p	_	_

1	If	if	IN	_	3	mark	_	_
2	pregnancy	pregnancy	NN	_	3	dep	_	_
3	occurs	occur	VBZ	_	15	advcl	_	_
4	while	while	IN	_	5	mark	_	_
5	taking	take	VBG	_	3	comp	_	_
6	drug1	drug0	NN	_	5	obj	_	_
7	,	,	,	_	15	p	_	_
8	continued	continued	JJ	_	9	attr	_	_
9	use	use	NN	_	15	dep	_	_
10	of	of	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	drug	drug	NN	_	9	ppmod	_	_
13	should	should	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	assessed	assess	VBN	_	0	root	_	_
16	.	.	.	_	15	p	_	_

1	Nursing	nurse	VBG	_	0	root	_	_
2	Mothers	mother	NNS	_	1	obj	_	_

1	It	it	PRP	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	known	know	VBN	_	0	root	_	_
5	whether	whether	IN	_	8	mark	_	_
6	drug1	drug0	NN	_	8	dep	_	_
7	is	be	VBZ	_	8	aux	_	_
8	excreted	excrete	VBN	_	4	comp	_	_
9	in	in	IN	_	11	case	_	_
10	human	human	JJ	_	11	attr	_	_
11	milk	milk	NN	_	8	ppmod	_	_
12	.	.	.	_	4	p	_	_

1	Because	because	IN	_	5	mark	_	_
2	many	many	JJ	_	3	attr	_	_
3	drugs	drug	NNS	_	5	dep	_	_
4	are	be	VBP	_	5	aux	_	_
5	excreted	excrete	VBN	_	0	root	_	_
6	in	in	IN	_	8	case	_	_
7	human	human	JJ	_	8	attr	_	_
8	milk	milk	NN	_	5	ppmod	_	_
9	,	,	,	_	5	p	_	_
10	and	and	CC	_	5	cc	_	_
11	because	because	IN	_	13	mark	_	_
12	there	there	EX	_	13	dep	_	_
13	exists	exist	VBZ	_	5	conj	_	_
14	the	the	DT	_	15	det	_	_
15	potential	potential	NN	_	13	obj	_	_
16	for	for	IN	_	19	case	_	_
17	serious	serious	JJ	_	19	attr	_	_
18	adverse	adverse	JJ	_	19	attr	_	_
19	reactions	reaction	NNS	_	15	ppmod	_	_
20	in	in	IN	_	22	case	_	_
21	nursing	nursing	JJ	_	22	attr	_	_
22	infants	infant	NNS	_	19	ppmod	_	_
23	from	from	IN	_	24	case	_	_
24	drug1	drug0	NN	_	22	ppmod	_	_
25	,	,	,	_	13	p	_	_
26	a	a	DT	_	27	det	_	_
27	decision	decision	NN	_	30	dep	_	_
28	should	should	MD	_	30	modal	_	_
29	be	be	VB	_	30	aux	_	_
30	made	make	VBN	_	5	conj	_	_
31	whether	whether	IN	_	33	mark	_	_
32	to	to	TO	_	33	aux	_	_
33	discontinue	discontinue	VBP	_	30	comp	_	_
34	nursing	nurse	VBG	_	33	comp	_	_
35	while	while	IN	_	36	mark	_	_
36	taking	take	VBG	_	34	comp	_	_
37	the	the	DT	_	38	det	_	_
38	drug	drug	NN	_	36	obj	_	_
39	or	or	CC	_	33	cc	_	_
40	to	to	TO	_	41	aux	_	_
41	discontinue	discontinue	VBP	_	33	conj	_	_
42	the	the	DT	_	43	det	_	_
43	use	use	NN	_	41	obj	_	_
44	of	of	IN	_	46	case	_	_
45	the	the	DT	_	46	det	_	_
46	drug	drug	NN	_	43	ppmod	_	_
47	,	,	,	_	41	p	_	_
48	taking	take	VBG	_	41	comp	_	_
49	into	into	IN	_	50	mark	_	_
50	account	account	VBP	_	48	comp	_	_
51	the	the	DT	_	52	det	_	_
52	importance	importance	NN	_	50	obj	_	_
53	of	of	IN	_	55	case	_	_
54	the	the	DT	_	55	det	_	_
55	drug	drug	NN	_	52	ppmod	_	_
56	to	to	TO	_	58	aux	_	_
57	the	the	DT	_	58	det	_	_
58	mother	mother	NN	_	52	ppmod	_	_
59	.	.	.	_	30	p	_	_

1	Geriatric	geriatric	JJ	_	2	attr	_	_
2	Use	use	NN	_	0	root	_	_

1	Of	of	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	1357	0	CD	_	4	num	_	_
4	patients	patient	NNS	_	17	ppmod	_	_
5	who	who	WP	_	6	dep	_	_
6	received	receive	VBD	_	4	relcl	_	_
7	drug1	drug0	NN	_	6	obj	_	_
8	in	in	IN	_	10	case	_	_
9	clinical	clinical	JJ	_	10	attr	_	_
10	trials	trial	NNS	_	6	ppmod	_	_
11	,	,	,	_	17	p	_	_
12	a	a	DT	_	13	det	_	_
13	total	total	NN	_	17	dep	_	_
14	of	of	IN	_	16	case	_	_
15	100	0	CD	_	16	num	_	_
16	patients	patient	NNS	_	13	ppmod	_	_
17	were	be	VBD	_	0	root	_	_

1	65	0	CD	_	2	num	_	_
2	years	year	NNS	_	0	root	_	_
3	of	of	IN	_	4	case	_	_
4	age	age	NN	_	2	ppmod	_	_
5	and	and	CC	_	2	cc	_	_
6	13	0	CD	_	7	num	_	_
7	patients	patient	NNS	_	2	conj	_	_
8	were	be	VBD	_	7	acl	_	_

1	75	0	CD	_	2	num	_	_
2	years	year	NNS	_	0	root	_	_
3	of	of	IN	_	4	case	_	_
4	age	age	NN	_	2	ppmod	_	_
5	.	.	.	_	2	p	_	_

1	No	no	DT	_	2	det	_	_
2	differences	difference	NNS	_	8	dep	_	_
3	in	in	IN	_	4	case	_	_
4	safety	safety	NN	_	2	ppmod	_	_
5	or	or	CC	_	4	cc	_	_
6	efficacy	efficacy	NN	_	4	conj	_	_
7	were	be	VBD	_	8	aux	_	_
8	observed	observe	VBN	_	0	root	_	_
9	between	between	IN	_	13	case	_	_
10	older	old	JJR	_	13	attr	_	_
11	and	and	CC	_	10	cc	_	_
12	younger	young	JJR	_	10	conj	_	_
13	patients	patient	NNS	_	8	ppmod	_	_
14	,	,	,	_	8	p	_	_
15	but	but	CC	_	8	cc	_	_
16	there	there	EX	_	17	dep	_	_
17	were	be	VBD	_	8	conj	_	_
18	not	not	RB	_	17	neg	_	_
19	sufficient	sufficient	JJ	_	17	dep	_	_
20	data	datum	NNS	_	22	dep	_	_
21	to	to	TO	_	22	aux	_	_
22	exclude	exclude	VB	_	19	comp	_	_
23	important	important	JJ	_	24	attr	_	_
24	differences	difference	NNS	_	22	obj	_	_
25	.	.	.	_	8	p	_	_

1	Because	because	IN	_	9	mark	_	_
2	the	the	DT	_	3	det	_	_
3	incidence	incidence	NN	_	9	dep	_	_
4	of	of	IN	_	5	case	_	_
5	infections	infection	NNS	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	certain	certain	JJ	_	8	attr	_	_
8	malignancies	malignancy	NNS	_	5	conj	_	_
9	is	be	VBZ	_	22	advcl	_	_
10	higher	high	JJR	_	9	dep	_	_
11	in	in	IN	_	14	case	_	_
12	the	the	DT	_	14	det	_	_
13	elderly	elderly	JJ	_	14	attr	_	_
14	population	population	NN	_	10	ppmod	_	_
15	,	,	,	_	10	p	_	_
16	in	in	IN	_	17	case	_	_
17	general	general	JJ	_	10	ppmod	_	_
18	,	,	,	_	22	p	_	_
19	caution	caution	NN	_	22	dep	_	_
20	should	should	MD	_	22	modal	_	_
21	be	be	VB	_	22	aux	_	_
22	used	use	VBN	_	0	root	_	_
23	in	in	IN	_	24	case	_	_
24	treating	treat	VBG	_	22	ppmod	_	_
25	the	the	DT	_	26	det	_	_
26	elderly	elderly	JJ	_	24	obj	_	_
27	.	.	.	_	22	p	_	_

1	Pediatric	pediatric	JJ	_	2	attr	_	_
2	Use	use	NN	_	0	root	_	_

1	The	the	DT	_	2	det	_	_
2	safety	safety	NN	_	13	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	efficacy	efficacy	NN	_	2	conj	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	2	ppmod	_	_
7	in	in	IN	_	9	case	_	_
8	pediatric	pediatric	JJ	_	9	attr	_	_
9	patients	patient	NNS	_	2	ppmod	_	_
10	have	have	VBP	_	13	aux	_	_
11	not	not	RB	_	13	neg	_	_
12	been	be	VBN	_	13	aux	_	_
13	studied	study	VBN	_	0	root	_	_
14	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	indicated	indicate	VBN	_	0	root	_	_
5	for	for	IN	_	7	case	_	_
6	pediatric	pediatric	JJ	_	7	attr	_	_
7	patients	patient	NNS	_	4	ppmod	_	_
8	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	prolong	prolong	VBP	_	0	root	_	_
3	and	and	CC	_	2	cc	_	_
4	intensify	intensify	VBP	_	2	conj	_	_
5	the	the	DT	_	7	det	_	_
6	anticholinergic	anticholinergic	JJ	_	7	attr	_	_
7	effects	effect	NNS	_	4	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	have	have	VB	_	0	root	_	_
4	additive	additive	JJ	_	5	attr	_	_
5	effects	effect	NNS	_	3	obj	_	_
6	with	with	IN	_	7	case	_	_
7	drug2	drug0	NN	_	3	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	other	other	JJ	_	10	attr	_	_
10	drug3	drug0	NN	_	7	conj	_	_
11	,	,	,	_	3	p	_	_
12	e.g.	e.g.	FW	_	14	adv	_	_
13	,	,	,	_	14	p	_	_
14	drug4	drug0	NN	_	3	ppmod	_	_
15	,	,	,	_	14	p	_	_
16	drug5	drug0	NN	_	14	appo	_	_
17	,	,	,	_	14	p	_	_
18	drug6	drug0	NN	_	14	appo	_	_
19	,	,	,	_	14	p	_	_
20	drug7	drug0	NN	_	14	appo	_	_
21	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	6	dep	_	_
4	has	have	VBZ	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	studied	study	VBN	_	1	acl	_	_
7	in	in	IN	_	10	case	_	_
8	rheumatoid	rheumatoid	JJ	_	10	attr	_	_
9	arthritis	arthritis	NN	_	10	com	_	_
10	patients	patient	NNS	_	6	ppmod	_	_
11	taking	take	VBG	_	10	acl	_	_
12	concomitant	concomitant	JJ	_	13	attr	_	_
13	drug3	drug0	NN	_	11	obj	_	_
14	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	data	datum	NNS	_	5	dep	_	_
3	do	do	VBP	_	5	aux	_	_
4	not	not	RB	_	5	neg	_	_
5	suggest	suggest	VBP	_	0	root	_	_
6	the	the	DT	_	7	det	_	_
7	need	need	NN	_	5	obj	_	_
8	for	for	IN	_	10	case	_	_
9	dose	dose	NN	_	10	com	_	_
10	adjustment	adjustment	NN	_	7	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	either	either	CC	_	13	cc	_	_
13	drug1	drug0	NN	_	10	ppmod	_	_
14	or	or	CC	_	13	cc	_	_
15	drug2	drug0	NN	_	13	conj	_	_
16	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Concurrent	concurrent	JJ	_	4	attr	_	_
4	administration	administration	NN	_	16	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	(	-lrb-	-LRB-	_	9	p	_	_
8	an	an	DT	_	9	det	_	_
9	drug3	drug0	NN	_	6	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	and	and	CC	_	6	cc	_	_
12	another	another	DT	_	13	det	_	_
13	drug4	drug0	NN	_	6	conj	_	_
14	has	have	VBZ	_	16	aux	_	_
15	been	be	VBN	_	16	aux	_	_
16	associated	associate	VBN	_	1	acl	_	_
17	with	with	IN	_	20	case	_	_
18	an	an	DT	_	20	det	_	_
19	increased	increase	VBN	_	20	attr	_	_
20	risk	risk	NN	_	16	ppmod	_	_
21	of	of	IN	_	23	case	_	_
22	serious	serious	JJ	_	23	attr	_	_
23	infections	infection	NNS	_	20	ppmod	_	_
24	,	,	,	_	20	p	_	_
25	an	an	DT	_	27	det	_	_
26	increased	increase	VBN	_	27	attr	_	_
27	risk	risk	NN	_	20	conj	_	_
28	of	of	IN	_	29	case	_	_
29	neutropenia	neutropenia	NN	_	27	ppmod	_	_
30	and	and	CC	_	27	cc	_	_
31	no	no	DT	_	33	det	_	_
32	additional	additional	JJ	_	33	attr	_	_
33	benefit	benefit	NN	_	20	conj	_	_
34	compared	compare	VBN	_	38	adv	_	_
35	to	to	TO	_	38	aux	_	_
36	these	these	DT	_	38	det	_	_
37	medicinal	medicinal	JJ	_	38	attr	_	_
38	products	product	NNS	_	33	ppmod	_	_
39	alone	alone	RB	_	38	adv	_	_
40	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	safety	safety	NN	_	15	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	efficacy	efficacy	NN	_	2	conj	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	2	ppmod	_	_
7	used	use	VBN	_	6	acl	_	_
8	in	in	IN	_	9	case	_	_
9	combination	combination	NN	_	7	ppmod	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NNS	_	9	ppmod	_	_
12	has	have	VBZ	_	15	aux	_	_
13	not	not	RB	_	15	neg	_	_
14	been	be	VBN	_	15	aux	_	_
15	studied	study	VBN	_	0	root	_	_
16	.	.	.	_	15	p	_	_

1	Therefore	therefore	RB	_	16	adv	_	_
2	the	the	DT	_	1	det	_	_
3	,	,	,	_	16	p	_	_
4	combination	combination	NN	_	16	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	with	with	IN	_	9	case	_	_
8	other	other	JJ	_	9	attr	_	_
9	drug2	drug0	NNS	_	4	ppmod	_	_
10	,	,	,	_	9	p	_	_
11	including	include	VBG	_	12	adv	_	_
12	drug3	drug0	NN	_	9	ppmod	_	_
13	,	,	,	_	9	p	_	_
14	may	may	MD	_	16	modal	_	_
15	also	also	RB	_	16	adv	_	_
16	result	result	VB	_	0	root	_	_
17	i	i	NN	_	19	advnp	_	_
18	n	n	NN	_	19	advnp	_	_
19	similar	similar	JJ	_	20	attr	_	_
20	toxicities	toxicity	NNS	_	16	obj	_	_
21	.	.	.	_	16	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	use	use	NN	_	13	dep	_	_
3	with	with	IN	_	7	case	_	_
4	other	other	JJ	_	7	attr	_	_
5	drug1	drug0	NN	_	7	attr	_	_
6	-containing	-containing	JJ	_	7	attr	_	_
7	medicines	medicine	NNS	_	2	ppmod	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	including	include	VBG	_	7	prn	_	_
10	drug2	drug0	NN	_	9	obj	_	_
11	)	-rrb-	-RRB-	_	9	p	_	_
12	may	may	MD	_	13	modal	_	_
13	cause	cause	VB	_	0	root	_	_
14	too	too	RB	_	15	adv	_	_
15	much	much	JJ	_	16	attr	_	_
16	drug3	drug0	NN	_	13	obj	_	_
17	in	in	IN	_	19	case	_	_
18	the	the	DT	_	19	det	_	_
19	blood	blood	NN	_	13	ppmod	_	_
20	or	or	CC	_	19	cc	_	_
21	urine	urine	NN	_	19	conj	_	_
22	,	,	,	_	19	p	_	_
23	which	which	WDT	_	25	dep	_	_
24	may	may	MD	_	25	modal	_	_
25	increase	increase	VB	_	19	relcl	_	_
26	the	the	DT	_	27	det	_	_
27	chance	chance	NN	_	25	obj	_	_
28	of	of	IN	_	30	case	_	_
29	side	side	JJ	_	30	attr	_	_
30	effects	effect	NNS	_	27	ppmod	_	_
31	.	.	.	_	13	p	_	_

1	Using	use	VBG	_	10	advcl	_	_
2	drug1	drug0	NN	_	1	obj	_	_
3	with	with	IN	_	4	case	_	_
4	drug2	drug0	NN	_	2	ppmod	_	_
5	(	-lrb-	-LRB-	_	7	p	_	_
6	heart	heart	NN	_	7	com	_	_
7	medicine	medicine	NN	_	4	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	may	may	MD	_	10	modal	_	_
10	cause	cause	VB	_	0	root	_	_
11	hypercalcemia	hypercalcemia	NN	_	10	obj	_	_
12	(	-lrb-	-LRB-	_	15	p	_	_
13	too	too	RB	_	14	adv	_	_
14	much	much	JJ	_	15	attr	_	_
15	drug3	drug0	NN	_	11	prn	_	_
16	in	in	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	blood	blood	NN	_	15	ppmod	_	_
19	)	-rrb-	-RRB-	_	15	p	_	_
20	,	,	,	_	11	p	_	_
21	which	which	WDT	_	23	dep	_	_
22	could	could	MD	_	23	modal	_	_
23	increase	increase	VB	_	11	relcl	_	_
24	the	the	DT	_	25	det	_	_
25	chance	chance	NN	_	23	obj	_	_
26	of	of	IN	_	27	case	_	_
27	developing	develop	VBG	_	25	ppmod	_	_
28	an	an	DT	_	30	det	_	_
29	irregular	irregular	JJ	_	30	attr	_	_
30	heartbeat	heartbeat	NN	_	27	obj	_	_
31	.	.	.	_	10	p	_	_

1	Tablet	tablet	NN	_	9	dep	_	_
2	If	if	IN	_	4	case	_	_
3	a	a	DT	_	4	det	_	_
4	patient	patient	NN	_	1	ppmod	_	_
5	receiving	receive	VBG	_	4	acl	_	_
6	drug1	drug0	NN	_	5	obj	_	_
7	is	be	VBZ	_	9	aux	_	_
8	also	also	RB	_	9	adv	_	_
9	taking	take	VBG	_	0	root	_	_
10	drug2	drug0	NN	_	9	obj	_	_
11	,	,	,	_	10	p	_	_
12	the	the	DT	_	13	det	_	_
13	effect	effect	NN	_	10	appo	_	_
14	of	of	IN	_	18	mark	_	_
15	drug3	drug0	NN	_	18	dep	_	_
16	may	may	MD	_	18	modal	_	_
17	be	be	VB	_	18	aux	_	_
18	reduced	reduce	VBN	_	13	acl	_	_
19	,	,	,	_	9	p	_	_
20	thus	thus	RB	_	21	adv	_	_
21	necessitating	necessitate	VBG	_	9	comp	_	_
22	an	an	DT	_	23	det	_	_
23	increase	increase	NN	_	21	obj	_	_
24	in	in	IN	_	25	case	_	_
25	dosage	dosage	NN	_	23	ppmod	_	_
26	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	enhance	enhance	VB	_	0	root	_	_
4	the	the	DT	_	6	det	_	_
5	CNS-depressive	cns-depressive	JJ	_	6	attr	_	_
6	effects	effect	NNS	_	3	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	,	,	,	_	8	p	_	_
10	drug3	drug0	NN	_	8	conj	_	_
11	or	or	CC	_	10	cc	_	_
12	other	other	JJ	_	13	attr	_	_
13	drug4	drug0	NN	_	8	conj	_	_
14	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	in	in	IN	_	3	case	_	_
3	combination	combination	NN	_	1	ppmod	_	_
4	with	with	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	enhances	enhance	VBZ	_	18	advcl	_	_
7	the	the	DT	_	8	det	_	_
8	manifestation	manifestation	NN	_	6	obj	_	_
9	of	of	IN	_	11	case	_	_
10	corneal	corneal	NN	_	11	com	_	_
11	lesions	lesion	NNS	_	8	ppmod	_	_
12	in	in	IN	_	13	case	_	_
13	rats	rat	NNS	_	6	ppmod	_	_
14	Epidural	epidural	JJ	_	16	attr	_	_
15	Injection	injection	NN	_	16	com	_	_
16	drug3	drug0	NN	_	18	dep	_	_
17	may	may	MD	_	18	modal	_	_
18	potentiate	potentiate	VB	_	0	root	_	_
19	the	the	DT	_	21	det	_	_
20	CNS-depressive	cns-depressive	JJ	_	21	attr	_	_
21	effect	effect	NN	_	18	obj	_	_
22	of	of	IN	_	23	case	_	_
23	drug4	drug0	NN	_	21	ppmod	_	_
24	,	,	,	_	23	p	_	_
25	drug5	drug0	NN	_	23	conj	_	_
26	or	or	CC	_	25	cc	_	_
27	other	other	JJ	_	28	attr	_	_
28	drug6	drug0	NN	_	23	conj	_	_
29	.	.	.	_	18	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	potentiate	potentiate	VB	_	0	root	_	_
4	the	the	DT	_	6	det	_	_
5	hypotensive	hypotensive	JJ	_	6	attr	_	_
6	effects	effect	NNS	_	3	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	antagonize	antagonize	VB	_	0	root	_	_
4	the	the	DT	_	6	det	_	_
5	hypotensive	hypotensive	JJ	_	6	attr	_	_
6	effects	effect	NNS	_	3	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	effects	effect	NNS	_	12	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	on	on	IN	_	9	case	_	_
6	drug2	drug0	NN	_	9	attr	_	_
7	s	s	NN	_	9	attr	_	_
8	analgesic	analgesic	JJ	_	9	attr	_	_
9	actions	action	NNS	_	2	ppmod	_	_
10	are	be	VBP	_	12	aux	_	_
11	not	not	RB	_	12	neg	_	_
12	known	know	VBN	_	0	root	_	_
13	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	exacerbate	exacerbate	VB	_	0	root	_	_
4	the	the	DT	_	6	det	_	_
5	hypertensive	hypertensive	JJ	_	6	attr	_	_
6	response	response	NN	_	3	obj	_	_
7	seen	see	VBN	_	6	acl	_	_
8	with	with	IN	_	10	case	_	_
9	drug2	drug0	NN	_	10	com	_	_
10	withdrawl	withdrawl	NN	_	7	ppmod	_	_
11	.	.	.	_	3	p	_	_

1	Also	also	RB	_	19	adv	_	_
2	,	,	,	_	19	p	_	_
3	due	due	JJ	_	6	adv	_	_
4	to	to	TO	_	6	aux	_	_
5	the	the	DT	_	6	det	_	_
6	potential	potential	NN	_	19	ppmod	_	_
7	for	for	IN	_	9	case	_	_
8	additive	additive	JJ	_	9	attr	_	_
9	effects	effect	NNS	_	6	ppmod	_	_
10	such	such	JJ	_	12	adv	_	_
11	as	as	IN	_	12	case	_	_
12	bradycardia	bradycardia	NN	_	9	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	AV	av	NN	_	15	com	_	_
15	block	block	NN	_	12	conj	_	_
16	,	,	,	_	19	p	_	_
17	caution	caution	NN	_	19	dep	_	_
18	is	be	VBZ	_	19	aux	_	_
19	warranted	warrant	VBN	_	0	root	_	_
20	in	in	IN	_	21	case	_	_
21	patients	patient	NNS	_	19	ppmod	_	_
22	receiving	receive	VBG	_	21	acl	_	_
23	drug1	drug0	NN	_	22	obj	_	_
24	with	with	IN	_	25	case	_	_
25	agents	agent	NNS	_	23	ppmod	_	_
26	known	know	VBN	_	25	acl	_	_
27	to	to	TO	_	28	aux	_	_
28	affect	affect	VB	_	26	comp	_	_
29	sinus	sinus	NN	_	30	com	_	_
30	node	node	NN	_	31	com	_	_
31	function	function	NN	_	28	obj	_	_
32	or	or	CC	_	23	cc	_	_
33	AV	av	NN	_	35	attr	_	_
34	nodal	nodal	JJ	_	35	attr	_	_
35	conduction	conduction	NN	_	23	conj	_	_
36	(	-lrb-	-LRB-	_	39	p	_	_
37	e.g.	e.g.	FW	_	39	ppmod	_	_
38	,	,	,	_	39	p	_	_
39	drug2	drug0	NN	_	35	prn	_	_
40	,	,	,	_	39	p	_	_
41	drug3	drug0	NN	_	39	conj	_	_
42	,	,	,	_	41	p	_	_
43	and	and	CC	_	41	cc	_	_
44	drug4	drug0	NN	_	39	conj	_	_
45	.	.	.	_	44	p	_	_
46	)	-rrb-	-RRB-	_	39	p	_	_

1	There	there	EX	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	one	#crd#	CD	_	5	num	_	_
4	reported	report	VBN	_	5	attr	_	_
5	case	case	NN	_	2	obj	_	_
6	of	of	IN	_	8	case	_	_
7	a	a	DT	_	8	det	_	_
8	patient	patient	NN	_	5	ppmod	_	_
9	with	with	IN	_	11	case	_	_
10	acute	acute	JJ	_	11	attr	_	_
11	delirium	delirium	NN	_	8	ppmod	_	_
12	associated	associate	VBN	_	11	acl	_	_
13	with	with	IN	_	16	case	_	_
14	the	the	DT	_	16	det	_	_
15	simultaneous	simultaneous	JJ	_	16	attr	_	_
16	use	use	NN	_	12	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug1	drug0	NN	_	16	ppmod	_	_
19	and	and	CC	_	18	cc	_	_
20	oral	oral	JJ	_	21	attr	_	_
21	drug2	drug0	NN	_	18	conj	_	_
22	.	.	.	_	2	p	_	_

1	Symptoms	symptom	NNS	_	2	dep	_	_
2	resolved	resolve	VBN	_	0	root	_	_
3	when	when	WRB	_	6	adv	_	_
4	drug1	drug0	NN	_	6	dep	_	_
5	was	be	VBD	_	6	aux	_	_
6	withdrawn	withdraw	VBN	_	2	comp	_	_
7	and	and	CC	_	2	cc	_	_
8	recurred	recur	VBN	_	2	conj	_	_
9	when	when	WRB	_	13	adv	_	_
10	the	the	DT	_	11	det	_	_
11	patient	patient	NN	_	13	dep	_	_
12	was	be	VBD	_	13	aux	_	_
13	rechallenged	rechallenged	VBN	_	8	comp	_	_
14	with	with	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	2	p	_	_

1	Epidural	epidural	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	prolong	prolong	VB	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	duration	duration	NN	_	4	obj	_	_
7	of	of	IN	_	9	case	_	_
8	pharmacologic	pharmacologic	JJ	_	9	attr	_	_
9	effects	effect	NNS	_	6	ppmod	_	_
10	of	of	IN	_	13	case	_	_
11	epidural	epidural	JJ	_	13	attr	_	_
12	local	local	JJ	_	13	attr	_	_
13	drug2	drug0	NN	_	9	ppmod	_	_
14	,	,	,	_	9	p	_	_
15	including	include	VBG	_	17	adv	_	_
16	both	both	CC	_	17	cc	_	_
17	sensory	sensory	NN	_	9	ppmod	_	_
18	and	and	CC	_	17	cc	_	_
19	motor	motor	NN	_	20	com	_	_
20	blockade	blockade	NN	_	17	conj	_	_
21	.	.	.	_	4	p	_	_

1	No	no	DT	_	2	det	_	_
2	evidence	evidence	NN	_	11	dep	_	_
3	of	of	IN	_	4	case	_	_
4	interaction	interaction	NN	_	2	ppmod	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	with	with	IN	_	9	case	_	_
8	other	other	JJ	_	9	attr	_	_
9	drugs	drug	NNS	_	4	ppmod	_	_
10	was	be	VBD	_	11	aux	_	_
11	observed	observe	VBN	_	0	root	_	_
12	in	in	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	course	course	NN	_	11	ppmod	_	_
15	of	of	IN	_	17	case	_	_
16	clinical	clinical	JJ	_	17	attr	_	_
17	trials	trial	NNS	_	14	ppmod	_	_
18	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	9	dep	_	_
2	(	-lrb-	-LRB-	_	5	p	_	_
3	drug2	drug0	NN	_	5	attr	_	_
4	ophthalmic	ophthalmic	JJ	_	5	attr	_	_
5	suspension	suspension	NN	_	1	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	1	0	CD	_	1	num	_	_
8	%	%	NN	_	7	meta	_	_
9	contains	contain	VBZ	_	0	root	_	_
10	a	a	DT	_	11	det	_	_
11	drug3	drug0	NN	_	9	obj	_	_
12	.	.	.	_	9	p	_	_

1	Acid-base	acid-base	NN	_	4	attr	_	_
2	and	and	CC	_	1	cc	_	_
3	electrolyte	electrolyte	NN	_	1	conj	_	_
4	alterations	alteration	NNS	_	7	dep	_	_
5	were	be	VBD	_	7	aux	_	_
6	not	not	RB	_	7	neg	_	_
7	reported	report	VBN	_	0	root	_	_
8	in	in	IN	_	11	case	_	_
9	the	the	DT	_	11	det	_	_
10	clinical	clinical	JJ	_	11	attr	_	_
11	trials	trial	NNS	_	7	ppmod	_	_
12	with	with	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	.	.	.	_	7	p	_	_

1	However	however	RB	_	16	adv	_	_
2	,	,	,	_	16	p	_	_
3	in	in	IN	_	4	case	_	_
4	patients	patient	NNS	_	16	ppmod	_	_
5	treated	treat	VBN	_	4	acl	_	_
6	with	with	IN	_	8	case	_	_
7	oral	oral	JJ	_	8	attr	_	_
8	drug1	drug0	NN	_	5	ppmod	_	_
9	,	,	,	_	16	p	_	_
10	rare	rare	JJ	_	11	attr	_	_
11	instances	instance	NNS	_	16	dep	_	_
12	of	of	IN	_	14	case	_	_
13	drug	drug	NN	_	14	com	_	_
14	interactions	interaction	NNS	_	11	ppmod	_	_
15	have	have	VBP	_	16	aux	_	_
16	occurred	occur	VBN	_	0	root	_	_
17	with	with	IN	_	20	case	_	_
18	high-dose	high-dose	JJ	_	20	attr	_	_
19	drug2	drug0	NN	_	20	com	_	_
20	therapy	therapy	NN	_	16	ppmod	_	_
21	.	.	.	_	16	p	_	_

1	Therefore	therefore	RB	_	11	adv	_	_
2	,	,	,	_	11	p	_	_
3	the	the	DT	_	4	det	_	_
4	potential	potential	NN	_	11	dep	_	_
5	for	for	IN	_	8	case	_	_
6	such	such	JJ	_	8	attr	_	_
7	drug	drug	NN	_	8	com	_	_
8	interaction	interaction	NN	_	4	ppmod	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	considered	consider	VBN	_	0	root	_	_
12	in	in	IN	_	13	case	_	_
13	patients	patient	NNS	_	11	ppmod	_	_
14	receiving	receive	VBG	_	13	acl	_	_
15	drug1	drug0	NN	_	14	obj	_	_
16	(	-lrb-	-LRB-	_	19	p	_	_
17	drug2	drug0	NN	_	19	attr	_	_
18	ophthalmic	ophthalmic	JJ	_	19	attr	_	_
19	suspension	suspension	NN	_	15	prn	_	_
20	)	-rrb-	-RRB-	_	19	p	_	_
21	1	0	CD	_	15	num	_	_
22	%	%	NN	_	21	meta	_	_
23	.	.	.	_	11	p	_	_

1	Certain	certain	JJ	_	2	attr	_	_
2	drug1	drug0	NNS	_	11	dep	_	_
3	,	,	,	_	2	p	_	_
4	especially	especially	RB	_	2	adv	_	_
5	drug2	drug0	NN	_	2	appo	_	_
6	,	,	,	_	5	p	_	_
7	drug3	drug0	NN	_	5	conj	_	_
8	and	and	CC	_	7	cc	_	_
9	drug4	drug0	NN	_	5	conj	_	_
10	,	,	,	_	2	p	_	_
11	have	have	VBP	_	0	root	_	_
12	a	a	DT	_	18	det	_	_
13	mild	mild	JJ	_	18	attr	_	_
14	but	but	CC	_	13	cc	_	_
15	definite	definite	JJ	_	13	conj	_	_
16	nondepolarizing	nondepolarizing	NN	_	18	com	_	_
17	blocking	blocking	NN	_	18	com	_	_
18	action	action	NN	_	11	obj	_	_
19	which	which	WDT	_	21	dep	_	_
20	may	may	MD	_	21	modal	_	_
21	accentuate	accentuate	VB	_	18	relcl	_	_
22	neuromuscular	neuromuscular	JJ	_	23	attr	_	_
23	block	block	NN	_	21	obj	_	_
24	.	.	.	_	11	p	_	_

1	These	these	DT	_	2	det	_	_
2	drug1	drug0	NNS	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	used	use	VBN	_	0	root	_	_
6	in	in	IN	_	9	case	_	_
7	the	the	DT	_	9	det	_	_
8	myasthenic	myasthenic	JJ	_	9	attr	_	_
9	patient	patient	NN	_	5	ppmod	_	_
10	only	only	RB	_	11	com	_	_
11	where	where	WRB	_	13	adv	_	_
12	definitely	definitely	RB	_	13	adv	_	_
13	indicated	indicate	VBN	_	9	relcl	_	_
14	,	,	,	_	5	p	_	_
15	and	and	CC	_	5	cc	_	_
16	then	then	RB	_	21	adv	_	_
17	careful	careful	JJ	_	18	attr	_	_
18	adjustment	adjustment	NN	_	21	dep	_	_
19	should	should	MD	_	21	modal	_	_
20	be	be	VB	_	21	aux	_	_
21	made	make	VBN	_	5	conj	_	_
22	of	of	IN	_	25	case	_	_
23	adjunctive	adjunctive	JJ	_	25	attr	_	_
24	drug2	drug0	NN	_	25	com	_	_
25	dosage	dosage	NN	_	21	ppmod	_	_
26	.	.	.	_	5	p	_	_

1	Local	local	JJ	_	5	attr	_	_
2	and	and	CC	_	1	cc	_	_
3	some	some	DT	_	4	det	_	_
4	general	general	JJ	_	1	conj	_	_
5	drug1	drug0	NN	_	18	dep	_	_
6	,	,	,	_	5	p	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	and	and	CC	_	7	cc	_	_
9	other	other	JJ	_	10	attr	_	_
10	drugs	drug	NNS	_	5	conj	_	_
11	that	that	WDT	_	12	dep	_	_
12	interfere	interfere	VBP	_	5	relcl	_	_
13	with	with	IN	_	15	case	_	_
14	neuromuscular	neuromuscular	JJ	_	15	attr	_	_
15	transmission	transmission	NN	_	12	ppmod	_	_
16	should	should	MD	_	18	modal	_	_
17	be	be	VB	_	18	aux	_	_
18	used	use	VBN	_	0	root	_	_
19	cautiously	cautiously	RB	_	18	adv	_	_
20	,	,	,	_	18	p	_	_
21	if	if	IN	_	22	case	_	_
22	at	at	IN	_	18	adv	_	_
23	all	all	DT	_	22	det	_	_
24	,	,	,	_	18	p	_	_
25	in	in	IN	_	26	case	_	_
26	patients	patient	NNS	_	18	ppmod	_	_
27	with	with	IN	_	29	case	_	_
28	myasthenia	myasthenia	JJ	_	29	attr	_	_
29	gravis	gravis	NNS	_	26	ppmod	_	_
30	;	;	:	_	18	p	_	_

1	the	the	DT	_	2	det	_	_
2	dose	dose	NN	_	6	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	may	may	MD	_	6	modal	_	_
6	have	have	VB	_	0	root	_	_
7	to	to	TO	_	9	aux	_	_
8	be	be	VB	_	9	aux	_	_
9	increased	increase	VBN	_	6	comp	_	_
10	accordingly	accordingly	RB	_	9	adv	_	_
11	.	.	.	_	6	p	_	_

1	The	the	DT	_	4	det	_	_
2	following	following	JJ	_	4	attr	_	_
3	drug	drug	NN	_	4	com	_	_
4	interactions	interaction	NNS	_	6	dep	_	_
5	were	be	VBD	_	6	aux	_	_
6	studied	study	VBN	_	0	root	_	_
7	with	with	IN	_	9	case	_	_
8	drug1	drug0	JJ	_	9	attr	_	_
9	doses	dose	NNS	_	6	ppmod	_	_
10	of	of	IN	_	12	case	_	_
11	200	0	CD	_	12	num	_	_
12	mg/day	mg/day	NN	_	9	ppmod	_	_
13	.	.	.	_	6	p	_	_

1	The	the	DT	_	2	det	_	_
2	possibility	possibility	NN	_	8	dep	_	_
3	of	of	IN	_	5	case	_	_
4	increased	increase	VBN	_	5	attr	_	_
5	interaction	interaction	NN	_	2	ppmod	_	_
6	should	should	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	kept	keep	VBN	_	0	root	_	_
9	in	in	IN	_	10	case	_	_
10	mind	mind	NN	_	8	ppmod	_	_
11	when	when	WRB	_	30	adv	_	_
12	drug1	drug0	JJ	_	13	attr	_	_
13	doses	dose	NNS	_	30	dep	_	_
14	greater	great	JJR	_	13	attr	_	_
15	than	than	IN	_	17	case	_	_
16	50	0	CD	_	17	num	_	_
17	mg	mg	NN	_	14	ppmod	_	_
18	as	as	IN	_	21	case	_	_
19	a	a	DT	_	21	det	_	_
20	single	single	JJ	_	21	attr	_	_
21	dose	dose	NN	_	17	ppmod	_	_
22	or	or	CC	_	17	cc	_	_
23	200	0	CD	_	24	num	_	_
24	mg	mg	NN	_	17	conj	_	_
25	of	of	IN	_	26	case	_	_
26	drug2	drug0	NN	_	24	ppmod	_	_
27	per	per	IN	_	28	case	_	_
28	day	day	NN	_	24	ppmod	_	_
29	are	be	VBP	_	30	aux	_	_
30	used	use	VBN	_	8	comp	_	_
31	concomitantly	concomitantly	RB	_	30	adv	_	_
32	with	with	IN	_	35	case	_	_
33	highly	highly	RB	_	34	adv	_	_
34	bound	bind	VBN	_	35	attr	_	_
35	drugs	drug	NNS	_	30	ppmod	_	_
36	.	.	.	_	8	p	_	_

1	1	0	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Concomitant	concomitant	JJ	_	4	attr	_	_
4	administration	administration	NN	_	11	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	does	do	VBZ	_	11	aux	_	_
10	not	not	RB	_	11	neg	_	_
11	interfere	interfere	VB	_	1	acl	_	_
12	with	with	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	rate	rate	NN	_	11	ppmod	_	_
15	or	or	CC	_	14	cc	_	_
16	extent	extent	NN	_	14	conj	_	_
17	of	of	IN	_	19	case	_	_
18	the	the	DT	_	19	det	_	_
19	absorption	absorption	NN	_	14	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	drug4	drug0	NNS	_	19	ppmod	_	_
22	administered	administer	VBN	_	21	acl	_	_
23	as	as	IN	_	24	case	_	_
24	drug5	drug0	NN	_	22	ppmod	_	_
25	.	.	.	_	1	p	_	_

1	2	0	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	6	dep	_	_
4	does	do	VBZ	_	6	aux	_	_
5	not	not	RB	_	6	neg	_	_
6	alter	alter	VB	_	1	acl	_	_
7	drug3	drug0	NN	_	8	com	_	_
8	absorption	absorption	NN	_	6	obj	_	_
9	;	;	:	_	1	p	_	_

1	however	however	RB	_	15	adv	_	_
2	,	,	,	_	15	p	_	_
3	in	in	IN	_	5	case	_	_
4	a	a	DT	_	5	det	_	_
5	study	study	NN	_	15	ppmod	_	_
6	of	of	IN	_	9	case	_	_
7	12	0	CD	_	9	num	_	_
8	normal	normal	JJ	_	9	attr	_	_
9	subjects	subject	NNS	_	5	ppmod	_	_
10	,	,	,	_	15	p	_	_
11	concurrent	concurrent	JJ	_	12	attr	_	_
12	administration	administration	NN	_	15	dep	_	_
13	of	of	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	decreased	decrease	VBD	_	0	root	_	_
16	drug2	drug0	NN	_	18	com	_	_
17	protein	protein	NN	_	18	com	_	_
18	binding	binding	NN	_	15	obj	_	_
19	and	and	CC	_	18	cc	_	_
20	increased	increase	VBN	_	23	attr	_	_
21	drug3	drug0	NN	_	23	com	_	_
22	plasma	plasma	NN	_	23	com	_	_
23	clearance	clearance	NN	_	18	conj	_	_
24	from	from	IN	_	26	case	_	_
25	0.07	0	CD	_	26	num	_	_
26	L/kg/h	l/kg/h	NN	_	15	ppmod	_	_
27	without	without	IN	_	28	case	_	_
28	drug4	drug0	NN	_	15	ppmod	_	_
29	to	to	TO	_	31	aux	_	_
30	0.11	0	NN	_	31	num	_	_
31	L/kg/h	l/kg/h	NN	_	15	ppmod	_	_
32	with	with	IN	_	33	case	_	_
33	drug5	drug0	NN	_	31	ppmod	_	_
34	.	.	.	_	15	p	_	_

1	The	the	DT	_	3	det	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	significance	significance	NN	_	11	dep	_	_
4	of	of	IN	_	6	case	_	_
5	these	these	DT	_	6	det	_	_
6	changes	change	NNS	_	3	ppmod	_	_
7	has	have	VBZ	_	11	aux	_	_
8	not	not	RB	_	11	neg	_	_
9	been	be	VBN	_	11	aux	_	_
10	adequately	adequately	RB	_	11	adv	_	_
11	studied	study	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	Therefore	therefore	RB	_	11	adv	_	_
2	,	,	,	_	11	p	_	_
3	concurrent	concurrent	JJ	_	4	attr	_	_
4	use	use	NN	_	11	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	is	be	VBZ	_	11	aux	_	_
10	not	not	RB	_	11	neg	_	_
11	recommended	recommend	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	3	0	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	10	dep	_	_
4	,	,	,	_	3	p	_	_
5	given	give	VBN	_	3	acl	_	_
6	concomitantly	concomitantly	RB	_	5	adv	_	_
7	with	with	IN	_	8	case	_	_
8	drug3	drug0	NN	_	5	ppmod	_	_
9	,	,	,	_	3	p	_	_
10	produces	produce	VBZ	_	1	acl	_	_
11	a	a	DT	_	12	det	_	_
12	reduction	reduction	NN	_	10	obj	_	_
13	in	in	IN	_	15	case	_	_
14	urinary	urinary	JJ	_	15	attr	_	_
15	potassium	potassium	NN	_	12	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	chloride	chloride	NN	_	18	com	_	_
18	excretion	excretion	NN	_	15	conj	_	_
19	compared	compare	VBN	_	21	adv	_	_
20	to	to	TO	_	21	aux	_	_
21	drug4	drug0	NN	_	10	ppmod	_	_
22	alone	alone	RB	_	21	adv	_	_
23	.	.	.	_	1	p	_	_

1	Patients	patient	NNS	_	4	dep	_	_
2	taking	take	VBG	_	1	acl	_	_
3	drug1	drug0	NN	_	2	obj	_	_
4	are	be	VBP	_	0	root	_	_
5	at	at	IN	_	8	case	_	_
6	a	a	DT	_	8	det	_	_
7	greater	great	JJR	_	8	attr	_	_
8	risk	risk	NN	_	4	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	developing	develop	VBG	_	8	ppmod	_	_
11	renal	renal	JJ	_	12	attr	_	_
12	failure	failure	NN	_	10	obj	_	_
13	secondary	secondary	JJ	_	12	attr	_	_
14	to	to	TO	_	16	aux	_	_
15	a	a	DT	_	16	det	_	_
16	decrease	decrease	NN	_	13	ppmod	_	_
17	in	in	IN	_	20	case	_	_
18	renal	renal	JJ	_	20	attr	_	_
19	blood	blood	NN	_	20	com	_	_
20	flow	flow	NN	_	16	ppmod	_	_
21	caused	cause	VBN	_	20	acl	_	_
22	by	by	IN	_	24	case	_	_
23	prostaglandin	prostaglandin	NN	_	24	com	_	_
24	inhibition	inhibition	NN	_	21	ppmod	_	_
25	.	.	.	_	4	p	_	_

1	4	0	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	5	case	_	_
4	a	a	DT	_	5	det	_	_
5	study	study	NN	_	24	ppmod	_	_
6	in	in	IN	_	8	case	_	_
7	12	0	CD	_	8	num	_	_
8	patients	patient	NNS	_	5	ppmod	_	_
9	with	with	IN	_	12	case	_	_
10	congestive	congestive	JJ	_	12	attr	_	_
11	heart	heart	NN	_	12	com	_	_
12	failure	failure	NN	_	8	ppmod	_	_
13	where	where	WRB	_	19	adv	_	_
14	drug2	drug0	NN	_	19	dep	_	_
15	and	and	CC	_	14	cc	_	_
16	drug3	drug0	NN	_	14	conj	_	_
17	were	be	VBD	_	19	aux	_	_
18	concomitantly	concomitantly	RB	_	19	adv	_	_
19	administered	administer	VBN	_	12	relcl	_	_
20	,	,	,	_	24	p	_	_
21	drug4	drug0	NNS	_	24	dep	_	_
22	did	do	VBD	_	24	aux	_	_
23	not	not	RB	_	24	neg	_	_
24	alter	alter	VB	_	1	acl	_	_
25	the	the	DT	_	27	det	_	_
26	serum	serum	NN	_	27	com	_	_
27	levels	level	NNS	_	24	obj	_	_
28	of	of	IN	_	29	case	_	_
29	drug5	drug0	NN	_	27	ppmod	_	_
30	.	.	.	_	1	p	_	_

1	5	0	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	17	dep	_	_
2	:	:	:	_	17	p	_	_
3	In	in	IN	_	7	case	_	_
4	a	a	DT	_	7	det	_	_
5	short-term	short-term	JJ	_	7	attr	_	_
6	controlled	controlled	JJ	_	7	attr	_	_
7	study	study	NN	_	17	ppmod	_	_
8	in	in	IN	_	11	case	_	_
9	14	0	CD	_	11	num	_	_
10	normal	normal	JJ	_	11	attr	_	_
11	volunteers	volunteer	NNS	_	7	ppmod	_	_
12	,	,	,	_	17	p	_	_
13	drug2	drug0	NN	_	17	dep	_	_
14	did	do	VBD	_	17	aux	_	_
15	not	not	RB	_	17	neg	_	_
16	significantly	significantly	RB	_	17	adv	_	_
17	interfere	interfere	VB	_	0	root	_	_
18	with	with	IN	_	20	case	_	_
19	the	the	DT	_	20	det	_	_
20	effect	effect	NN	_	17	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	drug3	drug0	NN	_	20	ppmod	_	_
23	on	on	IN	_	25	case	_	_
24	prothrombin	prothrombin	NN	_	25	com	_	_
25	time	time	NN	_	20	ppmod	_	_
26	.	.	.	_	17	p	_	_

1	Bleeding	bleeding	JJ	_	8	dep	_	_
2	from	from	IN	_	4	case	_	_
3	a	a	DT	_	4	det	_	_
4	number	number	NN	_	1	ppmod	_	_
5	of	of	IN	_	6	case	_	_
6	sites	site	NNS	_	4	ppmod	_	_
7	may	may	MD	_	8	modal	_	_
8	be	be	VB	_	0	root	_	_
9	a	a	DT	_	10	det	_	_
10	complication	complication	NN	_	8	obj	_	_
11	of	of	IN	_	13	case	_	_
12	drug1	drug0	NN	_	13	com	_	_
13	treatment	treatment	NN	_	10	ppmod	_	_
14	and	and	CC	_	10	cc	_	_
15	GI	gi	JJ	_	16	attr	_	_
16	bleeding	bleeding	JJ	_	18	attr	_	_
17	a	a	DT	_	18	det	_	_
18	complication	complication	NN	_	10	conj	_	_
19	of	of	IN	_	21	case	_	_
20	drug2	drug0	NN	_	21	com	_	_
21	treatment	treatment	NN	_	18	ppmod	_	_
22	.	.	.	_	8	p	_	_

1	Because	because	IN	_	3	mark	_	_
2	prostaglandina	prostaglandina	NNS	_	3	dep	_	_
3	play	play	VBP	_	11	advcl	_	_
4	an	an	DT	_	6	det	_	_
5	important	important	JJ	_	6	attr	_	_
6	role	role	NN	_	3	obj	_	_
7	in	in	IN	_	8	case	_	_
8	hemostasis	hemostasis	NN	_	3	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	drug1	drug0	NN	_	8	conj	_	_
11	has	have	VBZ	_	26	advcl	_	_
12	an	an	DT	_	13	det	_	_
13	effect	effect	NN	_	11	obj	_	_
14	on	on	IN	_	16	case	_	_
15	platelet	platelet	NN	_	16	com	_	_
16	function	function	NN	_	13	ppmod	_	_
17	as	as	IN	_	18	case	_	_
18	well	well	NN	_	11	ppmod	_	_
19	,	,	,	_	26	p	_	_
20	concurent	concurent	JJ	_	21	attr	_	_
21	therapy	therapy	NN	_	26	dep	_	_
22	with	with	IN	_	23	case	_	_
23	drug2	drug0	NN	_	21	ppmod	_	_
24	and	and	CC	_	23	cc	_	_
25	drug3	drug0	NN	_	23	conj	_	_
26	requires	require	VBZ	_	0	root	_	_
27	close	close	JJ	_	28	attr	_	_
28	monitoring	monitoring	NN	_	26	obj	_	_
29	of	of	IN	_	30	case	_	_
30	patients	patient	NNS	_	28	ppmod	_	_
31	on	on	IN	_	33	case	_	_
32	both	both	DT	_	33	det	_	_
33	drugs	drug	NNS	_	28	ppmod	_	_
34	.	.	.	_	26	p	_	_

1	6	0	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	4	dep	_	_
4	increases	increase	VBZ	_	1	acl	_	_
5	both	both	CC	_	6	cc	_	_
6	free	free	JJ	_	9	attr	_	_
7	and	and	CC	_	6	cc	_	_
8	bound	bound	JJ	_	6	conj	_	_
9	drug3	drug0	NN	_	4	obj	_	_
10	by	by	IN	_	11	case	_	_
11	reducing	reduce	VBG	_	4	ppmod	_	_
12	the	the	DT	_	14	det	_	_
13	plasma	plasma	NN	_	14	com	_	_
14	clearance	clearance	NN	_	11	obj	_	_
15	of	of	IN	_	16	case	_	_
16	drug4	drug0	NN	_	14	ppmod	_	_
17	to	to	TO	_	19	aux	_	_
18	about	about	RB	_	19	adv	_	_
19	one-third	one-third	CD	_	14	ppmod	_	_
20	,	,	,	_	11	p	_	_
21	as	as	RB	_	22	com	_	_
22	well	well	RB	_	11	cc	_	_
23	as	as	IN	_	22	com	_	_
24	decreasing	decrease	VBG	_	11	conj	_	_
25	its	its	PRP$	_	27	poss	_	_
26	protein	protein	NN	_	27	com	_	_
27	binding	binding	NN	_	24	obj	_	_
28	.	.	.	_	1	p	_	_

1	Therefore	therefore	RB	_	11	adv	_	_
2	,	,	,	_	11	p	_	_
3	the	the	DT	_	4	det	_	_
4	combination	combination	NN	_	11	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	is	be	VBZ	_	11	aux	_	_
10	not	not	RB	_	11	neg	_	_
11	recommended	recommend	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	7	0	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	10	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	,	,	,	_	10	p	_	_
5	like	like	IN	_	7	case	_	_
6	other	other	JJ	_	7	attr	_	_
7	drug3	drug0	NN	_	10	ppmod	_	_
8	,	,	,	_	10	p	_	_
9	may	may	MD	_	10	modal	_	_
10	cause	cause	VB	_	0	root	_	_
11	changes	change	NNS	_	10	obj	_	_
12	in	in	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	elimination	elimination	NN	_	11	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug4	drug0	NN	_	14	ppmod	_	_
17	leading	lead	VBG	_	16	acl	_	_
18	to	to	TO	_	21	aux	_	_
19	elevated	elevated	JJ	_	21	attr	_	_
20	serum	serum	NN	_	21	com	_	_
21	levels	level	NNS	_	17	ppmod	_	_
22	of	of	IN	_	24	case	_	_
23	the	the	DT	_	24	det	_	_
24	drug	drug	NN	_	21	ppmod	_	_
25	and	and	CC	_	24	cc	_	_
26	increased	increase	VBN	_	27	attr	_	_
27	toxicity	toxicity	NN	_	24	conj	_	_
28	.	.	.	_	10	p	_	_

1	8	0	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	have	have	VBP	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	reported	report	VBN	_	0	root	_	_
7	to	to	TO	_	8	aux	_	_
8	increase	increase	VB	_	6	comp	_	_
9	steadystate	steadystate	JJ	_	12	attr	_	_
10	plasma	plasma	NN	_	12	com	_	_
11	drug3	drug0	NN	_	12	com	_	_
12	levels	level	NNS	_	8	obj	_	_
13	.	.	.	_	6	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	recommended	recommend	VBN	_	0	root	_	_
4	that	that	IN	_	9	mark	_	_
5	plasma	plasma	NN	_	7	com	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	levels	level	NNS	_	9	dep	_	_
8	be	be	VB	_	9	aux	_	_
9	monitored	monitor	VBN	_	3	comp	_	_
10	when	when	WRB	_	13	adv	_	_
11	drug2	drug0	NN	_	13	dep	_	_
12	is	be	VBZ	_	13	aux	_	_
13	coadministered	coadministered	VBN	_	9	comp	_	_
14	with	with	IN	_	15	case	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	3	p	_	_

1	DRUG/LABORATORY	drug/laboratory	NN	_	3	com	_	_
2	TEST	test	NN	_	3	com	_	_
3	INTERACTIONS	interaction	NNS	_	0	root	_	_
4	:	:	:	_	3	p	_	_
5	EFFECT	effect	NN	_	10	dep	_	_
6	ON	on	IN	_	8	case	_	_
7	BLOOD	blood	NN	_	8	com	_	_
8	COAGULATION	coagulation	NN	_	5	ppmod	_	_
9	drug1	drug0	CD	_	8	num	_	_
10	decreases	decrease	VBZ	_	3	acl	_	_
11	platelet	platelet	NN	_	12	com	_	_
12	adhesion	adhesion	NN	_	10	obj	_	_
13	and	and	CC	_	12	cc	_	_
14	aggregation	aggregation	NN	_	12	conj	_	_
15	.	.	.	_	3	p	_	_

1	Therefore	therefore	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	it	it	PRP	_	5	dep	_	_
4	can	can	MD	_	5	modal	_	_
5	prolong	prolong	VB	_	0	root	_	_
6	bleeding	bleeding	JJ	_	7	attr	_	_
7	time	time	NN	_	5	obj	_	_
8	by	by	IN	_	13	case	_	_
9	approximately	approximately	RB	_	10	adv	_	_
10	3	0	CD	_	13	num	_	_
11	to	to	TO	_	10	cc	_	_
12	4	0	CD	_	10	conj	_	_
13	minutes	minute	NNS	_	5	ppmod	_	_
14	from	from	IN	_	16	case	_	_
15	baseline	baseline	NN	_	16	com	_	_
16	values	value	NNS	_	13	ppmod	_	_
17	.	.	.	_	5	p	_	_

1	There	there	EX	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	no	no	DT	_	5	det	_	_
4	significant	significant	JJ	_	5	attr	_	_
5	change	change	NN	_	2	obj	_	_
6	in	in	IN	_	8	case	_	_
7	platelet	platelet	NN	_	8	com	_	_
8	count	count	NN	_	5	ppmod	_	_
9	,	,	,	_	8	p	_	_
10	prothrombin	prothrombin	NN	_	11	com	_	_
11	time	time	NN	_	8	conj	_	_
12	,	,	,	_	11	p	_	_
13	partial	partial	JJ	_	15	attr	_	_
14	thromboplastin	thromboplastin	NN	_	15	com	_	_
15	time	time	NN	_	8	conj	_	_
16	,	,	,	_	15	p	_	_
17	or	or	CC	_	15	cc	_	_
18	thrombin	thrombin	NN	_	19	com	_	_
19	time	time	NN	_	8	conj	_	_
20	.	.	.	_	2	p	_	_

1	Because	because	IN	_	5	mark	_	_
2	drug1	drug0	NN	_	5	dep	_	_
3	have	have	VBP	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	shown	show	VBN	_	19	advcl	_	_
6	to	to	TO	_	7	aux	_	_
7	depress	depress	VB	_	5	comp	_	_
8	plasma	plasma	NN	_	10	com	_	_
9	prothrombin	prothrombin	NN	_	10	com	_	_
10	activity	activity	NN	_	7	obj	_	_
11	,	,	,	_	19	p	_	_
12	patients	patient	NNS	_	19	dep	_	_
13	who	who	WP	_	14	dep	_	_
14	are	be	VBP	_	12	relcl	_	_
15	on	on	IN	_	17	case	_	_
16	drug2	drug0	NN	_	17	com	_	_
17	therapy	therapy	NN	_	14	ppmod	_	_
18	may	may	MD	_	19	modal	_	_
19	require	require	VB	_	0	root	_	_
20	downward	downward	JJ	_	21	attr	_	_
21	adjustment	adjustment	NN	_	19	obj	_	_
22	of	of	IN	_	25	case	_	_
23	their	their	PRP$	_	25	poss	_	_
24	drug3	drug0	NN	_	25	com	_	_
25	dosage	dosage	NN	_	21	ppmod	_	_
26	.	.	.	_	19	p	_	_

1	Since	since	IN	_	5	mark	_	_
2	bacteriostatic	bacteriostatic	JJ	_	3	attr	_	_
3	drugs	drug	NNS	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	interfere	interfere	VB	_	14	advcl	_	_
6	with	with	IN	_	9	case	_	_
7	the	the	DT	_	9	det	_	_
8	bactericidal	bactericidal	JJ	_	9	attr	_	_
9	action	action	NN	_	5	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	,	,	,	_	14	p	_	_
13	it	it	PRP	_	14	dep	_	_
14	is	be	VBZ	_	0	root	_	_
15	advisable	advisable	JJ	_	14	dep	_	_
16	to	to	TO	_	17	aux	_	_
17	avoid	avoid	VB	_	15	comp	_	_
18	giving	giving	NN	_	19	com	_	_
19	drug2	drug0	NN	_	17	obj	_	_
20	in	in	IN	_	21	case	_	_
21	conjunction	conjunction	NN	_	17	ppmod	_	_
22	with	with	IN	_	23	case	_	_
23	drug3	drug0	NN	_	21	ppmod	_	_
24	.	.	.	_	14	p	_	_

1	Absorption	absorption	NN	_	5	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	is	be	VBZ	_	5	aux	_	_
5	impaired	impair	VBN	_	0	root	_	_
6	by	by	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	containing	contain	VBG	_	7	acl	_	_
9	drug3	drug0	NN	_	8	obj	_	_
10	,	,	,	_	9	p	_	_
11	drug4	drug0	NN	_	9	conj	_	_
12	,	,	,	_	11	p	_	_
13	or	or	CC	_	11	cc	_	_
14	drug5	drug0	NN	_	9	conj	_	_
15	,	,	,	_	14	p	_	_
16	and	and	CC	_	14	cc	_	_
17	drug6	drug0	NN	_	19	attr	_	_
18	-containing	-containing	JJ	_	19	attr	_	_
19	preparations	preparation	NNS	_	9	conj	_	_
20	.	.	.	_	5	p	_	_

1	Absorption	absorption	NN	_	5	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	is	be	VBZ	_	5	aux	_	_
5	impaired	impair	VBN	_	0	root	_	_
6	by	by	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	7	dep	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	,	,	,	_	3	p	_	_
5	and	and	CC	_	3	cc	_	_
6	drug3	drug0	NN	_	1	conj	_	_
7	decrease	decrease	VBP	_	0	root	_	_
8	the	the	DT	_	9	det	_	_
9	half-life	half-life	NN	_	7	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug4	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	7	p	_	_

1	The	the	DT	_	3	det	_	_
2	concurrent	concurrent	JJ	_	3	attr	_	_
3	use	use	NN	_	13	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	drug3	drug0	NN	_	7	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	has	have	VBZ	_	13	aux	_	_
12	been	be	VBN	_	13	aux	_	_
13	reported	report	VBN	_	0	root	_	_
14	to	to	TO	_	15	aux	_	_
15	result	result	VB	_	13	comp	_	_
16	in	in	IN	_	19	case	_	_
17	fatal	fatal	JJ	_	19	attr	_	_
18	renal	renal	JJ	_	19	attr	_	_
19	toxicity	toxicity	NN	_	15	ppmod	_	_
20	.	.	.	_	13	p	_	_

1	Concurrent	concurrent	JJ	_	2	attr	_	_
2	use	use	NN	_	6	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	may	may	MD	_	6	modal	_	_
6	render	render	VB	_	0	root	_	_
7	oral	oral	JJ	_	8	attr	_	_
8	drug2	drug0	NN	_	6	obj	_	_
9	less	less	RBR	_	10	adv	_	_
10	effective	effective	JJ	_	8	attr	_	_
11	.	.	.	_	6	p	_	_

1	Drug/Laboratory	drug/laboratory	JJ	_	5	attr	_	_
2	Test	test	NN	_	5	attr	_	_
3	Interactions	interaction	NNS	_	5	attr	_	_
4	False	false	JJ	_	5	attr	_	_
5	elevations	elevation	NNS	_	11	dep	_	_
6	of	of	IN	_	9	case	_	_
7	urinary	urinary	JJ	_	9	attr	_	_
8	catecholamine	catecholamine	NN	_	9	com	_	_
9	levels	level	NNS	_	5	ppmod	_	_
10	may	may	MD	_	11	modal	_	_
11	occur	occur	VB	_	0	root	_	_
12	due	due	JJ	_	11	dep	_	_
13	to	to	TO	_	14	aux	_	_
14	interference	interference	NN	_	12	ppmod	_	_
15	with	with	IN	_	18	case	_	_
16	the	the	DT	_	18	det	_	_
17	fluorescence	fluorescence	NN	_	18	com	_	_
18	test	test	NN	_	14	ppmod	_	_
19	.	.	.	_	11	p	_	_

1	General	general	JJ	_	6	attr	_	_
2	No	no	NN	_	6	attr	_	_
3	clinical	clinical	JJ	_	6	attr	_	_
4	drug	drug	NN	_	6	com	_	_
5	interaction	interaction	NN	_	6	com	_	_
6	studies	study	NNS	_	8	dep	_	_
7	were	be	VBD	_	8	aux	_	_
8	performed	performed	VBN	_	0	root	_	_
9	.	.	.	_	8	p	_	_

1	No	no	DT	_	2	det	_	_
2	evaluation	evaluation	NN	_	13	dep	_	_
3	of	of	IN	_	6	case	_	_
4	drug1	drug0	NN	_	6	com	_	_
5	s	s	NN	_	6	com	_	_
6	effects	effect	NNS	_	2	ppmod	_	_
7	on	on	IN	_	11	case	_	_
8	the	the	DT	_	11	det	_	_
9	cytochrome	cytochrome	NN	_	11	com	_	_
10	P450	p0	NN	_	11	com	_	_
11	system	system	NN	_	6	ppmod	_	_
12	was	be	VBD	_	13	aux	_	_
13	conducted	conduct	VBN	_	0	root	_	_
14	.	.	.	_	13	p	_	_

1	As	as	IN	_	4	case	_	_
2	with	with	IN	_	4	case	_	_
3	other	other	JJ	_	4	attr	_	_
4	drug1	drug0	NN	_	13	ppmod	_	_
5	,	,	,	_	13	p	_	_
6	blood	blood	NN	_	7	com	_	_
7	concentrations	concentration	NNS	_	13	dep	_	_
8	of	of	IN	_	10	case	_	_
9	dialyzable	dialyzable	JJ	_	10	attr	_	_
10	drugs	drug	NNS	_	7	ppmod	_	_
11	may	may	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	reduced	reduce	VBN	_	0	root	_	_
14	by	by	IN	_	15	case	_	_
15	dialysis	dialysis	NN	_	13	ppmod	_	_
16	.	.	.	_	13	p	_	_

1	Dosage	dosage	JJ	_	2	attr	_	_
2	adjustment	adjustment	NN	_	7	dep	_	_
3	of	of	IN	_	5	case	_	_
4	concomitant	concomitant	JJ	_	5	attr	_	_
5	medications	medication	NNS	_	2	ppmod	_	_
6	may	may	MD	_	7	modal	_	_
7	be	be	VB	_	0	root	_	_
8	necessary	necessary	JJ	_	7	dep	_	_
9	.	.	.	_	7	p	_	_

1	In	in	IN	_	2	case	_	_
2	patients	patient	NNS	_	22	ppmod	_	_
3	using	use	VBG	_	2	acl	_	_
4	drug1	drug0	NN	_	3	obj	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	drug2	drug0	NN	_	4	prn	_	_
7	and	and	CC	_	6	cc	_	_
8	others	other	NNS	_	6	conj	_	_
9	)	-rrb-	-RRB-	_	6	p	_	_
10	,	,	,	_	22	p	_	_
11	plasma	plasma	NN	_	12	com	_	_
12	levels	level	NNS	_	22	dep	_	_
13	of	of	IN	_	14	case	_	_
14	calcium	calcium	NN	_	12	ppmod	_	_
15	,	,	,	_	14	p	_	_
16	potassium	potassium	NN	_	14	conj	_	_
17	and	and	CC	_	16	cc	_	_
18	magnesium	magnesium	NN	_	14	conj	_	_
19	must	must	MD	_	22	modal	_	_
20	be	be	VB	_	22	aux	_	_
21	carefully	carefully	RB	_	22	adv	_	_
22	monitored	monitor	VBN	_	0	root	_	_
23	.	.	.	_	22	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	A	a	DT	_	5	det	_	_
4	clinical	clinical	JJ	_	5	attr	_	_
5	study	study	NN	_	11	dep	_	_
6	in	in	IN	_	10	case	_	_
7	6	0	CD	_	10	num	_	_
8	insulin-dependent	insulin-dependent	JJ	_	10	attr	_	_
9	diabetic	diabetic	JJ	_	10	attr	_	_
10	patients	patient	NNS	_	5	ppmod	_	_
11	demonstrated	demonstrate	VBD	_	1	acl	_	_
12	no	no	DT	_	13	det	_	_
13	effect	effect	NN	_	11	obj	_	_
14	of	of	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	on	on	IN	_	18	case	_	_
17	drug3	drug0	NN	_	18	com	_	_
18	absorption	absorption	NN	_	13	ppmod	_	_
19	from	from	IN	_	22	case	_	_
20	the	the	DT	_	22	det	_	_
21	peritoneal	peritoneal	JJ	_	22	attr	_	_
22	cavity	cavity	NN	_	18	ppmod	_	_
23	or	or	CC	_	18	cc	_	_
24	on	on	IN	_	27	case	_	_
25	drug4	drug0	NN	_	27	com	_	_
26	s	s	NN	_	27	com	_	_
27	ability	ability	NN	_	18	conj	_	_
28	to	to	TO	_	29	aux	_	_
29	control	control	VB	_	27	acl	_	_
30	blood	blood	NN	_	31	com	_	_
31	glucose	glucose	NN	_	29	obj	_	_
32	when	when	WRB	_	35	adv	_	_
33	drug5	drug0	NN	_	35	dep	_	_
34	was	be	VBD	_	35	aux	_	_
35	administered	administer	VBN	_	29	comp	_	_
36	intraperitoneally	intraperitoneally	RB	_	35	adv	_	_
37	with	with	IN	_	38	case	_	_
38	drug6	drug0	NN	_	35	ppmod	_	_
39	.	.	.	_	1	p	_	_

1	However	however	RB	_	10	adv	_	_
2	,	,	,	_	10	p	_	_
3	appropriate	appropriate	JJ	_	4	attr	_	_
4	monitoring	monitoring	NN	_	10	dep	_	_
5	of	of	IN	_	7	case	_	_
6	blood	blood	NN	_	7	com	_	_
7	glucose	glucose	NN	_	4	ppmod	_	_
8	should	should	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	performed	performed	VBN	_	0	root	_	_
11	when	when	WRB	_	12	adv	_	_
12	initiating	initiate	VBG	_	10	comp	_	_
13	drug1	drug0	NN	_	12	obj	_	_
14	in	in	IN	_	16	case	_	_
15	diabetic	diabetic	JJ	_	16	attr	_	_
16	patients	patient	NNS	_	13	ppmod	_	_
17	and	and	CC	_	10	cc	_	_
18	drug2	drug0	NN	_	19	com	_	_
19	dosage	dosage	NN	_	22	dep	_	_
20	should	should	MD	_	22	modal	_	_
21	be	be	VB	_	22	aux	_	_
22	adjusted	adjust	VBN	_	10	conj	_	_
23	if	if	IN	_	24	mark	_	_
24	needed	need	VBN	_	22	comp	_	_
25	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	No	no	DT	_	7	det	_	_
4	human	human	JJ	_	7	attr	_	_
5	drug	drug	NN	_	7	com	_	_
6	interaction	interaction	NN	_	7	com	_	_
7	studies	study	NNS	_	11	dep	_	_
8	with	with	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	were	be	VBD	_	11	aux	_	_
11	conducted	conduct	VBN	_	1	acl	_	_
12	.	.	.	_	1	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	studies	study	NNS	_	4	dep	_	_
4	demonstrated	demonstrate	VBD	_	0	root	_	_
5	no	no	DT	_	6	det	_	_
6	evidence	evidence	NN	_	4	obj	_	_
7	of	of	IN	_	8	case	_	_
8	incompatibility	incompatibility	NN	_	6	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	with	with	IN	_	12	case	_	_
12	drug2	drug0	NN	_	8	ppmod	_	_
13	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	No	no	DT	_	7	det	_	_
4	human	human	JJ	_	7	attr	_	_
5	drug	drug	NN	_	7	com	_	_
6	interaction	interaction	NN	_	7	com	_	_
7	studies	study	NNS	_	11	dep	_	_
8	with	with	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	were	be	VBD	_	11	aux	_	_
11	conducted	conduct	VBN	_	1	acl	_	_
12	.	.	.	_	1	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	studies	study	NNS	_	28	dep	_	_
4	evaluating	evaluate	VBG	_	3	acl	_	_
5	the	the	DT	_	8	det	_	_
6	minimum	minimum	JJ	_	8	attr	_	_
7	inhibitory	inhibitory	JJ	_	8	attr	_	_
8	concentration	concentration	NN	_	4	obj	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	MIC	mic	NN	_	8	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	8	ppmod	_	_
14	,	,	,	_	13	p	_	_
15	drug2	drug0	NN	_	13	conj	_	_
16	,	,	,	_	15	p	_	_
17	drug3	drug0	NN	_	13	conj	_	_
18	,	,	,	_	17	p	_	_
19	drug4	drug0	NN	_	20	com	_	_
20	/flucoxacillin	/flucoxacillin	NN	_	13	conj	_	_
21	,	,	,	_	20	p	_	_
22	drug5	drug0	NN	_	13	conj	_	_
23	,	,	,	_	22	p	_	_
24	drug6	drug0	NN	_	13	conj	_	_
25	,	,	,	_	24	p	_	_
26	and	and	CC	_	24	cc	_	_
27	drug7	drug0	NN	_	13	conj	_	_
28	demonstrated	demonstrate	VBD	_	0	root	_	_
29	no	no	DT	_	30	det	_	_
30	evidence	evidence	NN	_	28	obj	_	_
31	of	of	IN	_	32	case	_	_
32	incompatibility	incompatibility	NN	_	30	ppmod	_	_
33	of	of	IN	_	35	case	_	_
34	these	these	DT	_	35	det	_	_
35	drug8	drug0	NN	_	32	ppmod	_	_
36	with	with	IN	_	37	case	_	_
37	drug9	drug0	NN	_	35	ppmod	_	_
38	.	.	.	_	28	p	_	_

1	Drug/Laboratory	drug/laboratory	JJ	_	3	attr	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	11	dep	_	_
4	Blood	blood	NN	_	8	com	_	_
5	Glucose	glucose	NN	_	8	com	_	_
6	Blood	blood	NN	_	8	com	_	_
7	glucose	glucose	NN	_	8	com	_	_
8	measurement	measurement	NN	_	3	attr	_	_
9	must	must	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	done	do	VBN	_	0	root	_	_
12	with	with	IN	_	15	case	_	_
13	a	a	DT	_	15	det	_	_
14	glucose-specific	glucose-specific	JJ	_	15	attr	_	_
15	method	method	NN	_	11	ppmod	_	_
16	to	to	TO	_	17	aux	_	_
17	prevent	prevent	VB	_	15	acl	_	_
18	maltose	maltose	NN	_	19	com	_	_
19	interference	interference	NN	_	17	obj	_	_
20	with	with	IN	_	22	case	_	_
21	test	test	NN	_	22	com	_	_
22	results	result	NNS	_	19	ppmod	_	_
23	.	.	.	_	11	p	_	_

1	Since	since	IN	_	8	mark	_	_
2	falsely	falsely	RB	_	3	adv	_	_
3	elevated	elevated	JJ	_	5	attr	_	_
4	glucose	glucose	NN	_	5	com	_	_
5	levels	level	NNS	_	8	dep	_	_
6	have	have	VBP	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	observed	observe	VBN	_	35	advcl	_	_
9	with	with	IN	_	13	case	_	_
10	blood	blood	NN	_	13	com	_	_
11	glucose	glucose	NN	_	13	com	_	_
12	monitoring	monitoring	NN	_	13	com	_	_
13	devices	device	NNS	_	8	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	test	test	NN	_	16	com	_	_
16	strips	strip	NNS	_	13	conj	_	_
17	that	that	WDT	_	18	dep	_	_
18	use	use	VBP	_	13	relcl	_	_
19	glucose	glucose	NN	_	21	com	_	_
20	dehydrogenase	dehydrogenase	NN	_	21	com	_	_
21	pyrroloquinolinequinone	pyrroloquinolinequinone	NN	_	26	advnp	_	_
22	(	-lrb-	-LRB-	_	24	p	_	_
23	GDH	gdh	CD	_	24	num	_	_
24	PQQ	pqq	NN	_	21	prn	_	_
25	)	-rrb-	-RRB-	_	24	p	_	_
26	-based	-based	JJ	_	27	attr	_	_
27	methods	method	NNS	_	18	obj	_	_
28	,	,	,	_	35	p	_	_
29	GDH	gdh	CD	_	31	num	_	_
30	PQQ-based	pqq-based	JJ	_	31	attr	_	_
31	methods	method	NNS	_	35	dep	_	_
32	should	should	MD	_	35	modal	_	_
33	not	not	RB	_	35	neg	_	_
34	be	be	VB	_	35	aux	_	_
35	used	use	VBN	_	0	root	_	_
36	to	to	TO	_	37	aux	_	_
37	measure	measure	VB	_	35	comp	_	_
38	glucose	glucose	NN	_	39	com	_	_
39	levels	level	NNS	_	37	obj	_	_
40	in	in	IN	_	41	case	_	_
41	patients	patient	NNS	_	37	ppmod	_	_
42	administered	administer	VBN	_	41	acl	_	_
43	drug1	drug0	NN	_	42	comp	_	_
44	.	.	.	_	35	p	_	_
45	.	.	.	_	35	p	_	_

1	Serum	serum	NN	_	2	com	_	_
2	Amylase	amylase	NN	_	12	dep	_	_
3	An	an	DT	_	5	det	_	_
4	apparent	apparent	JJ	_	5	attr	_	_
5	decrease	decrease	NN	_	2	appo	_	_
6	in	in	IN	_	9	case	_	_
7	serum	serum	NN	_	9	com	_	_
8	amylase	amylase	NN	_	9	com	_	_
9	activity	activity	NN	_	5	ppmod	_	_
10	has	have	VBZ	_	12	aux	_	_
11	been	be	VBN	_	12	aux	_	_
12	observed	observe	VBN	_	0	root	_	_
13	in	in	IN	_	14	case	_	_
14	patients	patient	NNS	_	12	ppmod	_	_
15	administered	administer	VBN	_	14	acl	_	_
16	drug1	drug0	NN	_	15	obj	_	_
17	.	.	.	_	12	p	_	_

1	Preliminary	preliminary	JJ	_	2	attr	_	_
2	investigations	investigation	NNS	_	3	dep	_	_
3	indicate	indicate	VBP	_	0	root	_	_
4	that	that	IN	_	9	mark	_	_
5	drug1	drug0	NN	_	9	dep	_	_
6	and	and	CC	_	5	cc	_	_
7	its	its	PRP$	_	8	poss	_	_
8	metabolites	metabolite	NNS	_	5	conj	_	_
9	interfere	interfere	VBP	_	3	comp	_	_
10	with	with	IN	_	13	case	_	_
11	enzymatic-based	enzymatic-based	JJ	_	13	attr	_	_
12	amylase	amylase	NN	_	13	com	_	_
13	assays	assay	NNS	_	9	ppmod	_	_
14	,	,	,	_	9	p	_	_
15	resulting	result	VBG	_	9	comp	_	_
16	in	in	IN	_	19	case	_	_
17	inaccurately	inaccurately	RB	_	18	adv	_	_
18	low	low	JJ	_	19	attr	_	_
19	values	value	NNS	_	15	ppmod	_	_
20	.	.	.	_	3	p	_	_

1	This	this	DT	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	taken	take	VBN	_	0	root	_	_
5	into	into	IN	_	6	case	_	_
6	account	account	NN	_	4	ppmod	_	_
7	when	when	WRB	_	8	adv	_	_
8	evaluating	evaluate	VBG	_	4	comp	_	_
9	serum	serum	NN	_	11	com	_	_
10	amylase	amylase	NN	_	11	com	_	_
11	levels	level	NNS	_	8	obj	_	_
12	for	for	IN	_	13	case	_	_
13	diagnosis	diagnosis	NN	_	8	ppmod	_	_
14	or	or	CC	_	13	cc	_	_
15	monitoring	monitoring	NN	_	13	conj	_	_
16	of	of	IN	_	17	case	_	_
17	pancreatitis	pancreatitis	NN	_	15	ppmod	_	_
18	in	in	IN	_	19	case	_	_
19	patients	patient	NNS	_	15	ppmod	_	_
20	using	use	VBG	_	19	acl	_	_
21	drug1	drug0	NN	_	20	obj	_	_
22	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	used	use	VBN	_	0	root	_	_
5	with	with	IN	_	6	case	_	_
6	caution	caution	NN	_	4	ppmod	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	4	ppmod	_	_
9	who	who	WP	_	11	dep	_	_
10	are	be	VBP	_	11	aux	_	_
11	receiving	receive	VBG	_	8	relcl	_	_
12	a	a	DT	_	13	det	_	_
13	drug2	drug0	NN	_	11	obj	_	_
14	orally	orally	RB	_	13	adv	_	_
15	because	because	IN	_	18	case	_	_
16	of	of	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	potential	potential	NN	_	11	ppmod	_	_
19	for	for	IN	_	21	case	_	_
20	additive	additive	JJ	_	21	attr	_	_
21	effects	effect	NNS	_	18	ppmod	_	_
22	on	on	IN	_	24	case	_	_
23	systemic	systemic	JJ	_	24	attr	_	_
24	beta-blockade	beta-blockade	NN	_	21	ppmod	_	_
25	.	.	.	_	4	p	_	_

1	Close	close	JJ	_	2	attr	_	_
2	observation	observation	NN	_	7	dep	_	_
3	of	of	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	patient	patient	NN	_	2	ppmod	_	_
6	is	be	VBZ	_	7	aux	_	_
7	recommended	recommend	VBN	_	0	root	_	_
8	when	when	WRB	_	12	adv	_	_
9	a	a	DT	_	10	det	_	_
10	drug1	drug0	NN	_	12	dep	_	_
11	is	be	VBZ	_	12	aux	_	_
12	administered	administer	VBN	_	7	comp	_	_
13	to	to	TO	_	14	aux	_	_
14	patients	patient	NNS	_	12	ppmod	_	_
15	receiving	receive	VBG	_	14	acl	_	_
16	catecholamine-depleting	catecholamine-depleting	JJ	_	17	attr	_	_
17	drugs	drug	NNS	_	15	obj	_	_
18	such	such	JJ	_	20	adv	_	_
19	as	as	IN	_	20	case	_	_
20	drug2	drug0	NN	_	17	ppmod	_	_
21	,	,	,	_	17	p	_	_
22	because	because	IN	_	26	case	_	_
23	of	of	IN	_	26	case	_	_
24	possible	possible	JJ	_	26	attr	_	_
25	additive	additive	JJ	_	26	attr	_	_
26	effects	effect	NNS	_	17	ppmod	_	_
27	and	and	CC	_	26	cc	_	_
28	the	the	DT	_	29	det	_	_
29	production	production	NN	_	26	conj	_	_
30	of	of	IN	_	31	case	_	_
31	hypotension	hypotension	NN	_	29	ppmod	_	_
32	and/or	and/or	CC	_	31	cc	_	_
33	marked	marked	JJ	_	34	attr	_	_
34	bradycardia	bradycardia	NN	_	31	conj	_	_
35	,	,	,	_	17	p	_	_
36	which	which	WDT	_	38	dep	_	_
37	may	may	MD	_	38	modal	_	_
38	produce	produce	VB	_	17	relcl	_	_
39	vertigo	vertigo	NN	_	38	obj	_	_
40	,	,	,	_	39	p	_	_
41	syncope	syncope	NN	_	39	conj	_	_
42	,	,	,	_	41	p	_	_
43	or	or	CC	_	41	cc	_	_
44	postural	postural	JJ	_	45	attr	_	_
45	hypotension	hypotension	NN	_	39	conj	_	_
46	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	increase	increase	VB	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	plasma-level	plasma-level	NN	_	3	obj	_	_
6	of	of	IN	_	9	case	_	_
7	concomitantly	concomitantly	RB	_	8	adv	_	_
8	given	give	VBN	_	9	attr	_	_
9	drug2	drug0	NN	_	5	ppmod	_	_
10	.	.	.	_	3	p	_	_

1	In	in	IN	_	4	mark	_	_
2	order	order	NN	_	4	dep	_	_
3	to	to	TO	_	4	aux	_	_
4	avoid	avoid	VB	_	13	advcl	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	intoxication	intoxication	NN	_	4	obj	_	_
7	,	,	,	_	13	p	_	_
8	drug2	drug0	NN	_	10	com	_	_
9	plasma	plasma	NN	_	10	com	_	_
10	levels	level	NNS	_	13	dep	_	_
11	should	should	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	monitored	monitor	VBN	_	0	root	_	_
14	closely	closely	RB	_	13	adv	_	_
15	.	.	.	_	13	p	_	_

1	If	if	IN	_	4	mark	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	given	give	VBN	_	14	advcl	_	_
5	concomitantly	concomitantly	RB	_	4	adv	_	_
6	with	with	IN	_	7	case	_	_
7	drug2	drug0	NN	_	4	ppmod	_	_
8	,	,	,	_	14	p	_	_
9	the	the	DT	_	11	det	_	_
10	drug3	drug0	NN	_	11	com	_	_
11	dose	dose	NN	_	14	dep	_	_
12	should	should	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	reduced	reduce	VBN	_	0	root	_	_
15	(	-lrb-	-LRB-	_	18	p	_	_
16	by	by	IN	_	18	case	_	_
17	approx.	approx.	RB	_	18	adv	_	_
18	50	0	CD	_	14	num	_	_
19	%	%	NN	_	18	meta	_	_
20	)	-rrb-	-RRB-	_	18	p	_	_
21	,	,	,	_	14	p	_	_
22	because	because	IN	_	24	mark	_	_
23	drug4	drug0	NN	_	24	dep	_	_
24	amplifies	amplify	VBZ	_	14	comp	_	_
25	the	the	DT	_	27	det	_	_
26	therapeutic	therapeutic	JJ	_	27	attr	_	_
27	actions	action	NNS	_	24	obj	_	_
28	and	and	CC	_	27	cc	_	_
29	side-effects	side-effect	NNS	_	27	conj	_	_
30	of	of	IN	_	32	case	_	_
31	drug5	drug0	NN	_	32	com	_	_
32	massively	massively	NN	_	27	ppmod	_	_
33	.	.	.	_	14	p	_	_

1	Avoid	avoid	VB	_	0	root	_	_
2	the	the	DT	_	4	det	_	_
3	concomitant	concomitant	JJ	_	4	attr	_	_
4	use	use	NN	_	1	obj	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	drug3	drug0	NN	_	1	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	.	.	.	_	1	p	_	_

1	Massive	massive	JJ	_	2	attr	_	_
2	seizures	seizure	NNS	_	5	dep	_	_
3	may	may	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	encountered	encounter	VBN	_	0	root	_	_
6	with	with	IN	_	8	case	_	_
7	this	this	DT	_	8	det	_	_
8	combination	combination	NN	_	5	ppmod	_	_
9	.	.	.	_	5	p	_	_

1	Consider	consider	VB	_	0	root	_	_
2	additive	additive	JJ	_	4	attr	_	_
3	sedative	sedative	JJ	_	4	attr	_	_
4	effects	effect	NNS	_	9	dep	_	_
5	and	and	CC	_	4	cc	_	_
6	confusional	confusional	JJ	_	7	attr	_	_
7	states	state	NNS	_	4	conj	_	_
8	to	to	TO	_	9	aux	_	_
9	emerge	emerge	VB	_	1	comp	_	_
10	,	,	,	_	1	p	_	_
11	if	if	IN	_	14	mark	_	_
12	drug1	drug0	NN	_	14	dep	_	_
13	is	be	VBZ	_	14	aux	_	_
14	given	give	VBN	_	1	comp	_	_
15	with	with	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	or	or	CC	_	16	cc	_	_
18	drug3	drug0	NN	_	16	conj	_	_
19	.	.	.	_	1	p	_	_

1	Choose	choose	VBP	_	0	root	_	_
2	particular	particular	JJ	_	4	attr	_	_
3	low	low	JJ	_	4	attr	_	_
4	doses	dose	NNS	_	1	obj	_	_
5	of	of	IN	_	7	case	_	_
6	these	these	DT	_	7	det	_	_
7	drugs	drug	NNS	_	4	ppmod	_	_
8	.	.	.	_	1	p	_	_

1	Exert	exert	VBP	_	20	advcl	_	_
2	particular	particular	JJ	_	3	attr	_	_
3	caution	caution	NN	_	1	obj	_	_
4	in	in	IN	_	5	case	_	_
5	combining	combine	VBG	_	1	ppmod	_	_
6	drug1	drug0	NN	_	5	obj	_	_
7	with	with	IN	_	9	case	_	_
8	other	other	JJ	_	9	attr	_	_
9	drug2	drug0	NNS	_	5	ppmod	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	drug3	drug0	NN	_	9	prn	_	_
12	and	and	CC	_	11	cc	_	_
13	drug4	drug0	NN	_	11	conj	_	_
14	)	-rrb-	-RRB-	_	11	p	_	_
15	:	:	:	_	20	p	_	_
16	Particularly	particularly	RB	_	18	adv	_	_
17	the	the	DT	_	18	det	_	_
18	elderly	elderly	JJ	_	20	dep	_	_
19	may	may	MD	_	20	modal	_	_
20	develop	develop	VB	_	0	root	_	_
21	delirium	delirium	NN	_	20	obj	_	_
22	,	,	,	_	21	p	_	_
23	high	high	JJ	_	24	attr	_	_
24	fever	fever	NN	_	21	conj	_	_
25	,	,	,	_	24	p	_	_
26	severe	severe	JJ	_	27	attr	_	_
27	obstipation	obstipation	NN	_	21	conj	_	_
28	,	,	,	_	27	p	_	_
29	even	even	JJ	_	30	attr	_	_
30	ileus	ileus	NN	_	21	conj	_	_
31	and	and	CC	_	30	cc	_	_
32	glaucoma	glaucoma	NN	_	21	conj	_	_
33	.	.	.	_	20	p	_	_

1	There	there	EX	_	3	dep	_	_
2	have	have	VBP	_	3	aux	_	_
3	been	be	VBN	_	0	root	_	_
4	rare	rare	JJ	_	5	attr	_	_
5	reports	report	NNS	_	3	obj	_	_
6	of	of	IN	_	9	case	_	_
7	significant	significant	JJ	_	9	attr	_	_
8	respiratory	respiratory	JJ	_	9	attr	_	_
9	depression	depression	NN	_	5	ppmod	_	_
10	,	,	,	_	9	p	_	_
11	stupor	stupor	NN	_	9	conj	_	_
12	and/or	and/or	CC	_	11	cc	_	_
13	hypotension	hypotension	NN	_	9	conj	_	_
14	with	with	IN	_	17	case	_	_
15	the	the	DT	_	17	det	_	_
16	concomitant	concomitant	JJ	_	17	attr	_	_
17	use	use	NN	_	5	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug1	drug0	NN	_	17	ppmod	_	_
20	and	and	CC	_	19	cc	_	_
21	drug2	drug0	NN	_	19	conj	_	_
22	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	risk	risk	NN	_	15	dep	_	_
3	of	of	IN	_	4	case	_	_
4	using	use	VBG	_	2	ppmod	_	_
5	drug1	drug0	NN	_	4	obj	_	_
6	in	in	IN	_	7	case	_	_
7	combination	combination	NN	_	4	ppmod	_	_
8	with	with	IN	_	10	case	_	_
9	CNS-active	cns-active	JJ	_	10	attr	_	_
10	drugs	drug	NNS	_	7	ppmod	_	_
11	has	have	VBZ	_	15	aux	_	_
12	not	not	RB	_	15	neg	_	_
13	been	be	VBN	_	15	aux	_	_
14	systematically	systematically	RB	_	15	adv	_	_
15	evaluated	evaluate	VBN	_	0	root	_	_
16	.	.	.	_	15	p	_	_

1	Therefore	therefore	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	caution	caution	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	advised	advise	VBN	_	0	root	_	_
6	if	if	IN	_	16	mark	_	_
7	the	the	DT	_	9	det	_	_
8	concomitant	concomitant	JJ	_	9	attr	_	_
9	administration	administration	NN	_	16	dep	_	_
10	of	of	IN	_	14	case	_	_
11	drug1	drug0	JJ	_	14	attr	_	_
12	and	and	CC	_	11	cc	_	_
13	CNS-active	cns-active	JJ	_	11	conj	_	_
14	drugs	drug	NNS	_	9	ppmod	_	_
15	is	be	VBZ	_	16	aux	_	_
16	required	require	VBN	_	5	comp	_	_
17	.	.	.	_	5	p	_	_

1	No	no	DT	_	5	det	_	_
2	pharmacokinetic	pharmacokinetic	JJ	_	5	attr	_	_
3	drug-drug	drug-drug	JJ	_	5	attr	_	_
4	interaction	interaction	NN	_	5	com	_	_
5	studies	study	NNS	_	7	dep	_	_
6	were	be	VBD	_	7	aux	_	_
7	conducted	conduct	VBN	_	0	root	_	_
8	with	with	IN	_	14	case	_	_
9	drug1	drug0	NN	_	14	attr	_	_
10	(	-lrb-	-LRB-	_	14	p	_	_
11	drug2	drug0	NN	_	14	attr	_	_
12	USP	usp	NN	_	14	attr	_	_
13	)	-rrb-	-RRB-	_	14	p	_	_
14	Tablets	tablet	NNS	_	7	ppmod	_	_
15	.	.	.	_	7	p	_	_

1	The	the	DT	_	3	det	_	_
2	following	follow	VBG	_	3	attr	_	_
3	information	information	NN	_	5	dep	_	_
4	was	be	VBD	_	5	aux	_	_
5	obtained	obtain	VBN	_	0	root	_	_
6	from	from	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	literature	literature	NN	_	5	ppmod	_	_
9	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	6	dep	_	_
4	has	have	VBZ	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	reported	report	VBN	_	1	acl	_	_
7	to	to	TO	_	8	aux	_	_
8	increase	increase	VB	_	6	comp	_	_
9	the	the	DT	_	11	det	_	_
10	plasma	plasma	NN	_	11	com	_	_
11	levels	level	NNS	_	8	obj	_	_
12	and	and	CC	_	8	cc	_	_
13	cardiovascular	cardiovascular	VB	_	8	conj	_	_
14	effects	effect	NNS	_	13	obj	_	_
15	of	of	IN	_	16	case	_	_
16	drug3	drug0	NN	_	14	ppmod	_	_
17	.	.	.	_	1	p	_	_

1	Adjustment	adjustment	NN	_	6	dep	_	_
2	of	of	IN	_	4	case	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	dosage	dosage	NN	_	1	ppmod	_	_
5	may	may	MD	_	6	modal	_	_
6	be	be	VB	_	0	root	_	_
7	necessary	necessary	JJ	_	6	dep	_	_
8	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	may	may	MD	_	5	modal	_	_
5	counteract	counteract	VB	_	0	root	_	_
6	the	the	DT	_	8	det	_	_
7	anticholinesterase	anticholinesterase	NN	_	8	com	_	_
8	effect	effect	NN	_	5	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug3	drug0	NN	_	8	ppmod	_	_
11	,	,	,	_	5	p	_	_
12	thereby	thereby	RB	_	14	adv	_	_
13	potentially	potentially	RB	_	14	adv	_	_
14	aggravating	aggravate	VBG	_	5	comp	_	_
15	myasthenia	myasthenia	NN	_	16	com	_	_
16	gravis	gravis	NN	_	14	obj	_	_
17	.	.	.	_	5	p	_	_

1	If	if	IN	_	9	mark	_	_
2	drug1	drug0	NN	_	9	dep	_	_
3	or	or	CC	_	2	cc	_	_
4	other	other	JJ	_	7	attr	_	_
5	hepatic	hepatic	JJ	_	7	attr	_	_
6	enzyme	enzyme	NN	_	7	com	_	_
7	inducers	inducer	NNS	_	2	conj	_	_
8	are	be	VBP	_	9	aux	_	_
9	taken	take	VBN	_	22	advcl	_	_
10	concurrently	concurrently	RB	_	9	adv	_	_
11	with	with	IN	_	12	case	_	_
12	drug2	drug0	NN	_	9	ppmod	_	_
13	or	or	CC	_	12	cc	_	_
14	drug3	drug0	NN	_	12	conj	_	_
15	,	,	,	_	22	p	_	_
16	lower	low	JJR	_	18	attr	_	_
17	plasma	plasma	NN	_	18	com	_	_
18	levels	level	NNS	_	22	dep	_	_
19	of	of	IN	_	20	case	_	_
20	drug4	drug0	NN	_	18	ppmod	_	_
21	may	may	MD	_	22	modal	_	_
22	occur	occur	VB	_	0	root	_	_
23	.	.	.	_	22	p	_	_

1	Monitoring	monitoring	NN	_	7	dep	_	_
2	of	of	IN	_	5	case	_	_
3	drug1	drug0	NN	_	5	com	_	_
4	plasma	plasma	NN	_	5	com	_	_
5	levels	level	NNS	_	1	ppmod	_	_
6	is	be	VBZ	_	7	aux	_	_
7	recommended	recommend	VBN	_	0	root	_	_
8	in	in	IN	_	11	case	_	_
9	such	such	JJ	_	11	attr	_	_
10	concurrent	concurrent	JJ	_	11	attr	_	_
11	use	use	NN	_	7	ppmod	_	_
12	to	to	TO	_	13	aux	_	_
13	avoid	avoid	VB	_	7	comp	_	_
14	ineffective	ineffective	JJ	_	15	attr	_	_
15	therapy	therapy	NN	_	13	obj	_	_
16	.	.	.	_	7	p	_	_

1	Other	other	JJ	_	2	attr	_	_
2	drug1	drug0	NNS	_	17	dep	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	eg	eg	NN	_	2	prn	_	_
5	,	,	,	_	4	p	_	_
6	drug2	drug0	NN	_	4	appo	_	_
7	,	,	,	_	4	p	_	_
8	drug3	drug0	NN	_	4	appo	_	_
9	,	,	,	_	4	p	_	_
10	drug4	drug0	NN	_	4	appo	_	_
11	,	,	,	_	4	p	_	_
12	drug5	drug0	NN	_	4	appo	_	_
13	)	-rrb-	-RRB-	_	4	p	_	_
14	have	have	VBP	_	17	aux	_	_
15	occasionally	occasionally	RB	_	17	adv	_	_
16	been	be	VBN	_	17	aux	_	_
17	used	use	VBN	_	0	root	_	_
18	concurrently	concurrently	RB	_	17	adv	_	_
19	with	with	IN	_	20	case	_	_
20	drug6	drug0	NN	_	17	ppmod	_	_
21	.	.	.	_	17	p	_	_

1	Excessive	excessive	JJ	_	2	attr	_	_
2	widening	widening	NN	_	14	dep	_	_
3	of	of	IN	_	6	case	_	_
4	the	the	DT	_	6	det	_	_
5	QRS	qrs	NN	_	6	com	_	_
6	complex	complex	NN	_	2	ppmod	_	_
7	and/or	and/or	CC	_	2	cc	_	_
8	prolongation	prolongation	NN	_	2	conj	_	_
9	of	of	IN	_	12	case	_	_
10	the	the	DT	_	12	det	_	_
11	Q-T	q-t	JJ	_	12	attr	_	_
12	interval	interval	NNS	_	8	ppmod	_	_
13	may	may	MD	_	14	modal	_	_
14	occur	occur	VB	_	0	root	_	_
15	in	in	IN	_	17	case	_	_
16	these	these	DT	_	17	det	_	_
17	situations	situation	NNS	_	14	ppmod	_	_
18	.	.	.	_	14	p	_	_

1	In	in	IN	_	3	case	_	_
2	healthy	healthy	JJ	_	3	attr	_	_
3	subjects	subject	NNS	_	10	ppmod	_	_
4	,	,	,	_	10	p	_	_
5	no	no	DT	_	8	det	_	_
6	significant	significant	JJ	_	8	attr	_	_
7	drug-drug	drug-drug	JJ	_	8	attr	_	_
8	interaction	interaction	NN	_	10	dep	_	_
9	was	be	VBD	_	10	aux	_	_
10	observed	observe	VBN	_	0	root	_	_
11	when	when	WRB	_	14	adv	_	_
12	drug1	drug0	NN	_	14	dep	_	_
13	was	be	VBD	_	14	aux	_	_
14	coadministered	coadministered	VBN	_	10	comp	_	_
15	with	with	IN	_	17	case	_	_
16	either	either	CC	_	17	cc	_	_
17	drug2	drug0	NN	_	14	ppmod	_	_
18	or	or	CC	_	17	cc	_	_
19	drug3	drug0	NN	_	17	conj	_	_
20	.	.	.	_	10	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	administration	administration	NN	_	7	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	resulted	result	VBD	_	0	root	_	_
8	in	in	IN	_	10	case	_	_
9	slight	slight	JJ	_	10	attr	_	_
10	increases	increase	NNS	_	7	ppmod	_	_
11	in	in	IN	_	14	case	_	_
12	plasma	plasma	NN	_	14	com	_	_
13	drug3	drug0	NN	_	14	com	_	_
14	levels	level	NNS	_	10	ppmod	_	_
15	and	and	CC	_	10	cc	_	_
16	slight	slight	JJ	_	17	attr	_	_
17	decreases	decrease	NNS	_	10	conj	_	_
18	in	in	IN	_	21	case	_	_
19	plasma	plasma	NN	_	21	com	_	_
20	drug4	drug0	NN	_	21	com	_	_
21	levels	level	NNS	_	17	ppmod	_	_
22	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	does	do	VBZ	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	increase	increase	VB	_	0	root	_	_
5	serum	serum	NN	_	7	com	_	_
6	drug2	drug0	NN	_	7	com	_	_
7	levels	level	NNS	_	4	obj	_	_
8	.	.	.	_	4	p	_	_

1	Patients	patient	NNS	_	8	dep	_	_
2	taking	take	VBG	_	1	acl	_	_
3	drug1	drug0	NN	_	2	obj	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	concomitantly	concomitantly	RB	_	3	adv	_	_
7	may	may	MD	_	8	modal	_	_
8	develop	develop	VB	_	0	root	_	_
9	increased	increase	VBN	_	11	attr	_	_
10	serum	serum	NN	_	11	com	_	_
11	concentrations	concentration	NNS	_	8	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug3	drug0	NN	_	11	ppmod	_	_
14	resulting	result	VBG	_	13	acl	_	_
15	in	in	IN	_	17	case	_	_
16	excessive	excessive	JJ	_	17	attr	_	_
17	widening	widening	NN	_	14	ppmod	_	_
18	of	of	IN	_	21	case	_	_
19	the	the	DT	_	21	det	_	_
20	QRS	qrs	NN	_	21	com	_	_
21	complex	complex	NN	_	17	ppmod	_	_
22	and/or	and/or	CC	_	17	cc	_	_
23	prolongation	prolongation	NN	_	17	conj	_	_
24	of	of	IN	_	27	case	_	_
25	the	the	DT	_	27	det	_	_
26	Q-T	q-t	JJ	_	27	attr	_	_
27	interval	interval	NN	_	23	ppmod	_	_
28	.	.	.	_	8	p	_	_

1	Patients	patient	NNS	_	12	dep	_	_
2	taking	take	VBG	_	1	acl	_	_
3	drug1	drug0	JJ	_	7	attr	_	_
4	and	and	CC	_	3	cc	_	_
5	hepatic	hepatic	JJ	_	3	conj	_	_
6	enzyme	enzyme	NN	_	7	com	_	_
7	inhibitors	inhibitor	NNS	_	2	obj	_	_
8	concomitantly	concomitantly	RB	_	12	adv	_	_
9	should	should	MD	_	12	modal	_	_
10	be	be	VB	_	12	aux	_	_
11	closely	closely	RB	_	12	adv	_	_
12	monitored	monitor	VBN	_	0	root	_	_
13	.	.	.	_	12	p	_	_

1	Until	until	IN	_	11	mark	_	_
2	data	datum	NNS	_	11	dep	_	_
3	on	on	IN	_	5	case	_	_
4	possible	possible	JJ	_	5	attr	_	_
5	interactions	interaction	NNS	_	2	ppmod	_	_
6	between	between	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	are	be	VBP	_	11	aux	_	_
11	obtained	obtain	VBN	_	17	advcl	_	_
12	,	,	,	_	17	p	_	_
13	drug3	drug0	NN	_	17	dep	_	_
14	should	should	MD	_	17	modal	_	_
15	not	not	RB	_	17	neg	_	_
16	be	be	VB	_	17	aux	_	_
17	administered	administer	VBN	_	0	root	_	_
18	within	within	IN	_	20	case	_	_
19	48	0	CD	_	20	num	_	_
20	hours	hour	NNS	_	17	ppmod	_	_
21	before	before	IN	_	20	case	_	_
22	or	or	CC	_	20	cc	_	_
23	24	0	CD	_	24	num	_	_
24	hours	hour	NNS	_	20	conj	_	_
25	after	after	IN	_	27	case	_	_
26	drug4	drug0	NN	_	27	com	_	_
27	administration	administration	NN	_	24	ppmod	_	_
28	.	.	.	_	17	p	_	_

1	The	the	DT	_	2	det	_	_
2	potential	potential	NN	_	15	dep	_	_
3	for	for	IN	_	5	case	_	_
4	increased	increase	VBN	_	5	attr	_	_
5	sedation	sedation	NN	_	2	ppmod	_	_
6	when	when	WRB	_	9	adv	_	_
7	drug1	drug0	NN	_	9	dep	_	_
8	is	be	VBZ	_	9	aux	_	_
9	given	give	VBN	_	5	relcl	_	_
10	with	with	IN	_	12	case	_	_
11	other	other	JJ	_	12	attr	_	_
12	drug2	drug0	NN	_	9	ppmod	_	_
13	should	should	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	appreciated	appreciate	VBN	_	0	root	_	_
16	.	.	.	_	15	p	_	_

1	The	the	DT	_	2	det	_	_
2	administration	administration	NN	_	23	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	concomitantly	concomitantly	RB	_	10	adv	_	_
6	with	with	IN	_	10	case	_	_
7	known	known	JJ	_	10	attr	_	_
8	microsomal	microsomal	JJ	_	10	attr	_	_
9	enzyme	enzyme	NN	_	10	com	_	_
10	inducer	inducer	NN	_	2	ppmod	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	drug2	drug0	NN	_	10	prn	_	_
13	or	or	CC	_	12	cc	_	_
14	drug3	drug0	NN	_	12	conj	_	_
15	)	-rrb-	-RRB-	_	12	p	_	_
16	to	to	TO	_	18	aux	_	_
17	two	#crd#	CD	_	18	num	_	_
18	patients	patient	NNS	_	2	ppmod	_	_
19	with	with	IN	_	21	case	_	_
20	renal	renal	JJ	_	21	attr	_	_
21	impairment	impairment	NN	_	18	ppmod	_	_
22	reportedly	reportedly	RB	_	23	adv	_	_
23	resulted	result	VBD	_	0	root	_	_
24	in	in	IN	_	26	case	_	_
25	significant	significant	JJ	_	26	attr	_	_
26	reductions	reduction	NNS	_	23	ppmod	_	_
27	in	in	IN	_	29	case	_	_
28	elimination	elimination	NN	_	29	com	_	_
29	half-life	half-life	NN	_	26	ppmod	_	_
30	and	and	CC	_	29	cc	_	_
31	plasma	plasma	NN	_	32	com	_	_
32	concentration	concentration	NN	_	29	conj	_	_
33	.	.	.	_	23	p	_	_

1	In	in	IN	_	3	case	_	_
2	such	such	JJ	_	3	attr	_	_
3	cases	case	NNS	_	12	ppmod	_	_
4	,	,	,	_	12	p	_	_
5	therefore	therefore	RB	_	12	adv	_	_
6	,	,	,	_	12	p	_	_
7	more	more	RBR	_	8	adv	_	_
8	frequent	frequent	JJ	_	9	attr	_	_
9	dosing	dosing	NN	_	12	dep	_	_
10	may	may	MD	_	12	modal	_	_
11	be	be	VB	_	12	aux	_	_
12	required	require	VBN	_	0	root	_	_
13	to	to	TO	_	14	aux	_	_
14	achieve	achieve	VB	_	12	comp	_	_
15	or	or	CC	_	14	cc	_	_
16	maintain	maintain	VB	_	14	conj	_	_
17	the	the	DT	_	20	det	_	_
18	desired	desired	JJ	_	20	attr	_	_
19	hypotensive	hypotensive	JJ	_	20	attr	_	_
20	response	response	NN	_	16	obj	_	_
21	.	.	.	_	12	p	_	_

1	Further	far	RB	_	19	adv	_	_
2	,	,	,	_	19	p	_	_
3	if	if	IN	_	5	mark	_	_
4	drug1	drug0	NN	_	5	dep	_	_
5	is	be	VBZ	_	19	advcl	_	_
6	to	to	TO	_	8	aux	_	_
7	be	be	VB	_	8	aux	_	_
8	discontinued	discontinue	VBN	_	5	comp	_	_
9	in	in	IN	_	11	case	_	_
10	such	such	JJ	_	11	attr	_	_
11	patients	patient	NNS	_	8	ppmod	_	_
12	,	,	,	_	19	p	_	_
13	careful	careful	JJ	_	14	attr	_	_
14	tapering	tapering	NN	_	19	dep	_	_
15	of	of	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	dosage	dosage	NN	_	14	ppmod	_	_
18	may	may	MD	_	19	modal	_	_
19	be	be	VB	_	0	root	_	_
20	necessary	necessary	JJ	_	19	dep	_	_
21	in	in	IN	_	24	mark	_	_
22	order	order	NN	_	24	dep	_	_
23	to	to	TO	_	24	aux	_	_
24	avoid	avoid	VB	_	19	comp	_	_
25	rebound	rebound	JJ	_	26	attr	_	_
26	phenomena	phenomenon	NNS	_	24	obj	_	_
27	.	.	.	_	19	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	decrease	decrease	VBP	_	0	root	_	_
3	the	the	DT	_	5	det	_	_
4	hypotensive	hypotensive	JJ	_	5	attr	_	_
5	effect	effect	NN	_	2	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	10	dep	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	drug2	drug0	NN	_	1	prn	_	_
4	,	,	,	_	3	p	_	_
5	porpranolol	porpranolol	NN	_	3	appo	_	_
6	,	,	,	_	3	p	_	_
7	drug3	drug0	NN	_	3	appo	_	_
8	)	-rrb-	-RRB-	_	3	p	_	_
9	may	may	MD	_	10	modal	_	_
10	exacerbate	exacerbate	VB	_	0	root	_	_
11	rebound	rebound	JJ	_	12	attr	_	_
12	hypertension	hypertension	NN	_	10	obj	_	_
13	when	when	WRB	_	16	adv	_	_
14	drug4	drug0	NN	_	16	dep	_	_
15	is	be	VBZ	_	16	aux	_	_
16	withdrawn	withdraw	VBN	_	10	comp	_	_
17	.	.	.	_	10	p	_	_

1	The	the	DT	_	2	det	_	_
2	drug1	drug0	NN	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	withdrawn	withdraw	VBN	_	0	root	_	_
6	first	#ord#	RB	_	5	adv	_	_
7	.	.	.	_	5	p	_	_

1	The	the	DT	_	3	det	_	_
2	gradual	gradual	JJ	_	3	attr	_	_
3	withdrawal	withdrawal	NN	_	11	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	or	or	CC	_	5	cc	_	_
7	a	a	DT	_	8	det	_	_
8	drug2	drug0	NN	_	5	conj	_	_
9	could	could	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	substituted	substitute	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	4	attr	_	_
2	:	:	:	_	4	p	_	_
3	Ten	#crd#	CD	_	4	num	_	_
4	patients	patient	NNS	_	12	dep	_	_
5	who	who	WP	_	7	dep	_	_
6	were	be	VBD	_	7	aux	_	_
7	stabilized	stabilize	VBN	_	4	relcl	_	_
8	on	on	IN	_	10	case	_	_
9	oral	oral	JJ	_	10	attr	_	_
10	drug2	drug0	NN	_	7	ppmod	_	_
11	were	be	VBD	_	12	aux	_	_
12	given	give	VBN	_	0	root	_	_
13	drug3	drug0	NN	_	12	obj	_	_
14	,	,	,	_	13	p	_	_
15	1-2	0	CD	_	16	num	_	_
16	mg/day	mg/day	NN	_	13	appo	_	_
17	,	,	,	_	13	p	_	_
18	for	for	IN	_	20	case	_	_
19	4	0	CD	_	20	num	_	_
20	weeks	week	NNS	_	12	ppmod	_	_
21	.	.	.	_	12	p	_	_

1	No	no	DT	_	2	det	_	_
2	changes	change	NNS	_	4	dep	_	_
3	were	be	VBD	_	4	aux	_	_
4	observed	observe	VBN	_	0	root	_	_
5	in	in	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	degree	degree	NN	_	4	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	anticoagulation	anticoagulation	NN	_	7	ppmod	_	_
10	.	.	.	_	4	p	_	_

1	In	in	IN	_	4	case	_	_
2	several	several	JJ	_	4	attr	_	_
3	well-controlled	well-controlled	JJ	_	4	attr	_	_
4	studies	study	NNS	_	8	ppmod	_	_
5	,	,	,	_	8	p	_	_
6	drug1	drug0	NN	_	8	dep	_	_
7	was	be	VBD	_	8	aux	_	_
8	administered	administer	VBN	_	0	root	_	_
9	together	together	RB	_	8	adv	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NN	_	8	ppmod	_	_
12	with	with	IN	_	15	case	_	_
13	no	no	DT	_	15	det	_	_
14	drug	drug	NN	_	15	com	_	_
15	interactions	interaction	NNS	_	8	ppmod	_	_
16	reported	report	VBN	_	15	acl	_	_
17	.	.	.	_	8	p	_	_

1	In	in	IN	_	5	case	_	_
2	the	the	DT	_	5	det	_	_
3	long-term	long-term	JJ	_	5	attr	_	_
4	safety	safety	NN	_	5	com	_	_
5	studies	study	NNS	_	9	ppmod	_	_
6	,	,	,	_	9	p	_	_
7	drug1	drug0	NN	_	9	dep	_	_
8	was	be	VBD	_	9	aux	_	_
9	given	give	VBN	_	0	root	_	_
10	concomitantly	concomitantly	RB	_	9	adv	_	_
11	with	with	IN	_	13	case	_	_
12	many	many	JJ	_	13	attr	_	_
13	drugs	drug	NNS	_	9	ppmod	_	_
14	without	without	IN	_	15	case	_	_
15	evidence	evidence	NN	_	9	ppmod	_	_
16	of	of	IN	_	18	case	_	_
17	any	any	DT	_	18	det	_	_
18	interactions	interaction	NNS	_	15	ppmod	_	_
19	.	.	.	_	9	p	_	_

1	The	the	DT	_	3	det	_	_
2	principal	principal	JJ	_	3	attr	_	_
3	drugs	drug	NNS	_	12	dep	_	_
4	given	give	VBN	_	3	acl	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	number	number	NN	_	4	prn	_	_
7	of	of	IN	_	8	case	_	_
8	patients	patient	NNS	_	6	ppmod	_	_
9	in	in	IN	_	10	case	_	_
10	parentheses	parenthesis	NNS	_	8	ppmod	_	_
11	)	-rrb-	-RRB-	_	6	p	_	_
12	were	be	VBD	_	0	root	_	_
13	:	:	:	_	12	p	_	_
14	drug1	drug0	NN	_	12	dep	_	_
15	(	-lrb-	-LRB-	_	14	p	_	_
16	115	0	CD	_	14	num	_	_
17	)	-rrb-	-RRB-	_	14	p	_	_
18	,	,	,	_	14	p	_	_
19	drug2	drug0	NN	_	14	conj	_	_
20	and	and	CC	_	19	cc	_	_
21	drug3	drug0	NN	_	14	conj	_	_
22	(	-lrb-	-LRB-	_	21	p	_	_
23	103	0	CD	_	21	num	_	_
24	)	-rrb-	-RRB-	_	21	p	_	_
25	,	,	,	_	21	p	_	_
26	drug4	drug0	NN	_	21	conj	_	_
27	(	-lrb-	-LRB-	_	26	p	_	_
28	52	0	CD	_	26	num	_	_
29	)	-rrb-	-RRB-	_	26	p	_	_
30	,	,	,	_	26	p	_	_
31	oral	oral	JJ	_	32	attr	_	_
32	drug5	drug0	NN	_	21	conj	_	_
33	(	-lrb-	-LRB-	_	34	p	_	_
34	45	0	CD	_	32	num	_	_
35	)	-rrb-	-RRB-	_	34	p	_	_
36	,	,	,	_	32	p	_	_
37	cough	cough	NN	_	21	conj	_	_
38	and	and	CC	_	37	cc	_	_
39	cold	cold	JJ	_	40	attr	_	_
40	preparations	preparation	NNS	_	21	conj	_	_
41	(	-lrb-	-LRB-	_	42	p	_	_
42	45	0	CD	_	21	num	_	_
43	)	-rrb-	-RRB-	_	42	p	_	_
44	,	,	,	_	14	p	_	_
45	drug6	drug0	NN	_	14	conj	_	_
46	(	-lrb-	-LRB-	_	45	p	_	_
47	38	0	CD	_	45	num	_	_
48	)	-rrb-	-RRB-	_	45	p	_	_
49	,	,	,	_	45	p	_	_
50	drug7	drug0	NN	_	14	conj	_	_
51	(	-lrb-	-LRB-	_	50	p	_	_
52	29	0	CD	_	50	num	_	_
53	)	-rrb-	-RRB-	_	50	p	_	_
54	,	,	,	_	50	p	_	_
55	drug8	drug0	NN	_	14	conj	_	_
56	(	-lrb-	-LRB-	_	55	p	_	_
57	24	0	CD	_	55	num	_	_
58	)	-rrb-	-RRB-	_	55	p	_	_
59	,	,	,	_	55	p	_	_
60	oral	oral	JJ	_	61	attr	_	_
61	drug9	drug0	NN	_	14	conj	_	_
62	(	-lrb-	-LRB-	_	63	p	_	_
63	18	0	CD	_	61	num	_	_
64	)	-rrb-	-RRB-	_	63	p	_	_
65	,	,	,	_	61	p	_	_
66	drug10	drug0	NN	_	14	conj	_	_
67	(	-lrb-	-LRB-	_	66	p	_	_
68	13	0	CD	_	66	num	_	_
69	)	-rrb-	-RRB-	_	66	p	_	_
70	,	,	,	_	66	p	_	_
71	drug11	drug0	NN	_	14	conj	_	_
72	(	-lrb-	-LRB-	_	71	p	_	_
73	10	0	CD	_	71	num	_	_
74	)	-rrb-	-RRB-	_	71	p	_	_
75	,	,	,	_	71	p	_	_
76	and	and	CC	_	71	cc	_	_
77	drug12	drug0	NN	_	14	conj	_	_
78	(	-lrb-	-LRB-	_	77	p	_	_
79	10	0	CD	_	77	num	_	_
80	)	-rrb-	-RRB-	_	77	p	_	_
81	.	.	.	_	12	p	_	_

1	Laboratory	laboratory	NN	_	2	com	_	_
2	Test	test	NN	_	14	dep	_	_
3	In	in	IN	_	5	case	_	_
4	clinical	clinical	JJ	_	5	attr	_	_
5	trials	trial	NNS	_	2	ppmod	_	_
6	,	,	,	_	5	p	_	_
7	no	no	DT	_	12	det	_	_
8	clinically	clinically	RB	_	9	adv	_	_
9	relevant	relevant	JJ	_	12	attr	_	_
10	laboratory	laboratory	NN	_	12	com	_	_
11	test	test	NN	_	12	com	_	_
12	abnormalities	abnormality	NNS	_	5	appo	_	_
13	were	be	VBD	_	14	aux	_	_
14	identified	identify	VBN	_	0	root	_	_
15	as	as	IN	_	17	case	_	_
16	causally	causally	RB	_	17	adv	_	_
17	related	related	JJ	_	14	ppmod	_	_
18	to	to	TO	_	19	aux	_	_
19	drug	drug	NN	_	17	ppmod	_	_
20	during	during	IN	_	22	case	_	_
21	short-term	short-term	JJ	_	22	attr	_	_
22	treatment	treatment	NN	_	19	ppmod	_	_
23	with	with	IN	_	24	case	_	_
24	drug1	drug0	NN	_	22	ppmod	_	_
25	.	.	.	_	14	p	_	_

1	Drug/Laboratory	drug/laboratory	JJ	_	7	attr	_	_
2	Test	test	NN	_	7	com	_	_
3	Interactions	interaction	NNS	_	7	com	_	_
4	No	no	NN	_	7	com	_	_
5	laboratory	laboratory	NN	_	7	com	_	_
6	test	test	NN	_	7	com	_	_
7	abnormalities	abnormality	NNS	_	16	dep	_	_
8	related	related	JJ	_	7	attr	_	_
9	to	to	TO	_	11	aux	_	_
10	the	the	DT	_	11	det	_	_
11	use	use	NN	_	8	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	have	have	VBP	_	16	aux	_	_
15	been	be	VBN	_	16	aux	_	_
16	identified	identify	VBN	_	0	root	_	_
17	.	.	.	_	16	p	_	_

1	The	the	DT	_	2	det	_	_
2	interaction	interaction	NN	_	14	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	with	with	IN	_	10	case	_	_
6	other	other	JJ	_	10	attr	_	_
7	cardioactive	cardioactive	JJ	_	10	attr	_	_
8	or	or	CC	_	7	cc	_	_
9	cerebroactive	cerebroactive	JJ	_	7	conj	_	_
10	drugs	drug	NNS	_	2	ppmod	_	_
11	has	have	VBZ	_	14	aux	_	_
12	not	not	RB	_	14	neg	_	_
13	been	be	VBN	_	14	aux	_	_
14	studied	study	VBN	_	0	root	_	_
15	.	.	.	_	14	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	26	ppmod	_	_
3	to	to	TO	_	4	aux	_	_
4	bleeding	bleeding	JJ	_	2	ppmod	_	_
5	associated	associate	VBN	_	4	acl	_	_
6	with	with	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	,	,	,	_	26	p	_	_
11	drugs	drug	NNS	_	26	dep	_	_
12	that	that	WDT	_	13	dep	_	_
13	alter	alter	VBP	_	11	relcl	_	_
14	platelet	platelet	NN	_	15	com	_	_
15	function	function	NN	_	13	obj	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	such	such	JJ	_	13	prn	_	_
18	as	as	IN	_	19	case	_	_
19	drug3	drug0	NN	_	17	ppmod	_	_
20	,	,	,	_	19	p	_	_
21	drug4	drug0	NN	_	19	conj	_	_
22	and	and	CC	_	21	cc	_	_
23	drug5	drug0	NN	_	19	conj	_	_
24	)	-rrb-	-RRB-	_	17	p	_	_
25	may	may	MD	_	26	modal	_	_
26	increase	increase	VB	_	0	root	_	_
27	the	the	DT	_	28	det	_	_
28	risk	risk	NN	_	26	obj	_	_
29	of	of	IN	_	30	case	_	_
30	bleeding	bleeding	JJ	_	28	ppmod	_	_
31	if	if	IN	_	32	mark	_	_
32	administered	administer	VBN	_	30	acl	_	_
33	prior	prior	RB	_	32	adv	_	_
34	to	to	TO	_	33	ppmod	_	_
35	,	,	,	_	26	p	_	_
36	during	during	IN	_	26	ppmod	_	_
37	,	,	,	_	36	p	_	_
38	or	or	CC	_	36	cc	_	_
39	after	after	IN	_	41	case	_	_
40	drug6	drug0	NN	_	41	com	_	_
41	therapy	therapy	NN	_	36	conj	_	_
42	.	.	.	_	26	p	_	_

1	Use	use	NN	_	9	dep	_	_
2	of	of	IN	_	4	case	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	drug2	drug0	NN	_	1	ppmod	_	_
5	and	and	CC	_	1	cc	_	_
6	drug3	drug0	NN	_	1	conj	_	_
7	have	have	VBP	_	9	aux	_	_
8	been	be	VBN	_	9	aux	_	_
9	administered	administer	VBN	_	0	root	_	_
10	concomitantly	concomitantly	RB	_	9	adv	_	_
11	with	with	IN	_	14	case	_	_
12	and	and	CC	_	14	cc	_	_
13	following	follow	VBG	_	14	attr	_	_
14	infusions	infusion	NNS	_	9	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug4	drug0	NN	_	14	ppmod	_	_
17	in	in	IN	_	19	case	_	_
18	the	the	DT	_	19	det	_	_
19	management	management	NN	_	9	ppmod	_	_
20	of	of	IN	_	23	case	_	_
21	acute	acute	JJ	_	23	attr	_	_
22	myocardial	myocardial	JJ	_	23	attr	_	_
23	infarction	infarction	NN	_	19	ppmod	_	_
24	or	or	CC	_	23	cc	_	_
25	pulmonary	pulmonary	JJ	_	26	attr	_	_
26	embolism	embolism	NN	_	23	conj	_	_
27	.	.	.	_	9	p	_	_

1	Because	because	IN	_	9	mark	_	_
2	drug1	drug0	NN	_	9	dep	_	_
3	,	,	,	_	2	p	_	_
4	drug2	drug0	NN	_	2	conj	_	_
5	,	,	,	_	4	p	_	_
6	or	or	CC	_	4	cc	_	_
7	drug3	drug0	NN	_	2	conj	_	_
8	may	may	MD	_	9	modal	_	_
9	cause	cause	VB	_	17	advcl	_	_
10	bleeding	bleeding	JJ	_	11	attr	_	_
11	complications	complication	NNS	_	9	obj	_	_
12	,	,	,	_	17	p	_	_
13	careful	careful	JJ	_	14	attr	_	_
14	monitoring	monitoring	NN	_	17	dep	_	_
15	for	for	IN	_	16	case	_	_
16	bleeding	bleeding	JJ	_	14	ppmod	_	_
17	is	be	VBZ	_	0	root	_	_
18	advised	advised	JJ	_	17	dep	_	_
19	,	,	,	_	17	p	_	_
20	especially	especially	RB	_	24	adv	_	_
21	at	at	IN	_	24	case	_	_
22	arterial	arterial	JJ	_	24	attr	_	_
23	puncture	puncture	NN	_	24	com	_	_
24	sites	site	NNS	_	17	ppmod	_	_
25	.	.	.	_	17	p	_	_

1	The	the	DT	_	3	det	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	use	use	NN	_	17	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	or	or	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	during	during	IN	_	12	case	_	_
9	the	the	DT	_	12	det	_	_
10	first	#ord#	JJ	_	12	attr	_	_
11	24	0	CD	_	12	num	_	_
12	hours	hour	NNS	_	3	ppmod	_	_
13	following	follow	VBG	_	15	adv	_	_
14	symptom	symptom	NN	_	15	com	_	_
15	onset	onset	NN	_	12	ppmod	_	_
16	were	be	VBD	_	17	aux	_	_
17	prohibited	prohibit	VBD	_	0	root	_	_
18	in	in	IN	_	23	case	_	_
19	The	the	DT	_	23	det	_	_
20	NINDS	ninds	NN	_	23	attr	_	_
21	t-PA	t-pa	NN	_	23	attr	_	_
22	Stroke	stroke	JJ	_	23	attr	_	_
23	Trial	trial	NN	_	17	ppmod	_	_
24	.	.	.	_	17	p	_	_

1	The	the	DT	_	2	det	_	_
2	safety	safety	NN	_	16	dep	_	_
3	of	of	IN	_	6	case	_	_
4	such	such	JJ	_	6	attr	_	_
5	concomitant	concomitant	JJ	_	6	attr	_	_
6	use	use	NN	_	2	ppmod	_	_
7	with	with	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	for	for	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	management	management	NN	_	2	ppmod	_	_
12	of	of	IN	_	15	case	_	_
13	acute	acute	JJ	_	15	attr	_	_
14	ischemic	ischemic	JJ	_	15	attr	_	_
15	stroke	stroke	NN	_	11	ppmod	_	_
16	is	be	VBZ	_	0	root	_	_
17	unknown	unknown	JJ	_	16	dep	_	_
18	.	.	.	_	16	p	_	_

1	Drug-Drug	drug-drug	JJ	_	2	attr	_	_
2	Interactions	interaction	NNS	_	14	dep	_	_
3	Given	given	IN	_	7	case	_	_
4	the	the	DT	_	7	det	_	_
5	primary	primary	JJ	_	7	attr	_	_
6	CNS	cns	NN	_	7	com	_	_
7	effects	effect	NNS	_	14	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	14	p	_	_
11	caution	caution	NN	_	14	dep	_	_
12	should	should	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	used	use	VBN	_	0	root	_	_
15	when	when	WRB	_	18	adv	_	_
16	drug2	drug0	NN	_	18	dep	_	_
17	is	be	VBZ	_	18	aux	_	_
18	taken	take	VBN	_	14	comp	_	_
19	in	in	IN	_	20	case	_	_
20	combination	combination	NN	_	18	ppmod	_	_
21	with	with	IN	_	23	case	_	_
22	other	other	JJ	_	23	attr	_	_
23	drug3	drug0	NN	_	20	ppmod	_	_
24	and	and	CC	_	23	cc	_	_
25	drug4	drug0	NN	_	23	conj	_	_
26	.	.	.	_	14	p	_	_

1	Due	due	JJ	_	0	root	_	_
2	to	to	TO	_	3	aux	_	_
3	its	its	PRP$	_	1	ppmod	_	_

1	1-	0-	CD	_	4	num	_	_
2	adrenergic	adrenergic	JJ	_	4	attr	_	_
3	receptor	receptor	NN	_	4	com	_	_
4	antagonism	antagonism	NN	_	7	dep	_	_
5	,	,	,	_	4	p	_	_
6	drug1	drug0	NN	_	4	appo	_	_
7	has	have	VBZ	_	0	root	_	_
8	the	the	DT	_	9	det	_	_
9	potential	potential	NN	_	7	obj	_	_
10	to	to	TO	_	11	aux	_	_
11	enhance	enhance	VB	_	9	acl	_	_
12	the	the	DT	_	13	det	_	_
13	effect	effect	NN	_	11	obj	_	_
14	of	of	IN	_	16	case	_	_
15	certain	certain	JJ	_	16	attr	_	_
16	drug2	drug0	NNS	_	13	ppmod	_	_
17	.	.	.	_	7	p	_	_

1	Potential	potential	NN	_	9	dep	_	_
2	for	for	IN	_	4	case	_	_
3	Other	other	JJ	_	4	attr	_	_
4	Drugs	drug	NNS	_	1	ppmod	_	_
5	to	to	TO	_	8	aux	_	_
6	Affect	affect	NN	_	8	com	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	drug2	drug0	NNS	_	4	ppmod	_	_
9	is	be	VBZ	_	0	root	_	_
10	not	not	RB	_	9	neg	_	_
11	a	a	DT	_	12	det	_	_
12	substrate	substrate	NN	_	9	obj	_	_
13	of	of	IN	_	30	case	_	_
14	CYP1A1	cyp0a0	NN	_	30	attr	_	_
15	,	,	,	_	14	p	_	_
16	CYP1A2	cyp0a0	NN	_	14	conj	_	_
17	,	,	,	_	16	p	_	_
18	CYP2A6	cyp0a0	NN	_	14	conj	_	_
19	,	,	,	_	18	p	_	_
20	CYP2B6	cyp0b0	NN	_	14	conj	_	_
21	,	,	,	_	20	p	_	_
22	CYP2C8	cyp0c0	NN	_	14	conj	_	_
23	,	,	,	_	22	p	_	_
24	CYP2C9	cyp0c0	NN	_	14	conj	_	_
25	,	,	,	_	24	p	_	_
26	CYP2C19	cyp0c0	NN	_	14	conj	_	_
27	,	,	,	_	26	p	_	_
28	or	or	CC	_	26	cc	_	_
29	CYP2E1	cyp0e0	NN	_	14	conj	_	_
30	enzymes	enzyme	NNS	_	12	ppmod	_	_
31	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	also	also	RB	_	5	adv	_	_
3	does	do	VBZ	_	5	aux	_	_
4	not	not	RB	_	5	neg	_	_
5	undergo	undergo	VB	_	0	root	_	_
6	direct	direct	JJ	_	7	attr	_	_
7	glucuronidation	glucuronidation	NN	_	5	obj	_	_
8	.	.	.	_	5	p	_	_

1	This	this	DT	_	2	dep	_	_
2	suggests	suggest	VBZ	_	0	root	_	_
3	that	that	IN	_	23	mark	_	_
4	an	an	DT	_	5	det	_	_
5	interaction	interaction	NN	_	23	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	with	with	IN	_	9	case	_	_
9	inhibitors	inhibitor	NNS	_	5	ppmod	_	_
10	or	or	CC	_	9	cc	_	_
11	inducers	inducer	NNS	_	9	conj	_	_
12	of	of	IN	_	14	case	_	_
13	these	these	DT	_	14	det	_	_
14	enzymes	enzyme	NNS	_	9	ppmod	_	_
15	,	,	,	_	14	p	_	_
16	or	or	CC	_	14	cc	_	_
17	other	other	JJ	_	18	attr	_	_
18	factors	factor	NNS	_	14	conj	_	_
19	,	,	,	_	23	p	_	_
20	like	like	IN	_	21	case	_	_
21	smoking	smoking	NN	_	23	ppmod	_	_
22	,	,	,	_	23	p	_	_
23	is	be	VBZ	_	2	comp	_	_
24	unlikely	unlikely	JJ	_	23	dep	_	_
25	.	.	.	_	2	p	_	_

1	Both	both	CC	_	2	cc	_	_
2	CYP3A4	cyp0a0	NN	_	5	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	CYP2D6	cyp0d0	NN	_	2	conj	_	_
5	are	be	VBP	_	0	root	_	_
6	responsible	responsible	JJ	_	5	dep	_	_
7	for	for	IN	_	9	case	_	_
8	drug1	drug0	NN	_	9	com	_	_
9	metabolism	metabolism	NN	_	6	ppmod	_	_
10	.	.	.	_	5	p	_	_

1	Agents	agent	NNS	_	11	dep	_	_
2	that	that	WDT	_	3	dep	_	_
3	induce	induce	VBP	_	1	relcl	_	_
4	CYP3A4	cyp0a0	NN	_	3	obj	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	eg	eg	NN	_	4	prn	_	_
7	,	,	,	_	6	p	_	_
8	drug1	drug0	NN	_	6	appo	_	_
9	)	-rrb-	-RRB-	_	6	p	_	_
10	could	could	MD	_	11	modal	_	_
11	cause	cause	VB	_	0	root	_	_
12	an	an	DT	_	13	det	_	_
13	increase	increase	NN	_	11	obj	_	_
14	in	in	IN	_	16	case	_	_
15	drug2	drug0	NN	_	16	com	_	_
16	clearance	clearance	NN	_	13	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	lower	low	JJR	_	20	attr	_	_
19	blood	blood	NN	_	20	com	_	_
20	levels	level	NNS	_	16	conj	_	_
21	.	.	.	_	11	p	_	_

1	Inhibitors	inhibitor	NNS	_	22	dep	_	_
2	of	of	IN	_	3	case	_	_
3	CYP3A4	cyp0a0	NN	_	1	ppmod	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	eg	eg	NN	_	3	prn	_	_
6	,	,	,	_	5	p	_	_
7	drug1	drug0	NN	_	5	appo	_	_
8	)	-rrb-	-RRB-	_	5	p	_	_
9	or	or	CC	_	3	cc	_	_
10	CYP2D6	cyp0d0	NN	_	3	conj	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	eg	eg	NN	_	10	prn	_	_
13	,	,	,	_	12	p	_	_
14	drug2	drug0	NN	_	12	conj	_	_
15	,	,	,	_	14	p	_	_
16	drug3	drug0	NN	_	12	conj	_	_
17	,	,	,	_	16	p	_	_
18	or	or	CC	_	16	cc	_	_
19	drug4	drug0	NN	_	12	conj	_	_
20	)	-rrb-	-RRB-	_	12	p	_	_
21	can	can	MD	_	22	modal	_	_
22	inhibit	inhibit	VB	_	0	root	_	_
23	drug5	drug0	NN	_	24	com	_	_
24	elimination	elimination	NN	_	22	obj	_	_
25	and	and	CC	_	22	cc	_	_
26	cause	cause	VB	_	22	conj	_	_
27	increased	increase	VBN	_	29	attr	_	_
28	blood	blood	NN	_	29	com	_	_
29	levels	level	NNS	_	26	obj	_	_
30	.	.	.	_	22	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Coadministration	coadministration	NN	_	20	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	(	-lrb-	-LRB-	_	8	p	_	_
7	200	0	CD	_	8	num	_	_
8	mg/day	mg/day	NN	_	5	prn	_	_
9	for	for	IN	_	11	case	_	_
10	14	0	CD	_	11	num	_	_
11	days	day	NNS	_	8	ppmod	_	_
12	)	-rrb-	-RRB-	_	8	p	_	_
13	with	with	IN	_	17	case	_	_
14	a	a	DT	_	17	det	_	_
15	15-mg	0-mg	JJ	_	17	attr	_	_
16	single	single	JJ	_	17	attr	_	_
17	dose	dose	NN	_	3	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug3	drug0	NN	_	17	ppmod	_	_
20	increased	increase	VBD	_	1	acl	_	_
21	the	the	DT	_	22	det	_	_
22	AUC	auc	NN	_	20	obj	_	_
23	of	of	IN	_	24	case	_	_
24	drug4	drug0	NN	_	22	ppmod	_	_
25	and	and	CC	_	24	cc	_	_
26	its	its	PRP$	_	28	poss	_	_
27	active	active	JJ	_	28	attr	_	_
28	metabolite	metabolite	NN	_	24	conj	_	_
29	by	by	IN	_	30	case	_	_
30	63	0	CD	_	20	ppmod	_	_
31	%	%	NN	_	30	meta	_	_
32	and	and	CC	_	30	cc	_	_
33	77	0	CD	_	30	conj	_	_
34	%	%	NN	_	33	meta	_	_
35	,	,	,	_	20	p	_	_
36	respectively	respectively	RB	_	20	adv	_	_
37	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	15	dep	_	_
3	of	of	IN	_	7	case	_	_
4	a	a	DT	_	7	det	_	_
5	higher	high	JJR	_	7	attr	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	dose	dose	NN	_	2	ppmod	_	_
8	(	-lrb-	-LRB-	_	10	p	_	_
9	400	0	CD	_	10	num	_	_
10	mg/day	mg/day	NN	_	7	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	has	have	VBZ	_	15	aux	_	_
13	not	not	RB	_	15	neg	_	_
14	been	be	VBN	_	15	aux	_	_
15	studied	study	VBN	_	0	root	_	_
16	.	.	.	_	15	p	_	_

1	When	when	WRB	_	8	adv	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	administration	administration	NN	_	8	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drug2	drug0	NN	_	3	ppmod	_	_
8	occurs	occur	VBZ	_	14	advcl	_	_
9	,	,	,	_	14	p	_	_
10	drug3	drug0	NN	_	11	com	_	_
11	dose	dose	NN	_	14	dep	_	_
12	should	should	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	reduced	reduce	VBN	_	0	root	_	_
15	to	to	TO	_	16	aux	_	_
16	one-half	one-half	NN	_	14	ppmod	_	_
17	of	of	IN	_	20	case	_	_
18	its	its	PRP$	_	20	poss	_	_
19	normal	normal	JJ	_	20	attr	_	_
20	dose	dose	NN	_	16	ppmod	_	_
21	.	.	.	_	14	p	_	_

1	Other	other	JJ	_	3	attr	_	_
2	strong	strong	JJ	_	3	attr	_	_
3	inhibitors	inhibitor	NNS	_	11	dep	_	_
4	of	of	IN	_	5	case	_	_
5	CYP3A4	cyp0a0	NN	_	3	ppmod	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	drug1	drug0	NN	_	3	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	would	would	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	expected	expect	VBN	_	0	root	_	_
12	to	to	TO	_	13	aux	_	_
13	have	have	VBP	_	11	comp	_	_
14	similar	similar	JJ	_	15	attr	_	_
15	effects	effect	NNS	_	13	obj	_	_
16	and	and	CC	_	13	cc	_	_
17	need	need	VBP	_	13	conj	_	_
18	similar	similar	JJ	_	20	attr	_	_
19	dose	dose	NN	_	20	com	_	_
20	reductions	reduction	NNS	_	17	obj	_	_
21	;	;	:	_	11	p	_	_

1	weaker	weak	JJR	_	2	attr	_	_
2	inhibitors	inhibitor	NNS	_	12	dep	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	drug1	drug0	NN	_	2	prn	_	_
5	,	,	,	_	4	p	_	_
6	grapefruit	grapefruit	NN	_	7	com	_	_
7	juice	juice	NN	_	4	appo	_	_
8	)	-rrb-	-RRB-	_	4	p	_	_
9	have	have	VBP	_	12	aux	_	_
10	not	not	RB	_	12	neg	_	_
11	been	be	VBN	_	12	aux	_	_
12	studied	study	VBN	_	0	root	_	_
13	.	.	.	_	12	p	_	_

1	When	when	WRB	_	6	adv	_	_
2	the	the	DT	_	4	det	_	_
3	CYP3A4	cyp0a0	NN	_	4	com	_	_
4	inhibitor	inhibitor	NN	_	6	dep	_	_
5	is	be	VBZ	_	6	aux	_	_
6	withdrawn	withdraw	VBN	_	17	advcl	_	_
7	from	from	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	combination	combination	NN	_	10	com	_	_
10	therapy	therapy	NN	_	6	ppmod	_	_
11	,	,	,	_	17	p	_	_
12	drug1	drug0	NN	_	13	com	_	_
13	dose	dose	NN	_	17	dep	_	_
14	should	should	MD	_	17	modal	_	_
15	then	then	RB	_	17	adv	_	_
16	be	be	VB	_	17	aux	_	_
17	increased	increase	VBN	_	0	root	_	_
18	.	.	.	_	17	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Coadministration	coadministration	NN	_	27	dep	_	_
4	of	of	IN	_	8	case	_	_
5	a	a	DT	_	8	det	_	_
6	10-mg	0-mg	JJ	_	8	attr	_	_
7	single	single	JJ	_	8	attr	_	_
8	dose	dose	NN	_	3	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	with	with	IN	_	12	case	_	_
12	drug3	drug0	NN	_	3	ppmod	_	_
13	(	-lrb-	-LRB-	_	15	p	_	_
14	166	0	CD	_	15	num	_	_
15	mg/day	mg/day	NN	_	12	prn	_	_
16	for	for	IN	_	18	case	_	_
17	13	0	CD	_	18	num	_	_
18	days	day	NNS	_	15	ppmod	_	_
19	)	-rrb-	-RRB-	_	15	p	_	_
20	,	,	,	_	12	p	_	_
21	a	a	DT	_	23	det	_	_
22	potent	potent	JJ	_	23	attr	_	_
23	inhibitor	inhibitor	NN	_	12	appo	_	_
24	of	of	IN	_	25	case	_	_
25	CYP2D6	cyp0d0	NN	_	23	ppmod	_	_
26	,	,	,	_	12	p	_	_
27	increased	increase	VBD	_	1	acl	_	_
28	the	the	DT	_	29	det	_	_
29	AUC	auc	NN	_	27	obj	_	_
30	of	of	IN	_	31	case	_	_
31	drug4	drug0	NN	_	29	ppmod	_	_
32	by	by	IN	_	33	case	_	_
33	112	0	CD	_	27	ppmod	_	_
34	%	%	NN	_	33	meta	_	_
35	but	but	CC	_	27	cc	_	_
36	decreased	decrease	VBD	_	27	conj	_	_
37	the	the	DT	_	38	det	_	_
38	AUC	auc	NN	_	36	obj	_	_
39	of	of	IN	_	42	case	_	_
40	its	its	PRP$	_	42	poss	_	_
41	active	active	JJ	_	42	attr	_	_
42	metabolite	metabolite	NN	_	38	ppmod	_	_
43	,	,	,	_	42	p	_	_
44	drug5	drug0	NN	_	42	appo	_	_
45	,	,	,	_	42	p	_	_
46	by	by	IN	_	47	case	_	_
47	35	0	CD	_	36	ppmod	_	_
48	%	%	NN	_	47	meta	_	_
49	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	dose	dose	NN	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	reduced	reduce	VBN	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	one-half	one-half	NN	_	5	ppmod	_	_
8	of	of	IN	_	11	case	_	_
9	its	its	PRP$	_	11	poss	_	_
10	normal	normal	JJ	_	11	attr	_	_
11	dose	dose	NN	_	7	ppmod	_	_
12	when	when	WRB	_	19	adv	_	_
13	concomitant	concomitant	JJ	_	14	attr	_	_
14	administration	administration	NN	_	19	dep	_	_
15	of	of	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	with	with	IN	_	18	case	_	_
18	drug3	drug0	NN	_	14	ppmod	_	_
19	occurs	occur	VBZ	_	5	comp	_	_
20	.	.	.	_	5	p	_	_

1	Other	other	JJ	_	3	attr	_	_
2	significant	significant	JJ	_	3	attr	_	_
3	inhibitors	inhibitor	NNS	_	15	dep	_	_
4	of	of	IN	_	5	case	_	_
5	CYP2D6	cyp0d0	NN	_	3	ppmod	_	_
6	,	,	,	_	3	p	_	_
7	such	such	JJ	_	9	adv	_	_
8	as	as	IN	_	9	case	_	_
9	drug1	drug0	NN	_	3	ppmod	_	_
10	or	or	CC	_	9	cc	_	_
11	drug2	drug0	NN	_	9	conj	_	_
12	,	,	,	_	3	p	_	_
13	would	would	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	expected	expect	VBN	_	0	root	_	_
16	to	to	TO	_	17	aux	_	_
17	have	have	VB	_	15	comp	_	_
18	similar	similar	JJ	_	19	attr	_	_
19	effects	effect	NNS	_	17	obj	_	_
20	and	and	CC	_	15	cc	_	_
21	,	,	,	_	15	p	_	_
22	therefore	therefore	RB	_	15	adv	_	_
23	,	,	,	_	15	p	_	_
24	should	should	MD	_	26	modal	_	_
25	be	be	VB	_	26	aux	_	_
26	accompanied	accompany	VBN	_	15	conj	_	_
27	by	by	IN	_	30	case	_	_
28	similar	similar	JJ	_	30	attr	_	_
29	dose	dose	NN	_	30	com	_	_
30	reductions	reduction	NNS	_	26	ppmod	_	_
31	.	.	.	_	15	p	_	_

1	When	when	WRB	_	6	adv	_	_
2	the	the	DT	_	4	det	_	_
3	CYP2D6	cyp0d0	NN	_	4	com	_	_
4	inhibitor	inhibitor	NN	_	6	dep	_	_
5	is	be	VBZ	_	6	aux	_	_
6	withdrawn	withdraw	VBN	_	17	advcl	_	_
7	from	from	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	combination	combination	NN	_	10	com	_	_
10	therapy	therapy	NN	_	6	ppmod	_	_
11	,	,	,	_	17	p	_	_
12	drug1	drug0	NN	_	13	com	_	_
13	dose	dose	NN	_	17	dep	_	_
14	should	should	MD	_	17	modal	_	_
15	then	then	RB	_	17	adv	_	_
16	be	be	VB	_	17	aux	_	_
17	increased	increase	VBN	_	0	root	_	_
18	.	.	.	_	17	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Coadministration	coadministration	NN	_	24	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	(	-lrb-	-LRB-	_	9	p	_	_
7	200	0	CD	_	8	num	_	_
8	mg	mg	NN	_	9	com	_	_
9	BID	bid	NN	_	5	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	,	,	,	_	5	p	_	_
12	a	a	DT	_	15	det	_	_
13	potent	potent	JJ	_	15	attr	_	_
14	CYP3A4	cyp0a0	NN	_	15	com	_	_
15	inducer	inducer	NN	_	5	appo	_	_
16	,	,	,	_	5	p	_	_
17	with	with	IN	_	18	case	_	_
18	drug3	drug0	NN	_	3	ppmod	_	_
19	(	-lrb-	-LRB-	_	22	p	_	_
20	30	0	CD	_	22	num	_	_
21	mg	mg	NN	_	22	com	_	_
22	QD	qd	NN	_	18	prn	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	resulted	result	VBD	_	1	acl	_	_
25	in	in	IN	_	30	case	_	_
26	an	an	DT	_	30	det	_	_
27	approximate	approximate	JJ	_	30	attr	_	_
28	70	0	CD	_	30	num	_	_
29	%	%	NN	_	28	meta	_	_
30	decrease	decrease	NN	_	24	ppmod	_	_
31	in	in	IN	_	35	case	_	_
32	Cmax	cmax	NN	_	35	attr	_	_
33	and	and	CC	_	32	cc	_	_
34	AUC	auc	NN	_	32	conj	_	_
35	values	value	NNS	_	30	ppmod	_	_
36	of	of	IN	_	38	case	_	_
37	both	both	CC	_	38	cc	_	_
38	drug4	drug0	NN	_	35	ppmod	_	_
39	and	and	CC	_	38	cc	_	_
40	its	its	PRP$	_	42	poss	_	_
41	active	active	JJ	_	42	attr	_	_
42	metabolite	metabolite	NN	_	38	conj	_	_
43	,	,	,	_	42	p	_	_
44	drug5	drug0	NN	_	42	appo	_	_
45	.	.	.	_	1	p	_	_

1	When	when	WRB	_	4	adv	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	added	add	VBN	_	13	advcl	_	_
5	to	to	TO	_	7	aux	_	_
6	drug2	drug0	NN	_	7	com	_	_
7	therapy	therapy	NN	_	4	ppmod	_	_
8	,	,	,	_	13	p	_	_
9	drug3	drug0	NN	_	10	com	_	_
10	dose	dose	NN	_	13	dep	_	_
11	should	should	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	doubled	double	VBN	_	0	root	_	_
14	.	.	.	_	13	p	_	_

1	Additional	additional	JJ	_	3	attr	_	_
2	dose	dose	NN	_	3	com	_	_
3	increases	increase	NNS	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	based	base	VBN	_	0	root	_	_
7	on	on	IN	_	9	case	_	_
8	clinical	clinical	JJ	_	9	attr	_	_
9	evaluation	evaluation	NN	_	6	ppmod	_	_
10	.	.	.	_	6	p	_	_

1	When	when	WRB	_	4	adv	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	withdrawn	withdraw	VBN	_	15	advcl	_	_
5	from	from	IN	_	8	case	_	_
6	the	the	DT	_	8	det	_	_
7	combination	combination	NN	_	8	com	_	_
8	therapy	therapy	NN	_	4	ppmod	_	_
9	,	,	,	_	15	p	_	_
10	drug2	drug0	NN	_	11	com	_	_
11	dose	dose	NN	_	15	dep	_	_
12	should	should	MD	_	15	modal	_	_
13	then	then	RB	_	15	adv	_	_
14	be	be	VB	_	15	aux	_	_
15	reduced	reduce	VBN	_	0	root	_	_
16	.	.	.	_	15	p	_	_

1	No	no	DT	_	4	det	_	_
2	clinically	clinically	RB	_	3	adv	_	_
3	significant	significant	JJ	_	4	attr	_	_
4	effect	effect	NN	_	13	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	,	,	,	_	6	p	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	,	,	,	_	8	p	_	_
10	or	or	CC	_	8	cc	_	_
11	drug3	drug0	NN	_	6	conj	_	_
12	was	be	VBD	_	13	aux	_	_
13	seen	see	VBN	_	0	root	_	_
14	on	on	IN	_	16	case	_	_
15	the	the	DT	_	16	det	_	_
16	pharmacokinetics	pharmacokinetics	NNS	_	13	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug4	drug0	NN	_	16	ppmod	_	_
19	(	-lrb-	-LRB-	_	20	p	_	_
20	see	see	VB	_	13	prn	_	_
21	CLINICAL	clinical	JJ	_	22	attr	_	_
22	PHARMACOLOGY	pharmacology	NN	_	20	appo	_	_
23	:	:	:	_	20	p	_	_
24	Drug-	drug-	NN	_	26	com	_	_
25	Drug	drug	NN	_	26	com	_	_
26	Interactions	interaction	NNS	_	20	appo	_	_
27	)	-rrb-	-RRB-	_	20	p	_	_
28	.	.	.	_	13	p	_	_

1	Potential	potential	NN	_	9	dep	_	_
2	for	for	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	to	to	TO	_	5	aux	_	_
5	Affect	affect	VB	_	1	acl	_	_
6	Other	other	JJ	_	7	attr	_	_
7	Drugs	drug	NNS	_	5	obj	_	_
8	drug2	drug0	VBN	_	7	acl	_	_
9	is	be	VBZ	_	0	root	_	_
10	unlikely	unlikely	JJ	_	9	dep	_	_
11	to	to	TO	_	12	aux	_	_
12	cause	cause	VB	_	10	comp	_	_
13	clinically	clinically	RB	_	14	adv	_	_
14	important	important	JJ	_	16	attr	_	_
15	pharmacokinetic	pharmacokinetic	JJ	_	16	attr	_	_
16	interactions	interaction	NNS	_	12	obj	_	_
17	with	with	IN	_	18	case	_	_
18	drugs	drug	NNS	_	16	ppmod	_	_
19	metabolized	metabolize	VBN	_	18	acl	_	_
20	by	by	IN	_	23	case	_	_
21	cytochrome	cytochrome	NN	_	22	com	_	_
22	P450	p0	NN	_	23	com	_	_
23	enzymes	enzyme	NNS	_	19	ppmod	_	_
24	.	.	.	_	9	p	_	_

1	In	in	IN	_	4	case	_	_
2	in	in	FW	_	3	adv	_	_
3	vivo	vivo	FW	_	4	attr	_	_
4	studies	study	NNS	_	12	ppmod	_	_
5	,	,	,	_	12	p	_	_
6	10-	0-	CD	_	8	num	_	_
7	to	to	TO	_	8	adv	_	_
8	30-mg/day	0-mg/day	JJ	_	9	attr	_	_
9	doses	dose	NNS	_	12	dep	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	had	have	VBD	_	0	root	_	_
13	no	no	DT	_	15	det	_	_
14	significant	significant	JJ	_	15	attr	_	_
15	effect	effect	NN	_	12	obj	_	_
16	on	on	IN	_	17	case	_	_
17	metabolism	metabolism	NN	_	12	ppmod	_	_
18	by	by	IN	_	19	case	_	_
19	CYP2D6	cyp0d0	NN	_	17	ppmod	_	_
20	(	-lrb-	-LRB-	_	21	p	_	_
21	drug2	drug0	NN	_	19	prn	_	_
22	)	-rrb-	-RRB-	_	21	p	_	_
23	,	,	,	_	19	p	_	_
24	CYP2C9	cyp0c0	NN	_	19	conj	_	_
25	(	-lrb-	-LRB-	_	26	p	_	_
26	drug3	drug0	NN	_	24	prn	_	_
27	)	-rrb-	-RRB-	_	26	p	_	_
28	,	,	,	_	24	p	_	_
29	CYP2C19	cyp0c0	NN	_	19	conj	_	_
30	(	-lrb-	-LRB-	_	31	p	_	_
31	drug4	drug0	NN	_	29	prn	_	_
32	,	,	,	_	31	p	_	_
33	drug5	drug0	NN	_	31	appo	_	_
34	)	-rrb-	-RRB-	_	31	p	_	_
35	,	,	,	_	29	p	_	_
36	and	and	CC	_	29	cc	_	_
37	CYP3A4	cyp0a0	NN	_	41	attr	_	_
38	(	-lrb-	-LRB-	_	39	p	_	_
39	drug6	drug0	NN	_	37	prn	_	_
40	)	-rrb-	-RRB-	_	39	p	_	_
41	substrates	substrate	NNS	_	19	conj	_	_
42	.	.	.	_	12	p	_	_

1	Additionally	additionally	RB	_	8	adv	_	_
2	,	,	,	_	8	p	_	_
3	drug1	drug0	NN	_	8	dep	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	did	do	VBD	_	8	aux	_	_
7	not	not	RB	_	8	neg	_	_
8	show	show	VB	_	0	root	_	_
9	potential	potential	NN	_	8	obj	_	_
10	for	for	IN	_	11	case	_	_
11	altering	alter	VBG	_	8	ppmod	_	_
12	CYP1A2-mediated	cyp0a0-mediated	JJ	_	13	attr	_	_
13	metabolism	metabolism	NN	_	11	obj	_	_
14	in	in	FW	_	15	adv	_	_
15	vitro	vitro	FW	_	11	adv	_	_
16	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	There	there	EX	_	4	dep	_	_
4	was	be	VBD	_	1	acl	_	_
5	no	no	DT	_	7	det	_	_
6	significant	significant	JJ	_	7	attr	_	_
7	difference	difference	NN	_	4	obj	_	_
8	between	between	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	coadministered	coadministered	VBN	_	9	acl	_	_
11	with	with	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	placebo	placebo	NN	_	12	conj	_	_
15	coadministered	coadministered	VBN	_	12	acl	_	_
16	with	with	IN	_	17	case	_	_
17	drug4	drug0	NN	_	15	ppmod	_	_
18	on	on	IN	_	19	case	_	_
19	performance	performance	NN	_	17	ppmod	_	_
20	of	of	IN	_	23	case	_	_
21	gross	gross	JJ	_	23	attr	_	_
22	motor	motor	NN	_	23	com	_	_
23	skills	skill	NNS	_	19	ppmod	_	_
24	or	or	CC	_	23	cc	_	_
25	stimulus	stimulus	NN	_	26	com	_	_
26	response	response	NN	_	23	conj	_	_
27	in	in	IN	_	29	case	_	_
28	healthy	healthy	JJ	_	29	attr	_	_
29	subjects	subject	NNS	_	19	ppmod	_	_
30	.	.	.	_	1	p	_	_

1	As	as	IN	_	5	case	_	_
2	with	with	IN	_	5	case	_	_
3	most	most	JJS	_	5	attr	_	_
4	psychoactive	psychoactive	JJ	_	5	attr	_	_
5	medications	medication	NNS	_	10	ppmod	_	_
6	,	,	,	_	10	p	_	_
7	patients	patient	NNS	_	10	dep	_	_
8	should	should	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	advised	advise	VBN	_	0	root	_	_
11	to	to	TO	_	12	aux	_	_
12	avoid	avoid	VB	_	10	comp	_	_
13	drug1	drug0	NN	_	12	obj	_	_
14	while	while	IN	_	15	mark	_	_
15	taking	take	VBG	_	12	comp	_	_
16	drug2	drug0	NN	_	15	obj	_	_

1	.	.	.	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	The	the	DT	_	3	det	_	_
2	concurrent	concurrent	JJ	_	3	attr	_	_
3	use	use	NN	_	26	dep	_	_
4	of	of	IN	_	6	case	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	Injection	injection	NN	_	3	ppmod	_	_
7	with	with	IN	_	9	case	_	_
8	other	other	JJ	_	9	attr	_	_
9	drug2	drug0	NNS	_	3	ppmod	_	_
10	or	or	CC	_	9	cc	_	_
11	medications	medication	NNS	_	9	conj	_	_
12	with	with	IN	_	14	case	_	_
13	anticholinergic	anticholinergic	JJ	_	14	attr	_	_
14	activity	activity	NN	_	9	ppmod	_	_
15	,	,	,	_	9	p	_	_
16	such	such	JJ	_	18	adv	_	_
17	as	as	IN	_	18	case	_	_
18	drug3	drug0	NN	_	9	ppmod	_	_
19	,	,	,	_	18	p	_	_
20	drug4	drug0	NN	_	18	conj	_	_
21	,	,	,	_	20	p	_	_
22	or	or	CC	_	20	cc	_	_
23	drug5	drug0	NN	_	18	conj	_	_
24	,	,	,	_	9	p	_	_
25	may	may	MD	_	26	modal	_	_
26	intensify	intensify	VB	_	0	root	_	_
27	the	the	DT	_	29	det	_	_
28	antimuscarinic	antimuscarinic	JJ	_	29	attr	_	_
29	effects	effect	NNS	_	26	obj	_	_
30	and	and	CC	_	26	cc	_	_
31	may	may	MD	_	32	modal	_	_
32	result	result	VB	_	26	conj	_	_
33	in	in	IN	_	35	case	_	_
34	an	an	DT	_	35	det	_	_
35	increase	increase	NN	_	32	ppmod	_	_
36	in	in	IN	_	39	case	_	_
37	anticholinergic	anticholinergic	JJ	_	39	attr	_	_
38	side	side	JJ	_	39	attr	_	_
39	effects	effect	NNS	_	35	ppmod	_	_
40	.	.	.	_	26	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	administration	administration	NN	_	13	dep	_	_
3	of	of	IN	_	5	case	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	Injection	injection	NN	_	2	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	in	in	IN	_	11	case	_	_
9	a	a	DT	_	11	det	_	_
10	wax	wax	NN	_	11	com	_	_
11	matrix	matrix	NN	_	2	ppmod	_	_
12	may	may	MD	_	13	modal	_	_
13	increase	increase	VB	_	0	root	_	_
14	the	the	DT	_	15	det	_	_
15	severity	severity	NN	_	13	obj	_	_
16	of	of	IN	_	20	case	_	_
17	potassium	potassium	NN	_	20	attr	_	_
18	chloride-induced	chloride-induced	JJ	_	20	attr	_	_
19	gastrointestinal	gastrointestinal	JJ	_	20	attr	_	_
20	lesions	lesion	NNS	_	15	ppmod	_	_
21	as	as	IN	_	23	case	_	_
22	a	a	DT	_	23	det	_	_
23	result	result	NN	_	13	ppmod	_	_
24	of	of	IN	_	29	case	_	_
25	a	a	DT	_	29	det	_	_
26	slower	slow	JJR	_	29	attr	_	_
27	gastrointestinal	gastrointestinal	JJ	_	29	attr	_	_
28	transit	transit	NN	_	29	com	_	_
29	time	time	NN	_	23	ppmod	_	_
30	.	.	.	_	13	p	_	_

1	A	a	DT	_	4	det	_	_
2	possible	possible	JJ	_	4	attr	_	_
3	drug	drug	NN	_	4	com	_	_
4	interaction	interaction	NN	_	12	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	intravenous	intravenous	JJ	_	9	attr	_	_
9	drug2	drug0	NN	_	6	conj	_	_
10	has	have	VBZ	_	12	aux	_	_
11	been	be	VBN	_	12	aux	_	_
12	described	describe	VBN	_	0	root	_	_
13	.	.	.	_	12	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	treatment	treatment	NN	_	17	dep	_	_
3	of	of	IN	_	5	case	_	_
4	four	#crd#	CD	_	5	num	_	_
5	patients	patient	NNS	_	2	ppmod	_	_
6	in	in	IN	_	9	case	_	_
7	the	the	DT	_	9	det	_	_
8	United	united	JJ	_	9	attr	_	_
9	Kingdom	kingdom	NN	_	5	ppmod	_	_
10	with	with	IN	_	11	case	_	_
11	drug1	drug0	NN	_	2	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	intravenous	intravenous	JJ	_	14	attr	_	_
14	drug2	drug0	NN	_	11	conj	_	_
15	may	may	MD	_	17	modal	_	_
16	have	have	VB	_	17	aux	_	_
17	caused	cause	VBN	_	0	root	_	_
18	hypocalcemia	hypocalcemia	NN	_	17	obj	_	_
19	;	;	:	_	17	p	_	_

1	one	#crd#	CD	_	2	num	_	_
2	patient	patient	NN	_	3	dep	_	_
3	died	die	VBD	_	0	root	_	_
4	with	with	IN	_	6	case	_	_
5	severe	severe	JJ	_	6	attr	_	_
6	hypocalcemia	hypocalcemia	NN	_	3	ppmod	_	_
7	.	.	.	_	3	p	_	_

1	Toxicity	toxicity	NN	_	12	dep	_	_
2	associated	associate	VBN	_	1	acl	_	_
3	with	with	IN	_	5	case	_	_
4	concomitant	concomitant	JJ	_	5	attr	_	_
5	use	use	NN	_	2	ppmod	_	_
6	of	of	IN	_	8	case	_	_
7	aerosolized	aerosolized	JJ	_	8	attr	_	_
8	drug1	drug0	NN	_	5	ppmod	_	_
9	has	have	VBZ	_	12	aux	_	_
10	not	not	RB	_	12	neg	_	_
11	been	be	VBN	_	12	aux	_	_
12	reported	report	VBN	_	0	root	_	_
13	.	.	.	_	12	p	_	_

1	Because	because	IN	_	5	case	_	_
2	of	of	IN	_	5	case	_	_
3	drug1	drug0	NN	_	5	com	_	_
4	s	s	NN	_	5	com	_	_
5	tendency	tendency	NN	_	17	ppmod	_	_
6	to	to	TO	_	7	aux	_	_
7	cause	cause	VB	_	5	acl	_	_
8	renal	renal	JJ	_	9	attr	_	_
9	impairment	impairment	NN	_	7	obj	_	_
10	,	,	,	_	17	p	_	_
11	the	the	DT	_	12	det	_	_
12	use	use	NN	_	17	dep	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	should	should	MD	_	17	modal	_	_
16	be	be	VB	_	17	aux	_	_
17	avoided	avoid	VBN	_	0	root	_	_
18	in	in	IN	_	19	case	_	_
19	combination	combination	NN	_	17	ppmod	_	_
20	with	with	IN	_	23	case	_	_
21	potentially	potentially	RB	_	23	adv	_	_
22	nephrotoxic	nephrotoxic	JJ	_	23	attr	_	_
23	drugs	drug	NNS	_	19	ppmod	_	_
24	such	such	JJ	_	26	adv	_	_
25	as	as	IN	_	26	case	_	_
26	drug3	drug0	NN	_	23	ppmod	_	_
27	,	,	,	_	26	p	_	_
28	drug4	drug0	NN	_	26	conj	_	_
29	and	and	CC	_	28	cc	_	_
30	intravenous	intravenous	JJ	_	31	attr	_	_
31	drug5	drug0	NN	_	26	conj	_	_
32	unless	unless	IN	_	36	mark	_	_
33	the	the	DT	_	35	det	_	_
34	potential	potential	JJ	_	35	attr	_	_
35	benefits	benefit	NNS	_	36	dep	_	_
36	outweigh	outweigh	VBP	_	26	acl	_	_
37	the	the	DT	_	38	det	_	_
38	risks	risk	NNS	_	36	obj	_	_
39	to	to	TO	_	41	aux	_	_
40	the	the	DT	_	41	det	_	_
41	patient	patient	NN	_	38	ppmod	_	_
42	.	.	.	_	17	p	_	_

1	Since	since	IN	_	3	mark	_	_
2	drug1	drug0	NN	_	3	dep	_	_
3	decreases	decrease	VBZ	_	23	advcl	_	_
4	serum	serum	NN	_	5	com	_	_
5	concentrations	concentration	NNS	_	3	obj	_	_
6	of	of	IN	_	8	case	_	_
7	ionized	ionize	VBN	_	8	attr	_	_
8	calcium	calcium	NN	_	5	ppmod	_	_
9	,	,	,	_	23	p	_	_
10	concurrent	concurrent	JJ	_	11	attr	_	_
11	treatment	treatment	NN	_	23	dep	_	_
12	with	with	IN	_	14	case	_	_
13	other	other	JJ	_	14	attr	_	_
14	drugs	drug	NNS	_	11	ppmod	_	_
15	known	know	VBN	_	14	acl	_	_
16	to	to	TO	_	17	aux	_	_
17	influence	influence	VB	_	15	comp	_	_
18	serum	serum	NN	_	20	com	_	_
19	calcium	calcium	NN	_	20	com	_	_
20	concentrations	concentration	NNS	_	17	obj	_	_
21	should	should	MD	_	23	modal	_	_
22	be	be	VB	_	23	aux	_	_
23	used	use	VBN	_	0	root	_	_
24	with	with	IN	_	26	case	_	_
25	particular	particular	JJ	_	26	attr	_	_
26	caution	caution	NN	_	23	ppmod	_	_
27	.	.	.	_	23	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	pharmacokinetics	pharmacokinetics	NNS	_	11	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	were	be	VBD	_	11	aux	_	_
10	not	not	RB	_	11	neg	_	_
11	altered	alter	VBN	_	1	acl	_	_
12	in	in	IN	_	14	case	_	_
13	13	0	CD	_	14	num	_	_
14	patients	patient	NNS	_	11	ppmod	_	_
15	receiving	receive	VBG	_	14	acl	_	_
16	either	either	CC	_	18	cc	_	_
17	concomitant	concomitant	JJ	_	18	attr	_	_
18	therapy	therapy	NN	_	15	obj	_	_
19	or	or	CC	_	18	cc	_	_
20	daily	daily	JJ	_	22	attr	_	_
21	alternating	alternate	VBG	_	22	attr	_	_
22	therapy	therapy	NN	_	18	conj	_	_
23	for	for	IN	_	24	case	_	_
24	maintenance	maintenance	NN	_	18	ppmod	_	_
25	of	of	IN	_	27	case	_	_
26	CMV	cmv	NN	_	27	com	_	_
27	disease	disease	NN	_	24	ppmod	_	_
28	.	.	.	_	1	p	_	_

1	and/or	and/or	CC	_	4	cc	_	_
2	Drug/Laboratory	drug/laboratory	NN	_	4	com	_	_
3	Test	test	NN	_	4	com	_	_
4	Interactions	interaction	NNS	_	5	dep	_	_
5	See	see	VB	_	0	root	_	_
6	CLINICAL	clinical	JJ	_	7	attr	_	_
7	PHARMACOLOGY	pharmacology	NN	_	5	obj	_	_
8	,	,	,	_	7	p	_	_
9	Pharmacokinetics	pharmacokinetics	NNS	_	7	conj	_	_
10	and	and	CC	_	9	cc	_	_
11	Drug	drug	NN	_	12	com	_	_
12	Interactions	interaction	NNS	_	7	conj	_	_
13	.	.	.	_	5	p	_	_

1	Effect	effect	NN	_	19	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	on	on	IN	_	6	case	_	_
5	other	other	JJ	_	6	attr	_	_
6	drugs	drug	NNS	_	1	ppmod	_	_
7	:	:	:	_	6	p	_	_
8	Drugs	drug	NNS	_	6	appo	_	_
9	metabolized	metabolize	VBN	_	8	acl	_	_
10	by	by	IN	_	13	case	_	_
11	cytochrome	cytochrome	NN	_	13	com	_	_
12	P450	p0	NN	_	13	com	_	_
13	2D6	0d0	NN	_	9	ppmod	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	CYP2D6	cyp0d0	NN	_	13	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	:	:	:	_	6	p	_	_
18	drug2	drug0	NNS	_	6	appo	_	_
19	is	be	VBZ	_	0	root	_	_
20	a	a	DT	_	24	det	_	_
21	strong	strong	JJ	_	23	adv	_	_
22	in	in	FW	_	23	adv	_	_
23	vitro	vitro	FW	_	24	attr	_	_
24	inhibitor	inhibitor	NN	_	19	obj	_	_
25	of	of	IN	_	26	case	_	_
26	CYP2D6	cyp0d0	NN	_	24	ppmod	_	_
27	.	.	.	_	19	p	_	_

1	Therefore	therefore	RB	_	34	adv	_	_
2	,	,	,	_	34	p	_	_
3	dose	dose	NN	_	4	com	_	_
4	adjustments	adjustment	NNS	_	34	dep	_	_
5	of	of	IN	_	7	case	_	_
6	concomitant	concomitant	JJ	_	7	attr	_	_
7	medications	medication	NNS	_	4	ppmod	_	_
8	that	that	WDT	_	11	dep	_	_
9	are	be	VBP	_	11	aux	_	_
10	predominantly	predominantly	RB	_	11	adv	_	_
11	metabolized	metabolize	VBN	_	7	relcl	_	_
12	by	by	IN	_	13	case	_	_
13	CYP2D6	cyp0d0	NN	_	11	ppmod	_	_
14	and	and	CC	_	11	cc	_	_
15	have	have	VBP	_	11	conj	_	_
16	a	a	DT	_	19	det	_	_
17	narrow	narrow	JJ	_	19	attr	_	_
18	therapeutic	therapeutic	JJ	_	19	attr	_	_
19	index	index	NN	_	15	obj	_	_
20	(	-lrb-	-LRB-	_	23	p	_	_
21	e.g.	e.g.	FW	_	23	adv	_	_
22	,	,	,	_	23	p	_	_
23	drug1	drug0	NN	_	19	prn	_	_
24	,	,	,	_	23	p	_	_
25	drug2	drug0	NN	_	23	conj	_	_
26	,	,	,	_	25	p	_	_
27	drug3	drug0	NN	_	23	conj	_	_
28	and	and	CC	_	27	cc	_	_
29	most	most	JJS	_	30	attr	_	_
30	drug4	drug0	NNS	_	23	conj	_	_
31	)	-rrb-	-RRB-	_	23	p	_	_
32	may	may	MD	_	34	modal	_	_
33	be	be	VB	_	34	aux	_	_
34	required	require	VBN	_	0	root	_	_
35	.	.	.	_	34	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Concurrent	concurrent	JJ	_	4	attr	_	_
4	administration	administration	NN	_	16	dep	_	_
5	of	of	IN	_	7	case	_	_
6	25	0	CD	_	7	num	_	_
7	mg	mg	NN	_	4	ppmod	_	_
8	or	or	CC	_	7	cc	_	_
9	100	0	CD	_	10	num	_	_
10	mg	mg	NN	_	11	com	_	_
11	drug2	drug0	NN	_	7	conj	_	_
12	with	with	IN	_	15	case	_	_
13	50	0	CD	_	14	num	_	_
14	mg	mg	NN	_	15	com	_	_
15	drug3	drug0	NN	_	4	ppmod	_	_
16	increased	increase	VBD	_	1	acl	_	_
17	drug4	drug0	NN	_	18	com	_	_
18	exposure	exposure	NN	_	16	obj	_	_
19	and	and	CC	_	18	cc	_	_
20	drug5	drug0	NN	_	25	attr	_	_
21	(	-lrb-	-LRB-	_	23	p	_	_
22	active	active	JJ	_	23	attr	_	_
23	metabolite	metabolite	NN	_	20	prn	_	_
24	)	-rrb-	-RRB-	_	23	p	_	_
25	exposure	exposure	NN	_	18	conj	_	_
26	by	by	IN	_	28	case	_	_
27	approximately	approximately	RB	_	28	adv	_	_
28	20	0	CD	_	16	ppmod	_	_
29	%	%	NN	_	28	meta	_	_
30	in	in	IN	_	33	case	_	_
31	CYP2D6	cyp0d0	NN	_	33	attr	_	_
32	extensive	extensive	JJ	_	33	attr	_	_
33	metabolizers	metabolizers	NNS	_	28	ppmod	_	_
34	.	.	.	_	1	p	_	_

1	Effect	effect	NN	_	10	dep	_	_
2	of	of	IN	_	4	case	_	_
3	other	other	JJ	_	4	attr	_	_
4	drugs	drug	NNS	_	1	ppmod	_	_
5	on	on	IN	_	8	case	_	_
6	drug1	drug0	NN	_	8	attr	_	_
7	:	:	:	_	8	p	_	_
8	drug2	drug0	NN	_	1	ppmod	_	_
9	is	be	VBZ	_	10	aux	_	_
10	metabolized	metabolize	VBN	_	0	root	_	_
11	by	by	IN	_	15	case	_	_
12	multiple	multiple	JJ	_	15	attr	_	_
13	cytochrome	cytochrome	NN	_	15	com	_	_
14	P450	p0	NN	_	15	com	_	_
15	enzymes	enzyme	NNS	_	10	ppmod	_	_
16	,	,	,	_	15	p	_	_
17	primarily	primarily	RB	_	15	adv	_	_
18	CYP3A4	cyp0a0	NN	_	15	appo	_	_
19	,	,	,	_	18	p	_	_
20	CYP2D6	cyp0d0	NN	_	18	conj	_	_
21	,	,	,	_	20	p	_	_
22	and	and	CC	_	20	cc	_	_
23	CYP1A2	cyp0a0	NN	_	18	conj	_	_
24	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	is	be	VBZ	_	5	aux	_	_
5	metabolized	metabolize	VBN	_	0	root	_	_
6	in	in	IN	_	7	case	_	_
7	part	part	NN	_	5	ppmod	_	_
8	by	by	IN	_	9	case	_	_
9	CYP3A4	cyp0a0	NN	_	5	ppmod	_	_
10	.	.	.	_	5	p	_	_

1	Co-administration	co-administration	NN	_	11	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	,	,	,	_	3	p	_	_
5	a	a	DT	_	7	det	_	_
6	strong	strong	JJ	_	7	attr	_	_
7	inhibitor	inhibitor	NN	_	3	appo	_	_
8	of	of	IN	_	9	case	_	_
9	CYP3A4	cyp0a0	NN	_	7	ppmod	_	_
10	,	,	,	_	3	p	_	_
11	increased	increase	VBD	_	0	root	_	_
12	drug2	drug0	NN	_	13	com	_	_
13	exposure	exposure	NN	_	19	dat	_	_
14	following	follow	VBG	_	19	adv	_	_
15	a	a	DT	_	19	det	_	_
16	single	single	JJ	_	19	attr	_	_
17	90	0	CD	_	18	num	_	_
18	mg	mg	NN	_	19	com	_	_
19	dose	dose	NN	_	11	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	drug3	drug0	NN	_	19	ppmod	_	_
22	by	by	IN	_	24	case	_	_
23	2.3	0	CD	_	24	num	_	_
24	fold	fold	NN	_	21	ppmod	_	_
25	.	.	.	_	11	p	_	_

1	Dose	dose	NN	_	2	com	_	_
2	adjustment	adjustment	NN	_	7	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	may	may	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	required	require	VBN	_	0	root	_	_
8	and	and	CC	_	7	cc	_	_
9	PTH	pth	NN	_	17	dep	_	_
10	and	and	CC	_	9	cc	_	_
11	serum	serum	NN	_	13	com	_	_
12	calcium	calcium	NN	_	13	com	_	_
13	concentrations	concentration	NNS	_	9	conj	_	_
14	should	should	MD	_	17	modal	_	_
15	be	be	VB	_	17	aux	_	_
16	closely	closely	RB	_	17	adv	_	_
17	monitored	monitor	VBN	_	7	conj	_	_
18	if	if	IN	_	21	mark	_	_
19	a	a	DT	_	20	det	_	_
20	patient	patient	NN	_	21	dep	_	_
21	initiates	initiate	VBZ	_	17	comp	_	_
22	or	or	NN	_	24	com	_	_
23	discontinues	discontinues	NN	_	24	com	_	_
24	therapy	therapy	NN	_	21	obj	_	_
25	with	with	IN	_	29	case	_	_
26	a	a	DT	_	29	det	_	_
27	strong	strong	JJ	_	29	attr	_	_
28	CYP3A4	cyp0a0	NN	_	29	com	_	_
29	inhibitor	inhibitor	NN	_	24	ppmod	_	_
30	(	-lrb-	-LRB-	_	33	p	_	_
31	e.g.	e.g.	FW	_	33	ppmod	_	_
32	,	,	,	_	33	p	_	_
33	drug2	drug0	NN	_	29	prn	_	_
34	,	,	,	_	33	p	_	_
35	drug3	drug0	NN	_	33	appo	_	_
36	,	,	,	_	33	p	_	_
37	drug4	drug0	NN	_	33	appo	_	_
38	;	;	:	_	17	p	_	_

1	see	see	VB	_	0	root	_	_
2	DOSAGE	dosage	NN	_	1	obj	_	_
3	AND	and	CC	_	2	cc	_	_
4	ADMINISTRATION	administration	NN	_	2	conj	_	_
5	)	-rrb-	-RRB-	_	1	p	_	_
6	.	.	.	_	1	p	_	_

1	Special	special	JJ	_	2	attr	_	_
2	care	care	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	required	require	VBN	_	0	root	_	_
5	if	if	IN	_	9	mark	_	_
6	this	this	DT	_	7	det	_	_
7	drug	drug	NN	_	9	dep	_	_
8	is	be	VBZ	_	9	aux	_	_
9	given	give	VBN	_	4	comp	_	_
10	to	to	TO	_	11	aux	_	_
11	patients	patient	NNS	_	9	ppmod	_	_
12	receiving	receive	VBG	_	11	acl	_	_
13	drug1	drug0	NN	_	12	obj	_	_
14	because	because	IN	_	22	mark	_	_
15	a	a	DT	_	16	det	_	_
16	critical	critical	JJ	_	22	dep	_	_
17	fall	fall	VBP	_	16	acl	_	_
18	in	in	IN	_	20	case	_	_
19	blood	blood	NN	_	20	com	_	_
20	pressure	pressure	NN	_	17	ppmod	_	_
21	may	may	MD	_	22	modal	_	_
22	occur	occur	VB	_	9	comp	_	_
23	.	.	.	_	4	p	_	_

1	Usually	usually	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	severe	severe	JJ	_	5	attr	_	_
4	abdominal	abdominal	JJ	_	5	attr	_	_
5	symptoms	symptom	NNS	_	6	dep	_	_
6	appear	appear	VBP	_	0	root	_	_
7	before	before	IN	_	9	mark	_	_
8	there	there	EX	_	9	dep	_	_
9	is	be	VBZ	_	6	comp	_	_
10	such	such	IN	_	11	case	_	_
11	a	a	DT	_	9	ppmod	_	_
12	fall	fall	VBP	_	11	acl	_	_
13	in	in	IN	_	16	case	_	_
14	the	the	DT	_	16	det	_	_
15	blood	blood	NN	_	16	com	_	_
16	pressure	pressure	NN	_	12	ppmod	_	_
17	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	are	be	VBP	_	0	root	_	_
3	strong	strong	JJ	_	4	attr	_	_
4	drug2	drug0	NN	_	2	obj	_	_
5	,	,	,	_	2	p	_	_
6	but	but	CC	_	2	cc	_	_
7	regular	regular	JJ	_	8	attr	_	_
8	users	user	NNS	_	9	dep	_	_
9	develop	develop	VBP	_	2	conj	_	_
10	physiological	physiological	JJ	_	11	attr	_	_
11	tolerance	tolerance	NN	_	9	obj	_	_
12	allowing	allow	VBG	_	11	acl	_	_
13	gradually	gradually	RB	_	15	adv	_	_
14	increased	increase	VBN	_	15	attr	_	_
15	dosages	dosage	NNS	_	12	obj	_	_
16	.	.	.	_	2	p	_	_

1	In	in	IN	_	2	case	_	_
2	combination	combination	NN	_	10	ppmod	_	_
3	with	with	IN	_	5	case	_	_
4	other	other	JJ	_	5	attr	_	_
5	drug1	drug0	NN	_	2	ppmod	_	_
6	,	,	,	_	10	p	_	_
7	drug2	drug0	NN	_	10	dep	_	_
8	may	may	MD	_	10	modal	_	_
9	still	still	RB	_	10	adv	_	_
10	kill	kill	VB	_	0	root	_	_
11	even	even	RB	_	12	adv	_	_
12	experienced	experience	VBN	_	13	attr	_	_
13	users	user	NNS	_	10	obj	_	_
14	,	,	,	_	10	p	_	_
15	particularly	particularly	RB	_	23	adv	_	_
16	if	if	IN	_	23	mark	_	_
17	their	their	PRP$	_	18	poss	_	_
18	tolerance	tolerance	NN	_	23	dep	_	_
19	to	to	TO	_	21	aux	_	_
20	the	the	DT	_	21	det	_	_
21	drug	drug	NN	_	18	ppmod	_	_
22	has	have	VBZ	_	23	aux	_	_
23	reduced	reduce	VBN	_	10	comp	_	_
24	or	or	CC	_	23	cc	_	_
25	the	the	DT	_	26	det	_	_
26	strength	strength	NN	_	32	dep	_	_
27	of	of	IN	_	30	case	_	_
28	their	their	PRP$	_	30	poss	_	_
29	usual	usual	JJ	_	30	attr	_	_
30	dose	dose	NN	_	26	ppmod	_	_
31	has	have	VBZ	_	32	aux	_	_
32	increased	increase	VBN	_	23	conj	_	_
33	.	.	.	_	10	p	_	_

1	Toxicology	toxicology	JJ	_	2	attr	_	_
2	studies	study	NNS	_	7	dep	_	_
3	of	of	IN	_	6	case	_	_
4	drug1	drug0	JJ	_	6	attr	_	_
5	-related	-related	JJ	_	6	attr	_	_
6	deaths	death	NNS	_	2	ppmod	_	_
7	reveal	reveal	VBP	_	0	root	_	_
8	frequent	frequent	JJ	_	9	attr	_	_
9	involvement	involvement	NN	_	7	obj	_	_
10	of	of	IN	_	12	case	_	_
11	other	other	JJ	_	12	attr	_	_
12	drug2	drug0	NNS	_	9	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	including	include	VBG	_	15	adv	_	_
15	drug3	drug0	NN	_	12	ppmod	_	_
16	,	,	,	_	15	p	_	_
17	drug4	drug0	NNS	_	15	conj	_	_
18	such	such	JJ	_	20	adv	_	_
19	as	as	IN	_	20	case	_	_
20	drug5	drug0	NN	_	17	ppmod	_	_
21	(	-lrb-	-LRB-	_	22	p	_	_
22	drug6	drug0	NN	_	20	prn	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	,	,	,	_	17	p	_	_
25	and	and	CC	_	17	cc	_	_
26	,	,	,	_	17	p	_	_
27	to	to	TO	_	30	aux	_	_
28	a	a	DT	_	30	det	_	_
29	rising	rising	JJ	_	30	attr	_	_
30	degree	degree	NN	_	17	ppmod	_	_
31	,	,	,	_	17	p	_	_
32	drug7	drug0	NN	_	15	conj	_	_
33	.	.	.	_	7	p	_	_

1	Ironically	ironically	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	drug1	drug0	NN	_	6	dep	_	_
4	are	be	VBP	_	6	aux	_	_
5	often	often	RB	_	6	adv	_	_
6	used	use	VBN	_	0	root	_	_
7	in	in	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	treatment	treatment	NN	_	6	ppmod	_	_
10	of	of	IN	_	12	case	_	_
11	drug2	drug0	NN	_	12	com	_	_
12	addiction	addiction	NN	_	9	ppmod	_	_
13	while	while	IN	_	15	mark	_	_
14	they	they	PRP	_	15	dep	_	_
15	cause	cause	VBP	_	6	comp	_	_
16	much	much	RB	_	18	adv	_	_
17	more	more	RBR	_	18	adv	_	_
18	severe	severe	JJ	_	20	attr	_	_
19	withdrawal	withdrawal	NN	_	20	com	_	_
20	symptoms	symptom	NNS	_	15	obj	_	_
21	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	sometimes	sometimes	RB	_	3	adv	_	_
3	proves	prove	VBZ	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	be	be	VB	_	3	comp	_	_
6	fatal	fatal	JJ	_	5	dep	_	_
7	when	when	WRB	_	8	adv	_	_
8	used	use	VBN	_	5	comp	_	_
9	in	in	IN	_	10	case	_	_
10	combination	combination	NN	_	8	ppmod	_	_
11	with	with	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	physician	physician	NN	_	4	dep	_	_
3	should	should	MD	_	4	modal	_	_
4	be	be	VB	_	0	root	_	_
5	alert	alert	JJ	_	4	dep	_	_
6	for	for	IN	_	10	case	_	_
7	possible	possible	JJ	_	10	attr	_	_
8	combined	combined	JJ	_	10	attr	_	_
9	drug	drug	NN	_	10	com	_	_
10	actions	action	NNS	_	5	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	desirable	desirable	JJ	_	10	attr	_	_
13	or	or	CC	_	12	cc	_	_
14	undesirable	undesirable	JJ	_	12	conj	_	_
15	,	,	,	_	10	p	_	_
16	involving	involve	VBG	_	10	acl	_	_
17	drug1	drug0	NN	_	16	obj	_	_
18	even	even	RB	_	23	adv	_	_
19	though	though	IN	_	23	mark	_	_
20	drug2	drug0	NN	_	23	dep	_	_
21	has	have	VBZ	_	23	aux	_	_
22	been	be	VBN	_	23	aux	_	_
23	used	use	VBN	_	4	comp	_	_
24	successfully	successfully	RB	_	23	adv	_	_
25	concurrently	concurrently	RB	_	28	adv	_	_
26	with	with	IN	_	28	case	_	_
27	other	other	JJ	_	28	attr	_	_
28	drugs	drug	NNS	_	23	ppmod	_	_
29	,	,	,	_	28	p	_	_
30	including	include	VBG	_	33	adv	_	_
31	other	other	JJ	_	33	attr	_	_
32	cytotoxic	cytotoxic	JJ	_	33	attr	_	_
33	drugs	drug	NNS	_	28	ppmod	_	_
34	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	6	case	_	_
4	three	#crd#	CD	_	6	num	_	_
5	pharmacokinetic	pharmacokinetic	JJ	_	6	attr	_	_
6	studies	study	NNS	_	21	ppmod	_	_
7	including	include	VBG	_	12	adv	_	_
8	46	0	CD	_	12	num	_	_
9	normal	normal	JJ	_	12	attr	_	_
10	,	,	,	_	12	p	_	_
11	healthy	healthy	JJ	_	12	attr	_	_
12	subjects	subject	NNS	_	6	ppmod	_	_
13	,	,	,	_	21	p	_	_
14	drug2	drug0	NN	_	15	com	_	_
15	clearance	clearance	NN	_	21	dep	_	_
16	and	and	CC	_	15	cc	_	_
17	concentration	concentration	NN	_	15	conj	_	_
18	were	be	VBD	_	21	aux	_	_
19	not	not	RB	_	21	neg	_	_
20	significantly	significantly	RB	_	21	adv	_	_
21	altered	alter	VBN	_	1	acl	_	_
22	by	by	IN	_	24	case	_	_
23	the	the	DT	_	24	det	_	_
24	addition	addition	NN	_	21	ppmod	_	_
25	of	of	IN	_	26	case	_	_
26	drug3	drug0	NN	_	24	ppmod	_	_
27	.	.	.	_	1	p	_	_

1	In	in	IN	_	3	case	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	studies	study	NNS	_	13	ppmod	_	_
4	where	where	WRB	_	6	adv	_	_
5	patients	patient	NNS	_	6	dep	_	_
6	were	be	VBD	_	3	relcl	_	_
7	on	on	IN	_	10	case	_	_
8	chronic	chronic	JJ	_	10	attr	_	_
9	drug1	drug0	NN	_	10	com	_	_
10	therapy	therapy	NN	_	6	ppmod	_	_
11	,	,	,	_	13	p	_	_
12	drug2	drug0	NN	_	13	dep	_	_
13	had	have	VBD	_	0	root	_	_
14	no	no	DT	_	16	det	_	_
15	measurable	measurable	JJ	_	16	attr	_	_
16	effect	effect	NN	_	13	obj	_	_
17	on	on	IN	_	20	case	_	_
18	the	the	DT	_	20	det	_	_
19	mean	mean	JJ	_	20	attr	_	_
20	distribution	distribution	NN	_	13	ppmod	_	_
21	of	of	IN	_	23	case	_	_
22	drug3	drug0	NN	_	23	com	_	_
23	concentrations	concentration	NNS	_	20	ppmod	_	_
24	or	or	CC	_	23	cc	_	_
25	the	the	DT	_	27	det	_	_
26	mean	mean	JJ	_	27	attr	_	_
27	estimates	estimate	NNS	_	23	conj	_	_
28	of	of	IN	_	30	case	_	_
29	drug4	drug0	NN	_	30	com	_	_
30	clearance	clearance	NN	_	27	ppmod	_	_
31	.	.	.	_	13	p	_	_

1	Though	though	IN	_	5	mark	_	_
2	individual	individual	JJ	_	4	attr	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	levels	level	NNS	_	5	dep	_	_
5	fluctuated	fluctuate	VBD	_	8	advcl	_	_
6	,	,	,	_	8	p	_	_
7	there	there	EX	_	8	dep	_	_
8	were	be	VBD	_	0	root	_	_
9	no	no	DT	_	12	det	_	_
10	clinically	clinically	RB	_	11	adv	_	_
11	significant	significant	JJ	_	12	attr	_	_
12	symptoms	symptom	NNS	_	8	obj	_	_
13	of	of	IN	_	15	case	_	_
14	drug	drug	NN	_	15	com	_	_
15	inter-action	inter-action	NN	_	12	ppmod	_	_
16	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	:	:	:	_	1	p	_	_
5	drug3	drug0	NN	_	39	dep	_	_
6	and	and	CC	_	5	cc	_	_
7	drug4	drug0	NN	_	5	conj	_	_
8	containing	contain	VBG	_	5	acl	_	_
9	drug5	drug0	NN	_	8	obj	_	_
10	or	or	CC	_	9	cc	_	_
11	drug6	drug0	NN	_	9	conj	_	_
12	,	,	,	_	9	p	_	_
13	as	as	RB	_	14	com	_	_
14	well	well	RB	_	9	cc	_	_
15	as	as	IN	_	14	com	_	_
16	formulations	formulation	NNS	_	9	conj	_	_
17	containing	contain	VBG	_	16	acl	_	_
18	divalent	divalent	NN	_	17	obj	_	_
19	and	and	CC	_	18	cc	_	_
20	trivalent	trivalent	JJ	_	21	attr	_	_
21	cations	cation	NNS	_	18	conj	_	_
22	such	such	JJ	_	24	adv	_	_
23	as	as	IN	_	24	case	_	_
24	drug7	drug0	NN	_	21	ppmod	_	_
25	(	-lrb-	-LRB-	_	26	p	_	_
26	drug8	drug0	NN	_	24	prn	_	_
27	)	-rrb-	-RRB-	_	26	p	_	_
28	,	,	,	_	24	p	_	_
29	chewable/buffered	chewable/buffered	JJ	_	30	attr	_	_
30	tablets	tablet	NNS	_	24	conj	_	_
31	or	or	CC	_	30	cc	_	_
32	the	the	DT	_	34	det	_	_
33	pediatric	pediatric	JJ	_	34	attr	_	_
34	powder	powder	NN	_	24	conj	_	_
35	for	for	IN	_	37	case	_	_
36	oral	oral	JJ	_	37	attr	_	_
37	solution	solution	NN	_	21	ppmod	_	_
38	can	can	MD	_	39	modal	_	_
39	form	form	VB	_	1	acl	_	_
40	chelation	chelation	NN	_	41	com	_	_
41	complexes	complex	NNS	_	39	obj	_	_
42	with	with	IN	_	43	case	_	_
43	drug9	drug0	NN	_	41	ppmod	_	_
44	and	and	CC	_	39	cc	_	_
45	interfere	interfere	VB	_	39	conj	_	_
46	with	with	IN	_	48	case	_	_
47	its	its	PRP$	_	48	poss	_	_
48	bioavailability	bioavailability	NN	_	45	ppmod	_	_
49	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	7	dep	_	_
2	administered	administer	VBN	_	1	acl	_	_
3	2	0	CD	_	4	num	_	_
4	hours	hour	NNS	_	2	obj	_	_
5	before	before	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	resulted	result	VBD	_	0	root	_	_
8	in	in	IN	_	11	case	_	_
9	a	a	DT	_	11	det	_	_
10	slower	slow	JJR	_	11	attr	_	_
11	absorption	absorption	NN	_	7	ppmod	_	_
12	(	-lrb-	-LRB-	_	24	p	_	_
13	mean	mean	NN	_	15	com	_	_
14	C	c	NN	_	15	com	_	_
15	max	max	NN	_	24	dep	_	_
16	decreased	decrease	VBD	_	15	acl	_	_
17	by	by	IN	_	18	case	_	_
18	30	0	CD	_	16	ppmod	_	_
19	%	%	NN	_	18	meta	_	_
20	and	and	CC	_	18	cc	_	_
21	mean	mean	NN	_	23	com	_	_
22	T	t	NN	_	23	com	_	_
23	max	max	NN	_	18	conj	_	_
24	increased	increase	VBN	_	11	prn	_	_
25	by	by	IN	_	27	case	_	_
26	1	0	CD	_	27	num	_	_
27	hour	hour	NN	_	24	ppmod	_	_
28	)	-rrb-	-RRB-	_	24	p	_	_
29	and	and	CC	_	11	cc	_	_
30	a	a	DT	_	32	det	_	_
31	lesser	less	JJR	_	32	attr	_	_
32	extent	extent	NN	_	11	conj	_	_
33	of	of	IN	_	34	case	_	_
34	absorption	absorption	NN	_	32	ppmod	_	_
35	(	-lrb-	-LRB-	_	37	p	_	_
36	mean	mean	JJ	_	37	attr	_	_
37	AUC	auc	NN	_	34	prn	_	_
38	decreased	decrease	VBD	_	37	acl	_	_
39	by	by	IN	_	41	case	_	_
40	approximately	approximately	RB	_	41	adv	_	_
41	25	0	CD	_	38	ppmod	_	_
42	%	%	NN	_	41	meta	_	_
43	)	-rrb-	-RRB-	_	37	p	_	_
44	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	14	dep	_	_
2	-	-	CC	_	1	cc	_	_
3	and	and	CC	_	5	cc	_	_
4	drug2	drug0	NN	_	5	advnp	_	_
5	-containing	-containing	JJ	_	6	attr	_	_
6	drug3	drug0	NN	_	1	conj	_	_
7	,	,	,	_	1	p	_	_
8	administered	administer	VBN	_	1	acl	_	_
9	concomitantly	concomitantly	RB	_	8	adv	_	_
10	with	with	IN	_	11	case	_	_
11	drug4	drug0	NN	_	8	ppmod	_	_
12	,	,	,	_	1	p	_	_
13	significantly	significantly	RB	_	14	adv	_	_
14	decreased	decrease	VBD	_	0	root	_	_
15	the	the	DT	_	16	det	_	_
16	bioavailability	bioavailability	NN	_	14	obj	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	48	0	CD	_	16	num	_	_
19	%	%	NN	_	18	meta	_	_
20	)	-rrb-	-RRB-	_	18	p	_	_
21	of	of	IN	_	22	case	_	_
22	drug5	drug0	NN	_	16	ppmod	_	_
23	.	.	.	_	14	p	_	_

1	Separating	separate	VBG	_	0	root	_	_
2	the	the	DT	_	3	det	_	_
3	doses	dose	NNS	_	1	obj	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	1	cc	_	_
7	drug2	drug0	NN	_	8	dep	_	_
8	minimizes	minimize	VBZ	_	1	conj	_	_
9	this	this	DT	_	10	det	_	_
10	decrease	decrease	NN	_	8	obj	_	_
11	in	in	IN	_	12	case	_	_
12	bioavailability	bioavailability	NN	_	10	ppmod	_	_
13	;	;	:	_	1	p	_	_

1	therefore	therefore	RB	_	8	adv	_	_
2	,	,	,	_	8	p	_	_
3	administration	administration	NN	_	8	dep	_	_
4	of	of	IN	_	6	case	_	_
5	these	these	DT	_	6	det	_	_
6	agents	agent	NNS	_	3	ppmod	_	_
7	should	should	MD	_	8	modal	_	_
8	precede	precede	VBP	_	0	root	_	_
9	drug1	drug0	NN	_	10	com	_	_
10	dosing	dosing	NN	_	8	obj	_	_
11	by	by	IN	_	13	case	_	_
12	4	0	CD	_	13	num	_	_
13	hours	hour	NNS	_	8	ppmod	_	_
14	or	or	CC	_	8	cc	_	_
15	follow	follow	VBP	_	8	conj	_	_
16	drug2	drug0	NN	_	17	com	_	_
17	dosing	dosing	NN	_	15	obj	_	_
18	by	by	IN	_	22	case	_	_
19	at	at	IN	_	21	case	_	_
20	least	least	JJS	_	21	attr	_	_
21	2	0	CD	_	22	num	_	_
22	hours	hour	NNS	_	15	ppmod	_	_
23	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	20	dep	_	_
2	:	:	:	_	1	p	_	_
3	Two	#crd#	CD	_	4	com	_	_
4	hundred	#crd#	CD	_	5	num	_	_
5	mg	mg	NN	_	1	appo	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	1	ppmod	_	_
8	(	-lrb-	-LRB-	_	7	p	_	_
9	equivalent	equivalent	JJ	_	7	attr	_	_
10	to	to	TO	_	14	aux	_	_
11	1	0	CD	_	14	num	_	_
12	to	to	TO	_	11	cc	_	_
13	3	0	CD	_	11	conj	_	_
14	cups	cup	NNS	_	9	ppmod	_	_
15	of	of	IN	_	17	case	_	_
16	American	american	NNP	_	17	com	_	_
17	coffee	coffee	NN	_	14	ppmod	_	_
18	)	-rrb-	-RRB-	_	7	p	_	_
19	was	be	VBD	_	20	aux	_	_
20	administered	administer	VBN	_	0	root	_	_
21	to	to	TO	_	26	aux	_	_
22	16	0	CD	_	26	num	_	_
23	normal	normal	JJ	_	25	adv	_	_
24	,	,	,	_	25	p	_	_
25	healthy	healthy	JJ	_	26	attr	_	_
26	volunteers	volunteer	NNS	_	20	ppmod	_	_
27	who	who	WP	_	29	dep	_	_
28	had	have	VBD	_	29	aux	_	_
29	achieved	achieve	VBD	_	26	relcl	_	_
30	steady-state	steady-state	JJ	_	32	attr	_	_
31	blood	blood	NN	_	32	com	_	_
32	concentrations	concentration	NNS	_	29	obj	_	_
33	of	of	IN	_	34	case	_	_
34	drug3	drug0	NN	_	32	ppmod	_	_
35	after	after	IN	_	37	case	_	_
36	being	be	VBG	_	37	aux	_	_
37	dosed	dose	VBN	_	29	ppmod	_	_
38	at	at	IN	_	41	case	_	_
39	400	0	CD	_	40	num	_	_
40	mg	mg	NN	_	41	com	_	_
41	qd	qd	NN	_	37	ppmod	_	_
42	.	.	.	_	20	p	_	_

1	This	this	DT	_	4	dep	_	_
2	did	do	VBD	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	result	result	VB	_	0	root	_	_
5	in	in	IN	_	11	case	_	_
6	any	any	DT	_	11	det	_	_
7	statistically	statistically	RB	_	10	adv	_	_
8	or	or	CC	_	7	cc	_	_
9	clinically	clinically	RB	_	7	conj	_	_
10	relevant	relevant	JJ	_	11	attr	_	_
11	changes	change	NNS	_	4	ppmod	_	_
12	in	in	IN	_	15	case	_	_
13	the	the	DT	_	15	det	_	_
14	pharmacokinetic	pharmacokinetic	JJ	_	15	attr	_	_
15	parameters	parameter	NNS	_	11	ppmod	_	_
16	of	of	IN	_	18	case	_	_
17	either	either	CC	_	18	cc	_	_
18	drug1	drug0	NN	_	15	ppmod	_	_
19	or	or	CC	_	18	cc	_	_
20	its	its	PRP$	_	22	poss	_	_
21	major	major	JJ	_	22	attr	_	_
22	metabolite	metabolite	NN	_	18	conj	_	_
23	,	,	,	_	22	p	_	_
24	drug2	drug0	NN	_	22	appo	_	_
25	.	.	.	_	4	p	_	_

1	No	no	DT	_	2	det	_	_
2	data	datum	NNS	_	3	dep	_	_
3	are	be	VBP	_	0	root	_	_
4	available	available	JJ	_	3	dep	_	_
5	on	on	IN	_	7	case	_	_
6	potential	potential	JJ	_	7	attr	_	_
7	interactions	interaction	NNS	_	4	ppmod	_	_
8	in	in	IN	_	9	case	_	_
9	individuals	individual	NNS	_	7	ppmod	_	_
10	who	who	WP	_	11	dep	_	_
11	consume	consume	VBD	_	9	relcl	_	_
12	greater	great	JJR	_	11	dep	_	_
13	than	than	IN	_	15	case	_	_
14	200	0	CD	_	15	num	_	_
15	mg	mg	NN	_	12	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	drug1	drug0	NN	_	15	ppmod	_	_
18	per	per	IN	_	19	case	_	_
19	day	day	NN	_	15	ppmod	_	_
20	or	or	CC	_	19	cc	_	_
21	in	in	IN	_	22	case	_	_
22	those	those	DT	_	19	conj	_	_
23	,	,	,	_	9	p	_	_
24	such	such	JJ	_	28	adv	_	_
25	as	as	IN	_	28	case	_	_
26	the	the	DT	_	28	det	_	_
27	geriatric	geriatric	JJ	_	28	attr	_	_
28	population	population	NN	_	9	ppmod	_	_
29	,	,	,	_	9	p	_	_
30	who	who	WP	_	33	dep	_	_
31	are	be	VBP	_	33	aux	_	_
32	generally	generally	RB	_	33	adv	_	_
33	believed	believe	VBN	_	9	relcl	_	_
34	to	to	TO	_	35	aux	_	_
35	be	be	VB	_	33	comp	_	_
36	more	more	RBR	_	37	adv	_	_
37	susceptible	susceptible	JJ	_	35	dep	_	_
38	to	to	TO	_	40	aux	_	_
39	the	the	DT	_	40	det	_	_
40	development	development	NN	_	37	ppmod	_	_
41	of	of	IN	_	45	case	_	_
42	drug-induced	drug-induced	JJ	_	45	attr	_	_
43	CNS-related	cns-related	JJ	_	45	attr	_	_
44	adverse	adverse	JJ	_	45	attr	_	_
45	effects	effect	NNS	_	40	ppmod	_	_
46	.	.	.	_	3	p	_	_

1	Other	other	JJ	_	2	attr	_	_
2	drug1	drug0	NNS	_	4	dep	_	_
3	have	have	VBP	_	4	aux	_	_
4	demonstrated	demonstrate	VBN	_	0	root	_	_
5	moderate	moderate	JJ	_	4	dep	_	_
6	to	to	TO	_	8	aux	_	_
7	marked	marked	JJ	_	8	attr	_	_
8	interference	interference	NN	_	5	ppmod	_	_
9	with	with	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	metabolism	metabolism	NN	_	8	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	,	,	,	_	13	p	_	_
15	resulting	result	VBG	_	13	acl	_	_
16	in	in	IN	_	19	case	_	_
17	a	a	DT	_	19	det	_	_
18	reduced	reduce	VBN	_	19	attr	_	_
19	clearance	clearance	NN	_	15	ppmod	_	_
20	,	,	,	_	13	p	_	_
21	a	a	DT	_	22	det	_	_
22	prolongation	prolongation	NN	_	13	conj	_	_
23	of	of	IN	_	25	case	_	_
24	plasma	plasma	NN	_	25	com	_	_
25	half-life	half-life	NN	_	22	ppmod	_	_
26	,	,	,	_	22	p	_	_
27	and	and	CC	_	22	cc	_	_
28	an	an	DT	_	29	det	_	_
29	increase	increase	NN	_	13	conj	_	_
30	in	in	IN	_	31	case	_	_
31	symptoms	symptom	NNS	_	29	ppmod	_	_
32	that	that	WDT	_	33	dep	_	_
33	accompany	accompany	VBP	_	31	relcl	_	_
34	high	high	JJ	_	35	attr	_	_
35	levels	level	NNS	_	33	obj	_	_
36	of	of	IN	_	37	case	_	_
37	drug3	drug0	NN	_	35	ppmod	_	_
38	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	has	have	VBZ	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	demonstrated	demonstrate	VBN	_	0	root	_	_
7	to	to	TO	_	8	aux	_	_
8	interfere	interfere	VB	_	6	comp	_	_
9	with	with	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	elimination	elimination	NN	_	8	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	other	other	JJ	_	14	attr	_	_
14	drug3	drug0	NN	_	11	ppmod	_	_
15	.	.	.	_	6	p	_	_

1	This	this	DT	_	2	det	_	_
2	interference	interference	NN	_	4	dep	_	_
3	has	have	VBZ	_	4	aux	_	_
4	resulted	result	VBD	_	0	root	_	_
5	in	in	IN	_	7	case	_	_
6	significant	significant	JJ	_	7	attr	_	_
7	increases	increase	NNS	_	4	ppmod	_	_
8	in	in	IN	_	9	case	_	_
9	half-life	half-life	NN	_	7	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	AUC	auc	NN	_	9	conj	_	_
12	.	.	.	_	4	p	_	_

1	The	the	DT	_	2	det	_	_
2	interaction	interaction	NN	_	10	dep	_	_
3	between	between	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	has	have	VBZ	_	10	aux	_	_
8	not	not	RB	_	10	neg	_	_
9	been	be	VBN	_	10	aux	_	_
10	studied	study	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Elevated	elevated	JJ	_	5	attr	_	_
4	serum	serum	NN	_	5	com	_	_
5	levels	level	NNS	_	10	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	have	have	VBP	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	reported	report	VBN	_	1	acl	_	_
11	with	with	IN	_	13	case	_	_
12	concomitant	concomitant	JJ	_	13	attr	_	_
13	use	use	NN	_	10	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	with	with	IN	_	18	case	_	_
17	other	other	JJ	_	18	attr	_	_
18	members	member	NNS	_	13	ppmod	_	_
19	of	of	IN	_	21	case	_	_
20	the	the	DT	_	21	det	_	_
21	drug4	drug0	NN	_	18	ppmod	_	_
22	.	.	.	_	1	p	_	_

1	Interaction	interaction	NN	_	9	dep	_	_
2	between	between	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	has	have	VBZ	_	9	aux	_	_
7	not	not	RB	_	9	neg	_	_
8	been	be	VBN	_	9	aux	_	_
9	studied	study	VBN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	No	no	DT	_	6	det	_	_
4	clinically	clinically	RB	_	5	adv	_	_
5	significant	significant	JJ	_	6	attr	_	_
6	changes	change	NNS	_	21	dep	_	_
7	in	in	IN	_	9	case	_	_
8	drug2	drug0	NN	_	9	com	_	_
9	pharmacokinetics	pharmacokinetics	NNS	_	6	ppmod	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	AUC	auc	NN	_	9	prn	_	_
12	,	,	,	_	11	p	_	_
13	C	c	NN	_	14	com	_	_
14	max	max	NN	_	11	conj	_	_
15	,	,	,	_	14	p	_	_
16	or	or	CC	_	14	cc	_	_
17	T	t	NN	_	18	com	_	_
18	max	max	NN	_	11	conj	_	_
19	)	-rrb-	-RRB-	_	11	p	_	_
20	were	be	VBD	_	21	aux	_	_
21	observed	observe	VBN	_	1	acl	_	_
22	when	when	WRB	_	31	adv	_	_
23	a	a	DT	_	25	det	_	_
24	single	single	JJ	_	25	attr	_	_
25	dose	dose	NN	_	31	dep	_	_
26	of	of	IN	_	29	case	_	_
27	drug3	drug0	NN	_	29	attr	_	_
28	400	0	CD	_	29	num	_	_
29	mg	mg	NN	_	25	ppmod	_	_
30	was	be	VBD	_	31	aux	_	_
31	given	give	VBN	_	21	comp	_	_
32	after	after	IN	_	34	case	_	_
33	multiple	multiple	JJ	_	34	attr	_	_
34	doses	dose	NNS	_	31	ppmod	_	_
35	of	of	IN	_	36	case	_	_
36	drug4	drug0	NN	_	34	ppmod	_	_
37	(	-lrb-	-LRB-	_	40	p	_	_
38	20	0	CD	_	39	num	_	_
39	mg	mg	NN	_	40	com	_	_
40	qd	qd	NN	_	36	prn	_	_
41	)	-rrb-	-RRB-	_	40	p	_	_
42	in	in	IN	_	45	case	_	_
43	13	0	CD	_	45	num	_	_
44	healthy	healthy	JJ	_	45	attr	_	_
45	volunteers	volunteer	NNS	_	31	ppmod	_	_
46	.	.	.	_	1	p	_	_

1	Changes	change	NNS	_	7	dep	_	_
2	in	in	IN	_	4	case	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	pharmacokinetics	pharmacokinetics	NNS	_	1	ppmod	_	_
5	were	be	VBD	_	7	aux	_	_
6	not	not	RB	_	7	neg	_	_
7	studied	study	VBN	_	0	root	_	_
8	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	No	no	DT	_	5	det	_	_
4	significant	significant	JJ	_	5	attr	_	_
5	differences	difference	NNS	_	7	dep	_	_
6	were	be	VBD	_	7	aux	_	_
7	observed	observe	VBN	_	1	acl	_	_
8	in	in	IN	_	11	case	_	_
9	mean	mean	JJ	_	11	attr	_	_
10	drug2	drug0	NN	_	11	com	_	_
11	AUC	auc	NN	_	7	ppmod	_	_
12	,	,	,	_	11	p	_	_
13	C	c	NN	_	14	com	_	_
14	max	max	NN	_	11	conj	_	_
15	,	,	,	_	14	p	_	_
16	C	c	NN	_	17	com	_	_
17	min	min	NN	_	11	conj	_	_
18	or	or	CC	_	17	cc	_	_
19	T	t	NN	_	20	com	_	_
20	max	max	NN	_	11	conj	_	_
21	(	-lrb-	-LRB-	_	24	p	_	_
22	although	although	IN	_	24	case	_	_
23	C	c	NN	_	24	com	_	_
24	max	max	NN	_	7	prn	_	_
25	increased	increase	VBN	_	24	acl	_	_
26	by	by	IN	_	27	case	_	_
27	11	0	CD	_	25	ppmod	_	_
28	%	%	NN	_	27	meta	_	_
29	)	-rrb-	-RRB-	_	24	p	_	_
30	when	when	WRB	_	40	adv	_	_
31	extended	extended	JJ	_	33	attr	_	_
32	drug3	drug0	NN	_	33	com	_	_
33	capsules	capsule	NNS	_	40	dep	_	_
34	(	-lrb-	-LRB-	_	37	p	_	_
35	100	0	CD	_	36	num	_	_
36	mg	mg	NN	_	37	com	_	_
37	tid	tid	NN	_	33	prn	_	_
38	)	-rrb-	-RRB-	_	37	p	_	_
39	were	be	VBD	_	40	aux	_	_
40	coadministered	coadministered	VBN	_	7	comp	_	_
41	with	with	IN	_	42	case	_	_
42	drug4	drug0	NN	_	40	ppmod	_	_
43	(	-lrb-	-LRB-	_	46	p	_	_
44	400	0	CD	_	45	num	_	_
45	mg	mg	NN	_	46	com	_	_
46	qd	qd	NN	_	42	prn	_	_
47	)	-rrb-	-RRB-	_	46	p	_	_
48	for	for	IN	_	50	case	_	_
49	five	#crd#	CD	_	50	num	_	_
50	days	day	NNS	_	42	ppmod	_	_
51	in	in	IN	_	54	case	_	_
52	15	0	CD	_	54	num	_	_
53	healthy	healthy	JJ	_	54	attr	_	_
54	males	male	NNS	_	42	ppmod	_	_
55	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	unlikely	unlikely	JJ	_	2	dep	_	_
4	to	to	TO	_	5	aux	_	_
5	have	have	VB	_	3	comp	_	_
6	a	a	DT	_	8	det	_	_
7	significant	significant	JJ	_	8	attr	_	_
8	effect	effect	NN	_	5	obj	_	_
9	on	on	IN	_	11	case	_	_
10	drug2	drug0	NN	_	11	com	_	_
11	metabolism	metabolism	NN	_	5	ppmod	_	_
12	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	slows	slow	VBZ	_	0	root	_	_
5	the	the	DT	_	7	det	_	_
6	renal	renal	JJ	_	7	attr	_	_
7	elimination	elimination	NN	_	4	obj	_	_
8	of	of	IN	_	9	case	_	_
9	lome-floxacin	lome-floxacin	NN	_	7	ppmod	_	_
10	.	.	.	_	4	p	_	_

1	An	an	DT	_	2	det	_	_
2	increase	increase	NN	_	31	dep	_	_
3	of	of	IN	_	4	case	_	_
4	63	0	CD	_	2	ppmod	_	_
5	%	%	NN	_	4	meta	_	_
6	in	in	IN	_	9	case	_	_
7	the	the	DT	_	9	det	_	_
8	mean	mean	JJ	_	9	attr	_	_
9	AUC	auc	NN	_	2	ppmod	_	_
10	and	and	CC	_	2	cc	_	_
11	increases	increase	NNS	_	2	conj	_	_
12	of	of	IN	_	13	case	_	_
13	50	0	CD	_	11	ppmod	_	_
14	%	%	NN	_	13	meta	_	_
15	and	and	CC	_	13	cc	_	_
16	4	0	CD	_	13	conj	_	_
17	%	%	NN	_	16	meta	_	_
18	,	,	,	_	16	p	_	_
19	respectively	respectively	RB	_	16	adv	_	_
20	,	,	,	_	16	p	_	_
21	in	in	IN	_	25	case	_	_
22	the	the	DT	_	25	det	_	_
23	mean	mean	JJ	_	25	attr	_	_
24	T	t	NN	_	25	com	_	_
25	max	max	NN	_	13	conj	_	_
26	and	and	CC	_	25	cc	_	_
27	mean	mean	NN	_	29	com	_	_
28	C	c	NN	_	29	com	_	_
29	max	max	NN	_	25	conj	_	_
30	were	be	VBD	_	31	aux	_	_
31	noted	note	VBN	_	0	root	_	_
32	in	in	IN	_	34	case	_	_
33	1	0	CD	_	34	num	_	_
34	study	study	NN	_	31	ppmod	_	_
35	of	of	IN	_	37	case	_	_
36	6	0	CD	_	37	num	_	_
37	individuals	individual	NNS	_	34	ppmod	_	_
38	.	.	.	_	31	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	No	no	DT	_	6	det	_	_
4	clinically	clinically	RB	_	5	adv	_	_
5	significant	significant	JJ	_	6	attr	_	_
6	changes	change	NNS	_	7	dep	_	_
7	occurred	occur	VBD	_	1	acl	_	_
8	in	in	IN	_	10	case	_	_
9	heart	heart	NN	_	10	com	_	_
10	rate	rate	NN	_	7	ppmod	_	_
11	or	or	CC	_	10	cc	_	_
12	corrected	corrected	JJ	_	14	attr	_	_
13	QT	qt	VBG	_	14	attr	_	_
14	intervals	interval	NNS	_	10	conj	_	_
15	,	,	,	_	10	p	_	_
16	or	or	CC	_	10	cc	_	_
17	in	in	IN	_	19	case	_	_
18	drug2	drug0	NN	_	19	com	_	_
19	metabolite	metabolite	NN	_	10	conj	_	_
20	or	or	CC	_	19	cc	_	_
21	drug3	drug0	NN	_	22	com	_	_
22	pharmacokinetics	pharmacokinetics	NNS	_	19	conj	_	_
23	,	,	,	_	7	p	_	_
24	during	during	IN	_	26	case	_	_
25	concurrent	concurrent	JJ	_	26	attr	_	_
26	administration	administration	NN	_	7	ppmod	_	_
27	of	of	IN	_	28	case	_	_
28	drug4	drug0	NN	_	26	ppmod	_	_
29	and	and	CC	_	28	cc	_	_
30	drug5	drug0	NN	_	28	conj	_	_
31	at	at	IN	_	32	case	_	_
32	steady-state	steady-state	NN	_	26	ppmod	_	_
33	in	in	IN	_	36	case	_	_
34	28	0	CD	_	36	num	_	_
35	healthy	healthy	JJ	_	36	attr	_	_
36	males	male	NNS	_	32	ppmod	_	_
37	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	may	may	MD	_	5	modal	_	_
5	enhance	enhance	VB	_	0	root	_	_
6	the	the	DT	_	7	det	_	_
7	effects	effect	NNS	_	5	obj	_	_
8	of	of	IN	_	11	case	_	_
9	the	the	DT	_	11	det	_	_
10	oral	oral	JJ	_	11	attr	_	_
11	drug3	drug0	NN	_	7	ppmod	_	_
12	,	,	,	_	11	p	_	_
13	drug4	drug0	NN	_	11	conj	_	_
14	,	,	,	_	13	p	_	_
15	or	or	CC	_	13	cc	_	_
16	its	its	PRP$	_	17	poss	_	_
17	derivatives	derivative	NNS	_	11	conj	_	_
18	.	.	.	_	5	p	_	_

1	When	when	WRB	_	5	adv	_	_
2	these	these	DT	_	3	det	_	_
3	products	product	NNS	_	5	dep	_	_
4	are	be	VBP	_	5	aux	_	_
5	administered	administer	VBN	_	16	advcl	_	_
6	concomitantly	concomitantly	RB	_	5	adv	_	_
7	,	,	,	_	16	p	_	_
8	prothrombin	prothrombin	NN	_	16	dep	_	_
9	or	or	CC	_	8	cc	_	_
10	other	other	JJ	_	13	attr	_	_
11	suitable	suitable	JJ	_	13	attr	_	_
12	coagulation	coagulation	NN	_	13	com	_	_
13	tests	test	NNS	_	8	conj	_	_
14	should	should	MD	_	16	modal	_	_
15	be	be	VB	_	16	aux	_	_
16	monitored	monitor	VBN	_	0	root	_	_
17	closely	closely	RB	_	16	adv	_	_
18	.	.	.	_	16	p	_	_

1	However	however	RB	_	18	adv	_	_
2	,	,	,	_	18	p	_	_
3	no	no	DT	_	8	det	_	_
4	clinically	clinically	RB	_	7	adv	_	_
5	or	or	CC	_	7	cc	_	_
6	statistically	statistically	RB	_	7	adv	_	_
7	significant	significant	JJ	_	8	attr	_	_
8	differences	difference	NNS	_	18	dep	_	_
9	in	in	IN	_	12	case	_	_
10	prothrombin	prothrombin	NN	_	12	com	_	_
11	time	time	NN	_	12	com	_	_
12	ratio	ratio	NN	_	8	ppmod	_	_
13	or	or	CC	_	12	cc	_	_
14	drug1	drug0	NN	_	16	com	_	_
15	enantiomer	enantiomer	NN	_	16	com	_	_
16	pharmacokinetics	pharmacokinetics	NNS	_	12	conj	_	_
17	were	be	VBD	_	18	aux	_	_
18	observed	observe	VBN	_	0	root	_	_
19	in	in	IN	_	22	case	_	_
20	a	a	DT	_	22	det	_	_
21	small	small	JJ	_	22	attr	_	_
22	study	study	NN	_	18	ppmod	_	_
23	of	of	IN	_	26	case	_	_
24	7	0	CD	_	26	num	_	_
25	healthy	healthy	JJ	_	26	attr	_	_
26	males	male	NNS	_	22	ppmod	_	_
27	who	who	WP	_	28	dep	_	_
28	received	receive	VBD	_	26	relcl	_	_
29	both	both	CC	_	30	cc	_	_
30	drug2	drug0	NN	_	28	obj	_	_
31	and	and	CC	_	30	cc	_	_
32	drug3	drug0	NN	_	30	conj	_	_
33	under	under	IN	_	35	case	_	_
34	steady-state	steady-state	JJ	_	35	attr	_	_
35	conditions	condition	NNS	_	28	ppmod	_	_
36	.	.	.	_	18	p	_	_

1	drug1	drug0	NN	_	7	dep	_	_
2	,	,	,	_	1	p	_	_
3	a	a	DT	_	4	det	_	_
4	drug2	drug0	NN	_	1	appo	_	_
5	,	,	,	_	1	p	_	_
6	may	may	MD	_	7	modal	_	_
7	antagonize	antagonize	VB	_	0	root	_	_
8	the	the	DT	_	10	det	_	_
9	bactercidal	bactercidal	JJ	_	10	attr	_	_
10	effect	effect	NN	_	7	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	and	and	CC	_	7	cc	_	_
14	concurrent	concurrent	JJ	_	15	attr	_	_
15	use	use	NN	_	21	dep	_	_
16	of	of	IN	_	18	case	_	_
17	these	these	DT	_	18	det	_	_
18	drugs	drug	NNS	_	15	ppmod	_	_
19	should	should	MD	_	21	modal	_	_
20	be	be	VB	_	21	aux	_	_
21	avoided	avoid	VBN	_	7	conj	_	_
22	.	.	.	_	7	p	_	_

1	Prolonged	prolonged	JJ	_	3	attr	_	_
2	recovery	recovery	NN	_	3	com	_	_
3	time	time	NN	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	occur	occur	VB	_	0	root	_	_
6	if	if	IN	_	11	mark	_	_
7	drug1	drug0	NN	_	11	dep	_	_
8	and/or	and/or	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	are	be	VBP	_	11	aux	_	_
11	used	use	VBN	_	5	comp	_	_
12	concurrently	concurrently	RB	_	11	adv	_	_
13	with	with	IN	_	14	case	_	_
14	drug3	drug0	NN	_	11	ppmod	_	_
15	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	clinically	clinically	RB	_	4	adv	_	_
4	compatible	compatible	JJ	_	2	dep	_	_
5	with	with	IN	_	12	case	_	_
6	the	the	DT	_	12	det	_	_
7	commonly	commonly	RB	_	8	adv	_	_
8	used	use	VBN	_	12	attr	_	_
9	general	general	JJ	_	12	attr	_	_
10	and	and	CC	_	9	cc	_	_
11	local	local	JJ	_	9	conj	_	_
12	drug2	drug0	NNS	_	4	ppmod	_	_
13	when	when	WRB	_	19	adv	_	_
14	an	an	DT	_	17	det	_	_
15	adequate	adequate	JJ	_	17	attr	_	_
16	respiratory	respiratory	JJ	_	17	attr	_	_
17	exchange	exchange	NN	_	19	dep	_	_
18	is	be	VBZ	_	19	aux	_	_
19	maintained	maintain	VBN	_	2	comp	_	_
20	.	.	.	_	2	p	_	_

1	No	no	DT	_	5	det	_	_
2	formal	formal	JJ	_	5	attr	_	_
3	drug/drug	drug/drug	NN	_	5	com	_	_
4	interaction	interaction	NN	_	5	com	_	_
5	studies	study	NNS	_	9	dep	_	_
6	with	with	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	were	be	VBD	_	9	aux	_	_
9	performed	performed	VBN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	Cytochrome	cytochrome	NN	_	2	com	_	_
2	P-450	p-0	NN	_	5	dep	_	_
3	is	be	VBZ	_	5	aux	_	_
4	not	not	RB	_	5	neg	_	_
5	known	know	VBN	_	0	root	_	_
6	to	to	TO	_	8	aux	_	_
7	be	be	VB	_	8	aux	_	_
8	involved	involve	VBN	_	5	comp	_	_
9	in	in	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	metabolism	metabolism	NN	_	8	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	highly	highly	RB	_	4	adv	_	_
4	bound	bind	VBN	_	0	root	_	_
5	to	to	TO	_	7	aux	_	_
6	plasma	plasma	NN	_	7	com	_	_
7	proteins	protein	NNS	_	4	ppmod	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	96	0	CD	_	7	num	_	_
10	to	to	TO	_	9	cc	_	_
11	99	0	CD	_	9	conj	_	_
12	%	%	NN	_	9	meta	_	_
13	)	-rrb-	-RRB-	_	9	p	_	_
14	.	.	.	_	4	p	_	_

1	Laboratory	laboratory	NN	_	2	com	_	_
2	Tests	test	NNS	_	8	dep	_	_
3	Response	response	NN	_	2	acl	_	_
4	to	to	TO	_	5	aux	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	should	should	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	monitored	monitor	VBN	_	0	root	_	_
9	by	by	IN	_	10	case	_	_
10	measuring	measure	VBG	_	8	ppmod	_	_
11	serum	serum	NN	_	14	attr	_	_
12	total	total	JJ	_	14	attr	_	_
13	drug2	drug0	NN	_	14	com	_	_
14	concentrations	concentration	NNS	_	10	obj	_	_
15	just	just	RB	_	16	com	_	_
16	prior	prior	RB	_	14	adv	_	_
17	to	to	TO	_	18	aux	_	_
18	administration	administration	NN	_	16	ppmod	_	_
19	on	on	IN	_	20	case	_	_
20	Day	day	NN	_	10	ppmod	_	_
21	29	0	CD	_	20	num	_	_
22	and	and	CC	_	20	cc	_	_
23	every	every	DT	_	25	det	_	_
24	8	0	CD	_	25	num	_	_
25	weeks	week	NNS	_	20	conj	_	_
26	thereafter	thereafter	RB	_	25	adv	_	_
27	.	.	.	_	8	p	_	_

1	Serum	serum	NN	_	3	com	_	_
2	transaminase	transaminase	NN	_	3	com	_	_
3	levels	level	NNS	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	obtained	obtain	VBN	_	0	root	_	_
7	before	before	IN	_	8	case	_	_
8	starting	start	VBG	_	6	ppmod	_	_
9	treatment	treatment	NN	_	8	obj	_	_
10	with	with	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	8	cc	_	_
13	periodically	periodically	RB	_	8	conj	_	_
14	during	during	IN	_	15	case	_	_
15	treatment	treatment	NN	_	13	ppmod	_	_
16	.	.	.	_	6	p	_	_

1	Periodic	periodic	JJ	_	2	attr	_	_
2	measurement	measurement	NN	_	10	dep	_	_
3	of	of	IN	_	6	case	_	_
4	serum	serum	NN	_	6	com	_	_
5	PSA	psa	NN	_	6	com	_	_
6	levels	level	NNS	_	2	ppmod	_	_
7	may	may	MD	_	10	modal	_	_
8	also	also	RB	_	10	adv	_	_
9	be	be	VB	_	10	aux	_	_
10	considered	consider	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	The	the	DT	_	3	det	_	_
2	renal	renal	JJ	_	3	attr	_	_
3	effects	effect	NNS	_	9	dep	_	_
4	of	of	IN	_	6	case	_	_
5	nephrotoxic	nephrotoxic	JJ	_	6	attr	_	_
6	compounds	compound	NNS	_	3	ppmod	_	_
7	may	may	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	potentiated	potentiate	VBN	_	0	root	_	_
10	by	by	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	9	p	_	_

1	Many	many	JJ	_	3	attr	_	_
2	other	other	JJ	_	3	attr	_	_
3	medicines	medicine	NNS	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	increase	increase	VB	_	0	root	_	_
6	or	or	CC	_	5	cc	_	_
7	decrease	decrease	VB	_	5	conj	_	_
8	the	the	DT	_	9	det	_	_
9	effects	effect	NNS	_	7	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	or	or	CC	_	7	cc	_	_
13	affect	affect	VB	_	5	conj	_	_
14	your	your	NN	_	15	com	_	_
15	condition	condition	NN	_	13	obj	_	_
16	.	.	.	_	5	p	_	_

1	Before	before	IN	_	2	mark	_	_
2	taking	take	VBG	_	11	advcl	_	_
3	drug1	drug0	NN	_	2	obj	_	_
4	,	,	,	_	11	p	_	_
5	tell	tell	NN	_	7	com	_	_
6	your	your	NN	_	7	com	_	_
7	doctor	doctor	NN	_	11	dep	_	_
8	if	if	IN	_	9	case	_	_
9	you	you	NN	_	7	ppmod	_	_
10	are	be	VBP	_	11	aux	_	_
11	taking	take	VBG	_	0	root	_	_
12	any	any	DT	_	11	obj	_	_
13	of	of	IN	_	16	case	_	_
14	the	the	DT	_	16	det	_	_
15	following	following	JJ	_	16	attr	_	_
16	medicines	medicine	NNS	_	12	ppmod	_	_
17	:	:	:	_	11	p	_	_
18	-	-	:	_	11	p	_	_
19	drug2	drug0	NN	_	11	dep	_	_
20	or	or	CC	_	19	cc	_	_
21	another	another	DT	_	22	det	_	_
22	drug3	drug0	NN	_	19	conj	_	_
23	such	such	JJ	_	25	adv	_	_
24	as	as	IN	_	25	case	_	_
25	drug4	drug0	NN	_	22	ppmod	_	_
26	(	-lrb-	-LRB-	_	27	p	_	_
27	drug5	drug0	NN	_	25	prn	_	_
28	)	-rrb-	-RRB-	_	27	p	_	_
29	,	,	,	_	25	p	_	_
30	drug6	drug0	NN	_	25	conj	_	_
31	(	-lrb-	-LRB-	_	34	p	_	_
32	drug7	drug0	NN	_	34	dep	_	_
33	,	,	,	_	34	p	_	_
34	others	other	NNS	_	30	prn	_	_
35	)	-rrb-	-RRB-	_	34	p	_	_
36	,	,	,	_	30	p	_	_
37	drug8	drug0	NN	_	25	conj	_	_
38	(	-lrb-	-LRB-	_	39	p	_	_
39	drug9	drug0	NN	_	37	prn	_	_
40	)	-rrb-	-RRB-	_	39	p	_	_
41	,	,	,	_	37	p	_	_
42	drug10	drug0	NN	_	25	conj	_	_
43	(	-lrb-	-LRB-	_	44	p	_	_
44	drug11	drug0	NN	_	42	prn	_	_
45	)	-rrb-	-RRB-	_	44	p	_	_
46	,	,	,	_	42	p	_	_
47	or	or	CC	_	42	cc	_	_
48	drug12	drug0	NN	_	25	conj	_	_
49	(	-lrb-	-LRB-	_	50	p	_	_
50	drug13	drug0	NN	_	48	prn	_	_
51	)	-rrb-	-RRB-	_	50	p	_	_
52	;	;	:	_	11	p	_	_

1	-	-	CC	_	3	cc	_	_
2	a	a	DT	_	3	det	_	_
3	drug1	drug0	NN	_	0	root	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	drug2	drug0	NN	_	3	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	such	such	JJ	_	3	dep	_	_
8	as	as	IN	_	9	case	_	_
9	drug3	drug0	NN	_	7	ppmod	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	drug4	drug0	NN	_	9	prn	_	_
12	,	,	,	_	11	p	_	_
13	drug5	drug0	NN	_	11	appo	_	_
14	,	,	,	_	11	p	_	_
15	drug6	drug0	NN	_	11	appo	_	_
16	,	,	,	_	11	p	_	_
17	others	other	NNS	_	11	appo	_	_
18	)	-rrb-	-RRB-	_	11	p	_	_
19	,	,	,	_	9	p	_	_
20	drug7	drug0	NN	_	24	attr	_	_
21	(	-lrb-	-LRB-	_	24	p	_	_
22	drug8	drug0	NN	_	24	attr	_	_
23	,	,	,	_	24	p	_	_
24	drug9	drug0	NN	_	9	appo	_	_
25	,	,	,	_	24	p	_	_
26	drug10	drug0	CD	_	24	num	_	_
27	)	-rrb-	-RRB-	_	24	p	_	_
28	,	,	,	_	24	p	_	_
29	drug11	drug0	CD	_	33	num	_	_
30	(	-lrb-	-LRB-	_	33	p	_	_
31	drug12	drug0	CD	_	33	num	_	_
32	,	,	,	_	33	p	_	_
33	drug13	drug0	CD	_	24	num	_	_
34	)	-rrb-	-RRB-	_	33	p	_	_
35	,	,	,	_	33	p	_	_
36	drug14	drug0	CD	_	33	num	_	_
37	(	-lrb-	-LRB-	_	38	p	_	_
38	drug15	drug0	CD	_	36	num	_	_
39	)	-rrb-	-RRB-	_	38	p	_	_
40	,	,	,	_	33	p	_	_
41	drug16	drug0	CD	_	33	conj	_	_
42	(	-lrb-	-LRB-	_	43	p	_	_
43	drug17	drug0	CD	_	41	num	_	_
44	)	-rrb-	-RRB-	_	43	p	_	_
45	,	,	,	_	41	p	_	_
46	drug18	drug0	CD	_	33	conj	_	_
47	(	-lrb-	-LRB-	_	48	p	_	_
48	drug19	drug0	CD	_	46	num	_	_
49	)	-rrb-	-RRB-	_	48	p	_	_
50	,	,	,	_	46	p	_	_
51	drug20	drug0	CD	_	33	conj	_	_
52	(	-lrb-	-LRB-	_	53	p	_	_
53	drug21	drug0	CD	_	51	num	_	_
54	)	-rrb-	-RRB-	_	53	p	_	_
55	,	,	,	_	51	p	_	_
56	and	and	CC	_	51	cc	_	_
57	drug22	drug0	CD	_	33	conj	_	_
58	(	-lrb-	-LRB-	_	24	p	_	_
59	drug23	drug0	CD	_	24	num	_	_
60	,	,	,	_	24	p	_	_
61	drug24	drug0	CD	_	24	num	_	_
62	,	,	,	_	24	p	_	_
63	drug25	drug0	CD	_	24	num	_	_
64	)	-rrb-	-RRB-	_	24	p	_	_
65	;	;	:	_	24	p	_	_

1	-	-	CC	_	4	cc	_	_
2	a	a	DT	_	4	det	_	_
3	sulfa-based	sulfa-based	JJ	_	4	attr	_	_
4	drug	drug	NN	_	0	root	_	_
5	such	such	JJ	_	7	adv	_	_
6	as	as	IN	_	7	case	_	_
7	drug1	drug0	NN	_	4	ppmod	_	_
8	-	-	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	drug3	drug0	NN	_	7	prn	_	_
12	,	,	,	_	11	p	_	_
13	drug4	drug0	NN	_	11	appo	_	_
14	)	-rrb-	-RRB-	_	11	p	_	_
15	,	,	,	_	7	p	_	_
16	drug5	drug0	NN	_	7	conj	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	drug6	drug0	NN	_	16	prn	_	_
19	)	-rrb-	-RRB-	_	18	p	_	_
20	,	,	,	_	16	p	_	_
21	or	or	CC	_	16	cc	_	_
22	drug7	drug0	NN	_	7	conj	_	_
23	(	-lrb-	-LRB-	_	24	p	_	_
24	drug8	drug0	NN	_	22	prn	_	_
25	)	-rrb-	-RRB-	_	24	p	_	_
26	;	;	:	_	22	p	_	_

1	-	-	CC	_	3	cc	_	_
2	a	a	DT	_	3	det	_	_
3	drug1	drug0	NN	_	0	root	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	drug2	drug0	NN	_	3	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	such	such	JJ	_	9	adv	_	_
8	as	as	IN	_	9	case	_	_
9	drug3	drug0	NN	_	3	ppmod	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	drug4	drug0	NN	_	9	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	,	,	,	_	9	p	_	_
14	drug5	drug0	NN	_	9	conj	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	drug6	drug0	NN	_	14	prn	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	,	,	,	_	14	p	_	_
19	or	or	CC	_	14	cc	_	_
20	drug7	drug0	NN	_	9	conj	_	_
21	(	-lrb-	-LRB-	_	22	p	_	_
22	drug8	drug0	NN	_	20	prn	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	;	;	:	_	20	p	_	_

1	-	-	CC	_	3	cc	_	_
2	a	a	DT	_	3	det	_	_
3	drug1	drug0	NN	_	0	root	_	_
4	such	such	JJ	_	6	adv	_	_
5	as	as	IN	_	6	case	_	_
6	drug2	drug0	NN	_	3	ppmod	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	drug3	drug0	NN	_	6	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	,	,	,	_	6	p	_	_
11	drug4	drug0	NN	_	6	conj	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	drug5	drug0	NN	_	11	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	,	,	,	_	11	p	_	_
16	drug6	drug0	NN	_	6	conj	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	drug7	drug0	NN	_	16	prn	_	_
19	)	-rrb-	-RRB-	_	18	p	_	_
20	,	,	,	_	16	p	_	_
21	drug8	drug0	NN	_	6	conj	_	_
22	(	-lrb-	-LRB-	_	23	p	_	_
23	drug9	drug0	NN	_	21	prn	_	_
24	)	-rrb-	-RRB-	_	23	p	_	_
25	,	,	,	_	21	p	_	_
26	and	and	CC	_	21	cc	_	_
27	others	other	NNS	_	6	conj	_	_
28	;	;	:	_	3	p	_	_

1	-	-	CC	_	3	cc	_	_
2	a	a	DT	_	3	det	_	_
3	drug1	drug0	NN	_	0	root	_	_
4	(	-lrb-	-LRB-	_	6	p	_	_
5	water	water	NN	_	6	com	_	_
6	pill	pill	NN	_	3	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	such	such	JJ	_	10	adv	_	_
9	as	as	IN	_	10	case	_	_
10	drug2	drug0	NN	_	3	ppmod	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	drug3	drug0	NN	_	10	prn	_	_
13	,	,	,	_	12	p	_	_
14	drug4	drug0	NN	_	12	appo	_	_
15	)	-rrb-	-RRB-	_	12	p	_	_
16	,	,	,	_	10	p	_	_
17	drug5	drug0	NN	_	10	conj	_	_
18	(	-lrb-	-LRB-	_	19	p	_	_
19	drug6	drug0	NN	_	17	prn	_	_
20	)	-rrb-	-RRB-	_	19	p	_	_
21	,	,	,	_	17	p	_	_
22	and	and	CC	_	17	cc	_	_
23	others	other	NNS	_	10	conj	_	_
24	;	;	:	_	3	p	_	_

1	-	-	CC	_	3	cc	_	_
2	a	a	DT	_	3	det	_	_
3	drug1	drug0	NN	_	0	root	_	_
4	such	such	JJ	_	6	adv	_	_
5	as	as	IN	_	6	case	_	_
6	drug2	drug0	NN	_	3	ppmod	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	drug3	drug0	NN	_	6	prn	_	_
9	,	,	,	_	8	p	_	_
10	drug4	drug0	NN	_	8	appo	_	_
11	,	,	,	_	8	p	_	_
12	others	other	NNS	_	8	appo	_	_
13	)	-rrb-	-RRB-	_	8	p	_	_
14	,	,	,	_	6	p	_	_
15	drug5	drug0	NN	_	6	conj	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	drug6	drug0	NN	_	15	prn	_	_
18	,	,	,	_	17	p	_	_
19	others	other	NNS	_	17	appo	_	_
20	)	-rrb-	-RRB-	_	17	p	_	_
21	,	,	,	_	15	p	_	_
22	drug7	drug0	NN	_	6	conj	_	_
23	(	-lrb-	-LRB-	_	24	p	_	_
24	drug8	drug0	NN	_	22	prn	_	_
25	,	,	,	_	24	p	_	_
26	drug9	drug0	NN	_	24	appo	_	_
27	,	,	,	_	24	p	_	_
28	others	other	NNS	_	24	appo	_	_
29	)	-rrb-	-RRB-	_	24	p	_	_
30	,	,	,	_	22	p	_	_
31	and	and	CC	_	22	cc	_	_
32	others	other	NNS	_	6	conj	_	_
33	;	;	:	_	3	p	_	_

1	-	-	CC	_	3	cc	_	_
2	a	a	DT	_	3	det	_	_
3	drug1	drug0	NN	_	0	root	_	_
4	such	such	JJ	_	6	adv	_	_
5	as	as	IN	_	6	case	_	_
6	drug2	drug0	NN	_	3	ppmod	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	drug3	drug0	NN	_	6	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	,	,	,	_	6	p	_	_
11	drug4	drug0	NN	_	6	conj	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	drug5	drug0	NN	_	11	prn	_	_
14	,	,	,	_	13	p	_	_
15	drug6	drug0	NN	_	13	appo	_	_
16	)	-rrb-	-RRB-	_	13	p	_	_
17	,	,	,	_	11	p	_	_
18	drug7	drug0	NN	_	6	conj	_	_
19	(	-lrb-	-LRB-	_	20	p	_	_
20	drug8	drug0	NN	_	18	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	,	,	,	_	18	p	_	_
23	drug9	drug0	NN	_	6	conj	_	_
24	(	-lrb-	-LRB-	_	25	p	_	_
25	drug10	drug0	NN	_	23	prn	_	_
26	)	-rrb-	-RRB-	_	25	p	_	_
27	,	,	,	_	23	p	_	_
28	and	and	CC	_	23	cc	_	_
29	others	other	NNS	_	6	conj	_	_
30	;	;	:	_	3	p	_	_

1	-	-	CC	_	2	cc	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	drug2	drug0	NN	_	2	prn	_	_
5	)	-rrb-	-RRB-	_	4	p	_	_
6	;	;	:	_	2	p	_	_

1	-	-	CC	_	2	cc	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	drug2	drug0	NN	_	2	prn	_	_
5	)	-rrb-	-RRB-	_	4	p	_	_
6	;	;	:	_	2	p	_	_

1	-	-	CC	_	2	cc	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	drug2	drug0	NN	_	2	prn	_	_
5	,	,	,	_	4	p	_	_
6	drug3	drug0	NN	_	4	appo	_	_
7	)	-rrb-	-RRB-	_	4	p	_	_
8	;	;	:	_	2	p	_	_

1	or	or	CC	_	0	root	_	_
2	-	-	CC	_	1	cc	_	_
3	over-the-counter	over-the-counter	JJ	_	13	attr	_	_
4	cough	cough	NN	_	13	attr	_	_
5	,	,	,	_	4	p	_	_
6	cold	cold	NN	_	4	conj	_	_
7	,	,	,	_	6	p	_	_
8	allergy	allergy	NN	_	4	conj	_	_
9	,	,	,	_	8	p	_	_
10	or	or	CC	_	8	cc	_	_
11	weight	weight	NN	_	12	com	_	_
12	loss	loss	NN	_	4	conj	_	_
13	medications	medication	NNS	_	1	conj	_	_
14	.	.	.	_	1	p	_	_

1	You	you	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	require	require	VB	_	0	root	_	_
4	a	a	DT	_	6	det	_	_
5	dosage	dosage	JJ	_	6	attr	_	_
6	adjustment	adjustment	NN	_	3	obj	_	_
7	or	or	CC	_	6	cc	_	_
8	special	special	JJ	_	9	attr	_	_
9	monitoring	monitoring	NN	_	6	conj	_	_
10	if	if	IN	_	13	mark	_	_
11	you	you	RB	_	13	adv	_	_
12	are	be	VBP	_	13	aux	_	_
13	taking	take	VBG	_	3	comp	_	_
14	any	any	DT	_	13	obj	_	_
15	of	of	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	medicines	medicine	NNS	_	14	ppmod	_	_
18	listed	list	VBN	_	17	acl	_	_
19	above	above	RB	_	18	adv	_	_
20	.	.	.	_	3	p	_	_

1	Drugs	drug	NNS	_	9	dep	_	_
2	other	other	JJ	_	1	attr	_	_
3	than	than	IN	_	4	case	_	_
4	those	those	DT	_	2	ppmod	_	_
5	listed	list	VBN	_	4	acl	_	_
6	here	here	RB	_	5	adv	_	_
7	may	may	MD	_	9	modal	_	_
8	also	also	RB	_	9	adv	_	_
9	interact	interact	VB	_	0	root	_	_
10	with	with	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	or	or	CC	_	9	cc	_	_
13	affect	affect	VB	_	9	conj	_	_
14	your	your	NN	_	15	com	_	_
15	condition	condition	NN	_	13	obj	_	_
16	.	.	.	_	9	p	_	_

1	Talk	talk	NN	_	0	root	_	_
2	to	to	TO	_	4	aux	_	_
3	your	your	NN	_	4	com	_	_
4	doctor	doctor	NN	_	1	ppmod	_	_
5	and	and	CC	_	1	cc	_	_
6	pharmacist	pharmacist	VBP	_	1	conj	_	_
7	before	before	IN	_	10	case	_	_
8	taking	take	VBG	_	10	lv	_	_
9	any	any	DT	_	10	det	_	_
10	prescription	prescription	NN	_	6	ppmod	_	_
11	or	or	CC	_	10	cc	_	_
12	over-the-counter	over-the-counter	NN	_	13	com	_	_
13	medicines	medicine	NNS	_	10	conj	_	_
14	,	,	,	_	10	p	_	_
15	including	include	VBG	_	17	adv	_	_
16	herbal	herbal	JJ	_	17	attr	_	_
17	products	product	NNS	_	10	ppmod	_	_
18	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	14	dep	_	_
2	:	:	:	_	14	p	_	_
3	In	in	IN	_	6	case	_	_
4	a	a	DT	_	6	det	_	_
5	prospective	prospective	JJ	_	6	attr	_	_
6	study	study	NN	_	14	ppmod	_	_
7	involving	involve	VBG	_	6	acl	_	_
8	six-healthy-male	six-healthy-male	JJ	_	9	attr	_	_
9	volunteers	volunteer	NNS	_	7	obj	_	_
10	,	,	,	_	14	p	_	_
11	drug2	drug0	NN	_	14	dep	_	_
12	did	do	VBD	_	14	aux	_	_
13	not	not	RB	_	14	neg	_	_
14	affect	affect	VB	_	0	root	_	_
15	the	the	DT	_	16	det	_	_
16	metabolism	metabolism	NN	_	14	obj	_	_
17	of	of	IN	_	18	case	_	_
18	drug3	drug0	NN	_	16	ppmod	_	_
19	.	.	.	_	14	p	_	_

1	These	these	DT	_	3	det	_	_
2	six	#crd#	CD	_	3	num	_	_
3	volunteers	volunteer	NNS	_	4	dep	_	_
4	received	receive	VBD	_	0	root	_	_
5	drug1	drug0	NN	_	4	obj	_	_
6	alone	alone	RB	_	5	adv	_	_
7	(	-lrb-	-LRB-	_	9	p	_	_
8	60	0	CD	_	9	num	_	_
9	mg	mg	NN	_	5	prn	_	_
10	twice	twice	RB	_	11	com	_	_
11	daily	daily	RB	_	9	adv	_	_
12	)	-rrb-	-RRB-	_	9	p	_	_
13	for	for	IN	_	15	case	_	_
14	8	0	CD	_	15	num	_	_
15	days	day	NNS	_	4	ppmod	_	_
16	,	,	,	_	4	p	_	_
17	followed	followed	VBN	_	4	comp	_	_
18	by	by	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	in	in	IN	_	21	case	_	_
21	combination	combination	NN	_	19	ppmod	_	_
22	with	with	IN	_	23	case	_	_
23	drug3	drug0	NN	_	21	ppmod	_	_
24	(	-lrb-	-LRB-	_	26	p	_	_
25	500	0	CD	_	26	num	_	_
26	mg	mg	NN	_	23	prn	_	_
27	once	once	RB	_	28	adv	_	_
28	daily	daily	JJ	_	26	attr	_	_
29	)	-rrb-	-RRB-	_	26	p	_	_
30	for	for	IN	_	32	case	_	_
31	10	0	CD	_	32	num	_	_
32	days	day	NNS	_	19	ppmod	_	_
33	.	.	.	_	4	p	_	_

1	(	-lrb-	-LRB-	_	6	p	_	_
2	Both	both	DT	_	3	det	_	_
3	drugs	drug	NNS	_	6	dep	_	_
4	were	be	VBD	_	6	aux	_	_
5	thus	thus	RB	_	6	adv	_	_
6	dosed	dose	VBN	_	0	root	_	_
7	to	to	TO	_	9	aux	_	_
8	steady	steady	JJ	_	9	attr	_	_
9	state	state	NN	_	6	ppmod	_	_
10	.	.	.	_	6	p	_	_
11	)	-rrb-	-RRB-	_	6	p	_	_

1	The	the	DT	_	2	det	_	_
2	pharmacokinetics	pharmacokinetics	NNS	_	16	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	its	its	PRP$	_	8	poss	_	_
7	acid	acid	NN	_	8	com	_	_
8	metabolite	metabolite	NN	_	4	conj	_	_
9	and	and	CC	_	2	cc	_	_
10	the	the	DT	_	14	det	_	_
11	electrocardiographic	electrocardiographic	JJ	_	14	attr	_	_
12	QT	qt	JJ	_	14	attr	_	_
13	c	c	NN	_	14	com	_	_
14	interval	interval	NN	_	2	conj	_	_
15	were	be	VBD	_	16	aux	_	_
16	measured	measure	VBN	_	0	root	_	_
17	during	during	IN	_	19	case	_	_
18	both	both	DT	_	19	det	_	_
19	periods	period	NNS	_	16	ppmod	_	_
20	:	:	:	_	19	p	_	_
21	with	with	IN	_	22	case	_	_
22	drug2	drug0	NN	_	19	ppmod	_	_
23	alone	alone	RB	_	22	adv	_	_
24	,	,	,	_	22	p	_	_
25	and	and	CC	_	22	cc	_	_
26	with	with	IN	_	27	case	_	_
27	drug3	drug0	NN	_	22	conj	_	_
28	plus	plus	CC	_	27	cc	_	_
29	drug4	drug0	NN	_	27	conj	_	_
30	.	.	.	_	16	p	_	_

1	In	in	IN	_	3	case	_	_
2	five	#crd#	CD	_	3	num	_	_
3	men	man	NNS	_	7	ppmod	_	_
4	,	,	,	_	7	p	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	levels	level	NNS	_	7	dep	_	_
7	were	be	VBD	_	0	root	_	_
8	undetectable	undetectable	JJ	_	7	dep	_	_
9	(	-lrb-	-LRB-	_	11	p	_	_
10	5	0	CD	_	11	num	_	_
11	ng/mL	ng/ml	NN	_	7	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	throughout	throughout	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	study	study	NN	_	7	ppmod	_	_
16	;	;	:	_	7	p	_	_

1	in	in	IN	_	3	case	_	_
2	one	#crd#	CD	_	3	num	_	_
3	man	man	NN	_	10	ppmod	_	_
4	,	,	,	_	10	p	_	_
5	the	the	DT	_	7	det	_	_
6	C	c	NN	_	7	com	_	_
7	max	max	NN	_	10	dep	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	was	be	VBD	_	0	root	_	_
11	8.1	0	CD	_	12	num	_	_
12	ng/mL	ng/ml	NN	_	10	obj	_	_
13	with	with	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	alone	alone	RB	_	14	adv	_	_
16	and	and	CC	_	12	cc	_	_
17	7.2	0	CD	_	18	num	_	_
18	ng/mL	ng/ml	NN	_	12	conj	_	_
19	with	with	IN	_	20	case	_	_
20	drug3	drug0	NN	_	18	ppmod	_	_
21	plus	plus	CC	_	20	cc	_	_
22	drug4	drug0	NN	_	20	conj	_	_
23	.	.	.	_	10	p	_	_

1	The	the	DT	_	4	det	_	_
2	mean	mean	JJ	_	4	attr	_	_
3	C	c	NN	_	4	com	_	_
4	max	max	NN	_	20	dep	_	_
5	,	,	,	_	4	p	_	_
6	T	t	NN	_	7	com	_	_
7	max	max	NN	_	4	conj	_	_
8	,	,	,	_	7	p	_	_
9	and	and	CC	_	7	cc	_	_
10	AUC	auc	NN	_	4	conj	_	_
11	of	of	IN	_	14	case	_	_
12	the	the	DT	_	14	det	_	_
13	acid	acid	NN	_	14	com	_	_
14	metabolite	metabolite	NN	_	10	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	were	be	VBD	_	20	aux	_	_
18	not	not	RB	_	20	neg	_	_
19	significantly	significantly	RB	_	20	adv	_	_
20	changed	change	VBN	_	0	root	_	_
21	.	.	.	_	20	p	_	_

1	The	the	DT	_	5	det	_	_
2	mean	mean	JJ	_	5	attr	_	_
3	QT	qt	NN	_	5	com	_	_
4	c	c	NN	_	5	com	_	_
5	interval	interval	NN	_	9	dep	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	msec	msec	NNS	_	5	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	was	be	VBD	_	0	root	_	_
10	369	0	CD	_	9	obj	_	_
11	with	with	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	alone	alone	RB	_	12	adv	_	_
14	and	and	CC	_	10	cc	_	_
15	367	0	CD	_	10	conj	_	_
16	with	with	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	plus	plus	CC	_	17	cc	_	_
19	drug3	drug0	NN	_	17	conj	_	_
20	.	.	.	_	9	p	_	_

1	Also	also	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	in	in	FW	_	4	adv	_	_
4	vitro	vitro	FW	_	5	attr	_	_
5	experiments	experiment	NNS	_	6	dep	_	_
6	demonstrated	demonstrate	VBD	_	0	root	_	_
7	a	a	DT	_	8	det	_	_
8	lack	lack	NN	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	interaction	interaction	NN	_	8	ppmod	_	_
11	between	between	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	drug2	drug0	NN	_	12	conj	_	_
15	.	.	.	_	6	p	_	_

1	Thus	thus	RB	_	12	adv	_	_
2	,	,	,	_	12	p	_	_
3	the	the	DT	_	4	det	_	_
4	interaction	interaction	NN	_	12	dep	_	_
5	observed	observe	VBN	_	4	acl	_	_
6	between	between	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	is	be	VBZ	_	12	aux	_	_
11	not	not	RB	_	12	neg	_	_
12	expected	expect	VBN	_	0	root	_	_
13	for	for	IN	_	14	case	_	_
14	drug3	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	12	p	_	_

1	Serious	serious	JJ	_	3	attr	_	_
2	cardiac	cardiac	JJ	_	3	attr	_	_
3	dysrhythmias	dysrhythmia	NNS	_	11	dep	_	_
4	,	,	,	_	3	p	_	_
5	some	some	DT	_	3	appo	_	_
6	resulting	result	VBG	_	5	acl	_	_
7	in	in	IN	_	8	case	_	_
8	death	death	NN	_	6	ppmod	_	_
9	,	,	,	_	3	p	_	_
10	have	have	VBP	_	11	aux	_	_
11	occurred	occur	VBN	_	0	root	_	_
12	in	in	IN	_	13	case	_	_
13	patients	patient	NNS	_	11	ppmod	_	_
14	receiving	receive	VBG	_	13	acl	_	_
15	drug1	drug0	NN	_	14	obj	_	_
16	concomitantly	concomitantly	RB	_	19	adv	_	_
17	with	with	IN	_	19	case	_	_
18	other	other	JJ	_	19	attr	_	_
19	drug2	drug0	NNS	_	14	ppmod	_	_
20	.	.	.	_	11	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	7	ppmod	_	_
3	,	,	,	_	7	p	_	_
4	most	most	RBS	_	5	adv	_	_
5	drug1	drug0	JJ	_	7	dep	_	_
6	are	be	VBP	_	7	aux	_	_
7	contraindicated	contraindicate	VBN	_	0	root	_	_
8	in	in	IN	_	9	case	_	_
9	patients	patient	NNS	_	7	ppmod	_	_
10	receiving	receive	VBG	_	9	acl	_	_
11	drug2	drug0	NN	_	12	com	_	_
12	therapy	therapy	NN	_	10	obj	_	_
13	who	who	WP	_	14	dep	_	_
14	have	have	VBP	_	9	relcl	_	_
15	pre-existing	pre-existing	JJ	_	17	attr	_	_
16	cardiac	cardiac	JJ	_	17	attr	_	_
17	abnormalities	abnormality	NNS	_	14	obj	_	_
18	(	-lrb-	-LRB-	_	19	p	_	_
19	arrhythmia	arrhythmia	NN	_	17	prn	_	_
20	,	,	,	_	19	p	_	_
21	bradycardia	bradycardia	NN	_	19	conj	_	_
22	,	,	,	_	21	p	_	_
23	QT	qt	NN	_	26	com	_	_
24	c	c	NN	_	26	com	_	_
25	interval	interval	NN	_	26	com	_	_
26	prolongation	prolongation	NN	_	19	conj	_	_
27	,	,	,	_	26	p	_	_
28	ischemic	ischemic	JJ	_	30	attr	_	_
29	heart	heart	NN	_	30	com	_	_
30	disease	disease	NN	_	19	conj	_	_
31	,	,	,	_	30	p	_	_
32	congestive	congestive	JJ	_	34	attr	_	_
33	heart	heart	NN	_	34	com	_	_
34	failure	failure	NN	_	19	conj	_	_
35	,	,	,	_	34	p	_	_
36	etc.	etc.	NN	_	19	conj	_	_
37	)	-rrb-	-RRB-	_	19	p	_	_
38	or	or	CC	_	17	cc	_	_
39	electrolyte	electrolyte	NN	_	40	com	_	_
40	disturbances	disturbance	NNS	_	17	conj	_	_
41	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Following	follow	VBG	_	4	adv	_	_
4	co-administration	co-administration	NN	_	37	ppmod	_	_
5	of	of	IN	_	9	case	_	_
6	two	#crd#	CD	_	9	num	_	_
7	250-mg	0-mg	NN	_	9	com	_	_
8	drug2	drug0	NN	_	9	com	_	_
9	tablets	tablet	NNS	_	4	ppmod	_	_
10	administered	administer	VBN	_	9	acl	_	_
11	once	once	RB	_	12	com	_	_
12	daily	daily	RB	_	10	adv	_	_
13	with	with	IN	_	16	case	_	_
14	200-mg	0-mg	NN	_	16	com	_	_
15	drug3	drug0	NN	_	16	com	_	_
16	tablets	tablet	NNS	_	10	ppmod	_	_
17	administered	administer	VBN	_	16	acl	_	_
18	twice	twice	RB	_	19	com	_	_
19	daily	daily	RB	_	17	adv	_	_
20	for	for	IN	_	22	case	_	_
21	10	0	CD	_	22	num	_	_
22	days	day	NNS	_	17	ppmod	_	_
23	to	to	TO	_	26	aux	_	_
24	14	0	CD	_	26	num	_	_
25	healthy	healthy	JJ	_	26	attr	_	_
26	subjects	subject	NNS	_	17	ppmod	_	_
27	,	,	,	_	37	p	_	_
28	the	the	DT	_	31	det	_	_
29	steady-state	steady-state	JJ	_	31	attr	_	_
30	plasma	plasma	NN	_	31	com	_	_
31	concentration	concentration	NN	_	37	dep	_	_
32	of	of	IN	_	33	case	_	_
33	drug4	drug0	NN	_	31	ppmod	_	_
34	was	be	VBD	_	37	aux	_	_
35	not	not	RB	_	37	neg	_	_
36	significantly	significantly	RB	_	37	adv	_	_
37	altered	alter	VBN	_	1	acl	_	_
38	.	.	.	_	1	p	_	_

1	In	in	IN	_	2	case	_	_
2	general	general	JJ	_	17	ppmod	_	_
3	,	,	,	_	17	p	_	_
4	most	most	JJS	_	5	attr	_	_
5	patients	patient	NNS	_	17	dep	_	_
6	treated	treat	VBN	_	5	acl	_	_
7	with	with	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	who	who	WP	_	11	dep	_	_
10	are	be	VBP	_	11	aux	_	_
11	receiving	receive	VBG	_	5	relcl	_	_
12	concomitant	concomitant	JJ	_	14	attr	_	_
13	drug2	drug0	NN	_	14	com	_	_
14	therapy	therapy	NN	_	11	obj	_	_
15	may	may	MD	_	17	modal	_	_
16	not	not	RB	_	17	neg	_	_
17	require	require	VB	_	0	root	_	_
18	empiric	empiric	JJ	_	19	attr	_	_
19	adjustment	adjustment	NN	_	17	obj	_	_
20	of	of	IN	_	22	case	_	_
21	drug3	drug0	NN	_	22	com	_	_
22	dosage	dosage	NN	_	19	ppmod	_	_
23	or	or	CC	_	22	cc	_	_
24	monitoring	monitoring	NN	_	22	conj	_	_
25	of	of	IN	_	28	case	_	_
26	drug4	drug0	NN	_	28	com	_	_
27	plasma	plasma	NN	_	28	com	_	_
28	concentrations	concentration	NNS	_	24	ppmod	_	_
29	.	.	.	_	17	p	_	_

1	However	however	RB	_	8	adv	_	_
2	,	,	,	_	8	p	_	_
3	drug1	drug0	NN	_	5	com	_	_
4	plasma	plasma	NN	_	5	com	_	_
5	concentrations	concentration	NNS	_	8	dep	_	_
6	should	should	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	monitored	monitor	VBN	_	0	root	_	_
9	,	,	,	_	8	p	_	_
10	with	with	IN	_	12	case	_	_
11	dosage	dosage	NN	_	12	com	_	_
12	adjustment	adjustment	NN	_	8	ppmod	_	_
13	as	as	IN	_	14	case	_	_
14	appropriate	appropriate	JJ	_	12	ppmod	_	_
15	,	,	,	_	8	p	_	_
16	in	in	IN	_	17	case	_	_
17	patients	patient	NNS	_	8	ppmod	_	_
18	whose	whose	WP$	_	20	poss	_	_
19	pulmonary	pulmonary	JJ	_	20	attr	_	_
20	disease	disease	NN	_	21	dep	_	_
21	requires	require	VBZ	_	17	relcl	_	_
22	maintaining	maintain	VBG	_	21	comp	_	_
23	a	a	DT	_	27	det	_	_
24	given	given	JJ	_	27	attr	_	_
25	drug2	drug0	NN	_	27	com	_	_
26	plasma	plasma	NN	_	27	com	_	_
27	concentration	concentration	NN	_	22	obj	_	_
28	for	for	IN	_	31	case	_	_
29	optimal	optimal	JJ	_	31	attr	_	_
30	pulmonary	pulmonary	JJ	_	31	attr	_	_
31	function	function	NN	_	22	ppmod	_	_
32	or	or	CC	_	31	cc	_	_
33	in	in	IN	_	34	case	_	_
34	patients	patient	NNS	_	31	conj	_	_
35	with	with	IN	_	37	case	_	_
36	drug3	drug0	NN	_	37	com	_	_
37	concentrations	concentration	NNS	_	34	ppmod	_	_
38	at	at	IN	_	41	case	_	_
39	the	the	DT	_	41	det	_	_
40	higher	high	JJR	_	41	attr	_	_
41	end	end	NN	_	37	ppmod	_	_
42	of	of	IN	_	45	case	_	_
43	the	the	DT	_	45	det	_	_
44	therapeutic	therapeutic	JJ	_	45	attr	_	_
45	range	range	NN	_	41	ppmod	_	_
46	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	or	or	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	:	:	:	_	1	p	_	_
5	When	when	WRB	_	8	adv	_	_
6	drug3	drug0	NN	_	8	dep	_	_
7	is	be	VBZ	_	8	aux	_	_
8	administered	administer	VBN	_	21	advcl	_	_
9	immediately	immediately	RB	_	8	adv	_	_
10	following	follow	VBG	_	11	adv	_	_
11	drug4	drug0	NN	_	8	ppmod	_	_
12	or	or	CC	_	11	cc	_	_
13	drug5	drug0	NN	_	11	conj	_	_
14	,	,	,	_	21	p	_	_
15	the	the	DT	_	16	det	_	_
16	absorption	absorption	NN	_	21	dep	_	_
17	of	of	IN	_	18	case	_	_
18	drug6	drug0	NN	_	16	ppmod	_	_
19	is	be	VBZ	_	21	aux	_	_
20	slightly	slightly	RB	_	21	adv	_	_
21	enhanced	enhance	VBN	_	1	acl	_	_
22	.	.	.	_	1	p	_	_

1	The	the	DT	_	4	det	_	_
2	following	following	JJ	_	4	attr	_	_
3	drug	drug	NN	_	4	com	_	_
4	interactions	interaction	NNS	_	7	dep	_	_
5	have	have	VBP	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	reported	report	VBN	_	0	root	_	_
8	with	with	IN	_	10	case	_	_
9	drug1	drug0	NN	_	10	com	_	_
10	products	product	NNS	_	7	ppmod	_	_
11	.	.	.	_	7	p	_	_

1	It	it	PRP	_	5	dep	_	_
2	is	be	VBZ	_	5	aux	_	_
3	presently	presently	RB	_	5	adv	_	_
4	not	not	RB	_	5	neg	_	_
5	known	know	VBN	_	0	root	_	_
6	whether	whether	IN	_	11	mark	_	_
7	these	these	DT	_	10	det	_	_
8	same	same	JJ	_	10	attr	_	_
9	drug	drug	NN	_	10	com	_	_
10	interactions	interaction	NNS	_	11	dep	_	_
11	occur	occur	VBP	_	5	comp	_	_
12	with	with	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	.	.	.	_	5	p	_	_

1	Until	until	IN	_	4	mark	_	_
2	further	far	JJ	_	3	attr	_	_
3	data	datum	NNS	_	4	dep	_	_
4	are	be	VBP	_	19	advcl	_	_
5	available	available	JJ	_	4	dep	_	_
6	regarding	regard	VBG	_	9	adv	_	_
7	the	the	DT	_	9	det	_	_
8	potential	potential	JJ	_	9	attr	_	_
9	interaction	interaction	NN	_	5	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	with	with	IN	_	14	case	_	_
13	these	these	DT	_	14	det	_	_
14	compounds	compound	NNS	_	9	ppmod	_	_
15	,	,	,	_	19	p	_	_
16	caution	caution	NN	_	19	dep	_	_
17	should	should	MD	_	19	modal	_	_
18	be	be	VB	_	19	aux	_	_
19	used	use	VBN	_	0	root	_	_
20	during	during	IN	_	21	case	_	_
21	coadministration	coadministration	NN	_	19	ppmod	_	_
22	.	.	.	_	19	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	has	have	VBZ	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	reported	report	VBN	_	0	root	_	_
7	to	to	TO	_	8	aux	_	_
8	decrease	decrease	VB	_	6	comp	_	_
9	the	the	DT	_	10	det	_	_
10	clearance	clearance	NN	_	8	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	and	and	CC	_	8	cc	_	_
14	,	,	,	_	8	p	_	_
15	thus	thus	RB	_	8	adv	_	_
16	,	,	,	_	8	p	_	_
17	may	may	MD	_	18	modal	_	_
18	increase	increase	VB	_	8	conj	_	_
19	the	the	DT	_	21	det	_	_
20	pharmacologic	pharmacologic	JJ	_	21	attr	_	_
21	effect	effect	NN	_	18	obj	_	_
22	of	of	IN	_	23	case	_	_
23	drug4	drug0	NN	_	21	ppmod	_	_
24	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Concomitant	concomitant	JJ	_	4	attr	_	_
4	administration	administration	NN	_	11	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	has	have	VBZ	_	11	aux	_	_
10	been	be	VBN	_	11	aux	_	_
11	reported	report	VBN	_	1	acl	_	_
12	to	to	TO	_	13	aux	_	_
13	result	result	VB	_	11	comp	_	_
14	in	in	IN	_	18	case	_	_
15	elevated	elevated	JJ	_	18	attr	_	_
16	drug4	drug0	NN	_	18	com	_	_
17	serum	serum	NN	_	18	com	_	_
18	levels	level	NNS	_	13	ppmod	_	_
19	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	There	there	EX	_	5	dep	_	_
4	have	have	VBP	_	5	aux	_	_
5	been	be	VBN	_	1	acl	_	_
6	reports	report	NNS	_	5	obj	_	_
7	of	of	IN	_	10	case	_	_
8	increased	increase	VBN	_	10	attr	_	_
9	anticoagulant	anticoagulant	JJ	_	10	attr	_	_
10	effects	effect	NNS	_	6	ppmod	_	_
11	when	when	WRB	_	17	adv	_	_
12	drug2	drug0	NN	_	17	dep	_	_
13	and	and	CC	_	12	cc	_	_
14	oral	oral	JJ	_	15	attr	_	_
15	drug3	drug0	NN	_	12	conj	_	_
16	were	be	VBD	_	17	aux	_	_
17	used	use	VBN	_	5	comp	_	_
18	concomitantly	concomitantly	RB	_	17	adv	_	_
19	.	.	.	_	1	p	_	_

1	Increased	increase	VBN	_	3	attr	_	_
2	anticoagulation	anticoagulation	NN	_	3	com	_	_
3	effects	effect	NNS	_	12	dep	_	_
4	due	due	JJ	_	3	attr	_	_
5	to	to	TO	_	8	aux	_	_
6	a	a	DT	_	8	det	_	_
7	drug	drug	NN	_	8	com	_	_
8	interaction	interaction	NN	_	4	ppmod	_	_
9	with	with	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	may	may	MD	_	12	modal	_	_
12	be	be	VB	_	0	root	_	_
13	more	more	RBR	_	14	adv	_	_
14	pronounced	pronounced	JJ	_	12	dep	_	_
15	in	in	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	elderly	elderly	JJ	_	12	ppmod	_	_
18	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Concurrent	concurrent	JJ	_	4	attr	_	_
4	use	use	NN	_	13	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	or	or	CC	_	8	cc	_	_
10	drug4	drug0	NN	_	6	conj	_	_
11	has	have	VBZ	_	13	aux	_	_
12	been	be	VBN	_	13	aux	_	_
13	associated	associate	VBN	_	1	acl	_	_
14	in	in	IN	_	16	case	_	_
15	some	some	DT	_	16	det	_	_
16	patients	patient	NNS	_	13	ppmod	_	_
17	with	with	IN	_	20	case	_	_
18	acute	acute	JJ	_	20	attr	_	_
19	ergot	ergot	NN	_	20	com	_	_
20	toxicity	toxicity	NN	_	16	ppmod	_	_
21	characterized	characterize	VBN	_	20	acl	_	_
22	by	by	IN	_	25	case	_	_
23	severe	severe	JJ	_	25	attr	_	_
24	peripheral	peripheral	JJ	_	25	attr	_	_
25	vasospasm	vasospasm	NN	_	21	ppmod	_	_
26	and	and	CC	_	25	cc	_	_
27	dysesthesia	dysesthesia	NN	_	25	conj	_	_
28	.	.	.	_	1	p	_	_

1	Other	other	JJ	_	4	attr	_	_
2	drugs	drug	NNS	_	4	com	_	_
3	Drug	drug	NN	_	4	com	_	_
4	interactions	interaction	NNS	_	7	dep	_	_
5	have	have	VBP	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	reported	report	VBN	_	0	root	_	_
8	with	with	IN	_	10	case	_	_
9	concomitant	concomitant	JJ	_	10	attr	_	_
10	administration	administration	NN	_	7	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	other	other	JJ	_	15	attr	_	_
15	medications	medication	NNS	_	12	conj	_	_
16	,	,	,	_	15	p	_	_
17	including	include	VBG	_	18	adv	_	_
18	drug2	drug0	NN	_	15	ppmod	_	_
19	,	,	,	_	18	p	_	_
20	drug3	drug0	NN	_	18	conj	_	_
21	,	,	,	_	20	p	_	_
22	drug4	drug0	NN	_	18	conj	_	_
23	,	,	,	_	22	p	_	_
24	drug5	drug0	NN	_	18	conj	_	_
25	,	,	,	_	24	p	_	_
26	drug6	drug0	NN	_	18	conj	_	_
27	,	,	,	_	26	p	_	_
28	drug7	drug0	NN	_	18	conj	_	_
29	,	,	,	_	28	p	_	_
30	drug8	drug0	NN	_	18	conj	_	_
31	,	,	,	_	30	p	_	_
32	drug9	drug0	NN	_	18	conj	_	_
33	,	,	,	_	32	p	_	_
34	drug10	drug0	NN	_	18	conj	_	_
35	,	,	,	_	34	p	_	_
36	and	and	CC	_	34	cc	_	_
37	drug11	drug0	NN	_	18	conj	_	_
38	.	.	.	_	7	p	_	_

1	Injection	injection	NN	_	3	dep	_	_
2	There	there	EX	_	1	attr	_	_
3	is	be	VBZ	_	0	root	_	_
4	inadequate	inadequate	JJ	_	5	attr	_	_
5	systematic	systematic	JJ	_	3	obj	_	_
6	experience	experience	VBP	_	5	acl	_	_
7	with	with	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	use	use	NN	_	6	ppmod	_	_
10	of	of	IN	_	12	case	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	injection	injection	NN	_	9	ppmod	_	_
13	in	in	IN	_	14	case	_	_
14	combination	combination	NN	_	9	ppmod	_	_
15	with	with	IN	_	17	case	_	_
16	other	other	JJ	_	17	attr	_	_
17	medications	medication	NNS	_	14	ppmod	_	_
18	to	to	TO	_	19	aux	_	_
19	predict	predict	VB	_	14	acl	_	_
20	specific	specific	JJ	_	22	attr	_	_
21	drug-drug	drug-drug	JJ	_	22	attr	_	_
22	interactions	interaction	NNS	_	19	obj	_	_
23	.	.	.	_	3	p	_	_

1	Interactions	interaction	NNS	_	13	dep	_	_
2	attributed	attribute	VBN	_	1	acl	_	_
3	to	to	TO	_	6	aux	_	_
4	the	the	DT	_	6	det	_	_
5	combined	combined	JJ	_	6	attr	_	_
6	use	use	NN	_	2	ppmod	_	_
7	of	of	IN	_	9	case	_	_
8	drug1	drug0	JJ	_	9	attr	_	_
9	injection	injection	NN	_	6	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	epidural	epidural	JJ	_	12	attr	_	_
12	drug2	drug0	NN	_	9	conj	_	_
13	include	include	VBP	_	0	root	_	_
14	hypotension	hypotension	NN	_	13	obj	_	_
15	and	and	CC	_	14	cc	_	_
16	dyspnea	dyspnea	NN	_	14	conj	_	_
17	.	.	.	_	13	p	_	_

1	SIDE	side	JJ	_	2	attr	_	_
2	EFFECTS	effect	NNS	_	15	comp	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	drug1	drug0	NN	_	2	prn	_	_
5	)	-rrb-	-RRB-	_	4	p	_	_
6	The	the	DT	_	10	det	_	_
7	most	most	RBS	_	8	adv	_	_
8	common	common	JJ	_	10	attr	_	_
9	adverse	adverse	JJ	_	10	attr	_	_
10	reaction	reaction	NN	_	15	dep	_	_
11	during	during	IN	_	12	case	_	_
12	treatment	treatment	NN	_	10	ppmod	_	_
13	with	with	IN	_	14	case	_	_
14	drug2	drug0	NN	_	10	ppmod	_	_
15	is	be	VBZ	_	0	root	_	_
16	transient	transient	JJ	_	17	attr	_	_
17	drowsiness	drowsiness	NN	_	15	obj	_	_
18	(	-lrb-	-LRB-	_	19	p	_	_
19	10-63	0	CD	_	17	num	_	_
20	%	%	NN	_	19	meta	_	_
21	)	-rrb-	-RRB-	_	19	p	_	_
22	.	.	.	_	15	p	_	_

1	In	in	IN	_	4	case	_	_
2	one	#crd#	CD	_	4	num	_	_
3	controlled	controlled	JJ	_	4	attr	_	_
4	study	study	NN	_	12	ppmod	_	_
5	of	of	IN	_	7	case	_	_
6	175	0	CD	_	7	num	_	_
7	patients	patient	NNS	_	4	ppmod	_	_
8	,	,	,	_	12	p	_	_
9	transient	transient	JJ	_	10	attr	_	_
10	drowsiness	drowsiness	NN	_	12	dep	_	_
11	was	be	VBD	_	12	aux	_	_
12	observed	observe	VBN	_	0	root	_	_
13	in	in	IN	_	14	case	_	_
14	63	0	CD	_	12	ppmod	_	_
15	%	%	NN	_	14	meta	_	_
16	of	of	IN	_	17	case	_	_
17	those	those	DT	_	14	ppmod	_	_
18	receiving	receive	VBG	_	17	acl	_	_
19	drug1	drug0	NN	_	20	com	_	_
20	tablets	tablet	NNS	_	18	obj	_	_
21	compared	compare	VBN	_	23	adv	_	_
22	to	to	TO	_	23	aux	_	_
23	36	0	CD	_	18	ppmod	_	_
24	%	%	NN	_	23	meta	_	_
25	of	of	IN	_	26	case	_	_
26	those	those	DT	_	23	ppmod	_	_
27	in	in	IN	_	30	case	_	_
28	the	the	DT	_	30	det	_	_
29	placebo	placebo	NN	_	30	com	_	_
30	group	group	NN	_	26	ppmod	_	_
31	.	.	.	_	12	p	_	_

1	Other	other	JJ	_	4	attr	_	_
2	common	common	JJ	_	4	attr	_	_
3	adverse	adverse	JJ	_	4	attr	_	_
4	reactions	reaction	NNS	_	5	dep	_	_
5	are	be	VBP	_	0	root	_	_
6	dizziness	dizziness	NN	_	5	obj	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	5-15	0	CD	_	6	num	_	_
9	%	%	NN	_	8	meta	_	_
10	)	-rrb-	-RRB-	_	8	p	_	_
11	,	,	,	_	6	p	_	_
12	weakness	weakness	NN	_	6	conj	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	5-15	0	CD	_	12	num	_	_
15	%	%	NN	_	14	meta	_	_
16	)	-rrb-	-RRB-	_	14	p	_	_
17	and	and	CC	_	12	cc	_	_
18	fatigue	fatigue	NN	_	6	conj	_	_
19	(	-lrb-	-LRB-	_	20	p	_	_
20	2-4	0	CD	_	18	num	_	_
21	%	%	NN	_	20	meta	_	_
22	)	-rrb-	-RRB-	_	20	p	_	_
23	.	.	.	_	5	p	_	_

1	Others	other	NNS	_	2	dep	_	_
2	reported	report	VBN	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	Neuropsychiatric	neuropsychiatric	NN	_	2	dep	_	_
5	:	:	:	_	4	p	_	_
6	Confusion	confusion	NN	_	4	appo	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	1-11	0	CD	_	6	num	_	_
9	%	%	NN	_	8	meta	_	_
10	)	-rrb-	-RRB-	_	8	p	_	_
11	,	,	,	_	4	p	_	_
12	headache	headache	NN	_	4	appo	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	4-8	0	CD	_	12	num	_	_
15	%	%	NN	_	14	meta	_	_
16	)	-rrb-	-RRB-	_	14	p	_	_
17	,	,	,	_	4	p	_	_
18	insomnia	insomnia	NN	_	4	appo	_	_
19	(	-lrb-	-LRB-	_	20	p	_	_
20	2-7	0	CD	_	18	num	_	_
21	%	%	NN	_	20	meta	_	_
22	)	-rrb-	-RRB-	_	20	p	_	_
23	;	;	:	_	2	p	_	_

1	and	and	CC	_	5	cc	_	_
2	,	,	,	_	5	p	_	_
3	rarely	rarely	RB	_	5	adv	_	_
4	,	,	,	_	5	p	_	_
5	euphoria	euphoria	NN	_	0	root	_	_
6	,	,	,	_	5	p	_	_
7	excitement	excitement	NN	_	5	conj	_	_
8	,	,	,	_	7	p	_	_
9	depression	depression	NN	_	5	conj	_	_
10	,	,	,	_	9	p	_	_
11	hallucinations	hallucination	NNS	_	9	appo	_	_
12	,	,	,	_	9	p	_	_
13	paresthesia	paresthesia	NN	_	9	appo	_	_
14	,	,	,	_	9	p	_	_
15	muscle	muscle	NN	_	16	com	_	_
16	pain	pain	NN	_	9	appo	_	_
17	,	,	,	_	9	p	_	_
18	tinnitus	tinnitus	NN	_	9	appo	_	_
19	,	,	,	_	9	p	_	_
20	slurred	slurred	JJ	_	21	attr	_	_
21	speech	speech	NN	_	9	appo	_	_
22	,	,	,	_	9	p	_	_
23	coordination	coordination	NN	_	24	com	_	_
24	disorder	disorder	NN	_	9	appo	_	_
25	,	,	,	_	9	p	_	_
26	tremor	tremor	NN	_	9	appo	_	_
27	,	,	,	_	9	p	_	_
28	rigidity	rigidity	NN	_	9	appo	_	_
29	,	,	,	_	9	p	_	_
30	dystonia	dystonia	NN	_	9	appo	_	_
31	,	,	,	_	9	p	_	_
32	ataxia	ataxia	NN	_	9	appo	_	_
33	,	,	,	_	9	p	_	_
34	blurred	blurred	JJ	_	35	attr	_	_
35	vision	vision	NN	_	9	appo	_	_
36	,	,	,	_	9	p	_	_
37	nystagmus	nystagmus	NN	_	9	appo	_	_
38	,	,	,	_	9	p	_	_
39	strabismus	strabismus	NN	_	9	appo	_	_
40	,	,	,	_	9	p	_	_
41	miosis	miosis	NN	_	9	appo	_	_
42	,	,	,	_	9	p	_	_
43	mydriasis	mydriasis	NN	_	9	appo	_	_
44	,	,	,	_	9	p	_	_
45	diplopia	diplopia	NN	_	9	appo	_	_
46	,	,	,	_	9	p	_	_
47	dysarthria	dysarthria	NN	_	9	appo	_	_
48	,	,	,	_	9	p	_	_
49	epileptic	epileptic	JJ	_	50	attr	_	_
50	seizure	seizure	NN	_	9	appo	_	_
51	.	.	.	_	5	p	_	_

1	Cardiovascular	cardiovascular	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Hypotension	hypotension	NN	_	1	appo	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	0-9	0	CD	_	3	num	_	_
6	%	%	NN	_	5	meta	_	_
7	)	-rrb-	-RRB-	_	5	p	_	_
8	.	.	.	_	1	p	_	_

1	Rare	rare	JJ	_	2	attr	_	_
2	instances	instance	NNS	_	0	root	_	_
3	of	of	IN	_	4	case	_	_
4	dyspnea	dyspnea	NN	_	2	ppmod	_	_
5	,	,	,	_	4	p	_	_
6	palpitation	palpitation	NN	_	4	appo	_	_
7	,	,	,	_	4	p	_	_
8	chest	chest	NN	_	9	com	_	_
9	pain	pain	NN	_	4	appo	_	_
10	,	,	,	_	4	p	_	_
11	syncope	syncope	NN	_	4	appo	_	_
12	.	.	.	_	2	p	_	_

1	Gastrointestinal	gastrointestinal	JJ	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Nausea	nausea	NN	_	1	appo	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	4-12	0	CD	_	3	num	_	_
6	%	%	NN	_	5	meta	_	_
7	)	-rrb-	-RRB-	_	5	p	_	_
8	,	,	,	_	3	p	_	_
9	constipation	constipation	NN	_	3	appo	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	2-6	0	CD	_	9	num	_	_
12	%	%	NN	_	11	meta	_	_
13	)	-rrb-	-RRB-	_	11	p	_	_
14	;	;	:	_	1	p	_	_

1	and	and	CC	_	5	cc	_	_
2	,	,	,	_	5	p	_	_
3	rarely	rarely	RB	_	5	adv	_	_
4	,	,	,	_	5	p	_	_
5	dry	dry	VBP	_	0	root	_	_
6	mouth	mouth	NN	_	5	obj	_	_
7	,	,	,	_	6	p	_	_
8	anorexia	anorexia	NN	_	6	conj	_	_
9	,	,	,	_	8	p	_	_
10	taste	taste	JJ	_	11	attr	_	_
11	disorder	disorder	NN	_	6	conj	_	_
12	,	,	,	_	11	p	_	_
13	abdominal	abdominal	JJ	_	14	attr	_	_
14	pain	pain	NN	_	6	conj	_	_
15	,	,	,	_	14	p	_	_
16	vomiting	vomiting	NN	_	6	conj	_	_
17	,	,	,	_	16	p	_	_
18	diarrhea	diarrhea	NN	_	6	conj	_	_
19	,	,	,	_	18	p	_	_
20	and	and	CC	_	18	cc	_	_
21	positive	positive	JJ	_	22	attr	_	_
22	test	test	NN	_	6	conj	_	_
23	for	for	IN	_	25	case	_	_
24	occult	occult	JJ	_	25	attr	_	_
25	blood	blood	NN	_	6	ppmod	_	_
26	in	in	IN	_	27	case	_	_
27	stool	stool	NN	_	6	ppmod	_	_
28	.	.	.	_	5	p	_	_

1	Genitourinary	genitourinary	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Urinary	urinary	JJ	_	4	attr	_	_
4	frequency	frequency	NN	_	1	appo	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	2-6	0	CD	_	4	num	_	_
7	%	%	NN	_	6	meta	_	_
8	)	-rrb-	-RRB-	_	6	p	_	_
9	;	;	:	_	1	p	_	_

1	and	and	CC	_	14	adv	_	_
2	,	,	,	_	14	p	_	_
3	rarely	rarely	RB	_	14	adv	_	_
4	,	,	,	_	14	p	_	_
5	enuresis	enuresis	NN	_	14	dep	_	_
6	,	,	,	_	5	p	_	_
7	urinary	urinary	JJ	_	8	attr	_	_
8	retention	retention	NN	_	5	appo	_	_
9	,	,	,	_	5	p	_	_
10	dysuria	dysuria	NN	_	5	appo	_	_
11	,	,	,	_	5	p	_	_
12	impotence	impotence	NN	_	5	appo	_	_
13	,	,	,	_	5	p	_	_
14	inability	inability	NN	_	0	root	_	_
15	to	to	TO	_	16	aux	_	_
16	ejaculate	ejaculate	NN	_	14	ppmod	_	_
17	,	,	,	_	16	p	_	_
18	nocturia	nocturia	NN	_	16	appo	_	_
19	,	,	,	_	16	p	_	_
20	hematuria	hematuria	NN	_	16	appo	_	_
21	.	.	.	_	14	p	_	_

1	Other	other	JJ	_	3	dep	_	_
2	:	:	:	_	3	p	_	_
3	Instances	instance	NNS	_	0	root	_	_
4	of	of	IN	_	5	case	_	_
5	rash	rash	NN	_	3	ppmod	_	_
6	,	,	,	_	5	p	_	_
7	pruritus	pruritus	NN	_	5	appo	_	_
8	,	,	,	_	5	p	_	_
9	ankle	ankle	NN	_	10	com	_	_
10	edema	edema	NN	_	5	appo	_	_
11	,	,	,	_	5	p	_	_
12	excessive	excessive	JJ	_	13	attr	_	_
13	perspiration	perspiration	NN	_	5	appo	_	_
14	,	,	,	_	5	p	_	_
15	weight	weight	NN	_	16	com	_	_
16	gain	gain	NN	_	5	appo	_	_
17	,	,	,	_	5	p	_	_
18	nasal	nasal	JJ	_	19	attr	_	_
19	congestion	congestion	NN	_	5	appo	_	_
20	.	.	.	_	3	p	_	_

1	Some	some	DT	_	9	dep	_	_
2	of	of	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	CNS	cns	NN	_	1	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	genitourinary	genitourinary	JJ	_	7	attr	_	_
7	symptoms	symptom	NNS	_	4	conj	_	_
8	may	may	MD	_	9	modal	_	_
9	be	be	VB	_	0	root	_	_
10	related	related	JJ	_	9	dep	_	_
11	to	to	TO	_	14	aux	_	_
12	the	the	DT	_	14	det	_	_
13	underlying	underlying	JJ	_	14	attr	_	_
14	disease	disease	NN	_	10	ppmod	_	_
15	rather	rather	RB	_	14	cc	_	_
16	than	than	IN	_	15	com	_	_
17	to	to	TO	_	19	aux	_	_
18	drug	drug	NN	_	19	com	_	_
19	therapy	therapy	NN	_	14	conj	_	_
20	.	.	.	_	9	p	_	_

1	The	the	DT	_	4	det	_	_
2	following	following	JJ	_	4	attr	_	_
3	laboratory	laboratory	NN	_	4	com	_	_
4	tests	test	NNS	_	7	dep	_	_
5	have	have	VBP	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	found	find	VBN	_	0	root	_	_
8	to	to	TO	_	9	aux	_	_
9	be	be	VB	_	7	comp	_	_
10	abnormal	abnormal	JJ	_	9	dep	_	_
11	in	in	IN	_	14	case	_	_
12	a	a	DT	_	14	det	_	_
13	few	few	JJ	_	14	attr	_	_
14	patients	patient	NNS	_	10	ppmod	_	_
15	receiving	receive	VBG	_	14	acl	_	_
16	drug1	drug0	NN	_	15	obj	_	_
17	:	:	:	_	14	p	_	_
18	increased	increase	VBN	_	19	attr	_	_
19	SGOT	sgot	NN	_	14	appo	_	_
20	,	,	,	_	19	p	_	_
21	elevated	elevated	JJ	_	23	attr	_	_
22	alkaline	alkaline	NN	_	23	com	_	_
23	phosphatase	phosphatase	NN	_	19	conj	_	_
24	,	,	,	_	23	p	_	_
25	and	and	CC	_	23	cc	_	_
26	elevation	elevation	NN	_	19	conj	_	_
27	of	of	IN	_	29	case	_	_
28	blood	blood	NN	_	29	com	_	_
29	sugar	sugar	NN	_	26	ppmod	_	_
30	.	.	.	_	7	p	_	_

1	The	the	DT	_	4	det	_	_
2	adverse	adverse	JJ	_	4	attr	_	_
3	experience	experience	VBP	_	4	attr	_	_
4	profile	profile	NN	_	8	dep	_	_
5	seen	see	VBN	_	4	acl	_	_
6	with	with	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	was	be	VBD	_	0	root	_	_
9	similar	similar	JJ	_	8	dep	_	_
10	to	to	TO	_	11	aux	_	_
11	that	that	DT	_	9	ppmod	_	_
12	seen	see	VBN	_	11	acl	_	_
13	with	with	IN	_	15	case	_	_
14	drug2	drug0	JJ	_	15	attr	_	_
15	tablets	tablet	NNS	_	12	ppmod	_	_
16	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	9	dep	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	,	,	,	_	1	p	_	_
5	drug3	drug0	NN	_	1	appo	_	_
6	,	,	,	_	1	p	_	_
7	drug4	drug0	NN	_	1	appo	_	_
8	,	,	,	_	1	p	_	_
9	drug5	drug0	NN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	shown	show	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	have	have	VB	_	4	comp	_	_
7	no	no	DT	_	8	det	_	_
8	effect	effect	NN	_	6	obj	_	_
9	on	on	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	pharmacokinetics	pharmacokinetics	NNS	_	6	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	and	and	CC	_	11	cc	_	_
15	the	the	DT	_	16	det	_	_
16	pharmacodynamics	pharmacodynamics	NNS	_	11	conj	_	_
17	of	of	IN	_	18	case	_	_
18	drug3	drug0	NN	_	16	ppmod	_	_
19	and	and	CC	_	18	cc	_	_
20	drug4	drug0	NN	_	18	conj	_	_
21	.	.	.	_	4	p	_	_

1	Thus	thus	RB	_	5	adv	_	_
2	no	no	NN	_	4	com	_	_
3	dosing	dosing	NN	_	4	com	_	_
4	adjustments	adjustment	NNS	_	5	dep	_	_
5	are	be	VBP	_	0	root	_	_
6	necessary	necessary	JJ	_	5	dep	_	_
7	during	during	IN	_	9	case	_	_
8	concomitant	concomitant	JJ	_	9	attr	_	_
9	use	use	NN	_	6	ppmod	_	_
10	with	with	IN	_	12	case	_	_
11	these	these	DT	_	12	det	_	_
12	agents	agent	NNS	_	9	ppmod	_	_
13	.	.	.	_	5	p	_	_

1	Because	because	IN	_	5	mark	_	_
2	drug1	drug0	NN	_	5	dep	_	_
3	is	be	VBZ	_	5	aux	_	_
4	not	not	RB	_	5	neg	_	_
5	metabolized	metabolize	VBN	_	19	advcl	_	_
6	by	by	IN	_	10	case	_	_
7	the	the	DT	_	10	det	_	_
8	cytochrome	cytochrome	NN	_	10	com	_	_
9	P450	p0	NN	_	10	com	_	_
10	system	system	NN	_	5	ppmod	_	_
11	,	,	,	_	19	p	_	_
12	inhibitors	inhibitor	NNS	_	19	dep	_	_
13	of	of	IN	_	15	case	_	_
14	CYP450	cyp0	CD	_	15	num	_	_
15	enzyme	enzyme	NN	_	12	ppmod	_	_
16	would	would	MD	_	19	modal	_	_
17	not	not	RB	_	19	neg	_	_
18	be	be	VB	_	19	aux	_	_
19	expected	expect	VBN	_	0	root	_	_
20	to	to	TO	_	21	aux	_	_
21	affect	affect	VB	_	19	comp	_	_
22	its	its	PRP$	_	23	poss	_	_
23	metabolism	metabolism	NN	_	21	obj	_	_
24	,	,	,	_	19	p	_	_
25	and	and	CC	_	19	cc	_	_
26	drug2	drug0	NN	_	41	dep	_	_
27	and	and	CC	_	26	cc	_	_
28	drug3	drug0	NN	_	26	conj	_	_
29	,	,	,	_	26	p	_	_
30	potent	potent	JJ	_	31	attr	_	_
31	inhibitors	inhibitor	NNS	_	26	appo	_	_
32	of	of	IN	_	33	case	_	_
33	CYP3A	cyp0a	NN	_	31	ppmod	_	_
34	and	and	CC	_	33	cc	_	_
35	2C9	0c0	NN	_	33	conj	_	_
36	,	,	,	_	35	p	_	_
37	respectively	respectively	RB	_	33	conj	_	_
38	,	,	,	_	26	p	_	_
39	have	have	VBP	_	41	aux	_	_
40	been	be	VBN	_	41	aux	_	_
41	shown	show	VBN	_	19	conj	_	_
42	to	to	TO	_	43	aux	_	_
43	have	have	VB	_	41	comp	_	_
44	no	no	DT	_	45	det	_	_
45	effect	effect	NN	_	43	obj	_	_
46	on	on	IN	_	48	case	_	_
47	drug4	drug0	NN	_	48	com	_	_
48	pharmacokinetics	pharmacokinetics	NNS	_	43	ppmod	_	_
49	.	.	.	_	19	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	also	also	RB	_	3	adv	_	_
3	has	have	VBZ	_	0	root	_	_
4	no	no	DT	_	5	det	_	_
5	effect	effect	NN	_	3	obj	_	_
6	on	on	IN	_	8	case	_	_
7	drug2	drug0	NN	_	8	com	_	_
8	pharmacokinetics	pharmacokinetics	NNS	_	3	ppmod	_	_
9	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	13	attr	_	_
2	(	-lrb-	-LRB-	_	7	p	_	_
3	up	up	RB	_	5	adv	_	_
4	to	to	TO	_	5	attr	_	_
5	400	0	CD	_	6	num	_	_
6	mg	mg	NN	_	7	com	_	_
7	b.i.d.	b.i.d.	NN	_	1	prn	_	_
8	or	or	CC	_	7	cc	_	_
9	800	0	CD	_	10	num	_	_
10	mg	mg	NN	_	11	com	_	_
11	q.d.	q.d.	NN	_	7	conj	_	_
12	)	-rrb-	-RRB-	_	7	p	_	_
13	doses	dose	NNS	_	17	dep	_	_
14	have	have	VBP	_	17	aux	_	_
15	been	be	VBN	_	17	aux	_	_
16	safely	safely	RB	_	17	adv	_	_
17	used	use	VBN	_	0	root	_	_
18	concomitantly	concomitantly	RB	_	17	adv	_	_
19	with	with	IN	_	21	case	_	_
20	a	a	DT	_	21	det	_	_
21	drug2	drug0	NN	_	17	ppmod	_	_
22	(	-lrb-	-LRB-	_	23	p	_	_
23	drug3	drug0	NN	_	21	prn	_	_
24	)	-rrb-	-RRB-	_	23	p	_	_
25	.	.	.	_	17	p	_	_

1	drug1	drug0	JJ	_	2	attr	_	_
2	doses	dose	NNS	_	12	dep	_	_
3	of	of	IN	_	8	case	_	_
4	up	up	RB	_	6	adv	_	_
5	to	to	TO	_	6	attr	_	_
6	300	0	CD	_	7	num	_	_
7	mg	mg	NN	_	8	com	_	_
8	b.i.d.	b.i.d.	NN	_	2	ppmod	_	_
9	have	have	VBP	_	12	aux	_	_
10	been	be	VBN	_	12	aux	_	_
11	safely	safely	RB	_	12	adv	_	_
12	used	use	VBN	_	0	root	_	_
13	concomitantly	concomitantly	RB	_	12	adv	_	_
14	with	with	IN	_	16	case	_	_
15	sustained-release	sustained-release	NN	_	16	com	_	_
16	drug2	drug0	NN	_	12	ppmod	_	_
17	(	-lrb-	-LRB-	_	19	p	_	_
18	sustained-release	sustained-release	NN	_	19	com	_	_
19	drug3	drug0	NN	_	16	prn	_	_
20	)	-rrb-	-RRB-	_	19	p	_	_
21	with	with	IN	_	26	case	_	_
22	no	no	DT	_	26	det	_	_
23	clinically	clinically	RB	_	24	adv	_	_
24	significant	significant	JJ	_	26	attr	_	_
25	adverse	adverse	JJ	_	26	attr	_	_
26	interactions	interaction	NNS	_	16	ppmod	_	_
27	.	.	.	_	12	p	_	_

1	When	when	WRB	_	2	adv	_	_
2	administered	administer	VBN	_	9	advcl	_	_
3	concurrently	concurrently	RB	_	2	adv	_	_
4	,	,	,	_	9	p	_	_
5	the	the	DT	_	7	det	_	_
6	following	following	JJ	_	7	attr	_	_
7	drugs	drug	NNS	_	9	dep	_	_
8	may	may	MD	_	9	modal	_	_
9	interact	interact	VB	_	0	root	_	_
10	with	with	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	14	dep	_	_
2	or	or	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	drug3	drug0	NN	_	1	prn	_	_
6	and	and	CC	_	5	cc	_	_
7	related	related	JJ	_	8	attr	_	_
8	drugs	drug	NNS	_	5	conj	_	_
9	,	,	,	_	5	p	_	_
10	drug4	drug0	NN	_	5	appo	_	_
11	and	and	CC	_	10	cc	_	_
12	drug5	drug0	NN	_	10	conj	_	_
13	)	-rrb-	-RRB-	_	5	p	_	_
14	enhanced	enhance	VBD	_	0	root	_	_
15	hypokalemia	hypokalemia	NN	_	14	obj	_	_
16	.	.	.	_	14	p	_	_

1	Check	check	VB	_	0	root	_	_
2	serum	serum	NN	_	4	com	_	_
3	potassium	potassium	NN	_	4	com	_	_
4	levels	level	NNS	_	1	obj	_	_
5	at	at	IN	_	7	case	_	_
6	frequent	frequent	JJ	_	7	attr	_	_
7	intervals	interval	NNS	_	1	ppmod	_	_
8	;	;	:	_	1	p	_	_

1	use	use	NN	_	2	com	_	_
2	drug1	drug0	NN	_	3	dep	_	_
3	supplements	supplement	VBZ	_	0	root	_	_
4	if	if	IN	_	5	mark	_	_
5	necessary	necessary	JJ	_	3	comp	_	_
6	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	enhanced	enhance	VBD	_	0	root	_	_
3	possibility	possibility	NN	_	2	obj	_	_
4	of	of	IN	_	5	case	_	_
5	arrhythmias	arrhythmia	NNS	_	3	ppmod	_	_
6	or	or	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	8	com	_	_
8	toxicity	toxicity	NN	_	5	conj	_	_
9	associated	associate	VBN	_	5	acl	_	_
10	with	with	IN	_	11	case	_	_
11	hypokalemia	hypokalemia	NN	_	9	ppmod	_	_
12	.	.	.	_	2	p	_	_

1	Monitor	monitor	VB	_	0	root	_	_
2	serum	serum	NN	_	4	com	_	_
3	potassium	potassium	NN	_	4	com	_	_
4	levels	level	NNS	_	1	obj	_	_
5	;	;	:	_	1	p	_	_

1	use	use	NN	_	2	com	_	_
2	drug1	drug0	NN	_	3	dep	_	_
3	supplements	supplement	VBZ	_	0	root	_	_
4	if	if	IN	_	5	mark	_	_
5	necessary	necessary	JJ	_	3	comp	_	_
6	.	.	.	_	3	p	_	_

1	Oral	oral	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	3	dep	_	_
3	decreased	decrease	VBD	_	0	root	_	_
4	prothrombin	prothrombin	NN	_	6	com	_	_
5	time	time	NN	_	6	com	_	_
6	response	response	NN	_	3	obj	_	_
7	.	.	.	_	3	p	_	_

1	Monitor	monitor	VB	_	0	root	_	_
2	prothrombin	prothrombin	NN	_	3	com	_	_
3	levels	level	NNS	_	1	obj	_	_
4	and	and	CC	_	1	cc	_	_
5	adjust	adjust	VB	_	1	conj	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	dosage	dosage	NN	_	5	obj	_	_
8	accordingly	accordingly	RB	_	5	adv	_	_
9	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	8	dep	_	_
2	(	-lrb-	-LRB-	_	4	p	_	_
3	oral	oral	JJ	_	4	attr	_	_
4	agents	agent	NNS	_	1	prn	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NNS	_	4	conj	_	_
7	)	-rrb-	-RRB-	_	4	p	_	_
8	diminished	diminish	VBD	_	0	root	_	_
9	antidiabetic	antidiabetic	JJ	_	10	attr	_	_
10	effect	effect	NN	_	8	obj	_	_
11	.	.	.	_	8	p	_	_

1	Monitor	monitor	NN	_	0	root	_	_
2	for	for	IN	_	3	case	_	_
3	symptoms	symptom	NNS	_	1	ppmod	_	_
4	of	of	IN	_	5	case	_	_
5	hyperglycemia	hyperglycemia	NN	_	3	ppmod	_	_
6	;	;	:	_	1	p	_	_

1	adjust	adjust	NN	_	2	com	_	_
2	dosage	dosage	NN	_	5	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	upward	upward	VBN	_	0	root	_	_
6	if	if	IN	_	7	mark	_	_
7	necessary	necessary	JJ	_	5	comp	_	_
8	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	increased	increase	VBD	_	0	root	_	_
3	ulcerogenic	ulcerogenic	JJ	_	4	attr	_	_
4	effect	effect	NN	_	2	obj	_	_
5	;	;	:	_	2	p	_	_

1	decreased	decrease	VBD	_	0	root	_	_
2	pharmacologic	pharmacologic	JJ	_	3	attr	_	_
3	effect	effect	NN	_	1	obj	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	.	.	.	_	1	p	_	_

1	Rarely	rarely	RB	_	2	adv	_	_
2	drug1	drug0	JJ	_	3	attr	_	_
3	toxicity	toxicity	NN	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	occur	occur	VB	_	0	root	_	_
6	in	in	IN	_	7	case	_	_
7	patients	patient	NNS	_	5	ppmod	_	_
8	who	who	WP	_	10	dep	_	_
9	discontinue	discontinue	VBP	_	10	aux	_	_
10	drug2	drug0	VBN	_	7	relcl	_	_
11	after	after	IN	_	15	case	_	_
12	concurrent	concurrent	JJ	_	15	attr	_	_
13	high-dose	high-dose	JJ	_	15	attr	_	_
14	drug3	drug0	NN	_	15	com	_	_
15	therapy	therapy	NN	_	10	ppmod	_	_
16	.	.	.	_	5	p	_	_

1	Monitor	monitor	NN	_	3	com	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	levels	level	NNS	_	0	root	_	_
4	or	or	CC	_	3	cc	_	_
5	the	the	DT	_	7	det	_	_
6	therapeutic	therapeutic	JJ	_	7	attr	_	_
7	effect	effect	NN	_	3	conj	_	_
8	for	for	IN	_	9	case	_	_
9	which	which	WDT	_	12	ppmod	_	_
10	drug2	drug0	NN	_	12	dep	_	_
11	is	be	VBZ	_	12	aux	_	_
12	given	give	VBN	_	3	relcl	_	_
13	;	;	:	_	12	p	_	_

1	adjust	adjust	VB	_	0	root	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	dosage	dosage	NN	_	1	obj	_	_
4	accordingly	accordingly	RB	_	1	adv	_	_
5	if	if	IN	_	8	mark	_	_
6	effect	effect	NN	_	8	dep	_	_
7	is	be	VBZ	_	8	aux	_	_
8	altered	alter	VBN	_	1	comp	_	_
9	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	7	dep	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	,	,	,	_	3	p	_	_
5	or	or	CC	_	3	cc	_	_
6	drug3	drug0	NN	_	1	conj	_	_
7	increased	increase	VBD	_	0	root	_	_
8	metabolic	metabolic	JJ	_	9	attr	_	_
9	clearance	clearance	NN	_	7	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug4	drug0	NN	_	9	ppmod	_	_
12	because	because	IN	_	15	case	_	_
13	of	of	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	induction	induction	NN	_	7	ppmod	_	_
16	of	of	IN	_	18	case	_	_
17	hepatic	hepatic	JJ	_	18	attr	_	_
18	enzymes	enzyme	NNS	_	15	ppmod	_	_
19	.	.	.	_	7	p	_	_

1	Observe	observe	VBP	_	0	root	_	_
2	the	the	DT	_	3	det	_	_
3	patient	patient	NN	_	1	obj	_	_
4	for	for	IN	_	7	case	_	_
5	possible	possible	JJ	_	7	attr	_	_
6	diminished	diminish	VBN	_	7	attr	_	_
7	effect	effect	NN	_	3	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	and	and	CC	_	1	cc	_	_
11	increase	increase	VBP	_	1	conj	_	_
12	the	the	DT	_	14	det	_	_
13	drug2	drug0	NN	_	14	com	_	_
14	dosage	dosage	NN	_	11	obj	_	_
15	accordingly	accordingly	RB	_	11	adv	_	_
16	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	19	dep	_	_
2	(	-lrb-	-LRB-	_	6	p	_	_
3	particularly	particularly	RB	_	6	adv	_	_
4	C-17	c-0	NN	_	6	attr	_	_
5	alkylated	alkylated	JJ	_	6	attr	_	_
6	drug2	drug0	NNS	_	1	prn	_	_
7	such	such	JJ	_	9	adv	_	_
8	as	as	IN	_	9	case	_	_
9	drug3	drug0	NN	_	6	ppmod	_	_
10	,	,	,	_	9	p	_	_
11	drug4	drug0	NN	_	9	conj	_	_
12	,	,	,	_	11	p	_	_
13	drug5	drug0	NN	_	9	conj	_	_
14	,	,	,	_	13	p	_	_
15	and	and	CC	_	13	cc	_	_
16	similar	similar	JJ	_	17	attr	_	_
17	compounds	compound	NNS	_	9	conj	_	_
18	)	-rrb-	-RRB-	_	6	p	_	_
19	enhanced	enhance	VBD	_	0	root	_	_
20	tendency	tendency	NN	_	19	obj	_	_
21	toward	toward	IN	_	22	case	_	_
22	edema	edema	NN	_	20	ppmod	_	_
23	.	.	.	_	19	p	_	_

1	Use	use	VBP	_	0	root	_	_
2	caution	caution	NN	_	1	obj	_	_
3	when	when	WRB	_	4	adv	_	_
4	giving	give	VBG	_	1	comp	_	_
5	these	these	DT	_	6	det	_	_
6	drugs	drug	NNS	_	4	obj	_	_
7	together	together	RB	_	4	adv	_	_
8	,	,	,	_	4	p	_	_
9	especially	especially	RB	_	11	adv	_	_
10	in	in	IN	_	11	case	_	_
11	patients	patient	NNS	_	4	ppmod	_	_
12	with	with	IN	_	16	case	_	_
13	hepatic	hepatic	JJ	_	16	attr	_	_
14	or	or	CC	_	13	cc	_	_
15	cardiac	cardiac	JJ	_	13	conj	_	_
16	disease	disease	NN	_	11	ppmod	_	_
17	.	.	.	_	1	p	_	_

1	drug1	drug0	JJ	_	3	attr	_	_
2	neurological	neurological	JJ	_	3	attr	_	_
3	complications	complication	NNS	_	0	root	_	_
4	and	and	CC	_	3	cc	_	_
5	lack	lack	NN	_	3	conj	_	_
6	of	of	IN	_	8	case	_	_
7	antibody	antibody	NN	_	8	com	_	_
8	response	response	NN	_	5	ppmod	_	_
9	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	increased	increase	VBD	_	0	root	_	_
3	levels	level	NNS	_	2	obj	_	_
4	of	of	IN	_	6	case	_	_
5	corticosteroid-binding	corticosteroid-binding	JJ	_	6	attr	_	_
6	globulin	globulin	NN	_	3	ppmod	_	_
7	,	,	,	_	2	p	_	_
8	thereby	thereby	RB	_	9	adv	_	_
9	increasing	increase	VBG	_	2	comp	_	_
10	the	the	DT	_	15	det	_	_
11	bound	bind	VBN	_	15	attr	_	_
12	(	-lrb-	-LRB-	_	15	p	_	_
13	inactive	inactive	JJ	_	15	attr	_	_
14	)	-rrb-	-RRB-	_	15	p	_	_
15	fraction	fraction	NN	_	9	obj	_	_
16	;	;	:	_	2	p	_	_

1	this	this	DT	_	2	det	_	_
2	effect	effect	NN	_	3	dep	_	_
3	is	be	VBZ	_	0	root	_	_
4	at	at	IN	_	5	case	_	_
5	least	least	JJS	_	3	adv	_	_
6	balanced	balanced	JJ	_	3	dep	_	_
7	by	by	IN	_	9	case	_	_
8	decreased	decrease	VBN	_	9	attr	_	_
9	metabolism	metabolism	NN	_	6	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	3	p	_	_

1	When	when	WRB	_	5	adv	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	therapy	therapy	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	initiated	initiate	VBN	_	14	advcl	_	_
6	,	,	,	_	14	p	_	_
7	a	a	DT	_	8	det	_	_
8	reduction	reduction	NN	_	14	dep	_	_
9	in	in	IN	_	11	case	_	_
10	drug2	drug0	NN	_	11	com	_	_
11	dosage	dosage	NN	_	8	ppmod	_	_
12	may	may	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	required	require	VBN	_	0	root	_	_
15	,	,	,	_	14	p	_	_
16	and	and	CC	_	14	cc	_	_
17	increased	increase	VBN	_	18	attr	_	_
18	amounts	amount	NNS	_	21	dep	_	_
19	may	may	MD	_	21	modal	_	_
20	be	be	VB	_	21	aux	_	_
21	required	require	VBN	_	14	conj	_	_
22	when	when	WRB	_	25	adv	_	_
23	drug3	drug0	NN	_	25	dep	_	_
24	is	be	VBZ	_	25	aux	_	_
25	terminated	terminate	VBN	_	21	comp	_	_
26	.	.	.	_	14	p	_	_

1	Drug/Laboratory	drug/laboratory	NN	_	3	com	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	6	dep	_	_
4	drug1	drug0	RB	_	6	adv	_	_
5	may	may	MD	_	6	modal	_	_
6	affect	affect	VB	_	0	root	_	_
7	the	the	DT	_	9	det	_	_
8	nitrobluetetrazolium	nitrobluetetrazolium	NN	_	9	com	_	_
9	test	test	NN	_	6	obj	_	_
10	for	for	IN	_	12	case	_	_
11	bacterial	bacterial	JJ	_	12	attr	_	_
12	infection	infection	NN	_	9	ppmod	_	_
13	and	and	CC	_	6	cc	_	_
14	produce	produce	VB	_	6	conj	_	_
15	false-negative	false-negative	JJ	_	16	attr	_	_
16	results	result	NNS	_	14	obj	_	_

1	.	.	.	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	A	a	DT	_	2	det	_	_
2	number	number	NN	_	5	dep	_	_
3	of	of	IN	_	4	case	_	_
4	substances	substance	NNS	_	2	ppmod	_	_
5	affect	affect	VBP	_	0	root	_	_
6	glucose	glucose	NN	_	7	com	_	_
7	metabolism	metabolism	NN	_	5	obj	_	_
8	and	and	CC	_	5	cc	_	_
9	may	may	MD	_	10	modal	_	_
10	require	require	VBP	_	5	conj	_	_
11	drug1	drug0	NN	_	13	com	_	_
12	dose	dose	NN	_	13	com	_	_
13	adjustment	adjustment	NN	_	10	obj	_	_
14	and	and	CC	_	13	cc	_	_
15	particularly	particularly	RB	_	17	adv	_	_
16	close	close	JJ	_	17	attr	_	_
17	monitoring	monitoring	NN	_	13	conj	_	_
18	.	.	.	_	5	p	_	_

1	The	the	DT	_	2	det	_	_
2	following	following	NN	_	3	dep	_	_
3	are	be	VBP	_	0	root	_	_
4	examples	example	NNS	_	3	obj	_	_
5	of	of	IN	_	6	case	_	_
6	substances	substance	NNS	_	4	ppmod	_	_
7	that	that	WDT	_	9	dep	_	_
8	may	may	MD	_	9	modal	_	_
9	increase	increase	VB	_	6	relcl	_	_
10	the	the	DT	_	12	det	_	_
11	blood-glucose-lowering	blood-glucose-lowering	JJ	_	12	attr	_	_
12	effect	effect	NN	_	9	obj	_	_
13	and	and	CC	_	12	cc	_	_
14	susceptibility	susceptibility	NN	_	12	conj	_	_
15	to	to	TO	_	16	aux	_	_
16	hypoglycemia	hypoglycemia	NN	_	14	ppmod	_	_
17	:	:	:	_	4	p	_	_
18	oral	oral	JJ	_	20	attr	_	_
19	antidiabetes	antidiabetes	NNS	_	20	com	_	_
20	products	product	NNS	_	4	appo	_	_
21	,	,	,	_	20	p	_	_
22	drug1	drug0	NN	_	20	appo	_	_
23	,	,	,	_	22	p	_	_
24	drug2	drug0	NN	_	22	appo	_	_
25	,	,	,	_	22	p	_	_
26	drug3	drug0	NN	_	22	appo	_	_
27	,	,	,	_	22	p	_	_
28	drug4	drug0	NN	_	22	appo	_	_
29	,	,	,	_	22	p	_	_
30	drug5	drug0	NN	_	22	appo	_	_
31	,	,	,	_	22	p	_	_
32	drug6	drug0	NN	_	22	appo	_	_
33	,	,	,	_	22	p	_	_
34	drug7	drug0	NN	_	22	appo	_	_
35	,	,	,	_	22	p	_	_
36	drug8	drug0	NN	_	22	appo	_	_
37	(	-lrb-	-LRB-	_	40	p	_	_
38	e.g.	e.g.	FW	_	40	ppmod	_	_
39	,	,	,	_	40	p	_	_
40	drug9	drug0	NN	_	36	prn	_	_
41	)	-rrb-	-RRB-	_	40	p	_	_
42	,	,	,	_	22	p	_	_
43	drug10	drug0	NN	_	22	appo	_	_
44	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	following	following	NN	_	3	dep	_	_
3	are	be	VBP	_	0	root	_	_
4	examples	example	NNS	_	3	obj	_	_
5	of	of	IN	_	6	case	_	_
6	substances	substance	NNS	_	4	ppmod	_	_
7	that	that	WDT	_	9	dep	_	_
8	may	may	MD	_	9	modal	_	_
9	reduce	reduce	VB	_	6	relcl	_	_
10	the	the	DT	_	12	det	_	_
11	blood-glucose-lowering	blood-glucose-lowering	JJ	_	12	attr	_	_
12	effect	effect	NN	_	9	obj	_	_
13	of	of	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	:	:	:	_	4	p	_	_
16	drug2	drug0	NN	_	4	appo	_	_
17	,	,	,	_	16	p	_	_
18	drug3	drug0	NN	_	16	appo	_	_
19	,	,	,	_	16	p	_	_
20	drug4	drug0	NN	_	16	appo	_	_
21	,	,	,	_	16	p	_	_
22	drug5	drug0	NN	_	16	appo	_	_
23	(	-lrb-	-LRB-	_	24	p	_	_
24	e.g.	e.g.	FW	_	22	prn	_	_
25	,	,	,	_	24	p	_	_
26	drug6	drug0	NN	_	24	attr	_	_
27	,	,	,	_	24	p	_	_
28	drug7	drug0	NN	_	26	appo	_	_
29	,	,	,	_	24	p	_	_
30	drug8	drug0	NN	_	26	appo	_	_
31	)	-rrb-	-RRB-	_	24	p	_	_
32	,	,	,	_	16	p	_	_
33	drug9	drug0	NN	_	16	appo	_	_
34	,	,	,	_	16	p	_	_
35	drug10	drug0	NN	_	16	appo	_	_
36	,	,	,	_	16	p	_	_
37	drug11	drug0	CD	_	43	num	_	_
38	,	,	,	_	43	p	_	_
39	drug12	drug0	CD	_	43	num	_	_
40	,	,	,	_	43	p	_	_
41	drug13	drug0	CD	_	43	num	_	_
42	,	,	,	_	43	p	_	_
43	drug14	drug0	CD	_	16	num	_	_
44	(	-lrb-	-LRB-	_	49	p	_	_
45	e.g.	e.g.	FW	_	49	ppmod	_	_
46	,	,	,	_	49	p	_	_
47	in	in	IN	_	49	case	_	_
48	oral	oral	JJ	_	49	attr	_	_
49	drug15	drug0	NN	_	3	prn	_	_
50	)	-rrb-	-RRB-	_	49	p	_	_
51	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	12	dep	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	,	,	,	_	3	p	_	_
5	drug3	drug0	NN	_	6	com	_	_
6	salts	salt	NNS	_	1	conj	_	_
7	,	,	,	_	6	p	_	_
8	and	and	CC	_	6	cc	_	_
9	drug4	drug0	NN	_	1	conj	_	_
10	may	may	MD	_	12	modal	_	_
11	either	either	CC	_	12	cc	_	_
12	potentiate	potentiate	VB	_	0	root	_	_
13	or	or	CC	_	12	cc	_	_
14	weaken	weaken	VB	_	12	conj	_	_
15	the	the	DT	_	17	det	_	_
16	blood-glucose-lowering	blood-glucose-lowering	JJ	_	17	attr	_	_
17	effect	effect	NN	_	14	obj	_	_
18	of	of	IN	_	19	case	_	_
19	drug5	drug0	NN	_	17	ppmod	_	_
20	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	cause	cause	VB	_	0	root	_	_
4	hypoglycemia	hypoglycemia	NN	_	3	obj	_	_
5	,	,	,	_	4	p	_	_
6	which	which	WDT	_	10	dep	_	_
7	may	may	MD	_	10	modal	_	_
8	sometimes	sometimes	RB	_	10	adv	_	_
9	be	be	VB	_	10	aux	_	_
10	followed	followed	VBN	_	4	relcl	_	_
11	by	by	IN	_	12	case	_	_
12	hyperglycemia	hyperglycemia	NN	_	10	ppmod	_	_
13	.	.	.	_	3	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	28	ppmod	_	_
3	,	,	,	_	28	p	_	_
4	under	under	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	influence	influence	NN	_	28	ppmod	_	_
7	of	of	IN	_	10	case	_	_
8	sympatholytic	sympatholytic	JJ	_	10	attr	_	_
9	medicinal	medicinal	NN	_	10	com	_	_
10	products	product	NNS	_	6	ppmod	_	_
11	such	such	JJ	_	13	adv	_	_
12	as	as	IN	_	13	case	_	_
13	drug1	drug0	NN	_	10	ppmod	_	_
14	,	,	,	_	13	p	_	_
15	drug2	drug0	NN	_	13	conj	_	_
16	,	,	,	_	15	p	_	_
17	drug3	drug0	NN	_	13	conj	_	_
18	,	,	,	_	17	p	_	_
19	and	and	CC	_	17	cc	_	_
20	drug4	drug0	NN	_	13	conj	_	_
21	,	,	,	_	28	p	_	_
22	the	the	DT	_	23	det	_	_
23	signs	sign	NNS	_	28	dep	_	_
24	of	of	IN	_	25	case	_	_
25	hypoglycemia	hypoglycemia	NN	_	23	ppmod	_	_
26	may	may	MD	_	28	modal	_	_
27	be	be	VB	_	28	aux	_	_
28	reduced	reduce	VBN	_	0	root	_	_
29	or	or	CC	_	28	cc	_	_
30	absent	absent	JJ	_	28	conj	_	_
31	.	.	.	_	28	p	_	_

1	drug1	drug0	NN	_	7	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	-	-	CC	_	3	cc	_	_
5	drug3	drug0	NN	_	3	conj	_	_
6	may	may	MD	_	7	modal	_	_
7	decrease	decrease	VB	_	0	root	_	_
8	hepatic	hepatic	JJ	_	9	attr	_	_
9	toxicity	toxicity	NN	_	7	obj	_	_
10	in	in	IN	_	11	case	_	_
11	those	those	DT	_	7	ppmod	_	_
12	with	with	IN	_	14	case	_	_
13	drug4	drug0	NN	_	14	com	_	_
14	overdosage	overdosage	NN	_	11	ppmod	_	_
15	or	or	CC	_	14	cc	_	_
16	in	in	IN	_	17	case	_	_
17	those	those	DT	_	14	conj	_	_
18	taking	take	VBG	_	17	acl	_	_
19	drug5	drug0	NN	_	18	obj	_	_
20	.	.	.	_	7	p	_	_

1	Theoretically	theoretically	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	it	it	PRP	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	decrease	decrease	VB	_	0	root	_	_
6	hepatic	hepatic	JJ	_	7	attr	_	_
7	toxicity	toxicity	NN	_	5	obj	_	_
8	in	in	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	case	case	NN	_	5	ppmod	_	_
11	of	of	IN	_	15	case	_	_
12	other	other	JJ	_	15	attr	_	_
13	potential	potential	JJ	_	15	attr	_	_
14	hepatotoxic	hepatotoxic	JJ	_	15	attr	_	_
15	drugs	drug	NNS	_	10	ppmod	_	_
16	,	,	,	_	15	p	_	_
17	as	as	IN	_	18	case	_	_
18	well	well	NN	_	15	ppmod	_	_
19	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	-	-	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	may	may	MD	_	5	modal	_	_
5	protect	protect	VB	_	0	root	_	_
6	against	against	IN	_	9	case	_	_
7	the	the	DT	_	9	det	_	_
8	ototoxic	ototoxic	JJ	_	9	attr	_	_
9	effects	effect	NNS	_	5	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug3	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Administration	administration	NN	_	16	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	to	to	TO	_	7	aux	_	_
7	volunteers	volunteer	NNS	_	3	ppmod	_	_
8	under	under	IN	_	10	case	_	_
9	fasting	fasting	JJ	_	10	attr	_	_
10	conditions	condition	NNS	_	7	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	or	or	CC	_	10	cc	_	_
13	with	with	IN	_	15	case	_	_
14	drug3	drug0	NN	_	15	com	_	_
15	suspension	suspension	NN	_	10	conj	_	_
16	yielded	yield	VBD	_	1	acl	_	_
17	similar	similar	JJ	_	21	attr	_	_
18	serum	serum	NN	_	21	com	_	_
19	drug4	drug0	NN	_	21	com	_	_
20	time	time	NN	_	21	com	_	_
21	profiles	profile	NNS	_	16	obj	_	_
22	in	in	IN	_	24	case	_	_
23	young	young	JJ	_	24	attr	_	_
24	subjects	subject	NNS	_	21	ppmod	_	_
25	(	-lrb-	-LRB-	_	26	p	_	_
26	n=12	n=0	NN	_	24	prn	_	_
27	)	-rrb-	-RRB-	_	26	p	_	_
28	.	.	.	_	1	p	_	_

1	In	in	IN	_	3	case	_	_
2	geriatric	geriatric	JJ	_	3	attr	_	_
3	subjects	subject	NNS	_	8	ppmod	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	n=7	n=0	NN	_	3	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	there	there	EX	_	8	dep	_	_
8	was	be	VBD	_	0	root	_	_
9	a	a	DT	_	10	det	_	_
10	reduction	reduction	NN	_	8	obj	_	_
11	in	in	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	rate	rate	NN	_	10	ppmod	_	_
14	but	but	CC	_	13	cc	_	_
15	not	not	RB	_	14	com	_	_
16	the	the	DT	_	17	det	_	_
17	extent	extent	NN	_	13	conj	_	_
18	of	of	IN	_	20	case	_	_
19	drug1	drug0	NN	_	20	com	_	_
20	absorption	absorption	NN	_	17	ppmod	_	_
21	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	10	dep	_	_
4	like	like	IN	_	6	case	_	_
5	other	other	JJ	_	6	attr	_	_
6	drug3	drug0	NN	_	3	ppmod	_	_
7	,	,	,	_	3	p	_	_
8	has	have	VBZ	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	shown	show	VBN	_	1	acl	_	_
11	to	to	TO	_	12	aux	_	_
12	affect	affect	VB	_	10	comp	_	_
13	bleeding	bleeding	JJ	_	14	attr	_	_
14	parameters	parameter	NNS	_	12	obj	_	_
15	in	in	IN	_	16	case	_	_
16	patients	patient	NNS	_	14	ppmod	_	_
17	receiving	receive	VBG	_	16	acl	_	_
18	drug4	drug0	NNS	_	17	obj	_	_
19	,	,	,	_	10	p	_	_
20	and	and	CC	_	10	cc	_	_
21	serious	serious	JJ	_	23	attr	_	_
22	clinical	clinical	JJ	_	23	attr	_	_
23	bleeding	bleeding	JJ	_	26	dep	_	_
24	has	have	VBZ	_	26	aux	_	_
25	been	be	VBN	_	26	aux	_	_
26	reported	report	VBN	_	10	conj	_	_
27	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	physician	physician	NN	_	4	dep	_	_
3	should	should	MD	_	4	modal	_	_
4	be	be	VB	_	0	root	_	_
5	cautious	cautious	JJ	_	4	dep	_	_
6	when	when	WRB	_	7	adv	_	_
7	administering	administer	VBG	_	4	comp	_	_
8	drug1	drug0	NN	_	7	obj	_	_
9	to	to	TO	_	10	aux	_	_
10	patients	patient	NNS	_	7	ppmod	_	_
11	taking	take	VBG	_	10	acl	_	_
12	drug2	drug0	NN	_	11	obj	_	_
13	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Concurrent	concurrent	JJ	_	4	attr	_	_
4	administration	administration	NN	_	9	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	resulted	result	VBD	_	1	acl	_	_
10	in	in	IN	_	16	case	_	_
11	50	0	CD	_	13	num	_	_
12	%	%	NN	_	11	meta	_	_
13	lower	low	JJR	_	16	attr	_	_
14	serum	serum	NN	_	16	com	_	_
15	drug4	drug0	NN	_	16	com	_	_
16	concentrations	concentration	NNS	_	9	ppmod	_	_
17	.	.	.	_	1	p	_	_

1	This	this	DT	_	2	det	_	_
2	effect	effect	NN	_	20	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	(	-lrb-	-LRB-	_	2	p	_	_
6	which	which	WDT	_	8	dep	_	_
7	also	also	RB	_	8	adv	_	_
8	lowers	lower	VBZ	_	2	relcl	_	_
9	serum	serum	NN	_	10	com	_	_
10	concentrations	concentration	NNS	_	8	obj	_	_
11	of	of	IN	_	13	case	_	_
12	other	other	JJ	_	13	attr	_	_
13	drug2	drug0	NNS	_	10	ppmod	_	_
14	given	give	VBN	_	13	acl	_	_
15	with	with	IN	_	16	case	_	_
16	it	it	PRP	_	14	ppmod	_	_
17	)	-rrb-	-RRB-	_	2	p	_	_
18	has	have	VBZ	_	20	aux	_	_
19	been	be	VBN	_	20	aux	_	_
20	demonstrated	demonstrate	VBN	_	0	root	_	_
21	in	in	IN	_	22	case	_	_
22	patients	patient	NNS	_	20	ppmod	_	_
23	with	with	IN	_	25	case	_	_
24	rheumatoid	rheumatoid	JJ	_	25	attr	_	_
25	arthritis	arthritis	NN	_	22	ppmod	_	_
26	(	-lrb-	-LRB-	_	27	p	_	_
27	n=	n=	NN	_	25	prn	_	_
28	15	0	CD	_	27	num	_	_
29	)	-rrb-	-RRB-	_	27	p	_	_
30	as	as	RB	_	31	com	_	_
31	well	well	RB	_	22	cc	_	_
32	as	as	IN	_	31	com	_	_
33	normal	normal	JJ	_	34	attr	_	_
34	volunteers	volunteer	NNS	_	22	conj	_	_
35	(	-lrb-	-LRB-	_	36	p	_	_
36	n=	n=	NN	_	34	prn	_	_
37	16	0	CD	_	36	num	_	_
38	)	-rrb-	-RRB-	_	36	p	_	_
39	.	.	.	_	20	p	_	_

1	Concurrent	concurrent	JJ	_	2	attr	_	_
2	use	use	NN	_	10	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	is	be	VBZ	_	10	aux	_	_
8	therefore	therefore	RB	_	10	adv	_	_
9	not	not	RB	_	10	neg	_	_
10	recommended	recommend	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	effect	effect	NN	_	16	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	on	on	IN	_	10	case	_	_
8	blood	blood	NN	_	10	com	_	_
9	pressure	pressure	NN	_	10	com	_	_
10	response	response	NN	_	4	ppmod	_	_
11	to	to	TO	_	12	aux	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	drug4	drug0	NN	_	12	conj	_	_
15	was	be	VBD	_	16	aux	_	_
16	evaluated	evaluate	VBN	_	1	acl	_	_
17	in	in	IN	_	18	case	_	_
18	men	man	NNS	_	16	ppmod	_	_
19	with	with	IN	_	22	case	_	_
20	mild	mild	JJ	_	22	attr	_	_
21	uncomplicated	uncomplicated	JJ	_	22	attr	_	_
22	hypertension	hypertension	NN	_	18	ppmod	_	_
23	(	-lrb-	-LRB-	_	24	p	_	_
24	n	n	NN	_	22	prn	_	_
25	=	=	JJ	_	24	attr	_	_
26	10	0	CD	_	24	num	_	_
27	)	-rrb-	-RRB-	_	24	p	_	_
28	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	pretreatment	pretreatment	NN	_	3	dep	_	_
3	attenuated	attenuate	VBD	_	0	root	_	_
4	the	the	DT	_	6	det	_	_
5	hypotensive	hypotensive	JJ	_	6	attr	_	_
6	effect	effect	NN	_	3	obj	_	_
7	of	of	IN	_	10	case	_	_
8	a	a	DT	_	10	det	_	_
9	single	single	JJ	_	10	attr	_	_
10	dose	dose	NN	_	6	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	but	but	CC	_	12	cc	_	_
14	not	not	RB	_	13	com	_	_
15	drug3	drug0	NN	_	12	conj	_	_
16	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	did	do	VBD	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	appear	appear	VB	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	affect	affect	VB	_	4	comp	_	_
7	the	the	DT	_	9	det	_	_
8	beta-blocker-mediated	beta-blocker-mediated	JJ	_	9	attr	_	_
9	reduction	reduction	NN	_	6	obj	_	_
10	in	in	IN	_	12	case	_	_
11	heart	heart	NN	_	12	com	_	_
12	rate	rate	NN	_	9	ppmod	_	_
13	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	did	do	VBD	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	affect	affect	VB	_	0	root	_	_
5	the	the	DT	_	7	det	_	_
6	pharmacokinetic	pharmacokinetic	JJ	_	7	attr	_	_
7	profile	profile	NN	_	4	obj	_	_
8	of	of	IN	_	10	case	_	_
9	either	either	DT	_	10	det	_	_
10	drug	drug	NN	_	7	ppmod	_	_
11	,	,	,	_	4	p	_	_
12	and	and	CC	_	4	cc	_	_
13	the	the	DT	_	14	det	_	_
14	mechanism	mechanism	NN	_	24	dep	_	_
15	under	under	IN	_	16	case	_	_
16	lying	lie	VBG	_	14	ppmod	_	_
17	the	the	DT	_	18	det	_	_
18	interference	interference	NN	_	16	obj	_	_
19	with	with	IN	_	23	case	_	_
20	drug2	drug0	NN	_	23	attr	_	_
21	s	s	NN	_	23	attr	_	_
22	hypotensive	hypotensive	JJ	_	23	attr	_	_
23	effect	effect	NN	_	18	ppmod	_	_
24	is	be	VBZ	_	4	conj	_	_
25	unknown	unknown	JJ	_	24	dep	_	_
26	.	.	.	_	4	p	_	_

1	Patients	patient	NNS	_	10	dep	_	_
2	taking	take	VBG	_	1	acl	_	_
3	both	both	CC	_	4	cc	_	_
4	drug1	drug0	NN	_	2	obj	_	_
5	and	and	CC	_	4	cc	_	_
6	a	a	NN	_	7	com	_	_
7	drug2	drug0	NN	_	4	conj	_	_
8	should	should	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	monitored	monitor	VBN	_	0	root	_	_
11	to	to	TO	_	12	aux	_	_
12	ensure	ensure	VB	_	10	comp	_	_
13	that	that	IN	_	19	mark	_	_
14	a	a	DT	_	17	det	_	_
15	satisfactory	satisfactory	JJ	_	17	attr	_	_
16	hypotensive	hypotensive	JJ	_	17	attr	_	_
17	effect	effect	NN	_	19	dep	_	_
18	is	be	VBZ	_	19	aux	_	_
19	achieved	achieve	VBN	_	12	comp	_	_
20	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_
4	:	:	:	_	1	p	_	_
5	In	in	IN	_	7	case	_	_
6	normal	normal	JJ	_	7	attr	_	_
7	volunteers	volunteer	NNS	_	19	ppmod	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	n=9	n=0	NN	_	7	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	,	,	,	_	19	p	_	_
12	pretreatment	pretreatment	NN	_	19	dep	_	_
13	with	with	IN	_	14	case	_	_
14	drug3	drug0	NN	_	12	ppmod	_	_
15	or	or	CC	_	14	cc	_	_
16	drug4	drug0	NN	_	14	conj	_	_
17	did	do	VBD	_	19	aux	_	_
18	not	not	RB	_	19	neg	_	_
19	affect	affect	VB	_	1	acl	_	_
20	drug5	drug0	NN	_	21	com	_	_
21	pharmacokinetics	pharmacokinetics	NNS	_	19	obj	_	_
22	except	except	IN	_	44	case	_	_
23	that	that	IN	_	44	mark	_	_
24	a	a	DT	_	33	det	_	_
25	small	small	JJ	_	33	attr	_	_
26	(	-lrb-	-LRB-	_	27	p	_	_
27	13	0	CD	_	25	num	_	_
28	%	%	NN	_	27	meta	_	_
29	)	-rrb-	-RRB-	_	27	p	_	_
30	but	but	CC	_	25	cc	_	_
31	statistically	statistically	RB	_	32	adv	_	_
32	significant	significant	JJ	_	25	conj	_	_
33	increase	increase	NN	_	44	dep	_	_
34	in	in	IN	_	36	case	_	_
35	the	the	DT	_	36	det	_	_
36	area	area	NN	_	33	ppmod	_	_
37	under	under	IN	_	41	case	_	_
38	the	the	DT	_	41	det	_	_
39	serum	serum	NN	_	41	com	_	_
40	concentration	concentration	NN	_	41	com	_	_
41	curve	curve	NN	_	36	ppmod	_	_
42	of	of	IN	_	43	case	_	_
43	drug6	drug0	NN	_	41	ppmod	_	_
44	resulted	result	VBD	_	19	ppmod	_	_
45	with	with	IN	_	46	case	_	_
46	drug7	drug0	NN	_	44	ppmod	_	_
47	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	20	dep	_	_
2	:	:	:	_	1	p	_	_
3	Studies	study	NNS	_	1	appo	_	_
4	of	of	IN	_	6	case	_	_
5	concomitant	concomitant	JJ	_	6	attr	_	_
6	administration	administration	NN	_	3	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	drug3	drug0	NN	_	8	conj	_	_
11	to	to	TO	_	13	aux	_	_
12	healthy	healthy	JJ	_	13	attr	_	_
13	men	man	NNS	_	6	ppmod	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	n=	n=	NN	_	13	prn	_	_
16	14	0	CD	_	15	num	_	_
17	)	-rrb-	-RRB-	_	15	p	_	_
18	did	do	VBD	_	20	aux	_	_
19	not	not	RB	_	20	neg	_	_
20	show	show	VB	_	0	root	_	_
21	a	a	DT	_	22	det	_	_
22	change	change	NN	_	20	obj	_	_
23	in	in	IN	_	28	case	_	_
24	the	the	DT	_	28	det	_	_
25	steady	steady	JJ	_	28	attr	_	_
26	state	state	NN	_	28	com	_	_
27	serum	serum	NN	_	28	com	_	_
28	levels	level	NNS	_	22	ppmod	_	_
29	of	of	IN	_	31	case	_	_
30	either	either	DT	_	31	det	_	_
31	drug	drug	NN	_	28	ppmod	_	_
32	.	.	.	_	20	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Studies	study	NNS	_	8	dep	_	_
4	in	in	IN	_	6	case	_	_
5	normal	normal	JJ	_	6	attr	_	_
6	volunteers	volunteer	NNS	_	3	ppmod	_	_
7	have	have	VBP	_	8	aux	_	_
8	shown	show	VBN	_	1	acl	_	_
9	that	that	IN	_	16	mark	_	_
10	drug2	drug0	NN	_	16	dep	_	_
11	like	like	IN	_	13	case	_	_
12	other	other	JJ	_	13	attr	_	_
13	drug3	drug0	NN	_	16	ppmod	_	_
14	,	,	,	_	16	p	_	_
15	can	can	MD	_	16	modal	_	_
16	interfere	interfere	VB	_	8	comp	_	_
17	with	with	IN	_	19	case	_	_
18	the	the	DT	_	19	det	_	_
19	effects	effect	NNS	_	16	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	drug4	drug0	NN	_	19	ppmod	_	_
22	.	.	.	_	1	p	_	_

1	Although	although	IN	_	4	mark	_	_
2	results	result	NNS	_	4	dep	_	_
3	have	have	VBP	_	4	aux	_	_
4	varied	vary	VBD	_	13	advcl	_	_
5	from	from	IN	_	6	case	_	_
6	study	study	NN	_	4	ppmod	_	_
7	to	to	TO	_	8	aux	_	_
8	study	study	NN	_	4	ppmod	_	_
9	,	,	,	_	13	p	_	_
10	effects	effect	NNS	_	13	dep	_	_
11	have	have	VBP	_	13	aux	_	_
12	been	be	VBN	_	13	aux	_	_
13	shown	show	VBN	_	0	root	_	_
14	on	on	IN	_	17	case	_	_
15	drug1	drug0	JJ	_	17	attr	_	_
16	-stimulated	-stimulated	JJ	_	17	attr	_	_
17	diuresis	diuresis	NN	_	13	ppmod	_	_
18	,	,	,	_	17	p	_	_
19	natriuresis	natriuresis	NN	_	17	conj	_	_
20	,	,	,	_	19	p	_	_
21	and	and	CC	_	19	cc	_	_
22	kaliuresis	kaliuresis	NN	_	17	conj	_	_
23	.	.	.	_	13	p	_	_

1	Other	other	JJ	_	2	attr	_	_
2	drug1	drug0	NNS	_	9	dep	_	_
3	that	that	WDT	_	4	dep	_	_
4	inhibit	inhibit	VBP	_	2	relcl	_	_
5	prostaglandin	prostaglandin	NN	_	6	com	_	_
6	synthesis	synthesis	NN	_	4	obj	_	_
7	have	have	VBP	_	9	aux	_	_
8	been	be	VBN	_	9	aux	_	_
9	shown	show	VBN	_	0	root	_	_
10	to	to	TO	_	11	aux	_	_
11	interfere	interfere	VB	_	9	comp	_	_
12	with	with	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	in	in	IN	_	16	case	_	_
15	some	some	DT	_	16	det	_	_
16	studies	study	NNS	_	11	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	with	with	IN	_	19	case	_	_
19	drug3	drug0	NN	_	16	conj	_	_
20	.	.	.	_	9	p	_	_

1	Patients	patient	NNS	_	11	dep	_	_
2	receiving	receive	VBG	_	1	acl	_	_
3	drug1	drug0	NN	_	2	obj	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	or	or	CC	_	3	cc	_	_
7	other	other	JJ	_	8	attr	_	_
8	drug3	drug0	NN	_	3	conj	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	observed	observe	VBN	_	0	root	_	_
12	closely	closely	RB	_	11	adv	_	_
13	to	to	TO	_	14	aux	_	_
14	determine	determine	VB	_	11	comp	_	_
15	if	if	IN	_	20	mark	_	_
16	the	the	DT	_	18	det	_	_
17	desired	desired	JJ	_	18	attr	_	_
18	effect	effect	NN	_	20	dep	_	_
19	is	be	VBZ	_	20	aux	_	_
20	obtained	obtain	VBN	_	14	comp	_	_
21	.	.	.	_	11	p	_	_

1	Oral	oral	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	In	in	IN	_	6	case	_	_
5	one	#crd#	CD	_	6	num	_	_
6	study	study	NN	_	10	ppmod	_	_
7	,	,	,	_	10	p	_	_
8	drug2	drug0	NN	_	10	dep	_	_
9	was	be	VBD	_	10	aux	_	_
10	given	give	VBN	_	2	acl	_	_
11	to	to	TO	_	13	aux	_	_
12	adult	adult	JJ	_	13	attr	_	_
13	diabetics	diabetic	NNS	_	10	ppmod	_	_
14	who	who	WP	_	17	dep	_	_
15	were	be	VBD	_	17	aux	_	_
16	already	already	RB	_	17	adv	_	_
17	receiving	receive	VBG	_	13	relcl	_	_
18	drug3	drug0	NN	_	17	obj	_	_
19	(	-lrb-	-LRB-	_	20	p	_	_
20	n=4	n=0	NN	_	18	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	,	,	,	_	18	p	_	_
23	drug4	drug0	NN	_	18	appo	_	_
24	(	-lrb-	-LRB-	_	25	p	_	_
25	n=2	n=0	NN	_	23	prn	_	_
26	)	-rrb-	-RRB-	_	25	p	_	_
27	drug5	drug0	VBN	_	23	acl	_	_
28	with	with	IN	_	29	case	_	_
29	drug6	drug0	NN	_	27	ppmod	_	_
30	(	-lrb-	-LRB-	_	31	p	_	_
31	n=	n=	NN	_	29	prn	_	_
32	3	0	CD	_	31	num	_	_
33	)	-rrb-	-RRB-	_	31	p	_	_
34	or	or	CC	_	29	cc	_	_
35	drug7	drug0	NN	_	29	conj	_	_
36	with	with	IN	_	37	case	_	_
37	drug8	drug0	NN	_	35	ppmod	_	_
38	(	-lrb-	-LRB-	_	39	p	_	_
39	n=6	n=0	NN	_	35	prn	_	_
40	)	-rrb-	-RRB-	_	39	p	_	_
41	.	.	.	_	2	p	_	_

1	Although	although	IN	_	3	mark	_	_
2	there	there	EX	_	3	dep	_	_
3	was	be	VBD	_	20	advcl	_	_
4	a	a	DT	_	6	det	_	_
5	slight	slight	JJ	_	6	attr	_	_
6	reduction	reduction	NN	_	3	obj	_	_
7	in	in	IN	_	10	case	_	_
8	blood	blood	NN	_	10	com	_	_
9	sugar	sugar	NN	_	10	com	_	_
10	concentrations	concentration	NNS	_	6	ppmod	_	_
11	during	during	IN	_	13	case	_	_
12	concomitant	concomitant	JJ	_	13	attr	_	_
13	administration	administration	NN	_	3	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	drug2	drug0	NN	_	15	conj	_	_
18	,	,	,	_	20	p	_	_
19	there	there	EX	_	20	dep	_	_
20	were	be	VBD	_	0	root	_	_
21	no	no	DT	_	22	det	_	_
22	signs	sign	NNS	_	20	obj	_	_
23	or	or	CC	_	22	cc	_	_
24	symptoms	symptom	NNS	_	22	conj	_	_
25	of	of	IN	_	26	case	_	_
26	hypoglycemia	hypoglycemia	NN	_	22	ppmod	_	_
27	.	.	.	_	20	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	-	-	:	_	1	p	_	_
3	including	include	VBG	_	1	acl	_	_
4	drug2	drug0	NN	_	3	obj	_	_
5	,	,	,	_	4	p	_	_
6	drug3	drug0	NN	_	4	conj	_	_
7	and	and	CC	_	6	cc	_	_
8	drug4	drug0	NN	_	9	com	_	_
9	HC1	hc0	NN	_	4	conj	_	_
10	.	.	.	_	1	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	use	use	NN	_	8	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	may	may	MD	_	8	modal	_	_
8	cause	cause	VB	_	0	root	_	_
9	hypertension	hypertension	NN	_	8	obj	_	_
10	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	12	dep	_	_
2	-	-	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	and	and	CC	_	1	cc	_	_
5	the	the	DT	_	7	det	_	_
6	drug3	drug0	NN	_	7	com	_	_
7	drug4	drug0	NN	_	1	conj	_	_
8	may	may	MD	_	12	modal	_	_
9	have	have	VB	_	12	lv	_	_
10	synergistic	synergistic	JJ	_	12	attr	_	_
11	antidepressant	antidepressant	JJ	_	12	attr	_	_
12	activity	activity	NN	_	0	root	_	_
13	if	if	IN	_	14	mark	_	_
14	used	use	VBN	_	12	comp	_	_
15	concomitantly	concomitantly	RB	_	14	adv	_	_
16	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	-	-	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	may	may	MD	_	5	modal	_	_
5	potentiate	potentiate	VB	_	0	root	_	_
6	the	the	DT	_	8	det	_	_
7	tardive	tardive	JJ	_	8	attr	_	_
8	dyskinesia	dyskinesia	NN	_	10	attr	_	_
9	side	side	JJ	_	10	attr	_	_
10	reactions	reaction	NNS	_	5	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	if	if	IN	_	14	mark	_	_
14	used	use	VBN	_	5	comp	_	_
15	concomitantly	concomitantly	RB	_	14	adv	_	_
16	with	with	IN	_	17	case	_	_
17	them	them	PRP	_	14	ppmod	_	_
18	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	shown	show	VBN	_	0	root	_	_
5	in	in	FW	_	6	adv	_	_
6	vivo	vivo	FW	_	4	adv	_	_
7	to	to	TO	_	8	aux	_	_
8	induce	induce	VB	_	4	comp	_	_
9	CYP3A4	cyp0a0	NN	_	8	obj	_	_
10	.	.	.	_	4	p	_	_

1	Other	other	JJ	_	2	attr	_	_
2	compounds	compound	NNS	_	12	dep	_	_
3	that	that	WDT	_	4	dep	_	_
4	are	be	VBP	_	2	relcl	_	_
5	substrates	substrate	NNS	_	4	obj	_	_
6	of	of	IN	_	7	case	_	_
7	CYP3A4	cyp0a0	NN	_	5	ppmod	_	_
8	may	may	MD	_	12	modal	_	_
9	have	have	VBP	_	12	lv	_	_
10	decreased	decrease	VBN	_	12	attr	_	_
11	plasma	plasma	NN	_	12	com	_	_
12	concentrations	concentration	NNS	_	0	root	_	_
13	when	when	WRB	_	14	adv	_	_
14	coadministered	coadministered	VBN	_	12	comp	_	_
15	with	with	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	drug2	drug0	NN	_	16	prn	_	_
19	)	-rrb-	-RRB-	_	18	p	_	_
20	.	.	.	_	12	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	studies	study	NNS	_	5	dep	_	_
4	have	have	VBP	_	5	aux	_	_
5	demonstrated	demonstrate	VBN	_	0	root	_	_
6	that	that	IN	_	8	mark	_	_
7	drug1	drug0	NN	_	8	dep	_	_
8	inhibits	inhibit	VBZ	_	5	comp	_	_
9	2C9	0c0	NN	_	8	obj	_	_
10	,	,	,	_	9	p	_	_
11	2C19	0c0	NN	_	9	conj	_	_
12	,	,	,	_	11	p	_	_
13	and	and	CC	_	11	cc	_	_
14	3A4	0a0	NN	_	15	com	_	_
15	isozymes	isozymes	NNS	_	9	conj	_	_
16	in	in	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	range	range	NN	_	8	ppmod	_	_
19	of	of	IN	_	23	case	_	_
20	observed	observe	VBN	_	23	attr	_	_
21	drug2	drug0	NN	_	23	com	_	_
22	plasma	plasma	NN	_	23	com	_	_
23	concentrations	concentration	NNS	_	18	ppmod	_	_
24	.	.	.	_	5	p	_	_

1	Coadministration	coadministration	NN	_	12	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	5	case	_	_
5	drugs	drug	NNS	_	1	ppmod	_	_
6	primarily	primarily	RB	_	7	adv	_	_
7	metabolized	metabolize	VBN	_	5	acl	_	_
8	by	by	IN	_	10	case	_	_
9	these	these	DT	_	10	det	_	_
10	isozymes	isozymes	NNS	_	7	ppmod	_	_
11	may	may	MD	_	12	modal	_	_
12	result	result	VB	_	0	root	_	_
13	in	in	IN	_	16	case	_	_
14	altered	altered	JJ	_	16	attr	_	_
15	plasma	plasma	NN	_	16	com	_	_
16	concentrations	concentration	NNS	_	12	ppmod	_	_
17	of	of	IN	_	20	case	_	_
18	the	the	DT	_	20	det	_	_
19	coadministered	coadministered	JJ	_	20	attr	_	_
20	drug	drug	NN	_	16	ppmod	_	_
21	.	.	.	_	12	p	_	_

1	Therefore	therefore	RB	_	7	adv	_	_
2	,	,	,	_	7	p	_	_
3	appropriate	appropriate	JJ	_	5	attr	_	_
4	dose	dose	NN	_	5	com	_	_
5	adjustments	adjustment	NNS	_	7	dep	_	_
6	may	may	MD	_	7	modal	_	_
7	be	be	VB	_	0	root	_	_
8	necessary	necessary	JJ	_	7	dep	_	_
9	for	for	IN	_	11	case	_	_
10	these	these	DT	_	11	det	_	_
11	drugs	drug	NNS	_	8	ppmod	_	_
12	.	.	.	_	7	p	_	_

1	Drugs	drug	NNS	_	17	dep	_	_
2	which	which	WDT	_	3	dep	_	_
3	induce	induce	VBP	_	1	relcl	_	_
4	CYP3A4	cyp0a0	NN	_	5	com	_	_
5	activity	activity	NN	_	3	obj	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	eg	eg	NN	_	5	prn	_	_
8	,	,	,	_	7	p	_	_
9	drug1	drug0	NN	_	7	appo	_	_
10	,	,	,	_	7	p	_	_
11	drug2	drug0	NN	_	7	appo	_	_
12	,	,	,	_	7	p	_	_
13	drug3	drug0	NN	_	7	appo	_	_
14	)	-rrb-	-RRB-	_	7	p	_	_
15	would	would	MD	_	17	modal	_	_
16	be	be	VB	_	17	aux	_	_
17	expected	expect	VBN	_	0	root	_	_
18	to	to	TO	_	19	aux	_	_
19	increase	increase	VB	_	17	comp	_	_
20	the	the	DT	_	21	det	_	_
21	clearance	clearance	NN	_	19	obj	_	_
22	of	of	IN	_	23	case	_	_
23	drug4	drug0	NNS	_	21	ppmod	_	_
24	resulting	result	VBG	_	23	acl	_	_
25	in	in	IN	_	28	case	_	_
26	lowered	lowered	JJ	_	28	attr	_	_
27	plasma	plasma	NN	_	28	com	_	_
28	concentrations	concentration	NNS	_	24	ppmod	_	_
29	.	.	.	_	17	p	_	_

1	Drug	drug	NN	_	2	com	_	_
2	interactions	interaction	NNS	_	6	dep	_	_
3	with	with	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	are	be	VBP	_	6	aux	_	_
6	summarized	summarize	VBN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	Table	table	NN	_	6	ppmod	_	_
9	5	0	CD	_	8	num	_	_
10	.	.	.	_	6	p	_	_

1	Table	table	JJ	_	2	attr	_	_
2	5a	0a	NN	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	Drugs	drug	NNS	_	2	appo	_	_
5	That	that	WDT	_	9	dep	_	_
6	Should	should	MD	_	9	modal	_	_
7	Not	not	RB	_	9	neg	_	_
8	Be	be	VB	_	9	aux	_	_
9	Coadministered	coadministered	VBN	_	4	relcl	_	_
10	With	with	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_

1	Drug	drug	NN	_	2	com	_	_
2	Class	class	NN	_	0	root	_	_

1	Drugs	drug	NNS	_	0	root	_	_
2	Within	within	IN	_	7	mark	_	_
3	Class	class	NN	_	7	dep	_	_
4	Not	not	RB	_	7	neg	_	_
5	To	to	TO	_	7	aux	_	_
6	Be	be	VB	_	7	aux	_	_
7	Coadministered	coadministered	VBN	_	1	acl	_	_
8	With	with	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	6	com	_	_
4	GI	gi	NN	_	6	com	_	_
5	Motility	motility	NN	_	6	com	_	_
6	Agents	agent	NNS	_	1	appo	_	_
7	drug3	drug0	IN	_	8	case	_	_
8	drug4	drug0	NN	_	6	ppmod	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	drug2	drug0	NN	_	0	root	_	_
3	,	,	,	_	2	p	_	_
4	drug3	drug0	CC	_	2	cc	_	_
5	drug4	drug0	NN	_	7	com	_	_
6	ergot	ergot	NN	_	7	com	_	_
7	derivatives	derivative	NNS	_	8	com	_	_
8	drug5	drug0	NN	_	2	conj	_	_

1	Established	established	JJ	_	3	attr	_	_
2	Drug	drug	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	Drug	drug	NN	_	2	com	_	_
2	Name	name	NN	_	0	root	_	_

1	Effect	effect	NN	_	0	root	_	_

1	Clinical	clinical	JJ	_	2	attr	_	_
2	Comment	comment	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	When	when	WRB	_	2	adv	_	_
2	coadministered	coadministered	VBN	_	14	advcl	_	_
3	with	with	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	in	in	IN	_	7	case	_	_
6	treatment-naive	treatment-naive	JJ	_	7	attr	_	_
7	patients	patient	NNS	_	4	ppmod	_	_
8	,	,	,	_	14	p	_	_
9	the	the	DT	_	11	det	_	_
10	recommended	recommend	VBN	_	11	attr	_	_
11	dose	dose	NN	_	14	dep	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	is	be	VBZ	_	0	root	_	_
15	300	0	CD	_	16	num	_	_
16	mg	mg	NN	_	14	obj	_	_
17	with	with	IN	_	20	case	_	_
18	drug3	drug0	NN	_	20	attr	_	_
19	100	0	CD	_	20	num	_	_
20	mg	mg	NN	_	16	ppmod	_	_
21	and	and	CC	_	20	cc	_	_
22	drug4	drug0	NN	_	24	attr	_	_
23	600	0	CD	_	24	num	_	_
24	mg	mg	NN	_	20	conj	_	_
25	(	-lrb-	-LRB-	_	26	p	_	_
26	all	all	NN	_	24	prn	_	_
27	once	once	RB	_	28	adv	_	_
28	daily	daily	JJ	_	26	attr	_	_
29	)	-rrb-	-RRB-	_	26	p	_	_
30	.	.	.	_	14	p	_	_

1	Dosing	dosing	NN	_	2	com	_	_
2	recommendations	recommendation	NNS	_	13	dep	_	_
3	for	for	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	in	in	IN	_	9	case	_	_
8	treatment-experienced	treatment-experienced	JJ	_	9	attr	_	_
9	patients	patient	NNS	_	4	ppmod	_	_
10	have	have	VBP	_	13	aux	_	_
11	not	not	RB	_	13	neg	_	_
12	been	be	VBN	_	13	aux	_	_
13	established	establish	VBN	_	0	root	_	_
14	.	.	.	_	13	p	_	_

1	Established	established	JJ	_	3	attr	_	_
2	Drug	drug	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	0	root	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	continued	continued	JJ	_	3	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_

1	Drug	drug	NN	_	2	com	_	_
2	Name	name	NN	_	0	root	_	_

1	Effect	effect	NN	_	0	root	_	_

1	Clinical	clinical	JJ	_	2	attr	_	_
2	Comment	comment	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	concentration	concentration	NN	_	0	root	_	_

1	Plasma	plasma	NN	_	2	com	_	_
2	concentrations	concentration	NNS	_	3	dep	_	_
3	decreased	decrease	VBD	_	0	root	_	_
4	by	by	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	;	;	:	_	3	p	_	_

1	clinical	clinical	JJ	_	2	attr	_	_
2	significance	significance	NN	_	3	dep	_	_
3	unknown	unknown	JJ	_	0	root	_	_
4	.	.	.	_	3	p	_	_

1	In	in	IN	_	3	case	_	_
2	uninfected	uninfected	JJ	_	3	attr	_	_
3	volunteers	volunteer	NNS	_	7	ppmod	_	_
4	,	,	,	_	7	p	_	_
5	46	0	CD	_	7	num	_	_
6	%	%	NN	_	5	meta	_	_
7	developed	develop	VBD	_	0	root	_	_
8	rash	rash	NN	_	7	obj	_	_
9	while	while	IN	_	10	case	_	_
10	receiving	receive	VBG	_	7	ppmod	_	_
11	drug1	drug0	NN	_	10	obj	_	_
12	and	and	CC	_	11	cc	_	_
13	drug2	drug0	NN	_	11	conj	_	_
14	.	.	.	_	7	p	_	_

1	No	no	DT	_	3	det	_	_
2	dose	dose	NN	_	3	com	_	_
3	adjustment	adjustment	NN	_	7	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	is	be	VBZ	_	7	aux	_	_
7	recommended	recommend	VBN	_	0	root	_	_
8	when	when	WRB	_	9	adv	_	_
9	given	give	VBN	_	7	comp	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	7	p	_	_

1	Alternatives	alternative	NNS	_	11	dep	_	_
2	to	to	TO	_	3	aux	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	,	,	,	_	1	p	_	_
5	such	such	JJ	_	7	adv	_	_
6	as	as	IN	_	7	case	_	_
7	drug2	drug0	NN	_	1	ppmod	_	_
8	,	,	,	_	1	p	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	considered	consider	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	Other	other	JJ	_	2	attr	_	_
2	drug1	drug0	NNS	_	11	dep	_	_
3	,	,	,	_	2	p	_	_
4	such	such	JJ	_	6	adv	_	_
5	as	as	IN	_	6	case	_	_
6	drug2	drug0	NN	_	2	ppmod	_	_
7	,	,	,	_	2	p	_	_
8	have	have	VBP	_	11	aux	_	_
9	not	not	RB	_	11	neg	_	_
10	been	be	VBN	_	11	aux	_	_
11	studied	study	VBN	_	0	root	_	_
12	in	in	IN	_	13	case	_	_
13	combination	combination	NN	_	11	ppmod	_	_
14	with	with	IN	_	15	case	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	11	p	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	14-OH	0-oh	NN	_	3	com	_	_
2	metabolite	metabolite	NN	_	3	com	_	_
3	concentration	concentration	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	concentration	concentration	NN	_	0	root	_	_

1	The	the	DT	_	3	det	_	_
2	optimal	optimal	JJ	_	3	attr	_	_
3	dose	dose	NN	_	16	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	,	,	,	_	3	p	_	_
7	when	when	WRB	_	8	adv	_	_
8	given	give	VBN	_	3	relcl	_	_
9	in	in	IN	_	10	case	_	_
10	combination	combination	NN	_	8	ppmod	_	_
11	with	with	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	,	,	,	_	3	p	_	_
14	is	be	VBZ	_	16	aux	_	_
15	not	not	RB	_	16	neg	_	_
16	known	know	VBN	_	0	root	_	_
17	.	.	.	_	16	p	_	_

1	Increasing	increase	VBG	_	13	advcl	_	_
2	the	the	DT	_	4	det	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	dose	dose	NN	_	1	obj	_	_
5	to	to	TO	_	7	aux	_	_
6	1000	0	CD	_	7	num	_	_
7	mg	mg	NN	_	1	ppmod	_	_
8	every	every	DT	_	10	det	_	_
9	8	0	CD	_	10	num	_	_
10	hours	hour	NNS	_	7	appo	_	_
11	does	do	VBZ	_	13	aux	_	_
12	not	not	RB	_	13	neg	_	_
13	compensate	compensate	VB	_	0	root	_	_
14	for	for	IN	_	18	case	_	_
15	the	the	DT	_	18	det	_	_
16	increased	increase	VBN	_	18	attr	_	_
17	drug2	drug0	NN	_	18	com	_	_
18	metabolism	metabolism	NN	_	13	ppmod	_	_
19	due	due	JJ	_	18	attr	_	_
20	to	to	TO	_	21	aux	_	_
21	drug3	drug0	NN	_	19	ppmod	_	_
22	.	.	.	_	13	p	_	_

1	When	when	WRB	_	15	adv	_	_
2	drug1	drug0	NN	_	15	dep	_	_
3	at	at	IN	_	6	case	_	_
4	an	an	DT	_	6	det	_	_
5	increased	increase	VBN	_	6	attr	_	_
6	dose	dose	NN	_	2	ppmod	_	_
7	(	-lrb-	-LRB-	_	9	p	_	_
8	1000	0	CD	_	9	num	_	_
9	mg	mg	NN	_	6	prn	_	_
10	every	every	DT	_	12	det	_	_
11	8	0	CD	_	12	num	_	_
12	hours	hour	NNS	_	9	appo	_	_
13	)	-rrb-	-RRB-	_	9	p	_	_
14	was	be	VBD	_	15	aux	_	_
15	given	give	VBN	_	31	advcl	_	_
16	with	with	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	(	-lrb-	-LRB-	_	20	p	_	_
19	600	0	CD	_	20	num	_	_
20	mg	mg	NN	_	17	prn	_	_
21	once	once	RB	_	22	adv	_	_
22	daily	daily	JJ	_	20	attr	_	_
23	)	-rrb-	-RRB-	_	20	p	_	_
24	,	,	,	_	31	p	_	_
25	the	the	DT	_	27	det	_	_
26	drug3	drug0	NN	_	27	com	_	_
27	AUC	auc	NN	_	31	dep	_	_
28	and	and	CC	_	27	cc	_	_
29	Cmin	cmin	NN	_	27	conj	_	_
30	were	be	VBD	_	31	aux	_	_
31	decreased	decrease	VBN	_	0	root	_	_
32	on	on	IN	_	33	case	_	_
33	average	average	NN	_	31	ppmod	_	_
34	by	by	IN	_	35	case	_	_
35	33-46	0	CD	_	31	ppmod	_	_
36	%	%	NN	_	35	meta	_	_
37	and	and	CC	_	35	cc	_	_
38	39-57	0	CD	_	35	conj	_	_
39	%	%	NN	_	38	meta	_	_
40	,	,	,	_	38	p	_	_
41	respectively	respectively	RB	_	35	conj	_	_
42	,	,	,	_	31	p	_	_
43	compared	compare	VBN	_	55	adv	_	_
44	to	to	TO	_	55	aux	_	_
45	when	when	WRB	_	55	adv	_	_
46	drug4	drug0	NN	_	55	dep	_	_
47	(	-lrb-	-LRB-	_	49	p	_	_
48	800	0	CD	_	49	num	_	_
49	mg	mg	NN	_	46	prn	_	_
50	every	every	DT	_	52	det	_	_
51	8	0	CD	_	52	num	_	_
52	hours	hour	NNS	_	49	attr	_	_
53	)	-rrb-	-RRB-	_	49	p	_	_
54	was	be	VBD	_	55	aux	_	_
55	given	give	VBN	_	31	ppmod	_	_
56	alone	alone	RB	_	55	adv	_	_
57	.	.	.	_	31	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	/	/	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	concentration	concentration	NN	_	0	root	_	_

1	A	a	DT	_	3	det	_	_
2	dose	dose	NN	_	3	com	_	_
3	increase	increase	NN	_	24	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	/	/	:	_	5	p	_	_
7	drug2	drug0	NN	_	10	attr	_	_
8	to	to	TO	_	10	attr	_	_
9	533/133	0	CD	_	10	num	_	_
10	mg	mg	NN	_	5	appo	_	_
11	(	-lrb-	-LRB-	_	13	p	_	_
12	4	0	CD	_	13	num	_	_
13	capsules	capsule	NNS	_	10	prn	_	_
14	or	or	CC	_	13	cc	_	_
15	6.5	0	CD	_	16	num	_	_
16	mL	ml	NN	_	13	conj	_	_
17	)	-rrb-	-RRB-	_	13	p	_	_
18	twice	twice	RB	_	19	com	_	_
19	daily	daily	RB	_	10	adv	_	_
20	taken	take	VBN	_	10	acl	_	_
21	with	with	IN	_	22	case	_	_
22	food	food	NN	_	20	ppmod	_	_
23	is	be	VBZ	_	24	aux	_	_
24	recommended	recommend	VBN	_	0	root	_	_
25	when	when	WRB	_	26	adv	_	_
26	used	use	VBN	_	24	comp	_	_
27	in	in	IN	_	28	case	_	_
28	combination	combination	NN	_	26	ppmod	_	_
29	with	with	IN	_	30	case	_	_
30	drug3	drug0	NN	_	28	ppmod	_	_
31	.	.	.	_	24	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	concentration	concentration	NN	_	0	root	_	_

1	Coadministration	coadministration	NN	_	12	dep	_	_
2	in	in	IN	_	4	case	_	_
3	HIV-infected	hiv-infected	JJ	_	4	attr	_	_
4	individuals	individual	NNS	_	1	ppmod	_	_
5	with	with	IN	_	7	case	_	_
6	a	a	DT	_	7	det	_	_
7	history	history	NN	_	1	ppmod	_	_
8	of	of	IN	_	11	case	_	_
9	injection	injection	NN	_	11	com	_	_
10	drug	drug	NN	_	11	com	_	_
11	use	use	NN	_	7	ppmod	_	_
12	resulted	result	VBD	_	0	root	_	_
13	in	in	IN	_	16	case	_	_
14	decreased	decrease	VBN	_	16	attr	_	_
15	plasma	plasma	NN	_	16	com	_	_
16	levels	level	NNS	_	12	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug1	drug0	NN	_	16	ppmod	_	_
19	and	and	CC	_	16	cc	_	_
20	signs	sign	NNS	_	16	conj	_	_
21	of	of	IN	_	23	case	_	_
22	drug2	drug0	NN	_	23	com	_	_
23	withdrawal	withdrawal	NN	_	20	ppmod	_	_
24	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	dose	dose	NN	_	4	dep	_	_
3	was	be	VBD	_	4	aux	_	_
4	increased	increase	VBN	_	0	root	_	_
5	by	by	IN	_	7	case	_	_
6	a	a	DT	_	7	det	_	_
7	mean	mean	NN	_	4	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	22	0	CD	_	7	ppmod	_	_
10	%	%	NN	_	9	meta	_	_
11	to	to	TO	_	12	aux	_	_
12	alleviate	alleviate	VB	_	7	acl	_	_
13	withdrawal	withdrawal	NN	_	14	com	_	_
14	symptoms	symptom	NNS	_	12	obj	_	_
15	.	.	.	_	4	p	_	_

1	Patients	patient	NNS	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	monitored	monitor	VBN	_	0	root	_	_
5	for	for	IN	_	6	case	_	_
6	signs	sign	NNS	_	4	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	withdrawal	withdrawal	NN	_	6	ppmod	_	_
9	and	and	CC	_	4	cc	_	_
10	their	their	PRP$	_	12	poss	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	dose	dose	NN	_	13	dep	_	_
13	increased	increase	VBD	_	4	conj	_	_
14	as	as	IN	_	15	mark	_	_
15	required	require	VBN	_	13	comp	_	_
16	to	to	TO	_	17	aux	_	_
17	alleviate	alleviate	VB	_	15	comp	_	_
18	withdrawal	withdrawal	NN	_	19	com	_	_
19	symptoms	symptom	NNS	_	17	obj	_	_
20	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	concentration	concentration	NN	_	0	root	_	_

1	Plasma	plasma	NN	_	2	com	_	_
2	concentrations	concentration	NNS	_	3	dep	_	_
3	increased	increase	VBD	_	0	root	_	_
4	by	by	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	drug2	drug0	NN	_	3	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	;	;	:	_	3	p	_	_

1	clinical	clinical	JJ	_	2	attr	_	_
2	significance	significance	NN	_	3	dep	_	_
3	unknown	unknown	JJ	_	0	root	_	_
4	.	.	.	_	3	p	_	_

1	Because	because	IN	_	14	mark	_	_
2	the	the	DT	_	4	det	_	_
3	potential	potential	JJ	_	4	attr	_	_
4	interaction	interaction	NN	_	14	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	with	with	IN	_	9	case	_	_
8	oral	oral	JJ	_	9	attr	_	_
9	drug2	drug0	NN	_	4	ppmod	_	_
10	has	have	VBZ	_	14	aux	_	_
11	not	not	RB	_	14	neg	_	_
12	been	be	VBN	_	14	aux	_	_
13	fully	fully	RB	_	14	adv	_	_
14	characterized	characterize	VBN	_	24	advcl	_	_
15	,	,	,	_	24	p	_	_
16	a	a	DT	_	18	det	_	_
17	reliable	reliable	JJ	_	18	attr	_	_
18	method	method	NN	_	24	dep	_	_
19	of	of	IN	_	21	case	_	_
20	barrier	barrier	NN	_	21	com	_	_
21	contraception	contraception	NN	_	18	ppmod	_	_
22	should	should	MD	_	24	modal	_	_
23	be	be	VB	_	24	aux	_	_
24	used	use	VBN	_	0	root	_	_
25	in	in	IN	_	26	case	_	_
26	addition	addition	NN	_	24	ppmod	_	_
27	to	to	TO	_	29	aux	_	_
28	oral	oral	JJ	_	29	attr	_	_
29	drug3	drug0	NN	_	26	ppmod	_	_
30	.	.	.	_	24	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	concentration	concentration	NN	_	0	root	_	_

1	Increase	increase	VBP	_	0	root	_	_
2	daily	daily	JJ	_	3	attr	_	_
3	dose	dose	NN	_	1	obj	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	by	by	IN	_	7	case	_	_
7	50	0	CD	_	1	ppmod	_	_
8	%	%	NN	_	7	meta	_	_
9	.	.	.	_	1	p	_	_

1	Consider	consider	VB	_	2	dep	_	_
2	doubling	double	VBG	_	0	root	_	_
3	the	the	DT	_	5	det	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	dose	dose	NN	_	2	obj	_	_
6	in	in	IN	_	7	case	_	_
7	regimens	regimen	NNS	_	2	ppmod	_	_
8	where	where	WRB	_	11	adv	_	_
9	drug2	drug0	NN	_	11	dep	_	_
10	is	be	VBZ	_	11	aux	_	_
11	given	give	VBN	_	7	relcl	_	_
12	2	0	CD	_	15	num	_	_
13	or	or	CC	_	12	cc	_	_
14	3	0	CD	_	12	conj	_	_
15	times	time	NNS	_	11	obj	_	_
16	a	a	DT	_	17	det	_	_
17	week	week	NN	_	15	appo	_	_
18	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	concentration	concentration	NN	_	0	root	_	_

1	Clinical	clinical	JJ	_	2	attr	_	_
2	significance	significance	NN	_	7	dep	_	_
3	of	of	IN	_	6	case	_	_
4	reduced	reduce	VBN	_	6	attr	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	concentrations	concentration	NNS	_	2	ppmod	_	_
7	unknown	unknown	JJ	_	0	root	_	_
8	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	concentration	concentration	NN	_	0	root	_	_

1	Combination	combination	NN	_	3	dep	_	_
2	was	be	VBD	_	3	aux	_	_
3	associated	associate	VBN	_	0	root	_	_
4	with	with	IN	_	7	case	_	_
5	a	a	DT	_	7	det	_	_
6	higher	high	JJR	_	7	attr	_	_
7	frequency	frequency	NN	_	3	ppmod	_	_
8	of	of	IN	_	11	case	_	_
9	adverse	adverse	JJ	_	11	attr	_	_
10	clinical	clinical	JJ	_	11	attr	_	_
11	experiences	experience	NNS	_	7	ppmod	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	eg	eg	NN	_	11	prn	_	_
14	,	,	,	_	13	p	_	_
15	dizziness	dizziness	NN	_	13	appo	_	_
16	,	,	,	_	13	p	_	_
17	nausea	nausea	NN	_	13	appo	_	_
18	,	,	,	_	13	p	_	_
19	paresthesia	paresthesia	NN	_	13	appo	_	_
20	)	-rrb-	-RRB-	_	13	p	_	_
21	and	and	CC	_	11	cc	_	_
22	laboratory	laboratory	NN	_	23	com	_	_
23	abnormalities	abnormality	NNS	_	11	conj	_	_
24	(	-lrb-	-LRB-	_	27	p	_	_
25	elevated	elevated	JJ	_	27	attr	_	_
26	liver	liver	NN	_	27	com	_	_
27	enzymes	enzyme	NNS	_	23	prn	_	_
28	)	-rrb-	-RRB-	_	27	p	_	_
29	.	.	.	_	3	p	_	_

1	Monitoring	monitoring	NN	_	6	dep	_	_
2	of	of	IN	_	4	case	_	_
3	liver	liver	NN	_	4	com	_	_
4	enzymes	enzyme	NNS	_	1	ppmod	_	_
5	is	be	VBZ	_	6	aux	_	_
6	recommended	recommend	VBN	_	0	root	_	_
7	when	when	WRB	_	10	adv	_	_
8	drug1	drug0	NN	_	10	dep	_	_
9	is	be	VBZ	_	10	aux	_	_
10	used	use	VBN	_	6	comp	_	_
11	in	in	IN	_	12	case	_	_
12	combination	combination	NN	_	10	ppmod	_	_
13	with	with	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	concentration	concentration	NN	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	concentration	concentration	NN	_	0	root	_	_

1	Should	should	MD	_	4	modal	_	_
2	not	not	RB	_	4	neg	_	_
3	be	be	VB	_	4	aux	_	_
4	used	use	VBN	_	0	root	_	_
5	as	as	IN	_	7	case	_	_
6	sole	sole	JJ	_	7	attr	_	_
7	drug1	drug0	NN	_	4	ppmod	_	_
8	in	in	IN	_	9	case	_	_
9	combination	combination	NN	_	7	ppmod	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	concentration	concentration	NN	_	0	root	_	_

1	Increases	increase	NNS	_	7	dep	_	_
2	in	in	IN	_	4	case	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	dose	dose	NN	_	1	ppmod	_	_
5	should	should	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	guided	guide	VBN	_	0	root	_	_
8	by	by	IN	_	10	case	_	_
9	clinical	clinical	JJ	_	10	attr	_	_
10	response	response	NN	_	7	ppmod	_	_
11	.	.	.	_	7	p	_	_

1	Other	other	JJ	_	5	attr	_	_
2	Potentially	potentially	RB	_	4	adv	_	_
3	Clinically	clinically	RB	_	4	adv	_	_
4	Significant	significant	JJ	_	5	attr	_	_
5	Drug	drug	NN	_	0	root	_	_
6	or	or	CC	_	5	cc	_	_
7	Herbal	herbal	NN	_	9	com	_	_
8	Product	product	NN	_	9	com	_	_
9	Interactions	interaction	NNS	_	5	conj	_	_
10	With	with	IN	_	11	case	_	_
11	SUSTIVAb	sustivab	NN	_	5	ppmod	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	appo	_	_

1	Plasma	plasma	NN	_	2	com	_	_
2	concentrations	concentration	NNS	_	6	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	effects	effect	NNS	_	2	conj	_	_
5	potentially	potentially	RB	_	6	adv	_	_
6	increased	increase	VBN	_	0	root	_	_
7	or	or	CC	_	6	cc	_	_
8	decreased	decrease	VBN	_	6	conj	_	_
9	by	by	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	5	com	_	_
4	drug3	drug0	NN	_	5	com	_	_
5	drug4	drug0	NN	_	1	appo	_	_

1	Potential	potential	NN	_	0	root	_	_
2	for	for	IN	_	3	case	_	_
3	reduction	reduction	NN	_	1	ppmod	_	_
4	in	in	IN	_	5	case	_	_
5	drug1	drug0	NN	_	1	ppmod	_	_
6	and/or	and/or	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	9	com	_	_
8	plasma	plasma	NN	_	9	com	_	_
9	levels	level	NNS	_	5	conj	_	_
10	;	;	:	_	1	p	_	_

1	periodic	periodic	JJ	_	2	attr	_	_
2	monitoring	monitoring	NN	_	9	dep	_	_
3	of	of	IN	_	6	case	_	_
4	drug1	drug0	NN	_	6	com	_	_
5	plasma	plasma	NN	_	6	com	_	_
6	levels	level	NNS	_	2	ppmod	_	_
7	should	should	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	conducted	conduct	VBN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	4	com	_	_
4	drug3	drug0	NN	_	1	appo	_	_

1	Drug	drug	NN	_	3	com	_	_
2	interaction	interaction	NN	_	3	com	_	_
3	studies	study	NNS	_	14	dep	_	_
4	with	with	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	these	these	DT	_	8	det	_	_
8	drug2	drug0	NN	_	5	conj	_	_
9	and	and	CC	_	8	cc	_	_
10	drug3	drug0	NN	_	8	conj	_	_
11	have	have	VBP	_	14	aux	_	_
12	not	not	RB	_	14	neg	_	_
13	been	be	VBN	_	14	aux	_	_
14	conducted	conduct	VBN	_	0	root	_	_
15	.	.	.	_	14	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	has	have	VBZ	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	potential	potential	NN	_	2	obj	_	_
5	to	to	TO	_	8	aux	_	_
6	decrease	decrease	NN	_	8	com	_	_
7	plasma	plasma	NN	_	8	com	_	_
8	concentrations	concentration	NNS	_	4	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug3	drug0	NN	_	10	conj	_	_
13	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	/	/	:	_	3	p	_	_
5	drug3	drug0	CC	_	3	cc	_	_
6	combination	combination	NN	_	1	conj	_	_

1	No	no	DT	_	3	det	_	_
2	pharmacokinetic	pharmacokinetic	JJ	_	3	attr	_	_
3	data	datum	NNS	_	4	dep	_	_
4	are	be	VBP	_	0	root	_	_
5	available	available	JJ	_	4	dep	_	_
6	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	SUSTIVAhas	sustivahas	NNS	_	0	root	_	_
2	the	the	DT	_	3	det	_	_
3	potential	potential	NN	_	1	obj	_	_
4	to	to	TO	_	7	aux	_	_
5	decrease	decrease	NN	_	7	com	_	_
6	serum	serum	NN	_	7	com	_	_
7	concentrations	concentration	NNS	_	1	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	No	no	DT	_	2	det	_	_
2	studies	study	NNS	_	5	dep	_	_
3	have	have	VBP	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	performed	performed	VBN	_	0	root	_	_
6	with	with	IN	_	8	case	_	_
7	other	other	JJ	_	8	attr	_	_
8	drug1	drug0	NN	_	5	ppmod	_	_
9	.	.	.	_	5	p	_	_

1	St.	st.	NN	_	4	com	_	_
2	John	john	NN	_	4	com	_	_
3	s	s	NN	_	4	com	_	_
4	wort	wort	NN	_	0	root	_	_
5	(	-lrb-	-LRB-	_	7	p	_	_
6	Hypericum	hypericum	NN	_	7	com	_	_
7	perforatum	perforatum	NN	_	4	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_

1	Expected	expect	VBN	_	13	advcl	_	_
2	to	to	TO	_	4	aux	_	_
3	substantially	substantially	RB	_	4	adv	_	_
4	decrease	decrease	VB	_	1	comp	_	_
5	plasma	plasma	NN	_	6	com	_	_
6	levels	level	NNS	_	4	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	;	;	:	_	13	p	_	_
10	has	have	VBZ	_	13	aux	_	_
11	not	not	RB	_	13	neg	_	_
12	been	be	VBN	_	13	aux	_	_
13	studied	study	VBN	_	0	root	_	_
14	in	in	IN	_	15	case	_	_
15	combination	combination	NN	_	13	ppmod	_	_
16	with	with	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	.	.	.	_	13	p	_	_

1	a	a	NN	_	2	dep	_	_
2	See	see	VB	_	0	root	_	_
3	Tables	table	NNS	_	2	obj	_	_
4	1	0	CD	_	3	num	_	_
5	and	and	CC	_	4	cc	_	_
6	2	0	CD	_	4	conj	_	_
7	.	.	.	_	2	p	_	_

1	b	b	NN	_	3	attr	_	_
2	This	this	DT	_	3	attr	_	_
3	table	table	NN	_	4	dep	_	_
4	is	be	VBZ	_	0	root	_	_
5	not	not	RB	_	4	neg	_	_
6	all-inclusive	all-inclusive	JJ	_	4	dep	_	_
7	.	.	.	_	4	p	_	_

1	Other	other	JJ	_	2	attr	_	_
2	Drugs	drug	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	Based	base	VBN	_	17	advcl	_	_
5	on	on	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	results	result	NNS	_	4	ppmod	_	_
8	of	of	IN	_	11	case	_	_
9	drug	drug	NN	_	11	com	_	_
10	interaction	interaction	NN	_	11	com	_	_
11	studies	study	NNS	_	7	ppmod	_	_
12	,	,	,	_	17	p	_	_
13	no	no	DT	_	15	det	_	_
14	dosage	dosage	JJ	_	15	attr	_	_
15	adjustment	adjustment	NN	_	17	dep	_	_
16	is	be	VBZ	_	17	aux	_	_
17	recommended	recommend	VBN	_	2	acl	_	_
18	when	when	WRB	_	24	adv	_	_
19	drug1	drug0	NN	_	24	dep	_	_
20	(	-lrb-	-LRB-	_	21	p	_	_
21	drug2	drug0	NN	_	19	prn	_	_
22	)	-rrb-	-RRB-	_	21	p	_	_
23	is	be	VBZ	_	24	aux	_	_
24	given	give	VBN	_	17	comp	_	_
25	with	with	IN	_	27	case	_	_
26	the	the	DT	_	27	det	_	_
27	following	following	NN	_	24	ppmod	_	_
28	:	:	:	_	27	p	_	_
29	drug3	drug0	NN	_	27	conj	_	_
30	,	,	,	_	29	p	_	_
31	drug4	drug0	NN	_	27	conj	_	_
32	,	,	,	_	31	p	_	_
33	drug5	drug0	NN	_	27	conj	_	_
34	,	,	,	_	33	p	_	_
35	drug6	drug0	NN	_	27	conj	_	_
36	,	,	,	_	35	p	_	_
37	drug7	drug0	NN	_	27	conj	_	_
38	,	,	,	_	37	p	_	_
39	drug8	drug0	NN	_	27	conj	_	_
40	,	,	,	_	39	p	_	_
41	drug9	drug0	NN	_	27	conj	_	_
42	,	,	,	_	41	p	_	_
43	drug10	drug0	NN	_	27	conj	_	_
44	,	,	,	_	43	p	_	_
45	drug11	drug0	NN	_	27	conj	_	_
46	,	,	,	_	45	p	_	_
47	and	and	CC	_	45	cc	_	_
48	drug12	drug0	NN	_	27	conj	_	_
49	.	.	.	_	2	p	_	_

1	Specific	specific	JJ	_	4	attr	_	_
2	drug	drug	NN	_	4	com	_	_
3	interaction	interaction	NN	_	4	com	_	_
4	studies	study	NNS	_	8	dep	_	_
5	have	have	VBP	_	8	aux	_	_
6	not	not	RB	_	8	neg	_	_
7	been	be	VBN	_	8	aux	_	_
8	performed	performed	VBN	_	0	root	_	_
9	with	with	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug2	drug0	NN	_	10	conj	_	_
13	other	other	JJ	_	10	attr	_	_
14	than	than	IN	_	15	case	_	_
15	drug3	drug0	NN	_	13	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	drug4	drug0	NN	_	15	conj	_	_
18	.	.	.	_	8	p	_	_

1	Clinically	clinically	RB	_	2	adv	_	_
2	significant	significant	JJ	_	3	attr	_	_
3	interactions	interaction	NNS	_	7	dep	_	_
4	would	would	MD	_	7	modal	_	_
5	not	not	RB	_	7	neg	_	_
6	be	be	VB	_	7	aux	_	_
7	expected	expect	VBN	_	0	root	_	_
8	since	since	IN	_	12	mark	_	_
9	the	the	DT	_	10	det	_	_
10	drug1	drug0	NNS	_	12	dep	_	_
11	are	be	VBP	_	12	aux	_	_
12	metabolized	metabolize	VBN	_	7	comp	_	_
13	via	via	IN	_	16	case	_	_
14	a	a	DT	_	16	det	_	_
15	different	different	JJ	_	16	attr	_	_
16	route	route	NN	_	12	ppmod	_	_
17	than	than	IN	_	18	case	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	and	and	CC	_	7	cc	_	_
20	would	would	MD	_	21	modal	_	_
21	be	be	VB	_	7	conj	_	_
22	unlikely	unlikely	JJ	_	21	dep	_	_
23	to	to	TO	_	24	aux	_	_
24	compete	compete	VB	_	22	comp	_	_
25	for	for	IN	_	29	case	_	_
26	the	the	DT	_	29	det	_	_
27	same	same	JJ	_	29	attr	_	_
28	metabolic	metabolic	JJ	_	29	attr	_	_
29	enzymes	enzyme	NNS	_	24	ppmod	_	_
30	and	and	CC	_	29	cc	_	_
31	elimination	elimination	NN	_	32	com	_	_
32	pathways	pathway	NNS	_	29	conj	_	_
33	.	.	.	_	7	p	_	_

1	Formal	formal	JJ	_	4	attr	_	_
2	drug	drug	NN	_	4	com	_	_
3	interaction	interaction	NN	_	4	com	_	_
4	studies	study	NNS	_	10	dep	_	_
5	with	with	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	have	have	VBP	_	10	aux	_	_
8	not	not	RB	_	10	neg	_	_
9	been	be	VBN	_	10	aux	_	_
10	conducted	conduct	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	administered	administer	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	patients	patient	NNS	_	4	ppmod	_	_
7	with	with	IN	_	10	case	_	_
8	ischemic	ischemic	JJ	_	10	attr	_	_
9	heart	heart	NN	_	10	com	_	_
10	disease	disease	NN	_	6	ppmod	_	_
11	treated	treat	VBN	_	6	acl	_	_
12	concomitantly	concomitantly	RB	_	11	adv	_	_
13	with	with	IN	_	16	case	_	_
14	a	a	DT	_	16	det	_	_
15	broad	broad	JJ	_	16	attr	_	_
16	range	range	NN	_	11	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	medications	medication	NNS	_	16	ppmod	_	_
19	used	use	VBN	_	18	acl	_	_
20	in	in	IN	_	22	case	_	_
21	the	the	DT	_	22	det	_	_
22	treatment	treatment	NN	_	19	ppmod	_	_
23	of	of	IN	_	26	case	_	_
24	angina	angina	NN	_	26	attr	_	_
25	myocardial	myocardial	JJ	_	26	attr	_	_
26	infarction	infarction	NN	_	22	ppmod	_	_
27	and	and	CC	_	26	cc	_	_
28	hypertension	hypertension	NN	_	26	conj	_	_
29	.	.	.	_	4	p	_	_

1	These	these	DT	_	2	det	_	_
2	medications	medication	NNS	_	3	dep	_	_
3	have	have	VBP	_	0	root	_	_
4	included	include	VBD	_	3	comp	_	_
5	drug1	drug0	NN	_	4	obj	_	_
6	,	,	,	_	5	p	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	,	,	,	_	7	p	_	_
9	drug3	drug0	NN	_	5	conj	_	_
10	,	,	,	_	9	p	_	_
11	drug4	drug0	NN	_	5	conj	_	_
12	,	,	,	_	11	p	_	_
13	drug5	drug0	NN	_	5	conj	_	_
14	,	,	,	_	13	p	_	_
15	intravenous	intravenous	JJ	_	18	attr	_	_
16	and	and	CC	_	15	cc	_	_
17	oral	oral	JJ	_	15	conj	_	_
18	drug6	drug0	NN	_	5	conj	_	_
19	,	,	,	_	18	p	_	_
20	drug7	drug0	NN	_	5	conj	_	_
21	,	,	,	_	20	p	_	_
22	and	and	CC	_	20	cc	_	_
23	drug8	drug0	NN	_	5	conj	_	_
24	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	11	dep	_	_
2	,	,	,	_	1	p	_	_
3	other	other	JJ	_	4	attr	_	_
4	drug2	drug0	NN	_	1	conj	_	_
5	,	,	,	_	4	p	_	_
6	drug3	drug0	NN	_	1	conj	_	_
7	,	,	,	_	6	p	_	_
8	and	and	CC	_	6	cc	_	_
9	drug4	drug0	NN	_	1	conj	_	_
10	are	be	VBP	_	11	aux	_	_
11	associated	associate	VBN	_	0	root	_	_
12	with	with	IN	_	14	case	_	_
13	an	an	DT	_	14	det	_	_
14	increase	increase	NN	_	11	ppmod	_	_
15	in	in	IN	_	16	case	_	_
16	bleeding	bleeding	JJ	_	14	ppmod	_	_
17	.	.	.	_	11	p	_	_

1	Patients	patient	NNS	_	10	dep	_	_
2	with	with	IN	_	4	case	_	_
3	HACA	haca	NN	_	4	com	_	_
4	titers	titer	NNS	_	1	ppmod	_	_
5	may	may	MD	_	10	modal	_	_
6	have	have	VBP	_	10	lv	_	_
7	allergic	allergic	JJ	_	10	attr	_	_
8	or	or	CC	_	10	cc	_	_
9	hypersensitivity	hypersensitivity	NN	_	10	com	_	_
10	reactions	reaction	NNS	_	0	root	_	_
11	when	when	WRB	_	12	adv	_	_
12	treated	treat	VBN	_	10	comp	_	_
13	with	with	IN	_	15	case	_	_
14	other	other	JJ	_	15	attr	_	_
15	drug1	drug0	NN	_	12	ppmod	_	_
16	or	or	CC	_	15	cc	_	_
17	drug2	drug0	NN	_	15	conj	_	_
18	.	.	.	_	10	p	_	_

1	Effects	effect	NNS	_	7	dep	_	_
2	of	of	IN	_	4	case	_	_
3	Other	other	JJ	_	4	attr	_	_
4	Drugs	drug	NNS	_	1	ppmod	_	_
5	on	on	IN	_	6	case	_	_
6	drug1	drug0	NN	_	1	ppmod	_	_
7	Based	base	VBN	_	0	root	_	_
8	on	on	IN	_	10	case	_	_
9	in-vitro	in-vitro	FW	_	10	attr	_	_
10	studies	study	NNS	_	7	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	drug2	drug0	WDT	_	14	dep	_	_
13	is	be	VBZ	_	14	aux	_	_
14	metabolized	metabolize	VBN	_	10	relcl	_	_
15	by	by	IN	_	17	case	_	_
16	CYP	cyp	NN	_	17	com	_	_
17	3A4	0a0	NN	_	14	ppmod	_	_
18	.	.	.	_	7	p	_	_

1	Co-administration	co-administration	NN	_	26	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	,	,	,	_	3	p	_	_
5	drug2	drug0	NN	_	3	appo	_	_
6	,	,	,	_	3	p	_	_
7	drug3	drug0	NN	_	3	appo	_	_
8	,	,	,	_	7	p	_	_
9	drug4	drug0	NN	_	7	conj	_	_
10	,	,	,	_	9	p	_	_
11	drug5	drug0	NN	_	7	conj	_	_
12	,	,	,	_	11	p	_	_
13	drug6	drug0	NN	_	7	conj	_	_
14	,	,	,	_	13	p	_	_
15	drug7	drug0	NN	_	7	conj	_	_
16	,	,	,	_	15	p	_	_
17	drug8	drug0	NN	_	7	conj	_	_
18	,	,	,	_	17	p	_	_
19	drug9	drug0	NN	_	7	conj	_	_
20	,	,	,	_	19	p	_	_
21	drug10	drug0	CD	_	19	num	_	_
22	and	and	CC	_	19	cc	_	_
23	drug11	drug0	CD	_	7	conj	_	_
24	did	do	VBD	_	26	aux	_	_
25	not	not	RB	_	26	neg	_	_
26	result	result	VB	_	0	root	_	_
27	in	in	IN	_	30	case	_	_
28	clinically	clinically	RB	_	29	adv	_	_
29	significant	significant	JJ	_	30	attr	_	_
30	increases	increase	NNS	_	26	ppmod	_	_
31	in	in	IN	_	33	case	_	_
32	drug12	drug0	NN	_	33	com	_	_
33	exposure	exposure	NN	_	30	ppmod	_	_
34	.	.	.	_	26	p	_	_

1	Co-administration	co-administration	NN	_	4	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	reduced	reduce	VBD	_	0	root	_	_
5	drug2	drug0	NN	_	6	com	_	_
6	Cmax	cmax	NN	_	4	obj	_	_
7	up	up	RB	_	9	adv	_	_
8	to	to	TO	_	9	attr	_	_
9	50	0	CD	_	13	dat	_	_
10	%	%	NN	_	9	meta	_	_
11	after	after	IN	_	13	case	_	_
12	multiple	multiple	JJ	_	13	attr	_	_
13	dosing	dosing	NN	_	4	ppmod	_	_
14	.	.	.	_	4	p	_	_

1	Co-administration	co-administration	NN	_	4	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	resulted	result	VBD	_	0	root	_	_
5	in	in	IN	_	10	case	_	_
6	about	about	RB	_	10	adv	_	_
7	a	a	DT	_	10	det	_	_
8	50	0	CD	_	10	num	_	_
9	%	%	NN	_	8	meta	_	_
10	increase	increase	NN	_	4	ppmod	_	_
11	in	in	IN	_	13	case	_	_
12	drug2	drug0	NN	_	13	com	_	_
13	Cmax	cmax	NN	_	10	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	AUC	auc	NN	_	13	conj	_	_
16	after	after	IN	_	18	case	_	_
17	multiple	multiple	JJ	_	18	attr	_	_
18	dosing	dosing	NN	_	10	ppmod	_	_
19	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Co-administration	co-administration	NN	_	11	dep	_	_
4	of	of	IN	_	8	case	_	_
5	200	0	CD	_	6	num	_	_
6	mg	mg	NN	_	8	com	_	_
7	twice-daily	twice-daily	NN	_	8	com	_	_
8	drug2	drug0	NN	_	3	ppmod	_	_
9	with	with	IN	_	10	case	_	_
10	drug3	drug0	NN	_	3	ppmod	_	_
11	resulted	result	VBD	_	1	acl	_	_
12	in	in	IN	_	17	case	_	_
13	an	an	DT	_	17	det	_	_
14	approximate	approximate	JJ	_	17	attr	_	_
15	80	0	CD	_	17	num	_	_
16	%	%	NN	_	15	meta	_	_
17	increase	increase	NN	_	11	ppmod	_	_
18	in	in	IN	_	20	case	_	_
19	plasma	plasma	NN	_	20	com	_	_
20	levels	level	NNS	_	17	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	drug4	drug0	NN	_	20	ppmod	_	_
23	.	.	.	_	1	p	_	_

1	A	a	DT	_	5	det	_	_
2	400	0	CD	_	3	num	_	_
3	mg	mg	NN	_	5	attr	_	_
4	once-daily	once-daily	JJ	_	5	attr	_	_
5	dose	dose	NN	_	8	dep	_	_
6	was	be	VBD	_	8	aux	_	_
7	not	not	RB	_	8	neg	_	_
8	studied	study	VBN	_	0	root	_	_
9	but	but	CC	_	8	cc	_	_
10	would	would	MD	_	12	modal	_	_
11	be	be	VB	_	12	aux	_	_
12	expected	expect	VBN	_	8	conj	_	_
13	to	to	TO	_	14	aux	_	_
14	increase	increase	VB	_	12	comp	_	_
15	drug1	drug0	NN	_	17	com	_	_
16	blood	blood	NN	_	17	com	_	_
17	levels	level	NNS	_	14	obj	_	_
18	further	far	RB	_	14	adv	_	_
19	.	.	.	_	8	p	_	_

1	Effects	effect	NNS	_	7	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	on	on	IN	_	6	case	_	_
5	Other	other	JJ	_	6	attr	_	_
6	Drugs	drug	NNS	_	1	ppmod	_	_
7	drug2	drug0	VBP	_	0	root	_	_
8	does	do	VBZ	_	10	aux	_	_
9	not	not	RB	_	10	neg	32:neg	_
10	inhibit	inhibit	VB	_	7	comp	_	_
11	the	the	DT	_	13	det	_	_
12	CYP450	cyp0	CD	_	13	num	_	_
13	isoenzymes	isoenzymes	NNS	_	10	obj	_	_
14	(	-lrb-	-LRB-	_	17	p	_	_
15	CYP1A2	cyp0a0	NN	_	17	dep	_	_
16	,	,	,	_	17	p	_	_
17	2C8	0c0	NN	_	13	prn	_	_
18	,	,	,	_	17	p	_	_
19	2C9	0c0	NN	_	17	conj	_	_
20	,	,	,	_	19	p	_	_
21	2C19	0c0	NN	_	17	conj	_	_
22	,	,	,	_	21	p	_	_
23	2D6	0d0	NN	_	17	conj	_	_
24	,	,	,	_	23	p	_	_
25	2E1	0e0	NN	_	17	conj	_	_
26	,	,	,	_	25	p	_	_
27	and	and	CC	_	25	cc	_	_
28	CYP	cyp	NN	_	29	com	_	_
29	3A	0a	NN	_	17	conj	_	_
30	)	-rrb-	-RRB-	_	17	p	_	_
31	or	or	CC	_	10	cc	_	_
32	induce	induce	VB	_	10	conj	_	_
33	CYP	cyp	NN	_	34	com	_	_
34	3A4	0a0	NN	_	32	obj	_	_
35	.	.	.	_	7	p	_	_

1	Co-administration	co-administration	NN	_	7	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	did	do	VBD	_	7	aux	_	_
5	not	not	RB	_	7	neg	_	_
6	significantly	significantly	RB	_	7	adv	_	_
7	affect	affect	VB	_	0	root	_	_
8	the	the	DT	_	9	det	_	_
9	pharmacokinetics	pharmacokinetics	NNS	_	7	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	,	,	,	_	11	p	_	_
13	drug3	drug0	NN	_	11	conj	_	_
14	,	,	,	_	13	p	_	_
15	drug4	drug0	NN	_	11	conj	_	_
16	,	,	,	_	15	p	_	_
17	drug5	drug0	NN	_	11	conj	_	_
18	,	,	,	_	17	p	_	_
19	drug6	drug0	NN	_	11	conj	_	_
20	,	,	,	_	19	p	_	_
21	drug7	drug0	NN	_	11	conj	_	_
22	,	,	,	_	21	p	_	_
23	drug8	drug0	NN	_	11	conj	_	_
24	,	,	,	_	23	p	_	_
25	drug9	drug0	NN	_	11	conj	_	_
26	,	,	,	_	25	p	_	_
27	drug10	drug0	NN	_	11	conj	_	_
28	or	or	CC	_	27	cc	_	_
29	drug11	drug0	NN	_	11	conj	_	_
30	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	effects	effect	NNS	_	13	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	on	on	IN	_	9	case	_	_
8	drug3	drug0	NN	_	9	com	_	_
9	pharmacokinetics	pharmacokinetics	NNS	_	4	ppmod	_	_
10	have	have	VBP	_	13	aux	_	_
11	not	not	RB	_	13	neg	_	_
12	been	be	VBN	_	13	aux	_	_
13	evaluated	evaluate	VBN	_	1	acl	_	_
14	in	in	IN	_	18	case	_	_
15	a	a	DT	_	18	det	_	_
16	well-controlled	well-controlled	JJ	_	18	attr	_	_
17	clinical	clinical	JJ	_	18	attr	_	_
18	trial	trial	NN	_	13	ppmod	_	_
19	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	When	when	WRB	_	6	adv	_	_
4	drug2	drug0	NN	_	6	dep	_	_
5	was	be	VBD	_	6	aux	_	_
6	co-administered	co-administered	VBN	_	17	advcl	_	_
7	with	with	IN	_	8	case	_	_
8	drug3	drug0	NN	_	6	ppmod	_	_
9	,	,	,	_	17	p	_	_
10	the	the	DT	_	11	det	_	_
11	AUC	auc	NN	_	17	dep	_	_
12	and	and	CC	_	11	cc	_	_
13	Cmax	cmax	NN	_	11	conj	_	_
14	of	of	IN	_	15	case	_	_
15	drug4	drug0	NNS	_	11	ppmod	_	_
16	were	be	VBD	_	17	aux	_	_
17	reduced	reduce	VBN	_	1	acl	_	_
18	by	by	IN	_	20	case	_	_
19	about	about	RB	_	20	adv	_	_
20	30	0	CD	_	17	ppmod	_	_
21	%	%	NN	_	20	meta	_	_
22	and	and	CC	_	20	cc	_	_
23	50	0	CD	_	20	conj	_	_
24	%	%	NN	_	23	meta	_	_
25	,	,	,	_	23	p	_	_
26	respectively	respectively	RB	_	20	conj	_	_
27	.	.	.	_	1	p	_	_

1	No	no	DT	_	5	det	_	_
2	formal	formal	JJ	_	5	attr	_	_
3	drug	drug	NN	_	5	com	_	_
4	interaction	interaction	NN	_	5	com	_	_
5	studies	study	NNS	_	10	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	have	have	VBP	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	performed	performed	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	CYP450	cyp0	CD	_	4	num	_	_
2	Metabolized	metabolized	JJ	_	4	attr	_	_
3	Drugs	drug	NNS	_	4	com	_	_
4	Results	result	NNS	_	12	dep	_	_
5	from	from	IN	_	11	case	_	_
6	in	in	FW	_	7	adv	_	_
7	vitro	vitro	FW	_	11	attr	_	_
8	and	and	CC	_	7	cc	_	_
9	in	in	FW	_	10	adv	_	_
10	vivo	vivo	FW	_	7	conj	_	_
11	studies	study	NNS	_	4	ppmod	_	_
12	suggest	suggest	VBP	_	0	root	_	_
13	that	that	IN	_	15	mark	_	_
14	drug1	drug0	NN	_	15	dep	_	_
15	is	be	VBZ	_	12	comp	_	_
16	unlikely	unlikely	JJ	_	15	dep	_	_
17	to	to	TO	_	21	aux	_	_
18	have	have	VB	_	21	lv	_	_
19	significant	significant	JJ	_	21	attr	_	_
20	drug	drug	NN	_	21	com	_	_
21	interactions	interaction	NNS	_	16	comp	_	_
22	with	with	IN	_	25	case	_	_
23	concomitantly	concomitantly	RB	_	24	adv	_	_
24	administered	administer	VBN	_	25	attr	_	_
25	drugs	drug	NNS	_	21	ppmod	_	_
26	metabolized	metabolize	VBN	_	25	acl	_	_
27	by	by	IN	_	29	case	_	_
28	CYP450	cyp0	NN	_	29	com	_	_
29	enzymes	enzyme	NNS	_	26	ppmod	_	_
30	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	No	no	DT	_	5	det	_	_
4	drug	drug	NN	_	5	com	_	_
5	interactions	interaction	NNS	_	11	dep	_	_
6	with	with	IN	_	8	case	_	_
7	other	other	JJ	_	8	attr	_	_
8	drug2	drug0	NNS	_	5	ppmod	_	_
9	have	have	VBP	_	11	aux	_	_
10	been	be	VBN	_	11	aux	_	_
11	identified	identify	VBN	_	1	acl	_	_
12	that	that	WDT	_	14	dep	_	_
13	would	would	MD	_	14	modal	_	_
14	warrant	warrant	VBP	_	11	comp	_	_
15	alteration	alteration	NN	_	14	obj	_	_
16	of	of	IN	_	20	case	_	_
17	either	either	CC	_	20	cc	_	_
18	the	the	DT	_	20	det	_	_
19	drug3	drug0	NN	_	20	com	_	_
20	dose	dose	NN	_	15	ppmod	_	_
21	or	or	CC	_	20	cc	_	_
22	the	the	DT	_	23	det	_	_
23	dose	dose	NN	_	20	conj	_	_
24	of	of	IN	_	27	case	_	_
25	the	the	DT	_	27	det	_	_
26	other	other	JJ	_	27	attr	_	_
27	drug4	drug0	NNS	_	23	ppmod	_	_
28	.	.	.	_	1	p	_	_

1	Certain	certain	JJ	_	2	attr	_	_
2	drugs	drug	NNS	_	3	dep	_	_
3	tend	tend	VBP	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	produce	produce	VB	_	3	comp	_	_
6	hyperglycemia	hyperglycemia	NN	_	5	obj	_	_
7	and	and	CC	_	3	cc	_	_
8	may	may	MD	_	9	modal	_	_
9	lead	lead	VB	_	3	conj	_	_
10	to	to	TO	_	11	aux	_	_
11	loss	loss	NN	_	9	ppmod	_	_
12	of	of	IN	_	15	case	_	_
13	blood	blood	NN	_	15	com	_	_
14	glucose	glucose	NN	_	15	com	_	_
15	control	control	NN	_	11	ppmod	_	_
16	.	.	.	_	3	p	_	_

1	These	these	DT	_	2	det	_	_
2	drugs	drug	NNS	_	3	dep	_	_
3	include	include	VBP	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	drug1	drug0	NN	_	3	obj	_	_
6	and	and	CC	_	5	cc	_	_
7	other	other	JJ	_	8	attr	_	_
8	drug2	drug0	NNS	_	5	conj	_	_
9	,	,	,	_	5	p	_	_
10	drug3	drug0	NN	_	5	appo	_	_
11	,	,	,	_	10	p	_	_
12	drug4	drug0	NN	_	10	conj	_	_
13	,	,	,	_	12	p	_	_
14	drug5	drug0	NN	_	10	conj	_	_
15	,	,	,	_	14	p	_	_
16	drug6	drug0	NN	_	10	conj	_	_
17	,	,	,	_	16	p	_	_
18	oral	oral	JJ	_	19	attr	_	_
19	drug7	drug0	NN	_	10	conj	_	_
20	,	,	,	_	19	p	_	_
21	drug8	drug0	NN	_	10	conj	_	_
22	,	,	,	_	21	p	_	_
23	drug9	drug0	NN	_	10	conj	_	_
24	,	,	,	_	23	p	_	_
25	drug10	drug0	NN	_	10	conj	_	_
26	,	,	,	_	25	p	_	_
27	drug11	drug0	NN	_	10	conj	_	_
28	,	,	,	_	27	p	_	_
29	and	and	CC	_	27	cc	_	_
30	drug12	drug0	NN	_	10	conj	_	_
31	.	.	.	_	3	p	_	_

1	When	when	WRB	_	5	adv	_	_
2	such	such	JJ	_	3	attr	_	_
3	drugs	drug	NNS	_	5	dep	_	_
4	are	be	VBP	_	5	aux	_	_
5	administered	administer	VBN	_	17	advcl	_	_
6	to	to	TO	_	8	aux	_	_
7	a	a	DT	_	8	det	_	_
8	patient	patient	NN	_	5	ppmod	_	_
9	receiving	receive	VBG	_	8	acl	_	_
10	drug1	drug0	NN	_	9	obj	_	_
11	,	,	,	_	17	p	_	_
12	the	the	DT	_	13	det	_	_
13	patient	patient	NN	_	17	dep	_	_
14	should	should	MD	_	17	modal	_	_
15	be	be	VB	_	17	aux	_	_
16	closely	closely	RB	_	17	adv	_	_
17	observed	observe	VBN	_	0	root	_	_
18	for	for	IN	_	19	case	_	_
19	loss	loss	NN	_	17	ppmod	_	_
20	of	of	IN	_	23	case	_	_
21	blood	blood	NN	_	23	com	_	_
22	glucose	glucose	NN	_	23	com	_	_
23	control	control	NN	_	19	ppmod	_	_
24	.	.	.	_	17	p	_	_

1	When	when	WRB	_	5	adv	_	_
2	such	such	JJ	_	3	attr	_	_
3	drugs	drug	NNS	_	5	dep	_	_
4	are	be	VBP	_	5	aux	_	_
5	withdrawn	withdraw	VBN	_	20	advcl	_	_
6	from	from	IN	_	7	case	_	_
7	patients	patient	NNS	_	5	ppmod	_	_
8	receiving	receive	VBG	_	7	acl	_	_
9	drug1	drug0	NN	_	8	obj	_	_
10	in	in	IN	_	11	case	_	_
11	combination	combination	NN	_	8	ppmod	_	_
12	with	with	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	or	or	CC	_	13	cc	_	_
15	drug3	drug0	NN	_	13	conj	_	_
16	,	,	,	_	20	p	_	_
17	patients	patient	NNS	_	20	dep	_	_
18	should	should	MD	_	20	modal	_	_
19	be	be	VB	_	20	aux	_	_
20	observed	observe	VBN	_	0	root	_	_
21	closely	closely	RB	_	20	adv	_	_
22	for	for	IN	_	24	case	_	_
23	any	any	DT	_	24	det	_	_
24	evidence	evidence	NN	_	20	ppmod	_	_
25	of	of	IN	_	26	case	_	_
26	hypoglycemia	hypoglycemia	NN	_	24	ppmod	_	_
27	.	.	.	_	20	p	_	_

1	drug1	drug0	NN	_	22	dep	_	_
2	(	-lrb-	-LRB-	_	4	p	_	_
3	e.	e.	FW	_	4	attr	_	_
4	g.	g.	FW	_	1	prn	_	_
5	,	,	,	_	4	p	_	_
6	drug2	drug0	NN	_	4	appo	_	_
7	)	-rrb-	-RRB-	_	4	p	_	_
8	and	and	CC	_	1	cc	_	_
9	drug3	drug0	NN	_	1	conj	_	_
10	containing	contain	VBG	_	1	acl	_	_
11	carbohydrate-splitting	carbohydrate-splitting	JJ	_	12	attr	_	_
12	enzymes	enzyme	NNS	_	10	obj	_	_
13	(	-lrb-	-LRB-	_	15	p	_	_
14	e.	e.	FW	_	15	attr	_	_
15	g.	g.	FW	_	12	prn	_	_
16	,	,	,	_	15	p	_	_
17	drug4	drug0	NN	_	15	attr	_	_
18	,	,	,	_	15	p	_	_
19	drug5	drug0	NN	_	17	appo	_	_
20	)	-rrb-	-RRB-	_	15	p	_	_
21	may	may	MD	_	22	modal	_	_
22	reduce	reduce	VB	_	0	root	_	_
23	the	the	DT	_	24	det	_	_
24	effect	effect	NN	_	22	obj	_	_
25	of	of	IN	_	26	case	_	_
26	drug6	drug0	NN	_	24	ppmod	_	_
27	and	and	CC	_	22	cc	_	_
28	should	should	MD	_	31	modal	_	_
29	not	not	RB	_	31	neg	_	_
30	be	be	VB	_	31	aux	_	_
31	taken	take	VBN	_	22	conj	_	_
32	concomitantly	concomitantly	RB	_	31	adv	_	_
33	.	.	.	_	22	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	shown	show	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	change	change	VB	_	4	comp	_	_
7	the	the	DT	_	9	det	_	_
8	bioavailabillty	bioavailabillty	NN	_	9	com	_	_
9	drug2	drug0	NN	_	6	obj	_	_
10	when	when	WRB	_	13	adv	_	_
11	they	they	PRP	_	13	dep	_	_
12	are	be	VBP	_	13	aux	_	_
13	co-administered	co-administered	VBN	_	6	comp	_	_
14	,	,	,	_	13	p	_	_
15	which	which	WDT	_	17	dep	_	_
16	may	may	MD	_	17	modal	_	_
17	require	require	VB	_	13	comp	_	_
18	drug3	drug0	NN	_	20	com	_	_
19	dose	dose	NN	_	20	com	_	_
20	adjustment	adjustment	NN	_	17	obj	_	_
21	.	.	.	_	4	p	_	_

1	Studies	study	NNS	_	6	dep	_	_
2	in	in	IN	_	4	case	_	_
3	healthy	healthy	JJ	_	4	attr	_	_
4	volunteers	volunteer	NNS	_	1	ppmod	_	_
5	have	have	VBP	_	6	aux	_	_
6	shown	show	VBN	_	0	root	_	_
7	that	that	IN	_	9	mark	_	_
8	drug1	drug0	NN	_	9	dep	_	_
9	has	have	VBZ	_	6	comp	_	_
10	no	no	DT	_	11	det	_	_
11	effect	effect	NN	_	9	obj	_	_
12	on	on	IN	_	15	case	_	_
13	either	either	CC	_	15	cc	_	_
14	the	the	DT	_	15	det	_	_
15	pharmacokinetics	pharmacokinetics	NNS	_	9	ppmod	_	_
16	or	or	CC	_	15	cc	_	_
17	pharmacodynamics	pharmacodynamics	NNS	_	15	conj	_	_
18	of	of	IN	_	19	case	_	_
19	drug2	drug0	NN	_	15	ppmod	_	_
20	,	,	,	_	19	p	_	_
21	drug3	drug0	NN	_	19	conj	_	_
22	,	,	,	_	21	p	_	_
23	drug4	drug0	NN	_	19	conj	_	_
24	,	,	,	_	23	p	_	_
25	or	or	CC	_	23	cc	_	_
26	drug5	drug0	NN	_	19	conj	_	_
27	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	did	do	VBD	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	interfere	interfere	VB	_	0	root	_	_
5	with	with	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	absorption	absorption	NN	_	4	ppmod	_	_
8	or	or	CC	_	7	cc	_	_
9	disposition	disposition	NN	_	7	conj	_	_
10	of	of	IN	_	13	case	_	_
11	the	the	DT	_	13	det	_	_
12	drug2	drug0	NN	_	13	com	_	_
13	drug3	drug0	NN	_	7	ppmod	_	_
14	in	in	IN	_	16	case	_	_
15	diabetic	diabetic	JJ	_	16	attr	_	_
16	patients	patient	NNS	_	7	ppmod	_	_
17	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	affect	affect	VB	_	0	root	_	_
4	drug2	drug0	NN	_	5	com	_	_
5	bioavailabillty	bioavailabillty	NN	_	3	obj	_	_
6	and	and	CC	_	3	cc	_	_
7	may	may	MD	_	8	modal	_	_
8	require	require	VB	_	3	conj	_	_
9	dose	dose	NN	_	10	com	_	_
10	adjustment	adjustment	NN	_	8	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	by	by	IN	_	14	case	_	_
14	16	0	CD	_	8	ppmod	_	_
15	%	%	NN	_	14	meta	_	_
16	(	-lrb-	-LRB-	_	20	p	_	_
17	90	0	CD	_	20	num	_	_
18	%	%	NN	_	20	meta	_	_
19	confidence	confidence	NN	_	20	com	_	_
20	interval	interval	NN	_	14	prn	_	_
21	:	:	:	_	20	p	_	_
22	8-23	0	CD	_	20	num	_	_
23	%	%	NN	_	20	meta	_	_
24	)	-rrb-	-RRB-	_	20	p	_	_
25	,	,	,	_	8	p	_	_
26	decrease	decrease	VB	_	8	conj	_	_
27	mean	mean	NN	_	29	com	_	_
28	C	c	NN	_	29	com	_	_
29	max	max	NN	_	26	obj	_	_
30	drug4	drug0	VBN	_	29	acl	_	_
31	by	by	IN	_	32	case	_	_
32	26	0	CD	_	30	ppmod	_	_
33	%	%	NN	_	32	meta	_	_
34	(	-lrb-	-LRB-	_	38	p	_	_
35	90	0	CD	_	38	num	_	_
36	%	%	NN	_	38	meta	_	_
37	confidence	confidence	NN	_	38	com	_	_
38	interval	interval	NN	_	32	prn	_	_
39	:	:	:	_	38	p	_	_
40	16-34	0	CD	_	38	num	_	_
41	%	%	NN	_	38	meta	_	_
42	)	-rrb-	-RRB-	_	38	p	_	_
43	and	and	CC	_	26	cc	_	_
44	decrease	decrease	VB	_	8	conj	_	_
45	mean	mean	JJ	_	47	attr	_	_
46	trough	trough	NN	_	47	com	_	_
47	concentrations	concentration	NNS	_	44	obj	_	_
48	of	of	IN	_	49	case	_	_
49	drug5	drug0	NN	_	47	ppmod	_	_
50	by	by	IN	_	51	case	_	_
51	9	0	CD	_	44	ppmod	_	_
52	%	%	NN	_	51	meta	_	_
53	(	-lrb-	-LRB-	_	57	p	_	_
54	90	0	CD	_	57	num	_	_
55	%	%	NN	_	54	meta	_	_
56	confidence	confidence	NN	_	57	com	_	_
57	limit	limit	NN	_	51	prn	_	_
58	:	:	:	_	57	p	_	_
59	19	0	CD	_	61	num	_	_
60	%	%	NN	_	59	meta	_	_
61	decrease	decrease	NN	_	57	appo	_	_
62	to	to	TO	_	65	aux	_	_
63	2	0	CD	_	65	num	_	_
64	%	%	NN	_	63	meta	_	_
65	increase	increase	NN	_	61	ppmod	_	_
66	)	-rrb-	-RRB-	_	57	p	_	_
67	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	amount	amount	NN	_	5	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	absorbed	absorb	VBD	_	0	root	_	_
6	while	while	IN	_	9	mark	_	_
7	taking	take	VBG	_	8	attr	_	_
8	drug2	drug0	NN	_	9	dep	_	_
9	was	be	VBD	_	5	comp	_	_
10	bioequivalent	bioequivalent	JJ	_	9	dep	_	_
11	to	to	TO	_	13	aux	_	_
12	the	the	DT	_	13	det	_	_
13	amount	amount	NN	_	10	ppmod	_	_
14	absorbed	absorb	VBN	_	13	acl	_	_
15	when	when	WRB	_	16	adv	_	_
16	taking	take	VBG	_	14	comp	_	_
17	placebo	placebo	NN	_	16	obj	_	_
18	,	,	,	_	9	p	_	_
19	as	as	IN	_	20	mark	_	_
20	indicated	indicate	VBN	_	9	comp	_	_
21	by	by	IN	_	25	case	_	_
22	the	the	DT	_	25	det	_	_
23	plasma	plasma	NN	_	25	com	_	_
24	AUC	auc	NN	_	25	com	_	_
25	values	value	NNS	_	20	ppmod	_	_
26	.	.	.	_	5	p	_	_

1	However	however	RB	_	10	adv	_	_
2	,	,	,	_	10	p	_	_
3	the	the	DT	_	6	det	_	_
4	peak	peak	JJ	_	6	attr	_	_
5	plasma	plasma	NN	_	6	com	_	_
6	level	level	NN	_	10	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	was	be	VBD	_	10	aux	_	_
10	reduced	reduce	VBN	_	0	root	_	_
11	by	by	IN	_	13	case	_	_
12	approximately	approximately	RB	_	13	adv	_	_
13	20	0	CD	_	10	ppmod	_	_
14	%	%	NN	_	13	meta	_	_
15	when	when	WRB	_	16	adv	_	_
16	taking	take	VBG	_	10	comp	_	_
17	drug2	drug0	NN	_	16	obj	_	_
18	due	due	IN	_	22	case	_	_
19	to	to	TO	_	22	aux	_	_
20	a	a	DT	_	22	det	_	_
21	slight	slight	JJ	_	22	attr	_	_
22	delay	delay	NN	_	16	ppmod	_	_
23	in	in	IN	_	25	case	_	_
24	the	the	DT	_	25	det	_	_
25	absorption	absorption	NN	_	22	ppmod	_	_
26	of	of	IN	_	27	case	_	_
27	drug3	drug0	NN	_	25	ppmod	_	_
28	.	.	.	_	10	p	_	_

1	There	there	EX	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	little	little	JJ	_	2	dep	_	_
4	if	if	IN	_	8	case	_	_
5	any	any	DT	_	8	det	_	_
6	clinically	clinically	RB	_	7	adv	_	_
7	significant	significant	JJ	_	8	attr	_	_
8	interaction	interaction	NN	_	3	ppmod	_	_
9	between	between	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug2	drug0	NN	_	10	conj	_	_
13	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	interact	interact	VB	_	0	root	_	_
4	with	with	IN	_	5	case	_	_
5	drug2	drug0	NNS	_	3	ppmod	_	_
6	(	-lrb-	-LRB-	_	9	p	_	_
7	e.g.	e.g.	FW	_	9	adv	_	_
8	,	,	,	_	9	p	_	_
9	drug3	drug0	NN	_	5	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	,	,	,	_	5	p	_	_
12	drug4	drug0	NNS	_	5	conj	_	_
13	(	-lrb-	-LRB-	_	16	p	_	_
14	e.g.	e.g.	FW	_	16	adv	_	_
15	,	,	,	_	16	p	_	_
16	drug5	drug0	NN	_	12	prn	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	,	,	,	_	12	p	_	_
19	local	local	JJ	_	20	attr	_	_
20	drug6	drug0	NNS	_	5	conj	_	_
21	(	-lrb-	-LRB-	_	24	p	_	_
22	e.g.	e.g.	FW	_	24	adv	_	_
23	,	,	,	_	24	p	_	_
24	drug7	drug0	NN	_	20	prn	_	_
25	and	and	CC	_	24	cc	_	_
26	drug8	drug0	NN	_	24	conj	_	_
27	)	-rrb-	-RRB-	_	24	p	_	_
28	,	,	,	_	20	p	_	_
29	drug9	drug0	NN	_	33	advnp	_	_
30	(	-lrb-	-LRB-	_	33	p	_	_
31	drug10	drug0	NN	_	33	advnp	_	_
32	)	-rrb-	-RRB-	_	33	p	_	_
33	-containing	-containing	JJ	_	34	attr	_	_
34	preparations	preparation	NNS	_	5	conj	_	_
35	(	-lrb-	-LRB-	_	38	p	_	_
36	e.g.	e.g.	FW	_	38	ppmod	_	_
37	,	,	,	_	38	p	_	_
38	sunscreens	sunscreen	NNS	_	34	prn	_	_
39	and	and	CC	_	38	cc	_	_
40	some	some	DT	_	41	det	_	_
41	drug11	drug0	NN	_	38	conj	_	_
42	)	-rrb-	-RRB-	_	38	p	_	_
43	,	,	,	_	34	p	_	_
44	drug12	drug0	CD	_	5	conj	_	_
45	(	-lrb-	-LRB-	_	48	p	_	_
46	e.g.	e.g.	FW	_	48	ppmod	_	_
47	,	,	,	_	48	p	_	_
48	drug13	drug0	CD	_	44	num	_	_
49	)	-rrb-	-RRB-	_	48	p	_	_
50	,	,	,	_	44	p	_	_
51	drug14	drug0	CD	_	44	appo	_	_
52	(	-lrb-	-LRB-	_	54	p	_	_
53	sulfa	sulfa	NN	_	54	com	_	_
54	medicines	medicine	NNS	_	51	prn	_	_
55	)	-rrb-	-RRB-	_	54	p	_	_
56	,	,	,	_	44	p	_	_
57	drug15	drug0	CD	_	44	appo	_	_
58	(	-lrb-	-LRB-	_	59	p	_	_
59	use	use	NN	_	44	prn	_	_
60	of	of	IN	_	62	case	_	_
61	these	these	DT	_	62	det	_	_
62	medicines	medicine	NNS	_	59	ppmod	_	_
63	during	during	IN	_	66	case	_	_
64	the	the	DT	_	66	det	_	_
65	test	test	NN	_	66	com	_	_
66	period	period	NN	_	59	ppmod	_	_
67	will	will	MD	_	68	modal	_	_
68	affect	affect	VB	_	66	acl	_	_
69	the	the	DT	_	71	det	_	_
70	test	test	NN	_	71	com	_	_
71	results	result	NNS	_	68	obj	_	_
72	)	-rrb-	-RRB-	_	59	p	_	_
73	,	,	,	_	44	p	_	_
74	and	and	CC	_	44	cc	_	_
75	pancreatic	pancreatic	JJ	_	76	attr	_	_
76	supplements	supplement	NNS	_	5	conj	_	_
77	(	-lrb-	-LRB-	_	83	p	_	_
78	use	use	NN	_	83	dep	_	_
79	of	of	IN	_	81	case	_	_
80	pancreatic	pancreatic	JJ	_	81	attr	_	_
81	supplements	supplement	NNS	_	78	ppmod	_	_
82	may	may	MD	_	83	modal	_	_
83	give	give	VB	_	76	prn	_	_
84	false	false	JJ	_	86	attr	_	_
85	test	test	NN	_	86	com	_	_
86	results	result	NNS	_	83	obj	_	_
87	)	-rrb-	-RRB-	_	83	p	_	_
88	.	.	.	_	3	p	_	_

1	Known	known	JJ	_	3	attr	_	_
2	drug	drug	NN	_	3	com	_	_
3	interactions	interaction	NNS	_	4	dep	_	_
4	include	include	VBP	_	0	root	_	_
5	drug1	drug0	NN	_	4	obj	_	_
6	,	,	,	_	5	p	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	,	,	,	_	7	p	_	_
9	and	and	CC	_	7	cc	_	_
10	drug3	drug0	NN	_	5	conj	_	_
11	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	may	may	MD	_	5	modal	_	_
5	interact	interact	VB	_	0	root	_	_
6	with	with	IN	_	7	case	_	_
7	drug3	drug0	NN	_	5	ppmod	_	_
8	In	in	IN	_	9	case	_	_
9	studies	study	NNS	_	5	ppmod	_	_
10	with	with	IN	_	12	case	_	_
11	male	male	JJ	_	12	attr	_	_
12	rats	rat	NNS	_	9	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	drug4	drug0	WDT	_	16	dep	_	_
15	was	be	VBD	_	16	aux	_	_
16	found	find	VBN	_	12	relcl	_	_
17	to	to	TO	_	18	aux	_	_
18	inhibit	inhibit	VB	_	16	comp	_	_
19	the	the	DT	_	23	det	_	_
20	hepatic	hepatic	JJ	_	23	attr	_	_
21	microsomal	microsomal	JJ	_	23	attr	_	_
22	enzyme	enzyme	NN	_	23	com	_	_
23	system	system	NN	_	18	obj	_	_
24	at	at	IN	_	26	case	_	_
25	a	a	DT	_	26	det	_	_
26	dose	dose	NN	_	18	ppmod	_	_
27	of	of	IN	_	29	case	_	_
28	2	0	CD	_	29	num	_	_
29	mg/kg/day	mg/kg/day	NN	_	26	ppmod	_	_
30	.	.	.	_	5	p	_	_

1	Therefore	therefore	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	drug1	drug0	NN	_	4	dep	_	_
4	has	have	VBZ	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	potential	potential	NN	_	4	obj	_	_
7	to	to	TO	_	8	aux	_	_
8	prolong	prolong	VB	_	6	acl	_	_
9	the	the	DT	_	11	det	_	_
10	biological	biological	JJ	_	11	attr	_	_
11	half-lives	half-life	NNS	_	8	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drugs	drug	NNS	_	11	ppmod	_	_
14	for	for	IN	_	15	case	_	_
15	which	which	WDT	_	20	ppmod	_	_
16	the	the	DT	_	17	det	_	_
17	rate	rate	NN	_	20	dep	_	_
18	of	of	IN	_	19	case	_	_
19	elimination	elimination	NN	_	17	ppmod	_	_
20	is	be	VBZ	_	13	relcl	_	_
21	dependent	dependent	JJ	_	20	dep	_	_
22	on	on	IN	_	28	case	_	_
23	the	the	DT	_	28	det	_	_
24	microsomal	microsomal	JJ	_	28	attr	_	_
25	drug	drug	NN	_	28	com	_	_
26	metabolizing	metabolizing	NN	_	28	com	_	_
27	enzyme	enzyme	NN	_	28	com	_	_
28	system	system	NN	_	21	ppmod	_	_
29	.	.	.	_	4	p	_	_

1	Interacts	interact	VBZ	_	0	root	_	_
2	with	with	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_

1	No	no	DT	_	5	det	_	_
2	formal	formal	JJ	_	5	attr	_	_
3	drug	drug	NN	_	5	com	_	_
4	interaction	interaction	NN	_	5	com	_	_
5	studies	study	NNS	_	8	dep	_	_
6	have	have	VBP	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	performed	performed	VBN	_	0	root	_	_
9	with	with	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	8	p	_	_

1	May	may	MD	_	2	modal	_	_
2	interact	interact	VB	_	0	root	_	_
3	with	with	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	following	following	NN	_	2	ppmod	_	_
6	:	:	:	_	2	p	_	_
7	drug1	drug0	NN	_	2	dep	_	_
8	(	-lrb-	-LRB-	_	12	p	_	_
9	these	these	DT	_	10	det	_	_
10	medicines	medicine	NNS	_	12	dep	_	_
11	may	may	MD	_	12	modal	_	_
12	make	make	VB	_	7	prn	_	_
13	your	your	NN	_	15	advnp	_	_
14	condition	condition	NN	_	15	advnp	_	_
15	worse	bad	JJ	_	12	dep	_	_
16	and	and	CC	_	12	cc	_	_
17	prevent	prevent	VB	_	12	conj	_	_
18	the	the	DT	_	19	det	_	_
19	drug2	drug0	NN	_	17	obj	_	_
20	from	from	IN	_	21	case	_	_
21	working	working	NNP	_	19	ppmod	_	_
22	properly	properly	RB	_	17	adv	_	_
23	)	-rrb-	-RRB-	_	12	p	_	_
24	and	and	CC	_	7	cc	_	_
25	drug3	drug0	NN	_	7	conj	_	_
26	,	,	,	_	25	p	_	_
27	drug4	drug0	NN	_	25	conj	_	_
28	,	,	,	_	27	p	_	_
29	drug5	drug0	NN	_	25	conj	_	_
30	,	,	,	_	29	p	_	_
31	and	and	CC	_	29	cc	_	_
32	drug6	drug0	NN	_	25	conj	_	_
33	(	-lrb-	-LRB-	_	37	p	_	_
34	these	these	DT	_	35	det	_	_
35	medicines	medicine	NNS	_	37	dep	_	_
36	may	may	MD	_	37	modal	_	_
37	increase	increase	VB	_	25	prn	_	_
38	the	the	DT	_	39	det	_	_
39	risk	risk	NN	_	37	obj	_	_
40	of	of	IN	_	42	case	_	_
41	heart	heart	NN	_	42	com	_	_
42	problems	problem	NNS	_	39	ppmod	_	_
43	)	-rrb-	-RRB-	_	37	p	_	_
44	.	.	.	_	2	p	_	_

1	Interactions	interaction	NNS	_	13	dep	_	_
2	for	for	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	drug2	drug0	NN	_	3	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	:	:	:	_	1	p	_	_
8	drug3	drug0	NN	_	9	com	_	_
9	Therapy	therapy	NN	_	1	appo	_	_
10	:	:	:	_	1	p	_	_
11	drug4	drug0	NN	_	1	appo	_	_
12	may	may	MD	_	13	modal	_	_
13	potentiate	potentiate	VB	_	0	root	_	_
14	the	the	DT	_	15	det	_	_
15	effects	effect	NNS	_	13	obj	_	_
16	of	of	IN	_	20	case	_	_
17	drug5	drug0	JJ	_	20	attr	_	_
18	and	and	CC	_	17	cc	_	_
19	vasoactive	vasoactive	JJ	_	17	conj	_	_
20	drugs	drug	NNS	_	15	ppmod	_	_
21	resulting	result	VBG	_	20	acl	_	_
22	in	in	IN	_	24	case	_	_
23	postural	postural	JJ	_	24	attr	_	_
24	hypotension	hypotension	NN	_	21	ppmod	_	_
25	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	:	:	:	_	1	p	_	_
3	Concomitant	concomitant	JJ	_	4	attr	_	_
4	drug2	drug0	NN	_	1	appo	_	_
5	may	may	MD	_	6	modal	_	_
6	decrease	decrease	VB	_	0	root	_	_
7	the	the	DT	_	9	det	_	_
8	metabolic	metabolic	JJ	_	9	attr	_	_
9	clearance	clearance	NN	_	6	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug3	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	6	p	_	_

1	The	the	DT	_	3	det	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	relevance	relevance	NN	_	7	dep	_	_
4	of	of	IN	_	6	case	_	_
5	this	this	DT	_	6	det	_	_
6	finding	finding	NN	_	3	ppmod	_	_
7	is	be	VBZ	_	0	root	_	_
8	unclear	unclear	JJ	_	7	dep	_	_
9	.	.	.	_	7	p	_	_

1	Other	other	JJ	_	3	adv	_	_
2	:	:	:	_	3	p	_	_
3	Concomitant	concomitant	JJ	_	7	attr	_	_
4	drug1	drug0	JJ	_	7	attr	_	_
5	or	or	CC	_	4	cc	_	_
6	hot	hot	JJ	_	4	conj	_	_
7	drinks	drink	NNS	_	9	dep	_	_
8	may	may	MD	_	9	modal	_	_
9	increase	increase	VB	_	0	root	_	_
10	the	the	DT	_	12	det	_	_
11	side	side	JJ	_	12	attr	_	_
12	effects	effect	NNS	_	9	obj	_	_
13	of	of	IN	_	14	case	_	_
14	flushing	flushing	NN	_	12	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	pruritus	pruritus	NN	_	14	conj	_	_
17	and	and	CC	_	9	cc	_	_
18	should	should	MD	_	20	modal	_	_
19	be	be	VB	_	20	aux	_	_
20	avoided	avoid	VBN	_	9	conj	_	_
21	at	at	IN	_	23	case	_	_
22	the	the	DT	_	23	det	_	_
23	time	time	NN	_	20	ppmod	_	_
24	of	of	IN	_	26	case	_	_
25	drug	drug	NN	_	26	com	_	_
26	ingestion	ingestion	NN	_	23	ppmod	_	_
27	.	.	.	_	9	p	_	_

1	The	the	DT	_	3	det	_	_
2	following	follow	VBG	_	3	attr	_	_
3	agents	agent	NNS	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	increase	increase	VB	_	0	root	_	_
6	certain	certain	JJ	_	7	attr	_	_
7	actions	action	NNS	_	5	obj	_	_
8	or	or	CC	_	7	cc	_	_
9	side	side	JJ	_	10	attr	_	_
10	effects	effect	NNS	_	7	conj	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	10	p	_	_
14	drug2	drug0	NN	_	15	com	_	_
15	drug3	drug0	NN	_	10	appo	_	_
16	of	of	IN	_	17	case	_	_
17	class	class	NN	_	15	ppmod	_	_
18	(	-lrb-	-LRB-	_	20	p	_	_
19	e.g.	e.g.	FW	_	20	ppmod	_	_
20	drug4	drug0	NNS	_	17	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	,	,	,	_	17	p	_	_
23	drug5	drug0	NN	_	24	com	_	_
24	drug6	drug0	NN	_	17	appo	_	_
25	(	-lrb-	-LRB-	_	27	p	_	_
26	e.g.	e.g.	FW	_	27	ppmod	_	_
27	drug7	drug0	NN	_	24	prn	_	_
28	)	-rrb-	-RRB-	_	27	p	_	_
29	,	,	,	_	17	p	_	_
30	drug8	drug0	NN	_	17	appo	_	_
31	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	23	dep	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	(	-lrb-	-LRB-	_	7	p	_	_
5	e.g.	e.g.	FW	_	7	ppmod	_	_
6	,	,	,	_	7	p	_	_
7	drug3	drug0	NN	_	3	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	,	,	,	_	3	p	_	_
10	drug4	drug0	NN	_	1	conj	_	_
11	and	and	CC	_	10	cc	_	_
12	drug5	drug0	NN	_	10	conj	_	_
13	,	,	,	_	10	p	_	_
14	drug6	drug0	NN	_	1	conj	_	_
15	,	,	,	_	14	p	_	_
16	drug7	drug0	NN	_	1	conj	_	_
17	,	,	,	_	16	p	_	_
18	and	and	CC	_	16	cc	_	_
19	other	other	JJ	_	20	attr	_	_
20	drugs	drug	NNS	_	1	conj	_	_
21	having	have	VBG	_	23	lv	_	_
22	anticholinergic	anticholinergic	JJ	_	23	attr	_	_
23	activity	activity	NN	_	0	root	_	_
24	.	.	.	_	23	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	antagonize	antagonize	VBP	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	effects	effect	NNS	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	10	dep	_	_
2	in	in	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	presence	presence	NN	_	1	ppmod	_	_
5	of	of	IN	_	8	case	_	_
6	increased	increase	VBN	_	8	attr	_	_
7	intraocular	intraocular	JJ	_	8	attr	_	_
8	pressure	pressure	NN	_	4	ppmod	_	_
9	may	may	MD	_	10	modal	_	_
10	be	be	VB	_	0	root	_	_
11	hazardous	hazardous	JJ	_	10	dep	_	_
12	when	when	WRB	_	13	adv	_	_
13	taken	take	VBN	_	10	comp	_	_
14	concurrently	concurrently	RB	_	13	adv	_	_
15	with	with	IN	_	16	case	_	_
16	agents	agent	NNS	_	13	ppmod	_	_
17	such	such	JJ	_	20	adv	_	_
18	as	as	IN	_	20	case	_	_
19	corti	corti	NN	_	20	com	_	_
20	costeroids	costeroids	NNS	_	16	ppmod	_	_
21	.	.	.	_	10	p	_	_
22	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	affect	affect	VB	_	0	root	_	_
4	gastrointestinal	gastrointestinal	JJ	_	5	attr	_	_
5	absorption	absorption	NN	_	3	obj	_	_
6	of	of	IN	_	8	case	_	_
7	various	various	JJ	_	8	attr	_	_
8	drugs	drug	NNS	_	5	ppmod	_	_
9	,	,	,	_	8	p	_	_
10	such	such	JJ	_	15	adv	_	_
11	as	as	IN	_	15	case	_	_
12	slowly	slowly	RB	_	13	adv	_	_
13	dissolving	dissolve	VBG	_	15	attr	_	_
14	dosage	dosage	NN	_	15	com	_	_
15	forms	form	NNS	_	8	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	;	;	:	_	3	p	_	_

1	increased	increase	VBN	_	4	attr	_	_
2	serum	serum	NN	_	4	com	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	concentrations	concentration	NNS	_	6	dep	_	_
5	may	may	MD	_	6	modal	_	_
6	result	result	VB	_	0	root	_	_
7	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	antagonize	antagonize	VB	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	effects	effect	NNS	_	3	obj	_	_
6	of	of	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	drugs	drug	NNS	_	5	ppmod	_	_
9	that	that	WDT	_	10	dep	_	_
10	alter	alter	VBP	_	8	relcl	_	_
11	gastrointestinal	gastrointestinal	JJ	_	12	attr	_	_
12	motility	motility	NN	_	10	obj	_	_
13	,	,	,	_	8	p	_	_
14	such	such	JJ	_	16	adv	_	_
15	as	as	IN	_	16	case	_	_
16	drug2	drug0	NN	_	8	ppmod	_	_
17	.	.	.	_	3	p	_	_

1	Because	because	IN	_	4	mark	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	interfere	interfere	VB	_	18	advcl	_	_
5	with	with	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	absorption	absorption	NN	_	4	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	18	p	_	_
11	simultaneous	simultaneous	JJ	_	12	attr	_	_
12	use	use	NN	_	18	dep	_	_
13	of	of	IN	_	15	case	_	_
14	these	these	DT	_	15	det	_	_
15	drugs	drug	NNS	_	12	ppmod	_	_
16	should	should	MD	_	18	modal	_	_
17	be	be	VB	_	18	aux	_	_
18	avoided	avoid	VBN	_	0	root	_	_
19	.	.	.	_	18	p	_	_

1	The	the	DT	_	3	det	_	_
2	inhibiting	inhibiting	NN	_	3	com	_	_
3	effects	effect	NNS	_	12	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	on	on	IN	_	10	case	_	_
7	gastric	gastric	JJ	_	10	attr	_	_
8	hydrochloric	hydrochloric	JJ	_	10	attr	_	_
9	acid	acid	NN	_	10	com	_	_
10	secretion	secretion	NN	_	3	ppmod	_	_
11	are	be	VBP	_	12	aux	_	_
12	antagonized	antagonize	VBN	_	0	root	_	_
13	by	by	IN	_	14	case	_	_
14	agents	agent	NNS	_	12	ppmod	_	_
15	used	use	VBN	_	14	acl	_	_
16	to	to	TO	_	17	aux	_	_
17	treat	treat	VB	_	15	comp	_	_
18	achlorhydria	achlorhydria	NN	_	17	obj	_	_
19	and	and	CC	_	14	cc	_	_
20	those	those	DT	_	14	conj	_	_
21	used	use	VBN	_	20	acl	_	_
22	to	to	TO	_	23	aux	_	_
23	test	test	VB	_	21	comp	_	_
24	gastric	gastric	JJ	_	25	attr	_	_
25	secretion	secretion	NN	_	23	obj	_	_
26	.	.	.	_	12	p	_	_

1	No	no	DT	_	3	det	_	_
2	dose	dose	NN	_	3	com	_	_
3	adjustment	adjustment	NN	_	4	dep	_	_
4	is	be	VBZ	_	0	root	_	_
5	necessary	necessary	JJ	_	4	dep	_	_
6	when	when	WRB	_	9	adv	_	_
7	drug1	drug0	NN	_	9	dep	_	_
8	is	be	VBZ	_	9	aux	_	_
9	added	add	VBN	_	4	comp	_	_
10	to	to	TO	_	12	aux	_	_
11	triple-immunosuppression	triple-immunosuppression	JJ	_	12	attr	_	_
12	regimens	regimen	NNS	_	9	ppmod	_	_
13	including	include	VBG	_	14	adv	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	,	,	,	_	14	p	_	_
16	drug3	drug0	NN	_	14	conj	_	_
17	,	,	,	_	16	p	_	_
18	and	and	CC	_	16	cc	_	_
19	either	either	CC	_	20	cc	_	_
20	drug4	drug0	NN	_	14	conj	_	_
21	or	or	CC	_	20	cc	_	_
22	drug5	drug0	NN	_	20	conj	_	_
23	.	.	.	_	4	p	_	_

1	Three	#crd#	CD	_	3	num	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	trials	trial	NNS	_	5	dep	_	_
4	have	have	VBP	_	5	aux	_	_
5	investigated	investigate	VBN	_	0	root	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	use	use	NN	_	5	obj	_	_
8	in	in	IN	_	9	case	_	_
9	combination	combination	NN	_	5	ppmod	_	_
10	with	with	IN	_	12	case	_	_
11	triple-therapy	triple-therapy	JJ	_	12	attr	_	_
12	regimens	regimen	NNS	_	9	ppmod	_	_
13	.	.	.	_	5	p	_	_

1	Pharmacokinetics	pharmacokinetics	NNS	_	3	dep	_	_
2	were	be	VBD	_	3	aux	_	_
3	assessed	assess	VBN	_	0	root	_	_
4	in	in	IN	_	5	case	_	_
5	two	#crd#	CD	_	3	ppmod	_	_
6	of	of	IN	_	8	case	_	_
7	these	these	DT	_	8	det	_	_
8	trials	trial	NNS	_	5	ppmod	_	_
9	.	.	.	_	3	p	_	_

1	Total	total	JJ	_	3	attr	_	_
2	body	body	NN	_	3	com	_	_
3	clearance	clearance	NN	_	7	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	was	be	VBD	_	7	aux	_	_
7	reduced	reduce	VBN	_	0	root	_	_
8	by	by	IN	_	11	case	_	_
9	an	an	DT	_	11	det	_	_
10	average	average	JJ	_	11	attr	_	_
11	22	0	CD	_	7	ppmod	_	_
12	%	%	NN	_	11	meta	_	_
13	and	and	CC	_	11	cc	_	_
14	51	0	CD	_	11	conj	_	_
15	%	%	NN	_	14	meta	_	_
16	when	when	WRB	_	24	adv	_	_
17	drug2	drug0	NN	_	24	dep	_	_
18	and	and	CC	_	17	cc	_	_
19	drug3	drug0	NN	_	17	conj	_	_
20	,	,	,	_	24	p	_	_
21	respectively	respectively	RB	_	24	adv	_	_
22	,	,	,	_	24	p	_	_
23	were	be	VBD	_	24	aux	_	_
24	added	add	VBN	_	7	comp	_	_
25	to	to	TO	_	27	aux	_	_
26	a	a	DT	_	27	det	_	_
27	regimen	regimen	NN	_	24	ppmod	_	_
28	consisting	consist	VBG	_	27	acl	_	_
29	of	of	IN	_	30	case	_	_
30	drug4	drug0	NN	_	28	ppmod	_	_
31	,	,	,	_	30	p	_	_
32	USP	usp	NN	_	30	conj	_	_
33	(	-lrb-	-LRB-	_	34	p	_	_
34	MODIFIED	modified	JJ	_	32	prn	_	_
35	)	-rrb-	-RRB-	_	34	p	_	_
36	and	and	CC	_	32	cc	_	_
37	drug5	drug0	NN	_	30	conj	_	_
38	.	.	.	_	7	p	_	_

1	Nonetheless	nonetheless	RB	_	27	adv	_	_
2	,	,	,	_	27	p	_	_
3	the	the	DT	_	4	det	_	_
4	range	range	NN	_	27	dep	_	_
5	of	of	IN	_	9	case	_	_
6	individual	individual	JJ	_	9	attr	_	_
7	drug1	drug0	NN	_	9	com	_	_
8	clearance	clearance	NN	_	9	com	_	_
9	values	value	NNS	_	4	ppmod	_	_
10	in	in	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	presence	presence	NN	_	9	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	(	-lrb-	-LRB-	_	17	p	_	_
16	12-57	0	CD	_	17	num	_	_
17	mL/h	ml/h	NN	_	14	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	or	or	CC	_	14	cc	_	_
20	drug3	drug0	NN	_	14	conj	_	_
21	(	-lrb-	-LRB-	_	23	p	_	_
22	7-54	0	CD	_	23	num	_	_
23	mL/h	ml/h	NN	_	20	prn	_	_
24	)	-rrb-	-RRB-	_	23	p	_	_
25	did	do	VBD	_	27	aux	_	_
26	not	not	RB	_	27	neg	_	_
27	extend	extend	VB	_	0	root	_	_
28	outside	outside	IN	_	30	case	_	_
29	the	the	DT	_	30	det	_	_
30	range	range	NN	_	27	ppmod	_	_
31	observed	observe	VBN	_	30	acl	_	_
32	with	with	IN	_	34	case	_	_
33	dual	dual	JJ	_	34	attr	_	_
34	therapy	therapy	NN	_	31	ppmod	_	_
35	(	-lrb-	-LRB-	_	37	p	_	_
36	10-78	0	CD	_	37	num	_	_
37	mL/h	ml/h	NN	_	34	prn	_	_
38	)	-rrb-	-RRB-	_	37	p	_	_
39	.	.	.	_	27	p	_	_

1	The	the	DT	_	3	det	_	_
2	following	following	JJ	_	3	attr	_	_
3	medications	medication	NNS	_	6	dep	_	_
4	have	have	VBP	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	administered	administer	VBN	_	0	root	_	_
7	in	in	IN	_	9	case	_	_
8	clinical	clinical	JJ	_	9	attr	_	_
9	trials	trial	NNS	_	6	ppmod	_	_
10	with	with	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	with	with	IN	_	14	case	_	_
13	no	no	DT	_	14	det	_	_
14	increase	increase	NN	_	9	ppmod	_	_
15	in	in	IN	_	17	case	_	_
16	adverse	adverse	JJ	_	17	attr	_	_
17	reactions	reaction	NNS	_	14	ppmod	_	_
18	:	:	:	_	9	p	_	_
19	ATG/ALG	atg/alg	NN	_	9	appo	_	_
20	,	,	,	_	19	p	_	_
21	drug2	drug0	NN	_	19	conj	_	_
22	,	,	,	_	21	p	_	_
23	drug3	drug0	NN	_	19	conj	_	_
24	,	,	,	_	23	p	_	_
25	drug4	drug0	NN	_	19	conj	_	_
26	,	,	,	_	25	p	_	_
27	drug5	drug0	NN	_	19	conj	_	_
28	,	,	,	_	27	p	_	_
29	and	and	CC	_	27	cc	_	_
30	drug6	drug0	NN	_	19	conj	_	_
31	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	6	attr	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	drug2	drug0	NN	_	1	prn	_	_
4	)	-rrb-	-RRB-	_	3	p	_	_
5	blood	blood	NN	_	6	com	_	_
6	levels	level	NNS	_	9	dep	_	_
7	may	may	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	increased	increase	VBN	_	0	root	_	_
10	and	and	CC	_	9	cc	_	_
11	prolonged	prolong	VBD	_	9	conj	_	_
12	by	by	IN	_	14	case	_	_
13	concurrent	concurrent	JJ	_	14	attr	_	_
14	administration	administration	NN	_	11	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug3	drug0	NN	_	14	ppmod	_	_
17	.	.	.	_	9	p	_	_

1	Drug	drug	NN	_	2	com	_	_
2	Interactions	interaction	NNS	_	0	root	_	_
3	with	with	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	:	:	:	_	2	p	_	_
6	Concomitant	concomitant	JJ	_	7	attr	_	_
7	use	use	NN	_	14	dep	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	with	with	IN	_	11	case	_	_
11	drug3	drug0	NN	_	7	ppmod	_	_
12	should	should	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	avoided	avoid	VBN	_	2	acl	_	_
15	.	.	.	_	2	p	_	_

1	If	if	IN	_	5	mark	_	_
2	the	the	DT	_	3	det	_	_
3	drugs	drug	NNS	_	5	dep	_	_
4	are	be	VBP	_	5	aux	_	_
5	used	use	VBN	_	11	advcl	_	_
6	together	together	RB	_	5	adv	_	_
7	,	,	,	_	11	p	_	_
8	caution	caution	NN	_	11	dep	_	_
9	should	should	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	exercised	exercise	VBN	_	0	root	_	_
12	because	because	IN	_	16	mark	_	_
13	unexpected	unexpected	JJ	_	14	attr	_	_
14	hypotension	hypotension	NN	_	16	dep	_	_
15	could	could	MD	_	16	modal	_	_
16	result	result	VB	_	11	comp	_	_
17	from	from	IN	_	19	case	_	_
18	beta-blocker	beta-blocker	NN	_	19	com	_	_
19	inhibition	inhibition	NN	_	16	ppmod	_	_
20	of	of	IN	_	24	case	_	_
21	the	the	DT	_	24	det	_	_
22	sympathetic	sympathetic	JJ	_	24	attr	_	_
23	reflex	reflex	NN	_	24	com	_	_
24	response	response	NN	_	19	ppmod	_	_
25	to	to	TO	_	26	aux	_	_
26	drug1	drug0	NN	_	24	ppmod	_	_
27	.	.	.	_	11	p	_	_

1	Drug	drug	NN	_	2	com	_	_
2	Interactions	interaction	NNS	_	0	root	_	_
3	,	,	,	_	2	p	_	_
4	General	general	JJ	_	2	appo	_	_
5	:	:	:	_	2	p	_	_
6	Although	although	IN	_	9	mark	_	_
7	there	there	EX	_	9	dep	_	_
8	have	have	VBP	_	9	aux	_	_
9	been	be	VBN	_	19	advcl	_	_
10	no	no	DT	_	13	det	_	_
11	formal	formal	JJ	_	13	attr	_	_
12	interaction	interaction	NN	_	13	com	_	_
13	studies	study	NNS	_	9	obj	_	_
14	,	,	,	_	19	p	_	_
15	intravenous	intravenous	JJ	_	16	attr	_	_
16	drug1	drug0	NN	_	19	dep	_	_
17	has	have	VBZ	_	19	aux	_	_
18	been	be	VBN	_	19	aux	_	_
19	administered	administer	VBN	_	2	acl	_	_
20	safely	safely	RB	_	19	adv	_	_
21	with	with	IN	_	22	case	_	_
22	drugs	drug	NNS	_	19	ppmod	_	_
23	such	such	JJ	_	25	adv	_	_
24	as	as	IN	_	25	case	_	_
25	drug2	drug0	NN	_	22	ppmod	_	_
26	and	and	CC	_	25	cc	_	_
27	sublingual	sublingual	NN	_	28	com	_	_
28	drug3	drug0	NN	_	25	conj	_	_
29	.	.	.	_	2	p	_	_

1	There	there	EX	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	limited	limit	VBN	_	0	root	_	_
4	experience	experience	VBP	_	7	adv	_	_
5	with	with	IN	_	7	case	_	_
6	concomitant	concomitant	JJ	_	7	attr	_	_
7	drug1	drug0	NN	_	3	ppmod	_	_
8	such	such	JJ	_	10	adv	_	_
9	as	as	IN	_	10	case	_	_
10	drug2	drug0	NN	_	7	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	drug3	drug0	NN	_	10	conj	_	_
13	,	,	,	_	12	p	_	_
14	drug4	drug0	NN	_	10	conj	_	_
15	,	,	,	_	14	p	_	_
16	and	and	CC	_	14	cc	_	_
17	drug5	drug0	NN	_	10	conj	_	_
18	(	-lrb-	-LRB-	_	20	p	_	_
19	both	both	CC	_	20	cc	_	_
20	drug6	drug0	NN	_	10	prn	_	_
21	-like	-like	JJ	_	20	attr	_	_
22	and	and	CC	_	20	cc	_	_
23	loop	loop	NN	_	20	conj	_	_
24	)	-rrb-	-RRB-	_	20	p	_	_
25	.	.	.	_	3	p	_	_

1	No	no	DT	_	4	det	_	_
2	significant	significant	JJ	_	4	attr	_	_
3	drug	drug	NN	_	4	com	_	_
4	interactions	interaction	NNS	_	7	dep	_	_
5	have	have	VBP	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	reported	report	VBN	_	0	root	_	_
8	in	in	IN	_	9	case	_	_
9	studies	study	NNS	_	7	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	given	give	VBN	_	11	acl	_	_
13	with	with	IN	_	15	case	_	_
14	other	other	JJ	_	15	attr	_	_
15	drugs	drug	NNS	_	12	ppmod	_	_
16	such	such	JJ	_	18	adv	_	_
17	as	as	IN	_	18	case	_	_
18	drug2	drug0	NN	_	15	ppmod	_	_
19	,	,	,	_	18	p	_	_
20	drug3	drug0	NN	_	18	conj	_	_
21	,	,	,	_	20	p	_	_
22	drug4	drug0	NN	_	18	conj	_	_
23	,	,	,	_	22	p	_	_
24	drug5	drug0	NN	_	18	conj	_	_
25	,	,	,	_	24	p	_	_
26	drug6	drug0	NN	_	18	conj	_	_
27	,	,	,	_	26	p	_	_
28	and	and	CC	_	26	cc	_	_
29	oral	oral	JJ	_	30	attr	_	_
30	drug7	drug0	NN	_	18	conj	_	_
31	in	in	IN	_	33	case	_	_
32	healthy	healthy	JJ	_	33	attr	_	_
33	volunteers	volunteer	NNS	_	18	ppmod	_	_
34	,	,	,	_	12	p	_	_
35	or	or	CC	_	12	cc	_	_
36	given	give	VBN	_	12	conj	_	_
37	with	with	IN	_	38	case	_	_
38	drug8	drug0	NN	_	36	ppmod	_	_
39	to	to	TO	_	40	aux	_	_
40	patients	patient	NNS	_	36	ppmod	_	_
41	with	with	IN	_	43	case	_	_
42	heart	heart	NN	_	43	com	_	_
43	failure	failure	NN	_	40	ppmod	_	_
44	(	-lrb-	-LRB-	_	46	p	_	_
45	NYHA	nyha	NN	_	46	com	_	_
46	class	class	NN	_	43	prn	_	_
47	II	ii	CD	_	46	num	_	_
48	and	and	CC	_	46	cc	_	_
49	III	iii	CD	_	46	conj	_	_
50	)	-rrb-	-RRB-	_	46	p	_	_
51	.	.	.	_	7	p	_	_

1	Because	because	IN	_	6	mark	_	_
2	drug1	drug0	NN	_	6	dep	_	_
3	is	be	VBZ	_	6	aux	_	_
4	not	not	RB	_	6	neg	_	_
5	significantly	significantly	RB	_	6	adv	_	_
6	metabolized	metabolize	VBN	_	37	advcl	_	_
7	by	by	IN	_	11	case	_	_
8	the	the	DT	_	11	det	_	_
9	cytochrome	cytochrome	NN	_	11	com	_	_
10	P450	p0	NN	_	11	com	_	_
11	system	system	NN	_	6	ppmod	_	_
12	and	and	CC	_	6	cc	_	_
13	at	at	IN	_	15	case	_	_
14	therapeutic	therapeutic	JJ	_	15	attr	_	_
15	concentrations	concentration	NNS	_	16	ppmod	_	_
16	has	have	VBZ	_	6	conj	_	_
17	no	no	DT	_	18	det	_	_
18	effects	effect	NNS	_	16	obj	_	_
19	on	on	IN	_	21	case	_	_
20	P450	p0	NN	_	21	com	_	_
21	enzymes	enzyme	NNS	_	18	ppmod	_	_
22	,	,	,	_	37	p	_	_
23	interactions	interaction	NNS	_	37	dep	_	_
24	with	with	IN	_	25	case	_	_
25	drugs	drug	NNS	_	23	ppmod	_	_
26	that	that	WDT	_	27	dep	_	_
27	inhibit	inhibit	VBP	_	25	relcl	_	_
28	or	or	CC	_	27	cc	_	_
29	are	be	VBP	_	30	aux	_	_
30	metabolized	metabolize	VBN	_	27	conj	_	_
31	by	by	IN	_	33	case	_	_
32	those	those	DT	_	33	det	_	_
33	enzymes	enzyme	NNS	_	30	ppmod	_	_
34	would	would	MD	_	37	modal	_	_
35	not	not	RB	_	37	neg	_	_
36	be	be	VB	_	37	aux	_	_
37	expected	expect	VBN	_	0	root	_	_
38	.	.	.	_	37	p	_	_

1	drug1	drug0	NN	_	3	attr	_	_
2	Reversible	reversible	JJ	_	3	attr	_	_
3	increases	increase	NNS	_	12	dep	_	_
4	in	in	IN	_	7	case	_	_
5	serum	serum	NN	_	7	com	_	_
6	drug2	drug0	NN	_	7	com	_	_
7	concentrations	concentration	NNS	_	3	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	toxicity	toxicity	NN	_	7	conj	_	_
10	have	have	VBP	_	12	aux	_	_
11	been	be	VBN	_	12	aux	_	_
12	reported	report	VBN	_	0	root	_	_
13	during	during	IN	_	15	case	_	_
14	concomitant	concomitant	JJ	_	15	attr	_	_
15	administration	administration	NN	_	12	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	drug3	drug0	NN	_	15	ppmod	_	_
18	with	with	IN	_	19	case	_	_
19	drug4	drug0	NN	_	17	ppmod	_	_
20	,	,	,	_	19	p	_	_
21	and	and	CC	_	19	cc	_	_
22	with	with	IN	_	24	case	_	_
23	some	some	DT	_	24	det	_	_
24	drug5	drug0	NN	_	19	conj	_	_
25	.	.	.	_	12	p	_	_

1	An	an	DT	_	2	det	_	_
2	increase	increase	NN	_	9	dep	_	_
3	in	in	IN	_	6	case	_	_
4	serum	serum	NN	_	6	com	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	concentration	concentration	NN	_	2	ppmod	_	_
7	has	have	VBZ	_	9	aux	_	_
8	been	be	VBN	_	9	aux	_	_
9	reported	report	VBN	_	0	root	_	_
10	during	during	IN	_	12	case	_	_
11	concomitant	concomitant	JJ	_	12	attr	_	_
12	administration	administration	NN	_	9	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	with	with	IN	_	16	case	_	_
16	drug3	drug0	NN	_	12	ppmod	_	_
17	,	,	,	_	9	p	_	_
18	so	so	IN	_	26	mark	_	_
19	careful	careful	JJ	_	20	attr	_	_
20	monitoring	monitoring	NN	_	26	dep	_	_
21	of	of	IN	_	24	case	_	_
22	serum	serum	NN	_	24	com	_	_
23	drug4	drug0	NN	_	24	com	_	_
24	levels	level	NNS	_	20	ppmod	_	_
25	is	be	VBZ	_	26	aux	_	_
26	recommended	recommend	VBN	_	9	comp	_	_
27	during	during	IN	_	29	case	_	_
28	concomitant	concomitant	JJ	_	29	attr	_	_
29	use	use	NN	_	26	ppmod	_	_
30	.	.	.	_	9	p	_	_

1	Potential	potential	NN	_	6	dep	_	_
2	for	for	IN	_	4	case	_	_
3	Other	other	JJ	_	4	attr	_	_
4	Drugs	drug	NNS	_	1	ppmod	_	_
5	to	to	TO	_	6	aux	_	_
6	Affect	affect	VB	_	13	advcl	_	_
7	drug1	drug0	NN	_	6	obj	_	_
8	:	:	:	_	13	p	_	_
9	Both	both	CC	_	10	cc	_	_
10	CYP1A2	cyp0a0	NN	_	13	dep	_	_
11	and	and	CC	_	10	cc	_	_
12	CYP2D6	cyp0d0	NN	_	10	conj	_	_
13	are	be	VBP	_	0	root	_	_
14	responsible	responsible	JJ	_	13	dep	_	_
15	for	for	IN	_	17	case	_	_
16	drug2	drug0	NN	_	17	com	_	_
17	metabolism	metabolism	NN	_	14	ppmod	_	_
18	.	.	.	_	13	p	_	_

1	Inhibitors	inhibitor	NNS	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	CYP1A2	cyp0a0	NN	_	1	ppmod	_	_
4	:	:	:	_	1	p	_	_
5	Concomitant	concomitant	JJ	_	6	attr	_	_
6	use	use	NN	_	17	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	with	with	IN	_	10	case	_	_
10	drug2	drug0	NN	_	6	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	an	an	DT	_	13	det	_	_
13	inhibitor	inhibitor	NN	_	10	appo	_	_
14	of	of	IN	_	15	case	_	_
15	CYP1A2	cyp0a0	NN	_	13	ppmod	_	_
16	,	,	,	_	10	p	_	_
17	results	result	VBZ	_	1	acl	_	_
18	in	in	IN	_	22	case	_	_
19	approximately	approximately	RB	_	22	adv	_	_
20	a	a	DT	_	22	det	_	_
21	6-fold	0-fold	RB	_	22	adv	_	_
22	increase	increase	NN	_	17	ppmod	_	_
23	in	in	IN	_	24	case	_	_
24	AUC	auc	NN	_	22	ppmod	_	_
25	and	and	CC	_	22	cc	_	_
26	about	about	RB	_	29	adv	_	_
27	a	a	DT	_	29	det	_	_
28	2.5-fold	0-fold	JJ	_	29	attr	_	_
29	increase	increase	NN	_	22	conj	_	_
30	in	in	IN	_	31	case	_	_
31	Cmax	cmax	NN	_	29	ppmod	_	_
32	of	of	IN	_	33	case	_	_
33	drug3	drug0	NN	_	31	ppmod	_	_
34	.	.	.	_	1	p	_	_

1	Some	some	DT	_	2	det	_	_
2	drug1	drug0	NN	_	5	dep	_	_
3	would	would	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	expected	expect	VBN	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	have	have	VB	_	5	comp	_	_
8	similar	similar	JJ	_	9	attr	_	_
9	effects	effect	NNS	_	7	obj	_	_
10	and	and	CC	_	5	cc	_	_
11	these	these	DT	_	12	det	_	_
12	combinations	combination	NNS	_	15	dep	_	_
13	should	should	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	avoided	avoid	VBN	_	5	conj	_	_
16	.	.	.	_	5	p	_	_

1	Inhibitors	inhibitor	NNS	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	CYP2D6	cyp0d0	NN	_	1	ppmod	_	_
4	:	:	:	_	1	p	_	_
5	Because	because	IN	_	8	mark	_	_
6	CYP2D6	cyp0d0	NN	_	8	dep	_	_
7	is	be	VBZ	_	8	aux	_	_
8	involved	involve	VBN	_	23	advcl	_	_
9	in	in	IN	_	11	case	_	_
10	drug1	drug0	NN	_	11	com	_	_
11	metabolism	metabolism	NN	_	8	ppmod	_	_
12	,	,	,	_	23	p	_	_
13	concomitant	concomitant	JJ	_	14	attr	_	_
14	use	use	NN	_	23	dep	_	_
15	of	of	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	with	with	IN	_	19	case	_	_
18	potent	potent	JJ	_	19	attr	_	_
19	inhibitors	inhibitor	NNS	_	14	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	CYP2D6	cyp0d0	NN	_	19	ppmod	_	_
22	may	may	MD	_	23	modal	_	_
23	result	result	VB	_	1	acl	_	_
24	in	in	IN	_	26	case	_	_
25	higher	high	JJR	_	26	attr	_	_
26	concentrations	concentration	NNS	_	23	ppmod	_	_
27	of	of	IN	_	28	case	_	_
28	drug3	drug0	NN	_	26	ppmod	_	_
29	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	7	dep	_	_
2	(	-lrb-	-LRB-	_	5	p	_	_
3	20	0	CD	_	4	num	_	_
4	mg	mg	NN	_	5	com	_	_
5	QD	qd	NN	_	1	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	increased	increase	VBD	_	0	root	_	_
8	the	the	DT	_	9	det	_	_
9	concentration	concentration	NN	_	7	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	(	-lrb-	-LRB-	_	15	p	_	_
13	40	0	CD	_	14	num	_	_
14	mg	mg	NN	_	15	com	_	_
15	QD	qd	NN	_	11	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	by	by	IN	_	19	case	_	_
18	about	about	RB	_	19	adv	_	_
19	60	0	CD	_	7	ppmod	_	_
20	%	%	NN	_	19	meta	_	_
21	,	,	,	_	7	p	_	_
22	and	and	CC	_	7	cc	_	_
23	greater	great	JJR	_	24	attr	_	_
24	degrees	degree	NNS	_	28	dep	_	_
25	of	of	IN	_	26	case	_	_
26	inhibition	inhibition	NN	_	24	ppmod	_	_
27	are	be	VBP	_	28	aux	_	_
28	expected	expect	VBN	_	7	conj	_	_
29	with	with	IN	_	31	case	_	_
30	higher	high	JJR	_	31	attr	_	_
31	doses	dose	NNS	_	28	ppmod	_	_
32	of	of	IN	_	33	case	_	_
33	drug3	drug0	NN	_	31	ppmod	_	_
34	.	.	.	_	7	p	_	_

1	Similar	similar	JJ	_	2	attr	_	_
2	effects	effect	NNS	_	5	dep	_	_
3	would	would	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	expected	expect	VBN	_	0	root	_	_
6	with	with	IN	_	10	case	_	_
7	other	other	JJ	_	10	attr	_	_
8	potent	potent	JJ	_	10	attr	_	_
9	CYP2D6	cyp0d0	NN	_	10	com	_	_
10	inhibitors	inhibitor	NNS	_	5	ppmod	_	_
11	(	-lrb-	-LRB-	_	16	p	_	_
12	e.g.	e.g.	FW	_	14	adv	_	_
13	,	,	,	_	14	p	_	_
14	drug1	drug0	NN	_	16	ppmod	_	_
15	,	,	,	_	16	p	_	_
16	drug2	drug0	NNS	_	10	prn	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	.	.	.	_	5	p	_	_

1	Potential	potential	NN	_	5	dep	_	_
2	for	for	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	to	to	TO	_	5	aux	_	_
5	Affect	affect	VB	_	19	advcl	_	_
6	Other	other	JJ	_	7	attr	_	_
7	Drugs	drug	NNS	_	5	obj	_	_
8	:	:	:	_	19	p	_	_
9	Drugs	drug	NNS	_	10	dep	_	_
10	Metabolized	metabolize	VBN	_	19	advcl	_	_
11	by	by	IN	_	12	case	_	_
12	CYP1A2	cyp0a0	NN	_	10	ppmod	_	_
13	:	:	:	_	19	p	_	_
14	In	in	FW	_	15	adv	_	_
15	vitro	vitro	FW	_	18	attr	_	_
16	drug	drug	NN	_	18	com	_	_
17	interaction	interaction	NN	_	18	com	_	_
18	studies	study	NNS	_	19	dep	_	_
19	demonstrate	demonstrate	VBP	_	0	root	_	_
20	that	that	IN	_	24	mark	_	_
21	drug2	drug0	NN	_	24	dep	_	_
22	does	do	VBZ	_	24	aux	_	_
23	not	not	RB	_	24	neg	_	_
24	induce	induce	VB	_	19	comp	_	_
25	CYP1A2	cyp0a0	NN	_	26	com	_	_
26	activity	activity	NN	_	24	obj	_	_
27	,	,	,	_	24	p	_	_
28	and	and	CC	_	24	cc	_	_
29	it	it	PRP	_	30	dep	_	_
30	is	be	VBZ	_	24	conj	_	_
31	unlikely	unlikely	JJ	_	30	dep	_	_
32	to	to	TO	_	33	aux	_	_
33	have	have	VB	_	31	comp	_	_
34	a	a	DT	_	37	det	_	_
35	clinically	clinically	RB	_	36	adv	_	_
36	significant	significant	JJ	_	37	attr	_	_
37	effect	effect	NN	_	33	obj	_	_
38	on	on	IN	_	40	case	_	_
39	the	the	DT	_	40	det	_	_
40	metabolism	metabolism	NN	_	37	ppmod	_	_
41	of	of	IN	_	43	case	_	_
42	CYP1A2	cyp0a0	NN	_	43	com	_	_
43	substrates	substrate	NNS	_	40	ppmod	_	_
44	.	.	.	_	19	p	_	_

1	Drugs	drug	NNS	_	2	dep	_	_
2	Metabolized	metabolize	VBN	_	7	advcl	_	_
3	by	by	IN	_	4	case	_	_
4	CYP2D6	cyp0d0	NN	_	2	ppmod	_	_
5	:	:	:	_	7	p	_	_
6	drug1	drug0	NN	_	7	dep	_	_
7	is	be	VBZ	_	0	root	_	_
8	a	a	DT	_	10	det	_	_
9	moderate	moderate	JJ	_	10	attr	_	_
10	inhibitor	inhibitor	NN	_	7	obj	_	_
11	of	of	IN	_	12	case	_	_
12	CYP2D6	cyp0d0	NN	_	10	ppmod	_	_
13	.	.	.	_	7	p	_	_

1	When	when	WRB	_	4	adv	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	was	be	VBD	_	4	aux	_	_
4	administered	administer	VBN	_	32	advcl	_	_
5	(	-lrb-	-LRB-	_	8	p	_	_
6	at	at	IN	_	8	case	_	_
7	a	a	DT	_	8	det	_	_
8	dose	dose	NN	_	4	prn	_	_
9	of	of	IN	_	12	case	_	_
10	60	0	CD	_	11	num	_	_
11	mg	mg	NN	_	12	com	_	_
12	BID	bid	NN	_	8	ppmod	_	_
13	)	-rrb-	-RRB-	_	8	p	_	_
14	in	in	IN	_	15	case	_	_
15	conjunction	conjunction	NN	_	4	ppmod	_	_
16	with	with	IN	_	20	case	_	_
17	a	a	DT	_	20	det	_	_
18	single	single	JJ	_	20	attr	_	_
19	50-mg	0-mg	JJ	_	20	attr	_	_
20	dose	dose	NN	_	15	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	drug2	drug0	NN	_	20	ppmod	_	_
23	,	,	,	_	22	p	_	_
24	a	a	DT	_	26	det	_	_
25	CYP2D6	cyp0d0	NN	_	26	com	_	_
26	substrate	substrate	NN	_	22	appo	_	_
27	,	,	,	_	32	p	_	_
28	the	the	DT	_	29	det	_	_
29	AUC	auc	NN	_	32	dep	_	_
30	of	of	IN	_	31	case	_	_
31	drug3	drug0	NN	_	29	ppmod	_	_
32	increased	increase	VBD	_	0	root	_	_
33	3-fold	0-fold	RB	_	32	adv	_	_
34	.	.	.	_	32	p	_	_

1	Therefore	therefore	RB	_	56	adv	_	_
2	,	,	,	_	56	p	_	_
3	co-administration	co-administration	NN	_	56	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	with	with	IN	_	8	case	_	_
7	other	other	JJ	_	8	attr	_	_
8	drugs	drug	NNS	_	3	ppmod	_	_
9	that	that	WDT	_	12	dep	_	_
10	are	be	VBP	_	12	aux	_	_
11	extensively	extensively	RB	_	12	adv	_	_
12	metabolized	metabolize	VBN	_	8	advcl	_	_
13	by	by	IN	_	15	case	_	_
14	this	this	DT	_	15	det	_	_
15	isozyme	isozyme	NN	_	12	ppmod	_	_
16	and	and	CC	_	12	cc	_	_
17	which	which	WDT	_	18	dep	_	_
18	have	have	VBP	_	12	conj	_	_
19	a	a	DT	_	22	det	_	_
20	narrow	narrow	JJ	_	22	attr	_	_
21	therapeutic	therapeutic	JJ	_	22	attr	_	_
22	index	index	NN	_	18	obj	_	_
23	,	,	,	_	8	p	_	_
24	including	include	VBG	_	26	adv	_	_
25	certain	certain	JJ	_	26	attr	_	_
26	drug2	drug0	NNS	_	8	ppmod	_	_
27	(	-lrb-	-LRB-	_	28	p	_	_
28	drug3	drug0	NN	_	26	prn	_	_
29	[	-lsb-	-LRB-	_	30	p	_	_
30	drug4	drug0	NN	_	28	prn	_	_
31	]	-rsb-	-RRB-	_	30	p	_	_
32	,	,	,	_	28	p	_	_
33	such	such	JJ	_	28	dep	_	_
34	as	as	IN	_	35	case	_	_
35	drug5	drug0	NN	_	33	ppmod	_	_
36	,	,	,	_	35	p	_	_
37	drug6	drug0	NN	_	35	conj	_	_
38	,	,	,	_	37	p	_	_
39	and	and	CC	_	37	cc	_	_
40	drug7	drug0	NN	_	35	conj	_	_
41	)	-rrb-	-RRB-	_	28	p	_	_
42	,	,	,	_	26	p	_	_
43	drug8	drug0	NN	_	26	appo	_	_
44	and	and	CC	_	43	cc	_	_
45	drug9	drug0	NN	_	43	conj	_	_
46	(	-lrb-	-LRB-	_	51	p	_	_
47	e.g.	e.g.	FW	_	49	adv	_	_
48	,	,	,	_	49	p	_	_
49	drug10	drug0	NN	_	51	ppmod	_	_
50	,	,	,	_	51	p	_	_
51	drug11	drug0	NN	_	45	prn	_	_
52	)	-rrb-	-RRB-	_	51	p	_	_
53	,	,	,	_	26	p	_	_
54	should	should	MD	_	56	modal	_	_
55	be	be	VB	_	56	aux	_	_
56	approached	approach	VBN	_	0	root	_	_
57	with	with	IN	_	58	case	_	_
58	caution	caution	NN	_	56	ppmod	_	_
59	.	.	.	_	56	p	_	_

1	Plasma	plasma	NN	_	3	com	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	concentrations	concentration	NNS	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	need	need	VBP	_	0	root	_	_
6	to	to	TO	_	8	aux	_	_
7	be	be	VB	_	8	aux	_	_
8	monitored	monitor	VBN	_	5	comp	_	_
9	and	and	CC	_	5	cc	_	_
10	the	the	DT	_	11	det	_	_
11	dose	dose	NN	_	16	dep	_	_
12	of	of	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	drug2	drug0	NN	_	11	ppmod	_	_
15	may	may	MD	_	16	modal	_	_
16	need	need	VBP	_	5	conj	_	_
17	to	to	TO	_	19	aux	_	_
18	be	be	VB	_	19	aux	_	_
19	reduced	reduce	VBN	_	16	comp	_	_
20	if	if	IN	_	24	mark	_	_
21	a	a	DT	_	22	det	_	_
22	drug3	drug0	NN	_	24	dep	_	_
23	is	be	VBZ	_	24	aux	_	_
24	co-administered	co-administered	VBN	_	19	comp	_	_
25	with	with	IN	_	26	case	_	_
26	drug4	drug0	NN	_	24	ppmod	_	_
27	.	.	.	_	5	p	_	_

1	Because	because	IN	_	4	case	_	_
2	of	of	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	risk	risk	NN	_	27	ppmod	_	_
5	of	of	IN	_	8	case	_	_
6	serious	serious	JJ	_	8	attr	_	_
7	ventricular	ventricular	JJ	_	8	attr	_	_
8	arrhythmias	arrhythmia	NNS	_	4	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	sudden	sudden	NN	_	11	com	_	_
11	death	death	NN	_	8	conj	_	_
12	potentially	potentially	RB	_	13	adv	_	_
13	associated	associate	VBN	_	4	acl	_	_
14	with	with	IN	_	17	case	_	_
15	elevated	elevated	JJ	_	17	attr	_	_
16	plasma	plasma	NN	_	17	com	_	_
17	levels	level	NNS	_	13	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug1	drug0	NN	_	17	ppmod	_	_
20	,	,	,	_	27	p	_	_
21	drug2	drug0	NN	_	27	dep	_	_
22	and	and	CC	_	21	cc	_	_
23	drug3	drug0	NN	_	21	conj	_	_
24	should	should	MD	_	27	modal	_	_
25	not	not	RB	_	27	neg	_	_
26	be	be	VB	_	27	aux	_	_
27	co-administered	co-administered	VBN	_	0	root	_	_
28	.	.	.	_	27	p	_	_

1	Drugs	drug	NNS	_	2	dep	_	_
2	Metabolized	metabolize	VBN	_	11	advcl	_	_
3	by	by	IN	_	4	case	_	_
4	CYP3A	cyp0a	NN	_	2	ppmod	_	_
5	:	:	:	_	11	p	_	_
6	Results	result	NNS	_	11	dep	_	_
7	of	of	IN	_	10	case	_	_
8	in	in	FW	_	9	adv	_	_
9	vitro	vitro	FW	_	10	attr	_	_
10	studies	study	NNS	_	6	ppmod	_	_
11	demonstrate	demonstrate	VBP	_	0	root	_	_
12	that	that	IN	_	16	mark	_	_
13	drug1	drug0	NN	_	16	dep	_	_
14	does	do	VBZ	_	16	aux	_	_
15	not	not	RB	_	16	neg	18:neg	_
16	inhibit	inhibit	VB	_	11	comp	_	_
17	or	or	CC	_	16	cc	_	_
18	induce	induce	VB	_	16	conj	_	_
19	CYP3A	cyp0a	NN	_	20	com	_	_
20	activity	activity	NN	_	18	obj	_	_
21	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	7	dep	_	_
2	May	may	MD	_	7	modal	_	_
3	Have	have	VB	_	7	lv	_	_
4	a	a	DT	_	7	det	_	_
5	Clinically	clinically	RB	_	6	adv	_	_
6	Important	important	JJ	_	7	attr	_	_
7	Interaction	interaction	NN	_	0	root	_	_
8	with	with	IN	_	12	case	_	_
9	the	the	DT	_	12	det	_	_
10	Following	following	JJ	_	12	attr	_	_
11	Other	other	JJ	_	12	attr	_	_
12	Drugs	drug	NNS	_	7	ppmod	_	_
13	:	:	:	_	12	p	_	_
14	drug2	drug0	NN	_	12	appo	_	_
15	:	:	:	_	12	p	_	_
16	When	when	WRB	_	21	adv	_	_
17	drug3	drug0	NN	_	21	dep	_	_
18	and	and	CC	_	17	cc	_	_
19	drug4	drug0	NN	_	17	conj	_	_
20	were	be	VBD	_	21	aux	_	_
21	administered	administer	VBN	_	7	comp	_	_
22	several	several	JJ	_	23	attr	_	_
23	hours	hour	NNS	_	24	advnp	_	_
24	apart	apart	RB	_	21	adv	_	_
25	so	so	RB	_	21	adv	_	_
26	that	that	IN	_	37	mark	_	_
27	peak	peak	JJ	_	28	attr	_	_
28	concentrations	concentration	NNS	_	32	dep	_	_
29	of	of	IN	_	30	case	_	_
30	each	each	DT	_	28	ppmod	_	_
31	would	would	MD	_	32	modal	_	_
32	coincide	coincide	VB	_	37	advcl	_	_
33	,	,	,	_	37	p	_	_
34	drug5	drug0	NN	_	37	dep	_	_
35	did	do	VBD	_	37	aux	_	_
36	not	not	RB	_	37	neg	_	_
37	increase	increase	VB	_	21	comp	_	_
38	the	the	DT	_	39	det	_	_
39	impairment	impairment	NN	_	37	obj	_	_
40	of	of	IN	_	44	case	_	_
41	mental	mental	JJ	_	44	attr	_	_
42	and	and	CC	_	44	cc	_	_
43	motor	motor	NN	_	44	com	_	_
44	skills	skill	NNS	_	39	ppmod	_	_
45	caused	cause	VBN	_	44	acl	_	_
46	by	by	IN	_	47	case	_	_
47	drug6	drug0	NN	_	45	ppmod	_	_
48	.	.	.	_	7	p	_	_

1	In	in	IN	_	6	case	_	_
2	the	the	DT	_	6	det	_	_
3	drug1	drug0	JJ	_	5	attr	_	_
4	clinical	clinical	JJ	_	5	attr	_	_
5	trials	trial	NNS	_	6	com	_	_
6	database	database	NN	_	14	ppmod	_	_
7	,	,	,	_	14	p	_	_
8	three	#crd#	CD	_	11	num	_	_
9	drug2	drug0	JJ	_	11	attr	_	_
10	-treated	-treated	JJ	_	11	attr	_	_
11	patients	patient	NNS	_	14	dep	_	_
12	had	have	VBD	_	14	lv	_	_
13	liver	liver	NN	_	14	com	_	_
14	injury	injury	NN	_	0	root	_	_
15	as	as	IN	_	16	mark	_	_
16	manifested	manifest	VBN	_	14	comp	_	_
17	by	by	IN	_	22	case	_	_
18	ALT	alt	NN	_	22	attr	_	_
19	and	and	CC	_	18	cc	_	_
20	total	total	JJ	_	21	attr	_	_
21	bilirubin	bilirubin	NN	_	18	conj	_	_
22	elevations	elevation	NNS	_	16	ppmod	_	_
23	,	,	,	_	16	p	_	_
24	with	with	IN	_	25	case	_	_
25	evidence	evidence	NN	_	16	ppmod	_	_
26	of	of	IN	_	27	case	_	_
27	obstruction	obstruction	NN	_	25	ppmod	_	_
28	.	.	.	_	14	p	_	_

1	Substantial	substantial	JJ	_	4	attr	_	_
2	intercurrent	intercurrent	NN	_	4	com	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	use	use	NN	_	5	dep	_	_
5	was	be	VBD	_	0	root	_	_
6	present	present	JJ	_	5	dep	_	_
7	in	in	IN	_	8	case	_	_
8	each	each	DT	_	6	ppmod	_	_
9	of	of	IN	_	11	case	_	_
10	these	these	DT	_	11	det	_	_
11	cases	case	NNS	_	8	ppmod	_	_
12	,	,	,	_	5	p	_	_
13	and	and	CC	_	5	cc	_	_
14	this	this	DT	_	17	dep	_	_
15	may	may	MD	_	17	modal	_	_
16	have	have	VB	_	17	aux	_	_
17	contributed	contribute	VBN	_	5	conj	_	_
18	to	to	TO	_	20	aux	_	_
19	the	the	DT	_	20	det	_	_
20	abnormalities	abnormality	NNS	_	17	ppmod	_	_
21	seen	see	VBN	_	20	acl	_	_
22	.	.	.	_	5	p	_	_

1	CNS	cns	NN	_	3	com	_	_
2	Acting	acting	NN	_	3	com	_	_
3	Drugs	drug	NNS	_	0	root	_	_
4	:	:	:	_	3	p	_	_
5	Given	given	IN	_	9	case	_	_
6	the	the	DT	_	9	det	_	_
7	primary	primary	JJ	_	9	attr	_	_
8	CNS	cns	NN	_	9	com	_	_
9	effects	effect	NNS	_	16	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	,	,	,	_	16	p	_	_
13	it	it	PRP	_	16	dep	_	_
14	should	should	MD	_	16	modal	_	_
15	be	be	VB	_	16	aux	_	_
16	used	use	VBN	_	3	acl	_	_
17	with	with	IN	_	18	case	_	_
18	caution	caution	NN	_	16	ppmod	_	_
19	when	when	WRB	_	22	adv	_	_
20	it	it	PRP	_	22	dep	_	_
21	is	be	VBZ	_	22	aux	_	_
22	taken	take	VBN	_	16	comp	_	_
23	in	in	IN	_	24	case	_	_
24	combination	combination	NN	_	22	ppmod	_	_
25	with	with	IN	_	26	case	_	_
26	or	or	NN	_	24	ppmod	_	_
27	substituted	substitute	VBN	_	26	acl	_	_
28	for	for	IN	_	32	case	_	_
29	other	other	JJ	_	32	attr	_	_
30	centrally	centrally	RB	_	31	adv	_	_
31	acting	act	VBG	_	32	attr	_	_
32	drugs	drug	NNS	_	27	ppmod	_	_
33	,	,	,	_	32	p	_	_
34	including	include	VBG	_	35	adv	_	_
35	those	those	DT	_	32	ppmod	_	_
36	with	with	IN	_	39	case	_	_
37	a	a	DT	_	39	det	_	_
38	similar	similar	JJ	_	39	attr	_	_
39	mechanism	mechanism	NN	_	35	ppmod	_	_
40	of	of	IN	_	41	case	_	_
41	action	action	NN	_	39	ppmod	_	_
42	.	.	.	_	3	p	_	_

1	Potential	potential	NN	_	15	dep	_	_
2	for	for	IN	_	3	case	_	_
3	Interaction	interaction	NN	_	1	ppmod	_	_
4	with	with	IN	_	5	case	_	_
5	Drugs	drug	NNS	_	3	ppmod	_	_
6	that	that	WDT	_	7	dep	_	_
7	Affect	affect	VBP	_	5	relcl	_	_
8	Gastric	gastric	JJ	_	9	attr	_	_
9	Acidity	acidity	NN	_	7	obj	_	_
10	:	:	:	_	1	p	_	_
11	drug1	drug0	NN	_	1	appo	_	_
12	has	have	VBZ	_	15	lv	_	_
13	an	an	DT	_	15	det	_	_
14	enteric	enteric	JJ	_	15	attr	_	_
15	coating	coating	NN	_	0	root	_	_
16	that	that	WDT	_	17	dep	_	_
17	resists	resist	VBZ	_	15	relcl	_	_
18	dissolution	dissolution	NN	_	17	obj	_	_
19	until	until	IN	_	20	case	_	_
20	reaching	reach	VBG	_	17	ppmod	_	_
21	a	a	DT	_	22	det	_	_
22	segment	segment	NN	_	20	obj	_	_
23	of	of	IN	_	26	case	_	_
24	the	the	DT	_	26	det	_	_
25	gastrointestinal	gastrointestinal	JJ	_	26	attr	_	_
26	tract	tract	NN	_	22	ppmod	_	_
27	where	where	WRB	_	30	adv	_	_
28	the	the	DT	_	29	det	_	_
29	pH	ph	NN	_	30	dep	_	_
30	exceeds	exceed	VBZ	_	26	relcl	_	_
31	5.5	0	CD	_	30	obj	_	_
32	.	.	.	_	15	p	_	_

1	In	in	IN	_	4	case	_	_
2	extremely	extremely	RB	_	3	adv	_	_
3	acidic	acidic	JJ	_	4	attr	_	_
4	conditions	condition	NNS	_	15	ppmod	_	_
5	,	,	,	_	15	p	_	_
6	drug1	drug0	NN	_	15	dep	_	_
7	,	,	,	_	6	p	_	_
8	unprotected	unprotected	VBN	_	6	acl	_	_
9	by	by	IN	_	12	case	_	_
10	the	the	DT	_	12	det	_	_
11	enteric	enteric	JJ	_	12	attr	_	_
12	coating	coating	NN	_	8	ppmod	_	_
13	,	,	,	_	6	p	_	_
14	may	may	MD	_	15	modal	_	_
15	undergo	undergo	VB	_	0	root	_	_
16	hydrolysis	hydrolysis	NN	_	15	obj	_	_
17	to	to	TO	_	18	aux	_	_
18	form	form	VB	_	15	comp	_	_
19	naphthol	naphthol	NN	_	18	obj	_	_
20	.	.	.	_	15	p	_	_

1	Caution	caution	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	advised	advise	VBN	_	0	root	_	_
4	in	in	IN	_	5	case	_	_
5	using	use	VBG	_	3	ppmod	_	_
6	drug1	drug0	NN	_	5	obj	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	6	ppmod	_	_
9	with	with	IN	_	10	case	_	_
10	conditions	condition	NNS	_	8	ppmod	_	_
11	that	that	WDT	_	13	dep	_	_
12	may	may	MD	_	13	modal	_	_
13	slow	slow	JJ	_	10	relcl	_	_
14	gastric	gastric	JJ	_	15	attr	_	_
15	emptying	emptying	NN	_	13	obj	_	_
16	(	-lrb-	-LRB-	_	20	p	_	_
17	e.g.	e.g.	FW	_	20	adv	_	_
18	,	,	,	_	20	p	_	_
19	some	some	DT	_	20	det	_	_
20	diabetics	diabetic	NNS	_	15	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	.	.	.	_	3	p	_	_

1	Drugs	drug	NNS	_	8	dep	_	_
2	that	that	WDT	_	3	dep	_	_
3	raise	raise	VBP	_	1	relcl	_	_
4	the	the	DT	_	6	det	_	_
5	gastrointestinal	gastrointestinal	JJ	_	6	attr	_	_
6	pH	ph	NN	_	3	obj	_	_
7	may	may	MD	_	8	modal	_	_
8	lead	lead	VB	_	0	root	_	_
9	to	to	TO	_	12	aux	_	_
10	an	an	DT	_	12	det	_	_
11	earlier	early	JJR	_	12	attr	_	_
12	release	release	NN	_	8	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	8	p	_	_

1	However	however	RB	_	22	adv	_	_
2	,	,	,	_	22	p	_	_
3	co-administration	co-administration	NN	_	22	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drug2	drug0	NN	_	3	ppmod	_	_
8	-	-	CC	_	7	cc	_	_
9	and	and	CC	_	12	cc	_	_
10	drug3	drug0	NN	_	12	attr	_	_
11	-containing	-containing	JJ	_	12	attr	_	_
12	drug4	drug0	NN	_	7	conj	_	_
13	(	-lrb-	-LRB-	_	15	p	_	_
14	51	0	CD	_	15	num	_	_
15	mEq	meq	NN	_	12	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	or	or	CC	_	12	cc	_	_
18	drug5	drug0	NN	_	12	conj	_	_
19	with	with	IN	_	20	case	_	_
20	drug6	drug0	NN	_	3	ppmod	_	_
21	,	,	,	_	22	p	_	_
22	had	have	VBD	_	0	root	_	_
23	no	no	DT	_	25	det	_	_
24	significant	significant	JJ	_	25	attr	_	_
25	effect	effect	NN	_	22	obj	_	_
26	on	on	IN	_	28	case	_	_
27	the	the	DT	_	28	det	_	_
28	rate	rate	NN	_	22	ppmod	_	_
29	or	or	CC	_	28	cc	_	_
30	extent	extent	NN	_	28	conj	_	_
31	of	of	IN	_	33	case	_	_
32	drug7	drug0	NN	_	33	com	_	_
33	absorption	absorption	NN	_	28	ppmod	_	_
34	after	after	IN	_	35	case	_	_
35	administration	administration	NN	_	28	ppmod	_	_
36	of	of	IN	_	40	case	_	_
37	a	a	DT	_	40	det	_	_
38	40-mg	0-mg	JJ	_	40	attr	_	_
39	oral	oral	JJ	_	40	attr	_	_
40	dose	dose	NN	_	35	ppmod	_	_
41	.	.	.	_	22	p	_	_

1	It	it	PRP	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	unknown	unknown	JJ	_	2	dep	_	_
4	whether	whether	IN	_	10	mark	_	_
5	the	the	DT	_	7	det	_	_
6	concomitant	concomitant	JJ	_	7	attr	_	_
7	administration	administration	NN	_	10	dep	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	affects	affect	VBZ	_	2	comp	_	_
11	drug2	drug0	NN	_	12	com	_	_
12	absorption	absorption	NN	_	10	obj	_	_
13	.	.	.	_	2	p	_	_

1	In	in	IN	_	2	case	_	_
2	studies	study	NNS	_	8	ppmod	_	_
3	in	in	IN	_	5	case	_	_
4	normal	normal	JJ	_	5	attr	_	_
5	volunteers	volunteer	NNS	_	2	ppmod	_	_
6	,	,	,	_	8	p	_	_
7	there	there	EX	_	8	dep	_	_
8	was	be	VBD	_	0	root	_	_
9	no	no	DT	_	11	det	_	_
10	pharmacodynamic	pharmacodynamic	JJ	_	11	attr	_	_
11	interaction	interaction	NN	_	8	obj	_	_
12	between	between	IN	_	14	case	_	_
13	intravenous	intravenous	JJ	_	14	attr	_	_
14	drug1	drug0	NN	_	11	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	either	either	DT	_	17	det	_	_
17	drug2	drug0	NN	_	14	conj	_	_
18	,	,	,	_	17	p	_	_
19	drug3	drug0	NN	_	17	conj	_	_
20	,	,	,	_	19	p	_	_
21	or	or	CC	_	19	cc	_	_
22	drug4	drug0	NN	_	17	conj	_	_
23	.	.	.	_	8	p	_	_

1	However	however	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	drug1	drug0	NN	_	4	dep	_	_
4	has	have	VBZ	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	potential	potential	NN	_	4	obj	_	_
7	to	to	TO	_	8	aux	_	_
8	increase	increase	VB	_	6	acl	_	_
9	the	the	DT	_	11	det	_	_
10	hypotensive	hypotensive	JJ	_	11	attr	_	_
11	effect	effect	NN	_	8	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	drug3	drug0	NN	_	13	conj	_	_
16	.	.	.	_	4	p	_	_

1	Since	since	IN	_	3	mark	_	_
2	drug1	drug0	NN	_	3	dep	_	_
3	inhibits	inhibit	VBZ	_	8	advcl	_	_
4	platelet	platelet	NN	_	5	com	_	_
5	function	function	NN	_	3	obj	_	_
6	,	,	,	_	8	p	_	_
7	there	there	EX	_	8	dep	_	_
8	is	be	VBZ	_	0	root	_	_
9	a	a	DT	_	10	det	_	_
10	potential	potential	NN	_	8	obj	_	_
11	for	for	IN	_	13	case	_	_
12	increased	increase	VBN	_	13	attr	_	_
13	risk	risk	NN	_	10	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	bleeding	bleeding	JJ	_	13	ppmod	_	_
16	,	,	,	_	8	p	_	_
17	particularly	particularly	RB	_	19	adv	_	_
18	in	in	IN	_	19	case	_	_
19	patients	patient	NNS	_	8	ppmod	_	_
20	maintained	maintain	VBN	_	19	acl	_	_
21	on	on	IN	_	22	case	_	_
22	drug2	drug0	NN	_	20	ppmod	_	_
23	.	.	.	_	8	p	_	_

1	During	during	IN	_	3	case	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	trials	trial	NNS	_	7	ppmod	_	_
4	,	,	,	_	7	p	_	_
5	drug1	drug0	NN	_	7	dep	_	_
6	was	be	VBD	_	7	aux	_	_
7	used	use	VBN	_	0	root	_	_
8	concurrently	concurrently	RB	_	7	adv	_	_
9	with	with	IN	_	10	case	_	_
10	drug2	drug0	NN	_	7	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	drug3	drug0	NN	_	10	conj	_	_
13	,	,	,	_	12	p	_	_
14	drug4	drug0	NN	_	10	conj	_	_
15	,	,	,	_	14	p	_	_
16	drug5	drug0	NN	_	10	conj	_	_
17	,	,	,	_	16	p	_	_
18	drug6	drug0	NN	_	10	conj	_	_
19	,	,	,	_	18	p	_	_
20	drug7	drug0	NN	_	10	conj	_	_
21	,	,	,	_	20	p	_	_
22	drug8	drug0	NN	_	10	conj	_	_
23	,	,	,	_	22	p	_	_
24	drug9	drug0	NN	_	10	conj	_	_
25	,	,	,	_	24	p	_	_
26	and	and	CC	_	24	cc	_	_
27	other	other	JJ	_	28	attr	_	_
28	medications	medication	NNS	_	10	conj	_	_
29	.	.	.	_	7	p	_	_

1	Intravenous	intravenous	JJ	_	2	attr	_	_
2	infusion	infusion	NN	_	5	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	had	have	VBD	_	0	root	_	_
6	no	no	DT	_	7	det	_	_
7	effect	effect	NN	_	5	obj	_	_
8	on	on	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	pharmacokinetics	pharmacokinetics	NNS	_	5	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	did	do	VBD	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	alter	alter	VB	_	0	root	_	_
5	the	the	DT	_	8	det	_	_
6	clearance	clearance	NN	_	8	attr	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	pharmacokinetics	pharmacokinetics	NNS	_	4	obj	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	8	ppmod	_	_
12	.	.	.	_	4	p	_	_

1	Although	although	IN	_	7	mark	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	studies	study	NNS	_	7	dep	_	_
4	have	have	VBP	_	7	aux	_	_
5	not	not	RB	_	7	neg	_	_
6	been	be	VBN	_	7	aux	_	_
7	conducted	conduct	VBN	_	14	advcl	_	_
8	,	,	,	_	14	p	_	_
9	in	in	FW	_	10	adv	_	_
10	vitro	vitro	FW	_	11	attr	_	_
11	studies	study	NNS	_	14	dep	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	indicate	indicate	VBP	_	0	root	_	_
15	that	that	IN	_	26	mark	_	_
16	no	no	DT	_	18	det	_	_
17	relevant	relevant	JJ	_	18	attr	_	_
18	inhibition	inhibition	NN	_	26	dep	_	_
19	of	of	IN	_	23	case	_	_
20	cytochrome	cytochrome	NN	_	23	com	_	_
21	P450	p0	NN	_	23	com	_	_
22	drug	drug	NN	_	23	com	_	_
23	metabolism	metabolism	NN	_	18	ppmod	_	_
24	would	would	MD	_	26	modal	_	_
25	be	be	VB	_	26	aux	_	_
26	expected	expect	VBN	_	14	comp	_	_
27	.	.	.	_	14	p	_	_

1	Oral	oral	JJ	_	4	attr	_	_
2	drug1	drug0	NN	_	4	attr	_	_
3	Multiple	multiple	JJ	_	4	attr	_	_
4	doses	dose	NNS	_	7	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	had	have	VBD	_	0	root	_	_
8	no	no	DT	_	9	det	_	_
9	effect	effect	NN	_	7	obj	_	_
10	on	on	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	pharmacokinetics	pharmacokinetics	NNS	_	7	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug3	drug0	NN	_	12	ppmod	_	_
15	,	,	,	_	14	p	_	_
16	the	the	DT	_	18	det	_	_
17	estrogenic	estrogenic	JJ	_	18	attr	_	_
18	component	component	NN	_	14	appo	_	_
19	in	in	IN	_	22	case	_	_
20	most	most	JJS	_	22	attr	_	_
21	oral	oral	JJ	_	22	attr	_	_
22	drug4	drug0	NNS	_	18	ppmod	_	_
23	.	.	.	_	7	p	_	_

1	Although	although	IN	_	7	mark	_	_
2	the	the	DT	_	4	det	_	_
3	clinical	clinical	JJ	_	4	attr	_	_
4	significance	significance	NN	_	7	dep	_	_
5	is	be	VBZ	_	7	aux	_	_
6	not	not	RB	_	7	neg	_	_
7	known	know	VBN	_	12	advcl	_	_
8	,	,	,	_	12	p	_	_
9	it	it	PRP	_	12	dep	_	_
10	is	be	VBZ	_	12	aux	_	_
11	not	not	RB	_	12	neg	_	_
12	recommended	recommend	VBN	_	0	root	_	_
13	that	that	IN	_	16	mark	_	_
14	drug1	drug0	NN	_	16	dep	_	_
15	be	be	VB	_	16	aux	_	_
16	taken	take	VBN	_	12	comp	_	_
17	concomitantly	concomitantly	RB	_	16	adv	_	_
18	with	with	IN	_	19	case	_	_
19	drug2	drug0	NN	_	16	ppmod	_	_
20	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Co-administration	co-administration	NN	_	16	dep	_	_
4	of	of	IN	_	7	case	_	_
5	a	a	DT	_	7	det	_	_
6	single	single	JJ	_	7	attr	_	_
7	dose	dose	NN	_	3	ppmod	_	_
8	of	of	IN	_	11	case	_	_
9	intravenously	intravenously	RB	_	10	adv	_	_
10	administered	administer	VBN	_	11	attr	_	_
11	drug2	drug0	NN	_	7	ppmod	_	_
12	(	-lrb-	-LRB-	_	14	p	_	_
13	20	0	CD	_	14	num	_	_
14	mg	mg	NN	_	7	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	reduced	reduce	VBD	_	1	acl	_	_
17	the	the	DT	_	19	det	_	_
18	oral	oral	JJ	_	19	attr	_	_
19	absorption	absorption	NN	_	16	obj	_	_
20	of	of	IN	_	25	case	_	_
21	a	a	DT	_	25	det	_	_
22	single	single	JJ	_	25	attr	_	_
23	400	0	CD	_	24	num	_	_
24	mg	mg	NN	_	25	com	_	_
25	dose	dose	NN	_	19	ppmod	_	_
26	of	of	IN	_	27	case	_	_
27	drug3	drug0	NN	_	25	ppmod	_	_
28	administered	administer	VBN	_	25	acl	_	_
29	following	follow	VBG	_	31	adv	_	_
30	a	a	DT	_	31	det	_	_
31	meal	meal	NN	_	28	ppmod	_	_
32	,	,	,	_	16	p	_	_
33	as	as	IN	_	34	mark	_	_
34	evidenced	evidence	VBN	_	16	comp	_	_
35	by	by	IN	_	39	case	_	_
36	a	a	DT	_	39	det	_	_
37	27	0	CD	_	39	num	_	_
38	%	%	NN	_	37	meta	_	_
39	decrease	decrease	NN	_	34	ppmod	_	_
40	in	in	IN	_	42	case	_	_
41	mean	mean	JJ	_	42	attr	_	_
42	Cmax	cmax	NN	_	39	ppmod	_	_
43	and	and	CC	_	39	cc	_	_
44	a	a	DT	_	47	det	_	_
45	22	0	CD	_	47	num	_	_
46	%	%	NN	_	45	meta	_	_
47	decrease	decrease	NN	_	39	conj	_	_
48	in	in	IN	_	50	case	_	_
49	mean	mean	JJ	_	50	attr	_	_
50	AUC	auc	NN	_	47	ppmod	_	_
51	.	.	.	_	1	p	_	_

1	Although	although	IN	_	7	mark	_	_
2	the	the	DT	_	4	det	_	_
3	clinical	clinical	JJ	_	4	attr	_	_
4	significance	significance	NN	_	7	dep	_	_
5	is	be	VBZ	_	7	aux	_	_
6	not	not	RB	_	7	neg	_	_
7	known	know	VBN	_	12	advcl	_	_
8	,	,	,	_	12	p	_	_
9	it	it	PRP	_	12	dep	_	_
10	is	be	VBZ	_	12	aux	_	_
11	not	not	RB	_	12	neg	_	_
12	recommended	recommend	VBN	_	0	root	_	_
13	that	that	IN	_	16	mark	_	_
14	drug1	drug0	NN	_	16	dep	_	_
15	be	be	VB	_	16	aux	_	_
16	taken	take	VBN	_	12	comp	_	_
17	concomitantly	concomitantly	RB	_	16	adv	_	_
18	with	with	IN	_	19	case	_	_
19	drug2	drug0	NN	_	16	ppmod	_	_
20	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	As	as	IN	_	6	case	_	_
4	with	with	IN	_	6	case	_	_
5	other	other	JJ	_	6	attr	_	_
6	drug2	drug0	NNS	_	13	ppmod	_	_
7	,	,	,	_	13	p	_	_
8	co-administration	co-administration	NN	_	13	dep	_	_
9	of	of	IN	_	10	case	_	_
10	drug3	drug0	NN	_	8	ppmod	_	_
11	with	with	IN	_	12	case	_	_
12	drug4	drug0	NN	_	8	ppmod	_	_
13	resulted	result	VBD	_	1	acl	_	_
14	in	in	IN	_	16	case	_	_
15	an	an	DT	_	16	det	_	_
16	increase	increase	NN	_	13	ppmod	_	_
17	in	in	IN	_	20	case	_	_
18	the	the	DT	_	20	det	_	_
19	plasma	plasma	NN	_	20	com	_	_
20	exposure	exposure	NN	_	16	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	drug5	drug0	NN	_	20	ppmod	_	_
23	,	,	,	_	13	p	_	_
24	with	with	IN	_	28	case	_	_
25	a	a	DT	_	28	det	_	_
26	49	0	CD	_	28	num	_	_
27	%	%	NN	_	26	meta	_	_
28	increase	increase	NN	_	13	ppmod	_	_
29	in	in	IN	_	31	case	_	_
30	mean	mean	NN	_	31	com	_	_
31	Cmax	cmax	NN	_	28	ppmod	_	_
32	,	,	,	_	28	p	_	_
33	a	a	DT	_	36	det	_	_
34	122	0	CD	_	36	num	_	_
35	%	%	NN	_	36	meta	_	_
36	increase	increase	NN	_	28	conj	_	_
37	in	in	IN	_	39	case	_	_
38	mean	mean	JJ	_	39	attr	_	_
39	AUC	auc	NN	_	36	ppmod	_	_
40	,	,	,	_	36	p	_	_
41	and	and	CC	_	36	cc	_	_
42	a	a	DT	_	45	det	_	_
43	53	0	CD	_	45	num	_	_
44	%	%	NN	_	45	meta	_	_
45	increase	increase	NN	_	28	conj	_	_
46	in	in	IN	_	47	case	_	_
47	half-life	half-life	NN	_	45	ppmod	_	_
48	.	.	.	_	1	p	_	_

1	Drug/Laboratory	drug/laboratory	NN	_	3	com	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	6	dep	_	_
4	drug1	drug0	RB	_	6	adv	_	_
5	are	be	VBP	_	6	aux	_	_
6	known	know	VBN	_	0	root	_	_
7	to	to	TO	_	9	aux	_	_
8	occasionally	occasionally	RB	_	9	adv	_	_
9	induce	induce	VB	_	6	comp	_	_
10	a	a	DT	_	14	det	_	_
11	positive	positive	JJ	_	14	attr	_	_
12	direct	direct	JJ	_	14	attr	_	_
13	Coombs	coombs	NN	_	14	com	_	_
14	test	test	NN	_	9	obj	_	_
15	.	.	.	_	6	p	_	_

1	A	a	DT	_	3	det	_	_
2	false-positive	false-positive	JJ	_	3	attr	_	_
3	reaction	reaction	NN	_	10	dep	_	_
4	for	for	IN	_	5	case	_	_
5	glucose	glucose	NN	_	3	ppmod	_	_
6	in	in	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	urine	urine	NN	_	3	ppmod	_	_
9	may	may	MD	_	10	modal	_	_
10	occur	occur	VB	_	0	root	_	_
11	with	with	IN	_	14	case	_	_
12	copper	copper	NN	_	14	com	_	_
13	reduction	reduction	NN	_	14	com	_	_
14	tests	test	NNS	_	10	ppmod	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	Benedicts	benedicts	NNP	_	14	prn	_	_
17	or	or	CC	_	16	cc	_	_
18	Fehlings	fehlings	NNP	_	19	com	_	_
19	solution	solution	NN	_	16	conj	_	_
20	or	or	CC	_	16	cc	_	_
21	with	with	IN	_	23	case	_	_
22	CLINITEST	clinitest	JJ	_	23	attr	_	_
23	tablets	tablet	NNS	_	16	conj	_	_
24	)	-rrb-	-RRB-	_	23	p	_	_
25	,	,	,	_	14	p	_	_
26	but	but	CC	_	14	cc	_	_
27	not	not	RB	_	30	neg	_	_
28	with	with	IN	_	30	case	_	_
29	enzyme-based	enzyme-based	JJ	_	30	attr	_	_
30	tests	test	NNS	_	14	conj	_	_
31	for	for	IN	_	32	case	_	_
32	glycosuria	glycosuria	NN	_	30	ppmod	_	_
33	(	-lrb-	-LRB-	_	36	p	_	_
34	e.g.	e.g.	FW	_	36	ppmod	_	_
35	,	,	,	_	36	p	_	_
36	CLINISTIX	clinistix	NN	_	32	prn	_	_
37	,	,	,	_	36	p	_	_
38	TES-TAPE	tes-tape	NN	_	36	appo	_	_
39	)	-rrb-	-RRB-	_	36	p	_	_
40	.	.	.	_	10	p	_	_

1	As	as	IN	_	6	mark	_	_
2	a	a	DT	_	4	det	_	_
3	false-negative	false-negative	JJ	_	4	attr	_	_
4	result	result	NN	_	6	dep	_	_
5	may	may	MD	_	6	modal	_	_
6	occur	occur	VB	_	14	advcl	_	_
7	in	in	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	ferricyanide	ferricyanide	NN	_	10	com	_	_
10	test	test	NN	_	6	ppmod	_	_
11	,	,	,	_	14	p	_	_
12	it	it	PRP	_	14	dep	_	_
13	is	be	VBZ	_	14	aux	_	_
14	recommended	recommend	VBN	_	0	root	_	_
15	that	that	IN	_	24	mark	_	_
16	either	either	CC	_	19	cc	_	_
17	the	the	DT	_	19	det	_	_
18	glucose	glucose	NN	_	19	com	_	_
19	oxidase	oxidase	NN	_	24	dep	_	_
20	or	or	CC	_	19	cc	_	_
21	hexokinase	hexokinase	NN	_	22	com	_	_
22	method	method	NN	_	19	conj	_	_
23	be	be	VB	_	24	aux	_	_
24	used	use	VBN	_	14	comp	_	_
25	to	to	TO	_	26	aux	_	_
26	determine	determine	VB	_	24	comp	_	_
27	blood/plasma	blood/plasma	NN	_	29	com	_	_
28	glucose	glucose	NN	_	29	com	_	_
29	levels	level	NNS	_	26	obj	_	_
30	in	in	IN	_	31	case	_	_
31	patients	patient	NNS	_	29	ppmod	_	_
32	receiving	receive	VBG	_	31	acl	_	_
33	drug1	drug0	NN	_	32	obj	_	_
34	.	.	.	_	14	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	studied	study	VBN	_	0	root	_	_
5	in	in	IN	_	10	case	_	_
6	several	several	JJ	_	10	attr	_	_
7	human	human	JJ	_	10	attr	_	_
8	drug	drug	NN	_	10	com	_	_
9	interaction	interaction	NN	_	10	com	_	_
10	studies	study	NNS	_	4	ppmod	_	_
11	in	in	IN	_	12	case	_	_
12	which	which	WDT	_	15	ppmod	_	_
13	it	it	PRP	_	15	dep	_	_
14	was	be	VBD	_	15	aux	_	_
15	administered	administer	VBN	_	10	relcl	_	_
16	with	with	IN	_	18	case	_	_
17	a	a	DT	_	18	det	_	_
18	meal	meal	NN	_	15	ppmod	_	_
19	and	and	CC	_	18	cc	_	_
20	the	the	DT	_	22	det	_	_
21	test	test	NN	_	22	com	_	_
22	drug	drug	NN	_	18	conj	_	_
23	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	was	be	VBD	_	3	aux	_	_
3	found	find	VBN	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	have	have	VB	_	3	comp	_	_
6	no	no	DT	_	8	det	_	_
7	significant	significant	JJ	_	8	attr	_	_
8	effect	effect	NN	_	5	obj	_	_
9	on	on	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	bioavailability	bioavailability	NN	_	5	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	,	,	,	_	13	p	_	_
15	drug3	drug0	NN	_	13	conj	_	_
16	,	,	,	_	15	p	_	_
17	drug4	drug0	NN	_	13	conj	_	_
18	,	,	,	_	17	p	_	_
19	drug5	drug0	NN	_	13	conj	_	_
20	,	,	,	_	19	p	_	_
21	drug6	drug0	NN	_	13	conj	_	_
22	,	,	,	_	21	p	_	_
23	and	and	CC	_	21	cc	_	_
24	drug7	drug0	NN	_	13	conj	_	_
25	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	decreased	decrease	VBD	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	Cmax	cmax	NN	_	2	obj	_	_
5	and	and	CC	_	4	cc	_	_
6	AUC	auc	NN	_	4	conj	_	_
7	of	of	IN	_	9	case	_	_
8	sustained-release	sustained-release	NN	_	9	com	_	_
9	drug2	drug0	NN	_	4	ppmod	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	drug3	drug0	NN	_	9	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	by	by	IN	_	15	case	_	_
14	approximately	approximately	RB	_	15	adv	_	_
15	31	0	CD	_	2	ppmod	_	_
16	%	%	NN	_	15	meta	_	_
17	and	and	CC	_	15	cc	_	_
18	11	0	CD	_	15	conj	_	_
19	%	%	NN	_	18	meta	_	_
20	,	,	,	_	18	p	_	_
21	respectively	respectively	RB	_	15	conj	_	_
22	.	.	.	_	2	p	_	_

1	Since	since	IN	_	3	mark	_	_
2	there	there	EX	_	3	dep	_	_
3	is	be	VBZ	_	21	advcl	_	_
4	a	a	DT	_	6	det	_	_
5	high	high	JJ	_	6	attr	_	_
6	degree	degree	NN	_	3	obj	_	_
7	of	of	IN	_	8	case	_	_
8	variability	variability	NN	_	6	ppmod	_	_
9	in	in	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	bioavailability	bioavailability	NN	_	6	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	,	,	,	_	21	p	_	_
15	the	the	DT	_	17	det	_	_
16	clinical	clinical	JJ	_	17	attr	_	_
17	significance	significance	NN	_	21	dep	_	_
18	of	of	IN	_	20	case	_	_
19	this	this	DT	_	20	det	_	_
20	finding	finding	NN	_	17	ppmod	_	_
21	is	be	VBZ	_	0	root	_	_
22	unclear	unclear	JJ	_	21	dep	_	_
23	.	.	.	_	21	p	_	_

1	In	in	IN	_	3	case	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	studies	study	NNS	_	17	ppmod	_	_
4	,	,	,	_	17	p	_	_
5	coadministration	coadministration	NN	_	17	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	with	with	IN	_	9	case	_	_
9	drug2	drug0	NN	_	5	ppmod	_	_
10	,	,	,	_	9	p	_	_
11	drug3	drug0	NN	_	9	conj	_	_
12	,	,	,	_	11	p	_	_
13	or	or	CC	_	11	cc	_	_
14	drug4	drug0	NN	_	9	conj	_	_
15	did	do	VBD	_	17	aux	_	_
16	not	not	RB	_	17	neg	_	_
17	interfere	interfere	VB	_	0	root	_	_
18	with	with	IN	_	21	case	_	_
19	the	the	DT	_	21	det	_	_
20	lipid-lowering	lipid-lowering	JJ	_	21	attr	_	_
21	activity	activity	NN	_	17	ppmod	_	_
22	of	of	IN	_	24	case	_	_
23	the	the	DT	_	24	det	_	_
24	drug5	drug0	NN	_	21	ppmod	_	_
25	.	.	.	_	17	p	_	_

1	Other	other	JJ	_	2	attr	_	_
2	drugs	drug	NNS	_	6	dep	_	_
3	have	have	VBP	_	6	aux	_	_
4	not	not	RB	_	6	neg	_	_
5	been	be	VBN	_	6	aux	_	_
6	studied	study	VBN	_	0	root	_	_
7	.	.	.	_	6	p	_	_

1	When	when	WRB	_	2	adv	_	_
2	administering	administer	VBG	_	24	advcl	_	_
3	other	other	JJ	_	4	attr	_	_
4	drugs	drug	NNS	_	2	obj	_	_
5	for	for	IN	_	6	case	_	_
6	which	which	WDT	_	12	ppmod	_	_
7	alterations	alteration	NNS	_	12	dep	_	_
8	in	in	IN	_	10	case	_	_
9	blood	blood	NN	_	10	com	_	_
10	levels	level	NNS	_	7	ppmod	_	_
11	could	could	MD	_	12	modal	_	_
12	have	have	VB	_	4	relcl	_	_
13	a	a	DT	_	16	det	_	_
14	clinically	clinically	RB	_	15	adv	_	_
15	significant	significant	JJ	_	16	attr	_	_
16	effect	effect	NN	_	12	obj	_	_
17	on	on	IN	_	18	case	_	_
18	safety	safety	NN	_	12	ppmod	_	_
19	or	or	CC	_	18	cc	_	_
20	efficacy	efficacy	NN	_	18	conj	_	_
21	,	,	,	_	24	p	_	_
22	physicians	physician	NNS	_	24	dep	_	_
23	should	should	MD	_	24	modal	_	_
24	consider	consider	VB	_	0	root	_	_
25	monitoring	monitoring	NN	_	27	com	_	_
26	drug	drug	NN	_	27	com	_	_
27	levels	level	NNS	_	24	obj	_	_
28	or	or	CC	_	27	cc	_	_
29	effects	effect	NNS	_	27	conj	_	_
30	.	.	.	_	24	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	administered	administer	VBN	_	0	root	_	_
5	with	with	IN	_	6	case	_	_
6	caution	caution	NN	_	4	ppmod	_	_
7	to	to	TO	_	8	aux	_	_
8	patients	patient	NNS	_	4	ppmod	_	_
9	who	who	WP	_	11	dep	_	_
10	are	be	VBP	_	11	aux	_	_
11	taking	take	VBG	_	8	relcl	_	_
12	other	other	JJ	_	13	attr	_	_
13	drug2	drug0	NN	_	11	obj	_	_
14	or	or	CC	_	13	cc	_	_
15	drug3	drug0	NN	_	13	conj	_	_
16	,	,	,	_	8	p	_	_
17	including	include	VBG	_	18	adv	_	_
18	drug4	drug0	NN	_	8	ppmod	_	_
19	,	,	,	_	18	p	_	_
20	drug5	drug0	NN	_	18	conj	_	_
21	and	and	CC	_	20	cc	_	_
22	drug6	drug0	NN	_	18	conj	_	_
23	,	,	,	_	8	p	_	_
24	or	or	CC	_	8	cc	_	_
25	to	to	TO	_	26	aux	_	_
26	those	those	DT	_	8	conj	_	_
27	with	with	IN	_	29	case	_	_
28	a	a	DT	_	29	det	_	_
29	history	history	NN	_	26	ppmod	_	_
30	of	of	IN	_	32	case	_	_
31	psychiatric	psychiatric	JJ	_	32	attr	_	_
32	disorder	disorder	NN	_	29	ppmod	_	_
33	(	-lrb-	-LRB-	_	36	p	_	_
34	including	include	VBG	_	36	adv	_	_
35	manic-depressive	manic-depressive	JJ	_	36	attr	_	_
36	illness	illness	NN	_	32	prn	_	_
37	and	and	CC	_	36	cc	_	_
38	schizophrenia	schizophrenia	NN	_	36	conj	_	_
39	)	-rrb-	-RRB-	_	36	p	_	_
40	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	shown	show	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	have	have	VB	_	4	comp	_	_
7	an	an	DT	_	11	det	_	_
8	additive	additive	JJ	_	11	attr	_	_
9	CNS	cns	NN	_	11	attr	_	_
10	depressant	depressant	JJ	_	11	attr	_	_
11	effect	effect	NN	_	6	obj	_	_
12	when	when	WRB	_	13	adv	_	_
13	given	give	VBN	_	6	comp	_	_
14	with	with	IN	_	16	case	_	_
15	either	either	CC	_	16	cc	_	_
16	drug2	drug0	NN	_	13	ppmod	_	_
17	,	,	,	_	16	p	_	_
18	drug3	drug0	NN	_	16	conj	_	_
19	,	,	,	_	18	p	_	_
20	drug4	drug0	NN	_	16	conj	_	_
21	or	or	CC	_	20	cc	_	_
22	drug5	drug0	NN	_	16	conj	_	_
23	.	.	.	_	4	p	_	_

1	Drug	drug	NN	_	4	com	_	_
2	Laboratory	laboratory	NN	_	4	com	_	_
3	Test	test	NN	_	4	com	_	_
4	Interactions	interaction	NNS	_	0	root	_	_
5	:	:	:	_	4	p	_	_
6	Prolongation	prolongation	NN	_	14	dep	_	_
7	of	of	IN	_	11	case	_	_
8	the	the	DT	_	11	det	_	_
9	template	template	NN	_	11	attr	_	_
10	bleeding	bleeding	JJ	_	11	attr	_	_
11	time	time	NN	_	6	ppmod	_	_
12	has	have	VBZ	_	14	aux	_	_
13	been	be	VBN	_	14	aux	_	_
14	reported	report	VBN	_	4	acl	_	_
15	during	during	IN	_	18	case	_	_
16	continuous	continuous	JJ	_	18	attr	_	_
17	intravenous	intravenous	JJ	_	18	attr	_	_
18	infusion	infusion	NN	_	14	ppmod	_	_
19	of	of	IN	_	20	case	_	_
20	drug1	drug0	NN	_	18	ppmod	_	_
21	at	at	IN	_	22	case	_	_
22	dosages	dosage	NNS	_	18	ppmod	_	_
23	exceeding	exceed	VBG	_	22	acl	_	_
24	24	0	CD	_	25	num	_	_
25	g/day	g/day	NN	_	23	obj	_	_
26	.	.	.	_	4	p	_	_

1	Platelet	platelet	NN	_	3	com	_	_
2	function	function	NN	_	3	com	_	_
3	studies	study	NNS	_	9	dep	_	_
4	in	in	IN	_	6	case	_	_
5	these	these	DT	_	6	det	_	_
6	patients	patient	NNS	_	3	ppmod	_	_
7	have	have	VBP	_	9	aux	_	_
8	not	not	RB	_	9	neg	_	_
9	demonstrated	demonstrate	VBN	_	0	root	_	_
10	any	any	DT	_	13	det	_	_
11	significant	significant	JJ	_	13	attr	_	_
12	platelet	platelet	NN	_	13	com	_	_
13	dysfunction	dysfunction	NN	_	9	obj	_	_
14	.	.	.	_	9	p	_	_

1	However	however	RB	_	7	adv	_	_
2	,	,	,	_	7	p	_	_
3	in	in	FW	_	4	adv	_	_
4	vitro	vitro	FW	_	5	attr	_	_
5	studies	study	NNS	_	7	dep	_	_
6	have	have	VBP	_	7	aux	_	_
7	shown	show	VBN	_	0	root	_	_
8	that	that	IN	_	22	mark	_	_
9	at	at	IN	_	11	case	_	_
10	high	high	JJ	_	11	attr	_	_
11	concentrations	concentration	NNS	_	22	ppmod	_	_
12	(	-lrb-	-LRB-	_	17	p	_	_
13	7.4	0	CD	_	17	num	_	_
14	mMol/L	mmol/l	NN	_	13	attr	_	_
15	or	or	CC	_	13	cc	_	_
16	0.97	0	CD	_	13	conj	_	_
17	mg/mL	mg/ml	NNS	_	11	prn	_	_
18	and	and	CC	_	17	cc	_	_
19	greater	great	JJR	_	17	conj	_	_
20	)	-rrb-	-RRB-	_	17	p	_	_
21	drug1	drug0	NN	_	22	dep	_	_
22	inhibits	inhibit	VBZ	_	7	comp	_	_
23	ADP	adp	NN	_	22	obj	_	_
24	and	and	CC	_	23	cc	_	_
25	collagen-induced	collagen-induced	JJ	_	27	attr	_	_
26	platelet	platelet	NN	_	27	com	_	_
27	aggregation	aggregation	NN	_	23	conj	_	_
28	,	,	,	_	23	p	_	_
29	the	the	DT	_	30	det	_	_
30	release	release	NN	_	23	conj	_	_
31	of	of	IN	_	32	case	_	_
32	ATP	atp	NN	_	30	ppmod	_	_
33	and	and	CC	_	32	cc	_	_
34	serotonin	serotonin	NN	_	32	conj	_	_
35	,	,	,	_	30	p	_	_
36	and	and	CC	_	30	cc	_	_
37	the	the	DT	_	38	det	_	_
38	binding	binding	NN	_	23	conj	_	_
39	of	of	IN	_	40	case	_	_
40	fibrinogen	fibrinogen	NN	_	38	ppmod	_	_
41	to	to	TO	_	43	aux	_	_
42	the	the	DT	_	43	det	_	_
43	platelets	platelet	NNS	_	38	ppmod	_	_
44	in	in	IN	_	47	case	_	_
45	a	a	DT	_	47	det	_	_
46	concentration-response	concentration-response	JJ	_	47	attr	_	_
47	manner	manner	NN	_	22	ppmod	_	_
48	.	.	.	_	7	p	_	_

1	Following	follow	VBG	_	5	adv	_	_
2	a	a	DT	_	5	det	_	_
3	10	0	CD	_	5	num	_	_
4	g	g	NN	_	5	com	_	_
5	bolus	bolus	NN	_	21	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	,	,	,	_	21	p	_	_
9	transient	transient	JJ	_	12	attr	_	_
10	peak	peak	NN	_	12	com	_	_
11	plasma	plasma	NN	_	12	com	_	_
12	concentrations	concentration	NNS	_	21	dep	_	_
13	of	of	IN	_	18	case	_	_
14	4.6	0	CD	_	18	num	_	_
15	mMol/L	mmol/l	NN	_	14	attr	_	_
16	or	or	CC	_	14	cc	_	_
17	0.60	0	CD	_	14	conj	_	_
18	mg/mL	mg/ml	NN	_	12	ppmod	_	_
19	have	have	VBP	_	21	aux	_	_
20	been	be	VBN	_	21	aux	_	_
21	obtained	obtain	VBN	_	0	root	_	_
22	.	.	.	_	21	p	_	_

1	The	the	DT	_	2	det	_	_
2	concentration	concentration	NN	_	11	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	necessary	necessary	JJ	_	2	attr	_	_
6	to	to	TO	_	7	aux	_	_
7	maintain	maintain	VB	_	5	comp	_	_
8	inhibition	inhibition	NN	_	7	obj	_	_
9	of	of	IN	_	10	case	_	_
10	fibrinolysis	fibrinolysis	NN	_	8	ppmod	_	_
11	is	be	VBZ	_	0	root	_	_
12	0.99	0	CD	_	16	num	_	_
13	mMol/L	mmol/l	NN	_	12	attr	_	_
14	or	or	CC	_	12	cc	_	_
15	0.13	0	CD	_	12	conj	_	_
16	mg/mL	mg/ml	NN	_	11	obj	_	_
17	.	.	.	_	11	p	_	_

1	Administration	administration	NN	_	14	dep	_	_
2	of	of	IN	_	6	case	_	_
3	a	a	DT	_	6	det	_	_
4	5	0	CD	_	5	num	_	_
5	g	g	NN	_	6	com	_	_
6	bolus	bolus	NN	_	1	ppmod	_	_
7	followed	followed	VBN	_	6	acl	_	_
8	by	by	IN	_	12	case	_	_
9	1	0	CD	_	12	num	_	_
10	to	to	TO	_	9	cc	_	_
11	1.25	0	CD	_	9	conj	_	_
12	g/hr	g/hr	NN	_	7	ppmod	_	_
13	should	should	MD	_	14	modal	_	_
14	achieve	achieve	VB	_	0	root	_	_
15	and	and	CC	_	14	cc	_	_
16	sustain	sustain	VB	_	14	conj	_	_
17	plasma	plasma	NN	_	18	com	_	_
18	levels	level	NNS	_	16	obj	_	_
19	of	of	IN	_	21	case	_	_
20	0.13	0	CD	_	21	num	_	_
21	mg/mL	mg/ml	NN	_	18	ppmod	_	_
22	.	.	.	_	14	p	_	_

1	Thus	thus	RB	_	17	adv	_	_
2	,	,	,	_	17	p	_	_
3	concentrations	concentration	NNS	_	17	dep	_	_
4	which	which	WDT	_	7	dep	_	_
5	have	have	VBP	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	obtained	obtain	VBN	_	3	relcl	_	_
8	in	in	FW	_	9	adv	_	_
9	vivo	vivo	FW	_	7	adv	_	_
10	clinically	clinically	RB	_	7	adv	_	_
11	in	in	IN	_	12	case	_	_
12	patients	patient	NNS	_	7	ppmod	_	_
13	with	with	IN	_	16	case	_	_
14	normal	normal	JJ	_	16	attr	_	_
15	renal	renal	JJ	_	16	attr	_	_
16	function	function	NN	_	12	ppmod	_	_
17	are	be	VBP	_	0	root	_	_
18	considerably	considerably	RB	_	19	adv	_	_
19	lower	low	JJR	_	17	dep	_	_
20	than	than	IN	_	24	case	_	_
21	the	the	DT	_	24	det	_	_
22	in	in	FW	_	23	adv	_	_
23	vitro	vitro	FW	_	24	attr	_	_
24	concentrations	concentration	NNS	_	19	ppmod	_	_
25	found	find	VBN	_	24	acl	_	_
26	to	to	TO	_	27	aux	_	_
27	induce	induce	VB	_	25	comp	_	_
28	abnormalities	abnormality	NNS	_	27	obj	_	_
29	in	in	IN	_	32	case	_	_
30	platelet	platelet	NN	_	32	com	_	_
31	function	function	NN	_	32	com	_	_
32	tests	test	NNS	_	27	ppmod	_	_
33	.	.	.	_	17	p	_	_

1	However	however	RB	_	9	adv	_	_
2	,	,	,	_	9	p	_	_
3	higher	high	JJR	_	5	attr	_	_
4	plasma	plasma	NN	_	5	com	_	_
5	concentrations	concentration	NNS	_	9	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	may	may	MD	_	9	modal	_	_
9	occur	occur	VB	_	0	root	_	_
10	in	in	IN	_	11	case	_	_
11	patients	patient	NNS	_	9	ppmod	_	_
12	with	with	IN	_	15	case	_	_
13	severe	severe	JJ	_	15	attr	_	_
14	renal	renal	JJ	_	15	attr	_	_
15	failure	failure	NN	_	11	ppmod	_	_
16	.	.	.	_	9	p	_	_

1	Certain	certain	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	,	,	,	_	2	p	_	_
4	drug2	drug0	NN	_	2	conj	_	_
5	,	,	,	_	4	p	_	_
6	drug3	drug0	NN	_	2	conj	_	_
7	,	,	,	_	6	p	_	_
8	drug4	drug0	NN	_	2	conj	_	_
9	,	,	,	_	8	p	_	_
10	drug5	drug0	NN	_	2	conj	_	_
11	,	,	,	_	10	p	_	_
12	and	and	CC	_	10	cc	_	_
13	drug6	drug0	NN	_	2	conj	_	_
14	.	.	.	_	2	p	_	_

1	No	no	DT	_	2	det	_	_
2	information	information	NN	_	0	root	_	_
3	available	available	JJ	_	2	attr	_	_

1	.	.	.	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	Increased	increase	VBN	_	2	attr	_	_
2	nephrotoxicity	nephrotoxicity	NN	_	5	dep	_	_
3	has	have	VBZ	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	reported	report	VBN	_	0	root	_	_
6	following	follow	VBG	_	8	adv	_	_
7	concomitant	concomitant	JJ	_	8	attr	_	_
8	administration	administration	NN	_	5	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug2	drug0	NN	_	10	conj	_	_
13	.	.	.	_	5	p	_	_

1	Drug/Laboratory	drug/laboratory	JJ	_	3	attr	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	17	dep	_	_
4	As	as	IN	_	6	case	_	_
5	with	with	IN	_	6	case	_	_
6	drug1	drug0	NN	_	3	ppmod	_	_
7	,	,	,	_	6	p	_	_
8	high	high	JJ	_	9	attr	_	_
9	concentrations	concentration	NNS	_	6	appo	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	(	-lrb-	-LRB-	_	14	p	_	_
13	100	0	CD	_	14	num	_	_
14	micrograms/mL	micrograms/ml	NNS	_	11	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	may	may	MD	_	17	modal	_	_
17	interfere	interfere	VB	_	0	root	_	_
18	with	with	IN	_	19	case	_	_
19	measurement	measurement	NN	_	17	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	serum	serum	NN	_	19	ppmod	_	_
22	and	and	CC	_	21	cc	_	_
23	urine	urine	NN	_	25	com	_	_
24	creatinine	creatinine	NN	_	25	com	_	_
25	levels	level	NNS	_	21	conj	_	_
26	by	by	IN	_	29	case	_	_
27	the	the	DT	_	29	det	_	_
28	Jaff	jaff	NN	_	29	com	_	_
29	reaction	reaction	NN	_	17	ppmod	_	_
30	,	,	,	_	17	p	_	_
31	and	and	CC	_	17	cc	_	_
32	produce	produce	VB	_	17	conj	_	_
33	false	false	JJ	_	34	attr	_	_
34	increases	increase	NNS	_	32	obj	_	_
35	of	of	IN	_	37	case	_	_
36	modest	modest	JJ	_	37	attr	_	_
37	degree	degree	NN	_	34	ppmod	_	_
38	in	in	IN	_	40	case	_	_
39	the	the	DT	_	40	det	_	_
40	levels	level	NNS	_	34	ppmod	_	_
41	of	of	IN	_	42	case	_	_
42	creatinine	creatinine	NN	_	40	ppmod	_	_
43	reported	report	VBD	_	42	acl	_	_
44	.	.	.	_	17	p	_	_

1	Serum	serum	NN	_	2	com	_	_
2	samples	sample	NNS	_	11	dep	_	_
3	from	from	IN	_	4	case	_	_
4	patients	patient	NNS	_	2	ppmod	_	_
5	treated	treat	VBN	_	4	acl	_	_
6	with	with	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	should	should	MD	_	11	modal	_	_
9	not	not	RB	_	11	neg	_	_
10	be	be	VB	_	11	aux	_	_
11	analyzed	analyze	VBN	_	0	root	_	_
12	for	for	IN	_	13	case	_	_
13	creatinine	creatinine	NN	_	11	ppmod	_	_
14	if	if	IN	_	15	mark	_	_
15	withdrawn	withdraw	VBN	_	11	comp	_	_
16	within	within	IN	_	18	case	_	_
17	2	0	CD	_	18	num	_	_
18	hours	hour	NNS	_	15	ppmod	_	_
19	of	of	IN	_	21	case	_	_
20	drug	drug	NN	_	21	com	_	_
21	administration	administration	NN	_	18	ppmod	_	_
22	.	.	.	_	11	p	_	_

1	High	high	JJ	_	2	attr	_	_
2	concentrations	concentration	NNS	_	9	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	in	in	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	urine	urine	NN	_	4	ppmod	_	_
8	may	may	MD	_	9	modal	_	_
9	interfere	interfere	VB	_	0	root	_	_
10	with	with	IN	_	11	case	_	_
11	measurement	measurement	NN	_	9	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	urinary	urinary	JJ	_	14	attr	_	_
14	17-hydroxy-corticosteroids	0-hydroxy-corticosteroids	NNS	_	11	ppmod	_	_
15	by	by	IN	_	18	case	_	_
16	the	the	DT	_	18	det	_	_
17	Porter-Silber	porter-silber	NN	_	18	com	_	_
18	reaction	reaction	NN	_	9	ppmod	_	_
19	,	,	,	_	9	p	_	_
20	and	and	CC	_	9	cc	_	_
21	produce	produce	VB	_	9	conj	_	_
22	false	false	JJ	_	23	attr	_	_
23	increases	increase	NNS	_	21	obj	_	_
24	of	of	IN	_	26	case	_	_
25	modest	modest	JJ	_	26	attr	_	_
26	degree	degree	NN	_	23	ppmod	_	_
27	in	in	IN	_	29	case	_	_
28	the	the	DT	_	29	det	_	_
29	levels	level	NNS	_	26	ppmod	_	_
30	reported	report	VBN	_	29	acl	_	_
31	.	.	.	_	9	p	_	_

1	A	a	DT	_	3	det	_	_
2	false-positive	false-positive	JJ	_	3	attr	_	_
3	reaction	reaction	NN	_	10	dep	_	_
4	for	for	IN	_	5	case	_	_
5	glucose	glucose	NN	_	3	ppmod	_	_
6	in	in	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	urine	urine	NN	_	3	ppmod	_	_
9	may	may	MD	_	10	modal	_	_
10	occur	occur	VB	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	This	this	DT	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	observed	observe	VBN	_	0	root	_	_
5	with	with	IN	_	8	case	_	_
6	CLINITEST	clinitest	JJ	_	8	attr	_	_
7	reagent	reagent	JJ	_	8	attr	_	_
8	tablets	tablet	NNS	_	4	ppmod	_	_

1	.	.	.	_	0	root	_	_

1	Registered	registered	JJ	_	2	attr	_	_
2	trademark	trademark	NN	_	0	root	_	_
3	of	of	IN	_	5	case	_	_
4	Ames	ames	NN	_	5	com	_	_
5	Company	company	NN	_	2	ppmod	_	_
6	,	,	,	_	2	p	_	_
7	Division	division	NN	_	2	appo	_	_
8	of	of	IN	_	10	case	_	_
9	Miles	mile	NN	_	10	com	_	_
10	Laboratories	laboratory	NNS	_	7	ppmod	_	_
11	,	,	,	_	2	p	_	_
12	Inc.	inc.	NNP	_	2	appo	_	_

1	Drug/Laboratory	drug/laboratory	JJ	_	7	attr	_	_
2	Test	test	NN	_	7	attr	_	_
3	Interactions	interaction	NNS	_	7	attr	_	_
4	Positive	positive	JJ	_	7	attr	_	_
5	direct	direct	JJ	_	7	attr	_	_
6	Coombs	coombs	NN	_	7	com	_	_
7	tests	test	NNS	_	10	dep	_	_
8	have	have	VBP	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	reported	report	VBN	_	0	root	_	_
11	during	during	IN	_	12	case	_	_
12	treatment	treatment	NN	_	10	ppmod	_	_
13	with	with	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	drug1	drug0	NN	_	12	ppmod	_	_
16	.	.	.	_	10	p	_	_

1	In	in	IN	_	3	case	_	_
2	hematologic	hematologic	JJ	_	3	attr	_	_
3	studies	study	NNS	_	35	ppmod	_	_
4	or	or	CC	_	3	cc	_	_
5	in	in	IN	_	8	case	_	_
6	transfusion	transfusion	NN	_	8	com	_	_
7	cross-matching	cross-matching	NN	_	8	com	_	_
8	procedures	procedure	NNS	_	3	conj	_	_
9	when	when	WRB	_	13	adv	_	_
10	anti-globulin	anti-globulin	NN	_	11	com	_	_
11	tests	test	NNS	_	13	dep	_	_
12	are	be	VBP	_	13	aux	_	_
13	performed	performed	VBN	_	8	relcl	_	_
14	on	on	IN	_	17	case	_	_
15	the	the	DT	_	17	det	_	_
16	minor	minor	JJ	_	17	attr	_	_
17	side	side	NN	_	13	ppmod	_	_
18	or	or	CC	_	17	cc	_	_
19	in	in	IN	_	21	case	_	_
20	Coombs	coombs	NN	_	21	com	_	_
21	testing	testing	NN	_	17	conj	_	_
22	of	of	IN	_	23	case	_	_
23	newborns	newborn	NNS	_	21	ppmod	_	_
24	whose	whose	WP$	_	25	poss	_	_
25	mothers	mother	NNS	_	27	dep	_	_
26	have	have	VBP	_	27	aux	_	_
27	received	receive	VBN	_	23	relcl	_	_
28	drug1	drug0	NN	_	27	obj	_	_
29	before	before	IN	_	30	case	_	_
30	parturition	parturition	NN	_	27	ppmod	_	_
31	,	,	,	_	35	p	_	_
32	it	it	PRP	_	35	dep	_	_
33	should	should	MD	_	35	modal	_	_
34	be	be	VB	_	35	aux	_	_
35	recognized	recognize	VBN	_	0	root	_	_
36	that	that	IN	_	42	mark	_	_
37	a	a	DT	_	40	det	_	_
38	positive	positive	JJ	_	40	attr	_	_
39	Coombs	coombs	NN	_	40	com	_	_
40	test	test	NN	_	42	dep	_	_
41	may	may	MD	_	42	modal	_	_
42	be	be	VB	_	35	comp	_	_
43	due	due	JJ	_	42	dep	_	_
44	to	to	TO	_	46	aux	_	_
45	the	the	DT	_	46	det	_	_
46	drug	drug	NN	_	43	ppmod	_	_
47	.	.	.	_	35	p	_	_

1	Drug/Laboratory	drug/laboratory	JJ	_	3	attr	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	5	dep	_	_
4	None	none	NN	_	5	dep	_	_
5	known	know	VBN	_	0	root	_	_
6	.	.	.	_	5	p	_	_

1	Drug-Drug	drug-drug	JJ	_	2	attr	_	_
2	Interactions	interaction	NNS	_	3	com	_	_
3	drug1	drug0	NN	_	10	comp	_	_
4	:	:	:	_	10	p	_	_
5	Concomitant	concomitant	JJ	_	6	attr	_	_
6	use	use	NN	_	10	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	is	be	VBZ	_	10	aux	_	_
10	contraindicated	contraindicate	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	25	dep	_	_
2	at	at	IN	_	4	case	_	_
3	400	0	CD	_	4	num	_	_
4	mg	mg	NN	_	1	ppmod	_	_
5	BID	bid	JJ	_	4	attr	_	_
6	(	-lrb-	-LRB-	_	10	p	_	_
7	the	the	DT	_	10	det	_	_
8	usual	usual	JJ	_	10	attr	_	_
9	prescription	prescription	NN	_	10	com	_	_
10	dose	dose	NN	_	4	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	co-administered	co-administered	VBN	_	4	acl	_	_
13	with	with	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	(	-lrb-	-LRB-	_	17	p	_	_
16	500	0	CD	_	17	num	_	_
17	mcg	mcg	NN	_	14	prn	_	_
18	BID	bid	JJ	_	17	attr	_	_
19	)	-rrb-	-RRB-	_	17	p	_	_
20	for	for	IN	_	22	case	_	_
21	7	0	CD	_	22	num	_	_
22	days	day	NNS	_	1	ppmod	_	_
23	has	have	VBZ	_	25	aux	_	_
24	been	be	VBN	_	25	aux	_	_
25	shown	show	VBN	_	0	root	_	_
26	to	to	TO	_	27	aux	_	_
27	increase	increase	VB	_	25	comp	_	_
28	drug3	drug0	NN	_	30	com	_	_
29	plasma	plasma	NN	_	30	com	_	_
30	levels	level	NNS	_	27	obj	_	_
31	by	by	IN	_	32	case	_	_
32	58	0	CD	_	27	ppmod	_	_
33	%	%	NN	_	32	meta	_	_
34	.	.	.	_	25	p	_	_

1	drug1	drug0	NN	_	12	dep	_	_
2	at	at	IN	_	3	case	_	_
3	doses	dose	NNS	_	1	ppmod	_	_
4	of	of	IN	_	7	case	_	_
5	100	0	CD	_	6	num	_	_
6	mg	mg	NN	_	7	com	_	_
7	BID	bid	NN	_	3	ppmod	_	_
8	(	-lrb-	-LRB-	_	10	p	_	_
9	OTC	otc	NN	_	10	com	_	_
10	dose	dose	NN	_	7	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	resulted	result	VBD	_	0	root	_	_
13	in	in	IN	_	17	case	_	_
14	a	a	DT	_	17	det	_	_
15	13	0	CD	_	17	num	_	_
16	%	%	NN	_	15	meta	_	_
17	increase	increase	NN	_	12	ppmod	_	_
18	in	in	IN	_	21	case	_	_
19	drug2	drug0	NN	_	21	com	_	_
20	plasma	plasma	NN	_	21	com	_	_
21	levels	level	NNS	_	17	ppmod	_	_
22	(	-lrb-	-LRB-	_	26	p	_	_
23	500	0	CD	_	26	num	_	_
24	mcg	mcg	NN	_	26	attr	_	_
25	single	single	JJ	_	26	attr	_	_
26	dose	dose	NN	_	21	prn	_	_
27	)	-rrb-	-RRB-	_	26	p	_	_
28	.	.	.	_	12	p	_	_

1	No	no	DT	_	2	det	_	_
2	studies	study	NNS	_	5	dep	_	_
3	have	have	VBP	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	conducted	conduct	VBN	_	0	root	_	_
6	at	at	IN	_	8	case	_	_
7	intermediate	intermediate	JJ	_	8	attr	_	_
8	doses	dose	NNS	_	5	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	5	p	_	_

1	If	if	IN	_	4	mark	_	_
2	a	a	DT	_	3	det	_	_
3	patient	patient	NN	_	4	dep	_	_
4	requires	require	VBZ	_	12	advcl	_	_
5	drug1	drug0	NN	_	4	obj	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	8	com	_	_
8	therapy	therapy	NN	_	5	conj	_	_
9	,	,	,	_	12	p	_	_
10	it	it	PRP	_	12	dep	_	_
11	is	be	VBZ	_	12	aux	_	_
12	suggested	suggest	VBN	_	0	root	_	_
13	that	that	IN	_	27	mark	_	_
14	drug3	drug0	NN	_	27	dep	_	_
15	,	,	,	_	14	p	_	_
16	drug4	drug0	NN	_	14	conj	_	_
17	,	,	,	_	16	p	_	_
18	or	or	CC	_	16	cc	_	_
19	drug5	drug0	NN	_	14	conj	_	_
20	(	-lrb-	-LRB-	_	21	p	_	_
21	drug6	drug0	NN	_	19	prn	_	_
22	and	and	CC	_	21	cc	_	_
23	drug7	drug0	NN	_	24	com	_	_
24	s	s	NN	_	21	conj	_	_
25	)	-rrb-	-RRB-	_	21	p	_	_
26	be	be	VB	_	27	aux	_	_
27	used	use	VBN	_	12	comp	_	_
28	as	as	IN	_	29	case	_	_
29	alternatives	alternative	NNS	_	27	ppmod	_	_
30	to	to	TO	_	31	aux	_	_
31	drug8	drug0	NN	_	29	ppmod	_	_
32	,	,	,	_	27	p	_	_
33	as	as	IN	_	36	mark	_	_
34	these	these	DT	_	35	det	_	_
35	agents	agent	NNS	_	36	dep	_	_
36	have	have	VBP	_	27	comp	_	_
37	no	no	DT	_	38	det	_	_
38	effect	effect	NN	_	36	obj	_	_
39	on	on	IN	_	42	case	_	_
40	the	the	DT	_	42	det	_	_
41	pharmacokinetic	pharmacokinetic	JJ	_	42	attr	_	_
42	profile	profile	NN	_	36	ppmod	_	_
43	of	of	IN	_	44	case	_	_
44	drug9	drug0	NN	_	42	ppmod	_	_
45	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Concomitant	concomitant	JJ	_	4	attr	_	_
4	use	use	NN	_	8	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	is	be	VBZ	_	8	aux	_	_
8	contraindicated	contraindicate	VBN	_	1	acl	_	_
9	.	.	.	_	1	p	_	_

1	Co-administration	co-administration	NN	_	6	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	5	case	_	_
5	drug2	drug0	NN	_	1	ppmod	_	_
6	resulted	result	VBD	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	increases	increase	NNS	_	6	ppmod	_	_
9	in	in	IN	_	13	case	_	_
10	drug3	drug0	NN	_	13	com	_	_
11	peak	peak	NN	_	13	com	_	_
12	plasma	plasma	NN	_	13	com	_	_
13	levels	level	NNS	_	8	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	42	0	CD	_	13	ppmod	_	_
16	%	%	NN	_	15	meta	_	_
17	,	,	,	_	6	p	_	_
18	although	although	IN	_	26	mark	_	_
19	overall	overall	JJ	_	20	attr	_	_
20	exposure	exposure	NN	_	26	dep	_	_
21	to	to	TO	_	22	aux	_	_
22	drug4	drug0	NN	_	20	ppmod	_	_
23	was	be	VBD	_	26	aux	_	_
24	not	not	RB	_	26	neg	_	_
25	significantly	significantly	RB	_	26	adv	_	_
26	increased	increase	VBN	_	6	comp	_	_
27	.	.	.	_	6	p	_	_

1	In	in	IN	_	3	case	_	_
2	an	an	DT	_	3	det	_	_
3	analysis	analysis	NN	_	21	ppmod	_	_
4	of	of	IN	_	7	case	_	_
5	the	the	DT	_	7	det	_	_
6	supraventricular	supraventricular	JJ	_	7	attr	_	_
7	arrhythmia	arrhythmia	NNS	_	3	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	DIAMOND	diamond	JJ	_	11	attr	_	_
10	patient	patient	NN	_	11	com	_	_
11	populations	population	NNS	_	7	conj	_	_
12	,	,	,	_	21	p	_	_
13	the	the	DT	_	15	det	_	_
14	concomitant	concomitant	JJ	_	15	attr	_	_
15	administration	administration	NN	_	21	dep	_	_
16	of	of	IN	_	17	case	_	_
17	drug1	drug0	NN	_	15	ppmod	_	_
18	with	with	IN	_	19	case	_	_
19	drug2	drug0	NN	_	15	ppmod	_	_
20	was	be	VBD	_	21	aux	_	_
21	associated	associate	VBN	_	0	root	_	_
22	with	with	IN	_	25	case	_	_
23	a	a	DT	_	25	det	_	_
24	higher	high	JJR	_	25	attr	_	_
25	occurrence	occurrence	NN	_	21	ppmod	_	_
26	of	of	IN	_	29	case	_	_
27	torsade	torsade	NN	_	29	com	_	_
28	de	de	NN	_	29	com	_	_
29	pointes	point	NNS	_	25	ppmod	_	_
30	.	.	.	_	21	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Concomitant	concomitant	JJ	_	4	attr	_	_
4	use	use	NN	_	8	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	is	be	VBZ	_	8	aux	_	_
8	contraindicated	contraindicate	VBN	_	1	acl	_	_
9	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	26	dep	_	_
2	at	at	IN	_	4	case	_	_
3	400	0	CD	_	4	num	_	_
4	mg	mg	NN	_	1	ppmod	_	_
5	daily	daily	RB	_	4	adv	_	_
6	(	-lrb-	-LRB-	_	11	p	_	_
7	the	the	DT	_	11	det	_	_
8	maximum	maximum	JJ	_	11	attr	_	_
9	approved	approved	JJ	_	11	attr	_	_
10	prescription	prescription	NN	_	11	com	_	_
11	dose	dose	NN	_	4	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	co-administered	co-administered	VBN	_	4	acl	_	_
14	with	with	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	(	-lrb-	-LRB-	_	18	p	_	_
17	500	0	CD	_	18	num	_	_
18	mcg	mcg	NN	_	15	prn	_	_
19	BID	bid	JJ	_	18	attr	_	_
20	)	-rrb-	-RRB-	_	18	p	_	_
21	for	for	IN	_	23	case	_	_
22	7	0	CD	_	23	num	_	_
23	days	day	NNS	_	1	ppmod	_	_
24	has	have	VBZ	_	26	aux	_	_
25	been	be	VBN	_	26	aux	_	_
26	shown	show	VBN	_	0	root	_	_
27	to	to	TO	_	28	aux	_	_
28	increase	increase	VB	_	26	comp	_	_
29	drug3	drug0	NN	_	30	com	_	_
30	Cmax	cmax	NN	_	28	obj	_	_
31	by	by	IN	_	32	case	_	_
32	53	0	CD	_	30	ppmod	_	_
33	%	%	NN	_	32	meta	_	_
34	in	in	IN	_	35	case	_	_
35	males	male	NNS	_	32	ppmod	_	_
36	and	and	CC	_	32	cc	_	_
37	97	0	CD	_	32	conj	_	_
38	%	%	NN	_	37	meta	_	_
39	in	in	IN	_	40	case	_	_
40	females	female	NNS	_	37	ppmod	_	_
41	,	,	,	_	30	p	_	_
42	and	and	CC	_	30	cc	_	_
43	AUC	auc	NN	_	30	conj	_	_
44	by	by	IN	_	45	case	_	_
45	41	0	CD	_	28	ppmod	_	_
46	%	%	NN	_	45	meta	_	_
47	in	in	IN	_	48	case	_	_
48	males	male	NNS	_	45	ppmod	_	_
49	and	and	CC	_	45	cc	_	_
50	69	0	CD	_	45	conj	_	_
51	%	%	NN	_	50	meta	_	_
52	in	in	IN	_	53	case	_	_
53	females	female	NNS	_	50	ppmod	_	_
54	.	.	.	_	26	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	Alone	alone	RB	_	1	adv	_	_
3	or	or	CC	_	2	cc	_	_
4	in	in	IN	_	5	case	_	_
5	Combination	combination	NN	_	2	conj	_	_
6	with	with	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	:	:	:	_	1	p	_	_
9	Concomitant	concomitant	JJ	_	10	attr	_	_
10	use	use	NN	_	20	dep	_	_
11	of	of	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	alone	alone	RB	_	10	adv	_	_
14	or	or	CC	_	13	cc	_	_
15	in	in	IN	_	16	case	_	_
16	combination	combination	NN	_	13	conj	_	_
17	with	with	IN	_	18	case	_	_
18	drug4	drug0	NN	_	16	ppmod	_	_
19	is	be	VBZ	_	20	aux	_	_
20	contraindicated	contraindicate	VBN	_	1	acl	_	_
21	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	drug2	drug0	NN	_	1	prn	_	_
4	)	-rrb-	-RRB-	_	3	p	_	_
5	Alone	alone	RB	_	1	adv	_	_
6	or	or	CC	_	5	cc	_	_
7	in	in	IN	_	8	case	_	_
8	Combination	combination	NN	_	5	conj	_	_
9	with	with	IN	_	10	case	_	_
10	drug3	drug0	NN	_	8	ppmod	_	_
11	:	:	:	_	1	p	_	_
12	Concomitant	concomitant	JJ	_	13	attr	_	_
13	use	use	NN	_	23	dep	_	_
14	of	of	IN	_	15	case	_	_
15	drug4	drug0	NN	_	13	ppmod	_	_
16	alone	alone	RB	_	13	adv	_	_
17	or	or	CC	_	16	cc	_	_
18	in	in	IN	_	19	case	_	_
19	combination	combination	NN	_	16	conj	_	_
20	with	with	IN	_	21	case	_	_
21	drug5	drug0	NN	_	19	ppmod	_	_
22	is	be	VBZ	_	23	aux	_	_
23	contraindicated	contraindicate	VBN	_	1	acl	_	_
24	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	13	dep	_	_
2	50	0	CD	_	3	num	_	_
3	mg	mg	NN	_	4	com	_	_
4	QD	qd	NN	_	1	attr	_	_
5	or	or	CC	_	1	cc	_	_
6	drug2	drug0	NN	_	11	attr	_	_
7	/	/	:	_	11	p	_	_
8	drug3	drug0	NN	_	11	attr	_	_
9	50/100	0	CD	_	11	num	_	_
10	mg	mg	NN	_	11	com	_	_
11	QD	qd	NN	_	1	conj	_	_
12	was	be	VBD	_	13	aux	_	_
13	co-administered	co-administered	VBN	_	0	root	_	_
14	with	with	IN	_	15	case	_	_
15	drug4	drug0	NN	_	13	ppmod	_	_
16	(	-lrb-	-LRB-	_	18	p	_	_
17	500	0	CD	_	18	num	_	_
18	mcg	mcg	NN	_	15	prn	_	_
19	BID	bid	JJ	_	18	attr	_	_
20	)	-rrb-	-RRB-	_	18	p	_	_
21	for	for	IN	_	23	case	_	_
22	5	0	CD	_	23	num	_	_
23	days	day	NNS	_	13	ppmod	_	_
24	(	-lrb-	-LRB-	_	27	p	_	_
25	following	follow	VBG	_	27	attr	_	_
26	2	0	CD	_	27	num	_	_
27	days	day	NNS	_	23	prn	_	_
28	of	of	IN	_	30	case	_	_
29	drug5	drug0	NN	_	30	com	_	_
30	use	use	NN	_	27	ppmod	_	_
31	at	at	IN	_	33	case	_	_
32	half	half	NN	_	33	com	_	_
33	dose	dose	NN	_	30	ppmod	_	_
34	)	-rrb-	-RRB-	_	27	p	_	_
35	.	.	.	_	13	p	_	_

1	In	in	IN	_	2	case	_	_
2	patients	patient	NNS	_	9	ppmod	_	_
3	receiving	receive	VBG	_	2	acl	_	_
4	drug1	drug0	NN	_	3	obj	_	_
5	alone	alone	RB	_	4	adv	_	_
6	,	,	,	_	9	p	_	_
7	drug2	drug0	NN	_	8	com	_	_
8	AUC	auc	NN	_	9	dep	_	_
9	increased	increase	VBD	_	0	root	_	_
10	by	by	IN	_	11	case	_	_
11	27	0	CD	_	9	ppmod	_	_
12	%	%	NN	_	11	meta	_	_
13	and	and	CC	_	11	cc	_	_
14	Cmax	cmax	NN	_	11	conj	_	_
15	by	by	IN	_	16	case	_	_
16	21	0	CD	_	9	ppmod	_	_
17	%	%	NN	_	16	meta	_	_
18	.	.	.	_	9	p	_	_

1	However	however	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	the	the	DT	_	5	det	_	_
4	pharmacodynamic	pharmacodynamic	JJ	_	5	attr	_	_
5	effect	effect	NN	_	6	dep	_	_
6	increased	increase	VBD	_	0	root	_	_
7	by	by	IN	_	8	case	_	_
8	197	0	CD	_	6	ppmod	_	_
9	%	%	NN	_	8	meta	_	_
10	(	-lrb-	-LRB-	_	12	p	_	_
11	QTc	qtc	NN	_	12	com	_	_
12	increase	increase	NN	_	8	prn	_	_
13	over	over	IN	_	14	case	_	_
14	time	time	NN	_	12	ppmod	_	_
15	)	-rrb-	-RRB-	_	12	p	_	_
16	and	and	CC	_	8	cc	_	_
17	by	by	IN	_	18	case	_	_
18	95	0	CD	_	8	conj	_	_
19	%	%	NN	_	18	meta	_	_
20	(	-lrb-	-LRB-	_	23	p	_	_
21	maximum	maximum	NN	_	23	com	_	_
22	QTc	qtc	NN	_	23	com	_	_
23	increase	increase	NN	_	18	prn	_	_
24	)	-rrb-	-RRB-	_	23	p	_	_
25	.	.	.	_	6	p	_	_

1	However	however	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	the	the	DT	_	5	det	_	_
4	pharmacodynamic	pharmacodynamic	JJ	_	5	attr	_	_
5	effect	effect	NN	_	6	dep	_	_
6	increased	increase	VBD	_	0	root	_	_
7	by	by	IN	_	8	case	_	_
8	190	0	CD	_	6	ppmod	_	_
9	%	%	NN	_	8	meta	_	_
10	(	-lrb-	-LRB-	_	12	p	_	_
11	QTc	qtc	NN	_	12	com	_	_
12	increase	increase	NN	_	8	prn	_	_
13	over	over	IN	_	14	case	_	_
14	time	time	NN	_	12	ppmod	_	_
15	)	-rrb-	-RRB-	_	12	p	_	_
16	and	and	CC	_	8	cc	_	_
17	by	by	IN	_	18	case	_	_
18	84	0	CD	_	8	conj	_	_
19	%	%	NN	_	18	meta	_	_
20	(	-lrb-	-LRB-	_	23	p	_	_
21	Maximum	maximum	NN	_	23	com	_	_
22	QTc	qtc	NN	_	23	com	_	_
23	increase	increase	NN	_	18	prn	_	_
24	)	-rrb-	-RRB-	_	23	p	_	_
25	.	.	.	_	6	p	_	_

1	The	the	DT	_	3	det	_	_
2	pharmacodynamic	pharmacodynamic	JJ	_	3	attr	_	_
3	effects	effect	NNS	_	6	dep	_	_
4	can	can	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	explained	explain	VBN	_	0	root	_	_
7	by	by	IN	_	9	case	_	_
8	a	a	DT	_	9	det	_	_
9	combination	combination	NN	_	6	ppmod	_	_
10	of	of	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	increase	increase	NN	_	9	ppmod	_	_
13	in	in	IN	_	15	case	_	_
14	drug1	drug0	NN	_	15	com	_	_
15	exposure	exposure	NN	_	12	ppmod	_	_
16	and	and	CC	_	9	cc	_	_
17	the	the	DT	_	18	det	_	_
18	reductions	reduction	NNS	_	9	conj	_	_
19	in	in	IN	_	21	case	_	_
20	serum	serum	NN	_	21	com	_	_
21	potassium	potassium	NN	_	18	ppmod	_	_
22	.	.	.	_	6	p	_	_

1	In	in	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	DIAMOND	diamond	JJ	_	4	attr	_	_
4	trials	trial	NNS	_	9	ppmod	_	_
5	,	,	,	_	9	p	_	_
6	1252	0	CD	_	7	num	_	_
7	patients	patient	NNS	_	9	dep	_	_
8	were	be	VBD	_	9	aux	_	_
9	treated	treat	VBN	_	0	root	_	_
10	with	with	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	drug2	drug0	NN	_	11	conj	_	_
14	concomitantly	concomitantly	RB	_	9	adv	_	_
15	of	of	IN	_	16	case	_	_
16	whom	whom	WP	_	18	ppmod	_	_
17	493	0	CD	_	18	num	_	_
18	died	die	VBD	_	14	comp	_	_
19	compared	compare	VBN	_	22	adv	_	_
20	to	to	TO	_	22	aux	_	_
21	508	0	CD	_	22	num	_	_
22	deaths	death	NNS	_	18	ppmod	_	_
23	among	among	IN	_	26	case	_	_
24	the	the	DT	_	26	det	_	_
25	1248	0	CD	_	26	num	_	_
26	patients	patient	NNS	_	22	ppmod	_	_
27	receiving	receive	VBG	_	26	acl	_	_
28	placebo	placebo	NN	_	27	obj	_	_
29	and	and	CC	_	28	cc	_	_
30	drug3	drug0	NN	_	28	conj	_	_
31	.	.	.	_	9	p	_	_

1	Of	of	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	229	0	CD	_	4	num	_	_
4	patients	patient	NNS	_	27	ppmod	_	_
5	who	who	WP	_	6	dep	_	_
6	had	have	VBD	_	4	relcl	_	_
7	drug1	drug0	NN	_	6	obj	_	_
8	added	add	VBN	_	7	acl	_	_
9	to	to	TO	_	12	aux	_	_
10	their	their	PRP$	_	12	poss	_	_
11	concomitant	concomitant	JJ	_	12	attr	_	_
12	medications	medication	NNS	_	8	ppmod	_	_
13	in	in	IN	_	16	case	_	_
14	the	the	DT	_	16	det	_	_
15	DIAMOND	diamond	JJ	_	16	attr	_	_
16	trials	trial	NNS	_	12	ppmod	_	_
17	,	,	,	_	27	p	_	_
18	the	the	DT	_	19	det	_	_
19	patients	patient	NNS	_	27	dep	_	_
20	on	on	IN	_	21	case	_	_
21	drug2	drug0	NN	_	19	ppmod	_	_
22	had	have	VBD	_	27	lv	_	_
23	a	a	DT	_	27	det	_	_
24	non-significantly	non-significantly	RB	_	25	adv	_	_
25	reduced	reduce	VBN	_	27	attr	_	_
26	relative	relative	JJ	_	27	attr	_	_
27	risk	risk	NN	_	0	root	_	_
28	for	for	IN	_	29	case	_	_
29	death	death	NN	_	27	ppmod	_	_
30	of	of	IN	_	31	case	_	_
31	0.68	0	CD	_	29	ppmod	_	_
32	(	-lrb-	-LRB-	_	38	p	_	_
33	95	0	CD	_	38	num	_	_
34	%	%	NN	_	33	meta	_	_
35	CI	ci	JJR	_	33	attr	_	_
36	0.376	0	CD	_	35	num	_	_
37	,	,	,	_	38	p	_	_
38	1.230	0	CD	_	27	num	_	_
39	)	-rrb-	-RRB-	_	38	p	_	_
40	.	.	.	_	27	p	_	_

1	Potential	potential	JJ	_	3	attr	_	_
2	Drug	drug	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	4	com	_	_
4	drug1	drug0	NN	_	6	dep	_	_
5	is	be	VBZ	_	6	aux	_	_
6	eliminated	eliminate	VBN	_	0	root	_	_
7	in	in	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	kidney	kidney	NN	_	6	ppmod	_	_
10	by	by	IN	_	12	case	_	_
11	cationic	cationic	NN	_	12	com	_	_
12	secretion	secretion	NN	_	6	ppmod	_	_
13	.	.	.	_	6	p	_	_

1	Inhibitors	inhibitor	NNS	_	7	dep	_	_
2	of	of	IN	_	5	case	_	_
3	renal	renal	JJ	_	5	attr	_	_
4	cationic	cationic	NN	_	5	com	_	_
5	secretion	secretion	NN	_	1	ppmod	_	_
6	are	be	VBP	_	7	aux	_	_
7	contraindicated	contraindicate	VBN	_	0	root	_	_
8	with	with	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	.	.	.	_	7	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	23	ppmod	_	_
3	,	,	,	_	23	p	_	_
4	drugs	drug	NNS	_	23	dep	_	_
5	that	that	WDT	_	8	dep	_	_
6	are	be	VBP	_	8	aux	_	_
7	actively	actively	RB	_	8	adv	_	_
8	secreted	secrete	VBN	_	4	relcl	_	_
9	via	via	IN	_	11	case	_	_
10	this	this	DT	_	11	det	_	_
11	route	route	NN	_	8	ppmod	_	_
12	(	-lrb-	-LRB-	_	15	p	_	_
13	e.g.	e.g.	FW	_	15	adv	_	_
14	,	,	,	_	15	p	_	_
15	drug1	drug0	NN	_	11	prn	_	_
16	,	,	,	_	15	p	_	_
17	drug2	drug0	NN	_	15	conj	_	_
18	and	and	CC	_	17	cc	_	_
19	drug3	drug0	NN	_	15	conj	_	_
20	)	-rrb-	-RRB-	_	15	p	_	_
21	should	should	MD	_	23	modal	_	_
22	be	be	VB	_	23	aux	_	_
23	co-administered	co-administered	VBN	_	0	root	_	_
24	with	with	IN	_	25	case	_	_
25	care	care	NN	_	23	ppmod	_	_
26	as	as	IN	_	29	mark	_	_
27	they	they	PRP	_	29	dep	_	_
28	might	might	MD	_	29	modal	_	_
29	increase	increase	VB	_	23	comp	_	_
30	drug4	drug0	NN	_	31	com	_	_
31	levels	level	NNS	_	29	obj	_	_
32	.	.	.	_	23	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	metabolized	metabolize	VBN	_	0	root	_	_
4	to	to	TO	_	7	aux	_	_
5	a	a	DT	_	7	det	_	_
6	small	small	JJ	_	7	attr	_	_
7	extent	extent	NN	_	3	ppmod	_	_
8	by	by	IN	_	11	case	_	_
9	the	the	DT	_	11	det	_	_
10	CYP3A4	cyp0a0	NN	_	11	com	_	_
11	isoenzyme	isoenzyme	NN	_	3	ppmod	_	_
12	of	of	IN	_	16	case	_	_
13	the	the	DT	_	16	det	_	_
14	cytochrome	cytochrome	NN	_	16	com	_	_
15	P450	p0	NN	_	16	com	_	_
16	system	system	NN	_	11	ppmod	_	_
17	.	.	.	_	3	p	_	_

1	Inhibitors	inhibitor	NNS	_	7	dep	_	_
2	of	of	IN	_	5	case	_	_
3	the	the	DT	_	5	det	_	_
4	CYP3A4	cyp0a0	NN	_	5	com	_	_
5	isoenzyme	isoenzyme	NN	_	1	ppmod	_	_
6	could	could	MD	_	7	modal	_	_
7	increase	increase	VB	_	0	root	_	_
8	systemic	systemic	JJ	_	10	attr	_	_
9	drug1	drug0	NN	_	10	com	_	_
10	exposure	exposure	NN	_	7	obj	_	_
11	.	.	.	_	7	p	_	_

1	Inhibitors	inhibitor	NNS	_	36	dep	_	_
2	of	of	IN	_	4	case	_	_
3	this	this	DT	_	4	det	_	_
4	isoenzyme	isoenzyme	NN	_	1	ppmod	_	_
5	(	-lrb-	-LRB-	_	8	p	_	_
6	e.g.	e.g.	FW	_	8	ppmod	_	_
7	,	,	,	_	8	p	_	_
8	drug1	drug0	NN	_	4	prn	_	_
9	,	,	,	_	8	p	_	_
10	drug2	drug0	NN	_	8	appo	_	_
11	,	,	,	_	8	p	_	_
12	drug3	drug0	NN	_	8	appo	_	_
13	,	,	,	_	8	p	_	_
14	drug4	drug0	NN	_	8	appo	_	_
15	,	,	,	_	8	p	_	_
16	drug5	drug0	NN	_	8	appo	_	_
17	,	,	,	_	8	p	_	_
18	drug6	drug0	NN	_	8	appo	_	_
19	,	,	,	_	8	p	_	_
20	drug7	drug0	NN	_	8	appo	_	_
21	,	,	,	_	8	p	_	_
22	grapefruit	grapefruit	NN	_	23	com	_	_
23	juice	juice	NN	_	8	appo	_	_
24	,	,	,	_	8	p	_	_
25	drug8	drug0	NN	_	8	appo	_	_
26	,	,	,	_	8	p	_	_
27	drug9	drug0	NN	_	8	appo	_	_
28	,	,	,	_	8	p	_	_
29	drug10	drug0	NN	_	8	appo	_	_
30	,	,	,	_	8	p	_	_
31	drug11	drug0	NN	_	8	appo	_	_
32	)	-rrb-	-RRB-	_	8	p	_	_
33	should	should	MD	_	36	modal	_	_
34	be	be	VB	_	36	aux	_	_
35	cautiously	cautiously	RB	_	36	adv	_	_
36	coadministered	coadministered	VBN	_	0	root	_	_
37	with	with	IN	_	38	case	_	_
38	drug12	drug0	NN	_	36	ppmod	_	_
39	as	as	IN	_	43	mark	_	_
40	they	they	PRP	_	43	dep	_	_
41	can	can	MD	_	43	modal	_	_
42	potentially	potentially	RB	_	43	adv	_	_
43	increase	increase	VB	_	36	comp	_	_
44	drug13	drug0	NN	_	45	com	_	_
45	levels	level	NNS	_	43	obj	_	_
46	.	.	.	_	36	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	not	not	RB	_	2	neg	_	_
4	an	an	DT	_	5	det	_	_
5	inhibitor	inhibitor	NN	_	2	obj	_	_
6	of	of	IN	_	7	case	_	_
7	CYP3A4	cyp0a0	NN	_	5	ppmod	_	_
8	nor	nor	CC	_	7	cc	_	_
9	of	of	IN	_	13	case	_	_
10	other	other	JJ	_	13	attr	_	_
11	cytochrome	cytochrome	NN	_	13	com	_	_
12	P450	p0	NN	_	13	com	_	_
13	isoenzymes	isoenzymes	NNS	_	7	conj	_	_
14	(	-lrb-	-LRB-	_	19	p	_	_
15	e.g.	e.g.	FW	_	17	adv	_	_
16	,	,	,	_	17	p	_	_
17	CYP2C9	cyp0c0	NN	_	19	ppmod	_	_
18	,	,	,	_	19	p	_	_
19	CYP2D6	cyp0d0	NNS	_	13	prn	_	_
20	)	-rrb-	-RRB-	_	19	p	_	_
21	and	and	CC	_	2	cc	_	_
22	is	be	VBZ	_	24	aux	_	_
23	not	not	RB	_	24	neg	_	_
24	expected	expect	VBN	_	2	conj	_	_
25	to	to	TO	_	26	aux	_	_
26	increase	increase	VB	_	24	comp	_	_
27	levels	level	NNS	_	26	obj	_	_
28	of	of	IN	_	29	case	_	_
29	drugs	drug	NNS	_	27	ppmod	_	_
30	metabolized	metabolize	VBN	_	29	acl	_	_
31	by	by	IN	_	32	case	_	_
32	CYP3A4	cyp0a0	NN	_	30	ppmod	_	_
33	.	.	.	_	2	p	_	_

1	Other	other	JJ	_	5	attr	_	_
2	Drug	drug	NN	_	5	com	_	_
3	Interaction	interaction	NN	_	5	com	_	_
4	Information	information	NN	_	5	com	_	_
5	drug1	drug0	NN	_	0	root	_	_
6	:	:	:	_	5	p	_	_
7	Studies	study	NNS	_	12	dep	_	_
8	in	in	IN	_	10	case	_	_
9	healthy	healthy	JJ	_	10	attr	_	_
10	volunteers	volunteer	NNS	_	7	ppmod	_	_
11	have	have	VBP	_	12	aux	_	_
12	shown	show	VBN	_	5	acl	_	_
13	that	that	IN	_	17	mark	_	_
14	drug2	drug0	NN	_	17	dep	_	_
15	does	do	VBZ	_	17	aux	_	_
16	not	not	RB	_	17	neg	_	_
17	affect	affect	VB	_	12	comp	_	_
18	the	the	DT	_	19	det	_	_
19	pharmacokinetics	pharmacokinetics	NNS	_	17	obj	_	_
20	of	of	IN	_	21	case	_	_
21	drug3	drug0	NN	_	19	ppmod	_	_
22	.	.	.	_	5	p	_	_

1	In	in	IN	_	2	case	_	_
2	patients	patient	NNS	_	12	ppmod	_	_
3	,	,	,	_	12	p	_	_
4	the	the	DT	_	6	det	_	_
5	concomitant	concomitant	JJ	_	6	attr	_	_
6	administration	administration	NN	_	12	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	with	with	IN	_	10	case	_	_
10	drug2	drug0	NN	_	6	ppmod	_	_
11	was	be	VBD	_	12	aux	_	_
12	associated	associate	VBN	_	0	root	_	_
13	with	with	IN	_	16	case	_	_
14	a	a	DT	_	16	det	_	_
15	higher	high	JJR	_	16	attr	_	_
16	occurrence	occurrence	NN	_	12	ppmod	_	_
17	of	of	IN	_	20	case	_	_
18	torsade	torsade	NN	_	20	com	_	_
19	de	de	NN	_	20	com	_	_
20	pointes	point	NNS	_	16	ppmod	_	_
21	.	.	.	_	12	p	_	_

1	It	it	PRP	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	not	not	RB	_	2	neg	_	_
4	clear	clear	JJ	_	2	dep	_	_
5	whether	whether	IN	_	7	mark	_	_
6	this	this	DT	_	7	dep	_	_
7	represents	represent	VBZ	_	2	comp	_	_
8	an	an	DT	_	9	det	_	_
9	interaction	interaction	NN	_	7	obj	_	_
10	with	with	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	or	or	CC	_	9	cc	_	_
13	the	the	DT	_	14	det	_	_
14	presence	presence	NN	_	9	conj	_	_
15	of	of	IN	_	20	case	_	_
16	more	more	RBR	_	17	adv	_	_
17	severe	severe	JJ	_	18	adv	_	_
18	structural	structural	JJ	_	20	attr	_	_
19	heart	heart	NN	_	20	com	_	_
20	disease	disease	NN	_	14	ppmod	_	_
21	in	in	IN	_	22	case	_	_
22	patients	patient	NNS	_	14	ppmod	_	_
23	on	on	IN	_	24	case	_	_
24	drug2	drug0	NN	_	22	ppmod	_	_
25	;	;	:	_	2	p	_	_

1	structural	structural	JJ	_	3	attr	_	_
2	heart	heart	NN	_	3	com	_	_
3	disease	disease	NN	_	4	dep	_	_
4	is	be	VBZ	_	0	root	_	_
5	a	a	DT	_	8	det	_	_
6	known	known	JJ	_	8	attr	_	_
7	risk	risk	NN	_	8	com	_	_
8	factor	factor	NN	_	4	obj	_	_
9	for	for	IN	_	10	case	_	_
10	arrhythmia	arrhythmia	NN	_	8	ppmod	_	_
11	.	.	.	_	4	p	_	_

1	No	no	DT	_	2	det	_	_
2	increase	increase	NN	_	6	dep	_	_
3	in	in	IN	_	4	case	_	_
4	mortality	mortality	NN	_	2	ppmod	_	_
5	was	be	VBD	_	6	aux	_	_
6	observed	observe	VBN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	6	ppmod	_	_
9	taking	take	VBG	_	8	acl	_	_
10	drug1	drug0	NN	_	9	obj	_	_
11	as	as	IN	_	13	case	_	_
12	concomitant	concomitant	JJ	_	13	attr	_	_
13	medication	medication	NN	_	9	ppmod	_	_
14	.	.	.	_	6	p	_	_

1	Other	other	JJ	_	2	attr	_	_
2	Drugs	drug	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	In	in	IN	_	6	case	_	_
5	healthy	healthy	JJ	_	6	attr	_	_
6	volunteers	volunteer	NNS	_	42	ppmod	_	_
7	,	,	,	_	42	p	_	_
8	drug1	drug0	NN	_	42	dep	_	_
9	,	,	,	_	8	p	_	_
10	drug2	drug0	NN	_	8	conj	_	_
11	,	,	,	_	10	p	_	_
12	drug3	drug0	NN	_	8	conj	_	_
13	,	,	,	_	12	p	_	_
14	drug4	drug0	NN	_	8	conj	_	_
15	,	,	,	_	14	p	_	_
16	drug5	drug0	NN	_	8	conj	_	_
17	,	,	,	_	16	p	_	_
18	hormone	hormone	NN	_	20	com	_	_
19	replacement	replacement	NN	_	20	com	_	_
20	therapy	therapy	NN	_	8	conj	_	_
21	(	-lrb-	-LRB-	_	23	p	_	_
22	a	a	DT	_	23	det	_	_
23	combination	combination	NN	_	20	prn	_	_
24	of	of	IN	_	26	case	_	_
25	conjugated	conjugate	VBN	_	26	attr	_	_
26	drug6	drug0	NN	_	23	ppmod	_	_
27	and	and	CC	_	26	cc	_	_
28	drug7	drug0	NN	_	26	conj	_	_
29	)	-rrb-	-RRB-	_	23	p	_	_
30	,	,	,	_	20	p	_	_
31	drug8	drug0	NN	_	8	conj	_	_
32	(	-lrb-	-LRB-	_	36	p	_	_
33	drug9	drug0	CD	_	36	num	_	_
34	and	and	CC	_	33	cc	_	_
35	drug10	drug0	CD	_	33	conj	_	_
36	s	s	NNS	_	31	prn	_	_
37	)	-rrb-	-RRB-	_	36	p	_	_
38	and	and	CC	_	31	cc	_	_
39	drug11	drug0	NN	_	8	conj	_	_
40	did	do	VBD	_	42	aux	_	_
41	not	not	RB	_	42	neg	_	_
42	affect	affect	VB	_	2	acl	_	_
43	the	the	DT	_	44	det	_	_
44	pharmacokinetics	pharmacokinetics	NNS	_	42	obj	_	_
45	of	of	IN	_	46	case	_	_
46	drug12	drug0	NN	_	44	ppmod	_	_
47	.	.	.	_	2	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	9	ppmod	_	_
3	,	,	,	_	9	p	_	_
4	studies	study	NNS	_	9	dep	_	_
5	in	in	IN	_	7	case	_	_
6	healthy	healthy	JJ	_	7	attr	_	_
7	volunteers	volunteer	NNS	_	4	ppmod	_	_
8	have	have	VBP	_	9	aux	_	_
9	shown	show	VBN	_	0	root	_	_
10	that	that	IN	_	14	mark	_	_
11	drug1	drug0	NN	_	14	dep	_	_
12	does	do	VBZ	_	14	aux	_	_
13	not	not	RB	_	14	neg	_	_
14	affect	affect	VB	_	9	comp	_	_
15	the	the	DT	_	16	det	_	_
16	pharmacokinetics	pharmacokinetics	NNS	_	14	obj	_	_
17	or	or	CC	_	16	cc	_	_
18	pharmacodynamics	pharmacodynamics	NNS	_	16	conj	_	_
19	of	of	IN	_	20	case	_	_
20	drug2	drug0	NN	_	16	ppmod	_	_
21	,	,	,	_	20	p	_	_
22	or	or	CC	_	20	cc	_	_
23	the	the	DT	_	24	det	_	_
24	pharmacokinetics	pharmacokinetics	NNS	_	20	conj	_	_
25	of	of	IN	_	26	case	_	_
26	drug3	drug0	NN	_	24	ppmod	_	_
27	(	-lrb-	-LRB-	_	29	p	_	_
28	40	0	CD	_	29	num	_	_
29	mg	mg	NN	_	26	prn	_	_
30	twice	twice	RB	_	31	com	_	_
31	daily	daily	RB	_	29	adv	_	_
32	)	-rrb-	-RRB-	_	29	p	_	_
33	,	,	,	_	26	p	_	_
34	drug4	drug0	NN	_	26	conj	_	_
35	,	,	,	_	34	p	_	_
36	drug5	drug0	NN	_	26	conj	_	_
37	,	,	,	_	36	p	_	_
38	or	or	CC	_	36	cc	_	_
39	oral	oral	JJ	_	40	attr	_	_
40	drug6	drug0	NN	_	26	conj	_	_
41	.	.	.	_	9	p	_	_

1	Population	population	NN	_	3	attr	_	_
2	pharmacokinetic	pharmacokinetic	JJ	_	3	attr	_	_
3	analyses	analysis	NNS	_	5	dep	_	_
4	were	be	VBD	_	5	aux	_	_
5	conducted	conduct	VBN	_	0	root	_	_
6	on	on	IN	_	9	case	_	_
7	plasma	plasma	NN	_	9	com	_	_
8	concentration	concentration	NN	_	9	com	_	_
9	data	datum	NNS	_	5	ppmod	_	_
10	from	from	IN	_	12	case	_	_
11	1445	0	CD	_	12	num	_	_
12	patients	patient	NNS	_	9	ppmod	_	_
13	in	in	IN	_	15	case	_	_
14	clinical	clinical	JJ	_	15	attr	_	_
15	trials	trial	NNS	_	12	ppmod	_	_
16	to	to	TO	_	17	aux	_	_
17	examine	examine	VB	_	5	comp	_	_
18	the	the	DT	_	19	det	_	_
19	effects	effect	NNS	_	17	obj	_	_
20	of	of	IN	_	22	case	_	_
21	concomitant	concomitant	JJ	_	22	attr	_	_
22	medications	medication	NNS	_	19	ppmod	_	_
23	on	on	IN	_	24	case	_	_
24	clearance	clearance	NN	_	19	ppmod	_	_
25	or	or	CC	_	24	cc	_	_
26	volume	volume	NN	_	24	conj	_	_
27	of	of	IN	_	28	case	_	_
28	distribution	distribution	NN	_	24	ppmod	_	_
29	of	of	IN	_	30	case	_	_
30	drug1	drug0	NN	_	28	ppmod	_	_
31	.	.	.	_	5	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	medications	medication	NNS	_	4	dep	_	_
3	were	be	VBD	_	4	aux	_	_
4	grouped	group	VBN	_	0	root	_	_
5	as	as	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	,	,	,	_	6	p	_	_
8	oral	oral	JJ	_	9	attr	_	_
9	drug2	drug0	NN	_	6	conj	_	_
10	,	,	,	_	9	p	_	_
11	drug3	drug0	NN	_	6	conj	_	_
12	,	,	,	_	11	p	_	_
13	drug4	drug0	NN	_	6	conj	_	_
14	,	,	,	_	13	p	_	_
15	drug5	drug0	NN	_	6	conj	_	_
16	,	,	,	_	15	p	_	_
17	inducers	inducer	NNS	_	6	conj	_	_
18	of	of	IN	_	19	case	_	_
19	CYP3A4	cyp0a0	NN	_	17	ppmod	_	_
20	,	,	,	_	17	p	_	_
21	substrates	substrate	NNS	_	17	appo	_	_
22	and	and	CC	_	21	cc	_	_
23	inhibitors	inhibitor	NNS	_	21	conj	_	_
24	of	of	IN	_	25	case	_	_
25	CYP3A4	cyp0a0	NN	_	21	ppmod	_	_
26	,	,	,	_	17	p	_	_
27	substrates	substrate	NNS	_	17	appo	_	_
28	and	and	CC	_	27	cc	_	_
29	inhibitors	inhibitor	NNS	_	27	conj	_	_
30	of	of	IN	_	31	case	_	_
31	P-glycoprotein	p-glycoprotein	NN	_	29	ppmod	_	_
32	,	,	,	_	17	p	_	_
33	drug6	drug0	NN	_	6	conj	_	_
34	,	,	,	_	33	p	_	_
35	drug7	drug0	NN	_	6	conj	_	_
36	,	,	,	_	35	p	_	_
37	drug8	drug0	NN	_	6	conj	_	_
38	,	,	,	_	37	p	_	_
39	drug9	drug0	NN	_	6	conj	_	_
40	,	,	,	_	39	p	_	_
41	drug10	drug0	NN	_	6	conj	_	_
42	,	,	,	_	41	p	_	_
43	substrates	substrate	NNS	_	6	conj	_	_
44	and	and	CC	_	43	cc	_	_
45	inhibitors	inhibitor	NNS	_	43	conj	_	_
46	of	of	IN	_	50	case	_	_
47	tubular	tubular	JJ	_	50	attr	_	_
48	organic	organic	JJ	_	50	attr	_	_
49	cation	cation	NN	_	50	com	_	_
50	transport	transport	NN	_	45	ppmod	_	_
51	,	,	,	_	43	p	_	_
52	and	and	CC	_	43	cc	_	_
53	QTc-prolonging	qtc-prolonging	JJ	_	54	attr	_	_
54	drugs	drug	NNS	_	6	conj	_	_
55	.	.	.	_	4	p	_	_

1	Differences	difference	NNS	_	21	dep	_	_
2	in	in	IN	_	3	case	_	_
3	clearance	clearance	NN	_	1	ppmod	_	_
4	between	between	IN	_	5	case	_	_
5	patients	patient	NNS	_	1	ppmod	_	_
6	on	on	IN	_	8	case	_	_
7	these	these	DT	_	8	det	_	_
8	medications	medication	NNS	_	5	ppmod	_	_
9	(	-lrb-	-LRB-	_	12	p	_	_
10	at	at	IN	_	12	case	_	_
11	any	any	DT	_	12	det	_	_
12	occasion	occasion	NN	_	5	prn	_	_
13	in	in	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	study	study	NN	_	12	ppmod	_	_
16	)	-rrb-	-RRB-	_	12	p	_	_
17	and	and	CC	_	5	cc	_	_
18	those	those	DT	_	5	conj	_	_
19	off	off	RP	_	20	prt	_	_
20	medications	medication	NNS	_	18	ppmod	_	_
21	varied	vary	VBD	_	0	root	_	_
22	between	between	IN	_	23	case	_	_
23	-16	0	CD	_	21	ppmod	_	_
24	%	%	NN	_	23	meta	_	_
25	and	and	CC	_	23	cc	_	_
26	+3	0	CD	_	23	conj	_	_
27	%	%	NN	_	26	meta	_	_
28	.	.	.	_	21	p	_	_

1	The	the	DT	_	3	det	_	_
2	mean	mean	JJ	_	3	attr	_	_
3	clearances	clearance	NNS	_	6	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	were	be	VBD	_	0	root	_	_
7	16	0	CD	_	6	obj	_	_
8	%	%	NN	_	7	meta	_	_
9	and	and	CC	_	7	cc	_	_
10	15	0	CD	_	7	conj	_	_
11	%	%	NN	_	10	meta	_	_
12	lower	low	RBR	_	10	adv	_	_
13	in	in	IN	_	14	case	_	_
14	patients	patient	NNS	_	10	ppmod	_	_
15	on	on	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	and	and	CC	_	14	cc	_	_
18	inhibitors	inhibitor	NNS	_	14	conj	_	_
19	of	of	IN	_	23	case	_	_
20	tubular	tubular	JJ	_	23	attr	_	_
21	organic	organic	JJ	_	23	attr	_	_
22	cation	cation	NN	_	23	com	_	_
23	transport	transport	NN	_	18	ppmod	_	_
24	,	,	,	_	10	p	_	_
25	respectively	respectively	RB	_	7	conj	_	_
26	.	.	.	_	6	p	_	_

1	The	the	DT	_	3	det	_	_
2	CNS	cns	NN	_	3	com	_	_
3	effects	effect	NNS	_	8	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	may	may	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	enhanced	enhance	VBN	_	0	root	_	_
9	by	by	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	7	dep	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	and	and	CC	_	3	cc	_	_
5	drug3	drug0	NN	_	1	conj	_	_
6	may	may	MD	_	7	modal	_	_
7	enhance	enhance	VB	_	0	root	_	_
8	the	the	DT	_	9	det	_	_
9	effects	effect	NNS	_	7	obj	_	_
10	of	of	IN	_	14	case	_	_
11	:	:	:	_	14	p	_	_
12	other	other	JJ	_	14	attr	_	_
13	drug4	drug0	NN	_	14	com	_	_
14	s	s	NNS	_	9	ppmod	_	_
15	,	,	,	_	14	p	_	_
16	drug5	drug0	NN	_	14	appo	_	_
17	,	,	,	_	14	p	_	_
18	general	general	JJ	_	19	attr	_	_
19	drug6	drug0	NN	_	14	appo	_	_
20	,	,	,	_	14	p	_	_
21	drug7	drug0	NN	_	14	appo	_	_
22	such	such	JJ	_	24	adv	_	_
23	as	as	IN	_	24	case	_	_
24	drug8	drug0	NN	_	9	ppmod	_	_
25	,	,	,	_	24	p	_	_
26	drug9	drug0	NN	_	24	conj	_	_
27	,	,	,	_	26	p	_	_
28	or	or	CC	_	26	cc	_	_
29	other	other	JJ	_	30	attr	_	_
30	drug10	drug0	NN	_	24	conj	_	_
31	,	,	,	_	7	p	_	_
32	causing	cause	VBG	_	7	comp	_	_
33	increased	increase	VBN	_	35	attr	_	_
34	CNS	cns	NN	_	35	com	_	_
35	depression	depression	NN	_	32	obj	_	_
36	.	.	.	_	7	p	_	_

1	Drug/Laboratory	drug/laboratory	JJ	_	3	attr	_	_
2	Test	test	NN	_	3	com	_	_
3	Interactions	interaction	NNS	_	6	dep	_	_
4	drug1	drug0	NN	_	3	attr	_	_
5	may	may	MD	_	6	modal	_	_
6	produce	produce	VB	_	0	root	_	_
7	false-positive	false-positive	JJ	_	9	attr	_	_
8	test	test	NN	_	9	com	_	_
9	results	result	NNS	_	6	obj	_	_
10	for	for	IN	_	13	case	_	_
11	urinary	urinary	JJ	_	13	attr	_	_
12	5-hydroxyindoleacetic	0-hydroxyindoleacetic	JJ	_	13	attr	_	_
13	acid	acid	NN	_	9	ppmod	_	_
14	.	.	.	_	6	p	_	_

1	Use	use	NN	_	5	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	may	may	MD	_	5	modal	_	_
5	cause	cause	VB	_	0	root	_	_
6	an	an	DT	_	8	det	_	_
7	excessive	excessive	JJ	_	8	attr	_	_
8	increase	increase	NN	_	5	obj	_	_
9	in	in	IN	_	11	case	_	_
10	blood	blood	NN	_	11	com	_	_
11	pressure	pressure	NN	_	8	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	heart	heart	NN	_	14	com	_	_
14	stimulation	stimulation	NN	_	11	conj	_	_
15	.	.	.	_	5	p	_	_

1	If	if	IN	_	2	mark	_	_
2	you	you	VBN	_	5	advcl	_	_
3	are	be	VBP	_	5	aux	_	_
4	also	also	RB	_	5	adv	_	_
5	using	use	VBG	_	0	root	_	_
6	a	a	DT	_	8	det	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	inhaler	inhaler	NN	_	5	obj	_	_
9	,	,	,	_	5	p	_	_
10	take	take	VB	_	5	conj	_	_
11	drug2	drug0	NN	_	10	obj	_	_
12	first	#ord#	RB	_	10	adv	_	_
13	and	and	CC	_	10	cc	_	_
14	then	then	RB	_	15	adv	_	_
15	wait	wait	VBP	_	5	conj	_	_
16	about	about	IN	_	18	case	_	_
17	15	0	CD	_	18	num	_	_
18	minutes	minute	NNS	_	15	ppmod	_	_
19	before	before	IN	_	20	case	_	_
20	using	use	VBG	_	15	ppmod	_	_
21	the	the	DT	_	23	det	_	_
22	drug3	drug0	NN	_	23	com	_	_
23	inhaler	inhaler	NN	_	20	obj	_	_
24	.	.	.	_	5	p	_	_

1	This	this	DT	_	2	dep	_	_
2	allows	allow	VBZ	_	0	root	_	_
3	drug1	drug0	NN	_	5	dep	_	_
4	to	to	TO	_	5	aux	_	_
5	open	open	VB	_	2	comp	_	_
6	air	air	NN	_	7	com	_	_
7	passages	passage	NNS	_	5	obj	_	_
8	,	,	,	_	2	p	_	_
9	increasing	increase	VBG	_	2	comp	_	_
10	the	the	DT	_	11	det	_	_
11	effectiveness	effectiveness	NN	_	9	obj	_	_
12	of	of	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	drug2	drug0	NN	_	11	ppmod	_	_
15	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Patients	patient	NNS	_	19	dep	_	_
4	on	on	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	,	,	,	_	3	p	_	_
7	especially	especially	RB	_	3	adv	_	_
8	those	those	DT	_	3	appo	_	_
9	in	in	IN	_	10	case	_	_
10	whom	whom	WP	_	15	ppmod	_	_
11	diuretic	diuretic	JJ	_	12	attr	_	_
12	therapy	therapy	NN	_	15	dep	_	_
13	was	be	VBD	_	15	aux	_	_
14	recently	recently	RB	_	15	adv	_	_
15	instituted	institute	VBN	_	8	relcl	_	_
16	,	,	,	_	3	p	_	_
17	may	may	MD	_	19	modal	_	_
18	occasionally	occasionally	RB	_	19	adv	_	_
19	experience	experience	VBP	_	1	acl	_	_
20	an	an	DT	_	22	det	_	_
21	excessive	excessive	JJ	_	22	attr	_	_
22	reduction	reduction	NN	_	19	obj	_	_
23	of	of	IN	_	25	case	_	_
24	blood	blood	NN	_	25	com	_	_
25	pressure	pressure	NN	_	22	ppmod	_	_
26	after	after	IN	_	27	case	_	_
27	initiation	initiation	NN	_	22	ppmod	_	_
28	of	of	IN	_	29	case	_	_
29	therapy	therapy	NN	_	27	ppmod	_	_
30	with	with	IN	_	31	case	_	_
31	drug3	drug0	NN	_	27	ppmod	_	_
32	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	possibility	possibility	NN	_	10	dep	_	_
3	of	of	IN	_	5	case	_	_
4	hypotensive	hypotensive	JJ	_	5	attr	_	_
5	effects	effect	NNS	_	2	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	can	can	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	minimized	minimize	VBN	_	0	root	_	_
11	by	by	IN	_	13	case	_	_
12	either	either	CC	_	13	cc	_	_
13	discontinuing	discontinue	VBG	_	10	ppmod	_	_
14	the	the	DT	_	15	det	_	_
15	drug2	drug0	NN	_	13	obj	_	_
16	or	or	CC	_	13	cc	_	_
17	increasing	increase	VBG	_	13	conj	_	_
18	the	the	DT	_	20	det	_	_
19	salt	salt	NN	_	20	com	_	_
20	intake	intake	NN	_	17	obj	_	_
21	prior	prior	JJ	_	20	attr	_	_
22	to	to	TO	_	23	aux	_	_
23	initiation	initiation	NN	_	21	ppmod	_	_
24	of	of	IN	_	25	case	_	_
25	treatment	treatment	NN	_	23	ppmod	_	_
26	with	with	IN	_	27	case	_	_
27	drug3	drug0	NN	_	25	ppmod	_	_
28	.	.	.	_	10	p	_	_

1	If	if	IN	_	3	mark	_	_
2	this	this	DT	_	3	dep	_	_
3	is	be	VBZ	_	12	advcl	_	_
4	not	not	RB	_	3	neg	_	_
5	possible	possible	JJ	_	3	dep	_	_
6	,	,	,	_	12	p	_	_
7	the	the	DT	_	9	det	_	_
8	starting	start	VBG	_	9	attr	_	_
9	dose	dose	NN	_	12	dep	_	_
10	should	should	MD	_	12	modal	_	_
11	be	be	VB	_	12	aux	_	_
12	reduced	reduce	VBN	_	0	root	_	_
13	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	Supplements	supplement	NNS	_	7	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	drug2	drug0	NN	_	5	com	_	_
5	Lotensin	lotensin	NN	_	2	conj	_	_
6	can	can	MD	_	7	modal	_	_
7	attenuate	attenuate	VB	_	0	root	_	_
8	potassium	potassium	NN	_	9	com	_	_
9	loss	loss	NN	_	7	obj	_	_
10	caused	cause	VBN	_	9	acl	_	_
11	by	by	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	16	dep	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	drug2	drug0	NN	_	1	prn	_	_
4	,	,	,	_	3	p	_	_
5	drug3	drug0	NN	_	3	conj	_	_
6	,	,	,	_	5	p	_	_
7	drug4	drug0	NN	_	3	conj	_	_
8	,	,	,	_	7	p	_	_
9	and	and	CC	_	7	cc	_	_
10	others	other	NNS	_	3	conj	_	_
11	)	-rrb-	-RRB-	_	3	p	_	_
12	or	or	CC	_	1	cc	_	_
13	drug5	drug0	NN	_	14	com	_	_
14	supplements	supplement	NNS	_	1	conj	_	_
15	can	can	MD	_	16	modal	_	_
16	increase	increase	VB	_	0	root	_	_
17	the	the	DT	_	18	det	_	_
18	risk	risk	NN	_	16	obj	_	_
19	of	of	IN	_	20	case	_	_
20	hyperkalemia	hyperkalemia	NN	_	18	ppmod	_	_
21	.	.	.	_	16	p	_	_

1	Therefore	therefore	RB	_	15	adv	_	_
2	,	,	,	_	15	p	_	_
3	if	if	IN	_	10	mark	_	_
4	concomitant	concomitant	JJ	_	5	attr	_	_
5	use	use	NN	_	10	dep	_	_
6	of	of	IN	_	8	case	_	_
7	such	such	JJ	_	8	attr	_	_
8	agents	agent	NNS	_	5	ppmod	_	_
9	is	be	VBZ	_	10	aux	_	_
10	indicated	indicate	VBN	_	15	advcl	_	_
11	,	,	,	_	15	p	_	_
12	they	they	PRP	_	15	dep	_	_
13	should	should	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	given	give	VBN	_	0	root	_	_
16	with	with	IN	_	17	case	_	_
17	caution	caution	NN	_	15	ppmod	_	_
18	,	,	,	_	15	p	_	_
19	and	and	CC	_	15	cc	_	_
20	the	the	DT	_	21	det	_	_
21	patient	patient	NN	_	24	poss	_	_
22	's	's	POS	_	21	case	_	_
23	serum	serum	NN	_	24	com	_	_
24	potassium	potassium	NN	_	27	dep	_	_
25	should	should	MD	_	27	modal	_	_
26	be	be	VB	_	27	aux	_	_
27	monitored	monitor	VBN	_	15	conj	_	_
28	frequently	frequently	RB	_	27	adv	_	_
29	.	.	.	_	15	p	_	_

1	Oral	oral	JJ	_	4	attr	_	_
2	drug1	drug0	NN	_	4	com	_	_
3	Interaction	interaction	NN	_	4	com	_	_
4	studies	study	NNS	_	9	dep	_	_
5	with	with	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	failed	fail	VBD	_	0	root	_	_
10	to	to	TO	_	11	aux	_	_
11	identify	identify	VB	_	9	comp	_	_
12	any	any	DT	_	15	det	_	_
13	clinically	clinically	RB	_	14	adv	_	_
14	important	important	JJ	_	15	attr	_	_
15	effects	effect	NNS	_	11	obj	_	_
16	on	on	IN	_	19	case	_	_
17	the	the	DT	_	19	det	_	_
18	serum	serum	NN	_	19	com	_	_
19	concentrations	concentration	NNS	_	15	ppmod	_	_
20	or	or	CC	_	19	cc	_	_
21	clinical	clinical	JJ	_	22	attr	_	_
22	effects	effect	NNS	_	19	conj	_	_
23	of	of	IN	_	25	case	_	_
24	these	these	DT	_	25	det	_	_
25	drug4	drug0	NNS	_	19	ppmod	_	_
26	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Increased	increase	VBN	_	6	attr	_	_
4	serum	serum	NN	_	6	com	_	_
5	drug2	drug0	NN	_	6	com	_	_
6	levels	level	NNS	_	14	dep	_	_
7	and	and	CC	_	6	cc	_	_
8	symptoms	symptom	NNS	_	6	conj	_	_
9	of	of	IN	_	11	case	_	_
10	drug3	drug0	NN	_	11	com	_	_
11	toxicity	toxicity	NN	_	6	ppmod	_	_
12	have	have	VBP	_	14	aux	_	_
13	been	be	VBN	_	14	aux	_	_
14	reported	report	VBN	_	1	acl	_	_
15	in	in	IN	_	16	case	_	_
16	patients	patient	NNS	_	14	ppmod	_	_
17	receiving	receive	VBG	_	16	acl	_	_
18	drug4	drug0	NN	_	17	obj	_	_
19	during	during	IN	_	20	case	_	_
20	therapy	therapy	NN	_	17	ppmod	_	_
21	with	with	IN	_	22	case	_	_
22	drug5	drug0	NN	_	20	ppmod	_	_
23	.	.	.	_	1	p	_	_

1	These	these	DT	_	2	det	_	_
2	drugs	drug	NNS	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	coadministered	coadministered	VBN	_	0	root	_	_
6	with	with	IN	_	7	case	_	_
7	caution	caution	NN	_	5	ppmod	_	_
8	,	,	,	_	5	p	_	_
9	and	and	CC	_	5	cc	_	_
10	frequent	frequent	JJ	_	11	attr	_	_
11	monitoring	monitoring	NN	_	17	dep	_	_
12	of	of	IN	_	15	case	_	_
13	serum	serum	NN	_	15	com	_	_
14	drug1	drug0	NN	_	15	com	_	_
15	levels	level	NNS	_	11	ppmod	_	_
16	is	be	VBZ	_	17	aux	_	_
17	recommended	recommend	VBN	_	5	conj	_	_
18	.	.	.	_	5	p	_	_

1	If	if	IN	_	6	mark	_	_
2	a	a	DT	_	3	det	_	_
3	drug1	drug0	NN	_	6	dep	_	_
4	is	be	VBZ	_	6	aux	_	_
5	also	also	RB	_	6	adv	_	_
6	used	use	VBN	_	15	advcl	_	_
7	,	,	,	_	15	p	_	_
8	the	the	DT	_	9	det	_	_
9	risk	risk	NN	_	15	dep	_	_
10	of	of	IN	_	12	case	_	_
11	drug2	drug0	NN	_	12	com	_	_
12	toxicity	toxicity	NN	_	9	ppmod	_	_
13	may	may	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	increased	increase	VBN	_	0	root	_	_
16	.	.	.	_	15	p	_	_

1	Other	other	JJ	_	2	attr	_	_
2	No	no	NN	_	7	dep	_	_
3	clinically	clinically	RB	_	4	adv	_	_
4	important	important	JJ	_	6	attr	_	_
5	pharmacokinetic	pharmacokinetic	JJ	_	6	attr	_	_
6	interactions	interaction	NNS	_	7	dep	_	_
7	occurred	occur	VBD	_	0	root	_	_
8	when	when	WRB	_	11	adv	_	_
9	drug1	drug0	NN	_	11	dep	_	_
10	was	be	VBD	_	11	aux	_	_
11	administered	administer	VBN	_	7	comp	_	_
12	concomitantly	concomitantly	RB	_	11	adv	_	_
13	with	with	IN	_	14	case	_	_
14	drug2	drug0	NN	_	11	ppmod	_	_
15	,	,	,	_	14	p	_	_
16	drug3	drug0	NN	_	14	conj	_	_
17	,	,	,	_	16	p	_	_
18	drug4	drug0	NN	_	14	conj	_	_
19	,	,	,	_	18	p	_	_
20	drug5	drug0	NN	_	14	conj	_	_
21	,	,	,	_	20	p	_	_
22	drug6	drug0	NN	_	14	conj	_	_
23	,	,	,	_	22	p	_	_
24	drug7	drug0	NN	_	14	conj	_	_
25	,	,	,	_	24	p	_	_
26	drug8	drug0	NN	_	14	conj	_	_
27	,	,	,	_	26	p	_	_
28	or	or	CC	_	26	cc	_	_
29	drug9	drug0	NN	_	14	conj	_	_
30	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	used	use	VBN	_	0	root	_	_
5	concomitantly	concomitantly	RB	_	19	adv	_	_
6	with	with	IN	_	7	case	_	_
7	drug2	drug0	NN	_	19	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	drug3	drug0	NN	_	7	conj	_	_
10	,	,	,	_	9	p	_	_
11	drug4	drug0	NN	_	7	conj	_	_
12	,	,	,	_	11	p	_	_
13	drug5	drug0	NN	_	7	conj	_	_
14	,	,	,	_	13	p	_	_
15	and	and	CC	_	13	cc	_	_
16	drug6	drug0	NN	_	7	conj	_	_
17	,	,	,	_	19	p	_	_
18	without	without	IN	_	19	case	_	_
19	evidence	evidence	NN	_	4	ppmod	_	_
20	of	of	IN	_	24	case	_	_
21	clinically	clinically	RB	_	22	adv	_	_
22	important	important	JJ	_	24	attr	_	_
23	adverse	adverse	JJ	_	24	attr	_	_
24	interactions	interaction	NNS	_	19	ppmod	_	_
25	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	8	dep	_	_
2	,	,	,	_	8	p	_	_
3	like	like	IN	_	5	case	_	_
4	other	other	JJ	_	5	attr	_	_
5	drug2	drug0	NNS	_	8	ppmod	_	_
6	,	,	,	_	8	p	_	_
7	has	have	VBZ	_	8	aux	_	_
8	had	have	VBD	_	0	root	_	_
9	less	less	JJR	_	8	dep	_	_
10	than	than	IN	_	12	case	_	_
11	additive	additive	JJ	_	12	attr	_	_
12	effects	effect	NNS	_	9	ppmod	_	_
13	with	with	IN	_	14	case	_	_
14	drug3	drug0	NN	_	12	ppmod	_	_
15	,	,	,	_	8	p	_	_
16	presumably	presumably	RB	_	20	adv	_	_
17	because	because	IN	_	20	mark	_	_
18	both	both	DT	_	19	det	_	_
19	drugs	drug	NNS	_	20	dep	_	_
20	lower	low	JJR	_	8	comp	_	_
21	blood	blood	NN	_	22	com	_	_
22	pressure	pressure	NN	_	20	obj	_	_
23	by	by	IN	_	24	case	_	_
24	inhibiting	inhibit	VBG	_	20	ppmod	_	_
25	parts	part	NNS	_	24	obj	_	_
26	of	of	IN	_	29	case	_	_
27	the	the	DT	_	29	det	_	_
28	renin-angiotensin	renin-angiotensin	JJ	_	29	attr	_	_
29	system	system	NN	_	25	ppmod	_	_

1	.	.	.	_	0	root	_	_

1	fucking	fucking	NN	_	3	attr	_	_
2	empty	empty	JJ	_	3	attr	_	_
3	sentence	sentence	NN	_	0	root	_	_

1	Elevated	elevated	JJ	_	3	attr	_	_
2	plasma	plasma	NN	_	3	com	_	_
3	levels	level	NNS	_	8	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	have	have	VBP	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	reported	report	VBN	_	0	root	_	_
9	with	with	IN	_	11	case	_	_
10	concomitant	concomitant	JJ	_	11	attr	_	_
11	use	use	NN	_	8	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	some	some	DT	_	14	det	_	_
14	drug2	drug0	NNS	_	11	ppmod	_	_
15	.	.	.	_	8	p	_	_

1	There	there	EX	_	3	dep	_	_
2	have	have	VBP	_	3	aux	_	_
3	been	be	VBN	_	0	root	_	_
4	reports	report	NNS	_	3	obj	_	_
5	of	of	IN	_	8	case	_	_
6	drug1	drug0	JJ	_	8	attr	_	_
7	-related	-related	JJ	_	8	attr	_	_
8	side-effects	side-effect	NNS	_	4	ppmod	_	_
9	in	in	IN	_	10	case	_	_
10	patients	patient	NNS	_	8	ppmod	_	_
11	on	on	IN	_	13	case	_	_
12	concomitant	concomitant	JJ	_	13	attr	_	_
13	drug2	drug0	NN	_	10	ppmod	_	_
14	-	-	CC	_	13	cc	_	_
15	drug3	drug0	NN	_	16	com	_	_
16	therapy	therapy	NN	_	13	conj	_	_
17	.	.	.	_	3	p	_	_

1	Therefore	therefore	RB	_	10	adv	_	_
2	,	,	,	_	10	p	_	_
3	monitoring	monitoring	NN	_	10	dep	_	_
4	of	of	IN	_	7	case	_	_
5	drug1	drug0	NN	_	7	com	_	_
6	plasma	plasma	NN	_	7	com	_	_
7	levels	level	NNS	_	3	ppmod	_	_
8	should	should	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	considered	consider	VBN	_	0	root	_	_
11	and	and	CC	_	10	cc	_	_
12	dosage	dosage	NN	_	15	dep	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	adjusted	adjust	VBN	_	10	conj	_	_
16	as	as	IN	_	17	case	_	_
17	required	require	VBN	_	15	ppmod	_	_
18	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	have	have	VBP	_	5	aux	_	_
3	also	also	RB	_	5	adv	_	_
4	been	be	VBN	_	5	aux	_	_
5	shown	show	VBN	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	interfere	interfere	VB	_	5	comp	_	_
8	with	with	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	metabolism	metabolism	NN	_	7	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	5	p	_	_

1	This	this	DT	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	lead	lead	VB	_	0	root	_	_
4	to	to	TO	_	6	aux	_	_
5	reduced	reduce	VBN	_	6	attr	_	_
6	clearance	clearance	NN	_	3	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	6	cc	_	_
10	a	a	DT	_	11	det	_	_
11	prolongation	prolongation	NN	_	6	conj	_	_
12	of	of	IN	_	15	case	_	_
13	its	its	PRP$	_	15	poss	_	_
14	plasma	plasma	NN	_	15	com	_	_
15	half-life	half-life	NN	_	11	ppmod	_	_
16	.	.	.	_	3	p	_	_

1	Although	although	IN	_	7	mark	_	_
2	this	this	DT	_	3	det	_	_
3	interaction	interaction	NN	_	7	dep	_	_
4	has	have	VBZ	_	7	aux	_	_
5	not	not	RB	_	7	neg	_	_
6	been	be	VBN	_	7	aux	_	_
7	reported	report	VBN	_	14	advcl	_	_
8	with	with	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	14	p	_	_
11	caution	caution	NN	_	14	dep	_	_
12	should	should	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	exercised	exercise	VBN	_	0	root	_	_
15	when	when	WRB	_	18	adv	_	_
16	drug2	drug0	NN	_	18	dep	_	_
17	is	be	VBZ	_	18	aux	_	_
18	given	give	VBN	_	14	comp	_	_
19	concomitantly	concomitantly	RB	_	18	adv	_	_
20	with	with	IN	_	23	case	_	_
21	drug3	drug0	NN	_	23	attr	_	_
22	-containing	-containing	JJ	_	23	attr	_	_
23	products	product	NNS	_	18	ppmod	_	_
24	.	.	.	_	14	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	or	or	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	substantially	substantially	RB	_	5	adv	_	_
5	interfere	interfere	VBP	_	0	root	_	_
6	with	with	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	absorption	absorption	NN	_	5	ppmod	_	_
9	of	of	IN	_	11	case	_	_
10	some	some	DT	_	11	det	_	_
11	drug3	drug0	NN	_	8	ppmod	_	_
12	,	,	,	_	5	p	_	_
13	resulting	result	VBG	_	5	comp	_	_
14	in	in	IN	_	17	case	_	_
15	low	low	JJ	_	17	attr	_	_
16	urine	urine	NN	_	17	com	_	_
17	levels	level	NNS	_	13	ppmod	_	_
18	.	.	.	_	5	p	_	_

1	Also	also	RB	_	31	adv	_	_
2	,	,	,	_	31	p	_	_
3	concomitant	concomitant	JJ	_	4	attr	_	_
4	administration	administration	NN	_	31	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	with	with	IN	_	8	case	_	_
8	products	product	NNS	_	4	ppmod	_	_
9	containing	contain	VBG	_	8	acl	_	_
10	drug2	drug0	NN	_	9	obj	_	_
11	,	,	,	_	10	p	_	_
12	drug3	drug0	NN	_	14	com	_	_
13	containing	containing	NN	_	14	com	_	_
14	drug4	drug0	NN	_	10	conj	_	_
15	,	,	,	_	14	p	_	_
16	or	or	CC	_	14	cc	_	_
17	drug5	drug0	NN	_	22	attr	_	_
18	(	-lrb-	-LRB-	_	22	p	_	_
19	drug6	drug0	NN	_	22	attr	_	_
20	)	-rrb-	-RRB-	_	22	p	_	_
21	chewable/buffered	chewable/buffered	JJ	_	22	attr	_	_
22	tablets	tablet	NNS	_	10	conj	_	_
23	or	or	CC	_	22	cc	_	_
24	the	the	DT	_	26	det	_	_
25	pediatric	pediatric	JJ	_	26	attr	_	_
26	powder	powder	NN	_	10	conj	_	_
27	for	for	IN	_	29	case	_	_
28	oral	oral	JJ	_	29	attr	_	_
29	solution	solution	NN	_	26	ppmod	_	_
30	may	may	MD	_	31	modal	_	_
31	result	result	VB	_	0	root	_	_
32	in	in	IN	_	35	case	_	_
33	low	low	JJ	_	35	attr	_	_
34	urine	urine	NN	_	35	com	_	_
35	levels	level	NNS	_	31	ppmod	_	_
36	.	.	.	_	31	p	_	_

1	drug1	drug0	NN	_	7	dep	_	_
2	,	,	,	_	1	p	_	_
3	including	include	VBG	_	4	adv	_	_
4	drug2	drug0	NN	_	1	ppmod	_	_
5	,	,	,	_	1	p	_	_
6	may	may	MD	_	7	modal	_	_
7	enhance	enhance	VB	_	0	root	_	_
8	the	the	DT	_	9	det	_	_
9	effects	effect	NNS	_	7	obj	_	_
10	of	of	IN	_	12	case	_	_
11	oral	oral	JJ	_	12	attr	_	_
12	drug3	drug0	NN	_	9	ppmod	_	_
13	,	,	,	_	7	p	_	_
14	such	such	JJ	_	16	adv	_	_
15	as	as	IN	_	16	case	_	_
16	drug4	drug0	NN	_	7	ppmod	_	_
17	or	or	CC	_	16	cc	_	_
18	its	its	PRP$	_	19	poss	_	_
19	derivatives	derivative	NNS	_	16	conj	_	_
20	.	.	.	_	7	p	_	_

1	When	when	WRB	_	5	adv	_	_
2	these	these	DT	_	3	det	_	_
3	products	product	NNS	_	5	dep	_	_
4	are	be	VBP	_	5	aux	_	_
5	administered	administer	VBN	_	18	advcl	_	_
6	concomitantly	concomitantly	RB	_	5	adv	_	_
7	,	,	,	_	18	p	_	_
8	prothrombin	prothrombin	NN	_	9	com	_	_
9	time	time	NN	_	18	dep	_	_
10	or	or	CC	_	9	cc	_	_
11	other	other	JJ	_	14	attr	_	_
12	suitable	suitable	JJ	_	14	attr	_	_
13	coagulation	coagulation	NN	_	14	com	_	_
14	tests	test	NNS	_	9	conj	_	_
15	should	should	MD	_	18	modal	_	_
16	be	be	VB	_	18	aux	_	_
17	closely	closely	RB	_	18	adv	_	_
18	monitored	monitor	VBN	_	0	root	_	_
19	.	.	.	_	18	p	_	_

1	Seizures	seizure	NNS	_	4	dep	_	_
2	have	have	VBP	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	reported	report	VBN	_	0	root	_	_
5	in	in	IN	_	6	case	_	_
6	patients	patient	NNS	_	4	ppmod	_	_
7	taking	take	VBG	_	6	acl	_	_
8	another	another	DT	_	9	det	_	_
9	drug1	drug0	NN	_	7	obj	_	_
10	and	and	CC	_	4	cc	_	_
11	the	the	DT	_	13	det	_	_
12	drug2	drug0	NN	_	13	com	_	_
13	drug3	drug0	NN	_	4	conj	_	_
14	concurrently	concurrently	RB	_	13	adv	_	_
15	.	.	.	_	4	p	_	_

1	Animal	animal	NN	_	2	com	_	_
2	studies	study	NNS	_	4	dep	_	_
3	also	also	RB	_	4	adv	_	_
4	suggest	suggest	VBP	_	0	root	_	_
5	an	an	DT	_	7	det	_	_
6	increased	increase	VBN	_	7	attr	_	_
7	potential	potential	NN	_	4	obj	_	_
8	for	for	IN	_	9	case	_	_
9	seizures	seizure	NNS	_	7	ppmod	_	_
10	when	when	WRB	_	15	adv	_	_
11	these	these	DT	_	13	det	_	_
12	2	0	CD	_	13	num	_	_
13	drugs	drug	NNS	_	15	dep	_	_
14	are	be	VBP	_	15	aux	_	_
15	given	give	VBN	_	4	comp	_	_
16	concomitantly	concomitantly	RB	_	15	adv	_	_
17	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	not	not	RB	_	2	neg	_	_
4	approved	approved	JJ	_	2	dep	_	_
5	in	in	IN	_	8	case	_	_
6	the	the	DT	_	8	det	_	_
7	United	united	JJ	_	8	attr	_	_
8	States	state	NNS	_	2	ppmod	_	_
9	at	at	IN	_	11	case	_	_
10	this	this	DT	_	11	det	_	_
11	time	time	NN	_	2	ppmod	_	_
12	.	.	.	_	2	p	_	_

1	Physicians	physician	NNS	_	3	dep	_	_
2	are	be	VBP	_	3	aux	_	_
3	provided	provided	VBN	_	0	root	_	_
4	this	this	DT	_	5	det	_	_
5	information	information	NN	_	3	obj	_	_
6	to	to	TO	_	7	aux	_	_
7	increase	increase	VB	_	3	comp	_	_
8	awareness	awareness	NN	_	7	obj	_	_
9	of	of	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	potential	potential	NN	_	8	ppmod	_	_
12	for	for	IN	_	14	case	_	_
13	serious	serious	JJ	_	14	attr	_	_
14	interactions	interaction	NNS	_	11	ppmod	_	_
15	when	when	WRB	_	21	adv	_	_
16	drug1	drug0	NN	_	21	dep	_	_
17	and	and	CC	_	16	cc	_	_
18	certain	certain	JJ	_	19	attr	_	_
19	drug2	drug0	NN	_	16	conj	_	_
20	are	be	VBP	_	21	aux	_	_
21	administered	administer	VBN	_	7	comp	_	_
22	concomitantly	concomitantly	RB	_	21	adv	_	_
23	.	.	.	_	3	p	_	_

1	Elevated	elevated	JJ	_	4	attr	_	_
2	drug1	drug0	NN	_	4	com	_	_
3	serum	serum	NN	_	4	com	_	_
4	levels	level	NNS	_	7	dep	_	_
5	have	have	VBP	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	reported	report	VBN	_	0	root	_	_
8	with	with	IN	_	11	case	_	_
9	the	the	DT	_	11	det	_	_
10	concomitant	concomitant	JJ	_	11	attr	_	_
11	use	use	NN	_	7	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	drug3	drug0	NN	_	13	conj	_	_
16	.	.	.	_	7	p	_	_

1	Special	special	JJ	_	2	attr	_	_
2	consideration	consideration	NN	_	5	dep	_	_
3	should	should	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	given	give	VBN	_	0	root	_	_
6	to	to	TO	_	8	aux	_	_
7	the	the	DT	_	8	det	_	_
8	administration	administration	NN	_	5	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	in	in	IN	_	12	case	_	_
12	patients	patient	NNS	_	10	ppmod	_	_
13	receiving	receive	VBG	_	12	acl	_	_
14	drug2	drug0	NN	_	13	obj	_	_
15	or	or	CC	_	14	cc	_	_
16	other	other	JJ	_	17	attr	_	_
17	drugs	drug	NNS	_	14	conj	_	_
18	that	that	WDT	_	20	dep	_	_
19	could	could	MD	_	20	modal	_	_
20	cause	cause	VB	_	14	relcl	_	_
21	or	or	CC	_	20	cc	_	_
22	potentiate	potentiate	VB	_	20	conj	_	_
23	hypotension	hypotension	NN	_	22	obj	_	_
24	.	.	.	_	5	p	_	_

1	The	the	DT	_	2	det	_	_
2	administration	administration	NN	_	17	dep	_	_
3	of	of	IN	_	5	case	_	_
4	local	local	JJ	_	5	attr	_	_
5	drug1	drug0	NN	_	2	ppmod	_	_
6	containing	contain	VBG	_	5	acl	_	_
7	drug2	drug0	NN	_	6	obj	_	_
8	or	or	CC	_	7	cc	_	_
9	drug3	drug0	NN	_	7	conj	_	_
10	to	to	TO	_	11	aux	_	_
11	patients	patient	NNS	_	6	ppmod	_	_
12	receiving	receive	VBG	_	11	acl	_	_
13	drug4	drug0	NN	_	12	obj	_	_
14	or	or	CC	_	13	cc	_	_
15	drug5	drug0	NN	_	13	conj	_	_
16	may	may	MD	_	17	modal	_	_
17	produce	produce	VB	_	0	root	_	_
18	severe	severe	JJ	_	20	adv	_	_
19	,	,	,	_	20	p	_	_
20	prolonged	prolonged	JJ	_	21	attr	_	_
21	hypertension	hypertension	NN	_	17	obj	_	_
22	.	.	.	_	17	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	may	may	MD	_	5	modal	_	_
5	reduce	reduce	VB	_	0	root	_	_
6	or	or	CC	_	5	cc	_	_
7	reverse	reverse	VB	_	5	conj	_	_
8	the	the	DT	_	10	det	_	_
9	pressor	pressor	JJ	_	10	attr	_	_
10	effect	effect	NN	_	7	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	5	p	_	_

1	Concurrent	concurrent	JJ	_	2	attr	_	_
2	use	use	NN	_	9	dep	_	_
3	of	of	IN	_	5	case	_	_
4	these	these	DT	_	5	det	_	_
5	agents	agent	NNS	_	2	ppmod	_	_
6	should	should	MD	_	9	modal	_	_
7	generally	generally	RB	_	9	adv	_	_
8	be	be	VB	_	9	aux	_	_
9	avoided	avoid	VBN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	In	in	IN	_	2	case	_	_
2	situations	situation	NNS	_	12	ppmod	_	_
3	when	when	WRB	_	6	adv	_	_
4	concurrent	concurrent	JJ	_	5	attr	_	_
5	therapy	therapy	NN	_	6	dep	_	_
6	is	be	VBZ	_	2	relcl	_	_
7	necessary	necessary	JJ	_	6	dep	_	_
8	,	,	,	_	12	p	_	_
9	careful	careful	JJ	_	11	attr	_	_
10	patient	patient	NN	_	11	com	_	_
11	monitoring	monitoring	NN	_	12	dep	_	_
12	is	be	VBZ	_	0	root	_	_
13	essential	essential	JJ	_	12	dep	_	_
14	.	.	.	_	12	p	_	_

1	Concurrent	concurrent	JJ	_	2	attr	_	_
2	administration	administration	NN	_	19	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	(	-lrb-	-LRB-	_	8	p	_	_
6	for	for	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	treatment	treatment	NN	_	4	prn	_	_
9	of	of	IN	_	10	case	_	_
10	hypotension	hypotension	NN	_	8	ppmod	_	_
11	related	related	JJ	_	8	attr	_	_
12	to	to	TO	_	14	aux	_	_
13	obstetric	obstetric	JJ	_	14	attr	_	_
14	blocks	block	NNS	_	11	ppmod	_	_
15	)	-rrb-	-RRB-	_	8	p	_	_
16	and	and	CC	_	4	cc	_	_
17	drug2	drug0	NN	_	4	conj	_	_
18	may	may	MD	_	19	modal	_	_
19	cause	cause	VB	_	0	root	_	_
20	severe	severe	JJ	_	23	attr	_	_
21	,	,	,	_	23	p	_	_
22	persistent	persistent	JJ	_	23	attr	_	_
23	hypertension	hypertension	NN	_	19	obj	_	_
24	or	or	CC	_	23	cc	_	_
25	cerebrovascular	cerebrovascular	JJ	_	26	attr	_	_
26	accidents	accidents	NN	_	23	conj	_	_
27	.	.	.	_	19	p	_	_

1	Due	due	JJ	_	4	adv	_	_
2	to	to	TO	_	4	aux	_	_
3	the	the	DT	_	4	det	_	_
4	potential	potential	NN	_	14	ppmod	_	_
5	for	for	IN	_	7	case	_	_
6	additive	additive	JJ	_	7	attr	_	_
7	effects	effect	NNS	_	4	ppmod	_	_
8	,	,	,	_	14	p	_	_
9	caution	caution	NN	_	14	dep	_	_
10	and	and	CC	_	9	cc	_	_
11	careful	careful	JJ	_	12	attr	_	_
12	titration	titration	NN	_	9	conj	_	_
13	are	be	VBP	_	14	aux	_	_
14	warranted	warrant	VBN	_	0	root	_	_
15	in	in	IN	_	16	case	_	_
16	patients	patient	NNS	_	14	ppmod	_	_
17	receiving	receive	VBG	_	16	acl	_	_
18	drug1	drug0	NN	_	17	obj	_	_
19	concomitantly	concomitantly	RB	_	22	adv	_	_
20	with	with	IN	_	22	case	_	_
21	other	other	JJ	_	22	attr	_	_
22	agents	agent	NNS	_	17	ppmod	_	_
23	known	know	VBN	_	22	acl	_	_
24	to	to	TO	_	25	aux	_	_
25	affect	affect	VB	_	23	comp	_	_
26	cardiac	cardiac	JJ	_	27	attr	_	_
27	contractility	contractility	NN	_	25	obj	_	_
28	and/or	and/or	CC	_	27	cc	_	_
29	conduction	conduction	NN	_	27	conj	_	_
30	.	.	.	_	14	p	_	_

1	Pharmacologic	pharmacologic	JJ	_	2	attr	_	_
2	studies	study	NNS	_	3	dep	_	_
3	indicate	indicate	VBP	_	0	root	_	_
4	that	that	IN	_	7	mark	_	_
5	there	there	EX	_	7	dep	_	_
6	may	may	MD	_	7	modal	_	_
7	be	be	VB	_	3	comp	_	_
8	additive	additive	JJ	_	9	attr	_	_
9	effects	effect	NNS	_	7	obj	_	_
10	in	in	IN	_	11	case	_	_
11	prolonging	prolong	VBG	_	7	ppmod	_	_
12	AV	av	NN	_	13	com	_	_
13	conduction	conduction	NN	_	11	obj	_	_
14	when	when	WRB	_	15	adv	_	_
15	using	use	VBG	_	7	comp	_	_
16	drug1	drug0	NN	_	15	obj	_	_
17	or	or	CC	_	16	cc	_	_
18	drug2	drug0	NN	_	16	conj	_	_
19	concomitantly	concomitantly	RB	_	21	adv	_	_
20	with	with	IN	_	21	case	_	_
21	drug3	drug0	NN	_	16	ppmod	_	_
22	.	.	.	_	3	p	_	_

1	As	as	IN	_	4	case	_	_
2	with	with	IN	_	4	case	_	_
3	all	all	DT	_	4	det	_	_
4	drugs	drug	NNS	_	9	ppmod	_	_
5	,	,	,	_	9	p	_	_
6	care	care	NN	_	9	dep	_	_
7	should	should	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	exercised	exercise	VBN	_	0	root	_	_
10	when	when	WRB	_	11	adv	_	_
11	treating	treat	VBG	_	9	comp	_	_
12	patients	patient	NNS	_	11	obj	_	_
13	with	with	IN	_	15	case	_	_
14	multiple	multiple	JJ	_	15	attr	_	_
15	medications	medication	NNS	_	12	ppmod	_	_
16	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	both	both	CC	_	5	cc	_	_
4	a	a	DT	_	5	det	_	_
5	substrate	substrate	NN	_	2	obj	_	_
6	and	and	CC	_	5	cc	_	_
7	an	an	DT	_	8	det	_	_
8	inhibitor	inhibitor	NN	_	5	conj	_	_
9	of	of	IN	_	15	case	_	_
10	the	the	DT	_	15	det	_	_
11	cytochrome	cytochrome	NN	_	12	com	_	_
12	P-450	p-0	NN	_	15	com	_	_
13	3A4	0a0	NN	_	15	com	_	_
14	enzyme	enzyme	NN	_	15	com	_	_
15	system	system	NN	_	5	ppmod	_	_
16	.	.	.	_	2	p	_	_

1	Other	other	JJ	_	2	attr	_	_
2	drugs	drug	NNS	_	17	dep	_	_
3	that	that	WDT	_	4	dep	_	_
4	are	be	VBP	_	2	relcl	_	_
5	specific	specific	JJ	_	6	attr	_	_
6	substrates	substrate	NNS	_	4	obj	_	_
7	,	,	,	_	6	p	_	_
8	inhibitors	inhibitor	NNS	_	6	conj	_	_
9	,	,	,	_	8	p	_	_
10	or	or	CC	_	8	cc	_	_
11	inducers	inducer	NNS	_	6	conj	_	_
12	of	of	IN	_	15	case	_	_
13	the	the	DT	_	15	det	_	_
14	enzyme	enzyme	NN	_	15	com	_	_
15	system	system	NN	_	6	ppmod	_	_
16	may	may	MD	_	17	modal	_	_
17	have	have	VB	_	0	root	_	_
18	a	a	DT	_	20	det	_	_
19	significant	significant	JJ	_	20	attr	_	_
20	impact	impact	NN	_	17	obj	_	_
21	on	on	IN	_	23	case	_	_
22	the	the	DT	_	23	det	_	_
23	efficacy	efficacy	NN	_	17	ppmod	_	_
24	and	and	CC	_	23	cc	_	_
25	side	side	JJ	_	27	attr	_	_
26	effect	effect	NN	_	27	com	_	_
27	profile	profile	NN	_	23	conj	_	_
28	of	of	IN	_	29	case	_	_
29	drug1	drug0	NN	_	23	ppmod	_	_
30	.	.	.	_	17	p	_	_

1	Patients	patient	NNS	_	21	dep	_	_
2	taking	take	VBG	_	1	acl	_	_
3	other	other	JJ	_	4	attr	_	_
4	drugs	drug	NNS	_	2	obj	_	_
5	that	that	WDT	_	6	dep	_	_
6	are	be	VBP	_	4	relcl	_	_
7	substrates	substrate	NNS	_	6	obj	_	_
8	of	of	IN	_	10	case	_	_
9	CYP450	cyp0	NN	_	10	com	_	_
10	3A4	0a0	NN	_	7	ppmod	_	_
11	,	,	,	_	1	p	_	_
12	especially	especially	RB	_	1	adv	_	_
13	patients	patient	NNS	_	1	appo	_	_
14	with	with	IN	_	18	case	_	_
15	renal	renal	JJ	_	18	attr	_	_
16	and/or	and/or	CC	_	15	cc	_	_
17	hepatic	hepatic	JJ	_	15	conj	_	_
18	impairment	impairment	NN	_	13	ppmod	_	_
19	,	,	,	_	1	p	_	_
20	may	may	MD	_	21	modal	_	_
21	require	require	VBP	_	0	root	_	_
22	dosage	dosage	NN	_	23	com	_	_
23	adjustment	adjustment	NN	_	21	obj	_	_
24	when	when	WRB	_	25	adv	_	_
25	starting	start	VBG	_	21	comp	_	_
26	or	or	CC	_	25	cc	_	_
27	stopping	stop	VBG	_	25	conj	_	_
28	concomitantly	concomitantly	RB	_	29	adv	_	_
29	administered	administer	VBN	_	30	attr	_	_
30	drug1	drug0	NN	_	27	obj	_	_
31	in	in	IN	_	34	mark	_	_
32	order	order	NN	_	34	dep	_	_
33	to	to	TO	_	34	aux	_	_
34	maintain	maintain	VB	_	30	acl	_	_
35	optimum	optimum	JJ	_	38	attr	_	_
36	therapeutic	therapeutic	JJ	_	38	attr	_	_
37	blood	blood	NN	_	38	com	_	_
38	levels	level	NNS	_	34	obj	_	_
39	.	.	.	_	21	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	Controlled	controlled	JJ	_	5	attr	_	_
2	and	and	CC	_	5	cc	_	_
3	uncontrolled	uncontrolled	JJ	_	5	attr	_	_
4	domestic	domestic	JJ	_	5	attr	_	_
5	studies	study	NNS	_	6	dep	_	_
6	suggest	suggest	VBP	_	0	root	_	_
7	that	that	IN	_	17	mark	_	_
8	concomitant	concomitant	JJ	_	9	attr	_	_
9	use	use	NN	_	17	dep	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	drug2	drug0	NN	_	11	conj	_	_
14	is	be	VBZ	_	17	aux	_	_
15	usually	usually	RB	_	17	adv	_	_
16	well	well	RB	_	17	adv	_	_
17	tolerated	tolerate	VBN	_	6	comp	_	_
18	,	,	,	_	17	p	_	_
19	but	but	CC	_	17	cc	_	_
20	available	available	JJ	_	21	attr	_	_
21	data	datum	NNS	_	22	dep	_	_
22	are	be	VBP	_	17	conj	_	_
23	not	not	RB	_	22	neg	_	_
24	sufficient	sufficient	JJ	_	22	dep	_	_
25	to	to	TO	_	26	aux	_	_
26	predict	predict	VB	_	24	comp	_	_
27	the	the	DT	_	28	det	_	_
28	effects	effect	NNS	_	26	obj	_	_
29	of	of	IN	_	31	case	_	_
30	concomitant	concomitant	JJ	_	31	attr	_	_
31	treatment	treatment	NN	_	28	ppmod	_	_
32	in	in	IN	_	33	case	_	_
33	patients	patient	NNS	_	28	ppmod	_	_
34	with	with	IN	_	37	case	_	_
35	left	left	JJ	_	37	attr	_	_
36	ventricular	ventricular	JJ	_	37	attr	_	_
37	dysfunction	dysfunction	NN	_	33	ppmod	_	_
38	or	or	CC	_	37	cc	_	_
39	cardiac	cardiac	JJ	_	41	attr	_	_
40	conduction	conduction	NN	_	41	com	_	_
41	abnormalities	abnormality	NNS	_	37	conj	_	_
42	.	.	.	_	6	p	_	_

1	Administration	administration	NN	_	11	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	concomitantly	concomitantly	RB	_	6	adv	_	_
5	with	with	IN	_	6	case	_	_
6	drug2	drug0	NN	_	1	ppmod	_	_
7	in	in	IN	_	10	case	_	_
8	five	#crd#	CD	_	10	num	_	_
9	normal	normal	JJ	_	10	attr	_	_
10	volunteers	volunteer	NNS	_	6	ppmod	_	_
11	resulted	result	VBD	_	0	root	_	_
12	in	in	IN	_	15	case	_	_
13	increased	increase	VBN	_	15	attr	_	_
14	drug3	drug0	NN	_	15	com	_	_
15	levels	level	NNS	_	11	ppmod	_	_
16	in	in	IN	_	18	case	_	_
17	all	all	DT	_	18	det	_	_
18	subjects	subject	NNS	_	15	ppmod	_	_
19	and	and	CC	_	11	cc	_	_
20	bioavailability	bioavailability	NN	_	24	dep	_	_
21	of	of	IN	_	22	case	_	_
22	drug4	drug0	NN	_	20	ppmod	_	_
23	was	be	VBD	_	24	aux	_	_
24	increased	increase	VBN	_	11	conj	_	_
25	approximately	approximately	RB	_	26	adv	_	_
26	50	0	CD	_	24	obj	_	_
27	%	%	NN	_	26	meta	_	_
28	.	.	.	_	11	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	5	adv	_	_
3	,	,	,	_	5	p	_	_
4	drug1	drug0	NN	_	5	dep	_	_
5	appears	appear	VBZ	_	0	root	_	_
6	to	to	TO	_	8	aux	_	_
7	be	be	VB	_	8	aux	_	_
8	displaced	displace	VBN	_	5	comp	_	_
9	from	from	IN	_	12	case	_	_
10	its	its	PRP$	_	12	poss	_	_
11	binding	binding	NN	_	12	com	_	_
12	sites	site	NNS	_	8	ppmod	_	_
13	by	by	IN	_	14	case	_	_
14	drug2	drug0	NN	_	8	ppmod	_	_
15	.	.	.	_	5	p	_	_

1	If	if	IN	_	5	mark	_	_
2	combination	combination	NN	_	3	com	_	_
3	therapy	therapy	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	initiated	initiate	VBN	_	21	advcl	_	_
6	or	or	CC	_	5	cc	_	_
7	withdrawn	withdraw	VBN	_	5	conj	_	_
8	in	in	IN	_	9	case	_	_
9	conjunction	conjunction	NN	_	7	ppmod	_	_
10	with	with	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	,	,	,	_	21	p	_	_
13	an	an	DT	_	14	det	_	_
14	adjustment	adjustment	NN	_	21	dep	_	_
15	in	in	IN	_	18	case	_	_
16	the	the	DT	_	18	det	_	_
17	drug2	drug0	NN	_	18	com	_	_
18	dose	dose	NN	_	14	ppmod	_	_
19	may	may	MD	_	21	modal	_	_
20	be	be	VB	_	21	aux	_	_
21	warranted	warrant	VBN	_	0	root	_	_
22	.	.	.	_	21	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	A	a	DT	_	2	det	_	_
2	study	study	NN	_	8	dep	_	_
3	in	in	IN	_	6	case	_	_
4	six	#crd#	CD	_	6	num	_	_
5	healthy	healthy	JJ	_	6	attr	_	_
6	volunteers	volunteer	NNS	_	2	ppmod	_	_
7	has	have	VBZ	_	8	aux	_	_
8	shown	show	VBN	_	0	root	_	_
9	a	a	DT	_	11	det	_	_
10	significant	significant	JJ	_	11	attr	_	_
11	increase	increase	NN	_	8	obj	_	_
12	in	in	IN	_	16	case	_	_
13	peak	peak	NN	_	16	com	_	_
14	drug1	drug0	NN	_	16	com	_	_
15	plasma	plasma	NN	_	16	com	_	_
16	levels	level	NNS	_	11	ppmod	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	58	0	CD	_	16	num	_	_
19	%	%	NN	_	18	meta	_	_
20	)	-rrb-	-RRB-	_	18	p	_	_
21	and	and	CC	_	11	cc	_	_
22	AUC	auc	NN	_	11	conj	_	_
23	(	-lrb-	-LRB-	_	24	p	_	_
24	53	0	CD	_	22	num	_	_
25	%	%	NN	_	24	meta	_	_
26	)	-rrb-	-RRB-	_	24	p	_	_
27	after	after	IN	_	30	case	_	_
28	a	a	DT	_	30	det	_	_
29	1-week	0-week	JJ	_	30	attr	_	_
30	course	course	NN	_	8	ppmod	_	_
31	of	of	IN	_	34	case	_	_
32	drug2	drug0	NN	_	34	attr	_	_
33	1200	0	CD	_	34	num	_	_
34	mg/day	mg/day	NN	_	30	ppmod	_	_
35	and	and	CC	_	30	cc	_	_
36	a	a	DT	_	38	det	_	_
37	single	single	JJ	_	38	attr	_	_
38	dose	dose	NN	_	30	conj	_	_
39	of	of	IN	_	41	case	_	_
40	drug3	drug0	NN	_	41	com	_	_
41	60mg	0mg	NN	_	38	ppmod	_	_
42	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	produced	produce	VBD	_	0	root	_	_
3	smaller	small	JJR	_	5	adv	_	_
4	,	,	,	_	5	p	_	_
5	nonsignificant	nonsignificant	JJ	_	6	attr	_	_
6	increases	increase	NNS	_	2	obj	_	_
7	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	5	dep	_	_
3	may	may	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	mediated	mediate	VBN	_	0	root	_	_
6	by	by	IN	_	10	case	_	_
7	drug1	drug0	NN	_	10	attr	_	_
8	s	s	NN	_	10	attr	_	_
9	known	known	JJ	_	10	attr	_	_
10	inhibition	inhibition	NN	_	5	ppmod	_	_
11	of	of	IN	_	14	case	_	_
12	hepatic	hepatic	JJ	_	14	attr	_	_
13	cytochrome	cytochrome	NN	_	14	com	_	_
14	P-450	p-0	NN	_	10	ppmod	_	_
15	,	,	,	_	14	p	_	_
16	the	the	DT	_	18	det	_	_
17	enzyme	enzyme	NN	_	18	com	_	_
18	system	system	NN	_	14	appo	_	_
19	responsible	responsible	JJ	_	18	attr	_	_
20	for	for	IN	_	23	case	_	_
21	the	the	DT	_	23	det	_	_
22	first-pass	first-pass	NN	_	23	com	_	_
23	metabolism	metabolism	NN	_	19	ppmod	_	_
24	of	of	IN	_	25	case	_	_
25	drug2	drug0	NN	_	23	ppmod	_	_
26	.	.	.	_	5	p	_	_

1	Patients	patient	NNS	_	9	dep	_	_
2	currently	currently	RB	_	3	adv	_	_
3	receiving	receive	VBG	_	1	acl	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	therapy	therapy	NN	_	3	obj	_	_
6	should	should	MD	_	9	modal	_	_
7	be	be	VB	_	9	aux	_	_
8	carefully	carefully	RB	_	9	adv	_	_
9	monitored	monitor	VBN	_	0	root	_	_
10	for	for	IN	_	12	case	_	_
11	a	a	DT	_	12	det	_	_
12	change	change	NN	_	9	ppmod	_	_
13	in	in	IN	_	15	case	_	_
14	pharmacological	pharmacological	JJ	_	15	attr	_	_
15	effect	effect	NN	_	12	ppmod	_	_
16	when	when	WRB	_	17	adv	_	_
17	initiating	initiate	VBG	_	9	comp	_	_
18	and	and	CC	_	17	cc	_	_
19	discontinuing	discontinue	VBG	_	17	conj	_	_
20	therapy	therapy	NN	_	19	obj	_	_
21	with	with	IN	_	22	case	_	_
22	drug2	drug0	NN	_	19	ppmod	_	_
23	.	.	.	_	9	p	_	_

1	An	an	DT	_	2	det	_	_
2	adjustment	adjustment	NN	_	9	dep	_	_
3	in	in	IN	_	6	case	_	_
4	the	the	DT	_	6	det	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	dose	dose	NN	_	2	ppmod	_	_
7	may	may	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	warranted	warrant	VBN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	Administration	administration	NN	_	11	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	5	case	_	_
5	drug2	drug0	NN	_	1	ppmod	_	_
6	in	in	IN	_	10	case	_	_
7	24	0	CD	_	10	num	_	_
8	healthy	healthy	JJ	_	10	attr	_	_
9	male	male	JJ	_	10	attr	_	_
10	subjects	subject	NNS	_	1	ppmod	_	_
11	increased	increase	VBD	_	0	root	_	_
12	plasma	plasma	NN	_	14	com	_	_
13	drug3	drug0	NN	_	14	com	_	_
14	concentrations	concentration	NNS	_	11	obj	_	_
15	approximately	approximately	RB	_	16	adv	_	_
16	20	0	CD	_	14	num	_	_
17	%	%	NN	_	16	meta	_	_
18	.	.	.	_	11	p	_	_

1	Another	another	DT	_	2	det	_	_
2	investigator	investigator	NN	_	3	dep	_	_
3	found	find	VBD	_	0	root	_	_
4	no	no	DT	_	5	det	_	_
5	increase	increase	NN	_	3	obj	_	_
6	in	in	IN	_	8	case	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	levels	level	NNS	_	5	ppmod	_	_
9	in	in	IN	_	11	case	_	_
10	12	0	CD	_	11	num	_	_
11	patients	patient	NNS	_	8	ppmod	_	_
12	with	with	IN	_	15	case	_	_
13	coronary	coronary	JJ	_	15	attr	_	_
14	artery	artery	NN	_	15	com	_	_
15	disease	disease	NN	_	11	ppmod	_	_
16	.	.	.	_	3	p	_	_

1	Since	since	IN	_	4	mark	_	_
2	there	there	EX	_	4	dep	_	_
3	have	have	VBP	_	4	aux	_	_
4	been	be	VBN	_	16	advcl	_	_
5	conflicting	conflict	VBG	_	6	attr	_	_
6	results	result	NNS	_	4	obj	_	_
7	regarding	regard	VBG	_	9	adv	_	_
8	the	the	DT	_	9	det	_	_
9	effect	effect	NN	_	4	ppmod	_	_
10	of	of	IN	_	12	case	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	levels	level	NNS	_	9	ppmod	_	_
13	,	,	,	_	16	p	_	_
14	it	it	PRP	_	16	dep	_	_
15	is	be	VBZ	_	16	aux	_	_
16	recommended	recommend	VBN	_	0	root	_	_
17	that	that	IN	_	21	mark	_	_
18	drug2	drug0	NN	_	19	com	_	_
19	levels	level	NNS	_	21	dep	_	_
20	be	be	VB	_	21	aux	_	_
21	monitored	monitor	VBN	_	16	comp	_	_
22	when	when	WRB	_	23	adv	_	_
23	initiating	initiate	VBG	_	21	comp	_	_
24	,	,	,	_	23	p	_	_
25	adjusting	adjust	VBG	_	23	conj	_	_
26	,	,	,	_	25	p	_	_
27	and	and	CC	_	25	cc	_	_
28	discontinuing	discontinue	VBG	_	23	conj	_	_
29	drug3	drug0	NN	_	30	com	_	_
30	therapy	therapy	NN	_	28	obj	_	_
31	to	to	TO	_	32	aux	_	_
32	avoid	avoid	VB	_	30	acl	_	_
33	possible	possible	JJ	_	34	attr	_	_
34	over-	over-	NN	_	32	obj	_	_
35	or	or	CC	_	34	cc	_	_
36	under-digitalization	under-digitalization	NN	_	34	conj	_	_
37	.	.	.	_	16	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	The	the	DT	_	2	det	_	_
2	depression	depression	NN	_	22	dep	_	_
3	of	of	IN	_	5	case	_	_
4	cardiac	cardiac	JJ	_	5	attr	_	_
5	contractility	contractility	NN	_	2	ppmod	_	_
6	,	,	,	_	5	p	_	_
7	conductivity	conductivity	NN	_	5	conj	_	_
8	,	,	,	_	7	p	_	_
9	and	and	CC	_	7	cc	_	_
10	automaticity	automaticity	NN	_	5	conj	_	_
11	as	as	RB	_	12	com	_	_
12	well	well	RB	_	2	cc	_	_
13	as	as	IN	_	12	com	_	_
14	the	the	DT	_	16	det	_	_
15	vascular	vascular	JJ	_	16	attr	_	_
16	dilation	dilation	NN	_	2	conj	_	_
17	associated	associate	VBN	_	16	acl	_	_
18	with	with	IN	_	19	case	_	_
19	drug1	drug0	NN	_	17	ppmod	_	_
20	may	may	MD	_	22	modal	_	_
21	be	be	VB	_	22	aux	_	_
22	potentiated	potentiate	VBN	_	0	root	_	_
23	by	by	IN	_	24	case	_	_
24	drug2	drug0	NN	_	22	ppmod	_	_
25	.	.	.	_	22	p	_	_

1	When	when	WRB	_	2	adv	_	_
2	used	use	VBN	_	10	advcl	_	_
3	concomitantly	concomitantly	RB	_	2	adv	_	_
4	,	,	,	_	10	p	_	_
5	drug1	drug0	NN	_	10	dep	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	should	should	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	titrated	titrate	VBN	_	0	root	_	_
11	carefully	carefully	RB	_	10	adv	_	_
12	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	A	a	DT	_	3	det	_	_
2	pharmacokinetic	pharmacokinetic	JJ	_	3	attr	_	_
3	interaction	interaction	NN	_	10	dep	_	_
4	between	between	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	has	have	VBZ	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	observed	observe	VBN	_	0	root	_	_
11	during	during	IN	_	12	case	_	_
12	studies	study	NNS	_	10	ppmod	_	_
13	involving	involve	VBG	_	12	acl	_	_
14	renal	renal	JJ	_	18	attr	_	_
15	and	and	CC	_	14	cc	_	_
16	cardiac	cardiac	JJ	_	14	conj	_	_
17	transplant	transplant	NN	_	18	com	_	_
18	patients	patient	NNS	_	13	obj	_	_
19	.	.	.	_	10	p	_	_

1	In	in	IN	_	6	case	_	_
2	renal	renal	JJ	_	6	attr	_	_
3	and	and	CC	_	2	cc	_	_
4	cardiac	cardiac	JJ	_	2	conj	_	_
5	transplant	transplant	NN	_	6	com	_	_
6	recipients	recipient	NNS	_	20	ppmod	_	_
7	,	,	,	_	20	p	_	_
8	a	a	DT	_	9	det	_	_
9	reduction	reduction	NN	_	20	dep	_	_
10	of	of	IN	_	12	case	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	dose	dose	NN	_	9	ppmod	_	_
13	ranging	range	VBG	_	12	acl	_	_
14	from	from	IN	_	15	case	_	_
15	15	0	CD	_	13	ppmod	_	_
16	%	%	NN	_	15	meta	_	_
17	to	to	TO	_	18	aux	_	_
18	48	0	CD	_	13	ppmod	_	_
19	%	%	NN	_	18	meta	_	_
20	was	be	VBD	_	0	root	_	_
21	necessary	necessary	JJ	_	20	dep	_	_
22	to	to	TO	_	23	aux	_	_
23	maintain	maintain	VB	_	21	comp	_	_
24	drug2	drug0	NN	_	26	com	_	_
25	trough	trough	NN	_	26	com	_	_
26	concentrations	concentration	NNS	_	23	obj	_	_
27	similar	similar	JJ	_	26	attr	_	_
28	to	to	TO	_	29	aux	_	_
29	those	those	DT	_	27	ppmod	_	_
30	seen	see	VBN	_	29	acl	_	_
31	prior	prior	JJ	_	34	adv	_	_
32	to	to	TO	_	34	aux	_	_
33	the	the	DT	_	34	det	_	_
34	addition	addition	NN	_	30	ppmod	_	_
35	of	of	IN	_	36	case	_	_
36	drug3	drug0	NN	_	34	ppmod	_	_
37	.	.	.	_	20	p	_	_

1	If	if	IN	_	4	mark	_	_
2	these	these	DT	_	3	det	_	_
3	agents	agent	NNS	_	4	dep	_	_
4	are	be	VBP	_	14	advcl	_	_
5	to	to	TO	_	7	aux	_	_
6	be	be	VB	_	7	aux	_	_
7	administered	administer	VBN	_	4	comp	_	_
8	concurrently	concurrently	RB	_	7	adv	_	_
9	,	,	,	_	14	p	_	_
10	drug1	drug0	NN	_	11	com	_	_
11	concentrations	concentration	NNS	_	14	dep	_	_
12	should	should	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	monitored	monitor	VBN	_	0	root	_	_
15	,	,	,	_	14	p	_	_
16	especially	especially	RB	_	17	com	_	_
17	when	when	WRB	_	21	adv	_	_
18	drug2	drug0	NN	_	19	com	_	_
19	therapy	therapy	NN	_	21	dep	_	_
20	is	be	VBZ	_	21	aux	_	_
21	initiated	initiate	VBN	_	14	comp	_	_
22	,	,	,	_	21	p	_	_
23	adjusted	adjust	VBN	_	21	conj	_	_
24	,	,	,	_	23	p	_	_
25	or	or	CC	_	23	cc	_	_
26	discontinued	discontinue	VBN	_	21	conj	_	_
27	.	.	.	_	14	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	12	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	on	on	IN	_	8	case	_	_
6	drug2	drug0	NN	_	8	com	_	_
7	plasma	plasma	NN	_	8	com	_	_
8	concentrations	concentration	NNS	_	2	ppmod	_	_
9	has	have	VBZ	_	12	aux	_	_
10	not	not	RB	_	12	neg	_	_
11	been	be	VBN	_	12	aux	_	_
12	evaluated	evaluate	VBN	_	0	root	_	_
13	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	administration	administration	NN	_	9	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	with	with	IN	_	6	case	_	_
6	drug2	drug0	NN	_	2	ppmod	_	_
7	has	have	VBZ	_	9	aux	_	_
8	been	be	VBN	_	9	aux	_	_
9	reported	report	VBN	_	0	root	_	_
10	to	to	TO	_	11	aux	_	_
11	result	result	VB	_	9	comp	_	_
12	in	in	IN	_	15	case	_	_
13	elevated	elevated	JJ	_	15	attr	_	_
14	serum	serum	NN	_	15	com	_	_
15	levels	level	NNS	_	11	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	drug3	drug0	NN	_	15	ppmod	_	_
18	(	-lrb-	-LRB-	_	24	p	_	_
19	40	0	CD	_	24	num	_	_
20	%	%	NN	_	19	meta	_	_
21	to	to	TO	_	19	cc	_	_
22	72	0	CD	_	19	conj	_	_
23	%	%	NN	_	24	meta	_	_
24	increase	increase	NN	_	17	prn	_	_
25	)	-rrb-	-RRB-	_	24	p	_	_
26	,	,	,	_	11	p	_	_
27	resulting	result	VBG	_	11	comp	_	_
28	in	in	IN	_	29	case	_	_
29	toxicity	toxicity	NN	_	27	ppmod	_	_
30	in	in	IN	_	32	case	_	_
31	some	some	DT	_	32	det	_	_
32	cases	case	NNS	_	27	ppmod	_	_
33	.	.	.	_	9	p	_	_

1	Patients	patient	NNS	_	8	dep	_	_
2	receiving	receive	VBG	_	1	acl	_	_
3	these	these	DT	_	4	det	_	_
4	drugs	drug	NNS	_	2	obj	_	_
5	concurrently	concurrently	RB	_	8	adv	_	_
6	should	should	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	monitored	monitor	VBN	_	0	root	_	_
9	for	for	IN	_	13	case	_	_
10	a	a	DT	_	13	det	_	_
11	potential	potential	JJ	_	13	attr	_	_
12	drug	drug	NN	_	13	com	_	_
13	interaction	interaction	NN	_	8	ppmod	_	_
14	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	Studies	study	NNS	_	2	dep	_	_
2	showed	show	VBD	_	0	root	_	_
3	that	that	IN	_	5	mark	_	_
4	drug1	drug0	NN	_	5	dep	_	_
5	increased	increase	VBD	_	2	comp	_	_
6	the	the	DT	_	7	det	_	_
7	AUC	auc	NN	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	drug3	drug0	NN	_	9	conj	_	_
12	by	by	IN	_	14	case	_	_
13	3-4	0	JJ	_	14	num	_	_
14	fold	fold	NN	_	7	ppmod	_	_
15	and	and	CC	_	7	cc	_	_
16	the	the	DT	_	17	det	_	_
17	Cmax	cmax	NN	_	7	conj	_	_
18	by	by	IN	_	19	case	_	_
19	2-fold	0-fold	RB	_	5	ppmod	_	_
20	,	,	,	_	5	p	_	_
21	compared	compare	VBN	_	5	comp	_	_
22	to	to	TO	_	23	aux	_	_
23	placebo	placebo	NN	_	21	ppmod	_	_
24	.	.	.	_	2	p	_	_

1	The	the	DT	_	4	det	_	_
2	elimination	elimination	NN	_	4	com	_	_
3	half	half	NN	_	4	com	_	_
4	life	life	NN	_	10	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	also	also	RB	_	10	adv	_	_
10	increased	increase	VBD	_	0	root	_	_
11	(	-lrb-	-LRB-	_	13	p	_	_
12	1.5-2.5	0	CD	_	13	num	_	_
13	fold	fold	NN	_	10	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	during	during	IN	_	16	case	_	_
16	coadministration	coadministration	NN	_	10	ppmod	_	_
17	with	with	IN	_	18	case	_	_
18	drug3	drug0	NN	_	16	ppmod	_	_
19	.	.	.	_	10	p	_	_

1	These	these	DT	_	3	det	_	_
2	pharmacokinetic	pharmacokinetic	JJ	_	3	attr	_	_
3	effects	effect	NNS	_	9	dep	_	_
4	seen	see	VBN	_	3	acl	_	_
5	during	during	IN	_	7	case	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	coadministration	coadministration	NN	_	4	ppmod	_	_
8	can	can	MD	_	9	modal	_	_
9	result	result	VB	_	0	root	_	_
10	in	in	IN	_	13	case	_	_
11	increased	increase	VBN	_	13	attr	_	_
12	clinical	clinical	JJ	_	13	attr	_	_
13	effects	effect	NNS	_	9	ppmod	_	_
14	(	-lrb-	-LRB-	_	18	p	_	_
15	e.g.	e.g.	FW	_	18	adv	_	_
16	,	,	,	_	18	p	_	_
17	prolonged	prolonged	JJ	_	18	attr	_	_
18	sodation	sodation	NN	_	13	prn	_	_
19	)	-rrb-	-RRB-	_	18	p	_	_
20	of	of	IN	_	22	case	_	_
21	both	both	CC	_	22	cc	_	_
22	drug2	drug0	NN	_	13	ppmod	_	_
23	and	and	CC	_	22	cc	_	_
24	drug3	drug0	NN	_	22	conj	_	_
25	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	In	in	IN	_	4	case	_	_
2	a	a	DT	_	4	det	_	_
3	ten-subject	ten-subject	JJ	_	4	attr	_	_
4	study	study	NN	_	16	ppmod	_	_
5	,	,	,	_	16	p	_	_
6	coadministration	coadministration	NN	_	16	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	(	-lrb-	-LRB-	_	12	p	_	_
10	120	0	CD	_	11	num	_	_
11	mg	mg	NN	_	12	com	_	_
12	bid	bid	NN	_	8	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	with	with	IN	_	15	case	_	_
15	drug2	drug0	NN	_	6	ppmod	_	_
16	resulted	result	VBD	_	0	root	_	_
17	in	in	IN	_	21	case	_	_
18	a	a	DT	_	21	det	_	_
19	3-4	0	JJ	_	21	num	_	_
20	times	time	NNS	_	21	com	_	_
21	increase	increase	NN	_	16	ppmod	_	_
22	in	in	IN	_	25	case	_	_
23	mean	mean	JJ	_	25	attr	_	_
24	drug3	drug0	NN	_	25	com	_	_
25	AUC	auc	NN	_	21	ppmod	_	_
26	and	and	CC	_	25	cc	_	_
27	Cmax	cmax	NN	_	25	conj	_	_
28	vs.	vs.	CC	_	27	cc	_	_
29	drug4	drug0	NN	_	27	conj	_	_
30	alone	alone	RB	_	27	adv	_	_
31	;	;	:	_	16	p	_	_

1	no	no	DT	_	2	det	_	_
2	change	change	NN	_	9	dep	_	_
3	in	in	IN	_	5	case	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	AUC	auc	NN	_	2	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	Cmax	cmax	NN	_	5	conj	_	_
8	was	be	VBD	_	9	aux	_	_
9	observed	observe	VBN	_	0	root	_	_
10	during	during	IN	_	12	case	_	_
11	drug2	drug0	NN	_	12	com	_	_
12	coadministration	coadministration	NN	_	9	ppmod	_	_
13	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	3	com	_	_
2	plasma	plasma	NN	_	3	com	_	_
3	levels	level	NNS	_	7	dep	_	_
4	were	be	VBD	_	7	aux	_	_
5	not	not	RB	_	7	neg	_	_
6	significantly	significantly	RB	_	7	adv	_	_
7	affected	affect	VBN	_	0	root	_	_
8	by	by	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	or	or	CC	_	9	cc	_	_
11	drug3	drug0	NN	_	9	conj	_	_
12	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	0	root	_	_

1	Coadministration	coadministration	NN	_	6	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	5	case	_	_
5	drug2	drug0	NN	_	1	ppmod	_	_
6	lowered	lower	VBD	_	0	root	_	_
7	the	the	DT	_	10	det	_	_
8	drug3	drug0	NN	_	10	com	_	_
9	plasma	plasma	NN	_	10	com	_	_
10	concentrations	concentration	NNS	_	6	obj	_	_
11	to	to	TO	_	13	aux	_	_
12	undetectable	undetectable	JJ	_	13	attr	_	_
13	levels	level	NNS	_	6	ppmod	_	_
14	.	.	.	_	6	p	_	_

1	Coadministration	coadministration	NN	_	13	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	5	case	_	_
5	drug2	drug0	NN	_	1	ppmod	_	_
6	or	or	CC	_	5	cc	_	_
7	any	any	DT	_	10	det	_	_
8	known	known	JJ	_	10	attr	_	_
9	CYP3A4	cyp0a0	NN	_	10	com	_	_
10	inducer	inducer	NN	_	5	conj	_	_
11	should	should	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	avoided	avoid	VBN	_	0	root	_	_
14	when	when	WRB	_	15	adv	_	_
15	possible	possible	JJ	_	13	comp	_	_
16	,	,	,	_	13	p	_	_
17	and	and	CC	_	13	cc	_	_
18	alternative	alternative	JJ	_	19	attr	_	_
19	therapy	therapy	NN	_	20	dep	_	_
20	considered	consider	VBN	_	13	conj	_	_
21	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	drug2	drug0	NN	_	6	dep	_	_
3	may	may	MD	_	6	modal	_	_
4	delay	delay	VB	_	6	aux	_	_
5	or	or	CC	_	6	cc	_	_
6	reduce	reduce	VB	_	0	root	_	_
7	the	the	DT	_	8	det	_	_
8	absorption	absorption	NN	_	6	obj	_	_
9	of	of	IN	_	12	case	_	_
10	concomitant	concomitant	JJ	_	12	attr	_	_
11	oral	oral	JJ	_	12	attr	_	_
12	medication	medication	NN	_	8	ppmod	_	_
13	such	such	JJ	_	15	adv	_	_
14	as	as	IN	_	15	case	_	_
15	drug3	drug0	NN	_	12	ppmod	_	_
16	,	,	,	_	15	p	_	_
17	drug4	drug0	NN	_	15	conj	_	_
18	,	,	,	_	17	p	_	_
19	drug5	drug0	NN	_	15	conj	_	_
20	(	-lrb-	-LRB-	_	21	p	_	_
21	acidic	acidic	JJ	_	19	prn	_	_
22	)	-rrb-	-RRB-	_	21	p	_	_
23	or	or	CC	_	19	cc	_	_
24	drug6	drug0	NN	_	15	conj	_	_
25	(	-lrb-	-LRB-	_	26	p	_	_
26	basic	basic	JJ	_	15	prn	_	_
27	)	-rrb-	-RRB-	_	26	p	_	_
28	,	,	,	_	15	p	_	_
29	as	as	RB	_	30	com	_	_
30	well	well	RB	_	15	cc	_	_
31	as	as	IN	_	30	com	_	_
32	drug7	drug0	NN	_	33	com	_	_
33	drug8	drug0	NN	_	15	conj	_	_
34	,	,	,	_	33	p	_	_
35	drug9	drug0	NN	_	15	conj	_	_
36	,	,	,	_	35	p	_	_
37	thyroid	thyroid	NN	_	15	conj	_	_
38	and	and	CC	_	37	cc	_	_
39	drug10	drug0	NN	_	40	com	_	_
40	preparations	preparation	NNS	_	15	conj	_	_
41	,	,	,	_	12	p	_	_
42	drug11	drug0	CD	_	12	conj	_	_
43	and	and	CC	_	42	cc	_	_
44	drug12	drug0	CD	_	42	conj	_	_
45	,	,	,	_	42	p	_	_
46	and	and	CC	_	42	cc	_	_
47	drug13	drug0	NN	_	12	conj	_	_
48	.	.	.	_	6	p	_	_

1	Interference	interference	NN	_	11	dep	_	_
2	with	with	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	absorption	absorption	NN	_	1	ppmod	_	_
5	of	of	IN	_	8	case	_	_
6	oral	oral	JJ	_	8	attr	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	supplements	supplement	NNS	_	4	ppmod	_	_
9	has	have	VBZ	_	11	aux	_	_
10	been	be	VBN	_	11	aux	_	_
11	observed	observe	VBN	_	0	root	_	_
12	with	with	IN	_	17	case	_	_
13	another	another	DT	_	17	det	_	_
14	positively-charged	positively-charged	JJ	_	17	attr	_	_
15	bile	bile	NN	_	17	com	_	_
16	acid	acid	NN	_	17	com	_	_
17	sequestrant	sequestrant	NN	_	11	ppmod	_	_
18	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	drug2	drug0	NN	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	interfere	interfere	VB	_	0	root	_	_
5	with	with	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	pharmacokinetics	pharmacokinetics	NNS	_	4	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drugs	drug	NNS	_	7	ppmod	_	_
10	that	that	WDT	_	11	dep	_	_
11	undergo	undergo	VBP	_	9	relcl	_	_
12	enterohepatic	enterohepatic	JJ	_	13	attr	_	_
13	circulation	circulation	NN	_	11	obj	_	_
14	,	,	,	_	11	p	_	_
15	The	the	DT	_	16	det	_	_
16	discontinuance	discontinuance	NN	_	21	dep	_	_
17	of	of	IN	_	19	case	_	_
18	drug3	drug0	NN	_	19	com	_	_
19	drug4	drug0	NNS	_	16	ppmod	_	_
20	could	could	MD	_	21	modal	_	_
21	pose	pose	VB	_	11	comp	_	_
22	a	a	DT	_	23	det	_	_
23	hazard	hazard	NN	_	21	obj	_	_
24	to	to	TO	_	25	aux	_	_
25	health	health	NN	_	23	ppmod	_	_
26	if	if	IN	_	36	mark	_	_
27	a	a	DT	_	30	det	_	_
28	potentially	potentially	RB	_	29	adv	_	_
29	toxic	toxic	JJ	_	30	attr	_	_
30	drug	drug	NN	_	36	dep	_	_
31	such	such	JJ	_	33	adv	_	_
32	as	as	IN	_	33	case	_	_
33	drug5	drug0	NN	_	30	ppmod	_	_
34	has	have	VBZ	_	36	aux	_	_
35	been	be	VBN	_	36	aux	_	_
36	filtrated	filtrate	VBN	_	21	comp	_	_
37	to	to	TO	_	40	aux	_	_
38	a	a	DT	_	40	det	_	_
39	maintenance	maintenance	NN	_	40	com	_	_
40	level	level	NN	_	36	ppmod	_	_
41	while	while	IN	_	45	mark	_	_
42	the	the	DT	_	43	det	_	_
43	patient	patient	NN	_	45	dep	_	_
44	was	be	VBD	_	45	aux	_	_
45	taking	take	VBG	_	36	comp	_	_
46	drug6	drug0	NN	_	47	com	_	_
47	drug7	drug0	NN	_	45	obj	_	_
48	.	.	.	_	4	p	_	_

1	Because	because	IN	_	3	mark	_	_
2	drug1	drug0	NN	_	3	dep	_	_
3	binds	bind	VBZ	_	10	advcl	_	_
4	bile	bile	JJ	_	5	attr	_	_
5	acids	acid	NNS	_	3	obj	_	_
6	,	,	,	_	10	p	_	_
7	drug2	drug0	NN	_	8	com	_	_
8	drug3	drug0	NN	_	10	dep	_	_
9	may	may	MD	_	10	modal	_	_
10	interfere	interfere	VB	_	0	root	_	_
11	with	with	IN	_	14	case	_	_
12	normal	normal	JJ	_	14	attr	_	_
13	fat	fat	JJ	_	14	attr	_	_
14	digestion	digestion	NN	_	10	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	absorption	absorption	NN	_	14	conj	_	_
17	and	and	CC	_	10	cc	_	_
18	thus	thus	RB	_	20	adv	_	_
19	may	may	MD	_	20	modal	_	_
20	prevent	prevent	VB	_	10	conj	_	_
21	absorption	absorption	NN	_	20	obj	_	_
22	of	of	IN	_	23	case	_	_
23	drug4	drug0	NNS	_	21	ppmod	_	_
24	such	such	JJ	_	26	adv	_	_
25	as	as	IN	_	26	case	_	_
26	A	a	NN	_	23	ppmod	_	_
27	,	,	,	_	26	p	_	_
28	D	d	NN	_	26	conj	_	_
29	,	,	,	_	28	p	_	_
30	E	e	NN	_	26	conj	_	_
31	,	,	,	_	30	p	_	_
32	and	and	CC	_	30	cc	_	_
33	K	k	NN	_	26	conj	_	_
34	.	.	.	_	10	p	_	_

1	When	when	WRB	_	5	adv	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	drug2	drug0	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	given	give	VBN	_	25	advcl	_	_
6	for	for	IN	_	8	case	_	_
7	long	long	JJ	_	8	attr	_	_
8	periods	period	NNS	_	5	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	time	time	NN	_	8	ppmod	_	_
11	,	,	,	_	25	p	_	_
12	concomitant	concomitant	JJ	_	13	attr	_	_
13	supplementation	supplementation	NN	_	25	dep	_	_
14	with	with	IN	_	20	case	_	_
15	water-miscible	water-miscible	JJ	_	20	attr	_	_
16	(	-lrb-	-LRB-	_	15	p	_	_
17	or	or	CC	_	15	cc	_	_
18	parenteral	parenteral	JJ	_	15	conj	_	_
19	)	-rrb-	-RRB-	_	18	p	_	_
20	forms	form	NNS	_	13	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	drug3	drug0	NN	_	20	ppmod	_	_
23	should	should	MD	_	25	modal	_	_
24	be	be	VB	_	25	aux	_	_
25	considered	consider	VBN	_	0	root	_	_
26	.	.	.	_	25	p	_	_

1	SINCE	since	IN	_	5	mark	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	drug2	drug0	NN	_	5	dep	_	_
4	MAY	may	MD	_	5	modal	_	_
5	BIND	bind	VB	_	13	advcl	_	_
6	OTHER	other	JJ	_	7	attr	_	_
7	DRUGS	drug	NNS	_	5	obj	_	_
8	GIVEN	give	VBN	_	7	acl	_	_
9	CONCURRENTLY	concurrently	RB	_	8	adv	_	_
10	,	,	,	_	13	p	_	_
11	IT	it	PRP	_	13	dep	_	_
12	IS	be	VBZ	_	13	aux	_	_
13	RECOMMENDED	recommend	VBN	_	0	root	_	_
14	THAT	that	IN	_	16	mark	_	_
15	PATIENTS	patient	NNS	_	16	dep	_	_
16	TAKE	take	VBP	_	13	comp	_	_
17	OTHER	other	JJ	_	18	attr	_	_
18	DRUGS	drug	NNS	_	16	obj	_	_
19	AT	at	IN	_	21	case	_	_
20	LEAST	least	JJS	_	21	attr	_	_
21	1	0	CD	_	22	num	_	_
22	HOUR	hour	NN	_	18	ppmod	_	_
23	BEFORE	before	IN	_	22	case	_	_
24	OR	or	CC	_	18	cc	_	_
25	4	0	CD	_	28	num	_	_
26	TO	to	TO	_	25	cc	_	_
27	6	0	CD	_	25	conj	_	_
28	HOURS	hour	NNS	_	18	conj	_	_
29	AFTER	after	IN	_	31	case	_	_
30	drug3	drug0	NN	_	31	com	_	_
31	drug4	drug0	NN	_	28	ppmod	_	_
32	(	-lrb-	-LRB-	_	38	p	_	_
33	OR	or	CC	_	38	cc	_	_
34	AT	at	IN	_	38	case	_	_
35	AS	as	RB	_	38	adv	_	_
36	GREAT	great	JJ	_	38	attr	_	_
37	AN	an	DT	_	38	det	_	_
38	INTERVAL	interval	NN	_	31	prn	_	_
39	AS	as	IN	_	40	case	_	_
40	POSSIBLE	possible	JJ	_	38	ppmod	_	_
41	)	-rrb-	-RRB-	_	38	p	_	_
42	TO	to	TO	_	43	aux	_	_
43	AVOID	avoid	VB	_	16	comp	_	_
44	IMPEDING	impede	VBG	_	43	comp	_	_
45	THEIR	their	PRP$	_	46	poss	_	_
46	ABSORPTION	absorption	NN	_	44	obj	_	_
47	.	.	.	_	13	p	_	_

1	CYP3A4	cyp0a0	NN	_	2	com	_	_
2	Interactions	interaction	NNS	_	0	root	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	metabolized	metabolize	VBN	_	0	root	_	_
4	by	by	IN	_	5	case	_	_
5	CYP3A4	cyp0a0	NN	_	3	ppmod	_	_
6	but	but	CC	_	3	cc	_	_
7	has	have	VBZ	_	11	lv	_	_
8	no	no	DT	_	11	det	_	_
9	CYP3A4	cyp0a0	JJ	_	11	attr	_	_
10	inhibitory	inhibitory	JJ	_	11	attr	_	_
11	activity	activity	NN	_	3	conj	_	_
12	;	;	:	_	3	p	_	_

1	therefore	therefore	RB	_	5	adv	_	_
2	it	it	PRP	_	5	dep	_	_
3	is	be	VBZ	_	5	aux	_	_
4	not	not	RB	_	5	neg	_	_
5	expected	expect	VBN	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	affect	affect	VB	_	5	comp	_	_
8	the	the	DT	_	10	det	_	_
9	plasma	plasma	NN	_	10	com	_	_
10	concentrations	concentration	NNS	_	7	obj	_	_
11	of	of	IN	_	13	case	_	_
12	other	other	JJ	_	13	attr	_	_
13	drugs	drug	NNS	_	10	ppmod	_	_
14	metabolized	metabolize	VBN	_	13	acl	_	_
15	by	by	IN	_	16	case	_	_
16	CYP3A4	cyp0a0	NN	_	14	ppmod	_	_
17	.	.	.	_	5	p	_	_

1	Potent	potent	JJ	_	2	attr	_	_
2	inhibitors	inhibitor	NNS	_	8	dep	_	_
3	of	of	IN	_	4	case	_	_
4	CYP3A4	cyp0a0	NN	_	2	ppmod	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	below	below	IN	_	2	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	increase	increase	VBP	_	0	root	_	_
9	the	the	DT	_	10	det	_	_
10	risk	risk	NN	_	8	obj	_	_
11	of	of	IN	_	12	case	_	_
12	myopathy	myopathy	NN	_	10	ppmod	_	_
13	by	by	IN	_	14	case	_	_
14	reducing	reduce	VBG	_	8	ppmod	_	_
15	the	the	DT	_	16	det	_	_
16	elimination	elimination	NN	_	14	obj	_	_
17	of	of	IN	_	18	case	_	_
18	drug1	drug0	NN	_	16	ppmod	_	_
19	.	.	.	_	8	p	_	_

1	Pharmacokinetics	pharmacokinetics	NNS	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	7	com	_	_
2	drug2	drug0	NN	_	7	com	_	_
3	drug3	drug0	NN	_	7	com	_	_
4	drug4	drug0	NN	_	7	com	_	_
5	drug5	drug0	NN	_	7	com	_	_
6	drug6	drug0	NN	_	7	com	_	_
7	drug7	drug0	NN	_	0	root	_	_
8	drug8	drug0	IN	_	10	case	_	_
9	Large	large	JJ	_	10	attr	_	_
10	quantities	quantity	NNS	_	7	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	grapefruit	grapefruit	NN	_	13	com	_	_
13	juice	juice	NN	_	10	ppmod	_	_
14	(	-lrb-	-LRB-	_	16	p	_	_
15	1	0	CD	_	16	num	_	_
16	quart	quart	NN	_	7	prn	_	_
17	daily	daily	JJ	_	16	attr	_	_
18	)	-rrb-	-RRB-	_	16	p	_	_

1	Interactions	interaction	NNS	_	0	root	_	_
2	with	with	IN	_	4	case	_	_
3	lipid-lowering	lipid-lowering	JJ	_	4	attr	_	_
4	drugs	drug	NNS	_	1	ppmod	_	_
5	that	that	WDT	_	7	dep	_	_
6	can	can	MD	_	7	modal	_	_
7	cause	cause	VB	_	4	relcl	_	_
8	myopathy	myopathy	NN	_	7	obj	_	_
9	when	when	WRB	_	10	adv	_	_
10	given	give	VBN	_	7	comp	_	_
11	alone	alone	RB	_	10	adv	_	_
12	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	risk	risk	NN	_	7	dep	_	_
3	of	of	IN	_	4	case	_	_
4	myopathy	myopathy	NN	_	2	ppmod	_	_
5	is	be	VBZ	_	7	aux	_	_
6	also	also	RB	_	7	adv	_	_
7	increased	increase	VBN	_	0	root	_	_
8	by	by	IN	_	12	case	_	_
9	the	the	DT	_	12	det	_	_
10	following	following	JJ	_	12	attr	_	_
11	lipid-lowering	lipid-lowering	JJ	_	12	attr	_	_
12	drugs	drug	NNS	_	7	ppmod	_	_
13	that	that	WDT	_	14	dep	_	_
14	are	be	VBP	_	12	advcl	_	_
15	not	not	RB	_	14	neg	_	_
16	potent	potent	JJ	_	18	attr	_	_
17	CYP3A4	cyp0a0	JJ	_	18	attr	_	_
18	inhibitors	inhibitor	NNS	_	14	obj	_	_
19	,	,	,	_	14	p	_	_
20	but	but	CC	_	14	cc	_	_
21	which	which	WDT	_	23	dep	_	_
22	can	can	MD	_	23	modal	_	_
23	cause	cause	VB	_	14	conj	_	_
24	myopathy	myopathy	NN	_	23	obj	_	_
25	when	when	WRB	_	26	adv	_	_
26	given	give	VBN	_	23	comp	_	_
27	alone	alone	RB	_	26	adv	_	_
28	.	.	.	_	7	p	_	_

1	See	see	VB	_	0	root	_	_
2	WARNINGS	warning	NNS	_	1	obj	_	_
3	,	,	,	_	2	p	_	_
4	Myopathy/Rhabdomyolysis	myopathy/rhabdomyolysis	NN	_	2	appo	_	_
5	.	.	.	_	1	p	_	_

1	drug1	drug0	JJ	_	4	attr	_	_
2	Other	other	JJ	_	4	attr	_	_
3	drug2	drug0	NN	_	4	com	_	_
4	drug3	drug0	NN	_	0	root	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	drug4	drug0	NN	_	4	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	(	-lrb-	-LRB-	_	10	p	_	_
9	=1	0	CD	_	10	num	_	_
10	g/day	g/day	NN	_	4	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_

1	Other	other	JJ	_	3	attr	_	_
2	drug	drug	NN	_	3	com	_	_
3	interactions	interaction	NNS	_	0	root	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	risk	risk	NN	_	8	dep	_	_
5	of	of	IN	_	6	case	_	_
6	myopathy/rhabdomyolysis	myopathy/rhabdomyolysis	NN	_	4	ppmod	_	_
7	is	be	VBZ	_	8	aux	_	_
8	increased	increase	VBN	_	1	acl	_	_
9	by	by	IN	_	11	case	_	_
10	concomitant	concomitant	JJ	_	11	attr	_	_
11	administration	administration	NN	_	8	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	particularly	particularly	RB	_	17	adv	_	_
15	with	with	IN	_	17	case	_	_
16	higher	high	JJR	_	17	attr	_	_
17	doses	dose	NNS	_	11	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug3	drug0	NN	_	17	ppmod	_	_
20	(	-lrb-	-LRB-	_	21	p	_	_
21	see	see	VB	_	8	prn	_	_
22	WARNINGS	warning	NNS	_	21	obj	_	_
23	,	,	,	_	22	p	_	_
24	Myopathy/Rhabdomyolysis	myopathy/rhabdomyolysis	NNP	_	22	appo	_	_
25	)	-rrb-	-RRB-	_	21	p	_	_
26	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	or	or	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	:	:	:	_	1	p	_	_
5	The	the	DT	_	6	det	_	_
6	risk	risk	NN	_	10	dep	_	_
7	of	of	IN	_	8	case	_	_
8	myopathy/rhabdomyolysis	myopathy/rhabdomyolysis	NN	_	6	ppmod	_	_
9	is	be	VBZ	_	10	aux	_	_
10	increased	increase	VBN	_	1	acl	_	_
11	when	when	WRB	_	17	adv	_	_
12	either	either	CC	_	13	cc	_	_
13	drug3	drug0	NN	_	17	dep	_	_
14	or	or	CC	_	13	cc	_	_
15	drug4	drug0	NN	_	13	conj	_	_
16	is	be	VBZ	_	17	aux	_	_
17	used	use	VBN	_	10	comp	_	_
18	concomitantly	concomitantly	RB	_	17	adv	_	_
19	with	with	IN	_	23	case	_	_
20	a	a	DT	_	23	det	_	_
21	closely	closely	RB	_	22	adv	_	_
22	related	related	JJ	_	23	attr	_	_
23	member	member	NN	_	17	ppmod	_	_
24	of	of	IN	_	26	case	_	_
25	the	the	DT	_	26	det	_	_
26	drug5	drug0	NN	_	23	ppmod	_	_
27	(	-lrb-	-LRB-	_	28	p	_	_
28	see	see	VB	_	17	prn	_	_
29	WARNINGS	warning	NNS	_	28	obj	_	_
30	,	,	,	_	29	p	_	_
31	Myopathy/Rhabdomyolysis	myopathy/rhabdomyolysis	NNP	_	29	appo	_	_
32	)	-rrb-	-RRB-	_	28	p	_	_
33	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	s	s	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	In	in	IN	_	8	case	_	_
5	a	a	DT	_	8	det	_	_
6	small	small	JJ	_	8	attr	_	_
7	clinical	clinical	JJ	_	8	attr	_	_
8	trial	trial	NN	_	25	ppmod	_	_
9	in	in	IN	_	10	case	_	_
10	which	which	WDT	_	13	ppmod	_	_
11	drug2	drug0	NN	_	13	dep	_	_
12	was	be	VBD	_	13	aux	_	_
13	administered	administer	VBN	_	8	relcl	_	_
14	to	to	TO	_	15	aux	_	_
15	drug3	drug0	VB	_	13	comp	_	_
16	treated	treated	JJ	_	17	attr	_	_
17	patients	patient	NNS	_	15	obj	_	_
18	,	,	,	_	25	p	_	_
19	no	no	DT	_	20	det	_	_
20	effect	effect	NN	_	25	dep	_	_
21	on	on	IN	_	23	case	_	_
22	prothrombin	prothrombin	NN	_	23	com	_	_
23	time	time	NN	_	20	ppmod	_	_
24	was	be	VBD	_	25	aux	_	_
25	detected	detect	VBN	_	2	acl	_	_
26	.	.	.	_	2	p	_	_

1	However	however	RB	_	7	adv	_	_
2	,	,	,	_	7	p	_	_
3	another	another	DT	_	4	det	_	_
4	drug1	drug0	NN	_	7	dep	_	_
5	has	have	VBZ	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	found	find	VBN	_	0	root	_	_
8	to	to	TO	_	9	aux	_	_
9	produce	produce	VB	_	7	comp	_	_
10	a	a	DT	_	14	det	_	_
11	less	less	JJR	_	13	adv	_	_
12	than	than	IN	_	13	case	_	_
13	two-second	two-second	JJ	_	14	attr	_	_
14	increase	increase	NN	_	9	obj	_	_
15	in	in	IN	_	17	case	_	_
16	prothrombin	prothrombin	NN	_	17	com	_	_
17	time	time	NN	_	14	ppmod	_	_
18	in	in	IN	_	20	case	_	_
19	healthy	healthy	JJ	_	20	attr	_	_
20	volunteers	volunteer	NNS	_	14	ppmod	_	_
21	receiving	receive	VBG	_	20	acl	_	_
22	low	low	JJ	_	23	attr	_	_
23	doses	dose	NNS	_	21	obj	_	_
24	of	of	IN	_	25	case	_	_
25	drug2	drug0	NN	_	23	ppmod	_	_
26	.	.	.	_	7	p	_	_

1	Also	also	RB	_	10	adv	_	_
2	,	,	,	_	10	p	_	_
3	bleeding	bleeding	JJ	_	10	dep	_	_
4	and/or	and/or	CC	_	3	cc	_	_
5	increased	increase	VBN	_	7	attr	_	_
6	prothrombin	prothrombin	NN	_	7	com	_	_
7	time	time	NN	_	3	conj	_	_
8	have	have	VBP	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	reported	report	VBN	_	0	root	_	_
11	in	in	IN	_	14	case	_	_
12	a	a	DT	_	14	det	_	_
13	few	few	JJ	_	14	attr	_	_
14	patients	patient	NNS	_	10	ppmod	_	_
15	taking	take	VBG	_	14	acl	_	_
16	drug1	drug0	NN	_	17	com	_	_
17	s	s	NNS	_	15	obj	_	_
18	concomitantly	concomitantly	RB	_	20	adv	_	_
19	with	with	IN	_	20	case	_	_
20	drug2	drug0	NN	_	15	ppmod	_	_
21	.	.	.	_	10	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	recommended	recommend	VBN	_	0	root	_	_
4	that	that	IN	_	13	mark	_	_
5	in	in	IN	_	6	case	_	_
6	patients	patient	NNS	_	13	ppmod	_	_
7	taking	take	VBG	_	6	acl	_	_
8	drug1	drug0	NN	_	7	obj	_	_
9	,	,	,	_	13	p	_	_
10	prothrombin	prothrombin	NN	_	11	com	_	_
11	time	time	NN	_	13	dep	_	_
12	be	be	VB	_	13	aux	_	_
13	determined	determine	VBN	_	3	comp	_	_
14	before	before	IN	_	15	case	_	_
15	starting	start	VBG	_	13	ppmod	_	_
16	drug2	drug0	NN	_	15	obj	_	_
17	and	and	CC	_	15	cc	_	_
18	frequently	frequently	RB	_	15	conj	_	_
19	enough	enough	RB	_	18	adv	_	_
20	during	during	IN	_	22	case	_	_
21	early	early	JJ	_	22	attr	_	_
22	therapy	therapy	NN	_	18	ppmod	_	_
23	to	to	TO	_	24	aux	_	_
24	insure	insure	NN	_	22	ppmod	_	_
25	that	that	IN	_	32	mark	_	_
26	no	no	DT	_	28	det	_	_
27	significant	significant	JJ	_	28	attr	_	_
28	alteration	alteration	NN	_	32	dep	_	_
29	of	of	IN	_	31	case	_	_
30	prothrombin	prothrombin	NN	_	31	com	_	_
31	time	time	NN	_	28	ppmod	_	_
32	occurs	occur	VBZ	_	18	comp	15:comp	_
33	.	.	.	_	3	p	_	_

1	Once	once	IN	_	8	mark	_	_
2	a	a	DT	_	5	det	_	_
3	stable	stable	JJ	_	5	attr	_	_
4	prothrombin	prothrombin	NN	_	5	com	_	_
5	time	time	NN	_	8	dep	_	_
6	has	have	VBZ	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	documented	document	VBN	_	14	advcl	_	_
9	,	,	,	_	14	p	_	_
10	prothrombin	prothrombin	NN	_	11	com	_	_
11	times	time	NNS	_	14	dep	_	_
12	can	can	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	monitored	monitor	VBN	_	0	root	_	_
15	at	at	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	intervals	interval	NNS	_	14	ppmod	_	_
18	usually	usually	RB	_	19	adv	_	_
19	recommended	recommend	VBN	_	17	acl	_	_
20	for	for	IN	_	21	case	_	_
21	patients	patient	NNS	_	19	ppmod	_	_
22	on	on	IN	_	23	case	_	_
23	drug1	drug0	NN	_	21	ppmod	_	_
24	.	.	.	_	14	p	_	_

1	If	if	IN	_	7	mark	_	_
2	the	the	DT	_	3	det	_	_
3	dose	dose	NN	_	7	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	is	be	VBZ	_	7	aux	_	_
7	changed	change	VBN	_	14	advcl	_	_
8	,	,	,	_	14	p	_	_
9	the	the	DT	_	11	det	_	_
10	same	same	JJ	_	11	attr	_	_
11	procedure	procedure	NN	_	14	dep	_	_
12	should	should	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	repeated	repeat	VBN	_	0	root	_	_
15	.	.	.	_	14	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	therapy	therapy	NN	_	6	dep	_	_
3	has	have	VBZ	_	6	aux	_	_
4	not	not	RB	_	6	neg	_	_
5	been	be	VBN	_	6	aux	_	_
6	associated	associate	VBN	_	0	root	_	_
7	with	with	IN	_	8	case	_	_
8	bleeding	bleeding	JJ	_	6	ppmod	_	_
9	or	or	CC	_	8	cc	_	_
10	with	with	IN	_	11	case	_	_
11	changes	change	NNS	_	8	conj	_	_
12	in	in	IN	_	14	case	_	_
13	prothrombin	prothrombin	NN	_	14	com	_	_
14	time	time	NN	_	11	ppmod	_	_
15	in	in	IN	_	16	case	_	_
16	patients	patient	NNS	_	14	ppmod	_	_
17	not	not	RB	_	18	neg	_	_
18	taking	take	VBG	_	16	acl	_	_
19	drug2	drug0	NN	_	18	obj	_	_
20	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	5	case	_	_
4	normal	normal	JJ	_	5	attr	_	_
5	volunteers	volunteer	NNS	_	8	ppmod	_	_
6	,	,	,	_	8	p	_	_
7	there	there	EX	_	8	dep	_	_
8	was	be	VBD	_	1	acl	_	_
9	no	no	DT	_	15	det	_	_
10	clinically	clinically	RB	_	11	adv	_	_
11	significant	significant	JJ	_	15	attr	_	_
12	pharmacokinetic	pharmacokinetic	JJ	_	15	attr	_	_
13	or	or	CC	_	12	cc	_	_
14	pharmacodynamic	pharmacodynamic	JJ	_	12	conj	_	_
15	interaction	interaction	NN	_	8	obj	_	_
16	with	with	IN	_	18	case	_	_
17	concomitant	concomitant	JJ	_	18	attr	_	_
18	administration	administration	NN	_	15	ppmod	_	_
19	of	of	IN	_	21	case	_	_
20	single	single	JJ	_	21	attr	_	_
21	doses	dose	NNS	_	18	ppmod	_	_
22	of	of	IN	_	23	case	_	_
23	drug2	drug0	NN	_	21	ppmod	_	_
24	and	and	CC	_	23	cc	_	_
25	drug3	drug0	NN	_	23	conj	_	_
26	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	4	case	_	_
4	patients	patient	NNS	_	14	ppmod	_	_
5	with	with	IN	_	6	case	_	_
6	hypercholesterolemia	hypercholesterolemia	NN	_	4	ppmod	_	_
7	,	,	,	_	14	p	_	_
8	concomitant	concomitant	JJ	_	9	attr	_	_
9	administration	administration	NN	_	14	dep	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	drug3	drug0	NN	_	11	conj	_	_
14	resulted	result	VBD	_	1	acl	_	_
15	in	in	IN	_	17	case	_	_
16	no	no	DT	_	17	det	_	_
17	effect	effect	NN	_	14	ppmod	_	_
18	on	on	IN	_	21	case	_	_
19	drug4	drug0	NN	_	21	com	_	_
20	plasma	plasma	NN	_	21	com	_	_
21	concentrations	concentration	NNS	_	17	ppmod	_	_
22	.	.	.	_	1	p	_	_

1	Oral	oral	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	In	in	IN	_	6	case	_	_
5	pharmacokinetic	pharmacokinetic	JJ	_	6	attr	_	_
6	studies	study	NNS	_	17	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	in	in	IN	_	14	case	_	_
10	hypercholesterolemic	hypercholesterolemic	JJ	_	14	attr	_	_
11	noninsulin	noninsulin	NN	_	12	advnp	_	_
12	dependent	dependent	JJ	_	14	attr	_	_
13	diabetic	diabetic	JJ	_	14	attr	_	_
14	patients	patient	NNS	_	8	ppmod	_	_
15	,	,	,	_	17	p	_	_
16	there	there	EX	_	17	dep	_	_
17	was	be	VBD	_	2	acl	_	_
18	no	no	DT	_	20	det	_	_
19	drug	drug	NN	_	20	com	_	_
20	interaction	interaction	NN	_	17	obj	_	_
21	with	with	IN	_	22	case	_	_
22	drug3	drug0	NN	_	17	ppmod	_	_
23	or	or	CC	_	22	cc	_	_
24	with	with	IN	_	25	case	_	_
25	drug4	drug0	NN	_	22	conj	_	_

1	CNS	cns	NN	_	2	com	_	_
2	Drugs	drug	NNS	_	15	dep	_	_
3	-	-	:	_	15	p	_	_
4	Given	given	IN	_	8	case	_	_
5	the	the	DT	_	8	det	_	_
6	primary	primary	JJ	_	8	attr	_	_
7	CNS	cns	NN	_	8	com	_	_
8	effects	effect	NNS	_	15	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	,	,	,	_	15	p	_	_
12	caution	caution	NN	_	15	dep	_	_
13	should	should	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	used	use	VBN	_	0	root	_	_
16	when	when	WRB	_	19	adv	_	_
17	it	it	PRP	_	19	dep	_	_
18	is	be	VBZ	_	19	aux	_	_
19	taken	take	VBN	_	15	comp	_	_
20	in	in	IN	_	21	case	_	_
21	combination	combination	NN	_	19	ppmod	_	_
22	with	with	IN	_	26	case	_	_
23	other	other	JJ	_	26	attr	_	_
24	centrally	centrally	RB	_	25	adv	_	_
25	acting	act	VBG	_	26	attr	_	_
26	drugs	drug	NNS	_	21	ppmod	_	_
27	.	.	.	_	15	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	-	-	:	_	1	p	_	_
3	Although	although	IN	_	7	mark	_	_
4	drug2	drug0	NN	_	7	dep	_	_
5	did	do	VBD	_	7	aux	_	_
6	not	not	RB	_	7	neg	_	_
7	potentiate	potentiate	VB	_	35	advcl	_	_
8	the	the	DT	_	9	det	_	_
9	cognitive	cognitive	NN	_	7	obj	_	_
10	and	and	CC	_	9	cc	_	_
11	motor	motor	NN	_	12	com	_	_
12	effects	effect	NNS	_	9	conj	_	_
13	of	of	IN	_	14	case	_	_
14	drug3	drug0	NN	_	9	ppmod	_	_
15	in	in	IN	_	18	case	_	_
16	a	a	DT	_	18	det	_	_
17	clinical	clinical	JJ	_	18	attr	_	_
18	trial	trial	NN	_	9	ppmod	_	_
19	,	,	,	_	35	p	_	_
20	as	as	IN	_	23	case	_	_
21	with	with	IN	_	23	case	_	_
22	other	other	JJ	_	23	attr	_	_
23	drug4	drug0	NNS	_	35	ppmod	_	_
24	,	,	,	_	35	p	_	_
25	the	the	DT	_	26	det	_	_
26	use	use	NN	_	35	dep	_	_
27	of	of	IN	_	28	case	_	_
28	drug5	drug0	NN	_	26	ppmod	_	_
29	by	by	IN	_	30	case	_	_
30	patients	patient	NNS	_	26	ppmod	_	_
31	taking	take	VBG	_	30	acl	_	_
32	drug6	drug0	NN	_	31	obj	_	_
33	is	be	VBZ	_	35	aux	_	_
34	not	not	RB	_	35	neg	_	_
35	recommended	recommend	VBN	_	1	acl	_	_
36	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	drug2	drug0	NN	_	1	prn	_	_
4	)	-rrb-	-RRB-	_	3	p	_	_

1	Drugs	drug	NNS	_	0	root	_	_
2	That	that	WDT	_	3	dep	_	_
3	Interfere	interfere	VBP	_	1	relcl	_	_
4	With	with	IN	_	5	case	_	_
5	Hemostasis	hemostasis	NN	_	3	ppmod	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	drug1	drug0	NN	_	1	prn	_	_
8	,	,	,	_	7	p	_	_
9	drug2	drug0	NN	_	7	appo	_	_
10	,	,	,	_	7	p	_	_
11	drug3	drug0	NN	_	7	appo	_	_
12	,	,	,	_	7	p	_	_
13	etc	etc	NN	_	7	appo	_	_
14	.	.	.	_	7	p	_	_
15	)	-rrb-	-RRB-	_	7	p	_	_

1	Serotonin	serotonin	NN	_	2	com	_	_
2	release	release	NN	_	5	dep	_	_
3	by	by	IN	_	4	case	_	_
4	platelets	platelet	NNS	_	2	ppmod	_	_
5	plays	play	VBZ	_	0	root	_	_
6	an	an	DT	_	8	det	_	_
7	important	important	JJ	_	8	attr	_	_
8	role	role	NN	_	5	obj	_	_
9	in	in	IN	_	10	case	_	_
10	hemostasis	hemostasis	NN	_	5	ppmod	_	_
11	.	.	.	_	5	p	_	_

1	Epidemiological	epidemiological	JJ	_	2	attr	_	_
2	studies	study	NNS	_	32	dep	_	_
3	of	of	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	case-control	case-control	JJ	_	2	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	cohort	cohort	NN	_	8	com	_	_
8	design	design	NN	_	5	conj	_	_
9	that	that	WDT	_	11	dep	_	_
10	have	have	VBP	_	11	aux	_	_
11	demonstrated	demonstrate	VBN	_	2	relcl	_	_
12	an	an	DT	_	13	det	_	_
13	association	association	NN	_	11	obj	_	_
14	between	between	IN	_	15	case	_	_
15	use	use	NN	_	13	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	drug1	drug0	NN	_	15	ppmod	_	_
18	that	that	WDT	_	19	dep	_	_
19	interfere	interfere	VBP	_	17	relcl	_	_
20	with	with	IN	_	22	case	_	_
21	serotonin	serotonin	NN	_	22	com	_	_
22	reuptake	reuptake	NN	_	19	ppmod	_	_
23	and	and	CC	_	15	cc	_	_
24	the	the	DT	_	25	det	_	_
25	occurrence	occurrence	NN	_	15	conj	_	_
26	of	of	IN	_	29	case	_	_
27	upper	upper	JJ	_	29	attr	_	_
28	gastrointestinal	gastrointestinal	JJ	_	29	attr	_	_
29	bleeding	bleeding	JJ	_	25	ppmod	_	_
30	have	have	VBP	_	32	aux	_	_
31	also	also	RB	_	32	adv	_	_
32	shown	show	VBN	_	0	root	_	_
33	that	that	IN	_	41	mark	_	_
34	concurrent	concurrent	JJ	_	35	attr	_	_
35	use	use	NN	_	41	dep	_	_
36	of	of	IN	_	38	case	_	_
37	an	an	DT	_	38	det	_	_
38	drug2	drug0	NN	_	35	ppmod	_	_
39	or	or	CC	_	38	cc	_	_
40	drug3	drug0	NN	_	38	conj	_	_
41	potentiated	potentiate	VBD	_	32	comp	_	_
42	the	the	DT	_	43	det	_	_
43	risk	risk	NN	_	41	obj	_	_
44	of	of	IN	_	45	case	_	_
45	bleeding	bleeding	JJ	_	43	ppmod	_	_
46	.	.	.	_	32	p	_	_

1	Thus	thus	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	patients	patient	NNS	_	6	dep	_	_
4	should	should	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	cautioned	caution	VBN	_	0	root	_	_
7	about	about	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	use	use	NN	_	6	ppmod	_	_
10	of	of	IN	_	12	case	_	_
11	such	such	JJ	_	12	attr	_	_
12	drugs	drug	NNS	_	9	ppmod	_	_
13	concurrently	concurrently	RB	_	15	adv	_	_
14	with	with	IN	_	15	case	_	_
15	drug1	drug0	NN	_	12	ppmod	_	_
16	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	-	-	:	_	1	p	_	_
3	In	in	IN	_	4	case	_	_
4	subjects	subject	NNS	_	25	ppmod	_	_
5	who	who	WP	_	7	dep	_	_
6	had	have	VBD	_	7	aux	_	_
7	received	receive	VBN	_	4	relcl	_	_
8	21	0	CD	_	9	num	_	_
9	days	day	NNS	_	7	obj	_	_
10	of	of	IN	_	14	case	_	_
11	40	0	CD	_	12	num	_	_
12	mg/day	mg/day	NN	_	14	attr	_	_
13	racemic	racemic	JJ	_	14	attr	_	_
14	drug2	drug0	NN	_	9	ppmod	_	_
15	,	,	,	_	25	p	_	_
16	combined	combined	JJ	_	17	attr	_	_
17	administration	administration	NN	_	25	dep	_	_
18	of	of	IN	_	21	case	_	_
19	400	0	CD	_	20	num	_	_
20	mg/day	mg/day	NN	_	21	com	_	_
21	drug3	drug0	NN	_	17	ppmod	_	_
22	for	for	IN	_	24	case	_	_
23	8	0	CD	_	24	num	_	_
24	days	day	NNS	_	17	ppmod	_	_
25	resulted	result	VBD	_	1	acl	_	_
26	in	in	IN	_	28	case	_	_
27	an	an	DT	_	28	det	_	_
28	increase	increase	NN	_	25	ppmod	_	_
29	in	in	IN	_	31	case	_	_
30	drug4	drug0	NN	_	31	com	_	_
31	AUC	auc	NN	_	28	ppmod	_	_
32	and	and	CC	_	31	cc	_	_
33	Cmax	cmax	NN	_	31	conj	_	_
34	of	of	IN	_	35	case	_	_
35	43	0	CD	_	31	ppmod	_	_
36	%	%	NN	_	35	meta	_	_
37	and	and	CC	_	35	cc	_	_
38	39	0	CD	_	35	conj	_	_
39	%	%	NN	_	38	meta	_	_
40	,	,	,	_	38	p	_	_
41	respectively	respectively	RB	_	35	conj	_	_
42	.	.	.	_	1	p	_	_

1	The	the	DT	_	3	det	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	significance	significance	NN	_	7	dep	_	_
4	of	of	IN	_	6	case	_	_
5	these	these	DT	_	6	det	_	_
6	findings	finding	NNS	_	3	ppmod	_	_
7	is	be	VBZ	_	0	root	_	_
8	unknown	unknown	JJ	_	7	dep	_	_
9	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	-	-	:	_	1	p	_	_
3	In	in	IN	_	4	case	_	_
4	subjects	subject	NNS	_	32	ppmod	_	_
5	who	who	WP	_	7	dep	_	_
6	had	have	VBD	_	7	aux	_	_
7	received	receive	VBN	_	4	relcl	_	_
8	21	0	CD	_	9	num	_	_
9	days	day	NNS	_	7	obj	_	_
10	of	of	IN	_	14	case	_	_
11	40	0	CD	_	12	num	_	_
12	mg/day	mg/day	NN	_	14	attr	_	_
13	racemic	racemic	JJ	_	14	attr	_	_
14	drug2	drug0	NN	_	9	ppmod	_	_
15	,	,	,	_	32	p	_	_
16	combined	combined	JJ	_	17	attr	_	_
17	administration	administration	NN	_	32	dep	_	_
18	of	of	IN	_	19	case	_	_
19	drug3	drug0	NN	_	17	ppmod	_	_
20	and	and	CC	_	19	cc	_	_
21	drug4	drug0	NN	_	19	conj	_	_
22	(	-lrb-	-LRB-	_	24	p	_	_
23	single	single	JJ	_	24	attr	_	_
24	dose	dose	NN	_	19	prn	_	_
25	of	of	IN	_	27	case	_	_
26	1	0	CD	_	27	num	_	_
27	mg	mg	NN	_	24	ppmod	_	_
28	)	-rrb-	-RRB-	_	24	p	_	_
29	did	do	VBD	_	32	aux	_	_
30	not	not	RB	_	32	neg	_	_
31	significantly	significantly	RB	_	32	adv	_	_
32	affect	affect	VB	_	1	acl	_	_
33	the	the	DT	_	34	det	_	_
34	pharmacokinetics	pharmacokinetics	NNS	_	32	obj	_	_
35	of	of	IN	_	37	case	_	_
36	either	either	CC	_	37	cc	_	_
37	drug5	drug0	NN	_	34	ppmod	_	_
38	or	or	CC	_	37	cc	_	_
39	drug6	drug0	NN	_	37	conj	_	_
40	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	23	dep	_	_
2	-	-	CC	_	1	cc	_	_
3	Coadministration	coadministration	NN	_	1	conj	_	_
4	of	of	IN	_	6	case	_	_
5	racemic	racemic	JJ	_	6	attr	_	_
6	drug2	drug0	NN	_	1	ppmod	_	_
7	(	-lrb-	-LRB-	_	9	p	_	_
8	40	0	CD	_	9	num	_	_
9	mg/day	mg/day	NN	_	6	prn	_	_
10	for	for	IN	_	12	case	_	_
11	10	0	CD	_	12	num	_	_
12	days	day	NNS	_	9	ppmod	_	_
13	)	-rrb-	-RRB-	_	9	p	_	_
14	and	and	CC	_	6	cc	_	_
15	drug3	drug0	NN	_	6	conj	_	_
16	(	-lrb-	-LRB-	_	18	p	_	_
17	30	0	CD	_	18	num	_	_
18	mmol/day	mmol/day	NN	_	15	prn	_	_
19	for	for	IN	_	21	case	_	_
20	5	0	CD	_	21	num	_	_
21	days	day	NNS	_	18	ppmod	_	_
22	)	-rrb-	-RRB-	_	18	p	_	_
23	had	have	VBD	_	0	root	_	_
24	no	no	DT	_	26	det	_	_
25	significant	significant	JJ	_	26	attr	_	_
26	effect	effect	NN	_	23	obj	_	_
27	on	on	IN	_	29	case	_	_
28	the	the	DT	_	29	det	_	_
29	pharmacokinetics	pharmacokinetics	NNS	_	23	ppmod	_	_
30	of	of	IN	_	31	case	_	_
31	drug4	drug0	NN	_	29	ppmod	_	_
32	or	or	CC	_	31	cc	_	_
33	drug5	drug0	NN	_	31	conj	_	_
34	.	.	.	_	23	p	_	_

1	Nevertheless	nevertheless	RB	_	8	adv	_	_
2	,	,	,	_	8	p	_	_
3	plasma	plasma	NN	_	5	com	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	levels	level	NNS	_	8	dep	_	_
6	should	should	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	monitored	monitor	VBN	_	0	root	_	_
9	with	with	IN	_	11	case	_	_
10	appropriate	appropriate	JJ	_	11	attr	_	_
11	adjustment	adjustment	NN	_	8	ppmod	_	_
12	to	to	TO	_	15	aux	_	_
13	the	the	DT	_	15	det	_	_
14	drug2	drug0	JJ	_	15	attr	_	_
15	dose	dose	NN	_	11	ppmod	_	_
16	in	in	IN	_	17	case	_	_
17	accordance	accordance	NN	_	15	ppmod	_	_
18	with	with	IN	_	21	case	_	_
19	standard	standard	JJ	_	21	attr	_	_
20	clinical	clinical	JJ	_	21	attr	_	_
21	practice	practice	NN	_	17	ppmod	_	_
22	.	.	.	_	8	p	_	_

1	Because	because	IN	_	4	mark	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	enhance	enhance	VB	_	14	advcl	_	_
5	the	the	DT	_	7	det	_	_
6	serotonergic	serotonergic	JJ	_	7	attr	_	_
7	effects	effect	NNS	_	4	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	14	p	_	_
11	caution	caution	NN	_	14	dep	_	_
12	should	should	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	exercised	exercise	VBN	_	0	root	_	_
15	when	when	WRB	_	20	adv	_	_
16	drug3	drug0	NN	_	20	dep	_	_
17	and	and	CC	_	16	cc	_	_
18	drug4	drug0	NN	_	16	conj	_	_
19	are	be	VBP	_	20	aux	_	_
20	coadministered	coadministered	VBN	_	14	comp	_	_
21	.	.	.	_	14	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	-	-	:	_	1	p	_	_
5	In	in	IN	_	8	case	_	_
6	a	a	DT	_	8	det	_	_
7	controlled	controlled	JJ	_	8	attr	_	_
8	study	study	NN	_	30	ppmod	_	_
9	,	,	,	_	30	p	_	_
10	a	a	DT	_	12	det	_	_
11	single	single	JJ	_	12	attr	_	_
12	dose	dose	NN	_	30	dep	_	_
13	of	of	IN	_	16	case	_	_
14	drug3	drug0	NN	_	16	attr	_	_
15	2	0	CD	_	16	num	_	_
16	mg	mg	NN	_	12	ppmod	_	_
17	co-administered	co-administered	VBN	_	16	acl	_	_
18	with	with	IN	_	22	case	_	_
19	racemic	racemic	JJ	_	22	attr	_	_
20	drug4	drug0	NN	_	22	attr	_	_
21	40	0	CD	_	22	num	_	_
22	mg	mg	NN	_	17	ppmod	_	_
23	given	give	VBN	_	22	acl	_	_
24	once	once	IN	_	25	case	_	_
25	daily	daily	JJ	_	23	ppmod	_	_
26	for	for	IN	_	28	case	_	_
27	11	0	CD	_	28	num	_	_
28	days	day	NNS	_	23	ppmod	_	_
29	was	be	VBD	_	30	aux	_	_
30	associated	associate	VBN	_	1	acl	_	_
31	with	with	IN	_	34	case	_	_
32	a	a	DT	_	34	det	_	_
33	mean	mean	JJ	_	34	attr	_	_
34	increase	increase	NN	_	30	ppmod	_	_
35	in	in	IN	_	37	case	_	_
36	QTc	qtc	NN	_	37	com	_	_
37	values	value	NNS	_	34	ppmod	_	_
38	of	of	IN	_	41	case	_	_
39	approximately	approximately	RB	_	40	adv	_	_
40	10	0	CD	_	41	num	_	_
41	msec	msec	NNS	_	37	ppmod	_	_
42	compared	compare	VBN	_	34	acl	_	_
43	to	to	TO	_	44	aux	_	_
44	drug5	drug0	NN	_	42	ppmod	_	_
45	given	give	VBN	_	44	acl	_	_
46	alone	alone	RB	_	45	adv	_	_
47	.	.	.	_	1	p	_	_

1	Racemic	racemic	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	5	dep	_	_
3	did	do	VBD	_	5	aux	_	_
4	not	not	RB	_	5	neg	_	_
5	alter	alter	VB	_	0	root	_	_
6	the	the	DT	_	8	det	_	_
7	mean	mean	JJ	_	8	attr	_	_
8	AUC	auc	NN	_	5	obj	_	_
9	or	or	CC	_	8	cc	_	_
10	Cmax	cmax	NN	_	8	conj	_	_
11	of	of	IN	_	12	case	_	_
12	drug2	drug0	NN	_	8	ppmod	_	_
13	.	.	.	_	5	p	_	_

1	The	the	DT	_	2	det	_	_
2	mechanism	mechanism	NN	_	9	dep	_	_
3	of	of	IN	_	6	case	_	_
4	this	this	DT	_	6	det	_	_
5	pharmacodynamic	pharmacodynamic	JJ	_	6	attr	_	_
6	interaction	interaction	NN	_	2	ppmod	_	_
7	is	be	VBZ	_	9	aux	_	_
8	not	not	RB	_	9	neg	_	_
9	known	know	VBN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	-	-	:	_	1	p	_	_
3	There	there	EX	_	5	dep	_	_
4	have	have	VBP	_	5	aux	_	_
5	been	be	VBN	_	1	acl	_	_
6	rare	rare	JJ	_	8	attr	_	_
7	postmarketing	postmarketing	JJ	_	8	attr	_	_
8	reports	report	NNS	_	5	obj	_	_
9	describing	describe	VBG	_	8	acl	_	_
10	patients	patient	NNS	_	9	obj	_	_
11	with	with	IN	_	12	case	_	_
12	weakness	weakness	NN	_	10	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	hyperreflexia	hyperreflexia	NN	_	12	conj	_	_
15	,	,	,	_	14	p	_	_
16	and	and	CC	_	14	cc	_	_
17	incoordination	incoordination	NN	_	12	conj	_	_
18	following	follow	VBG	_	20	adv	_	_
19	the	the	DT	_	20	det	_	_
20	use	use	NN	_	5	ppmod	_	_
21	of	of	IN	_	23	case	_	_
22	a	a	DT	_	23	det	_	_
23	drug2	drug0	NN	_	20	ppmod	_	_
24	(	-lrb-	-LRB-	_	25	p	_	_
25	drug3	drug0	NN	_	23	prn	_	_
26	)	-rrb-	-RRB-	_	25	p	_	_
27	and	and	CC	_	23	cc	_	_
28	drug4	drug0	NN	_	23	conj	_	_
29	.	.	.	_	1	p	_	_

1	If	if	IN	_	26	mark	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	treatment	treatment	NN	_	26	dep	_	_
4	with	with	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	an	an	DT	_	8	det	_	_
8	drug2	drug0	NN	_	5	conj	_	_
9	(	-lrb-	-LRB-	_	12	p	_	_
10	e.g.	e.g.	FW	_	12	ppmod	_	_
11	,	,	,	_	12	p	_	_
12	drug3	drug0	NN	_	8	prn	_	_
13	,	,	,	_	12	p	_	_
14	drug4	drug0	NN	_	12	appo	_	_
15	,	,	,	_	12	p	_	_
16	drug5	drug0	NN	_	12	appo	_	_
17	,	,	,	_	12	p	_	_
18	drug6	drug0	NN	_	12	appo	_	_
19	,	,	,	_	12	p	_	_
20	drug7	drug0	NN	_	12	appo	_	_
21	,	,	,	_	12	p	_	_
22	drug8	drug0	NN	_	12	appo	_	_
23	)	-rrb-	-RRB-	_	12	p	_	_
24	is	be	VBZ	_	26	aux	_	_
25	clinically	clinically	RB	_	26	adv	_	_
26	warranted	warrant	VBN	_	33	advcl	_	_
27	,	,	,	_	33	p	_	_
28	appropriate	appropriate	JJ	_	29	attr	_	_
29	observation	observation	NN	_	33	dep	_	_
30	of	of	IN	_	32	case	_	_
31	the	the	DT	_	32	det	_	_
32	patient	patient	NN	_	29	ppmod	_	_
33	is	be	VBZ	_	0	root	_	_
34	advised	advised	JJ	_	33	dep	_	_
35	.	.	.	_	33	p	_	_

1	drug1	drug0	NN	_	29	dep	_	_
2	-	-	CC	_	1	cc	_	_
3	Combined	combined	JJ	_	4	attr	_	_
4	administration	administration	NN	_	1	conj	_	_
5	of	of	IN	_	7	case	_	_
6	racemic	racemic	JJ	_	7	attr	_	_
7	drug2	drug0	NN	_	4	ppmod	_	_
8	(	-lrb-	-LRB-	_	10	p	_	_
9	40	0	CD	_	10	num	_	_
10	mg/day	mg/day	NN	_	1	prn	_	_
11	for	for	IN	_	13	case	_	_
12	21	0	CD	_	13	num	_	_
13	days	day	NNS	_	10	ppmod	_	_
14	)	-rrb-	-RRB-	_	10	p	_	_
15	and	and	CC	_	1	cc	_	_
16	the	the	DT	_	19	det	_	_
17	CYP1A2	cyp0a0	NN	_	19	com	_	_
18	substrate	substrate	NN	_	19	com	_	_
19	drug3	drug0	NN	_	1	conj	_	_
20	(	-lrb-	-LRB-	_	22	p	_	_
21	single	single	JJ	_	22	attr	_	_
22	dose	dose	NN	_	19	prn	_	_
23	of	of	IN	_	25	case	_	_
24	300	0	CD	_	25	num	_	_
25	mg	mg	NN	_	22	ppmod	_	_
26	)	-rrb-	-RRB-	_	22	p	_	_
27	did	do	VBD	_	29	aux	_	_
28	not	not	RB	_	29	neg	_	_
29	affect	affect	VB	_	0	root	_	_
30	the	the	DT	_	31	det	_	_
31	pharmacokinetics	pharmacokinetics	NNS	_	29	obj	_	_
32	of	of	IN	_	33	case	_	_
33	drug4	drug0	NN	_	31	ppmod	_	_
34	.	.	.	_	29	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	12	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	on	on	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	pharmacokinetics	pharmacokinetics	NNS	_	2	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NNS	_	7	ppmod	_	_
10	was	be	VBD	_	12	aux	_	_
11	not	not	RB	_	12	neg	_	_
12	evaluated	evaluate	VBN	_	0	root	_	_
13	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	14	dep	_	_
2	-	-	CC	_	1	cc	_	_
3	Administration	administration	NN	_	1	conj	_	_
4	of	of	IN	_	8	case	_	_
5	40	0	CD	_	6	num	_	_
6	mg/day	mg/day	NN	_	8	attr	_	_
7	racemic	racemic	JJ	_	8	attr	_	_
8	drug2	drug0	NN	_	1	ppmod	_	_
9	for	for	IN	_	11	case	_	_
10	21	0	CD	_	11	num	_	_
11	days	day	NNS	_	1	ppmod	_	_
12	did	do	VBD	_	14	aux	_	_
13	not	not	RB	_	14	neg	_	_
14	affect	affect	VB	_	0	root	_	_
15	the	the	DT	_	16	det	_	_
16	pharmacokinetics	pharmacokinetics	NNS	_	14	obj	_	_
17	of	of	IN	_	18	case	_	_
18	drug3	drug0	NN	_	16	ppmod	_	_
19	,	,	,	_	18	p	_	_
20	a	a	DT	_	22	det	_	_
21	CYP3A4	cyp0a0	NN	_	22	com	_	_
22	substrate	substrate	NN	_	18	appo	_	_
23	.	.	.	_	14	p	_	_

1	Prothrombin	prothrombin	NN	_	2	com	_	_
2	time	time	NN	_	4	dep	_	_
3	was	be	VBD	_	4	aux	_	_
4	increased	increase	VBN	_	0	root	_	_
5	by	by	IN	_	6	case	_	_
6	5	0	CD	_	4	ppmod	_	_
7	%	%	NN	_	6	meta	_	_
8	,	,	,	_	6	p	_	_
9	the	the	DT	_	11	det	_	_
10	clinical	clinical	JJ	_	11	attr	_	_
11	significance	significance	NN	_	14	dep	_	_
12	of	of	IN	_	13	case	_	_
13	which	which	WDT	_	11	ppmod	_	_
14	is	be	VBZ	_	6	relcl	_	_
15	unknown	unknown	JJ	_	14	dep	_	_
16	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	-	-	:	_	1	p	_	_
3	Combined	combined	JJ	_	4	attr	_	_
4	administration	administration	NN	_	29	dep	_	_
5	of	of	IN	_	7	case	_	_
6	racemic	racemic	JJ	_	7	attr	_	_
7	drug2	drug0	NN	_	4	ppmod	_	_
8	(	-lrb-	-LRB-	_	10	p	_	_
9	40	0	CD	_	10	num	_	_
10	mg/day	mg/day	NN	_	7	prn	_	_
11	for	for	IN	_	13	case	_	_
12	14	0	CD	_	13	num	_	_
13	days	day	NNS	_	10	ppmod	_	_
14	)	-rrb-	-RRB-	_	10	p	_	_
15	and	and	CC	_	7	cc	_	_
16	drug3	drug0	NN	_	7	conj	_	_
17	(	-lrb-	-LRB-	_	21	p	_	_
18	titrated	titrated	JJ	_	21	attr	_	_
19	to	to	TO	_	21	attr	_	_
20	400	0	CD	_	21	num	_	_
21	mg/day	mg/day	NN	_	16	prn	_	_
22	for	for	IN	_	24	case	_	_
23	35	0	CD	_	24	num	_	_
24	days	day	NNS	_	21	ppmod	_	_
25	)	-rrb-	-RRB-	_	21	p	_	_
26	did	do	VBD	_	29	aux	_	_
27	not	not	RB	_	29	neg	_	_
28	significantly	significantly	RB	_	29	adv	_	_
29	affect	affect	VB	_	1	acl	_	_
30	the	the	DT	_	31	det	_	_
31	pharmacokinetics	pharmacokinetics	NNS	_	29	obj	_	_
32	of	of	IN	_	33	case	_	_
33	drug4	drug0	NN	_	31	ppmod	_	_
34	,	,	,	_	33	p	_	_
35	a	a	DT	_	37	det	_	_
36	CYP3A4	cyp0a0	NN	_	37	com	_	_
37	substrate	substrate	NN	_	33	appo	_	_
38	.	.	.	_	1	p	_	_

1	Although	although	IN	_	6	mark	_	_
2	trough	trough	NN	_	5	com	_	_
3	drug1	drug0	NN	_	5	com	_	_
4	plasma	plasma	NN	_	5	com	_	_
5	levels	level	NNS	_	6	dep	_	_
6	were	be	VBD	_	28	advcl	_	_
7	unaffected	unaffected	JJ	_	6	dep	_	_
8	,	,	,	_	6	p	_	_
9	given	given	IN	_	12	case	_	_
10	the	the	DT	_	12	det	_	_
11	enzyme-inducing	enzyme-inducing	JJ	_	12	attr	_	_
12	properties	property	NNS	_	6	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	,	,	,	_	28	p	_	_
16	the	the	DT	_	17	det	_	_
17	possibility	possibility	NN	_	28	dep	_	_
18	that	that	IN	_	21	mark	_	_
19	drug3	drug0	NN	_	21	dep	_	_
20	might	might	MD	_	21	modal	_	_
21	increase	increase	VB	_	17	acl	_	_
22	the	the	DT	_	23	det	_	_
23	clearance	clearance	NN	_	21	obj	_	_
24	of	of	IN	_	25	case	_	_
25	drug4	drug0	NN	_	23	ppmod	_	_
26	should	should	MD	_	28	modal	_	_
27	be	be	VB	_	28	aux	_	_
28	considered	consider	VBN	_	0	root	_	_
29	if	if	IN	_	34	mark	_	_
30	the	the	DT	_	32	det	_	_
31	two	#crd#	CD	_	32	num	_	_
32	drugs	drug	NNS	_	34	dep	_	_
33	are	be	VBP	_	34	aux	_	_
34	coadministered	coadministered	VBN	_	28	comp	_	_
35	.	.	.	_	28	p	_	_

1	drug1	drug0	NN	_	32	dep	_	_
2	-	-	CC	_	1	cc	_	_
3	Combined	combined	JJ	_	4	attr	_	_
4	administration	administration	NN	_	1	conj	_	_
5	of	of	IN	_	7	case	_	_
6	racemic	racemic	JJ	_	7	attr	_	_
7	drug2	drug0	NN	_	4	ppmod	_	_
8	(	-lrb-	-LRB-	_	1	p	_	_
9	titrated	titrate	VBN	_	1	acl	_	_
10	to	to	TO	_	12	aux	_	_
11	40	0	CD	_	12	num	_	_
12	mg/day	mg/day	NN	_	9	ppmod	_	_
13	for	for	IN	_	15	case	_	_
14	28	0	CD	_	15	num	_	_
15	days	day	NNS	_	12	ppmod	_	_
16	)	-rrb-	-RRB-	_	1	p	_	_
17	and	and	CC	_	1	cc	_	_
18	the	the	DT	_	21	det	_	_
19	CYP3A4	cyp0a0	NN	_	21	com	_	_
20	substrate	substrate	NN	_	21	com	_	_
21	drug3	drug0	NN	_	1	conj	_	_
22	(	-lrb-	-LRB-	_	24	p	_	_
23	single	single	JJ	_	24	attr	_	_
24	dose	dose	NN	_	21	prn	_	_
25	of	of	IN	_	27	case	_	_
26	0.25	0	CD	_	27	num	_	_
27	mg	mg	NN	_	24	ppmod	_	_
28	)	-rrb-	-RRB-	_	24	p	_	_
29	did	do	VBD	_	32	aux	_	_
30	not	not	RB	_	32	neg	_	_
31	significantly	significantly	RB	_	32	adv	_	_
32	affect	affect	VB	_	0	root	_	_
33	the	the	DT	_	34	det	_	_
34	pharmacokinetics	pharmacokinetics	NNS	_	32	obj	_	_
35	of	of	IN	_	37	case	_	_
36	either	either	CC	_	37	cc	_	_
37	drug4	drug0	NN	_	34	ppmod	_	_
38	or	or	CC	_	37	cc	_	_
39	drug5	drug0	NN	_	37	conj	_	_
40	.	.	.	_	32	p	_	_

1	drug1	drug0	NN	_	18	dep	_	_
2	-	-	CC	_	1	cc	_	_
3	Combined	combined	JJ	_	4	attr	_	_
4	administration	administration	NN	_	1	conj	_	_
5	of	of	IN	_	7	case	_	_
6	racemic	racemic	JJ	_	7	attr	_	_
7	drug2	drug0	NN	_	4	ppmod	_	_
8	(	-lrb-	-LRB-	_	10	p	_	_
9	40	0	CD	_	10	num	_	_
10	mg	mg	NN	_	1	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	and	and	CC	_	1	cc	_	_
13	drug3	drug0	NN	_	1	conj	_	_
14	(	-lrb-	-LRB-	_	16	p	_	_
15	200	0	CD	_	16	num	_	_
16	mg	mg	NN	_	13	prn	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	decreased	decrease	VBD	_	0	root	_	_
19	the	the	DT	_	20	det	_	_
20	Cmax	cmax	NN	_	18	obj	_	_
21	and	and	CC	_	20	cc	_	_
22	AUC	auc	NN	_	20	conj	_	_
23	of	of	IN	_	24	case	_	_
24	drug4	drug0	NN	_	20	ppmod	_	_
25	by	by	IN	_	26	case	_	_
26	21	0	CD	_	18	ppmod	_	_
27	%	%	NN	_	26	meta	_	_
28	and	and	CC	_	26	cc	_	_
29	10	0	CD	_	26	conj	_	_
30	%	%	NN	_	29	meta	_	_
31	,	,	,	_	29	p	_	_
32	respectively	respectively	RB	_	26	conj	_	_
33	,	,	,	_	18	p	_	_
34	and	and	CC	_	18	cc	_	_
35	did	do	VBD	_	38	aux	_	_
36	not	not	RB	_	38	neg	_	_
37	significantly	significantly	RB	_	38	adv	_	_
38	affect	affect	VB	_	18	conj	_	_
39	the	the	DT	_	40	det	_	_
40	pharmacokinetics	pharmacokinetics	NNS	_	38	obj	_	_
41	of	of	IN	_	42	case	_	_
42	drug5	drug0	NN	_	40	ppmod	_	_
43	.	.	.	_	18	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	-	-	:	_	1	p	_	_
3	Combined	combined	JJ	_	4	attr	_	_
4	administration	administration	NN	_	35	dep	_	_
5	of	of	IN	_	8	case	_	_
6	a	a	DT	_	8	det	_	_
7	single	single	JJ	_	8	attr	_	_
8	dose	dose	NN	_	4	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	(	-lrb-	-LRB-	_	13	p	_	_
12	600	0	CD	_	13	num	_	_
13	mg	mg	NN	_	10	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	,	,	,	_	10	p	_	_
16	both	both	CC	_	19	cc	_	_
17	a	a	DT	_	19	det	_	_
18	CYP3A4	cyp0a0	NN	_	19	com	_	_
19	substrate	substrate	NN	_	10	appo	_	_
20	and	and	CC	_	19	cc	_	_
21	a	a	DT	_	23	det	_	_
22	potent	potent	JJ	_	23	attr	_	_
23	inhibitor	inhibitor	NN	_	19	conj	_	_
24	of	of	IN	_	25	case	_	_
25	CYP3A4	cyp0a0	NN	_	23	ppmod	_	_
26	,	,	,	_	10	p	_	_
27	and	and	CC	_	8	cc	_	_
28	drug3	drug0	NN	_	8	conj	_	_
29	(	-lrb-	-LRB-	_	31	p	_	_
30	20	0	CD	_	31	num	_	_
31	mg	mg	NN	_	28	prn	_	_
32	)	-rrb-	-RRB-	_	31	p	_	_
33	did	do	VBD	_	35	aux	_	_
34	not	not	RB	_	35	neg	_	_
35	affect	affect	VB	_	1	acl	_	_
36	the	the	DT	_	37	det	_	_
37	pharmacokinetics	pharmacokinetics	NNS	_	35	obj	_	_
38	of	of	IN	_	40	case	_	_
39	either	either	CC	_	40	cc	_	_
40	drug4	drug0	NN	_	37	ppmod	_	_
41	or	or	CC	_	40	cc	_	_
42	drug5	drug0	NN	_	40	conj	_	_
43	.	.	.	_	1	p	_	_

1	CYP3A4	cyp0a0	NN	_	4	attr	_	_
2	and	and	CC	_	1	cc	_	_
3	-2C19	0c0	NN	_	1	conj	_	_
4	Inhibitors	inhibitor	NNS	_	9	dep	_	_
5	-	-	CC	_	4	cc	_	_
6	In	in	FW	_	7	adv	_	_
7	vitro	vitro	FW	_	8	attr	_	_
8	studies	study	NNS	_	4	conj	_	_
9	indicated	indicate	VBD	_	0	root	_	_
10	that	that	IN	_	14	mark	_	_
11	CYP3A4	cyp0a0	NN	_	14	dep	_	_
12	and	and	CC	_	11	cc	_	_
13	-2C19	0c0	NN	_	11	conj	_	_
14	are	be	VBP	_	9	comp	_	_
15	the	the	DT	_	17	det	_	_
16	primary	primary	JJ	_	17	attr	_	_
17	enzymes	enzyme	NNS	_	14	obj	_	_
18	involved	involve	VBN	_	17	acl	_	_
19	in	in	IN	_	21	case	_	_
20	the	the	DT	_	21	det	_	_
21	metabolism	metabolism	NN	_	18	ppmod	_	_
22	of	of	IN	_	23	case	_	_
23	drug1	drug0	NN	_	21	ppmod	_	_
24	.	.	.	_	9	p	_	_

1	However	however	RB	_	26	adv	_	_
2	,	,	,	_	26	p	_	_
3	coadministration	coadministration	NN	_	26	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	(	-lrb-	-LRB-	_	8	p	_	_
7	20	0	CD	_	8	num	_	_
8	mg	mg	NN	_	5	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	and	and	CC	_	5	cc	_	_
11	drug2	drug0	NN	_	5	conj	_	_
12	(	-lrb-	-LRB-	_	14	p	_	_
13	600	0	CD	_	14	num	_	_
14	mg	mg	NN	_	11	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	,	,	,	_	5	p	_	_
17	a	a	DT	_	19	det	_	_
18	potent	potent	JJ	_	19	attr	_	_
19	inhibitor	inhibitor	NN	_	5	appo	_	_
20	of	of	IN	_	21	case	_	_
21	CYP3A4	cyp0a0	NN	_	19	ppmod	_	_
22	,	,	,	_	5	p	_	_
23	did	do	VBD	_	26	aux	_	_
24	not	not	RB	_	26	neg	_	_
25	significantly	significantly	RB	_	26	adv	_	_
26	affect	affect	VB	_	0	root	_	_
27	the	the	DT	_	28	det	_	_
28	pharmacokinetics	pharmacokinetics	NNS	_	26	obj	_	_
29	of	of	IN	_	30	case	_	_
30	drug3	drug0	NN	_	28	ppmod	_	_
31	.	.	.	_	26	p	_	_

1	Because	because	IN	_	4	mark	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	metabolized	metabolize	VBN	_	18	advcl	_	_
5	by	by	IN	_	8	case	_	_
6	multiple	multiple	JJ	_	8	attr	_	_
7	enzyme	enzyme	NN	_	8	com	_	_
8	systems	system	NNS	_	4	ppmod	_	_
9	,	,	,	_	18	p	_	_
10	inhibition	inhibition	NN	_	18	dep	_	_
11	of	of	IN	_	14	case	_	_
12	a	a	DT	_	14	det	_	_
13	single	single	JJ	_	14	attr	_	_
14	enzyme	enzyme	NN	_	10	ppmod	_	_
15	may	may	MD	_	18	modal	_	_
16	not	not	RB	_	18	neg	_	_
17	appreciably	appreciably	RB	_	18	adv	_	_
18	decrease	decrease	VB	_	0	root	_	_
19	drug2	drug0	NN	_	20	com	_	_
20	clearance	clearance	NN	_	18	obj	_	_
21	.	.	.	_	18	p	_	_

1	Drugs	drug	NNS	_	12	dep	_	_
2	Metabolized	metabolize	VBN	_	1	acl	_	_
3	by	by	IN	_	5	case	_	_
4	Cytochrome	cytochrome	NN	_	5	com	_	_
5	P4502D6	p0d0	NN	_	2	ppmod	_	_
6	-	-	CC	_	5	cc	_	_
7	In	in	FW	_	8	adv	_	_
8	vitro	vitro	FW	_	9	attr	_	_
9	studies	study	NNS	_	5	conj	_	_
10	did	do	VBD	_	12	aux	_	_
11	not	not	RB	_	12	neg	_	_
12	reveal	reveal	VB	_	0	root	_	_
13	an	an	DT	_	15	det	_	_
14	inhibitory	inhibitory	JJ	_	15	attr	_	_
15	effect	effect	NN	_	12	obj	_	_
16	of	of	IN	_	17	case	_	_
17	drug1	drug0	NN	_	15	ppmod	_	_
18	on	on	IN	_	19	case	_	_
19	CYP2D6	cyp0d0	NN	_	15	ppmod	_	_
20	.	.	.	_	12	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	10	ppmod	_	_
3	,	,	,	_	10	p	_	_
4	steady	steady	JJ	_	6	attr	_	_
5	state	state	NN	_	6	com	_	_
6	levels	level	NNS	_	10	dep	_	_
7	of	of	IN	_	9	case	_	_
8	racemic	racemic	JJ	_	9	attr	_	_
9	drug1	drug0	NN	_	6	ppmod	_	_
10	were	be	VBD	_	0	root	_	_
11	not	not	RB	_	10	neg	_	_
12	significantly	significantly	RB	_	13	adv	_	_
13	different	different	JJ	_	10	dep	_	_
14	in	in	IN	_	16	case	_	_
15	poor	poor	JJ	_	16	attr	_	_
16	metabolizers	metabolizers	NNS	_	13	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	extensive	extensive	JJ	_	20	attr	_	_
19	CYP2D6	cyp0d0	NN	_	20	com	_	_
20	metabolizers	metabolizers	NNS	_	16	conj	_	_
21	after	after	IN	_	23	case	_	_
22	multiple-dose	multiple-dose	JJ	_	23	attr	_	_
23	administration	administration	NN	_	10	ppmod	_	_
24	of	of	IN	_	25	case	_	_
25	drug2	drug0	NN	_	23	ppmod	_	_
26	,	,	,	_	10	p	_	_
27	suggesting	suggest	VBG	_	10	comp	_	_
28	that	that	IN	_	41	mark	_	_
29	coadministration	coadministration	NN	_	41	dep	_	_
30	,	,	,	_	29	p	_	_
31	with	with	IN	_	32	case	_	_
32	drug3	drug0	NN	_	29	ppmod	_	_
33	,	,	,	_	29	p	_	_
34	of	of	IN	_	36	case	_	_
35	a	a	DT	_	36	det	_	_
36	drug	drug	NN	_	29	ppmod	_	_
37	that	that	WDT	_	38	dep	_	_
38	inhibits	inhibit	VBZ	_	36	relcl	_	_
39	CYP2D6	cyp0d0	NN	_	38	obj	_	_
40	,	,	,	_	29	p	_	_
41	is	be	VBZ	_	27	comp	_	_
42	unlikely	unlikely	JJ	_	41	dep	_	_
43	to	to	TO	_	44	aux	_	_
44	have	have	VB	_	42	comp	_	_
45	clinically	clinically	RB	_	46	adv	_	_
46	significant	significant	JJ	_	47	attr	_	_
47	effects	effect	NNS	_	44	obj	_	_
48	on	on	IN	_	50	case	_	_
49	drug4	drug0	NN	_	50	com	_	_
50	metabolism	metabolism	NN	_	44	ppmod	_	_
51	.	.	.	_	10	p	_	_

1	However	however	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	there	there	EX	_	5	dep	_	_
4	are	be	VBP	_	5	aux	_	_
5	limited	limit	VBN	_	0	root	_	_
6	in	in	IN	_	8	case	_	_
7	vivo	vivo	FW	_	8	attr	_	_
8	data	datum	NNS	_	5	ppmod	_	_
9	suggesting	suggest	VBG	_	8	acl	_	_
10	a	a	DT	_	14	det	_	_
11	modest	modest	JJ	_	14	attr	_	_
12	CYP2D6	cyp0d0	NN	_	14	attr	_	_
13	inhibitory	inhibitory	JJ	_	14	attr	_	_
14	effect	effect	NN	_	9	obj	_	_
15	for	for	IN	_	47	mark	_	_
16	drug1	drug0	NN	_	47	dep	_	_
17	,	,	,	_	47	p	_	_
18	i.e.	i.e.	FW	_	47	ppmod	_	_
19	,	,	,	_	47	p	_	_
20	coadministration	coadministration	NN	_	47	dep	_	_
21	of	of	IN	_	22	case	_	_
22	drug2	drug0	NN	_	20	ppmod	_	_
23	(	-lrb-	-LRB-	_	25	p	_	_
24	20	0	CD	_	25	num	_	_
25	mg/day	mg/day	NN	_	22	prn	_	_
26	for	for	IN	_	28	case	_	_
27	21	0	CD	_	28	num	_	_
28	days	day	NNS	_	25	ppmod	_	_
29	)	-rrb-	-RRB-	_	25	p	_	_
30	with	with	IN	_	33	case	_	_
31	the	the	DT	_	33	det	_	_
32	drug3	drug0	NN	_	33	com	_	_
33	drug4	drug0	NN	_	20	ppmod	_	_
34	(	-lrb-	-LRB-	_	36	p	_	_
35	single	single	JJ	_	36	attr	_	_
36	dose	dose	NN	_	33	prn	_	_
37	of	of	IN	_	39	case	_	_
38	50	0	CD	_	39	num	_	_
39	mg	mg	NN	_	36	ppmod	_	_
40	)	-rrb-	-RRB-	_	36	p	_	_
41	,	,	,	_	33	p	_	_
42	a	a	DT	_	43	det	_	_
43	substrate	substrate	NN	_	33	appo	_	_
44	for	for	IN	_	45	case	_	_
45	CYP2D6	cyp0d0	NN	_	43	ppmod	_	_
46	,	,	,	_	33	p	_	_
47	resulted	result	VBD	_	14	acl	_	_
48	in	in	IN	_	52	case	_	_
49	a	a	DT	_	52	det	_	_
50	40	0	CD	_	52	num	_	_
51	%	%	NN	_	50	meta	_	_
52	increase	increase	NN	_	47	ppmod	_	_
53	in	in	IN	_	54	case	_	_
54	Cmax	cmax	NN	_	52	ppmod	_	_
55	and	and	CC	_	52	cc	_	_
56	a	a	DT	_	59	det	_	_
57	100	0	CD	_	59	num	_	_
58	%	%	NN	_	57	meta	_	_
59	increase	increase	NN	_	52	conj	_	_
60	in	in	IN	_	61	case	_	_
61	AUC	auc	NN	_	59	ppmod	_	_
62	of	of	IN	_	63	case	_	_
63	drug5	drug0	NN	_	61	ppmod	_	_
64	.	.	.	_	5	p	_	_

1	The	the	DT	_	3	det	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	significance	significance	NN	_	7	dep	_	_
4	of	of	IN	_	6	case	_	_
5	this	this	DT	_	6	det	_	_
6	finding	finding	NN	_	3	ppmod	_	_
7	is	be	VBZ	_	0	root	_	_
8	unknown	unknown	JJ	_	7	dep	_	_
9	.	.	.	_	7	p	_	_

1	Nevertheless	nevertheless	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	caution	caution	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	indicated	indicate	VBN	_	0	root	_	_
6	in	in	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	coadministration	coadministration	NN	_	5	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drugs	drug	NNS	_	10	conj	_	_
13	metabolized	metabolize	VBN	_	10	acl	_	_
14	by	by	IN	_	15	case	_	_
15	CYP2D6	cyp0d0	NN	_	13	ppmod	_	_
16	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	14	dep	_	_
2	-	-	CC	_	1	cc	_	_
3	Administration	administration	NN	_	1	conj	_	_
4	of	of	IN	_	7	case	_	_
5	20	0	CD	_	6	num	_	_
6	mg/day	mg/day	NN	_	7	com	_	_
7	drug2	drug0	NN	_	1	ppmod	_	_
8	for	for	IN	_	10	case	_	_
9	21	0	CD	_	10	num	_	_
10	days	day	NNS	_	1	ppmod	_	_
11	in	in	IN	_	13	case	_	_
12	healthy	healthy	JJ	_	13	attr	_	_
13	volunteers	volunteer	NNS	_	10	ppmod	_	_
14	resulted	result	VBD	_	0	root	_	_
15	in	in	IN	_	19	case	_	_
16	a	a	DT	_	19	det	_	_
17	50	0	CD	_	19	num	_	_
18	%	%	NN	_	17	meta	_	_
19	increase	increase	NN	_	14	ppmod	_	_
20	in	in	IN	_	21	case	_	_
21	Cmax	cmax	NN	_	19	ppmod	_	_
22	and	and	CC	_	19	cc	_	_
23	82	0	CD	_	25	num	_	_
24	%	%	NN	_	23	meta	_	_
25	increase	increase	NN	_	19	conj	_	_
26	in	in	IN	_	27	case	_	_
27	AUC	auc	NN	_	25	ppmod	_	_
28	of	of	IN	_	31	case	_	_
29	the	the	DT	_	31	det	_	_
30	drug3	drug0	NN	_	31	com	_	_
31	drug4	drug0	NN	_	27	ppmod	_	_
32	(	-lrb-	-LRB-	_	27	p	_	_
33	given	give	VBN	_	27	acl	_	_
34	in	in	IN	_	37	case	_	_
35	a	a	DT	_	37	det	_	_
36	single	single	JJ	_	37	attr	_	_
37	dose	dose	NN	_	33	ppmod	_	_
38	of	of	IN	_	40	case	_	_
39	100	0	CD	_	40	num	_	_
40	mg	mg	NN	_	37	ppmod	_	_
41	)	-rrb-	-RRB-	_	27	p	_	_
42	.	.	.	_	14	p	_	_

1	Increased	increase	VBN	_	4	attr	_	_
2	drug1	drug0	NN	_	4	com	_	_
3	plasma	plasma	NN	_	4	com	_	_
4	levels	level	NNS	_	7	dep	_	_
5	have	have	VBP	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	associated	associate	VBN	_	0	root	_	_
8	with	with	IN	_	10	case	_	_
9	decreased	decrease	VBN	_	10	attr	_	_
10	cardioselectivity	cardioselectivity	NN	_	7	ppmod	_	_
11	.	.	.	_	7	p	_	_

1	Coadministration	coadministration	NN	_	6	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	had	have	VBD	_	0	root	_	_
7	no	no	DT	_	10	det	_	_
8	clinically	clinically	RB	_	9	adv	_	_
9	significant	significant	JJ	_	10	attr	_	_
10	effects	effect	NNS	_	6	obj	_	_
11	on	on	IN	_	13	case	_	_
12	blood	blood	NN	_	13	com	_	_
13	pressure	pressure	NN	_	6	ppmod	_	_
14	or	or	CC	_	13	cc	_	_
15	heart	heart	NN	_	16	com	_	_
16	rate	rate	NN	_	13	conj	_	_
17	.	.	.	_	6	p	_	_

1	Electroconvulsive	electroconvulsive	JJ	_	2	attr	_	_
2	Therapy	therapy	NN	_	0	root	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	ECT	ect	NN	_	2	prn	_	_
5	)	-rrb-	-RRB-	_	4	p	_	_
6	-	-	:	_	2	p	_	_
7	There	there	EX	_	8	dep	_	_
8	are	be	VBP	_	2	acl	_	_
9	no	no	DT	_	11	det	_	_
10	clinical	clinical	JJ	_	11	attr	_	_
11	studies	study	NNS	_	8	obj	_	_
12	of	of	IN	_	15	case	_	_
13	the	the	DT	_	15	det	_	_
14	combined	combined	JJ	_	15	attr	_	_
15	use	use	NN	_	11	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	ECT	ect	NN	_	15	ppmod	_	_
18	and	and	CC	_	17	cc	_	_
19	drug1	drug0	NN	_	17	conj	_	_
20	.	.	.	_	2	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	Administration	administration	NN	_	0	root	_	_
3	with	with	IN	_	6	case	_	_
4	Racemic	racemic	JJ	_	6	attr	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	drug2	drug0	NN	_	2	ppmod	_	_
7	-	-	:	_	2	p	_	_
8	Since	since	IN	_	10	mark	_	_
9	drug3	drug0	NN	_	10	dep	_	_
10	is	be	VBZ	_	27	advcl	_	_
11	the	the	DT	_	13	det	_	_
12	active	active	JJ	_	13	attr	_	_
13	isomer	isomer	NN	_	10	obj	_	_
14	of	of	IN	_	16	case	_	_
15	racemic	racemic	JJ	_	16	attr	_	_
16	drug4	drug0	NN	_	13	ppmod	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	drug5	drug0	NN	_	16	prn	_	_
19	)	-rrb-	-RRB-	_	18	p	_	_
20	,	,	,	_	27	p	_	_
21	the	the	DT	_	23	det	_	_
22	two	#crd#	CD	_	23	num	_	_
23	agents	agent	NNS	_	27	dep	_	_
24	should	should	MD	_	27	modal	_	_
25	not	not	RB	_	27	neg	_	_
26	be	be	VB	_	27	aux	_	_
27	coadministered	coadministered	VBN	_	2	acl	_	_
28	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	does	do	VBZ	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	exhibit	exhibit	VB	_	0	root	_	_
5	binding	binding	NN	_	4	obj	_	_
6	to	to	TO	_	8	aux	_	_
7	plasma	plasma	NN	_	8	com	_	_
8	proteins	protein	NNS	_	5	ppmod	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	other	other	JJ	_	8	prn	_	_
11	than	than	IN	_	12	case	_	_
12	thrombin	thrombin	NN	_	10	ppmod	_	_
13	)	-rrb-	-RRB-	_	10	p	_	_
14	or	or	CC	_	8	cc	_	_
15	red	red	JJ	_	17	attr	_	_
16	blood	blood	NN	_	17	com	_	_
17	cells	cell	NNS	_	8	conj	_	_
18	.	.	.	_	4	p	_	_

1	In	in	IN	_	3	case	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	trials	trial	NNS	_	23	ppmod	_	_
4	in	in	IN	_	5	case	_	_
5	patients	patient	NNS	_	3	ppmod	_	_
6	undergoing	undergo	VBG	_	5	acl	_	_
7	PTCA/PCI	ptca/pci	NN	_	6	obj	_	_
8	,	,	,	_	23	p	_	_
9	co-administration	co-administration	NN	_	23	dep	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	with	with	IN	_	13	case	_	_
13	drug2	drug0	NN	_	9	ppmod	_	_
14	,	,	,	_	13	p	_	_
15	drug3	drug0	NN	_	13	conj	_	_
16	,	,	,	_	15	p	_	_
17	drug4	drug0	NN	_	13	conj	_	_
18	or	or	CC	_	17	cc	_	_
19	glycoprotein	glycoprotein	NN	_	21	com	_	_
20	IIb/IIIa	iib/iiia	NN	_	21	com	_	_
21	inhibitors	inhibitor	NNS	_	13	conj	_	_
22	was	be	VBD	_	23	aux	_	_
23	associated	associate	VBN	_	0	root	_	_
24	with	with	IN	_	26	case	_	_
25	increased	increase	VBN	_	26	attr	_	_
26	risks	risk	NNS	_	23	ppmod	_	_
27	of	of	IN	_	30	case	_	_
28	major	major	JJ	_	30	attr	_	_
29	bleeding	bleeding	JJ	_	30	attr	_	_
30	events	event	NNS	_	26	ppmod	_	_
31	compared	compare	VBN	_	33	adv	_	_
32	to	to	TO	_	33	aux	_	_
33	patients	patient	NNS	_	30	ppmod	_	_
34	not	not	RB	_	35	neg	_	_
35	receiving	receive	VBG	_	33	acl	_	_
36	these	these	DT	_	38	det	_	_
37	concomitant	concomitant	JJ	_	38	attr	_	_
38	medications	medication	NNS	_	35	obj	_	_
39	.	.	.	_	23	p	_	_

1	There	there	EX	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	no	no	DT	_	2	obj	_	_
4	experience	experience	VBP	_	3	acl	_	_
5	with	with	IN	_	6	case	_	_
6	co-administration	co-administration	NN	_	4	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	plasma	plasma	NN	_	11	com	_	_
11	expanders	expander	NNS	_	8	conj	_	_
12	such	such	JJ	_	14	adv	_	_
13	as	as	IN	_	14	case	_	_
14	drug2	drug0	NN	_	8	ppmod	_	_
15	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	should	should	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	used	use	VBN	_	0	root	_	_
5	with	with	IN	_	6	case	_	_
6	caution	caution	NN	_	4	ppmod	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	4	ppmod	_	_
9	with	with	IN	_	11	case	_	_
10	disease	disease	NN	_	11	com	_	_
11	states	state	NNS	_	8	ppmod	_	_
12	associated	associate	VBN	_	11	acl	_	_
13	with	with	IN	_	16	case	_	_
14	an	an	DT	_	16	det	_	_
15	increased	increase	VBN	_	16	attr	_	_
16	risk	risk	NN	_	12	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	bleeding	bleeding	JJ	_	16	ppmod	_	_
19	.	.	.	_	4	p	_	_

1	Immunogenicity/Re-exposure	immunogenicity/re-exposure	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	6	case	_	_
4	in	in	FW	_	5	adv	_	_
5	vitro	vitro	FW	_	6	attr	_	_
6	studies	study	NNS	_	9	ppmod	_	_
7	,	,	,	_	9	p	_	_
8	drug1	drug0	NN	_	9	dep	_	_
9	exhibited	exhibit	VBD	_	1	acl	_	_
10	no	no	DT	_	13	det	_	_
11	platelet	platelet	NN	_	13	com	_	_
12	aggregation	aggregation	NN	_	13	com	_	_
13	response	response	NN	_	9	obj	_	_
14	against	against	IN	_	15	case	_	_
15	sera	sera	NN	_	9	ppmod	_	_
16	from	from	IN	_	17	case	_	_
17	patients	patient	NNS	_	15	ppmod	_	_
18	with	with	IN	_	20	case	_	_
19	a	a	DT	_	20	det	_	_
20	history	history	NN	_	17	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	HIT/HITTS	hit/hitts	NNS	_	20	ppmod	_	_
23	.	.	.	_	1	p	_	_

1	Among	among	IN	_	3	case	_	_
2	494	0	CD	_	3	num	_	_
3	subjects	subject	NNS	_	18	ppmod	_	_
4	who	who	WP	_	5	dep	_	_
5	received	receive	VBD	_	3	relcl	_	_
6	drug1	drug0	NN	_	5	obj	_	_
7	in	in	IN	_	9	case	_	_
8	clinical	clinical	JJ	_	9	attr	_	_
9	trials	trial	NNS	_	5	ppmod	_	_
10	and	and	CC	_	5	cc	_	_
11	were	be	VBD	_	12	aux	_	_
12	tested	test	VBN	_	5	conj	_	_
13	for	for	IN	_	14	case	_	_
14	antibodies	antibody	NNS	_	12	ppmod	_	_
15	,	,	,	_	18	p	_	_
16	2	0	CD	_	17	num	_	_
17	subjects	subject	NNS	_	18	dep	_	_
18	had	have	VBD	_	0	root	_	_
19	treatment-emergent	treatment-emergent	JJ	_	23	attr	_	_
20	positive	positive	JJ	_	23	attr	_	_
21	drug2	drug0	NN	_	23	com	_	_
22	antibody	antibody	NN	_	23	com	_	_
23	tests	test	NNS	_	18	obj	_	_
24	.	.	.	_	18	p	_	_

1	Neither	neither	DT	_	2	det	_	_
2	subject	subject	NN	_	3	dep	_	_
3	demonstrated	demonstrate	VBD	_	0	root	_	_
4	clinical	clinical	JJ	_	5	attr	_	_
5	evidence	evidence	NN	_	3	obj	_	_
6	of	of	IN	_	10	case	_	_
7	allergic	allergic	JJ	_	10	attr	_	_
8	or	or	CC	_	10	cc	_	_
9	anaphylactic	anaphylactic	JJ	_	10	attr	_	_
10	reactions	reaction	NNS	_	5	ppmod	_	_
11	and	and	CC	_	3	cc	_	_
12	repeat	repeat	NN	_	13	com	_	_
13	testing	testing	NN	_	16	dep	_	_
14	was	be	VBD	_	16	aux	_	_
15	not	not	RB	_	16	neg	_	_
16	performed	performed	VBN	_	3	conj	_	_
17	.	.	.	_	3	p	_	_

1	Nine	#crd#	CD	_	3	num	_	_
2	additional	additional	JJ	_	3	attr	_	_
3	patients	patient	NNS	_	9	dep	_	_
4	who	who	WP	_	5	dep	_	_
5	had	have	VBD	_	3	relcl	_	_
6	initial	initial	JJ	_	8	attr	_	_
7	positive	positive	JJ	_	8	attr	_	_
8	tests	test	NNS	_	5	obj	_	_
9	were	be	VBD	_	0	root	_	_
10	negative	negative	JJ	_	9	dep	_	_
11	on	on	IN	_	13	case	_	_
12	repeat	repeat	NN	_	13	com	_	_
13	testing	testing	NN	_	9	ppmod	_	_
14	.	.	.	_	9	p	_	_

1	Drug/	drug/	JJ	_	4	attr	_	_
2	Laboratory	laboratory	NN	_	4	com	_	_
3	Test	test	NN	_	4	com	_	_
4	Interactions	interaction	NNS	_	13	dep	_	_
5	Certain	certain	JJ	_	6	attr	_	_
6	endocrine	endocrine	NN	_	4	attr	_	_
7	and	and	CC	_	6	cc	_	_
8	liver	liver	NN	_	10	com	_	_
9	function	function	NN	_	10	com	_	_
10	tests	test	NNS	_	6	conj	_	_
11	may	may	MD	_	13	modal	_	_
12	be	be	VB	_	13	aux	_	_
13	affected	affect	VBN	_	0	root	_	_
14	by	by	IN	_	18	case	_	_
15	drug1	drug0	NN	_	16	advnp	_	_
16	-containing	-containing	JJ	_	18	attr	_	_
17	oral	oral	JJ	_	18	attr	_	_
18	drug2	drug0	NN	_	13	ppmod	_	_
19	.	.	.	_	13	p	_	_

1	The	the	DT	_	4	det	_	_
2	following	following	JJ	_	4	attr	_	_
3	similar	similar	JJ	_	4	attr	_	_
4	changes	change	NNS	_	7	dep	_	_
5	may	may	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	expected	expect	VBN	_	0	root	_	_
8	with	with	IN	_	10	case	_	_
9	larger	large	JJR	_	10	attr	_	_
10	doses	dose	NNS	_	7	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	:	:	:	_	7	p	_	_
14	-	-	CC	_	7	cc	_	_
15	Increased	increase	VBN	_	17	attr	_	_
16	sulfobromophthalein	sulfobromophthalein	NN	_	17	com	_	_
17	retention	retention	NN	_	7	conj	_	_

1	.	.	.	_	0	root	_	_

1	-	-	CC	_	3	cc	_	_
2	Increased	increase	VBN	_	3	attr	_	_
3	prothrombin	prothrombin	NN	_	0	root	_	_
4	and	and	CC	_	3	cc	_	_
5	factors	factor	NNS	_	6	com	_	_
6	VII	vii	NN	_	3	conj	_	_
7	,	,	,	_	6	p	_	_
8	VIII	viii	NN	_	6	conj	_	_
9	,	,	,	_	8	p	_	_
10	IX	ix	NN	_	6	conj	_	_
11	,	,	,	_	10	p	_	_
12	and	and	CC	_	10	cc	_	_
13	X	x	NN	_	6	conj	_	_
14	;	;	:	_	6	p	_	_

1	decreased	decrease	VBD	_	0	root	_	_
2	drug1	drug0	NN	_	1	obj	_	_
3	;	;	:	_	1	p	_	_

1	increased	increase	VBN	_	4	attr	_	_
2	norepinephrine-induced	norepinephrine-induced	JJ	_	4	attr	_	_
3	platelet	platelet	NN	_	4	com	_	_
4	aggregability	aggregability	NN	_	0	root	_	_

1	.	.	.	_	0	root	_	_

1	-	-	CC	_	4	cc	_	_
2	Increased	increase	VBN	_	4	attr	_	_
3	thyroid-binding	thyroid-binding	JJ	_	4	attr	_	_
4	globulin	globulin	NN	_	8	dep	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	TBG	tbg	NN	_	4	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	leading	lead	VBG	_	0	root	_	_
9	to	to	TO	_	14	aux	_	_
10	in-creased	in-creased	JJ	_	14	attr	_	_
11	circulating	circulate	VBG	_	14	attr	_	_
12	total	total	JJ	_	14	attr	_	_
13	thyroid	thyroid	NN	_	14	com	_	_
14	hormone	hormone	NN	_	8	ppmod	_	_
15	;	;	:	_	8	p	_	_

1	as	as	IN	_	2	case	_	_
2	measured	measure	VBN	_	0	root	_	_
3	by	by	IN	_	4	case	_	_
4	PBI	pbi	NN	_	2	ppmod	_	_
5	,	,	,	_	4	p	_	_
6	T4	t0	NN	_	4	appo	_	_
7	by	by	IN	_	8	case	_	_
8	column	column	NN	_	2	ppmod	_	_
9	,	,	,	_	8	p	_	_
10	or	or	CC	_	8	cc	_	_
11	T4	t0	NN	_	8	conj	_	_
12	by	by	IN	_	13	case	_	_
13	radioimmunoassay	radioimmunoassay	NN	_	2	ppmod	_	_
14	.	.	.	_	2	p	_	_

1	Free	free	JJ	_	4	attr	_	_
2	T3	t0	NN	_	4	com	_	_
3	resin	resin	NN	_	4	com	_	_
4	uptake	uptake	NN	_	6	dep	_	_
5	is	be	VBZ	_	6	aux	_	_
6	decreased	decrease	VBN	_	0	root	_	_
7	,	,	,	_	6	p	_	_
8	reflecting	reflect	VBG	_	6	comp	_	_
9	the	the	DT	_	11	det	_	_
10	elevated	elevated	JJ	_	11	attr	_	_
11	TBG	tbg	NN	_	8	obj	_	_
12	;	;	:	_	6	p	_	_

1	free	free	JJ	_	3	attr	_	_
2	T4	t0	NN	_	3	com	_	_
3	concentration	concentration	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	unaltered	unaltered	JJ	_	0	root	_	_

1	.	.	.	_	0	root	_	_

1	-	-	CC	_	4	cc	_	_
2	Impaired	impaired	JJ	_	4	attr	_	_
3	glucose	glucose	NN	_	4	com	_	_
4	tolerance	tolerance	NN	_	0	root	_	_

1	.	.	.	_	0	root	_	_

1	-	-	:	_	4	p	_	_
2	Decreased	decrease	VBN	_	4	attr	_	_
3	pregnanediol	pregnanediol	NN	_	4	com	_	_
4	excretion	excretion	NN	_	0	root	_	_

1	.	.	.	_	0	root	_	_

1	-	-	CC	_	3	cc	_	_
2	Reduced	reduced	JJ	_	3	attr	_	_
3	response	response	NN	_	0	root	_	_
4	to	to	TO	_	6	aux	_	_
5	metyrapone	metyrapone	NN	_	6	com	_	_
6	test	test	NN	_	3	ppmod	_	_

1	.	.	.	_	0	root	_	_

1	-	-	CC	_	5	cc	_	_
2	Reduced	reduced	JJ	_	5	attr	_	_
3	serum	serum	NN	_	5	com	_	_
4	folate	folate	NN	_	5	com	_	_
5	concentration	concentration	NN	_	0	root	_	_

1	.	.	.	_	0	root	_	_

1	-	-	CC	_	4	cc	_	_
2	Increased	increase	VBN	_	4	attr	_	_
3	serum	serum	NN	_	4	com	_	_
4	triglyceride	triglyceride	NN	_	0	root	_	_
5	and	and	CC	_	4	cc	_	_
6	phospholipid	phospholipid	NN	_	7	com	_	_
7	concentration	concentration	NN	_	4	conj	_	_
8	.	.	.	_	4	p	_	_

1	No	no	DT	_	5	det	_	_
2	formal	formal	JJ	_	5	attr	_	_
3	drug	drug	NN	_	5	com	_	_
4	interaction	interaction	NN	_	5	com	_	_
5	studies	study	NNS	_	8	dep	_	_
6	have	have	VBP	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	conducted	conduct	VBN	_	0	root	_	_
9	with	with	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	8	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	studies	study	NNS	_	8	dep	_	_
4	with	with	IN	_	7	case	_	_
5	human	human	JJ	_	7	attr	_	_
6	liver	liver	NN	_	7	com	_	_
7	microsomes	microsome	NNS	_	3	ppmod	_	_
8	indicate	indicate	VBP	_	0	root	_	_
9	that	that	IN	_	11	mark	_	_
10	drug1	drug0	NN	_	11	dep	_	_
11	is	be	VBZ	_	8	comp	_	_
12	primarily	primarily	RB	_	11	adv	_	_
13	a	a	DT	_	14	det	_	_
14	substrate	substrate	NN	_	11	obj	_	_
15	for	for	IN	_	18	case	_	_
16	cytochrome	cytochrome	NN	_	18	com	_	_
17	P450	p0	NN	_	18	com	_	_
18	3A4	0a0	NN	_	14	ppmod	_	_
19	,	,	,	_	18	p	_	_
20	2C19	0c0	NN	_	18	conj	_	_
21	,	,	,	_	20	p	_	_
22	and	and	CC	_	20	cc	_	_
23	1A2	0a0	NN	_	18	conj	_	_
24	.	.	.	_	8	p	_	_

1	Patients	patient	NNS	_	21	dep	_	_
2	who	who	WP	_	5	dep	_	_
3	are	be	VBP	_	5	aux	_	_
4	concomitantly	concomitantly	RB	_	5	adv	_	_
5	receiving	receive	VBG	_	1	relcl	_	_
6	drug1	drug0	NN	_	5	obj	_	_
7	and	and	CC	_	6	cc	_	_
8	drugs	drug	NNS	_	6	conj	_	_
9	that	that	WDT	_	10	dep	_	_
10	are	be	VBP	_	6	relcl	_	_
11	inhibitors	inhibitor	NNS	_	10	obj	_	_
12	or	or	CC	_	11	cc	_	_
13	inducers	inducer	NNS	_	11	conj	_	_
14	of	of	IN	_	17	case	_	_
15	cytochrome	cytochrome	NN	_	17	com	_	_
16	P450	p0	NN	_	17	com	_	_
17	3A4	0a0	NN	_	11	ppmod	_	_
18	should	should	MD	_	21	modal	_	_
19	be	be	VB	_	21	aux	_	_
20	closely	closely	RB	_	21	adv	_	_
21	monitored	monitor	VBN	_	0	root	_	_
22	for	for	IN	_	24	case	_	_
23	either	either	CC	_	24	cc	_	_
24	toxicities	toxicity	NNS	_	21	ppmod	_	_
25	or	or	CC	_	24	cc	_	_
26	reduced	reduce	VBN	_	27	attr	_	_
27	efficacy	efficacy	NN	_	24	conj	_	_
28	.	.	.	_	21	p	_	_

1	During	during	IN	_	3	case	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	trials	trial	NNS	_	9	ppmod	_	_
4	,	,	,	_	9	p	_	_
5	hypoglycemia	hypoglycemia	NN	_	9	dep	_	_
6	and	and	CC	_	5	cc	_	_
7	hyperglycemia	hyperglycemia	NN	_	5	conj	_	_
8	were	be	VBD	_	9	aux	_	_
9	reported	report	VBN	_	0	root	_	_
10	in	in	IN	_	12	case	_	_
11	diabetic	diabetic	JJ	_	12	attr	_	_
12	patients	patient	NNS	_	9	ppmod	_	_
13	receiving	receive	VBG	_	12	acl	_	_
14	oral	oral	JJ	_	15	attr	_	_
15	drug1	drug0	NN	_	13	obj	_	_
16	.	.	.	_	9	p	_	_

1	Patients	patient	NNS	_	9	dep	_	_
2	on	on	IN	_	4	case	_	_
3	oral	oral	JJ	_	4	attr	_	_
4	drug1	drug0	NN	_	1	ppmod	_	_
5	receiving	receive	VBG	_	1	acl	_	_
6	drug2	drug0	NN	_	7	com	_	_
7	treatment	treatment	NN	_	5	obj	_	_
8	may	may	MD	_	9	modal	_	_
9	require	require	VB	_	0	root	_	_
10	close	close	JJ	_	11	attr	_	_
11	monitoring	monitoring	NN	_	9	obj	_	_
12	of	of	IN	_	16	case	_	_
13	their	their	PRP$	_	16	poss	_	_
14	blood	blood	NN	_	16	com	_	_
15	glucose	glucose	NN	_	16	com	_	_
16	levels	level	NNS	_	11	ppmod	_	_
17	and	and	CC	_	11	cc	_	_
18	adjustment	adjustment	NN	_	11	conj	_	_
19	of	of	IN	_	21	case	_	_
20	the	the	DT	_	21	det	_	_
21	dose	dose	NN	_	18	ppmod	_	_
22	of	of	IN	_	24	case	_	_
23	their	their	PRP$	_	24	poss	_	_
24	drug3	drug0	NN	_	21	ppmod	_	_
25	.	.	.	_	9	p	_	_

1	Drug	drug	NN	_	4	com	_	_
2	Laboratory	laboratory	NN	_	4	com	_	_
3	Test	test	NN	_	4	com	_	_
4	Interactions	interaction	NNS	_	6	dep	_	_
5	None	none	NN	_	6	dep	_	_
6	known	know	VBN	_	0	root	_	_
7	.	.	.	_	6	p	_	_

